

APPROVED DRUG PRODUCTS

WITH

THERAPEUTIC EQUIVALENCE EVALUATIONS

42nd EDITION

THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2022

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2021.

42nd EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2022

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

CONTENTS

PAGE

FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations

PREFACE TO FORTY SECOND EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or effectiveness reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate revisions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments amended the FD&C Act to establish, among other things, the 505(b)(2) and 505(j) approval pathways. The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that have qualified under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA under section 505(b) of the FD&C Act or an ANDA under section 505(j) of the FD&C Act to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Central Document Room, Attn: Director, Division of Orange Book Publication and Regulatory Assessment (DOBPRA), Office of Generic Drug Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or effectiveness reasons subsequent to being discontinued from marketing.[1] This publication also includes indices of prescription and OTC drug products by proprietary name (brand name or trade name) or, if no proprietary name exists, established name of the active ingredient and by applicant name, which have been abbreviated for this publication. Established names for active ingredients generally conform to compendial names or ***United States Adopted Names*** (USAN) as described in 21 CFR 299.4(e). A list of uniform terms is provided in Appendix C.

The ***Addendum*** contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and effectiveness and for which NDAs are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. The Agency will list the drug product in the Orange Book and the date of approval as determined under Section 505(x).

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

[1] Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the Over-the-Counter Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Division of Orange Book Publication and Regulatory Assessment is otherwise notified before publication. See Section 1.12.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[2] They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules).[3] Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.[4] Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.[5]

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug

[2] 21 CFR 314.3(b).
[3] See 21 CFR 314.3(b).
[4] 21 CFR 314.3(b).
[5] 21 CFR 314.3(b).

product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (***e.g.***, weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (***e.g.***, weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (***e.g.***, certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).[6] Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.[7]

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available

[6] 21 CFR 314.3(b).
[7] 21 CFR 314.3(b).

at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.[8] Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid ***in vivo*** or ***in vitro*** test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an ***in vitro*** bioequivalence standard, especially when such an ***in vitro*** test has been correlated with human ***in vivo*** bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.[9]

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.[10]

[8] 21 CFR 314.3(b).
[9] 21 CFR 320.24.
[10] We note that prior to the 36th edition of the Orange Book, the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs and FDA Drugs guidance (Product-Specific Guidances for Generic Drug Development) Web page at https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development.

1.4 Reference Listed Drug and Reference Standard

A reference listed drug is the listed drug[11] identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.[12] FDA's general practice is to designate as RLDs drug products that have been approved for safety and effectiveness under section 505(c) of the FD&C Act. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.[13]

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an ***in vivo*** bioequivalence study required for approval.[14] FDA generally selects a single reference standard that ANDA applicants must use in ***in vivo*** bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances, the reference listed drug and the reference standard may be different. For example, where the reference listed drug has been withdrawn from sale for reasons other than safety or effectiveness, FDA may select an ANDA that is therapeutically equivalent to this reference listed drug as the reference standard.

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate a reference listed drug for that drug product. Section 1.7, ***Therapeutic Equivalence Evaluations Codes*** (***products meeting necessary bioequivalence requirements***) explains the character coding system (e.g., **AB, AB1, AB2, AB3**...) for multisource prescription drug products listed under the same heading with two or more reference listed drugs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any ***in vivo*** bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale.

---

[11] A "listed drug" is a new drug product that has been approved under section 505(c) of the FD&C Act for safety and effectiveness or under section 505(j) of the FD&C Act, which has not been withdrawn or suspended under section 505(e)(1) through (5) or section 505(j)(6) of the FD&C Act, and which has not been withdrawn from sale for what FDA has determined are reasons of safety or effectiveness. Listed drug status is evidenced by the drug product's identification in the current edition of FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations" (the list) as an approved drug. A drug product is deemed to be a listed drug on the date of approval for the NDA or ANDA for that drug product (21 CFR 314.3(b)).

[12] 21 CFR 314.3(b).

[13] 21 CFR 314.94(a)(3)(i).

[14] 21 CFR 314.3(b).

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an ***in vivo*** bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products

(particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available (i.e., not on the Discontinued Drug Product list) from more than one manufacturer. For such products, a therapeutic equivalence code generally is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. Products listed in the Orange Book are identified by the applicant's name (firm name on the Form FDA 356h in the application). Where the applicant's name does not appear on the label, a person wishing to relate a specific product to the applicant name in the Orange Book may refer to FDA's NDC Directory[15] and match its search terms to information on the label, such as the NDC Code if available.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an NDA or ANDA that has been approved and that has not been withdrawn for safety or effectiveness reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, prescription drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved

[15] https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory.

prescription drug product (e.g., a particular strength of an approved drug that is not on the Discontinued Drug Product list) as therapeutically equivalent to other pharmaceutically equivalent prescription drug products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX**, or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an **"A"** code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through ***in vivo*** and/or ***in vitro*** studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, ***Description of Certain Special Situations***. For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

For example, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate ***in vitro*** bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, ***Therapeutic Equivalence-Related Terms, Strength)*** generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to a reference listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered

therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon ***in vitro*** methodology. If bioequivalence needs to be demonstrated by ***in vivo*** methodology, then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these

products are on the market without FDA approval and FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms,* the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.[16] In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as x mg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as x mg/vial.

However, FDA subsequently realized that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book displays the strength of all new approvals of parenteral solutions. Previously (i.e., prior to 2003), we would have displayed only the concentration of an approved parenteral solution, e.g. 50 mg/mL. For example, if this application had a 20 mL and 60 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1 gm/20 mL (50 mg/mL) and 3 gm/60 mL (50 mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted, or the application contains adequate scientific evidence establishing through an *in vitro* approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of *in vivo* bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate *in vivo* bioequivalence data, and **BT** in the absence of such data.

[16] The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

"B" CODES

Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a **"B"** code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the **"B"** sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been

submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is

available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was

submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, ***all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.*** A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium.[17] Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.[18]

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3, and therefore, Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS

[17] In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

[18] The chart is current as of the date of publication of the annual edition. See the most current monthly cumulative supplement for updates to this information available at https://www.fda.gov/media/72973/download. Please consult the Active Section for information on other strengths.

AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM[19]	MYLAN	0.3MG	A076187	–	RS

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its reference listed drug, the reference listed drug that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an ***in vivo*** bioequivalence study required for approval. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.[20] (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, FDA will not accept for review and/or will not approve, as applicable, other applications blocked by the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for an ANDA or 505(b)(2) application that relies on the listed drug will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the

[19] Alvogen INC tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

[20] If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

holder of the NDA may waive its exclusivity as to any or all applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its exclusivity, qualified applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is generally an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's

code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the ***Federal Register*** of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "**Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.[21] Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform DOBPRA of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, applicants must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that applicants notify the Agency in writing within 180 days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1 or 2 of the Orange Book (as discussed in Section 1.1), must be submitted to DOBPRA by

[21] See, e.g., Section 506I(d) of the FD&C Act.

the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

In addition, DOBPRA generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already listed in the Orange Book, but rather intends to apply the change prospectively to drug products as they are added to the Orange Book.

You can contact DOBPRA by email at orangebook@fda.hhs.gov.

1.13 Availability of the Edition

The Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the Orange Book home page by clicking on Publications. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, https://www.gpo.gov/.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with **"A"** and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic

equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or effectiveness reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant *(Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT



*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION



THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE ***INTRODUCTION.***



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

ABACAVIR SULFATE

SOLUTION;ORAL

ABACAVIR SULFATE

AA		AUROBINDO PHARMA LTD	**EQ 20MG BASE/ML**	**A077950**	**001**	Mar 14, 2018
AA		HETERO LABS LTD III	**EQ 20MG BASE/ML**	**A201107**	**001**	Sep 26, 2016

ZIAGEN

AA	**+!**	VIIV HLTHCARE	**EQ 20MG BASE/ML**	**N020978**	**001**	Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATE

AB		AUROBINDO PHARMA LTD	**EQ 300MG BASE**	**A077844**	**001**	Dec 17, 2012
AB		CIPLA	**EQ 300MG BASE**	**A078119**	**001**	Nov 21, 2017
AB		HETERO LABS LTD III	**EQ 300MG BASE**	**A091560**	**001**	Sep 13, 2013
AB		MYLAN PHARMS INC	**EQ 300MG BASE**	**A091294**	**001**	Jun 18, 2012
AB		STRIDES PHARMA	**EQ 300MG BASE**	**A091050**	**001**	Oct 28, 2016

ZIAGEN

AB	**+!**	VIIV HLTHCARE	**EQ 300MG BASE**	**N020977**	**001**	Dec 17, 1998

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

	+!	VIIV HLTHCARE	EQ 600MG BASE;EQ 50MG BASE;300MG	N205551	001	Aug 22, 2014

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		AUROBINDO PHARMA LTD	**EQ 600MG BASE;300MG**	**A090159**	**001**	Nov 15, 2018
AB			**EQ 600MG BASE;300MG**	**A206151**	**001**	Mar 28, 2017
AB		CIPLA	**EQ 600MG BASE;300MG**	**A091144**	**001**	Mar 28, 2017
AB		LUPIN LTD	**EQ 600MG BASE;300MG**	**A204990**	**001**	Mar 28, 2017
AB		TEVA PHARMS USA	**EQ 600MG BASE;300MG**	**A079246**	**001**	Sep 29, 2016

EPZICOM

AB	**+!**	VIIV HLTHCARE	**EQ 600MG BASE;300MG**	**N021652**	**001**	Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB		LUPIN LTD	**EQ 300MG BASE;150MG;300MG**	**A202912**	**001**	Dec 05, 2013

TRIZIVIR

AB	**+!**	VIIV HLTHCARE	**EQ 300MG BASE;150MG;300MG**	**N021205**	**001**	Nov 14, 2000

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

	+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743	001	Apr 28, 2017

ABEMACICLIB

TABLET;ORAL

VERZENIO

	+	ELI LILLY AND CO	50MG	N208716	001	Sep 28, 2017
	+		100MG	N208716	002	Sep 28, 2017
	+		150MG	N208716	003	Sep 28, 2017
	+!		200MG	N208716	004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		AMNEAL PHARMS	**250MG**	**A208327**	**001**	Jan 07, 2019
AB			**500MG**	**A208327**	**002**	Dec 23, 2020
AB		APOTEX	**250MG**	**A208453**	**001**	Oct 31, 2018
AB		DR REDDYS LABS LTD	**250MG**	**A208416**	**001**	May 18, 2020
AB		GLENMARK PHARMS	**250MG**	**A209227**	**001**	Oct 16, 2019
AB		HIKMA	**250MG**	**A208339**	**001**	Oct 31, 2018
AB		MSN	**250MG**	**A210686**	**001**	Jul 10, 2019
AB		MYLAN	**250MG**	**A208446**	**001**	Oct 31, 2018
AB			**500MG**	**A208446**	**002**	Dec 14, 2020
AB		ONCOGEN PHARMA	**250MG**	**A215947**	**001**	Jan 05, 2022
AB			**500MG**	**A215947**	**002**	Jan 05, 2022
AB		QILU	**250MG**	**A212462**	**001**	Sep 27, 2019
AB			**500MG**	**A212462**	**002**	Jun 25, 2021
AB		RISING	**250MG**	**A208371**	**001**	Feb 25, 2019
AB		TEVA PHARMS USA	**250MG**	**A208432**	**001**	Oct 31, 2018
AB		WOCKHARDT BIO AG	**250MG**	**A208380**	**001**	Feb 27, 2019

ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

AB	**+**	JANSSEN BIOTECH	**250MG**	**N202379**	**001**	Apr 28, 2011
AB	**+!**		**500MG**	**N202379**	**002**	Apr 14, 2017

YONSA

	+!	SUN PHARMA GLOBAL	125MG	N210308	001	May 22, 2018

ACALABRUTINIB

CAPSULE;ORAL

CALQUENCE

	+!	ASTRAZENECA	100MG	N210259	001	Oct 31, 2017

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB	**!**	GLENMARK GENERICS	**333MG**	**A202229**	**001**	Jul 16, 2013
AB		MYLAN	**333MG**	**A200142**	**001**	Mar 11, 2014
AB		ZYDUS PHARMS	**333MG**	**A205995**	**001**	May 26, 2017

ACARBOSE

TABLET;ORAL

ACARBOSE

AB		EMCURE PHARMS LTD	**25MG**	**A202271**	**001**	Feb 07, 2012
AB			**50MG**	**A202271**	**002**	Feb 07, 2012
AB			**100MG**	**A202271**	**003**	Feb 07, 2012
AB		HIKMA	**25MG**	**A078470**	**001**	May 07, 2008
AB			**50MG**	**A078470**	**002**	May 07, 2008
AB			**100MG**	**A078470**	**003**	May 07, 2008
AB		IMPAX LABS	**25MG**	**A078441**	**001**	May 14, 2009
AB			**50MG**	**A078441**	**002**	May 14, 2009
AB			**100MG**	**A078441**	**003**	May 14, 2009
AB	**!**	STRIDES PHARMA	**25MG**	**A090912**	**001**	Jul 27, 2011
AB			**50MG**	**A090912**	**002**	Jul 27, 2011
AB			**100MG**	**A090912**	**003**	Jul 27, 2011
AB		VIRTUS PHARM	**25MG**	**A091343**	**001**	Oct 17, 2013
AB			**50MG**	**A091343**	**002**	Oct 17, 2013
AB			**100MG**	**A091343**	**003**	Oct 17, 2013
AB		WATSON LABS	**25MG**	**A077532**	**001**	May 07, 2008
AB			**50MG**	**A077532**	**002**	May 07, 2008
AB			**100MG**	**A077532**	**003**	May 07, 2008

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	**!**	AMNEAL PHARM	**EQ 200MG BASE**	**A075047**	**001**	Dec 30, 1999
AB	**!**		**EQ 400MG BASE**	**A075047**	**002**	Dec 30, 1999
AB		MYLAN	**EQ 200MG BASE**	**A074288**	**001**	Apr 24, 1995
AB			**EQ 400MG BASE**	**A074288**	**002**	Apr 24, 1995

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP		BAXTER HLTHCARE CORP	**1GM/100ML (10MG/ML)**	**A214331**	**001**	Sep 17, 2021
AP		CUSTOPHARM INC	**1GM/100ML (10MG/ML)**	**A202605**	**001**	Jun 13, 2016
AP		EUGIA PHARMA	**1GM/100ML (10MG/ML)**	**A210969**	**001**	Oct 21, 2020
AP		MYLAN	**1GM/100ML (10MG/ML)**	**A213255**	**001**	Aug 07, 2020
AP		SANDOZ INC	**1GM/100ML (10MG/ML)**	**A204052**	**001**	Mar 22, 2016

OFIRMEV

AP	**+!**	MALLINCKRODT HOSP	**1GM/100ML (10MG/ML)**	**N022450**	**001**	Nov 02, 2010

ACETAMINOPHEN

	+!	B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021
	+!		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021
		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

	+	KVK TECH INC	325MG;EQ 4.08MG BASE	N208653	002	Jan 04, 2019
	+		325MG;EQ 6.12MG BASE	N208653	001	Feb 23, 2018
	+!		325MG;EQ 8.16MG BASE	N208653	003	Jan 04, 2019

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		GRANULES	**300MG;50MG**	**A213115**	**001**	Nov 22, 2019
AA	**!**	MAYNE PHARMA INC	**300MG;50MG**	**A207313**	**001**	Dec 27, 2017

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		ALVOGEN	**300MG;50MG**	**A207635**	**001**	Jun 05, 2017
AA			**325MG;50MG**	**A205120**	**001**	Oct 30, 2015
AA		LARKEN LABS INC	**325MG;50MG**	**A203484**	**002**	Dec 04, 2015
AA	**!**	LGM PHARMA	**300MG;50MG**	**A090956**	**001**	Aug 23, 2011
AA		MIKART	**300MG;50MG**	**A207386**	**001**	Nov 15, 2016

BUTAPAP

AA	**!**	MIKART	**325MG;50MG**	**A089987**	**001**	Oct 26, 1992

ALLZITAL

	!	LARKEN LABS INC	325MG;25MG	A203484	001	Dec 04, 2015

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		AUROLIFE PHARMA LLC	**325MG;50MG;40MG**	**A204733**	**001**	Sep 26, 2018
AA		GRANULES	**300MG;50MG;40MG**	**A213321**	**001**	Apr 08, 2020
AA		LANNETT CO INC	**300MG;50MG;40MG**	**A212082**	**001**	Dec 17, 2019
AA			**325MG;50MG;40MG**	**A212083**	**001**	Dec 17, 2019
AA	**!**	LGM PHARMA	**300MG;50MG;40MG**	**A040885**	**001**	Nov 16, 2009
AA		MAYNE PHARMA INC	**300MG;50MG;40MG**	**A210817**	**001**	Dec 17, 2019
AA	**!**		**325MG;50MG;40MG**	**A089007**	**001**	Mar 17, 1986
AA		NUVO PHARMS INC	**300MG;50MG;40MG**	**A207118**	**001**	Oct 28, 2016
AA		RICONPHARMA LLC	**300MG;50MG;40MG**	**A215047**	**001**	Nov 17, 2021
AA		SENORES PHARMS	**300MG;50MG;40MG**	**A214087**	**001**	Aug 13, 2021
AA			**325MG;50MG;40MG**	**A214087**	**002**	Aug 13, 2021
AA		TARO PHARM INDS LTD	**300MG;50MG;40MG**	**A213046**	**001**	Jul 01, 2020
AA		XSPIRE PHARMA	**300MG;50MG;40MG**	**A206615**	**001**	Aug 04, 2017

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	!	MIKART	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ABHAI LLC	**325MG;50MG;40MG**	**A211106**	**001**	Sep 26, 2018
AA	**+**	ACTAVIS LABS UT INC	**325MG;50MG;40MG**	**A088616**	**001**	Nov 09, 1984
AA		ALVOGEN	**325MG;50MG;40MG**	**A204984**	**001**	Jan 10, 2017
AA		LANNETT CO INC	**325MG;50MG;40MG**	**A200243**	**001**	Sep 13, 2012
AA		LGM PHARMA	**325MG;50MG;40MG**	**A209587**	**001**	Oct 31, 2018
AA		MIKART	**325MG;50MG;40MG**	**A089175**	**001**	Jan 21, 1987
AA		NESHER PHARMS	**325MG;50MG;40MG**	**A211543**	**001**	Jul 17, 2020
AA	**!**	STRIDES PHARMA	**325MG;50MG;40MG**	**A040511**	**001**	Aug 27, 2003
AA			**325MG;50MG;40MG**	**A203647**	**001**	Sep 21, 2020

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		LGM PHARMA	**325MG;50MG;40MG;30MG**	**A076560**	**001**	Jun 10, 2004
AB		NOSTRUM LABS INC	**325MG;50MG;40MG;30MG**	**A075929**	**001**	Apr 22, 2002
AB		STRIDES PHARMA	**325MG;50MG;40MG;30MG**	**A204649**	**001**	Jul 08, 2020

FIORICET W/ CODEINE

AB	**+!**	ACTAVIS LABS UT INC	**325MG;50MG;40MG;30MG**	**N020232**	**001**	Jul 30, 1992

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

		LGM PHARMA	300MG;50MG;40MG;30MG	A076560	002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

		XSPIRE PHARMA	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

		LARKEN LABS INC	325MG;30MG;16MG	A204209	001	Sep 30, 2016

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AKORN	**120MG/5ML;12MG/5ML**	**A040119**	**001**	Apr 26, 1996
AA		ANDA REPOSITORY	**120MG/5ML;12MG/5ML**	**A089450**	**001**	Oct 27, 1992
AA	**!**	PHARM ASSOC	**120MG/5ML;12MG/5ML**	**A087508**	**001**	

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	**300MG;30MG**	**A040779**	**001**	May 29, 2008
AA		AUROLIFE PHARMA LLC	**300MG;15MG**	**A202800**	**001**	Apr 15, 2013
AA			**300MG;30MG**	**A202800**	**002**	Apr 15, 2013
AA			**300MG;60MG**	**A202800**	**003**	Apr 15, 2013
AA		ELITE LABS INC	**300MG;15MG**	**A212418**	**001**	Sep 10, 2019
AA			**300MG;30MG**	**A212418**	**002**	Sep 10, 2019
AA			**300MG;60MG**	**A212418**	**003**	Sep 10, 2019
AA		EYWA	**300MG;15MG**	**A211610**	**001**	Jun 27, 2019
AA			**300MG;30MG**	**A211610**	**002**	Jun 27, 2019
AA			**300MG;60MG**	**A211610**	**003**	Jun 27, 2019
AA		NOSTRUM LABS INC	**300MG;15MG**	**A088629**	**002**	Mar 06, 1985
AA			**300MG;30MG**	**A088629**	**003**	Mar 06, 1985
AA	**+!**		**300MG;60MG**	**A088629**	**001**	Mar 06, 1985
AA	**!**	SPECGX LLC	**300MG;15MG**	**A040419**	**001**	May 31, 2001
AA	**!**		**300MG;30MG**	**A040419**	**002**	May 31, 2001
AA			**300MG;60MG**	**A040419**	**003**	May 31, 2001
AA		SUN PHARM INDS LTD	**300MG;30MG**	**A085868**	**001**	
AA			**300MG;60MG**	**A087083**	**001**	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	**!**	ANDA REPOSITORY	**325MG/15ML;7.5MG/15ML**	**A040482**	**001**	Sep 25, 2003
AA		GENUS	**325MG/15ML;7.5MG/15ML**	**A040894**	**001**	Jul 19, 2011
AA	**!**	MIKART	**300MG/15ML;10MG/15ML**	**A040881**	**001**	Feb 25, 2010
AA		PHARM ASSOC	**325MG/15ML;7.5MG/15ML**	**A040838**	**001**	May 10, 2013
AA		TRIS PHARMA INC	**300MG/15ML;10MG/15ML**	**A201295**	**002**	Dec 30, 2021
AA			**325MG/15ML;7.5MG/15ML**	**A201295**	**001**	Dec 30, 2021
AA		VISTAPHARM	**325MG/15ML;7.5MG/15ML**	**A200343**	**001**	Jan 25, 2012
AA		WES PHARMA INC	**325MG/15ML;7.5MG/15ML**	**A211023**	**001**	Mar 08, 2019
	!	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET;ORAL

ANEXSIA 5/325

AA	**!**	SPECGX LLC	**325MG;5MG**	**A040409**	**001**	Oct 20, 2000

ANEXSIA 7.5/325

AA	**!**	SPECGX LLC	**325MG;7.5MG**	**A040405**	**001**	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ABHAI LLC	**300MG;5MG**	**A209036**	**001**	Jun 21, 2017
AA			**300MG;7.5MG**	**A209036**	**002**	Jun 21, 2017
AA			**300MG;10MG**	**A209036**	**003**	Jun 21, 2017
AA			**325MG;5MG**	**A209037**	**001**	Jun 21, 2017
AA			**325MG;7.5MG**	**A209037**	**002**	Jun 21, 2017
AA			**325MG;10MG**	**A209037**	**003**	Jun 21, 2017
AA		AMNEAL PHARMS	**300MG;10MG**	**A207137**	**001**	Nov 29, 2016
AA		AMNEAL PHARMS NY	**300MG;5MG**	**A206869**	**001**	Jun 23, 2017
AA			**325MG;5MG**	**A040736**	**001**	Aug 25, 2006
AA			**325MG;7.5MG**	**A040746**	**002**	May 10, 2016
AA			**325MG;10MG**	**A040746**	**001**	Aug 25, 2006
AA	**!**	ANDA REPOSITORY	**325MG;2.5MG**	**A040846**	**001**	Jun 09, 2010
AA			**325MG;7.5MG**	**A040432**	**001**	Jan 22, 2003
AA		ASCENT PHARMS INC	**325MG;2.5MG**	**A211487**	**001**	Nov 07, 2018
AA			**325MG;5MG**	**A211487**	**002**	Nov 07, 2018
AA			**325MG;7.5MG**	**A211487**	**003**	Nov 07, 2018
AA			**325MG;10MG**	**A211487**	**004**	Nov 07, 2018
AA		AUROLIFE PHARMA LLC	**300MG;5MG**	**A207709**	**001**	Sep 13, 2018
AA			**300MG;7.5MG**	**A207709**	**002**	Sep 13, 2018
AA			**300MG;10MG**	**A207709**	**003**	Sep 13, 2018
AA			**325MG;5MG**	**A201013**	**001**	Apr 11, 2012
AA			**325MG;7.5MG**	**A201013**	**002**	Apr 11, 2012
AA			**325MG;10MG**	**A201013**	**003**	Apr 11, 2012
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203863**	**001**	Mar 30, 2018
AA			**325MG;7.5MG**	**A203863**	**002**	Mar 30, 2018
AA			**325MG;10MG**	**A203863**	**003**	Mar 30, 2018
AA	**!**	MIKART	**300MG;5MG**	**A040658**	**001**	Jan 19, 2006
AA	**!**		**300MG;7.5MG**	**A040658**	**002**	Mar 24, 2006
AA	**!**		**300MG;10MG**	**A040658**	**003**	Jun 23, 2004
AA		NOVEL LABS INC	**300MG;5MG**	**A206142**	**001**	Nov 14, 2016
AA			**300MG;7.5MG**	**A206142**	**002**	Nov 14, 2016
AA			**300MG;10MG**	**A206142**	**003**	Nov 14, 2016
AA			**325MG;5MG**	**A206245**	**001**	Dec 01, 2016

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA			**325MG;7.5MG**	**A206245**	**002**	Dec 01, 2016
AA			**325MG;10MG**	**A206245**	**003**	Dec 01, 2016
AA		PRINSTON INC	**325MG;5MG**	**A214928**	**001**	Dec 30, 2021
AA			**325MG;7.5MG**	**A214928**	**002**	Dec 30, 2021
AA			**325MG;10MG**	**A214928**	**003**	Dec 30, 2021
AA		RHODES PHARMS	**300MG;5MG**	**A207808**	**001**	Mar 30, 2018
AA			**300MG;7.5MG**	**A207808**	**002**	Mar 30, 2018
AA			**300MG;10MG**	**A207808**	**003**	Mar 30, 2018
AA			**325MG;5MG**	**A202991**	**001**	Apr 12, 2016
AA			**325MG;7.5MG**	**A202991**	**002**	Apr 12, 2016
AA			**325MG;10MG**	**A202991**	**003**	Apr 12, 2016
AA		SPECGX LLC	**300MG;5MG**	**A206718**	**001**	Mar 31, 2017
AA			**300MG;7.5MG**	**A206718**	**002**	Mar 31, 2017
AA			**300MG;10MG**	**A206718**	**003**	Mar 31, 2017
AA	**!**		**325MG;10MG**	**A040400**	**001**	Jul 26, 2000
AA		STRIDES PHARMA	**325MG;5MG**	**A040655**	**001**	Jan 19, 2006
AA			**325MG;5MG**	**A202935**	**002**	Jun 15, 2016
AA			**325MG;7.5MG**	**A040656**	**001**	Jan 19, 2006
AA			**325MG;7.5MG**	**A202935**	**003**	Jun 15, 2016
AA			**325MG;10MG**	**A040355**	**001**	May 31, 2000
AA			**325MG;10MG**	**A202935**	**004**	Jun 15, 2016
AA		SUN PHARM INDS INC	**325MG;5MG**	**A090118**	**001**	Dec 23, 2008
AA			**325MG;7.5MG**	**A090118**	**002**	Dec 23, 2008
AA			**325MG;10MG**	**A090118**	**003**	Dec 23, 2008
AA		TRIS PHARMA INC	**300MG;5MG**	**A202214**	**004**	Mar 15, 2016
AA			**300MG;7.5MG**	**A202214**	**005**	Mar 15, 2016
AA			**300MG;10MG**	**A202214**	**006**	Mar 15, 2016
AA			**325MG;5MG**	**A202214**	**001**	Mar 27, 2013
AA			**325MG;7.5MG**	**A202214**	**002**	Mar 27, 2013
AA			**325MG;10MG**	**A202214**	**003**	Mar 27, 2013
AA		WES PHARMA INC	**300MG;5MG**	**A207509**	**001**	Oct 29, 2018
AA			**300MG;7.5MG**	**A207509**	**002**	Oct 29, 2018
AA			**300MG;10MG**	**A207509**	**003**	Oct 29, 2018
AA			**325MG;5MG**	**A210211**	**001**	Oct 30, 2017
AA			**325MG;7.5MG**	**A210211**	**002**	Oct 30, 2017
AA			**325MG;10MG**	**A210211**	**003**	Oct 30, 2017

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	**!**	ABHAI LLC	**325MG/5ML;5MG/5ML**	**A211499**	**001**	Dec 31, 2018
AA		NOSTRUM LABS INC	**325MG/5ML;5MG/5ML**	**A201448**	**001**	Aug 26, 2021
		MIKART INC	300MG/5ML;10MG/5ML	A202142	001	Nov 27, 2018

TABLET;ORAL

OXYCET

AA		SPECGX LLC	**325MG;5MG**	**A087463**	**001**	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

AA		ABHAI LLC	**325MG;2.5MG**	**A210644**	**001**	Feb 09, 2018
AA			**325MG;5MG**	**A210644**	**002**	Feb 09, 2018
AA			**325MG;7.5MG**	**A210644**	**003**	Feb 09, 2018
AA			**325MG;10MG**	**A210644**	**004**	Feb 09, 2018
AA		ACTAVIS ELIZABETH	**325MG;2.5MG**	**A201447**	**001**	Apr 12, 2013
AA			**325MG;5MG**	**A201447**	**002**	Apr 12, 2013
AA			**325MG;7.5MG**	**A201447**	**003**	Apr 12, 2013
AA			**325MG;10MG**	**A201447**	**004**	Apr 12, 2013
AA		ALVOGEN	**325MG;5MG**	**A202677**	**003**	Mar 08, 2016
AA			**325MG;7.5MG**	**A202677**	**001**	Jul 26, 2012
AA			**325MG;10MG**	**A202677**	**002**	Jul 26, 2012
AA		AMNEAL PHARMS	**325MG;5MG**	**A040777**	**001**	Nov 27, 2007
AA		AMNEAL PHARMS NY	**325MG;7.5MG**	**A040778**	**002**	Jun 27, 2014
AA			**325MG;10MG**	**A040778**	**001**	Nov 27, 2007
AA		ASCENT PHARMS INC	**325MG;2.5MG**	**A207419**	**001**	Mar 22, 2017
AA			**325MG;5MG**	**A207419**	**002**	Mar 22, 2017
AA			**325MG;7.5MG**	**A207419**	**003**	Mar 22, 2017
AA			**325MG;10MG**	**A207419**	**004**	Mar 22, 2017
AA		AUROLIFE PHARMA LLC	**325MG;2.5MG**	**A201972**	**001**	Jul 15, 2013
AA			**325MG;5MG**	**A201972**	**002**	Jul 15, 2013
AA			**325MG;7.5MG**	**A201972**	**003**	Jul 15, 2013
AA			**325MG;10MG**	**A201972**	**004**	Jul 15, 2013
AA		CHARTWELL	**325MG;5MG**	**A207834**	**001**	Aug 15, 2019

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

AA			**325MG;7.5MG**	**A207834**	**002**	Aug 15, 2019
AA			**325MG;10MG**	**A207834**	**003**	Aug 15, 2019
AA		EPIC PHARMA LLC	**325MG;5MG**	**A203864**	**001**	Jul 02, 2018
AA			**325MG;7.5MG**	**A203864**	**002**	Jul 02, 2018
AA			**325MG;10MG**	**A203864**	**003**	Jul 02, 2018
AA		MAYNE PHARMA INC	**325MG;2.5MG**	**A090177**	**001**	Oct 20, 2008
AA			**325MG;5MG**	**A090177**	**002**	Oct 20, 2008
AA			**325MG;7.5MG**	**A090177**	**003**	Oct 20, 2008
AA			**325MG;10MG**	**A090177**	**004**	Oct 20, 2008
AA		NESHER PHARMS	**325MG;2.5MG**	**A210079**	**001**	Dec 28, 2017
AA			**325MG;5MG**	**A210079**	**002**	Dec 28, 2017
AA			**325MG;7.5MG**	**A210079**	**003**	Dec 28, 2017
AA			**325MG;10MG**	**A210079**	**004**	Dec 28, 2017
AA		NOVEL LABS INC	**325MG;2.5MG**	**A204407**	**001**	Feb 24, 2017
AA			**325MG;5MG**	**A204407**	**002**	Feb 24, 2017
AA			**325MG;7.5MG**	**A204407**	**003**	Feb 24, 2017
AA			**325MG;10MG**	**A204407**	**004**	Feb 24, 2017
AA		RHODES PHARMS	**325MG;5MG**	**A201278**	**001**	Aug 28, 2014
AA			**325MG;7.5MG**	**A201278**	**002**	Aug 28, 2014
AA			**325MG;10MG**	**A201278**	**003**	Aug 28, 2014
AA		SPECGX LLC	**325MG;7.5MG**	**A040545**	**001**	Jun 30, 2004
AA			**325MG;10MG**	**A040545**	**002**	Jun 30, 2004
AA		SUN PHARM INDS INC	**325MG;2.5MG**	**A090535**	**001**	Dec 26, 2013
AA			**325MG;5MG**	**A090535**	**002**	Dec 26, 2013
AA			**325MG;7.5MG**	**A090535**	**003**	Dec 26, 2013
AA			**325MG;10MG**	**A090535**	**004**	Dec 26, 2013
AA		WES PHARMA INC	**325MG;5MG**	**A207510**	**001**	Mar 21, 2018
AA			**325MG;7.5MG**	**A207510**	**002**	Mar 21, 2018
AA			**325MG;10MG**	**A207510**	**003**	Mar 21, 2018

PERCOCET

AA	**!**	VINTAGE PHARMS LLC	**325MG;2.5MG**	**A040330**	**001**	Jun 25, 1999
AA	**!**		**325MG;5MG**	**A040330**	**002**	Jun 25, 1999
AA	**!**		**325MG;7.5MG**	**A040330**	**003**	Nov 23, 2001
AA	**!**		**325MG;10MG**	**A040330**	**004**	Nov 23, 2001

OXYCODONE AND ACETAMINOPHEN

	!	MIKART	300MG;2.5MG	A040608	001	Dec 30, 2005
	!		300MG;5MG	A040608	002	Dec 30, 2005
	!		300MG;7.5MG	A040608	003	Dec 30, 2005
	!		300MG;10MG	A040608	004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB		ALKEM LABS LTD	**325MG;37.5MG**	**A202076**	**001**	Mar 30, 2012
AB		AMNEAL PHARMS	**325MG;37.5MG**	**A090485**	**001**	Dec 09, 2009
AB		AUROBINDO PHARMA LTD	**325MG;37.5MG**	**A207152**	**001**	Mar 22, 2017
AB		MICRO LABS LTD INDIA	**325MG;37.5MG**	**A201952**	**001**	Dec 14, 2012
AB		RISING PHARMA	**325MG;37.5MG**	**A077858**	**001**	Sep 26, 2008
AB		SUN PHARM INDS INC	**325MG;37.5MG**	**A077184**	**001**	Dec 16, 2005
AB		ZYDUS PHARMS USA INC	**325MG;37.5MG**	**A090460**	**001**	Sep 06, 2012

ULTRACET

AB	**+!**	JANSSEN PHARMS	**325MG;37.5MG**	**N021123**	**001**	Aug 15, 2001

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB		ACCORD HLTHCARE	**500MG**	**A207659**	**001**	Oct 18, 2018
AB		ALEMBIC PHARMS LTD	**500MG**	**A210423**	**001**	Feb 19, 2019
AB		CADILA	**500MG**	**A205301**	**001**	Jan 16, 2019
AB		HERITAGE PHARMA	**500MG**	**A040904**	**001**	Dec 10, 2008
AB	**!**	INDICUS PHARMA	**500MG**	**A090779**	**001**	Jul 14, 2011
AB		MICRO LABS LTD INDIA	**500MG**	**A207401**	**001**	Oct 01, 2020
AB		NOSTRUM LABS INC	**500MG**	**A204691**	**001**	Mar 29, 2016
AB		NOVAST LABS	**500MG**	**A203434**	**001**	Sep 30, 2016

TABLET;ORAL

ACETAZOLAMIDE

AB		APPCO	**125MG**	**A211372**	**001**	Feb 22, 2021

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

AB			**250MG**	**A211372**	**002**	Feb 22, 2021
AB		BRECKENRIDGE	**125MG**	**A207503**	**001**	Apr 30, 2020
AB			**250MG**	**A207503**	**002**	Apr 30, 2020
AB		EYWA PHARMA	**125MG**	**A211556**	**001**	Oct 18, 2019
AB			**250MG**	**A211556**	**002**	Oct 18, 2019
AB		HERITAGE PHARMA	**125MG**	**A205530**	**001**	Oct 27, 2016
AB			**250MG**	**A205530**	**002**	Oct 27, 2016
AB		LANNETT	**250MG**	**A084840**	**001**	
AB		MANKIND PHARMA	**125MG**	**A214282**	**001**	Oct 07, 2020
AB			**250MG**	**A214282**	**002**	Oct 07, 2020
AB		NOVITIUM PHARMA	**125MG**	**A210588**	**001**	Oct 17, 2019
AB			**250MG**	**A210588**	**002**	Oct 17, 2019
AB		RUBICON	**125MG**	**A215101**	**001**	Aug 19, 2021
AB			**250MG**	**A215101**	**002**	Aug 19, 2021
AB		STRIDES PHARMA	**125MG**	**A209734**	**001**	Nov 20, 2017
AB			**250MG**	**A209734**	**002**	Nov 20, 2017
AB		TARO	**125MG**	**A040195**	**001**	May 28, 1997
AB	**!**		**250MG**	**A040195**	**002**	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP		EMCURE PHARMS LTD	**EQ 500MG BASE/VIAL**	**A202693**	**001**	Dec 19, 2014
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A040089**	**001**	Feb 28, 1995
AP		MYLAN ASI	**EQ 500MG BASE/VIAL**	**A200880**	**001**	May 09, 2012
AP	**!**	XGEN PHARMS	**EQ 500MG BASE/VIAL**	**A040784**	**001**	Dec 10, 2008
AP		ZYDUS PHARMS	**EQ 500MG BASE/VIAL**	**A206533**	**001**	Apr 15, 2019

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	**250MG/100ML**	**N018161**	**001**	
AT		BAXTER HLTHCARE	**250MG/100ML**	**N018523**	**001**	Feb 19, 1982
AT	**+!**	ICU MEDICAL INC	**250MG/100ML**	**N017656**	**001**	

SOLUTION/DROPS;OTIC

ACETIC ACID

AT		RISING	**2%**	**A207280**	**001**	Mar 09, 2018
AT		SAPTALIS PHARMS	**2%**	**A040607**	**001**	Feb 24, 2005
AT		TARO	**2%**	**A088638**	**001**	Sep 06, 1984
AT	**!**	WOCKHARDT BIO AG	**2%**	**A040166**	**001**	Jul 26, 1996

VOSOL

AT		AKORN	**2%**	**N012179**	**001**	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

HYDROCORTISONE AND ACETIC ACID

AT		COSETTE	**2%;1%**	**A040609**	**001**	Feb 06, 2006
AT		TARO PHARM INDS LTD	**2%;1%**	**A088759**	**001**	Mar 04, 1985

VOSOL HC

AT	**+!**	AKORN	**2%;1%**	**N012770**	**001**	

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

	+!	MISSION PHARMA	250MG	N018749	001	May 31, 1983

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

	+!	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTE

AP	**+!**	CUMBERLAND PHARMS	**6GM/30ML (200MG/ML)**	**N021539**	**001**	Jan 23, 2004

ACETYLCYSTEINE

AP		AKORN	**6GM/30ML (200MG/ML)**	**A203173**	**001**	Mar 24, 2015
AP		EUGIA PHARMA	**6GM/30ML (200MG/ML)**	**A207358**	**001**	Feb 29, 2016
AP		EXELA PHARMA	**6GM/30ML (200MG/ML)**	**A204797**	**001**	Apr 15, 2021
AP		FRESENIUS KABI USA	**6GM/30ML (200MG/ML)**	**A200644**	**001**	Nov 07, 2012
AP		SAGENT PHARMS INC	**6GM/30ML (200MG/ML)**	**A091684**	**001**	Oct 31, 2017
AP		ZYDUS PHARMS	**6GM/30ML (200MG/ML)**	**A208166**	**001**	Jul 20, 2018

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN		ALVOGEN	**10%**	**A204674**	**001**	Feb 11, 2014
AN			**20%**	**A203853**	**001**	Jun 21, 2012
AN	**!**	AM REGENT	**10%**	**A072489**	**001**	Jul 28, 1995
AN	**!**		**20%**	**A072547**	**001**	Jul 28, 1995
AN		HOSPIRA	**10%**	**A073664**	**001**	Aug 30, 1994
AN			**20%**	**A074037**	**001**	Aug 30, 1994

ACITRETIN

CAPSULE;ORAL

ACITRETIN

AB		BARR LABS INC	**10MG**	**A091455**	**001**	Apr 04, 2013
AB			**25MG**	**A091455**	**002**	Apr 04, 2013
AB		IMPAX LABS INC	**10MG**	**A202552**	**001**	Dec 23, 2015
AB			**17.5MG**	**A202552**	**002**	Dec 23, 2015
AB			**22.5MG**	**A202552**	**003**	Dec 23, 2015
AB			**25MG**	**A202552**	**004**	Dec 23, 2015
AB		MYLAN	**10MG**	**A202148**	**001**	Sep 10, 2015
AB			**25MG**	**A202148**	**002**	Sep 10, 2015
AB		SIGMAPHARM LABS LLC	**10MG**	**A204633**	**001**	May 22, 2015
AB			**17.5MG**	**A204633**	**002**	May 22, 2015
AB			**22.5MG**	**A204633**	**003**	May 22, 2015
AB	**!**		**25MG**	**A204633**	**004**	May 22, 2015
AB		TEVA PHARMS USA	**17.5MG**	**A202897**	**001**	Apr 04, 2013
AB			**22.5MG**	**A202897**	**002**	Apr 04, 2013

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

	+!	ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

	+!	ASTRAZENECA	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

AB	**!**	APOTEX	**200MG**	**A075677**	**001**	Sep 28, 2005
AB		CADILA	**200MG**	**A204313**	**001**	Mar 25, 2016
AB		CADILA PHARMS LTD	**200MG**	**A201445**	**001**	Mar 06, 2014
AB		CARLSBAD TECHNOLOGY	**200MG**	**A206261**	**001**	Aug 16, 2017
AB		HERITAGE PHARMS INC	**200MG**	**A074889**	**001**	Oct 31, 1997
AB		KENTON	**200MG**	**A075090**	**001**	Jan 26, 1999
AB		TEVA	**200MG**	**A074578**	**001**	Apr 22, 1997
AB		YILING	**200MG**	**A212173**	**001**	Sep 14, 2020

CREAM;TOPICAL

ACYCLOVIR

AB		AMNEAL	**5%**	**A208766**	**001**	Nov 09, 2020
AB	**!**	PADAGIS ISRAEL	**5%**	**A208702**	**001**	Feb 04, 2019

ZOVIRAX

AB	**+**	BAUSCH	**5%**	**N021478**	**001**	Dec 30, 2002

OINTMENT;TOPICAL

ACYCLOVIR

AB		ALEMBIC PHARMS LTD	**5%**	**A209000**	**001**	Apr 06, 2018
AB		AMNEAL PHARMS	**5%**	**A204605**	**001**	Jun 18, 2014
AB		APOTEX	**5%**	**A210774**	**001**	Sep 06, 2019
AB		CADILA	**5%**	**A205974**	**001**	Mar 15, 2019
AB		CIPLA	**5%**	**A211794**	**001**	Jan 18, 2019
AB		COSETTE	**5%**	**A205591**	**001**	Nov 13, 2017
AB		FOUGERA PHARMS INC	**5%**	**A206633**	**001**	May 11, 2016
AB		GLENMARK PHARMS SA	**5%**	**A205510**	**001**	Jul 31, 2017
AB		MACLEODS PHARMS LTD	**5%**	**A212444**	**001**	May 19, 2021
AB		MYLAN PHARMS INC	**5%**	**A202459**	**001**	Apr 03, 2013
AB		PRINSTON INC	**5%**	**A212202**	**001**	Nov 15, 2021
AB		SOLARIS PHARMA CORP	**5%**	**A212495**	**001**	Apr 07, 2020
AB		TARO	**5%**	**A205469**	**001**	Dec 21, 2016
AB		TORRENT	**5%**	**A209971**	**001**	Jan 11, 2019
AB		XIROMED	**5%**	**A201501**	**001**	Jan 29, 2020

ZOVIRAX

AB	**+!**	BAUSCH	**5%**	**N018604**	**001**	Mar 29, 1982

ACYCLOVIR						
SUSPENSION;ORAL						
ACYCLOVIR						
AB		ACTAVIS MID ATLANTIC	**200MG/5ML**	**A074738**	**001**	Apr 28, 1997
AB		AKORN	**200MG/5ML**	**A077026**	**001**	Jun 07, 2005
AB		HERITAGE PHARMS INC	**200MG/5ML**	**A212718**	**001**	Apr 23, 2020
AB		NOVITIUM PHARMA	**200MG/5ML**	**A212252**	**001**	Jul 10, 2020
AB		VISTAPHARM	**200MG/5ML**	**A213951**	**001**	Jan 11, 2021
ZOVIRAX						
AB	**+!**	MYLAN	**200MG/5ML**	**N019909**	**001**	Dec 22, 1989
TABLET;BUCCAL						
SITAVIG						
	+!	EPI HLTH	50MG	N203791	001	Apr 12, 2013
TABLET;ORAL						
ACYCLOVIR						
AB		APOTEX INC	**400MG**	**A077309**	**001**	Sep 29, 2005
AB			**800MG**	**A077309**	**002**	Sep 29, 2005
AB		CADILA PHARMS LTD	**400MG**	**A202168**	**001**	Nov 15, 2013
AB			**800MG**	**A202168**	**002**	Nov 15, 2013
AB		CARLSBAD	**400MG**	**A075382**	**001**	Apr 30, 1999
AB			**800MG**	**A075382**	**002**	Apr 30, 1999
AB		HERITAGE PHARMS INC	**400MG**	**A074891**	**001**	Oct 31, 1997
AB			**800MG**	**A074891**	**002**	Oct 31, 1997
AB		HETERO LABS LTD V	**400MG**	**A203834**	**001**	Oct 29, 2013
AB	**!**		**800MG**	**A203834**	**002**	Oct 29, 2013
AB		SQUARE PHARMS	**400MG**	**A209366**	**001**	Oct 07, 2019
AB			**800MG**	**A209366**	**002**	Oct 07, 2019
AB		STRIDES PHARMA	**400MG**	**A074946**	**001**	Nov 19, 1997
AB			**800MG**	**A074946**	**002**	Nov 19, 1997
AB		TEVA	**400MG**	**A074556**	**002**	Apr 22, 1997
AB			**800MG**	**A074556**	**003**	Apr 22, 1997
AB		YILING	**400MG**	**A210401**	**001**	Mar 07, 2018
AB			**800MG**	**A210401**	**002**	Mar 07, 2018
AB		ZYDUS PHARMS	**400MG**	**A204314**	**001**	Aug 19, 2014
AB			**800MG**	**A204314**	**002**	Aug 19, 2014
ACYCLOVIR SODIUM						
INJECTABLE;INJECTION						
ACYCLOVIR SODIUM						
AP		EUGIA PHARMA	**EQ 50MG BASE/ML**	**A203701**	**001**	Oct 11, 2013
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074930**	**001**	May 13, 1998
AP		NAMIGEN LLC	**EQ 50MG BASE/ML**	**A207919**	**001**	Jun 17, 2020
AP		ZYDUS PHARMS	**EQ 50MG BASE/ML**	**A206535**	**001**	Aug 31, 2018
ACYCLOVIR; HYDROCORTISONE						
CREAM;TOPICAL						
XERESE						
	+!	BAUSCH	5%;1%	N022436	001	Jul 31, 2009
ADAPALENE						
CREAM;TOPICAL						
ADAPALENE						
AB		FOUGERA PHARMS	**0.1%**	**A090824**	**001**	Jun 30, 2010
DIFFERIN						
AB	**+!**	GALDERMA LABS LP	**0.1%**	**N020748**	**001**	May 26, 2000
GEL;TOPICAL						
ADAPALENE						
AB		ACTAVIS MID ATLANTIC	**0.3%**	**A201000**	**001**	Oct 27, 2014
AB		ALEOR DERMACEUTICALS	**0.3%**	**A213508**	**001**	Jun 18, 2020
AB		TARO	**0.3%**	**A208322**	**001**	Jun 23, 2016
DIFFERIN						
AB	**+!**	GALDERMA LABS LP	**0.3%**	**N021753**	**001**	Jun 19, 2007
LOTION;TOPICAL						
DIFFERIN						
	+!	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010
SOLUTION;TOPICAL						
ADAPALENE						
AB		CALL INC	**0.1%**	**A203981**	**001**	Sep 23, 2016
AB			**0.1%**	**A204593**	**001**	Jan 05, 2016

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB		ACTAVIS MID ATLANTIC	**0.1%;2.5%**	**A203790**	**001**	Sep 30, 2015
AB		GLENMARK PHARMS LTD	**0.1%;2.5%**	**A208108**	**001**	Nov 08, 2019
AB		PADAGIS ISRAEL	**0.1%;2.5%**	**A205033**	**001**	Jan 23, 2018
AB		TARO	**0.1%;2.5%**	**A206959**	**001**	Jan 24, 2018
AB			**0.3%;2.5%**	**A209148**	**001**	Oct 17, 2018

EPIDUO

AB	**+!**	GALDERMA LABS LP	**0.1%;2.5%**	**N022320**	**001**	Dec 08, 2008

EPIDUO FORTE

AB	**+!**	GALDERMA LABS	**0.3%;2.5%**	**N207917**	**001**	Jul 15, 2015

ADEFOVIR DIPIVOXIL

TABLET;ORAL

ADEFOVIR DIPIVOXIL

AB		APOTEX	**10MG**	**A205459**	**001**	Jul 06, 2018
AB		SIGMAPHARM LABS LLC	**10MG**	**A202051**	**001**	Aug 29, 2013

HEPSERA

AB	**+!**	GILEAD	**10MG**	**N021449**	**001**	Sep 20, 2002

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP	**!**	AKORN	**3MG/ML**	**A078076**	**001**	Oct 31, 2008
AP		FRESENIUS KABI USA	**3MG/ML**	**A077133**	**001**	Apr 27, 2005
AP			**3MG/ML**	**A205568**	**001**	Apr 16, 2018
AP		GLAND PHARMA LTD	**3MG/ML**	**A077283**	**001**	Jun 14, 2007
AP			**3MG/ML**	**A206778**	**001**	Feb 16, 2018
AP		HIKMA	**3MG/ML**	**A076404**	**001**	Jun 16, 2004
AP			**3MG/ML**	**A076500**	**001**	Jun 16, 2004
AP		MYLAN LABS LTD	**3MG/ML**	**A078686**	**001**	May 13, 2009

SOLUTION;INTRAVENOUS

ADENOSINE

AP		AKORN	**60MG/20ML (3MG/ML)**	**A090450**	**001**	Oct 02, 2014
AP			**90MG/30ML (3MG/ML)**	**A090450**	**002**	Oct 02, 2014
AP		EMCURE PHARMS LTD	**60MG/20ML (3MG/ML)**	**A202313**	**001**	Sep 15, 2014
AP			**90MG/30ML (3MG/ML)**	**A202313**	**002**	Sep 15, 2014
AP		EUGIA PHARMA	**60MG/20ML (3MG/ML)**	**A205331**	**001**	Nov 02, 2017
AP			**90MG/30ML (3MG/ML)**	**A205331**	**002**	Nov 02, 2017
AP		FRESENIUS KABI USA	**60MG/20ML (3MG/ML)**	**A077897**	**001**	Nov 27, 2017
AP			**90MG/30ML (3MG/ML)**	**A077897**	**002**	Nov 27, 2017
AP		HOSPIRA INC	**60MG/20ML (3MG/ML)**	**A203883**	**001**	Mar 24, 2014
AP			**90MG/30ML (3MG/ML)**	**A203883**	**002**	Mar 24, 2014
AP		MYLAN ASI	**60MG/20ML (3MG/ML)**	**A090212**	**001**	Mar 28, 2014
AP			**90MG/30ML (3MG/ML)**	**A090212**	**002**	Mar 28, 2014
AP	**!**	TEVA PHARMS USA	**60MG/20ML (3MG/ML)**	**A077425**	**001**	Aug 29, 2013
AP	**!**		**90MG/30ML (3MG/ML)**	**A077425**	**002**	Aug 29, 2013

AFAMELANOTIDE

IMPLANT;SUBCUTANEOUS

SCENESSE

	+!	CLIVUNEL INC	16MG	N210797	001	Oct 08, 2019

AFATINIB DIMALEATE

TABLET;ORAL

GILOTRIF

	+	BOEHRINGER INGELHEIM	EQ 20MG BASE	N201292	001	Jul 12, 2013
	+		EQ 30MG BASE	N201292	002	Jul 12, 2013
	+!		EQ 40MG BASE	N201292	003	Jul 12, 2013

AIR POLYMER-TYPE A

FOAM;INTRAUTERINE

EXEM FOAM KIT

	+!	GISKIT	10ML	N212279	001	Nov 07, 2019

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

AB		ACTAVIS ELIZABETH	**200MG**	**A208094**	**001**	May 20, 2019
AB		CIPLA LTD	**200MG**	**A210434**	**001**	Sep 21, 2018
AB		DR REDDYS	**200MG**	**A211034**	**001**	Jan 26, 2021
AB		EDENBRIDGE PHARMS	**200MG**	**A211117**	**001**	May 14, 2019
AB		MSN	**200MG**	**A213435**	**001**	Jan 21, 2021

ALBENDAZOLE						
TABLET;ORAL						
ALBENDAZOLE						
AB		STRIDES PHARMA	**200MG**	**A210011**	**001**	Dec 07, 2018
AB		ZYDUS PHARMS	**200MG**	**A208979**	**001**	Dec 14, 2018
ALBENZA						
AB	**+!**	IMPAX LABS INC	**200MG**	**N020666**	**001**	Jun 11, 1996
ALBUMIN HUMAN						
INJECTABLE;INJECTION						
OPTISON						
	+!	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997
ALBUTEROL SULFATE						
AEROSOL, METERED;INHALATION						
ALBUTEROL SULFATE						
AB1		CIPLA	**EQ 0.09MG BASE/INH**	**A209959**	**001**	Apr 08, 2020
AB1		SANDOZ INC	**EQ 0.09MG BASE/INH**	**A207085**	**001**	Jun 01, 2021
PROVENTIL-HFA						
AB1	**+!**	KINDEVA	**EQ 0.09MG BASE/INH**	**N020503**	**001**	Aug 15, 1996
ALBUTEROL SULFATE						
AB2		LUPIN	**EQ 0.09MG BASE/INH**	**A209954**	**001**	Aug 24, 2020
PROAIR HFA						
AB2	**+!**	TEVA BRANDED PHARM	**EQ 0.09MG BASE/INH**	**N021457**	**001**	Oct 29, 2004
VENTOLIN HFA						
BX	+!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001
POWDER, METERED;INHALATION						
PROAIR DIGIHALER						
	+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018
PROAIR RESPICLICK						
	+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015
SOLUTION;INHALATION						
ACCUNEB						
AN	**+!**	MYLAN SPECIALITY LP	**EQ 0.021% BASE**	**N020949**	**002**	Apr 30, 2001
AN	**+!**		**EQ 0.042% BASE**	**N020949**	**001**	Apr 30, 2001
ALBUTEROL SULFATE						
AN		AKORN	**EQ 0.5% BASE**	**A074543**	**001**	Jan 15, 1998
AN		LUOXIN AUROVITAS	**EQ 0.083% BASE**	**A206224**	**001**	Oct 17, 2017
AN		NEPHRON	**EQ 0.021% BASE**	**A076355**	**002**	Mar 31, 2010
AN			**EQ 0.042% BASE**	**A076355**	**001**	Jun 28, 2004
AN	**!**		**EQ 0.083% BASE**	**A074880**	**001**	Sep 17, 1997
AN	**!**		**EQ 0.5% BASE**	**A075664**	**001**	Jun 26, 2001
AN		RITEDOSE CORP	**EQ 0.021% BASE**	**A214531**	**001**	Dec 28, 2021
AN			**EQ 0.042% BASE**	**A214531**	**002**	Dec 28, 2021
AN			**EQ 0.083% BASE**	**A077839**	**001**	Dec 16, 2008
AN		SUN PHARM	**EQ 0.083% BASE**	**A207857**	**001**	Jul 21, 2017
AN		WATSON LABS	**EQ 0.021% BASE**	**A077772**	**001**	Sep 25, 2007
AN			**EQ 0.042% BASE**	**A077772**	**002**	Sep 25, 2007
SYRUP;ORAL						
ALBUTEROL SULFATE						
AA		AKORN	**EQ 2MG BASE/5ML**	**A074749**	**001**	Jan 30, 1998
AA		AMNEAL PHARMS	**EQ 2MG BASE/5ML**	**A079241**	**001**	May 12, 2010
AA		COSETTE	**EQ 2MG BASE/5ML**	**A074454**	**001**	Sep 25, 1995
AA		LANNETT CO INC	**EQ 2MG BASE/5ML**	**A078105**	**001**	Dec 27, 2006
AA		QUAGEN	**EQ 2MG BASE/5ML**	**A212197**	**001**	Sep 06, 2019
AA	**!**	TEVA	**EQ 2MG BASE/5ML**	**A073419**	**001**	Mar 30, 1992
TABLET;ORAL						
ALBUTEROL SULFATE						
AB		AMNEAL PHARMS CO	**EQ 2MG BASE**	**A208804**	**001**	May 21, 2018
AB			**EQ 4MG BASE**	**A208804**	**002**	May 21, 2018
AB		APPCO	**EQ 2MG BASE**	**A210948**	**001**	Mar 15, 2019
AB			**EQ 4MG BASE**	**A210948**	**002**	Mar 15, 2019
AB		MYLAN	**EQ 2MG BASE**	**A072894**	**002**	Jan 17, 1991
AB	**!**		**EQ 4MG BASE**	**A072894**	**001**	Jan 17, 1991
AB		RISING	**EQ 2MG BASE**	**A207046**	**001**	Jun 29, 2018
AB			**EQ 4MG BASE**	**A207046**	**002**	Jun 29, 2018
AB		SUN PHARM INDUSTRIES	**EQ 2MG BASE**	**A072637**	**002**	Dec 05, 1989
AB			**EQ 4MG BASE**	**A072637**	**001**	Dec 05, 1989
AB		VIRTUS PHARM	**EQ 2MG BASE**	**A211397**	**001**	Oct 26, 2018
AB			**EQ 4MG BASE**	**A211397**	**002**	Oct 26, 2018
AB		ZYDUS PHARMS	**EQ 2MG BASE**	**A208884**	**001**	Oct 22, 2020
AB			**EQ 4MG BASE**	**A208884**	**002**	Oct 22, 2020

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE;ORAL

VOSPIRE ER

		STRIDES PHARMA	EQ 4MG BASE	A076130	002	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		CIPLA	**EQ 0.083% BASE;0.017%**	**A077559**	**001**	Dec 31, 2007
AN	**!**	NEPHRON	**EQ 0.083% BASE;0.017%**	**A076749**	**001**	Dec 31, 2007
AN		RITEDOSE CORP	**EQ 0.083% BASE;0.017%**	**A202496**	**001**	Oct 01, 2012
AN		SUN PHARM	**EQ 0.083% BASE;0.017%**	**A207875**	**001**	Aug 07, 2017

SPRAY, METERED;INHALATION

COMBIVENT RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH;0.02MG/INH	N021747	001	Oct 07, 2011

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**0.05%**	**A076973**	**001**	Jul 12, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079061**	**001**	Jun 23, 2009
AB		TARO	**0.05%**	**A076587**	**001**	Sep 15, 2005

OINTMENT;TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**0.05%**	**A076884**	**001**	Jul 18, 2005
AB		GLENMARK GENERICS	**0.05%**	**A079227**	**001**	Jul 30, 2009
AB		TARO	**0.05%**	**A076730**	**001**	Jul 29, 2004

ALCOHOL

SOLUTION;INTRA-ARTERIAL

ABLYSINOL

	+	BELCHER	99% (1ML)	N207987	001	Jun 21, 2018
	+!		99% (5ML)	N207987	002	Jun 21, 2018

ALECTINIB HYDROCHLORIDE

CAPSULE;ORAL

ALECENSA

	+!	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434	001	Dec 11, 2015

ALENDRONATE SODIUM

SOLUTION;ORAL

ALENDRONATE SODIUM

	!	HIKMA	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013

TABLET;ORAL

ALENDRONATE SODIUM

AB		APOTEX	**EQ 5MG BASE**	**A077982**	**001**	Aug 04, 2008
AB			**EQ 10MG BASE**	**A077982**	**002**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A077982**	**003**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A077982**	**004**	Aug 04, 2008
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A090124**	**001**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A090124**	**002**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A090124**	**003**	Aug 04, 2008
AB		CIPLA	**EQ 5MG BASE**	**A076768**	**001**	Aug 04, 2008
AB			**EQ 10MG BASE**	**A076768**	**002**	Aug 04, 2008
AB			**EQ 35MG BASE**	**A076768**	**003**	Aug 04, 2008
AB			**EQ 40MG BASE**	**A076768**	**004**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A076768**	**005**	Aug 04, 2008
AB		HANGZHOU BINJIANG	**EQ 5MG BASE**	**A090258**	**001**	Sep 24, 2009
AB			**EQ 10MG BASE**	**A090258**	**002**	Sep 24, 2009
AB			**EQ 35MG BASE**	**A090258**	**003**	Sep 24, 2009
AB			**EQ 70MG BASE**	**A090258**	**004**	Sep 24, 2009
AB		SUN PHARM	**EQ 5MG BASE**	**A090022**	**001**	Sep 10, 2008
AB			**EQ 10MG BASE**	**A090022**	**002**	Sep 10, 2008
AB			**EQ 35MG BASE**	**A090022**	**003**	Sep 10, 2008
AB			**EQ 70MG BASE**	**A090022**	**004**	Sep 10, 2008
AB		WATSON LABS	**EQ 35MG BASE**	**A076984**	**001**	Aug 04, 2008
AB			**EQ 40MG BASE**	**A076984**	**002**	Aug 04, 2008
AB			**EQ 70MG BASE**	**A076984**	**003**	Aug 04, 2008

FOSAMAX

AB	**+!**	MERCK AND CO INC	**EQ 70MG BASE**	**N020560**	**005**	Oct 20, 2000

TABLET, EFFERVESCENT;ORAL

BINOSTO

	+!	ASCEND THERAPS US	EQ 70MG BASE	N202344	001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

+	ORGANON	EQ 70MG BASE;2,800 IU	N021762	001	Apr 07, 2005
+!		EQ 70MG BASE;5,600 IU	N021762	002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION

ALFENTA

AP	**+!**	AKORN	**EQ 0.5MG BASE/ML**	**N019353**	**001**	Dec 29, 1986

ALFENTANIL

AP		HOSPIRA	**EQ 0.5MG BASE/ML**	**A075221**	**001**	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

AB		APOTEX INC	**10MG**	**A079013**	**001**	Jul 18, 2011
AB		AUROBINDO PHARMA LTD	**10MG**	**A079060**	**001**	Aug 30, 2012
AB		INVAGEN PHARMS	**10MG**	**A090284**	**001**	Jan 17, 2012
AB		SUN PHARM	**10MG**	**A079057**	**001**	Jul 18, 2011
AB		UNICHEM	**10MG**	**A203192**	**001**	Jan 28, 2016

UROXATRAL

AB	**+!**	CONCORDIA	**10MG**	**N021287**	**001**	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET;ORAL

ALISKIREN HEMIFUMARATE

AB		ANCHEN PHARMS	**EQ 150MG BASE**	**A206665**	**001**	Mar 22, 2019
AB			**EQ 300MG BASE**	**A206665**	**002**	Mar 22, 2019

TEKTURNA

AB	**+**	NODEN PHARMA	**EQ 150MG BASE**	**N021985**	**001**	Mar 05, 2007
AB	**+!**		**EQ 300MG BASE**	**N021985**	**002**	Mar 05, 2007

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

+!	NODEN PHARMA	EQ 300MG BASE;12.5MG	N022107	003	Jan 18, 2008
+!		EQ 300MG BASE;25MG	N022107	004	Jan 18, 2008

ALITRETINOIN

GEL;TOPICAL

PANRETIN

+!	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB		ACCORD HLTHCARE	**100MG**	**A203154**	**001**	May 06, 2013
AB			**300MG**	**A203154**	**002**	May 06, 2013
AB		CHARTWELL	**100MG**	**A077353**	**001**	Sep 08, 2005
AB			**300MG**	**A077353**	**002**	Sep 08, 2005
AB		INDOCO	**100MG**	**A204467**	**001**	Jul 28, 2016
AB			**300MG**	**A204467**	**002**	Jul 28, 2016
AB		IPCA LABS LTD	**100MG**	**A090637**	**001**	Mar 16, 2011
AB			**300MG**	**A090637**	**002**	Mar 16, 2011
AB		MYLAN	**100MG**	**A018659**	**001**	Oct 24, 1986
AB			**300MG**	**A018659**	**002**	Oct 24, 1986
AB		NORTHSTAR HLTHCARE	**100MG**	**A078253**	**001**	Sep 11, 2007
AB			**300MG**	**A078253**	**002**	Sep 11, 2007
AB		SUN PHARM INDUSTRIES	**100MG**	**A071450**	**002**	Jan 09, 1987
AB			**300MG**	**A071450**	**001**	Jan 09, 1987
AB		UNICHEM	**100MG**	**A211820**	**001**	Mar 12, 2019
AB			**300MG**	**A211820**	**002**	Mar 12, 2019
AB		VINTAGE PHARMS	**100MG**	**A075798**	**001**	Jun 27, 2003
AB			**300MG**	**A075798**	**002**	Jun 27, 2003
AB		WATSON LABS	**100MG**	**N018832**	**002**	Sep 28, 1984
AB			**300MG**	**N018877**	**001**	Sep 28, 1984
AB		ZYDUS PHARMS	**100MG**	**A210117**	**001**	Oct 12, 2017
AB			**300MG**	**A210117**	**002**	Oct 12, 2017

LOPURIN

AB		DR REDDYS LA	**100MG**	**A071586**	**001**	Apr 02, 1987
AB			**300MG**	**A071587**	**001**	Apr 02, 1987

ALLOPURINOL

TABLET;ORAL

ZYLOPRIM

AB	**+**	CASPER PHARMA LLC	**100MG**	**N016084**	**001**	
AB	**+!**		**300MG**	**N016084**	**002**	

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

ALLOPURINOL SODIUM

AP		HIKMA	**EQ 500MG BASE/VIAL**	**A076870**	**001**	Aug 26, 2004

ALOPRIM

AP	**+!**	MYLAN INSTITUTIONAL	**EQ 500MG BASE/VIAL**	**N020298**	**001**	May 17, 1996

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB		AJANTA PHARMA LTD	**EQ 6.25MG BASE**	**A205523**	**001**	Mar 03, 2016
AB	**!**		**EQ 12.5MG BASE**	**A205523**	**002**	Mar 03, 2016
AB		MYLAN	**EQ 6.25MG BASE**	**A205171**	**001**	Nov 09, 2015
AB			**EQ 12.5MG BASE**	**A205171**	**002**	Nov 09, 2015
AB		TEVA PHARMS USA	**EQ 6.25MG BASE**	**A078027**	**001**	Jul 07, 2015
AB			**EQ 12.5MG BASE**	**A078027**	**002**	Jul 07, 2015

ALOGLIPTIN BENZOATE

TABLET;ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+!		EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;500MG	N203414	001	Jan 25, 2013
+!		EQ 12.5MG BASE;1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 30MG BASE	N022426	005	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013
+		EQ 25MG BASE;EQ 15MG BASE	N022426	001	Jan 25, 2013
+		EQ 25MG BASE;EQ 30MG BASE	N022426	002	Jan 25, 2013
+!		EQ 25MG BASE;EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		AMNEAL PHARMS	**EQ 0.5MG BASE**	**A206647**	**001**	Dec 22, 2016
AB			**EQ 1MG BASE**	**A206647**	**002**	Dec 22, 2016
AB		HIKMA	**EQ 0.5MG BASE**	**A200652**	**001**	May 04, 2015
AB			**EQ 1MG BASE**	**A200652**	**002**	May 04, 2015
AB		MANKIND PHARMA	**EQ 0.5MG BASE**	**A213614**	**001**	Sep 09, 2020
AB			**EQ 1MG BASE**	**A213614**	**002**	Sep 09, 2020
AB		PAR PHARM INC	**EQ 0.5MG BASE**	**A206113**	**001**	Feb 23, 2018
AB			**EQ 1MG BASE**	**A206113**	**002**	Feb 23, 2018
AB		RISING	**EQ 0.5MG BASE**	**A209180**	**001**	Jan 14, 2019
AB			**EQ 1MG BASE**	**A209180**	**002**	Jan 14, 2019

LOTRONEX

AB	**+**	SEBELA IRELAND LTD	**EQ 0.5MG BASE**	**N021107**	**002**	Dec 23, 2003
AB	**+!**		**EQ 1MG BASE**	**N021107**	**001**	Feb 09, 2000

ALPELISIB

TABLET;ORAL

PIQRAY

+	NOVARTIS	50MG	N212526	001	May 24, 2019
+		150MG	N212526	002	May 24, 2019
+!		200MG	N212526	003	May 24, 2019

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION;INTRAVENOUS

INFUVITE ADULT

+!	SANDOZ CANADA INC	2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N021163	001	May 18, 2000
+!		2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML	N021163	002	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE;ORAL

ALPRAZOLAM

!	HIKMA	1MG/ML	A074312	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	**0.25MG**	**A074342**	**001**	Oct 31, 1993
AB		**0.5MG**	**A074342**	**002**	Oct 31, 1993
AB		**1MG**	**A074342**	**003**	Oct 31, 1993
AB		**2MG**	**A074342**	**004**	Oct 31, 1993
AB	APOTEX INC	**0.25MG**	**A077741**	**001**	Jan 19, 2007
AB		**0.5MG**	**A077741**	**002**	Jan 19, 2007
AB		**1MG**	**A077741**	**003**	Jan 19, 2007
AB		**2MG**	**A077741**	**004**	Jan 19, 2007
AB	AUROBINDO PHARMA LTD	**0.25MG**	**A203346**	**001**	Jul 31, 2015
AB		**0.5MG**	**A203346**	**002**	Jul 31, 2015
AB		**1MG**	**A203346**	**003**	Jul 31, 2015
AB		**2MG**	**A203346**	**004**	Jul 31, 2015
AB	BRECKENRIDGE	**0.25MG**	**A207507**	**001**	Jul 09, 2018
AB		**0.5MG**	**A207507**	**002**	Jul 09, 2018
AB		**1MG**	**A207507**	**003**	Jul 09, 2018
AB		**2MG**	**A207507**	**004**	Jul 09, 2018
AB	NATCO	**0.25MG**	**A200739**	**001**	Apr 15, 2015
AB		**0.5MG**	**A200739**	**002**	Apr 15, 2015
AB		**1MG**	**A200739**	**003**	Apr 15, 2015
AB		**2MG**	**A200739**	**004**	Apr 15, 2015
AB	NOVITIUM PHARMA	**0.25MG**	**A074174**	**001**	Oct 19, 1993
AB		**0.5MG**	**A074174**	**002**	Oct 19, 1993
AB		**1MG**	**A074174**	**003**	Oct 19, 1993
AB		**2MG**	**A074174**	**004**	Oct 19, 1993
AB	SANDOZ	**0.25MG**	**A074112**	**001**	Dec 29, 1995
AB		**0.5MG**	**A074112**	**002**	Dec 29, 1995
AB		**1MG**	**A074112**	**003**	Dec 29, 1995
AB		**2MG**	**A074909**	**001**	Mar 25, 1998
AB	STRIDES PHARMA	**0.25MG**	**A090248**	**001**	Sep 17, 2010
AB		**0.5MG**	**A090248**	**002**	Sep 17, 2010
AB		**1MG**	**A090248**	**003**	Sep 17, 2010
AB		**2MG**	**A090248**	**004**	Sep 17, 2010
AB	SUN PHARM	**0.25MG**	**A090082**	**001**	Jun 17, 2010
AB		**0.5MG**	**A090082**	**002**	Jun 17, 2010
AB		**1MG**	**A090082**	**003**	Jun 17, 2010
AB		**2MG**	**A090082**	**004**	Jun 17, 2010

XANAX

AB +	UPJOHN	**0.25MG**	**N018276**	**001**	
AB +		**0.5MG**	**N018276**	**002**	
AB +!		**1MG**	**N018276**	**003**	
AB +		**2MG**	**N018276**	**004**	Nov 27, 1985

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	**0.5MG**	**A078056**	**001**	Feb 13, 2007
AB		**1MG**	**A078056**	**002**	Feb 13, 2007
AB		**2MG**	**A078056**	**003**	Feb 13, 2007
AB		**3MG**	**A078056**	**004**	Feb 13, 2007
AB	AMNEAL PHARMS NY	**0.5MG**	**A078387**	**001**	May 30, 2008
AB		**1MG**	**A078387**	**002**	May 30, 2008
AB		**2MG**	**A078387**	**003**	May 30, 2008
AB		**3MG**	**A078387**	**004**	May 30, 2008
AB	ANCHEN PHARMS	**0.5MG**	**A078469**	**001**	Sep 29, 2011
AB		**1MG**	**A078469**	**002**	Sep 29, 2011

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB			**2MG**	**A078469**	**003**	Sep 29, 2011
AB			**3MG**	**A078469**	**004**	Sep 29, 2011
AB		APOTEX INC	**0.5MG**	**A078449**	**001**	Nov 12, 2008
AB			**1MG**	**A078449**	**004**	Dec 23, 2015
AB			**2MG**	**A078449**	**002**	Nov 12, 2008
AB			**3MG**	**A078449**	**003**	Nov 12, 2008
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A090871**	**001**	Jun 07, 2011
AB			**1MG**	**A090871**	**002**	Jun 07, 2011
AB			**2MG**	**A090871**	**003**	Jun 07, 2011
AB			**3MG**	**A090871**	**004**	Jun 07, 2011

XANAX XR

AB	**+**	UPJOHN	**0.5MG**	**N021434**	**001**	Jan 17, 2003
AB	**+**		**1MG**	**N021434**	**002**	Jan 17, 2003
AB	**+**		**2MG**	**N021434**	**003**	Jan 17, 2003
AB	**+!**		**3MG**	**N021434**	**004**	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

AB		ACTAVIS ELIZABETH	**0.25MG**	**A078561**	**001**	Mar 16, 2010
AB			**0.5MG**	**A078561**	**002**	Mar 16, 2010
AB			**1MG**	**A078561**	**003**	Mar 16, 2010
AB			**2MG**	**A078561**	**004**	Mar 16, 2010
AB		PAR PHARM	**0.25MG**	**A078088**	**001**	Jan 09, 2009
AB			**0.5MG**	**A078088**	**002**	Jan 09, 2009
AB	**!**		**1MG**	**A078088**	**003**	Jan 09, 2009
AB			**2MG**	**A078088**	**004**	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

AP		HIKMA	**0.5MG/ML**	**A074815**	**001**	Jan 20, 1998
AP		TEVA PHARMS USA	**0.5MG/ML**	**A075196**	**001**	Apr 30, 1999

CAVERJECT

AP	**+**	PFIZER	**0.01MG/VIAL**	**N020379**	**001**	Jul 06, 1995
AP	**+!**		**0.02MG/VIAL**	**N020379**	**002**	Jul 06, 1995
AP	**+!**		**0.04MG/VIAL**	**N020379**	**004**	May 19, 1997

EDEX

AP	**+**	AUXILIUM PHARMS LLC	**0.01MG/VIAL**	**N020649**	**002**	Jun 12, 1997
AP	**+**		**0.02MG/VIAL**	**N020649**	**003**	Jun 12, 1997
AP	**+!**		**0.04MG/VIAL**	**N020649**	**004**	Jun 12, 1997

PROSTIN VR PEDIATRIC

AP	**+!**	PFIZER	**0.5MG/ML**	**N018484**	**001**	

CAVERJECT IMPULSE

		PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002
			0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

	+!	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+!		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+!		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY;URETHRAL

MUSE

	+!	MYLAN SPECIALITY LP	0.125MG	N020700	001	Nov 19, 1996
	+!		0.25MG	N020700	002	Nov 19, 1996
	+!		0.5MG	N020700	003	Nov 19, 1996
	+!		1MG	N020700	004	Nov 19, 1996

ALVIMOPAN

CAPSULE;ORAL

ALVIMOPAN

AB		WATSON LABS TEVA	**12MG**	**A208295**	**001**	Dec 19, 2019

ENTEREG

AB	**+!**	CUBIST PHARMS	**12MG**	**N021775**	**001**	May 20, 2008

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**100MG**	**A208966**	**001**	Jun 21, 2017
AB	**!**	BIONPHARMA INC	**100MG**	**A078720**	**001**	May 29, 2008
AB		HERITAGE PHARMA	**100MG**	**A209171**	**001**	Jun 12, 2017
AB		NOVELGENIX THERAPS	**100MG**	**A210129**	**001**	Mar 02, 2020
AB		RUBICON	**100MG**	**A212044**	**001**	May 21, 2020

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB		SANDOZ	**100MG**	**A071293**	**001**	Feb 18, 1987
AB		UPSHER SMITH LABS	**100MG**	**A070589**	**001**	Aug 05, 1986
AB		WATSON LABS INC	**100MG**	**A208107**	**001**	Dec 06, 2016
AB		ZYDUS PHARMS	**100MG**	**A208278**	**001**	May 31, 2016
BX		STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

	+	ADAMAS PHARMA	EQ 68.5MG BASE	N208944	001	Aug 24, 2017
	+!		EQ 137MG BASE	N208944	002	Aug 24, 2017

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

AA	**!**	AKORN	**50MG/5ML**	**A074170**	**001**	Oct 28, 1994
AA	**!**	ANDA REPOSITORY	**50MG/5ML**	**A074028**	**001**	Jun 28, 1993
AA	**!**	CMP PHARMA INC	**50MG/5ML**	**A075819**	**001**	Sep 11, 2002
AA		NOVELGENIX THERAPS	**50MG/5ML**	**A214178**	**001**	Aug 20, 2021
AA	**!**	PHARM ASSOC	**50MG/5ML**	**A074509**	**001**	Jul 17, 1995

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**100MG**	**A214284**	**001**	Oct 15, 2020
AB		JUBILANT GENERICS	**100MG**	**A210403**	**001**	Feb 07, 2018
AB		NOVELGENIX THERAPS	**100MG**	**A210215**	**001**	Mar 10, 2020
AB	**!**	UPSHER SMITH LABS	**100MG**	**A076186**	**001**	Dec 16, 2002
AB		WATSON LABS INC	**100MG**	**A208096**	**001**	Dec 15, 2016
BX		STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

	+	ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018

AMBRISENTAN

TABLET;ORAL

AMBRISENTAN

AB		CIPLA	**5MG**	**A210715**	**001**	Apr 26, 2019
AB			**10MG**	**A210715**	**002**	Apr 26, 2019
AB		MYLAN	**5MG**	**A208441**	**001**	Mar 28, 2019
AB			**10MG**	**A208441**	**002**	Mar 28, 2019
AB		PAR PHARM INC	**5MG**	**A209509**	**001**	Apr 10, 2019
AB			**10MG**	**A209509**	**002**	Apr 10, 2019
AB		SIGMAPHARM LABS LLC	**5MG**	**A208354**	**001**	Apr 10, 2019
AB			**10MG**	**A208354**	**002**	Apr 10, 2019
AB		SUN PHARM	**5MG**	**A210784**	**001**	Mar 28, 2019
AB			**10MG**	**A210784**	**002**	Mar 28, 2019
AB		WATSON LABS INC	**5MG**	**A208252**	**001**	Mar 28, 2019
AB			**10MG**	**A208252**	**002**	Mar 28, 2019
AB		ZYDUS PHARMS	**5MG**	**A210058**	**001**	Mar 28, 2019
AB			**10MG**	**A210058**	**002**	Mar 28, 2019

LETAIRIS

AB	**+**	GILEAD	**5MG**	**N022081**	**001**	Jun 15, 2007
AB	**+!**		**10MG**	**N022081**	**002**	Jun 15, 2007

AMCINONIDE

CREAM;TOPICAL

AMCINONIDE

AB	**!**	FOUGERA PHARMS	**0.1%**	**A076065**	**001**	May 15, 2003
AB		TARO PHARM INDS	**0.1%**	**A076229**	**001**	May 31, 2002

LOTION;TOPICAL

AMCINONIDE

	!	FOUGERA PHARMS	0.1%	A076329	001	Nov 06, 2002

OINTMENT;TOPICAL

AMCINONIDE

AB	**!**	FOUGERA PHARMS	**0.1%**	**A076096**	**001**	Nov 19, 2002
AB		TARO PHARM INDS	**0.1%**	**A076367**	**001**	Mar 19, 2003

AMIFAMPRIDINE

TABLET;ORAL

RUZURGI

	+!	JACOBUS PHARM CO INC	10MG	N209321	001	May 06, 2019

AMIFAMPRIDINE PHOSPHATE
TABLET;ORAL
FIRDAPSE
+! CATALYST PHARMS EQ 10MG BASE N208078 001 Nov 28, 2018

AMIFOSTINE
INJECTABLE;INJECTION
AMIFOSTINE
AP SUN PHARM **500MG/VIAL** **A077126 001** Mar 14, 2008
ETHYOL
AP **+!** CLINIGEN **500MG/VIAL** **N020221 001** Dec 08, 1995

AMIKACIN SULFATE
INJECTABLE;INJECTION
AMIKACIN SULFATE
AP **!** EMCURE PHARMS LTD **EQ 250MG BASE/ML** **A204040 001** Dec 12, 2013
AP FRESENIUS KABI USA **EQ 50MG BASE/ML** **A205605 001** Dec 09, 2015
AP **EQ 250MG BASE/ML** **A205604 001** Dec 09, 2015
AP **!** HIKMA **EQ 50MG BASE/ML** **A063313 001** Apr 11, 1994
AP **EQ 250MG BASE/ML** **A063315 001** Apr 11, 1994
AP SAGENT PHARMS INC **EQ 250MG BASE/ML** **A203323 001** May 12, 2016
AP TEVA PHARMS USA **EQ 250MG BASE/ML** **A064045 002** Sep 28, 1993
SUSPENSION, LIPOSOMAL;INHALATION
ARIKAYCE KIT
+! INSMED INC EQ 590MG BASE/8.4ML N207356 001 Sep 28, 2018

AMILORIDE HYDROCHLORIDE
TABLET;ORAL
AMILORIDE HYDROCHLORIDE
AB **!** PAR PHARM **5MG** **A070346 001** Jan 22, 1986
AB SIGMAPHARM LABS LLC **5MG** **A079133 001** Jan 30, 2009
AB USPHARMA WINDLAS **5MG** **A204180 001** Aug 07, 2015
MIDAMOR
AB **+** PADAGIS US **5MG** **N018200 001**

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
AB BARR **EQ 5MG ANHYDROUS;50MG** **A071111 001** May 10, 1988
AB **!** RISING PHARMA **EQ 5MG ANHYDROUS;50MG** **A073209 001** Oct 31, 1991

AMINO ACIDS
INJECTABLE;INJECTION
AMINO ACIDS
B BRAUN 15%(150GM/1000ML) A091112 001 Apr 13, 2012
15%(300GM/2000ML) A091112 002 Apr 13, 2012
AMINOSYN II 10% IN PLASTIC CONTAINER
ICU MEDICAL INC 10% (10GM/100ML) N020015 001 Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER
ICU MEDICAL INC 15% (15GM/100ML) N020041 001 Dec 19, 1991
AMINOSYN-PF 10%
ICU MEDICAL INC 10% (10GM/100ML) N019492 002 Oct 17, 1986
AMINOSYN-PF 7%
ICU MEDICAL INC 7% (7GM/100ML) N019398 001 Sep 06, 1985
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
BAXTER HLTHCARE 15% (15GM/100ML) A020512 001 Aug 30, 1996
FREAMINE HBC 6.9%
B BRAUN 6.9% (6.9GM/100ML) N016822 006 May 17, 1983
FREAMINE III 10%
B BRAUN 10% (10GM/100ML) N016822 005
FREAMINE III 8.5%
B BRAUN 8.5% (8.5GM/100ML) N016822 004
HEPATAMINE 8%
B BRAUN 8% (8GM/100ML) N018676 001 Aug 03, 1982
NEPHRAMINE 5.4%
B BRAUN 5.4% (5.4GM/100ML) N017766 001
PREMASOL 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10% (10GM/100ML) A075880 002 Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER
BAXTER HLTHCARE 6% (6GM/100ML) A075880 001 Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER
+! BAXTER HLTHCARE 20% (20GM/100ML) N020849 001 Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10% (10MG/100ML) N018931 003 Aug 23, 1984

AMINO ACIDS

INJECTABLE;INJECTION

TRAVASOL 5.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931	001	Aug 23, 1984

TRAVASOL 8.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931	002	Aug 23, 1984

TROPHAMINE

+!	B BRAUN	6% (6GM/100ML)	N019018	001	Jul 20, 1984

TROPHAMINE 10%

+!	B BRAUN	10% (10GM/100ML)	N019018	003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PROCALAMINE

	B BRAUN	3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N018582	001	May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	002	Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	005	Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML	N020678	001	Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014
+		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014
+!		3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5GM/100ML (1440ML)	N200656	001	Aug 25, 2014

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

PERIKABIVEN IN PLASTIC CONTAINER

+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML)	N200656	002	Aug 25, 2014
+!		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML;124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML)	N200656	003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;10GM/100ML	N020734	002	Sep 29, 1997

CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;25GM/100ML	N020734	005	Sep 29, 1997

CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	2.75%;5GM/100ML	N020734	001	Sep 29, 1997

CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;10GM/100ML	N020734	008	Sep 29, 1997

CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;20GM/100ML	N020734	010	Sep 29, 1997

CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;25GM/100ML	N020734	011	Sep 29, 1997

CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	4.25%;5GM/100ML	N020734	007	Sep 29, 1997

CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;10GM/100ML	N020734	014	Sep 29, 1997

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997

CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997

CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997

CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES

	B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

FREAMINE III 3% W/ ELECTROLYTES

	B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML	N016822	003	

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP		LUITPOLD	**250MG/ML**	**A071192**	**001**	Dec 01, 1987

AMINOCAPROIC ACID IN PLASTIC CONTAINER

AP	**!**	HOSPIRA	**250MG/ML**	**A070010**	**001**	Mar 09, 1987

SOLUTION;ORAL

AMICAR

AA	**+!**	AKORN	**0.25GM/ML**	**N015230**	**002**	

AMINOCAPROIC ACID

AA		AMNEAL	**0.25GM/ML**	**A212780**	**001**	Aug 23, 2019
AA		BELCHER	**0.25GM/ML**	**A213825**	**001**	Apr 08, 2021
AA		LEADING PHARMA LLC	**0.25GM/ML**	**A214140**	**001**	Jan 26, 2021
AA		TULEX PHARMS INC	**0.25GM/ML**	**A212494**	**001**	Aug 11, 2020
AA		VISTAPHARM	**0.25GM/ML**	**A212814**	**001**	Feb 26, 2020

TABLET;ORAL

AMICAR

AB	**+**	AKORN	**500MG**	**N015197**	**001**	
AB	**+**		**1GM**	**N015197**	**002**	Jun 24, 2004

AMINOCAPROIC ACID

AB		AMNEAL	**500MG**	**A212492**	**001**	Nov 26, 2019
AB		ANI PHARMS	**500MG**	**A211629**	**001**	Dec 14, 2020
AB		LEADING PHARMA LLC	**500MG**	**A213928**	**001**	Feb 12, 2021
AB			**1GM**	**A213928**	**002**	Feb 12, 2021

AMINOCAPROIC ACID

TABLET;ORAL

AMINOCAPROIC ACID

AB		MSN	**500MG**	**A212938**	**001**	Nov 06, 2020
AB		SUNNY	**500MG**	**A209060**	**001**	Nov 27, 2018
AB	**!**		**1GM**	**A209060**	**002**	Nov 27, 2018

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION;ORAL

GLEOLAN

+!	NXDC	1.5GM/VIAL	N208630	001	Jun 06, 2017

GEL;TOPICAL

AMELUZ

+!	BIOFRONTERA	10%	N208081	001	May 10, 2016

SOLUTION;TOPICAL

LEVULAN

+!	DUSA	20%	N020965	001	Dec 03, 1999

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE;ORAL

PASER

!	JACOBUS	4GM/PACKET	A074346	001	Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

AP		ACELLA	**50MG/ML**	**A077610**	**001**	Oct 30, 2008
AP			**50MG/ML**	**A077834**	**001**	Oct 30, 2008
AP		EUGIA PHARMA	**50MG/ML**	**A204550**	**001**	Oct 25, 2017
AP	**!**	FRESENIUS KABI USA	**50MG/ML**	**A075761**	**001**	Oct 15, 2002
AP	**!**	GLAND PHARMA LTD	**50MG/ML**	**A077161**	**001**	Apr 20, 2005
AP		HIKMA FARMACEUTICA	**50MG/ML**	**A077234**	**001**	Feb 25, 2008
AP		HOSPIRA INC	**50MG/ML**	**A203884**	**001**	Nov 25, 2013
AP	**!**	MYLAN INSTITUTIONAL	**50MG/ML**	**A076217**	**001**	Oct 15, 2002

NEXTERONE

+!	BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
+!		360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**200MG**	**A204742**	**001**	Jun 03, 2016
AB		MAYNE PHARMA INC	**100MG**	**A075389**	**002**	Dec 28, 2017
AB			**200MG**	**A075389**	**001**	Jan 25, 2001
AB			**400MG**	**A075389**	**003**	Dec 28, 2017
AB		MURTY PHARMS	**100MG**	**A077069**	**003**	Oct 04, 2016
AB			**200MG**	**A077069**	**001**	Apr 08, 2005
AB			**400MG**	**A077069**	**002**	Apr 08, 2005
AB		RUBICON	**100MG**	**A078578**	**002**	Feb 26, 2021
AB			**200MG**	**A078578**	**001**	Nov 06, 2008
AB			**400MG**	**A078578**	**003**	Feb 26, 2021
AB		TARO	**100MG**	**A075424**	**002**	Dec 18, 2002
AB			**200MG**	**A075424**	**001**	Mar 30, 2001
AB			**400MG**	**A076362**	**001**	Nov 29, 2002
AB		TEVA PHARMS	**200MG**	**A074739**	**001**	Nov 30, 1998
AB		UNICHEM	**200MG**	**A213446**	**001**	Jul 21, 2020
AB	**!**	UPSHER SMITH LABS	**200MG**	**A075315**	**001**	Dec 23, 1998
AB			**400MG**	**A075315**	**002**	Jun 30, 2000
AB		ZYDUS PHARMS USA INC	**200MG**	**A079029**	**001**	Sep 16, 2008

PACERONE

AB		UPSHER SMITH LABS	**100MG**	**A075135**	**002**	Apr 12, 2005
AB			**200MG**	**A075135**	**001**	Apr 30, 1998
AB			**400MG**	**A075135**	**003**	Jul 02, 2020

AMIODARONE HYDROCHLORIDE

	TARO	300MG	A076362	002	Dec 02, 2003

AMISULPRIDE

SOLUTION;INTRAVENOUS

BARHEMSYS

+!	ACACIA	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020
+!		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	**10MG**	**A202446**	**001**	Jun 04, 2014
AB		**25MG**	**A202446**	**002**	Jun 04, 2014
AB		**50MG**	**A202446**	**003**	Jun 04, 2014
AB		**75MG**	**A202446**	**004**	Jun 04, 2014
AB		**100MG**	**A202446**	**005**	Jun 04, 2014
AB		**150MG**	**A202446**	**006**	Jun 04, 2014
AB	MANKIND PHARMA	**10MG**	**A213999**	**001**	Feb 19, 2021
AB		**25MG**	**A213999**	**002**	Feb 19, 2021
AB		**50MG**	**A213999**	**003**	Feb 19, 2021
AB		**75MG**	**A213999**	**004**	Feb 19, 2021
AB		**100MG**	**A213999**	**005**	Feb 19, 2021
AB		**150MG**	**A213999**	**006**	Feb 19, 2021
AB +	SANDOZ	**10MG**	**A085968**	**004**	
AB +!		**25MG**	**A085968**	**002**	
AB +		**50MG**	**A085968**	**001**	
AB +		**75MG**	**A085968**	**006**	
AB +		**100MG**	**A085968**	**003**	
AB +		**150MG**	**A085968**	**005**	
AB	SUN PHARM INDS INC	**10MG**	**A089399**	**002**	Jul 14, 1987
AB		**25MG**	**A089399**	**001**	Jul 14, 1987
AB		**50MG**	**A089399**	**003**	Jul 14, 1987
AB		**75MG**	**A089399**	**004**	Jul 14, 1987
AB		**100MG**	**A089399**	**005**	Jul 14, 1987
AB		**150MG**	**A089399**	**006**	Jul 14, 1987
AB	UNICHEM	**10MG**	**A214548**	**001**	May 19, 2021
AB		**25MG**	**A214548**	**002**	May 19, 2021
AB		**50MG**	**A214548**	**003**	May 19, 2021
AB		**75MG**	**A214548**	**004**	May 19, 2021
AB		**100MG**	**A214548**	**005**	May 19, 2021
AB		**150MG**	**A214548**	**006**	May 19, 2021
AB	UPSHER SMITH LABS	**10MG**	**A212654**	**002**	Sep 29, 2021
AB		**25MG**	**A212654**	**001**	Apr 07, 2020
AB		**50MG**	**A212654**	**003**	Sep 29, 2021
AB		**75MG**	**A212654**	**004**	Sep 29, 2021
AB		**100MG**	**A212654**	**005**	Sep 29, 2021
AB		**150MG**	**A212654**	**006**	Sep 29, 2021
AB	VINTAGE PHARMS	**10MG**	**A040218**	**001**	Sep 11, 1997
AB		**25MG**	**A040218**	**002**	Sep 11, 1997
AB		**50MG**	**A040218**	**003**	Sep 11, 1997
AB		**75MG**	**A040218**	**004**	Sep 11, 1997
AB		**100MG**	**A040218**	**005**	Sep 11, 1997
AB		**150MG**	**A040218**	**006**	Sep 11, 1997
AB	ZYDUS PHARMS	**10MG**	**A210086**	**001**	Oct 06, 2017
AB		**25MG**	**A210086**	**002**	Oct 06, 2017
AB		**50MG**	**A210086**	**003**	Oct 06, 2017
AB		**75MG**	**A210086**	**004**	Oct 06, 2017
AB		**100MG**	**A210086**	**005**	Oct 06, 2017
AB		**150MG**	**A210086**	**006**	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
!		EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
		10MG;4MG	A071443	003	Nov 10, 1988
!		25MG;2MG	A071443	004	Nov 10, 1988
!		25MG;4MG	A071443	005	Nov 10, 1988
!		50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BENZOATE

SUSPENSION;ORAL

KATERZIA

+!	AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A202553**	**001**	Apr 29, 2013
AB		**EQ 5MG BASE**	**A202553**	**002**	Apr 29, 2013
AB		**EQ 10MG BASE**	**A202553**	**003**	Apr 29, 2013
AB	ALKEM	**EQ 2.5MG BASE**	**A078925**	**001**	May 04, 2009
AB		**EQ 5MG BASE**	**A078925**	**002**	May 04, 2009
AB		**EQ 10MG BASE**	**A078925**	**003**	May 04, 2009
AB	APOTEX	**EQ 2.5MG BASE**	**A076719**	**001**	May 23, 2007
AB		**EQ 5MG BASE**	**A076719**	**002**	May 23, 2007
AB		**EQ 10MG BASE**	**A076719**	**003**	May 23, 2007
AB	AUROBINDO PHARMA	**EQ 2.5MG BASE**	**A078021**	**001**	Jul 17, 2007
AB		**EQ 5MG BASE**	**A078021**	**002**	Jul 17, 2007
AB		**EQ 10MG BASE**	**A078021**	**003**	Jul 17, 2007
AB	CHARTWELL RX	**EQ 2.5MG BASE**	**A076692**	**001**	Jul 20, 2007
AB		**EQ 5MG BASE**	**A076692**	**002**	Jul 20, 2007
AB		**EQ 10MG BASE**	**A076692**	**003**	Jul 20, 2007
AB	CHINA RESOURCES	**EQ 2.5MG BASE**	**A090752**	**003**	May 16, 2016
AB		**EQ 5MG BASE**	**A090752**	**001**	Apr 15, 2011
AB		**EQ 10MG BASE**	**A090752**	**002**	Apr 15, 2011
AB	CIPLA	**EQ 2.5MG BASE**	**A077073**	**001**	Sep 26, 2007
AB		**EQ 5MG BASE**	**A077073**	**002**	Sep 26, 2007
AB		**EQ 10MG BASE**	**A077073**	**003**	Sep 26, 2007
AB	EPIC PHARMA LLC	**EQ 2.5MG BASE**	**A078552**	**001**	Apr 08, 2009
AB		**EQ 5MG BASE**	**A078552**	**002**	Apr 08, 2009
AB		**EQ 10MG BASE**	**A078552**	**003**	Apr 08, 2009
AB	INVAGEN PHARMS	**EQ 2.5MG BASE**	**A077955**	**001**	Aug 28, 2007
AB		**EQ 2.5MG BASE**	**A206367**	**001**	Dec 10, 2015
AB		**EQ 5MG BASE**	**A077955**	**002**	Aug 28, 2007
AB		**EQ 5MG BASE**	**A206367**	**002**	Dec 10, 2015
AB		**EQ 10MG BASE**	**A077955**	**003**	Aug 28, 2007
AB		**EQ 10MG BASE**	**A206367**	**003**	Dec 10, 2015
AB	LUPIN	**EQ 2.5MG BASE**	**A078043**	**001**	Jul 12, 2007
AB		**EQ 5MG BASE**	**A078043**	**002**	Jul 12, 2007
AB		**EQ 10MG BASE**	**A078043**	**003**	Jul 12, 2007
AB	ORBION PHARMS	**EQ 2.5MG BASE**	**A078453**	**001**	Jul 02, 2009
AB		**EQ 5MG BASE**	**A078453**	**002**	Jul 02, 2009
AB		**EQ 10MG BASE**	**A078453**	**003**	Jul 02, 2009
AB	OXFORD PHARMS	**EQ 2.5MG BASE**	**A078414**	**001**	Apr 07, 2010
AB		**EQ 5MG BASE**	**A078414**	**002**	Apr 07, 2010
AB		**EQ 10MG BASE**	**A078414**	**003**	Apr 07, 2010
AB	POLYGEN PHARMS	**EQ 2.5MG BASE**	**A207821**	**001**	Jul 11, 2016
AB		**EQ 5MG BASE**	**A207821**	**002**	Jul 11, 2016
AB		**EQ 10MG BASE**	**A207821**	**003**	Jul 11, 2016
AB	STRIDES PHARMA	**EQ 2.5MG BASE**	**A077516**	**001**	Jul 11, 2007
AB		**EQ 5MG BASE**	**A077516**	**002**	Jul 11, 2007
AB		**EQ 10MG BASE**	**A077516**	**003**	Jul 11, 2007
AB	SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A077974**	**001**	Jul 09, 2007
AB		**EQ 5MG BASE**	**A077974**	**002**	Jul 09, 2007
AB		**EQ 10MG BASE**	**A077974**	**003**	Jul 09, 2007
AB	UNICHEM	**EQ 2.5MG BASE**	**A203245**	**001**	Oct 21, 2013
AB		**EQ 5MG BASE**	**A203245**	**002**	Oct 21, 2013
AB		**EQ 10MG BASE**	**A203245**	**003**	Oct 21, 2013
AB	ZYDUS PHARMS USA	**EQ 2.5MG BASE**	**A078226**	**001**	Jul 09, 2007
AB		**EQ 5MG BASE**	**A078226**	**002**	Jul 09, 2007
AB		**EQ 10MG BASE**	**A078226**	**003**	Jul 09, 2007

NORVASC

AB +	UPJOHN	**EQ 2.5MG BASE**	**N019787**	**001**	Jul 31, 1992
AB +		**EQ 5MG BASE**	**N019787**	**002**	Jul 31, 1992
AB +!		**EQ 10MG BASE**	**N019787**	**003**	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	APOTEX	**EQ 5MG BASE;EQ 10MG BASE**	**A205199**	**001**	Nov 18, 2019
AB		**EQ 5MG BASE;EQ 20MG BASE**	**A205199**	**002**	Nov 18, 2019
AB		**EQ 5MG BASE;EQ 40MG BASE**	**A205199**	**003**	Nov 18, 2019
AB		**EQ 5MG BASE;EQ 80MG BASE**	**A205199**	**004**	Nov 18, 2019
AB		**EQ 10MG BASE;EQ 10MG BASE**	**A205199**	**005**	Nov 18, 2019
AB		**EQ 10MG BASE;EQ 20MG BASE**	**A205199**	**006**	Nov 18, 2019
AB		**EQ 10MG BASE;EQ 40MG BASE**	**A205199**	**007**	Nov 18, 2019
AB		**EQ 10MG BASE;EQ 80MG BASE**	**A205199**	**008**	Nov 18, 2019
AB	DR REDDYS	**EQ 2.5MG BASE;EQ 10MG BASE**	**A203874**	**001**	Mar 07, 2014
AB		**EQ 2.5MG BASE;EQ 20MG BASE**	**A203874**	**002**	Mar 07, 2014
AB		**EQ 2.5MG BASE;EQ 40MG BASE**	**A203874**	**003**	Mar 07, 2014
AB		**EQ 5MG BASE;EQ 10MG BASE**	**A203874**	**004**	Mar 07, 2014
AB		**EQ 5MG BASE;EQ 20MG BASE**	**A203874**	**005**	Mar 07, 2014
AB		**EQ 5MG BASE;EQ 40MG BASE**	**A203874**	**006**	Mar 07, 2014
AB		**EQ 5MG BASE;EQ 80MG BASE**	**A203874**	**007**	Mar 07, 2014
AB		**EQ 10MG BASE;EQ 10MG BASE**	**A203874**	**008**	Mar 07, 2014
AB		**EQ 10MG BASE;EQ 20MG BASE**	**A203874**	**009**	Mar 07, 2014
AB		**EQ 10MG BASE;EQ 40MG BASE**	**A203874**	**010**	Mar 07, 2014
AB		**EQ 10MG BASE;EQ 80MG BASE**	**A203874**	**011**	Mar 07, 2014
AB	MYLAN	**EQ 5MG BASE;EQ 10MG BASE**	**A200465**	**004**	Nov 29, 2013
AB		**EQ 5MG BASE;EQ 20MG BASE**	**A200465**	**005**	Nov 29, 2013
AB		**EQ 5MG BASE;EQ 40MG BASE**	**A200465**	**006**	Nov 29, 2013
AB		**EQ 5MG BASE;EQ 80MG BASE**	**A200465**	**007**	Nov 29, 2013
AB		**EQ 10MG BASE;EQ 10MG BASE**	**A200465**	**008**	Nov 29, 2013
AB		**EQ 10MG BASE;EQ 20MG BASE**	**A200465**	**009**	Nov 29, 2013
AB		**EQ 10MG BASE;EQ 40MG BASE**	**A200465**	**010**	Nov 29, 2013
AB		**EQ 10MG BASE;EQ 80MG BASE**	**A200465**	**011**	Nov 29, 2013
AB	ZYDUS PHARMS	**EQ 2.5MG BASE;EQ 10MG BASE**	**A207762**	**001**	Jan 11, 2019
AB		**EQ 2.5MG BASE;EQ 20MG BASE**	**A207762**	**002**	Jan 11, 2019
AB		**EQ 2.5MG BASE;EQ 40MG BASE**	**A207762**	**003**	Jan 11, 2019
AB		**EQ 5MG BASE;EQ 10MG BASE**	**A207762**	**004**	Jan 11, 2019
AB		**EQ 5MG BASE;EQ 20MG BASE**	**A207762**	**005**	Jan 11, 2019
AB		**EQ 5MG BASE;EQ 40MG BASE**	**A207762**	**006**	Jan 11, 2019
AB		**EQ 5MG BASE;EQ 80MG BASE**	**A207762**	**007**	Jan 11, 2019
AB		**EQ 10MG BASE;EQ 10MG BASE**	**A207762**	**008**	Jan 11, 2019
AB		**EQ 10MG BASE;EQ 20MG BASE**	**A207762**	**009**	Jan 11, 2019
AB		**EQ 10MG BASE;EQ 40MG BASE**	**A207762**	**010**	Jan 11, 2019
AB		**EQ 10MG BASE;EQ 80MG BASE**	**A207762**	**011**	Jan 11, 2019

CADUET

AB	**+** PHARMACIA	**EQ 2.5MG BASE;EQ 10MG BASE**	**N021540**	**009**	Jul 29, 2004
AB	**+**	**EQ 2.5MG BASE;EQ 20MG BASE**	**N021540**	**010**	Jul 29, 2004
AB	**+**	**EQ 2.5MG BASE;EQ 40MG BASE**	**N021540**	**011**	Jul 29, 2004
AB	**+**	**EQ 5MG BASE;EQ 10MG BASE**	**N021540**	**001**	Jan 30, 2004
AB	**+**	**EQ 5MG BASE;EQ 20MG BASE**	**N021540**	**002**	Jan 30, 2004
AB	**+**	**EQ 5MG BASE;EQ 40MG BASE**	**N021540**	**003**	Jan 30, 2004
AB	**+**	**EQ 5MG BASE;EQ 80MG BASE**	**N021540**	**004**	Jan 30, 2004
AB	**+**	**EQ 10MG BASE;EQ 10MG BASE**	**N021540**	**005**	Jan 30, 2004
AB	**+**	**EQ 10MG BASE;EQ 20MG BASE**	**N021540**	**006**	Jan 30, 2004
AB	**+**	**EQ 10MG BASE;EQ 40MG BASE**	**N021540**	**007**	Jan 30, 2004
AB	**+!**	**EQ 10MG BASE;EQ 80MG BASE**	**N021540**	**008**	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	APOTEX	**EQ 2.5MG BASE;10MG**	**A091431**	**001**	Dec 30, 2013
AB		**EQ 5MG BASE;10MG**	**A091431**	**002**	Dec 30, 2013
AB		**EQ 5MG BASE;20MG**	**A091431**	**003**	Dec 30, 2013
AB		**EQ 5MG BASE;40MG**	**A091431**	**004**	Dec 30, 2013
AB		**EQ 10MG BASE;20MG**	**A091431**	**005**	Dec 30, 2013
AB		**EQ 10MG BASE;40MG**	**A091431**	**006**	Dec 30, 2013
AB	AUROBINDO PHARMA LTD	**EQ 2.5MG BASE;10MG**	**A202239**	**001**	Sep 05, 2012
AB		**EQ 5MG BASE;10MG**	**A202239**	**002**	Sep 05, 2012
AB		**EQ 5MG BASE;20MG**	**A202239**	**003**	Sep 05, 2012
AB		**EQ 5MG BASE;40MG**	**A202239**	**004**	Sep 05, 2012
AB		**EQ 10MG BASE;20MG**	**A202239**	**005**	Sep 05, 2012
AB		**EQ 10MG BASE;40MG**	**A202239**	**006**	Sep 05, 2012
AB	DR REDDYS LABS INC	**EQ 2.5MG BASE;10MG**	**A077183**	**001**	Apr 15, 2010
AB		**EQ 5MG BASE;10MG**	**A077183**	**002**	Apr 15, 2010
AB		**EQ 5MG BASE;20MG**	**A077183**	**003**	Apr 15, 2010

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB			EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011
AB			EQ 10MG BASE;20MG	A077183	004	Apr 15, 2010
AB			EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011
AB		LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466	001	Feb 05, 2010
AB			EQ 5MG BASE;10MG	A078466	002	Feb 05, 2010
AB			EQ 5MG BASE;20MG	A078466	003	Feb 05, 2010
AB			EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011
AB			EQ 10MG BASE;20MG	A078466	004	Feb 05, 2010
AB			EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011
AB		WATSON LABS	EQ 2.5MG BASE;10MG	A077890	001	Oct 14, 2010
AB			EQ 5MG BASE;10MG	A077890	002	Oct 14, 2010
AB			EQ 5MG BASE;20MG	A077890	003	Oct 14, 2010
AB			EQ 10MG BASE;20MG	A077890	004	Oct 14, 2010
AB		WATSON LABS INC	EQ 5MG BASE;40MG	A090364	001	Jul 05, 2011
AB			EQ 10MG BASE;40MG	A090364	002	Jul 05, 2011

LOTREL

AB	+	NOVARTIS	EQ 2.5MG BASE;10MG	N020364	002	Mar 03, 1995
AB	+		EQ 5MG BASE;10MG	N020364	003	Mar 03, 1995
AB	+		EQ 5MG BASE;20MG	N020364	004	Mar 03, 1995
AB	+		EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006
AB	+		EQ 10MG BASE;20MG	N020364	005	Jun 20, 2002
AB	+!		EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB		PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A206137	001	Oct 26, 2016
AB			EQ 5MG BASE;12.5MG;40MG	A206137	002	Oct 26, 2016
AB			EQ 5MG BASE;25MG;40MG	A206137	003	Oct 26, 2016
AB			EQ 10MG BASE;12.5MG;40MG	A206137	004	Oct 26, 2016
AB			EQ 10MG BASE;25MG;40MG	A206137	005	Oct 26, 2016
AB		TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016
AB			EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016
AB			EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016
AB			EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016
AB			EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016
AB		TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016
AB			EQ 5MG BASE;12.5MG;40MG	A203580	002	Oct 26, 2016
AB			EQ 5MG BASE;25MG;40MG	A203580	003	Oct 26, 2016
AB			EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016
AB			EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016

TRIBENZOR

AB	+	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
AB	+		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
AB	+		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
AB	+		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
AB	+!		EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017
AB			EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017
AB			EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017
AB			EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017
AB			EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017
AB		LUPIN LTD	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015
AB			EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015
AB			EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015
AB			EQ 10MG BASE;25MG;160MG	A200797	004	Jun 03, 2015
AB			EQ 10MG BASE;25MG;320MG	A200797	005	Jun 03, 2015

EXFORGE HCT

AB	+	NOVARTIS	EQ 5MG BASE;12.5MG;160MG	N022314	001	Apr 30, 2009
AB	+		EQ 5MG BASE;25MG;160MG	N022314	002	Apr 30, 2009
AB	+		EQ 10MG BASE;12.5MG;160MG	N022314	003	Apr 30, 2009
AB	+		EQ 10MG BASE;25MG;160MG	N022314	004	Apr 30, 2009
AB	+!		EQ 10MG BASE;25MG;320MG	N022314	005	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		AJANTA PHARMA LTD	**EQ 5MG BASE;20MG**	**A207216**	**001**	Oct 28, 2016
AB			**EQ 5MG BASE;40MG**	**A207216**	**002**	Oct 28, 2016
AB			**EQ 10MG BASE;20MG**	**A207216**	**003**	Oct 28, 2016
AB			**EQ 10MG BASE;40MG**	**A207216**	**004**	Oct 28, 2016
AB		ALEMBIC PHARMS LTD	**EQ 5MG BASE;20MG**	**A207073**	**001**	Jul 17, 2017
AB			**EQ 5MG BASE;40MG**	**A207073**	**002**	Jul 17, 2017
AB			**EQ 10MG BASE;20MG**	**A207073**	**003**	Jul 17, 2017
AB			**EQ 10MG BASE;40MG**	**A207073**	**004**	Jul 17, 2017
AB		ALKEM LABS LTD	**EQ 5MG BASE;20MG**	**A209042**	**001**	Aug 14, 2017
AB			**EQ 5MG BASE;40MG**	**A209042**	**002**	Aug 14, 2017
AB			**EQ 10MG BASE;20MG**	**A209042**	**003**	Aug 14, 2017
AB			**EQ 10MG BASE;40MG**	**A209042**	**004**	Aug 14, 2017
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE;20MG**	**A206906**	**001**	May 15, 2017
AB			**EQ 5MG BASE;40MG**	**A206906**	**002**	May 15, 2017
AB			**EQ 10MG BASE;20MG**	**A206906**	**003**	May 15, 2017
AB			**EQ 10MG BASE;40MG**	**A206906**	**004**	May 15, 2017
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE;20MG**	**A207807**	**001**	Jul 05, 2017
AB			**EQ 5MG BASE;40MG**	**A207807**	**002**	Jul 05, 2017
AB			**EQ 10MG BASE;20MG**	**A207807**	**003**	Jul 05, 2017
AB			**EQ 10MG BASE;40MG**	**A207807**	**004**	Jul 05, 2017
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE;20MG**	**A206884**	**001**	Oct 26, 2016
AB			**EQ 5MG BASE;40MG**	**A206884**	**003**	Oct 26, 2016
AB			**EQ 10MG BASE;20MG**	**A206884**	**002**	Oct 26, 2016
AB			**EQ 10MG BASE;40MG**	**A206884**	**004**	Oct 26, 2016
AB		MICRO LABS	**EQ 5MG BASE;20MG**	**A207435**	**001**	Nov 02, 2017
AB			**EQ 5MG BASE;40MG**	**A207435**	**002**	Nov 02, 2017
AB			**EQ 10MG BASE;20MG**	**A207435**	**003**	Nov 02, 2017
AB			**EQ 10MG BASE;40MG**	**A207435**	**004**	Nov 02, 2017
AB		TORRENT	**EQ 5MG BASE;20MG**	**A202933**	**001**	Nov 25, 2016
AB			**EQ 5MG BASE;40MG**	**A202933**	**002**	Nov 25, 2016
AB			**EQ 10MG BASE;20MG**	**A202933**	**003**	Nov 25, 2016
AB			**EQ 10MG BASE;40MG**	**A202933**	**004**	Nov 25, 2016
AB		ZYDUS PHARMS	**EQ 5MG BASE;20MG**	**A207771**	**001**	Sep 22, 2017
AB			**EQ 5MG BASE;40MG**	**A207771**	**002**	Sep 22, 2017
AB			**EQ 10MG BASE;20MG**	**A207771**	**003**	Sep 22, 2017
AB			**EQ 10MG BASE;40MG**	**A207771**	**004**	Sep 22, 2017

AZOR

AB	**+**	DAIICHI SANKYO	**EQ 5MG BASE;20MG**	**N022100**	**001**	Sep 26, 2007
AB	**+**		**EQ 5MG BASE;40MG**	**N022100**	**002**	Sep 26, 2007
AB	**+**		**EQ 10MG BASE;20MG**	**N022100**	**003**	Sep 26, 2007
AB	**+!**		**EQ 10MG BASE;40MG**	**N022100**	**004**	Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
	+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
	+!		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

AB		LUPIN LTD	**EQ 5MG BASE;40MG**	**A201586**	**001**	Jan 08, 2014
AB			**EQ 5MG BASE;80MG**	**A201586**	**003**	Jan 08, 2014
AB			**EQ 10MG BASE;40MG**	**A201586**	**002**	Jan 08, 2014
AB			**EQ 10MG BASE;80MG**	**A201586**	**004**	Jan 08, 2014
AB		MYLAN	**EQ 5MG BASE;40MG**	**A202516**	**001**	Aug 26, 2014
AB			**EQ 5MG BASE;80MG**	**A202516**	**003**	Aug 26, 2014
AB			**EQ 10MG BASE;40MG**	**A202516**	**002**	Aug 26, 2014
AB	**!**		**EQ 10MG BASE;80MG**	**A202516**	**004**	Aug 26, 2014
AB		TORRENT	**EQ 5MG BASE;40MG**	**A202517**	**001**	Jan 08, 2014
AB			**EQ 5MG BASE;80MG**	**A202517**	**003**	Jan 08, 2014
AB			**EQ 10MG BASE;40MG**	**A202517**	**002**	Jan 08, 2014
AB			**EQ 10MG BASE;80MG**	**A202517**	**004**	Jan 08, 2014

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB		ALEMBIC PHARMS LTD	**EQ 5MG BASE;160MG**	**A202713**	**001**	Apr 03, 2015
AB			**EQ 5MG BASE;320MG**	**A202713**	**003**	Apr 03, 2015
AB			**EQ 10MG BASE;160MG**	**A202713**	**002**	Apr 03, 2015
AB			**EQ 10MG BASE;320MG**	**A202713**	**004**	Apr 03, 2015
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE;160MG**	**A206512**	**001**	Apr 22, 2016
AB			**EQ 5MG BASE;320MG**	**A206512**	**002**	Apr 22, 2016
AB			**EQ 10MG BASE;160MG**	**A206512**	**003**	Apr 22, 2016
AB			**EQ 10MG BASE;320MG**	**A206512**	**004**	Apr 22, 2016
AB		INVAGEN PHARMS	**EQ 5MG BASE;160MG**	**A205137**	**001**	Sep 16, 2016
AB			**EQ 5MG BASE;320MG**	**A205137**	**003**	Sep 16, 2016
AB			**EQ 10MG BASE;160MG**	**A205137**	**002**	Sep 16, 2016
AB			**EQ 10MG BASE;320MG**	**A205137**	**004**	Sep 16, 2016
AB		LUPIN	**EQ 5MG BASE;160MG**	**A090245**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090245**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090245**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090245**	**004**	Mar 30, 2015
AB		MYLAN	**EQ 5MG BASE;160MG**	**A090483**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A090483**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A090483**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A090483**	**004**	Mar 30, 2015
AB		NOVEL LABS INC	**EQ 5MG BASE;160MG**	**A202829**	**001**	Mar 30, 2015
AB			**EQ 5MG BASE;320MG**	**A202829**	**003**	Mar 30, 2015
AB			**EQ 10MG BASE;160MG**	**A202829**	**002**	Mar 30, 2015
AB			**EQ 10MG BASE;320MG**	**A202829**	**004**	Mar 30, 2015

EXFORGE

AB	**+**	NOVARTIS	**EQ 5MG BASE;160MG**	**N021990**	**002**	Jun 20, 2007
AB	**+**		**EQ 5MG BASE;320MG**	**N021990**	**004**	Jun 20, 2007
AB	**+!**		**EQ 10MG BASE;160MG**	**N021990**	**003**	Jun 20, 2007
AB	**+!**		**EQ 10MG BASE;320MG**	**N021990**	**005**	Jun 20, 2007

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP		3D IMAGING DRUG	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203779**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)**	**A204352**	**001**	May 01, 2015
AP		BRIGHAM WOMENS HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203783**	**001**	Oct 30, 2014
AP		CARDINAL HLTH 414	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203700**	**001**	Feb 25, 2013
AP		DECATUR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204465**	**001**	Oct 23, 2014
AP		ESSENTIAL ISOTOPES	**3.75mCi-260mCi/ML**	**A205687**	**001**	Dec 17, 2015
AP	**+!**	FEINSTEIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**N022119**	**001**	Aug 23, 2007
AP		GEN HOSP	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A207025**	**001**	Feb 03, 2016
AP		IONETIX	**22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)**	**A210524**	**001**	Dec 21, 2018
AP		JOHNS HOPKINS UNIV	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204514**	**001**	Aug 19, 2014
AP		KREITCHMAN PET CTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203938**	**001**	Dec 09, 2013
AP		MCPRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203321**	**001**	Feb 25, 2013
AP		METHODIST	**3.75mCi-260mCi/ML**	**A215083**	**001**	Jul 09, 2021
AP		MIDWEST MEDCL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204457**	**001**	Nov 18, 2015
AP		MIPS CRF	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204535**	**001**	Nov 20, 2014
AP		NCM USA BRONX LLC	**3.75mCi-260mCi/ML**	**A204515**	**001**	Feb 04, 2015
AP		NUKEMED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204455**	**001**	Apr 23, 2015
AP		PETNET	**30mCi-300mCi (3.75-37.5mCi/ML)**	**A204510**	**001**	Nov 02, 2015
AP		PRECISION NUCLEAR	**3.75mCi-260mCi/ML**	**A204547**	**001**	Aug 14, 2015
AP		SHERTECH LABS LLC	**3.75mCi-260mCi/ML**	**A204366**	**001**	Sep 19, 2014
AP		SOFIE	**18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)**	**A204667**	**001**	Apr 22, 2015
AP	**!**		**3.75mCi-260mCi/ML**	**A203543**	**001**	Dec 14, 2012
AP		UCLA BIOMEDICAL	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A203812**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204496**	**001**	Mar 28, 2014
AP		UNIV TX SW MEDCTR	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A209507**	**001**	Nov 01, 2019
AP		UNIV WISCONSIN	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A211740**	**001**	Sep 09, 2020
AP		WA UNIV SCH MED	**30mCi-300mCi/8ML (3.75-37.5mCi/ML)**	**A204506**	**001**	Feb 07, 2014
AP		WISCONSIN	**3.75mCi-260mCi/ML**	**A204356**	**001**	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

	!	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	!	PADAGIS ISRAEL	**EQ 12% BASE**	**A075774**	**001**	May 01, 2002
AB		TARO	**EQ 12% BASE**	**A075883**	**001**	Apr 10, 2003

LOTION;TOPICAL

AMMONIUM LACTATE

AB	!	PADAGIS ISRAEL	**EQ 12% BASE**	**A075570**	**001**	Jun 23, 2004
AB		TARO	**EQ 12% BASE**	**A076216**	**001**	May 28, 2004

AMOXAPINE

TABLET;ORAL

AMOXAPINE

	WATSON LABS	25MG	A072691	002	Aug 28, 1992
		50MG	A072691	003	Aug 28, 1992
		100MG	A072691	004	Aug 28, 1992
!		150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB		AUROBINDO	**250MG**	**A065271**	**001**	Nov 09, 2005
AB			**500MG**	**A065271**	**002**	Nov 09, 2005
AB		CHARTWELL	**250MG**	**A062058**	**001**	
AB			**500MG**	**A062058**	**002**	
AB		HIKMA PHARMS	**250MG**	**A065291**	**001**	Feb 05, 2007
AB			**500MG**	**A065291**	**002**	Feb 05, 2007
AB		SANDOZ	**250MG**	**A064076**	**001**	Sep 30, 1994
AB			**500MG**	**A064076**	**002**	Sep 30, 1994
AB		TEVA	**250MG**	**A061926**	**001**	
AB	!		**500MG**	**A061926**	**003**	

AMOXIL

AB		US ANTIBIOTICS	**250MG**	**A062216**	**001**	
AB			**500MG**	**A062216**	**004**	

FOR SUSPENSION;ORAL

AMOXICILLIN

AB		AUROBINDO	**200MG/5ML**	**A065334**	**001**	Dec 28, 2006
AB			**400MG/5ML**	**A065334**	**002**	Dec 28, 2006
AB		AUROBINDO PHARMA LTD	**125MG/5ML**	**A204030**	**001**	Sep 15, 2014
AB			**250MG/5ML**	**A204030**	**002**	Sep 15, 2014
AB		DAVA PHARMS INC	**125MG/5ML**	**A062927**	**001**	Nov 25, 1988
AB			**250MG/5ML**	**A062927**	**002**	Nov 25, 1988
AB		HIKMA	**125MG/5ML**	**A065322**	**002**	Jun 19, 2006
AB			**200MG/5ML**	**A065325**	**002**	Jun 19, 2006
AB			**250MG/5ML**	**A065322**	**001**	Jun 19, 2006
AB			**400MG/5ML**	**A065325**	**001**	Jun 19, 2006
AB		SANDOZ	**125MG/5ML**	**A065387**	**001**	Mar 26, 2007
AB			**200MG/5ML**	**A065378**	**001**	Mar 26, 2007
AB			**250MG/5ML**	**A065387**	**002**	Mar 26, 2007
AB			**400MG/5ML**	**A065378**	**002**	Mar 26, 2007
AB		TEVA	**200MG/5ML**	**A065119**	**001**	Dec 04, 2002
AB	!		**250MG/5ML**	**A061931**	**002**	
AB	!		**400MG/5ML**	**A065119**	**002**	Dec 04, 2002
AB		WOCKHARDT BIO AG	**400MG/5ML**	**A065319**	**002**	Jun 18, 2007

AMOXICILLIN PEDIATRIC

AB		TEVA	**50MG/ML**	**A061931**	**003**	Dec 01, 1982

AMOXIL

AB		US ANTIBIOTICS	**50MG/ML**	**A062226**	**005**	
AB			**125MG/5ML**	**A062226**	**001**	
AB			**250MG/5ML**	**A062226**	**002**	

LAROTID

AB		US ANTIBIOTICS	**125MG/5ML**	**A062226**	**003**	
AB			**250MG/5ML**	**A062226**	**004**	

TABLET;ORAL

AMOXICILLIN

AB		AUROBINDO	**500MG**	**A065256**	**001**	Nov 09, 2005
AB			**875MG**	**A065256**	**002**	Nov 09, 2005
AB		HIKMA	**875MG**	**A065255**	**001**	Mar 29, 2006
AB		SANDOZ	**500MG**	**A065228**	**001**	Jul 13, 2005
AB			**875MG**	**A065228**	**002**	Jul 13, 2005
AB		TEVA	**500MG**	**A065056**	**001**	Sep 18, 2000
AB	!		**875MG**	**A065056**	**002**	Sep 18, 2000

AMOXICILLIN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

		TEVA	125MG	A064013	002	Sep 11, 1995
	!		250MG	A064013	001	Dec 22, 1992

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

AB	**!**	RISING	**500MG;500MG;30MG**	**A206006**	**001**	Oct 07, 2016
AB		SANDOZ INC	**500MG;500MG;30MG**	**A202588**	**001**	Mar 04, 2014

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	**125MG/5ML;EQ 31.25MG BASE/5ML**	**A209371**	**001**	Apr 19, 2019
AB			**200MG/5ML;EQ 28.5MG BASE/5ML**	**A201090**	**001**	Dec 20, 2011
AB			**250MG/5ML;EQ 62.5MG BASE/5ML**	**A209371**	**002**	Apr 19, 2019
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A201090**	**002**	Dec 20, 2011
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A201091**	**001**	Dec 20, 2011
AB		HIKMA PHARMS	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065191**	**002**	Jan 25, 2005
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065191**	**001**	Jan 25, 2005
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065373**	**001**	Nov 09, 2007
AB		MICRO LABS LTD INDIA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A205187**	**001**	May 21, 2021
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A205187**	**002**	May 21, 2021
AB		SANDOZ	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065066**	**001**	Jun 05, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065066**	**002**	Jun 05, 2002
AB		SANDOZ INC	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065098**	**001**	Dec 16, 2002
AB			**400MG/5ML;EQ 57MG BASE/5ML**	**A065098**	**002**	Dec 16, 2002
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065358**	**001**	Aug 13, 2007
AB		TEVA	**200MG/5ML;EQ 28.5MG BASE/5ML**	**A065089**	**001**	May 25, 2004
AB	**!**		**400MG/5ML;EQ 57MG BASE/5ML**	**A065089**	**002**	May 25, 2004
AB	**!**		**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065162**	**001**	Mar 12, 2004
AB		WOCKHARDT BIO AG	**250MG/5ML;EQ 62.5MG BASE/5ML**	**A065431**	**001**	Nov 25, 2008
AB			**600MG/5ML;EQ 42.9MG BASE/5ML**	**A065420**	**001**	Dec 02, 2013

AUGMENTIN '125'

AB	**+**	US ANTIBIOTICS	**125MG/5ML;EQ 31.25MG BASE/5ML**	**N050575**	**001**	Aug 06, 1984

AUGMENTIN '250'

AB	**+!**	US ANTIBIOTICS	**250MG/5ML;EQ 62.5MG BASE/5ML**	**N050575**	**002**	Aug 06, 1984

AUGMENTIN ES-600

AB	**+**	US ANTIBIOTICS	**600MG/5ML;EQ 42.9MG BASE/5ML**	**N050755**	**001**	Jun 22, 2001

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		AUROBINDO PHARMA LTD	**250MG;EQ 125MG BASE**	**A091569**	**001**	Jan 20, 2012
AB			**500MG;EQ 125MG BASE**	**A091569**	**002**	Jan 20, 2012
AB			**875MG;EQ 125MG BASE**	**A091568**	**001**	Jan 20, 2012
AB		HIKMA PHARMS	**875MG;EQ 125MG BASE**	**A203824**	**001**	Aug 23, 2016
AB		MICRO LABS LTD INDIA	**250MG;EQ 125MG BASE**	**A205707**	**001**	Dec 30, 2016
AB			**500MG;EQ 125MG BASE**	**A205707**	**002**	Dec 30, 2016
AB			**875MG;EQ 125MG BASE**	**A204755**	**003**	Dec 30, 2016
AB	**!**	SANDOZ	**250MG;EQ 125MG BASE**	**A065189**	**001**	Aug 23, 2005
AB			**500MG;EQ 125MG BASE**	**A065064**	**001**	Mar 15, 2002
AB	**!**		**875MG;EQ 125MG BASE**	**A065063**	**001**	Mar 14, 2002
AB	**!**	SANDOZ INC	**500MG;EQ 125MG BASE**	**A065117**	**001**	Nov 27, 2002
AB			**875MG;EQ 125MG BASE**	**A065093**	**001**	Nov 21, 2002
AB		TEVA	**500MG;EQ 125MG BASE**	**A065101**	**001**	Oct 30, 2002
AB		TEVA PHARMS USA	**875MG;EQ 125MG BASE**	**A065096**	**001**	Oct 29, 2002

AUGMENTIN '875'

AB	**+**	US ANTIBIOTICS	**875MG;EQ 125MG BASE**	**N050720**	**001**	Feb 13, 1996

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

		TEVA	200MG;EQ 28.5MG BASE	A065205	001	Feb 09, 2005
	!		400MG;EQ 57MG BASE	A065205	002	Feb 09, 2005

TABLET, EXTENDED RELEASE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	!	SANDOZ	1GM;EQ 62.5MG BASE	A090227	001	Apr 21, 2010

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE;ORAL

TALICIA

+!	REDHILL	250MG;EQ 10MG BASE;12.5MG	N213004	001	Nov 01, 2019

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

+	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016
+		EQ 6.3MG BASE	N204326	002	Jan 27, 2016
+		EQ 9.4MG BASE	N204326	003	Jan 27, 2016
+		EQ 12.5MG BASE	N204326	004	Jan 27, 2016
+		EQ 15.7MG BASE	N204326	005	Jan 27, 2016
+!		EQ 18.8MG BASE	N204326	006	Jan 27, 2016

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		RHODES PHARMS	**2.5MG;2.5MG;2.5MG;2.5MG**	**A213111**	**003**	Jan 13, 2021
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A213111**	**005**	Jan 13, 2021
AB			**5MG;5MG;5MG;5MG**	**A213111**	**006**	Jan 13, 2021

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB	+	TAKEDA PHARMS USA	**2.5MG;2.5MG;2.5MG;2.5MG**	**N021303**	**001**	Oct 11, 2001

ADDERALL XR 15

AB	+	TAKEDA PHARMS USA	**3.75MG;3.75MG;3.75MG;3.75MG**	**N021303**	**006**	May 22, 2002

ADDERALL XR 20

AB	+	TAKEDA PHARMS USA	**5MG;5MG;5MG;5MG**	**N021303**	**002**	Oct 11, 2001

ADDERALL XR 25

AB	+	TAKEDA PHARMS USA	**6.25MG;6.25MG;6.25MG;6.25MG**	**N021303**	**004**	May 22, 2002

ADDERALL XR 30

AB	+!	TAKEDA PHARMS USA	**7.5MG;7.5MG;7.5MG;7.5MG**	**N021303**	**003**	Oct 11, 2001

ADDERALL XR 5

AB	+	TAKEDA PHARMS USA	**1.25MG;1.25MG;1.25MG;1.25MG**	**N021303**	**005**	May 22, 2002

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ASCENT PHARMS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A214959**	**001**	Sep 29, 2021
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A214959**	**002**	Sep 29, 2021
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A214959**	**003**	Sep 29, 2021
AB			**5MG;5MG;5MG;5MG**	**A214959**	**004**	Sep 29, 2021
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A214959**	**005**	Sep 29, 2021
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A214959**	**006**	Sep 29, 2021
AB		LANNETT CO INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A214403**	**001**	Nov 26, 2021
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A214403**	**002**	Nov 26, 2021
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A214403**	**003**	Nov 26, 2021
AB			**5MG;5MG;5MG;5MG**	**A214403**	**004**	Nov 26, 2021
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A214403**	**005**	Nov 26, 2021
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A214403**	**006**	Nov 26, 2021

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A077302**	**001**	Jun 22, 2012
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A077302**	**002**	Jun 22, 2012
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A077302**	**003**	Jun 22, 2012
AB			**5MG;5MG;5MG;5MG**	**A077302**	**004**	Jun 22, 2012
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A077302**	**005**	Jun 22, 2012
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A077302**	**006**	Jun 22, 2012
AB		ANI PHARMS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A205401**	**001**	Jan 22, 2019
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A205401**	**002**	Jan 22, 2019
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A205401**	**003**	Jan 22, 2019
AB			**5MG;5MG;5MG;5MG**	**A205401**	**004**	Jan 22, 2019
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A205401**	**005**	Jan 22, 2019
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A205401**	**006**	Jan 22, 2019
AB		ELITE LABS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A212037**	**001**	Dec 11, 2019
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A212037**	**002**	Dec 11, 2019
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A212037**	**003**	Dec 11, 2019
AB			**5MG;5MG;5MG;5MG**	**A212037**	**004**	Dec 11, 2019
AB			**6.25MG;6.25MG;6.25MG;6.25MG**	**A212037**	**005**	Dec 11, 2019
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A212037**	**006**	Dec 11, 2019
AB		IMPAX LABS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A076852**	**001**	Feb 16, 2016
AB			**2.5MG;2.5MG;2.5MG;2.5MG**	**A076852**	**002**	Feb 16, 2016
AB			**3.75MG;3.75MG;3.75MG;3.75MG**	**A076852**	**003**	Feb 16, 2016
AB			**5MG;5MG;5MG;5MG**	**A076852**	**004**	Feb 16, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A076852**	**005**	Feb 16, 2016
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A076852**	**006**	Feb 16, 2016
AB	PAR PHARM INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A206159**	**001**	May 31, 2019
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A206159**	**002**	May 31, 2019
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A206159**	**003**	May 31, 2019
AB		**5MG;5MG;5MG;5MG**	**A206159**	**004**	May 31, 2019
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A206159**	**005**	May 31, 2019
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A206159**	**006**	May 31, 2019
AB	RHODES PHARMS	**1.25MG;1.25MG;1.25MG;1.25MG**	**A210651**	**001**	May 17, 2019
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A210651**	**002**	May 17, 2019
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A210651**	**003**	May 17, 2019
AB		**5MG;5MG;5MG;5MG**	**A210651**	**004**	May 17, 2019
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A210651**	**005**	May 17, 2019
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A210651**	**006**	May 17, 2019
AB	SPECGX LLC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A211547**	**001**	Apr 22, 2019
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A211547**	**002**	Apr 22, 2019
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A211547**	**003**	Apr 22, 2019
AB		**5MG;5MG;5MG;5MG**	**A211547**	**004**	Apr 22, 2019
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A211547**	**005**	Apr 22, 2019
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A211547**	**006**	Apr 22, 2019
AB	SUN PHARM INDUSTRIES	**1.25MG;1.25MG;1.25MG;1.25MG**	**A211715**	**001**	May 17, 2019
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A211715**	**002**	May 17, 2019
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A211715**	**003**	May 17, 2019
AB		**5MG;5MG;5MG;5MG**	**A211715**	**004**	May 17, 2019
AB		**6.25MG;6.25MG;6.25MG;6.25MG**	**A211715**	**005**	May 17, 2019
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A211715**	**006**	May 17, 2019

MYDAYIS

+	TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
+!		12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACCORD HLTHCARE	**1.25MG;1.25MG;1.25MG;1.25MG**	**A214347**	**001**	Nov 22, 2021
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A214347**	**002**	Nov 22, 2021
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A214347**	**003**	Nov 22, 2021
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A214347**	**004**	Nov 22, 2021
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A214347**	**005**	Nov 22, 2021
AB		**5MG;5MG;5MG;5MG**	**A214347**	**006**	Nov 22, 2021
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A214347**	**007**	Nov 22, 2021
AB	ACTAVIS ELIZABETH	**1.25MG;1.25MG;1.25MG;1.25MG**	**A206340**	**001**	Feb 05, 2016
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A206340**	**002**	Feb 05, 2016
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A206340**	**003**	Feb 05, 2016
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A206340**	**004**	Feb 05, 2016
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A206340**	**005**	Feb 05, 2016
AB		**5MG;5MG;5MG;5MG**	**A206340**	**006**	Feb 05, 2016
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A206340**	**007**	Feb 05, 2016
AB	ALVOGEN	**1.25MG;1.25MG;1.25MG;1.25MG**	**A207388**	**001**	Jul 28, 2017
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A207388**	**002**	Jul 28, 2017
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A207388**	**003**	Jul 28, 2017
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A207388**	**004**	Jul 28, 2017
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A207388**	**005**	Jul 28, 2017
AB		**5MG;5MG;5MG;5MG**	**A207388**	**006**	Jul 28, 2017
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A207388**	**007**	Jul 28, 2017
AB	ASCENT PHARMS INC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A213709**	**001**	Apr 22, 2021
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A213709**	**002**	Apr 22, 2021
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A213709**	**003**	Apr 22, 2021
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A213709**	**004**	Apr 22, 2021
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A213709**	**005**	Apr 22, 2021
AB		**5MG;5MG;5MG;5MG**	**A213709**	**006**	Apr 22, 2021
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A213709**	**007**	Apr 22, 2021
AB	AUROLIFE PHARMA LLC	**1.25MG;1.25MG;1.25MG;1.25MG**	**A202424**	**001**	Nov 27, 2013
AB		**1.875MG;1.875MG;1.875MG;1.875MG**	**A202424**	**002**	Nov 27, 2013
AB		**2.5MG;2.5MG;2.5MG;2.5MG**	**A202424**	**003**	Nov 27, 2013
AB		**3.125MG;3.125MG;3.125MG;3.125MG**	**A202424**	**004**	Nov 27, 2013
AB		**3.75MG;3.75MG;3.75MG;3.75MG**	**A202424**	**005**	Nov 27, 2013
AB		**5MG;5MG;5MG;5MG**	**A202424**	**006**	Nov 27, 2013
AB		**7.5MG;7.5MG;7.5MG;7.5MG**	**A202424**	**007**	Nov 27, 2013

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422	001	Feb 11, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040422	005	Mar 19, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040422	002	Feb 11, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040422	006	Mar 19, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040422	007	Mar 19, 2003
AB		5MG;5MG;5MG;5MG	A040422	003	Feb 11, 2002
AB !		7.5MG;7.5MG;7.5MG;7.5MG	A040422	004	Feb 11, 2002
AB	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018
AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A215771	001	Dec 28, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215771	002	Dec 28, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215771	003	Dec 28, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215771	004	Dec 28, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215771	005	Dec 28, 2021
AB		5MG;5MG;5MG;5MG	A215771	006	Dec 28, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215771	007	Dec 28, 2021
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017
AB	NUVO PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017
AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021
AB	SANDOZ	1.25MG;1.25MG;1.25MG;1.25MG	A040439	004	Sep 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040439	001	Jun 14, 2002
AB		5MG;5MG;5MG;5MG	A040439	002	Jun 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040439	003	Jun 14, 2002
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003
AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003
AB		5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003
AB	USPHARMA WINDLAS	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB			**5MG;5MG;5MG;5MG**	**A210293**	**005**	Apr 03, 2020
AB			**7.5MG;7.5MG;7.5MG;7.5MG**	**A210293**	**006**	Apr 03, 2020

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

AA		ALKEM LABS LTD	**5MG**	**A213720**	**001**	Oct 27, 2020
AA			**10MG**	**A213720**	**002**	Oct 27, 2020
AA		AMNEAL PHARMS	**5MG**	**A211139**	**001**	Sep 26, 2018
AA			**10MG**	**A211139**	**002**	Sep 26, 2018
AA		AUROLIFE PHARMA LLC	**5MG**	**A211639**	**001**	Apr 17, 2019
AA			**10MG**	**A211639**	**002**	Apr 17, 2019
AA		BIONPHARMA INC	**5MG**	**A212919**	**001**	Nov 22, 2019
AA			**10MG**	**A212919**	**002**	Nov 22, 2019
AA		CEROVENE INC	**5MG**	**A212582**	**001**	Feb 04, 2020
AA			**10MG**	**A212582**	**002**	Feb 04, 2020
AA		EPIC PHARMA LLC	**5MG**	**A213980**	**001**	Oct 27, 2020
AA			**10MG**	**A213980**	**002**	Oct 27, 2020
AA		GRANULES	**5MG**	**A212619**	**001**	Aug 05, 2019
AA			**10MG**	**A212619**	**002**	Aug 05, 2019
AA		PRINSTON INC	**5MG**	**A211861**	**001**	Mar 11, 2020
AA			**10MG**	**A211861**	**002**	Mar 11, 2020
AA		RHODES PHARMS	**5MG**	**A213852**	**001**	Sep 07, 2021
AA			**10MG**	**A213852**	**002**	Sep 07, 2021
AA		SENORES PHARMS	**5MG**	**A212901**	**001**	May 22, 2020
AA			**10MG**	**A212901**	**002**	May 22, 2020
AA		SPECGX LLC	**5MG**	**A213583**	**001**	Jan 22, 2021
AA			**10MG**	**A213583**	**002**	Jan 22, 2021
AA		SUN PHARM INDS INC	**5MG**	**A214574**	**001**	Jan 27, 2021
AA			**10MG**	**A214574**	**002**	Jan 27, 2021

EVEKEO

AA		ARBOR PHARMS LLC	**5MG**	**A200166**	**001**	Aug 09, 2012
AA	**!**		**10MG**	**A200166**	**002**	Aug 09, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019
+		10MG	N209905	002	Jan 30, 2019
+		15MG	N209905	003	Jan 30, 2019
+!		20MG	N209905	004	Jan 30, 2019

AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

SUSPENSION, EXTENDED RELEASE;ORAL

DYANAVEL XR

+!	TRIS PHARMA INC	2MG/ML;EQ 0.5MG BASE/ML	N208147	001	Oct 19, 2015

TABLET, EXTENDED RELEASE;ORAL

DYANAVEL XR 10

+	TRIS PHARMA INC	8MG;EQ 2MG BASE	N210526	002	Nov 04, 2021

DYANAVEL XR 15

+	TRIS PHARMA INC	12MG;EQ 3MG BASE	N210526	003	Nov 04, 2021

DYANAVEL XR 20

+!	TRIS PHARMA INC	16MG;EQ 4MG BASE	N210526	004	Nov 04, 2021

DYANAVEL XR 5

+	TRIS PHARMA INC	4MG;EQ 1MG BASE	N210526	001	Nov 04, 2021

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992

INJECTABLE, LIPID COMPLEX;INJECTION

ABELCET

+!	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995

INJECTABLE, LIPOSOMAL;INJECTION

AMBISOME

AB	**+!**	ASTELLAS	**50MG/VIAL**	**N050740**	**001**	Aug 11, 1997

AMPHOTERICIN B

AB		SPIL	**50MG/VIAL**	**A212514**	**001**	Dec 14, 2021

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP		ACS DOBFAR SPA	**EQ 10GM BASE/VIAL**	**A090889**	**001**	Apr 03, 2013
AP		ANTIBIOTICE	**EQ 250MG BASE/VIAL**	**A090354**	**001**	Dec 28, 2009
AP			**EQ 500MG BASE/VIAL**	**A090354**	**002**	Dec 28, 2009
AP			**EQ 1GM BASE/VIAL**	**A090354**	**003**	Dec 28, 2009
AP			**EQ 2GM BASE/VIAL**	**A090354**	**004**	Dec 28, 2009
AP		AUROBINDO PHARMA	**EQ 250MG BASE/VIAL**	**A065499**	**002**	Aug 17, 2010
AP			**EQ 500MG BASE/VIAL**	**A065499**	**003**	Aug 17, 2010
AP			**EQ 1GM BASE/VIAL**	**A065499**	**004**	Aug 17, 2010
AP			**EQ 2GM BASE/VIAL**	**A065499**	**005**	Aug 17, 2010
AP			**EQ 10GM BASE/VIAL**	**A065493**	**001**	Aug 17, 2010
AP		HQ SPECLT PHARMA	**EQ 250MG BASE/VIAL**	**A062772**	**006**	Apr 15, 1993
AP			**EQ 500MG BASE/VIAL**	**A062772**	**007**	Apr 15, 1993
AP			**EQ 1GM BASE/VIAL**	**A062772**	**001**	Apr 15, 1993
AP			**EQ 2GM BASE/VIAL**	**A062772**	**003**	Apr 15, 1993
AP			**EQ 10GM BASE/VIAL**	**A063142**	**001**	Apr 15, 1993
AP		ISTITUTO BIO ITA SPA	**EQ 10GM BASE/VIAL**	**A201404**	**001**	Dec 20, 2013
AP			**EQ 250MG BASE/VIAL**	**A062719**	**001**	May 12, 1987
AP			**EQ 500MG BASE/VIAL**	**A062719**	**003**	May 12, 1987
AP			**EQ 1GM BASE/VIAL**	**A062719**	**002**	May 12, 1987
AP			**EQ 2GM BASE/VIAL**	**A062797**	**002**	Jul 12, 1993
AP		MYLAN LABS LTD	**EQ 250MG BASE/VIAL**	**A201025**	**001**	Apr 09, 2014
AP			**EQ 500MG BASE/VIAL**	**A201025**	**002**	Apr 09, 2014
AP			**EQ 1GM BASE/VIAL**	**A201025**	**003**	Apr 09, 2014
AP			**EQ 2GM BASE/VIAL**	**A201025**	**004**	Apr 09, 2014
AP			**EQ 10GM BASE/VIAL**	**A202198**	**001**	Apr 07, 2014
AP		SAGENT PHARMS INC	**EQ 125MG BASE/VIAL**	**A090583**	**001**	Nov 27, 2015
AP			**EQ 250MG BASE/VIAL**	**A090583**	**002**	Nov 27, 2015
AP			**EQ 500MG BASE/VIAL**	**A090583**	**003**	Nov 27, 2015
AP			**EQ 1GM BASE/VIAL**	**A090583**	**004**	Nov 27, 2015
AP			**EQ 2GM BASE/VIAL**	**A090583**	**005**	Nov 27, 2015
AP			**EQ 10GM BASE/VIAL**	**A090581**	**001**	Oct 20, 2015
AP	**!**	SANDOZ	**EQ 125MG BASE/VIAL**	**A061395**	**001**	
AP	**!**		**EQ 250MG BASE/VIAL**	**A061395**	**002**	
AP	**!**		**EQ 500MG BASE/VIAL**	**A061395**	**003**	
AP	**!**		**EQ 1GM BASE/VIAL**	**A061395**	**004**	
AP	**!**		**EQ 2GM BASE/VIAL**	**A061395**	**005**	
AP	**!**		**EQ 10GM BASE/VIAL**	**A061395**	**006**	

POWDER;INTRAVENOUS

AMPICILLIN SODIUM

AP	**!**	SANDOZ	**EQ 1GM BASE/VIAL**	**A062738**	**001**	Feb 19, 1987
AP	**!**		**EQ 2GM BASE/VIAL**	**A062738**	**002**	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065406**	**001**	Dec 22, 2009
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065406**	**002**	Dec 22, 2009
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065403**	**001**	Dec 23, 2009
AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201406**	**001**	Dec 07, 2015
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201406**	**002**	Dec 07, 2015
AP		ASTRAL	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090579**	**001**	Jan 08, 2016
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090579**	**002**	Jan 08, 2016
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A090578**	**001**	Jan 11, 2016
AP		AUROBINDO PHARMA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090340**	**001**	Sep 20, 2010
AP			**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A090349**	**001**	Sep 20, 2010
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090340**	**002**	Sep 20, 2010
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A090349**	**002**	Sep 20, 2010
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A090339**	**001**	Sep 20, 2010
AP		HIKMA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065074**	**001**	Mar 19, 2002
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065074**	**002**	Mar 19, 2002
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065076**	**001**	Mar 19, 2002
AP		HQ SPECLT PHARMA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065176**	**001**	Nov 30, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065176**	**002**	Nov 30, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065188**	**001**	Nov 25, 2005
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065222**	**001**	Nov 29, 2005
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065222**	**002**	Nov 29, 2005
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065314**	**001**	Nov 27, 2006
AP		MYLAN LABS LTD	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A201024**	**001**	Apr 07, 2014

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A201024**	**002**	Apr 07, 2014
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A202197**	**001**	Apr 07, 2014
AP		SANDOZ	**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065241**	**001**	Jul 25, 2006
AP			**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065310**	**001**	Jul 25, 2006
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065241**	**002**	Jul 25, 2006
AP			**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A065310**	**002**	Jul 25, 2006
AP			**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**A065240**	**001**	Jul 25, 2006

UNASYN

AP	**!**	PFIZER	**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**A062901**	**002**	Feb 27, 1992
AP	**!**		**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A062901**	**001**	Nov 23, 1988
AP	**+!**		**EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL**	**N050608**	**002**	Dec 31, 1986
AP	**+!**		**EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL**	**N050608**	**001**	Dec 31, 1986
AP	**+!**		**EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL**	**N050608**	**005**	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

	!	SANDOZ	EQ 500MG BASE	A064082	002	Aug 29, 1995

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

AB		TAKEDA PHARMS USA	**EQ 0.5MG BASE**	**N020333**	**001**	Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

AB		IMPAX LABS	**EQ 0.5MG BASE**	**A076910**	**001**	Apr 18, 2005
AB			**EQ 1MG BASE**	**A076910**	**002**	Apr 18, 2005
AB		IVAX SUB TEVA PHARMS	**EQ 0.5MG BASE**	**A076468**	**001**	Apr 18, 2005
AB	**!**		**EQ 1MG BASE**	**A076468**	**002**	Apr 18, 2005
AB		TORRENT	**EQ 0.5MG BASE**	**A209151**	**001**	Jun 30, 2017
AB			**EQ 1MG BASE**	**A209151**	**002**	Jun 30, 2017

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB		ACCORD HLTHCARE	**1MG**	**A090568**	**001**	Jun 28, 2010
AB		BEIJING YILING	**1MG**	**A206037**	**001**	Nov 09, 2018
AB		CIPLA	**1MG**	**A091164**	**001**	Jun 28, 2010
AB		EUGIA PHARMA	**1MG**	**A212434**	**001**	Jul 24, 2020
AB		KENTON	**1MG**	**A078944**	**001**	Jun 28, 2010
AB		NATCO PHARMA LTD	**1MG**	**A079220**	**001**	Jun 28, 2010
AB		TEVA PHARMS	**1MG**	**A078058**	**001**	Jun 28, 2010
AB		ZYDUS PHARMS USA INC	**1MG**	**A078921**	**001**	Jun 28, 2010

ARIMIDEX

AB	**+!**	ANI PHARMS	**1MG**	**N020541**	**001**	Dec 27, 1995

ANGIOTENSIN II ACETATE

SOLUTION;INTRAVENOUS

GIAPREZA

	+!	LA JOLLA PHARMA	EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	N209360	003	Dec 23, 2021
	+!		EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017

ANIDULAFUNGIN

POWDER;INTRAVENOUS

ERAXIS

	+!	VICURON HOLDINGS	50MG/VIAL	N021632	001	Feb 17, 2006
	+!		100MG/VIAL	N021632	002	Nov 14, 2006

APALUTAMIDE

TABLET;ORAL

ERLEADA

	+!	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018

APIXABAN

TABLET;ORAL

APIXABAN

AB		ACCORD HLTHCARE	**2.5MG**	**A210180**	**001**	Jul 28, 2020
AB			**5MG**	**A210180**	**002**	Jul 28, 2020
AB		INDOCO	**2.5MG**	**A209898**	**001**	Sep 11, 2020
AB			**5MG**	**A209898**	**002**	Sep 11, 2020

ELIQUIS

AB	**+**	BRISTOL MYERS	**2.5MG**	**N202155**	**001**	Dec 28, 2012

APIXABAN
TABLET;ORAL
ELIQUIS
SQUIBB
AB +! 5MG N202155 002 Dec 28, 2012

APOMORPHINE HYDROCHLORIDE
FILM;SUBLINGUAL
KYNMOBI
\+ SUNOVION PHARMS INC 10MG N210875 001 May 21, 2020
\+ 15MG N210875 002 May 21, 2020
\+ 20MG N210875 003 May 21, 2020
\+ 25MG N210875 004 May 21, 2020
+! 30MG N210875 005 May 21, 2020
INJECTABLE;SUBCUTANEOUS
APOKYN
+! MDD US 30MG/3ML (10MG/ML) N021264 002 Apr 20, 2004

APRACLONIDINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
APRACLONIDINE HYDROCHLORIDE
AT AKORN **EQ 0.5% BASE** **A077764 001** Mar 12, 2009
IOPIDINE
AT +! NOVARTIS **EQ 0.5% BASE** **N020258 001** Jul 30, 1993
+! EQ 1% BASE N019779 001 Dec 31, 1987

APREMILAST
TABLET;ORAL
APREMILAST
AB ALKEM LABS LTD **10MG** **A211761 001** Sep 21, 2021
AB **20MG** **A211761 002** Sep 21, 2021
AB **30MG** **A211761 003** Sep 21, 2021
AB AMNEAL **10MG** **A211782 001** Jun 30, 2021
AB **20MG** **A211782 002** Jun 30, 2021
AB **30MG** **A211782 003** Jun 30, 2021
AB ZYDUS PHARMS **10MG** **A211859 001** Sep 21, 2021
AB **20MG** **A211859 002** Sep 21, 2021
AB **30MG** **A211859 003** Sep 21, 2021
OTEZLA
AB + AMGEN INC **10MG** **N205437 001** Mar 21, 2014
AB + **20MG** **N205437 002** Mar 21, 2014
AB +! **30MG** **N205437 003** Mar 21, 2014

APREPITANT
CAPSULE;ORAL
APREPITANT
AB GLENMARK PHARMS SA **40MG** **A207777 001** Oct 12, 2017
AB **80MG** **A207777 002** Oct 12, 2017
AB **125MG** **A207777 003** Oct 12, 2017
AB SANDOZ **40MG** **A090999 001** Sep 24, 2012
AB **80MG** **A090999 002** Sep 24, 2012
AB **125MG** **A090999 003** Sep 24, 2012
AB TORRENT **40MG** **A211835 001** Oct 21, 2020
AB **80MG** **A211835 002** Oct 21, 2020
AB **125MG** **A211835 003** Oct 21, 2020
EMEND
AB + MERCK **80MG** **N021549 001** Mar 26, 2003
AB +! **125MG** **N021549 002** Mar 26, 2003
EMULSION;INTRAVENOUS
CINVANTI
+! HERON THERAPS INC 130MG/18ML (7.2MG/ML) N209296 001 Nov 09, 2017
FOR SUSPENSION;ORAL
EMEND
+! MSD MERCK CO 125MG/KIT N207865 001 Dec 17, 2015

ARFORMOTEROL TARTRATE
SOLUTION;INHALATION
ARFORMOTEROL TARTRATE
AN AXAR PHARMS INC **EQ 0.015MG BASE/2ML** **A213762 001** Jun 22, 2021
AN CIPLA **EQ 0.015MG BASE/2ML** **A207306 001** Jun 22, 2021
AN GLENMARK PHARMS LTD **EQ 0.015MG BASE/2ML** **A213132 001** Jun 22, 2021
AN TEVA PHARMS USA **EQ 0.015MG BASE/2ML** **A200293 001** Nov 09, 2021
BROVANA
AN +! SUNOVION **EQ 0.015MG BASE/2ML** **N021912 001** Oct 06, 2006

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP		AMNEAL PHARMS CO	**250MG/2.5ML (100MG/ML)**	**A206698**	**001**	Jan 26, 2018
AP		CAPLIN	**50MG/50ML (1MG/ML)**	**A214235**	**001**	Jan 21, 2021
AP		FRESENIUS KABI USA	**250MG/2.5ML (100MG/ML)**	**N201811**	**001**	Mar 23, 2015
AP	**+!**	HIKMA PHARM CO LTD	**50MG/50ML (1MG/ML)**	**N203049**	**002**	Sep 30, 2016
AP	**+!**		**250MG/2.5ML (100MG/ML)**	**N203049**	**001**	Jan 05, 2012
AP		HOSPIRA INC	**250MG/2.5ML (100MG/ML)**	**A204120**	**001**	Sep 21, 2016
AP		MYLAN INSTITUTIONAL	**250MG/2.5ML (100MG/ML)**	**A202626**	**001**	Jun 30, 2014
AP	**+!**	NOVARTIS	**250MG/2.5ML (100MG/ML)**	**N020883**	**001**	Jun 30, 2000
AP		PAR STERILE PRODUCTS	**250MG/2.5ML (100MG/ML)**	**A091665**	**001**	Jun 30, 2014

INJECTABLE;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP		GLAND PHARMA LTD	**125MG/125ML (1MG/ML)**	**A205570**	**001**	May 22, 2017
AP	**+!**	SANDOZ	**125MG/125ML (1MG/ML)**	**N022485**	**001**	May 09, 2011

SOLUTION;INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

	+!	ACCORD HLTHCARE	50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021
		EUGIA PHARMA SPECLTS	50MG/50ML (1MG/ML)	N209552	001	Nov 27, 2018

ARGININE HYDROCHLORIDE

INJECTABLE;INJECTION

R-GENE 10

	+!	PHARMACIA AND UPJOHN	10GM/100ML	N016931	001	

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ABILIFY MAINTENA KIT

	+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013
	+		300MG	N202971	003	Sep 29, 2014
	+!		400MG/VIAL	N202971	002	Feb 28, 2013
	+		400MG	N202971	004	Sep 29, 2014

SOLUTION;ORAL

ARIPIPRAZOLE

AA	**!**	AMNEAL PHARMS	**1MG/ML**	**A203906**	**001**	Aug 14, 2015
AA		APOTEX INC	**1MG/ML**	**A204094**	**001**	Sep 30, 2015
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A210479**	**001**	Jan 29, 2019
AA		LANNETT CO INC	**1MG/ML**	**A204171**	**001**	Aug 14, 2015
AA		VISTAPHARM	**1MG/ML**	**A212870**	**001**	Dec 26, 2019

TABLET;ORAL

ABILIFY

AB	**+**	OTSUKA	**2MG**	**N021436**	**006**	Nov 15, 2002
AB	**+!**		**5MG**	**N021436**	**005**	Nov 15, 2002
AB	**+!**		**10MG**	**N021436**	**001**	Nov 15, 2002
AB	**+**		**15MG**	**N021436**	**002**	Nov 15, 2002
AB	**+**		**20MG**	**N021436**	**003**	Nov 15, 2002
AB	**+**		**30MG**	**N021436**	**004**	Nov 15, 2002

ARIPIPRAZOLE

AB		ACCORD HLTHCARE	**2MG**	**A206251**	**001**	Dec 07, 2016
AB			**5MG**	**A206251**	**002**	Dec 07, 2016
AB			**10MG**	**A206251**	**003**	Dec 07, 2016
AB			**15MG**	**A206251**	**004**	Dec 07, 2016
AB			**20MG**	**A206251**	**005**	Dec 07, 2016
AB			**30MG**	**A206251**	**006**	Dec 07, 2016
AB		AJANTA PHARMA LTD	**2MG**	**A206174**	**001**	Sep 12, 2016
AB			**5MG**	**A206174**	**002**	Sep 12, 2016
AB			**10MG**	**A206174**	**003**	Sep 12, 2016
AB			**15MG**	**A206174**	**004**	Sep 12, 2016
AB			**20MG**	**A206174**	**005**	Sep 12, 2016
AB			**30MG**	**A206174**	**006**	Sep 12, 2016
AB		ALEMBIC PHARMS LTD	**2MG**	**A202101**	**001**	Apr 28, 2015
AB			**5MG**	**A202101**	**002**	Apr 28, 2015
AB			**10MG**	**A202101**	**003**	Apr 28, 2015
AB			**15MG**	**A202101**	**004**	Apr 28, 2015
AB			**20MG**	**A202101**	**005**	Apr 28, 2015
AB			**30MG**	**A202101**	**006**	Apr 28, 2015
AB		ALKEM LABS LTD	**2MG**	**A207105**	**001**	Feb 21, 2019
AB			**5MG**	**A207105**	**002**	Feb 21, 2019
AB			**10MG**	**A207105**	**003**	Feb 21, 2019

ARIPIPRAZOLE

TABLET;ORAL

ARIPIPRAZOLE

AB		**15MG**	**A207105**	**004**	Feb 21, 2019
AB		**20MG**	**A207105**	**005**	Feb 21, 2019
AB		**30MG**	**A207105**	**006**	Feb 21, 2019
AB	AMNEAL PHARMS	**2MG**	**A204838**	**001**	Jun 17, 2016
AB		**5MG**	**A204838**	**002**	Jun 17, 2016
AB		**10MG**	**A204838**	**003**	Jun 17, 2016
AB		**15MG**	**A204838**	**004**	Jun 17, 2016
AB		**20MG**	**A204838**	**005**	Jun 17, 2016
AB		**30MG**	**A204838**	**006**	Jun 17, 2016
AB	APOTEX INC	**2MG**	**A078583**	**001**	Jul 24, 2015
AB		**5MG**	**A078583**	**002**	Jul 24, 2015
AB		**10MG**	**A078583**	**003**	Jul 24, 2015
AB		**15MG**	**A078583**	**004**	Jul 24, 2015
AB		**20MG**	**A078583**	**005**	Jul 24, 2015
AB		**30MG**	**A078583**	**006**	Jul 24, 2015
AB	AUROBINDO PHARMA LTD	**2MG**	**A203908**	**001**	Oct 08, 2015
AB		**5MG**	**A203908**	**002**	Oct 08, 2015
AB		**10MG**	**A203908**	**003**	Oct 08, 2015
AB		**15MG**	**A203908**	**004**	Oct 08, 2015
AB		**20MG**	**A203908**	**005**	Oct 08, 2015
AB		**30MG**	**A203908**	**006**	Oct 08, 2015
AB	BOSCOGEN	**2MG**	**A091279**	**001**	Jan 09, 2017
AB		**5MG**	**A091279**	**002**	Jan 09, 2017
AB		**10MG**	**A091279**	**003**	Jan 09, 2017
AB		**15MG**	**A091279**	**004**	Jan 09, 2017
AB		**20MG**	**A091279**	**005**	Jan 09, 2017
AB		**30MG**	**A091279**	**006**	Jan 09, 2017
AB	HETERO LABS LTD V	**2MG**	**A205064**	**001**	Apr 28, 2015
AB		**5MG**	**A205064**	**002**	Apr 28, 2015
AB		**10MG**	**A205064**	**003**	Apr 28, 2015
AB		**15MG**	**A205064**	**004**	Apr 28, 2015
AB		**20MG**	**A205064**	**005**	Apr 28, 2015
AB		**30MG**	**A205064**	**006**	Apr 28, 2015
AB	MACLEODS PHARMS LTD	**2MG**	**A204111**	**001**	Oct 07, 2016
AB		**5MG**	**A204111**	**002**	Oct 07, 2016
AB		**10MG**	**A204111**	**003**	Oct 07, 2016
AB		**15MG**	**A204111**	**004**	Oct 07, 2016
AB		**20MG**	**A204111**	**005**	Oct 07, 2016
AB		**30MG**	**A204111**	**006**	Oct 07, 2016
AB	ORBION PHARMS	**2MG**	**A202683**	**001**	May 23, 2017
AB		**5MG**	**A202683**	**002**	May 23, 2017
AB		**10MG**	**A202683**	**003**	May 23, 2017
AB		**15MG**	**A202683**	**004**	May 23, 2017
AB		**20MG**	**A202683**	**005**	May 23, 2017
AB		**30MG**	**A202683**	**006**	May 23, 2017
AB	PRINSTON INC	**2MG**	**A205363**	**001**	Dec 04, 2017
AB		**5MG**	**A205363**	**002**	Dec 04, 2017
AB		**10MG**	**A205363**	**003**	Dec 04, 2017
AB		**15MG**	**A205363**	**004**	Dec 04, 2017
AB		**20MG**	**A205363**	**005**	Dec 04, 2017
AB		**30MG**	**A205363**	**006**	Dec 04, 2017
AB	SCIEGEN PHARMS INC	**2MG**	**A206383**	**001**	Sep 29, 2016
AB		**5MG**	**A206383**	**002**	Sep 29, 2016
AB		**10MG**	**A206383**	**003**	Sep 29, 2016
AB		**15MG**	**A206383**	**004**	Sep 29, 2016
AB		**20MG**	**A206383**	**005**	Sep 29, 2016
AB		**30MG**	**A206383**	**006**	Sep 29, 2016
AB	TORRENT	**2MG**	**A201519**	**001**	Apr 28, 2015
AB		**10MG**	**A201519**	**003**	Apr 28, 2015
AB		**5MG**	**A201519**	**002**	Apr 28, 2015
AB		**15MG**	**A201519**	**004**	Apr 28, 2015
AB		**20MG**	**A201519**	**005**	Apr 28, 2015
AB		**30MG**	**A201519**	**006**	Apr 28, 2015
AB	UNICHEM	**2MG**	**A203025**	**001**	Dec 01, 2021
AB		**5MG**	**A203025**	**002**	Dec 01, 2021
AB		**10MG**	**A203025**	**003**	Dec 01, 2021
AB		**15MG**	**A203025**	**004**	Dec 01, 2021
AB		**20MG**	**A203025**	**005**	Dec 01, 2021
AB		**30MG**	**A203025**	**006**	Dec 01, 2021

ARIPIPRAZOLE

TABLET;ORAL

ABILIFY MYCITE KIT

	+	OTSUKA	2MG	N207202	001	Nov 13, 2017
	+!		5MG	N207202	002	Nov 13, 2017
	+		10MG	N207202	003	Nov 13, 2017
	+		15MG	N207202	004	Nov 13, 2017
	+		20MG	N207202	005	Nov 13, 2017
	+		30MG	N207202	006	Nov 13, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

ARIPIPRAZOLE

AB	!	ALEMBIC PHARMS LTD	**10MG**	**A202102**	**001**	Apr 28, 2015
AB			**15MG**	**A202102**	**002**	Apr 28, 2015
AB		ORBION PHARMS	**10MG**	**A202547**	**001**	Dec 11, 2017
AB			**15MG**	**A202547**	**002**	Dec 11, 2017
AB		SCIEGEN PHARMS INC	**10MG**	**A207240**	**001**	Apr 18, 2018
AB			**15MG**	**A207240**	**002**	Apr 18, 2018
AB		SQUARE PHARMS	**10MG**	**A090165**	**001**	Aug 28, 2018
AB			**15MG**	**A090165**	**002**	Aug 28, 2018
			20MG	A090165	003	Aug 28, 2018
			30MG	A090165	004	Aug 28, 2018

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA

	+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
	+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
	+!		882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
	+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017

ARISTADA INITIO KIT

	+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB		AUROBINDO PHARMA LTD	**50MG**	**A206069**	**001**	Mar 06, 2018
AB			**150MG**	**A206069**	**002**	Mar 06, 2018
AB			**200MG**	**A206069**	**004**	Dec 07, 2018
AB			**250MG**	**A206069**	**003**	Mar 06, 2018
AB		LUPIN LTD	**50MG**	**A200751**	**001**	Nov 28, 2016
AB			**150MG**	**A200751**	**003**	Nov 28, 2016
AB			**200MG**	**A200751**	**004**	Nov 28, 2016
AB			**250MG**	**A200751**	**005**	Nov 28, 2016
AB		MYLAN PHARMS INC	**50MG**	**A200043**	**001**	Jun 01, 2012
AB			**100MG**	**A200043**	**004**	May 09, 2019
AB			**150MG**	**A200043**	**002**	Jun 01, 2012
AB			**200MG**	**A200043**	**005**	May 09, 2019
AB			**250MG**	**A200043**	**003**	Jun 01, 2012
AB		NATCO PHARMA LTD	**50MG**	**A202768**	**001**	Nov 28, 2016
AB			**100MG**	**A202768**	**004**	Sep 28, 2017
AB			**150MG**	**A202768**	**002**	Nov 28, 2016
AB			**200MG**	**A202768**	**005**	Sep 28, 2017
AB			**250MG**	**A202768**	**003**	Nov 28, 2016

NUVIGIL

AB	+	CEPHALON	**50MG**	**N021875**	**001**	Jun 15, 2007
AB	+		**150MG**	**N021875**	**003**	Jun 15, 2007
AB	+		**200MG**	**N021875**	**005**	Mar 26, 2009
AB	+!		**250MG**	**N021875**	**004**	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP	AMNEAL	**1MG/ML**	**A210739**	**001**	Jan 25, 2021
AP		**2MG/ML**	**A210739**	**002**	Aug 19, 2021
AP	AMRING PHARMS	**1MG/ML**	**A210802**	**001**	Nov 13, 2018
AP	EUGIA PHARMA	**2MG/ML**	**A214011**	**001**	Oct 15, 2021
AP	FRESENIUS KABI USA	**1MG/ML**	**A208231**	**001**	Aug 31, 2018
AP	GLAND PHARMA LTD	**2MG/ML**	**A215059**	**001**	Oct 07, 2021
AP	INGENUS PHARMS LLC	**1MG/ML**	**A209315**	**001**	Nov 15, 2018
AP	NEXUS PHARMS	**1MG/ML**	**A209780**	**001**	Nov 15, 2018
AP	SANDOZ INC	**2MG/ML**	**A215359**	**001**	Dec 02, 2021
AP	STI PHARMA LLC	**1MG/ML**	**A209873**	**001**	May 06, 2019
AP	ZYDUS PHARMS	**1MG/ML**	**A206228**	**001**	Nov 13, 2018

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE						
AP			**2MG/ML**	**A206228**	**002**	Aug 30, 2019
TRISENOX						
AP	**+!**	CEPHALON	**2MG/ML**	**N021248**	**002**	Oct 13, 2017

ARTEMETHER; LUMEFANTRINE

TABLET;ORAL

COARTEM					
	+!	NOVARTIS	20MG;120MG	N022268	001 Apr 07, 2009

ARTESUNATE

POWDER;INTRAVENOUS

ARTESUNATE					
	+!	AMIVAS	110MG/VIAL	N213036	001 May 26, 2020

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

ORABLOC					
	+	PIERREL	4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)	N022466	001 Feb 26, 2010
	+!		4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)	N022466	002 Feb 26, 2010
SEPTOCAINE					
	+!	DEPROCO	4%; EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	N020971	002 Mar 30, 2006
	+!		4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971	001 Apr 03, 2000

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL

SCEMBLIX					
	+	NOVARTIS	EQ 20MG BASE	N215358	001 Oct 29, 2021
	+!		EQ 40MG BASE	N215358	002 Oct 29, 2021

ASCORBIC ACID

SOLUTION;INTRAVENOUS

ASCOR					
	+!	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001 Oct 02, 2017

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC					
	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	001 Feb 21, 2001
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)					
	+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002 Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS

M.V.I. PEDIATRIC					
	+!	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920	001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;INTRAVENOUS

M.V.I. ADULT					
	+!	HOSPIRA	200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL	N021625	001 Jan 30, 2004
M.V.I. ADULT (PHARMACY BULK PACKAGE)					
	+!	HOSPIRA	200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML	N021643	001 Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP

AA	**+!**	SALIX PHARMS	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**N021881**	**001**	Aug 02, 2006

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

AA		NOVEL LABS INC	**4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM**	**A090145**	**001**	Jan 25, 2012

PLENVU

	+!	SALIX	7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	N209381	001	May 04, 2018

ASENAPINE

SYSTEM;TRANSDERMAL

SECUADO

	+	HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019
	+		5.7MG/24HR	N212268	002	Oct 11, 2019
	+!		7.6MG/24HR	N212268	003	Oct 11, 2019

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

AB		ALEMBIC PHARMS LTD	**EQ 2.5MG BASE**	**A206098**	**003**	Jul 19, 2021
AB			**EQ 5MG BASE**	**A206098**	**001**	Dec 10, 2020
AB			**EQ 10MG BASE**	**A206098**	**002**	Dec 10, 2020
AB		BRECKENRIDGE	**EQ 2.5MG BASE**	**A205960**	**001**	Dec 10, 2020
AB			**EQ 5MG BASE**	**A205960**	**003**	Mar 08, 2021
AB			**EQ 10MG BASE**	**A205960**	**002**	Dec 10, 2020
AB		SIGMAPHARM LABS LLC	**EQ 5MG BASE**	**A206107**	**001**	Dec 10, 2020
AB			**EQ 10MG BASE**	**A206107**	**002**	Dec 10, 2020

SAPHRIS

AB	**+**	ALLERGAN	**EQ 2.5MG BASE**	**N022117**	**003**	Mar 12, 2015
AB	**+**		**EQ 5MG BASE**	**N022117**	**001**	Aug 13, 2009
AB	**+!**		**EQ 10MG BASE**	**N022117**	**002**	Aug 13, 2009

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

	+!	ESPERO	162.5MG	N200671	001	Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

FIORINAL

AA	**+!**	ALLERGAN	**325MG;50MG;40MG**	**N017534**	**005**	Apr 16, 1986

LANORINAL

AA		LANNETT	**325MG;50MG;40MG**	**A086996**	**002**	Oct 11, 1985

BUTALBITAL, ASPIRIN AND CAFFEINE

		LGM PHARMA	500MG;50MG;40MG	A205230	001	Oct 18, 2021

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

	!	STRIDES PHARMA	325MG;50MG;40MG	A204195	001	Sep 22, 2016

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB		LGM PHARMA	**325MG;50MG;40MG;30MG**	**A075231**	**001**	Nov 30, 2001
AB		MAYNE PHARMA INC	**325MG;50MG;40MG;30MG**	**A203335**	**001**	Oct 30, 2015
AB		STEVENS J	**325MG;50MG;40MG;30MG**	**A074951**	**001**	Aug 31, 1998

FIORINAL W/CODEINE

AB	**+!**	ALLERGAN	**325MG;50MG;40MG;30MG**	**N019429**	**003**	Oct 26, 1990

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENGESIC FORTE

	!	GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

	!	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

AGGRENOX

AB	**+!**	BOEHRINGER INGELHEIM	**25MG;200MG**	**N020884**	**001**	Nov 22, 1999

ASPIRIN AND DIPYRIDAMOLE

AB		AMNEAL PHARMS	**25MG;200MG**	**A206392**	**001**	Mar 08, 2016
AB		BARR	**25MG;200MG**	**A078804**	**001**	Aug 14, 2009

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB		DR REDDYS	**25MG;200MG**	**A209048**	**001**	Oct 10, 2018
AB		GLENMARK PHARMS SA	**25MG;200MG**	**A210318**	**001**	May 24, 2019
AB		MICRO LABS	**25MG;200MG**	**A209929**	**001**	Aug 11, 2021
AB		PAR PHARM INC	**25MG;200MG**	**A207944**	**001**	Jan 18, 2017
AB		SANDOZ INC	**25MG;200MG**	**A206739**	**001**	Jan 18, 2017
AB		ZYDUS PHARMS	**25MG;200MG**	**A206753**	**001**	Aug 29, 2017

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA		EPIC PHARMA LLC	**325MG;4.8355MG**	**A040910**	**001**	Jul 16, 2020

PERCODAN

AA	**+!**	ENDO PHARMS	**325MG;4.8355MG**	**N007337**	**007**	Aug 05, 2005

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB		AMNEAL	**EQ 150MG BASE**	**A209717**	**002**	Jun 01, 2020
AB			**EQ 200MG BASE**	**A209717**	**003**	Jun 01, 2020
AB			**EQ 300MG BASE**	**A209717**	**004**	Jun 01, 2020
AB		AUROBINDO PHARMA LTD	**EQ 100MG BASE**	**A204806**	**001**	Jun 25, 2018
AB			**EQ 150MG BASE**	**A204806**	**002**	Jun 25, 2018
AB			**EQ 200MG BASE**	**A204806**	**003**	Jun 25, 2018
AB			**EQ 300MG BASE**	**A204806**	**004**	Jun 25, 2018
AB		CIPLA	**EQ 100MG BASE**	**A200626**	**001**	Aug 09, 2018
AB			**EQ 150MG BASE**	**A200626**	**002**	Aug 09, 2018
AB			**EQ 200MG BASE**	**A200626**	**003**	Aug 09, 2018
AB			**EQ 300MG BASE**	**A200626**	**004**	Aug 09, 2018
AB		LAURUS	**EQ 150MG BASE**	**A212579**	**001**	Apr 30, 2021
AB			**EQ 200MG BASE**	**A212579**	**002**	Apr 30, 2021
AB			**EQ 300MG BASE**	**A212579**	**003**	Apr 30, 2021
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A091673**	**001**	Apr 22, 2014
AB			**EQ 150MG BASE**	**A091673**	**002**	Apr 22, 2014
AB			**EQ 200MG BASE**	**A091673**	**003**	Apr 22, 2014
AB			**EQ 300MG BASE**	**A091673**	**004**	Apr 22, 2014

REYATAZ

AB	**+**	BRISTOL MYERS SQUIBB	**EQ 150MG BASE**	**N021567**	**002**	Jun 20, 2003
AB	**+**		**EQ 200MG BASE**	**N021567**	**003**	Jun 20, 2003
AB	**+!**		**EQ 300MG BASE**	**N021567**	**004**	Oct 16, 2006

POWDER;ORAL

REYATAZ

	+!	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

	+!	BRISTOL-MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		ALVOGEN	**25MG**	**A072304**	**002**	Jul 31, 1992
AB			**50MG**	**A072304**	**003**	Jul 18, 1988
AB			**100MG**	**A072304**	**001**	Jul 15, 1988
AB		AUROBINDO PHARMA	**25MG**	**A078512**	**001**	Oct 31, 2007
AB			**50MG**	**A078512**	**002**	Oct 31, 2007
AB			**100MG**	**A078512**	**003**	Oct 31, 2007
AB		HLTHCARE	**25MG**	**A073026**	**002**	May 01, 1992
AB			**50MG**	**A073026**	**003**	Sep 17, 1991
AB			**100MG**	**A073026**	**001**	Sep 17, 1991
AB		IPCA LABS LTD	**25MG**	**A077877**	**001**	Dec 27, 2006
AB			**50MG**	**A077877**	**002**	Dec 27, 2006
AB			**100MG**	**A077877**	**003**	Dec 27, 2006
AB		MYLAN	**25MG**	**A073457**	**002**	Apr 26, 1999
AB			**50MG**	**A073457**	**003**	Jan 24, 1992
AB			**100MG**	**A073457**	**001**	Jan 24, 1992
AB		TEVA	**25MG**	**A074056**	**003**	Jul 19, 2004
AB			**50MG**	**A074056**	**001**	Jan 18, 1995

ATENOLOL

TABLET;ORAL

ATENOLOL

AB			**100MG**	**A074056**	**002**	Jan 18, 1995
AB		UNICHEM	**25MG**	**A213136**	**001**	Nov 21, 2019
AB			**50MG**	**A213136**	**002**	Nov 21, 2019
AB			**100MG**	**A213136**	**003**	Nov 21, 2019
AB		UNIQUE PHARM LABS	**25MG**	**A077443**	**001**	Sep 13, 2006
AB			**50MG**	**A077443**	**002**	Sep 13, 2006
AB			**100MG**	**A077443**	**003**	Sep 13, 2006
AB		ZYDUS PHARMS USA	**25MG**	**A076900**	**001**	Jan 28, 2005
AB			**50MG**	**A076900**	**002**	Jan 28, 2005
AB			**100MG**	**A076900**	**003**	Jan 28, 2005

TENORMIN

AB	**+**	ALMATICA	**25MG**	**N018240**	**004**	Apr 09, 1990
AB	**+**		**50MG**	**N018240**	**001**	
AB	**+!**		**100MG**	**N018240**	**002**	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ALVOGEN	**50MG;25MG**	**A072302**	**002**	May 31, 1990
AB			**100MG;25MG**	**A072302**	**001**	May 31, 1990
AB		NOVITIUM PHARMA	**50MG;25MG**	**A215560**	**001**	Oct 25, 2021
AB			**100MG;25MG**	**A215560**	**002**	Oct 25, 2021
AB		UNICHEM	**50MG;25MG**	**A213302**	**001**	Nov 25, 2020
AB			**100MG;25MG**	**A213302**	**002**	Nov 25, 2020
AB		WATSON LABS	**50MG;25MG**	**A073665**	**001**	Jul 02, 1992
AB			**100MG;25MG**	**A073665**	**002**	Jul 02, 1992
AB		ZYDUS PHARMS	**50MG;25MG**	**A210028**	**001**	Mar 08, 2019
AB			**100MG;25MG**	**A210028**	**002**	Mar 08, 2019

TENORETIC 100

AB	**+!**	ALMATICA	**100MG;25MG**	**N018760**	**001**	Jun 08, 1984

TENORETIC 50

AB	**+**	ALMATICA	**50MG;25MG**	**N018760**	**002**	Jun 08, 1984

ATOGEPANT

TABLET;ORAL

QULIPTA

+	ABBVIE INC	10MG	N215206	001	Sep 28, 2021
+		30MG	N215206	002	Sep 28, 2021
+!		60MG	N215206	003	Sep 28, 2021

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX	**10MG**	**A078983**	**001**	May 30, 2017
AB			**18MG**	**A078983**	**002**	May 30, 2017
AB			**25MG**	**A078983**	**003**	May 30, 2017
AB			**40MG**	**A078983**	**004**	May 30, 2017
AB			**60MG**	**A078983**	**005**	May 30, 2017
AB			**80MG**	**A078983**	**006**	May 30, 2017
AB			**100MG**	**A078983**	**007**	May 30, 2017
AB		AUROBINDO PHARMA LTD	**10MG**	**A079016**	**001**	May 30, 2017
AB			**18MG**	**A079016**	**002**	May 30, 2017
AB			**25MG**	**A079016**	**003**	May 30, 2017
AB			**40MG**	**A079016**	**004**	May 30, 2017
AB			**60MG**	**A079016**	**005**	May 30, 2017
AB			**80MG**	**A079016**	**006**	May 30, 2017
AB			**100MG**	**A079016**	**007**	May 30, 2017
AB		DR REDDYS LABS LTD	**10MG**	**A090609**	**001**	Feb 23, 2018
AB			**18MG**	**A090609**	**002**	Feb 23, 2018
AB			**25MG**	**A090609**	**003**	Feb 23, 2018
AB			**40MG**	**A090609**	**004**	Feb 23, 2018
AB			**60MG**	**A090609**	**005**	Feb 23, 2018
AB			**80MG**	**A090609**	**006**	Feb 23, 2018
AB			**100MG**	**A090609**	**007**	Feb 23, 2018
AB		GLENMARK PHARMS LTD	**10MG**	**A079019**	**001**	May 30, 2017
AB			**18MG**	**A079019**	**002**	May 30, 2017
AB			**25MG**	**A079019**	**003**	May 30, 2017
AB			**40MG**	**A079019**	**004**	May 30, 2017
AB			**60MG**	**A079019**	**005**	May 30, 2017
AB			**80MG**	**A079019**	**006**	May 30, 2017

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB			**100MG**	**A079019**	**007**	May 30, 2017
AB		HETERO LABS LTD V	**10MG**	**A202682**	**001**	Mar 11, 2021
AB			**18MG**	**A202682**	**002**	Mar 11, 2021
AB			**25MG**	**A202682**	**003**	Mar 11, 2021
AB			**40MG**	**A202682**	**004**	Mar 11, 2021
AB			**60MG**	**A202682**	**005**	Mar 11, 2021
AB			**80MG**	**A202682**	**006**	Mar 11, 2021
AB			**100MG**	**A202682**	**007**	Mar 11, 2021
AB		TEVA PHARMS USA	**10MG**	**A079022**	**001**	May 30, 2017
AB			**18MG**	**A079022**	**002**	May 30, 2017
AB			**25MG**	**A079022**	**003**	May 30, 2017
AB			**40MG**	**A079022**	**004**	May 30, 2017
AB			**60MG**	**A079022**	**005**	May 30, 2017
AB			**80MG**	**A079022**	**006**	May 30, 2017
AB			**100MG**	**A079022**	**007**	May 30, 2017
AB		ZYDUS PHARMS USA INC	**18MG**	**A079017**	**001**	Sep 17, 2010
AB			**25MG**	**A079017**	**002**	Sep 17, 2010
AB			**40MG**	**A079017**	**003**	Sep 17, 2010
AB			**60MG**	**A079017**	**004**	Sep 17, 2010
AB			**80MG**	**A079017**	**005**	Sep 17, 2010
AB			**100MG**	**A079017**	**006**	Sep 17, 2010

STRATTERA

AB	+	LILLY	**10MG**	**N021411**	**002**	Nov 26, 2002
AB	+		**18MG**	**N021411**	**003**	Nov 26, 2002
AB	+		**25MG**	**N021411**	**004**	Nov 26, 2002
AB	+		**40MG**	**N021411**	**005**	Nov 26, 2002
AB	+!		**60MG**	**N021411**	**006**	Nov 26, 2002
AB	+		**80MG**	**N021411**	**007**	Feb 14, 2005
AB	+		**100MG**	**N021411**	**008**	Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		ACCORD HLTHCARE	**EQ 10MG BASE**	**A207687**	**001**	Mar 30, 2018
AB			**EQ 20MG BASE**	**A207687**	**002**	Mar 30, 2018
AB			**EQ 40MG BASE**	**A207687**	**003**	Mar 30, 2018
AB			**EQ 80MG BASE**	**A207687**	**004**	Mar 30, 2018
AB		ALKEM LABS LTD	**EQ 10MG BASE**	**A209288**	**001**	Dec 21, 2018
AB			**EQ 20MG BASE**	**A209288**	**002**	Dec 21, 2018
AB			**EQ 40MG BASE**	**A209288**	**003**	Dec 21, 2018
AB			**EQ 80MG BASE**	**A209288**	**004**	Dec 21, 2018
AB		APOTEX INC	**EQ 10MG BASE**	**A090548**	**001**	May 29, 2012
AB			**EQ 20MG BASE**	**A090548**	**002**	May 29, 2012
AB			**EQ 40MG BASE**	**A090548**	**003**	May 29, 2012
AB			**EQ 80MG BASE**	**A090548**	**004**	May 29, 2012
AB		AUGUST	**EQ 10MG BASE**	**A214969**	**001**	Sep 02, 2021
AB			**EQ 20MG BASE**	**A214969**	**002**	Sep 02, 2021
AB			**EQ 40MG BASE**	**A214969**	**003**	Sep 02, 2021
AB			**EQ 80MG BASE**	**A214969**	**004**	Sep 02, 2021
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A091650**	**001**	Jul 17, 2012
AB			**EQ 20MG BASE**	**A091650**	**002**	Jul 17, 2012
AB			**EQ 40MG BASE**	**A091650**	**003**	Jul 17, 2012
AB			**EQ 80MG BASE**	**A202357**	**001**	Jul 17, 2012
AB		GRAVITI PHARMS	**EQ 10MG BASE**	**A209912**	**001**	Jun 18, 2018
AB			**EQ 20MG BASE**	**A209912**	**002**	Jun 18, 2018
AB			**EQ 40MG BASE**	**A209912**	**003**	Jun 18, 2018
AB			**EQ 80MG BASE**	**A209912**	**004**	Jun 18, 2018
AB		INVAGEN PHARMS	**EQ 10MG BASE**	**A204846**	**001**	Jan 09, 2017
AB			**EQ 20MG BASE**	**A204846**	**002**	Jan 09, 2017
AB			**EQ 40MG BASE**	**A204846**	**003**	Jan 09, 2017
AB			**EQ 80MG BASE**	**A204846**	**004**	Jan 09, 2017
AB		LANNETT CO INC	**EQ 10MG BASE**	**A091624**	**001**	Apr 05, 2013
AB			**EQ 20MG BASE**	**A091624**	**002**	Apr 05, 2013
AB			**EQ 40MG BASE**	**A091624**	**003**	Apr 05, 2013
AB			**EQ 80MG BASE**	**A091624**	**004**	Apr 05, 2013
AB		LUPIN LTD	**EQ 10MG BASE**	**A204991**	**001**	Mar 06, 2019
AB			**EQ 20MG BASE**	**A204991**	**002**	Mar 06, 2019
AB			**EQ 40MG BASE**	**A204991**	**003**	Mar 06, 2019
AB			**EQ 80MG BASE**	**A204991**	**004**	Mar 06, 2019

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB		MICRO LABS LTD INDIA	**EQ 10MG BASE**	**A205945**	**001**	Nov 07, 2019
AB			**EQ 20MG BASE**	**A205945**	**002**	Nov 07, 2019
AB			**EQ 40MG BASE**	**A205945**	**003**	Nov 07, 2019
AB			**EQ 80MG BASE**	**A205945**	**004**	Nov 07, 2019
AB		MSN	**EQ 10MG BASE**	**A211933**	**001**	Feb 08, 2019
AB			**EQ 20MG BASE**	**A211933**	**002**	Feb 08, 2019
AB			**EQ 40MG BASE**	**A211933**	**003**	Feb 08, 2019
AB			**EQ 80MG BASE**	**A211933**	**004**	Feb 08, 2019
AB		MYLAN PHARMS INC	**EQ 10MG BASE**	**A091226**	**001**	May 29, 2012
AB			**EQ 20MG BASE**	**A091226**	**002**	May 29, 2012
AB			**EQ 40MG BASE**	**A091226**	**003**	May 29, 2012
AB			**EQ 80MG BASE**	**A091226**	**004**	May 29, 2012
AB		SANDOZ INC	**EQ 10MG BASE**	**A077575**	**001**	May 29, 2012
AB			**EQ 20MG BASE**	**A077575**	**002**	May 29, 2012
AB			**EQ 40MG BASE**	**A077575**	**003**	May 29, 2012
AB			**EQ 80MG BASE**	**A077575**	**004**	May 29, 2012
AB		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A205519**	**001**	May 19, 2016
AB			**EQ 20MG BASE**	**A205519**	**002**	May 19, 2016
AB			**EQ 40MG BASE**	**A205519**	**003**	May 19, 2016
AB			**EQ 80MG BASE**	**A205519**	**004**	May 19, 2016
AB		SUN PHARM INDS LTD	**EQ 10MG BASE**	**A076477**	**001**	Nov 30, 2011
AB			**EQ 20MG BASE**	**A076477**	**002**	Nov 30, 2011
AB			**EQ 40MG BASE**	**A076477**	**003**	Nov 30, 2011
AB			**EQ 80MG BASE**	**A076477**	**004**	Nov 30, 2011
AB		TEVA PHARMS USA	**EQ 10MG BASE**	**A205300**	**001**	Mar 27, 2017
AB			**EQ 20MG BASE**	**A205300**	**002**	Mar 27, 2017
AB			**EQ 40MG BASE**	**A205300**	**003**	Mar 27, 2017
AB			**EQ 80MG BASE**	**A205300**	**004**	Mar 27, 2017
AB		UMEDICA LABS PVT LTD	**EQ 10MG BASE**	**A213853**	**001**	Aug 19, 2020
AB			**EQ 20MG BASE**	**A213853**	**002**	Aug 19, 2020
AB			**EQ 40MG BASE**	**A213853**	**003**	Aug 19, 2020
AB			**EQ 80MG BASE**	**A213853**	**004**	Aug 19, 2020
AB		ZYDUS PHARMS	**EQ 10MG BASE**	**A206536**	**001**	Nov 20, 2018
AB			**EQ 20MG BASE**	**A206536**	**002**	Nov 20, 2018
AB			**EQ 40MG BASE**	**A206536**	**003**	Nov 20, 2018
AB			**EQ 80MG BASE**	**A206536**	**004**	Nov 20, 2018

LIPITOR

AB	**+**	UPJOHN	**EQ 10MG BASE**	**N020702**	**001**	Dec 17, 1996
AB	**+**		**EQ 20MG BASE**	**N020702**	**002**	Dec 17, 1996
AB	**+**		**EQ 40MG BASE**	**N020702**	**003**	Dec 17, 1996
AB	**+!**		**EQ 80MG BASE**	**N020702**	**004**	Apr 07, 2000

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB		ABHAI LLC	**750MG/5ML**	**A210510**	**001**	May 31, 2019
AB		ABON PHARMS LLC	**750MG/5ML**	**A214272**	**001**	Oct 25, 2021
AB		AMNEAL PHARMS	**750MG/5ML**	**A202960**	**001**	Mar 18, 2014
AB		APOTEX	**750MG/5ML**	**A209750**	**001**	Oct 11, 2017
AB		BIONPHARMA INC	**750MG/5ML**	**A212918**	**001**	Mar 30, 2021
AB		GLENMARK PHARMS	**750MG/5ML**	**A209685**	**001**	Nov 21, 2018
AB		HETERO LABS LTD III	**750MG/5ML**	**A210692**	**001**	Oct 11, 2018
AB		LUPIN LTD	**750MG/5ML**	**A209105**	**001**	Sep 11, 2018
AB		PADAGIS US	**750MG/5ML**	**A207833**	**001**	Apr 28, 2017

MEPRON

AB	**+!**	GLAXOSMITHKLINE LLC	**750MG/5ML**	**N020500**	**001**	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	**62.5MG;25MG**	**A091211**	**002**	Apr 06, 2015
AB			**250MG;100MG**	**A091211**	**001**	Jan 12, 2011
AB		MYLAN	**62.5MG;25MG**	**A202362**	**001**	May 27, 2014
AB			**250MG;100MG**	**A202362**	**002**	May 27, 2014

MALARONE

AB	**+!**	GLAXOSMITHKLINE	**250MG;100MG**	**N021078**	**001**	Jul 14, 2000

MALARONE PEDIATRIC

AB	**+**	GLAXOSMITHKLINE	**62.5MG;25MG**	**N021078**	**002**	Jul 14, 2000

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP		EUGIA PHARMA	**10MG/ML**	**A206011**	**001**	Apr 08, 2015
AP	!	HIKMA	**10MG/ML**	**A074901**	**001**	Jul 18, 1997
AP		HOSPIRA INC	**10MG/ML**	**A090761**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091489**	**001**	Feb 17, 2012

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP		EUGIA PHARMA	**10MG/ML**	**A206010**	**001**	Apr 08, 2015
AP	!	HIKMA	**10MG/ML**	**A074900**	**001**	Jul 18, 1997
AP		HOSPIRA INC	**10MG/ML**	**A090782**	**001**	Oct 18, 2012
AP		MEITHEAL	**10MG/ML**	**A091488**	**001**	Feb 17, 2012

ATROPINE

SOLUTION;INTRAMUSCULAR

ATROPEN

	+!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
	+!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
	+!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
	+!		EQ 2MG SULFATE/0.7ML	N017106	001	

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP		ACCORD HLTHCARE	**0.25MG/5ML (0.05MG/ML)**	**A212868**	**001**	Jul 26, 2021
AP			**0.5MG/5ML (0.1MG/ML)**	**A212868**	**002**	Jul 26, 2021
AP			**1MG/10ML (0.1MG/ML)**	**A212868**	**003**	Jul 26, 2021
AP	**+!**	HOSPIRA	**0.25MG/5ML (0.05MG/ML)**	**N021146**	**002**	Jul 09, 2001
AP	**+!**		**0.5MG/5ML (0.1MG/ML)**	**N021146**	**004**	Aug 17, 2017
AP	**+!**		**1MG/10ML (0.1MG/ML)**	**N021146**	**003**	Jul 09, 2001
AP		INTL MEDICATION SYS	**1MG/10ML (0.1MG/ML)**	**A212461**	**001**	Oct 05, 2020
	+!	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020
	+!		1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

AP		ACCORD HLTHCARE	**8MG/20ML (0.4MG/ML)**	**A213424**	**001**	Mar 19, 2021
AP	**+!**	FRESENIUS KABI USA	**8MG/20ML (0.4MG/ML)**	**N209260**	**001**	Jan 26, 2018
AP		HIKMA	**8MG/20ML (0.4MG/ML)**	**A213561**	**001**	Dec 01, 2021

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

AT	**+!**	AKORN	**1%**	**N206289**	**001**	Jul 18, 2014
AT		APOTEX INC	**1%**	**A215624**	**001**	Nov 26, 2021

ISOPTO ATROPINE

	+!	ALCON LABS INC	1%	N208151	001	Dec 01, 2016

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

	+!	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	!	HIKMA	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS	**0.025MG;2.5MG**	**A086727**	**001**	
AA		BAYSHORE PHARMS LLC	**0.025MG;2.5MG**	**A210819**	**001**	Nov 13, 2018
AA		LANNETT	**0.025MG;2.5MG**	**A085372**	**001**	
AA		LEADING PHARMA LLC	**0.025MG;2.5MG**	**A213413**	**001**	Feb 20, 2020
AA		MAYNE PHARMA INC	**0.025MG;2.5MG**	**A210789**	**001**	Jun 03, 2020
AA		MYLAN	**0.025MG;2.5MG**	**A085762**	**001**	
AA		PHARMA LIFE	**0.025MG;2.5MG**	**A207128**	**001**	Oct 21, 2020
AA		SPECGX LLC	**0.025MG;2.5MG**	**A213335**	**001**	Oct 06, 2020
AA		UPSHER SMITH LABS	**0.025MG;2.5MG**	**A210571**	**001**	Aug 31, 2018
AA		WINDER LABS LLC	**0.025MG;2.5MG**	**A211362**	**001**	Jan 27, 2021

LOMOTIL

AA	**+!**	PFIZER	**0.025MG;2.5MG**	**N012462**	**001**	

ATROPINE; PRALIDOXIME CHLORIDE
INJECTABLE;INTRAMUSCULAR
DUODOTE

+!	MERIDIAN MEDCL	2.1MG/0.7ML;600MG/2ML		N021983	001	Sep 28, 2006

AURANOFIN
CAPSULE;ORAL
RIDAURA

+!	SEBELA IRELAND LTD	3MG		N018689	001	May 24, 1985

AVACOPAN
CAPSULE;ORAL
TAVNEOS

+!	CHEMOCENTRYX	10MG		N214487	001	Oct 07, 2021

AVANAFIL
TABLET;ORAL
STENDRA

+	METUCHEN PHARMS	50MG		N202276	001	Apr 27, 2012
+		100MG		N202276	002	Apr 27, 2012
+!		200MG		N202276	003	Apr 27, 2012

AVAPRITINIB
TABLET;ORAL
AYVAKIT

+	BLUEPRINT MEDICINES	25MG		N212608	004	Jun 16, 2021
+		50MG		N212608	005	Jun 16, 2021
+		100MG		N212608	001	Jan 09, 2020
+		200MG		N212608	002	Jan 09, 2020
+!		300MG		N212608	003	Jan 09, 2020

AVATROMBOPAG MALEATE
TABLET;ORAL
DOPTELET

+!	AKARX INC	EQ 20MG BASE		N210238	001	May 21, 2018

AVIBACTAM SODIUM; CEFTAZIDIME
POWDER;INTRAVENOUS
AVYCAZ

+!	ALLERGAN	EQ 0.5GM BASE;2GM/VIAL		N206494	001	Feb 25, 2015

AXITINIB
TABLET;ORAL
INLYTA

+	PF PRISM CV	1MG		N202324	001	Jan 27, 2012
+!		5MG		N202324	002	Jan 27, 2012

AZACITIDINE
POWDER;INTRAVENOUS, SUBCUTANEOUS
AZACITIDINE

AP	ACCORD HLTHCARE	**100MG/VIAL**		**A207475**	**001**	Jul 02, 2018
AP	ACTAVIS LLC	**100MG/VIAL**		**N208216**	**001**	Apr 29, 2016
AP	CIPLA	**100MG/VIAL**		**A209540**	**001**	May 04, 2018
AP	DR REDDYS	**100MG/VIAL**		**A201537**	**001**	Sep 16, 2013
AP	EUROHLTH INTL SARL	**100MG/VIAL**		**A209337**	**001**	Jun 08, 2020
AP	MEITHEAL	**100MG/VIAL**		**A212128**	**001**	Nov 02, 2020
AP	MYLAN INSTITUTIONAL	**100MG/VIAL**		**A204949**	**001**	Apr 28, 2016
AP	NATCO PHARMA LTD	**100MG/VIAL**		**A207234**	**001**	Jun 23, 2017
AP	SHILPA MEDICARE	**100MG/VIAL**		**A207518**	**001**	Sep 29, 2016

VIDAZA

AP	**+!** CELGENE	**100MG/VIAL**		**N050794**	**001**	May 19, 2004

TABLET;ORAL
ONUREG

+	CELGENE CORP	200MG		N214120	001	Sep 01, 2020
+!		300MG		N214120	002	Sep 01, 2020

AZATHIOPRINE
TABLET;ORAL
AZASAN

AB	AAIPHARMA LLC	**25MG**		**A075252**	**002**	Feb 03, 2003
AB		**50MG**		**A075252**	**001**	Jun 07, 1999
AB		**75MG**		**A075252**	**003**	Feb 03, 2003
AB		**100MG**		**A075252**	**004**	Feb 03, 2003

AZATHIOPRINE

AB	ALKEM LABS LTD	**25MG**		**A208687**	**001**	Mar 27, 2020
AB		**50MG**		**A208687**	**002**	Mar 27, 2020
AB		**75MG**		**A208687**	**003**	Mar 27, 2020

AZATHIOPRINE

TABLET;ORAL

AZATHIOPRINE

AB			**100MG**	**A208687**	**004**	Mar 27, 2020
AB		AMNEAL	**50MG**	**A074069**	**001**	Feb 16, 1996
AB			**75MG**	**A074069**	**002**	Nov 02, 2021
AB			**100MG**	**A074069**	**003**	Nov 02, 2021
AB		RISING	**50MG**	**A075568**	**001**	Dec 13, 1999
AB		ZYDUS PHARMS USA	**25MG**	**A077621**	**002**	Sep 05, 2008
AB			**50MG**	**A077621**	**001**	Mar 15, 2007
AB			**75MG**	**A077621**	**003**	Sep 05, 2008
AB			**100MG**	**A077621**	**004**	Sep 05, 2008

IMURAN

AB	**+!**	SEBELA IRELAND LTD	**50MG**	**N016324**	**001**	

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

AZATHIOPRINE SODIUM

	!	HIKMA	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

AB	**+!**	LEO PHARMA AS	**15%**	**N207071**	**001**	Jul 29, 2015

CREAM;TOPICAL

AZELEX

	+!	ALMIRALL	20%	N020428	001	Sep 13, 1995

GEL;TOPICAL

AZELAIC ACID

AB		ACTAVIS LABS UT INC	**15%**	**A208011**	**001**	Nov 19, 2018
AB		GLENMARK PHARMS	**15%**	**A204637**	**001**	Nov 19, 2018
AB		TARO	**15%**	**A210549**	**001**	Aug 23, 2019
AB		TOLMAR	**15%**	**A208724**	**001**	Nov 19, 2018

FINACEA

AB	**+!**	LEO PHARMA AS	**15%**	**N021470**	**001**	Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		AKORN	**0.05%**	**A203660**	**001**	Nov 08, 2016
AT		ALEMBIC PHARMS LTD	**0.05%**	**A209620**	**001**	Mar 20, 2019
AT		APOTEX INC	**0.05%**	**A078621**	**001**	Aug 03, 2009
AT		GLAND PHARMA LTD	**0.05%**	**A210092**	**001**	Feb 25, 2020
AT	!	SANDOZ INC	**0.05%**	**A202305**	**001**	May 31, 2012
AT		SOMERSET THERAPS LLC	**0.05%**	**A207411**	**001**	Mar 29, 2019
AT		SUN PHARM	**0.05%**	**A078738**	**001**	Jun 21, 2010

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB		AKORN	**0.137MG/SPRAY**	**A207610**	**001**	May 17, 2019
AB			**0.2055MG/SPRAY**	**A210032**	**001**	Aug 23, 2019
AB		ALKEM LABS LTD	**0.137MG/SPRAY**	**A208156**	**001**	Aug 18, 2017
AB		AMNEAL	**0.137MG/SPRAY**	**A204660**	**001**	Aug 28, 2017
AB			**0.2055MG/SPRAY**	**A208199**	**001**	Dec 15, 2017
AB	!	APOTEX INC	**0.137MG/SPRAY**	**A077954**	**001**	Apr 30, 2009
AB			**0.2055MG/SPRAY**	**A201846**	**001**	Aug 31, 2012
AB		AUROBINDO PHARMA LTD	**0.137MG/SPRAY**	**A212289**	**001**	May 08, 2020
AB			**0.2055MG/SPRAY**	**A212775**	**001**	Nov 12, 2020
AB		BRECKENRIDGE	**0.137MG/SPRAY**	**A090176**	**001**	Jul 28, 2015
AB		HIKMA	**0.137MG/SPRAY**	**A091444**	**001**	Oct 24, 2014
AB			**0.2055MG/SPRAY**	**A207243**	**001**	Sep 22, 2017
AB		PADAGIS ISRAEL	**0.2055MG/SPRAY**	**A202743**	**001**	May 08, 2014
AB		SUN PHARM	**0.137MG/SPRAY**	**A090423**	**001**	May 23, 2012
AB		UPSHER SMITH LABS	**0.137MG/SPRAY**	**A202609**	**001**	Mar 17, 2017
AB		ZYDUS PHARMS	**0.137MG/SPRAY**	**A091409**	**001**	Aug 14, 2017

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		APOTEX	**0.137MG/SPRAY;0.05MG/SPRAY**	**A207712**	**001**	Apr 28, 2017
AB		PADAGIS ISRAEL	**0.137MG/SPRAY;0.05MG/SPRAY**	**A208111**	**001**	Feb 18, 2021

DYMISTA

AB	**+!**	MYLAN SPECIALITY LP	**0.137MG/SPRAY;0.05MG/SPRAY**	**N202236**	**001**	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011
+!		EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

+	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011
+!		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	AMNEAL	**EQ 100MG BASE/5ML**	**A205666**	**001**	Jul 19, 2018
AB		**EQ 200MG BASE/5ML**	**A205666**	**002**	Jul 19, 2018
AB	AUROBINDO PHARMA LTD	**EQ 100MG BASE/5ML**	**A209201**	**001**	Oct 09, 2018
AB		**EQ 200MG BASE/5ML**	**A209201**	**002**	Oct 09, 2018
AB	EPIC PHARMA LLC	**EQ 100MG BASE/5ML**	**A207531**	**001**	Apr 09, 2018
AB		**EQ 200MG BASE/5ML**	**A207531**	**002**	Apr 09, 2018
AB	PLIVA	**EQ 100MG BASE/5ML**	**A065246**	**002**	Jul 05, 2006
AB		**EQ 200MG BASE/5ML**	**A065246**	**001**	Jul 05, 2006
AB	TARO	**EQ 200MG BASE/5ML**	**A211521**	**001**	Dec 11, 2019
AB	ZYDUS	**EQ 100MG BASE/5ML**	**A211147**	**001**	Jul 31, 2018
AB		**EQ 200MG BASE/5ML**	**A211147**	**002**	Jul 31, 2018

ZITHROMAX

AB **+**	PFIZER	**EQ 100MG BASE/5ML**	**N050710**	**001**	Oct 19, 1995
AB **+!**		**EQ 200MG BASE/5ML**	**N050710**	**002**	Oct 19, 1995
+!		EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994

INJECTABLE;INJECTION

AZITHROMYCIN

AP	EUGIA PHARMA	**EQ 500MG BASE/VIAL**	**A203294**	**001**	Jun 19, 2015
AP	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A065179**	**001**	Dec 13, 2005
AP	GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A065501**	**001**	Nov 09, 2009
AP	HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A203412**	**001**	Oct 09, 2018
AP	HOSPIRA	**EQ 500MG BASE/VIAL**	**A065500**	**001**	Jun 26, 2009
AP		**EQ 500MG BASE/VIAL**	**A065511**	**001**	Jun 26, 2009
AP	SUN PHARM INDS LTD	**EQ 500MG BASE/VIAL**	**A090923**	**001**	Apr 02, 2013

ZITHROMAX

AP **+!**	PFIZER	**EQ 500MG BASE/VIAL**	**N050733**	**001**	Jan 30, 1997

SOLUTION/DROPS;OPHTHALMIC

AZASITE

+!	AKORN	1%	N050810	001	Apr 27, 2007

TABLET;ORAL

AZITHROMYCIN

AB	ALEMBIC PHARMS LTD	**EQ 250MG BASE**	**A211791**	**001**	Jan 28, 2020
AB		**EQ 500MG BASE**	**A211792**	**001**	Jan 28, 2020
AB		**EQ 600MG BASE**	**A211793**	**001**	Jan 27, 2020
AB	AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A207370**	**001**	Jul 05, 2018
AB		**EQ 500MG BASE**	**A207398**	**001**	Jul 05, 2018
AB	BIONPHARMA INC	**EQ 250MG BASE**	**A210000**	**001**	Feb 26, 2019
AB		**EQ 500MG BASE**	**A210001**	**001**	Feb 26, 2019
AB		**EQ 600MG BASE**	**A209999**	**001**	Dec 26, 2018
AB	CSPC OUYI	**EQ 250MG BASE**	**A208250**	**001**	Apr 17, 2019
AB		**EQ 500MG BASE**	**A208249**	**001**	Oct 25, 2018
AB		**EQ 600MG BASE**	**A207566**	**001**	Sep 24, 2018
AB	LUPIN LTD	**EQ 250MG BASE**	**A065398**	**001**	May 15, 2015
AB		**EQ 500MG BASE**	**A065399**	**001**	May 15, 2015
AB		**EQ 600MG BASE**	**A065400**	**001**	May 15, 2015
AB	PLIVA	**EQ 250MG BASE**	**A065225**	**001**	Nov 14, 2005
AB		**EQ 500MG BASE**	**A065223**	**001**	Nov 14, 2005
AB **!**		**EQ 600MG BASE**	**A065218**	**001**	Nov 14, 2005
AB	SANDOZ	**EQ 250MG BASE**	**A065211**	**001**	Nov 14, 2005
AB		**EQ 500MG BASE**	**A065212**	**001**	Nov 14, 2005
AB		**EQ 600MG BASE**	**A065209**	**001**	Nov 14, 2005
AB	SUNSHINE	**EQ 250MG BASE**	**A209045**	**001**	Dec 07, 2018
AB		**EQ 500MG BASE**	**A209044**	**001**	Dec 07, 2018
AB		**EQ 600MG BASE**	**A209043**	**001**	Dec 06, 2018
AB	TEVA	**EQ 500MG BASE**	**A065193**	**001**	Nov 14, 2005
AB	WOCKHARDT	**EQ 250MG BASE**	**A065404**	**001**	Feb 11, 2008
AB		**EQ 500MG BASE**	**A065405**	**001**	Feb 11, 2008

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

AB			**EQ 600MG BASE**	**A065302**	**003**	Feb 11, 2008
AB		YUNG SHIN PHARM	**EQ 600MG BASE**	**A211068**	**001**	May 08, 2020

ZITHROMAX

AB	**+**	PFIZER	**EQ 250MG BASE**	**N050711**	**001**	Jul 18, 1996
AB	**+**		**EQ 500MG BASE**	**N050784**	**001**	May 24, 2002

AZTREONAM

FOR SOLUTION;INHALATION

CAYSTON

	+!	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010

INJECTABLE;INJECTION

AZACTAM

AP	**+!**	BRISTOL MYERS SQUIBB	**1GM/VIAL**	**N050580**	**002**	Dec 31, 1986
AP	**+!**		**2GM/VIAL**	**N050580**	**003**	Dec 31, 1986

AZTREONAM

AP		FRESENIUS KABI USA	**1GM/VIAL**	**A065439**	**002**	Jun 18, 2010
AP			**2GM/VIAL**	**A065439**	**003**	Jun 18, 2010
AP		HOSPIRA INC	**1GM/VIAL**	**A206517**	**001**	Nov 08, 2021
AP			**2GM/VIAL**	**A206517**	**002**	Nov 08, 2021
		FRESENIUS KABI USA	500MG/VIAL	A065439	001	Jun 18, 2010

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

	!	PADAGIS US	500 UNITS/GM	A061212	001	

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	!	PADAGIS US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT		AKORN	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A065213**	**001**	Jul 25, 2012
AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064068**	**001**	Oct 30, 1995

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT	**+**	CASPER PHARMA LLC	**EQ 400 UNITS/GM;EQ 3.5MG BASE/GM;EQ 10,000 UNITS/GM**	**N050417**	**001**	

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		AKORN	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A065088**	**001**	Feb 06, 2004
AT	**!**	BAUSCH AND LOMB	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064064**	**001**	Oct 30, 1995
AT		PADAGIS US	**400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A060764**	**002**	

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		AKORN	**500 UNITS/GM;10,000 UNITS/GM**	**A064028**	**001**	Jan 30, 1995
AT	**!**	BAUSCH AND LOMB	**500 UNITS/GM;10,000 UNITS/GM**	**A064046**	**001**	Jan 26, 1995
AT		PADAGIS US	**500 UNITS/GM;10,000 UNITS/GM**	**A065022**	**001**	Feb 27, 2002

BACLOFEN

GRANULES;ORAL

LYVISPAH

	+	SAOL THERAPS RES LTD	5MG/PACKET	N215422	001	Nov 22, 2021
	+		10MG/PACKET	N215422	002	Nov 22, 2021
	+!		20MG/PACKET	N215422	003	Nov 22, 2021

INJECTABLE;INTRATHECAL

BACLOFEN

AP		EMERALD INTL LTD	**0.05MG/ML**	**A091193**	**001**	May 03, 2016
AP			**0.5MG/ML**	**A091193**	**002**	May 03, 2016
AP			**2MG/ML**	**A091193**	**003**	May 03, 2016
AP		MAIA PHARMS INC	**0.05MG/ML**	**A210777**	**001**	Jan 15, 2021
AP			**0.5MG/ML**	**A210048**	**001**	Sep 11, 2019

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP			**1MG/ML**	**A210315**	**001**	Jul 30, 2019
AP			**2MG/ML**	**A210048**	**002**	Sep 11, 2019
AP		MYLAN LABS LTD	**0.5MG/ML**	**A209592**	**001**	Mar 21, 2018
AP			**1MG/ML**	**A209594**	**001**	Mar 06, 2018
AP			**2MG/ML**	**A209592**	**002**	Mar 21, 2018

GABLOFEN

AP	**+!**	PIRAMAL CRITICAL	**0.05MG/ML**	**N022462**	**001**	Nov 19, 2010
AP	**+!**		**0.5MG/ML**	**N022462**	**002**	Nov 19, 2010
AP	**+!**		**1MG/ML**	**N022462**	**004**	Jun 22, 2012
AP	**+!**		**2MG/ML**	**N022462**	**003**	Nov 19, 2010

LIORESAL

AP	**+!**	SAOL THERAPS RES LTD	**0.05MG/ML**	**N020075**	**003**	Nov 07, 1996
AP	**+!**		**0.5MG/ML**	**N020075**	**001**	Jun 17, 1992
AP	**+!**		**2MG/ML**	**N020075**	**002**	Jun 17, 1992

SOLUTION;ORAL

OZOBAX

	+!	METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019

TABLET;ORAL

BACLOFEN

AB		AUROBINDO PHARMA LTD	**10MG**	**A214099**	**001**	Jul 13, 2021
AB			**20MG**	**A214099**	**002**	Jul 13, 2021
AB		BEXIMCO PHARMS USA	**10MG**	**A214114**	**001**	Jul 16, 2021
AB			**20MG**	**A214114**	**002**	Jul 16, 2021
AB		EYWA PHARMA	**5MG**	**A211555**	**003**	Nov 30, 2021
AB			**10MG**	**A211555**	**001**	Feb 01, 2019
AB			**20MG**	**A211555**	**002**	Feb 01, 2019
AB		IMPAX	**5MG**	**A077971**	**003**	Jul 07, 2021
AB			**10MG**	**A077971**	**001**	Oct 26, 2007
AB			**20MG**	**A077971**	**002**	Oct 26, 2007
AB		INNOGENIX	**5MG**	**A212378**	**003**	Apr 30, 2021
AB			**10MG**	**A212378**	**001**	Oct 09, 2020
AB			**20MG**	**A212378**	**002**	Oct 09, 2020
AB		IVAX SUB TEVA PHARMS	**10MG**	**A072234**	**001**	Jul 21, 1988
AB	**!**		**20MG**	**A072235**	**001**	Jul 21, 1988
AB		KARTHA	**5MG**	**A214374**	**001**	Mar 05, 2021
AB			**10MG**	**A214374**	**002**	Mar 05, 2021
AB			**20MG**	**A214374**	**003**	Mar 05, 2021
AB		LANNETT CO INC	**5MG**	**A077241**	**003**	Sep 22, 2021
AB			**10MG**	**A077241**	**002**	Jul 06, 2007
AB			**20MG**	**A077241**	**001**	Dec 20, 2005
AB		NORTHSTAR HLTHCARE	**10MG**	**A078401**	**002**	Sep 18, 2009
AB			**20MG**	**A078401**	**001**	Sep 18, 2009
AB		OXFORD PHARMS	**10MG**	**A077088**	**002**	Oct 31, 2007
AB			**20MG**	**A077088**	**001**	Oct 31, 2007
AB		RUBICON	**5MG**	**A209102**	**001**	Nov 28, 2017
AB			**10MG**	**A209102**	**002**	Nov 28, 2017
AB			**20MG**	**A209102**	**003**	Nov 28, 2017
AB		UNICHEM	**10MG**	**A212067**	**001**	Jul 09, 2020
AB			**20MG**	**A212067**	**002**	Jul 09, 2020
AB		UPSHER SMITH LABS	**10MG**	**A074584**	**001**	Aug 19, 1996
AB			**20MG**	**A074584**	**002**	Aug 19, 1996
AB		VINTAGE PHARMS	**10MG**	**A077068**	**002**	Aug 30, 2005
AB			**20MG**	**A077068**	**001**	Aug 30, 2005
AB		ZYDUS	**5MG**	**A211659**	**003**	Apr 17, 2020
AB			**10MG**	**A211659**	**001**	Nov 23, 2018
AB			**20MG**	**A211659**	**002**	Nov 23, 2018

BALOXAVIR MARBOXIL

FOR SUSPENSION;ORAL

XOFLUZA

	+!	GENENTECH INC	2MG/ML	N214410	001	Nov 23, 2020

TABLET;ORAL

XOFLUZA

	+	GENENTECH INC	20MG	N210854	001	Oct 24, 2018
	+!		40MG	N210854	002	Oct 24, 2018
	+		80MG	N210854	003	Mar 18, 2021

BALSALAZIDE DISODIUM						
CAPSULE;ORAL						
BALSALAZIDE DISODIUM						
AB		APOTEX INC	**750MG**	**A077883**	**001**	Dec 28, 2007
AB		HIKMA	**750MG**	**A077806**	**001**	Dec 28, 2007
COLAZAL						
AB	**+!**	VALEANT PHARMS INTL	**750MG**	**N020610**	**001**	Jul 18, 2000
BARICITINIB						
TABLET;ORAL						
OLUMIANT						
	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019
	+!		2MG	N207924	001	May 31, 2018
BARIUM SULFATE						
FOR SUSPENSION;ORAL						
E-Z-HD						
	+!	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016
E-Z-PAQUE						
	+!	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017
VARIBAR THIN LIQUID						
	+!	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019
PASTE;ORAL						
VARIBAR PUDDING						
		BRACCO	40%	N208844	001	Oct 14, 2016
SUSPENSION;ORAL						
ENTERO VU 24%						
	+!	BRACCO	24% (144GM/600ML)	N208143	008	May 29, 2020
LIQUID E-Z-PAQUE						
	+!	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017
READI-CAT 2						
	+!	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016
READI-CAT 2 SMOOTHIE						
	+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016
TAGITOL V						
	+!	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017
VARIBAR HONEY						
	+!	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018
VARIBAR NECTAR						
	+!	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017
VARIBAR THIN HONEY						
	+!	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED						
TABLET;ORAL						
DUAVEE						
	+!	WYETH PHARMS	EQ 20MG BASE;0.45MG	N022247	001	Oct 03, 2013
BECLOMETHASONE DIPROPIONATE						
AEROSOL, METERED;INHALATION						
QVAR REDIHALER						
	+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017
	+		0.08MG/INH	N207921	002	Aug 03, 2017
AEROSOL, METERED;NASAL						
QNASL						
	+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014
	+!		0.08MG/ACTUATION	N202813	001	Mar 23, 2012
BECLOMETHASONE DIPROPIONATE MONOHYDRATE						
SPRAY, METERED;NASAL						
BECONASE AQ						
	+!	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389	001	Jul 27, 1987
BEDAQUILINE FUMARATE						
TABLET;ORAL						
SIRTURO						
	+	JANSSEN THERAP	EQ 20MG BASE	N204384	002	May 27, 2020
	+!		EQ 100MG BASE	N204384	001	Dec 28, 2012
BELINOSTAT						
POWDER;INTRAVENOUS						
BELEODAQ						
	+!	ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014

BELUMOSUDIL MESYLATE

TABLET;ORAL

REZUROCK

+!	KADMON PHARMS LLC	EQ 200MG BASE	N214783	001	Jul 16, 2021

BELZUTIFAN

TABLET;ORAL

WELIREG

+!	MERCK SHARP DOHME	40MG	N215383	001	Aug 13, 2021

BEMPEDOIC ACID

TABLET;ORAL

NEXLETOL

+!	ESPERION THERAPS INC	180MG	N211616	001	Feb 21, 2020

BEMPEDOIC ACID; EZETIMIBE

TABLET;ORAL

NEXLIZET

+!	ESPERION THERAPS INC	180MG;10MG	N211617	001	Feb 26, 2020

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS	**5MG**	**A076820**	**001**	Feb 03, 2006
AB			**10MG**	**A076820**	**002**	Feb 03, 2006
AB			**20MG**	**A076820**	**003**	Feb 03, 2006
AB			**40MG**	**A076820**	**004**	Feb 03, 2006
AB		ANNORA PHARMA	**5MG**	**A077128**	**001**	Mar 08, 2006
AB			**10MG**	**A077128**	**002**	Mar 08, 2006
AB			**20MG**	**A077128**	**003**	Mar 08, 2006
AB			**40MG**	**A077128**	**004**	Mar 08, 2006
AB		AUROBINDO PHARMA	**10MG**	**A078212**	**001**	May 22, 2008
AB			**20MG**	**A078212**	**002**	May 22, 2008
AB			**40MG**	**A078212**	**003**	May 22, 2008
AB		CADILA	**5MG**	**A078848**	**001**	May 23, 2008
AB			**10MG**	**A078848**	**002**	May 23, 2008
AB			**20MG**	**A078848**	**003**	May 23, 2008
AB			**40MG**	**A078848**	**004**	May 23, 2008
AB		CHARTWELL RX	**5MG**	**A076402**	**001**	Feb 11, 2004
AB			**10MG**	**A076402**	**002**	Feb 11, 2004
AB			**20MG**	**A076402**	**003**	Feb 11, 2004
AB			**40MG**	**A076402**	**004**	Feb 11, 2004
AB		PRINSTON INC	**5MG**	**A076118**	**001**	Feb 11, 2004
AB			**10MG**	**A076118**	**002**	Feb 11, 2004
AB			**20MG**	**A076118**	**003**	Feb 11, 2004
AB			**40MG**	**A076118**	**004**	Feb 11, 2004
AB		SUN PHARM INDS LTD	**5MG**	**A076344**	**001**	Feb 11, 2004
AB			**10MG**	**A076344**	**002**	Feb 11, 2004
AB			**20MG**	**A076344**	**003**	Feb 11, 2004
AB			**40MG**	**A076344**	**004**	Feb 11, 2004
AB		TEVA	**5MG**	**A076211**	**001**	Feb 11, 2004
AB			**10MG**	**A076211**	**002**	Feb 11, 2004
AB			**20MG**	**A076211**	**003**	Feb 11, 2004
AB			**40MG**	**A076211**	**004**	Feb 11, 2004

LOTENSIN

AB	+	VALIDUS PHARMS	**5MG**	**N019851**	**001**	Jun 25, 1991
AB	+		**10MG**	**N019851**	**002**	Jun 25, 1991
AB	+		**20MG**	**N019851**	**003**	Jun 25, 1991
AB	+!		**40MG**	**N019851**	**004**	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SANDOZ	**10MG;12.5MG**	**A076631**	**002**	Feb 11, 2004
AB			**20MG;12.5MG**	**A076631**	**003**	Feb 11, 2004
AB			**20MG;25MG**	**A076631**	**004**	Feb 11, 2004

LOTENSIN HCT

AB	+	VALIDUS PHARMS	**10MG;12.5MG**	**N020033**	**002**	May 19, 1992
AB	+		**20MG;12.5MG**	**N020033**	**004**	May 19, 1992
AB	+!		**20MG;25MG**	**N020033**	**003**	May 19, 1992

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	SANDOZ	5MG;6.25MG	A076631	001	Feb 11, 2004

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

TREANDA

+!	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009
+!		100MG/VIAL	N022249	001	Mar 20, 2008

SOLUTION;IV (INFUSION)

BELRAPZO

+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018

BENDEKA

+!	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALTAFLUOR BENOX

+!	ALTAIRE PHARMS INC	0.4%;0.25%	N208582	001	Dec 14, 2017

FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+!	BAUSCH LOMB IRELAND	0.4%;0.3%	N211039	001	Mar 09, 2020

BENZNIDAZOLE

TABLET;ORAL

BENZNIDAZOLE

+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017
+!		100MG	N209570	002	Aug 29, 2017

BENZONATATE

CAPSULE;ORAL

BENZONATATE

AA	ALEMBIC LABS	**100MG**	**A040682**	**001**	Jul 30, 2007
AA		**200MG**	**A040682**	**002**	Jul 30, 2007
AA	APOTEX INC	**100MG**	**A091310**	**001**	Jan 16, 2015
AA		**200MG**	**A091310**	**002**	Jan 16, 2015
AA	ASCENT PHARMS INC	**100MG**	**A211518**	**001**	Feb 22, 2019
AA		**150MG**	**A211518**	**002**	Feb 22, 2019
AA		**200MG**	**A211518**	**003**	Feb 22, 2019
AA	BIONPHARMA INC	**100MG**	**A081297**	**001**	Jan 29, 1993
AA		**200MG**	**A081297**	**002**	Oct 30, 2007
AA	CSPC-NBP PHARM	**100MG**	**A202765**	**002**	Aug 25, 2017
AA		**200MG**	**A202765**	**001**	Jul 31, 2015
AA	MIKART	**100MG**	**A040851**	**001**	Nov 09, 2009
AA		**150MG**	**A040851**	**002**	Nov 09, 2009
AA		**200MG**	**A040851**	**003**	Nov 09, 2009
AA	PURACAP PHARM LLC	**100MG**	**A206948**	**001**	Dec 19, 2018
AA		**200MG**	**A206948**	**002**	Dec 19, 2018
AA	QINGDAO BAHEAL PHARM	**100MG**	**A210562**	**001**	Nov 09, 2018
AA		**150MG**	**A210562**	**002**	Nov 09, 2018
AA		**200MG**	**A210562**	**003**	Nov 09, 2018
AA	STRIDES PHARMA	**100MG**	**A091133**	**001**	Jul 30, 2015
AA		**200MG**	**A091133**	**002**	Jul 30, 2015
AA !	THEPHARMANETWORK LLC	**100MG**	**A040627**	**001**	Mar 30, 2007
AA !		**150MG**	**A201209**	**001**	Sep 24, 2014
AA !		**200MG**	**A040749**	**001**	Jul 25, 2007
AA	ZYDUS PHARMS USA	**100MG**	**A040597**	**001**	Jun 08, 2007
AA		**200MG**	**A040597**	**002**	Jun 08, 2007

TESSALON

AA +	PFIZER	**100MG**	**N011210**	**001**	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

AB +!	BAUSCH	**2.5%;EQ 1.2% BASE**	**N050819**	**001**	Oct 23, 2008

BENZACLIN

AB +!	BAUSCH	**5%;EQ 1% BASE**	**N050756**	**001**	Dec 21, 2000

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	ACTAVIS LABS UT INC	**2.5%;EQ 1.2% BASE**	**A205128**	**001**	Jun 19, 2015
AB	ENCUBE	**5%;1.2%**	**A212433**	**001**	Apr 28, 2021
AB	GLENMARK PHARMS	**5%;EQ 1% BASE**	**A209252**	**001**	Mar 14, 2019
AB	MYLAN PHARMS INC	**5%;EQ 1% BASE**	**A065443**	**001**	Aug 11, 2009
AB	PADAGIS ISRAEL	**2.5%;EQ 1.2% BASE**	**A205397**	**001**	Sep 09, 2019
AB		**5%;EQ 1% BASE**	**A202440**	**001**	Sep 21, 2015
AB !		**5%;1.2%**	**A090979**	**001**	Jun 26, 2012
AB	TARO	**2.5%;EQ 1.2% BASE**	**A206575**	**001**	Aug 19, 2019
AB		**5%;EQ 1% BASE**	**A208776**	**001**	May 25, 2018
AB	TARO PHARMS	**5%;1.2%**	**A206218**	**001**	Dec 15, 2017

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB		ZYDUS PHARMS	**5%;1.2%**	**A210794**	**001**	Dec 28, 2018

DUAC

AB	**+**	STIEFEL	**5%;1.2%**	**N050741**	**001**	Aug 26, 2002

ONEXTON

	+!	BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

BENZAMYCIN

AB	**+!**	VALEANT INTL	**5%;3%**	**N050557**	**001**	Oct 26, 1984

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		LYNE	**5%;3%**	**A065385**	**001**	Sep 18, 2015

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL

TWYNEO

	+!	SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		ANDA REPOSITORY	**50MG**	**A090473**	**002**	Sep 15, 2010
AA		EPIC PHARMA LLC	**50MG**	**A090346**	**001**	Dec 15, 2015
AA	**!**	KVK TECH	**50MG**	**A090968**	**001**	Jul 20, 2010
		ANDA REPOSITORY	25MG	A090473	001	Sep 15, 2010

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

BENZTROPINE MESYLATE

AP		FRESENIUS KABI USA	**1MG/ML**	**A090233**	**001**	Jul 28, 2009
AP		HIKMA	**1MG/ML**	**A209442**	**001**	Oct 14, 2021
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A090287**	**001**	Aug 31, 2009
AP		NAVINTA LLC	**1MG/ML**	**A091525**	**001**	Feb 05, 2013

COGENTIN

AP	**+!**	AKORN	**1MG/ML**	**N012015**	**001**	

TABLET;ORAL

BENZTROPINE MESYLATE

AA	**!**	ASPEN GLOBAL INC	**0.5MG**	**A204713**	**001**	Apr 14, 2015
AA	**!**		**1MG**	**A204713**	**002**	Apr 14, 2015
AA	**!**		**2MG**	**A204713**	**003**	Apr 14, 2015
AA		CHARTWELL RX	**1MG**	**A081265**	**002**	Jan 23, 1992
AA			**2MG**	**A081265**	**001**	Jan 23, 1992
AA		EPIC PHARMA LLC	**0.5MG**	**A072264**	**001**	Feb 27, 1989
AA			**1MG**	**A072265**	**001**	Feb 27, 1989
AA			**2MG**	**A072266**	**001**	Feb 27, 1989
AA		INVAGEN PHARMS	**0.5MG**	**A090294**	**001**	Mar 29, 2010
AA			**1MG**	**A090294**	**002**	Mar 29, 2010
AA			**2MG**	**A090294**	**003**	Mar 29, 2010
AA		LEADING PHARMA LLC	**0.5MG**	**A090168**	**001**	Nov 28, 2012
AA			**1MG**	**A090168**	**002**	Nov 28, 2012
AA			**2MG**	**A090168**	**003**	Nov 28, 2012
AA		PLIVA	**0.5MG**	**A089058**	**001**	Aug 10, 1988
AA			**1MG**	**A089059**	**001**	Aug 10, 1988
AA			**2MG**	**A089060**	**001**	Aug 10, 1988
AA		VINTAGE	**0.5MG**	**A040715**	**001**	Aug 27, 2007
AA			**1MG**	**A040715**	**002**	Aug 27, 2007
AA			**2MG**	**A040715**	**003**	Aug 27, 2007

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT		APOTEX	**1.5%**	**A206066**	**001**	Mar 05, 2019
AT		MYLAN	**1.5%**	**A206220**	**001**	Mar 18, 2019

BEPREVE

AT	**+!**	BAUSCH AND LOMB INC	**1.5%**	**N022288**	**001**	Sep 08, 2009

BEROTRALSTAT HYDROCHLORIDE

CAPSULE;ORAL

ORLADEYO

	+	BIOCRYST	EQ 110MG BASE	N214094	001	Dec 03, 2020
	+!		EQ 150MG BASE	N214094	002	Dec 03, 2020

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BESIVANCE

	+!	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009

BETAINE

FOR SOLUTION;ORAL

BETAINE

AB		NOVITIUM PHARMA	**1GM/SCOOPFUL**	**A214864**	**001**	Nov 23, 2021

CYSTADANE

AB	**+!**	RECORDATI RARE	**1GM/SCOOPFUL**	**N020576**	**001**	Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

AB		AM REGENT	**3MG/ML;EQ 3MG BASE/ML**	**A090747**	**001**	Jul 31, 2009

CELESTONE SOLUSPAN

AB	**+!**	ORGANON	**3MG/ML;EQ 3MG BASE/ML**	**N014602**	**001**	

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A070885**	**001**	Feb 03, 1987
AB		COSETTE	**EQ 0.05% BASE**	**A210217**	**001**	Oct 12, 2018
AB	**+!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**N019137**	**001**	Jun 26, 1984
AB		TARO	**EQ 0.05% BASE**	**A073552**	**001**	Apr 30, 1992
AB		ZYDUS PHARMS	**EQ 0.05% BASE**	**A208885**	**001**	Jan 11, 2019

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A076215**	**001**	Dec 09, 2003
AB	**!**	GLENMARK GENERICS	**EQ 0.05% BASE**	**A078930**	**001**	Sep 23, 2008
AB		PADAGIS ISRAEL	**EQ 0.05% BASE**	**A076592**	**001**	Dec 09, 2003
AB		TARO	**EQ 0.05% BASE**	**A076543**	**001**	Dec 09, 2003

GEL, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	**!**	FOUGERA PHARMS	**EQ 0.05% BASE**	**A075276**	**001**	May 13, 2003
AB		TARO	**EQ 0.05% BASE**	**A076508**	**001**	Dec 02, 2003

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		AKORN	**EQ 0.05% BASE**	**A209896**	**001**	Feb 06, 2018
AB		COSETTE	**EQ 0.05% BASE**	**A071467**	**001**	Aug 10, 1987
AB	**!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**A070275**	**001**	Aug 12, 1985
AB		PADAGIS US	**EQ 0.05% BASE**	**A072538**	**001**	Jan 31, 1990

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		AKORN	**EQ 0.05% BASE**	**A208849**	**001**	Oct 11, 2019
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A077111**	**001**	May 21, 2007
AB	**!**	TARO	**EQ 0.05% BASE**	**A077477**	**001**	May 21, 2007
AB		TELIGENT	**EQ 0.05% BASE**	**A206389**	**001**	Feb 13, 2018

OINTMENT;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A071012**	**001**	Feb 03, 1987
AB		CADILA	**EQ 0.05% BASE**	**A214048**	**001**	Jul 14, 2020
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.05% BASE**	**N019141**	**001**	Sep 04, 1984
AB		TARO	**EQ 0.05% BASE**	**A074271**	**001**	Sep 15, 1994

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE**	**A074304**	**001**	Aug 31, 1995
AB		FOUGERA PHARMS	**EQ 0.05% BASE**	**A075373**	**001**	Jun 22, 1999
AB		LUPIN LTD	**EQ 0.05% BASE**	**A209106**	**001**	Dec 18, 2019
AB		TARO	**EQ 0.05% BASE**	**A076753**	**001**	Oct 12, 2004
AB		TELIGENT	**EQ 0.05% BASE**	**A206118**	**001**	Nov 09, 2017

DIPROLENE

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE**	**N018741**	**001**	Jul 27, 1983

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL

SERNIVO

	+!	PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

ENSTILAR

	+!	LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015

CREAM;TOPICAL

WYNZORA

	+!	MC2	0.064%;0.005%	N213422	001	Jul 20, 2020

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		PADAGIS ISRAEL	**0.064%;0.005%**	**A200174**	**001**	Dec 12, 2014
AB		TOLMAR	**0.064%;0.005%**	**A201615**	**001**	Jan 14, 2013

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N021852**	**001**	Jan 09, 2006

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB		TARO PHARMS	**0.064%;0.005%**	**A213269**	**001**	Sep 02, 2020
AB		TOLMAR	**0.064%;0.005%**	**A210765**	**001**	May 11, 2020

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

AB		PADAGIS ISRAEL	**0.064%;0.005%**	**A212367**	**001**	Sep 11, 2020

TACLONEX

AB	**+!**	LEO PHARMA AS	**0.064%;0.005%**	**N022185**	**001**	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.05% BASE;1%**	**A076002**	**001**	Aug 02, 2002
AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A075502**	**001**	Jun 05, 2001
AB		GLENMARK PHARMS	**EQ 0.05% BASE;1%**	**A202894**	**001**	Oct 30, 2015
AB		TARO	**EQ 0.05% BASE;1%**	**A075673**	**001**	May 29, 2001

LOTRISONE

AB	**+!**	MERCK SHARP DOHME	**EQ 0.05% BASE;1%**	**N018827**	**001**	Jul 10, 1984

LOTION;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	**EQ 0.05% BASE;1%**	**A076516**	**001**	Jun 16, 2005
AB	**!**	TARO	**EQ 0.05% BASE;1%**	**A076493**	**001**	Jul 28, 2004

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

BETAMETHASONE VALERATE

AB		PADAGIS ISRAEL	**0.12%**	**A078337**	**001**	Nov 26, 2012
AB		TARO	**0.12%**	**A208204**	**001**	May 24, 2017

LUXIQ

AB	**+!**	MYLAN	**0.12%**	**N020934**	**001**	Feb 28, 1999

CREAM;TOPICAL

BETA-VAL

AB		COSETTE	**EQ 0.1% BASE**	**N018642**	**001**	Mar 24, 1983

BETAMETHASONE VALERATE

AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018861**	**001**	Aug 31, 1983

DERMABET

AB		TARO	**EQ 0.1% BASE**	**A072041**	**001**	Jan 06, 1988

VALNAC

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070050**	**001**	Oct 10, 1984

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB		ANIMA	**EQ 0.1% BASE**	**A070052**	**001**	Jul 31, 1985
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018866**	**001**	Aug 31, 1983

OINTMENT;TOPICAL

BETA-VAL

AB		COSETTE	**EQ 0.1% BASE**	**A070069**	**001**	Dec 19, 1985

BETAMETHASONE VALERATE

AB		ACTAVIS MID ATLANTIC	**EQ 0.1% BASE**	**A070051**	**001**	Oct 10, 1984
AB	**+!**	FOUGERA PHARMS INC	**EQ 0.1% BASE**	**N018865**	**001**	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT		ACELLA	**EQ 0.5% BASE**	**A078694**	**001**	Nov 16, 2009
AT		AKORN	**EQ 0.5% BASE**	**A075386**	**001**	Jun 30, 2000
AT		MEDIMETRIKS PHARMS	**EQ 0.5% BASE**	**A075630**	**001**	Apr 12, 2001

BETOPTIC

AT	**+!**	SANDOZ INC	**EQ 0.5% BASE**	**N019270**	**001**	Aug 30, 1985

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC S

	+!	NOVARTIS	EQ 0.25% BASE	N019845	001	Dec 29, 1989

TABLET;ORAL

BETAXOLOL HYDROCHLORIDE

AB		EPIC PHARMA	**10MG**	**A075541**	**001**	Oct 22, 1999
AB	**!**		**20MG**	**A075541**	**002**	Oct 22, 1999
AB		KVK TECH	**10MG**	**A078962**	**001**	Jun 27, 2008
AB			**20MG**	**A078962**	**002**	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	**!**	AMNEAL PHARM	**5MG**	**A040855**	**001**	Nov 21, 2007
AA	**!**		**10MG**	**A040855**	**002**	Nov 21, 2007
AA	**!**		**25MG**	**A040855**	**003**	Nov 21, 2007
AA	**!**		**50MG**	**A040855**	**004**	Nov 21, 2007
AA		BIOPHARM	**5MG**	**A040728**	**002**	Oct 26, 2007
AA			**10MG**	**A040728**	**003**	Oct 26, 2007
AA			**25MG**	**A040728**	**004**	Oct 26, 2007
AA			**50MG**	**A040728**	**001**	Oct 26, 2007
AA		LANNETT CO INC	**5MG**	**A040677**	**002**	Mar 27, 2008
AA			**10MG**	**A040677**	**003**	Mar 27, 2008
AA			**25MG**	**A040677**	**004**	Mar 27, 2008
AA			**50MG**	**A040677**	**001**	Mar 27, 2008
AA		UPSHER SMITH LABS	**5MG**	**A040633**	**001**	Jun 01, 2005
AA			**10MG**	**A040634**	**001**	Jun 01, 2005
AA			**25MG**	**A040635**	**001**	Jun 01, 2005
AA			**50MG**	**A040636**	**001**	Jun 01, 2005

DUVOID

AA	CHARTWELL RX	**10MG**	**A086262**	**001**	
AA		**25MG**	**A086263**	**001**	
AA		**50MG**	**A085882**	**003**	

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

AB		AMNEAL PHARMS NY	**75MG**	**A210105**	**001**	Sep 04, 2018
AB		ANI PHARMS	**75MG**	**A209861**	**001**	May 08, 2018
AB		BIONPHARMA INC	**75MG**	**A203174**	**001**	Aug 12, 2014
AB		HIKMA	**75MG**	**A203663**	**001**	Jun 16, 2020
AB		TEVA PHARMS USA	**75MG**	**A209931**	**001**	Jan 14, 2021
AB		UPSHER SMITH LABS	**75MG**	**A209886**	**001**	Jul 25, 2018

TARGRETIN

AB	**+!**	VALEANT LUXEMBOURG	**75MG**	**N021055**	**001**	Dec 29, 1999

GEL;TOPICAL

TARGRETIN

	+!	BAUSCH	1%	N021056	001	Jun 28, 2000

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB		ACCORD HLTHCARE	**50MG**	**A078917**	**001**	Jul 06, 2009
AB		APOTEX INC	**50MG**	**A200274**	**001**	May 21, 2015
AB		KENTON	**50MG**	**A091011**	**001**	Jun 10, 2015
AB		SANDOZ	**50MG**	**A078575**	**001**	Jul 06, 2009
AB		SUN PHARM	**50MG**	**A079110**	**001**	Jul 06, 2009
AB		WATSON LABS TEVA	**50MG**	**A078634**	**001**	Aug 28, 2009
AB		ZYDUS PHARMS USA INC	**50MG**	**A079089**	**001**	Jul 06, 2009

CASODEX

AB	**+!**	ANI PHARMS	**50MG**	**N020498**	**001**	Oct 04, 1995

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

BIKTARVY

+	GILEAD SCIENCES INC	EQ 30MG BASE;120MG;EQ 15MG BASE	N210251	002	Oct 07, 2021
+!		EQ 50MG BASE;200MG;EQ 25MG BASE	N210251	001	Feb 07, 2018

BIMATOPROST

IMPLANT;OPHTHALMIC

DURYSTA

+!	ALLERGAN INC	10MCG	N211911	001	Mar 04, 2020

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AT	**!**	ALEMBIC PHARMS LTD	**0.03%**	**A210263**	**001**	Apr 12, 2019
AT		APOTEX INC	**0.03%**	**A090449**	**001**	Jul 20, 2015
AT		GLAND PHARMA LTD	**0.03%**	**A210126**	**001**	Mar 22, 2019
AT		LUPIN LTD	**0.03%**	**A203991**	**001**	Feb 20, 2015
AT		MICRO LABS	**0.03%**	**A202505**	**001**	Sep 08, 2020
AT		SANDOZ INC	**0.03%**	**A202565**	**001**	May 05, 2015
AT		SOMERSET THERAPS LLC	**0.03%**	**A207601**	**001**	Jun 19, 2019

LUMIGAN

+!	ALLERGAN	0.01%	N022184	001	Aug 31, 2010

SOLUTION/DROPS;TOPICAL

BIMATOPROST

AT		AKORN	**0.03%**	**A203051**	**001**	Oct 09, 2018
AT		ALEMBIC PHARMS LTD	**0.03%**	**A210515**	**001**	Jan 21, 2020
AT		APOTEX INC	**0.03%**	**A201894**	**001**	Dec 01, 2014
AT		SANDOZ INC	**0.03%**	**A202719**	**001**	Apr 19, 2016

LATISSE

AT	**+!**	ALLERGAN	**0.03%**	**N022369**	**001**	Dec 24, 2008

BINIMETINIB

TABLET;ORAL

MEKTOVI

+!	ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

PYLERA

+!	ALLERGAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

!	AILEX PHARMS LLC	262.4MG, N/A, N/A;N/A, 250MG, N/A;N/A, N/A, 500MG	A202584	001	Nov 30, 2018

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB		ALEMBIC LABS	**5MG**	**A204891**	**001**	Jan 11, 2017
AB			**10MG**	**A204891**	**002**	Jan 11, 2017
AB		AUROBINDO PHARMA	**5MG**	**A077910**	**001**	Dec 27, 2006
AB			**10MG**	**A077910**	**002**	Dec 27, 2006
AB		FRONTIDA BIOPHARM	**5MG**	**A075474**	**001**	Oct 25, 2002
AB			**10MG**	**A075474**	**002**	Oct 25, 2002
AB		NOVITIUM PHARMA	**5MG**	**A215563**	**001**	Oct 29, 2021
AB			**10MG**	**A215563**	**002**	Oct 29, 2021
AB		RUBICON	**5MG**	**A075643**	**001**	Nov 16, 2000
AB			**10MG**	**A075643**	**002**	Nov 16, 2000
AB		UNICHEM	**5MG**	**A078635**	**001**	Aug 18, 2009
AB	**!**		**10MG**	**A078635**	**002**	Aug 18, 2009

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB		EDENBRIDGE PHARMS	**2.5MG;6.25MG**	**A212678**	**001**	Jul 09, 2020
AB			**5MG;6.25MG**	**A212678**	**002**	Jul 09, 2020
AB			**10MG;6.25MG**	**A212678**	**003**	Jul 09, 2020
AB		MYLAN	**2.5MG;6.25MG**	**A075768**	**001**	Sep 25, 2000
AB			**5MG;6.25MG**	**A075768**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075768**	**003**	Sep 25, 2000
AB		NOVITIUM PHARMA	**2.5MG;6.25MG**	**A215562**	**001**	Nov 04, 2021
AB			**5MG;6.25MG**	**A215562**	**002**	Nov 04, 2021
AB			**10MG;6.25MG**	**A215562**	**003**	Nov 04, 2021
AB		SANDOZ	**2.5MG;6.25MG**	**A075579**	**001**	Sep 25, 2000

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB			**5MG;6.25MG**	**A075579**	**002**	Sep 25, 2000
AB			**10MG;6.25MG**	**A075579**	**003**	Sep 25, 2000
AB		UNICHEM	**2.5MG;6.25MG**	**A079106**	**001**	Jul 28, 2010
AB			**5MG;6.25MG**	**A079106**	**002**	Jul 28, 2010
AB			**10MG;6.25MG**	**A079106**	**003**	Jul 28, 2010

ZIAC

AB	+	TEVA BRANDED PHARM	**2.5MG;6.25MG**	**N020186**	**003**	Mar 26, 1993
AB	+		**5MG;6.25MG**	**N020186**	**001**	Mar 26, 1993
AB	+!		**10MG;6.25MG**	**N020186**	**002**	Mar 26, 1993

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

ANGIOMAX

AP	+!	SANDOZ INC	**250MG/VIAL**	**N020873**	**001**	Dec 15, 2000

BIVALIRUDIN

AP		ACCORD HLTHCARE	**250MG/VIAL**	**A206551**	**001**	Nov 22, 2017
AP		DR REDDYS LABS LTD	**250MG/VIAL**	**A201577**	**001**	May 26, 2017
AP		EUGIA PHARMA	**250MG/VIAL**	**A205962**	**001**	Jul 27, 2018
AP		FRESENIUS KABI USA	**250MG/VIAL**	**A090189**	**001**	Oct 28, 2016
AP		HAINAN POLY PHARM	**250MG/VIAL**	**A213078**	**001**	May 28, 2021
AP		HONG KONG	**250MG/VIAL**	**A091602**	**001**	Jul 16, 2018
AP		HOSPIRA INC	**250MG/VIAL**	**A090811**	**001**	Jul 14, 2015
AP			**250MG/VIAL**	**A090816**	**001**	Jul 14, 2015
AP		MYLAN INSTITUTIONAL	**250MG/VIAL**	**A202471**	**001**	Jun 01, 2018
AP		SHUANGCHENG	**250MG/VIAL**	**A210031**	**001**	Oct 23, 2019

SOLUTION;INTRAVENOUS

ANGIOMAX RTU

	+!	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374	001	Dec 21, 2017
	+!		500MG/100ML (5MG/ML)	N208374	002	Dec 21, 2017

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP	!	FRESENIUS KABI USA	**EQ 15 UNITS BASE/VIAL**	**A065185**	**001**	Jan 28, 2008
AP	!		**EQ 30 UNITS BASE/VIAL**	**A065185**	**002**	Jan 28, 2008
AP		HIKMA	**EQ 15 UNITS BASE/VIAL**	**A065042**	**002**	Oct 17, 2001
AP			**EQ 30 UNITS BASE/VIAL**	**A065042**	**001**	Oct 17, 2001
AP		HOSPIRA	**EQ 15 UNITS BASE/VIAL**	**A065031**	**001**	Mar 10, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065031**	**002**	Mar 10, 2000
AP		MEITHEAL	**EQ 15 UNITS BASE/VIAL**	**A205030**	**001**	Apr 20, 2018
AP			**EQ 30 UNITS BASE/VIAL**	**A205030**	**002**	Apr 20, 2018
AP		TEVA PHARMS USA	**EQ 15 UNITS BASE/VIAL**	**A065033**	**001**	Jun 27, 2000
AP			**EQ 30 UNITS BASE/VIAL**	**A065033**	**002**	Jun 27, 2000

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

VELCADE

	+!	TAKEDA PHARMS USA	3.5MG/VIAL	N021602	001	May 13, 2003

POWDER;INTRAVENOUS

BORTEZOMIB

		DR REDDYS LABS LTD	3.5MG/VIAL	N206927	001	Oct 04, 2019
		FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017

BOSENTAN

TABLET;ORAL

BOSENTAN

AB		HIKMA	**62.5MG**	**A208695**	**001**	Apr 26, 2019
AB			**125MG**	**A208695**	**002**	Apr 26, 2019
AB		PAR PHARM INC	**62.5MG**	**A205699**	**001**	Apr 26, 2019
AB			**125MG**	**A205699**	**002**	Apr 26, 2019
AB		SUN PHARM	**62.5MG**	**A209324**	**001**	Apr 26, 2019
AB			**125MG**	**A209324**	**002**	Apr 26, 2019
AB		WATSON LABS INC	**62.5MG**	**A207110**	**001**	Apr 26, 2019
AB			**125MG**	**A207110**	**002**	Apr 26, 2019
AB		ZYDUS PHARMS	**62.5MG**	**A207760**	**001**	Apr 26, 2019
AB			**125MG**	**A207760**	**002**	Apr 26, 2019

TRACLEER

AB	+	ACTELION	**62.5MG**	**N021290**	**001**	Nov 20, 2001
AB	+!		**125MG**	**N021290**	**002**	Nov 20, 2001

BOSENTAN
TABLET, FOR SUSPENSION;ORAL
TRACLEER
+! ACTELION 32MG N209279 001 Sep 05, 2017

BOSUTINIB MONOHYDRATE
TABLET;ORAL
BOSULIF
+! PF PRISM CV EQ 100MG BASE N203341 001 Sep 04, 2012
+ EQ 400MG BASE N203341 003 Oct 27, 2017
+ EQ 500MG BASE N203341 002 Sep 04, 2012

BREMELANOTIDE ACETATE
SOLUTION;SUBCUTANEOUS
VYLEESI (AUTOINJECTOR)
+! PALATIN TECHNOLOGIES EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) N210557 001 Jun 21, 2019

BRETYLIUM TOSYLATE
INJECTABLE;INJECTION
BRETYLIUM TOSYLATE
! BRECKENRIDGE 50MG/ML A204386 001 Dec 21, 2018

BREXANOLONE
SOLUTION;INTRAVENOUS
ZULRESSO
+! SAGE THERAP 100MG/20ML (5MG/ML) N211371 001 Jun 17, 2019

BREXPIPRAZOLE
TABLET;ORAL
REXULTI
+ OTSUKA 0.25MG N205422 001 Jul 10, 2015
+ 0.5MG N205422 002 Jul 10, 2015
+ 1MG N205422 003 Jul 10, 2015
+! 2MG N205422 004 Jul 10, 2015
+ 3MG N205422 005 Jul 10, 2015
+ 4MG N205422 006 Jul 10, 2015

BRIGATINIB
TABLET;ORAL
ALUNBRIG
+ TAKEDA PHARMS USA 30MG N208772 001 Apr 28, 2017
+ 90MG N208772 002 Apr 28, 2017
+! 180MG N208772 003 Oct 02, 2017

BRILLIANT BLUE G
SOLUTION;OPHTHALMIC
TISSUEBLUE
+! DUTCH OPHTHALMIC 0.025% N209569 001 Dec 20, 2019

BRIMONIDINE TARTRATE
GEL;TOPICAL
BRIMONIDINE TARTRATE
AB PADAGIS ISRAEL **EQ 0.33% BASE** **A209158 001** Sep 23, 2021
MIRVASO
AB **+!** GALDERMA LABS LP **EQ 0.33% BASE** **N204708 001** Aug 23, 2013
SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P
AT **+!** ALLERGAN **0.15%** **N021262 001** Mar 16, 2001
BRIMONIDINE TARTRATE
AT AKORN **0.2%** **A076439 001** Mar 14, 2006
AT **!** BAUSCH AND LOMB **0.2%** **A076260 001** May 28, 2003
AT INDOCO **0.2%** **A091691 001** Nov 18, 2014
AT SANDOZ INC **0.2%** **A076254 001** Sep 16, 2003
AT **0.2%** **A078075 001** Jan 30, 2008
AT SOMERSET THERAPS LLC **0.2%** **A208992 001** Mar 11, 2019
QOLIANA
AT **+!** SANDOZ INC **0.15%** **N021764 001** May 22, 2006
ALPHAGAN P
+! ALLERGAN 0.1% N021770 001 Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

SIMBRINZA

	+!	ALCON LABS INC	0.2%;1%	N204251	001	Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COMBIGAN

	+!	ALLERGAN	0.2%;EQ 0.5% BASE	N021398	001	Oct 30, 2007

BRINCIDOFOVIR

SUSPENSION;ORAL

TEMBEXA

	+!	CHIMERIX	10MG/ML	N214460	001	Jun 04, 2021

TABLET;ORAL

TEMBEXA

	+!	CHIMERIX	100MG	N214461	001	Jun 04, 2021

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

AZOPT

AB	**+!**	NOVARTIS	**1%**	**N020816**	**001**	Apr 01, 1998

BRINZOLAMIDE

AB		BAUSCH	**1%**	**A204884**	**001**	Aug 18, 2021
AB		WATSON LABS INC	**1%**	**A209406**	**001**	Nov 27, 2020

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

	+!	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016

SOLUTION;ORAL

BRIVIACT

	+!	UCB INC	10MG/ML	N205838	001	May 12, 2016

TABLET;ORAL

BRIVIACT

	+	UCB INC	10MG	N205836	001	May 12, 2016
	+		25MG	N205836	002	May 12, 2016
	+		50MG	N205836	003	May 12, 2016
	+		75MG	N205836	004	May 12, 2016
	+!		100MG	N205836	005	May 12, 2016

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2	**!**	AKORN	**EQ 0.09% ACID**	**A203395**	**001**	Jan 22, 2014
AT2		ALEMBIC PHARMS LTD	**EQ 0.09% ACID**	**A210560**	**001**	Jun 21, 2019
AT2		GLAND PHARMA LTD	**EQ 0.09% ACID**	**A211029**	**001**	Mar 17, 2020

BROMSITE

	+!	SUN PHARM	EQ 0.075% ACID	N206911	001	Apr 08, 2016

PROLENSA

	+!	BAUSCH AND LOMB	EQ 0.07% ACID	N203168	001	Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	**!**	MYLAN	**EQ 5MG BASE**	**A077226**	**001**	Apr 04, 2005
AB		ZYDUS PHARMS USA INC	**EQ 5MG BASE**	**A078899**	**001**	Jul 30, 2008

PARLODEL

AB	**+**	VALIDUS PHARMS	**EQ 5MG BASE**	**N017962**	**002**	Mar 01, 1982

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB	**!**	PADAGIS US	**EQ 2.5MG BASE**	**A077646**	**001**	Oct 01, 2008
AB		SANDOZ INC	**EQ 2.5MG BASE**	**A074631**	**001**	Jan 13, 1998

PARLODEL

AB	**+**	VALIDUS PHARMS	**EQ 2.5MG BASE**	**N017962**	**001**	

CYCLOSET

	+!	VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	**!**	WOCKHARDT BIO AG	**2MG/5ML;10MG/5ML;30MG/5ML**	**A088811**	**001**	Jun 07, 1985

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203375**	**001**	Sep 20, 2016
AA		ALKEM LABS LTD	**2MG/5ML;10MG/5ML;30MG/5ML**	**A210647**	**001**	Jul 14, 2020

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		BRECKENRIDGE	**2MG/5ML;10MG/5ML;30MG/5ML**	**A203997**	**001**	Sep 30, 2020
AA		EYWA	**2MG/5ML;10MG/5ML;30MG/5ML**	**A211170**	**001**	Jun 16, 2020
AA		LANNETT CO INC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A213125**	**001**	Apr 17, 2020
AA		MAYNE PHARMA INC	**2MG/5ML;10MG/5ML;30MG/5ML**	**A207676**	**001**	Dec 04, 2018
AA		PADAGIS US	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205292**	**001**	Jul 15, 2014
AA		RHODES PHARMS	**2MG/5ML;10MG/5ML;30MG/5ML**	**A202955**	**001**	Nov 05, 2020
AA		TARO	**2MG/5ML;10MG/5ML;30MG/5ML**	**A205112**	**001**	Feb 27, 2017

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+!	SALIX	2MG/ACTUATION	N205613	001 Oct 07, 2014

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

AB		AMNEAL PHARMS	**3MG**	**A206200**	**001**	Jul 31, 2017
AB		AUROBINDO PHARMA USA	**3MG**	**A090410**	**001**	May 16, 2011
AB		MAYNE PHARMA	**3MG**	**A206623**	**001**	Apr 08, 2016
AB		RISING	**3MG**	**A207367**	**001**	Apr 07, 2017
AB		SCIECURE PHARMA INC	**3MG**	**A209041**	**001**	Sep 28, 2017
AB		ZYDUS PHARMS	**3MG**	**A206134**	**001**	May 04, 2017

ENTOCORT EC

AB	**+!**	PADAGIS US	**3MG**	**N021324**	**001**	Oct 02, 2001

TARPEYO

	+!	CALLIDITAS	4MG	N215935	001	Dec 15, 2021

CAPSULE, EXTENDED RELEASE;ORAL

ORTIKOS

	+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019
	+!		9MG	N211929	002	Jun 13, 2019

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

	+	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006
	+!		0.16MG/INH	N021949	002	Jul 12, 2006

SUSPENSION;INHALATION

BUDESONIDE

AN		CIPLA	**0.25MG/2ML**	**A205710**	**001**	Nov 16, 2017
AN			**0.5MG/2ML**	**A205710**	**002**	Nov 16, 2017
AN			**1MG/2ML**	**A205710**	**003**	Nov 16, 2017
AN		IMPAX LABS INC	**0.25MG/2ML**	**A078404**	**001**	Jul 31, 2012
AN			**0.5MG/2ML**	**A078404**	**002**	Jul 31, 2012
AN		LUPIN	**0.5MG/2ML**	**A210897**	**001**	Nov 09, 2018
AN		NEPHRON	**0.25MG/2ML**	**A078202**	**001**	Mar 30, 2009
AN			**0.5MG/2ML**	**A078202**	**002**	Mar 30, 2009
AN		SANDOZ INC	**0.25MG/2ML**	**A201966**	**003**	Sep 27, 2013
AN			**0.5MG/2ML**	**A201966**	**002**	Sep 27, 2013
AN			**1MG/2ML**	**A201966**	**001**	Sep 27, 2013
AN		SUN PHARM	**0.25MG/2ML**	**A211922**	**001**	Apr 14, 2021
AN			**0.5MG/2ML**	**A211922**	**002**	Apr 14, 2021
AN			**1MG/2ML**	**A211922**	**003**	Apr 14, 2021
AN		TEVA PHARMS	**0.25MG/2ML**	**A077519**	**001**	Nov 18, 2008
AN			**0.5MG/2ML**	**A077519**	**002**	Nov 18, 2008
AN		TEVA PHARMS USA	**1MG/2ML**	**A204548**	**001**	Mar 08, 2016

PULMICORT RESPULES

AN	**+**	ASTRAZENECA	**0.25MG/2ML**	**N020929**	**001**	Aug 08, 2000
AN	**+**		**0.5MG/2ML**	**N020929**	**002**	Aug 08, 2000
AN	**+!**		**1MG/2ML**	**N020929**	**003**	Aug 08, 2000

TABLET, EXTENDED RELEASE;ORAL

BUDESONIDE

AB		ACTAVIS LABS FL INC	**9MG**	**A205457**	**001**	Jul 03, 2018
AB		MYLAN	**9MG**	**A208851**	**001**	Sep 17, 2020

UCERIS

AB	**+!**	SALIX	**9MG**	**N203634**	**001**	Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

SYMBICORT

	+!	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006
	+!		0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE						
AEROSOL, METERED;INHALATION						
BREZTRI AEROSPHERE						
	+!	ASTRAZENECA AB	0.16MG/INH;0.0048MG/INH;0.009MG/INH	N212122	001	Jul 23, 2020
BUMETANIDE						
INJECTABLE;INJECTION						
BUMETANIDE						
AP		HOSPIRA	**0.25MG/ML**	**A074332**	**001**	Oct 31, 1994
AP	**!**	WEST-WARD PHARMS INT	**0.25MG/ML**	**A079196**	**001**	Apr 30, 2008
TABLET;ORAL						
BUMETANIDE						
AB		AMNEAL PHARMS CO	**0.5MG**	**A209724**	**001**	Oct 18, 2017
AB			**1MG**	**A209724**	**002**	Oct 18, 2017
AB			**2MG**	**A209724**	**003**	Oct 18, 2017
AB		HERITAGE PHARMA	**0.5MG**	**A074225**	**001**	Apr 24, 1995
AB			**1MG**	**A074225**	**002**	Apr 24, 1995
AB			**2MG**	**A074225**	**003**	Apr 24, 1995
AB		SANDOZ	**0.5MG**	**A074700**	**001**	Nov 21, 1996
AB			**1MG**	**A074700**	**002**	Nov 21, 1996
AB	**!**		**2MG**	**A074700**	**003**	Nov 21, 1996
AB		UPSHER SMITH LABS	**0.5MG**	**A209916**	**001**	Jan 23, 2018
AB			**1MG**	**A209916**	**002**	Jan 23, 2018
AB			**2MG**	**A209916**	**003**	Jan 23, 2018
AB		ZYDUS PHARMS	**0.5MG**	**A202900**	**001**	Apr 30, 2018
AB			**1MG**	**A202900**	**002**	Apr 30, 2018
AB			**2MG**	**A202900**	**003**	Apr 30, 2018
BUMEX						
AB	**+**	VALIDUS PHARMS	**0.5MG**	**N018225**	**002**	Feb 28, 1983
AB	**+**		**1MG**	**N018225**	**001**	Feb 28, 1983
AB	**+**		**2MG**	**N018225**	**003**	Jun 14, 1985
BUMETANIDE						
BX		RISING	0.5MG	A212019	001	Dec 12, 2019
BX			1MG	A212019	002	Dec 12, 2019
BX			2MG	A212019	003	Dec 12, 2019
BUPIVACAINE						
INJECTABLE, LIPOSOMAL;INJECTION						
EXPAREL						
	+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011
	+!		266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011
BUPIVACAINE HYDROCHLORIDE						
IMPLANT;IMPLANTATION						
XARACOLL						
	+!	INNOCOLL PHARMS	100MG	N209511	001	Aug 28, 2020
INJECTABLE;INJECTION						
BUPIVACAINE HYDROCHLORIDE						
AP		EUGIA PHARMA	**0.25%**	**A207183**	**001**	May 13, 2016
AP			**0.5%**	**A207183**	**002**	May 13, 2016
AP		HIKMA PHARMS	**0.25%**	**A205141**	**001**	Feb 11, 2021
AP			**0.5%**	**A205141**	**002**	Feb 11, 2021
AP		HOSPIRA	**0.25%**	**A070583**	**001**	Feb 17, 1987
AP			**0.25%**	**A070590**	**001**	Feb 17, 1987
AP			**0.5%**	**A070584**	**001**	Feb 17, 1986
AP			**0.5%**	**A070597**	**001**	Mar 03, 1987
AP			**0.5%**	**A070609**	**001**	Mar 03, 1987
AP			**0.75%**	**A070585**	**001**	Mar 03, 1987
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP		EUGIA PHARMA	**0.25%**	**A203895**	**001**	Nov 05, 2013
AP			**0.5%**	**A203895**	**002**	Nov 05, 2013
AP			**0.75%**	**A203895**	**003**	Nov 05, 2013
AP		HIKMA PHARMS	**0.25%**	**A204842**	**001**	Feb 11, 2021
AP			**0.5%**	**A204842**	**002**	Feb 11, 2021
AP			**0.75%**	**A204842**	**003**	Feb 11, 2021
MARCAINE HYDROCHLORIDE						
AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**001**	
AP	**+!**		**0.5%**	**N016964**	**006**	
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP	**+!**	HOSPIRA	**0.25%**	**N016964**	**012**	
AP	**+!**		**0.5%**	**N016964**	**005**	
AP	**+!**		**0.75%**	**N016964**	**009**	

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%**	**A070552**	**001**	May 21, 1986
AP			**0.25%**	**N018304**	**001**	
AP			**0.5%**	**A070553**	**001**	May 21, 1986
AP			**0.5%**	**N018304**	**002**	
AP			**0.75%**	**A070554**	**001**	May 21, 1986
AP			**0.75%**	**N018304**	**003**	

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		B BRAUN MEDICAL INC	**0.75%**	**A209087**	**001**	Apr 02, 2019
AP		BAXTER HLTHCARE CORP	**0.75%**	**A207266**	**001**	Jul 25, 2016
AP		HOSPIRA	**0.75%**	**A071810**	**001**	Dec 11, 1987
AP		HUONS	**0.75%**	**A212822**	**001**	Dec 30, 2019

MARCAINE

AP	**+!**	HOSPIRA	**0.75%**	**N018692**	**001**	May 04, 1984

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	**!**	HOSPIRA	**0.5%;0.005MG/ML**	**A071168**	**001**	Jun 16, 1988
AP			**0.5%;0.005MG/ML**	**A071170**	**001**	Jun 16, 1988
	!		0.25%;0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%;0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**004**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**008**	

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

AP	**+!**	HOSPIRA	**0.25%;0.0091MG/ML**	**N016964**	**013**	
AP	**+!**		**0.5%;0.0091MG/ML**	**N016964**	**007**	
AP	**+!**		**0.75%;0.0091MG/ML**	**N016964**	**010**	

SENSORCAINE

AP		FRESENIUS KABI USA	**0.25%;0.0091MG/ML**	**A070966**	**001**	Oct 13, 1987
AP			**0.25%;0.0091MG/ML**	**A070967**	**001**	Oct 13, 1987
AP			**0.5%;0.0091MG/ML**	**A070968**	**001**	Oct 13, 1987
AP			**0.5%;0.0091MG/ML**	**N018304**	**004**	Sep 02, 1983
AP			**0.75%;0.0091MG/ML**	**N018304**	**005**	Sep 02, 1983

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

	!	SEPTODONT	0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE;PERIARTICULAR

ZYNRELEF KIT

	+!	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML)	N211988	001	May 12, 2021
	+!		200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021
	+!		300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML)	N211988	003	May 12, 2021
	+!		400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

AB		AMNEAL	**5MCG/HR**	**A211586**	**001**	Apr 14, 2020
AB			**7.5MCG/HR**	**A211586**	**002**	Apr 14, 2020
AB			**10MCG/HR**	**A211586**	**003**	Apr 14, 2020
AB			**15MCG/HR**	**A211586**	**004**	Apr 14, 2020
AB			**20MCG/HR**	**A211586**	**005**	Apr 14, 2020
AB		AVEVA	**5MCG/HR**	**A210272**	**001**	Sep 23, 2021
AB			**7.5MCG/HR**	**A210272**	**002**	Sep 23, 2021
AB			**10MCG/HR**	**A210272**	**003**	Sep 23, 2021
AB			**15MCG/HR**	**A210272**	**004**	Sep 23, 2021
AB			**20MCG/HR**	**A210272**	**005**	Sep 23, 2021
AB		WATSON LABS TEVA	**5MCG/HR**	**A204937**	**001**	Nov 20, 2018
AB			**7.5MCG/HR**	**A204937**	**005**	Jun 29, 2021
AB			**10MCG/HR**	**A204937**	**002**	Nov 20, 2018
AB			**15MCG/HR**	**A204937**	**003**	Nov 20, 2018
AB			**20MCG/HR**	**A204937**	**004**	Nov 20, 2018

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

AB	**+**	PURDUE PHARMA LP	**5MCG/HR**	**N021306**	**001**	Jun 30, 2010
AB	**+**		**7.5MCG/HR**	**N021306**	**005**	Jun 30, 2014
AB	**+**		**10MCG/HR**	**N021306**	**002**	Jun 30, 2010
AB	**+**		**15MCG/HR**	**N021306**	**004**	Jul 25, 2013
AB	**+!**		**20MCG/HR**	**N021306**	**003**	Jun 30, 2010

SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

SUBLOCADE

+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017
+!		300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017

BUPRENORPHINE HYDROCHLORIDE

FILM;BUCCAL

BELBUCA

AB	**+**	BDSI	**EQ 0.075MG BASE**	**N207932**	**001**	Oct 23, 2015
AB	**+**		**EQ 0.15MG BASE**	**N207932**	**002**	Oct 23, 2015
AB	**+**		**EQ 0.3MG BASE**	**N207932**	**003**	Oct 23, 2015
AB	**+**		**EQ 0.45MG BASE**	**N207932**	**004**	Oct 23, 2015
AB	**+**		**EQ 0.6MG BASE**	**N207932**	**005**	Oct 23, 2015
AB	**+**		**EQ 0.75MG BASE**	**N207932**	**006**	Oct 23, 2015
AB	**+!**		**EQ 0.9MG BASE**	**N207932**	**007**	Oct 23, 2015

BUPRENORPHINE HYDROCHLORIDE

AB		ALVOGEN	**EQ 0.075MG BASE**	**A211594**	**001**	Aug 03, 2021
AB			**EQ 0.15MG BASE**	**A211594**	**002**	Aug 03, 2021
AB			**EQ 0.3MG BASE**	**A211594**	**003**	Aug 03, 2021
AB			**EQ 0.45MG BASE**	**A211594**	**004**	Aug 03, 2021
AB			**EQ 0.6MG BASE**	**A211594**	**005**	Aug 03, 2021
AB			**EQ 0.75MG BASE**	**A211594**	**006**	Aug 03, 2021
AB			**EQ 0.9MG BASE**	**A211594**	**007**	Aug 03, 2021

INJECTABLE;INJECTION

BUPRENEX

AP	**+!**	INDIVIOR INC	**EQ 0.3MG BASE/ML**	**N018401**	**001**	

BUPRENORPHINE HYDROCHLORIDE

AP		AM REGENT	**EQ 0.3MG BASE/ML**	**A078331**	**001**	Mar 27, 2007
AP		HIKMA	**EQ 0.3MG BASE/ML**	**A076931**	**001**	Mar 02, 2005
AP		HOSPIRA	**EQ 0.3MG BASE/ML**	**A074137**	**001**	Jun 03, 1996
AP		PAR STERILE PRODUCTS	**EQ 0.3MG BASE/ML**	**A206586**	**001**	Jul 28, 2015

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090819**	**001**	Feb 19, 2015
AB			**EQ 8MG BASE**	**A090819**	**002**	Feb 19, 2015
AB		ETHYPHARM	**EQ 2MG BASE**	**A090622**	**001**	Sep 24, 2010
AB			**EQ 8MG BASE**	**A090622**	**002**	Sep 24, 2010
AB		HIKMA	**EQ 2MG BASE**	**A078633**	**001**	Oct 08, 2009
AB	**!**		**EQ 8MG BASE**	**A078633**	**002**	Oct 08, 2009
AB		RHODES PHARMS	**EQ 2MG BASE**	**A207276**	**001**	Mar 27, 2017
AB			**EQ 8MG BASE**	**A207276**	**002**	Mar 27, 2017
AB		RUBICON	**EQ 2MG BASE**	**A090279**	**001**	Jun 10, 2015
AB			**EQ 8MG BASE**	**A090279**	**002**	Jun 10, 2015
AB		SUN PHARM	**EQ 2MG BASE**	**A201760**	**001**	Jan 29, 2016
AB			**EQ 8MG BASE**	**A201760**	**002**	Jan 29, 2016

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ALVOGEN	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205954**	**001**	Jan 24, 2019
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205954**	**002**	Jan 24, 2019
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205954**	**003**	Jan 24, 2019
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205954**	**004**	Jan 24, 2019
AB		DR REDDYS LABS SA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205299**	**001**	Jun 14, 2018
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A205806**	**001**	Jun 14, 2018
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205299**	**002**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A205806**	**002**	Jun 14, 2018
AB		MYLAN TECHNOLOGIES	**EQ 2MG BASE;EQ 0.5MG BASE**	**A211785**	**001**	Apr 17, 2020
AB			**EQ 4MG BASE;EQ 1MG BASE**	**A211785**	**002**	Apr 17, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A207607**	**001**	Jun 14, 2018
AB			**EQ 12MG BASE;EQ 3MG BASE**	**A207607**	**002**	Jun 14, 2018

SUBOXONE

AB	**+**	INDIVIOR INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**N022410**	**001**	Aug 30, 2010
AB	**+**		**EQ 4MG BASE;EQ 1MG BASE**	**N022410**	**003**	Aug 10, 2012
AB	**+**		**EQ 8MG BASE;EQ 2MG BASE**	**N022410**	**002**	Aug 30, 2010

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

SUBOXONE

AB	**+!**		**EQ 12MG BASE;EQ 3MG BASE**	**N022410**	**004**	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE;EQ 0.5MG BASE**	**A091422**	**001**	Feb 22, 2013
AB	**!**		**EQ 8MG BASE;EQ 2MG BASE**	**A091422**	**002**	Feb 22, 2013
AB		ALKEM LABS LTD	**EQ 2MG BASE;EQ 0.5MG BASE**	**A214930**	**001**	Jun 15, 2021
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A214930**	**002**	Jun 15, 2021
AB		AMNEAL PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203136**	**001**	Feb 22, 2013
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A203136**	**002**	Feb 22, 2013
AB		ETHYPHARM USA CORP	**EQ 2MG BASE;EQ 0.5MG BASE**	**A204431**	**001**	Oct 16, 2015
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A204431**	**002**	Oct 16, 2015
AB		HIKMA	**EQ 2MG BASE;EQ 0.5MG BASE**	**A203326**	**001**	Jun 27, 2014
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A203326**	**002**	Jun 27, 2014
AB		LANNETT CO INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205022**	**001**	Sep 19, 2016
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205022**	**002**	Sep 19, 2016
AB		RHODES PHARMS	**EQ 2MG BASE;EQ 0.5MG BASE**	**A205601**	**001**	Mar 30, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A205601**	**002**	Mar 30, 2020
AB		SPECGX LLC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A207000**	**001**	Dec 13, 2017
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A207000**	**002**	Dec 13, 2017
AB		SUN PHARM	**EQ 2MG BASE;EQ 0.5MG BASE**	**A201633**	**001**	Aug 05, 2016
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A201633**	**002**	Aug 05, 2016
AB		WES PHARMA INC	**EQ 2MG BASE;EQ 0.5MG BASE**	**A209069**	**001**	Jul 17, 2020
AB			**EQ 8MG BASE;EQ 2MG BASE**	**A209069**	**002**	Jul 17, 2020

ZUBSOLV

+	OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242	006	Oct 04, 2016
+		EQ 1.4MG BASE;EQ 0.36MG BASE	N204242	001	Jul 03, 2013
+		EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015
+		EQ 5.7MG BASE;EQ 1.4MG BASE	N204242	002	Jul 03, 2013
+		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014
+!		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	BAUSCH	174MG	N022108	001	Apr 23, 2008
+		348MG	N022108	002	Apr 23, 2008
+!		522MG	N022108	003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**75MG**	**A203013**	**001**	Jun 08, 2018
AB			**100MG**	**A203013**	**002**	Jun 08, 2018
AB		APNAR PHARMA LP	**75MG**	**A075584**	**001**	Feb 07, 2000
AB			**100MG**	**A075584**	**002**	Feb 07, 2000
AB		APOTEX INC	**75MG**	**A076143**	**001**	Jan 17, 2006
AB	**!**		**100MG**	**A076143**	**002**	Jan 17, 2006
AB		CADILA PHARMS LTD	**75MG**	**A208606**	**001**	Jan 16, 2020
AB			**100MG**	**A208606**	**002**	Jan 16, 2020
AB		HERITAGE PHARMA	**75MG**	**A206975**	**001**	Aug 19, 2016
AB			**100MG**	**A206975**	**002**	Aug 19, 2016
AB		INVAGEN PHARMS	**75MG**	**A207389**	**001**	Sep 18, 2017
AB			**100MG**	**A207389**	**002**	Sep 18, 2017
AB		MICRO LABS	**75MG**	**A207403**	**001**	Apr 17, 2020
AB			**100MG**	**A207403**	**002**	Apr 17, 2020

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1		ACTAVIS LABS FL INC	**100MG**	**A079095**	**001**	Mar 24, 2009
AB1			**150MG**	**A079095**	**002**	Mar 24, 2009
AB1			**200MG**	**A079095**	**003**	Mar 24, 2009
AB1		ANCHEN PHARMS	**100MG**	**A091459**	**001**	Jun 09, 2011
AB1			**150MG**	**A091459**	**002**	Jun 09, 2011
AB1			**200MG**	**A091459**	**003**	Jun 09, 2011
AB1		IMPAX LABS	**100MG**	**A075913**	**001**	Jan 28, 2004
AB1			**150MG**	**A075913**	**002**	Mar 22, 2004
AB1		INVAGEN PHARMS	**100MG**	**A206674**	**001**	Feb 09, 2016
AB1			**150MG**	**A206674**	**002**	Feb 09, 2016
AB1			**200MG**	**A206674**	**003**	Feb 09, 2016
AB1		PRINSTON INC	**100MG**	**A202304**	**001**	May 26, 2015
AB1			**150MG**	**A202304**	**002**	May 26, 2015

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1			**200MG**	**A202304**	**003**	May 26, 2015
AB1		SANDOZ	**100MG**	**A075932**	**001**	Nov 25, 2003
AB1			**150MG**	**A075932**	**002**	Mar 22, 2004
AB1			**200MG**	**A075932**	**003**	Jun 22, 2005
AB1		SCIEGEN PHARMS INC	**100MG**	**A205794**	**001**	Mar 01, 2016
AB1			**150MG**	**A205794**	**002**	Mar 01, 2016
AB1			**200MG**	**A205794**	**003**	Mar 01, 2016
AB1		SUN PHARM	**100MG**	**A078866**	**001**	Apr 06, 2010
AB1			**150MG**	**A078866**	**002**	Apr 06, 2010
AB1			**200MG**	**A078866**	**003**	Apr 06, 2010
AB1		YICHANG HUMANWELL	**100MG**	**A211347**	**001**	Oct 16, 2018
AB1			**150MG**	**A211347**	**002**	Oct 16, 2018
AB1			**200MG**	**A211347**	**003**	Oct 16, 2018

WELLBUTRIN SR

AB1	**+**	GLAXOSMITHKLINE	**100MG**	**N020358**	**002**	Oct 04, 1996
AB1	**+**		**150MG**	**N020358**	**003**	Oct 04, 1996
AB1	**+!**		**200MG**	**N020358**	**004**	Jun 14, 2002

BUPROPION HYDROCHLORIDE

AB2	**!**	ACTAVIS LABS FL INC	**150MG**	**A079094**	**001**	Mar 24, 2009
AB2		ANCHEN PHARMS	**150MG**	**A091520**	**001**	Jun 09, 2011
AB2		IMPAX LABS	**150MG**	**A075914**	**001**	May 27, 2004
AB2		SANDOZ INC	**150MG**	**A077475**	**001**	Mar 12, 2008
AB2		SCIEGEN PHARMS INC	**150MG**	**A206122**	**001**	Aug 17, 2016
AB3		ACCORD HLTHCARE	**150MG**	**A210497**	**001**	Oct 31, 2018
AB3			**300MG**	**A210497**	**002**	Oct 31, 2018
AB3		ACTAVIS LABS FL INC	**150MG**	**A077715**	**001**	Nov 26, 2008
AB3		ADAPTIS	**150MG**	**A211020**	**001**	Jan 28, 2019
AB3			**300MG**	**A211020**	**002**	Jan 28, 2019
AB3		ANBISON LAB	**150MG**	**A207224**	**001**	Jun 30, 2017
AB3			**300MG**	**A207224**	**002**	Jun 30, 2017
AB3		ANCHEN PHARMS	**150MG**	**A077284**	**001**	Dec 14, 2006
AB3			**300MG**	**A077284**	**002**	Dec 14, 2006
AB3		INVAGEN PHARMS	**150MG**	**A206556**	**001**	Aug 26, 2016
AB3			**300MG**	**A206556**	**002**	Aug 26, 2016
AB3		LUPIN LTD	**150MG**	**A090693**	**001**	Apr 06, 2017
AB3			**300MG**	**A090693**	**002**	Apr 06, 2017
AB3		SCIEGEN PHARMS INC	**150MG**	**A207479**	**001**	Apr 12, 2017
AB3			**300MG**	**A207479**	**002**	Apr 12, 2017
AB3		SINOTHERAPEUTICS INC	**150MG**	**A208652**	**001**	Aug 21, 2017
AB3			**300MG**	**A208652**	**002**	Aug 21, 2017
AB3		SUN PHARM	**150MG**	**A200216**	**001**	Nov 30, 2020
AB3			**300MG**	**A203650**	**001**	Dec 31, 2020
AB3		TWI PHARMS	**150MG**	**A210081**	**001**	Nov 03, 2017
AB3			**300MG**	**A210081**	**002**	Nov 03, 2017
AB3		WATSON LABS INC	**150MG**	**A077285**	**001**	Nov 26, 2008
AB3			**300MG**	**A077285**	**002**	Aug 15, 2008
AB3		WOCKHARDT LTD	**150MG**	**A202189**	**001**	Nov 21, 2012
AB3		YICHANG HUMANWELL	**150MG**	**A210015**	**001**	Jun 14, 2018
AB3			**300MG**	**A210015**	**002**	Jun 14, 2018
AB3		ZHEJIANG JUTAI PHARM	**150MG**	**A211200**	**002**	Apr 29, 2020
AB3			**300MG**	**A211200**	**001**	Sep 05, 2019
AB3		ZYDUS PHARMS	**150MG**	**A201567**	**002**	Jul 23, 2018
AB3			**300MG**	**A201567**	**001**	Jan 17, 2014

WELLBUTRIN XL

AB3	**+**	BAUSCH	**150MG**	**N021515**	**001**	Aug 28, 2003
AB3	**+!**		**300MG**	**N021515**	**002**	Aug 28, 2003

FORFIVO XL

	+!	ALMATICA	450MG	N022497	001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

	+!	NALPROPION	90MG;8MG	N200063	001	Sep 10, 2014

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A202557**	**001**	Dec 30, 2014
AB			**7.5MG**	**A202557**	**002**	Dec 30, 2014
AB			**10MG**	**A202557**	**003**	Dec 30, 2014
AB			**15MG**	**A202557**	**004**	Dec 30, 2014
AB			**30MG**	**A202557**	**005**	Dec 30, 2014
AB		AMNEAL PHARMS CO	**5MG**	**A208829**	**001**	May 24, 2017
AB			**7.5MG**	**A208829**	**002**	May 24, 2017
AB			**10MG**	**A208829**	**003**	May 24, 2017
AB			**15MG**	**A208829**	**004**	May 24, 2017
AB			**30MG**	**A208829**	**005**	May 24, 2017
AB		AUROBINDO PHARMA LTD	**5MG**	**A078246**	**001**	Feb 27, 2009
AB			**7.5MG**	**A078246**	**005**	Feb 21, 2020
AB			**10MG**	**A078246**	**002**	Feb 27, 2009
AB			**15MG**	**A078246**	**003**	Feb 27, 2009
AB			**30MG**	**A078246**	**004**	Feb 27, 2009
AB		EPIC PHARMA LLC	**5MG**	**A208972**	**001**	Apr 16, 2019
AB			**7.5MG**	**A208972**	**002**	Apr 16, 2019
AB			**10MG**	**A208972**	**003**	Apr 16, 2019
AB			**15MG**	**A208972**	**004**	Apr 16, 2019
AB			**30MG**	**A208972**	**005**	Apr 16, 2019
AB		HERITAGE PHARMA	**5MG**	**A204582**	**001**	Sep 18, 2015
AB			**10MG**	**A204582**	**002**	Sep 18, 2015
AB			**15MG**	**A204582**	**003**	Sep 18, 2015
AB			**30MG**	**A204582**	**004**	Sep 18, 2015
AB		IMPAX LABS INC	**5MG**	**A074253**	**001**	Mar 28, 2001
AB			**10MG**	**A074253**	**002**	Mar 28, 2001
AB			**15MG**	**A074253**	**003**	Mar 13, 2002
AB		INVENTIA HLTHCARE	**5MG**	**A209696**	**001**	May 03, 2018
AB			**7.5MG**	**A209696**	**002**	May 03, 2018
AB			**10MG**	**A209696**	**003**	May 03, 2018
AB			**15MG**	**A209696**	**004**	May 03, 2018
AB			**30MG**	**A209696**	**005**	May 03, 2018
AB		MYLAN	**5MG**	**A076008**	**003**	Mar 01, 2002
AB	!		**7.5MG**	**A075467**	**002**	Mar 28, 2001
AB			**7.5MG**	**A076008**	**002**	Jul 08, 2013
AB			**10MG**	**A076008**	**004**	Mar 01, 2002
AB			**15MG**	**A076008**	**005**	Mar 28, 2001
AB			**30MG**	**A076008**	**001**	Jun 28, 2001
AB		OXFORD PHARMS	**5MG**	**A075388**	**001**	May 09, 2002
AB			**10MG**	**A075388**	**002**	May 09, 2002
AB			**15MG**	**A075388**	**003**	May 09, 2002
AB			**30MG**	**A078302**	**001**	Dec 17, 2007
AB		RUBICON	**5MG**	**A075521**	**001**	Apr 05, 2002
AB			**7.5MG**	**A075521**	**004**	Mar 16, 2021
AB			**10MG**	**A075521**	**002**	Apr 05, 2002
AB			**15MG**	**A075521**	**003**	Apr 05, 2002
AB			**30MG**	**A075521**	**005**	Mar 16, 2021
AB		STRIDES PHARMA	**5MG**	**A202330**	**001**	Aug 25, 2014
AB			**7.5MG**	**A202330**	**005**	Feb 17, 2017
AB			**10MG**	**A202330**	**002**	Aug 25, 2014
AB			**15MG**	**A202330**	**003**	Aug 25, 2014
AB			**30MG**	**A202330**	**004**	Aug 25, 2014
AB		TEVA	**5MG**	**A075022**	**001**	Feb 28, 2002
AB			**10MG**	**A075022**	**002**	Feb 28, 2002
AB	!		**15MG**	**A075022**	**003**	Feb 28, 2002
AB			**30MG**	**A075022**	**004**	Mar 25, 2004
AB		UNICHEM	**5MG**	**A210907**	**001**	Nov 14, 2019
AB			**10MG**	**A210907**	**002**	Nov 14, 2019
AB			**15MG**	**A210907**	**003**	Nov 14, 2019
AB			**30MG**	**A210907**	**004**	Nov 14, 2019
AB		YILING	**5MG**	**A202087**	**001**	Dec 16, 2015
AB			**10MG**	**A202087**	**002**	Dec 16, 2015
AB			**15MG**	**A202087**	**003**	Dec 16, 2015
AB			**30MG**	**A202087**	**004**	Dec 16, 2015
AB		ZYDUS PHARMS	**5MG**	**A078888**	**001**	Feb 07, 2014
AB			**10MG**	**A078888**	**002**	Feb 07, 2014
AB			**15MG**	**A078888**	**003**	Feb 07, 2014
AB			**30MG**	**A078888**	**004**	Feb 07, 2014

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP		ACCORD HLTHCARE INC	**6MG/ML**	**A210148**	**001**	Feb 22, 2019
AP		AM REGENT	**6MG/ML**	**A202259**	**001**	Dec 22, 2015
AP		AMNEAL	**6MG/ML**	**A209580**	**001**	Dec 18, 2017
AP		APOTEX	**6MG/ML**	**A210448**	**001**	May 07, 2019
AP		ARTHUR GRP	**6MG/ML**	**A205106**	**001**	Sep 21, 2018
AP		HOSPIRA INC	**6MG/ML**	**A205672**	**001**	Jul 31, 2018
AP		MEITHEAL	**6MG/ML**	**A212127**	**001**	Oct 23, 2020
AP		MYLAN INSTITUTIONAL	**6MG/ML**	**A208536**	**001**	Nov 20, 2017
AP		NEXUS PHARMS	**6MG/ML**	**A207794**	**001**	Jan 14, 2019
AP		PHARMASCIENCE INC	**6MG/ML**	**A207050**	**001**	Mar 24, 2017
AP		SHILPA	**6MG/ML**	**A210931**	**001**	Apr 18, 2019

BUSULFEX

AP	**+!**	OTSUKA PHARM	**6MG/ML**	**N020954**	**001**	Feb 04, 1999

TABLET;ORAL

MYLERAN

	+!	ASPEN GLOBAL	2MG	N009386	001

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

MENTAX

	+!	MYLAN	1%	N020524	001	Oct 18, 1996

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

GYNAZOLE-1

	!	PADAGIS ISRAEL	2%	A200923	001	May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE

AP		HIKMA	**2MG/ML**	**A075046**	**001**	Aug 12, 1998
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078400**	**001**	May 01, 2009
AP			**2MG/ML**	**A078400**	**002**	May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP		HIKMA	**1MG/ML**	**A075045**	**001**	Aug 12, 1998
AP			**2MG/ML**	**A075045**	**002**	Aug 12, 1998
AP	**!**	HOSPIRA	**1MG/ML**	**A074626**	**001**	Jan 23, 1997
AP	**!**		**2MG/ML**	**A074626**	**002**	Jan 23, 1997

SPRAY, METERED;NASAL

BUTORPHANOL TARTRATE

AB		APOTEX INC	**1MG/SPRAY**	**A075499**	**001**	Dec 04, 2002
AB		HIKMA	**1MG/SPRAY**	**A075824**	**001**	Mar 12, 2002
AB	**!**	RISING PHARMA	**1MG/SPRAY**	**A075759**	**001**	Aug 08, 2001

CABAZITAXEL

SOLUTION;INTRAVENOUS

CABAZITAXEL

	+!	ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021

JEVTANA KIT

	+!	SANOFI AVENTIS US	60MG/1.5ML (40MG/ML)	N201023	001	Jun 17, 2010

CABERGOLINE

TABLET;ORAL

CABERGOLINE

AB	**!**	INGENUS PHARMS LLC	**0.5MG**	**A204735**	**001**	Aug 01, 2018
AB		IVAX SUB TEVA PHARMS	**0.5MG**	**A077750**	**001**	Mar 07, 2007

CABOTEGRAVIR

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

APRETUDE

	+!	VIIV HLTHCARE	600MG/3ML (200MG/ML)	N215499	001	Dec 20, 2021

CABOTEGRAVIR SODIUM

TABLET;ORAL

VOCABRIA

	+!	VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

CABENUVA KIT

	+!	VIIV HLTHCARE	400MG/2ML (200MG/ML);600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021
	+!		600MG/3ML (200MG/ML);900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ

	+!	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012
	+		EQ 80MG BASE	N203756	002	Nov 29, 2012

TABLET;ORAL

CABOMETYX

	+	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016
	+		EQ 40MG BASE	N208692	002	Apr 25, 2016
	+!		EQ 60MG BASE	N208692	003	Apr 25, 2016

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

CAFCIT

AP	**+!**	HIKMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**001**	Sep 21, 1999

CAFFEINE CITRATE

AP		AM REGENT	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077906**	**001**	May 15, 2007
AP		EUGIA PHARMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A205013**	**001**	Sep 22, 2015
AP		EXELA PHARMA SCIENCE	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077233**	**001**	Sep 21, 2006
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077997**	**001**	Jul 20, 2007
AP		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A207400**	**001**	Dec 14, 2017
AP		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090827**	**001**	Aug 29, 2012

SOLUTION;ORAL

CAFCIT

AA	**+!**	HIKMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N020793**	**002**	Apr 12, 2000

CAFFEINE CITRATE

AA		EXELA PHARMA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A077304**	**001**	Sep 21, 2006
AA		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A078002**	**001**	Jan 31, 2008
AA		MICRO LABS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213202**	**001**	Dec 16, 2019
AA		SAGENT PHARMS	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A091102**	**001**	Aug 29, 2012
AA		SUN PHARM	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A090357**	**001**	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

	!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

	!	MIKART	100MG;1MG	A040590	001	Sep 16, 2005

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

	+!	EIRGEN	0.03MG	N208010	001	Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

	+!	MAYNE PHARMA	0.005%	N022563	001	Oct 06, 2010

CREAM;TOPICAL

CALCIPOTRIENE

AB		GLENMARK PHARMS	**0.005%**	**A205772**	**001**	Jun 09, 2015
AB		TOLMAR	**0.005%**	**A200935**	**001**	May 30, 2012

DOVONEX

AB	**+!**	LEO PHARMA AS	**0.005%**	**N020554**	**001**	Jul 22, 1996

OINTMENT;TOPICAL

CALCIPOTRIENE

	!	GLENMARK PHARMS INC	0.005%	A090633	001	Mar 24, 2010

SOLUTION;TOPICAL

CALCIPOTRIENE

AT		AKORN	**0.005%**	**A077579**	**001**	Nov 19, 2009
AT		COSETTE	**0.005%**	**A078468**	**001**	Mar 24, 2011
AT		FOUGERA PHARMS	**0.005%**	**A078305**	**001**	May 06, 2008
AT		NOVEL LABS INC	**0.005%**	**A207163**	**001**	Dec 26, 2017
AT	**!**	TOLMAR	**0.005%**	**A077029**	**001**	Nov 20, 2009

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

AP		CUSTOPHARM INC	**200 IU/ML**	**A212416**	**001**	May 14, 2021
AP		PAR STERILE PRODUCTS	**200 IU/ML**	**A209358**	**001**	Nov 10, 2021

MIACALCIN

AP	**+!**	MYLAN IRELAND LTD	**200 IU/ML**	**N017808**	**002**	Mar 29, 1991

SPRAY, METERED;NASAL

CALCITONIN-SALMON

AB	**!**	APOTEX INC	**200 IU/SPRAY**	**A076396**	**001**	Nov 17, 2008
AB		PAR PHARM	**200 IU/SPRAY**	**A076979**	**001**	Jun 08, 2009

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		AMNEAL PHARMS	**0.25MCG**	**A203289**	**002**	Jun 14, 2017
AB			**0.5MCG**	**A203289**	**001**	Jun 14, 2017
AB		BIONPHARMA INC	**0.25MCG**	**A091174**	**001**	May 24, 2013
AB			**0.5MCG**	**A091174**	**002**	May 24, 2013
AB		HIKMA	**0.25MCG**	**A076917**	**001**	Mar 27, 2006
AB		STRIDES PHARMA	**0.25MCG**	**A091356**	**001**	Dec 12, 2014
AB			**0.5MCG**	**A091356**	**002**	Dec 12, 2014
AB		SUN PHARM	**0.25MCG**	**A204556**	**001**	Feb 21, 2019
AB			**0.5MCG**	**A204556**	**002**	Feb 21, 2019
AB		TEVA	**0.25MCG**	**A075765**	**001**	Oct 12, 2001
AB			**0.5MCG**	**A075765**	**002**	Oct 12, 2001

ROCALTROL

AB	**+**	VALIDUS PHARMS	**0.25MCG**	**N018044**	**001**	
AB	**+!**		**0.5MCG**	**N018044**	**002**	

INJECTABLE;INJECTION

CALCITRIOL

AP	**!**	AKORN	**0.001MG/ML**	**A078066**	**001**	Jan 29, 2008
AP		GLAND PHARMA LTD	**0.001MG/ML**	**A211030**	**001**	Feb 03, 2020

OINTMENT;TOPICAL

VECTICAL

	+!	GALDERMA LABS LP	3MCG/GM	N022087	001	Jan 23, 2009

SOLUTION;ORAL

CALCITRIOL

AA		ELYSIUM	**1MCG/ML**	**A209798**	**001**	Nov 21, 2018
AA		HIKMA	**1MCG/ML**	**A076242**	**001**	Jul 18, 2003

ROCALTROL

AA	**+!**	VALIDUS PHARMS	**1MCG/ML**	**N021068**	**001**	Nov 20, 1998

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		CHARTWELL RX	**667MG**	**A091312**	**001**	Jun 01, 2012
AB		HERITAGE PHARMS INC	**667MG**	**A202315**	**001**	Jun 29, 2015
AB		HIKMA	**667MG**	**A077728**	**001**	Feb 26, 2008
AB		INVAGEN PHARMS	**667MG**	**A203135**	**001**	Feb 07, 2013
AB		LUPIN LTD	**667MG**	**A202127**	**001**	Jul 09, 2015
AB		NOSTRUM LABS INC	**667MG**	**A203179**	**001**	Oct 26, 2015
AB		SUVEN PHARMS	**667MG**	**A211038**	**001**	Feb 21, 2020

PHOSLO GELCAPS

AB	**+!**	FRESENIUS MEDCL	**667MG**	**N021160**	**003**	Apr 02, 2001

SOLUTION;ORAL

PHOSLYRA

	+!	FRESENIUS MEDCL	667MG/5ML	N022581	001	Apr 18, 2011

TABLET;ORAL

CALCIUM ACETATE

AB	**!**	CHARTWELL MOLECULAR	**667MG**	**A202420**	**001**	Feb 05, 2013
AB		HERITAGE PHARMS INC	**667MG**	**A202885**	**001**	Jan 22, 2015
AB		PADAGIS US	**667MG**	**A091561**	**001**	Apr 13, 2011

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

AP		AM REGENT	**100MG/ML**	**A209088**	**001**	Jul 27, 2017
AP		INTL MEDICATION SYS	**100MG/ML**	**A203477**	**001**	May 09, 2018
AP		MEDEFIL INC	**100MG/ML**	**A211553**	**001**	May 01, 2019

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**100MG/ML**	**N021117**	**001**	Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

BSS PLUS

	+!	ALCON	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N018469	001	

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**001**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**004**	Nov 30, 1984

DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**001**	Aug 19, 1992

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**002**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**005**	Nov 30, 1984

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**002**	Aug 19, 1992

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML**	**N018883**	**003**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N018883**	**006**	Nov 30, 1984

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	**+!**	FRESENIUS MEDCL	**18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020171**	**003**	Aug 19, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**001**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**002**	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020183**	**004**	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**012**	Jan 10, 1989

DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**013**	Jul 11, 1990

DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**014**	Jul 11, 1990

DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**015**	Jul 11, 1990

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**004**	
AT	**+**		**25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**001**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**005**	
AT	**+**		**25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**002**	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	**+**	BAXTER HLTHCARE	**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N017512**	**006**	
AT	**+**		**25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML**	**N020163**	**003**	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

	+!	LUKARE MEDICAL LLC	0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9 MG/ML;7.3MG/ML;0.2MG/ML	N020577	001	Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017608**	**001**	

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019634**	**003**	Feb 24, 1988

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016679**	**001**	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**006**	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**004**	Apr 05, 1985
AP			**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**005**	Apr 05, 1985
AP		FRESENIUS KABI USA	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**A211428**	**001**	Nov 09, 2021
AP	**+**	ICU MEDICAL INC	**20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML**	**N019685**	**002**	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**007**	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML**	**N019367**	**008**	Apr 05, 1985

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

		B BRAUN	10MG/100ML;2.5GM/100ML;15MG/100ML;300MG/100ML;160MG/100ML	N019634	001	Feb 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	002	Apr 05, 1985
			20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019367	003	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

		BAXTER HLTHCARE	20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML	N019367	001	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+!	HOSPIRA	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML; 16.1MG/ML	N018895	001	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

BALANCED SALT

AT		AKORN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A075503**	**001**	Sep 27, 2006
AT		B BRAUN	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**A091387**	**001**	Feb 03, 2010

BSS

AT	**+!**	ALCON	**0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML**	**N020742**	**001**	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE CORP	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/10	N207026	001	Jan 13, 2015

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**A075323**	**001**	Apr 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	**+!**	HOSPIRA	**17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML**	**N018608**	**001**	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N020002**	**001**	Apr 17, 1992
AP		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N016693**	**001**	
AP		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018251**	**001**	

SOLUTION;IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT		B BRAUN	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018156**	**001**	
AT		BAXTER HLTHCARE	**33MG/100ML;30MG/100ML;860MG/100ML**	**N018495**	**001**	Feb 19, 1982
AT		ICU MEDICAL INC	**33MG/100ML;30MG/100ML;860MG/100ML**	**N017635**	**001**	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019632**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N016682**	**001**	
AP		FRESENIUS KABI USA	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**A209338**	**001**	Jan 28, 2019
AP		ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N017641**	**001**	

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018681**	**001**	Dec 27, 1982
AT		BAXTER HLTHCARE	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018494**	**001**	Feb 19, 1982
AT	**+!**		**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N018921**	**001**	Apr 03, 1984
AT	**+!**	ICU MEDICAL INC	**20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML**	**N019416**	**001**	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE

+!	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	N208418	001	Jun 15, 2017
+!		5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017
+!		10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017

CALCIUM GLUCONATE IN SODIUM CHLORIDE

+!	FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021
+!		2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021
+!	HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906	001	Oct 29, 2018
+!		1GM/100ML (10MG/ML)	N210906	003	Jun 04, 2021
+!		2GM/100ML (20MG/ML)	N210906	002	Oct 29, 2018

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

SOLUTION;ORAL

XYWAV

+!	JAZZ	0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	N212690	001	Jul 21, 2020

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

+	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
+!		300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

INVOKAMET

+	JANSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014
+		50MG;1GM	N204353	002	Aug 08, 2014
+		150MG;500MG	N204353	003	Aug 08, 2014
+!		150MG;1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

+	JANSSEN PHARMS	50MG;500MG	N205879	001	Sep 20, 2016
+		50MG;1GM	N205879	002	Sep 20, 2016
+		150MG;500MG	N205879	003	Sep 20, 2016
+!		150MG;1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET;ORAL

ATACAND

AB	**+**	ANI PHARMS	**4MG**	**N020838**	**001**	Jun 04, 1998
AB	**+**		**8MG**	**N020838**	**002**	Jun 04, 1998
AB	**+**		**16MG**	**N020838**	**003**	Jun 04, 1998
AB	**+!**		**32MG**	**N020838**	**004**	Jun 04, 1998

CANDESARTAN CILEXETIL

AB		ALEMBIC PHARMS LTD	**4MG**	**A210302**	**001**	Dec 04, 2018
AB			**8MG**	**A210302**	**002**	Dec 04, 2018
AB			**16MG**	**A210302**	**003**	Dec 04, 2018
AB			**32MG**	**A209119**	**001**	Jun 20, 2017
AB		MACLEODS PHARMS LTD	**4MG**	**A203813**	**001**	Dec 05, 2016
AB			**8MG**	**A203813**	**002**	Dec 05, 2016
AB			**16MG**	**A203813**	**003**	Dec 05, 2016
AB			**32MG**	**A203813**	**004**	Dec 05, 2016
AB		MYLAN	**4MG**	**A078702**	**001**	May 03, 2013
AB			**8MG**	**A078702**	**002**	May 03, 2013
AB			**16MG**	**A078702**	**003**	May 03, 2013
AB			**32MG**	**A078702**	**004**	May 03, 2013
AB		ZYDUS PHARMS	**4MG**	**A091390**	**001**	Aug 23, 2017
AB			**8MG**	**A091390**	**002**	Aug 23, 2017
AB			**16MG**	**A091390**	**003**	Aug 23, 2017
AB			**32MG**	**A091390**	**004**	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ATACAND HCT

AB	**+**	ANI PHARMS	**16MG;12.5MG**	**N021093**	**001**	Sep 05, 2000
AB	**+**		**32MG;12.5MG**	**N021093**	**002**	Sep 05, 2000
AB	**+!**		**32MG;25MG**	**N021093**	**003**	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		DR REDDYS LABS LTD	**16MG;12.5MG**	**A202965**	**001**	Jun 03, 2013
AB			**32MG;12.5MG**	**A202965**	**002**	Jun 03, 2013
AB			**32MG;25MG**	**A202965**	**003**	Jun 03, 2013
AB		MACLEODS PHARMS LTD	**16MG;12.5MG**	**A204100**	**001**	Feb 27, 2015

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		**32MG;12.5MG**	**A204100**	**002**	Feb 27, 2015
AB		**32MG;25MG**	**A204100**	**003**	Feb 27, 2015
AB	MYLAN	**16MG;12.5MG**	**A090704**	**001**	Dec 04, 2012
AB		**32MG;12.5MG**	**A090704**	**002**	Dec 04, 2012
AB		**32MG;25MG**	**A090704**	**003**	Dec 04, 2012
AB	PRINSTON INC	**16MG;12.5MG**	**A207455**	**001**	Apr 11, 2018
AB		**32MG;12.5MG**	**A207455**	**002**	Apr 11, 2018
AB		**32MG;25MG**	**A207455**	**003**	Apr 11, 2018
AB	ZYDUS PHARMS	**16MG;12.5MG**	**A203466**	**001**	Nov 27, 2017
AB		**32MG;12.5MG**	**A203466**	**002**	Nov 27, 2017
AB		**32MG;25MG**	**A203466**	**003**	Nov 27, 2017

CANGRELOR

POWDER;INTRAVENOUS

KENGREAL

+!	CHIESI	50MG/VIAL	N204958	001	Jun 22, 2015

CANNABIDIOL

SOLUTION;ORAL

EPIDIOLEX

+!	GW RES LTD	100MG/ML	N210365	001	Sep 28, 2018

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	**150MG**	**A202593**	**001**	Apr 23, 2015
AB		**500MG**	**A202593**	**002**	Apr 23, 2015
AB	ALKEM LABS LTD	**150MG**	**A207652**	**001**	Nov 24, 2017
AB		**500MG**	**A207652**	**002**	Nov 24, 2017
AB	AMNEAL PHARMS	**150MG**	**A204741**	**001**	Feb 28, 2017
AB		**500MG**	**A204741**	**002**	Feb 28, 2017
AB	DR REDDYS LABS LTD	**150MG**	**A204345**	**001**	Dec 04, 2020
AB		**500MG**	**A204345**	**002**	Dec 04, 2020
AB	EUGIA PHARMA	**150MG**	**A210604**	**001**	Apr 17, 2018
AB		**500MG**	**A210604**	**002**	Apr 17, 2018
AB	HIKMA	**150MG**	**A200483**	**001**	Jul 14, 2016
AB		**500MG**	**A200483**	**002**	Jul 14, 2016
AB	MSN	**150MG**	**A209365**	**001**	Jul 02, 2018
AB		**500MG**	**A209365**	**002**	Jul 02, 2018
AB	RELIANCE LIFE	**150MG**	**A211724**	**001**	Apr 27, 2020
AB		**500MG**	**A211724**	**002**	Apr 27, 2020
AB	RISING PHARMA	**150MG**	**A090943**	**001**	Aug 08, 2014
AB		**500MG**	**A090943**	**002**	Aug 08, 2014
AB	SHILPA	**150MG**	**A207456**	**001**	Dec 12, 2016
AB		**500MG**	**A207456**	**002**	Dec 12, 2016
AB	SUN PHARM	**150MG**	**A204668**	**001**	Jun 21, 2019
AB		**500MG**	**A204668**	**002**	Jun 21, 2019
AB	TEVA PHARMS USA	**150MG**	**A091649**	**001**	Sep 16, 2013
AB		**500MG**	**A091649**	**002**	Sep 16, 2013

XELODA

AB **+**	HOFFMANN LA ROCHE	**150MG**	**N020896**	**001**	Apr 30, 1998
AB **+!**		**500MG**	**N020896**	**002**	Apr 30, 1998

CAPMATINIB HYDROCHLORIDE

TABLET;ORAL

TABRECTA

+	NOVARTIS PHARM	EQ 150MG BASE	N213591	001	May 06, 2020
+!		EQ 200MG BASE	N213591	002	May 06, 2020

CAPSAICIN

PATCH;TOPICAL

QUTENZA

+!	AVERITAS	8%	N022395	001	Nov 16, 2009

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB	AJANTA PHARMA LTD	**12.5MG**	**A212809**	**001**	Dec 13, 2019
AB		**25MG**	**A212809**	**002**	Dec 13, 2019
AB		**50MG**	**A212809**	**003**	Dec 13, 2019
AB		**100MG**	**A212809**	**004**	Dec 13, 2019
AB	ANNORA PHARMA	**12.5MG**	**A074737**	**001**	Oct 28, 1998

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB			**25MG**	**A074737**	**002**	Oct 28, 1998
AB			**50MG**	**A074737**	**003**	Oct 28, 1998
AB			**100MG**	**A074737**	**004**	Oct 28, 1998
AB		BOSCOGEN	**12.5MG**	**A074677**	**004**	May 30, 1997
AB			**25MG**	**A074677**	**002**	May 30, 1997
AB			**50MG**	**A074677**	**001**	May 30, 1997
AB			**100MG**	**A074677**	**003**	May 30, 1997
AB		HIKMA INTL PHARMS	**12.5MG**	**A074505**	**001**	Feb 13, 1996
AB			**25MG**	**A074505**	**002**	Feb 13, 1996
AB			**50MG**	**A074505**	**003**	Feb 13, 1996
AB	**!**		**100MG**	**A074505**	**004**	Feb 13, 1996
AB		PRINSTON INC	**12.5MG**	**A074477**	**001**	Feb 13, 1996
AB			**25MG**	**A074477**	**002**	Feb 13, 1996
AB			**50MG**	**A074477**	**003**	Feb 13, 1996
AB			**100MG**	**A074477**	**004**	Feb 13, 1996
AB		WOCKHARDT LTD	**12.5MG**	**A074532**	**001**	Mar 28, 1997
AB			**25MG**	**A074532**	**002**	Mar 28, 1997
AB			**50MG**	**A074532**	**003**	Mar 28, 1997
AB			**100MG**	**A074532**	**004**	Mar 28, 1997

CARBACHOL

SOLUTION;INTRAOCULAR

MIOSTAT

	+!	ALCON	0.01%	N016968	001	

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**100MG**	**A078986**	**001**	Nov 25, 2011
AB			**200MG**	**A078986**	**002**	Nov 25, 2011
AB			**300MG**	**A078986**	**003**	Nov 25, 2011
AB		NOSTRUM LABS INC	**100MG**	**A076697**	**001**	May 20, 2011
AB			**200MG**	**A076697**	**002**	May 20, 2011
AB			**300MG**	**A076697**	**003**	May 20, 2011
AB		TARO	**100MG**	**A201106**	**001**	Jun 21, 2013
AB			**200MG**	**A201106**	**002**	Jun 21, 2013
AB			**300MG**	**A201106**	**003**	Jun 21, 2013
AB		TEVA PHARMS	**100MG**	**A078592**	**001**	Sep 20, 2012
AB			**200MG**	**A078592**	**002**	Sep 20, 2012
AB			**300MG**	**A078592**	**003**	Sep 20, 2012

CARBATROL

AB	**+**	TAKEDA PHARMS USA	**100MG**	**N020712**	**003**	Sep 30, 1997
AB	**+**		**200MG**	**N020712**	**001**	Sep 30, 1997
AB	**+!**		**300MG**	**N020712**	**002**	Sep 30, 1997

EQUETRO

	+	VALIDUS PHARMS	100MG	N021710	001	Dec 10, 2004
	+		200MG	N021710	002	Dec 10, 2004
	+!		300MG	N021710	003	Dec 10, 2004

SUSPENSION;ORAL

CARBAMAZEPINE

AB		WOCKHARDT BIO AG	**100MG/5ML**	**A075714**	**001**	Jun 05, 2002

TEGRETOL

AB	**+!**	NOVARTIS	**100MG/5ML**	**N018927**	**001**	Dec 18, 1987

TERIL

AB		TARO	**100MG/5ML**	**A076729**	**001**	Sep 20, 2004

TABLET;ORAL

CARBAMAZEPINE

AB		APOTEX INC	**200MG**	**A075948**	**001**	Feb 27, 2002
AB		TARO	**200MG**	**A074649**	**001**	Oct 03, 1996
AB		TORRENT PHARMS	**100MG**	**A077272**	**001**	Dec 07, 2005
AB			**200MG**	**A077272**	**002**	Dec 07, 2005
AB		UMEDICA LABS PVT LTD	**100MG**	**A207798**	**001**	Apr 15, 2020
AB			**200MG**	**A207798**	**002**	Apr 15, 2020
AB		VGYAAN	**200MG**	**A214328**	**001**	Aug 16, 2021

EPITOL

AB		TEVA	**200MG**	**A070541**	**001**	Sep 17, 1986

TEGRETOL

AB	**+!**	NOVARTIS	**200MG**	**N016608**	**001**	

CARBAMAZEPINE

TABLET;ORAL

CARBAMAZEPINE

		TORRENT PHARMS	300MG	A077272	003	Dec 07, 2005
			400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE

AB	**!**	TARO PHARM INDS	**100MG**	**A075687**	**001**	Oct 24, 2000
AB		TORRENT PHARMS	**100MG**	**A075712**	**001**	Jul 05, 2001

EPITOL

AB		TEVA	**100MG**	**A073524**	**001**	Jul 29, 1992

CARBAMAZEPINE

	!	TARO PHARM INDS	200MG	A075687	002	Jul 29, 2002

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ANBISON LAB	**100MG**	**A212948**	**001**	Sep 30, 2021
AB			**200MG**	**A212948**	**002**	Sep 30, 2021
AB			**400MG**	**A212948**	**003**	Sep 30, 2021
AB		CSPC OUYI	**100MG**	**A213311**	**001**	Apr 13, 2021
AB			**200MG**	**A213311**	**002**	Apr 13, 2021
AB			**400MG**	**A213311**	**003**	Apr 13, 2021
AB		TARO	**100MG**	**A078115**	**001**	Mar 31, 2009
AB			**200MG**	**A078115**	**002**	Mar 31, 2009
AB			**400MG**	**A078115**	**003**	Mar 31, 2009
AB		UNIQUE PHARM	**100MG**	**A211623**	**001**	Apr 24, 2020
AB			**200MG**	**A211623**	**002**	Apr 24, 2020
AB			**400MG**	**A211623**	**003**	Apr 24, 2020
AB		ZYDUS PHARMS	**100MG**	**A205571**	**001**	Feb 07, 2019
AB			**200MG**	**A205571**	**002**	Feb 07, 2019
AB			**400MG**	**A205571**	**003**	Feb 07, 2019

TEGRETOL-XR

AB	**+**	NOVARTIS	**100MG**	**N020234**	**001**	Mar 25, 1996
AB	**+**		**200MG**	**N020234**	**002**	Mar 25, 1996
AB	**+!**		**400MG**	**N020234**	**003**	Mar 25, 1996

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB		ALVOGEN	**25MG**	**A204291**	**001**	Jan 08, 2016
AB		ANI PHARMS	**25MG**	**A203261**	**001**	Mar 10, 2014
AB		AUROBINDO PHARMA LTD	**25MG**	**A211055**	**001**	Oct 21, 2019
AB		EDENBRIDGE PHARMS	**25MG**	**A205304**	**001**	Feb 17, 2016
AB		NOVEL LABS INC	**25MG**	**A204763**	**001**	Oct 20, 2017
AB		ZYDUS PHARMS	**25MG**	**A209910**	**001**	May 07, 2018

LODOSYN

AB	**+!**	ATON	**25MG**	**N017830**	**001**	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB		SUN PHARM	**25MG;200MG;100MG**	**A079085**	**001**	May 10, 2012
AB			**37.5MG;200MG;150MG**	**A079085**	**002**	May 10, 2012

STALEVO 100

AB	**+**	ORION PHARMA	**25MG;200MG;100MG**	**N021485**	**002**	Jun 11, 2003

STALEVO 150

AB	**+**	ORION PHARMA	**37.5MG;200MG;150MG**	**N021485**	**003**	Jun 11, 2003

STALEVO 125

	+	ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008

STALEVO 200

	+!	ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007

STALEVO 50

	+!	ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003

STALEVO 75

	+	ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

	+	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015
	+		36.25MG;145MG	N203312	002	Jan 07, 2015
	+		48.75MG;195MG	N203312	003	Jan 07, 2015
	+!		61.25MG;245MG	N203312	004	Jan 07, 2015

CARBIDOPA; LEVODOPA

SUSPENSION;ENTERAL

DUOPA

	+!	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015

TABLET;ORAL

CARBIDOPA AND LEVODOPA

AB		ACTAVIS ELIZABETH	**10MG;100MG**	**A074260**	**001**	Sep 03, 1993
AB			**25MG;100MG**	**A074260**	**002**	Sep 03, 1993
AB	**!**		**25MG;250MG**	**A074260**	**003**	Sep 03, 1993
AB		APOTEX INC	**10MG;100MG**	**A077120**	**001**	Jun 02, 2008
AB			**25MG;100MG**	**A077120**	**002**	Jun 02, 2008
AB			**25MG;250MG**	**A077120**	**003**	Jun 02, 2008
AB		MAYNE PHARMA	**10MG;100MG**	**A073618**	**001**	Aug 28, 1992
AB			**25MG;100MG**	**A073589**	**001**	Aug 28, 1992
AB			**25MG;250MG**	**A073607**	**001**	Aug 28, 1992
AB		MYLAN	**10MG;100MG**	**A090324**	**001**	Sep 28, 2009
AB			**25MG;100MG**	**A090324**	**002**	Sep 28, 2009
AB			**25MG;250MG**	**A090324**	**003**	Sep 28, 2009
AB		SCIEGEN PHARMS INC	**10MG;100MG**	**A214092**	**001**	May 07, 2021
AB			**25MG;100MG**	**A214092**	**002**	May 07, 2021
AB			**25MG;250MG**	**A214092**	**003**	May 07, 2021
AB		SUN PHARM INDS	**10MG;100MG**	**A078536**	**001**	Oct 28, 2008
AB			**25MG;100MG**	**A078536**	**002**	Oct 28, 2008
AB			**25MG;250MG**	**A078536**	**003**	Oct 28, 2008

SINEMET

AB	**+**	ORGANON	**10MG;100MG**	**N017555**	**001**	
AB	**+**		**25MG;100MG**	**N017555**	**003**	
AB	**+**		**25MG;250MG**	**N017555**	**002**	

DHIVY

	+!	AVION PHARMS	25MG;100MG	N214869	001	Nov 12, 2021

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		ACCORD HLTHCARE	**25MG;100MG**	**A202323**	**001**	Feb 08, 2013
AB			**50MG;200MG**	**A202323**	**002**	Feb 08, 2013
AB		ALEMBIC PHARMS LTD	**25MG;100MG**	**A210341**	**001**	Jun 05, 2019
AB			**50MG;200MG**	**A210341**	**002**	Jun 05, 2019
AB		APOTEX	**25MG;100MG**	**A076212**	**001**	Jun 16, 2004
AB			**50MG;200MG**	**A076212**	**002**	Jun 16, 2004
AB		IMPAX LABS	**25MG;100MG**	**A076521**	**001**	May 14, 2004
AB			**50MG;200MG**	**A076521**	**002**	May 14, 2004
AB		MYLAN	**25MG;100MG**	**A075091**	**002**	Apr 21, 2000
AB			**50MG;200MG**	**A075091**	**001**	Sep 30, 1999
AB		SCIEGEN PHARMS INC	**25MG;100MG**	**A214091**	**001**	Oct 05, 2021
AB			**50MG;200MG**	**A214091**	**002**	Oct 05, 2021
AB		SUN PHARM INDS	**25MG;100MG**	**A077828**	**001**	Aug 23, 2007
AB	**!**		**50MG;200MG**	**A077828**	**002**	Aug 23, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

AB		SUN PHARM	**10MG;100MG**	**A078690**	**001**	Jul 31, 2009
AB			**25MG;100MG**	**A078690**	**002**	Jul 31, 2009
	!		25MG;250MG	A078690	003	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

	!	MIKART	4MG/5ML	A040458	001	Apr 25, 2003

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

	+!	AYTU	4MG/5ML	N022556	001	Mar 28, 2013

TABLET;ORAL

CARBINOXAMINE MALEATE

AA		INVAGEN PHARMS	**4MG**	**A090435**	**001**	Apr 15, 2010
AA	**!**	MIKART	**4MG**	**A040442**	**001**	Mar 19, 2003
AA		MISSION PHARMACAL CO	**4MG**	**A090756**	**001**	May 27, 2011
	!	MIKART	6MG	A207484	001	May 31, 2016

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		ACCORD HLTHCARE	**50MG/5ML (10MG/ML)**	**A206775**	**001**	Feb 09, 2017
AP			**150MG/15ML (10MG/ML)**	**A206775**	**002**	Feb 09, 2017
AP			**450MG/45ML (10MG/ML)**	**A206775**	**003**	Feb 09, 2017
AP			**600MG/60ML (10MG/ML)**	**A206775**	**004**	Feb 09, 2017

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		AKORN	**50MG/5ML (10MG/ML)**	**A090475**	**001**	Jul 29, 2009
AP			**150MG/15ML (10MG/ML)**	**A090475**	**002**	Jul 29, 2009
AP			**450MG/45ML (10MG/ML)**	**A090475**	**003**	Jul 29, 2009
AP			**600MG/60ML (10MG/ML)**	**A091268**	**002**	Jul 28, 2010
AP		CIPLA LTD	**50MG/5ML (10MG/ML)**	**A077861**	**001**	Jan 18, 2007
AP			**150MG/15ML (10MG/ML)**	**A077861**	**002**	Jan 18, 2007
AP			**450MG/45ML (10MG/ML)**	**A077861**	**003**	Jan 18, 2007
AP			**600MG/60ML (10MG/ML)**	**A077861**	**004**	Jan 18, 2007
AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A205487**	**001**	Mar 28, 2016
AP			**150MG/15ML (10MG/ML)**	**A205487**	**002**	Mar 28, 2016
AP			**450MG/45ML (10MG/ML)**	**A205487**	**003**	Mar 28, 2016
AP			**600MG/60ML (10MG/ML)**	**A205487**	**004**	Aug 03, 2020
AP		FRESENIUS KABI USA	**450MG/45ML (10MG/ML)**	**A077247**	**003**	Oct 21, 2004
AP			**450MG/45ML (10MG/ML)**	**A077266**	**003**	Feb 15, 2006
AP			**600MG/60ML (10MG/ML)**	**A077266**	**004**	Feb 15, 2006
AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A207324**	**001**	Feb 15, 2017
AP			**150MG/15ML (10MG/ML)**	**A207324**	**002**	Feb 15, 2017
AP			**450MG/45ML (10MG/ML)**	**A207324**	**003**	Feb 15, 2017
AP			**600MG/60ML (10MG/ML)**	**A207324**	**004**	Feb 15, 2017
AP		HIKMA	**50MG/5ML (10MG/ML)**	**A077244**	**001**	Oct 15, 2004
AP			**150MG/15ML (10MG/ML)**	**A077244**	**002**	Oct 15, 2004
AP			**450MG/45ML (10MG/ML)**	**A077244**	**003**	Oct 15, 2004
AP			**600MG/60ML (10MG/ML)**	**A077244**	**004**	Jan 20, 2006
AP	**!**	HOSPIRA	**50MG/5ML (10MG/ML)**	**A076517**	**001**	Oct 14, 2004
AP	**!**		**150MG/15ML (10MG/ML)**	**A076517**	**002**	Oct 14, 2004
AP	**!**		**450MG/45ML (10MG/ML)**	**A076517**	**003**	Oct 14, 2004
AP	**!**		**600MG/60ML (10MG/ML)**	**A077059**	**001**	Nov 23, 2004
AP		NOVAST LABS	**50MG/5ML (10MG/ML)**	**A208487**	**001**	Apr 26, 2017
AP			**150MG/15ML (10MG/ML)**	**A208487**	**002**	Apr 26, 2017
AP		PHARMACHEMIE BV	**50MG/5ML (10MG/ML)**	**A077269**	**001**	Oct 14, 2004
AP			**150MG/15ML (10MG/ML)**	**A077269**	**002**	Oct 14, 2004
AP			**450MG/45ML (10MG/ML)**	**A077269**	**003**	Oct 14, 2004
AP			**600MG/60ML (10MG/ML)**	**A077269**	**004**	Dec 28, 2007
AP		SANDOZ INC	**50MG/5ML (10MG/ML)**	**A078280**	**001**	May 08, 2008
AP			**150MG/15ML (10MG/ML)**	**A078280**	**002**	May 08, 2008
AP			**450MG/45ML (10MG/ML)**	**A078280**	**003**	May 08, 2008
AP		SUN PHARM	**50MG/5ML (10MG/ML)**	**A077926**	**001**	Sep 19, 2008
AP			**150MG/15ML (10MG/ML)**	**A077926**	**002**	Sep 19, 2008
AP			**450MG/45ML (10MG/ML)**	**A077926**	**003**	Sep 19, 2008
	!	ACCORD HLTHCARE	1GM/100ML (10MG/ML)	A206775	005	Apr 06, 2020

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP		DR REDDYS LABS LTD	**EQ 0.25MG BASE/ML**	**A211941**	**001**	Jul 02, 2019
AP		SUNNY	**EQ 0.25MG BASE/ML**	**A213118**	**001**	Mar 25, 2021

HEMABATE

AP	**+!**	PFIZER	**EQ 0.25MG BASE/ML**	**N017989**	**001**	

CARFILZOMIB

POWDER;INTRAVENOUS

CARFILZOMIB

AP		DR REDDYS	**60MG/VIAL**	**A209422**	**001**	Sep 09, 2019

KYPROLIS

AP	**+!**	ONYX THERAP	**60MG/VIAL**	**N202714**	**001**	Jul 20, 2012
	+		10MG/VIAL	N202714	003	Jun 07, 2018
	+		30MG/VIAL	N202714	002	Jun 03, 2016

CARGLUMIC ACID

TABLET, FOR SUSPENSION;ORAL

CARBAGLU

AB	**+!**	RECORDATI RARE	**200MG**	**N022562**	**001**	Mar 18, 2010

CARGLUMIC ACID

AB		NOVITIUM PHARMA	**200MG**	**A213729**	**001**	Oct 13, 2021

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

+	ALLERGAN	EQ 1.5MG BASE	N204370	001	Sep 17, 2015
+		EQ 3MG BASE	N204370	002	Sep 17, 2015
+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015
+!		EQ 6MG BASE	N204370	004	Sep 17, 2015

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

AA	ACCELRX LABS	**350MG**	**A040576**	**001**	Jun 07, 2005
AA	AUROBINDO PHARMA	**350MG**	**A040792**	**001**	Aug 06, 2009
AA	FOSUN PHARMA	**350MG**	**A081025**	**001**	Apr 13, 1989
AA	MLV	**350MG**	**A040245**	**001**	Sep 08, 1997
AA		**350MG**	**A211789**	**001**	Oct 20, 2021
AA	NATCO	**350MG**	**A090988**	**001**	Oct 28, 2014
AA	NOSTRUM LABS INC	**350MG**	**A207237**	**002**	Sep 21, 2020
AA	NOVAST LABS	**350MG**	**A040823**	**001**	Oct 22, 2008
AA	ORIENT PHARMA CO LTD	**350MG**	**A205085**	**001**	Oct 28, 2014
AA	OXFORD PHARMS	**350MG**	**A040188**	**001**	Mar 07, 1997
AA	SCIEGEN PHARMS INC	**350MG**	**A203374**	**001**	Jan 27, 2014
AA	WATSON LABS	**350MG**	**A087499**	**001**	Apr 20, 1982
AA	WILSHIRE PHARMS INC	**350MG**	**A205126**	**002**	Jul 08, 2015

SOMA

AA **+**	MYLAN SPECIALITY LP	**350MG**	**N011792**	**001**	

CARISOPRODOL

AB	AUROBINDO PHARMA	**250MG**	**A040792**	**002**	Nov 08, 2016
AB	NOSTRUM LABS INC	**250MG**	**A207237**	**001**	May 11, 2017
AB	WILSHIRE PHARMS INC	**250MG**	**A205126**	**001**	Jul 08, 2015

SOMA

AB **+!**	MYLAN SPECIALITY LP	**250MG**	**N011792**	**004**	Sep 13, 2007

CARMUSTINE

IMPLANT;INTRACRANIAL

GLIADEL

+!	ARBOR PHARMS LLC	7.7MG	N020637	001	Sep 23, 1996

INJECTABLE;INJECTION

BICNU

AP **+!**	AVET LIFESCIENCES	**100MG/VIAL**	**N017422**	**001**	

CARMUSTINE

AP	AMNEAL	**100MG/VIAL**	**A211229**	**001**	Oct 16, 2018
AP	DR REDDYS	**100MG/VIAL**	**A213207**	**001**	Oct 22, 2020
AP	JIANGSU PHARMS	**100MG/VIAL**	**A211202**	**001**	Mar 12, 2021
AP	MEITHEAL	**100MG/VIAL**	**A213460**	**001**	Aug 02, 2021
AP	NAVINTA LLC	**100MG/VIAL**	**A210179**	**001**	Sep 11, 2018
AP	STI PHARMA LLC	**100MG/VIAL**	**A209278**	**001**	Apr 02, 2019

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

!	SANDOZ INC	1%	A075476	001	Jan 03, 2000

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB	AUROBINDO PHARMA	**3.125MG**	**A078332**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078332**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078332**	**003**	Sep 05, 2007
AB		**25MG**	**A078332**	**004**	Sep 05, 2007
AB	BEXIMCO USA	**3.125MG**	**A078384**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078384**	**002**	Sep 05, 2007
AB		**12.5MG**	**A078384**	**003**	Sep 05, 2007
AB		**25MG**	**A078384**	**004**	Sep 05, 2007
AB	CHARTWELL MOLECULAR	**3.125MG**	**A077474**	**001**	Sep 05, 2007
AB		**6.25MG**	**A077474**	**002**	Sep 05, 2007
AB		**12.5MG**	**A077474**	**003**	Sep 05, 2007
AB		**25MG**	**A077474**	**004**	Sep 05, 2007
AB	DR REDDYS LABS LTD	**3.125MG**	**A076649**	**001**	Sep 05, 2007
AB		**6.25MG**	**A076649**	**002**	Sep 05, 2007
AB		**12.5MG**	**A076649**	**003**	Sep 05, 2007
AB		**25MG**	**A076649**	**004**	Sep 05, 2007
AB	GLENMARK GENERICS	**3.125MG**	**A078251**	**001**	Sep 05, 2007
AB		**6.25MG**	**A078251**	**002**	Sep 05, 2007

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB			**12.5MG**	**A078251**	**003**	Sep 05, 2007
AB			**25MG**	**A078251**	**004**	Sep 05, 2007
AB		LUPIN	**3.125MG**	**A078217**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078217**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078217**	**003**	Sep 05, 2007
AB			**25MG**	**A078217**	**004**	Sep 05, 2007
AB		MYLAN	**3.125MG**	**A077316**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077316**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077316**	**003**	Sep 05, 2007
AB			**25MG**	**A077316**	**004**	Sep 05, 2007
AB		RUBICON	**3.125MG**	**A078165**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078165**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078165**	**003**	Sep 05, 2007
AB			**25MG**	**A078165**	**004**	Sep 05, 2007
AB		SANDOZ	**3.125MG**	**A078227**	**001**	Sep 05, 2007
AB			**6.25MG**	**A078227**	**002**	Sep 05, 2007
AB			**12.5MG**	**A078227**	**003**	Sep 05, 2007
AB			**25MG**	**A078227**	**004**	Sep 05, 2007
AB		SUN PHARM INDS LTD	**3.125MG**	**A076989**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076989**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076989**	**003**	Sep 05, 2007
AB			**25MG**	**A076989**	**004**	Sep 05, 2007
AB		TARO	**3.125MG**	**A077780**	**001**	Sep 05, 2007
AB			**6.25MG**	**A077780**	**002**	Sep 05, 2007
AB			**12.5MG**	**A077780**	**003**	Sep 05, 2007
AB			**25MG**	**A077780**	**004**	Sep 05, 2007
AB		TEVA	**3.125MG**	**A076373**	**001**	Sep 05, 2007
AB			**6.25MG**	**A076373**	**002**	Sep 05, 2007
AB			**12.5MG**	**A076373**	**003**	Sep 05, 2007
AB			**25MG**	**A076373**	**004**	Sep 05, 2007
AB		ZYDUS PHARMS USA INC	**3.125MG**	**A077614**	**004**	Sep 05, 2007
AB			**6.25MG**	**A077614**	**001**	Sep 05, 2007
AB			**12.5MG**	**A077614**	**002**	Sep 05, 2007
AB			**25MG**	**A077614**	**003**	Sep 05, 2007

COREG

AB	+	WOODWARD	**3.125MG**	**N020297**	**004**	May 29, 1997
AB	+		**6.25MG**	**N020297**	**003**	Sep 14, 1995
AB	+!		**12.5MG**	**N020297**	**002**	Sep 14, 1995
AB	+		**25MG**	**N020297**	**001**	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

CARVEDILOL PHOSPHATE

AB		IMPAX LABS INC	**10MG**	**A204717**	**001**	May 07, 2018
AB			**20MG**	**A204717**	**002**	May 07, 2018
AB			**40MG**	**A204717**	**003**	May 07, 2018
AB			**80MG**	**A204717**	**004**	May 07, 2018
AB		SUN PHARM INDUSTRIES	**10MG**	**A090132**	**001**	Oct 25, 2017
AB			**20MG**	**A090132**	**002**	Oct 25, 2017
AB			**40MG**	**A090132**	**003**	Oct 25, 2017
AB			**80MG**	**A090132**	**004**	Oct 25, 2017

COREG CR

AB	+	WOODWARD	**10MG**	**N022012**	**001**	Oct 20, 2006
AB	+		**20MG**	**N022012**	**002**	Oct 20, 2006
AB	+!		**40MG**	**N022012**	**003**	Oct 20, 2006
AB	+		**80MG**	**N022012**	**004**	Oct 20, 2006

CASIMERSEN

SOLUTION;INTRAVENOUS

AMONDYS 45

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CANCIDAS

AP	+!	MERCK	**50MG/VIAL**	**N021227**	**001**	Jan 26, 2001
AP	+!		**70MG/VIAL**	**N021227**	**002**	Jan 26, 2001

CASPOFUNGIN ACETATE

AP		FRESENIUS KABI USA	**50MG/VIAL**	**N206110**	**001**	Dec 30, 2016

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

AP			**70MG/VIAL**	**N206110**	**002**	Dec 30, 2016
AP		GLAND	**50MG/VIAL**	**A207092**	**001**	Sep 29, 2017
AP			**70MG/VIAL**	**A207092**	**002**	Sep 29, 2017
AP		JIANGSU PHARMS	**50MG/VIAL**	**A200833**	**001**	Jun 28, 2018
AP			**70MG/VIAL**	**A200833**	**002**	Jun 28, 2018
AP		UBI	**50MG/VIAL**	**A211263**	**001**	Oct 01, 2021
AP			**70MG/VIAL**	**A211263**	**002**	Oct 01, 2021
AP		XELLIA PHARMS APS	**50MG/VIAL**	**A205923**	**001**	Jul 02, 2018
AP			**70MG/VIAL**	**A205923**	**002**	Jul 02, 2018

CEDAZURIDINE; DECITABINE

TABLET;ORAL

INQOVI

+!	OTSUKA	100MG;35MG	N212576	001	Jul 07, 2020

CEFACLOR

CAPSULE;ORAL

CEFACLOR

AB		HIKMA	**EQ 250MG BASE**	**A065350**	**001**	Apr 03, 2007
AB	**!**		**EQ 500MG BASE**	**A065350**	**002**	Apr 03, 2007
AB		YUNG SHIN PHARM	**EQ 250MG BASE**	**A065146**	**001**	Jan 22, 2004
AB			**EQ 500MG BASE**	**A065146**	**002**	Jan 22, 2004

FOR SUSPENSION;ORAL

CEFACLOR

	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012
		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012
		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012
!		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012

TABLET, EXTENDED RELEASE;ORAL

CEFACLOR

	TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
!		EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A065352**	**001**	Jan 25, 2007
AB		HIKMA	**EQ 500MG BASE**	**A065311**	**001**	Feb 07, 2006
AB		LUPIN	**EQ 500MG BASE**	**A065392**	**001**	May 29, 2007
AB		ORCHID HLTHCARE	**EQ 500MG BASE**	**A065309**	**001**	Sep 18, 2006
AB	**!**	TEVA PHARMS	**EQ 500MG BASE**	**A065282**	**001**	Jan 20, 2006

FOR SUSPENSION;ORAL

CEFADROXIL

AB		AUROBINDO	**EQ 250MG BASE/5ML**	**A065349**	**001**	Apr 25, 2013
AB			**EQ 500MG BASE/5ML**	**A065349**	**002**	Apr 25, 2013
AB		HIKMA PHARMS	**EQ 250MG BASE/5ML**	**A091036**	**001**	Nov 28, 2012
AB			**EQ 500MG BASE/5ML**	**A091036**	**002**	Nov 28, 2012
AB		LUPIN	**EQ 250MG BASE/5ML**	**A065396**	**001**	Feb 21, 2008
AB	**!**		**EQ 500MG BASE/5ML**	**A065396**	**002**	Feb 21, 2008
AB		ORCHID HLTHCARE	**EQ 250MG BASE/5ML**	**A065307**	**002**	Oct 16, 2006
AB			**EQ 500MG BASE/5ML**	**A065307**	**003**	Oct 16, 2006

TABLET;ORAL

CEFADROXIL

AB		HIKMA	**EQ 1GM BASE**	**A065260**	**001**	Mar 30, 2006
AB		ORCHID HLTHCARE	**EQ 1GM BASE**	**A065301**	**001**	Sep 18, 2006
!		TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065303**	**001**	Oct 22, 2008
AP			**EQ 1GM BASE/VIAL**	**A065303**	**002**	Oct 22, 2008
AP			**EQ 10GM BASE/VIAL**	**A065306**	**001**	Oct 22, 2008
AP	**!**	HIKMA FARMACEUTICA	**EQ 500MG BASE/VIAL**	**A065047**	**001**	Sep 18, 2001
AP	**!**		**EQ 1GM BASE/VIAL**	**A065047**	**002**	Sep 18, 2001
AP			**EQ 10GM BASE/VIAL**	**A065143**	**001**	Oct 18, 2004
AP		QILU	**EQ 1GM BASE/VIAL**	**A203661**	**001**	Dec 28, 2015
AP	**!**		**EQ 10GM BASE/VIAL**	**A209217**	**001**	Oct 17, 2018
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A062831**	**001**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A062831**	**002**	Dec 09, 1988
AP			**EQ 1GM BASE/VIAL**	**A065345**	**001**	May 09, 2007

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

CEFAZOLIN SODIUM

AP			**EQ 10GM BASE/VIAL**	**A062831**	**003**	Sep 25, 1992
	ANCEF IN PLASTIC CONTAINER					
	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A063002	002	Mar 28, 1991
	CEFAZOLIN AND DEXTROSE					
	+!	B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
	+		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012
	CEFAZOLIN SODIUM					
	!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014
	!	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
	!		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015

CEFDINIR

CAPSULE;ORAL

CEFDINIR

AB		ALKEM LABS LTD	**300MG**	**A210220**	**001**	Feb 19, 2021
AB		AUROBINDO PHARMA	**300MG**	**A065434**	**001**	Jan 07, 2008
AB		LUPIN	**300MG**	**A065264**	**001**	May 19, 2006
AB		ORCHID HLTHCARE	**300MG**	**A065418**	**001**	Jul 18, 2007
AB	**!**	SANDOZ	**300MG**	**A065330**	**001**	Apr 06, 2007
AB		TEVA PHARMS	**300MG**	**A065368**	**001**	May 09, 2007

FOR SUSPENSION;ORAL

CEFDINIR

AB		ALKEM LABS LTD	**125MG/5ML**	**A210534**	**001**	Feb 19, 2021
AB			**250MG/5ML**	**A210534**	**002**	Feb 19, 2021
AB		AUROBINDO PHARMA	**125MG/5ML**	**A065473**	**001**	Dec 14, 2007
AB			**250MG/5ML**	**A065473**	**002**	Dec 14, 2007
AB		LUPIN	**125MG/5ML**	**A065259**	**001**	May 31, 2006
AB			**250MG/5ML**	**A065259**	**002**	May 07, 2007
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065429**	**001**	Jul 18, 2007
AB			**250MG/5ML**	**A065429**	**002**	Jul 18, 2007
AB		SANDOZ	**125MG/5ML**	**A065337**	**001**	Apr 06, 2007
AB	**!**		**250MG/5ML**	**A065337**	**002**	Apr 06, 2007
AB		TEVA PHARMS	**125MG/5ML**	**A065332**	**001**	May 04, 2007
AB			**250MG/5ML**	**A065332**	**002**	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

CEFEPIME HYDROCHLORIDE

AP		ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065441**	**001**	Mar 20, 2008
AP			**EQ 2GM BASE/VIAL**	**A065441**	**002**	Mar 20, 2008
AP		QILU	**EQ 500MG BASE/VIAL**	**A203704**	**001**	Feb 01, 2016
AP			**EQ 1GM BASE/VIAL**	**A203704**	**002**	Feb 01, 2016
AP			**EQ 2GM BASE/VIAL**	**A203704**	**003**	Feb 01, 2016
AP		SAGENT PHARMS INC	**EQ 1GM BASE/VIAL**	**A091048**	**001**	Jan 04, 2017
AP			**EQ 2GM BASE/VIAL**	**A091048**	**002**	Jan 04, 2017

MAXIPIME

AP	**+!**	HOSPIRA INC	**EQ 500MG BASE/VIAL**	**N050679**	**001**	Jan 18, 1996
AP	**+!**		**EQ 1GM BASE/VIAL**	**N050679**	**002**	Jan 18, 1996
AP	**+!**		**EQ 2GM BASE/VIAL**	**N050679**	**003**	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

POWDER;INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018

CEFIDEROCOL SULFATE TOSYLATE

POWDER;INTRAVENOUS

FETROJA

+!	SHIONOGI INC	EQ 1GM BASE/VIAL	N209445	001	Nov 14, 2019

CEFIXIME							
CAPSULE;ORAL							
CEFIXIME							
	!	ALKEM LABS LTD	400MG	A210574	001	Oct 09, 2018
FOR SUSPENSION;ORAL							
CEFIXIME							
AB		ALKEM LABS LTD	**100MG/5ML**	**A211775**	**001**	Feb 19, 2021
AB			**200MG/5ML**	**A211775**	**002**	Feb 19, 2021
AB		AUROBINDO PHARMA LTD	**100MG/5ML**	**A204835**	**001**	Apr 14, 2015
AB			**200MG/5ML**	**A204835**	**002**	Apr 14, 2015
AB		BELCHER	**100MG/5ML**	**A206938**	**001**	Feb 06, 2017
AB			**200MG/5ML**	**A206938**	**002**	Feb 06, 2017
AB			**500MG/5ML**	**A206939**	**001**	Feb 06, 2017
SUPRAX							
AB	**+!**	LUPIN LTD	**500MG/5ML**	**N202091**	**001**	Feb 20, 2013
AB	**!**	LUPIN PHARMS	**200MG/5ML**	**A065355**	**001**	Apr 10, 2007
TABLET, CHEWABLE;ORAL							
SUPRAX							
		LUPIN LTD	100MG	A065380	001	Oct 25, 2010
			150MG	A065380	002	Oct 25, 2010
	!		200MG	A065380	003	Oct 25, 2010
CEFOTAXIME SODIUM							
INJECTABLE;INJECTION							
CEFOTAXIME							
	!	HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002
	!		EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002
	!		EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002
	!		EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002
CEFOTETAN DISODIUM							
INJECTABLE;INJECTION							
CEFOTAN							
AP	**+**	TELIGENT	**EQ 1GM BASE/VIAL**	**N050588**	**001**	Dec 27, 1985
AP	**+**		**EQ 2GM BASE/VIAL**	**N050588**	**002**	Dec 27, 1985
CEFOTETAN							
AP	**!**	FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A065374**	**001**	Aug 09, 2007
AP	**!**		**EQ 2GM BASE/VIAL**	**A065374**	**002**	Aug 09, 2007
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER							
	+!	B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007
	+!		EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007
CEFOXITIN SODIUM							
INJECTABLE;INJECTION							
CEFOXITIN							
AP	**!**	ACS DOBFAR	**EQ 1GM BASE/VIAL**	**A065414**	**001**	Jun 12, 2009
AP	**!**		**EQ 2GM BASE/VIAL**	**A065414**	**002**	Jun 12, 2009
AP	**!**		**EQ 10GM BASE/VIAL**	**A065415**	**001**	May 19, 2010
AP		HIKMA	**EQ 1GM BASE/VIAL**	**A065051**	**001**	Sep 11, 2000
AP			**EQ 2GM BASE/VIAL**	**A065051**	**002**	Sep 11, 2000
AP			**EQ 10GM BASE/VIAL**	**A065050**	**001**	Sep 11, 2000
AP		HIKMA FARMACEUTICA	**EQ 1GM BASE/VIAL**	**A065238**	**001**	Mar 12, 2010
AP			**EQ 2GM BASE/VIAL**	**A065238**	**002**	Mar 12, 2010
AP			**EQ 10GM BASE/VIAL**	**A065239**	**001**	Mar 02, 2010
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER							
AP	**+!**	B BRAUN	**EQ 1GM BASE/VIAL**	**N065214**	**001**	Mar 10, 2006
AP	**+!**		**EQ 2GM BASE/VIAL**	**N065214**	**002**	Mar 10, 2006
POWDER;INTRAVENOUS							
CEFOXITIN IN PLASTIC CONTAINER							
		SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015
CEFPODOXIME PROXETIL							
FOR SUSPENSION;ORAL							
CEFPODOXIME PROXETIL							
		AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007
	!		EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007
TABLET;ORAL							
CEFPODOXIME PROXETIL							
AB		AUROBINDO PHARMA	**EQ 100MG BASE**	**A065370**	**001**	Jun 11, 2007
AB			**EQ 200MG BASE**	**A065370**	**002**	Jun 11, 2007
AB		ORCHID HLTHCARE	**EQ 100MG BASE**	**A065388**	**001**	Nov 14, 2007
AB			**EQ 200MG BASE**	**A065388**	**002**	Nov 14, 2007
AB		SANDOZ	**EQ 100MG BASE**	**A065462**	**001**	May 28, 2008

CEFPODOXIME PROXETIL

TABLET;ORAL

CEFPODOXIME PROXETIL

AB	**!**		**EQ 200MG BASE**	**A065462**	**002**	May 28, 2008

CEFPROZIL

FOR SUSPENSION;ORAL

CEFPROZIL

AB		APOTEX INC	**125MG/5ML**	**A065351**	**001**	Feb 29, 2012
AB			**250MG/5ML**	**A065351**	**002**	Feb 29, 2012
AB		AUROBINDO PHARMA	**125MG/5ML**	**A065381**	**001**	Jan 30, 2007
AB			**250MG/5ML**	**A065381**	**002**	Jan 30, 2007
AB		LUPIN	**125MG/5ML**	**A065261**	**001**	Dec 19, 2005
AB	**!**		**250MG/5ML**	**A065261**	**002**	Dec 19, 2005
AB		ORCHID HLTHCARE	**125MG/5ML**	**A065284**	**002**	Dec 30, 2005
AB			**250MG/5ML**	**A065284**	**001**	Dec 30, 2005
AB		SANDOZ	**125MG/5ML**	**A065257**	**001**	Dec 08, 2005
AB			**250MG/5ML**	**A065257**	**002**	Dec 08, 2005

TABLET;ORAL

CEFPROZIL

AB		APOTEX INC	**250MG**	**A065327**	**001**	Mar 26, 2008
AB			**500MG**	**A065327**	**002**	Mar 26, 2008
AB		AUROBINDO PHARMA LTD	**250MG**	**A065340**	**001**	May 24, 2007
AB			**500MG**	**A065340**	**002**	May 24, 2007
AB		CHARTWELL RX	**250MG**	**A065235**	**001**	Nov 14, 2005
AB			**500MG**	**A065235**	**002**	Nov 14, 2005
AB		LUPIN	**250MG**	**A065276**	**001**	Dec 08, 2005
AB	**!**		**500MG**	**A065276**	**002**	Dec 08, 2005
AB		ORCHID HLTHCARE	**250MG**	**A065267**	**001**	Dec 19, 2005
AB			**500MG**	**A065267**	**002**	Dec 19, 2005
AB		TEVA	**250MG**	**A065208**	**001**	Dec 06, 2005
AB			**500MG**	**A065208**	**002**	Dec 06, 2005

CEFTAROLINE FOSAMIL

POWDER;INTRAVENOUS

CEFTAROLINE FOSAMIL

AP		APOTEX	**400MG/VIAL**	**A208075**	**001**	Sep 21, 2021
AP			**600MG/VIAL**	**A208075**	**002**	Sep 21, 2021

TEFLARO

AP	**+!**	ALLERGAN	**400MG/VIAL**	**N200327**	**001**	Oct 29, 2010
AP	**+!**		**600MG/VIAL**	**N200327**	**002**	Oct 29, 2010

CEFTAZIDIME

INJECTABLE;INJECTION

CEFTAZIDIME

AP		ACS DOBFAR	**1GM/VIAL**	**A062640**	**002**	Nov 20, 1985
AP			**2GM/VIAL**	**A062640**	**003**	Nov 20, 1985
AP			**6GM/VIAL**	**A062640**	**004**	Feb 03, 1992

FORTAZ

AP	**+!**	TELIGENT	**500MG/VIAL**	**N050578**	**001**	Jul 19, 1985
AP	**+!**		**1GM/VIAL**	**N050578**	**002**	Jul 19, 1985
AP	**+!**		**2GM/VIAL**	**N050578**	**003**	Jul 19, 1985
AP	**+!**		**6GM/VIAL**	**N050578**	**004**	Jul 19, 1985

TAZICEF

AP		HOSPIRA	**500MG/VIAL**	**A062662**	**001**	Mar 06, 1986
AP			**1GM/VIAL**	**A062662**	**002**	Mar 06, 1986
AP			**1GM/VIAL**	**A064032**	**001**	Oct 31, 1993
AP			**2GM/VIAL**	**A062662**	**003**	Mar 06, 1986
AP			**2GM/VIAL**	**A064032**	**002**	Oct 31, 1993
AP			**6GM/VIAL**	**A062662**	**004**	Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

	+	B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011
	+!		EQ 2GM BASE	N050823	002	Jun 13, 2011

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;INTRAVENOUS

ZERBAXA

	+!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL**	**A065329**	**001**	Jul 24, 2008
AP			**EQ 1GM BASE/VIAL**	**A065329**	**002**	Jul 24, 2008
AP			**EQ 2GM BASE/VIAL**	**A065329**	**003**	Jul 24, 2008
AP			**EQ 10GM BASE/VIAL**	**A065328**	**001**	Jul 24, 2008
AP		QILU	**EQ 10GM BASE/VIAL**	**A209218**	**001**	Oct 17, 2018
AP	!	SANDOZ	**EQ 10GM BASE/VIAL**	**A065168**	**001**	May 17, 2005
AP	!	SANDOZ INC	**EQ 1GM BASE/VIAL**	**A065204**	**001**	May 03, 2005
AP	!		**EQ 2GM BASE/VIAL**	**A065204**	**002**	May 03, 2005
AP		WOCKHARDT	**EQ 1GM BASE/VIAL**	**A065180**	**001**	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP	+!	B BRAUN	**EQ 1GM BASE/VIAL**	**N050796**	**001**	Apr 20, 2005
AP	+!		**EQ 2GM BASE/VIAL**	**N050796**	**002**	Apr 20, 2005

CEFTRIAXONE SODIUM

AP		ASTRAL	**EQ 10GM BASE/VIAL**	**A091117**	**001**	Jan 20, 2017
AP		HIKMA	**EQ 10GM BASE/VIAL**	**A090701**	**001**	Oct 04, 2017

CEFTRIAXONE

		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014

CEFTRIAXONE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
	!		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP		AKORN	**EQ 250MG BASE/VIAL**	**A065305**	**001**	Jan 11, 2008
AP			**EQ 500MG BASE/VIAL**	**A065305**	**002**	Jan 11, 2008
AP			**EQ 1GM BASE/VIAL**	**A065305**	**003**	Jan 11, 2008
AP			**EQ 2GM BASE/VIAL**	**A065305**	**004**	Jan 11, 2008
AP		ASTRAL	**EQ 250MG BASE/VIAL**	**A091049**	**001**	Jun 11, 2018
AP			**EQ 500MG BASE/VIAL**	**A091049**	**002**	Jun 11, 2018
AP			**EQ 1GM BASE/VIAL**	**A091049**	**003**	Jun 11, 2018
AP			**EQ 2GM BASE/VIAL**	**A091049**	**004**	Jun 11, 2018
AP		HIKMA FARMACEUTICA	**EQ 250MG BASE/VIAL**	**A065342**	**001**	Jan 10, 2008
AP			**EQ 500MG BASE/VIAL**	**A065342**	**002**	Jan 10, 2008
AP			**EQ 1GM BASE/VIAL**	**A065342**	**003**	Jan 10, 2008
AP			**EQ 2GM BASE/VIAL**	**A065342**	**004**	Jan 10, 2008
AP		LUPIN	**EQ 250MG BASE/VIAL**	**A065125**	**001**	Sep 30, 2003
AP			**EQ 500MG BASE/VIAL**	**A065125**	**002**	Sep 30, 2003
AP			**EQ 1GM BASE/VIAL**	**A065125**	**003**	Sep 30, 2003
AP			**EQ 2GM BASE/VIAL**	**A065125**	**004**	Sep 30, 2003
AP		QILU	**EQ 250MG BASE/VIAL**	**A203702**	**001**	Jun 29, 2016
AP			**EQ 500MG BASE/VIAL**	**A203702**	**002**	Jun 29, 2016
AP			**EQ 1GM BASE/VIAL**	**A203702**	**003**	Jun 29, 2016
AP			**EQ 2GM BASE/VIAL**	**A203702**	**004**	Jun 29, 2016
AP	!	SANDOZ	**EQ 250MG BASE/VIAL**	**A065169**	**001**	May 09, 2005
AP	!		**EQ 500MG BASE/VIAL**	**A065169**	**002**	May 09, 2005
AP	!		**EQ 1GM BASE/VIAL**	**A065169**	**003**	May 09, 2005
AP	!		**EQ 2GM BASE/VIAL**	**A065169**	**004**	May 09, 2005
AP		WOCKHARDT	**EQ 250MG BASE/VIAL**	**A065391**	**001**	Apr 12, 2007
AP			**EQ 500MG BASE/VIAL**	**A065391**	**002**	Apr 12, 2007
AP			**EQ 2GM BASE/VIAL**	**A065391**	**003**	Apr 12, 2007

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

AB		ALKEM LABS LTD	**EQ 250MG BASE**	**A065496**	**001**	Jun 07, 2010
AB			**EQ 500MG BASE**	**A065496**	**002**	Jun 07, 2010
AB		APOTEX	**EQ 250MG BASE**	**A065069**	**001**	Oct 02, 2002
AB			**EQ 500MG BASE**	**A065069**	**002**	Oct 02, 2002
AB		AUROBINDO PHARMA LTD	**EQ 125MG BASE**	**A065308**	**001**	Mar 29, 2006
AB			**EQ 250MG BASE**	**A065308**	**002**	Mar 29, 2006
AB			**EQ 500MG BASE**	**A065308**	**003**	Mar 29, 2006
AB		LUPIN	**EQ 250MG BASE**	**A065135**	**001**	Jul 25, 2003
AB	!		**EQ 500MG BASE**	**A065135**	**002**	Jul 25, 2003
AB		ORCHID HLTHCARE	**EQ 125MG BASE**	**A065359**	**001**	Feb 15, 2008
AB			**EQ 250MG BASE**	**A065359**	**002**	Feb 15, 2008
AB			**EQ 500MG BASE**	**A065359**	**003**	Feb 15, 2008
AB		WOCKHARDT	**EQ 125MG BASE**	**A065166**	**001**	Jul 29, 2005
AB			**EQ 250MG BASE**	**A065166**	**002**	Jul 29, 2005
AB			**EQ 500MG BASE**	**A065166**	**003**	Jul 29, 2005

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

AP	**+!**	B BRAUN	**EQ 750MG BASE/VIAL**	**N050780**	**001**	Feb 21, 2001
AP	**+!**		**EQ 1.5GM BASE/VIAL**	**N050780**	**002**	Feb 21, 2001

CEFUROXIME SODIUM

AP		ACS DOBFAR SPA	**EQ 1.5GM BASE/VIAL**	**A064125**	**002**	May 30, 1997
AP			**EQ 7.5GM BASE/VIAL**	**A064124**	**001**	May 30, 1997
AP		HIKMA FARMACEUTICA	**EQ 1.5GM BASE/VIAL**	**A065048**	**002**	Jan 09, 2004
AP			**EQ 7.5GM BASE/VIAL**	**A065046**	**001**	Jan 09, 2004

ZINACEF

AP	**+!**	TELIGENT	**EQ 1.5GM BASE/VIAL**	**N050558**	**003**	Oct 19, 1983
AP	**+!**		**EQ 7.5GM BASE/VIAL**	**N050558**	**004**	Oct 23, 1986

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB		ACS DOBFAR SPA	**EQ 750MG BASE/VIAL**	**A064125**	**001**	May 30, 1997
AB		HIKMA FARMACEUTICA	**EQ 750MG BASE/VIAL**	**A065048**	**001**	Jan 09, 2004

ZINACEF

AB	**+!**	TELIGENT	**EQ 750MG BASE/VIAL**	**N050558**	**002**	Oct 19, 1983

CELECOXIB

CAPSULE;ORAL

CELEBREX

AB	**+**	UPJOHN	**50MG**	**N020998**	**004**	Dec 15, 2006
AB	**+**		**100MG**	**N020998**	**001**	Dec 31, 1998
AB	**+**		**200MG**	**N020998**	**002**	Dec 31, 1998
AB	**+!**		**400MG**	**N020998**	**003**	Aug 29, 2002

CELECOXIB

AB		ALEMBIC PHARMS LTD	**50MG**	**A204519**	**001**	Aug 21, 2015
AB			**100MG**	**A204519**	**002**	Aug 21, 2015
AB			**200MG**	**A204519**	**003**	Aug 21, 2015
AB			**400MG**	**A204519**	**004**	Aug 21, 2015
AB		APOTEX INC	**50MG**	**A204197**	**001**	Jun 02, 2015
AB			**100MG**	**A204197**	**002**	Jun 02, 2015
AB			**200MG**	**A204197**	**003**	Jun 02, 2015
AB		AUROBINDO PHARMA LTD	**50MG**	**A206827**	**001**	Feb 01, 2016
AB			**100MG**	**A206827**	**002**	Feb 01, 2016
AB			**200MG**	**A206827**	**003**	Feb 01, 2016
AB			**400MG**	**A206827**	**004**	Feb 01, 2016
AB		CADILA PHARMS LTD	**50MG**	**A208701**	**001**	Nov 14, 2019
AB			**100MG**	**A208701**	**002**	Nov 14, 2019
AB			**200MG**	**A208701**	**003**	Nov 14, 2019
AB			**400MG**	**A208701**	**004**	Nov 14, 2019
AB		CIPLA	**50MG**	**A207446**	**001**	Sep 23, 2015
AB			**100MG**	**A207446**	**002**	Sep 23, 2015
AB			**200MG**	**A207446**	**003**	Sep 23, 2015
AB			**400MG**	**A207446**	**004**	Sep 23, 2015
AB		CSPC OUYI	**50MG**	**A210071**	**001**	Jan 23, 2018
AB			**100MG**	**A210071**	**002**	Jan 23, 2018
AB			**200MG**	**A210071**	**003**	Jan 23, 2018
AB		LUPIN LTD	**50MG**	**A202240**	**001**	Oct 29, 2014
AB			**100MG**	**A202240**	**002**	Jun 09, 2015
AB			**200MG**	**A202240**	**003**	Jun 09, 2015
AB			**400MG**	**A202240**	**004**	Jun 09, 2015
AB		MACLEODS PHARMS LTD	**50MG**	**A204590**	**001**	Mar 16, 2016
AB			**100MG**	**A204590**	**002**	Mar 16, 2016
AB			**200MG**	**A204590**	**003**	Mar 16, 2016
AB			**400MG**	**A204590**	**004**	Mar 16, 2016
AB		MICRO LABS	**50MG**	**A204776**	**001**	Apr 30, 2018
AB			**100MG**	**A204776**	**002**	Apr 30, 2018
AB			**200MG**	**A204776**	**003**	Apr 30, 2018
AB			**400MG**	**A204776**	**004**	Apr 30, 2018
AB		MYLAN	**50MG**	**A078857**	**001**	May 30, 2014
AB			**100MG**	**A078857**	**002**	Feb 11, 2015
AB			**200MG**	**A078857**	**003**	Feb 11, 2015
AB			**400MG**	**A078857**	**004**	Feb 11, 2015
AB		NANJING	**200MG**	**A213598**	**001**	May 13, 2020
AB		QINGDAO BAHEAL PHARM	**50MG**	**A208856**	**001**	Aug 07, 2019
AB			**100MG**	**A208856**	**002**	Aug 07, 2019
AB			**200MG**	**A208856**	**003**	Aug 07, 2019
AB			**400MG**	**A208856**	**004**	Aug 07, 2019

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	SCIEGEN PHARMS INC	**50MG**	**A205129**	**001**	Dec 03, 2020
AB		**100MG**	**A205129**	**002**	Dec 03, 2020
AB		**200MG**	**A205129**	**003**	Dec 03, 2020
AB		**400MG**	**A205129**	**004**	Dec 03, 2020
AB	TEVA	**50MG**	**A076898**	**001**	May 30, 2014
AB		**100MG**	**A076898**	**002**	May 30, 2014
AB		**200MG**	**A076898**	**003**	May 30, 2014
AB		**400MG**	**A076898**	**004**	May 30, 2014
AB	TIANJIN TIANYAO	**50MG**	**A207872**	**001**	Feb 25, 2020
AB		**100MG**	**A207872**	**002**	Feb 25, 2020
AB		**200MG**	**A207872**	**003**	Feb 25, 2020
AB		**400MG**	**A207872**	**004**	Feb 25, 2020
AB	TORRENT	**50MG**	**A207677**	**001**	Dec 23, 2015
AB		**100MG**	**A207677**	**002**	Dec 23, 2015
AB		**200MG**	**A207677**	**003**	Dec 23, 2015
AB		**400MG**	**A207677**	**004**	Dec 23, 2015
AB	UMEDICA LABS PVT LTD	**50MG**	**A210628**	**001**	Nov 27, 2019
AB		**100MG**	**A210628**	**002**	Nov 27, 2019
AB		**200MG**	**A210628**	**003**	Nov 27, 2019
AB		**400MG**	**A210628**	**004**	Nov 27, 2019
AB	UNICHEM	**50MG**	**A213301**	**001**	Jan 12, 2021
AB		**100MG**	**A213301**	**002**	Jan 12, 2021
AB		**200MG**	**A213301**	**003**	Jan 12, 2021
AB		**400MG**	**A213301**	**004**	Jan 12, 2021
AB	WATSON LABS INC	**50MG**	**A200562**	**001**	Feb 11, 2015
AB		**100MG**	**A200562**	**002**	Feb 11, 2015
AB		**200MG**	**A200562**	**003**	Feb 11, 2015
AB		**400MG**	**A200562**	**004**	Feb 11, 2015
AB	YILING	**50MG**	**A211412**	**001**	Mar 06, 2020
AB		**100MG**	**A211412**	**002**	Mar 06, 2020
AB		**200MG**	**A211412**	**003**	Mar 06, 2020
AB		**400MG**	**A211412**	**004**	Mar 06, 2020
BX	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018
BX		100MG	A208833	002	May 31, 2018
BX		200MG	A208833	003	May 31, 2018
BX		400MG	A208833	004	May 31, 2018

SOLUTION;ORAL

ELYXYB

+!	BDSI	25MG/ML	N212157	001	May 05, 2020

CELECOXIB; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

SEGLENTIS

+!	KOWA PHARMS	56MG;44MG	N213426	001	Oct 15, 2021

CENOBAMATE

TABLET;ORAL

XCOPRI

+!	SK LIFE	12.5MG	N212839	001	Mar 10, 2020
+		25MG	N212839	002	Mar 10, 2020
+		50MG	N212839	003	Mar 10, 2020
+		100MG	N212839	004	Mar 10, 2020
+		150MG	N212839	005	Mar 10, 2020
+		200MG	N212839	006	Mar 10, 2020

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

AB	ALKEM LABS LTD	**EQ 250MG BASE**	**A090836**	**001**	Dec 20, 2010
AB		**EQ 500MG BASE**	**A090836**	**002**	Dec 20, 2010
AB	AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A065253**	**001**	Nov 16, 2005
AB		**EQ 500MG BASE**	**A065253**	**002**	Nov 16, 2005
AB	BELCHER PHARMS	**EQ 250MG BASE**	**A062713**	**001**	Jul 15, 1988
AB		**EQ 500MG BASE**	**A062713**	**002**	Jul 15, 1988
AB	CHARTWELL RX	**EQ 250MG BASE**	**A065152**	**001**	Feb 24, 2005
AB		**EQ 500MG BASE**	**A065152**	**002**	Feb 24, 2005
AB	HIKMA	**EQ 250MG BASE**	**A065215**	**001**	Jan 24, 2006
AB		**EQ 500MG BASE**	**A065215**	**002**	Jan 24, 2006
AB	LUPIN	**EQ 250MG BASE**	**A065229**	**001**	Nov 25, 2005

CEPHALEXIN						
CAPSULE;ORAL						
CEPHALEXIN						
AB			**EQ 500MG BASE**	**A065229**	**002**	Nov 25, 2005
AB		ORCHID HLTHCARE	**EQ 250MG BASE**	**A065248**	**001**	Jun 28, 2005
AB			**EQ 500MG BASE**	**A065248**	**002**	Jun 28, 2005
AB		TEVA	**EQ 250MG BASE**	**A062702**	**001**	Feb 13, 1987
AB			**EQ 500MG BASE**	**A062702**	**002**	Feb 13, 1987
		ALKEM LABS LTD	EQ 333MG BASE	A090836	003	Mar 29, 2013
	!		EQ 750MG BASE	A090836	004	Mar 29, 2013
FOR SUSPENSION;ORAL						
CEPHALEXIN						
AB		ALKEM LABS LTD	**EQ 125MG BASE/5ML**	**A210221**	**001**	Mar 26, 2019
AB			**EQ 250MG BASE/5ML**	**A210221**	**002**	Mar 26, 2019
AB		LUPIN	**EQ 125MG BASE/5ML**	**A065234**	**001**	Aug 17, 2005
AB			**EQ 250MG BASE/5ML**	**A065234**	**002**	Aug 17, 2005
AB		ORCHID HLTHCARE	**EQ 125MG BASE/5ML**	**A065326**	**001**	Jul 10, 2006
AB			**EQ 250MG BASE/5ML**	**A065326**	**002**	Jul 10, 2006
AB		TEVA	**EQ 125MG BASE/5ML**	**A062703**	**001**	Feb 13, 1987
AB	**!**		**EQ 250MG BASE/5ML**	**A062703**	**002**	Feb 13, 1987
AB		YUNG SHIN PHARM	**EQ 125MG BASE/5ML**	**A065336**	**001**	Jul 25, 2007
AB			**EQ 250MG BASE/5ML**	**A065336**	**002**	Jul 25, 2007
TABLET;ORAL						
CEPHALEXIN						
		TEVA	EQ 250MG BASE	A063023	001	Jan 12, 1989
	!		EQ 500MG BASE	A063024	001	Jan 12, 1989
CERITINIB						
TABLET;ORAL						
ZYKADIA						
	+!	NOVARTIS	150MG	N211225	001	Mar 18, 2019
CETIRIZINE HYDROCHLORIDE						
SOLUTION;INTRAVENOUS						
QUZYTTIR						
	+!	JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019
SOLUTION/DROPS;OPHTHALMIC						
ZERVIATE						
	+!	EYEVANCE	EQ 0.24% BASE	N208694	001	May 30, 2017
SYRUP;ORAL						
CETIRIZINE HYDROCHLORIDE						
AA		AMNEAL PHARMS	**5MG/5ML**	**A090766**	**001**	Oct 07, 2009
AA		BRECKENRIDGE	**5MG/5ML**	**A078488**	**001**	Oct 06, 2008
AA		LANNETT CO INC	**5MG/5ML**	**A078876**	**001**	May 11, 2012
AA		MICRO LABS	**5MG/5ML**	**A090191**	**001**	Nov 12, 2009
AA	**!**	PADAGIS US	**5MG/5ML**	**A078398**	**001**	Jun 17, 2008
AA		TARO	**5MG/5ML**	**A076601**	**001**	Jun 20, 2008
AA		TEVA PHARMS	**5MG/5ML**	**A077279**	**001**	May 27, 2008
CETRORELIX						
INJECTABLE;INJECTION						
CETROTIDE						
	+!	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000
CEVIMELINE HYDROCHLORIDE						
CAPSULE;ORAL						
CEVIMELINE HYDROCHLORIDE						
AB		HIKMA	**30MG**	**A091591**	**001**	Jul 08, 2013
AB		NOVEL LABS INC	**30MG**	**A204746**	**001**	Dec 30, 2016
AB		RISING	**30MG**	**A203775**	**001**	Jun 04, 2014
EVOXAC						
AB	**+!**	DAIICHI SANKYO INC	**30MG**	**N020989**	**002**	Jan 11, 2000
CHENODIOL						
TABLET;ORAL						
CHENODIOL						
	!	LGM PHARMA	250MG	A091019	001	Oct 22, 2009
CHLORAMBUCIL						
TABLET;ORAL						
LEUKERAN						
	+!	ASPEN GLOBAL INC	2MG	N010669	002	

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB		BARR	**5MG**	**A084768**	**001**	
AB			**10MG**	**A083116**	**001**	
AB			**25MG**	**A084769**	**001**	

LIBRIUM

AB		VALEANT PHARM INTL	**5MG**	**A085461**	**001**	
AB			**10MG**	**A085472**	**001**	
AB	**+!**		**25MG**	**A085475**	**001**	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB		ALKEM LABS LTD	**5MG;2.5MG**	**A214065**	**001**	Apr 26, 2021
AB		AMNEAL	**5MG;2.5MG**	**A215555**	**001**	Oct 25, 2021
AB		DR REDDYS	**5MG;2.5MG**	**A214698**	**001**	May 10, 2021
AB		MISEMER	**5MG;2.5MG**	**A210579**	**001**	Jul 29, 2020
AB		NUVO PHARMS INC	**5MG;2.5MG**	**A211421**	**001**	Jul 07, 2020
AB		PHARMA LIFE	**5MG;2.5MG**	**A213530**	**001**	Oct 20, 2020
AB		TEVA PHARMS USA	**5MG;2.5MG**	**A211476**	**001**	Nov 02, 2021

LIBRAX

AB	**+!**	BAUSCH	**5MG;2.5MG**	**N012750**	**001**	

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT		AKORN	**0.12%**	**A074356**	**001**	May 07, 1996
AT		BAJAJ	**0.12%**	**A075561**	**001**	Nov 14, 2000
AT		LYNE	**0.12%**	**A074291**	**001**	Dec 28, 1995
AT		PHARM ASSOC	**0.12%**	**A074522**	**001**	Dec 15, 1995
AT		WOCKHARDT BIO AG	**0.12%**	**A075006**	**001**	Mar 03, 2004
AT		XTTRIUM	**0.12%**	**A077789**	**001**	Jun 18, 2009

PAROEX

AT		SUNSTAR AMERICAS	**0.12%**	**A076434**	**001**	Nov 29, 2005

PERIDEX

AT	**+!**	3M	**0.12%**	**N019028**	**001**	Aug 13, 1986

PERIOGARD

AT		COLGATE PALMOLIVE CO	**0.12%**	**A073695**	**001**	Jan 14, 1994
AT		COLGATE-PALMOLIVE CO	**0.12%**	**A203212**	**001**	Jan 28, 2016

TABLET;DENTAL

PERIOCHIP

	+!	DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP		HIKMA	**2%**	**A040273**	**001**	Sep 09, 1998
AP			**3%**	**A040273**	**002**	Sep 09, 1998

NESACAINE

AP	**+**	FRESENIUS KABI USA	**2%**	**N009435**	**002**	

NESACAINE-MPF

AP	**+!**	FRESENIUS KABI USA	**2%**	**N009435**	**006**	May 02, 1996
AP	**+!**		**3%**	**N009435**	**007**	May 02, 1996

NESACAINE

	+!	FRESENIUS KABI USA	1%	N009435	001	

SOLUTION;INTRATHECAL

CLOROTEKAL

	+	B BRAUN MEDICAL INC	50MG/5ML (10MG/ML)	N208791	001	Sep 26, 2017

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

AA		IPCA LABS LTD	**250MG**	**A090610**	**001**	Dec 03, 2009
AA			**500MG**	**A090249**	**001**	Dec 03, 2009
AA	**!**	NATCO PHARMA LTD	**250MG**	**A091621**	**001**	Jan 21, 2011
AA	**!**		**500MG**	**A090612**	**001**	Jan 21, 2011
AA		SUVEN PHARMS	**500MG**	**A214756**	**001**	Sep 03, 2021

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

	+!	SALIX PHARMS	250MG/5ML	N011870	001	

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP		AM REGENT	**EQ 500MG BASE/VIAL**	**A202561**	**001**	Apr 22, 2013
AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090896**	**001**	Oct 16, 2009
AP		RK PHARMA	**EQ 500MG BASE/VIAL**	**A202493**	**001**	Jun 18, 2014
AP		SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A202462**	**001**	May 29, 2015
AP		SUN PHARM	**EQ 500MG BASE/VIAL**	**A091546**	**001**	Jul 26, 2011

DIURIL

AP	**+!**	AKORN	**EQ 500MG BASE/VIAL**	**N011145**	**005**	

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE;ORAL

TUXARIN ER

		MAINPOINTE	8MG;54.3MG	N206323	001	Jun 22, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	!	PADAGIS US	4MG/5ML;5MG/5ML;60MG/5ML	A204627	001	Apr 29, 2014

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

	+!	AYTU	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

		ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007
	!		EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB		TRIS PHARMA INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091632**	**001**	Oct 01, 2010

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	**!**	NEOS THERAP INC	**EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML**	**A091671**	**001**	Jun 29, 2012

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	!	GENUS	30MG/ML	A214542	001	Jun 02, 2021
	!		100MG/ML	A214542	002	Jun 02, 2021

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

AP		EUGIA PHARMA	**25MG/ML**	**A211816**	**001**	Jul 07, 2020
AP	**!**	WEST-WARD PHARMS INT	**25MG/ML**	**A083329**	**001**	

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		ENALTEC	**10MG**	**A212630**	**001**	Nov 29, 2021
AB			**25MG**	**A212630**	**002**	Nov 29, 2021
AB			**50MG**	**A212630**	**003**	Nov 29, 2021
AB			**100MG**	**A212630**	**004**	Nov 29, 2021
AB			**200MG**	**A212630**	**005**	Nov 29, 2021
AB		GLENMARK PHARMS LTD	**10MG**	**A212144**	**001**	Mar 23, 2021
AB			**25MG**	**A212144**	**002**	Mar 23, 2021
AB			**50MG**	**A212144**	**003**	Mar 23, 2021
AB			**100MG**	**A212144**	**004**	Mar 23, 2021
AB			**200MG**	**A212144**	**005**	Mar 23, 2021
AB		LANNETT CO INC	**10MG**	**A212996**	**001**	Jan 22, 2021
AB			**25MG**	**A212996**	**002**	Jan 22, 2021
AB			**50MG**	**A212996**	**003**	Jan 22, 2021
AB			**100MG**	**A212996**	**004**	Jan 22, 2021
AB			**200MG**	**A212996**	**005**	Jan 22, 2021
AB		SUN PHARM	**10MG**	**A214256**	**001**	Oct 26, 2020
AB			**25MG**	**A214256**	**002**	Oct 26, 2020
AB			**50MG**	**A214256**	**003**	Oct 26, 2020
AB			**100MG**	**A214256**	**004**	Oct 26, 2020
AB			**200MG**	**A214256**	**005**	Oct 26, 2020

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		TEVA PHARMS	**10MG**	**A215659**	**001**	Oct 25, 2021
AB			**25MG**	**A215659**	**002**	Oct 25, 2021
AB			**50MG**	**A215659**	**003**	Oct 25, 2021
AB			**100MG**	**A215659**	**004**	Oct 25, 2021
AB			**200MG**	**A215659**	**005**	Oct 25, 2021
AB	+	UPSHER SMITH LABS	**10MG**	**A083386**	**001**	
AB	+!		**25MG**	**A084112**	**001**	
AB	+		**50MG**	**A084113**	**001**	
AB	+!		**100MG**	**A084114**	**001**	
AB	+		**200MG**	**A084115**	**001**	
AB		ZYDUS	**10MG**	**A213368**	**001**	Jan 17, 2020
AB			**25MG**	**A213368**	**002**	Jan 17, 2020
AB			**50MG**	**A213368**	**003**	Jan 17, 2020
AB			**100MG**	**A213368**	**004**	Jan 17, 2020
AB			**200MG**	**A213368**	**005**	Jan 17, 2020
BX		AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018
BX			25MG	A209755	002	Sep 10, 2018
BX			50MG	A209755	003	Sep 10, 2018
BX			100MG	A209755	004	Sep 10, 2018
BX			200MG	A209755	005	Sep 10, 2018

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB		AJANTA PHARMA LTD	**25MG**	**A214129**	**001**	Nov 27, 2020
AB			**50MG**	**A214129**	**002**	Nov 27, 2020
AB		ALKEM LABS LTD	**25MG**	**A213412**	**001**	Feb 11, 2020
AB			**50MG**	**A213412**	**002**	Feb 11, 2020
AB		AMNEAL PHARMS CO	**25MG**	**A207204**	**001**	Jul 01, 2019
AB			**50MG**	**A207204**	**002**	Jul 01, 2019
AB		APPCO	**25MG**	**A210742**	**001**	Oct 12, 2018
AB			**50MG**	**A210742**	**002**	Oct 12, 2018
AB	+	MYLAN	**25MG**	**A086831**	**002**	
AB	+!		**50MG**	**A086831**	**001**	
AB		NOVAST LABS	**25MG**	**A206904**	**001**	Mar 30, 2017
AB			**50MG**	**A206904**	**002**	Mar 30, 2017
AB		SUN PHARM INDUSTRIES	**25MG**	**A089286**	**002**	Jul 21, 1986
AB			**50MG**	**A089286**	**001**	Jul 21, 1986
AB		UNICHEM	**25MG**	**A211627**	**001**	Aug 06, 2019
AB			**50MG**	**A211627**	**002**	Aug 06, 2019
AB		VISTAPHARM	**25MG**	**A211063**	**001**	Feb 26, 2019
AB			**50MG**	**A211063**	**002**	Feb 26, 2019
AB		ZYDUS PHARMS	**25MG**	**A207813**	**001**	May 10, 2019
AB			**50MG**	**A207813**	**002**	May 10, 2019
BX		UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018
BX			50MG	A207222	002	May 24, 2018

THALITONE

BX	+!	CASPER PHARMA LLC	25MG	N019574	002	Feb 12, 1992
	+		15MG	N019574	001	Dec 20, 1988

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AA		AUROBINDO PHARMA LTD	**500MG**	**A089853**	**001**	May 04, 1988
AA		MAYNE PHARMA	**500MG**	**A211849**	**002**	Jul 21, 2020
AA	!	MIKART	**250MG**	**A207483**	**001**	Jun 24, 2016
AA		NOVITIUM PHARMA	**500MG**	**A212254**	**001**	Sep 12, 2019
AA		SENORES PHARMS	**250MG**	**A215158**	**001**	Jul 29, 2021
AA	!	WATSON LABS	**500MG**	**A089859**	**001**	May 04, 1988
AB		GLENMARK PHARMS LTD	**375MG**	**A212185**	**001**	May 26, 2020
AB			**750MG**	**A212185**	**002**	May 26, 2020
AB		I3 PHARMS	**375MG**	**A212053**	**001**	Sep 14, 2020
AB			**750MG**	**A212053**	**002**	Sep 14, 2020
AB		MAYNE PHARMA	**375MG**	**A211849**	**001**	Jul 21, 2020
AB			**750MG**	**A211849**	**003**	Jul 21, 2020
AB	!	MIKART	**375MG**	**A040861**	**001**	Jun 01, 2010
AB	!		**750MG**	**A040861**	**002**	Jun 01, 2010
AB		NOVITIUM PHARMA	**375MG**	**A212253**	**001**	Nov 27, 2019

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

AB			**750MG**	**A212253**	**002**	Nov 27, 2019
AB		PAR PHARM INC	**375MG**	**A212743**	**002**	Apr 29, 2021
AB			**750MG**	**A212743**	**001**	Nov 02, 2020
AB		TEVA PHARMS USA INC	**375MG**	**A212898**	**001**	Jun 17, 2020
AB			**750MG**	**A212898**	**002**	Jun 17, 2020

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB		AJANTA PHARMA LTD	**EQ 4GM RESIN/PACKET**	**A211119**	**001**	Apr 06, 2020
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211119**	**002**	Apr 06, 2020
AB		ALKEM LABS LTD	**EQ 4GM RESIN/PACKET**	**A211856**	**001**	Oct 19, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211856**	**002**	Oct 19, 2021
AB		ANI PHARMS	**EQ 4GM RESIN/PACKET**	**A074554**	**001**	Oct 02, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074554**	**002**	Oct 02, 1996
AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077204**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077204**	**002**	Aug 26, 2005
AB	**!**	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074557**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074557**	**002**	Aug 15, 1996
AB		TAGI	**EQ 4GM RESIN/PACKET**	**A209597**	**001**	Mar 09, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A209597**	**002**	Mar 09, 2021
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202901**	**001**	Jul 02, 2018

CHOLESTYRAMINE LIGHT

AB		ALKEM LABS LTD	**EQ 4GM RESIN/PACKET**	**A211799**	**001**	Oct 19, 2021
AB			**EQ 4GM RESIN/SCOOPFUL**	**A211799**	**002**	Oct 19, 2021
AB		PAR PHARM	**EQ 4GM RESIN/PACKET**	**A077203**	**001**	Aug 26, 2005
AB			**EQ 4GM RESIN/SCOOPFUL**	**A077203**	**002**	Aug 26, 2005
AB	**!**	SANDOZ	**EQ 4GM RESIN/PACKET**	**A074558**	**001**	Aug 15, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A074558**	**002**	Aug 15, 1996
AB		TAGI	**EQ 4GM RESIN/PACKET**	**A209599**	**001**	Nov 12, 2020
AB			**EQ 4GM RESIN/SCOOPFUL**	**A209599**	**002**	Nov 12, 2020
AB		ZYDUS PHARMS	**EQ 4GM RESIN/SCOOPFUL**	**A202902**	**001**	Apr 25, 2017

PREVALITE

AB		UPSHER SMITH LABS	**EQ 4GM RESIN/PACKET**	**A073263**	**001**	Feb 22, 1996
AB			**EQ 4GM RESIN/SCOOPFUL**	**A073263**	**002**	Oct 30, 1997

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

	+	TRAVERE	50MG	N205750	001	Mar 17, 2015
	+!		250MG	N205750	002	Mar 17, 2015

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

AP		DECATUR	**4-33.1mCi/ML**	**A206319**	**001**	Nov 13, 2015
AP	**+!**	MCPRF	**4-33.1mCi/ML**	**N203155**	**001**	Sep 12, 2012
AP		WA UNIV SCH MED	**4-33.1mCi/ML**	**A208413**	**001**	Jan 10, 2017
		UNIV TX MD ANDERSON	4-100mCi/ML	A205690	001	Oct 29, 2015

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB		ACTAVIS ELIZABETH	**EQ 45MG FENOFIBRIC ACID**	**A200920**	**001**	Oct 07, 2015
AB			**EQ 135MG FENOFIBRIC ACID**	**A200920**	**002**	Oct 07, 2015
AB		ADAPTIS	**EQ 45MG FENOFIBRIC ACID**	**A211626**	**001**	Jul 18, 2019
AB			**EQ 135MG FENOFIBRIC ACID**	**A211626**	**002**	Jul 18, 2019
AB		ALEMBIC PHARMS LTD	**EQ 45MG FENOFIBRIC ACID**	**A208705**	**001**	May 12, 2017
AB			**EQ 135MG FENOFIBRIC ACID**	**A208705**	**002**	May 12, 2017
AB		ANCHEN PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A201573**	**002**	Jul 18, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A201573**	**001**	Jul 18, 2013
AB		AUROBINDO PHARMA LTD	**EQ 45MG FENOFIBRIC ACID**	**A212598**	**001**	Jul 25, 2019
AB			**EQ 135MG FENOFIBRIC ACID**	**A212598**	**002**	Jul 25, 2019
AB		IMPAX LABS INC	**EQ 45MG FENOFIBRIC ACID**	**A200264**	**001**	Sep 07, 2016
AB			**EQ 135MG FENOFIBRIC ACID**	**A200264**	**002**	Sep 07, 2016
AB		LUPIN LTD	**EQ 45MG FENOFIBRIC ACID**	**A200750**	**001**	Dec 04, 2013
AB			**EQ 135MG FENOFIBRIC ACID**	**A200750**	**002**	Dec 04, 2013
AB		MICRO LABS	**EQ 45MG FENOFIBRIC ACID**	**A213450**	**001**	Jun 16, 2020
AB			**EQ 135MG FENOFIBRIC ACID**	**A213450**	**002**	Jun 16, 2020
AB		TWI PHARMS	**EQ 45MG FENOFIBRIC ACID**	**A210469**	**001**	Jul 05, 2019
AB			**EQ 135MG FENOFIBRIC ACID**	**A210469**	**002**	Jul 05, 2019

CHOLINE FENOFIBRATE							
CAPSULE, DELAYED RELEASE;ORAL							
FENOFIBRIC ACID							
AB		YICHANG HUMANWELL	**EQ 45MG FENOFIBRIC ACID**	**A212562**	**001**	Dec 23, 2020
AB			**EQ 135MG FENOFIBRIC ACID**	**A212562**	**002**	Dec 23, 2020
TRILIPIX							
AB	**+**	ABBVIE	**EQ 45MG FENOFIBRIC ACID**	**N022224**	**001**	Dec 15, 2008
AB	**+!**		**EQ 135MG FENOFIBRIC ACID**	**N022224**	**002**	Dec 15, 2008
CHROMIC CHLORIDE							
INJECTABLE;INJECTION							
CHROMIC CHLORIDE IN PLASTIC CONTAINER							
	+!	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986
CICLESONIDE							
AEROSOL, METERED;INHALATION							
ALVESCO							
	+!	COVIS	0.08MG/INH	N021658	002	Jan 10, 2008
	+!		0.16MG/INH	N021658	003	Jan 10, 2008
AEROSOL, METERED;NASAL							
ZETONNA							
	+!	COVIS	0.037MG/INH	N202129	001	Jan 20, 2012
SPRAY, METERED;NASAL							
OMNARIS							
	+!	COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006
CICLOPIROX							
CREAM;TOPICAL							
CICLOPIROX							
AB		COSETTE	**0.77%**	**A078463**	**001**	Dec 20, 2010
AB		FOUGERA PHARMS	**0.77%**	**A076435**	**001**	Dec 29, 2004
AB		GLENMARK PHARMS	**0.77%**	**A090273**	**001**	Nov 10, 2009
AB		PADAGIS ISRAEL	**0.77%**	**A077364**	**001**	Mar 03, 2006
AB		TARO	**0.77%**	**A076790**	**001**	Apr 12, 2005
LOPROX							
AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N018748**	**001**	Dec 30, 1982
GEL;TOPICAL							
CICLOPIROX							
AB	**+!**	ALVOGEN	**0.77%**	**N020519**	**001**	Jul 21, 1997
AB		FOUGERA PHARMS	**0.77%**	**A077896**	**001**	Jun 10, 2008
AB		GLENMARK GENERICS	**0.77%**	**A091595**	**001**	Feb 29, 2012
AB		PADAGIS US	**0.77%**	**A078266**	**001**	Jan 07, 2009
SHAMPOO;TOPICAL							
CICLOPIROX							
AT		ACTAVIS MID ATLANTIC	**1%**	**A090490**	**001**	Nov 24, 2009
AT		FOUGERA PHARMS	**1%**	**A090146**	**001**	May 25, 2010
AT		PADAGIS US	**1%**	**A078594**	**001**	Feb 16, 2010
AT		TARO	**1%**	**A090269**	**001**	Feb 23, 2011
AT		TELIGENT	**1%**	**A209975**	**001**	Apr 05, 2018
LOPROX							
AT	**+!**	BAUSCH	**1%**	**N021159**	**001**	Feb 28, 2003
SOLUTION;TOPICAL							
CICLOPIROX							
AT		ACELLA	**8%**	**A078172**	**001**	Sep 18, 2007
AT		ACTAVIS MID ATLANTIC	**8%**	**A078046**	**001**	Sep 18, 2007
AT		AKORN	**8%**	**A078270**	**001**	Sep 18, 2007
AT		COSETTE	**8%**	**A078233**	**001**	Sep 18, 2007
AT		PADAGIS US	**8%**	**A077623**	**001**	Sep 18, 2007
AT		RISING	**8%**	**A078124**	**001**	Sep 18, 2007
AT		TARO PHARM INDS	**8%**	**A078144**	**001**	Sep 18, 2007
PENLAC							
AT	**+!**	VALEANT BERMUDA	**8%**	**N021022**	**001**	Dec 17, 1999
SUSPENSION;TOPICAL							
CICLOPIROX							
AB		FOUGERA PHARMS	**0.77%**	**A076422**	**001**	Aug 06, 2004
AB		PADAGIS ISRAEL	**0.77%**	**A077676**	**001**	Dec 15, 2006
AB		TARO	**0.77%**	**A077092**	**001**	Aug 10, 2005
LOPROX							
AB	**+!**	MEDIMETRIKS PHARMS	**0.77%**	**N019824**	**001**	Dec 30, 1988

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP		EMCURE PHARMS LTD	**EQ 75MG BASE/ML**	**A202501**	**001**	Jul 26, 2012
AP	**!**	MYLAN INSTITUTIONAL	**EQ 75MG BASE/ML**	**A201276**	**001**	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAVENOUS

IMIPENEM AND CILASTATIN

AP		ACS DOBFAR	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A090577**	**002**	Dec 21, 2011
AP		HQ SPCLT PHARMA	**EQ 500MG BASE/VIAL;500MG/VIAL**	**A207594**	**001**	Dec 12, 2019

PRIMAXIN

AP	**+!**	MERCK	**EQ 500MG BASE/VIAL;500MG/VIAL**	**N050587**	**002**	Nov 26, 1985

IMIPENEM AND CILASTATIN

	!	ACS DOBFAR	EQ 250MG BASE/VIAL;250MG/VIAL	A090577	001	Dec 21, 2011

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

POWDER;INTRAVENOUS

RECARBRIO

	+!	MSD MERCK CO	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL	N212819	001	Jul 16, 2019

CILOSTAZOL

TABLET;ORAL

CILOSTAZOL

AB		APOTEX INC	**50MG**	**A077030**	**001**	Dec 10, 2004
AB			**100MG**	**A077030**	**002**	Dec 10, 2004
AB		CASI PHARMS INC	**50MG**	**A077310**	**001**	Nov 08, 2005
AB			**100MG**	**A077021**	**001**	Nov 23, 2004
AB		CHARTWELL RX	**50MG**	**A077831**	**002**	Sep 24, 2012
AB			**100MG**	**A077831**	**001**	Sep 24, 2012
AB		HIKMA	**50MG**	**A077024**	**001**	May 17, 2005
AB			**100MG**	**A077024**	**002**	May 17, 2005
AB		SLATE	**50MG**	**A077208**	**002**	Mar 29, 2006
AB			**100MG**	**A077208**	**001**	Mar 29, 2006
AB	**!**	TEVA	**50MG**	**A077027**	**001**	Nov 24, 2004
AB	**!**		**100MG**	**A077027**	**002**	Nov 24, 2004

CIMETIDINE

TABLET;ORAL

CIMETIDINE

AB		MYLAN	**200MG**	**A074246**	**001**	May 17, 1994
AB			**300MG**	**A074246**	**002**	May 17, 1994
AB			**400MG**	**A074246**	**003**	May 17, 1994
AB	**!**		**800MG**	**A074246**	**004**	May 17, 1994
AB		PLIVA	**800MG**	**A074566**	**001**	Feb 27, 1997
AB		TEVA	**200MG**	**A074151**	**001**	May 17, 1994
AB			**300MG**	**A074151**	**002**	May 17, 1994
AB			**400MG**	**A074151**	**003**	May 17, 1994
AB			**800MG**	**A074463**	**001**	May 17, 1994

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA	**!**	AKORN	**EQ 300MG BASE/5ML**	**A074664**	**001**	Oct 28, 1997
AA		PHARM ASSOC	**EQ 300MG BASE/5ML**	**A074553**	**001**	Jan 27, 1997
AA		WOCKHARDT BIO AG	**EQ 300MG BASE/5ML**	**A074757**	**001**	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 30MG BASE**	**A211892**	**001**	May 15, 2020
AB			**EQ 60MG BASE**	**A211892**	**002**	May 15, 2020
AB			**EQ 90MG BASE**	**A211892**	**003**	May 15, 2020
AB		ACME LABS	**EQ 30MG BASE**	**A213325**	**001**	May 18, 2020
AB			**EQ 60MG BASE**	**A213325**	**002**	May 18, 2020
AB			**EQ 90MG BASE**	**A213325**	**003**	May 18, 2020
AB		ALKEM LABS LTD	**EQ 30MG BASE**	**A210570**	**001**	May 17, 2019
AB			**EQ 60MG BASE**	**A210570**	**002**	May 17, 2019
AB			**EQ 90MG BASE**	**A210570**	**003**	May 17, 2019
AB		AMNEAL PHARMS	**30MG**	**A204364**	**001**	Dec 02, 2021
AB			**60MG**	**A204364**	**002**	Dec 02, 2021
AB			**90MG**	**A204364**	**003**	Dec 02, 2021
AB		AUROBINDO PHARMA LTD	**EQ 30MG BASE**	**A206125**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A206125**	**002**	Mar 08, 2018

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

AB			**EQ 90MG BASE**	**A206125**	**003**	Mar 08, 2018
AB		CIPLA	**EQ 30MG BASE**	**A208915**	**001**	Mar 08, 2018
AB			**EQ 60MG BASE**	**A208915**	**002**	Mar 08, 2018
AB			**EQ 90MG BASE**	**A208915**	**003**	Mar 08, 2018
AB		DR REDDYS	**EQ 30MG BASE**	**A208368**	**001**	Sep 18, 2020
AB			**EQ 60MG BASE**	**A208368**	**002**	Sep 18, 2020
AB			**EQ 90MG BASE**	**A208368**	**003**	Sep 18, 2020
AB		HETERO LABS LTD V	**EQ 30MG BASE**	**A209403**	**001**	Oct 07, 2020
AB			**EQ 60MG BASE**	**A209403**	**002**	Oct 07, 2020
AB			**EQ 90MG BASE**	**A209403**	**003**	Oct 07, 2020
AB		PIRAMAL HLTHCARE UK	**EQ 30MG BASE**	**A210207**	**001**	Aug 01, 2018
AB			**EQ 60MG BASE**	**A210207**	**002**	Aug 01, 2018
AB			**EQ 90MG BASE**	**A210207**	**003**	Aug 01, 2018
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209226**	**001**	Apr 30, 2018
AB			**EQ 60MG BASE**	**A209226**	**002**	Apr 30, 2018
AB			**EQ 90MG BASE**	**A209226**	**003**	Apr 30, 2018
AB		SUN PHARM	**EQ 30MG BASE**	**A207008**	**001**	Oct 11, 2018
AB			**EQ 60MG BASE**	**A207008**	**002**	Oct 11, 2018
AB			**EQ 90MG BASE**	**A207008**	**003**	Oct 11, 2018
AB		WATSON LABS TEVA	**EQ 30MG BASE**	**A204377**	**001**	Dec 27, 2018
AB			**EQ 60MG BASE**	**A204377**	**002**	Dec 27, 2018
AB			**EQ 90MG BASE**	**A204377**	**003**	Dec 27, 2018

SENSIPAR

AB	**+**	AMGEN	**EQ 30MG BASE**	**N021688**	**001**	Mar 08, 2004
AB	**+**		**EQ 60MG BASE**	**N021688**	**002**	Mar 08, 2004
AB	**+!**		**EQ 90MG BASE**	**N021688**	**003**	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

	+	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997
	+!		500MG/5ML	N020780	002	Sep 26, 1997

INJECTABLE;INJECTION

CIPROFLOXACIN

AP	**!**	BAXTER HLTHCARE CORP	**200MG/20ML (10MG/ML)**	**A078062**	**001**	Apr 29, 2008
AP	**!**		**400MG/40ML (10MG/ML)**	**A078062**	**002**	Apr 29, 2008
AP		HIKMA FARMACEUTICA	**200MG/20ML (10MG/ML)**	**A076717**	**001**	Dec 22, 2009
AP			**400MG/40ML (10MG/ML)**	**A076717**	**002**	Dec 22, 2009

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	**200MG/100ML**	**A078024**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078024**	**002**	Mar 18, 2008
AP		HIKMA FARMACEUTICA	**400MG/200ML**	**A078431**	**001**	Nov 18, 2009
AP	**!**	HOSPIRA	**200MG/100ML**	**A077753**	**001**	Mar 18, 2008
AP	**!**		**400MG/200ML**	**A077753**	**002**	Mar 18, 2008
AP		INFORLIFE	**200MG/100ML**	**A078252**	**001**	Mar 18, 2008
AP			**400MG/200ML**	**A078252**	**002**	Mar 18, 2008

INJECTABLE, SUSPENSION;OTIC

OTIPRIO

	+!	ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT;OPHTHALMIC

CILOXAN

	+!	NOVARTIS	EQ 0.3% BASE	N020369	001	Mar 30, 1998

SOLUTION/DROPS;OPHTHALMIC

CILOXAN

AT	**+!**	NOVARTIS	**EQ 0.3% BASE**	**N019992**	**001**	Dec 31, 1990

CIPROFLOXACIN HYDROCHLORIDE

AT		AKORN	**EQ 0.3% BASE**	**A076555**	**001**	Dec 11, 2008
AT		ALTAIRE PHARMS INC	**EQ 0.3% BASE**	**A204613**	**001**	May 03, 2018
AT		FDC LTD	**EQ 0.3% BASE**	**A077568**	**001**	Jun 30, 2008
AT		RISING	**EQ 0.3% BASE**	**A077689**	**001**	Dec 13, 2006
AT		TELIGENT	**EQ 0.3% BASE**	**A076754**	**001**	Jun 09, 2004
AT		WATSON LABS INC	**EQ 0.3% BASE**	**A076673**	**001**	Jan 21, 2005

SOLUTION/DROPS;OTIC

CETRAXAL

	+!	WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPRO

AB	**+**	BAYER HLTHCARE	**EQ 250MG BASE**	**N019537**	**002**	Oct 22, 1987
AB	**+!**		**EQ 500MG BASE**	**N019537**	**003**	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

AB	AUROBINDO PHARMA	**EQ 250MG BASE**	**A077859**	**001**	Apr 26, 2007
AB		**EQ 500MG BASE**	**A077859**	**002**	Apr 26, 2007
AB		**EQ 750MG BASE**	**A077859**	**003**	Apr 26, 2007
AB	CARLSBAD	**EQ 250MG BASE**	**A076126**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076126**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076126**	**004**	Jun 09, 2004
AB	CHARTWELL	**EQ 250MG BASE**	**A076896**	**001**	Nov 04, 2004
AB		**EQ 500MG BASE**	**A076896**	**002**	Nov 04, 2004
AB		**EQ 750MG BASE**	**A076896**	**003**	Nov 04, 2004
AB	DR REDDYS LABS LTD	**EQ 100MG BASE**	**A075593**	**002**	Jun 09, 2004
AB		**EQ 250MG BASE**	**A075593**	**003**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A075593**	**004**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A075593**	**001**	Jun 09, 2004
AB	HIKMA	**EQ 250MG BASE**	**A076558**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076558**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076558**	**004**	Jun 09, 2004
AB	IVAX SUB TEVA PHARMS	**EQ 250MG BASE**	**A076089**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076089**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076089**	**004**	Jun 09, 2004
AB	RISING PHARMA	**EQ 500MG BASE**	**A075817**	**003**	Jun 09, 2004
AB	TARO	**EQ 100MG BASE**	**A076912**	**001**	Feb 18, 2005
AB		**EQ 250MG BASE**	**A076912**	**002**	Oct 06, 2004
AB		**EQ 500MG BASE**	**A076912**	**003**	Oct 06, 2004
AB		**EQ 750MG BASE**	**A076912**	**004**	Oct 06, 2004
AB	UNIQUE PHARM LABS	**EQ 250MG BASE**	**A076639**	**001**	Sep 10, 2004
AB		**EQ 500MG BASE**	**A076639**	**002**	Sep 10, 2004
AB		**EQ 750MG BASE**	**A076639**	**003**	Sep 10, 2004
AB	WATSON LABS	**EQ 100MG BASE**	**A076794**	**001**	Feb 10, 2005
AB		**EQ 250MG BASE**	**A076794**	**002**	Jun 09, 2004
AB		**EQ 500MG BASE**	**A076794**	**003**	Jun 09, 2004
AB		**EQ 750MG BASE**	**A076794**	**004**	Jun 09, 2004
AB	YILING	**EQ 250MG BASE**	**A208921**	**001**	Jun 22, 2018
AB		**EQ 500MG BASE**	**A208921**	**002**	Jun 22, 2018

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

+!	LABORATORIOS SALVAT	EQ 0.3% BASE;0.025%	N208251	001	Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

+!	NOVARTIS	EQ 0.2% BASE;1%	N020805	001	Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	**!**	ANCHEN PHARMS	**425.2MG;EQ 574.9MG BASE**	**A078166**	**001**	Nov 27, 2007
AB		DR REDDYS LABS LTD	**425.2MG;EQ 574.9MG BASE**	**A077701**	**001**	Mar 26, 2007
	!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

AB	**+!**	NOVARTIS	**0.3%;0.1%**	**N021537**	**001**	Jul 18, 2003

CIPROFLOXACIN AND DEXAMETHASONE

AB		DR REDDYS LABS LTD	**0.3%;0.1%**	**A205548**	**001**	Aug 10, 2020

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP	EUGIA PHARMA	**EQ 2MG BASE/ML**	**A209144**	**001**	May 08, 2020
AP	FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203183**	**001**	Feb 26, 2015
AP	HOSPIRA INC	**EQ 2MG BASE/ML**	**A203236**	**001**	Mar 30, 2018
AP		**EQ 2MG BASE/ML**	**A203238**	**001**	Mar 30, 2018
AP		**EQ 10MG BASE/ML**	**A203236**	**002**	Mar 30, 2018
AP	JIANGSU PHARMS	**EQ 2MG BASE/ML**	**A209334**	**001**	Aug 30, 2017
AP	MEITHEAL	**EQ 2MG BASE/ML**	**A211668**	**001**	Apr 25, 2019

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE						
AP			**EQ 2MG BASE/ML**	**A211669**	**001**	Apr 25, 2019
AP			**EQ 10MG BASE/ML**	**A211668**	**002**	Apr 25, 2019
AP		SAGENT PHARMS INC	**EQ 2MG BASE/ML**	**A201836**	**001**	Nov 06, 2020
AP			**EQ 10MG BASE/ML**	**A201836**	**002**	Nov 06, 2020
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200159**	**001**	Feb 03, 2012
AP		SOMERSET	**EQ 2MG BASE/ML**	**A209132**	**001**	Apr 24, 2019
AP		ZYDUS PHARMS	**EQ 2MG BASE/ML**	**A212171**	**001**	Nov 04, 2019
AP			**EQ 10MG BASE/ML**	**A212171**	**002**	Nov 04, 2019
CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP		EUGIA PHARMA	**EQ 2MG BASE/ML**	**A209665**	**001**	Oct 27, 2020
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A203182**	**001**	Feb 26, 2015
AP			**EQ 10MG BASE/ML**	**A203182**	**002**	Feb 26, 2015
AP		JIANGSU PHARMS	**EQ 2MG BASE/ML**	**A204960**	**001**	Jan 27, 2017
AP			**EQ 10MG BASE/ML**	**A204960**	**002**	Sep 19, 2017
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A200154**	**001**	Feb 03, 2012
AP			**EQ 10MG BASE/ML**	**A200154**	**002**	Feb 03, 2012
AP		SOMERSET THERAPS LLC	**EQ 2MG BASE/ML**	**A206791**	**001**	Feb 20, 2019
AP			**EQ 10MG BASE/ML**	**A206791**	**002**	Feb 20, 2019
NIMBEX						
AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**001**	Dec 15, 1995
NIMBEX PRESERVATIVE FREE						
AP	**+!**	ABBVIE	**EQ 2MG BASE/ML**	**N020551**	**003**	Dec 15, 1995
AP	**+!**		**EQ 10MG BASE/ML**	**N020551**	**002**	Dec 15, 1995

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN						
AP		ACCORD HLTHCARE	**1MG/ML**	**A206774**	**001**	Aug 18, 2015
AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A074735**	**001**	Jul 16, 1999
AP		GLAND PHARMA LTD	**1MG/ML**	**A207323**	**001**	Mar 17, 2017
AP		HIKMA	**1MG/ML**	**A075036**	**001**	Nov 07, 2000
AP	**+**	HQ SPCLT PHARMA	**1MG/ML**	**N018057**	**004**	Nov 08, 1988
AP		PHARMACHEMIE BV	**1MG/ML**	**A074656**	**001**	May 16, 2000

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE						
AA		AUROBINDO PHARMA LTD	**EQ 10MG BASE/5ML**	**A077812**	**001**	Aug 28, 2006
AA		HETERO LABS LTD III	**EQ 10MG BASE/5ML**	**A201450**	**001**	Dec 15, 2015
AA	**!**	HIKMA	**EQ 10MG BASE/5ML**	**A077043**	**001**	Dec 13, 2004
AA		LANNETT CO INC	**EQ 10MG BASE/5ML**	**A077629**	**001**	Jun 15, 2006

TABLET;ORAL

CELEXA						
AB	**+**	ALLERGAN	**EQ 10MG BASE**	**N020822**	**001**	Apr 27, 2000
AB	**+**		**EQ 20MG BASE**	**N020822**	**002**	Jul 17, 1998
AB	**+!**		**EQ 40MG BASE**	**N020822**	**003**	Jul 17, 1998
CITALOPRAM HYDROBROMIDE						
AB		AMNEAL PHARMS NY	**EQ 10MG BASE**	**A077289**	**001**	Nov 30, 2006
AB			**EQ 20MG BASE**	**A077289**	**002**	Nov 30, 2006
AB			**EQ 40MG BASE**	**A077289**	**003**	Nov 30, 2006
AB		APOTEX INC	**EQ 10MG BASE**	**A077046**	**001**	Nov 24, 2004
AB		AUROBINDO	**EQ 10MG BASE**	**A077031**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077031**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077031**	**003**	Oct 28, 2004
AB		CHARTWELL MOLECULAR	**EQ 10MG BASE**	**A077044**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077044**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077044**	**003**	Nov 05, 2004
AB		COSETTE	**EQ 10MG BASE**	**A077048**	**001**	Nov 16, 2004
AB			**EQ 20MG BASE**	**A077048**	**002**	Nov 16, 2004
AB			**EQ 40MG BASE**	**A077048**	**003**	Nov 16, 2004
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A077038**	**001**	Oct 28, 2004
AB			**EQ 20MG BASE**	**A077038**	**002**	Oct 28, 2004
AB			**EQ 40MG BASE**	**A077038**	**003**	Oct 28, 2004
AB		EPIC PHARMA	**EQ 10MG BASE**	**A077045**	**003**	Apr 29, 2005
AB			**EQ 20MG BASE**	**A077045**	**002**	Apr 29, 2005
AB			**EQ 40MG BASE**	**A077045**	**001**	Apr 29, 2005
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A077654**	**001**	Feb 27, 2009
AB			**EQ 20MG BASE**	**A077654**	**002**	Feb 27, 2009
AB			**EQ 40MG BASE**	**A077654**	**003**	Feb 27, 2009

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB		INVAGEN PHARMS	**EQ 10MG BASE**	**A077534**	**001**	Oct 03, 2006
AB			**EQ 20MG BASE**	**A077534**	**002**	Oct 03, 2006
AB			**EQ 40MG BASE**	**A077534**	**003**	Oct 03, 2006
AB		MYLAN	**EQ 10MG BASE**	**A077042**	**001**	Nov 05, 2004
AB			**EQ 20MG BASE**	**A077042**	**002**	Nov 05, 2004
AB			**EQ 40MG BASE**	**A077042**	**003**	Nov 05, 2004
AB		TORPHARM	**EQ 20MG BASE**	**A077046**	**002**	Nov 24, 2004
AB			**EQ 40MG BASE**	**A077046**	**003**	Nov 24, 2004
AB		TORRENT PHARMS	**EQ 10MG BASE**	**A078216**	**001**	Mar 27, 2007
AB			**EQ 20MG BASE**	**A078216**	**002**	Mar 27, 2007
AB			**EQ 40MG BASE**	**A078216**	**003**	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+!	UNITED GUARDIAN	6.602GM/100ML;198MG/100ML;3.177GM/100ML	N019481	001	Oct 02, 1990

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL;VAGINAL

PHEXXI

+!	EVOFEM INC	1%;1.8%;0.4%	N208352	001	May 22, 2020

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION;ORAL

CLENPIQ

+!	FERRING PHARMS INC	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

+!	EXALENZ BIOSCIENCE	4GM;75MG	N021314	001	Dec 17, 2002

CLADRIBINE

INJECTABLE;INJECTION

CLADRIBINE

AP	**!**	FRESENIUS KABI USA	**1MG/ML**	**A076571**	**001**	Apr 22, 2004
AP		HIKMA	**1MG/ML**	**A075405**	**001**	Feb 28, 2000
AP		HISUN PHARM HANGZHOU	**1MG/ML**	**A210856**	**001**	Nov 25, 2019
AP		MYLAN LABS LTD	**1MG/ML**	**A200510**	**001**	Oct 06, 2011

TABLET;ORAL

MAVENCLAD

+!	EMD SERONO INC	10MG	N022561	001	Mar 29, 2019

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB		SANDOZ	**125MG/5ML**	**A065283**	**002**	Sep 04, 2007
AB	**!**		**250MG/5ML**	**A065283**	**003**	Sep 04, 2007

TABLET;ORAL

CLARITHROMYCIN

AB	**!**	AUROBINDO	**250MG**	**A065489**	**001**	Jul 25, 2012
AB	**!**		**500MG**	**A065489**	**002**	Jul 25, 2012
AB		CHARTWELL	**250MG**	**A065384**	**001**	Aug 20, 2007
AB			**500MG**	**A065384**	**002**	Aug 20, 2007
AB		HEC PHARM	**250MG**	**A203584**	**001**	Sep 28, 2015
AB			**500MG**	**A203584**	**002**	Sep 28, 2015
AB		SANDOZ	**250MG**	**A065144**	**001**	Oct 18, 2005
AB			**500MG**	**A065136**	**001**	Aug 25, 2005
AB		STRIDES PHARMA	**250MG**	**A202710**	**001**	Jun 10, 2013
AB			**500MG**	**A202710**	**002**	Jun 10, 2013
AB		TEVA	**250MG**	**A065155**	**001**	May 31, 2005
AB			**500MG**	**A065155**	**002**	May 31, 2005

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		ACTAVIS LABS FL INC	**500MG**	**A065145**	**001**	Jun 24, 2004
AB	**!**	MAYNE PHARMA	**500MG**	**A065154**	**001**	May 18, 2005
AB		SUNSHINE	**500MG**	**A208987**	**001**	Jul 09, 2018

CLASCOTERONE							
CREAM;TOPICAL							
WINLEVI							
	+!	SUN PHARM	1%		N213433	001	Aug 26, 2020
CLEMASTINE FUMARATE							
SYRUP;ORAL							
CLEMASTINE FUMARATE							
	!	GENUS	EQ 0.5MG BASE/5ML		A073399	001	Jun 30, 1994
TABLET;ORAL							
CLEMASTINE FUMARATE							
	!	TEVA	2.68MG		A073283	001	Jan 31, 1992
CLEVIDIPINE							
EMULSION;INTRAVENOUS							
CLEVIPREX							
	+!	CHIESI	25MG/50ML (0.5MG/ML)		N022156	001	Aug 01, 2008
	+!		50MG/100ML (0.5MG/ML)		N022156	002	Aug 01, 2008
CLINDAMYCIN HYDROCHLORIDE							
CAPSULE;ORAL							
CLEOCIN HYDROCHLORIDE							
AB	**+**	PFIZER	**EQ 75MG BASE**		**N050162**	**001**	
AB	**+**		**EQ 150MG BASE**		**N050162**	**002**	
AB	**+!**		**EQ 300MG BASE**		**N050162**	**003**	Apr 14, 1988
CLINDAMYCIN HYDROCHLORIDE							
AB		AUROBINDO PHARMA	**EQ 150MG BASE**		**A065442**	**001**	Aug 26, 2009
AB			**EQ 300MG BASE**		**A065442**	**002**	Aug 26, 2009
AB		COSETTE	**EQ 150MG BASE**		**A063029**	**001**	Sep 20, 1989
AB			**EQ 300MG BASE**		**A063029**	**002**	Aug 05, 2005
AB		EPIC PHARMA LLC	**EQ 150MG BASE**		**A065194**	**001**	Mar 22, 2004
AB			**EQ 300MG BASE**		**A065194**	**002**	Mar 22, 2004
AB		LANNETT CO INC	**EQ 75MG BASE**		**A065243**	**002**	Aug 12, 2005
AB		MICRO LABS	**EQ 75MG BASE**		**A207402**	**001**	Nov 05, 2018
AB			**EQ 150MG BASE**		**A207402**	**002**	Nov 05, 2018
AB			**EQ 300MG BASE**		**A207402**	**003**	Nov 05, 2018
AB		SUN PHARM INDS LTD	**EQ 150MG BASE**		**A065061**	**001**	Feb 02, 2001
AB			**EQ 300MG BASE**		**A065061**	**002**	Feb 02, 2001
AB		WATSON LABS	**EQ 150MG BASE**		**A063083**	**001**	Jul 31, 1991
AB			**EQ 300MG BASE**		**A063083**	**002**	Mar 18, 2003
AB		ZYDUS PHARMS USA	**EQ 75MG BASE**		**A065217**	**001**	Jan 31, 2005
AB			**EQ 150MG BASE**		**A065217**	**002**	Jan 31, 2005
AB			**EQ 300MG BASE**		**A065217**	**003**	Jan 31, 2005
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
FOR SOLUTION;ORAL							
CLEOCIN							
AA	**!**	PFIZER	**EQ 75MG BASE/5ML**		**A062644**	**001**	Apr 07, 1986
CLINDAMYCIN PALMITATE HYDROCHLORIDE							
AA		ALEMBIC LABS	**EQ 75MG BASE/5ML**		**A206958**	**001**	May 05, 2017
AA		AMNEAL PHARMS	**EQ 75MG BASE/5ML**		**A203513**	**001**	Mar 13, 2014
AA		AUROBINDO PHARMA LTD	**EQ 75MG BASE/5ML**		**A202409**	**001**	Apr 30, 2013
AA		HERITAGE PHARMS INC	**EQ 75MG BASE/5ML**		**A207047**	**001**	May 11, 2018
AA		LYNE	**EQ 75MG BASE/5ML**		**A201821**	**001**	Aug 28, 2012
AA		PADAGIS US	**EQ 75MG BASE/5ML**		**A090902**	**001**	Jul 07, 2010
CLINDAMYCIN PHOSPHATE							
AEROSOL, FOAM;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT		GLENMARK PHARMS LTD	**1%**		**A210778**	**001**	Sep 20, 2021
AT		PADAGIS ISRAEL	**1%**		**A090785**	**001**	Mar 31, 2010
EVOCLIN							
AT	**+!**	MYLAN	**1%**		**N050801**	**001**	Oct 22, 2004
CREAM;VAGINAL							
CLEOCIN							
AB	**+!**	PFIZER	**EQ 2% BASE**		**N050680**	**002**	Mar 02, 1998
CLINDAMYCIN PHOSPHATE							
AB		FOUGERA PHARMS	**EQ 2% BASE**		**A065139**	**001**	Dec 27, 2004
CLINDESSE							
	+!	PADAGIS US	EQ 2% BASE		N050793	001	Nov 30, 2004
GEL;TOPICAL							
CLEOCIN T							
AB1	**+!**	PFIZER	**EQ 1% BASE**		**N050615**	**001**	Jan 07, 1987

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1		ENCUBE	**EQ 1% BASE**	**A212438**	**001**	Mar 11, 2021
AB1		FOUGERA PHARMS	**EQ 1% BASE**	**A064160**	**001**	Jan 28, 2000
AB1		GLENMARK PHARMS LTD	**EQ 1% BASE**	**A214251**	**001**	Feb 10, 2021
AB1		PADAGIS ISRAEL	**EQ 1% BASE**	**A212104**	**001**	Dec 31, 2020
AB1		SOLARIS PHARMA CORP	**EQ 1% BASE**	**A211872**	**001**	Jul 29, 2020
AB1		TARO PHARMS	**EQ 1% BASE**	**A214052**	**001**	Nov 10, 2020

CLINDAGEL

AB2	**+!**	BAUSCH	**EQ 1% BASE**	**N050782**	**001**	Nov 27, 2000

CLINDAMYCIN PHOSPHATE

AB2		SOLARIS PHARMA CORP	**EQ 1% BASE**	**A212842**	**001**	Aug 13, 2021

GEL;VAGINAL

XACIATO

	+!	DARE	EQ 2% BASE	N215650	001	Dec 07, 2021

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

AP		PFIZER	**EQ 150MG BASE/ML**	**A062803**	**001**	Oct 16, 1987
AP	**+!**		**EQ 150MG BASE/ML**	**N050441**	**001**	

CLINDAMYCIN PHOSPHATE

AP		ALMAJECT	**EQ 150MG BASE/ML**	**A062800**	**001**	Jul 24, 1987
AP			**EQ 150MG BASE/ML**	**A062943**	**001**	Sep 29, 1988
AP		FRESENIUS KABI USA	**EQ 150MG BASE/ML**	**A065346**	**001**	Mar 29, 2007
AP			**EQ 150MG BASE/ML**	**A065347**	**001**	May 09, 2007
AP		HIKMA	**EQ 150MG BASE/ML**	**A062889**	**001**	Apr 25, 1988
AP			**EQ 150MG BASE/ML**	**A065206**	**001**	Sep 24, 2004
AP		SAGENT PHARMS INC	**EQ 150MG BASE/ML**	**A090108**	**001**	Sep 30, 2011
AP			**EQ 150MG BASE/ML**	**A090109**	**001**	Sep 30, 2011

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		AKORN	**EQ 6MG BASE/ML**	**A203048**	**001**	Apr 04, 2013
AP			**EQ 12MG BASE/ML**	**A203048**	**002**	Apr 04, 2013
AP			**EQ 18MG BASE/ML**	**A203048**	**003**	Apr 04, 2013
AP		BAXTER HLTHCARE CORP	**EQ 6MG BASE/ML**	**A208084**	**001**	Jun 28, 2017
AP			**EQ 12MG BASE/ML**	**A208084**	**002**	Jun 28, 2017
AP			**EQ 18MG BASE/ML**	**A208084**	**003**	Jun 28, 2017
AP	**!**	SANDOZ INC	**EQ 6MG BASE/ML**	**A201692**	**001**	May 31, 2012
AP	**!**		**EQ 12MG BASE/ML**	**A201692**	**002**	May 31, 2012
AP	**!**		**EQ 18MG BASE/ML**	**A201692**	**003**	May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

	+!	ABRAXIS PHARM	EQ 900MG BASE/100ML	N050635	001	Dec 22, 1989

LOTION;TOPICAL

CLEOCIN T

AB	**+!**	PFIZER	**EQ 1% BASE**	**N050600**	**001**	May 31, 1989

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	**EQ 1% BASE**	**A065067**	**001**	Jan 31, 2002
AB		PADAGIS ISRAEL	**EQ 1% BASE**	**A214604**	**001**	Mar 08, 2021
AB		TARO PHARMS	**EQ 1% BASE**	**A214526**	**001**	Jun 28, 2021

SOLUTION;INTRAVENOUS

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

	+!	BAXTER HLTHCARE CORP	EQ 300MG BASE/50ML (EQ 6MG BASE/ML)	N208083	001	Apr 20, 2017
	+!		EQ 600MG BASE/50ML (EQ 12MG BASE/ML)	N208083	002	Apr 20, 2017
	+!		EQ 900MG BASE/50ML (EQ 18MG BASE/ML)	N208083	003	Apr 20, 2017

SOLUTION;TOPICAL

CLINDA-DERM

AT		PADAGIS US	**EQ 1% BASE**	**A063329**	**001**	Sep 30, 1992

CLINDAMYCIN PHOSPHATE

AT		CADILA	**EQ 1% BASE**	**A208767**	**001**	Jul 16, 2018
AT		ENCUBE ETHICALS	**EQ 1% BASE**	**A209914**	**001**	Jan 28, 2019
AT		FOUGERA PHARMS INC	**EQ 1% BASE**	**A064159**	**001**	Jun 05, 1997
AT		GLASSHOUSE PHARMS	**EQ 1% BASE**	**A209846**	**001**	Feb 08, 2018
AT	**!**	PADAGIS US	**EQ 1% BASE**	**A064050**	**001**	Nov 30, 1995
AT		TARO PHARM INDS	**EQ 1% BASE**	**A065184**	**001**	Mar 31, 2004
AT		TELIGENT	**EQ 1% BASE**	**A206945**	**001**	Dec 30, 2016

SUPPOSITORY;VAGINAL

CLEOCIN

	+!	PFIZER	100MG	N050767	001	Aug 13, 1999

SWAB;TOPICAL

CLINDAMYCIN PHOSPHATE

AT		AKORN	**EQ 1% BASE**	**A065513**	**001**	Jun 17, 2010
AT	**!**	PADAGIS US	**EQ 1% BASE**	**A065049**	**001**	May 25, 2000

CLINDAMYCIN PHOSPHATE

SWAB;TOPICAL

CLINDETS

AT		PADAGIS US	**EQ 1% BASE**	**A064136**	**001**	Sep 30, 1996

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB		ACTAVIS MID ATLANTIC	**1.2%;0.025%**	**A202564**	**001**	Jun 12, 2015

ZIANA

AB	**+!**	BAUSCH	**1.2%;0.025%**	**N050802**	**001**	Nov 07, 2006

VELTIN

BX	+!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010

CLOBAZAM

FILM;ORAL

SYMPAZAN

	+	AQUESTIVE	5MG	N210833	001	Nov 01, 2018
	+		10MG	N210833	002	Nov 01, 2018
	+!		20MG	N210833	003	Nov 01, 2018

SUSPENSION;ORAL

CLOBAZAM

AB		ALKEM LABS LTD	**2.5MG/ML**	**A213039**	**001**	May 06, 2021
AB		AMNEAL	**2.5MG/ML**	**A210039**	**001**	Oct 22, 2018
AB		BIONPHARMA INC	**2.5MG/ML**	**A208819**	**001**	Oct 22, 2018
AB		HETERO LABS LTD III	**2.5MG/ML**	**A209796**	**001**	Feb 24, 2020
AB		HIKMA	**2.5MG/ML**	**A209715**	**001**	Oct 22, 2018
AB		LANNETT CO INC	**2.5MG/ML**	**A213110**	**001**	Apr 24, 2020
AB		LUPIN LTD	**2.5MG/ML**	**A210546**	**001**	Dec 28, 2018
AB		MYLAN	**2.5MG/ML**	**A211259**	**001**	Oct 22, 2018
AB		TARO	**2.5MG/ML**	**A210978**	**001**	Apr 15, 2019
AB		UPSHER SMITH LABS	**2.5MG/ML**	**A210569**	**001**	Oct 22, 2018
AB		VISTAPHARM	**2.5MG/ML**	**A210746**	**001**	Jul 10, 2019

ONFI

AB	**+!**	LUNDBECK PHARMS LLC	**2.5MG/ML**	**N203993**	**001**	Dec 14, 2012

TABLET;ORAL

CLOBAZAM

AB		ALKEM LABS LTD	**10MG**	**A212714**	**001**	Sep 06, 2019
AB			**20MG**	**A212714**	**002**	Sep 06, 2019
AB		AMNEAL PHARMS CO	**10MG**	**A209718**	**001**	Oct 22, 2018
AB			**20MG**	**A209718**	**002**	Oct 22, 2018
AB		BIONPHARMA INC	**10MG**	**A208825**	**001**	Oct 22, 2018
AB			**20MG**	**A208825**	**002**	Oct 22, 2018
AB		BRECKENRIDGE	**10MG**	**A209308**	**001**	Oct 22, 2018
AB			**20MG**	**A209308**	**002**	Oct 22, 2018
AB		HETERO LABS LTD III	**10MG**	**A209795**	**001**	Oct 22, 2018
AB			**20MG**	**A209795**	**002**	Oct 22, 2018
AB		HIKMA	**10MG**	**A208785**	**001**	Oct 22, 2018
AB			**20MG**	**A208785**	**002**	Oct 22, 2018
AB		LUPIN LTD	**10MG**	**A210545**	**001**	Dec 14, 2018
AB			**20MG**	**A210545**	**002**	Dec 14, 2018
AB		MICRO LABS	**10MG**	**A211711**	**001**	Jan 30, 2019
AB			**20MG**	**A211711**	**002**	Jan 30, 2019
AB		PIRAMAL HLTHCARE UK	**10MG**	**A209808**	**001**	Oct 22, 2018
AB			**20MG**	**A209808**	**002**	Oct 22, 2018
AB		UPSHER SMITH LABS	**10MG**	**A209687**	**001**	Oct 22, 2018
AB			**20MG**	**A209687**	**002**	Oct 22, 2018
AB		ZYDUS PHARMS	**10MG**	**A211449**	**001**	Oct 22, 2018
AB			**20MG**	**A211449**	**002**	Oct 22, 2018

ONFI

AB	**+**	LUNDBECK PHARMS LLC	**10MG**	**N202067**	**002**	Oct 21, 2011
AB	**+!**		**20MG**	**N202067**	**003**	Oct 21, 2011

CLOBAZAM

		ALKEM LABS LTD	5MG	A212714	003	Dec 21, 2020

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		GLENMARK PHARMS LTD	**0.05%**	**A210809**	**001**	Feb 15, 2019
AB1		PADAGIS ISRAEL	**0.05%**	**A077763**	**001**	Mar 10, 2008
AB1		TARO	**0.05%**	**A208779**	**001**	Oct 04, 2018

OLUX

AB1	**+!**	MYLAN	**0.05%**	**N021142**	**001**	May 26, 2000

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2		GLENMARK PHARMS LTD	**0.05%**	**A211450**	**001**	Sep 09, 2019
AB2		PADAGIS ISRAEL	**0.05%**	**A201402**	**001**	Aug 14, 2012

OLUX E

AB2	**+!**	MYLAN	**0.05%**	**N022013**	**001**	Jan 12, 2007

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1		ALEOR DERMACEUTICALS	**0.05%**	**A213291**	**001**	Jan 27, 2020
AB1		AMNEAL	**0.05%**	**A211256**	**001**	Dec 26, 2018
AB1		AUROBINDO PHARMA USA	**0.05%**	**A075338**	**001**	Feb 09, 2001
AB1		COSETTE	**0.05%**	**A074139**	**001**	Aug 03, 1994
AB1		ENCUBE	**0.05%**	**A212982**	**001**	Aug 28, 2020
AB1		FOUGERA PHARMS INC	**0.05%**	**A074392**	**001**	Sep 30, 1996
AB1		GLENMARK PHARMS	**0.05%**	**A209095**	**001**	May 10, 2018
AB1		LUPIN LTD	**0.05%**	**A210208**	**001**	Jan 30, 2018
AB1		RISING	**0.05%**	**A211401**	**001**	Jan 11, 2019
AB1		TARO	**0.05%**	**A074249**	**001**	Jul 08, 1996
AB1		TELIGENT	**0.05%**	**A209974**	**001**	Apr 17, 2018
AB1		TORRENT	**0.05%**	**A211836**	**001**	Dec 30, 2019
AB1		XIROMED	**0.05%**	**A210034**	**001**	Jun 15, 2018
AB1		ZYDUS PHARMS	**0.05%**	**A211074**	**001**	Oct 15, 2018

CORMAX

AB1	**!**	AKORN	**0.05%**	**A074220**	**001**	May 16, 1997

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2		ANI PHARMS	**0.05%**	**A075733**	**001**	Aug 22, 2001
AB2	**!**	FOUGERA PHARMS	**0.05%**	**A075430**	**001**	May 26, 1999
AB2		TARO	**0.05%**	**A075633**	**001**	May 17, 2000
AB2		TELIGENT	**0.05%**	**A209411**	**001**	Aug 21, 2017

EMBELINE E

AB2		AKORN	**0.05%**	**A075325**	**001**	Dec 24, 1998

IMPOYZ

	+!	PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	**!**	FOUGERA PHARMS	**0.05%**	**A075368**	**001**	Feb 15, 2000
AB		PADAGIS US	**0.05%**	**A075027**	**001**	Oct 31, 1997
AB		TARO	**0.05%**	**A075279**	**001**	May 28, 1999
AB		TELIGENT	**0.05%**	**A208881**	**001**	Mar 06, 2017

EMBELINE

AB		AKORN	**0.05%**	**A076141**	**001**	Apr 12, 2002

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078223**	**001**	Dec 04, 2008
AB		CADILA	**0.05%**	**A205249**	**001**	Sep 24, 2019
AB		LUPIN LTD	**0.05%**	**A209147**	**001**	Sep 22, 2017
AB		TARO	**0.05%**	**A200302**	**001**	Jul 02, 2012
AB		TELIGENT	**0.05%**	**A208667**	**001**	Nov 29, 2016

CLOBEX

AB	**+!**	GALDERMA LABS LP	**0.05%**	**N021535**	**001**	Jul 24, 2003

IMPEKLO

	+!	MYLAN	0.05%	N213691	001	May 19, 2020

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB		ALEOR DERMACEUTICALS	**0.05%**	**A211800**	**001**	Mar 04, 2019
AB		AUROBINDO PHARMA USA	**0.05%**	**A075057**	**001**	Aug 12, 1998
AB		COSETTE	**0.05%**	**A074089**	**001**	Feb 16, 1994
AB		ENCUBE	**0.05%**	**A211295**	**001**	Nov 15, 2019
AB	**!**	FOUGERA PHARMS	**0.05%**	**A074407**	**001**	Feb 23, 1996
AB		GLENMARK PHARMS	**0.05%**	**A208933**	**001**	Mar 20, 2017
AB		NOVEL LABS INC	**0.05%**	**A208841**	**001**	May 04, 2018
AB		TARO	**0.05%**	**A074248**	**001**	Jul 12, 1996
AB		TELIGENT	**0.05%**	**A208589**	**001**	Jan 23, 2019
AB		XIROMED	**0.05%**	**A209701**	**001**	Apr 17, 2018
AB		ZYDUS PHARMS	**0.05%**	**A210199**	**001**	Oct 27, 2017

EMBELINE

AB		AKORN	**0.05%**	**A074221**	**001**	Mar 31, 1995

CLOBETASOL PROPIONATE

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	**0.05%**	**A078854**	**001**	Jun 07, 2011
AB		AKORN	**0.05%**	**A209871**	**001**	Oct 27, 2017
AB		ALEOR DERMACEUTICALS	**0.05%**	**A213290**	**001**	May 18, 2020
AB		AMNEAL	**0.05%**	**A214895**	**001**	Jun 14, 2021
AB		PADAGIS ISRAEL	**0.05%**	**A090974**	**001**	Aug 09, 2012
AB		TARO PHARMS	**0.05%**	**A214867**	**001**	Mar 25, 2021

CLOBEX

AB	**+!**	GALDERMA LABS	**0.05%**	**N021644**	**001**	Feb 05, 2004

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT		ALEOR DERMACEUTICALS	**0.05%**	**A212881**	**001**	Oct 21, 2019
AT		COSETTE	**0.05%**	**A074331**	**001**	Dec 15, 1995
AT		FOUGERA PHARMS	**0.05%**	**A075391**	**001**	Feb 08, 1999
AT		GLENMARK PHARMS LTD	**0.05%**	**A210190**	**001**	Apr 18, 2018
AT		MACLEODS PHARMS LTD	**0.05%**	**A209361**	**001**	Oct 25, 2017
AT		NOVEL LABS INC	**0.05%**	**A206075**	**001**	Nov 23, 2015
AT		PRINSTON INC	**0.05%**	**A213139**	**001**	Feb 08, 2021
AT		SAPTALIS PHARMS	**0.05%**	**A211494**	**001**	Oct 02, 2019
AT		TARO	**0.05%**	**A075224**	**001**	Nov 16, 1998
AT			**0.05%**	**A075363**	**001**	Dec 29, 2000
AT		TOLMAR	**0.05%**	**A076977**	**001**	Aug 05, 2005
AT		WOCKHARDT BIO AG	**0.05%**	**A075205**	**001**	Nov 13, 1998

EMBELINE

AT	**!**	AKORN	**0.05%**	**A074222**	**001**	Dec 06, 1995

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

AT		ALEOR DERMACEUTICALS	**0.05%**	**A211191**	**001**	Oct 02, 2019
AT		GLENMARK PHARMS	**0.05%**	**A209004**	**001**	Mar 26, 2018
AT		LUPIN LTD	**0.05%**	**A208125**	**001**	Mar 26, 2018
AT		PADAGIS US	**0.05%**	**A090898**	**001**	Jun 16, 2011
AT		TARO	**0.05%**	**A208842**	**001**	Mar 26, 2018
AT		ZYDUS PHARMS	**0.05%**	**A206378**	**001**	Feb 16, 2017

CLOBEX

AT	**+!**	GALDERMA LABS LP	**0.05%**	**N021835**	**001**	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLOCORTOLONE PIVALATE

AB		TARO	**0.1%**	**A206370**	**001**	Apr 21, 2020

CLODERM

AB	**+!**	EPI HLTH	**0.1%**	**N017765**	**001**	

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP		ABON PHARMS LLC	**20MG/20ML (1MG/ML)**	**A204029**	**001**	May 09, 2017
AP		ACCORD HLTHCARE	**20MG/20ML (1MG/ML)**	**A212034**	**001**	Feb 22, 2019
AP		AMNEAL	**20MG/20ML (1MG/ML)**	**A208857**	**001**	Nov 06, 2017
AP		DR REDDYS LABS LTD	**20MG/20ML (1MG/ML)**	**A205375**	**001**	Nov 06, 2017
AP		GLAND PHARMA LTD	**20MG/20ML (1MG/ML)**	**A207831**	**001**	Oct 31, 2018
AP		MEITHEAL	**20MG/20ML (1MG/ML)**	**A213461**	**001**	Oct 23, 2020
AP		MSN	**20MG/20ML (1MG/ML)**	**A209775**	**001**	Dec 06, 2017
AP		MYLAN LABS LTD	**20MG/20ML (1MG/ML)**	**A208860**	**001**	Nov 06, 2017

CLOLAR

AP	**+!**	GENZYME	**20MG/20ML (1MG/ML)**	**N021673**	**001**	Dec 28, 2004

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMIPHENE CITRATE

	!	PAR PHARM	50MG	A075528	001	Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

ANAFRANIL

AB	**+!**	SPECGX LLC	**25MG**	**N019906**	**001**	Dec 29, 1989
AB	**+**		**50MG**	**N019906**	**002**	Dec 29, 1989
AB	**+**		**75MG**	**N019906**	**003**	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	**25MG**	**A213897**	**001**	Oct 02, 2020
AB		**50MG**	**A213897**	**002**	Oct 02, 2020
AB		**75MG**	**A213897**	**003**	Oct 02, 2020
AB	ALEMBIC PHARMS LTD	**25MG**	**A211822**	**001**	Aug 04, 2021
AB		**50MG**	**A211822**	**002**	Aug 04, 2021
AB		**75MG**	**A211822**	**003**	Aug 04, 2021
AB	AMNEAL PHARMS CO	**25MG**	**A208632**	**001**	Oct 31, 2018
AB		**50MG**	**A208632**	**002**	Oct 31, 2018
AB		**75MG**	**A208632**	**003**	Oct 31, 2018
AB	JUBILANT CADISTA	**25MG**	**A212218**	**001**	Oct 21, 2019
AB		**50MG**	**A212218**	**002**	Oct 21, 2019
AB		**75MG**	**A212218**	**003**	Oct 21, 2019
AB	LEADING PHARMA LLC	**25MG**	**A211364**	**001**	Feb 07, 2020
AB		**50MG**	**A211364**	**002**	Feb 07, 2020
AB		**75MG**	**A211364**	**003**	Feb 07, 2020
AB	LUPIN LTD	**25MG**	**A209294**	**001**	Nov 21, 2018
AB		**50MG**	**A209294**	**002**	Nov 21, 2018
AB		**75MG**	**A209294**	**003**	Nov 21, 2018
AB	MANKIND PHARMA	**25MG**	**A211767**	**001**	Apr 08, 2019
AB		**50MG**	**A211767**	**002**	Apr 08, 2019
AB		**75MG**	**A211767**	**003**	Apr 08, 2019
AB	MICRO LABS	**25MG**	**A213219**	**001**	Jun 22, 2020
AB		**50MG**	**A213219**	**002**	Jun 22, 2020
AB		**75MG**	**A213219**	**003**	Jun 22, 2020
AB	MYLAN	**25MG**	**A074947**	**001**	Apr 30, 1998
AB		**50MG**	**A074947**	**002**	Apr 30, 1998
AB		**75MG**	**A074947**	**003**	Apr 30, 1998
AB	SANDOZ	**25MG**	**A074364**	**001**	Mar 29, 1996
AB		**25MG**	**A074953**	**001**	Jun 25, 1997
AB		**50MG**	**A074364**	**002**	Mar 29, 1996
AB		**50MG**	**A074953**	**002**	Jun 25, 1997
AB		**75MG**	**A074364**	**003**	Mar 29, 1996
AB		**75MG**	**A074953**	**003**	Jun 25, 1997
AB	TARO	**25MG**	**A074694**	**001**	Dec 31, 1996
AB		**50MG**	**A074694**	**002**	Dec 31, 1996
AB		**75MG**	**A074694**	**003**	Dec 31, 1996
AB	TULEX PHARMS INC	**25MG**	**A210653**	**001**	Apr 03, 2020
AB		**50MG**	**A210653**	**002**	Apr 03, 2020
AB		**75MG**	**A210653**	**003**	Apr 03, 2020
AB	UNIQUE PHARM LABS	**25MG**	**A212285**	**001**	Aug 07, 2020
AB		**50MG**	**A212285**	**002**	Aug 07, 2020
AB		**75MG**	**A212285**	**003**	Aug 07, 2020
AB	VGYAAN	**25MG**	**A213221**	**001**	Jun 22, 2020
AB		**50MG**	**A213221**	**002**	Jun 22, 2020
AB		**75MG**	**A213221**	**003**	Jun 22, 2020
AB	ZYDUS PHARMS	**25MG**	**A208961**	**001**	Dec 27, 2017
AB		**50MG**	**A208961**	**002**	Dec 27, 2017
AB		**75MG**	**A208961**	**003**	Dec 27, 2017

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AB	ACCORD HLTHCARE	**0.5MG**	**A077147**	**001**	May 02, 2005
AB		**1MG**	**A077147**	**002**	May 02, 2005
AB		**2MG**	**A077147**	**003**	May 02, 2005
AB	ACTAVIS ELIZABETH	**0.5MG**	**A074869**	**001**	Oct 31, 1996
AB		**1MG**	**A074869**	**002**	Oct 31, 1996
AB		**2MG**	**A074869**	**003**	Oct 31, 1996
AB	PRINSTON INC	**0.5MG**	**A077856**	**001**	Jun 28, 2006
AB		**1MG**	**A077856**	**002**	Jun 28, 2006
AB		**2MG**	**A077856**	**003**	Jun 28, 2006
AB	SANDOZ	**0.5MG**	**A074979**	**001**	Aug 29, 1997
AB		**1MG**	**A074979**	**002**	Aug 29, 1997
AB		**2MG**	**A074979**	**003**	Aug 29, 1997
AB	TEVA	**0.5MG**	**A074569**	**001**	Sep 10, 1996
AB		**1MG**	**A074569**	**002**	Sep 10, 1996
AB		**2MG**	**A074569**	**003**	Sep 10, 1996

KLONOPIN

AB	**+** CHEPLAPHARM	**0.5MG**	**N017533**	**001**	
AB	**+!**	**1MG**	**N017533**	**002**	

CLONAZEPAM

TABLET;ORAL

KLONOPIN

AB	**+**		**2MG**	**N017533**	**003**	

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB		ALEMBIC PHARMS LTD	**0.125MG**	**A211033**	**001**	Jun 28, 2019
AB			**0.25MG**	**A211033**	**002**	Jun 28, 2019
AB			**0.5MG**	**A211033**	**003**	Jun 28, 2019
AB			**1MG**	**A211033**	**004**	Jun 28, 2019
AB			**2MG**	**A211033**	**005**	Jun 28, 2019
AB		BARR	**0.125MG**	**A077194**	**001**	Aug 10, 2005
AB			**0.25MG**	**A077194**	**002**	Aug 10, 2005
AB			**0.5MG**	**A077194**	**003**	Aug 10, 2005
AB			**1MG**	**A077194**	**004**	Aug 10, 2005
AB			**2MG**	**A077194**	**005**	Aug 10, 2005
AB		PAR PHARM	**0.125MG**	**A077171**	**001**	Aug 03, 2005
AB			**0.25MG**	**A077171**	**002**	Aug 03, 2005
AB			**0.5MG**	**A077171**	**003**	Aug 03, 2005
AB	**!**		**1MG**	**A077171**	**004**	Aug 03, 2005
AB			**2MG**	**A077171**	**005**	Aug 03, 2005
AB		SUN PHARM INDS INC	**0.125MG**	**A078654**	**001**	Aug 27, 2014
AB			**0.25MG**	**A078654**	**002**	Aug 27, 2014
AB			**0.5MG**	**A078654**	**003**	Aug 27, 2014
AB			**1MG**	**A078654**	**004**	Aug 27, 2014
AB			**2MG**	**A078654**	**005**	Aug 27, 2014

CLONIDINE

SYSTEM;TRANSDERMAL

CATAPRES-TTS-1

AB	**+**	LAVIPHARM	**0.1MG/24HR**	**N018891**	**001**	Oct 10, 1984

CATAPRES-TTS-2

AB	**+**	LAVIPHARM	**0.2MG/24HR**	**N018891**	**002**	Oct 10, 1984

CATAPRES-TTS-3

AB	**+!**	LAVIPHARM	**0.3MG/24HR**	**N018891**	**003**	Oct 10, 1984

CLONIDINE

AB		ACTAVIS LABS UT INC	**0.1MG/24HR**	**A090873**	**001**	May 06, 2014
AB			**0.2MG/24HR**	**A090873**	**002**	May 06, 2014
AB			**0.3MG/24HR**	**A090873**	**003**	May 06, 2014
AB		AVEVA	**0.1MG/24HR**	**A076157**	**001**	Aug 18, 2009
AB			**0.2MG/24HR**	**A076157**	**002**	Aug 18, 2009
AB			**0.3MG/24HR**	**A076157**	**003**	Aug 18, 2009
AB		MAYNE PHARMA	**0.1MG/24HR**	**A079090**	**001**	Aug 20, 2010
AB			**0.2MG/24HR**	**A079090**	**002**	Aug 20, 2010
AB			**0.3MG/24HR**	**A079090**	**003**	Aug 20, 2010
AB		MYLAN TECHNOLOGIES	**0.1MG/24HR**	**A076166**	**001**	Jul 16, 2010
AB			**0.2MG/24HR**	**A076166**	**002**	Jul 16, 2010
AB			**0.3MG/24HR**	**A076166**	**003**	Jul 16, 2010

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**1MG/10ML (0.1MG/ML)**	**A200673**	**001**	Jul 08, 2011
AP			**5MG/10ML (0.5MG/ML)**	**A200673**	**002**	Jul 08, 2011
AP		HIKMA FARMACEUTICA	**1MG/10ML (0.1MG/ML)**	**A200300**	**001**	Jan 26, 2011
AP	**!**		**5MG/10ML (0.5MG/ML)**	**A200300**	**002**	Jan 26, 2011
AP		XGEN PHARMS	**1MG/10ML (0.1MG/ML)**	**A203167**	**001**	Oct 29, 2013
AP			**5MG/10ML (0.5MG/ML)**	**A203167**	**002**	Oct 29, 2013
AP		ZYDUS PHARMS	**1MG/10ML (0.1MG/ML)**	**A202601**	**001**	Feb 20, 2014
AP			**5MG/10ML (0.5MG/ML)**	**A202601**	**002**	Feb 20, 2014

DURACLON

AP	**+**	MYLAN INSTITUTIONAL	**1MG/10ML (0.1MG/ML)**	**N020615**	**001**	Oct 02, 1996

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**0.1MG**	**A070974**	**001**	Dec 16, 1986
AB			**0.2MG**	**A070975**	**001**	Dec 16, 1986
AB			**0.3MG**	**A070976**	**001**	Dec 16, 1986
AB		ALEMBIC PHARMS LTD	**0.1MG**	**A091368**	**001**	Dec 06, 2011
AB			**0.2MG**	**A091368**	**002**	Dec 06, 2011
AB			**0.3MG**	**A091368**	**003**	Dec 06, 2011
AB		FRONTIDA BIOPHARM	**0.1MG**	**A070923**	**003**	Sep 04, 1987
AB			**0.2MG**	**A070923**	**002**	Sep 04, 1987
AB			**0.3MG**	**A070923**	**001**	Sep 04, 1987

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB		IMPAX LABS	0.1MG	A078099	001	Aug 27, 2009
AB			0.2MG	A078099	002	Aug 27, 2009
AB			0.3MG	A078099	003	Aug 27, 2009
AB		PRINSTON INC	0.1MG	A077901	001	Mar 09, 2007
AB			0.2MG	A077901	002	Mar 09, 2007
AB			0.3MG	A077901	003	Mar 09, 2007
AB		UNICHEM	0.1MG	A078895	001	Aug 26, 2009
AB			0.2MG	A078895	002	Aug 26, 2009
AB	!		0.3MG	A078895	003	Aug 26, 2009
AB		YUNG SHIN PHARM	0.1MG	A202297	001	Jun 13, 2013
AB			0.2MG	A202297	002	Jun 13, 2013
AB			0.3MG	A202297	003	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1		ACTAVIS ELIZABETH	0.1MG	A203320	001	May 15, 2015
AB1		AJANTA PHARMA LTD	0.1MG	A209686	001	Nov 20, 2017
AB1		AMNEAL PHARMS NY	0.1MG	A210052	001	Nov 20, 2017
AB1		ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013
AB1		JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018
AB1		LUPIN LTD	0.1MG	A209285	001	Oct 23, 2017
AB1		MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018
AB1		NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019
AB1		XIAMEN LP PHARM CO	0.1MG	A209757	001	Nov 20, 2017

KAPVAY

AB1	+!	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010

CLONIDINE HYDROCHLORIDE

AB2		ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB		ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013
AB			EQ 300MG BASE	A202925	002	Mar 27, 2013
AB		ACME LABS	EQ 75MG BASE	A078004	001	May 17, 2012
AB		AMNEAL PHARMS	EQ 75MG BASE	A203751	001	Apr 11, 2014
AB		APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012
AB	!		EQ 300MG BASE	A076274	002	Mar 04, 2014
AB		AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012
AB		DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008
AB		DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012
AB		GRAVITI PHARMS	EQ 75MG BASE	A204359	001	Feb 02, 2017
AB		MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014
AB		POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020
AB			EQ 300MG BASE	A213351	002	Jul 17, 2020
AB		PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018
AB			EQ 300MG BASE	A206376	002	May 07, 2018
AB		SCIEGEN PHARMS INC	EQ 75MG BASE	A204165	001	Sep 15, 2014
AB			EQ 300MG BASE	A204165	002	Sep 15, 2014
AB		SUN PHARM	EQ 75MG BASE	A090494	001	May 17, 2012
AB		TEVA	EQ 75MG BASE	A076999	001	May 17, 2012
AB		TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012

PLAVIX

AB	+	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997
AB	+		EQ 300MG BASE	N020839	002	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB		AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987
AB			7.5MG	A071858	003	Jul 17, 1987
AB	!		15MG	A071858	001	Jul 17, 1987
AB		TARO	3.75MG	A075731	003	Apr 27, 2000
AB			7.5MG	A075731	002	Apr 27, 2000
AB			15MG	A075731	001	Apr 27, 2000

TRANXENE

AB	+	RECORDATI RARE	7.5MG	N017105	007	

CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE

AB		FOUGERA PHARMS	**1%**	**A078338**	**001**	Sep 02, 2008
AB		GLENMARK PHARMS	**1%**	**A090219**	**001**	Aug 03, 2010
AB	!	TARO	**1%**	**A072640**	**001**	Aug 31, 1993

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT		NOVITIUM PHARMA	**1%**	**A209815**	**001**	Feb 14, 2019
AT	!	TARO	**1%**	**A074580**	**001**	Jul 29, 1996
AT		TASMAN PHARMA	**1%**	**A212281**	**001**	Jul 25, 2019
AT		TEVA	**1%**	**A073306**	**001**	Feb 28, 1995

TROCHE/LOZENGE;ORAL

CLOTRIMAZOLE

AB	!	HIKMA	**10MG**	**A076387**	**001**	Jul 29, 2004
AB		PADAGIS US	**10MG**	**A076763**	**001**	Oct 28, 2005

CLOZAPINE

SUSPENSION;ORAL

VERSACLOZ

	+!	TASMAN PHARMA	50MG/ML	N203479	001	Feb 06, 2013

TABLET;ORAL

CLOZAPINE

AB		ACCORD HLTHCARE	**25MG**	**A202873**	**001**	Nov 25, 2015
AB			**100MG**	**A202873**	**002**	Nov 25, 2015
AB		AUROBINDO PHARMA LTD	**25MG**	**A206433**	**001**	Nov 29, 2016
AB			**50MG**	**A206433**	**002**	Nov 29, 2016
AB			**100MG**	**A206433**	**003**	Nov 29, 2016
AB			**200MG**	**A206433**	**004**	Nov 29, 2016
AB		IVAX SUB TEVA PHARMS	**25MG**	**A074949**	**001**	Nov 26, 1997
AB			**50MG**	**A074949**	**004**	Apr 25, 2005
AB			**50MG**	**A076809**	**003**	Dec 16, 2005
AB			**100MG**	**A074949**	**002**	Nov 26, 1997
AB			**100MG**	**A076809**	**002**	Dec 16, 2005
AB			**200MG**	**A076809**	**001**	Dec 16, 2005
AB		MAYNE PHARMA	**25MG**	**A203807**	**001**	Sep 17, 2015
AB			**50MG**	**A203807**	**003**	Aug 22, 2017
AB			**100MG**	**A203807**	**002**	Sep 17, 2015
AB			**200MG**	**A203807**	**004**	Aug 22, 2017
AB		MYLAN	**25MG**	**A075417**	**001**	May 27, 1999
AB			**50MG**	**A075417**	**004**	Apr 15, 2010
AB			**100MG**	**A075417**	**002**	May 27, 1999
AB			**200MG**	**A075417**	**005**	Apr 15, 2010
AB		SUN PHARM INDS INC	**25MG**	**A075713**	**001**	Nov 15, 2002
AB			**50MG**	**A075713**	**003**	Aug 19, 2005
AB			**100MG**	**A075713**	**002**	Nov 15, 2002
AB			**200MG**	**A075713**	**004**	Nov 07, 2017

CLOZARIL

AB	+	HERITAGE LIFE	**25MG**	**N019758**	**001**	Sep 26, 1989
AB	+		**50MG**	**N019758**	**003**	May 20, 2019
AB	+!		**100MG**	**N019758**	**002**	Sep 26, 1989
AB	+		**200MG**	**N019758**	**004**	May 20, 2019

CLOZAPINE

		IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

AB		BARR LABS INC	**25MG**	**A090308**	**001**	Nov 25, 2015
AB	!		**100MG**	**A090308**	**002**	Nov 25, 2015
AB		MYLAN	**25MG**	**A201824**	**002**	Sep 15, 2015
AB			**100MG**	**A201824**	**003**	Sep 15, 2015
		BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018
		TEVA PHARMS USA	150MG	A203039	001	Nov 25, 2015
			200MG	A203039	002	Nov 25, 2015

COBICISTAT

TABLET;ORAL

TYBOST

	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014

COBICISTAT; DARUNAVIR

TABLET;ORAL

PREZCOBIX

	+!	JANSSEN PRODS	150MG;800MG	N205395	001	Jan 29, 2015

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

SYMTUZA

	+!	JANSSEN PRODS	150MG;800MG;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

GENVOYA

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE	N207561	001	Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

	+!	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100	001	Aug 27, 2012

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

	+!	GENENTECH INC	EQ 20MG BASE	N206192	001	Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

	+!	GENUS LIFESCIENCES	4%	N209963	001	Dec 14, 2017

NUMBRINO

	+!	CODY LABS INC	4%	N209575	001	Jan 10, 2020

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	**!**	PHARM ASSOC	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040660**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AKORN	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A040674**	**001**	Dec 23, 2014

PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AMNEAL PHARMS	**10MG/5ML;5MG/5ML;6.25MG/5ML**	**A200963**	**001**	Aug 26, 2015

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	**+!**	ACTAVIS MID ATLANTIC	**10MG/5ML;6.25MG/5ML**	**A088763**	**001**	Oct 31, 1984
AA		AKORN	**10MG/5ML;6.25MG/5ML**	**A040151**	**001**	Aug 26, 1997
AA		AMNEAL PHARMS	**10MG/5ML;6.25MG/5ML**	**A200894**	**001**	Apr 24, 2013
AA		NOSTRUM LABS INC	**10MG/5ML;6.25MG/5ML**	**A090180**	**001**	Mar 17, 2010
AA		QUAGEN	**10MG/5ML;6.25MG/5ML**	**A214238**	**001**	Oct 08, 2020
AA		TRIS PHARMA INC	**10MG/5ML;6.25MG/5ML**	**A200386**	**001**	Jun 29, 2012
AA		WOCKHARDT BIO AG	**10MG/5ML;6.25MG/5ML**	**A088875**	**001**	Dec 17, 1984

PROMETHAZINE WITH CODEINE

AA		PHARM ASSOC	**10MG/5ML;6.25MG/5ML**	**A040650**	**001**	Jan 31, 2006

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

	!	STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	A088704	001	Mar 22, 1985

CODEINE SULFATE

TABLET;ORAL

CODEINE SULFATE

AB	**+**	HIKMA	**15MG**	**N022402**	**001**	Jul 16, 2009
AB	**+**		**30MG**	**N022402**	**002**	Jul 16, 2009
AB	**+!**		**60MG**	**N022402**	**003**	Jul 16, 2009
AB		LANNETT CO INC	**15MG**	**A203046**	**001**	Jun 13, 2014
AB			**30MG**	**A203046**	**002**	Jun 13, 2014
AB			**60MG**	**A203046**	**003**	Jun 13, 2014

COLCHICINE

CAPSULE;ORAL

MITIGARE

	+!	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014

SOLUTION;ORAL

GLOPERBA

	+!	ROMEG	0.6MG/5ML	N210942	001	Jan 30, 2019

COLCHICINE

TABLET;ORAL

COLCHICINE

AB		ALKEM LABS LTD	**0.6MG**	**A211250**	**001**	Feb 08, 2019
AB		AMNEAL PHARMS	**0.6MG**	**A204711**	**001**	Sep 28, 2016
AB		AUROBINDO PHARMA LTD	**0.6MG**	**A215444**	**001**	Jan 06, 2022
AB		DR REDDYS	**0.6MG**	**A209876**	**001**	Sep 06, 2019
AB		GRANULES	**0.6MG**	**A210425**	**001**	Feb 05, 2020
AB		HETERO LABS LTD V	**0.6MG**	**A208993**	**001**	Aug 13, 2021
AB		MYLAN	**0.6MG**	**A209470**	**001**	Sep 16, 2019
AB		PAR PHARM INC	**0.6MG**	**A203976**	**001**	Aug 12, 2021
AB		WATSON LABS INC	**0.6MG**	**A204461**	**001**	Jul 31, 2019
AB		ZYDUS PHARMS	**0.6MG**	**A211519**	**001**	Feb 19, 2019

COLCRYS

AB	**+!**	TAKEDA PHARMS USA	**0.6MG**	**N022352**	**001**	Jul 29, 2009

COLCHICINE

		ZYDUS PHARMS	0.3MG	A211519	002	Nov 14, 2019

COLCHICINE; PROBENECID

TABLET;ORAL

COL-PROBENECID

AB	**+!**	WATSON LABS	**0.5MG;500MG**	**A084279**	**001**	

PROBENECID AND COLCHICINE

AB		NOVAST LABS	**0.5MG;500MG**	**A040618**	**001**	May 13, 2008

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**3.75GM/PACKET**	**A210316**	**001**	May 06, 2019
AB		GLENMARK PHARMS LTD	**3.75GM/PACKET**	**A202190**	**002**	Jul 16, 2018

WELCHOL

AB	**+!**	DAIICHI SANKYO	**3.75GM/PACKET**	**N022362**	**002**	Oct 02, 2009

COLESEVELAM HYDROCHLORIDE

		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

AB		ALKEM LABS LTD	**625MG**	**A209038**	**001**	Oct 05, 2018
AB		BEIJING TIDE PHARM	**625MG**	**A206036**	**001**	Oct 14, 2021
AB		BIONPHARMA INC	**625MG**	**A208670**	**001**	Sep 13, 2019
AB		DR REDDYS	**625MG**	**A210889**	**001**	Oct 05, 2018
AB		GLENMARK PHARMS LTD	**625MG**	**A203480**	**001**	May 18, 2018
AB		IMPAX LABS INC	**625MG**	**A091600**	**001**	May 16, 2018
AB		INVENTIA	**625MG**	**A212050**	**001**	Dec 04, 2020
AB		LUPIN LTD	**625MG**	**A201354**	**001**	Dec 17, 2020
AB		ZHEJIANG JINGXIN	**625MG**	**A209946**	**001**	Jul 15, 2020
AB		ZYDUS PHARMS	**625MG**	**A207765**	**001**	Oct 07, 2019

WELCHOL

AB	**+!**	DAIICHI SANKYO	**625MG**	**N021176**	**001**	May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

AB	**+**	PFIZER	**5GM/SCOOPFUL**	**N017563**	**003**	Sep 22, 1995
AB	**+!**		**5GM/PACKET**	**N017563**	**004**	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	**5GM/SCOOPFUL**	**A077277**	**001**	May 02, 2006
AB			**5GM/PACKET**	**A077277**	**002**	May 02, 2006

FLAVORED COLESTID

	+	PFIZER	5GM/PACKET	N017563	001	
	+		5GM/SCOOPFUL	N017563	002	

TABLET;ORAL

COLESTID

AB	**+!**	PFIZER	**1GM**	**N020222**	**001**	Jul 19, 1994

COLESTIPOL HYDROCHLORIDE

AB		IMPAX LABS	**1GM**	**A077510**	**001**	Oct 24, 2006

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP		EMCURE PHARMS LTD	**EQ 150MG BASE/VIAL**	**A202359**	**001**	Sep 28, 2012
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A065364**	**001**	Apr 17, 2008
AP		NEXUS PHARMS	**EQ 150MG BASE/VIAL**	**A065177**	**001**	Mar 19, 2004
AP		SAGENT PHARMS INC	**EQ 150MG BASE/VIAL**	**A201365**	**001**	Feb 19, 2014
AP		XELLIA PHARMS APS	**EQ 150MG BASE/VIAL**	**A205356**	**001**	May 29, 2015

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP		XGEN PHARMS	**EQ 150MG BASE/VIAL**	**A064216**	**001**	Feb 26, 1999

COLY-MYCIN M

AP	**+!**	PAR STERILE PRODUCTS	**EQ 150MG BASE/VIAL**	**N050108**	**002**	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

	+!	ENDO PHARMS INC	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

	+!	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008

COPANLISIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS

ALIQOPA

	+!	BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017

COPPER

INTRAUTERINE DEVICE;INTRAUTERINE

PARAGARD T 380A

	+!	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984

COPPER DOTATATE CU-64

SOLUTION;INTRAVENOUS

DETECTNET

	+!	RADIOMEDIX	4mL (1mCi/ML)	N213227	001	Sep 03, 2020

CORTICOTROPIN

INJECTABLE;INJECTION

ACTHAR GEL

	+!	MALLINCKRODT ARD	80 UNITS/ML	N008372	008	

PURIFIED CORTROPHIN GEL

	+!	ANI PHARMS	80 UNITS/ML	N008975	002	

CORTISONE ACETATE

TABLET;ORAL

CORTISONE ACETATE

	!	HIKMA INTL PHARMS	25MG	A080776	002	

COSYNTROPIN

INJECTABLE;INJECTION

CORTROSYN

AP	**+!**	AMPHASTAR PHARMS INC	**0.25MG/VIAL**	**N016750**	**001**	

COSYNTROPIN

AP		MYLAN INSTITUTIONAL	**0.25MG/VIAL**	**A090574**	**001**	Dec 17, 2009
AP		SANDOZ	**0.25MG/VIAL**	**A202147**	**001**	Jun 29, 2012

CRISABOROLE

OINTMENT;TOPICAL

EUCRISA

	+!	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016

CRIZOTINIB

CAPSULE;ORAL

XALKORI

	+	PF PRISM CV	200MG	N202570	001	Aug 26, 2011
	+!		250MG	N202570	002	Aug 26, 2011

CROFELEMER

TABLET, DELAYED RELEASE;ORAL

MYTESI

	+!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012

CROMOLYN SODIUM

CONCENTRATE;ORAL

CROMOLYN SODIUM

AA		AILEX PHARMS LLC	**100MG/5ML**	**A209264**	**001**	Oct 16, 2017
AA		MICRO LABS LTD INDIA	**100MG/5ML**	**A202745**	**001**	Apr 04, 2013
AA		RISING	**100MG/5ML**	**A202583**	**001**	Oct 27, 2011

CROMOLYN SODIUM						
CONCENTRATE;ORAL						
GASTROCROM						
AA	**+!**	MYLAN SPECIALITY LP	**100MG/5ML**	**N020479**	**001**	Feb 29, 1996
SOLUTION;INHALATION						
CROMOLYN SODIUM						
AN		AILEX PHARMS LLC	**10MG/ML**	**A209453**	**001**	Oct 16, 2017
AN	**!**	TEVA PHARMS	**10MG/ML**	**A075271**	**001**	Jan 18, 2000
AN		WOCKHARDT BIO AG	**10MG/ML**	**A075346**	**001**	Oct 25, 1999
SOLUTION/DROPS;OPHTHALMIC						
CROMOLYN SODIUM						
AT	**!**	AKORN	**4%**	**A074706**	**001**	Apr 29, 1998
AT		SANDOZ INC	**4%**	**A075282**	**001**	Jun 16, 1999
CROTAMITON						
LOTION;TOPICAL						
CROTAN						
AT		MARNEL PHARMS	**10%**	**A087204**	**001**	
EURAX						
AT	**+!**	JOURNEY	**10%**	**N009112**	**003**	
CUPRIC CHLORIDE						
INJECTABLE;INJECTION						
CUPRIC CHLORIDE IN PLASTIC CONTAINER						
	+!	HOSPIRA	EQ 0.4MG COPPER/ML	N018960	001	Jun 26, 1986
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE						
SOLUTION;INTRAVENOUS						
MULTRYS						
	+!	AM REGENT	EQ 60MCG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG SELENIUM/ML;EQ 1000MCG BASE/ML (1ML)	N209376	003	Jun 30, 2021
TRALEMENT						
	+!	AM REGENT	EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (1ML)	N209376	001	Jul 02, 2020
	+!		EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG SELENIUM/ML;EQ 3MG BASE/ML (5ML)	N209376	002	Dec 02, 2020
CYANOCOBALAMIN						
INJECTABLE;INJECTION						
CYANOCOBALAMIN						
AP	**+!**	AM REGENT	**1MG/ML**	**A080737**	**001**	
AP		EUGIA PHARMA	**1MG/ML**	**A213874**	**001**	Dec 08, 2020
AP		GLAND PHARMA LTD	**1MG/ML**	**A214390**	**001**	Sep 24, 2020
AP		MYLAN LABS LTD	**1MG/ML**	**A204829**	**001**	Jun 05, 2017
AP		SANDOZ INC	**1MG/ML**	**A212915**	**001**	Jan 04, 2021
AP		SOMERSET THERAPS LLC	**1MG/ML**	**A206503**	**001**	Dec 11, 2015
AP			**1MG/ML**	**A209429**	**001**	Dec 18, 2018
AP		VITRUVIAS THERAP	**1MG/ML**	**A209255**	**001**	Dec 18, 2018
AP		WEST-WARD PHARMS INT	**1MG/ML**	**A080515**	**002**	
VIBISONE						
AP	**+!**	FRESENIUS KABI USA	**1MG/ML**	**A080557**	**003**	
SPRAY, METERED;NASAL						
NASCOBAL						
	+!	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005
CYCLOBENZAPRINE HYDROCHLORIDE						
CAPSULE, EXTENDED RELEASE;ORAL						
AMRIX						
AB	**+**	TEVA PHARMS INTL	**15MG**	**N021777**	**001**	Feb 01, 2007
AB	**+!**		**30MG**	**N021777**	**002**	Feb 01, 2007
CYCLOBENZAPRINE HYDROCHLORIDE						
AB		APOTEX	**15MG**	**A206703**	**001**	Jul 24, 2018
AB			**30MG**	**A206703**	**002**	Jul 24, 2018
AB		TWI PHARMS INC	**15MG**	**A091281**	**001**	Jan 31, 2013
AB			**30MG**	**A091281**	**002**	Jan 31, 2013
TABLET;ORAL						
CYCLOBENZAPRINE HYDROCHLORIDE						
AB		ACTAVIS LABS FL INC	**5MG**	**A071611**	**002**	Feb 03, 2006
AB			**7.5MG**	**A071611**	**003**	Feb 03, 2006
AB			**10MG**	**A071611**	**001**	May 03, 1989
AB		ALEMBIC LABS	**5MG**	**A078218**	**002**	Jun 19, 2015
AB			**7.5MG**	**A078218**	**003**	Nov 03, 2020
AB			**10MG**	**A078218**	**001**	Apr 18, 2008

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ANDA REPOSITORY	**5MG**	**A073541**	**002**	Apr 06, 2006
AB			**10MG**	**A073541**	**001**	May 23, 1995
AB		AUROBINDO PHARMA	**5MG**	**A078643**	**001**	Sep 26, 2008
AB			**10MG**	**A078643**	**002**	Sep 26, 2008
AB		INVAGEN PHARMS	**5MG**	**A090478**	**001**	Jul 23, 2010
AB			**10MG**	**A090478**	**002**	Jul 23, 2010
AB		JUBILANT CADISTA	**5MG**	**A077563**	**001**	Apr 19, 2006
AB			**7.5MG**	**A077563**	**003**	Aug 25, 2017
AB			**10MG**	**A077563**	**002**	Apr 19, 2006
AB		KVK TECH	**5MG**	**A078048**	**001**	Feb 28, 2011
AB			**10MG**	**A078048**	**002**	Feb 28, 2011
AB		OXFORD PHARMS	**5MG**	**A077209**	**002**	Feb 03, 2006
AB			**10MG**	**A077209**	**001**	Oct 04, 2005
AB		PRINSTON INC	**5MG**	**A077797**	**001**	Feb 28, 2007
AB			**10MG**	**A077797**	**002**	Feb 28, 2007
AB		RUBICON	**5MG**	**A208170**	**001**	May 31, 2017
AB			**7.5MG**	**A208170**	**002**	May 31, 2017
AB	!		**10MG**	**A208170**	**003**	May 31, 2017
AB		SUN PHARM INDS LTD	**5MG**	**A078722**	**001**	May 12, 2008
AB			**7.5MG**	**A078722**	**002**	May 12, 2008
AB			**10MG**	**A078722**	**003**	May 12, 2008
AB		UNICHEM	**5MG**	**A213324**	**001**	Jul 06, 2020
AB			**7.5MG**	**A213324**	**002**	Jul 06, 2020
AB			**10MG**	**A213324**	**003**	Jul 05, 2020

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPENTOLATE

AT		AKORN	**1%**	**A040164**	**001**	Jan 13, 1997
AT			**2%**	**A040165**	**001**	Jan 13, 1997

CYCLOGYL

AT	**+!**	ALCON LABS INC	**0.5%**	**A084109**	**001**	
AT	**+!**		**1%**	**A084110**	**001**	
AT	**+!**		**2%**	**A084108**	**001**	

CYCLOPENTOLATE HYDROCHLORIDE

AT		AKORN	**0.5%**	**A205937**	**001**	Dec 09, 2015

PENTOLAIR

AT		BAUSCH AND LOMB	**1%**	**A040075**	**001**	Apr 29, 1994

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOMYDRIL

	!	ALCON LABS INC	0.2%;1%	A084300	001	

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

AB		ANI PHARMS	**25MG**	**A207014**	**001**	Mar 19, 2018
AB			**50MG**	**A207014**	**002**	Mar 19, 2018
AB		CIPLA	**25MG**	**A211608**	**001**	Jan 18, 2019
AB			**50MG**	**A211608**	**002**	Jan 18, 2019
AB	**+**	HIKMA	**25MG**	**N203856**	**001**	Sep 16, 2013
AB	**+!**		**50MG**	**N203856**	**002**	Sep 16, 2013
AB		STI PHARMA LLC	**25MG**	**A209872**	**001**	May 07, 2018
AB			**50MG**	**A209872**	**002**	May 07, 2018

INJECTABLE;INJECTION

CYCLOPHOSPHAMIDE

AP		AMNEAL	**500MG/VIAL**	**A210046**	**001**	May 25, 2018
AP			**1GM/VIAL**	**A210046**	**002**	May 25, 2018
AP			**2GM/VIAL**	**A210046**	**003**	May 25, 2018
AP	!	BAXTER HLTHCARE	**500MG/VIAL**	**A040745**	**001**	May 21, 2008
AP	!		**1GM/VIAL**	**A040745**	**002**	May 21, 2008
AP	!		**2GM/VIAL**	**A040745**	**003**	May 21, 2008
AP		JIANGSU PHARMS	**500MG/VIAL**	**A204555**	**001**	Oct 31, 2014
AP			**1GM/VIAL**	**A204555**	**002**	Oct 31, 2014
AP			**2GM/VIAL**	**A204555**	**003**	Oct 31, 2014

SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE

	+!	EUGIA PHARMA SPECLTS	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021
	+!		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021

CYCLOPHOSPHAMIDE

SOLUTION;INTRAVENOUS

CYCLOPHOSPHAMIDE

+!	INGENUS PHARMS LLC	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020
+!		1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020
+!		2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021

TABLET;ORAL

CYTOXAN

+	BAXTER HLTHCARE	25MG	N012141	002	
+!		50MG	N012141	001	

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

!	PURDUE	250MG	A060593	001	

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

AB1		APOTEX	**25MG**	**A210721**	**001**	Jul 10, 2019
AB1			**50MG**	**A210721**	**002**	Jul 10, 2019
AB1			**100MG**	**A210721**	**003**	Jul 10, 2019
AB1		IVAX SUB TEVA PHARMS	**25MG**	**A065110**	**003**	Mar 29, 2005
AB1			**50MG**	**A065110**	**001**	Mar 29, 2005
AB1			**100MG**	**A065110**	**002**	Mar 29, 2005
AB1		MAYNE PHARMA	**25MG**	**A065044**	**002**	Dec 20, 2000
AB1			**100MG**	**A065044**	**001**	Dec 20, 2000
AB1		SANDOZ	**25MG**	**A065017**	**002**	Jan 13, 2000
AB1			**100MG**	**A065017**	**001**	Jan 13, 2000

GENGRAF

AB1		ABBVIE	**25MG**	**A065003**	**001**	May 12, 2000
AB1			**100MG**	**A065003**	**003**	May 12, 2000

NEORAL

AB1	**+**	NOVARTIS	**25MG**	**N050715**	**001**	Jul 14, 1995
AB1	**+!**		**100MG**	**N050715**	**002**	Jul 14, 1995

CYCLOSPORINE

AB2		APOTEX	**25MG**	**A065040**	**001**	May 09, 2002
AB2			**100MG**	**A065040**	**002**	May 09, 2002

SANDIMMUNE

AB2	**+**	NOVARTIS	**25MG**	**N050625**	**001**	Mar 02, 1990
AB2	**+!**		**100MG**	**N050625**	**002**	Mar 02, 1990
BX	+		50MG	N050625	003	Nov 23, 1992

EMULSION;OPHTHALMIC

RESTASIS

+!	ALLERGAN	0.05%	N050790	001	Dec 23, 2002

RESTASIS MULTIDOSE

+!	ALLERGAN	0.05%	N050790	002	Oct 27, 2016

VERKAZIA

+!	SANTEN	0.1%	N214965	001	Jun 23, 2021

INJECTABLE;INJECTION

CYCLOSPORINE

AP		HIKMA	**50MG/ML**	**A065004**	**001**	Oct 29, 1999
AP		PADAGIS US	**50MG/ML**	**A065151**	**001**	Oct 07, 2003

SANDIMMUNE

AP	**+!**	NOVARTIS	**50MG/ML**	**N050573**	**001**	Nov 14, 1983

SOLUTION;OPHTHALMIC

CEQUA

+!	SUN PHARM	0.09%	N210913	001	Aug 14, 2018

SOLUTION;ORAL

CYCLOSPORINE

AB1		ABBVIE	**100MG/ML**	**A065025**	**001**	Mar 03, 2000
AB1		IVAX SUB TEVA PHARMS	**100MG/ML**	**A065078**	**001**	Mar 25, 2005
AB1		MAYNE PHARMA	**100MG/ML**	**A065054**	**001**	Dec 18, 2001

NEORAL

AB1	**+!**	NOVARTIS	**100MG/ML**	**N050716**	**001**	Jul 14, 1995

CYCLOSPORINE

AB2		WOCKHARDT BIO AG	**100MG/ML**	**A065133**	**001**	Sep 17, 2004

SANDIMMUNE

AB2	**+!**	NOVARTIS	**100MG/ML**	**N050574**	**001**	Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		ANDA REPOSITORY	**2MG/5ML**	**A204823**	**001**	Dec 27, 2016
AA		ELYSIUM	**2MG/5ML**	**A209108**	**001**	Oct 16, 2018
AA		LANNETT CO INC	**2MG/5ML**	**A203191**	**001**	Jul 13, 2017
AA	!	LYNE	**2MG/5ML**	**A040668**	**001**	Jun 28, 2006
AA		PHARM ASSOC	**2MG/5ML**	**A091295**	**001**	Mar 28, 2013
AA		QUAGEN	**2MG/5ML**	**A212423**	**001**	May 22, 2019
AA		TRIS PHARMA INC	**2MG/5ML**	**A205431**	**001**	Dec 21, 2021

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		APPCO	**4MG**	**A206553**	**001**	Nov 29, 2016
AA		BEXIMCO PHARMS USA	**4MG**	**A206676**	**001**	Apr 12, 2019
AA		BOSCOGEN	**4MG**	**A040644**	**001**	May 30, 2006
AA		ELYSIUM	**4MG**	**A207555**	**001**	Jan 31, 2017
AA	+!	HERITAGE PHARMA	**4MG**	**A087056**	**001**	
AA		MOUNTAIN	**4MG**	**A040537**	**001**	Sep 30, 2003
AA		NOVAST LABS	**4MG**	**A205087**	**001**	Sep 23, 2015
AA		QUAGEN	**4MG**	**A212491**	**001**	Feb 24, 2021
AA		RISING	**4MG**	**A207783**	**001**	Dec 29, 2016
AA		STRIDES PHARMA	**4MG**	**A209172**	**001**	Apr 11, 2018
AA		ZYDUS PHARMS	**4MG**	**A208938**	**001**	May 19, 2017

CYSTEAMINE BITARTRATE

CAPSULE;ORAL

CYSTAGON

	+	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
	+!		EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

	+	HORIZON	EQ 25MG BASE	N203389	001	Apr 30, 2013
	+!		EQ 75MG BASE	N203389	002	Apr 30, 2013

GRANULE, DELAYED RELEASE;ORAL

PROCYSBI

	+	HORIZON PHARMA USA	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020
	+!		EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYSTADROPS

	+!	RECORDATI RARE	EQ 0.37% BASE	N211302	001	Aug 19, 2020

CYSTARAN

	+!	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ELCYS

	+!	EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

AP	!	FRESENIUS KABI USA	**100MG/ML**	**A076512**	**001**	Jan 15, 2004
AP		GLAND PHARMA LTD	**100MG/VIAL**	**A211937**	**001**	Dec 23, 2019
AP			**2GM/VIAL**	**A211938**	**001**	Dec 23, 2019
AP		HIKMA	**100MG/VIAL**	**A071471**	**001**	Aug 02, 1989
AP	!	HOSPIRA	**20MG/ML**	**A071868**	**001**	Jun 04, 1990
AP	!		**20MG/ML**	**A072168**	**001**	Aug 31, 1990
AP	!		**20MG/ML**	**A072945**	**001**	Feb 28, 1994
AP			**100MG/ML**	**A075383**	**001**	Nov 22, 1999
AP		MEITHEAL	**100MG/ML**	**A205696**	**001**	Jul 17, 2018
AP		RISING PHARMA	**20MG/ML**	**A200915**	**001**	Dec 13, 2011
AP			**100MG/ML**	**A201784**	**001**	Jan 30, 2012
AP	!	WEST-WARD PHARMS INT	**2GM/VIAL**	**A074245**	**002**	Aug 31, 1994
	!	HIKMA	500MG/VIAL	A071472	001	Aug 02, 1989
	!	WEST-WARD PHARMS INT	1GM/VIAL	A074245	001	Aug 31, 1994

CYTARABINE; DAUNORUBICIN

POWDER;INTRAVENOUS

VYXEOS

	+!	CELATOR PHARMS	100MG;44MG	N209401	001	Aug 03, 2017

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

AB		ALKEM LABS LTD	**EQ 75MG BASE**	**A208040**	**001**	Mar 11, 2020
AB			**EQ 150MG BASE**	**A208040**	**002**	Mar 11, 2020
AB		HETERO LABS LTD III	**EQ 75MG BASE**	**A207961**	**001**	May 06, 2020
AB			**EQ 150MG BASE**	**A207961**	**002**	May 06, 2020

PRADAXA

AB	**+**	BOEHRINGER INGELHEIM	**EQ 75MG BASE**	**N022512**	**001**	Oct 19, 2010
AB	**+!**		**EQ 150MG BASE**	**N022512**	**002**	Oct 19, 2010
	+		EQ 110MG BASE	N022512	003	Nov 20, 2015

PELLETS;ORAL

PRADAXA

	+	BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021
	+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021
	+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021
	+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021
	+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021
	+!		EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

	+	NOVARTIS	EQ 50MG BASE	N202806	001	May 29, 2013
	+!		EQ 75MG BASE	N202806	002	May 29, 2013

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

AP	**!**	FRESENIUS KABI USA	**200MG/VIAL**	**A075371**	**002**	Aug 27, 1999
AP		HIKMA	**200MG/VIAL**	**A075812**	**001**	Jun 15, 2001
AP			**500MG/VIAL**	**A075812**	**002**	Oct 31, 2002
AP		HOSPIRA	**200MG/VIAL**	**A075940**	**001**	Oct 18, 2001
AP		TEVA PHARMS USA	**200MG/VIAL**	**A075259**	**002**	Aug 27, 1998
AP	**!**		**500MG/VIAL**	**A075259**	**001**	Sep 22, 2000
	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999

DACOMITINIB

TABLET;ORAL

VIZIMPRO

	+	PFIZER	15MG	N211288	001	Sep 27, 2018
	+		30MG	N211288	002	Sep 27, 2018
	+!		45MG	N211288	003	Sep 27, 2018

DACTINOMYCIN

INJECTABLE;INJECTION

COSMEGEN

AP	**+!**	RECORDATI RARE	**0.5MG/VIAL**	**N050682**	**001**	

DACTINOMYCIN

AP		EUGIA PHARMA	**0.5MG/VIAL**	**A203385**	**001**	Nov 09, 2017
AP		HISUN PHARM HANGZHOU	**0.5MG/VIAL**	**A207232**	**001**	Jul 16, 2019
AP		MEITHEAL	**0.5MG/VIAL**	**A213463**	**001**	Nov 13, 2020
AP		XGEN PHARMS	**0.5MG/VIAL**	**A203999**	**001**	May 20, 2019

DALBAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

DALVANCE

	+!	ALLERGAN	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	**+!**	ACORDA	**10MG**	**N022250**	**001**	Jan 22, 2010

DALFAMPRIDINE

AB		ACCORD HLTHCARE	**10MG**	**A206863**	**001**	Jul 11, 2018
AB		ACTAVIS LABS FL INC	**10MG**	**A206836**	**001**	Jan 23, 2017
AB		ALKEM LABS LTD	**10MG**	**A206765**	**001**	Jul 30, 2018
AB		AUROBINDO PHARMA LTD	**10MG**	**A206811**	**001**	Jan 23, 2017

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

DALFAMPRIDINE

AB		HIKMA	**10MG**	**A206646**	**001**	Oct 24, 2018
AB		MICRO LABS	**10MG**	**A210158**	**001**	Mar 11, 2019
AB		SUN PHARM	**10MG**	**A208292**	**001**	May 21, 2019

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE;INTRAVENOUS

SYNERCID

	+!	KING PHARMS	350MG/VIAL;150MG/VIAL	N050748	001	Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

FRAGMIN

	+	PFIZER	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994
	+		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996
	+		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002
	+		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998
	+		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007
	+		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007
	+		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007
	+!		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002

DANAZOL

CAPSULE;ORAL

DANAZOL

AB		BARR	**50MG**	**A074582**	**003**	May 29, 1998
AB			**100MG**	**A074582**	**002**	May 29, 1998
AB	**!**		**200MG**	**A074582**	**001**	Aug 09, 1996
AB		LANNETT CO INC	**50MG**	**A077246**	**002**	Apr 19, 2007
AB			**100MG**	**A077246**	**003**	Apr 19, 2007
AB			**200MG**	**A077246**	**001**	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE;ORAL

DANTRIUM

AB	**+**	PAR STERILE PRODUCTS	**25MG**	**N017443**	**001**	
AB	**+**		**50MG**	**N017443**	**003**	
AB	**+!**		**100MG**	**N017443**	**002**	

DANTROLENE SODIUM

AB		ELITE LABS INC	**25MG**	**A076686**	**001**	Oct 24, 2005
AB			**50MG**	**A076686**	**002**	Oct 24, 2005
AB			**100MG**	**A076686**	**003**	Oct 24, 2005
AB		IMPAX LABS	**25MG**	**A076856**	**001**	Mar 01, 2005
AB			**50MG**	**A076856**	**002**	Mar 01, 2005
AB			**100MG**	**A076856**	**003**	Mar 01, 2005

FOR SUSPENSION;INTRAVENOUS

RYANODEX

	+!	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014

INJECTABLE;INJECTION

DANTRIUM

AP	**+!**	PAR STERILE PRODUCTS	**20MG/VIAL**	**N018264**	**001**	

DANTROLENE SODIUM

AP		HIKMA	**20MG/VIAL**	**A204762**	**001**	Jun 19, 2017

REVONTO

AP		USWM	**20MG/VIAL**	**A078378**	**001**	Jul 24, 2007

DAPAGLIFLOZIN

TABLET;ORAL

FARXIGA

	+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014
	+!		10MG	N202293	002	Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

XIGDUO XR

	+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017
	+		5MG;500MG	N205649	001	Oct 29, 2014
	+		5MG;1GM	N205649	002	Oct 29, 2014
	+		10MG;500MG	N205649	003	Oct 29, 2014
	+!		10MG;1GM	N205649	004	Oct 29, 2014

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

QTERN

+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019
+!		10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017

DAPSONE

GEL;TOPICAL

ACZONE

AB	**+!**	ALLERGAN	**5%**	**N021794**	**001**	Jul 07, 2005
AB	**+!**	ALMIRALL	**7.5%**	**N207154**	**001**	Feb 24, 2016

DAPSONE

AB		TARO	**5%**	**A209506**	**001**	Oct 16, 2017
AB		TARO PHARMS	**7.5%**	**A210191**	**001**	Jun 26, 2019

TABLET;ORAL

DAPSONE

AB		ACTAVIS LLC	**25MG**	**A204380**	**001**	Mar 23, 2017
AB			**100MG**	**A204380**	**002**	Mar 23, 2017
AB		ALVOGEN	**25MG**	**A205429**	**001**	Jan 07, 2016
AB			**100MG**	**A205429**	**002**	Jan 07, 2016
AB	**+**	JACOBUS	**25MG**	**A086841**	**001**	
AB	**+!**		**100MG**	**A086842**	**001**	
AB		NOSTRUM LABS INC	**25MG**	**A203887**	**001**	May 06, 2016
AB			**100MG**	**A203887**	**002**	May 06, 2016
AB		NOVITIUM PHARMA	**25MG**	**A206505**	**001**	Dec 01, 2016
AB			**100MG**	**A206505**	**002**	Dec 01, 2016
AB		RISING	**100MG**	**A207165**	**001**	May 08, 2019
AB		VIRTUS PHARMS	**25MG**	**A204074**	**001**	May 10, 2016
AB			**100MG**	**A204074**	**002**	May 10, 2016

DAPTOMYCIN

POWDER;INTRAVENOUS

CUBICIN

AP	**+!**	CUBIST PHARMS LLC	**500MG/VIAL**	**N021572**	**002**	Sep 12, 2003

DAPTOMYCIN

AP		ACCORD HLTHCARE	**350MG/VIAL**	**A212667**	**001**	Jul 12, 2019
AP			**500MG/VIAL**	**A211961**	**001**	Jun 24, 2019
AP		BE PHARMS	**350MG/VIAL**	**A213425**	**001**	Aug 20, 2020
AP			**500MG/VIAL**	**A212513**	**001**	Jun 26, 2019
AP		DR REDDYS	**350MG/VIAL**	**A211403**	**001**	Aug 31, 2020
AP			**500MG/VIAL**	**A208375**	**001**	May 01, 2019
AP		EUGIA PHARMA	**500MG/VIAL**	**A213171**	**001**	Sep 02, 2021
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A206077**	**001**	Apr 11, 2018
AP		HANGZHOU ZHONGMEI	**500MG/VIAL**	**A215215**	**001**	Nov 26, 2021
AP		JIANGSU PHARMS	**500MG/VIAL**	**A212022**	**001**	Aug 22, 2019
AP		MEITHEAL	**350MG/VIAL**	**A213786**	**001**	Jun 29, 2021
AP			**500MG/VIAL**	**A213623**	**001**	Jun 29, 2021
AP		MYLAN LABS LTD	**500MG/VIAL**	**A205037**	**001**	Jun 05, 2018
AP		QILU PHARM HAINAN	**500MG/VIAL**	**A215316**	**001**	Aug 24, 2021
AP	**+!**	SAGENT PHARMS INC	**350MG/VIAL**	**N208385**	**001**	Sep 12, 2017
AP			**500MG/VIAL**	**A207104**	**001**	Nov 15, 2019
AP		TEVA PHARMS USA	**500MG/VIAL**	**A091039**	**001**	Mar 25, 2016
AP		XELLIA PHARMS APS	**500MG/VIAL**	**A206005**	**001**	Jun 15, 2016

CUBICIN RF

+!	CUBIST PHARMS LLC	500MG/VIAL	N021572	003	Jul 06, 2016

DAPTOMYCIN

+!	HOSPIRA INC	350MG/VIAL	N210282	001	Jun 21, 2021
+!		500MG/VIAL	N210282	002	Jun 21, 2021
+!	XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN

AB		MACLEODS PHARMS LTD	**EQ 7.5MG BASE**	**A207302**	**001**	Jul 28, 2017
AB	**!**		**EQ 15MG BASE**	**A207302**	**002**	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

AB		ALEMBIC PHARMS LTD	**EQ 7.5MG BASE**	**A207681**	**001**	Dec 08, 2017
AB			**EQ 15MG BASE**	**A207681**	**002**	Dec 08, 2017
AB		AUROBINDO PHARMA LTD	**EQ 7.5MG BASE**	**A206743**	**001**	Sep 19, 2016
AB			**EQ 15MG BASE**	**A206743**	**002**	Sep 19, 2016
AB		CIPLA	**EQ 7.5MG BASE**	**A207664**	**001**	Sep 01, 2016
AB			**EQ 15MG BASE**	**A207664**	**002**	Sep 01, 2016
AB		POLYGEN PHARMS	**EQ 7.5MG BASE**	**A211045**	**001**	Jan 06, 2020

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

AB			**EQ 15MG BASE**	**A211045**	**002**	Jan 06, 2020
AB		TORRENT	**EQ 7.5MG BASE**	**A205209**	**001**	Nov 17, 2016
AB			**EQ 15MG BASE**	**A205209**	**002**	Nov 17, 2016
BX		XIROMED	EQ 7.5MG BASE	A209571	002	Oct 22, 2019
BX			EQ 15MG BASE	A209571	001	Oct 22, 2019

DAROLUTAMIDE

TABLET;ORAL

NUBEQA

+!	BAYER HEALTHCARE	300MG	N212099	001	Jul 30, 2019

DARUNAVIR

SUSPENSION;ORAL

PREZISTA

+!	JANSSEN PRODS	100MG/ML	N202895	001	Dec 16, 2011

TABLET;ORAL

DARUNAVIR

AB		TEVA PHARMS USA	**600MG**	**A202118**	**001**	Nov 21, 2017

PREZISTA

AB	**+**	JANSSEN PRODS	**600MG**	**N021976**	**002**	Feb 25, 2008
	+		75MG	N021976	004	Dec 18, 2008
	+		150MG	N021976	005	Dec 18, 2008
	+!		800MG	N021976	006	Nov 09, 2012

DASATINIB

TABLET;ORAL

DASATINIB

AB		APOTEX	**80MG**	**A203180**	**001**	Nov 23, 2021
AB			**140MG**	**A203180**	**002**	Nov 23, 2021

SPRYCEL

AB	**+**	BRISTOL MYERS SQUIBB	**80MG**	**N021986**	**005**	Oct 28, 2010
AB	**+**		**140MG**	**N021986**	**006**	Oct 28, 2010
	+		20MG	N021986	001	Jun 28, 2006
	+		50MG	N021986	002	Jun 28, 2006
	+		70MG	N021986	003	Jun 28, 2006
	+!		100MG	N021986	004	May 30, 2008

DASIGLUCAGON HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ZEGALOGUE

+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021

ZEGALOGUE (AUTOINJECTOR)

+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

CERUBIDINE

AP	**!**	HIKMA	**EQ 20MG BASE/VIAL**	**A064103**	**001**	Feb 03, 1995

DAUNORUBICIN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 20MG BASE/VIAL**	**A065000**	**001**	May 25, 1999
AP	**+!**	HIKMA	**EQ 5MG BASE/ML**	**N050731**	**001**	Jan 30, 1998
AP		HISUN PHARM HANGZHOU	**EQ 5MG BASE/ML**	**A208759**	**001**	Apr 12, 2019
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A065035**	**001**	Jan 24, 2000
		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

AP	**+!**	OTSUKA	**50MG/VIAL**	**N021790**	**001**	May 02, 2006

DECITABINE

AP		ACCORD HLTHCARE	**50MG/VIAL**	**A203475**	**001**	Feb 27, 2017
AP		CHEMI SPA	**50MG/VIAL**	**A206033**	**001**	Sep 22, 2017
AP		DR REDDYS	**50MG/VIAL**	**A203131**	**001**	Jul 11, 2013
AP		EUGIA PHARMA	**50MG/VIAL**	**A214569**	**001**	Sep 20, 2021
AP		GLAND	**50MG/VIAL**	**A205539**	**001**	Nov 23, 2020
AP		INGENUS PHARMS LLC	**50MG/VIAL**	**A210984**	**001**	Sep 16, 2019
AP		LUPIN LTD	**50MG/VIAL**	**A210756**	**001**	Nov 09, 2018
AP		MEITHEAL	**50MG/VIAL**	**A212959**	**001**	Jul 02, 2021
AP		MSN	**50MG/VIAL**	**A212265**	**001**	Aug 28, 2019

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

AP		NIVAGEN PHARMS INC	**50MG/VIAL**	**A212117**	**001**	Dec 07, 2020
AP		PHARMASCIENCE INC	**50MG/VIAL**	**A204607**	**001**	May 31, 2017
AP		QILU PHARM HAINAN	**50MG/VIAL**	**A212826**	**001**	Apr 12, 2021
AP		SAGENT PHARMS INC	**50MG/VIAL**	**A207100**	**001**	Mar 16, 2018
AP		SANDOZ INC	**50MG/VIAL**	**A202969**	**001**	Aug 28, 2014
AP		WOCKHARDT BIO AG	**50MG/VIAL**	**A209056**	**001**	Apr 09, 2019
AP		ZYDUS PHARMS	**50MG/VIAL**	**A214486**	**001**	Nov 19, 2021

POWDER;INTRAVENOUS

DECITABINE

	+!	SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AB		ALKEM LABS LTD	**90MG**	**A213374**	**001**	Jul 14, 2020
AB			**180MG**	**A213374**	**002**	Jul 14, 2020
AB			**360MG**	**A213374**	**003**	Jul 14, 2020
AB		AMNEAL	**90MG**	**A214194**	**003**	Aug 02, 2021
AB			**180MG**	**A214194**	**001**	Feb 09, 2021
AB			**360MG**	**A214194**	**002**	Feb 09, 2021
AB		AUCTA	**90MG**	**A214559**	**001**	Mar 09, 2021
AB			**180MG**	**A214559**	**002**	Mar 09, 2021
AB			**360MG**	**A214559**	**003**	Mar 09, 2021
AB		MSN	**180MG**	**A214650**	**001**	Mar 17, 2021
AB			**360MG**	**A214650**	**002**	Mar 17, 2021
AB		TEVA PHARMS USA	**90MG**	**A214180**	**001**	Nov 19, 2021
AB			**180MG**	**A214180**	**002**	Nov 19, 2021
AB			**360MG**	**A214180**	**003**	Nov 19, 2021

JADENU SPRINKLE

AB	**+**	NOVARTIS	**90MG**	**N207968**	**001**	May 18, 2017
AB	**+**		**180MG**	**N207968**	**002**	May 18, 2017
AB	**+!**		**360MG**	**N207968**	**003**	May 18, 2017

TABLET;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**90MG**	**A208697**	**001**	Dec 13, 2019
AB			**180MG**	**A208697**	**002**	Dec 13, 2019
AB			**360MG**	**A208697**	**003**	Dec 13, 2019
AB		ALEMBIC PHARMS LTD	**90MG**	**A211824**	**001**	Nov 20, 2019
AB			**180MG**	**A211824**	**003**	Jun 15, 2020
AB			**360MG**	**A211824**	**002**	Nov 20, 2019
AB		ALKEM LABS LTD	**90MG**	**A210555**	**001**	Mar 30, 2020
AB			**180MG**	**A210555**	**003**	Jul 02, 2020
AB			**360MG**	**A210555**	**002**	Mar 30, 2020
AB		AMNEAL	**180MG**	**A210727**	**003**	Jun 15, 2020
AB		ANNORA PHARMA	**90MG**	**A214341**	**001**	May 14, 2021
AB			**180MG**	**A214341**	**002**	May 14, 2021
AB			**360MG**	**A214341**	**003**	May 14, 2021
AB		CELLTRION	**90MG**	**A212669**	**001**	May 27, 2021
AB			**180MG**	**A212669**	**002**	May 27, 2021
AB			**360MG**	**A212669**	**003**	May 27, 2021
AB		CIPLA	**90MG**	**A211852**	**001**	Feb 11, 2020
AB			**180MG**	**A211852**	**003**	Jun 15, 2020
AB			**360MG**	**A211852**	**002**	Feb 11, 2020
AB		MSN	**90MG**	**A210945**	**001**	Nov 20, 2019
AB			**180MG**	**A210945**	**003**	Jun 16, 2020
AB			**360MG**	**A210945**	**002**	Nov 20, 2019
AB		PIRAMAL HLTHCARE UK	**90MG**	**A212995**	**001**	Dec 30, 2019
AB			**180MG**	**A212995**	**003**	Jun 15, 2020
AB			**360MG**	**A212995**	**002**	Dec 30, 2019
AB		SUN PHARM	**90MG**	**A211641**	**001**	Jan 02, 2020
AB			**180MG**	**A211641**	**003**	Jun 15, 2020
AB			**360MG**	**A211641**	**002**	Jan 02, 2020
AB		TEVA PHARMS USA	**90MG**	**A209223**	**001**	Nov 25, 2019
AB			**180MG**	**A209223**	**003**	Apr 24, 2020
AB			**360MG**	**A209223**	**002**	Nov 25, 2019
AB		ZYDUS PHARMS	**90MG**	**A211383**	**001**	Nov 20, 2019
AB			**180MG**	**A211383**	**003**	Jun 15, 2020
AB			**360MG**	**A211383**	**002**	Nov 20, 2019

DEFERASIROX

TABLET;ORAL

JADENU

AB	**+**	NOVARTIS PHARMS CORP	**90MG**	**N206910**	**001**	Mar 30, 2015
AB	**+**		**180MG**	**N206910**	**002**	Mar 30, 2015
AB	**+!**		**360MG**	**N206910**	**003**	Mar 30, 2015

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

AB		ACTAVIS ELIZABETH	**125MG**	**A203560**	**001**	Jan 26, 2016
AB			**250MG**	**A203560**	**002**	Jan 26, 2016
AB			**500MG**	**A203560**	**003**	Jan 26, 2016
AB		ALEMBIC PHARMS LTD	**125MG**	**A210060**	**001**	Nov 20, 2019
AB			**250MG**	**A210060**	**002**	Nov 20, 2019
AB			**500MG**	**A210060**	**003**	Nov 20, 2019
AB		ALKEM LABS LTD	**125MG**	**A210519**	**001**	Nov 20, 2019
AB			**250MG**	**A210519**	**002**	Nov 20, 2019
AB			**500MG**	**A210519**	**003**	Nov 20, 2019
AB		BIONPHARMA INC	**125MG**	**A210920**	**001**	Nov 20, 2019
AB			**250MG**	**A210920**	**002**	Nov 20, 2019
AB			**500MG**	**A210920**	**003**	Nov 20, 2019
AB		ICHNOS	**125MG**	**A209433**	**001**	Jan 06, 2020
AB			**250MG**	**A209433**	**002**	Jan 06, 2020
AB			**500MG**	**A209433**	**003**	Jan 06, 2020
AB		MSN	**125MG**	**A209878**	**001**	Nov 20, 2019
AB			**250MG**	**A209878**	**002**	Nov 20, 2019
AB			**500MG**	**A209878**	**003**	Nov 20, 2019
AB		SUN PHARM	**125MG**	**A209782**	**001**	Nov 20, 2019
AB			**250MG**	**A209782**	**002**	Nov 20, 2019
AB			**500MG**	**A209782**	**003**	Nov 20, 2019

EXJADE

AB	**+**	NOVARTIS	**125MG**	**N021882**	**001**	Nov 02, 2005
AB	**+**		**250MG**	**N021882**	**002**	Nov 02, 2005
AB	**+!**		**500MG**	**N021882**	**003**	Nov 02, 2005

DEFERIPRONE

SOLUTION;ORAL

FERRIPROX

	+!	CHIESI	100MG/ML	N208030	001	Sep 09, 2015

TABLET;ORAL

DEFERIPRONE

AB		HIKMA	**500MG**	**A213239**	**001**	Mar 29, 2021
AB		TARO PHARM INDS LTD	**500MG**	**A208800**	**001**	Feb 08, 2019

FERRIPROX

AB	**+!**	CHIESI	**500MG**	**N021825**	**001**	Oct 14, 2011
	+		1GM	N021825	002	Jul 25, 2019
	+!		1GM	N212269	001	May 19, 2020

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

AP		FRESENIUS KABI USA	**500MG/VIAL**	**A078718**	**001**	Sep 15, 2009
AP			**2GM/VIAL**	**A078718**	**002**	Sep 15, 2009
AP		GLAND PHARMA LTD	**500MG/VIAL**	**A207384**	**001**	Sep 29, 2017
AP			**2GM/VIAL**	**A207384**	**002**	Sep 29, 2017
AP		HOSPIRA	**500MG/VIAL**	**A076019**	**001**	Mar 17, 2004
AP	**!**		**2GM/VIAL**	**A076019**	**002**	Mar 17, 2004
AP		WEST-WARD PHARMS INT	**500MG/VIAL**	**A078086**	**001**	May 30, 2007
AP			**2GM/VIAL**	**A078086**	**002**	May 30, 2007

DESFERAL

AP	**+!**	NOVARTIS	**500MG/VIAL**	**N016267**	**001**	

DEFIBROTIDE SODIUM

SOLUTION;INTRAVENOUS

DEFITELIO

	+!	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016

DEFLAZACORT

SUSPENSION;ORAL

EMFLAZA

	+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017

DEFLAZACORT

TABLET;ORAL

EMFLAZA

+	PTC THERAP	6MG	N208684	001	Feb 09, 2017
+		18MG	N208684	002	Feb 09, 2017
+		30MG	N208684	003	Feb 09, 2017
+!		36MG	N208684	004	Feb 09, 2017

DEGARELIX ACETATE

POWDER;SUBCUTANEOUS

FIRMAGON

+	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
+!		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER;INTRAVENOUS

BAXDELA

+!	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017

TABLET;ORAL

BAXDELA

+!	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB		AKORN	**150MG**	**A065389**	**001**	Dec 01, 2008
AB			**300MG**	**A065389**	**002**	Dec 01, 2008
AB		AMNEAL PHARM	**150MG**	**A065425**	**001**	Feb 27, 2008
AB	**!**		**300MG**	**A065425**	**002**	Feb 27, 2008
AB		EPIC PHARMA LLC	**150MG**	**A065447**	**001**	Aug 18, 2015
AB			**300MG**	**A065447**	**002**	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS

DEOXYCHOLIC ACID

AP		SLAYBACK PHARMA LLC	**20MG/2ML (10MG/ML)**	**A212296**	**001**	Apr 02, 2021

KYBELLA

AP	**+!**	KYTHERA BIOPHARMS	**20MG/2ML (10MG/ML)**	**N206333**	**001**	Apr 29, 2015

DESFLURANE

LIQUID;INHALATION

DESFLURANE

AN		SHANGHAI HENGRUI	**100%**	**A208234**	**001**	Feb 26, 2018

SUPRANE

AN	**+!**	BAXTER HLTHCARE	**100%**	**N020118**	**001**	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB		ACTAVIS TOTOWA	**10MG**	**A074430**	**001**	Feb 09, 1996
AB			**25MG**	**A071601**	**001**	Jun 05, 1987
AB			**50MG**	**A071588**	**001**	Jun 05, 1987
AB			**75MG**	**A071602**	**001**	Oct 05, 1987
AB			**100MG**	**A071766**	**001**	Oct 05, 1987
AB			**150MG**	**A074430**	**002**	Feb 09, 1996
AB		ALEMBIC PHARMS LTD	**10MG**	**A209785**	**001**	Jul 07, 2021
AB			**25MG**	**A209785**	**002**	Jul 07, 2021
AB			**50MG**	**A209785**	**003**	Jul 07, 2021
AB			**75MG**	**A209785**	**004**	Jul 07, 2021
AB			**100MG**	**A209785**	**005**	Jul 07, 2021
AB			**150MG**	**A209785**	**006**	Jul 07, 2021
AB		AMNEAL PHARMS CO	**10MG**	**A208105**	**001**	Mar 17, 2016
AB			**25MG**	**A208105**	**002**	Mar 17, 2016
AB			**50MG**	**A208105**	**003**	Mar 17, 2016
AB			**75MG**	**A208105**	**004**	Mar 17, 2016
AB			**100MG**	**A208105**	**005**	Mar 17, 2016
AB			**150MG**	**A208105**	**006**	Mar 17, 2016
AB		HERITAGE PHARMS INC	**10MG**	**A207433**	**001**	May 05, 2016
AB			**25MG**	**A207433**	**002**	May 05, 2016
AB			**50MG**	**A207433**	**003**	May 05, 2016
AB			**75MG**	**A207433**	**004**	May 05, 2016
AB			**100MG**	**A207433**	**005**	May 05, 2016
AB			**150MG**	**A207433**	**006**	May 05, 2016
AB		NOVAST LABS	**10MG**	**A204963**	**001**	Dec 26, 2017
AB			**25MG**	**A204963**	**002**	Dec 26, 2017

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB			**50MG**	**A204963**	**003**	Dec 26, 2017
AB			**75MG**	**A204963**	**004**	Dec 26, 2017
AB			**100MG**	**A204963**	**005**	Dec 26, 2017
AB			**150MG**	**A204963**	**006**	Dec 26, 2017
AB		SANDOZ	**10MG**	**A072099**	**001**	May 24, 1988
AB			**25MG**	**A072100**	**001**	May 24, 1988
AB			**50MG**	**A072101**	**001**	May 24, 1988
AB			**75MG**	**A072102**	**001**	Jun 20, 1988
AB			**100MG**	**A072103**	**001**	Jun 20, 1988
AB			**150MG**	**A072104**	**001**	Jun 20, 1988

NORPRAMIN

AB	**+**	VALIDUS PHARMS	**10MG**	**N014399**	**007**	Feb 11, 1982
AB	**+**		**25MG**	**N014399**	**001**	
AB	**+**		**50MG**	**N014399**	**003**	
AB	**+**		**75MG**	**N014399**	**004**	
AB	**+!**		**100MG**	**N014399**	**005**	
AB	**+**		**150MG**	**N014399**	**006**	

DESLORATADINE

TABLET;ORAL

CLARINEX

AB	**+!**	ORGANON	**5MG**	**N021165**	**001**	Dec 21, 2001

DESLORATADINE

AB		BELCHER PHARMS	**5MG**	**A078355**	**001**	Apr 19, 2012
AB		DR REDDYS LABS LTD	**5MG**	**A078365**	**001**	Mar 08, 2011
AB		LUPIN PHARMS	**5MG**	**A078352**	**001**	Oct 25, 2010
AB		ORBION PHARMS	**5MG**	**A078357**	**001**	Feb 19, 2010
AB		PERRIGO	**5MG**	**A078361**	**001**	Dec 22, 2011
AB		SANDOZ	**5MG**	**A078364**	**001**	Dec 03, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

DESLORATADINE

	REDDYS	2.5MG	A078367	001	Jul 12, 2010
!		5MG	A078367	002	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARINEX-D 12 HOUR

+!	ORGANON	2.5MG;120MG	N021313	001	Feb 01, 2006

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

!	DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION

DDAVP

AP	**+!**	FERRING PHARMS INC	**0.004MG/ML**	**N018938**	**001**	Mar 30, 1984

DESMOPRESSIN ACETATE

AP		AM REGENT	**0.004MG/ML**	**A091374**	**001**	Feb 14, 2019
AP		SAGENT PHARMS INC	**0.004MG/ML**	**A204695**	**001**	Aug 22, 2017
AP			**0.004MG/ML**	**A204751**	**001**	Aug 22, 2017
AP		SUN PHARM INDS LTD	**0.004MG/ML**	**A091280**	**001**	Jan 25, 2013
AP		TEVA PHARMS USA	**0.004MG/ML**	**A074888**	**001**	Oct 15, 1997
AP		UBI	**0.004MG/ML**	**A210218**	**001**	Feb 14, 2020
AP			**0.004MG/ML**	**A210223**	**001**	Sep 17, 2020

SPRAY, METERED;NASAL

DESMOPRESSIN ACETATE

AB	**!**	BAUSCH AND LOMB	**0.01MG/SPRAY**	**A074830**	**001**	Jan 25, 1999

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

AB		APOTEX INC	**0.01MG/SPRAY**	**A076703**	**001**	Jan 27, 2005
AB	**!**	SUN PHARM	**0.01MG/SPRAY**	**A078271**	**001**	Dec 23, 2013
AB		ZYDUS PHARMS	**0.01MG/SPRAY**	**A091345**	**001**	Oct 03, 2017

TABLET;ORAL

DDAVP

AB	**+**	FERRING PHARMS INC	**0.1MG**	**N019955**	**001**	Sep 06, 1995
AB	**+!**		**0.2MG**	**N019955**	**002**	Sep 06, 1995

DESMOPRESSIN ACETATE

AB		ABHAI LLC	**0.1MG**	**A210371**	**001**	Jan 28, 2019
AB			**0.2MG**	**A210371**	**002**	Jan 28, 2019
AB		ACTAVIS LABS FL INC	**0.1MG**	**A076470**	**001**	Jul 01, 2005
AB			**0.2MG**	**A076470**	**002**	Jul 01, 2005
AB		APOTEX INC	**0.1MG**	**A077414**	**001**	Mar 07, 2006
AB			**0.2MG**	**A077414**	**002**	Mar 07, 2006

DESMOPRESSIN ACETATE

TABLET;ORAL

DESMOPRESSIN ACETATE

AB		GLENMARK PHARMS LTD	**0.1MG**	**A201831**	**001**	May 28, 2015
AB			**0.2MG**	**A201831**	**002**	May 28, 2015
AB		HERITAGE PHARMA	**0.1MG**	**A207880**	**001**	May 26, 2017
AB			**0.2MG**	**A207880**	**002**	May 26, 2017
AB		NOVAST LABS	**0.1MG**	**A208357**	**001**	Jun 06, 2019
AB			**0.2MG**	**A208357**	**002**	Jun 06, 2019

TABLET;SUBLINGUAL

NOCDURNA

	+	FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018
	+!		0.0553MG	N022517	002	Jun 21, 2018

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

BEKYREE

AB		LUPIN LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202226**	**001**	Aug 12, 2015

CYCLESSA

AB	**+!**	ASPEN GLOBAL INC	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**N021090**	**001**	Dec 20, 2000

DESOGESTREL AND ETHINYL ESTRADIOL

AB	**!**	DURAMED PHARMS BARR	**0.15MG;0.03MG**	**A075256**	**002**	Aug 12, 1999
AB		MAYNE PHARMA	**0.15MG,N/A;0.02MG,0.01MG**	**A076916**	**001**	Dec 29, 2008
AB			**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A077182**	**001**	Jan 24, 2006
AB		MYLAN LABS LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A202296**	**001**	Aug 30, 2013
AB		NAARI PTE LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A209170**	**001**	Jun 05, 2017
AB		NOVAST LABS	**0.15MG;0.03MG**	**A091234**	**001**	Jul 12, 2013
AB		WATSON LABS	**0.15MG;0.03MG**	**A076915**	**001**	Jul 29, 2005

ENSKYCE

AB		LUPIN LTD	**0.15MG;0.03MG**	**A201887**	**001**	Mar 07, 2013

ISIBLOOM

AB		XIROMED	**0.15MG;0.03MG**	**A202789**	**001**	Aug 12, 2015

KALLIGA

AB		AUROBINDO PHARMA LTD	**0.15MG;0.03MG**	**A207081**	**001**	May 17, 2017

KARIVA

AB	**!**	BARR	**0.15MG,N/A;0.02MG,0.01MG**	**A075863**	**001**	Apr 05, 2002

KIMIDESS

AB		VINTAGE PHARMS	**0.15MG,N/A;0.02MG,0.01MG**	**A076681**	**001**	Apr 30, 2015

PIMTREA

AB		NOVAST LABS	**0.15MG,N/A;0.02MG,0.01MG**	**A091247**	**001**	Aug 01, 2013

SIMLIYA

AB		AUROBINDO PHARMA LTD	**0.15MG,N/A;0.02MG,0.01MG**	**A206853**	**001**	Mar 22, 2017

VELIVET

AB		DURAMED PHARMS BARR	**0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG**	**A076455**	**001**	Feb 24, 2004

VIORELE

AB		GLENMARK GENERICS	**0.15MG,N/A;0.02MG,0.01MG**	**A091346**	**001**	Apr 02, 2012

VOLNEA

AB		XIROMED	**0.15MG,N/A;0.02MG,0.01MG**	**A202689**	**001**	Sep 09, 2016

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

	+!	ALMIRALL	0.05%	N021978	001	Sep 19, 2006

CREAM;TOPICAL

DESONIDE

AB		CADILA	**0.05%**	**A210198**	**001**	Nov 20, 2019
AB		COSETTE	**0.05%**	**A074027**	**001**	Sep 28, 1992
AB		GLENMARK PHARMS	**0.05%**	**A209729**	**001**	Jul 24, 2017
AB	**+!**	PADAGIS US	**0.05%**	**N017010**	**001**	
AB		TARO	**0.05%**	**A073548**	**001**	Jun 30, 1992

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**N019048**	**001**	Dec 14, 1984

GEL;TOPICAL

DESONIDE

	!	CINTEX SVCS	0.05%	A202470	001	May 11, 2020

LOTION;TOPICAL

DESONIDE

AB		ALEOR DERMACEUTICALS	**0.05%**	**A213632**	**001**	Aug 24, 2020
AB		FOUGERA PHARMS	**0.05%**	**A075860**	**001**	Mar 19, 2002

DESONIDE

LOTION;TOPICAL

DESONIDE

AB		GLENMARK PHARMS	**0.05%**	**A209494**	**001**	Sep 26, 2017
AB		TARO	**0.05%**	**A202161**	**001**	Oct 31, 2014
AB		TELIGENT	**0.05%**	**A207855**	**001**	Sep 28, 2017

DESOWEN

AB	**!**	GALDERMA LABS LP	**0.05%**	**A072354**	**001**	Jan 24, 1992

OINTMENT;TOPICAL

DESONIDE

AB		AKORN	**0.05%**	**A208836**	**001**	Mar 27, 2017
AB		ALEOR DERMACEUTICALS	**0.05%**	**A212473**	**001**	Oct 23, 2019
AB		ENCUBE ETHICALS	**0.05%**	**A210998**	**001**	Jan 30, 2019
AB		FOUGERA PHARMS	**0.05%**	**A075751**	**001**	Mar 12, 2001
AB		GLENMARK PHARMS LTD	**0.05%**	**A209996**	**001**	Sep 15, 2017
AB	**+!**	PADAGIS US	**0.05%**	**N017426**	**001**	
AB		TARO	**0.05%**	**A074254**	**001**	Aug 03, 1994
AB		TELIGENT	**0.05%**	**A212002**	**001**	Mar 12, 2019

DESOWEN

AB		GALDERMA LABS LP	**0.05%**	**A071425**	**001**	Jun 15, 1988

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A205082**	**001**	Sep 04, 2015
AB		CADILA	**0.25%**	**A205620**	**001**	Sep 28, 2018
AB		COSETTE	**0.25%**	**A209595**	**001**	Mar 04, 2020
AB		FOUGERA PHARMS	**0.25%**	**A078369**	**001**	Jun 29, 2010
AB		LUPIN	**0.05%**	**A208163**	**001**	Jan 10, 2017
AB			**0.25%**	**A208164**	**001**	Jan 09, 2017
AB		PADAGIS ISRAEL	**0.25%**	**A076510**	**001**	Jul 01, 2003
AB		RISING	**0.05%**	**A210980**	**001**	Dec 21, 2018
AB			**0.25%**	**A205594**	**001**	Jul 02, 2018

TOPICORT

AB	**!**	TARO PHARM INDS LTD	**0.05%**	**A073210**	**001**	Nov 30, 1990
AB	**!**		**0.25%**	**A073193**	**001**	Nov 30, 1990

GEL;TOPICAL

DESOXIMETASONE

AB		AKORN	**0.05%**	**A090727**	**001**	Mar 10, 2011
AB		PADAGIS US	**0.05%**	**A077552**	**001**	Jan 09, 2006
AB		RISING	**0.05%**	**A204675**	**001**	Aug 12, 2016

TOPICORT

AB	**!**	TARO PHARM INDS LTD	**0.05%**	**A074904**	**001**	Jul 14, 1998

OINTMENT;TOPICAL

DESOXIMETASONE

AB		ACTAVIS MID ATLANTIC	**0.25%**	**A204965**	**001**	Nov 07, 2016
AB		AKORN	**0.25%**	**A201005**	**001**	Apr 24, 2014
AB		CADILA	**0.25%**	**A205206**	**001**	Sep 19, 2017
AB		COSETTE	**0.25%**	**A206740**	**001**	Dec 23, 2016
AB		FOUGERA PHARMS	**0.25%**	**A078657**	**001**	Sep 28, 2012
AB	**!**	GLENMARK GENERICS	**0.25%**	**A202838**	**001**	Sep 20, 2013
AB		LUPIN	**0.05%**	**A208044**	**001**	Dec 12, 2016
AB			**0.25%**	**A208104**	**001**	Dec 01, 2016
AB		NOVEL LABS INC	**0.25%**	**A206792**	**001**	May 10, 2016
AB		PADAGIS ISRAEL	**0.25%**	**A077770**	**001**	Apr 20, 2015
AB		RISING	**0.25%**	**A204272**	**001**	Nov 30, 2016
AB		TELIGENT	**0.05%**	**A209973**	**001**	Oct 23, 2018
AB			**0.25%**	**A208101**	**001**	Feb 25, 2016

TOPICORT

AB	**+!**	TARO PHARM INDS LTD	**0.05%**	**N018594**	**001**	Jan 17, 1985

SPRAY;TOPICAL

DESOXIMETASONE

AT		LUPIN	**0.25%**	**A208124**	**001**	Mar 16, 2018
AT		PADAGIS ISRAEL	**0.25%**	**A206441**	**001**	Jan 20, 2017

TOPICORT

AT	**+!**	TARO PHARMS	**0.25%**	**N204141**	**001**	Apr 11, 2013

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

	+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
	+!		100MG	N204150	002	Mar 04, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		ACTAVIS LABS FL	**EQ 25MG BASE**	**A204065**	**001**	Jul 29, 2016
AB			**EQ 50MG BASE**	**A204065**	**002**	Jul 29, 2016
AB			**EQ 100MG BASE**	**A204065**	**003**	Jul 29, 2016
AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A204003**	**003**	Sep 14, 2018
AB			**EQ 50MG BASE**	**A204003**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204003**	**002**	Jun 29, 2015
AB		HIKMA	**EQ 25MG BASE**	**A204082**	**002**	Aug 28, 2017
AB			**EQ 50MG BASE**	**A204082**	**001**	Feb 16, 2016
AB			**EQ 100MG BASE**	**A204083**	**001**	Feb 16, 2016
AB		INTELLIPHARMACEUTICS	**EQ 50MG BASE**	**A204805**	**001**	May 07, 2019
AB			**EQ 100MG BASE**	**A204805**	**002**	May 07, 2019
AB		LUPIN LTD	**EQ 50MG BASE**	**A204172**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204172**	**002**	Jun 29, 2015
AB		RUBICON	**EQ 50MG BASE**	**A204028**	**001**	Jun 29, 2015
AB			**EQ 100MG BASE**	**A204028**	**002**	Jun 29, 2015
AB		YICHANG HUMANWELL	**EQ 25MG BASE**	**A210014**	**003**	Oct 13, 2020
AB			**EQ 50MG BASE**	**A210014**	**001**	Oct 01, 2018
AB			**EQ 100MG BASE**	**A210014**	**002**	Oct 01, 2018
AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A204020**	**001**	Oct 11, 2017
AB			**EQ 100MG BASE**	**A204020**	**002**	Oct 11, 2017

PRISTIQ

AB	**+**	PF PRISM CV	**EQ 25MG BASE**	**N021992**	**003**	Aug 20, 2014
AB	**+**		**EQ 50MG BASE**	**N021992**	**001**	Feb 29, 2008
AB	**+!**		**EQ 100MG BASE**	**N021992**	**002**	Feb 29, 2008

DEUTETRABENAZINE

TABLET;ORAL

AUSTEDO

	+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
	+		9MG	N208082	002	Apr 03, 2017
	+!		12MG	N208082	003	Apr 03, 2017

DEXAMETHASONE

CONCENTRATE;ORAL

DEXAMETHASONE INTENSOL

	!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR;ORAL

DEXAMETHASONE

AA	**!**	ANIMA	**0.5MG/5ML**	**A084754**	**001**	
AA		LANNETT CO INC	**0.5MG/5ML**	**A091188**	**001**	May 11, 2011
AA		LYNE	**0.5MG/5ML**	**A090891**	**001**	Jul 12, 2011

IMPLANT;INTRAVITREAL

OZURDEX

	+!	ALLERGAN	0.7MG	N022315	001	Jun 17, 2009

INSERT;OPHTHALMIC

DEXTENZA

	+!	OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018

SOLUTION;ORAL

DEXAMETHASONE

	!	HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983

SUSPENSION;INTRAOCULAR

DEXYCU KIT

	+!	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

	+!	NOVARTIS	0.1%	N013422	001	

TABLET;ORAL

DEXAMETHASONE

AB		AMNEAL	**4MG**	**A215106**	**001**	Oct 14, 2021
AB			**6MG**	**A215106**	**002**	Oct 14, 2021
AB	**+**	HIKMA	**1.5MG**	**A084610**	**001**	
AB	**+**		**4MG**	**A084612**	**001**	
AB	**+!**		**6MG**	**A088316**	**001**	Sep 15, 1983
AB		LARKEN LABS INC	**1.5MG**	**A201270**	**001**	Jul 17, 2017

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

BP		ALVOGEN	0.5MG	A088481	002	Apr 28, 1983
BP			0.75MG	A088481	003	Apr 28, 1983
BP			4MG	A088481	004	Apr 28, 1983
BP			6MG	A088481	001	Nov 28, 1983
BP		HIKMA	0.5MG	A084611	001	
BP	+		0.75MG	A084613	001	
BP	+!		1MG	A088306	001	Sep 15, 1983
BP	+!		2MG	A087916	001	Aug 26, 1982
BP		XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983

HEMADY

	+!	DEXCEL PHARMA	20MG	N211379	001	Oct 03, 2019

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP		AMNEAL	**EQ 4MG PHOSPHATE/ML**	**A208689**	**001**	Aug 22, 2018
AP		EUGIA PHARMA	**EQ 4MG PHOSPHATE/ML**	**A206781**	**001**	Dec 01, 2015
AP			**EQ 10MG PHOSPHATE/ML**	**A210966**	**001**	Jun 05, 2020
AP			**EQ 10MG PHOSPHATE/ML**	**A210967**	**001**	Jun 07, 2019
AP	**!**	FRESENIUS KABI USA	**EQ 4MG PHOSPHATE/ML**	**A084916**	**001**	
AP			**EQ 4MG PHOSPHATE/ML**	**A203129**	**001**	Sep 30, 2015
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A040572**	**001**	Apr 22, 2005
AP			**EQ 10MG PHOSPHATE/ML**	**A209192**	**001**	Jul 06, 2018
AP		GLAND PHARMA LTD	**EQ 4MG PHOSPHATE/ML**	**A215654**	**001**	Aug 04, 2021
AP		MYLAN LABS LTD	**EQ 4MG PHOSPHATE/ML**	**A040803**	**001**	Aug 29, 2008
AP			**EQ 10MG PHOSPHATE/ML**	**A040802**	**001**	Aug 29, 2008
AP		SOMERSET	**EQ 4MG PHOSPHATE/ML**	**A207521**	**001**	Jun 08, 2018
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A211036**	**001**	May 10, 2019
AP		WEST-WARD PHARMS INT	**EQ 4MG PHOSPHATE/ML**	**A084282**	**001**	
AP	**!**		**EQ 10MG PHOSPHATE/ML**	**A087702**	**001**	Sep 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP		AMNEAL	**EQ 10MG PHOSPHATE/ML**	**A208690**	**001**	Aug 22, 2018
AP	**!**	FRESENIUS KABI USA	**EQ 10MG PHOSPHATE/ML**	**A040491**	**001**	Apr 11, 2003
AP		SOMERSET THERAPS LLC	**EQ 10MG PHOSPHATE/ML**	**A207442**	**001**	Apr 19, 2018

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

	!	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	**+!**	NOVARTIS	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**N050065**	**002**	

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A064063**	**001**	Jul 25, 1994
AT		PADAGIS US	**0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM**	**A062938**	**001**	Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064135**	**001**	Sep 13, 1995

MAXITROL

AT	**+!**	NOVARTIS	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N050023**	**002**	
AT		SANDOZ INC	**0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062341**	**001**	May 22, 1984

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

	+!	NOVARTIS	0.1%;0.3%	N050616	001	Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	**+!**	NOVARTIS	**0.1%;0.3%**	**N050592**	**001**	Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

AB		AMNEAL	**0.1%;0.3%**	**A212991**	**001**	Jul 15, 2021
AB		BAUSCH AND LOMB	**0.1%;0.3%**	**A064134**	**001**	Oct 27, 1999

TOBRADEX ST

	+!	EYEVANCE	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	**+!**	WOCKHARDT BIO AG	**2MG/5ML**	**A088251**	**001**	Mar 23, 1984

POLMON

AA		CAPELLON PHARMS LLC	**2MG/5ML**	**A202520**	**001**	Jul 16, 2018

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	**+!**	TAKEDA PHARMS USA	**60MG**	**N022287**	**002**	Jan 30, 2009

DEXLANSOPRAZOLE

AB		PAR PHARM INC	**60MG**	**A202294**	**001**	Apr 19, 2017

DEXILANT

	+	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204023**	**001**	Feb 09, 2016
AP		ACTAVIS INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204686**	**001**	Oct 17, 2016
AP		AKORN	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202585**	**001**	Nov 24, 2014
AP		AMNEAL PHARMS CO	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A207551**	**001**	May 20, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A207551**	**002**	May 20, 2020
AP		BAXTER HLTHCARE CORP	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208532**	**001**	Aug 21, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208532**	**002**	Aug 21, 2018
AP		EUGIA PHARMA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205867**	**001**	Mar 17, 2016
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A210321**	**001**	Dec 07, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A210321**	**002**	Dec 07, 2020
AP		FRESENIUS KABI USA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A208129**	**001**	Nov 29, 2018
AP			**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A201072**	**001**	Sep 18, 2015
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208129**	**002**	Nov 29, 2018
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208129**	**003**	Nov 29, 2018
AP		GLAND	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202126**	**001**	Aug 20, 2015
AP		GLAND PHARMA LTD	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A209307**	**001**	Jun 03, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A209307**	**002**	Jun 03, 2020
AP		HIKMA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205046**	**001**	Apr 26, 2017
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A206407**	**001**	Jan 30, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A206407**	**002**	Jan 30, 2020
AP		HONG KONG	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A204843**	**001**	Jan 18, 2019
AP		JIANGSU PHARMS	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A209065**	**002**	Jun 12, 2020
AP			**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A209065**	**001**	Sep 19, 2017
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A209065**	**003**	Jun 12, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A209065**	**004**	Jun 12, 2020
AP		MYLAN INSTITUTIONAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A202881**	**001**	Aug 18, 2014
AP		MYLAN LABS LTD	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212571**	**001**	Aug 27, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212571**	**002**	Aug 27, 2020
AP		PAR STERILE PRODUCTS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A203972**	**001**	Aug 18, 2014
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A208266**	**001**	Sep 15, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A208266**	**002**	Sep 15, 2020
AP		PIRAMAL CRITICAL	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A214794**	**001**	Sep 03, 2021
AP		SANDOZ INC	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A091465**	**001**	Jun 14, 2016
AP		SLAYBACK PHARMA LLC	**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212791**	**001**	Dec 04, 2019
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212791**	**002**	Dec 04, 2019
AP		TAGI	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**A212857**	**001**	Nov 23, 2020
AP			**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**A212857**	**002**	Nov 23, 2020
AP			**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**A212857**	**003**	Nov 23, 2020
AP		TEVA PHARMS USA	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A205272**	**001**	Nov 28, 2017
AP		ZYDUS PHARMS	**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**A206798**	**001**	Feb 27, 2018

PRECEDEX

AP	**+!**	HOSPIRA	**EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)**	**N021038**	**004**	Nov 14, 2014
AP	**+!**		**EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)**	**N021038**	**001**	Dec 17, 1999
AP	**+!**		**EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)**	**N021038**	**002**	Mar 13, 2013
AP	**+!**		**EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)**	**N021038**	**003**	Mar 13, 2013
	+!		EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

	+!	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015
	+		EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018
	+		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015
	+		EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ADARE PHARMS INC	5MG	A210279	001	Oct 09, 2018
AB			10MG	A210279	002	Oct 09, 2018
AB			15MG	A210279	003	Oct 09, 2018
AB			20MG	A210279	004	Oct 09, 2018
AB			25MG	A210279	005	Oct 09, 2018
AB			30MG	A210279	006	Oct 09, 2018
AB			35MG	A210279	007	Oct 09, 2018
AB			40MG	A210279	008	Oct 09, 2018
AB		ASCENT PHARMS INC	5MG	A215523	001	Dec 08, 2021
AB			10MG	A215523	002	Dec 08, 2021
AB			15MG	A215523	003	Dec 08, 2021
AB			20MG	A215523	004	Dec 08, 2021
AB			25MG	A215523	005	Dec 08, 2021
AB			30MG	A215523	006	Dec 08, 2021
AB			35MG	A215523	007	Dec 08, 2021
AB			40MG	A215523	008	Dec 08, 2021
AB		GRANULES	5MG	A213813	001	Sep 09, 2020
AB			10MG	A213813	002	Sep 09, 2020
AB			15MG	A213813	003	Sep 09, 2020
AB			20MG	A213813	004	Sep 09, 2020
AB			25MG	A213813	005	Sep 09, 2020
AB			30MG	A213813	006	Sep 09, 2020
AB			35MG	A213813	007	Sep 09, 2020
AB			40MG	A213813	008	Sep 09, 2020
AB		IMPAX LABS INC	5MG	A079108	001	Aug 05, 2015
AB			10MG	A079108	002	Aug 05, 2015
AB			15MG	A079108	003	May 19, 2014
AB			20MG	A079108	004	Dec 21, 2015
AB			25MG	A203614	001	Jul 05, 2017
AB			30MG	A079108	005	Nov 21, 2013
AB			35MG	A203614	002	Jul 05, 2017
AB		INTELLIPHARMACEUTICS	5MG	A078992	001	Nov 23, 2021
AB			10MG	A078992	002	Nov 23, 2021
AB			15MG	A078992	003	Nov 18, 2013
AB			30MG	A078992	004	Nov 18, 2013
AB			20MG	A078992	005	Nov 23, 2021
AB			40MG	A078992	006	Nov 23, 2021
AB		PAR PHARM INC	5MG	A202842	001	Nov 30, 2016
AB			10MG	A202842	002	Nov 30, 2016
AB			15MG	A202842	003	Nov 30, 2016
AB			20MG	A202842	004	Nov 30, 2016
AB			25MG	A202842	005	Nov 30, 2016
AB			30MG	A202842	006	Nov 30, 2016
AB			35MG	A202842	007	Nov 30, 2016
AB			40MG	A202842	008	Nov 30, 2016
AB		SUN PHARM INDS INC	5MG	A206734	001	Nov 05, 2021
AB			10MG	A206734	002	Nov 05, 2021
AB			15MG	A206734	003	Nov 05, 2021
AB			20MG	A206734	004	Nov 05, 2021
AB			25MG	A206734	005	Nov 05, 2021
AB			30MG	A206734	006	Nov 05, 2021
AB			35MG	A206734	007	Nov 05, 2021
AB			40MG	A206734	008	Nov 05, 2021
AB		TEVA PHARMS USA	5MG	A078908	001	Nov 19, 2013
AB			10MG	A078908	002	Nov 19, 2013
AB			15MG	A078908	004	May 19, 2014
AB			20MG	A078908	003	Nov 19, 2013
AB			25MG	A202731	001	Jul 05, 2017
AB			30MG	A202731	003	May 19, 2014
AB			35MG	A202731	004	Jul 05, 2017
AB			40MG	A202731	002	Nov 19, 2013

FOCALIN XR

AB	+	NOVARTIS	5MG	N021802	001	May 26, 2005
AB	+		10MG	N021802	002	May 26, 2005
AB	+		15MG	N021802	004	Aug 01, 2006
AB	+		20MG	N021802	003	May 26, 2005
AB	+		25MG	N021802	008	Apr 21, 2011
AB	+		30MG	N021802	005	Oct 23, 2009
AB	+		35MG	N021802	007	Apr 21, 2011

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FOCALIN XR

AB	**+!**		**40MG**	**N021802**	**006**	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI INC	**2.5MG**	**A206931**	**001**	Dec 04, 2015
AB			**5MG**	**A206931**	**002**	Dec 04, 2015
AB			**10MG**	**A206931**	**003**	Dec 04, 2015
AB		ALKEM LABS LTD	**2.5MG**	**A212631**	**001**	Jul 19, 2019
AB			**5MG**	**A212631**	**002**	Jul 19, 2019
AB			**10MG**	**A212631**	**003**	Jul 19, 2019
AB		CEDIPROF INC	**5MG**	**A209211**	**001**	Sep 19, 2018
AB			**10MG**	**A209211**	**002**	Sep 19, 2018
AB		NOVEL LABS INC	**2.5MG**	**A204534**	**001**	Dec 04, 2015
AB			**5MG**	**A204534**	**002**	Dec 04, 2015
AB			**10MG**	**A204534**	**003**	Dec 04, 2015
AB		RHODES PHARMS	**2.5MG**	**A208756**	**001**	Nov 20, 2017
AB			**5MG**	**A208756**	**002**	Nov 20, 2017
AB			**10MG**	**A208756**	**003**	Nov 20, 2017
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A201231**	**001**	Sep 24, 2015
AB			**5MG**	**A201231**	**002**	Sep 24, 2015
AB			**10MG**	**A201231**	**003**	Sep 24, 2015
AB		TRIS PHARMA INC	**2.5MG**	**A207901**	**001**	Aug 26, 2016
AB			**5MG**	**A207901**	**002**	Aug 26, 2016
AB			**10MG**	**A207901**	**003**	Aug 26, 2016

FOCALIN

AB	**+**	NOVARTIS	**2.5MG**	**N021278**	**001**	Nov 13, 2001
AB	**+**		**5MG**	**N021278**	**002**	Nov 13, 2001
AB	**+!**		**10MG**	**N021278**	**003**	Nov 13, 2001

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE;ORAL

AZSTARYS

+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021
+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021
+!		EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	**!**	EUGIA PHARMA	**EQ 250MG BASE/VIAL**	**A200752**	**001**	Oct 19, 2011
AP	**!**		**EQ 500MG BASE/VIAL**	**A200752**	**002**	Oct 19, 2011
AP		GLAND	**EQ 250MG BASE/VIAL**	**A207321**	**002**	Dec 16, 2019
AP			**EQ 500MG BASE/VIAL**	**A207321**	**001**	Nov 28, 2016
AP		HIKMA	**EQ 250MG BASE/VIAL**	**A076068**	**001**	Sep 28, 2004
AP			**EQ 500MG BASE/VIAL**	**A076068**	**002**	Sep 28, 2004

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXEDRINE

AB	**+**	IMPAX LABS INC	**5MG**	**N017078**	**001**	
AB	**+**		**10MG**	**N017078**	**002**	
AB	**+!**		**15MG**	**N017078**	**003**	

DEXTROAMPHETAMINE SULFATE

AB		ACTAVIS ELIZABETH	**5MG**	**A203901**	**001**	Nov 30, 2012
AB			**10MG**	**A203901**	**002**	Nov 30, 2012
AB			**15MG**	**A203901**	**003**	Nov 30, 2012
AB		MAYNE PHARMA	**5MG**	**A076137**	**001**	Jan 18, 2002
AB			**10MG**	**A076137**	**002**	Jan 18, 2002
AB			**15MG**	**A076137**	**003**	Jan 18, 2002
AB		NESHER PHARMS	**5MG**	**A209111**	**001**	Jun 27, 2017
AB			**10MG**	**A209111**	**002**	Jun 27, 2017
AB			**15MG**	**A209111**	**003**	Jun 27, 2017
AB		SPECGX LLC	**5MG**	**A076353**	**001**	May 06, 2003
AB			**10MG**	**A076353**	**002**	May 06, 2003
AB			**15MG**	**A076353**	**003**	May 06, 2003
AB		STRIDES PHARMA	**5MG**	**A205673**	**001**	Oct 31, 2017
AB			**10MG**	**A205673**	**002**	Oct 31, 2017
AB			**15MG**	**A205673**	**003**	Oct 31, 2017

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA	**!**	OUTLOOK PHARMS	**5MG/5ML**	**A040776**	**001**	Jan 29, 2008

DEXTROAMPHETAMINE SULFATE

SOLUTION;ORAL

DEXTROAMPHETAMINE SULFATE

AA		TRIS PHARMA INC	**5MG/5ML**	**A203644**	**001**	May 29, 2013

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		ARBOR PHARMS LLC	**2.5MG**	**A090533**	**001**	Oct 25, 2011
AA			**5MG**	**A090533**	**002**	Oct 25, 2011
AA			**7.5MG**	**A090533**	**003**	Oct 25, 2011
AA			**10MG**	**A090533**	**004**	Oct 25, 2011
AA			**15MG**	**A090533**	**005**	Oct 25, 2011
AA			**20MG**	**A090533**	**006**	Oct 25, 2011
AA			**30MG**	**A090533**	**007**	Oct 25, 2011
AA		AUROLIFE PHARMA LLC	**5MG**	**A202893**	**001**	Jul 31, 2013
AA			**10MG**	**A202893**	**002**	Jul 31, 2013
AA		AVANTHI INC	**5MG**	**A203548**	**001**	Nov 23, 2015
AA			**10MG**	**A203548**	**002**	Nov 23, 2015
AA		BARR	**5MG**	**A040361**	**001**	Jan 31, 2001
AA	**!**		**10MG**	**A040361**	**002**	Jan 31, 2001
AA		NESHER PHARMS	**5MG**	**A206588**	**001**	Mar 28, 2016
AA			**10MG**	**A206588**	**002**	Mar 28, 2016
AA		NOVEL LABS INC	**5MG**	**A204330**	**001**	Mar 16, 2016
AA			**10MG**	**A204330**	**002**	Mar 16, 2016
AA		NUVO PHARM	**5MG**	**A210059**	**001**	Oct 18, 2017
AA			**10MG**	**A210059**	**002**	Oct 18, 2017
AA		SPECGX LLC	**5MG**	**A040436**	**001**	Jan 29, 2002
AA			**10MG**	**A040436**	**002**	Jan 29, 2002
AA		WINDER LABS LLC	**2.5MG**	**A212160**	**001**	Jun 07, 2021
AA			**5MG**	**A212160**	**002**	Jun 07, 2021
AA			**7.5MG**	**A212160**	**003**	Jun 07, 2021
AA			**10MG**	**A212160**	**004**	Jun 07, 2021
AA			**15MG**	**A212160**	**005**	Jun 07, 2021
AA			**20MG**	**A212160**	**006**	Jun 07, 2021
AA			**30MG**	**A212160**	**007**	Jun 07, 2021

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE DM

AA	**!**	SLATE	**15MG/5ML;6.25MG/5ML**	**A040649**	**001**	Feb 14, 2006

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		AMNEAL PHARMS	**15MG/5ML;6.25MG/5ML**	**A090575**	**001**	Feb 08, 2011
AA		TRIS PHARMA INC	**15MG/5ML;6.25MG/5ML**	**A091687**	**001**	Jun 28, 2012

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		WOCKHARDT BIO AG	**15MG/5ML;6.25MG/5ML**	**A088864**	**001**	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		ACTAVIS ELIZABETH	**20MG;10MG**	**A202934**	**001**	Oct 10, 2017

NUEDEXTA

AB	**+!**	AVANIR PHARMS	**20MG;10MG**	**N021879**	**001**	Oct 29, 2010

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**10GM/100ML**	**N019626**	**004**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**10GM/100ML**	**N016694**	**001**	
AP		FRESENIUS KABI USA	**10GM/100ML**	**A209448**	**001**	Jul 16, 2018
AP	**+!**	ICU MEDICAL INC	**10GM/100ML**	**N018080**	**001**	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**50MG/ML**	**N016730**	**002**	
AP	**+!**		**5GM/100ML**	**N016730**	**001**	
AP	**+!**		**5GM/100ML**	**N019626**	**002**	Feb 02, 1988
AP	**+!**	BAXTER HLTHCARE	**50MG/ML**	**N016673**	**003**	Oct 30, 1985
AP	**+!**		**50MG/ML**	**N020179**	**002**	Dec 07, 1992
AP	**+!**		**5GM/100ML**	**N016673**	**001**	
AP	**+!**		**5GM/100ML**	**N020179**	**001**	Dec 07, 1992
AP		FRESENIUS KABI USA	**50MG/ML**	**A207449**	**001**	Oct 21, 2016
AP	**+!**	HOSPIRA	**5GM/100ML**	**N019466**	**001**	Jul 15, 1985
AP	**+!**		**5GM/100ML**	**N019479**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**50MG/ML**	**N016367**	**002**	

DEXTROSE 50%

AP	**+**	HOSPIRA	**500MG/ML**	**N019445**	**001**	Jun 03, 1986
AP		INTL MEDICATION SYS	**500MG/ML**	**A203451**	**001**	Mar 26, 2021

DEXTROSE

INJECTABLE;INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**50GM/100ML**	**N020047**	**001**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**50GM/100ML**	**N018563**	**001**	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**70GM/100ML**	**N019626**	**005**	Feb 18, 2015
AP	**+!**	BAXTER HLTHCARE	**70GM/100ML**	**N020047**	**003**	Jul 02, 1991
AP	**+!**	ICU MEDICAL INC	**70GM/100ML**	**N018561**	**001**	Mar 23, 1982
AP	**+!**		**70GM/100ML**	**N019893**	**001**	Dec 26, 1989

DEXTROSE 20% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982

DEXTROSE 25%

+!	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998

DEXTROSE 30% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

+!	ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019873	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML	N019513	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

	ICU MEDICAL INC	5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017609	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**5GM/100ML;75MG/100ML**	**N017634**	**004**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**5GM/100ML;150MG/100ML**	**N017634**	**001**	

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP	**+**	BAXTER HLTHCARE	**5GM/100ML;300MG/100ML**	**N017634**	**002**	

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;150MG/100ML**	**N019699**	**004**	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML;300MG/100ML**	**N019699**	**006**	Sep 29, 1989

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

	+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003	

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML;149MG/100ML	N018371	001	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP		BAXTER HLTHCARE	**5GM/100ML;75MG/100ML;200MG/100ML**	**N018037**	**006**	Apr 13, 1982
AP			**5GM/100ML;150MG/100ML;200MG/100ML**	**N018037**	**007**	Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP		BAXTER HLTHCARE	**5GM/100ML;224MG/100ML;200MG/100ML**	**N018037**	**004**	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ						
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037	008	Apr 13, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)						
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML	N018037	001	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ						
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;200MG/100ML	N018037	005	Apr 13, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ						
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;200MG/100ML	N018037	009	Apr 13, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ						
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;200MG/100ML	N018037	002	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)						
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;200MG/100ML	N018037	003	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629	005	Mar 23, 1982
AP			5GM/100ML;150MG/100ML;330MG/100ML	N018629	002	Mar 23, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629	003	Mar 23, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;330MG/100ML	N018629	004	Mar 23, 1982
AP			5GM/100ML;300MG/100ML;330MG/100ML	N018629	006	Mar 23, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;330MG/100ML	N018629	007	Mar 23, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;330MG/100ML	N018629	008	Mar 23, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;330MG/100ML	N018629	001	Mar 23, 1982
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008	010	
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N019630	008	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N019630	014	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML	N019630	020	Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;75MG/100ML;900MG/100ML	N019630	026	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N019630	010	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630	016	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630	022	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630	028	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630	012	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630	018	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630	024	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630	030	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008	005	Apr 28, 1982
AP			5GM/100ML;150MG/100ML;450MG/100ML	N018008	006	Apr 28, 1982
AP	+!	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983
AP	+!		5GM/100ML;149MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008	007	Apr 28, 1982
AP	+!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308	005	Apr 05, 1985
AP	+!	ICU MEDICAL INC	5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008	008	Apr 28, 1982
AP	+!	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML	N018362	002	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008	009	Apr 28, 1982
AP	+!	ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML	N018362	003	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP BAXTER HLTHCARE **5GM/100ML;300MG/100ML;900MG/100ML** **N019308 007** Apr 05, 1985

AP **+!** ICU MEDICAL INC **5GM/100ML;298MG/100ML;900MG/100ML** **N019691 009** Mar 24, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;37MG/100ML;200MG/100ML N019630 031 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;37MG/100ML;450MG/100ML N019630 037 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;37MG/100ML;900MG/100ML N019630 043 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;110MG/100ML N019630 001 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;200MG/100ML N019630 007 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;330MG/100ML N019630 013 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N019630 019 Feb 17, 1988

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N019630 025 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N019630 032 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N019630 038 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N019630 044 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N019630 049 May 07, 1992

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N019630 002 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N019630 033 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;450MG/100ML N019630 039 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML;900MG/100ML N019630 045 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;110MG/100ML;300MG/100ML N019630 050 May 07, 1992

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;110MG/100ML N019630 003 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;200MG/100ML N019630 009 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;330MG/100ML N019630 015 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;450MG/100ML N019630 021 Feb 17, 1988

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;110MG/100ML;900MG/100ML N019630 027 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;200MG/100ML N019630 034 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;450MG/100ML N019630 040 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;150MG/100ML;900MG/100ML N019630 046 Feb 17, 1988

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;150MG/100ML;300MG/100ML N019630 051 May 07, 1992

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;150MG/100ML;110MG/100ML N019630 004 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;200MG/100ML N019630 035 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;450MG/100ML N019630 041 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;900MG/100ML N019630 047 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML;300MG/100ML N019630 052 May 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;110MG/100ML N019630 005 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;200MG/100ML N019630 011 Feb 17, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;330MG/100ML N019630 017 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;450MG/100ML N019630 023 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;900MG/100ML N019630 029 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;200MG/100ML N019630 036 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;450MG/100ML N019630 042 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;900MG/100ML N019630 048 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;300MG/100ML;300MG/100ML N019630 053 May 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML;110MG/100ML N019630 006 Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;75MG/100ML;900MG/100ML N019308 004 Apr 05, 1985
5GM/100ML;150MG/100ML;900MG/100ML N019308 002 Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;149MG/100ML;225MG/100ML N018365 001

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;300MG/100ML;900MG/100ML N019308 003 Apr 05, 1985

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;224MG/100ML;900MG/100ML N019308 006 Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;150MG/100ML;450MG/100ML N018008 004

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
BAXTER HLTHCARE 5GM/100ML;150MG/100ML;900MG/100ML N019308 001 Apr 05, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **2.5GM/100ML;450MG/100ML** **N019631 004** Feb 24, 1988
AP **+!** BAXTER HLTHCARE **2.5GM/100ML;450MG/100ML** **N016697 001**
AP FRESENIUS KABI USA **2.5GM/100ML;450MG/100ML** **A211190 001** Dec 20, 2019

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;200MG/100ML** **N019631 007** Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.225%
AP FRESENIUS KABI USA **5GM/100ML;225MG/100ML** **A211221 001** Sep 15, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
AP **+!** ICU MEDICAL INC **5GM/100ML;225MG/100ML** **N017606 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
AP FRESENIUS KABI USA **5GM/100ML;300MG/100ML** **A211194 001** Aug 26, 2020
AP **+!** ICU MEDICAL INC **5GM/100ML;300MG/100ML** **N017799 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;330MG/100ML** **N019631 008** Feb 24, 1988

DEXTROSE 5% AND SODIUM CHLORIDE 0.45%
AP FRESENIUS KABI USA **5GM/100ML;450MG/100ML** **A211276 001** Sep 15, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;450MG/100ML** **N019631 009** Feb 24, 1988
AP **+** ICU MEDICAL INC **5GM/100ML;450MG/100ML** **N017607 001**

DEXTROSE 5% AND SODIUM CHLORIDE 0.9%
AP FRESENIUS KABI USA **5GM/100ML;900MG/100ML** **A211211 001** Sep 14, 2020

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP B BRAUN **5GM/100ML;900MG/100ML** **N019631 010** Feb 24, 1988
AP **+!** ICU MEDICAL INC **5GM/100ML;900MG/100ML** **N017585 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;200MG/100ML** **N016689 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;330MG/100ML** **N016687 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;450MG/100ML** **N016683 001**

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
AP BAXTER HLTHCARE **5GM/100ML;900MG/100ML** **N016678 001**

DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;110MG/100ML N019631 011 Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;200MG/100ML N019631 012 Feb 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;330MG/100ML	N019631	013	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;450MG/100ML	N019631	014	Feb 24, 1988

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	10GM/100ML;900MG/100ML	N019631	015	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;110MG/100ML	N019631	001	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;200MG/100ML	N019631	002	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988

DIATRIZOATE MEGLUMINE

SOLUTION;URETHRAL

CYSTOGRAFIN

+	BRACCO	30%	N010040	018	

CYSTOGRAFIN DILUTE

+	BRACCO	18%	N010040	022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION;ORAL, RECTAL

GASTROGRAFIN

AA	**+!**	BRACCO	**66%;10%**	**N011245**	**003**	

MD-GASTROVIEW

AA		LIEBEL-FLARSHEIM	**66%;10%**	**A087388**	**001**	

DIAZEPAM

CONCENTRATE;ORAL

DIAZEPAM INTENSOL

	!	HIKMA	5MG/ML	A071415	001	Apr 03, 1987

GEL;RECTAL

DIASTAT

	+	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997

DIASTAT ACUDIAL

	+	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005
	+!		20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005

INJECTABLE;INJECTION

DIAZEPAM

AP	**!**	BELOTECA INC	**10MG/2ML (5MG/ML)**	**A210363**	**001**	Mar 18, 2019
AP			**50MG/10ML (5MG/ML)**	**A211998**	**001**	Dec 26, 2019
AP		HIKMA	**10MG/2ML (5MG/ML)**	**A070313**	**001**	Dec 16, 1985
AP		HOSPIRA	**10MG/2ML (5MG/ML)**	**A072079**	**001**	Dec 20, 1988
AP	**!**		**50MG/10ML (5MG/ML)**	**A071583**	**001**	Oct 13, 1987

SOLUTION;ORAL

DIAZEPAM

AA	**!**	HIKMA	**5MG/5ML**	**A070928**	**001**	Apr 03, 1987
AA		LANNETT CO INC	**5MG/5ML**	**A206477**	**001**	Jun 24, 2016

SPRAY;NASAL

VALTOCO

	+	NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020
	+		7.5MG/SPRAY	N211635	002	Jan 10, 2020
	+!		10MG/SPRAY	N211635	003	Jan 10, 2020

TABLET;ORAL

DIAZEPAM

AB		IVAX SUB TEVA PHARMS	**2MG**	**A071307**	**001**	Dec 10, 1986
AB			**5MG**	**A071321**	**001**	Dec 10, 1986
AB			**10MG**	**A071322**	**001**	Dec 10, 1986
AB		MAYNE PHARMA	**2MG**	**A071134**	**001**	Feb 03, 1987
AB			**5MG**	**A071135**	**001**	Feb 03, 1987
AB			**10MG**	**A071136**	**001**	Feb 03, 1987
AB		MYLAN	**2MG**	**A070325**	**002**	Sep 04, 1985
AB			**5MG**	**A070325**	**003**	Sep 04, 1985
AB			**10MG**	**A070325**	**001**	Sep 04, 1985
AB		STRIDES PHARMA	**2MG**	**A077749**	**001**	Mar 31, 2006

DIAZEPAM							
TABLET;ORAL							
DIAZEPAM							
AB			**5MG**	**A077749**	**002**	Mar 31, 2006	
AB			**10MG**	**A077749**	**003**	Mar 31, 2006	
VALIUM							
AB	**+**	ROCHE	**2MG**	**N013263**	**002**		
AB	**+**		**5MG**	**N013263**	**004**		
AB	**+!**		**10MG**	**N013263**	**006**		
DIAZOXIDE							
SUSPENSION;ORAL							
DIAZOXIDE							
AB		E5 PHARMA INC	**50MG/ML**	**A211050**	**001**	Dec 20, 2019	
AB		NOVITIUM PHARMA	**50MG/ML**	**A210799**	**001**	Jul 08, 2020	
PROGLYCEM							
AB	**+!**	TEVA BRANDED PHARM	**50MG/ML**	**N017453**	**001**		
DICHLORPHENAMIDE							
TABLET;ORAL							
KEVEYIS							
	+!	XERIS	50MG	N011366	002	Aug 07, 2015	
DICLOFENAC							
CAPSULE;ORAL							
ZORVOLEX							
	+!	ZYLA	35MG	N204592	002	Oct 18, 2013	
DICLOFENAC EPOLAMINE							
SYSTEM;TOPICAL							
FLECTOR							
	+!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007	
LICART							
	+!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	
DICLOFENAC POTASSIUM							
CAPSULE;ORAL							
DICLOFENAC POTASSIUM							
AB		AUROBINDO PHARMA LTD	**25MG**	**A213875**	**001**	Oct 19, 2021	
AB		BIONPHARMA INC	**25MG**	**A204648**	**001**	Feb 23, 2016	
ZIPSOR							
AB	**+!**	ASSERTIO	**25MG**	**N022202**	**001**	Jun 16, 2009	
FOR SOLUTION;ORAL							
CAMBIA							
AB	**+!**	ASSERTIO	**50MG**	**N022165**	**001**	Jun 17, 2009	
DICLOFENAC POTASSIUM							
AB		PAR FORM	**50MG**	**A202964**	**001**	May 02, 2016	
TABLET;ORAL							
CATAFLAM							
AB		AMICI	**25MG**	**A076561**	**002**	Jul 21, 2021	
AB			**50MG**	**A076561**	**001**	Mar 18, 2004	
DICLOFENAC POTASSIUM							
AB		RICONPHARMA LLC	**50MG**	**A215585**	**001**	Oct 08, 2021	
AB	**!**	RK PHARMA	**50MG**	**A075463**	**001**	Jul 26, 1999	
AB		RUBICON	**25MG**	**A075229**	**002**	Sep 16, 2021	
AB			**50MG**	**A075229**	**001**	Nov 20, 1998	
AB		TEVA	**50MG**	**A075219**	**001**	Aug 06, 1998	
DICLOFENAC SODIUM							
GEL;TOPICAL							
DICLOFENAC SODIUM							
AB		ACTAVIS MID ATLANTIC	**3%**	**A206493**	**001**	Dec 02, 2015	
AB		AKORN	**1%**	**A209484**	**001**	Nov 21, 2018	
AB		CIPLA	**1%**	**A209903**	**001**	Aug 03, 2018	
AB		GLENMARK PHARMS LTD	**3%**	**A208301**	**001**	Sep 13, 2016	
AB		PADAGIS ISRAEL	**3%**	**A210893**	**001**	Jul 27, 2018	
AB	**!**	TARO	**3%**	**A206298**	**001**	Apr 28, 2016	
AB		TOLMAR	**3%**	**A200936**	**001**	Oct 28, 2013	
SOLUTION;TOPICAL							
DICLOFENAC SODIUM							
AT		AKORN	**1.5%**	**A206655**	**001**	Jan 28, 2021	
AT		AMNEAL PHARMS	**1.5%**	**A206116**	**001**	Sep 02, 2016	
AT		CADILA	**1.5%**	**A206411**	**001**	Apr 17, 2018	
AT		LUPIN LTD	**1.5%**	**A204132**	**001**	Aug 20, 2015	

DICLOFENAC SODIUM

SOLUTION;TOPICAL

DICLOFENAC SODIUM

AT		NOVEL LABS INC	**1.5%**	**A205878**	**001**	Dec 09, 2015
AT	!	TARO	**1.5%**	**A203818**	**001**	Nov 26, 2014
AT		TELIGENT	**1.5%**	**A202769**	**001**	Jul 08, 2015
AT		TWI PHARMS	**1.5%**	**A202393**	**001**	Nov 24, 2014
AT		WATSON LABS INC	**1.5%**	**A202852**	**001**	Nov 24, 2014

PENNSAID

	+!	HORIZON	2%	N204623	001	Jan 16, 2014

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

AT		AKORN	**0.1%**	**A077845**	**001**	Apr 17, 2008
AT		ALTAIRE PHARMS INC	**0.1%**	**A203383**	**001**	Nov 16, 2015
AT	!	BAUSCH AND LOMB	**0.1%**	**A078792**	**001**	Dec 28, 2007
AT		RISING	**0.1%**	**A078553**	**001**	Dec 28, 2007
AT		SANDOZ INC	**0.1%**	**A078031**	**001**	Feb 06, 2008

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

AB		ACTAVIS ELIZABETH	**50MG**	**A074514**	**001**	Mar 26, 1996
AB			**75MG**	**A074514**	**002**	Mar 26, 1996
AB		CARLSBAD	**25MG**	**A075185**	**002**	Nov 13, 1998
AB			**50MG**	**A075185**	**003**	Nov 13, 1998
AB			**75MG**	**A075185**	**001**	Nov 13, 1998
AB	!	UNIQUE PHARM LABS	**25MG**	**A090066**	**001**	Dec 01, 2010
AB	!		**50MG**	**A090066**	**002**	Dec 01, 2010
AB	!		**75MG**	**A077863**	**003**	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

AB	!	DEXCEL LTD	**100MG**	**A076201**	**001**	Nov 06, 2002
AB		VPNA	**100MG**	**A075492**	**001**	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

AB	+	PFIZER	**50MG;0.2MG**	**N020607**	**001**	Dec 24, 1997
AB	+!		**75MG;0.2MG**	**N020607**	**002**	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

AB		ACTAVIS LABS FL INC	**50MG;0.2MG**	**A201089**	**001**	Jul 09, 2012
AB			**75MG;0.2MG**	**A201089**	**002**	Jul 09, 2012
AB		AMNEAL PHARMS	**50MG;0.2MG**	**A203995**	**001**	Nov 25, 2016
AB			**75MG;0.2MG**	**A203995**	**002**	Nov 25, 2016
AB		MICRO LABS	**50MG;0.2MG**	**A204355**	**001**	Jul 15, 2021
AB			**75MG;0.2MG**	**A204355**	**002**	Jul 15, 2021
AB		SANDOZ	**50MG;0.2MG**	**A200158**	**001**	May 09, 2013
AB			**75MG;0.2MG**	**A200158**	**002**	May 09, 2013
AB		YUNG SHIN PHARM	**50MG;0.2MG**	**A205143**	**001**	Feb 19, 2020
AB			**75MG;0.2MG**	**A205143**	**002**	Feb 19, 2020

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

		TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982
	!		EQ 500MG BASE	A062286	002	Jun 03, 1982

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

DICYCLOMINE HYDROCHLORIDE

AB	!	LANNETT	**10MG**	**A084285**	**001**	
AB		MYLAN	**10MG**	**A040319**	**001**	Sep 07, 1999
AB		WATSON LABS	**10MG**	**A085082**	**001**	Jun 19, 1986
AB		WEST WARD	**10MG**	**A040204**	**001**	Feb 28, 1997

INJECTABLE;INJECTION

BENTYL

AP	+!	ALLERGAN	**10MG/ML**	**N008370**	**001**	Oct 15, 1984

BENTYL PRESERVATIVE FREE

AP	+!	ALLERGAN	**10MG/ML**	**N008370**	**002**	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

AP		AKORN	**10MG/ML**	**A207084**	**001**	May 04, 2018
AP		AM REGENT	**10MG/ML**	**A208353**	**001**	Feb 17, 2017
AP		CUSTOPHARM INC	**10MG/ML**	**A210788**	**001**	Feb 11, 2019
AP		FOSUN PHARMA	**10MG/ML**	**A210979**	**001**	Jul 02, 2018
AP		FRESENIUS KABI USA	**10MG/ML**	**A210257**	**001**	Jan 25, 2019
AP		GENE YORK PHARMS	**10MG/ML**	**A212058**	**001**	Apr 26, 2019

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

AP		NEXUS PHARMS	**10MG/ML**	**A206468**	**001**	Feb 01, 2019
AP		SLATE	**10MG/ML**	**A207076**	**001**	Nov 02, 2018

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

AP		HIKMA	**10MG/ML**	**A040465**	**001**	Jun 30, 2003

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

AA	!	GENERICS	**10MG/5ML**	**A040169**	**001**	Mar 24, 2005
AA		HIKMA	**10MG/5ML**	**A212286**	**001**	May 22, 2020
AA		NOVITIUM PHARMA	**10MG/5ML**	**A214721**	**001**	Apr 23, 2021

TABLET;ORAL

DICYCLOMINE HYDROCHLORIDE

AB		HIKMA PHARMS	**20MG**	**A040161**	**001**	Oct 01, 1996
AB		LANNETT	**20MG**	**A040230**	**001**	Feb 26, 1999
AB	!	WATSON LABS	**20MG**	**A085223**	**001**	Jul 30, 1986

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

	+!	BAYER HLTHCARE	N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A	N022252	001	May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

AA		AVANTHI INC	**25MG**	**A201212**	**001**	Dec 22, 2010
AA	!	LANNETT CO INC	**25MG**	**A200177**	**001**	Jul 18, 2011

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

AB	!	LANNETT CO INC	**75MG**	**A091680**	**001**	Oct 24, 2011

DIFELIKEFALIN ACETATE

SOLUTION;INTRAVENOUS

KORSUVA

	+!	CARA THERAP	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	!	ANI PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	!	TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		FOUGERA PHARMS	**0.05%**	**A075374**	**001**	Apr 27, 1999
AB		RISING	**0.05%**	**A207440**	**001**	Feb 27, 2017
AB	!	TARO	**0.05%**	**A075331**	**001**	May 14, 1999
AB		TELIGENT	**0.05%**	**A210753**	**001**	Jun 12, 2018

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	**500MG**	**A202845**	**001**	Mar 08, 2012
AB	!	TEVA	**500MG**	**A073673**	**001**	Jul 31, 1992
AB		ZYDUS PHARMS	**500MG**	**A203547**	**001**	Jun 16, 2017

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DIFLUPREDNATE

AB		AMNEAL	**0.05%**	**A211526**	**001**	Nov 17, 2021
AB		CIPLA	**0.05%**	**A211776**	**001**	Aug 09, 2021

DUREZOL

AB	**+!**	NOVARTIS	**0.05%**	**N022212**	**001**	Jun 23, 2008

DIGOXIN

ELIXIR;ORAL

DIGOXIN

AA	**+!**	HIKMA	**0.05MG/ML**	**N021648**	**001**	Aug 26, 2004
AA		NOVITIUM PHARMA	**0.05MG/ML**	**A213000**	**001**	Oct 04, 2019

INJECTABLE;INJECTION

DIGOXIN

AP		SANDOZ INC	**0.25MG/ML**	**A040481**	**001**	Aug 21, 2003
AP		WEST-WARD PHARMS INT	**0.25MG/ML**	**A083391**	**001**	

DIGOXIN							
INJECTABLE;INJECTION							
LANOXIN							
AP	**+!**	COVIS	**0.25MG/ML**	**N009330**	**002**		
LANOXIN PEDIATRIC							
	+!	COVIS	0.1MG/ML	N009330	004		
TABLET;ORAL							
DIGOXIN							
AB		HIKMA INTL PHARMS	**0.125MG**	**A077002**	**002**	Oct 30, 2007	
AB			**0.25MG**	**A077002**	**001**	Oct 30, 2007	
AB		IMPAX LABS	**0.125MG**	**A078556**	**001**	Jul 20, 2009	
AB			**0.25MG**	**A078556**	**002**	Jul 20, 2009	
AB		NOVITIUM PHARMA	**0.125MG**	**A215307**	**001**	Nov 22, 2021	
AB			**0.25MG**	**A215307**	**002**	Nov 22, 2021	
AB		RISING PHARMA	**0.125MG**	**A040282**	**001**	Dec 23, 1999	
AB			**0.25MG**	**A040282**	**002**	Dec 23, 1999	
AB		STEVENS J	**0.125MG**	**A076268**	**001**	Jul 26, 2002	
AB			**0.25MG**	**A076268**	**002**	Jul 26, 2002	
AB		SUN PHARM INDS INC	**0.125MG**	**A076363**	**001**	Jan 31, 2003	
AB			**0.25MG**	**A076363**	**002**	Jan 31, 2003	
LANOXIN							
AB	**+**	CONCORDIA	**0.125MG**	**N020405**	**002**	Sep 30, 1997	
AB	**+!**		**0.25MG**	**N020405**	**004**	Sep 30, 1997	
	+		0.0625MG	N020405	001	Sep 30, 1997	
DIHYDROERGOTAMINE MESYLATE							
INJECTABLE;INJECTION							
D.H.E. 45							
AP	**+!**	BAUSCH	**1MG/ML**	**N005929**	**001**		
DIHYDROERGOTAMINE MESYLATE							
AP		HIKMA	**1MG/ML**	**A040453**	**001**	Jun 09, 2003	
AP		HIKMA PHARMS	**1MG/ML**	**A206621**	**001**	Sep 15, 2017	
AP		PADAGIS US	**1MG/ML**	**A040475**	**001**	Apr 28, 2003	
AP		PROVEPHARM SAS	**1MG/ML**	**A212046**	**001**	Jan 07, 2020	
AP		SAGENT PHARMS INC	**1MG/ML**	**A207264**	**001**	Jul 11, 2018	
SPRAY, METERED;NASAL							
DIHYDROERGOTAMINE MESYLATE							
AB		AMNEAL	**0.5MG/SPRAY**	**A214105**	**001**	Jan 04, 2022	
AB		CIPLA	**0.5MG/SPRAY**	**A212907**	**001**	May 20, 2020	
AB		CUSTOPHARM INC	**0.5MG/SPRAY**	**A211393**	**001**	Feb 28, 2020	
MIGRANAL							
AB	**+!**	BAUSCH	**0.5MG/SPRAY**	**N020148**	**001**	Dec 08, 1997	
TRUDHESA							
	+!	IMPEL NEUROPHARMA	0.725MG/SPRAY	N213436	001	Sep 02, 2021	
DILTIAZEM HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
DILTIAZEM HYDROCHLORIDE							
AB1		GLENMARK PHARMS LTD	**60MG**	**A212317**	**001**	Mar 22, 2021	
AB1			**90MG**	**A212317**	**002**	Mar 22, 2021	
AB1			**120MG**	**A212317**	**003**	Mar 22, 2021	
AB1		MYLAN	**60MG**	**A074910**	**001**	May 02, 1997	
AB1			**90MG**	**A074910**	**002**	May 02, 1997	
AB1	**!**		**120MG**	**A074910**	**003**	May 02, 1997	
AB2		ACCORD HLTHCARE	**120MG**	**A206997**	**001**	Apr 28, 2020	
AB2			**180MG**	**A206997**	**002**	Apr 28, 2020	
AB2			**240MG**	**A206997**	**003**	Apr 28, 2020	
AB2		APOTEX	**120MG**	**A074943**	**003**	Dec 19, 2000	
AB2			**180MG**	**A074943**	**002**	Dec 19, 2000	
AB2	**!**		**240MG**	**A074943**	**001**	Aug 06, 1998	
CARDIZEM CD							
AB3	**+**	BAUSCH	**120MG**	**N020062**	**001**	Aug 10, 1992	
AB3	**+**		**180MG**	**N020062**	**002**	Dec 27, 1991	
AB3	**+**		**240MG**	**N020062**	**003**	Dec 27, 1991	
AB3	**+**		**300MG**	**N020062**	**004**	Dec 27, 1991	
AB3	**+!**		**360MG**	**N020062**	**005**	Aug 24, 1999	
CARTIA XT							
AB3		ACTAVIS LABS FL INC	**120MG**	**A074752**	**002**	Jul 09, 1998	
AB3			**180MG**	**A074752**	**001**	Jul 09, 1998	
AB3			**240MG**	**A074752**	**003**	Jul 09, 1998	
AB3			**300MG**	**A074752**	**004**	Jul 09, 1998	
DILTIAZEM HYDROCHLORIDE							
AB3		ACTAVIS ELIZABETH	**360MG**	**A202463**	**001**	Dec 07, 2012	

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILTIAZEM HYDROCHLORIDE

AB3		NOVAST LABS	**120MG**	**A208783**	**001**	Jun 14, 2019
AB3			**180MG**	**A208783**	**002**	Jun 14, 2019
AB3			**240MG**	**A208783**	**003**	Jun 14, 2019
AB3			**300MG**	**A208783**	**004**	Jun 14, 2019
AB3			**360MG**	**A208783**	**005**	Jun 14, 2019
AB3		PAR PHARM	**120MG**	**A074984**	**001**	Dec 20, 1999
AB3			**180MG**	**A074984**	**002**	Dec 20, 1999
AB3			**240MG**	**A074984**	**003**	Dec 20, 1999
AB3			**300MG**	**A074984**	**004**	Dec 20, 1999
AB3		SUN PHARM	**120MG**	**A090492**	**001**	Oct 28, 2011
AB3			**120MG**	**A203023**	**001**	Jun 08, 2017
AB3			**180MG**	**A090492**	**002**	Oct 28, 2011
AB3			**180MG**	**A203023**	**002**	Jun 08, 2017
AB3			**240MG**	**A090492**	**003**	Oct 28, 2011
AB3			**240MG**	**A203023**	**003**	Jun 08, 2017
AB3			**300MG**	**A090492**	**004**	Oct 28, 2011
AB3			**300MG**	**A203023**	**004**	Jun 08, 2017
AB3			**360MG**	**A090492**	**005**	Oct 28, 2011
AB3			**360MG**	**A203023**	**005**	Jun 08, 2017
AB3		TWI PHARMS	**120MG**	**A205231**	**001**	Aug 30, 2018
AB3			**180MG**	**A205231**	**002**	Aug 30, 2018
AB3			**240MG**	**A205231**	**003**	Aug 30, 2018
AB3			**300MG**	**A205231**	**004**	Aug 30, 2018
AB3			**360MG**	**A205231**	**005**	Aug 30, 2018
AB3		VALEANT PHARMS NORTH	**120MG**	**A075116**	**001**	Dec 23, 1999
AB3			**180MG**	**A075116**	**002**	Dec 23, 1999
AB3			**240MG**	**A075116**	**003**	Dec 23, 1999
AB3			**300MG**	**A075116**	**004**	Dec 23, 1999
AB3		ZYDUS PHARMS	**120MG**	**A206534**	**001**	Aug 08, 2017
AB3			**180MG**	**A206534**	**002**	Aug 08, 2017
AB3			**240MG**	**A206534**	**003**	Aug 08, 2017
AB3			**300MG**	**A206534**	**004**	Aug 08, 2017
AB3			**360MG**	**A206534**	**005**	Aug 08, 2017
AB4		SANDOZ	**120MG**	**A091022**	**001**	Sep 28, 2012
AB4			**180MG**	**A091022**	**002**	Sep 28, 2012
AB4			**240MG**	**A091022**	**003**	Sep 28, 2012
AB4			**300MG**	**A091022**	**004**	Sep 28, 2012
AB4			**360MG**	**A091022**	**005**	Sep 28, 2012
AB4			**420MG**	**A091022**	**006**	Sep 28, 2012
AB4		SUN PHARM	**120MG**	**A090421**	**001**	Nov 15, 2010
AB4			**180MG**	**A090421**	**002**	Nov 15, 2010
AB4			**240MG**	**A090421**	**003**	Nov 15, 2010
AB4			**300MG**	**A090421**	**004**	Nov 15, 2010
AB4			**360MG**	**A090421**	**005**	Nov 15, 2010
AB4		ZYDUS PHARMS	**120MG**	**A206641**	**001**	Aug 11, 2017
AB4			**180MG**	**A206641**	**002**	Aug 11, 2017
AB4			**240MG**	**A206641**	**003**	Aug 11, 2017
AB4			**300MG**	**A206641**	**004**	Aug 11, 2017
AB4			**360MG**	**A206641**	**005**	Aug 11, 2017
AB4			**420MG**	**A206641**	**006**	Aug 11, 2017

TAZTIA XT

AB4		ACTAVIS LABS FL INC	**120MG**	**A075401**	**001**	Apr 10, 2003
AB4			**180MG**	**A075401**	**002**	Apr 10, 2003
AB4			**240MG**	**A075401**	**003**	Apr 10, 2003
AB4			**300MG**	**A075401**	**004**	Apr 10, 2003
AB4			**360MG**	**A075401**	**005**	Apr 10, 2003

TIAZAC

AB4	+	BAUSCH	**120MG**	**N020401**	**001**	Sep 11, 1995
AB4	+		**180MG**	**N020401**	**002**	Sep 11, 1995
AB4	+		**240MG**	**N020401**	**003**	Sep 11, 1995
AB4	+		**300MG**	**N020401**	**004**	Sep 11, 1995
AB4	+		**360MG**	**N020401**	**005**	Sep 11, 1995
AB4	+!		**420MG**	**N020401**	**006**	Oct 16, 1998

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		AKORN	**5MG/ML**	**A075086**	**001**	Apr 09, 1998
AP	!	ATHENEX INC	**5MG/ML**	**A074617**	**001**	Feb 28, 1996
AP		HIKMA FARMACEUTICA	**5MG/ML**	**A202651**	**001**	Aug 09, 2012
AP		HOSPIRA	**5MG/ML**	**A074941**	**001**	Apr 15, 1998

DILTIAZEM HYDROCHLORIDE

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	**5MG/ML**	**A078538**	**001**	Dec 17, 2008
	!	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002

SOLUTION;INTRAVENOUS

DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

	+!	EXELA PHARMA	125MG/125ML (1MG/ML)	N215252	001	Oct 28, 2021
	+!		250MG/250ML (1MG/ML)	N215252	002	Oct 28, 2021

TABLET;ORAL

CARDIZEM

AB	**+**	BAUSCH	**30MG**	**N018602**	**001**	Nov 05, 1982
AB	**+**		**60MG**	**N018602**	**002**	Nov 05, 1982
AB	**+**		**90MG**	**N018602**	**003**	Dec 08, 1986
AB	**+!**		**120MG**	**N018602**	**004**	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

AB		EDENBRIDGE PHARMS	**30MG**	**A211596**	**001**	Nov 18, 2019
AB			**60MG**	**A211596**	**002**	Nov 18, 2019
AB			**90MG**	**A211596**	**003**	Nov 18, 2019
AB			**120MG**	**A211596**	**004**	Nov 18, 2019
AB		TEVA	**30MG**	**A074185**	**001**	May 31, 1995
AB			**60MG**	**A074185**	**002**	May 31, 1995
AB			**90MG**	**A074185**	**003**	May 31, 1995
AB			**120MG**	**A074185**	**004**	May 31, 1995

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	**+**	BAUSCH	**120MG**	**N021392**	**001**	Feb 06, 2003
AB	**+**		**180MG**	**N021392**	**002**	Feb 06, 2003
AB	**+**		**240MG**	**N021392**	**003**	Feb 06, 2003
AB	**+**		**300MG**	**N021392**	**004**	Feb 06, 2003
AB	**+**		**360MG**	**N021392**	**005**	Feb 06, 2003
AB	**+!**		**420MG**	**N021392**	**006**	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**120MG**	**A077686**	**006**	Mar 15, 2010
AB			**180MG**	**A077686**	**005**	Mar 15, 2010
AB			**240MG**	**A077686**	**004**	Mar 15, 2010
AB			**300MG**	**A077686**	**003**	Mar 15, 2010
AB			**360MG**	**A077686**	**002**	Mar 15, 2010
AB			**420MG**	**A077686**	**001**	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE;INJECTION

DIMENHYDRINATE

	!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004

DIMERCAPROL

INJECTABLE;INJECTION

BAL

	+!	AKORN	10%	N005939	001	

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB		ACCORD HLTHCARE	**120MG**	**A210499**	**001**	Sep 24, 2020
AB			**240MG**	**A210499**	**002**	Sep 24, 2020
AB		ALKEM LABS LTD	**120MG**	**A210440**	**001**	Sep 24, 2020
AB			**240MG**	**A210440**	**002**	Sep 24, 2020
AB		AMNEAL	**120MG**	**A210402**	**001**	Sep 24, 2020
AB			**240MG**	**A210402**	**002**	Sep 24, 2020
AB		CIPLA	**120MG**	**A210305**	**001**	Sep 24, 2020
AB			**240MG**	**A210305**	**002**	Sep 24, 2020
AB		GLENMARK PHARMS LTD	**120MG**	**A210309**	**001**	Oct 06, 2020
AB			**240MG**	**A210309**	**002**	Oct 06, 2020
AB		HETERO LABS LTD III	**120MG**	**A210500**	**001**	Sep 24, 2020
AB			**240MG**	**A210500**	**002**	Sep 24, 2020
AB		LUPIN	**120MG**	**A210226**	**001**	Oct 05, 2020
AB			**240MG**	**A210226**	**002**	Oct 05, 2020
AB		MSN	**120MG**	**A210460**	**001**	Sep 24, 2020
AB			**240MG**	**A210460**	**002**	Sep 24, 2020
AB		MYLAN	**120MG**	**A210531**	**001**	Aug 17, 2020
AB			**240MG**	**A210531**	**002**	Aug 17, 2020
AB		PHARMATHEN	**120MG**	**A210436**	**001**	Mar 26, 2021
AB			**240MG**	**A210436**	**002**	Mar 26, 2021

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

AB		SAWAI USA	**120MG**	**A210285**	**001**	Dec 21, 2021
AB			**240MG**	**A210285**	**002**	Dec 21, 2021
AB		TWI PHARMS	**120MG**	**A210382**	**001**	Oct 14, 2020
AB			**240MG**	**A210382**	**002**	Oct 14, 2020

TECFIDERA

AB	**+**	BIOGEN INC	**120MG**	**N204063**	**001**	Mar 27, 2013
AB	**+!**		**240MG**	**N204063**	**002**	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

RIMSO-50

	+!	MYLAN INSTITUTIONAL	50%	N017788	001

DINOPROSTONE

GEL;ENDOCERVICAL

PREPIDIL

	+!	PFIZER	0.5MG/3GM	N019617	001	Dec 09, 1992

INSERT, EXTENDED RELEASE;VAGINAL

CERVIDIL

	+!	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	!	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP		APP PHARMS	**50MG/ML**	**A040466**	**001**	May 28, 2002
AP		HOSPIRA	**50MG/ML**	**A040140**	**001**	Nov 20, 1998
AP		MICRO LABS	**50MG/ML**	**A205723**	**001**	Aug 22, 2018
AP		MYLAN INSTITUTIONAL	**50MG/ML**	**A040498**	**001**	Jul 12, 2005
AP	**+!**	WEST-WARD PHARMS INT	**50MG/ML**	**A080817**	**002**	

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**50MG/ML**	**A091526**	**001**	Mar 26, 2013

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

AP	**!**	ATHENEX INC	**5MG/ML**	**A074939**	**001**	Apr 13, 1998
AP		FRESENIUS KABI USA	**5MG/ML**	**A074956**	**001**	Sep 30, 1998
AP		HIKMA	**5MG/ML**	**A074521**	**001**	Oct 18, 1996

TABLET;ORAL

DIPYRIDAMOLE

AB		ANI PHARMS	**25MG**	**A086944**	**002**	Apr 16, 1991
AB			**50MG**	**A086944**	**001**	Feb 25, 1992
AB			**75MG**	**A086944**	**003**	Feb 25, 1992
AB		BARR	**25MG**	**A087184**	**001**	Oct 03, 1990
AB			**50MG**	**A087716**	**001**	Oct 03, 1990
AB			**75MG**	**A087717**	**001**	Oct 03, 1990
AB		IMPAX LABS	**25MG**	**A040782**	**001**	Jul 18, 2007
AB			**50MG**	**A040782**	**002**	Jul 18, 2007
AB			**75MG**	**A040782**	**003**	Jul 18, 2007
AB		MURTY PHARMS	**25MG**	**A040733**	**001**	Feb 13, 2007
AB			**50MG**	**A040733**	**002**	Feb 13, 2007
AB			**75MG**	**A040733**	**003**	Feb 13, 2007
AB		OXFORD PHARMS	**25MG**	**A040542**	**001**	Apr 21, 2006
AB			**50MG**	**A040542**	**002**	Apr 21, 2006
AB			**75MG**	**A040542**	**003**	Apr 21, 2006
AB		ZYDUS PHARMS USA INC	**25MG**	**A040874**	**001**	Jan 28, 2008
AB			**50MG**	**A040874**	**002**	Jan 28, 2008
AB			**75MG**	**A040874**	**003**	Jan 28, 2008

PERSANTINE

AB	**+**	BOEHRINGER INGELHEIM	**25MG**	**N012836**	**003**	Dec 22, 1986
AB	**+**		**50MG**	**N012836**	**004**	Feb 06, 1987
AB	**+!**		**75MG**	**N012836**	**005**	Feb 06, 1987

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

VUMERITY

	+!	BIOGEN INC	231MG	N211855	001	Oct 29, 2019

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

AB		TEVA	**EQ 100MG BASE**	**A070101**	**001**	Feb 22, 1985
AB			**EQ 150MG BASE**	**A070102**	**001**	Feb 22, 1985

NORPACE

AB	**+**	PFIZER	**EQ 100MG BASE**	**N017447**	**001**	
AB	**+!**		**EQ 150MG BASE**	**N017447**	**002**	

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

	+	PFIZER	EQ 100MG BASE	N018655	001	Jul 20, 1982
	+!		EQ 150MG BASE	N018655	002	Jul 20, 1982

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		ALVOGEN	**250MG**	**A091681**	**001**	Aug 08, 2013
AB		CHARTWELL MOLECULES	**250MG**	**A091563**	**001**	Dec 31, 2012
AB			**500MG**	**A091563**	**002**	Dec 31, 2012
AB		HIKMA	**250MG**	**A202652**	**001**	Feb 05, 2014
AB	**!**		**500MG**	**A202652**	**002**	Feb 05, 2014
AB		SIGMAPHARM LABS LLC	**250MG**	**A091619**	**001**	Mar 28, 2011
AB			**500MG**	**A091619**	**002**	Mar 28, 2011

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTE

AB	**+!**	ABBVIE	**EQ 125MG VALPROIC ACID**	**N019680**	**001**	Sep 12, 1989

DIVALPROEX SODIUM

AB		AJANTA PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A213181**	**001**	Mar 02, 2020
AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078979**	**001**	Jan 23, 2009
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A078919**	**001**	Jan 27, 2009

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE

AB	**+**	ABBVIE	**EQ 125MG VALPROIC ACID**	**N018723**	**003**	Oct 26, 1984
AB	**+**		**EQ 250MG VALPROIC ACID**	**N018723**	**001**	Mar 10, 1983
AB	**+!**		**EQ 500MG VALPROIC ACID**	**N018723**	**002**	Mar 10, 1983

DIVALPROEX SODIUM

AB		ACTAVIS LABS FL INC	**EQ 500MG VALPROIC ACID**	**A079080**	**001**	Feb 25, 2011
AB		APOTEX	**EQ 125MG VALPROIC ACID**	**A077615**	**003**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A077615**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A077615**	**001**	Jul 29, 2008
AB		AUROBINDO PHARMA LTD	**EQ 125MG VALPROIC ACID**	**A090554**	**001**	Apr 21, 2011
AB			**EQ 250MG VALPROIC ACID**	**A090554**	**002**	Apr 21, 2011
AB			**EQ 500MG VALPROIC ACID**	**A090554**	**003**	Apr 21, 2011
AB		CELLTRION	**EQ 125MG VALPROIC ACID**	**A077296**	**001**	Jul 31, 2008
AB			**EQ 250MG VALPROIC ACID**	**A077296**	**002**	Jul 31, 2008
AB			**EQ 500MG VALPROIC ACID**	**A077296**	**003**	Jul 31, 2008
AB		DR REDDYS LABS LTD	**EQ 125MG VALPROIC ACID**	**A078755**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078755**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078755**	**003**	Jul 29, 2008
AB		INVATECH	**EQ 125MG VALPROIC ACID**	**A078290**	**003**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078290**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078290**	**001**	Jul 29, 2008
AB		LUPIN	**EQ 125MG VALPROIC ACID**	**A078790**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078790**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078790**	**003**	Jul 29, 2008
AB		ORBION PHARMS	**EQ 125MG VALPROIC ACID**	**A078853**	**001**	Nov 25, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078853**	**002**	Nov 25, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078853**	**003**	Nov 25, 2008
AB		PRINSTON INC	**EQ 125MG VALPROIC ACID**	**A090210**	**001**	Nov 30, 2009
AB			**EQ 250MG VALPROIC ACID**	**A090210**	**002**	Nov 30, 2009
AB			**EQ 500MG VALPROIC ACID**	**A090210**	**003**	Nov 30, 2009
AB		SUN PHARM INDS	**EQ 125MG VALPROIC ACID**	**A078597**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078597**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078597**	**003**	Jul 29, 2008
AB		UNICHEM LABS LTD	**EQ 125MG VALPROIC ACID**	**A079163**	**001**	Apr 05, 2011

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

AB			**EQ 250MG VALPROIC ACID**	**A079163**	**002**	Apr 05, 2011
AB			**EQ 500MG VALPROIC ACID**	**A079163**	**003**	Apr 05, 2011
AB		UPSHER SMITH LABS	**EQ 125MG VALPROIC ACID**	**A078182**	**001**	Jul 29, 2008
AB			**EQ 250MG VALPROIC ACID**	**A078182**	**002**	Jul 29, 2008
AB			**EQ 500MG VALPROIC ACID**	**A078182**	**003**	Jul 29, 2008
AB		ZYDUS PHARMS USA INC	**EQ 125MG VALPROIC ACID**	**A077100**	**001**	Mar 05, 2009
AB			**EQ 250MG VALPROIC ACID**	**A077100**	**002**	Mar 05, 2009
AB			**EQ 500MG VALPROIC ACID**	**A077100**	**003**	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

AB	**+**	ABBVIE	**EQ 250MG VALPROIC ACID**	**N021168**	**002**	May 31, 2002
AB	**+!**		**EQ 500MG VALPROIC ACID**	**N021168**	**001**	Aug 04, 2000

DIVALPROEX SODIUM

AB		AMNEAL PHARMS	**EQ 250MG VALPROIC ACID**	**A203730**	**001**	May 29, 2015
AB			**EQ 500MG VALPROIC ACID**	**A203730**	**002**	May 29, 2015
AB		AUROBINDO PHARMA LTD	**EQ 250MG VALPROIC ACID**	**A202419**	**001**	Jun 02, 2014
AB			**EQ 500MG VALPROIC ACID**	**A202419**	**002**	Jun 02, 2014
AB		DR REDDYS LABS LTD	**EQ 250MG VALPROIC ACID**	**A090161**	**001**	Mar 15, 2012
AB		LUPIN LTD	**EQ 250MG VALPROIC ACID**	**A209286**	**001**	Oct 18, 2019
AB			**EQ 500MG VALPROIC ACID**	**A209286**	**002**	Oct 18, 2019
AB		MYLAN	**EQ 250MG VALPROIC ACID**	**A077567**	**001**	Jan 29, 2009
AB			**EQ 500MG VALPROIC ACID**	**A077567**	**002**	Jan 29, 2009
AB		REDDYS	**EQ 500MG VALPROIC ACID**	**A090070**	**001**	Mar 12, 2012
AB		WOCKHARDT	**EQ 250MG VALPROIC ACID**	**A078705**	**002**	Feb 10, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078705**	**001**	Aug 04, 2009
AB		ZYDUS PHARMS USA INC	**EQ 250MG VALPROIC ACID**	**A078239**	**001**	Feb 27, 2009
AB			**EQ 500MG VALPROIC ACID**	**A078239**	**002**	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

AP		HIKMA	**EQ 12.5MG BASE/ML**	**A074277**	**001**	Oct 31, 1994
AP	**!**	HOSPIRA	**EQ 12.5MG BASE/ML**	**A074086**	**001**	Nov 29, 1993

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**EQ 50MG BASE/100ML**	**N020255**	**001**	Oct 19, 1993
AP	**+!**		**EQ 100MG BASE/100ML**	**N020255**	**003**	Oct 19, 1993
AP	**+!**		**EQ 200MG BASE/100ML**	**N020255**	**004**	Oct 19, 1993
AP	**+!**		**EQ 400MG BASE/100ML**	**N020255**	**005**	Oct 19, 1993
AP	**+!**	HOSPIRA	**EQ 50MG BASE/100ML**	**N020201**	**003**	Oct 19, 1993
AP	**+!**		**EQ 100MG BASE/100ML**	**N020201**	**002**	Oct 19, 1993
AP	**+!**		**EQ 200MG BASE/100ML**	**N020201**	**001**	Oct 19, 1993
AP	**+!**		**EQ 400MG BASE/100ML**	**N020201**	**006**	Jul 07, 1994

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	**+**	ACCORD HLTHCARE	**20MG/ML (20MG/ML)**	**N201195**	**003**	Apr 20, 2012
AP	**+**		**80MG/4ML (20MG/ML)**	**N201195**	**004**	Apr 20, 2012
AP	**+!**		**160MG/8ML (20MG/ML)**	**N201195**	**005**	Apr 20, 2012
AP		ACTAVIS LLC	**20MG/ML (20MG/ML)**	**N203551**	**001**	Apr 12, 2013
AP			**80MG/4ML (20MG/ML)**	**N203551**	**002**	Apr 12, 2013
AP			**160MG/8ML (20MG/ML)**	**N203551**	**004**	Sep 21, 2015
AP		AMNEAL	**20MG/ML (20MG/ML)**	**A209640**	**001**	Jan 19, 2018
AP			**80MG/4ML (20MG/ML)**	**A209640**	**002**	Jan 19, 2018
AP			**160MG/8ML (20MG/ML)**	**A209640**	**003**	Jan 19, 2018
AP		DR REDDYS LABS LTD	**20MG/ML (20MG/ML)**	**A204193**	**001**	Nov 05, 2014
AP			**80MG/4ML (20MG/ML)**	**A204193**	**002**	Nov 05, 2014
AP		EUGIA PHARMA	**20MG/2ML (10MG/ML)**	**A214575**	**001**	Jun 25, 2021
AP			**80MG/8ML (10MG/ML)**	**A214575**	**002**	Jun 25, 2021
AP			**160MG/16ML (10MG/ML)**	**A214575**	**003**	Jun 25, 2021
AP		GLAND PHARMA LTD	**20MG/2ML (10MG/ML)**	**A213510**	**001**	Jul 01, 2021
AP			**80MG/8ML (10MG/ML)**	**A213510**	**002**	Jul 01, 2021
AP			**160MG/16ML (10MG/ML)**	**A213510**	**003**	Jul 01, 2021
AP		HIKMA	**20MG/ML (20MG/ML)**	**A204490**	**001**	Jan 14, 2021
AP			**80MG/4ML (20MG/ML)**	**A204490**	**002**	Jan 14, 2021
AP		HONG KONG	**20MG/2ML (10MG/ML)**	**A209634**	**001**	Aug 24, 2018
AP			**80MG/8ML (10MG/ML)**	**A209634**	**002**	Aug 24, 2018
AP			**160MG/16ML (10MG/ML)**	**A209634**	**003**	Aug 24, 2018

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	**+!**	HOSPIRA INC	**20MG/2ML (10MG/ML)**	**N022234**	**001**	Mar 08, 2011
AP	**+!**		**80MG/8ML (10MG/ML)**	**N022234**	**002**	Mar 08, 2011
AP	**+!**		**160MG/16ML (10MG/ML)**	**N022234**	**003**	Mar 08, 2011
AP		INGENUS PHARMS LLC	**80MG/8ML (10MG/ML)**	**A207563**	**002**	Aug 31, 2017
AP			**160MG/16ML (10MG/ML)**	**A207563**	**003**	Aug 31, 2017
AP		JIANGSU PHARMS	**20MG/ML (20MG/ML)**	**A207252**	**001**	Aug 09, 2017
AP			**80MG/4ML (20MG/ML)**	**A207252**	**002**	Aug 09, 2017
AP			**160MG/8ML (20MG/ML)**	**A207252**	**003**	Aug 09, 2017
AP		MYLAN LABS LTD	**20MG/2ML (10MG/ML)**	**A210072**	**001**	Jul 02, 2018
AP			**80MG/8ML (10MG/ML)**	**A210848**	**001**	Jul 06, 2018
AP			**160MG/8ML (20MG/ML)**	**A208137**	**001**	Apr 01, 2019
AP			**160MG/16ML (10MG/ML)**	**A208859**	**001**	Apr 30, 2018
AP		SANDOZ	**20MG/2ML (10MG/ML)**	**N201525**	**001**	Jun 29, 2011
AP			**80MG/8ML (10MG/ML)**	**N201525**	**002**	Jun 29, 2011
AP			**160MG/16ML (10MG/ML)**	**N201525**	**003**	Jun 29, 2011
AP		SHILPA	**20MG/ML (20MG/ML)**	**A210327**	**001**	May 16, 2019
AP	**+!**		**20MG/ML (20MG/ML)**	**N205934**	**001**	Dec 22, 2015
AP			**80MG/4ML (20MG/ML)**	**A210327**	**002**	May 16, 2019
AP	**+!**		**80MG/4ML (20MG/ML)**	**N205934**	**002**	Dec 22, 2015
AP			**160MG/8ML (20MG/ML)**	**A210327**	**003**	May 16, 2019
AP	**+!**		**160MG/8ML (20MG/ML)**	**N205934**	**003**	Dec 22, 2015

TAXOTERE

AP	**+!**	SANOFI AVENTIS US	**20MG/ML (20MG/ML)**	**N020449**	**003**	Aug 03, 2010
AP	**+!**		**80MG/4ML (20MG/ML)**	**N020449**	**004**	Aug 02, 2010
AP	**+!**		**160MG/8ML (20MG/ML)**	**N020449**	**005**	Apr 13, 2012

DOCETAXEL

		ACTAVIS LLC	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
	+	HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016
	+		80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016
	+		160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017

SOLUTION;INTRAVENOUS

DOCETAXEL

AP		SUN PHARM	**20MG/ML (20MG/ML)**	**N022534**	**003**	Jan 08, 2019
AP			**80MG/4ML (20MG/ML)**	**N022534**	**004**	Jan 08, 2019
AP			**160MG/8ML (20MG/ML)**	**N022534**	**005**	Jan 08, 2019

DOFETILIDE

CAPSULE;ORAL

DOFETILDE

AB		AUROBINDO PHARMA LTD	**0.125MG**	**A210740**	**001**	Jan 22, 2019
AB			**0.25MG**	**A210740**	**002**	Jan 22, 2019
AB			**0.5MG**	**A210740**	**003**	Jan 22, 2019

DOFETILIDE

AB		ACCORD HLTHCARE	**0.125MG**	**A213338**	**001**	Jun 19, 2020
AB			**0.25MG**	**A213338**	**002**	Jun 19, 2020
AB			**0.5MG**	**A213338**	**003**	Jun 19, 2020
AB		BIONPHARMA INC	**0.125MG**	**A208625**	**001**	Apr 10, 2018
AB			**0.25MG**	**A208625**	**002**	Apr 10, 2018
AB			**0.5MG**	**A208625**	**003**	Apr 10, 2018
AB		GRANULES	**0.125MG**	**A212750**	**001**	Oct 14, 2021
AB			**0.25MG**	**A212750**	**002**	Oct 14, 2021
AB			**0.5MG**	**A212750**	**003**	Oct 14, 2021
AB		MAYNE PHARMA INC	**0.125MG**	**A207058**	**001**	Jun 06, 2016
AB			**0.25MG**	**A207058**	**002**	Jun 06, 2016
AB			**0.5MG**	**A207058**	**003**	Jun 06, 2016
AB		MSN	**0.125MG**	**A213220**	**001**	Jan 29, 2020
AB			**0.25MG**	**A213220**	**002**	Jan 29, 2020
AB			**0.5MG**	**A213220**	**003**	Jan 29, 2020
AB		SIGMAPHARM LABS LLC	**0.125MG**	**A207746**	**001**	Mar 26, 2018
AB			**0.25MG**	**A207746**	**002**	Mar 26, 2018
AB			**0.5MG**	**A207746**	**003**	Mar 26, 2018
AB		STRIDES PHARMA	**0.125MG**	**A208519**	**001**	Oct 09, 2018
AB			**0.25MG**	**A208519**	**002**	Oct 09, 2018
AB			**0.5MG**	**A208519**	**003**	Oct 09, 2018
AB		SUN PHARM	**0.125MG**	**A210466**	**001**	Oct 09, 2018
AB			**0.25MG**	**A210466**	**002**	Oct 09, 2018
AB			**0.5MG**	**A210466**	**003**	Oct 09, 2018

TIKOSYN

AB	**+**	PFIZER	**0.125MG**	**N020931**	**001**	Oct 01, 1999

DOFETILIDE

CAPSULE;ORAL

TIKOSYN

AB	**+**		**0.25MG**	**N020931**	**002**	Oct 01, 1999
AB	**+!**		**0.5MG**	**N020931**	**003**	Oct 01, 1999

DOLASETRON MESYLATE

TABLET;ORAL

ANZEMET

+!	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

+	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016
+		EQ 25MG BASE	N204790	003	Jun 09, 2016
+!		EQ 50MG BASE	N204790	001	Aug 12, 2013

TABLET, FOR SUSPENSION;ORAL

TIVICAY PD

+!	VIIV HLTHCARE	EQ 5MG BASE	N213983	001	Jun 12, 2020

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

DOVATO

+!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

JULUCA

+!	VIIV HLTHCARE	EQ 50MG BASE;EQ 25MG BASE	N210192	001	Nov 21, 2017

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

ARICEPT

AB	**+**	EISAI INC	**5MG**	**N020690**	**002**	Nov 25, 1996
AB	**+!**		**10MG**	**N020690**	**001**	Nov 25, 1996
AB	**+!**		**23MG**	**N022568**	**001**	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

AB		ACI	**5MG**	**A078662**	**001**	May 31, 2011
AB			**10MG**	**A078662**	**002**	May 31, 2011
AB		ALEMBIC PHARMS LTD	**5MG**	**A201724**	**001**	Feb 25, 2013
AB			**10MG**	**A201724**	**002**	Feb 25, 2013
AB		AUROBINDO	**5MG**	**A090056**	**001**	May 31, 2011
AB			**10MG**	**A090056**	**002**	May 31, 2011
AB		CADILA	**5MG**	**A090100**	**001**	Oct 24, 2012
AB			**10MG**	**A090100**	**002**	Oct 24, 2012
AB		CADILA PHARMS LTD	**5MG**	**A204609**	**001**	Sep 19, 2017
AB			**10MG**	**A204609**	**002**	Sep 19, 2017
AB		CIPLA LTD	**5MG**	**A077518**	**001**	May 31, 2011
AB			**10MG**	**A077518**	**002**	May 31, 2011
AB		DEXCEL PHARMA	**23MG**	**A203713**	**001**	Feb 19, 2016
AB		DR REDDYS	**23MG**	**A202723**	**001**	Jul 24, 2013
AB		DR REDDYS LABS LTD	**5MG**	**A201001**	**001**	May 31, 2011
AB			**10MG**	**A201001**	**002**	May 31, 2011
AB		GRAVITI PHARMS	**5MG**	**A202114**	**001**	Jul 05, 2013
AB			**10MG**	**A202114**	**002**	Jul 05, 2013
AB		HETERO LABS LTD V	**5MG**	**A203034**	**001**	Jan 30, 2015
AB			**10MG**	**A203034**	**002**	Jan 30, 2015
AB		INDICUS PHARMA	**5MG**	**A201634**	**001**	Jun 13, 2012
AB			**10MG**	**A201634**	**002**	Jun 13, 2012
AB			**23MG**	**A203419**	**001**	Apr 12, 2016
AB		JUBILANT GENERICS	**5MG**	**A090768**	**001**	May 31, 2011
AB			**10MG**	**A090768**	**002**	May 31, 2011
AB		LUPIN LTD	**23MG**	**A202782**	**001**	Oct 30, 2015
AB		MACLEODS PHARMS LTD	**5MG**	**A201146**	**001**	Aug 17, 2012
AB			**10MG**	**A201146**	**002**	Aug 17, 2012
AB			**23MG**	**A202631**	**001**	Jan 22, 2014
AB		PLIVA HRVATSKA DOO	**5MG**	**A090425**	**001**	May 31, 2011
AB			**10MG**	**A090425**	**002**	May 31, 2011
AB		PRINSTON INC	**5MG**	**A200292**	**001**	May 31, 2011
AB			**10MG**	**A200292**	**002**	May 31, 2011
AB		SANDOZ	**5MG**	**A090290**	**001**	May 31, 2011
AB			**10MG**	**A090290**	**002**	May 31, 2011
AB		SCIEGEN PHARMS INC	**5MG**	**A203907**	**001**	Oct 29, 2014
AB			**10MG**	**A203907**	**002**	Oct 29, 2014

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB		STRIDES PHARMA	**5MG**	**A090551**	**001**	May 31, 2011
AB			**10MG**	**A090551**	**002**	May 31, 2011
AB		SUN PHARM INDS	**5MG**	**A090493**	**001**	May 31, 2011
AB			**10MG**	**A090493**	**002**	May 31, 2011
AB		TORRENT PHARMS	**5MG**	**A090686**	**001**	May 31, 2011
AB			**10MG**	**A090686**	**002**	May 31, 2011
AB		TWI PHARMS	**23MG**	**A203104**	**001**	Oct 29, 2014
AB		ZYDUS PHARMS	**23MG**	**A203162**	**001**	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

AB		HISUN PHARM HANGZHOU	**5MG**	**A205269**	**001**	Jul 27, 2018
AB			**10MG**	**A205269**	**002**	Jul 27, 2018
AB		MACLEODS PHARMS LTD	**5MG**	**A201787**	**001**	Dec 14, 2012
AB			**10MG**	**A201787**	**002**	Dec 14, 2012
AB		SANDOZ	**5MG**	**A091198**	**001**	May 10, 2011
AB	**!**		**10MG**	**A091198**	**002**	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMZARIC

+		ALLERGAN	10MG;7MG	N206439	003	Jul 18, 2016
+			10MG;14MG	N206439	001	Dec 23, 2014
+			10MG;21MG	N206439	004	Jul 18, 2016
+!			10MG;28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP		HIKMA INTL PHARMS	**40MG/ML**	**A207707**	**001**	Apr 11, 2018
AP			**80MG/ML**	**A207707**	**002**	Apr 11, 2018
AP	**+!**	HOSPIRA	**40MG/ML**	**N018132**	**001**	
AP	**+!**		**80MG/100ML**	**N018132**	**002**	Feb 04, 1982
AP	**+!**		**80MG/ML**	**N018132**	**004**	Jul 09, 1982
AP	**+!**		**160MG/100ML**	**N018132**	**003**	Feb 04, 1982

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

AP	**+!**	B BRAUN	**80MG/100ML**	**N019099**	**002**	Oct 15, 1986
AP	**+!**		**320MG/100ML**	**N019099**	**004**	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**160MG/100ML**	**N019099**	**003**	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**80MG/100ML**	**N019615**	**001**	Mar 27, 1987
AP	**+!**		**160MG/100ML**	**N019615**	**002**	Mar 27, 1987
AP	**+!**		**320MG/100ML**	**N019615**	**003**	Mar 27, 1987
AP	**+!**	HOSPIRA	**80MG/100ML**	**N018826**	**001**	Sep 30, 1983
AP	**+!**		**160MG/100ML**	**N018826**	**002**	Sep 30, 1983
AP	**+!**		**320MG/100ML**	**N018826**	**003**	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+!		B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+!		BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987

DORAVIRINE

TABLET;ORAL

PIFELTRO

+!		MSD MERCK CO	100MG	N210806	001	Aug 30, 2018

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

DELSTRIGO

+!		MSD MERCK CO	100MG;300MG;300MG	N210807	001	Aug 30, 2018

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		AKORN	**EQ 2% BASE**	**A077846**	**001**	Oct 28, 2008
AT		ALEMBIC PHARMS LTD	**EQ 2% BASE**	**A212639**	**001**	Aug 09, 2019
AT		BAUSCH AND LOMB	**EQ 2% BASE**	**A090143**	**001**	Jun 25, 2009
AT		FDC LTD	**EQ 2% BASE**	**A205294**	**001**	Jan 24, 2019
AT		INDOCO	**EQ 2% BASE**	**A202053**	**001**	Sep 11, 2014
AT		MICRO LABS	**EQ 2% BASE**	**A204778**	**001**	Nov 08, 2019
AT		SANDOZ INC	**EQ 2% BASE**	**A078748**	**001**	Nov 06, 2008

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE						
AT			**EQ 2% BASE**	**A078981**	**001**	Apr 13, 2009
TRUSOPT						
AT	**+!**	MERCK	**EQ 2% BASE**	**N020408**	**001**	Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT						
AT	**+!**	AKORN	**EQ 2% BASE;EQ 0.5% BASE**	**N020869**	**001**	Apr 07, 1998
COSOPT PF						
AT	**+!**	AKORN	**EQ 2% BASE;EQ 0.5% BASE**	**N202667**	**001**	Feb 01, 2012
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE						
AT		AKORN	**EQ 2% BASE;EQ 0.5% BASE**	**A077847**	**001**	Oct 28, 2008
AT			**EQ 2% BASE;EQ 0.5% BASE**	**A203058**	**001**	Sep 22, 2014
AT		ALEMBIC PHARMS LTD	**EQ 2% BASE;EQ 0.5% BASE**	**A213099**	**001**	May 04, 2021
AT		BAUSCH AND LOMB	**EQ 2% BASE;EQ 0.5% BASE**	**A090037**	**001**	Jul 14, 2009
AT		EUGIA PHARMA	**EQ 2% BASE;EQ 0.5% BASE**	**A207629**	**001**	May 14, 2021
AT			**EQ 2% BASE;EQ 0.5% BASE**	**A207630**	**001**	Jul 24, 2018
AT		FDC LTD	**EQ 2% BASE;EQ 0.5% BASE**	**A205295**	**001**	Jun 13, 2019
AT		INDOCO	**EQ 2% BASE;EQ 0.5% BASE**	**A202054**	**001**	Sep 03, 2014
AT		MICRO LABS	**EQ 2.0% BASE;EQ 0.5% BASE**	**A204777**	**001**	May 28, 2020
AT		SANDOZ	**EQ 2% BASE;EQ 0.5% BASE**	**A078749**	**001**	Nov 06, 2008
AT		SANDOZ INC	**EQ 2% BASE;EQ 0.5% BASE**	**A090604**	**001**	Nov 18, 2009
AT		SOMERSET	**EQ 2% BASE;EQ 0.5% BASE**	**A207523**	**001**	Jun 25, 2019
AT		TEVA PHARMS	**EQ 2% BASE;EQ 0.5% BASE**	**A078704**	**001**	Sep 28, 2009

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM						
AP	**+!**	HIKMA	**20MG/ML**	**N014879**	**001**	
DOXAPRAM HYDROCHLORIDE						
AP		ATHENEX INC	**20MG/ML**	**A076266**	**001**	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET;ORAL

CARDURA						
AB	**+!**	UPJOHN	**EQ 1MG BASE**	**N019668**	**001**	Nov 02, 1990
AB	**+**		**EQ 2MG BASE**	**N019668**	**002**	Nov 02, 1990
AB	**+**		**EQ 4MG BASE**	**N019668**	**003**	Nov 02, 1990
AB	**+**		**EQ 8MG BASE**	**N019668**	**004**	Nov 02, 1990
DOXAZOSIN MESYLATE						
AB		ACCORD HLTHCARE	**EQ 1MG BASE**	**A202824**	**001**	Jun 11, 2014
AB			**EQ 2MG BASE**	**A202824**	**002**	Jun 11, 2014
AB			**EQ 4MG BASE**	**A202824**	**003**	Jun 11, 2014
AB			**EQ 8MG BASE**	**A202824**	**004**	Jun 11, 2014
AB		APOTEX	**EQ 1MG BASE**	**A075580**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075580**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075580**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075580**	**004**	Oct 18, 2000
AB		PLIVA	**EQ 1MG BASE**	**A075750**	**001**	Jun 08, 2001
AB			**EQ 2MG BASE**	**A075750**	**002**	Jun 08, 2001
AB			**EQ 4MG BASE**	**A075750**	**003**	Jun 08, 2001
AB			**EQ 8MG BASE**	**A075750**	**004**	Jun 08, 2001
AB		TEVA	**EQ 1MG BASE**	**A075536**	**001**	Oct 18, 2000
AB			**EQ 2MG BASE**	**A075536**	**002**	Oct 18, 2000
AB			**EQ 4MG BASE**	**A075536**	**003**	Oct 18, 2000
AB			**EQ 8MG BASE**	**A075536**	**004**	Oct 18, 2000
AB		UPSHER SMITH LABS	**EQ 1MG BASE**	**A209013**	**001**	Apr 17, 2018
AB			**EQ 2MG BASE**	**A209013**	**002**	Apr 17, 2018
AB			**EQ 4MG BASE**	**A209013**	**003**	Apr 17, 2018
AB			**EQ 8MG BASE**	**A209013**	**004**	Apr 17, 2018
AB		ZYDUS PHARMS	**EQ 1MG BASE**	**A208719**	**001**	Jul 07, 2017
AB			**EQ 2MG BASE**	**A208719**	**002**	Jul 07, 2017
AB			**EQ 4MG BASE**	**A208719**	**003**	Jul 07, 2017
AB			**EQ 8MG BASE**	**A208719**	**004**	Jul 07, 2017
BX		HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018
BX			EQ 2MG BASE	A205210	002	Feb 13, 2018
BX			EQ 4MG BASE	A205210	003	Feb 13, 2018
BX			EQ 8MG BASE	A205210	004	Feb 13, 2018

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+	UPJOHN	EQ 4MG BASE	N021269	001	Feb 22, 2005
+!		EQ 8MG BASE	N021269	002	Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	**EQ 10MG BASE**	**A212624**	**001**	Sep 13, 2019
AB		**EQ 25MG BASE**	**A212624**	**002**	Sep 13, 2019
AB		**EQ 50MG BASE**	**A212624**	**003**	Sep 13, 2019
AB		**EQ 75MG BASE**	**A212624**	**004**	Sep 13, 2019
AB		**EQ 100MG BASE**	**A212624**	**005**	Sep 13, 2019
AB	ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A215076**	**001**	Apr 21, 2021
AB		**EQ 25MG BASE**	**A215076**	**002**	Apr 21, 2021
AB		**EQ 50MG BASE**	**A215076**	**003**	Apr 21, 2021
AB		**EQ 75MG BASE**	**A215076**	**004**	Apr 21, 2021
AB		**EQ 100MG BASE**	**A215076**	**005**	Apr 21, 2021
AB	AMNEAL PHARMS CO	**EQ 10MG BASE**	**A207482**	**001**	Jun 28, 2017
AB		**EQ 25MG BASE**	**A207482**	**002**	Jun 28, 2017
AB		**EQ 50MG BASE**	**A207482**	**003**	Jun 28, 2017
AB		**EQ 75MG BASE**	**A207482**	**004**	Jun 28, 2017
AB		**EQ 100MG BASE**	**A207482**	**005**	Jun 28, 2017
AB	APPCO	**EQ 10MG BASE**	**A214908**	**001**	Apr 01, 2021
AB		**EQ 25MG BASE**	**A214908**	**002**	Apr 01, 2021
AB		**EQ 50MG BASE**	**A214908**	**003**	Apr 01, 2021
AB		**EQ 75MG BASE**	**A214908**	**004**	Apr 01, 2021
AB		**EQ 100MG BASE**	**A214908**	**005**	Apr 01, 2021
AB	AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A211603**	**001**	Mar 27, 2019
AB		**EQ 25MG BASE**	**A211603**	**002**	Mar 27, 2019
AB		**EQ 50MG BASE**	**A211603**	**003**	Mar 27, 2019
AB		**EQ 75MG BASE**	**A211603**	**004**	Mar 27, 2019
AB		**EQ 100MG BASE**	**A211603**	**005**	Mar 27, 2019
AB	CONTRACT PHARMACAL	**EQ 10MG BASE**	**A213474**	**001**	Jul 28, 2020
AB		**EQ 25MG BASE**	**A213474**	**002**	Jul 28, 2020
AB		**EQ 50MG BASE**	**A213474**	**003**	Jul 28, 2020
AB		**EQ 75MG BASE**	**A213474**	**004**	Jul 28, 2020
AB		**EQ 100MG BASE**	**A213474**	**005**	Jul 28, 2020
AB	EPIC PHARMA LLC	**EQ 10MG BASE**	**A210675**	**001**	Oct 16, 2020
AB		**EQ 25MG BASE**	**A210675**	**002**	Oct 16, 2020
AB		**EQ 100MG BASE**	**A210675**	**003**	Oct 16, 2020
AB	LEADING PHARMA LLC	**EQ 10MG BASE**	**A211619**	**001**	Mar 09, 2021
AB		**EQ 25MG BASE**	**A211619**	**002**	Mar 09, 2021
AB		**EQ 50MG BASE**	**A211619**	**003**	Mar 09, 2021
AB		**EQ 75MG BASE**	**A211619**	**004**	Mar 09, 2021
AB		**EQ 100MG BASE**	**A211619**	**005**	Mar 09, 2021
AB		**EQ 150MG BASE**	**A211618**	**001**	Mar 01, 2021
AB	MYLAN PHARMS INC	**EQ 10MG BASE**	**A070791**	**002**	May 13, 1986
AB **!**		**EQ 25MG BASE**	**A070791**	**003**	May 13, 1986
AB		**EQ 50MG BASE**	**A070791**	**001**	May 13, 1986
AB		**EQ 75MG BASE**	**A070791**	**004**	May 13, 1986
AB **!**		**EQ 100MG BASE**	**A070791**	**005**	May 13, 1986
AB	PAR PHARM	**EQ 10MG BASE**	**A071422**	**002**	Nov 09, 1987
AB		**EQ 25MG BASE**	**A071422**	**003**	Nov 09, 1987
AB		**EQ 50MG BASE**	**A071422**	**004**	Nov 09, 1987
AB		**EQ 75MG BASE**	**A071422**	**005**	Nov 09, 1987
AB		**EQ 100MG BASE**	**A071422**	**001**	Nov 09, 1987
AB	TARO PHARM INDS LTD	**EQ 10MG BASE**	**A213063**	**001**	Jul 01, 2020
AB		**EQ 25MG BASE**	**A213063**	**002**	Jul 01, 2020
AB		**EQ 50MG BASE**	**A213063**	**003**	Jul 01, 2020
AB		**EQ 75MG BASE**	**A213063**	**004**	Jul 01, 2020
AB		**EQ 100MG BASE**	**A213063**	**005**	Jul 01, 2020
!	PAR PHARM	EQ 150MG BASE	A071422	006	Nov 09, 1987

CONCENTRATE;ORAL

DOXEPIN HYDROCHLORIDE

AA **!**	LANNETT CO INC	**EQ 10MG BASE/ML**	**A074721**	**001**	Dec 29, 1998
AA	WOCKHARDT BIO AG	**EQ 10MG BASE/ML**	**A071918**	**001**	Jul 20, 1988

CREAM;TOPICAL

ZONALON

+!	MYLAN	5%	N020126	001	Apr 01, 1994

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 3MG BASE**	**A201951**	**001**	Jul 26, 2013
AB			**EQ 6MG BASE**	**A201951**	**002**	Jul 26, 2013
AB		RK PHARMA	**EQ 3MG BASE**	**A202337**	**001**	Jan 20, 2016
AB			**EQ 6MG BASE**	**A202337**	**002**	Jan 20, 2016

SILENOR

AB	**+**	CURRAX	**EQ 3MG BASE**	**N022036**	**001**	Mar 17, 2010
AB	**+!**		**EQ 6MG BASE**	**N022036**	**002**	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE;ORAL

DOXERCALCIFEROL

AB		AVET	**0.5MCG**	**A205360**	**001**	Sep 15, 2020
AB			**1MCG**	**A205360**	**002**	Sep 15, 2020
AB			**2.5MCG**	**A205360**	**003**	Sep 15, 2020
AB		RISING	**0.5MCG**	**A201518**	**001**	Sep 09, 2016
AB			**1MCG**	**A201518**	**002**	Sep 09, 2016
AB			**2.5MCG**	**A201518**	**003**	Sep 09, 2016

HECTOROL

AB	**+**	SANOFI	**0.5MCG**	**N020862**	**002**	Apr 23, 2004
AB	**+**		**1MCG**	**N020862**	**003**	Jul 13, 2009
AB	**+!**		**2.5MCG**	**N020862**	**001**	Jun 09, 1999

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		AKORN	**2MCG/ML (2MCG/ML)**	**A203929**	**002**	Mar 28, 2016
AP			**4MCG/2ML (2MCG/ML)**	**A203929**	**001**	May 07, 2015
AP		AMNEAL	**2MCG/ML (2MCG/ML)**	**A208974**	**001**	May 24, 2017
AP			**4MCG/2ML (2MCG/ML)**	**A208974**	**002**	May 24, 2017
AP		GLAND PHARMA LTD	**4MCG/2ML (2MCG/ML)**	**A210452**	**001**	Sep 26, 2019
AP		HIKMA	**4MCG/2ML (2MCG/ML)**	**A091101**	**001**	Aug 30, 2013
AP	**+**	HOSPIRA INC	**4MCG/2ML (2MCG/ML)**	**N208614**	**001**	Jul 24, 2018
AP		LUPIN LTD	**4MCG/2ML (2MCG/ML)**	**A210801**	**001**	Nov 01, 2018
AP		MEITHEAL	**4MCG/2ML (2MCG/ML)**	**A211670**	**001**	Feb 07, 2020
AP		SANDOZ INC	**4MCG/2ML (2MCG/ML)**	**A091333**	**001**	May 05, 2014
AP			**4MCG/2ML (2MCG/ML)**	**A200926**	**001**	Feb 04, 2014

HECTOROL

AP	**+**	SANOFI	**2MCG/ML (2MCG/ML)**	**N021027**	**002**	Apr 06, 2000
AP	**+!**		**4MCG/2ML (2MCG/ML)**	**N021027**	**001**	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP		ACTAVIS INC	**2MG/ML**	**A203622**	**001**	Jun 27, 2014
AP			**200MG/100ML**	**A203622**	**002**	Jun 27, 2014
AP		AMNEAL	**20MG/VIAL**	**A208888**	**001**	Feb 17, 2017
AP			**50MG/VIAL**	**A208888**	**002**	Feb 17, 2017
AP		FRESENIUS KABI USA	**2MG/ML**	**A063277**	**001**	Oct 26, 1995
AP		GLAND PHARMA LTD	**2MG/ML**	**A209825**	**001**	Aug 11, 2017
AP		HIKMA	**2MG/ML**	**A062975**	**001**	Mar 17, 1989
AP	**!**		**10MG/VIAL**	**A062921**	**001**	Mar 17, 1989
AP	**!**		**20MG/VIAL**	**A062921**	**002**	Mar 17, 1989
AP	**!**		**50MG/VIAL**	**A062921**	**003**	Mar 17, 1989
AP			**200MG/100ML**	**A064097**	**001**	Sep 13, 1994
AP		MYLAN LABS LTD	**50MG/VIAL**	**A200170**	**002**	Oct 28, 2011
AP	**+!**	PFIZER	**2MG/ML**	**N050629**	**001**	Dec 23, 1987
AP	**+!**		**200MG/100ML**	**N050629**	**002**	May 03, 1988
AP		PHARMACHEMIE BV	**2MG/ML**	**A063336**	**001**	Feb 28, 1995
AP			**10MG/VIAL**	**A063097**	**001**	May 21, 1990
AP			**20MG/VIAL**	**A063097**	**002**	May 21, 1990
AP			**50MG/VIAL**	**A063097**	**003**	May 21, 1990
AP			**200MG/100ML**	**A063336**	**004**	Feb 28, 1995
AP		SAGENT PHARMS	**2MG/ML**	**A091495**	**001**	Mar 18, 2013
AP		SUN PHARM INDS	**2MG/ML**	**A091418**	**001**	Feb 15, 2012
AP		TEVA PHARMS USA	**2MG/ML**	**A064140**	**001**	Jul 28, 1995
AP			**200MG/100ML**	**A064140**	**002**	Jul 28, 1995
	+	PFIZER	150MG/75ML	N050629	003	Mar 28, 2011

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)

AB	**+**	BAXTER HLTHCARE CORP	**20MG/10ML (2MG/ML)**	**N050718**	**001**	Nov 17, 1995
AB	**+**		**50MG/25ML (2MG/ML)**	**N050718**	**002**	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL;INJECTION

DOXORUBICIN HYDROCHLORIDE

AB		AYANA PHARMA LTD	20MG/10ML (2MG/ML)	A207228	001	Oct 12, 2021
AB			50MG/25ML (2MG/ML)	A207228	002	Oct 12, 2021
AB		ZYDUS	20MG/10ML (2MG/ML)	A212299	001	Sep 10, 2020
AB			50MG/25ML (2MG/ML)	A212299	002	Sep 10, 2020

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB		DR REDDYS LABS LTD	20MG/10ML (2MG/ML)	A208657	001	May 15, 2017
AB			50MG/25ML (2MG/ML)	A208657	002	May 15, 2017
AB	!	SUN PHARM	20MG/10ML (2MG/ML)	A203263	001	Feb 04, 2013
AB	!		50MG/25ML (2MG/ML)	A203263	002	Feb 04, 2013

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB		ALEMBIC PHARMS LTD	EQ 75MG BASE	A209165	001	Jul 28, 2017
AB			EQ 100MG BASE	A209165	002	Jul 28, 2017
AB		COSETTE	EQ 50MG BASE	A204446	001	May 28, 2015
AB			EQ 75MG BASE	A204446	002	May 28, 2015
AB			EQ 100MG BASE	A204446	003	May 28, 2015
AB		IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011
AB		LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014
AB			EQ 75MG BASE	A204234	002	Mar 05, 2014
AB			EQ 100MG BASE	A204234	003	Mar 05, 2014
AB		MAYNE PHARMA INC	EQ 50MG BASE	A209396	001	Sep 29, 2017
AB			EQ 75MG BASE	A209396	002	Sep 29, 2017
AB			EQ 100MG BASE	A209396	003	Sep 29, 2017
AB		STRIDES PHARMA	EQ 50MG BASE	A065055	001	Dec 01, 2000
AB			EQ 100MG BASE	A065055	002	Dec 01, 2000
AB	!		EQ 150MG BASE	A065055	003	Jul 15, 2005
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000
AB			EQ 75MG BASE	A065053	003	Sep 10, 2003
AB	!		EQ 100MG BASE	A065053	002	Nov 22, 2000
AB		ZYDUS PHARMS	EQ 50MG BASE	A205115	001	Feb 18, 2016
AB			EQ 75MG BASE	A205115	002	Feb 18, 2016
AB			EQ 100MG BASE	A205115	003	Feb 18, 2016

MONODOX

AB	+	CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006
AB	+		EQ 100MG BASE	N050641	001	Dec 29, 1989

ORACEA

	+!	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB		CHARTWELL	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008
AB		LUPIN LTD	EQ 25MG BASE/5ML	A201678	001	Mar 18, 2013

VIBRAMYCIN

AB	+!	PFIZER	EQ 25MG BASE/5ML	N050006	001	

TABLET;ORAL

DOXYCYCLINE

AB		HERITAGE PHARMS INC	EQ 50MG BASE	A091605	001	Dec 20, 2011
AB			EQ 75MG BASE	A091605	002	Dec 20, 2011
AB			EQ 100MG BASE	A091605	003	Dec 20, 2011
AB	!		EQ 150MG BASE	A091605	004	Dec 20, 2011
AB		LANNETT CO INC	EQ 50MG BASE	A065285	001	Dec 08, 2005
AB			EQ 75MG BASE	A065285	003	Jul 30, 2008
AB			EQ 100MG BASE	A065285	002	Dec 08, 2005
AB			EQ 150MG BASE	A065285	004	Jul 30, 2008
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006
AB			EQ 75MG BASE	A065356	002	May 31, 2006
AB			EQ 100MG BASE	A065356	003	May 31, 2006
AB			EQ 150MG BASE	A065356	004	Jul 29, 2010
AB		ZYDUS PHARMS	EQ 50MG BASE	A209582	001	Sep 28, 2017
AB			EQ 75MG BASE	A209582	002	Sep 28, 2017
AB			EQ 100MG BASE	A209582	003	Sep 28, 2017
AB			EQ 150MG BASE	A209582	004	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION;ORAL

VIBRAMYCIN

	+!	PFIZER	EQ 50MG BASE/5ML	N050480	001	

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB		ACTAVIS LABS FL INC	**EQ 50MG BASE**	**A062031**	**002**	Oct 13, 1982
AB			**EQ 100MG BASE**	**A062031**	**001**	
AB		ALEMBIC PHARMS LTD	**EQ 50MG BASE**	**A210527**	**001**	Jun 13, 2018
AB			**EQ 100MG BASE**	**A210527**	**002**	Jun 13, 2018
AB		AMNEAL PHARMS	**EQ 100MG BASE**	**A207289**	**001**	Jun 27, 2016
AB		CHANGZHOU PHARM	**EQ 100MG BASE**	**A209402**	**001**	Oct 07, 2019
AB		CHARTWELL	**EQ 50MG BASE**	**A062500**	**001**	Sep 11, 1984
AB			**EQ 100MG BASE**	**A062500**	**002**	Sep 11, 1984
AB		HIKMA INTL PHARMS	**EQ 50MG BASE**	**A062396**	**002**	Nov 07, 1984
AB			**EQ 100MG BASE**	**A062396**	**001**	May 07, 1984
AB		NESHER PHARMS	**EQ 50MG BASE**	**A208263**	**001**	Nov 22, 2021
AB			**EQ 100MG BASE**	**A208263**	**002**	Nov 22, 2021
AB		SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A062676**	**002**	Jul 10, 1986
AB			**EQ 100MG BASE**	**A062676**	**001**	Jul 10, 1986
AB		ZYDUS PHARMS	**EQ 50MG BASE**	**A207774**	**001**	May 31, 2018
AB			**EQ 100MG BASE**	**A207774**	**002**	May 31, 2018

VIBRAMYCIN

AB	**+!**	PFIZER	**EQ 100MG BASE**	**N050007**	**002**	

INJECTABLE;INJECTION

DOXY 100

AP	**!**	FRESENIUS KABI USA	**EQ 100MG BASE/VIAL**	**A062475**	**001**	Dec 09, 1983

DOXY 200

AP	**!**	FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A062475**	**002**	Dec 09, 1983

DOXYCYCLINE

AP	**!**	HIKMA	**EQ 100MG BASE/VIAL**	**A062569**	**001**	Mar 09, 1988
AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A091406**	**001**	Aug 21, 2012
AP		ZYDUS PHARMS	**EQ 100MG BASE/VIAL**	**A207757**	**001**	Sep 28, 2017
AP			**EQ 200MG BASE/VIAL**	**A207757**	**002**	Sep 28, 2017

DOXYCYCLINE HYCLATE

AP		WEST-WARD PHARMS INT	**EQ 100MG BASE/VIAL**	**A062992**	**001**	Feb 16, 1989
AP			**EQ 200MG BASE/VIAL**	**A062992**	**002**	Feb 16, 1989

TABLET;ORAL

ACTICLATE

AB	**+**	ALMIRALL	**EQ 75MG BASE**	**N205931**	**001**	Jul 25, 2014
AB	**+!**		**EQ 150MG BASE**	**N205931**	**002**	Jul 25, 2014

DOXYCYCLINE HYCLATE

AB		ACELLA	**EQ 100MG BASE**	**A210664**	**001**	Mar 16, 2020
AB		ACTAVIS LABS FL INC	**EQ 100MG BASE**	**A062421**	**001**	Feb 02, 1983
AB		AJANTA PHARMA LTD	**EQ 75MG BASE**	**A211584**	**001**	Jun 01, 2020
AB			**EQ 150MG BASE**	**A211584**	**002**	Jun 01, 2020
AB		ALEMBIC PHARMS LTD	**EQ 20MG BASE**	**A210537**	**001**	Mar 03, 2020
AB			**EQ 50MG BASE**	**A210536**	**002**	Sep 14, 2021
AB			**EQ 75MG BASE**	**A211744**	**001**	Jun 30, 2020
AB			**EQ 150MG BASE**	**A211744**	**002**	Jun 30, 2020
AB		APOTEX	**EQ 75MG BASE**	**A209243**	**001**	Apr 15, 2019
AB			**EQ 150MG BASE**	**A209243**	**002**	Apr 15, 2019
AB		CADILA	**EQ 100MG BASE**	**A207773**	**001**	Oct 30, 2017
AB		CARIBE HOLDINGS	**EQ 50MG BASE**	**A062269**	**003**	Oct 05, 1983
AB	**!**		**EQ 100MG BASE**	**A062269**	**002**	Nov 08, 1982
AB		CHANGZHOU PHARM	**EQ 100MG BASE**	**A211343**	**001**	Oct 09, 2019
AB		CHARTWELL	**EQ 50MG BASE**	**A062505**	**002**	Jul 27, 2021
AB			**EQ 100MG BASE**	**A062505**	**001**	Sep 11, 1984
AB		EMCURE PHARMS LTD	**EQ 100MG BASE**	**A209969**	**001**	Nov 09, 2018
AB		EPIC PHARMA LLC	**EQ 20MG BASE**	**A065182**	**001**	May 13, 2005
AB			**EQ 75MG BASE**	**A214207**	**001**	Dec 16, 2020
AB			**EQ 150MG BASE**	**A214207**	**002**	Dec 16, 2020
AB		HIKMA INTL PHARMS	**EQ 100MG BASE**	**A065095**	**001**	Jul 02, 2003
AB	**!**	LANNETT CO INC	**EQ 20MG BASE**	**A065277**	**001**	Nov 10, 2005
AB		LARKEN LABS	**EQ 20MG BASE**	**A065287**	**001**	Feb 28, 2006
AB		LUPIN LTD	**EQ 75MG BASE**	**A208818**	**001**	Sep 27, 2017
AB			**EQ 150MG BASE**	**A208818**	**002**	Sep 27, 2017
AB		MAYNE PHARMA INC	**EQ 75MG BASE**	**A208765**	**001**	Jun 14, 2017
AB			**EQ 150MG BASE**	**A208765**	**002**	Jun 14, 2017

DOXYCYCLINE HYCLATE

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB		NOVEL LABS INC	**EQ 100MG BASE**	**A207558**	**001**	Sep 06, 2017
AB		SUN PHARM INDUSTRIES	**EQ 20MG BASE**	**A065134**	**001**	May 13, 2005
AB			**EQ 100MG BASE**	**A062677**	**001**	Jul 10, 1986

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	+	MAYNE PHARMA	**EQ 50MG BASE**	**N050795**	**006**	Dec 19, 2014
AB	+		**EQ 75MG BASE**	**N050795**	**001**	May 06, 2005
AB	+		**EQ 100MG BASE**	**N050795**	**002**	May 06, 2005
AB	+		**EQ 150MG BASE**	**N050795**	**003**	Jun 20, 2008
AB	+!		**EQ 200MG BASE**	**N050795**	**005**	Apr 11, 2013

DOXYCYCLINE HYCLATE

AB		ACTAVIS ELIZABETH	**EQ 50MG BASE**	**A090134**	**003**	May 22, 2018
AB			**EQ 75MG BASE**	**A090134**	**001**	Dec 14, 2011
AB			**EQ 100MG BASE**	**A090134**	**002**	Dec 14, 2011
AB			**EQ 200MG BASE**	**A090134**	**004**	May 22, 2018
AB		ALEMBIC PHARMS LTD	**EQ 75MG BASE**	**A213075**	**001**	Jan 03, 2022
AB			**EQ 100MG BASE**	**A213075**	**002**	Jan 03, 2022
AB			**EQ 150MG BASE**	**A213075**	**003**	Jan 03, 2022
AB			**EQ 200MG BASE**	**A213075**	**004**	Jan 03, 2022
AB		HERITAGE PHARMS INC	**EQ 75MG BASE**	**A200856**	**001**	Apr 30, 2013
AB			**EQ 100MG BASE**	**A200856**	**002**	Apr 30, 2013
AB			**EQ 150MG BASE**	**A200856**	**003**	Apr 30, 2013
AB			**EQ 200MG BASE**	**A200856**	**004**	Nov 13, 2018
AB		PRINSTON INC	**EQ 50MG BASE**	**A207494**	**003**	Feb 19, 2019
AB			**EQ 150MG BASE**	**A207494**	**001**	Nov 15, 2016
AB			**EQ 200MG BASE**	**A207494**	**002**	Nov 15, 2016

DORYX

	+	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013

DORYX MPC

	+!	MAYNE PHARMA	EQ 120MG BASE	N050795	008	May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

DICLEGIS

AB	**+!**	DUCHESNAY	**10MG;10MG**	**N021876**	**001**	Apr 08, 2013

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**10MG;10MG**	**A205811**	**001**	Aug 19, 2016
AB		MYLAN PHARMS INC	**10MG;10MG**	**A207825**	**001**	Jul 06, 2020
AB		PAR PHARM INC	**10MG;10MG**	**A208518**	**001**	Dec 06, 2017

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

	+!	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016

DRONABINOL

CAPSULE;ORAL

DRONABINOL

AB		AKORN	**2.5MG**	**A079217**	**001**	Jun 20, 2014
AB			**5MG**	**A079217**	**002**	Jun 20, 2014
AB			**10MG**	**A079217**	**003**	Jun 20, 2014
AB		ASCENT PHARMS INC	**2.5MG**	**A207421**	**001**	Feb 07, 2020
AB			**5MG**	**A207421**	**002**	Feb 07, 2020
AB			**10MG**	**A207421**	**003**	Feb 07, 2020
AB		LANNETT CO INC	**2.5MG**	**A201463**	**001**	May 18, 2018
AB			**5MG**	**A201463**	**002**	May 18, 2018
AB			**10MG**	**A201463**	**003**	May 18, 2018
AB		SVC PHARMA	**2.5MG**	**A078292**	**001**	Jun 27, 2008
AB			**5MG**	**A078292**	**002**	Jun 27, 2008
AB			**10MG**	**A078292**	**003**	Jun 27, 2008

MARINOL

AB	+	ALKEM LABS LTD	**2.5MG**	**N018651**	**001**	May 31, 1985
AB	**+!**		**5MG**	**N018651**	**002**	May 31, 1985
AB	+		**10MG**	**N018651**	**003**	May 31, 1985

SOLUTION;ORAL

SYNDROS

	+!	BENUVIA	5MG/ML	N205525	001	Mar 23, 2017

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

MULTAQ

	+!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

AP		AM REGENT	**2.5MG/ML**	**A072123**	**001**	Oct 24, 1988
AP		EUROHLTH INTL SARL	**2.5MG/ML**	**A208197**	**001**	Dec 14, 2017
AP		HOSPIRA	**2.5MG/ML**	**A071981**	**001**	Feb 29, 1988

INAPSINE

AP	**+!**	AKORN	**2.5MG/ML**	**N016796**	**001**	

DROSPIRENONE

TABLET;ORAL

SLYND

	+!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019

DROSPIRENONE; ESTETROL

TABLET;ORAL

NEXTSTELLIS

	+!	MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

	+	BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012
	+!		0.5MG;1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		BARR	**3MG;0.02MG**	**A078515**	**001**	Mar 30, 2009
AB		GLENMARK PHARMS LTD	**3MG;0.02MG**	**A204296**	**001**	Aug 17, 2015
AB		HETERO LABS LTD	**3MG;0.02MG**	**A211944**	**001**	Mar 22, 2019
AB		HLTHCARE	**3MG;0.02MG**	**A203291**	**001**	Jul 18, 2017
AB		MYLAN LABS LTD	**3MG;0.02MG**	**A202594**	**001**	Oct 22, 2015
AB		WATSON LABS	**3MG;0.02MG**	**A078833**	**001**	Nov 28, 2011

LO-ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.02MG**	**A209632**	**001**	Feb 27, 2018

LORYNA

AB		XIROMED	**3MG;0.02MG**	**A079221**	**001**	Mar 28, 2011

MELAMISA

AB		NOVAST LABS	**3MG;0.02MG**	**A202016**	**001**	Jan 26, 2016

NIKKI

AB		LUPIN LTD	**3MG;0.02MG**	**A201661**	**001**	May 27, 2014

YAZ

AB	**+!**	BAYER HLTHCARE	**3MG;0.02MG**	**N021676**	**001**	Mar 16, 2006

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		BARR	**3MG;0.03MG**	**A077527**	**001**	May 09, 2008
AB		GLENMARK PHARMS LTD	**3MG;0.03MG**	**A204848**	**001**	Mar 25, 2016
AB		HETERO LABS LTD	**3MG;0.03MG**	**A213034**	**001**	Jan 24, 2020
AB		LUPIN LTD	**3MG;0.03MG**	**A201663**	**001**	Dec 18, 2012
AB		MAYNE PHARMA	**3MG;0.03MG**	**A090081**	**001**	Sep 07, 2010
AB		MYLAN LABS LTD	**3MG;0.03MG**	**A202131**	**001**	May 04, 2015
AB		NAARI PTE LTD	**3MG;0.03MG**	**A207245**	**001**	Nov 22, 2016

SYEDA

AB		XIROMED	**3MG;0.03MG**	**A090114**	**001**	Mar 28, 2011

YAELA

AB		NOVAST LABS	**3MG;0.03MG**	**A202015**	**001**	Nov 19, 2014

YASMIN

AB	**+!**	BAYER HLTHCARE	**3MG;0.03MG**	**N021098**	**001**	May 11, 2001

ZUMANDIMINE

AB		AUROBINDO PHARMA LTD	**3MG;0.03MG**	**A209407**	**001**	Mar 26, 2018

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

BEYAZ

AB	**+!**	BAYER HLTHCARE	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**N022532**	**001**	Sep 24, 2010

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB		LUPIN LTD	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A205947**	**001**	Jun 13, 2018
AB		WATSON LABS INC	**3MG,N/A;0.02MG,N/A;0.451MG,0.451MG**	**A203593**	**001**	Oct 11, 2016

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB			**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A203594**	**001**	Oct 11, 2016

SAFYRAL

AB	**+!**	BAYER HLTHCARE	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**N022574**	**001**	Dec 16, 2010

TYDEMY

AB		LUPIN LTD	**3MG,N/A;0.03MG,N/A;0.451MG,0.451MG**	**A205948**	**001**	Dec 12, 2017

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB		AJANTA PHARMA LTD	**100MG**	**A214391**	**001**	Feb 18, 2021
AB			**200MG**	**A214391**	**002**	Feb 18, 2021
AB			**300MG**	**A214391**	**003**	Feb 18, 2021
AB		ALKEM LABS LTD	**100MG**	**A213911**	**001**	Feb 18, 2021
AB			**200MG**	**A213911**	**002**	Feb 18, 2021
AB			**300MG**	**A213911**	**003**	Feb 18, 2021
AB		ANNORA	**100MG**	**A211726**	**002**	Aug 09, 2021
AB			**200MG**	**A211726**	**003**	Aug 09, 2021
AB			**300MG**	**A211726**	**001**	Feb 18, 2021
AB		AUROBINDO PHARMA LTD	**100MG**	**A214387**	**001**	Feb 18, 2021
AB			**200MG**	**A214387**	**002**	Feb 18, 2021
AB			**300MG**	**A214387**	**003**	Feb 18, 2021
AB		BIONPHARMA INC	**100MG**	**A213033**	**001**	Apr 28, 2021
AB			**200MG**	**A213033**	**002**	Apr 28, 2021
AB			**300MG**	**A213033**	**003**	Apr 28, 2021
AB		HIKMA	**100MG**	**A212835**	**001**	Feb 18, 2021
AB			**200MG**	**A212835**	**002**	Feb 18, 2021
AB			**300MG**	**A212835**	**003**	Feb 18, 2021
AB		LUPIN PHARMS	**100MG**	**A211652**	**001**	Feb 18, 2021
AB			**200MG**	**A211652**	**002**	Feb 18, 2021
AB			**300MG**	**A211652**	**003**	Feb 18, 2021
AB		MSN PHARMS INC	**100MG**	**A211741**	**001**	Feb 18, 2021
AB			**200MG**	**A211741**	**002**	Feb 18, 2021
AB			**300MG**	**A211741**	**003**	Feb 18, 2021
AB		SCIEGEN PHARMS INC	**100MG**	**A214017**	**001**	Feb 18, 2021
AB			**200MG**	**A214017**	**002**	Feb 18, 2021
AB			**300MG**	**A214017**	**003**	Feb 18, 2021
AB		SLATE	**100MG**	**A215265**	**001**	Nov 01, 2021
AB			**200MG**	**A215265**	**002**	Nov 01, 2021
AB			**300MG**	**A215265**	**003**	Nov 01, 2021
AB		SUN PHARM	**100MG**	**A214384**	**001**	Feb 18, 2021
AB			**200MG**	**A214384**	**002**	Feb 18, 2021
AB			**300MG**	**A214384**	**003**	Feb 18, 2021
AB		TASMAN PHARMA	**100MG**	**A213661**	**001**	Feb 18, 2021
AB			**200MG**	**A213661**	**002**	Feb 18, 2021
AB			**300MG**	**A213661**	**003**	Feb 18, 2021
AB		TRIS PHARMA INC	**100MG**	**A214543**	**001**	May 05, 2021
AB			**200MG**	**A214543**	**002**	May 05, 2021
AB			**300MG**	**A214543**	**003**	May 05, 2021
AB		ZYDUS PHARMS	**100MG**	**A211818**	**001**	Feb 18, 2021
AB			**200MG**	**A211818**	**002**	Feb 18, 2021
AB			**300MG**	**A211818**	**003**	Feb 18, 2021

NORTHERA

AB	**+**	LUNDBECK NA LTD	**100MG**	**N203202**	**001**	Feb 18, 2014
AB	**+**		**200MG**	**N203202**	**002**	Feb 18, 2014
AB	**+!**		**300MG**	**N203202**	**003**	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

AB	**+**	LILLY	**EQ 20MG BASE**	**N021427**	**001**	Aug 03, 2004
AB	**+**		**EQ 30MG BASE**	**N021427**	**002**	Aug 03, 2004
AB	**+!**		**EQ 60MG BASE**	**N021427**	**004**	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 20MG BASE**	**A090776**	**001**	Dec 17, 2013
AB			**EQ 30MG BASE**	**A090776**	**002**	Dec 17, 2013
AB			**EQ 60MG BASE**	**A090776**	**003**	Dec 17, 2013
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A208706**	**001**	Jan 06, 2017
AB			**EQ 30MG BASE**	**A208706**	**002**	Jan 06, 2017
AB			**EQ 40MG BASE**	**A208706**	**004**	Mar 11, 2019
AB			**EQ 60MG BASE**	**A208706**	**003**	Jan 06, 2017

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	**EQ 20MG BASE**	**A202949**	**001**	Jun 09, 2014
AB		**EQ 30MG BASE**	**A202949**	**002**	Jun 09, 2014
AB		**EQ 60MG BASE**	**A202949**	**003**	Jun 09, 2014
AB	ALKEM LABS LTD	**EQ 20MG BASE**	**A203197**	**001**	Aug 26, 2015
AB		**EQ 30MG BASE**	**A203197**	**002**	Aug 26, 2015
AB		**EQ 60MG BASE**	**A203197**	**003**	Aug 26, 2015
AB	ANCHEN PHARMS	**EQ 20MG BASE**	**A090780**	**001**	Oct 28, 2015
AB		**EQ 30MG BASE**	**A090780**	**002**	Oct 28, 2015
AB		**EQ 60MG BASE**	**A090780**	**003**	Oct 28, 2015
AB	APOTEX	**EQ 20MG BASE**	**A202045**	**001**	Jun 11, 2014
AB		**EQ 30MG BASE**	**A202045**	**002**	Jun 11, 2014
AB		**EQ 60MG BASE**	**A202045**	**003**	Jun 11, 2014
AB	AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A090778**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090778**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090778**	**003**	Dec 11, 2013
AB	BRECKENRIDGE	**EQ 20MG BASE**	**A203088**	**001**	Jun 11, 2014
AB		**EQ 30MG BASE**	**A203088**	**002**	Jun 11, 2014
AB		**EQ 40MG BASE**	**A203088**	**004**	May 18, 2018
AB		**EQ 60MG BASE**	**A203088**	**003**	Jun 11, 2014
AB	CSPC OUYI	**EQ 20MG BASE**	**A211310**	**001**	Oct 16, 2018
AB		**EQ 30MG BASE**	**A211310**	**002**	Oct 16, 2018
AB		**EQ 60MG BASE**	**A211310**	**003**	Oct 16, 2018
AB	HETERO LABS LTD III	**EQ 20MG BASE**	**A204343**	**001**	Aug 03, 2016
AB		**EQ 30MG BASE**	**A204343**	**002**	Aug 03, 2016
AB		**EQ 60MG BASE**	**A204343**	**003**	Aug 03, 2016
AB	INVENTIA	**EQ 20MG BASE**	**A202336**	**001**	Oct 28, 2015
AB		**EQ 30MG BASE**	**A202336**	**002**	Oct 28, 2015
AB		**EQ 60MG BASE**	**A202336**	**003**	Oct 28, 2015
AB	LUPIN LTD	**EQ 20MG BASE**	**A090694**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090694**	**002**	Dec 11, 2013
AB		**EQ 40MG BASE**	**A090694**	**003**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090694**	**004**	Dec 11, 2013
AB	MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204815**	**001**	Mar 23, 2017
AB		**EQ 30MG BASE**	**A204815**	**002**	Mar 23, 2017
AB		**EQ 60MG BASE**	**A204815**	**003**	Mar 23, 2017
AB	MARKSANS PHARMA	**EQ 20MG BASE**	**A090723**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090723**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090723**	**003**	Dec 11, 2013
AB	PRINSTON INC	**EQ 20MG BASE**	**A206653**	**001**	May 18, 2017
AB		**EQ 30MG BASE**	**A206653**	**002**	May 18, 2017
AB		**EQ 60MG BASE**	**A206653**	**003**	May 18, 2017
AB	QINGDAO BAHEAL PHARM	**EQ 20MG BASE**	**A210599**	**001**	Apr 17, 2019
AB		**EQ 30MG BASE**	**A210599**	**002**	Apr 17, 2019
AB		**EQ 60MG BASE**	**A210599**	**003**	Apr 17, 2019
AB	SUN PHARM	**EQ 20MG BASE**	**A090745**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090745**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090745**	**003**	Dec 11, 2013
AB	SUNSHINE	**EQ 20MG BASE**	**A212328**	**001**	Feb 11, 2021
AB		**EQ 30MG BASE**	**A212328**	**002**	Feb 11, 2021
AB		**EQ 60MG BASE**	**A212328**	**003**	Feb 11, 2021
AB	TORRENT	**EQ 20MG BASE**	**A090774**	**001**	Dec 11, 2013
AB		**EQ 30MG BASE**	**A090774**	**002**	Dec 11, 2013
AB		**EQ 60MG BASE**	**A090774**	**003**	Dec 11, 2013
AB	ZYDUS HLTHCARE	**EQ 20MG BASE**	**A090739**	**001**	Jan 08, 2014
AB		**EQ 30MG BASE**	**A090739**	**002**	Jan 08, 2014
AB		**EQ 60MG BASE**	**A090739**	**003**	Jan 08, 2014
AB	ZYDUS PHARMS	**EQ 20MG BASE**	**A090728**	**001**	Jan 08, 2014
AB		**EQ 30MG BASE**	**A090728**	**002**	Jan 08, 2014
AB		**EQ 60MG BASE**	**A090728**	**003**	Jan 08, 2014

DRIZALMA SPRINKLE

+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019
+		EQ 30MG BASE	N212516	002	Jul 19, 2019
+		EQ 40MG BASE	N212516	003	Jul 19, 2019
+!		EQ 60MG BASE	N212516	004	Jul 19, 2019

DUTASTERIDE

CAPSULE;ORAL

AVODART

AB	**+!**	WOODWARD	**0.5MG**	**N021319**	**001**	Nov 20, 2001

DUTASTERIDE

AB		ACELLA	**0.5MG**	**A206373**	**001**	Mar 17, 2016
AB		AMNEAL PHARMS	**0.5MG**	**A203118**	**001**	Nov 20, 2015
AB		ASCENT PHARMS INC	**0.5MG**	**A206574**	**001**	Oct 21, 2016
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A202660**	**001**	Nov 20, 2015
AB		BARR	**0.5MG**	**A090095**	**001**	Dec 21, 2010
AB		BIONPHARMA INC	**0.5MG**	**A200899**	**001**	Nov 20, 2015
AB		CADILA	**0.5MG**	**A204373**	**001**	Oct 04, 2017
AB		HUMANWELL PURACAP	**0.5MG**	**A209909**	**001**	Nov 21, 2017
AB		MARKSANS PHARMA	**0.5MG**	**A204376**	**001**	Apr 07, 2017
AB		STRIDES PHARMA	**0.5MG**	**A204262**	**001**	Nov 20, 2015
AB		VINTAGE	**0.5MG**	**A202421**	**001**	Nov 20, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB		ANCHEN PHARMS	**0.5MG;0.4MG**	**A202509**	**001**	Feb 26, 2014
AB		ZYDUS PHARMS	**0.5MG;0.4MG**	**A207769**	**001**	May 24, 2018

JALYN

AB	**+!**	WOODWARD	**0.5MG;0.4MG**	**N022460**	**001**	Jun 14, 2010

DUVELISIB

CAPSULE;ORAL

COPIKTRA

+	SECURA	15MG	N211155	001	Sep 24, 2018
+!		25MG	N211155	002	Sep 24, 2018

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLOPRO

!	NOVOCOL INC	0.5%	A200480	001	Nov 20, 2018
!		1%	A200480	002	Nov 20, 2018

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

+!	FERA PHARMS LLC	0.125%	N011963	001	

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

+!	RESILIA PHARMS	1%	N205175	001	Oct 24, 2013

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	**!**	PADAGIS ISRAEL	**1%**	**A076479**	**001**	Jun 23, 2004
AB		TARO	**1%**	**A076005**	**001**	Nov 26, 2002
AB		TELIGENT	**1%**	**A076574**	**001**	Dec 17, 2004

SPECTAZOLE

AB	**+**	ALVOGEN	**1%**	**N018751**	**001**	Dec 23, 1982

EDARAVONE

SOLUTION;INTRAVENOUS

RADICAVA

+!	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017
+!		60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018

EDETATE CALCIUM DISODIUM

INJECTABLE;INJECTION

CALCIUM DISODIUM VERSENATE

+!	BAUSCH	200MG/ML	N008922	001	

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

+	DAIICHI SANKYO INC	EQ 15MG BASE	N206316	001	Jan 08, 2015
+		EQ 30MG BASE	N206316	002	Jan 08, 2015
+!		EQ 60MG BASE	N206316	003	Jan 08, 2015

EFAVIRENZ

CAPSULE;ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	**50MG**	**A078064**	**001**	Dec 15, 2017
AB			**200MG**	**A078064**	**003**	Dec 15, 2017

SUSTIVA

AB	+	BRISTOL MYERS SQUIBB	**50MG**	**N020972**	**001**	Sep 17, 1998
AB	+!		**200MG**	**N020972**	**003**	Sep 17, 1998

EFAVIRENZ

		AUROBINDO PHARMA LTD	100MG	A078064	002	Dec 15, 2017

TABLET;ORAL

EFAVIRENZ

AB		AUROBINDO PHARMA LTD	**600MG**	**A077673**	**001**	Sep 21, 2018
AB			**600MG**	**A205322**	**001**	Aug 30, 2018
AB		CIPLA	**600MG**	**A204766**	**001**	Jun 15, 2018
AB		HETERO LABS LTD III	**600MG**	**A078886**	**001**	Apr 27, 2018
AB		STRIDES PHARMA	**600MG**	**A204869**	**001**	Mar 12, 2018

SUSTIVA

AB	+!	BRISTOL MYERS SQUIBB	**600MG**	**N021360**	**002**	Feb 01, 2002

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

ATRIPLA

AB	+!	GILEAD SCIENCES	**600MG;200MG;300MG**	**N021937**	**001**	Jul 12, 2006

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	**600MG;200MG;300MG**	**A203041**	**001**	Sep 04, 2018
AB		CIPLA	**600MG;200MG;300MG**	**A206894**	**001**	Jun 03, 2019
AB		LAURUS	**600MG;200MG;300MG**	**A213541**	**001**	Dec 22, 2021
AB		MACLEODS PHARMS LTD	**600MG;200MG;300MG**	**A204287**	**001**	Sep 13, 2021
AB		TEVA PHARMS USA	**600MG;200MG;300MG**	**A091215**	**001**	Nov 09, 2018

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		LAURUS	**400MG;300MG;300MG**	**A213038**	**001**	May 14, 2020
AB			**600MG;300MG;300MG**	**A212786**	**001**	May 14, 2020

SYMFI

AB	+!	MYLAN LABS LTD	**600MG;300MG;300MG**	**N022142**	**001**	Mar 22, 2018

SYMFI LO

AB	+!	MYLAN	**400MG;300MG;300MG**	**N208255**	**001**	Feb 05, 2018

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

AB		ACRUX DDS	**10%**	**A211969**	**001**	Jun 21, 2021
AB		TEVA PHARMS USA	**10%**	**A211827**	**001**	Dec 16, 2020

JUBLIA

AB	+!	BAUSCH	**10%**	**N203567**	**001**	Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

	+!	SKINMEDICA	13.9%	N021145	001	Jul 27, 2000

ELAGOLIX SODIUM

TABLET;ORAL

ORILISSA

	+	ABBVIE INC	EQ 150MG BASE	N210450	001	Jul 23, 2018
	+!		EQ 200MG BASE	N210450	002	Jul 23, 2018

ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE;ORAL

ORIAHNN (COPACKAGED)

	+!	ABBVIE INC	EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	N213388	001	May 29, 2020

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

ZEPATIER

	+!	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A205186**	**001**	Aug 29, 2017
AB			**EQ 40MG BASE**	**A205186**	**002**	Aug 29, 2017
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A210708**	**001**	Jan 15, 2019
AB			**EQ 40MG BASE**	**A210708**	**002**	Jan 15, 2019
AB		MYLAN	**EQ 20MG BASE**	**A205152**	**001**	Aug 11, 2017
AB			**EQ 40MG BASE**	**A205152**	**002**	Aug 11, 2017
AB		TEVA PHARMS USA	**EQ 20MG BASE**	**A202040**	**001**	Jun 27, 2017
AB			**EQ 40MG BASE**	**A202040**	**002**	Jun 27, 2017
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A206409**	**001**	Jun 16, 2017
AB			**EQ 40MG BASE**	**A206409**	**002**	Jun 16, 2017

RELPAX

AB	**+**	UPJOHN	**EQ 20MG BASE**	**N021016**	**001**	Dec 26, 2002
AB	**+!**		**EQ 40MG BASE**	**N021016**	**002**	Dec 26, 2002

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET;ORAL

TRIKAFTA (COPACKAGED)

	+	VERTEX PHARMS INC	50MG,37.5MG,25MG; 75MG	N212273	002	Jun 08, 2021
	+!		100MG,75MG,50MG; 150MG	N212273	001	Oct 21, 2019

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

CERDELGA

AB	**+!**	GENZYME CORP	**EQ 84MG BASE**	**N205494**	**001**	Aug 19, 2014

ELIGLUSTAT TARTRATE

AB		APPCO	**EQ 84MG BASE**	**A212463**	**001**	Sep 08, 2021
AB		TEVA PHARMS USA INC	**EQ 84MG BASE**	**A212474**	**001**	Dec 27, 2021

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL

PROMACTA KIT

	+	NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018
	+!		EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015

TABLET;ORAL

PROMACTA

	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011
	+		EQ 25MG ACID	N022291	001	Nov 20, 2008
	+		EQ 50MG ACID	N022291	002	Nov 20, 2008
	+!		EQ 75MG ACID	N022291	003	Sep 08, 2009

ELUXADOLINE

TABLET;ORAL

VIBERZI

	+	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015
	+!		100MG	N206940	002	May 27, 2015

EMPAGLIFLOZIN

TABLET;ORAL

JARDIANCE

	+	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014
	+!		25MG	N204629	002	Aug 01, 2014

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET;ORAL

GLYXAMBI

	+	BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015
	+!		25MG;5MG	N206073	002	Jan 30, 2015

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRIJARDY XR

	+	BOEHRINGER INGELHEIM	5MG;2.5MG;1GM	N212614	001	Jan 27, 2020
	+		10MG;5MG;1GM	N212614	002	Jan 27, 2020
	+		12.5MG;2.5MG;1GM	N212614	003	Jan 27, 2020
	+!		25MG;5MG;1GM	N212614	004	Jan 27, 2020

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SYNJARDY

+	BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015
+		5MG;1GM	N206111	002	Aug 26, 2015
+		12.5MG;500MG	N206111	003	Aug 26, 2015
+!		12.5MG;1GM	N206111	004	Aug 26, 2015

TABLET, EXTENDED RELEASE;ORAL

SYNJARDY XR

+	BOEHRINGER INGELHEIM	5MG;1GM	N208658	001	Dec 09, 2016
+		10MG;1GM	N208658	002	Dec 09, 2016
+		12.5MG;1GM	N208658	003	Dec 09, 2016
+!		25MG;1GM	N208658	004	Dec 09, 2016

EMTRICITABINE

CAPSULE;ORAL

EMTRICITABINE

AB	CIPLA	**200MG**	**A091168**	**001**	Jul 02, 2018

EMTRIVA

AB	**+!**	GILEAD	**200MG**	**N021500**	**001**	Jul 02, 2003

SOLUTION;ORAL

EMTRIVA

+!	GILEAD	10MG/ML	N021896	001	Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

ODEFSEY

+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

COMPLERA

+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

DESCOVY

+!	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	HETERO LABS LTD III	**200MG;300MG**	**A201806**	**001**	Oct 07, 2021

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	AMNEAL PHARMS CO	**100MG;150MG**	**A209721**	**001**	Aug 22, 2018
AB		**133MG;200MG**	**A209721**	**002**	Aug 22, 2018
AB		**167MG;250MG**	**A209721**	**003**	Aug 22, 2018
AB		**200MG;300MG**	**A209721**	**004**	Aug 22, 2018
AB	APOTEX	**200MG;300MG**	**A208740**	**001**	Jun 16, 2021
AB	AUROBINDO PHARMA LTD	**200MG;300MG**	**A090513**	**001**	Jan 26, 2018
AB	CIPLA	**200MG;300MG**	**A090958**	**001**	Apr 02, 2021
AB	LAURUS	**200MG;300MG**	**A212114**	**001**	Jul 26, 2019
AB	LUPIN LTD	**200MG;300MG**	**A204131**	**001**	Jun 04, 2021
AB	MACLEODS PHARMS LTD	**200MG;300MG**	**A203442**	**001**	May 15, 2020
AB	MYLAN	**200MG;300MG**	**A206436**	**001**	Apr 09, 2018
AB	STRIDES PHARMA	**200MG;300MG**	**A091055**	**001**	Jan 13, 2021
AB	TEVA PHARMS USA	**200MG;300MG**	**A090894**	**001**	Jun 08, 2017
AB	ZYDUS PHARMS	**100MG;150MG**	**A212689**	**002**	Jul 01, 2021
AB		**133MG;200MG**	**A212689**	**003**	Jul 01, 2021
AB		**167MG;250MG**	**A212689**	**004**	Jul 01, 2021
AB		**200MG;300MG**	**A212689**	**001**	Feb 28, 2020

TRUVADA

AB	**+**	GILEAD	**100MG;150MG**	**N021752**	**002**	Mar 10, 2016
AB	**+**		**133MG;200MG**	**N021752**	**003**	Mar 10, 2016
AB	**+**		**167MG;250MG**	**N021752**	**004**	Mar 10, 2016
AB	**+!**		**200MG;300MG**	**N021752**	**001**	Aug 02, 2004

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB		BIONPHARMA INC	**1MG/ML**	**A212408**	**001**	Aug 10, 2021

EPANED

AB	**+!**	AZURITY	**1MG/ML**	**N208686**	**001**	Sep 20, 2016

TABLET;ORAL

ENALAPRIL MALEATE

AB		HERITAGE PHARMA	**2.5MG**	**A075479**	**001**	Aug 22, 2000
AB			**5MG**	**A075479**	**002**	Aug 22, 2000
AB			**10MG**	**A075479**	**003**	Aug 22, 2000
AB			**20MG**	**A075479**	**004**	Aug 22, 2000
AB		SANDOZ INC	**2.5MG**	**A075496**	**001**	Aug 22, 2000
AB			**5MG**	**A075496**	**002**	Aug 22, 2000
AB			**10MG**	**A075459**	**001**	Aug 22, 2000
AB			**20MG**	**A075459**	**002**	Aug 22, 2000
AB		TARO	**2.5MG**	**A075657**	**001**	Jan 23, 2001
AB			**5MG**	**A075657**	**002**	Jan 23, 2001
AB			**10MG**	**A075657**	**003**	Jan 23, 2001
AB			**20MG**	**A075657**	**004**	Jan 23, 2001
AB		WOCKHARDT LTD	**2.5MG**	**A075483**	**001**	Aug 22, 2000
AB			**5MG**	**A075483**	**002**	Aug 22, 2000
AB			**10MG**	**A075483**	**003**	Aug 22, 2000
AB			**20MG**	**A075483**	**004**	Aug 22, 2000

VASOTEC

AB	**+**	BAUSCH	**2.5MG**	**N018998**	**005**	Jul 26, 1988
AB	**+**		**5MG**	**N018998**	**001**	Dec 24, 1985
AB	**+**		**10MG**	**N018998**	**002**	Dec 24, 1985
AB	**+!**		**20MG**	**N018998**	**003**	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB		COSETTE	**5MG;12.5MG**	**A075727**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075727**	**002**	Sep 18, 2001
AB		DR REDDYS LABS LTD	**5MG;12.5MG**	**A075909**	**001**	Oct 15, 2001
AB			**10MG;25MG**	**A075909**	**002**	Oct 15, 2001
AB		TARO PHARM INDS	**5MG;12.5MG**	**A075788**	**001**	Sep 18, 2001
AB			**10MG;25MG**	**A075788**	**002**	Sep 18, 2001

VASERETIC

AB	**+**	BAUSCH	**5MG;12.5MG**	**N019221**	**003**	Jul 12, 1995
AB	**+!**		**10MG;25MG**	**N019221**	**001**	Oct 31, 1986

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP	**!**	ATHENEX INC	**1.25MG/ML**	**A075634**	**001**	Aug 22, 2000
AP		HIKMA FARMACEUTICA	**1.25MG/ML**	**A078687**	**001**	Dec 23, 2008
AP	**!**	HOSPIRA	**1.25MG/ML**	**A075458**	**001**	Aug 22, 2000

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

	+	CELGENE CORP	EQ 50MG BASE	N209606	001	Aug 01, 2017
	+!		EQ 100MG BASE	N209606	002	Aug 01, 2017

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

	+!	ARRAY BIOPHARMA INC	75MG	N210496	002	Jun 27, 2018

ENFUVIRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

	+!	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		AMPHASTAR PHARMS INC	**300MG/3ML (100MG/ML)**	**A208600**	**001**	Mar 14, 2019
AB		SANDOZ INC	**300MG/3ML (100MG/ML)**	**A078660**	**001**	Nov 28, 2011

LOVENOX

AB	**+**	SANOFI AVENTIS US	**300MG/3ML (100MG/ML)**	**N020164**	**009**	Jan 23, 2003

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		AMPHASTAR PHARM	**30MG/0.3ML (100MG/ML)**	**A076684**	**001**	Sep 19, 2011
AP			**40MG/0.4ML (100MG/ML)**	**A076684**	**002**	Sep 19, 2011
AP			**60MG/0.6ML (100MG/ML)**	**A076684**	**003**	Sep 19, 2011
AP			**80MG/0.8ML (100MG/ML)**	**A076684**	**004**	Sep 19, 2011
AP			**100MG/ML (100MG/ML)**	**A076684**	**005**	Sep 19, 2011
AP			**120MG/0.8ML (150MG/ML)**	**A076684**	**006**	Sep 19, 2011
AP			**150MG/ML (150MG/ML)**	**A076684**	**007**	Sep 19, 2011
AP		APOTEX INC	**30MG/0.3ML (100MG/ML)**	**A078990**	**001**	Sep 28, 2018
AP			**40MG/0.4ML (100MG/ML)**	**A078990**	**002**	Sep 28, 2018
AP			**60MG/0.6ML (100MG/ML)**	**A078990**	**003**	Sep 28, 2018
AP			**80MG/0.8ML (100MG/ML)**	**A078990**	**004**	Sep 28, 2018
AP			**100MG/ML (100MG/ML)**	**A078990**	**005**	Sep 28, 2018
AP			**120MG/0.8ML (150MG/ML)**	**A078990**	**006**	Sep 28, 2018
AP			**150MG/ML (150MG/ML)**	**A078990**	**007**	Sep 28, 2018
AP		NANJING KING-FRIEND	**30MG/0.3ML (100MG/ML)**	**A206834**	**001**	Nov 29, 2019
AP			**40MG/0.4ML (100MG/ML)**	**A206834**	**002**	Nov 29, 2019
AP			**60MG/0.6ML (100MG/ML)**	**A206834**	**003**	Nov 29, 2019
AP			**80MG/0.8ML (100MG/ML)**	**A206834**	**004**	Nov 29, 2019
AP			**100MG/ML (100MG/ML)**	**A206834**	**005**	Nov 29, 2019
AP			**120MG/0.8ML (150MG/ML)**	**A206834**	**006**	Nov 29, 2019
AP			**150MG/ML (150MG/ML)**	**A206834**	**007**	Nov 29, 2019
AP		SANDOZ	**30MG/0.3ML (100MG/ML)**	**A077857**	**002**	Jul 23, 2010
AP			**40MG/0.4ML (100MG/ML)**	**A077857**	**003**	Jul 23, 2010
AP			**60MG/0.6ML (100MG/ML)**	**A077857**	**004**	Jul 23, 2010
AP			**80MG/0.8ML (100MG/ML)**	**A077857**	**005**	Jul 23, 2010
AP			**100MG/ML (100MG/ML)**	**A077857**	**001**	Jul 23, 2010
AP			**120MG/0.8ML (150MG/ML)**	**A077857**	**006**	Jul 23, 2010
AP			**150MG/ML (150MG/ML)**	**A077857**	**007**	Jul 23, 2010
AP		ZYDUS PHARMS	**30MG/0.3ML (100MG/ML)**	**A076726**	**001**	Jun 23, 2014
AP			**40MG/0.4ML (100MG/ML)**	**A076726**	**002**	Jun 23, 2014
AP			**60MG/0.6ML (100MG/ML)**	**A076726**	**003**	Jun 23, 2014
AP			**80MG/0.8ML (100MG/ML)**	**A076726**	**004**	Jun 23, 2014
AP			**100MG/ML (100MG/ML)**	**A076726**	**005**	Jun 23, 2014
AP			**120MG/0.8ML (150MG/ML)**	**A076726**	**006**	Jun 23, 2014
AP			**150MG/ML (150MG/ML)**	**A076726**	**007**	Jun 23, 2014

LOVENOX (PRESERVATIVE FREE)

AP	+	SANOFI AVENTIS US	**30MG/0.3ML (100MG/ML)**	**N020164**	**001**	Mar 29, 1993
AP	+		**40MG/0.4ML (100MG/ML)**	**N020164**	**002**	Jan 30, 1998
AP	+		**60MG/0.6ML (100MG/ML)**	**N020164**	**003**	Mar 27, 1998
AP	+		**80MG/0.8ML (100MG/ML)**	**N020164**	**004**	Mar 27, 1998
AP	+!		**100MG/ML (100MG/ML)**	**N020164**	**005**	Mar 27, 1998
AP	+		**120MG/0.8ML (150MG/ML)**	**N020164**	**007**	Jun 02, 2000
AP	+		**150MG/ML (150MG/ML)**	**N020164**	**008**	Jun 02, 2000

ENTACAPONE

TABLET;ORAL

COMTAN

AB	+!	ORION PHARMA	**200MG**	**N020796**	**001**	Oct 19, 1999

ENTACAPONE

AB		AJANTA PHARMA LTD	**200MG**	**A205792**	**001**	Aug 31, 2017
AB		ALEMBIC PHARMS LTD	**200MG**	**A212601**	**001**	Jan 04, 2022
AB		ATLANTIDE	**200MG**	**A078941**	**001**	Aug 16, 2012
AB		AUROBINDO PHARMA LTD	**200MG**	**A203437**	**001**	Jun 19, 2015
AB		MACLEODS PHARMS LTD	**200MG**	**A207210**	**001**	Jun 05, 2017
AB		SUN PHARM	**200MG**	**A090690**	**001**	Jul 16, 2012
AB		SUNSHINE	**200MG**	**A206669**	**001**	Oct 03, 2018

ENTECAVIR

SOLUTION;ORAL

BARACLUDE

	+!	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005

TABLET;ORAL

BARACLUDE

AB	+	BRISTOL MYERS SQUIBB	**0.5MG**	**N021797**	**001**	Mar 29, 2005
AB	+!		**1MG**	**N021797**	**002**	Mar 29, 2005

ENTECAVIR

AB		ACCORD HLTHCARE	**0.5MG**	**A205824**	**001**	Aug 25, 2017
AB			**1MG**	**A205824**	**002**	Aug 25, 2017

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB		AMNEAL PHARMS	**0.5MG**	**A206652**	**001**	Nov 12, 2015
AB			**1MG**	**A206652**	**002**	Nov 12, 2015
AB		AUROBINDO PHARMA LTD	**0.5MG**	**A206217**	**001**	Aug 26, 2015
AB			**1MG**	**A206217**	**002**	Aug 26, 2015
AB		BRECKENRIDGE	**0.5MG**	**A208721**	**001**	Mar 15, 2018
AB			**1MG**	**A208721**	**002**	Mar 15, 2018
AB		BRIGHTGENE	**0.5MG**	**A212126**	**001**	Sep 25, 2019
AB			**1MG**	**A212126**	**002**	Sep 25, 2019
AB		CASI PHARMS INC	**0.5MG**	**A206672**	**001**	May 11, 2017
AB			**1MG**	**A206672**	**002**	May 11, 2017
AB		CIPLA	**0.5MG**	**A206872**	**001**	Dec 06, 2016
AB			**1MG**	**A206872**	**002**	Dec 06, 2016
AB		HETERO LABS LTD V	**0.5MG**	**A205740**	**001**	Aug 21, 2015
AB			**1MG**	**A205740**	**002**	Aug 21, 2015
AB		PHARMADAX INC	**0.5MG**	**A212106**	**001**	Aug 10, 2020
AB			**1MG**	**A212106**	**002**	Aug 10, 2020
AB		PRINSTON INC	**0.5MG**	**A208782**	**001**	Oct 10, 2017
AB			**1MG**	**A208782**	**002**	Oct 10, 2017
AB		YUNG SHIN PHARM	**0.5MG**	**A208195**	**001**	Nov 10, 2021
AB			**1MG**	**A208195**	**002**	Nov 10, 2021
AB		ZYDUS PHARMS	**0.5MG**	**A206745**	**001**	Jun 23, 2017
AB			**1MG**	**A206745**	**002**	Jun 23, 2017

ENTRECTINIB

CAPSULE;ORAL

ROZLYTREK

	+	GENENTECH INC	100MG	N212725	001	Aug 15, 2019
	+!		200MG	N212725	002	Aug 15, 2019

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

AB		ACTAVIS LABS FL INC	**40MG**	**A209614**	**001**	May 14, 2021

XTANDI

AB	**+!**	ASTELLAS	**40MG**	**N203415**	**001**	Aug 31, 2012

TABLET;ORAL

XTANDI

	+	ASTELLAS	40MG	N213674	001	Aug 04, 2020
	+!		80MG	N213674	002	Aug 04, 2020

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

	+!	ETON	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

AP	**+!**	EXELA PHARMA	**50MG/ML (50MG/ML)**	**N208289**	**001**	Apr 29, 2016

CORPHEDRA

AP		PAR STERILE PRODUCTS	**50MG/ML (50MG/ML)**	**N208943**	**001**	Jan 27, 2017

EPHEDRINE SULFATE

AP		AKORN	**50MG/ML (50MG/ML)**	**N208609**	**001**	Mar 01, 2017
AP		AMNEAL	**50MG/ML (50MG/ML)**	**A212932**	**001**	Oct 23, 2019
AP		DR REDDYS LABS LTD	**50MG/ML (50MG/ML)**	**A212649**	**001**	Oct 03, 2020
AP		EUGIA PHARMA	**50MG/ML (50MG/ML)**	**A214579**	**001**	Jun 14, 2021
AP		FRESENIUS KABI USA	**50MG/ML (50MG/ML)**	**A209646**	**001**	Aug 04, 2020
AP		HIKMA	**50MG/ML (50MG/ML)**	**A214334**	**001**	Dec 15, 2020
AP		SANDOZ INC	**50MG/ML (50MG/ML)**	**A209784**	**001**	Aug 23, 2017

AKOVAZ

	+!	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021

EMERPHED

	+!	NEXUS PHARMS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020

EPINASTINE HYDROCHLORIDE							
SOLUTION/DROPS;OPHTHALMIC							
ELESTAT							
AT	**+!**	ALLERGAN	**0.05%**	**N021565**	**001**	Oct 16, 2003
EPINASTINE HYDROCHLORIDE							
AT		AKORN	**0.05%**	**A204055**	**001**	May 05, 2017
AT		APOTEX	**0.05%**	**A090919**	**001**	Oct 31, 2011
AT		BRECKENRIDGE	**0.05%**	**A090870**	**001**	Mar 14, 2011
AT		SOMERSET THERAPS LLC	**0.05%**	**A090951**	**001**	Oct 31, 2011
EPINEPHRINE							
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS							
EPINEPHRINE (AUTOINJECTOR)							
AB		TEVA PHARMS USA	**0.15MG/DELIVERY**	**A090589**	**002**	Aug 16, 2018
AB			**0.3MG/DELIVERY**	**A090589**	**001**	Aug 16, 2018
EPIPEN							
AB	**+!**	MYLAN SPECIALITY LP	**0.3MG/DELIVERY**	**N019430**	**001**	Dec 22, 1987
EPIPEN JR.							
AB	**+!**	MYLAN SPECIALITY LP	**0.15MG/DELIVERY**	**N019430**	**002**	Dec 22, 1987
ADRENACLICK							
BX	+!	IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009
BX	+!		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
ADRENALIN							
AP	**+!**	PAR STERILE PRODUCTS	**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**N204640**	**001**	Dec 18, 2013
EPINEPHRINE							
AP		INTL MEDICATION SYS	**EQ 30MG BASE/30ML (EQ 1MG BASE/ML)**	**A211880**	**001**	Apr 24, 2020
ADRENALIN							
	+!	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS							
AUVI-Q							
BX	+!	KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012
BX	+		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012
	+		EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017
SYMJEPI							
	+!	ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018
	+!		0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017
SOLUTION;INTRAVENOUS							
EPINEPHRINE							
	+!	HOSPIRA INC	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019
SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS							
EPINEPHRINE							
	+!	BELCHER	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014
EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
LIGNOSPAN FORTE							
	!	DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985
LIGNOSPAN STANDARD							
	!	DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985
EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
CITANEST FORTE DENTAL							
AP	**+!**	DENTSPLY PHARM	**0.005MG/ML;4%**	**N021383**	**001**		
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE							
AP		SEPTODONT INC	**0.005MG/ML;4%**	**A078959**	**001**	Aug 30, 2011
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE							
AP		B BRAUN MEDICAL INC	**0.005MG/ML;1.5%**	**A208475**	**001**	Sep 08, 2021
AP		HOSPIRA	**0.005MG/ML;0.5%**	**A089635**	**001**	Jun 21, 1988
AP			**0.005MG/ML;1.5%**	**A088571**	**001**	Sep 13, 1985
AP			**0.005MG/ML;1.5%**	**A089645**	**001**	Jun 21, 1988
AP			**0.005MG/ML;2%**	**A089651**	**001**	Jun 21, 1988
AP			**0.01MG/ML;1%**	**A089644**	**001**	Jun 21, 1988
AP	**!**		**0.01MG/ML;2%**	**A089646**	**001**	Jun 21, 1988
XYLOCAINE W/ EPINEPHRINE							
AP	**+!**	FRESENIUS KABI USA	**0.005MG/ML;0.5%**	**N006488**	**012**	
AP	**+!**		**0.005MG/ML;1.5%**	**N006488**	**017**	
AP	**+!**		**0.005MG/ML;2%**	**N006488**	**019**	Nov 13, 1986

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

XYLOCAINE W/ EPINEPHRINE

AP	**+!**		**0.01MG/ML;1%**	**N006488**	**004**	
AP	**+!**		**0.02MG/ML;2%**	**N006488**	**005**	
	+!		0.005MG/ML;1%	N006488	018	Nov 13, 1986

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

ELLENCE

AP	**+!**	PFIZER INC	**200MG/100ML (2MG/ML)**	**N050778**	**001**	Sep 15, 1999
AP	**+**		**50MG/25ML (2MG/ML)**	**N050778**	**002**	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP		ACTAVIS TOTOWA	**50MG/25ML (2MG/ML)**	**A065445**	**002**	Sep 18, 2008
AP			**200MG/100ML (2MG/ML)**	**A065445**	**003**	Sep 18, 2008
AP		AKORN	**50MG/25ML (2MG/ML)**	**A090163**	**001**	Jun 24, 2009
AP		CIPLA LTD	**50MG/25ML (2MG/ML)**	**A065361**	**001**	Oct 22, 2007
AP			**200MG/100ML (2MG/ML)**	**A065361**	**002**	Oct 22, 2007
AP		HIKMA	**50MG/25ML (2MG/ML)**	**A065289**	**001**	Jun 27, 2007
AP			**200MG/100ML (2MG/ML)**	**A065289**	**002**	Jun 27, 2007
AP		HISUN PHARM HANGZHOU	**50MG/25ML (2MG/ML)**	**A090075**	**001**	Mar 25, 2010
AP			**200MG/100ML (2MG/ML)**	**A090075**	**002**	Mar 25, 2010
AP		IMPAX LABS INC	**50MG/25ML (2MG/ML)**	**A065331**	**001**	Aug 09, 2007
AP			**200MG/100ML (2MG/ML)**	**A065331**	**002**	Aug 09, 2007

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		ACCORD HLTHCARE	**25MG**	**A206922**	**001**	Jul 13, 2017
AB			**50MG**	**A206922**	**002**	Jul 13, 2017
AB		BRECKENRIDGE	**25MG**	**A208283**	**001**	Sep 14, 2018
AB			**50MG**	**A208283**	**002**	Sep 14, 2018
AB		CHARTWELL RX	**25MG**	**A078482**	**001**	Jul 30, 2008
AB			**50MG**	**A078482**	**002**	Jul 30, 2008
AB		PRASCO	**25MG**	**A203896**	**001**	Feb 02, 2017
AB			**50MG**	**A203896**	**002**	Feb 02, 2017
AB		SANDOZ	**25MG**	**A078510**	**001**	Aug 01, 2008
AB			**50MG**	**A078510**	**002**	Aug 01, 2008
AB		WESTMINSTER PHARMS	**25MG**	**A207842**	**001**	Oct 25, 2021
AB			**50MG**	**A207842**	**002**	Oct 25, 2021

INSPRA

AB	**+**	UPJOHN	**25MG**	**N021437**	**001**	Sep 27, 2002
AB	**+!**		**50MG**	**N021437**	**002**	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

EPOPROSTENOL SODIUM

AP1		TEVA PHARMS USA	**EQ 0.5MG BASE/VIAL**	**A078396**	**001**	Apr 23, 2008
AP1			**EQ 1.5MG BASE/VIAL**	**A078396**	**002**	Apr 23, 2008

FLOLAN

AP1	**+!**	GLAXOSMITHKLINE LLC	**EQ 0.5MG BASE/VIAL**	**N020444**	**001**	Sep 20, 1995
AP1	**+!**		**EQ 1.5MG BASE/VIAL**	**N020444**	**002**	Sep 20, 1995

EPOPROSTENOL SODIUM

AP2		SUN PHARM	**EQ 0.5MG BASE/VIAL**	**A210473**	**001**	Jan 15, 2021
AP2			**EQ 1.5MG BASE/VIAL**	**A210473**	**002**	Jan 15, 2021

VELETRI

AP2	**+!**	ACTELION	**EQ 0.5MG BASE/VIAL**	**N022260**	**002**	Jun 28, 2012
AP2	**+!**		**EQ 1.5MG BASE/VIAL**	**N022260**	**001**	Jun 27, 2008

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP		ACCORD HLTHCARE	**2MG/ML**	**A205557**	**001**	Nov 06, 2017
AP			**75MG/100ML**	**A205557**	**002**	Nov 06, 2017
AP		AKORN	**2MG/ML**	**A204589**	**001**	Apr 18, 2017
AP			**75MG/100ML**	**A204589**	**002**	Apr 18, 2017
AP		BAXTER HLTHCARE CORP	**2MG/ML**	**A208554**	**001**	Nov 23, 2018
AP			**75MG/100ML**	**A208554**	**002**	Nov 23, 2018
AP		EUGIA PHARMA	**2MG/ML**	**A206127**	**001**	Dec 08, 2015
AP			**75MG/100ML**	**A206127**	**002**	Dec 08, 2015
AP		HAINAN POLY PHARM	**2MG/ML**	**A209864**	**001**	Jan 25, 2019
AP			**75MG/100ML**	**A209864**	**002**	Jan 25, 2019
AP	**!**	MYLAN LABS LTD	**2MG/ML**	**A203258**	**001**	Jul 20, 2018

EPTIFIBATIDE

INJECTABLE;INJECTION

EPTIFIBATIDE

AP	**!**		**75MG/100ML**	**A203258**	**002**	Jul 20, 2018
AP		SAGENT PHARMS INC	**2MG/ML**	**A204693**	**001**	Mar 07, 2018
AP			**75MG/100ML**	**A204693**	**002**	Mar 07, 2018
AP		SHUANGCHENG	**2MG/ML**	**A213081**	**001**	Sep 07, 2021
AP		TEVA PHARMS USA	**2MG/ML**	**A090854**	**001**	Jun 12, 2015

ERAVACYCLINE DIHYDROCHLORIDE

POWDER;INTRAVENOUS

XERAVA

+!	TETRAPHASE PHARMS	EQ 50MG BASE/VIAL	N211109	001	Aug 27, 2018
+!		EQ 100MG BASE/VIAL	N211109	002	Jun 03, 2020

ERDAFITINIB

TABLET;ORAL

BALVERSA

+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019
+		4MG	N212018	002	Apr 12, 2019
+!		5MG	N212018	003	Apr 12, 2019

ERGOCALCIFEROL

CAPSULE;ORAL

DRISDOL

AA	**+!**	VALIDUS PHARMS	**50,000 IU**	**N003444**	**001**	

ERGOCALCIFEROL

AA		ALEMBIC LABS	**50,000 IU**	**A040833**	**001**	May 20, 2009
AA		PURACAP PHARM LLC	**50,000 IU**	**A204276**	**001**	Dec 07, 2018
AA		STRIDES PHARMA	**50,000 IU**	**A090455**	**001**	Aug 03, 2010
AA		SUN PHARM INDS INC	**50,000 IU**	**A040865**	**001**	Dec 29, 2009

VITAMIN D

AA		BIONPHARMA INC	**50,000 IU**	**A080704**	**001**	

ERGOLOID MESYLATES

TABLET;ORAL

ERGOLOID MESYLATES

!	SUN PHARM INDUSTRIES	1MG	A081113	001	Oct 31, 1991

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL

ERGOMAR

!	TERSERA	2MG	A087693	001	Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION;INTRAVENOUS

HALAVEN

+!	EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A214719**	**001**	Jul 08, 2021
AB			**EQ 100MG BASE**	**A214719**	**002**	Jul 08, 2021
AB			**EQ 150MG BASE**	**A214719**	**003**	Jul 08, 2021
AB		APOTEX	**EQ 25MG BASE**	**A208396**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A208396**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A208396**	**003**	Nov 05, 2019
AB		MSN	**EQ 25MG BASE**	**A214366**	**001**	May 10, 2021
AB			**EQ 100MG BASE**	**A214366**	**002**	May 10, 2021
AB			**EQ 150MG BASE**	**A214366**	**003**	May 10, 2021
AB		NATCO PHARMA LTD	**EQ 25MG BASE**	**A208488**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A208488**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A208488**	**003**	Nov 05, 2019
AB		RISING	**EQ 25MG BASE**	**A091002**	**001**	Jun 11, 2014
AB			**EQ 100MG BASE**	**A091002**	**002**	Jun 11, 2014
AB			**EQ 150MG BASE**	**A091002**	**003**	Jun 11, 2014
AB		SHILPA	**EQ 25MG BASE**	**A211960**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A211960**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A211960**	**003**	Nov 05, 2019
AB		SUN PHARM	**EQ 25MG BASE**	**A210300**	**001**	Nov 05, 2019
AB			**EQ 100MG BASE**	**A210300**	**002**	Nov 05, 2019
AB			**EQ 150MG BASE**	**A210300**	**003**	Nov 05, 2019
AB		TEVA PHARMS USA INC	**EQ 25MG BASE**	**A091059**	**001**	Nov 09, 2020
AB			**EQ 100MG BASE**	**A091059**	**002**	Aug 28, 2015

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

AB			**EQ 150MG BASE**	**A091059**	**003**	Aug 28, 2015
AB		ZYDUS PHARMS	**EQ 25MG BASE**	**A213065**	**001**	Apr 16, 2020
AB			**EQ 100MG BASE**	**A213065**	**002**	Apr 16, 2020
AB			**EQ 150MG BASE**	**A213065**	**003**	Apr 16, 2020

TARCEVA

AB	+	OSI PHARMS	**EQ 25MG BASE**	**N021743**	**001**	Nov 18, 2004
AB	+		**EQ 100MG BASE**	**N021743**	**002**	Nov 18, 2004
AB	+!		**EQ 150MG BASE**	**N021743**	**003**	Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

AP		ACS DOBFAR SPA	**EQ 1GM BASE/VIAL**	**A208790**	**001**	Apr 16, 2018
AP		EUGIA PHARMA	**EQ 1GM BASE/VIAL**	**A209133**	**001**	Jun 25, 2018
AP		GLAND PHARMA LTD	**EQ 1GM BASE/VIAL**	**A212040**	**001**	Mar 26, 2021
AP		SAVIOR LIFETEC CORP	**EQ 1GM BASE/VIAL**	**A207647**	**001**	Mar 19, 2019

INVANZ

AP	+!	MERCK SHARP DOHME	**EQ 1GM BASE/VIAL**	**N021337**	**001**	Nov 21, 2001

ERTUGLIFLOZIN

TABLET;ORAL

STEGLATRO

+	MERCK SHARP DOHME	5MG	N209803	001	Dec 19, 2017
+!		15MG	N209803	002	Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

SEGLUROMET

+	MERCK SHARP DOHME	2.5MG;500MG	N209806	001	Dec 19, 2017
+		2.5MG;1GM	N209806	002	Dec 19, 2017
+		7.5MG;500MG	N209806	003	Dec 19, 2017
+!		7.5MG;1GM	N209806	004	Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

STEGLUJAN

+	MERCK SHARP DOHME	5MG;EQ 100MG BASE	N209805	001	Dec 19, 2017
+!		15MG;EQ 100MG BASE	N209805	002	Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

AB	+!	MAYNE PHARMA	**250MG**	**N050536**	**001**	

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	**250MG**	**A062746**	**001**	Dec 22, 1986

GEL;TOPICAL

ERYGEL

AT	+!	MYLAN	**2%**	**N050617**	**001**	Oct 21, 1987

ERYTHROMYCIN

AT		FOUGERA PHARMS	**2%**	**A064184**	**001**	Sep 30, 1997
AT		PADAGIS US	**2%**	**A063211**	**001**	Jan 29, 1993
AT		TELIGENT	**2%**	**A208154**	**001**	Jul 19, 2017

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT		AKORN	**0.5%**	**A064030**	**001**	Jul 18, 1996
AT		BAUSCH AND LOMB	**0.5%**	**A064067**	**001**	Jul 29, 1994
AT	!	PADAGIS US	**0.5%**	**A062447**	**001**	Sep 26, 1983

SOLUTION;TOPICAL

ERYTHRA-DERM

AT		SAPTALIS PHARMS	**2%**	**A062687**	**001**	Feb 05, 1988

ERYTHROMYCIN

AT	!	PADAGIS US	**2%**	**A063038**	**001**	Jan 11, 1991
AT		TELIGENT	**2%**	**A208100**	**001**	Nov 20, 2017
AT		WOCKHARDT BIO AG	**2%**	**A062825**	**001**	Oct 23, 1987

SWAB;TOPICAL

ERYTHROMYCIN

AT		AKORN	**2%**	**A090215**	**001**	May 12, 2010
AT	!	PADAGIS US	**2%**	**A064126**	**001**	Jul 03, 1996

TABLET;ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS LLC	**250MG**	**A061621**	**001**	
AB	!		**500MG**	**A061621**	**002**	

ERYTHROMYCIN

TABLET;ORAL

ERYTHROMYCIN

AB		CADILA PHARMS LTD	**250MG**	**A213628**	**001**	Jun 28, 2021
AB			**500MG**	**A213628**	**002**	Jun 28, 2021
AB		TEVA PHARMS USA INC	**250MG**	**A214549**	**001**	Feb 11, 2021
AB			**500MG**	**A214549**	**002**	Feb 11, 2021
AB		TORRENT	**250MG**	**A212015**	**001**	Jul 06, 2020
AB			**500MG**	**A212015**	**002**	Jul 06, 2020
BX		AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018
BX			500MG	A209720	002	Mar 09, 2018

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB		ARBOR PHARMS LLC	**250MG**	**A062298**	**001**	
AB			**333MG**	**A062298**	**003**	Mar 29, 1982
AB	**!**		**500MG**	**A062298**	**002**	

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	**250MG**	**A210954**	**001**	Jul 02, 2019
AB			**333MG**	**A210954**	**002**	Jul 02, 2019
AB			**500MG**	**A210954**	**003**	Jul 02, 2019
AB		TORRENT	**250MG**	**A211975**	**001**	Jul 26, 2021
AB			**500MG**	**A211975**	**002**	Jul 26, 2021

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	**+**	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207**	**001**	

ERYPED

AB	**+**	ARBOR PHARMS LLC	**EQ 200MG BASE/5ML**	**N050207**	**003**	Mar 30, 1987
AB	**+!**		**EQ 400MG BASE/5ML**	**N050207**	**002**	

ERYTHROMYCIN ETHYLSUCCINATE

AB		AMNEAL PHARMS	**EQ 200MG BASE/5ML**	**A211204**	**001**	Nov 01, 2019
AB			**EQ 400MG BASE/5ML**	**A211204**	**002**	Nov 01, 2019
AB		ANI PHARMS	**EQ 200MG BASE/5ML**	**A062055**	**001**	
AB			**EQ 200MG BASE/5ML**	**A062055**	**003**	Nov 02, 2018
AB			**EQ 400MG BASE/5ML**	**A062055**	**002**	Nov 02, 2018

TABLET;ORAL

E.E.S. 400

BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061905	002	Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX	!	ARBOR PHARMS LLC	EQ 400MG BASE	A061904	001	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

AP		HOSPIRA	**EQ 500MG BASE/VIAL**	**A062638**	**001**	Oct 31, 1986
AP	**+!**		**EQ 500MG BASE/VIAL**	**N050609**	**001**	Sep 24, 1986

ERYTHROMYCIN LACTOBIONATE

AP		EXELA PHARMA	**EQ 500MG BASE/VIAL**	**A211086**	**001**	Sep 17, 2020

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

	!	ARBOR PHARMS LLC	EQ 250MG BASE	A060359	001	

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA		AMNEAL PHARMS	**EQ 5MG BASE/5ML**	**A202227**	**001**	Mar 14, 2012
AA		AUROBINDO PHARMA LTD	**EQ 5MG BASE/5ML**	**A079062**	**001**	Apr 02, 2012
AA	**!**	HETERO LABS LTD III	**EQ 5MG BASE/5ML**	**A202221**	**001**	Jun 12, 2012
AA		LANNETT CO INC	**EQ 5MG BASE/5ML**	**A090477**	**001**	Jun 12, 2013
AA		MACLEODS PHARMS LTD	**EQ 5MG BASE/5ML**	**A202754**	**001**	Mar 31, 2016
AA		TARO	**EQ 5MG BASE/5ML**	**A079121**	**001**	May 03, 2012

TABLET;ORAL

ESCITALOPRAM OXALATE

AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A202389**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A202389**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A202389**	**003**	Sep 11, 2012
AB		AMNEAL PHARMS	**EQ 5MG BASE**	**A205619**	**001**	May 17, 2017
AB			**EQ 10MG BASE**	**A205619**	**002**	May 17, 2017
AB			**EQ 20MG BASE**	**A205619**	**003**	May 17, 2017
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A090432**	**001**	Sep 11, 2012

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB			**EQ 10MG BASE**	**A090432**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090432**	**003**	Sep 11, 2012
AB		CADILA	**EQ 5MG BASE**	**A077734**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A077734**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A077734**	**003**	Sep 11, 2012
AB		GRAVITI PHARMS	**EQ 5MG BASE**	**A078777**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078777**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078777**	**003**	Sep 11, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078604**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078604**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078604**	**003**	Sep 11, 2012
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A202280**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A202280**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A202280**	**003**	Sep 12, 2012
AB		LUPIN LTD	**EQ 5MG BASE**	**A078169**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A078169**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A078169**	**003**	Sep 11, 2012
AB		PHARM ASSOC	**EQ 5MG BASE**	**A077512**	**001**	Sep 12, 2012
AB			**EQ 10MG BASE**	**A077512**	**002**	Sep 12, 2012
AB			**EQ 20MG BASE**	**A077512**	**003**	Sep 12, 2012
AB		PRINSTON INC	**EQ 5MG BASE**	**A078032**	**001**	Aug 28, 2015
AB			**EQ 10MG BASE**	**A078032**	**002**	Aug 28, 2015
AB			**EQ 20MG BASE**	**A078032**	**003**	Aug 28, 2015
AB		TEVA PHARMS USA	**EQ 5MG BASE**	**A076765**	**001**	Mar 14, 2012
AB			**EQ 10MG BASE**	**A076765**	**002**	Mar 14, 2012
AB			**EQ 20MG BASE**	**A076765**	**003**	Mar 14, 2012
AB		TORRENT PHARMS LTD	**EQ 5MG BASE**	**A090939**	**001**	Sep 11, 2012
AB			**EQ 10MG BASE**	**A090939**	**002**	Sep 11, 2012
AB			**EQ 20MG BASE**	**A090939**	**003**	Sep 11, 2012

LEXAPRO

AB	**+**	ALLERGAN	**EQ 5MG BASE**	**N021323**	**001**	Aug 14, 2002
AB	**+**		**EQ 10MG BASE**	**N021323**	**002**	Aug 14, 2002
AB	**+!**		**EQ 20MG BASE**	**N021323**	**003**	Aug 14, 2002

ESKETAMINE HYDROCHLORIDE

SPRAY;NASAL

SPRAVATO

	+!	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

AB	**+**	SUNOVION PHARMS INC	**200MG**	**N022416**	**001**	Nov 08, 2013
AB	**+**		**400MG**	**N022416**	**002**	Nov 08, 2013
AB	**+**		**600MG**	**N022416**	**003**	Nov 08, 2013
AB	**+!**		**800MG**	**N022416**	**004**	Nov 08, 2013

ESLICARBAZEPINE ACETATE

AB		DR REDDYS LABS LTD	**200MG**	**A211238**	**001**	Jun 29, 2021
AB			**400MG**	**A211238**	**002**	Jun 29, 2021
AB			**600MG**	**A211238**	**003**	Jun 29, 2021
AB			**800MG**	**A211238**	**004**	Jun 29, 2021

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC

AP	**+!**	BAXTER HLTHCARE	**10MG/ML**	**N019386**	**006**	Feb 25, 2003

ESMOLOL HYDROCHLORIDE

AP		EUGIA PHARMA	**10MG/ML**	**A205520**	**001**	Jul 23, 2015
AP		FRESENIUS KABI USA	**10MG/ML**	**A076573**	**001**	May 02, 2005
AP		GLAND PHARMA LTD	**10MG/ML**	**A208538**	**001**	Aug 14, 2019
AP		HIKMA	**10MG/ML**	**A076323**	**001**	Aug 10, 2004
AP		MYLAN INSTITUTIONAL	**10MG/ML**	**A076474**	**001**	May 02, 2005
AP		MYLAN LABS LTD	**10MG/ML**	**A206608**	**001**	Jun 08, 2018
AP			**20MG/ML**	**A206608**	**002**	Jun 08, 2018
AP		SAGENT PHARMS INC	**10MG/ML**	**A207107**	**001**	Jun 08, 2018
AP			**20MG/ML**	**A207107**	**002**	Jun 08, 2018

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27, 2003

BREVIBLOC IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16, 2001

ESMOLOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

+!	HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

+!	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		ALKEM LABS LTD	**EQ 20MG BASE**	**A208333**	**001**	Oct 20, 2017
AB			**EQ 40MG BASE**	**A208333**	**002**	Oct 20, 2017
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A205606**	**001**	Apr 21, 2016
AB			**EQ 40MG BASE**	**A205606**	**002**	Apr 21, 2016
AB		CISEN	**EQ 20MG BASE**	**A213158**	**001**	Sep 22, 2020
AB			**EQ 40MG BASE**	**A213158**	**002**	Sep 22, 2020
AB		CSPC OUYI	**EQ 20MG BASE**	**A212949**	**001**	Oct 02, 2020
AB			**EQ 40MG BASE**	**A212949**	**002**	Oct 02, 2020
AB		DR REDDYS LABS LTD	**EQ 20MG BASE**	**A078279**	**001**	Sep 25, 2015
AB			**EQ 40MG BASE**	**A078279**	**002**	Sep 25, 2015
AB		ETHYPHARM	**EQ 20MG BASE**	**A090841**	**001**	Mar 31, 2021
AB			**EQ 40MG BASE**	**A090841**	**002**	Mar 31, 2021
AB		GLENMARK PHARMS	**EQ 20MG BASE**	**A209495**	**001**	May 10, 2019
AB			**EQ 40MG BASE**	**A209495**	**002**	May 10, 2019
AB		GRAVITI PHARMS	**EQ 20MG BASE**	**A213486**	**001**	Mar 19, 2021
AB			**EQ 40MG BASE**	**A213486**	**002**	Mar 19, 2021
AB		HETERO LABS LTD III	**EQ 20MG BASE**	**A202784**	**001**	Sep 21, 2015
AB			**EQ 20MG BASE**	**A211977**	**001**	Jun 02, 2020
AB			**EQ 40MG BASE**	**A202784**	**002**	Sep 21, 2015
AB			**EQ 40MG BASE**	**A211977**	**002**	Jun 02, 2020
AB		INDCHEMIE HEALTH	**EQ 20MG BASE**	**A210559**	**001**	Feb 26, 2021
AB			**EQ 40MG BASE**	**A210559**	**002**	Feb 26, 2021
AB		IVAX SUB TEVA PHARMS	**EQ 20MG BASE**	**A078003**	**001**	Jan 26, 2015
AB			**EQ 40MG BASE**	**A078003**	**002**	Jan 26, 2015
AB		LANNETT CO INC	**EQ 20MG BASE**	**A205563**	**001**	Sep 01, 2017
AB			**EQ 40MG BASE**	**A205563**	**002**	Sep 01, 2017
AB		MYLAN	**EQ 20MG BASE**	**A078936**	**001**	Aug 02, 2015
AB			**EQ 40MG BASE**	**A078936**	**002**	Aug 03, 2015
AB		SUN PHARM	**EQ 20MG BASE**	**A209735**	**001**	Apr 30, 2018
AB			**EQ 40MG BASE**	**A209735**	**002**	Apr 30, 2018
AB		TORRENT	**EQ 20MG BASE**	**A203636**	**001**	Oct 19, 2015
AB			**EQ 40MG BASE**	**A203636**	**002**	Oct 19, 2015
AB		ZYDUS PHARMS	**EQ 20MG BASE**	**A206296**	**001**	May 22, 2019
AB			**EQ 40MG BASE**	**A206296**	**002**	May 22, 2019

NEXIUM

AB	+	ASTRAZENECA	**EQ 20MG BASE**	**N021153**	**001**	Feb 20, 2001
AB	+!		**EQ 40MG BASE**	**N021153**	**002**	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

AB		CIPLA	**EQ 10MG BASE/PACKET**	**A211752**	**001**	Mar 23, 2020
AB			**EQ 20MG BASE/PACKET**	**A211751**	**001**	Mar 23, 2020
AB			**EQ 40MG BASE/PACKET**	**A211751**	**002**	Mar 23, 2020

NEXIUM

AB	+	ASTRAZENECA	**EQ 10MG BASE/PACKET**	**N022101**	**001**	Feb 27, 2008
AB	+		**EQ 20MG BASE/PACKET**	**N021957**	**001**	Oct 20, 2006
AB	+!		**EQ 40MG BASE/PACKET**	**N021957**	**002**	Oct 20, 2006
	+		EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011
	+		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB		DR REDDYS LABS LTD	**EQ 20MG BASE;375MG**	**A204206**	**001**	Feb 18, 2020
AB			**EQ 20MG BASE;500MG**	**A204206**	**002**	Feb 18, 2020
AB		MYLAN	**EQ 20MG BASE;375MG**	**A204920**	**001**	Jul 20, 2021
AB			**EQ 20MG BASE;500MG**	**A204920**	**002**	Jul 20, 2021

VIMOVO

AB	+	HORIZON	**EQ 20MG BASE;375MG**	**N022511**	**002**	Apr 30, 2010
AB	+!		**EQ 20MG BASE;500MG**	**N022511**	**001**	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP		ACCORD HLTHCARE	**EQ 40MG BASE/VIAL**	**A205379**	**001**	Sep 25, 2015
AP		DEVA HOLDING AS	**EQ 40MG BASE/VIAL**	**A207181**	**001**	Mar 06, 2017
AP	**!**	EUGIA PHARMA	**EQ 40MG BASE/VIAL**	**A204657**	**002**	Aug 10, 2016
AP		GLAND PHARMA LTD	**EQ 20MG BASE/VIAL**	**A203349**	**001**	Apr 01, 2020
AP			**EQ 40MG BASE/VIAL**	**A203349**	**002**	Apr 01, 2020
AP		MYLAN LABS LTD	**EQ 40MG BASE/VIAL**	**A202686**	**002**	May 17, 2017
AP		SUN PHARMA GLOBAL	**EQ 40MG BASE/VIAL**	**A200882**	**002**	Mar 18, 2013

NEXIUM IV

AP	**+!**	ASTRAZENECA	**EQ 40MG BASE/VIAL**	**N021689**	**002**	Mar 31, 2005

ESTAZOLAM

TABLET;ORAL

ESTAZOLAM

AB		MAYNE PHARMA	**1MG**	**A074921**	**001**	Jul 10, 1997
AB	**!**		**2MG**	**A074921**	**002**	Jul 10, 1997
AB		NOVITIUM PHARMA	**1MG**	**A074826**	**001**	Jul 03, 1997
AB			**2MG**	**A074826**	**002**	Jul 03, 1997
AB		WATSON LABS	**1MG**	**A074818**	**001**	Aug 19, 1997
AB			**2MG**	**A074818**	**002**	Aug 19, 1997

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	**+!**	ALLERGAN	**0.01%**	**A086069**	**001**	Jan 31, 1984

ESTRADIOL

AB		ALVOGEN	**0.01%**	**A209767**	**001**	Mar 05, 2018
AB		MYLAN	**0.01%**	**A208788**	**001**	Dec 29, 2017
AB		PADAGIS ISRAEL	**0.01%**	**A210194**	**001**	Jan 22, 2018
AB		PRASCO LABS LLC	**0.01%**	**A212313**	**001**	Jul 15, 2021
AB		TEVA PHARMS USA	**0.01%**	**A210488**	**001**	Mar 30, 2018

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA

AB	**+**	BAYER HLTHCARE	**0.06MG/24HR**	**N020375**	**006**	May 27, 2003

ESTRADIOL

AB		MYLAN TECHNOLOGIES	**0.06MG/24HR**	**A075182**	**005**	Jul 20, 2006

CLIMARA

AB2	**+**	BAYER HLTHCARE	**0.025MG/24HR**	**N020375**	**004**	Mar 05, 1999
AB2	**+**		**0.0375MG/24HR**	**N020375**	**005**	May 27, 2003
AB2	**+**		**0.05MG/24HR**	**N020375**	**001**	Dec 22, 1994
AB2	**+**		**0.075MG/24HR**	**N020375**	**003**	Mar 23, 1998
AB2	**+!**		**0.1MG/24HR**	**N020375**	**002**	Dec 22, 1994

ESTRADIOL

AB2		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A075182**	**003**	Jan 26, 2005
AB2			**0.0375MG/24HR**	**A075182**	**004**	Jul 20, 2006
AB2			**0.05MG/24HR**	**A075182**	**006**	Feb 24, 2000
AB2			**0.075MG/24HR**	**A075182**	**002**	Jan 26, 2005
AB2			**0.1MG/24HR**	**A075182**	**001**	Feb 24, 2000
AB3		AMNEAL	**0.025MG/24HR**	**A211396**	**001**	Sep 28, 2020
AB3			**0.0375MG/24HR**	**A211396**	**002**	Sep 28, 2020
AB3			**0.05MG/24HR**	**A211396**	**003**	Sep 28, 2020
AB3			**0.075MG/24HR**	**A211396**	**004**	Sep 28, 2020
AB3			**0.1MG/24HR**	**A211396**	**005**	Sep 28, 2020
AB3		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A206685**	**001**	Aug 15, 2018
AB3			**0.0375MG/24HR**	**A206685**	**002**	Aug 15, 2018
AB3			**0.05MG/24HR**	**A206685**	**003**	Aug 15, 2018
AB3			**0.075MG/24HR**	**A206685**	**004**	Aug 15, 2018
AB3			**0.1MG/24HR**	**A206685**	**005**	Aug 15, 2018

MINIVELLE

AB3	**+**	NOVEN	**0.025MG/24HR**	**N203752**	**005**	Sep 23, 2014
AB3	**+**		**0.0375MG/24HR**	**N203752**	**001**	Oct 29, 2012
AB3	**+**		**0.05MG/24HR**	**N203752**	**003**	Oct 29, 2012
AB3	**+**		**0.075MG/24HR**	**N203752**	**002**	Oct 29, 2012
AB3	**+!**		**0.1MG/24HR**	**N203752**	**004**	Oct 29, 2012

GEL;TRANSDERMAL

DIVIGEL

	+!	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007

GEL, METERED;TRANSDERMAL

ELESTRIN

	+!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006

ESTRADIOL							
GEL, METERED;TRANSDERMAL							
ESTROGEL							
	+!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004
INSERT;VAGINAL							
IMVEXXY							
	+	THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018
	+!		0.01MG	N208564	002	May 29, 2018
INSERT, EXTENDED RELEASE;VAGINAL							
ESTRING							
	+!	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996
SPRAY;TRANSDERMAL							
EVAMIST							
	+!	PADAGIS US	1.53MG/SPRAY	N022014	001	Jul 27, 2007
SYSTEM;TRANSDERMAL							
ESTRADIOL							
AB1		MYLAN TECHNOLOGIES	**0.025MG/24HR**	**A201675**	**001**	Dec 19, 2014
AB1			**0.0375MG/24HR**	**A201675**	**002**	Dec 19, 2014
AB1			**0.05MG/24HR**	**A201675**	**003**	Dec 19, 2014
AB1			**0.075MG/24HR**	**A201675**	**004**	Dec 19, 2014
AB1			**0.1MG/24HR**	**A201675**	**005**	Dec 19, 2014
VIVELLE-DOT							
AB1	+	NOVARTIS	**0.025MG/24HR**	**N020538**	**009**	May 03, 2002
AB1	+		**0.0375MG/24HR**	**N020538**	**005**	Jan 08, 1999
AB1	+		**0.05MG/24HR**	**N020538**	**006**	Jan 08, 1999
AB1	+		**0.075MG/24HR**	**N020538**	**007**	Jan 08, 1999
AB1	+!		**0.1MG/24HR**	**N020538**	**008**	Jan 08, 1999
ESTRADIOL							
BX		AMNEAL	0.025MG/24HR	A211293	001	Feb 04, 2019
BX			0.0375MG/24HR	A211293	002	Feb 04, 2019
BX			0.05MG/24HR	A211293	003	Feb 04, 2019
BX			0.075MG/24HR	A211293	004	Feb 04, 2019
BX			0.1MG/24HR	A211293	005	Feb 04, 2019
MENOSTAR							
	+!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004
TABLET;ORAL							
ESTRADIOL							
AB		BARR LABS INC	**0.5MG**	**A040197**	**001**	Oct 22, 1997
AB			**1MG**	**A040197**	**002**	Oct 22, 1997
AB	!		**2MG**	**A040197**	**003**	Oct 22, 1997
AB		EPIC PHARMA INC	**0.5MG**	**A040275**	**001**	Dec 29, 1998
AB			**1MG**	**A040275**	**002**	Dec 29, 1998
AB			**2MG**	**A040275**	**003**	Dec 29, 1998
AB		MAYNE PHARMA	**0.5MG**	**A040114**	**003**	Mar 14, 1996
AB			**1MG**	**A040114**	**001**	Mar 14, 1996
AB			**2MG**	**A040114**	**002**	Mar 14, 1996
TABLET;VAGINAL							
ESTRADIOL							
AB		AMNEAL PHARMS	**10MCG**	**A205256**	**001**	May 29, 2015
AB		GLENMARK PHARMS LTD	**10MCG**	**A210264**	**001**	Sep 14, 2018
AB		TEVA PHARMS USA	**10MCG**	**A206388**	**001**	Jul 21, 2017
VAGIFEM							
AB	+!	NOVO NORDISK INC	**10MCG**	**N020908**	**002**	Nov 25, 2009
ESTRADIOL ACETATE							
INSERT, EXTENDED RELEASE;VAGINAL							
FEMRING							
	+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
	+!		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003
ESTRADIOL CYPIONATE							
INJECTABLE;INJECTION							
DEPO-ESTRADIOL							
	!	PFIZER	5MG/ML	A085470	003		
ESTRADIOL VALERATE							
INJECTABLE;INJECTION							
DELESTROGEN							
AO	+!	PAR STERILE PRODUCTS	**10MG/ML**	**N009402**	**002**		
AO	+!		**20MG/ML**	**N009402**	**004**		
AO	+!		**40MG/ML**	**N009402**	**003**		
ESTRADIOL VALERATE							
AO		AM REGENT	**20MG/ML**	**A090920**	**001**	Jan 19, 2010	

ESTRADIOL VALERATE						
INJECTABLE;INJECTION						
ESTRADIOL VALERATE						
AO			**40MG/ML**	**A090920**	**002**	Jan 19, 2010
AO	HIKMA		**10MG/ML**	**A203723**	**001**	Apr 21, 2020
AO			**20MG/ML**	**A203723**	**002**	Apr 21, 2020
AO			**40MG/ML**	**A203723**	**003**	Apr 21, 2020
ESTRADIOL; LEVONORGESTREL						
FILM, EXTENDED RELEASE;TRANSDERMAL						
CLIMARA PRO						
+!	BAYER HLTHCARE		0.045MG/24HR;0.015MG/24HR	N021258	001	Nov 21, 2003
ESTRADIOL; NORETHINDRONE ACETATE						
FILM, EXTENDED RELEASE;TRANSDERMAL						
COMBIPATCH						
+	NOVEN PHARMS INC		0.05MG/24HR;0.14MG/24HR	N020870	001	Aug 07, 1998
+!			0.05MG/24HR;0.25MG/24HR	N020870	002	Aug 07, 1998
TABLET;ORAL						
ACTIVELLA						
AB **+!**	AMNEAL		**1MG;0.5MG**	**N020907**	**001**	Nov 18, 1998
ESTRADIOL AND NORETHINDRONE ACETATE						
AB	BARR		**1MG;0.5MG**	**A079193**	**001**	May 11, 2010
AB	BRECKENRIDGE PHARM		**0.5MG;0.1MG**	**A078324**	**002**	Jun 09, 2011
AB			**1MG;0.5MG**	**A078324**	**001**	Apr 17, 2008
AB	MYLAN LABS LTD		**0.5MG;0.1MG**	**A207261**	**001**	Feb 10, 2017
AB			**1MG;0.5MG**	**A207261**	**002**	Feb 10, 2017
AB	NOVAST LABS		**0.5MG;0.1MG**	**A210612**	**001**	Apr 03, 2019
AB			**1MG;0.5MG**	**A210612**	**002**	Apr 03, 2019
AMABELZ						
BX	LUPIN LTD		0.5MG;0.1MG	A203339	001	Jun 20, 2016
BX			1MG;0.5MG	A203339	002	Jun 20, 2016
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX						
TABLET;ORAL						
MYFEMBREE						
+!	MYOVANT SCIENCES		1MG;0.5MG;40MG	N214846	001	May 26, 2021
ESTRADIOL; NORGESTIMATE						
TABLET;ORAL						
ESTRADIOL AND NORGESTIMATE						
!	BARR		1MG,1MG;N/A,0.09MG	A076812	001	Apr 29, 2005
ESTRADIOL; PROGESTERONE						
CAPSULE;ORAL						
BIJUVA						
+	THERAPEUTICSMD INC		0.5MG;100MG	N210132	002	Dec 28, 2021
+!			1MG;100MG	N210132	001	Oct 28, 2018
ESTRAMUSTINE PHOSPHATE SODIUM						
CAPSULE;ORAL						
EMCYT						
+!	PHARMACIA AND UPJOHN		EQ 140MG PHOSPHATE	N018045	001	
ESTROGENS, CONJUGATED						
CREAM;TOPICAL, VAGINAL						
PREMARIN						
+!	WYETH PHARMS		0.625MG/GM	N020216	001	
INJECTABLE;INJECTION						
PREMARIN						
+!	WYETH PHARMS		25MG/VIAL	N010402	001	
TABLET;ORAL						
PREMARIN						
+	WYETH PHARMS		0.3MG	N004782	003	
+			0.45MG	N004782	006	Jul 16, 2003
+!			0.625MG	N004782	004	
+!			0.9MG	N004782	005	Jan 26, 1984
+!			1.25MG	N004782	001	
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
TABLET;ORAL-28						
PREMPHASE 14/14						
+!	WYETH PHARMS		0.625MG,0.625MG;N/A,5MG	N020527	002	Nov 17, 1995
PREMPRO						
+!	WYETH PHARMS		0.3MG;1.5MG	N020527	005	Jun 04, 2003
+!			0.45MG;1.5MG	N020527	004	Mar 12, 2003

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPRO

+!		0.625MG;2.5MG	N020527	001	Nov 17, 1995
+!		0.625MG;5MG	N020527	003	Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET;ORAL

MENEST

	MONARCH PHARMS	0.3MG	A084951	001	
		0.625MG	A084948	001	
		1.25MG	A084950	001	
!		2.5MG	A084949	001	

ESTROPIPATE

TABLET;ORAL

OGEN 5

+	PFIZER	6MG	A083220	004	

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	AUROBINDO PHARMA LTD	**1MG**	**A208451**	**001**	Sep 15, 2016
AB		**2MG**	**A208451**	**002**	Sep 15, 2016
AB		**3MG**	**A208451**	**003**	Sep 15, 2016
AB	DR REDDYS LABS LTD	**1MG**	**A091024**	**001**	Apr 15, 2014
AB		**2MG**	**A091024**	**002**	Apr 15, 2014
AB		**3MG**	**A091024**	**003**	Apr 15, 2014
AB	GLENMARK GENERICS	**1MG**	**A091166**	**001**	Apr 15, 2014
AB		**2MG**	**A091166**	**002**	Apr 15, 2014
AB		**3MG**	**A091166**	**003**	Apr 15, 2014
AB	LUPIN LTD	**1MG**	**A091124**	**001**	Sep 13, 2011
AB		**2MG**	**A091124**	**002**	Sep 13, 2011
AB		**3MG**	**A091124**	**003**	Sep 13, 2011
AB	MACLEODS PHARMS LTD	**1MG**	**A202929**	**001**	Jan 30, 2015
AB		**2MG**	**A202929**	**002**	Jan 30, 2015
AB		**3MG**	**A202929**	**003**	Jan 30, 2015
AB	MYLAN PHARMS INC	**1MG**	**A091151**	**001**	Mar 26, 2013
AB		**2MG**	**A091151**	**002**	Mar 26, 2013
AB		**3MG**	**A091151**	**003**	Mar 26, 2013
AB	ORBION PHARMS	**1MG**	**A091113**	**001**	Jun 10, 2014
AB		**2MG**	**A091113**	**002**	Jun 10, 2014
AB		**3MG**	**A091113**	**003**	Jun 10, 2014
AB	SUN PHARM	**1MG**	**A091103**	**001**	Apr 03, 2013
AB		**2MG**	**A091103**	**002**	Apr 03, 2013
AB		**3MG**	**A091103**	**003**	Apr 03, 2013
AB	TEVA	**1MG**	**A091169**	**001**	May 23, 2011
AB		**2MG**	**A091169**	**002**	May 23, 2011
AB		**3MG**	**A091169**	**003**	May 23, 2011

LUNESTA

AB	**+**	SUNOVION PHARMS INC	**1MG**	**N021476**	**001**	Dec 15, 2004
AB	**+**		**2MG**	**N021476**	**002**	Dec 15, 2004
AB	**+!**		**3MG**	**N021476**	**003**	Dec 15, 2004

ETELCALCETIDE

SOLUTION;INTRAVENOUS

PARSABIV

+!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
+!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
+!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN

SOLUTION;INTRAVENOUS

EXONDYS 51

+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
+!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECRIN

AP	**+!**	BAUSCH	**EQ 50MG BASE/VIAL**	**N016093**	**001**	

ETHACRYNATE SODIUM

AP		MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A204634**	**001**	Aug 23, 2016
AP		PAR STERILE PRODUCTS	**EQ 50MG BASE/VIAL**	**A205473**	**001**	Jul 29, 2015

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

ETHACRYNATE SODIUM

AP		VPI PHARMS INC	**EQ 50MG BASE/VIAL**	**A208663**	**001**	Jun 09, 2020
AP		ZYDUS PHARMS	**EQ 50MG BASE/VIAL**	**A207758**	**001**	Nov 17, 2017

ETHACRYNIC ACID

TABLET;ORAL

EDECRIN

AB	**+!**	BAUSCH	**25MG**	**N016092**	**001**	

ETHACRYNIC ACID

AB		AGNITIO	**25MG**	**A211809**	**001**	Jul 12, 2019
AB		ALVOGEN	**25MG**	**A205709**	**001**	Jul 24, 2018
AB		AMNEAL PHARMS CO	**25MG**	**A208805**	**001**	May 08, 2018
AB		EDENBRIDGE PHARMS	**25MG**	**A205609**	**001**	Jun 30, 2016
AB		HIKMA	**25MG**	**A207262**	**001**	Feb 23, 2017
AB		LUPIN LTD	**25MG**	**A211719**	**001**	Sep 06, 2019
AB		PAR PHARM INC	**25MG**	**A208501**	**001**	Jul 21, 2017
AB		SCIEGEN PHARMS INC	**25MG**	**A211232**	**001**	Aug 27, 2019
AB		STRIDES PHARMA	**25MG**	**A213240**	**001**	Oct 19, 2020
AB		UPSHER SMITH LABS	**25MG**	**A212417**	**001**	Feb 19, 2020

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		AKORN	**100MG**	**A075095**	**001**	Nov 30, 1999
AB			**400MG**	**A075095**	**002**	Nov 30, 1999
AB		BARR	**400MG**	**A076057**	**001**	Nov 26, 2001
AB		LUPIN	**100MG**	**A078939**	**001**	Jun 17, 2009
AB			**400MG**	**A078939**	**002**	Jun 17, 2009

MYAMBUTOL

AB	**+**	STI PHARMA LLC	**100MG**	**N016320**	**001**	
AB	**+!**		**400MG**	**N016320**	**003**	

ETHANOLAMINE OLEATE

INJECTABLE;INJECTION

ETHAMOLIN

	+!	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB		MYLAN LABS LTD	**0.035MG;1MG**	**A204703**	**001**	Jul 28, 2016
AB			**0.05MG;1MG**	**A204704**	**001**	Feb 09, 2016

KELNOR

AB		BARR	**0.035MG;1MG**	**A076785**	**001**	May 23, 2005

LO-MALMOREDE

AB		NOVAST LABS	**0.035MG;1MG**	**A209548**	**001**	Feb 11, 2019

MALMOREDE

AB		NOVAST LABS	**0.05MG;1MG**	**A209547**	**001**	Jul 25, 2018

ZOVIA 1/35E-28

AB		MAYNE PHARMA	**0.035MG;1MG**	**A072721**	**001**	Dec 30, 1991

ZOVIA 1/50E-28

AB	**!**	WATSON LABS	**0.05MG;1MG**	**A072723**	**001**	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

ELURYNG

AB		AMNEAL	**0.015MG/24HR;0.12MG/24HR**	**A210830**	**001**	Dec 11, 2019

ETHINYL ESTRADIOL; ETONOGESTREL

AB		TEVA PHARMS USA INC	**0.015MG/24HR;0.12MG/24HR**	**A204305**	**001**	Jan 13, 2021

NUVARING

AB	**+!**	ORGANON SUB MERCK	**0.015MG/24HR;0.12MG/24HR**	**N021187**	**001**	Oct 03, 2001

VERARING

AB		DR REDDYS LABS SA	**0.015MG/24HR;0.12MG/24HR**	**A207577**	**001**	Dec 09, 2021

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM;TRANSDERMAL

TWIRLA

	+!	AGILE	0.03MG/24HR;0.12MG/24HR	N204017	001	Feb 14, 2020

TABLET;ORAL

ASHLYNA

AB		GLENMARK GENERICS	**0.03MG,0.01MG;0.15MG,N/A**	**A203163**	**001**	Feb 23, 2015

DAYSEE

AB		LUPIN LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A091467**	**001**	Apr 10, 2013

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

DOLISHALE						
AB		NOVAST LABS	**0.02MG;0.09MG**	**A091692**	**001**	Oct 22, 2020
ICLEVIA						
AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206850**	**001**	Jun 29, 2018
INTROVALE						
AB		XIROMED	**0.03MG;0.15MG**	**A079064**	**001**	Sep 27, 2010
JAIMIESS						
AB		XIROMED	**0.03MG,0.01MG;0.15MG,N/A**	**A203770**	**001**	Dec 27, 2017
LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A203871**	**001**	Nov 13, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A203872**	**001**	Dec 22, 2015
AB		GLENMARK GENERICS	**0.02MG;0.09MG**	**A202791**	**001**	Apr 09, 2015
AB		GLENMARK PHARMS LTD	**0.03MG;0.15MG**	**A203164**	**001**	Jun 12, 2015
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091440**	**001**	Oct 23, 2012
AB		MYLAN LABS LTD	**0.03MG;0.15MG**	**A200490**	**001**	Apr 21, 2015
AB	!	WATSON LABS	**0.02MG;0.09MG**	**A079218**	**001**	Jun 06, 2011
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL						
AB		LUPIN LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A091674**	**001**	Oct 26, 2011
AB		MAYNE PHARMA	**0.02MG,0.1MG;0.01MG,N/A**	**A200407**	**001**	Oct 25, 2011
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A078834**	**001**	May 31, 2011
AB		MYLAN LABS LTD	**0.02MG,0.15MG; 0.025MG,0.15MG;0.03MG,0.15MG;**	**A206053**	**001**	Oct 02, 2017
AB			**0.02MG,0.1MG;0.01MG,N/A**	**A200493**	**001**	Jun 17, 2015
AB			**0.03MG,0.01MG;0.15MG,N/A**	**A200492**	**001**	May 27, 2015
AB		XIROMED	**0.02MG,0.1MG;0.01MG,N/A**	**A205131**	**001**	Dec 14, 2017
LO SIMPESSE						
AB		AUROBINDO PHARMA LTD	**0.02MG,0.1MG;0.01MG,N/A**	**A206852**	**001**	Apr 28, 2017
LOSEASONIQUE						
AB		TEVA BRANDED PHARM	**0.02MG,0.1MG;0.01MG,N/A**	**N022262**	**001**	Oct 24, 2008
QUARTETTE						
AB	**+!**	TEVA BRANDED PHARM	**0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A**	**N204061**	**001**	Mar 28, 2013
QUASENSE						
AB		WATSON LABS	**0.03MG;0.15MG**	**A077101**	**001**	Sep 06, 2006
SEASONALE						
AB	**+!**	TEVA BRANDED PHARM	**0.03MG;0.15MG**	**N021544**	**001**	Sep 05, 2003
SEASONIQUE						
AB	**+!**	TEVA BRANDED PHARM	**0.03MG,0.01MG;0.15MG,N/A**	**N021840**	**001**	May 25, 2006
SETLAKIN						
AB		NOVAST LABS	**0.03MG;0.15MG**	**A090716**	**001**	Sep 15, 2014
SIMPESSE						
AB		AUROBINDO PHARMA LTD	**0.03MG,0.01MG;0.15MG,N/A**	**A206851**	**001**	Apr 07, 2017
BALCOLTRA						
	+!	AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018
TYBLUME						
	+!	EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020

TABLET;ORAL-28

ALTAVERA						
AB		XIROMED	**0.03MG;0.15MG**	**A079102**	**001**	Aug 03, 2010
AYUNA						
AB		AUROBINDO PHARMA LTD	**0.03MG;0.15MG**	**A206866**	**001**	Sep 23, 2016
ENPRESSE-28						
AB		DURAMED PHARMS BARR	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A075809**	**002**	Jul 16, 2001
KURVELO						
AB		LUPIN LTD	**0.03MG;0.15MG**	**A091408**	**001**	Oct 17, 2012
LEVONEST						
AB		NOVAST LABS LTD	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A090719**	**001**	Dec 29, 2010
LEVONORGESTREL AND ETHINYL ESTRADIOL						
AB		AMNEAL PHARMS	**0.03MG;0.15MG**	**A201095**	**001**	Dec 08, 2014
AB		MYLAN LABS LTD	**0.03MG;0.15MG**	**A091663**	**001**	Dec 21, 2012
AB		NAARI PTE LTD	**0.02MG;0.1MG**	**A207065**	**001**	Aug 17, 2020
AB			**0.03MG;0.15MG**	**A207033**	**001**	Oct 09, 2020
LEVORA 0.15/30-28						
AB	!	MAYNE PHARMA	**0.03MG;0.15MG**	**A073594**	**001**	Dec 13, 1993

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

	MARLISSA					
AB		GLENMARK GENERICS	**0.03MG;0.15MG**	**A091452**	**001**	Feb 29, 2012
	MYZILRA					
AB		VINTAGE PHARMS LLC	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A077502**	**001**	Nov 23, 2011
	PORTIA-28					
AB		BARR	**0.03MG;0.15MG**	**A075866**	**002**	May 23, 2002
	TRIVORA-28					
AB	!	MAYNE PHARMA	**0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG**	**A074538**	**002**	Dec 18, 1997
	AFIRMELLE					
AB1		AUROBINDO PHARMA LTD	**0.02MG;0.1MG**	**A206886**	**001**	Nov 14, 2016
	AVIANE-28					
AB1		DURAMED PHARMS BARR	**0.02MG;0.1MG**	**A075796**	**001**	Apr 30, 2001
	FALMINA					
AB1		NOVAST LABS LTD	**0.02MG;0.1MG**	**A090721**	**001**	Mar 28, 2012
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB1		AMNEAL PHARMS	**0.02MG;0.1MG**	**A201108**	**001**	Feb 05, 2014
AB1	!	MAYNE PHARMA	**0.02MG;0.1MG**	**A076625**	**001**	Nov 18, 2004
AB1		MYLAN LABS LTD	**0.02MG;0.1MG**	**A200245**	**001**	Oct 09, 2013
	VIENVA					
AB1		XIROMED	**0.02MG;0.1MG**	**A201088**	**001**	May 21, 2015
	LESSINA-28					
AB2		BARR	**0.02MG;0.1MG**	**A075803**	**002**	Mar 20, 2002
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB2	!	MAYNE PHARMA	**0.02MG;0.1MG**	**A077681**	**001**	May 31, 2006
BX		LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013
BX			0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

	ONSURA					
AB		TEVA PHARMS USA	**0.035MG/24HR;0.15MG/24HR**	**A213977**	**001**	Aug 25, 2021
	XULANE					
AB	!	MYLAN TECHNOLOGIES	**0.035MG/24HR;0.15MG/24HR**	**A200910**	**001**	Apr 16, 2014
	ETHINYL ESTRADIOL AND NORELGESTROMIN					
BX		AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

	NORTREL 1/35-21					
AB		BARR	**0.035MG;1MG**	**A072693**	**001**	Feb 28, 1992
	NORTREL 7/7/7					
		BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET;ORAL-28

	ALYACEN 1/35					
AB		GLENMARK GENERICS	**0.035MG;1MG**	**A091634**	**001**	Jan 19, 2012
	ALYACEN 7/7/7					
AB		GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A091636**	**001**	Jan 19, 2012
	ARANELLE					
AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**A076783**	**001**	Sep 29, 2004
	BALZIVA-28					
AB	!	BARR	**0.035MG;0.4MG**	**A076238**	**001**	Apr 22, 2004
	BRIELLYN					
AB		GLENMARK GENERICS	**0.035MG;0.4MG**	**A090538**	**001**	Mar 22, 2011
	CYONANZ					
AB		AUROBINDO PHARMA LTD	**0.035MG;0.5MG**	**A207055**	**001**	Oct 21, 2016
	DASETTA 1/35					
AB		NOVAST LABS LTD	**0.035MG;1MG**	**A090948**	**001**	Dec 22, 2011
	DASETTA 7/7/7					
AB	!	NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A090946**	**001**	Dec 22, 2011
	GILDAGIA					
AB		VINTAGE PHARMS	**0.035MG;0.4MG**	**A078376**	**001**	Nov 06, 2012
	NORETHINDRONE AND ETHINYL ESTRADIOL					
AB		MAYNE PHARMA	**0.035MG;0.5MG**	**A070686**	**001**	Jan 29, 1987
AB		NAARI PTE LTD	**0.035MG;1MG**	**A206864**	**001**	Apr 28, 2017
AB		WATSON LABS	**0.035MG;0.4MG**	**A078323**	**001**	Feb 04, 2010

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL						
AB		WATSON LABS TEVA	**0.035MG;1MG**	**A070687**	**001**	Jan 29, 1987
NORTREL 0.5/35-28						
AB		BARR	**0.035MG;0.5MG**	**A072695**	**001**	Feb 28, 1992
NORTREL 1/35-28						
AB	**!**	BARR	**0.035MG;1MG**	**A072696**	**001**	Feb 28, 1992
NORTREL 7/7/7						
AB		BARR	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A075478**	**002**	Aug 30, 2002
NYLIA 1/35						
AB		AUROBINDO PHARMA LTD	**0.035MG;1MG**	**A207056**	**001**	Oct 21, 2016
NYLIA 7/7/7						
AB		AUROBINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG**	**A207054**	**001**	Oct 21, 2016
PHILITH						
AB		NOVAST LABS LTD	**0.035MG;0.4MG**	**A090947**	**001**	Dec 22, 2011
TRI-NORINYL 28-DAY						
AB	**+!**	MAYNE PHARMA	**0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG**	**N018977**	**002**	Apr 13, 1984
VYFEMLA						
AB		LUPIN LTD	**0.035MG;0.4MG**	**A201886**	**001**	Sep 26, 2013
WERA						
AB	**!**	NOVAST LABS LTD	**0.035MG;0.5MG**	**A091204**	**001**	Mar 27, 2012
PIRMELLA 1/35						
BX		LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013
PIRMELLA 7/7/7						
BX		LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)						
		WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988

TABLET, CHEWABLE;ORAL

KAITLIB FE						
AB		LUPIN LTD	**0.025MG;0.8MG**	**A203448**	**001**	Dec 17, 2015
NEXESTA FE						
AB		AUROBINDO PHARMA LTD	**0.035MG;0.4MG**	**A207535**	**001**	Feb 02, 2017
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB		AMNEAL PHARMS	**0.035MG;0.4MG**	**A078892**	**001**	Sep 26, 2011
AB	**+!**	APIL	**0.025MG;0.8MG**	**N022573**	**001**	Dec 22, 2010
AB		BARR	**0.035MG;0.4MG**	**A078965**	**001**	Aug 05, 2010
AB		LUPIN LTD	**0.035MG;0.4MG**	**A091332**	**001**	Mar 23, 2016
AB		MYLAN LABS LTD	**0.025MG;0.8MG**	**A203371**	**001**	Apr 23, 2014
AB	**!**		**0.035MG;0.4MG**	**A202086**	**001**	Apr 01, 2015
AB		NAARI PTE LTD	**0.035MG;0.4MG**	**A207066**	**001**	Mar 29, 2017

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

GEMMILY						
AB		XIROMED	**0.02MG;1MG**	**A213317**	**001**	Nov 09, 2020
MERZEE						
AB		SLAYBACK PHARMA LLC	**0.02MG;1MG**	**A212706**	**001**	Dec 18, 2020
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB		AMNEAL PHARMS	**0.02MG;1MG**	**A214292**	**001**	Jul 20, 2021
TAYTULLA						
AB	**+!**	APIL	**0.02MG;1MG**	**N204426**	**001**	Apr 19, 2013

TABLET;ORAL

AUROVELA 24 FE						
AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207504**	**001**	Jun 15, 2017
BLISOVI 24 FE						
AB		LUPIN LTD	**0.02MG;1MG**	**A091398**	**001**	Oct 28, 2015
FYAVOLV						
AB		LUPIN LTD	**0.005MG;1MG**	**A204213**	**002**	Dec 10, 2015
AB			**0.0025MG;0.5MG**	**A204213**	**001**	Dec 10, 2015
GILDESS 24 FE						
AB		VINTAGE PHARMS	**0.02MG;1MG**	**A090293**	**001**	Dec 01, 2014
LARIN 24 FE						
AB		NOVAST LABS	**0.02MG;1MG**	**A202994**	**001**	Feb 18, 2015
LERIBANE						
AB		NOVAST LABS	**0.0025MG;0.5MG**	**A203435**	**002**	Jun 03, 2016
AB			**0.005MG;1MG**	**A203435**	**001**	Jun 03, 2016

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	**!**	BARR LABS INC	**0.005MG;1MG**	**A076221**	**001**	Nov 06, 2009
AB		GLENMARK GENERICS	**0.0025MG;0.5MG**	**A203038**	**001**	Apr 02, 2015
AB			**0.005MG;1MG**	**A203038**	**002**	Apr 02, 2015

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	**!**	AMNEAL PHARMS	**0.02MG;1MG**	**A078267**	**001**	Sep 01, 2009
AB		BARR LABS INC	**0.02MG;1MG**	**A090938**	**001**	Dec 01, 2014
AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A204847**	**001**	Nov 17, 2017

LO LOESTRIN FE

	+!	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010

TABLET;ORAL-21

AUROVELA 1.5/30

AB		AUROBINDO PHARMA LTD	**0.03MG;1.5MG**	**A207581**	**001**	Jun 26, 2017

AUROVELA 1/20

AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207506**	**001**	Jun 16, 2017

HAILEY 1.5/30

AB		GLENMARK PHARMS	**0.03MG;1.5MG**	**A209297**	**001**	Jun 05, 2018

JUNEL 1.5/30

AB		BARR	**0.03MG;1.5MG**	**A076381**	**001**	May 30, 2003

JUNEL 1/20

AB		BARR	**0.02MG;1MG**	**A076380**	**001**	May 30, 2003

LARIN 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A202996**	**001**	Mar 20, 2014

LARIN 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A202995**	**001**	Dec 04, 2013

LOESTRIN 21 1.5/30

AB	**+**	TEVA BRANDED PHARM	**0.03MG;1.5MG**	**N017875**	**001**	

LOESTRIN 21 1/20

AB	**+**	TEVA BRANDED PHARM	**0.02MG;1MG**	**N017876**	**001**	

LOESTRIN FE 1.5/30

AB	**+!**	TEVA BRANDED PHARM	**0.03MG;1.5MG**	**N017355**	**001**	

MICROGESTIN 1.5/30

AB		MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**002**	Jul 30, 2003

MICROGESTIN 1/20

AB		MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**002**	Jul 30, 2003

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206969**	**001**	Jan 20, 2016
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202771**	**001**	Nov 06, 2013
AB			**0.03MG;1.5MG**	**A202770**	**001**	Feb 19, 2015

TRI-LEGEST 21

		BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076405	001	Oct 26, 2007

TABLET;ORAL-28

AUROVELA FE 1.5/30

AB		AUROBINDO PHARMA LTD	**0.03MG;1.5MG**	**A207580**	**001**	Jun 15, 2017

AUROVELA FE 1/20

AB		AUROBINDO PHARMA LTD	**0.02MG;1MG**	**A207505**	**001**	Jun 16, 2017

BLISOVI FE 1/20

AB		LUPIN LTD	**0.02MG;1MG**	**A201584**	**001**	Nov 18, 2015

CHABELINA FE

AB	**!**	NOVAST LABS	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A202962**	**001**	Apr 15, 2020

HAILEY FE 1.5/30

AB		GLENMARK PHARMS	**0.03MG;1.5MG**	**A209031**	**001**	Jun 05, 2018

HAILEY FE 1/20

AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A206597**	**001**	Nov 21, 2017

JUNEL FE 1.5/30

AB		BARR	**0.03MG;1.5MG**	**A076064**	**001**	Sep 18, 2003

JUNEL FE 1/20

AB		BARR	**0.02MG;1MG**	**A076081**	**001**	Sep 18, 2003

LARIN FE 1.5/30

AB		NOVAST LABS	**0.03MG;1.5MG**	**A091453**	**001**	Aug 23, 2013

LARIN FE 1/20

AB		NOVAST LABS	**0.02MG;1MG**	**A091454**	**001**	Aug 26, 2013

LOESTRIN FE 1/20

AB	**+**	TEVA BRANDED PHARM	**0.02MG;1MG**	**N017354**	**001**	

MICROGESTIN FE 1.5/30

AB		MAYNE PHARMA	**0.03MG;1.5MG**	**A075548**	**001**	Feb 05, 2001

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-28

MICROGESTIN FE 1/20

AB		MAYNE PHARMA	**0.02MG;1MG**	**A075647**	**001**	Feb 05, 2001

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		MAYNE PHARMA	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076629**	**001**	Mar 18, 2010
AB		MYLAN LABS LTD	**0.02MG;1MG**	**A202772**	**001**	Nov 14, 2013
AB			**0.03MG;1.5MG**	**A202741**	**001**	Feb 20, 2015

TRI-LEGEST FE

AB		BARR	**0.02MG,0.03MG,0.035MG;1MG,1MG,1MG**	**A076105**	**001**	Oct 26, 2007

BLISOVI FE 1.5/30

BX		LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015

TABLET, CHEWABLE;ORAL

MIBELAS 24 FE

AB		LUPIN	**0.02MG;1MG**	**A206287**	**001**	May 24, 2016

MINASTRIN 24 FE

AB	**+!**	APIL	**0.02MG;1MG**	**N203667**	**001**	May 08, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	**0.02MG;1MG**	**A207514**	**001**	Sep 11, 2017
AB		GLENMARK PHARMS LTD	**0.02MG;1MG**	**A210369**	**001**	Dec 26, 2017
AB		XIROMED	**0.02MG;1MG**	**A209609**	**001**	Jul 16, 2018

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

ESTARYLLA

AB		XIROMED	**0.035MG;0.25MG**	**A090794**	**001**	Jan 30, 2013

MILI

AB		AUROBINDO PHARMA LTD	**0.035MG;0.25MG**	**A205449**	**001**	Jul 07, 2016

MONO-LINYAH

AB		NOVAST LABS LTD	**0.035MG;0.25MG**	**A090523**	**001**	May 23, 2012

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		AMNEAL PHARMS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A203870**	**001**	Nov 12, 2015
AB			**0.035MG;0.25MG**	**A203865**	**001**	Oct 27, 2015
AB			**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A203873**	**001**	May 12, 2016
AB	**!**	GLENMARK GENERICS	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A200494**	**001**	Jun 17, 2011
AB			**0.035MG;0.25MG**	**A200538**	**001**	Apr 05, 2012
AB	**!**	GLENMARK PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A204057**	**001**	Feb 23, 2016
AB		LUPIN LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205588**	**001**	Apr 26, 2016
AB			**0.035MG;0.25MG**	**A205630**	**001**	Oct 27, 2016
AB		LUPIN PHARMS	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A200541**	**001**	Jun 25, 2012
AB		NAARI PTE LTD	**0.035MG;0.035MG;0.035MG;0.18MG;0.215MG; 0.25MG**	**A200383**	**001**	Apr 07, 2015
AB			**0.035MG;0.25MG**	**A200384**	**001**	Apr 07, 2015

PREVIFEM

AB		VINTAGE PHARMS LLC	**0.035MG;0.25MG**	**A076334**	**001**	Jan 09, 2004

SPRINTEC

AB	**!**	BARR	**0.035MG;0.25MG**	**A075804**	**001**	Sep 25, 2002

TRI LO SPRINTEC

AB		BARR LABS INC	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A076784**	**001**	Jun 29, 2009

TRI-ESTARYLLA

AB		XIROMED	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090793**	**001**	Jan 30, 2013

TRI-LINYAH

AB		NOVAST LABS LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A090524**	**001**	May 30, 2012

TRI-LO-ESTARYLLA

AB		XIROMED	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A091232**	**001**	Jun 29, 2015

TRI-LO-MILI

AB		AUROBINDO PHARMA LTD	**0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG**	**A205762**	**001**	Nov 04, 2016

TRI-MILI

AB		AUROBINDO PHARMA LTD	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A205441**	**001**	Jul 06, 2016

TRI-SPRINTEC

AB		BARR	**0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG**	**A075808**	**001**	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

CRYSELLE

AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**001**	Nov 30, 2001

TABLET;ORAL-28

CRYSELLE

AB	DURAMED PHARMS BARR	**0.03MG;0.3MG**	**A075840**	**002**	Nov 30, 2001

ELINEST

AB	NOVAST LABS LTD	**0.03MG;0.3MG**	**A091105**	**001**	Mar 28, 2012

LOW-OGESTREL-28

AB	MAYNE PHARMA	**0.03MG;0.3MG**	**A075288**	**002**	Jul 28, 1999

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING;VAGINAL

ANNOVERA

+!	THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	N009190	001	

ETHIONAMIDE

TABLET;ORAL

TRECATOR

+!	WYETH PHARMS	250MG	N013026	002	

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	AKORN	**250MG**	**A040686**	**001**	May 28, 2008
AB	BIONPHARMA INC	**250MG**	**A040430**	**001**	Oct 28, 2002
AB	STRIDES PHARMA	**250MG**	**A211928**	**001**	Feb 19, 2019

ZARONTIN

AB	**+!** PARKE DAVIS	**250MG**	**N012380**	**001**	

ETHOSUXIMIDE

BX	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012
BX	PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020

SYRUP;ORAL

ETHOSUXIMIDE

AA	MIKART	**250MG/5ML**	**A040506**	**001**	Dec 22, 2003
AA	PHARM ASSOC	**250MG/5ML**	**A040253**	**001**	Nov 22, 2000

ZARONTIN

AA	**+!** PARKE-DAVIS	**250MG/5ML**	**A080258**	**001**	

ETODOLAC

CAPSULE;ORAL

ETODOLAC

AB	ANI PHARMS	**200MG**	**A075126**	**001**	Sep 16, 1999
AB		**300MG**	**A075126**	**002**	Sep 16, 1999
AB	APOTEX	**200MG**	**A075419**	**001**	Jul 28, 2000
AB		**300MG**	**A075419**	**002**	Jul 28, 2000
AB	TARO	**200MG**	**A075078**	**001**	Apr 30, 1998
AB	**!**	**300MG**	**A075078**	**002**	Apr 30, 1998

TABLET;ORAL

ETODOLAC

AB	AMNEAL PHARMS CO	**400MG**	**A208834**	**001**	Jun 07, 2018
AB		**500MG**	**A208834**	**002**	Jun 07, 2018
AB	APOTEX INC	**400MG**	**A076004**	**001**	Dec 03, 2002
AB		**500MG**	**A076004**	**002**	Dec 03, 2002
AB	BAYSHORE PHARMS LLC	**400MG**	**A210704**	**001**	Dec 16, 2020
AB		**500MG**	**A210704**	**002**	Dec 16, 2020
AB	EDENBRIDGE PHARMS	**400MG**	**A209888**	**001**	Nov 30, 2018
AB		**500MG**	**A209888**	**002**	Nov 30, 2018
AB	SANDOZ	**400MG**	**A074903**	**001**	Apr 11, 1997
AB		**500MG**	**A074903**	**002**	Apr 19, 1999
AB	TARO PHARM INDS	**400MG**	**A075074**	**001**	Mar 11, 1998
AB	**!**	**500MG**	**A075074**	**002**	Apr 25, 2000

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

AB	BAYSHORE PHARMS LLC	**400MG**	**A212263**	**001**	Nov 24, 2020
AB		**500MG**	**A212263**	**002**	Nov 24, 2020
AB		**600MG**	**A212263**	**003**	Nov 24, 2020
AB	TARO	**400MG**	**A076174**	**001**	Mar 13, 2003

ETODOLAC

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

AB			**500MG**	**A076174**	**002**	Mar 13, 2003
AB			**600MG**	**A076174**	**003**	Mar 13, 2003
AB		TEVA	**400MG**	**A075665**	**003**	Feb 05, 2001
AB			**500MG**	**A075665**	**002**	Jul 31, 2000
AB	**!**		**600MG**	**A075665**	**001**	Jul 31, 2000
AB		ZYDUS PHARMS	**400MG**	**A091134**	**001**	Jan 23, 2014
AB			**500MG**	**A091134**	**002**	Jan 23, 2014
AB			**600MG**	**A091134**	**003**	Jan 23, 2014

ETOMIDATE

INJECTABLE;INJECTION

AMIDATE

AP	**+!**	HOSPIRA	**2MG/ML**	**N018227**	**001**	Sep 07, 1982

ETOMIDATE

AP		CAPLIN	**2MG/ML**	**A215028**	**001**	Dec 18, 2020
AP		EMCURE PHARMS LTD	**2MG/ML**	**A204618**	**001**	Aug 13, 2014
AP		EUGIA PHARMA	**2MG/ML**	**A206126**	**001**	Feb 24, 2017
AP		GLAND PHARMA LTD	**2MG/ML**	**A209058**	**001**	Apr 18, 2017
AP		HIKMA	**2MG/ML**	**A074593**	**001**	Nov 04, 1996
AP			**2MG/ML**	**A202354**	**001**	Feb 25, 2016
AP		MYLAN LABS LTD	**2MG/ML**	**A201044**	**001**	Feb 07, 2017
AP		ZYDUS PHARMS	**2MG/ML**	**A202360**	**001**	Jul 18, 2014

ETONOGESTREL

IMPLANT;IMPLANTATION

NEXPLANON

	+!	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011

ETOPOSIDE

CAPSULE;ORAL

ETOPOSIDE

	!	MYLAN	50MG	A075635	001	Sep 19, 2001

INJECTABLE;INJECTION

ETOPOSIDE

AP		ACCORD HLTHCARE	**20MG/ML**	**A074513**	**001**	Mar 14, 1996
AP	**!**	FRESENIUS KABI USA	**20MG/ML**	**A074983**	**001**	Sep 30, 1998
AP		HIKMA	**20MG/ML**	**A074290**	**001**	Jul 17, 1995
AP		TEVA PHARMS USA	**20MG/ML**	**A074529**	**001**	Jul 24, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE;INJECTION

ETOPOPHOS PRESERVATIVE FREE

	+!	CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

AB		AMNEAL	**100MG**	**A214196**	**002**	Jun 14, 2021
AB			**200MG**	**A214196**	**003**	Jun 14, 2021

INTELENCE

AB	**+**	JANSSEN R AND D	**100MG**	**N022187**	**001**	Jan 18, 2008
AB	**+!**		**200MG**	**N022187**	**002**	Dec 22, 2010
	+		25MG	N022187	003	Mar 26, 2012

EVEROLIMUS

TABLET;ORAL

AFINITOR

AB	**+**	NOVARTIS	**2.5MG**	**N022334**	**003**	Jul 09, 2010
AB	**+!**		**5MG**	**N022334**	**001**	Mar 30, 2009
AB	**+**		**7.5MG**	**N022334**	**004**	Mar 30, 2012
AB	**+**		**10MG**	**N022334**	**002**	Mar 30, 2009

EVEROLIMUS

AB		ALKEM LABS LTD	**0.25MG**	**A214138**	**001**	Nov 26, 2021
AB			**0.5MG**	**A214138**	**002**	Nov 26, 2021
AB			**0.75MG**	**A214138**	**003**	Nov 26, 2021
AB			**1MG**	**A214138**	**004**	Nov 26, 2021
AB		BIOCON PHARMA	**2.5MG**	**A214182**	**001**	Feb 11, 2021
AB			**5MG**	**A214182**	**002**	Feb 11, 2021
AB			**7.5MG**	**A214182**	**003**	Feb 11, 2021
AB			**10MG**	**A214182**	**004**	Feb 11, 2021
AB		BRECKENRIDGE	**0.25MG**	**A205432**	**001**	May 20, 2021
AB			**0.5MG**	**A205432**	**002**	May 20, 2021

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

AB			**0.75MG**	**A205432**	**003**	May 20, 2021
AB			**2.5MG**	**A205426**	**001**	Mar 05, 2021
AB			**5MG**	**A205426**	**002**	Mar 05, 2021
AB			**7.5MG**	**A205426**	**003**	Mar 05, 2021
AB			**10MG**	**A205426**	**004**	Mar 05, 2021
AB		HIKMA	**0.25MG**	**A206133**	**001**	Apr 12, 2018
AB			**0.5MG**	**A206133**	**002**	Apr 12, 2018
AB			**0.75MG**	**A206133**	**003**	Apr 12, 2018
AB			**1MG**	**A206133**	**004**	Nov 18, 2021
AB			**2.5MG**	**A207486**	**001**	Jun 08, 2020
AB			**5MG**	**A207486**	**002**	Jun 08, 2020
AB			**7.5MG**	**A207486**	**003**	Jun 08, 2020
AB			**10MG**	**A207486**	**004**	Nov 23, 2021
AB		MYLAN	**2.5MG**	**A212936**	**001**	Jun 08, 2020
AB			**5MG**	**A212936**	**002**	Jun 08, 2020
AB			**7.5MG**	**A212936**	**003**	Jun 08, 2020
AB			**10MG**	**A212936**	**004**	Jun 08, 2020
AB		PAR PHARM	**0.25MG**	**A205775**	**001**	Oct 18, 2021
AB			**0.5MG**	**A205775**	**002**	Oct 18, 2021
AB			**0.75MG**	**A205775**	**003**	Oct 18, 2021
AB			**1MG**	**A205775**	**004**	Oct 18, 2021
AB			**2.5MG**	**A207934**	**001**	Dec 09, 2019
AB			**5MG**	**A207934**	**002**	Dec 09, 2019
AB			**7.5MG**	**A207934**	**003**	Dec 09, 2019
AB			**10MG**	**A207934**	**004**	Dec 09, 2020
AB		TEVA PHARMS USA	**2.5MG**	**A210050**	**001**	Dec 09, 2019
AB			**5MG**	**A210050**	**002**	Dec 09, 2019
AB			**7.5MG**	**A210050**	**003**	Dec 09, 2019

ZORTRESS

AB	+	NOVARTIS	**0.25MG**	**N021560**	**001**	Apr 20, 2010
AB	+		**0.5MG**	**N021560**	**002**	Apr 20, 2010
AB	+		**0.75MG**	**N021560**	**003**	Apr 20, 2010
AB	+!		**1MG**	**N021560**	**004**	Aug 10, 2018

TABLET, FOR SUSPENSION;ORAL

AFINITOR DISPERZ

AB	+	NOVARTIS PHARM	**2MG**	**N203985**	**001**	Aug 29, 2012
AB	+		**3MG**	**N203985**	**002**	Aug 29, 2012
AB	+!		**5MG**	**N203985**	**003**	Aug 29, 2012

EVEROLIMUS

AB		MYLAN	**2MG**	**A210130**	**001**	Apr 19, 2019
AB			**3MG**	**A210130**	**002**	Apr 19, 2019
AB			**5MG**	**A210130**	**003**	Apr 19, 2019

EXEMESTANE

TABLET;ORAL

AROMASIN

AB	+!	PFIZER	**25MG**	**N020753**	**001**	Oct 21, 1999

EXEMESTANE

AB		ALVOGEN	**25MG**	**A200898**	**001**	Jul 28, 2014
AB		BRECKENRIDGE	**25MG**	**A211031**	**001**	Feb 21, 2019
AB		CIPLA	**25MG**	**A210323**	**001**	Apr 27, 2018
AB		HIKMA	**25MG**	**A077431**	**001**	Apr 01, 2011
AB		QILU	**25MG**	**A213547**	**001**	Apr 13, 2020
AB		RISING	**25MG**	**A203315**	**001**	Mar 10, 2017
AB		UPSHER SMITH LABS	**25MG**	**A209208**	**001**	Jul 26, 2017
AB		ZYDUS PHARMS	**25MG**	**A202602**	**001**	Oct 03, 2018

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS

BYETTA

	+!	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
	+!		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

	+!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017

EZETIMIBE

TABLET;ORAL

EZETIMIBE

AB		ACCORD HLTHCARE	**10MG**	**A211550**	**001**	Oct 26, 2018
AB		ALKEM LABS LTD	**10MG**	**A209234**	**001**	Dec 21, 2017
AB		AMNEAL PHARMS CO	**10MG**	**A208803**	**001**	Jun 12, 2017
AB		APOTEX	**10MG**	**A208332**	**001**	Jun 12, 2017
AB		AURO BINDO PHARMA LTD	**10MG**	**A209838**	**001**	Aug 25, 2017
AB		GLENMARK PHARMS LTD	**10MG**	**A078560**	**001**	Jun 26, 2015
AB		OHM LABS INC	**10MG**	**A207311**	**001**	Jun 12, 2017
AB		SANDOZ INC	**10MG**	**A203931**	**001**	Jun 12, 2017
AB		SCIEGEN PHARMS INC	**10MG**	**A210673**	**001**	Oct 23, 2020
AB		WATSON LABS INC	**10MG**	**A200831**	**001**	Jun 12, 2017
AB		ZYDUS PHARMS	**10MG**	**A204331**	**001**	Jun 12, 2017

ZETIA

AB	**+!**	ORGANON	**10MG**	**N021445**	**001**	Oct 25, 2002

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSZET

+	ALTHERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021
+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021
+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021
+!		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

AB		ALKEM LABS LTD	**10MG;10MG**	**A209222**	**001**	Dec 22, 2017
AB			**10MG;20MG**	**A209222**	**002**	Dec 22, 2017
AB			**10MG;40MG**	**A209222**	**003**	Dec 22, 2017
AB			**10MG;80MG**	**A209222**	**004**	Dec 22, 2017
AB		AMNEAL PHARMS CO	**10MG;10MG**	**A208831**	**001**	Nov 21, 2017
AB			**10MG;20MG**	**A208831**	**002**	Nov 21, 2017
AB			**10MG;40MG**	**A208831**	**003**	Nov 21, 2017
AB			**10MG;80MG**	**A208831**	**004**	Nov 21, 2017
AB		DR REDDYS LABS SA	**10MG;10MG**	**A200909**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A200909**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A200909**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A200909**	**004**	Apr 26, 2017
AB		GLENMARK PHARMS LTD	**10MG;10MG**	**A208699**	**001**	Jun 27, 2019
AB			**10MG;20MG**	**A208699**	**002**	Jun 27, 2019
AB			**10MG;40MG**	**A208699**	**003**	Jun 27, 2019
AB			**10MG;80MG**	**A208699**	**004**	Jun 27, 2019
AB		WATSON LABS INC	**10MG;10MG**	**A202968**	**001**	Apr 26, 2017
AB			**10MG;20MG**	**A202968**	**002**	Apr 26, 2017
AB			**10MG;40MG**	**A202968**	**003**	Apr 26, 2017
AB			**10MG;80MG**	**A202968**	**004**	Apr 26, 2017

VYTORIN

AB	**+**	ORGANON	**10MG;10MG**	**N021687**	**001**	Jul 23, 2004
AB	**+**		**10MG;20MG**	**N021687**	**002**	Jul 23, 2004
AB	**+**		**10MG;40MG**	**N021687**	**003**	Jul 23, 2004
AB	**+!**		**10MG;80MG**	**N021687**	**004**	Jul 23, 2004

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB		APOTEX	**125MG**	**A091480**	**001**	Jul 22, 2011
AB			**250MG**	**A091480**	**002**	Jul 22, 2011
AB			**500MG**	**A091480**	**003**	Jul 22, 2011
AB		AURO BINDO PHARMA LTD	**125MG**	**A091114**	**001**	Mar 21, 2011
AB			**250MG**	**A091114**	**002**	Mar 21, 2011
AB			**500MG**	**A091114**	**003**	Mar 21, 2011
AB		CIPLA	**125MG**	**A078278**	**001**	Mar 21, 2011
AB			**250MG**	**A078278**	**002**	Mar 21, 2011
AB			**500MG**	**A078278**	**003**	Mar 21, 2011
AB		HETERO LABS LTD V	**125MG**	**A202438**	**001**	Sep 10, 2014
AB			**250MG**	**A202438**	**002**	Sep 10, 2014
AB			**500MG**	**A202438**	**003**	Sep 10, 2014
AB		MACLEODS PHARMS LTD	**125MG**	**A201022**	**001**	Jan 12, 2012
AB			**250MG**	**A201022**	**002**	Jan 12, 2012
AB			**500MG**	**A201022**	**003**	Jan 12, 2012

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

AB		TEVA PHARMS	**125MG**	**A077487**	**001**	Aug 24, 2007
AB			**250MG**	**A077487**	**002**	Aug 24, 2007
AB	!		**500MG**	**A077487**	**003**	Aug 24, 2007

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB		AKORN	**40MG/5ML**	**A201995**	**001**	May 30, 2014
AB	!	LUPIN LTD	**40MG/5ML**	**A090440**	**001**	Jun 29, 2010
AB		NAVINTA LLC	**40MG/5ML**	**A091020**	**001**	May 27, 2010
AB		NOVEL LABS INC	**40MG/5ML**	**A201695**	**001**	Dec 17, 2012
AB		NOVITIUM PHARMA	**40MG/5ML**	**A215043**	**001**	Apr 20, 2021

INJECTABLE;INJECTION

FAMOTIDINE

AP		ATHENEX INC	**10MG/ML**	**A075651**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075684**	**001**	Apr 16, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075709**	**001**	Apr 16, 2001
AP	!	HIKMA	**10MG/ML**	**A075488**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078641**	**001**	Jun 25, 2008

FAMOTIDINE PRESERVATIVE FREE

AP		ATHENEX INC	**10MG/ML**	**A075622**	**001**	Apr 16, 2001
AP			**10MG/ML**	**A075825**	**001**	Apr 17, 2001
AP		FRESENIUS KABI USA	**10MG/ML**	**A075813**	**001**	Apr 16, 2001
AP	!	HIKMA	**10MG/ML**	**A075486**	**001**	Apr 16, 2001
AP		MYLAN LABS LTD	**10MG/ML**	**A078642**	**001**	Jun 25, 2008

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

	!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001

TABLET;ORAL

FAMOTIDINE

AB		ALEMBIC PHARMS LTD	**20MG**	**A078916**	**001**	May 22, 2009
AB			**40MG**	**A078916**	**002**	May 22, 2009
AB		ANNORA PHARMA	**20MG**	**A215767**	**001**	Nov 04, 2021
AB			**40MG**	**A215767**	**002**	Nov 04, 2021
AB		APOTEX	**20MG**	**A075611**	**001**	Jul 23, 2001
AB			**40MG**	**A075611**	**002**	Jul 23, 2001
AB		ASCENT PHARMS INC	**20MG**	**A215689**	**001**	Oct 15, 2021
AB			**40MG**	**A215689**	**002**	Oct 15, 2021
AB		AUROBINDO PHARMA LTD	**20MG**	**A206530**	**001**	Dec 22, 2015
AB	!		**40MG**	**A206530**	**002**	Dec 22, 2015
AB		CARLSBAD	**20MG**	**A075805**	**001**	Apr 16, 2001
AB			**40MG**	**A075805**	**002**	Apr 16, 2001
AB		CELLTRION	**20MG**	**A075786**	**001**	Apr 16, 2001
AB			**40MG**	**A075786**	**002**	Apr 16, 2001
AB		DR REDDYS LABS LTD	**20MG**	**A075718**	**001**	Apr 16, 2001
AB			**40MG**	**A075718**	**002**	Apr 16, 2001
AB		IVAX SUB TEVA PHARMS	**20MG**	**A075511**	**001**	Apr 16, 2001
AB			**40MG**	**A075511**	**002**	Apr 16, 2001
AB		PERRIGO R AND D	**20MG**	**A077352**	**002**	Jul 27, 2005
AB			**40MG**	**A077352**	**001**	Jul 27, 2005
AB		VKT PHARMA	**20MG**	**A215630**	**001**	Jan 07, 2022
AB			**40MG**	**A215630**	**002**	Jan 07, 2022

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

DUEXIS

AB	**+!**	HORIZON	**26.6MG;800MG**	**N022519**	**001**	Apr 23, 2011

IBUPROFEN AND FAMOTIDINE

AB		ALKEM LABS LTD	**26.6MG;800MG**	**A211890**	**001**	Aug 03, 2021
AB		TEVA PHARMS USA	**26.6MG;800MG**	**A211278**	**001**	Oct 29, 2021

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB		ALEMBIC PHARMS LTD	**40MG**	**A205421**	**001**	Jul 01, 2019
AB			**80MG**	**A205421**	**002**	Jul 01, 2019
AB		ALKEM LABS LTD	**40MG**	**A212924**	**001**	Dec 07, 2021
AB			**80MG**	**A212924**	**002**	Dec 07, 2021
AB		DR REDDYS LABS LTD	**40MG**	**A205374**	**001**	Oct 22, 2020
AB			**80MG**	**A205374**	**002**	Oct 22, 2020

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

AB		HIKMA	**40MG**	**A205414**	**001**	Oct 15, 2019
AB			**80MG**	**A205414**	**002**	Oct 15, 2019
AB		INDOCO	**40MG**	**A210292**	**001**	Dec 30, 2019
AB			**80MG**	**A210292**	**002**	Dec 30, 2019
AB		MSN	**40MG**	**A210461**	**001**	Dec 30, 2019
AB			**80MG**	**A210461**	**002**	Dec 30, 2019
AB		MYLAN	**40MG**	**A205385**	**001**	Jul 01, 2019
AB			**80MG**	**A205385**	**002**	Jul 01, 2019
AB		SUN PHARM	**40MG**	**A205467**	**001**	Jul 01, 2019
AB			**80MG**	**A205467**	**002**	Jul 01, 2019
AB		SUNSHINE	**40MG**	**A213069**	**001**	Jun 02, 2020
AB			**80MG**	**A213069**	**002**	Jun 02, 2020

ULORIC

AB	**+**	TAKEDA PHARMS USA	**40MG**	**N021856**	**001**	Feb 13, 2009
AB	**+!**		**80MG**	**N021856**	**002**	Feb 13, 2009

FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL

INREBIC

	+!	IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019

FELBAMATE

SUSPENSION;ORAL

FELBAMATE

AB		AMNEAL PHARMS	**600MG/5ML**	**A202385**	**001**	Dec 16, 2011
AB		NOVITIUM PHARMA	**600MG/5ML**	**A211333**	**001**	May 31, 2019
AB		TARO	**600MG/5ML**	**A206314**	**001**	Jun 16, 2017

FELBATOL

AB	**+!**	MYLAN SPECIALITY LP	**600MG/5ML**	**N020189**	**003**	Jul 29, 1993

TABLET;ORAL

FELBAMATE

AB		ALVOGEN	**400MG**	**A204595**	**001**	Jan 11, 2016
AB			**600MG**	**A204595**	**002**	Jan 11, 2016
AB		AMNEAL PHARMS	**400MG**	**A201680**	**001**	Sep 13, 2011
AB			**600MG**	**A201680**	**002**	Sep 13, 2011
AB		ANI PHARMS	**400MG**	**A202284**	**001**	Nov 04, 2015
AB			**600MG**	**A202284**	**002**	Nov 04, 2015
AB		CADILA	**400MG**	**A208970**	**001**	May 30, 2017
AB			**600MG**	**A208970**	**002**	May 30, 2017
AB		TARO	**400MG**	**A207093**	**001**	Apr 20, 2017
AB			**600MG**	**A207093**	**002**	Apr 20, 2017

FELBATOL

AB	**+**	MYLAN SPECIALITY LP	**400MG**	**N020189**	**001**	Jul 29, 1993
AB	**+!**		**600MG**	**N020189**	**002**	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		AUROBINDO PHARMA LTD	**2.5MG**	**A203417**	**001**	Jan 17, 2013
AB			**5MG**	**A203417**	**002**	Jan 17, 2013
AB			**10MG**	**A203417**	**003**	Jan 17, 2013
AB		GLENMARK GENERICS	**2.5MG**	**A090365**	**001**	Dec 17, 2010
AB			**5MG**	**A090365**	**002**	Dec 17, 2010
AB			**10MG**	**A090365**	**003**	Dec 17, 2010
AB		HERITAGE PHARMS INC	**2.5MG**	**A201964**	**001**	Nov 08, 2013
AB			**5MG**	**A201964**	**002**	Nov 08, 2013
AB			**10MG**	**A201964**	**003**	Nov 08, 2013
AB		ORBION PHARMS	**2.5MG**	**A203032**	**001**	May 21, 2015
AB			**5MG**	**A203032**	**002**	May 21, 2015
AB			**10MG**	**A203032**	**003**	May 21, 2015
AB		SUN PHARM INDS LTD	**2.5MG**	**A091200**	**001**	Dec 13, 2013
AB			**5MG**	**A091200**	**002**	Dec 13, 2013
AB			**10MG**	**A091200**	**003**	Dec 13, 2013
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A075896**	**001**	Nov 02, 2004
AB			**5MG**	**A075896**	**002**	Nov 02, 2004
AB			**10MG**	**A075896**	**003**	Nov 02, 2004
AB		TORRENT PHARMS LTD	**2.5MG**	**A202170**	**001**	Nov 28, 2011
AB			**5MG**	**A202170**	**002**	Nov 28, 2011
AB	**!**		**10MG**	**A202170**	**003**	Nov 28, 2011

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

AB		VINTAGE PHARMS LLC	**2.5MG**	**A200815**	**001**	Oct 28, 2011
AB			**5MG**	**A200815**	**002**	Oct 28, 2011
AB			**10MG**	**A200815**	**003**	Oct 28, 2011
AB		YILING	**2.5MG**	**A210847**	**001**	Oct 26, 2018
AB			**5MG**	**A210847**	**002**	Oct 26, 2018
AB			**10MG**	**A210847**	**003**	Oct 26, 2018
AB		YUNG SHIN PHARM	**2.5MG**	**A204800**	**001**	Apr 29, 2019
AB			**5MG**	**A204800**	**002**	Apr 29, 2019
AB			**10MG**	**A204800**	**003**	Apr 29, 2019

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

	+!	ZOGENIX INC	EQ 2.2MG BASE/ML	N212102	001	Jun 25, 2020

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

AB	**+**	LUPIN	**43MG**	**N021695**	**001**	Nov 30, 2004
AB	**+!**		**130MG**	**N021695**	**003**	Nov 30, 2004

FENOFIBRATE

AB		SUN PHARM INDS LTD	**43MG**	**A201748**	**001**	Oct 31, 2014
AB			**130MG**	**A201748**	**002**	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

AB		AJANTA PHARMA LTD	**67MG**	**A210705**	**001**	Sep 10, 2018
AB			**134MG**	**A210705**	**002**	Sep 10, 2018
AB			**200MG**	**A210705**	**003**	Sep 10, 2018
AB		ALEMBIC PHARMS LTD	**67MG**	**A213842**	**001**	Oct 19, 2020
AB			**134MG**	**A213842**	**002**	Oct 19, 2020
AB			**200MG**	**A213842**	**003**	Oct 19, 2020
AB		ANI PHARMS	**67MG**	**A209504**	**001**	Apr 30, 2018
AB			**134MG**	**A209504**	**002**	Apr 30, 2018
AB			**200MG**	**A209504**	**003**	Apr 30, 2018
AB		APOTEX	**43MG**	**A202252**	**001**	Jul 26, 2013
AB			**130MG**	**A202252**	**002**	Jul 26, 2013
AB		AUROBINDO PHARMA LTD	**67MG**	**A212232**	**001**	Sep 20, 2021
AB			**134MG**	**A212232**	**002**	Sep 20, 2021
AB			**200MG**	**A212232**	**003**	Sep 20, 2021
AB		DR REDDYS LABS SA	**43MG**	**A090859**	**001**	Mar 01, 2012
AB			**130MG**	**A090859**	**002**	Mar 01, 2012
AB		GLENMARK PHARMS LTD	**67MG**	**A205566**	**001**	Apr 07, 2017
AB			**134MG**	**A205566**	**002**	Apr 07, 2017
AB			**200MG**	**A205566**	**003**	Apr 07, 2017
AB		IMPAX LABS	**67MG**	**A075868**	**001**	Oct 27, 2003
AB			**134MG**	**A075868**	**002**	Oct 27, 2003
AB	**!**		**200MG**	**A075868**	**003**	Oct 27, 2003
AB		INVAGEN PHARMS	**67MG**	**A207378**	**001**	Mar 28, 2017
AB			**134MG**	**A207378**	**002**	Mar 28, 2017
AB			**200MG**	**A207378**	**003**	Mar 28, 2017
AB		REYOUNG	**67MG**	**A207805**	**001**	Nov 16, 2017
AB			**134MG**	**A207805**	**002**	Nov 16, 2017
AB			**200MG**	**A207805**	**003**	Nov 16, 2017
AB		RHODES PHARMS	**67MG**	**A075753**	**001**	Sep 03, 2002
AB			**134MG**	**A075753**	**002**	Apr 09, 2002
AB			**200MG**	**A075753**	**003**	Apr 09, 2002
AB		TORRENT	**67MG**	**A210782**	**001**	Jun 26, 2018
AB			**134MG**	**A210782**	**002**	Jun 26, 2018
AB			**200MG**	**A210782**	**003**	Jun 26, 2018

ANTARA (MICRONIZED)

	+	LUPIN	30MG	N021695	004	Oct 18, 2013
	+!		90MG	N021695	005	Oct 18, 2013

LIPOFEN

	+	CIPHER PHARMS INC	50MG	N021612	001	Jan 11, 2006
	+!		150MG	N021612	003	Jan 11, 2006

TABLET;ORAL

FENOFIBRATE

AB		ADAPTIS	**54MG**	**A210606**	**001**	Aug 17, 2018
AB			**160MG**	**A210606**	**002**	Aug 17, 2018
AB		AJANTA PHARMA LTD	**54MG**	**A210138**	**001**	Jul 23, 2018
AB			**160MG**	**A210138**	**002**	Jul 23, 2018

FENOFIBRATE

TABLET;ORAL

FENOFIBRATE

AB		ALEMBIC LABS	**54MG**	**A209660**	**001**	Feb 11, 2019
AB			**160MG**	**A209660**	**002**	Feb 11, 2019
AB		ALEMBIC PHARMS LTD	**48MG**	**A210476**	**001**	Aug 09, 2019
AB			**145MG**	**A210476**	**002**	Aug 09, 2019
AB		AMNEAL	**48MG**	**A209951**	**001**	Feb 09, 2018
AB			**54MG**	**A209950**	**001**	Mar 19, 2018
AB			**145MG**	**A209951**	**002**	Feb 09, 2018
AB			**160MG**	**A209950**	**002**	Mar 19, 2018
AB		AUROBINDO PHARMA LTD	**48MG**	**A205118**	**001**	May 05, 2016
AB			**145MG**	**A205118**	**002**	May 05, 2016
AB		AUSTARPHARMA	**48MG**	**A208476**	**001**	Feb 10, 2021
AB			**54MG**	**A207803**	**001**	Dec 19, 2017
AB			**145MG**	**A208476**	**002**	Feb 10, 2021
AB			**160MG**	**A207803**	**002**	Dec 19, 2017
AB		CIPLA	**48MG**	**A208709**	**001**	Dec 15, 2016
AB			**145MG**	**A208709**	**002**	Dec 15, 2016
AB		DR REDDYS	**54MG**	**A210670**	**001**	Sep 06, 2019
AB			**160MG**	**A210670**	**002**	Sep 06, 2019
AB		GRAVITI PHARMS	**48MG**	**A211122**	**001**	Mar 18, 2020
AB			**145MG**	**A211122**	**002**	Mar 18, 2020
AB		HETERO LABS LTD III	**48MG**	**A204598**	**001**	Jul 12, 2016
AB			**145MG**	**A204598**	**002**	Jul 12, 2016
AB		IMPAX LABS	**54MG**	**A076509**	**001**	Mar 26, 2008
AB	**!**		**160MG**	**A076509**	**002**	Mar 26, 2008
AB		LUPIN LTD	**48MG**	**A090856**	**001**	Dec 23, 2011
AB			**54MG**	**A204019**	**001**	Aug 17, 2015
AB			**145MG**	**A090856**	**002**	Dec 23, 2011
AB			**160MG**	**A204019**	**002**	Aug 17, 2015
AB		MANKIND PHARMA	**54MG**	**A213864**	**001**	Jun 12, 2020
AB			**160MG**	**A213864**	**002**	Jun 12, 2020
AB		MYLAN	**54MG**	**A076520**	**001**	Oct 25, 2007
AB			**160MG**	**A076520**	**003**	Oct 25, 2007
AB		MYLAN PHARMS INC	**40MG**	**A204475**	**001**	Jun 23, 2016
AB			**48MG**	**A202856**	**001**	Dec 07, 2012
AB			**120MG**	**A204475**	**002**	Jun 23, 2016
AB			**145MG**	**A202856**	**002**	Dec 07, 2012
AB		PRINSTON INC	**48MG**	**A211080**	**001**	Aug 28, 2018
AB			**145MG**	**A211080**	**002**	Aug 28, 2018
AB		RHODES PHARMS	**54MG**	**A076433**	**001**	May 13, 2005
AB			**160MG**	**A076433**	**002**	May 13, 2005
AB		SUN PHARM	**48MG**	**A200884**	**001**	Sep 07, 2017
AB			**145MG**	**A200884**	**002**	Sep 07, 2017
AB		SUN PHARM INDS LTD	**54MG**	**A076635**	**001**	Oct 31, 2005
AB			**160MG**	**A076635**	**003**	Oct 31, 2005
AB		VALEANT PHARMS NORTH	**48MG**	**A090715**	**001**	Apr 05, 2012
AB			**145MG**	**A090715**	**002**	Apr 05, 2012

FENOGLIDE

AB	**+**	SALIX	**40MG**	**N022118**	**001**	Aug 10, 2007
AB	**+!**		**120MG**	**N022118**	**002**	Aug 10, 2007

TRICOR

AB	**+**	ABBVIE	**48MG**	**N021656**	**001**	Nov 05, 2004
AB	**+!**		**145MG**	**N021656**	**002**	Nov 05, 2004

TRIGLIDE

BX	+	SKYEPHARMA AG	160MG	N021350	002	May 07, 2005

FENOFIBRATE

		SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

	+!	ATHENA	105MG	N022418	002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

CORLOPAM

AP	**+!**	HOSPIRA	**EQ 10MG BASE/ML**	**N019922**	**001**	Sep 23, 1997

FENOLDOPAM MESYLATE

AP		HIKMA	**EQ 10MG BASE/ML**	**A076582**	**001**	Oct 12, 2004
AP		SANDOZ INC	**EQ 10MG BASE/ML**	**A077155**	**001**	Feb 15, 2005

FENOPROFEN CALCIUM

CAPSULE;ORAL

NALFON

+	XSPIRE PHARMA	EQ 200MG BASE	N017604	003	
+!		EQ 400MG BASE	N017604	004	Jul 21, 2009

TABLET;ORAL

FENOPROFEN CALCIUM

!	XSPIRE PHARMA	EQ 600MG BASE	A072267	001	Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

AB	AVEVA	**100MCG/HR**	**A077449**	**004**	Oct 20, 2008
AB	KINDEVA	**100MCG/HR**	**A202097**	**005**	Nov 04, 2016
AB	MYLAN TECHNOLOGIES	**100MCG/HR**	**A076258**	**004**	Jan 28, 2005
AB	SPECGX LLC	**100MCG/HR**	**A077154**	**004**	Feb 09, 2011

FENTANYL-12

AB	AVEVA	**12.5MCG/HR**	**A077449**	**005**	Sep 11, 2015
AB	KINDEVA	**12.5MCG/HR**	**A202097**	**001**	Nov 04, 2016
AB	MYLAN TECHNOLOGIES	**12.5MCG/HR**	**A076258**	**005**	Jan 23, 2007
AB	SPECGX LLC	**12.5MCG/HR**	**A077154**	**005**	Jun 11, 2015

FENTANYL-25

AB	AVEVA	**25MCG/HR**	**A077449**	**001**	Oct 20, 2008
AB	KINDEVA	**25MCG/HR**	**A202097**	**002**	Nov 04, 2016
AB	MYLAN TECHNOLOGIES	**25MCG/HR**	**A076258**	**001**	Jan 28, 2005
AB **!**	SPECGX LLC	**25MCG/HR**	**A077154**	**001**	Feb 09, 2011

FENTANYL-37

AB	AVEVA	**37.5MCG/HR**	**A077449**	**006**	Dec 06, 2017
AB	MYLAN TECHNOLOGIES	**37.5MCG/HR**	**A076258**	**006**	Dec 29, 2014
AB	SPECGX LLC	**37.5MCG/HR**	**A077154**	**006**	Jan 14, 2020

FENTANYL-50

AB	AVEVA	**50MCG/HR**	**A077449**	**002**	Oct 20, 2008
AB	KINDEVA	**50MCG/HR**	**A202097**	**003**	Nov 04, 2016
AB	MYLAN TECHNOLOGIES	**50MCG/HR**	**A076258**	**002**	Jan 28, 2005
AB	SPECGX LLC	**50MCG/HR**	**A077154**	**002**	Feb 09, 2011

FENTANYL-62

AB	AVEVA	**62.5MCG/HR**	**A077449**	**007**	Dec 06, 2017
AB	MYLAN TECHNOLOGIES	**62.5MCG/HR**	**A076258**	**007**	Dec 29, 2014
AB	SPECGX LLC	**62.5MCG/HR**	**A077154**	**007**	Jan 14, 2020

FENTANYL-75

AB	AVEVA	**75MCG/HR**	**A077449**	**003**	Oct 20, 2008
AB	KINDEVA	**75MCG/HR**	**A202097**	**004**	Nov 04, 2016
AB	MYLAN TECHNOLOGIES	**75MCG/HR**	**A076258**	**003**	Jan 28, 2005
AB	SPECGX LLC	**75MCG/HR**	**A077154**	**003**	Feb 09, 2011

FENTANYL-87

AB	AVEVA	**87.5MCG/HR**	**A077449**	**008**	Dec 06, 2017
AB	MYLAN TECHNOLOGIES	**87.5MCG/HR**	**A076258**	**008**	Dec 29, 2014

SPRAY;SUBLINGUAL

SUBSYS

+	BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012
+		0.2MG	N202788	002	Jan 04, 2012
+!		0.4MG	N202788	003	Jan 04, 2012
+		0.6MG	N202788	004	Jan 04, 2012
+		0.8MG	N202788	005	Jan 04, 2012
+		1.2MG	N202788	006	Aug 30, 2012
+		1.6MG	N202788	007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

AP	FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A212086**	**001**	Sep 01, 2020
AP	HOSPIRA	**EQ 0.05MG BASE/ML**	**N019115**	**001**	Jan 12, 1985

FENTANYL CITRATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A210762**	**001**	May 03, 2019
AP **+!**	HIKMA	**EQ 0.05MG BASE/ML**	**N019101**	**001**	Jul 11, 1984
AP	HOSPIRA	**EQ 0.05MG BASE/ML**	**A072786**	**001**	Sep 24, 1991

SUBLIMAZE PRESERVATIVE FREE

AP **+!**	AKORN	**EQ 0.05MG BASE/ML**	**N016619**	**001**	

SPRAY, METERED;NASAL

LAZANDA

+	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
+!		EQ 0.4MG BASE	N022569	002	Jun 30, 2011

FENTANYL CITRATE						
TABLET;BUCCAL, SUBLINGUAL						
FENTORA						
	+	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
	+		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
	+!		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
	+		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
	+		EQ 0.8MG BASE	N021947	005	Sep 25, 2006
TROCHE/LOZENGE;TRANSMUCOSAL						
ACTIQ						
AB	**+**	CEPHALON	**EQ 0.2MG BASE**	**N020747**	**001**	Nov 04, 1998
AB	**+!**		**EQ 0.4MG BASE**	**N020747**	**002**	Nov 04, 1998
AB	**+**		**EQ 0.6MG BASE**	**N020747**	**003**	Nov 04, 1998
AB	**+**		**EQ 0.8MG BASE**	**N020747**	**004**	Nov 04, 1998
AB	**+**		**EQ 1.2MG BASE**	**N020747**	**005**	Nov 04, 1998
AB	**+**		**EQ 1.6MG BASE**	**N020747**	**006**	Nov 04, 1998
FENTANYL CITRATE						
AB		SPECGX LLC	**EQ 0.2MG BASE**	**A078907**	**001**	Oct 30, 2009
AB			**EQ 0.4MG BASE**	**A078907**	**002**	Oct 30, 2009
AB			**EQ 0.6MG BASE**	**A078907**	**003**	Oct 30, 2009
AB			**EQ 0.8MG BASE**	**A078907**	**004**	Oct 30, 2009
AB			**EQ 1.2MG BASE**	**A078907**	**005**	Oct 30, 2009
AB			**EQ 1.6MG BASE**	**A078907**	**006**	Oct 30, 2009
FERRIC CARBOXYMALTOSE						
SOLUTION;INTRAVENOUS						
INJECTAFER						
	+!	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013
	+!		500MG IRON/10ML (50MG IRON/ML)	N203565	002	Oct 08, 2020
	+!		1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021
FERRIC CITRATE						
TABLET;ORAL						
AURYXIA						
	+!	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014
FERRIC DERISOMALTOSE						
SOLUTION;INTRAVENOUS						
MONOFERRIC						
	+!	PHARMACOSMOS AS	1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020
FERRIC HEXACYANOFERRATE(II)						
CAPSULE;ORAL						
RADIOGARDASE (PRUSSIAN BLUE)						
	+!	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003
FERRIC MALTOL						
CAPSULE;ORAL						
ACCRUFER						
	+!	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019
FERRIC OXYHYDROXIDE						
INJECTABLE;INJECTION						
FERRLECIT						
AB	**+!**	SANOFI AVENTIS US	**EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)**	**N020955**	**001**	Feb 18, 1999
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE						
AB		WEST-WARD PHARMS INT	**EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)**	**A078215**	**001**	Mar 31, 2011
INFED						
BP	+!	ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001	
INJECTABLE;INTRAVENOUS						
VENOFER						
	+	AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005
	+!		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000
	+		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007
TABLET, CHEWABLE;ORAL						
VELPHORO						
	+!	VIFOR FRESENIUS	EQ 500MG IRON	N205109	001	Nov 27, 2013
FERRIC PYROPHOSPHATE CITRATE						
FOR SOLUTION;INTRAVENOUS						
TRIFERIC						
	+!	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016

FERRIC PYROPHOSPHATE CITRATE							
SOLUTION;INTRAVENOUS							
TRIFERIC							
	+!	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015
TRIFERIC AVNU							
	+!	ROCKWELL MEDICAL INC	6.75MG IRON/4.5ML (1.5MG IRON/ML)	N212860	001	Mar 27, 2020
FERUMOXYTOL							
SOLUTION;INTRAVENOUS							
FERAHEME							
AB	**+!**	COVIS	**EQ 510MG IRON/17ML (EQ 30MG IRON/ML)**	**N022180**	**001**	Jun 30, 2009
FERUMOXYTOL							
AB		SANDOZ INC	**EQ 510MG IRON/17ML (EQ 30MG IRON/ML)**	**A206604**	**001**	Jan 15, 2021
FESOTERODINE FUMARATE							
TABLET, EXTENDED RELEASE;ORAL							
FESOTERODINE FUMARATE							
AB		AURO BINDO PHARMA LTD	**4MG**	**A205007**	**001**	Feb 17, 2017
AB			**8MG**	**A205007**	**002**	Feb 17, 2017
AB		ZYDUS PHARMS	**4MG**	**A204946**	**001**	Oct 03, 2017
AB			**8MG**	**A204946**	**002**	Oct 03, 2017
TOVIAZ							
AB	**+**	PFIZER	**4MG**	**N022030**	**001**	Oct 31, 2008
AB	**+!**		**8MG**	**N022030**	**002**	Oct 31, 2008
FEXINIDAZOLE							
TABLET;ORAL							
FEXINIDAZOLE							
	+!	SANOFI	600MG	N214429	001	Jul 16, 2021
FEXOFENADINE HYDROCHLORIDE							
TABLET;ORAL							
FEXOFENADINE HYDROCHLORIDE							
AB		DR REDDYS LABS LTD	**30MG**	**A076502**	**001**	Apr 11, 2006
AB			**60MG**	**A076502**	**002**	Apr 11, 2006
AB			**180MG**	**A076502**	**003**	Apr 11, 2006
AB		RISING	**60MG**	**A077081**	**003**	Apr 11, 2008
AB			**180MG**	**A077081**	**001**	Apr 16, 2007
AB		TEVA	**30MG**	**A076447**	**001**	Sep 01, 2005
AB			**60MG**	**A076447**	**002**	Sep 01, 2005
AB			**180MG**	**A076447**	**003**	Sep 01, 2005
FIDAXOMICIN							
FOR SUSPENSION;ORAL							
DIFICID							
	+!	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020
TABLET;ORAL							
DIFICID							
	+!	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011
FINASTERIDE							
TABLET;ORAL							
FINASTERIDE							
AB		ACCORD HLTHCARE	**1MG**	**A091643**	**001**	Nov 05, 2013
AB			**5MG**	**A090121**	**001**	Feb 23, 2010
AB		ALKEM LABS LTD	**1MG**	**A207750**	**001**	Jan 06, 2017
AB			**5MG**	**A204304**	**001**	Jan 05, 2017
AB		AUROBINDO PHARMA	**5MG**	**A078341**	**001**	Oct 30, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A203687**	**001**	Nov 05, 2013
AB		CIPLA	**1MG**	**A077335**	**001**	Nov 20, 2014
AB		DR REDDYS LABS INC	**1MG**	**A076436**	**001**	Jul 28, 2006
AB		DR REDDYS LABS LTD	**5MG**	**A076437**	**001**	Feb 28, 2007
AB		HETERO LABS LTD III	**1MG**	**A090060**	**001**	Jul 01, 2013
AB			**5MG**	**A090061**	**001**	Jun 07, 2010
AB		SUN PHARM	**1MG**	**A090508**	**001**	Jul 01, 2013
AB			**5MG**	**A090507**	**001**	Aug 16, 2011
AB		TEVA	**5MG**	**A076511**	**001**	Dec 15, 2006
AB		ZYDUS PHARMS USA INC	**5MG**	**A078900**	**001**	Dec 28, 2009
PROPECIA							
AB	**+!**	MERCK	**1MG**	**N020788**	**001**	Dec 19, 1997

FINASTERIDE

TABLET;ORAL

PROSCAR

AB	**+!**	MERCK	**5MG**	**N020180**	**001**	Jun 19, 1992

FINASTERIDE; TADALAFIL

CAPSULE;ORAL

ENTADFI

	+!	VERU	5MG;5MG	N215423	001 Dec 09, 2021

FINERENONE

TABLET;ORAL

KERENDIA

	+	BAYER HLTHCARE	10MG	N215341	001 Jul 09, 2021
	+!		20MG	N215341	002 Jul 09, 2021

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.5MG BASE**	**A207991**	**001**	Oct 28, 2020
AB		HEC PHARM CO LTD	**EQ 0.5MG BASE**	**A207939**	**001**	Nov 10, 2021
AB		MYLAN	**EQ 0.5MG BASE**	**A208005**	**001**	Jan 19, 2021
AB		TEVA PHARMS USA	**EQ 0.25MG BASE**	**A212152**	**001**	Nov 12, 2021

GILENYA

AB	**+**	NOVARTIS	**EQ 0.25MG BASE**	**N022527**	**002**	May 11, 2018
AB	**+!**		**EQ 0.5MG BASE**	**N022527**	**001**	Sep 21, 2010

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL

TASCENSO ODT

	+!	HANDA	EQ 0.25MG BASE	N214962	001 Dec 23, 2021

FISH OIL TRIGLYCERIDES

EMULSION;INTRAVENOUS

OMEGAVEN

	+!	FRESENIUS KABI USA	5GM/50ML (0.1GM/ML)	N210589	001 Jul 27, 2018
	+!		10GM/100ML (0.1GM/ML)	N210589	002 Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

SMOFLIPID 20%

	+!	FRESENIUS KABI USA	3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)	N207648	001 Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)	N207648	002 Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)	N207648	003 Jul 13, 2016
	+!		3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (1000ML)	N207648	004 Aug 10, 2018

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

AB		EPIC PHARMA	**100MG**	**A076835**	**001**	Nov 30, 2005
AB	**!**	PADAGIS US	**100MG**	**A076831**	**001**	Dec 16, 2004

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB		AMNEAL PHARM	**50MG**	**A075442**	**001**	Jul 31, 2001
AB			**100MG**	**A075442**	**002**	Jul 31, 2001
AB			**150MG**	**A075442**	**003**	Jul 31, 2001
AB		ANI PHARMS	**50MG**	**A075882**	**001**	Oct 28, 2002
AB			**100MG**	**A075882**	**002**	Oct 28, 2002
AB			**150MG**	**A075882**	**003**	Oct 28, 2002
AB		AUROBINDO PHARMA LTD	**50MG**	**A202821**	**001**	Nov 03, 2017
AB			**100MG**	**A202821**	**002**	Nov 03, 2017
AB			**150MG**	**A202821**	**003**	Nov 03, 2017
AB		BEXIMCO PHARMS USA	**50MG**	**A210683**	**001**	Sep 16, 2020
AB			**100MG**	**A210683**	**002**	Sep 16, 2020
AB			**150MG**	**A210683**	**003**	Sep 16, 2020
AB		HIKMA	**50MG**	**A076278**	**001**	Jan 14, 2003
AB			**100MG**	**A076278**	**002**	Jan 14, 2003
AB	**!**		**150MG**	**A076278**	**003**	Jan 14, 2003
AB		SUN PHARM INDS LTD	**50MG**	**A076421**	**001**	Mar 28, 2003
AB			**100MG**	**A076421**	**002**	Mar 28, 2003

FLECAINIDE ACETATE						
TABLET;ORAL						
FLECAINIDE ACETATE						
AB			**150MG**	**A076421**	**003**	Mar 28, 2003
FLIBANSERIN						
TABLET;ORAL						
ADDYI						
	+!	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015
FLORBETABEN F-18						
SOLUTION;INTRAVENOUS						
NEURACEQ						
	+!	LIFE MOLECULAR	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014
FLORBETAPIR F-18						
SOLUTION;INTRAVENOUS						
AMYVID						
	+!	AVID RADIOPHARMS INC	10-30ML (13.5-51mCi/ML)	N202008	002	Apr 06, 2012
	+!		10-50ML (13.5-51mCi/ML)	N202008	003	Apr 06, 2012
FLORTAUCIPIR F-18						
SOLUTION;INTRAVENOUS						
TAUVID						
	+!	AVID RADIOPHARMS INC	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020
	+!		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020
FLOXURIDINE						
INJECTABLE;INJECTION						
FLOXURIDINE						
AP		FRESENIUS KABI USA	**500MG/VIAL**	**A075837**	**001**	Feb 22, 2001
AP	**!**	HIKMA	**500MG/VIAL**	**A075387**	**001**	Apr 16, 2000
FLUCICLOVINE F-18						
SOLUTION;INTRAVENOUS						
AXUMIN						
	+!	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016
FLUCONAZOLE						
FOR SUSPENSION;ORAL						
DIFLUCAN						
AB	**+**	PFIZER	**50MG/5ML**	**N020090**	**001**	Dec 23, 1993
AB	**+!**		**200MG/5ML**	**N020090**	**002**	Dec 23, 1993
FLUCONAZOLE						
AB		AUROBINDO PHARMA LTD	**50MG/5ML**	**A079150**	**001**	Sep 18, 2009
AB			**200MG/5ML**	**A079150**	**002**	Sep 18, 2009
INJECTABLE;INJECTION						
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%						
AP		BAXTER HLTHCARE CORP	**200MG/100ML (2MG/ML)**	**A077947**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077947**	**002**	May 26, 2010
AP		FRESENIUS KABI USA	**200MG/100ML (2MG/ML)**	**A076145**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076145**	**002**	Jul 29, 2004
AP		HIKMA	**200MG/100ML (2MG/ML)**	**A076087**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076087**	**003**	Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A076736**	**001**	Aug 23, 2005
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE	**200MG/100ML (2MG/ML)**	**A076766**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076766**	**002**	Jul 29, 2004
AP		HIKMA FARMACEUTICA	**200MG/100ML (2MG/ML)**	**A078698**	**001**	Jan 30, 2012
AP			**400MG/200ML (2MG/ML)**	**A078698**	**002**	Jan 30, 2012
AP		HOSPIRA	**200MG/100ML (2MG/ML)**	**A076303**	**001**	Jul 29, 2004
AP			**400MG/200ML (2MG/ML)**	**A076303**	**002**	Jul 29, 2004
AP	**!**	INFORLIFE	**200MG/100ML (2MG/ML)**	**A079104**	**001**	Jul 30, 2009
AP	**!**		**400MG/200ML (2MG/ML)**	**A079104**	**002**	Jul 30, 2009
AP		WEST-WARD PHARMS INT	**200MG/100ML (2MG/ML)**	**A078107**	**001**	Jul 30, 2008
AP			**400MG/200ML (2MG/ML)**	**A078107**	**002**	Jul 30, 2008
AP		WOODWARD	**200MG/100ML (2MG/ML)**	**A077909**	**001**	May 26, 2010
AP			**400MG/200ML (2MG/ML)**	**A077909**	**002**	May 26, 2010
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%						
		HIKMA	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008

FLUCONAZOLE

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		WOODWARD	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015

TABLET;ORAL

DIFLUCAN

AB	**+**	PFIZER	**50MG**	**N019949**	**001**	Jan 29, 1990
AB	**+**		**100MG**	**N019949**	**002**	Jan 29, 1990
AB	**+**		**150MG**	**N019949**	**004**	Jun 30, 1994
AB	**+!**		**200MG**	**N019949**	**003**	Jan 29, 1990

FLUCONAZOLE

AB		ANI PHARMS	**50MG**	**A078423**	**001**	Mar 07, 2011
AB			**100MG**	**A078423**	**002**	Mar 07, 2011
AB			**150MG**	**A078423**	**003**	Mar 07, 2011
AB			**200MG**	**A078423**	**004**	Mar 07, 2011
AB		AUROBINDO PHARMA	**50MG**	**A077731**	**001**	Oct 07, 2008
AB			**100MG**	**A077731**	**002**	Oct 07, 2008
AB			**150MG**	**A077731**	**003**	Oct 07, 2008
AB			**200MG**	**A077731**	**004**	Oct 07, 2008
AB		CHARTWELL	**50MG**	**A076665**	**001**	Jul 29, 2004
AB			**100MG**	**A076665**	**002**	Jul 29, 2004
AB			**150MG**	**A076665**	**003**	Jul 29, 2004
AB			**200MG**	**A076665**	**004**	Jul 29, 2004
AB		DR REDDYS LABS INC	**50MG**	**A076658**	**001**	Jul 29, 2004
AB			**100MG**	**A076658**	**002**	Jul 29, 2004
AB			**150MG**	**A076658**	**003**	Jul 29, 2004
AB			**200MG**	**A076658**	**004**	Jul 29, 2004
AB		GLENMARK GENERICS	**50MG**	**A077253**	**001**	Jan 25, 2006
AB			**100MG**	**A077253**	**002**	Jan 25, 2006
AB			**150MG**	**A077253**	**003**	Jan 25, 2006
AB			**200MG**	**A077253**	**004**	Jan 25, 2006
AB		IVAX SUB TEVA PHARMS	**50MG**	**A076077**	**001**	Jul 29, 2004
AB			**100MG**	**A076077**	**002**	Jul 29, 2004
AB			**150MG**	**A076077**	**003**	Jul 29, 2004
AB			**200MG**	**A076077**	**004**	Jul 29, 2004
AB		TARO	**50MG**	**A076507**	**001**	Jul 29, 2004
AB			**100MG**	**A076507**	**002**	Jul 29, 2004
AB			**150MG**	**A076507**	**003**	Jul 29, 2004
AB			**200MG**	**A076507**	**004**	Jul 29, 2004
AB		UNIQUE PHARM LABS	**50MG**	**A076957**	**001**	Sep 28, 2005
AB			**100MG**	**A076957**	**002**	Sep 28, 2005
AB			**150MG**	**A076957**	**004**	Feb 27, 2017
AB			**200MG**	**A076957**	**003**	Sep 28, 2005
AB		ZYDUS PHARMS	**50MG**	**A208963**	**001**	Feb 16, 2017
AB			**100MG**	**A208963**	**002**	Feb 16, 2017
AB			**150MG**	**A208963**	**003**	Feb 16, 2017
AB			**200MG**	**A208963**	**004**	Feb 16, 2017

FLUCYTOSINE

CAPSULE;ORAL

ANCOBON

AB	**+**	BAUSCH	**250MG**	**N017001**	**001**	
AB	**+!**		**500MG**	**N017001**	**002**	

FLUCYTOSINE

AB		AUROBINDO PHARMA LTD	**250MG**	**A213665**	**001**	May 01, 2020
AB			**500MG**	**A213665**	**002**	May 01, 2020
AB		HIKMA	**250MG**	**A206550**	**001**	Oct 17, 2017
AB			**500MG**	**A206550**	**002**	Oct 17, 2017
AB		NOVEL LABS INC	**250MG**	**A204652**	**001**	Jul 07, 2017
AB			**500MG**	**A204652**	**002**	Jul 07, 2017
AB		SIGMAPHARM LABS LLC	**250MG**	**A201566**	**001**	Jun 28, 2011
AB			**500MG**	**A201566**	**002**	Jun 28, 2011

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP		ACTAVIS LLC	**50MG/2ML (25MG/ML)**	**A203738**	**001**	Feb 28, 2017
AP	**!**	ACTAVIS TOTOWA	**50MG/VIAL**	**A078610**	**001**	Feb 11, 2009
AP		AREVA PHARMS	**50MG/2ML (25MG/ML)**	**A090724**	**001**	Sep 27, 2010
AP		CUSTOPHARM INC	**50MG/VIAL**	**A076349**	**001**	Aug 28, 2003
AP	**!**	FRESENIUS KABI USA	**50MG/2ML (25MG/ML)**	**A078393**	**001**	Oct 15, 2007
AP			**50MG/VIAL**	**A078544**	**001**	Oct 15, 2007

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP		SAGENT PHARMS INC	**50MG/2ML (25MG/ML)**	**A076661**	**001**	Apr 28, 2004
AP	**+!**	SANDOZ	**50MG/2ML (25MG/ML)**	**N022137**	**001**	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP		3D IMAGING DRUG	**20-300mCi/ML**	**A203778**	**001**	Oct 30, 2015
AP		BIOMEDCL RES FDN	**20-300mCi/ML**	**A203710**	**001**	May 01, 2015
AP			**20-300mCi/ML**	**A203837**	**001**	May 01, 2015
AP		BRIGHAM WOMENS	**20-300mCi/ML**	**A203816**	**001**	Oct 30, 2014
AP		CARDINAL HEALTH 414	**20-300mCi/ML**	**A203603**	**001**	Nov 13, 2015
AP			**20-500mCi/ML**	**A203603**	**002**	Sep 27, 2018
AP		CHILDRENS HOSP MI	**20-300mCi/ML**	**A204385**	**001**	Oct 29, 2014
AP		DECATUR	**20-300mCi/ML**	**A204463**	**001**	Oct 21, 2014
AP		ESSENTIAL ISOTOPES	**20-300mCi/ML**	**A203946**	**001**	Feb 05, 2014
AP	**+!**	FEINSTEIN	**20-400mCi/ML**	**N021870**	**002**	Nov 21, 2008
AP		ISOLOGIC INNOVATIVE	**20-300mCi/ML**	**A204525**	**001**	Oct 29, 2014
AP		JUBILANT DRAXIMAGE	**20-300mCi/ML**	**A203920**	**001**	Jun 23, 2015
AP		KETTERING MEDCTR	**4-40mCi/ML**	**A204759**	**001**	Oct 27, 2015
AP		KREITCHMAN PET CTR	**10-100mCi/ML**	**A203942**	**001**	Apr 11, 2016
AP		MA GENERAL HOSP	**20-300mCi/ML**	**A204333**	**001**	Sep 25, 2014
AP		MCPRF	**20-240mCi/ML**	**A203612**	**001**	Aug 05, 2013
AP		MEM SLOAN-KETTERING	**20-300mCi/ML**	**A208679**	**001**	Dec 08, 2016
AP		METHODIST HOSP RES	**20-300mCi/ML**	**A203904**	**001**	Apr 23, 2015
AP		MIPS CRF	**20-300mCi/ML**	**A204472**	**001**	Sep 11, 2015
AP		NCM USA BRONX LLC	**20-300mCi/ML**	**A204512**	**001**	Jan 07, 2015
AP	**!**	PETNET	**20-200mCi/ML**	**A079086**	**001**	Feb 25, 2011
AP		PHARMALOGIC HLDGS	**20-200mCi/ML**	**A203664**	**001**	Feb 04, 2014
AP		PRECISION NUCLEAR	**20-500mCi/ML**	**A204546**	**001**	Apr 07, 2015
AP	**!**	QUEEN HAMAMATSU PET	**10-100mCi/ML**	**A203771**	**001**	Aug 31, 2015
AP		SHERTECH LABS LLC	**20-300mCi/ML**	**A204264**	**001**	Dec 18, 2014
AP		SOFIE	**20-300mCi/ML**	**A203591**	**001**	Aug 31, 2015
AP	**!**		**20-500mCi/ML**	**A203665**	**001**	Feb 14, 2013
AP		TRUSTEES UNIV PA	**20-200mCi/ML**	**A203801**	**001**	Oct 29, 2014
AP	**!**	UCLA BIOMEDICAL	**4-40mCi/ML**	**A203811**	**001**	Jun 27, 2013
AP		UCSF RODIOPHARM	**20-300mCi/ML**	**A203902**	**001**	May 09, 2014
AP		UIHC PET IMAGING	**20-300mCi/ML**	**A203990**	**001**	Aug 06, 2014
AP		UNIV MICHIGAN	**20-300mCi/ML**	**A204531**	**001**	Jul 17, 2015
AP		UNIV SOUTHERN CA	**20-300mCi/ML**	**A209341**	**001**	Dec 16, 2020
AP		UNIV TX MD ANDERSON	**20-300mCi/ML**	**A203246**	**002**	Jan 13, 2014
AP		UNIV UTAH CYCLOTRON	**20-300mCi/ML**	**A204498**	**001**	Jun 23, 2015
AP		WISCONSIN	**20-500mCi/ML**	**A203709**	**001**	Oct 23, 2013
AP		WUSM CYCLOTRON	**20-300mCi/ML**	**A203935**	**001**	Feb 05, 2014
		HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
		NORTHLAND	4-500mCi/ML	A203994	001	Feb 04, 2015
		NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015
		UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET;ORAL

FLUDROCORTISONE ACETATE

AB		BARR	**0.1MG**	**A040425**	**001**	Jan 21, 2003
AB	**!**	IMPAX LABS	**0.1MG**	**A040431**	**001**	Mar 18, 2002

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		BAXTER HLTHCARE CORP	**0.5MG/5ML (0.1MG/ML)**	**A076755**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076755**	**001**	Oct 12, 2004
AP		FRESENIUS KABI USA	**0.5MG/5ML (0.1MG/ML)**	**A076955**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076955**	**001**	Oct 12, 2004
AP		HIKMA	**0.5MG/5ML (0.1MG/ML)**	**A076256**	**002**	Oct 12, 2004
AP			**0.5MG/5ML (0.1MG/ML)**	**A076787**	**002**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076256**	**001**	Oct 12, 2004
AP			**1MG/10ML (0.1MG/ML)**	**A076787**	**001**	Oct 12, 2004
AP		HIKMA FARMACEUTICA	**0.5MG/5ML (0.1MG/ML)**	**A078527**	**001**	Mar 23, 2009
AP	**!**		**1MG/10ML (0.1MG/ML)**	**A078527**	**002**	Mar 23, 2009
AP		RISING PHARMA	**0.5MG/5ML (0.1MG/ML)**	**A078595**	**001**	May 13, 2008
AP		SAGENT PHARMS	**0.5MG/5ML (0.1MG/ML)**	**A090584**	**001**	Aug 28, 2012
AP			**1MG/10ML (0.1MG/ML)**	**A090584**	**002**	Aug 28, 2012

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP		SANDOZ INC	**0.5MG/5ML (0.1MG/ML)**	**A077071**	**001**	May 03, 2005
AP			**1MG/10ML (0.1MG/ML)**	**A077071**	**002**	May 03, 2005

FLUNISOLIDE

SPRAY, METERED;NASAL

FLUNISOLIDE

AB	!	BAUSCH AND LOMB	**0.025MG/SPRAY**	**A074805**	**001**	Feb 20, 2002
AB		RISING PHARMA	**0.025MG/SPRAY**	**A077704**	**001**	Aug 03, 2006
	!	APOTEX	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

AT		COSETTE	**0.01%**	**A089526**	**001**	Jul 26, 1988
AT			**0.025%**	**A210747**	**001**	Nov 05, 2018
AT		FOUGERA PHARMS INC	**0.01%**	**A088170**	**001**	Dec 16, 1982
AT			**0.025%**	**A088169**	**001**	Dec 16, 1982
AT		TARO	**0.025%**	**A087104**	**001**	Apr 27, 1982

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N012787**	**004**	
AT	**+!**		**0.025%**	**N012787**	**002**	
AT	**+!**		**0.025%**	**N012787**	**005**	

IMPLANT;INTRAVITREAL

ILUVIEN

	+!	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014

RETISERT

	+!	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005

YUTIQ

	+!	EYEPOINT PHARMS	0.18MG	N210331	001	Oct 12, 2018

OIL;TOPICAL

DERMA-SMOOTHE/FS

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**001**	Feb 03, 1988
AT	**+!**		**0.01%**	**N019452**	**002**	Nov 09, 2005

FLUCINOLONE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A210556**	**001**	Oct 25, 2018

FLUOCINOLONE ACETONIDE

AT		AMNEAL	**0.01%**	**A201759**	**001**	Oct 17, 2011
AT			**0.01%**	**A201764**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A090982**	**001**	Apr 25, 2016
AT			**0.01%**	**A203377**	**001**	Apr 25, 2016
AT		PADAGIS ISRAEL	**0.01%**	**A202847**	**001**	Aug 09, 2013
AT			**0.01%**	**A202848**	**001**	Aug 09, 2013
AT		QUAGEN	**0.01%**	**A212760**	**001**	Apr 02, 2021
AT			**0.01%**	**A212761**	**001**	Apr 02, 2021
AT		TARO	**0.01%**	**A202368**	**001**	May 19, 2016
AT			**0.01%**	**A209336**	**001**	May 19, 2016

FLUOCINONIDE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A210539**	**001**	Oct 26, 2018

OIL/DROPS;OTIC

DERMOTIC

AT	**+!**	HILL DERMAC	**0.01%**	**N019452**	**003**	Nov 09, 2005

FLAC

AT		ANDA REPOSITORY	**0.01%**	**A210736**	**001**	Apr 11, 2018

FLUOCINOLONE ACETONIDE

AT		AMNEAL	**0.01%**	**A091306**	**001**	Oct 17, 2011
AT		LYNE	**0.01%**	**A203378**	**001**	Apr 25, 2016
AT		PADAGIS ISRAEL	**0.01%**	**A202849**	**001**	Jul 17, 2017
AT		QUAGEN	**0.01%**	**A212762**	**001**	Apr 02, 2021
AT		TASMAN PHARMA	**0.01%**	**A213264**	**001**	Feb 05, 2021

FLUOCINONIDE ACETONIDE

AT		GLENMARK PHARMS LTD	**0.01%**	**A211815**	**001**	Dec 14, 2018

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

AT		COSETTE	**0.025%**	**A089524**	**001**	Jul 26, 1988
AT		FOUGERA PHARMS INC	**0.025%**	**A088168**	**001**	Dec 16, 1982
AT		TARO	**0.025%**	**A040041**	**001**	Sep 15, 1994

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.025%**	**N013960**	**001**	

FLUOCINOLONE ACETONIDE

SHAMPOO;TOPICAL

CAPEX

	+!	GALDERMA LABS LP	0.01%	N020001	001	Aug 27, 1990

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

AT		ENCUBE ETHICALS	**0.01%**	**A209913**	**001**	Feb 13, 2019
AT		FOUGERA PHARMS INC	**0.01%**	**A088167**	**001**	Dec 16, 1982
AT		GLASSHOUSE PHARMS	**0.01%**	**A209596**	**001**	Dec 26, 2017
AT		LUPIN	**0.01%**	**A206422**	**001**	Sep 02, 2015
AT		TARO	**0.01%**	**A089124**	**001**	Sep 11, 1985

SYNALAR

AT	**+!**	MEDIMETRIKS PHARMS	**0.01%**	**N015296**	**001**	

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

	+!	GALDERMA LABS LP	0.01%;4%;0.05%	N021112	001	Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

	!	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001	

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

AB		AMNEAL	**0.1%**	**A211111**	**001**	Jun 04, 2018
AB		CADILA	**0.1%**	**A208989**	**001**	Feb 10, 2020
AB		FOUGERA PHARMS INC	**0.1%**	**A200735**	**001**	Jul 14, 2014
AB		GLENMARK GENERICS	**0.1%**	**A091282**	**001**	Jul 14, 2014
AB		PADAGIS ISRAEL	**0.1%**	**A090256**	**001**	Jan 14, 2014
AB		TARO	**0.1%**	**A200734**	**001**	Jul 14, 2014
AB		TELIGENT	**0.1%**	**A211758**	**001**	Apr 03, 2019

VANOS

AB	**+!**	BAUSCH	**0.1%**	**N021758**	**001**	Feb 11, 2005

FLUOCINONIDE

AB1		AMNEAL	**0.05%**	**A210554**	**001**	Aug 21, 2018
AB1		COSETTE	**0.05%**	**A073085**	**001**	Feb 14, 1992
AB1		FOUGERA PHARMS INC	**0.05%**	**A073030**	**001**	Oct 17, 1994
AB1		TARO	**0.05%**	**A071500**	**001**	Jun 10, 1987
AB1	**+!**		**0.05%**	**N019117**	**001**	Jun 26, 1984
AB1		TEVA	**0.05%**	**A072488**	**001**	Feb 06, 1989

FLUOCINONIDE EMULSIFIED BASE

AB2		COSETTE	**0.05%**	**A074204**	**001**	Jun 13, 1995
AB2		FOUGERA PHARMS	**0.05%**	**A076586**	**001**	Jun 23, 2004
AB2	**!**	TARO PHARM INDS LTD	**0.05%**	**A072494**	**001**	Jan 19, 1989
AB2		TEVA	**0.05%**	**A072490**	**001**	Feb 07, 1989

LIDEX-E

AB2	**+**	ALVOGEN	**0.05%**	**N016908**	**003**	

GEL;TOPICAL

FLUOCINONIDE

AB	**+**	ALVOGEN	**0.05%**	**N017373**	**001**	
AB		COSETTE	**0.05%**	**A072537**	**001**	Feb 07, 1989
AB		FOUGERA PHARMS INC	**0.05%**	**A072933**	**001**	Dec 30, 1994
AB	**!**	TARO	**0.05%**	**A074935**	**001**	Jul 29, 1997
AB		TELIGENT	**0.05%**	**A209030**	**001**	Jun 19, 2018

OINTMENT;TOPICAL

FLUOCINONIDE

AB		FOUGERA PHARMS	**0.05%**	**A074905**	**001**	Aug 26, 1997
AB		NOVEL LABS INC	**0.05%**	**A207538**	**001**	Jul 31, 2017
AB	**!**	TARO	**0.05%**	**A075008**	**001**	Jun 30, 1999
AB		TELIGENT	**0.05%**	**A207680**	**001**	Sep 28, 2018
AB		TEVA	**0.05%**	**A073481**	**001**	Dec 27, 1991
AB		XIROMED	**0.05%**	**A212976**	**001**	Nov 26, 2019

LIDEX

AB	**+**	ALVOGEN	**0.05%**	**N016909**	**002**	

SOLUTION;TOPICAL

FLUOCINONIDE

AT		COSETTE	**0.05%**	**A071535**	**001**	Dec 02, 1988
AT		ENCUBE ETHICALS	**0.05%**	**A209699**	**001**	Nov 29, 2018
AT		FOUGERA PHARMS INC	**0.05%**	**A072934**	**001**	Feb 27, 1995
AT		GLASSHOUSE PHARMS	**0.05%**	**A209118**	**001**	Apr 23, 2018
AT		MACLEODS PHARMS LTD	**0.05%**	**A209283**	**001**	Apr 23, 2018

FLUOCINONIDE							
SOLUTION;TOPICAL							
FLUOCINONIDE							
AT		NOVEL LABS INC	**0.05%**	**A206003**	**001**	Jul 21, 2017
AT	**!**	TARO	**0.05%**	**A074799**	**001**	Dec 31, 1996
AT		TELIGENT	**0.05%**	**A207554**	**001**	Mar 18, 2019
AT		ZYDUS PHARMS	**0.05%**	**A208948**	**001**	Jul 17, 2018
LIDEX							
AT	**+**	ALVOGEN	**0.05%**	**N018849**	**001**	Apr 06, 1984
FLUORESCEIN SODIUM							
INJECTABLE;INTRAVENOUS							
AK-FLUOR 10%							
AP	**+**	AKORN	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N022186**	**001**	Aug 08, 2008
FLUORESCITE							
AP	**+!**	ALCON LABS INC	**EQ 500MG BASE/5ML (EQ 100MG BASE/ML)**	**N021980**	**001**	Mar 28, 2006
AK-FLUOR 25%							
	+!	AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008
FLUORODOPA F-18							
SOLUTION;INTRAVENOUS							
FLUORODOPA F18							
	+!	FEINSTEIN	0.42-8.33mCi/ML	N200655	001	Oct 10, 2019
FLUOROESTRADIOL F-18							
SOLUTION;INTRAVENOUS							
CERIANNA							
	+!	ZIONEXA	50ML (4-100mCi/ML)	N212155	001	May 20, 2020
FLUOROMETHOLONE							
OINTMENT;OPHTHALMIC							
FML							
	+!	ALLERGAN	0.1%	N017760	001	Sep 04, 1985
SUSPENSION/DROPS;OPHTHALMIC							
FML							
	+!	ALLERGAN	0.1%	N016851	002	Jul 28, 1982
FML FORTE							
	+!	ALLERGAN	0.25%	N019216	001	Apr 23, 1986
FLUOROMETHOLONE ACETATE							
SUSPENSION/DROPS;OPHTHALMIC							
FLAREX							
	+!	EYEVANCE	0.1%	N019079	001	Feb 11, 1986
FLUOROURACIL							
CREAM;TOPICAL							
EFUDEX							
AB	**+!**	BAUSCH	**5%**	**N016831**	**003**		
FLUOROURACIL							
AB		ACCORD HLTHCARE	**5%**	**A214845**	**001**	Oct 07, 2021
AB		MAYNE PHARMA	**5%**	**A077524**	**001**	Apr 11, 2008
AB		TARO	**5%**	**A090368**	**001**	Mar 05, 2010
CARAC							
	+!	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000
TOLAK							
	+!	HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015
INJECTABLE;INJECTION							
FLUOROURACIL							
AP	**!**	ACCORD HLTHCARE	**500MG/10ML (50MG/ML)**	**A040743**	**002**	Apr 26, 2007
AP	**!**		**1GM/20ML (50MG/ML)**	**A040743**	**001**	Apr 26, 2007
AP	**!**		**2.5GM/50ML (50MG/ML)**	**A040798**	**002**	Apr 26, 2007
AP	**!**		**5GM/100ML (50MG/ML)**	**A040798**	**001**	Apr 26, 2007
AP		FRESENIUS KABI USA	**500MG/10ML (50MG/ML)**	**A040279**	**002**	Sep 30, 1998
AP			**1GM/20ML (50MG/ML)**	**A040279**	**001**	Sep 30, 1998
AP			**2.5GM/50ML (50MG/ML)**	**A040278**	**001**	Sep 30, 1998
AP			**5GM/100ML (50MG/ML)**	**A040278**	**002**	Sep 30, 1998
AP		GLAND PHARMA LTD	**500MG/10ML (50MG/ML)**	**A210123**	**001**	Oct 27, 2017
AP			**1GM/20ML (50MG/ML)**	**A210123**	**002**	Oct 27, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A210124**	**001**	Dec 26, 2017
AP			**5GM/100ML (50MG/ML)**	**A210124**	**002**	Dec 26, 2017
AP		SAGENT PHARMS INC	**500MG/10ML (50MG/ML)**	**A203608**	**001**	May 11, 2017
AP			**1GM/20ML (50MG/ML)**	**A203608**	**002**	May 11, 2017
AP			**2.5GM/50ML (50MG/ML)**	**A203609**	**001**	Feb 17, 2016
AP			**5GM/100ML (50MG/ML)**	**A203609**	**002**	Feb 17, 2016
AP		TEVA PHARMS USA	**500MG/10ML (50MG/ML)**	**A040333**	**001**	Jan 27, 2000

FLUOROURACIL

SOLUTION;TOPICAL

EFUDEX

AT	**+!**	BAUSCH	**2%**	**N016831**	**001**	

FLUOROURACIL

AT		TARO	**2%**	**A076526**	**001**	Nov 05, 2003
	!		5%	A076526	002	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 40MG BASE**	**A090223**	**003**	Mar 19, 2009
AB		APNAR PHARMA LP	**EQ 40MG BASE**	**A075049**	**003**	Jan 29, 2002
AB		AUROBINDO PHARMA	**EQ 40MG BASE**	**A078619**	**003**	Jan 31, 2008
AB		CADILA PHARMS LTD	**EQ 40MG BASE**	**A206993**	**003**	May 23, 2019
AB		HERITAGE PHARMS INC	**EQ 40MG BASE**	**A201336**	**003**	Oct 01, 2012
AB		IVAX SUB TEVA PHARMS	**EQ 40MG BASE**	**A075245**	**003**	Sep 28, 2004
AB		MARKSANS PHARMA	**EQ 40MG BASE**	**A075465**	**003**	Aug 02, 2001
AB		SCIEGEN PHARMS INC	**EQ 40MG BASE**	**A204597**	**003**	Mar 16, 2015
AB		SUN PHARM INDS LTD	**EQ 40MG BASE**	**A076990**	**001**	Dec 13, 2004
AB		TEVA	**EQ 40MG BASE**	**A075452**	**003**	Jan 29, 2002

PROZAC

AB	**+!**	ELI LILLY AND CO	**EQ 40MG BASE**	**N018936**	**003**	Jun 15, 1999

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A090223**	**001**	Mar 19, 2009
AB1			**EQ 20MG BASE**	**A090223**	**002**	Mar 19, 2009
AB1		APNAR PHARMA LP	**EQ 10MG BASE**	**A075049**	**001**	Aug 02, 2001
AB1			**EQ 20MG BASE**	**A075049**	**002**	Jan 29, 2002
AB1		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078619**	**001**	Jan 31, 2008
AB1			**EQ 20MG BASE**	**A078619**	**002**	Jan 31, 2008
AB1		CADILA PHARMS LTD	**EQ 10MG BASE**	**A206993**	**001**	May 23, 2019
AB1			**EQ 20MG BASE**	**A206993**	**002**	May 23, 2019
AB1		HERITAGE PHARMS INC	**EQ 10MG BASE**	**A201336**	**001**	Oct 01, 2012
AB1			**EQ 20MG BASE**	**A201336**	**002**	Oct 01, 2012
AB1		IVAX SUB TEVA PHARMS	**EQ 10MG BASE**	**A075245**	**002**	Jan 31, 2002
AB1			**EQ 20MG BASE**	**A075245**	**001**	Jan 31, 2002
AB1		LANDELA PHARM	**EQ 10MG BASE**	**A075464**	**001**	Jan 30, 2002
AB1			**EQ 20MG BASE**	**A075464**	**002**	Jan 30, 2002
AB1		MARKSANS PHARMA	**EQ 10MG BASE**	**A075465**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075465**	**002**	Jan 29, 2002
AB1		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A204597**	**001**	Mar 16, 2015
AB1			**EQ 20MG BASE**	**A204597**	**002**	Mar 16, 2015
AB1		TEVA	**EQ 10MG BASE**	**A075452**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A075452**	**002**	Jan 29, 2002
AB1		TEVA PHARMS USA	**EQ 10MG BASE**	**A076001**	**001**	Jan 29, 2002
AB1			**EQ 20MG BASE**	**A076001**	**002**	Jan 29, 2002

PROZAC

AB1	**+**	ELI LILLY AND CO	**EQ 10MG BASE**	**N018936**	**006**	Dec 23, 1992
AB1	**+**		**EQ 20MG BASE**	**N018936**	**001**	Dec 29, 1987

CAPSULE, DELAYED REL PELLETS;ORAL

FLUOXETINE HYDROCHLORIDE

	!	DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

AA		AUROBINDO PHARMA LTD	**EQ 20MG BASE/5ML**	**A079209**	**001**	Mar 20, 2009
AA		LANNETT CO INC	**EQ 20MG BASE/5ML**	**A077849**	**001**	Feb 09, 2007
AA	**!**	PHARM ASSOC	**EQ 20MG BASE/5ML**	**A076015**	**001**	Jan 30, 2002
AA		TEVA	**EQ 20MG BASE/5ML**	**A075506**	**001**	Aug 02, 2001
AA		WOCKHARDT BIO AG	**EQ 20MG BASE/5ML**	**A075514**	**001**	Aug 29, 2002

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 10MG BASE**	**A208698**	**001**	Apr 05, 2017
AB			**EQ 20MG BASE**	**A208698**	**002**	Apr 05, 2017
AB	**+!**	ALMATICA	**EQ 60MG BASE**	**N202133**	**001**	Oct 06, 2011
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A213286**	**001**	Apr 08, 2020
AB			**EQ 20MG BASE**	**A213286**	**002**	Apr 08, 2020
AB			**EQ 60MG BASE**	**A213265**	**001**	Jun 10, 2020
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A076006**	**001**	Jan 30, 2002
AB	**!**		**EQ 20MG BASE**	**A076006**	**002**	Apr 23, 2018
AB			**EQ 60MG BASE**	**A211721**	**001**	Jan 25, 2019

FLUOXETINE HYDROCHLORIDE

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB		INVENTIA HLTHCARE	**EQ 60MG BASE**	**A209695**	**001**	Nov 20, 2017
AB		LUPIN LTD	**EQ 10MG BASE**	**A211653**	**001**	Apr 15, 2019
AB			**EQ 20MG BASE**	**A211653**	**002**	Apr 15, 2019
AB			**EQ 60MG BASE**	**A211632**	**001**	Feb 08, 2019
AB		PAR FORM	**EQ 10MG BASE**	**A203836**	**001**	Aug 19, 2016
AB			**EQ 20MG BASE**	**A203836**	**002**	Aug 19, 2016
AB		PAR PHARM INC	**EQ 60MG BASE**	**A209419**	**001**	Nov 16, 2017
AB		SCIEGEN PHARMS INC	**EQ 10MG BASE**	**A210935**	**001**	Mar 20, 2019
AB			**EQ 20MG BASE**	**A210935**	**002**	Mar 20, 2019
AB			**EQ 60MG BASE**	**A211282**	**001**	Jan 10, 2019
AB		TARO	**EQ 60MG BASE**	**A211477**	**001**	Nov 21, 2018
AB		TEVA	**EQ 10MG BASE**	**A075872**	**001**	Jan 29, 2002
AB			**EQ 20MG BASE**	**A075872**	**002**	Jan 04, 2019
AB		TEVA PHARMS USA	**EQ 60MG BASE**	**A211051**	**001**	Dec 03, 2018
AB		UPSHER SMITH LABS	**EQ 10MG BASE**	**A211696**	**001**	Jan 30, 2019
AB			**EQ 20MG BASE**	**A211696**	**002**	Jan 30, 2019
		TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016
	!		EQ 20MG BASE	A206937	002	Oct 21, 2016

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		PAR PHARM	**EQ 25MG BASE;EQ 3MG BASE**	**A077742**	**001**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077742**	**002**	Nov 02, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077742**	**003**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077742**	**004**	Nov 02, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077742**	**005**	Nov 02, 2012
AB		SANDOZ	**EQ 25MG BASE;EQ 3MG BASE**	**A078901**	**005**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A078901**	**001**	Nov 16, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A078901**	**003**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A078901**	**002**	Nov 16, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A078901**	**004**	Nov 16, 2012
AB		TEVA PHARMS	**EQ 25MG BASE;EQ 3MG BASE**	**A202074**	**001**	Mar 25, 2013
AB			**EQ 25MG BASE;EQ 6MG BASE**	**A077528**	**001**	Jun 19, 2012
AB			**EQ 25MG BASE;EQ 12MG BASE**	**A077528**	**002**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 6MG BASE**	**A077528**	**003**	Jun 19, 2012
AB			**EQ 50MG BASE;EQ 12MG BASE**	**A077528**	**004**	Jun 19, 2012

SYMBYAX

AB	**+**	LILLY	**EQ 25MG BASE;EQ 3MG BASE**	**N021520**	**001**	Apr 09, 2007
AB	**+**		**EQ 25MG BASE;EQ 6MG BASE**	**N021520**	**002**	Dec 24, 2003
AB	**+**		**EQ 25MG BASE;EQ 12MG BASE**	**N021520**	**004**	Dec 24, 2003
AB	**+!**		**EQ 50MG BASE;EQ 6MG BASE**	**N021520**	**003**	Dec 24, 2003
AB	**+**		**EQ 50MG BASE;EQ 12MG BASE**	**N021520**	**005**	Dec 24, 2003

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO		EUGIA PHARMA	**25MG/ML**	**A207739**	**001**	Oct 17, 2017
AO	**!**	FRESENIUS KABI USA	**25MG/ML**	**A071413**	**001**	Jul 14, 1987
AO		HIKMA	**25MG/ML**	**A074531**	**001**	Aug 30, 1996
AO		MYLAN LABS LTD	**25MG/ML**	**A075918**	**001**	Aug 17, 2001
AO		PAR STERILE PRODUCTS	**25MG/ML**	**A203732**	**001**	Jul 03, 2014

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

	!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

	!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996

INJECTABLE;INJECTION

FLUPHENAZINE HYDROCHLORIDE

	!	FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB		AMNEAL	**1MG**	**A213647**	**001**	Jul 09, 2020
AB			**2.5MG**	**A213647**	**002**	Jul 09, 2020
AB			**5MG**	**A213647**	**003**	Jul 09, 2020
AB			**10MG**	**A213647**	**004**	Jul 09, 2020
AB		CEROVENE INC	**1MG**	**A214534**	**001**	Jan 07, 2021

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

AB			**2.5MG**	**A214534**	**002**	Jan 07, 2021
AB			**5MG**	**A214534**	**003**	Jan 07, 2021
AB			**10MG**	**A214534**	**004**	Jan 07, 2021
AB		ENALTEC	**1MG**	**A215141**	**001**	Oct 20, 2021
AB			**2.5MG**	**A215141**	**002**	Oct 20, 2021
AB			**5MG**	**A215141**	**003**	Oct 20, 2021
AB			**10MG**	**A215141**	**004**	Oct 20, 2021
AB		LANNETT CO INC	**1MG**	**A089743**	**002**	Aug 25, 1988
AB			**2.5MG**	**A089743**	**003**	Aug 25, 1988
AB	**!**		**5MG**	**A089743**	**004**	Aug 25, 1988
AB			**10MG**	**A089743**	**001**	Aug 25, 1988
AB		NOVITIUM PHARMA	**1MG**	**A214674**	**001**	Mar 01, 2021
AB			**2.5MG**	**A214674**	**002**	Mar 01, 2021
AB			**5MG**	**A214674**	**003**	Mar 01, 2021
AB			**10MG**	**A214674**	**004**	Mar 01, 2021
AB		ZYDUS	**1MG**	**A214552**	**001**	May 27, 2021
AB			**2.5MG**	**A214552**	**002**	May 27, 2021
AB			**5MG**	**A214552**	**003**	May 27, 2021
AB			**10MG**	**A214552**	**004**	May 27, 2021

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

AT	**+!**	ALMIRALL	**0.05%**	**N012806**	**002**	

FLURANDRENOLIDE

AT		CINTEX SVCS	**0.05%**	**A205342**	**001**	Apr 13, 2016

LOTION;TOPICAL

CORDRAN

AT	**+!**	ALMIRALL	**0.05%**	**N013790**	**001**	

FLURANDRENOLIDE

AT		CINTEX SVCS	**0.05%**	**A205343**	**001**	Dec 22, 2016
AT		PADAGIS ISRAEL	**0.05%**	**A207133**	**001**	Aug 30, 2016

OINTMENT;TOPICAL

CORDRAN

AT	**+!**	ALMIRALL	**0.05%**	**N012806**	**001**	

FLURANDRENOLIDE

AT		TELIGENT	**0.05%**	**A207851**	**001**	Dec 30, 2016

TAPE;TOPICAL

CORDRAN

	+!	ALMIRALL	0.004MG/SQ CM	N016455	001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

		MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985
	!		30MG	A070345	001	Nov 27, 1985

FLURBIPROFEN

TABLET;ORAL

FLURBIPROFEN

	!	TEVA	100MG	A074431	001	May 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLURBIPROFEN SODIUM

	!	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

	!	WAYLIS THERAP	125MG	A075298	001	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE;INTRAVENOUS

VIZAMYL

	+!	GE HEALTHCARE	121.5mCi/30ML (4.05mCi/ML)	N203137	002	Oct 25, 2013

FLUTICASONE FUROATE

POWDER;INHALATION

ARNUITY ELLIPTA

	+!	GLAXOSMITHKLINE	0.05MG/INH	N205625	003	May 17, 2018
	+!		0.1MG/INH	N205625	001	Aug 20, 2014
	+!		0.2MG/INH	N205625	002	Aug 20, 2014

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION

TRELEGY ELLIPTA

	+!	GLAXOSMITHKLINE	0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	001	Sep 18, 2017
	+!		0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N209482	002	Sep 09, 2020

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

	+!	GLAXO GRP LTD	0.1MG/INH;EQ 0.025MG BASE/INH	N204275	001	May 10, 2013
	+!		0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015

FLUTICASONE PROPIONATE

AEROSOL, METERED;INHALATION

FLOVENT HFA

	+!	GLAXO GRP LTD	0.044MG/INH	N021433	003	May 14, 2004
	+!		0.11MG/INH	N021433	002	May 14, 2004
	+!		0.22MG/INH	N021433	001	May 14, 2004

CREAM;TOPICAL

FLUTICASONE PROPIONATE

AB		COSETTE	**0.05%**	**A077055**	**001**	Jun 30, 2006
AB		FOUGERA PHARMS	**0.05%**	**A076451**	**001**	May 14, 2004
AB	**!**	PADAGIS ISRAEL	**0.05%**	**A076793**	**001**	May 14, 2004

LOTION;TOPICAL

CUTIVATE

AB	**+!**	FOUGERA PHARMS	**0.05%**	**N021152**	**001**	Mar 31, 2005

FLUTICASONE PROPIONATE

AB		GLENMARK GENERICS	**0.05%**	**A090759**	**001**	May 02, 2011
AB		PADAGIS ISRAEL	**0.05%**	**A091553**	**001**	Jul 30, 2013

OINTMENT;TOPICAL

FLUTICASONE PROPIONATE

AB		COSETTE	**0.005%**	**A077168**	**001**	Mar 03, 2006
AB	**!**	PADAGIS ISRAEL	**0.005%**	**A076668**	**001**	May 14, 2004

POWDER;INHALATION

ARMONAIR DIGIHALER

	+	TEVA PHARM	0.055MG/INH	N208798	004	Feb 20, 2020
	+		0.113MG/INH	N208798	005	Feb 20, 2020
	+!		0.232MG/INH	N208798	006	Feb 20, 2020

FLOVENT DISKUS 100

	+!	GLAXO GRP LTD	0.1MG/INH	N020833	002	Sep 29, 2000

FLOVENT DISKUS 250

	+!	GLAXO GRP LTD	0.25MG/INH	N020833	003	Sep 29, 2000

FLOVENT DISKUS 50

	+!	GLAXO GRP LTD	0.05MG/INH	N020833	001	Sep 29, 2000

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

AB		AKORN	**0.05MG/SPRAY**	**A077570**	**001**	Jan 16, 2008
AB		APOTEX INC	**0.05MG/SPRAY**	**A077538**	**001**	Sep 12, 2007
AB	**!**	HIKMA	**0.05MG/SPRAY**	**A076504**	**001**	Feb 22, 2006
AB		WOCKHARDT BIO AG	**0.05MG/SPRAY**	**A078492**	**001**	Jan 09, 2012

XHANCE

	+!	OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED;INHALATION

ADVAIR HFA

	+!	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH	N021254	001	Jun 08, 2006
	+!		0.115MG/INH;EQ 0.021MG BASE/INH	N021254	002	Jun 08, 2006
	+!		0.23MG/INH;EQ 0.021MG BASE/INH	N021254	003	Jun 08, 2006

POWDER;INHALATION

ADVAIR DISKUS 100/50

AB	**+!**	GLAXO GRP LTD	**0.1MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**001**	Aug 24, 2000

ADVAIR DISKUS 250/50

AB	**+!**	GLAXO GRP LTD	**0.25MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**002**	Aug 24, 2000

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER;INHALATION

ADVAIR DISKUS 500/50

AB	**+!**	GLAXO GRP LTD	**0.5MG/INH;EQ 0.05MG BASE/INH**	**N021077**	**003**	Aug 24, 2000

FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

AB		HIKMA	**0.1MG/INH;EQ 0.05MG BASE/INH**	**A203433**	**001**	Dec 17, 2020
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**	**A203433**	**002**	Dec 17, 2020
AB		TEVA PHARMS USA	**0.1MG/INH;EQ 0.05MG BASE/INH**	**A213948**	**001**	Dec 13, 2021
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**	**A213948**	**002**	Dec 13, 2021
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**	**A213948**	**003**	Dec 13, 2021

WIXELA INHUB

AB		MYLAN	**0.1MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**001**	Jan 30, 2019
AB			**0.25MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**002**	Jan 30, 2019
AB			**0.5MG/INH;EQ 0.05MG BASE/INH**	**A208891**	**003**	Jan 30, 2019

AIRDUO DIGIHALER

	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	004	Jul 12, 2019
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	005	Jul 12, 2019
	+		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	006	Jul 12, 2019

AIRDUO RESPICLICK

	+	TEVA PHARM	0.055MG/INH;EQ 0.014MG BASE/INH	N208799	001	Jan 27, 2017
	+		0.113MG/INH;EQ 0.014MG BASE/INH	N208799	002	Jan 27, 2017
	+!		0.232MG/INH;EQ 0.014MG BASE/INH	N208799	003	Jan 27, 2017

FLUVASTATIN SODIUM

CAPSULE;ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090595**	**001**	Apr 11, 2012
AB	**!**		**EQ 40MG BASE**	**A090595**	**002**	Apr 11, 2012
AB		TEVA PHARMS	**EQ 20MG BASE**	**A078407**	**001**	Jun 12, 2012
AB			**EQ 40MG BASE**	**A078407**	**002**	Jun 12, 2012

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB		BEIJING	**EQ 80MG BASE**	**A209397**	**001**	Apr 26, 2021
AB		TEVA PHARMS USA	**EQ 80MG BASE**	**A079011**	**001**	Jan 27, 2016

LESCOL XL

AB	**+!**	NOVARTIS	**EQ 80MG BASE**	**N021192**	**001**	Oct 06, 2000

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

AB		ACTAVIS ELIZABETH	**100MG**	**A091482**	**001**	Apr 23, 2013
AB	**!**		**150MG**	**A091482**	**002**	Nov 18, 2013
AB		ANCHEN PHARMS	**100MG**	**A091476**	**001**	Mar 13, 2013
AB			**150MG**	**A091476**	**002**	Mar 13, 2013
AB		BIONPHARMA INC	**150MG**	**A212182**	**001**	May 11, 2020

TABLET;ORAL

FLUVOXAMINE MALEATE

AB		APOTEX	**25MG**	**A075902**	**001**	May 07, 2001
AB			**50MG**	**A075902**	**002**	May 07, 2001
AB			**100MG**	**A075902**	**003**	May 07, 2001
AB		UPSHER SMITH LABS	**25MG**	**A075888**	**001**	Nov 29, 2000
AB			**50MG**	**A075888**	**002**	Nov 29, 2000
AB	**!**		**100MG**	**A075888**	**003**	Nov 29, 2000

LUVOX

AB		ANI PHARMS	**25MG**	**N021519**	**001**	Dec 20, 2007
AB			**50MG**	**N021519**	**002**	Dec 20, 2007
AB			**100MG**	**N021519**	**003**	Dec 20, 2007

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

AP	**!**	FRESENIUS KABI USA	**5MG/ML**	**A089202**	**001**	Feb 18, 1986
AP		XGEN PHARMS	**5MG/ML**	**A202522**	**001**	Nov 06, 2019

TABLET;ORAL

FOLIC ACID

AA	**!**	AMNEAL PHARM	**1MG**	**A040625**	**001**	Jul 21, 2005
AA		ATHEM	**1MG**	**A211064**	**001**	Mar 08, 2019
AA		CADILA PHARMS LTD	**1MG**	**A202437**	**001**	Jan 27, 2014
AA		CHARTWELL MOLECULAR	**1MG**	**A090035**	**001**	Jun 09, 2009
AA		LEADING PHARMA LLC	**1MG**	**A040796**	**001**	Jan 12, 2009
AA		NUVO PHARMS INC	**1MG**	**A204418**	**001**	Jul 28, 2015
AA		QINGDAO BAHEAL PHARM	**1MG**	**A091145**	**001**	Jul 12, 2013
AA	**+!**	WATSON LABS	**1MG**	**A080680**	**001**	

FOMEPIZOLE

INJECTABLE;INJECTION

FOMEPIZOLE

AP		AM REGENT	**1.5GM/1.5ML (1GM/ML)**	**A078368**	**001**	Dec 14, 2007
AP	!	MYLAN INSTITUTIONAL	**1.5GM/1.5ML (1GM/ML)**	**A078639**	**001**	Mar 03, 2008
AP		NAVINTA LLC	**1.5GM/1.5ML (1GM/ML)**	**A078537**	**001**	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE;SUBCUTANEOUS

ARIXTRA

AP	**+!**	MYLAN IRELAND LTD	**2.5MG/0.5ML**	**N021345**	**001**	Dec 07, 2001
AP	**+!**		**5MG/0.4ML**	**N021345**	**002**	May 28, 2004
AP	**+!**		**7.5MG/0.6ML**	**N021345**	**003**	May 28, 2004
AP	**+!**		**10MG/0.8ML**	**N021345**	**004**	May 28, 2004

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	**2.5MG/0.5ML**	**A091316**	**001**	Jul 11, 2011
AP			**5MG/0.4ML**	**A091316**	**002**	Jul 11, 2011
AP			**7.5MG/0.6ML**	**A091316**	**003**	Jul 11, 2011
AP			**10MG/0.8ML**	**A091316**	**004**	Jul 11, 2011
AP		EUGIA PHARMA	**2.5MG/0.5ML**	**A206918**	**001**	Dec 26, 2017
AP			**5MG/0.4ML**	**A206918**	**002**	Dec 26, 2017
AP			**7.5MG/0.6ML**	**A206918**	**003**	Dec 26, 2017
AP			**10MG/0.8ML**	**A206918**	**004**	Dec 26, 2017
AP		JIANGSU PHARMS	**2.5MG/0.5ML**	**A206812**	**001**	May 15, 2018
AP			**5MG/0.4ML**	**A206812**	**002**	May 15, 2018
AP			**7.5MG/0.6ML**	**A206812**	**003**	May 15, 2018
AP			**10MG/0.8ML**	**A206812**	**004**	May 15, 2018
AP		SCINOPHARM TAIWAN	**2.5MG/0.5ML**	**A208615**	**001**	Nov 14, 2018
AP			**5MG/0.4ML**	**A208615**	**002**	Nov 14, 2018
AP			**7.5MG/0.6ML**	**A208615**	**003**	Nov 14, 2018
AP			**10MG/0.8ML**	**A208615**	**004**	Nov 14, 2018

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN		ALEMBIC PHARMS LTD	**0.02MG/2ML**	**A215078**	**001**	Nov 22, 2021
AN		TEVA PHARMS USA INC	**0.02MG/2ML**	**A091141**	**001**	Jun 22, 2021

PERFOROMIST

AN	**+!**	MYLAN SPECLT	**0.02MG/2ML**	**N022007**	**001**	May 11, 2007

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED;INHALATION

BEVESPI AEROSPHERE

	+!	ASTRAZENECA	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

DULERA

	+	ORGANON	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019
	+!		0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010
	+!		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION;ORAL

LEXIVA

	+!	VIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007

TABLET;ORAL

FOSAMPRENAVIR CALCIUM

AB		MYLAN	**EQ 700MG BASE**	**A204060**	**001**	Apr 15, 2016
AB		SUN PHARM	**EQ 700MG BASE**	**A204024**	**001**	Nov 20, 2019

LEXIVA

AB	**+!**	VIIV HLTHCARE	**EQ 700MG BASE**	**N021548**	**001**	Oct 20, 2003

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

EMEND

AP	**+!**	MERCK AND CO INC	**EQ 150MG BASE/VIAL**	**N022023**	**002**	Nov 12, 2010

FOSAPREPITANT DIMEGLUMINE

AP		ACCORD HLTHCARE	**EQ 150MG BASE/VIAL**	**A204025**	**001**	Aug 26, 2020
AP		APOTEX	**EQ 150MG BASE/VIAL**	**A205020**	**001**	Sep 05, 2019
AP		ASPIRO	**EQ 150MG BASE/VIAL**	**A214616**	**001**	Jul 29, 2021
AP		BAXTER HLTHCARE CORP	**EQ 150MG BASE/VIAL**	**A211860**	**001**	Sep 05, 2019
AP		BE PHARMS	**EQ 150MG BASE/VIAL**	**A212309**	**001**	Sep 05, 2019
AP		CHIA TAI TIANQING	**EQ 150MG BASE/VIAL**	**A212143**	**001**	Mar 03, 2021
AP		DR REDDYS	**EQ 150MG BASE/VIAL**	**A211160**	**001**	Dec 09, 2020

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP		EUGIA PHARMA	**EQ 150MG BASE/VIAL**	**A210625**	**001**	Jan 12, 2021
AP		FRESENIUS KABI USA	**EQ 150MG BASE/VIAL**	**A206197**	**001**	Jun 09, 2016
AP		LUPIN LTD	**EQ 150MG BASE/VIAL**	**A210689**	**001**	Sep 05, 2019
AP		MSN	**EQ 150MG BASE/VIAL**	**A209965**	**001**	Sep 05, 2019
AP		MYLAN LABS LTD	**EQ 150MG BASE/VIAL**	**A204015**	**002**	Sep 05, 2019
AP		NAVINTA LLC	**EQ 150MG BASE/VIAL**	**A212957**	**002**	Aug 20, 2020
AP		PRAXGEN	**EQ 150MG BASE/VIAL**	**A211624**	**001**	Sep 05, 2019
AP			**EQ 150MG BASE/VIAL**	**A213199**	**001**	Oct 04, 2021
AP		QILU PHARM HAINAN	**EQ 150MG BASE/VIAL**	**A213106**	**001**	Sep 08, 2020
AP		SANDOZ INC	**EQ 150MG BASE/VIAL**	**A203939**	**001**	Dec 08, 2020
		TEVA PHARMS USA	EQ 150MG BASE/VIAL	N210064	001	Sep 05, 2019

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

AP		FRESENIUS KABI USA	**2.4GM/100ML**	**A212483**	**001**	Jan 29, 2021
AP		GLAND PHARMA LTD	**2.4GM/100ML**	**A213001**	**001**	Apr 21, 2021

FOSCAVIR

AP	**+!**	CLINIGEN HLTHCARE	**2.4GM/100ML**	**N020068**	**001**	Sep 27, 1991

FOSDENOPTERIN HYDROBROMIDE

POWDER;INTRAVENOUS

NULIBRY

	+!	ORIGIN	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL

FOSFOMYCIN TROMETHAMINE

AA		ALKEM LABS LTD	**EQ 3GM BASE/PACKET**	**A214554**	**001**	Oct 21, 2021
AA		XIROMED	**EQ 3GM BASE/PACKET**	**A212548**	**001**	Oct 06, 2020

MONUROL

AA	**+!**	ZAMBON SPA	**EQ 3GM BASE/PACKET**	**N050717**	**001**	Dec 19, 1996

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

AB		APOTEX INC	**10MG**	**A076906**	**001**	May 17, 2005
AB			**20MG**	**A076906**	**002**	May 17, 2005
AB			**40MG**	**A076906**	**003**	May 17, 2005
AB		AUROBINDO PHARMA LTD	**10MG**	**A091163**	**001**	Mar 30, 2011
AB			**20MG**	**A091163**	**002**	Mar 30, 2011
AB			**40MG**	**A091163**	**003**	Mar 30, 2011
AB		CHARTWELL RX	**10MG**	**A076483**	**001**	Apr 23, 2004
AB			**20MG**	**A076483**	**002**	Apr 23, 2004
AB			**40MG**	**A076483**	**003**	Apr 23, 2004
AB		INVAGEN PHARMS	**10MG**	**A077222**	**001**	Apr 20, 2005
AB			**20MG**	**A077222**	**002**	Apr 20, 2005
AB			**40MG**	**A077222**	**003**	Apr 20, 2005
AB		PRINSTON INC	**10MG**	**A205670**	**001**	Aug 29, 2016
AB			**20MG**	**A205670**	**002**	Aug 29, 2016
AB			**40MG**	**A205670**	**003**	Aug 29, 2016
AB		TEVA	**10MG**	**A076139**	**001**	Nov 25, 2003
AB			**20MG**	**A076139**	**002**	Nov 25, 2003
AB	**!**		**40MG**	**A076139**	**003**	Nov 25, 2003

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**10MG;12.5MG**	**A079245**	**001**	Jul 09, 2009
AB	**!**		**20MG;12.5MG**	**A079245**	**002**	Jul 09, 2009
AB		INVAGEN PHARMS	**10MG;12.5MG**	**A090228**	**001**	Jul 09, 2009
AB			**20MG;12.5MG**	**A090228**	**002**	Jul 09, 2009
AB		SANDOZ	**10MG;12.5MG**	**A076961**	**001**	Sep 28, 2005
AB			**20MG;12.5MG**	**A076961**	**002**	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER;INTRAVENOUS

AKYNZEO

	+!	HELSINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

SOLUTION;INTRAVENOUS

AKYNZEO

	+!	HELSINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

AP	**+!**	PARKE DAVIS	**EQ 50MG PHENYTOIN NA/ML**	**N020450**	**001**	Aug 05, 1996

FOSPHENYTOIN SODIUM

AP		FRESENIUS KABI USA	**EQ 50MG PHENYTOIN NA/ML**	**A078052**	**001**	Aug 06, 2007
AP		HIKMA	**EQ 50MG PHENYTOIN NA/ML**	**A077481**	**001**	Aug 06, 2007
AP			**EQ 50MG PHENYTOIN NA/ML**	**A077989**	**001**	Aug 06, 2007
AP		HIKMA FARMACEUTICA	**EQ 50MG PHENYTOIN NA/ML**	**A078765**	**001**	Dec 02, 2009
AP		MYLAN LABS LTD	**EQ 50MG PHENYTOIN NA/ML**	**A078736**	**001**	Jun 08, 2010
AP		SUN PHARM	**EQ 50MG PHENYTOIN NA/ML**	**A078417**	**001**	Mar 18, 2008
AP		WOCKHARDT	**EQ 50MG PHENYTOIN NA/ML**	**A078137**	**001**	Aug 06, 2007

FOSTAMATINIB DISODIUM

TABLET;ORAL

TAVALISSE

	+	RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018
	+!		EQ 150MG BASE	N209299	002	Apr 17, 2018

FOSTEMSAVIR TROMETHAMINE

TABLET, EXTENDED RELEASE;ORAL

RUKOBIA

	+!	VIIV HLTHCARE	EQ 600MG BASE	N212950	001	Jul 02, 2020

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVA

AB	**+!**	ENDO PHARMS	**EQ 2.5MG BASE**	**N021006**	**001**	Nov 08, 2001

FROVATRIPTAN SUCCINATE

AB		AMNEAL PHARMS CO	**EQ 2.5MG BASE**	**A211292**	**001**	Nov 06, 2018
AB		GLENMARK PHARMS LTD	**EQ 2.5MG BASE**	**A204730**	**001**	Mar 11, 2016
AB		MYLAN	**EQ 2.5MG BASE**	**A202931**	**001**	Aug 28, 2014

FULVESTRANT

INJECTABLE;INTRAMUSCULAR

FASLODEX

AO	**+!**	ASTRAZENECA	**50MG/ML**	**N021344**	**001**	Apr 25, 2002

FULVESTRANT

AO		ACCORD HLTHCARE	**50MG/ML**	**A211689**	**001**	Nov 17, 2020
AO		AMNEAL	**50MG/ML**	**A210044**	**001**	Mar 04, 2019
AO		APOTEX	**50MG/ML**	**A211730**	**001**	Jun 11, 2021
AO		CHIA TAI TIANQING	**50MG/ML**	**A211422**	**001**	Feb 07, 2020
AO		DR REDDYS	**50MG/ML**	**A209246**	**001**	Aug 07, 2020
AO		EUGIA PHARMA	**50MG/ML**	**A208811**	**001**	Jul 23, 2019
AO		GLENMARK PHARMS INC	**50MG/ML**	**A207754**	**001**	Aug 22, 2019
AO		HBT LABS INC	**50MG/ML**	**A209714**	**001**	Nov 21, 2019
AO		SAGENT PHARMS INC	**50MG/ML**	**A205871**	**001**	Aug 22, 2019
AO		SANDOZ INC	**50MG/ML**	**A205935**	**001**	May 14, 2019
AO		XIROMED	**50MG/ML**	**A213553**	**001**	Aug 13, 2021

SOLUTION;INTRAMUSCULAR

FULVESTRANT

		FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019
		TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		ACCORD HLTHCARE	**10MG/ML**	**A070017**	**001**	Dec 15, 1986
AP		AREVA PHARMS	**10MG/ML**	**A208435**	**001**	Dec 18, 2020
AP		ATHENEX INC	**10MG/ML**	**A214766**	**001**	Jan 27, 2021
AP	**!**	BAXTER HLTHCARE CORP	**10MG/ML**	**A202747**	**001**	Jan 27, 2014
AP		EMCURE PHARMS LTD	**10MG/ML**	**A203428**	**001**	Aug 26, 2014
AP		EUGIA PHARMA	**10MG/ML**	**A212174**	**001**	May 03, 2019
AP		FRESENIUS KABI USA	**10MG/ML**	**N018902**	**001**	May 22, 1984
AP		GLAND PHARMA LTD	**10MG/ML**	**A213902**	**001**	Jul 01, 2020
AP		HOSPIRA	**10MG/ML**	**A075241**	**001**	May 28, 1999
AP			**10MG/ML**	**N018667**	**001**	May 28, 1982
AP		WOCKHARDT	**10MG/ML**	**A077941**	**001**	Mar 22, 2007

FUROSEMIDE

SOLUTION;ORAL

FUROSEMIDE

AA	**!**	HIKMA	**10MG/ML**	**A070434**	**001**	Apr 22, 1987
AA		WOCKHARDT BIO AG	**10MG/ML**	**A070655**	**001**	Oct 02, 1987
		HIKMA	40MG/5ML	A070433	001	Apr 22, 1987

TABLET;ORAL

FUROSEMIDE

AB		EPIC PHARMA LLC	**20MG**	**N018569**	**002**	
AB			**40MG**	**N018569**	**001**	
AB			**80MG**	**N018569**	**005**	Aug 14, 1984
AB		HIKMA	**20MG**	**N018823**	**001**	Nov 10, 1983
AB			**40MG**	**N018823**	**002**	Nov 10, 1983
AB			**80MG**	**A070086**	**001**	Jan 24, 1986
AB		IPCA LABS LTD	**20MG**	**A078010**	**001**	Sep 18, 2006
AB			**40MG**	**A078010**	**002**	Sep 18, 2006
AB			**80MG**	**A078010**	**003**	Sep 18, 2006
AB		LEADING PHARMA LLC	**20MG**	**A077293**	**001**	Nov 09, 2005
AB			**40MG**	**A077293**	**002**	Nov 09, 2005
AB			**80MG**	**A077293**	**003**	Nov 09, 2005
AB		MYLAN	**20MG**	**N018487**	**001**	
AB			**40MG**	**N018487**	**002**	
AB			**80MG**	**A070082**	**001**	Oct 29, 1986
AB		PRINSTON INC	**20MG**	**A076796**	**001**	Mar 26, 2004
AB			**40MG**	**A076796**	**002**	Mar 26, 2004
AB			**80MG**	**A076796**	**003**	Mar 26, 2004

LASIX

AB	**+**	VALIDUS PHARMS	**20MG**	**N016273**	**002**	
AB	**+**		**40MG**	**N016273**	**001**	
AB	**+!**		**80MG**	**N016273**	**003**	

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		ACI	**100MG**	**A206943**	**001**	May 14, 2018
AB			**300MG**	**A206943**	**002**	May 14, 2018
AB			**400MG**	**A206943**	**003**	May 14, 2018
AB		ACTAVIS ELIZABETH	**100MG**	**A075350**	**001**	Sep 12, 2003
AB			**300MG**	**A075350**	**002**	Sep 12, 2003
AB			**400MG**	**A075350**	**003**	Sep 12, 2003
AB		ALKEM	**100MG**	**A090858**	**001**	Dec 17, 2010
AB			**300MG**	**A090858**	**002**	Dec 17, 2010
AB			**400MG**	**A090858**	**003**	Dec 17, 2010
AB		AMNEAL PHARMS NY	**100MG**	**A078428**	**001**	Jul 25, 2007
AB			**300MG**	**A078428**	**002**	Jul 25, 2007
AB			**400MG**	**A078428**	**003**	Jul 25, 2007
AB		ASCENT PHARMS INC	**100MG**	**A214956**	**001**	May 10, 2021
AB			**300MG**	**A214956**	**002**	May 10, 2021
AB			**400MG**	**A214956**	**003**	May 10, 2021
AB		AUROBINDO PHARMA LTD	**100MG**	**A078787**	**001**	Jan 31, 2008
AB			**300MG**	**A078787**	**002**	Jan 31, 2008
AB			**400MG**	**A078787**	**003**	Jan 31, 2008
AB		CSPC OUYI	**100MG**	**A075477**	**001**	Mar 23, 2005
AB			**300MG**	**A075477**	**002**	Mar 23, 2005
AB			**400MG**	**A075477**	**003**	Mar 23, 2005
AB		GRANULES	**100MG**	**A075360**	**001**	Apr 06, 2005
AB			**300MG**	**A075360**	**002**	Apr 06, 2005
AB			**400MG**	**A075360**	**003**	Apr 06, 2005
AB		GRAVITI PHARMS	**100MG**	**A207099**	**001**	Mar 24, 2017
AB			**300MG**	**A207099**	**002**	Mar 24, 2017
AB			**400MG**	**A207099**	**003**	Mar 24, 2017
AB		INVAGEN PHARMS	**100MG**	**A090705**	**001**	Dec 30, 2009
AB			**300MG**	**A090705**	**002**	Dec 30, 2009
AB			**400MG**	**A090705**	**003**	Dec 30, 2009
AB		MARKSANS PHARMA	**100MG**	**A090007**	**001**	Jul 21, 2011
AB			**300MG**	**A090007**	**002**	Jul 21, 2011
AB			**400MG**	**A090007**	**003**	Jul 21, 2011
AB		SCIEGEN PHARMS INC	**100MG**	**A204989**	**001**	Feb 18, 2016
AB			**300MG**	**A204989**	**002**	Feb 18, 2016
AB			**400MG**	**A204989**	**003**	Feb 18, 2016
AB		STRIDES PHARMA	**100MG**	**A211314**	**001**	Oct 16, 2018
AB			**300MG**	**A211314**	**002**	Oct 16, 2018

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB			**400MG**	**A211314**	**003**	Oct 16, 2018
AB		SUN PHARM INDS LTD	**100MG**	**A077242**	**001**	Aug 24, 2006
AB			**300MG**	**A077242**	**002**	Aug 24, 2006
AB			**400MG**	**A077242**	**003**	Aug 24, 2006
AB		TARO	**100MG**	**A077261**	**001**	Aug 02, 2013
AB			**300MG**	**A077261**	**002**	Aug 02, 2013
AB			**400MG**	**A077261**	**003**	Aug 02, 2013
AB		ZHEJIANG YONGTAI	**100MG**	**A213603**	**001**	Aug 17, 2020
AB			**300MG**	**A213603**	**002**	Aug 17, 2020
AB			**400MG**	**A213603**	**003**	Aug 17, 2020

NEURONTIN

AB	**+**	UPJOHN	**100MG**	**N020235**	**001**	Dec 30, 1993
AB	**+**		**300MG**	**N020235**	**002**	Dec 30, 1993
AB	**+!**		**400MG**	**N020235**	**003**	Dec 30, 1993

SOLUTION;ORAL

GABAPENTIN

AA		ACELLA PHARMS LLC	**250MG/5ML**	**A076403**	**001**	May 01, 2012
AA		AKORN	**250MG/5ML**	**A078974**	**001**	Feb 18, 2011
AA		AMNEAL PHARMS	**250MG/5ML**	**A202024**	**001**	Mar 23, 2012
AA		TARO	**250MG/5ML**	**A076672**	**001**	Jul 03, 2013
AA		TRIS PHARMA INC	**250MG/5ML**	**A091286**	**001**	Mar 14, 2016

NEURONTIN

AA	**+!**	UPJOHN	**250MG/5ML**	**N021129**	**001**	Mar 02, 2000

TABLET;ORAL

GABAPENTIN

AB		ACI	**600MG**	**A203244**	**002**	Jul 12, 2013
AB			**800MG**	**A203244**	**001**	Jul 12, 2013
AB		ACTAVIS ELIZABETH	**600MG**	**A075694**	**001**	Oct 21, 2004
AB			**800MG**	**A075694**	**002**	Oct 21, 2004
AB		ALKEM LABS LTD	**600MG**	**A206402**	**001**	Dec 23, 2015
AB			**800MG**	**A206402**	**002**	Dec 23, 2015
AB		APOTEX INC	**100MG**	**A077894**	**001**	Oct 10, 2006
AB			**300MG**	**A077894**	**002**	Oct 10, 2006
AB			**400MG**	**A077894**	**003**	Oct 10, 2006
AB		ASCENT PHARMS INC	**600MG**	**A214957**	**001**	Oct 01, 2021
AB			**800MG**	**A214957**	**002**	Oct 01, 2021
AB		AUROBINDO PHARMA LTD	**600MG**	**A200651**	**001**	Oct 06, 2011
AB			**800MG**	**A200651**	**002**	Oct 06, 2011
AB		CSPC OUYI	**600MG**	**A207057**	**001**	Oct 26, 2017
AB			**800MG**	**A207057**	**002**	Oct 26, 2017
AB		GLENMARK PHARMS LTD	**600MG**	**A077662**	**001**	Aug 18, 2006
AB			**800MG**	**A077662**	**002**	Aug 18, 2006
AB		INVAGEN PHARMS	**600MG**	**A202764**	**001**	Oct 16, 2012
AB			**800MG**	**A202764**	**002**	Oct 16, 2012
AB		IVAX SUB TEVA PHARMS	**100MG**	**A076017**	**001**	Apr 28, 2004
AB			**300MG**	**A076017**	**002**	Apr 28, 2004
AB			**400MG**	**A076017**	**003**	Apr 28, 2004
AB		RUBICON	**600MG**	**A077661**	**004**	Sep 13, 2006
AB			**800MG**	**A077661**	**005**	Sep 13, 2006
AB		SCIEGEN PHARMS INC	**600MG**	**A205101**	**001**	Feb 04, 2016
AB			**800MG**	**A205101**	**002**	Feb 04, 2016
AB		SUN PHARM INDS LTD	**600MG**	**A077525**	**001**	Aug 24, 2006
AB			**800MG**	**A077525**	**002**	Aug 24, 2006
AB		ZYDUS PHARMS USA INC	**600MG**	**A078926**	**001**	Feb 11, 2011
AB			**800MG**	**A078926**	**002**	Feb 11, 2011

NEURONTIN

AB	**+**	UPJOHN	**600MG**	**N020882**	**001**	Oct 09, 1998
AB	**+!**		**800MG**	**N020882**	**002**	Oct 09, 1998

GRALISE

BX	+!	ALMATICA	300MG	N022544	001	Jan 28, 2011
BX	+!		600MG	N022544	002	Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

+	ARBOR PHARMS LLC	300MG	N022399	002	Dec 13, 2011
+!		600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE;INTRAVENOUS

MULTIHANCE

+!	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+!		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+!		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+!		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

+!	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+!		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION;INTRAVENOUS

GADAVIST

+!	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013
+!		4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
+!		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
+!		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
+!		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011
+!		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

+!	GE HEALTHCARE	287MG/ML	N020123	001	Jan 08, 1993
+!		28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

CLARISCAN

AP		GE HEALTHCARE	**7.538GM/20ML (376.9MG/ML)**	**A210016**	**003**	Nov 01, 2019
AP			**1.8845GM/5ML (376.9MG/ML)**	**A210016**	**005**	Nov 24, 2020
AP			**3.769GM/10ML (376.9MG/ML)**	**A210016**	**001**	Nov 01, 2019
AP			**5.6535GM/15ML (376.9MG/ML)**	**A210016**	**002**	Nov 01, 2019
AP			**37.69GM/100ML (376.9MG/ML)**	**A210016**	**004**	Aug 04, 2020

DOTAREM

AP	**+!**	GUERBET	**37.69GM/100ML (376.9MG/ML)**	**N204781**	**001**	Mar 20, 2013
AP	**+!**		**1.8845GM/5ML (376.9MG/ML)**	**N204781**	**005**	Mar 31, 2017
AP	**+!**		**3.769GM/10ML (376.9MG/ML)**	**N204781**	**002**	Mar 20, 2013
AP	**+!**		**5.6535GM/15ML (376.9MG/ML)**	**N204781**	**003**	Mar 20, 2013
AP	**+!**		**7.538GM/20ML (376.9MG/ML)**	**N204781**	**004**	Mar 20, 2013

GADOTERIDOL

INJECTABLE;INJECTION

PROHANCE

+!	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992

PROHANCE MULTIPACK

+!	BRACCO	279.3MG/ML	N021489	001	Oct 09, 2003

GADOXETATE DISODIUM

SOLUTION;INTRAVENOUS

EOVIST

+!	BAYER HLTHCARE	1.8143GM/10ML (181.43MG/ML)	N022090	001	Jul 03, 2008
+		2.72145GM/15ML (181.43MG/ML)	N022090	002	Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	**EQ 8MG BASE**	**A204895**	**001**	Aug 05, 2016
AB			**EQ 16MG BASE**	**A204895**	**002**	Aug 05, 2016
AB			**EQ 24MG BASE**	**A204895**	**003**	Aug 05, 2016
AB		BARR	**EQ 8MG BASE**	**A078189**	**001**	Sep 15, 2008
AB			**EQ 16MG BASE**	**A078189**	**002**	Sep 15, 2008
AB			**EQ 24MG BASE**	**A078189**	**003**	Sep 15, 2008
AB		SUN PHARM	**EQ 8MG BASE**	**A090178**	**001**	Feb 02, 2011
AB			**EQ 16MG BASE**	**A090178**	**002**	Feb 02, 2011
AB			**EQ 24MG BASE**	**A090178**	**003**	Feb 02, 2011
AB		WATSON LABS	**EQ 8MG BASE**	**A079028**	**001**	Dec 15, 2008
AB			**EQ 16MG BASE**	**A079028**	**002**	Dec 15, 2008

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

AB			**EQ 24MG BASE**	**A079028**	**003**	Dec 15, 2008

RAZADYNE ER

AB	**+!**	JANSSEN PHARMS	**EQ 8MG BASE**	**N021615**	**001**	Apr 01, 2005
AB	**+**		**EQ 16MG BASE**	**N021615**	**002**	Apr 01, 2005
AB	**+**		**EQ 24MG BASE**	**N021615**	**003**	Apr 01, 2005

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

	!	HIKMA	4MG/ML	A078185	001	Jan 30, 2009

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A090957**	**001**	Mar 29, 2011
AB			**EQ 8MG BASE**	**A090957**	**002**	Mar 29, 2011
AB			**EQ 12MG BASE**	**A090957**	**003**	Mar 29, 2011
AB		BARR	**EQ 4MG BASE**	**A077605**	**001**	Aug 28, 2008
AB			**EQ 8MG BASE**	**A077605**	**002**	Aug 28, 2008
AB			**EQ 12MG BASE**	**A077605**	**003**	Aug 28, 2008
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A077593**	**001**	Sep 11, 2008
AB			**EQ 8MG BASE**	**A077593**	**002**	Sep 11, 2008
AB			**EQ 12MG BASE**	**A077593**	**003**	Sep 11, 2008
AB		SANDOZ	**EQ 4MG BASE**	**A077589**	**001**	Jun 22, 2009
AB			**EQ 8MG BASE**	**A077589**	**002**	Jun 22, 2009
AB			**EQ 12MG BASE**	**A077589**	**003**	Jun 22, 2009
AB	**!**	YABAO PHARM	**EQ 4MG BASE**	**A077604**	**001**	Feb 06, 2009
AB			**EQ 8MG BASE**	**A077604**	**002**	Feb 06, 2009
AB			**EQ 12MG BASE**	**A077604**	**003**	Feb 06, 2009
AB		ZYDUS PHARMS USA INC	**EQ 4MG BASE**	**A078898**	**001**	Feb 17, 2011
AB			**EQ 8MG BASE**	**A078898**	**002**	Feb 17, 2011
AB			**EQ 12MG BASE**	**A078898**	**003**	Feb 17, 2011

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS		CURIUM	2mCi/ML	N018058	001
BS		LANTHEUS MEDCL	2mCi/ML	N017478	001

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

	+!	AAA USA INC	2.1-5.5mCi/ML	N208547	001	Jun 01, 2016

GALLIUM DOTATOC GA-68

SOLUTION;INTRAVENOUS

GALLIUM DOTATOC GA 68

	+!	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019

GALLIUM GA-68 GOZETOTIDE

POWDER;INTRAVENOUS

ILLUCCIX

	+!	TELIX	6.7mCi/ML	N214032	001	Dec 17, 2021

GALLIUM GA-68 PSMA-11

SOLUTION;INTRAVENOUS

GALLIUM GA 68 PSMA-11

	+!	UNIV CA LOS ANGELES	30ML (0.5-5mCi/mL)	N212642	001	Dec 01, 2020
	+!	UNIV OF CA SAN FRAN	20ML (0.5-5mCi/mL)	N212643	001	Dec 01, 2020

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

	+!	BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009

SOLUTION;INTRAVENOUS

GANZYK-RTU

	+!	EXELA PHARMA	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR SODIUM

AP		FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A090658**	**001**	Jun 21, 2010
AP		HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A204204**	**001**	Nov 08, 2018
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A076222**	**001**	Jul 16, 2003
AP		PAR STERILE	**EQ 500MG BASE/VIAL**	**A204950**	**001**	Dec 06, 2016

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

GANCICLOVIR SODIUM

		PRODUCTS				
AP	**!**	PHARMASCIENCE INC	**EQ 500MG BASE/VIAL**	**A207645**	**001**	Dec 08, 2017

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

AP	**+!**	ORGANON USA INC	**250MCG/0.5ML**	**N021057**	**001**	Jul 29, 1999
AP		SUN PHARM	**250MCG/0.5ML**	**A204246**	**001**	Nov 30, 2018

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT		AKORN	**0.5%**	**A203189**	**001**	Sep 03, 2014
AT		LUPIN LTD	**0.5%**	**A202653**	**001**	Aug 28, 2013
AT		SANDOZ INC	**0.5%**	**A204227**	**001**	Jul 11, 2016
AT		TORRENT	**0.5%**	**A213542**	**001**	Nov 03, 2021

ZYMAXID

AT	**+!**	ALLERGAN	**0.5%**	**N022548**	**001**	May 18, 2010

ZYMAR

	+!	ALLERGAN	0.3%	N021493	001	Mar 28, 2003

GEFITINIB

TABLET;ORAL

IRESSA

	+!	ASTRAZENECA	250MG	N206995	001	Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 200MG BASE/VIAL**	**A091594**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091594**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A091594**	**003**	Jul 25, 2011
AP		CIPLA	**EQ 200MG BASE/VIAL**	**A078759**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078759**	**002**	Jul 25, 2011
AP		DR REDDYS LABS LTD	**EQ 200MG BASE/VIAL**	**A091365**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A091365**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A202997**	**001**	May 07, 2013
AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A090799**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A090799**	**002**	Jul 25, 2011
AP			**EQ 2GM BASE/VIAL**	**A090242**	**003**	May 16, 2011
AP			**EQ 2GM BASE/VIAL**	**A090799**	**003**	May 16, 2011
AP		GLAND PHARMA LTD	**EQ 200MG BASE/VIAL**	**A204520**	**001**	Jan 05, 2016
AP			**EQ 1GM BASE/VIAL**	**A204520**	**002**	Jan 05, 2016
AP		HIKMA INTL PHARMS	**EQ 200MG BASE/VIAL**	**A206617**	**001**	Jun 25, 2021
AP			**EQ 1GM BASE/VIAL**	**A206617**	**002**	Jun 25, 2021
AP		HOSPIRA	**EQ 200MG BASE/VIAL**	**A078339**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078339**	**002**	Jul 25, 2011
AP	**+!**	HOSPIRA INC	**200MG/5.26ML (38MG/ML)**	**N200795**	**001**	Aug 04, 2011
AP	**+!**		**1GM/26.3ML (38MG/ML)**	**N200795**	**002**	Aug 04, 2011
AP	**!**		**EQ 2GM BASE/VIAL**	**A079183**	**001**	Nov 15, 2010
AP	**+!**		**2GM/52.6ML (38MG/ML)**	**N200795**	**003**	Aug 04, 2011
AP	**!**	JIANGSU HANSOH PHARM	**EQ 200MG BASE/VIAL**	**A202485**	**001**	May 07, 2013
AP	**!**		**EQ 1GM BASE/VIAL**	**A202485**	**002**	May 07, 2013
AP		MEITHEAL	**200MG/5.26ML (38MG/ML)**	**A212129**	**001**	Dec 11, 2020
AP			**1GM/26.3ML (38MG/ML)**	**A212129**	**002**	Dec 11, 2020
AP			**2GM/52.6ML (38MG/ML)**	**A212129**	**003**	Dec 11, 2020
AP		MYLAN LABS LTD	**200MG/5.26ML (38MG/ML)**	**A205242**	**001**	Dec 06, 2017
AP			**1GM/26.3ML (38MG/ML)**	**A205242**	**002**	Dec 06, 2017
AP			**2GM/52.6ML (38MG/ML)**	**A205242**	**003**	Dec 06, 2017
AP		SAGENT PHARMS INC	**200MG/5.26ML (38MG/ML)**	**A209077**	**001**	Jul 20, 2018
AP			**1GM/26.3ML (38MG/ML)**	**A209077**	**002**	Jul 20, 2018
AP			**2GM/52.6ML (38MG/ML)**	**A209077**	**003**	Jul 20, 2018
AP		SHILPA	**EQ 200MG BASE/VIAL**	**A207575**	**001**	Feb 22, 2019
AP			**200MG/5.26ML (38MG/ML)**	**A210991**	**001**	Oct 04, 2019
AP			**EQ 1GM BASE/VIAL**	**A207575**	**002**	Feb 22, 2019
AP			**1GM/26.3ML (38MG/ML)**	**A210991**	**002**	Oct 04, 2019
AP			**2GM/52.6ML (38MG/ML)**	**A210991**	**003**	Oct 04, 2019
AP		SUN PHARM	**EQ 200MG BASE/VIAL**	**A078433**	**001**	Jul 25, 2011
AP			**EQ 1GM BASE/VIAL**	**A078433**	**002**	Jul 25, 2011

GEMCITABINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

+!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017
+!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017
+!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017
+!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017

INFUGEM

+!	SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018
+!		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018
+!		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018
+!		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018
+!		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018
+!		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018
+!		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018
+!		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018
+!		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018
+!		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	APOTEX	**600MG**	**A075034**	**001**	Jul 20, 1998
AB	ASCENT PHARMS INC	**600MG**	**A214603**	**001**	Jan 13, 2021
AB	AUROBINDO PHARMA LTD	**600MG**	**A202726**	**001**	Sep 16, 2015
AB	CADILA	**600MG**	**A204189**	**001**	Aug 28, 2018
AB	CADILA PHARMS LTD	**600MG**	**A203266**	**001**	Jun 17, 2016
AB	CARIBE HOLDINGS	**600MG**	**A078012**	**001**	Mar 26, 2007
AB	CHARTWELL MOLECULES	**600MG**	**A074270**	**001**	Sep 27, 1993
AB	IMPAX PHARMS	**600MG**	**A078207**	**001**	Jun 01, 2007
AB	INVAGEN PHARMS	**600MG**	**A077836**	**001**	Jul 27, 2006
AB	NORTHSTAR HLTHCARE	**600MG**	**A079072**	**001**	Sep 13, 2010

LOPID

AB	**+!**	PFIZER PHARMS	**600MG**	**N018422**	**003**	Nov 20, 1986

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	**+!**	LG CHEM LTD	**EQ 320MG BASE**	**N021158**	**001**	Apr 04, 2003

GEMIFLOXACIN MESYLATE

AB		ORBION PHARMS	**EQ 320MG BASE**	**A090466**	**001**	Jun 15, 2015

GENTAMICIN SULFATE

CREAM;TOPICAL

GENTAMICIN SULFATE

AT		COSETTE	**EQ 0.1% BASE**	**A064056**	**001**	Apr 29, 1994
AT	**!**	PADAGIS US	**EQ 0.1% BASE**	**A062307**	**001**	

INJECTABLE;INJECTION

GENTAMICIN SULFATE

AP	**!**	FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A062366**	**002**	Feb 06, 1986
AP	**!**		**EQ 40MG BASE/ML**	**A062366**	**001**	Aug 04, 1983
AP		HOSPIRA	**EQ 10MG BASE/ML**	**A062420**	**001**	Aug 15, 1983
AP			**EQ 40MG BASE/ML**	**A062420**	**002**	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**EQ 1.2MG BASE/ML**	**A062373**	**007**	Sep 07, 1982
AP			**EQ 1.6MG BASE/ML**	**A062373**	**008**	Sep 07, 1982
AP			**EQ 80MG BASE/100ML**	**A062373**	**002**	Sep 07, 1982
AP			**EQ 100MG BASE/100ML**	**A062373**	**005**	Sep 07, 1982
AP		HOSPIRA	**EQ 1.2MG BASE/ML**	**A062414**	**001**	Aug 15, 1983
AP			**EQ 1.6MG BASE/ML**	**A062414**	**003**	Aug 15, 1983
AP			**EQ 80MG BASE/100ML**	**A062414**	**008**	Aug 15, 1983
AP			**EQ 100MG BASE/100ML**	**A062414**	**010**	Aug 15, 1983
	!	BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373	009	Sep 07, 1982
	!		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982

OINTMENT;OPHTHALMIC

GENTAMICIN SULFATE

AT	**!**	AKORN	**EQ 0.3% BASE**	**A064093**	**001**	Aug 31, 1995
AT		FERA PHARMS LLC	**EQ 0.3% BASE**	**A065024**	**001**	Jul 30, 2004

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT		COSETTE	**EQ 0.1% BASE**	**A064054**	**001**	Apr 29, 1994
AT		FOUGERA PHARMS INC	**EQ 0.1% BASE**	**A062533**	**001**	Oct 05, 1984
AT	**!**	PADAGIS US	**EQ 0.1% BASE**	**A062351**	**001**	Feb 18, 1982

GENTAMICIN SULFATE

OINTMENT;TOPICAL

GENTAMICIN SULFATE

AT		TARO	**EQ 0.1% BASE**	**A062477**	**001**	Dec 23, 1983
AT		TELIGENT	**EQ 0.1% BASE**	**A209233**	**001**	Dec 31, 2018

SOLUTION/DROPS;OPHTHALMIC

GENOPTIC

AT	**!**	ALLERGAN	**EQ 0.3% BASE**	**A062452**	**001**	Oct 10, 1984

GENTAK

AT		AKORN	**EQ 0.3% BASE**	**A064163**	**001**	Oct 12, 2001

GENTAMICIN SULFATE

AT		AKORN	**EQ 0.3% BASE**	**A062635**	**001**	Jan 08, 1987
AT		BAUSCH AND LOMB	**EQ 0.3% BASE**	**A064048**	**001**	May 11, 1994
AT		PADAGIS US	**EQ 0.3% BASE**	**A065121**	**001**	Jan 30, 2004
AT		SANDOZ INC	**EQ 0.3% BASE**	**A062196**	**001**	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

	+!	ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

	+!	ALLERGAN	EQ 0.3% BASE;1%	N050586	001	Jun 10, 1988

GILTERITINIB FUMARATE

TABLET;ORAL

XOSPATA

	+!	ASTELLAS	EQ 40MG BASE	N211349	001	Nov 28, 2018

GIVOSIRAN SODIUM

SOLUTION;SUBCUTANEOUS

GIVLAARI

	+!	ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194	001	Nov 20, 2019

GLASDEGIB MALEATE

TABLET;ORAL

DAURISMO

	+	PFIZER	EQ 25MG BASE	N210656	001	Nov 21, 2018
	+!		EQ 100MG BASE	N210656	002	Nov 21, 2018

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	**+!**	TEVA PHARMS USA	**20MG/ML**	**N020622**	**002**	Feb 12, 2002
AP	**+!**		**40MG/ML**	**N020622**	**003**	Jan 28, 2014

GLATIRAMER ACETATE

AP		MYLAN	**20MG/ML**	**A091646**	**001**	Oct 03, 2017
AP			**40MG/ML**	**A206936**	**001**	Oct 03, 2017

GLATOPA

AP		SANDOZ INC	**20MG/ML**	**A090218**	**001**	Apr 16, 2015
AP			**40MG/ML**	**A206921**	**001**	Feb 12, 2018

GLECAPREVIR; PIBRENTASVIR

PELLETS;ORAL

MAVYRET

	+!	ABBVIE INC	50MG;20MG/PACKET	N215110	001	Jun 10, 2021

TABLET;ORAL

MAVYRET

	+!	ABBVIE INC	100MG;40MG	N209394	001	Aug 03, 2017

GLIMEPIRIDE

TABLET;ORAL

AMARYL

AB	**+!**	SANOFI AVENTIS US	**1MG**	**N020496**	**001**	Nov 30, 1995
AB	**+**		**2MG**	**N020496**	**002**	Nov 30, 1995
AB	**+**		**4MG**	**N020496**	**003**	Nov 30, 1995

GLIMEPIRIDE

AB		ACCORD HLTHCARE	**1MG**	**A078181**	**001**	Aug 23, 2007
AB			**2MG**	**A078181**	**002**	Aug 23, 2007
AB			**4MG**	**A078181**	**003**	Aug 23, 2007
AB		AUROBINDO PHARMA LTD	**1MG**	**A202759**	**001**	Jun 29, 2012
AB			**2MG**	**A202759**	**002**	Jun 29, 2012
AB			**4MG**	**A202759**	**003**	Jun 29, 2012
AB		CARLSBAD	**1MG**	**A077911**	**001**	Sep 22, 2009
AB			**2MG**	**A077911**	**002**	Sep 22, 2009

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

AB			**4MG**	**A077911**	**003**	Sep 22, 2009
AB		DR REDDYS LABS LTD	**1MG**	**A077091**	**001**	Oct 06, 2005
AB			**2MG**	**A077091**	**002**	Oct 06, 2005
AB			**4MG**	**A077091**	**003**	Oct 06, 2005
AB		INDOCO REMEDIES	**1MG**	**A202112**	**001**	Apr 17, 2013
AB			**2MG**	**A202112**	**002**	Apr 17, 2013
AB			**4MG**	**A202112**	**003**	Apr 17, 2013
AB		INVAGEN PHARMS	**1MG**	**A077295**	**001**	Oct 06, 2005
AB			**2MG**	**A077295**	**002**	Oct 06, 2005
AB			**4MG**	**A077295**	**003**	Oct 06, 2005
AB		MICRO LABS	**1MG**	**A091220**	**001**	Jun 29, 2012
AB			**2MG**	**A091220**	**002**	Jun 29, 2012
AB			**4MG**	**A091220**	**004**	Jun 29, 2012
AB			**8MG**	**A091220**	**006**	Jun 29, 2012
AB		PRINSTON INC	**1MG**	**A077370**	**001**	Dec 23, 2005
AB			**2MG**	**A077370**	**002**	Dec 23, 2005
AB			**4MG**	**A077370**	**003**	Dec 23, 2005
AB			**8MG**	**A077370**	**004**	Dec 23, 2005
		MICRO LABS	3MG	A091220	003	Jun 29, 2012
			6MG	A091220	005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACT

AB	**+!**	TAKEDA PHARMS USA	**2MG;30MG**	**N021925**	**001**	Jul 28, 2006
AB	**+**		**4MG;30MG**	**N021925**	**002**	Jul 28, 2006

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

AB		SANDOZ	**2MG;30MG**	**A201049**	**001**	Jan 04, 2013
AB			**4MG;30MG**	**A201049**	**002**	Jan 04, 2013

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

AB		ACCORD HLTHCARE	**5MG**	**A074550**	**001**	Sep 11, 1997
AB			**10MG**	**A074550**	**002**	Sep 11, 1997
AB		ANI PHARMS	**5MG**	**A074497**	**001**	Aug 31, 1995
AB			**10MG**	**A074497**	**002**	Aug 31, 1995
AB		APOTEX	**5MG**	**A075795**	**001**	Jun 13, 2001
AB			**10MG**	**A075795**	**002**	Jun 13, 2001
AB		MYLAN	**5MG**	**A074226**	**001**	May 10, 1994
AB			**10MG**	**A074226**	**002**	May 10, 1994
AB		SANDOZ	**5MG**	**A074305**	**001**	Apr 07, 1995
AB			**10MG**	**A074305**	**002**	Apr 07, 1995
AB		SUN PHARM INDS INC	**5MG**	**A077820**	**001**	Jul 11, 2006
AB			**10MG**	**A077820**	**002**	Jul 11, 2006
AB		WATSON LABS TEVA	**5MG**	**A074223**	**001**	Feb 27, 1995
AB			**10MG**	**A074223**	**002**	Feb 27, 1995

GLUCOTROL

AB	**+**	PFIZER	**5MG**	**N017783**	**001**	May 08, 1984
AB	**+!**		**10MG**	**N017783**	**002**	May 08, 1984

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB		AUROBINDO PHARMA LTD	**2.5MG**	**A206928**	**001**	May 12, 2017
AB			**5MG**	**A206928**	**002**	May 12, 2017
AB			**10MG**	**A206928**	**003**	May 12, 2017
AB		UNIQUE PHARM LABS	**2.5MG**	**A204720**	**001**	Dec 29, 2016
AB			**5MG**	**A204720**	**002**	Dec 29, 2016
AB			**10MG**	**A204720**	**003**	Dec 29, 2016
AB		WATSON LABS	**2.5MG**	**A076467**	**003**	Mar 27, 2006
AB			**5MG**	**A076467**	**001**	Sep 08, 2003
AB			**10MG**	**A076467**	**002**	Nov 07, 2003
AB		ZYDUS PHARMS	**2.5MG**	**A203499**	**001**	Jul 16, 2018
AB			**5MG**	**A203499**	**002**	Jul 16, 2018
AB			**10MG**	**A203499**	**003**	Jul 16, 2018

GLUCOTROL XL

AB	**+**	PFIZER	**2.5MG**	**N020329**	**003**	Aug 10, 1999
AB	**+**		**5MG**	**N020329**	**001**	Apr 26, 1994
AB	**+!**		**10MG**	**N020329**	**002**	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB		EPIC PHARMA LLC	**2.5MG;250MG**	**A077507**	**001**	Oct 27, 2005
AB			**2.5MG;500MG**	**A077507**	**002**	Oct 27, 2005
AB			**5MG;500MG**	**A077507**	**003**	Oct 27, 2005
AB		HERITAGE PHARMS INC	**2.5MG;250MG**	**A078728**	**001**	Jun 23, 2010
AB			**2.5MG;500MG**	**A078728**	**002**	Jun 23, 2010
AB			**5MG;500MG**	**A078728**	**003**	Jun 23, 2010
AB		TEVA PHARMS	**2.5MG;250MG**	**A077270**	**001**	Oct 28, 2005
AB			**2.5MG;500MG**	**A077270**	**002**	Oct 28, 2005
AB	**!**		**5MG;500MG**	**A077270**	**003**	Oct 28, 2005
AB		ZYDUS PHARMS USA INC	**2.5MG;250MG**	**A078905**	**001**	Jan 31, 2011
AB			**2.5MG;500MG**	**A078905**	**002**	Jan 31, 2011
AB			**5MG;500MG**	**A078905**	**003**	Jan 31, 2011

GLUCAGON

INJECTABLE;INJECTION

GLUCAGON

AP		AMPHASTAR PHARMS INC	**1MG/VIAL**	**A208086**	**001**	Dec 28, 2020
AP	**+!**	LILLY	**1MG/VIAL**	**N020928**	**001**	Sep 11, 1998

POWDER;NASAL

BAQSIMI

	+!	ELI LILLY AND CO	3MG	N210134	001	Jul 24, 2019

SOLUTION;SUBCUTANEOUS

GVOKE HYPOPEN

	+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	003	Sep 10, 2019
	+!		1MG/0.2ML (1MG/0.2ML)	N212097	004	Sep 10, 2019

GVOKE PFS

	+!	XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019
	+!		1MG/0.2ML (1MG/0.2ML)	N212097	002	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGEN

	+!	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

	+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015

GLYBURIDE

TABLET;ORAL

GLYBURIDE (MICRONIZED)

AB		HIKMA	**1.5MG**	**A075890**	**001**	Jul 31, 2003
AB			**3MG**	**A075890**	**002**	Jul 31, 2003
AB			**6MG**	**A075890**	**003**	Jul 31, 2003
AB		TEVA	**1.5MG**	**A074686**	**001**	Apr 20, 1999
AB			**3MG**	**A074686**	**002**	Apr 20, 1999
AB			**6MG**	**A074686**	**004**	Apr 20, 1999

GLYNASE

AB	**+**	PFIZER	**1.5MG**	**N020051**	**001**	Mar 04, 1992
AB	**+**		**3MG**	**N020051**	**002**	Mar 04, 1992
AB	**+!**		**6MG**	**N020051**	**004**	Sep 24, 1993

GLYBURIDE

AB1		CADILA PHARMS LTD	**1.25MG**	**A203379**	**001**	Jan 04, 2019
AB1			**2.5MG**	**A203379**	**002**	Jan 04, 2019
AB1			**5MG**	**A203379**	**003**	Jan 04, 2019
AB1		EPIC PHARMA LLC	**1.25MG**	**A076257**	**001**	Jun 27, 2002
AB1			**2.5MG**	**A076257**	**002**	Jun 27, 2002
AB1			**5MG**	**A076257**	**003**	Jun 27, 2002
AB1		HERITAGE PHARMS INC	**1.25MG**	**A090937**	**001**	Feb 28, 2011
AB1			**2.5MG**	**A090937**	**002**	Feb 28, 2011
AB1			**5MG**	**A090937**	**003**	Feb 28, 2011
AB1		ORIENT PHARMA CO LTD	**1.25MG**	**A206483**	**001**	Feb 22, 2019
AB1			**2.5MG**	**A206483**	**002**	Feb 22, 2019
AB1			**5MG**	**A206483**	**003**	Feb 22, 2019
AB1		SUNNY	**1.25MG**	**A203581**	**001**	Apr 14, 2016
AB1			**2.5MG**	**A203581**	**002**	Apr 14, 2016
AB1			**5MG**	**A203581**	**003**	Apr 14, 2016
AB1		TEVA	**1.25MG**	**A074388**	**001**	Aug 29, 1995
AB1			**2.5MG**	**A074388**	**002**	Aug 29, 1995

GLYBURIDE

TABLET;ORAL

GLYBURIDE

AB1	**!**		**5MG**	**A074388**	**003**	Aug 29, 1995
AB1		ZYDUS PHARMS	**1.25mg**	**A206749**	**001**	May 10, 2016
AB1			**2.5mg**	**A206749**	**002**	May 10, 2016
AB1			**5MG**	**A206749**	**003**	May 10, 2016

DIABETA

AB2	**+**	SANOFI AVENTIS US	**1.25MG**	**N017532**	**001**	May 01, 1984
AB2	**+**		**2.5MG**	**N017532**	**002**	May 01, 1984
AB2	**+!**		**5MG**	**N017532**	**003**	May 01, 1984

GLYBURIDE

AB2		IMPAX LABS INC	**1.25MG**	**A206079**	**001**	Sep 30, 2015
AB2			**2.5MG**	**A206079**	**002**	Sep 30, 2015
AB2			**5MG**	**A206079**	**003**	Sep 30, 2015

GLYBURIDE (MICRONIZED)

		TEVA	4.5MG	A074686	003	Apr 20, 1999

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**1.25MG;250MG**	**A076716**	**001**	Jun 28, 2005
AB			**2.5MG;500MG**	**A076716**	**002**	Jun 28, 2005
AB			**5MG;500MG**	**A076716**	**003**	Jun 28, 2005
AB		AUROBINDO PHARMA	**1.25MG;250MG**	**A077870**	**001**	Nov 14, 2007
AB	**!**		**2.5MG;500MG**	**A077870**	**002**	Nov 14, 2007
AB			**5MG;500MG**	**A077870**	**003**	Nov 14, 2007
AB		IMPAX LABS INC	**1.25MG;250MG**	**A076345**	**001**	Feb 18, 2004
AB			**2.5MG;500MG**	**A076345**	**002**	Feb 18, 2004
AB			**5MG;500MG**	**A076345**	**003**	Feb 18, 2004
AB		ZYDUS PHARMS	**1.25MG;250MG**	**A206748**	**001**	Feb 29, 2016
AB			**2.5MG;500MG**	**A206748**	**002**	Feb 29, 2016
AB			**5MG;500MG**	**A206748**	**003**	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

	+!	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013

GLYCINE

SOLUTION;IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	**+!**	BAXTER HLTHCARE	**1.5GM/100ML**	**N017865**	**001**

GLYCINE 1.5% IN PLASTIC CONTAINER

AT		B BRAUN	**1.5GM/100ML**	**N016784**	**001**
AT		ICU MEDICAL INC	**1.5GM/100ML**	**N018315**	**001**

GLYCOPYRROLATE

INJECTABLE;INJECTION

GLYCOPYRROLATE

AP		ACCORD HLTHCARE	**0.2MG/ML**	**A213238**	**001**	Jul 08, 2020
AP		AM REGENT	**0.2MG/ML**	**A089335**	**001**	Jul 23, 1986
AP		AMNEAL	**0.2MG/ML**	**A208973**	**001**	Jun 15, 2017
AP		APOTEX	**0.2MG/ML**	**A210246**	**001**	Oct 29, 2019
AP		ATHENEX INC	**0.2MG/ML**	**A210083**	**001**	Feb 21, 2020
AP		CAPLIN	**0.2MG/ML**	**A211705**	**001**	Mar 20, 2019
AP		EUGIA PHARMA	**0.2MG/ML**	**A210244**	**001**	Nov 28, 2018
AP		FRESENIUS KABI USA	**0.2MG/ML**	**A209024**	**001**	Oct 31, 2018
AP			**0.2MG/ML**	**A209328**	**001**	Oct 27, 2017
AP		GLAND PHARMA LTD	**0.2MG/ML**	**A212612**	**001**	Sep 30, 2019
AP	**!**	HIKMA FARMACEUTICA	**0.2MG/ML**	**A090963**	**001**	Sep 21, 2011
AP		MEITHEAL	**0.2MG/ML**	**A212802**	**001**	Jul 06, 2021
AP		NIVAGEN PHARMS INC	**0.2MG/ML**	**A212591**	**001**	Oct 13, 2021
AP		PIRAMAL CRITICAL	**0.2MG/ML**	**A210842**	**001**	Oct 25, 2018
AP		PRINSTON INC	**0.2MG/ML**	**A210927**	**001**	Oct 31, 2018
AP		SANDOZ INC	**0.2MG/ML**	**A211334**	**001**	May 14, 2019
AP		SOMERSET THERAPS LLC	**0.2MG/ML**	**A207639**	**001**	Jun 23, 2017
AP		XIROMED	**0.2MG/ML**	**A212227**	**001**	Mar 04, 2021
AP		ZYDUS PHARMS	**0.2MG/ML**	**A214213**	**001**	Nov 09, 2021

SOLUTION;INHALATION

LONHALA MAGNAIR KIT

	+!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017

GLYCOPYRROLATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

GLYRX-PF

	+!	EXELA PHARMA	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018
	+!		0.4MG/2ML (0.2MG/ML)	N210997	002	Jul 11, 2018
	+!		0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020
	+!		1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020

SOLUTION;ORAL

CUVPOSA

AA	**+!**	MERZ PHARMS	**1MG/5ML**	**N022571**	**001**	Jul 28, 2010

GLYCOPYRROLATE

AA		PAR PHARM INC	**1MG/5ML**	**A204438**	**001**	Aug 09, 2021

TABLET;ORAL

GLYCOPYRROLATE

AA		ALEMBIC LABS	**1MG**	**A203657**	**001**	Nov 30, 2018
AA			**2MG**	**A203657**	**002**	Nov 30, 2018
AA		AUROLIFE PHARMA LLC	**1MG**	**A202675**	**001**	Apr 15, 2013
AA			**2MG**	**A202675**	**002**	Oct 30, 2018
AA		DR REDDYS LABS LTD	**1MG**	**A040847**	**001**	Mar 21, 2008
AA			**2MG**	**A040847**	**002**	Mar 21, 2008
AA		HERITAGE PHARMS INC	**1MG**	**A207201**	**001**	Jan 03, 2017
AA			**2MG**	**A207201**	**002**	Jan 03, 2017
AA		KENTON	**1MG**	**A091182**	**001**	Feb 03, 2014
AA			**2MG**	**A091182**	**002**	Feb 03, 2014
AA		LEADING PHARMA LLC	**1MG**	**A090195**	**001**	Sep 21, 2012
AA			**2MG**	**A090195**	**002**	Sep 21, 2012
AA		NATCO	**1MG**	**A091413**	**001**	Jun 20, 2016
AA			**2MG**	**A091413**	**002**	Jun 20, 2016
AA		OXFORD PHARMS	**1MG**	**A090020**	**001**	Oct 19, 2011
AA			**2MG**	**A090020**	**002**	Oct 19, 2011
AA	**!**	PAR PHARM	**1MG**	**A040653**	**001**	Aug 31, 2006
AA	**!**		**2MG**	**A040653**	**002**	Aug 31, 2006
AA		RISING	**1MG**	**A040821**	**001**	Dec 29, 2008
AA			**2MG**	**A040821**	**002**	Dec 29, 2008
AA		SUN PHARM INDS LTD	**1MG**	**A040844**	**001**	Aug 18, 2009
AA			**2MG**	**A040844**	**002**	Aug 18, 2009

ROBINUL

AA	**+**	CASPER PHARMA LLC	**1MG**	**N012827**	**001**	

ROBINUL FORTE

AA	**+**	CASPER PHARMA LLC	**2MG**	**N012827**	**002**	

GLYCOPYRROLATE

		LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

DARTISLA ODT

	+!	EDENBRIDGE PHARMS	1.7MG	N215019	001	Dec 16, 2021

GLYCOPYRRONIUM TOSYLATE

CLOTH;TOPICAL

QBREXZA

	+!	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018

GOLODIRSEN

SOLUTION;INTRAVENOUS

VYONDYS 53

	+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N211970	001	Dec 12, 2019

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

	+!	TERSERA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
	+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT		AMRING PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A065187**	**001**	Oct 28, 2005
AT	**!**	BAUSCH AND LOMB	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A064047**	**001**	Jan 31, 1996

NEOSPORIN

AT	**!**	MONARCH PHARMS	**0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML**	**A060582**	**001**	

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

	+!	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008

INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

SUSTOL

	+!	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP		AKORN	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A079119**	**001**	Sep 10, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A079078**	**001**	Sep 14, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A079078**	**002**	Sep 14, 2009
AP		BIONPHARMA INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078863**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078880**	**001**	Jun 30, 2008
AP	**!**	DR REDDYS	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078392**	**001**	Dec 31, 2007
AP	**!**		**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077297**	**001**	Jun 30, 2008
AP		EUGIA PHARMA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A204238**	**001**	Jul 06, 2016
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204238**	**002**	Jul 06, 2016
AP		FRESENIUS KABI USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078522**	**001**	Dec 31, 2007
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078090**	**001**	Jun 30, 2008
AP		HIKMA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A077913**	**001**	Jun 26, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077186**	**001**	Jun 30, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A077187**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A077177**	**001**	Dec 31, 2007
AP		HIKMA FARMACEUTICA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078629**	**001**	Dec 23, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078629**	**002**	Dec 23, 2009
AP		MYLAN ASI	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A091136**	**001**	Apr 09, 2010
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A091136**	**002**	Apr 09, 2010
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A091137**	**002**	Apr 09, 2010
AP		PUNISKA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078262**	**001**	Dec 31, 2007
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078258**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078258**	**002**	Jun 30, 2008
AP		SANDOZ INC	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078534**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078531**	**001**	Apr 30, 2009
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078835**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078531**	**002**	Apr 30, 2009
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078835**	**002**	Jun 30, 2008
AP		WOCKHARDT USA	**EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)**	**A078566**	**001**	Feb 29, 2008
AP			**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078564**	**001**	Jun 30, 2008
AP			**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A078565**	**001**	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		BIONPHARMA INC	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078863**	**002**	Jun 30, 2008
AP	**!**	FRESENIUS KABI USA	**EQ 1MG BASE/ML (EQ 1MG BASE/ML)**	**A078096**	**001**	Jun 30, 2008

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

AB		APOTEX INC	**EQ 1MG BASE**	**A078843**	**001**	Feb 27, 2008
AB		CHARTWELL MOLECULAR	**EQ 1MG BASE**	**A078037**	**001**	Feb 27, 2008
AB		DR REDDYS LABS LTD	**EQ 1MG BASE**	**A078846**	**001**	Feb 27, 2009
AB	**!**	HIKMA	**EQ 1MG BASE**	**A077842**	**001**	Dec 31, 2007
AB		NATCO PHARMA	**EQ 1MG BASE**	**A078969**	**001**	Jun 22, 2009
AB		ORBION PHARMS	**EQ 1MG BASE**	**A078678**	**001**	Feb 13, 2008
AB		TARO	**EQ 1MG BASE**	**A090817**	**001**	May 28, 2010

GRISEOFULVIN, MICROCRYSTALLINE

TABLET;ORAL

FULVICIN-U/F

AB	CHARTWELL RX	**250MG**	**A060569**	**002**	
AB		**500MG**	**A060569**	**001**	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

AB	**!**	ACTAVIS MID ATLANTIC	**125MG/5ML**	**A065394**	**001**	Jul 06, 2007
AB		CHARTWELL RX	**125MG/5ML**	**A065200**	**001**	Mar 02, 2005
AB		CIPLA	**125MG/5ML**	**A065354**	**001**	Sep 10, 2007
AB		COSETTE	**125MG/5ML**	**A065438**	**001**	Oct 08, 2010

TABLET;ORAL

GRISEOFULVIN

AB	**!**	SANDOZ INC	**500MG**	**A091592**	**002**	Aug 07, 2013
AB		SIGMAPHARM LABS LLC	**500MG**	**A202482**	**001**	Oct 22, 2012
		SANDOZ INC	250MG	A091592	001	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

AB		CHARTWELL RX	**125MG**	**A061996**	**001**	
AB			**250MG**	**A061996**	**002**	

FULVICIN P/G 165

AB		CHARTWELL RX	**165MG**	**A061996**	**003**	Apr 06, 1982

FULVICIN P/G 330

AB		CHARTWELL RX	**330MG**	**A061996**	**004**	Apr 06, 1982

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

GRIS-PEG

AB	+	BAUSCH	**125MG**	**N050475**	**001**	
AB	+		**250MG**	**N050475**	**002**	

GRISEOFULVIN, ULTRAMICROSIZE

AB		MOUNTAIN	**125MG**	**A204371**	**001**	Jan 09, 2014
AB	!		**250MG**	**A204371**	**002**	Jan 09, 2014
AB		SANDOZ INC	**125MG**	**A202805**	**001**	Dec 26, 2018
AB			**250MG**	**A202805**	**002**	Dec 26, 2018

GRISEOFULVIN,ULTRAMICROSIZE

AB		SIGMAPHARM LABS LLC	**125MG**	**A202545**	**001**	Oct 22, 2012
AB			**250MG**	**A202545**	**002**	Oct 22, 2012

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB		AMNEAL PHARM	**EQ 1MG BASE**	**A075109**	**001**	Nov 25, 1998
AB	!		**EQ 2MG BASE**	**A075109**	**002**	Nov 25, 1998
AB		EPIC PHARMA LLC	**EQ 1MG BASE**	**A074673**	**001**	Feb 28, 1997
AB			**EQ 2MG BASE**	**A074673**	**002**	Feb 28, 1997
AB		UNICHEM	**EQ 1MG BASE**	**A214689**	**001**	Mar 03, 2021
AB			**EQ 2MG BASE**	**A214689**	**002**	Mar 03, 2021
AB		WATSON LABS	**EQ 1MG BASE**	**A074145**	**001**	Oct 17, 1995
AB			**EQ 2MG BASE**	**A074145**	**002**	Oct 17, 1995

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 1MG BASE**	**A200881**	**001**	Oct 05, 2012
AB			**EQ 2MG BASE**	**A200881**	**002**	Oct 05, 2012
AB			**EQ 3MG BASE**	**A200881**	**003**	Oct 05, 2012
AB			**EQ 4MG BASE**	**A200881**	**004**	Oct 05, 2012
AB		APOTEX	**EQ 1MG BASE**	**A205430**	**001**	Jul 25, 2018
AB			**EQ 2MG BASE**	**A205430**	**002**	Jul 25, 2018
AB			**EQ 3MG BASE**	**A205430**	**003**	Jul 25, 2018
AB			**EQ 4MG BASE**	**A205430**	**004**	Jul 25, 2018
AB		SANDOZ INC	**EQ 1MG BASE**	**A202568**	**001**	Jun 03, 2015
AB			**EQ 2MG BASE**	**A202568**	**002**	Jun 03, 2015
AB			**EQ 3MG BASE**	**A202568**	**003**	Jun 03, 2015
AB			**EQ 4MG BASE**	**A202568**	**004**	Jun 03, 2015
AB		SUN PHARM	**EQ 1MG BASE**	**A205689**	**001**	Nov 16, 2017
AB			**EQ 2MG BASE**	**A205689**	**002**	Nov 16, 2017
AB			**EQ 3MG BASE**	**A205689**	**003**	Nov 16, 2017
AB			**EQ 4MG BASE**	**A205689**	**004**	Nov 16, 2017
AB		TEVA PHARMS USA	**EQ 1MG BASE**	**A201382**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201382**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201382**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201382**	**004**	Jun 02, 2015
AB		TWI PHARMS	**EQ 1MG BASE**	**A201408**	**001**	Jun 02, 2015
AB			**EQ 2MG BASE**	**A201408**	**002**	Jun 02, 2015
AB			**EQ 3MG BASE**	**A201408**	**003**	Jun 02, 2015
AB			**EQ 4MG BASE**	**A201408**	**004**	Jun 02, 2015

INTUNIV

AB	+	TAKEDA PHARMS USA	**EQ 1MG BASE**	**N022037**	**001**	Sep 02, 2009
AB	+		**EQ 2MG BASE**	**N022037**	**002**	Sep 02, 2009
AB	+		**EQ 3MG BASE**	**N022037**	**003**	Sep 02, 2009
AB	+!		**EQ 4MG BASE**	**N022037**	**004**	Sep 02, 2009

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

AB		GLASSHOUSE PHARMS	**0.1%**	**A214723**	**001**	Sep 08, 2021
AB		MYLAN	**0.1%**	**A211027**	**001**	Aug 12, 2019

HALCINONIDE							
CREAM;TOPICAL							
HALOG							
AB	**+!**	SUN PHARM INDS INC	**0.1%**	**N017556**	**001**		
OINTMENT;TOPICAL							
HALOG							
	+!	SUN PHARM INDS INC	0.1%	N017824	001		
SOLUTION;TOPICAL							
HALOG							
	+!	SUN PHARM INDS INC	0.1%	N017823	001		
HALOBETASOL PROPIONATE							
AEROSOL, FOAM;TOPICAL							
LEXETTE							
	+!	MAYNE PHARMA	0.05%	N210566	001	May 24, 2018	
CREAM;TOPICAL							
HALOBETASOL PROPIONATE							
AB	**!**	COSETTE	**0.05%**	**A078162**	**001**	Apr 24, 2007	
AB		FOUGERA PHARMS	**0.05%**	**A077001**	**001**	Dec 16, 2004	
AB		PADAGIS ISRAEL	**0.05%**	**A077123**	**001**	Dec 16, 2004	
AB		TARO	**0.05%**	**A077227**	**001**	Aug 04, 2005	
LOTION;TOPICAL							
BRYHALI							
	+!	BAUSCH	0.01%	N209355	001	Nov 06, 2018	
ULTRAVATE							
	+!	SUN PHARM INDUSTRIES	0.05%	N208183	001	Nov 06, 2015	
OINTMENT;TOPICAL							
HALOBETASOL PROPIONATE							
AB		COSETTE	**0.05%**	**A077109**	**001**	Jun 14, 2005	
AB	**!**	PADAGIS ISRAEL	**0.05%**	**A076872**	**001**	Dec 16, 2004	
AB		QUAGEN	**0.05%**	**A213560**	**001**	Oct 06, 2020	
AB		TARO	**0.05%**	**A076994**	**001**	Dec 16, 2004	
AB		TELIGENT	**0.05%**	**A209978**	**001**	Mar 20, 2018	
HALOBETASOL PROPIONATE; TAZAROTENE							
LOTION;TOPICAL							
DUOBRII							
	+!	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	
HALOPERIDOL							
TABLET;ORAL							
HALOPERIDOL							
AB		CYCLE PHARMS LTD	**2MG**	**A071130**	**001**	Feb 17, 1987	
AB			**5MG**	**A071131**	**001**	Feb 17, 1987	
AB			**10MG**	**A071132**	**001**	May 12, 1987	
AB		INNOGENIX	**0.5MG**	**A071173**	**002**	Jan 02, 1987	
AB			**1MG**	**A071173**	**003**	Jan 02, 1987	
AB			**2MG**	**A071173**	**004**	Jan 02, 1987	
AB			**5MG**	**A071173**	**005**	Jan 07, 1988	
AB			**10MG**	**A071173**	**001**	Jan 07, 1988	
AB			**20MG**	**A071173**	**006**	Jan 07, 1988	
AB		MYLAN	**0.5MG**	**A070278**	**006**	Jun 10, 1986	
AB			**1MG**	**A070278**	**004**	Jun 10, 1986	
AB	**!**		**2MG**	**A070278**	**001**	Jun 10, 1986	
AB			**5MG**	**A070278**	**005**	Jun 10, 1986	
AB			**10MG**	**A070278**	**002**	Jul 16, 2009	
AB			**20MG**	**A070278**	**003**	Jul 16, 2009	
AB		SANDOZ	**0.5MG**	**A071206**	**001**	Nov 17, 1986	
AB			**1MG**	**A071207**	**001**	Nov 17, 1986	
AB			**5MG**	**A071209**	**001**	Nov 17, 1986	
AB			**10MG**	**A071210**	**001**	Mar 11, 1988	
AB			**20MG**	**A071211**	**001**	Mar 11, 1988	
AB		UPSHER SMITH LABS	**0.5MG**	**A211061**	**001**	Jan 08, 2020	
AB			**1MG**	**A211061**	**002**	Jan 08, 2020	
AB			**2MG**	**A211061**	**003**	Jan 08, 2020	
AB			**5MG**	**A211061**	**004**	Jan 08, 2020	
AB			**10MG**	**A211061**	**005**	Jan 08, 2020	
AB			**20MG**	**A211061**	**006**	Jan 08, 2020	
AB		ZYDUS PHARMS USA	**5MG**	**A077580**	**003**	Nov 29, 2007	
AB			**10MG**	**A077580**	**004**	Nov 29, 2007	
AB			**20MG**	**A077580**	**005**	Nov 29, 2007	

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALDOL

AO	**+!**	JANSSEN PHARMS	**EQ 50MG BASE/ML**	**N018701**	**001**	Jan 14, 1986
AO	**+!**		**EQ 100MG BASE/ML**	**N018701**	**002**	Jan 31, 1997

HALOPERIDOL DECANOATE

AO		FRESENIUS KABI USA	**EQ 50MG BASE/ML**	**A074893**	**001**	Dec 19, 1997
AO			**EQ 100MG BASE/ML**	**A074893**	**002**	Dec 19, 1997
AO		GLAND PHARMA LTD	**EQ 50MG BASE/ML**	**A205241**	**001**	May 12, 2017
AO			**EQ 100MG BASE/ML**	**A205241**	**002**	May 12, 2017
AO		HIKMA	**EQ 50MG BASE/ML**	**A074811**	**001**	Jan 30, 1998
AO			**EQ 100MG BASE/ML**	**A075305**	**001**	Sep 28, 1998
AO		MEITHEAL	**EQ 50MG BASE/ML**	**A214507**	**001**	Jul 26, 2021
AO			**EQ 100MG BASE/ML**	**A214507**	**002**	Jul 26, 2021
AO		MYLAN LABS LTD	**EQ 50MG BASE/ML**	**A075440**	**001**	Feb 28, 2000
AO			**EQ 100MG BASE/ML**	**A075440**	**002**	Feb 28, 2000
AO		SOMERSET THERAPS LLC	**EQ 50MG BASE/ML**	**A209101**	**001**	Jul 03, 2018
AO			**EQ 100MG BASE/ML**	**A209101**	**002**	Jul 03, 2018
AO		TEVA PHARMS USA	**EQ 50MG BASE/ML**	**A075393**	**001**	May 11, 1999
AO			**EQ 100MG BASE/ML**	**A075393**	**002**	May 11, 1999
AO		ZYDUS PHARMS	**EQ 50MG BASE/ML**	**A211180**	**001**	Oct 22, 2019
AO			**EQ 100MG BASE/ML**	**A211180**	**002**	Oct 22, 2019

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL

AA		LANNETT CO INC	**EQ 2MG BASE/ML**	**A073364**	**001**	Sep 28, 1993
AA	**!**	PHARM ASSOC	**EQ 2MG BASE/ML**	**A073037**	**001**	Feb 26, 1993

INJECTABLE;INJECTION

HALOPERIDOL

AP		AKORN	**EQ 5MG BASE/ML**	**A204849**	**001**	Sep 06, 2017
AP		FRESENIUS KABI USA	**EQ 5MG BASE/ML**	**A075689**	**001**	Mar 09, 2001
AP			**EQ 5MG BASE/ML**	**A210356**	**001**	Jul 01, 2019
AP		GLAND PHARMA LTD	**EQ 5MG BASE/ML**	**A076774**	**001**	Aug 25, 2004
AP		HIKMA	**EQ 5MG BASE/ML**	**A075858**	**001**	Jun 18, 2001
AP	**!**	MYLAN LABS LTD	**EQ 5MG BASE/ML**	**A078347**	**001**	Sep 14, 2009
AP		SAGENT PHARMS	**EQ 5MG BASE/ML**	**A091637**	**001**	Sep 02, 2011
AP			**EQ 5MG BASE/ML**	**A200742**	**001**	Sep 02, 2011

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP		BE PHARMS	**1,000 UNITS/ML**	**A214804**	**001**	Dec 29, 2020
AP			**10,000 UNITS/ML**	**A214839**	**001**	Dec 29, 2020
AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**001**	
AP			**5,000 UNITS/ML**	**A206552**	**001**	Jun 10, 2016
AP	**+!**		**5,000 UNITS/ML**	**N017651**	**006**	
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**003**	
AP	**+!**		**20,000 UNITS/ML**	**N017029**	**004**	
AP		GLAND	**1,000 UNITS/ML**	**A205323**	**002**	Nov 18, 2019
AP			**5,000 UNITS/ML**	**A205323**	**001**	Feb 06, 2017
AP	**+!**	HIKMA	**1,000 UNITS/ML**	**N017037**	**001**	
AP	**+!**		**5,000 UNITS/ML**	**N017037**	**002**	
AP	**+!**		**10,000 UNITS/ML**	**N017037**	**003**	
AP		HOSPIRA INC	**1,000 UNITS/ML**	**A090571**	**001**	Aug 31, 2009
AP			**5,000 UNITS/ML**	**A090571**	**002**	Aug 31, 2009
AP			**10,000 UNITS/ML**	**A090571**	**003**	Aug 31, 2009
AP		MYLAN LABS LTD	**1,000 UNITS/ML**	**A203851**	**001**	Nov 30, 2017
AP			**5,000 UNITS/ML**	**A203851**	**002**	Nov 30, 2017
AP			**10,000 UNITS/ML**	**A203851**	**003**	Nov 30, 2017
AP			**20,000 UNITS/ML**	**A203852**	**001**	Nov 30, 2017
AP		NANJING KING-FRIEND	**1,000 UNITS/ML**	**A211005**	**001**	Dec 14, 2018
AP			**1,000 UNITS/ML**	**A211007**	**001**	May 28, 2019
AP			**5,000 UNITS/ML**	**A211007**	**002**	May 28, 2019
AP			**10,000 UNITS/ML**	**A211007**	**003**	May 28, 2019
AP			**20,000 UNITS/ML**	**A211004**	**001**	Feb 24, 2020
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090808**	**001**	Jun 30, 2010
AP			**5,000 UNITS/ML**	**A090808**	**002**	Jun 30, 2010
AP			**10,000 UNITS/ML**	**A090808**	**003**	Jun 30, 2010
AP			**20,000 UNITS/ML**	**A090809**	**001**	Jun 30, 2010
AP		SANDOZ	**1,000 UNITS/ML**	**A091682**	**001**	Jun 08, 2011
AP			**5,000 UNITS/ML**	**A091682**	**002**	Jun 08, 2011
AP			**10,000 UNITS/ML**	**A201002**	**001**	Jun 08, 2011

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

AP		SHENZHEN TECHDOW	**1,000 UNITS/ML**	**A202957**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202733**	**001**	Jun 12, 2014
AP			**5,000 UNITS/ML**	**A202957**	**002**	Jun 12, 2014
AP			**10,000 UNITS/ML**	**A203198**	**001**	Jun 12, 2014
AP			**20,000 UNITS/ML**	**A203198**	**002**	Jun 12, 2014

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**001**	Apr 28, 1982

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**200 UNITS/100ML**	**N019953**	**001**	Jul 20, 1992
AP		FRESENIUS KABI USA	**200 UNITS/100ML**	**A212441**	**001**	Jul 24, 2020
AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**010**	Jun 23, 1989

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		HOSPIRA	**10,000 UNITS/100ML**	**N019339**	**003**	Mar 27, 1985

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**200 UNITS/100ML**	**N018609**	**002**	Apr 28, 1982

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**200 UNITS/100ML**	**A212441**	**002**	Jul 24, 2020
AP	**+!**	HOSPIRA	**200 UNITS/100ML**	**N018916**	**011**	Jun 23, 1989

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**4,000 UNITS/100ML**	**N019952**	**001**	Jul 20, 1992
AP		HOSPIRA	**4,000 UNITS/100ML**	**N019805**	**001**	Jan 25, 1989

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**5,000 UNITS/100ML**	**N019952**	**004**	Jul 20, 1992
AP	**+!**		**10,000 UNITS/100ML**	**N019952**	**005**	Jul 20, 1992
AP		HOSPIRA	**5,000 UNITS/100ML**	**N019339**	**004**	Mar 27, 1985
AP			**5,000 UNITS/100ML**	**N019805**	**002**	Jan 25, 1989
AP			**10,000 UNITS/100ML**	**N019339**	**002**	Mar 27, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**013**	Dec 05, 1985
AP	**+!**		**5,000 UNITS/ML**	**N017029**	**014**	Dec 05, 1985
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**015**	Dec 05, 1985
AP	**+!**		**20,000 UNITS/ML**	**N017029**	**016**	Dec 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	**+!**	FRESENIUS KABI USA	**1,000 UNITS/ML**	**N017029**	**010**	Apr 28, 1986
AP	**+!**		**10,000 UNITS/ML**	**N017029**	**019**	Nov 22, 2010
AP		HOSPIRA	**10,000 UNITS/ML**	**A089522**	**001**	May 04, 1987
AP		SAGENT PHARMS	**1,000 UNITS/ML**	**A090810**	**001**	Jun 30, 2010

HEPARIN SODIUM

		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018
	+!	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	!	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+!	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	+!		5,000 UNITS/ML	N201370	002	Jul 21, 2011

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

		HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		BAXTER HLTHCARE	2,000 UNITS/1000ML	N018609	004	Apr 23, 2020

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

		HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
			10,000 UNITS/100ML	N018916	008	Jan 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

	+!	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE

SPONGE;TOPICAL

PRE-OP

AT	**+!**	DAVIS AND GECK	**480MG**	**N017433**	**001**	

PRE-OP II

AT	**+**	DAVIS AND GECK	**480MG**	**N017433**	**002**	

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION;INTRAVESICAL

CYSVIEW KIT

	+!	PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010

HISTRELIN ACETATE

IMPLANT;SUBCUTANEOUS

SUPPRELIN LA

	+!	ENDO PHARM	50MG	N022058	001	May 03, 2007

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYCODAN

AA	**+**	GENUS	**1.5MG/5ML;5MG/5ML**	**N005213**	**002**	Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA		ABHAI LLC	**1.5MG/5ML;5MG/5ML**	**A207487**	**001**	Feb 21, 2017
AA		ACTAVIS MID ATLANTIC	**1.5MG/5ML;5MG/5ML**	**A088017**	**001**	Jul 05, 1983
AA	**!**	AKORN	**1.5MG/5ML;5MG/5ML**	**A040613**	**001**	Feb 08, 2008
AA		NOVEL LABS INC	**1.5MG/5ML;5MG/5ML**	**A203535**	**001**	Feb 13, 2017
AA		PADAGIS US	**1.5MG/5ML;5MG/5ML**	**A205731**	**001**	Feb 15, 2017
AA		WOCKHARDT BIO AG	**1.5MG/5ML;5MG/5ML**	**A088008**	**001**	Mar 03, 1983

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AA		AVANTHI INC	**1.5MG;5MG**	**A207176**	**001**	Aug 07, 2017
AA	**!**	NOVEL LABS INC	**1.5MG;5MG**	**A091528**	**001**	Apr 20, 2011

HYCODAN

AA	**+**	GENUS	**1.5MG;5MG**	**N005213**	**001**	Jul 26, 1988

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	**!**	AKORN	**20MG/ML**	**A040730**	**001**	Apr 21, 2009
AP		AM REGENT	**20MG/ML**	**A040136**	**001**	Jun 30, 1997
AP		FRESENIUS KABI USA	**20MG/ML**	**A040388**	**001**	Mar 13, 2001
AP		HIKMA	**20MG/ML**	**A213667**	**001**	Dec 18, 2020
AP		I3 PHARMS	**20MG/ML**	**A203110**	**001**	Jun 29, 2015
AP		MYLAN INSTITUTIONAL	**20MG/ML**	**A204680**	**001**	Apr 28, 2016
AP		NAVINTA LLC	**20MG/ML**	**A202938**	**001**	Mar 28, 2013

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA		ALKEM LABS LTD	**10MG**	**A200737**	**001**	Dec 07, 2012
AA			**25MG**	**A200737**	**002**	Dec 07, 2012
AA			**50MG**	**A200737**	**003**	Dec 07, 2012
AA			**100MG**	**A200737**	**004**	Dec 07, 2012
AA		CADILA PHARMS LTD	**25MG**	**A203845**	**001**	Sep 18, 2014
AA			**50MG**	**A203845**	**002**	Sep 18, 2014
AA			**100MG**	**A203845**	**003**	Sep 18, 2014
AA		GLENMARK PHARMS LTD	**10MG**	**A090527**	**001**	May 27, 2009
AA			**25MG**	**A090527**	**002**	May 27, 2009
AA			**50MG**	**A090527**	**003**	May 27, 2009
AA			**100MG**	**A090527**	**004**	May 27, 2009
AA		HERITAGE PHARMS INC	**10MG**	**A086242**	**001**	Feb 04, 2010
AA			**25MG**	**A086242**	**003**	
AA			**50MG**	**A086242**	**002**	
AA			**100MG**	**A086242**	**004**	Feb 04, 2010
AA		HETERO LABS LTD III	**10MG**	**A040901**	**001**	Sep 12, 2008
AA			**25MG**	**A040901**	**002**	Sep 12, 2008
AA			**50MG**	**A040901**	**003**	Sep 12, 2008
AA			**100MG**	**A040901**	**004**	Sep 12, 2008
AA		INVAGEN PHARMS	**10MG**	**A090255**	**001**	Dec 15, 2008
AA			**25MG**	**A090255**	**002**	Dec 15, 2008
AA			**50MG**	**A090255**	**003**	Dec 15, 2008
AA			**100MG**	**A090255**	**004**	Dec 15, 2008
AA	**!**	PLIVA	**10MG**	**A089097**	**001**	Dec 18, 1985
AA	**+!**		**25MG**	**A088467**	**001**	May 01, 1984
AA	**+!**		**50MG**	**A088468**	**001**	May 01, 1984
AA	**!**		**100MG**	**A089098**	**001**	Dec 18, 1985
AA		SCIEGEN PHARMS INC	**10MG**	**A205236**	**001**	May 26, 2017
AA			**25MG**	**A205236**	**002**	May 26, 2017
AA			**50MG**	**A205236**	**003**	May 26, 2017
AA			**100MG**	**A205236**	**004**	May 26, 2017
AA		STRIDES PHARMA	**10MG**	**A087836**	**001**	Oct 05, 1982
AA			**25MG**	**A086961**	**002**	
AA			**25MG**	**A200770**	**001**	May 03, 2013
AA			**50MG**	**A086962**	**001**	
AA			**50MG**	**A200770**	**002**	May 03, 2013
AA			**100MG**	**A088391**	**001**	Sep 27, 1983
AA			**100MG**	**A200770**	**003**	May 03, 2013

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

	STRIDES PHARMA	25MG;25MG	A088957	001	Oct 21, 1985
!		50MG;50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

+!	ARBOR PHARMS LLC	37.5MG;20MG	N020727	001	Jun 23, 2005

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

AB		AUROBINDO PHARMA	**12.5MG**	**A078164**	**001**	Sep 18, 2007
AB		IPCA LABS LTD	**12.5MG**	**A079237**	**001**	Apr 02, 2009
AB		JUBILANT CADISTA	**12.5MG**	**A078391**	**001**	Feb 11, 2008
AB		MYLAN	**12.5MG**	**A075640**	**001**	Jan 28, 2000
AB		PRINSTON INC	**12.5MG**	**A075907**	**001**	Sep 17, 2002
AB		SCIEGEN PHARMS INC	**12.5MG**	**A203561**	**001**	Jan 14, 2019
AB		SUN PHARM INDS INC	**12.5MG**	**A090651**	**001**	Apr 07, 2014
AB		UNICHEM	**12.5MG**	**A090510**	**001**	Jan 19, 2010

MICROZIDE

AB	**+!**	TEVA BRANDED PHARM	**12.5MG**	**N020504**	**001**	Dec 27, 1996

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	**!**	ACCORD HLTHCARE	**12.5MG**	**A202556**	**001**	Sep 24, 2012
AB			**25MG**	**A202556**	**002**	Sep 24, 2012
AB			**50MG**	**A202556**	**003**	Sep 24, 2012
AB		ACTAVIS ELIZABETH	**12.5MG**	**A040707**	**001**	Feb 27, 2007
AB		AUROBINDO PHARMA	**25MG**	**A040780**	**001**	Jul 20, 2007
AB			**50MG**	**A040780**	**002**	Jul 20, 2007
AB		HERITAGE PHARMS INC	**25MG**	**A085182**	**002**	
AB			**50MG**	**A085182**	**001**	
AB		IPCA LABS LTD	**12.5MG**	**A040807**	**001**	Jul 20, 2007
AB			**25MG**	**A040807**	**002**	Jul 20, 2007
AB			**50MG**	**A040807**	**003**	Jul 20, 2007
AB	**+**	IVAX SUB TEVA PHARMS	**25MG**	**A083177**	**001**	
AB	**+!**		**50MG**	**A083177**	**002**	
AB		LEADING PHARMA LLC	**12.5MG**	**A040702**	**003**	May 10, 2017
AB			**25MG**	**A040702**	**001**	Mar 16, 2007
AB			**50MG**	**A040702**	**002**	Mar 16, 2007
AB		OXFORD PHARMS	**25MG**	**A087059**	**001**	
AB			**50MG**	**A087068**	**001**	
AB		PRINSTON INC	**25MG**	**A040412**	**001**	Mar 29, 2002
AB			**50MG**	**A040412**	**002**	Mar 29, 2002
AB		SCIEGEN PHARMS INC	**25MG**	**A203018**	**001**	Jul 23, 2014
AB			**50MG**	**A203018**	**002**	Jul 23, 2014
AB		UNICHEM	**25MG**	**A040907**	**001**	Aug 15, 2008
AB			**50MG**	**A040907**	**002**	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

AB	**+!**	SANOFI AVENTIS US	**12.5MG;150MG**	**N020758**	**002**	Sep 30, 1997
AB	**+!**		**12.5MG;300MG**	**N020758**	**003**	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;150MG**	**A091370**	**001**	Oct 15, 2012
AB			**12.5MG;300MG**	**A091370**	**002**	Oct 15, 2012
AB			**25MG;300MG**	**A091370**	**003**	Oct 12, 2016
AB		AUROBINDO PHARMA LTD	**12.5MG;150MG**	**A203630**	**001**	Feb 22, 2013
AB			**12.5MG;300MG**	**A203630**	**002**	Feb 22, 2013
AB			**25MG;300MG**	**A203630**	**003**	Mar 31, 2016
AB		DR REDDYS LABS LTD	**12.5MG;150MG**	**A203500**	**001**	Sep 27, 2012
AB			**12.5MG;300MG**	**A203500**	**002**	Sep 27, 2012
AB		HIKMA	**12.5MG;150MG**	**A090351**	**001**	Oct 15, 2012
AB			**12.5MG;300MG**	**A090351**	**002**	Oct 15, 2012
AB			**25MG;300MG**	**A090351**	**003**	Jun 08, 2017
AB		HISUN PHARM HANGZHOU	**12.5MG;150MG**	**A207896**	**001**	Oct 14, 2016
AB			**12.5MG;300MG**	**A207896**	**002**	Oct 14, 2016
AB		LUPIN LTD	**12.5MG;150MG**	**A201524**	**001**	Feb 27, 2013

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB			**12.5MG;300MG**	**A201524**	**002**	Feb 27, 2013
AB		MACLEODS PHARMS LTD	**12.5MG;150MG**	**A202414**	**001**	Sep 27, 2012
AB			**12.5MG;300MG**	**A202414**	**002**	Sep 27, 2012
AB		PRINSTON INC	**12.5MG;150MG**	**A203072**	**001**	May 09, 2014
AB			**12.5MG;300MG**	**A203072**	**002**	May 09, 2014
AB		SANDOZ	**12.5MG;150MG**	**A077446**	**001**	Sep 27, 2012
AB			**12.5MG;300MG**	**A077446**	**002**	Sep 27, 2012
AB		TEVA	**12.5MG;150MG**	**A077369**	**001**	Mar 30, 2012
AB			**12.5MG;300MG**	**A077369**	**002**	Mar 30, 2012
AB		UNICHEM	**12.5MG;150MG**	**A207018**	**001**	Sep 19, 2017
AB			**12.5MG;300MG**	**A207018**	**002**	Sep 19, 2017

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		AUROBINDO	**12.5MG;10MG**	**A077606**	**001**	Mar 14, 2006
AB			**12.5MG;20MG**	**A077606**	**002**	Mar 14, 2006
AB			**25MG;20MG**	**A077606**	**003**	Mar 14, 2006
AB		INVAGEN PHARMS	**12.5MG;10MG**	**A204058**	**001**	May 23, 2017
AB			**12.5MG;20MG**	**A204058**	**002**	May 23, 2017
AB			**25MG;20MG**	**A204058**	**003**	May 23, 2017
AB		LUPIN	**12.5MG;10MG**	**A077912**	**001**	Sep 27, 2006
AB			**12.5MG;20MG**	**A077912**	**002**	Sep 27, 2006
AB			**25MG;20MG**	**A077912**	**003**	Sep 27, 2006
AB		PRINSTON INC	**12.5MG;10MG**	**A076230**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076230**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076230**	**003**	Jul 01, 2002
AB		SANDOZ	**12.5MG;10MG**	**A076262**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076262**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076262**	**003**	Jul 01, 2002
AB		SUN PHARM INDS LTD	**12.5MG;10MG**	**A076007**	**001**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076007**	**002**	Jul 01, 2002
AB			**25MG;20MG**	**A076007**	**003**	Jul 01, 2002
AB		WATSON LABS	**12.5MG;10MG**	**A076194**	**003**	Jul 01, 2002
AB			**12.5MG;20MG**	**A076194**	**001**	Jul 01, 2002
AB			**25MG;20MG**	**A076194**	**002**	Jul 01, 2002

ZESTORETIC

AB	**+**	ALMATICA	**12.5MG;10MG**	**N019888**	**003**	Nov 18, 1993
AB	**+!**		**12.5MG;20MG**	**N019888**	**001**	Sep 20, 1990
AB	**+!**		**25MG;20MG**	**N019888**	**002**	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

AB	**+**	ORGANON	**12.5MG;50MG**	**N020387**	**001**	Apr 28, 1995
AB	**+**		**12.5MG;100MG**	**N020387**	**003**	Oct 20, 2005
AB	**+**		**25MG;100MG**	**N020387**	**002**	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;50MG**	**A091617**	**001**	Feb 17, 2012
AB			**12.5MG;100MG**	**A091617**	**002**	Feb 17, 2012
AB			**25MG;100MG**	**A091617**	**003**	Feb 17, 2012
AB		AUROBINDO PHARMA	**12.5MG;50MG**	**A091629**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A091629**	**002**	Oct 06, 2010
AB	**!**		**25MG;100MG**	**A091629**	**003**	Jan 06, 2010
AB		IPCA LABS LTD	**12.5MG;50MG**	**A201682**	**001**	Mar 01, 2013
AB			**12.5MG;100MG**	**A201682**	**002**	Mar 01, 2013
AB			**25MG;100MG**	**A201682**	**003**	Mar 01, 2013
AB		JUBILANT CADISTA	**12.5MG;50MG**	**A201845**	**001**	Sep 18, 2012
AB			**12.5MG;100MG**	**A201845**	**002**	Sep 18, 2012
AB			**25MG;100MG**	**A201845**	**003**	Sep 18, 2012
AB		LUPIN LTD	**12.5MG;50MG**	**A078245**	**001**	Oct 06, 2010
AB			**12.5MG;100MG**	**A078245**	**002**	May 21, 2010
AB			**25MG;100MG**	**A078245**	**003**	Oct 06, 2010
AB		MACLEODS PHARMS LTD	**12.5MG;50MG**	**A202289**	**001**	Aug 09, 2012
AB			**12.5MG;100MG**	**A202289**	**002**	Aug 09, 2012
AB			**25MG;100MG**	**A202289**	**003**	Aug 09, 2012
AB		PRINSTON INC	**12.5MG;50MG**	**A204901**	**001**	Nov 06, 2017
AB			**12.5MG;100MG**	**A204901**	**002**	Nov 06, 2017
AB			**25MG;100MG**	**A204901**	**003**	Nov 06, 2017
AB		SANDOZ	**12.5MG;50MG**	**A077948**	**001**	Oct 06, 2010

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB			**12.5MG;100MG**	**A077948**	**003**	Aug 19, 2010
AB			**25MG;100MG**	**A077948**	**002**	Oct 06, 2010
AB		TEVA PHARMS	**12.5MG;50MG**	**A077157**	**001**	Apr 06, 2010
AB			**12.5MG;100MG**	**A077157**	**002**	Apr 06, 2010
AB			**25MG;100MG**	**A077157**	**003**	Apr 06, 2010
AB		UNICHEM	**12.5MG;50MG**	**A204832**	**001**	Jul 21, 2017
AB			**12.5MG;100MG**	**A204832**	**002**	Jul 21, 2017
AB			**25MG;100MG**	**A204832**	**003**	Jul 21, 2017
AB		ZYDUS PHARMS USA INC	**12.5MG;50MG**	**A078385**	**001**	Oct 06, 2010
AB			**25MG;100MG**	**A078385**	**002**	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

AB	**+**	VALIDUS PHARMS	**25MG;50MG**	**N018303**	**001**	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**25MG;50MG**	**A202870**	**001**	Nov 06, 2013
AB	**!**		**25MG;100MG**	**A202870**	**002**	Nov 06, 2013
AB			**50MG;100MG**	**A202870**	**003**	Nov 06, 2013
AB		MYLAN	**25MG;50MG**	**A076792**	**001**	Aug 20, 2004
AB			**25MG;100MG**	**A076792**	**002**	Aug 20, 2004
AB			**50MG;100MG**	**A076792**	**003**	Aug 20, 2004
AB		SUN PHARM INDS	**25MG;50MG**	**A090654**	**001**	Jan 19, 2012
AB			**25MG;100MG**	**A090654**	**002**	Jan 19, 2012
AB			**50MG;100MG**	**A090654**	**003**	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		GLENMARK PHARMS	**12.5MG;7.5MG**	**A090718**	**001**	Mar 17, 2010
AB			**12.5MG;15MG**	**A090718**	**002**	Mar 17, 2010
AB			**25MG;15MG**	**A090718**	**003**	Mar 17, 2010
AB		TEVA	**12.5MG;7.5MG**	**A076980**	**001**	Mar 07, 2007
AB			**12.5MG;15MG**	**A076980**	**003**	Mar 07, 2007
AB	**!**		**25MG;15MG**	**A076980**	**002**	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR HCT

AB	**+**	DAIICHI SANKYO	**12.5MG;20MG**	**N021532**	**002**	Jun 05, 2003
AB	**+**		**12.5MG;40MG**	**N021532**	**003**	Jun 05, 2003
AB	**+!**		**25MG;40MG**	**N021532**	**005**	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

AB		ACCORD HLTHCARE	**12.5MG;20MG**	**A209281**	**001**	Feb 07, 2019
AB			**12.5MG;40MG**	**A209281**	**002**	Feb 07, 2019
AB			**25MG;40MG**	**A209281**	**003**	Feb 07, 2019
AB		ALEMBIC PHARMS LTD	**12.5MG;20MG**	**A204233**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A204233**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A204233**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA LTD	**12.5MG;20MG**	**A205391**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A205391**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A205391**	**003**	Apr 24, 2017
AB		PRINSTON INC	**12.5MG;20MG**	**A207804**	**001**	Apr 24, 2017
AB			**12.5MG;40MG**	**A207804**	**002**	Apr 24, 2017
AB			**25MG;40MG**	**A207804**	**003**	Apr 24, 2017
AB		TEVA PHARMS USA	**12.5MG;40MG**	**A200532**	**002**	Apr 24, 2017
AB		TORRENT	**12.5MG;20MG**	**A206515**	**001**	May 03, 2017
AB			**12.5MG;40MG**	**A206515**	**002**	May 03, 2017
AB			**25MG;40MG**	**A206515**	**003**	May 03, 2017
AB		UMEDICA LABS PVT LTD	**12.5MG;20MG**	**A208847**	**001**	Sep 17, 2019
AB			**12.5MG;40MG**	**A208847**	**003**	Sep 17, 2019
AB			**25MG;40MG**	**A208847**	**002**	Sep 17, 2019

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCURETIC

AB	+	PFIZER PHARMS	**12.5MG;EQ 10MG BASE**	**N020125**	**001**	Dec 28, 1999
AB	+		**12.5MG;EQ 20MG BASE**	**N020125**	**002**	Dec 28, 1999
AB	+!		**25MG;EQ 20MG BASE**	**N020125**	**003**	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		APOTEX CORP	**12.5MG;EQ 10MG BASE**	**A091524**	**001**	Mar 12, 2013
AB			**12.5MG;EQ 20MG BASE**	**A091524**	**002**	Mar 12, 2013
AB			**25MG;EQ 20MG BASE**	**A091524**	**003**	Mar 12, 2013
AB		AUROBINDO PHARMA	**12.5MG;EQ 10MG BASE**	**A078450**	**001**	Aug 24, 2007
AB			**12.5MG;EQ 20MG BASE**	**A078450**	**002**	Aug 24, 2007
AB			**25MG;EQ 20MG BASE**	**A078450**	**003**	Aug 24, 2007
AB		INVAGEN PHARMS	**12.5MG;EQ 10MG BASE**	**A201356**	**001**	Apr 20, 2011
AB			**12.5MG;EQ 20MG BASE**	**A201356**	**002**	Apr 20, 2011
AB			**25MG;EQ 20MG BASE**	**A201356**	**003**	Apr 20, 2011

QUINARETIC

AB		LUPIN	**12.5MG;EQ 10MG BASE**	**A076374**	**001**	Mar 31, 2004
AB			**12.5MG;EQ 20MG BASE**	**A076374**	**002**	Mar 31, 2004
AB			**25MG;EQ 20MG BASE**	**A076374**	**003**	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

ALDACTAZIDE

AB	+	PFIZER	**25MG;25MG**	**N012616**	**004**	Dec 30, 1982

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	**25MG;25MG**	**A086513**	**001**	
AB		SUN PHARM INDUSTRIES	**25MG;25MG**	**A089534**	**001**	Jul 02, 1987

ALDACTAZIDE

	+!	PFIZER	50MG;50MG	N012616	005	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

MICARDIS HCT

AB	+	BOEHRINGER INGELHEIM	**12.5MG;40MG**	**N021162**	**001**	Nov 17, 2000
AB	+		**12.5MG;80MG**	**N021162**	**002**	Nov 17, 2000
AB	+!		**25MG;80MG**	**N021162**	**003**	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;40MG**	**A203010**	**001**	Feb 25, 2014
AB			**12.5MG;80MG**	**A203010**	**002**	Feb 25, 2014
AB			**25MG;80MG**	**A203010**	**003**	Feb 25, 2014
AB		AUROBINDO PHARMA LTD	**12.5MG;40MG**	**A208727**	**001**	Dec 15, 2016
AB			**12.5MG;80MG**	**A208727**	**002**	Dec 15, 2016
AB			**25MG;80MG**	**A208727**	**003**	Dec 15, 2016
AB		GLENMARK PHARMS LTD	**12.5MG;40MG**	**A202544**	**001**	Mar 04, 2019
AB			**12.5MG;80MG**	**A202544**	**002**	Mar 04, 2019
AB			**25MG;80MG**	**A202544**	**003**	Mar 04, 2019
AB		LUPIN LTD	**12.5MG;40MG**	**A091351**	**001**	Aug 07, 2014
AB			**12.5MG;80MG**	**A091351**	**002**	Aug 07, 2014
AB			**25MG;80MG**	**A091351**	**003**	Aug 07, 2014
AB		PRINSTON INC	**12.5MG;40MG**	**A209028**	**001**	Nov 06, 2017
AB			**12.5MG;80MG**	**A209028**	**002**	Nov 06, 2017
AB			**25MG;80MG**	**A209028**	**003**	Nov 06, 2017
AB		ZYDUS PHARMS	**12.5MG;40MG**	**A204221**	**001**	Aug 15, 2017
AB			**12.5MG;80MG**	**A204221**	**002**	Aug 15, 2017
AB			**25MG;80MG**	**A204221**	**003**	Aug 15, 2017

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		CADILA	**25MG;37.5MG**	**A208358**	**001**	Feb 11, 2019
AB		LANNETT CO INC	**25MG;37.5MG**	**A201407**	**001**	Dec 09, 2011
AB		MYLAN	**25MG;37.5MG**	**A074701**	**001**	Jun 07, 1996
AB	!	SANDOZ	**25MG;37.5MG**	**A074821**	**001**	Jun 05, 1997

TABLET;ORAL

MAXZIDE

AB	+!	MYLAN PHARMS INC	**50MG;75MG**	**N019129**	**001**	Oct 22, 1984

MAXZIDE-25

AB	+	MYLAN PHARMS INC	**25MG;37.5MG**	**N019129**	**003**	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	**25MG;37.5MG**	**A071251**	**002**	May 05, 1998

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB			**50MG;75MG**	**A071251**	**001**	Apr 17, 1988
AB		SANDOZ	**25MG;37.5MG**	**A073281**	**001**	Apr 30, 1992
AB			**50MG;75MG**	**A072011**	**001**	Jun 17, 1988
AB		WATSON LABS	**25MG;37.5MG**	**A073449**	**001**	Sep 23, 1993
AB			**50MG;75MG**	**A071851**	**001**	Nov 30, 1988
AB		ZYDUS PHARMS	**25MG;37.5MG**	**A208360**	**001**	Jun 29, 2018
AB			**50MG;75MG**	**A208360**	**002**	Jun 29, 2018

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

DIOVAN HCT

AB	**+**	NOVARTIS	**12.5MG;80MG**	**N020818**	**001**	Mar 06, 1998
AB	**+**		**12.5MG;160MG**	**N020818**	**002**	Mar 06, 1998
AB	**+**		**12.5MG;320MG**	**N020818**	**004**	Apr 28, 2006
AB	**+**		**25MG;160MG**	**N020818**	**003**	Jan 17, 2002
AB	**+!**		**25MG;320MG**	**N020818**	**005**	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	**12.5MG;80MG**	**A201662**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A201662**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A201662**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A201662**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A201662**	**005**	Mar 21, 2013
AB		AUROBINDO PHARMA LTD	**12.5MG;80MG**	**A202519**	**001**	Mar 21, 2013
AB			**12.5MG;160MG**	**A202519**	**002**	Mar 21, 2013
AB			**12.5MG;320MG**	**A202519**	**003**	Mar 21, 2013
AB			**25MG;160MG**	**A202519**	**004**	Mar 21, 2013
AB			**25MG;320MG**	**A202519**	**005**	Mar 21, 2013
AB		LUPIN LTD	**12.5MG;80MG**	**A078946**	**003**	Mar 21, 2013
AB			**12.5MG;160MG**	**A078946**	**004**	Mar 21, 2013
AB			**12.5MG;320MG**	**A078946**	**001**	Mar 21, 2013
AB			**25MG;160MG**	**A078946**	**005**	Mar 21, 2013
AB			**25MG;320MG**	**A078946**	**002**	Mar 21, 2013
AB		MACLEODS PHARMS LTD	**12.5MG;80MG**	**A203145**	**001**	Apr 19, 2013
AB			**12.5MG;160MG**	**A203145**	**002**	Apr 19, 2013
AB			**12.5MG;320MG**	**A203145**	**003**	Apr 19, 2013
AB			**25MG;160MG**	**A203145**	**004**	Apr 19, 2013
AB			**25MG;320MG**	**A203145**	**005**	Apr 19, 2013
AB		MYLAN PHARMS INC	**12.5MG;80MG**	**A078020**	**001**	Sep 21, 2012
AB			**12.5MG;160MG**	**A078020**	**002**	Sep 21, 2012
AB			**12.5MG;320MG**	**A078020**	**004**	Sep 21, 2012
AB			**25MG;160MG**	**A078020**	**003**	Sep 21, 2012
AB			**25MG;320MG**	**A078020**	**005**	Sep 21, 2012
AB		PRINSTON INC	**12.5MG;80MG**	**A206083**	**001**	Feb 08, 2016
AB			**12.5MG;160MG**	**A206083**	**002**	Feb 08, 2016
AB			**12.5MG;320MG**	**A206083**	**003**	Feb 08, 2016
AB			**25MG;160MG**	**A206083**	**004**	Feb 08, 2016
AB			**25MG;320MG**	**A206083**	**005**	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

	!	ALVOGEN	10MG	A206986	001	Jan 21, 2020
			15MG	A206986	002	Jan 21, 2020
			20MG	A206986	003	Jan 21, 2020
			30MG	A206986	004	Jan 21, 2020
			40MG	A206986	005	Jan 21, 2020
			50MG	A206986	006	Jan 21, 2020

TABLET, EXTENDED RELEASE;ORAL

HYDROCODONE BITARTRATE

AB		ALVOGEN PINE BROOK	**20MG**	**A208269**	**001**	Mar 01, 2021
AB			**30MG**	**A208269**	**002**	Mar 01, 2021
AB			**40MG**	**A208269**	**003**	Mar 01, 2021
AB			**60MG**	**A208269**	**004**	Mar 01, 2021
AB			**80MG**	**A208269**	**005**	Mar 01, 2021
AB			**100MG**	**A208269**	**006**	Mar 01, 2021
AB			**120MG**	**A208269**	**007**	Mar 01, 2021

HYSINGLA ER

AB	**+!**	PURDUE PHARMA LP	**20MG**	**N206627**	**001**	Nov 20, 2014
AB	**+**		**30MG**	**N206627**	**002**	Nov 20, 2014
AB	**+**		**40MG**	**N206627**	**003**	Nov 20, 2014

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA ER

AB	+		**60MG**	**N206627**	**004**	Nov 20, 2014
AB	+		**80MG**	**N206627**	**005**	Nov 20, 2014
AB	+		**100MG**	**N206627**	**006**	Nov 20, 2014
AB	+		**120MG**	**N206627**	**007**	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE

AB		NOSTRUM LABS INC	**5MG;200MG**	**A077723**	**003**	Nov 06, 2006

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		ACTAVIS LABS FL INC	**7.5MG;200MG**	**A076604**	**001**	Dec 31, 2003
AB		AMNEAL PHARMS NY	**5MG;200MG**	**A076642**	**002**	Mar 18, 2004
AB	!		**7.5MG;200MG**	**A076642**	**001**	Oct 12, 2004
AB		AUROLIFE PHARMA LLC	**7.5MG;200MG**	**A204575**	**001**	Jun 02, 2016
AB		NOSTRUM LABS INC	**7.5MG;200MG**	**A077723**	**001**	Nov 06, 2006
			10MG;200MG	A077723	002	Nov 06, 2006

HYDROCORTISONE

CREAM;TOPICAL

ALA-CORT

AT		CROWN LABS	**2.5%**	**A080706**	**007**	Jan 05, 2016
AT			**1%**	**A080706**	**006**	

ANUSOL HC

AT		SALIX PHARMS	**2.5%**	**A088250**	**001**	Jun 06, 1984

HYDROCORTISONE

AT		ACTAVIS MID ATLANTIC	**1%**	**A087795**	**001**	May 03, 1983
AT			**2.5%**	**A089682**	**001**	Mar 10, 1988
AT	!	FOUGERA PHARMS INC	**1%**	**A080693**	**003**	
AT	!		**2.5%**	**A089414**	**001**	Dec 16, 1986
AT		LANNETT CO INC	**2.5%**	**A040503**	**001**	Mar 12, 2004
AT		PADAGIS US	**2.5%**	**A085025**	**001**	
AT		RISING	**2.5%**	**A040879**	**001**	Aug 20, 2010
AT		TARO PHARM INDS LTD	**2.5%**	**A088799**	**001**	Nov 09, 1984

ENEMA;RECTAL

COLOCORT

AB		CHARTWELL	**100MG/60ML**	**A075172**	**001**	Dec 03, 1999

CORTENEMA

AB	+!	ANI PHARMS	**100MG/60ML**	**N016199**	**001**	

GRANULE;ORAL

ALKINDI SPRINKLE

	+	ETON	0.5MG	N213876	001	Sep 29, 2020
	+		1MG	N213876	002	Sep 29, 2020
	+		2MG	N213876	003	Sep 29, 2020
	+!		5MG	N213876	004	Sep 29, 2020

LOTION;TOPICAL

HYDROCORTISONE

AT		LANNETT CO INC	**2.5%**	**A040417**	**001**	Jul 30, 2003
AT		TARO	**2.5%**	**A040247**	**001**	Jul 23, 1999

STIE-CORT

AT	!	PADAGIS US	**2.5%**	**A089074**	**001**	Nov 26, 1985

ALA-SCALP

		MARNEL PHARMS	2%	A083231	001	

OINTMENT;TOPICAL

HYDROCORTISONE

AT	+!	FOUGERA PHARMS	**1%**	**A080692**	**001**	
AT	!	FOUGERA PHARMS INC	**2.5%**	**A081203**	**001**	May 28, 1993
AT		PADAGIS US	**2.5%**	**A085027**	**001**	
AT		TARO	**1%**	**A086257**	**001**	

HYDROCORTISONE IN ABSORBASE

AT		CMP PHARMA INC	**1%**	**A088138**	**001**	Sep 06, 1985

SOLUTION;TOPICAL

TEXACORT

	!	MISSION PHARMA	2.5%	A081271	001	Apr 17, 1992

TABLET;ORAL

CORTEF

AB	+	PHARMACIA AND UPJOHN	**5MG**	**N008697**	**003**	
AB	+		**10MG**	**N008697**	**001**	
AB	+!		**20MG**	**N008697**	**002**	

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

AB	IMPAX LABS INC	**5MG**	**A040646**	**001**	Mar 30, 2007
AB		**10MG**	**A040646**	**002**	Mar 30, 2007
AB		**20MG**	**A040646**	**003**	Mar 30, 2007
AB	STRIDES PHARMA	**5MG**	**A207029**	**001**	Apr 27, 2017
AB		**10MG**	**A207029**	**002**	Apr 27, 2017
AB		**20MG**	**A207029**	**003**	Apr 27, 2017

HYDROCORTISONE ACETATE

AEROSOL, METERED;RECTAL

CORTIFOAM

+!	MYLAN SPECIALITY LP	10%	N017351	001	Feb 10, 1982

CREAM;TOPICAL

MICORT-HC

	SEBELA IRELAND LTD	2.5%	A040396	001	Feb 27, 2001

U-CORT

	TARO	1%	A089472	001	Jun 13, 1988

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL

EPIFOAM

BX	MYLAN SPECIALITY LP	1%;1%	A086457	001	

PROCTOFOAM HC

BX +!	MYLAN SPECIALITY LP	1%;1%	A086195	001	

CREAM;TOPICAL

PRAMOSONE

	SEBELA IRELAND LTD	0.5%;1%	A083778	001	
		1%;1%	A085368	001	

LOTION;TOPICAL

PRAMOSONE

	SEBELA IRELAND LTD	1%;1%	A085980	001	
		2.5%;1%	A085979	001	

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE

AB1	TARO PHARM INDS	**0.1%**	**A076654**	**001**	Aug 03, 2005

LOCOID

AB1 **+!**	BAUSCH	**0.1%**	**N018514**	**001**	Mar 31, 1982

HYDROCORTISONE BUTYRATE

AB2	ACTAVIS MID ATLANTIC	**0.1%**	**A205134**	**001**	Dec 08, 2017
AB2	GLENMARK GENERICS	**0.1%**	**A202145**	**001**	Sep 27, 2013

LOCOID LIPOCREAM

AB2 **+!**	PRECISION DERMAT	**0.1%**	**N020769**	**001**	Sep 08, 1997

LOTION;TOPICAL

HYDROCORTISONE BUTYRATE

AB	LUPIN LTD	**0.1%**	**A210209**	**001**	Aug 17, 2018
AB	TELIGENT	**0.1%**	**A209556**	**001**	Nov 21, 2017

LOCOID

AB **+!**	BAUSCH	**0.1%**	**N022076**	**001**	May 18, 2007

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE

AB	TARO	**0.1%**	**A076842**	**001**	Dec 27, 2004

LOCOID

AB **+!**	PRECISION DERMAT	**0.1%**	**N018652**	**001**	Oct 29, 1982

SOLUTION;TOPICAL

HYDROCORTISONE BUTYRATE

AT	TARO PHARM INDS	**0.1%**	**A076364**	**001**	Jan 14, 2004

LOCOID

AT **+!**	BAUSCH	**0.1%**	**N019116**	**001**	Feb 25, 1987

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL

PANDEL

+!	ANI PHARMS	0.1%	N020453	001	Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

SOLU-CORTEF

+!	PHARMACIA AND UPJOHN	EQ 100MG BASE/VIAL	N009866	001		
+!		EQ 250MG BASE/VIAL	N009866	002		
+!		EQ 500MG BASE/VIAL	N009866	003		
+!		EQ 1GM BASE/VIAL	N009866	004		

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

AB	COSETTE	**0.2%**	**A213724**	**001**	Feb 11, 2021	
AB	ENCUBE ETHICALS	**0.2%**	**A211047**	**001**	Nov 04, 2021	
AB	GLENMARK PHARMS LTD	**0.2%**	**A211129**	**001**	Oct 12, 2018	
AB	LUPIN LTD	**0.2%**	**A210307**	**001**	Aug 15, 2019	
AB	PADAGIS ISRAEL	**0.2%**	**A075666**	**001**	May 24, 2000	
AB !	TARO	**0.2%**	**A075042**	**001**	Aug 25, 1998	

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

AB	COSETTE	**0.2%**	**A211764**	**001**	Mar 04, 2020	
AB	GLENMARK PHARMS LTD	**0.2%**	**A211750**	**001**	Dec 14, 2018	
AB !	TARO	**0.2%**	**A075043**	**001**	Aug 25, 1998	

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT !	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064053**	**001**	Dec 29, 1995	
AT	SANDOZ INC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062423**	**001**	Aug 25, 1983	

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988	

SUSPENSION/DROPS;OTIC

CASPORYN HC

AT +!	CASPER PHARMA LLC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**N060613**	**001**		

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	AMRING PHARMS	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A065219**	**001**	May 01, 2006	
AT	SANDOZ INC	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A062488**	**001**	Nov 06, 1985	

OTICAIR

AT	BAUSCH AND LOMB	**1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML**	**A064065**	**001**	Aug 28, 1996	

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID

AP +!	FRESENIUS KABI USA	**1MG/ML**	**N019034**	**003**	Apr 30, 2009	
AP +!		**2MG/ML**	**N019034**	**004**	Apr 30, 2009	

HYDROMORPHONE HYDROCHLORIDE

AP	AKORN	**10MG/ML**	**A078228**	**001**	Apr 14, 2010	
AP		**10MG/ML**	**A078261**	**001**	Apr 14, 2010	
AP	EUROHLTH INTL SARL	**2MG/ML**	**A202159**	**001**	Apr 27, 2018	
AP	HOSPIRA INC	**1MG/ML**	**N200403**	**001**	Dec 01, 2011	
AP		**2MG/ML**	**N200403**	**002**	Dec 01, 2011	
AP		**4MG/ML**	**N200403**	**003**	Dec 01, 2011	
AP		**10MG/ML**	**A078591**	**001**	Jun 17, 2008	

DILAUDID

+!	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020	

SOLUTION;ORAL

DILAUDID

AA +!	RHODES PHARMS	**5MG/5ML**	**N019891**	**001**	Dec 07, 1992	

HYDROMORPHONE HYDROCHLORIDE

AA	ASCENT PHARMS INC	**5MG/5ML**	**A210176**	**001**	Oct 27, 2017	
AA	HIKMA	**5MG/5ML**	**A074653**	**001**	Jul 29, 1998	

TABLET;ORAL

DILAUDID

AB +	RHODES PHARMS	**2MG**	**N019892**	**003**	Nov 09, 2007	
AB +		**4MG**	**N019892**	**002**	Nov 09, 2007	
AB +!		**8MG**	**N019892**	**001**	Dec 07, 1992	

HYDROMORPHONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	**2MG**	**A210506**	**001**	Jan 17, 2018	
AB		**4MG**	**A210506**	**002**	Jan 17, 2018	
AB		**8MG**	**A210506**	**003**	Jan 17, 2018	
AB	AUROLIFE PHARMA LLC	**2MG**	**A205814**	**001**	May 13, 2016	
AB		**4MG**	**A205814**	**002**	May 13, 2016	
AB		**8MG**	**A205814**	**003**	May 13, 2016	

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		HIKMA	**4MG**	**A074597**	**003**	May 29, 2009
AB			**8MG**	**A074597**	**001**	Jul 29, 1998
AB		SPECGX LLC	**2MG**	**A076855**	**002**	Sep 19, 2007
AB			**4MG**	**A076855**	**003**	Sep 19, 2007
AB			**8MG**	**A076855**	**001**	Dec 23, 2004

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**8MG**	**A212133**	**001**	Sep 23, 2020
AB			**12MG**	**A212133**	**002**	Sep 23, 2020
AB			**16MG**	**A212133**	**003**	Sep 23, 2020
AB			**32MG**	**A212133**	**004**	Sep 23, 2020
AB		OSMOTICA PHARM US	**8MG**	**A205629**	**001**	Jul 07, 2016
AB			**12MG**	**A205629**	**002**	Jul 07, 2016
AB			**16MG**	**A205629**	**003**	Jul 07, 2016
AB	**!**		**32MG**	**A205629**	**004**	Jul 07, 2016
AB		PADAGIS US	**8MG**	**A204278**	**001**	Apr 06, 2015
AB			**12MG**	**A204278**	**002**	Apr 06, 2015
AB			**16MG**	**A204278**	**003**	Apr 06, 2015
AB			**32MG**	**A204278**	**004**	Sep 20, 2017

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

+!	SERB SA	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011

HYDROXOCOBALAMIN

!	ACTAVIS LLC	1MG/ML	A085998	001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

PAREMYD

+!	AKORN	1%;0.25%	N019261	001	Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

AB		ACCORD HLTHCARE	**200MG**	**A213342**	**001**	Apr 07, 2020
AB		ALKALOIDA ZRT	**200MG**	**A201691**	**001**	May 08, 2018
AB		AMNEAL PHARMS CO	**200MG**	**A210577**	**001**	May 15, 2018
AB		APPCO	**200MG**	**A210441**	**001**	May 01, 2018
AB		IPCA LABS LTD	**200MG**	**A040766**	**001**	Jun 14, 2007
AB		LAURUS	**200MG**	**A210959**	**001**	Jan 15, 2019
AB		LUPIN LTD	**200MG**	**A210543**	**001**	Jul 06, 2018
AB		MYLAN	**200MG**	**A040274**	**001**	May 29, 1998
AB		SANDOZ	**200MG**	**A040104**	**001**	Nov 30, 1995
AB		SENORES PHARMS	**200MG**	**A212902**	**001**	May 14, 2020
AB		TEVA PHARMS	**200MG**	**A040081**	**001**	Sep 30, 1994
AB		WATSON LABS	**200MG**	**A040133**	**001**	Nov 30, 1995
AB		ZYDUS PHARMS USA INC	**200MG**	**A040657**	**001**	Sep 21, 2007

PLAQUENIL

AB	**+!**	CONCORDIA	**200MG**	**N009768**	**001**	

HYDROXYCHLOROQUINE SULFATE

	ACCORD HLTHCARE	100MG	A213342	002	Aug 18, 2021
		300MG	A213342	003	Aug 18, 2021
		400MG	A213342	004	Aug 18, 2021

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

AP		AM REGENT	**250MG/ML (250MG/ML)**	**A210723**	**001**	Jun 21, 2018
AP		ASPEN	**250MG/ML (250MG/ML)**	**A211777**	**001**	Aug 08, 2019
AP		EUGIA PHARMA	**250MG/ML (250MG/ML)**	**A211071**	**001**	Apr 16, 2019
AP		SLAYBACK PHARMA LLC	**250MG/ML (250MG/ML)**	**A210877**	**001**	Mar 22, 2019

MAKENA PRESERVATIVE FREE

AP	**+!**	COVIS	**250MG/ML (250MG/ML)**	**N021945**	**002**	Feb 19, 2016

HYDROXYPROGESTERONE CAPROATE

AP1		EUGIA PHARMA	**1250MG/5ML (250MG/ML)**	**A211070**	**001**	Apr 16, 2019
AP1		SLAYBACK PHARMA LLC	**1250MG/5ML (250MG/ML)**	**A210618**	**001**	Dec 28, 2018
AP1		SUN PHARM	**1250MG/5ML (250MG/ML)**	**A208381**	**001**	Apr 09, 2019

MAKENA

AP1	**+!**	COVIS	**1250MG/5ML (250MG/ML)**	**N021945**	**001**	Feb 03, 2011

HYDROXYPROGESTERONE CAPROATE							
SOLUTION;INTRAMUSCULAR							
HYDROXYPROGESTERONE CAPROATE							
	!	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)		A200271	001	Aug 24, 2015
SOLUTION;SUBCUTANEOUS							
MAKENA (AUTOINJECTOR)							
	+!	COVIS	275MG/1.1ML (250MG/ML)		N021945	004	Feb 14, 2018
HYDROXYPROPYL CELLULOSE							
INSERT;OPHTHALMIC							
LACRISERT							
	+!	VALEANT PHARMS INTL	5MG		N018771	001	
HYDROXYUREA							
CAPSULE;ORAL							
HYDREA							
AB	**+!**	BRISTOL MYERS SQUIBB	**500MG**		**N016295**	**001**	
HYDROXYUREA							
AB		BARR	**500MG**		**A075143**	**001**	Oct 16, 1998
AB		LEADING PHARMA LLC	**500MG**		**A213438**	**001**	Apr 08, 2020
AB		PAR PHARM	**500MG**		**A075340**	**001**	Feb 24, 1999
DROXIA							
	+	BRISTOL MYERS SQUIBB	200MG		N016295	002	Feb 25, 1998
	+		300MG		N016295	003	Feb 25, 1998
	+		400MG		N016295	004	Feb 25, 1998
TABLET;ORAL							
SIKLOS							
	+	ADDMEDICA SAS	100MG		N208843	001	Dec 21, 2017
	+!		1GM		N208843	002	Dec 21, 2017
HYDROXYZINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
HYDROXYZINE HYDROCHLORIDE							
	!	AM REGENT	25MG/ML		A087408	001	
	!		50MG/ML		A087408	002	
SYRUP;ORAL							
HYDROXYZINE HYDROCHLORIDE							
AA	**!**	AKORN	**10MG/5ML**		**A040010**	**001**	Oct 28, 1994
AA		LANNETT CO INC	**10MG/5ML**		**A201674**	**001**	Aug 21, 2013
AA	**+!**	WOCKHARDT BIO AG	**10MG/5ML**		**A087294**	**001**	Apr 12, 1982
TABLET;ORAL							
HYDROXYZINE HYDROCHLORIDE							
AB		AMNEAL PHARM	**10MG**		**A040808**	**001**	Sep 24, 2008
AB			**25MG**		**A040808**	**002**	Sep 24, 2008
AB			**50MG**		**A040808**	**003**	Sep 24, 2008
AB		BIOPHARM	**10MG**		**A040804**	**001**	Jun 30, 2008
AB			**25MG**		**A040804**	**002**	Jun 30, 2008
AB			**50MG**		**A040804**	**003**	Jun 30, 2008
AB		EPIC PHARMA LLC	**10MG**		**A040604**	**002**	Dec 28, 2004
AB			**25MG**		**A040604**	**003**	Dec 28, 2004
AB			**50MG**		**A040604**	**001**	Dec 28, 2004
AB		HERITAGE PHARMA	**10MG**		**A204279**	**001**	Aug 20, 2014
AB			**25MG**		**A204279**	**002**	Aug 20, 2014
AB			**50MG**		**A204279**	**003**	Aug 20, 2014
AB		HETERO LABS LTD III	**10MG**		**A040805**	**001**	May 29, 2008
AB			**25MG**		**A040805**	**002**	May 29, 2008
AB			**50MG**		**A040805**	**003**	May 29, 2008
AB		INVAGEN PHARMS	**10MG**		**A040812**	**001**	Mar 12, 2008
AB			**25MG**		**A040812**	**002**	Mar 12, 2008
AB			**50MG**		**A040812**	**003**	Mar 12, 2008
AB		KVK TECH	**10MG**		**A040786**	**001**	Mar 20, 2007
AB			**25MG**		**A040786**	**002**	Mar 20, 2007
AB			**50MG**		**A040786**	**003**	Mar 20, 2007
AB		NORTHSTAR HLTHCARE	**10MG**		**A040840**	**002**	Mar 31, 2008
AB			**25MG**		**A040840**	**003**	Mar 31, 2008
AB			**50MG**		**A040840**	**001**	Mar 31, 2008
AB		NUVO PHARMS INC	**10MG**		**A207121**	**002**	Mar 29, 2017
AB			**25MG**		**A207121**	**001**	Mar 29, 2017
AB			**50MG**		**A207121**	**003**	Mar 29, 2017
AB	**+!**	PLIVA	**10MG**		**A088617**	**001**	Jan 10, 1986
AB	**+!**		**25MG**		**A088618**	**001**	Jan 10, 1986
AB	**+!**		**50MG**		**A088619**	**001**	Jan 10, 1986

HYDROXYZINE HYDROCHLORIDE						
TABLET;ORAL						
HYDROXYZINE HYDROCHLORIDE						
AB		PRINSTON INC	**10MG**	**A040580**	**003**	May 27, 2005
AB			**25MG**	**A040580**	**002**	May 27, 2005
AB			**50MG**	**A040580**	**001**	May 27, 2005
HYDROXYZINE PAMOATE						
CAPSULE;ORAL						
HYDROXYZINE PAMOATE						
AB		BARR	**EQ 25MG HYDROCHLORIDE**	**A088496**	**001**	Jun 15, 1984
AB			**EQ 50MG HYDROCHLORIDE**	**A088487**	**001**	Jun 15, 1984
AB		IMPAX LABS INC	**EQ 25MG HYDROCHLORIDE**	**A040156**	**001**	Jul 15, 1996
AB			**EQ 50MG HYDROCHLORIDE**	**A040156**	**002**	Jul 15, 1996
AB		SANDOZ	**EQ 25MG HYDROCHLORIDE**	**A087479**	**001**	
AB	**!**		**EQ 50MG HYDROCHLORIDE**	**A086183**	**001**	
VISTARIL						
AB	**+**	PFIZER	**EQ 25MG HYDROCHLORIDE**	**N011459**	**002**	
AB	**+**		**EQ 50MG HYDROCHLORIDE**	**N011459**	**004**	
HYDROXYZINE PAMOATE						
BX		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013
BX			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013
		BARR	EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984
IBANDRONATE SODIUM						
INJECTABLE;INTRAVENOUS						
IBANDRONATE SODIUM						
AP		ACCORD HLTHCARE	**EQ 3MG BASE/3ML**	**A206058**	**001**	Feb 05, 2016
AP	**!**	APOTEX	**EQ 3MG BASE/3ML**	**A204222**	**001**	Oct 16, 2015
AP		EUGIA PHARMA	**EQ 3MG BASE/3ML**	**A205332**	**001**	Aug 19, 2015
AP		MYLAN LABS LTD	**EQ 3MG BASE/3ML**	**A202671**	**001**	Sep 02, 2014
AP		SAGENT PHARMS INC	**EQ 3MG BASE/3ML**	**A202235**	**001**	Sep 02, 2014
AP		SUN PHARM	**EQ 3MG BASE/3ML**	**A090853**	**001**	Feb 14, 2014
TABLET;ORAL						
IBANDRONATE SODIUM						
AB		APOTEX INC	**EQ 150MG BASE**	**A078948**	**001**	Mar 19, 2012
AB		AUROBINDO PHARMA LTD	**EQ 150MG BASE**	**A204502**	**001**	Mar 11, 2016
AB	**!**	DR REDDYS LABS LTD	**EQ 150MG BASE**	**A078997**	**001**	Apr 30, 2012
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A206887**	**001**	Oct 31, 2017
AB		ORBION PHARMS	**EQ 150MG BASE**	**A078998**	**001**	Mar 19, 2012
AB		WATSON LABS TEVA	**EQ 150MG BASE**	**A079003**	**001**	Mar 20, 2012
IBREXAFUNGERP CITRATE						
TABLET;ORAL						
BREXAFEMME						
	+!	SCYNEXIS	EQ 150MG BASE	N214900	001	Jun 01, 2021
IBRUTINIB						
CAPSULE;ORAL						
IMBRUVICA						
	+	PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017
	+!		140MG	N205552	001	Nov 13, 2013
TABLET;ORAL						
IMBRUVICA						
	+	PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018
	+		280MG	N210563	002	Feb 16, 2018
	+		420MG	N210563	003	Feb 16, 2018
	+!		560MG	N210563	004	Feb 16, 2018
IBUPROFEN						
SOLUTION;INTRAVENOUS						
CALDOLOR						
	+!	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348	002	Jun 11, 2009
	+!		800MG/200ML (4MG/ML)	N022348	003	Jan 25, 2019
SUSPENSION;ORAL						
IBUPROFEN						
AB	**!**	ACTAVIS MID ATLANTIC	**100MG/5ML**	**A074978**	**001**	Mar 25, 1998
AB		AKORN	**100MG/5ML**	**A205647**	**001**	Nov 03, 2016
AB		PADAGIS US	**100MG/5ML**	**A076925**	**001**	Sep 23, 2004
AB		TARO	**100MG/5ML**	**A209204**	**001**	Jun 23, 2017
		AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018

IBUPROFEN

TABLET;ORAL

IBUPROFEN

AB		ALKEM LABS LTD	**400MG**	**A214699**	**001**	Sep 13, 2021
AB			**600MG**	**A214699**	**002**	Sep 13, 2021
AB			**800MG**	**A214699**	**003**	Sep 13, 2021
AB		AMNEAL PHARMS NY	**400MG**	**A071334**	**001**	Nov 25, 1986
AB			**400MG**	**A078558**	**001**	Jun 18, 2007
AB			**600MG**	**A071335**	**001**	Nov 25, 1986
AB			**600MG**	**A078558**	**002**	Jun 18, 2007
AB			**800MG**	**A071935**	**001**	Oct 13, 1987
AB			**800MG**	**A078558**	**003**	Jun 18, 2007
AB		AUROBINDO PHARMA LTD	**400MG**	**A213794**	**001**	May 08, 2020
AB			**600MG**	**A213794**	**002**	May 08, 2020
AB			**800MG**	**A213794**	**003**	May 08, 2020
AB		CONTRACT PHARMACAL	**400MG**	**A071268**	**002**	Oct 15, 1986
AB			**600MG**	**A071268**	**001**	Oct 15, 1986
AB			**800MG**	**A071268**	**003**	Jul 01, 1988
AB		DR REDDYS LA	**400MG**	**A075682**	**001**	Nov 14, 2001
AB			**600MG**	**A075682**	**002**	Nov 14, 2001
AB	**!**		**800MG**	**A075682**	**003**	Nov 14, 2001
AB		DR REDDYS LABS INC	**400MG**	**A076112**	**001**	Oct 31, 2001
AB			**600MG**	**A076112**	**002**	Oct 31, 2001
AB			**800MG**	**A076112**	**003**	Oct 31, 2001
AB		GRANULES	**400MG**	**A091625**	**001**	Sep 15, 2015
AB			**600MG**	**A091625**	**002**	Sep 15, 2015
AB			**800MG**	**A091625**	**003**	Sep 15, 2015
AB		L PERRIGO CO	**400MG**	**A077114**	**001**	Jul 18, 2005
AB			**600MG**	**A077114**	**002**	Jul 18, 2005
AB			**800MG**	**A077114**	**003**	Jul 18, 2005
AB		MARKSANS PHARMA	**400MG**	**A090796**	**001**	Dec 21, 2010
AB			**600MG**	**A090796**	**002**	Dec 21, 2010
AB			**800MG**	**A090796**	**003**	Dec 21, 2010
AB		SHANDONG XINHUA	**400MG**	**A202413**	**001**	Nov 23, 2016
AB			**600MG**	**A202413**	**002**	Nov 23, 2016
AB			**800MG**	**A202413**	**003**	Nov 23, 2016
AB		STRIDES PHARMA	**400MG**	**A078329**	**001**	Feb 05, 2009
AB			**600MG**	**A078329**	**002**	Feb 05, 2009
AB			**800MG**	**A078329**	**003**	Feb 05, 2009

IBUPROFEN LYSINE

INJECTABLE;INTRAVENOUS

IBUPROFEN LYSINE

AP		XGEN PHARMS	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**A202402**	**001**	Mar 30, 2016

NEOPROFEN

AP	**+!**	RECORDATI RARE	**EQ 20MG BASE/2ML (EQ 10MG BASE/ML)**	**N021903**	**001**	Apr 13, 2006

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

CORVERT

AP	**+!**	PFIZER	**0.1MG/ML**	**N020491**	**001**	Dec 28, 1995

IBUTILIDE FUMARATE

AP		MYLAN INSTITUTIONAL	**0.1MG/ML**	**A090643**	**001**	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

FIRAZYR

AP	**+!**	SHIRE ORPHAN THERAP	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**N022150**	**001**	Aug 25, 2011

ICATIBANT ACETATE

AP		CIPLA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A212446**	**001**	Jul 13, 2020
AP		FRESENIUS KABI USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A208317**	**001**	Jun 18, 2020
AP		GLENMARK PHARMS LTD	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A213222**	**001**	May 21, 2021
AP		JIANGSU HANSOH PHARM	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A211021**	**001**	Mar 09, 2020
AP		NANG KUANG PHARM CO	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A212081**	**001**	Dec 16, 2020
AP		SLAYBACK PHARMA LLC	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A211501**	**001**	Sep 01, 2020
AP		TEVA PHARMS USA	**EQ 30MG BASE/3ML (EQ 10MG BASE/ML)**	**A210118**	**001**	Jul 15, 2019

ICODEXTRIN						
SOLUTION;INTRAPERITONEAL						
EXTRANEAL						
	+!	BAXTER HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002
ICOSAPENT ETHYL						
CAPSULE;ORAL						
ICOSAPENT ETHYL						
AB		APOTEX	**1GM**	**A209437**	**001**	Jun 30, 2021
AB		DR REDDYS	**1GM**	**A209499**	**001**	Aug 07, 2020
AB		HIKMA	**1GM**	**A209457**	**001**	May 21, 2020
VASCEPA						
AB	**+!**	AMARIN PHARMS	**1GM**	**N202057**	**001**	Jul 26, 2012
	+		500MG	N202057	002	Feb 16, 2017
IDARUBICIN HYDROCHLORIDE						
INJECTABLE;INJECTION						
IDAMYCIN PFS						
AP	**+!**	PFIZER	**1MG/ML**	**N050734**	**001**	Feb 17, 1997
IDARUBICIN HYDROCHLORIDE						
AP		HIKMA	**1MG/ML**	**A065275**	**001**	Dec 14, 2006
AP			**1MG/ML**	**A065288**	**001**	May 15, 2007
IDARUBICIN HYDROCHLORIDE PFS						
AP		TEVA PHARMS USA	**1MG/ML**	**A065036**	**001**	May 01, 2002
IDELALISIB						
TABLET;ORAL						
ZYDELIG						
	+	GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014
	+!		150MG	N205858	002	Jul 23, 2014
IFOSFAMIDE						
INJECTABLE;INJECTION						
IFEX						
AP	**+**	BAXTER HLTHCARE	**1GM/VIAL**	**N019763**	**001**	Dec 30, 1988
AP	**+**		**3GM/VIAL**	**N019763**	**002**	Dec 30, 1988
IFOSFAMIDE						
AP	**!**	FRESENIUS KABI USA	**1GM/VIAL**	**A076078**	**001**	May 28, 2002
AP	**!**		**3GM/VIAL**	**A076078**	**002**	May 28, 2002
AP		HIKMA	**1GM/20ML (50MG/ML)**	**A076619**	**001**	Jun 29, 2011
AP			**3GM/60ML (50MG/ML)**	**A076619**	**002**	Jun 29, 2011
AP	**!**	TEVA PHARMS USA	**1GM/20ML (50MG/ML)**	**A076657**	**001**	Apr 04, 2007
AP	**!**		**3GM/60ML (50MG/ML)**	**A076657**	**002**	Apr 04, 2007
ILOPERIDONE						
TABLET;ORAL						
FANAPT						
	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009
	+		2MG	N022192	002	May 06, 2009
	+		4MG	N022192	003	May 06, 2009
	+		6MG	N022192	004	May 06, 2009
	+		8MG	N022192	005	May 06, 2009
	+		10MG	N022192	006	May 06, 2009
	+		12MG	N022192	007	May 06, 2009
ILOPROST						
SOLUTION;INHALATION						
VENTAVIS						
	+!	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005
	+!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009
IMATINIB MESYLATE						
TABLET;ORAL						
GLEEVEC						
AB	**+**	NOVARTIS	**EQ 100MG BASE**	**N021588**	**001**	Apr 18, 2003
AB	**+!**		**EQ 400MG BASE**	**N021588**	**002**	Apr 18, 2003
IMATINIB MESYLATE						
AB		APOTEX	**EQ 100MG BASE**	**A079179**	**001**	Aug 05, 2016
AB			**EQ 400MG BASE**	**A079179**	**002**	Aug 05, 2016
AB		BRECKENRIDGE	**EQ 100MG BASE**	**A205990**	**001**	Feb 08, 2019
AB			**EQ 400MG BASE**	**A205990**	**002**	Feb 08, 2019
AB		DR REDDYS	**EQ 100MG BASE**	**A206547**	**001**	Aug 13, 2018
AB			**EQ 400MG BASE**	**A206547**	**002**	Aug 13, 2018
AB		EUGIA PHARMA	**EQ 100MG BASE**	**A212773**	**001**	Jul 23, 2020
AB			**EQ 400MG BASE**	**A212773**	**002**	Jul 23, 2020
AB		HIKMA	**EQ 100MG BASE**	**A207586**	**001**	Jul 13, 2018

IMATINIB MESYLATE

TABLET;ORAL

IMATINIB MESYLATE

AB			**EQ 400MG BASE**	**A207586**	**002**	Jul 13, 2018
AB		MYLAN	**EQ 100MG BASE**	**A204644**	**001**	Jun 21, 2017
AB			**EQ 400MG BASE**	**A204644**	**002**	Jun 21, 2017
AB		NATCO PHARMA LTD	**EQ 100MG BASE**	**A207818**	**001**	Mar 01, 2019
AB			**EQ 400MG BASE**	**A207818**	**002**	Mar 01, 2019
AB		SHILPA	**EQ 100MG BASE**	**A208302**	**001**	Jan 17, 2019
AB			**EQ 400MG BASE**	**A208302**	**002**	Jan 17, 2019
AB		SUN PHARM	**EQ 100MG BASE**	**A078340**	**001**	Dec 03, 2015
AB			**EQ 400MG BASE**	**A078340**	**002**	Dec 03, 2015
AB		TEVA PHARMS USA	**EQ 100MG BASE**	**A204285**	**001**	Aug 04, 2016
AB			**EQ 400MG BASE**	**A204285**	**002**	Aug 04, 2016
AB		WOCKHARDT BIO AG	**EQ 100MG BASE**	**A208429**	**001**	Jan 17, 2019
AB			**EQ 400MG BASE**	**A208429**	**002**	Jan 17, 2019
AB		ZYDUS PHARMS	**EQ 100MG BASE**	**A210658**	**001**	Apr 08, 2020
AB			**EQ 400MG BASE**	**A210658**	**002**	Apr 08, 2020

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL

IMIPRAMINE HYDROCHLORIDE

AB		LEADING PHARMA LLC	**10MG**	**A040903**	**001**	Oct 24, 2012
AB			**25MG**	**A040903**	**002**	Oct 24, 2012
AB			**50MG**	**A040903**	**003**	Oct 24, 2012
AB		OXFORD PHARMS	**10MG**	**A040751**	**003**	Feb 28, 2008
AB			**25MG**	**A040751**	**002**	Feb 28, 2008
AB			**50MG**	**A040751**	**001**	Feb 28, 2008
AB		SANDOZ	**10MG**	**A084936**	**002**	
AB			**25MG**	**A083745**	**001**	
AB			**50MG**	**A084937**	**001**	
AB	+	SPECGX LLC	**10MG**	**A087846**	**002**	May 22, 1984
AB	+		**25MG**	**A087846**	**003**	May 22, 1984
AB		STRIDES PHARMA	**10MG**	**A088292**	**001**	Oct 21, 1983
AB			**25MG**	**A088262**	**001**	Oct 21, 1983
AB			**50MG**	**A088276**	**001**	Oct 21, 1983
AB		SUN PHARM INDUSTRIES	**10MG**	**A081048**	**001**	Jun 05, 1990
AB			**25MG**	**A081049**	**001**	Jun 05, 1990
AB			**50MG**	**A081050**	**001**	Jun 05, 1990

TOFRANIL

AB	**+!**	SPECGX LLC	**50MG**	**A087846**	**001**	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

AB	**!**	HIKMA	**EQ 75MG HYDROCHLORIDE**	**A091099**	**001**	Apr 16, 2010
AB			**EQ 100MG HYDROCHLORIDE**	**A091099**	**002**	Apr 16, 2010
AB			**EQ 125MG HYDROCHLORIDE**	**A091099**	**003**	Apr 16, 2010
AB			**EQ 150MG HYDROCHLORIDE**	**A091099**	**004**	Apr 16, 2010
AB		LUPIN LTD	**EQ 75MG HYDROCHLORIDE**	**A090444**	**001**	Apr 16, 2010
AB			**EQ 100MG HYDROCHLORIDE**	**A090444**	**002**	Apr 16, 2010
AB			**EQ 125MG HYDROCHLORIDE**	**A090444**	**003**	Apr 16, 2010
AB			**EQ 150MG HYDROCHLORIDE**	**A090444**	**004**	Apr 16, 2010

IMIQUIMOD

CREAM;TOPICAL

ALDARA

AB	**+!**	BAUSCH	**5%**	**N020723**	**001**	Feb 27, 1997

IMIQUIMOD

AB		APOTEX INC	**5%**	**A091308**	**001**	Apr 06, 2012
AB		FOUGERA PHARMS	**5%**	**A078548**	**001**	Feb 25, 2010
AB		GLENMARK GENERICS	**5%**	**A201994**	**001**	Mar 06, 2012
AB		PADAGIS ISRAEL	**5%**	**A078837**	**001**	Sep 07, 2010
AB		TARO	**3.75%**	**A205971**	**001**	Jan 26, 2021
AB			**5%**	**A200173**	**001**	Apr 15, 2011

ZYCLARA

AB	**+!**	BAUSCH	**3.75%**	**N022483**	**001**	Mar 25, 2010
	+!		2.5%	N022483	002	Jul 15, 2011

INAMRINONE LACTATE
INJECTABLE;INJECTION
AMRINONE LACTATE

	!	HIKMA	EQ 5MG BASE/ML	A075513	001	May 09, 2000

INCLISIRAN SODIUM
SOLUTION;SUBCUTANEOUS
LEQVIO

	+!	NOVARTIS	EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	N214012	001	Dec 22, 2021

INDAPAMIDE
TABLET;ORAL
INDAPAMIDE

AB		ACTAVIS ELIZABETH	**1.25MG**	**A074722**	**001**	Jun 17, 1996
AB			**2.5MG**	**A074722**	**002**	Jun 17, 1996
AB		ANI PHARMS	**1.25MG**	**A074299**	**002**	Apr 29, 1996
AB	**!**		**2.5MG**	**A074299**	**001**	Jul 27, 1995

INDIUM IN-111 CHLORIDE
INJECTABLE;INJECTION
INDIUM IN 111 CHLORIDE

	+!	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE
INJECTABLE;INJECTION
INDIUM IN 111 OXYQUINOLINE

AP		BWXT ITG	**1mCi/ML**	**A202586**	**001**	Jul 25, 2018
AP	**+!**	GE HEALTHCARE	**1mCi/ML**	**N019044**	**001**	Dec 24, 1985

INDIUM IN-111 PENTETATE DISODIUM
INJECTABLE;INTRATHECAL
MPI INDIUM DTPA IN 111

	+!	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT
INJECTABLE;INJECTION
OCTREOSCAN

	+!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994

INDOCYANINE GREEN
INJECTABLE;INJECTION
IC-GREEN

AP	**+!**	AKORN	**25MG/VIAL**	**N011525**	**001**	

INDOCYANINE GREEN

AP		RENEW PHARMS	**25MG/VIAL**	**A040811**	**001**	Nov 21, 2007

POWDER;INTRAVENOUS, INTERSTITIAL
SPY AGENT GREEN KIT

	+!	NOVADAQ TECH	25MG/VIAL	N211580	001	Nov 21, 2018

INDOMETHACIN
CAPSULE;ORAL
INDOMETHACIN

AB		CADILA	**25MG**	**A090403**	**001**	Nov 15, 2010
AB			**50MG**	**A090403**	**002**	Nov 15, 2010
AB		GLENMARK GENERICS	**25MG**	**A091276**	**001**	Dec 22, 2010
AB	**!**		**50MG**	**A091276**	**002**	Dec 22, 2010
AB		HETERO LABS LTD III	**25MG**	**A091240**	**001**	Apr 12, 2011
AB			**50MG**	**A091240**	**002**	Apr 12, 2011
AB		SANDOZ	**25MG**	**A070673**	**001**	Apr 29, 1987
AB			**50MG**	**A070674**	**001**	Apr 29, 1987

CAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

AB		AMNEAL PHARMS	**75MG**	**A091549**	**001**	Dec 01, 2010
AB		AVANTHI INC	**75MG**	**A079175**	**001**	Mar 06, 2009
AB		CHARTWELL RX	**75MG**	**A200529**	**001**	Nov 30, 2010
AB		GLENMARK PHARMS LTD	**75MG**	**A203501**	**001**	Jun 22, 2017
AB		HETERO LABS LTD III	**75MG**	**A201807**	**001**	Sep 28, 2012
AB		NOVAST LABS	**75MG**	**A204853**	**001**	May 08, 2017
AB	**!**	SANDOZ	**75MG**	**A074464**	**001**	May 28, 1998
AB		ZYDUS PHARMS	**75MG**	**A202711**	**001**	Sep 25, 2017

INJECTABLE;INJECTION
INDOMETHACIN

	+!	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N022536	001	Mar 17, 2010

SUPPOSITORY;RECTAL
INDOMETHACIN

	!	COSETTE	50MG	A073314	001	Aug 31, 1992

INDOMETHACIN						
SUSPENSION;ORAL						
INDOCIN						
+!	EGALET	25MG/5ML	N018332	001	Oct 10, 1985
INDOMETHACIN SODIUM						
INJECTABLE;INJECTION						
INDOMETHACIN SODIUM						
AP	HOSPIRA INC	**EQ 1MG BASE/VIAL**	**A204118**	**001**	Apr 19, 2016
AP !	NAVINTA LLC	**EQ 1MG BASE/VIAL**	**A206561**	**001**	Jul 19, 2017
AP	WEST-WARD PHARMS INT	**EQ 1MG BASE/VIAL**	**A078713**	**001**	Jul 16, 2008
INFIGRATINIB PHOSPHATE						
CAPSULE;ORAL						
TRUSELTIQ						
+	HELSINN HLTHCARE	25MG	N214622	001	May 28, 2021
+!		100MG	N214622	002	May 28, 2021
INOTERSEN SODIUM						
SOLUTION;SUBCUTANEOUS						
TEGSEDI						
+!	AKCEA THERAPS	EQ 284MG BASE/1.5ML (EQ 189.3MG BASE/ML)	N211172	001	Oct 05, 2018
IOBENGUANE I-131						
SOLUTION;INTRAVENOUS						
AZEDRA						
+!	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018
IOBENGUANE SULFATE I-123						
SOLUTION;INTRAVENOUS						
ADREVIEW						
+!	GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290	001	Sep 19, 2008
IODIXANOL						
INJECTABLE;INJECTION						
VISIPAQUE 270						
+!	GE HEALTHCARE	55%	N020351	001	Mar 22, 1996
VISIPAQUE 320						
+!	GE HEALTHCARE	65.2%	N020351	002	Mar 22, 1996
		65.2%	N020808	002	Aug 29, 1997
IOFLUPANE I-123						
SOLUTION;INTRAVENOUS						
DATSCAN						
+!	GE HLTHCARE INC	5mCi/2.5ML (2mCi/ML)	N022454	001	Jan 14, 2011
IOHEXOL						
INJECTABLE;INJECTION						
OMNIPAQUE 140						
+!	GE HEALTHCARE	30.2%	N018956	005	Nov 30, 1988
SOLUTION;INJECTION, ORAL						
OMNIPAQUE 350						
+!	GE HEALTHCARE	75.5%	N018956	004	Dec 26, 1985
		75.5%	N020608	003	Oct 24, 1995
SOLUTION;INJECTION, ORAL, RECTAL						
OMNIPAQUE 180						
+!	GE HEALTHCARE	38.8%	N018956	001	Dec 26, 1985
OMNIPAQUE 240						
+!	GE HEALTHCARE	51.8%	N018956	002	Dec 26, 1985
OMNIPAQUE 300						
+!	GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985
		64.7%	N020608	002	Oct 24, 1995
SOLUTION;ORAL						
OMNIPAQUE 12						
+!	GE HEALTHCARE	2.6%	N018956	009	Apr 17, 2018
OMNIPAQUE 9						
+!	GE HEALTHCARE	1.9%	N018956	008	Apr 17, 2018

IOPAMIDOL

INJECTABLE;INJECTION						
ISOVUE-200						
+!	BRACCO	41%	N018735	006	Jul 07, 1987	
ISOVUE-250						
+!	BRACCO	51%	N018735	007	Jul 06, 1992	
+!		51%	N020327	002	Oct 12, 1994	
ISOVUE-300						
+!	BRACCO	61%	N018735	002	Dec 31, 1985	
+!		61%	N020327	003	Oct 12, 1994	
ISOVUE-370						
+!	BRACCO	76%	N018735	003	Dec 31, 1985	
+!		76%	N020327	004	Oct 12, 1994	
ISOVUE-M 200						
+!	BRACCO	41%	N018735	001	Dec 31, 1985	
ISOVUE-M 300						
+!	BRACCO	61%	N018735	004	Dec 31, 1985	

IOPROMIDE

INJECTABLE;INJECTION						
ULTRAVIST (PHARMACY BULK)						
+!	BAYER HLTHCARE	62.3%	N021425	001	Sep 20, 2002	
+!		76.9%	N021425	002	Sep 20, 2002	
ULTRAVIST 300						
+!	BAYER HLTHCARE	62.3%	N020220	002	May 10, 1995	
ULTRAVIST 370						
+!	BAYER HLTHCARE	76.9%	N020220	001	May 10, 1995	

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION						
CONRAY						
+!	LIEBEL-FLARSHEIM	60%	N013295	001		
SOLUTION;INTRAVESICAL						
CYSTO-CONRAY II						
	LIEBEL-FLARSHEIM	17.2%	N017057	002		

IOTHALAMATE SODIUM I-125

INJECTABLE;INJECTION						
GLOFIL-125						
	ISOTEX	250-300uCi/ML	N017279	001		

IOVERSOL

INJECTABLE;INJECTION						
OPTIRAY 300						
+!	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	
+!		64%	N020923	004	May 13, 1999	
OPTIRAY 320						
+!	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	
+!		68%	N020923	002	May 29, 1998	
OPTIRAY 350						
+!	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	
+!		74%	N020923	003	May 28, 1998	

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION						
ATROVENT HFA						
+!	BOEHRINGER INGELHEIM	0.021MG/INH	N021527	001	Nov 27, 2004	
SOLUTION;INHALATION						
IPRATROPIUM BROMIDE						
AN	LUOXIN AUROVITAS	**0.02%**	**A206543**	**001**	Oct 27, 2016	
AN	NEPHRON	**0.02%**	**A075562**	**001**	Sep 27, 2001	
AN !	RITEDOSE CORP	**0.02%**	**A075693**	**001**	Jan 26, 2001	
AN	SUN PHARM	**0.02%**	**A207903**	**001**	Jan 03, 2017	
SPRAY, METERED;NASAL						
IPRATROPIUM BROMIDE						
AB	APOTEX INC	**0.021MG/SPRAY**	**A076156**	**001**	Apr 18, 2003	
AB		**0.042MG/SPRAY**	**A076155**	**001**	Apr 18, 2003	
AB	BAUSCH AND LOMB	**0.021MG/SPRAY**	**A076025**	**001**	Mar 31, 2003	
AB		**0.042MG/SPRAY**	**A076103**	**001**	Mar 31, 2003	
AB !	HIKMA	**0.021MG/SPRAY**	**A076664**	**001**	Nov 05, 2003	
AB !		**0.042MG/SPRAY**	**A076598**	**001**	Nov 05, 2003	

IRBESARTAN

TABLET;ORAL

AVAPRO

AB	+	SANOFI AVENTIS US	**75MG**	**N020757**	**001**	Sep 30, 1997
AB	+		**150MG**	**N020757**	**002**	Sep 30, 1997
AB	+!		**300MG**	**N020757**	**003**	Sep 30, 1997

IRBESARTAN

AB	ALEMBIC PHARMS LTD	**75MG**	**A091236**	**001**	Oct 15, 2012
AB		**150MG**	**A091236**	**002**	Oct 15, 2012
AB		**300MG**	**A091236**	**003**	Oct 15, 2012
AB	AMNEAL PHARMS	**75MG**	**A204740**	**001**	Apr 17, 2018
AB		**150MG**	**A204740**	**002**	Apr 17, 2018
AB		**300MG**	**A204740**	**003**	Apr 17, 2018
AB	AUROBINDO PHARMA LTD	**75MG**	**A203081**	**001**	Sep 27, 2012
AB		**150MG**	**A203081**	**002**	Sep 27, 2012
AB		**300MG**	**A203081**	**003**	Sep 27, 2012
AB	CHARTWELL MOLECULAR	**75MG**	**A077205**	**001**	Nov 14, 2012
AB		**150MG**	**A077205**	**002**	Nov 14, 2012
AB		**300MG**	**A077205**	**003**	Nov 14, 2012
AB	HETERO LABS LTD V	**75MG**	**A202910**	**001**	Sep 27, 2012
AB		**150MG**	**A202910**	**002**	Sep 27, 2012
AB		**300MG**	**A202910**	**003**	Sep 27, 2012
AB	HISUN PHARM HANGZHOU	**75MG**	**A206194**	**001**	Jun 14, 2016
AB		**150MG**	**A206194**	**002**	Jun 14, 2016
AB		**300MG**	**A206194**	**003**	Jun 14, 2016
AB	JUBILANT GENERICS	**75MG**	**A203534**	**001**	Feb 23, 2015
AB		**150MG**	**A203534**	**002**	Feb 23, 2015
AB		**300MG**	**A203534**	**003**	Feb 23, 2015
AB	LUPIN LTD	**75MG**	**A201531**	**001**	Oct 15, 2012
AB		**150MG**	**A201531**	**002**	Oct 15, 2012
AB		**300MG**	**A201531**	**003**	Oct 15, 2012
AB	MACLEODS PHARMS LTD	**75MG**	**A202254**	**001**	Oct 03, 2012
AB		**150MG**	**A202254**	**002**	Oct 03, 2012
AB		**300MG**	**A202254**	**003**	Oct 03, 2012
AB	PRINSTON INC	**75MG**	**A203071**	**001**	Sep 27, 2012
AB		**150MG**	**A203071**	**002**	Sep 27, 2012
AB		**300MG**	**A203071**	**003**	Sep 27, 2012
AB	SANDOZ	**75MG**	**A077466**	**001**	Sep 27, 2012
AB		**150MG**	**A077466**	**002**	Sep 27, 2012
AB		**300MG**	**A077466**	**003**	Sep 27, 2012
AB	SCIEGEN PHARMS INC	**75MG**	**A204774**	**001**	Dec 07, 2015
AB		**150MG**	**A204774**	**002**	Dec 07, 2015
AB		**300MG**	**A204774**	**003**	Dec 07, 2015
AB	TEVA PHARMS	**75MG**	**A077159**	**001**	Mar 30, 2012
AB		**150MG**	**A077159**	**002**	Mar 30, 2012
AB		**300MG**	**A077159**	**003**	Mar 30, 2012
AB	UNICHEM	**75MG**	**A203020**	**001**	Dec 07, 2015
AB		**150MG**	**A203020**	**002**	Dec 07, 2015
AB		**300MG**	**A203020**	**003**	Dec 07, 2015
AB	ZYDUS PHARMS USA INC	**75MG**	**A079213**	**001**	Sep 27, 2012
AB		**150MG**	**A079213**	**002**	Sep 27, 2012
AB		**300MG**	**A079213**	**003**	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR

AP	+!	PFIZER INC	**40MG/2ML (20MG/ML)**	**N020571**	**001**	Jun 14, 1996
AP	+!		**100MG/5ML (20MG/ML)**	**N020571**	**002**	Jun 14, 1996
AP	+!		**300MG/15ML (20MG/ML)**	**N020571**	**003**	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	**40MG/2ML (20MG/ML)**	**A079068**	**001**	Nov 21, 2008
AP		**100MG/5ML (20MG/ML)**	**A079068**	**002**	Nov 21, 2008
AP	ACTAVIS TOTOWA	**40MG/2ML (20MG/ML)**	**A078589**	**001**	Feb 27, 2008
AP		**100MG/5ML (20MG/ML)**	**A078589**	**002**	Feb 27, 2008
AP		**500MG/25ML (20MG/ML)**	**A078589**	**003**	Nov 18, 2015
AP	AKORN	**40MG/2ML (20MG/ML)**	**A090726**	**001**	Sep 16, 2009
AP		**100MG/5ML (20MG/ML)**	**A090726**	**002**	Sep 16, 2009
AP	EUGIA PHARMA	**40MG/2ML (20MG/ML)**	**A213278**	**001**	Nov 02, 2020
AP		**100MG/5ML (20MG/ML)**	**A213278**	**002**	Nov 02, 2020
AP		**300MG/15ML (20MG/ML)**	**A213278**	**003**	Nov 02, 2020

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

IRINOTECAN HYDROCHLORIDE

AP		FRESENIUS KABI USA	**40MG/2ML (20MG/ML)**	**A077776**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077776**	**002**	Feb 27, 2008
AP		GLAND PHARMA LTD	**40MG/2ML (20MG/ML)**	**A212993**	**001**	Nov 18, 2019
AP			**100MG/5ML (20MG/ML)**	**A212993**	**002**	Nov 18, 2019
AP		HIKMA FARMACEUTICA	**40MG/2ML (20MG/ML)**	**A091032**	**001**	Dec 20, 2010
AP			**100MG/5ML (20MG/ML)**	**A091032**	**002**	Dec 20, 2010
AP		HISUN PHARM HANGZHOU	**40MG/2ML (20MG/ML)**	**A090016**	**001**	Jan 28, 2009
AP			**100MG/5ML (20MG/ML)**	**A090016**	**002**	Jan 28, 2009
AP		HOSPIRA	**40MG/2ML (20MG/ML)**	**A077915**	**001**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A077915**	**002**	Feb 27, 2008
AP	**!**		**500MG/25ML (20MG/ML)**	**A078796**	**001**	Feb 27, 2008
AP		INTAS PHARMS USA	**40MG/2ML (20MG/ML)**	**A203054**	**001**	Aug 31, 2017
AP			**100MG/5ML (20MG/ML)**	**A203054**	**002**	Aug 31, 2017
AP		JIANGSU PHARMS	**40MG/2ML (20MG/ML)**	**A090675**	**002**	Dec 16, 2011
AP			**100MG/5ML (20MG/ML)**	**A090675**	**001**	Dec 16, 2011
AP		NOVAST LABS	**40MG/2ML (20MG/ML)**	**A206935**	**001**	May 26, 2017
AP			**100MG/5ML (20MG/ML)**	**A206935**	**002**	May 26, 2017
AP		QILU PHARM HAINAN	**40MG/2ML (20MG/ML)**	**A203380**	**001**	May 03, 2016
AP			**100MG/5ML (20MG/ML)**	**A203380**	**002**	May 03, 2016
AP			**300MG/15ML (20MG/ML)**	**A203380**	**003**	May 03, 2016
AP		SHILPA	**40MG/2ML (20MG/ML)**	**A208718**	**001**	Dec 28, 2018
AP			**100MG/5ML (20MG/ML)**	**A208718**	**002**	Dec 28, 2018
AP			**300MG/15ML (20MG/ML)**	**A208718**	**003**	Aug 16, 2019
AP		TEVA PHARMS USA	**40MG/2ML (20MG/ML)**	**A090101**	**002**	Feb 27, 2008
AP			**100MG/5ML (20MG/ML)**	**A090101**	**003**	Feb 27, 2008
AP			**500MG/25ML (20MG/ML)**	**A090101**	**001**	Nov 26, 2008
AP		WEST-WARD PHARMS INT	**40MG/2ML (20MG/ML)**	**A078753**	**001**	Dec 24, 2008
AP			**100MG/5ML (20MG/ML)**	**A078753**	**002**	Dec 24, 2008
AP		ZENNOVA	**40MG/2ML (20MG/ML)**	**A090393**	**002**	May 13, 2011
AP			**100MG/5ML (20MG/ML)**	**A090393**	**003**	May 13, 2011

INJECTABLE, LIPOSOMAL;INTRAVENOUS

ONIVYDE

	+!	IPSEN INC	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015

ISAVUCONAZONIUM SULFATE

CAPSULE;ORAL

CRESEMBA

	+!	ASTELLAS	186MG	N207500	001	Mar 06, 2015

POWDER;INTRAVENOUS

CRESEMBA

	+!	ASTELLAS	372MG	N207501	001	Mar 06, 2015

ISOCARBOXAZID

TABLET;ORAL

MARPLAN

	+!	VALIDUS PHARMS INC	10MG	N011961	001	

ISOFLURANE

LIQUID;INHALATION

FORANE

AN	**+!**	BAXTER HLTHCARE	**99.9%**	**N017624**	**001**	

ISOFLURANE

AN		HALOCARBON PRODS	**99.9%**	**A075225**	**001**	Oct 20, 1999
AN		PIRAMAL CRITICAL	**99.9%**	**A074416**	**001**	Sep 30, 1994
AN		PIRAMAL PHARMA	**99.9%**	**A074502**	**001**	Jun 27, 1995

ISONIAZID

INJECTABLE;INJECTION

ISONIAZID

	!	SANDOZ INC	100MG/ML	A040648	001	Jul 05, 2005

SYRUP;ORAL

ISONIAZID

	+!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983

TABLET;ORAL

ISONIAZID

AA		ANDA REPOSITORY	**100MG**	**A040090**	**001**	Jun 26, 1997
AA			**300MG**	**A040090**	**002**	Jun 26, 1997
AA	**!**	BARR	**100MG**	**A080936**	**001**	
AA	**!**		**300MG**	**A080937**	**002**	
AA		THEPHARMANETWORK	**100MG**	**A202610**	**001**	Oct 29, 2014

ISONIAZID

TABLET;ORAL

ISONIAZID

AA		LLC	**300MG**	**A202610**	**002**	Oct 29, 2014

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP		AMNEAL	**0.2MG/ML**	**A210576**	**001**	Oct 17, 2018
AP		AMPHASTAR PHARMS INC	**0.2MG/ML**	**A210106**	**001**	Jun 18, 2018
AP		AMRING PHARMS	**0.2MG/ML**	**A211237**	**001**	May 19, 2021
AP		AVET LIFESCIENCES	**0.2MG/ML**	**A212189**	**001**	Nov 19, 2021
AP		CIPLA	**0.2MG/ML**	**A210322**	**001**	Jun 12, 2018
AP		EUGIA PHARMA	**0.2MG/ML**	**A211864**	**001**	Feb 09, 2021
AP		MICRO LABS	**0.2MG/ML**	**A210845**	**001**	Feb 16, 2021
AP		NEXUS PHARMS	**0.2MG/ML**	**A206961**	**001**	Aug 02, 2017

ISUPREL

AP	**+!**	BAUSCH	**0.2MG/ML**	**N010515**	**001**	

ISOSORBIDE DINITRATE

TABLET;ORAL

ISORDIL

AB	**+**	BAUSCH	**5MG**	**N012093**	**007**	Jul 29, 1988
AB	**+!**		**40MG**	**N012093**	**001**	Jul 29, 1988

ISOSORBIDE DINITRATE

AB		HIKMA INTL PHARMS	**5MG**	**A086067**	**001**	Oct 29, 1987
AB			**10MG**	**A086066**	**001**	Oct 29, 1987
AB			**20MG**	**A088088**	**001**	Nov 02, 1987
AB		PAR PHARM	**5MG**	**A086923**	**001**	Mar 12, 1987
AB			**10MG**	**A086925**	**001**	Mar 12, 1987
AB			**20MG**	**A087537**	**001**	Oct 02, 1987
AB	**!**		**30MG**	**A087946**	**001**	Jan 12, 1988
AB		PAR PHARM INC	**40MG**	**A211290**	**001**	Nov 23, 2021
AB		SANDOZ	**5MG**	**A086221**	**001**	Jan 07, 1988
AB			**10MG**	**A086223**	**001**	Jan 07, 1988
AB			**20MG**	**A089367**	**001**	Apr 07, 1988
AB		ZYDUS	**5MG**	**A213057**	**001**	Nov 20, 2019
AB			**10MG**	**A213057**	**002**	Nov 20, 2019
AB			**20MG**	**A213057**	**003**	Nov 20, 2019
AB			**30MG**	**A213057**	**004**	Nov 20, 2019
AB			**40MG**	**A213057**	**005**	Nov 20, 2019

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE DINITRATE

	!	SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISOSORBIDE MONONITRATE

AB		ACTAVIS ELIZABETH	**10MG**	**A075037**	**002**	Oct 30, 1998
AB			**20MG**	**A075037**	**001**	Oct 30, 1998

MONOKET

AB	**+**	ECI PHARMS LLC	**10MG**	**N020215**	**002**	Jun 30, 1993
AB	**+!**		**20MG**	**N020215**	**001**	Jun 30, 1993

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

AB		DEXCEL LTD	**30MG**	**A075522**	**002**	Sep 20, 2016
AB			**60MG**	**A075522**	**001**	Apr 17, 2000
AB			**120MG**	**A210822**	**001**	Aug 29, 2018
AB		LANNETT CO INC	**30MG**	**A075155**	**002**	Jan 13, 2000
AB			**60MG**	**A075155**	**001**	Oct 30, 1998
AB	**!**		**120MG**	**A075155**	**003**	Aug 04, 2000
AB		NESHER PHARMS	**30MG**	**A075395**	**001**	Mar 16, 2000
AB			**60MG**	**A075395**	**002**	Mar 16, 2000
AB			**120MG**	**A075395**	**003**	Mar 16, 2000
AB		RICONPHARMA LLC	**30MG**	**A210918**	**001**	Nov 05, 2018
AB			**60MG**	**A210918**	**002**	Nov 05, 2018
AB			**120MG**	**A210918**	**003**	Nov 05, 2018
AB		TORRENT PHARMS	**30MG**	**A200270**	**001**	Jun 03, 2011
AB			**60MG**	**A200495**	**001**	Jun 03, 2011
AB			**120MG**	**A200495**	**002**	Jun 03, 2011

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

AP		EUGIA PHARMA	**1%**	**A206831**	**001**	Feb 02, 2016
AP		MEITHEAL	**1%**	**A213130**	**001**	Nov 03, 2021
AP	!	MYLAN INSTITUTIONAL	**1%**	**A090874**	**001**	Jul 20, 2010

ISOTRETINOIN

CAPSULE;ORAL

AMNESTEEM

AB1		MYLAN PHARMS INC	**10MG**	**A075945**	**001**	Nov 08, 2002
AB1			**20MG**	**A075945**	**002**	Nov 08, 2002
AB1			**40MG**	**A075945**	**003**	Nov 08, 2002

CLARAVIS

AB1		TEVA PHARMS USA	**10MG**	**A076356**	**001**	Apr 11, 2003
AB1			**20MG**	**A076135**	**002**	Apr 11, 2003
AB1			**30MG**	**A076135**	**003**	May 11, 2006
AB1	!		**40MG**	**A076135**	**001**	Apr 11, 2003

ISOTRETINOIN

AB1		AMNEAL PHARMS NY	**10MG**	**A207792**	**001**	Sep 29, 2017
AB1			**20MG**	**A207792**	**002**	Sep 29, 2017
AB1			**30MG**	**A207792**	**003**	Sep 29, 2017
AB1			**40MG**	**A207792**	**004**	Sep 29, 2017

MYORISAN

AB1		DOUGLAS PHARMS	**10MG**	**A076485**	**001**	Jan 19, 2012
AB1			**20MG**	**A076485**	**002**	Jan 19, 2012
AB1			**30MG**	**A076485**	**004**	Aug 25, 2015
AB1			**40MG**	**A076485**	**003**	Jan 19, 2012

ZENATANE

AB1		DR REDDYS LABS LTD	**10MG**	**A202099**	**001**	Mar 25, 2013
AB1			**20MG**	**A202099**	**002**	Mar 25, 2013
AB1			**30MG**	**A202099**	**004**	Feb 23, 2015
AB1			**40MG**	**A202099**	**003**	Mar 25, 2013

ABSORICA

AB2	+	SUN PHARM INDS INC	**10MG**	**N021951**	**001**	May 25, 2012
AB2	+		**20MG**	**N021951**	**002**	May 25, 2012
AB2	+		**25MG**	**N021951**	**005**	Aug 15, 2014
AB2	+		**30MG**	**N021951**	**003**	May 25, 2012
AB2	+		**35MG**	**N021951**	**006**	Aug 15, 2014
AB2	+!		**40MG**	**N021951**	**004**	May 25, 2012

ISOTRETINOIN

AB2		ACTAVIS LABS FL	**10MG**	**A205063**	**001**	Mar 31, 2021
AB2			**20MG**	**A205063**	**002**	Mar 31, 2021
AB2			**25MG**	**A205063**	**003**	Mar 31, 2021
AB2			**30MG**	**A205063**	**004**	Mar 31, 2021
AB2			**35MG**	**A205063**	**005**	Mar 31, 2021
AB2			**40MG**	**A205063**	**006**	Mar 31, 2021
AB2		UPSHER SMITH LABS	**10MG**	**A212333**	**001**	Sep 21, 2021
AB2			**20MG**	**A212333**	**002**	Sep 21, 2021
AB2			**30MG**	**A212333**	**003**	Sep 21, 2021
AB2			**40MG**	**A213571**	**001**	Apr 12, 2021

ABSORICA LD

	+	SUN PHARM	8MG	N211913	001	Nov 05, 2019
	+		16MG	N211913	002	Nov 05, 2019
	+		24MG	N211913	004	Nov 05, 2019
	+!		32MG	N211913	006	Nov 05, 2019

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB		ELITE LABS INC	**2.5MG**	**A077169**	**001**	Apr 24, 2006
AB			**5MG**	**A077169**	**002**	Apr 24, 2006
AB		WATSON LABS TEVA	**2.5MG**	**A077317**	**001**	Jan 05, 2006
AB	!		**5MG**	**A077317**	**002**	Jan 05, 2006

ISTRADEFYLLINE

TABLET;ORAL

NOURIANZ

	+	KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019
	+!		40MG	N022075	002	Aug 27, 2019

ITRACONAZOLE							
CAPSULE;ORAL							
ITRACONAZOLE							
AB		ACCORD HLTHCARE	**100MG**	**A205991**	**001**	May 26, 2016
AB		ALEMBIC PHARMS LTD	**100MG**	**A206741**	**001**	Dec 13, 2016
AB		ALKEM LABS LTD	**100MG**	**A208591**	**001**	Jun 12, 2017
AB		AMNEAL PHARMS	**100MG**	**A205080**	**001**	Sep 26, 2016
AB		JUBILANT GENERICS	**100MG**	**A203445**	**001**	Feb 23, 2017
AB		PAR PHARM INC	**100MG**	**A205724**	**001**	Dec 13, 2016
AB		SANDOZ	**100MG**	**A076104**	**001**	May 28, 2004
AB		TORRENT	**100MG**	**A209460**	**001**	Aug 24, 2018
AB		ZYDUS PHARMS	**100MG**	**A204672**	**001**	Sep 19, 2017
SPORANOX							
AB	**+!**	JANSSEN PHARMS	**100MG**	**N020083**	**001**	Sep 11, 1992
TOLSURA							
	+!	MAYNE PHARMA INTL	65MG	N208901	001	Dec 11, 2018
SOLUTION;ORAL							
ITRACONAZOLE							
AA		AMNEAL PHARMS	**10MG/ML**	**A205573**	**001**	Oct 30, 2015
AA		ANNORA PHARMA	**10MG/ML**	**A212239**	**001**	Sep 01, 2020
SPORANOX							
AA	**+!**	JANSSEN PHARMS	**10MG/ML**	**N020657**	**001**	Feb 21, 1997
IVABRADINE							
SOLUTION;ORAL							
CORLANOR							
	+!	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019
IVABRADINE HYDROCHLORIDE							
TABLET;ORAL							
CORLANOR							
AB	**+**	AMGEN INC	**EQ 5MG BASE**	**N206143**	**001**	Apr 15, 2015
AB	**+!**		**EQ 7.5MG BASE**	**N206143**	**002**	Apr 15, 2015
IVABRADINE HYDROCHLORIDE							
AB		CENTAUR PHARMS PVT	**EQ 5MG BASE**	**A214051**	**001**	Dec 30, 2021
AB			**EQ 7.5MG BASE**	**A214051**	**002**	Dec 30, 2021
IVACAFTOR							
GRANULE;ORAL							
KALYDECO							
	+	VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019
	+		50MG/PACKET	N207925	001	Mar 17, 2015
	+!		75MG/PACKET	N207925	002	Mar 17, 2015
TABLET;ORAL							
KALYDECO							
	+!	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012
IVACAFTOR; IVACAFTOR, TEZACAFTOR							
TABLET;ORAL							
SYMDEKO (COPACKAGED)							
	+	VERTEX PHARMS INC	75MG;75MG, 50MG	N210491	002	Jun 21, 2019
	+!		150MG;150MG, 100MG	N210491	001	Feb 12, 2018
IVACAFTOR; LUMACAFTOR							
GRANULE;ORAL							
ORKAMBI							
	+	VERTEX PHARMS INC	125MG/PACKET;100MG/PACKET	N211358	001	Aug 07, 2018
	+!		188MG/PACKET;150MG/PACKET	N211358	002	Aug 07, 2018
TABLET;ORAL							
ORKAMBI							
	+	VERTEX PHARMS INC	125MG;100MG	N206038	002	Sep 28, 2016
	+!		125MG;200MG	N206038	001	Jul 02, 2015
IVERMECTIN							
CREAM;TOPICAL							
IVERMECTIN							
AB		TEVA PHARMS USA	**1%**	**A210019**	**001**	Sep 13, 2019
SOOLANTRA							
AB	**+!**	GALDERMA LABS LP	**1%**	**N206255**	**001**	Dec 19, 2014
TABLET;ORAL							
IVERMECTIN							
AB		EDENBRIDGE PHARMS	**3MG**	**A204154**	**001**	Oct 24, 2014
STROMECTOL							
AB	**+!**	MERCK SHARP DOHME	**3MG**	**N050742**	**002**	Oct 08, 1998

IVOSIDENIB							
TABLET;ORAL							
TIBSOVO							
	+!	SERVIER	250MG	N211192	001	Jul 20, 2018
IXABEPILONE							
INJECTABLE;INTRAVENOUS							
IXEMPRA KIT							
	+!	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007
	+!		45MG/VIAL	N022065	002	Oct 16, 2007
IXAZOMIB CITRATE							
CAPSULE;ORAL							
NINLARO							
	+	TAKEDA PHARMS USA	EQ 2.3MG BASE	N208462	001	Nov 20, 2015
	+		EQ 3MG BASE	N208462	002	Nov 20, 2015
	+!		EQ 4MG BASE	N208462	003	Nov 20, 2015
KETAMINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
KETALAR							
AP	**+!**	PAR STERILE PRODUCTS	**EQ 10MG BASE/ML**	**N016812**	**001**		
AP	**+!**		**EQ 50MG BASE/ML**	**N016812**	**002**		
AP	**+!**		**EQ 100MG BASE/ML**	**N016812**	**003**		
KETAMINE HYDROCHLORIDE							
AP		EUGIA PHARMA	**EQ 10MG BASE/ML**	**A076092**	**001**	Sep 30, 2008
AP			**EQ 50MG BASE/ML**	**A076092**	**002**	Dec 28, 2001
AP			**EQ 100MG BASE/ML**	**A076092**	**003**	Oct 25, 2002
AP		HIKMA	**EQ 50MG BASE/ML**	**A074524**	**001**	Mar 22, 1996
AP			**EQ 100MG BASE/ML**	**A074524**	**002**	Mar 22, 1996
AP		HOSPIRA	**EQ 50MG BASE/ML**	**A074549**	**001**	Jun 27, 1996
AP			**EQ 100MG BASE/ML**	**A074549**	**002**	Jun 27, 1996
KETOCONAZOLE							
AEROSOL, FOAM;TOPICAL							
EXTINA							
AB	**+!**	MYLAN	**2%**	**N021738**	**001**	Jun 12, 2007
KETOCONAZOLE							
AB		PADAGIS ISRAEL	**2%**	**A091550**	**001**	Aug 25, 2011
AB		XIROMED	**2%**	**A213601**	**001**	May 21, 2021
CREAM;TOPICAL							
KETOCONAZOLE							
AB		ENCUBE	**2%**	**A212443**	**001**	May 20, 2021
AB		FOUGERA PHARMS	**2%**	**A076294**	**001**	Apr 28, 2004
AB		TASMAN PHARMA	**2%**	**A215185**	**001**	Nov 17, 2021
AB	**!**	TEVA	**2%**	**A075581**	**001**	Apr 25, 2000
KETOZOLE							
AB		TARO	**2%**	**A075638**	**001**	Dec 18, 2002
GEL;TOPICAL							
XOLEGEL							
	+!	ALMIRALL	2%	N021946	001	Jul 28, 2006
SHAMPOO;TOPICAL							
KETOCONAZOLE							
AB	**!**	PADAGIS ISRAEL	**2%**	**A076419**	**001**	Jan 07, 2004
AB		TOLMAR	**2%**	**A076942**	**001**	Apr 11, 2005
TABLET;ORAL							
KETOCONAZOLE							
AB		SENORES PHARMS	**200MG**	**A075912**	**001**	Jan 10, 2002
AB		STRIDES PHARMA	**200MG**	**A210457**	**001**	Jun 18, 2018
AB	**!**	TARO	**200MG**	**A075319**	**001**	Jun 15, 1999
KETOPROFEN							
CAPSULE;ORAL							
KETOPROFEN							
AB		MISEMER	**50MG**	**A074014**	**002**	Jan 29, 1993
AB		TEVA	**50MG**	**A073516**	**001**	Dec 22, 1992
		MISEMER	25MG	A074014	001	Jan 29, 1993
	!		75MG	A074014	003	Jan 29, 1993
CAPSULE, EXTENDED RELEASE;ORAL							
KETOPROFEN							
	!	MYLAN	200MG	A075679	001	Feb 20, 2002	

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP		BAXTER HLTHCARE CORP	**15MG/ML**	**A209900**	**002**	Jul 25, 2018
AP			**30MG/ML**	**A209900**	**001**	Sep 15, 2017
AP		FRESENIUS KABI USA	**15MG/ML**	**A075784**	**001**	Jan 11, 2002
AP			**15MG/ML**	**A203242**	**001**	Oct 07, 2015
AP			**30MG/ML**	**A075784**	**002**	Jan 11, 2002
AP			**30MG/ML**	**A203242**	**002**	Oct 07, 2015
AP		GLAND	**15MG/ML**	**A204216**	**001**	Nov 01, 2016
AP			**30MG/ML**	**A204216**	**002**	Nov 01, 2016
AP		HIKMA	**15MG/ML**	**A075772**	**001**	Jul 21, 2004
AP			**30MG/ML**	**A075772**	**002**	Jul 21, 2004
AP	**!**	HOSPIRA	**15MG/ML**	**A074802**	**001**	Jun 05, 1997
AP	**!**		**30MG/ML**	**A074802**	**002**	Jun 05, 1997
AP			**30MG/ML**	**A074993**	**002**	Jan 27, 1999
AP		NEPHRON	**30MG/ML**	**A211445**	**001**	Aug 20, 2020
AP		SAGENT PHARMS INC	**15MG/ML**	**A091065**	**001**	Nov 27, 2013
AP			**30MG/ML**	**A091065**	**002**	Nov 27, 2013
AP		SANDOZ INC	**30MG/ML**	**A076271**	**002**	Oct 06, 2004
AP		WOCKHARDT	**15MG/ML**	**A077942**	**001**	Mar 27, 2007
AP			**30MG/ML**	**A077942**	**002**	Mar 27, 2007

SOLUTION/DROPS;OPHTHALMIC

ACULAR

AT	**+!**	ALLERGAN	**0.5%**	**N019700**	**001**	Nov 09, 1992

ACULAR LS

AT	**+!**	ALLERGAN	**0.4%**	**N021528**	**001**	May 30, 2003

KETOROLAC TROMETHAMINE

AT		AKORN	**0.4%**	**A078399**	**001**	Nov 05, 2009
AT			**0.5%**	**A078434**	**001**	Nov 05, 2009
AT		APOTEX INC	**0.4%**	**A077308**	**001**	Nov 05, 2009
AT			**0.5%**	**A076109**	**001**	Nov 05, 2009
AT		MICRO LABS LTD INDIA	**0.5%**	**A203410**	**001**	Apr 05, 2019
AT		SANDOZ INC	**0.5%**	**A076583**	**001**	Nov 05, 2009
AT		SUN PHARM	**0.5%**	**A090017**	**001**	Nov 05, 2009

ACUVAIL

	+!	ALLERGAN	0.45%	N022427	001	Jul 22, 2009

SPRAY, METERED;NASAL

SPRIX

	+!	ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010

TABLET;ORAL

KETOROLAC TROMETHAMINE

AB		CYCLE PHARMS LTD	**10MG**	**A210616**	**001**	Aug 16, 2018
AB		MYLAN	**10MG**	**A074761**	**001**	May 16, 1997
AB	**!**	TEVA	**10MG**	**A074754**	**001**	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

AT		LUPIN LTD	**EQ 0.3% BASE;EQ 1% BASE**	**A210183**	**001**	Jul 01, 2019

OMIDRIA

AT	**+!**	OMEROS	**EQ 0.3% BASE;EQ 1% BASE**	**N205388**	**001**	May 30, 2014

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

	+	EMMAUS MEDCL	5GM/PACKET	N208587	001	Jul 07, 2017

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP		AKORN	**5MG/ML**	**A075431**	**001**	Nov 29, 1999
AP		BAXTER HLTHCARE CORP	**5MG/ML**	**A076051**	**001**	Jul 05, 2002
AP		CAPLIN	**5MG/ML**	**A214533**	**001**	Sep 07, 2021
AP		GLAND PHARMA LTD	**5MG/ML**	**A090699**	**001**	Apr 03, 2012
AP		HIKMA	**5MG/ML**	**A075303**	**001**	May 28, 1999
AP	**!**	HOSPIRA	**5MG/ML**	**A075239**	**001**	Nov 29, 1999
AP	**!**		**5MG/ML**	**A075240**	**001**	Nov 29, 1999

SOLUTION;INTRAVENOUS

LABETALOL HYDROCHLORIDE IN DEXTROSE

	+!	HIKMA	200MG/200ML (1MG/ML)	N213330	001	Nov 09, 2020

LABETALOL HYDROCHLORIDE						
SOLUTION;INTRAVENOUS						
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE						
	+!	HIKMA	100MG/100ML (1MG/ML)	N213330	002	Nov 09, 2020
	+!		200MG/200ML (1MG/ML)	N213330	003	Nov 09, 2020
	+!		300MG/300ML (1MG/ML)	N213330	004	Nov 09, 2020
TABLET;ORAL						
LABETALOL HYDROCHLORIDE						
AB		APPCO	**100MG**	**A209603**	**001**	Jun 20, 2018
AB			**200MG**	**A209603**	**002**	Jun 20, 2018
AB			**300MG**	**A209603**	**003**	Jun 20, 2018
AB		CADILA PHARMS LTD	**100MG**	**A211325**	**001**	May 13, 2019
AB			**200MG**	**A211325**	**002**	May 13, 2019
AB			**300MG**	**A211325**	**003**	May 13, 2019
AB		EPIC PHARMA LLC	**100MG**	**A212990**	**001**	Sep 30, 2020
AB			**200MG**	**A212990**	**002**	Sep 30, 2020
AB			**300MG**	**A212990**	**003**	Sep 30, 2020
AB		EYWA	**100MG**	**A207863**	**001**	Feb 04, 2019
AB			**200MG**	**A207863**	**002**	Feb 04, 2019
AB			**300MG**	**A207863**	**003**	Feb 04, 2019
AB		HERITAGE PHARMA	**100MG**	**A074787**	**001**	Aug 03, 1998
AB			**200MG**	**A074787**	**002**	Aug 03, 1998
AB			**300MG**	**A074787**	**003**	Aug 03, 1998
AB		INNOGENIX	**100MG**	**A075215**	**001**	Jul 29, 1999
AB			**200MG**	**A075215**	**002**	Jul 29, 1999
AB			**300MG**	**A075215**	**003**	Jul 29, 1999
AB		PAR FORM	**100MG**	**A200908**	**001**	Jul 10, 2012
AB	**!**		**200MG**	**A200908**	**002**	Jul 10, 2012
AB			**300MG**	**A200908**	**003**	Jul 10, 2012
AB		RUBICON	**100MG**	**A211953**	**001**	Aug 18, 2021
AB			**200MG**	**A211953**	**002**	Aug 18, 2021
AB			**300MG**	**A211953**	**003**	Aug 18, 2021
AB		SANDOZ	**100MG**	**A075113**	**001**	Aug 04, 1998
AB	**!**		**200MG**	**A075113**	**002**	Aug 04, 1998
AB			**300MG**	**A075113**	**003**	Aug 04, 1998
AB		WATSON LABS	**100MG**	**A075133**	**001**	Aug 03, 1998
AB			**200MG**	**A075133**	**002**	Aug 03, 1998
AB			**300MG**	**A075133**	**003**	Aug 03, 1998
AB		ZYDUS PHARMS	**100MG**	**A207743**	**001**	Sep 19, 2017
AB			**200MG**	**A207743**	**002**	Sep 19, 2017
AB			**300MG**	**A207743**	**003**	Sep 19, 2017
TRANDATE						
AB	**+**	ALVOGEN	**200MG**	**N018716**	**002**	Aug 01, 1984
AB	**+**		**300MG**	**N018716**	**003**	Aug 01, 1984
LACOSAMIDE						
SOLUTION;INTRAVENOUS						
VIMPAT						
	+!	UCB INC	200MG/20ML (10MG/ML)	N022254	001	Oct 28, 2008
SOLUTION;ORAL						
VIMPAT						
	+!	UCB INC	10MG/ML	N022255	001	Apr 20, 2010
TABLET;ORAL						
VIMPAT						
	+	UCB INC	50MG	N022253	001	Oct 28, 2008
	+		100MG	N022253	002	Oct 28, 2008
	+		150MG	N022253	003	Oct 28, 2008
	+!		200MG	N022253	004	Oct 28, 2008
LACTULOSE						
FOR SOLUTION;ORAL						
LACTULOSE						
	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997
	!		20GM/PACKET	A074712	002	Dec 10, 1997
SOLUTION;ORAL						
LACTULOSE						
AA	**!**	AKORN	**10GM/15ML**	**A074076**	**001**	Jul 03, 1995
AA		CHARTWELL RX	**10GM/15ML**	**A209517**	**001**	Nov 23, 2018
AA		FRESENIUS KABI	**10GM/15ML**	**A090503**	**001**	Jan 25, 2012
AA		LANNETT CO INC	**10GM/15ML**	**A075993**	**001**	Jul 26, 2001
AA		PHARM ASSOC	**10GM/15ML**	**A074623**	**001**	Jul 30, 1996
AA		TORRENT	**10GM/15ML**	**A207786**	**001**	Jun 11, 2018
AA		VISTAPHARM	**10GM/15ML**	**A074138**	**001**	Sep 30, 1992

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA		WOCKHARDT BIO AG	**10GM/15ML**	**A074602**	**001**	Nov 14, 1996
AA		XTTRIUM LABS INC	**10GM/15ML**	**A075911**	**001**	Feb 21, 2002

SOLUTION;ORAL, RECTAL

GENERLAC

AA		WOCKHARDT BIO AG	**10GM/15ML**	**A074603**	**001**	Oct 31, 1996

LACTULOSE

AA		AKORN	**10GM/15ML**	**A074077**	**001**	Jul 03, 1995
AA	!	FRESENIUS KABI	**10GM/15ML**	**A090502**	**001**	Jan 25, 2012
AA		TORRENT	**10GM/15ML**	**A203762**	**001**	Mar 27, 2015

LAMIVUDINE

SOLUTION;ORAL

EPIVIR

AA	**+!**	VIIV HLTHCARE	**10MG/ML**	**N020596**	**001**	Nov 17, 1995

LAMIVUDINE

AA		AUROBINDO PHARMA LTD	**10MG/ML**	**A077695**	**001**	Nov 21, 2016
AA		LANNETT CO INC	**10MG/ML**	**A203564**	**001**	Oct 31, 2014

EPIVIR-HBV

	+!	GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998

TABLET;ORAL

EPIVIR

AB	**+**	VIIV HLTHCARE	**150MG**	**N020564**	**001**	Nov 17, 1995
AB	**+!**		**300MG**	**N020564**	**003**	Jun 24, 2002

EPIVIR-HBV

AB	**+!**	GLAXOSMITHKLINE	**100MG**	**N021003**	**001**	Dec 08, 1998

LAMIVUDINE

AB		ANNORA	**100MG**	**A211306**	**001**	Mar 21, 2019
AB		APOTEX	**100MG**	**A202941**	**001**	Jan 02, 2014
AB			**150MG**	**A091606**	**001**	Dec 02, 2011
AB			**300MG**	**A091606**	**002**	Dec 02, 2011
AB		APPCO	**150MG**	**A206974**	**001**	Nov 21, 2016
AB			**300MG**	**A206974**	**002**	Nov 21, 2016
AB		AUROBINDO PHARMA LTD	**150MG**	**A077464**	**001**	Nov 21, 2016
AB			**150MG**	**A202032**	**001**	Nov 17, 2011
AB			**300MG**	**A077464**	**002**	Nov 21, 2016
AB			**300MG**	**A202032**	**002**	Nov 17, 2011
AB		BRECKENRIDGE	**150MG**	**A203586**	**001**	Nov 21, 2016
AB		CIPLA	**150MG**	**A077221**	**001**	Mar 03, 2017
AB			**300MG**	**A077221**	**002**	Mar 03, 2017
AB		HETERO LABS LTD V	**100MG**	**A203260**	**001**	Jan 02, 2014
AB			**150MG**	**A203277**	**001**	Jan 06, 2014
AB			**300MG**	**A203277**	**002**	Jan 06, 2014
AB		LUPIN LTD	**150MG**	**A205217**	**001**	Dec 18, 2014
AB			**300MG**	**A205217**	**002**	Dec 18, 2014
AB		MACLEODS PHARMS LTD	**150MG**	**A090198**	**001**	May 01, 2019
AB			**300MG**	**A090198**	**002**	May 01, 2019
AB		MYLAN LABS LTD	**150MG**	**A078545**	**001**	Mar 05, 2019
AB			**300MG**	**A078545**	**002**	Mar 05, 2019
AB		STRIDES PHARMA	**150MG**	**A090457**	**001**	Apr 19, 2018
AB			**300MG**	**A090457**	**002**	Apr 19, 2018

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

CIMDUO

	+!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

AB	**+!**	VIIV HLTHCARE	**150MG;300MG**	**N020857**	**001**	Sep 26, 1997

LAMIVUDINE AND ZIDOVUDINE

AB		ANDA REPOSITORY	**150MG;300MG**	**A206375**	**001**	Apr 10, 2018
AB		AUROBINDO PHARMA LTD	**150MG;300MG**	**A077558**	**001**	May 05, 2017
AB			**150MG;300MG**	**A202418**	**001**	May 15, 2012
AB		CIPLA	**150MG;300MG**	**A077411**	**001**	Sep 07, 2018
AB		HETERO LABS LTD III	**150MG;300MG**	**A079124**	**001**	Sep 17, 2015
AB		HETERO LABS LTD V	**150MG;300MG**	**A203259**	**001**	Feb 03, 2014
AB		LUPIN LTD	**150MG;300MG**	**A090246**	**001**	May 15, 2012

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		MACLEODS PHARMS LTD	**150MG;300MG**	**A090679**	**001**	Aug 29, 2018
AB		STRIDES PHARMA	**150MG;300MG**	**A079128**	**001**	May 13, 2015

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

AB	**+!**	GLAXOSMITHKLINE LLC	**25MG**	**N020241**	**005**	Dec 27, 1994
AB	**+**		**100MG**	**N020241**	**001**	Dec 27, 1994
AB	**+**		**150MG**	**N020241**	**002**	Dec 27, 1994
AB	**+**		**200MG**	**N020241**	**003**	Dec 27, 1994

LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	**25MG**	**A090607**	**001**	Jan 13, 2011
AB			**100MG**	**A090607**	**002**	Jan 13, 2011
AB			**150MG**	**A090607**	**003**	Jan 13, 2011
AB			**200MG**	**A090607**	**004**	Jan 13, 2011
AB		ALKEM LABS LTD	**25MG**	**A200694**	**001**	Jun 14, 2013
AB			**100MG**	**A200694**	**002**	Jun 14, 2013
AB			**150MG**	**A200694**	**003**	Jun 14, 2013
AB			**200MG**	**A200694**	**004**	Jun 14, 2013
AB		AUROBINDO PHARMA	**25MG**	**A078956**	**001**	Jan 27, 2009
AB			**100MG**	**A078956**	**002**	Jan 27, 2009
AB			**150MG**	**A078956**	**003**	Jan 27, 2009
AB			**200MG**	**A078956**	**004**	Jan 27, 2009
AB		DR REDDYS LABS LTD	**25MG**	**A076708**	**001**	Jan 27, 2009
AB			**100MG**	**A076708**	**002**	Jan 27, 2009
AB			**150MG**	**A076708**	**003**	Jan 27, 2009
AB			**200MG**	**A076708**	**004**	Jan 27, 2009
AB		GLENMARK GENERICS	**25MG**	**A090169**	**001**	May 12, 2012
AB			**100MG**	**A090169**	**002**	May 12, 2012
AB			**150MG**	**A090169**	**003**	May 12, 2012
AB			**200MG**	**A090169**	**004**	May 12, 2012
AB		JUBILANT CADISTA	**25MG**	**A079132**	**001**	Jan 27, 2009
AB			**100MG**	**A079132**	**002**	Jan 27, 2009
AB			**150MG**	**A079132**	**003**	Jan 27, 2009
AB			**200MG**	**A079132**	**004**	Jan 27, 2009
AB		LUPIN LTD	**25MG**	**A078691**	**001**	Jun 01, 2010
AB			**100MG**	**A078691**	**002**	Jun 01, 2010
AB			**150MG**	**A078691**	**003**	Jun 01, 2010
AB			**200MG**	**A078691**	**004**	Jun 01, 2010
AB		RUBICON	**25MG**	**A078625**	**001**	Jan 27, 2009
AB			**100MG**	**A078625**	**002**	Jan 27, 2009
AB			**150MG**	**A078625**	**003**	Jan 27, 2009
AB			**200MG**	**A078625**	**004**	Jan 27, 2009
AB		TARO PHARM INDS	**25MG**	**A078525**	**001**	Jan 27, 2009
AB			**100MG**	**A078525**	**002**	Jan 27, 2009
AB			**150MG**	**A078525**	**003**	Jan 27, 2009
AB			**200MG**	**A078525**	**004**	Jan 27, 2009
AB		TORRENT PHARMS	**25MG**	**A078947**	**001**	Jan 27, 2009
AB			**100MG**	**A078947**	**002**	Jan 27, 2009
AB			**150MG**	**A078947**	**003**	Jan 27, 2009
AB			**200MG**	**A078947**	**004**	Jan 27, 2009
AB		UNICHEM LABS LTD	**25MG**	**A090170**	**001**	Oct 06, 2011
AB			**100MG**	**A090170**	**002**	Oct 06, 2011
AB			**150MG**	**A090170**	**003**	Oct 06, 2011
AB			**200MG**	**A090170**	**004**	Oct 06, 2011
AB		ZYDUS PHARMS USA	**25MG**	**A077633**	**001**	Jan 27, 2009
AB			**100MG**	**A077633**	**003**	Jan 27, 2009
AB			**150MG**	**A077633**	**004**	Jan 27, 2009
AB			**200MG**	**A077633**	**005**	Jan 27, 2009
			50MG	A077633	002	Jan 27, 2009
			250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

AB	**+**	GLAXOSMITHKLINE LLC	**2MG**	**N020764**	**004**	Sep 08, 2000
AB	**+**		**5MG**	**N020764**	**001**	Aug 24, 1998
AB	**+!**		**25MG**	**N020764**	**002**	Aug 24, 1998

LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	**5MG**	**A201168**	**001**	Jun 12, 2014
AB			**25MG**	**A201168**	**002**	Jun 12, 2014
AB		AUROBINDO PHARMA	**5MG**	**A090401**	**002**	Nov 04, 2009

LAMOTRIGINE

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

AB			**25MG**	**A090401**	**003**	Nov 04, 2009
AB		DR REDDYS LABS LTD	**5MG**	**A076701**	**001**	Jan 22, 2009
AB			**25MG**	**A076701**	**002**	Jan 22, 2009
AB		GLENMARK PHARMS LTD	**5MG**	**A079099**	**001**	Feb 19, 2009
AB			**25MG**	**A079099**	**002**	Feb 19, 2009
AB		TARO	**5MG**	**A079204**	**001**	Feb 04, 2009
AB			**25MG**	**A079204**	**002**	Feb 04, 2009
AB		WATSON LABS	**2MG**	**A076928**	**001**	Jan 22, 2009
AB			**5MG**	**A076928**	**002**	Jan 22, 2009
AB			**25MG**	**A076928**	**003**	Jan 22, 2009
AB		ZYDUS PHARMS USA INC	**5MG**	**A078009**	**002**	Jan 22, 2009
AB			**25MG**	**A078009**	**003**	Jan 22, 2009

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	+	GLAXOSMITHKLINE LLC	**25MG**	**N022115**	**001**	May 29, 2009
AB	+!		**50MG**	**N022115**	**002**	May 29, 2009
AB	+		**100MG**	**N022115**	**003**	May 29, 2009
AB	+!		**200MG**	**N022115**	**004**	May 29, 2009
AB	+		**250MG**	**N022115**	**006**	Jun 21, 2011
AB	+		**300MG**	**N022115**	**005**	Apr 14, 2010

LAMOTRIGINE

AB		ACTAVIS ELIZABETH	**100MG**	**A200672**	**003**	Oct 17, 2013
AB			**200MG**	**A200672**	**004**	Oct 17, 2013
AB			**25MG**	**A200672**	**001**	Oct 17, 2013
AB			**50MG**	**A200672**	**002**	Oct 17, 2013
AB			**250MG**	**A200672**	**006**	Nov 13, 2013
AB			**300MG**	**A200672**	**005**	Oct 17, 2013
AB		AMNEAL PHARMS	**25MG**	**A207497**	**001**	Nov 30, 2018
AB			**50MG**	**A207497**	**002**	Nov 30, 2018
AB			**100MG**	**A207497**	**003**	Nov 30, 2018
AB			**200MG**	**A207497**	**004**	Nov 30, 2018
AB			**250MG**	**A207497**	**005**	Nov 30, 2018
AB			**300MG**	**A207497**	**006**	Nov 30, 2018
AB		ANCHEN PHARMS	**25MG**	**A201374**	**001**	Dec 26, 2012
AB			**50MG**	**A201374**	**002**	Dec 26, 2012
AB			**100MG**	**A201374**	**003**	Dec 26, 2012
AB			**200MG**	**A201374**	**004**	Dec 26, 2012
AB			**250MG**	**A201374**	**005**	Dec 26, 2012
AB			**300MG**	**A201374**	**006**	Dec 26, 2012
AB		ATLANTIDE	**25MG**	**A202498**	**001**	Jan 04, 2013
AB			**50MG**	**A202498**	**002**	Jan 04, 2013
AB			**100MG**	**A202498**	**003**	Jan 04, 2013
AB			**200MG**	**A202498**	**004**	Jan 04, 2013
AB			**300MG**	**A202498**	**005**	Jan 04, 2013
AB		DR REDDYS LABS LTD	**25MG**	**A202383**	**001**	Jun 19, 2013
AB			**50MG**	**A202383**	**002**	Jun 19, 2013
AB			**100MG**	**A202383**	**003**	Jun 19, 2013
AB			**200MG**	**A202383**	**004**	Jun 19, 2013
AB			**250MG**	**A202383**	**006**	Sep 06, 2018
AB			**300MG**	**A202383**	**005**	Jun 19, 2013
AB		PAR PHARM	**25MG**	**A201791**	**001**	Jan 18, 2013
AB			**50MG**	**A201791**	**002**	Jan 18, 2013
AB			**100MG**	**A201791**	**003**	Jan 18, 2013
AB			**200MG**	**A201791**	**004**	Jan 18, 2013
AB			**250MG**	**A201791**	**005**	Jan 18, 2013
AB			**300MG**	**A201791**	**006**	Jan 18, 2013
AB		RUBICON	**100MG**	**A202887**	**003**	Jun 17, 2013
AB			**200MG**	**A202887**	**004**	Jun 17, 2013
AB		TORRENT	**25MG**	**A203370**	**001**	Dec 23, 2013
AB			**50MG**	**A203370**	**002**	Dec 23, 2013
AB			**100MG**	**A203370**	**003**	Dec 23, 2013
AB			**200MG**	**A203370**	**004**	Dec 23, 2013
AB		YILING	**25MG**	**A213949**	**001**	Dec 08, 2021
AB			**50MG**	**A213949**	**002**	Dec 08, 2021
AB			**100MG**	**A213949**	**003**	Dec 08, 2021
AB			**200MG**	**A213949**	**004**	Dec 08, 2021
AB			**250MG**	**A213949**	**005**	Dec 08, 2021
AB			**300MG**	**A213949**	**006**	Dec 08, 2021
AB		ZYDUS PHARMS	**25MG**	**A207763**	**001**	Apr 01, 2020

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB			**50MG**	**A207763**	**002**	Apr 01, 2020
AB			**100MG**	**A207763**	**003**	Apr 01, 2020
AB			**200MG**	**A207763**	**004**	Apr 01, 2020
AB			**250MG**	**A207763**	**005**	Apr 01, 2020
AB			**300MG**	**A207763**	**006**	Apr 01, 2020

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

AB	**+**	GLAXOSMITHKLINE LLC	**25MG**	**N022251**	**001**	May 08, 2009
AB	**+!**		**50MG**	**N022251**	**002**	May 08, 2009
AB	**+**		**100MG**	**N022251**	**003**	May 08, 2009
AB	**+**		**200MG**	**N022251**	**004**	May 08, 2009

LAMOTRIGINE

AB		AJANTA PHARMA LTD	**25MG**	**A213271**	**001**	Jan 19, 2021
AB			**50MG**	**A213271**	**002**	Jan 19, 2021
AB			**100MG**	**A213271**	**003**	Jan 19, 2021
AB			**200MG**	**A213271**	**004**	Jan 19, 2021
AB		IMPAX LABS INC	**25MG**	**A200828**	**001**	Jul 15, 2013
AB			**50MG**	**A200828**	**002**	Jul 15, 2013
AB			**100MG**	**A200828**	**003**	Jul 15, 2013
AB			**200MG**	**A200828**	**004**	Jul 15, 2013
AB		PAR PHARM	**25MG**	**A204158**	**001**	Oct 27, 2015
AB			**50MG**	**A204158**	**002**	Oct 27, 2015
AB			**100MG**	**A204158**	**003**	Oct 27, 2015
AB			**200MG**	**A204158**	**004**	Oct 27, 2015
AB		SCIEGEN PHARMS INC	**25MG**	**A206382**	**001**	Jun 17, 2016
AB			**50MG**	**A206382**	**002**	Jun 17, 2016
AB			**100MG**	**A206382**	**003**	Jun 17, 2016
AB			**200MG**	**A206382**	**004**	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

LANREOTIDE ACETATE

+!	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N215395	001	Dec 17, 2021
+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N215395	002	Dec 17, 2021
+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N215395	003	Dec 17, 2021

SOMATULINE DEPOT

+!	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+!		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+!		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		ALKEM LABS LTD	**15MG**	**A207394**	**001**	Jan 18, 2019
AB			**30MG**	**A207394**	**002**	Jan 18, 2019
AB		DR REDDYS LABS LTD	**15MG**	**A091269**	**001**	Oct 15, 2010
AB			**30MG**	**A091269**	**002**	Oct 15, 2010
AB		HETERO LABS LTD III	**15MG**	**A203083**	**001**	May 18, 2020
AB			**30MG**	**A203083**	**002**	May 18, 2020
AB		INVENTIA	**15MG**	**A205868**	**001**	Aug 30, 2017
AB			**30MG**	**A205868**	**002**	Aug 30, 2017
AB		LANNETT CO INC	**15MG**	**A207156**	**001**	Sep 28, 2017
AB			**30MG**	**A207156**	**002**	Sep 28, 2017
AB		MYLAN PHARMS INC	**15MG**	**A090763**	**001**	Nov 10, 2009
AB			**30MG**	**A090763**	**002**	Nov 10, 2009
AB		NATCO PHARMA LTD	**15MG**	**A201921**	**001**	Dec 18, 2012
AB			**30MG**	**A201921**	**002**	Dec 18, 2012
AB		SANDOZ	**15MG**	**A090331**	**001**	Apr 23, 2010
AB			**30MG**	**A090331**	**002**	Apr 23, 2010
AB		SUN PHARM	**15MG**	**A202637**	**001**	Sep 13, 2013
AB			**30MG**	**A091509**	**001**	Sep 13, 2013
AB		TEVA PHARMS	**15MG**	**A077255**	**001**	Nov 10, 2009
AB			**30MG**	**A077255**	**002**	Nov 10, 2009
AB		WOCKHARDT USA	**15MG**	**A202176**	**001**	Sep 14, 2012
AB			**30MG**	**A202176**	**002**	Sep 14, 2012
AB		XIROMED	**15MG**	**A203203**	**001**	Jul 25, 2016
AB			**30MG**	**A203203**	**002**	Jul 25, 2016
AB		ZYDUS HLTHCARE	**15MG**	**A202366**	**001**	Aug 19, 2013
AB			**30MG**	**A202366**	**002**	Aug 19, 2013

LANSOPRAZOLE						
CAPSULE, DELAYED REL PELLETS;ORAL						
PREVACID						
AB	**+!**	TAKEDA PHARMS USA	**30MG**	**N020406**	**002**	May 10, 1995
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL						
LANSOPRAZOLE						
AB		DR REDDYS LABS LTD	**15MG**	**A210465**	**001**	Feb 01, 2021
AB			**30MG**	**A210465**	**002**	Feb 01, 2021
AB		MYLAN	**15MG**	**A202396**	**001**	Nov 28, 2018
AB			**30MG**	**A202396**	**002**	Nov 28, 2018
AB		TEVA PHARMS USA	**15MG**	**A208784**	**001**	Sep 21, 2017
AB			**30MG**	**A208784**	**002**	Sep 21, 2017
AB		ZYDUS PHARMS	**15MG**	**A200816**	**001**	Nov 27, 2018
AB			**30MG**	**A200816**	**002**	Nov 27, 2018
PREVACID						
AB	**+**	TAKEDA PHARMS USA	**15MG**	**N021428**	**001**	Aug 30, 2002
AB	**+!**		**30MG**	**N021428**	**002**	Aug 30, 2002
LANTHANUM CARBONATE						
POWDER;ORAL						
FOSRENOL						
	+	TAKEDA PHARMS USA	EQ 750MG BASE	N204734	001	Sep 24, 2014
	+!		EQ 1GM BASE	N204734	002	Sep 24, 2014
TABLET, CHEWABLE;ORAL						
FOSRENOL						
AB	**+**	TAKEDA PHARMS USA	**EQ 500MG BASE**	**N021468**	**002**	Oct 26, 2004
AB	**+**		**EQ 750MG BASE**	**N021468**	**003**	Nov 23, 2005
AB	**+!**		**EQ 1GM BASE**	**N021468**	**004**	Nov 23, 2005
LANTHANUM CARBONATE						
AB		NATCO PHARMA LTD	**EQ 500MG BASE**	**A090978**	**001**	Aug 11, 2017
AB			**EQ 750MG BASE**	**A090978**	**002**	Aug 11, 2017
AB			**EQ 1GM BASE**	**A090978**	**003**	Aug 11, 2017
LAPATINIB DITOSYLATE						
TABLET;ORAL						
LAPATINIB DITOSYLATE						
AB		NATCO PHARMA LTD	**EQ 250MG BASE**	**A203007**	**001**	Sep 29, 2020
TYKERB						
AB	**+!**	NOVARTIS	**EQ 250MG BASE**	**N022059**	**001**	Mar 13, 2007
LAROTRECTINIB SULFATE						
CAPSULE;ORAL						
VITRAKVI						
	+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018
	+!		EQ 100MG BASE	N210861	002	Nov 26, 2018
SOLUTION;ORAL						
VITRAKVI						
	+!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018
LASMIDITAN SUCCINATE						
TABLET;ORAL						
REYVOW						
	+	ELI LILLY AND CO	EQ 50MG BASE	N211280	001	Jan 31, 2020
	+!		EQ 100MG BASE	N211280	002	Jan 31, 2020
LATANOPROST						
EMULSION;OPHTHALMIC						
XELPROS						
	+!	SUN PHARM	0.005%	N206185	001	Sep 12, 2018
SOLUTION/DROPS;OPHTHALMIC						
LATANOPROST						
AT		AKORN	**0.005%**	**A090887**	**001**	Jul 19, 2011
AT		AMRING PHARMS	**0.005%**	**A200925**	**001**	Mar 22, 2011
AT		BAUSCH AND LOMB	**0.005%**	**A201006**	**001**	Mar 22, 2011
AT		DR REDDYS LABS LTD	**0.005%**	**A202077**	**001**	Feb 11, 2013
AT		FDC LTD	**0.005%**	**A202442**	**001**	Apr 22, 2016
AT		SANDOZ INC	**0.005%**	**A091449**	**001**	Mar 22, 2011
AT		SOMERSET	**0.005%**	**A201786**	**001**	Mar 22, 2011
XALATAN						
AT	**+!**	UPJOHN	**0.005%**	**N020597**	**001**	Jun 05, 1996

LATANOPROST; NETARSUDIL DIMESYLATE						
SOLUTION/DROPS;OPHTHALMIC						
ROCKLATAN						
	+!	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019
LATANOPROSTENE BUNOD						
SOLUTION/DROPS;OPHTHALMIC						
VYZULTA						
	+!	BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017
LEDIPASVIR; SOFOSBUVIR						
PELLETS;ORAL						
HARVONI						
	+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019
	+!		45MG;200MG/PACKET	N212477	002	Aug 28, 2019
TABLET;ORAL						
HARVONI						
	+	GILEAD SCIENCES INC	45MG;200MG	N205834	002	Aug 28, 2019
	+!		90MG;400MG	N205834	001	Oct 10, 2014
LEFAMULIN ACETATE						
SOLUTION;INTRAVENOUS						
XENLETA						
	+!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019
TABLET;ORAL						
XENLETA						
	+!	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019
LEFLUNOMIDE						
TABLET;ORAL						
ARAVA						
AB	**+**	SANOFI AVENTIS US	**10MG**	**N020905**	**001**	Sep 10, 1998
AB	**+!**		**20MG**	**N020905**	**002**	Sep 10, 1998
LEFLUNOMIDE						
AB		ABHAI LLC	**10MG**	**A212453**	**001**	Jun 03, 2019
AB			**20MG**	**A212453**	**002**	Jun 03, 2019
AB		ALEMBIC PHARMS LTD	**10MG**	**A091369**	**001**	Nov 21, 2011
AB			**20MG**	**A091369**	**002**	Nov 21, 2011
AB		APOTEX INC	**10MG**	**A077090**	**001**	Sep 13, 2005
AB			**20MG**	**A077090**	**002**	Sep 13, 2005
AB		AUROBINDO PHARMA LTD	**10MG**	**A213652**	**001**	Mar 29, 2021
AB			**20MG**	**A213652**	**002**	Mar 29, 2021
AB		FOSUN PHARMA	**10MG**	**A077087**	**001**	Sep 13, 2005
AB			**20MG**	**A077087**	**002**	Sep 13, 2005
AB		HERITAGE PHARMS INC	**10MG**	**A077086**	**001**	Sep 13, 2005
AB			**20MG**	**A077086**	**002**	Sep 13, 2005
AB		LUPIN LTD	**10MG**	**A211863**	**001**	Feb 04, 2020
AB			**20MG**	**A211863**	**002**	Feb 04, 2020
AB		ZYDUS	**10MG**	**A212308**	**001**	Apr 24, 2019
AB			**20MG**	**A212308**	**002**	Apr 24, 2019
ARAVA						
	+!	SANOFI AVENTIS US	100MG	N020905	003	Sep 10, 1998
LEMBOREXANT						
TABLET;ORAL						
DAYVIGO						
	+	EISAI INC	5MG	N212028	001	Apr 07, 2020
	+!		10MG	N212028	002	Apr 07, 2020
LENALIDOMIDE						
CAPSULE;ORAL						
LENALIDOMIDE						
AB		ARROW INTL	**5MG**	**A201452**	**001**	May 21, 2021
AB			**10MG**	**A201452**	**002**	May 21, 2021
AB			**15MG**	**A201452**	**003**	May 21, 2021
AB			**25MG**	**A201452**	**004**	May 21, 2021
AB		DR REDDYS	**2.5MG**	**A209348**	**001**	Oct 14, 2021
AB			**20MG**	**A209348**	**002**	Oct 14, 2021
REVLIMID						
AB	**+**	CELGENE	**2.5MG**	**N021880**	**005**	Dec 21, 2011
AB	**+**		**5MG**	**N021880**	**001**	Dec 27, 2005
AB	**+**		**10MG**	**N021880**	**002**	Dec 27, 2005
AB	**+**		**15MG**	**N021880**	**003**	Jun 29, 2006
AB	**+**		**20MG**	**N021880**	**006**	Jun 05, 2013
AB	**+!**		**25MG**	**N021880**	**004**	Jun 29, 2006

LENVATINIB MESYLATE

CAPSULE;ORAL

LENVIMA

+	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015
+!		EQ 10MG BASE	N206947	002	Feb 13, 2015

LETERMOVIR

SOLUTION;INTRAVENOUS

PREVYMIS

+!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017
+!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017

TABLET;ORAL

PREVYMIS

+	MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017
+!		480MG	N209939	002	Nov 08, 2017

LETROZOLE

TABLET;ORAL

FEMARA

AB	**+!**	NOVARTIS PHARMS	**2.5MG**	**N020726**	**001**	Jul 25, 1997

LETROZOLE

AB		ACCORD HLTHCARE	**2.5MG**	**A090934**	**001**	Jun 03, 2011
AB		BEIJING YILING	**2.5MG**	**A205869**	**001**	Nov 14, 2018
AB		DR REDDYS LABS LTD	**2.5MG**	**A091191**	**001**	Jun 03, 2011
AB		EUGIA PHARMA	**2.5MG**	**A211717**	**001**	Jan 11, 2019
AB		INDICUS PHARMA	**2.5MG**	**A201804**	**001**	Jun 03, 2011
AB		NATCO PHARMA LTD	**2.5MG**	**A200161**	**001**	Jun 03, 2011
AB		TEVA PHARMS	**2.5MG**	**A090289**	**001**	Jun 03, 2011

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+!	NOVARTIS	2.5MG;EQ 200MG BASE	N209935	001	May 04, 2017

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A207226**	**001**	Jul 27, 2018
AP	**!**	HIKMA	**EQ 50MG BASE/VIAL**	**A089384**	**001**	Sep 14, 1987
AP	**!**		**EQ 100MG BASE/VIAL**	**A089717**	**001**	Mar 28, 1988
AP		TEVA PHARMS USA	**EQ 100MG BASE/VIAL**	**A081277**	**001**	Sep 28, 1993
AP			**EQ 350MG BASE/VIAL**	**A040174**	**001**	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP		FRESENIUS KABI USA	**EQ 200MG BASE/VIAL**	**A040258**	**001**	Feb 26, 1999
AP	**!**		**EQ 500MG BASE/VIAL**	**A040286**	**001**	Feb 26, 1999
AP	**!**	HIKMA	**EQ 10MG BASE/ML**	**A040347**	**001**	Apr 25, 2000
AP	**!**		**EQ 200MG BASE/VIAL**	**A040056**	**001**	May 23, 1995
AP	**!**		**EQ 350MG BASE/VIAL**	**A040335**	**001**	Apr 20, 2000
AP		MYLAN LABS LTD	**EQ 100MG BASE/VIAL**	**A203800**	**001**	May 19, 2017
AP			**EQ 200MG BASE/VIAL**	**A203800**	**002**	May 19, 2017
AP			**EQ 350MG BASE/VIAL**	**A203800**	**003**	May 19, 2017
AP		SAGENT PHARMS	**EQ 50MG BASE/VIAL**	**A200753**	**001**	Sep 06, 2012
AP			**EQ 100MG BASE/VIAL**	**A200753**	**002**	Sep 06, 2012
AP			**EQ 200MG BASE/VIAL**	**A200753**	**003**	Sep 06, 2012
AP			**EQ 350MG BASE/VIAL**	**A200855**	**001**	Sep 06, 2012
AP		SAGENT PHARMS INC	**EQ 500MG BASE/VIAL**	**A209110**	**001**	Oct 26, 2017

LEUCOVORIN CALCIUM

	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018

TABLET;ORAL

LEUCOVORIN CALCIUM

AB		BARR	**EQ 5MG BASE**	**A071198**	**001**	Sep 24, 1987
AB			**EQ 25MG BASE**	**A071199**	**001**	Sep 24, 1987
AB		EPIC PHARMA LLC	**EQ 5MG BASE**	**A074544**	**001**	Aug 28, 1997
AB			**EQ 10MG BASE**	**A074544**	**003**	May 19, 2021
AB			**EQ 15MG BASE**	**A074544**	**004**	May 19, 2021
AB			**EQ 25MG BASE**	**A074544**	**002**	Aug 28, 1997
AB		HIKMA	**EQ 5MG BASE**	**A072733**	**001**	Feb 22, 1993
AB			**EQ 10MG BASE**	**A072734**	**001**	Feb 22, 1993
AB			**EQ 15MG BASE**	**A072735**	**001**	Feb 22, 1993
AB	**!**		**EQ 25MG BASE**	**A072736**	**001**	Feb 22, 1993
AB		LEADING PHARMA LLC	**EQ 5MG BASE**	**A213929**	**001**	Oct 22, 2020
AB			**EQ 10MG BASE**	**A213929**	**002**	Oct 22, 2020
AB			**EQ 15MG BASE**	**A213929**	**003**	Oct 22, 2020
AB			**EQ 25MG BASE**	**A213929**	**004**	Oct 22, 2020

LEUCOVORIN CALCIUM

TABLET;ORAL

LEUCOVORIN CALCIUM

AB		NOVAST LABS	**EQ 5MG BASE**	**A211132**	**001**	Jul 30, 2020
AB			**EQ 10MG BASE**	**A211132**	**002**	Jul 30, 2020
AB			**EQ 15MG BASE**	**A211132**	**003**	Jul 30, 2020
AB			**EQ 25MG BASE**	**A211132**	**004**	Jul 30, 2020

LEUPROLIDE ACETATE

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

AP	**!**	SANDOZ	**1MG/0.2ML**	**A074728**	**001**	Aug 04, 1998
AP		SUN PHARM	**1MG/0.2ML**	**A078885**	**001**	Mar 09, 2009
AP		TEVA PHARMS USA	**1MG/0.2ML**	**A075471**	**001**	Oct 25, 2000
AP		VGYAAN	**1MG/0.2ML**	**A213829**	**001**	Aug 13, 2021

LUPRON DEPOT

	+!	ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995
	+!		7.5MG/VIAL	N019732	001	Jan 26, 1989
	+!		11.25MG/VIAL	N020708	001	Mar 07, 1997
	+		22.5MG/VIAL	N020517	001	Dec 22, 1995
	+!		30MG/VIAL	N020517	002	May 30, 1997
	+!		45MG/VIAL	N020517	003	Jun 17, 2011

POWDER;INTRAMUSCULAR

LUPRON DEPOT-PED KIT

	+!	ABBVIE ENDOCRINE INC	7.5MG	N020263	002	Apr 16, 1993
	+!		11.25MG	N020263	005	Jan 21, 1994
	+!		11.25MG	N020263	007	Aug 15, 2011
	+!		15MG	N020263	006	Jan 21, 1994
	+!		30MG	N020263	008	Aug 15, 2011

POWDER;SUBCUTANEOUS

ELIGARD KIT

	+!	TOLMAR THERAP	7.5MG	N021343	001	Jan 23, 2002
	+!		22.5MG	N021379	001	Jul 24, 2002
	+!		30MG	N021488	001	Feb 13, 2003
	+!		45MG	N021731	001	Dec 14, 2004

FENSOLVI KIT

	+!	TOLMAR	45MG	N213150	001	May 01, 2020

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI KIT

	+!	FORESEE PHARMS	EQ 42MG BASE	N211488	001	May 25, 2021

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN		CIPLA	**EQ 0.021% BASE**	**A078171**	**002**	Dec 13, 2013
AN			**EQ 0.042% BASE**	**A078171**	**003**	Dec 13, 2013
AN			**EQ 0.0103% BASE**	**A078171**	**001**	Dec 13, 2013
AN		IMPAX LABS INC	**EQ 0.0103% BASE**	**A077756**	**003**	Apr 09, 2008
AN			**EQ 0.021% BASE**	**A077756**	**001**	Apr 09, 2008
AN			**EQ 0.042% BASE**	**A077756**	**002**	Apr 09, 2008
AN		LUOXIN AUROVITAS	**EQ 0.25% BASE**	**A207628**	**001**	Jan 31, 2017
AN			**EQ 0.0103% BASE**	**A207625**	**001**	Dec 30, 2016
AN			**EQ 0.021% BASE**	**A207625**	**002**	Dec 30, 2016
AN			**EQ 0.042% BASE**	**A207625**	**003**	Dec 30, 2016
AN		MYLAN SPECIALITY LP	**EQ 0.25% BASE**	**A078309**	**001**	Mar 20, 2009
AN		RITEDOSE CORP	**EQ 0.0103% BASE**	**A203653**	**001**	Mar 22, 2016
AN			**EQ 0.021% BASE**	**A203653**	**002**	Mar 22, 2016
AN			**EQ 0.042% BASE**	**A203653**	**003**	Mar 22, 2016
AN		SUN PHARM	**EQ 0.0103% BASE**	**A207820**	**001**	Nov 05, 2018
AN			**EQ 0.021% BASE**	**A207820**	**002**	Nov 05, 2018
AN			**EQ 0.042% BASE**	**A207820**	**003**	Nov 05, 2018
AN		TEVA PARENTERAL	**EQ 0.25% BASE**	**A200875**	**001**	Sep 11, 2014
AN		TEVA PHARMS USA	**EQ 0.0103% BASE**	**A090297**	**001**	Apr 26, 2013
AN			**EQ 0.021% BASE**	**A090297**	**002**	Apr 26, 2013
AN			**EQ 0.042% BASE**	**A090297**	**003**	Apr 26, 2013

XOPENEX

AN	**+!**	AKORN	**EQ 0.0103% BASE**	**N020837**	**003**	Jan 30, 2002
AN	**+!**		**EQ 0.021% BASE**	**N020837**	**001**	Mar 25, 1999
AN	**+!**		**EQ 0.042% BASE**	**N020837**	**002**	Mar 25, 1999
AN	**+!**		**EQ 0.25% BASE**	**N020837**	**004**	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED;INHALATION

XOPENEX HFA

	+!	SUNOVION	EQ 0.045MG BASE/INH	N021730	001	Mar 11, 2005

LEVAMLODIPINE MALEATE

TABLET;ORAL

CONJUPRI

	+	CSPC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019
	+!		EQ 5MG BASE	N212895	003	Dec 19, 2019

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

KEPPRA

AP	**+!**	UCB INC	**500MG/5ML (100MG/ML)**	**N021872**	**001**	Jul 31, 2006

LEVETIRACETAM

AP		EUGIA PHARMA	**500MG/5ML (100MG/ML)**	**A204312**	**001**	Feb 01, 2016
AP		FRESENIUS KABI USA	**500MG/5ML (100MG/ML)**	**A090876**	**001**	Aug 13, 2015
AP		HAINAN POLY PHARM	**500MG/5ML (100MG/ML)**	**A209781**	**001**	Mar 20, 2018
AP		HIKMA FARMACEUTICA	**500MG/5ML (100MG/ML)**	**A090981**	**001**	Oct 13, 2011
AP		HOSPIRA INC	**500MG/5ML (100MG/ML)**	**A202869**	**001**	Apr 06, 2012
AP		MICRO LABS	**500MG/5ML (100MG/ML)**	**A211954**	**001**	Aug 09, 2019
AP		MYLAN LABS LTD	**500MG/5ML (100MG/ML)**	**A203308**	**001**	Sep 16, 2016
AP		SAGENT PHARMS	**500MG/5ML (100MG/ML)**	**A091627**	**001**	Jun 26, 2013
AP		SUN PHARM INDS LTD	**500MG/5ML (100MG/ML)**	**A090754**	**001**	Jun 16, 2010
AP		XGEN PHARMS	**500MG/5ML (100MG/ML)**	**A091485**	**001**	Aug 05, 2011

LEVETIRACETAM IN SODIUM CHLORIDE

AP		EUGIA PHARMA	**500MG/100ML (5MG/ML)**	**A207160**	**001**	Jan 04, 2017
AP			**1GM/100ML (10MG/ML)**	**A207160**	**002**	Jan 04, 2017
AP			**1.5GM/100ML (15MG/ML)**	**A207160**	**003**	Jan 04, 2017
AP		GLAND PHARMA LTD	**500MG/100ML (5MG/ML)**	**A206880**	**001**	Oct 25, 2017
AP			**1GM/100ML (10MG/ML)**	**A206880**	**002**	Oct 25, 2017
AP			**1.5GM/100ML (15MG/ML)**	**A206880**	**003**	Oct 25, 2017
AP	**+!**	HQ SPECIALITY PHARMA	**500MG/100ML (5MG/ML)**	**N202543**	**001**	Nov 09, 2011
AP	**+!**		**1GM/100ML (10MG/ML)**	**N202543**	**002**	Nov 09, 2011
AP	**+!**		**1.5GM/100ML (15MG/ML)**	**N202543**	**003**	Nov 09, 2011
AP		NEXUS PHARMS	**500MG/100ML (5MG/ML)**	**A213532**	**001**	Jul 06, 2020
AP			**1GM/100ML (10MG/ML)**	**A213532**	**002**	Jul 06, 2020
AP			**1.5GM/100ML (15MG/ML)**	**A213532**	**003**	Jul 06, 2020
	+!	HQ SPECIALITY PHARMA	250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020

SOLUTION;ORAL

KEPPRA

AA	**+!**	UCB INC	**100MG/ML**	**N021505**	**001**	Jul 15, 2003

LEVETIRACETAM

AA		ACI	**100MG/ML**	**A078582**	**001**	Jan 15, 2009
AA		ACTAVIS MID ATLANTIC	**100MG/ML**	**A078976**	**001**	Jan 15, 2009
AA		AKORN	**100MG/ML**	**A090601**	**001**	Feb 28, 2012
AA		ALEMBIC LABS	**100MG/ML**	**A203067**	**001**	May 09, 2013
AA		AMNEAL PHARMS	**100MG/ML**	**A090992**	**001**	Oct 27, 2009
AA		AUROBINDO PHARMA LTD	**100MG/ML**	**A079063**	**001**	Jan 15, 2009
AA		BRECKENRIDGE	**100MG/ML**	**A079120**	**001**	Jan 16, 2009
AA		GENUS	**100MG/ML**	**A090079**	**001**	Apr 11, 2012
AA		HETERO LABS LTD III	**100MG/ML**	**A203052**	**001**	Feb 28, 2013
AA		LANNETT CO INC	**100MG/ML**	**A090263**	**001**	Apr 03, 2009
AA		LUPIN LTD	**100MG/ML**	**A090893**	**001**	Oct 17, 2011
AA		PHARM ASSOC	**100MG/ML**	**A201157**	**001**	Jun 04, 2015
AA		TARO	**100MG/ML**	**A078774**	**001**	Feb 10, 2009
AA		TRIS PHARMA INC	**100MG/ML**	**A090461**	**001**	Sep 30, 2010
AA		WOCKHARDT BIO AG	**100MG/ML**	**A090028**	**001**	Mar 03, 2010

TABLET;ORAL

KEPPRA

AB	+	UCB INC	**250MG**	**N021035**	**001**	Nov 30, 1999
AB	+		**500MG**	**N021035**	**002**	Nov 30, 1999
AB	+		**750MG**	**N021035**	**003**	Nov 30, 1999
AB	**+!**		**1GM**	**N021035**	**004**	Jan 06, 2006

LEVETIRACETAM

AB		ACCORD HLTHCARE	**250MG**	**A090843**	**001**	Feb 14, 2011
AB			**500MG**	**A090843**	**002**	Feb 14, 2011
AB			**750MG**	**A090843**	**003**	Feb 14, 2011
AB			**1GM**	**A090843**	**004**	Feb 14, 2011

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

AB	ACI	**250MG**	**A078042**	**001**	Jan 15, 2009
AB		**500MG**	**A078042**	**002**	Jan 15, 2009
AB		**750MG**	**A078042**	**003**	Jan 15, 2009
AB		**1GM**	**A078042**	**004**	Jan 15, 2009
AB	AUROBINDO PHARMA	**250MG**	**A078993**	**001**	Jan 15, 2009
AB		**500MG**	**A078993**	**002**	Jan 15, 2009
AB		**750MG**	**A078993**	**003**	Jan 15, 2009
AB		**1GM**	**A078993**	**004**	Jan 15, 2009
AB	CHARTWELL RX	**250MG**	**A201293**	**001**	Jun 14, 2011
AB		**500MG**	**A201293**	**002**	Jun 14, 2011
AB		**750MG**	**A201293**	**003**	Jun 14, 2011
AB		**1GM**	**A201293**	**004**	Jun 14, 2011
AB	DR REDDYS LABS LTD	**250MG**	**A076920**	**001**	Jan 15, 2009
AB		**500MG**	**A076920**	**002**	Jan 15, 2009
AB		**750MG**	**A076920**	**003**	Jan 15, 2009
AB		**1GM**	**A078904**	**001**	Jan 15, 2009
AB	HETERO LABS LTD III	**250MG**	**A090515**	**001**	Oct 08, 2010
AB		**500MG**	**A090515**	**002**	Oct 08, 2010
AB		**750MG**	**A090515**	**003**	Oct 08, 2010
AB		**1GM**	**A090515**	**004**	Oct 08, 2010
AB	INVAGEN PHARMS	**250MG**	**A078234**	**001**	Jan 15, 2009
AB		**500MG**	**A078234**	**002**	Jan 15, 2009
AB		**750MG**	**A078234**	**003**	Jan 15, 2009
AB	LOTUS PHARM CO LTD	**500MG**	**A090906**	**001**	Nov 05, 2010
AB	LUPIN	**250MG**	**A078154**	**001**	Jan 15, 2009
AB		**500MG**	**A078154**	**002**	Jan 15, 2009
AB		**750MG**	**A078154**	**003**	Jan 15, 2009
AB		**1GM**	**A090025**	**001**	Jan 15, 2009
AB	MYLAN	**250MG**	**A076919**	**001**	Nov 04, 2008
AB		**500MG**	**A076919**	**002**	Nov 04, 2008
AB		**750MG**	**A076919**	**003**	Nov 04, 2008
AB		**1GM**	**A090261**	**001**	Dec 08, 2009
AB	ORBION PHARMS	**250MG**	**A078526**	**001**	Jan 15, 2009
AB		**500MG**	**A078526**	**002**	Jan 15, 2009
AB		**750MG**	**A078526**	**003**	Jan 15, 2009
AB		**1GM**	**A090484**	**001**	Aug 05, 2010
AB	OXFORD PHARMS	**250MG**	**A077319**	**001**	Mar 20, 2009
AB		**500MG**	**A077319**	**002**	Mar 20, 2009
AB		**750MG**	**A077319**	**003**	Mar 20, 2009
AB	PRINSTON INC	**250MG**	**A078106**	**001**	Feb 10, 2009
AB		**500MG**	**A078106**	**002**	Feb 10, 2009
AB		**750MG**	**A078106**	**003**	Feb 10, 2009
AB		**1GM**	**A078106**	**004**	Feb 10, 2009
AB	SCIEGEN PHARMS INC	**750MG**	**A215069**	**001**	Jun 11, 2021
AB		**1GM**	**A215069**	**002**	Jun 11, 2021
AB	SECAN PHARMS	**500MG**	**A205102**	**004**	Dec 16, 2015
AB		**1GM**	**A205102**	**003**	Dec 16, 2015
AB	TARO	**250MG**	**A078960**	**004**	Feb 01, 2010
AB		**500MG**	**A078960**	**003**	Feb 01, 2010
AB		**750MG**	**A078960**	**002**	Feb 01, 2010
AB		**1GM**	**A078960**	**001**	Feb 01, 2010
AB	TORRENT PHARMS	**250MG**	**A078858**	**001**	Jan 15, 2009
AB		**500MG**	**A078858**	**002**	Jan 15, 2009
AB		**750MG**	**A078858**	**003**	Jan 15, 2009
AB		**1GM**	**A078858**	**004**	Jan 15, 2009
AB	VIWIT PHARM	**250MG**	**A078869**	**001**	Mar 13, 2009
AB		**500MG**	**A078869**	**002**	Mar 13, 2009
AB		**750MG**	**A078869**	**003**	Mar 13, 2009
AB		**1GM**	**A078869**	**004**	Mar 13, 2009
AB	VKT PHARMA	**250MG**	**A090767**	**001**	Jul 28, 2010
AB		**500MG**	**A090767**	**002**	Jul 28, 2010
AB		**750MG**	**A090767**	**003**	Jul 28, 2010
AB		**1GM**	**A090767**	**004**	Jul 28, 2010
AB	WOCKHARDT	**250MG**	**A079042**	**001**	Jan 15, 2009
AB		**500MG**	**A079042**	**002**	Jan 15, 2009
AB		**750MG**	**A079042**	**003**	Jan 15, 2009
AB		**1GM**	**A079042**	**004**	Jan 15, 2009
AB	ZHEJIANG JINGXIN	**250MG**	**A091491**	**001**	Dec 14, 2010
AB		**500MG**	**A091491**	**002**	Dec 14, 2010

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

AB			**750MG**	**A091491**	**003**	Dec 14, 2010
AB			**1GM**	**A091491**	**004**	Dec 14, 2010
AB		ZYDUS PHARMS USA INC	**250MG**	**A078918**	**001**	Apr 29, 2009
AB			**1GM**	**A078918**	**002**	Apr 29, 2009

TABLET, EXTENDED RELEASE;ORAL

KEPPRA XR

AB	+	UCB INC	**500MG**	**N022285**	**001**	Sep 12, 2008
AB	+!		**750MG**	**N022285**	**002**	Feb 12, 2009

LEVETIRACETAM

AB		ACTAVIS LABS FL INC	**500MG**	**A091093**	**001**	Sep 12, 2011
AB			**750MG**	**A091093**	**002**	Sep 12, 2011
AB		ANCHEN PHARMS	**500MG**	**A091360**	**001**	Oct 04, 2011
AB			**750MG**	**A091360**	**002**	Oct 04, 2011
AB		ANDA REPOSITORY	**500MG**	**A204511**	**001**	Feb 23, 2016
AB			**750MG**	**A204511**	**002**	Feb 23, 2016
AB		APOTEX INC	**500MG**	**A091261**	**001**	Sep 12, 2011
AB			**750MG**	**A091261**	**002**	Sep 12, 2011
AB		FLORIDA	**500MG**	**A202167**	**001**	Sep 04, 2015
AB			**750MG**	**A202167**	**002**	Sep 04, 2015
AB		GENUS LIFESCIENCES	**500MG**	**A204754**	**001**	Aug 26, 2016
AB			**750MG**	**A204754**	**002**	Aug 26, 2016
AB		HISUN PHARM HANGZHOU	**500MG**	**A207175**	**001**	Sep 28, 2017
AB			**750MG**	**A207175**	**002**	Sep 28, 2017
AB		LUPIN LTD	**500MG**	**A091399**	**001**	Sep 12, 2011
AB			**750MG**	**A091399**	**002**	Sep 12, 2011
AB		OVERSEAS	**750MG**	**A212688**	**001**	Jun 11, 2020
AB		PHARMADAX INC	**500MG**	**A201464**	**001**	May 25, 2012
AB			**750MG**	**A201464**	**002**	May 25, 2012
AB		PRINSTON INC	**500MG**	**A202533**	**001**	Jul 20, 2012
AB			**500MG**	**A203468**	**001**	May 21, 2015
AB			**750MG**	**A202533**	**002**	Jul 20, 2012
AB			**750MG**	**A203468**	**002**	May 21, 2015
AB		SCIEGEN PHARMS INC	**500MG**	**A205130**	**001**	Nov 27, 2020
AB			**750MG**	**A205130**	**002**	Nov 27, 2020
AB		SUN PHARM	**500MG**	**A203059**	**001**	Sep 09, 2013
AB			**750MG**	**A203059**	**002**	Sep 09, 2013

ELEPSIA XR

	+	TRIPOINT	1GM	N204417	001	Dec 20, 2018
	+!		1.5GM	N204417	002	Dec 20, 2018

LEVETIRACETAM

		APOTEX	1GM	A202958	001	Feb 25, 2015

TABLET, FOR SUSPENSION;ORAL

SPRITAM

	+	APRECIA PHARMS	250MG	N207958	001	Jul 31, 2015
	+		500MG	N207958	002	Jul 31, 2015
	+		750MG	N207958	003	Jul 31, 2015
	+!		1GM	N207958	004	Jul 31, 2015

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAGAN

AT	**+!**	ALLERGAN	**0.5%**	**N019219**	**002**	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

AT		BAUSCH AND LOMB	**0.5%**	**A074326**	**001**	Mar 04, 1994

LEVOCARNITINE

INJECTABLE;INJECTION

CARNITOR

AP	**+!**	LEADIANT BIOSCI INC	**200MG/ML**	**N020182**	**001**	Dec 16, 1992

LEVOCARNITINE

AP		AM REGENT	**200MG/ML**	**A075861**	**001**	Jun 22, 2001
AP		HIKMA	**200MG/ML**	**A075567**	**001**	Mar 29, 2001

SOLUTION;ORAL

CARNITOR

AA	**+!**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**001**	Apr 10, 1986

CARNITOR SF

AA	**+**	LEADIANT BIOSCI INC	**1GM/10ML**	**N019257**	**002**	Mar 28, 2007

LEVOCARNITINE

SOLUTION;ORAL

LEVOCARNITINE

AA		AKORN	**1GM/10ML**	**A077399**	**001**	Oct 25, 2007
AA		LYNE	**1GM/10ML**	**A076851**	**001**	Aug 10, 2004
AA		NOVITIUM PHARMA	**1GM/10ML**	**A211676**	**001**	Aug 14, 2019
AA		SAPTALIS PHARMS	**1GM/10ML**	**A212533**	**001**	Nov 10, 2021

LEVOCARNITINE SF

AA		NOVITIUM PHARMA	**1GM/10ML**	**A211676**	**002**	Aug 14, 2019

TABLET;ORAL

CARNITOR

AB	**+!**	LEADIANT BIOSCI INC	**330MG**	**N018948**	**001**	Dec 27, 1985

LEVOCARNITINE

AB		RISING	**330MG**	**A076858**	**001**	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA		LANNETT CO INC	**2.5MG/5ML**	**A204599**	**001**	May 15, 2017
AA	**!**	PADAGIS US	**2.5MG/5ML**	**A091263**	**001**	Nov 07, 2011
AA		TARO PHARM INDS LTD	**2.5MG/5ML**	**A202673**	**001**	Jul 26, 2013

LEVOCETIRIZINE HYDROCHLORIDE

AA		HETERO LABS LTD III	**2.5MG/5ML**	**A210914**	**001**	Apr 01, 2019

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	**5MG**	**A090392**	**001**	Feb 24, 2011
AB	**!**	GLENMARK GENERICS	**5MG**	**A090385**	**001**	Feb 24, 2011
AB		HETERO LABS LTD III	**5MG**	**A091264**	**001**	Jun 29, 2012
AB		MACLEODS PHARMS LTD	**5MG**	**A205564**	**001**	Jan 11, 2016
AB		MICRO LABS LTD INDIA	**5MG**	**A202046**	**001**	Sep 17, 2013
AB		SCIEGEN PHARMS INC	**5MG**	**A203646**	**001**	Sep 09, 2014
AB		SUN PHARM	**5MG**	**A090362**	**001**	Jan 31, 2013
AB		SYNTHON PHARMS	**5MG**	**A090229**	**001**	Nov 26, 2010
AB		TEVA PHARMS	**5MG**	**A090199**	**001**	Aug 22, 2011

LEVODOPA

POWDER;INHALATION

INBRIJA

	+!	ACORDA	42MG	N209184	001	Dec 21, 2018

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP		AKORN	**EQ 500MG/20ML (EQ 25MG/ML)**	**A091644**	**001**	Jun 20, 2011
AP			**EQ 750MG/30ML (EQ 25MG/ML)**	**A091644**	**002**	Jun 20, 2011
AP		BAXTER HLTHCARE CORP	**EQ 500MG/20ML (EQ 25MG/ML)**	**A091436**	**001**	Jun 05, 2013
AP	**!**	EUGIA PHARMA	**EQ 500MG/20ML (EQ 25MG/ML)**	**A202328**	**001**	Jan 24, 2013
AP	**!**		**EQ 750MG/30ML (EQ 25MG/ML)**	**A202328**	**002**	Jan 24, 2013
AP		GLAND PHARMA LTD	**EQ 500MG/20ML (EQ 25MG/ML)**	**A205540**	**001**	Apr 22, 2020
AP			**EQ 750MG/30ML (EQ 25MG/ML)**	**A205540**	**002**	Apr 22, 2020

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091397**	**001**	Aug 08, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091397**	**002**	Aug 08, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091397**	**003**	Aug 08, 2013
AP		EUGIA PHARMA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A206919**	**001**	Feb 10, 2016
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A206919**	**002**	Feb 10, 2016
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A206919**	**003**	Feb 10, 2016
AP		FRESENIUS KABI USA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A200674**	**001**	Jun 19, 2013
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A200674**	**002**	Jun 19, 2013
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A200674**	**003**	Jun 19, 2013
AP		GLAND PHARMA LTD	**EQ 250MG/50ML (EQ 5MG/ML)**	**A206908**	**001**	Dec 30, 2020
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A206908**	**002**	Dec 30, 2020
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A206908**	**003**	Dec 30, 2020
AP		HIKMA FARMACEUTICA	**EQ 250MG/50ML (EQ 5MG/ML)**	**A091375**	**001**	Sep 16, 2011
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A091375**	**002**	Sep 16, 2011
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A091375**	**003**	Sep 16, 2011
AP		HOSPIRA INC	**EQ 250MG/50ML (EQ 5MG/ML)**	**A078579**	**001**	Sep 03, 2015
AP			**EQ 500MG/100ML (EQ 5MG/ML)**	**A078579**	**002**	Sep 03, 2015
AP			**EQ 750MG/150ML (EQ 5MG/ML)**	**A078579**	**003**	Sep 03, 2015
AP	**!**	INFORLIFE	**EQ 250MG/50ML (EQ 5MG/ML)**	**A090343**	**001**	Jul 07, 2011
AP	**!**		**EQ 500MG/100ML (EQ 5MG/ML)**	**A090343**	**002**	Jul 07, 2011

LEVOFLOXACIN						
INJECTABLE;INJECTION						
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	**!**		**EQ 750MG/150ML (EQ 5MG/ML)**	**A090343**	**003**	Jul 07, 2011
SOLUTION;ORAL						
LEVOFLOXACIN						
AA	**!**	AKORN	**250MG/10ML**	**A091678**	**001**	Jun 20, 2011
AA		LANNETT CO INC	**250MG/10ML**	**A205222**	**001**	May 25, 2018
SOLUTION/DROPS;OPHTHALMIC						
LEVOFLOXACIN						
AT		AKORN	**0.5%**	**A090268**	**001**	Dec 20, 2010
AT	**!**	RISING	**0.5%**	**A077700**	**001**	Dec 20, 2010
		MICRO LABS LTD INDIA	1.5%	A205600	001	Feb 27, 2019
TABLET;ORAL						
LEVOFLOXACIN						
AB		APOTEX INC	**250MG**	**A090787**	**001**	Sep 29, 2011
AB			**500MG**	**A090787**	**002**	Sep 29, 2011
AB			**750MG**	**A090787**	**003**	Sep 29, 2011
AB		AUROBINDO PHARMA LTD	**250MG**	**A201043**	**001**	Jun 20, 2011
AB			**500MG**	**A201043**	**002**	Jun 20, 2011
AB	**!**		**750MG**	**A201043**	**003**	Jun 20, 2011
AB		CADILA	**250MG**	**A077652**	**001**	Sep 07, 2012
AB			**500MG**	**A077652**	**002**	Sep 07, 2012
AB			**750MG**	**A077652**	**003**	Sep 07, 2012
AB		CELLTRION	**250MG**	**A090367**	**001**	Jun 20, 2011
AB			**500MG**	**A090367**	**002**	Jun 20, 2011
AB			**750MG**	**A090367**	**003**	Jun 20, 2011
AB		CIPLA LTD	**250MG**	**A076890**	**001**	Mar 30, 2012
AB			**500MG**	**A076890**	**002**	Mar 30, 2012
AB			**750MG**	**A076890**	**003**	Mar 30, 2012
AB		DR REDDYS LABS INC	**250MG**	**A076710**	**001**	Jun 20, 2011
AB			**500MG**	**A076710**	**002**	Jun 20, 2011
AB			**750MG**	**A076710**	**003**	Jun 20, 2011
AB		GLENMARK GENERICS	**250MG**	**A200250**	**001**	Jun 20, 2011
AB			**500MG**	**A200250**	**002**	Jun 20, 2011
AB			**750MG**	**A200250**	**003**	Jun 20, 2011
AB		HEC PHARM	**250MG**	**A204968**	**001**	Feb 05, 2019
AB			**500MG**	**A204968**	**002**	Feb 05, 2019
AB			**750MG**	**A204968**	**003**	Feb 05, 2019
AB		HETERO LABS LTD V	**250MG**	**A202801**	**001**	Jan 08, 2015
AB			**500MG**	**A202801**	**002**	Jan 08, 2015
AB			**750MG**	**A202801**	**003**	Jan 08, 2015
AB		LUPIN	**250MG**	**A078424**	**001**	Jun 20, 2011
AB			**500MG**	**A078424**	**002**	Jun 20, 2011
AB			**750MG**	**A078424**	**003**	Jun 20, 2011
AB		MACLEODS PHARMS LTD	**250MG**	**A200839**	**001**	Mar 22, 2012
AB			**500MG**	**A200839**	**002**	Mar 22, 2012
AB			**750MG**	**A200839**	**003**	Mar 22, 2012
AB		ORBION PHARMS	**250MG**	**A202200**	**001**	Jan 30, 2012
AB			**500MG**	**A202200**	**002**	Jan 30, 2012
AB			**750MG**	**A202200**	**003**	Jan 30, 2012
AB		SANDOZ	**250MG**	**A077438**	**001**	Jun 20, 2011
AB			**500MG**	**A077438**	**002**	Jun 20, 2011
AB			**750MG**	**A077438**	**003**	Jun 20, 2011
AB		TEVA	**250MG**	**A076361**	**001**	Jun 20, 2011
AB			**500MG**	**A076361**	**002**	Jun 20, 2011
AB			**750MG**	**A076361**	**003**	Jun 20, 2011
LEVOKETOCONAZOLE						
TABLET;ORAL						
RECORLEV						
	+!	STRONGBRIDGE	150MG	N214133	001	Dec 30, 2021
LEVOLEUCOVORIN						
POWDER;INTRAVENOUS						
KHAPZORY						
	+!	ACROTECH	175MG/VIAL	N211226	001	Oct 19, 2018
	+!		300MG/VIAL	N211226	002	Oct 19, 2018

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

FUSILEV

AP	**+!**	ACROTECH	**EQ 50MG BASE/VIAL**	**N020140**	**001**	Mar 07, 2008

LEVOLEUCOVORIN CALCIUM

AP		HIKMA	**EQ 50MG BASE/VIAL**	**A206263**	**001**	Jun 16, 2016
AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A211003**	**001**	Aug 22, 2019

SOLUTION;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP		AMNEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A207548**	**001**	Sep 08, 2017
AP	**!**	GLAND PHARMA LTD	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A210892**	**001**	Sep 14, 2018
AP	**!**		**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A210892**	**002**	Sep 14, 2018
AP		MEITHEAL	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A211002**	**001**	Aug 16, 2019
AP			**EQ 250MG BASE/25ML (EQ 10MG BASE/ML)**	**A211002**	**002**	Aug 16, 2019
AP		PRAXGEN	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A213797**	**001**	Nov 02, 2021
AP		SANDOZ INC	**EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)**	**A203563**	**001**	Mar 09, 2015

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

+	ALLERGAN	EQ 20MG BASE	N204168	001	Jul 25, 2013
+		EQ 40MG BASE	N204168	002	Jul 25, 2013
+		EQ 80MG BASE	N204168	003	Jul 25, 2013
+!		EQ 120MG BASE	N204168	004	Jul 25, 2013

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

SCANDONEST L

!	DEPROCO	0.05MG/ML;2%	A088388	001	Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

KYLEENA

+!	BAYER HLTHCARE	19.5MG	N208224	001	Sep 16, 2016

LILETTA

+!	MEDICINES360	52MG	N206229	001	Feb 26, 2015

MIRENA

+!	BAYER HLTHCARE	52MG	N021225	001	Dec 06, 2000

SKYLA

+!	BAYER HLTHCARE	13.5MG	N203159	001	Jan 09, 2013

TABLET;ORAL

LEVONORGESTREL

!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

AB		NOVITIUM PHARMA	**2MG**	**A213479**	**001**	Jul 01, 2020
AB			**3MG**	**A213479**	**002**	Jan 12, 2021
AB	**!**	SENTYNL THERAPS INC	**2MG**	**A074278**	**001**	Mar 31, 2000
AB	**!**		**3MG**	**A074278**	**003**	Jun 18, 2018
AB		SPECGX LLC	**2MG**	**A212024**	**001**	Dec 13, 2019
AB		SUN PHARM INDS INC	**2MG**	**A213906**	**001**	Jun 17, 2021
AB		VIRTUS PHARMS	**2MG**	**A211484**	**001**	Dec 13, 2018
		NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

AB		TEVA PHARMS USA INC	**0.112MG**	**A211369**	**003**	Apr 16, 2021

TIROSINT

AB	**+**	INSTITUT BIOCHIMIQUE	**0.112MG**	**N021924**	**008**	Oct 02, 2009
	+		0.013MG	N021924	013	Aug 01, 2007
	+		0.025MG	N021924	002	Oct 13, 2006
	+		0.05MG	N021924	003	Oct 13, 2006
	+		0.075MG	N021924	004	Oct 13, 2006
	+		0.088MG	N021924	010	Oct 02, 2009
	+		0.1MG	N021924	005	Oct 13, 2006
	+		0.125MG	N021924	006	Oct 13, 2006
	+		0.137MG	N021924	009	Oct 02, 2009
	+		0.15MG	N021924	007	Oct 13, 2006
	+		0.175MG	N021924	011	Apr 25, 2017
	+!		0.200MG	N021924	012	Apr 25, 2017

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	**+!**	FRESENIUS KABI USA	**100MCG/VIAL**		**N202231**	**001**	Jun 24, 2011
AP	**+!**		**200MCG/VIAL**		**N202231**	**002**	Jun 24, 2011
AP	**+!**		**500MCG/VIAL**		**N202231**	**003**	Jun 24, 2011
AP		MAIA PHARMS INC	**100MCG/VIAL**		**A208749**	**001**	Dec 21, 2018
AP			**200MCG/VIAL**		**A208749**	**002**	Dec 21, 2018
AP			**500MCG/VIAL**		**A208749**	**003**	Dec 21, 2018
AP		PIRAMAL CRITICAL	**100MCG/VIAL**		**A206163**	**001**	Jun 29, 2016
AP			**500MCG/VIAL**		**A206163**	**002**	Jun 29, 2016

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

	+!	CUSTOPHARM INC	100MCG/ML		N214253	001 Apr 17, 2021
	+!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)		N210632	001 Apr 11, 2019
	+!		200MCG/5ML (40MCG/ML)		N210632	002 Apr 11, 2019
	+!		500MCG/5ML (100MCG/ML)		N210632	003 Apr 11, 2019

SOLUTION;ORAL

THYQUIDITY

	+!	VISTAPHARM	100MCG/5ML		N214047	001 Nov 30, 2020

TIROSINT-SOL

	+	INSTITUT BIOCHIMIQUE	13MCG/ML		N206977	001 Dec 15, 2016
	+		25MCG/ML		N206977	002 Dec 15, 2016
	+		37.5MCG/ML		N206977	013 Jan 13, 2021
	+		44MCG/ML		N206977	014 Jan 13, 2021
	+		50MCG/ML		N206977	003 Dec 15, 2016
	+		62.5MCG/ML		N206977	015 Jan 13, 2021
	+		75MCG/ML		N206977	004 Dec 15, 2016
	+		88MCG/ML		N206977	005 Dec 15, 2016
	+		100MCG/ML		N206977	006 Dec 15, 2016
	+		112MCG/ML		N206977	007 Dec 15, 2016
	+		125MCG/ML		N206977	008 Dec 15, 2016
	+		137MCG/ML		N206977	009 Dec 15, 2016
	+		150MCG/ML		N206977	010 Dec 15, 2016
	+		175MCG/ML		N206977	011 Dec 15, 2016
	+!		200MCG/ML		N206977	012 Dec 15, 2016

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

SYNTHROID

-->	**+**	ABBVIE	**--> AB1,AB2**	**0.025MG**	N021402	001	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.05MG**	N021402	002	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.075MG**	N021402	003	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.088MG**	N021402	004	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.1MG**	N021402	005	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.112MG**	N021402	006	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.125MG**	N021402	007	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.137MG**	N021402	008	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.15MG**	N021402	009	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.175MG**	N021402	010	Jul 24, 2002
-->	**+**		**--> AB1,AB2**	**0.2MG**	N021402	012	Jul 24, 2002
-->	**+!**		**--> AB1,AB2**	**0.3MG**	N021402	011	Jul 24, 2002

LEVO-T

-->		CEDIPROF INC	**--> AB1,AB2,AB3**	**0.025MG**	N021342	001	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.05MG**	N021342	002	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.075MG**	N021342	003	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.088MG**	N021342	004	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.1MG**	N021342	005	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.112MG**	N021342	006	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.125MG**	N021342	007	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.137MG**	N021342	012	Dec 08, 2003
-->			**--> AB1,AB2,AB3**	**0.15MG**	N021342	008	Mar 01, 2002
-->			**--> AB1,AB2,AB3**	**0.175MG**	N021342	009	Mar 01, 2002

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

	LEVO-T						
-->			--> AB1,AB2,AB3	0.2MG	N021342	010	Mar 01, 2002
-->			--> AB1,AB2,AB3	0.3MG	N021342	011	Mar 01, 2002
	LEVOTHYROXINE SODIUM						
-->		LUPIN	--> AB1,AB2,AB3	0.025MG	A209713	001	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.05MG	A209713	002	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.075MG	A209713	003	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.088MG	A209713	004	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.1MG	A209713	005	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.112MG	A209713	006	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.125MG	A209713	007	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.137MG	A209713	008	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.15MG	A209713	009	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.175MG	A209713	010	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.2MG	A209713	011	Jan 18, 2019
-->			--> AB1,AB2,AB3	0.3MG	A209713	012	Jan 18, 2019
	UNITHROID						
-->	+	STEVENS J	--> AB1,AB2,AB3	0.025MG	N021210	001	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.05MG	N021210	002	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.075MG	N021210	003	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.088MG	N021210	004	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.1MG	N021210	005	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.112MG	N021210	006	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.125MG	N021210	007	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.137MG	N021210	012	Feb 08, 2008
-->	+		--> AB1,AB2,AB3	0.15MG	N021210	008	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.175MG	N021210	009	Aug 21, 2000
-->	+		--> AB1,AB2,AB3	0.2MG	N021210	010	Aug 21, 2000
-->	+!		--> AB1,AB2,AB3	0.3MG	N021210	011	Aug 21, 2000
	LEVOTHYROXINE SODIUM						
-->		MYLAN	--> AB1,AB2,AB3,AB4	0.025MG	A076187	001	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.05MG	A076187	002	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.075MG	A076187	003	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.088MG	A076187	004	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.1MG	A076187	005	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.112MG	A076187	006	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.125MG	A076187	007	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.137MG	A076187	012	Dec 13, 2006
-->			--> AB1,AB2,AB3,AB4	0.15MG	A076187	008	Jun 05, 2002
-->			--> AB1,AB2,AB3,AB4	0.175MG	A076187	009	Jun 05, 2002
-->			--> AB1,AB2,	0.2MG	A076187	010	Jun 05, 2002

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOTHYROXINE SODIUM							
			AB3,AB4	**0.2MG**			
-->	**!**		**-->**	**0.3MG**	A076187	011	Jun 05, 2002
			AB1,AB2,AB3,AB4				
THYRO-TABS							
-->	**+**	ALVOGEN	**--> AB1,AB2,AB4**	**0.025MG**	N021116	001	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.05MG**	N021116	002	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.075MG**	N021116	003	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.088MG**	N021116	010	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.1MG**	N021116	004	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.112MG**	N021116	011	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.125MG**	N021116	005	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.137MG**	N021116	012	Dec 07, 2004
-->	**+**		**--> AB1,AB2,AB4**	**0.15MG**	N021116	006	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.175MG**	N021116	007	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.2MG**	N021116	008	Oct 24, 2002
-->	**+**		**--> AB1,AB2,AB4**	**0.3MG**	N021116	009	Oct 24, 2002
LEVOXYL							
-->	**+**	KING PHARMS	**--> AB1,AB3**	**0.025MG**	N021301	001	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.05MG**	N021301	002	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.075MG**	N021301	003	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.088MG**	N021301	004	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.1MG**	N021301	005	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.112MG**	N021301	006	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.125MG**	N021301	007	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.137MG**	N021301	008	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.15MG**	N021301	009	May 25, 2001
-->	**+**		**--> AB1,AB3**	**0.175MG**	N021301	010	May 25, 2001
-->	**+!**		**--> AB1,AB3**	**0.2MG**	N021301	011	May 25, 2001
EUTHYROX							
AB2		PROVELL	**0.025MG**		**N021292**	**001**	May 31, 2002
AB2			**0.05MG**		**N021292**	**002**	May 31, 2002
AB2			**0.075MG**		**N021292**	**003**	May 31, 2002
AB2			**0.088MG**		**N021292**	**004**	May 31, 2002
AB2			**0.1MG**		**N021292**	**005**	May 31, 2002
AB2			**0.112MG**		**N021292**	**006**	May 31, 2002
AB2			**0.125MG**		**N021292**	**007**	May 31, 2002
AB2			**0.137MG**		**N021292**	**008**	May 31, 2002
AB2			**0.15MG**		**N021292**	**009**	May 31, 2002
AB2			**0.175MG**		**N021292**	**010**	May 31, 2002
AB2			**0.2MG**		**N021292**	**011**	May 31, 2002
LEVOTHYROXINE SODIUM							
AB2		ACCORD HLTHCARE	**0.025MG**		**A212399**	**001**	Oct 19, 2020
AB2			**0.05MG**		**A212399**	**002**	Oct 19, 2020
AB2			**0.075MG**		**A212399**	**003**	Oct 19, 2020
AB2			**0.088MG**		**A212399**	**004**	Oct 19, 2020
AB2			**0.1MG**		**A212399**	**005**	Oct 19, 2020
AB2			**0.112MG**		**A212399**	**006**	Oct 19, 2020
AB2			**0.125MG**		**A212399**	**007**	Oct 19, 2020
AB2			**0.137MG**		**A212399**	**008**	Oct 19, 2020
AB2			**0.15MG**		**A212399**	**009**	Oct 19, 2020
AB2			**0.175MG**		**A212399**	**010**	Oct 19, 2020
AB2			**0.2MG**		**A212399**	**011**	Oct 19, 2020
AB2			**0.3MG**		**A212399**	**012**	Oct 19, 2020

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT		ALEOR DERMACEUTICALS	**5%**	**A211469**	**001**	Nov 23, 2018
AT		ALKEM LABS LTD	**5%**	**A207810**	**001**	Mar 10, 2017
AT		AMNEAL PHARMS	**5%**	**A206297**	**001**	Aug 07, 2015
AT		COSETTE	**5%**	**A211019**	**001**	Dec 12, 2018
AT		DR REDDYS	**5%**	**A208660**	**001**	Jan 05, 2021
AT	**+!**	FOUGERA PHARMS INC	**5%**	**A080198**	**001**	
AT		GLENMARK PHARMS LTD	**5%**	**A206498**	**001**	Sep 09, 2016
AT		MACLEODS PHARMS LTD	**5%**	**A211697**	**001**	Mar 16, 2020
AT		QUAGEN	**5%**	**A212695**	**001**	Apr 20, 2021
AT		SEPTODONT INC	**5%**	**A040911**	**001**	May 23, 2011
AT		STRIDES PHARMA	**5%**	**A210958**	**001**	Dec 11, 2018
AT		TARO	**5%**	**A086724**	**001**	
AT		TELIGENT	**5%**	**A205318**	**001**	Feb 01, 2016
AT		VITRUVIAS THERAP	**5%**	**A208822**	**001**	Sep 25, 2017

PATCH;TOPICAL

LIDOCAINE

AB		ACTAVIS LABS UT INC	**5%**	**A200675**	**001**	Aug 23, 2012
AB		AMNEAL	**5%**	**A206463**	**001**	Aug 24, 2020
AB		MYLAN TECHNOLOGIES	**5%**	**A202346**	**001**	Aug 07, 2015
AB		NAL PHARM	**5%**	**A205882**	**001**	Apr 29, 2021
AB		RHODES PHARMS	**5%**	**A209190**	**001**	Apr 30, 2020

LIDODERM

AB	**+!**	TEIKOKU PHARMA USA	**5%**	**N020612**	**001**	Mar 19, 1999

ZTLIDO

	+!	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

AKTEN

	+!	AKORN	3.5%	N022221	001	Oct 07, 2008

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP		ASPIRO	**1%**	**A214336**	**001**	Nov 08, 2021
AP			**1%**	**A214339**	**001**	Nov 08, 2021
AP			**2%**	**A214339**	**002**	Nov 08, 2021
AP		B BRAUN MEDICAL INC	**1%**	**A208474**	**001**	Aug 03, 2018
AP		EUGIA PHARMA	**1%**	**A207182**	**001**	Oct 30, 2017
AP			**2%**	**A207182**	**002**	Oct 30, 2017
AP		FRESENIUS KABI USA	**1%**	**A080404**	**002**	
AP			**2%**	**A080404**	**003**	
AP		HOSPIRA	**0.5%**	**A088328**	**001**	May 17, 1984
AP	**!**		**1%**	**A083158**	**001**	
AP			**1%**	**A088329**	**001**	May 17, 1984
AP			**2%**	**A040078**	**001**	Jun 23, 1995
AP	**!**		**2%**	**A083158**	**002**	
AP			**2%**	**A088294**	**001**	May 17, 1984
AP		HUONS	**1%**	**A212821**	**001**	May 07, 2020
AP		INTL MEDICATION	**1%**	**A083173**	**001**	
AP			**2%**	**A083173**	**002**	
AP		SPECTRA MDCL DEVICES	**1%**	**A208017**	**001**	Apr 18, 2018
AP		WEST-WARD PHARMS INT	**1%**	**A080407**	**001**	
AP			**2%**	**A080407**	**002**	

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**200MG/100ML**	**N019830**	**002**	Apr 08, 1992
AP		BAXTER HLTHCARE	**200MG/100ML**	**N018461**	**002**	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**400MG/100ML**	**N019830**	**003**	Apr 08, 1992
AP		BAXTER HLTHCARE	**400MG/100ML**	**N018461**	**003**	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**800MG/100ML**	**N019830**	**004**	Apr 08, 1992
AP		BAXTER HLTHCARE	**800MG/100ML**	**N018461**	**004**	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**1%**	**A088586**	**001**	Jul 24, 1985
AP		HOSPIRA	**0.5%**	**A088325**	**001**	Jul 31, 1984
AP			**1%**	**A088299**	**001**	Jul 31, 1984
AP			**2%**	**A088327**	**001**	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE							
INJECTABLE;INJECTION							
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP		EUGIA PHARMA	**1%**	**A203040**	**001**	Mar 14, 2013
AP			**1%**	**A203082**	**001**	Mar 14, 2013
AP			**2%**	**A203040**	**002**	Mar 14, 2013
AP			**2%**	**A203082**	**002**	Mar 14, 2013
AP		FRESENIUS KABI USA	**2%**	**N017584**	**001**	
AP			**4%**	**N017584**	**002**	
AP		HOSPIRA	**1%**	**A080408**	**001**	
AP			**1.5%**	**A080408**	**002**	
AP		WEST-WARD PHARMS INT	**1%**	**A084625**	**001**	
AP			**2%**	**A084625**	**002**	
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER							
AP		HOSPIRA	**1%**	**A040302**	**001**	Sep 28, 1998
AP			**2%**	**A040302**	**002**	Sep 28, 1998
XYLOCAINE							
AP	**+!**	FRESENIUS KABI USA	**0.5%**	**N006488**	**008**	
AP	**+!**		**1%**	**N006488**	**007**	
AP	**+!**		**1.5%**	**N006488**	**010**	
AP	**+!**		**2%**	**N006488**	**002**	
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE							
	!	HOSPIRA	4%	A088295	001	May 17, 1984
INJECTABLE;SPINAL							
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%							
	!	HOSPIRA	5%	A083914	001	
JELLY;TOPICAL							
GLYDO							
AT		SAGENT PHARMS INC	**2%**	**A201094**	**001**	Apr 28, 2014
LIDOCAINE HYDROCHLORIDE							
AT	**!**	AKORN	**2%**	**A040433**	**001**	Feb 12, 2003
AT		INTL MEDICATION	**2%**	**A086283**	**001**	
SOLUTION;ORAL							
LIDOCAINE HYDROCHLORIDE							
AT	**!**	AKORN	**2%**	**A040014**	**001**	Jul 10, 1995
AT		WOCKHARDT BIO AG	**2%**	**A087872**	**001**	Nov 18, 1982
LIDOCAINE HYDROCHLORIDE VISCOUS							
AT		LANNETT CO INC	**2%**	**A040708**	**001**	Feb 27, 2007
LIDOCAINE VISCOUS							
AT		HIKMA	**2%**	**A088802**	**001**	Apr 26, 1985
SOLUTION;TOPICAL							
LARYNG-O-JET KIT							
AT		INTL MEDICATION	**4%**	**A086364**	**001**	
LIDOCAINE HYDROCHLORIDE							
AT	**!**	HIKMA	**4%**	**A088803**	**001**	Apr 03, 1985
AT		LANNETT CO INC	**4%**	**A040710**	**001**	Feb 27, 2007
AT		TELIGENT	**4%**	**A204494**	**001**	Mar 12, 2014
AT		WOCKHARDT BIO AG	**4%**	**A087881**	**001**	Nov 18, 1982
SYSTEM;INTRADERMAL							
ZINGO							
		POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007
LIDOCAINE; PRILOCAINE							
CREAM;TOPICAL							
EMLA							
AB	**+!**	TEVA BRANDED PHARM	**2.5%;2.5%**	**N019941**	**001**	Dec 30, 1992
LIDOCAINE AND PRILOCAINE							
AB		ACRUX DDS PTY	**2.5%;2.5%**	**A212482**	**001**	Jul 27, 2021
AB		AKORN	**2.5%;2.5%**	**A076290**	**001**	Sep 25, 2003
AB		FOUGERA PHARMS	**2.5%;2.5%**	**A076453**	**001**	Aug 18, 2003
AB		TELIGENT	**2.5%;2.5%**	**A205887**	**001**	Jun 29, 2018
AB		TOLMAR	**2.5%;2.5%**	**A076320**	**001**	Aug 27, 2003
GEL;PERIODONTAL							
ORAQIX							
	+!	DENTSPLY PHARM	2.5%;2.5%	N021451	001	Dec 19, 2003
LIDOCAINE; TETRACAINE							
CREAM;TOPICAL							
PLIAGLIS							
	+!	TARO PHARMS	7%;7%	N021717	001	Jun 29, 2006

LIDOCAINE; TETRACAINE
PATCH;TOPICAL
SYNERA
+! GALEN SPECIALTY 70MG;70MG N021623 001 Jun 23, 2005

LIFITEGRAST
SOLUTION/DROPS;OPHTHALMIC
XIIDRA
+! NOVARTIS 5% N208073 001 Jul 11, 2016

LINACLOTIDE
CAPSULE;ORAL
LINZESS
+! ALLERGAN 72MCG N202811 003 Jan 25, 2017
+! 145MCG N202811 001 Aug 30, 2012
+ 290MCG N202811 002 Aug 30, 2012

LINAGLIPTIN
TABLET;ORAL
LINAGLIPTIN
AB SUNSHINE **5MG** **A208335 001** Aug 31, 2021
TRADJENTA
AB **+!** BOEHRINGER INGELHEIM **5MG** **N201280 001** May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL
JENTADUETO
AB **+** BOEHRINGER INGELHEIM **2.5MG;500MG** **N201281 001** Jan 30, 2012
AB **+** **2.5MG;850MG** **N201281 002** Jan 30, 2012
AB **+!** **2.5MG;1GM** **N201281 003** Jan 30, 2012
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
AB SUNSHINE **2.5MG;500MG** **A208336 001** Aug 30, 2021
AB **2.5MG;850MG** **A208336 002** Aug 30, 2021
AB **2.5MG;1GM** **A208336 003** Aug 30, 2021
TABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR
+ BOEHRINGER INGELHEIM 2.5MG;1GM N208026 001 May 27, 2016
+! 5MG;1GM N208026 002 May 27, 2016

LINCOMYCIN
INJECTABLE;INJECTION
LINCOMYCIN
AP MICRO LABS **EQ 300MG BASE/ML** **A215082 001** Nov 08, 2021

LINCOMYCIN HYDROCHLORIDE
INJECTABLE;INJECTION
LINCOCIN
AP **+!** PFIZER **EQ 300MG BASE/ML** **N050317 001**
LINCOMYCIN
AP XGEN PHARMS **EQ 300MG BASE/ML** **A201746 001** Jun 04, 2015

LINDANE
SHAMPOO;TOPICAL
LINDANE
! WOCKHARDT BIO AG 1% A088191 001 Sep 18, 1984

LINEZOLID
FOR SUSPENSION;ORAL
LINEZOLID
AB HIKMA **100MG/5ML** **A200068 001** Jun 03, 2015
ZYVOX
AB **+!** PFIZER **100MG/5ML** **N021132 001** Apr 18, 2000
SOLUTION;INTRAVENOUS
LINEZOLID
AP EUGIA PHARMA **600MG/300ML (2MG/ML)** **A206917 001** Aug 04, 2016
AP FRESENIUS KABI USA **600MG/300ML (2MG/ML)** **A204764 001** Mar 15, 2016
AP HOSPIRA INC **600MG/300ML (2MG/ML)** **A205442 001** Jul 07, 2015
AP HQ SPCLT PHARMA **200MG/100ML (2MG/ML)** **A207001 001** Jul 07, 2017
AP **600MG/300ML (2MG/ML)** **A207001 002** Jul 07, 2017
AP MYLAN LABS LTD **200MG/100ML (2MG/ML)** **A205154 001** Dec 06, 2017
AP **600MG/300ML (2MG/ML)** **A205154 002** Dec 06, 2017
AP NANG KUANG PHARM CO **200MG/100ML (2MG/ML)** **A207354 001** Dec 20, 2016
AP **600MG/300ML (2MG/ML)** **A207354 002** Dec 20, 2016
AP SAGENT PHARMS INC **200MG/100ML (2MG/ML)** **A204696 001** Mar 02, 2017

LINEZOLID						
SOLUTION;INTRAVENOUS						
LINEZOLID						
AP			**600MG/300ML (2MG/ML)**	**A204696**	**002**	Mar 02, 2017
AP		SANDOZ INC	**200MG/100ML (2MG/ML)**	**A200904**	**001**	Jul 16, 2015
AP			**600MG/300ML (2MG/ML)**	**A200904**	**002**	Jul 16, 2015
AP		TEVA PHARMS	**600MG/300ML (2MG/ML)**	**A200222**	**001**	Jun 27, 2012
ZYVOX						
AP	+	PFIZER	**200MG/100ML (2MG/ML)**	**N021131**	**001**	Apr 18, 2000
AP	+!		**600MG/300ML (2MG/ML)**	**N021131**	**003**	Apr 18, 2000
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	+!	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015
TABLET;ORAL						
LINEZOLID						
AB		ALEMBIC PHARMS LTD	**600MG**	**A205233**	**001**	Dec 21, 2015
AB		ALKEM LABS LTD	**600MG**	**A205517**	**001**	Dec 21, 2015
AB		AMNEAL PHARMS	**600MG**	**A204536**	**001**	Dec 21, 2015
AB		CELLTRION	**600MG**	**A210702**	**001**	Apr 25, 2019
AB		GLENMARK PHARMS	**600MG**	**A078987**	**001**	Dec 21, 2015
AB		HETERO LABS LTD V	**600MG**	**A204239**	**001**	Dec 21, 2015
AB		NOVEL LABS INC	**600MG**	**A207526**	**001**	Aug 22, 2016
AB		ZYDUS PHARMS	**600MG**	**A206097**	**001**	Feb 22, 2017
ZYVOX						
AB	+!	PFIZER	**600MG**	**N021130**	**002**	Apr 18, 2000
LIOTHYRONINE SODIUM						
INJECTABLE;INJECTION						
LIOTHYRONINE SODIUM						
AP		XGEN PHARMS	**EQ 0.01MG BASE/ML**	**A076923**	**001**	Aug 17, 2005
TRIOSTAT						
AP	+!	PAR STERILE PRODUCTS	**EQ 0.01MG BASE/ML**	**N020105**	**001**	Dec 31, 1991
TABLET;ORAL						
CYTOMEL						
AB	+	KING PHARMS	**EQ 0.005MG BASE**	**N010379**	**001**	
AB	+		**EQ 0.025MG BASE**	**N010379**	**002**	
AB	+		**EQ 0.05MG BASE**	**N010379**	**003**	
LIOTHYRONINE SODIUM						
AB		MAYNE PHARMA INC	**EQ 0.005MG BASE**	**A090097**	**001**	Mar 20, 2009
AB			**EQ 0.025MG BASE**	**A090097**	**002**	Mar 20, 2009
AB			**EQ 0.05MG BASE**	**A090097**	**003**	Mar 20, 2009
AB		SIGMAPHARM LABS LLC	**EQ 0.005MG BASE**	**A200295**	**001**	Nov 29, 2012
AB			**EQ 0.025MG BASE**	**A200295**	**002**	Nov 29, 2012
AB	!		**EQ 0.05MG BASE**	**A200295**	**003**	Nov 29, 2012
AB		SUN PHARM	**EQ 0.005MG BASE**	**A091382**	**001**	Apr 20, 2016
AB			**EQ 0.025MG BASE**	**A091382**	**002**	Apr 20, 2016
AB			**EQ 0.05MG BASE**	**A091382**	**003**	Apr 20, 2016
AB		TEVA PHARMS USA	**EQ 0.005MG BASE**	**A211510**	**001**	Oct 26, 2018
AB			**EQ 0.025MG BASE**	**A211510**	**002**	Oct 26, 2018
AB			**EQ 0.05MG BASE**	**A211510**	**003**	Oct 26, 2018
AB		ZYDUS	**EQ 0.005MG BASE**	**A214803**	**001**	Jan 22, 2021
AB			**EQ 0.025MG BASE**	**A214803**	**002**	Jan 22, 2021
AB			**EQ 0.05MG BASE**	**A214803**	**003**	Jan 22, 2021
LIRAGLUTIDE RECOMBINANT						
SOLUTION;SUBCUTANEOUS						
SAXENDA						
	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014
VICTOZA						
	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010
LISDEXAMFETAMINE DIMESYLATE						
CAPSULE;ORAL						
VYVANSE						
	+	TAKEDA PHARMS USA	10MG	N021977	007	Oct 30, 2014
	+		20MG	N021977	004	Dec 10, 2007
	+		30MG	N021977	001	Feb 23, 2007
	+		40MG	N021977	005	Dec 10, 2007
	+		50MG	N021977	002	Feb 23, 2007
	+		60MG	N021977	006	Dec 10, 2007
	+!		70MG	N021977	003	Feb 23, 2007
TABLET, CHEWABLE;ORAL						
VYVANSE						
	+	TAKEDA PHARMS USA	10MG	N208510	001	Jan 28, 2017

LISDEXAMFETAMINE DIMESYLATE

TABLET, CHEWABLE;ORAL

VYVANSE

+		20MG	N208510	002	Jan 28, 2017
+		30MG	N208510	003	Jan 28, 2017
+		40MG	N208510	004	Jan 28, 2017
+		50MG	N208510	005	Jan 28, 2017
+!		60MG	N208510	006	Jan 28, 2017

LISINOPRIL

SOLUTION;ORAL

QBRELIS

+!	AZURITY	1MG/ML	N208401	001	Jul 29, 2016

TABLET;ORAL

LISINOPRIL

AB	ACCORD HLTHCARE	**2.5MG**	**A202554**	**001**	Jul 30, 2013
AB		**5MG**	**A202554**	**002**	Jul 30, 2013
AB		**10MG**	**A202554**	**003**	Jul 30, 2013
AB		**20MG**	**A202554**	**004**	Jul 30, 2013
AB		**30MG**	**A202554**	**005**	Jul 30, 2013
AB		**40MG**	**A202554**	**006**	Jul 30, 2013
AB	ASCENT PHARMS INC	**2.5MG**	**A075903**	**001**	Jul 01, 2002
AB		**5MG**	**A075903**	**002**	Jul 01, 2002
AB		**10MG**	**A075903**	**003**	Jul 01, 2002
AB		**20MG**	**A075903**	**004**	Jul 01, 2002
AB		**30MG**	**A075903**	**005**	Jul 01, 2002
AB		**40MG**	**A075903**	**006**	Jul 01, 2002
AB	ATLANTIDE	**2.5MG**	**A078402**	**001**	Apr 19, 2007
AB		**5MG**	**A078402**	**002**	Apr 19, 2007
AB		**10MG**	**A078402**	**003**	Apr 19, 2007
AB		**20MG**	**A078402**	**004**	Apr 19, 2007
AB		**30MG**	**A078402**	**005**	Apr 19, 2007
AB		**40MG**	**A078402**	**006**	Apr 19, 2007
AB	AUROBINDO	**2.5MG**	**A077622**	**001**	Feb 22, 2006
AB		**5MG**	**A077622**	**002**	Feb 22, 2006
AB		**10MG**	**A077622**	**003**	Feb 22, 2006
AB		**20MG**	**A077622**	**004**	Feb 22, 2006
AB		**30MG**	**A077622**	**005**	Feb 22, 2006
AB		**40MG**	**A077622**	**006**	Feb 22, 2006
AB	CHARTWELL RX	**2.5MG**	**A075994**	**001**	Jul 01, 2002
AB		**5MG**	**A075994**	**002**	Jul 01, 2002
AB		**10MG**	**A075994**	**003**	Jul 01, 2002
AB		**20MG**	**A075994**	**004**	Jul 01, 2002
AB		**30MG**	**A075994**	**005**	Jul 01, 2002
AB		**40MG**	**A075994**	**006**	Jul 01, 2002
AB	COREPHARMA	**2.5MG**	**A076102**	**001**	Sep 30, 2002
AB		**5MG**	**A076102**	**002**	Sep 30, 2002
AB		**10MG**	**A076102**	**003**	Sep 30, 2002
AB		**20MG**	**A076102**	**004**	Sep 30, 2002
AB		**30MG**	**A076102**	**005**	Sep 30, 2002
AB		**40MG**	**A076102**	**006**	Sep 30, 2002
AB	INVAGEN PHARMS	**2.5MG**	**A203508**	**001**	Oct 29, 2013
AB		**5MG**	**A203508**	**002**	Oct 29, 2013
AB		**10MG**	**A203508**	**003**	Oct 29, 2013
AB		**20MG**	**A203508**	**004**	Oct 29, 2013
AB		**30MG**	**A203508**	**005**	Oct 29, 2013
AB		**40MG**	**A203508**	**006**	Oct 29, 2013
AB	LUPIN	**2.5MG**	**A077321**	**001**	Sep 09, 2005
AB		**5MG**	**A077321**	**002**	Sep 09, 2005
AB		**10MG**	**A077321**	**003**	Sep 09, 2005
AB		**20MG**	**A077321**	**004**	Sep 09, 2005
AB		**30MG**	**A077321**	**005**	Sep 09, 2005
AB		**40MG**	**A077321**	**006**	Sep 09, 2005
AB	PRINSTON INC	**2.5MG**	**A075743**	**001**	Jul 01, 2002
AB		**2.5MG**	**A076164**	**004**	Jul 01, 2002
AB		**5MG**	**A075743**	**002**	Jul 01, 2002
AB		**5MG**	**A076164**	**005**	Jul 01, 2002
AB		**10MG**	**A075743**	**003**	Jul 01, 2002
AB		**10MG**	**A076164**	**006**	Jul 01, 2002
AB		**20MG**	**A075743**	**004**	Jul 01, 2002
AB		**20MG**	**A076164**	**001**	Jul 01, 2002
AB		**30MG**	**A075743**	**005**	Jul 01, 2002
AB		**30MG**	**A076164**	**002**	Jul 01, 2002

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB			40MG	A075743	006	Jul 01, 2002
AB			40MG	A076164	003	Jul 01, 2002
AB		SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002
AB			5MG	A075944	002	Jul 01, 2002
AB			10MG	A075944	003	Jul 01, 2002
AB			20MG	A075944	004	Jul 01, 2002
AB			30MG	A075944	006	Feb 11, 2003
AB			40MG	A075944	005	Jul 01, 2002
AB		WATSON LABS	2.5MG	A076059	001	Jul 01, 2002
AB			5MG	A076059	002	Jul 01, 2002
AB			10MG	A076059	003	Jul 01, 2002
AB			20MG	A076059	004	Jul 01, 2002
AB			30MG	A076059	005	Jul 01, 2002
AB			40MG	A076059	006	Jul 01, 2002
AB		YILING	2.5MG	A212041	001	Sep 15, 2020
AB			5MG	A212041	002	Sep 15, 2020
AB			10MG	A212041	003	Sep 15, 2020
AB			20MG	A208920	001	Mar 04, 2021
AB			30MG	A208920	002	Mar 04, 2021
AB			40MG	A208920	003	Mar 04, 2021

PRINIVIL

AB		MERCK	5MG	N019558	001	Dec 29, 1987
AB			40MG	N019558	004	Oct 25, 1988

ZESTRIL

AB	+	ALMATICA	2.5MG	N019777	005	Apr 29, 1993
AB	+		5MG	N019777	001	May 19, 1988
AB	+		10MG	N019777	002	May 19, 1988
AB	+		20MG	N019777	003	May 19, 1988
AB	+		30MG	N019777	006	Jan 20, 1999
AB	+!		40MG	N019777	004	May 19, 1988

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB		ALEMBIC LTD	150MG	A079159	001	Jan 12, 2009
AB			300MG	A079159	002	Jan 12, 2009
AB			600MG	A079159	003	Jan 12, 2009
AB		GLENMARK GENERICS	150MG	A079139	001	Feb 03, 2009
AB			300MG	A079139	002	Feb 03, 2009
AB			600MG	A079139	003	Feb 03, 2009
AB		HETERO LABS LTD III	150MG	A090702	001	Sep 25, 2009
AB			300MG	A090702	002	Sep 25, 2009
AB			600MG	A090702	003	Sep 25, 2009
AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987
AB	+		300MG	N017812	001	
AB	+!		600MG	N017812	003	Jan 28, 1987

TABLET;ORAL

LITHIUM CARBONATE

AB	+!	HIKMA	300MG	N018558	001	Jan 29, 1982
AB		SUN PHARM INDS INC	300MG	A091027	001	Jun 24, 2010

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

AB		GLENMARK GENERICS	450MG	A091616	001	Feb 14, 2011
AB		GLENMARK PHARMS INC	300MG	A091544	001	Dec 27, 2010
AB		HERITAGE PHARMA	300MG	A205532	001	Sep 29, 2016
AB		HIKMA	300MG	A076832	001	Oct 28, 2004
AB	!		450MG	A076691	001	Jan 05, 2004
AB		MYLAN PHARMS INC	300MG	A202288	001	Jun 29, 2012
AB			450MG	A202219	001	Aug 08, 2012
AB		UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015
AB			450MG	A205663	001	Jun 05, 2017

LITHOBID

AB	+!	ANI PHARMS	300MG	N018027	001	

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

AA	**+!**	HIKMA	**EQ 300MG CARBONATE/5ML**	**N018421**	**001**	
AA		WOCKHARDT BIO AG	**EQ 300MG CARBONATE/5ML**	**A070755**	**001**	May 21, 1986

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

	+!	NOVARTIS	EQ 0.1% BASE	N020191	001 Sep 23, 1993

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LUCEMYRA

	+!	USWM	EQ 0.18MG BASE	N209229	001 May 16, 2018

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

	+	AMRYT	EQ 5MG BASE	N203858	001 Dec 21, 2012
	+		EQ 10MG BASE	N203858	002 Dec 21, 2012
	+		EQ 20MG BASE	N203858	003 Dec 21, 2012
	+		EQ 30MG BASE	N203858	004 Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

	+	CORDEN PHARMA	10MG	N017588	001
	+		40MG	N017588	002
	+!		100MG	N017588	003

LONAFARNIB

CAPSULE;ORAL

ZOKINVY

	+	EIGER BIOPHARMS	50MG	N213969	001 Nov 20, 2020
	+!		75MG	N213969	002 Nov 20, 2020

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

AB		BIONPHARMA INC	**2MG**	**A215579**	**001**	Oct 22, 2021
AB		EDENBRIDGE PHARMS	**2MG**	**A215001**	**001**	Oct 06, 2021
AB	**!**	MYLAN	**2MG**	**A072741**	**001**	Sep 18, 1991
AB		TEVA	**2MG**	**A073192**	**001**	Apr 30, 1992

LOPINAVIR; RITONAVIR

SOLUTION;ORAL

KALETRA

AA	**+!**	ABBVIE	**80MG/ML;20MG/ML**	**N021251**	**001**	Sep 15, 2000

LOPINAVIR AND RITONAVIR

AA		LANNETT CO INC	**80MG/ML;20MG/ML**	**A207407**	**001**	Dec 27, 2016

TABLET;ORAL

KALETRA

AB	**+**	ABBVIE	**100MG;25MG**	**N021906**	**002**	Nov 09, 2007
AB	**+!**		**200MG;50MG**	**N021906**	**001**	Oct 28, 2005

LOPINAVIR AND RITONAVIR

AB		HETERO LABS LTD III	**100MG;25MG**	**A091677**	**001**	Jun 04, 2021
AB			**200MG;50MG**	**A091677**	**002**	Jun 04, 2021

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL

LOREEV XR

	+	ALMATICA	1MG	N214826	001 Aug 27, 2021
	+		2MG	N214826	002 Aug 27, 2021
	+!		3MG	N214826	003 Aug 27, 2021

CONCENTRATE;ORAL

LORAZEPAM

AA		AKORN	**2MG/ML**	**A200169**	**001**	Jan 30, 2012
AA		AMNEAL PHARMS	**2MG/ML**	**A091383**	**001**	Dec 23, 2009
AA		LANNETT CO INC	**2MG/ML**	**A079244**	**001**	Apr 28, 2009
AA		LUPIN LTD	**2MG/ML**	**A091407**	**001**	Feb 19, 2013
AA		PHARM ASSOC	**2MG/ML**	**A090260**	**001**	Jun 15, 2010

LORAZEPAM INTENSOL

AA	**!**	HIKMA	**2MG/ML**	**A072755**	**001**	Jun 28, 1991

LORAZEPAM							
INJECTABLE;INJECTION							
ATIVAN							
AP	**+!**	HIKMA	**2MG/ML**	**N018140**	**001**		
AP	**+!**		**4MG/ML**	**N018140**	**002**		
LORAZEPAM							
AP		AKORN	**2MG/ML**	**A075025**	**001**	Jul 23, 1998	
AP		HOSPIRA	**2MG/ML**	**A074243**	**001**	Apr 12, 1994	
AP			**2MG/ML**	**A074282**	**001**	May 27, 1994	
AP			**4MG/ML**	**A074243**	**002**	Apr 12, 1994	
AP			**4MG/ML**	**A074282**	**002**	May 27, 1994	
AP		INTL MEDICATION SYS	**2MG/ML**	**A076150**	**001**	Nov 15, 2004	
TABLET;ORAL							
ATIVAN							
AB	**+**	BAUSCH	**0.5MG**	**N017794**	**001**		
AB	**+**		**1MG**	**N017794**	**002**		
AB	**+!**		**2MG**	**N017794**	**003**		
LORAZEPAM							
AB		AMNEAL PHARMS	**0.5MG**	**A078826**	**001**	Jun 23, 2010	
AB			**1MG**	**A078826**	**002**	Jun 23, 2010	
AB			**2MG**	**A078826**	**003**	Jun 23, 2010	
AB		AUROLIFE PHARMA LLC	**0.5MG**	**A203572**	**001**	Dec 22, 2017	
AB			**1MG**	**A203572**	**002**	Dec 22, 2017	
AB			**2MG**	**A203572**	**003**	Dec 22, 2017	
AB		LEADING PHARMA LLC	**0.5MG**	**A078203**	**001**	Jul 30, 2007	
AB			**1MG**	**A078203**	**002**	Jul 30, 2007	
AB			**2MG**	**A078203**	**003**	Jul 30, 2007	
AB		OXFORD PHARMS	**0.5MG**	**A077754**	**001**	May 10, 2006	
AB			**1MG**	**A077754**	**002**	May 10, 2006	
AB			**2MG**	**A077754**	**003**	May 10, 2006	
AB		SANDOZ	**0.5MG**	**A071141**	**002**	Apr 21, 1987	
AB			**1MG**	**A071141**	**003**	Apr 21, 1987	
AB			**2MG**	**A071141**	**001**	Apr 21, 1987	
AB		WATSON LABS	**0.5MG**	**A072926**	**001**	Oct 31, 1991	
AB			**1MG**	**A072927**	**001**	Oct 31, 1991	
AB			**2MG**	**A072928**	**001**	Oct 31, 1991	
LORLATINIB							
TABLET;ORAL							
LORBRENA							
	+	PFIZER	25MG	N210868	001	Nov 02, 2018	
	+!		100MG	N210868	002	Nov 02, 2018	
LOSARTAN POTASSIUM							
TABLET;ORAL							
COZAAR							
AB	**+**	ORGANON	**25MG**	**N020386**	**001**	Apr 14, 1995	
AB	**+**		**50MG**	**N020386**	**002**	Apr 14, 1995	
AB	**+!**		**100MG**	**N020386**	**003**	Oct 13, 1998	
LOSARTAN POTASSIUM							
AB		ALEMBIC PHARMS LTD	**25MG**	**A090428**	**001**	Oct 06, 2010	
AB			**50MG**	**A090428**	**002**	Oct 06, 2010	
AB			**100MG**	**A090428**	**003**	Oct 06, 2010	
AB		AUROBINDO PHARMA	**25MG**	**A090083**	**001**	Oct 06, 2010	
AB			**50MG**	**A090083**	**002**	Oct 06, 2010	
AB			**100MG**	**A090083**	**003**	Oct 06, 2010	
AB		HETERO LABS LTD V	**25MG**	**A203835**	**001**	Aug 12, 2015	
AB			**50MG**	**A203835**	**002**	Aug 12, 2015	
AB			**100MG**	**A203835**	**003**	Aug 12, 2015	
AB		HIKMA	**25MG**	**A077459**	**001**	Oct 06, 2010	
AB			**50MG**	**A077459**	**002**	Oct 06, 2010	
AB			**100MG**	**A077459**	**003**	Oct 06, 2010	
AB		IPCA LABS LTD	**25MG**	**A200290**	**001**	Aug 30, 2013	
AB			**50MG**	**A200290**	**002**	Aug 30, 2013	
AB			**100MG**	**A200290**	**003**	Aug 30, 2013	
AB		JUBILANT CADISTA	**25MG**	**A201170**	**001**	Sep 18, 2012	
AB			**50MG**	**A201170**	**002**	Sep 18, 2012	
AB			**100MG**	**A201170**	**003**	Sep 18, 2012	
AB		LUPIN LTD	**25MG**	**A078232**	**001**	Oct 06, 2010	
AB			**50MG**	**A078232**	**002**	Oct 06, 2010	
AB			**100MG**	**A078232**	**003**	Oct 06, 2010	
AB		MACLEODS PHARMS LTD	**25MG**	**A202230**	**001**	May 30, 2012	
AB			**50MG**	**A202230**	**002**	May 30, 2012	

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB			**100MG**	**A202230**	**003**	May 30, 2012
AB		MICRO LABS	**25MG**	**A091541**	**001**	Sep 24, 2012
AB			**50MG**	**A091541**	**002**	Sep 24, 2012
AB			**100MG**	**A091541**	**003**	Sep 24, 2012
AB		PRINSTON INC	**25MG**	**A091497**	**001**	Jun 06, 2011
AB			**50MG**	**A091497**	**002**	Jun 06, 2011
AB			**100MG**	**A091497**	**003**	Jun 06, 2011
AB		SANDOZ	**25MG**	**A077424**	**001**	Oct 06, 2010
AB			**50MG**	**A077424**	**002**	Oct 06, 2010
AB			**100MG**	**A077424**	**003**	Oct 06, 2010
AB		STRIDES PHARMA	**25MG**	**A090382**	**001**	Oct 06, 2010
AB			**50MG**	**A090382**	**002**	Oct 06, 2010
AB			**100MG**	**A090382**	**003**	Oct 06, 2010
AB		UNICHEM	**25MG**	**A203030**	**001**	Oct 14, 2015
AB			**50MG**	**A203030**	**002**	Oct 14, 2015
AB			**100MG**	**A203030**	**003**	Oct 14, 2015
AB		WATSON LABS	**25MG**	**A091129**	**001**	Oct 06, 2010
AB			**50MG**	**A091129**	**002**	Oct 06, 2010
AB			**100MG**	**A091129**	**003**	Oct 06, 2010
AB		ZYDUS PHARMS USA INC	**25MG**	**A078243**	**001**	Oct 06, 2010
AB			**50MG**	**A078243**	**002**	Oct 06, 2010
AB			**100MG**	**A078243**	**003**	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

AB	**+!**	BAUSCH AND LOMB INC	**0.5%**	**N202872**	**001**	Sep 28, 2012

LOTEPREDNOL ETABONATE

AB		AKORN	**0.5%**	**A212080**	**001**	Feb 10, 2021

LOTEMAX SM

	+!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019

OINTMENT;OPHTHALMIC

LOTEMAX

	+!	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011

SUSPENSION/DROPS;OPHTHALMIC

LOTEMAX

AB	**+!**	BAUSCH AND LOMB	**0.5%**	**N020583**	**001**	Mar 09, 1998

LOTEPREDNOL ETABONATE

AB		AKORN	**0.5%**	**A207609**	**001**	Apr 17, 2019
AB		SUN PHARM	**0.5%**	**A212450**	**001**	Feb 26, 2021

ALREX

	+!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998

EYSUVIS

	+!	KALA PHARMS INC	0.25%	N210933	001	Oct 26, 2020

INVELTYS

	+!	KALA PHARMS INC	1%	N210565	001	Aug 22, 2018

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

	+!	BAUSCH AND LOMB	0.5%;0.3%	N050804	001	Dec 14, 2004

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		ACTAVIS ELIZABETH	**10MG**	**A075828**	**001**	Dec 17, 2001
AB			**20MG**	**A075828**	**002**	Dec 17, 2001
AB			**40MG**	**A075828**	**003**	Dec 17, 2001
AB		BEXIMCO PHARMS USA	**10MG**	**A075300**	**001**	Dec 17, 2001
AB			**20MG**	**A075300**	**002**	Dec 17, 2001
AB			**40MG**	**A075300**	**003**	Dec 17, 2001
AB		CARLSBAD	**10MG**	**A075991**	**001**	Jun 05, 2002
AB			**20MG**	**A075991**	**002**	Jun 05, 2002
AB	**!**		**40MG**	**A075991**	**003**	Jun 05, 2002
AB		COREPHARMA	**10MG**	**A077748**	**001**	Feb 28, 2007
AB			**20MG**	**A077748**	**002**	Feb 28, 2007
AB			**40MG**	**A077748**	**003**	Feb 28, 2007
AB		LUPIN	**10MG**	**A078296**	**001**	Mar 14, 2008
AB			**20MG**	**A078296**	**002**	Nov 01, 2007
AB			**40MG**	**A078296**	**003**	Nov 01, 2007

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		SANDOZ	**10MG**	**A075636**	**001**	Dec 17, 2001
AB			**20MG**	**A075636**	**002**	Dec 17, 2001
AB			**40MG**	**A075636**	**003**	Dec 17, 2001
AB		TEVA	**10MG**	**A075551**	**003**	Dec 17, 2001
AB			**20MG**	**A075551**	**002**	Dec 17, 2001
AB			**40MG**	**A075551**	**001**	Dec 17, 2001

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

	+	COVIS	20MG	N021316	002	Jun 26, 2002
	+		40MG	N021316	003	Jun 26, 2002
	+!		60MG	N021316	004	Jun 26, 2002

LOXAPINE

POWDER;INHALATION

ADASUVE

	+!	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB		ELITE LABS INC	**EQ 5MG BASE**	**A076868**	**001**	Aug 04, 2005
AB			**EQ 10MG BASE**	**A076868**	**002**	Aug 04, 2005
AB			**EQ 25MG BASE**	**A076868**	**003**	Aug 04, 2005
AB			**EQ 50MG BASE**	**A076868**	**004**	Aug 04, 2005
AB		LANNETT CO INC	**EQ 5MG BASE**	**A090695**	**001**	Sep 26, 2011
AB			**EQ 10MG BASE**	**A090695**	**002**	Sep 26, 2011
AB			**EQ 25MG BASE**	**A090695**	**003**	Sep 26, 2011
AB			**EQ 50MG BASE**	**A090695**	**004**	Sep 26, 2011
AB		WATSON LABS	**EQ 5MG BASE**	**A072204**	**001**	Jun 15, 1988
AB			**EQ 10MG BASE**	**A072205**	**001**	Jun 15, 1988
AB	!		**EQ 25MG BASE**	**A072206**	**001**	Jun 15, 1988
AB			**EQ 50MG BASE**	**A072062**	**001**	Jun 15, 1988

LUBIPROSTONE

CAPSULE;ORAL

AMITIZA

AB	+	SUCAMPO PHARMA LLC	**8MCG**	**N021908**	**002**	Apr 29, 2008
AB	+!		**24MCG**	**N021908**	**001**	Jan 31, 2006

LUBIPROSTONE

AB		AMNEAL	**8MCG**	**A209450**	**001**	Nov 30, 2021
AB			**24MCG**	**A209450**	**002**	Nov 30, 2021

LULICONAZOLE

CREAM;TOPICAL

LUZU

	+!	BAUSCH	1%	N204153	001	Nov 14, 2013

LUMASIRAN SODIUM

SOLUTION;SUBCUTANEOUS

OXLUMO

	+!	ALNYLAM PHARMS INC	EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE)	N214103	001	Nov 23, 2020

LUMATEPERONE TOSYLATE

CAPSULE;ORAL

CAPLYTA

	+!	INTRA-CELLULAR	EQ 42MG BASE	N209500	001	Dec 20, 2019

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LATUDA

AB	+	SUNOVION PHARMS INC	**20MG**	**N200603**	**003**	Dec 07, 2011
AB	+!		**40MG**	**N200603**	**001**	Oct 28, 2010
AB	+		**60MG**	**N200603**	**005**	Jul 12, 2013
AB	+		**80MG**	**N200603**	**002**	Oct 28, 2010
AB	+		**120MG**	**N200603**	**004**	Apr 26, 2012

LURASIDONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**20MG**	**A208049**	**001**	Jan 03, 2019
AB			**40MG**	**A208049**	**002**	Jan 03, 2019
AB			**60MG**	**A208049**	**003**	Jan 03, 2019
AB			**80MG**	**A208049**	**004**	Jan 03, 2019
AB			**120MG**	**A208049**	**005**	Jan 03, 2019
AB		ALEMBIC PHARMS LTD	**20MG**	**A213248**	**001**	May 13, 2021

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB		**40MG**	**A213248**	**002**	May 13, 2021
AB		**60MG**	**A213248**	**003**	May 13, 2021
AB		**80MG**	**A213248**	**004**	May 13, 2021
AB		**120MG**	**A213248**	**005**	May 13, 2021
AB	DR REDDYS LABS LTD	**20MG**	**A208047**	**001**	Aug 24, 2021
AB		**40MG**	**A208047**	**002**	Aug 24, 2021
AB		**60MG**	**A208047**	**003**	Aug 24, 2021
AB		**80MG**	**A208047**	**004**	Aug 24, 2021
AB	SUN PHARM	**20MG**	**A208066**	**001**	Jan 04, 2019
AB		**40MG**	**A208066**	**002**	Jan 04, 2019
AB		**60MG**	**A208066**	**003**	Jan 04, 2019
AB		**80MG**	**A208066**	**004**	Jan 04, 2019
AB		**120MG**	**A208066**	**005**	Jan 04, 2019

LURBINECTEDIN

POWDER;INTRAVENOUS

ZEPZELCA

+!	JAZZ	4MG/VIAL	N213702	001	Jun 15, 2020

LUSUTROMBOPAG

TABLET;ORAL

MULPLETA

+!	SHIONOGI INC	3MG	N210923	001	Jul 31, 2018

LUTETIUM DOTATATE LU-177

SOLUTION;INTRAVENOUS

LUTATHERA

+!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

+!	NOVO	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017

MACITENTAN

TABLET;ORAL

OPSUMIT

+!	ACTELION	10MG	N204410	001	Oct 18, 2013

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

+!	RISING	EQ 85MG BASE/GM	N016763	001	

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

AT	NOVAST LABS	**5%**	**A206716**	**001**	Jul 31, 2017
AT	PAR FORM	**5%**	**A201511**	**001**	Feb 12, 2013

SULFAMYLON

AT	**+!**	MYLAN INSTITUTIONAL	**5%**	**N019832**	**003**	Jun 05, 1998

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+!	B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019696	001	Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

ISOLYTE S IN PLASTIC CONTAINER

	B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

	ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017586	001	

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001	

PLASMA-LYTE A IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	002	Nov 22, 1982

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

		B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019024	001	Jun 08, 1984

PHYSIOSOL IN PLASTIC CONTAINER

		ICU MEDICAL INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N017637	002	Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

	+!	DIALYSIS SUPS	0.21GM/100ML;2.8GM/100ML;9.07GM/100ML	N021910	001	Jul 26, 2006

NORMOCARB HF 35

	+!	DIALYSIS SUPS	0.21GM/100ML;3.97GM/100ML;8.3GM/100ML	N021910	002	Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE

AP		B BRAUN MEDICAL INC	**2GM/50ML (40MG/ML)**	**A207967**	**001**	Apr 26, 2021
AP			**4GM/100ML (40MG/ML)**	**A207967**	**002**	Apr 26, 2021
AP			**4GM/50ML (80MG/ML)**	**A207967**	**003**	Apr 26, 2021

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		B BRAUN MEDICAL INC	**1GM/100ML**	**A207966**	**001**	Oct 27, 2020
AP		BAXTER HLTHCARE CORP	**1GM/100ML**	**A211965**	**001**	Aug 11, 2020
AP		FRESENIUS KABI USA	**1GM/100ML**	**A206486**	**001**	Mar 07, 2016
AP	**+!**	HOSPIRA	**1GM/100ML**	**N020488**	**001**	Jul 11, 1995
AP		HQ SPCLT PHARMA	**1GM/100ML**	**A207349**	**001**	Mar 02, 2016
AP		MYLAN LABS LTD	**1GM/100ML**	**A209932**	**001**	Sep 10, 2018

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE CORP	**2GM/50ML (40MG/ML)**	**A211966**	**001**	Jun 01, 2020
AP			**4GM/50ML (80MG/ML)**	**A211966**	**002**	Jun 01, 2020
AP			**4GM/100ML (40MG/ML)**	**A211966**	**003**	Jun 01, 2020
AP		FRESENIUS KABI USA	**4GM/100ML (40MG/ML)**	**A206485**	**001**	Mar 15, 2016
AP			**4GM/50ML (80MG/ML)**	**A206485**	**002**	Mar 15, 2016
AP			**2GM/50ML (40MG/ML)**	**A206485**	**003**	Mar 15, 2016
AP			**20GM/500ML (40MG/ML)**	**A206485**	**004**	Mar 15, 2016
AP			**40GM/1000ML (40MG/ML)**	**A206485**	**005**	Mar 15, 2016
AP		GLAND PHARMA LTD	**2GM/50ML (40MG/ML)**	**A213917**	**001**	Jul 10, 2020
AP			**4GM/100ML (40MG/ML)**	**A213917**	**002**	Jul 10, 2020
AP	**+**	HOSPIRA	**2GM/50ML (40MG/ML)**	**N020309**	**003**	Jan 26, 2007
AP	**+!**		**4GM/100ML (40MG/ML)**	**N020309**	**001**	Jun 24, 1994
AP	**+!**		**4GM/50ML (80MG/ML)**	**N020309**	**002**	Jun 24, 1994
AP	**+**		**20GM/500ML (40MG/ML)**	**N020309**	**004**	Jan 18, 1995
AP	**+**		**40GM/1000ML (40MG/ML)**	**N020309**	**005**	Jan 18, 1995
AP		HQ SPCLT PHARMA	**2GM/50ML (40MG/ML)**	**A207350**	**001**	Dec 06, 2017
AP			**4GM/100ML (40MG/ML)**	**A207350**	**002**	Dec 06, 2017
AP			**4GM/50ML (80MG/ML)**	**A207350**	**003**	Dec 06, 2017
AP			**20GM/500ML (40MG/ML)**	**A207350**	**004**	Dec 06, 2017
AP			**40GM/1000ML (40MG/ML)**	**A207350**	**005**	Dec 06, 2017
AP		MYLAN LABS LTD	**2GM/50ML (40MG/ML)**	**A209911**	**001**	Sep 14, 2018
AP			**4GM/100ML (40MG/ML)**	**A209911**	**002**	Sep 14, 2018
AP		PTS CONSULTING	**2GM/50ML (40MG/ML)**	**A209642**	**001**	Nov 08, 2021
AP			**4GM/100ML (40MG/ML)**	**A209642**	**002**	Nov 08, 2021
AP			**4GM/50ML (80MG/ML)**	**A209642**	**003**	Nov 08, 2021

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

	+!	HOSPIRA	2GM/100ML	N020488	002	Jul 11, 1995

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP		EXELA PHARMA	**5GM/10ML (500MG/ML)**	**A206039**	**001**	Dec 18, 2014
AP	**+!**	FRESENIUS KABI USA	**5GM/10ML (500MG/ML)**	**N019316**	**001**	Sep 08, 1986
AP	**+!**		**10GM/20ML (500MG/ML)**	**N019316**	**003**	Jan 29, 2016
AP	**!**	HOSPIRA	**5GM/10ML (500MG/ML)**	**A075151**	**001**	Apr 25, 2000
AP		HOSPIRA INC	**10GM/20ML (500MG/ML)**	**A202411**	**001**	May 14, 2015
	+!	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986
	+!		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018508**	**001**	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT		BAXTER HLTHCARE	**20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML**	**N018336**	**001**	

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET;ORAL

SUTAB

	+!	BRAINTREE LABS	0.225GM;0.188GM;1.479GM	N213135	001	Nov 10, 2020

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA		NOVEL LABS INC	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**A202511**	**001**	Feb 23, 2017

SUPREP BOWEL PREP KIT

AA	**+!**	BRAINTREE LABS	**1.6GM/BOT;3.13GM/BOT;17.5GM/BOT**	**N022372**	**001**	Aug 05, 2010

MALATHION

LOTION;TOPICAL

MALATHION

	!	SUVEN PHARMS	0.5%	A091559	001	May 23, 2012

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

	+!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP		B BRAUN	**10GM/100ML**	**N020006**	**002**	Jul 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP		B BRAUN	**15GM/100ML**	**N020006**	**003**	Jul 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER

AP		B BRAUN	**20GM/100ML**	**N020006**	**004**	Jul 26, 1993
AP		ICU MEDICAL INC	**20GM/100ML**	**N019603**	**004**	Jan 08, 1990

MANNITOL 25%

AP		FRESENIUS KABI USA	**12.5GM/50ML**	**A080677**	**001**	
AP		HOSPIRA	**12.5GM/50ML**	**N016269**	**006**	Aug 25, 1994

MANNITOL 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N020006**	**001**	Jul 26, 1993

OSMITROL 10% IN WATER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**002**	

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**10GM/100ML**	**N013684**	**006**	

OSMITROL 15% IN WATER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**004**	

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**15GM/100ML**	**N013684**	**008**	

OSMITROL 20% IN WATER

AP		BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**003**	

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**20GM/100ML**	**N013684**	**007**	

OSMITROL 5% IN WATER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**001**	

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	**5GM/100ML**	**N013684**	**005**	

POWDER;INHALATION

ARIDOL KIT

	+!	PHARMAXIS LTD	N/A,5MG,10MG,20MG,40MG	N022368	001	Oct 05, 2010

BRONCHITOL

	+!	CHIESI	40MG	N202049	001	Oct 30, 2020

SOLUTION;IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML	N016772	002	

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL IN PLASTIC CONTAINER

	+!	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316	001	

MARALIXIBAT CHLORIDE
SOLUTION;ORAL
LIVMARLI

	+!	MIRUM	EQ 9.5MG BASE/ML	N214662	001	Sep 29, 2021

MARAVIROC
SOLUTION;ORAL
SELZENTRY

	+!	VIIV HLTHCARE	20MG/ML	N208984	001	Nov 04, 2016

TABLET;ORAL
SELZENTRY

	+	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016
	+		75MG	N022128	004	Nov 04, 2016
	+		150MG	N022128	001	Aug 06, 2007
	+!		300MG	N022128	002	Aug 06, 2007

MARIBAVIR
TABLET;ORAL
LIVTENCITY

	+!	TAKEDA PHARMS USA	200MG	N215596	001	Nov 23, 2021

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
EMVERM

	!	IMPAX LABS INC	100MG	A073580	001	Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE
TABLET;ORAL
MECAMYLAMINE HYDROCHLORIDE

	!	LGM PHARMA	2.5MG	A204054	001	Mar 19, 2013

MECHLORETHAMINE HYDROCHLORIDE
GEL;TOPICAL
VALCHLOR

	+!	HELSINN	EQ 0.016% BASE	N202317	001	Aug 23, 2013

MECLIZINE HYDROCHLORIDE
TABLET;ORAL
ANTIVERT

AA	**+**	CASPER PHARMA LLC	**12.5MG**	**N010721**	**006**	
AA	**+**		**25MG**	**N010721**	**004**	
AA	**+**		**50MG**	**N010721**	**001**	Jan 20, 1982
	MECLIZINE HYDROCHLORIDE					
AA	**!**	AMNEAL PHARMS	**12.5MG**	**A201451**	**001**	Feb 23, 2011
AA	**!**		**25MG**	**A201451**	**002**	Feb 23, 2011
AA		ANI PHARMS	**12.5MG**	**A084657**	**002**	
AA			**25MG**	**A084657**	**001**	
AA		ANNORA PHARMA	**12.5MG**	**A087128**	**002**	
AA			**25MG**	**A087128**	**001**	
AA		EPIC PHARMA LLC	**12.5MG**	**A200294**	**001**	Apr 13, 2012
AA			**25MG**	**A200294**	**002**	Apr 13, 2012
AA		INDICUS PHARMA	**12.5MG**	**A205136**	**001**	Feb 22, 2019
AA			**25MG**	**A205136**	**002**	Feb 22, 2019
AA			**50MG**	**A205136**	**003**	Feb 22, 2019
AA		INVATECH	**25MG**	**A084092**	**003**	May 22, 1989
AA		JUBILANT CADISTA	**12.5MG**	**A040659**	**001**	Jun 04, 2010
AA			**25MG**	**A040659**	**002**	Jun 04, 2010
AA		SANDOZ	**12.5MG**	**A084843**	**002**	May 22, 1989
AA		ZYDUS	**12.5MG**	**A213957**	**001**	Jun 23, 2020
AA			**25MG**	**A213957**	**002**	Jun 23, 2020

TABLET, CHEWABLE;ORAL
ANTIVERT

AA	**+**	CASPER PHARMA LLC	**25MG**	**N010721**	**005**	

MECLOFENAMATE SODIUM
CAPSULE;ORAL
MECLOFENAMATE SODIUM

		MYLAN	EQ 50MG BASE	A071081	002	Sep 03, 1986
	!		EQ 100MG BASE	A071081	001	Sep 03, 1986

MEDROXYPROGESTERONE ACETATE						
INJECTABLE;INJECTION						
DEPO-PROVERA						
AB	**+!**	PFIZER	**150MG/ML**	**N020246**	**001**	Oct 29, 1992
MEDROXYPROGESTERONE ACETATE						
AB		AMPHASTAR PHARMS INC	**150MG/ML**	**A077235**	**001**	Nov 28, 2017
AB			**150MG/ML**	**A077334**	**001**	Nov 28, 2017
AB		MYLAN LABS LTD	**150MG/ML**	**A210227**	**001**	Oct 12, 2018
AB		SUN PHARM	**150MG/ML**	**A210760**	**001**	May 01, 2019
AB			**150MG/ML**	**A210761**	**001**	Apr 24, 2019
AB		TEVA PHARMS USA	**150MG/ML**	**A076553**	**001**	Jul 28, 2004
INJECTABLE;SUBCUTANEOUS						
DEPO-SUBQ PROVERA 104						
	+!	PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004
TABLET;ORAL						
MEDROXYPROGESTERONE ACETATE						
AB		BARR	**2.5MG**	**A040159**	**001**	Aug 09, 1996
AB			**5MG**	**A040159**	**002**	Aug 09, 1996
AB			**10MG**	**A040159**	**003**	Aug 09, 1996
PROVERA						
AB	**+**	PFIZER	**2.5MG**	**N011839**	**001**	
AB	**+**		**5MG**	**N011839**	**003**	
AB	**+!**		**10MG**	**N011839**	**004**	
MEFENAMIC ACID						
CAPSULE;ORAL						
MEFENAMIC ACID						
AB		BELCHER	**250MG**	**A091608**	**001**	Jun 02, 2014
AB		LUPIN LTD	**250MG**	**A091322**	**001**	Jul 22, 2011
AB		MICRO LABS	**250MG**	**A090562**	**001**	Nov 19, 2010
PONSTEL						
AB	**+!**	AVION PHARMS	**250MG**	**N015034**	**003**	
MEFLOQUINE HYDROCHLORIDE						
TABLET;ORAL						
MEFLOQUINE HYDROCHLORIDE						
AB	**!**	BARR	**250MG**	**A076392**	**001**	Dec 29, 2003
AB		HIKMA	**250MG**	**A076523**	**001**	Oct 01, 2004
MEGESTROL ACETATE						
SUSPENSION;ORAL						
MEGACE ES						
AB	**+!**	ENDO PHARMS INC	**125MG/ML**	**N021778**	**001**	Jul 05, 2005
MEGESTROL ACETATE						
AB		AKORN	**40MG/ML**	**A203960**	**001**	Jun 09, 2017
AB		BRECKENRIDGE	**125MG/ML**	**A204688**	**001**	Dec 01, 2017
AB	**!**	STRIDES PHARMA	**40MG/ML**	**A075671**	**001**	Jul 25, 2001
AB		TWI PHARMS	**125MG/ML**	**A203139**	**001**	Aug 27, 2014
AB		WOCKHARDT BIO AG	**40MG/ML**	**A076721**	**001**	Nov 01, 2004
TABLET;ORAL						
MEGESTROL ACETATE						
AB		BARR	**20MG**	**A074621**	**002**	Aug 16, 1996
AB			**40MG**	**A074621**	**001**	Nov 30, 1995
AB		STRIDES PHARMA	**20MG**	**A072422**	**001**	Aug 08, 1988
AB	**!**		**40MG**	**A072423**	**001**	Aug 08, 1988
MELOXICAM						
CAPSULE;ORAL						
MELOXICAM						
AB		LUPIN LTD	**5MG**	**A209487**	**001**	Jun 01, 2020
AB	**!**		**10MG**	**A209487**	**002**	Jun 01, 2020
AB		NOVITIUM PHARMA	**5MG**	**A211398**	**001**	Mar 09, 2021
AB			**10MG**	**A211398**	**002**	Mar 09, 2021
SOLUTION;INTRAVENOUS						
ANJESO						
	+!	BAUDAX	30MG/ML (30MG/ML)	N210583	001	Feb 20, 2020
TABLET;ORAL						
MELOXICAM						
AB		APOTEX INC	**7.5MG**	**A077882**	**001**	Jul 20, 2006
AB			**15MG**	**A077882**	**002**	Jul 20, 2006
AB		AUROBINDO PHARMA	**7.5MG**	**A078008**	**001**	Oct 02, 2006
AB			**15MG**	**A078008**	**002**	Oct 02, 2006
AB		CIPLA	**7.5MG**	**A077929**	**001**	Jul 19, 2006
AB			**15MG**	**A077929**	**002**	Jul 19, 2006

MELOXICAM

TABLET;ORAL

MELOXICAM

AB		DR REDDYS LABS INC	**7.5MG**	**A077931**	**001**	Jul 25, 2006
AB			**15MG**	**A077931**	**002**	Jul 25, 2006
AB		GLENMARK GENERICS	**7.5MG**	**A077932**	**001**	Jul 19, 2006
AB			**15MG**	**A077932**	**002**	Jul 19, 2006
AB		LUPIN PHARMS	**7.5MG**	**A077944**	**001**	Jul 19, 2006
AB			**15MG**	**A077944**	**002**	Jul 19, 2006
AB		PURACAP PHARM	**7.5MG**	**A077938**	**001**	Jul 19, 2006
AB			**15MG**	**A077938**	**002**	Jul 19, 2006
AB		STRIDES PHARMA	**7.5MG**	**A077928**	**001**	May 13, 2009
AB			**15MG**	**A077928**	**002**	May 13, 2009
AB		TARO	**7.5MG**	**A078102**	**001**	Nov 07, 2006
AB			**15MG**	**A078102**	**002**	Nov 07, 2006
AB		UNICHEM	**7.5MG**	**A077927**	**001**	Dec 20, 2006
AB			**15MG**	**A077927**	**002**	Dec 20, 2006
AB		YUNG SHIN PHARM	**7.5MG**	**A077918**	**001**	Dec 07, 2006
AB			**15MG**	**A077918**	**002**	Dec 07, 2006
AB		ZYDUS PHARMS USA	**7.5MG**	**A077921**	**001**	Jul 19, 2006
AB			**15MG**	**A077921**	**002**	Jul 19, 2006

MOBIC

AB	**+**	BOEHRINGER INGELHEIM	**7.5MG**	**N020938**	**001**	Apr 13, 2000
AB	**+!**		**15MG**	**N020938**	**002**	Aug 23, 2000

MELPHALAN

TABLET;ORAL

MELPHALAN

	!	ALVOGEN	2MG	A207809	001	Mar 22, 2017

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

MELPHALAN HYDROCHLORIDE

AP		ACTAVIS LLC	**EQ 50MG BASE/VIAL**	**A206018**	**001**	Dec 19, 2016
AP		ALMAJECT	**EQ 50MG BASE/VIAL**	**A204817**	**001**	May 17, 2019
AP		BPI LABS LLC	**EQ 50MG BASE/VIAL**	**A209197**	**001**	May 08, 2020
AP		DR REDDYS LABS LTD	**EQ 50MG BASE/VIAL**	**A203655**	**001**	Dec 08, 2017
AP		FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A203393**	**001**	Dec 22, 2017
AP		GLAND PHARMA LTD	**EQ 50MG BASE/VIAL**	**A209826**	**001**	May 28, 2019
AP		HIKMA	**EQ 50MG BASE/VIAL**	**A090303**	**001**	Oct 28, 2010
AP		INGENUS PHARMS LLC	**EQ 50MG BASE/VIAL**	**A210947**	**001**	Feb 18, 2020
AP		MEITHEAL	**EQ 50MG BASE/VIAL**	**A212960**	**001**	May 28, 2021
AP	**!**	MYLAN INSTITUTIONAL	**EQ 50MG BASE/VIAL**	**A090270**	**001**	Jun 09, 2009
AP		SAGENT PHARMS INC	**EQ 50MG BASE/VIAL**	**A201379**	**001**	Feb 28, 2017

POWDER;INTRAVENOUS

EVOMELA

	+!	ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	**7MG**	**A205825**	**001**	Oct 12, 2016
AB			**14MG**	**A205825**	**002**	Oct 12, 2016
AB			**21MG**	**A205825**	**003**	Oct 12, 2016
AB			**28MG**	**A205825**	**004**	Oct 12, 2016
AB		ANCHEN PHARMS	**7MG**	**A205784**	**001**	Jun 09, 2017
AB			**14MG**	**A205784**	**002**	Jun 09, 2017
AB			**21MG**	**A205784**	**003**	Jun 09, 2017
AB			**28MG**	**A205784**	**004**	Jun 09, 2017
AB		ANI PHARMS	**7MG**	**A205365**	**001**	Feb 28, 2020
AB			**14MG**	**A205365**	**002**	Feb 28, 2020
AB			**21MG**	**A205365**	**003**	Feb 28, 2020
AB			**28MG**	**A205365**	**004**	Feb 28, 2020
AB		APOTEX	**7MG**	**A206135**	**001**	Nov 22, 2016
AB			**14MG**	**A206135**	**002**	Nov 22, 2016
AB			**21MG**	**A206135**	**003**	Nov 22, 2016
AB			**28MG**	**A206135**	**004**	Nov 22, 2016
AB		AUROBINDO PHARMA LTD	**7MG**	**A214651**	**001**	Aug 09, 2021
AB			**14MG**	**A214651**	**002**	Aug 09, 2021
AB			**21MG**	**A214651**	**003**	Aug 09, 2021
AB			**28MG**	**A214651**	**004**	Aug 09, 2021
AB		LUPIN LTD	**7MG**	**A206028**	**001**	Sep 28, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE

AB			14MG	A206028	002	Sep 28, 2016
AB			21MG	A206028	003	Sep 28, 2016
AB			28MG	A206028	004	Sep 28, 2016
AB		YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021
AB			14MG	A211100	002	Apr 02, 2021
AB			21MG	A211100	003	Apr 02, 2021
AB			28MG	A211100	004	Apr 02, 2021
AB		ZYDUS PHARMS	7MG	A203293	001	Aug 03, 2017
AB			14MG	A203293	002	Aug 03, 2017
AB			21MG	A203293	003	Aug 03, 2017
AB			28MG	A203293	004	Aug 03, 2017

NAMENDA XR

AB	+	ALLERGAN	7MG	N022525	001	Jun 21, 2010
AB	+		14MG	N022525	002	Jun 21, 2010
AB	+		21MG	N022525	003	Jun 21, 2010
AB	+!		28MG	N022525	004	Jun 21, 2010

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX	2MG/ML	A209955	001	Feb 09, 2018
AA	!	LANNETT CO INC	2MG/ML	A204033	001	Oct 13, 2015
AA		MACLEODS PHARMS LTD	2MG/ML	A202790	001	Oct 13, 2015
AA		SETON PHARMS	2MG/ML	A210319	001	Aug 31, 2020

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	5MG	A206528	001	Nov 30, 2015
AB			10MG	A206528	002	Nov 30, 2015
AB		ALEMBIC PHARMS LTD	5MG	A200891	001	Oct 13, 2015
AB			10MG	A200891	002	Oct 13, 2015
AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015
AB			10MG	A090041	002	Apr 10, 2015
AB		AUROBINDO PHARMA LTD	5MG	A203175	001	Oct 13, 2015
AB			10MG	A203175	002	Oct 13, 2015
AB		CADILA	5MG	A090961	001	Jul 10, 2017
AB			10MG	A090961	002	Jul 10, 2017
AB		CELLTRION	5MG	A090073	001	Sep 04, 2015
AB			10MG	A090073	002	Sep 04, 2015
AB		CSPC OUYI	5MG	A209527	001	May 07, 2018
AB			10MG	A209527	002	May 07, 2018
AB		DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010
AB			10MG	A090048	002	Apr 14, 2010
AB		HIKMA	5MG	A208173	001	Feb 28, 2020
AB			10MG	A208173	002	Feb 28, 2020
AB		LANNETT CO INC	5MG	A207236	001	Nov 10, 2016
AB			10MG	A207236	002	Nov 10, 2016
AB		LUPIN LTD	5MG	A090051	001	Apr 10, 2015
AB			10MG	A090051	002	Apr 10, 2015
AB		MACLEODS PHARMS LTD	5MG	A202840	001	Oct 13, 2015
AB			10MG	A202840	002	Oct 13, 2015
AB		POLYGEN PHARMS	5MG	A210587	001	Dec 11, 2020
AB			10MG	A210587	002	Dec 11, 2020
AB		PURACAP PHARM LLC	5MG	A206855	001	Nov 17, 2015
AB			10MG	A206855	002	Nov 17, 2015
AB		STRIDES PHARMA	5MG	A202350	001	May 23, 2017
AB			10MG	A202350	002	May 23, 2017
AB		SUN PHARM	5MG	A090058	001	May 05, 2010
AB			10MG	A090058	002	May 05, 2010
AB		UNICHEM	5MG	A200022	001	Oct 13, 2015
AB			10MG	A200022	002	Oct 13, 2015
AB		UPSHER SMITH LABS	5MG	A090043	001	Jul 31, 2015
AB			10MG	A090043	002	Jul 31, 2015

NAMENDA

AB	+	ALLERGAN	5MG	N021487	001	Oct 16, 2003
AB	+!		10MG	N021487	002	Oct 16, 2003

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

AP	**+!**	HOSPIRA	**25MG/ML**	**N021171**	**001**	
AP	**+!**		**50MG/ML**	**N021171**	**002**	
AP	**+!**		**75MG/ML**	**N021171**	**003**	
AP	**+!**		**100MG/ML**	**N021171**	**004**	

MEPERIDINE HYDROCHLORIDE

AP		WEST-WARD PHARMS INT	**25MG/ML**	**A080445**	**001**	
AP			**25MG/ML**	**A080455**	**007**	
AP			**50MG/ML**	**A080445**	**002**	
AP			**50MG/ML**	**A080455**	**008**	
AP			**75MG/ML**	**A080445**	**003**	
AP			**75MG/ML**	**A080455**	**009**	
AP			**100MG/ML**	**A080445**	**004**	
AP			**100MG/ML**	**A080455**	**010**	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

	!	WEST-WARD PHARMS INT	10MG/ML	A081002	001 Jul 30, 1993

SYRUP;ORAL

MEPERIDINE HYDROCHLORIDE

	!	HIKMA	50MG/5ML	A088744	001 Jan 30, 1985

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

		EPIC PHARMA	50MG	A040331	001 May 28, 1999
			100MG	A040331	002 May 28, 1999

MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CARBOCAINE

AP	**+!**	HOSPIRA	**1%**	**N012250**	**001**	
AP	**+!**		**1.5%**	**N012250**	**005**	
AP	**+!**		**2%**	**N012250**	**002**	

POLOCAINE

AP		FRESENIUS KABI USA	**1%**	**A089407**	**001**	Dec 01, 1986
AP			**2%**	**A089410**	**001**	Dec 01, 1986

POLOCAINE-MPF

AP		FRESENIUS KABI USA	**1%**	**A089406**	**001**	Dec 01, 1986
AP			**1.5%**	**A089408**	**001**	Dec 01, 1986
AP			**2%**	**A089409**	**001**	Dec 01, 1986

SCANDONEST PLAIN

AP	**!**	DEPROCO	**3%**	**A088387**	**001**	Oct 10, 1984

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA	**!**	ALEMBIC PHARMS LTD	**200MG**	**A090122**	**001**	Feb 18, 2009
AA	**!**		**400MG**	**A090122**	**002**	Feb 18, 2009
AA		INVAGEN PHARMS	**200MG**	**A040797**	**001**	Feb 27, 2008
AA			**400MG**	**A040797**	**002**	Feb 27, 2008

MERCAPTOPURINE

SUSPENSION;ORAL

PURIXAN

	+!	NOVA LABS LTD	20MG/ML	N205919 001	Apr 28, 2014

TABLET;ORAL

MERCAPTOPURINE

AB		DR REDDYS LABS SA	**50MG**	**A040461**	**001**	Feb 11, 2004
AB	**!**	HIKMA	**50MG**	**A040528**	**001**	Feb 13, 2004
AB		MYLAN	**50MG**	**A040594**	**001**	Jul 01, 2005

PURINETHOL

AB	**+**	STASON PHARMS	**50MG**	**N009053**	**002**

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

AP		ACS DOBFAR	**500MG/VIAL**	**A091404**	**001**	Oct 26, 2011
AP			**1GM/VIAL**	**A091404**	**002**	Oct 26, 2011
AP		ACS DOBFAR SPA	**500MG/VIAL**	**A204139**	**001**	Jun 09, 2016
AP			**1GM/VIAL**	**A204139**	**002**	Jun 09, 2016
AP		AMNEAL PHARMS	**500MG/VIAL**	**A205883**	**001**	Apr 12, 2016
AP			**1GM/VIAL**	**A205883**	**002**	Apr 12, 2016
AP		DAEWOONG PHARM CO	**500MG/VIAL**	**A204854**	**001**	Dec 18, 2015
AP			**1GM/VIAL**	**A204854**	**002**	Dec 18, 2015

MEROPENEM						
INJECTABLE;INJECTION						
MEROPENEM						
AP		EUGIA PHARMA	**500MG/VIAL**	**A205835**	**001**	Mar 27, 2017
AP			**1GM/VIAL**	**A205835**	**002**	Mar 27, 2017
AP		GLAND	**500MG/VIAL**	**A206141**	**001**	Jun 08, 2016
AP			**1GM/VIAL**	**A206141**	**002**	Jun 08, 2016
AP		HQ SPCLT PHARMA	**500MG/VIAL**	**A210773**	**001**	Aug 16, 2019
AP			**1GM/VIAL**	**A210773**	**002**	Aug 16, 2019
AP		SAVIOR LIFETEC CORP	**500MG/VIAL**	**A206086**	**001**	Apr 19, 2016
AP			**1GM/VIAL**	**A206086**	**002**	Apr 19, 2016
MERREM						
AP	**+!**	PFIZER	**500MG/VIAL**	**N050706**	**003**	Jun 21, 1996
AP	**+!**		**1GM/VIAL**	**N050706**	**001**	Jun 21, 1996
POWDER;INTRAVENOUS						
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER						
		B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015
			1GM/VIAL	N202106	002	Apr 30, 2015
MEROPENEM; VABORBACTAM						
POWDER;INTRAVENOUS						
VABOMERE						
	+!	REMPEX	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017
MESALAMINE						
CAPSULE, DELAYED RELEASE;ORAL						
DELZICOL						
AB	**+!**	APIL	**400MG**	**N204412**	**001**	Feb 01, 2013
MESALAMINE						
AB		TEVA PHARMS USA	**400MG**	**A207873**	**001**	May 09, 2019
CAPSULE, EXTENDED RELEASE;ORAL						
APRISO						
AB	**+!**	VALEANT PHARMS INTL	**375MG**	**N022301**	**001**	Oct 31, 2008
MESALAMINE						
AB		ALKEM LABS LTD	**375MG**	**A214242**	**001**	Jul 15, 2021
AB		MYLAN	**375MG**	**A207271**	**001**	Nov 20, 2019
AB		ZYDUS PHARMS	**375MG**	**A208954**	**001**	Aug 12, 2021
PENTASA						
	+	TAKEDA PHARMS USA	250MG	N020049	001	May 10, 1993
	+!		500MG	N020049	002	Jul 08, 2004
ENEMA;RECTAL						
MESALAMINE						
AB		PADAGIS ISRAEL	**4GM/60ML**	**A076751**	**001**	Sep 17, 2004
ROWASA						
AB	**+!**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**001**	Dec 24, 1987
SFROWASA						
AB	**+**	MYLAN SPECIALITY LP	**4GM/60ML**	**N019618**	**002**	Jun 20, 2008
SUPPOSITORY;RECTAL						
CANASA						
AB	**+!**	ALLERGAN	**1GM**	**N021252**	**002**	Nov 05, 2004
MESALAMINE						
AB		ACTAVIS MID ATLANTIC	**1GM**	**A205654**	**001**	Aug 14, 2020
AB		AMNEAL	**1GM**	**A210509**	**001**	Jan 02, 2020
AB		AMRING PHARMS	**1GM**	**A208362**	**001**	Jun 21, 2019
AB		ANNORA PHARMA	**1GM**	**A213377**	**001**	Mar 19, 2020
AB		MYLAN	**1GM**	**A204354**	**001**	Nov 24, 2015
AB		PHARM SOURCING	**1GM**	**A207448**	**001**	Apr 19, 2019
AB		SANDOZ INC	**1GM**	**A202065**	**001**	Jun 12, 2019
AB		ZYDUS PHARMS	**1GM**	**A208953**	**001**	Feb 12, 2020
TABLET, DELAYED RELEASE;ORAL						
ASACOL HD						
AB	**+!**	APIL	**800MG**	**N021830**	**001**	May 29, 2008
LIALDA						
AB	**+!**	TAKEDA PHARMS USA	**1.2GM**	**N022000**	**001**	Jan 16, 2007
MESALAMINE						
AB		ACTAVIS LABS FL	**1.2GM**	**A203817**	**001**	Mar 23, 2018
AB		SUN PHARM	**1.2GM**	**A211858**	**001**	Jan 25, 2019
AB		ZYDUS PHARMS	**800MG**	**A203286**	**001**	Jul 21, 2017
AB			**1.2GM**	**A091640**	**001**	Jun 05, 2017

MESNA
INJECTABLE;INTRAVENOUS
MESNA

AP		FRESENIUS KABI USA	**100MG/ML**	**A075811**	**001**	Apr 26, 2001
AP		GLAND	**100MG/ML**	**A206992**	**001**	Dec 18, 2017
AP		HIKMA	**100MG/ML**	**A075739**	**001**	Jan 09, 2004
AP		SAGENT PHARMS INC	**100MG/ML**	**A090913**	**001**	Apr 13, 2010

MESNEX

AP	**+!**	BAXTER HLTHCARE	**100MG/ML**	**N019884**	**001**	Dec 30, 1988

TABLET;ORAL
MESNEX

	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

METAPROTERENOL SULFATE
SYRUP;ORAL
METAPROTERENOL SULFATE

	!	GENUS	10MG/5ML	A073632	001	Jul 22, 1992

METARAMINOL BITARTRATE
INJECTABLE;INJECTION
METARAMINOL BITARTRATE

		SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021

METAXALONE
TABLET;ORAL
METAXALONE

AB		ACTAVIS LABS FL INC	**800MG**	**A203695**	**001**	Jun 15, 2017
AB		AMNEAL PHARMS	**800MG**	**A203399**	**001**	Jun 21, 2013
AB		LANNETT CO INC	**800MG**	**A204770**	**001**	Nov 22, 2016
AB		MOUNTAIN	**400MG**	**A040486**	**001**	Feb 27, 2015
AB		SANDOZ	**800MG**	**A040445**	**001**	Mar 31, 2010
AB		SCIEGEN PHARMS INC	**400MG**	**A207466**	**002**	Mar 13, 2020
AB			**800MG**	**A207466**	**001**	Aug 31, 2017

SKELAXIN

AB	**+!**	KING PHARMS	**800MG**	**N013217**	**003**	Aug 30, 2002

METAXALONE

BX		APPCO	800MG	A208774	001	Sep 24, 2018

METFORMIN HYDROCHLORIDE
SOLUTION;ORAL
METFORMIN HYDROCHLORIDE

AB		SAPTALIS PHARMS	**500MG/5ML**	**A211309**	**001**	Mar 03, 2020

RIOMET

AB	**+!**	RANBAXY	**500MG/5ML**	**N021591**	**001**	Sep 11, 2003

TABLET;ORAL
METFORMIN HYDROCHLORIDE

AB		ALKEM	**500MG**	**A091184**	**001**	Nov 01, 2010
AB			**850MG**	**A091184**	**002**	Nov 01, 2010
AB			**1GM**	**A091184**	**003**	Nov 01, 2010
AB		AMNEAL PHARMS NY	**500MG**	**A077880**	**001**	Jun 05, 2006
AB			**850MG**	**A077880**	**002**	Jun 05, 2006
AB			**1GM**	**A077880**	**003**	Jun 05, 2006
AB		APOTEX	**500MG**	**A075984**	**001**	Apr 23, 2002
AB			**500MG**	**A090666**	**001**	Dec 07, 2011
AB			**850MG**	**A075984**	**002**	Apr 23, 2002
AB			**850MG**	**A090666**	**002**	Dec 07, 2011
AB			**1GM**	**A075984**	**003**	Apr 23, 2002
AB			**1GM**	**A090666**	**003**	Dec 07, 2011
AB		ATLAS PHARMS LLC	**500MG**	**A076033**	**001**	Jan 24, 2002
AB			**850MG**	**A076033**	**002**	Jan 24, 2002
AB			**1GM**	**A076033**	**003**	Jan 24, 2002
AB		AUROBINDO	**500MG**	**A077095**	**001**	Jan 14, 2005
AB			**850MG**	**A077095**	**002**	Jan 14, 2005
AB			**1GM**	**A077095**	**003**	Jan 14, 2005
AB		CHARTWELL	**500MG**	**A075972**	**001**	Jan 24, 2002
AB			**850MG**	**A075972**	**002**	Jan 24, 2002
AB			**1GM**	**A075972**	**003**	Jan 24, 2002
AB		CSPC OUYI	**500MG**	**A205096**	**001**	Jul 11, 2016
AB			**850MG**	**A205096**	**002**	Jul 11, 2016
AB			**1GM**	**A205096**	**003**	Jul 11, 2016
AB		DR REDDYS LABS INC	**500MG**	**A077787**	**001**	Aug 23, 2006
AB			**850MG**	**A077787**	**002**	Aug 23, 2006
AB			**1GM**	**A077787**	**003**	Aug 23, 2006
AB		GLENMARK GENERICS	**500MG**	**A078170**	**001**	May 23, 2008

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB			**850MG**	**A078170**	**002**	May 23, 2008
AB			**1GM**	**A078170**	**003**	May 23, 2008
AB		GRANULES INDIA	**500MG**	**A090564**	**001**	Apr 22, 2010
AB			**850MG**	**A090564**	**002**	Apr 22, 2010
AB	!		**1GM**	**A090564**	**003**	Apr 22, 2010
AB		HARMAN FINOCHEM	**500MG**	**A213320**	**001**	Dec 03, 2021
AB			**850MG**	**A213320**	**002**	Dec 03, 2021
AB			**1GM**	**A213320**	**003**	Dec 03, 2021
AB		LAURUS	**500MG**	**A209882**	**001**	Aug 27, 2018
AB			**850MG**	**A209882**	**002**	Aug 27, 2018
AB			**1GM**	**A209882**	**003**	Aug 27, 2018
AB		MARKSANS PHARMA	**500MG**	**A090888**	**001**	Mar 12, 2012
AB			**850MG**	**A090888**	**002**	Mar 12, 2012
AB			**1GM**	**A090888**	**003**	Mar 12, 2012
AB		MYLAN	**500MG**	**A075973**	**001**	Jan 25, 2002
AB			**850MG**	**A075973**	**002**	Jan 25, 2002
AB			**1GM**	**A075973**	**003**	Jan 25, 2002
AB		SANDOZ	**500MG**	**A075965**	**001**	Jan 25, 2002
AB			**850MG**	**A075965**	**002**	Jan 25, 2002
AB			**1GM**	**A075965**	**003**	Jan 25, 2002
AB		SCIEGEN PHARMS INC	**500MG**	**A203769**	**001**	Sep 11, 2013
AB			**850MG**	**A203769**	**002**	Sep 11, 2013
AB			**1GM**	**A203769**	**003**	Sep 11, 2013
AB		SUN PHARM INDS INC	**500MG**	**A075967**	**001**	Jan 29, 2002
AB			**850MG**	**A075967**	**002**	Jan 29, 2002
AB			**1GM**	**A075967**	**003**	Jan 29, 2002
AB		ZYDUS HLTHCARE	**500MG**	**A203686**	**001**	Aug 28, 2014
AB			**850MG**	**A203686**	**002**	Aug 28, 2014
AB			**1GM**	**A203686**	**003**	Aug 28, 2014
AB		ZYDUS PHARMS USA	**500MG**	**A077064**	**001**	Apr 18, 2005
AB			**850MG**	**A077064**	**002**	Apr 18, 2005
AB			**1GM**	**A077064**	**003**	Apr 18, 2005
		CHARTWELL	625MG	A075972	005	Jan 24, 2002
			750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	**750MG**	**A076869**	**001**	Apr 12, 2005
AB	!	ALKEM LABS LTD	**750MG**	**A206145**	**002**	Oct 22, 2018
AB		AUROBINDO PHARMA LTD	**750MG**	**A079118**	**002**	Jul 20, 2012
AB		BEXIMCO PHARMS USA	**750MG**	**A207427**	**002**	Dec 13, 2016
AB		CADILA	**750MG**	**A077078**	**001**	Apr 21, 2005
AB		CSPC OUYI	**750MG**	**A078321**	**002**	Apr 17, 2008
AB		GRANULES	**750MG**	**A209313**	**002**	Mar 16, 2018
AB		INTELLIPHARMACEUTICS	**750MG**	**A202306**	**002**	Feb 23, 2017
AB		MACLEODS PHARMS LTD	**750MG**	**A206955**	**002**	Dec 07, 2016
AB		MARKSANS PHARMA	**750MG**	**A090295**	**002**	Apr 29, 2016
AB		NOSTRUM PHARMS LLC	**750MG**	**A076756**	**002**	Dec 12, 2011
AB		PRINSTON INC	**750MG**	**A208880**	**002**	Sep 10, 2018
AB		SUN PHARM INDS (IN)	**750MG**	**A077336**	**002**	Feb 09, 2006
AB		TEVA	**750MG**	**A076864**	**001**	Apr 12, 2005
AB		UNICHEM	**750MG**	**A213359**	**002**	Aug 11, 2021
AB		YICHANG HUMANWELL	**750MG**	**A211052**	**002**	Sep 24, 2018
AB1		ALIGNSCIENCE PHARMA	**500MG**	**A209303**	**001**	Mar 19, 2018
AB1		ALKEM LABS LTD	**500MG**	**A206145**	**001**	Oct 22, 2018
AB1		AUROBINDO PHARMA LTD	**500MG**	**A079118**	**001**	Jul 20, 2012
AB1		BEXIMCO PHARMS USA	**500MG**	**A207427**	**001**	Dec 13, 2016
AB1		CADILA	**500MG**	**A077060**	**001**	Apr 20, 2005
AB1		CSPC OUYI	**500MG**	**A078321**	**001**	Apr 17, 2008
AB1		GRANULES	**500MG**	**A209313**	**001**	Mar 16, 2018
AB1		INTELLIPHARMACEUTICS	**500MG**	**A202306**	**001**	Feb 23, 2017
AB1		INVENTIA	**500MG**	**A201991**	**001**	Jan 18, 2012
AB1		MACLEODS PHARMS LTD	**500MG**	**A206955**	**001**	Dec 07, 2016
AB1		MARKSANS PHARMA	**500MG**	**A090295**	**001**	Apr 29, 2016
AB1		NOSTRUM PHARMS LLC	**500MG**	**A076756**	**001**	Jul 26, 2006
AB1		PRINSTON INC	**500MG**	**A208880**	**001**	Sep 10, 2018
AB1		SANDOZ	**500MG**	**A076873**	**001**	Dec 14, 2004

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE						
AB1		SUN PHARM INDS (IN)	**500MG**	**A077336**	**001**	Feb 09, 2006
AB1		TEVA	**500MG**	**A076269**	**001**	Jun 18, 2004
AB1		UNICHEM	**500MG**	**A213359**	**001**	Aug 11, 2021
AB1		YICHANG HUMANWELL	**500MG**	**A211052**	**001**	Sep 24, 2018
FORTAMET						
AB2	+	ANDRX LABS LLC	**1GM**	**N021574**	**002**	Apr 27, 2004
METFORMIN HYDROCHLORIDE						
AB2		AJANTA PHARMA LTD	**500MG**	**A213651**	**001**	Apr 09, 2020
AB2			**1GM**	**A213651**	**002**	Apr 09, 2020
AB2		AMTA	**500MG**	**A213394**	**001**	Aug 03, 2021
AB2			**1GM**	**A213394**	**002**	Aug 03, 2021
AB2		LUPIN LTD	**500MG**	**A090692**	**001**	Jun 29, 2011
AB2	!		**1GM**	**A090692**	**002**	Jun 29, 2011
AB2		MYLAN PHARMS INC	**500MG**	**A200690**	**001**	Aug 01, 2012
AB2			**1GM**	**A200690**	**002**	Aug 01, 2012
AB2		NOSTRUM LABS INC	**500MG**	**A203832**	**001**	Dec 26, 2017
AB2			**1GM**	**A203832**	**002**	Dec 26, 2017
AB2		NOVAST LABS	**500MG**	**A209674**	**001**	Nov 02, 2018
AB2			**1GM**	**A209674**	**002**	Nov 02, 2018
AB2		QINGDAO BAHEAL PHARM	**500MG**	**A209993**	**001**	Dec 27, 2018
AB2			**1GM**	**A209993**	**002**	Dec 27, 2018
AB2		TWI PHARMS	**500MG**	**A213247**	**001**	Sep 29, 2021
AB2			**1GM**	**A213247**	**002**	Sep 29, 2021
GLUMETZA						
AB3	+	SANTARUS INC	**500MG**	**N021748**	**001**	Jun 03, 2005
AB3	+!		**1GM**	**N021748**	**002**	Jun 03, 2005
METFORMIN HYDROCHLORIDE						
AB3		ACTAVIS LABS FL INC	**500MG**	**A203755**	**001**	Aug 01, 2016
AB3			**1GM**	**A203755**	**002**	Aug 01, 2016
AB3		AJANTA PHARMA LTD	**500MG**	**A213962**	**001**	Mar 09, 2021
AB3			**1GM**	**A213962**	**002**	Mar 09, 2021
AB3		APOTEX	**500MG**	**A213356**	**001**	Dec 13, 2021
AB3			**1GM**	**A213356**	**002**	Dec 13, 2021
AB3		GLENMARK PHARMS LTD	**500MG**	**A212969**	**001**	Nov 25, 2019
AB3			**1GM**	**A212969**	**002**	Nov 25, 2019
AB3		GRANULES	**500MG**	**A213344**	**001**	Jan 12, 2021
AB3			**1GM**	**A213344**	**002**	Jan 12, 2021
AB3		LUPIN LTD	**500MG**	**A091664**	**001**	Jul 19, 2013
AB3			**1GM**	**A091664**	**002**	Jul 19, 2013
AB3		SCIEGEN PHARMS INC	**500MG**	**A213334**	**001**	Apr 16, 2021
AB3			**1GM**	**A213334**	**002**	Apr 16, 2021
AB3		SUN PHARM	**500MG**	**A202917**	**001**	Aug 01, 2016
AB3			**1GM**	**A202917**	**002**	Aug 01, 2016
BX		AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008
BX			750MG	A078596	002	Jan 03, 2008

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET						
AB	+	TAKEDA PHARMS USA	**500MG;EQ 15MG BASE**	**N021842**	**001**	Aug 29, 2005
AB	+!		**850MG;EQ 15MG BASE**	**N021842**	**002**	Aug 29, 2005
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**500MG;EQ 15MG BASE**	**A200823**	**001**	Feb 13, 2013
AB			**850MG;EQ 15MG BASE**	**A200823**	**002**	Feb 13, 2013
AB		MACLEODS PHARMS LTD	**500MG;EQ 15MG BASE**	**A204802**	**001**	Nov 05, 2015
AB			**850MG;EQ 15MG BASE**	**A204802**	**002**	Nov 05, 2015
AB		TEVA PHARMS USA	**500MG;EQ 15MG BASE**	**A091155**	**001**	Mar 10, 2014
AB			**850MG;EQ 15MG BASE**	**A091155**	**002**	Mar 10, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR						
	+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
	+		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
	+!		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007
+!		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012
+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+!		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+!	METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA		HIKMA	**10MG/ML**	**A040180**	**001**	Apr 30, 1998
AA		LANNETT CO INC	**10MG/ML**	**A212093**	**001**	Nov 02, 2020
AA		SPECGX LLC	**10MG/ML**	**A207368**	**001**	Aug 22, 2019
AA		VISTAPHARM	**10MG/ML**	**A040088**	**001**	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

AA		HIKMA	**10MG/ML**	**A089897**	**001**	Sep 06, 1988

METHADOSE

AA	**+!**	SPECGX LLC	**10MG/ML**	**N017116**	**002**	

INJECTABLE;INJECTION

METHADONE HYDROCHLORIDE

AP		AKORN	**10MG/ML**	**A208306**	**001**	Oct 27, 2017
AP	**+!**	MYLAN INSTITUTIONAL	**10MG/ML**	**N021624**	**001**	

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA	**+!**	HIKMA	**5MG/5ML**	**A087393**	**001**	
AA	**+!**		**10MG/5ML**	**A087997**	**001**	Aug 30, 1982
AA		SPECGX LLC	**5MG/5ML**	**A207537**	**001**	Oct 02, 2019
AA			**10MG/5ML**	**A207537**	**002**	Oct 01, 2019
AA		VISTAPHARM	**5MG/5ML**	**A090707**	**001**	Jun 30, 2010
AA			**10MG/5ML**	**A090707**	**002**	Jun 30, 2010

TABLET;ORAL

METHADONE HYDROCHLORIDE

AA		ASCENT PHARMS INC	**5MG**	**A211228**	**001**	Jan 03, 2019
AA			**10MG**	**A211228**	**002**	Jan 03, 2019
AA		AUROLIFE PHARMA LLC	**5MG**	**A203502**	**001**	Aug 31, 2015
AA			**10MG**	**A203502**	**002**	Aug 31, 2015
AA		EPIC PHARMA LLC	**5MG**	**A090065**	**001**	Aug 18, 2015
AA			**10MG**	**A090065**	**002**	Aug 18, 2015
AA		NOSTRUM LABS INC	**5MG**	**A210484**	**001**	Aug 02, 2018
AA			**10MG**	**A210484**	**002**	Aug 02, 2018
AA		ROXANE	**5MG**	**A088108**	**001**	Mar 08, 1983
AA			**10MG**	**A088109**	**001**	Mar 08, 1983
AA	**!**	SPECGX LLC	**5MG**	**A040517**	**001**	Apr 27, 2004
AA	**!**		**10MG**	**A040517**	**002**	Apr 27, 2004
AA		SUN PHARM INDUSTRIES	**5MG**	**A208305**	**001**	Mar 30, 2018
AA			**10MG**	**A208305**	**002**	Mar 30, 2018
AA		THEPHARMANETWORK LLC	**5MG**	**A090635**	**002**	Sep 22, 2020
AA			**10MG**	**A090635**	**001**	Nov 25, 2009
AA		VISTAPHARM	**10MG**	**A040241**	**002**	May 29, 1998
AA			**10MG**	**A204166**	**001**	Mar 16, 2020

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	**+!**	HIKMA	**40MG**	**N017058**	**001**	
AA		SPECGX LLC	**40MG**	**A077142**	**001**	Jul 12, 2005
AA		VISTAPHARM	**40MG**	**A075082**	**001**	Mar 25, 1998

METHADOSE

AA		SPECGX LLC	**40MG**	**A074184**	**001**	Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

AA	**+!**	RECORDATI RARE	**5MG**	**N005378**	**002**	

METHAMPHETAMINE HYDROCHLORIDE

AA		HIKMA	**5MG**	**A203846**	**001**	Nov 17, 2015
AA		MAYNE PHARMA INC	**5MG**	**A091189**	**001**	Apr 21, 2010

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		ANI PHARMS	**25MG**	**A040001**	**001**	Jun 30, 1993
AB			**50MG**	**A040001**	**002**	Jun 30, 1993
AB		BAUSCH	**25MG**	**A207438**	**001**	Oct 05, 2018
AB			**50MG**	**A207438**	**002**	Oct 05, 2018
AB		MIKART	**25MG**	**A040062**	**001**	Jan 27, 1994
AB	**!**		**50MG**	**A040062**	**002**	Jan 27, 1994
AB		SANDOZ	**25MG**	**A040036**	**001**	Jun 30, 1993
AB			**50MG**	**A040036**	**002**	Jun 30, 1993

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB	**!**	AUROBINDO PHARMA LTD	**1GM**	**A205661**	**001**	Jul 05, 2016
AB		MICRO LABS	**1GM**	**A212172**	**001**	Aug 01, 2019
AB		NOVAST LABS	**1GM**	**A210068**	**001**	Nov 27, 2020

UREX

AB		ALVOGEN	**1GM**	**N016151**	**001**	

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		BIOPHARM	**5MG**	**A040547**	**001**	Feb 18, 2005
AB			**10MG**	**A040547**	**002**	Feb 18, 2005
AB		CHARTWELL RX	**5MG**	**A040411**	**001**	Mar 27, 2001
AB			**10MG**	**A040411**	**002**	Mar 27, 2001
AB		HERITAGE PHARMA	**5MG**	**A040734**	**001**	Dec 14, 2007
AB			**10MG**	**A040734**	**002**	Dec 14, 2007
AB		MYLAN	**5MG**	**A040350**	**001**	Mar 29, 2000
AB	**!**		**10MG**	**A040350**	**002**	Mar 29, 2000
AB		RISING	**5MG**	**A202068**	**001**	Mar 07, 2012
AB			**10MG**	**A202068**	**002**	Mar 07, 2012

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP		AM REGENT	**1GM/10ML (100MG/ML)**	**A207496**	**001**	Jun 22, 2017
AP		EUGIA PHARMA	**1GM/10ML (100MG/ML)**	**A206128**	**001**	May 27, 2016
AP		FRESENIUS KABI USA	**1GM/10ML (100MG/ML)**	**A209331**	**001**	Apr 17, 2018
AP		GLAND PHARMA LTD	**1GM/10ML (100MG/ML)**	**A211504**	**001**	Oct 26, 2018
AP		MONTEREY PHARMS LLC	**1GM/10ML (100MG/ML)**	**A205354**	**001**	Oct 27, 2016
AP		MYLAN INSTITUTIONAL	**1GM/10ML (100MG/ML)**	**A204404**	**001**	Dec 05, 2014
AP		NAVINTA LLC	**1GM/10ML (100MG/ML)**	**A206071**	**001**	Nov 24, 2017
AP		SAGENT PHARMS INC	**1GM/10ML (100MG/ML)**	**A205404**	**001**	Jul 18, 2017
AP		SLATE	**1GM/10ML (100MG/ML)**	**A208116**	**001**	Jan 19, 2017
AP		SOMERSET THERAPS LLC	**1GM/10ML (100MG/ML)**	**A207522**	**001**	Jul 31, 2017

ROBAXIN

AP	**+!**	HIKMA	**1GM/10ML (100MG/ML)**	**N011790**	**001**	

TABLET;ORAL

METHOCARBAMOL

AA		AUSTARPHARMA LLC	**500MG**	**A200958**	**001**	Oct 21, 2011
AA			**750MG**	**A200958**	**002**	Oct 21, 2011
AA		BEXIMCO PHARMS USA	**500MG**	**A208507**	**001**	Jul 21, 2017
AA			**750MG**	**A208507**	**002**	Jul 21, 2017
AA		DBL PHARMS	**500MG**	**A203550**	**001**	Feb 08, 2017
AA			**750MG**	**A203550**	**002**	Feb 08, 2017
AA	**!**	GRANULES	**500MG**	**A209312**	**001**	May 07, 2018
AA	**!**		**750MG**	**A209312**	**002**	May 07, 2018
AA		HETERO LABS LTD III	**500MG**	**A090200**	**001**	Nov 06, 2009
AA			**750MG**	**A090200**	**002**	Nov 06, 2009
AA		MLV	**500MG**	**A212623**	**001**	Apr 30, 2021
AA			**750MG**	**A212623**	**002**	Apr 30, 2021
AA		OXFORD PHARMS	**500MG**	**A040489**	**001**	Jan 29, 2003

METHOCARBAMOL						
TABLET;ORAL						
METHOCARBAMOL						
AA			**750MG**	**A040489**	**002**	Jan 29, 2003
AA		PRINSTON INC	**500MG**	**A086989**	**001**	
AA			**750MG**	**A086988**	**001**	
	!	AUSTARPHARMA LLC	1GM	A200958	003	Dec 06, 2021
METHOHEXITAL SODIUM						
INJECTABLE;INJECTION						
BREVITAL SODIUM						
	+!	PAR STERILE PRODUCTS	500MG/VIAL	N011559	001	
METHOTREXATE						
SOLUTION;SUBCUTANEOUS						
OTREXUP						
	+!	OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
	+!		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
	+!		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
	+!		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
	+!		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
	+!		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
	+!		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013
RASUVO						
	+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
	+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
	+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
	+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
	+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
	+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
	+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
	+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
	+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014
REDITREX						
	+!	CUMBERLAND PHARMS	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019
	+!		10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019
	+!		12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019
	+!		15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019
	+!		17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019
	+!		20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019
	+!		22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019
	+!		25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019
METHOTREXATE SODIUM						
INJECTABLE;INJECTION						
METHOTREXATE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A040266**	**001**	Feb 26, 1999
METHOTREXATE SODIUM						
AP	**!**	FRESENIUS KABI USA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040263**	**001**	Feb 26, 1999
AP	**!**	HIKMA	**EQ 100MG BASE/4ML (EQ 25MG BASE/ML)**	**A089341**	**001**	Sep 16, 1986
AP	**+!**	HOSPIRA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**N011719**	**010**	Dec 15, 2004
METHOTREXATE SODIUM PRESERVATIVE FREE						
AP	**!**	ACCORD HLTHCARE	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040767**	**001**	Apr 30, 2007
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040768**	**001**	Apr 30, 2007
AP	**!**		**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040716**	**001**	Apr 30, 2007
AP	**!**	HIKMA	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A089340**	**001**	Sep 16, 1986
AP	**!**		**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A089343**	**001**	Sep 16, 1986
AP	**+!**	HOSPIRA	**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**N011719**	**012**	Apr 13, 2005
AP		PHARMACHEMIE BV	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A040843**	**002**	Jan 11, 2010
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A040843**	**004**	Jan 11, 2010
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A040843**	**001**	Jan 11, 2010
AP		SAGENT PHARMS INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A203407**	**001**	Aug 09, 2018
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A203407**	**002**	Aug 09, 2018
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A203407**	**003**	Aug 09, 2018
AP		SANDOZ INC	**EQ 50MG BASE/2ML (EQ 25MG BASE/ML)**	**A090039**	**001**	Mar 31, 2009
AP			**EQ 250MG BASE/10ML (EQ 25MG BASE/ML)**	**A090039**	**002**	Mar 31, 2009
AP			**EQ 1GM BASE/40ML (EQ 25MG BASE/ML)**	**A090029**	**001**	Mar 31, 2009
METHOTREXATE SODIUM						
	!	HIKMA	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986
METHOTREXATE SODIUM PRESERVATIVE FREE						
	!	HIKMA	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005
		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012

METHOTREXATE SODIUM							
SOLUTION;ORAL							
XATMEP							
	+!	AZURITY	EQ 2.5MG BASE/ML	N208400	001	Apr 25, 2017
TABLET;ORAL							
METHOTREXATE SODIUM							
AB		ACCORD HLTHCARE	**EQ 2.5MG BASE**	**A213343**	**001**	Jan 24, 2020
AB		AMNEAL PHARMS	**EQ 2.5MG BASE**	**A210040**	**001**	Dec 22, 2017
AB		BARR	**EQ 2.5MG BASE**	**A081099**	**001**	Oct 15, 1990
AB		EUGIA PHARMA	**EQ 2.5MG BASE**	**A210454**	**001**	Jan 30, 2020
AB	**!**	HIKMA	**EQ 2.5MG BASE**	**A040054**	**001**	Aug 01, 1994
AB		LOTUS PHARM CO LTD	**EQ 2.5MG BASE**	**A209787**	**001**	Apr 23, 2021
AB		MYLAN	**EQ 2.5MG BASE**	**A081235**	**001**	May 15, 1992
AB		SUN PHARM	**EQ 2.5MG BASE**	**A201749**	**001**	May 21, 2015
AB		ZYDUS PHARMS	**EQ 2.5MG BASE**	**A207812**	**001**	Jan 13, 2017
TREXALL							
		BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
			EQ 7.5MG BASE	A040385	002	Mar 21, 2001
			EQ 10MG BASE	A040385	003	Mar 21, 2001
	!		EQ 15MG BASE	A040385	004	Mar 21, 2001
METHOXSALEN							
CAPSULE;ORAL							
METHOXSALEN							
AB		STRIDES PHARMA	**10MG**	**A202687**	**001**	Jun 05, 2014
OXSORALEN-ULTRA							
AB	**+!**	BAUSCH	**10MG**	**N019600**	**001**	Oct 30, 1986
INJECTABLE;INJECTION							
UVADEX							
	+!	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999
METHSCOPOLAMINE BROMIDE							
TABLET;ORAL							
METHSCOPOLAMINE BROMIDE							
AA		BAYSHORE PHARMS LLC	**2.5MG**	**A200602**	**001**	Sep 24, 2012
AA	**!**		**5MG**	**A200602**	**002**	Sep 24, 2012
AA		BRECKENRIDGE PHARM	**2.5MG**	**A040642**	**001**	Dec 06, 2011
AA			**5MG**	**A040642**	**002**	Dec 06, 2011
METHSUXIMIDE							
CAPSULE;ORAL							
CELONTIN							
	+!	PARKE DAVIS	300MG	N010596	008	
METHYLDOPA							
TABLET;ORAL							
METHYLDOPA							
		ACCORD HLTHCARE	250MG	A070084	001	Oct 15, 1985
	!		500MG	A070085	001	Oct 15, 1985
METHYLENE BLUE							
SOLUTION;INTRAVENOUS							
PROVAYBLUE							
	+!	PROVEPHARM SAS	10MG/2ML (5MG/ML)	N204630	002	Jul 18, 2019
	+!		50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016
METHYLERGONOVINE MALEATE							
INJECTABLE;INJECTION							
METHERGINE							
AP	**+!**	EDISON THERAPS LLC	**0.2MG/ML**	**N006035**	**004**	
METHYLERGONOVINE MALEATE							
AP		AM REGENT	**0.2MG/ML**	**A090193**	**001**	Nov 24, 2008
AP		BRECKENRIDGE	**0.2MG/ML**	**A040889**	**001**	Sep 13, 2010
TABLET;ORAL							
METHYLERGONOVINE MALEATE							
AB		AMNEAL PHARMS	**0.2MG**	**A211483**	**001**	Sep 10, 2018
AB		GRANULES	**0.2MG**	**A210424**	**001**	May 15, 2018
AB	**!**	NOVEL LABS INC	**0.2MG**	**A091577**	**001**	May 02, 2011
AB		RISING	**0.2MG**	**A211919**	**001**	Jan 15, 2021
AB		TEVA PHARMS USA	**0.2MG**	**A211455**	**001**	Mar 20, 2019
AB		TULEX PHARMS INC	**0.2MG**	**A212233**	**001**	May 01, 2020

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

RELISTOR

+!	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010
+!		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008
+!		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010

TABLET;ORAL

RELISTOR

+!	SALIX	150MG	N208271	001	Jul 19, 2016

METHYLPHENIDATE

FILM, EXTENDED RELEASE;TRANSDERMAL

DAYTRANA

+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	N021514	001	Apr 06, 2006
+		15MG/9HR (1.6MG/HR)	N021514	002	Apr 06, 2006
+		20MG/9HR (2.2MG/HR)	N021514	003	Apr 06, 2006
+!		30MG/9HR (3.3MG/HR)	N021514	004	Apr 06, 2006

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017
+		17.3MG	N205489	002	Jun 19, 2017
+!		25.9MG	N205489	003	Jun 19, 2017

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1		GRANULES	**10MG**	**A211796**	**001**	May 23, 2019
AB1			**20MG**	**A211796**	**002**	May 23, 2019
AB1			**30MG**	**A211796**	**003**	May 23, 2019
AB1			**40MG**	**A211796**	**004**	May 23, 2019
AB1			**60MG**	**A211796**	**005**	May 23, 2019
AB1		MAYNE PHARMA	**10MG**	**A200886**	**001**	Feb 26, 2018
AB1			**20MG**	**A078458**	**001**	Dec 01, 2011
AB1			**30MG**	**A078458**	**002**	Dec 01, 2011
AB1			**40MG**	**A078458**	**003**	Dec 01, 2011
AB1	!		**60MG**	**A078458**	**004**	Jun 23, 2016

RITALIN LA

AB1	+	NOVARTIS	**10MG**	**N021284**	**004**	Apr 10, 2004
AB1	+		**20MG**	**N021284**	**001**	Jun 05, 2002
AB1	+		**30MG**	**N021284**	**002**	Jun 05, 2002
AB1	+		**40MG**	**N021284**	**003**	Jun 05, 2002

METADATE CD

AB2	+	LANNETT CO INC	**10MG**	**N021259**	**003**	May 27, 2003
AB2	+		**20MG**	**N021259**	**001**	Apr 03, 2001
AB2	+		**30MG**	**N021259**	**002**	Jun 19, 2003
AB2	+		**40MG**	**N021259**	**004**	Feb 19, 2006
AB2	+		**50MG**	**N021259**	**005**	Feb 19, 2006
AB2	+!		**60MG**	**N021259**	**006**	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

AB2		IMPAX LABS INC	**10MG**	**A205105**	**001**	Jul 28, 2016
AB2			**20MG**	**A205105**	**002**	Jul 28, 2016
AB2			**30MG**	**A205105**	**003**	Jul 28, 2016
AB2			**40MG**	**A205105**	**004**	Jul 28, 2016
AB2			**50MG**	**A205105**	**005**	Jul 28, 2016
AB2			**60MG**	**A205105**	**006**	Jul 28, 2016
AB2		SPECGX LLC	**10MG**	**A203583**	**001**	Sep 29, 2015
AB2			**20MG**	**A203583**	**002**	Sep 29, 2015
AB2			**30MG**	**A203583**	**003**	Sep 29, 2015
AB2			**40MG**	**A203583**	**004**	Sep 29, 2015
AB2			**50MG**	**A203583**	**005**	Sep 29, 2015
AB2			**60MG**	**A203583**	**006**	Sep 29, 2015
AB2		TEVA PHARMS	**10MG**	**A077707**	**001**	Jul 19, 2012
AB2			**20MG**	**A077707**	**002**	Jul 19, 2012
AB2			**30MG**	**A077707**	**003**	Jul 19, 2012
AB2			**40MG**	**A078873**	**001**	Jul 19, 2012
AB2			**50MG**	**A078873**	**002**	Jul 19, 2012
AB2			**60MG**	**A078873**	**003**	Jul 19, 2012

APTENSIO XR

AB3	+	RHODES PHARMS	**10MG**	**N205831**	**001**	Apr 17, 2015
AB3	+		**15MG**	**N205831**	**002**	Apr 17, 2015
AB3	+		**20MG**	**N205831**	**003**	Apr 17, 2015
AB3	+		**30MG**	**N205831**	**004**	Apr 17, 2015
AB3	+		**40MG**	**N205831**	**005**	Apr 17, 2015

METHYLPHENIDATE HYDROCHLORIDE							
CAPSULE, EXTENDED RELEASE;ORAL							
APTENSIO XR							
AB3	**+**		**50MG**	**N205831**	**006**	Apr 17, 2015
AB3	**+!**		**60MG**	**N205831**	**007**	Apr 17, 2015
METHYLPHENIDATE HYDROCHLORIDE							
AB3		ACTAVIS ELIZABETH	**10MG**	**A208861**	**001**	Dec 13, 2018
AB3			**15MG**	**A208861**	**002**	Dec 13, 2018
AB3			**20MG**	**A208861**	**003**	Dec 13, 2018
AB3			**30MG**	**A208861**	**004**	Dec 13, 2018
AB3			**40MG**	**A208861**	**005**	Dec 13, 2018
AB3			**50MG**	**A208861**	**006**	Dec 13, 2018
AB3			**60MG**	**A208861**	**007**	Dec 13, 2018
ADHANSIA XR							
	+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019
	+		35MG	N212038	002	Feb 27, 2019
	+		45MG	N212038	003	Feb 27, 2019
	+		55MG	N212038	004	Feb 27, 2019
	+		70MG	N212038	005	Feb 27, 2019
	+!		85MG	N212038	006	Feb 27, 2019
JORNAY PM							
	+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018
	+		40MG	N209311	002	Aug 08, 2018
	+		60MG	N209311	003	Aug 08, 2018
	+		80MG	N209311	004	Aug 08, 2018
	+!		100MG	N209311	005	Aug 08, 2018
FOR SUSPENSION, EXTENDED RELEASE;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
AB		ACTAVIS LABS FL INC	**5MG/ML**	**A206049**	**001**	May 17, 2018
QUILLIVANT XR							
AB	**+!**	NEXTWAVE	**5MG/ML**	**N202100**	**001**	Sep 27, 2012
SOLUTION;ORAL							
METHYLIN							
AA	**+!**	SPECGX LLC	**5MG/5ML**	**N021419**	**001**	Dec 19, 2002
AA	**+!**		**10MG/5ML**	**N021419**	**002**	Dec 19, 2002
METHYLPHENIDATE HYDROCHLORIDE							
AA		ABHAI LLC	**5MG/5ML**	**A207485**	**001**	Nov 18, 2016
AA			**10MG/5ML**	**A207485**	**002**	Nov 18, 2016
AA		ALKEM LABS LTD	**5MG/5ML**	**A211647**	**001**	Mar 30, 2020
AA			**10MG/5ML**	**A211647**	**002**	Mar 30, 2020
AA		ANDA REPOSITORY	**5MG/5ML**	**A210764**	**001**	Apr 10, 2020
AA			**10MG/5ML**	**A210764**	**002**	Apr 10, 2020
AA		ASCENT PHARMS INC	**5MG/5ML**	**A207417**	**001**	Jan 29, 2021
AA			**10MG/5ML**	**A207417**	**002**	Jan 29, 2021
AA		BRECKENRIDGE	**5MG/5ML**	**A201466**	**001**	Nov 12, 2013
AA			**10MG/5ML**	**A201466**	**002**	Nov 12, 2013
AA		EYWA	**5MG/5ML**	**A210139**	**001**	Oct 03, 2018
AA			**10MG/5ML**	**A210139**	**002**	Oct 03, 2018
AA		NOVEL LABS INC	**5MG/5ML**	**A204602**	**001**	Aug 14, 2015
AA			**10MG/5ML**	**A204602**	**002**	Aug 14, 2015
AA		QUAGEN	**5MG/5ML**	**A213567**	**001**	Jun 04, 2020
AA			**10MG/5ML**	**A213567**	**002**	Jun 04, 2020
AA		TRIS PHARMA INC	**5MG/5ML**	**A091601**	**001**	Jul 23, 2010
AA			**10MG/5ML**	**A091601**	**002**	Jul 23, 2010
TABLET;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
AB		ABHAI INC	**5MG**	**A206932**	**001**	May 11, 2017
AB			**10MG**	**A206932**	**002**	May 11, 2017
AB			**20MG**	**A206932**	**003**	May 11, 2017
AB		ACCORD HLTHCARE	**5MG**	**A213936**	**001**	Oct 28, 2020
AB			**10MG**	**A213936**	**002**	Oct 28, 2020
AB			**20MG**	**A213936**	**003**	Oct 28, 2020
AB		ALKEM LABS LTD	**5MG**	**A211779**	**001**	Oct 04, 2019
AB			**10MG**	**A211779**	**002**	Oct 04, 2019
AB			**20MG**	**A211779**	**003**	Oct 04, 2019
AB		ASCENT PHARMS INC	**5MG**	**A207416**	**001**	Sep 22, 2015
AB			**10MG**	**A207416**	**002**	Sep 22, 2015
AB			**20MG**	**A207416**	**003**	Sep 22, 2015
AB		BIONPHARMA INC	**5MG**	**A209753**	**001**	Mar 02, 2018
AB			**10MG**	**A209753**	**002**	Mar 02, 2018
AB			**20MG**	**A209753**	**003**	Mar 02, 2018
AB		MOUNTAIN	**5MG**	**A091159**	**001**	Mar 12, 2014

METHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB			10MG	A091159	002	Mar 12, 2014
AB			20MG	A091159	003	Mar 12, 2014
AB		NOVEL LABS INC	5MG	A207884	001	Nov 13, 2015
AB			10MG	A207884	002	Nov 13, 2015
AB			20MG	A207884	003	Nov 13, 2015
AB		OXFORD PHARMS	5MG	A202892	001	Sep 23, 2014
AB			10MG	A202892	002	Sep 23, 2014
AB			20MG	A202892	003	Sep 23, 2014
AB		PRINSTON INC	5MG	A212697	001	Jul 23, 2020
AB			10MG	A212697	002	Jul 23, 2020
AB			20MG	A212697	003	Jul 23, 2020
AB		SPECGX LLC	5MG	A040300	001	Nov 27, 1998
AB			10MG	A040300	002	Nov 27, 1998
AB			20MG	A040300	003	Nov 27, 1998
AB		SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012
AB			10MG	A090710	002	Mar 15, 2012
AB			20MG	A090710	003	Mar 15, 2012

RITALIN

AB	+	NOVARTIS	5MG	N010187	003	
AB	+		10MG	N010187	006	
AB	+!		20MG	N010187	010	

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		ASCENT PHARMS INC	2.5MG	A210354	001	Dec 29, 2017
AB			5MG	A210354	002	Dec 29, 2017
AB	!		10MG	A210354	003	Dec 29, 2017
AB		RISING	2.5MG	A205756	001	Nov 07, 2016
AB			5MG	A205756	002	Nov 07, 2016
AB			10MG	A205756	003	Nov 07, 2016

TABLET, EXTENDED RELEASE;ORAL

CONCERTA

AB	+	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000
AB	+		27MG	N021121	004	Apr 01, 2002
AB	+		36MG	N021121	002	Aug 01, 2000
AB	+!		54MG	N021121	003	Dec 08, 2000

METHYLIN ER

AB		SPECGX LLC	10MG	A075629	001	May 09, 2000
AB			20MG	A075629	002	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

AB		ABHAI LLC	10MG	A207488	001	Jun 09, 2015
AB	!		20MG	A207488	002	Jun 09, 2015
AB		ACTAVIS LABS FL	18MG	A076772	001	Mar 22, 2018
AB			27MG	A076772	002	Mar 22, 2018
AB			36MG	A076772	003	Mar 22, 2018
AB			54MG	A076655	001	Mar 21, 2018
AB		ALKEM LABS LTD	20MG	A212288	001	Oct 06, 2020
AB		ALVOGEN	10MG	A204772	001	Feb 29, 2016
AB			18MG	A210818	001	Nov 30, 2018
AB			20MG	A204772	002	Feb 29, 2016
AB			27MG	A210818	002	Nov 30, 2018
AB			36MG	A210818	003	Nov 30, 2018
AB			54MG	A210818	004	Nov 30, 2018
AB		ANDOR PHARMS	18MG	A211918	001	Apr 24, 2019
AB			27MG	A211918	002	Apr 24, 2019
AB			36MG	A211918	003	Apr 24, 2019
AB			54MG	A211918	004	Apr 24, 2019
AB		ASCENT PHARMS INC	18MG	A211009	001	Sep 03, 2019
AB			27MG	A211009	002	Sep 03, 2019
AB			36MG	A211009	003	Sep 03, 2019
AB			54MG	A211009	004	Sep 03, 2019
AB		AUROLIFE PHARMA LLC	18MG	A206726	001	Oct 21, 2016
AB			27MG	A206726	002	Oct 21, 2016
AB			36MG	A206726	003	Oct 21, 2016
AB			54MG	A206726	004	Oct 21, 2016
AB		DR REDDYS	18MG	A213473	001	Jul 29, 2020
AB			27MG	A213473	002	Jul 29, 2020
AB			36MG	A213473	003	Jul 29, 2020
AB			54MG	A213473	004	Jul 29, 2020
AB		GRANULES	10MG	A210992	001	Nov 21, 2018

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB			**20MG**	**A210992**	**002**	Nov 21, 2018
AB		OSMOTICA	**18MG**	**A205327**	**001**	Jul 28, 2017
AB			**27MG**	**A205327**	**002**	Jul 28, 2017
AB			**36MG**	**A205327**	**003**	Jul 28, 2017
AB			**54MG**	**A205327**	**004**	Jul 28, 2017
AB		SUN PHARM INDS INC	**18MG**	**A205135**	**001**	Aug 19, 2020
AB			**27MG**	**A205135**	**002**	Aug 19, 2020
AB			**36MG**	**A205135**	**003**	Aug 19, 2020
AB			**54MG**	**A205135**	**004**	Aug 19, 2020
BX		AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018
BX			27MG	A207515	002	Feb 01, 2018
BX			36MG	A207515	003	Feb 01, 2018
BX			54MG	A207515	004	Feb 01, 2018
BX		LANNETT CO INC	18MG	A091695	001	Jul 09, 2013
BX			27MG	A091695	002	Jul 09, 2013
BX			36MG	A091695	003	Sep 23, 2013
BX			54MG	A091695	004	Sep 23, 2013
BX		SPECGX LLC	27MG	A202608	001	Dec 28, 2012
BX			36MG	A202608	002	Dec 28, 2012
BX			54MG	A202608	003	Dec 28, 2012
	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER

	+	NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015
	+		30MG	N207960	002	Dec 04, 2015
	+!		40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

AB	**+**	PFIZER	**2MG**	**N011153**	**002**	
AB	**+**		**4MG**	**N011153**	**001**	
AB	**+**		**8MG**	**N011153**	**004**	
AB	**+**		**16MG**	**N011153**	**003**	
AB	**+!**		**32MG**	**N011153**	**006**	

METHYLPREDNISOLONE

AB		AMNEAL	**4MG**	**A207481**	**001**	Sep 21, 2021
AB			**8MG**	**A207481**	**002**	Sep 21, 2021
AB			**16MG**	**A207481**	**003**	Sep 21, 2021
AB			**32MG**	**A207481**	**004**	Sep 21, 2021
AB		JUBILANT CADISTA	**4MG**	**A040189**	**001**	Oct 31, 1997
AB			**8MG**	**A040189**	**002**	Oct 31, 1997
AB			**16MG**	**A040189**	**003**	Jul 20, 2007
AB			**32MG**	**A040189**	**004**	Jul 20, 2007
AB		PRAXGEN	**4MG**	**A212262**	**001**	Jun 27, 2019
AB		SANDOZ	**4MG**	**A040194**	**001**	Oct 31, 1997
AB		TIANJIN TIANYAO	**4MG**	**A204072**	**001**	May 14, 2018
AB		VINTAGE PHARMS	**4MG**	**A040183**	**001**	Dec 22, 1998
AB		WATSON LABS	**4MG**	**A040232**	**001**	Oct 16, 1997
AB		ZYDUS PHARMS	**4MG**	**A206751**	**001**	Apr 23, 2018
AB			**8MG**	**A206751**	**002**	Apr 23, 2018
AB			**16MG**	**A206751**	**003**	Apr 23, 2018
AB			**32MG**	**A206751**	**004**	Apr 23, 2018

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

DEPO-MEDROL

AB	**+!**	PFIZER	**20MG/ML**	**N011757**	**002**	
AB	**+!**		**40MG/ML**	**N011757**	**001**	
AB	**+!**		**80MG/ML**	**N011757**	**004**	

METHYLPREDNISOLONE ACETATE

AB		AMNEAL	**40MG/ML**	**A210043**	**001**	May 20, 2019
AB			**80MG/ML**	**A210043**	**002**	May 20, 2019
AB		SAGENT PHARMS INC	**20MG/ML**	**A201835**	**001**	Jun 27, 2018
AB			**40MG/ML**	**A201835**	**002**	Jun 27, 2018
AB			**80MG/ML**	**A201835**	**003**	Jun 27, 2018
AB		SANDOZ INC	**40MG/ML**	**A040719**	**001**	Jan 29, 2009
AB			**40MG/ML**	**A040794**	**001**	Mar 05, 2009
AB			**80MG/ML**	**A040719**	**002**	Jan 29, 2009
AB			**80MG/ML**	**A040794**	**002**	Mar 05, 2009

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB		TEVA PHARMS USA	**40MG/ML**	**A040557**	**001**	Feb 23, 2005
AB			**40MG/ML**	**A040620**	**001**	Oct 27, 2006
AB			**80MG/ML**	**A040557**	**002**	Feb 23, 2005
AB			**80MG/ML**	**A040620**	**002**	Oct 27, 2006

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP		AMNEAL	**EQ 40MG BASE/VIAL**	**A207549**	**001**	Nov 09, 2016
AP			**EQ 125MG BASE/VIAL**	**A207549**	**002**	Nov 09, 2016
AP		EUGIA PHARMA	**EQ 40MG BASE/VIAL**	**A207667**	**001**	Dec 15, 2015
AP			**EQ 125MG BASE/VIAL**	**A207667**	**002**	Dec 15, 2015
AP			**EQ 500MG BASE/VIAL**	**A207667**	**003**	Dec 15, 2015
AP			**EQ 2GM BASE/VIAL**	**A207667**	**004**	Dec 15, 2015
AP		FRESENIUS KABI USA	**EQ 40MG BASE/VIAL**	**A040583**	**001**	Jul 30, 2004
AP			**EQ 125MG BASE/VIAL**	**A040583**	**002**	Jul 30, 2004
AP			**EQ 1GM BASE/VIAL**	**A040612**	**001**	Aug 12, 2004
AP		HIKMA	**EQ 500MG BASE/VIAL**	**A202691**	**001**	Feb 16, 2016
AP			**EQ 1GM BASE/VIAL**	**A202691**	**002**	Feb 16, 2016
AP		SAGENT PHARMS INC	**EQ 40MG BASE/VIAL**	**A040888**	**001**	Jul 18, 2011
AP			**EQ 125MG BASE/VIAL**	**A040888**	**002**	Jul 18, 2011
AP			**EQ 500MG BASE/VIAL**	**A040888**	**003**	Jul 18, 2011
AP			**EQ 1GM BASE/VIAL**	**A040888**	**004**	Jul 18, 2011
AP			**EQ 2GM BASE/VIAL**	**A040888**	**005**	Jul 18, 2011

SOLU-MEDROL

AP	**+!**	PHARMACIA AND UPJOHN	**EQ 40MG BASE/VIAL**	**N011856**	**003**	
AP	**+!**		**EQ 125MG BASE/VIAL**	**N011856**	**004**	
AP	**+!**		**EQ 500MG BASE/VIAL**	**N011856**	**005**	
AP	**+!**		**EQ 1GM BASE/VIAL**	**N011856**	**006**	
AP	**+!**		**EQ 2GM BASE/VIAL**	**N011856**	**007**	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

	!	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015

TABLET;ORAL

ANDROID 25

BP		VALEANT PHARM INTL	25MG	A087147	001	

METHYLTESTOSTERONE

BP		IMPAX LABS	10MG	A080767	002	

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE

AP		EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204756**	**001**	Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 5MG BASE/ML**	**A091392**	**001**	Apr 19, 2013
AP	**!**	HOSPIRA	**EQ 5MG BASE/ML**	**A073118**	**001**	Jan 17, 1991
AP		TEVA PHARMS USA	**EQ 5MG BASE/ML**	**A073135**	**001**	Nov 27, 1991

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA		ANI PHARMS	**EQ 5MG BASE/5ML**	**A071402**	**001**	Jun 25, 1993
AA		PHARM ASSOC	**EQ 5MG BASE/5ML**	**A072744**	**001**	May 28, 1991
AA		VISTAPHARM	**EQ 5MG BASE/5ML**	**A075051**	**001**	Jan 26, 2001
AA	**!**	WOCKHARDT BIO AG	**EQ 5MG BASE/5ML**	**A074703**	**001**	Oct 31, 1997

SPRAY, METERED;NASAL

GIMOTI

	+!	EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB		IMPAX LABS INC	**EQ 5MG BASE**	**A071250**	**002**	Dec 28, 1995
AB			**EQ 10MG BASE**	**A071250**	**001**	Feb 03, 1988
AB		IPCA LABS LTD	**EQ 5MG BASE**	**A078807**	**001**	Jun 12, 2008
AB			**EQ 10MG BASE**	**A078807**	**002**	Jun 12, 2008
AB		STRIDES PHARMA	**EQ 5MG BASE**	**A077878**	**001**	Aug 28, 2006
AB			**EQ 10MG BASE**	**A070581**	**001**	Oct 17, 1985
AB			**EQ 10MG BASE**	**A077878**	**002**	Aug 28, 2006
AB		TEVA	**EQ 5MG BASE**	**A072801**	**001**	Jun 15, 1993
AB			**EQ 10MG BASE**	**A070184**	**001**	Jul 29, 1985

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

REGLAN

AB	**+**	ANI PHARMS	**EQ 5MG BASE**	**N017854**	**002**	May 05, 1987
AB	**+!**		**EQ 10MG BASE**	**N017854**	**001**	

TABLET, ORALLY DISINTEGRATING;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014
!		EQ 10MG BASE	A202191	002	Aug 15, 2014

METOLAZONE

TABLET;ORAL

METOLAZONE

AB		ALEMBIC PHARMS LTD	**2.5MG**	**A213251**	**001**	Dec 02, 2020
AB			**5MG**	**A213251**	**002**	Dec 02, 2020
AB			**10MG**	**A213251**	**003**	Dec 02, 2020
AB		BAYSHORE PHARMS LLC	**2.5MG**	**A214799**	**001**	Mar 30, 2021
AB			**5MG**	**A214799**	**002**	Mar 30, 2021
AB			**10MG**	**A214799**	**003**	Mar 30, 2021
AB		INNOGENIX	**2.5MG**	**A213827**	**001**	Mar 30, 2021
AB			**5MG**	**A213827**	**002**	Mar 30, 2021
AB			**10MG**	**A213827**	**003**	Mar 30, 2021
AB		MYLAN	**2.5MG**	**A076698**	**001**	Dec 23, 2003
AB			**5MG**	**A076698**	**002**	Oct 19, 2004
AB			**10MG**	**A076698**	**003**	Oct 19, 2004
AB		RUBICON	**2.5MG**	**A215184**	**001**	Aug 20, 2021
AB			**5MG**	**A215184**	**002**	Aug 20, 2021
AB			**10MG**	**A215184**	**003**	Aug 20, 2021
AB		SANDOZ	**2.5MG**	**A076732**	**001**	Dec 19, 2003
AB	**!**		**5MG**	**A076466**	**001**	Dec 19, 2003
AB	**!**		**10MG**	**A076466**	**002**	Dec 19, 2003

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

KAPSPARGO SPRINKLE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018
+!		EQ 200MG TARTRATE	N210428	004	Jan 26, 2018

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB		ACTAVIS ELIZABETH	**EQ 25MG TARTRATE**	**A204161**	**001**	Nov 25, 2016
AB			**EQ 50MG TARTRATE**	**A204161**	**002**	Nov 25, 2016
AB			**EQ 100MG TARTRATE**	**A204161**	**003**	Nov 25, 2016
AB			**EQ 200MG TARTRATE**	**A204161**	**004**	Nov 25, 2016
AB		ACTAVIS LABS FL INC	**EQ 50MG TARTRATE**	**A076862**	**001**	Aug 03, 2009
AB		ALKEM LABS LTD	**EQ 25MG TARTRATE**	**A211143**	**001**	Nov 25, 2020
AB			**EQ 50MG TARTRATE**	**A211143**	**002**	Nov 25, 2020
AB			**EQ 100MG TARTRATE**	**A211143**	**003**	Nov 25, 2020
AB			**EQ 200MG TARTRATE**	**A211143**	**004**	Nov 25, 2020
AB		CIPLA	**EQ 50MG TARTRATE**	**A207465**	**001**	Oct 26, 2018
AB			**EQ 100MG TARTRATE**	**A207465**	**002**	Oct 26, 2018
AB			**EQ 200MG TARTRATE**	**A207465**	**003**	Oct 26, 2018
AB		DR REDDYS LABS LTD	**EQ 25MG TARTRATE**	**A090617**	**001**	Aug 01, 2012
AB			**EQ 50MG TARTRATE**	**A090617**	**002**	Aug 01, 2012
AB		HETERO LABS LTD III	**EQ 25MG TARTRATE**	**A205541**	**001**	Nov 06, 2020
AB			**EQ 50MG TARTRATE**	**A205541**	**002**	Nov 06, 2020
AB			**EQ 100MG TARTRATE**	**A205541**	**003**	Nov 06, 2020
AB			**EQ 200MG TARTRATE**	**A205541**	**004**	Nov 06, 2020
AB		MYLAN PHARMS INC	**EQ 25MG TARTRATE**	**A202033**	**001**	Dec 15, 2011
AB			**EQ 50MG TARTRATE**	**A202033**	**002**	Dec 15, 2011
AB			**EQ 100MG TARTRATE**	**A202033**	**003**	Dec 15, 2011
AB			**EQ 200MG TARTRATE**	**A202033**	**004**	Dec 15, 2011
AB		NOVAST LABS	**EQ 25MG TARTRATE**	**A204106**	**001**	Feb 06, 2018
AB			**EQ 50MG TARTRATE**	**A204106**	**002**	Feb 06, 2018
AB			**EQ 100MG TARTRATE**	**A204106**	**003**	Feb 06, 2018
AB			**EQ 200MG TARTRATE**	**A204106**	**004**	Feb 06, 2018
AB		PHARMADAX INC	**EQ 25MG TARTRATE**	**A203028**	**001**	Mar 31, 2020
AB			**EQ 50MG TARTRATE**	**A203028**	**002**	Mar 31, 2020
AB			**EQ 100MG TARTRATE**	**A203699**	**001**	Mar 30, 2020
AB			**EQ 200MG TARTRATE**	**A203699**	**002**	Mar 30, 2020
AB		PRINSTON INC	**EQ 100MG TARTRATE**	**A210597**	**001**	Jan 04, 2022
AB			**EQ 200MG TARTRATE**	**A210597**	**002**	Jan 04, 2022

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB		REDDYS	**EQ 100MG TARTRATE**	**A078889**	**001**	Aug 15, 2012
AB			**EQ 200MG TARTRATE**	**A078889**	**002**	Aug 15, 2012
AB		VISUM PHARM	**EQ 25MG TARTRATE**	**A207206**	**001**	Dec 19, 2018
AB			**EQ 50MG TARTRATE**	**A207206**	**002**	Dec 19, 2018
AB			**EQ 100MG TARTRATE**	**A207206**	**003**	Dec 19, 2018
AB			**EQ 200MG TARTRATE**	**A207206**	**004**	Dec 19, 2018
AB		WOCKHARDT	**EQ 25MG TARTRATE**	**A090615**	**001**	Jul 22, 2010
AB			**EQ 50MG TARTRATE**	**A090615**	**002**	Jul 22, 2010
AB			**EQ 100MG TARTRATE**	**A090615**	**003**	Jul 22, 2010
AB			**EQ 200MG TARTRATE**	**A090615**	**004**	Jul 22, 2010
AB		YICHANG HUMANWELL	**EQ 50MG TARTRATE**	**A213854**	**003**	Nov 08, 2021
AB			**EQ 100MG TARTRATE**	**A213854**	**001**	Feb 12, 2021
AB			**EQ 200MG TARTRATE**	**A213854**	**002**	Feb 12, 2021
AB		ZYDUS PHARMS	**EQ 25MG TARTRATE**	**A203894**	**001**	Mar 23, 2018
AB			**EQ 50MG TARTRATE**	**A203894**	**002**	Mar 23, 2018
AB			**EQ 100MG TARTRATE**	**A203894**	**003**	Mar 23, 2018
AB			**EQ 200MG TARTRATE**	**A203894**	**004**	Mar 23, 2018

TOPROL-XL

AB	**+**	TOPROL	**EQ 25MG TARTRATE**	**N019962**	**004**	Feb 05, 2001
AB	**+!**		**EQ 50MG TARTRATE**	**N019962**	**001**	Jan 10, 1992
AB	**+**		**EQ 100MG TARTRATE**	**N019962**	**002**	Jan 10, 1992
AB	**+!**		**EQ 200MG TARTRATE**	**N019962**	**003**	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		BAXTER HLTHCARE CORP	**1MG/ML**	**A078950**	**001**	Apr 29, 2013
AP		FRESENIUS KABI USA	**1MG/ML**	**A091045**	**001**	Oct 25, 2010
AP		GLAND PHARMA LTD	**1MG/ML**	**A204205**	**001**	Aug 27, 2014
AP		HIKMA	**1MG/ML**	**A076495**	**001**	Jul 07, 2003
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A077761**	**001**	May 30, 2007
AP		HOSPIRA	**1MG/ML**	**A074133**	**001**	Dec 21, 1993
AP			**1MG/ML**	**A075160**	**001**	Jul 06, 1998
AP	**!**		**1MG/ML**	**A078085**	**001**	Apr 29, 2008
AP		SANDOZ INC	**1MG/ML**	**A077360**	**001**	Oct 02, 2007

TABLET;ORAL

LOPRESSOR

AB	**+**	VALIDUS PHARMS	**50MG**	**N017963**	**001**	
AB	**+**		**100MG**	**N017963**	**002**	

METOPROLOL TARTRATE

AB		ALEMBIC PHARMS LTD	**25MG**	**A202871**	**001**	May 28, 2013
AB			**50MG**	**A202871**	**002**	May 28, 2013
AB			**100MG**	**A202871**	**003**	May 28, 2013
AB		AUROBINDO PHARMA	**25MG**	**A077739**	**001**	Sep 11, 2007
AB			**50MG**	**A077739**	**002**	Sep 11, 2007
AB			**100MG**	**A077739**	**003**	Sep 11, 2007
AB		IPCA LABS LTD	**25MG**	**A078459**	**001**	Jun 17, 2008
AB			**50MG**	**A078459**	**002**	Jun 17, 2008
AB			**100MG**	**A078459**	**003**	Jun 17, 2008
AB		MYLAN	**25MG**	**A076704**	**001**	Jan 16, 2004
AB			**37.5MG**	**A076704**	**004**	Mar 18, 2015
AB			**50MG**	**A076704**	**002**	Jan 16, 2004
AB			**75MG**	**A076704**	**005**	Mar 18, 2015
AB	**!**		**100MG**	**A076704**	**003**	Jan 16, 2004
AB		RUBICON	**25MG**	**A200981**	**001**	Oct 28, 2014
AB			**37.5MG**	**A200981**	**004**	Aug 21, 2019
AB			**50MG**	**A200981**	**002**	Oct 28, 2014
AB			**75MG**	**A200981**	**005**	Aug 21, 2019
AB			**100MG**	**A200981**	**003**	Oct 28, 2014
AB		SUN PHARM INDS INC	**25MG**	**A076670**	**001**	Jan 15, 2004
AB			**50MG**	**A074644**	**001**	Dec 10, 1996
AB			**100MG**	**A074644**	**002**	Dec 10, 1996
AB		YOUNGTECH PHARMS INC	**25MG**	**A208955**	**001**	Feb 05, 2020
AB			**50MG**	**A208955**	**002**	Feb 05, 2020
AB			**100MG**	**A208955**	**003**	Feb 05, 2020

METRONIDAZOLE

CAPSULE;ORAL

FLAGYL						
AB	**+!**	PFIZER	**375MG**	**N020334**	**001**	May 03, 1995
METRONIDAZOLE						
AB		ALEMBIC PHARMS LTD	**375MG**	**A079065**	**001**	Jun 23, 2009
AB		STRIDES PHARMA	**375MG**	**A076522**	**001**	Jan 29, 2004

CREAM;TOPICAL

METROCREAM						
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020531**	**001**	Sep 20, 1995
METRONIDAZOLE						
AB		COSETTE	**0.75%**	**A077549**	**001**	Dec 19, 2007
AB		FOUGERA PHARMS	**0.75%**	**A076408**	**001**	May 28, 2004
NORITATE						
	+!	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997

GEL;TOPICAL

METROGEL						
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N019737**	**001**	Nov 22, 1988
AB	**+!**		**1%**	**N021789**	**001**	Jun 30, 2005
METRONIDAZOLE						
AB		ALEOR DERMACEUTICALS	**1%**	**A212646**	**001**	Sep 03, 2021
AB		COSETTE	**0.75%**	**A078178**	**001**	Jan 19, 2011
AB		FOUGERA PHARMS	**0.75%**	**A077018**	**001**	Jun 06, 2006
AB		TARO	**0.75%**	**A077819**	**001**	Jul 18, 2006
AB			**1%**	**A204651**	**001**	Mar 14, 2017
AB		TOLMAR	**0.75%**	**A077547**	**001**	Jul 13, 2006
AB			**1%**	**A090903**	**001**	Jul 22, 2011

GEL;VAGINAL

METROGEL-VAGINAL						
AB	**+!**	BAUSCH	**0.75%**	**N020208**	**001**	Aug 17, 1992
METRONIDAZOLE						
AB		PADAGIS ISRAEL	**0.75%**	**A211786**	**001**	Jul 02, 2019
AB		SOLARIS PHARMA CORP	**0.75%**	**A213648**	**001**	Oct 14, 2021
AB		TOLMAR	**0.75%**	**A077264**	**001**	Oct 31, 2006
VANDAZOLE						
BX	!	TEVA PHARMS	0.75%	N021806	001	May 20, 2005
NUVESSA						
	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014

INJECTABLE;INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER						
AP	**+!**	BAXTER HLTHCARE	**500MG/100ML**	**N018657**	**001**	
METRO I.V. IN PLASTIC CONTAINER						
AP	**+!**	B BRAUN	**500MG/100ML**	**N018900**	**001**	Sep 29, 1983
METRONIDAZOLE IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE CORP	**500MG/100ML**	**A078084**	**001**	Mar 31, 2008
AP		GLAND PHARMA LTD	**500MG/100ML**	**A212435**	**001**	Aug 03, 2020
AP	**+!**	HOSPIRA	**500MG/100ML**	**N018890**	**002**	Nov 18, 1983
AP		INFORLIFE	**500MG/100ML**	**A206191**	**001**	Feb 25, 2019

LOTION;TOPICAL

METROLOTION						
AB	**+!**	GALDERMA LABS LP	**0.75%**	**N020901**	**001**	Nov 24, 1998
METRONIDAZOLE						
AB		FOUGERA PHARMS	**0.75%**	**A077197**	**001**	May 24, 2006

TABLET;ORAL

FLAGYL						
AB	**+**	PFIZER	**250MG**	**N012623**	**001**	
AB	**+!**		**500MG**	**N012623**	**003**	
METRONIDAZOLE						
AB		ALEMBIC LABS	**250MG**	**A208681**	**001**	Jun 20, 2017
AB			**500MG**	**A208681**	**002**	Jun 20, 2017
AB		ALEMBIC PHARMS LTD	**250MG**	**A079067**	**001**	Mar 13, 2009
AB			**500MG**	**A079067**	**002**	Mar 13, 2009
AB		AMICI	**250MG**	**A070772**	**001**	Jul 16, 1986
AB			**500MG**	**A070772**	**002**	Jul 16, 1986
AB		AUROBINDO PHARMA LTD	**250MG**	**A203974**	**001**	May 29, 2015
AB			**500MG**	**A203974**	**002**	May 29, 2015
AB		CADILA	**250MG**	**A206560**	**001**	Nov 16, 2016
AB			**500MG**	**A206560**	**002**	Nov 16, 2016
AB		CADILA PHARMS LTD	**250MG**	**A209794**	**001**	Dec 12, 2017

METRONIDAZOLE
TABLET;ORAL
METRONIDAZOLE

AB		**500MG**	**A209794**	**002**	Dec 12, 2017
AB	FLAMINGO PHARMS	**250MG**	**A207309**	**001**	May 16, 2016
AB		**500MG**	**A207309**	**002**	May 16, 2016
AB	HERITAGE PHARMS INC	**250MG**	**A205245**	**001**	Sep 23, 2015
AB		**500MG**	**A205245**	**002**	Sep 23, 2015
AB	LUPIN LTD	**250MG**	**A209096**	**001**	Sep 12, 2017
AB		**500MG**	**A209096**	**002**	Sep 12, 2017
AB	PLIVA	**500MG**	**A070033**	**001**	Dec 06, 1984
AB	STRIDES PHARMA	**250MG**	**A070040**	**001**	Jan 29, 1985
AB		**250MG**	**A208162**	**001**	May 25, 2016
AB		**500MG**	**A070039**	**001**	Jan 29, 1985
AB		**500MG**	**A208162**	**002**	May 25, 2016
AB	TEVA PHARMS USA	**250MG**	**A070027**	**001**	Nov 06, 1984
AB	UNICHEM	**250MG**	**A203458**	**001**	Jan 22, 2014
AB		**500MG**	**A203458**	**002**	Jan 22, 2014
AB	WATSON LABS	**250MG**	**A070035**	**001**	Dec 20, 1984
AB	WATSON LABS INC	**500MG**	**A070044**	**001**	Feb 08, 1985

METYRAPONE
CAPSULE;ORAL
METOPIRONE

+!	HRA PHARMA	250MG	N012911	002	Aug 09, 1996

METYROSINE
CAPSULE;ORAL
METYROSINE

BX	AMNEAL	250MG	A213734	001	Jul 24, 2020

DEMSER

+!	BAUSCH	250MG	N017871	001	

MEXILETINE HYDROCHLORIDE
CAPSULE;ORAL
MEXILETINE HYDROCHLORIDE

AB	ANI PHARMS	**150MG**	**A074450**	**001**	May 16, 1996
AB		**200MG**	**A074450**	**002**	May 16, 1996
AB		**250MG**	**A074450**	**003**	May 16, 1996
AB	CROSSMEDIKA SA	**150MG**	**A213500**	**001**	Jul 22, 2020
AB		**200MG**	**A213500**	**002**	Jul 22, 2020
AB		**250MG**	**A213500**	**003**	Jul 22, 2020
AB	NOVAST LABS	**150MG**	**A214352**	**001**	Jan 25, 2021
AB		**200MG**	**A214352**	**002**	Jan 25, 2021
AB		**250MG**	**A214352**	**003**	Jan 25, 2021
AB	SENORES PHARMS	**150MG**	**A214089**	**001**	Oct 01, 2021
AB		**200MG**	**A214089**	**002**	Oct 01, 2021
AB		**250MG**	**A214089**	**003**	Oct 01, 2021
AB	TEVA	**150MG**	**A074377**	**001**	May 16, 1995
AB		**200MG**	**A074377**	**002**	May 16, 1995
AB	**!**	**250MG**	**A074377**	**003**	May 16, 1995

MICAFUNGIN SODIUM
INJECTABLE;INTRAVENOUS
MICAFUNGIN SODIUM

AP	APOTEX	**EQ 50MG BASE/VIAL**	**A208366**	**001**	Nov 05, 2020
AP		**EQ 100MG BASE/VIAL**	**A208366**	**002**	Nov 05, 2020
AP	FRESENIUS KABI USA	**EQ 50MG BASE/VIAL**	**A207344**	**001**	May 17, 2019
AP		**EQ 100MG BASE/VIAL**	**A207344**	**002**	May 17, 2019
AP	HIKMA	**EQ 50MG BASE/VIAL**	**A213261**	**001**	Jul 09, 2021
AP		**EQ 100MG BASE/VIAL**	**A213261**	**002**	Jul 09, 2021
AP	JIANGSU HANSOH PHARM	**EQ 50MG BASE/VIAL**	**A213363**	**001**	Jul 09, 2021
AP		**EQ 100MG BASE/VIAL**	**A213363**	**002**	Jul 09, 2021
AP	XELLIA PHARMS APS	**EQ 50MG BASE/VIAL**	**A211713**	**001**	Jun 02, 2021
AP		**EQ 100MG BASE/VIAL**	**A211713**	**002**	Jun 02, 2021

MYCAMINE

AP	**+!** ASTELLAS	**EQ 50MG BASE/VIAL**	**N021506**	**002**	Mar 16, 2005
AP	**+!**	**EQ 100MG BASE/VIAL**	**N021506**	**003**	Jun 27, 2006

POWDER;INTRAVENOUS
MICAFUNGIN

+!	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021
+!		EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021

MICONAZOLE						
TABLET;BUCCAL						
ORAVIG						
	+!	GALT PHARMS	50MG	N022404	001	Apr 16, 2010
MICONAZOLE NITRATE						
SUPPOSITORY;VAGINAL						
MICONAZOLE NITRATE						
AB		ACTAVIS PHARMA	**200MG**	**A073508**	**001**	Nov 19, 1993
MONISTAT 3						
AB	**+!**	MEDTECH PRODUCTS	**200MG**	**N018888**	**001**	Aug 15, 1984
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE						
OINTMENT;TOPICAL						
VUSION						
	+!	MYLAN	0.25%;81.35%;15%	N021026	001	Feb 16, 2006
MIDAZOLAM						
SOLUTION;INTRAVENOUS						
MIDAZOLAM IN 0.9% SODIUM CHLORIDE						
	+!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021
	+!		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021
SPRAY;NASAL						
NAYZILAM						
	+!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019
MIDAZOLAM HYDROCHLORIDE						
INJECTABLE;INJECTION						
MIDAZOLAM HYDROCHLORIDE						
AP		AKORN	**EQ 1MG BASE/ML**	**A075494**	**001**	Jun 30, 2000
AP			**EQ 5MG BASE/ML**	**A075494**	**002**	Jun 30, 2000
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075154**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075154**	**001**	Jun 20, 2000
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A090696**	**001**	Feb 29, 2012
AP			**EQ 5MG BASE/ML**	**A090850**	**001**	Jan 25, 2012
AP		HIKMA	**EQ 1MG BASE/ML**	**A075243**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075247**	**002**	Jun 23, 2000
AP			**EQ 1MG BASE/ML**	**A075324**	**001**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A075421**	**002**	Jun 20, 2000
AP			**EQ 1MG BASE/ML**	**A212847**	**001**	Dec 11, 2020
AP			**EQ 5MG BASE/ML**	**A075243**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075247**	**001**	Jun 23, 2000
AP			**EQ 5MG BASE/ML**	**A075324**	**002**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A075421**	**001**	Jun 20, 2000
AP			**EQ 5MG BASE/ML**	**A212847**	**002**	Dec 11, 2020
AP	**!**	HOSPIRA	**EQ 1MG BASE/ML**	**A075293**	**001**	Jun 20, 2000
AP	**!**		**EQ 5MG BASE/ML**	**A075293**	**002**	Jun 20, 2000
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE						
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A203460**	**001**	Aug 22, 2014
AP			**EQ 5MG BASE/ML**	**A203460**	**002**	Aug 22, 2014
AP	**!**	HOSPIRA	**EQ 1MG BASE/ML**	**A075857**	**001**	Jul 22, 2002
AP	**!**		**EQ 5MG BASE/ML**	**A075857**	**002**	Jul 22, 2002
MIDAZOLAM HYDROCHLORIDE						
		FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017
SOLUTION;INTRAMUSCULAR						
SEIZALAM						
	+!	MERIDIAN MEDCL TECHN	EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	N209566	001	Sep 14, 2018
SYRUP;ORAL						
MIDAZOLAM HYDROCHLORIDE						
AA		AKORN	**EQ 2MG BASE/ML**	**A075958**	**001**	Sep 04, 2003
AA	**!**	HIKMA	**EQ 2MG BASE/ML**	**A075873**	**001**	Apr 30, 2002
AA		PADAGIS US	**EQ 2MG BASE/ML**	**A076379**	**001**	May 02, 2005
MIDODRINE HYDROCHLORIDE						
TABLET;ORAL						
MIDODRINE HYDROCHLORIDE						
AB		ALEMBIC PHARMS LTD	**2.5MG**	**A214734**	**001**	Jan 21, 2021
AB			**5MG**	**A214734**	**002**	Jan 21, 2021
AB			**10MG**	**A214734**	**003**	Jan 21, 2021
AB		APOTEX	**2.5MG**	**A077746**	**001**	Sep 12, 2006
AB			**5MG**	**A077746**	**002**	Sep 12, 2006
AB			**10MG**	**A077746**	**003**	Sep 12, 2006
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A212774**	**001**	Aug 10, 2020

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB			**5MG**	**A212774**	**002**	Aug 10, 2020
AB			**10MG**	**A212774**	**003**	Aug 10, 2020
AB		IMPAX PHARMS	**2.5MG**	**A076449**	**001**	May 27, 2004
AB			**5MG**	**A076449**	**002**	May 27, 2004
AB			**10MG**	**A076449**	**003**	Dec 16, 2005
AB		MYLAN PHARMS INC	**2.5MG**	**A076577**	**001**	Sep 10, 2003
AB			**5MG**	**A076577**	**002**	Sep 10, 2003
AB			**10MG**	**A076577**	**003**	Sep 10, 2003
AB		PAR PHARM INC	**2.5MG**	**A207169**	**001**	Oct 29, 2018
AB			**5MG**	**A207169**	**002**	Oct 29, 2018
AB			**10MG**	**A207169**	**003**	Oct 29, 2018
AB		RUBICON	**2.5MG**	**A212543**	**001**	Aug 19, 2019
AB			**5MG**	**A212543**	**002**	Aug 19, 2019
AB			**10MG**	**A212543**	**003**	Aug 19, 2019
AB		UNIQUE PHARM LABS	**2.5MG**	**A207613**	**001**	Nov 02, 2018
AB			**5MG**	**A207613**	**002**	Nov 02, 2018
AB			**10MG**	**A207613**	**003**	Nov 02, 2018
AB		XIROMED	**2.5MG**	**A207849**	**001**	Oct 01, 2020
AB			**5MG**	**A207849**	**002**	Oct 01, 2020
AB			**10MG**	**A207849**	**003**	Oct 01, 2020
AB		ZYDUS	**2.5MG**	**A213055**	**001**	Sep 01, 2020
AB			**5MG**	**A213055**	**002**	Sep 01, 2020
AB			**10MG**	**A213055**	**003**	Sep 01, 2020

ORVATEN

AB		UPSHER SMITH LABS	**2.5MG**	**A076725**	**001**	Nov 03, 2004
AB	**!**		**5MG**	**A076725**	**002**	Nov 03, 2004
AB			**10MG**	**A076725**	**003**	Nov 03, 2004

MIDOSTAURIN

CAPSULE;ORAL

RYDAPT

	+!	NOVARTIS	25MG	N207997	001	Apr 28, 2017

MIFEPRISTONE

TABLET;ORAL

KORLYM

AB	**+!**	CORCEPT THERAP	**300MG**	**N202107**	**001**	Feb 17, 2012

MIFEPREX

AB	**+!**	DANCO LABS LLC	**200MG**	**N020687**	**001**	Sep 28, 2000

MIFEPRISTONE

AB		GENBIOPRO	**200MG**	**A091178**	**001**	Apr 11, 2019
AB		TEVA PHARMS USA INC	**300MG**	**A211436**	**001**	Aug 03, 2020

MIGALASTAT HYDROCHLORIDE

CAPSULE;ORAL

GALAFOLD

	+!	AMICUS THERAP US	EQ 123MG BASE	N208623	001	Aug 10, 2018

MIGLITOL

TABLET;ORAL

GLYSET

AB	**+!**	PFIZER	**25MG**	**N020682**	**001**	Dec 18, 1996
AB	**+**		**50MG**	**N020682**	**002**	Dec 18, 1996
AB	**+**		**100MG**	**N020682**	**003**	Dec 18, 1996

MIGLITOL

AB		ORIENT PHARMA CO LTD	**25MG**	**A203965**	**001**	Feb 24, 2015
AB			**50MG**	**A203965**	**002**	Feb 24, 2015
AB			**100MG**	**A203965**	**003**	Feb 24, 2015

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

AB		ANI PHARMS	**100MG**	**A208342**	**001**	Apr 17, 2018
AB		EDENBRIDGE PHARMS	**100MG**	**A209821**	**001**	Aug 06, 2020

ZAVESCA

AB	**+!**	ACTELION	**100MG**	**N021348**	**001**	Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

SAVELLA

+	ALLERGAN	12.5MG	N022256	001	Jan 14, 2009
+		25MG	N022256	002	Jan 14, 2009
+!		50MG	N022256	003	Jan 14, 2009
+		100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP		CAPLIN	**EQ 1MG BASE/ML**	**A214380**	**001**	Apr 16, 2021
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A075936**	**001**	May 28, 2002
AP		HIKMA	**EQ 1MG BASE/ML**	**A075530**	**001**	May 28, 2002
AP			**EQ 1MG BASE/ML**	**A075660**	**001**	May 28, 2002
AP	!	HIKMA FARMACEUTICA	**EQ 1MG BASE/ML**	**A077966**	**001**	Dec 03, 2010
AP		HOSPIRA INC	**EQ 1MG BASE/ML**	**A203280**	**001**	Sep 03, 2014
AP		MEITHEAL	**EQ 1MG BASE/ML**	**A211671**	**001**	Mar 24, 2020

MILRINONE LACTATE IN DEXTROSE 5%

AP		EUGIA PHARMA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A209666**	**001**	Sep 03, 2020
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A209666**	**002**	Sep 03, 2020
AP		WOODWARD	**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A077151**	**002**	Jul 20, 2005

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!	BAXTER HLTHCARE	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075834**	**001**	May 28, 2002
AP	!		**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075834**	**002**	May 28, 2002
AP		GLAND PHARMA LTD	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A213585**	**001**	Jul 16, 2020
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A213585**	**002**	Jul 16, 2020
AP		HOSPIRA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A075885**	**001**	May 28, 2002
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A075885**	**002**	May 28, 2002
AP		WEST-WARD PHARMS INT	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A078113**	**001**	May 21, 2008
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A078113**	**002**	May 21, 2008

MILRINONE LACTATE IN PLASTIC CONTAINER

AP		HIKMA FARMACEUTICA	**EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)**	**A090038**	**001**	Jan 21, 2010
AP			**EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)**	**A090038**	**002**	Jan 21, 2010

MILTEFOSINE

CAPSULE;ORAL

IMPAVIDO

+!	KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+!	VYNE	EQ 4% BASE	N212379	001	Oct 18, 2019

ZILXI

+!	VYNE	EQ 1.5% BASE	N213690	001	May 28, 2020

CAPSULE;ORAL

DYNACIN

AB		ALVOGEN	**EQ 50MG BASE**	**A063067**	**003**	Aug 14, 1990
AB			**EQ 75MG BASE**	**A063067**	**002**	Sep 15, 1999
AB			**EQ 100MG BASE**	**A063067**	**001**	Jul 31, 1990

MINOCIN

AB	+	BAUSCH	**EQ 50MG BASE**	**N050649**	**001**	May 31, 1990
AB	+		**EQ 100MG BASE**	**N050649**	**002**	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA	**EQ 50MG BASE**	**A065470**	**001**	Mar 11, 2008
AB			**EQ 75MG BASE**	**A065470**	**002**	Mar 11, 2008
AB			**EQ 100MG BASE**	**A065470**	**003**	Mar 11, 2008
AB		IMPAX LABS	**EQ 50MG BASE**	**A065005**	**001**	Mar 23, 1999
AB			**EQ 75MG BASE**	**A065005**	**003**	Apr 18, 2001
AB			**EQ 100MG BASE**	**A065005**	**002**	Mar 23, 1999
AB		SUN PHARM INDS INC	**EQ 50MG BASE**	**A090867**	**001**	May 13, 2013
AB			**EQ 75MG BASE**	**A090867**	**002**	May 13, 2013
AB			**EQ 100MG BASE**	**A090867**	**003**	May 13, 2013
AB		TORRENT	**EQ 50MG BASE**	**A065062**	**001**	Nov 30, 2000
AB			**EQ 75MG BASE**	**A065062**	**002**	Nov 30, 2000
AB			**EQ 100MG BASE**	**A065062**	**003**	Nov 30, 2000
AB		WATSON LABS	**EQ 75MG BASE**	**A063065**	**002**	Jun 10, 1999
AB			**EQ 100MG BASE**	**A063065**	**001**	Dec 30, 1991
AB		WATSON LABS TEVA	**EQ 50MG BASE**	**A063181**	**001**	Dec 30, 1991
AB		ZYDUS	**EQ 50MG BASE**	**A063011**	**001**	Mar 02, 1992
AB			**EQ 75MG BASE**	**A063009**	**002**	Aug 12, 2003
AB	!		**EQ 100MG BASE**	**A063009**	**001**	Mar 02, 1992

MINOCYCLINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

	JOURNEY	EQ 45MG BASE	N201922	001	Jul 11, 2012
		EQ 90MG BASE	N201922	003	Jul 11, 2012
		EQ 135MG BASE	N201922	005	Jul 11, 2012

INJECTABLE;INJECTION

MINOCIN

+!	REMPEX	EQ 100MG BASE/VIAL	N050444	001	

POWDER, EXTENDED RELEASE;DENTAL

ARESTIN

+!	ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	**EQ 50MG BASE**	**A213662**	**001**	May 01, 2020
AB		**EQ 75MG BASE**	**A213662**	**002**	May 01, 2020
AB		**EQ 100MG BASE**	**A213662**	**003**	May 01, 2020
AB	DR REDDYS LABS LTD	**EQ 50MG BASE**	**A065436**	**001**	Dec 26, 2007
AB		**EQ 75MG BASE**	**A065436**	**002**	Dec 26, 2007
AB		**EQ 100MG BASE**	**A065436**	**003**	Dec 26, 2007
AB	STRIDES PHARMA	**EQ 50MG BASE**	**A065131**	**001**	Apr 16, 2003
AB		**EQ 75MG BASE**	**A065131**	**002**	Apr 16, 2003
AB !		**EQ 100MG BASE**	**A065131**	**003**	Apr 16, 2003
AB	SUN PHARM INDUSTRIES	**EQ 50MG BASE**	**A090217**	**001**	Jan 29, 2016
AB		**EQ 75MG BASE**	**A090217**	**002**	Jan 29, 2016
AB		**EQ 100MG BASE**	**A090217**	**003**	Jan 29, 2016
AB	TORRENT	**EQ 50MG BASE**	**A065156**	**001**	Jan 06, 2004
AB		**EQ 75MG BASE**	**A065156**	**002**	Jan 06, 2004
AB		**EQ 100MG BASE**	**A065156**	**003**	Jan 06, 2004

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	ALKEM LABS LTD	**EQ 45MG BASE**	**A204453**	**001**	Sep 28, 2016
AB		**EQ 55MG BASE**	**A204453**	**008**	Dec 19, 2019
AB		**EQ 65MG BASE**	**A204453**	**006**	Mar 16, 2018
AB		**EQ 80MG BASE**	**A204453**	**002**	Sep 28, 2016
AB		**EQ 90MG BASE**	**A204453**	**003**	Sep 28, 2016
AB		**EQ 105MG BASE**	**A204453**	**004**	Sep 28, 2016
AB		**EQ 115MG BASE**	**A204453**	**007**	Mar 16, 2018
AB		**EQ 135MG BASE**	**A204453**	**005**	Sep 28, 2016
AB	AUROBINDO PHARMA LTD	**EQ 45MG BASE**	**A202261**	**001**	Nov 19, 2012
AB		**EQ 55MG BASE**	**A202261**	**008**	Aug 21, 2019
AB		**EQ 65MG BASE**	**A202261**	**002**	Sep 28, 2018
AB		**EQ 80MG BASE**	**A202261**	**006**	Jun 13, 2016
AB		**EQ 90MG BASE**	**A202261**	**003**	Nov 19, 2012
AB		**EQ 105MG BASE**	**A202261**	**007**	Jun 13, 2016
AB		**EQ 115MG BASE**	**A202261**	**004**	Sep 28, 2018
AB		**EQ 135MG BASE**	**A202261**	**005**	Nov 19, 2012
AB	LUPIN LTD	**EQ 45MG BASE**	**A091424**	**001**	Nov 30, 2011
AB		**EQ 55MG BASE**	**A091424**	**002**	Nov 30, 2011
AB		**EQ 90MG BASE**	**A091424**	**003**	Nov 30, 2011
AB		**EQ 135MG BASE**	**A091424**	**004**	Nov 30, 2011
AB	SANDOZ	**EQ 45MG BASE**	**A090422**	**001**	Aug 13, 2009
AB		**EQ 90MG BASE**	**A090422**	**002**	Aug 13, 2009
AB !		**EQ 135MG BASE**	**A090422**	**003**	Aug 13, 2009
AB	SIDMAK LABS INDIA	**EQ 45MG BASE**	**A204394**	**001**	Dec 30, 2015
AB		**EQ 80MG BASE**	**A204394**	**004**	Dec 30, 2015
AB		**EQ 105MG BASE**	**A204394**	**005**	Dec 30, 2015
AB		**EQ 135MG BASE**	**A204394**	**007**	Dec 30, 2015
AB	SUN PHARM INDS LTD	**EQ 45MG BASE**	**A091118**	**001**	Sep 25, 2014
AB		**EQ 65MG BASE**	**A091118**	**003**	Dec 03, 2019
AB		**EQ 80MG BASE**	**A091118**	**004**	Sep 25, 2014
AB		**EQ 90MG BASE**	**A091118**	**005**	Sep 25, 2014
AB		**EQ 105MG BASE**	**A091118**	**006**	Sep 25, 2014
AB		**EQ 115MG BASE**	**A091118**	**007**	Dec 03, 2019
AB		**EQ 135MG BASE**	**A091118**	**008**	Sep 25, 2014
AB	ZYDUS PHARMS	**EQ 45MG BASE**	**A203553**	**001**	Nov 16, 2017
AB		**EQ 80MG BASE**	**A203553**	**004**	Nov 16, 2017
AB		**EQ 90MG BASE**	**A203553**	**005**	Nov 16, 2017
AB		**EQ 105MG BASE**	**A203553**	**006**	Nov 16, 2017
AB		**EQ 135MG BASE**	**A203553**	**008**	Nov 16, 2017

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SOLODYN

AB	**+**	BAUSCH	**EQ 55MG BASE**	**N050808**	**008**	Aug 27, 2010
AB	**+**		**EQ 65MG BASE**	**N050808**	**004**	Jul 23, 2009
AB	**+**		**EQ 80MG BASE**	**N050808**	**007**	Aug 27, 2010
AB	**+**		**EQ 105MG BASE**	**N050808**	**006**	Aug 27, 2010
AB	**+!**		**EQ 115MG BASE**	**N050808**	**005**	Jul 23, 2009

MINOLIRA

	EPI HLTH	EQ 105MG BASE	N209269	001	May 08, 2017
!		EQ 135MG BASE	N209269	002	May 08, 2017

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB		PAR PHARM	**2.5MG**	**A071826**	**001**	Nov 14, 1988
AB			**10MG**	**A071839**	**001**	Nov 14, 1988
AB		SUN PHARM INDUSTRIES	**2.5MG**	**A072709**	**002**	Dec 14, 1995
AB			**10MG**	**A072709**	**001**	Dec 14, 1995
AB		WATSON LABS	**2.5MG**	**A071344**	**001**	Mar 03, 1987
AB	**!**		**10MG**	**A071345**	**001**	Mar 03, 1987

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MYRBETRIQ GRANULES

+!	APGDI	8MG/ML	N213801	001	Mar 25, 2021

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

+!	APGDI	25MG	N202611	001	Jun 28, 2012
+!		50MG	N202611	002	Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

AB		APOTEX INC	**15MG**	**A077666**	**001**	Aug 22, 2007
AB			**30MG**	**A077666**	**002**	Aug 22, 2007
AB			**45MG**	**A077666**	**003**	Aug 22, 2007
AB		AUROBINDO	**7.5MG**	**A076921**	**001**	Oct 22, 2004
AB			**15MG**	**A076921**	**002**	Oct 22, 2004
AB			**30MG**	**A076921**	**003**	Oct 22, 2004
AB			**45MG**	**A076921**	**004**	Oct 22, 2004
AB		MYLAN	**15MG**	**A076122**	**001**	Jun 19, 2003
AB			**30MG**	**A076122**	**002**	Jun 19, 2003
AB			**45MG**	**A076122**	**003**	Jun 19, 2003
AB		SUN PHARM INDS INC	**7.5MG**	**A076541**	**004**	Apr 22, 2004
AB			**15MG**	**A076541**	**001**	Apr 22, 2004
AB			**30MG**	**A076541**	**002**	Apr 22, 2004
AB			**45MG**	**A076541**	**003**	Apr 22, 2004
AB		TEVA	**15MG**	**A076119**	**001**	Jan 24, 2003
AB			**30MG**	**A076119**	**002**	Jan 24, 2003
AB			**45MG**	**A076119**	**003**	Jun 19, 2003
AB		UPSHER SMITH LABS	**15MG**	**A076219**	**001**	Jun 19, 2003
AB			**30MG**	**A076219**	**002**	Jun 19, 2003
AB			**45MG**	**A076219**	**003**	Jun 19, 2003

REMERON

AB	**+!**	ORGANON USA INC	**15MG**	**N020415**	**001**	Jun 14, 1996
AB	**+**		**30MG**	**N020415**	**002**	Jun 14, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

AB		AUROBINDO PHARMA LTD	**15MG**	**A077376**	**002**	Dec 08, 2005
AB			**30MG**	**A077376**	**003**	Dec 08, 2005
AB			**45MG**	**A077376**	**004**	Feb 28, 2006
AB		ZYDUS PHARMS	**15MG**	**A205798**	**001**	Jun 01, 2017
AB			**30MG**	**A205798**	**002**	Jun 01, 2017
AB			**45MG**	**A205798**	**003**	Jun 01, 2017

REMERON SOLTAB

AB	**+!**	ORGANON USA INC	**15MG**	**N021208**	**001**	Jan 12, 2001
AB	**+**		**30MG**	**N021208**	**002**	Jan 12, 2001
AB	**+**		**45MG**	**N021208**	**003**	Jan 12, 2001

MISOPROSTOL						
TABLET;ORAL						
MISOPROSTOL						
BX		NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012
BX			0.2MG	A091667	002	Jul 25, 2012
CYTOTEC						
+		PFIZER	0.1MG	N019268	003	Sep 21, 1990
+!			0.2MG	N019268	001	Dec 27, 1988
MITOMYCIN						
FOR SOLUTION;TOPICAL						
MITOSOL						
+!		MOBIUS THERAP	0.2MG/VIAL	N022572	001	Feb 07, 2012
INJECTABLE;INJECTION						
MITOMYCIN						
AP	**!**	ACCORD HLTHCARE	**5MG/VIAL**	**A064144**	**001**	Apr 30, 1998
AP	**!**		**20MG/VIAL**	**A064144**	**002**	Apr 30, 1998
AP	**!**		**40MG/VIAL**	**A064144**	**003**	Aug 11, 2009
AP		GLAND PHARMA LTD	**5MG/VIAL**	**A215687**	**001**	Oct 20, 2021
AP			**20MG/VIAL**	**A215687**	**002**	Oct 20, 2021
AP		HIKMA	**5MG/VIAL**	**A064180**	**001**	Dec 23, 1999
AP			**20MG/VIAL**	**A064117**	**002**	Apr 19, 1995
AP			**20MG/VIAL**	**A064180**	**002**	Dec 23, 1999
AP			**40MG/VIAL**	**A064117**	**003**	Jun 02, 1999
AP		RK PHARMA	**5MG/VIAL**	**A202670**	**001**	Oct 13, 2017
AP			**20MG/VIAL**	**A202670**	**002**	Oct 13, 2017
AP			**40MG/VIAL**	**A203386**	**001**	Oct 13, 2017
POWDER;PYELOCALYCEAL						
JELMYTO						
+!		UROGEN PHARMA	40MG/VIAL	N211728	001	Apr 15, 2020
MITOTANE						
TABLET;ORAL						
LYSODREN						
+!		HRA PHARMA	500MG	N016885	001	
MITOXANTRONE HYDROCHLORIDE						
INJECTABLE;INJECTION						
MITOXANTRONE HYDROCHLORIDE						
AP		FRESENIUS KABI USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077496**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077496**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077496**	**003**	Apr 11, 2006
AP		HIKMA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076611**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076611**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076611**	**003**	Apr 11, 2006
AP	**!**	HOSPIRA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A076871**	**001**	Apr 11, 2006
AP	**!**		**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A076871**	**002**	Apr 11, 2006
AP	**!**		**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A076871**	**003**	Apr 11, 2006
AP		TEVA PHARMS USA	**EQ 20MG BASE/10ML (EQ 2MG BASE/ML)**	**A077356**	**001**	Apr 11, 2006
AP			**EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)**	**A077356**	**002**	Apr 11, 2006
AP			**EQ 30MG BASE/15ML (EQ 2MG BASE/ML)**	**A077356**	**003**	Apr 11, 2006
MIVACURIUM CHLORIDE						
SOLUTION;INTRAVENOUS						
MIVACURIUM CHLORIDE						
		WOODWARD	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	A209708	001	Oct 12, 2021
			EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A209708	002	Oct 12, 2021
MOBOCERTINIB SUCCINATE						
CAPSULE;ORAL						
EXKIVITY						
+!		TAKEDA PHARMS USA	EQ 40MG BASE	N215310	001	Sep 15, 2021
MODAFINIL						
TABLET;ORAL						
MODAFINIL						
AB		ALEMBIC PHARMS LTD	**100MG**	**A202700**	**001**	Oct 18, 2012
AB			**200MG**	**A202700**	**002**	Oct 18, 2012
AB		APOTEX INC	**100MG**	**A077667**	**001**	Feb 03, 2014
AB			**200MG**	**A077667**	**002**	Feb 03, 2014
AB		APPCO	**100MG**	**A207196**	**001**	Aug 16, 2017
AB			**200MG**	**A207196**	**002**	Aug 16, 2017
AB		AUROBINDO PHARMA LTD	**100MG**	**A202566**	**001**	Sep 27, 2012
AB			**200MG**	**A202566**	**002**	Sep 27, 2012
AB		CADILA	**100MG**	**A209966**	**001**	Sep 14, 2017

MODAFINIL

TABLET;ORAL

MODAFINIL

AB			**200MG**	**A209966**	**002**	Sep 14, 2017
AB		ORBION PHARMS	**100MG**	**A078963**	**001**	Sep 26, 2012
AB			**200MG**	**A078963**	**002**	Sep 26, 2012
AB		WATSON LABS INC	**100MG**	**A076715**	**001**	Nov 01, 2012
AB			**200MG**	**A076715**	**002**	Nov 01, 2012

PROVIGIL

AB	**+**	CEPHALON	**100MG**	**N020717**	**001**	Dec 24, 1998
AB	**+!**		**200MG**	**N020717**	**002**	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

AB		APOTEX INC	**7.5MG**	**A078454**	**001**	Jun 02, 2008
AB			**15MG**	**A078454**	**002**	Jun 02, 2008
AB		CHARTWELL RX	**7.5MG**	**A077536**	**001**	Nov 30, 2006
AB			**15MG**	**A077536**	**002**	Nov 30, 2006
AB		GLENMARK GENERICS	**7.5MG**	**A090416**	**001**	Mar 30, 2010
AB			**15MG**	**A090416**	**002**	Mar 30, 2010
AB		TEVA	**7.5MG**	**A076204**	**001**	May 08, 2003
AB	**!**		**15MG**	**A076204**	**002**	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

		EPIC PHARMA LLC	5MG	A090453	001	Mar 20, 2015
			10MG	A090453	002	Mar 20, 2015
	!		25MG	A090453	003	Mar 20, 2015

MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

ASMANEX HFA

	+	ORGANON	0.05MG/INH	N205641	003	Aug 12, 2019
	+		0.10MG/INH	N205641	001	Apr 25, 2014
	+!		0.20MG/INH	N205641	002	Apr 25, 2014

CREAM;TOPICAL

MOMETASONE FUROATE

AB		COSETTE	**0.1%**	**A077447**	**001**	May 22, 2006
AB	**!**	GLENMARK GENERICS	**0.1%**	**A078541**	**001**	May 28, 2008
AB		TARO	**0.1%**	**A076679**	**001**	Dec 21, 2004

IMPLANT;IMPLANTATION

SINUVA

	+	INTERSECT ENT INC	1.35MG	N209310	001	Dec 08, 2017

LOTION;TOPICAL

ELOCON

AB	**+!**	MERCK SHARP DOHME	**0.1%**	**N019796**	**001**	Mar 30, 1989

MOMETASONE FUROATE

AB		COSETTE	**0.1%**	**A077678**	**001**	Nov 21, 2007
AB		FOUGERA PHARMS	**0.1%**	**A075919**	**001**	Nov 29, 2007
AB		GLENMARK GENERICS	**0.1%**	**A090506**	**001**	Aug 09, 2010
AB		PADAGIS ISRAEL	**0.1%**	**A077180**	**001**	Apr 06, 2005
AB		TARO	**0.1%**	**A076788**	**001**	Mar 15, 2006

OINTMENT;TOPICAL

MOMETASONE FUROATE

AB		COSETTE	**0.1%**	**A077401**	**001**	Jun 20, 2006
AB		FOUGERA PHARMS	**0.1%**	**A077061**	**001**	Mar 28, 2005
AB	**!**	GLENMARK GENERICS	**0.1%**	**A078571**	**001**	May 28, 2008
AB		PADAGIS US	**0.1%**	**A076067**	**001**	Mar 18, 2002

POWDER;INHALATION

ASMANEX TWISTHALER

	+	ORGANON	0.11MG/INH	N021067	002	Feb 01, 2008
	+!		0.22MG/INH	N021067	001	Mar 30, 2005

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB		AMNEAL PHARMS	**0.05MG/SPRAY**	**A207989**	**001**	Apr 03, 2017
AB	**!**	APOTEX INC	**0.05MG/SPRAY**	**A091161**	**001**	Mar 22, 2016

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

BAFIERTAM

	+!	BANNER LIFE SCIENCES	95MG	N210296	001	Apr 28, 2020

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	**EQ 4MG BASE/PACKET**	**A203438**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE/PACKET**	**A213471**	**001**	Feb 18, 2020
AB		DR REDDYS LABS LTD	**EQ 4MG BASE/PACKET**	**A202906**	**001**	Sep 17, 2012
AB		TEVA PHARMS	**EQ 4MG BASE/PACKET**	**A090955**	**001**	Aug 03, 2012
AB		TORRENT	**EQ 4MG BASE/PACKET**	**A210431**	**001**	Jul 31, 2018

SINGULAIR

AB	**+!**	MERCK	**EQ 4MG BASE/PACKET**	**N021409**	**001**	Jul 26, 2002

TABLET;ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	**EQ 10MG BASE**	**A202717**	**001**	Sep 21, 2012
AB		ADAPTIS	**EQ 10MG BASE**	**A209012**	**001**	Apr 24, 2017
AB		AMNEAL PHARMS	**EQ 10MG BASE**	**A204604**	**001**	Sep 04, 2015
AB		ANBISON LAB	**EQ 10MG BASE**	**A205683**	**001**	Jan 12, 2016
AB		AUROBINDO PHARMA LTD	**EQ 10MG BASE**	**A202468**	**001**	Aug 03, 2012
AB		CIPLA	**EQ 10MG BASE**	**A207463**	**001**	Oct 28, 2016
AB		DR REDDYS LABS LTD	**EQ 10MG BASE**	**A201582**	**001**	Aug 06, 2012
AB		GLENMARK GENERICS	**EQ 10MG BASE**	**A090926**	**001**	Aug 03, 2012
AB		HETERO LABS LTD V	**EQ 10MG BASE**	**A202843**	**001**	Sep 10, 2014
AB		L PERRIGO CO	**EQ 10MG BASE**	**A206112**	**001**	Apr 26, 2017
AB		LANNETT CO INC	**EQ 10MG BASE**	**A201522**	**001**	Aug 03, 2012
AB		MACLEODS PHARMS LTD	**EQ 10MG BASE**	**A203366**	**001**	Sep 11, 2014
AB		SANDOZ INC	**EQ 10MG BASE**	**A200889**	**001**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 10MG BASE**	**A078605**	**001**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 10MG BASE**	**A201515**	**001**	Aug 03, 2012
AB		UNICHEM	**EQ 10MG BASE**	**A204290**	**001**	Oct 08, 2015
AB		UNIMARK REMEDIES LTD	**EQ 10MG BASE**	**A202859**	**001**	Oct 30, 2014

SINGULAIR

AB	**+!**	MSD MERCK CO	**EQ 10MG BASE**	**N020829**	**002**	Feb 20, 1998

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		ADAPTIS	**EQ 4MG BASE**	**A209011**	**001**	Apr 18, 2017
AB			**EQ 5MG BASE**	**A209011**	**002**	Apr 18, 2017
AB		AMNEAL PHARMS	**EQ 4MG BASE**	**A205107**	**001**	Sep 04, 2020
AB			**EQ 5MG BASE**	**A205107**	**002**	Sep 04, 2020
AB		ANBISON LAB	**EQ 4MG BASE**	**A205695**	**001**	Nov 05, 2015
AB			**EQ 5MG BASE**	**A205695**	**002**	Nov 05, 2015
AB		AUROBINDO PHARMA LTD	**EQ 4MG BASE**	**A202096**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A202096**	**002**	Aug 03, 2012
AB		CIPLA	**EQ 4MG BASE**	**A207464**	**001**	Dec 06, 2018
AB			**EQ 5MG BASE**	**A207464**	**002**	Dec 06, 2018
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A201581**	**001**	Aug 06, 2012
AB			**EQ 5MG BASE**	**A201581**	**002**	Aug 06, 2012
AB		HETERO LABS LTD V	**EQ 4MG BASE**	**A204093**	**001**	May 22, 2015
AB			**EQ 5MG BASE**	**A204093**	**002**	May 22, 2015
AB		LANNETT CO INC	**EQ 4MG BASE**	**A200405**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A200405**	**002**	Aug 03, 2012
AB		MACLEODS PHARMS LTD	**EQ 4MG BASE**	**A203582**	**001**	Mar 12, 2015
AB			**EQ 5MG BASE**	**A203582**	**002**	Mar 12, 2015
AB		SANDOZ INC	**EQ 4MG BASE**	**A091414**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A091414**	**002**	Aug 03, 2012
AB		TEVA PHARMS	**EQ 4MG BASE**	**A078723**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A078723**	**002**	Aug 03, 2012
AB		TORRENT PHARMS LTD	**EQ 4MG BASE**	**A090984**	**001**	Aug 03, 2012
AB			**EQ 5MG BASE**	**A090984**	**002**	Aug 03, 2012
AB		UNICHEM	**EQ 4MG BASE**	**A208621**	**001**	Jul 02, 2018
AB			**EQ 5MG BASE**	**A208621**	**002**	Jul 02, 2018
AB		UNIMARK REMEDIES LTD	**EQ 4MG BASE**	**A203037**	**001**	Oct 30, 2014
AB			**EQ 5MG BASE**	**A203037**	**002**	Oct 30, 2014

SINGULAIR

AB	**+**	MSD MERCK CO	**EQ 4MG BASE**	**N020830**	**002**	Mar 03, 2000

MONTELUKAST SODIUM						
TABLET, CHEWABLE;ORAL						
SINGULAIR						
AB	**+!**		**EQ 5MG BASE**	**N020830**	**001**	Feb 20, 1998
MORPHINE SULFATE						
CAPSULE, EXTENDED RELEASE;ORAL						
MORPHINE SULFATE						
AB		IMPAX LABS INC	**20MG**	**A200411**	**001**	Apr 12, 2016
AB			**30MG**	**A200411**	**002**	Apr 12, 2016
AB			**50MG**	**A200411**	**003**	Apr 12, 2016
AB			**60MG**	**A200411**	**004**	Apr 12, 2016
AB			**80MG**	**A200411**	**005**	Apr 12, 2016
AB			**100MG**	**A200411**	**006**	Apr 12, 2016
AB		NORTEC DEV ASSOC	**20MG**	**A203158**	**001**	Aug 04, 2021
AB			**30MG**	**A203158**	**002**	Aug 04, 2021
AB			**50MG**	**A203158**	**003**	Aug 04, 2021
AB			**60MG**	**A203158**	**004**	Aug 04, 2021
AB			**80MG**	**A203158**	**005**	Aug 04, 2021
AB			**100MG**	**A203158**	**006**	Aug 04, 2021
AB		UPSHER SMITH LABS	**20MG**	**A202104**	**002**	Jun 03, 2013
AB			**30MG**	**A202104**	**003**	Jun 03, 2013
AB			**50MG**	**A202104**	**004**	Jun 03, 2013
AB			**60MG**	**A202104**	**005**	Jun 03, 2013
AB			**80MG**	**A202104**	**006**	Jun 03, 2013
AB	**!**		**100MG**	**A202104**	**007**	Jun 03, 2013
		ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
			45MG	A079040	002	Jan 16, 2013
			60MG	A079040	003	Jan 16, 2013
			75MG	A079040	004	Jan 16, 2013
			90MG	A079040	005	Jan 16, 2013
	!		120MG	A079040	006	Jan 16, 2013
		IMPAX LABS INC	40MG	A200411	007	Jul 25, 2018
	!	UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013
INJECTABLE;INJECTION						
DURAMORPH PF						
AP	**+!**	HIKMA	**0.5MG/ML**	**N018565**	**001**	Sep 18, 1984
AP	**+!**		**1MG/ML**	**N018565**	**002**	Sep 18, 1984
INFUMORPH						
AP	**+!**	HIKMA	**10MG/ML**	**N018565**	**003**	Jul 19, 1991
AP	**+!**		**25MG/ML**	**N018565**	**004**	Jul 19, 1991
MITIGO						
AP		PIRAMAL CRITICAL	**10MG/ML**	**A204393**	**001**	Jul 16, 2018
AP			**25MG/ML**	**A204393**	**002**	Jul 16, 2018
MORPHINE SULFATE						
AP	**!**	HIKMA	**4MG/ML**	**A205758**	**001**	May 21, 2015
AP	**!**		**8MG/ML**	**A205758**	**002**	May 21, 2015
AP			**10MG/ML**	**A205758**	**003**	May 21, 2015
AP		HOSPIRA	**0.5MG/ML**	**A071849**	**001**	May 11, 1988
AP			**0.5MG/ML**	**A073509**	**001**	Sep 30, 1992
AP			**1MG/ML**	**A073510**	**001**	Sep 30, 1992
AP	**+**	HOSPIRA INC	**4MG/ML**	**N202515**	**002**	Nov 14, 2011
AP	**+**		**8MG/ML**	**N202515**	**003**	Nov 14, 2011
AP	**+**		**10MG/ML**	**N202515**	**004**	Nov 14, 2011
	+!		2MG/ML	N202515	001	Nov 14, 2011
	+!		50MG/ML	N202515	006	Apr 29, 2021
SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
MORPHINE SULFATE						
	+!	FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
	+!		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
	+!		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
	+!		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
	+!		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013
SOLUTION;ORAL						
MORPHINE SULFATE						
AA		AKORN	**100MG/5ML**	**A208809**	**001**	Jul 06, 2017
AA	**+**	HIKMA	**10MG/5ML**	**N022195**	**001**	Mar 17, 2008
AA	**+**		**20MG/5ML**	**N022195**	**002**	Mar 17, 2008
AA	**+!**		**100MG/5ML**	**N022195**	**003**	Jan 25, 2010
AA		PADAGIS US	**100MG/5ML**	**A201574**	**001**	Aug 06, 2012
AA		PHARM ASSOC	**100MG/5ML**	**A206573**	**001**	Nov 14, 2016
AA		RHODES PHARMS	**10MG/5ML**	**A206308**	**001**	Jun 22, 2017
AA			**20MG/5ML**	**A206420**	**001**	Jul 12, 2016

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

AA			**100MG/5ML**	**A206308**	**002**	Jun 22, 2017
AA		SPECGX LLC	**100MG/5ML**	**A202348**	**001**	Jul 15, 2011
AA		TRIS PHARMA INC	**10MG/5ML**	**A203518**	**001**	May 12, 2015
AA			**20MG/5ML**	**A203519**	**001**	May 18, 2016
AA			**100MG/5ML**	**A203518**	**002**	May 12, 2015

TABLET;ORAL

MORPHINE SULFATE

AB		ALKEM LABS LTD	**15MG**	**A212451**	**001**	Dec 03, 2020
AB			**30MG**	**A212451**	**002**	Dec 03, 2020
AB	+	HIKMA	**15MG**	**N022207**	**001**	Mar 17, 2008
AB	+!		**30MG**	**N022207**	**002**	Mar 17, 2008
AB		MAYNE PHARMA INC	**15MG**	**A207270**	**001**	Jan 12, 2022
AB			**30MG**	**A207270**	**002**	Jan 12, 2022
AB		UPSHER SMITH LABS	**15MG**	**A210610**	**001**	Jul 22, 2019
AB			**30MG**	**A210610**	**002**	Jul 22, 2019

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	**15MG**	**A203849**	**001**	Apr 06, 2015
AB			**30MG**	**A203849**	**002**	Apr 06, 2015
AB			**60MG**	**A203849**	**003**	Apr 06, 2015
AB			**100MG**	**A203849**	**004**	Apr 06, 2015
AB			**200MG**	**A203849**	**005**	Apr 06, 2015
AB		DAVA PHARMS INC	**15MG**	**A075407**	**001**	Jan 28, 2000
AB		MAYNE PHARMA INC	**15MG**	**A205386**	**001**	Oct 28, 2016
AB			**30MG**	**A205386**	**002**	Oct 28, 2016
AB			**60MG**	**A205386**	**003**	Oct 28, 2016
AB			**100MG**	**A205386**	**004**	Oct 28, 2016
AB		NESHER PHARMS	**30MG**	**A076720**	**002**	Dec 23, 2005
AB			**60MG**	**A076720**	**001**	May 19, 2004
AB		NOVEL LABS INC	**15MG**	**A203602**	**001**	Dec 16, 2015
AB			**30MG**	**A203602**	**002**	Dec 16, 2015
AB			**60MG**	**A203602**	**003**	Dec 16, 2015
AB			**100MG**	**A203602**	**004**	Dec 16, 2015
AB			**200MG**	**A203602**	**005**	Dec 16, 2015
AB		RHODES PHARMS	**15MG**	**A074862**	**001**	Jul 07, 1998
AB			**30MG**	**A074862**	**002**	Jul 07, 1998
AB			**60MG**	**A074862**	**003**	Jul 07, 1998
AB			**100MG**	**A074769**	**001**	Jul 02, 1998
AB			**200MG**	**A074769**	**002**	Jul 02, 1998
AB		SPECGX LLC	**15MG**	**A076412**	**001**	Jul 31, 2003
AB			**30MG**	**A076412**	**002**	Jul 31, 2003
AB			**60MG**	**A076412**	**003**	Jul 31, 2003
AB			**100MG**	**A076438**	**001**	Jul 03, 2003
AB			**200MG**	**A076438**	**002**	Jul 03, 2003
AB		STRIDES PHARMA	**15MG**	**A075295**	**001**	Oct 28, 1998
AB			**30MG**	**A075295**	**002**	Oct 28, 1998
AB			**60MG**	**A075295**	**003**	Oct 28, 1998
AB			**100MG**	**A075295**	**004**	Sep 15, 2000
AB			**200MG**	**A075295**	**005**	Sep 15, 2000
AB		SUN PHARM INDS LTD	**15MG**	**A078761**	**001**	May 11, 2012
AB			**30MG**	**A078761**	**002**	May 11, 2012
AB			**60MG**	**A078761**	**003**	May 11, 2012
AB			**100MG**	**A078761**	**004**	May 11, 2012
AB			**200MG**	**A078761**	**005**	May 11, 2012

MS CONTIN

AB	+	PURDUE PHARMA LP	**15MG**	**N019516**	**003**	Sep 12, 1989
AB	+		**30MG**	**N019516**	**001**	May 29, 1987
AB	+		**60MG**	**N019516**	**002**	Apr 08, 1988
AB	+!		**100MG**	**N019516**	**004**	Jan 16, 1990
AB	+		**200MG**	**N019516**	**005**	Nov 08, 1993

MOXIDECTIN

TABLET;ORAL

MOXIDECTIN

	+!	MDGH	2MG	N210867	001	Jun 13, 2018

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

MOXIFLOXACIN HYDROCHLORIDE

	+!	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

	!	MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1		AKORN	**EQ 0.5% BASE**	**A202916**	**001**	Nov 09, 2017
AT1		ALEMBIC PHARMS LTD	**EQ 0.5% BASE**	**A209469**	**001**	Feb 13, 2019
AT1		APOTEX	**EQ 0.5% BASE**	**A090080**	**001**	Jun 30, 2017
AT1		EUGIA PHARMA	**EQ 0.5% BASE**	**A206242**	**001**	Oct 04, 2017
AT1		GLAND PHARMA LTD	**EQ 0.5% BASE**	**A208778**	**001**	Mar 30, 2020
AT1		LUPIN LTD	**EQ 0.5% BASE**	**A202867**	**001**	Sep 04, 2014
AT1		MYLAN	**EQ 0.5% BASE**	**A206447**	**001**	Mar 30, 2020
AT1		UPSHER SMITH LABS	**EQ 0.5% BASE**	**A212616**	**001**	Feb 10, 2021
AT1		WATSON LABS INC	**EQ 0.5% BASE**	**A202525**	**001**	Mar 06, 2015

VIGAMOX

AT1	**+!**	NOVARTIS	**EQ 0.5% BASE**	**N021598**	**001**	Apr 15, 2003

MOXEZA

AT2	**+!**	NOVARTIS	**EQ 0.5% BASE**	**N022428**	**001**	Nov 19, 2010

MOXIFLOXACIN HYDROCHLORIDE

AT2		LUPIN LTD	**EQ 0.5% BASE**	**A204079**	**001**	May 28, 2015

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 400MG BASE**	**A202632**	**001**	Mar 04, 2014
AB		CROSSMEDIKA SA	**EQ 400MG BASE**	**A205348**	**001**	Jan 14, 2016
AB	**!**	DR REDDYS LABS LTD	**EQ 400MG BASE**	**A076938**	**001**	Mar 04, 2014
AB		MSN	**EQ 400MG BASE**	**A208682**	**001**	Sep 22, 2017
AB		NOVEL LABS INC	**EQ 400MG BASE**	**A207285**	**001**	Feb 13, 2017
AB		TEVA PHARMS USA	**EQ 400MG BASE**	**A077437**	**001**	Feb 18, 2014
AB		TORRENT	**EQ 400MG BASE**	**A200160**	**001**	Apr 03, 2014

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB		FOUGERA PHARMS	**2%**	**A065192**	**001**	Nov 30, 2005
AB		GLENMARK PHARMS	**2%**	**A090480**	**001**	Jun 08, 2011
AB	**!**	PADAGIS ISRAEL	**2%**	**A065123**	**001**	Nov 07, 2003
AB		TARO	**2%**	**A065170**	**001**	Sep 23, 2005
AB		TEVA	**2%**	**A065085**	**001**	Nov 07, 2003

CENTANY

BX		PADAGIS US	2%	N050788	001	Dec 04, 2002

MUPIROCIN CALCIUM

CREAM;TOPICAL

MUPIROCIN

AB		ALEOR DERMACEUTICALS	**EQ 2% BASE**	**A213053**	**001**	Nov 16, 2021
AB		ENCUBE	**EQ 2% BASE**	**A213076**	**001**	Aug 31, 2021
AB	**!**	GLENMARK PHARMS INC	**EQ 2% BASE**	**A201587**	**001**	Jan 24, 2013
AB		TARO	**EQ 2% BASE**	**A207116**	**001**	Apr 27, 2020

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**250MG**	**N050722**	**001**	May 03, 1995

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	**250MG**	**A090253**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**250MG**	**A200197**	**001**	Jun 13, 2013
AB		CONCORD BIOTECH LTD	**250MG**	**A210181**	**001**	Jan 08, 2019
AB		HIKMA	**250MG**	**A065410**	**001**	Jul 29, 2008
AB		MYLAN	**250MG**	**A065520**	**001**	May 04, 2009
AB		SANDOZ	**250MG**	**A065379**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**250MG**	**A090055**	**001**	Jun 10, 2010
AB		TEVA PHARMS	**250MG**	**A065491**	**001**	May 06, 2009
AB		ZHEJIANG HISUN PHARM	**250MG**	**A204077**	**001**	Nov 13, 2017

FOR SUSPENSION;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**200MG/ML**	**N050759**	**001**	Oct 01, 1998

MYCOPHENOLATE MOFETIL

AB		ALKEM LABS LTD	**200MG/ML**	**A203005**	**001**	Nov 14, 2014

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB		AMNEAL	**200MG/ML**	**A214871**	**001**	Nov 02, 2021
AB		LANNETT CO INC	**200MG/ML**	**A214525**	**001**	Jul 29, 2021
AB		VISTAPHARM	**200MG/ML**	**A210370**	**001**	Feb 12, 2019

TABLET;ORAL

CELLCEPT

AB	**+!**	ROCHE PALO	**500MG**	**N050723**	**001**	Jun 19, 1997

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	**500MG**	**A065416**	**001**	May 04, 2009
AB		ALKEM LABS LTD	**500MG**	**A091249**	**001**	Nov 04, 2011
AB		CONCORD BIOTECH LTD	**500MG**	**A212087**	**001**	Jul 31, 2020
AB		HIKMA	**500MG**	**A065413**	**001**	Jul 29, 2008
AB		MYLAN	**500MG**	**A065521**	**001**	May 04, 2009
AB		SANDOZ	**500MG**	**A065451**	**001**	Oct 15, 2008
AB		STRIDES PHARMA	**500MG**	**A090456**	**001**	Jun 10, 2010
AB		ZHEJIANG HISUN PHARM	**500MG**	**A204076**	**001**	Nov 16, 2017

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

CELLCEPT

AP	**+!**	ROCHE PALO	**500MG/VIAL**	**N050758**	**001**	Aug 12, 1998

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP		AKORN	**500MG/VIAL**	**A204043**	**001**	Feb 28, 2017
AP		MEITHEAL	**500MG/VIAL**	**A212130**	**001**	Jan 15, 2021
AP		MYLAN LABS LTD	**500MG/VIAL**	**A203859**	**001**	Mar 31, 2017
AP		PAR STERILE PRODUCTS	**500MG/VIAL**	**A203575**	**001**	Oct 28, 2016
AP		ZYDUS PHARMS	**500MG/VIAL**	**A204473**	**001**	Aug 31, 2017

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB		BIOCON PHARMA	**EQ 180MG BASE**	**A214630**	**001**	Nov 29, 2021
AB			**EQ 360MG BASE**	**A214630**	**002**	Nov 29, 2021

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

AB		ACCORD HLTHCARE	**EQ 180MG BASE**	**A202555**	**001**	Aug 23, 2017
AB			**EQ 360MG BASE**	**A202555**	**002**	Aug 23, 2017
AB		ALKEM LABS LTD	**EQ 180MG BASE**	**A208315**	**001**	Sep 23, 2021
AB			**EQ 360MG BASE**	**A208315**	**002**	Sep 23, 2021
AB		AMTA	**EQ 180MG BASE**	**A214376**	**001**	Feb 10, 2021
AB			**EQ 360MG BASE**	**A214376**	**002**	Feb 10, 2021
AB		APOTEX INC	**EQ 180MG BASE**	**A091558**	**001**	Aug 21, 2012
AB			**EQ 360MG BASE**	**A091558**	**002**	Aug 19, 2014
AB		CONCORD BIOTECH LTD	**EQ 180MG BASE**	**A211173**	**001**	Dec 13, 2019
AB			**EQ 360MG BASE**	**A211173**	**002**	Dec 13, 2019
AB		RK PHARMA	**EQ 180MG BASE**	**A091248**	**002**	Jan 08, 2014
AB			**EQ 360MG BASE**	**A091248**	**001**	Jan 08, 2014
AB		TWI PHARMS	**EQ 180MG BASE**	**A214289**	**001**	Nov 03, 2021
AB			**EQ 360MG BASE**	**A214289**	**002**	Nov 03, 2021

MYFORTIC

AB	**+**	NOVARTIS	**EQ 180MG BASE**	**N050791**	**001**	Feb 27, 2004
AB	**+!**		**EQ 360MG BASE**	**N050791**	**002**	Feb 27, 2004

NABILONE

CAPSULE;ORAL

CESAMET

	+!	BAUSCH	1MG	N018677	001	Dec 26, 1985

NABUMETONE

TABLET;ORAL

NABUMETONE

AB		ANNORA PHARMA	**500MG**	**A090445**	**001**	Jan 12, 2011
AB			**750MG**	**A090445**	**002**	Jan 12, 2011
AB		CHARTWELL MOLECULES	**500MG**	**A076009**	**001**	Jan 24, 2003
AB			**750MG**	**A076009**	**002**	Jan 24, 2003
AB		CHARTWELL RX	**500MG**	**A075280**	**001**	Feb 25, 2002
AB			**750MG**	**A075280**	**002**	Feb 25, 2002
AB		INVAGEN PHARMS	**500MG**	**A078671**	**001**	Mar 07, 2008
AB	**!**		**750MG**	**A078671**	**002**	Mar 07, 2008

NABUMETONE

TABLET;ORAL

NABUMETONE

AB		LGM PHARMA	**500MG**	**A203166**	**001**	Aug 30, 2019
AB			**750MG**	**A203166**	**002**	Aug 30, 2019
AB		SCIEGEN PHARMS INC	**500MG**	**A078420**	**001**	Sep 24, 2008
AB			**750MG**	**A078420**	**002**	Sep 24, 2008
AB		WATSON LABS	**500MG**	**A091083**	**001**	Jun 13, 2011
AB			**750MG**	**A091083**	**002**	Jun 13, 2011
		LGM PHARMA	1GM	A203166	003	Aug 30, 2019

NADOLOL

TABLET;ORAL

CORGARD

AB	+	USWM	**20MG**	**N018063**	**005**	Oct 28, 1986
AB	+		**40MG**	**N018063**	**001**	
AB	+!		**80MG**	**N018063**	**002**	

NADOLOL

AB		AMNEAL PHARMS CO	**20MG**	**A208832**	**001**	Jun 02, 2017
AB			**40MG**	**A208832**	**002**	Jun 02, 2017
AB			**80MG**	**A208832**	**003**	Jun 02, 2017
AB		AUROBINDO PHARMA LTD	**40MG**	**A201893**	**001**	Sep 16, 2015
AB			**80MG**	**A201893**	**002**	Sep 16, 2015
AB		BEXIMCO PHARMS USA	**20MG**	**A210955**	**001**	Jul 23, 2018
AB			**40MG**	**A210955**	**002**	Jul 23, 2018
AB			**80MG**	**A210955**	**003**	Jul 23, 2018
AB		HERITAGE PHARMA	**20MG**	**A074229**	**001**	Aug 30, 1996
AB			**40MG**	**A074229**	**002**	Aug 30, 1996
AB			**80MG**	**A074255**	**001**	Jan 24, 1996
AB		INVAGEN PHARMS	**20MG**	**A203455**	**001**	Dec 18, 2015
AB			**40MG**	**A203455**	**002**	Dec 18, 2015
AB			**80MG**	**A203455**	**003**	Dec 18, 2015
AB		LUPIN LTD	**20MG**	**A209309**	**001**	Oct 05, 2017
AB			**40MG**	**A209309**	**002**	Oct 05, 2017
AB			**80MG**	**A209309**	**003**	Oct 05, 2017
AB		RISING	**20MG**	**A074172**	**001**	Oct 31, 1993
AB			**40MG**	**A074172**	**002**	Oct 31, 1993
AB			**80MG**	**A074172**	**003**	Oct 31, 1993
AB		SANDOZ	**20MG**	**A074501**	**001**	Nov 09, 1995
AB			**40MG**	**A074501**	**002**	Nov 09, 1995
AB			**80MG**	**A074501**	**003**	Nov 09, 1995
AB		VGYAAN	**20MG**	**A212856**	**001**	Sep 13, 2019
AB			**40MG**	**A212856**	**002**	Sep 13, 2019
AB			**80MG**	**A212856**	**003**	Sep 13, 2019
AB		ZYDUS PHARMS	**20MG**	**A207761**	**001**	Jul 28, 2017
AB			**40MG**	**A207761**	**002**	Jul 28, 2017
AB			**80MG**	**A207761**	**003**	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

	+!	PFIZER	EQ 0.2MG BASE/SPRAY	N019886	001	Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP		ANTIBIOTICE	**EQ 1GM BASE/VIAL**	**A090560**	**001**	Oct 03, 2011
AP			**EQ 2GM BASE/VIAL**	**A090560**	**002**	Oct 03, 2011
AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A091613**	**001**	Dec 26, 2012
AP			**EQ 2GM BASE/VIAL**	**A091613**	**002**	Dec 26, 2012
AP			**EQ 10GM BASE/VIAL**	**A091614**	**001**	Dec 26, 2012
AP		FRESENIUS	**EQ 10GM BASE/VIAL**	**A206761**	**001**	Jun 02, 2020
AP		ISTITUTO BIO ITA SPA	**EQ 1GM BASE/VIAL**	**A090002**	**001**	Jun 30, 2011
AP			**EQ 2GM BASE/VIAL**	**A090002**	**002**	Jun 30, 2011
AP			**EQ 10GM BASE/VIAL**	**A090005**	**001**	Apr 20, 2011
AP		SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A090582**	**001**	Aug 24, 2012
AP			**EQ 2GM BASE/VIAL**	**A090582**	**002**	Aug 24, 2012
AP			**EQ 10GM BASE/VIAL**	**A090580**	**001**	Aug 24, 2012
AP	!	SANDOZ	**EQ 1GM BASE/VIAL**	**A062527**	**002**	Aug 02, 1984
AP	!		**EQ 1GM BASE/VIAL**	**A062732**	**001**	Dec 23, 1986
AP	!		**EQ 2GM BASE/VIAL**	**A062527**	**003**	Aug 02, 1984

NAFCILLIN SODIUM

INJECTABLE;INJECTION

NAFCILLIN SODIUM

AP	**!**		**EQ 2GM BASE/VIAL**	**A062732**	**002**	Dec 23, 1986
AP	**!**		**EQ 10GM BASE/VIAL**	**A062527**	**004**	Aug 02, 1984

NALLPEN IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+!		EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		TARO PHARMS	**2%**	**A206901**	**001**	Jan 06, 2016
AB		TOLMAR	**2%**	**A206960**	**001**	Apr 10, 2017
AB		XIROMED	**2.0%**	**A210038**	**001**	Sep 22, 2020

NAFTIN

AB	**+!**	SEBELA IRELAND LTD	**2%**	**N019599**	**002**	Jan 13, 2012

NAFTIFINE HYDROCHLORIDE

	!	TARO PHARMS	1%	A205975	001	Sep 08, 2016

GEL;TOPICAL

NAFTIFINE HYDROCHLORIDE

AB		TOLMAR	**1%**	**A206165**	**001**	Mar 20, 2019

NAFTIN

AB	**+!**	SEBELA IRELAND LTD	**1%**	**N019356**	**001**	Jun 18, 1990
AB	**+!**		**2%**	**N204286**	**001**	Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

AP	**!**	HOSPIRA	**10MG/ML**	**A070914**	**001**	Feb 03, 1989
AP	**!**		**10MG/ML**	**A070915**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070916**	**001**	Feb 03, 1989
AP	**!**		**20MG/ML**	**A070918**	**001**	Feb 03, 1989

NALDEMEDINE TOSYLATE

TABLET;ORAL

SYMPROIC

	+!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017

NALOXEGOL OXALATE

TABLET;ORAL

MOVANTIK

	+	REDHILL	EQ 12.5MG BASE	N204760	001	Sep 16, 2014
	+!		EQ 25MG BASE	N204760	002	Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

AP		HIKMA	**0.4MG/ML**	**A070299**	**001**	Sep 24, 1986

NALOXONE HYDROCHLORIDE

AP		AKORN	**0.4MG/ML**	**A208871**	**001**	Feb 28, 2017
AP			**0.4MG/ML**	**A208872**	**001**	Mar 14, 2017
AP		BAXTER HLTHCARE CORP	**0.4MG/ML**	**A214785**	**001**	Jan 29, 2021
AP		DR REDDYS	**1MG/ML**	**A213209**	**001**	Mar 16, 2020
AP		EUGIA PHARMA	**0.4MG/ML**	**A212455**	**001**	Oct 15, 2019
AP			**1MG/ML**	**A213279**	**001**	Jan 14, 2021
AP			**0.4MG/ML**	**A212456**	**001**	Nov 04, 2019
AP	**!**	HOSPIRA	**0.4MG/ML**	**A070172**	**001**	Sep 24, 1986
AP	**!**		**0.4MG/ML**	**A070256**	**001**	Jan 07, 1987
AP	**!**		**0.4MG/ML**	**A070257**	**001**	Jan 07, 1987
AP	**!**	INTL MEDICATION	**1MG/ML**	**A072076**	**001**	Mar 24, 1988
AP		MYLAN INSTITUTIONAL	**0.4MG/ML**	**A204997**	**001**	Mar 06, 2014
AP			**0.4MG/ML**	**A205014**	**001**	Jun 29, 2016
AP		SOMERSET THERAPS LLC	**0.4MG/ML**	**A207633**	**001**	Aug 08, 2017
AP			**0.4MG/ML**	**A207634**	**001**	Jul 26, 2017

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

ZIMHI

	+!	ADAMIS PHARMS CORP	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021

SPRAY;NASAL

KLOXXADO

	+!	HIKMA	8MG/SPRAY	N212045	001	Apr 29, 2021

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NALOXONE HYDROCHLORIDE

AB		TEVA PHARMS USA	**4MG/SPRAY**	**A209522**	**001**	Apr 19, 2019

NARCAN

AB	**+!**	EMERGENT	**4MG/SPRAY**	**N208411**	**001**	Nov 18, 2015

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		LUPIN	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075735**	**001**	Jul 11, 2001
AB		SUN PHARM INDS LTD	**EQ 0.5MG BASE;EQ 50MG BASE**	**A075523**	**001**	Mar 17, 2000
AB	**!**	WATSON LABS	**EQ 0.5MG BASE;EQ 50MG BASE**	**A074736**	**001**	Jan 21, 1997

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

VIVITROL

	+!	ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**50MG**	**A091205**	**001**	Aug 17, 2011
AB		BARR	**50MG**	**A074918**	**001**	May 08, 1998
AB		CHARTWELL	**50MG**	**A207905**	**001**	Jul 21, 2017
AB		ELITE LABS	**50MG**	**A075274**	**001**	May 26, 1999
AB	**!**	SPECGX LLC	**50MG**	**A076264**	**002**	Mar 22, 2002
AB		SUN PHARM	**50MG**	**A090356**	**001**	Feb 24, 2012
		SPECGX LLC	25MG	A076264	001	Mar 22, 2002
			100MG	A076264	003	Mar 22, 2002

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB	**+**	ATNAHS PHARMA US	**25MG/ML**	**N018965**	**001**	Mar 23, 1987

NAPROXEN

AB		AMNEAL	**25MG/ML**	**A212705**	**001**	Jul 31, 2020
AB	**!**	HIKMA	**25MG/ML**	**A074190**	**001**	Mar 30, 1994
AB		NOVITIUM PHARMA	**25MG/ML**	**A211910**	**001**	Mar 10, 2021

TABLET;ORAL

NAPROSYN

AB	**+!**	ATNAHS PHARMA US	**500MG**	**N017581**	**004**	Apr 15, 1982

NAPROXEN

AB		AMNEAL PHARMS NY	**250MG**	**A075927**	**001**	Dec 18, 2001
AB			**375MG**	**A075927**	**002**	Dec 18, 2001
AB			**500MG**	**A075927**	**003**	Dec 18, 2001
AB		AUROBINDO PHARMA LTD	**250MG**	**A200429**	**001**	Nov 08, 2011
AB			**375MG**	**A200429**	**002**	Nov 08, 2011
AB			**500MG**	**A200429**	**003**	Nov 08, 2011
AB		GLENMARK GENERICS	**250MG**	**A078250**	**001**	Mar 28, 2007
AB			**375MG**	**A078250**	**002**	Mar 28, 2007
AB			**500MG**	**A078250**	**003**	Mar 28, 2007
AB		GRANULES	**250MG**	**A074140**	**001**	Dec 21, 1993
AB			**375MG**	**A074140**	**002**	Dec 21, 1993
AB			**500MG**	**A074140**	**003**	Dec 21, 1993
AB		INVAGEN PHARMS	**250MG**	**A091305**	**001**	Aug 24, 2011
AB			**375MG**	**A091305**	**002**	Aug 24, 2011
AB			**500MG**	**A091305**	**003**	Aug 24, 2011
AB		L PERRIGO CO	**250MG**	**A077339**	**001**	Apr 27, 2005
AB			**375MG**	**A077339**	**002**	Apr 27, 2005
AB			**500MG**	**A077339**	**003**	Apr 27, 2005
AB		MARKSANS PHARMA	**250MG**	**A091416**	**001**	Feb 14, 2011
AB			**375MG**	**A091416**	**002**	Feb 14, 2011
AB			**500MG**	**A091416**	**003**	Feb 14, 2011
AB		SCIEGEN PHARMS INC	**250MG**	**A212517**	**001**	Feb 21, 2020
AB			**375MG**	**A212517**	**002**	Feb 21, 2020
AB			**500MG**	**A212517**	**003**	Feb 21, 2020
AB		TEVA	**250MG**	**A074201**	**001**	Dec 21, 1993
AB			**375MG**	**A074201**	**002**	Dec 21, 1993
AB			**500MG**	**A074201**	**003**	Dec 21, 1993
AB		ZYDUS PHARMS USA	**250MG**	**A078620**	**001**	Jun 07, 2007
AB			**375MG**	**A078620**	**002**	Jun 07, 2007
AB			**500MG**	**A078620**	**003**	Jun 07, 2007

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB	**+!**	ATNAHS PHARMA US	**375MG**	**N020067**	**002**	Oct 14, 1994
AB	**+!**		**500MG**	**N020067**	**003**	Oct 14, 1994

NAPROXEN

AB		NUVO PHARMS INC	**375MG**	**A091432**	**001**	Sep 19, 2011
AB			**500MG**	**A091432**	**002**	Sep 19, 2011
AB		TEVA	**375MG**	**A075227**	**001**	Jun 30, 1998
AB			**500MG**	**A075227**	**002**	Jun 30, 1998

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX DS

AB	**+!**	ATNAHS PHARMA US	**EQ 500MG BASE**	**N018164**	**003**	Sep 30, 1987

NAPROXEN SODIUM

AB		AMNEAL PHARMS NY	**EQ 250MG BASE**	**A078432**	**001**	Apr 25, 2007
AB			**EQ 500MG BASE**	**A078432**	**002**	Apr 25, 2007
AB		AUROBINDO PHARMA LTD	**EQ 250MG BASE**	**A200629**	**001**	Oct 31, 2011
AB			**EQ 500MG BASE**	**A200629**	**002**	Oct 31, 2011
AB		DR REDDYS LABS LTD	**EQ 250MG BASE**	**A078486**	**001**	Jul 26, 2007
AB			**EQ 500MG BASE**	**A078486**	**002**	Jul 26, 2007
AB		GLENMARK PHARMS LTD	**EQ 250MG BASE**	**A078314**	**001**	Apr 27, 2007
AB			**EQ 500MG BASE**	**A078314**	**002**	Apr 27, 2007
AB		SCIEGEN PHARMS INC	**EQ 250MG BASE**	**A212199**	**001**	Oct 30, 2019
AB			**EQ 500MG BASE**	**A212199**	**002**	Oct 30, 2019

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB	**+**	ALMATICA	**EQ 375MG BASE**	**N020353**	**001**	Jan 05, 1996
AB	**+**		**EQ 500MG BASE**	**N020353**	**002**	Jan 05, 1996
AB	**+!**		**EQ 750MG BASE**	**N020353**	**003**	Jan 05, 1996

NAPROXEN SODIUM

AB		ACTAVIS LABS FL INC	**EQ 375MG BASE**	**A075416**	**002**	Apr 23, 2003
AB			**EQ 500MG BASE**	**A075416**	**001**	Aug 27, 2002
AB			**EQ 750MG BASE**	**A075416**	**003**	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB		AUROBINDO PHARMA LTD	**500MG;EQ 85MG BASE**	**A207457**	**001**	Feb 15, 2018
AB		RISING	**500MG;EQ 85MG BASE**	**A090872**	**001**	Sep 04, 2018
AB		SUN PHARM	**500MG;EQ 85MG BASE**	**A202803**	**001**	Jul 20, 2018

TREXIMET

AB	**+!**	CURRAX	**500MG;EQ 85MG BASE**	**N021926**	**001**	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

AB	**+**	GLAXOSMITHKLINE LLC	**EQ 1MG BASE**	**N020763**	**002**	Feb 10, 1998
AB	**+!**		**EQ 2.5MG BASE**	**N020763**	**001**	Feb 10, 1998

NARATRIPTAN

AB		HERITAGE PHARMS INC	**EQ 1MG BASE**	**A200502**	**001**	Feb 28, 2011
AB			**EQ 2.5MG BASE**	**A200502**	**002**	Feb 28, 2011
AB		HIKMA	**EQ 1MG BASE**	**A090381**	**001**	Jul 07, 2010
AB			**EQ 2.5MG BASE**	**A090381**	**002**	Jul 07, 2010
AB		ORBION PHARMS	**EQ 1MG BASE**	**A091441**	**001**	Apr 30, 2012
AB			**EQ 2.5MG BASE**	**A091441**	**002**	Apr 30, 2012
AB		PADAGIS US	**EQ 1MG BASE**	**A091326**	**001**	Jul 08, 2010
AB			**EQ 2.5MG BASE**	**A091326**	**002**	Jul 08, 2010
AB		SUN PHARM INDS LTD	**EQ 2.5MG BASE**	**A091552**	**001**	Feb 14, 2011

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

	+!	EYEVANCE	5%	N050514	001	

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB		CADILA PHARMS LTD	**60MG**	**A206432**	**001**	Apr 19, 2019
AB			**120MG**	**A206432**	**002**	Apr 19, 2019
AB		DR REDDYS LABS LTD	**60MG**	**A077461**	**001**	Sep 09, 2009
AB			**120MG**	**A077461**	**002**	Sep 09, 2009

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE						
AB		RISING	**60MG**	**A205544**	**001**	Jun 18, 2018
AB			**120MG**	**A205544**	**002**	Jun 18, 2018
AB		STRIDES PHARMA	**60MG**	**A077463**	**001**	Sep 09, 2009
AB			**120MG**	**A077463**	**002**	Sep 09, 2009
AB		WATSON LABS	**60MG**	**A077462**	**001**	Mar 30, 2011
AB			**120MG**	**A077462**	**002**	Mar 30, 2011
AB		ZYDUS PHARMS	**60MG**	**A205248**	**001**	Jul 06, 2016
AB	!		**120MG**	**A205248**	**002**	Jul 06, 2016

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC						
AB	+	ALLERGAN	**EQ 2.5MG BASE**	**N021742**	**002**	Dec 17, 2007
AB	+		**EQ 5MG BASE**	**N021742**	**003**	Dec 17, 2007
AB	+		**EQ 10MG BASE**	**N021742**	**004**	Dec 17, 2007
AB	+!		**EQ 20MG BASE**	**N021742**	**005**	Oct 08, 2008
NEBIVOLOL HYDROCHLORIDE						
AB		ANI PHARMS	**EQ 2.5MG BASE**	**A203659**	**001**	Apr 16, 2015
AB			**EQ 5MG BASE**	**A203659**	**002**	Apr 16, 2015
AB			**EQ 10MG BASE**	**A203659**	**003**	Apr 16, 2015
AB			**EQ 20MG BASE**	**A203659**	**004**	Apr 16, 2015
AB		AUROBINDO PHARMA LTD	**EQ 2.5MG BASE**	**A211053**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A211053**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A211053**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A211053**	**004**	Dec 17, 2021
AB		CADILA PHARMS LTD	**EQ 2.5MG BASE**	**A208717**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A208717**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A208717**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A208717**	**004**	Dec 17, 2021
AB		HETERO LABS LTD III	**EQ 2.5MG BASE**	**A203825**	**001**	Nov 03, 2020
AB			**EQ 5MG BASE**	**A203825**	**002**	Nov 03, 2020
AB			**EQ 10MG BASE**	**A203825**	**003**	Nov 03, 2020
AB			**EQ 20MG BASE**	**A203825**	**004**	Nov 03, 2020
AB		INDCHEMIE HEALTH	**EQ 2.5MG BASE**	**A203828**	**001**	Jul 29, 2015
AB			**EQ 5MG BASE**	**A203828**	**002**	Jul 29, 2015
AB			**EQ 10MG BASE**	**A203828**	**003**	Jul 29, 2015
AB			**EQ 20MG BASE**	**A203828**	**004**	Jul 29, 2015
AB		REYOUNG	**EQ 2.5MG BASE**	**A212917**	**001**	Dec 17, 2021
AB			**EQ 5MG BASE**	**A212917**	**002**	Dec 17, 2021
AB			**EQ 10MG BASE**	**A212917**	**003**	Dec 17, 2021
AB			**EQ 20MG BASE**	**A212917**	**004**	Dec 17, 2021
AB		TORRENT	**EQ 2.5MG BASE**	**A203966**	**001**	Mar 02, 2018
AB			**EQ 5MG BASE**	**A203966**	**002**	Mar 02, 2018
AB			**EQ 10MG BASE**	**A203966**	**003**	Mar 02, 2018
AB			**EQ 20MG BASE**	**A203966**	**004**	Mar 02, 2018

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALOCRIL						
AT	+!	ALLERGAN	**2%**	**N021009**	**001**	Dec 08, 1999
NEDOCROMIL SODIUM						
AT		AKORN	**2%**	**A090638**	**001**	Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE						
		TEVA	50MG	A076037	001	Sep 16, 2003
			100MG	A076037	002	Sep 16, 2003
			150MG	A076037	003	Sep 16, 2003
			200MG	A076037	004	Sep 16, 2003
	!		250MG	A076037	005	Sep 16, 2003

NELARABINE

INJECTABLE;INTRAVENOUS

ARRANON						
AP	+!	NOVARTIS	**250MG/50ML (5MG/ML)**	**N021877**	**001**	Oct 28, 2005
NELARABINE						
AP		ZYDUS PHARMS	**250MG/50ML (5MG/ML)**	**A215037**	**001**	Nov 17, 2021

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

+!	AGOURON PHARMS	EQ 250MG BASE	N020779	001	Mar 14, 1997
+!		EQ 625MG BASE	N021503	001	Apr 30, 2003

NEOMYCIN SULFATE

TABLET;ORAL

NEOMYCIN SULFATE

AA	**!**	TEVA	**500MG**	**A060304**	**001**	
AA		XGEN PHARMS	**500MG**	**A065220**	**001**	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A062664**	**001**	Apr 08, 1986
AT		XGEN PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065106**	**001**	Jan 31, 2006
AT			**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A065108**	**001**	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	**!**	MONARCH PHARMS	**EQ 40MG BASE/ML;200,000 UNITS/ML**	**A060707**	**001**	

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

AP	**+!**	EXELA PHARMA	**5MG/10ML (0.5MG/ML)**	**N204078**	**001**	May 31, 2013
AP	**+!**		**10MG/10ML (1MG/ML)**	**N204078**	**002**	May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		AM REGENT	**5MG/10ML (0.5MG/ML)**	**A209182**	**001**	May 04, 2018
AP			**10MG/10ML (1MG/ML)**	**A209182**	**002**	May 04, 2018
AP		AMNEAL	**5MG/10ML (0.5MG/ML)**	**A210051**	**001**	Jun 15, 2018
AP			**10MG/10ML (1MG/ML)**	**A210051**	**002**	Jun 15, 2018
AP		AMPHASTAR PHARMS INC	**5MG/10ML (0.5MG/ML)**	**A209933**	**001**	Sep 25, 2017
AP			**10MG/10ML (1MG/ML)**	**A209933**	**002**	Sep 25, 2017
AP		AMRING PHARMS	**5MG/10ML (0.5MG/ML)**	**A210989**	**001**	Aug 22, 2018
AP			**10MG/10ML (1MG/ML)**	**A210989**	**002**	Aug 22, 2018
AP		BE PHARMS	**5MG/10ML (0.5MG/ML)**	**A212512**	**001**	May 13, 2019
AP			**10MG/10ML (1MG/ML)**	**A212512**	**002**	May 13, 2019
AP		CAPLIN	**5MG/10ML (0.5MG/ML)**	**A213074**	**001**	Apr 20, 2021
AP			**10MG/10ML (1MG/ML)**	**A213074**	**002**	Apr 20, 2021
AP		DR REDDYS	**5MG/10ML (0.5MG/ML)**	**A209135**	**001**	Jul 10, 2018
AP			**10MG/10ML (1MG/ML)**	**A209135**	**002**	Jul 10, 2018
AP		EUROHLTH INTL SARL	**5MG/10ML (0.5MG/ML)**	**A207042**	**001**	Dec 28, 2015
AP			**10MG/10ML (1MG/ML)**	**A207042**	**002**	Dec 28, 2015
AP		GLAND PHARMA LTD	**5MG/10ML (0.5MG/ML)**	**A212968**	**001**	Oct 16, 2019
AP			**10MG/10ML (1MG/ML)**	**A212968**	**002**	Oct 16, 2019
AP		INDOCO	**5MG/10ML (0.5MG/ML)**	**A210652**	**001**	Oct 01, 2021
AP			**10MG/10ML (1MG/ML)**	**A210652**	**002**	Oct 01, 2021
AP		MEITHEAL	**5MG/10ML (0.5MG/ML)**	**A212804**	**001**	Apr 05, 2021
AP			**10MG/10ML (1MG/ML)**	**A212804**	**002**	Apr 05, 2021
AP		PAR STERILE PRODUCTS	**5MG/10ML (0.5MG/ML)**	**A208405**	**001**	Apr 26, 2017
AP			**10MG/10ML (1MG/ML)**	**A208405**	**002**	Apr 26, 2017
	+!	FRESENIUS KABI USA	3MG/3ML (1MG/ML)	N203629	003	Sep 18, 2018
	+!		5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015
	+!		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015

NEPAFENAC

SUSPENSION/DROPS;OPHTHALMIC

ILEVRO

+!	NOVARTIS	0.3%	N203491	001	Oct 16, 2012

NEVANAC

+!	NOVARTIS	0.1%	N021862	001	Aug 19, 2005

NERATINIB MALEATE

TABLET;ORAL

NERLYNX

+!	PUMA BIOTECH	EQ 40MG BASE	N208051	001	Jul 17, 2017

NETARSUDIL MESYLATE

SOLUTION/DROPS;OPHTHALMIC

RHOPRESSA

+!	AERIE PHARMS INC	EQ 0.02% BASE	N208254	001	Dec 18, 2017

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE;ORAL

AKYNZEO

	+!	HELSINN HLTHCARE	300MG;EQ 0.5MG BASE	N205718	001	Oct 10, 2014

NEVIRAPINE

SUSPENSION;ORAL

NEVIRAPINE

AA		AUROBINDO	**50MG/5ML**	**A077702**	**001**	May 22, 2012
AA		CIPLA	**50MG/5ML**	**A207684**	**001**	Aug 03, 2017

VIRAMUNE

AA	**+!**	BOEHRINGER INGELHEIM	**50MG/5ML**	**N020933**	**001**	Sep 11, 1998

TABLET;ORAL

NEVIRAPINE

AB		AUROBINDO	**200MG**	**A077521**	**001**	May 22, 2012
AB		CIPLA	**200MG**	**A077956**	**001**	May 22, 2012
AB		HETERO LABS LTD III	**200MG**	**A078584**	**001**	May 22, 2012
AB		MACLEODS PHARMS LTD	**200MG**	**A090688**	**001**	Jan 14, 2019
AB		MICRO LABS LTD	**200MG**	**A203080**	**001**	May 22, 2012
AB		MYLAN PHARMS INC	**200MG**	**A202523**	**001**	May 22, 2012
AB		PRINSTON INC	**200MG**	**A078644**	**001**	May 22, 2012
AB		STRIDES PHARMA	**200MG**	**A078195**	**001**	May 22, 2012

VIRAMUNE

AB	**+!**	BOEHRINGER INGELHEIM	**200MG**	**N020636**	**001**	Jun 21, 1996

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB		ALVOGEN	**100MG**	**A204621**	**002**	Nov 09, 2015
AB			**400MG**	**A204621**	**001**	Jul 10, 2015
AB		AUROBINDO PHARMA LTD	**100MG**	**A208616**	**001**	Nov 23, 2016
AB			**400MG**	**A207698**	**001**	Feb 28, 2017
AB		MACLEODS PHARMS LTD	**400MG**	**A206879**	**001**	Oct 06, 2017
AB		MYLAN	**400MG**	**A205651**	**001**	Oct 27, 2014
AB		SANDOZ INC	**400MG**	**A203411**	**001**	Apr 03, 2014

VIRAMUNE XR

AB	**+**	BOEHRINGER INGELHEIM	**100MG**	**N201152**	**002**	Nov 08, 2012
AB	**+!**		**400MG**	**N201152**	**001**	Mar 25, 2011

NIACIN

TABLET;ORAL

NIACOR

	!	AVONDALE PHARMS	500MG	A040378	001	May 03, 2000

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		AMNEAL PHARMS	**500MG**	**A203578**	**001**	Jul 24, 2015
AB			**750MG**	**A204178**	**001**	Dec 11, 2015
AB			**1GM**	**A203578**	**002**	Jul 24, 2015
AB		AUROBINDO PHARMA LTD	**500MG**	**A209236**	**001**	Feb 01, 2018
AB			**750MG**	**A209236**	**002**	Feb 01, 2018
AB			**1GM**	**A209236**	**003**	Feb 01, 2018
AB		BARR	**500MG**	**A076378**	**001**	Apr 26, 2005
AB			**750MG**	**A076378**	**002**	Apr 26, 2005
AB			**1GM**	**A076250**	**001**	Apr 14, 2005
AB		BEIJING	**500MG**	**A214428**	**001**	Nov 22, 2021
AB			**1GM**	**A214428**	**002**	Nov 22, 2021
AB		LANNETT CO INC	**500MG**	**A203899**	**001**	Jun 16, 2017
AB			**1GM**	**A203899**	**002**	Jun 16, 2017
AB		LUPIN LTD	**500MG**	**A090860**	**001**	Mar 20, 2014
AB			**750MG**	**A090892**	**001**	Mar 20, 2014
AB			**1GM**	**A090446**	**001**	Mar 20, 2014
AB		SUN PHARM	**500MG**	**A200484**	**001**	Apr 23, 2014
AB	**!**		**750MG**	**A201273**	**001**	Apr 23, 2014
AB	**!**		**1GM**	**A200484**	**002**	Apr 23, 2014

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		ANI PHARMS	**20MG**	**A074670**	**001**	Oct 28, 1996
AB			**30MG**	**A074670**	**002**	Oct 28, 1996
AB		EPIC PHARMA	**20MG**	**A074928**	**001**	Mar 19, 1998
AB	**!**		**30MG**	**A074928**	**002**	Mar 19, 1998

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP	**!**	AM REGENT	**25MG/10ML (2.5MG/ML)**	**A090534**	**001**	Nov 17, 2009
AP		EUGIA PHARMA	**25MG/10ML (2.5MG/ML)**	**A211121**	**001**	Apr 08, 2021
AP		SUN PHARM	**25MG/10ML (2.5MG/ML)**	**N078405**	**001**	Nov 17, 2009
	+!	EXELA PHARMA SCIENCE	25MG/10ML (2.5MG/ML)	N022276	001	Jul 24, 2008

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

	+!	CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

	+!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

	+!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

	+!	EXELA PHARMA SCIENCE	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016
	+!		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016

NICOTINE

INHALANT;ORAL

NICOTROL

	+!	PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED;NASAL

NICOTROL

	+!	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		ACELLA	**10MG**	**A072781**	**001**	Jul 30, 1993
AB		ACTAVIS ELIZABETH	**10MG**	**A072579**	**001**	Jan 08, 1991
AB			**20MG**	**A072556**	**001**	Sep 20, 1990
AB		HERITAGE PHARMA	**10MG**	**A202644**	**001**	Apr 25, 2013
AB			**20MG**	**A202644**	**002**	Apr 25, 2013
AB		LEADING PHARMA LLC	**10MG**	**A073250**	**001**	Oct 08, 1991
AB			**20MG**	**A074045**	**001**	Apr 30, 1992

PROCARDIA

AB	**+!**	PFIZER	**10MG**	**N018482**	**001**	

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB1		AUROBINDO PHARMA LTD	**30MG**	**A213361**	**001**	Jul 19, 2021
AB1			**60MG**	**A213361**	**002**	Jul 19, 2021
AB1			**90MG**	**A213361**	**003**	Jul 19, 2021
AB1		NOVAST LABS	**30MG**	**A202987**	**001**	Aug 25, 2016
AB1	**!**		**60MG**	**A202987**	**002**	Aug 25, 2016
AB1	**!**		**90MG**	**A202987**	**003**	Aug 25, 2016
AB1		VALEANT PHARMS NORTH	**30MG**	**A075269**	**001**	Dec 04, 2000
AB1			**60MG**	**A075269**	**002**	Dec 04, 2000
AB1			**90MG**	**A076070**	**001**	Aug 16, 2002
AB1		ZYDUS PHARMS	**30MG**	**A210184**	**001**	Jun 29, 2018
AB1			**60MG**	**A210184**	**002**	Jun 29, 2018
AB1			**90MG**	**A210184**	**003**	Jun 29, 2018
AB2		ELITE PHARM SOLUTION	**90MG**	**A212016**	**001**	Nov 18, 2020
AB2		NOVAST LABS	**30MG**	**A210614**	**001**	Mar 12, 2019
AB2			**60MG**	**A210614**	**002**	Mar 12, 2019
AB2			**90MG**	**A210614**	**003**	Mar 12, 2019
AB2		OSMOTICA PHARM US	**30MG**	**A077127**	**001**	Nov 21, 2005
AB2			**60MG**	**A077127**	**002**	Nov 21, 2005
AB2			**90MG**	**A077127**	**003**	Oct 03, 2007
AB2		SPIL	**30MG**	**A210838**	**001**	Apr 16, 2019
AB2			**60MG**	**A210838**	**002**	Apr 16, 2019
AB2			**90MG**	**A210838**	**003**	Apr 16, 2019
AB2		TWI PHARMS	**30MG**	**A203126**	**001**	Apr 03, 2014
AB2			**60MG**	**A203126**	**002**	Apr 03, 2014
AB2			**90MG**	**A203126**	**003**	Apr 03, 2014
AB2		VALEANT PHARMS NORTH	**30MG**	**A075289**	**002**	Feb 06, 2001
AB2			**60MG**	**A075289**	**001**	Sep 27, 2000
AB2		ZYDUS PHARMS	**30MG**	**A210012**	**001**	Dec 19, 2017
AB2			**60MG**	**A210012**	**002**	Dec 19, 2017

NIFEDIPINE
TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

AB2			**90MG**	**A210012**	**003**	Dec 19, 2017
PROCARDIA XL							
AB2	+	PFIZER	**30MG**	**N019684**	**001**	Sep 06, 1989
AB2	+		**60MG**	**N019684**	**002**	Sep 06, 1989
AB2	+!		**90MG**	**N019684**	**003**	Sep 06, 1989

NIFURTIMOX
TABLET;ORAL
LAMPIT

+	BAYER HEALTHCARE	30MG	N213464	001	Aug 06, 2020
+!		120MG	N213464	002	Aug 06, 2020

NILOTINIB HYDROCHLORIDE
CAPSULE;ORAL
TASIGNA

+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018
+		EQ 150MG BASE	N022068	002	Jun 17, 2010
+!		EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE
TABLET;ORAL
NILANDRON

AB	**+!**	CONCORDIA	**150MG**	**N020169**	**002**	Apr 30, 1999
NILUTAMIDE							
AB		ANI PHARMS	**150MG**	**A207631**	**001**	Jul 15, 2016

NIMODIPINE
CAPSULE;ORAL
NIMODIPINE

AB	**!**	BIONPHARMA INC	**30MG**	**A076740**	**001**	Jan 17, 2008
AB		HERITAGE PHARMS INC	**30MG**	**A077811**	**001**	May 02, 2007
AB		THEPHARMANETWORK LLC	**30MG**	**A090103**	**001**	Apr 07, 2014

SOLUTION;ORAL
NYMALIZE

+!	ARBOR PHARMS LLC	6MG/ML	N203340	002	Apr 08, 2020

NINTEDANIB ESYLATE
CAPSULE;ORAL
OFEV

+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014
+!		EQ 150MG BASE	N205832	002	Oct 15, 2014

NIRAPARIB TOSYLATE
CAPSULE;ORAL
ZEJULA

+!	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017

NISOLDIPINE
TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

AB		MYLAN	**8.5MG**	**A091001**	**001**	Jan 26, 2011
AB			**17MG**	**A091001**	**002**	Jan 26, 2011
AB			**34MG**	**A091001**	**004**	Jan 26, 2011
SULAR							
AB	**+!**	COVIS	**8.5MG**	**N020356**	**008**	Jan 02, 2008
AB	**+!**		**17MG**	**N020356**	**007**	Jan 02, 2008
AB	**+!**		**34MG**	**N020356**	**005**	Jan 02, 2008
NISOLDIPINE							
!		MYLAN	20MG	A079051	001	Jul 25, 2008
			25.5MG	A091001	003	Jan 26, 2011
			30MG	A079051	002	Jul 25, 2008
!			40MG	A079051	003	Jul 25, 2008

NITAZOXANIDE
FOR SUSPENSION;ORAL
ALINIA

+!	ROMARK	100MG/5ML	N021498	001	Nov 22, 2002

TABLET;ORAL
ALINIA

AB	**+!**	ROMARK	**500MG**	**N021497**	**001**	Jul 21, 2004

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

AB		RISING	**500MG**	**A213820**	**001**	Nov 27, 2020

NITISINONE

CAPSULE;ORAL

NITISINONE

AB		NOVITIUM PHARMA	**2MG**	**A211041**	**001**	Aug 26, 2019
AB			**5MG**	**A211041**	**002**	Aug 26, 2019
AB			**10MG**	**A211041**	**003**	Aug 26, 2019

ORFADIN

AB	**+**	SWEDISH ORPHAN	**2MG**	**N021232**	**001**	Jan 18, 2002
AB	**+**		**5MG**	**N021232**	**002**	Jan 18, 2002
AB	**+**		**10MG**	**N021232**	**003**	Jan 18, 2002
	+!		20MG	N021232	004	Jun 13, 2016

SUSPENSION;ORAL

ORFADIN

	+!	SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016

TABLET;ORAL

NITYR

	+	CYCLE PHARMS LTD	2MG	N209449	001	Jul 26, 2017
	+		5MG	N209449	002	Jul 26, 2017
	+!		10MG	N209449	003	Jul 26, 2017

NITRIC OXIDE

GAS;INHALATION

INOMAX

AA	**+!**	MALLINCKRODT HOSP	**800PPM**	**N020845**	**003**	Dec 23, 1999

NOXIVENT

AA		PRAXAIR DISTRIBUTION	**800PPM**	**A207141**	**002**	Oct 02, 2018

GENOSYL

	+!	VERO BIOTECH	800PPM	N202860	001	Dec 20, 2019

NOXIVENT

		PRAXAIR DISTRIBUTION	100PPM	A207141	001	Oct 02, 2018

NITROFURANTOIN

SUSPENSION;ORAL

FURADANTIN

AB	**+!**	CASPER PHARMA LLC	**25MG/5ML**	**N009175**	**001**	

NITROFURANTOIN

AB		ACTAVIS MID ATLANTIC	**25MG/5ML**	**A205180**	**001**	May 03, 2016
AB		AMNEAL PHARMS	**25MG/5ML**	**A201679**	**001**	May 11, 2011
AB		NOSTRUM LABS INC	**25MG/5ML**	**A201355**	**001**	Aug 14, 2013
AB		NOVEL LABS INC	**25MG/5ML**	**A201693**	**001**	Sep 08, 2014

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

AB	**+**	ALMATICA	**25MG**	**N016620**	**003**	
AB	**+**		**50MG**	**N016620**	**001**	
AB	**+!**		**100MG**	**N016620**	**002**	

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	**25MG**	**A091095**	**001**	Jun 18, 2015
AB			**50MG**	**A091095**	**002**	Jun 18, 2015
AB			**100MG**	**A091095**	**003**	Jun 18, 2015
AB		ALEMBIC PHARMS LTD	**25MG**	**A211935**	**001**	Jun 25, 2021
AB			**50MG**	**A211935**	**002**	Jun 25, 2021
AB			**100MG**	**A211935**	**003**	Jun 25, 2021
AB		IMPAX LABS INC	**50MG**	**A073671**	**001**	Jan 28, 1993
AB			**100MG**	**A073652**	**001**	Jan 28, 1993
AB		NOVEL LABS INC	**50MG**	**A203233**	**001**	Jul 09, 2018
AB			**100MG**	**A203233**	**002**	Jul 09, 2018
AB		SUN PHARM INDUSTRIES	**25MG**	**A201722**	**001**	Feb 16, 2016
AB			**50MG**	**A201722**	**002**	Feb 16, 2016
AB			**100MG**	**A201722**	**003**	Feb 16, 2016
AB		ZYDUS PHARMS	**50MG**	**A205005**	**001**	Dec 12, 2017
AB			**100MG**	**A205005**	**002**	Dec 12, 2017

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACROBID

AB	**+!**	ALMATICA	**75MG;25MG**	**N020064**	**001**	Dec 24, 1991

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB		AMNEAL PHARMS	**75MG;25MG**	**A207372**	**001**	May 15, 2017
AB		SANDOZ	**75MG;25MG**	**A077066**	**001**	Apr 05, 2005
AB		SUNNY	**75MG;25MG**	**A208516**	**001**	May 24, 2018
AB		WATSON LABS INC	**75MG;25MG**	**A202250**	**001**	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

NITROMIST

	+!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006

FILM, EXTENDED RELEASE;TRANSDERMAL

NITROGLYCERIN

AB2		HERCON PHARM	**0.1MG/HR**	**A089885**	**002**	Oct 30, 2017
AB2			**0.2MG/HR**	**A089884**	**001**	Oct 30, 1998
AB2			**0.4MG/HR**	**A089885**	**001**	Oct 30, 1998
AB2			**0.6MG/HR**	**A089886**	**001**	Oct 30, 1998
AB2	**!**	MYLAN TECHNOLOGIES	**0.1MG/HR**	**A074559**	**004**	Feb 06, 1998
AB2	**!**		**0.2MG/HR**	**A074559**	**003**	Aug 30, 1996
AB2	**!**		**0.4MG/HR**	**A074559**	**002**	Aug 30, 1996
AB2	**!**		**0.6MG/HR**	**A074559**	**001**	Aug 30, 1996

NITRO-DUR

	+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995
	+!		0.2MG/HR	N020145	002	Apr 04, 1995
	+!		0.3MG/HR	N020145	003	Apr 04, 1995
	+!		0.4MG/HR	N020145	004	Apr 04, 1995
	+!		0.6MG/HR	N020145	005	Apr 04, 1995
	+!		0.8MG/HR	N020145	006	Apr 04, 1995

INJECTABLE;INJECTION

NITROGLYCERIN IN DEXTROSE 5%

AP	**+!**	BAXTER HLTHCARE	**10MG/100ML**	**N019970**	**001**	Dec 29, 1989
AP	**+!**		**20MG/100ML**	**N019970**	**002**	Dec 29, 1989
AP	**+!**		**40MG/100ML**	**N019970**	**003**	Dec 29, 1989

NITROGLYCERIN

	!	AM REGENT	5MG/ML	A072034	001	May 24, 1988

OINTMENT;INTRA-ANAL

RECTIV

	+!	ALLERGAN	0.4%	N021359	001	Jun 21, 2011

OINTMENT;TRANSDERMAL

NITROGLYCERIN

	!	FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988

SPRAY, METERED;SUBLINGUAL

NITROGLYCERIN

AB		PADAGIS ISRAEL	**0.4MG/SPRAY**	**A091496**	**001**	Sep 20, 2013

NITROLINGUAL PUMPSPRAY

AB	**+!**	POHL BOSKAMP	**0.4MG/SPRAY**	**N018705**	**002**	Jan 10, 1997

TABLET;SUBLINGUAL

NITROGLYCERIN

AB		ALVOGEN	**0.3MG**	**A211604**	**001**	Apr 30, 2019
AB			**0.4MG**	**A211604**	**002**	Apr 30, 2019
AB			**0.6MG**	**A211604**	**003**	Apr 30, 2019
AB		DR REDDYS	**0.3MG**	**A208191**	**001**	Aug 26, 2016
AB			**0.4MG**	**A208191**	**002**	Aug 26, 2016
AB			**0.6MG**	**A208191**	**003**	Aug 26, 2016
AB		GLENMARK PHARMS SA	**0.3MG**	**A206391**	**001**	Sep 19, 2017
AB			**0.4MG**	**A206391**	**002**	Sep 19, 2017
AB			**0.6MG**	**A206391**	**003**	Sep 19, 2017
AB		RUBICON	**0.3MG**	**A209779**	**001**	May 03, 2021
AB			**0.4MG**	**A209779**	**002**	May 03, 2021
AB			**0.6MG**	**A209779**	**003**	May 03, 2021

NITROSTAT

AB	**+**	UPJOHN	**0.3MG**	**N021134**	**001**	May 01, 2000
AB	**+**		**0.4MG**	**N021134**	**002**	May 01, 2000
AB	**+!**		**0.6MG**	**N021134**	**003**	May 01, 2000

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

AB		DR REDDYS LABS LTD	**150MG**	**A077314**	**001**	Sep 15, 2005
AB			**300MG**	**A077314**	**002**	Sep 15, 2005
AB		GLENMARK GENERICS	**150MG**	**A090618**	**001**	Jul 15, 2011
AB			**300MG**	**A090618**	**002**	Jul 15, 2011
AB		SANDOZ	**150MG**	**A076178**	**001**	Jul 05, 2002
AB			**300MG**	**A076178**	**002**	Jul 05, 2002
AB		WATSON LABS	**150MG**	**A075616**	**001**	Jul 09, 2002
AB	**!**		**300MG**	**A075616**	**002**	Jul 09, 2002

SOLUTION;ORAL

NIZATIDINE

	!	AMNEAL PHARMS	15MG/ML	A090576	001 Nov 18, 2009

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

LEVOPHED

AP	**+!**	HOSPIRA	**EQ 1MG BASE/ML**	**N007513**	**001**	

NOREPINEPHRINE BITARTRATE

AP		AMNEAL	**EQ 1MG BASE/ML**	**A210839**	**001**	Dec 17, 2018
AP		BAXTER HLTHCARE CORP	**EQ 1MG BASE/ML**	**A040859**	**001**	Mar 27, 2012
AP		BRECKENRIDGE	**EQ 1MG BASE/ML**	**A214455**	**001**	Jan 22, 2021
AP		FRESENIUS KABI USA	**EQ 1MG BASE/ML**	**A211382**	**001**	Nov 03, 2020
AP		GLAND PHARMA LTD	**EQ 1MG BASE/ML**	**A214323**	**001**	May 06, 2021
AP		HIKMA	**EQ 1MG BASE/ML**	**A040462**	**001**	Oct 31, 2003
AP			**EQ 1MG BASE/ML**	**A203662**	**001**	Nov 07, 2018
AP		MYLAN LABS LTD	**EQ 1MG BASE/ML**	**A211242**	**001**	Oct 04, 2018
AP		SANDOZ INC	**EQ 1MG BASE/ML**	**A211359**	**001**	Oct 18, 2018
AP		SUN PHARM	**EQ 1MG BASE/ML**	**A211980**	**001**	Jan 29, 2021
AP		TEVA PHARMS USA	**EQ 1MG BASE/ML**	**A040455**	**001**	Mar 03, 2003

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

	+!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001 Jan 15, 2021
	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002 Jan 15, 2021

NORETHINDRONE

TABLET;ORAL-28

CAMILA

AB1		MAYNE PHARMA	**0.35MG**	**A076177**	**001**	Oct 21, 2002

HEATHER

AB1		GLENMARK GENERICS	**0.35MG**	**A090454**	**001**	Apr 23, 2010

INCASSIA

AB1		AUROBINDO PHARMA LTD	**0.35MG**	**A207304**	**001**	Sep 23, 2016

NOR-QD

AB1	**+!**	TEVA BRANDED PHARM	**0.35MG**	**N017060**	**001**	

NORETHINDRONE

AB1		AMNEAL PHARMS	**0.35MG**	**A202260**	**001**	Aug 01, 2013
AB1		LUPIN LTD	**0.35MG**	**A091325**	**001**	Sep 19, 2011
AB1		MYLAN LABS LTD	**0.35MG**	**A201483**	**001**	Jun 24, 2013
AB1		NAARI PTE LTD	**0.35MG**	**A206807**	**001**	Dec 13, 2016
AB1		NOVAST LABS	**0.35MG**	**A202014**	**001**	Sep 13, 2013

ERRIN

AB2		MAYNE PHARMA	**0.35MG**	**A076225**	**001**	Oct 21, 2002

JENCYCLA

AB2		LUPIN LTD	**0.35MG**	**A091323**	**001**	Mar 28, 2013

NORETHINDRONE

AB2		GLENMARK GENERICS	**0.35MG**	**A091209**	**001**	Jul 22, 2010
AB2	**!**	MYLAN LABS LTD	**0.35MG**	**A200980**	**001**	Jun 12, 2013
AB2		NOVAST LABS	**0.35MG**	**A200961**	**001**	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET;ORAL

NORETHINDRONE ACETATE

AB		AMNEAL PHARMS	**5MG**	**A200275**	**001**	Jul 30, 2012
AB	**!**	BARR	**5MG**	**A075951**	**001**	May 25, 2001
AB		GLENMARK GENERICS	**5MG**	**A091090**	**001**	Jul 21, 2010
AB		MYLAN LABS LTD	**5MG**	**A205278**	**001**	Nov 10, 2016
AB		NOVAST LABS	**5MG**	**A206490**	**001**	Nov 05, 2018

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB		MAYNE PHARMA	**EQ 10MG BASE**	**A073556**	**002**	Mar 30, 1992
AB			**EQ 25MG BASE**	**A073556**	**003**	Mar 30, 1992
AB			**EQ 50MG BASE**	**A073556**	**004**	Mar 30, 1992
AB			**EQ 75MG BASE**	**A073556**	**001**	Mar 30, 1992
AB		TARO	**EQ 10MG BASE**	**A075520**	**004**	May 08, 2000
AB			**EQ 25MG BASE**	**A075520**	**003**	May 08, 2000
AB			**EQ 50MG BASE**	**A075520**	**001**	May 08, 2000
AB			**EQ 75MG BASE**	**A075520**	**002**	May 08, 2000
AB		TEVA	**EQ 10MG BASE**	**A074132**	**001**	Mar 27, 1995
AB			**EQ 25MG BASE**	**A074132**	**002**	Mar 27, 1995
AB			**EQ 50MG BASE**	**A074132**	**003**	Mar 27, 1995
AB			**EQ 75MG BASE**	**A074132**	**004**	Mar 27, 1995

PAMELOR

AB	+	SPECGX LLC	**EQ 10MG BASE**	**N018013**	**001**	
AB	+		**EQ 25MG BASE**	**N018013**	**002**	
AB	+		**EQ 50MG BASE**	**N018013**	**004**	
AB	+!		**EQ 75MG BASE**	**N018013**	**003**	

SOLUTION;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	!	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A075606**	**001**	Aug 28, 2000
AA		TARO	**EQ 10MG BASE/5ML**	**A077965**	**001**	Jun 20, 2006

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

SPINRAZA

	+!	BIOGEN IDEC	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531	001	Dec 23, 2016

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062949**	**001**	Jun 13, 1988
AT		COSETTE	**100,000 UNITS/GM**	**A061966**	**001**	
AT		CROWN LABS INC	**100,000 UNITS/GM**	**A207733**	**001**	Sep 26, 2017
AT		FOUGERA PHARMS	**100,000 UNITS/GM**	**A062129**	**001**	
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM**	**A213566**	**001**	Aug 10, 2021
AT		PADAGIS US	**100,000 UNITS/GM**	**A062225**	**001**	
AT	!	TARO	**100,000 UNITS/GM**	**A064022**	**001**	Jan 29, 1993
AT		TORRENT	**100,000 UNITS/GM**	**A212557**	**001**	Jul 24, 2019

OINTMENT;TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	**100,000 UNITS/GM**	**A062840**	**001**	Nov 13, 1987
AT		CADILA	**100,000 UNITS/GM**	**A207767**	**001**	May 25, 2018
AT		COSETTE	**100,000 UNITS/GM**	**A209114**	**001**	Oct 06, 2017
AT	!	FOUGERA PHARMS	**100,000 UNITS/GM**	**A062124**	**002**	Sep 23, 1982
AT		LYNE	**100,000 UNITS/GM**	**A209082**	**001**	May 21, 2018
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM**	**A213826**	**001**	Jan 14, 2021
AT		PADAGIS US	**100,000 UNITS/GM**	**A062472**	**001**	Feb 13, 1984
AT		TORRENT	**100,000 UNITS/GM**	**A211838**	**001**	Jan 28, 2019

POWDER;TOPICAL

NYSTATIN

AT		EPIC PHARMA LLC	**100,000 UNITS/GM**	**A210532**	**001**	Apr 30, 2018
AT		LUPIN	**100,000 UNITS/GM**	**A065138**	**001**	Jul 23, 2004
AT		LYNE	**100,000 UNITS/GM**	**A208838**	**001**	May 30, 2017
AT	!	MAYNE PHARMA INC	**100,000 UNITS/GM**	**A065203**	**001**	Jul 15, 2004
AT		UPSHER SMITH LABS	**100,000 UNITS/GM**	**A065183**	**001**	May 03, 2005
AT		XGEN PHARMS	**100,000 UNITS/GM**	**A065175**	**001**	Dec 17, 2004
AT		ZYDUS PHARMS	**100,000 UNITS/GM**	**A208581**	**001**	Jun 08, 2017

NYSTOP

AT		PADAGIS US	**100,000 UNITS/GM**	**A064118**	**001**	Aug 16, 1996

SUSPENSION;ORAL

NYSTATIN

AA		AKORN	**100,000 UNITS/ML**	**A064042**	**001**	Feb 28, 1994
AA		DASTECH GENERICS	**100,000 UNITS/ML**	**A062832**	**001**	Dec 27, 1991
AA		FOUGERA PHARMS INC	**100,000 UNITS/ML**	**A062517**	**001**	Jun 07, 1984
AA		GENUS	**100,000 UNITS/ML**	**A065148**	**001**	Jun 28, 2005
AA		PHARM ASSOC	**100,000 UNITS/ML**	**A203621**	**001**	Jan 07, 2016
AA		TARO	**100,000 UNITS/ML**	**A062876**	**001**	Feb 29, 1988
AA		VISTAPHARM	**100,000 UNITS/ML**	**A064142**	**001**	Jun 25, 1998
AA			**100,000 UNITS/ML**	**A065422**	**001**	Mar 07, 2011

NYSTATIN

SUSPENSION;ORAL

NYSTATIN

AA	**!**	WOCKHARDT BIO AG	**100,000 UNITS/ML**	**A062512**	**001**	Oct 29, 1984

TABLET;ORAL

NYSTATIN

AA		HERITAGE PHARMS INC	**500,000 UNITS**	**A062474**	**001**	Dec 22, 1983
AA		SUN PHARM INDUSTRIES	**500,000 UNITS**	**A062838**	**001**	Dec 22, 1988
AA	**!**	TEVA	**500,000 UNITS**	**A062506**	**001**	Jan 16, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT		COSETTE	**100,000 UNITS/GM;0.1%**	**A062367**	**001**	May 28, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		ALEOR DERMACEUTICALS	**100,000 UNITS/GM;0.1%**	**A214090**	**001**	Mar 31, 2021
AT		AMNEAL	**100,000 UNITS/GM;0.1%**	**A209990**	**001**	Feb 15, 2018
AT		CROWN LABS INC	**100,000 UNITS/GM;0.1%**	**A207730**	**001**	Dec 26, 2017
AT		DR REDDYS	**100,000 UNITS/GM;0.1%**	**A208326**	**001**	Oct 26, 2016
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062599**	**001**	Oct 08, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208136**	**001**	Oct 24, 2016
AT		LUPIN LTD	**100,000 UNITS/GM;0.1%**	**A208205**	**001**	May 31, 2018
AT		PADAGIS ISRAEL	**100,000 UNITS/GM;0.1%**	**A208479**	**001**	Aug 14, 2017
AT	**!**	TARO	**100,000 UNITS/GM;0.1%**	**A062364**	**001**	Dec 22, 1987
AT		TORRENT	**100,000 UNITS/GM;0.1%**	**A213142**	**001**	Jul 14, 2020

OINTMENT;TOPICAL

MYKACET

AT		COSETTE	**100,000 UNITS/GM;0.1%**	**A062733**	**001**	Mar 06, 1987

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AKORN	**100,000 UNITS/GM;0.1%**	**A207217**	**001**	Aug 04, 2017
AT		CADILA	**100,000 UNITS/GM;0.1%**	**A207764**	**001**	Nov 08, 2018
AT		DR REDDYS	**100,000 UNITS/GM;0.1%**	**A207741**	**001**	Jan 31, 2017
AT		FOUGERA PHARMS INC	**100,000 UNITS/GM;0.1%**	**A062602**	**001**	Oct 09, 1985
AT		GLENMARK PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A208300**	**001**	Jun 23, 2016
AT		MACLEODS PHARMS LTD	**100,000 UNITS/GM;0.1%**	**A214751**	**001**	Aug 17, 2021
AT		PADAGIS ISRAEL	**100,000 UNITS/GM;0.1%**	**A207380**	**001**	Dec 20, 2016
AT		RISING	**100,000 UNITS/GM;0.1%**	**A206785**	**001**	Dec 29, 2016
AT		STRIDES PHARMA	**100,000 UNITS/GM;0.1%**	**A210077**	**001**	Jan 29, 2018
AT	**!**	TARO	**100,000 UNITS/GM;0.1%**	**A063305**	**001**	Mar 29, 1993
AT		TELIGENT	**100,000 UNITS/GM;0.1%**	**A208287**	**001**	Dec 30, 2016

OBETICHOLIC ACID

TABLET;ORAL

OCALIVA

	+	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016
	+!		10MG	N207999	002	May 27, 2016

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL

MYCAPSSA

	+!	CHIASMA	EQ 20MG BASE	N208232	001	Jun 26, 2020

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

AP		FRESENIUS KABI USA	**EQ 0.2MG BASE/ML**	**A077450**	**001**	Feb 10, 2006
AP			**EQ 1MG BASE/ML**	**A077450**	**002**	Feb 10, 2006
AP		SAGENT PHARMS INC	**EQ 0.2MG BASE/ML**	**A091041**	**001**	Nov 12, 2013
AP			**EQ 1MG BASE/ML**	**A091041**	**002**	Nov 12, 2013
AP		TEVA PHARMS USA	**EQ 0.05MG BASE/ML**	**A075957**	**001**	Oct 03, 2005
AP			**EQ 0.1MG BASE/ML**	**A075957**	**002**	Oct 03, 2005
AP			**EQ 0.2MG BASE/ML**	**A075959**	**001**	Nov 21, 2005
AP			**EQ 0.5MG BASE/ML**	**A075957**	**003**	Oct 03, 2005
AP			**EQ 1MG BASE/ML**	**A075959**	**002**	Nov 21, 2005
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.2MG BASE/ML**	**A076330**	**001**	Apr 08, 2005
AP	**!**		**EQ 1MG BASE/ML**	**A076330**	**002**	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		FRESENIUS KABI USA	**EQ 0.05MG BASE/ML**	**A077457**	**001**	Feb 10, 2006
AP			**EQ 0.1MG BASE/ML**	**A077457**	**002**	Feb 10, 2006
AP			**EQ 0.5MG BASE/ML**	**A077457**	**003**	Feb 10, 2006
AP		MYLAN INSTITUTIONAL	**EQ 0.05MG BASE/ML**	**A079198**	**001**	Feb 10, 2011
AP			**EQ 0.1MG BASE/ML**	**A079198**	**002**	Feb 10, 2011
AP			**EQ 0.5MG BASE/ML**	**A079198**	**003**	Feb 10, 2011

OCTREOTIDE ACETATE

INJECTABLE;INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP		SAGENT PHARMS INC	**EQ 0.05MG BASE/ML**	**A090834**	**001**	Nov 12, 2013
AP			**EQ 0.1MG BASE/ML**	**A090834**	**002**	Nov 12, 2013
AP			**EQ 0.5MG BASE/ML**	**A090834**	**003**	Nov 12, 2013
AP	**!**	WEST-WARD PHARMS INT	**EQ 0.05MG BASE/ML**	**A076313**	**001**	Mar 28, 2005
AP	**!**		**EQ 0.1MG BASE/ML**	**A076313**	**003**	Mar 28, 2005
AP	**!**		**EQ 0.5MG BASE/ML**	**A076313**	**002**	Mar 28, 2005

SANDOSTATIN

AP	**+!**	NOVARTIS	**EQ 0.05MG BASE/ML**	**N019667**	**001**	Oct 21, 1988
AP	**+!**		**EQ 0.1MG BASE/ML**	**N019667**	**002**	Oct 21, 1988
AP	**+!**		**EQ 0.5MG BASE/ML**	**N019667**	**003**	Oct 21, 1988

SANDOSTATIN LAR

	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+!		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

	+	ALBIREO	0.4MG	N215498	002	Jul 20, 2021
	+!		1.2MG	N215498	004	Jul 20, 2021

CAPSULE, PELLETS;ORAL

BYLVAY

	+	ALBIREO	0.2MG	N215498	001	Jul 20, 2021
	+!		0.6MG	N215498	003	Jul 20, 2021

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OCUFLOX

AT	**+!**	ALLERGAN	**0.3%**	**N019921**	**001**	Jul 30, 1993

OFLOXACIN

AT		AKORN	**0.3%**	**A076407**	**001**	Apr 15, 2008
AT			**0.3%**	**A076615**	**001**	May 14, 2004
AT		ALTAIRE PHARMS INC	**0.3%**	**A202692**	**001**	Apr 29, 2013
AT		APOTEX INC	**0.3%**	**A076513**	**001**	May 14, 2004
AT		BAUSCH AND LOMB	**0.3%**	**A076622**	**001**	May 14, 2004
AT		FDC LTD	**0.3%**	**A078559**	**001**	Feb 25, 2009

SOLUTION/DROPS;OTIC

OFLOXACIN

AT		AKORN	**0.3%**	**A076616**	**001**	Mar 17, 2008
AT		AMNEAL	**0.3%**	**A211525**	**001**	Aug 30, 2019
AT		APOTEX INC	**0.3%**	**A076527**	**001**	Sep 28, 2007
AT	**!**	BAUSCH AND LOMB	**0.3%**	**A076128**	**001**	Mar 17, 2008

TABLET;ORAL

OFLOXACIN

AB		CADILA PHARMS LTD	**200MG**	**A091656**	**001**	Sep 18, 2014
AB			**300MG**	**A091656**	**002**	Sep 18, 2014
AB			**400MG**	**A091656**	**003**	Sep 18, 2014
AB		DR REDDYS LABS LTD	**200MG**	**A077098**	**001**	Feb 10, 2006
AB			**300MG**	**A077098**	**002**	Feb 10, 2006
AB			**400MG**	**A077098**	**003**	Feb 10, 2006
AB		LARKEN LABS	**400MG**	**A076093**	**003**	Sep 02, 2003
AB		TEVA	**200MG**	**A076182**	**001**	Sep 02, 2003
AB			**300MG**	**A076182**	**002**	Sep 02, 2003
AB	**!**		**400MG**	**A076182**	**003**	Sep 02, 2003

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

OLANZAPINE

AP		AM REGENT	**10MG/VIAL**	**A201741**	**001**	Mar 20, 2012
AP		EUGIA PHARMA	**10MG/VIAL**	**A210968**	**001**	Oct 22, 2020
AP		SANDOZ INC	**10MG/VIAL**	**A201588**	**001**	Oct 24, 2011

ZYPREXA

AP	**+!**	LILLY	**10MG/VIAL**	**N021253**	**001**	Mar 29, 2004

TABLET;ORAL

OLANZAPINE

AB		ALKEM LABS LTD	**2.5MG**	**A202295**	**001**	Oct 20, 2015
AB			**5MG**	**A202295**	**002**	Oct 20, 2015
AB			**7.5MG**	**A202295**	**003**	Oct 20, 2015
AB			**10MG**	**A202295**	**004**	Oct 20, 2015
AB			**15MG**	**A202295**	**005**	Oct 20, 2015

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB			**20MG**	**A202295**	**006**	Oct 20, 2015
AB		APOTEX INC	**2.5MG**	**A090798**	**001**	Apr 23, 2012
AB			**5MG**	**A090798**	**002**	Apr 23, 2012
AB			**7.5MG**	**A090798**	**003**	Apr 23, 2012
AB			**10MG**	**A090798**	**004**	Apr 23, 2012
AB			**15MG**	**A090798**	**005**	Apr 23, 2012
AB			**20MG**	**A090798**	**006**	Apr 23, 2012
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A202050**	**001**	Apr 23, 2012
AB			**5MG**	**A202050**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202050**	**003**	Apr 23, 2012
AB			**10MG**	**A202050**	**004**	Apr 23, 2012
AB			**15MG**	**A202050**	**005**	Apr 23, 2012
AB			**20MG**	**A202050**	**006**	Apr 23, 2012
AB		DR REDDYS LABS LTD	**2.5MG**	**A076255**	**001**	Apr 23, 2012
AB			**5MG**	**A076255**	**002**	Apr 23, 2012
AB			**7.5MG**	**A076255**	**003**	Apr 23, 2012
AB			**10MG**	**A076255**	**004**	Apr 23, 2012
AB			**15MG**	**A076133**	**001**	Apr 23, 2012
AB			**20MG**	**A076133**	**002**	Oct 24, 2011
AB		INDOCO	**2.5MG**	**A206155**	**001**	Jul 31, 2020
AB			**5MG**	**A206155**	**002**	Jul 31, 2020
AB			**7.5MG**	**A206155**	**003**	Jul 31, 2020
AB			**10MG**	**A206155**	**004**	Jul 31, 2020
AB			**15MG**	**A206155**	**005**	Jul 31, 2020
AB			**20MG**	**A206155**	**006**	Jul 31, 2020
AB		INVAGEN PHARMS	**2.5MG**	**A203333**	**001**	Mar 15, 2016
AB			**5MG**	**A203333**	**002**	Mar 15, 2016
AB			**7.5MG**	**A203333**	**003**	Mar 15, 2016
AB			**10MG**	**A203333**	**004**	Mar 15, 2016
AB			**15MG**	**A203333**	**005**	Mar 15, 2016
AB			**20MG**	**A203333**	**006**	Mar 15, 2016
AB		MACLEODS PHARMS LTD	**2.5MG**	**A202862**	**001**	Aug 15, 2014
AB			**5MG**	**A202862**	**002**	Aug 15, 2014
AB			**7.5MG**	**A202862**	**003**	Aug 15, 2014
AB			**10MG**	**A202862**	**004**	Aug 15, 2014
AB			**15MG**	**A202862**	**005**	Aug 15, 2014
AB			**20MG**	**A202862**	**006**	Aug 15, 2014
AB		ORBION PHARMS	**2.5MG**	**A202287**	**001**	Apr 23, 2012
AB			**5MG**	**A202287**	**002**	Apr 23, 2012
AB			**7.5MG**	**A202287**	**003**	Apr 23, 2012
AB			**10MG**	**A202287**	**004**	Apr 23, 2012
AB			**15MG**	**A202287**	**005**	Apr 23, 2012
AB			**20MG**	**A202287**	**006**	Apr 23, 2012
AB		QILU	**2.5MG**	**A204319**	**001**	Jan 27, 2016
AB			**5MG**	**A204319**	**002**	Jan 27, 2016
AB			**7.5MG**	**A204319**	**003**	Jan 27, 2016
AB			**10MG**	**A204319**	**004**	Jan 27, 2016
AB			**15MG**	**A204319**	**005**	Jan 27, 2016
AB			**20MG**	**A204319**	**006**	Jan 27, 2016
AB		SUN PHARM INDS	**2.5MG**	**A091038**	**001**	Apr 23, 2012
AB			**5MG**	**A091038**	**002**	Apr 23, 2012
AB			**7.5MG**	**A091038**	**003**	Apr 23, 2012
AB			**10MG**	**A091038**	**004**	Apr 23, 2012
AB			**15MG**	**A091038**	**005**	Apr 23, 2012
AB			**20MG**	**A091038**	**006**	Apr 23, 2012
AB		ZYDUS PHARMS	**2.5MG**	**A090459**	**001**	Jul 16, 2018
AB			**5MG**	**A090459**	**002**	Jul 16, 2018
AB			**7.5MG**	**A090459**	**003**	Jul 16, 2018
AB			**10MG**	**A090459**	**004**	Jul 16, 2018
AB			**15MG**	**A090459**	**005**	Jul 16, 2018
AB			**20MG**	**A090459**	**006**	Jul 16, 2018

ZYPREXA

AB	+	LILLY	**2.5MG**	**N020592**	**001**	Sep 30, 1996
AB	+!		**5MG**	**N020592**	**002**	Sep 30, 1996
AB	+		**7.5MG**	**N020592**	**003**	Sep 30, 1996
AB	+		**10MG**	**N020592**	**004**	Sep 30, 1996
AB	+		**15MG**	**N020592**	**005**	Sep 09, 1997
AB	+		**20MG**	**N020592**	**006**	Sep 09, 1997

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	APOTEX INC	**5MG**	**A091265**	**001**	Oct 24, 2011
AB		**10MG**	**A091265**	**002**	Oct 24, 2011
AB		**15MG**	**A091265**	**003**	Oct 24, 2011
AB		**20MG**	**A091265**	**004**	Oct 24, 2011
AB	AUROBINDO PHARMA LTD	**5MG**	**A203708**	**001**	May 15, 2014
AB		**10MG**	**A203708**	**002**	May 15, 2014
AB		**15MG**	**A203708**	**003**	May 15, 2014
AB		**20MG**	**A203708**	**004**	May 15, 2014
AB	BARR LABS INC	**5MG**	**A077243**	**001**	Jan 30, 2012
AB		**10MG**	**A077243**	**002**	Jan 30, 2012
AB		**15MG**	**A077243**	**003**	Jan 30, 2012
AB		**20MG**	**A077243**	**004**	Jan 30, 2012
AB	DR REDDYS LABS LTD	**5MG**	**A076534**	**001**	Oct 24, 2011
AB		**10MG**	**A076534**	**002**	Oct 24, 2011
AB		**15MG**	**A076534**	**003**	Oct 24, 2011
AB		**20MG**	**A076534**	**004**	Oct 24, 2011
AB	HEC PHARM	**5MG**	**A208146**	**001**	Jul 02, 2018
AB		**10MG**	**A208146**	**002**	Jul 02, 2018
AB		**15MG**	**A208146**	**003**	Jul 02, 2018
AB		**20MG**	**A208146**	**004**	Jul 02, 2018
AB	INVAGEN PHARMS	**5MG**	**A203456**	**001**	Mar 16, 2016
AB		**10MG**	**A203456**	**002**	Mar 16, 2016
AB		**15MG**	**A203456**	**003**	Mar 16, 2016
AB		**20MG**	**A203456**	**004**	Mar 16, 2016
AB	JUBILANT GENERICS	**5MG**	**A200221**	**001**	Sep 12, 2012
AB		**10MG**	**A200221**	**002**	Sep 12, 2012
AB		**15MG**	**A200221**	**003**	Sep 12, 2012
AB		**20MG**	**A200221**	**004**	Sep 12, 2012
AB	MACLEODS PHARMS LTD	**5MG**	**A203044**	**001**	Feb 20, 2015
AB		**10MG**	**A203044**	**002**	Feb 20, 2015
AB		**15MG**	**A203044**	**003**	Feb 20, 2015
AB		**20MG**	**A203044**	**004**	Feb 20, 2015
AB	MYLAN	**5MG**	**A202285**	**001**	May 12, 2014
AB		**10MG**	**A202285**	**002**	May 12, 2014
AB		**15MG**	**A202285**	**003**	May 12, 2014
AB		**20MG**	**A202285**	**004**	May 12, 2014
AB	ORBION PHARMS	**5MG**	**A202937**	**001**	Mar 02, 2015
AB		**10MG**	**A202937**	**002**	Mar 02, 2015
AB		**15MG**	**A202937**	**003**	Mar 02, 2015
AB		**20MG**	**A202937**	**004**	Mar 02, 2015
AB	STRIDES PHARMA	**5MG**	**A078109**	**001**	Oct 24, 2011
AB		**10MG**	**A078109**	**002**	Oct 24, 2011
AB		**15MG**	**A078109**	**003**	Oct 24, 2011
AB		**20MG**	**A078109**	**004**	Oct 24, 2011
AB	SUN PHARM INDS	**5MG**	**A090881**	**001**	Feb 28, 2012
AB		**10MG**	**A090881**	**002**	Feb 28, 2012
AB		**15MG**	**A090881**	**003**	Feb 28, 2012
AB		**20MG**	**A090881**	**004**	Feb 28, 2012
AB	TORRENT	**5MG**	**A091415**	**001**	Oct 25, 2011
AB		**10MG**	**A091415**	**002**	Oct 25, 2011
AB		**15MG**	**A091415**	**003**	Oct 25, 2011
AB		**20MG**	**A091415**	**004**	Oct 25, 2011

ZYPREXA ZYDIS

AB	**+!** LILLY	**5MG**	**N021086**	**001**	Apr 06, 2000
AB	**+**	**10MG**	**N021086**	**002**	Apr 06, 2000
AB	**+**	**15MG**	**N021086**	**003**	Apr 06, 2000
AB	**+**	**20MG**	**N021086**	**004**	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173	001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173	002	Dec 11, 2009
+!		EQ 405MG BASE/VIAL	N022173	003	Dec 11, 2009

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET;ORAL

LYBALVI

+!	ALKERMES INC	5MG;EQ 10MG BASE	N213378	001	May 28, 2021
+		10MG;EQ 10MG BASE	N213378	002	May 28, 2021
+		15MG;EQ 10MG BASE	N213378	003	May 28, 2021
+		20MG;EQ 10MG BASE	N213378	004	May 28, 2021

OLAPARIB

TABLET;ORAL

LYNPARZA

+	ASTRAZENECA	100MG	N208558	001	Aug 17, 2017
+!		150MG	N208558	002	Aug 17, 2017

OLICERIDINE

SOLUTION;INTRAVENOUS

OLINVYK

+!	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020
+!		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020
+!		30MG/30ML (1MG/ML)	N210730	003	Oct 30, 2020

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

+!	BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET;ORAL

BENICAR

AB	**+**	DAIICHI SANKYO	**5MG**	**N021286**	**001**	Apr 25, 2002
AB	**+**		**20MG**	**N021286**	**003**	Apr 25, 2002
AB	**+!**		**40MG**	**N021286**	**004**	Apr 25, 2002

OLMESARTAN MEDOXOMIL

AB		ACCORD HLTHCARE	**5MG**	**A207662**	**001**	Apr 24, 2017
AB			**20MG**	**A207662**	**002**	Apr 24, 2017
AB			**40MG**	**A207662**	**003**	Apr 24, 2017
AB		ALEMBIC PHARMS LTD	**5MG**	**A203012**	**001**	Apr 24, 2017
AB			**20MG**	**A203012**	**002**	Apr 24, 2017
AB			**40MG**	**A203012**	**003**	Apr 24, 2017
AB		ALKEM LABS LTD	**5MG**	**A206763**	**001**	Apr 24, 2017
AB			**20MG**	**A206763**	**002**	Apr 24, 2017
AB			**40MG**	**A206763**	**003**	Apr 24, 2017
AB		AUROBINDO PHARMA LTD	**5MG**	**A204798**	**001**	Apr 24, 2017
AB			**20MG**	**A204798**	**002**	Apr 24, 2017
AB			**40MG**	**A204798**	**003**	Apr 24, 2017
AB		GLENMARK PHARMS LTD	**5MG**	**A203281**	**001**	May 25, 2017
AB			**20MG**	**A203281**	**002**	May 25, 2017
AB			**40MG**	**A203281**	**003**	May 25, 2017
AB		MACLEODS PHARMS LTD	**5MG**	**A204814**	**001**	Apr 24, 2017
AB			**20MG**	**A204814**	**002**	Apr 24, 2017
AB			**40MG**	**A204814**	**003**	Apr 24, 2017
AB		MICRO LABS	**5MG**	**A206372**	**001**	Sep 17, 2019
AB			**20MG**	**A206372**	**002**	Sep 17, 2019
AB			**40MG**	**A206372**	**003**	Sep 17, 2019
AB		QILU	**5MG**	**A210552**	**001**	Jan 10, 2019
AB			**20MG**	**A210552**	**002**	Jan 10, 2019
AB			**40MG**	**A210552**	**003**	Jan 10, 2019
AB		SANDOZ INC	**5MG**	**A090237**	**001**	Apr 13, 2020
AB			**20MG**	**A090237**	**002**	Apr 13, 2020
AB			**40MG**	**A090237**	**003**	Apr 13, 2020
AB		SCIEGEN PHARMS INC	**5MG**	**A208130**	**001**	Jun 29, 2018
AB			**20MG**	**A208130**	**002**	Jun 29, 2018
AB			**40MG**	**A208130**	**003**	Jun 29, 2018
AB		SUNSHINE	**5MG**	**A211049**	**001**	Feb 22, 2019
AB			**20MG**	**A211049**	**002**	Feb 22, 2019
AB			**40MG**	**A211049**	**003**	Feb 22, 2019
AB		TORRENT	**5MG**	**A202375**	**001**	Apr 24, 2017
AB			**20MG**	**A202375**	**002**	Apr 24, 2017
AB			**40MG**	**A202375**	**003**	Apr 24, 2017
AB		UMEDICA LABS PVT LTD	**5MG**	**A207135**	**001**	Jul 18, 2019
AB			**20MG**	**A207135**	**002**	Jul 18, 2019
AB			**40MG**	**A207135**	**003**	Jul 18, 2019

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB		ZYDUS PHARMS	**5MG**	**A205192**	**001**	Apr 24, 2017
AB			**20MG**	**A205192**	**002**	Apr 24, 2017
AB			**40MG**	**A205192**	**003**	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

		SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB		AKORN	**0.665MG/SPRAY**	**A213757**	**001**	Aug 19, 2020
AB		AMNEAL	**0.665MG/SPRAY**	**A210901**	**001**	Jan 28, 2020
AB		APOTEX INC	**0.665MG/SPRAY**	**A091572**	**001**	Oct 08, 2014
AB		PADAGIS ISRAEL	**0.665MG/SPRAY**	**A202853**	**001**	Jan 31, 2017

PATANASE

AB	**+!**	NOVARTIS	**0.665MG/SPRAY**	**N021861**	**001**	Apr 15, 2008

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

	+!	MYLAN SPCLT VIATRIS	250MG	N019715	001	Jul 31, 1990

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS

SYNRIBO

	+!	TEVA PHARMS INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012

OMADACYCLINE TOSYLATE

POWDER;INTRAVENOUS

NUZYRA

	+!	PARATEK PHARMS INC	EQ 100MG BASE/VIAL	N209817	001	Oct 02, 2018

TABLET;ORAL

NUZYRA

	+!	PARATEK PHARMS INC	EQ 150MG BASE	N209816	001	Oct 02, 2018

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	**+!**	WOODWARD	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**N021654**	**001**	Nov 10, 2004

OMEGA-3-ACID ETHYL ESTERS

AB		AMNEAL PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A204940**	**001**	Nov 27, 2015
AB		APOTEX	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A090973**	**001**	Sep 30, 2014
AB		ASCENT PHARMS INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A207420**	**001**	Feb 25, 2019
AB		BIONPHARMA INC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A206455**	**001**	Aug 07, 2019
AB		CSPC-NBP PHARM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211979**	**001**	May 12, 2020
AB		GLW	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A212504**	**001**	Aug 19, 2020
AB		MANKIND PHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A215458**	**001**	Nov 15, 2021
AB		PURACAP PHARM LLC	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A210093**	**001**	Jun 15, 2020
AB		SOFGEN PHARMS	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A211355**	**001**	Jul 10, 2019
AB		STRIDES PHARMA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A203893**	**001**	Sep 19, 2017
AB		SUN PHARM	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A210834**	**001**	Jan 09, 2020

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB		TEVA PHARMS USA	**1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS**	**A091028**	**001**	Apr 07, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB		ACTAVIS LABS FL INC	**10MG**	**A075347**	**001**	May 30, 2008
AB			**20MG**	**A075347**	**002**	May 30, 2008
AB			**40MG**	**A075347**	**003**	May 30, 2008
AB		APOTEX	**10MG**	**A076048**	**001**	Oct 22, 2007
AB			**20MG**	**A076048**	**002**	Oct 22, 2007
AB			**40MG**	**A076048**	**003**	Jan 21, 2009
AB		AUROBINDO PHARMA LTD	**10MG**	**A203270**	**001**	Aug 19, 2015
AB			**20MG**	**A203270**	**002**	Aug 19, 2015
AB			**40MG**	**A203270**	**003**	Aug 19, 2015
AB		BRECKENRIDGE	**10MG**	**A203481**	**001**	Jul 03, 2017
AB			**20MG**	**A203481**	**002**	Jul 03, 2017
AB			**40MG**	**A203481**	**003**	Jul 03, 2017
AB		DR REDDYS LABS LTD	**10MG**	**A075576**	**003**	Oct 22, 2007
AB			**10MG**	**A078490**	**002**	Mar 16, 2009
AB			**20MG**	**A075576**	**002**	Oct 22, 2007
AB			**20MG**	**A078490**	**003**	Mar 16, 2009
AB			**40MG**	**A075576**	**001**	Jan 21, 2009
AB			**40MG**	**A078490**	**001**	Apr 17, 2009
AB		GLENMARK GENERICS	**10MG**	**A091672**	**001**	Oct 31, 2014
AB			**20MG**	**A091672**	**002**	Oct 31, 2014
AB			**40MG**	**A091672**	**003**	Oct 31, 2014
AB		HETERO LABS LTD III	**10MG**	**A204012**	**001**	Sep 26, 2019
AB			**20MG**	**A204012**	**002**	Sep 26, 2019
AB		IMPAX LABS	**10MG**	**A075785**	**001**	Oct 22, 2007
AB			**20MG**	**A075785**	**002**	Oct 22, 2007
AB			**40MG**	**A075785**	**003**	Jan 21, 2009
AB		LANNETT CO INC	**10MG**	**A075410**	**001**	Nov 01, 2002
AB			**20MG**	**A075410**	**002**	Nov 01, 2002
AB			**40MG**	**A075410**	**003**	Jan 23, 2009
AB		SANDOZ	**10MG**	**A075757**	**001**	Jan 28, 2003
AB	**!**		**20MG**	**A075757**	**002**	Jan 28, 2003
AB	**!**		**40MG**	**A076515**	**001**	Jan 21, 2009
AB		TEVA PHARMS USA	**20MG**	**A204661**	**001**	Jun 13, 2017
AB		XIROMED	**10MG**	**A212977**	**001**	Dec 10, 2020
AB			**20MG**	**A212977**	**002**	Dec 10, 2020
AB		ZYDUS PHARMS USA INC	**10MG**	**A091352**	**001**	Nov 19, 2012
AB			**20MG**	**A091352**	**002**	Nov 19, 2012
AB			**40MG**	**A091352**	**003**	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

	+	COVIS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
	+!		EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG;1.1GM**	**A204228**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204228**	**002**	Jul 15, 2016
AB		AUROLIFE PHARMA LLC	**20MG;1.1GM**	**A204922**	**001**	Aug 19, 2016
AB			**40MG;1.1GM**	**A204922**	**002**	Aug 19, 2016
AB		DR REDDYS LABS LTD	**20MG;1.1GM**	**A204068**	**001**	Jul 15, 2016
AB			**40MG;1.1GM**	**A204068**	**002**	Jul 15, 2016
AB		GUARDIAN DRUG	**20MG;1.1GM**	**A212587**	**001**	Apr 30, 2020
AB			**40MG;1.1GM**	**A212587**	**002**	Apr 30, 2020
AB		SCIEGEN PHARMS INC	**20MG;1.1GM**	**A207476**	**001**	Dec 06, 2016
AB			**40MG;1.1GM**	**A207476**	**002**	Dec 06, 2016
AB		ZYDUS PHARMS	**20MG;1.1GM**	**A203290**	**001**	May 25, 2018
AB			**40MG;1.1GM**	**A203290**	**002**	May 25, 2018

ZEGERID

AB	**+**	SALIX	**20MG;1.1GM**	**N021849**	**001**	Feb 27, 2006
AB	**+!**		**40MG;1.1GM**	**N021849**	**002**	Feb 27, 2006

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB		AJANTA PHARMA LTD	**20MG/PACKET;1.68GM/PACKET**	**A205545**	**001**	Jul 27, 2016
AB			**40MG/PACKET;1.68GM/PACKET**	**A205545**	**002**	Jul 27, 2016
AB		STRIDES PHARMA	**20MG/PACKET;1.68GM/PACKET**	**A079182**	**001**	Apr 19, 2013
AB			**40MG/PACKET;1.68GM/PACKET**	**A079182**	**002**	Apr 19, 2013

ZEGERID

AB	+	SALIX	**20MG/PACKET;1.68GM/PACKET**	**N021636**	**001**	Jun 15, 2004
AB	+!		**40MG/PACKET;1.68GM/PACKET**	**N021636**	**002**	Dec 21, 2004

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

AB		AUROBINDO PHARMA	**4MG**	**A090469**	**001**	Apr 12, 2010
AB	!		**8MG**	**A090469**	**002**	Apr 12, 2010
AB		GLENMARK GENERICS	**4MG**	**A078152**	**001**	Jun 27, 2007
AB			**8MG**	**A078152**	**002**	Jun 27, 2007
AB		MYLAN	**4MG**	**A078139**	**001**	Jun 25, 2007
AB			**8MG**	**A078139**	**002**	Jun 25, 2007
AB		SANDOZ	**4MG**	**A078050**	**001**	Aug 13, 2007
AB			**8MG**	**A078050**	**002**	Aug 13, 2007
AB		SUN PHARM INDS	**4MG**	**A077557**	**001**	Aug 02, 2007
AB			**8MG**	**A077557**	**002**	Aug 02, 2007
AB		SUN PHARM INDS LTD	**4MG**	**A078602**	**001**	Feb 24, 2011
AB			**8MG**	**A078602**	**002**	Feb 24, 2011

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206846**	**001**	Jul 13, 2015
AP		EUGIA PHARMA	**EQ 2MG BASE/ML**	**A202599**	**001**	Dec 21, 2012
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076974**	**001**	Dec 26, 2006
AP		GLAND PHARMA LTD	**EQ 2MG BASE/ML**	**A079224**	**001**	Sep 25, 2009
AP	!		**EQ 2MG BASE/ML**	**A090648**	**001**	Jun 15, 2012
AP		HIKMA	**EQ 2MG BASE/ML**	**A076967**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077365**	**001**	Dec 26, 2006
AP		HIKMA FARMACEUTICA	**EQ 2MG BASE/ML**	**A076781**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077473**	**001**	Dec 26, 2006
AP	!	QILU PHARM HAINAN	**EQ 2MG BASE/ML**	**A203711**	**001**	Sep 08, 2014
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A077430**	**001**	Jun 27, 2007
AP		TEVA	**EQ 2MG BASE/ML**	**A076876**	**001**	Nov 22, 2006
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077577**	**001**	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP		ACCORD HLTHCARE	**EQ 2MG BASE/ML**	**A206845**	**001**	Mar 10, 2016
AP	!	BAXTER HLTHCARE CORP	**EQ 2MG BASE/ML**	**A078287**	**001**	Feb 22, 2013
AP		EUGIA PHARMA	**EQ 2MG BASE/ML**	**A202600**	**001**	Dec 21, 2012
AP		FRESENIUS KABI USA	**EQ 2MG BASE/ML**	**A076972**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A202253**	**001**	Jul 19, 2013
AP		HIKMA	**EQ 2MG BASE/ML**	**A077011**	**001**	Dec 26, 2006
AP			**EQ 2MG BASE/ML**	**A077541**	**001**	Dec 26, 2006
AP		HOSPIRA	**EQ 2MG BASE/ML**	**A077548**	**001**	Dec 26, 2006
AP		SANDOZ INC	**EQ 2MG BASE/ML**	**A077551**	**001**	Jun 27, 2007
AP		WOCKHARDT	**EQ 2MG BASE/ML**	**A077716**	**001**	Dec 26, 2006

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA		AMNEAL PHARMS	**EQ 4MG BASE/5ML**	**A091483**	**001**	Jan 31, 2011
AA		AUROBINDO PHARMA	**EQ 4MG BASE/5ML**	**A078776**	**001**	Nov 28, 2007
AA		HIKMA	**EQ 4MG BASE/5ML**	**A076960**	**001**	Dec 26, 2006
AA		LANNETT CO INC	**EQ 4MG BASE/5ML**	**A091342**	**001**	Jan 27, 2011
AA		PHARM ASSOC	**EQ 4MG BASE/5ML**	**A078127**	**001**	Jun 25, 2007
AA		TARO	**EQ 4MG BASE/5ML**	**A077009**	**001**	Nov 30, 2007

ZOFRAN

AA	+!	NOVARTIS	**EQ 4MG BASE/5ML**	**N020605**	**001**	Jan 24, 1997

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB		APOTEX	**EQ 4MG BASE**	**A077306**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077306**	**002**	Jun 25, 2007
AB		AUROBINDO PHARMA	**EQ 4MG BASE**	**A078539**	**001**	Jul 31, 2007
AB			**EQ 8MG BASE**	**A078539**	**002**	Jul 31, 2007
AB			**EQ 24MG BASE**	**A078539**	**003**	Jul 31, 2007
AB		CASI PHARMS INC	**EQ 4MG BASE**	**A077517**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077517**	**002**	Jun 25, 2007

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB			**EQ 24MG BASE**	**A077517**	**003**	Jun 25, 2007
AB		DR REDDYS LABS LTD	**EQ 4MG BASE**	**A076183**	**003**	Dec 26, 2006
AB			**EQ 8MG BASE**	**A076183**	**002**	Dec 26, 2006
AB			**EQ 24MG BASE**	**A076183**	**001**	Dec 26, 2006
AB		GLENMARK GENERICS	**EQ 4MG BASE**	**A077535**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077535**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A077535**	**003**	Jun 25, 2007
AB		IPCA LABS LTD	**EQ 4MG BASE**	**A203761**	**001**	Jan 23, 2014
AB			**EQ 8MG BASE**	**A203761**	**002**	Jan 23, 2014
AB		NATCO PHARMA LTD	**EQ 4MG BASE**	**A077851**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077851**	**002**	Jun 25, 2007
AB		SUN PHARM INDS (IN)	**EQ 4MG BASE**	**A077050**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A077050**	**002**	Jun 25, 2007
AB		TEVA	**EQ 4MG BASE**	**A076252**	**001**	Jun 25, 2007
AB			**EQ 8MG BASE**	**A076252**	**002**	Jun 25, 2007
AB			**EQ 24MG BASE**	**A076252**	**003**	Jun 25, 2007

ZOFRAN

AB	**+**	NOVARTIS	**EQ 4MG BASE**	**N020103**	**001**	Dec 31, 1992
AB	**+**		**EQ 8MG BASE**	**N020103**	**002**	Dec 31, 1992
AB	**+!**		**EQ 24MG BASE**	**N020103**	**003**	Aug 27, 1999

ONDANSETRON HYDROCHLORIDE

		DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006

OPICAPONE

CAPSULE;ORAL

ONGENTYS

	+	NEUROCRINE	25MG	N212489	001	Apr 24, 2020
	+!		50MG	N212489	002	Apr 24, 2020

ORITAVANCIN DIPHOSPHATE

POWDER;INTRAVENOUS

KIMYRSA

	+!	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021

ORBACTIV

	+!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014

ORLISTAT

CAPSULE;ORAL

XENICAL

	+!	CHEPLAPHARM	120MG	N020766	001	Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

AP	**!**	AKORN	**30MG/ML**	**A040484**	**001**	May 24, 2006
AP		HIKMA	**30MG/ML**	**A040463**	**001**	Mar 04, 2003
AP		SAGENT PHARMS	**30MG/ML**	**A090585**	**001**	Aug 30, 2011
AP		WATSON LABS	**30MG/ML**	**A084779**	**001**	Mar 15, 1982

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB		ANDA REPOSITORY	**100MG**	**A040249**	**001**	Jan 29, 1999
AB		INVAGEN PHARMS	**100MG**	**A091158**	**001**	Jul 27, 2012
AB		LUPIN	**100MG**	**A040284**	**001**	Jun 19, 1998
AB	**!**	SANDOZ	**100MG**	**A040327**	**001**	Feb 15, 2000

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB		ALEMBIC PHARMS LTD	**EQ 30MG BASE**	**A211823**	**001**	Jun 24, 2019
AB			**EQ 45MG BASE**	**A211823**	**002**	Jun 24, 2019
AB			**EQ 75MG BASE**	**A211823**	**003**	Jun 24, 2019
AB		AMNEAL PHARMS	**EQ 30MG BASE**	**A209093**	**001**	May 17, 2017
AB			**EQ 45MG BASE**	**A209093**	**002**	May 17, 2017
AB			**EQ 75MG BASE**	**A209093**	**003**	May 17, 2017
AB		EPIC PHARMA LLC	**EQ 30MG BASE**	**A215208**	**001**	Oct 01, 2021
AB			**EQ 45MG BASE**	**A215208**	**002**	Oct 01, 2021
AB			**EQ 75MG BASE**	**A215208**	**003**	Oct 01, 2021
AB		HETERO LABS LTD III	**EQ 30MG BASE**	**A209438**	**001**	Feb 23, 2018
AB			**EQ 45MG BASE**	**A209438**	**002**	Feb 23, 2018
AB			**EQ 75MG BASE**	**A209438**	**003**	Feb 23, 2018
AB		LUPIN	**EQ 30MG BASE**	**A208348**	**001**	Jan 09, 2018
AB			**EQ 45MG BASE**	**A208348**	**002**	Jan 09, 2018

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB			**EQ 75MG BASE**	**A208348**	**003**	Jan 09, 2018
AB		MACLEODS PHARMS LTD	**EQ 30MG BASE**	**A207211**	**001**	Sep 14, 2017
AB			**EQ 45MG BASE**	**A207211**	**002**	Sep 14, 2017
AB			**EQ 75MG BASE**	**A207211**	**003**	Sep 14, 2017
AB		MSN	**EQ 30MG BASE**	**A212544**	**001**	May 20, 2020
AB			**EQ 45MG BASE**	**A212544**	**002**	May 20, 2020
AB			**EQ 75MG BASE**	**A212544**	**003**	May 20, 2020
AB		NATCO	**EQ 30MG BASE**	**A202595**	**001**	Aug 03, 2016
AB			**EQ 45MG BASE**	**A202595**	**002**	Aug 03, 2016
AB			**EQ 75MG BASE**	**A202595**	**003**	Aug 03, 2016
AB		STRIDES PHARMA	**EQ 30MG BASE**	**A209421**	**001**	Jun 08, 2018
AB			**EQ 45MG BASE**	**A209421**	**002**	Jun 08, 2018
AB			**EQ 75MG BASE**	**A209421**	**003**	Jun 08, 2018
AB		ZYDUS PHARMS	**EQ 30MG BASE**	**A208578**	**001**	Feb 24, 2017
AB			**EQ 45MG BASE**	**A208578**	**002**	Feb 24, 2017
AB			**EQ 75MG BASE**	**A208578**	**003**	Feb 24, 2017

TAMIFLU

AB	**+**	ROCHE	**EQ 30MG BASE**	**N021087**	**003**	Jul 02, 2007
AB	**+**		**EQ 45MG BASE**	**N021087**	**002**	Jul 02, 2007
AB	**+!**		**EQ 75MG BASE**	**N021087**	**001**	Oct 27, 1999

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		AJANTA PHARMA LTD	**EQ 6MG BASE/ML**	**A212784**	**001**	May 27, 2020
AB		ALVOGEN PINE BROOK	**EQ 6MG BASE/ML**	**A208823**	**001**	Oct 31, 2017
AB		AMNEAL PHARMS NY	**EQ 6MG BASE/ML**	**A210186**	**001**	Feb 27, 2018
AB		APTAPHARMA INC	**EQ 6MG BASE/ML**	**A212858**	**001**	Aug 30, 2021
AB		LUPIN	**EQ 6MG BASE/ML**	**A208347**	**001**	Feb 20, 2018
AB		SUNSHINE	**EQ 6MG BASE/ML**	**A213594**	**001**	Jan 05, 2022
AB		TEVA PHARMS USA	**EQ 6MG BASE/ML**	**A211125**	**001**	Feb 27, 2019
AB		ZYDUS PHARMS	**EQ 6MG BASE/ML**	**A209113**	**001**	Sep 14, 2017

TAMIFLU

AB	**+!**	ROCHE	**EQ 6MG BASE/ML**	**N021246**	**002**	Mar 21, 2011

OSILODROSTAT PHOSPHATE

TABLET;ORAL

ISTURISA

+	RECORDATI RARE	EQ 1MG BASE	N212801	001	Mar 06, 2020
+		EQ 5MG BASE	N212801	002	Mar 06, 2020
+!		EQ 10MG BASE	N212801	003	Mar 06, 2020

OSIMERTINIB MESYLATE

TABLET;ORAL

TAGRISSO

+	ASTRAZENECA	EQ 40MG BASE	N208065	001	Nov 13, 2015
+!		EQ 80MG BASE	N208065	002	Nov 13, 2015

OSPEMIFENE

TABLET;ORAL

OSPHENA

+!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP		AUROBINDO PHARMA LTD	**EQ 1GM BASE/VIAL**	**A201539**	**001**	Jan 18, 2013
AP			**EQ 2GM BASE/VIAL**	**A201539**	**002**	Jan 18, 2013
AP			**EQ 10GM BASE/VIAL**	**A201538**	**001**	Jan 18, 2013
AP		FRESENIUS KABI USA	**EQ 1GM BASE/VIAL**	**A206198**	**001**	Jul 20, 2020
AP			**EQ 2GM BASE/VIAL**	**A206198**	**002**	Jul 20, 2020
AP			**EQ 10GM BASE/VIAL**	**A206199**	**001**	Jul 27, 2020
AP		PIRAMAL CRITICAL	**EQ 1GM BASE/VIAL**	**A206681**	**001**	Sep 11, 2017
AP			**EQ 2GM BASE/VIAL**	**A206681**	**002**	Sep 11, 2017
AP			**EQ 10GM BASE/VIAL**	**A206760**	**001**	Oct 26, 2017
AP	**!**	SAGENT PHARMS	**EQ 1GM BASE/VIAL**	**A091246**	**001**	Mar 30, 2012
AP	**!**		**EQ 2GM BASE/VIAL**	**A091246**	**002**	Mar 30, 2012
AP	**!**		**EQ 10GM BASE/VIAL**	**A091245**	**001**	Mar 30, 2012
AP		WOCKHARDT BIO AG	**EQ 1GM BASE/VIAL**	**A207147**	**001**	Jul 31, 2017
AP			**EQ 2GM BASE/VIAL**	**A207147**	**002**	Jul 31, 2017
AP			**EQ 10GM BASE/VIAL**	**A207148**	**001**	Nov 24, 2017

OXACILLIN SODIUM

INJECTABLE;INJECTION

BACTOCILL IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989
	+!		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989

OXALIPLATIN

INJECTABLE;INTRAVENOUS

ELOXATIN

AP	**+!**	SANOFI AVENTIS US	**50MG/10ML (5MG/ML)**	**N021759**	**001**	Jan 31, 2005
AP	**+!**		**100MG/20ML (5MG/ML)**	**N021759**	**002**	Jan 31, 2005

OXALIPLATIN

AP		ACCORD HLTHCARE	**50MG/10ML (5MG/ML)**	**A207474**	**001**	Mar 21, 2017
AP			**100MG/20ML (5MG/ML)**	**A207474**	**002**	Mar 21, 2017
AP		ACTAVIS LLC	**50MG/10ML (5MG/ML)**	**A204880**	**001**	Mar 05, 2018
AP			**100MG/20ML (5MG/ML)**	**A204880**	**002**	Mar 05, 2018
AP	**!**	ACTAVIS TOTOWA	**50MG/VIAL**	**A078803**	**001**	Aug 08, 2012
AP	**!**		**100MG/VIAL**	**A078803**	**002**	Aug 08, 2012
AP		EUGIA PHARMA	**50MG/10ML (5MG/ML)**	**A205529**	**001**	Sep 06, 2017
AP			**100MG/20ML (5MG/ML)**	**A205529**	**002**	Sep 06, 2017
AP		FRESENIUS KABI USA	**50MG/10ML (5MG/ML)**	**A078811**	**001**	Jun 10, 2010
AP			**100MG/20ML (5MG/ML)**	**A078811**	**002**	Jun 10, 2010
AP			**50MG/VIAL**	**A078819**	**001**	Jun 02, 2010
AP			**50MG/10ML (5MG/ML)**	**A090030**	**001**	Jan 31, 2017
AP			**100MG/VIAL**	**A078819**	**002**	Jun 02, 2010
AP			**100MG/20ML (5MG/ML)**	**A090030**	**002**	Jan 31, 2017
AP		GLAND	**50MG/10ML (5MG/ML)**	**A207325**	**001**	Feb 10, 2017
AP			**100MG/20ML (5MG/ML)**	**A207325**	**002**	Feb 10, 2017
AP		GLAND PHARMA LTD	**50MG/VIAL**	**A207385**	**001**	May 23, 2017
AP			**100MG/VIAL**	**A207385**	**002**	May 23, 2017
AP		HOSPIRA WORLDWIDE	**50MG/10ML (5MG/ML)**	**A078813**	**001**	Aug 07, 2009
AP			**100MG/20ML (5MG/ML)**	**A078813**	**002**	Aug 07, 2009
AP		JIANGSU PHARMS	**50MG/10ML (5MG/ML)**	**A203869**	**001**	Jun 18, 2014
AP			**100MG/20ML (5MG/ML)**	**A203869**	**002**	Jun 18, 2014
AP		MYLAN LABS LTD	**50MG/10ML (5MG/ML)**	**A091358**	**001**	Aug 07, 2012
AP			**100MG/20ML (5MG/ML)**	**A091358**	**002**	Aug 07, 2012
AP		NOVAST LABS	**50MG/10ML (5MG/ML)**	**A207562**	**001**	Oct 16, 2018
AP			**100MG/20ML (5MG/ML)**	**A207562**	**002**	Oct 16, 2018
AP		QILU PHARM HAINAN	**50MG/10ML (5MG/ML)**	**A204368**	**001**	Jun 07, 2016
AP			**50MG/VIAL**	**A204616**	**001**	May 11, 2016
AP			**100MG/20ML (5MG/ML)**	**A204368**	**002**	Jun 07, 2016
AP			**100MG/VIAL**	**A204616**	**002**	May 11, 2016
AP		SANDOZ	**50MG/10ML (5MG/ML)**	**A078817**	**001**	Jan 24, 2011
AP			**100MG/20ML (5MG/ML)**	**A078817**	**002**	Jan 24, 2011
AP	**+!**	TEVA PHARMS	**50MG/10ML (5MG/ML)**	**N022160**	**001**	Aug 07, 2009
AP	**+!**		**100MG/20ML (5MG/ML)**	**N022160**	**002**	Aug 07, 2009
	!	QILU PHARM HAINAN	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016

OXANDROLONE

TABLET;ORAL

OXANDROLONE

AB		PAR PHARM	**2.5MG**	**A077827**	**001**	Jun 22, 2007
AB	**!**		**10MG**	**A077827**	**002**	Jun 22, 2007
AB		UPSHER SMITH LABS	**2.5MG**	**A076761**	**001**	Dec 01, 2006
AB			**10MG**	**A078033**	**001**	Mar 22, 2007

OXAPROZIN

TABLET;ORAL

DAYPRO

AB	**+!**	PFIZER	**600MG**	**N018841**	**004**	Oct 29, 1992

OXAPROZIN

AB		AMNEAL PHARMS CO	**600MG**	**A208633**	**001**	May 04, 2017
AB		CHARTWELL	**600MG**	**A075987**	**001**	Sep 02, 2004
AB		DR REDDYS LABS LTD	**600MG**	**A075855**	**001**	Jan 31, 2001
AB		SANDOZ	**600MG**	**A075845**	**001**	Jan 31, 2001
AB		TEVA	**600MG**	**A075849**	**001**	Jul 03, 2002

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB		ACTAVIS ELIZABETH	**10MG**	**A072253**	**002**	Apr 14, 1988
AB			**15MG**	**A072253**	**003**	Apr 14, 1988
AB	**!**		**30MG**	**A072253**	**001**	Apr 14, 1988
AB		FRONTIDA BIOPHARM	**10MG**	**A071026**	**002**	Aug 10, 1987

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB			**15MG**	**A071026**	**003**	Aug 10, 1987
AB			**30MG**	**A071026**	**001**	Aug 10, 1987
AB		SANDOZ	**10MG**	**A071813**	**001**	Apr 19, 1988
AB			**15MG**	**A071756**	**001**	Apr 19, 1988
AB			**30MG**	**A071814**	**001**	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB		AKORN	**300MG/5ML**	**A211420**	**001**	Jul 09, 2021
AB		AMNEAL PHARMS	**300MG/5ML**	**A202961**	**001**	Sep 17, 2012
AB		GLASSHOUSE PHARMS	**300MG/5ML**	**A212428**	**001**	Jun 21, 2021
AB		HIKMA	**300MG/5ML**	**A201193**	**001**	Oct 03, 2012
AB		SUN PHARM INDS LTD	**300MG/5ML**	**A078734**	**001**	Jun 26, 2009

TRILEPTAL

AB	**+!**	NOVARTIS	**300MG/5ML**	**N021285**	**001**	May 25, 2001

TABLET;ORAL

OXCARBAZEPINE

AB		ANNORA PHARMA	**150MG**	**A215939**	**001**	Jan 11, 2022
AB			**300MG**	**A215939**	**002**	Jan 11, 2022
AB			**600MG**	**A215939**	**003**	Jan 11, 2022
AB		BRECKENRIDGE PHARM	**150MG**	**A078069**	**001**	Jan 11, 2008
AB			**300MG**	**A078069**	**002**	Jan 11, 2008
AB			**600MG**	**A078069**	**003**	Jan 11, 2008
AB		GLENMARK PHARMS LTD	**150MG**	**A077802**	**001**	Oct 09, 2007
AB			**300MG**	**A077802**	**002**	Oct 09, 2007
AB			**600MG**	**A077802**	**003**	Oct 09, 2007
AB		RUBICON	**150MG**	**A077747**	**001**	Apr 09, 2008
AB			**300MG**	**A077747**	**002**	Apr 09, 2008
AB			**600MG**	**A077747**	**003**	Apr 09, 2008
AB		SUN PHARM INDS	**150MG**	**A077794**	**001**	Oct 09, 2007
AB			**300MG**	**A077794**	**002**	Oct 09, 2007
AB			**600MG**	**A077794**	**003**	Oct 09, 2007
AB		TARO	**150MG**	**A077801**	**001**	Nov 15, 2007
AB			**300MG**	**A077801**	**002**	Nov 15, 2007
AB			**600MG**	**A077801**	**003**	Nov 15, 2007

TRILEPTAL

AB	**+**	NOVARTIS	**150MG**	**N021014**	**001**	Jan 14, 2000
AB	**+**		**300MG**	**N021014**	**002**	Jan 14, 2000
AB	**+!**		**600MG**	**N021014**	**003**	Jan 14, 2000

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

	+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
	+		300MG	N202810	002	Oct 19, 2012
	+!		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM;TOPICAL

OXICONAZOLE NITRATE

AB		TARO PHARMS	**EQ 1% BASE**	**A205076**	**001**	Mar 07, 2016

OXISTAT

AB	**+!**	FOUGERA PHARMS	**EQ 1% BASE**	**N019828**	**001**	Dec 30, 1988

LOTION;TOPICAL

OXISTAT

	+!	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

	+!	ALLERGAN	3.9MG/24HR	N021351	002	Feb 26, 2003

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

	+!	ALLERGAN	10% (100MG/PACKET)	N022204	001	Jan 27, 2009

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

AA		LANNETT CO INC	**5MG/5ML**	**A074520**	**001**	Mar 29, 1996
AA		PHARM ASSOC	**5MG/5ML**	**A075137**	**001**	Dec 18, 1998
AA	**!**	WOCKHARDT BIO AG	**5MG/5ML**	**A074868**	**001**	Feb 12, 1997

OXYBUTYNIN CHLORIDE

TABLET;ORAL

OXYBUTYNIN CHLORIDE

AB		ABHAI LLC	**5MG**	**A209335**	**001**	Dec 22, 2017
AB		APPCO	**5MG**	**A209025**	**001**	Dec 21, 2017
AB		LEADING PHARMA LLC	**5MG**	**A212798**	**001**	Apr 06, 2020
AB		NOVAST LABS	**5MG**	**A210611**	**001**	Oct 30, 2019
AB		NOVITIUM PHARMA	**5MG**	**A209823**	**001**	Oct 23, 2017
AB	!	STRIDES PHARMA	**5MG**	**A075079**	**001**	Oct 31, 1997
AB		TEVA PHARMS USA	**5MG**	**A071655**	**001**	Nov 14, 1988
AB		TULEX PHARMS INC	**5MG**	**A210125**	**001**	Sep 06, 2018
AB		UPSHER SMITH LABS	**5MG**	**A074625**	**001**	Jul 31, 1996
BX		EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019
BX		EYWA	5MG	A211062	001	Feb 06, 2019

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

AB	+	JANSSEN PHARMS	**5MG**	**N020897**	**001**	Dec 16, 1998
AB	+		**10MG**	**N020897**	**002**	Dec 16, 1998

OXYBUTYNIN CHLORIDE

AB		ACCORD HLTHCARE	**5MG**	**A207138**	**001**	Feb 29, 2016
AB			**10MG**	**A207138**	**002**	Feb 29, 2016
AB	!		**15MG**	**A207138**	**003**	Feb 29, 2016
AB		AJANTA PHARMA LTD	**5MG**	**A211655**	**001**	Feb 28, 2019
AB			**10MG**	**A211655**	**002**	Feb 28, 2019
AB			**15MG**	**A211655**	**003**	Feb 28, 2019
AB		AMNEAL PHARMS	**5MG**	**A204010**	**001**	Nov 23, 2015
AB			**10MG**	**A204010**	**002**	Nov 23, 2015
AB			**15MG**	**A204010**	**003**	Nov 23, 2015
AB		BIONPHARMA INC	**5MG**	**A210717**	**001**	Dec 17, 2019
AB			**10MG**	**A210717**	**002**	Dec 17, 2019
AB			**15MG**	**A210717**	**003**	Dec 17, 2019
AB		OSMOTICA PHARM US	**5MG**	**A078503**	**001**	Feb 04, 2009
AB			**10MG**	**A078503**	**002**	Feb 04, 2009
AB			**15MG**	**A078503**	**003**	Feb 04, 2009
AB		RUBICON	**5MG**	**A214415**	**001**	Oct 27, 2020
AB			**10MG**	**A214415**	**002**	Oct 27, 2020
AB			**15MG**	**A214415**	**003**	Oct 27, 2020
AB		UNIQUE PHARM LABS	**5MG**	**A206121**	**001**	May 27, 2016
AB			**10MG**	**A206121**	**002**	May 27, 2016
AB			**15MG**	**A206121**	**003**	May 27, 2016
AB		ZYDUS PHARMS	**5MG**	**A202332**	**001**	Jun 26, 2017
AB			**10MG**	**A202332**	**002**	Jun 26, 2017
AB			**15MG**	**A202332**	**003**	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

	+	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
	+		13.5MG	N208090	002	Apr 26, 2016
	+		18MG	N208090	003	Apr 26, 2016
	+		27MG	N208090	004	Apr 26, 2016
	+!		36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB		ANI PHARMS	**5MG**	**A205177**	**001**	Mar 31, 2016
AB		AVANTHI INC	**5MG**	**A202773**	**001**	Aug 17, 2015
AB	+!	GENUS LIFESCIENCES	**5MG**	**N200534**	**001**	Oct 20, 2010
AB		MAYNE PHARMA INC	**5MG**	**A203107**	**001**	Jul 26, 2012
AB		NOVEL LABS INC	**5MG**	**A204752**	**001**	Aug 24, 2015

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA		ABHAI LLC	**5MG/5ML**	**A208593**	**001**	Jul 21, 2017
AA			**100MG/5ML**	**A208593**	**002**	Jul 21, 2017
AA		AKORN	**5MG/5ML**	**A208817**	**001**	Aug 10, 2017
AA			**100MG/5ML**	**A208795**	**001**	Aug 07, 2017
AA		ALKEM LABS LTD	**5MG/5ML**	**A211748**	**001**	Feb 07, 2019
AA			**100MG/5ML**	**A211749**	**001**	Feb 04, 2019
AA		ANI PHARMS	**5MG/5ML**	**A204979**	**001**	Jun 01, 2015
AA		ASCENT PHARMS INC	**5MG/5ML**	**A209021**	**001**	Nov 09, 2017
AA			**100MG/5ML**	**A209021**	**002**	Nov 09, 2017
AA		EYWA	**5MG/5ML**	**A207511**	**001**	Nov 23, 2016

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA			**100MG/5ML**	**A209897**	**001**	Sep 06, 2017
AA	+	GENUS LIFESCIENCES	**5MG/5ML**	**N200535**	**002**	Aug 22, 2013
AA	+!		**100MG/5ML**	**N200535**	**001**	Oct 20, 2010
AA		HIKMA	**5MG/5ML**	**A204037**	**001**	Jul 15, 2013
AA		MAYNE PHARMA INC	**100MG/5ML**	**A204092**	**001**	Jun 05, 2014
AA		NOVEL LABS INC	**100MG/5ML**	**A204603**	**001**	Apr 29, 2015
AA		PHARM ASSOC	**5MG/5ML**	**A206914**	**001**	Feb 01, 2019
AA			**100MG/5ML**	**A206822**	**001**	Aug 15, 2017
AA		QUAGEN	**5MG/5ML**	**A213761**	**001**	Jun 02, 2021
AA			**100MG/5ML**	**A213761**	**002**	Jun 02, 2021
AA		SPECGX LLC	**5MG/5ML**	**A210758**	**001**	Apr 30, 2018
AA			**100MG/5ML**	**A210758**	**002**	Apr 30, 2018
AA	+!	VISTAPHARM	**5MG/5ML**	**N201194**	**001**	Jan 12, 2012
AA			**100MG/5ML**	**A202537**	**001**	Jul 30, 2012
AA		WOCKHARDT BIO AG	**5MG/5ML**	**A206456**	**001**	Jun 16, 2015

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

AB		ALVOGEN	**5MG**	**A202116**	**001**	Dec 30, 2011
AB			**15MG**	**A202116**	**002**	Dec 30, 2011
AB			**30MG**	**A202116**	**003**	Dec 30, 2011
AB		AMNEAL PHARMS	**5MG**	**A203638**	**001**	Jun 03, 2014
AB			**10MG**	**A203638**	**002**	Jun 03, 2014
AB			**15MG**	**A203638**	**003**	Jun 03, 2014
AB			**20MG**	**A203638**	**004**	Jun 03, 2014
AB			**30MG**	**A203638**	**005**	Jun 03, 2014
AB		ASCENT PHARMS INC	**15MG**	**A207418**	**001**	Aug 07, 2017
AB			**30MG**	**A207418**	**002**	Aug 07, 2017
AB		AUROLIFE PHARMA LLC	**5MG**	**A202160**	**001**	Nov 19, 2012
AB			**15MG**	**A202160**	**002**	Nov 19, 2012
AB			**30MG**	**A202160**	**003**	Nov 19, 2012
AB		AVANTHI INC	**5MG**	**A091393**	**001**	Aug 31, 2009
AB	!		**10MG**	**A091393**	**002**	Aug 31, 2009
AB			**15MG**	**A091393**	**003**	Aug 31, 2009
AB			**20MG**	**A091393**	**004**	Aug 31, 2009
AB			**30MG**	**A091393**	**005**	Aug 31, 2009
AB		EPIC PHARMA LLC	**5MG**	**A090895**	**001**	Aug 24, 2009
AB			**5MG**	**A202662**	**001**	Sep 22, 2015
AB			**10MG**	**A202662**	**002**	Sep 22, 2015
AB			**15MG**	**A090895**	**002**	Aug 24, 2009
AB			**15MG**	**A202662**	**003**	Sep 22, 2015
AB			**20MG**	**A202662**	**005**	Apr 27, 2017
AB			**30MG**	**A090895**	**003**	Aug 24, 2009
AB			**30MG**	**A202662**	**004**	Sep 22, 2015
AB		NOVEL LABS INC	**5MG**	**A204021**	**001**	Jun 12, 2017
AB			**10MG**	**A204021**	**002**	Jun 12, 2017
AB			**15MG**	**A204021**	**003**	Jun 12, 2017
AB			**20MG**	**A204021**	**004**	Jun 12, 2017
AB			**30MG**	**A204021**	**005**	Jun 12, 2017
AB		NUVO PHARM	**5MG**	**A207119**	**001**	Apr 12, 2016
AB			**10MG**	**A207119**	**002**	Apr 12, 2016
AB			**15MG**	**A207119**	**003**	Apr 12, 2016
AB			**20MG**	**A207119**	**004**	Apr 12, 2016
AB			**30MG**	**A207119**	**005**	Apr 12, 2016
AB		RHODES PHARMS	**5MG**	**A091490**	**001**	Mar 09, 2011
AB			**10MG**	**A091490**	**002**	Mar 09, 2011
AB			**15MG**	**A091490**	**003**	Mar 09, 2011
AB			**20MG**	**A091490**	**004**	Mar 09, 2011
AB			**30MG**	**A091490**	**005**	Mar 09, 2011
AB		SPECGX LLC	**5MG**	**A076758**	**003**	Mar 19, 2007
AB			**10MG**	**A076758**	**004**	Oct 12, 2021
AB			**15MG**	**A076758**	**001**	Jun 30, 2004
AB			**20MG**	**A076758**	**005**	Oct 12, 2021
AB			**30MG**	**A076758**	**002**	Jun 30, 2004
AB		SUN PHARM INDS INC	**5MG**	**A090659**	**001**	Apr 10, 2009
AB			**10MG**	**A090659**	**005**	Nov 06, 2012
AB			**15MG**	**A090659**	**002**	Apr 10, 2009
AB			**20MG**	**A090659**	**004**	Nov 06, 2012
AB			**30MG**	**A090659**	**003**	Apr 10, 2009

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

ROXICODONE

AB	**+**	SPECGX LLC	**5MG**	**N021011**	**003**	May 15, 2009
AB	**+!**		**15MG**	**N021011**	**001**	Aug 31, 2000
AB	**+**		**30MG**	**N021011**	**002**	Aug 31, 2000

OXAYDO

	+	ZYLA	5MG	N202080	001	Jun 17, 2011
	+		7.5MG	N202080	002	Jun 17, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYCONTIN

	+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
	+		15MG	N022272	002	Apr 05, 2010
	+		20MG	N022272	003	Apr 05, 2010
	+		30MG	N022272	004	Apr 05, 2010
	+!		40MG	N022272	005	Apr 05, 2010
	+		60MG	N022272	006	Apr 05, 2010
	+		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

	+!	EPI HLTH	1%	N208552	001	Jan 18, 2017

SOLUTION/DROPS;OPHTHALMIC

UPNEEQ

	+!	RVL PHARMS	0.1%	N212520	001	Jul 08, 2020

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

	+!	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	**5MG**	**A210175**	**001**	Feb 02, 2018
AB			**10MG**	**A210175**	**002**	Feb 02, 2018
AB		AUROLIFE PHARMA LLC	**5MG**	**A204459**	**001**	Apr 26, 2016
AB			**10MG**	**A204459**	**002**	Apr 26, 2016
AB		AVANTHI INC	**5MG**	**A203601**	**001**	Jan 30, 2013
AB	**!**		**10MG**	**A203601**	**002**	Jan 30, 2013
AB		EPIC PHARMA LLC	**5MG**	**A201187**	**001**	Dec 15, 2014
AB			**10MG**	**A201187**	**002**	Dec 15, 2014
AB		HIKMA	**5MG**	**A090964**	**001**	Sep 27, 2010
AB			**10MG**	**A090964**	**002**	Sep 27, 2010
AB		SPECGX LLC	**5MG**	**A202321**	**001**	Apr 25, 2013
AB			**10MG**	**A202321**	**002**	Apr 25, 2013
AB		TEVA	**5MG**	**A091443**	**002**	Feb 15, 2011
AB			**10MG**	**A091443**	**001**	Feb 15, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

		IMPAX LABS	5MG	A079087	001	Jun 14, 2010
			7.5MG	A079087	002	Dec 21, 2010
			10MG	A079087	003	Jun 14, 2010
			15MG	A079087	004	Dec 21, 2010
			20MG	A079087	005	Jun 14, 2010
			30MG	A079087	006	Jul 22, 2010
	!		40MG	A079087	007	Jun 14, 2010

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	**+!**	FRESENIUS KABI USA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018248**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018248**	**002**	
AP	**+!**	HIKMA	**10USP UNITS/ML (10USP UNITS/ML)**	**N018243**	**001**	
AP	**+!**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018243**	**002**	Jan 10, 2007
AP		HIKMA FARMACEUTICA	**10USP UNITS/ML (10USP UNITS/ML)**	**A200219**	**001**	Feb 13, 2013
AP		SAGENT PHARMS INC	**10USP UNITS/ML (10USP UNITS/ML)**	**A091676**	**001**	Jul 13, 2018
AP			**100USP UNITS/10ML (10USP UNITS/ML)**	**A091676**	**002**	Jul 13, 2018

PITOCIN

AP	**+!**	PAR STERILE PRODUCTS	**10USP UNITS/ML (10USP UNITS/ML)**	**N018261**	**001**	
AP	**+**		**100USP UNITS/10ML (10USP UNITS/ML)**	**N018261**	**002**	Jul 27, 2007

OXYTOCIN							
INJECTABLE;INJECTION							
OXYTOCIN							
	+!	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007
PITOCIN							
	+	PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012
OZANIMOD HYDROCHLORIDE							
CAPSULE;ORAL							
ZEPOSIA							
	+	CELGENE INTL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020
	+		EQ 0.46MG BASE	N209899	002	Mar 25, 2020
	+!		EQ 0.92MG BASE	N209899	003	Mar 25, 2020
OZENOXACIN							
CREAM;TOPICAL							
XEPI							
	+!	FERRER INTERNACIONAL	1%	N208945	001	Dec 11, 2017
PACLITAXEL							
INJECTABLE;INJECTION							
PACITAXEL							
AP		GLAND PHARMA LTD	**6MG/ML**	**A207326**	**001**	Aug 23, 2016
PACLITAXEL							
AP		ACCORD HLTHCARE	**6MG/ML**	**A205720**	**001**	Aug 17, 2018
AP		ACTAVIS TOTOWA	**6MG/ML**	**A090130**	**001**	Dec 09, 2009
AP		FRESENIUS KABI USA	**6MG/ML**	**A077574**	**001**	Nov 27, 2006
AP		HIKMA	**6MG/ML**	**A075190**	**001**	Jan 28, 2002
AP	**!**	HOSPIRA	**6MG/ML**	**A076131**	**001**	May 08, 2002
AP		MSN	**6MG/ML**	**A213434**	**001**	Aug 24, 2020
AP		TEVA PHARMS	**6MG/ML**	**A075184**	**001**	Jan 25, 2002
POWDER;INTRAVENOUS							
ABRAXANE							
	+!	ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005
PAFOLACIANINE SODIUM							
SOLUTION;INTRAVENOUS							
CYTALUX							
	+!	ON TARGET LABS	EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML)	N214907	001	Nov 29, 2021
PALBOCICLIB							
CAPSULE;ORAL							
IBRANCE							
	+	PFIZER	75MG	N207103	001	Feb 03, 2015
	+		100MG	N207103	002	Feb 03, 2015
	+!		125MG	N207103	003	Feb 03, 2015
TABLET;ORAL							
IBRANCE							
	+	PFIZER	75MG	N212436	001	Nov 01, 2019
	+		100MG	N212436	002	Nov 01, 2019
	+!		125MG	N212436	003	Nov 01, 2019
PALIPERIDONE							
TABLET, EXTENDED RELEASE;ORAL							
INVEGA							
AB	**+**	JANSSEN PHARMS	**1.5MG**	**N021999**	**006**	Aug 26, 2008
AB	**+**		**3MG**	**N021999**	**001**	Dec 19, 2006
AB	**+!**		**6MG**	**N021999**	**002**	Dec 19, 2006
AB	**+**		**9MG**	**N021999**	**003**	Dec 19, 2006
PALIPERIDONE							
AB		ACTAVIS LABS FL INC	**1.5MG**	**A202645**	**001**	Aug 03, 2015
AB			**3MG**	**A202645**	**002**	Aug 03, 2015
AB			**6MG**	**A202645**	**003**	Aug 03, 2015
AB			**9MG**	**A202645**	**004**	Aug 03, 2015
AB		CSPC OUYI	**1.5MG**	**A212807**	**001**	Oct 29, 2020
AB			**3MG**	**A212807**	**002**	Oct 29, 2020
AB			**6MG**	**A212807**	**003**	Oct 29, 2020
AB			**9MG**	**A212807**	**004**	Oct 29, 2020
AB		INVENTIA	**1.5MG**	**A204452**	**001**	Jun 12, 2019
AB			**3MG**	**A204452**	**002**	Jun 12, 2019
AB			**6MG**	**A204452**	**003**	Jun 12, 2019
AB			**9MG**	**A204452**	**004**	Jun 12, 2019
AB		RK PHARMA	**1.5MG**	**A203802**	**001**	Sep 24, 2015
AB			**3MG**	**A203802**	**002**	Sep 24, 2015

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB			**6MG**	**A203802**	**003**	Sep 24, 2015
AB			**9MG**	**A203802**	**004**	Sep 24, 2015
AB		SUN PHARM	**1.5mg**	**A205618**	**001**	Apr 06, 2018
AB			**3MG**	**A205618**	**002**	Apr 06, 2018
AB			**6MG**	**A205618**	**003**	Apr 06, 2018
AB			**9MG**	**A205618**	**004**	Apr 06, 2018
BX		AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019
BX			3MG	A204707	002	Sep 23, 2019
BX			6MG	A204707	003	Sep 23, 2019
BX			9MG	A204707	004	Sep 23, 2019

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA HAFYERA

	+	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021
	+		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021

INVEGA SUSTENNA

	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
	+!		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

INVEGA TRINZA

	+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015
	+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015
	+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015
	+!		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP		BAXTER HLTHCARE CORP	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206916**	**001**	Nov 12, 2021
AP		CIPLA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206396**	**001**	Sep 19, 2018
AP	**!**	DR REDDYS LABS LTD	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A201533**	**002**	Apr 21, 2016
AP		EMCURE PHARMS LTD	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202951**	**002**	Jun 29, 2021
AP		EUGIA PHARMA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204702**	**001**	Nov 06, 2018
AP		FRESENIUS KABI USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206801**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206802**	**001**	Sep 19, 2018
AP		HOSPIRA INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A207005**	**001**	Sep 19, 2018
AP		INGENUS PHARMS LLC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A208789**	**001**	May 22, 2020
AP		MYLAN INSTITUTIONAL	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A206416**	**001**	Sep 19, 2018
AP		QILU PHARM HAINAN	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205648**	**001**	Sep 19, 2018
AP		SAGENT PHARMS INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A204289**	**001**	Sep 19, 2018
AP			**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A205870**	**001**	Sep 19, 2018
AP		SANDOZ INC	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A202521**	**001**	Oct 13, 2015
AP		TEVA PHARMS USA	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A090713**	**001**	Mar 23, 2018
AP		VIRTUS PHARM	**EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)**	**A209287**	**001**	Sep 19, 2018
		EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

		HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)	N207963	001	Aug 22, 2016

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP		AREVA PHARMS	**30MG/VIAL**	**A077433**	**001**	Nov 26, 2008
AP			**90MG/VIAL**	**A077433**	**003**	Nov 26, 2008
AP		DR REDDYS	**30MG/10ML (3MG/ML)**	**A078156**	**001**	Aug 19, 2008
AP			**60MG/10ML (6MG/ML)**	**A078156**	**002**	Aug 19, 2008
AP			**90MG/10ML (9MG/ML)**	**A078156**	**003**	Aug 19, 2008
AP		HIKMA	**30MG/VIAL**	**A075290**	**001**	Apr 30, 2001
AP	**+!**		**30MG/10ML (3MG/ML)**	**N021113**	**001**	Mar 04, 2002
AP			**90MG/VIAL**	**A075290**	**003**	Apr 30, 2001
AP	**+!**		**90MG/10ML (9MG/ML)**	**N021113**	**002**	Mar 04, 2002
AP	**!**	HOSPIRA	**30MG/10ML (3MG/ML)**	**A075841**	**001**	Jun 27, 2002
AP	**!**		**60MG/10ML (6MG/ML)**	**A075841**	**002**	Jun 27, 2002
AP	**!**		**90MG/10ML (9MG/ML)**	**A075841**	**003**	Jun 27, 2002
AP		MYLAN LABS LTD	**30MG/10ML (3MG/ML)**	**A078520**	**001**	Oct 31, 2008
AP			**90MG/10ML (9MG/ML)**	**A078520**	**002**	Oct 31, 2008

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

PAMIDRONATE DISODIUM

AP		SAGENT PHARMS INC	**30MG/10ML (3MG/ML)**	**A078373**	**001**	Dec 23, 2008
AP			**90MG/10ML (9MG/ML)**	**A078373**	**002**	Dec 23, 2008
		AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

AP	**!**	DR REDDYS	**1MG/ML**	**A072759**	**001**	Jul 31, 1990
AP		HOSPIRA	**1MG/ML**	**A072320**	**001**	Jan 19, 1989
	!	DR REDDYS	2MG/ML	A072760	001	Jul 31, 1990

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		SUN PHARM	**EQ 40MG BASE**	**A213725**	**001**	Jun 30, 2020

PROTONIX

AB	**+!**	WYETH PHARMS	**EQ 40MG BASE**	**N022020**	**001**	Nov 14, 2007

INJECTABLE;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP		ACIC PHARMS	**EQ 40MG BASE/VIAL**	**A209524**	**001**	Aug 30, 2021
AP		AKORN	**EQ 40MG BASE/VIAL**	**A079197**	**001**	Nov 08, 2012
AP		EUGIA PHARMA	**EQ 40MG BASE/VIAL**	**A205675**	**001**	Mar 30, 2016
AP		SANDOZ INC	**EQ 40MG BASE/VIAL**	**A090296**	**001**	Jul 14, 2015
AP		SUN PHARM	**EQ 40MG BASE/VIAL**	**A077674**	**001**	Aug 19, 2019

PROTONIX IV

AP	**+!**	WYETH PHARMS	**EQ 40MG BASE/VIAL**	**N020988**	**001**	Mar 22, 2001

POWDER;INTRAVENOUS

PANTOPRAZOLE SODIUM

	+!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB		ACTAVIS TOTOWA	**EQ 20MG BASE**	**A090797**	**001**	Feb 07, 2011
AB			**EQ 40MG BASE**	**A090797**	**002**	Feb 07, 2011
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A205119**	**001**	Jan 26, 2016
AB			**EQ 40MG BASE**	**A205119**	**002**	Jan 26, 2016
AB		ATLANTIDE	**EQ 20MG BASE**	**A091231**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A091231**	**002**	Jan 19, 2011
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A202038**	**001**	Sep 28, 2012
AB			**EQ 40MG BASE**	**A202038**	**002**	Sep 28, 2012
AB		DR REDDYS LABS LTD	**EQ 20MG BASE**	**A077619**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A077619**	**002**	Jan 19, 2011
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A202882**	**001**	Sep 10, 2014
AB			**EQ 40MG BASE**	**A202882**	**002**	Sep 10, 2014
AB		INGENUS PHARMS LLC	**EQ 40MG BASE**	**A211368**	**001**	Mar 01, 2019
AB		L PERRIGO CO	**EQ 20MG BASE**	**A203024**	**001**	May 07, 2014
AB		LANNETT CO INC	**EQ 20MG BASE**	**A078281**	**001**	Jan 20, 2011
AB			**EQ 40MG BASE**	**A078281**	**002**	Jan 20, 2011
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A090970**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090970**	**002**	Jan 19, 2011
AB		ORBION PHARMS	**EQ 20MG BASE**	**A202052**	**001**	Dec 02, 2014
AB			**EQ 40MG BASE**	**A202052**	**002**	Dec 02, 2014
AB		RUBICON	**EQ 20MG BASE**	**A090807**	**001**	May 02, 2012
AB			**EQ 40MG BASE**	**A090807**	**002**	May 02, 2012
AB		TORRENT PHARMS	**EQ 20MG BASE**	**A090074**	**001**	Jan 19, 2011
AB			**EQ 40MG BASE**	**A090074**	**002**	Jan 19, 2011

PROTONIX

AB	**+**	WYETH PHARMS	**EQ 20MG BASE**	**N020987**	**002**	Jun 12, 2001
AB	**+!**		**EQ 40MG BASE**	**N020987**	**001**	Feb 02, 2000

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB		AMNEAL PHARMS	**1MCG**	**A204327**	**001**	Jan 13, 2016
AB			**2MCG**	**A204327**	**002**	Jan 13, 2016
AB			**4MCG**	**A204327**	**003**	Jan 13, 2016
AB		AUROBINDO PHARMA LTD	**1MCG**	**A207672**	**001**	Jan 14, 2016
AB			**2MCG**	**A207672**	**002**	Jan 14, 2016
AB			**4MCG**	**A207672**	**003**	Jan 14, 2016
AB		BIONPHARMA INC	**1MCG**	**A202539**	**001**	Mar 27, 2014

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB			**2MCG**	**A202539**	**002**	Mar 27, 2014
AB			**4MCG**	**A202539**	**003**	Mar 27, 2014
AB		DR REDDYS LABS LTD	**1MCG**	**A091412**	**001**	Jun 24, 2014
AB			**2MCG**	**A091412**	**002**	Jun 24, 2014
AB			**4MCG**	**A091412**	**003**	Jun 24, 2014
AB		MARKSANS PHARMA	**1MCG**	**A204948**	**001**	Oct 07, 2016
AB			**2MCG**	**A204948**	**002**	Oct 07, 2016
AB			**4MCG**	**A204948**	**003**	Oct 07, 2016
AB		RISING	**1MCG**	**A202124**	**001**	Jun 24, 2014
AB			**2MCG**	**A202124**	**002**	Jun 24, 2014
AB			**4MCG**	**A202124**	**003**	Jun 24, 2014
AB		TEVA PHARMS USA	**1MCG**	**A090829**	**001**	Sep 27, 2013
AB			**2MCG**	**A090829**	**002**	Sep 27, 2013
AB	**!**		**4MCG**	**A090829**	**003**	Sep 27, 2013

ZEMPLAR

AB	**+**	ABBVIE	**1MCG**	**N021606**	**001**	May 26, 2005
AB	**+**		**2MCG**	**N021606**	**002**	May 26, 2005

SOLUTION;INTRAVENOUS

PARICALCITOL

AP		ACCORD HLTHCARE	**0.002MG/ML (0.002MG/ML)**	**N207174**	**001**	Feb 04, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**N207174**	**002**	Feb 04, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**N207174**	**003**	Feb 04, 2016
AP		AKORN	**0.005MG/ML (0.005MG/ML)**	**A207692**	**001**	Oct 16, 2017
AP		AMNEAL PHARMS CO	**0.002MG/ML (0.002MG/ML)**	**A206699**	**001**	Mar 09, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A206699**	**002**	Mar 09, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A206699**	**003**	Mar 09, 2017
AP		DR REDDYS	**0.002MG/ML (0.002MG/ML)**	**A204910**	**001**	Aug 17, 2016
AP			**0.005MG/ML (0.005MG/ML)**	**A204910**	**002**	Aug 17, 2016
AP			**0.01MG/2ML (0.005MG/ML)**	**A204910**	**003**	Aug 17, 2016
AP		EUGIA PHARMA	**0.002MG/ML (0.002MG/ML)**	**A205982**	**001**	Oct 09, 2018
AP			**0.005MG/ML (0.005MG/ML)**	**A205982**	**002**	Oct 09, 2018
AP			**0.01MG/2ML (0.005MG/ML)**	**A205982**	**003**	Oct 09, 2018
AP		HIKMA PHARMS	**0.002MG/ML (0.002MG/ML)**	**N205917**	**001**	Nov 18, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N205917**	**002**	Nov 18, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N205917**	**003**	Nov 18, 2014
AP		HOSPIRA INC	**0.002MG/ML (0.002MG/ML)**	**N201657**	**001**	Oct 21, 2014
AP			**0.005MG/ML (0.005MG/ML)**	**N201657**	**002**	Oct 21, 2014
AP			**0.01MG/2ML (0.005MG/ML)**	**N201657**	**003**	Oct 21, 2014
AP		RISING	**0.002MG/ML (0.002MG/ML)**	**A203897**	**001**	Nov 02, 2017
AP			**0.005MG/ML (0.005MG/ML)**	**A203897**	**002**	Nov 02, 2017
AP			**0.01MG/2ML (0.005MG/ML)**	**A203897**	**003**	Nov 02, 2017
AP		SANDOZ INC	**0.002MG/ML (0.002MG/ML)**	**A091108**	**001**	Jul 27, 2011
AP			**0.005MG/ML (0.005MG/ML)**	**A091108**	**002**	Jul 27, 2011
AP			**0.01MG/2ML (0.005MG/ML)**	**A091108**	**003**	Jul 27, 2011

ZEMPLAR

AP	**+!**	ABBVIE	**0.002MG/ML (0.002MG/ML)**	**N020819**	**002**	Feb 01, 2000
AP	**+!**		**0.005MG/ML (0.005MG/ML)**	**N020819**	**001**	Apr 17, 1998
AP	**+!**		**0.01MG/2ML (0.005MG/ML)**	**N020819**	**003**	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE;ORAL

PAROMOMYCIN SULFATE

AA		HERITAGE PHARMS INC	**EQ 250MG BASE**	**A065173**	**001**	Dec 14, 2007
AA	**!**	SUN PHARM INDS INC	**EQ 250MG BASE**	**A064171**	**001**	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

AB		NOVITIUM PHARMA	**EQ 10MG BASE/5ML**	**A215003**	**001**	Sep 03, 2021

PAXIL

AB	**+!**	APOTEX TECHNOLOGIES	**EQ 10MG BASE/5ML**	**N020710**	**001**	Jun 25, 1997

TABLET;ORAL

PAROXETINE

AB		PRINSTON INC	**EQ 10MG BASE**	**A203854**	**001**	Oct 31, 2014
AB			**EQ 20MG BASE**	**A203854**	**002**	Oct 31, 2014
AB			**EQ 30MG BASE**	**A203854**	**003**	Oct 31, 2014
AB			**EQ 40MG BASE**	**A203854**	**004**	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

AB		APOTEX	**EQ 10MG BASE**	**A075356**	**001**	Jul 30, 2003
AB			**EQ 20MG BASE**	**A075356**	**002**	Jul 30, 2003

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB			**EQ 30MG BASE**	**A075356**	**003**	Jul 30, 2003
AB			**EQ 40MG BASE**	**A075356**	**004**	Jul 30, 2003
AB		AUROBINDO PHARMA	**EQ 10MG BASE**	**A078406**	**001**	Jul 25, 2007
AB			**EQ 20MG BASE**	**A078406**	**002**	Jul 25, 2007
AB			**EQ 30MG BASE**	**A078406**	**003**	Jul 25, 2007
AB			**EQ 40MG BASE**	**A078406**	**004**	Jul 25, 2007
AB		MYLAN	**EQ 10MG BASE**	**A078902**	**001**	Mar 13, 2008
AB			**EQ 20MG BASE**	**A078902**	**002**	Mar 13, 2008
AB			**EQ 30MG BASE**	**A078902**	**003**	Mar 13, 2008
AB			**EQ 40MG BASE**	**A078902**	**004**	Mar 13, 2008
AB		OXFORD PHARMS	**EQ 10MG BASE**	**A076968**	**001**	Jun 21, 2010
AB			**EQ 20MG BASE**	**A076968**	**002**	Jun 21, 2010
AB			**EQ 30MG BASE**	**A076968**	**003**	Jun 21, 2010
AB			**EQ 40MG BASE**	**A076968**	**004**	Jun 21, 2010
AB		TEVA	**EQ 10MG BASE**	**A076618**	**001**	Aug 15, 2005
AB			**EQ 20MG BASE**	**A076618**	**002**	Aug 15, 2005
AB			**EQ 30MG BASE**	**A076618**	**003**	Aug 15, 2005
AB			**EQ 40MG BASE**	**A076618**	**004**	Aug 15, 2005
AB		YILING	**EQ 10MG BASE**	**A211248**	**001**	Nov 02, 2021
AB			**EQ 20MG BASE**	**A211248**	**002**	Nov 02, 2021
AB			**EQ 30MG BASE**	**A211248**	**003**	Nov 02, 2021
AB			**EQ 40MG BASE**	**A211248**	**004**	Nov 02, 2021
AB		ZYDUS PHARMS USA	**EQ 10MG BASE**	**A077584**	**001**	Mar 07, 2007
AB			**EQ 20MG BASE**	**A077584**	**002**	Mar 07, 2007
AB			**EQ 30MG BASE**	**A077584**	**003**	Mar 07, 2007
AB			**EQ 40MG BASE**	**A077584**	**004**	Mar 07, 2007

PAXIL

AB	+	APOTEX TECHNOLOGIES	**EQ 10MG BASE**	**N020031**	**001**	Dec 29, 1992
AB	+		**EQ 20MG BASE**	**N020031**	**002**	Dec 29, 1992
AB	+		**EQ 30MG BASE**	**N020031**	**003**	Dec 29, 1992
AB	+!		**EQ 40MG BASE**	**N020031**	**005**	Dec 29, 1992

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	**EQ 12.5MG BASE**	**A077873**	**001**	Jun 29, 2007
AB			**EQ 25MG BASE**	**A077873**	**002**	Jun 29, 2007
AB			**EQ 37.5MG BASE**	**A091427**	**001**	Apr 14, 2011
AB		CADILA PHARMS LTD	**EQ 12.5MG BASE**	**A212645**	**001**	Aug 27, 2021
AB			**EQ 25MG BASE**	**A212645**	**002**	Aug 27, 2021
AB			**EQ 37.5MG BASE**	**A212645**	**003**	Aug 27, 2021
AB		CSPC OUYI	**EQ 12.5MG BASE**	**A213485**	**001**	Feb 16, 2021
AB			**EQ 25MG BASE**	**A213485**	**002**	Feb 16, 2021
AB			**EQ 37.5MG BASE**	**A213485**	**003**	Feb 16, 2021
AB		LANNETT CO INC	**EQ 12.5MG BASE**	**A204744**	**001**	Jun 10, 2016
AB			**EQ 25MG BASE**	**A204744**	**002**	Jun 10, 2016
AB			**EQ 37.5MG BASE**	**A204744**	**003**	Jun 10, 2016
AB		LUPIN LTD	**EQ 12.5MG BASE**	**A204134**	**001**	Jan 20, 2017
AB			**EQ 25MG BASE**	**A204134**	**002**	Jan 20, 2017
AB			**EQ 37.5MG BASE**	**A204134**	**003**	Jan 20, 2017
AB		SCIECURE PHARMA INC	**EQ 12.5MG BASE**	**A209293**	**001**	Jun 12, 2018
AB			**EQ 25MG BASE**	**A209293**	**002**	Jun 12, 2018
AB			**EQ 37.5MG BASE**	**A209293**	**003**	Jun 12, 2018
AB		SINOTHERAPEUTICS INC	**EQ 12.5MG BASE**	**A213612**	**001**	Aug 11, 2021
AB			**EQ 25MG BASE**	**A213612**	**002**	Aug 11, 2021

PAXIL CR

AB	+	APOTEX TECHNOLOGIES	**EQ 12.5MG BASE**	**N020936**	**001**	Feb 16, 1999
AB	+		**EQ 25MG BASE**	**N020936**	**002**	Feb 16, 1999
AB	+!		**EQ 37.5MG BASE**	**N020936**	**003**	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE;ORAL

BRISDELLE

AB	+!	SEBELA IRELAND LTD	**EQ 7.5MG BASE**	**N204516**	**001**	Jun 28, 2013

PAROXETINE MESYLATE

AB		ACTAVIS LABS FL INC	**EQ 7.5MG BASE**	**A207139**	**001**	Jun 20, 2017
AB		PRINSTON INC	**EQ 7.5MG BASE**	**A207188**	**001**	Aug 18, 2017

TABLET;ORAL

PEXEVA

	+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299	001	Jul 03, 2003

PAROXETINE MESYLATE
TABLET;ORAL
PEXEVA

+		EQ 20MG BASE	N021299	002	Jul 03, 2003
+		EQ 30MG BASE	N021299	003	Jul 03, 2003
+!		EQ 40MG BASE	N021299	004	Jul 03, 2003

PASIREOTIDE DIASPARTATE
SOLUTION;SUBCUTANEOUS
SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
+!		EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012

PASIREOTIDE PAMOATE
FOR SUSPENSION;INTRAMUSCULAR
SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014
+!		EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014

PATIROMER SORBITEX CALCIUM
POWDER;ORAL
VELTASSA

+	VIFOR PHARMA	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015
+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015
+!		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015

PATISIRAN SODIUM
SOLUTION;INTRAVENOUS
ONPATTRO

+!	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922	001	Aug 10, 2018

PAZOPANIB HYDROCHLORIDE
TABLET;ORAL
VOTRIENT

+!	NOVARTIS	EQ 200MG BASE	N022465	001	Oct 19, 2009

PEGCETACOPLAN
SOLUTION;SUBCUTANEOUS
EMPAVELI

+!	APELLIS PHARMS	1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021

PEMETREXED
SOLUTION;INTRAVENOUS
PEMFEXY

+!	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020

PEMETREXED DISODIUM
POWDER;INTRAVENOUS
ALIMTA

+!	LILLY	EQ 100MG BASE/VIAL	N021462	002	Sep 07, 2007
+!		EQ 500MG BASE/VIAL	N021462	001	Feb 04, 2004

PEMIGATINIB
TABLET;ORAL
PEMAZYRE

+	INCYTE CORP	4.5MG	N213736	001	Apr 17, 2020
+		9MG	N213736	002	Apr 17, 2020
+!		13.5MG	N213736	003	Apr 17, 2020

PENCICLOVIR
CREAM;TOPICAL
DENAVIR

+!	MYLAN	1%	N020629	001	Sep 24, 1996

PENICILLAMINE
CAPSULE;ORAL
CUPRIMINE

AB	**+!**	VALEANT PHARMS INTL	**250MG**	**N019853**	**001**	

PENICILLAMINE

AB		ANI PHARMS	**250MG**	**A209921**	**001**	May 07, 2019
AB		APOTEX	**250MG**	**A213310**	**001**	Apr 28, 2020
AB		BRECKENRIDGE	**250MG**	**A215409**	**001**	Aug 23, 2021
AB		DR REDDYS	**250MG**	**A211867**	**001**	Aug 04, 2020
AB		GRANULES	**250MG**	**A211735**	**001**	Dec 02, 2020

PENICILLAMINE
CAPSULE;ORAL
PENICILLAMINE

AB		INVAGEN PHARMS	**250MG**	**A213293**	**001**	Aug 19, 2021
AB		NAVINTA LLC	**250MG**	**A214363**	**001**	Oct 08, 2021
AB		PAR PHARM INC	**250MG**	**A211231**	**001**	Dec 23, 2019
AB		WATSON LABS INC	**250MG**	**A210976**	**001**	Jun 24, 2019

TABLET;ORAL
DEPEN

AB	**+!**	MYLAN SPECIALITY LP	**250MG**	**N019854**	**001**	

PENICILLAMINE

AB		LUPIN LTD	**250MG**	**A212933**	**001**	Nov 30, 2020
AB		PAR PHARM INC	**250MG**	**A211196**	**001**	Dec 23, 2019

PENICILLIN G BENZATHINE
INJECTABLE;INJECTION
BICILLIN L-A

BC	+!	KING PHARMS LLC	600,000 UNITS/ML	N050141	001	

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE
INJECTABLE;INJECTION
BICILLIN C-R

	+!	KING PHARMS LLC	300,000 UNITS/ML;300,000 UNITS/ML	N050138	001	

BICILLIN C-R 900/300

	+!	KING PHARMS LLC	900,000 UNITS/2ML;300,000 UNITS/2ML	N050138	003	

PENICILLIN G POTASSIUM
INJECTABLE;INJECTION
PENICILLIN G POTASSIUM

AP		ACS DOBFAR SPA	**20,000,000 UNITS/VIAL**	**A205043**	**002**	Oct 26, 2018
AP			**5,000,000 UNITS/VIAL**	**A205043**	**001**	Oct 26, 2018
AP		HQ SPECLT PHARMA	**5,000,000 UNITS/VIAL**	**A065149**	**002**	Jul 23, 2009
AP			**20,000,000 UNITS/VIAL**	**A065149**	**003**	Jul 23, 2009
AP		ISTITUTO BIO ITA SPA	**5,000,000 UNITS/VIAL**	**A065448**	**001**	Aug 18, 2009
AP			**20,000,000 UNITS/VIAL**	**A065448**	**002**	Aug 18, 2009
AP		SANDOZ	**5,000,000 UNITS/VIAL**	**A065079**	**002**	Aug 30, 2002
AP			**20,000,000 UNITS/VIAL**	**A065079**	**003**	Aug 30, 2002

PFIZERPEN

AP	**!**	PFIZER	**5,000,000 UNITS/VIAL**	**A060657**	**002**	
AP	**!**		**20,000,000 UNITS/VIAL**	**A060657**	**003**	

PENICILLIN G POTASSIUM

		HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	20,000 UNITS/ML	N050638	001	Jun 25, 1990
	+!		40,000 UNITS/ML	N050638	002	Jun 25, 1990
	+!		60,000 UNITS/ML	N050638	003	Jun 25, 1990

PENICILLIN G PROCAINE
INJECTABLE;INJECTION
PENICILLIN G PROCAINE

	!	KING PHARMS LLC	300,000 UNITS/ML	A060101	002	
	!		600,000 UNITS/ML	A060101	001	

PENICILLIN G SODIUM
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
PENICILLIN G SODIUM

	!	SANDOZ	5,000,000 UNITS/VIAL	A065068	001	Feb 26, 2001

PENICILLIN V POTASSIUM
FOR SOLUTION;ORAL
PENICILLIN-VK

		TEVA	EQ 125MG BASE/5ML	A060456	001	
	!		EQ 250MG BASE/5ML	A060456	002	

TABLET;ORAL
PENICILLIN V POTASSIUM

AB		AUROBINDO PHARMA	**EQ 250MG BASE**	**A065435**	**001**	Apr 29, 2008
AB			**EQ 500MG BASE**	**A065435**	**002**	Apr 29, 2008
AB		HIKMA PHARMS	**EQ 250MG BASE**	**A090549**	**001**	Oct 11, 2013
AB			**EQ 500MG BASE**	**A090549**	**002**	Oct 11, 2013
AB		SANDOZ	**EQ 250MG BASE**	**A064071**	**001**	Nov 30, 1995
AB	**!**		**EQ 500MG BASE**	**A064071**	**002**	Nov 30, 1995
AB		STRIDES PHARMA	**EQ 250MG BASE**	**A062936**	**001**	Nov 25, 1988
AB			**EQ 500MG BASE**	**A062935**	**001**	Nov 23, 1988

PENICILLIN V POTASSIUM

TABLET;ORAL

PENICILLIN-VK

AB		TEVA	**EQ 250MG BASE**	**A060711**	**002**	
AB			**EQ 500MG BASE**	**A060711**	**003**	

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

AN	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019887**	**001**	Jun 15, 1989

PENTAMIDINE ISETHIONATE

AN		SETON PHARMS	**300MG/VIAL**	**A206667**	**001**	Apr 24, 2019

INJECTABLE;INJECTION

PENTAM

AP	**+!**	FRESENIUS KABI USA	**300MG/VIAL**	**N019264**	**001**	Oct 16, 1984

PENTAMIDINE ISETHIONATE

AP		EMCURE PHARMS LTD	**300MG/VIAL**	**A213806**	**001**	Jan 07, 2021
AP		SETON PHARMS	**300MG/VIAL**	**A206666**	**001**	Sep 28, 2017

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

NEMBUTAL SODIUM

AP	**+!**	AKORN	**50MG/ML**	**A083246**	**001**	

PENTOBARBITAL SODIUM

AP		ATHENEX	**50MG/ML**	**A206677**	**001**	Nov 27, 2017
AP		CUSTOPHARM INC	**50MG/ML**	**A203619**	**001**	Nov 13, 2017
AP		SAGENT PHARMS INC	**50MG/ML**	**A206404**	**001**	May 23, 2016

PENTOSAN POLYSULFATE SODIUM

CAPSULE;ORAL

ELMIRON

	+!	JANSSEN PHARMS	100MG	N020193	001	Sep 26, 1996

PENTOSTATIN

INJECTABLE;INJECTION

NIPENT

AP	**+!**	HOSPIRA INC	**10MG/VIAL**	**N020122**	**001**	Oct 11, 1991

PENTOSTATIN

AP		WEST-WARD PHARMS INT	**10MG/VIAL**	**A077841**	**001**	Aug 07, 2007

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	**!**	APOTEX	**400MG**	**A075191**	**001**	Jun 09, 1999
AB		VALEANT PHARMS	**400MG**	**A075028**	**001**	Jul 20, 1998

PERAMIVIR

SOLUTION;INTRAVENOUS

RAPIVAB

	+!	BIOCRYST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014

PERAMPANEL

SUSPENSION;ORAL

FYCOMPA

	+!	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016

TABLET;ORAL

FYCOMPA

	+	EISAI INC	2MG	N202834	001	Oct 22, 2012
	+		4MG	N202834	002	Oct 22, 2012
	+		6MG	N202834	003	Oct 22, 2012
	+		8MG	N202834	004	Oct 22, 2012
	+		10MG	N202834	005	Oct 22, 2012
	+!		12MG	N202834	006	Oct 22, 2012

PERFLUTREN

INJECTABLE;INTRAVENOUS

DEFINITY

	+!	LANTHEUS MEDCL	6.52MG/ML	N021064	001	Jul 31, 2001

DEFINITY RT

	+!	LANTHEUS MEDCL	6.52MG/ML	N021064	002	Nov 17, 2020

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

AB		AUROBINDO PHARMA	**2MG**	**A079070**	**001**	Nov 10, 2009
AB			**4MG**	**A079070**	**002**	Nov 10, 2009
AB	**!**		**8MG**	**A079070**	**003**	Nov 10, 2009
AB		HIKMA	**2MG**	**A090072**	**001**	Nov 10, 2009
AB			**4MG**	**A090072**	**002**	Nov 10, 2009
AB			**8MG**	**A090072**	**003**	Nov 10, 2009

PERMETHRIN

CREAM;TOPICAL

PERMETHRIN

AB		ACTAVIS LABS	**5%**	**A074806**	**001**	Jan 23, 1998
AB		ENCUBE ETHICALS	**5%**	**A211303**	**001**	Apr 03, 2019
AB	**!**	PADAGIS ISRAEL	**5%**	**A076369**	**001**	Apr 21, 2003

PERPHENAZINE

TABLET;ORAL

PERPHENAZINE

AB		MYLAN	**2MG**	**A206691**	**001**	Apr 14, 2017
AB			**4MG**	**A206691**	**002**	Apr 14, 2017
AB			**8MG**	**A206691**	**003**	Apr 14, 2017
AB			**16MG**	**A206691**	**004**	Apr 14, 2017
AB		RISING	**2MG**	**A205056**	**001**	Mar 01, 2019
AB			**4MG**	**A205056**	**002**	Mar 01, 2019
AB			**8MG**	**A205056**	**003**	Mar 01, 2019
AB			**16MG**	**A205056**	**004**	Mar 01, 2019
AB		SANDOZ	**2MG**	**A089685**	**002**	Dec 08, 1988
AB			**4MG**	**A089685**	**003**	Dec 08, 1988
AB			**8MG**	**A089685**	**001**	Dec 08, 1988
AB	**!**		**16MG**	**A089685**	**004**	Dec 08, 1988
AB		VINTAGE PHARMS	**2MG**	**A040226**	**001**	Dec 31, 1998
AB			**4MG**	**A040226**	**002**	Dec 31, 1998
AB			**8MG**	**A040226**	**003**	Dec 31, 1998
AB			**16MG**	**A040226**	**004**	Dec 31, 1998
AB		WATSON LABS INC	**2MG**	**A207582**	**001**	Oct 17, 2016
AB			**4MG**	**A207582**	**002**	Oct 17, 2016
AB			**8MG**	**A207582**	**003**	Oct 17, 2016
AB			**16MG**	**A207582**	**004**	Oct 17, 2016
AB		WILSHIRE PHARMS INC	**2MG**	**A205973**	**001**	Dec 17, 2015
AB			**4MG**	**A205973**	**002**	Dec 17, 2015
AB			**8MG**	**A205973**	**003**	Dec 17, 2015
AB			**16MG**	**A205973**	**004**	Dec 17, 2015
AB		ZYDUS PHARMS	**2MG**	**A205232**	**001**	Apr 06, 2020
AB			**4MG**	**A205232**	**002**	Apr 06, 2020
AB			**8MG**	**A205232**	**003**	Apr 06, 2020
AB			**16MG**	**A205232**	**004**	Apr 06, 2020

PEXIDARTINIB HYDROCHLORIDE

CAPSULE;ORAL

TURALIO

	+!	DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENDIMETRAZINE TARTRATE

	+!	VIRTUS PHARMS	105MG	N018074	001	

TABLET;ORAL

BONTRIL PDM

AA	**+!**	VALEANT	**35MG**	**A085272**	**001**	

PHENDIMETRAZINE TARTRATE

AA		ELITE LABS INC	**35MG**	**A040762**	**001**	Jan 28, 2008
AA		KVK TECH	**35MG**	**A091042**	**001**	Aug 31, 2010
AA		MIKART	**35MG**	**A089452**	**001**	Oct 30, 1991
AA		VIRTUS PHARMS	**35MG**	**A085588**	**001**	

PHENELZINE SULFATE

TABLET;ORAL

NARDIL

AB	**+!**	PARKE DAVIS	**EQ 15MG BASE**	**N011909**	**002**	

PHENELZINE SULFATE

AB		NOVEL LABS INC	**EQ 15MG BASE**	**A200181**	**001**	Dec 08, 2010

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE							
AB	**+**	CONCORDIA	**10MG**	**N008708**	**001**		
PHENOXYBENZAMINE HYDROCHLORIDE							
AB		AMNEAL	**10MG**	**A212568**	**001**	Oct 27, 2020	
AB		HIKMA	**10MG**	**A201050**	**001**	Jul 16, 2012	
AB	**!**	PAR PHARM INC	**10MG**	**A204522**	**001**	Jan 24, 2017	

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

ADIPEX-P							
AA	**+!**	TEVA	**37.5MG**	**A088023**	**001**	Aug 02, 1983	
PHENTERMINE HYDROCHLORIDE							
AA		AUROLIFE PHARMA LLC	**15MG**	**A204318**	**001**	Nov 09, 2016	
AA			**30MG**	**A204318**	**002**	Nov 09, 2016	
AA		ELITE LABS	**15MG**	**A202248**	**001**	Sep 28, 2012	
AA			**30MG**	**A202248**	**002**	Sep 28, 2012	
AA		ELITE LABS INC	**37.5MG**	**A040228**	**001**	Jun 19, 1997	
AA		INVAGEN PHARMS	**15MG**	**A202858**	**001**	Feb 14, 2014	
AA			**30MG**	**A202858**	**002**	Feb 14, 2014	
AA			**30MG**	**A204414**	**001**	May 05, 2014	
AA			**37.5MG**	**A202846**	**001**	Feb 05, 2014	
AA		KVK TECH	**15MG**	**A040886**	**002**	Mar 31, 2008	
AA			**30MG**	**A040875**	**001**	Mar 21, 2008	
AA			**30MG**	**A040886**	**001**	Mar 31, 2008	
AA			**37.5MG**	**A040887**	**001**	Apr 24, 2008	
AA		LANNETT	**15MG**	**A087022**	**002**	Jan 20, 2012	
AA			**30MG**	**A087022**	**001**	Feb 03, 1983	
AA		LANNETT CO INC	**37.5MG**	**A201961**	**001**	Jul 20, 2011	
AA		NUVO PHARM	**15MG**	**A205019**	**001**	Dec 05, 2014	
AA			**30MG**	**A205019**	**002**	Dec 05, 2014	
AA			**37.5MG**	**A205017**	**001**	Sep 25, 2014	
AA	**+!**	SANDOZ	**15MG**	**A087190**	**002**		
AA	**+!**		**30MG**	**A086945**	**001**	Jul 20, 1983	
AA	**!**		**30MG**	**A087190**	**001**		
AA		SUN PHARM INDUSTRIES	**30MG**	**A040525**	**001**	Oct 23, 2003	

TABLET;ORAL

ADIPEX-P							
AA	**+!**	TEVA	**37.5MG**	**A085128**	**001**		
LOMAIRA							
AA	**!**	AVANTHI INC	**8MG**	**A203495**	**001**	Sep 12, 2016	
PHENTERMINE HYDROCHLORIDE							
AA		AUROLIFE PHARMA LLC	**37.5MG**	**A203068**	**001**	Aug 06, 2014	
AA		ELITE LABS	**37.5MG**	**A200272**	**001**	Jan 31, 2011	
AA		ELITE LABS INC	**37.5MG**	**A040190**	**001**	May 30, 1997	
AA		INVAGEN PHARMS	**37.5MG**	**A202942**	**001**	Feb 05, 2014	
AA		KVK TECH	**37.5MG**	**A040876**	**001**	Mar 31, 2008	
AA		KVK TECH INC	**8MG**	**A203436**	**001**	Mar 17, 2017	
AA		LANNETT	**37.5MG**	**A040555**	**001**	Apr 15, 2005	
AA		MERRO PHARM USA	**37.5MG**	**A206342**	**001**	Nov 18, 2016	
AA		NUVO PHARM	**37.5MG**	**A205008**	**001**	Sep 25, 2014	
AA		PRINSTON INC	**37.5MG**	**A040377**	**001**	Jan 04, 2002	
AA		SUN PHARM INDUSTRIES	**37.5MG**	**A040526**	**001**	Oct 23, 2003	

TABLET, ORALLY DISINTEGRATING;ORAL

PHENTERMINE HYDROCHLORIDE						
	ZYDUS PHARMS	15MG	A204663	001	Jun 28, 2017	
		30MG	A204663	002	Jun 28, 2017	
		37.5MG	A204663	003	Jun 28, 2017	

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QSYMIA						
+	VIVUS	EQ 3.75MG BASE;23MG	N022580	001	Jul 17, 2012	
+		EQ 7.5MG BASE;46MG	N022580	002	Jul 17, 2012	
+		EQ 11.25MG BASE;69MG	N022580	003	Jul 17, 2012	
+!		EQ 15MG BASE;92MG	N022580	004	Jul 17, 2012	

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

PHENTOLAMINE MESYLATE

AP	**!**	HIKMA	**5MG/VIAL**	**A040235**	**001**	Mar 11, 1998
AP		PRECISION DOSE INC	**5MG/VIAL**	**A207686**	**001**	Jul 14, 2017

ORAVERSE

	+!	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		AMNEAL	**10MG/ML (10MG/ML)**	**A211079**	**001**	Jul 05, 2018
AP1			**50MG/5ML (10MG/ML)**	**A211078**	**001**	Jul 19, 2018
AP1			**100MG/10ML (10MG/ML)**	**A211078**	**002**	Jul 19, 2018
AP1		CAPLIN	**10MG/ML (10MG/ML)**	**A213318**	**001**	Jun 11, 2020
AP1			**50MG/5ML (10MG/ML)**	**A213318**	**002**	Jun 11, 2020
AP1			**100MG/10ML (10MG/ML)**	**A213318**	**003**	Jun 11, 2020
AP1		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A210697**	**001**	Nov 13, 2020
AP1			**100MG/10ML (10MG/ML)**	**A210697**	**002**	Nov 13, 2020
AP1		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A210666**	**001**	Jan 30, 2019
AP1			**100MG/10ML (10MG/ML)**	**A210666**	**002**	Jan 30, 2019
AP1		GLAND PHARMA LTD	**10MG/ML (10MG/ML)**	**A211920**	**003**	Apr 08, 2021
AP1			**50MG/5ML (10MG/ML)**	**A211920**	**001**	Jun 05, 2020
AP1			**100MG/10ML (10MG/ML)**	**A211920**	**002**	Jun 05, 2020
AP1		MEITHEAL	**50MG/5ML (10MG/ML)**	**A210333**	**001**	Apr 27, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210333**	**002**	Apr 27, 2018
AP1		PAR STERILE PRODUCTS	**10MG/ML (10MG/ML)**	**A210025**	**001**	Dec 21, 2018
AP1			**50MG/5ML (10MG/ML)**	**A210025**	**002**	Dec 21, 2018
AP1			**100MG/10ML (10MG/ML)**	**A210025**	**003**	Dec 21, 2018
AP1		PROVEPHARM SAS	**10MG/ML (10MG/ML)**	**A211081**	**001**	Jul 17, 2020
AP1			**50MG/5ML (10MG/ML)**	**A211081**	**002**	Jul 17, 2020
AP1			**100MG/10ML (10MG/ML)**	**A211081**	**003**	Jul 17, 2020
AP1		SAGENT PHARMS INC	**10MG/ML (10MG/ML)**	**A209967**	**001**	Jan 16, 2020
AP1			**50MG/5ML (10MG/ML)**	**A209967**	**002**	Jan 16, 2020
AP1			**100MG/10ML (10MG/ML)**	**A209967**	**003**	Jan 16, 2020
AP1		SANDOZ INC	**10MG/ML (10MG/ML)**	**A208905**	**001**	Jan 31, 2019
AP1			**50MG/5ML (10MG/ML)**	**A208905**	**002**	Jan 31, 2019
AP1			**100MG/10ML (10MG/ML)**	**A208905**	**003**	Jan 31, 2019

VAZCULEP

AP1	**+!**	EXELA PHARMA	**10MG/ML (10MG/ML)**	**N204300**	**001**	Jun 27, 2014
AP1	**+!**		**50MG/5ML (10MG/ML)**	**N204300**	**002**	Jun 27, 2014
AP1	**+!**		**100MG/10ML (10MG/ML)**	**N204300**	**003**	Jun 27, 2014

PHENYLEPHRINE HYDROCHLORIDE

AP2		EUGIA PHARMA	**10MG/ML (10MG/ML)**	**A210696**	**001**	Jan 07, 2021
AP2		FRESENIUS KABI USA	**10MG/ML (10MG/ML)**	**A210665**	**001**	Jan 29, 2019
AP2	**+!**	HIKMA	**10MG/ML (10MG/ML)**	**N203826**	**001**	Dec 20, 2012
AP2	**+!**		**50MG/5ML (10MG/ML)**	**N203826**	**002**	Jun 19, 2019
AP2	**+!**		**100MG/10ML (10MG/ML)**	**N203826**	**003**	Jun 19, 2019
AP2		MEITHEAL	**10MG/ML (10MG/ML)**	**A210334**	**001**	Apr 27, 2018

BIORPHEN

	+!	ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	**+!**	AKORN	**2.5%**	**N207926**	**001**	Jan 15, 2015
AT	**+!**		**10%**	**N207926**	**002**	Jan 15, 2015
AT	**+!**	PARAGON BIOTECK	**2.5%**	**N203510**	**001**	Mar 21, 2013
AT	**+!**		**10%**	**N203510**	**002**	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA		AKORN	**5MG/5ML;6.25MG/5ML**	**A040675**	**001**	Dec 23, 2014
AA	**!**	PHARM ASSOC	**5MG/5ML;6.25MG/5ML**	**A040654**	**001**	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

AA		AMNEAL PHARMS	**5MG/5ML;6.25MG/5ML**	**A040902**	**001**	Aug 25, 2009

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

AB	**+!**	UPJOHN	**125MG/5ML**	**N008762**	**001**	

PHENYTOIN

AB		TARO	**125MG/5ML**	**A040521**	**001**	Mar 08, 2004
AB		VISTAPHARM	**125MG/5ML**	**A040342**	**001**	Jan 31, 2001

PHENYTOIN						
SUSPENSION;ORAL						
PHENYTOIN						
AB			**125MG/5ML**	**A040610**	**001**	Aug 18, 2005
AB		WOCKHARDT BIO AG	**125MG/5ML**	**A040420**	**001**	Apr 19, 2002
TABLET, CHEWABLE;ORAL						
DILANTIN						
AB	**+!**	PHARMACIA	**50MG**	**A084427**	**001**	
PHENYTOIN						
AB		EPIC PHARMA LLC	**50MG**	**A040884**	**001**	Nov 28, 2014
AB		RISING	**50MG**	**A200691**	**001**	Dec 26, 2012
AB		TARO	**50MG**	**A200565**	**001**	Apr 17, 2014
PHENYTOIN SODIUM						
CAPSULE;ORAL						
DILANTIN						
AB	**+!**	UPJOHN	**100MG EXTENDED**	**A084349**	**002**	
EXTENDED PHENYTOIN SODIUM						
AB		AMNEAL PHARMS NY	**100MG EXTENDED**	**A040765**	**001**	Nov 12, 2008
AB		MYLAN	**100MG EXTENDED**	**A040298**	**001**	Dec 28, 1998
AB		SUN PHARM INDS	**200MG EXTENDED**	**A040731**	**001**	Jun 30, 2008
AB			**300MG EXTENDED**	**A040731**	**002**	Jun 30, 2008
AB		TARO	**100MG EXTENDED**	**A040684**	**001**	Sep 05, 2006
PHENYTEK						
AB		MYLAN	**200MG EXTENDED**	**A040298**	**002**	Dec 06, 2001
AB	**!**		**300MG EXTENDED**	**A040298**	**003**	Dec 06, 2001
PHENYTOIN SODIUM						
AB		AURORBINDO PHARMA LTD	**100MG EXTENDED**	**A204309**	**001**	Jun 10, 2015
DILANTIN						
	+!	UPJOHN	30MG EXTENDED	A084349	001	
INJECTABLE;INJECTION						
PHENYTOIN SODIUM						
AP		ACELLA	**50MG/ML**	**A040573**	**001**	Sep 13, 2006
AP	**+!**	WEST-WARD PHARMS INT	**50MG/ML**	**A084307**	**001**	
PHYTONADIONE						
INJECTABLE;INJECTION						
PHYTONADIONE						
AB		DR REDDYS LABS LTD	**10MG/ML**	**A207719**	**001**	May 22, 2019
VITAMIN K1						
AB	**+!**	HOSPIRA	**10MG/ML**	**A087955**	**001**	Jul 25, 1983
PHYTONADIONE						
BP	+!	INTL MEDICATION	1MG/0.5ML	A083722	001	
VITAMIN K1						
BP	+!	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983
TABLET;ORAL						
MEPHYTON						
AB	**+!**	BAUSCH	**5MG**	**N010104**	**003**	
PHYTONADIONE						
AB		AMNEAL PHARMS CO	**5MG**	**A209373**	**001**	May 11, 2018
AB		ZYDUS	**5MG**	**A210189**	**001**	Feb 20, 2019
PIFLUFOLASTAT F-18						
SOLUTION;INTRAVENOUS						
PYLARIFY						
	+!	PROGENICS PHARMS INC	50ML (1-80mCi/ML)	N214793	001	May 26, 2021
PILOCARPINE HYDROCHLORIDE						
SOLUTION;OPHTHALMIC						
ISOPTO CARPINE						
AT	**+**	NOVARTIS	**1%**	**N200890**	**001**	Jun 22, 2010
AT	**+**		**2%**	**N200890**	**002**	Jun 22, 2010
AT	**+!**		**4%**	**N200890**	**003**	Jun 22, 2010
PILOCARPINE HYDROCHLORIDE						
AT		AKORN	**1%**	**A204398**	**001**	Sep 27, 2017
AT			**2%**	**A204398**	**002**	Sep 27, 2017
AT			**4%**	**A204398**	**003**	Sep 27, 2017
AT		AMNEAL	**1%**	**A214193**	**001**	Sep 21, 2020
AT			**2%**	**A214193**	**002**	Sep 21, 2020
AT			**4%**	**A214193**	**003**	Sep 21, 2020
AT		SOMERSET THERAPS LLC	**1%**	**A210384**	**001**	Nov 25, 2019

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

AT			**2%**	**A210384**	**002**	Nov 25, 2019
AT			**4%**	**A210384**	**003**	Nov 25, 2019

VUITY

+!	ABBVIE INC	1.25%	N214028	001	Oct 28, 2021

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AMICI	**5MG**	**A076963**	**001**	Dec 22, 2004
AB			**7.5MG**	**A076963**	**002**	Feb 27, 2007
AB		AUROBINDO PHARMA LTD	**5MG**	**A212377**	**001**	Aug 13, 2019
AB			**7.5MG**	**A212377**	**002**	Aug 13, 2019
AB		IMPAX LABS	**5MG**	**A077248**	**001**	Mar 31, 2006
AB			**7.5MG**	**A077248**	**002**	Mar 31, 2006
AB		LANNETT CO INC	**5MG**	**A077220**	**001**	Oct 14, 2005
AB			**7.5MG**	**A077220**	**002**	May 06, 2009
AB		PADAGIS US	**5MG**	**A076746**	**001**	Nov 16, 2004

SALAGEN

AB	**+**	CONCORDIA	**5MG**	**N020237**	**001**	Mar 22, 1994
AB	**+!**		**7.5MG**	**N020237**	**002**	Apr 18, 2003

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

+!	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018

TABLET;ORAL

NUPLAZID

+!	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018

PIMECROLIMUS

CREAM;TOPICAL

ELIDEL

AB	**+!**	BAUSCH	**1%**	**N021302**	**001**	Dec 13, 2001

PIMECROLIMUS

AB		ACTAVIS LABS UT INC	**1%**	**A209345**	**001**	Dec 27, 2018
AB		GLENMARK PHARMS LTD	**1%**	**A211769**	**001**	Aug 29, 2019

PIMOZIDE

TABLET;ORAL

PIMOZIDE

	PAR PHARM	1MG	A204521	001	Sep 28, 2015
!		2MG	A204521	002	Sep 28, 2015

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		ANI PHARMS	**5MG**	**A073609**	**002**	Mar 29, 1993
AB			**10MG**	**A073609**	**001**	Mar 29, 1993
AB		BAYSHORE PHARMS LLC	**5MG**	**A211712**	**001**	Aug 01, 2019
AB			**10MG**	**A211712**	**002**	Aug 01, 2019
AB		MYLAN PHARMS INC	**5MG**	**A074019**	**001**	Sep 03, 1992
AB	**!**		**10MG**	**A074019**	**002**	Sep 03, 1992
AB		NOSTRUM LABS INC	**5MG**	**A205415**	**001**	Jan 13, 2016
AB			**10MG**	**A205415**	**002**	Jan 13, 2016
AB		SUN PHARM INDUSTRIES	**5MG**	**A074063**	**001**	Jan 27, 1994
AB			**10MG**	**A074063**	**002**	Jan 27, 1994

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOS

AB	**+**	TAKEDA PHARMS USA	**EQ 15MG BASE**	**N021073**	**001**	Jul 15, 1999
AB	**+**		**EQ 30MG BASE**	**N021073**	**002**	Jul 15, 1999
AB	**+!**		**EQ 45MG BASE**	**N021073**	**003**	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 15MG BASE**	**A200044**	**001**	Feb 13, 2013
AB			**EQ 30MG BASE**	**A200044**	**002**	Feb 13, 2013
AB			**EQ 45MG BASE**	**A200044**	**003**	Feb 13, 2013
AB		ANNORA PHARMA	**EQ 15MG BASE**	**A204133**	**001**	Apr 07, 2014
AB			**EQ 30MG BASE**	**A204133**	**002**	Apr 07, 2014
AB			**EQ 45MG BASE**	**A204133**	**003**	Apr 07, 2014
AB		AUROBINDO PHARMA LTD	**EQ 15MG BASE**	**A200268**	**001**	Feb 13, 2013

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		**EQ 30MG BASE**	**A200268**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A200268**	**003**	Feb 13, 2013
AB	CELLTRION	**EQ 15MG BASE**	**A076798**	**001**	Oct 26, 2012
AB		**EQ 30MG BASE**	**A076798**	**002**	Oct 26, 2012
AB		**EQ 45MG BASE**	**A076798**	**003**	Oct 26, 2012
AB	MACLEODS PHARMS LTD	**EQ 15MG BASE**	**A202467**	**001**	Feb 06, 2013
AB		**EQ 30MG BASE**	**A202467**	**002**	Feb 06, 2013
AB		**EQ 45MG BASE**	**A202467**	**003**	Feb 06, 2013
AB	PRINSTON INC	**EQ 15MG BASE**	**A207806**	**001**	Apr 17, 2018
AB		**EQ 30MG BASE**	**A207806**	**002**	Apr 17, 2018
AB		**EQ 45MG BASE**	**A207806**	**003**	Apr 17, 2018
AB	PURACAP PHARM LLC	**EQ 15MG BASE**	**A206738**	**001**	Oct 06, 2017
AB		**EQ 30MG BASE**	**A206738**	**002**	Oct 06, 2017
AB		**EQ 45MG BASE**	**A206738**	**003**	Oct 06, 2017
AB	SANDOZ	**EQ 15MG BASE**	**A078670**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A078670**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A078670**	**003**	Feb 13, 2013
AB	SHUANGCHENG	**EQ 15MG BASE**	**A210165**	**001**	Jan 22, 2021
AB		**EQ 30MG BASE**	**A210165**	**002**	Jan 22, 2021
AB		**EQ 45MG BASE**	**A210165**	**003**	Jan 22, 2021
AB	TEVA PHARMS USA	**EQ 15MG BASE**	**A077210**	**001**	Jan 10, 2014
AB		**EQ 30MG BASE**	**A077210**	**002**	Jan 10, 2014
AB		**EQ 45MG BASE**	**A077210**	**003**	Jan 10, 2014
AB	ZYDUS PHARMS USA INC	**EQ 15MG BASE**	**A202456**	**001**	Feb 13, 2013
AB		**EQ 30MG BASE**	**A202456**	**002**	Feb 13, 2013
AB		**EQ 45MG BASE**	**A202456**	**003**	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
!		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
!		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
!		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	ASTRAL	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A212287**	**001**	Jul 29, 2019
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A212287**	**002**	Jul 29, 2019
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A212287**	**003**	Jul 29, 2019
AP	AUROBINDO PHARMA LTD	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065498**	**001**	May 23, 2011
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065498**	**002**	May 23, 2011
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065498**	**003**	May 23, 2011
AP	FRESENIUS KABI	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A203719**	**001**	May 18, 2018
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A203719**	**002**	May 18, 2018
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A203719**	**003**	May 18, 2018
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203720**	**001**	May 11, 2018
AP	FRESENIUS KABI USA	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A206204**	**001**	May 11, 2018
AP	ISTITUTO BIO ITA SPA	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065523**	**001**	May 31, 2011
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065523**	**002**	May 31, 2011
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065523**	**003**	May 31, 2011
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A090498**	**001**	May 31, 2011
AP	PROVEPHARM SAS	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A207847**	**001**	Jan 13, 2017
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A207847**	**002**	Jan 13, 2017
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207848**	**002**	Jan 13, 2017
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A207847**	**003**	Jan 13, 2017
AP		**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A207848**	**001**	May 11, 2018
AP	QILU	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A204959**	**001**	Aug 10, 2018
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A204959**	**002**	Aug 10, 2018
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A204959**	**003**	Aug 10, 2018
AP	SAGENT PHARMS INC	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A208674**	**001**	Feb 16, 2021
AP		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A208674**	**002**	Feb 16, 2021
AP		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A208674**	**003**	Feb 16, 2021
AP		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A208675**	**001**	Feb 16, 2021
AP	SANDOZ	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065362**	**001**	Oct 21, 2010
AP		**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A065363**	**001**	Oct 21, 2010

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065362**	**002**	Oct 21, 2010
AP			**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A065363**	**002**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065362**	**003**	Oct 21, 2010
AP			**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A065363**	**003**	Oct 21, 2010
AP		SANDOZ INC	**EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL**	**A203557**	**001**	Oct 29, 2014
AP			**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A203557**	**002**	Jul 08, 2021
AP	**!**	WOCKHARDT BIO AG	**EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL**	**A206996**	**001**	Mar 22, 2017
AP	**!**		**EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL**	**A206996**	**002**	Mar 22, 2017
AP	**!**		**EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL**	**A206996**	**003**	Mar 22, 2017
AP	**!**		**EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL**	**A207146**	**001**	Mar 17, 2017

ZOSYN IN PLASTIC CONTAINER

+!	WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
+!		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
+!		EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

AB	**+!**	GENENTECH INC	**267MG**	**N022535**	**001**	Oct 15, 2014

PIRFENIDONE

AB		AMNEAL	**267MG**	**A212569**	**001**	Jan 03, 2022

TABLET;ORAL

ESBRIET

+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017
+!		801MG	N208780	003	Jan 11, 2017

PIROXICAM

CAPSULE;ORAL

FELDENE

AB	**+**	PFIZER	**10MG**	**N018147**	**002**	Apr 06, 1982
AB	**+!**		**20MG**	**N018147**	**003**	Apr 06, 1982

PIROXICAM

AB		CADILA	**10MG**	**A205585**	**001**	Jul 17, 2018
AB			**20MG**	**A205585**	**002**	Jul 17, 2018
AB		FLAMINGO PHARMS	**10MG**	**A207938**	**001**	Sep 09, 2016
AB			**20MG**	**A207938**	**002**	Sep 09, 2016
AB		HIKMA	**10MG**	**A209256**	**001**	Aug 11, 2017
AB			**20MG**	**A209256**	**002**	Aug 11, 2017
AB		MICRO LABS	**10MG**	**A206152**	**001**	Dec 29, 2017
AB			**20MG**	**A206152**	**002**	Dec 29, 2017
AB		NOSTRUM LABS INC	**10MG**	**A074118**	**002**	Jun 15, 1993
AB			**20MG**	**A074118**	**001**	Jun 15, 1993
AB		STRIDES PHARMA	**10MG**	**A206136**	**001**	Jun 20, 2017
AB			**10MG**	**A210347**	**001**	Jan 26, 2018
AB			**20MG**	**A206136**	**002**	Jun 20, 2017
AB			**20MG**	**A210347**	**002**	Jan 26, 2018
AB		TEVA	**10MG**	**A074131**	**001**	Dec 11, 1992
AB			**20MG**	**A074131**	**002**	Dec 11, 1992
BX		UNICHEM	10MG	A208340	001	Apr 13, 2017
BX			20MG	A208340	002	Apr 13, 2017

PITAVASTATIN CALCIUM

TABLET;ORAL

LIVALO

AB	**+**	KOWA CO	**EQ 1MG BASE**	**N022363**	**001**	Aug 03, 2009
AB	**+**		**EQ 2MG BASE**	**N022363**	**002**	Aug 03, 2009
AB	**+!**		**EQ 4MG BASE**	**N022363**	**003**	Aug 03, 2009

PITAVASTATIN CALCIUM

AB		AUROBINDO PHARMA LTD	**EQ 1MG BASE**	**A206015**	**001**	Dec 20, 2016
AB			**EQ 2MG BASE**	**A206015**	**002**	Dec 20, 2016
AB			**EQ 4MG BASE**	**A206015**	**003**	Dec 20, 2016
AB		ORIENT PHARMA CO LTD	**EQ 1MG BASE**	**A205932**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205932**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205932**	**003**	Feb 03, 2017
AB		SAWAI USA	**EQ 1MG BASE**	**A205955**	**001**	Feb 03, 2017
AB			**EQ 2MG BASE**	**A205955**	**002**	Feb 03, 2017
AB			**EQ 4MG BASE**	**A205955**	**003**	Feb 03, 2017

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	MEDICURE	EQ 2MG BASE	N208379	002	Jul 14, 2017
+!		EQ 4MG BASE	N208379	003	Jul 14, 2017

PITOLISANT HYDROCHLORIDE

TABLET;ORAL

WAKIX

+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019
+!		EQ 17.8MG BASE	N211150	002	Aug 14, 2019

PLAZOMICIN SULFATE

SOLUTION;INTRAVENOUS

ZEMDRI

+!	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018

PLECANATIDE

TABLET;ORAL

TRULANCE

+!	SALIX	3MG	N208745	001	Jan 19, 2017

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

+!	GENZYME	24MG/1.2ML (20MG/ML)	N022311	001	Dec 15, 2008

PODOFILOX

GEL;TOPICAL

CONDYLOX

+!	ALLERGAN	0.5%	N020529	001	Mar 13, 1997

SOLUTION;TOPICAL

CONDYLOX

AT	**+!**	TEVA BRANDED PHARM	**0.5%**	**N019795**	**001**	Dec 13, 1990

PODOFILOX

AT	PADAGIS US	**0.5%**	**A075600**	**001**	Jan 29, 2002

POLIDOCANOL

SOLUTION;INTRAVENOUS

ASCLERA

+	CHEMISCH FBRK KRSSLR	10MG/2ML (5MG/ML)	N021201	001	Mar 30, 2010
+!		20MG/2ML (10MG/ML)	N021201	002	Mar 30, 2010

VARITHENA

+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017
+!		180MG/18ML (10MG/ML)	N205098	001	Nov 25, 2013

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

LAX-LYTE WITH FLAVOR PACKS

AA		L PERRIGO CO	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A079232**	**001**	Feb 25, 2010

NULYTELY

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**001**	Apr 22, 1991

NULYTELY-FLAVORED

AA	**+!**	BRAINTREE	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**N019797**	**002**	Nov 18, 1994

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

AA	NOVEL LABS INC	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A090019**	**001**	May 27, 2009
AA	STRIDES PHARMA	**420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT**	**A204559**	**001**	Apr 13, 2015

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

AA	MYLAN SPECIALITY LP	**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**N018983**	**012**	Oct 08, 1998

GOLYTELY

AA	**+!**	BRAINTREE	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**N019011**	**001**	Jul 13, 1984

PEG 3350 AND ELECTROLYTES

AA	NOVEL LABS INC	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A090231**	**001**	Jun 01, 2009
AA		**240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT**	**A090186**	**001**	Jun 01, 2009

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

AA		STRIDES PHARMA	**236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT**	**A204558**	**001**	Dec 21, 2018

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP		EUGIA PHARMA	**EQ 500,000 UNITS BASE/VIAL**	**A206589**	**001**	Apr 04, 2016
AP		FRESENIUS KABI USA	**EQ 500,000 UNITS BASE/VIAL**	**A065372**	**001**	Jan 10, 2008
AP	**!**	XELLIA PHARMS APS	**EQ 500,000 UNITS BASE/VIAL**	**A202766**	**001**	Jan 15, 2014
AP		XGEN PHARMS	**EQ 500,000 UNITS BASE/VIAL**	**A063000**	**001**	Sep 30, 1994

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

POLYTRIM

AT	**+!**	ALLERGAN	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**N050567**	**001**	Oct 20, 1988

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		AKORN	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A065006**	**001**	Dec 17, 1998
AT		BAUSCH AND LOMB	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064120**	**001**	Feb 14, 1997
AT		SANDOZ INC	**10,000 UNITS/ML;EQ 1MG BASE/ML**	**A064211**	**001**	Apr 13, 1998

POMALIDOMIDE

CAPSULE;ORAL

POMALYST

+		CELGENE	1MG	N204026	001	Feb 08, 2013
+			2MG	N204026	002	Feb 08, 2013
+			3MG	N204026	003	Feb 08, 2013
+!			4MG	N204026	004	Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

+		TAKEDA PHARMS USA	EQ 10MG BASE	N203469	004	Dec 18, 2020
+			EQ 15MG BASE	N203469	001	Dec 14, 2012
+			EQ 30MG BASE	N203469	003	Apr 23, 2015
+!			EQ 45MG BASE	N203469	002	Dec 14, 2012

PONESIMOD

TABLET;ORAL

PONVORY

+		JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021
+			3MG	N213498	002	Mar 18, 2021
+			4MG	N213498	003	Mar 18, 2021
+			5MG	N213498	004	Mar 18, 2021
+			6MG	N213498	005	Mar 18, 2021
+			7MG	N213498	006	Mar 18, 2021
+			8MG	N213498	007	Mar 18, 2021
+			9MG	N213498	008	Mar 18, 2021
+			10MG	N213498	009	Mar 18, 2021
+!			20MG	N213498	010	Mar 18, 2021

PORFIMER SODIUM

INJECTABLE;INJECTION

PHOTOFRIN

		PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

NOXAFIL POWDERMIX KIT

+!		MSD MERCK CO	300MG	N214770	001	May 31, 2021

SOLUTION;INTRAVENOUS

NOXAFIL

+!		MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014

SUSPENSION;ORAL

NOXAFIL

+!		SCHERING	40MG/ML	N022003	001	Sep 15, 2006

TABLET, DELAYED RELEASE;ORAL

NOXAFIL

AB	**+!**	MERCK SHARP DOHME	**100MG**	**N205053**	**001**	Nov 25, 2013

POSACONAZOLE

AB		AET PHARMA	**100MG**	**A213454**	**001**	Feb 01, 2021
AB		SINOTHERAPEUTICS INC	**100MG**	**A212411**	**001**	Aug 21, 2019

POTASSIUM ACETATE

INJECTABLE;INJECTION

POTASSIUM ACETATE

AP		EXELA PHARMA	**2MEQ/ML**	**A206203**	**001**	Dec 29, 2015
AP			**2MEQ/ML**	**A212692**	**001**	Oct 20, 2021
AP	**+!**	HOSPIRA	**2MEQ/ML**	**N018896**	**001**	Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB		UPSHER SMITH LABS	**8MEQ**	**A203106**	**001**	Jul 10, 2015
AB			**10MEQ**	**A203106**	**002**	Jul 10, 2015

POTASSIUM CHLORIDE

AB		ACTAVIS LABS FL INC	**8MEQ**	**A077419**	**001**	Jun 02, 2008
AB	**!**		**10MEQ**	**A077419**	**002**	Jun 02, 2008
AB		ADARE PHARMS INC	**8MEQ**	**A208864**	**001**	Mar 17, 2017
AB			**10MEQ**	**A208864**	**002**	Mar 17, 2017
AB		AMNEAL PHARMS	**10MEQ**	**A202128**	**001**	Feb 22, 2013
AB		ANCHEN PHARMS	**8MEQ**	**A202886**	**001**	Dec 26, 2013
AB			**10MEQ**	**A202886**	**002**	Dec 26, 2013
AB		GLENMARK PHARMS LTD	**10MEQ**	**A202868**	**001**	Jan 19, 2016
AB		GRANULES	**8MEQ**	**A214686**	**001**	Feb 16, 2021
AB			**10MEQ**	**A214686**	**002**	Feb 16, 2021
AB		LANNETT CO INC	**8MEQ**	**A204210**	**001**	Mar 28, 2016
AB			**10MEQ**	**A204210**	**002**	Mar 28, 2016
AB		LUPIN LTD	**8MEQ**	**A203002**	**001**	Dec 18, 2015
AB			**10MEQ**	**A203002**	**002**	Dec 18, 2015
AB		NOVEL LABS INC	**8MEQ**	**A204828**	**001**	Aug 16, 2016
AB			**10MEQ**	**A204828**	**002**	Aug 16, 2016
AB		PADAGIS US	**8MEQ**	**A200185**	**001**	May 18, 2011
AB			**10MEQ**	**A200185**	**002**	May 18, 2011
AB		PRINSTON INC	**8MEQ**	**A209026**	**001**	Jun 11, 2019
AB			**10MEQ**	**A209026**	**002**	Jun 11, 2019
AB		STRIDES PHARMA	**8MEQ**	**A205549**	**001**	Dec 08, 2015
AB			**10MEQ**	**A205549**	**002**	Dec 08, 2015
AB		TRIS PHARMA INC	**8MEQ**	**A201944**	**001**	Mar 04, 2016
AB			**10MEQ**	**A201944**	**002**	Mar 04, 2016
AB		ZYDUS PHARMS	**8MEQ**	**A208445**	**001**	Mar 11, 2019
AB			**10MEQ**	**A208445**	**002**	Mar 11, 2019

FOR SOLUTION;ORAL

KLOR-CON

AA		UPSHER SMITH LABS	**20MEQ**	**A209662**	**001**	Oct 23, 2017

POTASSIUM CHLORIDE

AA		AMNEAL	**20MEQ**	**A210902**	**001**	May 23, 2019
AA		BELCHER	**20MEQ**	**A212183**	**001**	May 06, 2019
AA		EPIC PHARMA LLC	**20MEQ**	**A210200**	**001**	Nov 23, 2018
AA		NOVEL LABS INC	**20MEQ**	**A210241**	**001**	Nov 21, 2018
AA	**+!**	PHARMA RES SOFTWARE	**20MEQ**	**N208019**	**001**	Aug 19, 2015

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

AP		B BRAUN	**2MEQ/ML**	**A085870**	**001**	
AP	**+**	FRESENIUS KABI USA	**2MEQ/ML**	**A080225**	**001**	
AP	**!**	HOSPIRA	**2MEQ/ML**	**A080205**	**001**	

POTASSIUM CHLORIDE 10MEQ

AP		NEXUS PHARMS	**14.9MG/ML**	**A214727**	**001**	Mar 18, 2021
AP			**745MG/100ML**	**A214727**	**002**	Mar 18, 2021

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**14.9MG/ML**	**N019904**	**001**	Dec 26, 1989
AP	**+!**		**746MG/100ML**	**N019904**	**005**	Dec 17, 1990
AP	**+!**	ICU MEDICAL INC	**14.9MG/ML**	**N020161**	**005**	Nov 30, 1992
AP	**+!**		**745MG/100ML**	**N020161**	**001**	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ

AP		NEXUS PHARMS	**29.8MG/ML**	**A214727**	**003**	Mar 18, 2021
AP			**1.49GM/100ML**	**A214727**	**004**	Mar 18, 2021

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**29.8MG/ML**	**N019904**	**002**	Dec 26, 1989
AP	**+!**		**1.49GM/100ML**	**N019904**	**006**	Dec 17, 1990
AP	**+!**	ICU MEDICAL INC	**29.8MG/ML**	**N020161**	**006**	Aug 11, 1998
AP	**+!**		**1.49GM/100ML**	**N020161**	**002**	Nov 30, 1992

POTASSIUM CHLORIDE 40MEQ

AP		NEXUS PHARMS	**2.98GM/100ML**	**A214727**	**005**	Mar 18, 2021

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	**+!**	BAXTER HLTHCARE	**2.98GM/100ML**	**N019904**	**004**	Dec 26, 1989
AP	**+!**	ICU MEDICAL INC	**2.98GM/100ML**	**N020161**	**004**	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	**2MEQ/ML**	**A088901**	**001**	Jan 25, 1985
AP			**2MEQ/ML**	**A088908**	**001**	Jan 25, 1985

POTASSIUM CHLORIDE

	!	FRESENIUS KABI USA	3MEQ/ML	A080225	003	

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		AMNEAL	**20MEQ/15ML**	**A210041**	**001**	Jul 19, 2018
AA			**40MEQ/15ML**	**A210041**	**002**	Jul 19, 2018
AA		APOTEX	**20MEQ/15ML**	**A211067**	**001**	Aug 08, 2018
AA			**40MEQ/15ML**	**A211067**	**002**	Aug 08, 2018
AA	**+**	GENUS LIFESCIENCES	**20MEQ/15ML**	**N206814**	**001**	Dec 22, 2014
AA	**+!**		**40MEQ/15ML**	**N206814**	**002**	Dec 22, 2014
AA		GRANULES	**20MEQ/15ML**	**A213392**	**001**	Jan 29, 2021
AA			**40MEQ/15ML**	**A213392**	**002**	Jan 29, 2021
AA		NOVEL LABS INC	**20MEQ/15ML**	**A209786**	**001**	Aug 29, 2018
AA			**40MEQ/15ML**	**A209786**	**002**	Aug 29, 2018
AA		PHARM ASSOC	**20MEQ/15ML**	**A210766**	**001**	Mar 29, 2019
AA			**40MEQ/15ML**	**A210766**	**002**	Mar 29, 2019
AA		SAPTALIS PHARMS	**20MEQ/15ML**	**A211648**	**001**	May 21, 2021
AA			**40MEQ/15ML**	**A211648**	**002**	May 21, 2021

TABLET, EXTENDED RELEASE;ORAL

KLOR-CON M10

AB1		UPSHER SMITH LABS	**10MEQ**	**A074726**	**002**	Aug 09, 2000

KLOR-CON M15

AB1		UPSHER SMITH LABS	**15MEQ**	**A074726**	**003**	Jun 06, 2003

KLOR-CON M20

AB1	**!**	UPSHER SMITH LABS	**20MEQ**	**A074726**	**001**	Nov 20, 1998

POTASSIUM CHLORIDE

AB1		ACTAVIS LABS FL INC	**10MEQ**	**A075604**	**001**	Apr 10, 2002
AB1			**20MEQ**	**A075604**	**002**	Apr 10, 2002
AB1		ADARE PHARMS INC	**10MEQ**	**A076368**	**002**	Jun 05, 2019
AB1			**20MEQ**	**A076368**	**001**	Aug 18, 2004
AB1		AMNEAL	**10MEQ**	**A212861**	**001**	May 08, 2020
AB1			**20MEQ**	**A212861**	**003**	May 08, 2020
AB1		ASCENT PHARMS INC	**10MEQ**	**A214422**	**001**	Dec 29, 2020
AB1			**15MEQ**	**A214422**	**002**	Dec 29, 2020
AB1			**20MEQ**	**A214422**	**003**	Dec 29, 2020
AB1		GLENMARK PHARMS LTD	**10MEQ**	**A203562**	**001**	Jul 26, 2016
AB1			**20MEQ**	**A203562**	**002**	Jul 26, 2016
AB1		GRANULES	**10MEQ**	**A214452**	**001**	Oct 21, 2020
AB1			**20MEQ**	**A214452**	**002**	Oct 21, 2020
AB1		NOVEL LABS INC	**10MEQ**	**A206347**	**001**	Jan 21, 2016
AB1			**20MEQ**	**A206347**	**002**	Jan 21, 2016
AB1		PRINSTON INC	**10MEQ**	**A209922**	**001**	Apr 30, 2019
AB1			**15MEQ**	**A209922**	**002**	Apr 30, 2019
AB1			**20MEQ**	**A209922**	**003**	Apr 30, 2019
AB1		ZYDUS PHARMS	**10MEQ**	**A210395**	**001**	Sep 17, 2020
AB1			**20MEQ**	**A210395**	**002**	Sep 17, 2020

KLOR-CON

AB2	**+**	UPSHER SMITH LABS	**8MEQ**	**N019123**	**001**	Apr 17, 1986
AB2	**+!**		**10MEQ**	**N019123**	**002**	Apr 17, 1986

POTASSIUM CHLORIDE

AB2		AUROBINDO PHARMA LTD	**8MEQ**	**A210921**	**001**	Dec 19, 2018
AB2			**10MEQ**	**A210921**	**002**	Dec 19, 2018
AB2		GRANULES	**8MEQ**	**A211797**	**001**	Mar 04, 2020
AB2			**10MEQ**	**A211797**	**002**	Mar 04, 2020
AB2		MYLAN	**8MEQ**	**A204662**	**001**	Aug 21, 2014
AB2			**10MEQ**	**A204662**	**002**	Aug 21, 2014
AB2		NOVEL LABS INC	**8MEQ**	**A206759**	**001**	Aug 09, 2016
AB2			**10MEQ**	**A206759**	**002**	Aug 09, 2016
AB2		PADAGIS US	**8MEQ**	**A205993**	**001**	Nov 05, 2015
AB2			**10MEQ**	**A205993**	**002**	Nov 05, 2015
AB2		STRIDES PHARMA	**8MEQ**	**A210733**	**001**	Aug 31, 2018
AB2			**10MEQ**	**A210733**	**002**	Aug 31, 2018

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE						
AB2		YICHANG HUMANWELL	**8MEQ**	**A209314**	**001**	Jun 22, 2018
AB2			**10MEQ**	**A209314**	**002**	Jun 22, 2018
K-TAB						
AB3	**+**	ABBVIE	**10MEQ**	**N018279**	**001**	
AB3	**+!**		**20MEQ**	**N018279**	**003**	Nov 25, 2013
POTASSIUM CHLORIDE						
AB3		VITRUVIAS THERAP	**10MEQ**	**A209688**	**001**	Jan 12, 2018
AB3			**20MEQ**	**A209688**	**002**	Jan 12, 2018
AB3		YICHANG HUMANWELL	**10MEQ**	**A212561**	**001**	Sep 30, 2019
AB3			**20MEQ**	**A212561**	**002**	Sep 30, 2019
K-TAB						
BC	+	ABBVIE	8MEQ	N018279	002	Aug 01, 1988

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	**149MG/100ML;450MG/100ML**	**A078446**	**001**	Sep 10, 2008
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%						
AP	**+!**	BAXTER HLTHCARE	**150MG/100ML;900MG/100ML**	**N017648**	**001**	
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		B BRAUN	**150MG/100ML;900MG/100ML**	**N019708**	**004**	Sep 29, 1989
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	**149MG/100ML;900MG/100ML**	**N019686**	**001**	Oct 17, 1988
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		ICU MEDICAL INC	**298MG/100ML;900MG/100ML**	**N019686**	**002**	Oct 17, 1988
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%						
	+!	BAXTER HLTHCARE	150MG/100ML;450MG/100ML	N017648	005	Nov 26, 2002
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%						
	+!	BAXTER HLTHCARE	300MG/100ML;900MG/100ML	N017648	002	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE						
AB		ANI PHARMS	**10MEQ**	**A212779**	**001**	Jan 14, 2020
AB			**15MEQ**	**A212779**	**002**	Jan 14, 2020
AB		ASCENT PHARMS INC	**5MEQ**	**A214420**	**001**	Feb 05, 2021
AB			**10MEQ**	**A214420**	**002**	Feb 05, 2021
AB			**15MEQ**	**A214420**	**003**	Feb 05, 2021
AB		BIONPHARMA INC	**10MEQ**	**A212799**	**001**	Jun 29, 2020
AB			**15MEQ**	**A212799**	**002**	Jun 29, 2020
AB		EYWA	**5MEQ**	**A214426**	**001**	Feb 19, 2021
AB			**10MEQ**	**A214426**	**002**	Feb 19, 2021
AB			**15MEQ**	**A214426**	**003**	Feb 19, 2021
AB		RISING	**5MEQ**	**A077440**	**001**	Jun 09, 2006
AB			**10MEQ**	**A077440**	**002**	Jun 09, 2006
AB		STRIDES PHARMA	**5MEQ**	**A206813**	**001**	Sep 11, 2017
AB			**10MEQ**	**A206813**	**002**	Sep 11, 2017
AB			**15MEQ**	**A206813**	**003**	Sep 11, 2017
AB		TEVA PHARMS USA INC	**5MEQ**	**A209758**	**001**	Mar 05, 2018
AB			**10MEQ**	**A209758**	**002**	Mar 05, 2018
AB			**15MEQ**	**A209758**	**003**	Mar 05, 2018
AB		ZYDUS PHARMS	**5MEQ**	**A203546**	**001**	Aug 06, 2014
AB			**10MEQ**	**A203546**	**002**	Aug 06, 2014
AB			**15MEQ**	**A203546**	**003**	Aug 06, 2014
UROCIT-K						
AB	**+**	MISSION PHARMA	**5MEQ**	**N019071**	**001**	Aug 30, 1985
AB	**+**		**10MEQ**	**N019071**	**002**	Aug 31, 1992
AB	**+!**		**15MEQ**	**N019071**	**003**	Dec 30, 2009

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES						
	+!	CMP DEV LLC	4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)	N212121	001	Sep 19, 2019
	+!	FRESENIUS KABI USA	1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)	N212832	001	Nov 26, 2019
	+!		3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)	N212832	002	Nov 26, 2019
	+!		11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML)	N212832	003	Nov 26, 2019

POVIDONE-IODINE						
SOLUTION/DROPS;OPHTHALMIC						
BETADINE						
	+!	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986
PRALATREXATE						
SOLUTION;INTRAVENOUS						
FOLOTYN						
	+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
	+!		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009
PRALIDOXIME CHLORIDE						
INJECTABLE;INJECTION						
PROTOPAM CHLORIDE						
	+!	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	
PRALSETINIB						
CAPSULE;ORAL						
GAVRETO						
	+!	GENENTECH INC	100MG	N213721	001	Sep 04, 2020
PRAMIPEXOLE DIHYDROCHLORIDE						
TABLET;ORAL						
MIRAPEX						
AB	+	BOEHRINGER INGELHEIM	**0.125MG**	**N020667**	**001**	Jul 01, 1997
AB	+!		**0.25MG**	**N020667**	**002**	Jul 01, 1997
AB	+		**0.5MG**	**N020667**	**006**	Feb 12, 1998
AB	+		**0.75MG**	**N020667**	**007**	Jul 30, 2007
AB	+		**1MG**	**N020667**	**003**	Jul 01, 1997
AB	+		**1.5MG**	**N020667**	**005**	Jul 01, 1997
PRAMIPEXOLE DIHYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	**0.125MG**	**A202633**	**001**	Oct 26, 2012
AB			**0.25MG**	**A202633**	**002**	Oct 26, 2012
AB			**0.5MG**	**A202633**	**003**	Oct 26, 2012
AB			**0.75MG**	**A202633**	**004**	Oct 26, 2012
AB			**1MG**	**A202633**	**005**	Oct 26, 2012
AB			**1.5MG**	**A202633**	**006**	Oct 26, 2012
AB		GLENMARK GENERICS	**0.125MG**	**A090781**	**001**	Oct 08, 2010
AB			**0.25MG**	**A090781**	**002**	Oct 08, 2010
AB			**0.5MG**	**A090781**	**003**	Oct 08, 2010
AB			**0.75MG**	**A090781**	**006**	Sep 11, 2015
AB			**1MG**	**A090781**	**004**	Oct 08, 2010
AB			**1.5MG**	**A090781**	**005**	Oct 08, 2010
AB		GRAVITI PHARMS	**0.25MG**	**A211088**	**001**	Oct 03, 2018
AB			**0.5MG**	**A211088**	**002**	Oct 03, 2018
AB			**0.75MG**	**A211088**	**003**	Oct 03, 2018
AB			**1MG**	**A211088**	**004**	Oct 03, 2018
AB			**1.5MG**	**A211088**	**005**	Oct 03, 2018
AB		SCIEGEN PHARMS INC	**0.125MG**	**A203855**	**001**	Oct 28, 2014
AB			**0.25MG**	**A203855**	**002**	Oct 28, 2014
AB			**0.5MG**	**A203855**	**003**	Oct 28, 2014
AB			**0.75MG**	**A203855**	**004**	Oct 28, 2014
AB			**1MG**	**A203855**	**005**	Oct 28, 2014
AB			**1.5MG**	**A203855**	**006**	Oct 28, 2014
AB		STRIDES PHARMA	**0.125MG**	**A202702**	**001**	Jun 03, 2014
AB			**0.25MG**	**A202702**	**002**	Jun 03, 2014
AB			**0.5MG**	**A202702**	**003**	Jun 03, 2014
AB			**0.75MG**	**A202702**	**004**	Jun 03, 2014
AB			**1MG**	**A202702**	**005**	Jun 03, 2014
AB			**1.5MG**	**A202702**	**006**	Jun 03, 2014
AB		TORRENT PHARMS	**0.125MG**	**A090865**	**001**	Oct 08, 2010
AB			**0.25MG**	**A090865**	**002**	Oct 08, 2010
AB			**0.5MG**	**A090865**	**003**	Oct 08, 2010
AB			**0.75MG**	**A090865**	**004**	Oct 08, 2010
AB			**1MG**	**A090865**	**005**	Oct 08, 2010
AB			**1.5MG**	**A090865**	**006**	Oct 08, 2010
AB		ZENNOVA	**0.125MG**	**A090151**	**001**	Apr 30, 2012
AB			**0.25MG**	**A090151**	**002**	Apr 30, 2012
AB			**0.5MG**	**A090151**	**003**	Apr 30, 2012
AB			**0.75MG**	**A090151**	**006**	Apr 30, 2012
AB			**1MG**	**A090151**	**004**	Apr 30, 2012
AB			**1.5MG**	**A090151**	**005**	Apr 30, 2012

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	**0.125MG**	**A078920**	**001**	Jul 06, 2010
AB			**0.25MG**	**A078920**	**002**	Jul 06, 2010
AB			**0.5MG**	**A078920**	**003**	Jul 06, 2010
AB			**1MG**	**A078920**	**004**	Jul 06, 2010
AB			**1.5MG**	**A078920**	**005**	Jul 06, 2010

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB	**+!**	BOEHRINGER INGELHEIM	**0.375MG**	**N022421**	**001**	Feb 19, 2010
AB	+		**0.75MG**	**N022421**	**002**	Feb 19, 2010
AB	+		**1.5MG**	**N022421**	**003**	Feb 19, 2010
AB	+		**2.25MG**	**N022421**	**006**	Jun 17, 2011
AB	+		**3MG**	**N022421**	**004**	Feb 19, 2010
AB	+		**3.75MG**	**N022421**	**007**	Jun 17, 2011
AB	+		**4.5MG**	**N022421**	**005**	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**0.375MG**	**A201963**	**001**	Apr 21, 2016
AB			**0.75MG**	**A201963**	**002**	Apr 21, 2016
AB			**1.5MG**	**A201963**	**003**	Apr 21, 2016
AB			**2.25MG**	**A203615**	**001**	Oct 14, 2016
AB			**3MG**	**A201963**	**004**	Apr 21, 2016
AB			**3.75MG**	**A203615**	**002**	Jan 03, 2017
AB			**4.5MG**	**A201963**	**005**	Apr 21, 2016
AB		ANCHEN PHARMS	**0.375MG**	**A202206**	**001**	Feb 06, 2014
AB			**0.75MG**	**A202206**	**002**	Feb 06, 2014
AB			**1.5MG**	**A202206**	**003**	Feb 06, 2014
AB			**2.25MG**	**A202206**	**004**	Feb 06, 2014
AB			**3MG**	**A202206**	**005**	Feb 06, 2014
AB			**3.75MG**	**A202206**	**006**	Feb 06, 2014
AB			**4.5MG**	**A202206**	**007**	Feb 06, 2014
AB		DR REDDYS	**0.375MG**	**A203354**	**001**	Aug 07, 2015
AB			**0.75MG**	**A203354**	**002**	Aug 07, 2015
AB			**1.5MG**	**A203354**	**003**	Aug 07, 2015
AB			**3MG**	**A203354**	**004**	Aug 07, 2015
AB			**4.5MG**	**A203354**	**005**	Aug 07, 2015
AB		MACLEODS PHARMS LTD	**0.375MG**	**A206156**	**001**	Jun 24, 2016
AB			**0.75MG**	**A206156**	**002**	Jun 24, 2016
AB			**1.5MG**	**A206156**	**003**	Jun 24, 2016
AB			**2.25MG**	**A206156**	**004**	Jun 24, 2016
AB			**3MG**	**A206156**	**005**	Jun 24, 2016
AB			**3.75MG**	**A206156**	**007**	Jan 23, 2017
AB			**4.5MG**	**A206156**	**006**	Jun 24, 2016
AB		SANDOZ INC	**0.375MG**	**A202353**	**001**	Dec 04, 2014
AB			**0.75MG**	**A202353**	**002**	Dec 04, 2014
AB			**1.5MG**	**A202353**	**003**	Dec 04, 2014
AB			**3MG**	**A202353**	**004**	Dec 04, 2014
AB			**4.5MG**	**A202353**	**005**	Dec 04, 2014
AB		XIAMEN LP PHARM CO	**0.375MG**	**A212797**	**001**	Jun 11, 2021
AB			**0.75MG**	**A212797**	**002**	Jun 11, 2021
AB		ZYDUS PHARMS	**0.375MG**	**A202891**	**001**	Dec 12, 2017
AB			**0.75MG**	**A202891**	**002**	Dec 12, 2017
AB			**1.5MG**	**A202891**	**003**	Dec 12, 2017
AB			**2.25MG**	**A202891**	**004**	Dec 12, 2017
AB			**3MG**	**A202891**	**005**	Dec 12, 2017
AB			**3.75MG**	**A202891**	**006**	Dec 12, 2017
AB			**4.5MG**	**A202891**	**007**	Dec 12, 2017

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

	+	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
	+!		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007

PRASTERONE

INSERT;VAGINAL

INTRAROSA

	+!	MILLICENT	6.5MG	N208470	001	Nov 16, 2016

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

EFFIENT

AB	**+**	DAIICHI SANKYO INC	**EQ 5MG BASE**	**N022307**	**001**	Jul 10, 2009
AB	**+!**		**EQ 10MG BASE**	**N022307**	**002**	Jul 10, 2009

PRASUGREL

AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A205987**	**001**	Feb 02, 2018
AB			**EQ 10MG BASE**	**A205987**	**002**	Feb 02, 2018
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A205888**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205888**	**002**	Oct 16, 2017
AB		HEC PHARM	**EQ 5MG BASE**	**A206021**	**001**	Jan 16, 2019
AB			**EQ 10MG BASE**	**A206021**	**002**	Jan 16, 2019
AB		MYLAN	**EQ 5MG BASE**	**A205927**	**001**	Jul 12, 2017
AB			**EQ 10MG BASE**	**A205927**	**002**	Jul 12, 2017
AB		PANACEA	**EQ 5MG BASE**	**A205897**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205897**	**002**	Oct 16, 2017
AB		USPHARMA WINDLAS	**EQ 5MG BASE**	**A205790**	**001**	Oct 16, 2017
AB			**EQ 10MG BASE**	**A205790**	**002**	Oct 16, 2017
BX		AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018
BX			EQ 10MG BASE	A205913	002	Jun 19, 2018

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

AB		ACCORD HLTHCARE	**10MG**	**A207068**	**001**	Nov 17, 2016
AB			**20MG**	**A207068**	**002**	Nov 17, 2016
AB			**40MG**	**A207068**	**003**	Nov 17, 2016
AB			**80MG**	**A207068**	**004**	Nov 17, 2016
AB		APNAR PHARMA LP	**10MG**	**A077491**	**002**	Oct 23, 2006
AB			**20MG**	**A077491**	**003**	Oct 23, 2006
AB			**40MG**	**A077491**	**004**	Oct 23, 2006
AB			**80MG**	**A077491**	**001**	Feb 11, 2008
AB		APOTEX	**10MG**	**A076341**	**001**	Oct 23, 2006
AB			**20MG**	**A076341**	**002**	Oct 23, 2006
AB			**40MG**	**A076341**	**003**	Oct 23, 2006
AB			**80MG**	**A076341**	**004**	Dec 28, 2007
AB		AUROBINDO PHARMA LTD	**10MG**	**A203367**	**001**	Feb 02, 2017
AB			**20MG**	**A203367**	**002**	Feb 02, 2017
AB			**40MG**	**A203367**	**003**	Feb 02, 2017
AB			**80MG**	**A203367**	**004**	Feb 02, 2017
AB		BIOCON PHARMA	**10MG**	**A209869**	**001**	Apr 13, 2018
AB			**20MG**	**A209869**	**002**	Apr 13, 2018
AB			**40MG**	**A209869**	**003**	Apr 13, 2018
AB			**80MG**	**A209869**	**004**	Apr 13, 2018
AB		CIPLA	**10MG**	**A077904**	**001**	Oct 23, 2006
AB			**20MG**	**A077904**	**002**	Oct 23, 2006
AB			**40MG**	**A077904**	**003**	Oct 23, 2006
AB			**80MG**	**A077904**	**004**	Mar 22, 2016
AB		DR REDDYS LABS INC	**10MG**	**A076714**	**001**	Oct 23, 2006
AB			**20MG**	**A076714**	**002**	Oct 23, 2006
AB			**40MG**	**A076714**	**003**	Oct 23, 2006
AB			**80MG**	**A076714**	**004**	Dec 28, 2007
AB		GLENMARK GENERICS	**10MG**	**A077987**	**001**	May 11, 2007
AB			**20MG**	**A077987**	**002**	May 11, 2007
AB			**40MG**	**A077987**	**003**	May 11, 2007
AB			**80MG**	**A077987**	**004**	Dec 28, 2007
AB		LUPIN PHARMS	**10MG**	**A077917**	**001**	Jan 08, 2008
AB			**20MG**	**A077917**	**002**	Jan 08, 2008
AB			**40MG**	**A077917**	**003**	Jan 08, 2008
AB			**80MG**	**A077917**	**004**	Jan 08, 2008
AB		TEVA	**10MG**	**A076056**	**001**	Apr 24, 2006
AB			**20MG**	**A076056**	**002**	Apr 24, 2006
AB			**40MG**	**A076056**	**003**	Apr 24, 2006
AB	**!**	TEVA PHARMS	**80MG**	**A077793**	**001**	Jan 15, 2008
AB		WATSON LABS	**10MG**	**A076939**	**004**	Oct 23, 2006
AB			**20MG**	**A076939**	**003**	Oct 23, 2006
AB			**40MG**	**A076939**	**002**	Oct 23, 2006
AB			**80MG**	**A076939**	**001**	Dec 28, 2007
AB		ZYDUS PHARMS USA	**20MG**	**A077751**	**002**	Apr 30, 2008
AB			**40MG**	**A077751**	**003**	Apr 30, 2008
AB			**80MG**	**A077751**	**004**	Apr 30, 2008

PRAZIQUANTEL
TABLET;ORAL
BILTRICIDE
AB **+!** BAYER HLTHCARE **600MG** **N018714 001** Dec 29, 1982
PRAZIQUANTEL
AB PAR PHARM INC **600MG** **A208820 001** Nov 27, 2017

PRAZOSIN HYDROCHLORIDE
CAPSULE;ORAL
MINIPRESS
AB **+** PFIZER **EQ 1MG BASE** **N017442 002**
AB **+!** **EQ 2MG BASE** **N017442 003**
AB **+** **EQ 5MG BASE** **N017442 001**
PRAZOSIN HYDROCHLORIDE
AB ANI PHARMS **EQ 1MG BASE** **A072577 002** May 16, 1989
AB **EQ 2MG BASE** **A072577 001** May 16, 1989
AB **EQ 5MG BASE** **A072577 003** May 16, 1989
AB GRANULES **EQ 1MG BASE** **A214608 001** Dec 23, 2021
AB **EQ 2MG BASE** **A214608 002** Dec 23, 2021
AB **EQ 5MG BASE** **A214608 003** Dec 23, 2021
AB MYLAN **EQ 1MG BASE** **A072575 003** May 16, 1989
AB **EQ 2MG BASE** **A072575 002** May 16, 1989
AB **EQ 5MG BASE** **A072575 001** May 16, 1989
AB NOVITIUM PHARMA **EQ 1MG BASE** **A210971 001** Oct 03, 2018
AB **EQ 2MG BASE** **A210971 002** Oct 03, 2018
AB **EQ 5MG BASE** **A210971 003** Oct 03, 2018
AB TEVA PHARMS **EQ 1MG BASE** **A071745 002** Sep 12, 1988
AB **EQ 2MG BASE** **A071745 003** Sep 12, 1988
AB **EQ 5MG BASE** **A071745 001** Sep 12, 1988

PREDNICARBATE
OINTMENT;TOPICAL
PREDNICARBATE
! FOUGERA PHARMS 0.1% A077236 001 Mar 09, 2007

PREDNISOLONE
SYRUP;ORAL
PREDNISOLONE
AA **!** AKORN **15MG/5ML** **A040401 001** Feb 27, 2003
AA CHARTWELL RX **15MG/5ML** **A040323 001** May 13, 1999
AA LANNETT CO INC **15MG/5ML** **A040775 001** Sep 21, 2007
AA PHARM ASSOC **15MG/5ML** **A040399 001** Mar 05, 2003
AA WOCKHARDT BIO AG **15MG/5ML** **A040313 001** Sep 10, 2003
PRELONE
AA TEVA **15MG/5ML** **A089081 001** Feb 04, 1986
TABLET;ORAL
PREDNISOLONE
! WATSON LABS 5MG A080354 001

PREDNISOLONE ACETATE
SUSPENSION/DROPS;OPHTHALMIC
OMNIPRED
AB **+!** NOVARTIS **1%** **N017469 001**
PRED FORTE
AB **+!** ALLERGAN **1%** **N017011 001**
PRED MILD
+! ALLERGAN 0.12% N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT;OPHTHALMIC
BLEPHAMIDE S.O.P.
! ALLERGAN 0.2%;10% A087748 001 Dec 03, 1986
SUSPENSION;OPHTHALMIC
BLEPHAMIDE
+! ALLERGAN 0.2%;10% N012813 002

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION;ORAL
PEDIAPRED
AA **+!** SETON PHARM **EQ 5MG BASE/5ML** **N019157 001** May 28, 1986
PREDNISOLONE SODIUM PHOSPHATE
AA AKORN **EQ 5MG BASE/5ML** **A075183 001** Mar 26, 2003
AA CHARTWELL RX **EQ 5MG BASE/5ML** **A075988 001** May 25, 2004
AA EDENBRIDGE PHARMS **EQ 10MG BASE/5ML** **A203559 001** Dec 20, 2016
AA **EQ 20MG BASE/5ML** **A203559 002** Dec 20, 2016

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	**!**	PHARM ASSOC	**EQ 10MG BASE/5ML**	**A078465**	**001**	Mar 07, 2008
AA			**EQ 15MG BASE/5ML**	**A076913**	**001**	Apr 25, 2005
AA	**!**		**EQ 20MG BASE/5ML**	**A078988**	**001**	Jun 09, 2008
AA		WOCKHARDT BIO AG	**EQ 5MG BASE/5ML**	**A075099**	**001**	Jun 28, 2002
AA	**!**		**EQ 15MG BASE/5ML**	**A076895**	**001**	Oct 04, 2004
	!	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010
		PHARM ASSOC	EQ 30MG BASE/5ML	A204962	001	Mar 11, 2020

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.9% PHOSPHATE	A040070	001	Jul 29, 1994

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

+	CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006
+		EQ 15MG BASE	N021959	002	Jun 01, 2006
+!		EQ 30MG BASE	N021959	003	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995

PREDNISONE

SOLUTION;ORAL

PREDNISONE

!	HIKMA	5MG/5ML	A088703	001	Nov 08, 1984

PREDNISONE INTENSOL

!	HIKMA	5MG/ML	A088810	001	Feb 20, 1985

TABLET;ORAL

PREDNISONE

AB		AMNEAL	**1MG**	**A213385**	**001**	Jun 16, 2020
AB			**5MG**	**A213385**	**002**	Jun 16, 2020
AB			**10MG**	**A213386**	**001**	Jun 24, 2020
AB			**20MG**	**A213386**	**002**	Jun 24, 2020
AB		AUROBINDO PHARMA LTD	**1MG**	**A215671**	**001**	Nov 16, 2021
AB		GENEYORK PHARMS	**1MG**	**A211496**	**001**	Dec 28, 2018
AB			**2.5MG**	**A211495**	**001**	Dec 07, 2018
AB			**5MG**	**A211495**	**002**	Dec 07, 2018
AB			**10MG**	**A210525**	**001**	Dec 04, 2018
AB			**20MG**	**A210525**	**002**	Dec 04, 2018
AB			**50MG**	**A210525**	**003**	Dec 04, 2018
AB	**+!**	HIKMA	**1MG**	**A087800**	**001**	Apr 22, 1982
AB	**!**		**2.5MG**	**A087801**	**001**	Apr 22, 1982
AB	**!**		**5MG**	**A080352**	**001**	
AB	**+!**		**10MG**	**A084122**	**001**	
AB	**+!**		**20MG**	**A087342**	**001**	
AB	**!**		**50MG**	**A084283**	**001**	
AB		JUBILANT CADISTA	**1MG**	**A040611**	**001**	Jun 06, 2005
AB			**5MG**	**A040362**	**002**	Aug 29, 2001
AB			**10MG**	**A040362**	**001**	Aug 29, 2001
AB			**20MG**	**A040362**	**003**	Jun 29, 2005
AB		MYLAN	**5MG**	**A080292**	**001**	
AB			**10MG**	**A088832**	**001**	Dec 04, 1985
AB			**20MG**	**A083677**	**001**	
AB		NOVITIUM PHARMA	**1MG**	**A215246**	**001**	Jul 06, 2021
AB			**2.5MG**	**A211575**	**001**	Nov 15, 2019
AB			**5MG**	**A211575**	**002**	Nov 15, 2019
AB			**10MG**	**A211575**	**003**	Nov 15, 2019
AB			**20MG**	**A211575**	**004**	Nov 15, 2019
AB			**50MG**	**A211575**	**005**	Nov 15, 2019
AB		STRIDES PHARMA	**1MG**	**A210785**	**001**	Sep 02, 2020
AB			**2.5MG**	**A209727**	**001**	Nov 20, 2020
AB			**5MG**	**A209727**	**002**	Nov 20, 2020
AB			**10MG**	**A208412**	**001**	Feb 11, 2021
AB			**20MG**	**A208412**	**002**	Feb 11, 2021
AB			**50MG**	**A208412**	**003**	Jan 11, 2022
AB		SUN PHARM INDUSTRIES	**5MG**	**A089247**	**002**	Dec 04, 1985
AB			**10MG**	**A089247**	**003**	Dec 04, 1985
AB			**20MG**	**A089247**	**001**	Dec 04, 1985

PREDNISONE

TABLET;ORAL

PREDNISONE

AB		VINTAGE PHARMS	**1MG**	**A040584**	**001**	Dec 21, 2004
AB			**2.5MG**	**A040581**	**001**	Dec 21, 2004
AB			**5MG**	**A040256**	**001**	Jul 12, 2002
AB			**10MG**	**A040256**	**002**	Jul 12, 2002
AB			**20MG**	**A040392**	**001**	Feb 12, 2003
AB		WATSON LABS	**5MG**	**A080356**	**001**	
AB			**10MG**	**A085162**	**001**	
AB			**20MG**	**A085161**	**001**	

TABLET, DELAYED RELEASE;ORAL

RAYOS

	+	HORIZON	1MG	N202020	001	Jul 26, 2012
	+		2MG	N202020	002	Jul 26, 2012
	+!		5MG	N202020	003	Jul 26, 2012

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	**+**	UPJOHN	**25MG**	**N021446**	**001**	Dec 30, 2004
AB	**+**		**50MG**	**N021446**	**002**	Dec 30, 2004
AB	**+**		**75MG**	**N021446**	**003**	Dec 30, 2004
AB	**+**		**100MG**	**N021446**	**004**	Dec 30, 2004
AB	**+**		**150MG**	**N021446**	**005**	Dec 30, 2004
AB	**+**		**200MG**	**N021446**	**006**	Dec 30, 2004
AB	**+**		**225MG**	**N021446**	**007**	Dec 30, 2004
AB	**+!**		**300MG**	**N021446**	**008**	Dec 30, 2004

PREGABALIN

AB		ACTAVIS ELIZABETH	**25MG**	**A091025**	**001**	Jul 09, 2020
AB			**50MG**	**A091025**	**002**	Jul 09, 2020
AB			**75MG**	**A091025**	**003**	Jul 09, 2020
AB			**100MG**	**A091025**	**004**	Jul 09, 2020
AB			**150MG**	**A091025**	**005**	Jul 09, 2020
AB			**200MG**	**A091025**	**006**	Jul 09, 2020
AB			**225MG**	**A091025**	**007**	Jul 09, 2020
AB			**300MG**	**A091025**	**008**	Jul 09, 2020
AB		ALEMBIC PHARMS LTD	**25MG**	**A203459**	**001**	Jul 19, 2019
AB			**50MG**	**A203459**	**002**	Jul 19, 2019
AB			**75MG**	**A203459**	**003**	Jul 19, 2019
AB			**100MG**	**A203459**	**004**	Jul 19, 2019
AB			**150MG**	**A203459**	**005**	Jul 19, 2019
AB			**200MG**	**A203459**	**006**	Jul 19, 2019
AB			**225MG**	**A203459**	**007**	Jul 19, 2019
AB			**300MG**	**A203459**	**008**	Jul 19, 2019
AB		ALKEM LABS LTD	**25MG**	**A207799**	**007**	Sep 30, 2019
AB			**50MG**	**A207799**	**008**	Sep 30, 2019
AB			**75MG**	**A207799**	**001**	Jul 19, 2019
AB			**100MG**	**A207799**	**002**	Jul 19, 2019
AB			**150MG**	**A207799**	**003**	Jul 19, 2019
AB			**200MG**	**A207799**	**004**	Jul 19, 2019
AB			**225MG**	**A207799**	**005**	Jul 19, 2019
AB			**300MG**	**A207799**	**006**	Jul 19, 2019
AB		AMNEAL PHARMS CO	**25MG**	**A209743**	**001**	Jul 19, 2019
AB			**50MG**	**A209743**	**002**	Jul 19, 2019
AB			**75MG**	**A209743**	**003**	Jul 19, 2019
AB			**100MG**	**A209743**	**004**	Jul 19, 2019
AB			**150MG**	**A209743**	**005**	Jul 19, 2019
AB			**200MG**	**A209743**	**006**	Jul 19, 2019
AB			**225MG**	**A209743**	**007**	Jul 19, 2019
AB			**300MG**	**A209743**	**008**	Jul 19, 2019
AB		APOTEX	**25MG**	**A211685**	**001**	Jul 07, 2021
AB			**50MG**	**A211685**	**002**	Jul 07, 2021
AB			**75MG**	**A211685**	**003**	Jul 07, 2021
AB			**100MG**	**A211685**	**004**	Jul 07, 2021
AB			**150MG**	**A211685**	**005**	Jul 07, 2021
AB			**200MG**	**A211685**	**006**	Jul 07, 2021
AB			**225MG**	**A211685**	**007**	Jul 07, 2021
AB			**300MG**	**A211685**	**008**	Jul 07, 2021
AB		CELLTRION	**50MG**	**A212865**	**001**	Mar 20, 2020
AB			**75MG**	**A212865**	**002**	Mar 20, 2020
AB			**100MG**	**A212865**	**003**	Mar 20, 2020
AB			**150MG**	**A212865**	**004**	Mar 20, 2020

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB	CHANGZHOU PHARM	**50MG**	**A214322**	**001**	Jul 15, 2021
AB		**75MG**	**A214322**	**002**	Jul 15, 2021
AB		**100MG**	**A214322**	**003**	Jul 15, 2021
AB		**150MG**	**A214322**	**004**	Jul 15, 2021
AB		**200MG**	**A214322**	**005**	Jul 15, 2021
AB		**225MG**	**A214322**	**006**	Jul 15, 2021
AB		**300MG**	**A214322**	**007**	Jul 15, 2021
AB	CIPLA	**25MG**	**A212280**	**001**	Jan 10, 2020
AB		**50MG**	**A212280**	**002**	Jan 10, 2020
AB		**75MG**	**A212280**	**003**	Jan 10, 2020
AB		**100MG**	**A212280**	**004**	Jan 10, 2020
AB		**150MG**	**A212280**	**005**	Jan 10, 2020
AB		**200MG**	**A212280**	**006**	Jan 10, 2020
AB		**225MG**	**A212280**	**007**	Jan 10, 2020
AB		**300MG**	**A212280**	**008**	Jan 10, 2020
AB	CSPC OUYI	**50MG**	**A210585**	**001**	Dec 26, 2019
AB		**75MG**	**A210585**	**002**	Dec 26, 2019
AB		**100MG**	**A210585**	**003**	Dec 26, 2019
AB		**150MG**	**A210585**	**004**	Dec 26, 2019
AB		**200MG**	**A210585**	**005**	Dec 26, 2019
AB		**300MG**	**A210585**	**006**	Dec 26, 2019
AB	DR REDDYS	**25MG**	**A209664**	**001**	Jul 19, 2019
AB		**50MG**	**A209664**	**002**	Jul 19, 2019
AB		**75MG**	**A209664**	**003**	Jul 19, 2019
AB		**100MG**	**A209664**	**004**	Jul 19, 2019
AB		**150MG**	**A209664**	**005**	Jul 19, 2019
AB		**200MG**	**A209664**	**006**	Jul 19, 2019
AB		**225MG**	**A209664**	**007**	Jul 19, 2019
AB		**300MG**	**A209664**	**008**	Jul 19, 2019
AB	HETERO LABS LTD III	**25MG**	**A206912**	**001**	Oct 08, 2019
AB		**50MG**	**A206912**	**002**	Oct 08, 2019
AB		**75MG**	**A206912**	**003**	Oct 08, 2019
AB		**100MG**	**A206912**	**004**	Oct 08, 2019
AB		**150MG**	**A206912**	**005**	Oct 08, 2019
AB		**200MG**	**A206912**	**006**	Oct 08, 2019
AB		**225MG**	**A206912**	**007**	Oct 08, 2019
AB		**300MG**	**A206912**	**008**	Oct 08, 2019
AB	HIKAL	**25MG**	**A213423**	**001**	Mar 23, 2020
AB		**50MG**	**A213423**	**002**	Mar 23, 2020
AB		**75MG**	**A213423**	**003**	Mar 23, 2020
AB		**100MG**	**A213423**	**004**	Mar 23, 2020
AB		**150MG**	**A213423**	**005**	Mar 23, 2020
AB		**200MG**	**A213423**	**006**	Mar 23, 2020
AB		**225MG**	**A213423**	**007**	Mar 23, 2020
AB		**300MG**	**A213423**	**008**	Mar 23, 2020
AB	INVAGEN PHARMS	**25MG**	**A211384**	**001**	Jul 19, 2019
AB		**50MG**	**A211384**	**002**	Jul 19, 2019
AB		**75MG**	**A211384**	**003**	Jul 19, 2019
AB		**100MG**	**A211384**	**004**	Jul 19, 2019
AB		**150MG**	**A211384**	**005**	Jul 19, 2019
AB		**200MG**	**A211384**	**006**	Jul 19, 2019
AB		**225MG**	**A211384**	**007**	Jul 19, 2019
AB		**300MG**	**A211384**	**008**	Jul 19, 2019
AB	MSN	**25MG**	**A209357**	**001**	Jul 19, 2019
AB		**50MG**	**A209357**	**002**	Jul 19, 2019
AB		**75MG**	**A209357**	**003**	Jul 19, 2019
AB		**100MG**	**A209357**	**004**	Jul 19, 2019
AB		**150MG**	**A209357**	**005**	Jul 19, 2019
AB		**200MG**	**A209357**	**006**	Jul 19, 2019
AB		**225MG**	**A209357**	**007**	Jul 19, 2019
AB		**300MG**	**A209357**	**008**	Jul 19, 2019
AB	RISING	**25MG**	**A210432**	**001**	Jul 19, 2019
AB		**50MG**	**A210432**	**002**	Jul 19, 2019
AB		**75MG**	**A210432**	**003**	Jul 19, 2019
AB		**100MG**	**A210432**	**004**	Jul 19, 2019
AB		**150MG**	**A210432**	**005**	Jul 19, 2019
AB		**200MG**	**A210432**	**006**	Jul 19, 2019
AB		**225MG**	**A210432**	**007**	Jul 19, 2019
AB		**300MG**	**A210432**	**008**	Jul 19, 2019

PREGABALIN

CAPSULE;ORAL

PREGABALIN

AB		SCIEGEN PHARMS INC	**25MG**	**A208677**	**001**	Jul 19, 2019
AB			**50MG**	**A208677**	**002**	Jul 19, 2019
AB			**75MG**	**A208677**	**003**	Jul 19, 2019
AB			**100MG**	**A208677**	**004**	Jul 19, 2019
AB			**150MG**	**A208677**	**005**	Jul 19, 2019
AB			**200MG**	**A208677**	**006**	Jul 19, 2019
AB			**225MG**	**A208677**	**007**	Jul 19, 2019
AB			**300MG**	**A208677**	**008**	Jul 19, 2019
AB		SHUANGCHENG	**75MG**	**A210891**	**001**	Sep 30, 2019
AB			**300MG**	**A210891**	**002**	Sep 30, 2019
AB		SUN PHARM	**25MG**	**A091157**	**001**	Nov 29, 2019
AB			**50MG**	**A091157**	**002**	Nov 29, 2019
AB			**75MG**	**A091157**	**003**	Nov 29, 2019
AB			**100MG**	**A091157**	**004**	Nov 29, 2019
AB			**150MG**	**A091157**	**005**	Nov 29, 2019
AB			**200MG**	**A091157**	**006**	Nov 29, 2019
AB			**225MG**	**A091157**	**007**	Nov 29, 2019
AB			**300MG**	**A091157**	**008**	Nov 29, 2019
AB		TEVA PHARMS	**25MG**	**A091219**	**001**	Jul 19, 2019
AB			**50MG**	**A091219**	**002**	Jul 19, 2019
AB			**75MG**	**A091224**	**001**	Jul 19, 2019
AB			**100MG**	**A091224**	**002**	Jul 19, 2019
AB			**150MG**	**A091224**	**003**	Jul 19, 2019
AB			**200MG**	**A091224**	**004**	Jul 19, 2019
AB			**225MG**	**A091224**	**005**	Jul 19, 2019
AB			**300MG**	**A091224**	**006**	Jul 19, 2019

SOLUTION;ORAL

LYRICA

AA	**+!**	UPJOHN	**20MG/ML**	**N022488**	**001**	Jan 04, 2010

PREGABALIN

AA		ALKEM LABS LTD	**20MG/ML**	**A207623**	**001**	Jul 19, 2019

TABLET, EXTENDED RELEASE;ORAL

LYRICA CR

AB	**+**	UPJOHN	**82.5MG**	**N209501**	**001**	Oct 11, 2017
AB	**+**		**165MG**	**N209501**	**002**	Oct 11, 2017
AB	**+!**		**330MG**	**N209501**	**003**	Oct 11, 2017

PREGABALIN

AB		ALVOGEN	**82.5MG**	**A211593**	**001**	Apr 13, 2021
AB			**165MG**	**A211593**	**002**	Apr 13, 2021
AB			**330MG**	**A211593**	**003**	Apr 13, 2021
AB		APOTEX	**165MG**	**A213313**	**001**	Apr 13, 2021
AB			**330MG**	**A213313**	**002**	Apr 13, 2021
AB		MSN	**82.5MG**	**A213226**	**001**	Apr 13, 2021
AB			**165MG**	**A213226**	**002**	Apr 13, 2021
AB			**330MG**	**A213226**	**003**	Apr 13, 2021
AB		MYLAN	**82.5MG**	**A211948**	**001**	Apr 13, 2021
AB			**165MG**	**A211967**	**001**	Nov 04, 2021
AB		SUN PHARM	**82.5MG**	**A211889**	**001**	Apr 13, 2021
AB			**165MG**	**A211889**	**002**	Apr 13, 2021
AB			**330MG**	**A211889**	**003**	Apr 13, 2021

PRETOMANID

TABLET;ORAL

PRETOMANID

	+!	MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019

PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRILOCAINE HYDROCHLORIDE

	!	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE

AB	**+!**	SANOFI AVENTIS US	**EQ 15MG BASE**	**N008316**	**001**	

PRIMAQUINE PHOSPHATE

AB		BAYSHORE PHARMS LLC	**EQ 15MG BASE**	**A204476**	**001**	Feb 25, 2014
AB		NOVAST LABS	**EQ 15MG BASE**	**A206043**	**001**	Jun 23, 2016

PRIMIDONE

TABLET;ORAL

MYSOLINE

AB	**+!**	VALEANT	**50MG**	**N009170**	**003**	
AB	**+**		**250MG**	**N009170**	**002**	

PRIMIDONE

AB		AMNEAL PHARM	**50MG**	**A040866**	**001**	Apr 23, 2008
AB			**250MG**	**A040866**	**002**	Apr 23, 2008
AB		ANDA REPOSITORY	**50MG**	**A040626**	**001**	Sep 29, 2005
AB			**250MG**	**A040626**	**002**	Sep 29, 2005
AB		LANNETT	**50MG**	**A084903**	**002**	May 24, 2001
AB			**250MG**	**A084903**	**001**	
AB		OXFORD PHARMS	**50MG**	**A040586**	**001**	Feb 24, 2005
AB			**250MG**	**A040586**	**002**	Feb 24, 2005
AB		WATSON LABS	**250MG**	**A083551**	**001**	

PROBENECID

TABLET;ORAL

PROBALAN

AB		LANNETT	**500MG**	**A080966**	**001**	

PROBENECID

AB	**!**	WATSON LABS TEVA	**500MG**	**A084442**	**004**	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

AP	**!**	HOSPIRA	**100MG/ML**	**A089069**	**001**	Feb 12, 1986
AP		INTL MEDICATION	**100MG/ML**	**A088636**	**001**	Jul 31, 1984
AP		NEXUS PHARMS	**100MG/ML**	**A206332**	**001**	Oct 13, 2017
AP			**500MG/ML**	**A206332**	**002**	Oct 13, 2017
	!	HOSPIRA	500MG/ML	A089070	001	Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE

CAPSULE;ORAL

MATULANE

	+!	LEADIANT BIOSCI INC	EQ 50MG BASE	N016785	001	

PROCHLORPERAZINE

SUPPOSITORY;RECTAL

COMPRO

AB		PADAGIS US	**25MG**	**A040246**	**001**	Jun 28, 2000

PROCHLORPERAZINE

AB	**!**	COSETTE	**25MG**	**A040058**	**001**	Nov 24, 1993

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP		ATHENEX INC	**EQ 5MG BASE/ML**	**A040540**	**001**	May 28, 2004
AP		CAPLIN	**EQ 5MG BASE/ML**	**A214379**	**001**	Apr 22, 2021
AP	**!**	EMCURE PHARMS LTD	**EQ 5MG BASE/ML**	**A204147**	**001**	Oct 15, 2013
AP		GLAND PHARMA LTD	**EQ 5MG BASE/ML**	**A214107**	**001**	Sep 22, 2021
AP		HIKMA	**EQ 5MG BASE/ML**	**A089903**	**001**	Aug 29, 1989
AP		MYLAN LABS LTD	**EQ 5MG BASE/ML**	**A210710**	**001**	Oct 25, 2018
AP		NEXUS PHARMS	**EQ 5MG BASE/ML**	**A204860**	**001**	Feb 15, 2019
AP		VIWIT PHARM	**EQ 5MG BASE/ML**	**A213626**	**001**	Sep 28, 2021

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

AB		MYLAN	**EQ 5MG BASE**	**A040185**	**002**	Oct 28, 1996
AB			**EQ 10MG BASE**	**A040185**	**001**	Oct 28, 1996

PROCOMP

AB		JUBILANT CADISTA	**EQ 5MG BASE**	**A040268**	**001**	Feb 27, 1998
AB	**!**		**EQ 10MG BASE**	**A040268**	**002**	Feb 27, 1998

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		AMNEAL PHARMS NY	**100MG**	**A207724**	**001**	Sep 07, 2017
AB			**200MG**	**A207724**	**002**	Sep 07, 2017
AB		BIONPHARMA INC	**100MG**	**A200900**	**001**	Aug 16, 2013
AB			**200MG**	**A200900**	**002**	Aug 16, 2013
AB		DR REDDYS	**100MG**	**A208801**	**001**	Feb 28, 2017
AB			**200MG**	**A208801**	**002**	Feb 28, 2017
AB		EUGIA PHARMA	**100MG**	**A211285**	**001**	Oct 26, 2018
AB			**200MG**	**A211285**	**002**	Oct 26, 2018

PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

AB		XIROMED	**100MG**	**A205229**	**001**	Oct 20, 2017
AB			**200MG**	**A205229**	**002**	Oct 20, 2017

PROMETRIUM

AB	**+**	VIRTUS PHARMS	**100MG**	**N019781**	**001**	May 14, 1998
AB	**+!**		**200MG**	**N019781**	**002**	Oct 15, 1999

PROGESTERONE

BX		SOFGEN PHARMS	100MG	A200456	001	Sep 28, 2012
BX			200MG	A200456	002	Sep 28, 2012

GEL;VAGINAL

CRINONE

	+!	ALLERGAN	4%	N020701	001	Jul 31, 1997
	+!		8%	N020701	002	Jul 31, 1997

INJECTABLE;INJECTION

PROGESTERONE

AO	**+!**	ACTAVIS LABS UT INC	**50MG/ML**	**N017362**	**002**	
AO		EUGIA PHARMA	**50MG/ML**	**A210965**	**001**	Dec 06, 2018
AO		FRESENIUS KABI USA	**50MG/ML**	**A075906**	**001**	Apr 25, 2001
AO		HIKMA FARMACEUTICA	**50MG/ML**	**A091033**	**001**	Oct 28, 2010
AO		XIROMED	**50MG/ML**	**A215634**	**001**	Jan 05, 2022

INSERT;VAGINAL

ENDOMETRIN

	+!	FERRING	100MG	N022057	001	Jun 21, 2007

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	**!**	WEST-WARD PHARMS INT	**25MG/ML**	**A083312**	**001**	
AP	**!**		**50MG/ML**	**A083312**	**002**	
AP		XGEN PHARMS	**25MG/ML**	**A040737**	**001**	Apr 24, 2008
AP			**50MG/ML**	**A040737**	**002**	Apr 24, 2008

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

AB		COSETTE	**12.5MG**	**A040428**	**002**	Mar 31, 2003
AB	**!**		**25MG**	**A040428**	**001**	Feb 05, 2002
AB		PADAGIS ISRAEL	**12.5MG**	**A040500**	**001**	Jun 30, 2003
AB			**25MG**	**A040500**	**002**	Jun 30, 2003
AB		TARO	**12.5MG**	**A040603**	**001**	Oct 26, 2006
AB			**25MG**	**A040603**	**002**	Oct 26, 2006

PROMETHEGAN

	!	COSETTE	50MG	A087165	001	Aug 14, 1987

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA		AKORN	**6.25MG/5ML**	**A040026**	**001**	Sep 25, 1998
AA		AMNEAL PHARMS	**6.25MG/5ML**	**A040882**	**001**	Dec 30, 2009
AA		NOSTRUM LABS INC	**6.25MG/5ML**	**A040891**	**001**	Mar 13, 2009
AA		PHARM ASSOC	**6.25MG/5ML**	**A040643**	**001**	Apr 26, 2006
AA		QUAGEN	**6.25MG/5ML**	**A213890**	**001**	Jul 12, 2021
AA		TARO	**6.25MG/5ML**	**A040718**	**001**	Apr 04, 2007
AA		TRIS PHARMA INC	**6.25MG/5ML**	**A091675**	**001**	Jun 28, 2012

PROMETHAZINE PLAIN

AA	**+!**	WOCKHARDT BIO AG	**6.25MG/5ML**	**A087953**	**001**	Nov 15, 1982

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	**12.5MG**	**A091179**	**001**	Dec 13, 2010
AB			**25MG**	**A091179**	**002**	Dec 13, 2010
AB			**50MG**	**A091179**	**003**	Dec 13, 2010
AB		KVK TECH	**12.5MG**	**A040712**	**002**	May 04, 2007
AB			**25MG**	**A040712**	**001**	Jul 31, 2006
AB			**50MG**	**A040712**	**003**	Jul 31, 2006
AB		PRINSTON INC	**12.5MG**	**A040622**	**001**	Jul 18, 2006
AB			**25MG**	**A040622**	**002**	Jul 18, 2006
AB			**50MG**	**A040622**	**003**	Jul 18, 2006
AB		QUAGEN	**12.5MG**	**A040673**	**001**	Mar 05, 2008
AB			**25MG**	**A040673**	**002**	Mar 05, 2008
AB			**50MG**	**A040673**	**003**	Mar 05, 2008
AB	**+**	SANDOZ	**25MG**	**A084176**	**003**	
AB	**+!**		**50MG**	**A084176**	**001**	
AB		STRIDES PHARMA	**12.5MG**	**A209177**	**001**	Jun 30, 2017
AB			**25MG**	**A209177**	**002**	Jun 30, 2017

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

AB			**50MG**	**A209177**	**003**	Jun 30, 2017
AB		SUN PHARM INDS INC	**12.5MG**	**A040863**	**001**	Dec 30, 2008
AB			**25MG**	**A040863**	**002**	Dec 30, 2008
AB			**50MG**	**A040863**	**003**	Dec 30, 2008
AB		WATSON LABS	**25MG**	**A083426**	**001**	
AB			**50MG**	**A083711**	**001**	
AB		ZYDUS PHARMS USA	**12.5MG**	**A040596**	**001**	Nov 18, 2005
AB			**25MG**	**A040596**	**002**	Nov 18, 2005
AB			**50MG**	**A040596**	**003**	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	**225MG**	**A205268**	**001**	Sep 08, 2017
AB			**325MG**	**A205268**	**002**	Sep 08, 2017
AB			**425MG**	**A205268**	**003**	Sep 08, 2017
AB		RISING	**225MG**	**A205956**	**001**	Jul 02, 2018
AB			**325MG**	**A205956**	**002**	Jul 02, 2018
AB			**425MG**	**A205956**	**003**	Jul 02, 2018
AB		STRIDES PHARMA	**225MG**	**A078540**	**001**	Oct 18, 2010
AB			**325MG**	**A078540**	**002**	Oct 18, 2010
AB			**425MG**	**A078540**	**003**	Oct 18, 2010
AB		TWI PHARMS	**225MG**	**A212928**	**001**	Jun 18, 2020
AB			**325MG**	**A212928**	**002**	Jun 18, 2020
AB			**425MG**	**A212928**	**003**	Jun 18, 2020
AB		UPSHER SMITH LABS	**225MG**	**A212744**	**001**	Jun 25, 2020
AB			**325MG**	**A212744**	**002**	Jun 25, 2020
AB			**425MG**	**A212744**	**003**	Jun 25, 2020
AB		WATSON LABS INC	**225MG**	**A202688**	**001**	Aug 24, 2015
AB			**325MG**	**A202688**	**002**	Aug 24, 2015
AB			**425MG**	**A202688**	**003**	Aug 24, 2015
AB		ZYDUS	**225MG**	**A214184**	**001**	Apr 21, 2021
AB			**325MG**	**A214184**	**002**	Apr 21, 2021
AB			**425MG**	**A214184**	**003**	Apr 21, 2021

RYTHMOL SR

AB	**+**	GLAXOSMITHKLINE LLC	**225MG**	**N021416**	**001**	Sep 04, 2003
AB	**+**		**325MG**	**N021416**	**002**	Sep 04, 2003
AB	**+!**		**425MG**	**N021416**	**003**	Sep 04, 2003

PROPAFENONE HYDROCHLORIDE

BX		SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019
BX			325MG	A210339	002	Jan 04, 2019
BX			425MG	A210339	003	Jan 04, 2019

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS	**150MG**	**A076550**	**001**	Apr 23, 2004
AB			**225MG**	**A076550**	**002**	Apr 23, 2004
AB			**300MG**	**A076550**	**003**	Apr 23, 2004
AB		AUROBINDO PHARMA LTD	**150MG**	**A202445**	**001**	May 11, 2016
AB			**225MG**	**A202445**	**002**	May 11, 2016
AB			**300MG**	**A202445**	**003**	May 11, 2016
AB		STRIDES PHARMA	**150MG**	**A075938**	**001**	Oct 17, 2002
AB			**225MG**	**A075938**	**002**	Oct 17, 2002
AB	**!**		**300MG**	**A075938**	**003**	Oct 17, 2002
AB		SUN PHARM INDUSTRIES	**150MG**	**A075998**	**001**	Nov 29, 2001
AB			**225MG**	**A075998**	**002**	Nov 29, 2001
AB			**300MG**	**A075998**	**003**	Nov 29, 2001
AB		WATSON LABS	**150MG**	**A075203**	**001**	Oct 24, 2000
AB			**225MG**	**A075203**	**002**	Oct 24, 2000

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

AT		ALCON LABS INC	**0.5%**	**A080027**	**001**	

PROPARACAINE HYDROCHLORIDE

AT	**!**	AKORN	**0.5%**	**A040277**	**001**	Mar 16, 2000
AT		BAUSCH AND LOMB	**0.5%**	**A040074**	**001**	Sep 29, 1995

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN

AB	**+!**	FRESENIUS KABI USA	**10MG/ML**	**N019627**	**002**	Jun 11, 1996

PROPOFOL

AB		DR REDDYS	**10MG/ML**	**A205067**	**001**	Nov 15, 2018
AB		EMCURE PHARMS LTD	**10MG/ML**	**A206408**	**001**	Oct 12, 2021
AB		HIKMA	**10MG/ML**	**A074848**	**001**	Apr 19, 2005
AB		HOSPIRA	**10MG/ML**	**A077908**	**001**	Mar 17, 2006
AB		INNOPHARMA	**10MG/ML**	**A205576**	**001**	Sep 16, 2020
AB		SAGENT PHARMS INC	**10MG/ML**	**A075102**	**001**	Jan 04, 1999
AB		WATSON LABS INC	**10MG/ML**	**A205307**	**001**	Dec 22, 2015

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB	**+**	ANI PHARMS	**60MG**	**N018553**	**004**	Mar 18, 1987
AB	**+**		**80MG**	**N018553**	**002**	Apr 19, 1983
AB	**+**		**120MG**	**N018553**	**003**	Apr 19, 1983
AB	**+!**		**160MG**	**N018553**	**001**	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**60MG**	**A078494**	**001**	Aug 10, 2007
AB			**80MG**	**A078494**	**002**	Aug 10, 2007
AB			**120MG**	**A078494**	**003**	Aug 10, 2007
AB			**160MG**	**A078494**	**004**	Aug 10, 2007
AB		ADARE PHARMS INC	**60MG**	**A078703**	**001**	Jul 15, 2011
AB			**80MG**	**A078703**	**002**	Jul 15, 2011
AB			**120MG**	**A078703**	**003**	Jul 15, 2011
AB			**160MG**	**A078703**	**004**	Jul 15, 2011
AB		AMTA	**60MG**	**A212026**	**001**	Jan 06, 2020
AB			**80MG**	**A212026**	**002**	Jan 06, 2020
AB			**120MG**	**A212026**	**003**	Jan 06, 2020
AB			**160MG**	**A212026**	**004**	Jan 06, 2020
AB		NORTEC DEV ASSOC	**60MG**	**A078065**	**001**	Jan 26, 2007
AB			**80MG**	**A078065**	**002**	Jan 26, 2007
AB			**120MG**	**A078065**	**003**	Jan 26, 2007
AB			**160MG**	**A078065**	**004**	Jan 26, 2007
AB		ZYDUS PHARMS USA INC	**60MG**	**A090321**	**001**	Mar 25, 2011
AB			**80MG**	**A090321**	**002**	Mar 25, 2011
AB			**120MG**	**A090321**	**003**	Mar 25, 2011
AB			**160MG**	**A090321**	**004**	Mar 25, 2011

INNOPRAN XL

BX	+	ANI PHARMS	80MG	N021438	001	Mar 12, 2003
BX	+!		120MG	N021438	002	Mar 12, 2003

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP		ATHENEX INC	**1MG/ML**	**A075792**	**001**	Aug 29, 2000
AP		FRESENIUS KABI USA	**1MG/ML**	**A075826**	**001**	Aug 31, 2001
	!	HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008

SOLUTION;ORAL

HEMANGEOL

	+!	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

	!	HIKMA	20MG/5ML	A070979	001	May 15, 1987
	!		40MG/5ML	A070690	001	May 15, 1987

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		IMPAX LABS INC	**10MG**	**A071972**	**001**	Apr 06, 1988
AB			**20MG**	**A071972**	**002**	Apr 06, 1988
AB			**40MG**	**A071972**	**003**	Apr 06, 1988
AB			**60MG**	**A071976**	**002**	May 13, 1986
AB		INNOGENIX	**10MG**	**A070322**	**002**	Oct 22, 1985
AB			**20MG**	**A070322**	**003**	Oct 22, 1985
AB			**40MG**	**A070322**	**004**	Oct 22, 1985
AB			**60MG**	**A070322**	**005**	Sep 24, 1986
AB			**80MG**	**A070322**	**001**	Aug 04, 1986
AB		IPCA LABS LTD	**10MG**	**A078955**	**001**	Jun 02, 2008
AB			**20MG**	**A078955**	**002**	Jun 02, 2008
AB			**40MG**	**A078955**	**003**	Jun 02, 2008
AB			**60MG**	**A078955**	**004**	Jun 02, 2008
AB			**80MG**	**A078955**	**005**	Jun 02, 2008
AB		MYLAN	**10MG**	**A070213**	**002**	Nov 19, 1985

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB			**20MG**	**A070213**	**003**	Nov 19, 1985
AB			**40MG**	**A070213**	**001**	Nov 19, 1985
AB			**60MG**	**A070213**	**005**	Apr 08, 2011
AB			**80MG**	**A070213**	**004**	Nov 19, 1985
AB		NORTHSTAR HLTHCARE	**10MG**	**A078213**	**001**	Jan 10, 2008
AB			**20MG**	**A078213**	**002**	Jan 10, 2008
AB			**40MG**	**A078213**	**003**	Jan 10, 2008
AB			**60MG**	**A078213**	**004**	Jan 10, 2008
AB			**80MG**	**A078213**	**005**	Jan 10, 2008
AB		VINTAGE PHARMS	**10MG**	**A070221**	**002**	Aug 01, 1986
AB			**20MG**	**A070221**	**003**	Aug 01, 1986
AB			**40MG**	**A070221**	**004**	Aug 01, 1986
AB			**60MG**	**A070221**	**005**	Sep 24, 1986
AB			**80MG**	**A070221**	**001**	Apr 14, 1986
AB		WATSON LABS	**10MG**	**A070175**	**001**	May 13, 1986
AB			**20MG**	**A070176**	**001**	May 13, 1986
AB			**40MG**	**A070177**	**001**	May 13, 1986
AB	**!**		**80MG**	**A070178**	**001**	May 13, 1986

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD		ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+!	DAVA PHARMS INC	50MG	N006188	001	
BD		QUAGEN	50MG	A080154	001	

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

	!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB		EPIC PHARMA LLC	**5MG**	**A202220**	**001**	Nov 19, 2012
AB			**10MG**	**A202220**	**002**	Nov 19, 2012
AB		HIKMA	**5MG**	**A078913**	**001**	Sep 16, 2008
AB	**!**		**10MG**	**A078913**	**002**	Sep 16, 2008
AB		SIGMAPHARM LABS LLC	**5MG**	**A090462**	**001**	May 03, 2010
AB			**10MG**	**A090462**	**002**	May 03, 2010

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

MOTEGRITY

	+	TAKEDA PHARMS USA	EQ 1MG BASE	N210166	001	Dec 14, 2018
	+!		EQ 2MG BASE	N210166	002	Dec 14, 2018

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

AB	**!**	AKORN	**500MG**	**A081319**	**001**	Jun 30, 1992
AB		MACLEODS PHARMS LTD	**500MG**	**A212541**	**001**	Jul 27, 2020
AB	**+**	NOVITIUM PHARMA	**500MG**	**A080157**	**001**	

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION

MESTINON

AP	**+!**	BAUSCH	**5MG/ML**	**N009830**	**001**	

REGONOL

AP		SANDOZ INC	**5MG/ML**	**N017398**	**001**	

SYRUP;ORAL

MESTINON

AA	**+!**	BAUSCH	**60MG/5ML**	**N015193**	**001**	

PYRIDOSTIGMINE BROMIDE

AA		AMNEAL	**60MG/5ML**	**A212702**	**001**	Jan 10, 2020
AA		ELYSIUM	**60MG/5ML**	**A208797**	**001**	Jan 09, 2020
AA		NOVITIUM PHARMA	**60MG/5ML**	**A211694**	**001**	Mar 08, 2019

TABLET;ORAL

MESTINON

AB	**+!**	BAUSCH	**60MG**	**N009829**	**002**	

PYRIDOSTIGMINE BROMIDE

AB		EYWA	**60MG**	**A211181**	**001**	Jul 20, 2018

PYRIDOSTIGMINE BROMIDE
TABLET;ORAL
PYRIDOSTIGMINE BROMIDE

AB		IMPAX LABS	**60MG**	**A040502**	**001**	Apr 24, 2003
AB		ZYDUS PHARMS	**60MG**	**A205650**	**001**	Jun 22, 2015
		EYWA	30MG	A211181	002	May 14, 2019

TABLET, EXTENDED RELEASE;ORAL
MESTINON

AB	**+!**	BAUSCH	**180MG**	**N011665**	**001**	

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN	**180MG**	**A204737**	**001**	Jun 26, 2015
AB		IMPAX LABS INC	**180MG**	**A203184**	**001**	Sep 15, 2015
AB		RISING	**180MG**	**A205464**	**001**	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE
INJECTABLE;INJECTION
PYRIDOXINE HYDROCHLORIDE

	+!	FRESENIUS KABI USA	100MG/ML	A080618	001	

PYRIMETHAMINE
TABLET;ORAL
DARAPRIM

AB	**+!**	VYERA PHARMS LLC	**25MG**	**N008578**	**001**	

PYRIMETHAMINE

AB		ALVOGEN	**25MG**	**A211271**	**001**	Jul 27, 2021
AB		CEROVENE INC	**25MG**	**A207127**	**001**	Feb 28, 2020
AB		TEVA PHARMS	**25MG**	**A215506**	**001**	Aug 13, 2021

QUAZEPAM
TABLET;ORAL
DORAL

	+!	GALT PHARMS	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE
TABLET;ORAL
QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	**EQ 25MG BASE**	**A202152**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A202152**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A202152**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A202152**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A202152**	**005**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A202152**	**006**	Mar 27, 2012
AB		ALKEM LABS LTD	**EQ 25MG BASE**	**A201504**	**001**	Feb 12, 2013
AB			**EQ 50MG BASE**	**A201504**	**002**	Feb 12, 2013
AB			**EQ 100MG BASE**	**A201504**	**003**	Feb 12, 2013
AB			**EQ 150MG BASE**	**A201504**	**004**	Feb 12, 2013
AB			**EQ 200MG BASE**	**A201504**	**005**	Feb 12, 2013
AB			**EQ 300MG BASE**	**A201504**	**006**	Feb 12, 2013
AB			**EQ 400MG BASE**	**A201504**	**007**	Feb 12, 2013
AB		AUROBINDO PHARMA LTD	**EQ 25MG BASE**	**A091388**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A091388**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A091388**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A091388**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A091388**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A091388**	**006**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A091388**	**007**	Mar 27, 2012
AB		DR REDDYS LABS LTD	**EQ 25MG BASE**	**A077380**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A077380**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A077380**	**003**	Mar 27, 2012
AB			**EQ 150MG BASE**	**A077380**	**004**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A077380**	**005**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A077380**	**006**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A077380**	**007**	Mar 27, 2012
AB		HIKMA	**EQ 25MG BASE**	**A090120**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A090749**	**001**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A090749**	**002**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A090749**	**003**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A090749**	**004**	Mar 27, 2012
AB			**EQ 400MG BASE**	**A090749**	**005**	Mar 27, 2012
AB		LUPIN LTD	**EQ 25MG BASE**	**A201109**	**001**	Mar 27, 2012
AB			**EQ 50MG BASE**	**A201109**	**002**	Mar 27, 2012
AB			**EQ 100MG BASE**	**A201109**	**003**	Mar 27, 2012
AB			**EQ 200MG BASE**	**A201109**	**004**	Mar 27, 2012
AB			**EQ 300MG BASE**	**A201109**	**005**	Mar 27, 2012

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB		**EQ 400MG BASE**	**A201109**	**006**	Mar 27, 2012
AB	MACLEODS PHARMS LTD	**EQ 25MG BASE**	**A203359**	**001**	May 17, 2016
AB		**EQ 50MG BASE**	**A203359**	**002**	May 17, 2016
AB		**EQ 100MG BASE**	**A203359**	**003**	May 17, 2016
AB		**EQ 200MG BASE**	**A203359**	**004**	May 17, 2016
AB		**EQ 300MG BASE**	**A203359**	**005**	May 17, 2016
AB		**EQ 400MG BASE**	**A203359**	**006**	May 17, 2016
AB	SANDOZ	**EQ 25MG BASE**	**A078679**	**001**	Dec 14, 2012
AB		**EQ 50MG BASE**	**A078679**	**002**	Dec 14, 2012
AB		**EQ 100MG BASE**	**A078679**	**003**	Dec 14, 2012
AB		**EQ 150MG BASE**	**A078679**	**004**	Dec 14, 2012
AB		**EQ 200MG BASE**	**A078679**	**005**	Dec 14, 2012
AB		**EQ 300MG BASE**	**A078679**	**006**	Dec 14, 2012
AB		**EQ 400MG BASE**	**A078679**	**007**	Dec 14, 2012
AB	SUN PHARM	**EQ 25MG BASE**	**A201190**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A201190**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A201190**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A201190**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A201190**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A201190**	**006**	Mar 27, 2012
AB	TEVA PHARMS	**EQ 25MG BASE**	**A077745**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A077745**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A077745**	**003**	Mar 27, 2012
AB		**EQ 150MG BASE**	**A077745**	**004**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A077745**	**005**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A077745**	**006**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A077745**	**007**	Mar 27, 2012
AB	UNICHEM	**EQ 25MG BASE**	**A202674**	**001**	Mar 08, 2016
AB		**EQ 50MG BASE**	**A202674**	**002**	Mar 08, 2016
AB		**EQ 100MG BASE**	**A202674**	**003**	Mar 08, 2016
AB		**EQ 200MG BASE**	**A202674**	**004**	Mar 08, 2016
AB		**EQ 300MG BASE**	**A202674**	**005**	Mar 08, 2016
AB		**EQ 400MG BASE**	**A202674**	**006**	Mar 08, 2016
AB	ZENNOVA	**EQ 25MG BASE**	**A090960**	**001**	Mar 27, 2012
AB		**EQ 50MG BASE**	**A090960**	**002**	Mar 27, 2012
AB		**EQ 100MG BASE**	**A090960**	**003**	Mar 27, 2012
AB		**EQ 200MG BASE**	**A090960**	**004**	Mar 27, 2012
AB		**EQ 300MG BASE**	**A090960**	**005**	Mar 27, 2012
AB		**EQ 400MG BASE**	**A090960**	**006**	Mar 27, 2012

SEROQUEL

AB	**+!**	ASTRAZENECA	**EQ 25MG BASE**	**N020639**	**001**	Sep 26, 1997
AB	**+**		**EQ 50MG BASE**	**N020639**	**007**	Oct 04, 2005
AB	**+**		**EQ 100MG BASE**	**N020639**	**002**	Sep 26, 1997
AB	**+**		**EQ 200MG BASE**	**N020639**	**003**	Sep 26, 1997
AB	**+!**		**EQ 300MG BASE**	**N020639**	**005**	Jul 26, 2000
AB	**+**		**EQ 400MG BASE**	**N020639**	**006**	Oct 04, 2005

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	**EQ 50MG BASE**	**A206252**	**001**	Nov 29, 2017
AB		**EQ 150MG BASE**	**A090681**	**001**	May 09, 2017
AB		**EQ 200MG BASE**	**A090681**	**002**	May 09, 2017
AB		**EQ 300MG BASE**	**A090681**	**003**	May 09, 2017
AB		**EQ 400MG BASE**	**A090681**	**004**	Nov 01, 2016
AB	ALIGNSCIENCE PHARMA	**EQ 150MG BASE**	**A209497**	**001**	Sep 28, 2018
AB		**EQ 200MG BASE**	**A209497**	**002**	Sep 28, 2018
AB	AUROBINDO PHARMA LTD	**EQ 50MG BASE**	**A207655**	**001**	Nov 29, 2017
AB		**EQ 150MG BASE**	**A207655**	**002**	Nov 29, 2017
AB		**EQ 200MG BASE**	**A207655**	**003**	Nov 29, 2017
AB		**EQ 300MG BASE**	**A207655**	**004**	Nov 29, 2017
AB		**EQ 400MG BASE**	**A207655**	**005**	Nov 29, 2017
AB	INTELLIPHARMACEUTICS	**EQ 50MG BASE**	**A202939**	**001**	May 09, 2017
AB		**EQ 150MG BASE**	**A202939**	**002**	May 09, 2017
AB		**EQ 200MG BASE**	**A202939**	**003**	May 09, 2017
AB		**EQ 300MG BASE**	**A202939**	**004**	May 09, 2017
AB		**EQ 400MG BASE**	**A202939**	**005**	May 09, 2017
AB	LUPIN LTD	**EQ 50MG BASE**	**A204203**	**001**	May 17, 2017
AB		**EQ 150MG BASE**	**A204203**	**002**	May 17, 2017
AB		**EQ 200MG BASE**	**A204203**	**003**	May 17, 2017

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AB			**EQ 300MG BASE**	**A204203**	**004**	May 17, 2017
AB			**EQ 400MG BASE**	**A204203**	**005**	May 17, 2017
AB		MACLEODS PHARMS LTD	**EQ 150MG BASE**	**A204253**	**001**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A204253**	**002**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A204253**	**003**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A204253**	**004**	Nov 29, 2017
AB		NOVAST LABS	**EQ 50MG BASE**	**A208947**	**001**	Nov 29, 2017
AB			**EQ 150MG BASE**	**A208947**	**002**	Nov 29, 2017
AB			**EQ 200MG BASE**	**A208947**	**003**	Nov 29, 2017
AB			**EQ 300MG BASE**	**A208947**	**004**	Nov 29, 2017
AB			**EQ 400MG BASE**	**A208947**	**005**	Nov 29, 2017
AB		PAR PHARM	**EQ 50MG BASE**	**A090482**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A090482**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A090482**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A090482**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A090482**	**005**	May 09, 2017
AB		PHARMADAX INC	**EQ 50MG BASE**	**A206260**	**001**	May 09, 2017
AB			**EQ 150MG BASE**	**A206260**	**002**	May 09, 2017
AB			**EQ 200MG BASE**	**A206260**	**003**	May 09, 2017
AB			**EQ 300MG BASE**	**A206260**	**004**	May 09, 2017
AB			**EQ 400MG BASE**	**A206260**	**005**	May 09, 2017

SEROQUEL XR

AB	**+**	ASTRAZENECA	**EQ 50MG BASE**	**N022047**	**001**	May 17, 2007
AB	**+**		**EQ 150MG BASE**	**N022047**	**005**	Aug 11, 2008
AB	**+!**		**EQ 200MG BASE**	**N022047**	**002**	May 17, 2007
AB	**+**		**EQ 300MG BASE**	**N022047**	**003**	May 17, 2007
AB	**+**		**EQ 400MG BASE**	**N022047**	**004**	May 17, 2007

QUETIAPINE FUMARATE

BX		SCIEGEN PHARMS INC	EQ 50MG BASE	A209635	005	Nov 16, 2018
BX			EQ 150MG BASE	A209635	001	Nov 29, 2017
BX			EQ 200MG BASE	A209635	002	Nov 29, 2017
BX			EQ 300MG BASE	A209635	003	Nov 29, 2017
BX			EQ 400MG BASE	A209635	004	Nov 29, 2017

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

AB	**+**	PFIZER PHARMS	**EQ 5MG BASE**	**N019885**	**001**	Nov 19, 1991
AB	**+**		**EQ 10MG BASE**	**N019885**	**002**	Nov 19, 1991
AB	**+**		**EQ 20MG BASE**	**N019885**	**003**	Nov 19, 1991
AB	**+!**		**EQ 40MG BASE**	**N019885**	**004**	Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202725**	**001**	Apr 29, 2013
AB			**EQ 10MG BASE**	**A202725**	**002**	Apr 29, 2013
AB			**EQ 20MG BASE**	**A202725**	**003**	Apr 29, 2013
AB			**EQ 40MG BASE**	**A202725**	**004**	Apr 29, 2013
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A078457**	**001**	Aug 24, 2007
AB			**EQ 10MG BASE**	**A078457**	**002**	Aug 24, 2007
AB			**EQ 20MG BASE**	**A078457**	**003**	Aug 24, 2007
AB			**EQ 40MG BASE**	**A078457**	**004**	Aug 24, 2007
AB		LUPIN	**EQ 5MG BASE**	**A077690**	**001**	Jun 20, 2006
AB			**EQ 10MG BASE**	**A077690**	**002**	Jun 20, 2006
AB			**EQ 20MG BASE**	**A077690**	**003**	Jun 20, 2006
AB			**EQ 40MG BASE**	**A077690**	**004**	Jun 20, 2006
AB		PRINSTON INC	**EQ 5MG BASE**	**A205823**	**001**	Sep 15, 2016
AB			**EQ 10MG BASE**	**A205823**	**002**	Sep 15, 2016
AB			**EQ 20MG BASE**	**A205823**	**003**	Sep 15, 2016
AB			**EQ 40MG BASE**	**A205823**	**004**	Sep 15, 2016

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

AB		EYWA	**324MG**	**A212589**	**001**	Sep 17, 2021
AB	**!**	SUN PHARM INDUSTRIES	**324MG**	**A089338**	**001**	Feb 11, 1987

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

	!	SANDOZ	200MG	A088072	002	
	!		300MG	A088072	001	Sep 26, 1983

QUININE SULFATE

CAPSULE;ORAL

QUALAQUIN

AB	**+!**	SUN PHARM INDUSTRIES	**324MG**	**N021799**	**001**	Aug 12, 2005

QUININE SULFATE

AB		AMNEAL PHARMS	**324MG**	**A203729**	**001**	Jul 15, 2015
AB		LUPIN LTD	**324MG**	**A203112**	**001**	Apr 24, 2015
AB		NOVAST LABS	**324MG**	**A204372**	**001**	Jul 22, 2015
AB		TEVA PHARMS	**324MG**	**A091661**	**001**	Sep 28, 2012

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

AB	**+!**	WOODWARD	**20MG**	**N020973**	**002**	Aug 19, 1999

RABEPRAZOLE SODIUM

AB		ALKEM LABS LTD	**20MG**	**A208644**	**001**	Apr 24, 2018
AB		AMNEAL PHARMS	**20MG**	**A204179**	**001**	Jul 31, 2015
AB		AUROBINDO PHARMA LTD	**20MG**	**A205761**	**001**	Feb 17, 2017
AB		DR REDDYS	**20MG**	**A076824**	**001**	Nov 08, 2013
AB		LANNETT CO INC	**20MG**	**A090678**	**001**	Nov 08, 2013
AB		LUPIN LTD	**20MG**	**A078964**	**001**	Nov 08, 2013
AB		RUBICON	**20MG**	**A204237**	**001**	Nov 18, 2015
AB		TEVA PHARMS USA	**20MG**	**A076822**	**001**	Nov 08, 2013
AB		TORRENT	**20MG**	**A202376**	**001**	Nov 08, 2013

RADIUM RA-223 DICHLORIDE

SOLUTION;INTRAVENOUS

XOFIGO

	+!	BAYER HLTHCARE	162mCi/6ML (27mCi/ML)	N203971	001	May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB	**+!**	LILLY	**60MG**	**N020815**	**001**	Dec 09, 1997

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	**60MG**	**A208206**	**001**	Apr 08, 2016
AB		AUROBINDO PHARMA LTD	**60MG**	**A204310**	**001**	Aug 28, 2015
AB		CADILA PHARMS LTD	**60MG**	**A211324**	**001**	Aug 18, 2020
AB		GLENMARK PHARMS LTD	**60MG**	**A204491**	**001**	Mar 22, 2016
AB		INVAGEN PHARMS	**60MG**	**A090842**	**001**	Sep 24, 2014
AB		SCIEGEN PHARMS INC	**60MG**	**A206384**	**001**	Oct 12, 2016
AB		TEVA PHARMS USA	**60MG**	**A078193**	**001**	Mar 04, 2014
AB		WATSON LABS INC	**60MG**	**A200825**	**001**	Jan 21, 2015

RALTEGRAVIR POTASSIUM

POWDER;ORAL

ISENTRESS

	+!	MERCK SHARP DOHME	EQ 100MG BASE/PACKET	N205786	001	Dec 20, 2013

TABLET;ORAL

ISENTRESS

	+!	MERCK SHARP DOHME	EQ 400MG BASE	N022145	001	Oct 12, 2007

ISENTRESS HD

	+!	MERCK SHARP DOHME	EQ 600MG BASE	N022145	002	May 26, 2017

TABLET, CHEWABLE;ORAL

ISENTRESS

	+	MERCK SHARP DOHME	EQ 25MG BASE	N203045	001	Dec 21, 2011
	+!		EQ 100MG BASE	N203045	002	Dec 21, 2011

RAMELTEON

TABLET;ORAL

RAMELTEON

AB		ACTAVIS LABS FL INC	**8MG**	**A091610**	**001**	Aug 19, 2015
AB		APPCO	**8MG**	**A213815**	**001**	Oct 26, 2020
AB		DR REDDYS LABS SA	**8MG**	**A091693**	**001**	Jul 26, 2013
AB		GRANULES	**8MG**	**A213186**	**001**	Aug 21, 2020
AB		I3 PHARMS	**8MG**	**A212650**	**001**	Apr 10, 2020
AB		ZYDUS PHARMS	**8MG**	**A211567**	**001**	Jul 22, 2019

RAMELTEON

TABLET;ORAL

ROZEREM

AB	**+!**	TAKEDA PHARMS USA	**8MG**	**N021782**	**001**	Jul 22, 2005

RAMIPRIL

CAPSULE;ORAL

ALTACE

AB	**+**	KING PHARMS LLC	**1.25MG**	**N019901**	**001**	Jan 28, 1991
AB	**+**		**2.5MG**	**N019901**	**002**	Jan 28, 1991
AB	**+**		**5MG**	**N019901**	**003**	Jan 28, 1991
AB	**+!**		**10MG**	**N019901**	**004**	Jan 28, 1991

RAMIPRIL

AB		ACCORD HLTHCARE	**1.25MG**	**A202392**	**001**	Apr 15, 2014
AB			**2.5MG**	**A202392**	**002**	Apr 15, 2014
AB			**5MG**	**A202392**	**003**	Apr 15, 2014
AB			**10MG**	**A202392**	**004**	Apr 15, 2014
AB		APOTEX	**1.25MG**	**A079116**	**001**	Jun 20, 2008
AB			**2.5MG**	**A079116**	**002**	Jun 20, 2008
AB			**5MG**	**A079116**	**003**	Jun 20, 2008
AB			**10MG**	**A079116**	**004**	Jun 20, 2008
AB		AUROBINDO PHARMA LTD	**1.25MG**	**A091604**	**001**	Jun 08, 2011
AB			**2.5MG**	**A091604**	**002**	Jun 08, 2011
AB			**5MG**	**A091604**	**003**	Jun 08, 2011
AB			**10MG**	**A091604**	**004**	Jun 08, 2011
AB		CHARTWELL MOLECULAR	**1.25MG**	**A078745**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078745**	**002**	Jun 18, 2008
AB			**5MG**	**A078745**	**003**	Jun 18, 2008
AB			**10MG**	**A078745**	**004**	Jun 18, 2008
AB		DR REDDYS LABS LTD	**1.25MG**	**A078191**	**001**	Jun 18, 2008
AB			**2.5MG**	**A078191**	**002**	Jun 18, 2008
AB			**5MG**	**A078191**	**003**	Jun 18, 2008
AB			**10MG**	**A078191**	**004**	Jun 18, 2008
AB		HIKMA	**1.25MG**	**A077900**	**001**	Jun 18, 2008
AB			**2.5MG**	**A077900**	**002**	Jun 18, 2008
AB			**5MG**	**A077900**	**003**	Jun 18, 2008
AB			**10MG**	**A077900**	**004**	Jun 18, 2008
AB		LUPIN	**1.25MG**	**A077626**	**001**	Jun 09, 2008
AB			**2.5MG**	**A077626**	**002**	Jun 09, 2008
AB			**5MG**	**A077626**	**003**	Jun 09, 2008
AB			**10MG**	**A077626**	**004**	Jun 09, 2008
AB		WATSON LABS	**1.25MG**	**A076549**	**001**	Oct 24, 2005
AB			**2.5MG**	**A076549**	**002**	Oct 24, 2005
AB			**10MG**	**A076549**	**004**	Oct 24, 2005
AB		ZYDUS PHARMS USA	**1.25MG**	**A078832**	**001**	Sep 02, 2008
AB			**2.5MG**	**A078832**	**002**	Sep 02, 2008
AB			**5MG**	**A078832**	**003**	Sep 02, 2008
AB			**10MG**	**A078832**	**004**	Sep 02, 2008

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AB		DR REDDYS LABS LTD	**EQ 150MG BASE**	**A075742**	**001**	Nov 29, 2000
AB			**EQ 300MG BASE**	**A075742**	**002**	Nov 29, 2000
AB		SANDOZ	**EQ 150MG BASE**	**A074655**	**001**	Oct 22, 1997
AB	**!**		**EQ 300MG BASE**	**A074655**	**002**	Oct 22, 1997

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

AP		HIKMA	**EQ 25MG BASE/ML**	**A074777**	**001**	Mar 02, 2005
AP			**EQ 25MG BASE/ML**	**A077458**	**001**	Feb 16, 2006
AP		MYLAN LABS LTD	**EQ 25MG BASE/ML**	**A079076**	**001**	Jun 09, 2016
AP		ZYDUS PHARMS USA INC	**EQ 25MG BASE/ML**	**A091534**	**001**	Feb 22, 2013

ZANTAC

AP	**+!**	TELIGENT	**EQ 25MG BASE/ML**	**N019090**	**001**	Oct 19, 1984

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

AA		LANNETT CO INC	**EQ 15MG BASE/ML**	**A078890**	**001**	Jul 01, 2010
AA			**EQ 15MG BASE/ML**	**A091288**	**001**	Dec 09, 2010
AA	**!**	PHARM ASSOC	**EQ 15MG BASE/ML**	**A077405**	**001**	Sep 21, 2007

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB		APOTEX	**EQ 150MG BASE**	**A074680**	**001**	Sep 12, 1997
AB			**EQ 300MG BASE**	**A074680**	**002**	Sep 12, 1997
AB		DR REDDYS LABS INC	**EQ 150MG BASE**	**A076705**	**001**	Jul 27, 2005
AB			**EQ 300MG BASE**	**A076705**	**002**	Jul 27, 2005
AB		GLENMARK PHARMS INC	**EQ 150MG BASE**	**A078542**	**001**	Nov 19, 2008
AB			**EQ 300MG BASE**	**A078542**	**002**	Nov 19, 2008
AB		PAR PHARM	**EQ 150MG BASE**	**A075180**	**001**	Jan 28, 1999
AB			**EQ 300MG BASE**	**A075180**	**002**	Jan 28, 1999
AB		SANDOZ	**EQ 150MG BASE**	**A074467**	**001**	Aug 29, 1997
AB			**EQ 300MG BASE**	**A074467**	**002**	Aug 29, 1997
AB		VKT PHARMA	**EQ 150MG BASE**	**A211289**	**001**	Jan 31, 2019
AB			**EQ 300MG BASE**	**A211289**	**002**	Jan 31, 2019

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

AB	**+**	GILEAD	**500MG**	**N021526**	**002**	Jan 27, 2006
AB	**+!**		**1GM**	**N021526**	**001**	Feb 12, 2007

RANOLAZINE

AB		ACTAVIS ELIZABETH	**500MG**	**A208862**	**001**	May 28, 2019
AB			**1GM**	**A208862**	**002**	May 28, 2019
AB		AJANTA PHARMA LTD	**500MG**	**A210054**	**001**	May 28, 2019
AB			**1GM**	**A210054**	**002**	May 28, 2019
AB		ALKEM LABS LTD	**500MG**	**A209953**	**001**	Nov 30, 2020
AB			**1GM**	**A209953**	**002**	Nov 30, 2020
AB		CADILA	**500MG**	**A210188**	**001**	Aug 19, 2019
AB			**1GM**	**A210188**	**002**	Aug 19, 2019
AB		GLENMARK PHARMS LTD	**500MG**	**A211082**	**001**	Jul 05, 2019
AB			**1GM**	**A211082**	**002**	Jul 05, 2019
AB		GRAVITI PHARMS	**500MG**	**A212889**	**001**	Jan 28, 2021
AB			**1GM**	**A212889**	**002**	Jan 28, 2021
AB		LUPIN LTD	**500MG**	**A201046**	**001**	Jul 29, 2013
AB			**1GM**	**A201046**	**002**	Jul 29, 2013
AB		MANKIND PHARMA	**500MG**	**A212284**	**001**	Feb 12, 2020
AB			**1GM**	**A212284**	**002**	Feb 12, 2020
AB		MICRO LABS	**500MG**	**A211745**	**001**	Feb 27, 2020
AB			**1GM**	**A211745**	**002**	Feb 27, 2020
AB		PRAXGEN	**500MG**	**A212781**	**001**	Mar 23, 2020
AB			**1GM**	**A212781**	**002**	Mar 23, 2020
AB		SCIEGEN PHARMS INC	**500MG**	**A211829**	**001**	Jun 04, 2019
AB			**1GM**	**A211829**	**002**	Jun 04, 2019
AB		SUN PHARM	**500MG**	**A211707**	**001**	May 28, 2019
AB			**1GM**	**A211707**	**002**	May 28, 2019
AB		SUNSHINE	**500MG**	**A211865**	**001**	Mar 23, 2020
AB			**1GM**	**A211865**	**002**	Mar 23, 2020

RASAGILINE MESYLATE

TABLET;ORAL

AZILECT

AB	**+**	TEVA	**EQ 0.5MG BASE**	**N021641**	**001**	May 16, 2006
AB	**+!**		**EQ 1MG BASE**	**N021641**	**002**	May 16, 2006

RASAGILINE MESYLATE

AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A201889**	**001**	Oct 30, 2017
AB			**EQ 1MG BASE**	**A201889**	**002**	Oct 30, 2017
AB		AUROBINDO PHARMA USA	**EQ 0.5MG BASE**	**A201971**	**001**	May 15, 2017
AB			**EQ 1MG BASE**	**A201971**	**002**	May 15, 2017
AB		DR REDDYS	**EQ 0.5MG BASE**	**A201942**	**001**	Nov 18, 2021
AB			**EQ 1MG BASE**	**A201942**	**002**	Nov 18, 2021
AB		INDOCO	**EQ 0.5MG BASE**	**A206153**	**001**	Oct 04, 2019
AB			**EQ 1MG BASE**	**A206153**	**002**	Oct 04, 2019
AB		MICRO LABS	**EQ 0.5MG BASE**	**A207004**	**001**	Mar 29, 2019
AB			**EQ 1MG BASE**	**A207004**	**002**	Mar 29, 2019
AB		ORBION PHARMS	**EQ 0.5MG BASE**	**A201970**	**001**	Mar 15, 2016
AB			**EQ 1MG BASE**	**A201970**	**002**	Mar 15, 2016
AB		SANDOZ INC	**EQ 0.5MG BASE**	**A201892**	**001**	Jul 27, 2018
AB			**EQ 1MG BASE**	**A201892**	**002**	Jul 27, 2018

REGADENOSON
SOLUTION;INTRAVENOUS
LEXISCAN

	+!	ASTELLAS	0.4MG/5ML (0.08MG/ML)	N022161	001	Apr 10, 2008

REGORAFENIB
TABLET;ORAL
STIVARGA

	+!	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012

RELUGOLIX
TABLET;ORAL
ORGOVYX

	+!	MYOVANT SCIENCES	120MG	N214621	001	Dec 18, 2020

REMDESIVIR
POWDER;INTRAVENOUS
VEKLURY

	+!	GILEAD SCIENCES INC	100MG/VIAL	N214787	001	Oct 22, 2020

SOLUTION;INTRAVENOUS
VEKLURY

	+!	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787	002	Oct 22, 2020

REMIFENTANIL HYDROCHLORIDE
INJECTABLE;INJECTION
REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	**EQ 1MG BASE/VIAL**	**A206223**	**001**	Jan 16, 2018
AP			**EQ 2MG BASE/VIAL**	**A206223**	**002**	Jan 16, 2018
AP			**EQ 5MG BASE/VIAL**	**A206223**	**003**	Jan 16, 2018
AP		NAVINTA LLC	**EQ 1MG BASE/VIAL**	**A210594**	**001**	Oct 13, 2020
AP			**EQ 2MG BASE/VIAL**	**A210594**	**002**	Oct 13, 2020
AP			**EQ 5MG BASE/VIAL**	**A210594**	**003**	Oct 13, 2020

ULTIVA

AP	**+**	MYLAN INSTITUTIONAL	**EQ 1MG BASE/VIAL**	**N020630**	**001**	Jul 12, 1996
AP	**+**		**EQ 2MG BASE/VIAL**	**N020630**	**002**	Jul 12, 1996
AP	**+!**		**EQ 5MG BASE/VIAL**	**N020630**	**003**	Jul 12, 1996

REMIMAZOLAM BESYLATE
POWDER;INTRAVENOUS
BYFAVO

	+!	ACACIA	EQ 20MG BASE/VIAL	N212295	001	Oct 06, 2020

REPAGLINIDE
TABLET;ORAL
REPAGLINIDE

AB		AUROBINDO PHARMA LTD	**0.5MG**	**A203820**	**001**	Jan 22, 2014
AB			**1MG**	**A203820**	**002**	Jan 22, 2014
AB	**!**		**2MG**	**A203820**	**003**	Jan 22, 2014
AB		BOSCOGEN	**0.5MG**	**A091517**	**001**	Apr 24, 2015
AB			**1MG**	**A091517**	**002**	Apr 24, 2015
AB			**2MG**	**A091517**	**003**	Apr 24, 2015
AB		CHARTWELL RX	**0.5MG**	**A078555**	**001**	Nov 22, 2013
AB			**1MG**	**A078555**	**002**	Jan 22, 2014
AB			**2MG**	**A078555**	**003**	Jan 22, 2014
AB		PADAGIS US	**0.5MG**	**A201189**	**001**	Jul 17, 2013
AB			**1MG**	**A201189**	**002**	Jan 22, 2014
AB			**2MG**	**A201189**	**003**	Jan 22, 2014
AB		SUN PHARM INDS INC	**1MG**	**A077571**	**002**	Jul 11, 2013
AB			**2MG**	**A077571**	**003**	Jul 11, 2013

RETAPAMULIN
OINTMENT;TOPICAL
ALTABAX

	+!	ALMIRALL	1%	N022055	001	Apr 12, 2007

REVEFENACIN
SOLUTION;INHALATION
YUPELRI

	+!	MYLAN IRELAND LTD	175MCG/3ML	N210598	001	Nov 09, 2018

RIBAVIRIN

CAPSULE;ORAL

REBETOL

AB	**+!**	MERCK SHARP DOHME	**200MG**	**N020903**	**002**	Jul 25, 2001

RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079117**	**001**	Sep 17, 2009
AB		ZYDUS PHARMS USA	**200MG**	**A077224**	**001**	Oct 28, 2005

FOR SOLUTION;INHALATION

RIBAVIRIN

AN		NAVINTA LLC	**6GM/VIAL**	**A207366**	**001**	Oct 06, 2016

VIRAZOLE

AN	**+!**	BAUSCH	**6GM/VIAL**	**N018859**	**001**	Dec 31, 1985

TABLET;ORAL

RIBAVIRIN

AB		AUROBINDO PHARMA	**200MG**	**A079111**	**001**	Sep 17, 2009
AB		SANDOZ	**200MG**	**A077743**	**001**	Oct 03, 2006
AB		ZYDUS PHARMS USA	**200MG**	**A077094**	**001**	Dec 05, 2005

RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI

	+!	NOVARTIS	EQ 200MG BASE	N209092	001	Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

	+!	GLAUKOS	0.146%	N203324	001	Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

	+!	GLAUKOS	0.146%	N203324	002	Apr 15, 2016

RIFABUTIN

CAPSULE;ORAL

MYCOBUTIN

AB	**+!**	PFIZER	**150MG**	**N050689**	**001**	Dec 23, 1992

RIFABUTIN

AB		LUPIN LTD	**150MG**	**A090033**	**001**	Feb 24, 2014
AB		NOVITIUM PHARMA	**150MG**	**A215041**	**001**	Dec 17, 2021

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

AB		AKORN	**150MG**	**A065028**	**001**	Mar 14, 2001
AB			**300MG**	**A065028**	**002**	Mar 14, 2001
AB		LANNETT CO INC	**150MG**	**A065390**	**001**	Mar 28, 2008
AB			**300MG**	**A065390**	**002**	Mar 28, 2008
AB		LUPIN PHARMS	**150MG**	**A090034**	**001**	Aug 21, 2013
AB	**!**		**300MG**	**A090034**	**002**	Aug 21, 2013
AB		SANDOZ	**150MG**	**A064150**	**002**	Jan 02, 1998
AB			**300MG**	**A064150**	**001**	May 28, 1997

RIMACTANE

AB		OXFORD PHARMS	**300MG**	**N050429**	**001**	

INJECTABLE;INJECTION

RIFADIN

AP	**+!**	SANOFI AVENTIS US	**600MG/VIAL**	**N050627**	**001**	May 25, 1989

RIFAMPIN

AP		AKORN	**600MG/VIAL**	**A065502**	**001**	Sep 21, 2010
AP		FRESENIUS KABI USA	**600MG/VIAL**	**A091181**	**001**	Aug 21, 2014
AP		HIKMA	**600MG/VIAL**	**A064217**	**001**	Oct 29, 1999
AP		HIKMA PHARMS	**600MG/VIAL**	**A205039**	**001**	Mar 03, 2016
AP		MYLAN LABS LTD	**600MG/VIAL**	**A065421**	**001**	May 22, 2008

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE;ORAL

AEMCOLO

	+!	REDHILL	EQ 194MG BASE	N210910	001	Nov 16, 2018

RIFAPENTINE

TABLET;ORAL

PRIFTIN

	+!	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998

RIFAXIMIN
TABLET;ORAL
XIFAXAN

	+!	SALIX PHARMS	200MG	N021361	001	May 25, 2004
	+!		550MG	N021361	002	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE
TABLET;ORAL
EDURANT

	+!	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011

RILUZOLE
FILM;ORAL
EXSERVAN

	+!	MITSUBISHI HOLDINGS	50MG	N212640	001	Nov 22, 2019

SUSPENSION;ORAL
TIGLUTIK KIT

	+!	ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018

TABLET;ORAL
RILUTEK

AB	**+!**	COVIS	**50MG**	**N020599**	**001**	Dec 12, 1995

RILUZOLE

AB		ALKEM LABS LTD	**50MG**	**A204048**	**001**	Mar 30, 2016
AB		GLENMARK PHARMS LTD	**50MG**	**A091394**	**001**	Jun 18, 2013
AB		IMPAX LABS	**50MG**	**A076173**	**001**	Jan 29, 2003
AB		KENTON	**50MG**	**A206045**	**001**	Dec 09, 2019
AB		MYLAN PHARMS INC	**50MG**	**A203042**	**001**	Jul 01, 2013
AB		SUN PHARM INDS LTD	**50MG**	**A091417**	**001**	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE
TABLET;ORAL
FLUMADINE

AB	**+!**	SUN PHARM INDS INC	**100MG**	**N019649**	**001**	Sep 17, 1993

RIMANTADINE HYDROCHLORIDE

AB		IMPAX LABS	**100MG**	**A076132**	**001**	Aug 30, 2002

RIMEGEPANT SULFATE
TABLET, ORALLY DISINTEGRATING;ORAL
NURTEC ODT

	+!	BIOHAVEN IRELAND	EQ 75MG BASE	N212728	001	Feb 27, 2020

RIOCIGUAT
TABLET;ORAL
ADEMPAS

	+	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
	+		1MG	N204819	002	Oct 08, 2013
	+		1.5MG	N204819	003	Oct 08, 2013
	+		2MG	N204819	004	Oct 08, 2013
	+!		2.5MG	N204819	005	Oct 08, 2013

RIPRETINIB
TABLET;ORAL
QINLOCK

	+!	DECIPHERA PHARMS	50MG	N213973	001	May 15, 2020

RISDIPLAM
FOR SOLUTION;ORAL
EVRYSDI

	+!	GENENTECH INC	0.75MG/ML	N213535	001	Aug 07, 2020

RISEDRONATE SODIUM
TABLET;ORAL
ACTONEL

AB	**+**	APIL	**5MG**	**N020835**	**002**	Apr 14, 2000
AB	**+**		**30MG**	**N020835**	**001**	Mar 27, 1998
AB	**+!**		**35MG**	**N020835**	**003**	May 25, 2002
AB	**+!**		**150MG**	**N020835**	**005**	Apr 22, 2008

RISEDRONATE SODIUM

AB		APOTEX INC	**35MG**	**A090877**	**001**	Nov 30, 2015
AB			**75MG**	**A090877**	**002**	Jun 10, 2014
AB			**150MG**	**A090877**	**003**	Jun 10, 2014
AB		AUROBINDO PHARMA LTD	**5MG**	**A200296**	**001**	Nov 30, 2015
AB			**30MG**	**A200296**	**002**	Nov 30, 2015
AB			**35MG**	**A200296**	**003**	Nov 30, 2015
AB			**150MG**	**A206768**	**001**	Oct 21, 2016
AB		MACLEODS PHARMS LTD	**5MG**	**A203533**	**001**	Dec 09, 2015

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

AB			**30MG**	**A203533**	**002**	Dec 09, 2015
AB			**35MG**	**A203533**	**003**	Nov 29, 2016
AB		ORBION PHARMS	**30MG**	**A205280**	**001**	May 13, 2019
AB			**35MG**	**A205280**	**002**	May 13, 2019
AB		SUN PHARM	**5MG**	**A090886**	**001**	Nov 30, 2015
AB			**30MG**	**A090886**	**002**	Nov 30, 2015
AB			**35MG**	**A090886**	**003**	Nov 30, 2015
AB			**75MG**	**A090886**	**004**	Jun 10, 2014
AB			**150MG**	**A090886**	**005**	Jun 10, 2014
AB		TEVA PHARMS USA	**5MG**	**A077132**	**001**	Oct 05, 2007
AB			**30MG**	**A077132**	**002**	Oct 05, 2007
AB			**35MG**	**A077132**	**003**	Oct 05, 2007
AB			**150MG**	**A079215**	**001**	Jun 13, 2014

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	**+!**	APIL	**35MG**	**N022560**	**001**	Oct 08, 2010

RISEDRONATE SODIUM

AB		SUN PHARM	**35MG**	**A203925**	**001**	Jul 09, 2019
AB		TEVA PHARMS USA	**35MG**	**A203217**	**001**	May 18, 2015

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

PERSERIS KIT

	+	INDIVIOR INC	90MG	N210655	001	Jul 27, 2018
	+!		120MG	N210655	002	Jul 27, 2018

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

	+	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
	+!		25MG/VIAL	N021346	001	Oct 29, 2003
	+		37.5MG/VIAL	N021346	002	Oct 29, 2003
	+		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION;ORAL

RISPERDAL

AA	**+!**	JANSSEN PHARMS	**1MG/ML**	**N020588**	**001**	Jun 10, 1996

RISPERIDONE

AA		AMNEAL PHARMS	**1MG/ML**	**A091384**	**001**	May 25, 2011
AA		AUROBINDO PHARMA LTD	**1MG/ML**	**A078452**	**001**	Sep 04, 2009
AA		HIKMA	**1MG/ML**	**A076904**	**001**	Jul 29, 2009
AA		LANNETT CO INC	**1MG/ML**	**A079158**	**001**	Dec 03, 2010
AA		PHARM ASSOC	**1MG/ML**	**A077719**	**001**	Jul 29, 2009
AA		TARO	**1MG/ML**	**A090347**	**001**	Feb 07, 2011
AA		TRIS PHARMA INC	**1MG/ML**	**A079059**	**001**	Dec 12, 2012

TABLET;ORAL

RISPERDAL

AB	**+**	JANSSEN PHARMS	**0.25MG**	**N020272**	**008**	May 10, 1999
AB	**+**		**0.5MG**	**N020272**	**007**	Jan 27, 1999
AB	**+!**		**1MG**	**N020272**	**001**	Dec 29, 1993
AB	**+**		**2MG**	**N020272**	**002**	Dec 29, 1993
AB	**+**		**3MG**	**N020272**	**003**	Dec 29, 1993
AB	**+**		**4MG**	**N020272**	**004**	Dec 29, 1993

RISPERIDONE

AB		AJANTA PHARMA LTD	**0.25MG**	**A201003**	**001**	Aug 24, 2011
AB			**0.5MG**	**A201003**	**002**	Aug 24, 2011
AB			**1MG**	**A201003**	**003**	Aug 24, 2011
AB			**2MG**	**A201003**	**004**	Aug 24, 2011
AB			**3MG**	**A201003**	**005**	Aug 24, 2011
AB			**4MG**	**A201003**	**006**	Aug 24, 2011
AB		AMNEAL	**0.25MG**	**A078071**	**001**	Jun 17, 2009
AB			**0.5MG**	**A078071**	**002**	Jun 17, 2009
AB			**1MG**	**A078071**	**003**	Jun 17, 2009
AB			**2MG**	**A078071**	**004**	Jun 17, 2009
AB			**3MG**	**A078071**	**005**	Jun 17, 2009
AB			**4MG**	**A078071**	**006**	Jun 17, 2009
AB		APOTEX INC	**0.25MG**	**A077953**	**001**	Sep 15, 2008
AB			**0.5MG**	**A077953**	**002**	Sep 15, 2008
AB			**1MG**	**A077953**	**003**	Sep 15, 2008
AB			**2MG**	**A077953**	**004**	Sep 15, 2008
AB			**3MG**	**A077953**	**005**	Sep 15, 2008
AB			**4MG**	**A077953**	**006**	Sep 15, 2008

RISPERIDONE

TABLET;ORAL

RISPERIDONE

AB	CELLTRION	**0.25MG**	**A078871**	**001**	Oct 09, 2008
AB		**0.5MG**	**A078871**	**002**	Oct 09, 2008
AB		**1MG**	**A078871**	**003**	Oct 09, 2008
AB		**2MG**	**A078871**	**004**	Oct 09, 2008
AB		**3MG**	**A078871**	**005**	Oct 09, 2008
AB		**4MG**	**A078871**	**006**	Oct 09, 2008
AB	CHARTWELL MOLECULAR	**0.25MG**	**A077543**	**001**	May 18, 2011
AB		**0.5MG**	**A077543**	**002**	May 18, 2011
AB		**1MG**	**A077543**	**003**	May 18, 2011
AB		**2MG**	**A077543**	**004**	May 18, 2011
AB		**3MG**	**A077543**	**005**	May 18, 2011
AB		**4MG**	**A077543**	**006**	May 18, 2011
AB	DR REDDYS LABS LTD	**0.25MG**	**A076879**	**001**	Oct 24, 2008
AB		**0.5MG**	**A076879**	**002**	Oct 24, 2008
AB		**1MG**	**A076879**	**003**	Oct 24, 2008
AB		**2MG**	**A076879**	**004**	Oct 24, 2008
AB		**3MG**	**A076879**	**005**	Oct 24, 2008
AB		**4MG**	**A076879**	**006**	Oct 24, 2008
AB	PRINSTON INC	**0.25MG**	**A077493**	**001**	Nov 29, 2011
AB		**0.5MG**	**A077493**	**002**	Nov 29, 2011
AB		**1MG**	**A077493**	**003**	Nov 29, 2011
AB		**2MG**	**A077493**	**004**	Nov 29, 2011
AB		**3MG**	**A077493**	**005**	Nov 29, 2011
AB		**4MG**	**A077493**	**006**	Nov 29, 2011
AB	RENATA	**0.25MG**	**A078707**	**001**	Dec 29, 2008
AB		**0.5MG**	**A078707**	**002**	Dec 29, 2008
AB		**1MG**	**A078707**	**003**	Dec 29, 2008
AB		**2MG**	**A078707**	**004**	Dec 29, 2008
AB		**3MG**	**A078707**	**005**	Dec 29, 2008
AB		**4MG**	**A078707**	**006**	Dec 29, 2008
AB	RISING	**0.25MG**	**A078269**	**001**	Oct 08, 2008
AB		**0.5MG**	**A078269**	**002**	Oct 08, 2008
AB		**1MG**	**A078269**	**003**	Oct 08, 2008
AB		**2MG**	**A078269**	**004**	Oct 08, 2008
AB		**3MG**	**A078269**	**005**	Oct 08, 2008
AB		**4MG**	**A078269**	**006**	Oct 08, 2008
AB	SANDOZ	**0.25MG**	**A078528**	**001**	Oct 16, 2009
AB		**0.5MG**	**A078528**	**002**	Oct 16, 2009
AB		**1MG**	**A078528**	**003**	Oct 16, 2009
AB		**2MG**	**A078528**	**004**	Oct 16, 2009
AB		**3MG**	**A078528**	**005**	Oct 16, 2009
AB		**4MG**	**A078528**	**006**	Oct 16, 2009
AB	TORRENT PHARMS	**0.25MG**	**A079088**	**001**	Oct 30, 2008
AB		**0.5MG**	**A079088**	**002**	Oct 30, 2008
AB		**1MG**	**A079088**	**003**	Oct 30, 2008
AB		**2MG**	**A079088**	**004**	Oct 30, 2008
AB		**3MG**	**A079088**	**005**	Oct 30, 2008
AB		**4MG**	**A079088**	**006**	Oct 30, 2008
AB	ZYDUS PHARMS USA INC	**0.25MG**	**A078040**	**001**	Oct 16, 2008
AB		**0.5MG**	**A078040**	**002**	Oct 16, 2008
AB		**1MG**	**A078040**	**003**	Oct 16, 2008
AB		**2MG**	**A078040**	**004**	Oct 16, 2008
AB		**3MG**	**A078040**	**005**	Oct 16, 2008
AB		**4MG**	**A078040**	**006**	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB	DR REDDYS LABS LTD	**0.5MG**	**A077328**	**001**	Feb 24, 2009
AB		**1MG**	**A077328**	**002**	Oct 05, 2009
AB		**2MG**	**A077328**	**003**	Feb 24, 2009
AB		**3MG**	**A077328**	**004**	Nov 30, 2009
AB		**4MG**	**A077328**	**005**	Nov 30, 2009
AB	JUBILANT GENERICS	**0.5MG**	**A090839**	**001**	Nov 04, 2011
AB !		**1MG**	**A090839**	**002**	Nov 04, 2011
AB		**2MG**	**A090839**	**003**	Nov 04, 2011
AB		**3MG**	**A090839**	**004**	Nov 04, 2011
AB		**4MG**	**A090839**	**005**	Nov 04, 2011
AB	PAR PHARM	**0.5MG**	**A077494**	**002**	Apr 30, 2009
AB		**1MG**	**A077494**	**003**	Oct 26, 2009
AB		**2MG**	**A077494**	**004**	Apr 30, 2009

RISPERIDONE
TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB		**3MG**	**A077494**	**005**	Apr 30, 2009
AB		**4MG**	**A077494**	**006**	Apr 30, 2009
AB	SANDOZ	**0.5MG**	**A078116**	**001**	Dec 22, 2009
AB		**1MG**	**A078116**	**002**	Dec 22, 2009
AB		**2MG**	**A078116**	**003**	Dec 22, 2009
AB		**3MG**	**A078116**	**004**	Dec 22, 2009
AB		**4MG**	**A078116**	**005**	Dec 22, 2009
AB	SUN PHARM INDS LTD	**0.5MG**	**A077542**	**001**	Aug 06, 2010
AB		**0.5MG**	**A078464**	**001**	Apr 08, 2013
AB		**1MG**	**A077542**	**002**	Aug 06, 2010
AB		**1MG**	**A078464**	**002**	Apr 08, 2013
AB		**2MG**	**A077542**	**003**	Aug 06, 2010
AB		**2MG**	**A078464**	**003**	Apr 08, 2013
AB		**3MG**	**A078464**	**004**	Apr 08, 2013
AB		**3MG**	**A078474**	**001**	Aug 06, 2010
AB		**4MG**	**A078464**	**005**	Apr 08, 2013
AB		**4MG**	**A078474**	**002**	Aug 06, 2010
AB	ZYDUS PHARMS USA	**0.5MG**	**A078516**	**001**	May 01, 2009
AB		**2MG**	**A078516**	**003**	May 01, 2009
	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR
POWDER;ORAL
NORVIR

+!	ABBVIE INC	100MG/PACKET	N209512	001	Jun 07, 2017

SOLUTION;ORAL
NORVIR

+!	ABBVIE	80MG/ML	N020659	001	Mar 01, 1996

TABLET;ORAL
NORVIR

AB	**+!**	ABBVIE	**100MG**	**N022417**	**001**	Feb 10, 2010

RITONAVIR

AB		AMNEAL	**100MG**	**A208890**	**001**	Sep 17, 2018
AB		AUROBINDO PHARMA LTD	**100MG**	**A206614**	**001**	Sep 17, 2018
AB		HETERO LABS LTD III	**100MG**	**A204587**	**001**	Sep 17, 2018
AB		HIKMA	**100MG**	**A202573**	**001**	Jan 15, 2015

RIVAROXABAN
FOR SUSPENSION;ORAL
XARELTO

+!	JANSSEN PHARMS	1MG/ML	N215859	001	Dec 20, 2021

TABLET;ORAL
XARELTO

+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018
+		10MG	N022406	001	Jul 01, 2011
+		15MG	N022406	002	Nov 04, 2011
+!		20MG	N022406	003	Nov 04, 2011

RIVASTIGMINE
FILM, EXTENDED RELEASE;TRANSDERMAL
EXELON

AB	**+**	NOVARTIS	**4.6MG/24HR**	**N022083**	**001**	Jul 06, 2007
AB	**+!**		**9.5MG/24HR**	**N022083**	**002**	Jul 06, 2007
AB	**+**		**13.3MG/24HR**	**N022083**	**005**	Aug 31, 2012

RIVASTIGMINE

AB	ALVOGEN	**4.6MG/24HR**	**A204403**	**001**	Sep 03, 2015
AB		**9.5MG/24HR**	**A204403**	**002**	Sep 03, 2015
AB		**13.3MG/24HR**	**A204403**	**003**	Aug 31, 2015
AB	AMNEAL PHARMS	**4.6MG/24HR**	**A207308**	**001**	Jan 08, 2019
AB		**9.5MG/24HR**	**A207308**	**002**	Jan 08, 2019
AB		**13.3MG/24HR**	**A207308**	**003**	Jan 08, 2019
AB	BRECKENRIDGE	**4.6MG/24HR**	**A209063**	**001**	Nov 26, 2019
AB		**9.5MG/24HR**	**A209063**	**002**	Nov 26, 2019
AB		**13.3MG/24HR**	**A209063**	**003**	Nov 26, 2019
AB	MYLAN TECHNOLOGIES	**4.6MG/24HR**	**A205622**	**001**	Jun 20, 2018
AB		**9.5MG/24HR**	**A205622**	**002**	Jun 20, 2018
AB		**13.3MG/24HR**	**A205622**	**003**	Jun 20, 2018
AB	ZYDUS NOVELTECH INC	**4.6MG/24HR**	**A206318**	**001**	Mar 04, 2019
AB		**9.5MG/24HR**	**A206318**	**002**	Mar 04, 2019
AB		**13.3MG/24HR**	**A206318**	**003**	Mar 04, 2019

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		ALEMBIC PHARMS LTD	**EQ 1.5MG BASE**	**A091689**	**001**	Jun 12, 2012
AB			**EQ 3MG BASE**	**A091689**	**002**	Jun 12, 2012
AB			**EQ 4.5MG BASE**	**A091689**	**003**	Jun 12, 2012
AB			**EQ 6MG BASE**	**A091689**	**004**	Jun 12, 2012
AB		AUROBINDO PHARMA LTD	**EQ 1.5MG BASE**	**A204572**	**001**	Mar 25, 2016
AB			**EQ 3MG BASE**	**A204572**	**002**	Mar 25, 2016
AB			**EQ 4.5MG BASE**	**A204572**	**003**	Mar 25, 2016
AB			**EQ 6MG BASE**	**A204572**	**004**	Mar 25, 2016
AB		CADILA PHARMS LTD	**EQ 1.5MG BASE**	**A203844**	**001**	Feb 13, 2017
AB			**EQ 3MG BASE**	**A203844**	**002**	Feb 13, 2017
AB			**EQ 4.5MG BASE**	**A203844**	**003**	Feb 13, 2017
AB			**EQ 6MG BASE**	**A203844**	**004**	Feb 13, 2017
AB		CHARTWELL RX	**EQ 1.5MG BASE**	**A207797**	**001**	Sep 28, 2017
AB			**EQ 3MG BASE**	**A207797**	**002**	Sep 28, 2017
AB			**EQ 4.5MG BASE**	**A207797**	**003**	Sep 28, 2017
AB			**EQ 6MG BASE**	**A207797**	**004**	Sep 28, 2017
AB	**!**	DR REDDYS LABS INC	**EQ 1.5MG BASE**	**A077130**	**001**	Oct 31, 2007
AB			**EQ 3MG BASE**	**A077130**	**002**	Oct 31, 2007
AB			**EQ 4.5MG BASE**	**A077130**	**003**	Oct 31, 2007
AB	**!**		**EQ 6MG BASE**	**A077130**	**004**	Oct 31, 2007
AB		MACLEODS PHARMS LTD	**EQ 1.5MG BASE**	**A203148**	**001**	Aug 22, 2014
AB			**EQ 3MG BASE**	**A203148**	**002**	Aug 22, 2014
AB			**EQ 4.5MG BASE**	**A203148**	**003**	Aug 22, 2014
AB			**EQ 6MG BASE**	**A203148**	**004**	Aug 22, 2014
AB		ORBION PHARMS	**EQ 1.5MG BASE**	**A090879**	**001**	Jun 10, 2015
AB			**EQ 3MG BASE**	**A090879**	**002**	Jun 10, 2015
AB			**EQ 4.5MG BASE**	**A090879**	**003**	Jun 10, 2015
AB			**EQ 6MG BASE**	**A090879**	**004**	Jun 10, 2015
AB		SUN PHARM	**EQ 1.5MG BASE**	**A077131**	**001**	Oct 22, 2007
AB			**EQ 3MG BASE**	**A077131**	**002**	Oct 22, 2007
AB			**EQ 4.5MG BASE**	**A077131**	**003**	Oct 22, 2007
AB			**EQ 6MG BASE**	**A077131**	**004**	Oct 22, 2007
AB		WATSON LABS	**EQ 1.5MG BASE**	**A077129**	**001**	Jan 08, 2008
AB			**EQ 3MG BASE**	**A077129**	**002**	Jan 08, 2008
AB			**EQ 4.5MG BASE**	**A077129**	**003**	Jan 08, 2008
AB			**EQ 6MG BASE**	**A077129**	**004**	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET;ORAL

MAXALT

AB	**+!**	MERCK	**EQ 10MG BASE**	**N020864**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB		ALKEM LABS LTD	**EQ 5MG BASE**	**A203269**	**001**	Feb 18, 2016
AB			**EQ 10MG BASE**	**A203269**	**002**	Feb 18, 2016
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A202490**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202490**	**002**	Dec 31, 2012
AB		CELLTRION	**EQ 5MG BASE**	**A077526**	**001**	Mar 26, 2013
AB			**EQ 10MG BASE**	**A077526**	**002**	Mar 26, 2013
AB		GLENMARK GENERICS	**EQ 5MG BASE**	**A201967**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A201967**	**002**	Dec 31, 2012
AB		INVAGEN PHARMS	**EQ 5MG BASE**	**A204339**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A204339**	**002**	Jul 01, 2013
AB		JUBILANT GENERICS	**EQ 5MG BASE**	**A203252**	**001**	Dec 31, 2014
AB			**EQ 10MG BASE**	**A203252**	**002**	Dec 31, 2014
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203147**	**001**	Feb 11, 2014
AB			**EQ 10MG BASE**	**A203147**	**002**	Feb 11, 2014
AB		MYLAN PHARMS INC	**EQ 5MG BASE**	**A201993**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A201993**	**002**	Dec 31, 2012
AB		NATCO PHARMA LTD	**EQ 5MG BASE**	**A200482**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A200482**	**002**	Dec 31, 2012
AB		PHARMA LIFE	**EQ 5MG BASE**	**A202047**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A202047**	**002**	Dec 31, 2012
AB		SANDOZ	**EQ 5MG BASE**	**A079230**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A079230**	**002**	Dec 31, 2012
AB		TEVA PHARMS	**EQ 5MG BASE**	**A077263**	**001**	Dec 31, 2012
AB			**EQ 10MG BASE**	**A077263**	**002**	Dec 31, 2012

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

MAXALT-MLT

AB	**+!**	MERCK	**EQ 10MG BASE**	**N020865**	**002**	Jun 29, 1998

RIZATRIPTAN BENZOATE

AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A203062**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203062**	**002**	Jul 01, 2013
AB		GLENMARK PHARMS LTD	**EQ 5MG BASE**	**A201914**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A201914**	**002**	Jul 01, 2013
AB		MACLEODS PHARMS LTD	**EQ 5MG BASE**	**A203146**	**001**	Sep 19, 2014
AB			**EQ 10MG BASE**	**A203146**	**002**	Sep 19, 2014
AB		NATCO PHARMA LTD	**EQ 5MG BASE**	**A203478**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A203478**	**002**	Jul 01, 2013
AB		PANACEA	**EQ 5MG BASE**	**A204722**	**001**	Jan 11, 2017
AB			**EQ 10MG BASE**	**A204722**	**002**	Jan 11, 2017
AB		SANDOZ	**EQ 5MG BASE**	**A078739**	**001**	Jul 01, 2013
AB			**EQ 10MG BASE**	**A078739**	**002**	Jul 01, 2013
AB		UNICHEM	**EQ 5MG BASE**	**A207835**	**001**	Mar 07, 2017
AB			**EQ 10MG BASE**	**A207835**	**002**	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP		EUGIA PHARMA	**50MG/5ML (10MG/ML)**	**A206206**	**001**	Apr 12, 2017
AP			**100MG/10ML (10MG/ML)**	**A206206**	**002**	Apr 12, 2017
AP		FRESENIUS KABI USA	**50MG/5ML (10MG/ML)**	**A078651**	**001**	Dec 29, 2008
AP			**100MG/10ML (10MG/ML)**	**A078651**	**002**	Dec 29, 2008
AP		GLAND PHARMA LTD	**50MG/5ML (10MG/ML)**	**A205656**	**001**	Apr 04, 2018
AP			**100MG/10ML (10MG/ML)**	**A205656**	**002**	Apr 04, 2018
AP		HOSPIRA	**50MG/5ML (10MG/ML)**	**A078519**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A078519**	**002**	Nov 26, 2008
AP		MYLAN INSTITUTIONAL	**50MG/5ML (10MG/ML)**	**A079199**	**001**	Nov 26, 2008
AP			**100MG/10ML (10MG/ML)**	**A079199**	**002**	Nov 26, 2008
AP		PIRAMAL CRITICAL	**50MG/5ML (10MG/ML)**	**A210437**	**001**	Aug 13, 2019
AP			**100MG/10ML (10MG/ML)**	**A210437**	**002**	Aug 13, 2019
AP		SAGENT PHARMS INC	**50MG/5ML (10MG/ML)**	**A091458**	**001**	Jul 28, 2010
AP			**100MG/10ML (10MG/ML)**	**A091458**	**002**	Jul 28, 2010
AP	**!**	SANDOZ INC	**50MG/5ML (10MG/ML)**	**A079195**	**001**	Dec 05, 2008
AP	**!**		**100MG/10ML (10MG/ML)**	**A079195**	**002**	Dec 05, 2008
AP		TAMARANG	**50MG/5ML (10MG/ML)**	**A091115**	**001**	Aug 27, 2012
AP			**100MG/10ML (10MG/ML)**	**A091115**	**002**	Aug 27, 2012
AP		WEST WARD PHARM CORP	**50MG/5ML (10MG/ML)**	**A204679**	**001**	Feb 28, 2017
AP			**100MG/10ML (10MG/ML)**	**A204679**	**002**	Feb 28, 2017

ROFLUMILAST

TABLET;ORAL

DALIRESP

AB	**+!**	ASTRAZENECA	**500MCG**	**N022522**	**001**	Feb 28, 2011

ROFLUMILAST

AB		HETERO LABS LTD III	**500MCG**	**A208213**	**001**	Nov 23, 2018
AB		STRIDES PHARMA	**500MCG**	**A208247**	**001**	Mar 30, 2020
AB		TORRENT	**500MCG**	**A208272**	**001**	Aug 06, 2018

DALIRESP

	+	ASTRAZENECA	250MCG	N022522	002	Jan 23, 2018

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

	+!	TERSERA	EQ 90MG BASE	N206500	001	Sep 01, 2015

ROMIDEPSIN

POWDER;INTRAVENOUS

ISTODAX

AP	**+!**	CELGENE	**10MG/VIAL**	**N022393**	**001**	Nov 05, 2009

ROMIDEPSIN

AP		FRESENIUS KABI USA	**10MG/VIAL**	**A206254**	**001**	Oct 12, 2021

SOLUTION;INTRAVENOUS

ROMIDEPSIN

	+!	TEVA PHARMS USA INC	27.5MG/5.5ML (5MG/ML)	N208574	002	Mar 13, 2020

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**EQ 0.25MG BASE**	**A204022**	**001**	Feb 28, 2017
AB			**EQ 0.5MG BASE**	**A204022**	**002**	Feb 28, 2017
AB			**EQ 1MG BASE**	**A204022**	**003**	Feb 28, 2017
AB			**EQ 2MG BASE**	**A204022**	**004**	Feb 28, 2017
AB			**EQ 3MG BASE**	**A204022**	**005**	Feb 28, 2017
AB			**EQ 4MG BASE**	**A204022**	**006**	Feb 28, 2017
AB			**EQ 5MG BASE**	**A204022**	**007**	Feb 28, 2017
AB		ALEMBIC LTD	**EQ 0.25MG BASE**	**A090429**	**001**	Mar 24, 2010
AB			**EQ 0.5MG BASE**	**A090429**	**002**	Mar 24, 2010
AB			**EQ 1MG BASE**	**A090429**	**003**	Mar 24, 2010
AB			**EQ 2MG BASE**	**A090429**	**004**	Mar 24, 2010
AB			**EQ 3MG BASE**	**A090429**	**005**	Mar 24, 2010
AB			**EQ 4MG BASE**	**A090429**	**006**	Mar 24, 2010
AB			**EQ 5MG BASE**	**A090429**	**007**	Mar 24, 2010
AB		CADILA	**EQ 0.25MG BASE**	**A090411**	**001**	Jun 01, 2009
AB			**EQ 0.5MG BASE**	**A090411**	**002**	Jun 01, 2009
AB			**EQ 1MG BASE**	**A090411**	**003**	Jun 01, 2009
AB			**EQ 2MG BASE**	**A090411**	**004**	Jun 01, 2009
AB			**EQ 3MG BASE**	**A090411**	**005**	Jun 01, 2009
AB			**EQ 4MG BASE**	**A090411**	**006**	Jun 01, 2009
AB			**EQ 5MG BASE**	**A090411**	**007**	Jun 01, 2009
AB		CELLTRION	**EQ 0.25MG BASE**	**A079050**	**001**	May 29, 2008
AB			**EQ 0.5MG BASE**	**A079050**	**002**	May 29, 2008
AB			**EQ 1MG BASE**	**A079050**	**003**	May 29, 2008
AB			**EQ 2MG BASE**	**A079050**	**004**	May 29, 2008
AB			**EQ 3MG BASE**	**A079050**	**005**	May 29, 2008
AB			**EQ 4MG BASE**	**A079050**	**006**	May 29, 2008
AB			**EQ 5MG BASE**	**A079050**	**007**	May 29, 2008
AB		GLENMARK GENERICS	**EQ 0.25MG BASE**	**A090135**	**001**	Feb 25, 2010
AB			**EQ 0.5MG BASE**	**A090135**	**002**	Feb 25, 2010
AB			**EQ 1MG BASE**	**A090135**	**003**	Feb 25, 2010
AB			**EQ 2MG BASE**	**A090135**	**004**	Feb 25, 2010
AB			**EQ 3MG BASE**	**A090135**	**005**	Feb 25, 2010
AB			**EQ 4MG BASE**	**A090135**	**006**	Feb 25, 2010
AB			**EQ 5MG BASE**	**A090135**	**007**	Feb 25, 2010
AB		MLV	**EQ 0.25MG BASE**	**A079165**	**001**	Feb 07, 2012
AB			**EQ 0.5MG BASE**	**A079165**	**002**	Feb 07, 2012
AB			**EQ 1MG BASE**	**A079165**	**003**	Feb 07, 2012
AB			**EQ 2MG BASE**	**A079165**	**004**	Feb 07, 2012
AB			**EQ 3MG BASE**	**A079165**	**005**	Feb 07, 2012
AB			**EQ 4MG BASE**	**A079165**	**006**	Feb 07, 2012
AB			**EQ 5MG BASE**	**A079165**	**007**	Feb 07, 2012
AB		MYLAN	**EQ 0.25MG BASE**	**A078881**	**001**	May 05, 2008
AB			**EQ 0.5MG BASE**	**A078881**	**002**	May 05, 2008
AB			**EQ 1MG BASE**	**A078881**	**003**	May 05, 2008
AB			**EQ 2MG BASE**	**A078881**	**004**	May 05, 2008
AB			**EQ 3MG BASE**	**A078881**	**005**	May 05, 2008
AB			**EQ 4MG BASE**	**A078881**	**006**	May 05, 2008
AB			**EQ 5MG BASE**	**A078881**	**007**	May 19, 2008
AB		ORBION PHARMS	**EQ 0.25MG BASE**	**A079229**	**001**	Nov 28, 2012
AB			**EQ 0.5MG BASE**	**A079229**	**002**	Nov 28, 2012
AB			**EQ 1MG BASE**	**A079229**	**003**	Nov 28, 2012
AB			**EQ 2MG BASE**	**A079229**	**004**	Nov 28, 2012
AB			**EQ 3MG BASE**	**A079229**	**005**	Nov 28, 2012
AB			**EQ 4MG BASE**	**A079229**	**006**	Nov 28, 2012
AB			**EQ 5MG BASE**	**A079229**	**007**	Nov 28, 2012
AB	**!**	PRINSTON INC	**EQ 0.25MG BASE**	**A078110**	**001**	May 05, 2008
AB			**EQ 0.5MG BASE**	**A078110**	**002**	May 05, 2008
AB			**EQ 1MG BASE**	**A078110**	**003**	May 05, 2008
AB			**EQ 2MG BASE**	**A078110**	**004**	May 05, 2008
AB			**EQ 3MG BASE**	**A078110**	**005**	May 05, 2008
AB			**EQ 4MG BASE**	**A078110**	**006**	May 05, 2008
AB			**EQ 5MG BASE**	**A078110**	**007**	Jul 11, 2008

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	**EQ 2MG BASE**	**A090869**	**001**	May 17, 2012
AB			**EQ 4MG BASE**	**A090869**	**002**	May 17, 2012
AB			**EQ 6MG BASE**	**A090869**	**003**	May 17, 2012
AB			**EQ 8MG BASE**	**A090869**	**004**	May 17, 2012

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

AB			EQ 12MG BASE	A090869	005	May 17, 2012
AB		ALEMBIC PHARMS LTD	EQ 2MG BASE	A202786	001	Apr 22, 2013
AB			EQ 4MG BASE	A202786	002	Apr 22, 2013
AB			EQ 6MG BASE	A202786	003	Apr 22, 2013
AB			EQ 8MG BASE	A202786	004	Apr 22, 2013
AB			EQ 12MG BASE	A202786	005	Apr 22, 2013
AB		CELLTRION	EQ 2MG BASE	A091395	001	Aug 27, 2012
AB			EQ 4MG BASE	A091395	002	Aug 27, 2012
AB			EQ 6MG BASE	A091395	003	Aug 27, 2012
AB			EQ 8MG BASE	A091395	004	Aug 27, 2012
AB			EQ 12MG BASE	A091395	005	Aug 27, 2012
AB	!	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012
AB			EQ 4MG BASE	A201576	002	Jun 06, 2012
AB			EQ 6MG BASE	A201576	003	Jun 06, 2012
AB			EQ 8MG BASE	A201576	004	Jun 06, 2012
AB			EQ 12MG BASE	A201576	005	Jun 06, 2012
AB		SANDOZ INC	EQ 2MG BASE	A201047	001	Jun 06, 2012
AB			EQ 4MG BASE	A201047	003	Jun 06, 2012
AB			EQ 6MG BASE	A201047	004	Jun 06, 2012
AB			EQ 8MG BASE	A201047	005	Jun 06, 2012
AB			EQ 12MG BASE	A201047	006	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

AP	+	FRESENIUS KABI USA	20MG/10ML (2MG/ML)	N020533	001	May 01, 1998
AP	+		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996
AP	+		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998
AP	+		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996
AP	+		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996
AP	+		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996
AP	+		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996
AP	+!		200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996
AP	+		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996
AP	+		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011
AP	+		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

AP		AKORN	200MG/100ML (2MG/ML)	A204636	001	Mar 16, 2018
AP			400MG/200ML (2MG/ML)	A204636	002	Mar 16, 2018
AP			150MG/30ML (5MG/ML)	A203955	001	Apr 11, 2016
AP		CAPLIN	40MG/20ML (2MG/ML)	A212808	001	Apr 09, 2020
AP			100MG/20ML (5MG/ML)	A212808	002	Apr 09, 2020
AP			150MG/30ML (5MG/ML)	A212808	003	Apr 09, 2020
AP			200MG/20ML (10MG/ML)	A212808	004	Apr 09, 2020
AP		EUGIA PHARMA	40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016
AP			100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016
AP			100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016
AP			150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016
AP			150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016
AP			200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016
AP			200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016
AP		HIKMA	40MG/20ML (2MG/ML)	A214074	001	Jul 20, 2020
AP			150MG/30ML (5MG/ML)	A214074	002	Jul 20, 2020
AP			150MG/20ML (7.5MG/ML)	A214074	003	Jul 20, 2020
AP			200MG/20ML (10MG/ML)	A214074	004	Jul 20, 2020
AP		HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014
AP			40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014
AP			100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014
AP			150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014
AP			150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014
AP			200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014
AP		INFORLIFE	200MG/100ML (2MG/ML)	A206166	001	Jun 11, 2018
AP			400MG/200ML (2MG/ML)	A206166	002	Jun 11, 2018
AP			500MG/100ML (5MG/ML)	A206166	003	Jun 11, 2018
AP			1GM/200ML (5MG/ML)	A206166	004	Jun 11, 2018
AP		NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014
AP			200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014
AP		SOMERSET THERAPS LLC	20MG/10ML (2MG/ML)	A207636	001	Jun 15, 2018
AP			40MG/20ML (2MG/ML)	A207636	002	Jun 15, 2018

ROPIVACAINE HYDROCHLORIDE						
SOLUTION;INJECTION						
ROPIVACAINE HYDROCHLORIDE						
AP			**100MG/20ML (5MG/ML)**	**A207636**	**003**	Jun 15, 2018
AP			**100MG/10ML (10MG/ML)**	**A207636**	**006**	Jun 15, 2018
AP			**150MG/30ML (5MG/ML)**	**A207636**	**004**	Jun 15, 2018
AP			**150MG/20ML (7.5MG/ML)**	**A207636**	**005**	Jun 15, 2018
AP			**200MG/20ML (10MG/ML)**	**A207636**	**007**	Jun 15, 2018
ROSIGLITAZONE MALEATE						
TABLET;ORAL						
AVANDIA						
+		WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999
+			EQ 4MG BASE	N021071	003	May 25, 1999
ROSUVASTATIN CALCIUM						
CAPSULE;ORAL						
EZALLOR SPRINKLE						
+		SUN PHARM	EQ 5MG BASE	N208647	001	Dec 18, 2018
+			EQ 10MG BASE	N208647	002	Dec 18, 2018
+			EQ 20MG BASE	N208647	003	Dec 18, 2018
+!			EQ 40MG BASE	N208647	004	Dec 18, 2018
TABLET;ORAL						
CRESTOR						
AB	**+**	IPR	**EQ 5MG BASE**	**N021366**	**002**	Aug 12, 2003
AB	**+**		**EQ 10MG BASE**	**N021366**	**003**	Aug 12, 2003
AB	**+**		**EQ 20MG BASE**	**N021366**	**004**	Aug 12, 2003
AB	**+!**		**EQ 40MG BASE**	**N021366**	**005**	Aug 12, 2003
ROSUVASTATIN CALCIUM						
AB		ACCORD HLTHCARE	**EQ 5MG BASE**	**A206434**	**001**	Oct 31, 2016
AB			**EQ 10MG BASE**	**A206434**	**002**	Oct 31, 2016
AB			**EQ 20MG BASE**	**A206434**	**003**	Oct 31, 2016
AB			**EQ 40MG BASE**	**A206434**	**004**	Oct 31, 2016
AB		ALKEM LABS LTD	**EQ 5MG BASE**	**A206465**	**001**	Mar 21, 2017
AB			**EQ 10MG BASE**	**A206465**	**002**	Mar 21, 2017
AB			**EQ 20MG BASE**	**A206465**	**003**	Mar 21, 2017
AB			**EQ 40MG BASE**	**A206465**	**004**	Mar 21, 2017
AB		AUROBINDO PHARMA LTD	**EQ 5MG BASE**	**A079170**	**001**	Jul 19, 2016
AB			**EQ 10MG BASE**	**A079170**	**002**	Jul 19, 2016
AB			**EQ 20MG BASE**	**A079170**	**003**	Jul 19, 2016
AB			**EQ 40MG BASE**	**A079170**	**004**	Jul 19, 2016
AB		BIOCON PHARMA	**EQ 5MG BASE**	**A207752**	**001**	Oct 31, 2016
AB			**EQ 10MG BASE**	**A207752**	**002**	Oct 31, 2016
AB			**EQ 20MG BASE**	**A207752**	**003**	Oct 31, 2016
AB			**EQ 40MG BASE**	**A207752**	**004**	Oct 31, 2016
AB		CADILA PHARMS LTD	**EQ 5MG BASE**	**A207453**	**001**	Nov 23, 2016
AB			**EQ 10MG BASE**	**A207453**	**002**	Nov 23, 2016
AB			**EQ 20MG BASE**	**A207453**	**003**	Nov 23, 2016
AB			**EQ 40MG BASE**	**A207453**	**004**	Nov 23, 2016
AB		CHANGZHOU PHARM	**EQ 5MG BASE**	**A207408**	**001**	Oct 31, 2016
AB			**EQ 10MG BASE**	**A207408**	**002**	Oct 31, 2016
AB			**EQ 20MG BASE**	**A207408**	**003**	Oct 31, 2016
AB			**EQ 40MG BASE**	**A207408**	**004**	Oct 31, 2016
AB		CHARTWELL RX	**EQ 5MG BASE**	**A079168**	**001**	Jul 19, 2016
AB			**EQ 10MG BASE**	**A079168**	**002**	Jul 19, 2016
AB			**EQ 20MG BASE**	**A079168**	**003**	Jul 19, 2016
AB			**EQ 40MG BASE**	**A079168**	**004**	Jul 19, 2016
AB		GLENMARK PHARMS	**EQ 5MG BASE**	**A079172**	**001**	Jul 19, 2016
AB			**EQ 10MG BASE**	**A079172**	**002**	Jul 19, 2016
AB			**EQ 20MG BASE**	**A079172**	**003**	Jul 19, 2016
AB			**EQ 40MG BASE**	**A079172**	**004**	Jul 19, 2016
AB		HETERO LABS LTD V	**EQ 5MG BASE**	**A207616**	**001**	Oct 31, 2016
AB			**EQ 10MG BASE**	**A207616**	**002**	Oct 31, 2016
AB			**EQ 20MG BASE**	**A207616**	**003**	Oct 31, 2016
AB			**EQ 40MG BASE**	**A207616**	**004**	Oct 31, 2016
AB		LUPIN	**EQ 5MG BASE**	**A205587**	**001**	Jul 31, 2017
AB			**EQ 10MG BASE**	**A205587**	**002**	Jul 31, 2017
AB			**EQ 20MG BASE**	**A205587**	**003**	Jul 31, 2017
AB			**EQ 40MG BASE**	**A205587**	**004**	Jul 31, 2017
AB		MSN	**EQ 5MG BASE**	**A208898**	**001**	Nov 22, 2017
AB			**EQ 10MG BASE**	**A208898**	**002**	Nov 22, 2017
AB			**EQ 20MG BASE**	**A208898**	**003**	Nov 22, 2017
AB			**EQ 40MG BASE**	**A208898**	**004**	Nov 22, 2017

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB		RENATA	**EQ 5MG BASE**	**A207062**	**001**	Oct 31, 2016
AB			**EQ 10MG BASE**	**A207062**	**002**	Oct 31, 2016
AB			**EQ 20MG BASE**	**A207062**	**003**	Oct 31, 2016
AB			**EQ 40MG BASE**	**A207062**	**004**	Oct 31, 2016
AB		SANDOZ INC	**EQ 5MG BASE**	**A079171**	**001**	Jul 19, 2016
AB			**EQ 10MG BASE**	**A079171**	**002**	Jul 19, 2016
AB			**EQ 20MG BASE**	**A079171**	**003**	Jul 19, 2016
AB			**EQ 40MG BASE**	**A079171**	**004**	Jul 19, 2016
AB		SHANDONG	**EQ 5MG BASE**	**A207375**	**001**	May 07, 2019
AB			**EQ 10MG BASE**	**A207375**	**002**	May 07, 2019
AB			**EQ 20MG BASE**	**A207375**	**003**	May 07, 2019
AB			**EQ 40MG BASE**	**A207375**	**004**	May 07, 2019
AB		SUN PHARM	**EQ 5MG BASE**	**A079169**	**001**	Jul 19, 2016
AB			**EQ 10MG BASE**	**A079169**	**002**	Jul 19, 2016
AB			**EQ 20MG BASE**	**A079169**	**003**	Jul 19, 2016
AB			**EQ 40MG BASE**	**A079169**	**004**	Jul 19, 2016
AB		TORRENT	**EQ 5MG BASE**	**A201619**	**001**	Oct 31, 2016
AB			**EQ 10MG BASE**	**A201619**	**002**	Oct 31, 2016
AB			**EQ 20MG BASE**	**A201619**	**003**	Oct 31, 2016
AB			**EQ 40MG BASE**	**A201619**	**004**	Oct 31, 2016
AB		WATSON LABS INC	**EQ 5MG BASE**	**A079167**	**001**	Apr 29, 2016
AB			**EQ 10MG BASE**	**A079167**	**002**	Apr 29, 2016
AB			**EQ 20MG BASE**	**A079167**	**003**	Apr 29, 2016
AB			**EQ 40MG BASE**	**A079167**	**004**	Apr 29, 2016
AB		ZHEJIANG YONGTAI	**EQ 5MG BASE**	**A212059**	**001**	Nov 04, 2019
AB			**EQ 10MG BASE**	**A212059**	**002**	Nov 04, 2019
AB			**EQ 20MG BASE**	**A212059**	**003**	Nov 04, 2019
AB			**EQ 40MG BASE**	**A212059**	**004**	Nov 04, 2019

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NEUPRO

+	UCB INC	1MG/24HR	N021829	004	Apr 02, 2012
+!		2MG/24HR	N021829	001	May 09, 2007
+		3MG/24HR	N021829	005	Apr 02, 2012
+		4MG/24HR	N021829	002	May 09, 2007
+		6MG/24HR	N021829	003	May 09, 2007
+		8MG/24HR	N021829	006	Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE;INJECTION

CARDIOGEN-82

	BRACCO	N/A	N019414	001	Dec 29, 1989

SOLUTION;INTRAVENOUS

RUBY-FILL

	JUBILANT	N/A	N202153	001	Sep 30, 2016

RUCAPARIB CAMSYLATE

TABLET;ORAL

RUBRACA

+	CLOVIS ONCOLOGY INC	EQ 200MG BASE	N209115	001	Dec 19, 2016
+		EQ 250MG BASE	N209115	003	May 01, 2017
+!		EQ 300MG BASE	N209115	002	Dec 19, 2016

RUFINAMIDE

SUSPENSION;ORAL

BANZEL

AB	**+!**	EISAI INC	**40MG/ML**	**N201367**	**001**	Mar 03, 2011

RUFINAMIDE

AB		ALKEM LABS LTD	**40MG/ML**	**A213410**	**001**	Feb 23, 2021
AB		BIONPHARMA INC	**40MG/ML**	**A211388**	**001**	Apr 23, 2019
AB		HIKMA	**40MG/ML**	**A207363**	**001**	Apr 23, 2019
AB		LUPIN LTD	**40MG/ML**	**A213457**	**001**	Dec 18, 2020

TABLET;ORAL

BANZEL

AB	**+**	EISAI INC	**200MG**	**N021911**	**002**	Nov 14, 2008
AB	**+!**		**400MG**	**N021911**	**003**	Nov 14, 2008

RUFINAMIDE

AB		GLENMARK PHARMS LTD	**200MG**	**A205075**	**001**	May 16, 2016
AB			**400MG**	**A205075**	**002**	May 16, 2016
AB		HETERO LABS LTD III	**200MG**	**A204993**	**001**	May 11, 2021

RUFINAMIDE
TABLET;ORAL
RUFINAMIDE

AB			**400MG**	**A204993**	**002**	May 11, 2021
AB		HIKMA	**200MG**	**A204988**	**001**	May 16, 2016
AB			**400MG**	**A204988**	**002**	May 16, 2016
AB		MYLAN	**200MG**	**A205095**	**001**	May 16, 2016
AB			**400MG**	**A205095**	**002**	May 16, 2016

RUXOLITINIB PHOSPHATE
CREAM;TOPICAL
OPZELURA

+!	INCYTE CORP	EQ 1.5% BASE	N215309	001	Sep 21, 2021

TABLET;ORAL
JAKAFI

+	INCYTE CORP	EQ 5MG BASE	N202192	001	Nov 16, 2011
+		EQ 10MG BASE	N202192	002	Nov 16, 2011
+		EQ 15MG BASE	N202192	003	Nov 16, 2011
+		EQ 20MG BASE	N202192	004	Nov 16, 2011
+!		EQ 25MG BASE	N202192	005	Nov 16, 2011

SACUBITRIL; VALSARTAN
TABLET;ORAL
ENTRESTO

+	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015
+		49MG;51MG	N207620	002	Jul 07, 2015
+!		97MG;103MG	N207620	003	Jul 07, 2015

SAFINAMIDE MESYLATE
TABLET;ORAL
XADAGO

+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017
+!		EQ 100MG BASE	N207145	002	Mar 21, 2017

SALMETEROL XINAFOATE
POWDER;INHALATION
SEREVENT

+!	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
INJECTABLE;INJECTION
QUADRAMET

+!	LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE
POWDER;ORAL
KUVAN

AB	**+!**	BIOMARIN PHARM	**100MG/PACKET**	**N205065**	**001**	Dec 19, 2013
AB	**+**		**500MG/PACKET**	**N205065**	**002**	Oct 27, 2015

SAPROPTERIN DIHYDROCHLORIDE

AB		DR REDDYS	**100MG/PACKET**	**A209452**	**001**	Mar 30, 2021
AB		PAR PHARM INC	**100MG/PACKET**	**A207207**	**001**	Aug 20, 2019
AB			**500MG/PACKET**	**A210027**	**001**	Aug 20, 2019

TABLET;ORAL
KUVAN

AB	**+!**	BIOMARIN PHARM	**100MG**	**N022181**	**001**	Dec 13, 2007

SAPROPTERIN DIHYDROCHLORIDE

AB		DR REDDYS	**100MG**	**A207685**	**001**	Jun 15, 2021
AB		PAR PHARM INC	**100MG**	**A207200**	**001**	May 10, 2019

SARECYCLINE HYDROCHLORIDE
TABLET;ORAL
SEYSARA

+	ALMIRALL	EQ 60MG BASE	N209521	001	Oct 01, 2018
+		EQ 100MG BASE	N209521	002	Oct 01, 2018
+!		EQ 150MG BASE	N209521	003	Oct 01, 2018

SAXAGLIPTIN HYDROCHLORIDE
TABLET;ORAL
ONGLYZA

+	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009
+!		EQ 5MG BASE	N022350	002	Jul 31, 2009

SCOPOLAMINE

SYSTEM;TRANSDERMAL

SCOPOLAMINE

AB		ACTAVIS LABS UT INC	**1MG/72HR**	**A208769**	**001**	Jan 10, 2022
AB		MYLAN TECHNOLOGIES	**1MG/72HR**	**A203753**	**001**	Jun 19, 2019
AB		PADAGIS US	**1MG/72HR**	**A078830**	**001**	Jan 30, 2015
AB		RICONPHARMA LLC	**1MG/72HR**	**A212342**	**001**	Nov 24, 2020

TRANSDERM SCOP

AB	**+!**	BAXTER HLTHCARE CORP	**1MG/72HR**	**N017874**	**001**	

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

	+!	LUPIN	2GM/PACKET	N209363	001	Sep 15, 2017

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION;INTRAVENOUS

CHIRHOSTIM

	+!	CHIRHOCLIN	16MCG/VIAL	N021256	001	Apr 09, 2004
	+		40MCG/VIAL	N021256	002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EMSAM

	+!	SOMERSET	6MG/24HR	N021336	001	Feb 27, 2006
	+		9MG/24HR	N021336	002	Feb 27, 2006
	+		12MG/24HR	N021336	003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

AB	**!**	APOTEX	**5MG**	**A075321**	**001**	Dec 04, 1998
AB		NOVITIUM PHARMA	**5MG**	**A075352**	**001**	Nov 30, 1998
AB		RISING	**5MG**	**A206803**	**001**	Apr 02, 2019

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

AB	**!**	APOTEX INC	**5MG**	**A074871**	**001**	Jun 06, 1997
AB		BOSCOGEN	**5MG**	**A074912**	**001**	Apr 30, 1998
AB		I3 PHARMS	**5MG**	**A074672**	**001**	Apr 01, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

	+!	BAUSCH	1.25MG	N021479	001	Jun 14, 2006

SELENIOUS ACID

SOLUTION;INTRAVENOUS

SELENIOUS ACID

	+!	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021
	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021
	+!		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

SELENIUM SULFIDE

AT	**!**	PADAGIS US	**2.5%**	**A089996**	**001**	Jan 10, 1991
AT		WOCKHARDT BIO AG	**2.5%**	**A088228**	**001**	Sep 01, 1983

SELEXIPAG

POWDER;INTRAVENOUS

UPTRAVI

	+!	ACTELION	1.8MG/VIAL	N214275	001	Jul 29, 2021

TABLET;ORAL

UPTRAVI

	+	ACTELION	0.2MG	N207947	001	Dec 21, 2015
	+!		0.4MG	N207947	002	Dec 21, 2015
	+		0.6MG	N207947	003	Dec 21, 2015
	+		0.8MG	N207947	004	Dec 21, 2015
	+		1MG	N207947	005	Dec 21, 2015
	+		1.2MG	N207947	006	Dec 21, 2015
	+		1.4MG	N207947	007	Dec 21, 2015
	+		1.6MG	N207947	008	Dec 21, 2015

SELINEXOR
TABLET;ORAL
XPOVIO

+!	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019
+		40MG	N212306	002	Apr 15, 2021
+		50MG	N212306	003	Apr 15, 2021
+		60MG	N212306	004	Apr 15, 2021

SELPERCATINIB
CAPSULE;ORAL
RETEVMO

+	LOXO ONCOLOGY INC	40MG	N213246	001	May 08, 2020
+!		80MG	N213246	002	May 08, 2020

SELUMETINIB SULFATE
CAPSULE;ORAL
KOSELUGO

+	ASTRAZENECA	EQ 10MG BASE	N213756	001	Apr 10, 2020
+!		EQ 25MG BASE	N213756	002	Apr 10, 2020

SEMAGLUTIDE
SOLUTION;SUBCUTANEOUS
OZEMPIC

+!	NOVO	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017
+!		4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019

WEGOVY

+!	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	001	Jun 04, 2021
+!		0.5MG/0.5ML (0.5MG/0.5ML)	N215256	002	Jun 04, 2021
+!		1MG/0.5ML (1MG/0.5ML)	N215256	003	Jun 04, 2021
+!		1.7MG/0.75ML (1.7MG/0.75ML)	N215256	004	Jun 04, 2021
+!		2.4MG/0.75ML (2.4MG/0.75ML)	N215256	005	Jun 04, 2021

TABLET;ORAL
RYBELSUS

+	NOVO	3MG	N213051	001	Sep 20, 2019
+		7MG	N213051	002	Sep 20, 2019
+!		14MG	N213051	003	Sep 20, 2019

SERTACONAZOLE NITRATE
CREAM;TOPICAL
ERTACZO

+!	BAUSCH	2%	N021385	001	Dec 10, 2003

SERTRALINE HYDROCHLORIDE
CAPSULE;ORAL
SERTRALINE HYDROCHLORIDE

+	ALMATICA	EQ 150MG BASE	N215133	001	Oct 04, 2021
+!		EQ 200MG BASE	N215133	002	Oct 04, 2021

CONCENTRATE;ORAL
SERTRALINE HYDROCHLORIDE

AA	ACI	**EQ 20MG BASE/ML**	**A076934**	**001**	Jun 30, 2006
AA	AUROBINDO PHARMA	**EQ 20MG BASE/ML**	**A078861**	**001**	Oct 31, 2008

ZOLOFT

AA	**+!**	UPJOHN	**EQ 20MG BASE/ML**	**N020990**	**001**	Dec 07, 1999

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	**EQ 25MG BASE**	**A202825**	**001**	Nov 07, 2014
AB		**EQ 50MG BASE**	**A202825**	**002**	Nov 07, 2014
AB		**EQ 100MG BASE**	**A202825**	**003**	Nov 07, 2014
AB	ACI	**EQ 25MG BASE**	**A076881**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A076881**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A076881**	**003**	Feb 06, 2007
AB	ASCENT PHARMS INC	**EQ 25MG BASE**	**A214790**	**001**	May 03, 2021
AB		**EQ 50MG BASE**	**A214790**	**002**	May 03, 2021
AB		**EQ 100MG BASE**	**A214790**	**003**	May 03, 2021
AB	AUROBINDO PHARMA	**EQ 25MG BASE**	**A077206**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077206**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077206**	**003**	Feb 06, 2007
AB	GRANULES	**EQ 25MG BASE**	**A078403**	**001**	Jan 08, 2008
AB		**EQ 50MG BASE**	**A078403**	**002**	Jan 08, 2008
AB		**EQ 100MG BASE**	**A078403**	**003**	Jan 08, 2008
AB	INVAGEN PHARMS	**EQ 25MG BASE**	**A077397**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077397**	**002**	Feb 06, 2007
AB		**EQ 100MG BASE**	**A077397**	**003**	Feb 06, 2007
AB	LUPIN	**EQ 25MG BASE**	**A077670**	**001**	Feb 06, 2007
AB		**EQ 50MG BASE**	**A077670**	**002**	Feb 06, 2007

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB			**EQ 100MG BASE**	**A077670**	**003**	Feb 06, 2007
AB		OXFORD PHARMS	**EQ 25MG BASE**	**A078175**	**001**	Jul 21, 2010
AB			**EQ 50MG BASE**	**A078175**	**002**	Jul 21, 2010
AB			**EQ 100MG BASE**	**A078175**	**003**	Jul 21, 2010
AB		REYOUNG	**EQ 25MG BASE**	**A078677**	**001**	Mar 04, 2009
AB			**EQ 50MG BASE**	**A078677**	**002**	Mar 04, 2009
AB			**EQ 100MG BASE**	**A078677**	**003**	Mar 04, 2009
AB		SCIEGEN PHARMS INC	**EQ 25MG BASE**	**A076442**	**001**	Apr 30, 2007
AB			**EQ 50MG BASE**	**A076442**	**002**	Apr 30, 2007
AB			**EQ 100MG BASE**	**A076442**	**003**	Apr 30, 2007
AB		VIWIT PHARM	**EQ 25MG BASE**	**A076882**	**001**	Feb 06, 2007
AB			**EQ 50MG BASE**	**A076882**	**002**	Feb 06, 2007
AB			**EQ 100MG BASE**	**A076882**	**003**	Feb 06, 2007

ZOLOFT

AB	**+**	UPJOHN	**EQ 25MG BASE**	**N019839**	**005**	Mar 06, 1996
AB	**+**		**EQ 50MG BASE**	**N019839**	**001**	Dec 30, 1991
AB	**+!**		**EQ 100MG BASE**	**N019839**	**002**	Dec 30, 1991

SETMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

IMCIVREE

	+!	RHYTHM	EQ 10MG/ML BASE (EQ 10MG/ML BASE)	N213793	001	Nov 25, 2020

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

RENVELA

AB	**+**	GENZYME	**800MG/PACKET**	**N022318**	**001**	Aug 12, 2009
AB	**+!**		**2.4GM/PACKET**	**N022318**	**002**	Feb 18, 2009

SEVELAMER CARBONATE

AB		AUROBINDO PHARMA LTD	**800MG/PACKET**	**A207624**	**001**	Jun 13, 2017
AB			**2.4GM/PACKET**	**A207624**	**002**	Jun 13, 2017
AB		BIONPHARMA INC	**800MG/PACKET**	**A209374**	**001**	May 17, 2021
AB		DR REDDYS LABS LTD	**800MG/PACKET**	**A210464**	**001**	Oct 25, 2018
AB			**2.4GM/PACKET**	**A210464**	**002**	Oct 25, 2018
AB		IMPAX	**800MG/PACKET**	**A211316**	**001**	Nov 20, 2020
AB			**2.4GM/PACKET**	**A211316**	**002**	Nov 20, 2020
AB		LUPIN LTD	**800MG/PACKET**	**A201513**	**001**	Dec 23, 2021
AB			**2.4GM/PACKET**	**A201513**	**002**	Dec 23, 2021

TABLET;ORAL

RENVELA

AB	**+!**	SANOFI	**800MG**	**N022127**	**001**	Oct 19, 2007

SEVELAMER CARBONATE

AB		AMNEAL PHARMS CO	**800MG**	**A207288**	**001**	Nov 28, 2017
AB		ANXIN	**800MG**	**A212970**	**001**	Apr 09, 2020
AB		AUROBINDO PHARMA LTD	**800MG**	**A207179**	**001**	Jul 17, 2017
AB		DR REDDYS LABS LTD	**800MG**	**A206094**	**001**	Sep 29, 2017
AB		INVAGEN PHARMS	**800MG**	**A203860**	**001**	Oct 26, 2017
AB		LUPIN LTD	**800MG**	**A204600**	**001**	Jan 14, 2021
AB		RISING	**800MG**	**A204451**	**001**	Nov 29, 2018
AB		TWI PHARMS	**800MG**	**A200959**	**001**	Mar 20, 2018
AB		ZYDUS PHARMS	**800MG**	**A207759**	**001**	Aug 11, 2020

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	**+**	GENZYME	**400MG**	**N021179**	**001**	Jul 12, 2000
AB	**+!**		**800MG**	**N021179**	**002**	Jul 12, 2000

SEVELAMER HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	**400MG**	**A204724**	**001**	Feb 08, 2019
AB			**800MG**	**A204724**	**002**	Feb 08, 2019
AB		LUPIN LTD	**400MG**	**A213145**	**001**	Jun 16, 2021
AB			**800MG**	**A213145**	**002**	Jun 16, 2021

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

AN		BAXTER HLTHCARE	**100%**	**A075895**	**001**	Jul 02, 2002
AN		HALOCARBON PRODS	**100%**	**A078650**	**001**	Nov 19, 2007
AN		SHANGHAI HENGRUI	**100%**	**A203793**	**001**	Nov 03, 2015

SEVOFLURANE						
LIQUID;INHALATION						
SOJOURN						
AN		PIRAMAL CRITICAL	**100%**	**A077867**	**001**	May 02, 2007
ULTANE						
AN	**+!**	ABBVIE	**100%**	**N020478**	**001**	Jun 07, 1995
SILDENAFIL CITRATE						
FOR SUSPENSION;ORAL						
REVATIO						
AB	**+!**	UPJOHN	**EQ 10MG BASE/ML**	**N203109**	**001**	Aug 30, 2012
SILDENAFIL CITRATE						
AB		AJANTA PHARMA LTD	**EQ 10MG BASE/ML**	**A212883**	**001**	Nov 27, 2019
AB		ALKEM LABS LTD	**EQ 10MG BASE/ML**	**A212440**	**001**	Nov 27, 2019
AB		AMNEAL PHARMS	**EQ 10MG BASE/ML**	**A211092**	**001**	Nov 27, 2019
AB		APPCO	**EQ 10MG BASE/ML**	**A213814**	**001**	Apr 29, 2021
AB		APTAPHARMA INC	**EQ 10MG BASE/ML**	**A213041**	**001**	Aug 06, 2020
AB		HETERO LABS LTD V	**EQ 10MG BASE/ML**	**A213014**	**001**	May 11, 2021
AB		NOVITIUM PHARMA	**EQ 10MG BASE/ML**	**A212260**	**001**	May 31, 2019
AB		TARO PHARM INDS LTD	**EQ 10MG BASE/ML**	**A215522**	**001**	Nov 16, 2021
AB		TEVA PHARMS USA	**EQ 10MG BASE/ML**	**A211534**	**001**	May 29, 2020
AB		TRIS PHARMA INC	**EQ 10MG BASE/ML**	**A212312**	**001**	Nov 17, 2021
SOLUTION;INTRAVENOUS						
REVATIO						
AP	**+!**	UPJOHN	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**N022473**	**001**	Nov 18, 2009
SILDENAFIL CITRATE						
AP		EUGIA PHARMA	**EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)**	**A203988**	**001**	Apr 01, 2015
TABLET;ORAL						
REVATIO						
AB	**+!**	UPJOHN	**EQ 20MG BASE**	**N021845**	**001**	Jun 03, 2005
SILDENAFIL CITRATE						
AB		AJANTA PHARMA LTD	**EQ 20MG BASE**	**A210394**	**001**	May 04, 2018
AB			**EQ 25MG BASE**	**A206401**	**001**	Oct 12, 2018
AB			**EQ 50MG BASE**	**A206401**	**002**	Oct 12, 2018
AB			**EQ 100MG BASE**	**A206401**	**003**	Oct 12, 2018
AB		AMNEAL PHARMS	**EQ 20MG BASE**	**A202025**	**001**	Feb 28, 2013
AB		AMNEAL PHARMS NY	**EQ 25MG BASE**	**A202023**	**001**	Jun 27, 2018
AB			**EQ 50MG BASE**	**A202023**	**002**	Jun 27, 2018
AB			**EQ 100MG BASE**	**A202023**	**003**	Jun 27, 2018
AB		APPCO	**EQ 25MG BASE**	**A207178**	**001**	Mar 02, 2020
AB			**EQ 50MG BASE**	**A207178**	**002**	Mar 02, 2020
AB			**EQ 100MG BASE**	**A207178**	**003**	Mar 02, 2020
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A203963**	**001**	Nov 18, 2015
AB			**EQ 25MG BASE**	**A203962**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A203962**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A203962**	**003**	Jun 11, 2018
AB		CHARTWELL RX	**EQ 20MG BASE**	**A202598**	**001**	Nov 06, 2012
AB		HETERO LABS LTD V	**EQ 20MG BASE**	**A203623**	**001**	Nov 26, 2014
AB			**EQ 25MG BASE**	**A202659**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A202659**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A202659**	**003**	Jun 11, 2018
AB		LUPIN LTD	**EQ 25MG BASE**	**A212051**	**001**	Mar 22, 2019
AB			**EQ 50MG BASE**	**A212051**	**002**	Mar 22, 2019
AB			**EQ 100MG BASE**	**A212051**	**003**	Mar 22, 2019
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A203814**	**001**	Dec 17, 2013
AB		MYLAN	**EQ 25MG BASE**	**A201171**	**001**	Mar 25, 2019
AB			**EQ 50MG BASE**	**A201171**	**002**	Mar 25, 2019
AB			**EQ 100MG BASE**	**A201171**	**003**	Mar 25, 2019
AB		MYLAN PHARMS INC	**EQ 20MG BASE**	**A201150**	**001**	Nov 09, 2012
AB		REYOUNG	**EQ 25MG BASE**	**A208494**	**001**	Jun 12, 2020
AB			**EQ 50MG BASE**	**A208494**	**002**	Jun 12, 2020
AB			**EQ 100MG BASE**	**A208494**	**003**	Jun 12, 2020
AB		RUBICON	**EQ 20MG BASE**	**A204883**	**001**	Jun 20, 2016
AB			**EQ 25MG BASE**	**A204882**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A204882**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A204882**	**003**	Jun 11, 2018
AB		SUNSHINE	**EQ 25MG BASE**	**A213032**	**001**	Jun 11, 2020
AB			**EQ 50MG BASE**	**A213032**	**002**	Jun 11, 2020
AB			**EQ 100MG BASE**	**A213032**	**003**	Jun 11, 2020
AB		TEVA	**EQ 25MG BASE**	**A077342**	**001**	Mar 09, 2016
AB			**EQ 50MG BASE**	**A077342**	**002**	Mar 09, 2016
AB			**EQ 100MG BASE**	**A077342**	**003**	Mar 09, 2016

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

AB		TEVA PHARMS	**EQ 20MG BASE**	**A078380**	**001**	Jan 07, 2013
AB		TORRENT	**EQ 25MG BASE**	**A091448**	**001**	Jun 11, 2018
AB			**EQ 50MG BASE**	**A091448**	**002**	Jun 11, 2018
AB			**EQ 100MG BASE**	**A091448**	**003**	Jun 11, 2018
AB		TORRENT PHARMS LTD	**EQ 20MG BASE**	**A091479**	**001**	Nov 06, 2012
AB		UMEDICA LABS PVT LTD	**EQ 25MG BASE**	**A209302**	**003**	Jun 15, 2021
AB			**EQ 50MG BASE**	**A209302**	**001**	Aug 25, 2020
AB			**EQ 100MG BASE**	**A209302**	**002**	Aug 25, 2020
AB		WATSON LABS INC	**EQ 20MG BASE**	**A202503**	**001**	Nov 06, 2012

VIAGRA

AB	**+**	UPJOHN	**EQ 25MG BASE**	**N020895**	**001**	Mar 27, 1998
AB	**+**		**EQ 50MG BASE**	**N020895**	**002**	Mar 27, 1998
AB	**+!**		**EQ 100MG BASE**	**N020895**	**003**	Mar 27, 1998

SILODOSIN

CAPSULE;ORAL

RAPAFLO

AB	**+!**	ALLERGAN	**4MG**	**N022206**	**001**	Oct 08, 2008
AB	**+**		**8MG**	**N022206**	**002**	Oct 08, 2008

SILODOSIN

AB		AJANTA PHARMA LTD	**4MG**	**A211060**	**001**	Dec 03, 2018
AB			**8MG**	**A211060**	**002**	Dec 03, 2018
AB		AMNEAL PHARMS CO	**4MG**	**A209745**	**001**	Dec 03, 2018
AB			**8MG**	**A209745**	**002**	Dec 03, 2018
AB		AUROBINDO PHARMA LTD	**4MG**	**A210626**	**001**	Dec 10, 2018
AB			**8MG**	**A210626**	**002**	Dec 10, 2018
AB		HETERO LABS LTD V	**4MG**	**A204793**	**001**	Feb 14, 2020
AB			**8MG**	**A204793**	**002**	Feb 14, 2020
AB		LUPIN LTD	**4MG**	**A206541**	**001**	Dec 03, 2018
AB			**8MG**	**A206541**	**002**	Dec 03, 2018
AB		MACLEODS PHARMS LTD	**4MG**	**A211166**	**001**	Dec 03, 2018
AB			**8MG**	**A211166**	**002**	Dec 03, 2018
AB		MSN	**4MG**	**A210687**	**001**	Dec 03, 2018
AB			**8MG**	**A210687**	**002**	Dec 03, 2018
AB		PRINSTON INC	**4MG**	**A209029**	**001**	Jan 04, 2022
AB			**8MG**	**A209029**	**002**	Jan 04, 2022
AB		SANDOZ INC	**4MG**	**A204726**	**001**	Mar 31, 2017
AB			**8MG**	**A204726**	**002**	Mar 31, 2017
AB		UPSHER SMITH LABS	**4MG**	**A213230**	**001**	Jan 03, 2022
AB			**8MG**	**A213230**	**002**	Jan 03, 2022

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

AB	**+!**	KING PHARMS LLC	**1%**	**N017381**	**001**	

SSD

AB		DR REDDYS LA	**1%**	**N018578**	**001**	Feb 25, 1982

THERMAZENE

AB		THEPHARMANETWORK LLC	**1%**	**N018810**	**001**	Dec 23, 1985

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

	+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016
	+!		40MG/5ML	N206679	002	Apr 21, 2016

TABLET;ORAL

SIMVASTATIN

AB		ACCORD HLTHCARE	**5MG**	**A078155**	**005**	Apr 05, 2013
AB			**10MG**	**A078155**	**002**	Feb 26, 2008
AB			**20MG**	**A078155**	**003**	Feb 26, 2008
AB			**40MG**	**A078155**	**004**	Feb 26, 2008
AB			**80MG**	**A078155**	**001**	Feb 26, 2008
AB		AUROBINDO PHARMA	**5MG**	**A077691**	**001**	Dec 20, 2006
AB			**10MG**	**A077691**	**002**	Dec 20, 2006
AB			**20MG**	**A077691**	**003**	Dec 20, 2006
AB			**40MG**	**A077691**	**004**	Dec 20, 2006
AB			**80MG**	**A077691**	**005**	Dec 20, 2006
AB		BIOCON PHARMA	**5MG**	**A078034**	**001**	Dec 20, 2006

SIMVASTATIN
TABLET;ORAL
SIMVASTATIN

AB			**10MG**	**A078034**	**002**	Dec 20, 2006
AB			**20MG**	**A078034**	**003**	Dec 20, 2006
AB			**40MG**	**A078034**	**004**	Dec 20, 2006
AB			**80MG**	**A078034**	**005**	Dec 20, 2006
AB		DR REDDYS LABS INC	**5MG**	**A077752**	**005**	Jan 23, 2008
AB			**10MG**	**A077752**	**001**	Dec 20, 2006
AB			**20MG**	**A077752**	**002**	Dec 20, 2006
AB			**40MG**	**A077752**	**003**	Dec 20, 2006
AB			**80MG**	**A077752**	**004**	Dec 20, 2006
AB		HETERO LABS LTD III	**5MG**	**A200895**	**001**	Nov 25, 2014
AB			**10MG**	**A200895**	**002**	Nov 25, 2014
AB			**20MG**	**A200895**	**003**	Nov 25, 2014
AB			**40MG**	**A200895**	**004**	Nov 25, 2014
AB			**80MG**	**A200895**	**005**	Nov 25, 2014
AB		HISUN PHARM HANGZHOU	**10MG**	**A206557**	**001**	Nov 13, 2017
AB			**20MG**	**A206557**	**002**	Nov 13, 2017
AB			**40MG**	**A206557**	**003**	Nov 13, 2017
AB			**80MG**	**A206557**	**004**	Nov 13, 2017
AB		LUPIN	**5MG**	**A078103**	**005**	Apr 14, 2009
AB			**10MG**	**A078103**	**001**	May 11, 2007
AB			**20MG**	**A078103**	**002**	May 11, 2007
AB			**40MG**	**A078103**	**003**	May 11, 2007
AB	!		**80MG**	**A078103**	**004**	May 11, 2007
AB		MICRO LABS	**5MG**	**A090383**	**001**	Sep 16, 2011
AB			**10MG**	**A090383**	**002**	Sep 16, 2011
AB			**20MG**	**A090383**	**003**	Sep 16, 2011
AB			**40MG**	**A090383**	**004**	Sep 16, 2011
AB			**80MG**	**A090383**	**005**	Sep 16, 2011
AB		OXFORD PHARMS	**5MG**	**A078735**	**001**	Aug 30, 2010
AB			**10MG**	**A078735**	**002**	Aug 30, 2010
AB			**20MG**	**A078735**	**003**	Aug 30, 2010
AB			**40MG**	**A078735**	**004**	Aug 30, 2010
AB			**80MG**	**A078735**	**005**	Aug 30, 2010
AB		WATSON LABS TEVA	**5MG**	**A076685**	**001**	Dec 20, 2006
AB			**10MG**	**A076685**	**002**	Dec 20, 2006
AB			**20MG**	**A076685**	**003**	Dec 20, 2006
AB			**40MG**	**A076685**	**004**	Dec 20, 2006
AB			**80MG**	**A076685**	**005**	Dec 20, 2006
AB		ZYDUS PHARMS USA	**5MG**	**A077837**	**001**	Dec 20, 2006
AB			**10MG**	**A077837**	**002**	Dec 20, 2006
AB			**20MG**	**A077837**	**003**	Dec 20, 2006
AB			**40MG**	**A077837**	**004**	Dec 20, 2006
AB			**80MG**	**A077837**	**005**	Dec 20, 2006
	ZOCOR					
AB	+	ORGANON	**5MG**	**N019766**	**001**	Dec 23, 1991
AB	+		**10MG**	**N019766**	**002**	Dec 23, 1991
AB	+		**20MG**	**N019766**	**003**	Dec 23, 1991
AB	+		**40MG**	**N019766**	**004**	Dec 23, 1991

SINCALIDE
INJECTABLE;INJECTION
KINEVAC

+!	BRACCO	0.005MG/VIAL	N017697	001	

SINECATECHINS
OINTMENT;TOPICAL
VEREGEN

+!	ANI PHARMS	15%	N021902	001	Oct 31, 2006

SIPONIMOD FUMARIC ACID
TABLET;ORAL
MAYZENT

+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019
+		EQ 1MG BASE	N209884	003	Aug 24, 2021
+!		EQ 2MG BASE	N209884	002	Mar 26, 2019

SIROLIMUS							
POWDER;INTRAVENOUS							
FYARRO							
	+!	AADI	100MG/VIAL	N213312	001	Nov 22, 2021
SOLUTION;ORAL							
RAPAMUNE							
AA	**+!**	PF PRISM CV	**1MG/ML**	**N021083**	**001**	Sep 15, 1999
SIROLIMUS							
AA		AMNEAL	**1MG/ML**	**A211212**	**001**	Oct 18, 2019
AA		APOTEX	**1MG/ML**	**A211406**	**001**	Oct 22, 2019
AA		NOVITIUM PHARMA	**1MG/ML**	**A211040**	**001**	Jan 28, 2019
AA		TORRENT	**1MG/ML**	**A215016**	**001**	Dec 27, 2021
TABLET;ORAL							
RAPAMUNE							
AB	**+**	PF PRISM CV	**0.5MG**	**N021110**	**004**	Jan 25, 2010
AB	**+**		**1MG**	**N021110**	**001**	Aug 25, 2000
AB	**+!**		**2MG**	**N021110**	**002**	Aug 22, 2002
SIROLIMUS							
AB		ALKEM LABS LTD	**0.5MG**	**A214753**	**001**	Mar 12, 2021
AB			**1MG**	**A214753**	**002**	Mar 12, 2021
AB			**2MG**	**A214753**	**003**	Mar 12, 2021
AB		DR REDDYS LABS LTD	**1MG**	**A201578**	**001**	Oct 27, 2014
AB			**2MG**	**A201578**	**002**	Oct 27, 2014
AB		GLENMARK PHARMS LTD	**0.5MG**	**A208691**	**001**	Oct 16, 2020
AB			**1MG**	**A208691**	**002**	Oct 16, 2020
AB			**2MG**	**A208691**	**003**	Oct 16, 2020
AB		ZYDUS PHARMS	**0.5MG**	**A201676**	**003**	Jan 08, 2014
SITAGLIPTIN PHOSPHATE							
TABLET;ORAL							
JANUVIA							
	+	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006
	+		EQ 50MG BASE	N021995	002	Oct 16, 2006
	+!		EQ 100MG BASE	N021995	003	Oct 16, 2006
SODIUM ACETATE							
INJECTABLE;INJECTION							
SODIUM ACETATE							
AP	**+!**	HOSPIRA	**2MEQ/ML**	**N018893**	**001**	May 04, 1983
AP		MILLA PHARMS	**2MEQ/ML**	**A214805**	**001**	May 04, 2021
		FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017
SODIUM BENZOATE; SODIUM PHENYLACETATE							
SOLUTION;INTRAVENOUS							
AMMONUL							
AP	**+!**	BAUSCH	**10%;10% (5GM/50ML;5GM/50ML)**	**N020645**	**001**	Feb 17, 2005
SODIUM PHENYLACETATE AND SODIUM BENZOATE							
AP		AILEX PHARMS LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A207096**	**001**	Feb 24, 2016
AP		MAIA PHARMS INC	**10%;10% (5GM/50ML;5GM/50ML)**	**A208521**	**001**	May 08, 2017
AP		NAVINTA LLC	**10%;10% (5GM/50ML;5GM/50ML)**	**A205880**	**001**	Aug 04, 2016
	+!	MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021
SODIUM BICARBONATE							
INJECTABLE;INJECTION							
SODIUM BICARBONATE							
AP	**!**	EXELA PHARMA	**0.5MEQ/ML**	**A211091**	**001**	Jun 20, 2019
AP	**!**		**0.9MEQ/ML**	**A211091**	**002**	Jun 20, 2019
AP	**!**		**1MEQ/ML**	**A211091**	**003**	Jun 20, 2019
AP		HOSPIRA INC	**0.5MEQ/ML**	**A202679**	**001**	Mar 07, 2017
AP			**0.5MEQ/ML**	**A202981**	**001**	Mar 04, 2016
AP			**0.9MEQ/ML**	**A202494**	**001**	Mar 06, 2017
AP			**1MEQ/ML**	**A202432**	**001**	Sep 26, 2017
AP			**1MEQ/ML**	**A202494**	**002**	Mar 06, 2017
AP		INTL MEDICATION SYS	**1MEQ/ML**	**A203449**	**001**	Sep 19, 2017
		HOSPIRA INC	1MEQ/ML	A202495	001	Mar 06, 2017
SODIUM CHLORIDE							
INJECTABLE;INJECTION							
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP		FRESENIUS KABI USA	**9MG/ML**	**A088911**	**001**	Feb 07, 1985
AP	**+!**	HOSPIRA	**9MG/ML**	**N018800**	**001**	Oct 29, 1982
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	**+**	B BRAUN	**450MG/100ML**	**N019635**	**001**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**450MG/100ML**	**N018016**	**001**	
AP		FRESENIUS KABI USA	**450MG/100ML**	**A208122**	**001**	Jul 23, 2018

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		HOSPIRA	**450MG/100ML**	**N019759**	**001**	Jun 08, 1988
AP	**+!**	ICU MEDICAL INC	**450MG/100ML**	**N018090**	**001**	

SODIUM CHLORIDE 0.9%

AP		HIKMA	**9MG/ML**	**A201850**	**001**	Jan 20, 2012
AP		SPECTRA MDCL DEVICES	**9MG/ML**	**A206171**	**001**	Jul 21, 2017

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	**+!**	B BRAUN	**900MG/100ML**	**N017464**	**001**	
AP	**+!**		**900MG/100ML**	**N019635**	**002**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**9MG/ML**	**N016677**	**004**	Oct 30, 1985
AP	**+**		**9MG/ML**	**N020178**	**002**	Dec 07, 1992
AP	**+!**		**900MG/100ML**	**N016677**	**001**	
AP	**+!**		**900MG/100ML**	**N020178**	**001**	Dec 07, 1992
AP	**!**	FRESENIUS KABI USA	**9MG/ML**	**A088912**	**001**	Jan 10, 1985
AP			**900MG/100ML**	**A207310**	**001**	Sep 19, 2017
AP		FRESENIUS MEDCL	**900MG/100ML**	**A078177**	**001**	Apr 12, 2007
AP		HAEMONETICS	**900MG/100ML**	**A076316**	**001**	Oct 27, 2004
AP	**+!**	HOSPIRA	**9MG/ML**	**N018803**	**001**	Oct 29, 1982
AP	**+**		**9MG/ML**	**N019465**	**002**	Jul 15, 1985
AP	**+!**		**900MG/100ML**	**N019465**	**001**	Jul 15, 1985
AP	**+!**		**900MG/100ML**	**N019480**	**001**	Sep 17, 1985
AP	**+!**	ICU MEDICAL INC	**900MG/100ML**	**N016366**	**001**	
AP		LABORATORIOS GRIFOLS	**900MG/100ML**	**A207956**	**001**	May 25, 2017
AP		NEPHRON	**9MG/ML**	**A211968**	**001**	Apr 23, 2020
AP	**!**	TARO	**9MG/ML**	**A077407**	**001**	Aug 11, 2006

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

AP		B BRAUN	**3GM/100ML**	**N019635**	**003**	Mar 09, 1988
AP	**+!**	BAXTER HLTHCARE	**3GM/100ML**	**N019022**	**001**	Nov 01, 1983
AP		FRESENIUS KABI USA	**3GM/100ML**	**A209476**	**001**	Mar 13, 2019

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

AP		B BRAUN	**5GM/100ML**	**N019635**	**004**	Mar 09, 1988
AP	**+**	BAXTER HLTHCARE	**5GM/100ML**	**N019022**	**002**	Nov 01, 1983

SODIUM CHLORIDE 0.9%

	+	B BRAUN	9MG/10ML	N019635	005	Aug 11, 2016
		HIKMA	9MG/ML	A201833	001	Sep 24, 2013
	+!	MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006

SODIUM CHLORIDE 23.4%

		FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 14.6%

AP		FRESENIUS KABI USA	**100MEQ/40ML (2.5MEQ/ML)**	**A212070**	**002**	Apr 28, 2021
AP	**+!**	HOSPIRA	**100MEQ/40ML (2.5MEQ/ML)**	**N018897**	**002**	Jul 20, 1984
		FRESENIUS KABI USA	50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021

SODIUM CHLORIDE 23.4%

	+!	HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	**+!**	B BRAUN	**900MG/100ML**	**N016733**	**001**	
AT		BAXTER HLTHCARE	**900MG/100ML**	**N017427**	**001**	
AT			**900MG/100ML**	**N017867**	**001**	
AT	**+**	ICU MEDICAL INC	**900MG/100ML**	**N017514**	**001**	
AT			**900MG/100ML**	**N018314**	**001**	

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

	+!	BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		3D IMAGING DRUG	**10-200mCi/ML**	**A203777**	**001**	Oct 19, 2015
AP		BIOMEDCL RES FDN	**10-200mCi/ML**	**A204351**	**001**	Jan 09, 2015
AP		CARDINAL HEALTH 414	**10-200mCi/ML**	**A203780**	**001**	Jul 30, 2015
AP		ESSENTIAL ISOTOPES	**10-200mCi/ML**	**A204541**	**001**	Oct 29, 2014
AP		HOT SHOTS NM LLC	**10-200mCi/ML**	**A204530**	**001**	Jul 29, 2015
AP		JUBILANT DRAXIMAGE	**10-200mCi/ML**	**A203968**	**001**	Oct 23, 2015
AP		KREITCHMAN PET CTR	**10-200mCi/ML**	**A203936**	**001**	May 19, 2016
AP		MIDWEST MEDCL	**10-200mCi/ML**	**A204440**	**001**	Nov 17, 2015

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		MIPS CRF	**10-200mCi/ML**	**A204517**	**001**	Jul 21, 2015
AP		NCM USA BRONX LLC	**10-200mCi/ML**	**A204513**	**001**	Nov 28, 2014
AP		NUKEMED	**10-200mCi/ML**	**A203912**	**001**	Apr 22, 2015
AP		PETNET	**10-200mCi/ML**	**A203890**	**001**	Sep 28, 2015
AP		PRECISION NUCLEAR	**10-200mCi/ML**	**A204542**	**001**	Feb 27, 2015
AP		SHERTECH LABS LLC	**10-200mCi/ML**	**A204315**	**001**	Sep 22, 2014
AP		SOFIE	**10-200mCi/ML**	**A203592**	**001**	Aug 18, 2015
AP	**!**		**10-200mCi/ML**	**A203544**	**001**	Dec 26, 2012
AP		UNIV UTAH CYCLOTRON	**10-200mCi/ML**	**A204497**	**001**	Apr 20, 2015
	!	MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
		THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	**+!**	CARDINAL HEALTH 418	**100uCi**	**N018671**	**001**	May 27, 1982
AA	**+!**		**200uCi**	**N018671**	**002**	May 27, 1982
AA		CURIUM	**100uCi**	**A071909**	**001**	Feb 28, 1989
AA			**200uCi**	**A071910**	**001**	Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

	+	JUBILANT	0.009-0.1mCi	N021305	006	May 19, 2005

SOLUTION;ORAL

HICON

AA	**+!**	JUBILANT	**250-1000mCi**	**N021305**	**007**	Dec 05, 2011

SODIUM IODIDE I 131

AA		INTL ISOTOPES	**250-1000mCi**	**A209166**	**001**	Feb 05, 2020

SODIUM NITRITE

SOLUTION;INTRAVENOUS

SODIUM NITRITE

	+!	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

NITHIODOTE

	+!	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML (250MG/ML)	N201444	001	Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

NITROPRESS

AP	**!**	HOSPIRA	**25MG/ML**	**A071961**	**001**	Aug 01, 1988

SODIUM NITROPRUSSIDE

AP		AKORN	**25MG/ML**	**A208635**	**001**	May 04, 2017
AP		AMNEAL	**25MG/ML**	**A209493**	**001**	Nov 07, 2017
AP		BE PHARMS	**25MG/ML**	**A214971**	**001**	Jul 12, 2021
AP		DR REDDYS LABS LTD	**25MG/ML**	**A210114**	**001**	Apr 10, 2019
AP		HAINAN POLY PHARM	**25MG/ML**	**A214199**	**001**	Aug 25, 2020
AP		HONG KONG	**25MG/ML**	**A211016**	**001**	Nov 29, 2019
AP		MEDICURE	**25MG/ML**	**A209584**	**001**	Aug 10, 2018
AP		MICRO LABS	**25MG/ML**	**A209352**	**001**	Dec 08, 2017
AP		MYLAN LABS LTD	**25MG/ML**	**A210763**	**001**	Apr 17, 2018
AP		NEXUS PHARMS	**25MG/ML**	**A207499**	**001**	May 25, 2017
AP		SAGENT PHARMS INC	**25MG/ML**	**A207426**	**001**	Dec 08, 2016
AP		SOMERSET THERAPS LLC	**25MG/ML**	**A210882**	**001**	Aug 17, 2018
AP		XIROMED	**25MG/ML**	**A211277**	**001**	Oct 29, 2020

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

	+!	EXELA PHARMA	20MG/100ML (0.2MG/ML)	N209387	003	Jul 13, 2018
	+!		50MG/100ML (0.5MG/ML)	N209387	001	Mar 08, 2017

SODIUM OXYBATE

SOLUTION;ORAL

XYREM

	+!	JAZZ PHARMS	0.5GM/ML	N021196	001	Jul 17, 2002

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB	**+!**	HORIZON THERAP	**3GM/TEASPOONFUL**	**N020573**	**001**	Apr 30, 1996

SODIUM PHENYLBUTYRATE

AB		PAR PHARM	**3GM/TEASPOONFUL**	**A203918**	**001**	Jun 15, 2016
AB		SIGMAPHARM LABS LLC	**3GM/TEASPOONFUL**	**A202819**	**001**	Mar 22, 2013

TABLET;ORAL

BUPHENYL

AB	**+!**	HORIZON THERAP	**500MG**	**N020572**	**001**	May 13, 1996

SODIUM PHENYLBUTYRATE

AB		PAR PHARM	**500MG**	**A204395**	**001**	Apr 15, 2016

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB		NOVEL LABS INC	**0.398GM;1.102GM**	**A079247**	**001**	Dec 30, 2011

OSMOPREP

AB	**+!**	SALIX PHARMS	**0.398GM;1.102GM**	**N021892**	**001**	Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

	+!	HOSPIRA	142MG/ML;276MG/ML	N018892	001	May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

AA	**!**	KVK TECH	**454GM/BOT**	**A040905**	**001**	Mar 30, 2009

KIONEX

AA		ANI PHARMS	**454GM/BOT**	**A040029**	**001**	Feb 06, 1998

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER	**454GM/BOT**	**A205727**	**001**	Feb 23, 2016
AA		BIOPHARM	**453.6GM/BOT**	**A090313**	**001**	Dec 21, 2011
AA		CHARTWELL RX	**454GM/BOT**	**A206815**	**001**	Feb 18, 2016
AA		CMP PHARMA INC	**454GM/BOT**	**A089910**	**001**	Jan 19, 1989
AA		EPIC PHARMA LLC	**453.6GM/BOT**	**A202333**	**001**	Mar 19, 2014
AA		NUVO PHARMS INC	**454GM/BOT**	**A204071**	**001**	Nov 28, 2014

KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

		NUVO PHARMS INC	15GM/BOT	A204071	002	Nov 28, 2014

SUSPENSION;ORAL, RECTAL

SPS

	+!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SODIUM TETRADECYL SULFATE

AP		CUSTOPHARM INC	**60MG/2ML (30MG/ML)**	**A209937**	**001**	Dec 09, 2019

SOTRADECOL

AP	**!**	MYLAN INSTITUTIONAL	**60MG/2ML (30MG/ML)**	**A040541**	**002**	Nov 12, 2004
	!		20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION;INTRAVENOUS

SODIUM THIOSULFATE

	+!	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION;ORAL

LOKELMA

	+	ASTRAZENECA	5GM/PACKET	N207078	001	May 18, 2018
	+!		10GM/PACKET	N207078	002	May 18, 2018

SOFOSBUVIR

PELLETS;ORAL

SOVALDI

	+	GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019
	+!		200MG/PACKET	N212480	002	Aug 28, 2019

TABLET;ORAL

SOVALDI

	+	GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019
	+!		400MG	N204671	001	Dec 06, 2013

SOFOSBUVIR; VELPATASVIR

PELLETS;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	150MG;37.5MG/PACKET	N214187	001	Jun 10, 2021
+!		200MG;50MG/PACKET	N214187	002	Jun 10, 2021

TABLET;ORAL

EPCLUSA

+	GILEAD SCIENCES INC	200MG;50MG	N208341	002	Mar 19, 2020
+!		400MG;100MG	N208341	001	Jun 28, 2016

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET;ORAL

VOSEVI

+!	GILEAD SCIENCES INC	400MG;100MG;100MG	N209195	001	Jul 18, 2017

SOLIFENACIN SUCCINATE

SUSPENSION;ORAL

VESICARE LS

+!	ASTELLAS	1MG/ML	N209529	001	May 26, 2020

TABLET;ORAL

SOLIFENACIN SUCCINATE

AB	ACCORD HLTHCARE	**5MG**	**A207477**	**001**	Jan 04, 2022
AB		**10MG**	**A207477**	**002**	Jan 04, 2022
AB	ALEMBIC PHARMS LTD	**5MG**	**A205575**	**001**	May 20, 2019
AB		**10MG**	**A205575**	**002**	May 20, 2019
AB	ALKEM LABS LTD	**5MG**	**A210224**	**001**	May 20, 2019
AB		**10MG**	**A210224**	**002**	May 20, 2019
AB	AMNEAL PHARMS CO	**5MG**	**A209719**	**001**	May 20, 2019
AB		**10MG**	**A209719**	**002**	May 20, 2019
AB	AUSTARPHARMA	**5MG**	**A210281**	**001**	May 20, 2019
AB		**10MG**	**A210281**	**002**	May 20, 2019
AB	CELLTRION	**5MG**	**A210582**	**001**	May 20, 2019
AB		**10MG**	**A210582**	**002**	May 20, 2019
AB	CIPLA	**5MG**	**A209839**	**001**	May 20, 2019
AB		**10MG**	**A209839**	**002**	May 20, 2019
AB	GLENMARK PHARMS INC	**5MG**	**A209239**	**001**	May 20, 2019
AB		**10MG**	**A209239**	**002**	May 20, 2019
AB	GRAVITI PHARMS	**5MG**	**A211423**	**001**	Dec 11, 2019
AB		**10MG**	**A211423**	**002**	Dec 11, 2019
AB	MSN	**5MG**	**A210688**	**001**	May 20, 2019
AB		**10MG**	**A210688**	**002**	May 20, 2019
AB	QILU	**5MG**	**A209333**	**001**	May 20, 2019
AB		**10MG**	**A209333**	**002**	May 20, 2019
AB	SCIEGEN PHARMS INC	**5MG**	**A211657**	**001**	May 20, 2019
AB		**10MG**	**A211657**	**002**	May 20, 2019
AB	STRIDES PHARMA	**5MG**	**A212214**	**001**	Sep 26, 2019
AB		**10MG**	**A212214**	**002**	Sep 26, 2019
AB	TEVA PHARMS USA	**5MG**	**A091464**	**001**	Apr 02, 2014
AB		**10MG**	**A091464**	**002**	Apr 02, 2014
AB	UNICHEM	**5MG**	**A211701**	**001**	Aug 27, 2019
AB		**10MG**	**A211701**	**002**	Aug 27, 2019
AB	WATSON LABS INC	**5MG**	**A202551**	**001**	May 20, 2019
AB		**10MG**	**A202551**	**002**	May 20, 2019

VESICARE

AB	**+**	ASTELLAS	**5MG**	**N021518**	**001**	Nov 19, 2004
AB	**+!**		**10MG**	**N021518**	**002**	Nov 19, 2004

SOLRIAMFETOL HYDROCHLORIDE

TABLET;ORAL

SUNOSI

+	JAZZ	EQ 75MG BASE	N211230	001	Jun 17, 2019
+!		EQ 150MG BASE	N211230	002	Jun 17, 2019

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

+!	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015

SORAFENIB TOSYLATE

TABLET;ORAL

NEXAVAR

+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005

SORBITOL

SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	3GM/100ML	N017863	001	

SORBITOL 3.3% IN PLASTIC CONTAINER

	B BRAUN	3.3GM/100ML	N016741	001	

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

+!	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009

SOLUTION;ORAL

SOTYLIZE

+!	ARBOR PHARMS LLC	5MG/ML (5MG/ML)	N205108	001	Oct 22, 2014

TABLET;ORAL

BETAPACE

AB	**+**	COVIS	**80MG**	**N019865**	**001**	Oct 30, 1992
AB	**+**		**120MG**	**N019865**	**005**	Apr 20, 1994
AB	**+!**		**160MG**	**N019865**	**002**	Oct 30, 1992
AB	**+**		**240MG**	**N019865**	**003**	Oct 30, 1992

BETAPACE AF

AB	**+**	COVIS	**80MG**	**N021151**	**001**	Feb 22, 2000
AB	**+**		**120MG**	**N021151**	**002**	Feb 22, 2000
AB	**+!**		**160MG**	**N021151**	**003**	Feb 22, 2000

SORINE

AB		UPSHER SMITH LABS	**80MG**	**A075500**	**001**	Apr 27, 2001
AB			**120MG**	**A075500**	**004**	Apr 27, 2001
AB			**160MG**	**A075500**	**002**	Apr 27, 2001
AB			**240MG**	**A075500**	**003**	Apr 27, 2001

SOTALOL HYDROCHLORIDE

AB		APOTEX	**80MG**	**A076140**	**001**	Sep 26, 2002
AB			**80MG**	**A076214**	**001**	Aug 27, 2003
AB			**120MG**	**A076140**	**002**	Sep 26, 2002
AB			**120MG**	**A076214**	**002**	Aug 27, 2003
AB			**160MG**	**A076140**	**003**	Sep 26, 2002
AB			**160MG**	**A076214**	**003**	Aug 27, 2003
AB			**240MG**	**A076140**	**004**	Sep 26, 2002
AB		BEXIMCO PHARMS USA	**80MG**	**A207428**	**001**	Oct 21, 2016
AB			**80MG**	**A207429**	**001**	Nov 02, 2018
AB			**120MG**	**A207428**	**002**	Oct 21, 2016
AB			**120MG**	**A207429**	**002**	Nov 02, 2018
AB			**160MG**	**A207428**	**003**	Oct 21, 2016
AB			**160MG**	**A207429**	**003**	Nov 02, 2018
AB		EPIC PHARMA INC	**80MG**	**A077070**	**001**	Nov 04, 2005
AB			**120MG**	**A077070**	**002**	Nov 04, 2005
AB			**160MG**	**A077070**	**003**	Nov 04, 2005
AB		OXFORD PHARMS	**80MG**	**A075563**	**001**	Nov 07, 2003
AB			**120MG**	**A075563**	**002**	Nov 07, 2003
AB			**160MG**	**A075563**	**003**	Nov 07, 2003
AB			**240MG**	**A075563**	**004**	Nov 07, 2003
AB		TEVA	**80MG**	**A075429**	**001**	May 01, 2000
AB			**120MG**	**A075429**	**002**	May 01, 2000
AB			**160MG**	**A075429**	**003**	May 01, 2000
AB			**240MG**	**A075429**	**004**	May 01, 2000

SOTORASIB

TABLET;ORAL

LUMAKRAS

+!	AMGEN INC	120MG	N214665	001	May 28, 2021

SOYBEAN OIL

INJECTABLE;INJECTION

INTRALIPID 10%

AP	**+!**	FRESENIUS	**10%**	**N017643**	**001**	

INTRALIPID 20%

AP	**+!**	FRESENIUS	**20%**	**N018449**	**001**	
AP	**+!**		**20%**	**N020248**	**001**	Aug 07, 1996

NUTRILIPID 10%

AP	**+!**	B BRAUN	**10%**	**N019531**	**001**	May 28, 1993

NUTRILIPID 20%

AP	**+!**	B BRAUN	**20%**	**N019531**	**002**	May 28, 1993

INTRALIPID 30%

+!	FRESENIUS	30%	N019942	001	Dec 30, 1993

SPINOSAD							
SUSPENSION;TOPICAL							
NATROBA							
	+!	PARAPRO LLC	0.9%		N022408	001	Jan 18, 2011
SPIRONOLACTONE							
SUSPENSION;ORAL							
CAROSPIR							
	+!	CMP DEV LLC	25MG/5ML		N209478	001	Aug 04, 2017
TABLET;ORAL							
ALDACTONE							
AB	**+**	PFIZER	**25MG**		**N012151**	**009**	Dec 30, 1983
AB	**+**		**50MG**		**N012151**	**008**	Dec 30, 1982
AB	**+!**		**100MG**		**N012151**	**010**	Dec 30, 1983
SPIRONOLACTONE							
AB		ACCORD HLTHCARE	**25MG**		**A203512**	**001**	Sep 19, 2016
AB			**50MG**		**A203512**	**002**	Sep 19, 2016
AB			**100MG**		**A203512**	**003**	Sep 19, 2016
AB		AMNEAL PHARMS	**25MG**		**A091426**	**001**	Jul 02, 2010
AB			**50MG**		**A091426**	**002**	Jul 02, 2010
AB			**100MG**		**A091426**	**003**	Jul 02, 2010
AB		AUROBINDO PHARMA LTD	**25MG**		**A202187**	**001**	Mar 06, 2014
AB			**50MG**		**A202187**	**002**	Mar 06, 2014
AB			**100MG**		**A202187**	**003**	Mar 06, 2014
AB		JUBILANT GENERICS	**25MG**		**A203253**	**001**	Apr 23, 2014
AB			**50MG**		**A203253**	**002**	Apr 23, 2014
AB			**100MG**		**A203253**	**003**	Apr 23, 2014
AB		MYLAN	**25MG**		**A040424**	**001**	Aug 20, 2001
AB			**50MG**		**A040424**	**002**	Aug 20, 2001
AB			**100MG**		**A040424**	**003**	Aug 20, 2001
AB		SUN PHARM INDUSTRIES	**25MG**		**A089424**	**001**	Jul 23, 1986
AB			**50MG**		**A089424**	**002**	Aug 11, 1999
AB			**100MG**		**A089424**	**003**	Aug 11, 1999
AB		ZYDUS PHARMS	**25MG**		**A205936**	**001**	Jul 18, 2018
AB			**50MG**		**A205936**	**002**	Jul 18, 2018
AB			**100MG**		**A205936**	**003**	Jul 18, 2018
STERILE WATER FOR INJECTION							
LIQUID;N/A							
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER							
AP	**+!**	HOSPIRA	**100%**		**N018802**	**001**	Oct 27, 1982
STERILE WATER FOR INJECTION							
AP		FRESENIUS KABI USA	**100%**		**A209689**	**001**	Nov 24, 2017
AP		HIKMA	**100% (10ML)**		**A206369**	**001**	Sep 02, 2015
AP	**+!**	HOSPIRA	**100% (10ML)**		**N018801**	**002**	Oct 27, 1982
AP		MEDEFIL INC	**100% (10ML)**		**A211188**	**005**	Dec 02, 2019
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER							
AP	**+!**	B BRAUN	**100%**		**N019633**	**001**	Feb 29, 1988
AP	**+!**	BAXTER HLTHCARE	**100%**		**N018632**	**001**	Jun 30, 1982
AP	**+!**		**100%**		**N018632**	**002**	Apr 19, 1988
AP		FRESENIUS KABI USA	**100%**		**A088400**	**001**	Jan 16, 1984
AP	**+!**	ICU MEDICAL INC	**100%**		**N018233**	**001**	
AP	**+!**		**100%**		**N019869**	**001**	Dec 26, 1989
AP		TARO	**100%**		**A077393**	**001**	Aug 11, 2006
STERILE WATER FOR INJECTION							
	+!	HOSPIRA	100% (20ML)		N018801	003	Oct 27, 1982
	+!		100% (50ML)		N018801	004	Oct 27, 1982
	+!		100% (100ML)		N018801	005	Oct 27, 1982
		MEDEFIL INC	100% (1ML)		A211188	001	Dec 02, 2019
	!		100% (2.5ML)		A211188	002	Dec 02, 2019
	!		100% (3ML)		A211188	003	Dec 02, 2019
	!		100% (5ML)		A211188	004	Dec 02, 2019
STERILE WATER FOR IRRIGATION							
LIQUID;IRRIGATION							
STERILE WATER							
AT	**+**	BAXTER HLTHCARE	**100%**		**N017428**	**001**	
STERILE WATER IN PLASTIC CONTAINER							
AT	**+**	B BRAUN	**100%**		**N016734**	**001**	
AT		BAXTER HLTHCARE	**100%**		**N017866**	**001**	
AT		ICU MEDICAL INC	**100%**		**N017513**	**001**	
AT			**100%**		**N018313**	**001**	

STIRIPENTOL

CAPSULE;ORAL

DIACOMIT

+	BIOCODEX SA	250MG	N206709	001	Aug 20, 2018
+!		500MG	N206709	002	Aug 20, 2018

FOR SUSPENSION;ORAL

DIACOMIT

+	BIOCODEX SA	250MG/PACKET	N207223	001	Aug 20, 2018
+!		500MG/PACKET	N207223	002	Aug 20, 2018

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

!	XGEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

+!	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON

AP	**+!**	Q BIOMED	**1mCi/ML**	**N020134**	**001**	Jun 18, 1993

STRONTIUM CHLORIDE SR-89

AP		Q BIOMED	**1mCi/ML**	**A075941**	**001**	Jan 06, 2003

SUCCIMER

CAPSULE;ORAL

CHEMET

+!	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

AP	**+!**	SANDOZ INC	**20MG/ML**	**N008453**	**002**	

QUELICIN

AP	**+!**	HOSPIRA	**20MG/ML**	**N008845**	**006**	

SUCCINYLCHOLINE CHLORIDE

AP		ACCORD HLTHCARE	**20MG/ML**	**A213705**	**001**	May 20, 2020
AP		AMNEAL	**20MG/ML**	**A211432**	**001**	Nov 16, 2018
AP		AMRING PHARMS	**20MG/ML**	**A210231**	**001**	Jun 04, 2018
AP		ASPIRO	**20MG/ML**	**A213810**	**001**	May 04, 2020
AP		BRECKENRIDGE	**20MG/ML**	**A212638**	**001**	Oct 09, 2019
AP		DEVA HOLDING AS	**20MG/ML**	**A214491**	**001**	Dec 21, 2020
AP		DR REDDYS	**20MG/ML**	**A210698**	**001**	Aug 02, 2019
AP		FRESENIUS KABI USA	**20MG/ML**	**A211346**	**001**	Nov 20, 2020
AP		GLAND PHARMA LTD	**20MG/ML**	**A214246**	**001**	Jun 16, 2020
AP		HIKMA	**20MG/ML**	**A213229**	**001**	Jun 12, 2020
AP		HONG KONG	**20MG/ML**	**A214514**	**001**	Oct 19, 2021
AP		INDOCO	**20MG/ML**	**A214308**	**001**	May 22, 2020
AP		MICRO LABS	**20MG/ML**	**A214879**	**001**	Nov 24, 2020
AP		NEXUS PHARMS	**20MG/ML**	**A213552**	**001**	Oct 27, 2020
AP		NIVAGEN PHARMS INC	**20MG/ML**	**A211625**	**001**	May 19, 2020
AP		SAGENT PHARMS INC	**20MG/ML**	**A215022**	**001**	Mar 29, 2021
AP		SOMERSET THERAPS LLC	**20MG/ML**	**A211589**	**001**	Jan 15, 2020
AP	**!**	ZYDUS PHARMS	**20MG/ML**	**A209467**	**001**	May 04, 2018

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

+!	HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021

SUCRALFATE

SUSPENSION;ORAL

CARAFATE

AB	**+!**	ALLERGAN	**1GM/10ML**	**N019183**	**001**	Dec 16, 1993

SUCRALFATE

AB		AMNEAL	**1GM/10ML**	**A209356**	**001**	Dec 02, 2019

TABLET;ORAL

CARAFATE

AB	**+!**	ALLERGAN	**1GM**	**N018333**	**001**	

SUCRALFATE

AB		NOSTRUM LABS INC	**1GM**	**A074415**	**001**	Jun 08, 1998
AB		TEVA	**1GM**	**A070848**	**001**	Mar 29, 1996

SUFENTANIL CITRATE						
INJECTABLE;INJECTION						
SUFENTA PRESERVATIVE FREE						
AP	**+!**	AKORN	**EQ 0.05MG BASE/ML**	**N019050**	**001**	May 04, 1984
SUFENTANIL CITRATE						
AP		HIKMA	**EQ 0.05MG BASE/ML**	**A074413**	**001**	Dec 15, 1995
AP		HOSPIRA	**EQ 0.05MG BASE/ML**	**A074534**	**001**	Dec 11, 1996
TABLET;SUBLINGUAL						
DSUVIA						
	+!	ACELRX PHARMS	EQ 0.03MG BASE	N209128	001	Nov 02, 2018
SUGAMMADEX SODIUM						
SOLUTION;INTRAVENOUS						
BRIDION						
	+	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015
	+!		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015
SULCONAZOLE NITRATE						
CREAM;TOPICAL						
EXELDERM						
	+!	JOURNEY	1%	N018737	001	Feb 28, 1989
SOLUTION;TOPICAL						
EXELDERM						
	+!	JOURNEY	1%	N018738	001	Aug 30, 1985
SULFACETAMIDE SODIUM						
LOTION;TOPICAL						
KLARON						
AB	**+!**	BAUSCH	**10%**	**N019931**	**001**	Dec 23, 1996
SULFACETAMIDE SODIUM						
AB		FOUGERA PHARMS	**10%**	**A077015**	**001**	Nov 17, 2006
AB		PADAGIS US	**10%**	**A078649**	**001**	Mar 23, 2009
AB		TARO	**10%**	**A078668**	**001**	May 20, 2009
OINTMENT;OPHTHALMIC						
SULFACETAMIDE SODIUM						
	!	PADAGIS US	10%	A080029	001	
SOLUTION/DROPS;OPHTHALMIC						
BLEPH-10						
AT	**+!**	ALLERGAN	**10%**	**A080028**	**001**	
SULFACETAMIDE SODIUM						
AT		AKORN	**10%**	**A040215**	**001**	May 25, 1999
AT		BAUSCH AND LOMB	**10%**	**A040066**	**001**	Dec 28, 1994
AT		SANDOZ INC	**10%**	**A089560**	**001**	Oct 18, 1988
SULFADIAZINE						
TABLET;ORAL						
SULFADIAZINE						
	!	SANDOZ	500MG	A040091	001	Jul 29, 1994
SULFAMETHOXAZOLE; TRIMETHOPRIM						
INJECTABLE;INJECTION						
SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AP	**!**	MYLAN LABS LTD	**80MG/ML;16MG/ML**	**A206607**	**001**	Aug 30, 2017
AP		SOMERSET	**80MG/ML;16MG/ML**	**A212231**	**001**	Jun 26, 2019
AP		TEVA PHARMS USA	**80MG/ML;16MG/ML**	**A073303**	**001**	Oct 31, 1991
SUSPENSION;ORAL						
SULFAMETHOXAZOLE AND TRIMETHOPRIM						
AB	**!**	AKORN	**200MG/5ML;40MG/5ML**	**A074650**	**001**	Dec 29, 1997
AB		AUROBINDO PHARMA	**200MG/5ML;40MG/5ML**	**A091348**	**001**	Jun 08, 2010
AB		LANNETT CO INC	**200MG/5ML;40MG/5ML**	**A077785**	**001**	Jan 24, 2007
AB		LUPIN LTD	**200MG/5ML;40MG/5ML**	**A212699**	**001**	Jan 05, 2021
AB		PRASCO	**200MG/5ML;40MG/5ML**	**A077612**	**001**	Nov 13, 2006
SULFATRIM PEDIATRIC						
AB		PHARM ASSOC	**200MG/5ML;40MG/5ML**	**N018615**	**001**	Jan 07, 1983
TABLET;ORAL						
BACTRIM						
AB	**+**	SUN PHARM INDUSTRIES	**400MG;80MG**	**N017377**	**001**	
BACTRIM DS						
AB	**+!**	SUN PHARM INDUSTRIES	**800MG;160MG**	**N017377**	**002**	
SEPTRA						
AB		MONARCH PHARMS	**400MG;80MG**	**N017376**	**001**	
SEPTRA DS						
AB		MONARCH PHARMS	**800MG;160MG**	**N017376**	**002**	

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		AMNEAL PHARMS NY	**400MG;80MG**	**A076899**	**001**	Jan 27, 2005
AB			**800MG;160MG**	**A076899**	**002**	Jan 27, 2005
AB		AUROBINDO PHARMA	**400MG;80MG**	**A090624**	**001**	Feb 16, 2010
AB			**800MG;160MG**	**A090624**	**002**	Feb 16, 2010
AB		CHARTWELL MOLECULES	**400MG;80MG**	**A078060**	**002**	Jan 25, 2007
AB			**800MG;160MG**	**A078060**	**001**	Jan 25, 2007
AB		GLENMARK GENERICS	**400MG;80MG**	**A090828**	**002**	Dec 22, 2010
AB			**800MG;160MG**	**A090828**	**001**	Dec 22, 2010
AB		SUN PHARM INDUSTRIES	**400MG;80MG**	**A071017**	**002**	Aug 25, 1986
AB			**800MG;160MG**	**A071017**	**001**	Aug 25, 1986
AB		VISTA PHARMS	**400MG;80MG**	**A076817**	**001**	Oct 07, 2005
AB			**800MG;160MG**	**A076817**	**002**	Oct 07, 2005

SULFASALAZINE

TABLET;ORAL

AZULFIDINE

AB	**+!**	PFIZER	**500MG**	**N007073**	**001**	

SULFASALAZINE

AB		CHARTWELL	**500MG**	**A080197**	**001**	
AB		NUVO PHARMS INC	**500MG**	**A040349**	**001**	Jan 11, 2002
AB		WATSON LABS	**500MG**	**A085828**	**001**	

TABLET, DELAYED RELEASE;ORAL

AZULFIDINE EN-TABS

AB	**+!**	PFIZER	**500MG**	**N007073**	**002**	Apr 06, 1983

SULFASALAZINE

AB		NUVO PHARMS INC	**500MG**	**A075339**	**001**	Jan 11, 2002

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION;INTRAVENOUS

LUMASON

	+!	BRACCO	60.7MG/25MG	N203684	001	Oct 15, 2014

SULINDAC

TABLET;ORAL

SULINDAC

AB		EPIC PHARMA	**150MG**	**A072710**	**001**	Mar 25, 1991
AB			**200MG**	**A072711**	**001**	Mar 25, 1991
AB		SUN PHARM INDUSTRIES	**150MG**	**A072050**	**001**	Apr 17, 1991
AB			**200MG**	**A072051**	**001**	Apr 17, 1991
AB		WATSON LABS	**150MG**	**A071891**	**001**	Apr 03, 1990
AB	**!**		**200MG**	**A071795**	**001**	Apr 03, 1990

SUMATRIPTAN

SPRAY;NASAL

IMITREX

AB	**+!**	GLAXOSMITHKLINE	**5MG/SPRAY**	**N020626**	**001**	Aug 26, 1997
AB	**+!**		**20MG/SPRAY**	**N020626**	**003**	Aug 26, 1997

SUMATRIPTAN

AB		CIPLA	**20MG/SPRAY**	**A214209**	**001**	Feb 22, 2021
AB		FLORIDA	**20MG/SPRAY**	**A208967**	**001**	Feb 17, 2021
AB		LANNETT CO INC	**5MG/SPRAY**	**A204841**	**001**	Feb 19, 2016
AB			**20MG/SPRAY**	**A204841**	**002**	Feb 19, 2016
AB		PADAGIS ISRAEL	**20MG/SPRAY**	**A213465**	**001**	Sep 21, 2020

TOSYMRA

	+!	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

AB	**+!**	GLAXOSMITHKLINE	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**N020080**	**002**	Feb 01, 2006
AB	**+!**		**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080**	**003**	Dec 23, 1996

SUMATRIPTAN SUCCINATE

AB		ANTARES PHARMA INC	**EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)**	**A078319**	**001**	Dec 10, 2015
AB			**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078319**	**002**	Dec 10, 2015
AB		DR REDDYS	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090495**	**001**	Jan 29, 2014
AB		SUN PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A090358**	**001**	Jun 21, 2011

IMITREX

AP	**+!**	GLAXOSMITHKLINE	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**N020080**	**001**	Dec 28, 1992

SUMATRIPTAN SUCCINATE

AP		CAPLIN	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A213998**	**001**	Jul 13, 2021

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP		EUGIA PHARMA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A202758 001**	Apr 23, 2013
AP		FRESENIUS KABI USA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079242 001**	Mar 02, 2009
AP		HIKMA	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A200183 001**	Sep 16, 2013
AP		PAR PHARM	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A077332 001**	Oct 09, 2009
AP		WEST-WARD PHARMS INT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A079123 001**	Feb 06, 2009
AP		WOCKHARDT	**EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)**	**A078593 001**	Feb 06, 2009

POWDER;NASAL

ONZETRA XSAIL

	+!	CURRAX	EQ 11MG BASE	N206099 001	Jan 27, 2016

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

	+	UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223 001	Jan 28, 2016

SPRAY;NASAL

SUMATRIPTAN

AB		PADAGIS ISRAEL	**5MG/SPRAY**	**A213465 002**	Sep 21, 2020

TABLET;ORAL

IMITREX

AB	**+**	GLAXOSMITHKLINE	**EQ 25MG BASE**	**N020132 002**	Jun 01, 1995
AB	**+**		**EQ 50MG BASE**	**N020132 003**	Jun 01, 1995
AB	**+!**		**EQ 100MG BASE**	**N020132 001**	Jun 01, 1995

SUMATRIPTAN SUCCINATE

AB		AUROBINDO PHARMA	**EQ 25MG BASE**	**A078327 001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078327 002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078327 003**	Aug 10, 2009
AB		COREPHARMA	**EQ 25MG BASE**	**A200263 001**	Jun 19, 2012
AB			**EQ 50MG BASE**	**A200263 002**	Jun 19, 2012
AB			**EQ 100MG BASE**	**A200263 003**	Jun 19, 2012
AB		DR REDDYS LABS INC	**EQ 25MG BASE**	**A076847 001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076847 002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076847 003**	Aug 10, 2009
AB		MYLAN	**EQ 25MG BASE**	**A077744 001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A077744 002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A077744 003**	Aug 10, 2009
AB		ORBION PHARMS	**EQ 25MG BASE**	**A078284 001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078284 002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078284 003**	Aug 10, 2009
AB		SUN PHARM INDS	**EQ 25MG BASE**	**A078295 001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A078295 002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A078295 003**	Aug 10, 2009
AB		SUN PHARM INDS LTD	**EQ 25MG BASE**	**A076554 001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076554 002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076572 001**	Feb 09, 2009
AB		WATSON LABS	**EQ 25MG BASE**	**A076933 001**	Aug 10, 2009
AB			**EQ 50MG BASE**	**A076933 002**	Aug 10, 2009
AB			**EQ 100MG BASE**	**A076933 003**	Aug 10, 2009

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB		MYLAN	**EQ 12.5MG BASE**	**A201275 001**	Dec 06, 2021
AB			**EQ 25MG BASE**	**A201275 002**	Dec 06, 2021
AB			**EQ 37.5MG BASE**	**A201275 003**	Dec 06, 2021
AB			**EQ 50MG BASE**	**A201275 004**	Dec 06, 2021
AB		SUN PHARM	**EQ 12.5MG BASE**	**A213914 001**	Aug 16, 2021
AB			**EQ 25MG BASE**	**A213914 002**	Aug 16, 2021
AB			**EQ 37.5MG BASE**	**A213914 003**	Aug 16, 2021
AB			**EQ 50MG BASE**	**A213914 004**	Aug 16, 2021
AB		TEVA PHARMS USA	**EQ 12.5MG BASE**	**A213803 001**	Nov 30, 2021
AB			**EQ 25MG BASE**	**A213803 002**	Nov 30, 2021
AB			**EQ 37.5MG BASE**	**A213803 003**	Nov 30, 2021
AB			**EQ 50MG BASE**	**A213803 004**	Nov 30, 2021

SUTENT

AB	**+**	CPPI CV	**EQ 12.5MG BASE**	**N021938 001**	Jan 26, 2006
AB	**+**		**EQ 25MG BASE**	**N021938 002**	Jan 26, 2006
AB	**+**		**EQ 37.5MG BASE**	**N021938 004**	Mar 31, 2009
AB	**+!**		**EQ 50MG BASE**	**N021938 003**	Jan 26, 2006

SUVOREXANT

TABLET;ORAL

BELSOMRA

+	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
+		10MG	N204569	002	Aug 13, 2014
+		15MG	N204569	003	Aug 13, 2014
+!		20MG	N204569	004	Aug 13, 2014

TACROLIMUS

CAPSULE;ORAL

PROGRAF

AB	**+**	ASTELLAS	**EQ 0.5MG BASE**	**N050708**	**003**	Aug 24, 1998
AB	**+**		**EQ 1MG BASE**	**N050708**	**001**	Apr 08, 1994
AB	**+!**		**EQ 5MG BASE**	**N050708**	**002**	Apr 08, 1994

TACROLIMUS

AB		ACCORD HLTHCARE	**EQ 0.5MG BASE**	**A091195**	**001**	Aug 31, 2011
AB			**EQ 1MG BASE**	**A091195**	**002**	Aug 31, 2011
AB			**EQ 5MG BASE**	**A091195**	**003**	Aug 31, 2011
AB		ALKEM LABS LTD	**EQ 0.5MG BASE**	**A203740**	**001**	Nov 12, 2020
AB			**EQ 1MG BASE**	**A203740**	**002**	Nov 12, 2020
AB			**EQ 5MG BASE**	**A203740**	**003**	Nov 12, 2020
AB		BELCHER	**EQ 0.5MG BASE**	**A206651**	**001**	Nov 30, 2017
AB			**EQ 1MG BASE**	**A206651**	**002**	Nov 30, 2017
AB			**EQ 5MG BASE**	**A206651**	**003**	Nov 30, 2017
AB		BIOCON PHARMA	**EQ 0.5MG BASE**	**A212297**	**001**	Nov 10, 2020
AB			**EQ 1MG BASE**	**A212297**	**002**	Nov 10, 2020
AB			**EQ 5MG BASE**	**A212297**	**003**	Nov 10, 2020
AB		CONCORD BIOTECH LTD	**EQ 1MG BASE**	**A213112**	**002**	Nov 10, 2020
AB			**EQ 5MG BASE**	**A213112**	**003**	Nov 10, 2020
AB		DR REDDYS LABS LTD	**EQ 0.5MG BASE**	**A090509**	**001**	May 12, 2010
AB			**EQ 1MG BASE**	**A090509**	**002**	May 12, 2010
AB			**EQ 5MG BASE**	**A090509**	**003**	May 12, 2010
AB		GLENMARK PHARMS LTD	**EQ 0.5MG BASE**	**A206662**	**001**	Nov 10, 2020
AB			**EQ 1MG BASE**	**A206662**	**002**	Nov 10, 2020
AB			**EQ 5MG BASE**	**A206662**	**003**	Nov 10, 2020
AB		MYLAN	**EQ 0.5MG BASE**	**A090596**	**001**	Sep 17, 2010
AB			**EQ 1MG BASE**	**A090596**	**002**	Sep 17, 2010
AB			**EQ 5MG BASE**	**A090596**	**003**	Sep 17, 2010
AB		PANACEA	**EQ 0.5MG BASE**	**A090802**	**001**	Sep 28, 2012
AB			**EQ 1MG BASE**	**A090802**	**002**	Sep 28, 2012
AB			**EQ 5MG BASE**	**A090802**	**003**	Sep 28, 2012
AB		SANDOZ	**EQ 0.5MG BASE**	**A065461**	**001**	Aug 10, 2009
AB			**EQ 1MG BASE**	**A065461**	**002**	Aug 10, 2009
AB			**EQ 5MG BASE**	**A065461**	**003**	Aug 10, 2009
AB		STRIDES PHARMA	**EQ 0.5MG BASE**	**A090687**	**001**	Jul 22, 2014
AB			**EQ 1MG BASE**	**A090687**	**002**	Jul 22, 2014
AB			**EQ 5MG BASE**	**A090687**	**003**	Jul 22, 2014

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013
+		EQ 1MG BASE	N204096	002	Jul 19, 2013
+!		EQ 5MG BASE	N204096	003	Jul 19, 2013

FOR SUSPENSION;ORAL

PROGRAF

+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018
+!		EQ 1MG BASE/PACKET	N210115	002	May 24, 2018

INJECTABLE;INJECTION

PROGRAF

AP	**+!**	ASTELLAS	**EQ 5MG BASE/ML**	**N050709**	**001**	Apr 08, 1994

TACROLIMUS

AP		HOSPIRA INC	**EQ 5MG BASE/ML**	**A203900**	**001**	Aug 25, 2017

OINTMENT;TOPICAL

PROTOPIC

AB	**+!**	LEO PHARMA AS	**0.03%**	**N050777**	**001**	Dec 08, 2000
AB	**+!**		**0.1%**	**N050777**	**002**	Dec 08, 2000

TACROLIMUS

AB		ACCORD HLTHCARE	**0.03%**	**A211688**	**001**	Jan 31, 2019
AB			**0.1%**	**A211688**	**002**	Jan 31, 2019
AB		FOUGERA PHARMS INC	**0.03%**	**A200744**	**001**	Sep 09, 2014
AB			**0.1%**	**A200744**	**002**	Sep 09, 2014
AB		GLENMARK PHARMS LTD	**0.1%**	**A210393**	**001**	Apr 16, 2018

TACROLIMUS

TABLET, EXTENDED RELEASE;ORAL

ENVARSUS XR

+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015
+		EQ 1MG BASE	N206406	002	Jul 10, 2015
+!		EQ 4MG BASE	N206406	003	Jul 10, 2015

TADALAFIL

TABLET;ORAL

CIALIS

AB1	**+**	LILLY	**2.5MG**	**N021368**	**004**	Jan 07, 2008
AB1	**+**		**5MG**	**N021368**	**001**	Nov 21, 2003
AB1	**+**		**10MG**	**N021368**	**002**	Nov 21, 2003
AB1	**+!**		**20MG**	**N021368**	**003**	Nov 21, 2003

TADALAFIL

AB1	ACCORD HLTHCARE	**2.5MG**	**A209167**	**001**	Mar 26, 2019
AB1		**5MG**	**A209167**	**002**	Mar 26, 2019
AB1		**10MG**	**A209167**	**003**	Oct 23, 2019
AB1		**20MG**	**A209167**	**004**	Mar 26, 2019
AB1	AJANTA PHARMA LTD	**2.5MG**	**A209654**	**001**	Mar 26, 2019
AB1		**5MG**	**A209654**	**002**	Mar 26, 2019
AB1		**10MG**	**A209654**	**003**	Mar 26, 2019
AB1		**20MG**	**A209654**	**004**	Mar 26, 2019
AB1	ALEMBIC PHARMS LTD	**2.5MG**	**A204809**	**001**	Mar 26, 2019
AB1		**5MG**	**A204809**	**002**	Mar 26, 2019
AB1		**10MG**	**A204809**	**003**	Mar 26, 2019
AB1		**20MG**	**A204809**	**004**	Mar 26, 2019
AB1	AMNEAL PHARMS CO	**2.5MG**	**A209744**	**001**	Mar 26, 2019
AB1		**5MG**	**A209744**	**002**	Mar 26, 2019
AB1		**10MG**	**A209744**	**003**	Mar 26, 2019
AB1		**20MG**	**A209744**	**004**	Mar 26, 2019
AB1	AUROBINDO PHARMA LTD	**2.5MG**	**A206285**	**001**	Mar 26, 2019
AB1		**5MG**	**A206285**	**002**	Mar 26, 2019
AB1		**10MG**	**A206285**	**003**	Mar 26, 2019
AB1		**20MG**	**A206285**	**004**	Mar 26, 2019
AB1	CIPLA	**2.5MG**	**A209539**	**001**	Mar 26, 2019
AB1		**5MG**	**A209539**	**002**	Mar 26, 2019
AB1		**10MG**	**A209539**	**003**	Mar 26, 2019
AB1		**20MG**	**A209539**	**004**	Mar 26, 2019
AB1	DR REDDYS LABS LTD	**2.5MG**	**A210069**	**001**	Mar 26, 2019
AB1		**5MG**	**A210069**	**002**	Mar 26, 2019
AB1		**10MG**	**A210069**	**003**	Mar 26, 2019
AB1		**20MG**	**A210069**	**004**	Mar 26, 2019
AB1	HETERO LABS LTD III	**2.5MG**	**A209908**	**001**	Mar 26, 2019
AB1		**5MG**	**A209908**	**002**	Mar 26, 2019
AB1		**10MG**	**A209908**	**003**	Mar 26, 2019
AB1		**20MG**	**A209908**	**004**	Mar 26, 2019
AB1	LUPIN LTD	**2.5MG**	**A210567**	**001**	Mar 26, 2019
AB1		**5MG**	**A210567**	**002**	Mar 26, 2019
AB1		**10MG**	**A210567**	**003**	Mar 26, 2019
AB1		**20MG**	**A210567**	**004**	Mar 26, 2019
AB1	MACLEODS PHARMS LTD	**2.5MG**	**A207244**	**001**	Oct 07, 2019
AB1		**5MG**	**A207244**	**002**	Oct 07, 2019
AB1		**10MG**	**A207244**	**003**	Oct 07, 2019
AB1		**20MG**	**A207244**	**004**	Oct 07, 2019
AB1	QILU PHARM HAINAN	**2.5MG**	**A210420**	**001**	Mar 26, 2019
AB1		**5MG**	**A210420**	**002**	Mar 26, 2019
AB1		**10MG**	**A210420**	**003**	Mar 26, 2019
AB1		**20MG**	**A210420**	**004**	Mar 26, 2019
AB1	SUN PHARM	**2.5MG**	**A208934**	**001**	Mar 26, 2019
AB1		**5MG**	**A208934**	**002**	Mar 26, 2019
AB1		**10MG**	**A208934**	**003**	Mar 26, 2019
AB1		**20MG**	**A208934**	**004**	Mar 26, 2019
AB1	SUNSHINE	**2.5MG**	**A211335**	**001**	Mar 26, 2019
AB1		**5MG**	**A211335**	**002**	Mar 26, 2019
AB1		**10MG**	**A211335**	**003**	Mar 26, 2019
AB1		**20MG**	**A211335**	**004**	Mar 26, 2019
AB1	TEVA PHARMS USA	**2.5MG**	**A090141**	**001**	May 22, 2018
AB1		**5MG**	**A090141**	**002**	May 22, 2018
AB1		**10MG**	**A090141**	**003**	May 22, 2018
AB1		**20MG**	**A090141**	**004**	May 22, 2018
AB1	TORRENT	**2.5MG**	**A211839**	**001**	Mar 26, 2019

TADALAFIL

TABLET;ORAL

TADALAFIL

AB1			**5MG**	**A211839**	**002**	Mar 26, 2019
AB1			**10MG**	**A211839**	**003**	Mar 26, 2019
AB1			**20MG**	**A211839**	**004**	Mar 26, 2019
AB1		UMEDICA LABS PVT LTD	**2.5MG**	**A211298**	**001**	Oct 23, 2020
AB1			**5MG**	**A211298**	**002**	Oct 23, 2020
AB1			**10MG**	**A211298**	**003**	Oct 23, 2020
AB1			**20MG**	**A211298**	**004**	Oct 23, 2020
AB1		VKT PHARMA	**2.5MG**	**A215556**	**001**	Nov 04, 2021
AB1			**5MG**	**A215556**	**002**	Nov 04, 2021
AB1			**10MG**	**A215556**	**003**	Nov 04, 2021
AB1			**20MG**	**A215556**	**004**	Nov 04, 2021
AB1		YANGLING BUCHANG	**2.5MG**	**A208824**	**001**	Oct 27, 2020
AB1			**5MG**	**A208824**	**002**	Oct 27, 2020
AB1			**10MG**	**A208824**	**003**	Oct 27, 2020
AB1			**20MG**	**A208824**	**004**	Oct 27, 2020
AB1		ZYDUS PHARMS	**2.5MG**	**A206693**	**001**	Mar 26, 2019
AB1			**5MG**	**A206693**	**002**	Mar 26, 2019
AB1			**10MG**	**A206693**	**003**	Mar 26, 2019
AB1			**20MG**	**A206693**	**004**	Mar 26, 2019

ADCIRCA

AB2	**+!**	ELI LILLY CO	**20MG**	**N022332**	**001**	May 22, 2009

ALYQ

AB2		TEVA PHARMS USA	**20MG**	**A209942**	**001**	Feb 05, 2019

TADALAFIL

AB2		AJANTA PHARMA LTD	**20MG**	**A210392**	**001**	Feb 05, 2019
AB2		AUROBINDO PHARMA LTD	**20MG**	**A206286**	**001**	Feb 05, 2019
AB2		CIPLA	**20MG**	**A210255**	**001**	Feb 05, 2019
AB2		DR REDDYS LABS LTD	**20MG**	**A210145**	**001**	Feb 05, 2019
AB2		HETERO LABS LTD III	**20MG**	**A209907**	**001**	Feb 05, 2019
AB2		LUPIN LTD	**20MG**	**A210572**	**001**	Feb 05, 2019
AB2		MACLEODS PHARMS LTD	**20MG**	**A207290**	**001**	Oct 16, 2019
AB2		SUNSHINE	**20MG**	**A213496**	**001**	Nov 23, 2020
AB2		TORRENT	**20MG**	**A212062**	**001**	Mar 26, 2019
BX		UNICHEM	2.5MG	A209250	001	Mar 26, 2019
BX			5MG	A209250	002	Mar 26, 2019
BX			10MG	A209250	003	Mar 26, 2019
BX			20MG	A209250	004	Mar 26, 2019

TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX

	+!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

	+!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019

TAFENOQUINE SUCCINATE

TABLET;ORAL

ARAKODA

	+!	60 DEGREES PHARMS	EQ 100MG BASE	N210607	001	Aug 08, 2018

KRINTAFEL

	+!	GLAXOSMITHKLINE	EQ 150MG BASE	N210795	001	Jul 20, 2018

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

AT		MICRO LABS	**0.0015%**	**A209051**	**001**	Aug 19, 2019

ZIOPTAN

AT	**+!**	AKORN	**0.0015%**	**N202514**	**001**	Feb 10, 2012

TALAZOPARIB TOSYLATE

CAPSULE;ORAL

TALZENNA

	+	PFIZER	EQ 0.25MG BASE	N211651	001	Oct 16, 2018
	+		EQ 0.5MG BASE	N211651	003	Sep 20, 2021
	+		EQ 0.75MG BASE	N211651	004	Sep 20, 2021
	+!		EQ 1MG BASE	N211651	002	Oct 16, 2018

TALC						
AEROSOL;INTRAPLEURAL						
SCLEROSOL						
	+!	SCIARRA LABS	4GM/SPRAY	N020587	001	Dec 24, 1997
POWDER;INTRAPLEURAL						
STERITALC						
	+	NOVATECH SA	2GM/VIAL	N205555	001	May 01, 2017
	+		3GM/VIAL	N205555	002	May 01, 2017
	+!		4GM/VIAL	N205555	003	May 01, 2017
TALC						
	+!	SCIARRA LABS	5GM/BOT	N021388	001	Dec 15, 2003
TAMOXIFEN CITRATE						
SOLUTION;ORAL						
SOLTAMOX						
	+!	MAYNE PHARMA INC	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005
TABLET;ORAL						
TAMOXIFEN CITRATE						
AB		ACTAVIS LABS FL INC	**EQ 10MG BASE**	**A070929**	**001**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A070929**	**002**	Feb 20, 2003
AB		APOTEX	**EQ 10MG BASE**	**A090878**	**001**	Sep 23, 2011
AB			**EQ 20MG BASE**	**A090878**	**002**	Sep 23, 2011
AB		EUGIA PHARMA	**EQ 10MG BASE**	**A213358**	**001**	Aug 14, 2020
AB			**EQ 20MG BASE**	**A213358**	**002**	Aug 14, 2020
AB		MAYNE PHARMA	**EQ 10MG BASE**	**A075797**	**001**	Feb 20, 2003
AB	**!**		**EQ 20MG BASE**	**A075797**	**002**	Feb 20, 2003
AB		MYLAN	**EQ 10MG BASE**	**A074732**	**002**	Feb 20, 2003
AB			**EQ 20MG BASE**	**A074732**	**001**	Feb 20, 2003
AB		ZYDUS PHARMS	**EQ 10MG BASE**	**A206694**	**001**	Oct 27, 2017
AB			**EQ 20MG BASE**	**A206694**	**002**	Oct 27, 2017
TAMSULOSIN HYDROCHLORIDE						
CAPSULE;ORAL						
FLOMAX						
AB	**+!**	SANOFI	**0.4MG**	**N020579**	**001**	Apr 15, 1997
TAMSULOSIN HYDROCHLORIDE						
AB		ALKEM LABS LTD	**0.4MG**	**A207405**	**001**	Aug 11, 2017
AB		ANBISON LAB	**0.4MG**	**A211885**	**001**	Oct 17, 2019
AB		AUROBINDO PHARMA LTD	**0.4MG**	**A202433**	**001**	Apr 30, 2013
AB		IMPAX LABS	**0.4MG**	**A090377**	**001**	Mar 02, 2010
AB		MACLEODS PHARMS LTD	**0.4MG**	**A204645**	**001**	Jan 20, 2017
AB		SANDOZ	**0.4MG**	**A078015**	**001**	Apr 27, 2010
AB		SUN PHARM INDS LTD	**0.4MG**	**A090931**	**001**	Jul 15, 2010
AB		SYNTHON PHARMS	**0.4MG**	**A078801**	**001**	Apr 27, 2010
AB		TEVA PHARMS	**0.4MG**	**A077630**	**001**	Apr 27, 2010
AB		WOCKHARDT	**0.4MG**	**A078938**	**001**	Apr 27, 2010
AB		ZYDUS PHARMS USA INC	**0.4MG**	**A078225**	**001**	Apr 27, 2010
TAPENTADOL HYDROCHLORIDE						
TABLET;ORAL						
NUCYNTA						
	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008
	+		EQ 75MG BASE	N022304	002	Nov 20, 2008
	+!		EQ 100MG BASE	N022304	003	Nov 20, 2008
TABLET, EXTENDED RELEASE;ORAL						
NUCYNTA ER						
	+	COLLEGIUM PHARM INC	EQ 50MG BASE	N200533	001	Aug 25, 2011
	+		EQ 100MG BASE	N200533	002	Aug 25, 2011
	+		EQ 150MG BASE	N200533	003	Aug 25, 2011
	+		EQ 200MG BASE	N200533	004	Aug 25, 2011
	+!		EQ 250MG BASE	N200533	005	Aug 25, 2011
TASIMELTEON						
CAPSULE;ORAL						
HETLIOZ						
	+!	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014
SUSPENSION;ORAL						
HETLIOZ LQ						
	+!	VANDA PHARMS INC	4MG/ML	N214517	001	Dec 01, 2020

TAVABOROLE							
SOLUTION;TOPICAL							
KERYDIN							
AB	**+!**	ANACOR PHARMS INC	**5%**	**N204427**	**001**	Jul 07, 2014
TAVABOROLE							
AB		ALEOR DERMACEUTICALS	**5%**	**A212188**	**001**	Oct 21, 2020
AB		AMNEAL	**5%**	**A212256**	**001**	Nov 25, 2020
AB		CIPLA	**5%**	**A212224**	**001**	Feb 09, 2021
AB		ENCUBE	**5%**	**A211297**	**001**	Oct 13, 2020
AB		LUPIN LTD	**5%**	**A212168**	**001**	Feb 08, 2021
AB		PADAGIS US	**5%**	**A211848**	**001**	Oct 13, 2020
AB		TARO PHARMS	**5%**	**A212215**	**001**	May 07, 2021
TAZAROTENE							
AEROSOL, FOAM;TOPICAL							
FABIOR							
	+!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012
CREAM;TOPICAL							
AVAGE							
AB	**+!**	ALLERGAN	**0.1%**	**N021184**	**003**	Sep 30, 2002
TAZAROTENE							
AB		COSETTE	**0.1%**	**A208662**	**001**	Dec 22, 2017
AB		TARO PHARMS	**0.1%**	**A208258**	**001**	Apr 03, 2017
TAZORAC							
AB	**+!**	ALLERGAN	**0.1%**	**N021184**	**002**	Sep 29, 2000
	+!		0.05%	N021184	001	Sep 29, 2000
GEL;TOPICAL							
TAZORAC							
	+!	ALLERGAN	0.05%	N020600	001	Jun 13, 1997
	+!		0.1%	N020600	002	Jun 13, 1997
LOTION;TOPICAL							
ARAZLO							
	+!	BAUSCH	0.045%	N211882	001	Dec 18, 2019
TAZEMETOSTAT HYDROBROMIDE							
TABLET;ORAL							
TAZVERIK							
	+!	EPIZYME INC	EQ 200MG BASE	N211723	001	Jan 23, 2020
TECHNETIUM TC-99M BICISATE KIT							
INJECTABLE;INJECTION							
NEUROLITE							
	+!	LANTHEUS MEDCL	N/A	N020256	001	Nov 23, 1994
TECHNETIUM TC-99M EXAMETAZIME KIT							
INJECTABLE;INJECTION							
CERETEC							
	+!	GE HEALTHCARE	N/A	N019829	001	Dec 30, 1988
POWDER;INTRAVENOUS							
DRAX EXAMETAZIME							
		JUBILANT	N/A	N208870	001	Aug 17, 2017
TECHNETIUM TC-99M MEBROFENIN KIT							
INJECTABLE;INJECTION							
CHOLETEC							
AP	**+!**	BRACCO	**N/A**	**N018963**	**001**	Jan 21, 1987
TECHNETIUM TC-99M MEBROFENIN							
AP		SUN PHARM INDS INC	**N/A**	**A078242**	**001**	Jan 29, 2008
TECHNETIUM TC-99M MEDRONATE							
INJECTABLE;INJECTION							
DRAXIMAGE MDP-25							
	+!	JUBILANT	N/A	N018035	002	Feb 27, 2004
TECHNETIUM TC-99M MEDRONATE KIT							
INJECTABLE;INJECTION							
CIS-MDP							
AP		SUN PHARM INDS INC	**N/A**	**N018124**	**001**	
TECHNETIUM TC-99M MEDRONATE KIT							
AP		CARDINAL HEALTH 414	**N/A**	**N018107**	**001**	

TECHNETIUM TC-99M MERTIATIDE KIT
INJECTABLE;INJECTION
TECHNESCAN MAG3

AP	**+!**	CURIUM	**N/A**	**N019882**	**001**	Jun 15, 1990

TECHNETIUM TC99M MERTIATIDE KIT

AP		SOMMER PHARMS II LLC	**N/A**	**A206489**	**001**	Feb 06, 2020
AP		SUN PHARM INDS INC	**N/A**	**A208994**	**001**	Jul 12, 2019

TECHNETIUM TC-99M OXIDRONATE KIT
INJECTABLE;INJECTION
TECHNESCAN

+!	CURIUM	N/A	N018321	001	

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
DRAXIMAGE DTPA

+!	JUBILANT	N/A	N018511	001	Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
CIS-PYRO

AP		SUN PHARM INDS INC	**N/A**	**N019039**	**001**	Jun 30, 1987

TECHNESCAN PYP KIT

AP		CURIUM	**N/A**	**N017538**	**001**	

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
ULTRATAG

+!	CURIUM	N/A	N019981	001	Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
CARDIOLITE

AP	**+!**	LANTHEUS MEDCL	**N/A**	**N019785**	**001**	Dec 21, 1990

TECHNETIUM TC 99M SESTAMIBI

AP		CARDINAL HEALTH 414	**N/A**	**A078809**	**001**	Apr 28, 2009
AP		CURIUM	**N/A**	**A078098**	**001**	Sep 22, 2008
AP		JUBILANT DRAXIMAGE	**N/A**	**A078806**	**001**	Apr 29, 2009
AP		SUN PHARM INDS INC	**10-30mCi**	**A079157**	**001**	Jul 10, 2009

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INTRAVENOUS
TECHNELITE

+!	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014

ULTRA-TECHNEKOW FM

+!	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014

SOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
AN-SULFUR COLLOID

+!	SUN PHARM INDS INC	N/A	N017858	001	

TECHNETIUM TC-99M TETROFOSMIN KIT
INJECTABLE;INJECTION
MYOVIEW 30ML

+!	GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT
INJECTABLE;INJECTION
LYMPHOSEEK KIT

+!	CARDINAL HEALTH 414	N/A	N202207	001	Mar 13, 2013

TECOVIRIMAT
CAPSULE;ORAL
TPOXX

+!	SIGA TECHNOLOGIES	200MG	N208627	001	Jul 13, 2018

TEDIZOLID PHOSPHATE
POWDER;INTRAVENOUS
SIVEXTRO

+!	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014

TABLET;ORAL
SIVEXTRO

+!	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER;SUBCUTANEOUS

GATTEX KIT

+!	NPS PHARMS INC	5MG/VIAL	N203441	001	Dec 21, 2012

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

+!	ALFASIGMA	EQ 6MG BASE	N021200	002	Jul 24, 2002

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

+!	CUMBERLAND PHARMS	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009

TELMISARTAN

TABLET;ORAL

MICARDIS

AB	**+**	BOEHRINGER INGELHEIM	**20MG**	**N020850**	**003**	Apr 04, 2000
AB	**+**		**40MG**	**N020850**	**001**	Nov 10, 1998
AB	**+!**		**80MG**	**N020850**	**002**	Nov 10, 1998

TELMISARTAN

AB		ALEMBIC PHARMS LTD	**20MG**	**A202130**	**001**	Jul 07, 2014
AB			**40MG**	**A202130**	**002**	Jul 07, 2014
AB			**80MG**	**A202130**	**003**	Jul 07, 2014
AB		AMNEAL PHARMS	**20MG**	**A204415**	**001**	Sep 08, 2015
AB			**40MG**	**A204415**	**002**	Sep 08, 2015
AB			**80MG**	**A204415**	**003**	Sep 08, 2015
AB		AUROBINDO PHARMA LTD	**20MG**	**A206511**	**001**	Sep 03, 2015
AB			**40MG**	**A206511**	**002**	Sep 03, 2015
AB			**80MG**	**A206511**	**003**	Sep 03, 2015
AB		CADILA PHARMS LTD	**20MG**	**A208605**	**001**	Jul 25, 2017
AB			**40MG**	**A208605**	**002**	Jul 25, 2017
AB			**80MG**	**A208605**	**003**	Jul 25, 2017
AB		CELLTRION	**20MG**	**A078710**	**001**	Jan 08, 2014
AB			**40MG**	**A078710**	**002**	Jan 08, 2014
AB			**80MG**	**A078710**	**003**	Jan 08, 2014
AB		GLENMARK PHARMS LTD	**20MG**	**A090032**	**001**	Jul 07, 2014
AB			**40MG**	**A090032**	**002**	Jul 07, 2014
AB			**80MG**	**A090032**	**003**	Jul 07, 2014
AB		HETERO LABS LTD V	**20MG**	**A205901**	**001**	Apr 22, 2016
AB			**40MG**	**A205901**	**002**	Apr 22, 2016
AB			**80MG**	**A205901**	**003**	Apr 22, 2016
AB		INVENTIA	**20MG**	**A205150**	**001**	Oct 30, 2015
AB			**40MG**	**A205150**	**002**	Oct 30, 2015
AB			**80MG**	**A205150**	**003**	Oct 30, 2015
AB		MICRO LABS	**20MG**	**A207016**	**001**	Oct 03, 2017
AB			**40MG**	**A207016**	**002**	Oct 03, 2017
AB			**80MG**	**A207016**	**003**	Oct 03, 2017
AB		MYLAN	**20MG**	**A202397**	**001**	Jul 07, 2014
AB			**40MG**	**A202397**	**002**	Jul 07, 2014
AB			**80MG**	**A202397**	**003**	Jul 07, 2014
AB		PRINSTON INC	**20MG**	**A207882**	**001**	May 03, 2017
AB			**40MG**	**A207882**	**002**	May 03, 2017
AB			**80MG**	**A207882**	**003**	May 03, 2017
AB		SANDOZ INC	**20MG**	**A203867**	**001**	Nov 03, 2014
AB			**40MG**	**A203867**	**002**	Nov 03, 2014
AB			**80MG**	**A203867**	**003**	Nov 03, 2014
AB		ZYDUS PHARMS	**20MG**	**A203325**	**001**	Aug 26, 2014
AB			**40MG**	**A203325**	**002**	Aug 26, 2014
AB			**80MG**	**A203325**	**003**	Aug 26, 2014

TELOTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

+!	TERSERA	EQ 250MG BASE	N208794	001	Feb 28, 2017

TEMAZEPAM

CAPSULE;ORAL

RESTORIL							
AB	+	SPECGX LLC	**7.5MG**	**N018163**	**003**	Oct 25, 1991
AB	+		**15MG**	**N018163**	**001**	
AB	+		**22.5MG**	**N018163**	**004**	Nov 02, 2004
AB	+!		**30MG**	**N018163**	**002**	
TEMAZEPAM							
AB		ACTAVIS ELIZABETH	**15MG**	**A071620**	**002**	Aug 07, 1987
AB			**30MG**	**A071620**	**001**	Aug 07, 1987
AB		ALEMBIC PHARMS LTD	**7.5MG**	**A211542**	**001**	Nov 23, 2018
AB			**15MG**	**A211542**	**002**	Nov 23, 2018
AB			**22.5MG**	**A211542**	**003**	Nov 23, 2018
AB			**30MG**	**A211542**	**004**	Nov 23, 2018
AB		AMNEAL PHARMS	**7.5MG**	**A203482**	**001**	May 23, 2016
AB			**15MG**	**A203482**	**002**	May 23, 2016
AB			**22.5MG**	**A203482**	**003**	May 23, 2016
AB			**30MG**	**A203482**	**004**	May 23, 2016
AB		NOVEL LABS INC	**7.5MG**	**A071457**	**002**	Jun 22, 2012
AB			**15MG**	**A071456**	**001**	Apr 21, 1987
AB			**22.5MG**	**A071457**	**003**	Jun 22, 2012
AB			**30MG**	**A071457**	**001**	Apr 21, 1987
AB		PRINSTON INC	**7.5MG**	**A201781**	**001**	Jun 04, 2015
AB			**15MG**	**A201781**	**002**	Jun 04, 2015
AB			**22.5MG**	**A201781**	**003**	Jun 04, 2015
AB			**30MG**	**A201781**	**004**	Jun 04, 2015
AB		SANDOZ	**15MG**	**A071427**	**001**	Jan 12, 1988
AB			**30MG**	**A071428**	**001**	Jan 12, 1988
AB		SUN PHARM INDUSTRIES	**7.5MG**	**A078581**	**001**	Sep 08, 2009
AB			**22.5MG**	**A071175**	**002**	Sep 14, 2009

TEMOZOLOMIDE

CAPSULE;ORAL

TEMODAR							
AB	+	MERCK SHARP DOHME	**5MG**	**N021029**	**001**	Aug 11, 1999
AB	+		**20MG**	**N021029**	**002**	Aug 11, 1999
AB	+		**100MG**	**N021029**	**003**	Aug 11, 1999
AB	+		**140MG**	**N021029**	**005**	Oct 19, 2006
AB	+		**180MG**	**N021029**	**006**	Oct 19, 2006
AB	+!		**250MG**	**N021029**	**004**	Aug 11, 1999
TEMOZOLOMIDE							
AB		ACCORD HLTHCARE	**5MG**	**A201528**	**001**	Feb 27, 2017
AB			**20MG**	**A201528**	**002**	Feb 27, 2017
AB			**100MG**	**A201528**	**003**	Feb 27, 2017
AB			**140MG**	**A201528**	**004**	Feb 27, 2017
AB			**180MG**	**A201528**	**005**	Feb 27, 2017
AB			**250MG**	**A201528**	**006**	Feb 27, 2017
AB		AMNEAL PHARMS	**5MG**	**A203691**	**001**	May 08, 2015
AB			**20MG**	**A203691**	**002**	May 08, 2015
AB			**100MG**	**A203691**	**003**	May 08, 2015
AB			**140MG**	**A203691**	**004**	May 08, 2015
AB			**180MG**	**A203691**	**005**	May 08, 2015
AB			**250MG**	**A203691**	**006**	May 08, 2015
AB		ANI PHARMS	**5MG**	**A203490**	**001**	Jul 13, 2016
AB			**20MG**	**A203490**	**002**	Jul 13, 2016
AB			**100MG**	**A203490**	**003**	Jul 13, 2016
AB			**140MG**	**A203490**	**004**	Jul 13, 2016
AB			**180MG**	**A203490**	**005**	Jul 13, 2016
AB			**250MG**	**A203490**	**006**	Jul 13, 2016
AB		CHARTWELL	**5MG**	**A206413**	**001**	Apr 12, 2016
AB			**20MG**	**A206413**	**002**	Apr 12, 2016
AB			**100MG**	**A206413**	**003**	Apr 12, 2016
AB			**140MG**	**A206413**	**004**	Apr 12, 2016
AB			**180MG**	**A206413**	**005**	Apr 12, 2016
AB			**250MG**	**A206413**	**006**	Apr 12, 2016
AB		CHEMI SPA	**5MG**	**A204639**	**001**	Nov 23, 2016
AB			**20MG**	**A204639**	**002**	Nov 23, 2016
AB			**100MG**	**A204639**	**003**	Nov 23, 2016
AB			**140MG**	**A204639**	**004**	Nov 23, 2016
AB			**180MG**	**A204639**	**005**	Nov 23, 2016
AB			**250MG**	**A204639**	**006**	Nov 23, 2016
AB		DEVA HOLDING AS	**5MG**	**A207658**	**001**	Apr 26, 2017

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

AB			**20MG**	**A207658**	**002**	Apr 26, 2017
AB			**100MG**	**A207658**	**003**	Apr 26, 2017
AB			**140MG**	**A207658**	**004**	Apr 26, 2017
AB			**180MG**	**A207658**	**005**	Apr 26, 2017
AB			**250MG**	**A207658**	**006**	Apr 26, 2017
AB		NIVAGEN PHARMS INC	**5MG**	**A213328**	**001**	Nov 23, 2021
AB			**20MG**	**A213328**	**002**	Nov 23, 2021
AB			**100MG**	**A213328**	**003**	Nov 23, 2021
AB			**140MG**	**A213328**	**004**	Nov 23, 2021
AB			**180MG**	**A213328**	**005**	Nov 23, 2021
AB			**250MG**	**A213328**	**006**	Nov 23, 2021
AB		RISING	**5MG**	**A206309**	**001**	Apr 27, 2016
AB			**20MG**	**A206309**	**002**	Apr 27, 2016
AB			**100MG**	**A206309**	**003**	Apr 27, 2016
AB			**140MG**	**A206309**	**004**	Apr 27, 2016
AB			**180MG**	**A206309**	**005**	Apr 27, 2016
AB			**250MG**	**A206309**	**006**	Apr 27, 2016
AB		SUN PHARM	**5MG**	**A201742**	**001**	Feb 12, 2014
AB			**20MG**	**A201742**	**002**	Feb 12, 2014
AB			**100MG**	**A201742**	**003**	Feb 12, 2014
AB			**140MG**	**A201742**	**004**	Feb 12, 2014
AB			**180MG**	**A201742**	**005**	Feb 12, 2014
AB			**250MG**	**A201742**	**006**	Feb 12, 2014
AB		ZYDUS PHARMS	**5MG**	**A206750**	**001**	Jul 31, 2017
AB			**20MG**	**A206750**	**002**	Jul 31, 2017
AB			**100MG**	**A206750**	**003**	Jul 31, 2017
AB			**140MG**	**A206750**	**004**	Jul 31, 2017
AB			**180MG**	**A206750**	**005**	Jul 31, 2017
AB			**250MG**	**A206750**	**006**	Jul 31, 2017

POWDER;INTRAVENOUS

TEMODAR

	+!	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009

TEMSIROLIMUS

SOLUTION;INTRAVENOUS

TEMSIROLIMUS

AP		ACCORD HLTHCARE	**25MG/ML (25MG/ML)**	**A203153**	**001**	Jul 30, 2018
AP		GLAND PHARMA LTD	**25MG/ML (25MG/ML)**	**A207383**	**001**	Aug 16, 2019

TORISEL

AP	**+!**	PF PRISM CV	**25MG/ML (25MG/ML)**	**N022088**	**001**	May 30, 2007

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

VEMLIDY

	+!	GILEAD SCIENCES INC	EQ 25MG BASE	N208464	001	Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER;ORAL

VIREAD

	+!	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	**150MG**	**A090647**	**001**	Jan 26, 2018
AB			**200MG**	**A090647**	**002**	Jan 26, 2018
AB			**250MG**	**A090647**	**003**	Jan 26, 2018
AB			**300MG**	**A090647**	**004**	Jan 26, 2018
AB		CASI PHARMS INC	**300MG**	**A209550**	**001**	Feb 26, 2018
AB		CIPLA	**300MG**	**A078800**	**001**	Jan 26, 2018
AB		HETERO LABS LTD III	**300MG**	**A090636**	**001**	Jan 26, 2018
AB		MACLEODS PHARMS LTD	**300MG**	**A203232**	**001**	Jan 26, 2018
AB		QILU	**200MG**	**A209498**	**001**	Mar 02, 2018
AB			**250MG**	**A209498**	**002**	Mar 02, 2018
AB			**300MG**	**A209498**	**003**	Mar 02, 2018
AB		STRIDES PHARMA	**300MG**	**A090742**	**001**	Jan 26, 2018
AB		TEVA PHARMS USA	**150MG**	**A091612**	**002**	Jan 26, 2018
AB			**200MG**	**A091612**	**003**	Jan 26, 2018
AB			**250MG**	**A091612**	**004**	Jan 26, 2018
AB			**300MG**	**A091612**	**001**	Mar 18, 2015

VIREAD

AB	**+**	GILEAD SCIENCES INC	**150MG**	**N021356**	**002**	Jan 18, 2012

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

VIREAD

AB	**+**		**200MG**	**N021356**	**003**	Jan 18, 2012
AB	**+**		**250MG**	**N021356**	**004**	Jan 18, 2012
AB	**+!**		**300MG**	**N021356**	**001**	Oct 26, 2001

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL

TEPMETKO

	+!	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB		APNAR PHARMA LP	**EQ 1MG BASE**	**A074823**	**001**	Mar 30, 1998
AB			**EQ 2MG BASE**	**A074823**	**002**	Mar 30, 1998
AB			**EQ 5MG BASE**	**A074823**	**003**	Mar 30, 1998
AB			**EQ 10MG BASE**	**A074823**	**004**	Mar 30, 1998
AB		HERITAGE PHARMA AVET	**EQ 1MG BASE**	**A075614**	**002**	Jan 30, 2001
AB			**EQ 2MG BASE**	**A075614**	**001**	Jan 30, 2001
AB			**EQ 5MG BASE**	**A075614**	**003**	Jan 30, 2001
AB			**EQ 10MG BASE**	**A075614**	**004**	Jan 30, 2001
AB	**!**	JUBILANT CADISTA	**EQ 1MG BASE**	**A075317**	**001**	Dec 20, 2004
AB			**EQ 2MG BASE**	**A075317**	**002**	Dec 20, 2004
AB			**EQ 5MG BASE**	**A075317**	**003**	Dec 20, 2004
AB			**EQ 10MG BASE**	**A075317**	**004**	Dec 20, 2004

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

AB	**!**	AUROBINDO PHARMA	**EQ 250MG BASE**	**A078297**	**001**	Jul 02, 2007
AB		BRECKENRIDGE PHARM	**EQ 250MG BASE**	**A077714**	**001**	Jun 04, 2010
AB		CIPLA	**EQ 250MG BASE**	**A077137**	**001**	Jul 02, 2007
AB		DR REDDYS LABS INC	**EQ 250MG BASE**	**A076390**	**001**	Jul 02, 2007
AB		EMED MEDCL	**EQ 250MG BASE**	**A077919**	**001**	Jul 02, 2007
AB		GLENMARK GENERICS	**EQ 250MG BASE**	**A078157**	**001**	Jul 02, 2007
AB		HERITAGE PHARMA AVET	**EQ 250MG BASE**	**A076377**	**001**	Jul 02, 2007
AB		INVAGEN PHARMS	**EQ 250MG BASE**	**A077533**	**001**	Jul 02, 2007
AB		ORBION PHARMS	**EQ 250MG BASE**	**A078163**	**001**	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

AP		AKORN	**1MG/ML**	**A078151**	**001**	Jan 07, 2008
AP	**!**	ATHENEX INC	**1MG/ML**	**A076770**	**001**	Apr 23, 2004
AP		FRESENIUS KABI USA	**1MG/ML**	**A076887**	**001**	May 26, 2004
AP		HIKMA FARMACEUTICA	**1MG/ML**	**A078630**	**001**	May 20, 2009
AP		UNITED BIOMEDCL	**1MG/ML**	**A200122**	**001**	Nov 08, 2013

TABLET;ORAL

BRETHINE

AB	**+**	ANI PHARMS	**2.5MG**	**N017849**	**001**	
AB	**+**		**5MG**	**N017849**	**002**	

TERBUTALINE SULFATE

AB		IMPAX LABS	**2.5MG**	**A075877**	**001**	Jun 26, 2001
AB			**5MG**	**A075877**	**002**	Jun 26, 2001
AB		LANNETT CO INC	**2.5MG**	**A077152**	**001**	Mar 25, 2005
AB	**!**		**5MG**	**A077152**	**002**	Mar 25, 2005
AB		TWI PHARMS	**2.5MG**	**A211832**	**001**	Jun 19, 2020
AB			**5MG**	**A211832**	**002**	Jun 19, 2020

TERCONAZOLE

CREAM;VAGINAL

TERCONAZOLE

AB		FOUGERA PHARMS	**0.4%**	**A076712**	**001**	Feb 18, 2005
AB	**!**	TARO	**0.4%**	**A076043**	**001**	Jan 19, 2005
BX	+!	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004
BX	!	TARO	0.8%	A075953	001	Apr 06, 2004

SUPPOSITORY;VAGINAL

TERCONAZOLE

AB	**!**	PADAGIS ISRAEL	**80MG**	**A077149**	**001**	Mar 17, 2006
AB		TARO	**80MG**	**A077553**	**001**	Mar 09, 2007

TERIFLUNOMIDE							
TABLET;ORAL							
AUBAGIO							
AB	**+**	SANOFI AVENTIS US	**7MG**	**N202992**	**001**	Sep 12, 2012
AB	**+!**		**14MG**	**N202992**	**002**	Sep 12, 2012
TERIFLUNOMIDE							
AB		ACCORD HLTHCARE	**7MG**	**A209690**	**001**	Jan 07, 2019
AB			**14MG**	**A209690**	**002**	Jan 07, 2019
AB		ALEMBIC PHARMS LTD	**7MG**	**A209572**	**001**	Apr 19, 2019
AB			**14MG**	**A209572**	**002**	Apr 19, 2019
AB		GLENMARK PHARMS	**7MG**	**A209663**	**001**	Nov 15, 2018
AB			**14MG**	**A209663**	**002**	Nov 15, 2018
AB		SANDOZ INC	**7MG**	**A209710**	**001**	Jan 03, 2019
AB			**14MG**	**A209710**	**002**	Jan 03, 2019
TERIPARATIDE							
SOLUTION;SUBCUTANEOUS							
BONSITY							
		ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019
FORTEO							
	+!	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008
TESTOSTERONE							
FILM, EXTENDED RELEASE;TRANSDERMAL							
ANDRODERM							
	+!	ALLERGAN	2MG/24HR	N020489	003	Oct 20, 2011
	+!		4MG/24HR	N020489	004	Oct 20, 2011
GEL;TRANSDERMAL							
ANDROGEL							
AB1	**+**	ABBVIE	**25MG/2.5GM PACKET**	**N021015**	**001**	Feb 28, 2000
AB1	**+!**		**50MG/5GM PACKET**	**N021015**	**002**	Feb 28, 2000
TESTOSTERONE							
AB1		ACTAVIS LABS UT INC	**25MG/2.5GM PACKET**	**A076737**	**001**	Jan 27, 2006
AB1			**50MG/5GM PACKET**	**A076737**	**002**	Jan 27, 2006
AB1		ENCUBE	**50MG/5GM PACKET**	**A212984**	**001**	Nov 09, 2021
AB1		STRIDES PHARMA	**25MG/2.5GM PACKET**	**A076744**	**001**	May 23, 2007
AB1			**50MG/5GM PACKET**	**A076744**	**002**	May 23, 2007
ANDROGEL							
AB2	**+**	ABBVIE	**1.62% (20.25MG/1.25GM PACKET)**	**N022309**	**002**	Sep 07, 2012
AB2	**+!**		**1.62% (40.5MG/2.5GM PACKET)**	**N022309**	**003**	Sep 07, 2012
TESTIM							
AB2	**+!**	AUXILIUM PHARMS LLC	**50MG/5GM PACKET**	**N021454**	**001**	Oct 31, 2002
TESTOSTERONE							
AB2		ACTAVIS LABS UT INC	**1.62% (20.25MG/1.25GM PACKET)**	**A204570**	**002**	Jul 17, 2020
AB2			**1.62% (40.5MG/2.5GM PACKET)**	**A204570**	**003**	Jul 17, 2020
AB2			**50MG/5GM PACKET**	**A091073**	**001**	Sep 18, 2017
AB2		PADAGIS ISRAEL	**1.62% (20.25MG/1.25GM PACKET)**	**A205781**	**001**	Jul 12, 2017
AB2			**1.62% (40.5MG/2.5GM PACKET)**	**A205781**	**002**	Jul 12, 2017
VOGELXO							
AB2		UPSHER SMITH LABS	**50MG/5GM PACKET**	**N204399**	**002**	Jun 04, 2014
GEL, METERED;NASAL							
NATESTO							
		ACERUS	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014
GEL, METERED;TRANSDERMAL							
ANDROGEL							
AB	**+!**	ABBVIE	**1.62% (20.25MG/1.25GM ACTUATION)**	**N022309**	**001**	Apr 29, 2011
FORTESTA							
AB	**+!**	ENDO PHARMS	**10MG/0.5GM ACTUATION**	**N021463**	**001**	Dec 29, 2010
TESTOSTERONE							
AB		ACTAVIS LABS UT INC	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204570**	**001**	Apr 10, 2019
AB			**10MG/0.5GM ACTUATION**	**A204571**	**001**	Aug 05, 2015
AB		AMNEAL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A207373**	**001**	Apr 10, 2019
AB		DR REDDYS	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208620**	**001**	Apr 10, 2019
AB		LUPIN	**1.62% (20.25MG/1.25GM ACTUATION)**	**A208560**	**001**	Apr 10, 2019
AB		PADAGIS ISRAEL	**1.62% (20.25MG/1.25GM ACTUATION)**	**A204268**	**001**	Aug 04, 2015
AB		TWI PHARMS	**1.62% (20.25MG/1.25GM ACTUATION)**	**A209390**	**001**	Sep 23, 2019
AB		XIROMED	**1.62% (20.25MG/1.25GM ACTUATION)**	**A210835**	**001**	Apr 16, 2020
BX	!	ACTAVIS LABS UT INC	12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015
VOGELXO							
BX		UPSHER SMITH LABS	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014
PELLET;IMPLANTATION							
TESTOPEL							
	!	AUXILIUM PHARMS INC	75MG	A080911	001		

TESTOSTERONE							
SOLUTION, METERED;TRANSDERMAL							
TESTOSTERONE							
AT		ACTAVIS LABS UT INC	**30MG/1.5ML ACTUATION**	**A205328**	**001**	Aug 07, 2017
AT		CIPLA	**30MG/1.5ML ACTUATION**	**A209533**	**001**	Jan 29, 2018
AT		DASH PHARMS	**30MG/1.5ML ACTUATION**	**A212301**	**001**	Jan 11, 2021
AT		LUPIN LTD	**30MG/1.5ML ACTUATION**	**A208061**	**001**	Oct 23, 2017
AT	!	PADAGIS ISRAEL	**30MG/1.5ML ACTUATION**	**A204255**	**001**	Feb 28, 2017
AT		TWI PHARMS	**30MG/1.5ML ACTUATION**	**A209836**	**001**	Sep 03, 2021
TESTOSTERONE CYPIONATE							
INJECTABLE;INJECTION							
DEPO-TESTOSTERONE							
AO	+!	PFIZER	**100MG/ML**	**A085635**	**002**		
AO	+!		**200MG/ML**	**A085635**	**003**		
TESTOSTERONE CYPIONATE							
AO		AM REGENT	**200MG/ML**	**A207742**	**001**	Jun 16, 2017
AO		CIPLA	**100MG/ML**	**A210362**	**001**	Jun 19, 2018
AO			**200MG/ML**	**A210362**	**002**	Jun 19, 2018
AO		HIKMA	**100MG/ML**	**A090387**	**001**	Jul 15, 2010
AO			**200MG/ML**	**A090387**	**002**	Jul 15, 2010
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091244**	**001**	May 01, 2012
AO		PADAGIS US	**200MG/ML**	**A040530**	**001**	Jan 31, 2005
AO		SANDOZ INC	**100MG/ML**	**A040615**	**001**	Aug 10, 2006
AO			**200MG/ML**	**A040615**	**002**	Aug 10, 2006
AO		SUN PHARM INDS LTD	**100MG/ML**	**A201720**	**001**	Jun 03, 2013
AO			**200MG/ML**	**A201720**	**002**	Jun 03, 2013
AO		WATSON PHARMS INC	**200MG/ML**	**A086030**	**001**	
AO		WILSHIRE PHARMS INC	**200MG/ML**	**A206368**	**001**	Apr 24, 2019
TESTOSTERONE ENANTHATE							
INJECTABLE;INJECTION							
TESTOSTERONE ENANTHATE							
AO		HIKMA FARMACEUTICA	**200MG/ML**	**A091120**	**001**	Sep 18, 2012
AO		NEXUS PHARMS	**200MG/ML**	**A040575**	**001**	Jun 14, 2006
AO	!	WATSON PHARMS INC	**200MG/ML**	**A085598**	**001**	
SOLUTION;SUBCUTANEOUS							
XYOSTED (AUTOINJECTOR)							
	+!	ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018
	+!		75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018
	+!		100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018
TESTOSTERONE UNDECANOATE							
CAPSULE;ORAL							
JATENZO							
	+	CLARUS	158MG	N206089	001	Mar 27, 2019
	+		198MG	N206089	002	Mar 27, 2019
	+!		237MG	N206089	003	Mar 27, 2019
INJECTABLE;INTRAMUSCULAR							
AVEED							
	+!	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014
TETRABENAZINE							
TABLET;ORAL							
TETRABENAZINE							
AB		ACTAVIS LABS FL INC	**25MG**	**A206686**	**001**	Jul 07, 2017
AB		APOTEX	**12.5MG**	**A206093**	**001**	Mar 17, 2020
AB			**25MG**	**A206093**	**002**	Mar 17, 2020
AB		BIONPHARMA INC	**12.5MG**	**A208826**	**001**	Dec 18, 2017
AB			**25MG**	**A208826**	**002**	Dec 18, 2017
AB		DR REDDYS	**12.5MG**	**A209284**	**001**	Jan 08, 2018
AB			**25MG**	**A209284**	**002**	Jan 08, 2018
AB		HETERO LABS LTD V	**12.5MG**	**A204574**	**001**	Feb 03, 2016
AB			**25MG**	**A204574**	**002**	Feb 03, 2016
AB		HIKMA	**12.5MG**	**A209739**	**001**	Apr 08, 2019
AB			**25MG**	**A209739**	**002**	Apr 08, 2019
AB		LUPIN LTD	**12.5MG**	**A210544**	**001**	Apr 20, 2018
AB			**25MG**	**A210544**	**002**	Apr 20, 2018
AB		MYLAN	**12.5MG**	**A207682**	**001**	Jan 31, 2017
AB			**25MG**	**A207682**	**002**	Jan 31, 2017
AB		PIRAMAL HLTHCARE UK	**12.5MG**	**A213316**	**001**	Jan 22, 2020
AB			**25MG**	**A213316**	**002**	Jan 22, 2020
AB		SUN PHARM	**12.5MG**	**A206129**	**001**	Aug 17, 2015
AB			**25MG**	**A206129**	**002**	Aug 17, 2015

TETRABENAZINE
TABLET;ORAL
XENAZINE

AB	**+**	BAUSCH	**12.5MG**	**N021894**	**001**	Aug 15, 2008
AB	**+!**		**25MG**	**N021894**	**002**	Aug 15, 2008

TETRACAINE HYDROCHLORIDE
SOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

	+!	ALCON LABS	0.5%	N208135	001 Feb 29, 2016
	+!	BAUSCH LOMB IRELAND	0.5%	N210821	001 Mar 12, 2019

TETRACYCLINE HYDROCHLORIDE
CAPSULE;ORAL
ACHROMYCIN V

AB	**+**	AVET	**250MG**	**N050278**	**003**	
AB	**+!**		**500MG**	**N050278**	**001**	

TETRACYCLINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	**250MG**	**A210674**	**001**	Sep 18, 2018
AB			**500MG**	**A210674**	**002**	Sep 18, 2018
AB		BRECKENRIDGE	**250MG**	**A210662**	**001**	Nov 07, 2018
AB			**500MG**	**A210662**	**002**	Nov 07, 2018
AB		CHARTWELL TETRA	**250MG**	**A062752**	**001**	Aug 12, 1988
AB			**500MG**	**A062752**	**002**	Aug 12, 1988
AB		STRIDES PHARMA	**250MG**	**A212635**	**001**	Mar 03, 2020
AB			**500MG**	**A212635**	**002**	Mar 03, 2020
AB		WATSON LABS	**250MG**	**A061837**	**001**	
AB			**500MG**	**A061837**	**002**	

TETRAHYDROZOLINE HYDROCHLORIDE
SOLUTION;NASAL
TYZINE

	!	FOUGERA PHARMS	0.05%	A086576	002
			0.1%	A086576	001

SPRAY;NASAL
TYZINE

	!	FOUGERA PHARMS	0.1%	A086576	003

THALIDOMIDE
CAPSULE;ORAL
THALOMID

	+	CELGENE	50MG	N020785	001 Jul 16, 1998
	+		100MG	N020785	002 Jan 17, 2003
	+		150MG	N020785	004 Jan 10, 2007
	+!		200MG	N020785	003 Jan 17, 2003

THALLOUS CHLORIDE TL-201
INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

AP	**+!**	CURIUM	**1mCi/ML**	**N018150**	**001**	
AP	**+!**	LANTHEUS MEDCL	**1mCi/ML**	**N017806**	**001**	

THEOPHYLLINE
CAPSULE, EXTENDED RELEASE;ORAL
THEO-24

		ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983
	!	AUXILIUM PHARMS INC	400MG	A081034	001	Feb 28, 1992
	+	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983
			300MG	A087944	001	Aug 22, 1983

INJECTABLE;INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

	+!	B BRAUN	40MG/100ML	N019826	001 Aug 14, 1992

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

	+!	B BRAUN	80MG/100ML	N019826	002 Aug 14, 1992

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

	+!	B BRAUN	160MG/100ML	N019826	003 Aug 14, 1992

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

	+!	B BRAUN	320MG/100ML	N019826	006 Aug 14, 1992

SOLUTION;ORAL
THEOPHYLLINE

AA	**!**	LANNETT CO INC	**80MG/15ML**	**A091156**	**001**	Apr 13, 2011
AA		TRIS PHARMA INC	**80MG/15ML**	**A091586**	**001**	Jun 15, 2012

SOLUTION, ELIXIR;ORAL
ELIXOPHYLLIN

AA	**+!**	NOSTRUM LABS INC	**80MG/15ML**	**A085186**	**001**	

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL

THEOPHYLLINE

AA		PHARM ASSOC	**80MG/15ML**	**A206344**	**001**	Dec 16, 2016

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

AB		ALEMBIC PHARMS LTD	**300MG**	**A090430**	**001**	Oct 27, 2010
AB	**!**		**450MG**	**A090430**	**002**	Oct 27, 2010
AB		GLENMARK GENERICS	**400MG**	**A090355**	**001**	Jul 13, 2010
AB			**600MG**	**A090355**	**002**	Jul 13, 2010
AB		GLENMARK PHARMS LTD	**300MG**	**A212184**	**001**	Jun 03, 2021
AB			**450MG**	**A212184**	**002**	Jun 03, 2021
AB		HERITAGE PHARMA AVET	**300MG**	**A089763**	**001**	Apr 30, 1990
AB			**450MG**	**A081236**	**001**	Nov 09, 1992
AB		NOSTRUM LABS INC	**400MG**	**A040560**	**003**	Apr 21, 2006
AB	**!**		**600MG**	**A040560**	**002**	Apr 21, 2006
AB	**+**	RHODES PHARMS	**400MG**	**A040086**	**002**	Sep 01, 1982
AB			**600MG**	**A040086**	**001**	Apr 15, 1996

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

THIAMINE HYDROCHLORIDE

AP	**+!**	FRESENIUS KABI USA	**100MG/ML**	**A080556**	**001**	
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091623**	**001**	Jun 25, 2012
AP		SAGENT PHARMS INC	**100MG/ML**	**A206106**	**001**	Dec 01, 2017
AP		WEST-WARD PHARMS INT	**100MG/ML**	**A080575**	**001**	

THIOGUANINE

TABLET;ORAL

THIOGUANINE

	+!	ASPEN GLOBAL INC	40MG	N012429	001	

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

		MYLAN	10MG	A088004	002	Mar 15, 1983
			25MG	A088004	003	Mar 15, 1983
			50MG	A088004	004	Mar 15, 1983
	!		100MG	A088004	001	Nov 18, 1983

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

AP		BELOTECA INC	**15MG/VIAL**	**A211831**	**001**	Dec 08, 2021
AP		DR REDDYS	**15MG/VIAL**	**A210337**	**001**	May 04, 2018
AP		JIANGSU PHARMS	**15MG/VIAL**	**A209150**	**001**	May 04, 2018
AP		STI PHARMA LLC	**15MG/VIAL**	**A208242**	**001**	Jan 10, 2020
AP	**!**	WEST-WARD PHARMS INT	**15MG/VIAL**	**A075547**	**001**	Apr 02, 2001

POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

TEPADINA

AP	**+!**	ADIENNE SA	**15MG/VIAL**	**N208264**	**001**	Jan 26, 2017
AP	**+!**		**100MG/VIAL**	**N208264**	**002**	Jan 26, 2017

THIOTEPA

AP		GLAND PHARMA LTD	**15MG/VIAL**	**A214222**	**001**	Mar 08, 2021
AP			**100MG/VIAL**	**A214222**	**002**	Jan 03, 2022
AP		MSN	**15MG/VIAL**	**A213049**	**001**	Mar 04, 2020
AP			**100MG/VIAL**	**A213049**	**002**	Mar 04, 2020

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

AB		MYLAN	**1MG**	**A071093**	**002**	Jun 23, 1987
AB			**2MG**	**A071093**	**003**	Jun 23, 1987
AB			**5MG**	**A071093**	**004**	Jun 23, 1987
AB			**10MG**	**A071093**	**001**	Jun 23, 1987
AB		NOVITIUM PHARMA	**1MG**	**A211642**	**001**	Apr 05, 2019
AB			**2MG**	**A211642**	**002**	Apr 05, 2019
AB	**!**		**5MG**	**A211642**	**003**	Apr 05, 2019
AB			**10MG**	**A211642**	**004**	Apr 05, 2019

TIAGABINE HYDROCHLORIDE

TABLET;ORAL

GABITRIL

AB	**+**	CEPHALON	**2MG**	**N020646**	**005**	Apr 16, 1999
AB	**+!**		**4MG**	**N020646**	**001**	Sep 30, 1997
AB	**+**		**12MG**	**N020646**	**002**	Sep 30, 1997
AB	**+**		**16MG**	**N020646**	**003**	Sep 30, 1997

TIAGABINE HYDROCHLORIDE

AB		AMNEAL PHARMS CO	**2MG**	**A208181**	**001**	Dec 08, 2017
AB			**4MG**	**A208181**	**002**	Dec 08, 2017
AB			**12MG**	**A208181**	**003**	Dec 08, 2017
AB			**16MG**	**A208181**	**004**	Dec 08, 2017
AB		MSN	**2MG**	**A214816**	**001**	Nov 16, 2021
AB			**4MG**	**A214816**	**002**	Nov 16, 2021
AB			**12MG**	**A214816**	**003**	Nov 16, 2021
AB			**16MG**	**A214816**	**004**	Nov 16, 2021
AB		SUN PHARM INDS	**2MG**	**A077555**	**001**	Nov 04, 2011
AB			**4MG**	**A077555**	**002**	Nov 04, 2011

TICAGRELOR

TABLET;ORAL

BRILINTA

AB	**+**	ASTRAZENECA	**60MG**	**N022433**	**002**	Sep 03, 2015
AB	**+!**		**90MG**	**N022433**	**001**	Jul 20, 2011

TICAGRELOR

AB		HISUN PHARM HANGZHOU	**90MG**	**A208575**	**001**	Jan 23, 2019
AB		MYLAN	**60MG**	**A208597**	**001**	Jul 09, 2021
AB			**90MG**	**A208597**	**002**	Jul 09, 2021

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

AB		APOTEX	**250MG**	**A075089**	**001**	Jul 01, 1999
AB	**!**	TEVA	**250MG**	**A075149**	**001**	Aug 20, 1999

TIGECYCLINE

POWDER;INTRAVENOUS

TIGECYCLINE

AP		AMNEAL	**50MG/VIAL**	**N211158**	**001**	Aug 02, 2018
AP		APOTEX	**50MG/VIAL**	**A204439**	**001**	Dec 21, 2018
AP		EUGIA PHARMA	**50MG/VIAL**	**A206335**	**001**	Jun 11, 2019
AP	**+!**	FRESENIUS KABI USA	**50MG/VIAL**	**N205645**	**001**	Dec 01, 2016
AP		MEITHEAL	**50MG/VIAL**	**A214020**	**001**	May 13, 2021
AP		SANDOZ INC	**50MG/VIAL**	**A091620**	**001**	May 27, 2015
AP		XELLIA PHARMS APS	**50MG/VIAL**	**A205722**	**001**	Oct 18, 2019

TYGACIL

AP	**+!**	PF PRISM CV	**50MG/VIAL**	**N021821**	**001**	Jun 15, 2005

TIGECYCLINE

		ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

AT	**+!**	AKORN	**EQ 0.25% BASE**	**N020439**	**001**	Mar 31, 1995
AT	**+!**		**EQ 0.5% BASE**	**N020439**	**002**	Mar 31, 1995

TIMOLOL

AT		AKORN	**EQ 0.25% BASE**	**A205309**	**001**	Sep 30, 2016
AT			**EQ 0.5% BASE**	**A205309**	**002**	Sep 30, 2016

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AB	**!**	ALEMBIC PHARMS LTD	**EQ 0.25% BASE**	**A212942**	**001**	Oct 22, 2020
AB	**!**		**EQ 0.5% BASE**	**A212942**	**002**	Oct 22, 2020
AB	**+!**	SANDOZ INC	**EQ 0.25% BASE**	**N020963**	**001**	Oct 21, 1998
AB	**+!**		**EQ 0.5% BASE**	**N020963**	**002**	Oct 21, 1998

TIMOPTIC-XE

AB	**+**	VALEANT PHARMS LLC	**EQ 0.25% BASE**	**N020330**	**001**	Nov 04, 1993
AB	**+**		**EQ 0.5% BASE**	**N020330**	**002**	Nov 04, 1993

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT1		AKORN	**EQ 0.5% BASE**	**A074466**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074516**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A075163**	**001**	Sep 10, 2002

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AT1		BAUSCH AND LOMB	**EQ 0.25% BASE**	**A074778**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074776**	**001**	Mar 25, 1997
AT1		FDC LTD	**EQ 0.25% BASE**	**A077259**	**001**	Apr 30, 2008
AT1			**EQ 0.5% BASE**	**A077259**	**002**	Apr 30, 2008
AT1		MANKIND PHARMA	**EQ 0.25% BASE**	**A078771**	**001**	Sep 28, 2009
AT1			**EQ 0.5% BASE**	**A078771**	**002**	Sep 28, 2009
AT1		PACIFIC PHARMA	**EQ 0.25% BASE**	**A074746**	**001**	Mar 25, 1997
AT1			**EQ 0.5% BASE**	**A074747**	**001**	Mar 25, 1997
AT1	!	SANDOZ INC	**EQ 0.25% BASE**	**A074261**	**001**	Apr 28, 1995
AT1	!		**EQ 0.5% BASE**	**A074262**	**001**	Apr 28, 1995

TIMOPTIC

AT1	+	VALEANT PHARMS INTL	**EQ 0.25% BASE**	**N018086**	**001**	
AT1	+		**EQ 0.5% BASE**	**N018086**	**002**	

ISTALOL

AT2	+!	BAUSCH AND LOMB	**EQ 0.5% BASE**	**N021516**	**001**	Jun 04, 2004

TIMOLOL MALEATE

AT2		APOTEX	**EQ 0.5% BASE**	**A204936**	**001**	Apr 17, 2015
AT3		AKORN	**EQ 0.5% BASE**	**A212291**	**001**	Sep 11, 2020
AT3		AMRING PHARMS	**EQ 0.25% BASE**	**A212592**	**001**	Dec 13, 2021
AT3			**EQ 0.5% BASE**	**A212592**	**002**	Dec 13, 2021

TIMOPTIC IN OCUDOSE

AT3	+!	BAUSCH	**EQ 0.25% BASE**	**N019463**	**001**	Nov 05, 1986
AT3	+!		**EQ 0.5% BASE**	**N019463**	**002**	Nov 05, 1986

TABLET;ORAL

TIMOLOL MALEATE

AB		ELYSIUM	**5MG**	**A207556**	**001**	May 02, 2019
AB			**10MG**	**A207556**	**002**	May 02, 2019
AB			**20MG**	**A207556**	**003**	May 02, 2019
AB		MYLAN	**5MG**	**A072668**	**002**	Jun 08, 1990
AB			**10MG**	**A072668**	**003**	Jun 08, 1990
AB	!		**20MG**	**A072668**	**001**	Jun 08, 1990

TINIDAZOLE

TABLET;ORAL

TINDAMAX

AB	+	MISSION PHARMA	**250MG**	**N021618**	**001**	May 17, 2004
AB	+!		**500MG**	**N021618**	**002**	May 17, 2004

TINIDAZOLE

AB		EDENBRIDGE PHARMS	**250MG**	**A203808**	**001**	Aug 04, 2015
AB			**500MG**	**A203808**	**002**	Aug 04, 2015
AB		HIKMA	**250MG**	**A201172**	**001**	Apr 30, 2012
AB			**500MG**	**A201172**	**002**	Apr 30, 2012
AB		NOVEL LABS INC	**250MG**	**A202044**	**001**	Apr 30, 2012
AB			**500MG**	**A202044**	**002**	Apr 30, 2012
AB		UNIQUE PHARM LABS	**250MG**	**A202489**	**001**	Oct 09, 2013
AB			**500MG**	**A202489**	**002**	Oct 09, 2013

TIOPRONIN

TABLET;ORAL

THIOLA

AB	+!	MISSION PHARMA	**100MG**	**N019569**	**001**	Aug 11, 1988

TIOPRONIN

AB		TEVA PHARMS USA INC	**100MG**	**A214326**	**001**	Apr 26, 2021

TABLET, DELAYED RELEASE;ORAL

THIOLA EC

	+	MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019
	+!		300MG	N211843	002	Jun 28, 2019

TIOTROPIUM BROMIDE

POWDER;INHALATION

SPIRIVA

	+!	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004

SPRAY, METERED;INHALATION

SPIRIVA RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015
	+!		EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL

LONSURF

+	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015
+!		EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015

TIPRANAVIR

CAPSULE;ORAL

APTIVUS

+!	BOEHRINGER INGELHEIM	250MG	N021814	001	Jun 22, 2005

SOLUTION;ORAL

APTIVUS

+!	BOEHRINGER INGELHEIM	100MG/ML	N022292	001	Jun 23, 2008

TIRBANIBULIN

OINTMENT;TOPICAL

KLISYRI

+!	ALMIRALL	1%	N213189	001	Dec 14, 2020

TIROFIBAN HYDROCHLORIDE

SOLUTION;INJECTION

AGGRASTAT

+!	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016

SOLUTION;INTRAVENOUS

AGGRASTAT

AP	**+!**	MEDICURE	**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**	**N020913**	**003**	Apr 20, 2000

TIROFIBAN HYDROCHLORIDE

AP		GLAND PHARMA LTD	**EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)**	**A206888**	**001**	Apr 08, 2021

AGGRASTAT

+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002

TIVOZANIB HYDROCHLORIDE

CAPSULE;ORAL

FOTIVDA

+	AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021
+!		EQ 1.34MG BASE	N212904	002	Mar 10, 2021

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	**EQ 2MG BASE**	**A213223**	**001**	Jan 13, 2020
AB			**EQ 4MG BASE**	**A213223**	**002**	Jan 13, 2020
AB			**EQ 6MG BASE**	**A213223**	**003**	Jan 13, 2020
AB		ALKEM LABS LTD	**EQ 2MG BASE**	**A212196**	**001**	Mar 27, 2019
AB			**EQ 4MG BASE**	**A212196**	**002**	Mar 27, 2019
AB			**EQ 6MG BASE**	**A212196**	**003**	Mar 27, 2019
AB		APOTEX INC	**EQ 2MG BASE**	**A078868**	**001**	Feb 03, 2012
AB			**EQ 4MG BASE**	**A078868**	**002**	Feb 03, 2012
AB			**EQ 6MG BASE**	**A078868**	**003**	Feb 03, 2012
AB		AUROBINDO PHARMA LTD	**EQ 2MG BASE**	**A213544**	**001**	Mar 24, 2020
AB			**EQ 4MG BASE**	**A213544**	**002**	Mar 24, 2020
AB			**EQ 6MG BASE**	**A213544**	**003**	Mar 24, 2020
AB		CADILA PHARMS LTD	**EQ 2MG BASE**	**A210021**	**001**	Mar 26, 2019
AB			**EQ 4MG BASE**	**A210021**	**002**	Mar 26, 2019
AB			**EQ 6MG BASE**	**A210021**	**003**	Mar 26, 2019
AB		JUBILANT GENERICS	**EQ 2MG BASE**	**A209605**	**001**	Aug 04, 2017
AB			**EQ 4MG BASE**	**A209605**	**002**	Aug 04, 2017
AB			**EQ 6MG BASE**	**A209605**	**003**	Aug 04, 2017
AB		NOVAST LABS	**EQ 2MG BASE**	**A210267**	**001**	Mar 12, 2019
AB			**EQ 4MG BASE**	**A210267**	**002**	Mar 12, 2019
AB			**EQ 6MG BASE**	**A210267**	**003**	Mar 12, 2019
AB		RUBICON	**EQ 2MG BASE**	**A213798**	**001**	May 27, 2020
AB			**EQ 4MG BASE**	**A213798**	**002**	May 27, 2020
AB			**EQ 6MG BASE**	**A213798**	**003**	May 27, 2020
AB		ZYDUS PHARMS	**EQ 2MG BASE**	**A208622**	**001**	Mar 03, 2017
AB			**EQ 4MG BASE**	**A208622**	**002**	Mar 03, 2017
AB			**EQ 6MG BASE**	**A208622**	**003**	Mar 03, 2017

ZANAFLEX

AB	**+**	COVIS	**EQ 2MG BASE**	**N021447**	**001**	Aug 29, 2002
AB	**+**		**EQ 4MG BASE**	**N021447**	**002**	Aug 29, 2002
AB	**+!**		**EQ 6MG BASE**	**N021447**	**003**	Aug 29, 2002

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB		ALKEM LABS LTD	**EQ 2MG BASE**	**A211798**	**001**	Jan 25, 2019
AB			**EQ 4MG BASE**	**A211798**	**002**	Jan 25, 2019
AB		APOTEX	**EQ 2MG BASE**	**A076533**	**001**	Jan 16, 2004
AB			**EQ 4MG BASE**	**A076533**	**002**	Jan 16, 2004
AB		CADILA	**EQ 2MG BASE**	**A208187**	**001**	Mar 09, 2018
AB			**EQ 4MG BASE**	**A208187**	**002**	Mar 09, 2018
AB		CASI PHARMS INC	**EQ 2MG BASE**	**A076280**	**001**	Nov 26, 2002
AB			**EQ 4MG BASE**	**A076280**	**002**	Jun 27, 2002
AB		DR REDDYS LABS INC	**EQ 2MG BASE**	**A076286**	**001**	Jul 03, 2002
AB			**EQ 4MG BASE**	**A076286**	**002**	Jul 03, 2002
AB		EPIC PHARMA LLC	**EQ 2MG BASE**	**A076347**	**001**	Oct 11, 2002
AB			**EQ 4MG BASE**	**A076347**	**002**	Oct 11, 2002
AB		OXFORD PHARMS	**EQ 2MG BASE**	**A076281**	**001**	Oct 20, 2003
AB			**EQ 4MG BASE**	**A076281**	**002**	Oct 20, 2003
AB		SUN PHARM INDS INC	**EQ 2MG BASE**	**A076416**	**001**	Sep 29, 2003
AB			**EQ 4MG BASE**	**A076416**	**002**	Sep 29, 2003
AB		UNICHEM LABS LTD	**EQ 2MG BASE**	**A091283**	**001**	Nov 28, 2012
AB			**EQ 4MG BASE**	**A091283**	**002**	Nov 28, 2012

ZANAFLEX

AB	**+!**	COVIS	**EQ 4MG BASE**	**N020397**	**001**	Nov 27, 1996

TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBREX

	+!	NOVARTIS	0.3%	N050555	001	

POWDER;INHALATION

TOBI PODHALER

	+!	MYLAN SPECIALITY LP	28MG	N201688	001	Mar 22, 2013

SOLUTION;INHALATION

BETHKIS

AN	**+!**	CHIESI	**300MG/4ML**	**N201820**	**001**	Oct 12, 2012

KITABIS PAK

AN		PULMOFLOW INC	**300MG/5ML**	**N205433**	**001**	Dec 02, 2014

TOBI

AN	**+!**	MYLAN SPECIALITY LP	**300MG/5ML**	**N050753**	**001**	Dec 22, 1997

TOBRAMYCIN

AN		AKORN	**300MG/5ML**	**A201422**	**001**	May 28, 2014
AN		ALKEM LABS LTD	**300MG/5ML**	**A212848**	**001**	Apr 01, 2021
AN		AMNEAL PHARMS	**300MG/5ML**	**A205501**	**001**	Jul 13, 2015
AN		DR REDDYS LABS SA	**300MG/5ML**	**A207080**	**001**	Jul 09, 2018
AN		LUPIN	**300MG/5ML**	**A208964**	**001**	Mar 22, 2017
AN		SUN PHARM	**300MG/5ML**	**A207136**	**001**	Dec 26, 2019
AN		TEVA PHARMS USA	**300MG/5ML**	**A091589**	**001**	Oct 10, 2013
AN			**300MG/4ML**	**A210915**	**001**	Jun 26, 2019

SOLUTION/DROPS;OPHTHALMIC

AKTOB

AT		AKORN	**0.3%**	**A064096**	**001**	Jan 31, 1996

TOBRAMYCIN

AT		ALEMBIC PHARMS LTD	**0.3%**	**A211847**	**001**	Apr 19, 2019
AT		BAUSCH AND LOMB	**0.3%**	**A064052**	**001**	Nov 29, 1993
AT		FERA PHARMS	**0.3%**	**A065026**	**001**	Sep 11, 2001
AT		GLAND PHARMA LTD	**0.3%**	**A212628**	**001**	Mar 09, 2021
AT		SOMERSET THERAPS LLC	**0.3%**	**A207444**	**001**	Jun 28, 2017

TOBREX

AT	**+!**	NOVARTIS	**0.3%**	**N050541**	**001**	
AT		SANDOZ INC	**0.3%**	**A062535**	**001**	Dec 13, 1984

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP		AKORN	**EQ 40MG BASE/ML**	**A205179**	**001**	Sep 16, 2014
AP		BAXTER HLTHCARE CORP	**EQ 40MG BASE/ML**	**A206965**	**001**	Jul 01, 2016
AP		FRESENIUS KABI USA	**EQ 10MG BASE/ML**	**A065122**	**001**	Nov 29, 2002
AP	**!**		**EQ 40MG BASE/ML**	**A065122**	**002**	Nov 29, 2002
AP			**EQ 1.2GM BASE/VIAL**	**N050789**	**001**	Jul 13, 2004
AP		GLAND PHARMA LTD	**EQ 10MG BASE/ML**	**A209621**	**001**	Feb 11, 2021
AP			**EQ 40MG BASE/ML**	**A209621**	**002**	Feb 11, 2021
AP			**EQ 1.2GM BASE/VIAL**	**A211189**	**001**	May 18, 2021
AP		HIKMA	**EQ 40MG BASE/ML**	**A063117**	**001**	Apr 26, 1991

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

AP	**!**	HOSPIRA	**EQ 10MG BASE/ML**	**A063112**	**001**	Apr 30, 1991
AP			**EQ 40MG BASE/ML**	**A063111**	**001**	Apr 30, 1991
AP		MYLAN LABS LTD	**EQ 40MG BASE/ML**	**A065407**	**001**	Mar 11, 2008
AP		TEVA PHARMS USA	**EQ 40MG BASE/ML**	**A063100**	**001**	Jan 30, 1992
AP		XELLIA PHARMS APS	**EQ 1.2GM BASE/VIAL**	**A205685**	**001**	Sep 16, 2014
AP	**!**	XGEN PHARMS	**EQ 1.2GM BASE/VIAL**	**A065013**	**001**	Aug 17, 2001

TOBRAMYCIN SULFATE (PHARMACY BULK)

AP	**!**	FRESENIUS KABI USA	**EQ 40MG BASE/ML**	**A065120**	**001**	Nov 29, 2002
AP		GLAND PHARMA LTD	**EQ 40MG BASE/ML**	**A209346**	**001**	Feb 09, 2021

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	!	HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990
	!		EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
	!		EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990

TOFACITINIB CITRATE

SOLUTION;ORAL

XELJANZ

	+!	PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020

TABLET;ORAL

XELJANZ

	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012
	+!		EQ 10MG BASE	N203214	002	May 30, 2018

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB

AB		ZYDUS PHARMS	**EQ 11MG BASE**	**A214264**	**001**	Aug 19, 2021
AB			**EQ 22MG BASE**	**A214264**	**002**	Aug 19, 2021

XELJANZ XR

AB	**+**	PFIZER	**EQ 11MG BASE**	**N208246**	**001**	Feb 23, 2016
AB	**+!**		**EQ 22MG BASE**	**N208246**	**002**	Dec 12, 2019

TOLCAPONE

TABLET;ORAL

TASMAR

AB	**+!**	BAUSCH	**100MG**	**N020697**	**001**	Jan 29, 1998

TOLCAPONE

AB		NOVAST LABS	**100MG**	**A208937**	**001**	Aug 07, 2018
AB		PAR PHARM INC	**100MG**	**A204584**	**001**	Mar 26, 2015

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROL LA

AB	**+**	UPJOHN	**2MG**	**N021228**	**001**	Dec 22, 2000
AB	**+!**		**4MG**	**N021228**	**002**	Dec 22, 2000

TOLTERODINE TARTRATE

AB		AJANTA PHARMA LTD	**2MG**	**A213397**	**001**	May 19, 2020
AB			**4MG**	**A213397**	**002**	May 19, 2020
AB		AMTA	**2MG**	**A213858**	**001**	Feb 02, 2021
AB			**4MG**	**A213858**	**002**	Feb 02, 2021
AB		HETERO LABS LTD III	**2MG**	**A206419**	**001**	Dec 12, 2017
AB			**4MG**	**A206419**	**002**	Dec 12, 2017
AB		INVENTIA HLTHCARE	**2MG**	**A204562**	**001**	Aug 19, 2019
AB			**4MG**	**A204562**	**002**	Aug 19, 2019
AB		TEVA PHARMS USA	**2MG**	**A079141**	**001**	Nov 22, 2016
AB			**4MG**	**A079141**	**002**	Nov 22, 2016
AB		TORRENT	**2MG**	**A203016**	**001**	Aug 11, 2015
AB			**4MG**	**A203016**	**002**	Aug 11, 2015

TABLET;ORAL

DETROL

AB	**+**	UPJOHN	**1MG**	**N020771**	**001**	Mar 25, 1998
AB	**+!**		**2MG**	**N020771**	**002**	Mar 25, 1998

TOLTERODINE TARTRATE

AB		ATHEM	**1MG**	**A210775**	**001**	Dec 30, 2019
AB			**2MG**	**A210775**	**002**	Dec 30, 2019
AB		HETERO LABS LTD V	**1MG**	**A204397**	**001**	Aug 02, 2021
AB			**2MG**	**A204397**	**002**	Aug 02, 2021
AB		IVAX SUB TEVA PHARMS	**1MG**	**A077006**	**001**	Feb 23, 2015
AB			**2MG**	**A077006**	**002**	Feb 23, 2015
AB		MACLEODS PHARMS LTD	**1MG**	**A203409**	**001**	Aug 31, 2015
AB			**2MG**	**A203409**	**002**	Aug 31, 2015
AB		UNICHEM	**1MG**	**A205399**	**001**	Aug 05, 2020

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

AB			**2MG**	**A205399**	**002**	Aug 05, 2020
AB		UNIQUE PHARM LABS	**1MG**	**A204721**	**001**	Jan 24, 2020
AB			**2MG**	**A204721**	**002**	Jan 24, 2020

TOLVAPTAN

TABLET;ORAL

SAMSCA

AB	**+!**	OTSUKA	**30MG**	**N022275**	**002**	May 19, 2009

TOLVAPTAN

AB		ALKEM LABS LTD	**30MG**	**A211891**	**001**	May 19, 2020
AB		APOTEX	**30MG**	**A207605**	**001**	May 19, 2020
AB		HETERO LABS LTD V	**30MG**	**A205646**	**001**	Jul 16, 2021

JYNARQUE

+	OTSUKA	15MG	N204441	001	Apr 23, 2018
+		30MG	N204441	002	Apr 23, 2018
+!		45MG	N204441	003	Apr 23, 2018
+		60MG	N204441	004	Apr 23, 2018
+		90MG	N204441	005	Apr 23, 2018

SAMSCA

+	OTSUKA	15MG	N022275	001	May 19, 2009

TOLVAPTAN

	ALKEM LABS LTD	60MG	A211891	002	May 19, 2020

TOPIRAMATE

CAPSULE;ORAL

TOPAMAX

AB	**+**	JANSSEN PHARMS	**15MG**	**N020844**	**001**	Oct 26, 1998
AB	**+!**		**25MG**	**N020844**	**002**	Oct 26, 1998

TOPIRAMATE

AB		TEVA	**15MG**	**A076575**	**001**	Apr 17, 2009
AB			**25MG**	**A076575**	**002**	Apr 17, 2009
AB		WATSON LABS	**15MG**	**A077868**	**001**	Apr 15, 2009
AB			**25MG**	**A077868**	**002**	Apr 15, 2009
AB		ZYDUS PHARMS USA INC	**15MG**	**A078877**	**001**	Oct 14, 2009
AB			**25MG**	**A078877**	**002**	Oct 14, 2009

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

AB1		ZYDUS PHARMS	**25MG**	**A207382**	**001**	Nov 24, 2017
AB1			**50MG**	**A207382**	**002**	Nov 24, 2017
AB1			**100MG**	**A207382**	**003**	Nov 24, 2017

TROKENDI XR

AB1	**+**	SUPERNUS PHARMS	**25MG**	**N201635**	**001**	Aug 16, 2013
AB1	**+**		**50MG**	**N201635**	**002**	Aug 16, 2013
AB1	**+**		**100MG**	**N201635**	**003**	Aug 16, 2013

QUDEXY XR

AB2	**+**	UPSHER SMITH LABS	**25MG**	**N205122**	**001**	Mar 11, 2014
AB2	**+**		**50MG**	**N205122**	**002**	Mar 11, 2014
AB2	**+**		**100MG**	**N205122**	**003**	Mar 11, 2014
AB2	**+**		**150MG**	**N205122**	**004**	Mar 11, 2014
AB2	**+!**		**200MG**	**N205122**	**005**	Mar 11, 2014

TOPIRAMATE

AB2		GLENMARK PHARMS LTD	**25MG**	**A210278**	**001**	Feb 01, 2021
AB2			**50MG**	**A210278**	**002**	Feb 01, 2021
AB2			**100MG**	**A210278**	**003**	Feb 01, 2021
AB2			**150MG**	**A210278**	**004**	Feb 01, 2021
AB2			**200MG**	**A210278**	**005**	Feb 01, 2021

TROKENDI XR

BC	+!	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013

SOLUTION;ORAL

EPRONTIA

+!	AZURITY	25MG/ML	N214679	001	Nov 05, 2021

TABLET;ORAL

TOPAMAX

AB	**+**	JANSSEN PHARMS	**25MG**	**N020505**	**004**	Dec 24, 1996
AB	**+**		**50MG**	**N020505**	**005**	Dec 24, 1996
AB	**+!**		**100MG**	**N020505**	**001**	Dec 24, 1996
AB	**+**		**200MG**	**N020505**	**002**	Dec 24, 1996

TOPIRAMATE

AB		ACCORD HLTHCARE	**25MG**	**A076311**	**001**	Mar 27, 2009
AB			**50MG**	**A076311**	**002**	Mar 27, 2009

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

AB		**100MG**	**A076311**	**003**	Mar 27, 2009
AB		**200MG**	**A076311**	**004**	Mar 27, 2009
AB	ASCENT PHARMS INC	**25MG**	**A215414**	**001**	Aug 26, 2021
AB		**50MG**	**A215414**	**002**	Aug 26, 2021
AB		**100MG**	**A215414**	**003**	Aug 26, 2021
AB		**200MG**	**A215414**	**004**	Aug 26, 2021
AB	AUROBINDO PHARMA	**25MG**	**A078462**	**001**	Mar 27, 2009
AB		**50MG**	**A078462**	**002**	Mar 27, 2009
AB		**100MG**	**A078462**	**003**	Mar 27, 2009
AB		**200MG**	**A078462**	**004**	Mar 27, 2009
AB	CIPLA LTD	**25MG**	**A076343**	**001**	Mar 27, 2009
AB		**50MG**	**A076343**	**002**	Mar 27, 2009
AB		**100MG**	**A076343**	**003**	Mar 27, 2009
AB		**200MG**	**A076343**	**004**	Mar 27, 2009
AB	GLENMARK GENERICS	**25MG**	**A077627**	**001**	Mar 27, 2009
AB		**50MG**	**A077627**	**002**	Mar 27, 2009
AB		**100MG**	**A077627**	**003**	Mar 27, 2009
AB		**200MG**	**A077627**	**004**	Mar 27, 2009
AB	INVAGEN PHARMS	**25MG**	**A079162**	**001**	Mar 27, 2009
AB		**50MG**	**A079162**	**002**	Mar 27, 2009
AB		**100MG**	**A079162**	**003**	Mar 27, 2009
AB		**200MG**	**A079162**	**004**	Mar 27, 2009
AB	SUN PHARM	**25MG**	**A090278**	**001**	Mar 27, 2009
AB		**50MG**	**A090278**	**002**	Mar 27, 2009
AB		**100MG**	**A090278**	**003**	Mar 27, 2009
AB		**200MG**	**A090278**	**004**	Mar 27, 2009
AB	SUN PHARM INDS LTD	**25MG**	**A076327**	**001**	Mar 27, 2009
AB		**100MG**	**A076327**	**002**	Mar 27, 2009
AB		**200MG**	**A076327**	**003**	Mar 27, 2009
AB	TEVA	**25MG**	**A076317**	**001**	Mar 27, 2009
AB		**50MG**	**A076317**	**002**	Mar 27, 2009
AB		**100MG**	**A076317**	**003**	Mar 27, 2009
AB		**200MG**	**A076317**	**004**	Mar 27, 2009
AB	UNICHEM LABS LTD	**25MG**	**A090162**	**001**	Mar 27, 2009
AB		**50MG**	**A090162**	**002**	Mar 27, 2009
AB		**100MG**	**A090162**	**003**	Mar 27, 2009
AB		**200MG**	**A090162**	**004**	Feb 19, 2013
AB	UPSHER SMITH LABS	**25MG**	**A078499**	**001**	Jan 07, 2010
AB		**50MG**	**A078499**	**002**	Jan 07, 2010
AB		**100MG**	**A078499**	**003**	Jan 07, 2010
AB		**200MG**	**A078499**	**004**	Jan 07, 2010
AB	VIWIT PHARM	**25MG**	**A077733**	**001**	Mar 27, 2009
AB		**50MG**	**A077733**	**002**	Mar 27, 2009
AB		**100MG**	**A077733**	**003**	Mar 27, 2009
AB		**200MG**	**A077733**	**004**	Mar 27, 2009
AB	ZYDUS PHARMS USA INC	**25MG**	**A078235**	**001**	Mar 27, 2009
AB		**50MG**	**A078235**	**002**	Mar 27, 2009
AB		**100MG**	**A078235**	**003**	Mar 27, 2009
AB		**200MG**	**A078235**	**004**	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

+	NOVARTIS	EQ 0.25MG BASE	N020981	001	Oct 11, 2007
+!		EQ 1MG BASE	N020981	002	Oct 11, 2007

INJECTABLE;INJECTION

HYCAMTIN

AP	**+!** NOVARTIS	**EQ 4MG BASE/VIAL**	**N020671**	**001**	May 28, 1996

TOPOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	**EQ 4MG BASE/VIAL**	**A202351**	**001**	Jun 26, 2013
AP	ACTAVIS TOTOWA	**EQ 4MG BASE/VIAL**	**A090620**	**001**	Dec 02, 2010
AP	CIPLA	**EQ 4MG BASE/VIAL**	**A091199**	**001**	Dec 01, 2010
AP	DR REDDYS LABS LTD	**EQ 4MG BASE/VIAL**	**A201191**	**001**	Mar 09, 2011
AP	FRESENIUS KABI USA	**EQ 4MG BASE/VIAL**	**A091089**	**001**	Nov 29, 2010
AP	NOVAST LABS	**EQ 4MG BASE/VIAL**	**A206962**	**001**	Nov 30, 2016
AP	SAGENT PHARMS	**EQ 4MG BASE/VIAL**	**A091284**	**001**	Jan 26, 2011

SOLUTION;INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

AP	ACCORD HLTHCARE	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A204406**	**002**	Jul 06, 2017

TOPOTECAN HYDROCHLORIDE						
SOLUTION;INTRAVENOUS						
TOPOTECAN HYDROCHLORIDE						
AP	**+!**	HOSPIRA INC	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N200582**	**001**	Feb 02, 2011
AP		MYLAN LABS LTD	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**A206074**	**001**	Nov 24, 2017
AP		TEVA PHARMS USA	**EQ 4MG BASE/4ML (EQ 1MG BASE/ML)**	**N022453**	**001**	Dec 20, 2012
		ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017
TOREMIFENE CITRATE						
TABLET;ORAL						
FARESTON						
AB	**+!**	KYOWA KIRIN	**EQ 60MG BASE**	**N020497**	**001**	May 29, 1997
TOREMIFENE CITRATE						
AB		MSN	**EQ 60MG BASE**	**A212818**	**001**	Aug 18, 2020
AB		RISING	**EQ 60MG BASE**	**A208813**	**001**	Dec 04, 2018
TORSEMIDE						
TABLET;ORAL						
TORSEMIDE						
AB		AURO BINDO PHARMA	**5MG**	**A078249**	**001**	Oct 17, 2007
AB			**10MG**	**A078249**	**002**	Oct 17, 2007
AB			**20MG**	**A078249**	**003**	Oct 17, 2007
AB			**100MG**	**A078249**	**004**	Oct 17, 2007
AB		COREPHARMA	**5MG**	**A076894**	**001**	May 31, 2005
AB			**10MG**	**A076894**	**002**	May 31, 2005
AB			**20MG**	**A076894**	**003**	May 31, 2005
AB			**100MG**	**A076894**	**004**	May 31, 2005
AB		HETERO LABS LTD III	**5MG**	**A079234**	**001**	Jan 27, 2009
AB			**10MG**	**A079234**	**002**	Jan 27, 2009
AB			**20MG**	**A079234**	**003**	Jan 27, 2009
AB			**100MG**	**A079234**	**004**	Jan 27, 2009
AB		HIKMA	**5MG**	**A076943**	**001**	Mar 01, 2005
AB			**10MG**	**A076943**	**002**	Mar 01, 2005
AB			**20MG**	**A076943**	**003**	Mar 01, 2005
AB		PLIVA PHARM IND	**5MG**	**A076346**	**001**	May 30, 2003
AB			**10MG**	**A076346**	**002**	May 30, 2003
AB	**!**		**20MG**	**A076346**	**003**	May 30, 2003
AB			**100MG**	**A076346**	**004**	Oct 19, 2004
AB		STRIDES PHARMA	**5MG**	**A076226**	**001**	May 27, 2003
AB			**5MG**	**A090613**	**001**	Mar 22, 2011
AB			**10MG**	**A076226**	**002**	May 27, 2003
AB			**10MG**	**A090613**	**002**	Mar 22, 2011
AB			**20MG**	**A076226**	**003**	May 27, 2003
AB			**20MG**	**A090613**	**003**	Mar 22, 2011
AB			**100MG**	**A076226**	**004**	May 27, 2003
AB			**100MG**	**A090613**	**004**	Mar 22, 2011
AB		TEVA	**5MG**	**A076110**	**001**	May 14, 2002
AB			**10MG**	**A076110**	**002**	May 14, 2002
AB			**20MG**	**A076110**	**003**	May 14, 2002
AB			**100MG**	**A076110**	**004**	May 14, 2002
SOAANZ						
	+!	SARFE PHARMS	20MG	N213218	001	Jun 14, 2021
	+		40MG	N213218	003	Nov 17, 2021
	+		60MG	N213218	002	Jun 14, 2021
TRABECTEDIN						
POWDER;INTRAVENOUS						
YONDELIS						
	+!	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015
TRAMADOL HYDROCHLORIDE						
CAPSULE, EXTENDED RELEASE;ORAL						
CONZIP						
	+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
	+		200MG	N022370	002	May 07, 2010
	+		300MG	N022370	003	May 07, 2010
SOLUTION;ORAL						
QDOLO						
	+!	ATHENA	5MG/ML	N214044	001	Sep 01, 2020
TABLET;ORAL						
TRAMADOL HYDROCHLORIDE						
AB		ACI	**50MG**	**A202075**	**001**	Nov 28, 2011
AB		AMNEAL PHARMS	**50MG**	**A076003**	**001**	Jun 20, 2002
AB		APOTEX	**50MG**	**A075981**	**001**	Jul 10, 2002

TRAMADOL HYDROCHLORIDE							
TABLET;ORAL							
TRAMADOL HYDROCHLORIDE							
AB		AUROBINDO PHARMA LTD	**50MG**	**A203494**	**001**	Mar 31, 2014
AB		CSPC OUYI PHARM CO	**50MG**	**A091498**	**001**	Mar 29, 2013
AB		IPCA LABS LTD	**50MG**	**A201973**	**001**	Nov 16, 2012
AB		MERRO PHARM USA	**50MG**	**A206706**	**001**	Jul 02, 2019
AB		MYLAN	**50MG**	**A075986**	**001**	Jun 21, 2002
AB		PLIVA	**50MG**	**A075982**	**001**	Jul 01, 2002
AB		RUBICON	**50MG**	**A208708**	**001**	Jun 28, 2019
AB			**100MG**	**A208708**	**002**	Jun 28, 2019
AB		SUN PHARM INDS INC	**50MG**	**A075964**	**001**	Jun 19, 2002
AB		TEVA	**50MG**	**A075977**	**001**	Jun 19, 2002
AB		UNICHEM	**50MG**	**A211825**	**001**	Aug 09, 2019
AB		ZYDUS PHARMS USA INC	**50MG**	**A090404**	**001**	Jan 31, 2011
ULTRAM							
AB	**+!**	JANSSEN PHARMS	**50MG**	**N020281**	**002**	Mar 03, 1995
TABLET, EXTENDED RELEASE;ORAL							
TRAMADOL HYDROCHLORIDE							
AB1	**!**	LUPIN LTD	**100MG**	**A200503**	**001**	Aug 29, 2011
AB1			**200MG**	**A200503**	**002**	Aug 29, 2011
AB1			**300MG**	**A200503**	**003**	Aug 29, 2011
AB1		MYLAN	**100MG**	**A205257**	**001**	Dec 22, 2015
AB1			**200MG**	**A205257**	**002**	Dec 22, 2015
AB1			**300MG**	**A205257**	**003**	Dec 22, 2015
AB1		SUN PHARM	**100MG**	**A201384**	**001**	Dec 07, 2011
AB1			**200MG**	**A201384**	**002**	Dec 07, 2011
AB1			**300MG**	**A201384**	**003**	Dec 07, 2011
AB2		ACTAVIS ELIZABETH	**100MG**	**A091609**	**001**	Jun 27, 2012
AB2			**200MG**	**A091609**	**002**	Jun 27, 2012
AB2			**300MG**	**A091609**	**003**	Jun 27, 2012
AB2	**!**	SUN PHARM	**100MG**	**A091607**	**001**	Dec 30, 2011
AB2			**200MG**	**A091607**	**002**	Dec 30, 2011
AB2			**300MG**	**A091607**	**003**	Dec 30, 2011
TRAMETINIB DIMETHYL SULFOXIDE							
TABLET;ORAL							
MEKINIST							
	+	NOVARTIS	EQ 0.5MG	N204114	001	May 29, 2013
	+!		EQ 2MG	N204114	003	May 29, 2013
TRANDOLAPRIL							
TABLET;ORAL							
TRANDOLAPRIL							
AB		AUROBINDO PHARMA	**1MG**	**A078438**	**001**	Jun 12, 2007
AB			**2MG**	**A078438**	**002**	Jun 12, 2007
AB			**4MG**	**A078438**	**003**	Jun 12, 2007
AB		EPIC PHARMA	**1MG**	**A078508**	**003**	Jun 18, 2008
AB			**2MG**	**A078508**	**001**	Jun 18, 2008
AB			**4MG**	**A078508**	**002**	Jun 18, 2008
AB		LUPIN	**1MG**	**A077522**	**001**	Jun 12, 2007
AB			**2MG**	**A077522**	**002**	Jun 12, 2007
AB	**!**		**4MG**	**A077522**	**003**	Jun 12, 2007
AB		TEVA PHARMS	**1MG**	**A077489**	**001**	Dec 12, 2006
AB			**2MG**	**A077489**	**002**	Dec 12, 2006
AB			**4MG**	**A077489**	**003**	Dec 12, 2006
TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE							
TABLET, EXTENDED RELEASE;ORAL							
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE							
		GLENMARK GENERICS	1MG;240MG	A079135	004	Aug 30, 2010
			2MG;180MG	A079135	001	May 26, 2010
			2MG;240MG	A079135	002	May 26, 2010
	!		4MG;240MG	A079135	003	May 05, 2010
TRANEXAMIC ACID							
INJECTABLE;INJECTION							
CYKLOKAPRON							
AP	**+!**	PFIZER	**100MG/ML**	**N019281**	**001**	Dec 30, 1986
TRANEXAMIC ACID							
AP		ACIC PHARMS	**100MG/ML**	**A202436**	**001**	Feb 11, 2014
AP		AKORN	**100MG/ML**	**A202373**	**001**	Nov 17, 2011
AP			**100MG/ML**	**A206594**	**001**	Sep 28, 2017

TRANEXAMIC ACID							
INJECTABLE;INJECTION							
TRANEXAMIC ACID							
AP			**100MG/ML**	**A206634**	**001**	Jun 09, 2016
AP		AM REGENT	**100MG/ML**	**A201885**	**001**	Aug 10, 2011
AP		AMNEAL PHARMS CO	**100MG/ML**	**A208840**	**001**	Feb 28, 2017
AP		APOTEX	**100MG/ML**	**A209860**	**001**	Jan 14, 2020
AP		CAPLIN	**100MG/ML**	**A212360**	**001**	Jul 17, 2019
AP		EMCURE PHARMS LTD	**100MG/ML**	**A203521**	**001**	Aug 12, 2014
AP		EUGIA PHARMA	**100MG/ML**	**A205035**	**001**	Jan 14, 2016
AP		FRESENIUS KABI USA	**100MG/ML**	**A091596**	**001**	Mar 02, 2012
AP		GLAND	**100MG/ML**	**A207239**	**001**	Feb 13, 2017
AP		MICRO LABS	**100MG/ML**	**A206713**	**001**	Jun 27, 2017
AP		MYLAN INSTITUTIONAL	**100MG/ML**	**A091657**	**001**	Nov 03, 2011
AP		PROVEPHARM SAS	**100MG/ML**	**A212676**	**001**	Jul 17, 2019
AP		XGEN PHARMS	**100MG/ML**	**A201580**	**001**	Jun 14, 2013
SOLUTION;INTRAVENOUS							
TRANEXAMIC ACID							
	+!	EXELA PHARMA	1GM/100ML (10MG/ML)	N212020	001	Apr 15, 2019
TABLET;ORAL							
LYSTEDA							
AB	**+!**	AMRING PHARMS	**650MG**	**N022430**	**001**	Nov 13, 2009
TRANEXAMIC ACID							
AB		ACTAVIS LABS FL INC	**650MG**	**A202093**	**001**	Dec 27, 2012
AB		ANI PHARMS	**650MG**	**A203256**	**001**	Jul 25, 2016
TRANYLCYPROMINE SULFATE							
TABLET;ORAL							
PARNATE							
AB	**+!**	CONCORDIA	**EQ 10MG BASE**	**N012342**	**003**	Aug 16, 1985
TRANYLCYPROMINE SULFATE							
AB		NOVITIUM PHARMA	**EQ 10MG BASE**	**A206856**	**001**	Apr 17, 2018
AB		STRIDES PHARMA	**EQ 10MG BASE**	**A040640**	**001**	Jun 29, 2006
TRAVOPROST							
SOLUTION/DROPS;OPHTHALMIC							
TRAVATAN Z							
AT	**+!**	NOVARTIS	**0.004%**	**N021994**	**001**	Sep 21, 2006
TRAVOPROST							
AT		APOTEX	**0.004%**	**A203431**	**001**	Jul 10, 2015
AT		MICRO LABS	**0.004%**	**A203767**	**001**	Mar 19, 2021
AT		MYLAN	**0.004%**	**A205050**	**001**	Jul 07, 2017
AT1		ALEMBIC PHARMS LTD	**0.004%**	**A210458**	**001**	Dec 20, 2019
AT1	**!**	STRIDES PHARMA	**0.004%**	**A091340**	**001**	Mar 01, 2013
TRAZODONE HYDROCHLORIDE							
TABLET;ORAL							
TRAZODONE HYDROCHLORIDE							
AB		ACCORD HLTHCARE	**50MG**	**A206923**	**001**	Sep 08, 2017
AB			**100MG**	**A206923**	**002**	Sep 08, 2017
AB			**150MG**	**A206923**	**003**	Sep 08, 2017
AB			**300MG**	**A206923**	**004**	Sep 08, 2017
AB		APOTEX	**50MG**	**A071258**	**001**	Mar 25, 1987
AB	**!**	APOTEX INC	**100MG**	**A071196**	**001**	Mar 25, 1987
AB			**150MG**	**A071196**	**002**	Apr 26, 1999
AB			**300MG**	**A071196**	**003**	Apr 26, 1999
AB		AUROLIFE PHARMA LLC	**50MG**	**A204852**	**001**	Feb 05, 2020
AB			**100MG**	**A204852**	**002**	Feb 05, 2020
AB			**150MG**	**A204852**	**003**	Feb 05, 2020
AB			**300MG**	**A204852**	**004**	Feb 05, 2020
AB		OXFORD PHARMS	**50MG**	**A072192**	**001**	Feb 02, 1989
AB			**100MG**	**A072193**	**001**	Feb 02, 1989
AB		PLIVA	**150MG**	**A071525**	**001**	Mar 09, 1988
AB		SUN PHARM INDUSTRIES	**50MG**	**A073137**	**002**	Mar 24, 1993
AB			**100MG**	**A073137**	**001**	Mar 24, 1993
AB			**150MG**	**A073137**	**003**	Dec 22, 1995
AB		TEVA PHARMS USA	**50MG**	**A071523**	**001**	Dec 11, 1987
AB			**100MG**	**A071524**	**001**	Dec 11, 1987
AB		TORRENT	**50MG**	**A202180**	**001**	Nov 27, 2013
AB			**100MG**	**A202180**	**002**	Nov 27, 2013
AB			**150MG**	**A202180**	**003**	Nov 27, 2013
AB			**300MG**	**A202180**	**004**	Nov 27, 2013
AB		ZYDUS PHARMS	**50MG**	**A205253**	**001**	Oct 10, 2017

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

AB			**100MG**	**A205253**	**002**	Oct 10, 2017
AB			**150MG**	**A205253**	**003**	Oct 10, 2017
AB			**300MG**	**A205253**	**004**	Oct 10, 2017

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

AP	**+!**	UNITED THERAP	**1MG/ML**	**N021272**	**001**	May 21, 2002
AP	**+!**		**2.5MG/ML**	**N021272**	**002**	May 21, 2002
AP	**+!**		**5MG/ML**	**N021272**	**003**	May 21, 2002
AP	**+!**		**10MG/ML**	**N021272**	**004**	May 21, 2002

TREPROSTINIL

AP		ALEMBIC GLOBAL	**1MG/ML**	**A211574**	**001**	Feb 11, 2021
AP			**2.5MG/ML**	**A211574**	**002**	Feb 11, 2021
AP			**5MG/ML**	**A211574**	**003**	Feb 11, 2021
AP			**10MG/ML**	**A211574**	**004**	Feb 11, 2021
AP		PAR STERILE PRODUCTS	**1MG/ML**	**A209382**	**001**	Sep 24, 2019
AP			**2.5MG/ML**	**A209382**	**002**	Sep 24, 2019
AP			**5MG/ML**	**A209382**	**003**	Sep 24, 2019
AP			**10MG/ML**	**A209382**	**004**	Sep 24, 2019
AP		SANDOZ INC	**1MG/ML**	**A203649**	**001**	Nov 30, 2017
AP			**2.5MG/ML**	**A203649**	**002**	Nov 30, 2017
AP			**5MG/ML**	**A203649**	**003**	Nov 30, 2017
AP			**10MG/ML**	**A203649**	**004**	Nov 30, 2017
AP		TEVA PHARMS USA	**1MG/ML**	**A206648**	**001**	Sep 26, 2019
AP			**2.5MG/ML**	**A206648**	**002**	Sep 26, 2019
AP			**5MG/ML**	**A206648**	**003**	Sep 26, 2019
AP			**10MG/ML**	**A206648**	**004**	Sep 26, 2019

REMODULIN

	+!	UNITED THERAP	20MG/ML	N021272	005	Jul 30, 2021

SOLUTION;INHALATION

TYVASO

	+!	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

	+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
	+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
	+!		EQ 1MG BASE	N203496	003	Dec 20, 2013
	+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
	+		EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE;ORAL

TRETINOIN

AB		ANCHEN PHARMS	**10MG**	**A201687**	**001**	Oct 24, 2012
AB	**!**	BARR LABS INC	**10MG**	**A077684**	**001**	Jun 22, 2007
AB		GLENMARK PHARMS LTD	**10MG**	**A208279**	**001**	Dec 23, 2016

CREAM;TOPICAL

AVITA

AB		MYLAN PHARMS INC	**0.025%**	**N020404**	**003**	Jan 14, 1997

RETIN-A

AB	**+!**	VALEANT BERMUDA	**0.025%**	**N019049**	**001**	Sep 16, 1988
AB	**+!**	VALEANT PHARMS NORTH	**0.1%**	**N017340**	**001**	

TRETINOIN

AB		PADAGIS US	**0.025%**	**A075264**	**001**	Dec 24, 1998
AB			**0.1%**	**A075213**	**001**	Dec 24, 1998
AB		TARO PHARMS	**0.1%**	**A211645**	**001**	Jan 22, 2019

RETIN-A

AB1	**+!**	VALEANT BERMUDA	**0.05%**	**N017522**	**001**	

TRETINOIN

AB1		PADAGIS US	**0.05%**	**A075265**	**001**	Dec 24, 1998
AB1		TARO PHARMS	**0.05%**	**A211644**	**001**	Jan 25, 2019

RENOVA

	+!	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000

TRETINOIN							
GEL;TOPICAL							
ATRALIN							
AB	**+!**	DOW PHARM	**0.05%**	**N022070**	**001**	Jul 26, 2007
RETIN-A							
AB	**+!**	VALEANT INTL	**0.01%**	**N017955**	**001**	
AB	**+!**		**0.025%**	**N017579**	**002**	
TRETINOIN							
AB		MYLAN	**0.05%**	**A207955**	**001**	Aug 13, 2015
AB		PADAGIS US	**0.01%**	**A075589**	**001**	Jun 11, 2002
AB			**0.025%**	**A075529**	**001**	Feb 22, 2000
AVITA							
BT		MYLAN	0.025%	N020400	001	Jan 29, 1998
RETIN-A MICRO							
	+!	VALEANT INTL	0.04%	N020475	002	May 10, 2002
	+!		0.1%	N020475	001	Feb 07, 1997
RETIN-A-MICRO							
	+!	VALEANT INTL	0.06%	N020475	004	Oct 23, 2017
	+!		0.08%	N020475	003	Jan 28, 2014
LOTION;TOPICAL							
ALTRENO							
	+!	DOW PHARM	0.05%	N209353	001	Aug 23, 2018
TRIAMCINOLONE ACETONIDE							
CREAM;TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		ALKEM LABS LTD	**0.025%**	**A207651**	**001**	Dec 26, 2017
AT			**0.1%**	**A207651**	**002**	Dec 26, 2017
AT			**0.5%**	**A207651**	**003**	Dec 26, 2017
AT		COSETTE	**0.025%**	**A089797**	**001**	May 31, 1991
AT			**0.1%**	**A089798**	**001**	May 31, 1991
AT	**+!**	FOUGERA PHARMS	**0.025%**	**A085692**	**001**	
AT	**+!**		**0.1%**	**A085692**	**003**	
AT	**+!**		**0.5%**	**A085692**	**002**	
AT		GLENMARK PHARMS LTD	**0.1%**	**A207117**	**001**	Aug 05, 2016
AT		LUPIN	**0.025%**	**A208763**	**001**	Feb 01, 2017
AT			**0.1%**	**A208763**	**002**	Feb 01, 2017
AT			**0.5%**	**A208763**	**003**	Feb 01, 2017
AT		MACLEODS PHARMS LTD	**0.025%**	**A209535**	**001**	May 18, 2018
AT			**0.1%**	**A209535**	**002**	May 18, 2018
AT			**0.5%**	**A209535**	**003**	May 18, 2018
AT		MICRO LABS	**0.025%**	**A040671**	**001**	Jun 09, 2006
AT			**0.1%**	**A040671**	**002**	Jun 09, 2006
AT		PADAGIS US	**0.025%**	**A086413**	**002**	
AT			**0.1%**	**A086413**	**003**	
AT			**0.5%**	**A086413**	**001**	
AT		STRIDES PHARMA	**0.025%**	**A210346**	**001**	Feb 11, 2019
AT			**0.1%**	**A210346**	**002**	Feb 11, 2019
AT			**0.5%**	**A210346**	**003**	Feb 11, 2019
AT		TARO PHARM INDS LTD	**0.1%**	**A040039**	**001**	Nov 26, 1997
AT		TELIGENT	**0.1%**	**A208848**	**001**	Sep 18, 2017
TRIDERM							
AT		CROWN LABS	**0.025%**	**A088042**	**002**	Mar 25, 2015
AT			**0.1%**	**A088042**	**001**	Mar 19, 1984
AT			**0.5%**	**A088042**	**003**	Mar 25, 2015
FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR							
ZILRETTA							
	+!	FLEXION THERAPS INC	32MG/VIAL	N208845	001	Oct 06, 2017
INJECTABLE;INJECTION							
KENALOG-40							
AB	**+!**	APOTHECON	**40MG/ML**	**N014901**	**001**	
TRIAMCINOLONE ACETONIDE							
AB		TEVA PHARMS USA	**40MG/ML**	**A209852**	**001**	Oct 05, 2018
BX		AMNEAL	40MG/ML	A207550	001	Dec 11, 2017
KENALOG-10							
	+	APOTHECON	10MG/ML	N012041	001	
KENALOG-80							
	+!	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019
INJECTABLE;INTRAVITREAL							
TRIESENCE							
	+!	NOVARTIS	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007

TRIAMCINOLONE ACETONIDE

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.025%**	**A202374**	**001**	May 08, 2013
AT			**0.1%**	**A202374**	**002**	May 08, 2013
AT		COSETTE	**0.1%**	**A089129**	**001**	Aug 14, 1986
AT		FOUGERA PHARMS	**0.025%**	**A040467**	**001**	Apr 21, 2003
AT			**0.1%**	**A040467**	**002**	Apr 21, 2003
AT		MICRO LABS	**0.1%**	**A040672**	**002**	Dec 13, 2006
AT		QUAGEN	**0.025%**	**A213559**	**001**	Jul 01, 2020
AT			**0.1%**	**A213559**	**002**	Jul 01, 2020
AT		TELIGENT	**0.025%**	**A204608**	**001**	Jul 07, 2016
AT			**0.1%**	**A204606**	**001**	Jul 07, 2016
AT	**!**	WOCKHARDT BIO AG	**0.025%**	**A088450**	**001**	Apr 01, 1985
AT	**!**		**0.1%**	**A088451**	**001**	Apr 03, 1985

OINTMENT;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		CINTEX SVCS	**0.05%**	**A213619**	**001**	Nov 10, 2020
AT		COSETTE	**0.025%**	**A089795**	**001**	Dec 23, 1988
AT			**0.1%**	**A089796**	**001**	Dec 23, 1988
AT			**0.5%**	**A208925**	**001**	Oct 06, 2017
AT		ENCUBE	**0.05%**	**A212384**	**001**	Nov 29, 2019
AT		FOUGERA PHARMS	**0.025%**	**A085691**	**001**	
AT			**0.1%**	**A085691**	**003**	
AT			**0.5%**	**A085691**	**002**	
AT		GLENMARK PHARMS	**0.1%**	**A208320**	**001**	Aug 22, 2017
AT		GLENMARK PHARMS LTD	**0.5%**	**A206379**	**001**	Jul 22, 2016
AT		MACLEODS PHARMS LTD	**0.025%**	**A209828**	**001**	Nov 23, 2018
AT			**0.1%**	**A209828**	**002**	Nov 23, 2018
AT			**0.5%**	**A209828**	**003**	Nov 23, 2018
AT		NOVEL LABS INC	**0.1%**	**A207365**	**001**	Oct 12, 2018
AT		PADAGIS ISRAEL	**0.05%**	**A212460**	**001**	Feb 05, 2021
AT	**+!**	PADAGIS US	**0.025%**	**A087385**	**002**	
AT	**+!**		**0.1%**	**A087385**	**003**	
AT	**+!**		**0.5%**	**A087385**	**001**	
AT		STRIDES PHARMA	**0.05%**	**A212356**	**001**	Jun 01, 2020
AT		TARO PHARM INDS LTD	**0.1%**	**A040037**	**001**	Sep 30, 1994
AT		TELIGENT	**0.1%**	**A205373**	**001**	May 13, 2016
AT			**0.5%**	**A208590**	**001**	Mar 03, 2017

TRIANEX

AT	**!**	CMP PHARMA INC	**0.05%**	**A089595**	**001**	Mar 23, 1995

PASTE;DENTAL

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.1%**	**A206312**	**001**	Aug 11, 2016
AT		COSETTE	**0.1%**	**A205592**	**001**	Jan 12, 2017
AT		LYNE	**0.1%**	**A040771**	**001**	Jul 01, 2010
AT	**!**	TARO	**0.1%**	**A070730**	**001**	Oct 01, 1986

SPRAY;TOPICAL

KENALOG

AT	**+!**	SUN PHARM INDS INC	**0.147MG/GM**	**N012104**	**001**	

TRIAMCINOLONE ACETONIDE

AT		AKORN	**0.147MG/GM**	**A207094**	**001**	Dec 07, 2016
AT		PADAGIS ISRAEL	**0.147MG/GM**	**A205782**	**001**	Apr 13, 2015
AT		RISING	**0.147MG/GM**	**A206786**	**001**	Sep 08, 2017

SPRAY, METERED;NASAL

NASACORT AQ

AB	**+**	SANOFI AVENTIS US	**0.055MG/SPRAY**	**N020468**	**001**	May 20, 1996

SUSPENSION;INJECTION

XIPERE

	+!	BAUSCH AND LOMB INC	40MG/ML	N211950	001	Oct 22, 2021

TRIAMCINOLONE HEXACETONIDE

INJECTABLE;INJECTION

ARISTOSPAN

	+!	SANDOZ INC	5MG/ML	N016466	001	
	+!		20MG/ML	N016466	002	

TRIAMTERENE							
CAPSULE;ORAL							
DYRENIUM							
AB	**+**	CONCORDIA	**50MG**	**N013174**	**001**		
AB	**+!**		**100MG**	**N013174**	**002**		
TRIAMTERENE							
AB		AGNITIO	**50MG**	**A211581**	**001**	Aug 19, 2019	
AB			**100MG**	**A211581**	**002**	Aug 19, 2019	
TRIAZOLAM							
TABLET;ORAL							
HALCION							
AB	**+**	PFIZER	**0.125MG**	**N017892**	**003**	Apr 26, 1985	
AB	**+!**		**0.25MG**	**N017892**	**001**	Nov 15, 1982	
TRIAZOLAM							
AB		HIKMA	**0.125MG**	**A074224**	**001**	Jun 01, 1994	
AB			**0.25MG**	**A074224**	**002**	Jun 01, 1994	
AB		NOVAST LABS	**0.125MG**	**A214219**	**001**	Oct 20, 2020	
AB			**0.25MG**	**A214219**	**002**	Oct 20, 2020	
TRICLABENDAZOLE							
TABLET;ORAL							
EGATEN							
	+!	NOVARTIS	250MG	N208711	001	Feb 13, 2019	
TRIENTINE HYDROCHLORIDE							
CAPSULE;ORAL							
SYPRINE							
AB	**+!**	BAUSCH	**250MG**	**N019194**	**001**	Nov 08, 1985	
TRIENTINE HYDROCHLORIDE							
AB		ACCORD HLTHCARE	**250MG**	**A212929**	**001**	Aug 30, 2021	
AB		DR REDDYS LABS LTD	**250MG**	**A211076**	**001**	Jul 03, 2019	
AB		LUPIN LTD	**250MG**	**A211637**	**001**	May 21, 2020	
AB		NAVINTA LLC	**250MG**	**A211251**	**001**	Jan 16, 2019	
AB		PAR PHARM INC	**250MG**	**A210096**	**001**	Sep 25, 2019	
AB		PHARMA LIFE	**250MG**	**A209945**	**001**	Aug 13, 2021	
AB		RISING	**250MG**	**A212238**	**001**	Feb 20, 2020	
AB		WATSON LABS TEVA	**250MG**	**A207567**	**001**	Feb 07, 2018	
AB		ZYDUS PHARMS	**250MG**	**A211554**	**001**	Apr 26, 2019	
BX		MSN	250MG	A211134	001	May 22, 2019	
TRIFAROTENE							
CREAM;TOPICAL							
AKLIEF							
	+!	GALDERMA LABS LP	0.005%	N211527	001	Oct 04, 2019	
TRIFLUOPERAZINE HYDROCHLORIDE							
TABLET;ORAL							
TRIFLUOPERAZINE HYDROCHLORIDE							
AB		MYLAN	**EQ 1MG BASE**	**A040209**	**001**	Jul 07, 1997	
AB			**EQ 2MG BASE**	**A040209**	**002**	Jul 07, 1997	
AB			**EQ 5MG BASE**	**A040209**	**003**	Jul 07, 1997	
AB	**!**		**EQ 10MG BASE**	**A040209**	**004**	Jul 07, 1997	
AB		SANDOZ	**EQ 1MG BASE**	**A085785**	**001**		
AB			**EQ 2MG BASE**	**A085786**	**001**		
AB			**EQ 5MG BASE**	**A085789**	**001**		
AB			**EQ 10MG BASE**	**A085788**	**001**		
TRIFLURIDINE							
SOLUTION/DROPS;OPHTHALMIC							
TRIFLURIDINE							
AT		AKORN	**1%**	**A205438**	**001**	Jul 28, 2017	
AT		SANDOZ INC	**1%**	**A074311**	**001**	Oct 06, 1995	
VIROPTIC							
AT	**+!**	MONARCH PHARMS	**1%**	**N018299**	**001**		
TRIHEPTANOIN							
LIQUID;ORAL							
DOJOLVI							
	+!	ULTRAGENYX PHARM INC	100% w/w	N213687	001	Jun 30, 2020	

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		MIKART	**2MG/5ML**	**A040251**	**001**	Sep 27, 1999
AA	**!**	PHARM ASSOC	**2MG/5ML**	**A040177**	**001**	Apr 17, 1997

TABLET;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

AA		NATCO PHARMA LTD	**2MG**	**A091630**	**001**	Nov 17, 2010
AA			**5MG**	**A091630**	**002**	Nov 17, 2010
AA		NOVITIUM PHARMA	**2MG**	**A040254**	**001**	Dec 24, 1998
AA			**5MG**	**A040254**	**002**	Dec 24, 1998
AA	**!**	WATSON LABS	**2MG**	**A084363**	**001**	
AA	**!**		**5MG**	**A084364**	**001**	

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS

COSELA

	+!	G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB		LUPIN	**300MG**	**A076546**	**001**	Aug 20, 2003
AB	**!**	SUN PHARM INDUSTRIES	**300MG**	**A076570**	**001**	Aug 28, 2003

INJECTABLE;INJECTION

TIGAN

	+!	PAR STERILE PRODUCTS	100MG/ML	N017530	001	

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

AB	**+!**	MAYNE PHARMA	**100MG**	**N018679**	**001**	Jul 30, 1982
AB		NOVEL LABS INC	**100MG**	**A091437**	**001**	Jun 15, 2011
AB		WATSON LABS	**100MG**	**A070049**	**001**	Jun 06, 1985

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB		CROSSMEDIKA SA	**EQ 25MG BASE**	**A208127**	**001**	Apr 15, 2016
AB	**!**		**EQ 50MG BASE**	**A208127**	**002**	Apr 15, 2016
AB			**EQ 100MG BASE**	**A208127**	**003**	Apr 15, 2016
AB		ELITE LABS INC	**EQ 25MG BASE**	**A077361**	**001**	Aug 02, 2006
AB			**EQ 50MG BASE**	**A077361**	**002**	Aug 02, 2006
AB			**EQ 100MG BASE**	**A077361**	**003**	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

	+!	ARBOR PHARMS LLC	EQ 22.5MG BASE/VIAL	N208956	001	Jun 29, 2017

INJECTABLE;INTRAMUSCULAR

TRELSTAR

	+!	VERITY	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
	+!		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001
	+!		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010

TROMETHAMINE

SOLUTION;INJECTION

THAM

	+!	HOSPIRA	18GM/500ML (3.6GM/100ML)	N013025	002	

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

AT	**+!**	ALCON LABS INC	**1%**	**A084306**	**001**	
AT	**+!**	SANDOZ INC	**0.5%**	**A084305**	**001**	

TROPICACYL

AT		AKORN	**0.5%**	**A040314**	**001**	Sep 29, 2000
AT			**1%**	**A040315**	**001**	Sep 29, 2000

TROPICAMIDE

AT		BAUSCH AND LOMB	**0.5%**	**A040067**	**001**	Jul 27, 1994
AT			**1%**	**A040064**	**001**	Jul 27, 1994
AT		SOMERSET THERAPS LLC	**1%**	**A207524**	**001**	Dec 12, 2019

TROSPIUM CHLORIDE						
CAPSULE, EXTENDED RELEASE;ORAL						
TROSPIUM CHLORIDE						
AB	**!**	ACTAVIS LABS FL INC	**60MG**	**A091289**	**001**	Oct 12, 2012
AB		AMTA	**60MG**	**A214760**	**001**	Apr 30, 2021
AB		GRANULES	**60MG**	**A213185**	**001**	Apr 23, 2020
AB		PADAGIS US	**60MG**	**A201291**	**001**	May 24, 2013
TABLET;ORAL						
TROSPIUM CHLORIDE						
AB		APOTEX	**20MG**	**A091513**	**001**	Dec 06, 2011
AB	**!**	GLENMARK GENERICS	**20MG**	**A091575**	**001**	Aug 13, 2010
AB		HERITAGE PHARMS INC	**20MG**	**A204945**	**001**	Aug 30, 2016
AB		INVAGEN PHARMS	**20MG**	**A091688**	**001**	Aug 23, 2016
AB		PADAGIS US	**20MG**	**A091573**	**001**	Nov 17, 2010
TRYPAN BLUE						
SOLUTION;OPHTHALMIC						
MEMBRANEBLUE						
	+!	DORC	0.15%	N022278	001	Feb 20, 2009
VISIONBLUE						
	+!	DORC	0.06%	N021670	001	Dec 16, 2004
TUCATINIB						
TABLET;ORAL						
TUKYSA						
	+	SEAGEN	50MG	N213411	001	Apr 17, 2020
	+!		150MG	N213411	002	Apr 17, 2020
UBROGEPANT						
TABLET;ORAL						
UBRELVY						
	+	ALLERGAN	50MG	N211765	001	Dec 23, 2019
	+!		100MG	N211765	002	Dec 23, 2019
ULIPRISTAL ACETATE						
TABLET;ORAL						
ELLA						
AB	**+!**	LAB HRA PHARMA	**30MG**	**N022474**	**001**	Aug 13, 2010
LOGILIA						
AB		TEVA PHARMS USA	**30MG**	**A207952**	**001**	Feb 13, 2017
UMBRALISIB TOSYLATE						
TABLET;ORAL						
UKONIQ						
	+!	TG THERAPS	EQ 200MG BASE	N213176	001	Feb 05, 2021
UMECLIDINIUM BROMIDE						
POWDER;INHALATION						
INCRUSE ELLIPTA						
	+!	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE						
POWDER;INHALATION						
ANORO ELLIPTA						
	+!	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013
UPADACITINIB						
TABLET, EXTENDED RELEASE;ORAL						
RINVOQ						
	+!	ABBVIE INC	15MG	N211675	001	Aug 16, 2019
UREA, C-14						
CAPSULE;ORAL						
PYTEST						
	+!	AVENT	1uCi	N020617	001	May 09, 1997
PYTEST KIT						
	+!	AVENT	1uCi	N020617	002	May 09, 1997
URIDINE TRIACETATE						
GRANULE;ORAL						
VISTOGARD						
	+!	WELLSTAT THERAP	10GM/PACKET	N208159	001	Dec 11, 2015
XURIDEN						
	+!	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	**+!**	ALLERGAN	**300MG**	**N019594**	**002**	Dec 31, 1987

URSODIOL

AB		ABHAI LLC	**300MG**	**A210707**	**001**	May 17, 2018
AB		AMNEAL PHARMS CO	**300MG**	**A211301**	**001**	Oct 16, 2018
AB		CHARTWELL RX	**300MG**	**A213555**	**001**	Aug 17, 2020
AB		EPIC PHARMA	**300MG**	**A075517**	**001**	Mar 14, 2000
AB		EYWA PHARMA	**300MG**	**A212452**	**001**	Oct 30, 2019
AB		LANNETT CO INC	**300MG**	**A079082**	**001**	Dec 15, 2008
AB		MYLAN	**300MG**	**A090530**	**001**	Feb 17, 2010
AB		RISING	**300MG**	**A213200**	**001**	Feb 12, 2020
AB		STRIDES PHARMA	**300MG**	**A210344**	**001**	Jan 22, 2021
AB		TEVA PHARMS	**300MG**	**A075592**	**001**	May 25, 2000
AB		VGYAAN	**300MG**	**A214329**	**001**	Jul 28, 2021
AB		ZYDUS	**300MG**	**A214295**	**001**	Oct 16, 2020
		LGM PHARMA	200MG	A205789	001	May 08, 2020
	!		400MG	A205789	002	May 08, 2020

TABLET;ORAL

URSO 250

AB	**+**	ALLERGAN	**250MG**	**N020675**	**001**	Dec 10, 1997

URSO FORTE

AB	**+!**	ALLERGAN	**500MG**	**N020675**	**002**	Jul 21, 2004

URSODIOL

AB		GLENMARK GENERICS	**250MG**	**A090801**	**001**	Jul 12, 2011
AB			**500MG**	**A090801**	**002**	Jul 12, 2011
AB		PAR PHARM	**250MG**	**A202540**	**001**	Feb 14, 2013
AB			**500MG**	**A202540**	**002**	Feb 14, 2013
AB		STRIDES PHARMA	**250MG**	**A213504**	**001**	Aug 20, 2020
AB			**500MG**	**A213504**	**002**	Aug 20, 2020
AB		ZYDUS	**250MG**	**A211145**	**001**	Oct 30, 2018
AB			**500MG**	**A211145**	**002**	Oct 30, 2018

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		APOTEX	**EQ 500MG BASE**	**A090500**	**001**	Apr 04, 2014
AB			**EQ 1GM BASE**	**A090500**	**002**	Apr 04, 2014
AB		ATLANTIDE	**EQ 500MG BASE**	**A090216**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090216**	**002**	May 24, 2010
AB		AUROBINDO PHARMA	**EQ 500MG BASE**	**A090682**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A090682**	**002**	May 24, 2010
AB		CADILA	**EQ 500MG BASE**	**A079137**	**001**	Dec 29, 2017
AB			**EQ 1GM BASE**	**A079137**	**002**	Dec 29, 2017
AB		CIPLA	**EQ 500MG BASE**	**A077135**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A077135**	**002**	May 24, 2010
AB		HETERO LABS LTD V	**EQ 500MG BASE**	**A203047**	**001**	Apr 08, 2015
AB			**EQ 1GM BASE**	**A203047**	**002**	Apr 08, 2015
AB		JUBILANT GENERICS	**EQ 500MG BASE**	**A201506**	**001**	Apr 03, 2012
AB			**EQ 1GM BASE**	**A201506**	**002**	Apr 03, 2012
AB		MYLAN PHARMS INC	**EQ 500MG BASE**	**A078518**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A078518**	**002**	May 24, 2010
AB		SANDOZ	**EQ 500MG BASE**	**A077478**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A077478**	**002**	May 24, 2010
AB		SUN PHARM INDS LTD	**EQ 500MG BASE**	**A076588**	**001**	Jan 31, 2007
AB			**EQ 1GM BASE**	**A076588**	**002**	Jan 31, 2007
AB		TIME-CAP LABS INC	**EQ 500MG BASE**	**A079012**	**001**	May 24, 2010
AB			**EQ 1GM BASE**	**A079012**	**002**	May 24, 2010
AB		YILING	**EQ 500MG BASE**	**A209553**	**001**	Mar 18, 2020
AB			**EQ 1GM BASE**	**A209553**	**002**	Mar 18, 2020

VALTREX

AB	**+**	GLAXOSMITHKLINE	**EQ 500MG BASE**	**N020487**	**001**	Jun 23, 1995
AB	**+!**		**EQ 1GM BASE**	**N020487**	**002**	Jun 23, 1995

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

	+	NEUROCRINE	EQ 40MG BASE	N209241	001	Apr 11, 2017
	+		EQ 60MG BASE	N209241	003	Apr 23, 2021
	+!		EQ 80MG BASE	N209241	002	Oct 04, 2017

VALGANCICLOVIR HYDROCHLORIDE						
FOR SOLUTION;ORAL						
VALCYTE						
AB	**+!**	HOFFMANN LA ROCHE	**50MG/ML**	**N022257**	**001**	Aug 28, 2009
VALGANCICLOVIR HYDROCHLORIDE						
AB		ACTAVIS LABS FL INC	**50MG/ML**	**A205220**	**001**	Jul 18, 2016
AB		AJANTA PHARMA LTD	**50MG/ML**	**A212890**	**001**	Jan 13, 2020
AB		GRANULES	**50MG/ML**	**A213306**	**001**	Jan 31, 2020
TABLET;ORAL						
VALCYTE						
AB	**+!**	HOFFMANN LA ROCHE	**EQ 450MG BASE**	**N021304**	**001**	Mar 29, 2001
VALGANCICLOVIR HYDROCHLORIDE						
AB		AJANTA PHARMA LTD	**EQ 450MG BASE**	**A212234**	**001**	Dec 26, 2019
AB		AUROBINDO PHARMA LTD	**EQ 450MG BASE**	**A204750**	**001**	Mar 31, 2016
AB		CIPLA	**EQ 450MG BASE**	**A209672**	**001**	Nov 09, 2018
AB		DR REDDYS	**EQ 450MG BASE**	**A206876**	**001**	Dec 12, 2017
AB		DR REDDYS LABS LTD	**EQ 450MG BASE**	**A203511**	**001**	Nov 04, 2014
AB		HETERO LABS LTD V	**EQ 450MG BASE**	**A205166**	**001**	Mar 18, 2016
AB		MYLAN	**EQ 450MG BASE**	**A205151**	**001**	Mar 03, 2021
AB		STRIDES PHARMA	**EQ 450MG BASE**	**A200790**	**001**	Nov 04, 2014
VALPROATE SODIUM						
INJECTABLE;INJECTION						
VALPROATE SODIUM						
AP		ATHENEX INC	**EQ 100MG BASE/ML**	**A076295**	**001**	Nov 14, 2002
AP		FRESENIUS KABI USA	**EQ 100MG BASE/ML**	**A076539**	**001**	Jun 26, 2003
AP	**!**	HIKMA FARMACEUTICA	**EQ 100MG BASE/ML**	**A078523**	**001**	Feb 17, 2010
AP		MYLAN	**EQ 100MG BASE/ML**	**A208120**	**001**	Dec 22, 2021
VALPROIC ACID						
CAPSULE;ORAL						
VALPROIC ACID						
AB	**!**	BIONPHARMA INC	**250MG**	**A073484**	**001**	Jun 29, 1993
AB		CATALENT	**250MG**	**A073229**	**001**	Oct 29, 1991
AB		SUN PHARM INDS LTD	**250MG**	**A091037**	**001**	Feb 22, 2013
BX		EYWA	250MG	A207611	001	Aug 05, 2019
SYRUP;ORAL						
VALPROIC ACID						
AA		BIOPHARM	**250MG/5ML**	**A090517**	**001**	May 28, 2010
AA		CHARTWELL RX	**250MG/5ML**	**A075782**	**001**	Dec 22, 2000
AA		HIGH TECH PHARMA	**250MG/5ML**	**A074060**	**001**	Jan 13, 1995
AA		LANNETT CO INC	**250MG/5ML**	**A077960**	**001**	Oct 13, 2006
AA	**!**	PHARM ASSOC	**250MG/5ML**	**A075379**	**001**	Dec 15, 2000
AA		WOCKHARDT BIO AG	**250MG/5ML**	**A070868**	**001**	Jul 01, 1986
VALRUBICIN						
SOLUTION;INTRAVESICAL						
VALRUBICIN						
AO		CUSTOPHARM INC	**40MG/ML**	**A206430**	**001**	Apr 19, 2019
VALSTAR PRESERVATIVE FREE						
AO	**+!**	ENDO PHARM	**40MG/ML**	**N020892**	**001**	Sep 25, 1998
VALSARTAN						
SOLUTION;ORAL						
VALSARTAN						
		NOVITIUM PHARMA	20MG/5ML	A214102	001	Nov 02, 2021
TABLET;ORAL						
DIOVAN						
AB	**+**	NOVARTIS	**40MG**	**N021283**	**004**	Aug 14, 2002
AB	**+**		**80MG**	**N021283**	**001**	Jul 18, 2001
AB	**+**		**160MG**	**N021283**	**002**	Jul 18, 2001
AB	**+!**		**320MG**	**N021283**	**003**	Jul 18, 2001
VALSARTAN						
AB		ALEMBIC PHARMS LTD	**40MG**	**A091367**	**001**	Jan 05, 2015
AB			**80MG**	**A091367**	**002**	Jan 05, 2015
AB			**160MG**	**A091367**	**003**	Jan 05, 2015
AB			**320MG**	**A091367**	**004**	Jan 05, 2015
AB		ALKEM LABS LTD	**40MG**	**A205536**	**001**	Mar 12, 2019
AB			**80MG**	**A205536**	**002**	Mar 12, 2019
AB			**160MG**	**A205536**	**003**	Mar 12, 2019
AB			**320MG**	**A205536**	**004**	Mar 12, 2019
AB		AMNEAL PHARMS	**40MG**	**A204011**	**001**	Jan 11, 2016
AB			**80MG**	**A204011**	**002**	Jan 11, 2016
AB			**160MG**	**A204011**	**003**	Jan 11, 2016

VALSARTAN

TABLET;ORAL

VALSARTAN

AB		**320MG**	**A204011**	**004**	Jan 11, 2016
AB	AUROBINDO PHARMA LTD	**40MG**	**A202223**	**001**	Jan 05, 2015
AB		**80MG**	**A202223**	**002**	Jan 05, 2015
AB		**160MG**	**A202223**	**003**	Jan 05, 2015
AB		**320MG**	**A202223**	**004**	Jan 05, 2015
AB	DR REDDYS	**40MG**	**A201618**	**001**	Oct 05, 2021
AB		**80MG**	**A201618**	**002**	Oct 05, 2021
AB		**160MG**	**A201618**	**003**	Oct 05, 2021
AB		**320MG**	**A201618**	**004**	Oct 05, 2021
AB	HETERO LABS LTD V	**40MG**	**A203311**	**001**	Jan 05, 2015
AB		**80MG**	**A203311**	**002**	Jan 05, 2015
AB		**160MG**	**A203311**	**003**	Jan 05, 2015
AB		**320MG**	**A203311**	**004**	Jan 05, 2015
AB	IVAX PHARMS	**40MG**	**A077530**	**001**	Jan 04, 2016
AB		**80MG**	**A077530**	**002**	Jan 04, 2016
AB		**160MG**	**A077530**	**003**	Jan 04, 2016
AB		**320MG**	**A077530**	**004**	Jan 04, 2016
AB	JUBILANT GENERICS	**40MG**	**A203536**	**001**	Jan 05, 2015
AB		**80MG**	**A203536**	**002**	Jan 05, 2015
AB		**160MG**	**A203536**	**003**	Jan 05, 2015
AB		**320MG**	**A203536**	**004**	Jan 05, 2015
AB	LUPIN LTD	**40MG**	**A201677**	**001**	Jan 05, 2015
AB		**80MG**	**A201677**	**002**	Jan 05, 2015
AB		**160MG**	**A201677**	**003**	Jan 05, 2015
AB		**320MG**	**A201677**	**004**	Jan 05, 2015
AB	MACLEODS PHARMS LTD	**40MG**	**A202696**	**001**	Sep 16, 2016
AB		**80MG**	**A202696**	**002**	Sep 16, 2016
AB		**160MG**	**A202696**	**003**	Sep 16, 2016
AB		**320MG**	**A202696**	**004**	Sep 16, 2016
AB	MYLAN	**40MG**	**A090866**	**001**	Jan 05, 2015
AB		**80MG**	**A090866**	**002**	Jan 05, 2015
AB		**160MG**	**A090866**	**003**	Jan 05, 2015
AB		**320MG**	**A090866**	**004**	Jan 05, 2015
AB	OHM LABS INC	**40MG**	**A077492**	**001**	Jun 26, 2014
AB		**80MG**	**A077492**	**002**	Jun 26, 2014
AB		**160MG**	**A077492**	**003**	Jun 26, 2014
AB		**320MG**	**A077492**	**004**	Jun 26, 2014
AB	PRINSTON INC	**40MG**	**A204821**	**001**	Jun 09, 2015
AB		**80MG**	**A204821**	**002**	Jun 09, 2015
AB		**160MG**	**A204821**	**003**	Jun 09, 2015
AB		**320MG**	**A204821**	**004**	Jun 09, 2015
AB	SCIEGEN PHARMS INC	**40MG**	**A204038**	**001**	Oct 27, 2021
AB		**80MG**	**A204038**	**002**	Oct 27, 2021
AB		**160MG**	**A204038**	**003**	Oct 27, 2021
AB		**320MG**	**A204038**	**004**	Oct 27, 2021
AB	SQUARE PHARMS	**40MG**	**A205347**	**001**	Apr 09, 2018
AB		**80MG**	**A205347**	**002**	Apr 09, 2018
AB		**160MG**	**A205347**	**003**	Apr 09, 2018
AB		**320MG**	**A205347**	**004**	Apr 09, 2018

VANCOMYCIN

SOLUTION;INTRAVENOUS, ORAL

VANCOMYCIN

+!	XELLIA PHARMS APS	5GM/100ML (50MG/ML)	N213895	001	Aug 26, 2021

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOCIN HYDROCHLORIDE

AB	**+** ANI PHARMS	**EQ 125MG BASE**	**N050606**	**001**	Apr 15, 1986
AB	**+!**	**EQ 250MG BASE**	**N050606**	**002**	Apr 15, 1986

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	**EQ 125MG BASE**	**A065478**	**001**	Apr 09, 2012
AB		**EQ 250MG BASE**	**A065478**	**002**	Apr 09, 2012
AB	LUPIN LTD	**EQ 125MG BASE**	**A090439**	**001**	Jan 28, 2015
AB		**EQ 250MG BASE**	**A090439**	**002**	Jan 28, 2015
AB	ORIENT PHARMA CO LTD	**EQ 125MG BASE**	**A210729**	**001**	Apr 29, 2019
AB		**EQ 250MG BASE**	**A210729**	**002**	Apr 29, 2019
AB	STRIDES PHARMA	**EQ 125MG BASE**	**A065490**	**001**	Apr 09, 2012
AB		**EQ 250MG BASE**	**A065490**	**002**	Apr 09, 2012

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL							
VANCOMYCIN HYDROCHLORIDE							
AB		WATSON LABS	**EQ 125MG BASE**	**A065510**	**001**	Apr 09, 2012
AB			**EQ 250MG BASE**	**A065510**	**002**	Apr 09, 2012
FOR SOLUTION;ORAL							
FIRVANQ KIT							
	+!	AZURITY	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018
	+!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018
VANCOCIN HYDROCHLORIDE							
	!	ANI PHARMS	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983
INJECTABLE;INJECTION							
VANCOMYCIN HYDROCHLORIDE							
AP		EUGIA PHARMA	**EQ 500MG BASE/VIAL**	**A205780**	**001**	Mar 31, 2016
AP			**EQ 1GM BASE/VIAL**	**A205780**	**002**	Mar 31, 2016
AP			**EQ 5GM BASE/VIAL**	**A205779**	**001**	Mar 29, 2016
AP			**EQ 10GM BASE/VIAL**	**A205779**	**002**	Mar 29, 2016
AP	**!**	FRESENIUS KABI USA	**EQ 500MG BASE/VIAL**	**A062663**	**001**	Mar 17, 1987
AP			**EQ 750MG BASE/VIAL**	**A062663**	**005**	Aug 17, 2016
AP	**!**		**EQ 1GM BASE/VIAL**	**A062663**	**002**	Jul 31, 1987
AP	**!**		**EQ 5GM BASE/VIAL**	**A062663**	**003**	Jun 03, 1988
AP	**!**		**EQ 10GM BASE/VIAL**	**A062663**	**004**	Nov 28, 1997
AP		GLAND PHARMA LTD	**EQ 500MG BASE/VIAL**	**A205694**	**001**	Jan 21, 2016
AP			**EQ 1GM BASE/VIAL**	**A205694**	**002**	Jan 21, 2016
AP		HAINAN POLY	**EQ 5GM BASE/VIAL**	**A215821**	**001**	Nov 18, 2021
AP			**EQ 10GM BASE/VIAL**	**A215821**	**002**	Nov 18, 2021
AP		HAINAN POLY PHARM	**EQ 500MG BASE/VIAL**	**A212332**	**001**	Jun 12, 2019
AP			**EQ 1GM BASE/VIAL**	**A212332**	**002**	Jun 12, 2019
AP		HIKMA	**EQ 5GM BASE/VIAL**	**A204360**	**001**	Oct 15, 2018
AP			**EQ 10GM BASE/VIAL**	**A204360**	**002**	Oct 15, 2018
AP		HIKMA PHARMS	**EQ 750MG BASE/VIAL**	**A206616**	**001**	Oct 03, 2018
AP	**!**	HOSPIRA	**EQ 500MG BASE/VIAL**	**A062911**	**001**	Aug 04, 1988
AP	**!**		**EQ 500MG BASE/VIAL**	**A062931**	**001**	Oct 29, 1992
AP	**!**		**EQ 750MG BASE/VIAL**	**A062912**	**002**	Jan 07, 2009
AP	**!**		**EQ 750MG BASE/VIAL**	**A062933**	**002**	May 27, 2009
AP	**!**		**EQ 1GM BASE/VIAL**	**A062912**	**001**	Aug 04, 1988
AP	**!**		**EQ 1GM BASE/VIAL**	**A062933**	**001**	Oct 29, 1992
AP	**!**		**EQ 5GM BASE/VIAL**	**A063076**	**001**	Dec 21, 1990
AP			**EQ 10GM BASE/VIAL**	**A063076**	**002**	Sep 14, 2020
AP		HOSPIRA INC	**EQ 10GM BASE/VIAL**	**A065455**	**001**	Apr 29, 2009
AP		MYLAN LABS LTD	**EQ 500MG BASE/VIAL**	**A065397**	**001**	Dec 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065397**	**002**	Dec 30, 2008
AP			**EQ 5GM BASE/VIAL**	**A065432**	**001**	Dec 30, 2008
AP	**!**		**EQ 10GM BASE/VIAL**	**A091554**	**001**	Sep 19, 2011
AP		PHARM ASSOC	**EQ 500MG BASE/VIAL**	**A065401**	**001**	Jun 30, 2008
AP			**EQ 1GM BASE/VIAL**	**A065401**	**002**	Jun 30, 2008
AP		SAGENT PHARMS	**EQ 5GM BASE/VIAL**	**A200837**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A200837**	**002**	Sep 02, 2014
AP		SANDOZ	**EQ 500MG BASE/VIAL**	**A090250**	**001**	Apr 27, 2010
AP			**EQ 1GM BASE/VIAL**	**A090250**	**002**	Apr 27, 2010
AP		SANDOZ INC	**EQ 5GM BASE/VIAL**	**A201048**	**001**	Aug 10, 2012
AP			**EQ 10GM BASE/VIAL**	**A201048**	**002**	Aug 10, 2012
AP		XELLIA PHARMS APS	**EQ 5GM BASE/VIAL**	**A204125**	**001**	Dec 28, 2015
AP			**EQ 10GM BASE/VIAL**	**A204125**	**002**	Dec 28, 2015
AP			**EQ 500MG BASE/VIAL**	**A204107**	**001**	Dec 28, 2015
AP			**EQ 1GM BASE/VIAL**	**A204107**	**002**	Dec 28, 2015
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
	+!	BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
	+!		EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010
	+!		EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999
VANCOMYCIN HYDROCHLORIDE							
	!	HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020
POWDER;INTRAVENOUS							
VANCOMYCIN HYDROCHLORIDE							
	+!	MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018
	+!		EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018
	+!		EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018
	+!		EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER							
		SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016

VANCOMYCIN HYDROCHLORIDE						
SOLUTION;INTRAVENOUS						
VANCOMYCIN HYDROCHLORIDE						
	+!	XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019
	+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020
	+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019
	+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020
	+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019
	+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020
	+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019
VANDETANIB						
TABLET;ORAL						
CAPRELSA						
	+	GENZYME CORP	100MG	N022405	001	Apr 06, 2011
	+!		300MG	N022405	002	Apr 06, 2011
VARDENAFIL HYDROCHLORIDE						
TABLET;ORAL						
LEVITRA						
AB	**+!**	BAYER HLTHCARE	**EQ 20MG BASE**	**N021400**	**004**	Aug 19, 2003
VARDENAFIL HYDROCHLORIDE						
AB		ALEMBIC PHARMS LTD	**EQ 2.5MG BASE**	**A214031**	**001**	Aug 04, 2020
AB			**EQ 5MG BASE**	**A214031**	**002**	Aug 04, 2020
AB			**EQ 10MG BASE**	**A214031**	**003**	Aug 04, 2020
AB			**EQ 20MG BASE**	**A214031**	**004**	Aug 04, 2020
AB		CROSSMEDIKA SA	**EQ 2.5MG BASE**	**A209057**	**001**	Oct 31, 2018
AB			**EQ 5MG BASE**	**A209057**	**002**	Oct 31, 2018
AB			**EQ 10MG BASE**	**A209057**	**003**	Oct 31, 2018
AB			**EQ 20MG BASE**	**A209057**	**004**	Oct 31, 2018
AB		MACLEODS PHARMS LTD	**EQ 2.5MG BASE**	**A204632**	**001**	Oct 22, 2019
AB			**EQ 5MG BASE**	**A204632**	**002**	Oct 22, 2019
AB			**EQ 10MG BASE**	**A204632**	**003**	Oct 22, 2019
AB			**EQ 20MG BASE**	**A204632**	**004**	Oct 22, 2019
AB		TEVA PHARMS	**EQ 2.5MG BASE**	**A091347**	**001**	May 03, 2012
AB			**EQ 5MG BASE**	**A091347**	**002**	May 03, 2012
AB			**EQ 10MG BASE**	**A091347**	**003**	May 03, 2012
AB			**EQ 20MG BASE**	**A091347**	**004**	May 03, 2012
AB		ZYDUS PHARMS	**EQ 2.5MG BASE**	**A208960**	**001**	Oct 31, 2018
AB			**EQ 5MG BASE**	**A208960**	**002**	Oct 31, 2018
AB			**EQ 10MG BASE**	**A208960**	**003**	Oct 31, 2018
AB			**EQ 20MG BASE**	**A208960**	**004**	Oct 31, 2018
TABLET, ORALLY DISINTEGRATING;ORAL						
STAXYN						
AB	**+!**	BAYER HLTHCARE	**10MG**	**N200179**	**001**	Jun 17, 2010
VARDENAFIL HYDROCHLORIDE						
AB		ALEMBIC PHARMS LTD	**10MG**	**A208324**	**001**	Nov 16, 2018
AB		MACLEODS PHARMS LTD	**10MG**	**A205988**	**001**	Mar 10, 2020
VARENICLINE TARTRATE						
SOLUTION;NASAL						
TYRVAYA						
	+!	OYSTER POINT PHARMA	EQ 0.03MG BASE/SPRAY	N213978	001	Oct 15, 2021
TABLET;ORAL						
CHANTIX						
AB	**+**	PF PRISM CV	**EQ 0.5MG BASE**	**N021928**	**001**	May 10, 2006
AB	**+!**		**EQ 1MG BASE**	**N021928**	**002**	May 10, 2006
VARENICLINE TARTRATE						
AB		PAR PHARM INC	**EQ 0.5MG BASE**	**A201785**	**001**	Aug 11, 2021
AB			**EQ 1MG BASE**	**A201785**	**002**	Aug 11, 2021
VASOPRESSIN						
SOLUTION;INTRAVENOUS						
VASOPRESSIN						
AP		EAGLE PHARMS	**20UNITS/ML (20UNITS/ML)**	**A211538**	**001**	Dec 15, 2021
VASOSTRICT						
AP	**+!**	PAR STERILE PRODUCTS	**20UNITS/ML (20UNITS/ML)**	**N204485**	**001**	Apr 17, 2014
VASOPRESSIN						
	+!	AM REGENT	20UNITS/ML (20UNITS/ML)	N212593	001	Aug 03, 2020
VASOSTRICT						
	+!	PAR STERILE PRODUCTS	20UNITS/100ML (0.2UNITS/ML)	N204485	005	Apr 21, 2021
	+!		40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020
	+!		60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020

VASOPRESSIN
SOLUTION;INTRAVENOUS
VASOSTRICT

	+!		200UNITS/10ML (20UNITS/ML)	N204485 002	Dec 17, 2016

VECURONIUM BROMIDE
INJECTABLE;INJECTION
VECURONIUM BROMIDE

AP		EUGIA PHARMA	**10MG/VIAL**	**A206670 001**	Dec 20, 2018
AP			**20MG/VIAL**	**A206670 002**	Dec 20, 2018
AP		GLAND	**10MG/VIAL**	**A205390 001**	May 26, 2016
AP			**20MG/VIAL**	**A205390 002**	May 26, 2016
AP		HIKMA	**10MG/VIAL**	**A075549 001**	Jun 13, 2000
AP			**10MG/VIAL**	**A203725 001**	Jul 30, 2019
AP			**20MG/VIAL**	**A075549 002**	Jun 13, 2000
AP			**20MG/VIAL**	**A203725 002**	Jul 30, 2019
AP		HOSPIRA	**10MG/VIAL**	**A075164 001**	Oct 21, 1999
AP			**20MG/VIAL**	**A075164 002**	Oct 21, 1999
AP		MYLAN LABS LTD	**10MG/VIAL**	**A090243 001**	May 11, 2010
AP			**20MG/VIAL**	**A090243 002**	May 11, 2010
AP		SAGENT PHARMS INC	**10MG/VIAL**	**A078274 001**	Dec 29, 2008
AP			**20MG/VIAL**	**A078274 002**	Dec 29, 2008
AP	!	SUN PHARM	**10MG/VIAL**	**A079001 001**	Jun 17, 2009
AP	!		**20MG/VIAL**	**A079001 002**	Jun 17, 2009
AP		TEVA PHARMS USA	**10MG/VIAL**	**A074688 001**	Aug 25, 1999
AP			**20MG/VIAL**	**A074688 002**	Aug 25, 1999

VEMURAFENIB
TABLET;ORAL
ZELBORAF

	+!	HOFFMANN LA ROCHE	240MG	N202429 001	Aug 17, 2011

VENETOCLAX
TABLET;ORAL
VENCLEXTA

	+	ABBVIE INC	10MG	N208573 001	Apr 11, 2016
	+		50MG	N208573 002	Apr 11, 2016
	+!		100MG	N208573 003	Apr 11, 2016

VENLAFAXINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
EFFEXOR XR

AB	+	UPJOHN	**EQ 37.5MG BASE**	**N020699 001**	Oct 20, 1997
AB	+		**EQ 75MG BASE**	**N020699 002**	Oct 20, 1997
AB	+!		**EQ 150MG BASE**	**N020699 004**	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

AB		ANNORA PHARMA	**EQ 37.5MG BASE**	**A212277 001**	Jul 08, 2019
AB			**EQ 75MG BASE**	**A212277 002**	Jul 08, 2019
AB			**EQ 150MG BASE**	**A212277 003**	Jul 08, 2019
AB		ATLANTIDE	**EQ 37.5MG BASE**	**A078865 001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A078865 002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A078865 003**	Apr 14, 2011
AB		AUROBINDO PHARMA LTD	**EQ 37.5MG BASE**	**A200834 001**	Apr 14, 2011
AB			**EQ 75MG BASE**	**A200834 002**	Apr 14, 2011
AB			**EQ 150MG BASE**	**A200834 003**	Apr 14, 2011
AB		DR REDDYS LABS LTD	**EQ 37.5MG BASE**	**A078421 001**	May 06, 2011
AB			**EQ 75MG BASE**	**A078421 002**	May 06, 2011
AB			**EQ 150MG BASE**	**A078421 003**	May 06, 2011
AB		INTELLIPHARMACEUTICS	**EQ 37.5MG BASE**	**A201272 001**	Nov 23, 2018
AB			**EQ 75MG BASE**	**A201272 002**	Nov 23, 2018
AB			**EQ 150MG BASE**	**A201272 003**	Nov 23, 2018
AB		INVENTIA HLTHCARE	**EQ 37.5MG BASE**	**A203332 001**	Mar 12, 2020
AB			**EQ 75MG BASE**	**A203332 002**	Mar 12, 2020
AB			**EQ 150MG BASE**	**A203332 003**	Mar 12, 2020
AB		MACLEODS PHARMS LTD	**EQ 37.5MG BASE**	**A204889 001**	Oct 05, 2017
AB			**EQ 75MG BASE**	**A204889 002**	Oct 05, 2017
AB			**EQ 150MG BASE**	**A204889 003**	Oct 05, 2017
AB		ORBION PHARMS	**EQ 37.5MG BASE**	**A091123 001**	Jul 11, 2011
AB			**EQ 75MG BASE**	**A091123 002**	Jul 11, 2011
AB			**EQ 150MG BASE**	**A091123 003**	Jul 11, 2011
AB		TEVA	**EQ 37.5MG BASE**	**A076565 001**	Jun 28, 2010
AB			**EQ 75MG BASE**	**A076565 002**	Jun 28, 2010
AB			**EQ 150MG BASE**	**A076565 003**	Jun 28, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	TORRENT	**EQ 37.5MG BASE**	**A090899**	**001**	Jun 01, 2011
AB		**EQ 75MG BASE**	**A090899**	**002**	Jun 01, 2011
AB		**EQ 150MG BASE**	**A090899**	**003**	Jun 01, 2011
AB	VALEANT PHARMS NORTH	**EQ 37.5MG BASE**	**A090071**	**001**	Apr 15, 2011
AB		**EQ 75MG BASE**	**A090071**	**002**	Apr 15, 2011
AB		**EQ 150MG BASE**	**A090071**	**003**	Apr 15, 2011
AB	YICHANG HUMANWELL	**EQ 37.5MG BASE**	**A214654**	**001**	Aug 06, 2021
AB		**EQ 75MG BASE**	**A214654**	**002**	Aug 06, 2021
AB		**EQ 150MG BASE**	**A214654**	**003**	Aug 06, 2021
AB	ZYDUS PHARMS USA INC	**EQ 37.5MG BASE**	**A090174**	**001**	Apr 14, 2011
AB		**EQ 75MG BASE**	**A090174**	**002**	Apr 14, 2011
AB		**EQ 150MG BASE**	**A090174**	**003**	Apr 14, 2011

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	**EQ 25MG BASE**	**A078932**	**001**	Dec 14, 2010
AB		**EQ 37.5MG BASE**	**A078932**	**002**	Dec 14, 2010
AB		**EQ 50MG BASE**	**A078932**	**003**	Dec 14, 2010
AB		**EQ 75MG BASE**	**A078932**	**004**	Dec 14, 2010
AB		**EQ 100MG BASE**	**A078932**	**005**	Dec 14, 2010
AB	AMNEAL PHARMS	**EQ 25MG BASE**	**A079098**	**001**	May 11, 2010
AB		**EQ 37.5MG BASE**	**A079098**	**002**	May 11, 2010
AB		**EQ 50MG BASE**	**A079098**	**003**	May 11, 2010
AB		**EQ 75MG BASE**	**A079098**	**004**	May 11, 2010
AB		**EQ 100MG BASE**	**A079098**	**005**	May 11, 2010
AB	AUROBINDO PHARMA	**EQ 25MG BASE**	**A090555**	**001**	Apr 07, 2010
AB		**EQ 37.5MG BASE**	**A090555**	**002**	Apr 07, 2010
AB		**EQ 50MG BASE**	**A090555**	**003**	Apr 07, 2010
AB		**EQ 75MG BASE**	**A090555**	**004**	Apr 07, 2010
AB		**EQ 100MG BASE**	**A090555**	**005**	Apr 07, 2010
AB	CADILA PHARMS LTD	**EQ 25MG BASE**	**A206250**	**001**	Nov 21, 2018
AB		**EQ 37.5MG BASE**	**A206250**	**002**	Nov 21, 2018
AB		**EQ 50MG BASE**	**A206250**	**003**	Nov 21, 2018
AB		**EQ 75MG BASE**	**A206250**	**004**	Nov 21, 2018
AB		**EQ 100MG BASE**	**A206250**	**005**	Nov 21, 2018
AB	DR REDDYS LABS LTD	**EQ 25MG BASE**	**A078301**	**001**	Jun 13, 2008
AB		**EQ 37.5MG BASE**	**A078301**	**002**	Jun 13, 2008
AB		**EQ 50MG BASE**	**A078301**	**003**	Jun 13, 2008
AB		**EQ 75MG BASE**	**A078301**	**004**	Jun 13, 2008
AB		**EQ 100MG BASE**	**A078301**	**005**	Jun 13, 2008
AB	HERITAGE PHARMS INC	**EQ 25MG BASE**	**A078554**	**001**	Jan 09, 2009
AB		**EQ 37.5MG BASE**	**A078554**	**002**	Jan 09, 2009
AB		**EQ 50MG BASE**	**A078554**	**003**	Jan 09, 2009
AB		**EQ 75MG BASE**	**A078554**	**004**	Jan 09, 2009
AB		**EQ 100MG BASE**	**A078554**	**005**	Jan 09, 2009
AB	SUN PHARM INDS INC	**EQ 25MG BASE**	**A078627**	**001**	Jun 13, 2008
AB		**EQ 37.5MG BASE**	**A078627**	**002**	Jun 13, 2008
AB		**EQ 50MG BASE**	**A078627**	**003**	Jun 13, 2008
AB		**EQ 75MG BASE**	**A078627**	**004**	Jun 13, 2008
AB		**EQ 100MG BASE**	**A078627**	**005**	Jun 13, 2008
AB	TEVA	**EQ 25MG BASE**	**A076690**	**001**	Aug 03, 2006
AB		**EQ 37.5MG BASE**	**A076690**	**002**	Aug 03, 2006
AB !		**EQ 50MG BASE**	**A076690**	**003**	Aug 03, 2006
AB		**EQ 75MG BASE**	**A076690**	**004**	Aug 03, 2006
AB		**EQ 100MG BASE**	**A076690**	**005**	Aug 03, 2006
AB	YAOPHARMA CO LTD	**EQ 25MG BASE**	**A202036**	**001**	May 28, 2015
AB		**EQ 37.5MG BASE**	**A202036**	**002**	May 28, 2015
AB		**EQ 50MG BASE**	**A202036**	**003**	May 28, 2015
AB		**EQ 75MG BASE**	**A202036**	**004**	May 28, 2015
AB		**EQ 100MG BASE**	**A202036**	**005**	May 28, 2015
AB	ZYDUS PHARMS USA	**EQ 25MG BASE**	**A077653**	**001**	Jun 13, 2008
AB		**EQ 37.5MG BASE**	**A077653**	**002**	Jun 13, 2008
AB		**EQ 50MG BASE**	**A077653**	**003**	Jun 13, 2008
AB		**EQ 75MG BASE**	**A077653**	**004**	Jun 13, 2008
AB		**EQ 100MG BASE**	**A077653**	**005**	Jun 13, 2008

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ALKEM LABS LTD	**EQ 37.5MG BASE**	**A214127**	**001**	Jun 10, 2021
AB		**EQ 75MG BASE**	**A214127**	**002**	Jun 10, 2021

VENLAFAXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB			**EQ 150MG BASE**	**A214127**	**003**	Jun 10, 2021
AB			**EQ 225MG BASE**	**A214127**	**004**	Jun 10, 2021
AB		APPCO	**EQ 150MG BASE**	**A214609**	**001**	Jun 30, 2021
AB			**EQ 225MG BASE**	**A214609**	**002**	Jun 30, 2021
AB		ASCENT PHARMS INC	**EQ 37.5MG BASE**	**A214419**	**001**	Oct 21, 2020
AB			**EQ 75MG BASE**	**A214419**	**002**	Oct 21, 2020
AB			**EQ 150MG BASE**	**A214419**	**003**	Oct 21, 2020
AB			**EQ 225MG BASE**	**A214419**	**004**	Oct 21, 2020
AB		CADILA PHARMS LTD	**EQ 75MG BASE**	**A211323**	**001**	Aug 29, 2019
AB			**EQ 150MG BASE**	**A211323**	**002**	Aug 29, 2019
AB			**EQ 225MG BASE**	**A211323**	**003**	Aug 29, 2019
AB		DEXCEL PHARMA	**EQ 75MG BASE**	**A213927**	**001**	Jan 21, 2021
AB			**EQ 150MG BASE**	**A209193**	**001**	Oct 31, 2019
AB			**EQ 225MG BASE**	**A209193**	**002**	Oct 31, 2019
AB		NOSTRUM LABS INC	**EQ 150MG BASE**	**A205468**	**002**	Mar 24, 2017
AB			**EQ 225MG BASE**	**A205468**	**003**	Mar 24, 2017
AB	**+**	OSMOTICA PHARM	**EQ 37.5MG BASE**	**N022104**	**001**	May 20, 2008
AB	**+**		**EQ 75MG BASE**	**N022104**	**002**	May 20, 2008
AB	**+!**		**EQ 150MG BASE**	**N022104**	**003**	May 20, 2008
AB	**+**		**EQ 225MG BASE**	**N022104**	**004**	May 20, 2008
AB		PHARMADAX INC	**EQ 75MG BASE**	**A214423**	**001**	Jan 04, 2022
AB			**EQ 150MG BASE**	**A214423**	**002**	Jan 04, 2022
AB		SUN PHARM	**EQ 37.5MG BASE**	**A091272**	**001**	Aug 18, 2010
AB			**EQ 75MG BASE**	**A091272**	**002**	Aug 18, 2010
AB			**EQ 150MG BASE**	**A091272**	**003**	Aug 18, 2010
AB			**EQ 225MG BASE**	**A091272**	**004**	Jan 08, 2019

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

AB		MYLAN	**120MG**	**A075138**	**001**	Apr 20, 1999
AB			**180MG**	**A075138**	**002**	Apr 20, 1999
AB			**240MG**	**A075138**	**003**	Apr 20, 1999

VERELAN

AB	**+**	RECRO GAINESVILLE	**120MG**	**N019614**	**001**	May 29, 1990
AB	**+**		**180MG**	**N019614**	**003**	Jan 09, 1992
AB	**+**		**240MG**	**N019614**	**002**	May 29, 1990
	+!		360MG	N019614	004	May 10, 1996

VERELAN PM

	+	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998
	+		200MG	N020943	002	Nov 25, 1998
	+!		300MG	N020943	003	Nov 25, 1998

INJECTABLE;INJECTION

VERAPAMIL HYDROCHLORIDE

AP	**!**	EUGIA PHARMA	**2.5MG/ML**	**A212965**	**001**	Jul 06, 2020
AP		GLAND PHARMA LTD	**2.5MG/ML**	**A214361**	**001**	Oct 15, 2020
AP		ZYDUS PHARMS	**2.5MG/ML**	**A214215**	**001**	Oct 15, 2020

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP		AMNEAL	**5MG/2ML (2.5MG/ML)**	**A210994**	**001**	Jul 13, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A210994**	**002**	Jul 13, 2018
AP		AREVA PHARMS	**5MG/2ML (2.5MG/ML)**	**A213352**	**002**	Sep 16, 2020
AP			**10MG/4ML (2.5MG/ML)**	**A213352**	**001**	Mar 17, 2020
AP		CAPLIN	**5MG/2ML (2.5MG/ML)**	**A213232**	**001**	Mar 25, 2020
AP			**10MG/4ML (2.5MG/ML)**	**A213232**	**002**	Mar 25, 2020
AP		EXELA PHARMA	**5MG/2ML (2.5MG/ML)**	**N018925**	**001**	Mar 30, 1984
AP	**!**	HOSPIRA	**5MG/2ML (2.5MG/ML)**	**A070738**	**001**	May 06, 1987
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A075136**	**001**	Oct 20, 1998
AP	**!**		**5MG/2ML (2.5MG/ML)**	**A070737**	**001**	May 06, 1987
AP	**!**		**10MG/4ML (2.5MG/ML)**	**A070737**	**002**	May 06, 1987
AP		MICRO LABS	**5MG/2ML (2.5MG/ML)**	**A211370**	**001**	Dec 28, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211370**	**002**	Dec 28, 2018
AP		SOMERSET	**5MG/2ML (2.5MG/ML)**	**A211035**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211035**	**002**	Jun 18, 2018
AP		SOMERSET THERAPS LLC	**5MG/2ML (2.5MG/ML)**	**A211015**	**001**	Jun 18, 2018
AP			**10MG/4ML (2.5MG/ML)**	**A211015**	**002**	Jun 18, 2018

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB		HERITAGE PHARMS INC	**40MG**	**A071881**	**002**	Oct 14, 2015

VERAPAMIL HYDROCHLORIDE

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

AB			**80MG**	**A071881**	**003**	Apr 05, 1988
AB	!		**120MG**	**A071881**	**001**	Apr 05, 1988
AB		WATSON LABS	**40MG**	**A072924**	**001**	Jun 29, 1993
AB			**80MG**	**A070995**	**001**	Oct 01, 1986
AB			**120MG**	**A070994**	**001**	Oct 01, 1986

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

AB	+!	PFIZER	**120MG**	**N019152**	**003**	Mar 06, 1991
AB	+!		**240MG**	**N019152**	**001**	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

AB		CADILA PHARMS LTD	**180MG**	**A206173**	**001**	May 05, 2017
AB			**240MG**	**A206173**	**002**	May 05, 2017
AB		GLENMARK GENERICS	**120MG**	**A090700**	**001**	Aug 03, 2011
AB	!		**180MG**	**A090700**	**002**	Aug 03, 2011
AB			**240MG**	**A078906**	**001**	Sep 17, 2009
AB		IVAX SUB TEVA PHARMS	**120MG**	**A073568**	**002**	Oct 10, 1997
AB			**180MG**	**A074330**	**001**	Jan 31, 1994
AB			**240MG**	**A073568**	**001**	Jul 31, 1992
AB		STRIDES PHARMA	**120MG**	**A075072**	**001**	May 25, 1999
AB			**240MG**	**A075072**	**003**	May 25, 1999
AB		SUN PHARM INDS INC	**120MG**	**A090529**	**001**	Dec 30, 2011
AB			**180MG**	**A090529**	**002**	Dec 30, 2011
AB			**240MG**	**A090529**	**003**	Dec 30, 2011

VERICIGUAT

TABLET;ORAL

VERQUVO

	+	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021
	+		5MG	N214377	002	Jan 19, 2021
	+!		10MG	N214377	003	Jan 19, 2021

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+!	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000

VIBEGRON

TABLET;ORAL

GEMTESA

	+!	UROVANT	75MG	N213006	001	Dec 23, 2020

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

AA	+!	LUNDBECK PHARMS LLC	**500MG/PACKET**	**N022006**	**001**	Aug 21, 2009

VIGABATRIN

AA		ACCORD HLTHCARE	**500MG/PACKET**	**A214425**	**001**	Nov 13, 2020
AA		ALKEM LABS LTD	**500MG/PACKET**	**A213375**	**001**	Dec 02, 2020
AA		AMNEAL PHARMS	**500MG/PACKET**	**A210155**	**001**	Mar 13, 2018
AA		ANNORA PHARMA	**500MG/PACKET**	**A213519**	**001**	Jan 26, 2021
AA		AUROBINDO PHARMA LTD	**500MG/PACKET**	**A213899**	**001**	Sep 29, 2021
AA		DEXCEL PHARMA	**500MG/PACKET**	**A214992**	**001**	May 13, 2021
AA		DR REDDYS LABS LTD	**500MG/PACKET**	**A211481**	**001**	Nov 20, 2018
AA		GRANULES	**500MG/PACKET**	**A213469**	**001**	Apr 24, 2020
AA		INVAGEN PHARMS	**500MG/PACKET**	**A211592**	**001**	Dec 03, 2019
AA		PAR PHARM INC	**500MG/PACKET**	**A208218**	**001**	Apr 27, 2017
AA		PROPEL PHARMA	**500MG/PACKET**	**A213390**	**001**	Jul 29, 2021
AA		TEVA PHARMS USA	**500MG/PACKET**	**A209824**	**001**	Apr 23, 2018

VIGADRONE

AA		AUCTA	**500MG/PACKET**	**A210196**	**001**	Jun 21, 2018

TABLET;ORAL

SABRIL

AB	+!	LUNDBECK PHARMS LLC	**500MG**	**N020427**	**001**	Aug 21, 2009

VIGABATRIN

AB		DEXCEL PHARMA	**500MG**	**A215109**	**001**	Sep 23, 2021
AB		DR REDDYS	**500MG**	**A211539**	**001**	Jan 29, 2021
AB		TEVA PHARMS USA	**500MG**	**A209822**	**001**	Jan 14, 2019

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

AB	**+!**	ALLERGAN	**10MG**	**N022567**	**001**	Jan 21, 2011
AB	**+**		**20MG**	**N022567**	**002**	Jan 21, 2011
AB	**+**		**40MG**	**N022567**	**003**	Jan 21, 2011

VILAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	**10MG**	**A208209**	**001**	Apr 27, 2021
AB			**20MG**	**A208209**	**002**	Apr 27, 2021
AB			**40MG**	**A208209**	**003**	Apr 27, 2021
AB		ALEMBIC PHARMS LTD	**10MG**	**A208202**	**001**	Jan 10, 2020
AB			**20MG**	**A208202**	**002**	Jan 10, 2020
AB			**40MG**	**A208202**	**003**	Jan 10, 2020
AB		INVAGEN PHARMS	**10MG**	**A208200**	**001**	Apr 07, 2021
AB			**40MG**	**A208200**	**002**	Apr 07, 2021

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

QELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021
+		EQ 150MG BASE	N211964	002	Apr 02, 2021
+!		EQ 200MG BASE	N211964	003	Apr 02, 2021

VILTOLARSEN

SOLUTION;INTRAVENOUS

VILTEPSO

+!	NIPPON SHINYAKU	250MG/5ML (50MG/ML)	N212154	001	Aug 12, 2020

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

!	FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987
!	HIKMA	10MG/VIAL	A089395	001	Apr 09, 1987

VINCRISTINE SULFATE

INJECTABLE;INJECTION

VINCRISTINE SULFATE PFS

AP	**!**	HOSPIRA	**1MG/ML**	**A071484**	**001**	Apr 19, 1988
AP		TEVA PHARMS USA	**1MG/ML**	**A075493**	**001**	Sep 01, 1999

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	**EQ 10MG BASE/ML**	**A078011**	**001**	Jul 22, 2009
AP		DR REDDYS	**EQ 10MG BASE/ML**	**A202017**	**001**	Sep 12, 2013
AP		HIKMA	**EQ 10MG BASE/ML**	**A075992**	**001**	Jun 10, 2003
AP			**EQ 10MG BASE/ML**	**A076461**	**001**	Dec 11, 2003
AP		JIANGSU HANSOH PHARM	**EQ 10MG BASE/ML**	**A091106**	**001**	Sep 26, 2012
AP		TEVA PHARMS USA	**EQ 10MG BASE/ML**	**A076028**	**001**	Feb 03, 2003

VISMODEGIB

CAPSULE;ORAL

ERIVEDGE

+!	GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE;INJECTION

AQUASOL A

+!	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001	

VOCLOSPORIN

CAPSULE;ORAL

LUPKYNIS

+!	AURINIA	7.9MG	N213716	001	Jan 22, 2021

VORAPAXAR SULFATE

TABLET;ORAL

ZONTIVITY

+!	XSPIRE PHARMA	EQ 2.08MG BASE	N204886	001	May 08, 2014

VORICONAZOLE

FOR SUSPENSION;ORAL

VFEND

AB	**+!**	PF PRISM CV	**200MG/5ML**	**N021630**	**001**	Dec 19, 2003

VORICONAZOLE

AB		AMNEAL PHARMS	**200MG/5ML**	**A205034**	**001**	Apr 13, 2016
AB		NOVEL LABS INC	**200MG/5ML**	**A206799**	**001**	May 31, 2016

VORICONAZOLE						
INJECTABLE;INTRAVENOUS						
VFEND						
AP	**+!** PF PRISM CV	**200MG/VIAL**	**N021267**	**001**	May 24, 2002	
VORICONAZOLE						
AP	ALMAJECT	**200MG/VIAL**	**A206398**	**001**	Mar 23, 2016	
AP	GLAND PHARMA LTD	**200MG/VIAL**	**A211099**	**001**	Mar 31, 2020	
AP	HAINAN POLY PHARM	**200MG/VIAL**	**A211661**	**001**	Nov 30, 2018	
AP	SANDOZ INC	**200MG/VIAL**	**A090862**	**001**	May 30, 2012	
AP	ZYDUS PHARMS	**200MG/VIAL**	**A208983**	**001**	Jul 16, 2018	
POWDER;INTRAVENOUS						
VORICONAZOLE						
AP	XELLIA PHARMS APS	**200MG/VIAL**	**N208562**	**001**	Mar 09, 2017	
TABLET;ORAL						
VFEND						
AB	**+** PF PRISM CV	**50MG**	**N021266**	**001**	May 24, 2002	
AB	**+!**	**200MG**	**N021266**	**002**	May 24, 2002	
VORICONAZOLE						
AB	AJANTA PHARMA LTD	**50MG**	**A206181**	**001**	May 24, 2016	
AB		**200MG**	**A206181**	**002**	May 24, 2016	
AB	AKORN	**50MG**	**A207049**	**001**	Sep 07, 2016	
AB		**200MG**	**A207049**	**002**	Sep 07, 2016	
AB	AUROBINDO PHARMA LTD	**50MG**	**A206837**	**001**	Jan 22, 2016	
AB		**200MG**	**A206837**	**002**	Jan 22, 2016	
AB	CADILA	**50MG**	**A206747**	**001**	May 24, 2016	
AB		**200MG**	**A206747**	**002**	May 24, 2016	
AB	GLENMARK PHARMS LTD	**50MG**	**A203503**	**001**	Sep 02, 2015	
AB		**200MG**	**A203503**	**002**	Sep 02, 2015	
AB	MYLAN PHARMS INC	**50MG**	**A090547**	**001**	Apr 22, 2010	
AB		**200MG**	**A090547**	**002**	Apr 22, 2010	
AB	NOVEL LABS INC	**50MG**	**A207371**	**001**	May 24, 2016	
AB		**200MG**	**A207371**	**002**	May 24, 2016	
AB	PRINSTON INC	**50MG**	**A206654**	**001**	Aug 08, 2016	
AB		**200MG**	**A206654**	**002**	Aug 08, 2016	
AB	RISING	**50MG**	**A206762**	**001**	May 24, 2016	
AB		**200MG**	**A206762**	**002**	May 24, 2016	
AB	SANDOZ INC	**50MG**	**A200265**	**001**	Dec 12, 2011	
AB		**200MG**	**A200265**	**002**	Dec 12, 2011	
VORINOSTAT						
CAPSULE;ORAL						
ZOLINZA						
+!	MERCK	100MG	N021991	001	Oct 06, 2006	
VORTIOXETINE HYDROBROMIDE						
TABLET;ORAL						
TRINTELLIX						
AB	**+** TAKEDA PHARMS USA	**EQ 5MG BASE**	**N204447**	**001**	Sep 30, 2013	
AB	**+**	**EQ 10MG BASE**	**N204447**	**002**	Sep 30, 2013	
AB	**+!**	**EQ 20MG BASE**	**N204447**	**004**	Sep 30, 2013	
VORTIOXETINE HYDROBROMIDE						
AB	ZYDUS PHARMS	**EQ 5MG BASE**	**A211146**	**001**	Sep 17, 2021	
AB		**EQ 10MG BASE**	**A211146**	**002**	Sep 17, 2021	
AB		**EQ 20MG BASE**	**A211146**	**003**	Sep 17, 2021	
VOSORITIDE						
POWDER;SUBCUTANEOUS						
VOXZOGO						
+!	BIOMARIN PHARM	0.4MG/VIAL	N214938	001	Nov 19, 2021	
+!		0.56MG/VIAL	N214938	002	Nov 19, 2021	
+!		1.2MG/VIAL	N214938	003	Nov 19, 2021	
VOXELOTOR						
TABLET;ORAL						
OXBRYTA						
+!	GLOBAL BLOOD THERAPS	500MG	N213137	001	Nov 25, 2019	
TABLET, FOR SUSPENSION;ORAL						
OXBRYTA						
+!	GLOBAL BLOOD THERAPS	300MG	N216157	001	Dec 17, 2021	

WARFARIN SODIUM

TABLET;ORAL

JANTOVEN

AB	UPSHER SMITH LABS	1MG	A040416	001	Oct 02, 2003
AB		2MG	A040416	002	Oct 02, 2003
AB		2.5MG	A040416	003	Oct 02, 2003
AB		3MG	A040416	004	Oct 02, 2003
AB		4MG	A040416	005	Oct 02, 2003
AB		5MG	A040416	006	Oct 02, 2003
AB		6MG	A040416	007	Oct 02, 2003
AB		7.5MG	A040416	008	Oct 02, 2003
AB		10MG	A040416	009	Oct 02, 2003

WARFARIN SODIUM

AB	AMNEAL PHARMS	1MG	A202202	001	Mar 04, 2013
AB		2MG	A202202	002	Mar 04, 2013
AB		2.5MG	A202202	003	Mar 04, 2013
AB		3MG	A202202	004	Mar 04, 2013
AB		4MG	A202202	005	Mar 04, 2013
AB		5MG	A202202	006	Mar 04, 2013
AB		6MG	A202202	007	Mar 04, 2013
AB		7.5MG	A202202	008	Mar 04, 2013
AB		10MG	A202202	009	Mar 04, 2013
AB	BARR	1MG	A040145	001	Mar 26, 1997
AB		2MG	A040145	002	Mar 26, 1997
AB		2.5MG	A040145	003	Mar 26, 1997
AB		3MG	A040145	008	Nov 05, 1998
AB		4MG	A040145	004	Mar 26, 1997
AB		5MG	A040145	005	Mar 26, 1997
AB		6MG	A040145	009	Nov 05, 1998
AB		7.5MG	A040145	006	Mar 26, 1997
AB		10MG	A040145	007	Mar 26, 1997
AB	INVAGEN PHARMS	1MG	A090935	001	May 25, 2011
AB		2MG	A090935	002	May 25, 2011
AB		2.5MG	A090935	003	May 25, 2011
AB		3MG	A090935	004	May 25, 2011
AB		4MG	A090935	005	May 25, 2011
AB		5MG	A090935	006	May 25, 2011
AB		6MG	A090935	007	May 25, 2011
AB		7.5MG	A090935	008	May 25, 2011
AB		10MG	A090935	009	May 25, 2011
AB	IPCA LABS LTD	1MG	A200104	001	Jun 27, 2013
AB		2MG	A200104	002	Jun 27, 2013
AB		2.5MG	A200104	003	Jun 27, 2013
AB		3MG	A200104	004	Jun 27, 2013
AB		4MG	A200104	005	Jun 27, 2013
AB		5MG	A200104	006	Jun 27, 2013
AB		6MG	A200104	007	Jun 27, 2013
AB		7.5MG	A200104	008	Jun 27, 2013
AB		10MG	A200104	009	Jun 27, 2013
AB	PLIVA	1MG	A040616	009	Jul 05, 2006
AB		2MG	A040616	001	Jul 05, 2006
AB		2.5MG	A040616	002	Jul 05, 2006
AB		3MG	A040616	003	Jul 05, 2006
AB		4MG	A040616	004	Jul 05, 2006
AB		5MG	A040616	005	Jul 05, 2006
AB		6MG	A040616	006	Jul 05, 2006
AB		7.5MG	A040616	007	Jul 05, 2006
AB !		10MG	A040616	008	Jul 05, 2006
AB	TARO	1MG	A040301	002	Jul 15, 1999
AB		2MG	A040301	003	Jul 15, 1999
AB		2.5MG	A040301	004	Jul 15, 1999
AB		3MG	A040301	005	Jul 15, 1999
AB		4MG	A040301	006	Jul 15, 1999
AB		5MG	A040301	007	Jul 15, 1999
AB		6MG	A040301	008	Jul 15, 1999
AB		7.5MG	A040301	009	Jul 15, 1999
AB		10MG	A040301	001	Jul 15, 1999
AB	ZYDUS PHARMS USA	1MG	A040663	001	May 30, 2006
AB		2MG	A040663	002	May 30, 2006
AB		2.5MG	A040663	003	May 30, 2006
AB		3MG	A040663	004	May 30, 2006
AB		4MG	A040663	005	May 30, 2006

WARFARIN SODIUM						
TABLET;ORAL						
WARFARIN SODIUM						
AB			**5MG**	**A040663**	**006**	May 30, 2006
AB			**6MG**	**A040663**	**007**	May 30, 2006
AB			**7.5MG**	**A040663**	**008**	May 30, 2006
AB			**10MG**	**A040663**	**009**	May 30, 2006
XENON XE-133						
GAS;INHALATION						
XENON XE 133						
		CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982
			20mCi/VIAL	N018327	002	Mar 09, 1982
		LANTHEUS MEDCL	10mCi/VIAL	N017284	001	
			20mCi/VIAL	N017284	002	
ZAFIRLUKAST						
TABLET;ORAL						
ACCOLATE						
AB	**+**	STRIDES PHARMA	**10MG**	**N020547**	**003**	Sep 17, 1999
AB	**+!**		**20MG**	**N020547**	**001**	Sep 26, 1996
ZAFIRLUKAST						
AB		ANNORA PHARMA	**10MG**	**A212475**	**001**	Sep 10, 2020
AB			**20MG**	**A212475**	**002**	Sep 10, 2020
AB		DR REDDYS LABS LTD	**10MG**	**A090372**	**001**	Nov 18, 2010
AB			**20MG**	**A090372**	**002**	Nov 18, 2010
ZALEPLON						
CAPSULE;ORAL						
SONATA						
AB	**+**	PFIZER	**5MG**	**N020859**	**001**	Aug 13, 1999
AB	**+!**		**10MG**	**N020859**	**002**	Aug 13, 1999
ZALEPLON						
AB		AUROBINDO PHARMA	**5MG**	**A078829**	**001**	Jun 06, 2008
AB			**10MG**	**A078829**	**002**	Jun 06, 2008
AB		CIPLA LTD	**5MG**	**A077505**	**001**	Jun 20, 2008
AB			**10MG**	**A077505**	**002**	Jun 20, 2008
AB		HIKMA	**5MG**	**A077237**	**001**	Jun 06, 2008
AB			**10MG**	**A077237**	**002**	Jun 06, 2008
AB		ORBION PHARMS	**5MG**	**A090374**	**001**	Sep 17, 2009
AB			**10MG**	**A090374**	**002**	Sep 17, 2009
AB		UNICHEM	**5MG**	**A078989**	**001**	Jun 06, 2008
AB			**10MG**	**A078989**	**002**	Jun 06, 2008
ZANAMIVIR						
POWDER;INHALATION						
RELENZA						
	+!	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999
ZANUBRUTINIB						
CAPSULE;ORAL						
BRUKINSA						
	+!	BEIGENE	80MG	N213217	001	Nov 14, 2019
ZICONOTIDE ACETATE						
INJECTABLE;INTRATHECAL						
PRIALT						
	+!	TERSERA	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
	+!		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
	+!		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004
ZIDOVUDINE						
CAPSULE;ORAL						
RETROVIR						
AB	**+!**	VIIV HLTHCARE	**100MG**	**N019655**	**001**	Mar 19, 1987
ZIDOVUDINE						
AB		AUROBINDO PHARMA LTD	**100MG**	**A078128**	**001**	Mar 27, 2006
AB		CIPLA LTD	**100MG**	**A078349**	**001**	May 23, 2007
INJECTABLE;INJECTION						
RETROVIR						
	+!	VIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990
SOLUTION;ORAL						
RETROVIR						
AA	**+!**	VIIV HLTHCARE	**50MG/5ML**	**N019910**	**001**	Sep 28, 1989

ZIDOVUDINE

SOLUTION;ORAL

ZIDOVUDINE

AA		AUROBINDO	**50MG/5ML**	**A077268**	**001**	Sep 19, 2005
AA		CIPLA LTD	**50MG/5ML**	**A077981**	**001**	Jun 26, 2008

TABLET;ORAL

ZIDOVUDINE

AB		AUROBINDO	**300MG**	**A077267**	**001**	Sep 19, 2005
AB		CIPLA	**300MG**	**A090561**	**001**	Oct 27, 2010
AB	**!**	HETERO LABS LTD III	**300MG**	**A090092**	**001**	Apr 25, 2008
AB		MYLAN PHARMS INC	**300MG**	**A078922**	**001**	Feb 14, 2008

ZILEUTON

TABLET;ORAL

ZYFLO

	+!	CHIESI	600MG	N020471	003	Dec 09, 1996

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

AB		DASH PHARMS	**600MG**	**A211390**	**001**	Oct 23, 2020
AB		RISING	**600MG**	**A204929**	**001**	Mar 17, 2017
AB		STRIDES PHARMA	**600MG**	**A212670**	**001**	Dec 16, 2019

ZYFLO CR

AB	**+!**	CHIESI	**600MG**	**N022052**	**001**	May 30, 2007

ZILEUTON

BX		LUPIN LTD	600MG	A211972	001	Nov 05, 2019

ZINC ACETATE

CAPSULE;ORAL

GALZIN

	+	TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
	+!		EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

AP		EXELA PHARMA	**EQ 1MG ZINC/ML**	**A212007**	**001**	May 21, 2021

ZINC CHLORIDE IN PLASTIC CONTAINER

AP	**+!**	HOSPIRA	**EQ 1MG ZINC/ML**	**N018959**	**001**	Jun 26, 1986

ZINC SULFATE

SOLUTION;INTRAVENOUS

ZINC SULFATE

	+!	AM REGENT	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020
	+!		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019
	+!		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

GEODON

AB	**+!**	UPJOHN	**EQ 20MG BASE**	**N020825**	**001**	Feb 05, 2001
AB	**+**		**EQ 40MG BASE**	**N020825**	**002**	Feb 05, 2001
AB	**+**		**EQ 60MG BASE**	**N020825**	**003**	Feb 05, 2001
AB	**+**		**EQ 80MG BASE**	**N020825**	**004**	Feb 05, 2001

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX	**EQ 20MG BASE**	**A077561**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077561**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077561**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077561**	**004**	Mar 02, 2012
AB		AUROBINDO PHARMA LTD	**EQ 20MG BASE**	**A204117**	**001**	Dec 27, 2016
AB			**EQ 40MG BASE**	**A204117**	**002**	Dec 27, 2016
AB			**EQ 60MG BASE**	**A204117**	**003**	Dec 27, 2016
AB			**EQ 80MG BASE**	**A204117**	**004**	Dec 27, 2016
AB		CADILA	**EQ 20MG BASE**	**A208988**	**001**	Aug 22, 2017
AB			**EQ 40MG BASE**	**A208988**	**002**	Aug 22, 2017
AB			**EQ 60MG BASE**	**A208988**	**003**	Aug 22, 2017
AB			**EQ 80MG BASE**	**A208988**	**004**	Aug 22, 2017
AB		CHARTWELL RX	**EQ 20MG BASE**	**A090348**	**001**	Sep 05, 2012
AB			**EQ 40MG BASE**	**A090348**	**002**	Sep 05, 2012
AB			**EQ 60MG BASE**	**A090348**	**003**	Sep 05, 2012
AB			**EQ 80MG BASE**	**A090348**	**004**	Sep 05, 2012
AB		DR REDDYS LABS INC	**EQ 20MG BASE**	**A077565**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077565**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077565**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077565**	**004**	Mar 02, 2012

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB		LUPIN PHARMS	**EQ 20MG BASE**	**A077560**	**001**	Mar 02, 2012
AB			**EQ 40MG BASE**	**A077560**	**002**	Mar 02, 2012
AB			**EQ 60MG BASE**	**A077560**	**003**	Mar 02, 2012
AB			**EQ 80MG BASE**	**A077560**	**004**	Mar 02, 2012
AB		MACLEODS PHARMS LTD	**EQ 20MG BASE**	**A204375**	**001**	Feb 17, 2017
AB			**EQ 40MG BASE**	**A204375**	**002**	Feb 17, 2017
AB			**EQ 60MG BASE**	**A204375**	**003**	Feb 17, 2017
AB			**EQ 80MG BASE**	**A204375**	**004**	Feb 17, 2017
AB		SANDOZ INC	**EQ 20MG BASE**	**A077562**	**001**	Jun 01, 2012
AB			**EQ 40MG BASE**	**A077562**	**002**	Jun 01, 2012
AB			**EQ 60MG BASE**	**A077562**	**003**	Jun 01, 2012
AB			**EQ 80MG BASE**	**A077562**	**004**	Jun 01, 2012

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR

GEODON

AP	**+!**	UPJOHN	**EQ 20MG BASE/ML**	**N020919**	**001**	Jun 21, 2002

ZIPRASIDONE MESYLATE

AP		GLAND PHARMA LTD	**EQ 20MG BASE/ML**	**A211908**	**001**	Dec 26, 2019

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

RECLAST

AP	**+!**	NOVARTIS	**EQ 5MG BASE/100ML**	**N021817**	**001**	Apr 16, 2007

ZOLEDRONIC

AP		GLAND PHARMA LTD	**EQ 4MG BASE/100ML**	**A205749**	**001**	Jun 29, 2018

ZOLEDRONIC ACID

AP		ACCORD HLTHCARE	**EQ 4MG BASE/5ML**	**A205279**	**001**	Nov 28, 2016
AP		AKORN	**EQ 4MG BASE/5ML**	**A202548**	**001**	May 22, 2014
AP			**EQ 5MG BASE/100ML**	**A200918**	**001**	Aug 21, 2014
AP		APOTEX	**EQ 5MG BASE/100ML**	**A204367**	**001**	Dec 24, 2015
AP		BPI LABS LLC	**EQ 4MG BASE/5ML**	**A207341**	**001**	Dec 29, 2017
AP		BRECKENRIDGE	**EQ 4MG BASE/5ML**	**A091170**	**001**	Mar 04, 2013
AP			**EQ 4MG BASE/5ML**	**A202571**	**001**	May 07, 2013
AP			**EQ 5MG BASE/100ML**	**A202163**	**001**	Aug 05, 2013
AP		DR REDDYS LABS LTD	**EQ 4MG BASE/5ML**	**A091186**	**001**	Mar 04, 2013
AP			**EQ 5MG BASE/100ML**	**A091363**	**001**	Mar 29, 2013
AP		EUGIA PHARMA	**EQ 4MG BASE/5ML**	**A207751**	**001**	Sep 26, 2016
AP			**EQ 5MG BASE/100ML**	**A209125**	**001**	Dec 08, 2017
AP		FRESENIUS KABI USA	**EQ 4MG BASE/5ML**	**A091516**	**001**	Apr 23, 2015
AP		GLAND	**EQ 5MG BASE/100ML**	**A204217**	**001**	Aug 18, 2016
AP		GLAND PHARMA LTD	**EQ 4MG BASE/5ML**	**A202930**	**001**	Aug 05, 2013
AP			**EQ 5MG BASE/100ML**	**A209578**	**001**	Aug 08, 2019
AP		HIKMA FARMACEUTICA	**EQ 4MG BASE/5ML**	**A202182**	**001**	Jun 03, 2013
AP		HOSPIRA INC	**EQ 4MG BASE/5ML**	**A090621**	**001**	Mar 19, 2015
AP			**EQ 5MG BASE/100ML**	**A202837**	**001**	Apr 05, 2013
AP		INFORLIFE	**EQ 4MG BASE/100ML**	**N203231**	**001**	Aug 02, 2013
AP			**EQ 5MG BASE/100ML**	**A202828**	**001**	Sep 23, 2013
AP		INGENUS PHARMS LLC	**EQ 4MG BASE/5ML**	**A208968**	**001**	Feb 19, 2020
AP		MYLAN LABS LTD	**EQ 4MG BASE/5ML**	**A202650**	**001**	Mar 04, 2013
AP			**EQ 5MG BASE/100ML**	**A203841**	**001**	Feb 14, 2017
AP			**EQ 5MG BASE/100ML**	**A205254**	**001**	Oct 27, 2017
AP		PUNISKA	**EQ 4MG BASE/100ML**	**A210174**	**001**	Oct 27, 2017
AP		SAGENT PHARMS INC	**EQ 4MG BASE/5ML**	**A091493**	**001**	Nov 24, 2014
AP		USV	**EQ 4MG BASE/5ML**	**A202923**	**001**	Sep 04, 2014

ZOMETA

AP	**+!**	NOVARTIS	**EQ 4MG BASE/5ML**	**N021223**	**002**	Mar 07, 2003
AP	**+!**		**EQ 4MG BASE/100ML**	**N021223**	**003**	Jun 17, 2011

SOLUTION;INTRAVENOUS

ZOLEDRONIC ACID

		HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015

ZOLMITRIPTAN

SPRAY;NASAL

ZOLMITRIPTAN

AB		PADAGIS ISRAEL	**2.5MG/SPRAY**	**A212469**	**001**	Sep 30, 2021
AB			**5MG/SPRAY**	**A212469**	**002**	Sep 30, 2021

ZOMIG

AB	**+**	ASTRAZENECA	**2.5MG/SPRAY**	**N021450**	**003**	Sep 16, 2013
AB	**+!**		**5MG/SPRAY**	**N021450**	**004**	Sep 30, 2003

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB		AJANTA PHARMA LTD	**2.5MG**	**A204041**	**001**	May 20, 2016
AB			**5MG**	**A204041**	**002**	May 20, 2016
AB		ALEMBIC PHARMS LTD	**2.5MG**	**A204232**	**001**	Sep 30, 2015
AB			**5MG**	**A204232**	**002**	Sep 30, 2015
AB		APPCO	**2.5MG**	**A206973**	**001**	Jun 30, 2017
AB			**5MG**	**A206973**	**002**	Jun 30, 2017
AB		AUROBINDO PHARMA LTD	**2.5MG**	**A207021**	**001**	May 11, 2016
AB			**5MG**	**A207021**	**002**	May 11, 2016
AB		GLENMARK GENERICS	**2.5MG**	**A201779**	**001**	May 14, 2013
AB			**5MG**	**A201779**	**002**	May 14, 2013
AB		INVAGEN PHARMS	**2.5MG**	**A204284**	**001**	Apr 09, 2014
AB			**5MG**	**A204284**	**002**	Apr 09, 2014
AB		JUBILANT GENERICS	**2.5MG**	**A202279**	**001**	Nov 20, 2014
AB			**5MG**	**A202279**	**002**	Nov 20, 2014
AB		ORBION PHARMS	**2.5MG**	**A203726**	**001**	Oct 21, 2019
AB			**5MG**	**A203726**	**002**	Oct 21, 2019
AB		PLD ACQUISITIONS LLC	**2.5MG**	**A207867**	**001**	Feb 27, 2017
AB			**5MG**	**A207867**	**002**	Feb 27, 2017
AB		ZYDUS PHARMS	**2.5MG**	**A203019**	**001**	Jul 11, 2018
AB			**5MG**	**A203019**	**002**	Jul 11, 2018

ZOMIG

AB	**+**	IPR	**2.5MG**	**N020768**	**001**	Nov 25, 1997
AB	**+!**		**5MG**	**N020768**	**002**	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

AB		ALEMBIC PHARMS LTD	**2.5MG**	**A205074**	**001**	Dec 01, 2016
AB			**5MG**	**A205074**	**002**	Dec 01, 2016
AB		GLENMARK GENERICS	**2.5MG**	**A202560**	**001**	May 14, 2013
AB			**5MG**	**A202560**	**002**	May 14, 2013
AB		JUBILANT GENERICS	**2.5MG**	**A202956**	**001**	Sep 17, 2015
AB			**5MG**	**A202956**	**002**	Sep 17, 2015
AB		ZYDUS PHARMS USA INC	**2.5MG**	**A202890**	**001**	May 15, 2013
AB			**5MG**	**A202890**	**002**	May 15, 2013

ZOMIG-ZMT

AB	**+**	ASTRAZENECA	**2.5MG**	**N021231**	**001**	Feb 13, 2001
AB	**+!**		**5MG**	**N021231**	**002**	Sep 17, 2001

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

	+!	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008

TABLET;ORAL

AMBIEN

AB	**+**	SANOFI AVENTIS US	**5MG**	**N019908**	**001**	Dec 16, 1992
AB	**+!**		**10MG**	**N019908**	**002**	Dec 16, 1992

ZOLPIDEM TARTRATE

AB		ACME LABS	**5MG**	**A077214**	**001**	Apr 23, 2007
AB			**10MG**	**A077214**	**002**	Apr 23, 2007
AB		APOTEX INC	**5MG**	**A077884**	**001**	Apr 23, 2007
AB			**10MG**	**A077884**	**002**	Apr 23, 2007
AB		AUROBINDO PHARMA	**5MG**	**A078413**	**001**	May 04, 2007
AB			**10MG**	**A078413**	**002**	May 04, 2007
AB		CIPLA LTD	**5MG**	**A077388**	**001**	Jul 30, 2012
AB			**10MG**	**A077388**	**002**	Jul 30, 2012
AB		INVAGEN PHARMS	**5MG**	**A078184**	**001**	Sep 07, 2007
AB			**10MG**	**A078184**	**002**	Sep 07, 2007
AB		SANDOZ INC	**5MG**	**A077322**	**001**	Apr 23, 2007
AB			**10MG**	**A077322**	**002**	Apr 23, 2007
AB		TEVA	**5MG**	**A076410**	**001**	Apr 23, 2007
AB			**10MG**	**A076410**	**002**	Apr 23, 2007
AB		TORRENT PHARMS	**5MG**	**A077903**	**001**	Aug 17, 2007
AB			**10MG**	**A077903**	**002**	Aug 17, 2007

TABLET;SUBLINGUAL

EDLUAR

AB	**+**	MYLAN SPECIALITY LP	**5MG**	**N021997**	**001**	Mar 13, 2009
AB	**+!**		**10MG**	**N021997**	**002**	Mar 13, 2009

ZOLPIDEM TARTRATE

TABLET;SUBLINGUAL

ZOLPIDEM TARTRATE

AB		DR REDDYS	**1.75MG**	**A204503**	**001**	Nov 18, 2016
AB			**3.5MG**	**A204503**	**002**	Nov 18, 2016
AB		NOVEL LABS INC	**1.75MG**	**A204299**	**001**	Jun 03, 2015
AB	**!**		**3.5MG**	**A204299**	**002**	Jun 03, 2015
AB		PAR FORM	**5MG**	**A201509**	**001**	Aug 01, 2016
AB			**10MG**	**A201509**	**002**	Aug 01, 2016
AB		PAR PHARM INC	**1.75MG**	**A204229**	**001**	Sep 11, 2017
AB			**3.5MG**	**A204229**	**002**	Sep 11, 2017

TABLET, EXTENDED RELEASE;ORAL

AMBIEN CR

AB	**+**	SANOFI AVENTIS US	**6.25MG**	**N021774**	**002**	Sep 02, 2005
AB	**+!**		**12.5MG**	**N021774**	**001**	Sep 02, 2005

ZOLPIDEM TARTRATE

AB		ACTAVIS LABS FL INC	**6.25MG**	**A090153**	**001**	Mar 25, 2013
AB			**12.5MG**	**A090153**	**002**	Mar 25, 2013
AB		ANCHEN PHARMS	**6.25MG**	**A078148**	**002**	Apr 14, 2011
AB			**12.5MG**	**A078148**	**001**	Dec 03, 2010
AB		APOTEX INC	**6.25MG**	**A200266**	**001**	Sep 10, 2013
AB			**12.5MG**	**A200266**	**002**	Sep 10, 2013
AB		BRECKENRIDGE	**6.25MG**	**A213592**	**001**	Jun 04, 2020
AB			**12.5MG**	**A213592**	**002**	Jun 04, 2020
AB		LUPIN LTD	**6.25MG**	**A078970**	**001**	Sep 11, 2013
AB			**12.5MG**	**A078970**	**002**	Sep 11, 2013
AB		SANDOZ	**6.25MG**	**A090107**	**001**	Jul 01, 2011
AB			**12.5MG**	**A090107**	**002**	Jul 01, 2011
AB		SUN PHARM	**6.25MG**	**A204170**	**001**	Jan 24, 2017
AB			**12.5MG**	**A204170**	**002**	Jan 24, 2017

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	**+**	CONCORDIA	**25MG**	**N020789**	**003**	Aug 22, 2003
AB	**+!**		**100MG**	**N020789**	**001**	Mar 27, 2000

ZONISAMIDE

AB		APOTEX INC	**25MG**	**A077642**	**001**	Dec 22, 2005
AB			**50MG**	**A077642**	**002**	Dec 22, 2005
AB			**100MG**	**A077642**	**003**	Dec 22, 2005
AB		AUROBINDO PHARMA LTD	**25MG**	**A077645**	**002**	Sep 29, 2006
AB			**50MG**	**A077645**	**003**	Sep 29, 2006
AB			**100MG**	**A077645**	**001**	Dec 22, 2005
AB		BIONPHARMA INC	**25MG**	**A077813**	**001**	Aug 16, 2006
AB			**50MG**	**A077813**	**002**	Aug 16, 2006
AB			**100MG**	**A077813**	**003**	Aug 16, 2006
AB		CADILA	**25MG**	**A077625**	**001**	Oct 16, 2006
AB			**50MG**	**A077625**	**002**	Oct 16, 2006
AB			**100MG**	**A077625**	**003**	Oct 16, 2006
AB		GLENMARK GENERICS	**25MG**	**A077651**	**001**	Jan 30, 2006
AB			**50MG**	**A077651**	**002**	Jan 30, 2006
AB			**100MG**	**A077651**	**003**	Jan 30, 2006
AB		GRANULES	**25MG**	**A077636**	**003**	Jul 27, 2006
AB			**50MG**	**A077636**	**002**	Jul 27, 2006
AB			**100MG**	**A077636**	**001**	Dec 22, 2005
AB		INVAGEN PHARMS	**25MG**	**A077869**	**001**	May 31, 2006
AB			**50MG**	**A077869**	**002**	May 31, 2006
AB			**100MG**	**A077869**	**003**	May 31, 2006
AB		SUN PHARM INDS (IN)	**25MG**	**A077634**	**001**	Mar 17, 2006
AB			**50MG**	**A077634**	**002**	Mar 17, 2006
AB			**100MG**	**A077634**	**003**	Mar 17, 2006
AB		UNICHEM	**25MG**	**A214492**	**001**	Jan 26, 2021
AB			**50MG**	**A214492**	**002**	Jan 26, 2021
AB			**100MG**	**A214492**	**003**	Jan 26, 2021

ACETAMINOPHEN

SUPPOSITORY;RECTAL						
ACEPHEN						
	COSETTE	120MG		N018060	001	
		325MG		A072344	001	Mar 27, 1992
		650MG		A072237	001	Mar 27, 1992
ACETAMINOPHEN						
	PERRIGO NEW YORK	120MG		A070607	001	Apr 06, 1987
		650MG		A070608	001	Dec 01, 1986
+	TARO PHARM INDS LTD	120MG		N018337	003	Sep 12, 1983
+		325MG		N018337	002	
+!		650MG		N018337	001	
INFANTS' FEVERALL						
+	TARO PHARM INDS LTD	80MG		N018337	004	Aug 26, 1992
TABLET, EXTENDED RELEASE;ORAL						
ACETAMINOPHEN						
	AUROBINDO PHARMA LTD	650MG		A207229	001	Nov 09, 2016
	GRANULES	650MG		A211544	001	Apr 16, 2019
	HERITAGE PHARMA	650MG		A207035	001	May 31, 2018
	MARKSANS PHARMA	650MG		A215486	001	Aug 25, 2021
	OHM LABS	650MG		A076200	001	Mar 19, 2002
	PERRIGO	650MG		A075077	001	Feb 25, 2000
	SUN PHARM INDS LTD	650MG		A078569	001	Dec 14, 2011
TYLENOL						
+!	J AND J CONSUMER INC	650MG		N019872	001	Jun 08, 1994
+!		650MG		N019872	002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL						
ACETAMINOPHEN, ASPIRIN AND CAFFEINE						
	GRANULES	250MG;250MG;65MG		A214039	001	Feb 23, 2021
	PERRIGO	250MG;250MG;65MG		A075794	001	Nov 26, 2001
EXCEDRIN (MIGRAINE)						
+!	GLAXOSMITHKLINE CONS	250MG;250MG;65MG		N020802	001	Jan 14, 1998

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL						
ADVIL DUAL ACTION WITH ACETAMINOPHEN						
+!	GLAXOSMITHKLINE	250MG;125MG		N211733	001	Feb 28, 2020

ADAPALENE

GEL;TOPICAL						
ADAPALENE						
	GLENMARK GENERICS	0.1%		A091314	001	Jul 01, 2010
	P AND L	0.1%		A090962	001	Jun 02, 2010
DIFFERIN						
+!	GALDERMA LABS LP	0.1%		N020380	002	Jul 08, 2016

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC						
LASTACAFT						
+!	ALLERGAN	0.25%		N022134	001	Jul 28, 2010

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL						
AVAGARD						
+!	3M	61%;1%		N021074	001	Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL						
GAVISCON						
+	CHATTEM SANOFI	80MG;20MG		N018685	001	Dec 09, 1983

ASPIRIN

CAPSULE;ORAL						
VAZALORE						
+	PLX PHARMA	81MG		N203697	002	Feb 26, 2021
+!		325MG		N203697	001	Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM;TOPICAL

ANTHELIOS SX

+!	LOREAL USA	2%;2%;10%	N021502	001	Jul 21, 2006

CAPITAL SOLEIL 15

+!	LOREAL USA	2%;3%;10%	N021501	001	Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM;TOPICAL

ANTHELIOS 20

+!	LOREAL USA	2%;2%;10%;2%	N021471	001	Oct 05, 2006

ANTHELIOS 40

+!	LOREAL USA	2%;3%;10%;5%	N022009	001	Mar 31, 2008
+!		2%;3%;10%;5%	N022009	002	Oct 29, 2009

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

ASTEPRO ALLERGY

+!	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	001	Jun 17, 2021

CHILDREN'S ASTEPRO ALLERGY

+!	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	002	Jun 17, 2021

BENTOQUATAM

LOTION;TOPICAL

IVY BLOCK

+!	STAND HOMEOPATH	5%	N020532	001	Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

LUMIFY

+!	BAUSCH AND LOMB INC	0.025%	N208144	001	Dec 22, 2017

BUDESONIDE

SPRAY, METERED;NASAL

BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015

RHINOCORT ALLERGY

+!	J AND J CONSUMER INC	0.032MG/SPRAY	N020746	003	Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

BUTENAFINE HYDROCHLORIDE

	TARO PHARMS	1%	A205181	001	Nov 16, 2017

LOTRIMIN ULTRA

+!	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

	PERRIGO R AND D	800MG;10MG;165MG	A077355	001	Feb 06, 2008
		800MG;10MG;165MG	A204782	001	Aug 29, 2016

PEPCID COMPLETE

+!	J AND J CONSUMER INC	800MG;10MG;165MG	N020958	001	Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	APOTEX	10MG	A207235	001	Aug 12, 2016
	AUROBINDO PHARMA LTD	10MG	A209107	001	Jul 20, 2018
+	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009
+!		10MG	N022429	004	Jul 23, 2009
	CATALENT	10MG	A213105	001	Sep 21, 2020
	STRIDES PHARMA	10MG	A205291	001	Jul 21, 2017

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	AUROBINDO PHARMA LTD	10MG	A209107	002	Jul 20, 2018
+	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009
+!		10MG	N022429	002	Jul 23, 2009

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009
	AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010
	HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

LANNETT CO INC	5MG/5ML	A091130	001	Apr 22, 2011
MICRO LABS	5MG/5ML	A091327	001	Oct 17, 2011
PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013
	5MG/5ML	A090254	002	Apr 09, 2008
QUAGEN	5MG/5ML	A212266	001	May 16, 2019
TARO	5MG/5ML	A090182	002	Apr 22, 2008
	5MG/5ML	A201546	001	May 20, 2011
TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010
LANNETT CO INC	5MG/5ML	A091130	002	Apr 22, 2011
MICRO LABS	5MG/5ML	A091327	002	Oct 17, 2011
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008
TARO	5MG/5ML	A090182	001	Apr 22, 2008
	5MG/5ML	A201546	002	May 20, 2011
TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010
	10MG	A078780	004	Jan 21, 2010
APOTEX INC	5MG	A078317	001	Dec 27, 2007
	10MG	A078317	002	Dec 27, 2007
AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015
	10MG	A090760	003	Aug 05, 2015
CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
GRANULES	10MG	A209274	001	Dec 22, 2017
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
	10MG	A202277	004	Mar 11, 2014
MARKSANS PHARMA	5MG	A078933	001	Jun 15, 2010
	10MG	A078933	002	Jun 15, 2010
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORBION PHARMS	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MARKSANS PHARMA	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORBION PHARMS	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL					
CETIRIZINE HYDROCHLORIDE HIVES					
	SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
		10MG	A077498	004	Dec 27, 2007
	UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
!		10MG	A077829	002	Aug 26, 2009
CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
		10MG	A078780	002	Jan 21, 2010
	AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015
		10MG	A090760	004	Aug 05, 2015
	TARO	10MG	A078072	002	Jul 22, 2009
		10MG	A078072	004	Jul 22, 2009
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N019835	004	Nov 16, 2007
TABLET, CHEWABLE;ORAL					
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY					
	JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015
		10MG	A091116	002	Feb 19, 2015
	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016
		10MG	A206793	002	Mar 08, 2016
	SANDOZ	5MG	A078692	001	Feb 14, 2008
!		10MG	A078692	002	Feb 14, 2008
	SUN PHARM	5MG	A090142	001	Aug 30, 2011
		10MG	A090142	002	Aug 30, 2011
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
	JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015
		10MG	A091116	004	Feb 19, 2015
	SUN PHARM	5MG	A090142	003	Aug 30, 2011
		10MG	A090142	004	Aug 30, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
CETIRIZINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	10MG	A213557	001	Sep 11, 2020
CETIRIZINE HYDROCHLORIDE ALLERGY					
	PERRIGO R AND D	10MG	A205490	001	Sep 02, 2015
ZYRTEC ALLERGY					
+!	J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
	PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018
	PLD ACQUISITIONS	5MG;120MG	A077991	001	Mar 05, 2008
	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR					
+!	J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL					
EXIDINE					
+!	XTTRIUM	4%	N019127	001	Dec 24, 1984
CLOTH;TOPICAL					
CHLORHEXIDINE GLUCONATE					
+!	SAGE PRODS	2%	N021669	001	Apr 25, 2005
READYPREP CHG					
	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018
SOLUTION;TOPICAL					
CHG SCRUB					
	ECOLAB	4%	N019258	002	Jul 22, 1986
CHLORHEXIDINE GLUCONATE					
	BAJAJ	0.75%	N020111	001	Sep 11, 1997
CIDA-STAT					
	ECOLAB	2%	N019258	001	Jul 22, 1986
EXIDINE					
+!	XTTRIUM	2%	N019422	001	Dec 17, 1985
		4%	N019125	001	Dec 24, 1984

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL					
HIBICLENS					
+!	MOLNLYCKE HLTH	4%	N017768	001	
HIBISTAT					
+!	MOLNLYCKE HLTH	0.5%	N018300	001	
SPONGE;TOPICAL					
BIOSCRUB					
	GRIFFEN	4%	N019822	001	Mar 31, 1989
CHLORHEXIDINE GLUCONATE					
!	BECTON DICKINSON	4%	A072525	001	Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION;TOPICAL					
SOLUPREP					
+!	3M HEALTH CARE	2%;70%	N208288	001	Aug 08, 2018
SPONGE;TOPICAL					
CHLORAPREP ONE-STEP					
+!	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000
+!		2%;70% (10.5ML)	N020832	004	Aug 20, 2003
+!		2%;70% (26ML)	N020832	006	Nov 21, 2006
+!		2%;70% (1ML)	N020832	008	Oct 23, 2008
CHLORAPREP ONE-STEP FREPP					
+!	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
CHLORAPREP WITH TINT					
+!	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005
+!		2%;70% (10.5ML)	N020832	005	Apr 03, 2006
+!		2%;70% (3ML)	N020832	007	Oct 10, 2006
SWAB;TOPICAL					
CHLORAPREP ONE-STEP SEPP					
+!	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
CHLORAPREP SINGLE SWABSTICK					
+!	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005
CHLORAPREP TRIPLE SWABSTICK					
+!	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
PREVANTICS MAXI SWABSTICK					
+!	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
PREVANTICS SWAB					
+!	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
PREVANTICS SWABSTICK					
+!	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL					
CHLORPHENIRAMINE MALEATE					
!	AVANTHI INC	12MG	A040829	001	May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL					
ADVIL ALLERGY AND CONGESTION RELIEF					
+!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	001	Dec 21, 2011
ADVIL MULTI-SYMPTOM COLD & FLU					
+!	GLAXOSMITHKLINE	4MG;200MG;10MG	N022113	002	Apr 28, 2017

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL					
CHILDREN'S ADVIL ALLERGY SINUS					
+!	GLAXOSMITHKLINE	1MG/5ML;100MG/5ML;15MG/5ML	N021587	001	Feb 24, 2004
TABLET;ORAL					
ADVIL ALLERGY SINUS					
+!	GLAXOSMITHKLINE	2MG;200MG;30MG	N021441	001	Dec 19, 2002

CIMETIDINE

TABLET;ORAL					
CIMETIDINE					
	APOTEX	100MG	A074948	001	Jun 19, 1998
		200MG	A074948	002	Jul 26, 2002
	IVAX SUB TEVA PHARMS	200MG	A075345	001	Jun 16, 1999
	L PERRIGO CO	200MG	A075285	001	Oct 29, 1998
TAGAMET HB					
+!	MEDTECH PRODUCTS	200MG	N020238	002	Aug 21, 1996

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

!	L PERRIGO CO	1.34MG	A074512	001	Nov 22, 1995

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

!	P AND L	1%	A074165	001	Jul 16, 1993
	TARO	1%	A072641	001	Dec 04, 1995

TRIVAGIZOLE 3

	TARO	2%	N021143	001	Apr 12, 2000

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

!	BAUSCH AND LOMB	5.2MG/SPRAY	A075702	001	Jul 03, 2001
	PERRIGO	5.2MG/SPRAY	A075427	001	Dec 12, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL	30MG;600MG	A091070	001	Aug 31, 2015
		60MG;1.2GM	A091070	002	Aug 31, 2015
	AMNEAL PHARMS	30MG;600MG	A209692	001	Nov 01, 2018
		60MG;1.2GM	A209692	002	Nov 01, 2018
	AUROBINDO PHARMA LTD	30MG;600MG	A206941	001	Mar 17, 2017
		60MG;1.2GM	A206941	002	Mar 17, 2017
	PERRIGO R AND D	30MG;600MG	A207602	002	Mar 05, 2018
		60MG;1.2GM	A207602	001	Mar 05, 2018
	SUN PHARM	30MG;600MG	A214781	001	Jul 01, 2021
		60MG;1.2GM	A214781	002	Jul 01, 2021

MUCINEX DM

+	RB HLTH	30MG;600MG	N021620	002	Apr 29, 2004
+!		60MG;1.2GM	N021620	001	Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+!	RB HLTH	EQ 30MG HYDROBROMIDE/5ML	N018658	001	Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

	AMNEAL	EQ 30MG HYDROBROMIDE/5ML	A203133	001	Jul 28, 2017
	TRIS PHARMA INC	EQ 30MG HYDROBROMIDE/5ML	A091135	001	May 25, 2012

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016
	AUROLIFE PHARMA LLC	1%	A204306	001	May 06, 2019
	ENCUBE	1%	A210986	001	Jan 27, 2020
	PERRIGO PHARMA INTL	1%	A211253	001	May 16, 2019

VOLTAREN ARTHRITIS PAIN

+!	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+!	GLAXOSMITHKLINE	38MG;200MG	N021394	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

	DR REDDYS LABS LTD	38MG;200MG	A090619	001	Jul 08, 2009
	PERRIGO R AND D	38MG;200MG	A079113	001	Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+!	GLAXOSMITHKLINE	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	N021393	001	Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019
	BIONPHARMA INC	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010
	STRIDES PHARMA	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL					
ALEVE PM					
+!	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE					
	AMNEAL PHARMS CO	25MG;220MG	A209726	001	Oct 23, 2018
	APOTEX	25MG;220MG	A211830	001	Aug 22, 2019
	GRANULES	25MG;220MG	A213663	001	Sep 24, 2020
	PERRIGO R AND D	25MG;220MG	A208499	001	May 10, 2019

DOCOSANOL

CREAM;TOPICAL					
ABREVA					
+!	GLAXOSMITHKLINE	10%	N020941	001	Jul 25, 2000
DOCOSANOL					
	P AND L	10%	A208754	001	Nov 19, 2018

DOXYLAMINE SUCCINATE

TABLET;ORAL					
DOXYLAMINE SUCCINATE					
	LNK	25MG	A040564	001	Aug 27, 2004
	PERRIGO	25MG	A040167	001	Sep 18, 1996
UNISOM					
+!	CHATTEM	25MG	N018066	001	

EPINEPHRINE

AEROSOL, METERED;INHALATION					
PRIMATENE MIST					
+!	ARMSTRONG PHARMS	0.125MG/INH	N205920	001	Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
	AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A209339	001	Oct 16, 2017
	DR REDDYS LABS LTD	EQ 20MG BASE	A207673	001	May 15, 2018
	HETERO LABS LTD III	EQ 20MG BASE	A208939	001	May 28, 2020
		EQ 20MG BASE	A212507	001	Jun 02, 2020
	PERRIGO R AND D	EQ 20MG BASE	A207193	001	Aug 18, 2017
	SUN PHARM	EQ 20MG BASE	A212866	001	May 04, 2020
NEXIUM 24HR					
+!	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014
TABLET, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
	DR REDDYS LABS LTD	EQ 20MG BASE	A211571	001	May 14, 2020
	MYLAN	EQ 20MG BASE	A212088	001	Jun 25, 2020
NEXIUM 24HR					
+!	ASTRAZENECA LP	EQ 20MG BASE	N207920	001	Nov 23, 2015
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE MAGNESIUM					
+!	DEXCEL PHARMA	EQ 20MG BASE	N214278	001	Oct 20, 2020

FAMOTIDINE

TABLET;ORAL					
FAMOTIDINE					
	ANNORA PHARMA	10MG	A215766	001	Nov 08, 2021
		20MG	A215766	002	Nov 08, 2021
	ASCENT PHARMS INC	10MG	A216030	001	Nov 03, 2021
		20MG	A216030	002	Nov 03, 2021
	AUROBINDO PHARMA LTD	10MG	A206531	001	Apr 26, 2016
		20MG	A206531	002	Apr 26, 2016
	DR REDDYS LABS LTD	10MG	A077367	002	Aug 17, 2001
		20MG	A077367	001	Sep 25, 2006
	P AND L	10MG	A075512	001	Jul 26, 2001
	PERRIGO	10MG	A075400	001	Mar 18, 2005
	PERRIGO R AND D	20MG	A077351	001	Sep 25, 2006
	SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009
		20MG	A090283	002	Nov 17, 2009
	WOCKHARDT	10MG	A077146	001	Mar 07, 2005
		20MG	A090837	001	Aug 04, 2010
PEPCID AC					
+	J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995

FAMOTIDINE

TABLET;ORAL

PEPCID AC

		10MG	N020902	001	Aug 05, 1999
+!		20MG	N020325	002	Sep 23, 2003

TABLET, CHEWABLE;ORAL

FAMOTIDINE

	PERRIGO	10MG	A075715	001	Aug 22, 2003

PEPCID AC

+!	J AND J CONSUMER INC	20MG	N020801	002	Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+!	CHATTEM SANOFI	30MG/5ML	N201373	001	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	P AND L	30MG/5ML	A203330	001	Nov 18, 2014
	TARO	30MG/5ML	A208123	001	Nov 09, 2017

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

!	P AND L	30MG/5ML	A203330	002	Nov 18, 2014
	TARO	30MG/5ML	A208123	002	Nov 09, 2017

TABLET;ORAL

ALLEGRA ALLERGY

+	CHATTEM SANOFI	60MG	N020872	007	Jan 24, 2011
+!		180MG	N020872	010	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

	AUROLIFE PHARMA LLC	30MG	A202039	001	Nov 19, 2014
	DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011
	HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016
	SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012
	TEVA	30MG	A076447	004	Apr 13, 2011
	WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011
	SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012
	TEVA	30MG	A076447	005	Apr 13, 2011
	WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE

	L PERRIGO CO	60MG	A212971	001	Feb 24, 2020
		180MG	A212971	002	Feb 24, 2020

FEXOFENADINE HYDROCHLORIDE ALLERGY

	AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014
		180MG	A202039	003	Nov 19, 2014
	DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011
		180MG	A076502	008	Apr 12, 2011
	GRANULES	60MG	A211075	001	Oct 18, 2019
		180MG	A211075	002	Oct 18, 2019
	HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016
		180MG	A204097	003	Aug 19, 2016
	RISING	60MG	A077081	006	Jul 21, 2011
		180MG	A077081	008	Jul 21, 2011
	SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015
		180MG	A204507	003	Sep 16, 2015
	SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012
		180MG	A091567	006	Feb 06, 2012
	TEVA	60MG	A076447	006	Apr 13, 2011
		180MG	A076447	008	Apr 13, 2011
	UNIQUE PHARM LABS	180MG	A210137	001	Aug 13, 2018
	WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012
		180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

	DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011
		180MG	A076502	009	Apr 12, 2011
	RISING	60MG	A077081	007	Jul 21, 2011
		180MG	A077081	009	Jul 21, 2011
	SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015
		180MG	A204507	005	Sep 16, 2015
	SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012
		180MG	A091567	005	Feb 06, 2012
	TEVA	60MG	A076447	007	Apr 13, 2011
	WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012
		180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION					
+!	SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION					
+!	SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	60MG;120MG	A209116	001	Oct 30, 2017
	DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014
		180MG;240MG	A079043	002	Jun 22, 2011
	SUN PHARM	60MG;120MG	A090818	001	Jan 29, 2015

FLUTICASONE FUROATE

SPRAY, METERED;NASAL					
FLONASE SENSIMIST ALLERGY RELIEF					
+!	GLAXOSMITHKLINE CONS	0.0275MG/SPRAY	N022051	002	Aug 02, 2016

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL					
FLONASE ALLERGY RELIEF					
+	GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014
FLUTICASONE PROPIONATE					
	AKORN	0.05MG/SPRAY	A208024	001	Apr 17, 2019
	APOTEX	0.05MG/SPRAY	A208150	001	Feb 29, 2016
!	HIKMA	0.05MG/SPRAY	A207957	001	May 26, 2016

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL					
GUAIFENESIN					
	ACTAVIS LABS FL	1.2GM	A091009	002	Sep 03, 2015
	AMNEAL PHARMS	600MG	A207342	001	Jul 11, 2018
		1.2GM	A207342	002	Jul 11, 2018
	AUROBINDO PHARMA LTD	600MG	A210453	001	Oct 21, 2019
		1.2GM	A210453	002	Oct 21, 2019
	GRANULES	600MG	A213420	001	May 08, 2020
		1.2GM	A213420	002	May 08, 2020
	GUARDIAN DRUG	600MG	A209215	001	Sep 06, 2017
		1.2GM	A209215	002	Sep 06, 2017
	OHM LABS INC	600MG	A209254	001	Jul 16, 2018
		1.2GM	A209254	002	Jul 16, 2018
	PERRIGO R AND D	600MG	A078912	001	Nov 23, 2011
		1.2GM	A078912	002	Nov 05, 2020
MUCINEX					
+	RB HLTH	600MG	N021282	001	Jul 12, 2002
+!		1.2GM	N021282	002	Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	ACTAVIS LABS FL	600MG;60MG	A091071	001	May 27, 2015
		1.2GM;120MG	A091071	002	May 27, 2015
	AUROBINDO PHARMA LTD	600MG;60MG	A213203	001	Mar 25, 2020
		1.2GM;120MG	A213203	002	Mar 25, 2020
	DR REDDYS LABS LTD	600MG;60MG	A208369	001	Dec 29, 2017
		1.2GM;120MG	A208369	002	Dec 29, 2017
	SUN PHARM INDS INC	600MG;60MG	A212542	001	Apr 28, 2020
		1.2GM;120MG	A212542	002	Apr 28, 2020
MUCINEX D					
+	RB HLTH	600MG;60MG	N021585	001	Jun 22, 2004
+!		1.2GM;120MG	N021585	002	Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL					
ADVIL LIQUI-GELS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	001	Apr 20, 1995
ADVIL MIGRAINE LIQUI-GELS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT	N020402	002	Mar 16, 2000
IBUPROFEN					
	AMNEAL PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A202300	001	Dec 23, 2011
	ASCENT PHARMS INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A206999	001	Dec 21, 2017
	AUROBINDO PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A207753	001	Jun 29, 2018

IBUPROFEN

CAPSULE;ORAL					
IBUPROFEN					
	LTD				
	BIONPHARMA INC	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009
	HUMANWELL PURACAP	EQ 200MG FREE ACID AND POTASSIUM SALT	A206568	001	Jun 21, 2016
	MARKSANS PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A079205	001	Jun 26, 2009
	P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009
	SOFGEN PHARMS	EQ 200MG FREE ACID AND POTASSIUM SALT	A203599	001	Sep 07, 2016
MIDOL LIQUID GELS					
+!	BIONPHARMA INC	200MG	N021472	001	Oct 18, 2002
SUSPENSION;ORAL					
CHILDREN'S ADVIL					
	GLAXOSMITHKLINE	100MG/5ML	N020589	001	Jun 27, 1996
CHILDREN'S ADVIL-FLAVORED					
	GLAXOSMITHKLINE	100MG/5ML	N020589	002	Nov 07, 1997
CHILDREN'S IBUPROFEN					
	PERRIGO	100MG/5ML	A074937	001	Dec 22, 1998
CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995
IBUPROFEN					
	APTAPHARMA INC	100MG/5ML	A210602	001	Nov 23, 2018
	ARISE	100MG/5ML	A200457	001	Aug 18, 2011
	AUROBINDO PHARMA LTD	100MG/5ML	A209179	001	Apr 17, 2018
	GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018
	P AND L	100MG/5ML	A074916	001	Apr 30, 1999
	TARO	100MG/5ML	A209207	001	Jun 27, 2017
SUSPENSION/DROPS;ORAL					
CHILDREN'S MOTRIN					
+!	J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996
IBUPROFEN					
	GUARDIAN DRUG	40MG/ML	A210755	001	Sep 26, 2018
	L PERRIGO CO	40MG/ML	A075217	001	Dec 16, 1998
	TRIS PHARMA INC	40MG/ML	A079058	001	Aug 31, 2009
INFANT'S ADVIL					
+!	GLAXOSMITHKLINE	50MG/1.25ML	N020812	002	Jan 12, 2000
TABLET;ORAL					
ADVIL					
+!	GLAXOSMITHKLINE	200MG	N018989	001	May 18, 1984
IBUPROFEN					
	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
	AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
		200MG	A072199	001	May 23, 1988
	AUROBINDO PHARMA LTD	200MG	A208865	001	Nov 08, 2017
	AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
	CONTRACT PHARMACAL	200MG	A072299	001	Jul 01, 1988
	DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
	DR REDDYS LABS INC	200MG	A076117	001	Nov 20, 2001
	GRANULES	200MG	A202312	001	Oct 07, 2016
	GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
	LNK	200MG	A075010	001	Mar 01, 1999
		200MG	A075139	001	Mar 01, 1999
	MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
		200MG	A091239	001	Feb 01, 2011
	MCNEIL	200MG	A073019	001	Mar 30, 1994
	OHM	200MG	A071163	001	Jul 15, 1986
	PERRIGO	200MG	A072096	001	Dec 08, 1987
		200MG	A075995	001	Mar 14, 2002
!	PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
	SHANDONG XINHUA	200MG	A207095	001	May 05, 2017
		200MG	A207095	002	Aug 21, 2018
	STRIDES PHARMA	200MG	A070481	001	Sep 24, 1986
		200MG	A079129	001	Mar 28, 2011
		200MG	A091355	001	Apr 04, 2011
		200MG	A206989	001	Jun 29, 2018
		200MG	A207052	001	May 30, 2017
	VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
JUNIOR STRENGTH ADVIL					
	GLAXOSMITHKLINE	100MG	N020267	002	Dec 13, 1996

IBUPROFEN

TABLET;ORAL					
JUNIOR STRENGTH IBUPROFEN					
	L PERRIGO CO	100MG	A075367	001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN					
	J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996
MOTRIN IB					
+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990
TAB-PROFEN					
	PERRIGO	200MG	A072095	001	Dec 08, 1987
TABLET, CHEWABLE;ORAL					
CHILDREN'S ADVIL					
	GLAXOSMITHKLINE	50MG	N020944	001	Dec 18, 1998
IBUPROFEN					
!	PERRIGO	100MG	A076359	002	Jan 16, 2004
JUNIOR STRENGTH ADVIL					
	GLAXOSMITHKLINE	100MG	N020944	002	Dec 18, 1998

IBUPROFEN SODIUM

TABLET;ORAL					
ADVIL					
+!	GLAXOSMITHKLINE	EQ 200MG BASE	N201803	001	Jun 12, 2012

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL					
ADVIL CONGESTION RELIEF					
+!	GLAXOSMITHKLINE	200MG;10MG	N022565	001	May 27, 2010
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE					
	PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL					
ADVIL COLD AND SINUS					
+!	GLAXOSMITHKLINE	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	N021374	001	May 30, 2002
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT;30MG	A209235	001	Dec 01, 2017
SUSPENSION;ORAL					
CHILDREN'S ADVIL COLD					
	GLAXOSMITHKLINE	100MG/5ML;15MG/5ML	N021373	001	Apr 18, 2002
CHILDREN'S MOTRIN COLD					
+!	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	PERRIGO	100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003
TABLET;ORAL					
ADVIL COLD AND SINUS					
+!	GLAXOSMITHKLINE	200MG;30MG	N019771	001	Sep 19, 1989
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	DR REDDYS LABS LTD	200MG;30MG	A077628	001	Aug 14, 2006
IBUPROHM COLD AND SINUS					
	OHM LABS	200MG;30MG	A074567	001	Apr 17, 2001
SINE-AID IB					
	J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE;TOPICAL					
DURAPREP					
+!	3M	EQ 0.7% IODINE;74% (6ML)	N021586	001	Sep 29, 2006
+!		EQ 0.7% IODINE;74% (26ML)	N021586	002	Sep 29, 2006

IVERMECTIN

LOTION;TOPICAL					
IVERMECTIN					
	TARO	0.5%	A210720	001	May 06, 2020
SKLICE					
+!	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL ANTI-DANDRUFF					
+!	KRAMER	1%	N020310	001	Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY					
	BAUSCH	EQ 0.035% BASE	A208158	001	Sep 24, 2020
+!	BAUSCH AND LOMB	EQ 0.025% BASE	N021996	001	Dec 01, 2006
+		EQ 0.035% BASE	N021996	002	Feb 11, 2015
KETOTIFEN FUMARATE					
	AKORN	EQ 0.025% BASE	A077958	001	Jul 26, 2007
	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006
	BAYSHORE PHARMS LLC	EQ 0.025% BASE	A204059	001	Jun 01, 2020
ZADITOR					
!	ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE					
	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
	LANNETT CO INC	15MG	A207157	001	Sep 29, 2017
	MYLAN	15MG	A203187	001	Jun 01, 2016
	NATCO	15MG	A203306	001	Jan 13, 2016
	PERRIGO R AND D	15MG	A202319	001	May 18, 2012
	WOCKHARDT LTD	15MG	A202727	001	May 18, 2012
PREVACID 24 HR					
+!	PERRIGO PHARMA INTL	15MG	N022327	001	May 18, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE					
	DEXCEL PHARMA	15MG	N208025	001	Jun 07, 2016

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR					
+!	SANOFI	2.5MG/5ML	N209090	001	Jan 31, 2017

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE					
	APOTEX	5MG	A211443	001	Apr 21, 2021
	DR REDDYS LABS LTD	5MG	A210375	001	Jan 19, 2018
	HETERO LABS LTD III	5MG	A213513	001	Apr 29, 2020
	MICRO LABS	5MG	A211551	001	Nov 20, 2018
	PERRIGO R AND D	5MG	A211983	001	Mar 28, 2019
XYZAL ALLERGY 24HR					
+!	SANOFI	5MG	N209089	001	Jan 31, 2017

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT					
	AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015
FALLBACK SOLO					
	LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
HER STYLE					
	NOVAST LABS	1.5MG	A207976	001	Mar 11, 2016
LEVONORGESTREL					
	GLENMARK PHARMS LTD	1.5MG	A207044	001	Mar 25, 2016
!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010
	LABORATOIRE HRA	1.5MG	A204044	001	Jul 03, 2018
	MYLAN LABS LTD	1.5MG	A202739	001	Oct 31, 2014
	NAARI PTE LTD	1.5MG	A202380	001	May 29, 2015
	NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
	PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014
	XIROMED	1.5MG	A205329	001	Sep 18, 2018
OPCICON ONE-STEP					
	SUN PHARM	1.5MG	A202635	001	Sep 11, 2014
PLAN B ONE-STEP					
+!	FDN CONSUMER	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL					
LOPERAMIDE HYDROCHLORIDE					
+	BIONPHARMA INC	1MG	N021855	001	Aug 04, 2005
+!		2MG	N021855	002	Aug 04, 2005
	STRIDES PHARMA	2MG	A213070	001	Aug 11, 2021
SOLUTION;ORAL					
IMODIUM A-D					
+!	J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE					
	AKORN	1MG/5ML	A074352	001	Nov 17, 1995
	PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997
SUSPENSION;ORAL					
IMODIUM A-D					
+!	J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004
LOPERAMIDE HYDROCHLORIDE					
	PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011
TABLET;ORAL					
IMODIUM A-D					
+!	J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE					
	AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015
	L PERRIGO CO	2MG	A075232	001	Jan 06, 2000
	LNK	2MG	A076497	001	Jun 10, 2003
	OHM LABS	2MG	A074091	001	Dec 10, 1992

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL					
IMODIUM MULTI-SYMPTOM RELIEF					
+!	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE					
	AUROBINDO PHARMA LTD	2MG;125MG	A211059	001	Dec 14, 2020
	BIONPHARMA INC	2MG;125MG	A213484	001	Sep 10, 2021
	GUARDIAN DRUG	2MG;125MG	A214541	001	May 27, 2021
	HETERO LABS LTD V	2MG;125MG	A211438	001	Jun 17, 2021
	PERRIGO R AND D	2MG;125MG	A209837	001	Sep 05, 2018
	SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006
TABLET, CHEWABLE;ORAL					
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE					
!	PERRIGO	2MG;125MG	A076029	001	Aug 30, 2002

LORATADINE

CAPSULE;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008
LORATADINE					
	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018
	MARKSANS PHARMA	10MG	A206214	001	Sep 23, 2016
SUSPENSION;ORAL					
LORATADINE					
+!	TARO	1MG/ML	N021734	001	Oct 04, 2005
SYRUP;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002
LORATADINE					
	AUROBINDO PHARMA LTD	1MG/ML	A208931	001	Jun 29, 2018
	HETERO LABS LTD III	1MG/ML	A210409	001	May 07, 2021
	LANNETT CO INC	1MG/ML	A077421	001	Jun 29, 2006
	PERRIGO	1MG/ML	A075728	001	Aug 20, 2004
	TARO	1MG/ML	A076805	001	Aug 20, 2004
		1MG/ML	A201865	001	Jul 31, 2015
	WOCKHARDT BIO AG	1MG/ML	A075815	001	Aug 20, 2004
TABLET;ORAL					
CLARITIN					
+!	BAYER HEALTHCARE	10MG	N019658	002	Nov 27, 2002

LORATADINE

TABLET;ORAL

CLARITIN

	LLC				

CLARITIN HIVES RELIEF

+!	BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003

LORATADINE

	APOTEX INC	10MG	A076471	001	Feb 14, 2006
	APPCO	10MG	A207569	001	Mar 12, 2019
	AUROBINDO PHARMA LTD	10MG	A208314	001	Apr 16, 2018
	GRANULES	10MG	A210722	001	Dec 23, 2019
	MYLAN	10MG	A076154	001	Aug 20, 2003
	PERRIGO	10MG	A076301	001	Jun 25, 2004
	PLD ACQUISITIONS LLC	10MG	A075209	001	Jan 21, 2003
	SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003
	UNIQUE PHARM	10MG	A214684	001	Jan 07, 2021

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+!	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006

CLARITIN

+	BAYER HEALTHCARE LLC	10MG	N021891	002	Nov 21, 2018

LORATADINE

	PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019
	SUN PHARM	5MG	A210088	001	Apr 16, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

ALAVERT

	FDN CONSUMER	10MG	N021375	001	Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+!	BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003

CLARITIN REDITABS

+!	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006
+!		10MG	N020704	002	Nov 27, 2002

LORATADINE

	AUROBINDO PHARMA LTD	10MG	A208477	001	Apr 11, 2018
	PERRIGO PHARMA INTL	10MG	A076011	001	Sep 29, 2003
	RUBICON	10MG	A214280	001	Sep 10, 2020
	TENSHI	5MG	A212795	001	Sep 18, 2020
		10MG	A213294	001	Oct 30, 2020

LORATADINE REDIDOSE

	SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+!	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002

CLARITIN-D 24 HOUR

+!	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

	P AND L	10MG;240MG	A075706	001	Feb 21, 2003
	PERRIGO PHARMA INTL	5MG;120MG	A076050	001	Jan 30, 2003
		10MG;240MG	A075989	001	Mar 04, 2004
	SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+!	HISAMITSU PHARM CO	3%;10%	N022029	001	Feb 20, 2008
+		3%;10%	N022029	002	Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

	PERRIGO	2%,4%	A076357	001	Mar 30, 2004

MONISTAT 3 COMBINATION PACK

+	MEDTECH PRODUCTS	2%,4%	N021261	003	Jun 17, 2003

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL					
MONISTAT 3 COMBINATION PACK (PREFILLED)					
+!	MEDTECH PRODUCTS	2%,4%	N021261	001	Feb 02, 2001
CREAM;VAGINAL					
MICONAZOLE 3					
	TARO	4%	A076773	001	Mar 02, 2005
MICONAZOLE 7					
	P AND L	2%	A074164	001	Mar 29, 1996
MICONAZOLE NITRATE					
	COSETTE	2%	A074366	001	Feb 22, 1996
	PERRIGO	2%	A074760	001	May 15, 1997
	PERRIGO R AND D	4%	A091366	001	Jan 15, 2010
	TARO PHARMS	2%	A074444	001	Jan 13, 1997
MONISTAT 3					
+!	MEDTECH PRODUCTS	4%	N020827	001	Mar 30, 1998
MONISTAT 7					
+!	MEDTECH PRODUCTS	2%	N017450	002	Feb 15, 1991
CREAM, INSERT;TOPICAL, VAGINAL					
MICONAZOLE NITRATE					
	PERRIGO R AND D	2%,1.2GM	A079114	001	Jun 02, 2010
MONISTAT 1 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,1.2GM	N021308	001	Jun 29, 2001
CREAM, SUPPOSITORY;TOPICAL, VAGINAL					
M-ZOLE 3 COMBINATION PACK					
	P AND L	2%,200MG	A074926	001	Apr 16, 1999
MICONAZOLE NITRATE COMBINATION PACK					
	L PERRIGO CO	2%,200MG	A075329	001	Apr 20, 1999
MONISTAT 3 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,200MG	N020670	002	Apr 16, 1996
MONISTAT 7 COMBINATION PACK					
+!	MEDTECH PRODUCTS	2%,100MG	N020288	002	Apr 26, 1993
SUPPOSITORY;VAGINAL					
MICONAZOLE NITRATE					
	COSETTE	100MG	A074414	001	Apr 30, 1997
	P AND L	100MG	A073507	001	Nov 19, 1993
!	PERRIGO	100MG	A074395	001	Mar 20, 1997
MONISTAT 7					
+!	MEDTECH PRODUCTS	100MG	N018520	002	Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL					
MEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	001	Jan 20, 2006
MINOXIDIL					
	PERRIGO	5%	A091344	001	Apr 28, 2011
MINOXIDIL (FOR MEN)					
	P AND L	5%	A208092	001	Feb 17, 2017
	TARO	5%	A209074	001	Dec 31, 2018
MINOXIDIL (FOR WOMEN)					
	P AND L	5%	A208092	002	Jul 27, 2017
	TARO	5%	A209074	002	Apr 22, 2019
WOMEN'S ROGAINE					
+!	JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014
SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
	AKORN	2%	A074731	001	Dec 24, 1996
	L PERRIGO CO	2%	A075357	001	Jul 30, 1999
	P AND L	2%	A074588	001	Apr 05, 1996
	WOCKHARDT BIO AG	2%	A074767	001	Feb 28, 1997
MINOXIDIL (FOR WOMEN)					
	AKORN	2%	A074731	002	May 11, 2005
	L PERRIGO CO	2%	A075357	002	Jul 30, 1999
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	P AND L	5%	A075518	001	Nov 17, 2000
	PERRIGO	5%	A075598	001	Jun 13, 2001
	PERRIGO NEW YORK	5%	A075737	001	Mar 15, 2002
	WOCKHARDT BIO AG	5%	A075438	001	Feb 27, 2003
ROGAINE (FOR MEN)					
+!	JOHNSON AND JOHNSON	2%	N019501	002	Feb 09, 1996
ROGAINE (FOR WOMEN)					
+!	JOHNSON AND JOHNSON	2%	N019501	003	Feb 09, 1996

MINOXIDIL

SOLUTION;TOPICAL					
ROGAINE EXTRA STRENGTH (FOR MEN)					
+!	JOHNSON AND JOHNSON	5%	N020834	001	Nov 14, 1997
THEROXIDIL					
	EI INC	2%	A078176	001	Nov 09, 2007
		5%	A076239	001	Aug 24, 2004

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC					
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE					
	AKORN	0.025%;0.3%	A202795	001	Jan 24, 2013
	ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
NAPHCON-A					
+!	ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994
OPCON-A					
+!	BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994
VISINE					
+!	JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL					
NAPROXEN SODIUM					
+!	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006
	CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019
	PURACAP PHARM LLC	EQ 200MG BASE	A208363	001	Mar 15, 2018
TABLET;ORAL					
ALEVE					
+!	BAYER	220MG	N020204	002	Jan 11, 1994
NAPROXEN SODIUM					
	AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008
	AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016
	CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997
	DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998
	GRANULES INDIA	220MG	A091353	001	Sep 20, 2011
	LNK INTL INC	220MG	A204872	001	Jan 23, 2017
	MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011
	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018
	PERRIGO	220MG	A074661	001	Jan 13, 1997
	SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
ALEVE-D SINUS & COLD					
+!	BAYER	220MG;120MG	N021076	001	Nov 29, 1999
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006
	PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL					
HABITROL					
+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+		14MG/24HR	N020076	005	Nov 12, 1999
+!		21MG/24HR	N020076	006	Nov 12, 1999
NICODERM CQ					
+	CHATTEM SANOFI	7MG/24HR	N020165	006	Aug 02, 1996
+		14MG/24HR	N020165	005	Aug 02, 1996
+!		21MG/24HR	N020165	004	Aug 02, 1996
NICOTINE					
	AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
		14MG/24HR	A074612	003	Oct 20, 1997
		21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL					
NICORETTE					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+		EQ 2MG BASE	N018612	004	Sep 25, 2000
+!		EQ 4MG BASE	N020066	002	Feb 09, 1996
+		EQ 4MG BASE	N020066	004	Sep 25, 2000
NICORETTE (MINT)					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+		EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
	EQ 2MG BASE	A076776	001	Sep 16, 2004
	EQ 2MG BASE	A076777	001	Sep 16, 2004
	EQ 4MG BASE	A076778	001	Sep 16, 2004
	EQ 4MG BASE	A076779	001	Sep 16, 2004
	EQ 4MG BASE	A076789	001	Sep 16, 2004
P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999
	EQ 2MG BASE	A076569	001	Jul 29, 2004
	EQ 2MG BASE	A078699	001	Dec 29, 2008
	EQ 2MG BASE	A079044	001	Jul 08, 2009
	EQ 2MG BASE	A079216	001	Jul 08, 2009
	EQ 2MG BASE	A204794	001	May 10, 2016
	EQ 4MG BASE	A074707	001	Mar 19, 1999
	EQ 4MG BASE	A076568	002	Jul 29, 2004
	EQ 4MG BASE	A078697	001	Dec 29, 2008
	EQ 4MG BASE	A079038	001	Jul 08, 2009
	EQ 4MG BASE	A079219	001	Jul 08, 2009
	EQ 4MG BASE	A204833	001	Feb 26, 2016
PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
	EQ 2MG BASE	A078547	001	May 24, 2007
	EQ 2MG BASE	A078967	001	Apr 23, 2008
	EQ 2MG BASE	A091349	001	Jul 20, 2011
	EQ 2MG BASE	A206394	001	Dec 15, 2016
	EQ 4MG BASE	A078326	001	Oct 30, 2006
	EQ 4MG BASE	A078546	001	May 24, 2007
	EQ 4MG BASE	A078968	001	Apr 23, 2008
	EQ 4MG BASE	A091354	001	Jul 20, 2011
	EQ 4MG BASE	A206393	001	Dec 15, 2016

TROCHE/LOZENGE;ORAL

NICORETTE

+	GLAXOSMITHKLINE	EQ 2MG BASE	N022360	001	May 18, 2009
+!		EQ 4MG BASE	N022360	002	May 18, 2009
+	GLAXOSMITHKLINE CONS	EQ 2MG BASE	N021330	001	Oct 31, 2002
+!		EQ 4MG BASE	N021330	002	Oct 31, 2002

NICOTINE POLACRILEX

AUROBINDO PHARMA LTD	EQ 2MG BASE	A213266	001	Aug 03, 2021
	EQ 4MG BASE	A213266	002	Aug 03, 2021
DR REDDYS LABS SA	EQ 2MG BASE	A212796	001	Jan 08, 2020
	EQ 2MG BASE	A212983	001	Feb 21, 2020
	EQ 2MG BASE	A213233	001	Aug 04, 2020
	EQ 4MG BASE	A212796	002	Jan 08, 2020
	EQ 4MG BASE	A212983	002	Feb 21, 2020
	EQ 4MG BASE	A213233	002	Aug 04, 2020
P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019
	EQ 2MG BASE	A209206	001	Jun 26, 2018
	EQ 2MG BASE	A209519	001	Jul 02, 2018
	EQ 2MG BASE	A209520	001	Oct 31, 2019
	EQ 2MG BASE	A210711	001	Oct 31, 2019
	EQ 2MG BASE	A210712	001	Sep 06, 2019
	EQ 2MG BASE	A212056	001	Jul 26, 2019
	EQ 2MG BASE	A212057	001	May 14, 2020
	EQ 4MG BASE	A208875	002	Oct 31, 2019
	EQ 4MG BASE	A209206	002	Jun 26, 2018
	EQ 4MG BASE	A209519	002	Jul 02, 2018
	EQ 4MG BASE	A209520	002	Oct 31, 2019
	EQ 4MG BASE	A210711	002	Oct 31, 2019
	EQ 4MG BASE	A210712	002	Sep 06, 2019
	EQ 4MG BASE	A212056	002	Jul 26, 2019
	EQ 4MG BASE	A212057	002	May 14, 2020
PERRIGO R AND D	EQ 2MG BASE	A077007	001	Jan 31, 2006
	EQ 2MG BASE	A090711	001	Jul 10, 2009
	EQ 2MG BASE	A090821	001	Jul 10, 2009
	EQ 2MG BASE	A203690	001	Oct 09, 2012
	EQ 4MG BASE	A077007	002	Jan 31, 2006
	EQ 4MG BASE	A090711	002	Jul 10, 2009
	EQ 4MG BASE	A090821	002	Jul 10, 2009
	EQ 4MG BASE	A203690	002	Oct 09, 2012
PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

		EQ 4MG BASE	A207868	002	Feb 07, 2019

NIZATIDINE

TABLET;ORAL

AXID AR

+!	GLAXOSMITHKLINE	75MG	N020555	001	May 09, 1996

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	AKORN	EQ 0.1% BASE	A204532	001	Jan 10, 2017
		EQ 0.2% BASE	A204723	001	Dec 05, 2017
	ALEMBIC PHARMS LTD	EQ 0.1% BASE	A209919	001	Dec 07, 2018
		EQ 0.2% BASE	A209420	001	Apr 29, 2019
	APOTEX	EQ 0.1% BASE	A078350	001	Dec 07, 2015
	APOTEX INC	EQ 0.2% BASE	A090918	001	Dec 05, 2017
	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015
	EUGIA PHARMA	EQ 0.1% BASE	A204812	001	Dec 18, 2015
		EQ 0.2% BASE	A209995	001	Apr 04, 2019
	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019
		EQ 0.2% BASE	A209752	001	May 20, 2020
	MYLAN	EQ 0.2% BASE	A204620	001	Jun 16, 2020
	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015

PATADAY ONCE DAILY RELIEF

+!	ALCON LABS INC	EQ 0.2% BASE	N021545	001	Dec 22, 2004
+!		EQ 0.7% BASE	N206276	001	Jan 30, 2015

PATADAY TWICE DAILY RELIEF

+!	ALCON LABS INC	EQ 0.1% BASE	N020688	001	Dec 18, 1996

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

	APOTEX	20MG	A210070	001	Feb 11, 2019
+!	DEXCEL PHARMA	20MG	N022032	001	Dec 04, 2007
	DR REDDYS	20MG	A207740	001	Nov 05, 2018
	SUN PHARM	20MG	A207891	001	Oct 12, 2018

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+	DEXCEL PHARMA	20MG	N209400	001	Jul 05, 2017

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878	001	Jun 05, 2009
	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA LTD	EQ 20MG BASE	A206877	001	Jun 06, 2018
	HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020
	P AND L	EQ 20MG BASE	A206582	001	Jun 01, 2020
	PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015

PRILOSEC OTC

+!	ASTRAZENECA	EQ 20MG BASE	N021229	001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	AUROLIFE PHARMA LLC	20MG;1.1GM	A204923	001	Nov 07, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361	001	Jul 15, 2016
	ZYDUS PHARMS	20MG;1.1GM	A203345	001	Mar 16, 2018

ZEGERID OTC

+!	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+!	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013

ORLISTAT

CAPSULE;ORAL

ALLI

+!	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+!	ALLERGAN	3.9MG/24HR	N202211	001	Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VISINE L.R.

+!	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL

NIX

+!	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990

PERMETHRIN

	ACTAVIS MID ATLANTIC	1%	A075014	001	Mar 28, 2000
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

MIRALAX

+!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006

POLYETHYLENE GLYCOL 3350

	ANI PHARMS	17GM/SCOOPFUL	A202850	001	Dec 15, 2015
	ANNORA PHARMA	17GM/SCOOPFUL	A214990	001	Apr 14, 2021
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018
	LGM PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
	MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
		17GM/SCOOPFUL	A078915	002	Oct 06, 2009
	NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
	NOVELGENIX THERAPS	17GM/SCOOPFUL	A202071	001	Dec 28, 2012
	NUVO PHARMS INC	17GM/SCOOPFUL	A206105	001	Oct 28, 2016
	PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
		17GM/SCOOPFUL	A090685	002	Oct 06, 2009
	STRIDES PHARMA	17GM/SCOOPFUL	A079214	001	Jan 31, 2013
		17GM/SCOOPFUL	A203928	001	Aug 24, 2016
		17GM/PACKET	A203928	002	Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

!	MISSION PHARMACAL CO	65MG/ML	A206211	001	Mar 24, 2016

TABLET;ORAL

IOSAT

+	ANBEX	65MG	N018664	002	May 12, 2011
+!		130MG	N018664	001	Oct 14, 1982

THYROSAFE

!	BTG INTL	65MG	A076350	001	Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+!	ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989

SPONGE;TOPICAL

E-Z SCRUB 201

+!	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985

E-Z SCRUB 241

+!	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	120MG	A209008	001	Jun 09, 2017
	L PERRIGO CO	120MG	A075153	001	Feb 26, 1999
	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SUDAFED 12 HOUR					
!	MCNEIL CONS	120MG	A073585	001	Oct 31, 1991
SUDAFED 24 HOUR					
+!	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH					
+!	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE					
	DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
		EQ 150MG BASE	A078192	001	Aug 31, 2007
	PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
	PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
		EQ 150MG BASE	A091429	002	May 11, 2011
	UNIQUE PHARM LABS	EQ 75MG BASE	A210250	001	Aug 30, 2019
		EQ 150MG BASE	A210228	001	Aug 30, 2019

TERBINAFINE

GEL;TOPICAL

LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021958	001	Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM;TOPICAL

LAMISIL					
+!	GLAXOSMITHKLINE	1%	N020980	001	Mar 09, 1999
TERBINAFINE HYDROCHLORIDE					
	TARO	1%	A077511	001	Jul 02, 2007

SOLUTION;TOPICAL

LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021124	001	Mar 17, 2000

SPRAY;TOPICAL

LAMISIL AT					
+!	GLAXOSMITHKLINE CONS	1%	N021124	002	Mar 17, 2000

TIOCONAZOLE

OINTMENT;VAGINAL

TIOCONAZOLE					
	PERRIGO	6.5%	A075915	001	Nov 21, 2001
VAGISTAT-1					
+!	COMBE	6.5%	N020676	001	Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR					
+!	SANOFI AVENTIS US	0.055MG/SPRAY	N020468	002	Oct 11, 2013
TRIAMCINOLONE ACETONIDE					
	PERRIGO	0.055MG/SPRAY	A078104	002	Nov 14, 2014

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

0.9% SODIUM CHLORIDE INJECTION USP SOLUTION
INJECTABLE; INJECTION
NONE
FRESENIUS KABI AG N125695 Sep 05, 2019

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP
INJECTABLE; INJECTION
NONE
HAEMONETICS MANUFACTURING INC N760305 Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)
INJECTABLE; INJECTION
CITRA LABS LLC N020037 Aug 26, 2003
ACD-A SOLUTION
TERUMO BCT INC A010228 Feb 25, 2002
ADSOL WITH ACD-A
FENWAL INC N000922 Aug 29, 2002
ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A
HAEMONETICS CORP A980728 Feb 06, 2002
AS3 SOLUTION/ACD-A
TERUMO BCT INC N001214 May 29, 2002
NONE

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP
INJECTABLE; INJECTION
NONE
FENWAL INC N160918 Mar 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)
INJECTABLE; INJECTION
CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3
HAEMONETICS CORP N000127 Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION
INJECTABLE; INJECTION
NONE
TERUMO MEDICAL CORP N820528 Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)
INJECTABLE; INJECTION
CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS
FENWAL INC N770420 May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP
INJECTABLE; INJECTION
BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER
FENWAL INC N940404 Jul 28, 1994

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS MANUFACTURING INC		N800077	Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC		N900223	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC		N900224	Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

MACOPHARMA		N040083	Nov 21, 2005

NONE

TERUMO BCT INC		A070025	Jan 06, 2009

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N170401	Dec 06, 1977
		N811012	Jun 28, 1983
PALL CORP		N800222	Aug 23, 1982
TERUMO MEDICAL CORP		N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC		N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP		N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS MANUFACTURING INC	0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML	N820915	Oct 19, 1984

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP	0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML	N820915	Sep 22, 1983

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE		N980123	Mar 03, 2000
HAEMONETICS CORPORATION		A125697	Oct 25, 2019
LABORATORIES GRIFOIS, S.A.			
TERUMO BCT		A125608	Jun 26, 2018

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CITRA LABS, LLC		N010409	Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC		N770923	Jan 20, 1978
TERUMO MEDICAL CORP		N781214	Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA		N125552	Dec 21, 2016

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB		N830715	Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC	10GM/100ML;5GM/100ML	A720563	Oct 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC	10GM/100ML;0.9GM/100ML	A720562	Oct 30, 1992

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC	6GM/100ML	N200952	Mar 31, 1999

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
HOSPIRA INC	6GM/100ML;0.9GM/100ML	A740193	Jan 30, 1995
HESPAN IN PLASTIC CONTAINER			
B BRAUN MEDICAL INC	6GM/100ML;0.9GM/100ML	N890105	Apr 04, 1991
NONE			
TEVA PHARMACEUTICALS USA INC	6GM/100ML;0.9GM/100ML	A740592	Nov 12, 1998

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION			
TERUMO BCT		N90067	Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL			
HEMERUS MEDICAL, LLC		N110059	Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTION

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL			
CITRA LABS LLC		N950522	Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION			
FRESENIUS KABI USA, LLC	2.26GM/500ML;2.21GM/500ML;1.59GM/500ML;1.53GM/500ML;0.465GM/500ML	N080041	Dec 09, 2009

ABACAVIR SULFATE				
TABLET;ORAL				
ABACAVIR SULFATE				
	APOTEX INC	EQ 300MG BASE	A201570 001	Dec 17, 2012
ABACAVIR SULFATE; LAMIVUDINE				
TABLET;ORAL				
ABACAVIR SULFATE AND LAMIVUDINE				
	ZYDUS PHARMS	EQ 600MG BASE;300MG	A208990 001	Nov 15, 2018
ABAMETAPIR				
LOTION;TOPICAL				
XEGLYZE				
+	DR REDDYS LABS SA	0.74%	N206966 001	Jul 24, 2020
ABARELIX				
INJECTABLE;INTRAMUSCULAR				
PLENAXIS				
	SPECIALITY EUROPEAN	100MG/VIAL	N021320 001	Nov 25, 2003
ACAMPROSATE CALCIUM				
TABLET, DELAYED RELEASE;ORAL				
ACAMPROSATE CALCIUM				
	BARR LABS DIV TEVA	333MG	A200143 001	Nov 18, 2013
CAMPRAL				
+	FOREST LABS	333MG **	N021431 001	Jul 29, 2004
ACARBOSE				
TABLET;ORAL				
ACARBOSE				
	HANGZHOU ZHONGMEI	25MG	A213821 001	Aug 18, 2020
		50MG	A213821 002	Aug 18, 2020
		100MG	A213821 003	Aug 18, 2020
	MYLAN	25MG	A091053 001	Jan 06, 2011
		50MG	A091053 002	Jan 06, 2011
		100MG	A091053 003	Jan 06, 2011
PRECOSE				
+	BAYER HLTHCARE	25MG **	N020482 004	May 29, 1997
+		50MG **	N020482 001	Sep 06, 1995
+		100MG **	N020482 002	Sep 06, 1995
ACEBUTOLOL HYDROCHLORIDE				
CAPSULE;ORAL				
ACEBUTOLOL HYDROCHLORIDE				
	ANI PHARMS	EQ 200MG BASE	A074007 001	Oct 18, 1995
		EQ 400MG BASE	A074007 002	Oct 18, 1995
SECTRAL				
+	PROMIUS PHARMA	EQ 200MG BASE **	N018917 001	Dec 28, 1984
+		EQ 400MG BASE **	N018917 003	Dec 28, 1984
ACETAMINOPHEN				
INJECTABLE;INJECTION				
INJECTAPAP				
	ORTHO MCNEIL PHARM	100MG/ML	N017785 001	Mar 07, 1986
POWDER;INTRAVENOUS				
ACETAMINOPHEN				
+	RISING PHARMA	1GM/VIAL	N206610 001	Jan 15, 2021
SUPPOSITORY;RECTAL				
ACEPHEN				
	COSETTE	120MG	A072218 001	Mar 27, 1992
		325MG	N018060 003	Dec 18, 1986
		650MG	N018060 002	
ACETAMINOPHEN				
	ABLE	120MG	A073106 001	Feb 27, 1995
		325MG	A073107 001	Feb 27, 1995
		650MG	A073108 001	Feb 27, 1995
	ACINO PRODS	120MG	A071010 001	May 12, 1987
		650MG	A071011 001	May 12, 1987
NEOPAP				
	POLYMEDICA	120MG	N016401 001	
TYLENOL				
	J AND J CONSUMER INC	120MG	N017756 002	
		650MG	N017756 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN					
	SUN PHARM INDS LTD	650MG	A090205	001	Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE;ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE					
	MIKART	150MG;180MG;15MG	A081095	001	Oct 26, 1990
		150MG;180MG;30MG	A081096	001	Oct 26, 1990
		150MG;180MG;60MG	A081097	001	Oct 26, 1990
CODEINE, ASPIRIN, APAP FORMULA NO. 2					
+	SCHERER LABS	150MG;180MG;15MG	A085640	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 3					
+	SCHERER LABS	150MG;180MG;30MG	A085639	001	
CODEINE, ASPIRIN, APAP FORMULA NO. 4					
	SCHERER LABS	150MG;180MG;60MG	A085638	001	

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BANCAP					
	FOREST PHARMS	325MG;50MG	A088889	001	Jan 16, 1986
BUCET					
	MALLINCKRODT	650MG;50MG	A088991	001	Jun 28, 1985
PHRENILIN FORTE					
	VALEANT	650MG;50MG	A088831	001	Jun 19, 1985
TENCON					
	MALLINCKRODT	650MG;50MG	A089405	001	May 15, 1990
TRIAPRIN					
	DUNHALL	325MG;50MG	A089268	001	Jul 02, 1987

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN					
	HALSEY	325MG;50MG	A089568	001	Oct 05, 1988
+	WATSON LABS	325MG;50MG	A087550	001	Oct 19, 1984
BUTAPAP					
	MIKART	650MG;50MG	A089988	001	Oct 26, 1992
PHRENILIN					
+	VALEANT	325MG;50MG **	A087811	001	Jun 19, 1985
SEDAPAP					
	MAYRAND	650MG;50MG	A088944	001	Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

ANOQUAN					
	SHIRE	325MG;50MG;40MG	A087628	001	Oct 01, 1986
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
+	GILBERT LABS	325MG;50MG;40MG **	A088825	001	Dec 05, 1984
	GRAHAM DM	325MG;50MG;40MG	A088743	001	Jul 18, 1985
		325MG;50MG;40MG	A088765	001	Mar 27, 1985
		325MG;50MG;40MG	A089067	001	Apr 19, 1985
	HIKMA	500MG;50MG;40MG	A040261	001	Oct 28, 1998
	MALLINCKRODT	325MG;50MG;40MG	A088758	001	Mar 27, 1985
ESGIC-PLUS					
	MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996
FEMCET					
	MALLINCKRODT	325MG;50MG;40MG	A089102	001	Jun 19, 1985
MEDIGESIC PLUS					
	US CHEM	325MG;50MG;40MG	A089115	001	Jan 14, 1986
TRIAD					
	MALLINCKRODT	325MG;50MG;40MG	A089023	001	Jun 19, 1985

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE					
	ABLE	325MG;50MG;40MG	A040390	001	Jul 23, 2001
		500MG;50MG;40MG	A040394	001	Jul 23, 2001
	GILBERT LABS	325MG;50MG;40MG	A087629	001	Nov 13, 1984
	GRANULES	325MG;50MG;40MG	A040864	001	Dec 01, 2008
	HIKMA	500MG;50MG;40MG	A040336	001	Aug 18, 1999
	HIKMA PHARMS	325MG;50MG;40MG	A089718	001	Jun 12, 1995
	MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003
	MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008
	SPECGX LLC	325MG;50MG;40MG	A087804	001	Jan 24, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL				
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE				
	SUN PHARM INDUSTRIES	325MG;50MG;40MG	A040601 001	Jul 29, 2005
	VINTAGE PHARMS	500MG;50MG;40MG	A040513 001	Aug 25, 2003
	WATSON LABS	325MG;50MG;40MG	A089536 001	Feb 16, 1988
		500MG;50MG;40MG	A040267 001	Jul 30, 1998
ESGIC				
	FOREST PHARMS	325MG;50MG;40MG	A089660 001	Dec 23, 1988
ESGIC-PLUS				
	MIKART	500MG;50MG;40MG	A089451 001	May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL				
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE				
	ABLE	325MG;50MG;40MG;30MG	A076528 001	Aug 21, 2003
	HIKMA INTL PHARMS	325MG;50MG;40MG;30MG	A075618 001	Mar 23, 2001
PHRENILIN WITH CAFFEINE AND CODEINE				
	VALEANT	325MG;50MG;40MG;30MG	A074911 001	Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL				
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE				
	MIKART	356.4MG;30MG;16MG	A040109 001	Aug 26, 1997
	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688 001	Apr 03, 2007
DHC PLUS				
	PHARM RES ASSOC	356.4MG;30MG;16MG	A088584 001	Mar 04, 1986
SYNALGOS-DC-A				
	LEITNER PHARMS	356.4MG;30MG;16MG	A089166 001	May 14, 1986
TABLET;ORAL				
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE				
	BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701 001	Apr 03, 2007
	MIKART	712.8MG;60MG;32MG	A040316 001	Apr 28, 1999
	WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637 001	Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL				
TAVIST ALLERGY/SINUS/HEADACHE				
	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082 001	Mar 01, 2001

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	TEVA	300MG;15MG	A088537 001	Jun 04, 1984
		300MG;30MG	A088324 001	Dec 29, 1983
		300MG;60MG	A088599 001	Jun 01, 1984
PHENAPHEN W/ CODEINE NO. 2				
	ROBINS AH	325MG;15MG	A084444 001	
PHENAPHEN W/ CODEINE NO. 3				
+	ROBINS AH	325MG;30MG	A084445 001	
PHENAPHEN W/ CODEINE NO. 4				
+	ROBINS AH	325MG;60MG	A084446 001	
PROVAL #3				
	SOLVAY	325MG;30MG	A085685 001	
TYLENOL W/ CODEINE NO. 3				
	ORTHO MCNEIL PHARM	300MG;30MG	A087422 001	
TYLENOL W/ CODEINE NO. 4				
	ORTHO MCNEIL PHARM	300MG;60MG	A087421 001	
SOLUTION;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	ACI	120MG/5ML;12MG/5ML	A086366 001	
+	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861 001	
	DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098 001	Sep 20, 1996
	LANNETT CO INC	120MG/5ML;12MG/5ML	A091238 001	Nov 10, 2011
	WOCKHARDT BIO AG	120MG/5ML;12MG/5ML	A087006 001	
TYLENOL W/ CODEINE				
+	ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057 001	
SUSPENSION;ORAL				
CAPITAL AND CODEINE				
	ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883 001	
	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	ABLE	300MG;30MG	A040452	001	Aug 01, 2002
		300MG;60MG	A040459	001	Aug 01, 2002
	AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
		300MG;15MG	A089481	001	Mar 03, 1987
		300MG;30MG	A089479	001	Mar 03, 1987
		300MG;30MG	A089482	001	Mar 03, 1987
		300MG;60MG	A089480	001	Mar 03, 1987
		300MG;60MG	A089483	001	Mar 03, 1987
	DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
		300MG;15MG	A088353	001	Feb 06, 1984
		300MG;30MG	A040223	002	Nov 18, 1997
		300MG;30MG	A088354	001	Feb 06, 1984
		300MG;60MG	A040223	003	Nov 18, 1997
		300MG;60MG	A088355	001	Feb 06, 1984
	EVERYLIFE	325MG;30MG	A085217	001	
	FOSUN PHARMA	300MG;30MG	A081250	001	Jul 16, 1992
		300MG;60MG	A081249	001	Jul 16, 1992
	HALSEY	300MG;15MG	A083871	001	
		300MG;30MG	A083872	001	
		300MG;60MG	A086549	001	
	KV PHARM	300MG;30MG	A085288	001	
		300MG;60MG	A085365	001	
		325MG;15MG	A085364	001	
		325MG;45MG **	A085363	001	
	LEDERLE	300MG;30MG	A087141	001	
	MIKART	300MG;30MG	A089238	001	Feb 25, 1986
		300MG;60MG	A089244	001	Feb 25, 1986
		650MG;30MG	A089231	001	Mar 03, 1986
		650MG;60MG	A089363	001	Sep 09, 1991
	MUTUAL PHARM	300MG;15MG	A085795	001	
		300MG;30MG	A085794	001	
		300MG;60MG	A087653	001	Apr 13, 1982
	PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
+	PUREPAC PHARM	300MG;30MG	A086681	001	
		300MG;30MG	A089080	001	Jul 17, 1986
		300MG;60MG	A086683	001	
	RHODES PHARMS	300MG;15MG	A089673	002	Feb 10, 1988
		300MG;30MG	A089673	003	Feb 10, 1988
		300MG;60MG	A089673	001	Feb 10, 1988
	ROXANE	300MG;15MG	A084659	001	
		300MG;30MG	A084656	001	
		300MG;60MG	A084667	001	
		500MG;15MG	A089511	001	Apr 25, 1989
		500MG;30MG	A089512	001	Apr 25, 1989
		500MG;60MG	A089513	001	Apr 25, 1989
+	SANDOZ	300MG;15MG	A087433	001	
		300MG;30MG	A085291	002	
+		300MG;30MG	A085917	001	
		300MG;60MG	A085964	001	
		300MG;60MG	A087423	001	
	STRIDES PHARMA	300MG;15MG	A089990	001	Sep 30, 1988
		300MG;30MG	A089805	001	Sep 30, 1988
		300MG;60MG	A089828	001	Sep 30, 1988
	SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
		300MG;30MG	A089184	001	Oct 18, 1985
		300MG;30MG	A089253	001	May 19, 1986
		300MG;60MG	A089185	001	Oct 18, 1985
		300MG;60MG	A089254	001	May 19, 1986
	USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
		300MG;60MG	A087920	001	Jun 22, 1982
	VALEANT PHARM INTL	300MG;30MG	A085896	001	
	VITARINE	300MG;30MG	A085676	001	
	WARNER CHILCOTT	300MG;15MG	A085992	001	
		300MG;30MG	A085218	002	
		300MG;60MG	A087306	001	
	WATSON LABS	300MG;15MG	A087277	001	May 26, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL				
ACETAMINOPHEN AND CODEINE PHOSPHATE				
	300MG;15MG	A089997	001	Dec 28, 1994
	300MG;30MG	A087276	001	May 26, 1982
	300MG;30MG	A089998	001	Dec 28, 1994
	300MG;60MG	A087275	001	May 26, 1982
	300MG;60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
	300MG;30MG	A040443	002	Jan 22, 2003
	300MG;60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
	300MG;60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG;30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
	500MG;30MG	A040441	001	Mar 27, 2003
	500MG;60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG;30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG;60MG	A083951	002	
PAPA-DEINE #3				
VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG;30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056	001	
	325MG;15MG **	A085056	002	
	325MG;30MG **	A085056	003	
	325MG;60MG **	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG;7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
+ JANSSEN PHARMS	300MG;15MG	A085055	002	
TYLENOL W/ CODEINE NO. 3				
+ JANSSEN PHARMS	300MG;30MG	A085055	003	
TYLENOL W/ CODEINE NO. 4				
+ JANSSEN PHARMS	300MG;60MG	A085055	004	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
DRIXORAL PLUS				
SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL				
ACETAMINOPHEN AND HYDROCODONE BITARTRATE				
CENT PHARMS	500MG;5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG;5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG;5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG;5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG;5MG	A088956	001	Jul 19, 1985
	500MG;5MG	A089006	001	Aug 09, 1985
MIKART	500MG;5MG	A081067	001	Nov 30, 1989
	500MG;5MG	A081068	001	Nov 30, 1989
	500MG;5MG	A081069	001	Nov 30, 1989
	500MG;5MG	A081070	001	Nov 30, 1989
	500MG;5MG	A089008	001	Feb 21, 1986
LORCET-HD				
MALLINCKRODT	500MG;5MG	A087336	001	Jul 08, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG/15ML;7.5MG/15ML	A040418	001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML;10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML;5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML;5MG/15ML	A089557	001	Apr 29, 1992
	500MG/15ML;7.5MG/15ML	A081051	001	Aug 28, 1992
NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366	001	Jan 23, 2002
PHARM ASSOC	500MG/15ML;7.5MG/15ML	A040182	001	Mar 13, 1998
VINTAGE PHARMS	500MG/15ML;7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL				
CYPRESS PHARM INC	325MG/15ML;7.5MG/15ML	A090468	001	Apr 14, 2016
TABLET;ORAL				
ANEXSIA				
MALLINCKRODT	500MG;5MG	A089160	001	Apr 23, 1987
	750MG;10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650				
MALLINCKRODT	650MG;7.5MG	A089725	001	Sep 30, 1987
CO-GESIC				
UCB INC	500MG;5MG	A087757	001	May 03, 1982
DURADYNE DHC				
FOREST PHARMS	500MG;5MG	A087809	001	Mar 17, 1983
HY-PHEN				
ASCHER	500MG;5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG;5MG	A040478	001	Nov 08, 2002
	325MG;7.5MG	A040464	001	Oct 23, 2002
	325MG;10MG	A040464	002	Oct 23, 2002
	500MG;5MG	A040477	001	Nov 06, 2002
	500MG;7.5MG	A040490	001	May 21, 2003
	500MG;10MG	A040473	001	Nov 06, 2002
	650MG;7.5MG	A040474	001	Jan 02, 2003
	650MG;10MG	A040476	001	Oct 23, 2002
	750MG;7.5MG	A040469	001	Oct 25, 2002
ACTAVIS LABS FL INC	300MG;5MG	A206470	001	Jun 02, 2016
	300MG;7.5MG	A206470	002	Jun 02, 2016
	300MG;10MG	A206470	003	Jun 02, 2016
ALVOGEN	300MG;5MG	A208540	001	Nov 08, 2018
	300MG;7.5MG	A208540	002	Nov 08, 2018
	300MG;10MG	A208540	003	Nov 08, 2018
	325MG;2.5MG	A209958	001	Oct 24, 2018
	325MG;5MG	A209958	002	Oct 24, 2018
	325MG;7.5MG	A209958	003	Oct 24, 2018
	325MG;10MG	A209958	004	Oct 24, 2018
AMNEAL PHARMS NY	500MG;5MG	A040729	001	Aug 25, 2006
	500MG;7.5MG	A040748	001	Aug 25, 2006
	500MG;10MG	A040813	001	Feb 23, 2007
	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
CEROVENE INC	325MG;5MG	A211690	001	Feb 07, 2020
	325MG;7.5MG	A211690	002	Feb 07, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	325MG;10MG	A211690	003	Feb 07, 2020
GRANULES	325MG;5MG	A211729	001	Jan 03, 2020
	325MG;7.5MG	A211729	002	Jan 03, 2020
	325MG;10MG	A211729	003	Jan 03, 2020
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017
	300MG;7.5MG	A207171	002	Jun 20, 2017
	300MG;10MG	A207171	003	Jun 20, 2017
	325MG;5MG	A207172	001	Jun 22, 2017
	325MG;7.5MG	A207172	002	Jun 22, 2017
	325MG;10MG	A207172	003	Jun 22, 2017
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
NOSTRUM LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018
	325MG;5MG	A209924	002	Nov 16, 2018
	325MG;7.5MG	A209924	003	Nov 16, 2018
	325MG;10MG	A209924	004	Nov 16, 2018
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
STRIDES PHARMA	300MG;5MG	A205001	001	Jul 05, 2016
	300MG;7.5MG	A205001	002	Jul 05, 2016
	300MG;10MG	A205001	003	Jul 05, 2016
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007
UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017
	325MG;7.5MG	A206484	002	Mar 24, 2017
	325MG;10MG	A206484	003	Mar 24, 2017
USL PHARMA	500MG;5MG	A089290	001	May 29, 1987
	500MG;5MG	A089291	001	May 29, 1987
VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011
	300MG;7.5MG	A090415	002	Jan 24, 2011
	300MG;10MG	A090415	003	Jan 24, 2011
	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040281	001	Sep 30, 1998
	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL				
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
WATSON LABS	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
NORCO				
APIL	325MG;2.5MG	A040148	004	Jul 07, 2014
	325MG;5MG	A040099	001	Jun 25, 1997
	325MG;5MG	A040148	005	Jul 07, 2014
	325MG;7.5MG	A040148	003	Sep 12, 2000
	325MG;10MG	A040148	001	Feb 14, 1997
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL				
OXYCODONE AND ACETAMINOPHEN				
ACTAVIS ELIZABETH	500MG;5MG	A040199	001	Dec 30, 1998
BARR	500MG;5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG;5MG	A040289	001	Mar 16, 1999
HALSEY	500MG;5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG;5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG;5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG;5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG;5MG	A040234	001	Oct 30, 1997
ROXILOX				
ROXANE	500MG;5MG	A040061	001	Jul 03, 1995
TYLOX				
JANSSEN PHARMS	500MG;5MG	A088790	001	Dec 12, 1984
TYLOX-325				
ORTHO MCNEIL PHARM	325MG;5MG	A088246	001	Nov 08, 1984
SOLUTION;ORAL				
OXYCODONE AND ACETAMINOPHEN				
SPECGX LLC	325MG/5ML;5MG/5ML	A040680	001	Sep 29, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL					
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN					
	VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014
ROXICET					
	HIKMA	325MG/5ML;5MG/5ML	A089351	001	Dec 03, 1986
TABLET;ORAL					
OXYCODONE 2.5/APAP 500					
	BRISTOL MYERS SQUIBB	500MG;2.5MG	A085910	001	
OXYCODONE 5/APAP 500					
+	BRISTOL MYERS SQUIBB	500MG;5MG	A085911	001	
OXYCODONE AND ACETAMINOPHEN					
	ACTAVIS ELIZABETH	325MG;5MG	A040203	001	Mar 15, 1999
		325MG;7.5MG	A040800	001	Apr 03, 2012
		325MG;10MG	A040800	002	Apr 03, 2012
	AMNEAL PHARMS NY	500MG;7.5MG	A040789	001	Nov 27, 2007
		650MG;10MG	A040789	002	Nov 27, 2007
	BARR	325MG;5MG	A087406	001	
	CEROVENE INC	325MG;5MG	A207574	001	Dec 13, 2016
	DURAMED PHARMS BARR	325MG;5MG	A040272	001	Jun 30, 1998
	GRANULES	325MG;2.5MG	A211708	001	Oct 31, 2019
		325MG;5MG	A211708	002	Oct 31, 2019
		325MG;7.5MG	A211708	003	Oct 31, 2019
		325MG;10MG	A211708	004	Oct 31, 2019
	LANNETT CO INC	325MG;5MG	A207333	001	Sep 25, 2017
		325MG;10MG	A207333	002	Sep 25, 2017
	MALLINCKRODT	500MG;7.5MG	A040550	001	Jun 30, 2004
		650MG;10MG	A040550	002	Jun 30, 2004
	MAYNE PHARMA INC	500MG;7.5MG	A090177	005	Oct 20, 2008
		650MG;10MG	A090177	006	Oct 20, 2008
	MIKART	400MG;2.5MG	A040679	001	May 16, 2006
		400MG;5MG	A040687	001	Apr 27, 2006
		400MG;7.5MG	A040698	001	Apr 27, 2006
		400MG;10MG	A040692	001	Apr 27, 2006
		500MG;10MG	A040676	001	Apr 19, 2006
	NOSTRUM LABS INC	325MG;5MG	A209385	001	Jul 02, 2018
		325MG;7.5MG	A209385	002	Jul 02, 2018
		325MG;10MG	A209385	003	Jul 02, 2018
	VINTAGE PHARMS	325MG;2.5MG	A090733	001	Jul 11, 2013
		325MG;5MG	A040105	001	Jul 30, 1996
		325MG;7.5MG	A090734	001	Jul 11, 2013
		325MG;10MG	A090734	002	Jul 11, 2013
	WATSON LABS	325MG;5MG	A040171	001	Oct 30, 1997
		325MG;7.5MG	A040535	001	Sep 05, 2003
		325MG;10MG	A040535	002	Sep 05, 2003
		500MG;7.5MG	A040371	001	Dec 29, 2000
		650MG;10MG	A040371	002	Dec 29, 2000
PERCOCET					
+	VINTAGE PHARMS LLC	325MG;5MG	A085106	002	
		500MG;7.5MG	A040341	001	Jul 26, 1999
		650MG;10MG	A040341	002	Jul 26, 1999
ROXICET					
+	HIKMA	325MG;5MG	A087003	001	
ROXICET 5/500					
	ROXANE	500MG;5MG	A089775	001	Jan 12, 1989
TABLET, EXTENDED RELEASE;ORAL					
XARTEMIS XR					
+	MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE;ORAL					
TYLOX					
	ORTHO MCNEIL PHARM	500MG;4.5MG;0.38MG	A085375	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL				
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE				
GAVIS PHARMS	650MG;EQ 25MG BASE	A076202	001	Aug 02, 2002
WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000
TALACEN				
SANOFI AVENTIS US	650MG;EQ 25MG BASE	N018458	001	Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET;ORAL				
DARVOCET				
AAIPHARMA LLC	325MG;32.5MG	N016844	001	
DOLENE AP-65				
LEDERLE	650MG;65MG	A085100	001	
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN				
MYLAN	325MG;32MG	A083689	001	
	650MG;65MG	A083978	001	
SANDOZ	650MG;65MG	A089959	001	Jul 18, 1989
VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG;65MG	A040139	001	Dec 16, 1996
WYGESIC				
CARACO	650MG;65MG	A084999	001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET;ORAL				
DARVOCET A500				
XANODYNE PHARM	500MG;100MG	A076429	001	Sep 10, 2003
DARVOCET-N 100				
XANODYNE PHARM	650MG;100MG	N017122	002	
DARVOCET-N 50				
XANODYNE PHARM	325MG;50MG	N017122	001	
PROPACET 100				
TEVA	650MG;100MG	A070107	001	Jun 12, 1985
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN				
ABLE	650MG;100MG	A075838	001	Jul 11, 2001
ACTAVIS ELIZABETH	650MG;100MG	A070910	001	Jan 02, 1987
CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004
	500MG;100MG	A076750	001	Jun 28, 2004
HALSEY	325MG;50MG	A072105	001	May 13, 1988
	650MG;100MG	A072106	001	May 13, 1988
IVAX SUB TEVA PHARMS	650MG;100MG	A070146	001	Aug 02, 1985
MALLINCKRODT	650MG;100MG	A075738	001	Feb 02, 2001
MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008
MUTUAL PHARM	325MG;50MG	A070115	001	Jun 12, 1985
	650MG;100MG	A070116	001	Jun 12, 1985
	650MG;100MG	A070615	001	Mar 21, 1986
	650MG;100MG	A070771	001	Mar 21, 1986
	650MG;100MG	A070775	001	Mar 21, 1986
MYLAN	650MG;100MG	A072195	001	Feb 16, 1988
MYLAN PHARMS INC	650MG;100MG	A070145	001	Jun 12, 1985
SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987
TEVA	650MG;100MG	A070732	001	Jan 03, 1986
	650MG;100MG	A074119	001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
	650MG;100MG	A074843	001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
	650MG;100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
	650MG;100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
	650MG;100MG	A077677	002	Mar 16, 2007

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL				
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN				
GRAVITI PHARMS	325MG;37.5MG	A076914	001	Jul 26, 2006
MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017
NOSTRUM LABS INC	325MG;37.5MG	A078778	001	Apr 07, 2014
STRIDES PHARMA	325MG;37.5MG	A076475	001	Apr 21, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL					
ACETAZOLAMIDE					
	RISING	500MG	A203917	001	Jun 18, 2019
DIAMOX					
+	TEVA BRANDED PHARM	500MG **	N012945	001	
TABLET;ORAL					
ACETAZOLAMIDE					
	ALRA	250MG	A083320	001	
	ASCOT	250MG	A087686	001	Oct 20, 1982
	HERITAGE PHARMA	250MG	A088882	001	Oct 22, 1985
	SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988
		250MG	A089753	001	Jun 22, 1988
	VANGARD	250MG	A087654	001	Feb 05, 1982
	WATSON LABS	250MG	A084498	002	
DIAMOX					
+	TEVA BRANDED PHARM	125MG **	N008943	001	
+		250MG **	N008943	002	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION					
ACETAZOLAMIDE SODIUM					
	HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017
DIAMOX					
+	TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC					
ACETASOL					
	ACTAVIS MID ATLANTIC	2%	A087146	001	
ACETIC ACID					
	KV PHARM	2%	A085493	001	
ORLEX					
	WARNER CHILCOTT	2%	A086845	001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC					
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE					
	BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994
BOROFAIR					
	PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985
DOMEBORO					
+	BAYER PHARMS	2%;0.79%	A084476	001	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS;OTIC					
TRIDESILON					
	BAYER PHARMS	2%;0.05%	N017914	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC					
ACETASOL HC					
	ACTAVIS MID ATLANTIC	2%;1%	A087143	001	Jan 13, 1982
ACETIC ACID W/ HYDROCORTISONE					
	KV PHARM	2%;1%	A085492	001	
HYDROCORTISONE AND ACETIC ACID					
	BAUSCH AND LOMB	2%;1%	A040097	001	Oct 31, 1994
	WOCKHARDT	2%;1%	A040168	001	Aug 30, 1996
ORLEX HC					
	WARNER CHILCOTT	2%;1%	A086844	001	

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS;OTIC					
NEO-CORT-DOME					
	BAYER PHARMS	2%;1%;EQ 0.35% BASE	N050238	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACETOHEXAMIDE				
TABLET;ORAL				
ACETOHEXAMIDE				
ANI PHARMS	250MG	A070870	002	Feb 09, 1987
	500MG	A070870	001	Feb 09, 1987
USL PHARMA	250MG	A070753	001	Nov 03, 1986
	500MG	A070754	001	Nov 03, 1986
WATSON LABS TEVA	250MG	A071893	001	Nov 25, 1987
	500MG	A071894	001	Nov 25, 1987
DYMELOR				
LILLY	250MG	N013378	002	
	500MG	N013378	001	
ACETOPHENAZINE MALEATE				
TABLET;ORAL				
TINDAL				
SCHERING	20MG	N012254	002	
ACETRIZOATE SODIUM				
SOLUTION;INTRAUTERINE				
SALPIX				
ORTHO MCNEIL PHARM	53%	N009008	001	
ACETYLCHOLINE CHLORIDE				
FOR SOLUTION;OPHTHALMIC				
MIOCHOL				
+ NOVARTIS	20MG/VIAL **	N016211	001	
ACETYLCYSTEINE				
INJECTABLE;INTRAVENOUS				
ACETYLCYSTEINE				
RISING	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015
SOLUTION;INHALATION, ORAL				
ACETYLCYSTEINE				
HOSPIRA	10%	A071364	001	May 01, 1989
	20%	A071365	001	May 01, 1989
ROXANE	10%	A072323	001	Apr 30, 1992
	10%	A072621	001	Sep 30, 1992
	20%	A072324	001	Apr 30, 1992
	20%	A072622	001	Sep 30, 1992
MUCOMYST				
+ APOTHECON	10% **	N013601	002	
+	20% **	N013601	001	
MUCOSIL-10				
DEY	10%	A070575	001	Oct 14, 1986
MUCOSIL-20				
DEY	20%	A070576	001	Oct 14, 1986
TABLET, EFFERVESCENT;ORAL				
CETYLEV				
+ ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016
+	2.5GM	N207916	002	Jan 29, 2016
ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE				
SOLUTION;INHALATION				
MUCOMYST W/ ISOPROTERENOL				
MEAD JOHNSON	10%;0.05%	N017366	001	
ACETYLDIGITOXIN				
TABLET;ORAL				
ACYLANID				
NOVARTIS	0.1MG	N009436	001	
ACITRETIN				
CAPSULE;ORAL				
ACITRETIN				
MYLAN	17.5MG	A203707	001	Sep 10, 2015
	22.5MG	A203707	002	Sep 10, 2015
SORIATANE				
+ STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996
+	17.5MG	N019821	003	Aug 06, 2009
+	22.5MG	N019821	004	Aug 06, 2009
+	25MG	N019821	002	Oct 28, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACRISORCIN

CREAM;TOPICAL					
AKRINOL					
	SCHERING	2MG/GM	N012470	001	
ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE					
CAPSULE;ORAL					
SEMPREX-D					
+	AUXILIUM PHARMS LLC	8MG;60MG	N019806	001	Mar 25, 1994
ACYCLOVIR					
CAPSULE;ORAL					
ACYCLOVIR					
	ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997
	CHARTWELL MOLECULES	200MG	A074872	001	Apr 22, 1997
	IVAX SUB TEVA PHARMS	200MG	A074674	001	Apr 22, 1997
	LEK PHARM	200MG	A074750	001	Apr 22, 1997
	MYLAN	200MG	A074727	001	Apr 22, 1997
		200MG	A074977	001	Apr 13, 1998
	RANBAXY	200MG	A074975	001	Sep 30, 1998
	ROXANE	200MG	A074570	002	Apr 22, 1997
	STRIDES PHARMA	200MG	A074833	001	Apr 22, 1997
	TEVA	200MG	A074828	001	Apr 22, 1997
	TEVA PHARMS	200MG	A074914	001	Nov 26, 1997
	WATSON LABS	200MG	A075101	001	Apr 15, 1998
ZOVIRAX					
+	MYLAN	200MG **	N018828	001	Jan 25, 1985
OINTMENT;OPHTHALMIC					
AVACLYR					
+	FERA PHARMS LLC	3% **	N202408	001	Mar 29, 2019
OINTMENT;TOPICAL					
ACYCLOVIR					
	ANDA REPOSITORY	5%	A206437	001	Jul 31, 2017
	PADAGIS ISRAEL	5%	A205659	001	Feb 20, 2019
TABLET;ORAL					
ACYCLOVIR					
	ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
		800MG	A074870	002	Jun 05, 1997
	CHARTWELL MOLECULES	400MG	A074834	001	Apr 24, 1997
		800MG	A074834	002	Apr 24, 1997
	IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
		800MG	A074836	002	Apr 22, 1997
	LEK PHARM	400MG	A074658	001	Apr 22, 1997
		800MG	A074658	002	Apr 22, 1997
	MYLAN	400MG	A074976	001	Apr 13, 1998
		400MG	A075211	001	Sep 28, 1998
		800MG	A074976	002	Apr 13, 1998
		800MG	A075211	002	Sep 28, 1998
	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998
		800MG	A074980	002	Sep 30, 1998
	TEVA	200MG **	A074556	001	Apr 22, 1997
	TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
		800MG	A075021	002	Mar 18, 1998
ZOVIRAX					
+	MYLAN	400MG **	N020089	001	Apr 30, 1991
+		800MG **	N020089	002	Apr 30, 1991
ACYCLOVIR SODIUM					
INJECTABLE;INJECTION					
ACYCLOVIR					
	ABBVIE	EQ 50MG BASE/ML	A075114	001	Jul 26, 1999
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE					
	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997
		EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997
ACYCLOVIR SODIUM					
	APOTHECON	EQ 500MG BASE/VIAL	A074897	001	Feb 27, 1998
		EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
	ATHENEX INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997
	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997
		EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ACYCLOVIR SODIUM

INJECTABLE;INJECTION					
ACYCLOVIR SODIUM					
	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015	001	Apr 30, 1998
	HIKMA	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016
		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016
	HOSPIRA	EQ 25MG BASE/ML	A074720	001	Apr 22, 1997
		EQ 50MG BASE/ML	A075065	001	Feb 25, 1999
		EQ 500MG BASE/VIAL	A074663	001	Apr 22, 1997
		EQ 500MG BASE/VIAL	A074758	001	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074663	002	Apr 22, 1997
		EQ 1GM BASE/VIAL	A074758	002	Apr 22, 1997
	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927	001	Mar 29, 2017
		EQ 1GM BASE/VIAL	A203927	002	Mar 29, 2017
	TEVA PARENTERAL	EQ 50MG BASE/ML	A075627	001	Mar 28, 2001
		EQ 500MG BASE/VIAL	A074969	001	Aug 26, 1997
		EQ 1GM BASE/VIAL	A074969	002	Aug 26, 1997
	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206606	001	Jun 13, 2017
		EQ 1GM BASE/VIAL	A206606	002	Jun 13, 2017
ZOVIRAX					
+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N018603	003	Aug 30, 1983
+		EQ 500MG BASE/VIAL **	N018603	001	Oct 22, 1982
+		EQ 1GM BASE/VIAL **	N018603	002	Jun 29, 1989

ADAPALENE

GEL;TOPICAL					
ADAPALENE					
	ENCUBE ETHICALS	0.3%	A200298	001	Jun 14, 2012
SOLUTION;TOPICAL					
DIFFERIN					
+	GALDERMA LABS LP	0.1% **	N020338	001	May 31, 1996

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL					
ADAPALENE AND BENZOYL PEROXIDE					
	ENCUBE	0.1%;2.5%	A206164	001	May 23, 2018

ADENOSINE

INJECTABLE;INJECTION					
ADENOCARD					
+	ASTELLAS	3MG/ML **	N019937	002	Oct 30, 1989
ADENOSINE					
	AM REGENT	3MG/ML	A090010	001	Apr 28, 2009
	HIKMA	3MG/ML	A076501	001	Jun 16, 2004
	MYLAN LABS LTD	3MG/ML	A078640	001	Mar 21, 2014
	TEVA PHARMS USA	3MG/ML	A076564	001	Jun 16, 2004
		3MG/ML	A078676	001	Jul 31, 2008
	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009
SOLUTION;INTRAVENOUS					
ADENOSCAN					
+	ASTELLAS	60MG/20ML (3MG/ML) **	N020059	001	May 18, 1995
+		90MG/30ML (3MG/ML) **	N020059	002	May 18, 1995

ALATROFLOXACIN MESYLATE

INJECTABLE;INJECTION					
TROVAN PRESERVATIVE FREE					
	PFIZER	EQ 200MG BASE/VIAL	N020760	001	Dec 18, 1997
		EQ 300MG BASE/VIAL	N020760	002	Dec 18, 1997

ALBENDAZOLE

TABLET;ORAL					
ALBENDAZOLE					
	LUPIN LTD	200MG	A211636	001	Jun 10, 2020

ALBUTEROL

AEROSOL, METERED;INHALATION					
ALBUTEROL					
	ARMSTRONG PHARMS	0.09MG/INH	A072273	001	Aug 14, 1996
	GENPHARM	0.09MG/INH	A073045	001	Aug 19, 1997
	IVAX SUB TEVA PHARMS	0.09MG/INH	A073272	001	Dec 28, 1995
	PLIVA	0.09MG/INH	A074072	001	Aug 01, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALBUTEROL				
AEROSOL, METERED;INHALATION				
PROVENTIL				
SCHERING	0.09MG/INH	N017559	001	
VENTOLIN				
GLAXOSMITHKLINE	0.09MG/INH	N018473	001	
ALBUTEROL SULFATE				
AEROSOL, METERED;INHALATION				
ALBUTEROL SULFATE				
PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020
CAPSULE;INHALATION				
VENTOLIN ROTACAPS				
GLAXOSMITHKLINE	EQ 0.2MG BASE	N019489	001	May 04, 1988
SOLUTION;INHALATION				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 0.083% BASE	A073533	001	Sep 26, 1995
AKORN	EQ 0.083% BASE	A075063	001	Feb 09, 1999
APOTEX INC	EQ 0.021% BASE	A078623	001	Apr 05, 2010
	EQ 0.042% BASE	A078623	002	Apr 05, 2010
	EQ 0.083% BASE	A075717	001	Feb 02, 2007
	EQ 0.5% BASE	A076391	001	Apr 01, 2003
BAUSCH AND LOMB	EQ 0.083% BASE	A075358	001	Mar 29, 2000
	EQ 0.5% BASE	A075050	001	Jun 18, 1998
COPLEY PHARM	EQ 0.083% BASE	A073495	001	May 28, 1993
	EQ 0.5% BASE	A073307	001	Nov 27, 1991
LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006
LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020
	EQ 0.042% BASE	A211888	002	Apr 20, 2020
MYLAN SPECLT	EQ 0.083% BASE **	A072652	001	Feb 21, 1992
ROXANE	EQ 0.083% BASE	A075129	001	Feb 13, 2001
TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999
WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003
WOCKHARDT EU OPERATN	EQ 0.083% BASE	A075394	001	Nov 22, 1999
PROVENTIL				
+ SCHERING	EQ 0.083% BASE **	N019243	002	Jan 14, 1987
+	EQ 0.5% BASE **	N019243	001	Jan 14, 1987
VENTOLIN				
+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773	001	Apr 23, 1992
	EQ 0.5% BASE **	N019269	002	Jan 16, 1987
SYRUP;ORAL				
ALBUTEROL SULFATE				
ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262	001	Mar 30, 1999
CHARTWELL RX	EQ 2MG BASE/5ML	A077788	001	Jun 26, 2007
MOVA	EQ 2MG BASE/5ML	A074302	001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165	001	Apr 29, 1993
PROVENTIL				
+ SCHERING	EQ 2MG BASE/5ML **	N018062	001	Jan 19, 1983
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621	001	Jun 10, 1987
TABLET;ORAL				
ALBUTEROL SULFATE				
AM THERAP	EQ 2MG BASE	A072449	001	Dec 05, 1989
	EQ 4MG BASE	A072450	001	Dec 05, 1989
AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657	001	May 14, 2020
	EQ 4MG BASE	A213657	002	May 14, 2020
CHARTWELL RX	EQ 2MG BASE	A072151	001	Dec 05, 1989
	EQ 4MG BASE	A072152	001	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966	001	Nov 22, 1991
	EQ 4MG BASE	A072967	001	Nov 22, 1991
EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020
	EQ 4MG BASE	A213524	002	Oct 08, 2020
PLIVA	EQ 2MG BASE	A072316	001	Dec 05, 1989
	EQ 4MG BASE	A072317	001	Dec 05, 1989
STRIDES PHARMA	EQ 2MG BASE	A072860	002	Dec 20, 1989
	EQ 4MG BASE	A072860	001	Dec 20, 1989
TEVA	EQ 2MG BASE	A072619	001	Dec 05, 1989
	EQ 2MG BASE	A072779	001	Jun 25, 1993
	EQ 2MG BASE	A072938	001	Mar 30, 1990
	EQ 4MG BASE	A072620	001	Dec 05, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALBUTEROL SULFATE

TABLET;ORAL				
ALBUTEROL SULFATE				
	EQ 4MG BASE	A072780	001	Jun 25, 1993
	EQ 4MG BASE	A072939	001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120	001	Sep 29, 1992
	EQ 4MG BASE	A073121	001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817	001	Jan 09, 1990
	EQ 4MG BASE	A072818	001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629	001	Jan 31, 1991
	EQ 2MG BASE	A072764	001	Aug 28, 1991
	EQ 4MG BASE	A072630	001	Jan 31, 1991
	EQ 4MG BASE	A072765	001	Aug 28, 1991
PROVENTIL				
+ SCHERING	EQ 2MG BASE **	N017853	001	May 07, 1982
+	EQ 4MG BASE **	N017853	002	May 07, 1982
VENTOLIN				
GLAXOSMITHKLINE	EQ 2MG BASE	N019112	001	Jul 10, 1986
	EQ 4MG BASE	N019112	002	Jul 10, 1986
TABLET, EXTENDED RELEASE;ORAL				
ALBUTEROL SULFATE				
RISING PHARMA	EQ 4MG BASE	A078092	002	Jan 29, 2007
	EQ 8MG BASE	A078092	001	Jan 29, 2007
PROVENTIL				
SCHERING	EQ 4MG BASE	N019383	001	Jul 13, 1987
VOLMAX				
+ MURO	EQ 4MG BASE	N019604	002	Dec 23, 1992
+	EQ 8MG BASE	N019604	001	Dec 23, 1992
VOSPIRE ER				
STRIDES PHARMA	EQ 8MG BASE	A076130	003	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION				
COMBIVENT				
BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996
SOLUTION;INHALATION				
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE				
APOTEX INC	EQ 0.083% BASE;0.017%	A077117	001	Dec 31, 2007
FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006
LUOXIN AUROVITAS	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020
TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007
WATSON LABS TEVA	EQ 0.083% BASE;0.017%	A077063	001	Dec 31, 2007
DUONEB				
+ MYLAN SPECIALITY LP	EQ 0.083% BASE;0.017% **	N020950	001	Mar 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **	N018707	001	Dec 14, 1982
OINTMENT;TOPICAL				
ACLOVATE				
+ FOUGERA PHARMS	0.05% **	N018702	001	Dec 14, 1982

ALENDRONATE SODIUM

SOLUTION;ORAL				
FOSAMAX				
+ MERCK	EQ 70MG BASE/75ML **	N021575	001	Sep 17, 2003
TABLET;ORAL				
ALENDRONATE SODIUM				
CHARTWELL RX	EQ 5MG BASE	A075871	001	Apr 22, 2009
	EQ 10MG BASE	A075871	002	Apr 22, 2009
	EQ 35MG BASE	A075871	004	Apr 22, 2009
	EQ 40MG BASE	A075871	003	Apr 22, 2009
	EQ 70MG BASE	A075871	005	Apr 22, 2009
IMPAX LABS INC	EQ 5MG BASE	A075710	001	Feb 06, 2008
	EQ 10MG BASE	A075710	002	Feb 06, 2008
	EQ 35MG BASE	A075710	003	Feb 06, 2008
	EQ 40MG BASE	A075710	004	Feb 06, 2008
	EQ 70MG BASE	A075710	005	Feb 06, 2008
JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010
	EQ 10MG BASE	A090557	002	Feb 18, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALENDRONATE SODIUM

TABLET;ORAL					
ALENDRONATE SODIUM					
		EQ 35MG BASE	A090557	003	Feb 18, 2010
		EQ 70MG BASE	A090557	004	Feb 18, 2010
	MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008
		EQ 70MG BASE	A078638	002	Aug 04, 2008
	PICKET PHARMS	EQ 5MG BASE	A079049	003	Aug 04, 2008
		EQ 10MG BASE	A079049	004	Aug 04, 2008
		EQ 35MG BASE	A079049	001	Aug 04, 2008
		EQ 70MG BASE	A079049	002	Aug 04, 2008
	RISING PHARMA	EQ 5MG BASE	A076584	001	Aug 04, 2008
		EQ 10MG BASE	A076584	002	Aug 04, 2008
		EQ 35MG BASE	A076584	003	Aug 04, 2008
		EQ 70MG BASE	A076584	004	Aug 04, 2008
	TEVA PHARMS	EQ 35MG BASE	A076184	002	Aug 04, 2008
		EQ 70MG BASE	A076184	001	Feb 06, 2008
FOSAMAX					
+	MERCK AND CO INC	EQ 5MG BASE **	N020560	003	Apr 25, 1997
+		EQ 10MG BASE **	N020560	001	Sep 29, 1995
+		EQ 35MG BASE **	N020560	004	Oct 20, 2000
+		EQ 40MG BASE **	N020560	002	Sep 29, 1995

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
ALFUZOSIN HYDROCHLORIDE					
	HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011
	MYLAN	10MG	A079014	001	Jul 18, 2011
	TORRENT PHARMS	10MG	A079054	001	Jul 18, 2011
	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET;ORAL					
TEKTURNA					
+	NODEN PHARMA	EQ 37.5MG BASE	N210709	001	Nov 14, 2017

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL					
TEKAMLO					
	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010
		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010
		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010
		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
AMTURNIDE					
	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010
		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010
		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
TEKTURNA HCT					
+	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008
+		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET;ORAL					
VALTURNA					
	NOVARTIS	EQ 150MG BASE;160MG	N022217	001	Sep 16, 2009
		EQ 300MG BASE;320MG	N022217	002	Sep 16, 2009

ALKAVERVIR

TABLET;ORAL					
VERILOID					
	3M	2MG	N007336	002	
		3MG	N007336	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

FOSUN PHARMA	100MG	A070268	001	Dec 31, 1985
MUTUAL PHARM	100MG	A070466	001	Dec 24, 1985
	300MG	A070467	001	Dec 24, 1985
PURACAP PHARM	100MG	A070150	001	Dec 10, 1985
	300MG	A070147	001	Dec 10, 1985
PUREPAC PHARM	100MG	A070579	001	Apr 14, 1986
	300MG	A070580	001	Apr 14, 1986
SANDOZ	300MG	A070269	001	Dec 31, 1985
SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007
	300MG	A078390	002	Aug 30, 2007
SUPERPHARM	100MG	A070950	001	Nov 30, 1988
	300MG	A070951	001	Nov 30, 1988
WATSON LABS	100MG	N018241	001	Nov 16, 1984
	100MG	N018785	001	Sep 28, 1984
	300MG	N018241	002	Nov 16, 1984
	300MG	N018785	002	Sep 28, 1984

LOPURIN

ABBOTT	100MG	N018297	001	
	300MG	N018297	002	

ALLOPURINOL; LESINURAD

TABLET;ORAL

DUZALLO

+	IRONWOOD PHARMS INC	200MG;200MG	N209203	001	Aug 18, 2017
+		300MG;200MG	N209203	002	Aug 18, 2017

ALMOTRIPTAN MALATE

TABLET;ORAL

AXERT

+	JANSSEN PHARMS	EQ 6.25MG BASE **	N021001	001	May 07, 2001
+		EQ 12.5MG BASE **	N021001	002	May 07, 2001

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019
	EQ 1MG BASE	A211621	002	Sep 16, 2019

ALPRAZOLAM

SOLUTION;ORAL

ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

ANI PHARMS	0.25MG	A074085	001	Feb 16, 1994
	0.5MG	A074085	002	Feb 16, 1994
	1MG	A074085	003	Feb 16, 1994
	2MG	A074085	004	Feb 26, 1996
IVAX SUB TEVA PHARMS	0.25MG	A074294	001	Jul 29, 1994
	0.5MG	A074294	002	Jul 29, 1994
	1MG	A074294	003	Jul 29, 1994
	2MG	A074294	004	Jul 29, 1994
MYLAN	0.25MG	A074215	001	Jan 27, 1994
	0.5MG	A074215	002	Jan 27, 1994
	1MG	A074215	003	Jan 27, 1994
	2MG	A074215	004	Jan 27, 1994
MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993
	0.5MG	A074046	002	Oct 19, 1993
	1MG	A074046	003	Oct 19, 1993
	2MG	A074046	004	May 07, 1997
OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008
	0.5MG	A078491	002	Sep 25, 2008
	1MG	A078491	003	Sep 25, 2008
	2MG	A078491	004	Dec 12, 2008
ROXANE	0.25MG	A074199	001	Oct 19, 1993
	0.5MG	A074199	002	Oct 19, 1993
	1MG	A074199	003	Oct 19, 1993
WATSON LABS	0.25MG	A074456	001	Aug 31, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALPRAZOLAM

TABLET;ORAL					
ALPRAZOLAM					
		0.25MG	A074479	001	Jan 21, 1997
		0.5MG	A074456	002	Aug 31, 1995
		0.5MG	A074479	002	Jan 21, 1997
		1MG	A074456	003	Aug 31, 1995
		1MG	A074479	003	Jan 21, 1997
TABLET, EXTENDED RELEASE;ORAL					
ALPRAZOLAM					
	ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010
		1MG	A077198	002	May 13, 2010
		2MG	A077198	003	May 13, 2010
		3MG	A077198	004	May 13, 2010
	ANI PHARMS	0.5MG	A077725	001	Jul 31, 2006
		0.5MG	A077979	001	Feb 28, 2007
		1MG	A077725	002	Jul 31, 2006
		1MG	A077979	002	Feb 28, 2007
		2MG	A077725	004	Jul 31, 2006
		2MG	A077979	003	Feb 28, 2007
		3MG	A077725	003	Jul 31, 2006
		3MG	A077979	004	Feb 28, 2007
	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008
		1MG	A078489	002	Oct 17, 2008
		2MG	A078489	003	Oct 17, 2008
		3MG	A078489	004	Oct 17, 2008
	IMPAX LABS	0.5MG	A077968	004	May 24, 2007
		1MG	A077968	003	May 24, 2007
		2MG	A077968	002	May 24, 2007
		3MG	A077968	001	May 24, 2007
	IMPAX LABS INC	0.5MG	A077996	001	Jan 31, 2007
		1MG	A077996	002	Jan 31, 2007
		2MG	A077996	003	Jan 31, 2007
		3MG	A077996	004	Jan 31, 2007
	MYLAN	0.5MG	A077391	002	Jan 26, 2006
		1MG	A077391	003	Jan 26, 2006
		2MG	A077391	004	Jan 26, 2006
		3MG	A077391	001	Jan 26, 2006
	SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006
		1MG	A077777	002	Jun 30, 2006
		2MG	A077777	003	Jun 30, 2006
		3MG	A077777	004	Jun 30, 2006
	VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007
		1MG	A078442	002	Oct 15, 2007
		2MG	A078442	003	Oct 15, 2007
		3MG	A078442	004	Oct 15, 2007
TABLET, ORALLY DISINTEGRATING;ORAL					
NIRAVAM					
+	UCB INC	0.25MG **	N021726	001	Jan 19, 2005
+		0.5MG **	N021726	002	Jan 19, 2005
+		1MG **	N021726	003	Jan 19, 2005
+		2MG **	N021726	004	Jan 19, 2005

ALPROSTADIL

INJECTABLE;INJECTION					
CAVERJECT					
+	PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996
		0.005MG/ML	N020755	001	Oct 31, 1997
		0.01MG/ML	N020755	002	Oct 01, 1997
		0.02MG/ML	N020755	003	Oct 01, 1997
EDEX					
	AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997

ALSEROXYLON

TABLET;ORAL				
RAUTENSIN				
	NOVARTIS	2MG	N009215	001
RAUWILOID				
	3M	2MG	N008867	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ALTRETAMINE

CAPSULE;ORAL					
HEXALEN					
+	EISAI INC	50MG	N019926	001	Dec 26, 1990

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL					
ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE					
	PENNEX	80MG;20MG	A089449	001	Nov 27, 1987
FOAMCOAT					
	GUARDIAN DRUG	80MG;20MG	A071793	001	Sep 04, 1987
FOAMICON					
	NOVARTIS	80MG;20MG	A072687	001	Jun 28, 1989
GAVISCON					
+	CHATTEM SANOFI	160MG;40MG	N018685	002	Dec 09, 1983

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL					
AMANTADINE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006
	INVAGEN PHARMS	100MG	A207570	001	Sep 30, 2016
	LANNETT CO INC	100MG	A209221	001	Jun 15, 2017
	WATSON LABS	100MG	A071382	001	Jan 21, 1987
SYMADINE					
	SOLVAY	100MG	A071000	001	Sep 04, 1986
SYMMETREL					
+	ENDO PHARMS	100MG **	N016020	001	
SYRUP;ORAL					
AMANTADINE HYDROCHLORIDE					
	G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
	GENUS	50MG/5ML	A076352	001	Sep 10, 2004
	TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
	VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006
	WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998
SYMMETREL					
+	ENDO PHARMS	50MG/5ML **	N016023	002	
TABLET;ORAL					
AMANTADINE HYDROCHLORIDE					
	INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017
SYMMETREL					
+	ENDO PHARMS	100MG **	N018101	001	
TABLET, EXTENDED RELEASE;ORAL					
OSMOLEX ER					
+	ADAMAS PHARMA	EQ 161MG BASE	N209410	004	Apr 22, 2020
+		EQ 258MG BASE	N209410	003	Feb 16, 2018

AMBENONIUM CHLORIDE

TABLET;ORAL					
MYTELASE					
	SANOFI AVENTIS US	10MG	N010155	002	

AMCINONIDE

CREAM;TOPICAL					
CYCLOCORT					
+	ASTELLAS	0.025%	N018116	001	
+		0.1%	N018116	002	
LOTION;TOPICAL					
CYCLOCORT					
+	ASTELLAS	0.1%	N019729	001	Jun 13, 1988
OINTMENT;TOPICAL					
CYCLOCORT					
+	ASTELLAS	0.1%	N018498	001	

AMDINOCILLIN

INJECTABLE;INJECTION					
COACTIN					
	ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
		500MG/VIAL	N050565	002	Dec 21, 1984
		1GM/VIAL	N050565	003	Dec 21, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMIFOSTINE

INJECTABLE;INJECTION					
AMIFOSTINE					
	AUROMEDICS PHARMA	500MG/VIAL	A204363	001	Jul 17, 2017
ETHYOL					
	CLINIGEN	375MG/VIAL	N020221	002	Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE;INJECTION					
AMIKACIN SULFATE					
	ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
		EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
	HIKMA	EQ 50MG BASE/ML	A063274	001	May 18, 1992
		EQ 250MG BASE/ML	A063275	001	May 18, 1992
	HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994
		EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
		EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
		EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
		EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
		EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
		EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
	IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
		EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
	TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
AMIKIN					
	APOTHECON	EQ 50MG BASE/ML	A062311	001	
		EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
+		EQ 50MG BASE/ML **	N050495	001	
		EQ 250MG BASE/ML	A062311	002	
		EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
+		EQ 250MG BASE/ML **	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
		EQ 10MG BASE/ML	N050618	001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	CHARTWELL RX	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991
	TEVA	EQ 5MG ANHYDROUS;50MG	A070795	001	Apr 17, 1988
	WATSON LABS	EQ 5MG ANHYDROUS;50MG	A073334	001	Jul 19, 1991
HYDRO-RIDE					
	PAR PHARM	EQ 5MG ANHYDROUS;50MG	A070347	001	Dec 25, 1990
MODURETIC 5-50					
+	MERCK	EQ 5MG ANHYDROUS;50MG **	N018201	001	

AMINO ACIDS

INJECTABLE;INJECTION					
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE					
	HOSPIRA	5.2% (5.2GM/100ML)	N018901	001	Apr 06, 1984
AMINOSYN 10%					
	ICU MEDICAL INC	10% (10GM/100ML)	N017673	003	
AMINOSYN 10% (PH6)					
	ICU MEDICAL INC	10% (10GM/100ML)	N017673	008	Nov 18, 1985
AMINOSYN 3.5%					
	ICU MEDICAL INC	3.5% (3.5GM/100ML)	N017789	004	
AMINOSYN 3.5% IN PLASTIC CONTAINER					
	ABBOTT	3.5% (3.5GM/100ML)	N018804	001	May 15, 1984
		3.5% (3.5GM/100ML)	N018875	001	Aug 08, 1984
AMINOSYN 5%					
	ICU MEDICAL INC	5% (5GM/100ML)	N017673	001	
AMINOSYN 7%					
	ICU MEDICAL INC	7% (7GM/100ML)	N017673	002	
AMINOSYN 7% (PH6)					
	ICU MEDICAL INC	7% (7GM/100ML)	N017673	006	Nov 18, 1985
AMINOSYN 8.5%					
	ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	004	

AMINO ACIDS

INJECTABLE;INJECTION

AMINOSYN 8.5% (PH6)				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N017673	007	Nov 18, 1985
AMINOSYN II 10%				
ICU MEDICAL INC	10% (10GM/100ML)	N019438	005	Apr 03, 1986
AMINOSYN II 3.5%				
ICU MEDICAL INC	3.5% (3.5GM/100ML)	N019438	001	Apr 03, 1986
AMINOSYN II 3.5% IN PLASTIC CONTAINER				
ABBOTT	3.5% (3.5GM/100ML)	N019491	001	Oct 10, 1986
AMINOSYN II 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986
AMINOSYN II 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986
AMINOSYN II 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986
AMINOSYN-HBC 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
AMINOSYN-HF 8%				
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996
AMINOSYN-RF 5.2%				
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001	
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	002	Nov 07, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML	N019683	003	Nov 07, 1988

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2 2.4MG/100ML;261MG/100ML;205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986
	3.5%;25GM/100ML	N019713	006	Sep 09, 1988
HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986
	3.5%;5GM/100ML	N019713	002	Sep 09, 1988
HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986
	4.25%;25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986
	5%;25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML ;261MG/100ML;205MG/100ML	N019564	002	Dec 16, 1986

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML;51MG/100ML;22.4MG/100M L;261MG/100ML;205MG/100ML	N019564	004	Dec 16, 1986

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML	N019682	001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;30MG/100ML;97MG/100ML; 120MG/100ML;49.3MG/100ML	N019564	003	Dec 16, 1986
HOSPIRA INC	4.25%;5GM/100ML;30MG/100ML;97MG/100ML;1 20MG/100ML;49.3MG/100ML	N019682	002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	002	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	003	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	004	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML	N020147	005	Oct 23, 1995

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML;51MG/100ML;261MG/100ML; 216MG/100ML;112MG/100ML	N020147	001	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	007	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	008	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	009	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML	N020147	010	Oct 23, 1995

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML;51MG/100ML;261MG/100ML; 297MG/100ML;77MG/100ML	N020147	006	Oct 23, 1995

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N017789	003	

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018804	002	May 15, 1984
	3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML	N018875	002	Aug 08, 1984

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%;21MG/100ML;128MG/100ML;234MG/100ML	N017789	005	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML	N019493	001	Oct 16, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

VEINAMINE 8%

HOSPIRA INC	8%;61MG/100ML;211MG/100ML;56MG/100ML;38MG/100ML	N017957	001	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC	10%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	004	Apr 03, 1986

AMINOSYN II 7% W/ ELECTROLYTES

ICU MEDICAL INC	7%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	006	Apr 03, 1986

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML	N019437	005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE;INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML	N017673	009	Oct 25, 2002

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC	8.5%;102MG/100ML;492MG/100ML;60MG/100ML;425MG/100ML	N019437	008	Oct 25, 2002

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC	3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML	N019437	007	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N017493	003	

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N020173	001	Oct 27, 1995

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML	N017493	001	

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML	N020173	002	Oct 27, 1995

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;	N017493	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
TRAVASOL 8.5% W/ ELECTROLYTES				
	594MG/100ML;154MG/100ML			
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE				
INJECTABLE;INJECTION				
AMINOSYN 7% W/ ELECTROLYTES				
ICU MEDICAL INC	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002	
AMINOSYN 8.5% W/ ELECTROLYTES				
ICU MEDICAL INC	8.5%;102MG/100ML;522MG/100ML;410MG/100ML	N017673	005	
AMINOCAPROIC ACID				
INJECTABLE;INJECTION				
AMICAR				
+ AKORN	250MG/ML **	N015229	002	
AMINOCAPROIC ACID				
ABRAXIS PHARM	250MG/ML	A070522	001	Jun 17, 1986
BAXTER HLTHCARE	250MG/ML	N018590	001	Oct 29, 1982
HOSPIRA	250MG/ML	A070888	001	Jun 16, 1988
SOLUTION;ORAL				
AMINOCAPROIC ACID				
AKORN	0.25GM/ML	A074759	001	Sep 02, 1998
TABLET;ORAL				
AMINOCAPROIC				
AKORN	500MG	A075602	001	May 24, 2001
AMINOCAPROIC ACID				
EDENBRIDGE PHARMS	500MG	A212110	001	Jun 14, 2021
AMINOGLUTETHIMIDE				
TABLET;ORAL				
CYTADREN				
NOVARTIS	250MG	N018202	001	
AMINOHIPPURATE SODIUM				
INJECTABLE;INJECTION				
AMINOHIPPURATE SODIUM				
MERCK	20%	N005619	001	
AMINOPHYLLINE				
ENEMA;RECTAL				
SOMOPHYLLIN				
FISONS	300MG/5ML	N018232	001	Apr 02, 1982
INJECTABLE;INJECTION				
AMINOPHYLLIN				
+ GD SEARLE LLC	25MG/ML	A087243	001	May 24, 1982
+	25MG/ML	A087621	001	May 24, 1982
AMINOPHYLLINE				
ABRAXIS PHARM	25MG/ML	A084568	001	
	25MG/ML	A087200	001	
	25MG/ML	A087250	001	Jan 06, 1982
	25MG/ML	A087886	001	Aug 30, 1983
	25MG/ML	A088407	001	Jan 25, 1984
AM REGENT	25MG/ML	A087600	001	
ELKINS SINN	25MG/ML	A087239	001	
HOSPIRA	25MG/ML	A087601	001	Jul 23, 1982
INTL MEDICATION	25MG/ML	A087209	001	Feb 01, 1982
	25MG/ML	A087867	001	Nov 10, 1983
	25MG/ML	A087868	001	Nov 10, 1983
KING PHARMS	25MG/ML	A086606	001	
LUITPOLD	25MG/ML	A087240	001	
LYPHOMED	25MG/ML	A087431	001	
PHARMA SERVE NY	25MG/ML	A087387	001	Jun 03, 1983
	25MG/ML	A087392	001	Dec 15, 1983
SMITH AND NEPHEW	25MG/ML	A088429	001	May 30, 1985
	25MG/ML	A088749	001	May 30, 1985
TEVA PARENTERAL	25MG/ML	A081142	001	Sep 25, 1991
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100MG/100ML	A088147	002	May 03, 1983
	200MG/100ML	A088147	003	May 03, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINOPHYLLINE

INJECTABLE;INJECTION				
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
HOSPIRA	100MG/100ML	N018924	001	Dec 12, 1984
	200MG/100ML	N018924	002	Dec 12, 1984
	400MG/100ML	N018924	003	Dec 12, 1984
	500MG/100ML	N018924	004	Dec 12, 1984
SOLUTION;ORAL				
AMINOPHYLLINE				
MORTON GROVE	105MG/5ML	A088156	001	Dec 05, 1983
ROXANE	105MG/5ML	A088126	001	Aug 19, 1983
AMINOPHYLLINE DYE FREE				
ACTAVIS MID ATLANTIC	105MG/5ML	A087727	001	Apr 16, 1982
SOMOPHYLLIN				
FISONS	105MG/5ML	A086466	001	
SOMOPHYLLIN-DF				
FISONS	105MG/5ML	A087045	001	
SUPPOSITORY;RECTAL				
TRUPHYLLINE				
COSETTE	250MG	A085498	001	Mar 23, 1983
	500MG	A085498	002	Jan 03, 1983
TABLET;ORAL				
AMINOPHYLLIN				
GD SEARLE LLC	100MG	N002386	002	
	200MG	N002386	003	
AMINOPHYLLINE				
ANI PHARMS	100MG	A085261	004	
	200MG	A085261	002	
ASCOT	100MG	A087522	001	Feb 12, 1982
	200MG	A087523	001	Feb 12, 1982
BARR	100MG	A088297	001	Aug 19, 1983
	200MG	A088298	001	Aug 19, 1983
DURAMED PHARMS BARR	100MG	A088182	001	Mar 31, 1983
	200MG	A088183	001	Mar 31, 1983
HALSEY	100MG	A084674	001	
HIKMA INTL PHARMS	100MG	A084540	001	
	200MG	A085003	001	
IMPAX LABS	100MG	A084574	001	
	200MG	A084576	001	
KV PHARM	100MG	A085284	001	
	200MG	A085289	001	
LANNETT	100MG	A084588	001	
	200MG	A084588	002	
PAL PAK	100MG	A084533	001	
PANRAY	100MG	A084552	001	
	200MG	A084552	002	
PUREPAC PHARM	100MG	A084699	001	
	200MG	A085333	001	
ROXANE	100MG	A087500	001	Feb 09, 1982
	200MG	A087501	001	Feb 09, 1982
VALEANT PHARM INTL	200MG	A084563	001	
VANGARD	100MG	A088314	001	Oct 03, 1983
	200MG	A088319	001	Oct 03, 1983
VINTAGE PHARMS	100MG	A085409	001	
	200MG	A085410	001	
WATSON LABS	100MG	A085567	001	
	200MG	A085564	001	
TABLET, DELAYED RELEASE;ORAL				
AMINOPHYLLINE				
IMPAX LABS	100MG	A084577	001	
	200MG	A084575	001	
TABLICAPS	100MG	A084632	002	
VALE	100MG	A084531	001	
	200MG	A084530	001	
TABLET, EXTENDED RELEASE;ORAL				
PHYLLOCONTIN				
PHARM RES ASSOC	225MG	A086760	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMINOSALICYLATE SODIUM				
POWDER;ORAL				
P.A.S. SODIUM				
CENTURY PHARMS	4GM/PACKET		A080947 001	
SODIUM AMINOSALICYLATE				
HEXCEL	100%		A080097 001	
TABLET;ORAL				
PARASAL SODIUM				
PANRAY	500MG		N006811 006	
	1GM		N006811 011	
SODIUM P.A.S.				
LANNETT	500MG		A080138 002	
TEEBACIN				
CONSOLIDATED MIDLAND	500MG		N007320 002	
AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID				
TABLET;ORAL				
NEOPASALATE				
MEDPOINTE PHARM HLC	846MG;112MG		A080059 002	
AMINOSALICYLIC ACID				
TABLET;ORAL				
PARASAL				
PANRAY	500MG		N006811 001	
	1GM		N006811 002	
AMINOSALICYLIC ACID RESIN COMPLEX				
POWDER;ORAL				
REZIPAS				
BRISTOL MYERS SQUIBB	EQ 500MG BASE/GM		N009052 001	
AMIODARONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
AMIODARONE HYDROCHLORIDE				
AKORN	50MG/ML		A076232 001	Jul 05, 2006
BEDFORD	50MG/ML		A076018 001	Oct 15, 2002
BEDFORD LABS	50MG/ML		A076299 001	Oct 24, 2002
BEN VENUE	50MG/ML		A076088 001	Oct 15, 2002
DR REDDYS	50MG/ML		A076163 001	Sep 05, 2003
HOSPIRA	50MG/ML		A075955 001	Oct 18, 2002
	50MG/ML		A076108 001	Oct 15, 2002
HOSPIRA INC	50MG/ML		A203885 001	Nov 25, 2013
INTL MEDICATION SYS	50MG/ML		N021594 001	Feb 04, 2004
PAR STERILE PRODUCTS	50MG/ML		A076394 001	Apr 25, 2003
CORDARONE				
+ WYETH PHARMS INC	50MG/ML **		N020377 001	Aug 03, 1995
NEXTERONE				
+ BAXTER HLTHCARE	50MG/ML **		N022325 001	Dec 24, 2008
TABLET;ORAL				
AMIODARONE HYDROCHLORIDE				
MYLAN	200MG		A075188 001	Feb 24, 1999
TEVA	200MG		A074895 001	Apr 16, 1999
CORDARONE				
+ WYETH PHARMS	200MG **		N018972 001	Dec 24, 1985
AMITRIPTYLINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
ENDEP				
+ ROCHE	40MG/ML		A085749 001	
INJECTABLE;INJECTION				
AMITRIPTYLINE HYDROCHLORIDE				
WATSON LABS	10MG/ML		A085594 001	
ELAVIL				
ASTRAZENECA	10MG/ML		N012704 001	
TABLET;ORAL				
AMITID				
BRISTOL MYERS SQUIBB	10MG		A086454 001	
	25MG		A086454 002	
	50MG		A086454 003	
	75MG		A086454 004	
	100MG		A086454 005	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIL				
WARNER CHILCOTT	10MG	A083939	001	
	25MG	A083937	001	
	50MG	A083938	002	
	75MG	A084957	001	
	100MG	A085093	001	
	150MG	A086295	001	
AMITRIPTYLINE HYDROCHLORIDE				
AM THERAP	25MG	A088672	001	Nov 20, 1984
	50MG	A088673	001	Nov 20, 1984
	75MG	A088674	001	Nov 20, 1984
	100MG	A088675	001	Nov 20, 1984
ANI PHARMS	10MG	A085031	002	
	25MG	A085031	001	
	50MG	A085031	003	
	75MG	A085031	004	
AUROBINDO PHARMA USA	10MG	A086009	002	
	25MG	A086009	003	
	50MG	A086009	001	
	75MG	A086009	004	
	100MG	A086009	005	
	150MG	A086009	006	
COPLEY PHARM	10MG	A088421	001	Apr 30, 1984
	25MG	A088422	001	Apr 30, 1984
	50MG	A088423	001	Apr 30, 1984
	75MG	A088424	001	Apr 30, 1984
	100MG	A088425	001	Apr 30, 1984
	150MG	A088426	001	Apr 30, 1984
HALSEY	10MG	A085923	001	
	25MG	A085922	001	
	50MG	A085925	001	
	50MG	A087557	001	Mar 05, 1982
	75MG	A085926	001	May 20, 1983
	100MG	A085927	001	May 20, 1983
LEDERLE	10MG	A086744	001	
	10MG	A087366	001	Jan 04, 1982
	25MG	A086746	001	
	25MG	A087367	001	May 03, 1982
	50MG	A086743	001	
	50MG	A087181	001	Jan 04, 1982
	75MG	A086745	001	
	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE					
		50MG	A088077	001	Sep 16, 1983
		50MG	A088105	001	Jul 18, 1983
		75MG	A088078	001	Sep 16, 1983
		75MG	A088106	001	Jul 18, 1983
		100MG	A088079	001	Sep 16, 1983
		100MG	A088107	001	Jul 18, 1983
	ROXANE	10MG	A086002	001	
		10MG	A086144	001	
		25MG	A085944	001	
		25MG	A086145	001	
		50MG	A085945	001	
		50MG	A086143	001	
		75MG	A086004	001	
		75MG	A086147	001	
		100MG	A086003	001	
		100MG	A086146	001	
		150MG	A086090	001	
		150MG	A086148	001	
	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008
		25MG	A040816	001	Jun 27, 2008
		50MG	A040816	003	Jun 27, 2008
		75MG	A040816	004	Jun 27, 2008
		100MG	A040816	005	Jun 27, 2008
		150MG	A040816	006	Jun 27, 2008
	SUPERPHARM	10MG	A088853	001	Nov 13, 1984
		25MG	A088854	001	Nov 13, 1984
		50MG	A088855	001	Nov 13, 1984
		75MG	A088856	001	Nov 13, 1984
		100MG	A088857	001	Nov 13, 1984
	TEVA	10MG	A086610	001	
		25MG	A086859	001	
		50MG	A086857	001	
		75MG	A086860	001	
		100MG	A085836	001	
		100MG	A086854	001	
		150MG	A086853	001	
	UCB INC	10MG	A085864	001	
		25MG	A085935	001	
		50MG	A085936	001	
		75MG	A086337	001	
		100MG	A086336	001	
		150MG	A086335	001	
	USL PHARMA	25MG	A087775	001	Feb 10, 1982
	VANGARD	10MG	A087632	001	Feb 01, 1982
		50MG	A087616	001	Feb 08, 1982
		75MG	A087617	001	Feb 05, 1982
		100MG	A087639	001	Feb 08, 1982
	WATSON LABS	10MG	A085816	001	
		10MG	A088620	001	Mar 02, 1984
		25MG	A085817	001	
		25MG	A088621	001	Mar 02, 1984
		50MG	A085815	001	
		50MG	A088622	001	Mar 02, 1984
		75MG	A085819	001	
		75MG	A088633	001	Mar 02, 1984
		100MG	A085820	001	
		100MG	A088634	001	Mar 02, 1984
		150MG	A085821	001	
		150MG	A088635	001	Mar 02, 1984
	WEST WARD	10MG	A087647	001	Mar 05, 1982
		25MG	A087278	001	
ELAVIL					
+	ASTRAZENECA	10MG **	N012703	001	
+		25MG **	N012703	003	
+		50MG **	N012703	004	
+		75MG **	N012703	005	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL				
ELAVIL				
+		100MG **	N012703 006	
+		150MG **	N012703 007	
ENDEP				
	ROCHE	10MG	A083639 001	
		25MG	A083639 002	
		50MG	A083639 003	
		75MG	A083639 004	
		100MG	A083639 005	
		150MG	A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL				
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE				
	FRONTIDA BIOPHARM	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
		EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
	HERITAGE PHARMA	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
		EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988
	STRIDES PHARMA	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
		EQ 25MG BASE;10MG	A072278 001	May 09, 1988
	USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
		EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988
LIMBITROL				
+	HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG **	N016949 001	
LIMBITROL DS				
+	HERITAGE PHARMS INC	EQ 25MG BASE;10MG **	N016949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL				
ETRAFON 2-10				
	SCHERING	10MG;2MG **	N014713 007	
ETRAFON 2-25				
	SCHERING	25MG;2MG **	N014713 004	
ETRAFON-A				
	SCHERING	10MG;4MG **	N014713 002	
ETRAFON-FORTE				
	SCHERING	25MG;4MG **	N014713 006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE				
	FOSUN PHARMA	10MG;2MG	A071062 001	Nov 27, 1987
		10MG;4MG	A071862 001	Dec 21, 1987
		25MG;2MG	A071063 001	Nov 27, 1987
		25MG;4MG	A071064 001	Nov 27, 1987
		50MG;4MG	A071863 001	Dec 21, 1987
	HERITAGE PHARMA	10MG;2MG	A073007 001	Oct 17, 1991
		10MG;4MG	A073009 001	Oct 17, 1991
		25MG;2MG	A073008 001	Oct 17, 1991
		25MG;4MG	A073010 001	Oct 17, 1991
	IVAX SUB TEVA PHARMS	10MG;2MG	A070935 001	Sep 11, 1986
		10MG;4MG	A070937 001	Sep 11, 1986
		25MG;2MG	A070936 001	Sep 11, 1986
		25MG;4MG	A070938 001	Sep 11, 1986
		50MG;4MG	A070939 001	Sep 12, 1986
	PAR PHARM	10MG;2MG	A070565 001	Sep 11, 1986
		10MG;4MG	A070620 001	Sep 11, 1986
		25MG;2MG	A070621 001	Sep 11, 1986
		25MG;4MG	A070595 001	Sep 11, 1986
		50MG;4MG	A070574 001	Sep 11, 1986
	SUN PHARM INDUSTRIES	10MG;2MG	A071077 001	Nov 12, 1986
		10MG;4MG	A071078 001	Nov 12, 1986
		25MG;2MG	A070297 001	Nov 12, 1986
		25MG;4MG	A071079 001	Nov 12, 1986
	WATSON LABS	10MG;2MG	A070373 001	Aug 25, 1986
		10MG;2MG	A072539 001	Feb 15, 1989
		10MG;4MG	A070375 001	Aug 25, 1986
		10MG;4MG	A072540 001	Feb 15, 1989
		25MG;2MG	A070374 001	Aug 25, 1986
		25MG;2MG	A072541 001	Feb 15, 1989
		25MG;4MG	A070376 001	Aug 25, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	25MG;4MG	A072134	001	Feb 15, 1989
	50MG;4MG	A070377	001	Nov 04, 1986
	50MG;4MG	A071558	001	Mar 02, 1987
	50MG;4MG	A072135	001	Feb 15, 1989

TRIAVIL 2-10

NEW RIVER	10MG;2MG **	N014715	004	

TRIAVIL 2-25

NEW RIVER	25MG;2MG **	N014715	002	

TRIAVIL 4-10

NEW RIVER	10MG;4MG **	N014715	003	

TRIAVIL 4-25

NEW RIVER	25MG;4MG **	N014715	005	

TRIAVIL 4-50

NEW RIVER	50MG;4MG **	N014715	006	

AMLEXANOX

PASTE;DENTAL

APHTHASOL

ULURU	5%	N020511	001	Dec 17, 1996

PATCH;TOPICAL

AMLEXANOX

ULURU	2MG	N021727	001	Sep 29, 2004

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AMNEAL PHARMS NY	EQ 2.5MG BASE	A078477	001	Jan 16, 2008
	EQ 5MG BASE	A078477	002	Jan 16, 2008
	EQ 10MG BASE	A078477	003	Jan 16, 2008
GEDEON RICHTER USA	EQ 2.5MG BASE	A077333	001	Jul 17, 2007
	EQ 5MG BASE	A077333	002	Jul 17, 2007
	EQ 10MG BASE	A077333	003	Jul 17, 2007
GENPHARM	EQ 2.5MG BASE	A077362	001	Jul 09, 2007
	EQ 5MG BASE	A077362	002	Jul 09, 2007
	EQ 10MG BASE	A077362	003	Jul 09, 2007
HIKMA	EQ 2.5MG BASE	A077262	001	Jul 09, 2007
	EQ 5MG BASE	A077262	002	Jul 09, 2007
	EQ 10MG BASE	A077262	003	Jul 09, 2007
HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011
	EQ 5MG BASE	A077771	002	Apr 12, 2011
	EQ 10MG BASE	A077771	003	Apr 12, 2011
MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012
	EQ 10MG BASE	A201380	002	Apr 13, 2012
MYLAN	EQ 2.5MG BASE	A076418	001	Oct 03, 2005
	EQ 2.5MG BASE	A078224	001	Feb 27, 2008
	EQ 5MG BASE	A076418	002	Oct 03, 2005
	EQ 5MG BASE	A078224	002	Feb 27, 2008
	EQ 10MG BASE	A076418	003	Oct 03, 2005
	EQ 10MG BASE	A078224	003	Feb 27, 2008
PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007
	EQ 5MG BASE	A078131	002	Sep 04, 2007
	EQ 10MG BASE	A078131	003	Sep 04, 2007
SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015
	EQ 5MG BASE	A204900	002	Jul 23, 2015
	EQ 10MG BASE	A204900	003	Jul 23, 2015
SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007
	EQ 5MG BASE	A078231	002	Nov 30, 2007
	EQ 10MG BASE	A078231	003	Nov 30, 2007
SUN PHARM INDUSTRIES	EQ 2.5MG BASE	A078081	001	Jan 31, 2008
	EQ 5MG BASE	A078081	002	Jan 31, 2008
	EQ 10MG BASE	A078081	003	Jan 31, 2008
SUNSHINE	EQ 2.5MG BASE	A206524	001	May 04, 2018
	EQ 5MG BASE	A206524	002	May 04, 2018
	EQ 10MG BASE	A206524	003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080	001	Jun 27, 2007
	EQ 5MG BASE	A077080	002	Jun 27, 2007
	EQ 10MG BASE	A077080	003	Jun 27, 2007

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007
	EQ 5MG BASE	A076846	002	Jun 28, 2007
	EQ 10MG BASE	A076846	003	Jun 28, 2007
TORRENT PHARMS	EQ 2.5MG BASE	A078573	001	Sep 22, 2008
	EQ 5MG BASE	A078573	002	Sep 22, 2008
	EQ 10MG BASE	A078573	003	Sep 22, 2008
UPSHER SMITH LABS	EQ 2.5MG BASE	A077759	001	Jul 09, 2007
	EQ 5MG BASE	A077759	002	Jul 09, 2007
	EQ 10MG BASE	A077759	003	Jul 09, 2007
WATSON LABS	EQ 2.5MG BASE	A077671	001	Jul 19, 2007
	EQ 5MG BASE	A077671	002	Jul 19, 2007
	EQ 10MG BASE	A077671	003	Jul 19, 2007
WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007
	EQ 5MG BASE	A078500	002	Sep 06, 2007
	EQ 10MG BASE	A078500	003	Sep 06, 2007
YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007
	EQ 5MG BASE	A076859	002	Sep 10, 2007
	EQ 10MG BASE	A076859	003	Sep 10, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS	EQ 2.5MG BASE	N022026	001	Sep 27, 2007
	EQ 5MG BASE	N022026	002	Sep 27, 2007
	EQ 10MG BASE	N022026	003	Sep 27, 2007

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

MYLAN	EQ 2.5MG BASE;EQ 10MG BASE	A200465	001	Nov 29, 2013
	EQ 2.5MG BASE;EQ 20MG BASE	A200465	002	Nov 29, 2013
	EQ 2.5MG BASE;EQ 40MG BASE	A200465	003	Nov 29, 2013

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018
	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018
	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018
	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018
MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010
	EQ 5MG BASE;10MG	A077375	002	May 21, 2010
	EQ 5MG BASE;20MG	A077375	003	May 21, 2010
	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011
	EQ 10MG BASE;20MG	A077375	004	May 21, 2010
	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011
STRIDES PHARMA	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010
	EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010
	EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010
	EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010
	EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010
	EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010
TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007
	EQ 5MG BASE;10MG	A077179	002	May 18, 2007
	EQ 5MG BASE;20MG	A077179	003	May 18, 2007
	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011
	EQ 10MG BASE;20MG	A077179	004	May 18, 2007
	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+	PURPLE BIOTECH	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018
+		EQ 10MG BASE;200MG	N210045	003	May 31, 2018

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

STRIDES PHARMA	EQ 5MG BASE;12.5MG;160MG	A201087	001	Jun 01, 2015
	EQ 5MG BASE;25MG;160MG	A201087	002	Jun 01, 2015
	EQ 10MG BASE;12.5MG;160MG	A201087	003	Jun 01, 2015
	EQ 10MG BASE;25MG;160MG	A201087	004	Jun 01, 2015
	EQ 10MG BASE;25MG;320MG	A201087	005	Jun 01, 2015
TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435	001	Sep 25, 2012
	EQ 5MG BASE;25MG;160MG	A200435	002	Sep 25, 2012
	EQ 10MG BASE;12.5MG;160MG	A200435	005	Sep 25, 2012
	EQ 10MG BASE;25MG;160MG	A200435	003	Sep 25, 2012
	EQ 10MG BASE;25MG;320MG	A200435	004	Sep 25, 2012
TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593	001	Jun 03, 2015
	EQ 5MG BASE;25MG;160MG	A201593	002	Jun 03, 2015
	EQ 10MG BASE;12.5MG;160MG	A201593	003	Jun 03, 2015
	EQ 10MG BASE;25MG;160MG	A201593	004	Jun 03, 2015
	EQ 10MG BASE;25MG;320MG	A201593	005	Jun 03, 2015

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018
	EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018
	EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018
	EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018
JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017
	EQ 5MG BASE;40MG	A207450	002	May 15, 2017
	EQ 10MG BASE;20MG	A207450	003	May 15, 2017
	EQ 10MG BASE;40MG	A207450	004	May 15, 2017
SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010	001	Dec 03, 2018
	EQ 5MG BASE;40MG	A209010	002	Dec 03, 2018
	EQ 10MG BASE;20MG	A209010	003	Dec 03, 2018
	EQ 10MG BASE;40MG	A209010	004	Dec 03, 2018
TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016
	EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016
	EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016
	EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

ALEMBIC PHARMS LTD	EQ 5MG BASE;40MG	A205234	001	Nov 17, 2016
	EQ 5MG BASE;80MG	A205234	003	Nov 17, 2016
	EQ 10MG BASE;40MG	A205234	002	Nov 17, 2016
	EQ 10MG BASE;80MG	A205234	004	Nov 17, 2016

TWYNSTA

+	BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG	N022401	001	Oct 16, 2009
+		EQ 5MG BASE;80MG	N022401	003	Oct 16, 2009
+		EQ 10MG BASE;40MG	N022401	002	Oct 16, 2009
+		EQ 10MG BASE;80MG	N022401	004	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

STRIDES PHARMA	EQ 5MG BASE;160MG	A090011	001	Mar 28, 2013
	EQ 5MG BASE;320MG	A090011	003	Mar 28, 2013
	EQ 10MG BASE;160MG	A090011	002	Mar 28, 2013
	EQ 10MG BASE;320MG	A090011	004	Mar 28, 2013
TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015
	EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015
	EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015
	EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015
TORRENT	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015
	EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015
	EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015
	EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMLODIPINE MALEATE
TABLET;ORAL
AMVAZ

DR REDDYS LABS INC	2.5MG	N021435	001	Oct 31, 2003
	5MG	N021435	002	Oct 31, 2003
	10MG	N021435	003	Oct 31, 2003

AMMONIA N-13
INJECTABLE;INTRAVENOUS
AMMONIA N 13

CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015
UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014

AMMONIUM CHLORIDE
INJECTABLE;INJECTION
AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130	001	
GD SEARLE LLC	3MEQ/ML	A086205	001	

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW	900MG/100ML	N006580	001	

AMMONIUM CHLORIDE 2.14%

B BRAUN	40MEQ/100ML	A085734	001	

AMMONIUM LACTATE
CREAM;TOPICAL
AMMONIUM LACTATE

WATSON LABS INC	EQ 12% BASE	A076829	001	Feb 07, 2006

LAC-HYDRIN

SUN PHARM INDS INC	EQ 12% BASE **	N020508	001	Aug 29, 1996

LOTION;TOPICAL
AMMONIUM LACTATE

WATSON LABS INC	EQ 12% BASE	A075575	001	Jun 11, 2002

LAC-HYDRIN

+	SUN PHARM INDS INC	EQ 12% BASE **	N019155	001	Apr 24, 1985

AMODIAQUINE HYDROCHLORIDE
TABLET;ORAL
CAMOQUIN HYDROCHLORIDE

PARKE DAVIS	EQ 200MG BASE	N006441	001	

AMOXAPINE
TABLET;ORAL
AMOXAPINE

CHARTWELL RX	25MG	A072943	001	Jun 28, 1991
	50MG	A072944	001	Jun 28, 1991
	100MG	A072878	001	Jun 28, 1991
	150MG	A072879	001	Jun 28, 1991
WATSON PHARMS TEVA	25MG	A072418	001	Aug 01, 1989
	50MG	A072419	001	Aug 01, 1989
	100MG	A072420	001	May 11, 1989
	150MG	A072421	001	May 11, 1989

ASENDIN

LEDERLE	25MG	N018021	001	
	50MG	N018021	002	
	100MG	N018021	003	
	150MG	N018021	004	

AMOXICILLIN
CAPSULE;ORAL
AMOXICILLIN

LABS ATRAL	250MG	A062528	001	Aug 07, 1985
	500MG	A062528	002	Aug 07, 1985
MYLAN	250MG	A062067	001	
	500MG	A062067	002	
STRIDES PHARMA	250MG	A062884	001	Feb 25, 1988
	500MG	A062881	001	Feb 25, 1988
SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999
	500MG	A065016	002	Apr 08, 1999
TEVA	250MG	A062853	001	Dec 22, 1987
	250MG	A063030	001	Feb 28, 1989
	500MG	A062854	001	Dec 22, 1987
	500MG	A063031	001	Feb 28, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN

CAPSULE;ORAL				
AMOXIL				
+	GLAXOSMITHKLINE	250MG **	N050459 001	
+		500MG **	N050459 002	
TRIMOX				
	APOTHECON	250MG	A061885 001	
		250MG	A062098 001	
		250MG	A062152 001	
		250MG	A063099 001	Mar 20, 1992
		500MG	A061885 002	
		500MG	A062098 002	
		500MG	A062152 002	
		500MG	A063099 002	Mar 20, 1992
UTIMOX				
	PARKE DAVIS	250MG	A062107 001	
		500MG	A062107 002	
WYMOX				
	WYETH AYERST	250MG	A062120 001	
		500MG	A062120 002	
FOR SUSPENSION;ORAL				
AMOXICILLIN				
	BELCHER PHARMS	125MG/5ML	A062059 001	
		250MG/5ML	A062059 002	
	MYLAN	125MG/5ML	A062090 001	
		250MG/5ML	A062090 002	
	SUN PHARM INDS LTD	200MG/5ML	A065113 001	Nov 29, 2002
		400MG/5ML	A065113 002	Nov 29, 2002
	TEVA	125MG/5ML	A061931 001	
		125MG/5ML	A062946 001	Nov 01, 1988
		250MG/5ML	A063001 001	Jan 06, 1989
AMOXIL				
+	GLAXOSMITHKLINE	50MG/ML **	N050460 005	
+		125MG/5ML **	N050460 001	
+		250MG/5ML **	N050460 002	
+	US ANTIBIOTICS	200MG/5ML **	N050760 001	Apr 15, 1999
+		400MG/5ML **	N050760 002	Apr 15, 1999
LAROTID				
+	GLAXOSMITHKLINE	50MG/ML **	N050460 006	
POLYMOX				
	APOTHECON	125MG/5ML	A061851 001	
		125MG/5ML	A062323 001	
		250MG/5ML	A061851 002	
		250MG/5ML	A062323 002	
TRIMOX				
	APOTHECON	50MG/ML	A061886 001	
		125MG/5ML	A061886 002	
		125MG/5ML	A062099 001	
		125MG/5ML	A062154 001	
		125MG/5ML	A062885 001	Mar 08, 1988
		250MG/5ML	A061886 003	
		250MG/5ML	A062099 002	
		250MG/5ML	A062154 002	
		250MG/5ML	A062885 002	Mar 08, 1988
UTIMOX				
	PARKE DAVIS	125MG/5ML	A062127 001	
		250MG/5ML	A062127 002	
WYMOX				
	WYETH AYERST	125MG/5ML	A062131 001	
		250MG/5ML	A062131 002	
TABLET;ORAL				
AMOXICILLIN				
	STRIDES PHARMA	875MG	A065344 001	Jan 15, 2009
	SUN PHARM INDS LTD	500MG	A065059 001	Nov 24, 2000
		875MG	A065059 002	Nov 24, 2000
AMOXIL				
+	US ANTIBIOTICS	500MG **	N050754 002	Jul 10, 1998
+		875MG **	N050754 001	Jul 10, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN

TABLET, CHEWABLE;ORAL				
AMOXICILLIN				
APOTHECON	125MG	A064131	001	May 06, 1996
	250MG	A064131	002	May 06, 1996
HIKMA	125MG	A205274	001	Jun 25, 2020
	250MG	A205274	002	Jun 25, 2020
STRIDES PHARMA	125MG	A064139	001	Jan 29, 1996
	250MG	A064139	002	Jan 29, 1996
SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999
	200MG	A065060	001	Nov 29, 2000
	250MG	A065021	002	Dec 23, 1999
	400MG	A065060	002	Nov 29, 2000
TEVA	125MG	A064031	001	Dec 19, 1996
	250MG	A064031	002	Dec 19, 1996
AMOXIL				
+ US ANTIBIOTICS	125MG **	N050542	002	
	200MG	N050761	001	Apr 15, 1999
+	250MG **	N050542	001	
	400MG	N050761	002	Apr 15, 1999
TABLET, EXTENDED RELEASE;ORAL				
MOXATAG				
+ PRAGMA	775MG	N050813	001	Jan 23, 2008
TABLET, FOR SUSPENSION;ORAL				
AMOXICILLIN				
AUROBINDO PHARMA LTD	200MG	A065324	001	Jan 17, 2007
	400MG	A065324	002	Jan 17, 2007
DISPERMOX				
RANBAXY LABS LTD	200MG	A065080	002	Aug 11, 2003
	400MG	A065080	001	Aug 11, 2003
	600MG	A065159	001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL				
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)				
ANI PHARMS	500MG;500MG;30MG	A200218	001	Aug 30, 2013
PREVPAC (COPACKAGED)				
+ TAKEDA PHARMS USA	500MG;500MG;30MG **	N050757	001	Dec 02, 1997

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL				
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN				
+ CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL				
AMOXICILLIN AND CLAVULANATE POTASSIUM				
SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003
	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003
	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007
AUGMENTIN '200'				
+ US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996
AUGMENTIN '400'				
+ US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996
TABLET;ORAL				
AMOXICILLIN AND CLAVULANATE POTASSIUM				
APOTEX INC	250MG;EQ 125MG BASE	A065333	001	Feb 24, 2009
	500MG;EQ 125MG BASE	A065333	002	Feb 24, 2009
	875MG;EQ 125MG BASE	A065317	003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002
	875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002
AUGMENTIN '250'				
+ US ANTIBIOTICS	250MG;EQ 125MG BASE **	N050564	001	Aug 06, 1984
AUGMENTIN '500'				
+ US ANTIBIOTICS	500MG;EQ 125MG BASE **	N050564	002	Aug 06, 1984
TABLET, CHEWABLE;ORAL				
AMOXICILLIN AND CLAVULANATE POTASSIUM				
SANDOZ	200MG;EQ 28.5MG BASE	A065065	001	Apr 18, 2002
	400MG;EQ 57MG BASE	A065065	002	Apr 18, 2002
SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMOXICILLIN; CLAVULANATE POTASSIUM					
TABLET, CHEWABLE;ORAL					
AMOXICILLIN AND CLAVULANATE POTASSIUM		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003
AUGMENTIN '125'					
+	US ANTIBIOTICS	125MG;EQ 31.25MG BASE **	N050597	001	Jul 22, 1985
AUGMENTIN '200'					
+	US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996
AUGMENTIN '250'					
+	US ANTIBIOTICS	250MG;EQ 62.5MG BASE **	N050597	002	Jul 22, 1985
AUGMENTIN '400'					
+	US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726	002	May 31, 1996
TABLET, EXTENDED RELEASE;ORAL					
AUGMENTIN XR					
+	US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002
AMPHETAMINE					
SUSPENSION, EXTENDED RELEASE;ORAL					
ADZENYS ER					
+	NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017
AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE					
CAPSULE;ORAL					
DELCOBESE					
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG **	A083564	001	
		2.5MG;2.5MG;2.5MG;2.5MG **	A083564	002	
		3.75MG;3.75MG;3.75MG;3.75MG **	A083564	003	
		5MG;5MG;5MG;5MG **	A083564	004	
TABLET;ORAL					
DELCOBESE					
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A083563	004	
		2.5MG;2.5MG;2.5MG;2.5MG	A083563	003	
		3.75MG;3.75MG;3.75MG;3.75MG	A083563	002	
		5MG;5MG;5MG;5MG	A083563	001	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE					
CAPSULE, EXTENDED RELEASE;ORAL					
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211876	001	Jun 24, 2020
		2.5MG;2.5MG;2.5MG;2.5MG	A211876	002	Jun 24, 2020
		3.75MG;3.75MG;3.75MG;3.75MG	A211876	003	Jun 24, 2020
		5MG;5MG;5MG;5MG	A211876	004	Jun 24, 2020
		6.25MG;6.25MG;6.25MG;6.25MG	A211876	005	Jun 24, 2020
		7.5MG;7.5MG;7.5MG;7.5MG	A211876	006	Jun 24, 2020
	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019
		2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019
		3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019
		5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019
		6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019
		7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019
	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013
		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013
		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013
		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013
		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013
		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE					
	BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb 12, 2013
		2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb 12, 2013
		3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb 12, 2013
		5MG;5MG;5MG;5MG	A076536	004	Feb 12, 2013
		6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb 12, 2013
		7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb 12, 2013
TABLET;ORAL					
ADDERALL 10					
+	TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **	N011522	007	Feb 13, 1996
ADDERALL 12.5					
+	TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **	N011522	012	Aug 31, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL					
ADDERALL 15					
+	TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **	N011522	013	Aug 31, 2000
ADDERALL 20					
+	TEVA WOMENS	5MG;5MG;5MG;5MG **	N011522	008	Feb 13, 1996
ADDERALL 30					
+	TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **	N011522	010	May 12, 1997
ADDERALL 5					
+	TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **	N011522	009	May 12, 1997
ADDERALL 7.5					
+	TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **	N011522	011	Aug 31, 2000
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003
		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003
	MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015
		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015
		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015
		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015
		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015
		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015
		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015
	TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003
		2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003
		5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003
		7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL				
BIPHETAMINE 12.5				
	UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007
BIPHETAMINE 20				
	UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093	003
BIPHETAMINE 7.5				
	UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009

AMPHETAMINE SULFATE

TABLET;ORAL					
AMPHETAMINE SULFATE					
	GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021
		10MG	A212186	002	Jan 27, 2021
+	LANNETT	5MG	A083901	001	Aug 31, 1984
+		10MG	A083901	002	Aug 31, 1984
	MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020
		10MG	A213898	002	Jul 14, 2020
	NOVAST LABS	5MG	A213763	001	Aug 24, 2020
		10MG	A213763	002	Aug 24, 2020
TABLET, ORALLY DISINTEGRATING;ORAL					
EVEKEO ODT					
+	ARBOR PHARMS LLC	2.5MG	N209905	005	Apr 16, 2021

AMPHOTERICIN B

CREAM;TOPICAL					
FUNGIZONE					
	APOTHECON	3%	N050314	001	
INJECTABLE;INJECTION					
AMPHOTERICIN B					
	ABBOTT	50MG/VIAL	A064141	001	Dec 23, 1996
	ABRAXIS PHARM	50MG/VIAL	A062728	001	Apr 13, 1987
	TEVA PARENTERAL	50MG/VIAL	A064062	001	Mar 31, 1995
FUNGIZONE					
	APOTHECON	50MG/VIAL	A060517	001	
INJECTABLE, LIPID COMPLEX;INJECTION					
AMPHOTEC					
	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996
		100MG/VIAL	N050729	002	Nov 22, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPHOTERICIN B				
LOTION;TOPICAL				
FUNGIZONE				
APOTHECON	3%		A060570 001	
OINTMENT;TOPICAL				
FUNGIZONE				
APOTHECON	3%		N050313 001	
SUSPENSION;ORAL				
FUNGIZONE				
BRISTOL MYERS SQUIBB	100MG/ML		N050341 003	
AMPICILLIN SODIUM				
INJECTABLE;INJECTION				
AMPICILLIN SODIUM				
ACS DOBFAR SPA	EQ 500MG BASE/VIAL		A090884 001	Apr 03, 2013
	EQ 1GM BASE/VIAL		A090884 002	Apr 03, 2013
	EQ 2GM BASE/VIAL		A090884 003	Apr 03, 2013
APOTHECON	EQ 125MG BASE/VIAL		A062860 001	Feb 05, 1988
	EQ 250MG BASE/VIAL		A062860 002	Feb 05, 1988
	EQ 500MG BASE/VIAL		A062860 003	Feb 05, 1988
	EQ 1GM BASE/VIAL		A062860 004	Feb 05, 1988
	EQ 2GM BASE/VIAL		A062860 005	Feb 05, 1988
AUROBINDO PHARMA	EQ 125MG BASE/VIAL		A065499 001	Aug 17, 2010
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL		A061936 005	
	EQ 250MG BASE/VIAL		A061936 001	
	EQ 500MG BASE/VIAL		A061936 002	
	EQ 1GM BASE/VIAL		A061936 003	
	EQ 2GM BASE/VIAL		A061936 004	
HIKMA	EQ 125MG BASE/VIAL		A062692 001	Jun 24, 1986
	EQ 250MG BASE/VIAL		A062692 002	Jun 24, 1986
	EQ 500MG BASE/VIAL		A062692 003	Jun 24, 1986
	EQ 1GM BASE/VIAL		A062692 004	Jun 24, 1986
	EQ 2GM BASE/VIAL		A062692 005	Jun 24, 1986
	EQ 10GM BASE/VIAL		A062692 006	Jun 24, 1986
HOSPIRA INC	EQ 250MG BASE/VIAL		A202864 001	Sep 04, 2015
	EQ 500MG BASE/VIAL		A202864 002	Sep 04, 2015
	EQ 1GM BASE/VIAL		A202864 003	Sep 04, 2015
	EQ 2GM BASE/VIAL		A202864 004	Sep 04, 2015
	EQ 10GM BASE/VIAL		A202865 001	Sep 04, 2015
HQ SPECLT PHARMA	EQ 125MG BASE/VIAL		A062772 005	Apr 15, 1993
	EQ 500MG BASE/VIAL		A062772 008	Apr 15, 1993
	EQ 1GM BASE/VIAL		A062772 002	Apr 15, 1993
	EQ 2GM BASE/VIAL		A062772 004	Apr 15, 1993
INTL MEDICATION	EQ 1GM BASE/VIAL		A062634 002	Jan 09, 1987
	EQ 2GM BASE/VIAL		A062634 003	Jan 09, 1987
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL		A062797 001	Jul 12, 1993
LILLY	EQ 500MG BASE/VIAL		A062565 001	Apr 04, 1985
	EQ 1GM BASE/VIAL		A062565 002	Apr 04, 1985
	EQ 2GM BASE/VIAL		A062565 003	Jun 24, 1986
WATSON LABS INC	EQ 125MG BASE/VIAL		A062816 001	Oct 24, 1988
	EQ 250MG BASE/VIAL		A062816 002	Oct 24, 1988
	EQ 500MG BASE/VIAL		A062816 003	Oct 24, 1988
	EQ 1GM BASE/VIAL		A062816 004	Oct 24, 1988
	EQ 2GM BASE/VIAL		A062816 005	Oct 24, 1988
	EQ 10GM BASE/VIAL		A062994 001	Sep 15, 1988
OMNIPEN-N				
WYETH AYERST	EQ 125MG BASE/VIAL		A060626 001	
	EQ 125MG BASE/VIAL		A062718 001	Dec 16, 1986
	EQ 250MG BASE/VIAL		A060626 002	
	EQ 250MG BASE/VIAL		A062718 002	Dec 16, 1986
	EQ 500MG BASE/VIAL		A060626 003	
	EQ 500MG BASE/VIAL		A062718 003	Dec 16, 1986
	EQ 1GM BASE/VIAL		A060626 004	
	EQ 1GM BASE/VIAL		A062718 004	Dec 16, 1986
	EQ 2GM BASE/VIAL		A060626 005	
	EQ 2GM BASE/VIAL		A062718 005	Dec 16, 1986
PENBRITIN-S				
+ WYETH AYERST	EQ 125MG BASE/VIAL **		N050072 001	
+	EQ 250MG BASE/VIAL **		N050072 002	
+	EQ 500MG BASE/VIAL **		N050072 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN SODIUM				
INJECTABLE;INJECTION				
PENBRITIN-S				
+		EQ 1GM BASE/VIAL **	N050072 004	
+		EQ 2GM BASE/VIAL **	N050072 005	
+		EQ 4GM BASE/VIAL **	N050072 006	
POLYCILLIN-N				
	BRISTOL	EQ 125MG BASE/VIAL **	N050309 001	
		EQ 250MG BASE/VIAL **	N050309 002	
		EQ 500MG BASE/VIAL **	N050309 003	
		EQ 1GM BASE/VIAL **	N050309 004	
		EQ 2GM BASE/VIAL **	N050309 005	
TOTACILLIN-N				
	GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677 001	
		EQ 250MG BASE/VIAL	A060677 002	
		EQ 500MG BASE/VIAL	A060677 003	
		EQ 1GM BASE/VIAL	A060677 004	
		EQ 1GM BASE/VIAL	A062727 001	Dec 19, 1986
		EQ 2GM BASE/VIAL	A060677 005	
		EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
		EQ 10GM BASE/VIAL	A060677 006	
AMPICILLIN SODIUM; SULBACTAM SODIUM				
INJECTABLE;INJECTION				
AMPICILLIN AND SULBACTAM				
	HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375 001	Dec 21, 2011
		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653 001	Dec 21, 2011
		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375 002	Dec 21, 2011
		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653 002	Dec 21, 2011
		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646 001	Dec 21, 2011
	PHARM ASSOC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316 001	Jun 29, 2007
		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316 002	Jun 29, 2007
UNASYN				
	PFIZER	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608 003	Dec 31, 1986
AMPICILLIN/AMPICILLIN TRIHYDRATE				
CAPSULE;ORAL				
AMCILL				
	PARKE DAVIS	EQ 250MG BASE	A062041 001	
		EQ 500MG BASE	A062041 002	
AMPICILLIN TRIHYDRATE				
	BELCHER PHARMS	EQ 250MG BASE	A061602 001	
		EQ 500MG BASE	A061602 002	
	HERITAGE PHARMA	EQ 250MG BASE	A061502 001	
		EQ 500MG BASE	A061502 002	
	IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765 001	
		EQ 500MG BASE	A060765 002	
	LEDERLE	EQ 250MG BASE	A062208 001	
		EQ 500MG BASE	A062208 002	
	MYLAN	EQ 250MG BASE	A061755 001	
		EQ 500MG BASE	A061755 002	
	PUREPAC PHARM	EQ 250MG BASE	A061853 001	
		EQ 500MG BASE	A061853 002	
	SANDOZ	EQ 250MG BASE	A064082 001	Aug 29, 1995
	STRIDES PHARMA	EQ 250MG BASE	A062883 001	Feb 25, 1988
		EQ 500MG BASE	A062882 001	Feb 25, 1988
	VITARINE	EQ 250MG BASE	A061387 001	
		EQ 500MG BASE	A061387 003	
OMNIPEN (AMPICILLIN)				
	WYETH AYERST	250MG	A060624 001	
		500MG	A060624 002	
PENBRITIN				
	WYETH AYERST	EQ 250MG BASE	A060908 001	
		EQ 500MG BASE	A060908 002	
PFIZERPEN-A				
	PFIZER	EQ 250MG BASE	A062050 001	
		EQ 500MG BASE	A062050 002	
POLYCILLIN				
	BRISTOL	EQ 250MG BASE	N050310 001	
		EQ 500MG BASE	N050310 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL				
PRINCIPEN				
APOTHECON	EQ 250MG BASE	A062888	001	Mar 04, 1988
	EQ 500MG BASE	A062888	002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392	001	
	EQ 500MG BASE	A061392	002	
PRINCIPEN '250'				
APOTHECON	EQ 250MG BASE	A062157	002	
	EQ 250MG BASE	N050056	001	
PRINCIPEN '500'				
APOTHECON	EQ 500MG BASE	A062157	001	
	EQ 500MG BASE	N050056	002	
TOTACILLIN				
GLAXOSMITHKLINE	EQ 250MG BASE	A060060	001	
	EQ 250MG BASE	A062212	001	
	EQ 500MG BASE	A060060	002	
	EQ 500MG BASE	A062212	002	
FOR SUSPENSION;ORAL				
AMCILL				
PARKE DAVIS	EQ 125MG BASE/5ML	A062030	001	
	EQ 250MG BASE/5ML	A062030	002	
AMPICILLIN TRIHYDRATE				
BELCHER PHARMS	EQ 125MG BASE/5ML	A061601	001	
	EQ 250MG BASE/5ML	A061601	002	
DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989
	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989
MYLAN	EQ 125MG BASE/5ML	A061829	002	
	EQ 250MG BASE/5ML	A061829	001	
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980	001	
	EQ 250MG BASE/5ML	A061980	002	
TEVA	EQ 125MG BASE/5ML	A061370	001	
	EQ 250MG BASE/5ML	A061370	002	
OMNIPEN (AMPICILLIN)				
WYETH AYERST	100MG/ML	A060625	001	
	125MG/5ML	A060625	002	
	250MG/5ML	A060625	003	
	500MG/5ML	A060625	004	
PENBRITIN				
WYETH AYERST	EQ 100MG BASE/ML	N050019	001	
	EQ 125MG BASE/5ML	N050019	002	
	EQ 250MG BASE/5ML	N050019	003	
PFIZERPEN-A				
PFIZER	EQ 125MG BASE/5ML	A062049	001	
	EQ 250MG BASE/5ML	A062049	002	
POLYCILLIN				
APOTHECON	EQ 125MG BASE/5ML	A062297	001	
	EQ 250MG BASE/5ML	A062297	002	
BRISTOL	EQ 100MG BASE/ML	N050308	004	
	EQ 125MG BASE/5ML	N050308	001	
	EQ 250MG BASE/5ML	N050308	002	
	EQ 500MG BASE/5ML	N050308	003	
PRINCIPEN				
APOTHECON	EQ 100MG BASE/ML	A061394	001	
	EQ 125MG BASE/5ML	A061394	002	
	EQ 250MG BASE/5ML	A061394	003	
PRINCIPEN '125'				
APOTHECON	EQ 125MG BASE/5ML	A060127	002	
	EQ 125MG BASE/5ML	A062151	001	
PRINCIPEN '250'				
APOTHECON	EQ 250MG BASE/5ML	A060127	001	
	EQ 250MG BASE/5ML	A062151	002	
TOTACILLIN				
GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666	001	
	EQ 125MG BASE/5ML	A062223	001	
	EQ 250MG BASE/5ML	A060666	002	
	EQ 250MG BASE/5ML	A062223	002	

AMPICILLIN/AMPICILLIN TRIHYDRATE

TABLET, CHEWABLE;ORAL

POLYCILLIN				
BRISTOL	EQ 125MG BASE	N050093	001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

PRINCIPEN W/ PROBENECID				
APOTHECON	EQ 389MG BASE;111MG	A062150	001	
	EQ 389MG BASE;111MG	N050488	001	

FOR SUSPENSION;ORAL

POLYCILLIN-PRB				
APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898	001	
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457	001	
PROBAMPACIN				
COSETTE	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001	

AMPRENAVIR

CAPSULE;ORAL

AGENERASE				
GLAXOSMITHKLINE	50MG	N021007	001	Apr 15, 1999
	150MG	N021007	002	Apr 15, 1999

SOLUTION;ORAL

AGENERASE				
+ GLAXOSMITHKLINE	15MG/ML **	N021039	001	Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN				
+ TAKEDA PHARMS USA	EQ 1MG BASE **	N020333	002	Mar 14, 1997
ANAGRELIDE HYDROCHLORIDE				
BARR	EQ 0.5MG BASE	A076530	001	Apr 18, 2005
	EQ 1MG BASE	A076530	002	Apr 18, 2005
CHARTWELL RX	EQ 0.5MG BASE	A076683	001	Apr 18, 2005
	EQ 1MG BASE	A076683	002	Apr 18, 2005
MYLAN	EQ 0.5MG BASE	A076811	001	Apr 18, 2005
	EQ 1MG BASE	A076811	002	Apr 18, 2005
MYLAN PHARMS INC	EQ 0.5MG BASE	A077613	001	Jun 27, 2006
	EQ 1MG BASE	A077613	002	Jun 27, 2006
ROXANE	EQ 0.5MG BASE	A076489	001	Apr 18, 2005
	EQ 1MG BASE	A076489	002	Apr 18, 2005
WATSON LABS	EQ 0.5MG BASE	A076417	001	Apr 18, 2005
	EQ 1MG BASE	A076417	002	Apr 18, 2005

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE				
APOTEX INC	1MG	A200654	001	May 11, 2012
FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010
HIKMA	1MG	A078485	001	Jun 28, 2010
IMPAX LABS INC	1MG	A091242	001	May 31, 2012
LANNETT CO INC	1MG	A091331	001	Jan 05, 2011
MYLAN	1MG	A091051	001	Jun 28, 2010
PICKET PHARMS	1MG	A090732	001	Jun 28, 2010
SANDOZ	1MG	A079007	001	Jun 28, 2010
SUN PHARM INDS LTD	1MG	A091177	001	Jul 15, 2011
SYNTHON PHARMS	1MG	A078322	001	Jun 28, 2010
WATSON LABS TEVA	1MG	A078984	001	Jun 28, 2010

ANGIOTENSIN II ACETATE

SOLUTION;INTRAVENOUS

GIAPREZA				
+ LA JOLLA PHARMA	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017

ANILERIDINE HYDROCHLORIDE

TABLET;ORAL

LERITINE				
MERCK	EQ 25MG BASE	N010585	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ANILERIDINE PHOSPHATE
INJECTABLE;INJECTION
LERITINE

MERCK	25MG/ML	N010520	003	

ANISINDIONE
TABLET;ORAL
MIRADON

SCHERING	50MG	N010909	003	

ANISOTROPINE METHYLBROMIDE
TABLET;ORAL
ANISOTROPINE METHYLBROMIDE

WATSON LABS	50MG	A086046	001	

VALPIN 50

ENDO PHARMS	50MG	N013428	001	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
VASOCON-A

NOVARTIS	0.5%;0.05%	N018746	002	Jul 11, 1994

APIXABAN
TABLET;ORAL
APIXABAN

BIONPHARMA INC	2.5MG	A210152	001	Apr 08, 2020
	5MG	A210152	002	Apr 08, 2020
BRECKENRIDGE	2.5MG	A209845	001	Jul 26, 2021
	5MG	A209845	002	Jul 26, 2021
MICRO LABS	2.5MG	A210013	001	Dec 23, 2019
	5MG	A210013	002	Dec 23, 2019
MYLAN	2.5MG	A210128	001	Dec 23, 2019
	5MG	A210128	002	Dec 23, 2019

APOMORPHINE HYDROCHLORIDE
INJECTABLE;SUBCUTANEOUS
APOKYN

MDD US	20MG/2ML (10MG/ML)	N021264	001	Apr 20, 2004

APREMILAST
TABLET;ORAL
APREMILAST

UNICHEM	10MG	A211819	001	Feb 17, 2021
	20MG	A211819	002	Feb 17, 2021
	30MG	A211819	003	Feb 17, 2021

APREPITANT
CAPSULE;ORAL
EMEND

+	MERCK	40MG **	N021549	003	Jun 30, 2006

ARBUTAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
GENESA

GENSIA AUTOMEDICS	0.05MG/ML	N020420	001	Sep 12, 1997

ARDEPARIN SODIUM
INJECTABLE;INJECTION
NORMIFLO

+	PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **	N020227	002	May 23, 1997
+		10,000 UNITS/0.5ML **	N020227	001	May 23, 1997

ARGATROBAN
INJECTABLE;INTRAVENOUS
ARGATROBAN IN 0.9% SODIUM CHLORIDE

TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014

ARGATROBAN IN SODIUM CHLORIDE

+	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011

SOLUTION;INTRAVENOUS
ARGATROBAN IN DEXTROSE

SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ARIPIPRAZOLE

INJECTABLE;INTRAMUSCULAR					
ABILIFY					
	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006
SOLUTION;ORAL					
ABILIFY					
+	OTSUKA	1MG/ML **	N021713	001	Dec 10, 2004
TABLET;ORAL					
ARIPIPRAZOLE					
	MYLAN	2MG	A206240	001	Sep 19, 2018
		5MG	A206240	002	Sep 19, 2018
		10MG	A206240	003	Sep 19, 2018
		15MG	A206240	004	Sep 19, 2018
		20MG	A206240	005	Sep 19, 2018
		30MG	A206240	006	Sep 19, 2018
	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015
		5MG	A078607	002	Apr 28, 2015
		10MG	A078608	001	Apr 28, 2015
		15MG	A078708	001	Apr 28, 2015
		20MG	A078708	002	Apr 28, 2015
		30MG	A078708	003	Apr 28, 2015
	ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019
		5MG	A090472	002	Jan 07, 2019
		10MG	A090472	003	Jan 07, 2019
		15MG	A090472	004	Jan 07, 2019
		20MG	A090472	005	Jan 07, 2019
		30MG	A090472	006	Jan 07, 2019
TABLET, ORALLY DISINTEGRATING;ORAL					
ABILIFY					
+	OTSUKA	10MG **	N021729	002	Jun 07, 2006
+		15MG **	N021729	003	Jun 07, 2006
+		20MG **	N021729	004	Jun 07, 2006
+		30MG **	N021729	005	Jun 07, 2006

ARMODAFINIL

TABLET;ORAL					
ARMODAFINIL					
	APOTEX INC	50MG	A201514	001	Mar 25, 2019
		150MG	A201514	002	Mar 25, 2019
		250MG	A201514	003	Mar 25, 2019
	WATSON LABS INC	100MG	A200156	002	Aug 29, 2012
		200MG	A200156	004	Aug 29, 2012
NUVIGIL					
+	CEPHALON	100MG **	N021875	002	Mar 26, 2009

ARSENIC TRIOXIDE

INJECTABLE;INJECTION					
ARSENIC TRIOXIDE					
	INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021
TRISENOX					
+	CEPHALON	1MG/ML **	N021248	001	Sep 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION					
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE					
	HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138	001	Jun 18, 2010
ULTACAN					
	HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751	001	Jul 11, 2017
ULTACAN FORTE					
	HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750	001	Jul 11, 2017

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION					
BEROCCA PN					
	ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML; 100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071	003	Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.C. 9+3

ABRAXIS PHARM	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018440	002	Aug 08, 1985

M.V.I.-12 ADULT

HOSPIRA	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N008809	004	Aug 08, 1985
+	20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML	N008809	006	Sep 09, 2004

MVC PLUS

WATSON LABS	10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/	N018439	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 ADULT

HOSPIRA	20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M	N008809	005	Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

VITAPED

HOSPIRA	N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A	N020176	001	Dec 29, 1993

ASPIRIN

TABLET;ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER	500MG	N021317	001	Oct 18, 2001

TABLET, EXTENDED RELEASE;ORAL

8-HOUR BAYER

BAYER	650MG	N016030	001	

MEASURIN

BAYER	650MG	N016030	002	

ASPIRIN; BUTALBITAL

TABLET;ORAL

AXOTAL

SAVAGE LABS	650MG;50MG	A088305	001	Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

NOSTRUM LABS INC	325MG;50MG;40MG	A078149	001	Jun 13, 2007
WATSON LABS	325MG;50MG;40MG	A086231	002	Feb 12, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH	325MG;50MG;40MG	A086710	002	Aug 23, 1983
FOSUN PHARMA	325MG;50MG;40MG	A086398	002	Apr 06, 1984
HALSEY	325MG;50MG;40MG	A089448	001	Dec 01, 1986
HIKMA INTL PHARMS	325MG;50MG;40MG	A086162	002	Feb 16, 1984
IVAX PHARMS	325MG;50MG;40MG	A085441	002	Oct 31, 1984
PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN; BUTALBITAL; CAFFEINE					
TABLET;ORAL					
BUTALBITAL, ASPIRIN AND CAFFEINE					
	QUANTUM PHARMICS	325MG;50MG;40MG	A088972	001	Jun 18, 1985
	WATSON LABS	325MG;50MG;40MG	A086237	002	Mar 23, 1984
FIORINAL					
+	ALLERGAN	325MG;50MG;40MG **	N017534	003	Apr 16, 1986
LANORINAL					
	LANNETT	325MG;50MG;40MG	A086986	002	Oct 18, 1985
ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE					
CAPSULE;ORAL					
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE					
	STRIDES PHARMA	325MG;50MG;40MG;30MG	A075351	001	Mar 05, 1999
	WATSON LABS	325MG;50MG;40MG;30MG	A074359	001	Aug 31, 1995
ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE					
CAPSULE;ORAL					
SYNALGOS-DC					
+	SUN PHARM INDUSTRIES	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983
ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE					
TABLET;ORAL					
INVAGESIC					
	SANDOZ	385MG;30MG;25MG	A074817	001	Nov 27, 1996
INVAGESIC FORTE					
	SANDOZ	770MG;60MG;50MG	A074817	002	Nov 27, 1996
NORGESIC					
+	BAUSCH	385MG;30MG;25MG **	N013416	003	Oct 27, 1982
NORGESIC FORTE					
+	BAUSCH	770MG;60MG;50MG **	N013416	004	Oct 27, 1982
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE					
	SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996
		770MG;60MG;50MG	A074654	002	Dec 31, 1996
	STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999
		770MG;60MG;50MG	A074988	002	Apr 30, 1999
ORPHENGESIC					
	GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998
ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE					
CAPSULE;ORAL					
COMPOUND 65					
	ALRA	389MG;32.4MG;65MG	A084553	002	Aug 17, 1983
DARVON COMPOUND					
	XANODYNE PHARM	389MG;32.4MG;32MG	N010996	006	Mar 08, 1983
DARVON COMPOUND-65					
	XANODYNE PHARM	389MG;32.4MG;65MG	N010996	007	Mar 08, 1983
PROPOXYPHENE COMPOUND 65					
	IVAX SUB TEVA PHARMS	389MG;32.4MG;65MG	A083077	002	Dec 07, 1984
+	SANDOZ	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983
	TEVA	389MG;32.4MG;65MG	A089025	001	Mar 29, 1985
PROPOXYPHENE COMPOUND-65					
	SANDOZ	389MG;32.4MG;65MG	A083101	002	Jun 24, 1985
PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE					
	WATSON LABS	389MG;32.4MG;65MG	A085732	002	Sep 03, 1984
ASPIRIN; CARISOPRODOL					
TABLET;ORAL					
CARISOPRODOL AND ASPIRIN					
	HERITAGE PHARMS INC	325MG;200MG	A089594	001	Mar 31, 1989
	NOVAST LABS	325MG;200MG	A040832	001	Jan 07, 2010
	OXFORD PHARMS	325MG;200MG	A040252	001	Dec 10, 1997
	SANDOZ	325MG;200MG	A040116	001	Apr 25, 1996
CARISOPRODOL COMPOUND					
	WATSON LABS	325MG;200MG	A088809	001	Oct 03, 1985
SOMA COMPOUND					
	MEDA PHARMS	325MG;200MG **	N012365	005	Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

OXFORD PHARMS	325MG;200MG;16MG	A040283	001	Dec 29, 1998
SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996

SOMA COMPOUND W/ CODEINE

MEDA PHARMS	325MG;200MG;16MG **	N012366	002	Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

ANI PHARMS	25MG;200MG	A206964	001	Jan 18, 2017
LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019
SUN PHARM	25MG;200MG	A208572	001	Aug 21, 2018

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

AZDONE

SCHWARZ PHARMA	500MG;5MG **	A089420	001	Jan 25, 1988

HYDROCODONE BITARTRATE AND ASPIRIN

LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021

VICOPRIN

ABBOTT	500MG;5MG	A086333	001	Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET;ORAL

EQUAGESIC

SUN PHARM INDUSTRIES	325MG;200MG	N011702	003	Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ	325MG;200MG	A089127	001	Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM	325MG;200MG	A089126	001	Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC	325MG;200MG	A084978	001	

Q-GESIC

QUANTUM PHARMICS	325MG;200MG	A088740	001	Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS	325MG;400MG	A087211	001	Dec 22, 1982
MCNEIL	325MG;400MG	A089193	001	Feb 12, 1986
PAR PHARM	325MG;400MG	A089657	001	Nov 04, 1988
STEVENS J	325MG;400MG	A081145	001	Jan 31, 1995

ROBAXISAL

ROBINS AH	325MG;400MG	N012281	001	

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

+	GENUS LIFESCIENCES	81MG;40MG	N205103	001	Sep 14, 2016
+		325MG;40MG	N205103	002	Sep 14, 2016

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011
MAYNE PHARMA INC	325MG;4.8355MG	A091670	001	Mar 16, 2011

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET;ORAL

CODOXY

HALSEY	325MG;4.5MG;0.38MG	A087464	001	Jul 01, 1982

OXYCODONE AND ASPIRIN

ANI PHARMS	325MG;4.5MG;0.38MG	A040255	001	Feb 27, 1998
SUN PHARM INDUSTRIES	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998
	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE	325MG;2.25MG;0.19MG	A087742	001	Jun 04, 1982

PERCODAN

ENDO PHARMS	325MG;4.5MG;0.38MG **	N007337	006	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE				
TABLET;ORAL				
PERCODAN-DEMI				
	ENDO PHARMS	325MG;2.25MG;0.19MG **	N007337 005	
ROXIPRIN				
	ROXANE	325MG;4.5MG;0.38MG	A087743 001	Jun 04, 1982
ASPIRIN; PENTAZOCINE HYDROCHLORIDE				
TABLET;ORAL				
TALWIN COMPOUND				
+	SANOFI AVENTIS US	325MG;EQ 12.5MG BASE **	N016891 001	
ASPIRIN; PRAVASTATIN SODIUM				
TABLET;ORAL				
PRAVIGARD PAC (COPACKAGED)				
	BRISTOL MYERS SQUIBB	81MG;20MG	N021387 001	Jun 24, 2003
		81MG;40MG	N021387 002	Jun 24, 2003
		81MG;80MG	N021387 003	Jun 24, 2003
		325MG;20MG	N021387 004	Jun 24, 2003
		325MG;40MG	N021387 005	Jun 24, 2003
		325MG;80MG	N021387 006	Jun 24, 2003
ASPIRIN; PROPOXYPHENE HYDROCHLORIDE				
CAPSULE;ORAL				
DARVON W/ ASA				
	XANODYNE PHARM	325MG;65MG	N010996 005	
ASPIRIN; PROPOXYPHENE NAPSYLATE				
CAPSULE;ORAL				
DARVON-N W/ ASA				
	AAIPHARMA LLC	325MG;100MG	N016829 001	
TABLET;ORAL				
DARVON-N W/ ASA				
	AAIPHARMA LLC	325MG;100MG	N016863 001	
ATAZANAVIR SULFATE				
CAPSULE;ORAL				
ATAZANAVIR SULFATE				
	AMNEAL	EQ 100MG BASE	A209717 001	Jun 01, 2020
	MYLAN	EQ 150MG BASE	A208177 001	Sep 24, 2018
		EQ 200MG BASE	A208177 002	Sep 24, 2018
		EQ 300MG BASE	A208177 003	Sep 24, 2018
	ZYDUS PHARMS	EQ 150MG BASE	A210575 001	Jun 04, 2020
		EQ 200MG BASE	A210575 002	Jun 04, 2020
		EQ 300MG BASE	A210575 003	Jun 04, 2020
REYATAZ				
+	BRISTOL MYERS SQUIBB	EQ 100MG BASE **	N021567 001	Jun 20, 2003
ATENOLOL				
INJECTABLE;INJECTION				
TENORMIN				
+	ASTRAZENECA	0.5MG/ML **	N019058 001	Sep 13, 1989
TABLET;ORAL				
ATENOLOL				
	ABLE	25MG	A076907 001	Jul 30, 2004
		50MG	A076907 002	Jul 30, 2004
		100MG	A076907 003	Jul 30, 2004
	APOTHECON	50MG	A073317 001	Mar 20, 1992
		100MG	A073318 001	Mar 20, 1992
	INVATECH	25MG	A074265 001	Feb 28, 1994
		50MG	A074265 002	Feb 28, 1994
		100MG	A074265 003	Feb 28, 1994
	MYLAN	25MG	A074126 003	Aug 26, 1998
		50MG	A074126 001	Mar 23, 1994
		100MG	A074126 002	Mar 23, 1994
	NORTHSTAR HLTHCARE	25MG	A078254 001	Sep 25, 2009
		50MG	A078254 002	Sep 25, 2009
		100MG	A078254 003	Sep 25, 2009
	NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
		100MG	A074127 002	Feb 21, 1995
	PLIVA	25MG	A074101 001	Jul 17, 1997
		50MG	A074101 002	Jul 17, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATENOLOL

TABLET;ORAL

ATENOLOL

	100MG	A074101	003	Jul 17, 1997
SCS	50MG	A073676	001	Oct 30, 1992
	100MG	A073676	002	Oct 30, 1992
STRIDES PHARMA	25MG	A074099	001	Apr 28, 1992
	50MG	A073542	001	Dec 19, 1991
	100MG	A073543	001	Dec 19, 1991
SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007
	50MG	A078210	002	Jul 10, 2007
	100MG	A078210	003	Jul 10, 2007
SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997
	50MG	A073475	001	Mar 30, 1993
	100MG	A073476	001	Mar 30, 1993
TEVA	50MG	A073315	001	May 28, 1993
	100MG	A073316	001	May 28, 1993
TEVA PHARMS	50MG	A074120	001	Feb 24, 1995
	100MG	A074120	002	Feb 24, 1995
WATSON LABS	50MG	A073352	001	Dec 27, 1991
WATSON LABS TEVA	100MG	A073353	001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

MYLAN	50MG;25MG	A074203	001	Oct 31, 1993
	100MG;25MG	A074203	002	Oct 31, 1993
NOSTRUM LABS	50MG;25MG	A074404	001	May 14, 1998
	100MG;25MG	A074404	002	May 14, 1998
PLIVA	50MG;25MG	A074107	001	Sep 24, 1997
	100MG;25MG	A074107	002	Sep 24, 1997
SUN PHARM INDUSTRIES	50MG;25MG	A073582	002	Apr 29, 1993
	100MG;25MG	A073582	001	Apr 29, 1993

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

MYLAN	10MG	A079021	001	Feb 18, 2021
	18MG	A079021	002	Feb 18, 2021
	25MG	A079021	003	Feb 18, 2021
	40MG	A079021	004	Feb 18, 2021
	60MG	A079021	005	Feb 18, 2021
	80MG	A079021	006	Feb 18, 2021
	100MG	A079021	007	Feb 18, 2021

STRATTERA

LILLY	5MG	N021411	001	Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

DR REDDYS LABS LTD	EQ 10MG BASE	A214659	001	Jul 14, 2021
	EQ 20MG BASE	A214659	002	Jul 14, 2021
	EQ 40MG BASE	A214659	003	Jul 14, 2021
	EQ 80MG BASE	A214659	004	Jul 14, 2021
PERRIGO R AND D	EQ 10MG BASE	A208478	001	Jun 23, 2020
	EQ 20MG BASE	A208478	002	Jun 23, 2020
TEVA PHARMS	EQ 10MG BASE	A078773	001	May 29, 2012
	EQ 20MG BASE	A078773	002	May 29, 2012
	EQ 40MG BASE	A078773	003	May 29, 2012
	EQ 80MG BASE	A078773	004	May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017
	EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017
	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017
	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017

LIPTRUZET

+	ORGANON	EQ 10MG BASE;10MG **	N200153	001	May 03, 2013
+		EQ 20MG BASE;10MG **	N200153	002	May 03, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL					
LIPTRUZET					
+		EQ 40MG BASE;10MG **	N200153	003	May 03, 2013
+		EQ 80MG BASE;10MG **	N200153	004	May 03, 2013

ATOVAQUONE

TABLET;ORAL					
MEPRON					
+	GLAXOSMITHKLINE LLC	250MG **	N020259	001	Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE;INJECTION					
ATRACURIUM BESYLATE					
	BAXTER HLTHCARE	10MG/ML	A074824	001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074753	001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074632	001	Dec 23, 1996
		10MG/ML	A074740	001	Mar 28, 1997
	MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017
	TEVA PARENTERAL	10MG/ML	A074784	001	Jun 11, 1997
	WATSON PHARMS TEVA	10MG/ML	A074945	001	Jul 28, 1998
ATRACURIUM BESYLATE PRESERVATIVE FREE					
	BAXTER HLTHCARE	10MG/ML	A074825	001	Sep 30, 1997
	BAXTER HLTHCARE CORP	10MG/ML	A074768	001	Jan 23, 1997
	HOSPIRA	10MG/ML	A074633	001	Dec 23, 1996
		10MG/ML	A074639	001	Mar 25, 1997
		10MG/ML	A074741	001	Mar 28, 1997
	MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017
	WATSON LABS INC	10MG/ML	A074944	001	Jul 28, 1998
TRACRIUM					
+	HOSPIRA	10MG/ML **	N018831	002	Jun 20, 1985
TRACRIUM PRESERVATIVE FREE					
+	HOSPIRA	10MG/ML **	N018831	001	Nov 23, 1983

ATROPINE

SOLUTION;INTRAMUSCULAR					
ATROPINE					
	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987
ATROPINE (AUTOINJECTOR)					
	RAFA LABS LTD	EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)	N212319	001	Jul 09, 2018

ATROPINE SULFATE

AEROSOL, METERED;INHALATION					
ATROPINE SULFATE					
	US ARMY	EQ 0.36MG BASE/INH	N020056	001	Sep 19, 1990
SOLUTION;INTRAVENOUS					
ATROPINE SULFATE					
+	HOSPIRA	0.5MG/5ML (0.1MG/ML) **	N021146	001	Jul 09, 2001

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL					
MOTOFEN HALF-STRENGTH					
	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE;ORAL					
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE					
	SCHERER RP	0.025MG;2.5MG	A086440	001	
SOLUTION;ORAL					
COLONAID					
	MEDPOINTE PHARM HLC	0.025MG/5ML;2.5MG/5ML	A085735	001	
LOMANATE					
	ALPHARMA US PHARMS	0.025MG/5ML;2.5MG/5ML	A085746	001	
LOMOTIL					
	GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001	
TABLET;ORAL					
COLONAID					
	MEDPOINTE PHARM HLC	0.025MG;2.5MG	A085737	001	
DI-ATRO					
	MD PHARM	0.025MG;2.5MG	A085266	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE	0.025MG;2.5MG	A040395	001	Nov 27, 2000
ASCOT	0.025MG;2.5MG	A087934	001	Jul 19, 1983
FOSUN PHARMA	0.025MG;2.5MG	A086173	001	
HEATHER	0.025MG;2.5MG	A086798	001	
HIKMA	0.025MG;2.5MG	A087765	001	Mar 15, 1982
INWOOD LABS	0.025MG;2.5MG	A085509	001	
KV PHARM	0.025MG;2.5MG	A085659	001	
LEDERLE	0.025MG;2.5MG	A086950	001	
PARKE DAVIS	0.025MG;2.5MG	A087131	001	
PVT FORM	0.025MG;2.5MG	A085766	001	
R AND S PHARMA	0.025MG;2.5MG	A085035	001	
ROXANE	0.025MG;2.5MG	A086057	001	
STRIDES PHARMA	0.025MG;2.5MG	A040357	001	May 02, 2000
SUN PHARM INDUSTRIES	0.025MG;2.5MG	A085506	001	
USL PHARMA	0.025MG;2.5MG	A087842	001	Mar 29, 1982
VALEANT PHARM INTL	0.025MG;2.5MG	A087195	001	Feb 16, 1982
WATSON LABS	0.025MG;2.5MG	A085876	001	

LO-TROL

VANGARD	0.025MG;2.5MG	A088009	001	Mar 25, 1983

LOGEN

SUPERPHARM	0.025MG;2.5MG	A088962	001	May 10, 1985

LONOX

FOSUN PHARMA	0.025MG;2.5MG	A085311	002	

LOW-QUEL

HALSEY	0.025MG;2.5MG	A085211	001	

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

+	MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991
	MYLAN INSTITUTIONAL	0.14MG/ML;10MG/ML	N019677	001	Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ATROPINE AND DEMEROL

ABBVIE	0.4MG/ML;50MG/ML	A087853	001	Nov 26, 1982
	0.4MG/ML;75MG/ML	A087847	001	Nov 26, 1982
	0.4MG/ML;100MG/ML	A087848	001	Nov 26, 1982

MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST	0.4MG/ML;50MG/ML	A085121	001	
	0.4MG/ML;75MG/ML	A085121	002	
	0.4MG/ML;100MG/ML	A085121	003	

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

ATNAA

US ARMY	2.1MG/0.7ML;600MG/2ML	N021175	001	Jan 17, 2002

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019

AZATADINE MALEATE

TABLET;ORAL

OPTIMINE

SCHERING	1MG	N017601	001	

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

TRINALIN

SCHERING	1MG;120MG	N018506	001	Mar 23, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AZATHIOPRINE

TABLET;ORAL

IMURAN

+	SEBELA IRELAND LTD	25MG **	N016324 002	

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

+	CASPER PHARMA LLC	EQ 100MG BASE/VIAL **	N017391 001	

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

AZELAIC ACID

	TEVA PHARMS USA	15%	A210928 001	Oct 07, 2020

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OPTIVAR

+	MYLAN SPECIALITY LP	0.05% **	N021127 001	May 22, 2000

SPRAY, METERED;NASAL

ASTELIN

+	MYLAN SPCLT VIATRIS	0.137MG/SPRAY	N020114 001	Nov 01, 1996

ASTEPRO

+	MYLAN SPECIALITY LP	0.137MG/SPRAY	N022203 001	Oct 15, 2008
		0.2055MG/SPRAY	N022203 002	Aug 31, 2009

AZITHROMYCIN

CAPSULE;ORAL

ZITHROMAX

+	PFIZER	EQ 250MG BASE **	N050670 001	Nov 01, 1991

FOR SUSPENSION;ORAL

AZITHROMYCIN

	LUPIN LTD	EQ 100MG BASE/5ML	A065488 001	May 15, 2015
		EQ 200MG BASE/5ML	A065488 002	May 15, 2015
	SANDOZ	EQ 100MG BASE/5ML	A065297 001	Sep 18, 2006
		EQ 200MG BASE/5ML	A065297 002	Sep 18, 2006
	TEVA PHARMS	EQ 100MG BASE/5ML	A065419 001	Jun 24, 2008
		EQ 200MG BASE/5ML	A065419 002	Jun 24, 2008

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+	PF PRISM CV	EQ 2GM BASE/BOT	N050797 001	Jun 10, 2005

INJECTABLE;INJECTION

AZITHROMYCIN

	HIKMA	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007
	MYLAN ASI	EQ 500MG BASE/VIAL	A065506 001	Mar 24, 2009
	RISING PHARMA	EQ 500MG BASE/VIAL	A204732 001	Jan 26, 2017
	TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006
		EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006

TABLET;ORAL

AZITHROMYCIN

	APOTEX CORP	EQ 250MG BASE	A065507 001	Jul 13, 2011
		EQ 500MG BASE	A065509 001	Jul 13, 2011
		EQ 600MG BASE	A065508 001	Jul 13, 2011
	MYLAN	EQ 250MG BASE	A065365 001	May 30, 2007
		EQ 500MG BASE	A065366 001	May 30, 2007
		EQ 600MG BASE	A065360 001	Jan 08, 2007
	TEVA	EQ 250MG BASE	A065153 001	Nov 14, 2005
		EQ 600MG BASE	A065150 001	Nov 14, 2005
	YUNG SHIN PHARM	EQ 500MG BASE	A211318 001	Mar 17, 2021

ZITHROMAX

+	PFIZER	EQ 600MG BASE **	N050730 001	Jun 12, 1996

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET;ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

	PFIZER	EQ 1GM BASE,N/A;N/A,EQ 100MG BASE	N050762 001	Dec 18, 1998

AZLOCILLIN SODIUM
INJECTABLE;INJECTION
AZLIN

BAYER PHARMS	EQ 2GM BASE/VIAL	A062388	001	Sep 08, 1982
	EQ 2GM BASE/VIAL	A062417	001	Oct 12, 1982
	EQ 2GM BASE/VIAL	N050562	001	Sep 03, 1982
	EQ 3GM BASE/VIAL	A062388	002	Sep 08, 1982
	EQ 3GM BASE/VIAL	A062417	002	Oct 12, 1982
	EQ 3GM BASE/VIAL	N050562	002	Sep 03, 1982
	EQ 4GM BASE/VIAL	A062388	003	Sep 08, 1982
	EQ 4GM BASE/VIAL	A062417	003	Oct 12, 1982
	EQ 4GM BASE/VIAL	N050562	003	Sep 03, 1982

AZTREONAM
INJECTABLE;INJECTION
AZACTAM

BRISTOL MYERS SQUIBB	500MG/VIAL	N050580	001	Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB	10MG/ML	N050632	003	May 24, 1989
+	20MG/ML	N050632	002	May 24, 1989
+	40MG/ML	N050632	001	May 24, 1989

AZTREONAM

HIKMA	1GM/VIAL	A065286	001	Mar 23, 2011
	2GM/VIAL	A065286	002	Mar 23, 2011

BACAMPICILLIN HYDROCHLORIDE
FOR SUSPENSION;ORAL
SPECTROBID

PFIZER	125MG/5ML	N050556	001	Mar 23, 1982

TABLET;ORAL
SPECTROBID

PFIZER	400MG	N050520	001	
	800MG	N050520	002	Sep 12, 1983

BACITRACIN
INJECTABLE;INJECTION
BACIIM

X GEN PHARMS	50,000 UNITS/VIAL	A064153	001	May 09, 1997

BACITRACIN

AKORN	50,000 UNITS/VIAL	A206719	001	Oct 20, 2017
FRESENIUS KABI USA	50,000 UNITS/VIAL	A065116	001	Dec 03, 2002
MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010
PFIZER	50,000 UNITS/VIAL	A060282	001	
PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	
	50,000 UNITS/VIAL	A060733	002	
XELLIA PHARMS APS	50,000 UNITS/VIAL	A203177	001	Aug 25, 2014

OINTMENT;OPHTHALMIC
BACIGUENT

PHARMACIA AND UPJOHN	500 UNITS/GM	A060734	001	

BACITRACIN

LILLY	500 UNITS/GM	A060687	001	
PHARMADERM	500 UNITS/GM	A062158	001	
PHARMAFAIR	500 UNITS/GM	A062453	001	Mar 28, 1984

OINTMENT;TOPICAL
BACITRACIN

COMBE	500 UNITS/GM	A062799	001	May 14, 1987
NASKA	500 UNITS/GM	A062857	001	Nov 13, 1987

POWDER;FOR RX COMPOUNDING
BACI-RX

X GEN PHARMS	5,000,000 UNITS/BOT	A061580	001	

BACITRACIN

APOTHEKERNES	5,000,000 UNITS/BOT	A061699	001	
PADDOCK LLC	5,000,000 UNITS/BOT	A062456	001	Jul 27, 1983

BACITRACIN ZINC
POWDER;FOR RX COMPOUNDING
ZIBA-RX

X GEN PHARMS	500,000 UNITS/BOT	A061737	001	

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
CORTISPORIN				
+	CASPER PHARMA LLC	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **	N050416 002	
ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE				
	PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062389 001	Jul 02, 1982
OINTMENT;TOPICAL				
CORTISPORIN				
+	MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168 002	May 04, 1984
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE				
	PHARMAFAIR	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062381 001	Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL				
LANABIOTIC				
	COMBE	400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM	A062499 001	Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
	PHARMAFAIR	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062386 001	Sep 09, 1982
BACITRACIN-NEOMYCIN-POLYMYXIN				
	PHARMADERM	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062167 001	
NEO-POLYCIN				
	DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060647 001	
OINTMENT;TOPICAL				
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE				
	NASKA	400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM	A062833 001	Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL				
POLYSPORIN				
	GLAXOSMITHKLINE	10,000 UNITS/GM;2,000,000 UNITS/GM	N050167 002	Mar 01, 1985
OINTMENT;OPHTHALMIC				
OCUMYCIN				
	PHARMAFAIR	500 UNITS/GM;10,000 UNITS/GM	A062430 001	Apr 08, 1983
POLYSPORIN				
	MONARCH PHARMS	500 UNITS/GM;10,000 UNITS/GM **	A061229 001	
OINTMENT;TOPICAL				
BACITRACIN ZINC-POLYMYXIN B SULFATE				
	NASKA	500 UNITS/GM;10,000 UNITS/GM	A062849 001	Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE				
	ALTANA	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060731 002	

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
MYCITRACIN				
	PHARMACIA AND UPJOHN	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A061048 001	

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL				
LANABIOTIC				
	COMBE	500 UNITS/GM;5,000 UNITS/GM	N050598 001	Sep 22, 1986

BACLOFEN

TABLET;ORAL				
BACLOFEN				
	MYLAN	10MG	A077181 001	Jul 29, 2005
		20MG	A077121 002	Jul 29, 2005
	MYLAN PHARMS INC	10MG	A090334 001	Feb 18, 2010
		20MG	A090334 002	Feb 18, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BACLOFEN

TABLET;ORAL					
BACLOFEN					
	SUN PHARM INDS INC	10MG	A077862	001	Aug 14, 2006
		20MG	A077862	002	Aug 14, 2006
	TEVA	10MG	A073043	001	Feb 27, 1992
		20MG	A073044	001	Feb 27, 1992
	USL PHARMA	10MG	A071260	001	May 06, 1988
		20MG	A071261	001	May 06, 1988
	WATSON LABS	10MG	A072824	001	Sep 18, 1991
		10MG	A073092	001	Jan 28, 1994
		10MG	A074698	001	Aug 20, 1996
		20MG	A072825	001	Sep 18, 1991
		20MG	A073093	001	Jan 28, 1994
		20MG	A074698	002	Aug 20, 1996
LIORESAL					
+	NOVARTIS	10MG **	N017851	001	
+		20MG **	N017851	003	Jan 20, 1982
TABLET, ORALLY DISINTEGRATING;ORAL					
KEMSTRO					
+	UCB INC	10MG	N021589	001	Oct 30, 2003
+		20MG	N021589	002	Oct 30, 2003

BALSALAZIDE DISODIUM

CAPSULE;ORAL					
BALSALAZIDE DISODIUM					
	MYLAN	750MG	A077807	001	Dec 28, 2007
TABLET;ORAL					
BALSALAZIDE DISODIUM					
	STRIDES PHARMA	1.1GM	A206336	001	Sep 08, 2015
GIAZO					
+	VALEANT PHARMS INTL	1.1GM **	N022205	001	Feb 03, 2012

BARIUM SULFATE

FOR SUSPENSION;ORAL					
E-Z-CAT DRY					
+	BRACCO	40% (9GM/POUCH)	N208036	003	Jan 03, 2017

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION					
BECLOVENT					
	GLAXOSMITHKLINE	0.042MG/INH	N018153	001	
QVAR 40					
+	TEVA BRANDED PHARM	0.04MG/INH **	N020911	002	Sep 15, 2000
QVAR 80					
+	TEVA BRANDED PHARM	0.08MG/INH **	N020911	001	Sep 15, 2000
VANCERIL					
	SCHERING	0.042MG/INH	N017573	001	
VANCERIL DOUBLE STRENGTH					
	SCHERING	0.084MG/INH	N020486	001	Dec 24, 1996
AEROSOL, METERED;NASAL					
BECONASE					
	GLAXOSMITHKLINE	0.042MG/INH	N018584	001	
VANCENASE					
	SCHERING	0.042MG/INH	N018521	001	

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL					
VANCENASE AQ					
	SCHERING	EQ 0.042MG DIPROP/SPRAY	N019589	001	Dec 23, 1987
		EQ 0.084MG DIPROP/SPRAY	N020469	001	Jun 26, 1996

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL					
BENAZEPRIL HYDROCHLORIDE					
	ANI PHARMS	5MG	A076333	001	Feb 11, 2004
		10MG	A076333	002	Feb 11, 2004
		20MG	A076333	003	Feb 11, 2004
		40MG	A076333	004	Feb 11, 2004
	GENPHARM	5MG	A076476	001	Feb 11, 2004
		10MG	A076476	002	Feb 11, 2004
		20MG	A076476	003	Feb 11, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL					
BENAZEPRIL HYDROCHLORIDE					
		40MG	A076476	004	Feb 11, 2004
	HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004
		10MG	A076267	002	Feb 11, 2004
		20MG	A076267	003	Feb 11, 2004
		40MG	A076267	004	Feb 11, 2004
	RISING PHARMA	5MG	A076430	001	Feb 11, 2004
		10MG	A076430	002	Feb 11, 2004
		20MG	A076430	003	Feb 11, 2004
		40MG	A076430	004	Feb 11, 2004

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	ANI PHARMS	5MG;6.25MG	A076342	001	Feb 11, 2004
		5MG;6.25MG	A076348	001	Feb 11, 2004
		10MG;12.5MG	A076342	002	Feb 11, 2004
		10MG;12.5MG	A076348	002	Feb 11, 2004
		20MG;12.5MG	A076342	003	Feb 11, 2004
		20MG;12.5MG	A076348	003	Feb 11, 2004
		20MG;25MG	A076342	004	Feb 11, 2004
		20MG;25MG	A076348	004	Feb 11, 2004
	APOTEX	5MG;6.25MG	A078794	001	Aug 21, 2014
		10MG;12.5MG	A078794	002	Aug 21, 2014
		20MG;12.5MG	A078794	003	Aug 21, 2014
		20MG;25MG	A078794	004	Aug 21, 2014
	AUROBINDO PHARMA USA	5MG;6.25MG	A076688	001	Feb 11, 2004
		10MG;12.5MG	A076688	002	Feb 11, 2004
		20MG;12.5MG	A076688	003	Feb 11, 2004
		20MG;25MG	A076688	004	Feb 11, 2004
	MYLAN PHARMS INC	5MG;6.25MG	A076612	001	Feb 11, 2004
		10MG;12.5MG	A076612	002	Feb 11, 2004
		20MG;12.5MG	A076612	003	Feb 11, 2004
		20MG;25MG	A076612	004	Feb 11, 2004
	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005
		10MG;12.5MG	A077483	002	Sep 08, 2005
		20MG;12.5MG	A077483	003	Sep 08, 2005
		20MG;25MG	A077483	004	Sep 08, 2005
LOTENSIN HCT					
+	VALIDUS PHARMS	5MG;6.25MG **	N020033	001	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)					
TREANDA					
+	CEPHALON	45MG/0.5ML (90MG/ML)	N022249	003	Sep 13, 2013
+		180MG/2ML (90MG/ML)	N022249	004	Sep 13, 2013

BENDROFLUMETHIAZIDE

TABLET;ORAL					
NATURETIN-10					
	APOTHECON	10MG	N012164	003	
NATURETIN-2.5					
	APOTHECON	2.5MG	N012164	001	
NATURETIN-5					
	APOTHECON	5MG	N012164	002	

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL					
CORZIDE					
+	KING PHARMS LLC	5MG;40MG	N018647	001	May 25, 1983
+		5MG;80MG	N018647	002	May 25, 1983
NADOLOL AND BENDROFLUMETHIAZIDE					
	IMPAX LABS	5MG;40MG	A077833	001	Mar 30, 2007
		5MG;80MG	A077833	002	Mar 30, 2007
	MYLAN	5MG;40MG	A078688	001	Feb 15, 2008
		5MG;80MG	A078688	002	Feb 15, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENOXINATE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
BENOXINATE HYDROCHLORIDE				
	SOLA BARNES HIND	0.4%	A084149 001	
BENTIROMIDE				
SOLUTION;ORAL				
CHYMEX				
	SAVAGE LABS	500MG/7.5ML	N018366 001	Dec 29, 1983
BENZONATATE				
CAPSULE;ORAL				
BENZONATATE				
	NESHER PHARMS	100MG	A040795 001	Oct 31, 2007
		200MG	A040795 002	Oct 31, 2007
	SUN PHARM INDS INC	100MG	A040587 001	Mar 19, 2008
		200MG	A040587 002	Mar 19, 2008
TESSALON				
+	PFIZER	200MG **	N011210 003	Jun 25, 1999
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE				
GEL;TOPICAL				
BENZACLIN				
	BAUSCH	5%;EQ 1% BASE	N050756 002	Apr 20, 2007
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE				
	ANDA REPOSITORY	2.5%;EQ 1.2% BASE	A207194 001	Aug 19, 2019
	ENCUBE	5%;EQ 1% BASE	A204087 001	Jun 27, 2017
	TARO	3.75%;EQ 1.2% BASE	A208683 001	Jun 05, 2018
	TOLMAR	5%;1.2%	A203688 001	Aug 25, 2016
BENZOYL PEROXIDE; ERYTHROMYCIN				
GEL;TOPICAL				
AKTIPAK				
+	BIOFRONTERA	5%;3%	N050769 001	Nov 27, 2000
ERYTHROMYCIN AND BENZOYL PEROXIDE				
	TOLMAR	5%;3%	A065112 001	Mar 29, 2004
BENZPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
BENZPHETAMINE HYDROCHLORIDE				
	EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012
	EPIC PHARMA LLC	50MG	A040714 001	Oct 29, 2007
	IMPAX LABS	50MG	A040845 001	Nov 18, 2008
	SCINOPHARM TAIWAN	50MG	A040578 001	Apr 17, 2006
	SPECGX LLC	50MG	A040773 001	Apr 25, 2007
	TEDOR PHARM	25MG	A040747 002	Nov 20, 2015
		50MG	A040747 001	Mar 30, 2007
DIDREX				
+	PFIZER	25MG **	N012427 003	
+		50MG **	N012427 002	
BENZQUINAMIDE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMETE-CON				
	PFIZER	EQ 50MG BASE/VIAL	N016820 001	
SUPPOSITORY;RECTAL				
EMETE-CON				
	ROERIG	EQ 100MG BASE	N016818 006	
BENZTHIAZIDE				
TABLET;ORAL				
AQUATAG				
	SOLVAY	25MG	N016001 001	
		50MG	N016001 002	
BENZTHIAZIDE				
	PVT FORM	50MG	A083206 001	
EXNA				
	AH ROBINS INC	50MG	N012489 001	
FOVANE				
	PFIZER	50MG	N012128 002	
URESE				
	PFIZER	25MG	N012128 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BENZTROPINE MESYLATE				
INJECTABLE;INJECTION				
BENZTROPINE MESYLATE				
LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010
TABLET;ORAL				
BENZTROPINE MESYLATE				
LANNETT CO INC	0.5MG **	A088877	001	Apr 11, 1985
	1MG **	A088894	001	Apr 11, 1985
	2MG **	A088895	001	Apr 11, 1985
OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008
	1MG	A040706	003	Feb 14, 2008
	2MG	A040706	001	Feb 14, 2008
QUANTUM PHARMICS	0.5MG	A088514	001	Jan 31, 1984
	1MG	A088510	001	Jan 31, 1984
	2MG	A088511	001	Jan 31, 1984
UPSHER SMITH LABS	0.5MG	A040103	001	Dec 12, 1996
	1MG	A040103	002	Dec 12, 1996
	2MG	A040103	003	Dec 12, 1996
USL PHARMA	0.5MG	A089211	001	Jun 14, 1988
	1MG	A089212	001	Jun 14, 1988
	2MG	A089213	001	Jun 14, 1988
COGENTIN				
+ MERCK	0.5MG **	N009193	004	
+	1MG **	N009193	003	
+	2MG **	N009193	002	
BENZYL ALCOHOL				
LOTION;TOPICAL				
ULESFIA				
+ SHIONOGI INC	5%	N022129	001	Apr 09, 2009
BENZYL BENZOATE				
EMULSION;TOPICAL				
BENZYL BENZOATE				
LANNETT	50%	A084535	001	
BEPRIDIL HYDROCHLORIDE				
TABLET;ORAL				
BEPADIN				
MEDPOINTE PHARM HLC	200MG	N019001	001	Dec 28, 1990
	300MG	N019001	002	Dec 28, 1990
	400MG	N019001	003	Dec 28, 1990
VASCOR				
JOHNSON AND JOHNSON	200MG	N019002	001	Dec 28, 1990
	300MG	N019002	002	Dec 28, 1990
	400MG	N019002	003	Dec 28, 1990
BETA CAROTENE				
CAPSULE;ORAL				
SOLATENE				
ROCHE	30MG	N017589	001	
BETAMETHASONE				
CREAM;TOPICAL				
CELESTONE				
SCHERING	0.2%	N014762	001	
SYRUP;ORAL				
CELESTONE				
MERCK SHARP DOHME	0.6MG/5ML	N014215	002	
TABLET;ORAL				
CELESTONE				
SCHERING	0.6MG	N012657	003	
BETAMETHASONE BENZOATE				
CREAM;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N016998	002	
GEL;TOPICAL				
UTICORT				
PARKE DAVIS	0.025%	N017244	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETAMETHASONE BENZOATE

LOTION;TOPICAL				
UTICORT				
	PARKE DAVIS	0.025%	N017528 001	
OINTMENT;TOPICAL				
UTICORT				
	PARKE DAVIS	0.025%	N018089 001	

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL				
ALPHATREX				
	SAVAGE LABS	EQ 0.05% BASE	N019138 001	Jun 26, 1984
BETAMETHASONE DIPROPIONATE				
	PERRIGO NEW YORK	EQ 0.05% BASE	A072536 001	Jan 31, 1990
		EQ 0.05% BASE	A074579 001	Nov 26, 1997
	PHARMADERM	EQ 0.05% BASE	N019136 001	Jun 26, 1984
	TARO	EQ 0.05% BASE	A071143 001	Jun 17, 1987
	TEVA	EQ 0.05% BASE	A071476 001	Aug 10, 1987
DIPROSONE				
	SCHERING	EQ 0.05% BASE	N017536 001	
CREAM, AUGMENTED;TOPICAL				
BETAMETHASONE DIPROPIONATE				
	ANDA REPOSITORY	EQ 0.05% BASE	A076603 001	Jan 23, 2004
DIPROLENE				
	SCHERING	EQ 0.05% BASE	N019408 001	Jan 31, 1986
DIPROLENE AF				
+	MERCK SHARP DOHME	EQ 0.05% BASE **	N019555 001	Apr 27, 1987
DISC;TOPICAL				
DIPROSONE				
	SCHERING	EQ 0.1% BASE	N017829 001	
GEL, AUGMENTED;TOPICAL				
DIPROLENE				
	SCHERING	EQ 0.05% BASE	N019408 002	Nov 22, 1991
LOTION;TOPICAL				
ALPHATREX				
	SAVAGE LABS	EQ 0.05% BASE	A070273 001	Aug 12, 1985
BETAMETHASONE DIPROPIONATE				
	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070281 001	Jul 31, 1985
	ALPHARMA US PHARMS	EQ 0.05% BASE	A071085 001	Feb 03, 1987
	COSETTE	EQ 0.05% BASE	A071882 001	Jun 06, 1988
	PHARMGEN	EQ 0.05% BASE	A070274 001	Aug 12, 1985
	TARO	EQ 0.05% BASE	A072276 001	Aug 24, 1988
		EQ 0.05% BASE	A074272 001	Sep 30, 1994
DIPROSONE				
+	SCHERING	EQ 0.05% BASE **	N017781 001	
LOTION, AUGMENTED;TOPICAL				
DIPROLENE				
+	MERCK SHARP DOHME	EQ 0.05% BASE **	N019716 001	Aug 01, 1988
OINTMENT;TOPICAL				
ALPHATREX				
	SAVAGE LABS	EQ 0.05% BASE	N019143 001	Sep 04, 1984
BETAMETHASONE DIPROPIONATE				
	PERRIGO NEW YORK	EQ 0.05% BASE	A072526 001	Jan 31, 1990
	PHARMADERM	EQ 0.05% BASE	N019140 001	Sep 04, 1984
	TEVA	EQ 0.05% BASE	A071477 001	Aug 10, 1987
DIPROSONE				
	SCHERING	EQ 0.05% BASE	N017691 001	
SPRAY;TOPICAL				
BETAMETHASONE DIPROPIONATE				
	TARO PHARMS	EQ 0.05% BASE/SPRAY	A211722 001	Jun 17, 2020

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL				
LOTRISONE				
+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010 001	Dec 08, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
BETAMETHASONE SODIUM PHOSPHATE				
	WATSON LABS	EQ 3MG BASE/ML	A085738 001	
CELESTONE				
+	SCHERING	EQ 3MG BASE/ML **	N017561 001	

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL				
BETAMETHASONE VALERATE				
	RICONPHARMA LLC	0.12%	A207144 001	May 24, 2017
CREAM;TOPICAL				
BETADERM				
	ROACO	EQ 0.1% BASE	N018839 001	Jun 30, 1983
BETAMETHASONE VALERATE				
	PERRIGO NEW YORK	EQ 0.1% BASE	A070053 001	Jun 10, 1986
	PHARMADERM	EQ 0.1% BASE	N018860 002	Aug 31, 1983
	PHARMAFAIR	EQ 0.1% BASE	A070485 001	May 29, 1987
	TARO	EQ 0.1% BASE	A070062 001	May 14, 1985
BETATREX				
	SAVAGE LABS	EQ 0.1% BASE	N018862 001	Aug 31, 1983
VALISONE				
	SCHERING	EQ 0.01% BASE	N016322 002	
		EQ 0.1% BASE	N016322 001	
LOTION;TOPICAL				
BETA-VAL				
	COSETTE	EQ 0.1% BASE	A070072 001	Jun 27, 1985
BETAMETHASONE VALERATE				
	PHARMADERM	EQ 0.1% BASE	N018870 001	Aug 31, 1983
	PHARMAFAIR	EQ 0.1% BASE	A070484 001	May 29, 1987
	TEVA PHARMS	EQ 0.1% BASE	A071883 001	Apr 22, 1988
BETATREX				
	SAVAGE LABS	EQ 0.1% BASE	N018867 001	Aug 31, 1983
VALISONE				
	SCHERING	EQ 0.1% BASE	N016932 001	
OINTMENT;TOPICAL				
BETAMETHASONE VALERATE				
	PERRIGO NEW YORK	EQ 0.1% BASE	A071478 001	Dec 23, 1987
	PHARMADERM	EQ 0.1% BASE	N018864 001	Aug 31, 1983
	PHARMAFAIR	EQ 0.1% BASE	A070486 001	May 29, 1987
BETATREX				
	SAVAGE LABS	EQ 0.1% BASE	N018863 001	Aug 31, 1983
VALISONE				
	SCHERING	EQ 0.1% BASE	N016740 001	

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
BETAXOLOL HYDROCHLORIDE				
	APOTEX INC	EQ 0.5% BASE	A075446 001	Sep 28, 2000
TABLET;ORAL				
KERLONE				
	SANOFI AVENTIS US	10MG **	N019507 001	Oct 27, 1989
		20MG **	N019507 002	Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET;ORAL				
KERLEDEX				
	SANOFI AVENTIS US	5MG;12.5MG	N019807 001	Oct 30, 1992
		10MG;12.5MG	N019807 002	Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC				
BETOPTIC PILO				
	ALCON	EQ 0.25% BASE;1.75%	N020619 001	Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE;INJECTION				
HISTALOG				
	LILLY	50MG/ML	N009344 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETHANECHOL CHLORIDE

INJECTABLE;INJECTION					
URECHOLINE					
+	ODYSSEY PHARMS	5MG/ML **	N006536	001	
TABLET;ORAL					
BETHANECHOL CHLORIDE					
	ABLE	5MG	A040492	001	Jul 27, 2004
		10MG	A040483	001	Jul 27, 2004
		25MG	A040485	001	Jul 27, 2004
		50MG	A040509	001	Jul 27, 2004
	ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004
		10MG	A040553	001	Oct 28, 2004
		25MG	A040554	001	Oct 28, 2004
		50MG	A040551	001	Oct 28, 2004
	ASCOT	10MG	A088288	001	Jun 08, 1983
		25MG	A088289	001	Jun 08, 1983
	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010
		10MG	A091256	002	May 04, 2010
		25MG	A091256	003	May 04, 2010
		50MG	A091256	004	May 04, 2010
	IMPAX LABS	5MG	A040721	001	Nov 01, 2006
		10MG	A040721	002	Nov 01, 2006
		25MG	A040721	003	Nov 01, 2006
		50MG	A040721	004	Nov 01, 2006
	IVAX SUB TEVA PHARMS	25MG	A084689	001	
	LANNETT	5MG	A084702	001	
		10MG	A084712	001	
		25MG	A084074	001	
	SANDOZ	5MG	A084353	001	
		10MG	A084378	001	
		10MG	A084379	001	
		25MG	A084383	001	
		25MG	A084384	001	
	SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009
		10MG	A040897	002	Apr 22, 2009
		25MG	A040897	003	Apr 22, 2009
		50MG	A040897	004	Apr 22, 2009
	WATSON LABS	5MG	A084402	001	
		5MG	A085230	002	
		5MG	A085841	001	
		10MG	A084408	001	
		10MG	A085228	001	
		10MG	A085842	001	
		25MG	A084441	001	
		25MG	A085229	001	
		25MG	A085839	001	
		50MG	A087397	001	
		50MG	A087444	001	
	WOCKHARDT	5MG	A040532	001	Sep 29, 2003
		10MG	A040533	001	Sep 29, 2003
		25MG	A040534	001	Sep 29, 2003
		50MG	A040518	001	Sep 29, 2003
MYOTONACHOL					
	GLENWOOD	5MG	A084188	001	
		10MG	A084188	003	
		25MG	A084188	004	
URECHOLINE					
	ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985
+		5MG **	N006536	003	
+		10MG	A088440	001	May 29, 1984
+		10MG **	N006536	002	
+		25MG	A088441	001	May 29, 1984
+		25MG **	N006536	004	
		50MG	A089096	001	Dec 19, 1985
+		50MG **	N006536	005	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BETHANIDINE SULFATE

TABLET;ORAL					
TENATHAN					
	ROBINS AH	10MG	N017675	001	
		25MG	N017675	002	

BETRIXABAN

CAPSULE;ORAL					
BEVYXXA					
+	PORTOLA PHARMS INC	40MG	N208383	001	Jun 23, 2017
+		80MG	N208383	002	Jun 23, 2017

BICALUTAMIDE

TABLET;ORAL					
BICALUTAMIDE					
	FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010
	KUDCO IRELAND	50MG	A077995	001	Jul 06, 2009
	MYLAN	50MG	A079185	001	Jul 06, 2009
	ROXANE	50MG	A078285	001	Mar 24, 2011
	SYNTHON PHARMS	50MG	A077973	001	Jul 06, 2009
	TEVA	50MG	A076932	001	Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC					
BIMATOPROST					
	AKORN	0.03%	A203299	001	Nov 08, 2018
LUMIGAN					
+	ALLERGAN	0.03% **	N021275	001	Mar 16, 2001

BIPERIDEN HYDROCHLORIDE

TABLET;ORAL					
AKINETON					
	ABBVIE	2MG	N012003	001	

BIPERIDEN LACTATE

INJECTABLE;INJECTION					
AKINETON					
	ABBVIE	5MG/ML	N012418	002	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL					
HALFLYTELY					
+	BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM **	N021551	003	Jul 16, 2010
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL					
	NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM	A202217	001	Aug 20, 2014

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL					
HELIDAC					
+	CASPER PHARMA LLC	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG **	N050719	001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET;ORAL					
BISOPROLOL FUMARATE					
	MYLAN	5MG	A075831	001	Dec 14, 2005
		10MG	A075831	002	Dec 14, 2005
	TEVA PHARMS	5MG	A075644	001	Jun 26, 2001
		10MG	A075644	002	Jun 26, 2001
ZEBETA					
+	TEVA WOMENS	5MG **	N019982	002	Jul 31, 1992
+		10MG **	N019982	001	Jul 31, 1992

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE					
	ACTAVIS ELIZABETH	2.5MG;6.25MG	A075672	001	Sep 25, 2000
		5MG;6.25MG	A075672	002	Sep 25, 2000
		10MG;6.25MG	A075672	003	Sep 25, 2000
	APOTHECON	2.5MG;6.25MG	A075642	002	Dec 27, 2000
		5MG;6.25MG	A075642	001	Dec 27, 2000
		10MG;6.25MG	A075642	003	Dec 27, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS	2.5MG;6.25MG	A075632	001	Sep 27, 2000
	5MG;6.25MG	A075632	002	Sep 27, 2000
	10MG;6.25MG	A075632	003	Sep 27, 2000
SANDOZ	2.5MG;6.25MG	A075527	001	Sep 25, 2000
	5MG;6.25MG	A075527	003	Sep 25, 2000
	10MG;6.25MG	A075527	002	Sep 25, 2000
TEVA	2.5MG;6.25MG	A075686	001	Jan 19, 2001
	5MG;6.25MG	A075686	002	Jan 19, 2001
	10MG;6.25MG	A075686	003	Jan 19, 2001
WATSON LABS TEVA	2.5MG;6.25MG	A075469	001	Sep 25, 2000
	5MG;6.25MG	A075469	002	Sep 25, 2000
	10MG;6.25MG	A075469	003	Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED;INHALATION

TORNALATE

SANOFI AVENTIS US	0.37MG/INH	N018770	001	Dec 28, 1984

SOLUTION;INHALATION

TORNALATE

SANOFI AVENTIS US	0.2%	N019548	001	Feb 19, 1992

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

BIVALIRUDIN

APOTEX	250MG/VIAL	A204876	001	Jul 06, 2017

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLENOXANE

+ BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL **	N050443	001	
+	EQ 30 UNITS BASE/VIAL **	N050443	002	Sep 07, 1995

BLEOMYCIN SULFATE

CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019
PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201	001	Dec 13, 2007
TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084	001	Jun 01, 1996
	EQ 30 UNITS BASE/VIAL	A064084	002	Jun 01, 1996

BOCEPREVIR

CAPSULE;ORAL

VICTRELIS

MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011

BOSENTAN

TABLET;ORAL

BOSENTAN

ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020
	125MG	A211461	002	Jan 23, 2020
ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019
	125MG	A206002	002	Apr 26, 2019
AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019
	125MG	A209742	002	Apr 26, 2019
CIPLA	62.5MG	A210342	001	Jan 03, 2020
	125MG	A210342	002	Jan 03, 2020
MYLAN	62.5MG	A205173	001	Jan 15, 2020
	125MG	A205173	002	Jan 15, 2020
NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019
	125MG	A206987	002	Apr 26, 2019

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
HIKMA	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
+ HOSPIRA	50MG/ML **	N019030	001	Apr 29, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BRETYLIUM TOSYLATE				
INJECTABLE;INJECTION				
BRETYLIUM TOSYLATE				
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%				
ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
	200MG/100ML	N019121	002	Apr 29, 1986
	400MG/100ML	N019121	003	Apr 29, 1986
BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986
BRETYLOL				
HOSPIRA	50MG/ML	N017954	001	
BRIMONIDINE TARTRATE				
SOLUTION/DROPS;OPHTHALMIC				
ALPHAGAN				
+ ALLERGAN	0.2% **	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE				
TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004
BROMFENAC SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
BROMDAY				
+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	002	Oct 16, 2010
BROMFENAC SODIUM				
AMRING PHARMS	EQ 0.09% ACID	A202030	001	Jan 09, 2013
APOTEX	EQ 0.09% ACID	A202435	001	Jun 19, 2014
	EQ 0.09% ACID	A202620	001	Jun 23, 2014
COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011
NOVITIUM PHARMA	EQ 0.09% ACID	A201941	001	Feb 10, 2015
RISING PHARMA	EQ 0.09% ACID	A203368	001	Jun 03, 2019
XIBROM				
+ BAUSCH AND LOMB INC	EQ 0.09% ACID **	N021664	001	Mar 24, 2005
BROMOCRIPTINE MESYLATE				
CAPSULE;ORAL				
BROMOCRIPTINE MESYLATE				
LEK PHARM	EQ 5MG BASE	A075100	001	Dec 10, 1998
TABLET;ORAL				
BROMOCRIPTINE MESYLATE				
MYLAN	EQ 2.5MG BASE	A076962	001	Sep 24, 2004
BROMODIPHENHYDRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
AMBODRYL				
PARKE DAVIS	25MG	N007984	001	
BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE				
SYRUP;ORAL				
AMBENYL				
FOREST LABS	12.5MG/5ML;10MG/5ML	N009319	006	Jan 10, 1984
BROMANYL				
ALPHARMA US PHARMS	12.5MG/5ML;10MG/5ML	A088343	001	Aug 15, 1984
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE				
WOCKHARDT	12.5MG/5ML;10MG/5ML	A088626	001	Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR;ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS	2MG/5ML	A086936	001	
KV PHARM	2MG/5ML	A085466	001	
PHARM ASSOC	2MG/5ML	A087517	001	
USL PHARMA	2MG/5ML	A087964	001	Jan 25, 1983

INJECTABLE;INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS	10MG/ML	A083821	001	
	100MG/ML	A083820	001	

DIMETANE-TEN

WYETH AYERST	10MG/ML	N011418	002	

TABLET;ORAL

BROMPHENIRAMINE MALEATE

BARR	4MG	A084468	001	
IVAX SUB TEVA PHARMS	4MG	A084351	001	
NEWTRON PHARMS	4MG	A086987	001	
NEXGEN PHARMA INC	4MG	A086187	001	
PAR PHARM	4MG	A087009	001	
PIONEER PHARMS	4MG	A088604	001	Jul 13, 1984
UPSHER SMITH LABS	4MG	A083215	001	
VITARINE	4MG	A085850	001	
WATSON LABS	4MG	A083123	001	
	4MG	A085769	001	

DIMETANE

WYETH CONS	4MG	N010799	003	

TABLET, EXTENDED RELEASE;ORAL

DIMETANE

WYETH CONS	8MG	N010799	010	Jun 10, 1983
	12MG	N010799	011	Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMANATE DM

ALPHARMA US PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A088722	001	Mar 07, 1985

BROMFED-DM

WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A089681	001	Dec 22, 1988

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

PHARM ASSOC	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014

DIMETANE-DX

+	ROBINS AH	2MG/5ML;10MG/5ML;30MG/5ML **	N019279	001	Aug 24, 1984

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA	16MG;240MG	N019672	001	Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET;ORAL

BUCLADIN-S

STUART PHARMS	50MG	N010911	006	

BUDESONIDE

AEROSOL, METERED;NASAL

RHINOCORT

ASTRAZENECA	0.032MG/INH	N020233	001	Feb 14, 1994

CAPSULE, DELAYED RELEASE;ORAL

BUDESONIDE

ALVOGEN	3MG	A206724	001	Nov 23, 2016
BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014

POWDER, METERED;INHALATION

PULMICORT

ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997
	0.32MG/INH	N020441	003	Jun 24, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUMETANIDE
INJECTABLE;INJECTION
BUMETANIDE

ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995
HOSPIRA	0.25MG/ML	A074160	001	Oct 30, 1997
TEVA PARENTERAL	0.25MG/ML	A074613	001	Nov 18, 1997

BUMEX

+	VALIDUS PHARMS	0.25MG/ML **	N018226	001	Feb 28, 1983

BUPIVACAINE
SOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR

+	DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021

BUPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE

HOSPIRA	0.25%	A070586	001	Mar 03, 1987
	0.25%	N018053	002	
	0.5%	N018053	001	
	0.75%	A070587	001	Mar 03, 1987
	0.75%	N018053	003	
MYLAN ASI	0.25%	A091503	001	Oct 18, 2011
	0.5%	A091503	002	Oct 18, 2011
NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA	0.075%	N019978	001	Sep 03, 1992
	0.114%	N019978	002	Sep 03, 1992
	0.23%	N019978	003	Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED	0.25%	A076012	001	Jan 09, 2002
	0.5%	A076012	002	Jan 09, 2002
	0.75%	A076012	003	Jan 09, 2002
MYLAN ASI	0.25%	A091487	002	Oct 18, 2011
	0.5%	A091487	001	Oct 18, 2011
	0.75%	A091487	003	Oct 18, 2011

INJECTABLE;SPINAL
SENSORCAINE

FRESENIUS KABI USA	0.75%	A071202	001	Apr 15, 1987

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE
INJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA	0.25%;0.005MG/ML	A071166	001	Jun 16, 1988
	0.5%;0.005MG/ML	A071169	001	Jun 16, 1988
	0.75%;0.005MG/ML	A071171	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE
INJECTABLE;INJECTION
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

+	HOSPIRA	0.5%;0.0091MG/ML	N022046	001	Jul 13, 1983

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
DUOCAINE

AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003

BUPRENORPHINE
FILM, EXTENDED RELEASE;TRANSDERMAL
BUPRENORPHINE

MYLAN TECH VIATRIS	5MCG/HR	A210162	001	May 03, 2021
	7.5MCG/HR	A210162	002	May 03, 2021
	10MCG/HR	A210162	003	May 03, 2021
	15MCG/HR	A210162	004	May 03, 2021
	20MCG/HR	A210162	005	May 03, 2021

BUPRENORPHINE HYDROCHLORIDE

IMPLANT;IMPLANTATION				
PROBUPHINE				
+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442 001	May 26, 2016
TABLET;SUBLINGUAL				
BUPRENORPHINE HYDROCHLORIDE				
	BARR	EQ 2MG BASE	A090360 001	May 07, 2010
		EQ 8MG BASE	A090360 002	May 07, 2010
	MYLAN	EQ 2MG BASE	A201066 001	Mar 06, 2015
		EQ 8MG BASE	A201066 002	Mar 06, 2015
SUBUTEX				
+	INDIVIOR INC	EQ 2MG BASE **	N020732 002	Oct 08, 2002
+		EQ 8MG BASE **	N020732 003	Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL				
BUNAVAIL				
+	BDSI	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637 001	Jun 06, 2014
+		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637 002	Jun 06, 2014
+		EQ 6.3MG BASE;EQ 1MG BASE	N205637 003	Jun 06, 2014
FILM;SUBLINGUAL				
CASSIPA				
+	TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042 001	Sep 07, 2018
TABLET;SUBLINGUAL				
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE				
	MAYNE PHARMA INC	EQ 2MG BASE;EQ 0.5MG BASE	A206953 001	Jul 17, 2020
		EQ 8MG BASE;EQ 2MG BASE	A206953 002	Jul 17, 2020
	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149 001	Sep 08, 2014
		EQ 8MG BASE;EQ 2MG BASE	A091149 002	Sep 08, 2014
SUBOXONE				
+	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE **	N020733 001	Oct 08, 2002
+		EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET;ORAL				
BUPROPION HYDROCHLORIDE				
	AUROBINDO PHARMA USA	75MG	A075491 001	Apr 17, 2000
		100MG	A075491 002	Apr 17, 2000
	HERITAGE PHARMA	75MG	A075310 001	Nov 29, 1999
		100MG	A075310 002	Nov 29, 1999
	INVATECH	75MG	A075613 002	Oct 10, 2000
		100MG	A075613 001	Oct 10, 2000
WELLBUTRIN				
+	GLAXOSMITHKLINE	50MG **	N018644 001	Dec 30, 1985
+		75MG **	N018644 002	Dec 30, 1985
+		100MG **	N018644 003	Dec 30, 1985
TABLET, EXTENDED RELEASE;ORAL				
BUPROPION HYDROCHLORIDE				
	ACTAVIS LABS FL INC	300MG	A077715 002	Jun 13, 2007
	AUROBINDO PHARMA USA	100MG	A090325 001	Apr 08, 2010
		150MG	A090325 002	Apr 08, 2010
		150MG	A090942 001	Jul 14, 2010
		200MG	A090325 003	Apr 08, 2010
		300MG	A090942 002	Jul 14, 2010
	IMPAX LABS	150MG	A077415 001	Nov 26, 2008
		200MG	A076711 001	Dec 03, 2004
		300MG	A077415 002	Dec 15, 2006
	JUBILANT GENERICS	100MG	A202774 001	Oct 11, 2013
		150MG	A202774 002	Oct 11, 2013
		150MG	A202775 001	Oct 11, 2013
		150MG	A207459 001	Jun 30, 2017
		200MG	A202774 003	Oct 11, 2013
		300MG	A207459 002	Jun 30, 2017
	MYLAN	150MG	A090941 001	May 03, 2010
	SANDOZ	100MG	A076845 001	Jul 14, 2005
		150MG	A076834 001	Jul 14, 2005
		150MG	A076845 002	Jul 14, 2005
	SUN PHARM	150MG	A200695 001	Dec 18, 2014
	TORRENT	100MG	A203969 001	Oct 31, 2014
		150MG	A203969 002	Oct 31, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUPROPION HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
BUPROPION HYDROCHLORIDE				
	200MG	A203969	003	Oct 31, 2014
WATSON LABS INC	100MG	A077455	001	Jul 19, 2010
	150MG	A077455	002	Mar 12, 2008
	200MG	A077455	003	Jul 19, 2010
WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012
	150MG	A201331	002	Aug 30, 2012
	200MG	A201331	003	Aug 30, 2012
WELLBUTRIN SR				
GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996
ZYBAN				
GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997
+	150MG	N020711	003	May 14, 1997
BUSPIRONE HYDROCHLORIDE				
CAPSULE;ORAL				
BUSPAR				
BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000
	7.5MG	N021190	002	Dec 20, 2000
	10MG	N021190	003	Dec 20, 2000
	15MG	N021190	004	Dec 20, 2000
TABLET;ORAL				
BUSPAR				
+ BRISTOL MYERS SQUIBB	5MG **	N018731	001	Sep 29, 1986
+	10MG **	N018731	002	Sep 29, 1986
+	15MG **	N018731	003	Apr 22, 1996
+	30MG **	N018731	004	Apr 22, 1996
BUSPIRONE HYDROCHLORIDE				
EGIS	5MG	A075119	001	Mar 14, 2002
	10MG	A075119	002	Mar 14, 2002
	15MG	A075119	003	Jan 23, 2003
FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002
	10MG	A075413	002	Mar 19, 2002
	15MG	A075413	003	Mar 19, 2002
IVAX SUB TEVA PHARMS	5MG **	A075385	001	Mar 01, 2002
	10MG **	A075385	002	Mar 01, 2002
	15MG **	A075385	003	Mar 01, 2002
MYLAN	5MG	A075467	001	Feb 28, 2002
	10MG	A075467	003	Feb 28, 2002
	15MG	A075467	004	Feb 28, 2002
NESHER PHARMS	5MG	A075572	001	Feb 27, 2002
	10MG	A075572	002	Feb 27, 2002
	15MG	A075572	003	Feb 27, 2002
BUSULFAN				
INJECTABLE;INJECTION				
BUSULFAN				
ACTAVIS LLC	6MG/ML	A205139	001	Dec 08, 2017
MYLAN LABS LTD	6MG/ML	A205184	001	Jul 13, 2018
BUTABARBITAL SODIUM				
CAPSULE;ORAL				
BUTICAPS				
MEDPOINTE PHARM HLC	15MG	A085381	001	
	30MG	A085381	002	
	50MG	A085381	003	
	100MG	A085381	004	
ELIXIR;ORAL				
BUTABARB				
ALPHARMA US PHARMS	30MG/5ML	A085873	001	
BUTABARBITAL SODIUM				
WOCKHARDT	30MG/5ML	A085383	001	
BUTALAN				
LANNETT	33.3MG/5ML	A085880	001	
BUTISOL SODIUM				
MEDA PHARMS	30MG/5ML	A085380	001	
SARISOL				
HALSEY	30MG/5ML	A084723	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUTABARBITAL SODIUM				
TABLET;ORAL				
BUTABARBITAL				
BUNDY	30MG	A085550	001	
BUTABARBITAL SODIUM				
SANDOZ	15MG	A084292	003	Feb 09, 1982
+	15MG	A085938	001	
	30MG	A084272	002	
	30MG	A085934	001	
SOLVAY	16.2MG	A083606	001	
	32.4MG	A083898	001	
	48.6MG	A083897	001	
	97.2MG	A083896	001	
TEVA	15MG	A088632	001	May 18, 1985
	30MG	A088631	001	May 01, 1985
WATSON LABS	15MG	A085764	001	
	30MG	A085772	001	
WHITEWORTH TOWN PLSN	15MG	A083325	002	
	30MG	A083337	001	
BUTISOL SODIUM				
MYLAN SPECIALITY LP	15MG **	N000793	002	
+	30MG	N000793	004	
	50MG **	N000793	003	
	100MG **	N000793	005	
SARISOL NO. 1				
HALSEY	15MG	A084719	001	
SARISOL NO. 2				
HALSEY	30MG	A084719	002	
SODIUM BUTABARBITAL				
HIKMA	15MG	A085418	001	
	30MG	A085432	001	
IVAX SUB TEVA PHARMS	15MG	A083484	001	
	30MG	A084040	001	
LANNETT	15MG	A085849	001	
	30MG	A085866	001	
	100MG	A085881	001	
MARSHALL PHARMA	16.2MG	A083524	001	
	32.4MG	A083858	001	
BUTENAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
MENTAX-TC				
MYLAN	1%	N021408	001	Oct 17, 2002
BUTOCONAZOLE NITRATE				
CREAM;VAGINAL				
BUTOCONAZOLE NITRATE				
PADAGIS US	2%	N019881	001	Feb 07, 1997
FEMSTAT				
ROCHE PALO	2%	N019215	001	Nov 25, 1985
FEMSTAT 3				
+ BAYER	2%	N020421	001	Dec 21, 1995
SUPPOSITORY;VAGINAL				
FEMSTAT				
ROCHE PALO	100MG	N019359	001	Nov 25, 1985
BUTORPHANOL TARTRATE				
INJECTABLE;INJECTION				
BUTORPHANOL TARTRATE				
BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001
HIKMA FARMACEUTICA	2MG/ML	A078247	001	Apr 29, 2009
HOSPIRA	1MG/ML	A075342	001	Nov 04, 1999
	1MG/ML	A075559	001	Mar 20, 2000
	2MG/ML	A075342	002	Nov 04, 1999
	2MG/ML	A075559	002	Mar 20, 2000
BUTORPHANOL TARTRATE PRESERVATIVE FREE				
BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001
	2MG/ML	A075695	002	Oct 23, 2001
HOSPIRA	1MG/ML	A074620	001	Jan 22, 1997
	1MG/ML	A075170	001	Sep 28, 1998
	2MG/ML	A074620	002	Jan 22, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

BUTORPHANOL TARTRATE				
INJECTABLE;INJECTION				
BUTORPHANOL TARTRATE PRESERVATIVE FREE				
	2MG/ML	A075170	002	Sep 28, 1998
STADOL				
+ APOTHECON	2MG/ML **	N017857	004	
STADOL PRESERVATIVE FREE				
+ APOTHECON	1MG/ML **	N017857	001	
+	2MG/ML **	N017857	002	
SPRAY, METERED;NASAL				
STADOL				
BRISTOL MYERS SQUIBB	1MG/SPRAY **	N019890	001	Dec 12, 1991
CABERGOLINE				
TABLET;ORAL				
CABERGOLINE				
ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008
APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013
IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007
MYLAN	0.5MG	A202947	001	Dec 02, 2013
STRIDES PHARMA	0.5MG	A076310	001	Dec 29, 2005
DOSTINEX				
+ PFIZER	0.5MG **	N020664	001	Dec 23, 1996
CAFFEINE CITRATE				
SOLUTION;INTRAVENOUS				
CAFFEINE CITRATE				
SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090077	001	Sep 30, 2009
SOLUTION;ORAL				
CAFFEINE CITRATE				
AM REGENT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009
CAFFEINE; ERGOTAMINE TARTRATE				
SUPPOSITORY;RECTAL				
CAFERGOT				
+ NOVARTIS	100MG;2MG **	N009000	002	
TABLET;ORAL				
CAFERGOT				
NOVARTIS	100MG;1MG	N006620	001	
+ SANDOZ	100MG;1MG	A084294	001	
ERGOTAMINE TARTRATE AND CAFFEINE				
HIKMA INTL PHARMS	100MG;1MG	A040510	001	Sep 17, 2004
WIGRAINE				
ORGANON USA INC	100MG;1MG	A086562	001	
CALCIFEDIOL				
CAPSULE;ORAL				
CALDEROL				
ORGANON USA INC	0.02MG	N018312	001	
	0.05MG	N018312	002	
CALCIPOTRIENE				
OINTMENT;TOPICAL				
DOVONEX				
+ LEO PHARMA AS	0.005% **	N020273	001	Dec 29, 1993
SOLUTION;TOPICAL				
DOVONEX				
+ LEO PHARM	0.005% **	N020611	001	Mar 03, 1997
CALCITONIN HUMAN				
INJECTABLE;INJECTION				
CIBACALCIN				
NOVARTIS	0.5MG/VIAL	N018470	001	Oct 31, 1986
CALCITONIN SALMON				
INJECTABLE;INJECTION				
CALCIMAR				
+ SANOFI AVENTIS US	200 IU/ML **	N017769	001	
	400 IU/VIAL	N017497	001	
CALCITONIN-SALMON				
IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCITONIN SALMON

INJECTABLE;INJECTION					
MIACALCIN					
+	MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986
SPRAY, METERED;NASAL					
MIACALCIN					
+	MYLAN IRELAND LTD	200 IU/SPRAY **	N020313	002	Aug 17, 1995

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL					
FORTICAL					
	UPSHER SMITH LABS	200 IU/SPRAY **	N021406	001	Aug 12, 2005

CALCITRIOL

INJECTABLE;INJECTION					
CALCIJEX					
+	ABBVIE	0.001MG/ML **	N018874	001	Sep 25, 1986
+		0.002MG/ML **	N018874	002	Sep 25, 1986
CALCITRIOL					
	AKORN	0.002MG/ML	A078066	002	Jan 29, 2008
	AM REGENT	0.001MG/ML	A075746	001	Sep 26, 2003
		0.002MG/ML	A075746	002	Sep 26, 2003
	FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002
		0.002MG/ML	A075836	002	Dec 31, 2002
	FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003
		0.002MG/ML	A075766	002	Feb 20, 2003
	HOSPIRA	0.001MG/ML	A075816	001	Jan 16, 2004
		0.002MG/ML	A075816	002	Jan 16, 2004
	ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003
	SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006
	TEVA PARENTERAL	0.001MG/ML	A075823	001	Mar 31, 2003
		0.002MG/ML	A075823	002	Mar 31, 2003

CALCIUM ACETATE

CAPSULE;ORAL					
CALCIUM ACETATE					
	AMNEAL PHARMS	667MG	A201658	001	Oct 06, 2014
	LOTUS PHARM CO LTD	667MG	A203298	001	Jul 26, 2016
PHOSLO					
	FRESENIUS MEDCL	333.5MG	N021160	001	Apr 02, 2001
		667MG	N021160	002	Apr 02, 2001
TABLET;ORAL					
CALCIUM ACETATE					
	HIKMA	667MG	A077693	001	Jan 30, 2008
ELIPHOS					
	CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008
PHOSLO					
+	FRESENIUS MEDCL	667MG **	N019976	001	Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET;ORAL					
ACTONEL WITH CALCIUM (COPACKAGED)					
+	WARNER CHILCOTT	EQ 500MG BASE;35MG **	N021823	001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION					
METHOTREXATE SODIUM					
	AKORN	0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N020079	001	Feb 26, 1999

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008
PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML; 3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

	BAXTER HLTHCARE CORP	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

	BAXTER HLTHCARE CORP	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML; 2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

	BAXTER HLTHCARE CORP	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE CORP	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

	BAXTER HLTHCARE CORP	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864	001	Jun 10, 1993

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N018271	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019867	001	Dec 20, 1993

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018269	002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML **	N017390	001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

	B BRAUN	510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	001	Aug 26, 1983
		510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML	N018807	003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

	B BRAUN	510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML	N018807	002	Aug 26, 1983
		510MG/100ML;50GM/100ML;200MG/100ML;9.4	N018807	004	Aug 26, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER					
		GM/100ML;11GM/100ML			
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	B BRAUN	29MG/100ML;2.5GM/100ML;15MG/100ML;610MG /100ML;560MG/100ML	N018460	006	Jan 29, 1986
DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	B BRAUN	29MG/100ML;1.5GM/100ML;15MG/100ML;610MG /100ML;560MG/100ML	N018460	001	
DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	B BRAUN	29MG/100ML;4.25GM/100ML;15MG/100ML;610M G/100ML;560MG/100ML	N018460	003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N018379	002	
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N018379	003	
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N018379	007	Jun 24, 1988
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML	N018379	001	
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/ 100ML;450MG/100ML	N018460	007	Jan 29, 1986
		26MG/100ML;1.5GM/100ML;15MG/100ML;560MG /100ML;390MG/100ML	N018460	002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/ 100ML;450MG/100ML	N018460	005	Nov 02, 1983
		26MG/100ML;5GM/100ML;5MG/100ML;530MG/10 0ML;450MG/100ML	N018460	008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	B BRAUN	26MG/100ML;4.25GM/100ML;5MG/100ML;530MG /100ML;450MG/100ML	N018460	009	Jan 29, 1986
		26MG/100ML;4.25GM/100ML;15MG/100ML;560M G/100ML;390MG/100ML	N018460	004	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N017512	001	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N017512	003	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML	N017512	002	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;5 67MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML; 567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	A020374	001	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	A020374	002	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;5 38MG/100ML;448MG/100ML	A020374	003	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER					
	FRESENIUS	18.4MG/100ML;4.25GM/100ML;5.08MG/100ML; 538MG/100ML;448MG/100ML	A020374	004	Jun 13, 1994

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;380MG/1 00ML;600MG/100ML	N018258	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER					
	HOSPIRA	33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML	N018254	001	
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML	N018256	001	
		33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML	N020000	001	Apr 17, 1992
	BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;860MG/1 00ML	N016695	001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	4MG/100ML;4GM/100ML;6MG/100ML;120MG/100 ML;62MG/100ML	N019634	002	Feb 24, 1988
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER					
	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 00ML;310MG/100ML	N017510	001	
	MILES	20MG/100ML;5GM/100ML;30MG/100ML;600MG/1 00ML;310MG/100ML	N018499	001	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/ 100ML;310MG/100ML	N019685	005	Oct 17, 1988
+		20MG/100ML;5GM/100ML;179MG/100ML;600MG/ 100ML;310MG/100ML	N019685	006	Oct 17, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/ 100ML;310MG/100ML	N019685	007	Oct 17, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/ 100ML;310MG/100ML	N019685	008	Oct 17, 1988
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/ 100ML;310MG/100ML	N019685	003	Oct 17, 1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;328MG/100ML;600MG/ 100ML;310MG/100ML	N019685	004	Oct 17, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/ 100ML;310MG/100ML	N019685	001	Oct 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL				
INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML	N019395	001	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML	N019395	002	Mar 26, 1986
INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML	N019395	003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
TPN ELECTROLYTES IN PLASTIC CONTAINER				
ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML	N019399	001	Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE;INJECTION				
ISOLYTE E IN PLASTIC CONTAINER				
B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N018899	001	Oct 31, 1983
	35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML	N019718	001	Sep 29, 1989

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION				
PLASMA-LYTE R IN PLASTIC CONTAINER				
BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N017438	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
ACETATED RINGER'S IN PLASTIC CONTAINER				
B BRAUN	20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML	N018725	001	Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
RINGER'S IN PLASTIC CONTAINER				
B BRAUN	33MG/100ML;30MG/100ML;860MG/100ML	N018721	001	Nov 09, 1982
SOLUTION;IRRIGATION				
RINGER'S IN PLASTIC CONTAINER				
ABBOTT	33MG/100ML;30MG/100ML;860MG/100ML	N018462	001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
ABBOTT	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019485	001	Oct 24, 1985
B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018023	001	
MILES	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N018417	001	
SOLUTION;IRRIGATION				
LACTATED RINGER'S IN PLASTIC CONTAINER				
BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	N019933	001	Aug 29, 1989

CALCIUM GLUCEPTATE

INJECTABLE;INJECTION				
CALCIUM GLUCEPTATE				
+ ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001	
	EQ 90MG CALCIUM/5ML	A083159	001	
ABRAXIS PHARM	EQ 90MG CALCIUM/5ML	A089373	001	Apr 30, 1987
LILLY	EQ 90MG CALCIUM/5ML	N006470	001	

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE;INJECTION				
ISOPAQUE 440				
	GE HEALTHCARE	0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML	N016847 001	

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE;INJECTION				
ISOPAQUE 280				
	GE HEALTHCARE	0.35MG/ML;140.1MG/ML;461.8MG/ML	N017506 001	

CANDESARTAN CILEXETIL

TABLET;ORAL				
CANDESARTAN CILEXETIL				
	APOTEX INC	4MG	A202079 001	Jan 10, 2014
		8MG	A202079 002	Jan 10, 2014
		16MG	A202079 003	Jan 10, 2014
		32MG	A202079 004	Jan 10, 2014

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE				
	APOTEX INC	16MG;12.5MG	A202884 001	Dec 04, 2012
		32MG;12.5MG	A202884 002	Dec 04, 2012
		32MG;25MG	A202884 003	Jun 03, 2013

CANDICIDIN

OINTMENT;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	0.6MG/GM	A061596 001	
TABLET;VAGINAL				
VANOBID				
	SANOFI AVENTIS US	3MG	A061613 001	

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION				
CAPASTAT SULFATE				
+	AKORN	EQ 1GM BASE/VIAL	N050095 001	
CAPREOMYCIN SULFATE				
	HISUN PHARM HANGZHOU	EQ 1GM BASE/VIAL	A204796 001	Oct 18, 2018
	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A202634 001	Nov 27, 2017

CAPTOPRIL

TABLET;ORAL				
CAPOTEN				
+	STRIDES PHARMA	12.5MG **	N018343 005	Jan 17, 1985
+		25MG **	N018343 002	
+		37.5MG **	N018343 006	Sep 17, 1986
+		50MG **	N018343 001	
+		75MG **	N018343 007	Jun 13, 1995
+		100MG **	N018343 003	
+		150MG **	N018343 004	Jun 13, 1995
CAPTOPRIL				
	APOTHECON	12.5MG	A074472 001	Mar 31, 1995
		25MG	A074472 002	Mar 31, 1995
		50MG	A074472 003	Mar 31, 1995
		100MG	A074472 004	Mar 31, 1995
	CHARTWELL RX	12.5MG	A074363 001	Nov 09, 1995
		12.5MG	A074519 001	Feb 13, 1996
		25MG	A074363 002	Nov 09, 1995
		25MG	A074519 002	Feb 13, 1996
		50MG	A074363 003	Nov 09, 1995
		50MG	A074519 003	Feb 13, 1996
		100MG	A074363 004	Nov 09, 1995
		100MG	A074519 004	Feb 13, 1996
	COSETTE	12.5MG	A074433 001	Feb 13, 1996
		12.5MG	A074462 001	Feb 13, 1996
		12.5MG	A074483 001	Feb 13, 1996
		25MG	A074433 002	Feb 13, 1996
		25MG	A074462 002	Feb 13, 1996
		25MG	A074483 002	Feb 13, 1996
		50MG	A074433 003	Feb 13, 1996
		50MG	A074462 003	Feb 13, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	50MG	A074483	003	Feb 13, 1996
	100MG	A074433	004	Feb 13, 1996
	100MG	A074462	004	Feb 13, 1996
	100MG	A074483	004	Feb 13, 1996
DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996
	25MG	A074423	002	Feb 13, 1996
	50MG	A074423	003	Feb 13, 1996
	100MG	A074423	004	Feb 13, 1996
EGIS PHARMS	12.5MG	A074748	004	May 29, 1997
	25MG	A074748	002	May 29, 1997
	50MG	A074748	001	May 29, 1997
	100MG	A074748	003	May 29, 1997
G AND W LABS INC	12.5MG	A074590	004	Aug 30, 1996
	25MG	A074590	002	Aug 30, 1996
	50MG	A074590	001	Aug 30, 1996
	100MG	A074590	003	Aug 30, 1996
MYLAN	12.5MG	A074434	001	Feb 13, 1996
	25MG	A074434	002	Feb 13, 1996
	50MG	A074434	003	Feb 13, 1996
	100MG	A074434	004	Feb 13, 1996
OXFORD PHARMS	12.5MG	A074418	001	Feb 13, 1996
	25MG	A074418	002	Feb 13, 1996
	50MG	A074418	003	Feb 13, 1996
	100MG	A074418	004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640	001	Mar 31, 1997
	25MG	A074640	002	Mar 31, 1997
	50MG	A074640	003	Mar 31, 1997
	100MG	A074640	004	Mar 31, 1997
SANDOZ	12.5MG	A074481	001	Feb 13, 1996
	25MG	A074481	002	Feb 13, 1996
	50MG	A074481	003	Feb 13, 1996
	100MG	A074481	004	Feb 13, 1996
SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019
	25MG	A212223	002	Oct 30, 2019
	50MG	A212223	003	Oct 30, 2019
	100MG	A212223	004	Oct 30, 2019
STRIDES PHARMA	12.5MG	A074493	001	Feb 13, 1996
	25MG	A074493	002	Feb 13, 1996
	50MG	A074493	003	Feb 13, 1996
	100MG	A074493	004	Feb 13, 1996
TEVA	12.5MG	A074322	001	Feb 13, 1996
	25MG	A074322	002	Feb 13, 1996
	50MG	A074322	003	Feb 13, 1996
	100MG	A074322	004	Feb 13, 1996
WATSON LABS	12.5MG	A074386	001	May 23, 1996
	12.5MG	A074451	001	Feb 13, 1996
	12.5MG	A074576	001	Apr 23, 1996
	25MG	A074386	002	May 23, 1996
	25MG	A074451	002	Feb 13, 1996
	25MG	A074576	002	Apr 23, 1996
	50MG	A074386	003	May 23, 1996
	50MG	A074451	003	Feb 13, 1996
	50MG	A074576	003	Apr 23, 1996
	100MG	A074386	004	May 23, 1996
	100MG	A074451	004	Feb 13, 1996
	100MG	A074576	004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPOZIDE 25/15				
+ APOTHECON	25MG;15MG **	N018709	001	Oct 12, 1984
CAPOZIDE 25/25				
+ APOTHECON	25MG;25MG **	N018709	002	Oct 12, 1984
CAPOZIDE 50/15				
+ APOTHECON	50MG;15MG **	N018709	004	Oct 12, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPTOPRIL; HYDROCHLOROTHIAZIDE					
TABLET;ORAL					
CAPOZIDE 50/25					
+	APOTHECON	50MG;25MG **	N018709	003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE					
	COSETTE	25MG;15MG	A074827	001	Dec 29, 1997
		25MG;25MG	A074827	002	Dec 29, 1997
		50MG;15MG	A074827	004	Dec 29, 1997
		50MG;25MG	A074827	003	Dec 29, 1997
	IVAX SUB TEVA PHARMS	25MG;15MG	A075055	001	Jun 18, 1998
		25MG;25MG	A075055	002	Jun 18, 1998
		50MG;15MG	A075055	004	Jun 18, 1998
		50MG;25MG	A075055	003	Jun 18, 1998
	RISING PHARMA	25MG;15MG	A074896	001	Dec 29, 1997
		25MG;25MG	A074896	002	Dec 29, 1997
		50MG;15MG	A074896	004	Dec 29, 1997
		50MG;25MG	A074896	003	Dec 29, 1997
	STRIDES PHARMA	25MG;15MG	A074788	001	Dec 29, 1997
		25MG;25MG	A074788	002	Dec 29, 1997
		50MG;15MG	A074788	004	Dec 29, 1997
		50MG;25MG	A074788	003	Dec 29, 1997
	WATSON LABS	50MG;25MG	A074832	001	Dec 29, 1997
CARBACHOL					
SOLUTION;INTRAOCULAR					
CARBACHOL					
	PHARMAFAIR	0.01%	A070292	001	May 21, 1986
CARBASTAT					
	NOVARTIS	0.01%	A073677	001	Apr 28, 1995
CARBAMAZEPINE					
SOLUTION;INTRAVENOUS					
CARNEXIV					
+	LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030	001	Oct 07, 2016
SUSPENSION;ORAL					
CARBAMAZEPINE					
	TARO	100MG/5ML	A075875	001	Dec 21, 2000
TABLET;ORAL					
CARBAMAZEPINE					
	ACTAVIS ELIZABETH	200MG	A071696	001	Nov 09, 1987
	INWOOD LABS	200MG	A070231	001	Aug 14, 1986
	PLIVA	200MG	A071479	001	Jul 24, 1987
	USL PHARMA	200MG	A070300	001	May 15, 1986
	WARNER CHILCOTT	200MG	A070429	001	Jan 02, 1987
TERIL					
	TARO	200MG	A076525	001	Sep 26, 2003
TABLET, CHEWABLE;ORAL					
CARBAMAZEPINE					
	JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988
TEGRETOL					
+	NOVARTIS	100MG	N018281	001	
CARBENICILLIN DISODIUM					
INJECTABLE;INJECTION					
GEOPEN					
	ROERIG	EQ 1GM BASE/VIAL	N050306	001	
		EQ 2GM BASE/VIAL	N050306	004	
		EQ 5GM BASE/VIAL	N050306	002	
		EQ 10GM BASE/VIAL	N050306	006	
		EQ 30GM BASE/VIAL	N050306	007	
PYOPEN					
	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298	001	
		EQ 2GM BASE/VIAL	N050298	002	
		EQ 5GM BASE/VIAL	N050298	003	
		EQ 10GM BASE/VIAL	N050298	006	
		EQ 20GM BASE/VIAL	N050298	007	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBENICILLIN INDANYL SODIUM

TABLET;ORAL				
GEOCILLIN				
PFIZER	EQ 382MG BASE	N050435	001	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL				
CARBIDOPA, LEVODOPA AND ENTACAPONE				
MYLAN	12.5MG;200MG;50MG	A203424	001	Aug 13, 2020
	18.75MG;200MG;75MG	A203424	002	Aug 13, 2020
	25MG;200MG;100MG	A203424	003	Aug 13, 2020
	31.25MG;200MG;125MG	A203424	004	Aug 13, 2020
	37.5MG;200MG;150MG	A203424	005	Aug 13, 2020
	50MG;200MG;200MG	A203424	006	Aug 13, 2020
WOCKHARDT LTD	12.5MG;200MG;50MG	A090786	001	Nov 20, 2012
	18.75MG;200MG;75MG	A090833	001	Nov 20, 2012
	25MG;200MG;100MG	A090833	002	Nov 20, 2012
	31.25MG;200MG;125MG	A090833	003	Nov 20, 2012
	37.5MG;200MG;150MG	A090833	004	Nov 20, 2012
	50MG;200MG;200MG	A090833	005	Nov 20, 2012

CARBIDOPA; LEVODOPA

TABLET;ORAL				
CARBIDOPA AND LEVODOPA				
ANI PHARMS	10MG;100MG	A073587	002	Jun 29, 1995
	25MG;100MG	A073587	001	Jun 29, 1995
	25MG;250MG	A073587	003	Jun 29, 1995
SCS	10MG;100MG	A074080	001	Mar 25, 1994
	25MG;100MG	A074080	002	Mar 25, 1994
	25MG;250MG	A074080	003	Mar 25, 1994
WATSON LABS	10MG;100MG	A073381	001	Sep 28, 1993
	25MG;100MG	A073382	001	Sep 28, 1993
	25MG;250MG	A073383	001	Sep 28, 1993
TABLET, EXTENDED RELEASE;ORAL				
CARBIDOPA AND LEVODOPA				
KV PHARM	50MG;200MG	A076663	001	Jun 24, 2004
SINEMET CR				
+ ORGANON	25MG;100MG	N019856	002	Dec 24, 1992
+	50MG;200MG	N019856	001	May 30, 1991
TABLET, FOR SUSPENSION;ORAL				
CARBILEV				
RANBAXY	10MG;100MG	A076643	001	Jun 10, 2005
	25MG;100MG	A076643	002	Jun 10, 2005
	25MG;250MG	A076643	003	Jun 10, 2005
TABLET, ORALLY DISINTEGRATING;ORAL				
CARBIDOPA AND LEVODOPA				
IMPAX LABS	10MG;100MG	A090631	001	Jun 08, 2010
	25MG;100MG	A090631	002	Jun 08, 2010
	25MG;250MG	A090631	003	Jun 08, 2010
RISING PHARMA	10MG;100MG	A078893	001	Sep 18, 2008
	25MG;100MG	A078893	002	Sep 18, 2008
	25MG;250MG	A078893	003	Sep 18, 2008
PARCOPA				
UCB INC	10MG;100MG **	A076699	001	Aug 27, 2004
	25MG;100MG **	A076699	002	Aug 27, 2004
	25MG;250MG **	A076699	003	Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR;ORAL				
CLISTIN				
+ MCNEIL	4MG/5ML **	N008955	001	
SOLUTION;ORAL				
CARBINOXAMINE MALEATE				
CYPRESS PHARM	4MG/5ML	A090418	001	May 04, 2010
VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008
TABLET;ORAL				
CARBINOXAMINE MALEATE				
CYPRESS PHARM	4MG	A090417	001	Aug 23, 2010
STRIDES PHARMA	4MG	A040639	002	May 30, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBINOXAMINE MALEATE

TABLET;ORAL

CLISTIN

+	ORTHO MCNEIL PHARM	4MG **	N008915	001	

CARBOPLATIN

INJECTABLE;INJECTION

CARBOPLATIN

	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006
		150MG/VIAL	A077383	002	Jan 27, 2006
		450MG/VIAL	A077383	003	Jan 27, 2006
	FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004
		150MG/VIAL	A076235	002	Oct 14, 2004
		450MG/VIAL	A076235	003	Oct 14, 2004
	HIKMA	50MG/VIAL	A076099	001	Oct 14, 2004
		150MG/VIAL	A076099	002	Oct 14, 2004
		450MG/VIAL	A076099	003	Oct 14, 2004
	HOSPIRA	50MG/VIAL	A076473	001	Oct 27, 2004
		150MG/VIAL	A076473	002	Oct 27, 2004
		450MG/VIAL	A076473	003	Oct 27, 2004
	MYLAN LABS LTD	50MG/VIAL	A091510	001	May 29, 2012
		150MG/VIAL	A091510	002	May 29, 2012
		450MG/VIAL	A091510	003	May 29, 2012
	PLIVA	50MG/VIAL	A076602	001	Nov 16, 2004
		150MG/VIAL	A076602	002	Nov 16, 2004
		450MG/VIAL	A076602	003	Nov 16, 2004
	SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005
		150MG/VIAL	A076959	002	Mar 18, 2005
		450MG/VIAL	A076959	003	Mar 18, 2005
	WATSON LABS TEVA	50MG/VIAL	A076162	001	Oct 14, 2004
		150MG/VIAL	A076162	002	Oct 14, 2004
		450MG/VIAL	A076162	003	Oct 14, 2004

PARAPLATIN

+	CORDEN PHARMA	50MG/VIAL **	N019880	001	Mar 03, 1989
+		150MG/VIAL **	N019880	002	Mar 03, 1989
+		450MG/VIAL **	N019880	003	Mar 03, 1989

INJECTABLE;INTRAVENOUS

CARBOPLATIN

	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012
		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012
		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012
		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012
	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006
		150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006
		450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006
		50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004
		50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006
		150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004
		150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006
	MEITHEAL	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005
		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005
		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005
		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013
	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007
		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007
		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007
	MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011
		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011
		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011
		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011
		1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011
	NOVAST LABS	450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017
		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017
	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009
		150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009
		450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009
	PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008
		150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008
		450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008
		600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARBOPLATIN

INJECTABLE;INTRAVENOUS					
CARBOPLATIN					
	TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
		150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
		450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007
	TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005
		150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005
		450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005
		600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005
PARAPLATIN					
+	CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452	001	Jul 14, 2003
+		150MG/15ML (10MG/ML) **	N020452	002	Jul 14, 2003
+		450MG/45ML (10MG/ML) **	N020452	003	Jul 14, 2003
+		600MG/60ML (10MG/ML) **	N020452	004	Jan 15, 2004

CARFILZOMIB

POWDER;INTRAVENOUS					
CARFILZOMIB					
	APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020
		60MG/VIAL	A209425	001	Mar 16, 2020
	BRECKENRIDGE	10MG/VIAL	A209330	001	Jun 11, 2021
		60MG/VIAL	A209330	002	Jun 11, 2021

CARISOPRODOL

CAPSULE;ORAL					
SOMA					
+	MYLAN SPECIALITY LP	250MG	N011792	003	
TABLET;ORAL					
CARISOPRODOL					
	ABLE	350MG	A040421	001	Jun 21, 2001
	EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000
	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996
	PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
	SANDOZ	350MG	A089566	001	Aug 30, 1988
	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015
		350MG	A205513	002	Nov 12, 2015
	SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007
	SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991
	WATSON LABS	350MG	A040152	001	Dec 03, 1996
		350MG	A085433	001	
	WATSON LABS TEVA	350MG	A086179	001	
RELA					
	SCHERING	350MG	N012155	001	

CARPHENAZINE MALEATE

CONCENTRATE;ORAL					
PROKETAZINE					
	WYETH AYERST	50MG/ML	N014173	001	
TABLET;ORAL					
PROKETAZINE					
	WYETH AYERST	12.5MG	N012768	001	
		25MG	N012768	002	
		50MG	N012768	004	

CARPROFEN

TABLET;ORAL					
RIMADYL					
	ROCHE	100MG	N018550	002	Dec 31, 1987
		150MG	N018550	003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
CARTEOLOL HYDROCHLORIDE					
	APOTEX INC	1%	A076097	001	Feb 06, 2002
	BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000
OCUPRESS					
+	NOVARTIS	1% **	N019972	001	May 23, 1990
TABLET;ORAL					
CARTROL					
	ABBVIE	2.5MG	N019204	001	Dec 28, 1988
		5MG	N019204	002	Dec 28, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CARTEOLOL HYDROCHLORIDE

TABLET;ORAL

CARTROL

	10MG	N019204	003	Dec 28, 1988

CARVEDILOL

TABLET;ORAL

CARVEDILOL

ACI	3.125MG	A078786	001	Dec 22, 2009
	6.25MG	A078786	002	Dec 22, 2009
	12.5MG	A078786	003	Dec 22, 2009
	25MG	A078786	004	Dec 22, 2009
HIKMA	3.125MG	A077887	001	Sep 07, 2007
	6.25MG	A077887	002	Sep 07, 2007
	12.5MG	A077887	003	Sep 07, 2007
	25MG	A077887	004	Sep 07, 2007
PLIVA HRVATSKA DOO	3.125MG	A078240	001	Oct 30, 2007
	6.25MG	A078240	002	Oct 30, 2007
	12.5MG	A078240	003	Oct 30, 2007
	25MG	A078240	004	Oct 30, 2007
SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007
	6.25MG	A077346	001	Sep 05, 2007
	12.5MG	A077346	002	Sep 05, 2007
	25MG	A077346	003	Sep 05, 2007

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018
	70MG/VIAL	A209489	002	Jul 12, 2018
MYLAN LABS LTD	50MG/VIAL	A207650	001	Sep 29, 2017
	70MG/VIAL	A207650	002	Sep 29, 2017

CEFACLOR

CAPSULE;ORAL

CECLOR

+ LILLY	EQ 250MG BASE **	N050521	001	
+	EQ 500MG BASE **	N050521	002	

CEFACLOR

CEPH INTL	EQ 250MG BASE	A062205	001	
	EQ 500MG BASE	A062205	002	
DAVA PHARMS INC	EQ 250MG BASE	A064107	001	Apr 27, 1995
	EQ 500MG BASE	A064107	002	Apr 27, 1995
HERITAGE PHARMA	EQ 250MG BASE	A064148	001	May 23, 1996
	EQ 500MG BASE	A064148	002	May 23, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A064061	001	Apr 27, 1995
	EQ 500MG BASE	A064061	002	Apr 27, 1995
RANBAXY	EQ 250MG BASE	A064156	001	Aug 28, 1997
	EQ 500MG BASE	A064156	002	Aug 28, 1997
TEVA	EQ 250MG BASE	A064081	001	Sep 16, 1996
	EQ 250MG BASE	A064145	001	Jun 24, 1996
	EQ 500MG BASE	A064081	002	Sep 16, 1996
	EQ 500MG BASE	A064145	002	Jun 24, 1996

FOR SUSPENSION;ORAL

CECLOR

+ LILLY	EQ 125MG BASE/5ML **	N050522	001	
+	EQ 250MG BASE/5ML **	N050522	002	

CEFACLOR

DAVA PHARMS INC	EQ 125MG BASE/5ML	A064114	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064115	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064116	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064110	001	Apr 28, 1995
FACTA FARMA	EQ 125MG BASE/5ML	A062206	001	
	EQ 187MG BASE/5ML	A062206	003	Apr 20, 1988
	EQ 250MG BASE/5ML	A062206	002	
	EQ 375MG BASE/5ML	A062206	004	Apr 20, 1988
IVAX SUB TEVA PHARMS	EQ 125MG BASE/5ML	A064087	001	Apr 28, 1995
	EQ 187MG BASE/5ML	A064086	001	Apr 28, 1995
	EQ 250MG BASE/5ML	A064085	001	Apr 28, 1995
	EQ 375MG BASE/5ML	A064070	001	Apr 28, 1995
RANBAXY	EQ 125MG BASE/5ML	A064166	001	Oct 02, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFACLOR

FOR SUSPENSION;ORAL				
CEFACLOR				
	EQ 187MG BASE/5ML		A064165 001	Oct 02, 1997
	EQ 250MG BASE/5ML		A064164 001	Oct 02, 1997
	EQ 375MG BASE/5ML		A064155 001	Oct 02, 1997
WATSON LABS INC	EQ 125MG BASE/5ML		A064204 001	Feb 18, 1998
	EQ 187MG BASE/5ML		A064205 001	Feb 18, 1998
	EQ 250MG BASE/5ML		A064206 001	Feb 18, 1998
	EQ 375MG BASE/5ML		A064207 001	Feb 18, 1998
TABLET, CHEWABLE;ORAL				
RANICLOR				
RANBAXY LABS LTD	EQ 125MG BASE		A065092 001	Dec 22, 2003
	EQ 187MG BASE		A065092 002	Dec 22, 2003
	EQ 250MG BASE		A065092 003	Dec 22, 2003
	EQ 375MG BASE		A065092 004	Dec 22, 2003
TABLET, EXTENDED RELEASE;ORAL				
CECLOR CD				
LILLY	EQ 375MG BASE **		N050673 001	Jun 28, 1996
	EQ 500MG BASE **		N050673 002	Jun 28, 1996
CEFACLOR				
WORLD GEN	EQ 500MG BASE		A065057 001	Jan 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL				
CEFADROXIL				
CSPC OUYI	EQ 500MG BASE		A205072 001	Jul 28, 2017
IVAX SUB TEVA PHARMS	EQ 500MG BASE		A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE		A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE		A065015 001	Jun 22, 1999
SANDOZ	EQ 500MG BASE		A062291 001	
TEVA	EQ 500MG BASE		A062695 001	Feb 10, 1989
DURICEF				
WARNER CHILCOTT	EQ 250MG BASE		N050512 002	
+	EQ 500MG BASE **		N050512 001	
ULTRACEF				
BRISTOL	EQ 500MG BASE		A062378 001	Mar 16, 1982
FOR SUSPENSION;ORAL				
CEFADROXIL				
ANI PHARMS	EQ 125MG BASE/5ML		A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML		A062698 002	Mar 01, 1989
	EQ 250MG BASE/5ML		A065278 001	Jan 20, 2006
	EQ 500MG BASE/5ML		A062698 003	Mar 01, 1989
	EQ 500MG BASE/5ML		A065278 002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML		A062334 001	
	EQ 250MG BASE/5ML		A062334 002	
	EQ 500MG BASE/5ML		A062334 003	
SUN PHARM INDS LTD	EQ 125MG BASE/5ML		A065115 001	Mar 26, 2003
	EQ 250MG BASE/5ML		A065115 002	Mar 26, 2003
	EQ 500MG BASE/5ML		A065115 003	Mar 26, 2003
DURICEF				
+ WARNER CHILCOTT	EQ 125MG BASE/5ML **		N050527 002	
+	EQ 250MG BASE/5ML **		N050527 003	
+	EQ 500MG BASE/5ML **		N050527 001	
ULTRACEF				
BRISTOL	EQ 125MG BASE/5ML		A062376 001	Mar 16, 1982
	EQ 250MG BASE/5ML		A062376 002	Mar 16, 1982
	EQ 500MG BASE/5ML		A062376 003	Mar 16, 1982
TABLET;ORAL				
CEFADROXIL				
RANBAXY	EQ 1GM BASE		A065018 001	Apr 23, 1999
DURICEF				
+ WARNER CHILCOTT	EQ 1GM BASE **		N050528 001	
ULTRACEF				
APOTHECON	EQ 1GM BASE		A062390 001	Jun 10, 1982
BRISTOL	EQ 1GM BASE		A062408 001	Aug 31, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFAMANDOLE NAFATE				
INJECTABLE;INJECTION				
MANDOL				
	LILLY	EQ 500MG BASE/VIAL	N050504 001	
		EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
		EQ 1GM BASE/VIAL	N050504 002	
		EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
		EQ 2GM BASE/VIAL	N050504 003	
		EQ 10GM BASE/VIAL	N050504 004	
CEFAZOLIN SODIUM				
INJECTABLE;INJECTION				
ANCEF				
+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461 001	
+		EQ 500MG BASE/VIAL	N050461 002	
+		EQ 1GM BASE/VIAL **	N050461 003	
+		EQ 5GM BASE/VIAL **	N050461 004	
+		EQ 10GM BASE/VIAL **	N050461 005	
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 004	Jun 08, 1983
ANCEF IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002 001	Mar 28, 1991
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566 002	Jun 08, 1983
CEFAZOLIN AND DEXTROSE				
	B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
CEFAZOLIN SODIUM				
	ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
		EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
		EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986
		EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987
	AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
		EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008
	BEDFORD	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
		EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
		EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
		EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988
		EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
	CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
		EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
		EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
		EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
	DR REDDYS	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
		EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
		EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
		EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
		EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
		EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
	FACTA FARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991
		EQ 1GM BASE/VIAL	A063207 001	Dec 27, 1991
		EQ 10GM BASE/VIAL	A063209 001	Dec 27, 1991
		EQ 20GM BASE/VIAL	A063209 002	Apr 30, 1999
	FRESENIUS KABI USA	EQ 500MG BASE/VIAL **	A064169 001	Aug 14, 1998
		EQ 1GM BASE/VIAL **	A064169 002	Aug 14, 1998
		EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
		EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
	GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
	HIKMA	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
		EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
		EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
		EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
		EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
		EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005
		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005
		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005
		EQ 1GM BASE/VIAL	A201654 001	Feb 03, 2016
		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFAZOLIN SODIUM

INJECTABLE;INJECTION				
CEFAZOLIN SODIUM				
STERI PHARMA	EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016	001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016	002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016	003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018	001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018	002	Mar 05, 1990
KEFZOL				
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773	001	
	EQ 500MG BASE/VIAL	A061773	002	
	EQ 1GM BASE/VIAL	A061773	003	
	EQ 10GM BASE/VIAL	A061773	004	
	EQ 20GM BASE/VIAL	A061773	005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557	002	Sep 10, 1985

CEFDINIR

CAPSULE;ORAL				
OMNICEF				
+ ABBVIE	300MG **	N050739	001	Dec 04, 1997
FOR SUSPENSION;ORAL				
OMNICEF				
+ ABBVIE	125MG/5ML **	N050749	001	Dec 04, 1997
+	250MG/5ML **	N050749	002	Jul 29, 2004

CEFDITOREN PIVOXIL

TABLET;ORAL				
SPECTRACEF				
VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001
	400MG	N021222	002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION				
CEFEPIME HYDROCHLORIDE				
ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020
	EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020
FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010
	EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010
	EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007
	EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007
	EQ 1GM BASE/VIAL	A202268	001	Jul 30, 2012
	EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007
	EQ 2GM BASE/VIAL	A202268	002	Jul 30, 2012

CEFIXIME

CAPSULE;ORAL				
SUPRAX				
+ LUPIN LTD	400MG **	N203195	001	Jun 01, 2012
FOR SUSPENSION;ORAL				
CEFIXIME				
SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017
	200MG/5ML	A206144	002	Nov 17, 2017
SUPRAX				
+ LEDERLE	100MG/5ML **	N050622	001	Apr 28, 1989
LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004
TABLET;ORAL				
SUPRAX				
+ LEDERLE	200MG **	N050621	001	Apr 28, 1989
+	400MG **	N050621	002	Apr 28, 1989
LUPIN PHARMS	400MG	A065130	001	Feb 12, 2004

CEFMENOXIME HYDROCHLORIDE

INJECTABLE;INJECTION				
CEFMAX				
TAP PHARM	EQ 500MG BASE/VIAL	N050571	001	Dec 30, 1987
	EQ 1GM BASE/VIAL	N050571	002	Dec 30, 1987
	EQ 2GM BASE/VIAL	N050571	003	Dec 30, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFMETAZOLE SODIUM				
INJECTABLE;INJECTION				
ZEFAZONE				
+ PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL **	N050637	001	Dec 11, 1989
+	EQ 2GM BASE/VIAL **	N050637	002	Dec 11, 1989
ZEFAZONE IN PLASTIC CONTAINER				
+ PHARMACIA AND UPJOHN	EQ 20MG BASE/ML **	N050683	001	Dec 29, 1992
+	EQ 40MG BASE/ML **	N050683	002	Dec 29, 1992
CEFONICID SODIUM				
INJECTABLE;INJECTION				
MONOCID				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	N050579	001	May 23, 1984
	EQ 1GM BASE/VIAL	A063295	001	Jul 26, 1993
	EQ 1GM BASE/VIAL	N050579	002	May 23, 1984
	EQ 2GM BASE/VIAL	N050579	003	May 23, 1984
	EQ 10GM BASE/VIAL	N050579	004	May 23, 1984
CEFOPERAZONE SODIUM				
INJECTABLE;INJECTION				
CEFOBID				
PFIZER	EQ 1GM BASE/VIAL	A063333	001	Mar 31, 1995
	EQ 1GM BASE/VIAL	N050551	001	Nov 18, 1982
	EQ 2GM BASE/VIAL	A063333	002	Mar 31, 1995
	EQ 2GM BASE/VIAL	N050551	002	Nov 18, 1982
	EQ 10GM BASE/VIAL	N050551	003	Mar 05, 1990
CEFOBID IN PLASTIC CONTAINER				
PFIZER	EQ 20MG BASE/ML	N050613	002	Jul 31, 1987
	EQ 40MG BASE/ML	N050613	001	Jul 23, 1986
CEFORANIDE				
INJECTABLE;INJECTION				
PRECEF				
APOTHECON	500MG/VIAL	A062579	001	Nov 26, 1984
	1GM/VIAL	A062579	002	Nov 26, 1984
	2GM/VIAL	A062579	003	Nov 26, 1984
	10GM/VIAL	A062579	004	Nov 26, 1984
	20GM/VIAL	A062579	005	Nov 26, 1984
BRISTOL	500MG/VIAL	N050554	001	May 24, 1984
	1GM/VIAL	N050554	002	May 24, 1984
	2GM/VIAL	N050554	003	May 24, 1984
	10GM/VIAL	N050554	004	May 24, 1984
	20GM/VIAL	N050554	005	May 24, 1984
CEFOTAXIME SODIUM				
INJECTABLE;INJECTION				
CEFOTAXIME				
FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A064200	001	Mar 24, 2000
	EQ 1GM BASE/VIAL	A064200	002	Mar 24, 2000
	EQ 2GM BASE/VIAL	A064200	003	Mar 24, 2000
	EQ 10GM BASE/VIAL	A064201	001	Mar 24, 2000
	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER				
B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CEFOTAXIME SODIUM				
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006
	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016
	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006
	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006
	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016
	EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFOTAXIME SODIUM					
INJECTABLE;INJECTION					
CEFOTAXIME SODIUM					
	LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003
		EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003
		EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003
	WOCKHARDT	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008
		EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008
CLAFORAN					
	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987
		EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987
+	VALIDUS PHARMS	EQ 500MG BASE/VIAL **	N050547	001	
+		EQ 1GM BASE/VIAL **	N050547	002	
+		EQ 2GM BASE/VIAL **	N050547	003	
+		EQ 10GM BASE/VIAL **	N050547	004	Dec 29, 1983
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985
		EQ 40MG BASE/ML	N050596	004	May 20, 1985
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985
		EQ 40MG BASE/ML	N050596	003	May 20, 1985
CEFOTETAN DISODIUM					
INJECTABLE;INJECTION					
CEFOTAN					
	TELIGENT	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
CEFOTAN IN PLASTIC CONTAINER					
	TELIGENT	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993
CEFOTETAN					
	FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007
	HIKMA	EQ 1GM BASE/VIAL	A091031	001	Oct 26, 2011
		EQ 2GM BASE/VIAL	A091031	002	Oct 26, 2011
	WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011
CEFOTIAM HYDROCHLORIDE					
INJECTABLE;INJECTION					
CERADON					
	TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988
CEFOXITIN SODIUM					
INJECTABLE;INJECTION					
CEFOXITIN					
	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011
		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011
		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011
	FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012	001	Jul 03, 2000
		EQ 2GM BASE/VIAL **	A065012	002	Jul 03, 2000
		EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006
		EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006
		EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006
MEFOXIN					
	MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
+		EQ 1GM BASE/VIAL **	N050517	001	
		EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
+		EQ 2GM BASE/VIAL **	N050517	002	
+		EQ 10GM BASE/VIAL **	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	003	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	004	Sep 20, 1984
MEFOXIN IN PLASTIC CONTAINER					
	MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
		EQ 40MG BASE/ML	A063182	002	Jan 25, 1993
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	MERCK	EQ 20MG BASE/ML **	N050581	002	Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	001	Sep 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE;INJECTION				
CEFPIRAMIDE SODIUM				
WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL				
BANAN				
SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992
CEFPODOXIME PROXETIL				
SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009
	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009
SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
	EQ 100MG BASE/5ML	A065082	002	May 31, 2002
VANTIN				
+ PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML **	N050675	001	Aug 07, 1992
+	EQ 100MG BASE/5ML **	N050675	002	Aug 07, 1992
TABLET;ORAL				
BANAN				
SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
	EQ 200MG BASE	N050687	002	Aug 07, 1992
CEFPODOXIME PROXETIL				
SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003
	EQ 200MG BASE	A065083	002	Aug 20, 2003
VANTIN				
+ PHARMACIA AND UPJOHN	EQ 100MG BASE **	N050674	001	Aug 07, 1992
+	EQ 200MG BASE **	N050674	002	Aug 07, 1992

CEFPROZIL

FOR SUSPENSION;ORAL				
CEFPROZIL				
RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006
	250MG/5ML	A065202	002	Jun 30, 2006
TEVA PHARMS	125MG/5ML	A065236	001	Dec 08, 2005
	250MG/5ML	A065236	002	Dec 08, 2005
CEFZIL				
+ CORDEN PHARMA	125MG/5ML **	N050665	001	Dec 23, 1991
+	250MG/5ML **	N050665	002	Dec 23, 1991
TABLET;ORAL				
CEFPROZIL				
RANBAXY LABS LTD	250MG	A065198	001	Dec 13, 2006
	500MG	A065198	002	Dec 13, 2006
WOCKHARDT	250MG	A065428	001	Jun 14, 2007
	500MG	A065428	002	Jun 14, 2007
CEFZIL				
+ CORDEN PHARMA	250MG **	N050664	001	Dec 23, 1991
+	500MG **	N050664	002	Dec 23, 1991

CEFTAZIDIME

INJECTABLE;INJECTION				
CEFTAZIDIME				
ACS DOBFAR	500MG/VIAL	A062640	001	Nov 20, 1985
AUROBINDO PHARMA LTD	500MG/VIAL	A065481	001	May 28, 2010
	1GM/VIAL	A065481	002	May 28, 2010
	2GM/VIAL	A065481	003	May 28, 2010
	6GM/VIAL	A065482	001	May 28, 2010
WOCKHARDT	1GM/VIAL	A065196	001	Oct 15, 2008
CEPTAZ				
GLAXOSMITHKLINE	500MG/VIAL	N050646	001	Sep 27, 1990
	1GM/VIAL	N050646	002	Sep 27, 1990
	2GM/VIAL	N050646	003	Sep 27, 1990
	10GM/VIAL	N050646	004	Sep 27, 1990
PENTACEF				
GLAXOSMITHKLINE	1GM/VIAL	A063322	001	Nov 07, 1995
	1GM/VIAL	A064006	001	Mar 31, 1992
	2GM/VIAL	A063322	002	Nov 07, 1995
	2GM/VIAL	A064006	002	Mar 31, 1992
	6GM/VIAL	A064008	001	Mar 31, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFTAZIDIME				
INJECTABLE;INJECTION				
PENTACEF				
	10GM/VIAL		A064008 002	Mar 31, 1992
TAZIDIME				
LILLY	1GM/VIAL		A062655 001	Nov 20, 1985
	2GM/VIAL		A062655 002	Nov 20, 1985
TAZIDIME IN PLASTIC CONTAINER				
LILLY	1GM/VIAL		A062739 001	Jul 10, 1986
	2GM/VIAL		A062739 002	Jul 10, 1986
CEFTAZIDIME SODIUM				
INJECTABLE;INJECTION				
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 10MG BASE/ML		A063221 001	Apr 29, 1993
	EQ 20MG BASE/ML		A063221 002	Apr 29, 1993
	EQ 40MG BASE/ML		A063221 003	Apr 29, 1993
FORTAZ IN PLASTIC CONTAINER				
TELIGENT	EQ 10MG BASE/ML		N050634 001	Apr 28, 1989
+	EQ 20MG BASE/ML		N050634 002	Apr 28, 1989
+	EQ 40MG BASE/ML		N050634 003	Apr 28, 1989
CEFTIBUTEN DIHYDRATE				
CAPSULE;ORAL				
CEDAX				
SI PHARMS	EQ 400MG BASE		N050685 002	Dec 20, 1995
FOR SUSPENSION;ORAL				
CEDAX				
+ SI PHARMS	EQ 90MG BASE/5ML **		N050686 001	Dec 20, 1995
+	EQ 180MG BASE/5ML **		N050686 002	Dec 20, 1995
CEFTIZOXIME SODIUM				
INJECTABLE;INJECTION				
CEFIZOX				
ASTELLAS	EQ 500MG BASE/VIAL		N050560 001	Sep 15, 1983
	EQ 1GM BASE/VIAL		A063294 002	Mar 31, 1994
	EQ 1GM BASE/VIAL		N050560 002	Sep 15, 1983
	EQ 2GM BASE/VIAL		A063294 003	Mar 31, 1994
	EQ 2GM BASE/VIAL		N050560 003	Sep 15, 1983
	EQ 10GM BASE/VIAL		N050560 005	Mar 19, 1993
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML		N050589 001	Oct 03, 1984
	EQ 40MG BASE/ML		N050589 002	Oct 03, 1984
CEFIZOX IN PLASTIC CONTAINER				
ASTELLAS	EQ 20MG BASE/ML		N050589 003	Apr 13, 1995
	EQ 40MG BASE/ML		N050589 004	Apr 13, 1995
CEFTRIAXONE SODIUM				
INJECTABLE;INJECTION				
CEFTRIAXONE				
AGILA SPECLTS	EQ 10GM BASE/VIAL		A091068 001	Jan 07, 2013
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL		A065504 001	Jul 31, 2008
BEDFORD	EQ 10GM BASE/VIAL		A065475 001	Aug 18, 2008
FACTA FARMA	EQ 10GM BASE/VIAL		A065269 001	Feb 28, 2007
FRESENIUS KABI USA	EQ 10GM BASE/VIAL		A065252 001	Feb 15, 2006
HOSPIRA INC	EQ 1GM BASE/VIAL		A065231 001	Aug 02, 2005
	EQ 1GM BASE/VIAL		A202563 001	Aug 20, 2012
	EQ 2GM BASE/VIAL		A065231 002	Aug 02, 2005
	EQ 2GM BASE/VIAL		A202563 002	Aug 20, 2012
	EQ 10GM BASE/VIAL		A065232 001	Aug 02, 2005
LUPIN	EQ 10GM BASE/VIAL		A065263 001	Sep 12, 2006
TEVA	EQ 10GM BASE/VIAL		A065274 001	May 01, 2006
ROCEPHIN				
HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL		A063239 001	Aug 13, 1993
	EQ 500MG BASE/VIAL		A062654 001	Apr 30, 1987
	EQ 500MG BASE/VIAL		A063239 002	Aug 13, 1993
	EQ 1GM BASE/VIAL		A062654 002	Apr 30, 1987
	EQ 1GM BASE/VIAL		A063239 003	Aug 13, 1993
	EQ 2GM BASE/VIAL		A062654 003	Apr 30, 1987
+	EQ 10GM BASE/VIAL **		N050585 005	Dec 21, 1984
ROCHE	EQ 250MG BASE/VIAL		A062510 001	Mar 12, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION					
ROCEPHIN					
		EQ 500MG BASE/VIAL	A062510	002	Mar 12, 1985
		EQ 1GM BASE/VIAL	A062510	003	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER					
+	HOFFMANN LA ROCHE	EQ 10MG BASE/ML **	N050624	001	Feb 11, 1987
+		EQ 20MG BASE/ML **	N050624	002	Feb 11, 1987
+		EQ 40MG BASE/ML **	N050624	003	Feb 11, 1987
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
CEFTRIAXONE					
	AUROBINDO PHARMA LTD	EQ 250MG BASE/VIAL	A065505	001	Jul 31, 2008
		EQ 500MG BASE/VIAL	A065505	002	Jul 31, 2008
		EQ 1GM BASE/VIAL	A065505	003	Jul 31, 2008
		EQ 2GM BASE/VIAL	A065505	004	Jul 31, 2008
	BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008
		EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008
		EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008
		EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008
	CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294	001	Mar 26, 2007
		EQ 500MG BASE/VIAL	A065294	002	Mar 26, 2007
		EQ 1GM BASE/VIAL	A065294	003	Mar 26, 2007
		EQ 2GM BASE/VIAL	A065294	004	Mar 26, 2007
	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007
		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
		EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
		EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
		EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005
		EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005
		EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005
		EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005
	TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
		EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
	TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
		EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007
ROCEPHIN					
+	HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL **	N050585	001	Dec 21, 1984
+		EQ 500MG BASE/VIAL **	N050585	002	Dec 21, 1984
+		EQ 1GM BASE/VIAL **	N050585	003	Dec 21, 1984
+		EQ 2GM BASE/VIAL **	N050585	004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE;INJECTION					
ROCEPHIN KIT					
	HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585	007	May 08, 1996
		EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL					
CEFTIN					
+	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997
CEFUROXIME AXETIL					
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008
		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008
TABLET;ORAL					
CEFTIN					
+	GLAXOSMITHKLINE	EQ 125MG BASE **	N050605	001	Dec 28, 1987
+		EQ 250MG BASE **	N050605	002	Dec 28, 1987
+		EQ 500MG BASE **	N050605	003	Dec 28, 1987
CEFUROXIME AXETIL					
	ANI PHARMS	EQ 250MG BASE	A065190	001	Oct 18, 2004
		EQ 500MG BASE	A065190	002	Oct 18, 2004
	FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003
		EQ 500MG BASE	A065126	002	Oct 28, 2003
	RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEFUROXIME AXETIL

TABLET;ORAL

CEFUROXIME AXETIL

	EQ 250MG BASE	A065043	002	Feb 15, 2002
	EQ 500MG BASE	A065043	001	Feb 15, 2002
SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003
	EQ 250MG BASE	A065118	002	Apr 25, 2003
	EQ 500MG BASE	A065118	003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008
	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008
	EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986

ZINACEF IN PLASTIC CONTAINER

TELIGENT	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001	001	May 30, 2001
HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986

INJECTABLE;INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986

CELECOXIB

CAPSULE;ORAL

CELECOXIB

ACIC PHARMS	200MG	A212925	001	Dec 09, 2020
	400MG	A212925	002	Dec 09, 2020
JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017
	100MG	A207061	002	Apr 04, 2017
	200MG	A207061	003	Apr 04, 2017
	400MG	A207061	004	Apr 04, 2017

CELLULOSE SODIUM PHOSPHATE

POWDER;ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHALEXIN

CAPSULE;ORAL				
CEPHALEXIN				
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118	001	
	EQ 500MG BASE	A062118	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
	EQ 500MG BASE	A062869	001	Mar 17, 1988
SUN PHARM INDS (IN)	EQ 250MG BASE	A062791	001	Jun 11, 1987
	EQ 500MG BASE	A062791	002	Jun 11, 1987
SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999
	EQ 500MG BASE	A065007	002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760	001	Apr 24, 1987
	EQ 250MG BASE	A062821	001	Feb 05, 1988
	EQ 500MG BASE	A062761	001	Apr 24, 1987
	EQ 500MG BASE	A062823	001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872	001	Jun 20, 1988
	EQ 500MG BASE	A062871	001	Jul 05, 1988
KEFLEX				
+ PRAGMA	EQ 250MG BASE	N050405	002	
+	EQ 333MG BASE **	N050405	004	May 12, 2006
+	EQ 500MG BASE	N050405	003	
+	EQ 750MG BASE	N050405	005	May 12, 2006
FOR SUSPENSION;ORAL				
CEPHALEXIN				
APOTHECON	EQ 125MG BASE/5ML	A062986	001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987	001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778	001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777	001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML **	A062117	001	
	EQ 125MG BASE/5ML **	A062117	002	
	EQ 250MG BASE/5ML **	A062117	003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767	001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873	001	May 23, 1988
	EQ 250MG BASE/5ML	A062768	001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867	001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779	001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781	001	Dec 22, 1987
KEFLEX				
+ PRAGMA	EQ 100MG BASE/ML **	N050406	003	
+	EQ 125MG BASE/5ML **	N050406	001	
+	EQ 250MG BASE/5ML **	N050406	002	
TABLET;ORAL				
CEPHALEXIN				
BARR	EQ 250MG BASE	A062826	001	Aug 17, 1987
	EQ 500MG BASE	A062827	001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863	001	Aug 11, 1988
	EQ 500MG BASE	A062863	002	Aug 11, 1988
	EQ 1GM BASE	A062863	003	Aug 11, 1988
KEFLET				
LILLY	EQ 250MG BASE	A062745	001	Dec 01, 1986
	EQ 250MG BASE	N050440	003	Feb 26, 1987
	EQ 500MG BASE	A062745	002	Dec 01, 1986
	EQ 500MG BASE	N050440	001	
	EQ 1GM BASE	N050440	002	
TABLET, FOR SUSPENSION;ORAL				
PANIXINE DISPERDOSE				
RANBAXY LABS LTD	EQ 125MG BASE	A065100	002	Sep 11, 2003
	EQ 250MG BASE	A065100	001	Sep 11, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL				
KEFTAB				
LILLY	EQ 250MG BASE	N050614	001	Oct 29, 1987
	EQ 333MG BASE	N050614	003	May 16, 1988
	EQ 500MG BASE	N050614	002	Oct 29, 1987

CEPHALOGLYCIN

CAPSULE;ORAL				
KAFOCIN				
LILLY	250MG	N050219	001	

CEPHALOTHIN SODIUM

INJECTABLE;INJECTION				
CEPHALOTHIN				
INTL MEDICATION	EQ 500MG BASE/VIAL	A062426	001	May 03, 1985
	EQ 1GM BASE/VIAL	A062426	002	May 03, 1985
	EQ 2GM BASE/VIAL	A062426	003	May 03, 1985
	EQ 4GM BASE/VIAL	A062426	004	May 03, 1985
CEPHALOTHIN SODIUM				
ABBOTT	EQ 1GM BASE/VIAL	A062547	001	Sep 11, 1985
	EQ 1GM BASE/VIAL	A062548	001	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062547	002	Sep 11, 1985
	EQ 2GM BASE/VIAL	A062548	002	Sep 11, 1985
ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062666	002	Jun 10, 1987
	EQ 2GM BASE/VIAL	A062666	001	Jun 10, 1987
BRISTOL	EQ 1GM BASE/VIAL	A062464	001	May 07, 1984
	EQ 2GM BASE/VIAL	A062464	002	May 07, 1984
	EQ 4GM BASE/VIAL	A062464	003	May 07, 1984
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	003	Jan 31, 1984
	EQ 20MG BASE/ML	A062422	005	Jul 16, 1991
	EQ 20MG BASE/ML	A062730	001	Mar 05, 1987
	EQ 40MG BASE/ML	A062422	004	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	006	Jul 16, 1991
	EQ 40MG BASE/ML	A062730	002	Mar 05, 1987
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	EQ 20MG BASE/ML	A062422	001	Jan 31, 1984
	EQ 40MG BASE/ML	A062422	002	Jan 31, 1984
KEFLIN				
LILLY	EQ 1GM BASE/VIAL	N050482	001	
	EQ 2GM BASE/VIAL	N050482	002	
	EQ 4GM BASE/VIAL	N050482	003	
	EQ 20GM BASE/VIAL	N050482	007	
KEFLIN IN PLASTIC CONTAINER				
LILLY	EQ 1GM BASE/VIAL	A062549	001	Sep 10, 1985
	EQ 2GM BASE/VIAL	A062549	002	Sep 10, 1985
SEFFIN				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A062435	001	Nov 15, 1983
	EQ 2GM BASE/VIAL	A062435	002	Nov 15, 1983
	EQ 10GM BASE/VIAL	A062435	003	Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE;INJECTION				
CEFADYL				
APOTHECON	EQ 500MG BASE/VIAL	A062961	001	Sep 20, 1988
	EQ 500MG BASE/VIAL	N050446	005	
	EQ 1GM BASE/VIAL	A061769	001	
	EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
	EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
	EQ 1GM BASE/VIAL	N050446	001	
	EQ 2GM BASE/VIAL	A061769	002	
	EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
	EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
	EQ 2GM BASE/VIAL	N050446	002	
	EQ 4GM BASE/VIAL	A061769	003	
	EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
	EQ 4GM BASE/VIAL	N050446	003	
	EQ 20GM BASE/VIAL	N050446	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CEPHAPIRIN SODIUM

INJECTABLE;INJECTION				
CEPHAPIRIN SODIUM				
ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
	EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
	EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
HIKMA	EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987
	EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
	EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
	EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987

CEPHRADINE

CAPSULE;ORAL				
ANSPOR				
GLAXOSMITHKLINE	250MG	A061859	001	
	500MG	A061859	002	
CEPHRADINE				
BARR	250MG	A062850	001	Apr 22, 1988
	500MG	A062851	001	Apr 22, 1988
IVAX SUB TEVA PHARMS	250MG	A062762	001	Mar 06, 1987
	500MG	A062762	002	Mar 06, 1987
TEVA	250MG	A062683	001	Jan 09, 1987
	500MG	A062683	002	Jan 09, 1987
VITARINE	250MG	A062813	001	Feb 25, 1988
	500MG	A062813	002	Feb 25, 1988
VELOSEF				
APOTHECON	250MG	A061764	001	
	500MG	A061764	002	
VELOSEF '250'				
ERSANA	250MG	N050548	001	
VELOSEF '500'				
ERSANA	500MG	N050548	002	
FOR SUSPENSION;ORAL				
ANSPOR				
GLAXOSMITHKLINE	125MG/5ML	A061866	001	
	250MG/5ML	A061866	002	
CEPHRADINE				
BARR	125MG/5ML	A062858	001	May 19, 1988
	250MG/5ML	A062859	001	May 19, 1988
TEVA	125MG/5ML	A062693	001	Jan 09, 1987
	250MG/5ML	A062693	002	Jan 09, 1987
VELOSEF '125'				
APOTHECON	125MG/5ML	A061763	001	
VELOSEF '250'				
APOTHECON	250MG/5ML	A061763	002	
INJECTABLE;INJECTION				
VELOSEF				
APOTHECON	250MG/VIAL	A061976	001	
	500MG/VIAL	A061976	002	
	1GM/VIAL	A061976	004	
	2GM/VIAL	A061976	003	
	4GM/VIAL	A061976	005	
TABLET;ORAL				
VELOSEF				
BRISTOL MYERS SQUIBB	1GM	N050530	001	

CERITINIB

CAPSULE;ORAL				
ZYKADIA				
+ NOVARTIS	150MG	N205755	001	Apr 29, 2014

CERIVASTATIN SODIUM

TABLET;ORAL				
BAYCOL				
BAYER PHARMS	0.05MG	N020740	001	Jun 26, 1997
	0.1MG	N020740	002	Jun 26, 1997
	0.2MG	N020740	003	Jun 26, 1997
	0.3MG	N020740	004	Jun 26, 1997
	0.4MG	N020740	005	May 24, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CERIVASTATIN SODIUM

TABLET;ORAL

BAYCOL

	0.8MG	N020740	006	Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE;INJECTION

TYMTRAN

PHARMACIA AND UPJOHN	0.02MG/ML	N018296	001	

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	5MG/5ML	A078617	001	Feb 02, 2010
AUROBINDO PHARMA LTD	5MG/5ML	A090751	001	Dec 16, 2009
LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009
PHARM ASSOC	5MG/5ML	A078412	001	Jun 18, 2008
RANBAXY LABS LTD	5MG/5ML	A077472	001	Jun 18, 2008
TORRENT	5MG/5ML	A078870	001	Apr 27, 2009
WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	002	May 09, 2008
CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008
PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008
TORRENT	5MG/5ML	A090474	002	Mar 30, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC	5MG/5ML	A090378	001	May 09, 2008
CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008
PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008
RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008
TORRENT	5MG/5ML	A090474	001	Mar 30, 2009

ZYRTEC

J AND J CONSUMER INC	5MG/5ML **	N020346	001	Sep 27, 1996

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CIPLA LTD	5MG	A077318	001	Jul 25, 2013
	10MG	A077318	002	Jul 25, 2013
HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007
	10MG	A078615	004	Dec 28, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

ZYRTEC ALLERGY

+ J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007

ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC	5MG	A077631	004	Jan 11, 2008
	10MG	A077631	003	Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC	5MG	A077631	001	Jan 11, 2008
	10MG	A077631	002	Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC	2.5MG	N021621	007	Nov 30, 2020
+	5MG **	N021621	003	Nov 16, 2007
+	10MG **	N021621	004	Nov 16, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CETIRIZINE HYDROCHLORIDE					
TABLET, CHEWABLE;ORAL					
CHILDREN'S ZYRTEC HIVES RELIEF					
+	J AND J CONSUMER INC	5MG **	N021621	005	Nov 16, 2007
+		10MG **	N021621	006	Nov 16, 2007
CETRORELIX					
INJECTABLE;INJECTION					
CETROTIDE					
	EMD SERONO INC	EQ 3MG BASE/ML	N021197	002	Aug 11, 2000
CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL					
FOR SUSPENSION;INTRATRACHEAL					
EXOSURF NEONATAL					
	GLAXOSMITHKLINE	12MG/VIAL;108MG/VIAL;8MG/VIAL	N020044	001	Aug 02, 1990
CEVIMELINE HYDROCHLORIDE					
CAPSULE;ORAL					
CEVIMELINE HYDROCHLORIDE					
	APOTEX INC	30MG	A091260	001	Aug 25, 2011
CHENODIOL					
TABLET;ORAL					
CHENIX					
+	LEADIANT BIOSCI INC	250MG **	N018513	002	Jul 28, 1983
CHLOPHEDIANOL HYDROCHLORIDE					
SYRUP;ORAL					
ULO					
	3M	25MG/5ML	N012126	001	
CHLORAMPHENICOL					
CREAM;TOPICAL					
CHLOROMYCETIN					
	PARKE DAVIS	1%	N050183	001	
FOR SOLUTION;OPHTHALMIC					
CHLOROMYCETIN					
	PARKEDALE	25MG/VIAL	N050143	001	
INJECTABLE;INJECTION					
CHLOROMYCETIN					
	PARKE DAVIS	250MG/ML	N050153	001	
OINTMENT;OPHTHALMIC					
CHLORAMPHENICOL					
	ALTANA	1%	A060133	001	
CHLOROFAIR					
	PHARMAFAIR	1%	A062439	001	Apr 21, 1983
CHLOROMYCETIN					
	PARKEDALE	1%	N050156	001	
CHLOROPTIC S.O.P.					
	ALLERGAN	1%	A061187	001	
ECONOCHLOR					
	ALCON	1%	A061648	001	
SOLUTION/DROPS;OPHTHALMIC					
CHLORAMPHENICOL					
	AKORN	0.5%	A062042	001	
	ALCON	0.5%	A062628	001	Sep 25, 1985
CHLOROFAIR					
	PHARMAFAIR	0.5%	A062437	001	Apr 14, 1983
CHLOROPTIC					
	ALLERGAN	0.5%	N050091	001	
ECONOCHLOR					
	ALCON	0.5%	A061645	001	
OPHTHOCHLOR					
	PARKEDALE	0.5%	A061220	001	
OPTOMYCIN					
	OPTOPICS	0.5%	A062171	001	Mar 31, 1982
SOLUTION/DROPS;OTIC					
CHLOROMYCETIN					
	PARKEDALE	0.5%	N050205	001	

CHLORAMPHENICOL SODIUM SUCCINATE				
INJECTABLE;INJECTION				
CHLORAMPHENICOL				
ELKINS SINN	EQ 1GM BASE/VIAL		A062406 001	Nov 09, 1982
CHLORAMPHENICOL SODIUM SUCCINATE				
GRUPPO LEPETIT	EQ 1GM BASE/VIAL		A062278 001	
CHLOROMYCETIN				
+ PARKEDALE	EQ 1GM BASE/VIAL		N050155 001	
MYCHEL-S				
ANGUS	EQ 1GM BASE/VIAL		A060132 001	
CHLORAMPHENICOL; HYDROCORTISONE ACETATE				
FOR SUSPENSION;OPHTHALMIC				
CHLOROMYCETIN HYDROCORTISONE				
PARKEDALE	12.5MG/VIAL;25MG/VIAL		N050202 001	
CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
OPHTHOCORT				
PARKEDALE	10MG/GM;5MG/GM;10,000 UNITS/GM		N050201 002	
CHLORAMPHENICOL; POLYMYXIN B SULFATE				
OINTMENT;OPHTHALMIC				
CHLOROMYXIN				
PARKE DAVIS	1%;10,000 UNITS/GM		N050203 002	
CHLORAMPHENICOL; PREDNISOLONE				
OINTMENT;OPHTHALMIC				
CHLOROPTIC-P S.O.P.				
ALLERGAN	1%;0.5%		A061188 001	
CHLORDIAZEPOXIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
LIBRELEASE				
VALEANT PHARM INTL	30MG		N017813 001	Sep 12, 1983
TABLET;ORAL				
LIBRITABS				
VALEANT PHARM INTL	5MG		A085482 001	
	10MG		A085481 001	
	25MG		A085488 001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
CAPSULE;ORAL				
A-POXIDE				
ABBOTT	5MG		A085447 001	
	5MG		A085517 001	
	10MG		A085447 002	
	10MG		A085518 001	
	25MG		A085447 003	
	25MG		A085513 001	
CHLORDIAZACHEL				
RACHELLE	5MG		A085086 001	
	10MG		A084639 001	
	25MG		A085087 001	
CHLORDIAZEPOXIDE HYDROCHLORIDE				
ASCOT	5MG		A087525 001	Jan 07, 1982
	10MG		A087524 001	Jan 07, 1982
	25MG		A087512 001	Jan 07, 1982
CHARTWELL RX	5MG		A084678 001	
	10MG		A084041 001	
	25MG		A084679 002	
FERRANTE	5MG		A085118 001	
	10MG		A085119 001	
	25MG		A085120 001	
HALSEY	5MG		A085340 001	
	10MG		A085339 001	
	25MG		A084685 001	
IMPAX LABS	5MG		A086213 001	
	10MG		A085113 001	
	25MG		A086212 001	
IVAX SUB TEVA PHARMS	5MG		A083741 001	
	10MG		A083742 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	25MG	A083570 001		
LEDERLE	5MG	A086892 001		
	5MG	A087234 001		
	10MG	A086876 001		
	10MG	A087037 001		
	25MG	A086893 001		
	25MG	A087231 001		
MAST MM	10MG	A086217 001		
MYLAN	5MG	A084886 001		
	10MG	A084601 001		
	25MG	A084887 001		
PARKE DAVIS	5MG	A085163 001		
	10MG	A084598 001		
	25MG	A085164 001		
PIONEER PHARMS	10MG	A089533 001	Jul 15, 1988	
	25MG	A089558 001	Jul 15, 1988	
PUREPAC PHARM	5MG	A085155 001		
	10MG	A084939 002		
	25MG	A085144 001		
ROXANE	5MG	A084706 001		
	10MG	A084700 001		
	25MG	A084705 001		
SUPERPHARM	5MG	A088987 001	Apr 25, 1985	
	10MG	A088986 001	Apr 25, 1985	
	25MG	A088988 001	Apr 25, 1985	
TEVA	5MG	A088705 001	Jan 18, 1985	
	10MG	A088706 001	Jan 18, 1985	
	25MG	A086494 001		
	25MG	A088707 001	Jan 18, 1985	
UPSHER SMITH LABS	5MG	A084919 001		
+	10MG	A084920 001		
	25MG	A084823 001		
USL PHARMA	5MG	A084644 001		
	10MG	A084623 001		
	25MG	A084645 001		
VANGARD	5MG	A088129 001	Mar 28, 1983	
	10MG	A088010 001	Mar 28, 1983	
	25MG	A088130 001	Mar 28, 1983	
WATSON LABS	5MG	A086383 001		
	10MG	A086294 001		
	25MG	A086382 001		
WEST WARD	5MG	A085014 001		
	10MG	A085000 001		
	25MG	A085294 001		

LIBRIUM

+ VALEANT PHARM INTL	5MG **	N012249 002		
+	10MG **	N012249 001		
+	25MG **	N012249 003		

LYGEN

ALRA	5MG	A085107 001		
	10MG	A085009 001		
	25MG	A085108 001		

INJECTABLE;INJECTION

LIBRIUM

BAUSCH	100MG/AMP	N012301 001		

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET;ORAL

MENRIUM 10-4

ROCHE	10MG;0.4MG	N014740 006		

MENRIUM 5-2

ROCHE	5MG;0.2MG	N014740 002		

MENRIUM 5-4

ROCHE	5MG;0.4MG	N014740 004		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORHEXIDINE GLUCONATE				
SOLUTION;TOPICAL				
BRIAN CARE				
SOAPCO	4%	A071419	001	Dec 17, 1987
EXIDINE				
XTTRIUM	2.5%	N019421	001	Dec 17, 1985
MICRODERM				
J AND J	4%	A072255	001	Apr 15, 1991
PREVACARE R				
J AND J	0.5%	A072292	001	Jan 28, 1992
STERI-STAT				
MATRIX MEDCL	4%	A070104	001	Jul 24, 1986
SPONGE;TOPICAL				
CHLORHEXIDINE GLUCONATE				
KENDALL IL	4%	N019490	001	Mar 27, 1987
E-Z SCRUB				
BECTON DICKINSON	4%	A073416	001	Mar 14, 2000
HIBICLENS				
+ MOLNLYCKE HLTH	4% **	N018423	001	
MICRODERM				
J AND J	4%	A072295	001	Feb 28, 1991
PHARMASEAL SCRUB CARE				
CAREFUSION 2200	4%	N019793	001	Dec 02, 1988
CHLORMERODRIN HG-197				
INJECTABLE;INJECTION				
CHLORMERODRIN HG 197				
BRACCO	0.6-1.4mCi/ML	N017269	001	
CHLORMEZANONE				
TABLET;ORAL				
TRANCOPAL				
SANOFI AVENTIS US	100MG	N011467	003	
	200MG	N011467	005	
CHLOROPROCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CHLOROPROCAINE HYDROCHLORIDE				
HOSPIRA	2%	A087447	001	Apr 16, 1982
	3%	A087446	001	Apr 16, 1982
NESACAINE-MPF				
FRESENIUS KABI USA	2%	N009435	003	
	3%	N009435	004	
CHLOROQUINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARALEN HYDROCHLORIDE				
SANOFI AVENTIS US	EQ 40MG BASE/ML	N006002	002	
CHLOROQUINE PHOSPHATE				
TABLET;ORAL				
ARALEN				
+ SANOFI AVENTIS US	500MG **	N006002	001	
CHLOROQUINE PHOSPHATE				
HIKMA PHARMS	250MG	A083082	001	
	500MG	A083082	002	Sep 17, 1999
IMPAX LABS	250MG	A080880	001	
	500MG	A040516	001	Aug 29, 2003
MD PHARM	250MG	A087228	001	
PUREPAC PHARM	250MG	A080886	001	
TEVA	250MG	A087504	001	Jan 13, 1982
WATSON LABS	250MG	A087979	001	Dec 21, 1982
	500MG	A088030	001	Dec 21, 1982
CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE				
TABLET;ORAL				
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE				
SANOFI AVENTIS US	EQ 300MG BASE;EQ 45MG BASE	N014860	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLOROTHIAZIDE

TABLET;ORAL				
CHLOROTHIAZIDE				
ABC HOLDING	250MG	A085569	001	
HIKMA INTL PHARMS	250MG	A086028	001	Jul 14, 1982
	500MG	A087736	001	Jul 14, 1982
LEDERLE	250MG	A086940	001	
	500MG	A086938	001	
MYLAN	250MG	A084217	002	
	500MG	A084217	001	
SANDOZ	250MG	A085485	001	
WATSON LABS	250MG	A085165	001	
	250MG	A085173	001	
	250MG	A086795	001	Aug 15, 1983
	500MG	A084026	001	Sep 01, 1982
	500MG	A086796	001	Aug 15, 1983
DIURIL				
+ AKORN	250MG **	N011145	004	
+	500MG **	N011145	002	

CHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL				
ALDOCLOR-150				
MERCK	150MG;250MG	N016016	001	
ALDOCLOR-250				
MERCK	250MG;250MG	N016016	002	
METHYLDOPA AND CHLOROTHIAZIDE				
PAR PHARM	150MG;250MG	A070783	001	Nov 06, 1987
	250MG;250MG	A070654	001	Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
CHLOROTHIAZIDE AND RESERPINE				
HIKMA	250MG;0.125MG	A088557	001	Dec 22, 1983
	500MG;0.125MG	A088365	001	Dec 22, 1983
CHLOROTHIAZIDE W/ RESERPINE				
WATSON LABS	250MG;0.125MG	A084853	001	
	500MG;0.125MG	A088151	001	Jun 09, 1983
CHLOROTHIAZIDE-RESERPINE				
MYLAN	250MG;0.125MG	A087744	001	May 06, 1982
	500MG;0.125MG	A087745	001	May 06, 1982
DIUPRES-250				
MERCK	250MG;0.125MG	N011635	003	Aug 26, 1987
DIUPRES-500				
MERCK	500MG;0.125MG	N011635	006	Aug 26, 1987

CHLOROTRIANISENE

CAPSULE;ORAL				
CHLOROTRIANISENE				
BANNER PHARMACAPS	12MG	A084652	001	
TACE				
SANOFI AVENTIS US	12MG	N008102	004	
	25MG	N011444	001	
	72MG	N016235	001	

CHLOROXINE

SHAMPOO;TOPICAL				
CAPITROL				
WESTWOOD SQUIBB	2%	N017594	001	

CHLORPHENESIN CARBAMATE

TABLET;ORAL				
MAOLATE				
PAMLAB LLC	400MG	N014217	002	

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL				
CHLORPHENIRAMINE MALEATE				
AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988
TELDRIN				
GLAXOSMITHKLINE	8MG	N017369	001	
	12MG	N017369	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPHENIRAMINE MALEATE

INJECTABLE;INJECTION				
CHLOR-TRIMETON				
	SCHERING PLOUGH	10MG/ML	N008826 001	
		100MG/ML	N008794 001	
CHLORPHENIRAMINE MALEATE				
	BEL MAR	10MG/ML	A080821 001	
	ELKINS SINN	10MG/ML	A080797 001	
	WATSON LABS	10MG/ML	A083593 001	
		10MG/ML	A086096 001	
		100MG/ML	A086095 001	
PYRIDAMAL 100				
	BEL MAR	100MG/ML	A083733 001	
SYRUP;ORAL				
CHLOR-TRIMETON				
	SCHERING	2MG/5ML	N006921 006	
CHLORPHENIRAMINE MALEATE				
	PHARM ASSOC	2MG/5ML	A087520 001	Feb 10, 1982
TABLET;ORAL				
ANTAGONATE				
	BAYER PHARMS	4MG	A083381 001	
CHLOR-TRIMETON				
	SCHERING	4MG	N006921 002	
CHLORPHENIRAMINE MALEATE				
	ANABOLIC	4MG	A083078 001	
	AUROLIFE PHARMA LLC	4MG	A080961 001	
	BELL PHARMA	4MG	A083062 001	
	ELKINS SINN	4MG	A080938 001	
	IMPAX LABS	4MG	A080809 001	
	IVAX SUB TEVA PHARMS	4MG	A080779 001	
	KV PHARM	4MG	A087164 001	
	LEDERLE	4MG	A086941 001	
	NEWTRON PHARMS	4MG	A086519 001	
	PANRAY	4MG	A083243 001	
	PHARMAVITE	4MG	A085104 001	
	PHARMERAL	4MG	A083753 001	
	PIONEER PHARMS	4MG	A088556 001	Jul 13, 1984
	PUREPAC PHARM	4MG	A086306 001	
	PVT FORM	4MG	A080786 001	
	ROXANE	4MG	A080626 001	
	SUN PHARM INDUSTRIES	4MG	A080700 001	
	VITARINE	4MG	A085837 001	
	WATSON LABS	4MG	A080696 001	
		4MG	A080791 001	
		4MG	A085139 001	
	WEST WARD	4MG	A083787 001	
KLOROMIN				
	HALSEY	4MG	A083629 001	
PHENETRON				
	LANNETT	4MG	A080846 001	
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+	BAYER HEALTHCARE LLC	8MG **	N007638 001	
+		12MG **	N007638 002	
EFIDAC 24 CHLORPHENIRAMINE MALEATE				
	ALZA	16MG	N019746 002	Nov 18, 1994

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL				
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE				
	ACELLA	4MG/5ML;5MG/5ML	A206891 001	Jun 09, 2017
	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438 001	Jan 27, 2015
VITUZ				
+	PERSION	4MG/5ML;5MG/5ML	N204307 001	Feb 20, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL					
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015
	TORRENT	4MG/5ML;5MG/5ML;60MG/5ML	A206660	001	May 15, 2017
	TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838	001	Nov 26, 2014
ZUTRIPRO					
+	PERSION	4MG/5ML;5MG/5ML;60MG/5ML **	N022439	001	Jun 08, 2011

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
COLD CAPSULE IV					
	GRAHAM DM	12MG;75MG	N018793	001	Apr 25, 1985
COLD CAPSULE V					
	GRAHAM DM	8MG;75MG	N018794	001	Apr 23, 1985
TABLET, EXTENDED RELEASE;ORAL					
TRIAMINIC-12					
	NOVARTIS	12MG;75MG	N018115	001	

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
CODIMAL-L.A. 12					
	SCHWARZ PHARMA	12MG;120MG	N018935	001	Apr 15, 1985
ISOCLOR					
	FISONS	8MG;120MG	N018747	001	Mar 06, 1986
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE					
	CENT PHARMS	8MG;120MG	N019428	001	Aug 02, 1988
	GRAHAM DM	8MG;120MG	N018844	001	Mar 20, 1985
		12MG;120MG	N018843	001	Mar 18, 1985
	KV PHARM	12MG;120MG	A071455	001	Mar 01, 1989

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL					
CHLOR-TRIMETON					
+	BAYER HEALTHCARE LLC	8MG;120MG	N018397	001	

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL					
CODEPREX					
	LANNETT CO INC	EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML	N021369	001	Jun 21, 2004
PENNTUSS					
	FISONS	EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML	N018928	001	Aug 14, 1985

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL					
TUSSIONEX PENNKINETIC					
+	UCB INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML **	N019111	001	Dec 31, 1987

CHLORPHENTERMINE HYDROCHLORIDE

TABLET;ORAL					
PRE-SATE					
	PARKE DAVIS	EQ 65MG BASE	N014696	001	

CHLORPROMAZINE

SUPPOSITORY;RECTAL					
THORAZINE					
+	GLAXOSMITHKLINE	25MG **	N009149	024	
+		100MG **	N009149	033	

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
THORAZINE					
	GLAXOSMITHKLINE	30MG	N011120	016	
		75MG	N011120	017	
		150MG	N011120	018	
		200MG	N011120	019	
		300MG	N011120	020	
CONCENTRATE;ORAL					
CHLORPROMAZINE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	
	PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999
		100MG/ML	A040224	001	Jan 26, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL					
CHLORPROMAZINE HYDROCHLORIDE					
	WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
		100MG/ML	A087053	001	
CHLORPROMAZINE HYDROCHLORIDE INTENSOL					
	HIKMA	30MG/ML	A088157	001	Apr 27, 1983
		100MG/ML	A088158	001	Apr 27, 1983
SONAZINE					
	FOSUN PHARMA	30MG/ML	A080983	004	
		100MG/ML	A080983	005	
THORAZINE					
+	GLAXOSMITHKLINE	30MG/ML **	N009149	032	
+		100MG/ML **	N009149	043	
INJECTABLE;INJECTION					
CHLORPROMAZINE HYDROCHLORIDE					
	ABRAXIS PHARM	25MG/ML	A084911	001	
	DR REDDYS	25MG/ML	A080365	001	
	MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
	WATSON LABS	25MG/ML	A085591	001	
	WYETH AYERST	25MG/ML	A080370	001	
THORAZINE					
+	GLAXOSMITHKLINE	25MG/ML **	N009149	011	
SYRUP;ORAL					
CHLORPROMAZINE HYDROCHLORIDE					
	ALPHARMA US PHARMS	10MG/5ML	A086712	001	
SONAZINE					
	FOSUN PHARMA	10MG/5ML	A083040	001	
THORAZINE					
+	GLAXOSMITHKLINE	10MG/5ML **	N009149	022	
TABLET;ORAL					
CHLORPROMAZINE HYDROCHLORIDE					
	ABBOTT	10MG	A084414	001	
		25MG	A084415	001	
		50MG	A084411	001	
		100MG	A084412	001	
		200MG	A084413	001	
	CYCLE PHARMS LTD	10MG	A085331	001	
		25MG	A085331	002	
		50MG	A085331	003	
		100MG	A085331	004	
		200MG	A085331	005	
	IVAX SUB TEVA PHARMS	10MG	A083549	001	
		25MG	A083549	002	
		50MG	A083549	003	
		100MG	A083574	001	
		200MG	A083575	001	
	KV PHARM	10MG	A085750	002	Jan 04, 1982
		25MG	A085751	001	
		50MG	A085484	001	
		100MG	A085752	001	
		200MG	A085748	002	Jan 04, 1982
	LEDERLE	10MG	A084803	001	
		25MG	A084801	001	
		50MG	A084800	001	
		100MG	A084789	001	
		200MG	A084802	001	
	MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020
		25MG	A213590	002	Aug 31, 2020
		50MG	A213590	003	Aug 31, 2020
		100MG	A213590	004	Aug 31, 2020
		200MG	A213590	005	Aug 31, 2020
	PUREPAC PHARM	10MG	A080403	004	
		25MG	A080403	001	
		50MG	A080403	002	
		100MG	A080403	003	
		200MG	A080403	005	
	PVT FORM	25MG	A080340	001	
		50MG	A080340	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	200MG	A080340 003	
SANDOZ	10MG **	A080439 001	
	25MG **	A080439 002	
	50MG **	A080439 003	
	100MG **	A080439 004	
	200MG **	A080439 005	
VANGARD	10MG	A088038 001	Aug 16, 1982
	25MG	A087645 001	
	50MG	A087646 001	
WATSON LABS	10MG	A085959 001	
	25MG	A085956 001	
	50MG	A085960 001	
	100MG	A085957 001	
	200MG	A085958 001	
WEST WARD	10MG	A087783 001	Sep 16, 1982
	25MG	A087865 001	Sep 16, 1982
	50MG	A087878 001	Sep 15, 1982
	100MG	A087884 001	Sep 15, 1982
	200MG	A087880 001	Sep 16, 1982

PROMAPAR

PARKE DAVIS	10MG	A086886 001	
	25MG	A084423 001	
	50MG	A086887 001	
	100MG	A086888 001	
	200MG	A086885 001	

THORAZINE

GLAXOSMITHKLINE	10MG **	N009149 002	
	25MG **	N009149 007	
	50MG **	N009149 013	
	100MG **	N009149 018	
	200MG **	N009149 020	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

ANI PHARMS	100MG	A088768 001	Oct 11, 1984
	100MG	A088812 001	Oct 19, 1984
	100MG	A088840 001	Oct 25, 1984
	100MG	A088918 001	Oct 16, 1984
	100MG	A088921 001	Apr 12, 1985
	100MG	A089446 001	Nov 17, 1986
	250MG	A087353 001	
	250MG	A088813 001	Oct 19, 1984
	250MG	A088826 001	Sep 26, 1984
	250MG	A088919 001	Oct 16, 1984
	250MG	A088922 001	Apr 12, 1985
	250MG	A089447 001	Nov 17, 1986
DAVA PHARMS INC	100MG	A089561 001	Sep 04, 1987
	250MG	A089562 001	Sep 04, 1987
HALSEY	100MG	A089321 001	Jan 16, 1986
	250MG	A088662 001	Jan 09, 1986
MYLAN	100MG	A088549 002	Jun 01, 1984
	250MG	A088549 001	Jun 01, 1984
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
RISING	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984
SANDOZ	250MG	A084669 001	
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852 001	Sep 26, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORPROPAMIDE				
TABLET;ORAL				
DIABINESE				
+ PFIZER	100MG		N011641 003	
+	250MG		N011641 006	
GLUCAMIDE				
ANI PHARMS	250MG		A088641 001	Oct 11, 1984
CHLORPROTHIXENE				
CONCENTRATE;ORAL				
TARACTAN				
ROCHE	100MG/5ML		N016149 002	
INJECTABLE;INJECTION				
TARACTAN				
ROCHE	12.5MG/ML		N012487 001	
TABLET;ORAL				
TARACTAN				
ROCHE	10MG		N012486 005	
	25MG		N012486 004	
	50MG		N012486 003	
	100MG		N012486 001	
CHLORTETRACYCLINE HYDROCHLORIDE				
OINTMENT;OPHTHALMIC				
AUREOMYCIN				
LEDERLE	1%		N050404 001	
CHLORTHALIDONE				
TABLET;ORAL				
CHLORTHALIDONE				
ABBOTT	25MG		A087364 001	
	50MG		A087384 001	
ANI PHARMS	25MG		A087296 001	
	25MG		A087706 001	
	25MG		A088164 001	Jan 09, 1984
	50MG		A087689 001	
ASCOT	25MG		A087698 001	Oct 20, 1982
	50MG		A087699 001	Oct 20, 1982
BARR LABS INC	25MG		A088902 001	Sep 19, 1985
	50MG		A088903 001	Sep 19, 1985
COSETTE	50MG		A088651 001	May 30, 1985
DAVA PHARMS INC	25MG		A087451 001	
	50MG		A087450 001	
IVAX PHARMS	25MG		A087555 001	
	50MG		A087176 001	
	50MG		A087947 001	Feb 27, 1984
KV PHARM	25MG		A087311 001	
	50MG		A087312 001	
MUTUAL PHARM	25MG		A087292 001	
	25MG		A089738 001	Sep 19, 1988
	50MG		A087293 001	
	50MG		A089739 001	Sep 19, 1988
PIONEER PHARMS	50MG		A089591 001	Jul 21, 1988
PUREPAC PHARM	25MG		A088139 001	Jul 16, 1986
	50MG		A088140 001	Aug 11, 1983
SANDOZ	25MG		A087380 001	
	50MG		A087118 001	
	50MG		A087381 001	
SUPERPHARM	25MG		A087473 001	Feb 09, 1983
	50MG		A087247 001	Feb 09, 1983
USL PHARMA	25MG		A089051 001	Jun 01, 1987
	50MG		A089052 001	Jun 01, 1987
VANGARD	25MG		A088012 001	Jul 14, 1982
	50MG		A088073 001	Mar 25, 1983
WARNER CHILCOTT	25MG		A087515 001	Jan 24, 1983
	50MG		A087516 001	Feb 09, 1983
WATSON LABS	25MG		A087050 001	
	25MG		A087100 001	
	50MG		A087029 001	
	50MG		A087082 001	
	50MG		A087521 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHLORTHALIDONE				
TABLET;ORAL				
HYGROTON				
+	SANOFI AVENTIS US	25MG **	N012283 004	
+		50MG **	N012283 003	
THALITONE				
	MONARCH PHARMS	25MG	A088051 001	Nov 12, 1982
CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE				
TABLET;ORAL				
CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE				
	PAR PHARM	15MG;0.1MG	A071179 001	Dec 16, 1987
		15MG;0.2MG	A071178 001	Dec 16, 1987
		15MG;0.3MG	A071142 001	Dec 16, 1987
CLORPRES				
	MYLAN	15MG;0.1MG	A071325 003	Feb 09, 1987
		15MG;0.2MG	A071325 002	Feb 09, 1987
		15MG;0.3MG	A071325 001	Feb 09, 1987
COMBIPRES				
+	BOEHRINGER INGELHEIM	15MG;0.1MG **	N017503 001	
+		15MG;0.2MG **	N017503 002	
+		15MG;0.3MG **	N017503 003	Apr 10, 1984
CHLORTHALIDONE; METOPROLOL TARTRATE				
CAPSULE;ORAL				
LOPRESSIDONE				
	NOVARTIS	25MG;100MG	N019451 001	Dec 31, 1987
		25MG;200MG	N019451 002	Dec 31, 1987
CHLORTHALIDONE; RESERPINE				
TABLET;ORAL				
DEMI-REGROTON				
	SANOFI AVENTIS US	25MG;0.125MG	N015103 002	
REGROTON				
	SANOFI AVENTIS US	50MG;0.25MG	N015103 001	
CHLORZOXAZONE				
TABLET;ORAL				
CHLORZOXAZONE				
	ACTAVIS ELIZABETH	250MG	A088928 001	May 08, 1987
		500MG	A040113 001	Sep 29, 1995
	BARR	500MG	A089895 001	May 04, 1988
	OHM LABS	250MG	A081298 001	Dec 29, 1993
		500MG	A081299 001	Dec 29, 1993
	PIONEER PHARMS	250MG	A089592 001	Jan 06, 1989
		500MG	A089948 001	Jan 06, 1989
	RISING	250MG	A089852 001	May 04, 1988
	STRIDES PHARMA	250MG	A087981 001	Sep 20, 1983
	SUN PHARM INDUSTRIES	500MG	A089970 001	Sep 27, 1990
	WATSON LABS	250MG	A086901 001	
		250MG	A086948 001	Aug 09, 1982
		500MG	A040137 001	Aug 09, 1996
		500MG	A081019 001	Jul 29, 1991
		500MG	A081040 001	Aug 22, 1989
PARAFLEX				
+	ORTHO MCNEIL PHARM	250MG **	N011300 003	
PARAFON FORTE DSC				
+	JANSSEN R AND D	500MG **	N011529 002	Jun 15, 1987
STRIFON FORTE DSC				
	FERNDALE LABS	500MG	A081008 001	Dec 23, 1988
CHOLESTYRAMINE				
BAR, CHEWABLE;ORAL				
CHOLYBAR				
	PARKE DAVIS	EQ 4GM RESIN/BAR	A071621 001	May 26, 1988
		EQ 4GM RESIN/BAR	A071739 001	May 26, 1988
POWDER;ORAL				
CHOLESTYRAMINE				
	IVAX SUB TEVA PHARMS	EQ 4GM RESIN/PACKET	A074771 001	Jul 09, 1997
		EQ 4GM RESIN/SCOOPFUL	A074771 002	Jul 09, 1997
	TEVA	EQ 4GM RESIN/PACKET	A074347 001	May 28, 1998
		EQ 4GM RESIN/SCOOPFUL	A074347 002	May 28, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CHOLESTYRAMINE

POWDER;ORAL				
CHOLESTYRAMINE LIGHT				
TEVA	EQ 4GM RESIN/PACKET	A074348	001	May 28, 1998
	EQ 4GM RESIN/SCOOPFUL	A074348	002	May 28, 1998
TEVA PHARMS	EQ 4GM RESIN/PACKET	A074555	001	Sep 30, 1998
	EQ 4GM RESIN/SCOOPFUL	A074555	002	Sep 30, 1998
LOCHOLEST				
CHARTWELL RX	EQ 4GM RESIN/PACKET	A074561	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074561	002	Aug 15, 1996
LOCHOLEST LIGHT				
CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996
	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996
QUESTRAN				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N016640	001	
+	EQ 4GM RESIN/SCOOPFUL **	N016640	003	
QUESTRAN LIGHT				
+ BRISTOL MYERS	EQ 4GM RESIN/PACKET **	N019669	001	Dec 05, 1988
+	EQ 4GM RESIN/SCOOPFUL **	N019669	003	Dec 05, 1988
TABLET;ORAL				
QUESTRAN				
APOTHECON	EQ 800MG RESIN	A073403	002	Dec 27, 1999
	EQ 1GM RESIN	A073403	001	Apr 28, 1994

CHOLINE C-11

INJECTABLE;INTRAVENOUS				
CHOLINE C-11				
UCSF RODIOPHARM	4-33.1mCi/ML	A208444	001	Nov 20, 2017

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL				
FENOFIBRIC ACID				
MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013
	EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013

CHROMIC CHLORIDE

INJECTABLE;INJECTION				
CHROMIC CHLORIDE				
ABRAXIS PHARM	EQ 0.004MG CHROMIUM/ML	N019271	001	May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE;INJECTION				
PHOSPHOCOL P32				
CURIUM	5mCi/ML	N017084	001	

CICLOPIROX

SOLUTION;TOPICAL				
CICLOPIROX				
AKORN	8%	A078975	001	Feb 17, 2010
ENCUBE	8%	A077687	001	Sep 18, 2007
MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007
TEVA PHARMS	8%	A078079	001	Sep 18, 2007

CIDOFOVIR

INJECTABLE;INJECTION				
VISTIDE				
+ GILEAD SCIENCES INC	EQ 75MG BASE/ML **	N020638	001	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE;INJECTION				
PRIMAXIN				
MERCK	EQ 250MG BASE/VIAL;250MG/VIAL	A062756	001	Jan 08, 1987
	EQ 500MG BASE/VIAL;500MG/VIAL	A062756	002	Jan 08, 1987
POWDER;INTRAMUSCULAR				
PRIMAXIN				
MERCK	EQ 500MG BASE/VIAL;500MG/VIAL	N050630	001	Dec 14, 1990
	EQ 750MG BASE/VIAL;750MG/VIAL	N050630	002	Dec 14, 1990
POWDER;INTRAVENOUS				
IMIPENEM AND CILASTATIN				
HOSPIRA INC	EQ 250MG BASE/VIAL;250MG/VIAL	A090825	001	Nov 16, 2011
	EQ 500MG BASE/VIAL;500MG/VIAL	A090825	002	Nov 16, 2011
	EQ 500MG BASE/VIAL;500MG/VIAL	A091007	001	Nov 16, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CILASTATIN SODIUM; IMIPENEM					
POWDER;INTRAVENOUS					
PRIMAXIN					
+	MERCK	EQ 250MG BASE/VIAL;250MG/VIAL **	N050587	001	Nov 26, 1985
CILOSTAZOL					
TABLET;ORAL					
CILOSTAZOL					
	ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004
	EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005
		100MG	A077022	001	Nov 23, 2004
	IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
	MYLAN	50MG	A077323	002	Apr 20, 2006
		100MG	A077323	001	Apr 20, 2006
	MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004
		100MG	A077019	002	Nov 23, 2004
	NOSTRUM LABS INC	50MG	A077708	001	Sep 28, 2009
		100MG	A077708	002	Sep 28, 2009
	PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007
		100MG	A077898	002	Oct 29, 2007
PLETAL					
+	OTSUKA	50MG **	N020863	001	Jan 15, 1999
+		100MG **	N020863	002	Jan 15, 1999
CIMETIDINE					
SUSPENSION;ORAL					
TAGAMET HB 200					
	GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999
TABLET;ORAL					
CIMETIDINE					
	CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994
		300MG	A074329	003	May 17, 1994
		400MG	A074329	004	May 17, 1994
		800MG	A074329	001	May 17, 1994
	CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
		200MG	A074963	001	Jun 19, 1998
	CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994
		400MG	A074361	002	Dec 23, 1994
		800MG	A074371	001	Dec 23, 1994
	HIKMA	200MG	A074890	001	Dec 18, 1998
		300MG	A074890	002	Dec 18, 1998
		400MG	A074890	003	Dec 18, 1998
		800MG	A074890	004	Dec 18, 1998
	IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
		200MG	A074424	001	Jul 28, 1995
		300MG	A074401	002	May 30, 1995
		300MG	A074424	002	Jul 28, 1995
		400MG	A074401	003	May 30, 1995
		400MG	A074424	003	Jul 28, 1995
		800MG	A074402	001	May 30, 1995
		800MG	A074424	004	Jul 28, 1995
	NOVITIUM PHARMA	300MG	A074340	001	Jun 23, 1995
		400MG	A074340	002	Jun 23, 1995
		800MG	A074339	001	Jun 23, 1995
	PERRIGO	100MG	A074972	001	Jun 19, 1998
	PLIVA	200MG	A074568	001	Feb 27, 1997
		300MG	A074568	002	Feb 27, 1997
		400MG	A074568	003	Feb 27, 1997
	SANDOZ INC	100MG	A075122	001	Jun 19, 1998
		200MG	A074250	001	Jun 29, 1995
		200MG	A075122	002	Jun 19, 1998
		300MG	A074250	002	Jun 29, 1995
		400MG	A074250	003	Jun 29, 1995
		800MG	A074250	004	Jun 29, 1995
	TEVA	200MG	A074365	001	Feb 28, 1995
		300MG	A074365	002	Feb 28, 1995
		400MG	A074365	003	Feb 28, 1995
		800MG	A074365	004	Feb 28, 1995
	UPSHER SMITH LABS	200MG	A074506	001	Jan 24, 1996
		300MG	A074506	002	Jan 24, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIMETIDINE

TABLET;ORAL					
CIMETIDINE					
		400MG	A074506	003	Jan 24, 1996
		800MG	A074506	004	Jan 24, 1996
	WATSON LABS INC	200MG	A074349	001	Aug 30, 1996
		300MG	A074349	002	Aug 30, 1996
		400MG	A074349	003	Aug 30, 1996
		800MG	A074316	001	Feb 28, 1996
	WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999
	YAOPHARMA CO LTD	200MG	A074100	001	Jan 31, 1995
		300MG	A074100	002	Jan 31, 1995
		400MG	A074100	003	Jan 31, 1995
		800MG	A074100	004	Jan 31, 1995
TAGAMET					
+	GLAXOSMITHKLINE	200MG **	N017920	002	
+		300MG **	N017920	003	
+		400MG **	N017920	004	Dec 14, 1983
+		800MG **	N017920	005	Apr 30, 1986
TAGAMET HB					
+	MEDTECH PRODUCTS	100MG **	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE;INJECTION					
CIMETIDINE HYDROCHLORIDE					
	DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996
	HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
		EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995
		EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995
		EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
		EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
	LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
	TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252	001	Nov 26, 1997
	VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994
CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994
		EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
		EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
		EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
		EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
		EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
		EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994
TAGAMET					
	GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939	002	
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	GLAXOSMITHKLINE	EQ 6MG BASE/ML **	N019434	001	Oct 31, 1985
SOLUTION;ORAL					
CIMETIDINE HYDROCHLORIDE					
	ANI PHARMS	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996
		EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998
		EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998
	CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997
	G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994
	LANNETT CO INC	EQ 300MG BASE/5ML	A074251	001	Dec 22, 1994
	PHARM ASSOC	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000
TAGAMET					
	GLAXOSMITHKLINE	EQ 300MG BASE/5ML **	N017924	001	

CINACALCET HYDROCHLORIDE

TABLET;ORAL					
CINACALCET HYDROCHLORIDE					
	LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019
		EQ 60MG BASE	A210548	002	Jun 28, 2019
		EQ 90MG BASE	A210548	003	Jun 28, 2019
	MYLAN	EQ 30MG BASE	A203422	001	Oct 16, 2018
		EQ 60MG BASE	A203422	002	Oct 16, 2018
		EQ 90MG BASE	A203422	003	Oct 16, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CINOXACIN

CAPSULE;ORAL				
CINOBAC				
	LILLY	250MG	N018067 001	
		500MG	N018067 002	
CINOXACIN				
	TEVA	250MG	A073005 001	Feb 28, 1992
		500MG	A073006 001	Feb 28, 1992

CIPROFLOXACIN

FOR SUSPENSION;ORAL				
CIPROFLOXACIN				
	CHARTWELL	250MG/5ML	A200563 001	Mar 05, 2014
		500MG/5ML	A200563 002	Mar 05, 2014
INJECTABLE;INJECTION				
CIPRO				
+	BAYER HLTHCARE	400MG/40ML (10MG/ML) **	N019847 001	Dec 26, 1990
+		200MG/20ML (10MG/ML) **	N019847 002	Dec 26, 1990
		1200MG/120ML (10MG/ML) **	N019847 003	Dec 26, 1990
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	BAYER HLTHCARE	200MG/100ML **	N019857 001	Dec 26, 1990
+		400MG/200ML **	N019857 002	Dec 26, 1990
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	BAYER PHARMS	200MG/100ML	N019858 001	Dec 26, 1990
CIPROFLOXACIN				
	BEDFORD LABS	200MG/20ML (10MG/ML)	A076992 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076992 002	Aug 28, 2006
		1200MG/120ML (10MG/ML)	A076993 001	Aug 28, 2006
	DR REDDYS	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006
	FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A076484 002	Aug 28, 2006
	HOSPIRA	200MG/20ML (10MG/ML)	A077245 001	Aug 28, 2006
		400MG/40ML (10MG/ML)	A077245 002	Aug 28, 2006
CIPROFLOXACIN IN DEXTROSE 5%				
	HIKMA FARMACEUTICA	200MG/100ML	A076757 001	Apr 21, 2008
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008
		400MG/200ML	A077888 002	Mar 18, 2008
	BEDFORD	200MG/100ML	A078114 001	Mar 18, 2008
		400MG/200ML	A078114 002	Mar 18, 2008
	TEVA PHARMS	200MG/100ML	A077138 001	Mar 18, 2008
		400MG/200ML	A077138 002	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
CIPROFLOXACIN HYDROCHLORIDE				
	AMRING PHARMS	EQ 0.3% BASE	A078598 001	Jan 16, 2008
	RUBICON	EQ 0.3% BASE	A075928 001	Jun 09, 2004
TABLET;ORAL				
CIPRO				
+	BAYER HLTHCARE	EQ 100MG BASE **	N019537 001	Apr 08, 1996
+		EQ 750MG BASE **	N019537 004	Oct 22, 1987
CIPROFLOXACIN HYDROCHLORIDE				
	AMNEAL	EQ 100MG BASE	A075939 001	Mar 03, 2005
		EQ 250MG BASE	A075939 002	Jun 09, 2004
		EQ 500MG BASE	A075939 003	Jun 09, 2004
		EQ 750MG BASE	A075939 004	Jun 09, 2004
	BARR	EQ 250MG BASE	A074124 001	Jun 09, 2004
		EQ 500MG BASE	A074124 002	Jun 09, 2004
		EQ 750MG BASE	A074124 003	Jun 09, 2004
	FOSUN PHARMA	EQ 250MG BASE	A076593 002	Jun 09, 2004
		EQ 500MG BASE	A076593 003	Jun 09, 2004
		EQ 750MG BASE	A076593 004	Jun 09, 2004
	MYLAN	EQ 250MG BASE	A075685 002	Jun 09, 2004
		EQ 500MG BASE	A075685 003	Jun 09, 2004
		EQ 750MG BASE	A075685 001	Jun 09, 2004
	NOSTRUM LABS	EQ 250MG BASE	A076138 001	Jun 09, 2004
		EQ 500MG BASE	A076138 002	Jun 09, 2004
		EQ 750MG BASE	A076138 003	Jun 09, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL				
CIPROFLOXACIN HYDROCHLORIDE				
PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005
	EQ 250MG BASE	A076426	002	Jun 15, 2005
	EQ 500MG BASE	A076426	003	Jun 15, 2005
	EQ 750MG BASE	A076426	004	Jun 15, 2005
RISING PHARMA	EQ 100MG BASE	A075817	001	Jun 25, 2007
	EQ 250MG BASE	A075817	002	Jun 09, 2004
	EQ 750MG BASE	A075817	004	Jun 09, 2004
SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004
	EQ 500MG BASE	A075747	002	Jun 09, 2004
	EQ 750MG BASE	A075747	003	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136	001	Jun 09, 2004
	EQ 500MG BASE	A076136	002	Jun 09, 2004
	EQ 750MG BASE	A076136	003	Jun 09, 2004
TABLET, EXTENDED RELEASE;ORAL				
PROQUIN XR				
DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
CIPRO XR				
BAYER HLTHCARE	212.6MG;EQ 287.5MG BASE **	N021473	001	Dec 13, 2002
	425.2MG;EQ 574.9MG BASE **	N021473	002	Aug 28, 2003
CIPROFLOXACIN EXTENDED RELEASE				
ANI PHARMS	212.6MG;EQ 287.5MG BASE	A077809	002	Nov 30, 2010
	425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010
DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007
FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007
MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007
	425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION;ORAL				
PROPULSID				
JANSSEN PHARMS	EQ 1MG BASE/ML	N020398	001	Sep 15, 1995
TABLET;ORAL				
PROPULSID				
JANSSEN PHARMS	EQ 10MG BASE	N020210	001	Jul 29, 1993
	EQ 20MG BASE	N020210	002	Dec 23, 1993
TABLET, ORALLY DISINTEGRATING;ORAL				
PROPULSID QUICKSOLV				
JANSSEN PHARMA	EQ 20MG BASE	N020767	001	Nov 07, 1997

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION				
CISATRACURIUM BESYLATE				
ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017
PIRAMAL HLTHCARE UK	EQ 2MG BASE/ML	A212190	001	May 04, 2020
SAGENT PHARMS INC	EQ 2MG BASE/ML	A201851	001	Nov 06, 2020
ZYDUS PHARMS	EQ 2MG BASE/ML	A213527	001	Aug 31, 2020
CISATRACURIUM BESYLATE PRESERVATIVE FREE				
ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017
	EQ 10MG BASE/ML	A205872	002	Jun 16, 2017

CISPLATIN

INJECTABLE;INJECTION				
CISPLATIN				
BEDFORD	10MG/VIAL	A074713	001	Nov 14, 2000
	50MG/VIAL	A074713	002	Nov 14, 2000
MYLAN LABS LTD	1MG/ML	A091062	001	Apr 18, 2012
TEVA PHARMS USA	1MG/ML	A074814	001	May 16, 2000
PLATINOL				
+ HQ SPCLT PHARMA	10MG/VIAL	N018057	001	
+	50MG/VIAL	N018057	002	
PLATINOL-AQ				
+ HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL				
CITALOPRAM HYDROBROMIDE				
MYLAN PHARMS INC	EQ 10MG BASE	A077668	001	Feb 28, 2007
	EQ 20MG BASE	A077668	002	Feb 28, 2007
	EQ 40MG BASE	A077668	003	Feb 28, 2007
SOLUTION;ORAL				
CELEXA				
+ FOREST LABS	EQ 10MG BASE/5ML **	N021046	001	Dec 22, 1999
CITALOPRAM HYDROBROMIDE				
PHARM ASSOC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005
TABLET;ORAL				
CELEXA				
ALLERGAN	EQ 60MG BASE	N020822	004	Jul 17, 1998
CITALOPRAM HYDROBROMIDE				
EPIC PHARMA LLC	EQ 10MG BASE	A077036	001	Oct 28, 2004
	EQ 20MG BASE	A077036	002	Oct 28, 2004
	EQ 40MG BASE	A077036	003	Oct 28, 2004
FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004
	EQ 10MG BASE	A077040	001	Aug 17, 2005
	EQ 20MG BASE	A077035	002	Oct 28, 2004
	EQ 20MG BASE	A077040	002	Aug 17, 2005
	EQ 40MG BASE	A077035	003	Oct 28, 2004
	EQ 40MG BASE	A077040	003	Aug 17, 2005
HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004
	EQ 10MG BASE	A077034	001	Jun 30, 2005
	EQ 10MG BASE	A077213	001	Mar 31, 2006
	EQ 10MG BASE	A077232	001	Oct 31, 2005
	EQ 20MG BASE	A077033	002	Oct 28, 2004
	EQ 20MG BASE	A077034	002	Jun 30, 2005
	EQ 20MG BASE	A077213	002	Mar 31, 2006
	EQ 20MG BASE	A077232	002	Oct 31, 2005
	EQ 40MG BASE	A077033	003	Oct 28, 2004
	EQ 40MG BASE	A077034	003	Jun 30, 2005
	EQ 40MG BASE	A077213	003	Mar 31, 2006
	EQ 40MG BASE	A077232	003	Oct 31, 2005
JUBILANT GENERICS	EQ 10MG BASE	A205407	001	Dec 23, 2015
	EQ 20MG BASE	A205407	002	Dec 23, 2015
	EQ 40MG BASE	A205407	003	Dec 23, 2015
MYLAN	EQ 10MG BASE	A077039	001	Feb 03, 2005
	EQ 20MG BASE	A077039	002	Feb 03, 2005
	EQ 40MG BASE	A077039	003	Feb 03, 2005
MYLAN PHARMS INC	EQ 10MG BASE	A077037	001	Nov 05, 2004
	EQ 20MG BASE	A077037	002	Nov 05, 2004
	EQ 40MG BASE	A077037	003	Nov 05, 2004
NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008
	EQ 40MG BASE	A077141	001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
	EQ 20MG BASE	A077041	002	Nov 23, 2004
	EQ 40MG BASE	A077041	003	Nov 23, 2004
SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004
	EQ 20MG BASE	A077032	002	Nov 12, 2004
	EQ 40MG BASE	A077032	003	Nov 12, 2004
SUN PHARM INDUSTRIES	EQ 10MG BASE	A077052	001	Jul 03, 2006
	EQ 20MG BASE	A077052	002	Jul 03, 2006
	EQ 40MG BASE	A077052	003	Jul 03, 2006
TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006
	EQ 20MG BASE	A077278	002	Mar 22, 2006
	EQ 40MG BASE	A077278	003	Mar 22, 2006
TABLET, ORALLY DISINTEGRATING;ORAL				
CITALOPRAM HYDROBROMIDE				
+ BIOVAIL LABS INTL	EQ 10MG BASE	N021763	001	Dec 20, 2005
+	EQ 20MG BASE	N021763	002	Dec 20, 2005
+	EQ 40MG BASE	N021763	003	Dec 20, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION;IRRIGATION					
IRRIGATING SOLUTION G IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	3.24GM/100ML;380MG/100ML;430MG/100ML	N018519	001	Jun 22, 1982
UROLOGIC G IN PLASTIC CONTAINER					
	HOSPIRA	3.24GM/100ML;380MG/100ML;430MG/100ML	N018904	001	May 27, 1983

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL					
PREPOPIK					
+	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACKET **	N202535	001	Jul 16, 2012

CLADRIBINE

INJECTABLE;INJECTION					
LEUSTATIN					
+	JANSSEN PHARMS	1MG/ML **	N020229	001	Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION;ORAL					
BIAXIN					
+	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993
		187MG/5ML	N050698	003	Sep 30, 1998
+		250MG/5ML	N050698	002	Dec 23, 1993
CLARITHROMYCIN					
	SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007
		250MG/5ML	A065382	002	Aug 30, 2007
TABLET;ORAL					
BIAXIN					
+	ABBVIE	250MG **	N050662	001	Oct 31, 1991
+		500MG **	N050662	002	Oct 31, 1991
CLARITHROMYCIN					
	AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019
		500MG	A206714	002	Apr 25, 2019
	HIKMA	250MG	A065178	002	May 25, 2004
		500MG	A065178	001	May 25, 2004
	IVAX SUB TEVA PHARMS	250MG	A065137	001	May 31, 2005
		500MG	A065137	002	May 31, 2005
	MYLAN	250MG	A065195	001	Mar 11, 2005
		500MG	A065195	002	Mar 11, 2005
	SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004
		500MG	A065174	002	Sep 24, 2004
	WOCKHARDT	250MG	A065266	001	May 31, 2006
		500MG	A065266	002	May 31, 2006
TABLET, EXTENDED RELEASE;ORAL					
BIAXIN XL					
+	ABBVIE	500MG **	N050775	001	Mar 03, 2000
CLARITHROMYCIN					
	ANI PHARMS	500MG	A065250	001	Aug 25, 2005
	LUPIN LTD	500MG	A202532	001	Sep 15, 2015
	NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016
	RANBAXY	1GM	A065210	001	Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION					
TIMENTIN					
	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985
		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
TIMENTIN IN PLASTIC CONTAINER					
	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP;ORAL					
CLEMASTINE FUMARATE					
	ACTAVIS MID ATLANTIC	EQ 0.5MG BASE/5ML	A074075	001	Oct 31, 1993
	APOTEX INC	EQ 0.5MG BASE/5ML	A075703	001	Nov 27, 2000
	LANNETT CO INC	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997
	TEVA PHARMS	EQ 0.5MG BASE/5ML	A073095	001	Apr 21, 1992
	WOCKHARDT BIO AG	EQ 0.5MG BASE/5ML	A074863	001	Mar 13, 1998

CLEMASTINE FUMARATE				
SYRUP;ORAL				
TAVIST				
+ NOVARTIS	EQ 0.5MG BASE/5ML **	N018675	001	Jun 28, 1985
TABLET;ORAL				
CLEMASTINE FUMARATE				
ANI PHARMS	1.34MG	A073282	001	Jan 31, 1992
	1.34MG	A073282	002	Dec 03, 1992
PLD ACQUISITIONS LLC	1.34MG	A073458	001	Oct 31, 1993
SANDOZ	2.68MG	A073459	001	Oct 31, 1993
TAVIST				
+ NOVARTIS	2.68MG	N017661	001	
TAVIST-1				
+ GLAXOSMITHKLINE CONS	1.34MG **	N020925	001	Aug 21, 1992
NOVARTIS	1.34MG	N017661	002	
	1.34MG	N017661	003	Aug 21, 1992
CLEVIDIPINE				
EMULSION;INTRAVENOUS				
CLEVIPREX				
+ CHIESI	125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013
CLIDINIUM BROMIDE				
CAPSULE;ORAL				
QUARZAN				
ROCHE	2.5MG	N010355	001	
	5MG	N010355	002	
CLINDAMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE	A061809	001	
	EQ 150MG BASE	A061809	002	
CLINDAMYCIN HYDROCHLORIDE				
LANNETT CO INC	EQ 150MG BASE	A065243	003	Aug 12, 2005
	EQ 300MG BASE	A065243	001	Aug 12, 2005
MYLAN PHARMS INC	EQ 75MG BASE	A091225	001	May 31, 2011
	EQ 150MG BASE	A091225	002	May 31, 2011
	EQ 300MG BASE	A091225	003	May 31, 2011
TEVA	EQ 75MG BASE	A063027	001	Sep 20, 1989
WATSON LABS	EQ 75MG BASE	A063082	001	Jul 31, 1991
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
FOR SOLUTION;ORAL				
CLEOCIN				
PHARMACIA AND UPJOHN	EQ 75MG BASE/5ML **	A061827	001	
CLINDAMYCIN PALMITATE HYDROCHLORIDE				
MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016
CLINDAMYCIN PHOSPHATE				
AEROSOL, FOAM;TOPICAL				
CLINDAMYCIN PHOSPHATE				
TARO PHARM INDS LTD	1%	A210004	001	Mar 11, 2020
CREAM;VAGINAL				
CLEOCIN				
PFIZER	EQ 2% BASE	N050680	001	Aug 11, 1992
INJECTABLE;INJECTION				
CLEOCIN PHOSPHATE				
PHARMACIA AND UPJOHN	EQ 150MG BASE/ML	A061839	001	
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ PFIZER	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989
+	EQ 12MG BASE/ML	N050639	002	Aug 30, 1989
+	EQ 18MG BASE/ML	N050639	003	Apr 10, 1991
CLINDAMYCIN PHOSPHATE				
ABRAXIS PHARM	EQ 150MG BASE/ML	A062747	001	Jun 03, 1988
ALMAJECT	EQ 150MG BASE/ML	A062801	001	Jul 24, 1987
BEDFORD	EQ 150MG BASE/ML	A063163	001	Jun 30, 1994
BRISTOL MYERS SQUIBB	EQ 150MG BASE/ML	A062908	001	Feb 01, 1989
HIKMA	EQ 150MG BASE/ML	A062806	001	Oct 15, 1987
	EQ 150MG BASE/ML	A062953	001	Apr 21, 1988
	EQ 150MG BASE/ML	A063068	001	Aug 28, 1989
IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION				
CLINDAMYCIN PHOSPHATE				
LOCH	EQ 150MG BASE/ML	A062905	001	May 09, 1988
MARSAM PHARMS LLC	EQ 150MG BASE/ML	A062913	001	Oct 20, 1988
RISING PHARMA	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017
	EQ 150MG BASE/ML	A204749	001	Oct 10, 2017
SOLOPAK	EQ 150MG BASE/ML	A062819	001	Mar 15, 1988
	EQ 150MG BASE/ML	A062852	001	Mar 17, 1988
TEVA PARENTERAL	EQ 150MG BASE/ML	A063041	001	Dec 29, 1989
	EQ 150MG BASE/ML	A063282	001	May 29, 1992
WATSON LABS	EQ 150MG BASE/ML	A062900	001	Jun 08, 1988
	EQ 150MG BASE/ML	A063079	001	Mar 05, 1990
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%				
ABRAXIS PHARM	EQ 12MG BASE/ML	N050636	001	Dec 22, 1989
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001
	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001
	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001
BAXTER HLTHCARE	EQ 6MG BASE/ML	N050648	001	Dec 29, 1989
	EQ 12MG BASE/ML	N050648	002	Dec 29, 1989
	EQ 900MG BASE/100ML	N050648	003	Dec 29, 1989
SOLUTION;TOPICAL				
CLEOCIN T				
+ PFIZER	EQ 1% BASE	N050537	001	
PHARMACIA AND UPJOHN	EQ 1% BASE	A062363	001	Feb 08, 1982
CLINDAMYCIN PHOSPHATE				
BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989
FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006
G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988
NOVAST LABS	EQ 1% BASE	A064108	001	Sep 27, 1996
VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989
	EQ 1% BASE	A203343	001	May 29, 2015
WOCKHARDT BIO AG	EQ 1% BASE	A063304	001	Jul 15, 1997
SWAB;TOPICAL				
CLEOCIN				
+ PFIZER	EQ 1% BASE	N050537	002	Feb 22, 1994

CLIOQUINOL; NYSTATIN

OINTMENT;TOPICAL				
NYSTAFORM				
BAYER PHARMS	10MG/GM;100,000 UNITS/GM	N050235	001	

CLOBAZAM

SUSPENSION;ORAL				
CLOBAZAM				
TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020
TABLET;ORAL				
CLOBAZAM				
ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019
	20MG	A212398	002	May 23, 2019
APOTEX	10MG	A209853	001	Jun 09, 2020
	20MG	A209853	002	Jun 09, 2020
BRECKENRIDGE	5MG	A209308	003	Oct 19, 2021
CELLTRION	10MG	A211959	001	Dec 09, 2020
	20MG	A211959	002	Dec 09, 2020
LANNETT CO INC	10MG	A212092	001	Oct 30, 2019
	20MG	A212092	002	Oct 30, 2019
MSN	10MG	A213404	001	May 11, 2021
	20MG	A213404	002	May 11, 2021
TARO	10MG	A209440	001	Oct 22, 2018
	20MG	A209440	002	Oct 22, 2018
ONFI				
+ LUNDBECK PHARMS LLC	5MG **	N202067	001	Oct 21, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL				
CLOBETASOL PROPIONATE				
INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017
CREAM;TOPICAL				
CLOBETASOL PROPIONATE				
PAI HOLDINGS PHARM	0.05%	A211207	001	Mar 26, 2021
TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N019322	001	Dec 27, 1985
TEMOVATE E				
+ FOUGERA PHARMS	0.05% **	N020340	001	Jun 17, 1994
GEL;TOPICAL				
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N020337	001	Apr 29, 1994
LOTION;TOPICAL				
CLOBETASOL PROPIONATE				
AKORN	0.05%	A211348	001	Oct 26, 2018
OINTMENT;TOPICAL				
CLOBETASOL PROPIONATE				
ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
AMNEAL	0.05%	A210551	001	Aug 21, 2018
TORRENT	0.05%	A212926	001	Oct 25, 2019
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N019323	001	Dec 27, 1985
SOLUTION;TOPICAL				
TEMOVATE				
+ FOUGERA PHARMS	0.05% **	N019966	001	Feb 22, 1990
SPRAY;TOPICAL				
CLOBETASOL PROPIONATE				
AKORN	0.05%	A207218	001	Apr 28, 2017
APOTEX	0.05%	A210446	001	Apr 17, 2018

CLOFARABINE

SOLUTION;INTRAVENOUS				
CLOFARABINE				
HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018
NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018

CLOFAZIMINE

CAPSULE;ORAL				
LAMPRENE				
+ NOVARTIS	50MG	N019500	002	Dec 15, 1986
	100MG	N019500	001	Dec 15, 1986

CLOFIBRATE

CAPSULE;ORAL				
ATROMID-S				
WYETH AYERST	500MG	N016099	002	
CLOFIBRATE				
BANNER PHARMACAPS	500MG	A073396	001	Mar 20, 1992
SANDOZ	500MG	A072191	001	May 02, 1988
TEVA	500MG	A072600	001	Jul 25, 1991
USL PHARMA	500MG	A070531	001	Jun 16, 1986
WATSON LABS	500MG	A071603	001	Sep 18, 1987

CLOMIPHENE CITRATE

TABLET;ORAL				
CLOMID				
+ SANOFI AVENTIS US	50MG **	N016131	002	
MILOPHENE				
GRANATA BIO	50MG	A072196	001	Dec 20, 1988
SEROPHENE				
EMD SERONO	50MG	N018361	001	Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
CLOMIPRAMINE HYDROCHLORIDE				
TEVA	25MG	A074849	001	Apr 04, 1997
	25MG	A074958	001	Aug 26, 1997
	50MG	A074849	002	Apr 04, 1997
	50MG	A074958	002	Aug 26, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL					
CLOMIPRAMINE HYDROCHLORIDE					
		75MG	A074849	003	Apr 04, 1997
		75MG	A074958	003	Aug 26, 1997
	WATSON LABS	25MG	A074600	001	Nov 27, 1996
		25MG	A074751	001	Sep 30, 1998
		50MG	A074600	002	Nov 27, 1996
		50MG	A074751	002	Sep 30, 1998
		75MG	A074600	003	Nov 27, 1996
		75MG	A074751	003	Sep 30, 1998

CLONAZEPAM

TABLET;ORAL					
CLONAZEPAM					
	AUROBINDO PHARMA USA	0.5MG	A075150	001	Oct 05, 1998
		1MG	A075150	002	Oct 05, 1998
		2MG	A075150	003	Oct 05, 1998
	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997
		1MG	A074940	002	Oct 30, 1997
		2MG	A074940	003	Oct 30, 1997
	RUBICON	0.5MG	A075468	001	Oct 06, 2000
		1MG	A075468	002	Oct 06, 2000
		2MG	A075468	003	Oct 06, 2000
	SANDOZ	0.5MG	A074925	001	Sep 30, 1997
		1MG	A074925	002	Sep 30, 1997
		2MG	A074925	003	Sep 30, 1997
	SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001
		1MG	A075423	002	Apr 27, 2001
		2MG	A075423	003	Apr 27, 2001
	TEVA	0.5MG	A074920	001	Aug 04, 1998
		1MG	A074920	002	Aug 04, 1998
		2MG	A074920	003	Aug 04, 1998
	WATSON LABS	0.5MG	A074964	001	Dec 30, 1997
		1MG	A074964	002	Dec 30, 1997
		2MG	A074964	003	Dec 30, 1997
KLONOPIN					
	CHEPLAPHARM	0.125MG	N017533	005	Apr 09, 1997
		0.25MG	N017533	006	Apr 09, 1997
TABLET, ORALLY DISINTEGRATING;ORAL					
KLONOPIN RAPIDLY DISINTEGRATING					
+	ROCHE	0.125MG **	N020813	001	Dec 23, 1997
+		0.25MG **	N020813	002	Dec 23, 1997
+		0.5MG **	N020813	003	Dec 23, 1997
+		1MG **	N020813	004	Dec 23, 1997
+		2MG **	N020813	005	Dec 23, 1997

CLONIDINE

SUSPENSION, EXTENDED RELEASE;ORAL					
CLONIDINE					
	TRIS PHARMA INC	EQ 0.09MG BASE/ML	N022499	001	Dec 03, 2009
TABLET, EXTENDED RELEASE;ORAL					
NEXICLON XR					
	TRIS PHARMA INC	EQ 0.17MG BASE	N022500	001	Dec 03, 2009
		EQ 0.26MG BASE	N022500	002	Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION					
CLONIDINE HYDROCHLORIDE					
	AM REGENT	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009
		5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009
DURACLON					
+	MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999
TABLET;ORAL					
CATAPRES					
+	BOEHRINGER INGELHEIM	0.1MG	N017407	001	
+		0.2MG	N017407	002	
+		0.3MG	N017407	003	
CLONIDINE HYDROCHLORIDE					
	AM THERAP	0.1MG	A070881	001	Jul 08, 1986
		0.2MG	A070882	001	Jul 08, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	0.3MG	A070883	001	Jul 08, 1986
AUROBINDO PHARMA LTD	0.1MG	A070886	002	Aug 31, 1988
	0.2MG	A070886	001	Aug 31, 1988
	0.3MG	A070886	003	Aug 31, 1988
CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988
	0.2MG	A071785	003	Apr 05, 1988
	0.3MG	A071785	001	Apr 05, 1988
DURAMED PHARMS BARR	0.1MG	A071103	001	Aug 14, 1986
	0.2MG	A071102	001	Aug 14, 1986
	0.3MG	A071101	001	Aug 14, 1986
INTERPHARM	0.1MG	A071252	001	Oct 01, 1986
	0.2MG	A071253	001	Oct 01, 1986
	0.3MG	A071254	001	Oct 01, 1986
PAR PHARM	0.1MG	A070461	001	Jul 08, 1986
	0.2MG	A070460	001	Jul 08, 1986
	0.3MG	A070459	001	Jul 08, 1986
RISING PHARMA	0.1MG	A070317	002	Jul 09, 1987
	0.2MG	A070317	003	Jun 09, 1987
	0.3MG	A070317	001	Jun 09, 1987
SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014
	0.2MG	A090329	002	Jul 03, 2014
	0.3MG	A090329	003	Jul 03, 2014
TEVA	0.1MG	A070747	001	Jul 08, 1986
	0.2MG	A070702	001	Jul 08, 1986
	0.3MG	A070659	001	Jul 08, 1986
WARNER CHILCOTT	0.1MG	A072138	001	Jun 13, 1988
	0.2MG	A072139	001	Jun 13, 1988
	0.3MG	A072140	001	Jun 13, 1988
WATSON LABS	0.1MG	A070395	001	Mar 23, 1987
	0.1MG	A070965	001	Jul 08, 1986
	0.2MG	A070396	001	Mar 23, 1987
	0.2MG	A070964	001	Jul 08, 1986
	0.3MG	A070397	001	Mar 23, 1987
	0.3MG	A070963	001	Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH	0.2MG	A202792	002	May 15, 2015
	0.2MG	A203320	002	May 15, 2015
ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014
	0.2MG	A202983	002	Apr 02, 2014
	0.2MG	A202984	002	Sep 30, 2013
UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018

JENLOGA

+ CONCORDIA PHARMS INC	0.1MG **	N022331	001	Sep 30, 2009
+	0.2MG **	N022331	002	May 25, 2010

KAPVAY

+ CONCORDIA PHARMS INC	0.2MG **	N022331	004	Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013
ANI PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012
	EQ 300MG BASE	A091216	001	May 17, 2012
CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012
CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012
	EQ 300MG BASE	A202266	002	Nov 20, 2012
RISING	EQ 75MG BASE	A077665	001	May 17, 2012
	EQ 300MG BASE	A077665	002	May 17, 2012
SUN PHARM INDUSTRIES	EQ 75MG BASE	A078133	001	Jun 10, 2013

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL					
CLORAZEPATE DIPOTASSIUM					
ABLE	3.75MG		A071777	001	Jul 14, 1987
	7.5MG		A071778	001	Jul 14, 1987
	15MG		A071779	001	Jul 14, 1987
AM THERAP	3.75MG		A071429	001	Jun 23, 1987
	7.5MG		A071430	001	Jun 23, 1987
	15MG		A071431	001	Jun 23, 1987
DAVA PHARMS INC	3.75MG		A071742	001	Dec 14, 1987
	7.5MG		A071743	001	Dec 14, 1987
	15MG		A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG		A071727	001	Dec 18, 1987
	7.5MG		A071728	001	Dec 18, 1987
	15MG		A071729	001	Dec 18, 1987
MYLAN	3.75MG		A071509	001	Oct 19, 1987
	7.5MG		A071510	001	Oct 19, 1987
	15MG		A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG		A071924	001	Apr 25, 1988
	7.5MG		A071925	001	Apr 25, 1988
	15MG		A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG		A071549	001	Sep 12, 1988
	7.5MG		A071550	001	Sep 12, 1988
	15MG		A071522	001	Sep 12, 1988
RISING	3.75MG		A072112	002	Aug 26, 1988
	7.5MG		A072112	003	Aug 26, 1988
	15MG		A072112	001	Aug 26, 1988
USL PHARMA	3.75MG		A071242	001	Jun 23, 1987
	7.5MG		A071243	001	Jun 23, 1987
	15MG		A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG		A071774	001	Mar 01, 1988
	7.5MG		A071775	001	Mar 01, 1988
	15MG		A071776	001	Mar 01, 1988
WATSON LABS	3.75MG		A071878	001	Mar 15, 1988
	7.5MG		A071879	001	Mar 15, 1988
	15MG		A071860	001	Mar 15, 1988
TRANXENE					
+ RECORDATI RARE	3.75MG **		N017105	001	
+	7.5MG **		N017105	002	
+	15MG **		N017105	003	
TABLET;ORAL					
CLORAZEPATE DIPOTASSIUM					
ABLE	3.75MG		A071780	001	Jun 26, 1987
	7.5MG		A071781	001	Jun 26, 1987
	15MG		A071782	001	Jun 26, 1987
AM THERAP	3.75MG		A071747	001	Jun 23, 1987
	7.5MG		A071748	001	Jun 23, 1987
	15MG		A071749	001	Jun 23, 1987
AUROLIFE PHARMA LLC	3.75MG		A072514	002	May 11, 1990
	7.5MG		A072514	003	May 11, 1990
	15MG		A072514	001	May 11, 1990
LEDERLE	3.75MG		A072013	001	Dec 15, 1987
	7.5MG		A072014	001	Dec 15, 1987
	15MG		A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG		A072330	001	Aug 08, 1988
	7.5MG		A072331	001	Aug 08, 1988
	15MG		A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG		A071730	001	Oct 26, 1987
	7.5MG		A071731	001	Oct 26, 1987
	15MG		A071702	001	Oct 26, 1987
SUN PHARM INDS LTD	3.75MG		A076911	001	Sep 29, 2004
	7.5MG		A076911	002	Sep 29, 2004
	15MG		A076911	003	Sep 29, 2004
WARNER CHILCOTT	3.75MG		A071828	001	Mar 03, 1988
	7.5MG		A071829	001	Mar 03, 1988
	15MG		A071830	001	Mar 03, 1988
WATSON LABS	3.75MG		A071852	001	Feb 09, 1988
	7.5MG		A071853	001	Feb 09, 1988
	15MG		A071854	001	Feb 09, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL				
GEN-XENE				
ALRA	3.75MG		A071787 001	Apr 26, 1988
	7.5MG		A071788 001	Apr 26, 1988
	15MG		A071789 001	Apr 26, 1988
TRANXENE				
+ RECORDATI RARE	3.75MG **		N017105 006	
+	15MG **		N017105 008	
TRANXENE SD				
+ RECORDATI RARE	11.25MG **		N017105 005	
+	22.5MG **		N017105 004	

CLOTRIMAZOLE

CREAM;TOPICAL				
LOTRIMIN				
SCHERING PLOUGH	1% **		N017619 001	
MYCELEX				
BAYER HEALTHCARE LLC	1%		N018183 001	
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	1% **		N018052 002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	2%		N020574 001	Nov 24, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	1%		N018230 002	Dec 26, 1991
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,200MG		N020526 002	Jul 29, 1996
GYNE-LOTRIMIN COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,100MG		N020289 002	Apr 26, 1993
MYCELEX-7 COMBINATION PACK				
BAYER HEALTHCARE LLC	1%,100MG		N020389 002	Jun 23, 1994
LOTION;TOPICAL				
LOTRIMIN				
SCHERING	1%		N018813 001	Feb 17, 1984
SOLUTION;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1% **		N017613 001	
MYCELEX				
+ BAYER HLTHCARE	1% **		N018181 001	
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	100MG		N017717 002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	200MG		N020525 001	Jul 29, 1996
GYNIX				
TEVA PHARMS	100MG		A073249 001	Feb 13, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	100MG		N018182 002	Dec 26, 1991
MYCELEX-G				
BAYER PHARMS	500MG		N019069 001	Apr 19, 1985
TROCHE/LOZENGE;ORAL				
MYCELEX				
+ BAYER HLTHCARE	10MG **		N018713 001	Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE;ORAL				
CLOXACILLIN SODIUM				
APOTHECON	EQ 250MG BASE		A061452 001	
	EQ 500MG BASE		A061452 002	
TEVA	EQ 250MG BASE		A062240 001	
	EQ 500MG BASE		A062240 002	
CLOXAPEN				
GLAXOSMITHKLINE	EQ 250MG BASE		A061806 001	
	EQ 250MG BASE		A062233 001	
	EQ 500MG BASE		A061806 002	
	EQ 500MG BASE		A062233 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CLOXACILLIN SODIUM

FOR SOLUTION;ORAL

CLOXACILLIN SODIUM

TEVA	EQ 125MG BASE/5ML	A062268	001	
	EQ 125MG BASE/5ML	A062978	001	Apr 06, 1989

TEGOPEN

APOTHECON	EQ 125MG BASE/5ML	A061453	001	
	EQ 125MG BASE/5ML	N050192	001	

CLOZAPINE

TABLET;ORAL

CLOZAPINE

MYLAN	12.5MG	A075417	003	Apr 15, 2010
PAR PHARM	25MG	A075162	001	Apr 26, 2005
	100MG	A075162	002	Apr 26, 2005
SANDOZ	25MG	A074546	001	Aug 30, 1996
	100MG	A074546	002	Aug 30, 1996
ZYDUS PHARMS	25MG	A209480	001	Dec 06, 2017
	50MG	A209480	002	Dec 06, 2017
	100MG	A209480	003	Dec 06, 2017
	200MG	A209480	004	Dec 06, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

+	JAZZ	12.5MG **	N021590	004	May 30, 2007
+		25MG **	N021590	001	Feb 10, 2004
		50MG **	N021590	003	Jun 03, 2005
+		100MG **	N021590	002	Feb 10, 2004
+		150MG **	N021590	005	Jul 09, 2010
+		200MG **	N021590	006	Jul 09, 2010

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

+	ANI PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML **	N008306	005	Apr 02, 1984

PHERAZINE VC W/ CODEINE

	HALSEY	10MG/5ML;5MG/5ML;6.25MG/5ML	A088870	001	Mar 02, 1987

PROMETH VC W/ CODEINE

	NOSTRUM LABS INC	10MG/5ML;5MG/5ML;6.25MG/5ML	A088764	001	Oct 31, 1984

PROMETHAZINE VC W/ CODEINE

	CENCI	10MG/5ML;5MG/5ML;6.25MG/5ML	A088816	001	Nov 22, 1985
	WOCKHARDT	10MG/5ML;5MG/5ML;6.25MG/5ML	A088896	001	Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

+	ANI PHARMS	10MG/5ML;6.25MG/5ML **	N008306	004	Apr 02, 1984

PHERAZINE W/ CODEINE

	HALSEY	10MG/5ML;6.25MG/5ML	A088739	001	Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

	PHARM ASSOC	10MG/5ML;6.25MG/5ML	A089647	001	Dec 22, 1988

PROMETHAZINE W/ CODEINE

	CENCI	10MG/5ML;6.25MG/5ML	A088814	001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

	GLAXOSMITHKLINE	10MG/5ML;30MG/5ML;1.25MG/5ML	N012575	003	Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

	CENCI	10MG/5ML;30MG/5ML;1.25MG/5ML	A089018	001	Jul 23, 1986

TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE

	WOCKHARDT	10MG/5ML;30MG/5ML;1.25MG/5ML	A088833	001	Nov 16, 1984

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

	HIKMA	30MG/5ML	N202245	001	Jun 30, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

COLCHICINE				
CAPSULE;ORAL				
COLCHICINE				
PAR PHARM INC	0.6MG		A208678 001	Nov 29, 2018
COLCHICINE; PROBENECID				
TABLET;ORAL				
COLBENEMID				
+ MERCK	0.5MG;500MG **		N012383 001	
PROBEN-C				
WATSON LABS	0.5MG;500MG		A085552 001	
PROBENECID AND COLCHICINE				
ANI PHARMS	0.5MG;500MG		A083734 001	
BEECHAM	0.5MG;500MG		A084321 001	
IMPAX LABS	0.5MG;500MG		A083720 002	
SANDOZ	0.5MG;500MG		A086130 001	
PROBENECID W/ COLCHICINE				
LEDERLE	0.5MG;500MG		A086954 001	
WATSON LABS	0.5MG;500MG		A083221 001	
COLESEVELAM HYDROCHLORIDE				
BAR, CHEWABLE;ORAL				
WELCHOL				
+ DAIICHI SANKYO INC	3.75GM		N210895 001	Apr 03, 2019
CAPSULE;ORAL				
WELCHOL				
DAIICHI SANKYO	375MG		N021141 001	May 26, 2000
FOR SUSPENSION;ORAL				
COLESEVELAM HYDROCHLORIDE				
WATSON LABS INC	1.875GM/PACKET		A202178 001	Sep 01, 2020
	3.75GM/PACKET		A202178 002	Sep 01, 2020
WELCHOL				
+ DAIICHI SANKYO	1.875GM/PACKET **		N022362 001	Oct 02, 2009
TABLET;ORAL				
COLESEVELAM HYDROCHLORIDE				
INVAGEN PHARMS	625MG		A212602 001	Apr 20, 2020
WATSON LABS INC	625MG		A200830 001	Sep 02, 2020
COLISTIN SULFATE				
SUSPENSION;ORAL				
COLY-MYCIN S				
PARKE DAVIS	EQ 25MG BASE/5ML		N050355 001	
CONIVAPTAN HYDROCHLORIDE				
INJECTABLE;INTRAVENOUS				
VAPRISOL				
CUMBERLAND PHARMS	20MG/4ML (5MG/ML)		N021697 001	Dec 29, 2005
COPPER				
INTRAUTERINE DEVICE;INTRAUTERINE				
CU-7				
GD SEARLE LLC	89MG		N017408 001	
TATUM-T				
GD SEARLE LLC	120MG		N018205 001	
CORTICOTROPIN				
INJECTABLE;INJECTION				
ACTH				
PARKEDALE	25 UNITS/VIAL		N008317 002	
	40 UNITS/VIAL		N008317 004	
ACTHAR				
SANOFI AVENTIS US	25 UNITS/VIAL		N007504 002	
	40 UNITS/VIAL		N007504 003	
ACTHAR GEL				
MALLINCKRODT ARD	40 UNITS/ML		N008372 006	
CORTICOTROPIN				
ORGANICS LAGRANGE	40 UNITS/ML		N010831 001	
	80 UNITS/ML		N010831 002	
WATSON LABS	40 UNITS/VIAL		A088772 001	Nov 21, 1984
PURIFIED CORTROPHIN GEL				
ANI PHARMS	40 UNITS/ML		N008975 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE;INJECTION				
CORTROPHIN-ZINC				
	ANI PHARMS	40 UNITS/ML	N009854 001	

CORTISONE ACETATE

INJECTABLE;INJECTION				
CORTISONE ACETATE				
	PHARMACIA AND UPJOHN	25MG/ML	N008126 002	
	WATSON LABS	25MG/ML	A083147 003	
		25MG/ML	A085677 001	
		50MG/ML	A083147 004	
		50MG/ML	A085677 002	
CORTONE				
	MERCK	25MG/ML	N007110 002	
		50MG/ML	N007110 003	
TABLET;ORAL				
CORTISONE ACETATE				
	BARR	25MG	A083471 001	
	ELKINS SINN	25MG	A080836 001	
	EVERYLIFE	25MG	A084246 001	
	HEATHER	25MG	A085736 001	
	IMPAX LABS	25MG	N009458 001	
	INWOOD LABS	25MG	A080731 001	
	IVAX SUB TEVA PHARMS	25MG	A080630 001	
		25MG	A083536 001	
	LANNETT	25MG	A080694 001	
	PANRAY	5MG	N008284 002	
		25MG	N008284 001	
	PHARMACIA AND UPJOHN	5MG	N008126 003	
		10MG	N008126 004	
		25MG	N008126 001	
	PUREPAC PHARM	25MG	A080493 001	
	VITARINE	25MG	A080333 001	
	WATSON LABS	25MG	A085884 001	
	WHITEWORTH TOWN PLSN	25MG	A080341 001	
CORTONE				
+	MERCK	25MG **	N007750 003	

COSYNTROPIN

SOLUTION;INTRAVENOUS				
COSYNTROPIN				
	SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028 001	Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED;INHALATION				
INTAL				
	KING PHARMS LLC	0.8MG/INH	N018887 001	Dec 05, 1985
CAPSULE;INHALATION				
INTAL				
+	SANOFI AVENTIS US	20MG **	N016990 001	
CAPSULE;ORAL				
GASTROCROM				
	UCB INC	100MG	N019188 001	Dec 22, 1989
CONCENTRATE;ORAL				
CROMOLYN SODIUM				
	GENERA PHARMS	100MG/5ML	A090954 001	Dec 18, 2009
SOLUTION;INHALATION				
CROMOLYN SODIUM				
	ACTAVIS MID ATLANTIC	10MG/ML	A075067 001	Jul 19, 1999
	BAUSCH AND LOMB	10MG/ML	A075585 001	Dec 21, 2000
	FERA PHARMS LLC	10MG/ML	A075437 001	Apr 21, 2000
	HIKMA	10MG/ML	A075333 001	Apr 30, 2002
	MYLAN SPECIALITY LP	10MG/ML	A074209 001	Apr 26, 1994
	ROXANE	10MG/ML	A075175 001	Sep 30, 1999
	WATSON LABS	10MG/ML	A076469 001	Jun 17, 2005
INTAL				
+	KING PHARMS LLC	10MG/ML **	N018596 001	May 28, 1982

CROMOLYN SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
CROLOM				
BAUSCH AND LOMB	4%	A074443	001	Jan 30, 1995
CROMOLYN SODIUM				
APOTEX INC	4%	A075615	001	Jan 26, 2001
CROMOPTIC				
KING PHARMS	4%	A075088	001	Apr 27, 1999
OPTICROM				
+ ALLERGAN	4% **	N018155	001	Oct 03, 1984
SPRAY, METERED;NASAL				
CROMOLYN SODIUM				
ACTAVIS MID ATLANTIC	5.2MG/SPRAY	A074800	001	Jul 26, 2001
HH AND P	5.2MG/SPRAY	A077976	001	Sep 07, 2007
NASALCROM				
+ BLACKSMITH BRANDS	5.2MG/SPRAY **	N020463	001	Jan 03, 1997
CROTAMITON				
CREAM;TOPICAL				
EURAX				
+ JOURNEY	10%	N006927	001	
CRYPTENAMINE ACETATES				
INJECTABLE;INJECTION				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT/ML	N008814	001	
CRYPTENAMINE TANNATES				
TABLET;ORAL				
UNITENSEN				
MEDPOINTE PHARM HLC	260CSR UNIT	N009217	001	
CUPRIC SULFATE				
INJECTABLE;INJECTION				
CUPRIC SULFATE				
+ ABRAXIS PHARM	EQ 0.4MG COPPER/ML	N019350	001	May 05, 1987
CYANOCOBALAMIN				
GEL, METERED;NASAL				
NASCOBAL				
PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996
INJECTABLE;INJECTION				
BERUBIGEN				
PHARMACIA AND UPJOHN	1MG/ML	N006798	001	
BETALIN 12				
LILLY	0.1MG/ML	A080855	001	
	1MG/ML	A080855	002	
COBAVITE				
WATSON LABS	0.1MG/ML	A083013	001	
	1MG/ML	A083064	001	
CYANOCOBALAMIN				
ABRAXIS PHARM	0.03MG/ML	A080510	003	
	0.1MG/ML	A080510	001	
	1MG/ML	A080510	002	
AKORN	1MG/ML	A087969	001	Nov 10, 1983
DELL LABS	0.03MG/ML	A080689	001	
	0.1MG/ML	A080689	002	
	1MG/ML	A080689	003	
DR REDDYS	0.1MG/ML	A080573	002	
	1MG/ML	A080573	001	
FRESENIUS KABI USA	0.1MG/ML	A080557	002	
LUITPOLD	0.03MG/ML	A080668	001	
LYPHOMED	1MG/ML	A083075	001	
MYLAN INSTITUTIONAL	1MG/ML	A040451	001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564	001	
SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085	002	
WATSON LABS	0.1MG/ML	A083120	001	
	1MG/ML	A083120	002	
WYETH AYERST	0.1MG/ML	A080554	001	
	1MG/ML	A080554	002	
XIROMED	1MG/ML	A215046	001	Aug 20, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYANOCOBALAMIN

INJECTABLE;INJECTION				
DODEX				
	ACCORD HLTHCARE	1MG/ML	A083022 001	
REDISOL				
	MERCK	1MG/ML	N006668 010	
RUBIVITE				
	BEL MAR	0.03MG/ML	N010791 004	
		0.05MG/ML	N010791 001	
		0.1MG/ML	N010791 002	
		0.12MG/ML	N010791 005	
		1MG/ML	N010791 003	
RUBRAMIN PC				
	BRISTOL MYERS SQUIBB	0.1MG/ML	N006799 002	
+		1MG/ML **	N006799 004	
+		1MG/ML **	N006799 010	Apr 28, 1988
RUVITE				
	SAVAGE LABS	1MG/ML	A080570 002	
VI-TWEL				
	BAYER HLTHCARE	1MG/ML	N007012 002	
SPRAY, METERED;NASAL				
CALOMIST				
	PAR PHARM	25MCG/SPRAY	N022102 001	Jul 27, 2007
CYANOCOBALAMIN				
	PADAGIS ISRAEL	0.5MG/SPRAY	A212458 001	Sep 09, 2020
TABLET;ORAL				
CYANOCOBALAMIN				
	WEST WARD	1MG	A084264 001	

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A;N/A				
DICOPAC KIT				
	GE HEALTHCARE	N/A;N/A;N/A	N017406 001	

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE;INJECTION				
DEPINAR				
	ARMOUR PHARM	0.5MG/ML;2.3MG/ML;1MG/ML	N011208 001	

CYCLACILLIN

FOR SUSPENSION;ORAL				
CYCLAPEN-W				
	WYETH AYERST	125MG/5ML	N050508 001	
		250MG/5ML	N050508 002	
		500MG/5ML	N050508 003	
TABLET;ORAL				
CYCLACILLIN				
	TEVA	250MG	A062895 001	Aug 04, 1988
		500MG	A062895 002	Aug 04, 1988
CYCLAPEN-W				
	WYETH AYERST	250MG	N050509 001	
		500MG	N050509 002	

CYCLIZINE LACTATE

INJECTABLE;INJECTION				
MAREZINE				
	GLAXOSMITHKLINE	50MG/ML	N009495 001	

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL				
CYCLOBENZAPRINE HYDROCHLORIDE				
	CHARTWELL RX	5MG	A072854 002	Feb 03, 2006
		10MG	A072854 001	Nov 19, 1991
	PLIVA	10MG	A074421 001	Sep 29, 1995
	RISING PHARMA	5MG	A073144 002	Feb 03, 2006
		7.5MG	A073144 003	Mar 25, 2013
		10MG	A073144 001	May 30, 1991
	SANDOZ	10MG	A073683 001	Feb 26, 1993
	WATSON LABS	10MG	A073143 001	Nov 27, 1991
		10MG	A074436 001	Nov 30, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYCLOBENZAPRINE HYDROCHLORIDE				
TABLET;ORAL				
FLEXERIL				
+ JANSSEN RES AND DEV	5MG **	N017821	001	
+	10MG **	N017821	002	
CYCLOPENTOLATE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AK-PENTOLATE				
AKORN	1%	A085555	001	
CYCLOPENTOLATE HYDROCHLORIDE				
ALCON PHARMS LTD	1%	A089162	001	Jan 24, 1991
SOLA BARNES HIND	1%	A084150	001	
	1%	A084863	001	
PENTOLAIR				
PHARMAFAIR	0.5%	A088643	001	Feb 09, 1987
	1%	A088150	001	Feb 25, 1983
CYCLOPHOSPHAMIDE				
INJECTABLE;INJECTION				
CYCLOPHOSPHAMIDE				
BAXTER HLTHCARE	100MG/VIAL	A088371	001	Jul 03, 1986
	200MG/VIAL	A088372	001	Jul 03, 1986
	500MG/VIAL	A088373	001	Jul 03, 1986
	1GM/VIAL	A088374	001	Sep 24, 1986
CYTOXAN				
+ BAXTER HLTHCARE	100MG/VIAL **	N012142	001	
+	200MG/VIAL **	N012142	002	
CYTOXAN (LYOPHILIZED)				
+ BAXTER HLTHCARE	500MG/VIAL	N012142	003	
+	500MG/VIAL **	N012142	008	Jan 04, 1984
+	1GM/VIAL	N012142	004	Aug 30, 1982
+	1GM/VIAL **	N012142	010	Sep 24, 1985
+	2GM/VIAL	N012142	005	Aug 30, 1982
+	2GM/VIAL **	N012142	009	Dec 10, 1985
LYOPHILIZED CYTOXAN				
+ BAXTER HLTHCARE	100MG/VIAL **	N012142	006	Dec 05, 1985
+	200MG/VIAL **	N012142	007	Dec 10, 1985
NEOSAR				
BEDFORD	100MG/VIAL	A087442	001	Feb 16, 1982
	200MG/VIAL	A087442	002	Feb 16, 1982
	500MG/VIAL	A087442	003	Feb 16, 1982
	1GM/VIAL	A087442	004	Jul 08, 1983
	2GM/VIAL	A087442	005	Mar 30, 1989
TEVA PARENTERAL	100MG/VIAL	A040015	001	Apr 29, 1993
	200MG/VIAL	A040015	002	Apr 29, 1993
	500MG/VIAL	A040015	003	Apr 29, 1993
	1GM/VIAL	A040015	004	Apr 29, 1993
	2GM/VIAL	A040015	005	Apr 29, 1993
TABLET;ORAL				
CYCLOPHOSPHAMIDE				
ROXANE	25MG	A040032	001	Aug 17, 1999
	50MG	A040032	002	Aug 17, 1999
CYCLOSPORINE				
CAPSULE;ORAL				
GENGRAF				
ABBVIE	50MG	A065003	002	May 12, 2000
NEORAL				
+ NOVARTIS	50MG **	N050715	003	Jul 14, 1995
SOLUTION;ORAL				
CYCLOSPORINE				
PHARM ASSOC	100MG/ML	A065167	001	Jan 05, 2005
CYCLOTHIAZIDE				
TABLET;ORAL				
ANHYDRON				
LILLY	2MG	N013157	002	
FLUIDIL				
PHARMACIA AND UPJOHN	2MG	N018173	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CYCRIMINE HYDROCHLORIDE

TABLET;ORAL				
PAGITANE				
	LILLY	1.25MG	N008951 001	
		2.5MG	N008951 002	

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL				
CYPROHEPTADINE HYDROCHLORIDE				
+	ACTAVIS MID ATLANTIC	2MG/5ML **	A086833 001	
	HALSEY	2MG/5ML	A089199 001	Jul 03, 1986
	MORTON GROVE	2MG/5ML	A087001 001	Nov 04, 1982
	NASKA	2MG/5ML	A089021 001	Dec 21, 1987
PERIACTIN				
+	MERCK	2MG/5ML **	N013220 002	
TABLET;ORAL				
CYPROHEPTADINE HYDROCHLORIDE				
	AM THERAP	4MG	A088798 001	Feb 15, 1985
	ASCOT	4MG	A087685 001	Oct 25, 1982
	CHARTWELL RX	4MG	A088212 001	May 26, 1983
	DURAMED PHARMS BARR	4MG	A088232 001	Oct 25, 1983
	FOSUN PHARMA	4MG	A086808 001	
	HALSEY	4MG	A089057 001	Jul 03, 1986
	KV PHARM	4MG	A086737 001	
	MD PHARM	4MG	A087566 001	Nov 10, 1982
	MYLAN	4MG	A086678 001	
	PIONEER PHARMS	4MG	A087839 001	Feb 08, 1984
	PLIVA	4MG	A088205 001	Jul 26, 1983
	STRIDES PHARMA	4MG	A087129 001	
	SUPERPHARM	4MG	A087405 001	
	VITARINE	4MG	A087284 001	
	WATSON LABS	4MG	A085245 001	
		4MG	A086165 001	
		4MG	A086580 001	
PERIACTIN				
+	MERCK	4MG **	N012649 001	

CYSTEINE HYDROCHLORIDE

INJECTABLE;INJECTION				
CYSTEINE HYDROCHLORIDE				
+	HOSPIRA	7.25% **	N019523 001	Oct 22, 1986
SOLUTION;INTRAVENOUS				
NOURESS				
+	BAXTER HLTHCARE CORP	500MG/10ML (50MG/ML)	N212535 001	Dec 13, 2019

CYTARABINE

INJECTABLE;INJECTION				
CYTARABINE				
	HONG KONG	20MG/ML	A206189 001	Jun 26, 2020
	MEITHEAL	20MG/ML	A206190 001	Nov 09, 2017
	MYLAN LABS LTD	20MG/ML	A200916 001	Dec 13, 2011
	RISING PHARMA	20MG/ML	A200914 001	Dec 13, 2011
+	TEVA PARENTERAL	100MG/VIAL **	N016793 001	
+		500MG/VIAL **	N016793 002	
+		1GM/VIAL **	N016793 003	Dec 21, 1987
+		2GM/VIAL **	N016793 004	Dec 21, 1987
CYTOSAR-U				
	TEVA PHARMS USA	100MG/VIAL	A075206 001	Dec 30, 1998
		500MG/VIAL	A075206 002	Dec 30, 1998
		1GM/VIAL	A075206 004	Dec 30, 1998
		2GM/VIAL	A075206 003	Dec 30, 1998
INJECTABLE, LIPOSOMAL;INJECTION				
DEPOCYT				
+	PACIRA PHARMS INC	10MG/ML	N021041 001	Apr 01, 1999

DACARBAZINE

INJECTABLE;INJECTION					
DACARBAZINE					
	ABRAXIS PHARM	100MG/VIAL	A070962	001	Aug 28, 1986
		200MG/VIAL	A070990	001	Aug 28, 1986
DTIC-DOME					
+	BAYER HLTHCARE	100MG/VIAL **	N017575	001	
+		200MG/VIAL **	N017575	002	

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL					
DAKLINZA					
+	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015
+		EQ 60MG BASE	N206843	002	Jul 24, 2015
+		EQ 90MG BASE	N206843	003	Apr 13, 2016

DACTINOMYCIN

INJECTABLE;INJECTION					
DACTINOMYCIN					
	AM REGENT	0.5MG/VIAL	A202562	001	Aug 23, 2013
	HIKMA	0.5MG/VIAL	A090304	001	Mar 16, 2010

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL					
DALFAMPRIDINE					
	RISING PHARMA	10MG	A206858	001	Jul 06, 2020

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE;INTRAVENOUS					
SYNERCID					
	KING PHARMS	420MG/VIAL;180MG/VIAL	N050748	002	Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE;INJECTION					
FRAGMIN					
	PFIZER	7,500 IU/0.75ML	N020287	008	Apr 04, 2002
INJECTABLE;SUBCUTANEOUS					
FRAGMIN					
	PFIZER	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007
		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE;INJECTION					
ORGARAN					
	ASPEN GLOBAL INC	750 UNITS/0.6ML	N020430	001	Dec 24, 1996

DANAZOL

CAPSULE;ORAL					
DANAZOL					
	AM THERAP	200MG	A071569	001	Dec 30, 1987
DANOCRINE					
	SANOFI AVENTIS US	50MG **	N017557	003	
		100MG **	N017557	004	
		200MG **	N017557	002	

DANTROLENE SODIUM

INJECTABLE;INJECTION					
DANTROLENE SODIUM					
	AUROMEDICS PHARMA	20MG/VIAL	A205239	001	Feb 18, 2016

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
QTERNMET XR					
+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019
+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019
+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019
+		10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019

DAPIPRAZOLE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE

+	FERA PHARMS	0.5% **	N019849	001	Dec 31, 1990
	WOODWARD	0.5%	A204902	001	May 30, 2019

DAPSONE
TABLET;ORAL
DAPSONE

TARO	25MG	A209430	001	Mar 01, 2019
	100MG	A209430	002	Mar 01, 2019

DAPTOMYCIN
POWDER;INTRAVENOUS
CUBICIN

CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003

DAPTOMYCIN

HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021
HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014

DARIFENACIN HYDROBROMIDE
TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015
	EQ 15MG BASE	A091190	002	Mar 13, 2015
JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016
	EQ 15MG BASE	A205550	002	Oct 12, 2016

ENABLEX

+	APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004
+		EQ 15MG BASE	N021513	002	Dec 22, 2004

DARUNAVIR
TABLET;ORAL
PREZISTA

+	JANSSEN PRODS	300MG **	N021976	001	Jun 23, 2006
+		400MG **	N021976	003	Oct 21, 2008

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR
TABLET;ORAL
VIEKIRA PAK (COPACKAGED)

+	ABBVIE INC	EQ 250MG BASE;12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR
TABLET, EXTENDED RELEASE;ORAL
VIEKIRA XR

+	ABBVIE INC	EQ 200MG BASE;8.33MG;50MG;33.33MG **	N208624	001	Jul 22, 2016

DASATINIB
TABLET;ORAL
DASATINIB

APOTEX INC	20MG	A202103	001	Jun 10, 2016
	50MG	A202103	002	Jun 10, 2016
	70MG	A202103	003	Jun 10, 2016
	100MG	A202103	004	Jun 10, 2016

DAUNORUBICIN CITRATE
INJECTABLE, LIPOSOMAL;INJECTION
DAUNOXOME

GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
CERUBIDINE

SANOFI AVENTIS US	EQ 20MG BASE/VIAL	A061876	001	
WYETH AYERST	EQ 20MG BASE/VIAL **	N050484	001	

DAUNORUBICIN HYDROCHLORIDE

HISUN PHARM HANGZHOU	EQ 20MG BASE/VIAL	A206195	001	Apr 25, 2019
TEVA PARENTERAL	EQ 20MG BASE/VIAL	A064212	001	Jun 23, 1998
	EQ 50MG BASE/VIAL	A064212	002	May 03, 1999

DECAMETHONIUM BROMIDE				
INJECTABLE;INJECTION				
SYNCURINE				
	GLAXOSMITHKLINE	1MG/ML	N006931 002	
DECITABINE				
INJECTABLE;INTRAVENOUS				
DECITABINE				
	CIPLA	50MG/VIAL	A208601 001	Nov 16, 2017
DEFERASIROX				
TABLET;ORAL				
DEFERASIROX				
	AMNEAL	90MG	A210727 001	Dec 27, 2019
		360MG	A210727 002	Dec 27, 2019
TABLET, FOR SUSPENSION;ORAL				
DEFERASIROX				
	ZYDUS PHARMS	125MG	A208882 001	May 05, 2020
		250MG	A208882 002	May 05, 2020
		500MG	A208882 003	May 05, 2020
DEFERIPRONE				
SOLUTION;ORAL				
FERRIPROX				
+	CHIESI	80MG/ML	N208030 002	Apr 20, 2018
DEFEROXAMINE MESYLATE				
INJECTABLE;INJECTION				
DEFEROXAMINE MESYLATE				
	DR REDDYS	500MG/VIAL	A076806 001	Mar 31, 2006
		2GM/VIAL	A076806 002	Mar 31, 2006
DESFERAL				
+	NOVARTIS	2GM/VIAL	N016267 002	May 25, 2000
DELAVIRDINE MESYLATE				
TABLET;ORAL				
RESCRIPTOR				
+	VIIV HLTHCARE	100MG	N020705 001	Apr 04, 1997
+		200MG	N020705 002	Jul 14, 1999
DEMECARIUM BROMIDE				
SOLUTION/DROPS;OPHTHALMIC				
HUMORSOL				
	MERCK	0.125%	N011860 002	
		0.25%	N011860 001	
DEMECLOCYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
DECLOMYCIN				
	LEDERLE	150MG	N050262 001	
SYRUP;ORAL				
DECLOMYCIN				
	LEDERLE	75MG/5ML	N050257 001	
TABLET;ORAL				
DECLOMYCIN				
	COREPHARMA	75MG	N050261 001	
		150MG	N050261 002	
		300MG	N050261 003	
DEMECLOCYCLINE HYDROCHLORIDE				
	BARR	150MG	A065171 001	Dec 13, 2004
		300MG	A065171 002	Dec 13, 2004
	IMPAX LABS	150MG	A065094 001	Mar 22, 2004
		300MG	A065094 002	Mar 22, 2004
DESERPIDINE				
TABLET;ORAL				
HARMONYL				
	ABBVIE	0.1MG	N010796 001	
		0.25MG	N010796 002	

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET;ORAL				
ORETICYL 25				
	ABBVIE	0.125MG;25MG	N012148 001	
ORETICYL 50				
	ABBVIE	0.125MG;50MG	N012148 003	
ORETICYL FORTE				
	ABBVIE	0.25MG;25MG	N012148 002	

DESERPIDINE; METHYCLOTHIAZIDE

TABLET;ORAL				
ENDURONYL				
	ABBOTT	0.25MG;5MG	N012775 001	
ENDURONYL FORTE				
	ABBOTT	0.5MG;5MG	N012775 002	
METHYCLOTHIAZIDE AND DESERPIDINE				
	WATSON LABS	0.25MG;5MG	A088486 001	Aug 10, 1984
		0.5MG;5MG	A088452 001	Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
PERTOFRANE				
	SANOFI AVENTIS US	25MG	N013621 001	
		50MG	N013621 002	
TABLET;ORAL				
DESIPRAMINE HYDROCHLORIDE				
	ANI PHARMS	10MG	A205153 001	Oct 28, 2016
		25MG	A071803 002	Dec 08, 1987
		25MG	A205153 002	Oct 28, 2016
		50MG	A071803 003	Dec 08, 1987
		50MG	A205153 003	Oct 28, 2016
		75MG	A071803 004	Dec 08, 1987
		75MG	A205153 004	Oct 28, 2016
		100MG	A071803 001	May 29, 1997
		100MG	A205153 005	Oct 28, 2016
		150MG	A071803 005	May 29, 1997
		150MG	A205153 006	Oct 28, 2016
	USL PHARMA	25MG	A071864 001	Sep 09, 1987
		50MG	A071865 001	Sep 09, 1987
		75MG	A071866 001	Sep 09, 1987
		100MG	A071867 001	Sep 09, 1987

DESLANOSIDE

INJECTABLE;INJECTION				
CEDILANID-D				
	NOVARTIS	0.2MG/ML	N009282 002	

DESLORATADINE

SOLUTION;ORAL				
CLARINEX				
+	MERCK SHARP DOHME	0.5MG/ML	N021300 001	Sep 01, 2004
DESLORATADINE				
	TARO	0.5MG/ML	A202936 001	May 26, 2016
	TARO PHARM INDS LTD	0.5MG/ML	A202592 001	Jun 30, 2015
TABLET;ORAL				
DESLORATADINE				
	MYLAN PHARMS INC	5MG	A078351 001	Feb 10, 2012
	SUN PHARM INDS	5MG	A078359 001	Nov 16, 2010
TABLET, ORALLY DISINTEGRATING;ORAL				
CLARINEX				
+	MERCK SHARP DOHME	2.5MG	N021312 002	Jul 14, 2005
+		5MG	N021312 001	Jun 26, 2002

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL				
CLARINEX D 24 HOUR				
+	MERCK SHARP DOHME	5MG;240MG	N021605 001	Mar 03, 2005

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION					
DDAVP					
	FERRING PHARMS INC	0.015MG/ML	N018938	002	Apr 25, 1995
DESMOPRESSIN ACETATE					
	BEDFORD	0.004MG/ML	A074575	001	Feb 18, 2000
	HOSPIRA	0.004MG/ML	A075220	001	Aug 28, 2000
DESMOPRESSIN ACETATE PRESERVATIVE FREE					
	BEDFORD	0.004MG/ML	A074574	001	Feb 18, 2000
SOLUTION;NASAL					
CONCENTRAID					
	FERRING	0.01%	N019776	001	Dec 26, 1990
DDAVP					
+	FERRING PHARMS INC	0.01%	N017922	001	
DESMOPRESSIN ACETATE					
	SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012
SPRAY, METERED;NASAL					
DDAVP					
+	FERRING PHARMS INC	0.01MG/SPRAY **	N017922	002	Feb 06, 1989
DDAVP (NEEDS NO REFRIGERATION)					
+	FERRING PHARMS INC	0.01MG/SPRAY	N017922	003	Aug 07, 1996
MINIRIN					
+	FERRING	0.01MG/SPRAY	N021333	001	Sep 16, 2002
NOCTIVA					
+	SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017
+		0.00166MG/SPRAY	N201656	002	Mar 03, 2017
STIMATE					
	FERRING PHARMS INC	0.15MG/SPRAY	N020355	001	Mar 07, 1994
STIMATE (NEEDS NO REFRIGERATION)					
+	FERRING PHARMS INC	0.15MG/SPRAY	N020355	002	Oct 24, 2007
TABLET;ORAL					
DESMOPRESSIN ACETATE					
	FERRING	0.1MG	N021795	001	May 08, 2008
		0.2MG	N021795	002	May 08, 2008
	IMPAX LABS INC	0.1MG	A077122	001	Jan 25, 2006
		0.2MG	A077122	002	Jan 25, 2006
	MYLAN	0.1MG	A200653	001	Jun 27, 2014
		0.2MG	A200653	002	Jun 27, 2014

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21					
DESOGEN					
	ORGANON USA INC	0.15MG;0.03MG	N020071	001	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL					
	DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	001	Aug 12, 1999
ORTHO-CEPT					
+	JANSSEN PHARMS	0.15MG;0.03MG **	N020301	001	Dec 14, 1992
TABLET;ORAL-28					
DESOGEN					
	ORGANON USA INC	0.15MG;0.03MG	N020071	002	Dec 10, 1992
DESOGESTREL AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.15MG;0.03MG	A202085	001	May 20, 2015
	NAARI PTE LTD	0.15MG;0.03MG	A207067	001	Sep 13, 2018
EMOQUETTE					
	VINTAGE PHARMS LLC	0.15MG;0.03MG	A076675	001	Feb 25, 2011
MIRCETTE					
+	TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG **	N020713	001	Apr 22, 1998
ORTHO-CEPT					
+	JANSSEN PHARMS	0.15MG;0.03MG **	N020301	002	Dec 14, 1992

DESONIDE

GEL;TOPICAL					
DESONATE					
+	LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DESOXIMETASONE				
CREAM;TOPICAL				
DESOXIMETASONE				
AKORN	0.05%	A203787	001	Jan 06, 2017
	0.25%	A203234	001	Jun 12, 2015
TOPICORT				
+ TARO PHARM INDS LTD	0.25% **	N017856	001	
TOPICORT LP				
+ TARO PHARM INDS LTD	0.05% **	N018309	001	
GEL;TOPICAL				
TOPICORT				
+ TARO PHARM INDS LTD	0.05% **	N018586	001	Mar 29, 1982
OINTMENT;TOPICAL				
DESOXIMETASONE				
ALTANA	0.25%	A073440	001	Apr 01, 1998
TOPICORT				
TARO PHARM INDS LTD	0.25%	A074286	001	Jun 07, 1996
+	0.25% **	N018763	001	Sep 30, 1983
DESOXYCORTICOSTERONE ACETATE				
INJECTABLE;INJECTION				
DOCA				
ORGANON USA INC	5MG/ML	N001104	001	
PELLET;IMPLANTATION				
PERCORTEN				
NOVARTIS	125MG	N005151	001	
DESOXYCORTICOSTERONE PIVALATE				
INJECTABLE;INJECTION				
PERCORTEN				
NOVARTIS	25MG/ML	N008822	001	
DESVENLAFAXINE				
TABLET, EXTENDED RELEASE;ORAL				
KHEDEZLA				
OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
	100MG	N204683	002	Jul 10, 2013
DESVENLAFAXINE FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE				
+ SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014
+	EQ 100MG BASE	N205583	002	Jan 28, 2014
TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013
	EQ 100MG BASE	N205208	002	Oct 11, 2013
DESVENLAFAXINE SUCCINATE				
TABLET, EXTENDED RELEASE;ORAL				
DESVENLAFAXINE SUCCINATE				
MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015
	EQ 100MG BASE	A204095	002	Jun 29, 2015
DEXAMETHASONE				
AEROSOL;TOPICAL				
AEROSEB-DEX				
ALLERGAN HERBERT	0.01% **	A083296	002	
DECASPRAY				
+ MERCK	0.04% **	N012731	002	
ELIXIR;ORAL				
DECADRON				
MERCK	0.5MG/5ML	N012376	002	
DEXAMETHASONE				
ALPHARMA US PHARMS	0.5MG/5ML	A088997	001	Oct 10, 1986
+ WOCKHARDT BIO AG	0.5MG/5ML	A088254	001	Jul 27, 1983
HEXADROL				
ASPEN GLOBAL INC	0.5MG/5ML	N012674	001	
GEL;TOPICAL				
DECADERM				
MERCK	0.1%	N013538	001	
SUSPENSION/DROPS;OPHTHALMIC				
DEXAMETHASONE				
WATSON LABS	0.1%	A089170	001	May 09, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE				
TABLET;ORAL				
DECADRON				
+ MERCK	0.25MG **	N011664	004	
+	0.5MG **	N011664	001	
+	0.75MG **	N011664	002	
+	1.5MG **	N011664	003	
+	4MG **	N011664	005	
+	6MG **	N011664	006	Jul 30, 1982
DEXAMETHASONE				
BAUSCH	1.5MG	A040700	001	Aug 15, 2008
HERITAGE PHARMA	1.5MG	A085456	001	
IMPAX LABS	0.75MG	A085376	001	
PHOENIX LABS NY	0.75MG	A083806	001	
PRASCO	0.75MG	A080399	001	
PVT FORM	0.75MG	A083420	001	
ROXANE	0.25MG	A084614	001	
STRIDES PHARMA	0.25MG	A088149	001	Apr 28, 1983
SUN PHARM INDUSTRIES	0.25MG	A084013	001	
	0.25MG	A084764	001	
	0.5MG	A084084	001	
	0.5MG	A084766	001	
	0.75MG	A084081	001	
	0.75MG	A084765	001	
	1.5MG	A084086	001	
	1.5MG	A084763	001	
UPSHER SMITH	0.75MG	A087534	001	
	1.5MG	A087533	001	
WATSON LABS	0.25MG	A085455	001	
	0.5MG	A085458	001	
	0.75MG	A080968	001	
	0.75MG	A084457	001	
	0.75MG	A085818	001	
	1.5MG	A085840	001	
WHITEWORTH TOWN PLSN	0.75MG	A084327	001	
DEXONE 0.5				
SOLVAY	0.5MG	A084991	001	
DEXONE 0.75				
SOLVAY	0.75MG	A084993	001	
DEXONE 1.5				
SOLVAY	1.5MG	A084990	001	
DEXONE 4				
SOLVAY	4MG	A084992	001	
HEXADROL				
ASPEN GLOBAL INC	0.5MG	N012675	004	
	0.75MG	N012675	007	
	1.5MG	N012675	009	
	4MG	N012675	010	
DEXAMETHASONE ACETATE				
INJECTABLE;INJECTION				
DECADRON-LA				
+ MERCK	EQ 8MG BASE/ML **	N016675	001	
DEXAMETHASONE ACETATE				
WATSON LABS	EQ 8MG BASE/ML	A084315	001	
WATSON LABS TEVA	EQ 16MG BASE/ML	A087711	001	May 24, 1982
DEXAMETHASONE SODIUM PHOSPHATE				
AEROSOL;NASAL				
DEXACORT				
UCB INC	EQ 0.1MG PHOSPHATE/INH	N014242	001	
AEROSOL, METERED;INHALATION				
DEXACORT				
UCB INC	EQ 0.1MG PHOSPHATE/INH	N013413	001	
CREAM;TOPICAL				
DECADRON				
MERCK	EQ 0.1% PHOSPHATE	N011983	002	
INJECTABLE;INJECTION				
DECADRON				
+ MERCK	EQ 4MG PHOSPHATE/ML **	N012071	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION				
DECADRON				
+		EQ 24MG PHOSPHATE/ML **	N012071 004	
DEXACEN-4				
	CENT PHARMS	EQ 4MG PHOSPHATE/ML	A084342 001	
DEXAMETHASONE				
	ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448 001	Jan 25, 1984
	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469 001	Jan 25, 1984
DEXAMETHASONE SODIUM PHOSPHATE				
	AKORN	EQ 4MG PHOSPHATE/ML	A084493 001	
	BEL MAR	EQ 4MG PHOSPHATE/ML	A084752 001	
	DELL LABS	EQ 4MG PHOSPHATE/ML	A083161 001	
	DR REDDYS	EQ 4MG PHOSPHATE/ML	A089169 001	Apr 09, 1986
	INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522 001	Feb 17, 1984
+	LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440 001	Jul 21, 1982
	LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065 001	
	TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125 001	Aug 31, 1990
		EQ 10MG PHOSPHATE/ML	A081126 001	Aug 31, 1990
	WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702 001	
		EQ 4MG PHOSPHATE/ML	A084355 001	
		EQ 10MG PHOSPHATE/ML	A087668 001	Jul 01, 1982
		EQ 24MG PHOSPHATE/ML	A085606 001	
	WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001	
HEXADROL				
+	ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694 002	
+		EQ 10MG PHOSPHATE/ML **	N014694 003	
		EQ 20MG PHOSPHATE/ML	N014694 004	
OINTMENT;OPHTHALMIC				
DECADRON				
	MERCK	EQ 0.05% PHOSPHATE	N011977 001	
DEXAIR				
	PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982
MAXIDEX				
	ALCON	EQ 0.05% PHOSPHATE	A083342 001	
SOLUTION/DROPS;OPHTHALMIC				
DEXAIR				
	PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983
DEXAMETHASONE SODIUM PHOSPHATE				
	SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001	
		EQ 0.1% PHOSPHATE	A084173 001	
SOLUTION/DROPS;OPHTHALMIC, OTIC				
DECADRON				
+	MERCK	EQ 0.1% PHOSPHATE	N011984 001	
DEXAMETHASONE SODIUM PHOSPHATE				
	SANDOZ INC	EQ 0.1% PHOSPHATE	A088771 001	Jan 16, 1985
SOLUTION/DROPS;OTIC				
DEXAMETHASONE SODIUM PHOSPHATE				
	AKORN	EQ 0.1% PHOSPHATE	A084855 001	

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DECADRON W/ XYLOCAINE				
	MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334 002	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324 001	
SOLUTION/DROPS;OPHTHALMIC				
NEODECADRON				
	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322 001	
NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE				
	BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE				
	ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986
	PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566 001	Feb 22, 1985
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411 001	May 16, 1983
SUSPENSION/DROPS;OPHTHALMIC				
DEXACIDIN				
	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544 001	Oct 29, 1984
DEXASPORIN				
	PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428 001	May 18, 1983
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE				
	ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL				
DISOMER				
	SCHERING	2MG/5ML	N011814 002	
TABLET;ORAL				
DISOMER				
	SCHERING	2MG	N011814 001	

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL				
DISOPHROL				
	SCHERING	2MG;60MG	N012394 002	
TABLET, EXTENDED RELEASE;ORAL				
BROMPHERIL				
	COPLEY PHARM	6MG;120MG	A089116 001	Jan 22, 1987
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE				
	AVANTHI INC	6MG;120MG	A078648 001	Feb 27, 2013
DISOBROM				
	SANDOZ	6MG;120MG	A070770 001	Sep 30, 1991
DISOPHROL				
	SCHERING PLOUGH	6MG;120MG	N013483 004	Sep 13, 1982
DRIXORAL				
+	SCHERING PLOUGH	6MG;120MG **	N013483 003	Sep 13, 1982
RESPORAL				
	PIONEER PHARMS	6MG;120MG	A089139 001	Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL				
POLARAMINE				
	SCHERING	2MG/5ML	A086837 001	Jul 19, 1982
TABLET;ORAL				
DEXCHLORPHENIRAMINE MALEATE				
	ANI PHARMS	2MG	A088682 001	Jan 17, 1986
POLARAMINE				
+	SCHERING	2MG	A086835 001	

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
DEXILANT SOLUTAB				
+	TAKEDA PHARMS USA	30MG	N208056 001	Jan 26, 2016

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION				
DEXMEDETOMIDINE HYDROCHLORIDE				
	AM REGENT	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203773 001	May 12, 2017
	SLAYBACK PHARMA LLC	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	A212791 003	May 08, 2020

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
DEXMETHYLPHENIDATE HYDROCHLORIDE				
	AUROLIFE PHARMA LLC	5MG	A204266 001	Aug 25, 2015
		10MG	A204266 002	Aug 25, 2015
		15MG	A204266 003	Aug 25, 2015
		20MG	A204266 004	Dec 21, 2015
		25MG	A204266 005	May 04, 2021
		30MG	A202580 001	Aug 28, 2013
		35MG	A204266 006	May 04, 2021
		40MG	A204266 007	Aug 25, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020
	10MG	A209754	002	Mar 24, 2020
LANNETT CO INC	2.5MG	A209468	001	Sep 25, 2017
	5MG	A209468	002	Sep 25, 2017
	10MG	A209468	003	Sep 25, 2017
TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007
	5MG	A077107	001	Jan 29, 2007
	10MG	A077107	002	Jan 29, 2007

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

TOTECT

+ CLINIGEN	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

ZINECARD

+ PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995
+	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995

DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DEXAMPEX

TEVA	15MG	A085355	001	

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

ABLE	5MG	A076814	001	Aug 25, 2004
	10MG	A076814	002	Aug 25, 2004
	15MG	A076814	003	Aug 25, 2004
MYLAN	5MG	A206735	001	Jan 27, 2016
	10MG	A206735	002	Jan 27, 2016
	15MG	A206735	003	Jan 27, 2016
STRIDES PHARMA	5MG	A205077	001	Jun 21, 2019
	10MG	A205077	002	Jun 21, 2019
	15MG	A205077	003	Jun 21, 2019

ELIXIR;ORAL

DEXEDRINE

GLAXOSMITHKLINE	5MG/5ML **	A083902	001	

TABLET;ORAL

DEXAMPEX

TEVA	5MG	A083735	001	
	10MG	A083735	002	

DEXEDRINE

+ GLAXOSMITHKLINE	5MG **	A084935	001	

DEXTROAMPHETAMINE SULFATE

ANI PHARMS	5MG	A085370	001	
EPIC PHARMA LLC	5MG	A090652	001	Mar 07, 2014
	10MG	A090652	002	Mar 07, 2014
HALSEY	10MG	A083930	001	
LANNETT	5MG	A083903	001	
	10MG	A083903	003	
	15MG	A085652	001	
MAST MM	5MG	A086521	001	
NESHER PHARMS	5MG	A040365	001	Oct 31, 2002
	10MG	A040367	001	Oct 31, 2002
PUREPAC PHARM	5MG	A084125	001	
SANDOZ	10MG	A085371	001	
STRIDES PHARMA	5MG	A040299	001	May 13, 1999
VITARINE	5MG	A084986	001	
	10MG	A085892	001	

DEXTROSTAT

+ SHIRE	5MG **	A084051	001	
+	10MG **	A084051	002	

FERNDEX

FERNDALE LABS	5MG	A084001	001	

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL					
PHERAZINE DM					
	HALSEY	15MG/5ML;6.25MG/5ML	A088913	001	Mar 02, 1987
PROMETH W/ DEXTROMETHORPHAN					
	G AND W LABS INC	15MG/5ML;6.25MG/5ML **	A088762	001	Oct 31, 1984
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
	AKORN	15MG/5ML;6.25MG/5ML	A040027	001	Jul 31, 1996
+	ANI PHARMS	15MG/5ML;6.25MG/5ML **	N011265	002	Apr 02, 1984

DEXTROSE

INJECTABLE;INJECTION					
DEXTROSE 10% IN PLASTIC CONTAINER					
	B BRAUN	10GM/100ML	N018046	001	
	MILES	10GM/100ML	N018504	001	
DEXTROSE 2.5% IN PLASTIC CONTAINER					
	B BRAUN	2.5GM/100ML	N018358	001	
		2.5GM/100ML	N019626	001	Feb 02, 1988
DEXTROSE 20% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	20GM/100ML **	N017521	004	
DEXTROSE 30% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	30GM/100ML **	N017521	003	
DEXTROSE 38.5% IN PLASTIC CONTAINER					
	ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984
DEXTROSE 40% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	40GM/100ML **	N017521	002	
DEXTROSE 5% IN PLASTIC CONTAINER					
	DHL	5GM/100ML	N019971	001	Sep 28, 1995
+	ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984
DEXTROSE 50% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	50GM/100ML **	N017521	001	
	ICU MEDICAL INC	50GM/100ML	N019894	001	Dec 26, 1989
DEXTROSE 60%					
	B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982
DEXTROSE 60% IN PLASTIC CONTAINER					
	B BRAUN	60GM/100ML	N017995	001	
+	BAXTER HLTHCARE	60GM/100ML **	N017521	005	Mar 26, 1982
		60GM/100ML	N020047	002	Jul 02, 1991
	HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985
DEXTROSE 7.7% IN PLASTIC CONTAINER					
	B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988
DEXTROSE 70% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	70GM/100ML **	N017521	006	Mar 26, 1982

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML	N017385	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION					
ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML	N019025	001	Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION					
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML	N019515	001	May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N019844	001	Jun 10, 1993
ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML	N018273	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION					
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N019843	001	Aug 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018274	001	
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION					
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%					
	FRESENIUS KABI USA	5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%					
	FRESENIUS KABI USA	5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;37MG/100ML	N019699	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;75MG/100ML	N018744	001	Nov 09, 1982
		5GM/100ML;75MG/100ML	N019699	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;110MG/100ML	N019699	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;150MG/100ML	N018744	002	Nov 09, 1982
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;220MG/100ML	N018744	003	Nov 09, 1982
		5GM/100ML;220MG/100ML	N019699	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;300MG/100ML	N018744	004	Nov 09, 1982
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML	N018371	003	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML	N018371	002	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION					
IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML	N019514	001	May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N019870	001	Jun 10, 1993
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML	N018270	001	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION					
DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%					
	B BRAUN	5GM/100ML;75MG/100ML;200MG/100ML	N018268	009	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;150MG/100ML;200MG/100ML	N018268	004	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;220MG/100ML;200MG/100ML	N018268	005	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N018268	006	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;75MG/100ML;330MG/100ML	N018268	011	Jan 18, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML		N018268 012	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;220MG/100ML;330MG/100ML		N018268 013	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML		N018268 014	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%					
	B BRAUN	5GM/100ML;75MG/100ML;450MG/100ML		N018268 010	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML		N018268 001	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;220MG/100ML;450MG/100ML		N018268 002	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML		N018268 003	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML		N018008 003	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML		N018008 001	
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML		N018008 002	
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML		A212348 001	Jul 30, 2021
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML **		N018365 002	Jul 05, 1983
+		5GM/100ML;149MG/100ML;225MG/100ML **		N018365 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML		N018876 001	Jan 17, 1986
		5GM/100ML;149MG/100ML;300MG/100ML		N018876 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
	FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML		A213523 001	Mar 09, 2021
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML		N019691 002	Mar 24, 1988
+		5GM/100ML;149MG/100ML;900MG/100ML		N019691 004	Mar 24, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML **		N018365 008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML		N018876 007	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;224MG/100ML;450MG/100ML		N018362 006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML		N019691 006	Mar 24, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML		A212348 002	Jul 30, 2021
+	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML **		N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML		N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML		A213523 002	Mar 09, 2021
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;298MG/100ML;450MG/100ML		N018362 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML		A213445 001	Mar 09, 2021
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;298MG/100ML;900MG/100ML		N019691 008	Mar 24, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;149MG/100ML;300MG/100ML		N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;225MG/100ML **		N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;224MG/100ML;300MG/100ML		N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
	FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML		A213523 003	Mar 09, 2021
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	ICU MEDICAL INC	5GM/100ML;224MG/100ML;900MG/100ML		N019691 007	Mar 24, 1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;225MG/100ML **		N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	ICU MEDICAL INC	5GM/100ML;298MG/100ML;300MG/100ML		N018876 004	Mar 28, 1988

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%				
	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523 004	Mar 09, 2021
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%				
	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445 002	Mar 09, 2021
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;225MG/100ML **	N018365 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;225MG/100ML **	N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;300MG/100ML	N018876 005	Mar 28, 1988
		5GM/100ML;149MG/100ML;300MG/100ML	N018876 009	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 008	Mar 28, 1988
+		5GM/100ML;149MG/100ML;450MG/100ML	N018362 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 001	Mar 24, 1988
+		5GM/100ML;149MG/100ML;900MG/100ML	N019691 003	Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;200MG/100ML	N018386 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;450MG/100ML	N018229 001	
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	10GM/100ML;900MG/100ML	N018047 001	
	BAXTER HLTHCARE	10GM/100ML;900MG/100ML	N016696 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;450MG/100ML	N018030 001	
	HOSPIRA	2.5GM/100ML;450MG/100ML	N018096 001	
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	B BRAUN	2.5GM/100ML;900MG/100ML	N018376 001	
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ABBOTT	3.3GM/100ML;300MG/100ML	N018055 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;110MG/100ML	N018030 005	
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;200MG/100ML	N018030 004	
	MILES	5GM/100ML;200MG/100ML	N018399 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;225MG/100ML	N019482 001	Oct 04, 1985
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;300MG/100ML	N019486 001	Oct 04, 1985
	MILES	5GM/100ML;300MG/100ML	N018501 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
	B BRAUN	5GM/100ML;330MG/100ML	N018030 003	
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;450MG/100ML	N019484 001	Oct 04, 1985
	B BRAUN	5GM/100ML;450MG/100ML	N018030 002	
	MILES	5GM/100ML;450MG/100ML	N018400 001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	ABBOTT	5GM/100ML;900MG/100ML	N019483 001	Oct 04, 1985
	B BRAUN	5GM/100ML;900MG/100ML	N018026 001	
	MILES	5GM/100ML;900MG/100ML	N018500 001	

DEXTROTHYROXINE SODIUM

TABLET;ORAL

CHOLOXIN				
	ABBVIE	1MG	N012302 005	
		2MG	N012302 002	
		4MG	N012302 004	
		6MG	N012302 006	

DEZOCINE

INJECTABLE;INJECTION

DALGAN				
	ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989
		10MG/ML	N019082 002	Dec 29, 1989
		15MG/ML	N019082 003	Dec 29, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIATRIZOATE MEGLUMINE

INJECTABLE;INJECTION				
ANGIOVIST 282				
BAYER HLTHCARE	60%	A087726	001	Sep 23, 1982
CARDIOGRAFIN				
BRACCO	85%	N011620	002	
DIATRIZOATE MEGLUMINE				
BRACCO	76%	N010040	017	
HYPAQUE				
GE HEALTHCARE	30%	N016403	002	
	60%	N016403	001	
RENO-60				
BRACCO	60%	N010040	016	
RENO-DIP				
BRACCO	30%	N010040	012	
UROVIST MEGLUMINE DIU/CT				
BAYER HLTHCARE	30%	A087739	001	Sep 23, 1982
SOLUTION;URETERAL				
RENO-30				
BRACCO	30%	N010040	021	
UROVIST CYSTO				
BAYER HLTHCARE	30%	A087729	001	Sep 23, 1982
UROVIST CYSTO PEDIATRIC				
BAYER HLTHCARE	30%	A087731	001	Sep 23, 1982
SOLUTION;URETHRAL				
HYPAQUE-CYSTO				
GE HEALTHCARE	30%	N016403	003	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION				
ANGIOVIST 292				
BAYER HLTHCARE	52%;8%	A087724	001	Sep 23, 1982
ANGIOVIST 370				
BAYER HLTHCARE	66%;10%	A087723	001	Sep 23, 1982
DIATRIZOATE-60				
INTL MEDICATION	52%;8%	A088166	001	Jun 17, 1983
HYPAQUE-76				
GE HEALTHCARE	66%;10%	A086505	001	
HYPAQUE-M,75%				
GE HEALTHCARE	50%;25%	N010220	003	
HYPAQUE-M,90%				
GE HEALTHCARE	60%;30%	N010220	002	
MD-60				
MALLINCKRODT	52%;8%	A087074	001	
MD-76				
MALLINCKRODT	66%;10%	A087073	001	
MD-76R				
+ LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989
RENOCAL-76				
BRACCO	66%;10%	A089347	001	Jun 01, 1988
RENOGRAFIN-60				
BRACCO	52%;8%	N010040	006	
RENOGRAFIN-76				
+ BRACCO	66%;10%	N010040	001	
RENOVIST				
BRACCO	34.3%;35%	N010040	020	
RENOVIST II				
BRACCO	28.5%;29.1%	N010040	019	
SOLUTION;ORAL, RECTAL				
GASTROVIST				
BAYER HLTHCARE	66%;10%	A087728	001	Sep 23, 1982

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION;INTRAUTERINE				
SINOGRAFIN				
+ BRACCO	52.7%;26.8%	N011324	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIATRIZOATE SODIUM				
FOR SOLUTION;ORAL, RECTAL				
HYPAQUE				
GE HEALTHCARE	100%	N011386 001		
INJECTABLE;INJECTION				
HYPAQUE				
GE HEALTHCARE	25%	N009561 003		
	50%	N009561 001		
MD-50				
MALLINCKRODT	50%	A087075 001		
UROVIST SODIUM 300				
BAYER HLTHCARE	50%	A087725 001	Sep 23, 1982	
SOLUTION;ORAL, RECTAL				
HYPAQUE				
GE HEALTHCARE	40%	N011386 003		
SOLUTION;URETERAL				
HYPAQUE SODIUM 20%				
GE HEALTHCARE	20%	N009561 002		
DIAZEPAM				
CAPSULE, EXTENDED RELEASE;ORAL				
VALRELEASE				
ROCHE	15MG	N018179 001		
CONCENTRATE;ORAL				
DIAZEPAM				
LANNETT CO INC	5MG/ML	A204433 001	Apr 14, 2014	
GEL;RECTAL				
DIASTAT				
+ BAUSCH	5MG/ML (5MG/ML) **	N020648 002	Jul 29, 1997	
+	10MG/2ML (5MG/ML) **	N020648 003	Jul 29, 1997	
+	15MG/3ML (5MG/ML) **	N020648 004	Jul 29, 1997	
+	20MG/4ML (5MG/ML) **	N020648 005	Jul 29, 1997	
INJECTABLE;INJECTION				
DIAZEPAM				
ABRAXIS PHARM	5MG/ML	A070662 001	Jun 25, 1986	
HIKMA	5MG/ML	A070311 001	Dec 16, 1985	
	5MG/ML	A070312 001	Dec 16, 1985	
	5MG/ML	A071308 001	Jul 17, 1987	
	5MG/ML	A071309 001	Jul 17, 1987	
	5MG/ML	A071310 001	Jul 17, 1987	
HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987	
MARSAM PHARMS LLC	5MG/ML	A072371 001	Jan 29, 1993	
PARENTA PHARMS	5MG/ML	A076815 001	Apr 15, 2004	
US ARMY	5MG/ML **	N020124 001	Dec 05, 1990	
WARNER CHILCOTT	5MG/ML	A071613 001	Oct 22, 1987	
	5MG/ML	A071614 001	Oct 22, 1987	
WATSON LABS	5MG/ML	A070296 001	Feb 12, 1986	
	5MG/ML	A070911 001	Aug 28, 1986	
	5MG/ML	A070912 001	Aug 28, 1986	
	5MG/ML	A070930 001	Dec 01, 1986	
WATSON LABS INC	5MG/ML	A072370 001	Jan 29, 1993	
	5MG/ML	A072397 001	Jan 29, 1993	
DIZAC				
PHARMACIA AND UPJOHN	5MG/ML **	N019287 001	Jun 18, 1993	
VALIUM				
+ ROCHE	5MG/ML **	N016087 001		
TABLET;ORAL				
DIAZEPAM				
ACTAVIS ELIZABETH	2MG	A070781 001	Mar 19, 1986	
	5MG	A070706 001	Mar 19, 1986	
	10MG	A070707 001	Mar 19, 1986	
BARR	2MG	A070152 001	Nov 01, 1985	
	10MG	A070154 001	Nov 01, 1985	
DAVA PHARMS INC	2MG	A070228 002	Sep 26, 1985	
	5MG	A070228 003	Sep 26, 1985	
	10MG	A070228 001	Sep 26, 1985	
DURAMED PHARMS BARR	2MG	A070894 001	Aug 27, 1986	
	5MG	A070895 001	Aug 27, 1986	
	10MG	A070896 001	Aug 27, 1986	
FERNDALE LABS	2MG	A070903 001	Apr 01, 1987	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIAZEPAM

TABLET;ORAL					
DIAZEPAM					
		5MG	A070904	001	Apr 01, 1987
		10MG	A070905	001	Apr 01, 1987
	HALSEY	2MG	A070987	001	Aug 15, 1986
		5MG	A070996	001	Aug 15, 1986
		10MG	A070956	001	Aug 15, 1986
	IVAX SUB TEVA PHARMS	2MG	A070360	001	Sep 04, 1985
		5MG	A070361	001	Sep 04, 1985
		10MG	A070362	001	Sep 04, 1985
	MARTEC USA LLC	10MG	A072402	001	Apr 25, 1989
	NUVO PHARM	10MG	A070464	001	Feb 25, 1986
	PIONEER PHARMS	2MG	A070787	001	Aug 02, 1988
		5MG	A070788	001	Aug 02, 1988
		10MG	A070776	001	Aug 02, 1988
	ROXANE	2MG	A070356	001	Jun 17, 1986
		5MG	A070357	001	Jun 17, 1986
		10MG	A070358	001	Jun 17, 1986
	TEVA PHARMS	5MG	A070153	001	Nov 01, 1985
	UPSHER SMITH LABS	2MG	A070302	001	Dec 20, 1985
		5MG	A070303	001	Dec 20, 1985
		10MG	A070304	001	Dec 20, 1985
	VIRTUS PHARMS	2MG	A070462	001	Feb 25, 1986
		5MG	A070463	001	Feb 25, 1986
	WARNER CHILCOTT	2MG	A070209	001	Sep 04, 1985
		5MG	A070210	001	Sep 04, 1985
		10MG	A070222	001	Sep 04, 1985
	WATSON LABS	2MG	A070456	001	Nov 01, 1985
		5MG	A070457	001	Nov 01, 1985
		10MG	A070458	001	Nov 01, 1985
Q-PAM					
	QUANTUM PHARMICS	2MG	A070423	001	Dec 12, 1985
		2MG	A072431	001	Apr 29, 1988
		5MG	A070424	001	Dec 12, 1985
		5MG	A072432	001	Apr 29, 1988
		10MG	A070425	001	Dec 12, 1985
		10MG	A072433	001	Apr 29, 1988

DIAZOXIDE

CAPSULE;ORAL					
PROGLYCEM					
	TEVA BRANDED PHARM	50MG	N017425	001	
		100MG	N017425	002	
INJECTABLE;INJECTION					
DIAZOXIDE					
	ABRAXIS PHARM	15MG/ML	A071519	001	Aug 26, 1987
HYPERSTAT					
	SCHERING	15MG/ML	N016996	001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
HEAVY SOLUTION NUPERCAINE					
	NOVARTIS	2.5MG/ML	N006203	001	

DICHLORPHENAMIDE

TABLET;ORAL					
DARANIDE					
+	XERIS	50MG **	N011366	001	

DICLOFENAC

CAPSULE;ORAL					
ZORVOLEX					
+	ZYLA	18MG	N204592	001	Oct 18, 2013

DICLOFENAC POTASSIUM

CAPSULE;ORAL					
DICLOFENAC POTASSIUM					
	STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DICLOFENAC POTASSIUM				
TABLET;ORAL				
CATAFLAM				
+ NOVARTIS	25MG **	N020142	001	Nov 24, 1993
+	50MG **	N020142	002	Nov 24, 1993
DICLOFENAC POTASSIUM				
SANDOZ	50MG	A075582	001	Feb 23, 2001
SUN PHARM INDUSTRIES	50MG	A075470	001	Feb 21, 2002
WATSON LABS TEVA	50MG	A075152	001	Nov 27, 1998
DICLOFENAC SODIUM				
GEL;TOPICAL				
SOLARAZE				
+ FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000
SOLUTION;INTRAVENOUS				
DICLOFENAC SODIUM				
RISING PHARMA	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019
DYLOJECT				
+ JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML) **	N022396	001	Dec 23, 2014
SOLUTION;TOPICAL				
DICLOFENAC SODIUM				
APOTEX INC	1.5%	A202027	001	May 27, 2014
RISING	1.5%	A206715	001	Aug 07, 2017
PENNSAID				
+ NUVO PHARMS INC	1.5% **	N020947	001	Nov 04, 2009
SOLUTION/DROPS;OPHTHALMIC				
DICLOFENAC SODIUM				
FALCON PHARMS	0.1%	N020809	001	May 04, 1998
RUBICON	0.1%	A077600	001	Nov 13, 2008
VOLTAREN				
+ NOVARTIS	0.1%	N020037	001	Mar 28, 1991
TABLET, DELAYED RELEASE;ORAL				
DICLOFENAC SODIUM				
AUROBINDO PHARMA USA	50MG	A075281	002	Feb 12, 2002
	75MG	A075281	003	Feb 12, 2002
CHARTWELL RX	25MG	A074376	001	Sep 28, 1995
	50MG	A074376	002	Sep 28, 1995
	75MG	A074394	001	Nov 30, 1995
MICRO LABS	50MG	A074986	001	Feb 26, 1999
	75MG	A074986	002	Feb 26, 1999
PLIVA	50MG	A074432	002	Jul 29, 1999
	75MG	A074432	003	Jul 29, 1999
ROXANE	25MG	A074391	001	Jun 29, 1995
	50MG	A074391	002	Jun 29, 1995
	75MG	A074391	003	Jun 29, 1995
TEVA	50MG	A074723	001	Mar 30, 1999
	75MG	A074390	001	Aug 15, 1996
TEVA PHARMS	25MG	A074459	001	Jun 25, 1997
	50MG	A074459	002	Jun 25, 1997
	75MG	A074459	003	Jun 25, 1997
VOLTAREN				
+ NOVARTIS	25MG **	N019201	001	Jul 28, 1988
+	50MG **	N019201	002	Jul 28, 1988
+	75MG **	N019201	003	Jul 28, 1988
TABLET, EXTENDED RELEASE;ORAL				
DICLOFENAC SODIUM				
ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002
MYLAN	100MG	A076152	001	Dec 13, 2001
VOLTAREN-XR				
+ NOVARTIS	100MG **	N020254	001	Mar 08, 1996
DICLOFENAC SODIUM; MISOPROSTOL				
TABLET, DELAYED RELEASE;ORAL				
DICLOFENAC SODIUM AND MISOPROSTOL				
EXELA HOLDINGS	50MG;0.2MG	A200540	001	Mar 14, 2014
	75MG;0.2MG	A200540	002	Mar 14, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DICLOXACILLIN SODIUM				
CAPSULE;ORAL				
DICLOXACILLIN SODIUM				
SANDOZ	EQ 125MG BASE		A061454 002	
	EQ 250MG BASE		A061454 001	
	EQ 500MG BASE		A061454 003	
DYCILL				
GLAXOSMITHKLINE	EQ 250MG BASE		A060254 002	
	EQ 250MG BASE		A062238 001	
	EQ 500MG BASE		A060254 003	
	EQ 500MG BASE		A062238 002	
PATHOCIL				
+ WYETH AYERST	EQ 250MG BASE **		N050011 002	
+	EQ 500MG BASE **		N050011 003	Mar 28, 1983
FOR SUSPENSION;ORAL				
DICLOXACILLIN SODIUM				
APOTHECON	EQ 62.5MG BASE/5ML		A061455 001	
DYNAPEN				
APOTHECON	EQ 62.5MG BASE/5ML		N050337 002	
PATHOCIL				
WYETH AYERST	EQ 62.5MG BASE/5ML		N050092 001	
DICUMAROL				
CAPSULE;ORAL				
DICUMAROL				
LILLY	25MG		N005509 003	
	50MG		N005509 001	
TABLET;ORAL				
DICUMAROL				
ABBVIE	25MG		N005545 003	
	50MG		N005545 004	
	100MG		N005545 005	
DICYCLOMINE HYDROCHLORIDE				
CAPSULE;ORAL				
BENTYL				
+ ALLERGAN	10MG **		N007409 003	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
PIONEER PHARMS	10MG		A089361 001	Jan 10, 1989
SUN PHARM INDUSTRIES	10MG		A084505 001	Oct 21, 1986
WATSON LABS	10MG		A083179 001	Feb 12, 1986
INJECTABLE;INJECTION				
DICYCLOMINE HYDROCHLORIDE				
DR REDDYS	10MG/ML		A080614 001	Feb 11, 1986
SYRUP;ORAL				
BENTYL				
+ APTALIS PHARMA US	10MG/5ML **		N007961 002	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML		A084479 001	
TABLET;ORAL				
BENTYL				
+ ALLERGAN	20MG **		N007409 001	Oct 15, 1984
DICYCLOMINE HYDROCHLORIDE				
AUROBINDO PHARMA USA	20MG		A040317 001	Sep 07, 1999
PIONEER PHARMS	20MG		A088585 001	Aug 20, 1986
SUN PHARM INDUSTRIES	20MG		A084600 001	Jul 29, 1985
WATSON LABS	20MG		A084361 001	Feb 06, 1986
DIDANOSINE				
CAPSULE, DELAYED REL PELLETS;ORAL				
DIDANOSINE				
AUROBINDO PHARMA	125MG		A090094 001	Sep 24, 2008
	200MG		A090094 002	Sep 24, 2008
	250MG		A090094 003	Sep 24, 2008
	400MG		A090094 004	Sep 24, 2008
BARR	200MG		A077167 001	Dec 03, 2004
	250MG		A077167 002	Dec 03, 2004
	400MG		A077167 003	Dec 03, 2004
MYLAN PHARMS INC	125MG		A090788 001	Apr 08, 2010
	200MG		A090788 002	Apr 08, 2010
	250MG		A090788 003	Apr 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL				
DIDANOSINE				
	400MG		A090788 004	Apr 08, 2010
VIDEX EC				
+ BRISTOL MYERS SQUIBB	125MG		N021183 001	Oct 31, 2000
+	200MG		N021183 002	Oct 31, 2000
+	250MG		N021183 003	Oct 31, 2000
+	400MG		N021183 004	Oct 31, 2000
FOR SOLUTION;ORAL				
DIDANOSINE				
AUROBINDO PHARMA	10MG/ML		A078112 001	Mar 08, 2007
VIDEX				
BRISTOL MYERS SQUIBB	100MG/PACKET		N020155 003	Oct 09, 1991
	167MG/PACKET		N020155 004	Oct 09, 1991
	250MG/PACKET		N020155 005	Oct 09, 1991
	375MG/PACKET		N020155 006	Oct 09, 1991
+ BRISTOL-MYERS SQUIBB	10MG/ML		N020156 001	Oct 09, 1991
TABLET, CHEWABLE;ORAL				
VIDEX				
+ BRISTOL MYERS SQUIBB	25MG **		N020154 002	Oct 09, 1991
+	50MG **		N020154 003	Oct 09, 1991
+	100MG **		N020154 004	Oct 09, 1991
+	150MG **		N020154 005	Oct 09, 1991
+	200MG **		N020154 006	Oct 28, 1999
TABLET, FOR SUSPENSION;ORAL				
DIDANOSINE				
AUROBINDO	100MG		A077275 001	Aug 14, 2012
	150MG		A077275 002	Aug 14, 2012
	200MG		A077275 003	Aug 14, 2012

DIENESTROL

CREAM;VAGINAL				
DIENESTROL				
ORTHO MCNEIL PHARM	0.01%		N006110 005	
DV				
SANOFI AVENTIS US	0.01%		A083518 001	
ESTRAGUARD				
SOLVAY	0.01%		A084436 001	
SUPPOSITORY;VAGINAL				
DV				
SANOFI AVENTIS US	0.7MG		A083517 001	

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL				
HETRAZAN				
LEDERLE	50MG		N006459 001	

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL				
DIETHYLPROPION HYDROCHLORIDE				
CHARTWELL RX	25MG		A088267 001	Aug 25, 1983
	25MG		A088268 001	Aug 25, 1983
EPIC PHARMA LLC	25MG		A040828 001	Nov 05, 2008
SANDOZ	25MG		A085916 001	
TEVA	25MG		A088642 001	Sep 20, 1984
UCB INC	25MG		A085544 001	
WATSON LABS	25MG		A085741 001	
TENUATE				
+ NOSTRUM LABS INC	25MG		N011722 002	
SANOFI AVENTIS US	25MG		N017668 001	
TEPANIL				
3M	25MG		N011673 001	
TABLET, EXTENDED RELEASE;ORAL				
TENUATE				
SANOFI AVENTIS US	75MG		N017669 001	
TENUATE DOSPAN				
+ NOSTRUM LABS INC	75MG		N012546 001	
TEPANIL TEN-TAB				
3M	75MG		N017956 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIETHYLSTILBESTROL

INJECTABLE;INJECTION				
STILBESTROL				
	BRISTOL MYERS SQUIBB	0.2MG/ML	N004056 003	
		0.5MG/ML	N004056 004	
		1MG/ML	N004056 005	
		5MG/ML	N004056 006	
SUPPOSITORY;VAGINAL				
DIETHYLSTILBESTROL				
	LILLY	0.1MG	N004040 001	
		0.5MG	N004040 002	
STILBESTROL				
	BRISTOL MYERS SQUIBB	0.1MG	N004056 001	
		0.5MG	N004056 002	
TABLET;ORAL				
DIETHYLSTILBESTROL				
	LILLY	0.1MG	N004041 002	
		0.5MG	N004041 003	
		1MG	N004041 004	
		5MG	N004041 005	
STILBESTROL				
	TABLICAPS	0.5MG	A083004 001	
		1MG	A083002 001	
		5MG	A083006 001	
STILBETIN				
	BRISTOL MYERS SQUIBB	0.1MG	N004056 007	
		0.25MG	N004056 017	
		0.5MG	N004056 008	
		1MG	N004056 009	
		5MG	N004056 010	
TABLET, DELAYED RELEASE;ORAL				
DIETHYLSTILBESTROL				
	LILLY	0.1MG	N004039 002	
		0.25MG	N004039 005	
		0.5MG	N004039 003	
		1MG	N004039 004	
		5MG	N004039 006	
STILBESTROL				
	TABLICAPS	0.5MG	A083003 001	
		1MG	A083005 001	
		5MG	A083007 001	
STILBETIN				
	BRISTOL MYERS SQUIBB	0.1MG	N004056 011	
		0.5MG	N004056 012	
		1MG	N004056 013	
		5MG	N004056 014	

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE;INJECTION				
STILPHOSTROL				
	BAYER PHARMS	250MG/5ML	N010010 001	
TABLET;ORAL				
STILPHOSTROL				
	BAYER PHARMS	50MG	N010010 002	

DIFLORASONE DIACETATE

CREAM;TOPICAL				
DIFLORASONE DIACETATE				
	FOUGERA PHARMS	0.05%	A075187 001	Mar 30, 1998
FLORONE				
	PFIZER	0.05% **	N017741 001	
FLORONE E				
	PFIZER	0.05%	N019259 001	Aug 28, 1985
PSORCON				
+	TARO PHARMS NORTH	0.05% **	N020205 001	Nov 20, 1992
OINTMENT;TOPICAL				
DIFLORASONE DIACETATE				
	AKORN	0.05%	A206572 001	Jul 24, 2015
PSORCON				
+	PFIZER	0.05%	N019260 001	Aug 28, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIFLORASONE DIACETATE

OINTMENT;TOPICAL				
PSORCON E				
	PFIZER	0.05%	N017994 001	
DIFLUNISAL				
TABLET;ORAL				
DIFLUNISAL				
	ANI PHARMS	500MG	A074604 001	Jun 10, 1996
	DASTECH INTL	250MG	A073562 001	Nov 27, 1992
		500MG	A073563 001	Nov 27, 1992
	PUREPAC PHARM	250MG	A074285 001	May 07, 1996
		500MG	A074285 002	May 07, 1996
	TEVA	250MG	A073679 001	Jul 31, 1992
	WATSON LABS	250MG	A074400 001	Jul 17, 1997
		500MG	A074400 002	Jul 17, 1997
DOLOBID				
+	MERCK	250MG **	N018445 001	Apr 19, 1982
+		500MG **	N018445 002	Apr 19, 1982
DIGITOXIN				
INJECTABLE;INJECTION				
CRYSTODIGIN				
	LILLY	0.2MG/ML	A084100 005	
DIGOXIN				
CAPSULE;ORAL				
LANOXICAPS				
	GLAXOSMITHKLINE LLC	0.05MG	N018118 002	Jul 26, 1982
		0.1MG	N018118 003	Jul 26, 1982
		0.15MG	N018118 004	Sep 24, 1984
		0.2MG	N018118 001	Jul 26, 1982
INJECTABLE;INJECTION				
DIGOXIN				
	ABRAXIS PHARM	0.25MG/ML	A083217 001	
	HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996
		0.25MG/ML	A040206 001	Aug 28, 1998
	WYETH AYERST	0.25MG/ML	A084386 001	
DIGOXIN PEDIATRIC				
	HOSPIRA	0.1MG/ML	A040092 001	Apr 25, 1996
TABLET;ORAL				
LANOXIN				
+	CONCORDIA	0.1875MG	N020405 003	Sep 30, 1997
		0.375MG	N020405 005	Sep 30, 1997
		0.5MG	N020405 006	Sep 30, 1997
DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
EMBOLEX				
	NOVARTIS	0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML	N018885 001	Nov 30, 1984
		0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML	N018885 002	Nov 30, 1984
DILTIAZEM HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
CARDIZEM SR				
+	BIOVAIL	60MG **	N019471 001	Jan 23, 1989
+		90MG **	N019471 002	Jan 23, 1989
+		120MG **	N019471 003	Jan 23, 1989
+		180MG **	N019471 004	Jan 23, 1989
DILACOR XR				
+	ALLERGAN	120MG **	N020092 001	May 29, 1992
+		180MG **	N020092 002	May 29, 1992
+		240MG **	N020092 003	May 29, 1992
DILT-CD				
	APOTEX	120MG	A076151 001	May 20, 2004
		180MG	A076151 002	May 20, 2004
		240MG	A076151 003	May 20, 2004
		300MG	A076151 004	May 20, 2004
DILTIAZEM HYDROCHLORIDE				
	ACTAVIS LABS FL INC	120MG	A074852 001	Oct 10, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
DILTIAZEM HYDROCHLORIDE					
	180MG		A074852	002	Oct 10, 1997
	240MG		A074852	003	Oct 10, 1997
BIOVAIL	60MG		A074845	001	Sep 15, 1999
	90MG		A074845	002	Sep 15, 1999
	120MG		A074845	003	Sep 15, 1999
	120MG		N020939	001	Jan 28, 2000
	180MG		N020939	002	Jan 28, 2000
	240MG		N020939	003	Jan 28, 2000
	300MG		N020939	004	Jan 28, 2000
	360MG		N020939	005	Sep 14, 2001
	420MG		N020939	006	Sep 14, 2001
MYLAN	120MG		A075124	002	Mar 18, 1998
	180MG		A075124	003	Mar 18, 1998
	240MG		A075124	001	Mar 18, 1998
NESHER PHARMS	120MG		A076563	002	Sep 12, 2006
	180MG		A076563	003	Sep 12, 2006
	240MG		A076563	004	Sep 12, 2006
	300MG		A076563	005	Sep 12, 2006
	360MG		A076563	006	Sep 12, 2006
	420MG		A076563	001	Sep 12, 2006
PAR PHARM	360MG		A209766	001	May 30, 2018
TEVA	60MG		A074079	001	Nov 30, 1993
	90MG		A074079	002	Nov 30, 1993
	120MG		A074079	003	Nov 30, 1993
DILTZAC					
APOTEX	120MG		A076395	001	Feb 01, 2006
	180MG		A076395	002	Feb 01, 2006
	240MG		A076395	003	Feb 01, 2006
	300MG		A076395	004	Feb 01, 2006
	360MG		A076395	005	Feb 01, 2006
INJECTABLE;INJECTION					
CARDIZEM					
BIOVAIL	100MG/VIAL **		N020792	001	Sep 05, 1997
+ BIOVAIL LABS INTL	5MG/ML **		N020027	001	Oct 24, 1991
+	25MG/VIAL **		N020027	003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE					
DR REDDYS	5MG/ML		A074894	001	Aug 26, 1997
HOSPIRA	5MG/ML		A075004	001	Feb 16, 2000
	5MG/ML		A075106	001	Apr 29, 1999
INTL MEDICATION	5MG/ML		A075749	001	Nov 21, 2001
MYLAN LABS LTD	5MG/ML		A075375	001	Sep 30, 1999
TABLET;ORAL					
DILTIAZEM HYDROCHLORIDE					
APOTHECON	30MG		A074051	001	Mar 31, 1993
	60MG		A074051	002	Mar 31, 1993
	90MG		A074051	003	Mar 31, 1993
	120MG		A074051	004	Mar 31, 1993
CHARTWELL MOLECULES	30MG		A074093	001	Nov 05, 1992
	60MG		A074093	002	Nov 05, 1992
	90MG		A074093	003	Nov 05, 1992
	120MG		A074093	004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG		A074168	001	Mar 03, 1995
	60MG		A074168	002	Mar 03, 1995
	90MG		A074168	003	Mar 03, 1995
	120MG		A074168	004	Mar 03, 1995
RISING PHARMA	30MG		A072838	004	Nov 05, 1992
	60MG		A072838	003	Nov 05, 1992
	90MG		A072838	002	Nov 05, 1992
	120MG		A072838	001	Nov 05, 1992
TEVA	30MG		A074084	001	Feb 25, 1994
	60MG		A074084	002	Feb 25, 1994
TEVA PHARMS	30MG		A074067	001	Nov 05, 1992
	60MG		A074067	002	Nov 05, 1992
	90MG		A074067	003	Nov 05, 1992
	120MG		A074067	004	Nov 05, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DILTIAZEM MALATE				
TABLET, EXTENDED RELEASE;ORAL				
TIAMATE				
	MERCK	EQ 120MG HYDROCHLORIDE	N020506 001	Oct 04, 1996
		EQ 180MG HYDROCHLORIDE	N020506 002	Oct 04, 1996
		EQ 240MG HYDROCHLORIDE	N020506 003	Oct 04, 1996
DILTIAZEM MALATE; ENALAPRIL MALEATE				
TABLET, EXTENDED RELEASE;ORAL				
TECZEM				
	BIOVAIL	EQ 180MG HYDROCHLORIDE;5MG	N020507 001	Oct 04, 1996
DIMENHYDRINATE				
INJECTABLE;INJECTION				
DIMENHYDRINATE				
	BAXTER HLTHCARE	50MG/ML	A084767 001	
	WATSON LABS	50MG/ML	A083531 001	
+	WATSON LABS TEVA	50MG/ML	A080615 001	
	WYETH AYERST	50MG/ML	A084316 001	
LIQUID;ORAL				
DIMENHYDRINATE				
	ALRA	12.5MG/4ML	A080715 001	
TABLET;ORAL				
DIMENHYDRINATE				
	HEATHER	50MG	A080841 001	
	NEXGEN PHARMA INC	50MG	A085985 001	
+	WATSON LABS	50MG	A085166 001	
DIMETHYL FUMARATE				
CAPSULE, DELAYED RELEASE;ORAL				
DIMETHYL FUMARATE				
	ZYDUS PHARMS	120MG	A210538 001	Sep 24, 2020
		240MG	A210538 002	Sep 24, 2020
DIMETHYL SULFOXIDE				
SOLUTION;INTRAVESICAL				
DIMETHYL SULFOXIDE				
	MYLAN INSTITUTIONAL	50%	A076185 001	Nov 29, 2002
DIMYRISTOYL LECITHIN; PERFLEXANE				
INJECTABLE;INTRAVENOUS				
IMAGENT				
	VESSELON SPV LLC	0.92MG/VIAL;0.092MG/VIAL	N021191 001	May 31, 2002
DINOPROST TROMETHAMINE				
INJECTABLE;INJECTION				
PROSTIN F2 ALPHA				
	PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001	
DINOPROSTONE				
SUPPOSITORY;VAGINAL				
PROSTIN E2				
+	PFIZER	20MG	N017810 001	
DIPHEMANIL METHYLSULFATE				
TABLET;ORAL				
PRANTAL				
	SCHERING	100MG	N008114 004	
DIPHENHYDRAMINE HYDROCHLORIDE				
CAPSULE;ORAL				
BENADRYL				
	MCNEIL CONS	25MG	N005845 007	
		50MG	N005845 001	
DIPHENHYDRAMINE HYDROCHLORIDE				
	ALRA	25MG	A080519 004	
		50MG	A080519 003	
	ANABOLIC	50MG	A083275 001	
	ELKINS SINN	25MG	A085701 001	
		50MG	A085701 002	
	FOSUN PHARMA	25MG	A080832 001	
		25MG	A080845 002	
		50MG	A080832 002	
		50MG	A080845 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
HALSEY	50MG	A087914	001	Jun 04, 1984
HEATHER	25MG	A084524	001	
	50MG	A083953	001	
HERITAGE PHARMA	50MG	A080727	001	
	50MG	A080738	001	
HIKMA INTL PHARMS	50MG	A083567	001	
IMPAX LABS	25MG	A080807	001	
	50MG	A080807	002	
IVAX SUB TEVA PHARMS	25MG	A080762	001	
	50MG	A080762	002	
LANNETT	25MG	A080868	001	
	50MG	A080868	002	
LEDERLE	25MG	A086874	001	
	50MG	A086875	001	
LNK	25MG	A087977	001	Jan 27, 1983
	50MG	A087978	001	Jan 27, 1983
MK LABS	25MG	A083087	001	
	50MG	A083087	002	
MUTUAL PHARM	25MG	A084506	001	
NEWTRON PHARMS	25MG	A086543	001	
	50MG	A086544	001	
NEXGEN PHARMA INC	25MG	A083634	001	
PERRIGO	25MG	A083061	001	
	50MG	A083061	002	
PIONEER PHARMS	25MG	A089101	001	Dec 20, 1985
	50MG	A088880	001	Dec 20, 1985
PUREPAC PHARM	25MG	A085156	001	
	50MG	A085150	001	
PVT FORM	25MG	A083027	001	
	50MG	A083027	002	
ROXANE	50MG	A080635	001	
SUN PHARM INDUSTRIES	25MG	A089488	001	Jan 02, 1987
	50MG	A089489	001	Jan 02, 1987
SUPERPHARM	25MG	A089040	001	May 15, 1985
	50MG	A089041	001	May 15, 1985
TEVA	25MG	A085874	001	
	50MG	A085874	002	
VALEANT PHARM INTL	25MG	A080596	001	
	50MG	A080592	001	
VANGARD	25MG	A088034	001	Oct 27, 1982
	50MG	A087630	001	
WATSON LABS	25MG	A080728	001	
	25MG	A083797	001	
	25MG	A085138	001	
	50MG	A083797	002	
	50MG	A085083	001	
WHITEWORTH TOWN PLSN	25MG	A083441	001	
	50MG	A080800	001	
ELIXIR;ORAL				
BELIX				
HALSEY	12.5MG/5ML	A086586	001	Oct 03, 1983
BENADRYL				
MCNEIL CONS	12.5MG/5ML	N005845	004	
DIBENIL				
CENCI	12.5MG/5ML	A088304	001	Dec 16, 1983
DIPHEN				
USL PHARMA	12.5MG/5ML	A084640	001	
DIPHENHYDRAMINE HYDROCHLORIDE				
BUNDY	12.5MG/5ML	A083674	001	
CENCI	12.5MG/5ML	A087941	001	Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001	
LANNETT	12.5MG/5ML	A080939	002	
LEDERLE	12.5MG/5ML	A086937	001	
MK LABS	12.5MG/5ML	A083088	002	
NASKA	12.5MG/5ML	A088680	001	May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR;ORAL				
DIPHENHYDRAMINE HYDROCHLORIDE				
	PUREPAC PHARM	12.5MG/5ML	A083237 001	Jan 25, 1982
	PVT FORM	12.5MG/5ML	A085287 001	
	ROXANE	12.5MG/5ML	A080643 001	
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A080763 002	
INJECTABLE;INJECTION				
BENADRYL				
	MCNEIL CONS	10MG/ML	N006146 001	
+		50MG/ML **	N006146 002	
BENADRYL PRESERVATIVE FREE				
+	MCNEIL CONS	50MG/ML **	N009486 001	
DIPHENHYDRAMINE HYDROCHLORIDE				
	BEL MAR	10MG/ML	A080822 001	
	DR REDDYS	10MG/ML	A080873 001	
		50MG/ML	A080873 002	
	EUROHLTH INTL SARL	50MG/ML	A083183 001	
	LYPHOMED	10MG/ML	A087066 001	
	WATSON LABS	10MG/ML	A083533 001	
	WYETH AYERST	50MG/ML	A080577 001	
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE				
	ABRAXIS PHARM	50MG/ML	A080586 002	
	DR REDDYS	50MG/ML	A080873 003	
	INTL MEDICATION	50MG/ML	A084094 001	
SYRUP;ORAL				
ANTITUSSIVE				
	PERRIGO	12.5MG/5ML	A071292 001	Apr 10, 1987
BELDIN				
	HALSEY	12.5MG/5ML	A089179 001	Jun 05, 1986
BENYLIN				
	PARKE DAVIS	12.5MG/5ML	N006514 004	
DIPHEN				
	MORTON GROVE	12.5MG/5ML	A070118 001	Oct 01, 1985
DIPHENHYDRAMINE HYDROCHLORIDE				
	AKORN	12.5MG/5ML	A072416 001	Sep 28, 1990
	ALPHARMA US PHARMS	12.5MG/5ML	A070497 001	Apr 25, 1989
	CUMBERLAND SWAN	12.5MG/5ML	A073611 001	Aug 20, 1992
HYDRAMINE				
	ALPHARMA US PHARMS	12.5MG/5ML	A070205 001	Jan 28, 1986
SILPHEN				
	LANNETT CO INC	12.5MG/5ML	A072646 001	Feb 27, 1992
VICKS FORMULA 44				
	WARNER CHILCOTT	12.5MG/5ML	A070524 001	Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL				
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE				
	P AND L	25MG;220MG	A207597 001	Jan 25, 2019

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL				
BENYLIN				
	PARKE DAVIS	12.5MG/5ML;30MG/5ML	N019014 001	Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL				
VONTROL				
	GLAXOSMITHKLINE	EQ 25MG BASE	N016033 001	

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
HISPRIL				
	GLAXOSMITHKLINE	5MG	N011945 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
AKPRO				
	AKORN	0.1%	A074382 001	Sep 29, 1995
DIPIVEFRIN HYDROCHLORIDE				
	BAUSCH AND LOMB	0.1%	A074188 001	May 19, 1995
	FALCON PHARMS	0.1%	A073636 001	Jun 30, 1994
PROPINE				
	ALLERGAN	0.1%	N018239 001	

DIPYRIDAMOLE

INJECTABLE;INJECTION				
DIPYRIDAMOLE				
	AUROMEDICS PHARMA	5MG/ML	A075769 001	Nov 27, 2002
	DR REDDYS	5MG/ML	A074952 001	Nov 26, 1997
	HOSPIRA	5MG/ML	A074601 001	Dec 19, 1997
IV PERSANTINE				
+	BOEHRINGER INGELHEIM	5MG/ML **	N019817 001	Dec 13, 1990
TABLET;ORAL				
DIPYRIDAMOLE				
	GENUS	25MG	A040898 001	Apr 23, 2008
		50MG	A040898 002	Apr 23, 2008
		75MG	A040898 003	Apr 23, 2008
	GLENMARK GENERICS	25MG	A088999 001	Feb 05, 1991
		50MG	A089000 001	Feb 05, 1991
		75MG	A089001 001	Feb 05, 1991
	PUREPAC PHARM	25MG	A089425 001	Jul 12, 1990
		50MG	A089426 001	Jul 12, 1990
		75MG	A089427 001	Jul 12, 1990
	WATSON LABS	50MG	A087160 001	Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL				
DYNABAC				
	LILLY RES LABS	250MG	N050678 001	Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL				
DISOPYRAMIDE PHOSPHATE				
	INTERPHARM	EQ 100MG BASE	A071190 001	Jan 15, 1987
		EQ 150MG BASE	A071191 001	Jan 15, 1987
	IVAX SUB TEVA PHARMS	EQ 100MG BASE	A070186 001	Nov 18, 1985
		EQ 150MG BASE	A070187 001	Nov 18, 1985
	MAYNE PHARMA	EQ 100MG BASE	A070173 001	May 31, 1985
		EQ 150MG BASE	A070173 002	May 31, 1985
	MYLAN	EQ 100MG BASE	A070138 001	Jun 14, 1985
		EQ 150MG BASE	A070139 001	Jun 14, 1985
	RISING	EQ 100MG BASE	A070470 001	Dec 10, 1985
		EQ 150MG BASE	A070471 001	Dec 10, 1985
	SUN PHARM INDUSTRIES	EQ 100MG BASE	A070351 001	Dec 17, 1985
		EQ 150MG BASE	A070352 001	Dec 17, 1985
	SUPERPHARM	EQ 100MG BASE	A070940 001	Feb 09, 1987
		EQ 150MG BASE	A070941 001	Feb 09, 1987
	WATSON LABS	EQ 100MG BASE	A070240 001	Feb 02, 1986
		EQ 150MG BASE	A070241 001	Feb 02, 1986
CAPSULE, EXTENDED RELEASE;ORAL				
DISOPYRAMIDE PHOSPHATE				
	NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987

DISULFIRAM

TABLET;ORAL				
ANTABUSE				
+	ODYSSEY PHARMS	250MG	A088482 001	Dec 08, 1983
+		500MG	A088483 001	Dec 08, 1983
+	TEVA WOMENS	250MG **	N007883 003	
+		500MG **	N007883 002	
DISULFIRAM				
	MYLAN	250MG	A203916 001	Mar 04, 2015
		500MG	A203916 002	Mar 04, 2015
	STRIDES PHARMA	250MG	A088792 001	Aug 14, 1984
		500MG	A088793 001	Aug 14, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISULFIRAM

TABLET;ORAL

DISULFIRAM

WATSON LABS	250MG	A086889	001	
	250MG	A087973	001	Aug 05, 1983
	500MG	A087974	001	Aug 05, 1983
WATSON LABS TEVA	500MG	A086890	001	

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011
TEVA PHARMS USA	EQ 125MG VALPROIC ACID	A211505	001	Nov 17, 2020

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP

ABBOTT	EQ 250MG BASE	N019794	001	Jul 11, 1990
	EQ 500MG BASE	N019794	002	Jul 11, 1990

DIVALPROEX SODIUM

ANCHEN PHARMS	EQ 500MG VALPROIC ACID	A078411	001	Nov 03, 2008
MYLAN	EQ 125MG VALPROIC ACID	A077254	001	Jul 29, 2008
	EQ 125MG VALPROIC ACID	A090062	001	Mar 17, 2009
	EQ 250MG VALPROIC ACID	A077254	002	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A090062	002	Mar 17, 2009
	EQ 500MG VALPROIC ACID	A077254	003	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A090062	003	Mar 17, 2009
TEVA	EQ 125MG VALPROIC ACID	A076941	001	Jul 29, 2008
	EQ 250MG VALPROIC ACID	A076941	002	Jul 29, 2008
	EQ 500MG VALPROIC ACID	A076941	003	Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AMTA	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021
	EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021
ANCHEN PHARMS	EQ 250MG VALPROIC ACID	A078445	001	Feb 26, 2009
	EQ 500MG VALPROIC ACID	A078445	002	Aug 04, 2009
COSETTE	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009
IMPAX LABS	EQ 250MG VALPROIC ACID	A078791	001	May 06, 2009
	EQ 500MG VALPROIC ACID	A078791	002	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE	EQ 12.5MG BASE/ML	A074381	001	Sep 26, 1996
DR REDDYS	EQ 12.5MG BASE/ML	A074995	001	Mar 31, 1998
HOSPIRA	EQ 12.5MG BASE/ML	A074292	001	Feb 16, 1995
	EQ 1.25GM BASE/100ML	A074634	001	Sep 27, 1996
LUITPOLD	EQ 12.5MG BASE/ML	A074545	001	Jun 25, 1998
TELIGENT	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995
TEVA PARENTERAL	EQ 12.5MG BASE/ML	A074206	001	Oct 19, 1993
WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993
WATSON LABS INC	EQ 12.5MG BASE/ML	A074279	001	Feb 18, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA	EQ 50MG BASE/100ML	N020269	001	Oct 19, 1993
	EQ 100MG BASE/100ML	N020269	002	Oct 19, 1993
	EQ 200MG BASE/100ML	N020269	003	Oct 19, 1993

DOBUTREX

+ LILLY	EQ 12.5MG BASE/ML **	N017820	002	

DOCETAXEL

INJECTABLE;INJECTION

DOCEFREZ

+ SUN PHARM	20MG/VIAL	N022534	001	May 03, 2011
+	80MG/VIAL	N022534	002	May 03, 2011

DOCETAXEL

+ ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
+	80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012
	80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012
DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017
	80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017
	200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017
+ HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOCETAXEL

INJECTABLE;INJECTION					
DOCETAXEL					
	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017
	JIANGSU PHARMS	40MG/ML	A203170	001	Feb 15, 2017
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014
	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015
		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015
TAXOTERE					
+	SANOFI AVENTIS US	40MG/ML **	N020449	001	May 14, 1996

DOFETILIDE

CAPSULE;ORAL					
DOFETILIDE					
	NOVAST LABS	0.125MG	A212410	001	Dec 27, 2019
		0.25MG	A212410	002	Dec 27, 2019
		0.5MG	A212410	003	Dec 27, 2019
	PRINSTON INC	0.125MG	A211223	001	Dec 17, 2019
		0.25MG	A211223	002	Dec 17, 2019
		0.5MG	A211223	003	Dec 17, 2019

DOLASETRON MESYLATE

INJECTABLE;INJECTION					
ANZEMET					
+	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001
TABLET;ORAL					
ANZEMET					
+	VALIDUS PHARMS	100MG	N020623	002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

SOLUTION;ORAL					
ARICEPT					
	EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004
TABLET;ORAL					
DONEPEZIL HYDROCHLORIDE					
	ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011
		10MG	A201335	002	Aug 29, 2011
	ACTAVIS ELIZABETH	23MG	A202415	001	Dec 17, 2015
	APOTEX	5MG	A078841	001	Jun 02, 2011
		10MG	A078841	002	Jun 02, 2011
	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011
		10MG	A077344	002	May 31, 2011
	HIKMA PHARMS	5MG	A090247	001	May 31, 2011
		10MG	A090247	002	May 31, 2011
	HISUN PHARM HANGZHOU	23MG	A202410	001	Mar 24, 2017
	MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011
		10MG	A090521	002	May 31, 2011
	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016
	PAR PHARM	23MG	A202542	001	Jul 24, 2013
	RISING PHARMA	23MG	A202656	001	Oct 22, 2015
	SUN PHARM	23MG	A204293	001	Jun 05, 2015
	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010
		10MG	A076786	002	Nov 26, 2010
	UNICHEM	5MG	A203656	001	Jun 23, 2016
		10MG	A203656	002	Jun 23, 2016
	WOCKHARDT	5MG	A091267	001	May 31, 2011
		10MG	A091267	002	May 31, 2011
TABLET, ORALLY DISINTEGRATING;ORAL					
ARICEPT ODT					
+	EISAI INC	5MG	N021720	001	Oct 18, 2004
+		10MG	N021720	002	Oct 18, 2004
DONEPEZIL HYDROCHLORIDE					
	HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010
		10MG	A078388	001	Nov 26, 2010
	SUN PHARM INDUSTRIES	5MG	A077975	002	Dec 11, 2009
		10MG	A077975	001	Dec 11, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

UNICHEM	5MG	A204831	001	Nov 10, 2016
	10MG	A204831	002	Nov 10, 2016
ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011
	10MG	A090175	002	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AMNEAL PHARMS	10MG;14MG	A208328	001	Jan 27, 2017
	10MG;28MG	A208328	002	Jan 27, 2017

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
AM REGENT	40MG/ML	A070799	001	Feb 11, 1987
	80MG/ML	A070820	001	Feb 11, 1987
	160MG/ML	A070826	001	Feb 11, 1987
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TELIGENT	40MG/ML	N018656	001	Jun 28, 1983
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995

INTROPIN

HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DORIPENEM

INJECTABLE;INTRAVENOUS

DORIBAX

+	SHIONOGI INC	250MG/VIAL	N022106	002	Oct 05, 2010
+		500MG/VIAL	N022106	001	Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AM REGENT	EQ 2% BASE	A079186	001	Nov 18, 2009
RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008
TEVA PHARMS	EQ 2% BASE	A078756	001	Dec 04, 2008
ZAMBON SPA	EQ 2% BASE	A091034	001	Dec 04, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

LANNETT CO INC	EQ 2% BASE;EQ 0.5% BASE	A201998	001	Dec 17, 2014
RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008
ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013

DOXACURIUM CHLORIDE

INJECTABLE;INJECTION

NUROMAX

ABBVIE	EQ 1MG BASE/ML	N019946	001	Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
ANI PHARMS	EQ 1MG BASE	A075432	001	Oct 18, 2000
	EQ 2MG BASE	A075432	002	Oct 18, 2000
	EQ 4MG BASE	A075432	003	Oct 18, 2000
	EQ 8MG BASE	A075432	004	Oct 18, 2000
AUROBINDO PHARMA USA	EQ 1MG BASE	A075509	001	Oct 19, 2000
	EQ 2MG BASE	A075509	002	Oct 19, 2000
	EQ 4MG BASE	A075509	003	Oct 19, 2000
	EQ 8MG BASE	A075509	004	Oct 19, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
STRIDES PHARMA	EQ 1MG BASE	A076161	001	Jun 10, 2004
	EQ 2MG BASE	A076161	002	Jun 10, 2004
	EQ 4MG BASE	A076161	003	Jun 10, 2004
	EQ 8MG BASE	A076161	004	Jun 10, 2004
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001
	EQ 4MG BASE	A075353	003	Jan 12, 2001
	EQ 8MG BASE	A075353	004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426	001	Oct 18, 2000
	EQ 2MG BASE	A075426	002	Oct 18, 2000
	EQ 4MG BASE	A075426	003	Oct 18, 2000
	EQ 8MG BASE	A075426	004	Oct 18, 2000
YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

CHARTWELL RX	EQ 10MG BASE	A210268	001	Sep 04, 2020
	EQ 25MG BASE	A210268	002	Sep 04, 2020
	EQ 50MG BASE	A210268	003	Sep 04, 2020
	EQ 75MG BASE	A210268	004	Sep 04, 2020
	EQ 100MG BASE	A210268	005	Sep 04, 2020
DAVA PHARMS INC	EQ 10MG BASE	A071685	001	Jan 05, 1988
	EQ 25MG BASE	A071686	001	Jan 05, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL				
DOXEPIN HYDROCHLORIDE				
	EQ 50MG BASE	A071673	001	Jan 05, 1988
	EQ 75MG BASE	A071674	001	Jan 05, 1988
	EQ 100MG BASE	A071675	001	Jan 05, 1988
	EQ 150MG BASE	A071676	001	Jan 05, 1988
LANNETT CO INC	EQ 10MG BASE	A212997	001	Jul 24, 2020
	EQ 25MG BASE	A212997	002	Jul 24, 2020
	EQ 50MG BASE	A212997	003	Jul 24, 2020
	EQ 75MG BASE	A212997	004	Jul 24, 2020
	EQ 100MG BASE	A212997	005	Jul 24, 2020
NEW RIVER	EQ 10MG BASE	N016987	001	
	EQ 25MG BASE	N016987	002	
	EQ 50MG BASE	N016987	003	
	EQ 75MG BASE	N016987	006	
	EQ 100MG BASE	N016987	004	
	EQ 150MG BASE	N016987	007	Apr 13, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054	001	Dec 28, 1990
	EQ 25MG BASE	A072109	001	Dec 28, 1990
	EQ 50MG BASE	A073055	001	Dec 28, 1990
	EQ 75MG BASE	A072386	001	Sep 08, 1988
	EQ 100MG BASE	A072110	001	Sep 08, 1988
	EQ 150MG BASE	A072387	001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972	001	Sep 29, 1987
	EQ 25MG BASE	A070973	001	Sep 29, 1987
	EQ 50MG BASE	A070931	001	Sep 29, 1987
	EQ 75MG BASE	A070932	001	Sep 29, 1987
	EQ 100MG BASE	A072375	001	Mar 15, 1989
	EQ 150MG BASE	A072376	001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487	001	Mar 02, 1987
	EQ 25MG BASE	A070827	001	May 15, 1986
	EQ 50MG BASE	A070828	001	May 15, 1986
	EQ 75MG BASE	A070825	001	May 15, 1986
	EQ 100MG BASE	A071562	001	Mar 02, 1987
SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502	001	Feb 18, 1988
	EQ 50MG BASE	A071653	001	Feb 18, 1988
	EQ 75MG BASE	A071654	001	Feb 18, 1988
	EQ 100MG BASE	A071521	001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952	001	Mar 04, 1987
	EQ 10MG BASE	A071485	001	Apr 30, 1987
	EQ 10MG BASE	A072985	001	Mar 29, 1991
	EQ 25MG BASE	A070953	001	May 15, 1986
	EQ 25MG BASE	A071486	001	Apr 30, 1987
	EQ 25MG BASE	A072986	001	Mar 29, 1991
	EQ 50MG BASE	A070954	001	May 15, 1986
	EQ 50MG BASE	A071238	001	Apr 30, 1987
	EQ 75MG BASE	A071326	001	Apr 30, 1987
	EQ 75MG BASE	A071763	001	Feb 09, 1988
	EQ 100MG BASE	A070955	001	May 15, 1986
	EQ 100MG BASE	A071239	001	Apr 30, 1987
	EQ 150MG BASE	A071764	001	Feb 09, 1988
WATSON LABS TEVA	EQ 50MG BASE	A072987	001	Mar 29, 1991
SINEQUAN				
+ PFIZER	EQ 10MG BASE **	N016798	003	
+	EQ 25MG BASE **	N016798	001	
+	EQ 50MG BASE **	N016798	002	
+	EQ 75MG BASE **	N016798	006	
+	EQ 100MG BASE **	N016798	005	
+	EQ 150MG BASE **	N016798	007	
CONCENTRATE;ORAL				
DOXEPIN HYDROCHLORIDE				
PHARM ASSOC	EQ 10MG BASE/ML	A075924	001	Jan 15, 2004
TEVA PHARMS	EQ 10MG BASE/ML	A071609	001	Nov 09, 1987
SINEQUAN				
+ PFIZER	EQ 10MG BASE/ML **	N017516	001	
TABLET;ORAL				
DOXEPIN HYDROCHLORIDE				
STRIDES ARCOLAB LTD	EQ 3MG BASE	A202510	001	Jul 24, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXEPIN HYDROCHLORIDE				
TABLET;ORAL				
DOXEPIN HYDROCHLORIDE				
	EQ 6MG BASE	A202510	002	Jul 24, 2020
DOXERCALCIFEROL				
CAPSULE;ORAL				
DOXERCALCIFEROL				
HIKMA	0.5MCG	A091433	001	Sep 23, 2011
	1MCG	A091433	002	Jan 14, 2014
	2.5MCG	A091433	003	Jan 14, 2014
INJECTABLE;INJECTION				
DOXERCALCIFEROL				
AMNEAL	4MCG/2ML (2MCG/ML)	A208975	001	May 24, 2017
+ HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018
SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019
	4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019
DOXORUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
ADRIAMYCIN PFS				
PFIZER	2MG/ML	A063165	001	Jan 30, 1991
	200MG/100ML	A063165	002	Jan 30, 1991
DOXORUBICIN HYDROCHLORIDE				
ALMAJECT	2MG/ML	A065515	001	Nov 08, 2012
HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019
HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012
MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012
	10MG/VIAL	A200170	001	Oct 28, 2011
PFIZER	10MG/VIAL	N050467	001	
	20MG/VIAL	N050467	003	May 20, 1985
	50MG/VIAL	N050467	002	
	150MG/VIAL	N050467	004	Jul 22, 1987
RUBEX				
BRISTOL MYERS SQUIBB	10MG/VIAL	A062926	001	Apr 13, 1989
	50MG/VIAL	A062926	002	Apr 13, 1989
	100MG/VIAL	A062926	003	Apr 13, 1989
DOXYCYCLINE				
CAPSULE;ORAL				
DOXYCYCLINE				
MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012
RISING PHARMA	EQ 50MG BASE	A208942	001	Jan 21, 2021
	EQ 75MG BASE	A208942	002	Jan 21, 2021
	EQ 100MG BASE	A208942	003	Jan 21, 2021
SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000
	EQ 100MG BASE	A065032	002	Jun 30, 2000
STRIDES PHARMA	EQ 75MG BASE	A065055	004	Apr 18, 2005
WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000
	EQ 100MG BASE	A065041	002	Apr 28, 2000
FOR SUSPENSION;ORAL				
DOXYCHEL				
RACHELLE	EQ 25MG BASE/5ML	A061720	001	
TABLET;ORAL				
DOXYCYCLINE				
MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006
	EQ 75MG BASE	A065377	002	Nov 07, 2006
	EQ 100MG BASE	A065377	003	Nov 07, 2006
	EQ 150MG BASE	A065427	001	Jun 07, 2007
SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006
	EQ 75MG BASE	A065353	002	Nov 27, 2006
	EQ 100MG BASE	A065353	003	Nov 27, 2006
STRIDES PHARMA	EQ 50MG BASE	A065070	001	Dec 15, 2000
	EQ 75MG BASE	A065070	003	Dec 30, 2002
	EQ 100MG BASE	A065070	002	Dec 15, 2000
	EQ 150MG BASE	A065070	004	Jul 14, 2005
SUN PHARM INDUSTRIES	EQ 50MG BASE	A065471	001	Apr 17, 2009
	EQ 75MG BASE	A065471	002	Apr 17, 2009
	EQ 100MG BASE	A065471	003	Apr 17, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYCYCLINE HYCLATE

CAPSULE;ORAL					
ACTICLATE CAP					
+	ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016
DOXY-LEMMON					
	TEVA	EQ 50MG BASE	A062497	001	Aug 23, 1984
		EQ 100MG BASE	A062497	002	Jun 15, 1984
DOXYCYCLINE HYCLATE					
	AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018
		EQ 100MG BASE	A211012	002	Sep 24, 2018
	HALSEY	EQ 50MG BASE	A062119	002	May 24, 1985
		EQ 100MG BASE	A062119	001	May 24, 1985
	HEATHER	EQ 50MG BASE	A062463	001	Dec 07, 1983
		EQ 100MG BASE	A062463	002	Dec 07, 1983
	HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005
	INTERPHARM	EQ 50MG BASE	A062763	001	Sep 02, 1988
		EQ 100MG BASE	A062763	002	Sep 02, 1988
	MUTUAL PHARM	EQ 50MG BASE	A062418	001	Jan 28, 1983
		EQ 100MG BASE	A062418	002	Jan 28, 1983
	MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982
		EQ 100MG BASE	A062337	002	Mar 29, 1982
	NOSTRUM LABS INC	EQ 50MG BASE	A209393	001	Dec 10, 2020
		EQ 100MG BASE	A209393	002	Dec 10, 2020
	PAR PHARM	EQ 50MG BASE	A062434	001	Oct 19, 1984
		EQ 100MG BASE	A062442	001	Dec 22, 1983
	PVT FORM	EQ 50MG BASE	A062631	001	Jul 24, 1986
		EQ 100MG BASE	A062631	002	Jul 24, 1986
	RANBAXY	EQ 50MG BASE	A062479	001	Dec 23, 1983
		EQ 100MG BASE	A062479	002	Dec 23, 1983
	SUPERPHARM	EQ 50MG BASE	A062469	001	Oct 31, 1984
		EQ 100MG BASE	A062469	002	Oct 31, 1984
	WARNER CHILCOTT	EQ 50MG BASE	A062594	001	Dec 05, 1985
		EQ 100MG BASE	A062594	002	Dec 05, 1985
	WATSON LABS	EQ 50MG BASE	A061717	001	
		EQ 50MG BASE	A062142	001	
		EQ 100MG BASE	A061717	002	
		EQ 100MG BASE	A062142	002	
	ZHEJIANG YONGTAI	EQ 50MG BASE	A212610	001	Mar 31, 2020
		EQ 100MG BASE	A212610	002	Mar 31, 2020
PERIOSTAT					
+	COLLAGENEX	EQ 20MG BASE **	N050744	001	Sep 30, 1998
VIBRAMYCIN					
+	PFIZER	EQ 50MG BASE **	N050007	001	
CAPSULE, COATED PELLETS;ORAL					
DOXYCYCLINE HYCLATE					
	PLIVA	EQ 100MG BASE	A063187	001	Jun 30, 1992
CAPSULE, DELAYED RELEASE;ORAL					
DORYX					
+	MAYNE PHARMA INTL	EQ 75MG BASE	N050582	002	Aug 13, 2001
+		EQ 100MG BASE	N050582	001	Jul 22, 1985
	WARNER CHILCOTT	EQ 100MG BASE	A062653	001	Oct 30, 1985
DOXYCYCLINE HYCLATE					
	BAUSCH	EQ 75MG BASE	A065281	001	Dec 21, 2005
		EQ 100MG BASE	A065281	002	Dec 21, 2005
INJECTABLE;INJECTION					
DOXYCHEL HYCLATE					
	RACHELLE	EQ 100MG BASE/VIAL	A061953	001	
DOXYCYCLINE					
	HIKMA	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983
		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988
VIBRAMYCIN					
+	PFIZER	EQ 100MG BASE/VIAL **	N050442	002	
+		EQ 200MG BASE/VIAL **	N050442	001	
SYSTEM, EXTENDED RELEASE;PERIODONTAL					
ATRIDOX					
+	DEN-MAT	50MG	N050751	001	Sep 03, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DOXYCYCLINE HYCLATE				
TABLET;ORAL				
DOXY-LEMMON				
TEVA	EQ 100MG BASE	A062581	001	Mar 15, 1985
DOXYCYCLINE HYCLATE				
ALEMBIC PHARMS LTD	EQ 100MG BASE	A210536	001	May 14, 2020
AMICI	EQ 100MG BASE	A213475	001	Mar 10, 2021
AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017
	EQ 150MG BASE	A209372	002	Oct 06, 2017
HEATHER	EQ 100MG BASE	A062462	001	May 11, 1983
HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005
INTERPHARM	EQ 100MG BASE	A062764	001	Sep 02, 1988
MUTUAL PHARM	EQ 100MG BASE	A062391	001	Sep 30, 1982
MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983
RISING PHARMA	EQ 75MG BASE	A209987	001	Oct 05, 2020
	EQ 150MG BASE	A209987	002	Oct 05, 2020
STRIDES PHARMA	EQ 100MG BASE	A062538	001	Apr 07, 1986
SUPERPHARM	EQ 100MG BASE	A062494	001	Feb 20, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062593	001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392	001	Mar 31, 1983
	EQ 100MG BASE	A062392	002	Mar 31, 1983
LYMEPAK				
+ CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018
PERIOSTAT				
+ GALDERMA LABS LP	EQ 20MG BASE **	N050783	001	Feb 02, 2001
VIBRA-TABS				
+ PFIZER	EQ 100MG BASE **	N050533	001	
TABLET, DELAYED RELEASE;ORAL				
DORYX MPC				
+ MAYNE PHARMA	EQ 60MG BASE **	N050795	007	May 20, 2016
DOXYCYCLINE HYCLATE				
IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010
	EQ 100MG BASE	A090505	002	Dec 28, 2010
MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012
RISING PHARMA	EQ 50MG BASE	A090431	003	May 23, 2016
	EQ 75MG BASE	A090431	001	Dec 28, 2010
	EQ 80MG BASE	A090431	004	Apr 29, 2016
	EQ 100MG BASE	A090431	002	Dec 28, 2010
	EQ 200MG BASE	A090431	005	May 19, 2016
ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018
	EQ 100MG BASE	A206772	002	Dec 21, 2018
	EQ 150MG BASE	A206772	003	Dec 21, 2018
DOXYLAMINE SUCCINATE				
CAPSULE;ORAL				
UNISOM				
PFIZER	25MG	N019440	001	Feb 05, 1986
TABLET;ORAL				
DECAPRYN				
SANOFI AVENTIS US	12.5MG	N006412	015	
	25MG	N006412	014	
DOXY-SLEEP-AID				
PAR PHARM	25MG	A070156	001	Jul 02, 1987
DOXYLAMINE SUCCINATE				
COPLEY PHARM	25MG	A088900	002	Feb 12, 1988
QUANTUM PHARMICS	25MG	A088603	001	Aug 07, 1984
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
BENDECTIN				
SANOFI AVENTIS US	10MG;10MG **	N010598	002	
DROMOSTANOLONE PROPIONATE				
INJECTABLE;INJECTION				
DROLBAN				
LILLY	50MG/ML	N012936	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DRONABINOL

CAPSULE;ORAL

DRONABINOL

INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011
	5MG	A078501	002	Aug 19, 2011
	10MG	A078501	003	Aug 19, 2011

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

ABRAXIS PHARM	2.5MG/ML	A070992	001	Nov 17, 1986
	2.5MG/ML	A070993	001	Nov 17, 1986
ASTRAZENECA	2.5MG/ML	A072018	001	Oct 20, 1988
HOSPIRA	2.5MG/ML	A071645	001	Apr 07, 1988
	2.5MG/ML	A072272	001	Aug 31, 1995
IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988
	2.5MG/ML	A072020	001	Oct 19, 1988
	2.5MG/ML	A072021	001	Oct 19, 1988
LUITPOLD	2.5MG/ML	A072335	001	Oct 24, 1988
SMITH AND NEPHEW	2.5MG/ML	A071750	001	Sep 06, 1988
SOLOPAK	2.5MG/ML	A071754	001	Sep 06, 1988
	2.5MG/ML	A071755	001	Sep 06, 1988
WATSON LABS	2.5MG/ML	A073520	001	Nov 27, 1991
	2.5MG/ML	A073521	001	Nov 27, 1991
	2.5MG/ML	A073523	001	Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	A072026	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072027	001	Apr 13, 1989
	2.5MG/ML;EQ 0.05MG BASE/ML	A072028	001	Apr 13, 1989
HOSPIRA	2.5MG/ML;EQ 0.05MG BASE/ML	A071982	001	May 04, 1988

INNOVAR

AKORN	2.5MG/ML;EQ 0.05MG BASE/ML	N016049	001	

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017

KYRA

SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

APOTEX	3MG;0.03MG	A205876	001	Sep 21, 2016
JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018

KEMEYA

SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021
	200MG	A213162	002	Feb 18, 2021
	300MG	A213162	003	Feb 18, 2021

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013
	EQ 30MG BASE	A090783	002	Dec 11, 2013
	EQ 60MG BASE	A090783	003	Dec 11, 2013
YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019
	EQ 30MG BASE	A207219	002	Aug 16, 2019
	EQ 60MG BASE	A207219	003	Aug 16, 2019

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

	ACTAVIS LABS FL INC	0.5MG	A202808 001	Nov 20, 2015
	APOTEX INC	0.5MG	A204292 001	Nov 24, 2015
	HERITAGE PHARMS INC	0.5MG	A207935 001	Oct 13, 2017
	HIKMA	0.5MG	A202204 001	Nov 23, 2015
	MYLAN	0.5MG	A203241 001	Jun 14, 2016
	NOSTRUM LABS INC	0.5MG	A204705 001	Nov 20, 2015
	RISING	0.5MG	A202530 001	Nov 20, 2015
	STRIDES PHARMA	0.5MG	A208227 001	Jun 22, 2018

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

	ACTAVIS LABS FL INC	0.5MG;0.4MG	A202975 001	Nov 20, 2015

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLONE

+	ASTRAZENECA	0.5% **	N009925 002	
+		1% **	N009925 001	

DYDROGESTERONE

TABLET;ORAL

GYNOREST

+	SOLVAY	5MG **	N017388 001	
+		10MG **	N017388 002	

DYPHYLLINE

ELIXIR;ORAL

NEOTHYLLINE

	TEVA	160MG/15ML	N007794 003	

INJECTABLE;INJECTION

NEOTHYLLINE

	TEVA	250MG/ML	N009088 001	

TABLET;ORAL

DILOR

	SAVAGE LABS	200MG	A084514 001	

DILOR-400

	SAVAGE LABS	400MG	A084751 001	

LUFYLLIN

	MYLAN SPECIALITY LP	200MG	A084566 001	
		400MG	A084566 002	

NEOTHYLLINE

	TEVA	200MG	N007794 001	
		400MG	N007794 002	

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

	FERA PHARMS LLC	0.03%	N011963 002	
		0.06%	N011963 004	
		0.25%	N011963 003	

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

	CHARTWELL RX	1%	A076075 001	Nov 26, 2002
	MYLAN	1%	A210364 001	Apr 18, 2018

EDETATE CALCIUM DISODIUM

TABLET;ORAL

CALCIUM DISODIUM VERSENATE

	BAUSCH	500MG	N008922 002	

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

EDROPHONIUM CHLORIDE

	HOSPIRA	10MG/ML	A040131 001	Feb 24, 1998
	WATSON LABS	10MG/ML	A040044 001	Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

	WATSON LABS	10MG/ML	A040043 001	Mar 20, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EDROPHONIUM CHLORIDE
INJECTABLE;INJECTION
ENLON
MYLAN INSTITUTIONAL 10MG/ML A088873 001 Aug 06, 1985
REVERSOL
ORGANON USA INC 10MG/ML A089624 001 May 13, 1988
TENSILON
\+ TELIGENT 10MG/ML ** N007959 001
TENSILON PRESERVATIVE FREE
\+ TELIGENT 10MG/ML ** N007959 002

EFAVIRENZ
CAPSULE;ORAL
SUSTIVA
\+ BRISTOL MYERS SQUIBB 100MG ** N020972 002 Sep 17, 1998
TABLET;ORAL
EFAVIRENZ
MYLAN 600MG A091471 001 Feb 17, 2016
STRIDES PHARMA 600MG A078509 001 Jun 16, 2021
SUSTIVA
\+ BRISTOL MYERS SQUIBB 300MG ** N021360 001 Feb 01, 2002

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
TABLET;ORAL
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
\+ AUROBINDO PHARMA LTD 600MG;300MG;300MG N022343 001 Aug 15, 2018
MACLEODS PHARMS LTD 400MG;300MG;300MG N210649 001 Mar 15, 2019

EFINACONAZOLE
SOLUTION;TOPICAL
EFINACONAZOLE
AUROBINDO PHARMA LTD 10% A212066 001 Mar 29, 2021
PADAGIS US 10% A211851 001 Dec 16, 2020

EFLORNITHINE HYDROCHLORIDE
INJECTABLE;INJECTION
ORNIDYL
SANOFI AVENTIS US 200MG/ML N019879 002 Nov 28, 1990

ELETRIPTAN HYDROBROMIDE
TABLET;ORAL
ELETRIPTAN HYDROBROMIDE
AMNEAL PHARMS CO EQ 20MG BASE A206787 001 May 25, 2018
EQ 40MG BASE A206787 002 May 25, 2018
YUNG SHIN PHARM EQ 20MG BASE A209680 001 Jul 13, 2020
EQ 40MG BASE A209680 002 Jul 13, 2020

ELTROMBOPAG OLAMINE
TABLET;ORAL
PROMACTA
\+ NOVARTIS EQ 100MG ACID ** N022291 005 Nov 16, 2012

ELVITEGRAVIR
TABLET;ORAL
VITEKTA
\+ GILEAD SCIENCES INC 85MG N203093 001 Sep 24, 2014
\+ 150MG N203093 002 Sep 24, 2014

EMEDASTINE DIFUMARATE
SOLUTION/DROPS;OPHTHALMIC
EMADINE
\+ NOVARTIS 0.05% N020706 001 Dec 29, 1997

ENALAPRIL MALEATE
FOR SOLUTION;ORAL
EPANED KIT
\+ SILVERGATE PHARMS 1MG/ML ** N204308 001 Aug 13, 2013
TABLET;ORAL
ENALAPRIL MALEATE
APOTHECON 2.5MG A075583 001 Aug 22, 2000
5MG A075583 002 Aug 22, 2000
10MG A075583 003 Aug 22, 2000
20MG A075583 004 Aug 22, 2000
AUROBINDO PHARMA USA 2.5MG A075480 001 Aug 22, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

	5MG	A075480	002	Aug 22, 2000
	10MG	A075480	003	Aug 22, 2000
	20MG	A075480	004	Aug 22, 2000
BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000
	5MG	A075621	002	Aug 22, 2000
	10MG	A075621	003	Aug 22, 2000
	20MG	A075621	004	Aug 22, 2000
IVAX SUB TEVA PHARMS	2.5MG	A075482	001	Aug 22, 2000
	5MG	A075482	002	Aug 22, 2000
	10MG	A075482	003	Aug 22, 2000
	20MG	A075482	004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370	001	Aug 22, 2000
	5MG	A075370	002	Aug 22, 2000
	10MG	A075369	001	Aug 22, 2000
	20MG	A075369	002	Aug 22, 2000
MYLAN	2.5MG	A075472	001	Aug 22, 2000
	5MG	A075472	002	Aug 22, 2000
	10MG	A075472	003	Aug 22, 2000
	20MG	A075472	004	Aug 22, 2000
NOSTRUM LABS INC	2.5MG	A075178	002	Mar 23, 2001
	5MG	A075178	001	Mar 23, 2001
	10MG	A075178	003	Mar 23, 2001
	20MG	A075178	004	Mar 23, 2001
SANDOZ	2.5MG	A075048	001	Aug 22, 2000
	5MG	A075048	002	Aug 22, 2000
	10MG	A075048	003	Aug 22, 2000
	20MG	A075048	004	Aug 22, 2000
SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000
	5MG	A075556	002	Aug 22, 2000
	10MG	A075556	003	Aug 22, 2000
	20MG	A075556	004	Aug 22, 2000
WATSON LABS	2.5MG	A075501	001	Aug 22, 2000
	5MG	A075501	002	Aug 22, 2000
	10MG	A075501	003	Aug 22, 2000
	20MG	A075501	004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

LEXXEL

ASTRAZENECA	5MG;2.5MG	N020668	002	Oct 28, 1998
	5MG;5MG	N020668	001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	5MG;12.5MG	A076116	001	Sep 19, 2001
	10MG;25MG	A076116	002	Sep 19, 2001
IVAX SUB TEVA PHARMS	5MG;12.5MG	A075736	001	Mar 25, 2003
	10MG;25MG	A075736	002	Mar 25, 2003
NOSTRUM LABS INC	5MG;12.5MG	A076486	001	Oct 27, 2004
	10MG;25MG	A076486	002	Oct 27, 2004
RISING PHARMA	5MG;12.5MG	A075624	001	Sep 18, 2001
	10MG;25MG	A075624	002	Sep 18, 2001

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000
HOSPIRA	1.25MG/ML	A075456	001	Aug 22, 2000
	1.25MG/ML	A075571	001	Aug 22, 2000

VASOTEC

+	BIOVAIL LABS INTL	1.25MG/ML **	N019309	001	Feb 09, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ENCORAFENIB				
CAPSULE;ORAL				
BRAFTOVI				
+ ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018
ENFLURANE				
LIQUID;INHALATION				
ENFLURANE				
ABBOTT	99.9%	A070803	001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396	001	Jul 29, 1994
ETHRANE				
BAXTER HLTHCARE	99.9%	N017087	001	
ENOXACIN				
TABLET;ORAL				
PENETREX				
SANOFI AVENTIS US	200MG	N019616	004	Dec 31, 1991
	400MG	N019616	005	Dec 31, 1991
ENOXAPARIN SODIUM				
INJECTABLE;SUBCUTANEOUS				
LOVENOX (PRESERVATIVE FREE)				
+ SANOFI AVENTIS US	90MG/0.6ML (150MG/ML) **	N020164	006	Jun 02, 2000
ENTACAPONE				
TABLET;ORAL				
ENTACAPONE				
MYLAN PHARMS INC	200MG	A202394	001	May 13, 2013
ENTECAVIR				
TABLET;ORAL				
ENTECAVIR				
RISING PHARMA	0.5MG	A206226	001	Mar 26, 2019
	1MG	A206226	002	Mar 26, 2019
STRIDES PHARMA	0.5MG	A206294	001	Nov 23, 2016
	1MG	A206294	002	Nov 23, 2016
SUNSHINE	0.5MG	A211978	001	May 20, 2020
	1MG	A211978	002	May 20, 2020
TEVA PHARMS USA	0.5MG	A202122	001	Aug 26, 2014
	1MG	A202122	002	Aug 26, 2014
YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019
	1MG	A212201	002	Nov 04, 2019
EPHEDRINE HYDROCHLORIDE				
SOLUTION;INTRAVENOUS				
REZIPRES				
+ ETON	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021
+	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021
EPHEDRINE SULFATE				
SOLUTION;INTRAVENOUS				
EPHEDRINE SULFATE				
+ ENDO VENTURES	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020
EPINASTINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
EPINASTINE HYDROCHLORIDE				
CHARTWELL RX	0.05%	A203384	001	Dec 07, 2016
SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011
EPINEPHRINE				
AEROSOL, METERED;INHALATION				
BRONKAID MIST				
STERLING	0.25MG/INH	N016803	001	
EPINEPHRINE				
ARMSTRONG PHARMS	0.2MG/INH	A087907	001	May 23, 1984
PRIMATENE MIST				
WYETH CONS	0.2MG/INH	N016126	001	
INJECTABLE;INJECTION				
SUS-PHRINE SULFITE FREE				
FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999
	5MG/ML	N007942	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPINEPHRINE				
INJECTABLE;INTRAMUSCULAR				
EPI E Z PEN JR				
	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430 004	Aug 03, 1995
EPIPEN E Z PEN				
	MYLAN SPECIALITY LP	0.3MG/DELIVERY	N019430 003	Aug 03, 1995
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS				
TWINJECT 0.15				
	IMPAX	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004
TWINJECT 0.3				
	IMPAX	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS				
EPINEPHRINE				
	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568 001	Jul 06, 2018
EPINEPHRINE BITARTRATE				
AEROSOL, METERED;INHALATION				
BRONITIN MIST				
	WYETH CONS	0.3MG/INH	N016126 002	
MEDIHALER-EPI				
	3M	0.3MG/INH	N010374 003	
EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.005MG/ML;1% **	N017751 006	
+		0.005MG/ML;1.5% **	N017751 007	
+	DENTSPLY PHARM	0.005MG/ML;1.5% **	N021384 001	
EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
CITANEST FORTE				
	ASTRAZENECA	0.005MG/ML;4%	N014763 008	
EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.005MG/ML;0.5% **	N017751 004	
EPINEPHRINE; LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE				
	CARLISLE	0.01MG/ML;2%	A084720 001	
		0.02MG/ML;2%	A084732 001	
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
	BELMORA LLC	0.01MG/ML;2%	A080504 004	Oct 19, 1983
		0.02MG/ML;2%	A080504 005	Oct 19, 1983
	EASTMAN KODAK	0.01MG/ML;2%	A040057 002	Feb 26, 1993
		0.02MG/ML;2%	A040057 001	Feb 26, 1993
	HOSPIRA	0.005MG/ML;1%	A089649 001	Jun 21, 1988
		0.005MG/ML;1.5%	A089650 001	Jun 21, 1988
		0.01MG/ML;2%	A078772 001	May 12, 2008
		0.02MG/ML;2%	A078772 002	May 12, 2008
	WEST-WARD PHARMS INT	0.01MG/ML;1%	A080406 001	
		0.01MG/ML;2%	A080406 002	
LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE				
	ABBOTT	0.01MG/ML;1%	A083154 001	
	BEL MAR	0.01MG/ML;1%	A080820 001	
		0.01MG/ML;2%	A080757 001	
	DELL LABS	0.01MG/ML;1%	A083389 001	
		0.01MG/ML;2%	A083390 001	
	INTL MEDICATION	0.01MG/ML;1%	A086402 001	
	WATSON LABS	0.01MG/ML;1%	A080377 003	
		0.01MG/ML;1%	A085463 001	
		0.01MG/ML;2%	A080377 004	
LIDOCATON				
	PHARMATON	0.01MG/ML;2%	A084729 001	Aug 17, 1983
		0.02MG/ML;2%	A084728 001	Aug 17, 1983
OCTOCAINE				
	SEPTODONT	0.01MG/ML;2%	A084048 001	
		0.02MG/ML;2%	A084048 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
XYLOCAINE DENTAL WITH EPINEPHRINE				
DENTSPLY PHARM	0.01MG/ML;2% **	N021381	001	
	0.02MG/ML;2% **	N021381	002	
XYLOCAINE W/ EPINEPHRINE				
ASTRAZENECA	0.005MG/ML;1%	N010418	006	
	0.005MG/ML;1.5%	N010418	010	
	0.005MG/ML;2%	N010418	008	
FRESENIUS KABI USA	0.01MG/ML;2%	N006488	003	
PATCH;IONTOPHORESIS, TOPICAL				
LIDOSITE TOPICAL SYSTEM KIT				
VYTERIS	1.05MG/PATCH;100MG/PATCH	N021504	001	May 06, 2004
SOLUTION;IONTOPHORESIS				
IONTOCAINE				
IOMED	0.01MG/ML;2%	N020530	001	Dec 21, 1995
SOLUTION;IONTOPHORESIS, TOPICAL				
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE				
EMPI	0.01MG/ML;2%	N021486	001	Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PROCAINE HYDROCHLORIDE W/ EPINEPHRINE				
BEL MAR	0.02MG/ML;1%	A080758	001	
	0.02MG/ML;2%	A080759	001	

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION				
EPIRUBICIN HYDROCHLORIDE				
ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008
EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007
	50MG/25ML (2MG/ML)	A065408	002	Oct 15, 2007
	150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007
	200MG/100ML (2MG/ML)	A065408	004	Oct 15, 2007
	200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007
	50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007
HOSPIRA	10MG/5ML (2MG/ML)	A065343	001	Apr 19, 2007
	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
	150MG/75ML (2MG/ML)	A065343	003	Apr 19, 2007
	200MG/100ML (2MG/ML)	A065343	004	Apr 19, 2007
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007
	200MG/100ML (2MG/ML)	A065371	002	Nov 28, 2007
MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012
	200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012
ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
POWDER;INTRAVENOUS				
EPIRUBICIN HYDROCHLORIDE				
HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006
	200MG/VIAL	N050807	002	Sep 15, 2006

EPLERENONE

TABLET;ORAL				
EPLERENONE				
PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020
	50MG	A212765	002	Aug 10, 2020
INSPRA				
UPJOHN	100MG	N021437	003	Sep 27, 2002

EPROSARTAN MESYLATE

TABLET;ORAL				
EPROSARTAN MESYLATE				
MYLAN PHARMS INC	EQ 400MG BASE	A202012	001	Nov 16, 2011
	EQ 600MG BASE	A202012	002	Nov 16, 2011
TEVETEN				
ABBVIE	EQ 300MG BASE **	N020738	004	Dec 22, 1997
+	EQ 400MG BASE **	N020738	005	Dec 22, 1997
+	EQ 600MG BASE **	N020738	006	May 27, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
TEVETEN HCT				
ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001
	600MG;25MG	N021268	002	Nov 01, 2001
EPTIFIBATIDE				
INJECTABLE;INJECTION				
EPTIFIBATIDE				
AMNEAL PHARMS	2MG/ML	A205581	001	Dec 08, 2016
	75MG/100ML	A205581	002	Dec 08, 2016
HYBIO	2MG/ML	A207864	001	Mar 20, 2020
	75MG/100ML	A207864	002	Mar 20, 2020
TEVA PHARMS USA	75MG/100ML	A091555	001	Jun 05, 2015
USV	2MG/ML	A204361	001	Mar 14, 2019
	2MG/ML	A204362	001	Mar 11, 2019
	75MG/100ML	A204361	002	Mar 14, 2019
INTEGRILIN				
+ SCHERING	2MG/ML	N020718	001	May 18, 1998
+	75MG/100ML	N020718	002	May 18, 1998
ERGOCALCIFEROL				
CAPSULE;ORAL				
DELTALIN				
LILLY	50,000 IU	A080884	001	
ERGOCALCIFEROL				
SIGMAPHARM LABS LLC	50,000 IU	A091004	001	Jul 14, 2010
VITAMIN D				
CHASE CHEM	50,000 IU	A080747	001	
EVERYLIFE	50,000 IU	A080956	001	
IMPAX LABS	50,000 IU	A080951	001	
LANNETT	50,000 IU	A080825	001	
VITARINE	50,000 IU	A084053	001	
WEST WARD	50,000 IU	A083102	001	
ERGOLOID MESYLATES				
CAPSULE;ORAL				
HYDERGINE LC				
NOVARTIS	1MG	N018706	001	Jan 18, 1983
SOLUTION;ORAL				
HYDERGINE				
NOVARTIS	1MG/ML	N018418	001	
TABLET;ORAL				
ERGOLOID MESYLATES				
MUTUAL PHARM	1MG	A088891	001	Nov 01, 1985
WATSON LABS	1MG	A086433	001	May 27, 1982
	1MG	A087244	001	Aug 16, 1982
GERIMAL				
WATSON LABS	1MG	A088207	001	Mar 22, 1984
HYDERGINE				
NOVARTIS	0.5MG	N017993	003	
+	1MG	N017993	001	
TABLET;SUBLINGUAL				
ALKERGOT				
SANDOZ	0.5MG	A085153	001	
	1MG	A087417	001	
CIRCANOL				
3M	0.5MG	A084868	001	
	1MG	A085809	001	
DEAPRIL-ST				
BRISTOL MYERS SQUIBB	1MG	A085020	002	
ERGOLOID MESYLATES				
KV PHARM	0.5MG	A085899	001	
	0.5MG	A086265	001	
	1MG	A085900	001	
	1MG	A086264	001	
LEDERLE	0.5MG	A086984	001	
	1MG	A086985	001	
SUN PHARM INDUSTRIES	0.5MG	A087407	001	
	1MG	A087552	001	
SUPERPHARM	0.5MG	A089233	001	Sep 23, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERGOLOID MESYLATES				
TABLET;SUBLINGUAL				
ERGOLOID MESYLATES				
	1MG	A089234	001	Sep 23, 1986
VANGARD	0.5MG	A088013	001	Sep 20, 1982
	1MG	A088014	001	Sep 20, 1982
WATSON LABS	0.5MG	A084930	001	
	0.5MG	A087233	001	
	1MG	A085177	001	
	1MG	A087183	001	
GERIMAL				
WATSON LABS	0.5MG	A086189	001	
	1MG	A086188	001	
HYDERGINE				
NOVARTIS	0.5MG	N009087	002	
	1MG	N009087	001	
HYDROGENATED ERGOT ALKALOIDS				
IVAX PHARMS	0.5MG	A087186	001	
	1MG	A087185	001	
ERGOTAMINE TARTRATE				
AEROSOL, METERED;INHALATION				
MEDIHALER ERGOTAMINE				
3M	0.36MG/INH	N012102	001	
TABLET;SUBLINGUAL				
ERGOSTAT				
WATSON LABS INC	2MG	A088337	001	Jun 08, 1984
WIGRETTES				
ORGANON USA INC	2MG	A086750	001	Jul 29, 1982
ERLOTINIB HYDROCHLORIDE				
TABLET;ORAL				
ERLOTINIB HYDROCHLORIDE				
ACCORD HLTHCARE	EQ 25MG BASE	A211083	001	Jul 02, 2020
	EQ 100MG BASE	A211083	002	Jul 02, 2020
	EQ 150MG BASE	A211083	003	Jul 02, 2020
ERYTHROMYCIN				
CAPSULE, DELAYED REL PELLETS;ORAL				
ERYC				
PARKE DAVIS	250MG	A062546	001	Jul 25, 1985
	250MG	A062618	001	Sep 25, 1985
WARNER CHILCOTT LLC	250MG	A062338	001	
ERYC 125				
PARKE DAVIS	125MG	A062648	001	Oct 24, 1985
ERYC SPRINKLES				
HOSPIRA	125MG	N050593	001	Jul 22, 1985
ERYTHROMYCIN				
BARR	250MG	A063098	001	May 04, 1989
GEL;TOPICAL				
E-GLADES				
MYLAN	2%	A065009	001	Mar 18, 2002
EMGEL				
ALTANA	2%	A063107	001	Aug 23, 1991
LOTION;TOPICAL				
E-SOLVE 2				
SYOSSET	2%	A062467	001	Jul 03, 1985
OINTMENT;OPHTHALMIC				
ERYTHROMYCIN				
PHARMADERM	5MG/GM	A062446	001	Sep 26, 1983
PHARMAFAIR	5MG/GM	A062481	001	Apr 05, 1984
ILOTYCIN				
DISTA	0.5% **	N050368	001	
OINTMENT;TOPICAL				
AKNE-MYCIN				
+ BAUSCH	2%	N050584	001	Jan 10, 1985
POWDER;FOR RX COMPOUNDING				
ERYTHROMYCIN				
PADDOCK LLC	100%	N050610	001	Nov 07, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN				
SOLUTION;TOPICAL				
A/T/S				
TARO	2%		A062405 001	Nov 18, 1982
C-SOLVE-2				
FOUGERA PHARMS	2%		A062468 001	Jul 03, 1985
ERYDERM				
ARBOR PHARMS INC	2%		A062290 001	
ERYMAX				
MERZ PHARMS	2%		A062508 002	Jul 11, 1985
ERYTHRO-STATIN				
AKORN	2%		A064101 001	Oct 22, 1996
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%		A062328 001	Apr 19, 1982
	2%		A062326 001	Apr 19, 1982
	2%		A062327 001	Apr 19, 1982
	2%		A062342 001	Feb 25, 1982
	2%		A062957 001	Jul 21, 1988
BAUSCH AND LOMB	2%		A064039 001	Jan 27, 1994
FOUGERA PHARMS	2%		A064187 001	Sep 30, 1997
LILLY	2%		N050532 001	
PHARMAFAIR	1.5%		A062485 001	Jul 11, 1984
	2%		A062616 001	Jul 25, 1985
RENAISSANCE PHARMA	2%		A064127 001	Feb 14, 1997
SANSAC				
DOW PHARM	2%		A062522 001	Jan 24, 1985
STATICIN				
+ WESTWOOD SQUIBB	1.5% **		N050526 001	
T-STAT				
WESTWOOD SQUIBB	2% **		A062436 001	Mar 09, 1983
SWAB;TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%		A062751 001	Jul 30, 1993
ERYCETTE				
+ JOHNSON AND JOHNSON	2% **		N050594 001	Feb 15, 1985
ERYTHROMYCIN				
FOUGERA PHARMS	2%		A065320 001	Jul 25, 2006
MYLAN	2%		A064128 001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%		A062748 001	Jul 23, 1987
TABLET, COATED PARTICLES;ORAL				
PCE				
+ ARBOR PHARMS LLC	333MG		N050611 001	Sep 09, 1986
+	500MG		N050611 002	Aug 22, 1990
TABLET, DELAYED RELEASE;ORAL				
E-BASE				
BARR	333MG		A063028 001	May 15, 1990
	333MG		A063086 001	May 15, 1990
	500MG		A062999 001	Nov 25, 1988
E-MYCIN				
ARBOR PHARMS INC	250MG		A060272 001	
	333MG		A060272 002	
ILOTYCIN				
DISTA	250MG		A061910 001	
R-P MYCIN				
SOLVAY	250MG		A061659 001	
ROBIMYCIN				
ROBINS AH	250MG		A061633 001	
ERYTHROMYCIN ESTOLATE				
CAPSULE;ORAL				
ERYTHROMYCIN ESTOLATE				
BARR	EQ 125MG BASE		A062162 001	
	EQ 250MG BASE		A062162 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE		A062237 001	
WATSON LABS	EQ 250MG BASE		A062087 001	
ILOSONE				
LILLY	EQ 125MG BASE		A061897 001	
	EQ 250MG BASE		A061897 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN ESTOLATE

FOR SUSPENSION;ORAL				
ILOSONE				
	DISTA	EQ 125MG BASE/5ML	A061893 001	
SUSPENSION;ORAL				
ERYTHROMYCIN ESTOLATE				
	ALPHARMA US PHARMS	EQ 125MG BASE/5ML	A062353 001	Nov 18, 1982
		EQ 250MG BASE/5ML	A062409 001	Dec 16, 1982
	COSETTE	EQ 125MG BASE/5ML	A062169 001	Oct 17, 1990
		EQ 250MG BASE/5ML	A062169 002	Oct 17, 1990
	LIFE LABS	EQ 250MG BASE/5ML	A062362 001	Dec 17, 1982
ILOSONE				
	LILLY	EQ 125MG BASE/5ML	A061894 001	
		EQ 125MG BASE/5ML	N050010 001	
		EQ 250MG BASE/5ML	A061894 002	
		EQ 250MG BASE/5ML	N050010 002	
SUSPENSION/DROPS;ORAL				
ILOSONE				
	LILLY	EQ 100MG BASE/ML	A061894 003	
TABLET;ORAL				
ILOSONE				
	LILLY	EQ 500MG BASE	A061896 001	
TABLET, CHEWABLE;ORAL				
ILOSONE				
	DISTA	EQ 125MG BASE	A061895 001	
		EQ 250MG BASE	A061895 002	

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL				
ILOSONE SULFA				
	LILLY	EQ 125MG BASE/5ML;EQ 600MG BASE/5ML	N050599 001	Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE				
	PAR PHARM INC	EQ 200MG BASE/5ML	A211991 001	Oct 23, 2019
		EQ 400MG BASE/5ML	A211991 002	Oct 23, 2019
PEDIAMYCIN				
	ROSS LABS	EQ 200MG BASE/5ML	A062305 001	
SUSPENSION;ORAL				
E-MYCIN E				
	PHARMACIA AND UPJOHN	EQ 200MG BASE/5ML	A062198 001	
		EQ 400MG BASE/5ML	A062198 002	
E.E.S. 200				
	ARBOR PHARMS LLC	EQ 200MG BASE/5ML **	A061639 001	
E.E.S. 400				
	ARBOR PHARMS LLC	EQ 400MG BASE/5ML **	A061639 002	
ERYTHROMYCIN ETHYLSUCCINATE				
	ALPHARMA US PHARMS	EQ 200MG BASE/5ML	A062200 001	
		EQ 400MG BASE/5ML	A062200 002	
	DISTA	EQ 200MG BASE/5ML	A062177 001	
		EQ 400MG BASE/5ML	A062177 002	
	NASKA	EQ 400MG BASE/5ML	A062674 001	Mar 10, 1987
	PARKE DAVIS	EQ 200MG BASE/5ML	A062231 001	
		EQ 400MG BASE/5ML	A062231 002	
	PHARMAFAIR	EQ 200MG BASE/5ML	A062559 001	Mar 15, 1985
		EQ 400MG BASE/5ML	A062558 001	Mar 15, 1985
PEDIAMYCIN				
	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304 001	
PEDIAMYCIN 400				
	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304 002	
WYAMYCIN E				
	WYETH AYERST	EQ 200MG BASE/5ML	A062123 002	
		EQ 400MG BASE/5ML	A062123 001	
SUSPENSION/DROPS;ORAL				
PEDIAMYCIN				
	ROSS LABS	EQ 100MG BASE/2.5ML	A062305 002	
TABLET;ORAL				
E.E.S. 400				
	ARBOR PHARMS LLC	EQ 400MG BASE	A061905 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN ETHYLSUCCINATE

TABLET;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE				
BARR	EQ 400MG BASE		A062256 001	
MYLAN	EQ 400MG BASE		A062847 001	Sep 14, 1988
TABLET, CHEWABLE;ORAL				
E.E.S.				
ARBOR PHARMS INC	EQ 200MG BASE		N050297 002	
ERYPED				
ARBOR PHARMS INC	EQ 200MG BASE		N050297 003	Jul 05, 1988
PEDIAMYCIN				
ROSS LABS	EQ 200MG BASE		A062306 001	

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL				
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL				
BARR	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML		A062759 001	May 20, 1988
ERYZOLE				
ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML		A062758 001	Jun 15, 1988
PEDIAZOLE				
ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML		N050529 001	

ERYTHROMYCIN GLUCEPTATE

INJECTABLE;INJECTION				
ILOTYCIN GLUCEPTATE				
DISTA	EQ 250MG BASE/VIAL		N050370 001	
	EQ 500MG BASE/VIAL		N050370 002	
	EQ 1GM BASE/VIAL		N050370 003	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION				
ERYTHROCIN				
ABBOTT	EQ 500MG BASE/VIAL		A062586 001	Jan 04, 1988
	EQ 1GM BASE/VIAL		A062586 002	Jan 04, 1988
HOSPIRA	EQ 500MG BASE/VIAL		N050182 002	
	EQ 1GM BASE/VIAL		A062638 002	Oct 31, 1986
	EQ 1GM BASE/VIAL		N050182 003	
+	EQ 1GM BASE/VIAL		N050609 002	Sep 24, 1986
ERYTHROMYCIN				
ELKINS SINN	EQ 500MG BASE/VIAL		A062563 001	Mar 28, 1985
	EQ 1GM BASE/VIAL		A062563 002	Mar 28, 1985
ERYTHROMYCIN LACTOBIONATE				
ABRAXIS PHARM	EQ 500MG BASE/VIAL		A062604 001	Nov 24, 1986
	EQ 1GM BASE/VIAL		A062604 002	Nov 24, 1986
BAXTER HLTHCARE	EQ 500MG BASE/VIAL		A062993 001	May 09, 1989
	EQ 1GM BASE/VIAL		A062993 002	May 09, 1989
TEVA PARENTERAL	EQ 500MG BASE/VIAL		A063253 001	Jul 30, 1993
	EQ 1GM BASE/VIAL		A063253 002	Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET;ORAL				
BRISTAMYCIN				
BRISTOL	EQ 250MG BASE		A061304 001	
	EQ 250MG BASE		A061887 001	
ERYPAR				
PARKE DAVIS	EQ 250MG BASE		A062032 001	
	EQ 500MG BASE		A062032 002	
WARNER CHILCOTT	EQ 250MG BASE		A062322 001	
ERYTHROCIN STEARATE				
ARBOR PHARMS LLC	EQ 125MG BASE		A060359 002	
	EQ 500MG BASE		A060359 003	
ERYTHROMYCIN STEARATE				
ANI PHARMS	EQ 250MG BASE		A061461 001	
	EQ 250MG BASE		A061591 001	
	EQ 500MG BASE		A061461 002	
	EQ 500MG BASE		A063179 001	May 15, 1990
LEDERLE	EQ 250MG BASE		A062089 001	
	EQ 500MG BASE		A062089 002	
MYLAN	EQ 250MG BASE		A061505 001	
	EQ 500MG BASE		A061505 002	
PUREPAC PHARM	EQ 250MG BASE		A061743 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROMYCIN STEARATE

WATSON LABS	EQ 250MG BASE	A062121 002		
	EQ 500MG BASE	A062121 001		

ETHRIL 250

BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061605 001		

ETHRIL 500

BRISTOL MYERS SQUIBB	EQ 500MG BASE	A061605 002		

PFIZER-E

PFIZER	EQ 250MG BASE	A061791 001		
	EQ 500MG BASE	A061791 002		

WYAMYCIN S

WYETH AYERST	EQ 250MG BASE	A061675 001		
	EQ 500MG BASE	A061675 002		

ESCITALOPRAM OXALATE

CAPSULE;ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC	EQ 5MG BASE	A077660 001	Jul 31, 2007	
	EQ 10MG BASE	A077660 002	Jul 31, 2007	
	EQ 20MG BASE	A077660 003	Jul 31, 2007	

SOLUTION;ORAL

ESCITALOPRAM OXALATE

ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967 001	May 26, 2015	

LEXAPRO

+ ALLERGAN	EQ 5MG BASE/5ML **	N021365 001	Nov 27, 2002	

TABLET;ORAL

ESCITALOPRAM OXALATE

HIKMA PHARMS	EQ 5MG BASE	A078766 001	Sep 11, 2012	
	EQ 10MG BASE	A078766 002	Sep 11, 2012	
	EQ 20MG BASE	A078766 003	Sep 11, 2012	
MACLEODS PHARMS LTD	EQ 5MG BASE	A202210 001	Sep 11, 2012	
	EQ 10MG BASE	A202210 002	Sep 11, 2012	
	EQ 20MG BASE	A202210 003	Sep 11, 2012	
MYLAN	EQ 5MG BASE	A077550 001	May 14, 2015	
	EQ 10MG BASE	A077550 002	May 14, 2015	
	EQ 20MG BASE	A077550 003	May 14, 2015	

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC

BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988	
	20MG/ML	N019386 007	May 28, 2003	

ESMOLOL HYDROCHLORIDE

AM REGENT	10MG/ML	A201126 001	Feb 20, 2015	

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY	EQ 20MG BASE	A209647 001	Apr 10, 2019	
	EQ 40MG BASE	A209647 002	Apr 10, 2019	
AMTA	EQ 20MG BASE	A213859 001	Nov 18, 2020	
	EQ 40MG BASE	A213859 002	Nov 18, 2020	
HEC PHARM	EQ 20MG BASE	A207265 002	May 18, 2018	
	EQ 40MG BASE	A207265 001	May 18, 2018	

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

MYLAN	EQ 20MG BASE	A212376 001	Oct 16, 2019	

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

P AND L	EQ 20MG BASE	A209202 001	Mar 05, 2019	

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

EUGIA PHARMA	EQ 20MG BASE/VIAL	A204657 001	Aug 10, 2016	
MYLAN LABS LTD	EQ 20MG BASE/VIAL	A202686 001	May 17, 2017	
SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882 001	Mar 18, 2013	

NEXIUM IV

+ ASTRAZENECA	EQ 20MG BASE/VIAL **	N021689 001	Mar 31, 2005	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESOMEPRAZOLE STRONTIUM					
CAPSULE, DELAYED RELEASE;ORAL					
ESOMEPRAZOLE STRONTIUM					
+	BELCHER	24.65MG	N202342	001	Aug 06, 2013
+		49.3MG	N202342	002	Aug 06, 2013
ESTAZOLAM					
TABLET;ORAL					
PROSOM					
+	ABBOTT	1MG **	N019080	001	Dec 26, 1990
+		2MG **	N019080	002	Dec 26, 1990
ESTRADIOL					
FILM, EXTENDED RELEASE;TRANSDERMAL					
ALORA					
	ALLERGAN	0.025MG/24HR	N020655	004	Apr 05, 2002
		0.05MG/24HR	N020655	001	Dec 20, 1996
		0.075MG/24HR	N020655	002	Dec 20, 1996
		0.1MG/24HR	N020655	003	Dec 20, 1996
FEMPATCH					
	PARKE DAVIS	0.025MG/24HR	N020417	001	Dec 03, 1996
GEL;TOPICAL					
ESTROGEL					
	ASCEND THERAPS US	0.06%	N021166	001	Feb 09, 2004
SYSTEM;TRANSDERMAL					
ESCLIM					
	WOMEN FIRST HLTHCARE	0.025MG/24HR	N020847	001	Aug 04, 1998
		0.0375MG/24HR	N020847	002	Aug 04, 1998
		0.05MG/24HR	N020847	003	Aug 04, 1998
		0.075MG/24HR	N020847	004	Aug 04, 1998
		0.1MG/24HR	N020847	005	Aug 04, 1998
ESTRADERM					
+	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
+		0.1MG/24HR	N019081	003	Sep 10, 1986
ESTRADIOL					
	ORTHO MCNEIL PHARM	0.05MG/24HR	N021048	001	Sep 20, 1999
		0.075MG/24HR	N021048	002	Sep 20, 1999
		0.1MG/24HR	N021048	003	Sep 20, 1999
VIVELLE					
	NOVARTIS	0.025MG/24HR	N020323	005	Aug 16, 2000
		0.0375MG/24HR	N020323	001	Oct 28, 1994
		0.05MG/24HR	N020323	002	Oct 28, 1994
		0.075MG/24HR	N020323	003	Oct 28, 1994
		0.1MG/24HR	N020323	004	Oct 28, 1994
TABLET;ORAL					
ESTRACE					
	BRISTOL MYERS SQUIBB	0.5MG	A081295	001	Jun 30, 1993
+		1MG	A084499	001	
+		2MG	A084500	001	
ESTRADIOL					
	LANNETT HOLDINGS INC	0.5MG	A040138	001	Jan 30, 1998
		1MG	A040138	002	Jan 30, 1998
		2MG	A040138	003	Jan 30, 1998
	MYLAN	0.5MG	A040326	001	Apr 21, 1999
		1MG	A040326	002	Apr 21, 1999
		2MG	A040326	003	Apr 21, 1999
	USL PHARMA	0.5MG	A040297	001	Apr 17, 2002
		1MG	A040297	002	Apr 17, 2002
		2MG	A040297	003	Apr 17, 2002
GYNODIOL					
	DURAMED PHARMS BARR	0.5MG	A040212	001	Dec 29, 1997
		1MG	A040212	002	Dec 29, 1997
		1.5MG	A040212	003	Dec 29, 1997
		2MG	A040212	004	Dec 29, 1997
INNOFEM					
	NOVO NORDISK INC	0.5MG	A040312	001	Nov 19, 1999
		1MG	A040312	002	Nov 19, 1999
		2MG	A040312	003	Nov 19, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTRADIOL				
TABLET;VAGINAL				
VAGIFEM				
+	NOVO NORDISK INC	25MCG **	N020908 001	Mar 26, 1999
ESTRADIOL ACETATE				
TABLET;ORAL				
FEMTRACE				
+	APIL	0.45MG	N021633 001	Aug 20, 2004
+		0.9MG	N021633 002	Aug 20, 2004
+		1.8MG	N021633 003	Aug 20, 2004
ESTRADIOL CYPIONATE				
INJECTABLE;INJECTION				
DEPO-ESTRADIOL				
	PFIZER	1MG/ML	A085470 001	
		3MG/ML	A085470 002	
ESTRADIOL CYPIONATE				
	DR REDDYS	5MG/ML	A085620 001	
ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE				
INJECTABLE;INTRAMUSCULAR				
LUNELLE				
	PHARMACIA AND UPJOHN	5MG/0.5ML;25MG/0.5ML	N020874 001	Oct 05, 2000
ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE				
INJECTABLE;INJECTION				
DEPO-TESTADIOL				
	PHARMACIA AND UPJOHN	2MG/ML;50MG/ML	N017968 001	
TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE				
	WATSON LABS	2MG/ML;50MG/ML	A085603 001	Mar 13, 1986
ESTRADIOL HEMIHYDRATE				
EMULSION;TOPICAL				
ESTRASORB				
+	EXELTIS USA INC	0.25%	N021371 001	Oct 09, 2003
ESTRADIOL VALERATE				
INJECTABLE;INJECTION				
ESTRADIOL VALERATE				
	DR REDDYS	20MG/ML	A083547 001	
		40MG/ML	A083714 001	
	FOSUN PHARMA	10MG/ML	A040628 001	Oct 04, 2007
		20MG/ML	A040628 002	Oct 04, 2007
		40MG/ML	A040628 003	Oct 04, 2007
	WATSON LABS	10MG/ML	A083546 001	
ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE				
INJECTABLE;INJECTION				
DITATE-DS				
	SAVAGE LABS	8MG/ML;180MG/ML	A086423 001	
TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE				
	WATSON LABS	4MG/ML;90MG/ML	A085865 001	
		8MG/ML;180MG/ML	A085860 001	
ESTRADIOL; NORETHINDRONE ACETATE				
TABLET;ORAL				
ACTIVELLA				
+	AMNEAL	0.5MG;0.1MG	N020907 002	Dec 28, 2006
ESTRADIOL AND NORETHINDRONE ACETATE				
	NAARI PTE LTD	1MG;0.5MG	A210233 001	Feb 28, 2018
	TEVA PHARMS USA	0.5MG;0.1MG	A200747 001	Mar 08, 2012
ESTRADIOL; NORGESTIMATE				
TABLET;ORAL				
PREFEST				
+	TEVA WOMENS	1MG,1MG;N/A,0.09MG **	N021040 001	Oct 22, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTROGENS, CONJUGATED				
TABLET;ORAL				
PREMARIN				
	WYETH PHARMS	2.5MG	N004782 002	
ESTROGENS, CONJUGATED SYNTHETIC A				
CREAM;VAGINAL				
SYNTHETIC CONJUGATED ESTROGENS A				
	TEVA WOMENS	0.625MG/GM	N021788 001	Nov 28, 2008
TABLET;ORAL				
CENESTIN				
+	ASPEN	0.3MG **	N020992 001	Jun 21, 2002
+		0.45MG **	N020992 005	Feb 05, 2004
+		0.625MG **	N020992 002	Mar 24, 1999
+		0.9MG **	N020992 003	Mar 24, 1999
+		1.25MG **	N020992 004	Mar 13, 2000
ESTROGENS, CONJUGATED SYNTHETIC B				
TABLET;ORAL				
ENJUVIA				
	ASPEN	0.3MG	N021443 001	Dec 20, 2004
		0.45MG	N021443 002	Dec 20, 2004
		0.625MG **	N021443 003	May 10, 2004
		0.9MG	N021443 005	Apr 27, 2007
		1.25MG **	N021443 004	May 10, 2004
ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE				
TABLET;ORAL-28				
PREMPHASE (PREMARIN;CYCRIN 14/14)				
	WYETH PHARMS INC	0.625MG,0.625MG;N/A,5MG	N020303 002	Dec 30, 1994
PREMPRO (PREMARIN;CYCRIN)				
	WYETH PHARMS INC	0.625MG,0.625MG;2.5MG,2.5MG	N020303 001	Dec 30, 1994
ESTROGENS, CONJUGATED; MEPROBAMATE				
TABLET;ORAL				
MILPREM-200				
	MEDPOINTE PHARM HLC	0.45MG;200MG	N011045 002	
MILPREM-400				
	MEDPOINTE PHARM HLC	0.45MG;400MG	N011045 001	
PMB 200				
	WYETH AYERST	0.45MG;200MG	N010971 005	
PMB 400				
	WYETH AYERST	0.45MG;400MG	N010971 003	
ESTROGENS, ESTERIFIED				
TABLET;ORAL				
AMNESTROGEN				
	BRISTOL MYERS SQUIBB	0.3MG	A083266 001	
		0.625MG	A083266 002	
		1.25MG	A083266 003	
		2.5MG	A083266 004	
ESTERIFIED ESTROGENS				
	PVT FORM	0.625MG	A083414 001	
		1.25MG	A083765 001	
		2.5MG	A085907 001	
	SANDOZ	1.25MG	A085302 001	
ESTRATAB				
	SOLVAY	0.3MG	A086715 001	
		0.625MG	A083209 001	
		1.25MG	A083856 001	
		2.5MG	A083857 001	
EVEX				
	ROCHE PALO	0.625MG	A084215 001	
		1.25MG	A083376 002	
FEMOGEN				
	PVT FORM	0.625MG	A085076 001	
		1.25MG	A085008 001	
		2.5MG	A085007 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ESTRONE

INJECTABLE;INJECTION				
ESTROGENIC SUBSTANCE				
	WYETH AYERST	2MG/ML	A083488 001	
ESTRONE				
	DR REDDYS	5MG/ML	A085239 001	
	WATSON LABS	2MG/ML	A083397 001	
NATURAL ESTROGENIC SUBSTANCE-ESTRONE				
	WATSON LABS	2MG/ML	A085237 001	Nov 23, 1982
THEELIN				
	PARKEDALE	1MG/ML	N003977 001	
		2MG/ML	N003977 002	
		5MG/ML	N003977 003	

ESTROPIPATE

CREAM;VAGINAL				
OGEN				
	PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001	
TABLET;ORAL				
ESTROPIPATE				
	BARR	0.75MG	A040135 001	Nov 27, 1996
		1.5MG	A040135 002	Nov 27, 1996
		3MG	A040135 003	Nov 27, 1996
	DURAMED PHARMS BARR	0.75MG	A040296 001	Nov 01, 1999
		1.5MG	A040296 002	Nov 01, 1999
		3MG	A040296 003	Nov 01, 1999
	MYLAN	0.75MG	A040359 001	Aug 26, 1999
		1.5MG	A040359 002	Aug 26, 1999
		3MG	A040359 003	Aug 26, 1999
	WATSON LABS	0.75MG	A081213 001	Sep 23, 1993
		1.5MG	A081214 001	Sep 23, 1993
		6MG	A081216 001	Sep 23, 1993
	WATSON LABS TEVA	3MG	A081215 001	Sep 23, 1993
OGEN .625				
+	PFIZER	0.75MG	A083220 001	
OGEN 1.25				
+	PFIZER	1.5MG	A083220 002	
OGEN 2.5				
+	PFIZER	3MG	A083220 003	
ORTHO-EST				
	SUN PHARM INDS INC	0.75MG	A089567 001	Feb 27, 1991
		1.5MG	A089582 001	Jul 17, 1991

ESZOPICLONE

TABLET;ORAL				
ESZOPICLONE				
	HIKMA	1MG	A091153 001	Apr 15, 2014
		2MG	A091153 002	Apr 15, 2014
		3MG	A091153 003	Apr 15, 2014
	NOSTRUM LABS INC	1MG	A203087 001	May 08, 2019
		2MG	A203087 002	May 08, 2019
		3MG	A203087 003	May 08, 2019
	WOCKHARDT LTD	1MG	A091165 001	Jul 14, 2011
		2MG	A091165 002	Jul 14, 2011
		3MG	A091165 003	Jul 14, 2011

ETHACRYNIC ACID

TABLET;ORAL				
EDECRIN				
	BAUSCH	50MG	N016092 002	

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL				
MYAMBUTOL				
	STI PHARMA LLC	200MG	N016320 002	
		500MG	N016320 004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHCHLORVYNOL

CAPSULE;ORAL				
ETHCHLORVYNOL				
BANNER PHARMACAPS	100MG		A084463 001	
	200MG		A084463 002	
	500MG		A084463 003	
	750MG		A084463 004	
PLACIDYL				
ABBVIE	100MG		N010021 004	
	200MG		N010021 007	
	500MG		N010021 002	
	750MG		N010021 010	

ETHINAMATE

CAPSULE;ORAL				
VALMID				
DISTA	500MG		N009750 001	

ETHINYL ESTRADIOL

TABLET;ORAL				
ESTINYL				
SCHERING	0.02MG		N005292 001	
	0.05MG		N005292 002	
	0.5MG		N005292 003	
FEMINONE				
PHARMACIA AND UPJOHN	0.05MG		N016649 001	
LYNORAL				
ORGANON USA INC	0.01MG		N005490 003	
	0.05MG		N005490 002	

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21				
DEMULEN 1/35-21				
GD SEARLE LLC	0.035MG;1MG **		N018168 001	
DEMULEN 1/50-21				
GD SEARLE LLC	0.05MG;1MG		N016927 001	
ZOVIA 1/35E-21				
WATSON PHARMS TEVA	0.035MG;1MG		A072720 001	Dec 30, 1991
ZOVIA 1/50E-21				
WATSON LABS	0.05MG;1MG		A072722 001	Dec 30, 1991
TABLET;ORAL-28				
DEMULEN 1/35-28				
GD SEARLE LLC	0.035MG;1MG **		N018160 001	
DEMULEN 1/50-28				
GD SEARLE LLC	0.05MG;1MG **		N016936 001	

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28				
NORQUEST FE				
PFIZER	0.035MG;75MG;1MG		N018926 001	Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28				
NORLESTRIN FE 1/50				
PARKE DAVIS	0.05MG;75MG;1MG		N016766 001	
NORLESTRIN FE 2.5/50				
PARKE DAVIS	0.05MG;75MG;2.5MG		N016854 001	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL				
FAYOSIM				
LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A		A205943 001	Mar 29, 2016
LYBREL				
+ WYETH PHARMS INC	0.02MG;0.09MG **		N021864 001	May 22, 2007
PREVEN EMERGENCY CONTRACEPTIVE KIT				
TEVA BRANDED PHARM	0.05MG;0.25MG		N020946 001	Sep 01, 1998
SYLEVIA				
SUN PHARM	0.03MG;0.15MG		A202988 001	Feb 06, 2019
TABLET;ORAL-21				
ALESSE				
+ CADENCE HEALTH	0.02MG;0.1MG **		N020683 001	Mar 27, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-21					
AVIANE-21					
	DURAMED PHARMS BARR	0.02MG;0.1MG	A075796	002	Apr 30, 2001
ENPRESSE-21					
	DURAMED PHARMS BARR	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A075809	001	Jul 16, 2001
LESSINA-21					
	BARR	0.02MG;0.1MG	A075803	001	Mar 20, 2002
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	001	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	BARR	0.02MG;0.1MG	A075862	001	Apr 29, 2003
LEVORA 0.15/30-21					
	WATSON LABS	0.03MG;0.15MG	A073592	001	Dec 13, 1993
NORDETTE-21					
	TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982
PORTIA-21					
	BARR	0.03MG;0.15MG	A075866	001	May 23, 2002
TRIPHASIL-21					
+	WYETH PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019192	001	Nov 01, 1984
TRIVORA-21					
	MAYNE PHARMA	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A074538	001	Dec 18, 1997
TABLET;ORAL-28					
ALESSE					
+	CADENCE HEALTH	0.02MG;0.1MG **	N020683	002	Mar 27, 1997
CERINTA					
	SUN PHARM	0.02MG;0.1MG	A202817	001	Jan 07, 2019
ELIFEMME					
	XIROMED	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015
LEVLITE					
+	BAYER HLTHCARE	0.02MG;0.1MG **	N020860	002	Jul 13, 1998
LEVONORGESTREL AND ETHINYL ESTRADIOL					
	BARR	0.02MG;0.1MG	A075862	002	Apr 29, 2003
	MYLAN LABS LTD	0.02MG;0.1MG	A202247	001	Dec 08, 2014
		0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018
NORDETTE-28					
+	TEVA BRANDED PHARM	0.03MG;0.15MG **	N018782	001	Jul 21, 1982
ORSYTHIA					
	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099	001	May 11, 2011
TRIPHASIL-28					
+	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **	N019190	001	Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL					
ORTHO EVRA					
+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR **	N021180	001	Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21					
BALZIVA-21					
	BARR	0.035MG;0.4MG	A076198	001	Apr 22, 2004
BREVICON 21-DAY					
	ALLERGAN	0.035MG;0.5MG	N017566	001	
GENCEPT 10/11-21					
	BARR	0.035MG,0.035MG;0.5MG,1MG	A072694	001	Feb 28, 1992
MODICON 21					
	ORTHO MCNEIL PHARM	0.035MG;0.5MG **	N017488	001	
N.E.E. 1/35 21					
	LPI	0.035MG;1MG	A071541	001	Dec 14, 1987
NORCEPT-E 1/35 21					
	ORTHO MCNEIL PHARM	0.035MG;1MG	A071545	001	Feb 09, 1989
NORETHIN 1/35E-21					
	WATSON PHARMS TEVA	0.035MG;1MG	A071480	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
	WATSON LABS	0.035MG;0.4MG	A078379	001	Feb 23, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21					
NORETHINDRONE AND ETHINYL ESTRADIOL					
	0.035MG;0.5MG		A070684	001	Jan 29, 1987
WATSON PHARMS TEVA	0.035MG;1MG		A070685	001	Jan 29, 1987
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)					
WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		A071043	001	Apr 01, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG		A071041	001	Sep 24, 1991
NORINYL 1+35 21-DAY					
ALLERGAN	0.035MG;1MG		N017565	001	
NORTREL 0.5/35-21					
BARR	0.035MG;0.5MG		A072692	001	Feb 28, 1992
ORTHO-NOVUM 1/35-21					
ORTHO MCNEIL PHARM	0.035MG;1MG **		N017489	002	
ORTHO-NOVUM 10/11-21					
+ ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG **		N018354	001	Jan 11, 1982
ORTHO-NOVUM 7/14-21					
ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **		N019004	001	Apr 04, 1984
ORTHO-NOVUM 7/7/7-21					
JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG		N018985	001	Apr 04, 1984
OVCON-35					
+ WARNER CHILCOTT	0.035MG;0.4MG **		N018127	001	
OVCON-50					
WARNER CHILCOTT	0.05MG;1MG		N018128	001	
TRI-NORINYL 21-DAY					
MAYNE PHARMA	0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG		N018977	001	Apr 13, 1984
TABLET;ORAL-28					
BREVICON 28-DAY					
ALLERGAN	0.035MG;0.5MG		N017743	001	
CYCLAFEM 0.5/35					
VINTAGE PHARMS	0.035MG;0.5MG		A203413	001	Dec 16, 2015
CYCLAFEM 1/35					
VINTAGE PHARMS LLC	0.035MG;1MG		A076337	001	Nov 12, 2010
CYCLAFEM 7/7/7					
VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG		A076338	001	Nov 16, 2010
GENCEPT 10/11-28					
BARR	0.035MG,0.035MG;0.5MG,1MG		A072697	001	Feb 28, 1992
MODICON 28					
+ JANSSEN PHARMS	0.035MG;0.5MG		N017735	001	
N.E.E. 1/35 28					
LPI	0.035MG;1MG		A071542	001	Dec 14, 1987
NORCEPT-E 1/35 28					
ORTHO MCNEIL PHARM	0.035MG;1MG		A071546	001	Feb 09, 1989
NORETHIN 1/35E-28					
WATSON LABS	0.035MG;1MG		A071481	001	Apr 12, 1988
NORETHINDRONE AND ETHINYL ESTRADIOL					
MYLAN LABS LTD	0.035MG;0.4MG		A200897	001	May 11, 2015
	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG		A200486	001	Dec 28, 2015
	0.035MG;0.5MG		A200488	001	Oct 21, 2015
	0.035MG;1MG		A200489	001	Oct 21, 2015
	0.05MG;1MG		A203006	001	Aug 05, 2013
WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG		A076393	001	Feb 04, 2010
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)					
WATSON LABS	0.035MG,0.035MG;0.5MG,1MG		A071042	001	Sep 24, 1991
NORINYL 1+35 28-DAY					
ALLERGAN	0.035MG;1MG		N017565	002	
ORTHO-NOVUM 1/35-28					
+ JANSSEN PHARMS	0.035MG;1MG **		N017919	002	
ORTHO-NOVUM 10/11-28					
+ ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG		N018354	002	Jan 11, 1982
ORTHO-NOVUM 7/14-28					
ORTHO MCNEIL PHARM	0.035MG,0.035MG;0.5MG,1MG **		N019004	002	Apr 04, 1984
ORTHO-NOVUM 7/7/7-28					
+ JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG		N018985	002	Apr 04, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28					
OVCON-35					
+	WARNER CHILCOTT LLC	0.035MG;0.4MG **	N017716	001	
OVCON-50					
	WARNER CHILCOTT LLC	0.05MG;1MG **	N017576	001	
TABLET, CHEWABLE;ORAL					
FEMCON FE					
+	APIL	0.035MG;0.4MG **	N021490	001	Nov 14, 2003

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL					
FEMHRT					
+	APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005
+		0.005MG;1MG **	N021065	002	Oct 15, 1999
LOESTRIN 24 FE					
+	TEVA BRANDED PHARM	0.02MG;1MG **	N021871	001	Feb 17, 2006
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.0025MG;0.5MG	A207260	001	Feb 02, 2017
		0.005MG;1MG	A207259	001	Dec 27, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	APOTEX	0.02MG;1MG	A208639	001	Mar 21, 2018
	MYLAN LABS LTD	0.02MG;1MG	A202742	001	Oct 30, 2014
TABLET;ORAL-21					
ESTROSTEP 21					
+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG **	N020130	001	Oct 09, 1996
GILDESS 1.5/30					
	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012
GILDESS 1/20					
	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012
NORLESTRIN 21 1/50					
	PARKE DAVIS	0.05MG;1MG	N016749	001	
NORLESTRIN 21 2.5/50					
	PARKE DAVIS	0.05MG;2.5MG	N016852	001	
TABLET;ORAL-28					
ESTROSTEP FE					
+	APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996
GILDESS FE 1.5/30					
	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	001	Apr 28, 2005
GILDESS FE 1/20					
	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	001	May 20, 2005
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018
NORLESTRIN 28 1/50					
	PARKE DAVIS	0.05MG;1MG	N016723	001	
TABLET, CHEWABLE;ORAL					
FINZALA					
	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	MYLAN LABS LTD	0.02MG;1MG	A206120	001	Sep 12, 2017
TABLET, CHEWABLE, TABLET;ORAL					
LO MINASTRIN FE					
+	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21					
ORTHO CYCLEN-21					
	JANSSEN PHARMS	0.035MG;0.25MG **	N019653	001	Dec 29, 1989
ORTHO TRI-CYCLEN					
	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	N019697	002	Jul 03, 1992
TABLET;ORAL-28					
NORGESTIMATE AND ETHINYL ESTRADIOL					
	MYLAN	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A201897	001	Jan 27, 2016
		0.035MG;0.25MG	A201896	001	Jan 27, 2016
	MYLAN LABS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	A202132	001	Sep 09, 2015
	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,	A090479	001	Mar 09, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28					
NORGESTIMATE AND ETHINYL ESTRADIOL					
		0.25MG			
		0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A076626	001	Aug 17, 2006
		0.035MG;0.25MG	A076627	001	Aug 17, 2006
ORTHO CYCLEN-28					
+	JANSSEN PHARMS	0.035MG;0.25MG **	N019653	002	Dec 29, 1989
ORTHO TRI-CYCLEN					
+	JANSSEN PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	N019697	001	Jul 03, 1992
ORTHO TRI-CYCLEN LO					
+	JANSSEN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG	N021241	001	Aug 22, 2002
TRI-PREVIFEM					
	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG	A076335	001	Mar 26, 2004

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21					
LO/OVRAL					
	CADENCE HEALTH	0.03MG;0.3MG	N017612	001	
LOW-OGESTREL-21					
	MAYNE PHARMA	0.03MG;0.3MG	A075288	001	Jul 28, 1999
OGESTREL 0.5/50-21					
	WATSON LABS	0.05MG;0.5MG	A075406	001	Dec 15, 1999
OVRAL					
	WYETH PHARMS	0.05MG;0.5MG	N016672	001	
TABLET;ORAL-28					
LO/OVRAL-28					
	WYETH PHARMS	0.03MG;0.3MG **	N017802	001	
NORGESTREL AND ETHINYL ESTRADIOL					
	MYLAN LABS LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016
		0.05MG;0.5MG	A202875	001	May 08, 2017
OGESTREL 0.5/50-28					
	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999
OVRAL-28					
	WYETH PHARMS	0.05MG;0.5MG	N016806	001	

ETHOPROPAZINE HYDROCHLORIDE

TABLET;ORAL					
PARSIDOL					
	PARKE DAVIS	10MG	N009078	003	
		50MG	N009078	006	
		100MG	N009078	008	

ETHOSUXIMIDE

SYRUP;ORAL					
ETHOSUXIMIDE					
	TEVA PHARMS	250MG/5ML	A081306	001	Jul 30, 1993

ETHOTOIN

TABLET;ORAL					
PEGANONE					
+	RECORDATI RARE	250MG	N010841	001	
		500MG	N010841	003	

ETHOXZOLAMIDE

TABLET;ORAL					
CARDRASE					
	PHARMACIA AND UPJOHN	62.5MG	N011047	002	
		125MG	N011047	001	
ETHAMIDE					
	ALLERGAN	125MG	N016144	001	

ETHYLESTRENOL

ELIXIR;ORAL					
MAXIBOLIN					
	ORGANON USA INC	2MG/5ML	N014006	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETHYLESTRENOL				
TABLET;ORAL				
MAXIBOLIN				
	ORGANON USA INC	2MG	N014005 002	
ETHYNODIOL DIACETATE; MESTRANOL				
TABLET;ORAL-20				
OVULEN				
	GD SEARLE LLC	1MG;0.1MG	N016029 002	
TABLET;ORAL-21				
OVULEN-21				
	GD SEARLE LLC	1MG;0.1MG	N016029 003	
TABLET;ORAL-28				
OVULEN-28				
	GD SEARLE LLC	1MG;0.1MG	N016705 001	
ETIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DURANEST				
+	ASTRAZENECA	0.5% **	N017751 003	
+		1% **	N017751 005	
ETIDRONATE DISODIUM				
INJECTABLE;INJECTION				
DIDRONEL				
	MGI PHARMA INC	50MG/ML	N019545 001	Apr 20, 1987
TABLET;ORAL				
DIDRONEL				
+	APIL	200MG **	N017831 001	
+		400MG **	N017831 002	
ETIDRONATE DISODIUM				
	MYLAN	200MG	A075800 001	Jan 24, 2003
		400MG	A075800 002	Jan 24, 2003
ETODOLAC				
CAPSULE;ORAL				
ETODOLAC				
	ANI PHARMS	200MG	A074840 001	Aug 29, 1997
		200MG	A074844 001	Dec 23, 1997
		200MG	A074899 001	Jul 08, 1997
		300MG	A074840 002	Aug 29, 1997
		300MG	A074844 002	Dec 23, 1997
		300MG	A074899 002	Jul 08, 1997
	BIOPHARM	300MG	A074929 001	Jan 30, 1998
	CHARTWELL MOLECULES	200MG	A074842 001	Jul 17, 1997
		300MG	A074842 002	Jul 17, 1997
	MYLAN	200MG	A074932 001	May 16, 1997
		200MG	A075071 001	Sep 30, 1998
		300MG	A074932 002	May 16, 1997
		300MG	A075071 002	Sep 30, 1998
	SANDOZ	200MG	A074942 001	Sep 30, 1997
		300MG	A074942 002	Sep 30, 1997
LODINE				
+	WYETH PHARMS INC	200MG **	N018922 002	Jan 31, 1991
+		300MG	N018922 003	Jan 31, 1991
TABLET;ORAL				
ETODOLAC				
	BIOPHARM	400MG	A074927 001	Oct 30, 1997
	CHARTWELL MOLECULES	400MG	A074841 001	Jun 27, 1997
	IVAX SUB TEVA PHARMS	400MG	A074883 001	Feb 28, 1997
		500MG	A074883 002	Nov 20, 1998
	MYLAN	400MG	A075012 001	Sep 30, 1998
		400MG	A075104 001	Feb 06, 1998
		500MG	A075012 002	Sep 30, 1998
		500MG	A075104 002	Nov 20, 1998
	OXFORD PHARMS	400MG	A074819 001	Feb 28, 1997
		500MG	A074819 002	Apr 28, 1998
	PHARMGEN	400MG	A074839 001	Jul 11, 1997
		400MG	A074846 001	Feb 28, 1997
	RANBAXY LABS LTD	400MG	A075226 001	Nov 24, 1998
		500MG	A075226 002	Nov 24, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETODOLAC					
TABLET;ORAL					
ETODOLAC					
	TEVA	400MG	A074847	001	Apr 23, 1999
		400MG	A075009	001	Nov 26, 1997
		500MG	A074847	002	Apr 23, 1999
		500MG	A075009	002	Dec 28, 1999
	WATSON LABS	400MG	A074892	001	Apr 16, 1997
		400MG	A075069	001	Apr 16, 1998
		500MG	A074892	002	Oct 29, 1998
LODINE					
+	WYETH PHARMS INC	400MG **	N018922	004	Jul 29, 1993
+		500MG **	N018922	005	Jun 28, 1996
TABLET, EXTENDED RELEASE;ORAL					
ETODOLAC					
	ACTAVIS ELIZABETH	400MG	A075696	001	Jul 31, 2000
	ANI PHARMS	400MG	A075943	001	Jul 26, 2002
		500MG	A075943	002	Jul 26, 2002
		600MG	A075943	003	Jul 26, 2002
	WATSON LABS FLORIDA	400MG	A075829	001	Nov 30, 2001
		500MG	A075829	002	Nov 30, 2001
LODINE XL					
	WYETH PHARMS INC	400MG **	N020584	001	Oct 25, 1996
		500MG **	N020584	003	Jan 20, 1998
+		600MG **	N020584	002	Oct 25, 1996
ETOMIDATE					
INJECTABLE;INJECTION					
ETOMIDATE					
	LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009
	PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012
	RISING PHARMA	2MG/ML	A078289	001	Jan 02, 2009
ETONOGESTREL					
IMPLANT;IMPLANTATION					
IMPLANON					
	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006
ETOPOSIDE					
CAPSULE;ORAL					
VEPESID					
+	STRIDES PHARMA	50MG	N019557	001	Dec 30, 1986
+		100MG	N019557	002	Dec 30, 1986
INJECTABLE;INJECTION					
ETOPOSIDE					
	HOSPIRA	20MG/ML	A074320	001	Aug 30, 1995
		20MG/ML	A074351	001	Aug 30, 1995
	MYLAN LABS LTD	20MG/ML	A203507	001	Nov 20, 2017
		20MG/ML	A204927	001	Oct 31, 2017
	PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996
	PIERRE FABRE	20MG/ML	A074813	001	Jul 09, 1997
	TEVA PARENTERAL	20MG/ML	A074510	001	Jun 29, 1995
	TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994
	WATSON LABS	20MG/ML	A074228	001	Oct 15, 1996
	WATSON LABS INC	20MG/ML	A074968	001	Jan 09, 1998
TOPOSAR					
	TEVA PARENTERAL	20MG/ML	A074166	001	Feb 27, 1995
VEPESID					
+	CORDEN PHARMA	20MG/ML **	N018768	001	Nov 10, 1983
ETOPOSIDE PHOSPHATE					
INJECTABLE;INJECTION					
ETOPOPHOS PRESERVATIVE FREE					
	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N020906	001	Feb 27, 1998
		EQ 1GM BASE/VIAL	N020906	002	Feb 27, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ETRAVIRINE
TABLET;ORAL
ETRAVIRINE

AMNEAL	25MG	A214196	001	Jun 14, 2021

ETRETINATE
CAPSULE;ORAL
TEGISON

ROCHE	10MG	N019369	001	Sep 30, 1986
	25MG	N019369	002	Sep 30, 1986

EVANS BLUE
INJECTABLE;INJECTION
EVANS BLUE

PARKE DAVIS	0.5% **	N008041	001	

EVEROLIMUS
TABLET;ORAL
EVEROLIMUS

TEVA PHARMS USA	10MG	A210050	004	Dec 09, 2019

EXEMESTANE
TABLET;ORAL
EXEMESTANE

AMNEAL PHARMS	25MG	A206421	001	Dec 28, 2018
MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019

EXENATIDE SYNTHETIC
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON

+	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012

BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014

EZETIMIBE
TABLET;ORAL
EZETIMIBE

RISING PHARMA	10MG	A201790	001	Apr 26, 2019
TEVA PHARMS USA	10MG	A078724	001	Jun 12, 2017

EZETIMIBE; SIMVASTATIN
TABLET;ORAL
EZETIMIBE AND SIMVASTATIN

ANI PHARMS	10MG;10MG	A201890	001	Apr 26, 2017
	10MG;20MG	A201890	002	Apr 26, 2017
	10MG;40MG	A201890	003	Apr 26, 2017
	10MG;80MG	A201890	004	Apr 26, 2017
AUROBINDO PHARMA USA	10MG;10MG	A200082	001	Dec 17, 2020
	10MG;20MG	A200082	002	Dec 17, 2020
	10MG;40MG	A200082	003	Dec 17, 2020
	10MG;80MG	A200082	004	Dec 17, 2020

EZOGABINE
TABLET;ORAL
POTIGA

+	GLAXOSMITHKLINE	50MG	N022345	001	Jun 10, 2011
+		200MG	N022345	002	Jun 10, 2011
+		300MG	N022345	003	Jun 10, 2011
+		400MG	N022345	004	Jun 10, 2011

FAMCICLOVIR
TABLET;ORAL
FAMCICLOVIR

HIKMA	125MG	A090128	001	Mar 21, 2011
	250MG	A090128	002	Mar 21, 2011
	500MG	A090128	003	Mar 21, 2011
MYLAN	125MG	A201333	001	Mar 24, 2011
	250MG	A201333	002	Mar 24, 2011
	500MG	A201333	003	Mar 24, 2011

FAMVIR

+	NOVARTIS	125MG **	N020363	003	Dec 11, 1995
+		250MG **	N020363	001	Apr 26, 1996
+		500MG **	N020363	002	Jun 29, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FAMOTIDINE

FOR SUSPENSION;ORAL					
PEPCID					
+	SALIX PHARMS	40MG/5ML	N019527	001	Feb 02, 1987
INJECTABLE;INJECTION					
FAMOTIDINE					
	APOTEX INC	10MG/ML	A075942	001	Aug 02, 2002
	APOTHECON	10MG/ML	A075707	001	Apr 16, 2001
	HIKMA	10MG/ML	A075799	001	Apr 30, 2002
	HOSPIRA	10MG/ML	A075705	001	Apr 16, 2001
		10MG/ML	A075870	001	Nov 23, 2001
		10MG/ML	A075905	001	Nov 23, 2001
FAMOTIDINE PRESERVATIVE FREE					
	APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002
	APOTHECON	10MG/ML	A075708	001	Apr 16, 2001
	HIKMA	10MG/ML	A075789	001	Apr 30, 2002
	HOSPIRA	10MG/ML	A075669	001	Apr 16, 2001
FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)					
	APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER					
	ABBVIE	0.4MG/ML	A075729	001	Dec 17, 2001
PEPCID					
+	MERCK	10MG/ML **	N019510	001	Nov 04, 1986
PEPCID PRESERVATIVE FREE					
+	MERCK	10MG/ML **	N019510	004	Nov 04, 1986
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
+	MERCK SHARP DOHME	0.4MG/ML **	N020249	001	Feb 18, 1994
TABLET;ORAL					
FAMOTIDINE					
	ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001
		40MG	A075650	002	Sep 14, 2001
	APOTEX	10MG	A075610	001	Mar 12, 2002
	MANKIND PHARMA	20MG	A075302	001	Apr 16, 2001
		40MG	A075302	002	Apr 16, 2001
	MYLAN	10MG	A075674	001	Dec 21, 2001
	MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
		40MG	A075457	002	Apr 18, 2001
	RISING PHARMA	20MG	A075704	001	Apr 16, 2001
		40MG	A075704	002	Apr 16, 2001
	SANDOZ	10MG	A076101	001	Oct 21, 2002
		20MG	A075607	001	May 10, 2001
		20MG	A075793	001	Apr 16, 2001
		40MG	A075607	002	May 10, 2001
		40MG	A075793	002	Apr 16, 2001
	SUN PHARM INDUSTRIES	20MG	A075639	002	Dec 12, 2001
		40MG	A075639	001	Dec 12, 2001
	TEVA	10MG	A075312	001	May 31, 2001
		20MG	A075311	001	Apr 16, 2001
		40MG	A075311	002	Apr 16, 2001
	WATSON LABS	10MG	A075404	001	Nov 28, 2001
		20MG	A075062	002	Apr 16, 2001
		40MG	A075062	001	Apr 16, 2001
PEPCID					
+	BAUSCH	20MG	N019462	001	Oct 15, 1986
+		40MG	N019462	002	Oct 15, 1986
TABLET, CHEWABLE;ORAL					
PEPCID AC					
+	J AND J CONSUMER INC	10MG **	N020801	001	Sep 24, 1998
TABLET, ORALLY DISINTEGRATING;ORAL					
FLUXID					
	UCB INC	20MG	N021712	001	Sep 24, 2004
		40MG	N021712	002	Sep 24, 2004
PEPCID RPD					
	MERCK	20MG	N020752	001	May 28, 1998
		40MG	N020752	002	May 28, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FELODIPINE				
TABLET, EXTENDED RELEASE;ORAL				
FELODIPINE				
JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016
	5MG	A203983	002	Aug 19, 2016
	10MG	A203983	003	Aug 19, 2016
MYLAN	2.5MG	A078855	001	Apr 17, 2008
	5MG	A078855	002	Apr 17, 2008
	10MG	A078855	003	Apr 17, 2008
WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012
	5MG	A091484	002	Aug 15, 2012
	10MG	A091484	003	Aug 15, 2012
PLENDIL				
+ ASTRAZENECA	2.5MG **	N019834	004	Sep 22, 1994
+	5MG **	N019834	001	Jul 25, 1991
+	10MG **	N019834	002	Jul 25, 1991
FENOFIBRATE				
CAPSULE;ORAL				
ANTARA (MICRONIZED)				
LUPIN	87MG	N021695	002	Nov 30, 2004
FENOFIBRATE (MICRONIZED)				
MYLAN PHARMS INC	43MG	A202579	001	Jan 10, 2013
	130MG	A202579	002	Jan 10, 2013
NOVAST LABS	67MG	A207564	001	Apr 19, 2019
	134MG	A207564	002	Apr 19, 2019
	200MG	A207564	003	Apr 19, 2019
RISING PHARMA	67MG	A202676	001	Oct 23, 2012
	134MG	A202676	002	Oct 23, 2012
	200MG	A202676	003	Oct 23, 2012
LIPIDIL				
ABBVIE	100MG	N019304	001	Dec 31, 1993
LIPOFEN				
CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006
TRICOR (MICRONIZED)				
+ ABBVIE	67MG **	N019304	002	Feb 09, 1998
+	134MG **	N019304	003	Jun 30, 1999
+	200MG **	N019304	004	Jun 30, 1999
TABLET;ORAL				
FENOFIBRATE				
ALEMBIC PHARMS LTD	54MG	A213252	001	Jan 17, 2020
	160MG	A213252	002	Jan 17, 2020
MYLAN	107MG	A076520	002	Dec 29, 2005
TRICOR				
+ ABBVIE INC	54MG **	N021203	001	Sep 04, 2001
+	160MG **	N021203	003	Sep 04, 2001
TRIGLIDE				
SKYEPHARMA AG	50MG	N021350	001	May 07, 2005
FENOFIBRIC ACID				
TABLET;ORAL				
FIBRICOR				
+ ATHENA	35MG	N022418	001	Aug 14, 2009
FENOLDOPAM MESYLATE				
INJECTABLE;INJECTION				
FENOLDOPAM MESYLATE				
LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826	001	Mar 07, 2007
FENOPROFEN CALCIUM				
CAPSULE;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988
	EQ 300MG BASE	A072308	001	Aug 22, 1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988
	EQ 300MG BASE	A072356	001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988
	EQ 300MG BASE	A072438	001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988
	EQ 300MG BASE	A071738	001	Aug 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FENOPROFEN CALCIUM

CAPSULE;ORAL				
FENOPROFEN CALCIUM				
RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988
	EQ 300MG BASE	A072395	001	Oct 17, 1988
WARNER CHILCOTT	EQ 200MG BASE	A072946	001	Apr 30, 1991
	EQ 300MG BASE	A072472	001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294	001	Aug 17, 1988
	EQ 200MG BASE	A072981	001	Aug 19, 1991
	EQ 300MG BASE	A072293	001	Aug 17, 1988
	EQ 300MG BASE	A072982	001	Aug 19, 1991
NALFON				
XSPIRE PHARMA	EQ 300MG BASE	N017604	002	
TABLET;ORAL				
FENOPROFEN CALCIUM				
AM THERAP	EQ 600MG BASE	A072309	001	Aug 17, 1988
ANI PHARMS	EQ 600MG BASE	A072274	001	May 02, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326	001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357	001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557	001	Aug 29, 1988
PAR PHARM	EQ 600MG BASE	A072429	001	Aug 17, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194	001	Aug 17, 1988
RISING	EQ 600MG BASE	A072396	001	Oct 17, 1988
SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902	001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362	001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165	001	Aug 17, 1988
	EQ 600MG BASE	A072602	001	Oct 11, 1988
WATSON LABS TEVA	EQ 600MG BASE	A072407	001	Aug 17, 1988
NALFON				
DISTA	EQ 600MG BASE	N017710	001	

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL				
DURAGESIC-100				
+ JANSSEN PHARMS	100MCG/HR	N019813	001	Aug 07, 1990
DURAGESIC-12				
+ JANSSEN PHARMS	12.5MCG/HR	N019813	005	Feb 04, 2005
DURAGESIC-25				
+ JANSSEN PHARMS	25MCG/HR	N019813	004	Aug 07, 1990
DURAGESIC-37				
+ JANSSEN PHARMS	37.5MCG/HR	N019813	006	Jan 24, 2018
DURAGESIC-50				
+ JANSSEN PHARMS	50MCG/HR	N019813	003	Aug 07, 1990
DURAGESIC-75				
+ JANSSEN PHARMS	75MCG/HR	N019813	002	Aug 07, 1990
FENTANYL-100				
ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007
LAVIPHARM LABS	100MCG/HR	A077051	004	Aug 04, 2006
MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007
NOVEN	100MCG/HR	A077775	004	Oct 16, 2009
FENTANYL-25				
ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007
LAVIPHARM LABS	25MCG/HR	A077051	001	Aug 04, 2006
MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007
NOVEN	25MCG/HR	A077775	001	Oct 16, 2009
FENTANYL-50				
ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007
LAVIPHARM LABS	50MCG/HR	A077051	002	Aug 04, 2006
MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007
NOVEN	50MCG/HR	A077775	002	Oct 16, 2009
FENTANYL-75				
ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007
LAVIPHARM LABS	75MCG/HR	A077051	003	Aug 04, 2006
MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007
NOVEN	75MCG/HR	A077775	003	Oct 16, 2009

FENTANYL CITRATE				
FILM;BUCCAL				
ONSOLIS				
BDSI	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
	EQ 0.4MG BASE	N022266	002	Jul 16, 2009
	EQ 0.6MG BASE	N022266	003	Jul 16, 2009
	EQ 0.8MG BASE	N022266	004	Jul 16, 2009
	EQ 1.2MG BASE	N022266	005	Jul 16, 2009
INJECTABLE;INJECTION				
FENTANYL CITRATE				
ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992
FENTANYL CITRATE PRESERVATIVE FREE				
DR REDDYS	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998
SPRAY, METERED;NASAL				
LAZANDA				
+ BTCP PHARMA	EQ 0.3MG BASE	N022569	003	Dec 21, 2015
TABLET;BUCCAL, SUBLINGUAL				
FENTANYL CITRATE				
WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011
	EQ 0.2MG BASE	A079075	002	Jan 07, 2011
	EQ 0.4MG BASE	A079075	003	Jan 07, 2011
	EQ 0.6MG BASE	A079075	004	Jan 07, 2011
	EQ 0.8MG BASE	A079075	005	Jan 07, 2011
FENTORA				
+ CEPHALON	EQ 0.3MG BASE **	N021947	006	Mar 02, 2007
TABLET;SUBLINGUAL				
ABSTRAL				
+ SENTYNL THERAPS INC	EQ 0.1MG BASE **	N022510	001	Jan 07, 2011
+	EQ 0.2MG BASE **	N022510	002	Jan 07, 2011
+	EQ 0.3MG BASE **	N022510	003	Jan 07, 2011
+	EQ 0.4MG BASE **	N022510	004	Jan 07, 2011
+	EQ 0.6MG BASE **	N022510	005	Jan 07, 2011
+	EQ 0.8MG BASE **	N022510	006	Jan 07, 2011
FENTANYL CITRATE				
ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017
	EQ 0.2MG BASE	A207338	002	Nov 17, 2017
	EQ 0.3MG BASE	A207338	003	Nov 17, 2017
	EQ 0.4MG BASE	A207338	004	Nov 17, 2017
	EQ 0.6MG BASE	A207338	005	Nov 17, 2017
	EQ 0.8MG BASE	A207338	006	Nov 17, 2017
TROCHE/LOZENGE;ORAL				
FENTANYL				
CEPHALON	EQ 0.1MG BASE	N020195	007	Oct 30, 1995
	EQ 0.2MG BASE	N020195	001	Oct 04, 1993
	EQ 0.3MG BASE	N020195	002	Oct 04, 1993
	EQ 0.4MG BASE	N020195	003	Oct 04, 1993
TROCHE/LOZENGE;TRANSMUCOSAL				
FENTANYL CITRATE				
PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009
	EQ 0.4MG BASE	A077312	002	Oct 30, 2009
	EQ 0.6MG BASE	A077312	003	Oct 30, 2009
	EQ 0.8MG BASE	A077312	004	Oct 30, 2009
	EQ 1.2MG BASE	A077312	005	Oct 30, 2009
	EQ 1.6MG BASE	A077312	006	Oct 30, 2009
FENTANYL HYDROCHLORIDE				
SYSTEM;IONTOPHORESIS, TRANSDERMAL				
IONSYS				
+ THE MEDICINES CO	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006
FERRIC AMMONIUM CITRATE				
FOR SOLUTION;ORAL				
FERRISELTZ				
OTSUKA	600MG/PACKET	N020292	001	Oct 14, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FERRIC DERISOMALTOSE				
SOLUTION;INTRAVENOUS				
MONOFERRIC				
+ PHARMACOSMOS AS	100MG/ML (100MG/ML)	N208171	001	Jan 16, 2020
+	500MG/5ML (100MG/ML)	N208171	002	Jan 16, 2020
FERRIC OXYHYDROXIDE				
INJECTABLE;INJECTION				
DEXFERRUM				
AM REGENT	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
IRON DEXTRAN				
SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002	
PROFERDEX				
NEW RIVER	EQ 50MG IRON/ML	N017807	001	
INJECTABLE;INTRAVENOUS				
VENOFER				
AM REGENT	EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013
	EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005
FERRIC PYROPHOSPHATE CITRATE				
SOLUTION;INTRAVENOUS				
TRIFERIC				
+ ROCKWELL MEDICAL INC	272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015
FERROUS CITRATE, FE-59				
INJECTABLE;INJECTION				
FERROUS CITRATE FE 59				
MALLINCKRODT	25uCi/ML	N016729	001	
FERROUS SULFATE; FOLIC ACID				
CAPSULE;ORAL				
FOLVRON				
LEDERLE	182MG;0.33MG	N006012	003	
FERUMOXIDES				
INJECTABLE;INJECTION				
FERIDEX I.V.				
AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416	001	Aug 30, 1996
FERUMOXSIL				
SUSPENSION;ORAL				
GASTROMARK				
AMAG PHARMS INC	EQ 0.175MG IRON/ML	N020410	001	Dec 06, 1996
FESOTERODINE FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
FESOTERODINE FUMARATE				
ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015
	8MG	A204827	002	Dec 10, 2015
DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019
	8MG	A204975	002	Aug 13, 2019
FEXOFENADINE HYDROCHLORIDE				
CAPSULE;ORAL				
ALLEGRA				
SANOFI AVENTIS US	60MG **	N020625	001	Jul 25, 1996
FEXOFENADINE HYDROCHLORIDE				
BARR	60MG	A076169	001	Jul 13, 2005
SUSPENSION;ORAL				
ALLEGRA				
+ CHATTEM SANOFI	30MG/5ML	N021963	001	Oct 16, 2006
CHILDREN'S ALLEGRA HIVES				
+ CHATTEM SANOFI	30MG/5ML **	N201373	002	Jan 24, 2011
FEXOFENADINE HYDROCHLORIDE				
P AND L	30MG/5ML	A201311	001	Jul 25, 2012
TABLET;ORAL				
ALLEGRA HIVES				
+ CHATTEM SANOFI	60MG	N020872	008	Jan 24, 2011
+	180MG	N020872	009	Jan 24, 2011
CHILDREN'S ALLEGRA ALLERGY				
+ CHATTEM SANOFI	30MG **	N020872	005	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES				
+ CHATTEM SANOFI	30MG	N020872	006	Jan 24, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL				
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
	RISING	30MG	A077081 004	Jul 21, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
	RISING	30MG	A077081 005	Jul 21, 2011
FEXOFENADINE HYDROCHLORIDE				
	BARR	30MG	A076191 001	Aug 31, 2005
		60MG	A076191 002	Aug 31, 2005
		180MG	A076191 003	Aug 31, 2005
	RISING	30MG	A077081 002	Apr 11, 2008
TABLET, ORALLY DISINTEGRATING;ORAL				
CHILDREN'S ALLEGRA ALLERGY				
+	CHATTEM SANOFI	30MG	N021909 002	Jan 24, 2011
CHILDREN'S ALLEGRA HIVES				
+	CHATTEM SANOFI	30MG **	N021909 003	Jan 24, 2011
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY				
	DR REDDYS LABS LTD	30MG	A202978 001	Jan 18, 2013
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES				
	DR REDDYS LABS LTD	30MG	A202978 002	Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE				
	BARR	60MG;120MG	A076236 001	Apr 14, 2005
	IMPAX PHARMS	60MG;120MG	A076298 001	Nov 12, 2010

FINAFLOXACIN

SUSPENSION/DROPS;OTIC				
XTORO				
+	MERLION PHARMS GMBH	0.3%	N206307 001	Dec 17, 2014

FINASTERIDE

TABLET;ORAL				
FINASTERIDE				
	ACTAVIS TOTOWA	1MG	A078371 001	Nov 05, 2013
	ACTAVIS TOTOWA TEVA	5MG	A077914 001	Mar 28, 2007
	GEDEON RICHTER USA	5MG	A077251 001	Dec 22, 2006
	IVAX SUB TEVA PHARMS	5MG	A076340 001	Jun 19, 2006
	MYLAN	1MG	A078161 001	Nov 05, 2013
		5MG	A077578 001	Dec 18, 2006
	TEVA	1MG	A076905 001	Nov 05, 2013

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL				
FINGOLIMOD HYDROCHLORIDE				
	ALKEM LABS LTD	EQ 0.5MG BASE	A208004 001	Dec 30, 2020
	APOTEX	EQ 0.5MG BASE	A207993 001	Dec 18, 2020
	BIOCON LTD	EQ 0.5MG BASE	A207979 001	Dec 04, 2019
	DR REDDYS	EQ 0.5MG BASE	A208000 001	Mar 05, 2021
	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985 001	Jun 18, 2020
	HETERO LABS LTD V	EQ 0.5MG BASE	A207933 001	May 18, 2020
	STRIDES PHARMA	EQ 0.5MG BASE	A207971 001	Jun 29, 2020
	SUN PHARM	EQ 0.5MG BASE	A208014 001	Dec 04, 2019
	TEVA PHARMS USA	EQ 0.5MG BASE	A208008 001	Jul 02, 2020
	ZYDUS PHARMS	EQ 0.5MG BASE	A207994 001	Oct 14, 2020

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL				
FLAVOXATE HYDROCHLORIDE				
	IMPAX PHARMS	100MG	A076234 001	Aug 28, 2003
URISPAS				
	ORTHO MCNEIL JANSSEN	100MG	N016769 001	

FLECAINIDE ACETATE

TABLET;ORAL				
FLECAINIDE ACETATE				
	ANI PHARMS	50MG	A076030 001	Oct 28, 2002
		100MG	A076030 002	Oct 28, 2002
		150MG	A076030 003	Oct 28, 2002
	APOTEX INC	50MG	A079164 001	Jul 09, 2009
		100MG	A079164 002	Jul 09, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLECAINIDE ACETATE					
TABLET;ORAL					
FLECAINIDE ACETATE					
		150MG	A079164	003	Jul 09, 2009
TAMBOCOR					
+	ALVOGEN	50MG **	N018830	004	Aug 23, 1988
+		100MG **	N018830	001	Oct 31, 1985
+		150MG **	N018830	003	Jun 03, 1988
		200MG	N018830	002	Oct 31, 1985
FLORBETAPIR F-18					
SOLUTION;INTRAVENOUS					
AMYVID					
	AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)	N202008	001	Apr 06, 2012
FLOXURIDINE					
INJECTABLE;INJECTION					
FLOXURIDINE					
	AM REGENT	500MG/VIAL	A203008	001	Nov 22, 2017
FUDR					
+	HOSPIRA	500MG/VIAL **	N016929	001	
FLUCONAZOLE					
FOR SUSPENSION;ORAL					
FLUCONAZOLE					
	HIKMA	50MG/5ML	A076246	001	Jul 29, 2004
		200MG/5ML	A076246	002	Jul 29, 2004
	IVAX SUB TEVA PHARMS	50MG/5ML	A077523	001	Sep 12, 2007
		200MG/5ML	A077523	002	Sep 12, 2007
	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004
		200MG/5ML	A076332	002	Jul 29, 2004
	TARO PHARM INDS	50MG/5ML	A076918	001	Dec 18, 2006
		200MG/5ML	A076918	002	Dec 18, 2006
INJECTABLE;INJECTION					
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	PFIZER	200MG/100ML (2MG/ML)	N019950	003	Sep 29, 1992
+		400MG/200ML (2MG/ML)	N019950	005	Jul 08, 1994
DIFLUCAN IN SODIUM CHLORIDE 0.9%					
+	PFIZER	200MG/100ML (2MG/ML)	N019950	001	Jan 29, 1990
+		400MG/200ML (2MG/ML)	N019950	006	Jan 29, 1990
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	PFIZER	200MG/100ML (2MG/ML)	N019950	002	Jan 29, 1990
+		400MG/200ML (2MG/ML)	N019950	004	Jan 29, 1990
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764	001	Jan 30, 2012
		400MG/200ML (2MG/ML)	A078764	002	Jan 30, 2012
	HOSPIRA	200MG/100ML (2MG/ML)	A076304	001	Jul 29, 2004
		400MG/200ML (2MG/ML)	A076304	002	Jul 29, 2004
	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076888	001	Mar 25, 2005
		400MG/200ML (2MG/ML)	A076888	002	Mar 25, 2005
	WOODWARD	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010
		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%					
	DR REDDYS	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004
		400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
		400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005
	HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
		400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
	MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
		400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005
TABLET;ORAL					
FLUCONAZOLE					
	ANI PHARMS	50MG	A076086	001	Jul 29, 2004
		100MG	A076086	002	Jul 29, 2004
		150MG	A076086	003	Jul 29, 2004
		200MG	A076086	004	Jul 29, 2004
	GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
		100MG	A076432	002	Jul 29, 2004
		150MG	A076432	003	Jul 29, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUCONAZOLE				
TABLET;ORAL				
FLUCONAZOLE				
	200MG	A076432	004	Jul 29, 2004
MYLAN	50MG	A076351	001	Jul 29, 2004
	100MG	A076351	002	Jul 29, 2004
	150MG	A076351	003	Jul 29, 2004
	200MG	A076351	004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
	100MG	A076042	002	Jul 29, 2004
	150MG	A076042	003	Jul 29, 2004
	200MG	A076042	004	Jul 29, 2004
PLIVA	50MG	A076424	001	Jul 29, 2004
	100MG	A076424	002	Jul 29, 2004
	150MG	A076424	003	Jul 29, 2004
	200MG	A076424	004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
	100MG	A076386	002	Jul 29, 2004
	150MG	A076386	003	Jul 29, 2004
	200MG	A076386	004	Jul 29, 2004
ROXANE	50MG	A076213	001	Jul 29, 2004
	100MG	A076213	002	Jul 29, 2004
	150MG	A076213	003	Jul 29, 2004
	200MG	A076213	004	Jul 29, 2004
TEVA	50MG	A074681	001	Jul 29, 2004
	100MG	A074681	002	Jul 29, 2004
	150MG	A074681	003	Jul 29, 2004
	200MG	A074681	004	Jul 29, 2004
FLUCYTOSINE				
CAPSULE;ORAL				
FLUCYTOSINE				
STRIDES PHARMA	250MG	A207536	001	Jun 18, 2018
	250MG	A212632	001	Apr 17, 2020
	500MG	A207536	002	Jun 18, 2018
	500MG	A212632	002	Apr 17, 2020
FLUDARABINE PHOSPHATE				
INJECTABLE;INJECTION				
FLUDARA				
+ GENZYME CORP	50MG/VIAL **	N020038	001	Apr 18, 1991
FLUDARABINE PHOSPHATE				
HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007
MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011
	50MG/VIAL	A200648	001	Oct 16, 2012
TABLET;ORAL				
OFORTA				
SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008
FLUDEOXYGLUCOSE F-18				
INJECTABLE;INJECTION				
FLUDEOXYGLUCOSE F18				
+ DOWNSTATE CLINCL	4-40mCi/ML **	N020306	001	Aug 19, 1994
+	4-90mCi/ML **	N020306	002	Sep 25, 2001
INJECTABLE;INTRAVENOUS				
FLUDEOXYGLUCOSE F18				
+ FEINSTEIN	20-200mCi/ML **	N021870	001	Aug 19, 2005
MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015
UNIV TX SW MEDCTR	20-200mCi/ML	A210265	001	Feb 06, 2020
WEILL MEDCL COLL	10-100mCi/ML **	N021768	001	Aug 05, 2004
FLUDROCORTISONE ACETATE				
TABLET;ORAL				
FLORINEF				
+ CASPER PHARMA LLC	0.1MG **	N010060	001	
FLUDROCORTISONE ACETATE				
HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011

FLUMAZENIL				
INJECTABLE;INJECTION				
FLUMAZENIL				
DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004
	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004
RISING PHARMA	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008
ROMAZICON				
+ HOFFMANN LA ROCHE	1MG/10ML (0.1MG/ML) **	N020073	001	Dec 20, 1991
+	0.5MG/5ML (0.1MG/ML) **	N020073	002	Dec 20, 1991
FLUMETHASONE PIVALATE				
CREAM;TOPICAL				
LOCORTEN				
NOVARTIS	0.03%	N016379	001	
FLUNISOLIDE				
AEROSOL, METERED;INHALATION				
AEROBID				
ROCHE PALO	0.25MG/INH	N018340	001	Aug 17, 1984
AEROSPAN HFA				
+ MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006
SPRAY, METERED;NASAL				
NASALIDE				
+ IVAX RES	0.025MG/SPRAY **	N018148	001	
NASAREL				
TEVA BRANDED PHARM	0.029MG/SPRAY	N020409	001	Mar 08, 1995
FLUOCINOLONE ACETONIDE				
CREAM;TOPICAL				
FLUOCET				
ALPHARMA US PHARMS	0.025%	A088360	001	Jan 16, 1984
FLUOCINOLONE ACETONIDE				
ALLIED	0.01%	A088047	001	Dec 16, 1982
	0.025%	A088045	001	Dec 16, 1982
ALPHARMA US PHARMS	0.01%	A088361	001	Jan 16, 1984
COSETTE	0.025%	A089525	001	Jul 26, 1988
PERRIGO NEW YORK	0.01%	A086810	001	Mar 04, 1982
	0.025%	A086811	001	Mar 04, 1982
PHARMAFAIR	0.01%	A088499	001	Aug 02, 1984
	0.025%	A088506	001	Aug 02, 1984
TARO	0.01%	A040035	001	Oct 31, 1994
	0.01%	A087102	001	Apr 27, 1982
	0.025%	A040042	001	Oct 31, 1994
USL PHARMA	0.01%	A088757	001	Feb 11, 1985
	0.025%	A088756	001	Mar 28, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087156	002	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.01%	A088174	001	May 06, 1983
	0.025%	A088173	001	Mar 09, 1983
SYNALAR-HP				
MEDIMETRIKS PHARMS	0.2%	N016161	002	
GEL;TOPICAL				
FLUONID				
ALLERGAN HERBERT	0.025%	A087300	001	May 27, 1982
OIL;TOPICAL				
FLUOCINOLONE ACETONIDE				
AKORN	0.01%	A091514	001	Jun 25, 2015
OIL/DROPS;OTIC				
FLUOCINOLONE ACETONIDE				
AKORN	0.01%	A202705	001	Sep 09, 2016
OINTMENT;TOPICAL				
FLUOCINOLONE ACETONIDE				
PHARMADERM	0.025%	A088046	001	Dec 16, 1982
PHARMAFAIR	0.025%	A088507	001	Feb 27, 1984
USL PHARMA	0.025%	A088742	001	Feb 08, 1985
FLUONID				
ALLERGAN HERBERT	0.025%	A087157	001	Sep 06, 1984
FLUOTREX				
SAVAGE LABS	0.025%	A088172	001	Mar 09, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOCINOLONE ACETONIDE

SOLUTION;TOPICAL					
FLUOCINOLONE ACETONIDE					
	ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016
	ALLIED	0.01%	A088048	001	Dec 16, 1982
	ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
	BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
	COSETTE	0.01%	A207441	001	Sep 28, 2016
	MORTON GROVE	0.01%	A088312	001	Jan 27, 1984
	PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984
FLUONID					
	ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983
FLUOTREX					
	SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983

FLUOCINONIDE

CREAM;TOPICAL					
FLUOCINONIDE					
	PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
	TELIGENT	0.05%	A211410	001	Oct 16, 2018
LIDEX					
+	ALVOGEN	0.05%	N016908	002	
SOLUTION;TOPICAL					
FLUOCINONIDE					
	TARO	0.05%	A072857	001	Aug 02, 1989
	TEVA	0.05%	A072511	001	Feb 07, 1989
	TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE;INJECTION					
FUNDUSCEIN-25					
+	NOVARTIS	25% **	N017869	001	

FLUOROMETHOLONE

CREAM;TOPICAL					
OXYLONE					
	PHARMACIA AND UPJOHN	0.025%	N011748	001	
SUSPENSION/DROPS;OPHTHALMIC					
FLUOR-OP					
	NOVARTIS	0.1%	A070185	001	Feb 27, 1986

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC					
TOBRASONE					
	EYEVANCE	0.1%;0.3%	N050628	001	Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS;OPHTHALMIC					
FML-S					
	ALLERGAN	0.1%;10%	N019525	001	Sep 29, 1989

FLUOROURACIL

CREAM;TOPICAL					
FLUOROPLEX					
+	ALMIRALL	1%	N016988	001	
FLUOROURACIL					
	MYLAN	0.5%	A203122	001	Apr 20, 2015
INJECTABLE;INJECTION					
ADRUCIL					
	PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
+		50MG/ML	N017959	001	
	TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
		50MG/ML	A081225	001	Aug 28, 1991
FLUOROURACIL					
	ABIC	50MG/ML	A088929	001	Mar 04, 1986
	ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
		50MG/ML	A089428	001	Jan 12, 1987
		50MG/ML	A089519	001	Mar 12, 1987
	AUROMEDICS PHARMA	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012
		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012
		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012
		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOROURACIL

INJECTABLE;INJECTION					
FLUOROURACIL					
	BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
	EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008
	FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
		50MG/ML	A040379	001	Nov 15, 2000
	MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
	NOVAST LABS	500MG/10ML (50MG/ML)	A209219	001	Dec 12, 2019
		1GM/20ML (50MG/ML)	A209219	002	Dec 12, 2019
		2.5GM/50ML (50MG/ML)	A209271	002	Dec 11, 2019
		5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019
	SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011
		5GM/100ML (50MG/ML)	A091299	002	May 02, 2011
	SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
		50MG/ML	A088767	001	Dec 28, 1984
		50MG/ML	A089434	001	Mar 26, 1987
	SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
+		500MG/10ML (50MG/ML) **	N012209	001	
+		2.5GM/50ML (50MG/ML) **	N012209	002	Jul 29, 2016
	TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000
		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000
SOLUTION;TOPICAL					
EFUDEX					
+	BAUSCH	5% **	N016831	002	
FLUOROPLEX					
	ELORAC	1%	N016765	001	

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL					
FLUOXETINE					
	SUN PHARM INDUSTRIES	EQ 10MG BASE	A075787	001	Jan 29, 2002
		EQ 20MG BASE	A075787	002	Jan 29, 2002
	WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
		EQ 20MG BASE	A075662	002	Jan 29, 2002
FLUOXETINE HYDROCHLORIDE					
	ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020
		EQ 20MG BASE	A202729	002	Aug 27, 2020
		EQ 40MG BASE	A202729	003	Aug 27, 2020
	ANI PHARMS	EQ 10MG BASE	A076287	001	May 20, 2008
		EQ 20MG BASE	A076287	002	May 20, 2008
	BARR	EQ 10MG BASE	A074803	002	Jan 30, 2002
		EQ 20MG BASE	A074803	001	Aug 02, 2001
		EQ 40MG BASE	A076251	001	May 18, 2005
	BEXIMCO PHARMS USA	EQ 10MG BASE	A075807	001	Jan 29, 2002
		EQ 20MG BASE	A075807	002	Jan 29, 2002
	CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
		EQ 20MG BASE	A076022	002	Jan 30, 2002
	CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
		EQ 20MG BASE	A076165	002	Feb 01, 2002
	GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008
		EQ 20MG BASE	A078143	002	Jan 16, 2008
		EQ 40MG BASE	A078143	003	Jan 16, 2008
	MYLAN	EQ 10MG BASE	A075207	001	Jan 30, 2002
		EQ 10MG BASE	A078045	001	Nov 17, 2008
		EQ 20MG BASE	A075207	002	Jan 30, 2002
		EQ 20MG BASE	A078045	002	Nov 17, 2008
		EQ 40MG BASE	A075207	003	May 25, 2007
	MYLAN PHARMS INC	EQ 10MG BASE	A075577	001	Jan 29, 2002
		EQ 20MG BASE	A075577	002	Jan 29, 2002
	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008
		EQ 20MG BASE	A077469	002	Nov 17, 2008
	SPECGX LLC	EQ 10MG BASE	A075658	001	Jan 29, 2002
		EQ 20MG BASE	A075658	002	Jan 29, 2002
	STRIDES PHARMA	EQ 10MG BASE	A076922	001	Dec 16, 2004
		EQ 20MG BASE	A076922	002	Dec 16, 2004
		EQ 40MG BASE	A076922	003	Dec 16, 2004
PROZAC					
	ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL				
SARAFEM				
+	ELI LILLY AND CO	EQ 10MG BASE **	N018936 007	Jul 06, 2000
+		EQ 20MG BASE **	N018936 008	Jul 06, 2000
CAPSULE, DELAYED REL PELLETS;ORAL				
FLUOXETINE HYDROCHLORIDE				
	BARR	EQ 90MG BASE	A076237 001	Mar 24, 2010
PROZAC WEEKLY				
+	LILLY	EQ 90MG BASE **	N021235 001	Feb 26, 2001
SOLUTION;ORAL				
FLUOXETINE HYDROCHLORIDE				
	ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690 001	Jan 31, 2002
	AKORN	EQ 20MG BASE/5ML	A075525 001	Jun 27, 2002
	LANNETT CO INC	EQ 20MG BASE/5ML	A076458 001	May 14, 2004
	NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292 001	Feb 07, 2002
	SPECGX LLC	EQ 20MG BASE/5ML	A075920 001	Jan 29, 2002
PROZAC				
+	LILLY	EQ 20MG BASE/5ML **	N020101 001	Apr 24, 1991
TABLET;ORAL				
FLUOXETINE HYDROCHLORIDE				
	BARR	EQ 10MG BASE	A075810 001	Feb 01, 2002
	FOSUN PHARMA	EQ 10MG BASE	A076024 001	Jan 29, 2002
	G AND W LABS INC	EQ 60MG BASE	A212191 001	Jul 05, 2019
	IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865 001	Feb 28, 2002
		EQ 40MG BASE	A075865 003	Aug 30, 2004
	RISING PHARMA	EQ 10MG BASE	A075755 001	Aug 02, 2001
		EQ 20MG BASE	A075755 002	Aug 02, 2001
PROZAC				
+	LILLY	EQ 10MG BASE **	N020974 001	Mar 09, 1999
+		EQ 20MG BASE **	N020974 002	Mar 09, 1999
SARAFEM				
+	APIL	EQ 10MG BASE	N021860 001	May 19, 2006
+		EQ 15MG BASE **	N021860 002	May 19, 2006
+		EQ 20MG BASE	N021860 003	May 19, 2006
SELFEMRA				
	TEVA PHARMS USA	EQ 10MG BASE	A200151 001	Feb 03, 2014
		EQ 15MG BASE	A200151 002	Feb 03, 2014
		EQ 20MG BASE	A200151 003	Feb 03, 2014

FLUOXYMESTERONE

TABLET;ORAL				
ANDROID-F				
	VALEANT PHARM INTL	10MG	A087196 001	
FLUOXYMESTERONE				
	UPSHER SMITH LABS	10MG	A088342 001	Oct 21, 1983
	VALEANT PHARM INTL	10MG	A088221 001	May 05, 1983
	WATSON LABS	2MG	A088260 001	Dec 06, 1983
		5MG	A088265 001	Dec 06, 1983
		10MG	A088309 001	Dec 06, 1983
HALOTESTIN				
	PHARMACIA AND UPJOHN	2MG	N010611 002	
		5MG	N010611 006	
		10MG	N010611 010	
ORA-TESTRYL				
	BRISTOL MYERS SQUIBB	2MG	N011359 001	
		5MG	N011359 002	

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION				
FLUPHENAZINE DECANOATE				
	HOSPIRA	25MG/ML	A074966 001	Apr 16, 1998
	TEVA PARENTERAL	25MG/ML	A074795 001	Sep 10, 1996
PROLIXIN DECANOATE				
+	BRISTOL MYERS SQUIBB	25MG/ML **	N016727 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUPHENAZINE ENANTHATE				
INJECTABLE;INJECTION				
PROLIXIN ENANTHATE				
APOTHECON	25MG/ML **	N016110	001	
FLUPHENAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
ANI PHARMS	5MG/ML	A073058	001	Aug 30, 1991
PERMITIL				
SCHERING	5MG/ML **	N016008	001	
PROLIXIN				
APOTHECON	5MG/ML	A070533	001	Nov 07, 1985
ELIXIR;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
ANI PHARMS	2.5MG/5ML	A081310	001	Apr 29, 1993
PROLIXIN				
+ APOTHECON	2.5MG/5ML **	N012145	003	
INJECTABLE;INJECTION				
PROLIXIN				
APOTHECON	2.5MG/ML **	N011751	005	
TABLET;ORAL				
FLUPHENAZINE HYDROCHLORIDE				
MYLAN	1MG	A089804	002	Aug 12, 1988
	2.5MG	A089804	003	Aug 12, 1988
	5MG	A089804	004	Aug 12, 1988
	10MG	A089804	001	Aug 12, 1988
SANDOZ	1MG	A089586	002	Oct 16, 1987
	2.5MG	A089586	003	Oct 16, 1987
	5MG	A089586	004	Oct 16, 1987
	10MG	A089586	001	Oct 16, 1987
WATSON LABS	1MG	A088555	001	Dec 18, 1987
	2.5MG	A088544	001	Dec 18, 1987
	5MG	A088527	001	Dec 18, 1987
	10MG	A088550	001	Dec 18, 1987
PERMITIL				
SCHERING	0.25MG	N012034	001	
	2.5MG	N012034	004	
	5MG	N012034	005	
	10MG	N012034	006	
PROLIXIN				
+ APOTHECON	1MG **	N011751	004	
+	2.5MG **	N011751	001	
+	5MG **	N011751	003	
+	10MG **	N011751	002	
TABLET, EXTENDED RELEASE;ORAL				
PERMITIL				
SCHERING	1MG	N012419	004	
FLUPREDNISOLONE				
TABLET;ORAL				
ALPHADROL				
PHARMACIA AND UPJOHN	1.5MG	N012259	002	
FLURANDRENOLIDE				
CREAM;TOPICAL				
CORDRAN SP				
+ ALMIRALL	0.025%	N012806	003	
LOTION;TOPICAL				
FLURANDRENOLIDE				
ALPHARMA US PHARMS	0.05%	A087203	001	Apr 29, 1982
OINTMENT;TOPICAL				
CORDRAN				
+ ALMIRALL	0.025% **	N012806	004	

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM;TOPICAL				
CORDRAN N				
	LILLY	0.05%;EQ 3.5MG BASE/GM	N050346 001	
OINTMENT;TOPICAL				
CORDRAN N				
	LILLY	0.05%;EQ 3.5MG BASE/GM	N050345 001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL				
DALMANE				
	VALEANT PHARM INTL	15MG **	N016721 001	
+		30MG **	N016721 002	
FLURAZEPAM HYDROCHLORIDE				
	HALSEY	15MG	A071808 001	Jan 07, 1988
		30MG	A071809 001	Jan 07, 1988
	HERITAGE PHARMA	15MG	A071205 001	Nov 25, 1986
		15MG	A072368 001	Mar 30, 1989
		30MG	A071068 001	Nov 25, 1986
		30MG	A072369 001	Mar 30, 1989
	HIKMA	30MG	A071108 001	Dec 08, 1986
	HIKMA INTL PHARMS	15MG	A071107 001	Dec 08, 1986
	PUREPAC PHARM	15MG	A071927 001	Sep 09, 1987
		30MG	A071551 001	Sep 09, 1987
	RISING	15MG	A071717 002	Jul 31, 1991
		30MG	A071717 001	Jul 31, 1991
	STRIDES PHARMA	15MG	A070444 001	Mar 20, 1986
		30MG	A070445 001	Mar 20, 1986
	SUN PHARM INDUSTRIES	15MG	A070454 001	Aug 04, 1986
		30MG	A070455 001	Aug 04, 1986
	SUPERPHARM	15MG	A071659 001	Aug 04, 1988
		30MG	A071660 001	Aug 04, 1988
	USL PHARMA	15MG	A070562 001	Jul 09, 1987
		30MG	A070563 001	Jul 09, 1987
	WARNER CHILCOTT	15MG	A071767 001	Dec 04, 1987
		30MG	A071768 001	Dec 04, 1987

FLURBIPROFEN

TABLET;ORAL				
ANSAID				
	PHARMACIA AND UPJOHN	50MG	N018766 002	Oct 31, 1988
		100MG	N018766 003	Oct 31, 1988
FLURBIPROFEN				
	IVAX SUB TEVA PHARMS	50MG	A074411 001	May 31, 1995
		100MG	A074411 002	May 31, 1995
	MYLAN	50MG	A074358 001	Jun 20, 1994
		100MG	A074358 002	Jun 20, 1994
	PLIVA	50MG	A074647 001	Apr 01, 1997
		100MG	A074647 002	Apr 01, 1997
	RISING	50MG	A074448 001	Jul 28, 1995
		100MG	A074448 002	Jul 28, 1995
	SUN PHARM INDS INC	50MG	A075058 001	Apr 27, 2001
		100MG	A075058 002	Apr 27, 2001
	TEVA	50MG	A074405 002	May 24, 1995
		100MG	A074405 001	May 24, 1995
	THERAGEN	100MG	A074560 002	May 16, 1997

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC				
OCUFEN				
+	ALLERGAN	0.03%	N019404 001	Dec 31, 1986

FLUTAMIDE

CAPSULE;ORAL				
EULEXIN				
+	SCHERING	125MG **	N018554 001	Jan 27, 1989
FLUTAMIDE				
	ACTAVIS LABS FL INC	125MG	A075820 001	Sep 18, 2001
	CIPLA	125MG	A075780 001	Sep 19, 2001
	MYLAN	125MG	A076224 001	May 09, 2003
	YAOPHARMA CO LTD	125MG	A075818 001	Sep 18, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUTEMETAMOL F-18				
INJECTABLE;INTRAVENOUS				
VIZAMYL				
+	GE HEALTHCARE	40.5mCi/10ML (4.05mCi/ML)	N203137 001	Oct 25, 2013
FLUTICASONE PROPIONATE				
AEROSOL, METERED;INHALATION				
FLOVENT				
	GLAXOSMITHKLINE	0.044MG/INH	N020548 001	Mar 27, 1996
		0.11MG/INH	N020548 002	Mar 27, 1996
		0.22MG/INH	N020548 003	Mar 27, 1996
CREAM;TOPICAL				
CUTIVATE				
+	FOUGERA PHARMS	0.05% **	N019958 001	Dec 18, 1990
FLUTICASONE PROPIONATE				
	ANDA REPOSITORY	0.05%	A076633 001	May 14, 2004
	NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004
OINTMENT;TOPICAL				
CUTIVATE				
+	FOUGERA PHARMS	0.005% **	N019957 001	Dec 14, 1990
FLUTICASONE PROPIONATE				
	FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004
	TARO PHARM INDS	0.005%	A077145 001	Jun 14, 2005
POWDER;INHALATION				
ARMONAIR RESPICLICK				
+	TEVA PHARM	0.03MG/INH	N208798 007	Jul 09, 2021
+		0.055MG/INH	N208798 001	Jan 27, 2017
+		0.113MG/INH	N208798 002	Jan 27, 2017
+		0.232MG/INH	N208798 003	Jan 27, 2017
FLOVENT				
	GLAXOSMITHKLINE	0.044MG/INH	N020549 001	Nov 07, 1997
		0.088MG/INH	N020549 002	Nov 07, 1997
		0.22MG/INH	N020549 003	Nov 07, 1997
SPRAY, METERED;NASAL				
FLONASE				
+	GLAXOSMITHKLINE	0.05MG/SPRAY **	N020121 001	Oct 19, 1994
FLUVASTATIN SODIUM				
CAPSULE;ORAL				
LESCOL				
+	NOVARTIS	EQ 20MG BASE **	N020261 001	Dec 31, 1993
+		EQ 40MG BASE **	N020261 002	Dec 31, 1993
TABLET, EXTENDED RELEASE;ORAL				
FLUVASTATIN SODIUM				
	MYLAN	EQ 80MG BASE	A202458 001	Sep 11, 2015
FLUVOXAMINE MALEATE				
CAPSULE, EXTENDED RELEASE;ORAL				
FLUVOXAMINE MALEATE				
	BIONPHARMA INC	100MG	A212182 002	Sep 16, 2020
	TORRENT	100MG	A203240 001	Oct 31, 2014
		150MG	A203240 002	Oct 31, 2014
LUVOX CR				
+	JAZZ PHARMS	100MG **	N022033 001	Feb 28, 2008
+		150MG **	N022033 002	Feb 28, 2008
TABLET;ORAL				
FLUVOXAMINE MALEATE				
	ACTAVIS ELIZABETH	25MG	A075901 001	Dec 28, 2000
		50MG	A075901 002	Dec 28, 2000
		100MG	A075901 003	Dec 28, 2000
	ANI PHARMS	25MG	A075897 001	Jan 25, 2001
		25MG	A075898 001	Mar 12, 2001
		50MG	A075897 002	Jan 25, 2001
		50MG	A075898 002	Mar 12, 2001
		100MG	A075897 003	Jan 25, 2001
		100MG	A075898 003	Mar 12, 2001
	HERITAGE PHARMA	25MG	A075894 001	Apr 18, 2001
		50MG	A075894 002	Apr 18, 2001
		100MG	A075894 003	Apr 18, 2001
	MYLAN	25MG	A075889 001	Nov 29, 2000
		50MG	A075889 002	Nov 29, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

	50MG	A075950	001	Oct 15, 2001
	100MG	A075889	003	Nov 29, 2000
	100MG	A075950	002	Oct 15, 2001
PHARMA LIFE	25MG	A075900	001	Feb 23, 2006
	50MG	A075900	002	Feb 23, 2006
	100MG	A075900	003	Feb 23, 2006
SUN PHARM INDUSTRIES	25MG	A076125	001	Apr 29, 2002
	50MG	A076125	002	Apr 29, 2002
	100MG	A076125	003	Apr 29, 2002
SYNTHON PHARMS	25MG	A075899	001	Jan 17, 2001
	50MG	A075899	002	Jan 17, 2001
	100MG	A075899	003	Jan 17, 2001
TEVA	25MG	A075893	001	Sep 10, 2002
	50MG	A075893	002	Sep 10, 2002
	100MG	A075893	003	Sep 10, 2002
UPSHER SMITH LABS	25MG	A075887	001	Jan 05, 2001
	50MG	A075887	002	Jan 05, 2001
	100MG	A075887	003	Jan 05, 2001

LUVOX

+ SOLVAY	25MG **	N020243	001	Dec 05, 1994
+	50MG **	N020243	002	Dec 05, 1994
+	100MG **	N020243	003	Dec 05, 1994
+	150MG **	N020243	004	Dec 05, 1994

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

BEN VENUE	5MG/ML	A081066	001	Dec 29, 1993

FOLVITE

+ WYETH PHARMS INC	5MG/ML	N005897	008	

TABLET;ORAL

FOLIC ACID

BARR	1MG	A089177	001	Jan 08, 1986
CONTRACT PHARMACAL	1MG	A085061	001	
EVERYLIFE	1MG	A080755	001	
HALSEY	1MG	A083598	001	
HIKMA PHARMS	1MG	A080600	001	
IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
LANNETT	1MG	A080816	001	
LILLY	1MG **	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
SUN PHARM INDUSTRIES	1MG	A040582	001	Jul 18, 2005
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE	1MG	A040756	001	Jun 04, 2010
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	

FOLICET

MISSION PHARMA	1MG	A087438	001	

FOLVITE

WYETH PHARMS INC	1MG	N005897	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FOMEPIZOLE				
INJECTABLE;INJECTION				
ANTIZOL				
+	PAR PHARM INC	1.5GM/1.5ML (1GM/ML) **	N020696 001	Dec 04, 1997
FOMEPIZOLE				
	MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033 001	Apr 07, 2009
FOMIVIRSEN SODIUM				
INJECTABLE;INJECTION				
VITRAVENE PRESERVATIVE FREE				
	NOVARTIS	6.6MG/ML	N020961 001	Aug 26, 1998
FORMOTEROL FUMARATE				
POWDER;INHALATION				
FORADIL				
+	NOVARTIS	0.012MG/INH	N020831 001	Feb 16, 2001
FORADIL CERTIHALER				
	NOVARTIS	0.0085MG/INH	N021592 001	Dec 15, 2006
FOSAPREPITANT DIMEGLUMINE				
POWDER;INTRAVENOUS				
EMEND				
+	MERCK AND CO INC	EQ 115MG BASE/VIAL **	N022023 001	Jan 25, 2008
FOSAPREPITANT DIMEGLUMINE				
	MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015 001	Sep 05, 2019
FOSCARNET SODIUM				
INJECTABLE;INJECTION				
FOSCARNET SODIUM				
	HOSPIRA	2.4GM/100ML	A077174 001	May 31, 2005
FOSINOPRIL SODIUM				
TABLET;ORAL				
FOSINOPRIL SODIUM				
	ACTAVIS LABS FL INC	10MG	A076620 001	Oct 15, 2004
		20MG	A076620 002	Oct 15, 2004
		40MG	A076620 003	Oct 15, 2004
	RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004
		20MG	A076580 002	Apr 23, 2004
		40MG	A076580 003	Apr 23, 2004
	UPSHER SMITH LABS	10MG	A076188 001	Oct 08, 2004
		20MG	A076188 002	Oct 08, 2004
		40MG	A076188 003	Oct 08, 2004
	WATSON LABS	10MG	A076987 001	Dec 23, 2004
		10MG	A077531 001	Aug 31, 2006
		20MG	A076987 002	Dec 23, 2004
		20MG	A077531 002	Aug 31, 2006
		40MG	A076987 003	Dec 23, 2004
		40MG	A077531 003	Aug 31, 2006
MONOPRIL				
+	BRISTOL MYERS SQUIBB	10MG **	N019915 002	May 16, 1991
+		20MG **	N019915 003	May 16, 1991
+		40MG **	N019915 004	Mar 28, 1995
FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE				
TABLET;ORAL				
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE				
	ANI PHARMS	10MG;12.5MG	A076608 001	Dec 03, 2004
		10MG;12.5MG	A077144 001	Aug 16, 2005
		20MG;12.5MG	A076608 002	Dec 03, 2004
		20MG;12.5MG	A077144 002	Aug 16, 2005
	EMCURE PHARMS LTD	10MG;12.5MG	A079025 001	Sep 17, 2010
		20MG;12.5MG	A079025 002	Sep 17, 2010
	MYLAN	10MG;12.5MG	A077705 001	Aug 14, 2006
		20MG;12.5MG	A077705 002	Aug 14, 2006
	SUN PHARM INDS LTD	10MG;12.5MG	A076739 001	Dec 17, 2004
		20MG;12.5MG	A076739 002	Dec 17, 2004
	TEVA	10MG;12.5MG	A076945 001	Jul 05, 2006
		20MG;12.5MG	A076945 002	Jul 05, 2006
MONOPRIL-HCT				
+	BRISTOL MYERS SQUIBB	10MG;12.5MG **	N020286 002	Nov 30, 1994
+		20MG;12.5MG **	N020286 001	Nov 30, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FOSPHENYTOIN SODIUM				
INJECTABLE;INJECTION				
FOSPHENYTOIN SODIUM				
AM REGENT	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007
	EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010
AMNEAL	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008
APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126	001	Aug 06, 2007
DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007
HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158	001	Aug 06, 2007
SOLUTION;INTRAVENOUS				
SESQUIENT				
+ LUPIN	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020
+	EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020
FOSPROPOFOL DISODIUM				
SOLUTION;INTRAVENOUS				
LUSEDRA				
EISAI INC	1050MG/30ML (35MG/ML)	N022244	001	Dec 12, 2008
FULVESTRANT				
INJECTABLE;INTRAMUSCULAR				
FULVESTRANT				
ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021
FURAZOLIDONE				
SUSPENSION;ORAL				
FUROXONE				
SHIRE	50MG/15ML	N011323	002	
TABLET;ORAL				
FUROXONE				
SHIRE	100MG	N011270	002	
FUROSEMIDE				
INJECTABLE;INJECTION				
FUROSEMIDE				
ABRAXIS PHARM	10MG/ML	N018507	001	Jul 30, 1982
	10MG/ML	N019036	001	Aug 13, 1984
+ AM REGENT	10MG/ML **	N018579	001	Nov 30, 1983
AMNEAL PHARMS CO	10MG/ML	A207552	001	Jul 20, 2016
ASTRAZENECA	10MG/ML	A070014	001	Sep 09, 1985
HIKMA	10MG/ML	A071439	001	Sep 14, 1990
	10MG/ML	N018267	001	
HOSPIRA	10MG/ML	A070578	001	Jul 08, 1987
	10MG/ML	A072080	001	Aug 13, 1991
	10MG/ML	A074337	001	Oct 31, 1994
IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985
	10MG/ML	A070096	001	Sep 09, 1985
INTL MEDICATION	10MG/ML	N018025	001	
MARSAM PHARMS LLC	10MG/ML	A074017	001	Jun 30, 1994
SMITH AND NEPHEW	10MG/ML	A070023	001	Feb 05, 1986
	10MG/ML	A070078	001	Feb 05, 1986
WARNER CHILCOTT	10MG/ML	N018420	001	Feb 26, 1982
WATSON LABS	10MG/ML	A070019	001	Sep 22, 1986
	10MG/ML	A070604	001	Jan 02, 1987
WYETH AYERST	10MG/ML	N018670	001	Jul 20, 1982
LASIX				
+ SANOFI AVENTIS US	10MG/ML **	N016363	001	
SOLUTION;ORAL				
LASIX				
SANOFI AVENTIS US	10MG/ML	N017688	001	
TABLET;ORAL				
FUROSEMIDE				
ANI PHARMS	20MG	A071379	001	Jan 02, 1987
	40MG	A070413	001	Feb 26, 1986
	80MG	A071594	001	Feb 09, 1988
AVET	20MG	N018413	001	Nov 30, 1983
	40MG	N018413	002	Nov 30, 1983
INTL MEDICATION	20MG	N018753	001	Feb 28, 1984
	40MG	N018753	002	Feb 28, 1984
KALAPHARM	20MG	N018868	001	Jun 28, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FUROSEMIDE

TABLET;ORAL

FUROSEMIDE

	40MG	N018868	002	Jun 28, 1983
SANDOZ	40MG	N018750	002	Jul 30, 1984
STRIDES PHARMA	20MG	N018415	001	Jul 27, 1982
	40MG	N018415	002	Jul 27, 1982
	80MG	N018415	003	Nov 26, 1984
SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014
	40MG	A091258	002	Apr 01, 2014
	40MG	N018790	001	Nov 29, 1983
	80MG	A091258	003	Apr 01, 2014
SUN PHARM INDUSTRIES	20MG	A070043	001	Sep 26, 1985
	80MG	A070100	001	Jan 26, 1988
SUPERPHARM	20MG	N018370	002	Jun 26, 1984
	40MG	N018370	001	Feb 10, 1983
WARNER CHILCOTT	20MG	N018419	001	Jan 31, 1983
	40MG	N018419	002	Jan 31, 1983
	80MG	N018419	003	Nov 13, 1984
WATSON LABS	20MG	A070412	001	Feb 26, 1986
	20MG	N018369	001	May 14, 1982
	40MG	A070450	001	Nov 22, 1985
	40MG	N018369	002	May 14, 1982
WATSON LABS TEVA	20MG	A070449	001	Nov 22, 1985
	80MG	A070528	001	Jan 07, 1986

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

HIKMA	100MG	A078150	001	Sep 25, 2007
	300MG	A078150	002	Sep 25, 2007
	400MG	A078150	003	Sep 25, 2007
JIANGSU PHARMS	100MG	A091008	001	Oct 26, 2017
	300MG	A091008	002	Oct 26, 2017
	400MG	A091008	003	Oct 26, 2017
MYLAN	100MG	A090158	001	Feb 14, 2011
	300MG	A090158	002	Feb 14, 2011
	400MG	A090158	003	Feb 14, 2011
SANDOZ	100MG	A075428	001	Jan 24, 2006
	100MG	A075539	001	Apr 06, 2005
	300MG	A075428	002	Jan 24, 2006
	300MG	A075539	002	Apr 06, 2005
	400MG	A075428	003	Jan 24, 2006
	400MG	A075539	003	Apr 06, 2005
SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005
	300MG	A076606	002	Oct 07, 2005
	400MG	A076606	003	Oct 07, 2005
SUN PHARM INDUSTRIES	100MG	A076537	001	Jun 30, 2005
	300MG	A076537	002	Jun 30, 2005
	400MG	A076537	003	Jun 30, 2005
TEVA PHARMS	100MG	A075435	001	Oct 08, 2004
	300MG	A075435	002	Oct 08, 2004
	400MG	A075435	003	Oct 08, 2004
WATSON LABS	100MG	A075485	003	May 11, 2007
	300MG	A075485	002	May 11, 2007
	400MG	A075485	001	May 11, 2007

SOLUTION;ORAL

GABAPENTIN

NOVITIUM PHARMA	250MG/5ML	A211330	001	Dec 03, 2019

TABLET;ORAL

GABAPENTIN

HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011
	800MG	A078782	002	Jul 21, 2011
INVATECH	600MG	A076877	001	Jul 06, 2006
	800MG	A076877	002	Jul 06, 2006
IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005
	800MG	A076017	005	Apr 29, 2005
LUPIN LTD	600MG	A209306	001	Aug 24, 2018
	800MG	A209306	002	Aug 24, 2018
MYLAN PHARMS INC	600MG	A090335	001	Jun 01, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GABAPENTIN

TABLET;ORAL				
GABAPENTIN				
	800MG		A090335 002	Jun 01, 2010
RANBAXY	600MG		A076605 001	Sep 14, 2005
	800MG		A076605 002	Sep 14, 2005
SANDOZ	600MG		A076120 001	Jan 27, 2006
	800MG		A076120 002	Jan 27, 2006
TEVA	600MG		A075827 001	Dec 15, 2004
	800MG		A075827 002	Dec 15, 2004
TEVA PHARMS USA	600MG		A205807 001	Mar 10, 2017
	800MG		A205807 002	Mar 10, 2017

GADODIAMIDE

INJECTABLE;INJECTION				
OMNISCAN				
GE HEALTHCARE	14.35GM/50ML (287MG/ML)		N022066 001	Sep 05, 2007

GADOFOSVESET TRISODIUM

SOLUTION;INTRAVENOUS				
ABLAVAR				
LANTHEUS MEDCL	2440MG/10ML (244MG/ML)		N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)		N021711 002	Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE;INJECTION				
MAGNEVIST				
+ BAYER HLTHCARE	469.01MG/ML		N019596 001	Jun 02, 1988
+	469.01MG/ML		N021037 001	Mar 10, 2000

GADOVERSETAMIDE

INJECTABLE;INJECTION				
OPTIMARK				
+ LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)		N020937 001	Dec 08, 1999
+	3309MG/10ML (330.9MG/ML)		N020937 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)		N020937 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)		N020937 004	Dec 08, 1999
+	16.545GM/50ML (330.9MG/ML)		N020975 001	Dec 08, 1999
OPTIMARK IN PLASTIC CONTAINER				
+ LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)		N020976 002	Dec 08, 1999
+	4963.5MG/15ML (330.9MG/ML)		N020976 003	Dec 08, 1999
+	6618MG/20ML (330.9MG/ML)		N020976 004	Dec 08, 1999
+	9927MG/30ML (330.9MG/ML)		N020976 001	Dec 08, 1999

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL				
GALANTAMINE HYDROBROMIDE				
IMPAX LABS	EQ 8MG BASE		A078484 001	May 27, 2009
	EQ 16MG BASE		A078484 002	May 27, 2009
	EQ 24MG BASE		A078484 003	May 27, 2009
MYLAN	EQ 8MG BASE		A090900 001	Jan 24, 2011
	EQ 16MG BASE		A090900 002	Jan 24, 2011
	EQ 24MG BASE		A090900 003	Jan 24, 2011
SOLUTION;ORAL				
RAZADYNE				
JANSSEN PHARMS	4MG/ML **		N021224 001	Jun 22, 2001
TABLET;ORAL				
GALANTAMINE HYDROBROMIDE				
APOTEX INC	EQ 4MG BASE		A077781 001	Sep 27, 2011
	EQ 8MG BASE		A077781 002	Sep 27, 2011
	EQ 12MG BASE		A077781 003	Sep 27, 2011
HERITAGE PHARMA	EQ 4MG BASE		A077585 001	Sep 15, 2009
	EQ 4MG BASE		A077587 001	Jul 09, 2009
	EQ 8MG BASE		A077585 002	Sep 15, 2009
	EQ 8MG BASE		A077587 002	Jul 09, 2009
	EQ 12MG BASE		A077585 003	Sep 15, 2009
	EQ 12MG BASE		A077587 003	Jul 09, 2009
HIKMA	EQ 4MG BASE		A077608 001	Feb 11, 2009
	EQ 8MG BASE		A077608 002	Feb 11, 2009
	EQ 12MG BASE		A077608 003	Feb 11, 2009
MYLAN	EQ 4MG BASE		A077590 001	May 29, 2009
	EQ 4MG BASE		A077603 001	Aug 28, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GALANTAMINE HYDROBROMIDE				
TABLET;ORAL				
GALANTAMINE HYDROBROMIDE				
	EQ 8MG BASE	A077590	002	May 29, 2009
	EQ 8MG BASE	A077603	002	Aug 28, 2008
	EQ 12MG BASE	A077590	003	May 29, 2009
	EQ 12MG BASE	A077603	003	Aug 28, 2008
RAZADYNE				
+ JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001
+	EQ 8MG BASE	N021169	002	Feb 28, 2001
+	EQ 12MG BASE	N021169	003	Feb 28, 2001
GALLAMINE TRIETHIODIDE				
INJECTABLE;INJECTION				
FLAXEDIL				
DAVIS AND GECK	20MG/ML	N007842	001	
	100MG/ML	N007842	002	
GALLIUM CITRATE GA-67				
INJECTABLE;INJECTION				
GALLIUM CITRATE GA 67				
GE HEALTHCARE	1mCi/ML	N017700	001	
NEOSCAN				
GE HEALTHCARE	2mCi/ML	N017655	001	
GALLIUM NITRATE				
INJECTABLE;INJECTION				
GANITE				
CHAPTER 7 TRUSTEE	25MG/ML **	N019961	002	Jan 17, 1991
GANCICLOVIR				
CAPSULE;ORAL				
CYTOVENE				
+ ROCHE PALO	250MG **	N020460	001	Dec 22, 1994
+	500MG **	N020460	002	Dec 12, 1997
GANCICLOVIR				
RANBAXY LABS LTD	250MG	A076457	001	Jun 27, 2003
	500MG	A076457	002	Jun 27, 2003
IMPLANT;IMPLANTATION				
VITRASERT				
BAUSCH AND LOMB	4.5MG	N020569	001	Mar 04, 1996
GANCICLOVIR SODIUM				
INJECTABLE;INJECTION				
CYTOVENE				
+ CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989
GANCICLOVIR SODIUM				
AM REGENT	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013
CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019
MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017
GATIFLOXACIN				
SOLUTION/DROPS;OPHTHALMIC				
GATIFLOXACIN				
APOTEX INC	0.3%	A079084	001	Aug 19, 2011
MYLAN	0.5%	A206446	001	Jun 08, 2018
GEFITINIB				
TABLET;ORAL				
IRESSA				
ASTRAZENECA	250MG	N021399	001	May 05, 2003
GEMCITABINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
GEMCITABINE HYDROCHLORIDE				
ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016
	1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016
	2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016
ACTAVIS TOTOWA	EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A079160	003	Jul 28, 2016
AM REGENT	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013
	EQ 1GM BASE/VIAL	A202031	002	May 07, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GEMCITABINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
GEMCITABINE HYDROCHLORIDE				
APOTEX	200MG/5.26ML (38MG/ML)	A206776	001	May 23, 2017
	1GM/26.3ML (38MG/ML)	A206776	002	May 23, 2017
	2GM/52.6ML (38MG/ML)	A206776	003	May 23, 2017
EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063	001	Sep 11, 2012
	EQ 1GM BASE/VIAL	A202063	002	Sep 11, 2012
HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012
	EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012
MYLAN LABS LTD	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011
	EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011
	EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011
NOVAST LABS	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019
	1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019
	2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019
SAGENT PHARMS	EQ 200MG BASE/VIAL	A091597	001	May 07, 2013
	EQ 1GM BASE/VIAL	A091597	002	May 07, 2013
TEVA PHARMS	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011
	EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011
GEMZAR				
+ LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996
+	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996
GEMFIBROZIL				
CAPSULE;ORAL				
GEMFIBROZIL				
MYLAN	300MG	A073466	001	Jan 25, 1993
PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993
LOPID				
PFIZER PHARMS	200MG	N018422	001	
	300MG	N018422	002	
TABLET;ORAL				
GEMFIBROZIL				
HIKMA PHARMS	600MG	A078599	001	Aug 16, 2010
MYLAN	600MG	A074452	001	Feb 16, 1995
PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008
TEVA	600MG	A074256	001	Oct 31, 1993
WATSON LABS	600MG	A074156	001	Oct 24, 1994
	600MG	A074442	001	Apr 28, 1995
YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995
GENTAMICIN SULFATE				
CREAM;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060462	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983
FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984
PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984
TARO	EQ 0.1% BASE	A062427	001	May 26, 1983
INJECTABLE;INJECTION				
APOGEN				
KING PHARMS	EQ 10MG BASE/ML	A062289	001	
	EQ 40MG BASE/ML	A062289	002	
BRISTAGEN				
BRISTOL	EQ 40MG BASE/ML	A062288	001	
GARAMYCIN				
SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	
GENTAFAIR				
PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985
GENTAMICIN				
INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GENTAMICIN SULFATE

INJECTABLE;INJECTION				
GENTAMICIN SULFATE				
ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
HIKMA	EQ 10MG BASE/ML	A062251	002	
	EQ 40MG BASE/ML	A062251	001	
HOSPIRA	EQ 10MG BASE/ML	A062612	004	Feb 20, 1986
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814	004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814	005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814	006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814	007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814	008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814	009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814	010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814	011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814	012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814	013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814	014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414	002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414	004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414	005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414	006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414	007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414	009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986
U-GENCIN				
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	
INJECTABLE;INTRATHECAL				
GARAMYCIN				
+ SCHERING	EQ 2MG BASE/ML **	N050505	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GENTAMICIN SULFATE

OINTMENT;OPHTHALMIC				
GARAMYCIN				
SCHERING	EQ 0.3% BASE	N050425	001	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
GENTAFAIR				
PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
OINTMENT;TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE **	A060463	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
SOLUTION/DROPS;OPHTHALMIC				
GARAMYCIN				
+ SCHERING	EQ 0.3% BASE **	N050039	002	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
GENTAFAIR				
PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
GENTAMICIN SULFATE				
ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY;VAGINAL				
GVS				
SAVAGE LABS	0.4%	A083513	001	
TAMPON;VAGINAL				
GENAPAX				
KEY PHARMS	5MG	A085017	001	

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS				
COPAXONE				
TEVA PHARMS USA	20MG/VIAL	N020622	001	Dec 20, 1996

GLIMEPIRIDE

TABLET;ORAL				
GLIMEPIRIDE				
ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010
	2MG	A076995	002	Apr 27, 2010
	4MG	A076995	003	Apr 27, 2010
EPIC PHARMA LLC	1MG	A077274	001	Oct 06, 2005
	2MG	A077274	002	Oct 06, 2005
	4MG	A077274	003	Oct 06, 2005
HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013
	2MG	A078952	002	Aug 01, 2013
	4MG	A078952	003	Aug 01, 2013
MYLAN	1MG	A077486	001	Feb 10, 2006
	1MG	A077624	001	Nov 28, 2005
	2MG	A077486	002	Feb 10, 2006
	2MG	A077624	002	Nov 28, 2005
	4MG	A077486	003	Feb 10, 2006
	4MG	A077624	003	Nov 28, 2005
RANBAXY	3MG	A077366	001	Oct 06, 2005
	6MG	A077366	002	Oct 06, 2005
RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005
	2MG	A076875	002	Oct 06, 2005
	4MG	A076875	003	Oct 06, 2005
	8MG	A076875	004	Oct 06, 2005
TEVA	1MG	A076802	001	Oct 06, 2005
	2MG	A076802	002	Oct 06, 2005
	4MG	A076802	003	Oct 06, 2005
WATSON LABS	1MG	A077280	001	Feb 03, 2006
	2MG	A077280	002	Feb 03, 2006
	4MG	A077280	003	Feb 03, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL				
AVANDARYL				
+	SB PHARMCO	1MG;4MG **	N021700 001	Nov 23, 2005
+		2MG;4MG **	N021700 002	Nov 23, 2005
+		2MG;8MG **	N021700 004	Mar 30, 2007
+		4MG;4MG **	N021700 003	Nov 23, 2005
+		4MG;8MG **	N021700 005	Mar 30, 2007
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE				
	TEVA PHARMS USA	1MG;4MG	A078709 001	Apr 01, 2016
		2MG;4MG	A078709 002	Apr 01, 2016
		2MG;8MG	A078709 004	Apr 01, 2016
		4MG;4MG	A078709 003	Apr 01, 2016
		4MG;8MG	A078709 005	Apr 01, 2016

GLIPIZIDE

TABLET;ORAL				
GLIPIZIDE				
	ANI PHARMS	5MG	A074387 001	Mar 04, 1996
		10MG	A074387 002	Mar 04, 1996
	BARR LABS INC	5MG	A074619 001	Apr 04, 1997
		10MG	A074619 002	Apr 04, 1997
	BEXIMCO PHARMS USA	5MG	A074542 001	Jun 20, 1995
		10MG	A074542 002	Jun 20, 1995
	MYLAN	5MG	A074438 001	Jun 20, 1995
		10MG	A074438 002	Jun 20, 1995
	OXFORD PHARMS	5MG	A074378 001	Nov 28, 1994
		10MG	A074378 002	Nov 28, 1994
	WATSON LABS	5MG	A074370 001	Nov 22, 1994
		10MG	A074370 002	Nov 22, 1994
GLUCOTROL				
+	PFIZER	2.5MG	N017783 003	May 11, 1993
TABLET, EXTENDED RELEASE;ORAL				
GLIPIZIDE				
	MYLAN	2.5MG	A202298 001	May 19, 2015
		5MG	A202298 002	May 19, 2015
		10MG	A202298 003	May 19, 2015
	PAR PHARM	5MG	A076159 002	Sep 20, 2013
		10MG	A076159 001	Sep 20, 2013

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL				
GLIPIZIDE AND METFORMIN HYDROCHLORIDE				
	MYLAN	2.5MG;250MG	A078083 001	Apr 12, 2007
		2.5MG;500MG	A078083 002	Apr 12, 2007
		5MG;500MG	A078083 003	Apr 12, 2007
	SUN PHARM INDS INC	2.5MG;250MG	A077620 001	Jan 11, 2008
		2.5MG;500MG	A077620 002	Jan 11, 2008
		5MG;500MG	A077620 003	Jan 11, 2008
METAGLIP				
+	BRISTOL MYERS SQUIBB	2.5MG;250MG **	N021460 001	Oct 21, 2002
+		2.5MG;500MG **	N021460 002	Oct 21, 2002
+		5MG;500MG **	N021460 003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION				
GLUCAGON				
+	LILLY	EQ 1MG BASE/VIAL **	N012122 001	
+		EQ 10MG BASE/VIAL **	N012122 002	

GLUTETHIMIDE

CAPSULE;ORAL				
DORIDEN				
	SANOFI AVENTIS US	500MG	N009519 008	
TABLET;ORAL				
DORIDEN				
	SANOFI AVENTIS US	250MG	N009519 002	
		500MG	N009519 005	
GLUTETHIMIDE				
	HALSEY	250MG	A089458 001	Oct 10, 1986
		500MG	A089459 001	Oct 10, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLUTETHIMIDE

TABLET;ORAL

GLUTETHIMIDE

	LANNETT	250MG	A083475 001	
		500MG	A085571 001	
	UCB INC	500MG	A085171 001	
	UPSHER SMITH LABS	500MG	A083234 002	
	VITARINE	500MG	A087297 001	
	WATSON LABS	500MG	A084362 001	
		500MG	A085763 001	

GLYBURIDE

TABLET;ORAL

GLYBURIDE

	ACTAVIS ELIZABETH	1.5MG	A075947 001	Nov 14, 2002
		3MG	A075947 002	Nov 14, 2002
		6MG	A075947 003	Nov 14, 2002
	AUROBINDO PHARMA	1.25MG	A077537 001	Oct 18, 2007
		2.5MG	A077537 002	Oct 18, 2007
		5MG	A077537 003	Oct 18, 2007

GLYBURIDE (MICRONIZED)

	MYLAN	1.5MG	A074792 001	Jun 26, 1998
		3MG	A074792 002	Jun 26, 1998
		6MG	A074792 003	Aug 17, 1999
	SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992
		3MG	N020055 002	Apr 17, 1992
		6MG	N020055 003	Mar 08, 2000
	STRIDES PHARMA	1.5MG	A074591 001	Dec 22, 1997
		3MG	A074591 002	Dec 22, 1997
		4.5MG	A074591 003	Dec 22, 1997
		6MG	A074591 004	Dec 22, 1997
	YAOPHARMA CO LTD	1.5MG	A075174 001	Jun 22, 1998
		3MG	A075174 002	Jun 22, 1998

GLYNASE

+	PFIZER	4.5MG **	N020051 003	Sep 24, 1993

MICRONASE

+	PFIZER	1.25MG **	N017498 001	May 01, 1984
		2.5MG	N017498 002	May 01, 1984
+		5MG **	N017498 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLUCOVANCE

+	BRISTOL MYERS SQUIBB	1.25MG;250MG **	N021178 001	Jul 31, 2000
+		2.5MG;500MG **	N021178 002	Jul 31, 2000
+		5MG;500MG **	N021178 003	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

	HERITAGE PHARMS INC	1.25MG;250MG	A079009 001	Jun 03, 2009
		2.5MG;500MG	A079009 002	Jun 03, 2009
		5MG;500MG	A079009 003	Jun 03, 2009
	IMPAX LABS INC	1.25MG;250MG	A076731 001	Nov 19, 2004
		2.5MG;500MG	A076731 002	Nov 19, 2004
		5MG;500MG	A076731 003	Nov 19, 2004
	TEVA	1.25MG;250MG	A076821 001	Jan 27, 2005
		2.5MG;500MG	A076821 002	Jan 27, 2005
		5MG;500MG	A076821 003	Jan 27, 2005

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

	PAR PHARM INC	1.1GM/ML	A205742 001	Dec 02, 2021

GLYCINE

SOLUTION;IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
	HOSPIRA	1.5GM/100ML	N017633 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GLYCOPYRROLATE

INJECTABLE;INJECTION				
GLYCOPYRROLATE				
	ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
	HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
	TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
	WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983
ROBINUL				
+	HIKMA	0.2MG/ML **	N017558 001	
	ROBINS AH	0.2MG/ML	N014764 001	
POWDER;INHALATION				
SEEBRI				
+	NOVARTIS	15.6MCG/INH	N207923 001	Oct 29, 2015
TABLET;ORAL				
GLYCOPYRROLATE				
	HIKMA INTL PHARMS	1MG	A040836 001	Mar 05, 2009
		2MG	A040836 002	Mar 05, 2009
	RENATA	1MG	A040568 001	Dec 22, 2004
		2MG	A040568 002	Dec 22, 2004
	WATSON LABS	1MG	A085562 001	
		1MG	A086902 001	
		2MG	A085563 001	
		2MG	A086178 001	
		2MG	A086900 001	

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER;INHALATION				
UTIBRON				
+	NOVARTIS	15.6MCG/INH;27.5MCG/INH	N207930 001	Oct 29, 2015

GONADORELIN ACETATE

INJECTABLE;INJECTION				
LUTREPULSE KIT				
	FERRING	0.8MG/VIAL	N019687 001	Oct 10, 1989
		3.2MG/VIAL	N019687 002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE;INJECTION				
FACTREL				
	HIKMA	EQ 0.1MG BASE/VIAL	N018123 001	Sep 30, 1982
		EQ 0.2MG BASE/VIAL	N018123 002	Sep 30, 1982
		EQ 0.5MG BASE/VIAL	N018123 003	Sep 30, 1982

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC				
NEO-POLYCIN				
	DOW PHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A060427 001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN				
	IPHARM	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062818 001	Oct 11, 1988
	WATSON LABS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062788 001	Jun 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN				
	PHARMAFAIR	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A062383 001	Aug 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION				
GRANISETRON HYDROCHLORIDE				
	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274 001	Sep 22, 2010
	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008
		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008
	MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454 001	Apr 04, 2017
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454 002	Apr 04, 2017
		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453 001	Jan 31, 2017
	SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008
	TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963 001	Jan 03, 2008
	YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647 001	Mar 06, 2020
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648 001	Jun 29, 2020
		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648 002	Jun 29, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION				
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007
KYTRIL				
+ ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239	003	Sep 17, 2004
+	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239	004	Mar 11, 1994
+	EQ 3MG BASE/ML **	N020239	001	Dec 29, 1993
+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239	002	Mar 11, 1994
SOLUTION;ORAL				
GRANISOL				
INTRA SANA LABS	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008
KYTRIL				
+ ROCHE	EQ 2MG BASE/10ML **	N021238	001	Jun 27, 2001
TABLET;ORAL				
GRANISETRON HYDROCHLORIDE				
BARR	EQ 1MG BASE	A078221	001	Dec 31, 2007
EPIC PHARMA LLC	EQ 1MG BASE	A078260	001	Dec 31, 2007
MYLAN	EQ 1MG BASE	A078725	001	Jan 30, 2008
TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007
KYTRIL				
+ ROCHE	EQ 1MG BASE **	N020305	001	Mar 16, 1995
+	EQ 2MG BASE **	N020305	002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET;ORAL				
RAXAR				
OTSUKA	EQ 200MG BASE	N020695	001	Nov 06, 1997
	EQ 400MG BASE	N020695	002	May 14, 1998
	EQ 600MG BASE	N020695	003	May 14, 1998

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL				
GRISACTIN				
WYETH AYERST	125MG	N050051	002	
	250MG	N050051	001	
SUSPENSION;ORAL				
GRIFULVIN V				
+ JOHNSON AND JOHNSON	125MG/5ML **	N050448	001	
TABLET;ORAL				
GRIFULVIN V				
J AND J	125MG	A060618	001	
	250MG	A060618	002	
	500MG	A060618	003	
VALEANT LUXEMBOURG	125MG	A062279	001	
	250MG **	A062279	002	
GRISACTIN				
WYETH AYERST	500MG	A060212	001	

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	125MG/5ML **	A062483	001	Jan 26, 1984
TABLET;ORAL				
GRIFULVIN V				
VALEANT LUXEMBOURG	500MG	A062279	003	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL				
GRISACTIN ULTRA				
WYETH AYERST	125MG	A062178	001	
	165MG	A062438	001	Nov 17, 1983
	250MG	A062178	002	
	330MG	A062438	002	Nov 17, 1983
ULTRAGRIS-165				
PLIVA	165MG	A062645	001	Jun 30, 1992
ULTRAGRIS-330				
PLIVA	330MG	A062646	001	Jun 30, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL					
FLOWTUSS					
	BKK PHARMS	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015
OBREDON					
+	SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014
TABLET;ORAL					
XTRELUS					
+	ECI PHARMS LLC	400MG;5MG	N208085	001	Apr 25, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL					
HYCOFENIX					
+	BKK PHARMS	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015

GUANABENZ ACETATE

TABLET;ORAL					
GUANABENZ ACETATE					
	ANI PHARMS	EQ 4MG BASE	A074149	001	Apr 07, 1995
		EQ 4MG BASE	A074267	001	Jun 01, 1994
		EQ 8MG BASE	A074149	002	Apr 07, 1995
		EQ 8MG BASE	A074267	002	Jun 01, 1994
	CHARTWELL RX	EQ 4MG BASE	A074517	001	Sep 30, 1998
		EQ 8MG BASE	A074517	002	Sep 30, 1998
	WATSON LABS	EQ 4MG BASE	A074025	001	Feb 28, 1994
		EQ 8MG BASE	A074025	002	Feb 28, 1994
WYTENSIN					
	WYETH AYERST	EQ 4MG BASE	N018587	001	Sep 07, 1982
		EQ 8MG BASE	N018587	002	Sep 07, 1982
		EQ 16MG BASE	N018587	003	Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL					
HYLOREL					
	PHARMACIA AND UPJOHN	10MG	N018104	001	Dec 29, 1982
		25MG	N018104	002	Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL					
GUANETHIDINE MONOSULFATE					
	WATSON LABS	EQ 10MG SULFATE	A086113	001	Mar 26, 1985
		EQ 25MG SULFATE	A086114	001	Mar 26, 1985
ISMELIN					
	NOVARTIS	EQ 10MG SULFATE	N012329	001	
		EQ 25MG SULFATE	N012329	002	

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL					
ESIMIL					
	NOVARTIS	10MG;25MG	N013553	001	

GUANFACINE HYDROCHLORIDE

TABLET;ORAL					
GUANFACINE HYDROCHLORIDE					
	AUROBINDO PHARMA USA	EQ 1MG BASE	A074796	001	Jan 27, 1997
		EQ 2MG BASE	A074796	002	Jan 27, 1997
	WATSON LABS	EQ 1MG BASE	A074762	001	Jun 25, 1997
		EQ 2MG BASE	A074762	002	Jun 25, 1997
TENEX					
+	PROMIUS PHARMA	EQ 1MG BASE **	N019032	001	Oct 27, 1986
+		EQ 2MG BASE **	N019032	002	Nov 07, 1988
		EQ 3MG BASE **	N019032	003	Nov 07, 1988
TABLET, EXTENDED RELEASE;ORAL					
GUANFACINE HYDROCHLORIDE					
	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015
		EQ 2MG BASE	A202238	002	Oct 20, 2015
		EQ 3MG BASE	A202238	003	Oct 20, 2015
		EQ 4MG BASE	A202238	004	Oct 20, 2015
	MYLAN	EQ 1MG BASE	A202578	001	Jun 02, 2015
		EQ 2MG BASE	A202578	002	Jun 02, 2015
		EQ 3MG BASE	A202578	003	Jun 02, 2015
		EQ 4MG BASE	A202578	004	Jun 02, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

GUANFACINE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
GUANFACINE HYDROCHLORIDE				
YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020
	EQ 2MG BASE	A213428	002	Nov 25, 2020
	EQ 3MG BASE	A213428	003	Nov 25, 2020
	EQ 4MG BASE	A213428	004	Nov 25, 2020
GUANIDINE HYDROCHLORIDE				
TABLET;ORAL				
GUANIDINE HYDROCHLORIDE				
MERCK SHARP DOHME	125MG	N001546	001	
HALAZEPAM				
TABLET;ORAL				
PAXIPAM				
SCHERING	20MG	N017736	003	
	40MG	N017736	004	
HALCINONIDE				
CREAM;TOPICAL				
HALOG				
WESTWOOD SQUIBB	0.025%	N017818	001	
HALOG-E				
SUN PHARM INDS INC	0.1%	N018234	001	
OINTMENT;TOPICAL				
HALOG				
BRISTOL MYERS SQUIBB	0.025%	N018125	001	
HALOBETASOL PROPIONATE				
CREAM;TOPICAL				
ULTRAVATE				
+ SUN PHARM INDS INC	0.05% **	N019967	001	Dec 27, 1990
LOTION;TOPICAL				
HALOBETASOL PROPIONATE				
PADAGIS ISRAEL	0.05%	A211464	001	Jun 03, 2020
OINTMENT;TOPICAL				
HALOBETASOL PROPIONATE				
COSETTE	0.05%	A077721	001	Sep 07, 2006
FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004
ULTRAVATE				
+ SUN PHARM INDS INC	0.05%	N019968	001	Dec 17, 1990
HALOFANTRINE HYDROCHLORIDE				
TABLET;ORAL				
HALFAN				
GLAXOSMITHKLINE	250MG	N020250	001	Jul 24, 1992
HALOPERIDOL				
TABLET;ORAL				
HALDOL				
+ ORTHO MCNEIL	0.5MG **	N015921	001	
+	1MG **	N015921	002	
+	2MG **	N015921	003	
+	5MG **	N015921	004	
+	10MG **	N015921	005	
+	20MG **	N015921	006	Feb 02, 1982
HALDOL SOLUTAB				
ORTHO MCNEIL PHARM	1MG	N017079	001	
HALOPERIDOL				
CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987
	1MG	A071129	001	Feb 17, 1987
	20MG	A071133	001	May 12, 1987
DURAMED PHARMS BARR	0.5MG	A071216	001	Dec 04, 1986
	1MG	A071217	001	Dec 04, 1986
	2MG	A071218	001	Dec 04, 1986
	5MG	A071219	001	Dec 04, 1986
	10MG	A071220	001	Jul 07, 1987
	20MG	A071221	001	Jul 07, 1987
LEDERLE	0.5MG	A072727	001	Sep 19, 1989
	1MG	A072728	001	Sep 19, 1989
	2MG	A072729	001	Sep 19, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HALOPERIDOL				
TABLET;ORAL				
HALOPERIDOL				
	5MG	A072730	001	Sep 19, 1989
	10MG	A072731	001	Sep 19, 1989
	20MG	A072732	001	Sep 19, 1989
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SANDOZ	2MG	A071208	001	Nov 17, 1986
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
STRIDES PHARMA	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991
HALOPERIDOL DECANOATE				
INJECTABLE;INJECTION				
HALOPERIDOL DECANOATE				
HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005
HALOPERIDOL LACTATE				
CONCENTRATE;ORAL				
HALDOL				
+ ORTHO MCNEIL	EQ 2MG BASE/ML **	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987
TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988
HALOPERIDOL INTENSOL				
HIKMA	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HALOPERIDOL LACTATE				
INJECTABLE;INJECTION				
HALDOL				
+ JANSSEN PHARMS	EQ 5MG BASE/ML	N015923 001		
HALOPERIDOL				
ABRAXIS PHARM	EQ 5MG BASE/ML	A071187 001	Jan 20, 1987	
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004	
	EQ 5MG BASE/ML	A076828 001	Aug 25, 2004	
FOSUN PHARMA	EQ 5MG BASE/ML	A076464 001	Sep 29, 2004	
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516 001	Feb 25, 1993	
	EQ 5MG BASE/ML	A072517 001	Feb 25, 1993	
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802 001	Dec 14, 1987	
SOLOPAK	EQ 5MG BASE/ML	A070800 001	Dec 14, 1987	
	EQ 5MG BASE/ML	A070801 001	Dec 14, 1987	
	EQ 5MG BASE/ML	A070864 001	Dec 14, 1987	
TEVA PHARMS USA	EQ 5MG BASE/ML	A076035 001	Aug 29, 2001	
WATSON LABS	EQ 5MG BASE/ML	A070713 001	May 17, 1988	
	EQ 5MG BASE/ML	A070714 001	May 17, 1988	
	EQ 5MG BASE/ML	A070744 001	May 17, 1988	
SOLUTION;ORAL				
HALOPERIDOL LACTATE				
ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536 001	Nov 02, 1995	
HALOPROGIN				
CREAM;TOPICAL				
HALOTEX				
WESTWOOD SQUIBB	1%	N016942 001		
SOLUTION;TOPICAL				
HALOTEX				
WESTWOOD SQUIBB	1%	N016943 001		
HALOTHANE				
LIQUID;INHALATION				
FLUOTHANE				
WYETH AYERST	99.99%	N011338 001		
HALOTHANE				
BH	99.99%	A084977 001		
HALOCARBON	99.99%	A080810 001		
HOSPIRA	99.99%	A083254 001		
HEPARIN CALCIUM				
INJECTABLE;INJECTION				
CALCIPARINE				
SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001		
HEPARIN SODIUM				
INJECTABLE;INJECTION				
HEPARIN LOCK FLUSH				
HOSPIRA	100 UNITS/ML	N005264 010		
INTL MEDICATION	10 UNITS/ML	A086357 001		
	500 UNITS/ML	A086357 002		
LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985	
	100 UNITS/ML	A089064 001	Oct 09, 1985	
PARKE DAVIS	10 UNITS/ML	N017346 006		
SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983	
	10 UNITS/ML	A087958 001	Apr 20, 1983	
	10 UNITS/ML	A088458 001	Jul 26, 1984	
	10 UNITS/ML	A088580 001	Oct 25, 1984	
	100 UNITS/ML	A087906 001	Apr 20, 1983	
	100 UNITS/ML	A087959 001	Apr 20, 1983	
	100 UNITS/ML	A088460 001	Jul 26, 1984	
	100 UNITS/ML	A088581 001	Oct 25, 1984	
SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983	
	10 UNITS/ML	A088457 001	Oct 25, 1984	
	100 UNITS/ML	A087905 001	Apr 20, 1983	
	100 UNITS/ML	A088459 001	Jul 26, 1984	
HEPARIN SODIUM				
ABRAXIS PHARM	1,000 UNITS/ML	N017033 001		
	1,000 UNITS/ML	N017979 001		
	5,000 UNITS/ML	N017979 003		
	10,000 UNITS/ML	N017979 002		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

	AKORN	1,000 UNITS/ML	N017486	001	
		5,000 UNITS/ML	N017486	002	
		10,000 UNITS/ML	N017486	003	
		20,000 UNITS/ML	N017486	004	
		40,000 UNITS/ML	N017486	005	
	CASI PHARMS INC	5,000 UNITS/ML	A091659	001	Jun 08, 2011
	CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
		5,000 UNITS/ML	N017130	002	
		10,000 UNITS/ML	N017130	003	
		20,000 UNITS/ML	N017130	004	
	DELL LABS	1,000 UNITS/ML	N017540	001	
		5,000 UNITS/ML	N017540	002	
		10,000 UNITS/ML	N017540	003	
		20,000 UNITS/ML	N017540	004	
		40,000 UNITS/ML	N017540	005	
	DR REDDYS	1,000 UNITS/ML	A040007	001	Jun 07, 1996
		1,000 UNITS/ML	N017064	002	
		2,500 UNITS/ML	N017064	015	
		3,000 UNITS/ML	N017064	016	
		4,000 UNITS/ML	N017064	017	
		5,000 UNITS/ML	N017064	003	
		6,000 UNITS/ML	N017064	018	
		7,500 UNITS/ML	N017064	019	
		10,000 UNITS/ML	N017064	004	
		20,000 UNITS/ML	N017064	005	
		40,000 UNITS/ML	N017064	006	
	FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
		5,000 UNITS/ML	N017029	002	
		10,000 UNITS/ML	N017651	003	
		20,000 UNITS/ML	N017651	008	
	HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
	HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
		10,000 UNITS/ML	A040095	001	Jul 26, 1996
	LILLY	1,000 UNITS/ML	N005521	001	
		10,000 UNITS/ML	N005521	002	
		20,000 UNITS/ML	N005521	004	
	LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020
	ORGANON USA INC	1,000 UNITS/ML	N000552	008	
		5,000 UNITS/ML	N000552	009	
		10,000 UNITS/ML	N000552	010	
	PARKE DAVIS	1,000 UNITS/ML	N017346	001	
		5,000 UNITS/ML	N017346	002	
		7,500 UNITS/ML	N017346	003	
		10,000 UNITS/ML	N017346	004	
		20,000 UNITS/ML	N017346	005	
+	PFIZER	10,000 UNITS/ML	N201370	003	Jul 21, 2011
	PHARM SPEC	1,000 UNITS/ML	N017780	001	
		5,000 UNITS/ML	N017780	002	
		10,000 UNITS/ML	N017780	003	
		20,000 UNITS/ML	N017780	004	
		40,000 UNITS/ML	N017780	005	
	PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
		5,000 UNITS/ML	N004570	002	
		10,000 UNITS/ML	N004570	003	
	SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
	SOLOPAK	1,000 UNITS/ML	A087043	001	
		5,000 UNITS/ML	A087077	001	
		5,000 UNITS/0.5ML	A087395	001	
		10,000 UNITS/ML	A087107	001	
		10,000 UNITS/0.5ML	A087363	001	
	WATSON LABS INC	1,000 UNITS/ML	A040008	001	Oct 10, 1995
+	WEST-WARD PHARMS INT	1,000 UNITS/ML **	N017007	001	
+		2,500 UNITS/ML **	N017007	007	
+		5,000 UNITS/ML **	N017007	002	
+		5,000 UNITS/0.5ML **	N017007	010	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM				
+	7,500 UNITS/ML **	N017007	003	
+	10,000 UNITS/ML **	N017007	004	
+	15,000 UNITS/ML **	N017007	005	
+	20,000 UNITS/ML **	N017007	006	
HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5%				
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%				
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%				
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
DR REDDYS	1,000 UNITS/ML	A089464	001	Jun 03, 1986
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEPARIN SODIUM				
INJECTABLE;INJECTION				
LIPO-HEPIN				
	3M	1,000 UNITS/0.5ML	N017027 001	
		1,000 UNITS/ML	N017027 006	
		5,000 UNITS/0.5ML	N017027 002	
		5,000 UNITS/ML	N017027 008	
		7,500 UNITS/0.5ML	N017027 010	
		10,000 UNITS/0.5ML	N017027 003	
		10,000 UNITS/ML	N017027 009	
		15,000 UNITS/0.5ML	N017027 011	
		20,000 UNITS/0.5ML	N017027 004	
		20,000 UNITS/ML	N017027 007	
		40,000 UNITS/ML	N017027 005	
LIQUAEMIN LOCK FLUSH				
	ORGANON USA INC	100 UNITS/ML	N000552 007	
LIQUAEMIN SODIUM				
	ORGANON USA INC	1,000 UNITS/ML	N000552 004	
		5,000 UNITS/ML	N000552 003	
		10,000 UNITS/ML	N000552 005	
		20,000 UNITS/ML	N000552 001	
		40,000 UNITS/ML	N000552 002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
	ORGANON USA INC	1,000 UNITS/ML	N000552 011	Apr 11, 1986
		5,000 UNITS/ML	N000552 012	Apr 11, 1986
		10,000 UNITS/ML	N000552 013	Apr 11, 1986
PANHEPRIN				
	HOSPIRA	1,000 UNITS/ML	N005264 004	
		5,000 UNITS/ML	N005264 006	
		10,000 UNITS/ML	N005264 007	
		20,000 UNITS/ML	N005264 008	
		40,000 UNITS/ML	N005264 009	
SODIUM HEPARIN				
	ABRAXIS PHARM	5,000 UNITS/ML	N017033 002	
		10,000 UNITS/ML	N017033 003	
		20,000 UNITS/ML	N017033 004	
	BAXTER HLTHCARE	1,000 UNITS/ML	N017036 001	Mar 04, 1988
HETACILLIN				
FOR SUSPENSION;ORAL				
VERSAPEN				
	BRISTOL	EQ 112.5MG AMPICIL/ML	A061398 001	
		EQ 112.5MG AMPICIL/5ML	N050060 001	
		EQ 112.5MG AMPICIL/ML	N050060 003	
		EQ 225MG AMPICIL/5ML	A061398 002	
HETACILLIN POTASSIUM				
CAPSULE;ORAL				
VERSAPEN-K				
	BRISTOL	EQ 225MG AMPICIL	A061396 001	
		EQ 450MG AMPICIL	A061396 002	
HEXACHLOROPHENE				
AEROSOL;TOPICAL				
SEPTISOL				
	VESTAL LABS	0.23%	N017424 001	
TURGEX				
	XTTRIUM	3%	N018375 001	
EMULSION;TOPICAL				
HEXA-GERM				
	HUNTINGTON LABS	3%	N017411 001	
PHISOHEX				
	SANOFI AVENTIS US	3%	N006882 001	
		3%	N008402 001	
SOY-DOME				
	BAYER PHARMS	3%	N017405 001	
TURGEX				
	XTTRIUM	3%	N019055 001	Nov 30, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HEXACHLOROPHENE				
SOAP;TOPICAL				
GAMOPHEN				
	ARBROOK	2%	N006270 003	
SOLUTION;TOPICAL				
DIAL				
	DIAL	0.25%	N017421 002	
GERMA-MEDICA				
	HUNTINGTON LABS	1%	N017412 001	
GERMA-MEDICA "MG"				
	HUNTINGTON LABS	0.25%	N017412 002	
SEPTI-SOFT				
	CALGON	0.25%	N017460 001	
SEPTISOL				
	VESTAL LABS	0.25%	N017423 001	
SPONGE;TOPICAL				
E-Z SCRUB				
	BECTON DICKINSON	450MG	N017452 001	
HEXASCRUB				
	PROF DSPLS	3%	N018363 001	
PHISO-SCRUB				
	SANOFI AVENTIS US	3%	N017446 001	
SCRUBTEAM SURGICAL SPONGEBRUSH				
	3M	330MG	N017413 001	
HEXAFLUORENIUM BROMIDE				
INJECTABLE;INJECTION				
MYLAXEN				
	MEDPOINTE PHARM HLC	20MG/ML	N009789 003	
HEXOCYCLIUM METHYLSULFATE				
TABLET;ORAL				
TRAL				
	ABBVIE	25MG	N010599 001	
HEXYLCAINE HYDROCHLORIDE				
SOLUTION;TOPICAL				
CYCLAINE				
	MERCK	5%	N008472 001	
HISTAMINE PHOSPHATE				
INJECTABLE;INJECTION				
HISTAMINE PHOSPHATE				
	LILLY	EQ 0.1MG BASE/ML	N000734 003	
		EQ 0.2MG BASE/ML	N000734 002	
		EQ 1MG BASE/ML	N000734 001	
HISTRELIN ACETATE				
IMPLANT;SUBCUTANEOUS				
VANTAS				
+	ENDO PHARM	50MG	N021732 001	Oct 12, 2004
INJECTABLE;INJECTION				
SUPPRELIN				
	SHIRE	EQ 0.2MG BASE/ML	N019836 001	Dec 24, 1991
		EQ 0.5MG BASE/ML	N019836 002	Dec 24, 1991
		EQ 1MG BASE/ML	N019836 003	Dec 24, 1991
HOMATROPINE METHYLBROMIDE				
TABLET;ORAL				
HOMAPIN-10				
	MISSION PHARMA	10MG	A086308 001	
HOMAPIN-5				
	MISSION PHARMA	5MG	A086309 001	
TABLET, CHEWABLE;ORAL				
EQUIPIN				
	MISSION PHARMA	3MG	A086310 001	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL					
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
	IVAX SUB TEVA PHARMS	1.5MG/5ML;5MG/5ML	A040285	001	Jul 19, 1999
	NOSTRUM LABS INC	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019
	TORRENT	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017
HYDROPANE					
	HALSEY	1.5MG/5ML;5MG/5ML	A088066	001	Jun 28, 1985
TABLET;ORAL					
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE					
	ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000
TUSSIGON					
	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION					
APRESOLINE					
+	NOVARTIS	20MG/ML **	N008303	003	
HYDRALAZINE HYDROCHLORIDE					
	ABRAXIS PHARM	20MG/ML	A089532	001	Aug 11, 1987
	SMITH AND NEPHEW	20MG/ML	A088518	001	Apr 20, 1984
	SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
	TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000
TABLET;ORAL					
APRESOLINE					
+	NOVARTIS	10MG **	N008303	004	
+		25MG **	N008303	001	
+		50MG **	N008303	002	
+		100MG **	N008303	005	
DRALZINE					
	TEVA	25MG	A084301	001	
HYDRALAZINE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
		50MG	A088649	001	Oct 18, 1984
	ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013
		25MG	A091679	002	Mar 04, 2013
		50MG	A091679	003	Mar 04, 2013
		100MG	A091679	004	Mar 04, 2013
	ANDA REPOSITORY	10MG	A089359	001	Jul 25, 1986
		25MG	A089258	001	May 05, 1986
		50MG	A089259	001	May 05, 1986
		100MG	A088729	001	Apr 11, 1985
	ASCOT	25MG	A088310	001	Dec 19, 1984
		50MG	A088311	001	Dec 19, 1984
	CHARTWELL RX	10MG	A088846	001	Feb 26, 1985
		25MG	A088847	001	Feb 26, 1985
		50MG	A088848	001	Feb 26, 1985
		100MG	A088849	001	Feb 26, 1985
	HALSEY	10MG	A089218	001	Jan 22, 1986
		25MG	A089130	001	Jan 15, 1986
		50MG	A089222	001	Jan 22, 1986
		100MG	A089178	001	Jan 15, 1986
	HERITAGE PHARMS INC	10MG	A040858	001	Feb 26, 2010
		25MG	A040858	002	Feb 26, 2010
		50MG	A040858	003	Feb 26, 2010
		100MG	A040858	004	Feb 26, 2010
	IMPAX LABS	25MG	A084922	001	
		50MG	A084923	001	
	IVAX SUB TEVA PHARMS	10MG	A084443	001	
		25MG	A084437	001	
		50MG	A084469	002	
		100MG	A084581	001	
	MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
		25MG	A084106	002	
		50MG	A084107	002	
	MYLAN	10MG	A090413	001	Dec 08, 2010
		25MG	A090413	002	Dec 08, 2010
		50MG	A090413	003	Dec 08, 2010
		100MG	A090413	004	Dec 08, 2010
	PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
UPSHER SMITH LABS	10MG	A083241	001	
	10MG	A209251	001	Jul 09, 2018
	25MG	A083560	001	
	25MG	A209251	002	Jul 09, 2018
	50MG	A083561	001	
	50MG	A085088	001	
	50MG	A209251	003	Jul 09, 2018
	100MG	A209251	004	Jul 09, 2018
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

APRESAZIDE

+	NOVARTIS	25MG;25MG	A084735	001	
+		50MG;50MG	A084810	001	
		100MG;50MG	A084811	001	

HYDRA-ZIDE

STRIDES PHARMA	100MG;50MG	A088961	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG;25MG	A087608	001	Feb 08, 1982
	50MG;50MG	A087213	001	Feb 08, 1982
	100MG;50MG	A087609	001	Feb 08, 1982
SUPERPHARM	25MG;25MG	A089200	001	Feb 09, 1987
	50MG;50MG	A089201	001	Feb 09, 1987
WATSON LABS	25MG;25MG	A085457	001	Mar 04, 1982
	50MG;50MG	A085446	001	Mar 04, 1982
	100MG;50MG	A085440	001	Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG;50MG	A088358	001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG;25MG	A088356	001	Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG;50MG	A088357	001	Apr 10, 1984

TABLET;ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG;15MG	N012026	002	

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG;15MG	A085827	001	

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG;15MG	A085373	001	

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CAM-AP-ES

CHARTWELL RX	25MG;15MG;0.1MG	A084897	001	

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A084291	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL				
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE				
	MYLAN	25MG;15MG;0.1MG	A087085 001	
HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE				
	WATSON LABS	25MG;15MG;0.1MG	A085771 001	
HYDRAP-ES				
	SANDOZ	25MG;15MG;0.1MG	A084876 001	
HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE				
	WATSON LABS	25MG;15MG;0.1MG	A083770 001	
HYDROSERPINE PLUS (R-H-H)				
	IVAX SUB TEVA PHARMS	25MG;15MG;0.1MG	A083877 001	
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
	SOLVAY	25MG;15MG;0.1MG	A088376 001	Oct 28, 1983
	SUN PHARM INDUSTRIES	25MG;15MG;0.1MG	A088570 001	Apr 10, 1984
	WATSON LABS	25MG;15MG;0.1MG	A085549 001	
		25MG;15MG;0.1MG	A087556 001	
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE				
	LEDERLE	25MG;15MG;0.1MG	A087709 001	May 13, 1982
SER-A-GEN				
	SOLVAY	25MG;15MG;0.1MG	A087210 001	
SER-AP-ES				
	NOVARTIS	25MG;15MG;0.1MG	N012193 005	
UNIPRES				
	SOLVAY	25MG;15MG;0.1MG	A085893 001	
		25MG;15MG;0.1MG	A086298 001	

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET;ORAL				
DRALSERP				
	SANDOZ	25MG;0.1MG	A084617 001	
SERPASIL-APRESOLINE				
	NOVARTIS	25MG;0.1MG	N009296 004	
		50MG;0.2MG	N009296 002	

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL				
HYDROCHLOROTHIAZIDE				
	ALEMBIC PHARMS LTD	12.5MG	A200645 001	Nov 30, 2010
	APOTEX	12.5MG	A078389 001	May 16, 2008
	HIKMA INTL PHARMS	12.5MG	A077885 001	Nov 26, 2007
	IVAX SUB TEVA PHARMS	12.5MG	A077005 001	Jul 13, 2005
	LANNETT CO INC	12.5MG	A091662 001	Jan 27, 2012
SOLUTION;ORAL				
HYDROCHLOROTHIAZIDE				
	MORTON GROVE	50MG/5ML	A089661 001	Jun 20, 1988
+	ROXANE	50MG/5ML	A088587 001	Jul 02, 1984
HYDROCHLOROTHIAZIDE INTENSOL				
	ROXANE	100MG/ML	A088588 001	Jul 02, 1984
TABLET;ORAL				
ESIDRIX				
	NOVARTIS	25MG	N011793 005	
		50MG	N011793 008	
		100MG	N011793 009	
HYDRO-D				
	HALSEY	25MG	A086504 001	
		50MG	A083891 002	
HYDROCHLOROTHIAZIDE				
	ABC HOLDING	50MG	A085672 001	
	ACTAVIS ELIZABETH	25MG	A085054 002	
		50MG	A085208 001	
	ALRA	25MG	A086369 001	
		50MG	A083554 001	
	APOTEX	25MG	A040774 001	Oct 03, 2007
		50MG	A040774 002	Oct 03, 2007
	ASCOT	25MG	A087539 001	Feb 03, 1982
		50MG	A087540 001	Feb 03, 1982
	AUROLIFE PHARMA LLC	25MG	A083899 001	
		50MG	A085219 001	
	BARR	50MG	A084771 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

	CHARTWELL RX	25MG	A085683	001	
		50MG	A083965	001	
	DAVA PHARMS INC	100MG	A087060	001	
	ELKINS SINN	50MG	A085152	002	
	HEATHER	50MG	A084135	001	
	HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
		50MG	A084878	001	
	IMPAX LABS	25MG	A084029	001	
		50MG	A083607	002	
		100MG	A085098	001	
	INWOOD LABS	25MG	A084776	001	
		25MG	A085067	001	
		50MG	A084776	002	
	IVAX SUB TEVA PHARMS	50MG	A084658	001	
+		100MG	A085022	001	
	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
		50MG	A040809	002	Sep 04, 2007
	LANNETT CO INC	25MG	A084325	001	
		50MG	A084324	001	
	MAST MM	25MG	A086192	001	
		50MG	A086192	002	
	MYLAN	25MG	A084880	001	
		50MG	A085112	001	
	MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
		25MG	A040735	002	Jan 23, 2007
		50MG	A040735	003	Jan 23, 2007
	PVT FORM	50MG	A086597	001	
	ROXANE	25MG	A085004	001	
		50MG	A084536	002	
		50MG	A085005	001	
	SOLVAY	25MG	A085323	001	
	SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008
		25MG	A040810	001	Mar 27, 2007
		50MG	A040810	002	Mar 27, 2007
	SUN PHARM INDUSTRIES	25MG	A083972	001	
		50MG	A083972	002	
		100MG	A083972	003	
	SUPERPHARM	25MG	A088827	001	Dec 28, 1984
		50MG	A088828	001	Dec 28, 1984
		100MG	A088829	001	Dec 28, 1984
	TEVA	25MG	A088924	001	Feb 07, 1985
		50MG	A088923	001	Feb 07, 1985
	USL PHARMA	25MG	A087827	001	Apr 19, 1982
		50MG	A087752	001	Apr 19, 1982
	VANGARD	25MG	A087638	001	
		50MG	A087610	001	
	WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
		50MG	A087587	001	May 03, 1982
	WATSON LABS	25MG	A081189	001	Jan 24, 1992
		25MG	A083458	001	
		25MG	A085232	002	
		50MG	A083456	001	
		50MG	A085233	001	
		50MG	A086087	001	
		50MG	A086594	001	
		100MG	A081190	001	Jan 24, 1992
		100MG	A085099	001	
		100MG	A087002	001	
	WATSON LABS TEVA	50MG	A083232	001	
	WEST WARD	25MG	A084899	001	
	WHITEWORTH TOWN PLSN	25MG	A083809	002	
		50MG	A083809	001	
		100MG	A085347	001	
	YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982
		50MG	A084912	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDRODIURIL

+	MERCK	25MG **	N011835	003	
+		50MG **	N011835	006	
+		100MG **	N011835	007	

ORETIC

	ABBVIE	25MG	N011971	001	
		50MG	N011971	002	

ZIDE

	SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

AVALIDE

+	SANOFI AVENTIS US	12.5MG;75MG **	N020758	001	Sep 30, 1997
+		25MG;300MG **	N020758	004	Mar 15, 2005

IRBESARTAN AND HYDROCHLOROTHIAZIDE

	APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012
		12.5MG;300MG	A201505	002	Oct 15, 2012
	ATLAS PHARMS LLC	12.5MG;150MG	A203036	001	Jan 15, 2016
		12.5MG;300MG	A203036	002	Jan 15, 2016
		25MG;300MG	A203036	003	Jan 15, 2016
	MYLAN PHARMS INC	12.5MG;150MG	A077969	001	Sep 27, 2012
		12.5MG;300MG	A077969	002	Sep 27, 2012
		25MG;300MG	A077969	003	Jul 20, 2016
	TEVA	25MG;300MG	A077369	003	Mar 30, 2012
	WATSON LABS INC	12.5MG;150MG	A091539	001	Oct 22, 2012
		12.5MG;300MG	A091539	002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET;ORAL

NORMOZIDE

	SCHERING	25MG;100MG	N019046	001	Apr 06, 1987
		25MG;200MG	N019046	002	Apr 06, 1987
		25MG;300MG	N019046	003	Apr 06, 1987
		25MG;400MG	N019046	004	Apr 06, 1987

TRANDATE HCT

	GLAXOSMITHKLINE	25MG;100MG	N019174	001	Apr 10, 1987
		25MG;200MG	N019174	002	Apr 10, 1987
		25MG;300MG	N019174	003	Apr 10, 1987
		25MG;400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

	COREPHARMA	12.5MG;10MG	A076674	001	Oct 05, 2004
		12.5MG;20MG	A076674	002	Oct 05, 2004
		25MG;20MG	A076674	003	Oct 05, 2004
	HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002
		12.5MG;20MG	A075776	002	Jul 01, 2002
		25MG;20MG	A075776	003	Jul 01, 2002
	HIKMA INTL PHARMS	12.5MG;10MG	A076265	001	Jul 08, 2002
		12.5MG;20MG	A076265	002	Jul 08, 2002
		25MG;20MG	A076265	003	Jul 08, 2002
	MYLAN	12.5MG;10MG	A076113	001	Jul 01, 2002
		12.5MG;20MG	A076113	002	Jul 01, 2002
		25MG;20MG	A076113	003	Jul 01, 2002
	SANDOZ	12.5MG;10MG	A075926	001	Jul 01, 2002
		12.5MG;20MG	A075926	002	Jul 01, 2002
		25MG;20MG	A075926	003	Jul 01, 2002
	TEVA	12.5MG;10MG	A075869	001	Jul 01, 2002
		12.5MG;20MG	A075869	002	Jul 01, 2002
		25MG;20MG	A075869	003	Jul 01, 2002

PRINZIDE

+	MERCK	12.5MG;10MG **	N019778	003	Nov 18, 1993
+		12.5MG;20MG **	N019778	001	Feb 16, 1989
+		25MG;20MG **	N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010
	12.5MG;100MG	A090150	002	Aug 11, 2010
	25MG;100MG	A090150	003	Oct 06, 2010
HIKMA	12.5MG;50MG	A077732	002	Oct 06, 2010
	12.5MG;100MG	A077732	001	Apr 06, 2010
	25MG;100MG	A077732	003	Oct 06, 2010
MYLAN	12.5MG;50MG	A091652	001	Oct 06, 2010
	12.5MG;100MG	A091652	002	Apr 06, 2010
	25MG;100MG	A091652	003	Oct 06, 2010
TORRENT PHARMS	12.5MG;50MG	A090528	001	Oct 06, 2010
	12.5MG;100MG	A090528	003	Apr 06, 2010
	25MG;100MG	A090528	002	Oct 06, 2010
WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011
	12.5MG;100MG	A200180	002	Jan 12, 2011
	25MG;100MG	A200180	003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

ALDORIL 15

MERCK	15MG;250MG	N013402	001	

ALDORIL 25

MERCK	25MG;250MG	N013402	002	

ALDORIL D30

MERCK	30MG;500MG	N013402	003	

ALDORIL D50

MERCK	50MG;500MG	N013402	004	

METHYLDOPA AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	15MG;250MG	A070182	001	Jan 15, 1986
	25MG;250MG	A070183	001	Jan 15, 1986
	30MG;500MG	A070543	001	Jan 15, 1986
	50MG;500MG	A070544	001	Jan 15, 1986
DAVA PHARMS INC	15MG;250MG	A072507	001	Jun 02, 1989
	25MG;250MG	A072508	001	Jun 02, 1989
	30MG;500MG	A072509	001	Jun 02, 1989
	50MG;500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG;250MG	A071458	001	Mar 08, 1988
	25MG;250MG	A071459	001	Mar 08, 1988
	30MG;500MG	A071460	001	Mar 08, 1988
	50MG;500MG	A071461	001	Mar 08, 1988
PARKE DAVIS	15MG;250MG	A071897	001	Nov 23, 1987
	25MG;250MG	A071898	001	Nov 23, 1987
	30MG;500MG	A071899	001	Nov 23, 1987
	50MG;500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG;250MG	A070853	001	Oct 08, 1986
	25MG;250MG	A070688	001	Apr 24, 1986
	30MG;500MG	A070854	001	Oct 08, 1986
	50MG;500MG	A070689	001	Apr 24, 1986
RISING	15MG;250MG	A070265	002	Jan 23, 1986
	25MG;250MG	A070265	001	Jan 23, 1986
SANDOZ	15MG;250MG	A070829	001	Mar 09, 1987
	25MG;250MG	A070830	001	Mar 09, 1987
STRIDES PHARMA	15MG;250MG	A070616	001	Feb 02, 1987
	25MG;250MG	A070612	001	Feb 02, 1987
	30MG;500MG	A070613	001	Feb 02, 1987
	50MG;500MG	A070614	001	Feb 02, 1987
TEVA	15MG;250MG	A071819	001	Apr 08, 1988
	25MG;250MG	A071820	001	Apr 08, 1988
	30MG;500MG	A071821	001	Apr 08, 1988
	50MG;500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG;250MG	A070365	001	Mar 19, 1986
	15MG;250MG	A070958	001	Feb 06, 1989
	15MG;250MG	A071920	001	Aug 29, 1988
	25MG;250MG	A070366	001	Apr 16, 1986
	25MG;250MG	A070959	001	Jan 19, 1989
	25MG;250MG	A071921	001	Aug 29, 1988
	30MG;500MG	A070367	001	Mar 19, 1986
	30MG;500MG	A071069	001	Jan 19, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	30MG;500MG	A071922	001	Aug 29, 1988
	50MG;500MG	A070368	001	Apr 16, 1986
	50MG;500MG	A070960	001	Feb 06, 1989
	50MG;500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

+	CONCORDIA	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
+		12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

LOPRESSOR HCT

+	VALIDUS PHARMS	25MG;100MG	N018303	002	Dec 31, 1984
+		50MG;100MG **	N018303	003	Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	CHARTWELL RX	12.5MG;7.5MG	A090096	001	Sep 25, 2008
		12.5MG;15MG	A090096	002	Sep 25, 2008
		25MG;15MG	A090096	003	Sep 25, 2008
	HERITAGE PHARMS INC	12.5MG;7.5MG	A202150	001	Mar 07, 2014
		12.5MG;15MG	A202150	002	Mar 07, 2014
		25MG;15MG	A202150	003	Mar 07, 2014

UNIRETIC

	UCB INC	12.5MG;7.5MG **	N020729	001	Jun 27, 1997
		12.5MG;15MG **	N020729	003	Feb 14, 2002
		25MG;15MG **	N020729	002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

	MYLAN	12.5MG;20MG	A078827	001	Oct 26, 2016
		12.5MG;40MG	A078827	002	Oct 26, 2016
		25MG;40MG	A078827	003	Oct 26, 2016
	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017
		25MG;40MG	A200532	003	Apr 24, 2017

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET;ORAL

VISKAZIDE

	NOVARTIS	25MG;5MG	N018872	001	Jul 22, 1987
		25MG;10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERIDE LA 120/50

	WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985

INDERIDE LA 160/50

	WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985

INDERIDE LA 80/50

	WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985

TABLET;ORAL

INDERIDE-40/25

+	WYETH PHARMS INC	25MG;40MG **	N018031	001	

INDERIDE-80/25

+	WYETH PHARMS INC	25MG;80MG **	N018031	002	

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

	DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987
		25MG;80MG	A071127	001	Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986
		25MG;80MG	A070852	001	May 15, 1986
	ANI PHARMS	25MG;40MG	A070705	002	Oct 01, 1986
		25MG;40MG	A072043	002	Mar 14, 1988
		25MG;80MG	A070705	001	Oct 01, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	25MG;80MG	A072043	001	Mar 14, 1988
IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988
	25MG;80MG	A071553	001	Dec 01, 1988
MYLAN	25MG;40MG	A070947	002	Mar 04, 1987
	25MG;80MG	A070947	001	Apr 01, 1987
WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
	25MG;80MG	A071772	001	Jan 26, 1988
WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986
	25MG;40MG	A071498	001	Dec 18, 1991
	25MG;80MG	A070305	001	Apr 18, 1986
	25MG;80MG	A071501	001	Dec 18, 1991
YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987
	25MG;80MG	A071061	001	Aug 26, 1987

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005
	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005
	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005
SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009
	12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009
	25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

H.R.-50

WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338	001	

HYDRO-RESERP

ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982

HYDRO-SERP "25"

SANDOZ	25MG;0.125MG	A084827	001	

HYDRO-SERP "50"

SANDOZ	50MG;0.125MG	A085213	001	

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572	001	
	25MG;0.125MG	A083571	001	
	50MG;0.1MG	A083568	001	
	50MG;0.125MG	A083573	001	
PHARMERAL	25MG;0.125MG	A085421	001	
	50MG;0.125MG	A085420	001	
ROXANE	50MG;0.125MG	A084603	001	
WATSON LABS	25MG;0.125MG	A084466	001	
	25MG;0.125MG	A085317	001	
	25MG;0.125MG	A086330	002	
	50MG;0.125MG	A083666	001	
	50MG;0.125MG	A084467	001	
	50MG;0.125MG	A086331	001	

HYDROPRES 25

MERCK	25MG;0.125MG	N011958	002	

HYDROPRES 50

MERCK	50MG;0.125MG	N011958	003	

RESERPINE AND HYDROCHLOROTHIAZIDE

BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984

RESERPINE AND HYDROCHLOROTHIAZIDE-50

WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984

SERPASIL-ESIDRIX #1

NOVARTIS	25MG;0.1MG	N011878	003	

SERPASIL-ESIDRIX #2

NOVARTIS	50MG;0.1MG	N011878	005	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG;25MG	A088025	001	Nov 23, 1984
CHARTWELL RX	25MG;25MG	A086881	001	
MUTUAL PHARM	25MG;25MG	A087267	001	
PUREPAC PHARM	25MG;25MG	A087999	001	Nov 06, 1985
SUPERPHARM	25MG;25MG	A089137	001	Aug 26, 1985
WATSON LABS	25MG;25MG	A087398	001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG;25MG	A087004	002	May 24, 1982
LEDERLE	25MG;25MG	A087511	001	
PARKE DAVIS	25MG;25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG;25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG;25MG	A087553	001	
USL PHARMA	25MG;25MG	A087651	001	
VANGARD	25MG;25MG	A087655	001	
WATSON LABS	25MG;25MG	A085974	001	
	25MG;25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

MACLEODS PHARMS LTD	12.5MG;40MG	A204169	001	Nov 02, 2015
	12.5MG;80MG	A204169	002	Nov 02, 2015
	25MG;80MG	A204169	003	Nov 02, 2015
MYLAN	12.5MG;40MG	A091648	001	Feb 25, 2014
	12.5MG;80MG	A091648	002	Feb 25, 2014
	25MG;80MG	A091648	003	Feb 25, 2014
TORRENT	12.5MG;40MG	A201192	001	Feb 25, 2014
	12.5MG;80MG	A201192	002	Feb 25, 2014
	25MG;80MG	A201192	003	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET;ORAL

TIMOLIDE 10-25

MERCK	25MG;10MG	N018061	001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

DYAZIDE

+	GLAXOSMITHKLINE LLC	25MG;37.5MG	N016042	003	Mar 03, 1994
		25MG;50MG	N016042	002	

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS	25MG;37.5MG	A074970	001	Jan 06, 1998
	25MG;50MG	A074259	001	Mar 30, 1995
CHARTWELL RX	25MG;50MG	A073191	001	Jul 31, 1991
DURAMED PHARMS BARR	25MG;37.5MG	A075052	001	Jun 18, 1999
NOVARTIS	25MG;37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG;50MG	A071737	001	Feb 12, 1988

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG;75MG	A072022	001	Apr 17, 1988
ANI PHARMS	50MG;75MG	A073467	001	Jan 31, 1996
PLIVA	25MG;37.5MG	A074026	001	Apr 26, 1996
QUANTUM PHARMICS	50MG;75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG;75MG	A071969	001	Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013
	12.5MG;160MG	A203026	002	Mar 21, 2013
	12.5MG;320MG	A203026	003	Mar 21, 2013
	25MG;160MG	A203026	004	Mar 21, 2013
	25MG;320MG	A203026	005	Mar 21, 2013
CADILA	12.5MG;80MG	A203000	001	Mar 15, 2019
	12.5MG;160MG	A203000	002	Mar 15, 2019
	12.5MG;320MG	A203000	003	Mar 15, 2019
	25MG;160MG	A203000	004	Mar 15, 2019
	25MG;320MG	A203000	005	Mar 15, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

WATSON LABS TEVA	12.5MG;80MG	A091519	001	Mar 21, 2013
	12.5MG;160MG	A091519	002	Mar 21, 2013
	12.5MG;320MG	A091519	003	Mar 21, 2013
	25MG;160MG	A091519	004	Mar 21, 2013
	25MG;320MG	A091519	005	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+	RECRO GAINESVILLE	10MG	N202880	001	Oct 25, 2013
+		15MG	N202880	002	Oct 25, 2013
+		20MG	N202880	003	Oct 25, 2013
+		30MG	N202880	004	Oct 25, 2013
+		40MG	N202880	005	Oct 25, 2013
+		50MG	N202880	006	Oct 25, 2013

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

+	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017
+		30MG	N207975	002	Jan 17, 2017
+		45MG	N207975	003	Jan 17, 2017
+		60MG	N207975	004	Jan 17, 2017
+		90MG	N207975	005	Jan 17, 2017

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

ANI PHARMS	5MG;200MG	A077454	001	Jun 23, 2010
SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013
	5MG;200MG	A091633	002	May 28, 2013
	7.5MG;200MG	A091633	003	May 28, 2013
	10MG;200MG	A091633	004	May 28, 2013
TEVA	7.5MG;200MG	A076023	001	Apr 11, 2003

REPREXAIN

AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007
	10MG;200MG	A076642	004	Oct 19, 2007

VICOPROFEN

+	ABBVIE	7.5MG;200MG **	N020716	001	Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP;ORAL

CODAMINE

ALPHARMA US PHARMS	5MG/5ML;25MG/5ML	A075103	001	Sep 29, 2000

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015
PADAGIS US	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014
TORRENT	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019
TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014

REZIRA

+	PERSION	5MG/5ML;60MG/5ML **	N022442	001	Jun 08, 2011

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT;TOPICAL

MAGNACORT

PFIZER	0.5%	N010554	001	

HYDROCORTISONE

AEROSOL;TOPICAL

AEROSEB-HC

ALLERGAN HERBERT	0.5%	A085805	001	

CREAM;TOPICAL

CORT-DOME

BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	

DERMACORT

MONARCH PHARMS	1%	A083011	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE

CREAM;TOPICAL

ELDECORT				
VALEANT PHARM INTL	1%	A080459 001		
	2.5%	A084055 001		
FLEXICORT				
WESTWOOD SQUIBB	0.5%	A087136 003	Apr 08, 1982	
	1%	A087136 002	Apr 08, 1982	
	2.5%	A087136 001	Apr 08, 1982	
H-CORT				
PHARM ASSOC	0.5%	A086823 001		
HC #1				
BAYER PHARMS	0.5%	A080438 001		
HC #4				
BAYER PHARMS	1%	A080438 002		
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080482 003		
	1%	A080482 004		
HI-COR				
C AND M PHARMA	2.5%	A080483 001		
HYDROCORTISONE				
ALPHARMA US PHARMS	2.5%	A089754 001	Feb 01, 1989	
ALTANA	0.5%	A080848 002		
	1%	A080848 003		
AMBIX	1%	A086080 001		
	2.5%	A086271 001		
EVERYLIFE	0.5%	A080452 001		
	1%	A080452 002		
G AND W LABS	1%	A084059 001		
INGRAM PHARM	0.5%	A080456 002		
	1%	A080456 003		
IVAX PHARMS	1%	A085733 001		
NASKA	1%	A089706 001	Mar 10, 1988	
PERRIGO NEW YORK	0.5%	A084970 002		
	1%	A085026 001		
PHARMADERM	1%	A088845 001	Feb 27, 1986	
	2.5%	A089413 001	Dec 16, 1986	
PHARMAFAIR	1%	A087838 001	Jul 28, 1982	
STIEFEL	1%	A086170 001		
SYOSSET	0.5%	A085527 001		
TARO	0.5%	A086154 001		
TARO PHARM INDS LTD	1%	A086155 001		
TELIGENT	2.5%	A203810 001	Jul 23, 2018	
TEVA	0.5%	A080400 002		
	1%	A080400 003		
	1%	A085191 001		
	2.5%	A080400 004		
TOPIDERM	1%	A089273 001	Feb 17, 1989	
USL PHARMA	1%	A088027 001	Sep 27, 1983	
	2.5%	A088029 001	Sep 27, 1983	
WHITEWORTH TOWN PLSN	1%	A080496 002		
HYTONE				
+ VALEANT INTL	1% **	A080472 003		
+	2.5% **	A080472 004		
NOGENIC HC				
IVAX PHARMS	1%	A087427 001	Apr 04, 1988	
NUTRACORT				
BAUSCH	0.5%	A080442 002		
	1%	A080442 003		
PENECORT				
ALLERGAN HERBERT	1%	A088216 001	Jun 06, 1984	
PROCTOCORT				
MONARCH PHARMS	1%	A083011 001		
SYNACORT				
BAUSCH	0.5%	A087459 001		
+	1%	A087458 001		
+	2.5%	A087457 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE

ENEMA;RECTAL				
HYDROCORTISONE				
TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994
GEL;TOPICAL				
NUTRACORT				
HEALTHPOINT	1%	A084698	001	
PENECORT				
ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984
INJECTABLE;INJECTION				
CORTEF				
PHARMACIA AND UPJOHN	50MG/ML	N009864	001	
LOTION;TOPICAL				
ACTICORT				
BAKER NORTON	1%	A086535	001	
ALA-CORT				
CROWN LABS	1%	A083201	001	
BALNEOL-HC				
SOLVAY	1%	A088041	001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%	A089495	001	Jan 25, 1988
CETACORT				
BAUSCH	0.5%	A080426	002	
	1%	A080426	001	
CORT-DOME				
BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	
DERMACORT				
SOLVAY	0.5%	A084573	002	
	1%	A086462	001	
EPICORT				
BLULINE	0.5%	A083219	002	
GLYCORT				
HERAN	1%	A087489	001	Oct 03, 1983
H-CORT				
PHARM ASSOC	0.5%	A086824	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
	1%	A087315	001	Jun 07, 1982
FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000
MERICON	0.5%	A085282	001	
	1%	A085282	002	Feb 26, 1987
NASKA	1%	A089705	001	Apr 25, 1988
PERRIGO NEW YORK	0.5%	A085662	001	
	1%	A085663	001	
TARO	1%	A089024	001	Feb 12, 1986
TELIGENT	2.5%	A203804	001	Jul 27, 2018
HYTONE				
+ VALEANT INTL	1% **	A080473	003	
+	2.5% **	A080473	004	Nov 30, 1982
NUTRACORT				
DOW PHARM	0.5%	A080443	002	
	1%	A080443	003	
	2.5%	A087644	001	Aug 24, 1982
STIE-CORT				
PADAGIS US	1%	A089066	001	Nov 25, 1985
OINTMENT;TOPICAL				
CORTRIL				
PFIZER GLOBAL	1%	N009176	001	
	2.5%	N009176	002	
HC (HYDROCORTISONE)				
C AND M PHARMA	0.5%	A080481	001	
	1%	A080481	002	
HYDROCORTISONE				
ACTAVIS MID ATLANTIC	1%	A087796	001	Oct 13, 1982
ALTANA	0.5%	A080489	002	
	1%	A080489	003	
AMBIX	1%	A086079	001	
	2.5%	A086272	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE				
OINTMENT;TOPICAL				
HYDROCORTISONE				
NASKA	1%	A089704	001	Mar 10, 1988
PERRIGO NEW YORK	0.5%	A084969	003	
	1%	A085028	001	
PHARMADERM	1%	A088842	001	Feb 09, 1987
TARO	0.5%	A086256	001	
	2.5%	A040310	001	Dec 29, 2000
USL PHARMA	1%	A088061	001	Sep 27, 1983
	2.5%	A088039	001	Sep 27, 1983
HYTONE				
+ DERMIK LABS	1% **	A080474	003	
+	2.5% **	A080474	004	
PENECORT				
ALLERGAN HERBERT	2.5%	A088217	001	Jun 06, 1984
POWDER;FOR RX COMPOUNDING				
H-CORT				
TORCH	100%	A087834	001	Mar 29, 1982
HYDRO-RX				
X GEN PHARMS	100%	A085982	001	
HYDROCORTISONE				
PADDOCK LLC	100%	A088082	001	Apr 08, 1983
SOLUTION;TOPICAL				
PENECORT				
+ ALLERGAN HERBERT	1%	A088214	001	Jun 06, 1984
TEXACORT				
MISSION PHARMA	1%	A080425	001	
TABLET;ORAL				
CORTRIL				
PFIZER	10MG	N009127	005	
	20MG	N009127	003	
HYDROCORTISONE				
BARR	20MG	A083999	001	
ELKINS SINN	20MG	A080624	001	
FERRANTE	10MG	A080568	001	
	20MG	A080568	002	
HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015
	10MG	A083365	003	Feb 23, 2015
	20MG	A083365	001	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
STRIDES PHARMA	5MG	A040761	001	Jul 16, 2007
	10MG	A040761	002	Jul 16, 2007
	20MG	A040761	003	Jul 16, 2007
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	
	20MG	N008506	011	
TABLET;VAGINAL				
CORTRIL				
PFIPHARMECS	10MG	N009796	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE ACETATE

CREAM;TOPICAL				
CARMOL HC				
+	FOUGERA PHARMS	1%	A080505 001	
HEMSOL-HC				
	ABLE	1%	A081274 001	Jun 19, 1992
HYDROCORTISONE ACETATE				
	CENCI	1%	A080419 001	Jan 25, 1982
	IMPERIUM	2.5%	A040259 001	Jul 29, 1999
	PARKE DAVIS	1%	A089914 001	Jan 03, 1989
	PUREPAC PHARM	0.5%	A086050 001	
+		1%	A086052 001	
MICORT-HC				
	SEBELA IRELAND LTD	2%	A040398 001	Mar 29, 2002
INJECTABLE;INJECTION				
CORTEF ACETATE				
	PHARMACIA AND UPJOHN	50MG/ML	N009378 002	
CORTRIL				
	PFIZER	25MG/ML	N009164 001	
HYDROCORTISONE ACETATE				
	AKORN	25MG/ML	N009637 001	
		50MG/ML	N009637 002	
	BEL MAR	25MG/ML	A083739 001	
		50MG/ML	A083739 002	
	WATSON LABS	25MG/ML	A083128 001	
		25MG/ML	A083759 001	
		50MG/ML	A083759 002	
		50MG/ML	A085214 001	
HYDROCORTONE				
	MERCK	25MG/ML	N008228 001	
		50MG/ML	N008228 004	
LOTION;TOPICAL				
DRICORT				
	INGRAM PHARM	0.5%	A086207 001	
OINTMENT;OPHTHALMIC				
HYDROCORTISONE ACETATE				
	FERA PHARMS	0.5%	A080828 001	
OINTMENT;OPHTHALMIC, OTIC				
HYDROCORTONE				
	MERCK	1.5%	N009018 003	
OINTMENT;TOPICAL				
CORTEF ACETATE				
	PHARMACIA AND UPJOHN	1%	N008917 002	
+		2.5% **	N008917 001	
PASTE;TOPICAL				
ORABASE HCA				
	COLGATE	0.5%	A083205 001	
POWDER;FOR RX COMPOUNDING				
HYDROCORTISONE ACETATE				
	X GEN PHARMS	100%	A085981 001	

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049 001	
		2.5%;EQ 3.5MG BASE/GM	A061049 002	
OINTMENT;OPHTHALMIC				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610 001	
		1.5%;EQ 3.5MG BASE/GM	A060610 002	
OINTMENT;TOPICAL				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751 001	
		1%;EQ 3.5MG BASE/GM	A060751 002	
		2.5%;EQ 3.5MG BASE/GM	A060751 003	
SUSPENSION/DROPS;OPHTHALMIC				
COR-OTICIN				
	AKORN	1.5%;EQ 3.5MG BASE/ML	A060188 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE				
SUSPENSION/DROPS;OPHTHALMIC				
NEO-CORTEF				
	PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612 002	
		1.5%;EQ 3.5MG BASE/ML	A060612 001	
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE				
CREAM;TOPICAL				
CORTISPORIN				
+	MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050218 001	Aug 09, 1985
HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE				
SUSPENSION;OPHTHALMIC				
TERRA-CORTRIL				
	PFIZER	1.5%;EQ 5MG BASE/ML	A061016 001	
HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE				
AEROSOL, METERED;TOPICAL				
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%				
	GENUS	1%;1%	A089440 001	May 17, 1988
LOTION;TOPICAL				
PRAMOSONE				
	FERNDALE LABS	0.5%;1%	A083213 002	
HYDROCORTISONE BUTYRATE				
CREAM;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N018795 001	Jan 07, 1983
OINTMENT;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N019106 001	Jul 03, 1984
SOLUTION;TOPICAL				
LOCOID				
	YAMANOUCHI	0.1%	N019819 001	Sep 15, 1988
HYDROCORTISONE CYPIONATE				
SUSPENSION;ORAL				
CORTEF				
	PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900 001	
HYDROCORTISONE SODIUM PHOSPHATE				
INJECTABLE;INJECTION				
HYDROCORTONE				
+	MERCK	EQ 50MG BASE/ML	N012052 001	
HYDROCORTISONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
A-HYDROCORT				
	ABBOTT	EQ 100MG BASE/VIAL	A085928 001	
		EQ 100MG BASE/VIAL	A089577 001	Apr 11, 1989
		EQ 250MG BASE/VIAL	A089578 001	Apr 11, 1989
		EQ 500MG BASE/VIAL	A089579 001	Apr 11, 1989
		EQ 1GM BASE/VIAL	A089580 001	Apr 11, 1989
	HOSPIRA	EQ 100MG BASE/VIAL	A040666 001	Apr 06, 2006
		EQ 100MG BASE/VIAL	A085929 001	
		EQ 250MG BASE/VIAL	A085930 001	
		EQ 500MG BASE/VIAL	A085931 001	
		EQ 1GM BASE/VIAL	A085932 001	
HYDROCORTISONE SODIUM SUCCINATE				
	ABRAXIS PHARM	EQ 100MG BASE/VIAL	A088667 001	Jun 08, 1984
		EQ 100MG BASE/VIAL	A088712 001	Jun 08, 1984
		EQ 250MG BASE/VIAL	A088668 001	Jun 08, 1984
		EQ 500MG BASE/VIAL	A088669 001	Jun 08, 1984
		EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
	BAXTER HLTHCARE	EQ 100MG BASE/VIAL	A086619 001	
		EQ 250MG BASE/VIAL	A087567 001	
		EQ 500MG BASE/VIAL	A087568 001	
		EQ 1GM BASE/VIAL	A087569 001	
	INTL MEDICATION	EQ 100MG BASE/VIAL	A087532 001	Mar 19, 1982
	WATSON LABS	EQ 100MG BASE/VIAL	A084737 002	
		EQ 100MG BASE/VIAL	A084738 001	
		EQ 250MG BASE/VIAL	A084737 001	
		EQ 500MG BASE/VIAL	A084747 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION				
HYDROCORTISONE SODIUM SUCCINATE				
	EQ 1GM BASE/VIAL		A084748 001	

HYDROCORTISONE VALERATE

CREAM;TOPICAL				
HYDROCORTISONE VALERATE				
COSETTE	0.2%		A074489 001	Aug 12, 1998
WESTCORT				
+ SUN PHARM INDS INC	0.2% **		N017950 001	
OINTMENT;TOPICAL				
HYDROCORTISONE VALERATE				
FOUGERA PHARMS	0.2%		A075085 001	Jul 31, 2001
WESTCORT				
+ SUN PHARM INDS INC	0.2% **		N018726 001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM;TOPICAL				
NEO-CORT-DOME				
BAYER PHARMS	0.5%;EQ 3.5MG BASE/GM		N050237 006	Jun 05, 1984
	1%;EQ 3.5MG BASE/GM		N050237 005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
CORTISPORIN				
+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **		N050479 001	
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE				
AMRING PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A065216 001	Oct 31, 2005
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A062394 001	Sep 29, 1982
OTOCORT				
WATSON LABS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A060730 002	
SUSPENSION/DROPS;OPHTHALMIC				
CORTISPORIN				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		N050169 001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A062623 001	Sep 24, 1985
SUSPENSION/DROPS;OTIC				
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A062617 001	Sep 18, 1985
OTICAIR				
PHARMAFAIR	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A062399 001	Nov 18, 1982
OTOBIONE				
SCHERING	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A061816 001	
OTOCORT				
ACTAVIS LABS FL INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A062521 001	Jul 11, 1985
PEDIOTIC				
MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML		A062822 001	Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC				
OTOBIOTIC				
SCHERING	5MG/ML;EQ 10,000 UNITS BASE/ML		A062302 001	
PYOCIDIN				
FOREST LABS	5MG/ML;EQ 10,000 UNITS BASE/ML		A061606 001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC				
ACHROMYCIN				
LEDERLE	1.5%;1%		N050272 001	

HYDROCORTISONE; UREA

CREAM;TOPICAL				
ALPHADERM				
BIOGLAN	1%;10%		A086008 001	
CALMURID HC				
PHARMACIA AND UPJOHN	1%;10%		A083947 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROFLUMETHIAZIDE

TABLET;ORAL				
DIUCARDIN				
	WYETH AYERST	50MG	A083383 001	
HYDROFLUMETHIAZIDE				
	PAR PHARM	50MG	A088850 001	May 31, 1985
	WATSON LABS	50MG	A088031 001	Apr 06, 1983
		50MG	A088528 001	Aug 15, 1984
SALURON				
+	SHIRE LLC	50MG	N011949 001	

HYDROFLUMETHIAZIDE; RESERPINE

TABLET;ORAL				
HYDROFLUMETHIAZIDE AND RESERPINE				
	USL PHARMA	50MG;0.125MG	A088195 001	Oct 26, 1983
	WATSON LABS	25MG;0.125MG	A088127 001	Mar 22, 1983
		50MG;0.125MG	A088110 001	Mar 22, 1983
RESERPINE AND HYDROFLUMETHIAZIDE				
	IVAX PHARMS	50MG;0.125MG	A088932 001	Jan 11, 1985
	PAR PHARM	50MG;0.125MG	A088907 001	Sep 20, 1985
SALUTENSIN				
	SHIRE	50MG;0.125MG	N012359 003	
SALUTENSIN-DEMI				
	SHIRE	25MG;0.125MG	N012359 004	

HYDROGEN PEROXIDE

SOLUTION;TOPICAL				
ESKATA				
+	ACLARIS	40%	N209305 001	Dec 14, 2017

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
PALLADONE				
	PURDUE PHARMA LP	12MG	N021044 001	Sep 24, 2004
		16MG	N021044 002	Sep 24, 2004
		24MG	N021044 003	Sep 24, 2004
		32MG	N021044 004	Sep 24, 2004
INJECTABLE;INJECTION				
DILAUDID				
+	FRESENIUS KABI USA	4MG/ML	N019034 005	Apr 30, 2009
DILAUDID-HP				
+	FRESENIUS KABI USA	10MG/ML	N019034 001	Jan 11, 1984
		250MG/VIAL	N019034 002	Aug 04, 1994
HYDROMORPHONE HYDROCHLORIDE				
	BARR	10MG/ML	A076444 001	Apr 25, 2003
	HOSPIRA	10MG/ML	A074598 001	Jun 19, 1997
	WATSON LABS	10MG/ML	A074317 001	Aug 23, 1995
SOLUTION;ORAL				
HYDROMORPHONE HYDROCHLORIDE				
	GENUS	5MG/5ML	A207108 001	Apr 22, 2020
TABLET;ORAL				
HYDROMORPHONE HYDROCHLORIDE				
	GENUS	2MG	A077471 002	Dec 09, 2009
		4MG	A077471 003	Dec 09, 2009
		8MG	A077471 001	Dec 09, 2009
	NESHER PHARMS	2MG	A077311 001	Nov 09, 2005
		4MG	A077311 002	Nov 09, 2005
		8MG	A077311 003	Nov 09, 2005
	NOSTRUM LABS INC	8MG	A076723 001	Oct 18, 2005
TABLET, EXTENDED RELEASE;ORAL				
EXALGO				
+	SPECGX LLC	8MG **	N021217 001	Mar 01, 2010
+		12MG **	N021217 002	Mar 01, 2010
+		16MG **	N021217 003	Mar 01, 2010
+		32MG **	N021217 004	Aug 24, 2012
HYDROMORPHONE HYDROCHLORIDE				
	ACTAVIS LABS FL INC	8MG	A202144 001	May 12, 2014
		12MG	A202144 002	May 12, 2014
		16MG	A202144 003	May 12, 2014
		32MG	A202144 004	Jun 30, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXOCOBALAMIN

INJECTABLE;INJECTION				
ALPHAREDISOL				
	MERCK	1MG/ML	A080778 001	
CYANOKIT				
	SERB SA	2.5GM/VIAL (5GM/KIT)	N022041 002	Dec 15, 2006
HYDROXOCOBALAMIN				
	ABRAXIS PHARM	1MG/ML	A084921 001	
	WATSON LABS	1MG/ML	A085528 001	
HYDROXOMIN				
	BEL MAR	1MG/ML	A084629 001	

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS;OPHTHALMIC				
PAREDRINE				
	PHARMICS	1%	N000004 004	

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL				
HYDROXYCHLOROQUINE SULFATE				
	HIKMA PHARMS	200MG	A040760 001	Aug 15, 2007
	INVATECH	200MG	A040150 001	Jan 27, 1996

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION				
HYDROXYPROGESTERONE CAPROATE				
	AKORN	125MG/ML	N018004 001	
	ALLERGAN	125MG/ML	N017439 001	
		250MG/ML	N017439 002	
SOLUTION;INTRAMUSCULAR				
DELALUTIN				
+	BRISTOL MYERS SQUIBB	125MG/ML (125MG/ML) **	N010347 004	
+		125MG/ML (125MG/ML) **	N016911 001	
+		250MG/ML (250MG/ML) **	N010347 002	
+		250MG/ML (250MG/ML) **	N016911 002	
HYDROXYPROGESTERONE CAPROATE				
	AM REGENT	1250MG/5ML (250MG/ML)	A210724 001	Aug 09, 2019
	EUGIA PHARMA	1250MG/5ML (250MG/ML)	A211142 001	May 09, 2019

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE;INJECTION				
HYDROXYSTILBAMIDINE ISETHIONATE				
	SANOFI AVENTIS US	225MG/AMP	N009166 001	

HYDROXYUREA

CAPSULE;ORAL				
HYDROXYUREA				
	BARR	250MG	A075143 002	Sep 21, 2000
	BARR LABS INC	250MG	A075020 002	Jun 26, 2000
		500MG	A075020 001	Jul 30, 1998
	ROXANE	500MG	A074476 001	Aug 18, 1995
TABLET;ORAL				
HYDROXYUREA				
	BARR	1GM	A075734 001	Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HYDROXYZINE				
	BAXTER HLTHCARE	50MG/ML	A085551 002	
HYDROXYZINE HYDROCHLORIDE				
	ALTANA	25MG/ML	A087273 001	Apr 20, 1982
		50MG/ML	A087273 002	Apr 20, 1982
	BAXTER HLTHCARE	25MG/ML	A085551 001	
	DR REDDYS	50MG/ML	A085779 001	
	FRESENIUS KABI USA	25MG/ML	A087329 001	
		25MG/ML	A088184 001	Mar 31, 1983
		50MG/ML	A087329 002	
		50MG/ML	A088185 001	Mar 31, 1983
	HOSPIRA	25MG/ML	A087416 001	
		50MG/ML	A086821 001	
		50MG/ML	A087546 001	
	PHARMAFAIR	25MG/ML	A088862 001	Feb 14, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
HYDROXYZINE HYDROCHLORIDE				
	25MG/ML	A089106	001	Feb 14, 1986
	50MG/ML	A088881	001	Feb 14, 1986
	50MG/ML	A089107	001	Feb 14, 1986
SMITH AND NEPHEW	25MG/ML	A087592	001	
SOLOPAK	25MG/ML	A086822	001	
	25MG/ML	A087591	001	
	50MG/ML	A087310	001	
	50MG/ML	A087593	001	
	50MG/ML	A087595	001	
	50MG/ML	A087596	001	
WATSON LABS	25MG/ML	A085778	001	
	25MG/ML	A087274	001	
	50MG/ML	A087274	002	
WYETH AYERST	25MG/ML	A086258	001	
	50MG/ML	A086258	002	
ORGATRAX				
ORGANON USA INC	25MG/ML	A087014	001	
	50MG/ML	A087014	002	
VISTARIL				
+ PFIZER	25MG/ML **	N011111	001	
+	50MG/ML **	N011111	002	
SYRUP;ORAL				
ATARAX				
ROERIG	10MG/5ML **	N010485	001	
HYDROXYZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	10MG/5ML	A088785	001	Feb 03, 1988
ANIMA	10MG/5ML	A086880	001	
KV PHARM	10MG/5ML	A087730	001	Jul 01, 1982
TORRENT	10MG/5ML	A210634	001	Feb 26, 2019
VINTAGE PHARMS	10MG/5ML	A040391	001	Apr 10, 2002
TABLET;ORAL				
ATARAX				
+ PFIZER	10MG **	N010392	001	
+	25MG **	N010392	004	
+	50MG **	N010392	006	
+	100MG **	N010392	005	
HYDROXYZINE HYDROCHLORIDE				
ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
AUROBINDO PHARMA LTD	10MG	A087871	002	Dec 20, 1982
	25MG	A087871	003	Dec 20, 1982
	50MG	A087871	001	Dec 20, 1982
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

RISING PHARMA	10MG	A091176	001	Jun 07, 2010
	25MG	A091176	002	Jun 07, 2010
	50MG	A091176	003	Jun 07, 2010
SANDOZ	10MG	A087246	002	
	25MG	A085247	001	
	50MG	A087245	001	
STRIDES PHARMA	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
	25MG	A040899	002	Jun 10, 2008
	50MG	A040899	003	Jun 10, 2008
SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
	25MG	A089382	001	May 19, 1986
	50MG	A089383	001	May 19, 1986
	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HY-PAM "25"

TEVA	EQ 25MG HYDROCHLORIDE	A088713	001	Mar 04, 1985

HYDROXYZINE PAMOATE

BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991
DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593	001	Feb 29, 1984
	EQ 50MG HYDROCHLORIDE	A088594	001	Feb 29, 1984
	EQ 100MG HYDROCHLORIDE	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761	001	Mar 05, 1982
	EQ 50MG HYDROCHLORIDE	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656	001	Jun 11, 1982
	EQ 25MG HYDROCHLORIDE	A089145	001	Mar 17, 1986
	EQ 50MG HYDROCHLORIDE	A087657	001	Jun 11, 1982
	EQ 50MG HYDROCHLORIDE	A089146	001	Mar 17, 1986
	EQ 100MG HYDROCHLORIDE	A087658	001	Jun 11, 1982
SANDOZ	EQ 50MG HYDROCHLORIDE	A081128	001	Jun 28, 1991
	EQ 100MG HYDROCHLORIDE	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031	001	Jan 02, 1987
	EQ 50MG HYDROCHLORIDE	A089032	001	Jan 02, 1987
	EQ 100MG HYDROCHLORIDE	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HYDROCHLORIDE	A088392	001	Sep 19, 1983
	EQ 50MG HYDROCHLORIDE	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HYDROCHLORIDE	A086698	001	
	EQ 25MG HYDROCHLORIDE	A086840	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A086695	001	
	EQ 50MG HYDROCHLORIDE	A086705	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A087767	001	Aug 16, 1982
	EQ 100MG HYDROCHLORIDE	A086697	001	
	EQ 100MG HYDROCHLORIDE	A086728	001	Oct 05, 1982
	EQ 100MG HYDROCHLORIDE	A087790	001	Aug 16, 1982

VISTARIL

PFIZER	EQ 100MG HYDROCHLORIDE **	N011459	006	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

HYDROXYZINE PAMOATE				
SUSPENSION;ORAL				
VISTARIL				
	PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795 001	
IBANDRONATE SODIUM				
INJECTABLE;INTRAVENOUS				
BONIVA				
+	ROCHE	EQ 3MG BASE/3ML	N021858 001	Jan 06, 2006
IBANDRONATE SODIUM				
	EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987 001	Sep 02, 2014
	NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329 001	Jun 16, 2021
TABLET;ORAL				
BONIVA				
+	HOFFMANN LA ROCHE	EQ 2.5MG BASE **	N021455 001	May 16, 2003
+		EQ 150MG BASE	N021455 002	Mar 24, 2005
IBANDRONATE SODIUM				
	MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012
	SUN PHARM INDUSTRIES	EQ 150MG BASE	A078996 001	Aug 15, 2012
IBRUTINIB				
CAPSULE;ORAL				
IBRUTINIB				
	ZYDUS	70MG	A211344 001	Mar 31, 2021
		140MG	A211344 002	Mar 31, 2021
IBUPROFEN				
CAPSULE;ORAL				
IBUPROFEN				
	CONTRACT PHARMACAL	200MG	A074782 001	Jul 06, 1998
	STRIDES PHARMA	EQ 200MG FREE ACID AND POTASSIUM SALT	A204469 001	Mar 28, 2018
MIDOL				
	BAYER	200MG **	A070626 001	Sep 02, 1987
		200MG **	A071002 001	Sep 02, 1987
SOLUTION;INTRAVENOUS				
CALDOLOR				
	CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348 001	Jun 11, 2009
SUSPENSION;ORAL				
CHILDREN'S ADVIL				
	GLAXOSMITHKLINE	100MG/5ML	N019833 002	Sep 19, 1989
CHILDREN'S ELIXSURE				
	MOBERG PHARMA NORTH	100MG/5ML	N021604 001	Jan 07, 2004
IBU				
	ABBOTT	100MG/5ML	N019784 001	Dec 18, 1989
IBUPROFEN				
	STRIDES PHARMA	100MG/5ML	A211666 001	Feb 22, 2021
MOTRIN				
+	MCNEIL CONSUMER	100MG/5ML **	N019842 001	Sep 19, 1989
SUSPENSION/DROPS;ORAL				
MOTRIN				
	MCNEIL	40MG/ML	N020476 001	May 25, 1995
PEDIATRIC ADVIL				
+	GLAXOSMITHKLINE	100MG/2.5ML	N020812 001	Jan 30, 1998
TABLET;ORAL				
ACHES-N-PAIN				
	LEDERLE	200MG	A071065 001	May 28, 1987
CAP-PROFEN				
	PERRIGO	200MG	A072097 001	Dec 08, 1987
IBU				
	BASF	400MG	A070083 001	Feb 22, 1985
		400MG	N018197 001	
		600MG	A070088 001	Feb 08, 1985
		600MG	A070099 001	Mar 29, 1985
		800MG	A070745 001	Jul 23, 1986
IBU-TAB				
	ALRA	400MG	A071058 001	Aug 11, 1988
		600MG	A071059 001	Aug 11, 1988
		800MG	A071965 001	Aug 11, 1988
IBU-TAB 200				
	ALRA	200MG	A071057 001	Aug 11, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN

TABLET;ORAL

IBUPRIN				
PLIVA	200MG	A071773	001	Jul 16, 1987
IBUPROFEN				
ABBOTT	600MG	A070556	001	Jun 14, 1985
	800MG	A071264	001	Jul 25, 1986
ANI PHARMS	200MG	A071144	001	Jan 20, 1987
	200MG	A072901	001	Dec 19, 1991
	200MG	A072903	001	Dec 19, 1991
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
	200MG	A071265	002	Sep 10, 1987
	200MG	A071735	001	Sep 10, 1987
	200MG	A073691	001	Feb 25, 1994
	200MG	A074931	001	Jul 20, 1998
HALSEY	200MG	A071027	001	Sep 29, 1987
	300MG	A071028	001	Mar 23, 1987
	400MG	A071029	001	Mar 23, 1987
	600MG	A071030	001	Mar 23, 1987
	800MG	A072137	001	Feb 05, 1988
HEC PHARM	400MG	A204062	001	Sep 10, 2018
	600MG	A204062	002	Sep 10, 2018
	800MG	A204062	003	Sep 10, 2018
IVAX SUB TEVA PHARMS	200MG	A071154	001	Oct 27, 1987
	200MG	A072040	001	Apr 29, 1988
	400MG	A071145	001	Sep 23, 1986
	600MG	A071146	001	Sep 23, 1986
	800MG	A071769	001	May 08, 1987
J AND J CONSUMER INC	400MG	A070081	001	Jun 16, 1986
LEDERLE	400MG	A070629	001	Sep 19, 1986
	600MG	A070630	001	Sep 19, 1986
LEINER	300MG	A071266	001	Oct 15, 1986
LNK	100MG	A076741	001	Jun 17, 2004
MCNEIL	600MG	A070476	001	Jun 16, 1986
MERRO PHARM	200MG	A070985	001	Oct 02, 1987
MYLAN	200MG	A071870	001	May 05, 1988
	400MG	A070045	001	Sep 24, 1985
	600MG	A070057	001	Sep 24, 1985
	800MG	A071999	001	Dec 03, 1987
NORTHSTAR HLTHCARE	400MG	A078132	001	Sep 10, 2007
	600MG	A078132	002	Sep 10, 2007
	800MG	A078132	003	Sep 10, 2007
OHM LABS	400MG	A070818	001	Dec 26, 1985
P AND L DEV LLC	200MG	A070733	001	Sep 19, 1986
PAR PHARM	300MG	A070328	001	Aug 06, 1985
PERRIGO	200MG	A072098	001	Dec 08, 1987
PLIVA	400MG	A071666	001	Jun 18, 1987
	600MG	A071667	001	Jun 18, 1987
	800MG	A071668	001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122	001	Oct 03, 1986
	200MG	A071664	001	Feb 03, 1987
	300MG	A071123	001	Sep 19, 1986
	400MG	A071124	001	Sep 19, 1986
	600MG	A071125	001	Sep 19, 1986
	800MG	A071964	001	Feb 01, 1988
RISING	300MG	A070736	002	Jun 12, 1986
	400MG	A070736	003	Jun 12, 1986
	600MG	A070736	001	Jun 12, 1986
	800MG	A071938	001	Jan 14, 1988
SANDOZ	200MG	A071807	001	Feb 25, 1988
	200MG	A074525	001	Dec 15, 1995
	200MG	A074533	001	Dec 15, 1995
	400MG	A072064	001	Jan 14, 1988
	600MG	A072065	001	Jan 14, 1988
	800MG	A072169	001	Dec 11, 1987
STRIDES PHARMA	200MG	A071575	001	May 08, 1987
	400MG	A070329	001	Aug 06, 1985
	600MG	A070330	001	Aug 06, 1985
	800MG	A070986	001	Jul 25, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN

TABLET;ORAL						
IBUPROFEN						
	SUN PHARM INDUSTRIES	200MG		A070493	001	Dec 24, 1985
		200MG		A070908	001	Sep 26, 1986
		200MG		A071462	001	Oct 02, 1986
		400MG		A070079	001	Jul 24, 1985
		600MG		A070080	001	Jul 24, 1985
		800MG		A071448	001	Feb 18, 1987
	SUPERPHARM	600MG		A070709	001	Apr 25, 1986
	TEVA	200MG		A073141	001	May 29, 1992
		400MG		A073343	001	Jun 30, 1992
		600MG		A073344	001	Jun 30, 1992
		800MG		A073345	001	Jun 30, 1992
	ULTRATAB LABS INC	200MG		A209076	001	Jan 06, 2020
	VINTAGE PHARMS	200MG		A071639	001	Feb 02, 1988
		200MG		A072249	001	Jan 10, 1989
		300MG		A071230	001	Oct 22, 1986
		400MG		A071231	001	Oct 22, 1986
		400MG		A071644	001	Feb 01, 1988
		600MG		A071232	001	Oct 22, 1986
		800MG		A072004	001	Nov 18, 1987
	WATSON LABS	200MG		A070435	001	Mar 05, 1986
		200MG		A071765	001	Sep 04, 1987
		200MG		A071905	001	Mar 08, 1988
		300MG		A071338	001	Dec 01, 1986
		400MG		A070038	001	Sep 06, 1985
		400MG		A070436	001	Aug 21, 1985
		600MG		A070041	001	Sep 06, 1985
		600MG		A070437	001	Aug 21, 1985
		800MG		A071547	001	Jul 02, 1987
		800MG		A071911	001	Oct 13, 1987
	YICHANG HUMANWELL	200MG		A214003	001	Oct 19, 2020
IBUPROHM						
	OHM LABS	200MG		A071214	001	Dec 01, 1986
		400MG		A070469	001	Aug 29, 1985
MEDIPREN						
	MCNEIL	200MG		A070475	001	Feb 06, 1986
		200MG		A071215	001	Jun 26, 1986
MIDOL						
	BAYER	200MG		A070591	001	Sep 02, 1987
		200MG		A071001	001	Sep 02, 1987
MOTRIN						
+	MCNEIL CONSUMER	300MG	**	N017463	003	
+		400MG	**	N017463	002	
+		600MG	**	N017463	004	
+		800MG	**	N017463	005	May 22, 1985
	MCNEIL PED	100MG		N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN						
	J AND J CONSUMER INC	200MG		N019012	004	Feb 25, 2000
NUPRIN						
	BRISTOL MYERS	200MG		A072035	001	Feb 16, 1988
		200MG		A072036	001	Feb 16, 1988
	J AND J CONSUMER INC	200MG		N019012	001	May 18, 1984
		200MG		N019012	002	Jul 29, 1987
RUFEN						
	BASF	600MG		N018197	002	Mar 05, 1984
TABLET, CHEWABLE;ORAL						
CHILDREN'S MOTRIN						
+	J AND J CONSUMER INC	50MG		N020601	001	Nov 15, 1996
IBUPROFEN						
	PERRIGO	50MG		A076359	001	Jan 16, 2004
JUNIOR STRENGTH MOTRIN						
+	J AND J CONSUMER INC	100MG		N020601	003	Nov 15, 1996
MOTRIN						
	MCNEIL PED	50MG		N020135	001	Nov 16, 1994
		100MG		N020135	002	Nov 16, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IBUPROFEN SODIUM				
TABLET;ORAL				
IBUPROFEN SODIUM				
PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015
IBUPROFEN; OXYCODONE HYDROCHLORIDE				
TABLET;ORAL				
COMBUNOX				
+ FOREST LABS	400MG;5MG **	N021378	001	Nov 26, 2004
OXYCODONE HYDROCHLORIDE AND IBUPROFEN				
ACTAVIS ELIZABETH	400MG;5MG	A078769	001	Jan 04, 2008
BARR LABS INC	400MG;5MG	A078316	001	Nov 29, 2007
WATSON LABS	400MG;5MG	A078394	001	Nov 26, 2007
IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE				
TABLET;ORAL				
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr 08, 2002
IBUTILIDE FUMARATE				
INJECTABLE;INJECTION				
IBUTILIDE FUMARATE				
LUITPOLD	0.1MG/ML	A090240	001	Jan 11, 2010
MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010
ICATIBANT ACETATE				
INJECTABLE;SUBCUTANEOUS				
ICATIBANT ACETATE				
DR REDDYS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020
ICOSAPENT ETHYL				
CAPSULE;ORAL				
ICOSAPENT ETHYL				
TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020
	1GM	A209525	002	Sep 11, 2020
IDARUBICIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
IDAMYCIN				
PFIZER	5MG/VIAL	N050661	002	Sep 27, 1990
	10MG/VIAL	N050661	001	Sep 27, 1990
	20MG/VIAL	N050661	003	Apr 25, 1995
IDARUBICIN HYDROCHLORIDE				
FRESENIUS KABI USA	1MG/ML	A065440	001	Aug 04, 2009
MYLAN LABS LTD	1MG/ML	A200144	001	Oct 11, 2012
SANDOZ	1MG/ML	A091293	001	Mar 29, 2011
TEVA PARENTERAL	5MG/VIAL	A065037	003	May 01, 2002
	10MG/VIAL	A065037	002	May 01, 2002
	20MG/VIAL	A065037	001	May 01, 2002
IDOXURIDINE				
OINTMENT;OPHTHALMIC				
STOXIL				
GLAXOSMITHKLINE	0.5%	N015868	001	
SOLUTION/DROPS;OPHTHALMIC				
DENDRID				
+ ALCON	0.1%	N014169	001	
HERPLEX				
ALLERGAN	0.1%	N013935	002	
STOXIL				
GLAXOSMITHKLINE	0.1%	N013934	001	
IFOSFAMIDE				
INJECTABLE;INJECTION				
IFOSFAMIDE				
FRESENIUS KABI USA	1GM/20ML (50MG/ML)	A090181	001	Sep 22, 2009
	3GM/60ML (50MG/ML)	A090181	002	Sep 22, 2009
MYLAN LABS LTD	1GM/20ML (50MG/ML)	A201689	001	Nov 26, 2012
	3GM/60ML (50MG/ML)	A201689	002	Nov 26, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IFOSFAMIDE; MESNA				
INJECTABLE;INJECTION				
IFEX/MESNEX KIT				
BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N019763	003	Oct 10, 1992
	3GM/VIAL;100MG/ML	N019763	004	Oct 10, 1992
INJECTABLE;INTRAVENOUS				
IFOSFAMIDE/MESNA KIT				
TEVA PHARMS USA	1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	001	Feb 26, 2002
	3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)	A075874	002	Feb 26, 2002
ILOPERIDONE				
TABLET;ORAL				
ILOPERIDONE				
INVENTIA	1MG	A207231	001	Nov 28, 2016
	2MG	A207231	002	Nov 28, 2016
	4MG	A207231	003	Nov 28, 2016
	6MG	A207231	004	Nov 28, 2016
	8MG	A207231	005	Nov 28, 2016
	10MG	A207231	006	Nov 28, 2016
	12MG	A207231	007	Nov 28, 2016
TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019
	2MG	A207098	002	Jul 22, 2019
	4MG	A207098	003	Jul 22, 2019
	6MG	A207098	004	Jul 22, 2019
	8MG	A207098	005	Jul 22, 2019
	10MG	A207098	006	Jul 22, 2019
	12MG	A207098	007	Jul 22, 2019
ILOPROST				
SOLUTION;INHALATION				
VENTAVIS				
ACTELION	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004
IMATINIB MESYLATE				
CAPSULE;ORAL				
GLEEVEC				
+ NOVARTIS	EQ 50MG BASE **	N021335	001	May 10, 2001
+	EQ 100MG BASE **	N021335	002	May 10, 2001
TABLET;ORAL				
IMATINIB MESYLATE				
AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019
	EQ 400MG BASE	A207495	002	Feb 08, 2019
IMIPRAMINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
IMIPRAMINE HYDROCHLORIDE				
NOVARTIS	25MG/ML	A086765	001	
INJECTABLE;INJECTION				
TOFRANIL				
NOVARTIS	12.5MG/ML	N011838	002	
TABLET;ORAL				
IMIPRAMINE HYDROCHLORIDE				
CHARTWELL	10MG	A090441	002	Mar 11, 2010
	25MG	A090441	003	Mar 11, 2010
	50MG	A090441	001	Mar 11, 2010
LEDERLE	10MG	A086269	001	
	25MG	A086267	001	
	50MG	A086268	001	
PAR PHARM	10MG	A089422	001	Jul 14, 1987
	25MG	A089497	001	Jul 14, 1987
ROXANE	10MG	A083799	001	
	25MG	A083799	002	
	50MG	A083799	003	
SANDOZ	10MG	A085200	001	
	25MG	A084869	002	
	50MG	A085133	001	
TEVA	10MG	A083729	001	
	25MG	A083729	004	
	50MG	A083729	003	
USL PHARMA	25MG	A087776	001	Feb 10, 1982
VANGARD	10MG	A088036	001	Nov 03, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IMIPRAMINE HYDROCHLORIDE				
TABLET;ORAL				
IMIPRAMINE HYDROCHLORIDE				
	25MG	A087619	001	Feb 09, 1982
	50MG	A087631	001	Jan 04, 1982
WATSON LABS	10MG	A085220	001	
	10MG	A085875	001	
	25MG	A084252	002	
	25MG	A085878	001	
	50MG	A085221	001	
	50MG	A085877	001	
WEST WARD	25MG	A088222	001	May 26, 1983
	50MG	A088223	001	May 26, 1983
JANIMINE				
ABBOTT	10MG	N017895	001	
	25MG	N017895	002	
	50MG	N017895	003	
PRAMINE				
ALRA	10MG	A083827	001	
	25MG	A083827	002	
	50MG	A083827	003	
PRESAMINE				
SANOFI AVENTIS US	10MG	N011836	006	
	25MG	N011836	003	
	50MG	N011836	007	
IMIPRAMINE PAMOATE				
CAPSULE;ORAL				
IMIPRAMINE PAMOATE				
RISING	EQ 75MG HYDROCHLORIDE	A202338	001	Jun 28, 2013
	EQ 100MG HYDROCHLORIDE	A202338	002	Jun 28, 2013
	EQ 125MG HYDROCHLORIDE	A202338	003	Jun 28, 2013
	EQ 150MG HYDROCHLORIDE	A202338	004	Jun 28, 2013
TOFRANIL-PM				
+ SPECGX LLC	EQ 75MG HYDROCHLORIDE **	N017090	001	
+	EQ 100MG HYDROCHLORIDE **	N017090	004	
+	EQ 125MG HYDROCHLORIDE **	N017090	003	
+	EQ 150MG HYDROCHLORIDE **	N017090	002	
IMIQUIMOD				
CREAM;TOPICAL				
IMIQUIMOD				
ANDA REPOSITORY	5%	A091044	001	Feb 28, 2011
COSETTE	5%	A200481	001	Apr 18, 2011
STRIDES PHARMA	5%	A202002	001	Jun 24, 2014
INAMRINONE LACTATE				
INJECTABLE;INJECTION				
AMRINONE LACTATE				
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A075542	001	May 10, 2000
HOSPIRA	EQ 5MG BASE/ML	A074616	001	Aug 03, 1998
INOCOR				
SANOFI AVENTIS US	EQ 5MG BASE/ML	N018700	001	Jul 31, 1984
INDACATEROL MALEATE				
POWDER;INHALATION				
ARCAPTA NEOHALER				
+ NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011
INDAPAMIDE				
TABLET;ORAL				
INDAPAMIDE				
ANI PHARMS	1.25MG	A074498	002	Feb 12, 1998
	1.25MG	A075201	001	Dec 04, 1998
	2.5MG	A074498	001	Oct 31, 1996
	2.5MG	A075201	002	Dec 04, 1998
MYLAN PHARMS INC	1.25MG	A075105	001	Jul 23, 1998
	2.5MG	A075105	002	Jul 23, 1998
RISING	1.25MG	A074461	002	Mar 26, 1997
	2.5MG	A074461	001	Mar 27, 1996
TEVA	1.25MG	A074665	001	Apr 04, 1997
	2.5MG	A074665	002	Apr 04, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INDAPAMIDE					
TABLET;ORAL					
INDAPAMIDE					
	WATSON LABS	1.25MG	A074585	001	Sep 26, 1996
		2.5MG	A074585	002	Sep 26, 1996
	YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996
		2.5MG	A074594	002	May 23, 1996
LOZOL					
+	SANOFI AVENTIS US	1.25MG **	N018538	002	Apr 29, 1993
+		2.5MG **	N018538	001	Jul 06, 1983
INDECAINIDE HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
DECABID					
	LILLY	EQ 50MG BASE	N019693	001	Dec 29, 1989
		EQ 75MG BASE	N019693	002	Dec 29, 1989
		EQ 100MG BASE	N019693	003	Dec 29, 1989
INDINAVIR SULFATE					
CAPSULE;ORAL					
CRIXIVAN					
	MERCK SHARP DOHME	EQ 100MG BASE	N020685	006	Apr 19, 2000
+		EQ 200MG BASE	N020685	003	Mar 13, 1996
		EQ 333MG BASE	N020685	005	Dec 17, 1998
+		EQ 400MG BASE	N020685	001	Mar 13, 1996
INDIUM IN-111 CHLORIDE					
INJECTABLE;INJECTION					
INDICLOR					
+	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
INDOCYANINE GREEN					
INJECTABLE;INJECTION					
IC-GREEN					
	AKORN	10MG/VIAL **	N011525	003	
		40MG/VIAL **	N011525	004	
		50MG/VIAL **	N011525	002	
INDOMETHACIN					
CAPSULE;ORAL					
INDO-LEMMON					
	TEVA	25MG	A070266	001	Nov 07, 1985
		50MG	A070267	001	Nov 07, 1985
INDOCIN					
+	EGALET	25MG **	N016059	001	
+		50MG **	N016059	002	
INDOMETHACIN					
	ABLE	25MG	A076666	001	Dec 17, 2003
		50MG	A076666	002	Dec 17, 2003
	ANI PHARMS	25MG	A071148	001	Mar 18, 1987
		50MG	A071149	001	Mar 18, 1987
	CHARTWELL MOLECULES	25MG	N018829	002	Aug 06, 1984
		50MG	A070651	001	Mar 05, 1986
		50MG	N018829	001	Aug 06, 1984
	CYCLE PHARMS LTD	25MG	A070353	001	Jun 18, 1985
		50MG	A070354	001	Jun 18, 1985
	DURAMED PHARMS BARR	25MG	A070326	001	Oct 18, 1985
		50MG	A070327	001	Oct 18, 1985
	HALSEY	25MG	A070782	001	Jun 03, 1987
		50MG	A070635	001	Jun 03, 1987
	HERITAGE	25MG	N018851	001	May 18, 1984
		50MG	N018851	002	May 18, 1984
	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986
		50MG	A070756	001	Feb 12, 1986
	IVAX SUB TEVA PHARMS	25MG	N018730	001	May 04, 1984
		50MG	N018730	002	May 04, 1984
	JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017
		50MG	A205215	002	Aug 25, 2017
	MUTUAL PHARM	25MG	A070067	001	Oct 03, 1986
		50MG	A070068	001	Oct 03, 1986
	PARKE DAVIS	25MG	N018806	001	Nov 23, 1984
		50MG	N018806	002	Nov 23, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INDOMETHACIN				
CAPSULE;ORAL				
INDOMETHACIN				
PIONEER PHARMS	25MG	A070813	001	Aug 11, 1986
	50MG	A070592	001	Aug 11, 1986
RISING	25MG	N018858	001	Apr 20, 1984
	50MG	A070624	001	Sep 04, 1985
	50MG	N018858	002	Apr 20, 1984
SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013
	50MG	A091401	002	Mar 28, 2013
SUN PHARM INDUSTRIES	25MG	A070900	002	Feb 09, 1987
	50MG	A070900	001	Feb 09, 1987
SUPERPHARM	25MG	A070487	001	Oct 10, 1986
	50MG	A070488	001	Oct 10, 1986
TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984
TIVORBEX				
+ GENUS	20MG	N204768	001	Feb 24, 2014
+	40MG	N204768	002	Feb 24, 2014
CAPSULE, EXTENDED RELEASE;ORAL				
INDOCIN SR				
+ EGALET	75MG **	N018185	001	Feb 23, 1982
INDOMETHACIN				
ABLE	75MG	A076114	001	Feb 06, 2002
AUROBINDO PHARMA LTD	75MG	A204243	001	Dec 27, 2016
INWOOD LABS	75MG	A072410	001	Mar 15, 1989
JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015
RISING PHARMA	75MG	A202139	001	Mar 20, 2014
WATSON LABS INC	75MG	A202572	001	Dec 09, 2013
SUPPOSITORY;RECTAL				
INDOCIN				
+ EGALET	50MG **	N017814	001	Aug 13, 1984
SUSPENSION;ORAL				
INDOMETHACIN				
HIKMA	25MG/5ML	A071412	001	Mar 18, 1987
INDOMETHACIN SODIUM				
INJECTABLE;INJECTION				
INDOCIN				
+ RECORDATI RARE	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985
INGENOL MEBUTATE				
GEL;TOPICAL				
INGENOL MEBUTATE				
PADAGIS ISRAEL	0.015%	A209018	001	Jan 07, 2019
	0.05%	A209019	001	Jan 09, 2019
PICATO				
+ LEO LABS	0.015%	N202833	001	Jan 23, 2012
+	0.05%	N202833	002	Jan 23, 2012
INULIN				
INJECTABLE;INJECTION				
INULIN AND SODIUM CHLORIDE				
ISO TEX	100MG/ML	N002282	001	
INVERT SUGAR				
INJECTABLE;INJECTION				
TRAVERT 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	10GM/100ML	N016717	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IOBENGUANE SULFATE I-131
INJECTABLE;INJECTION
IOBENGUANE SULFATE I 131
PHARMALUCENCE 2.3mCi/ML N020084 001 Mar 25, 1994

IOCETAMIC ACID
TABLET;ORAL
CHOLEBRINE
MALLINCKRODT 750MG N017129 001

IODAMIDE MEGLUMINE
INJECTABLE;INJECTION
RENOVUE-65
BRACCO 65% N017902 001
RENOVUE-DIP
BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINE
INJECTABLE;INJECTION
CHOLOGRAFIN MEGLUMINE
BRACCO 10.3% N009321 007
\+ 52% N009321 003

IODIPAMIDE SODIUM
INJECTABLE;INJECTION
CHOLOGRAFIN SODIUM
BRACCO 20% N009321 001

IODIXANOL
INJECTABLE;INJECTION
VISIPAQUE 270
GE HEALTHCARE 55% N020808 001 Aug 29, 1997

IODOHIPPURATE SODIUM I-123
INJECTABLE;INJECTION
NEPHROFLOW
GE HEALTHCARE 1mCi/ML N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131
INJECTABLE;INJECTION
HIPPURAN I 131
MALLINCKRODT 0.25mCi/ML N016666 001
HIPPUTOPE
BRACCO 1-2mCi/VIAL N015419 002
IODOHIPPURATE SODIUM I 131
PHARMALUCENCE 0.2mCi/ML N017313 001

IODOXAMATE MEGLUMINE
INJECTABLE;INJECTION
CHOLOVUE
BRACCO 9.9% N018077 001
40.3% N018076 001

IOFETAMINE HYDROCHLORIDE I-123
INJECTABLE;INJECTION
SPECTAMINE
IMP 1mCi/ML N019432 001 Dec 24, 1987

IOHEXOL
FOR SOLUTION;ORAL
ORALTAG
INTERPHARMA PRAHA AS 9.7GM/BOT N205383 001 Mar 26, 2015
INJECTABLE;INJECTION
OMNIPAQUE 210
GE HEALTHCARE 45.3% N018956 006 Jun 30, 1989
SOLUTION;INJECTION, ORAL, RECTAL
OMNIPAQUE 240
GE HEALTHCARE 51.8% N020608 001 Oct 24, 1995
SOLUTION;URETHRAL
OMNIPAQUE 70
GE HEALTHCARE 15.1% N018956 007 Jun 01, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IOPAMIDOL

INJECTABLE;INJECTION

IOPAMIDOL

BAXTER HLTHCARE	41%	A074629	001	Nov 06, 1996
	51%	A074629	004	Mar 31, 1998
	61%	A074629	002	Nov 06, 1996
	76%	A074629	003	Nov 06, 1996
HOSPIRA	61%	A074734	001	Dec 10, 1996
	76%	A074734	002	Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING	41%	A074881	001	Jul 28, 2000
HOSPIRA	41%	A074898	001	Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA	41%	A074636	001	Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING	51%	A074881	002	Jul 28, 2000
FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997
HOSPIRA	51%	A074898	002	Dec 30, 1997
	51%	A075005	001	Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA	51%	A074636	002	Dec 30, 1997

IOPAMIDOL-300

ABBVIE	61%	A074638	001	Apr 30, 1997
COOK IMAGING	61%	A074881	003	Jul 28, 2000
FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997
HOSPIRA	61%	A074898	003	Dec 30, 1997
	61%	A075005	002	Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA	61%	A074636	003	Dec 30, 1997
	61%	A074637	001	Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING	76%	A074881	004	Jul 28, 2000
FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997
HOSPIRA	76%	A074898	004	Dec 30, 1997
	76%	A075005	003	Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA	76%	A074636	004	Dec 30, 1997

ISOVUE-128

BRACCO	26%	N018735	005	Oct 21, 1986

ISOVUE-200

BRACCO	41%	N020327	001	Oct 12, 1994

SCANLUX-300

SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010

SCANLUX-370

SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010

IOPANOIC ACID

TABLET;ORAL

TELEPAQUE

GE HEALTHCARE	500MG	N008032	001	

IOPHENDYLATE

INJECTABLE;INJECTION

PANTOPAQUE

ALCON	100%	N005319	001	

IOPROMIDE

INJECTABLE;INJECTION

ULTRAVIST (PHARMACY BULK)

+	BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004

ULTRAVIST 150

+	BAYER HLTHCARE	31.2%	N020220	004	May 10, 1995

ULTRAVIST 240

+	BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995

ULTRAVIST 300 IN PLASTIC CONTAINER

+	BAYER HLTHCARE	62.3%	N020220	005	Nov 18, 2008

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION				
CONRAY 30				
+	LIEBEL-FLARSHEIM	30%	N016983 001	
CONRAY 43				
+	LIEBEL-FLARSHEIM	43%	N013295 002	

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE;INJECTION				
VASCORAY				
	MALLINCKRODT	52%;26%	N016783 001	

IOTHALAMATE SODIUM

INJECTABLE;INJECTION				
ANGIO-CONRAY				
	MALLINCKRODT	80%	N013319 001	
CONRAY 325				
	MALLINCKRODT	54.3%	N017685 001	
CONRAY 400				
	MALLINCKRODT	66.8%	N014295 001	

IOTROLAN

INJECTABLE;INTRATHECAL				
OSMOVIST 190				
	BAYER HLTHCARE	40.6%	N019580 001	Dec 07, 1989
OSMOVIST 240				
	BAYER HLTHCARE	51.3%	N019580 002	Dec 07, 1989

IOVERSOL

INJECTABLE;INJECTION				
OPTIRAY 160				
	LIEBEL-FLARSHEIM	34%	N019710 003	Dec 30, 1988
OPTIRAY 240				
+	LIEBEL-FLARSHEIM	51%	N019710 002	Dec 30, 1988
		51%	N020923 001	May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE;INJECTION				
HEXABRIX				
	GUERBET	39.3%;19.6%	N018905 002	Jul 26, 1985

IOXILAN

INJECTABLE;INJECTION				
OXILAN-300				
	GUERBET	62%	N020316 001	Dec 21, 1995
OXILAN-350				
	GUERBET	73%	N020316 002	Dec 21, 1995

IPODATE CALCIUM

GRANULE;ORAL				
ORAGRAFIN CALCIUM				
	BRACCO	3GM/PACKET	N012968 001	

IPODATE SODIUM

CAPSULE;ORAL				
BILIVIST				
	BAYER HLTHCARE	500MG	A087768 001	Aug 11, 1982
ORAGRAFIN SODIUM				
	BRACCO	500MG	N012967 001	

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION				
ATROVENT				
	BOEHRINGER INGELHEIM	0.018MG/INH	N019085 001	Dec 29, 1986
SOLUTION;INHALATION				
ATROVENT				
+	BOEHRINGER INGELHEIM	0.02% **	N020228 001	Sep 29, 1993
IPRATROPIUM BROMIDE				
	ACTAVIS MID ATLANTIC	0.02%	A075111 001	Apr 22, 1999
	APOTEX INC	0.02%	A075441 001	Mar 28, 2001
	BAUSCH AND LOMB INC	0.02%	A075835 001	Oct 15, 2001
	LANDELA PHARM	0.02%	A077072 001	Jul 19, 2005
	MYLAN SPECIALITY LP	0.02%	A074755 001	Jan 10, 1997
	ROXANE	0.02%	A075867 001	Jul 22, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IPRATROPIUM BROMIDE				
SOLUTION;INHALATION				
IPRATROPIUM BROMIDE				
	TEVA PHARMS USA	0.02%	A075313 001	Feb 07, 2000
	WATSON LABS	0.02%	A076291 001	May 09, 2005
	ZENNOVA	0.02%	A075507 001	Jan 19, 2001
SPRAY, METERED;NASAL				
ATROVENT				
+	BOEHRINGER INGELHEIM	0.021MG/SPRAY **	N020393 001	Oct 20, 1995
+		0.042MG/SPRAY **	N020394 001	Oct 20, 1995
IPRATROPIUM BROMIDE				
	MYLAN SPECIALITY LP	0.021MG/SPRAY	A075552 001	Mar 31, 2003
		0.042MG/SPRAY	A075553 001	Mar 31, 2003
IRBESARTAN				
TABLET;ORAL				
IRBESARTAN				
	AJANTA PHARMA LTD	75MG	A203685 001	Dec 10, 2015
		150MG	A203685 002	Dec 10, 2015
		300MG	A203685 003	Dec 10, 2015
	APOTEX INC	75MG	A200832 001	Oct 15, 2012
		150MG	A200832 002	Oct 15, 2012
		300MG	A200832 003	Oct 15, 2012
	HIKMA	75MG	A090201 001	Oct 15, 2012
		150MG	A090201 002	Oct 15, 2012
		300MG	A090201 003	Oct 15, 2012
	MYLAN PHARMS INC	75MG	A200461 001	Sep 27, 2012
		150MG	A200461 002	Sep 27, 2012
		300MG	A200461 003	Sep 27, 2012
	PICKET PHARMS	75MG	A203161 001	Sep 27, 2012
		150MG	A203161 002	Sep 27, 2012
		300MG	A203161 003	Sep 27, 2012
	WATSON LABS INC	75MG	A090720 001	Oct 12, 2012
		150MG	A090720 002	Oct 12, 2012
		300MG	A090720 003	Oct 12, 2012
IRINOTECAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
IRINOTECAN HYDROCHLORIDE				
	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008
		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008
	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012
		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012
	FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188 001	Feb 27, 2008
		100MG/5ML (20MG/ML)	A078188 002	Feb 27, 2008
	PICKET PHARMS	40MG/2ML (20MG/ML)	A078953 001	Apr 15, 2010
		100MG/5ML (20MG/ML)	A078953 002	Apr 15, 2010
	PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122 001	Oct 31, 2008
		100MG/5ML (20MG/ML)	A078122 002	Oct 31, 2008
	SANDOZ	40MG/2ML (20MG/ML)	A077994 001	Feb 27, 2008
		100MG/5ML (20MG/ML)	A077994 002	Feb 27, 2008
	SANDOZ INC	40MG/2ML (20MG/ML)	A090137 001	Nov 12, 2009
		100MG/5ML (20MG/ML)	A090137 002	Nov 12, 2009
	SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805 001	Apr 21, 2008
		100MG/5ML (20MG/ML)	A078805 002	Apr 21, 2008
ISOETHARINE HYDROCHLORIDE				
SOLUTION;INHALATION				
BETA-2				
	NEPHRON	1%	A086711 001	
BRONKOSOL				
	SANOFI AVENTIS US	0.25%	N012339 009	
		1%	N012339 008	
ISOETHARINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	1%	A087101 001	
+	ASTRAZENECA	0.062%	A087937 001	Nov 15, 1982
		0.062%	A089614 001	Jun 13, 1991
+		0.125%	A087938 001	Nov 15, 1982
		0.125%	A089615 001	Jun 13, 1991
+		0.167%	A088470 001	Mar 14, 1984
		0.167%	A089616 001	Jun 13, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOETHARINE HYDROCHLORIDE				
SOLUTION;INHALATION				
ISOETHARINE HYDROCHLORIDE				
+	0.2%	A088471	001	Mar 14, 1984
	0.2%	A089617	001	Jun 13, 1991
+	0.25%	A088472	001	Mar 14, 1984
	0.25%	A089618	001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144	001	Jul 29, 1983
	0.14%	A088145	001	Mar 26, 1984
	0.25%	A088146	001	Aug 01, 1983
DEY	0.08%	A088187	001	Dec 03, 1982
	0.1%	A087389	001	
	0.17%	A087390	001	
	0.25%	A088188	001	Dec 03, 1982
+	1%	A086763	001	
INTL MEDICATION	0.077%	A086651	001	
	0.08%	A086651	002	
	0.1%	A086651	003	
	0.143%	A086651	004	
	0.167%	A086651	005	
	0.2%	A086651	006	
	0.25%	A086651	007	
	1%	A086651	008	
PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986
ISOETHARINE MESYLATE				
AEROSOL, METERED;INHALATION				
BRONKOMETER				
SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984
ISOFLURANE				
LIQUID;INHALATION				
ISOFLURANE				
HOSPIRA	99.9%	A074097	001	Jan 25, 1993
WATSON LABS INC	99.9%	A074393	001	May 12, 1995
ISOFLUROPHATE				
OINTMENT;OPHTHALMIC				
FLOROPRYL				
MERCK	0.025%	N010656	001	
ISONIAZID				
INJECTABLE;INJECTION				
NYDRAZID				
SANDOZ	100MG/ML **	N008662	001	
RIMIFON				
ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	
SYRUP;ORAL				
ISONIAZID				
ANDA REPOSITORY	50MG/5ML	A081118	001	Jul 21, 1997
LANIAZID				
LANNETT	50MG/5ML	A089243	001	Feb 03, 1986
RIMIFON				
ROCHE	50MG/5ML	N008420	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISONIAZID

TABLET;ORAL					
DOW-ISONIAZID					
	DOW PHARM	300MG	A080330	002	
HYZYD					
	MEDPOINTE PHARM HLC	100MG	A080134	003	
		300MG	A080134	004	
INH					
	NOVARTIS	300MG	A080935	001	
ISONIAZID					
	DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
		300MG	A088119	001	Mar 17, 1983
	HALSEY	50MG	A083632	001	
	HIKMA INTL PHARMS	100MG	A080212	001	
		300MG	A087425	001	
	IMPAX LABS	100MG	A080153	001	
	IVAX SUB TEVA PHARMS	100MG	A080270	001	
		300MG	A083610	001	
	LILLY	100MG	N008499	002	
		300MG	N008499	003	
	MK LABS	100MG	A080941	001	
	NEXGEN PHARMA INC	100MG	A084050	001	
	PANRAY	50MG	N008428	001	
		100MG	N008428	002	
		300MG	N008428	003	
	PERRIGO	100MG	A083060	001	
	PHARMAVITE	100MG	A085091	001	
	PHOENIX LABS NY	50MG	A080368	001	
		100MG	A080368	002	
	PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
		100MG	A080132	004	Jul 14, 1982
+	SANDOZ	100MG **	N008678	002	
+		300MG **	N008678	003	
	SUN PHARM INDUSTRIES	100MG	A080136	001	
		300MG	A083633	001	
	WATSON LABS	50MG	A080522	001	
		100MG	A080401	001	
		100MG	A080523	001	
		100MG	A085790	001	
		300MG	A080521	001	
		300MG	A083178	001	
		300MG	A085784	001	
	WHITEWORTH TOWN PLSN	100MG	A080120	002	
LANIAZID					
	LANNETT	50MG	A080140	001	
		100MG	A080140	002	
		300MG	A089776	001	Jun 13, 1988
NYDRAZID					
	BRISTOL MYERS SQUIBB	100MG	N008392	003	
STANOZIDE					
	EVERYLIFE	100MG	A080126	001	
		300MG	A080126	002	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET;ORAL					
RIFATER					
+	SANOFI AVENTIS US	50MG;300MG;120MG	N050705	001	May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE;ORAL					
RIFAMATE					
	SANOFI AVENTIS US	150MG;300MG	A061884	001	
RIFAMPIN AND ISONIAZID					
	HIKMA INTL PHARMS	150MG;300MG	A065221	001	Jul 29, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOPROPAMIDE IODIDE
TABLET;ORAL
DARBID
GLAXOSMITHKLINE EQ 5MG BASE N010744 001

ISOPROPYL ALCOHOL
SOLUTION;TOPICAL
ZURAGARD
\+ ZUREX PHARMA 70% N210872 001 Apr 26, 2019

ISOPROTERENOL HYDROCHLORIDE
AEROSOL, METERED;INHALATION
ISOPROTERENOL HYDROCHLORIDE
3M 0.12MG/INH N010375 004
ALPHARMA US PHARMS 0.12MG/INH A085904 001
ISUPREL
SANOFI AVENTIS US 0.103MG/INH N011178 001
DISC;INHALATION
NORISODRINE AEROTROL
ABBOTT 0.25% N016814 001
INJECTABLE;INJECTION
ISOPROTERENOL HYDROCHLORIDE
ABRAXIS PHARM 0.2MG/ML A083431 001
BAXTER HLTHCARE 0.2MG/ML A083486 001
CIPLA 0.2MG/ML A211738 001 Jun 28, 2019
HOSPIRA 0.02MG/ML A083283 001
0.2MG/ML A083346 001
INTL MEDICATION 0.2MG/ML A083724 001
SOLUTION;INHALATION
AEROLONE
LILLY 0.25% N007245 001
ISOPROTERENOL HYDROCHLORIDE
ARMOUR PHARM 0.031% A087935 001 Nov 18, 1982
0.062% A087936 001 Nov 18, 1982
DEY 0.5% A086764 001 Jan 04, 1982
PARKE DAVIS 0.25% A085994 001
0.5% A085540 001
ISUPREL
SANOFI AVENTIS US 0.5% N006327 002
1% N006327 003
VAPO-ISO
FISONS 0.5% N016813 001
TABLET;RECTAL, SUBLINGUAL
ISUPREL
SANOFI AVENTIS US 10MG N006328 001
15MG N006328 002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE
AEROSOL, METERED;INHALATION
DUO-MEDIHALER
3M 0.16MG/INH;0.24MG/INH N013296 001

ISOPROTERENOL SULFATE
AEROSOL, METERED;INHALATION
MEDIHALER-ISO
3M 0.08MG/INH N010375 003
POWDER;INHALATION
NORISODRINE
ABBVIE 10% N006905 003
25% N006905 002

ISOSORBIDE
SOLUTION;ORAL
ISMOTIC
ALCON 100GM/220ML N017063 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOSORBIDE DINITRATE					
CAPSULE, EXTENDED RELEASE;ORAL					
DILATRATE-SR					
+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988
ISORDIL					
	WYETH AYERST	40MG	N012882	002	Jul 29, 1988
TABLET;ORAL					
ISORDIL					
+	BAUSCH	10MG **	N012093	002	Jul 29, 1988
+		20MG **	N012093	006	Jul 29, 1988
+		30MG **	N012093	005	Jul 29, 1988
ISOSORBIDE DINITRATE					
	ANI PHARMS	10MG	A086032	001	Jan 07, 1988
	HIKMA INTL PHARMS	30MG	A040591	001	Jan 10, 2007
	SUN PHARM INDUSTRIES	5MG	A086166	002	Sep 19, 1986
		10MG	A086169	001	Sep 19, 1986
		20MG	A086167	001	Sep 19, 1986
		30MG	A087564	001	Sep 18, 1986
	SUPERPHARM	5MG	A089190	001	Feb 17, 1987
		10MG	A089191	001	Feb 17, 1987
		20MG	A089192	001	Feb 17, 1987
	WATSON LABS	5MG	A086034	001	Jan 06, 1988
SORBITRATE					
	ASTRAZENECA	5MG	N016192	001	Apr 01, 1996
		10MG	N016192	002	Apr 01, 1996
		20MG	A086405	002	Aug 21, 1990
		30MG	A088124	001	Aug 21, 1990
		40MG	A088125	001	Aug 21, 1990
TABLET;SUBLINGUAL					
ISORDIL					
+	BIOVAIL	2.5MG **	N012940	004	Jul 29, 1988
+		5MG **	N012940	003	Jul 29, 1988
+		10MG **	N012940	005	Jul 29, 1988
ISOSORBIDE DINITRATE					
	HIKMA INTL PHARMS	2.5MG	A086054	001	Oct 29, 1987
		5MG	A086055	001	Nov 02, 1987
	SANDOZ	2.5MG	A086225	001	Feb 19, 1988
		5MG	A086222	001	Feb 19, 1988
	SUN PHARM INDUSTRIES	2.5MG	A084204	001	Sep 18, 1986
		5MG	A086168	001	Sep 18, 1986
		10MG	A087545	001	Sep 18, 1986
	WATSON LABS	2.5MG **	A086033	001	Feb 26, 1988
	WATSON LABS TEVA	5MG **	A086031	001	Sep 29, 1987
SORBITRATE					
	ASTRAZENECA	2.5MG	N016191	002	Apr 01, 1996
		5MG	N016191	001	Apr 01, 1996
TABLET, CHEWABLE;ORAL					
SORBITRATE					
	ASTRAZENECA	5MG	N016776	002	Apr 01, 1996
		10MG	N016776	003	Apr 01, 1996
TABLET, EXTENDED RELEASE;ORAL					
ISORDIL					
	WYETH AYERST	40MG	N012882	001	Jul 29, 1988
ISOSORBIDE DINITRATE					
	IMPAX LABS INC	40MG	A040723	001	Mar 17, 2008
ISOSORBIDE MONONITRATE					
TABLET;ORAL					
ISMO					
	PROMIUS PHARMA	20MG	N019091	001	Dec 30, 1991
ISOSORBIDE MONONITRATE					
	ANI PHARMS	20MG	A075147	001	Nov 27, 1998
	HIKMA PHARMS	20MG	A075361	001	Oct 05, 2000
TABLET, EXTENDED RELEASE;ORAL					
IMDUR					
+	SCHERING PLOUGH	30MG **	N020225	001	Aug 12, 1993
+		60MG **	N020225	002	Aug 12, 1993
+		120MG **	N020225	003	Mar 30, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL					
ISOSORBIDE MONONITRATE					
	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017
		60MG	A209684	002	Oct 24, 2017
		120MG	A209684	003	Oct 24, 2017
	ACTAVIS ELIZABETH	30MG	A075306	001	Dec 31, 1998
		60MG	A075306	002	Dec 31, 1998
	ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22, 1998
	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006
		60MG	A076813	001	Jan 07, 2005
	IVAX SUB TEVA PHARMS	30MG	A075448	002	Aug 07, 2001
		60MG	A075448	001	Jun 19, 2000
		120MG	A075448	003	Aug 07, 2001
	SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999
	STRIDES PHARMA	30MG	A090598	001	Aug 11, 2010
		60MG	A090598	002	Aug 11, 2010
		120MG	A090598	003	Aug 11, 2010

ISOSULFAN BLUE

INJECTABLE;INJECTION					
ISOSULFAN BLUE					
	BELOTECA INC	1%	A210714	001	Jan 16, 2019
	SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019
LYMPHAZURIN					
+	COVIDIEN	1% **	N018310	001	

ISOTRETINOIN

CAPSULE;ORAL					
ABSORICA LD					
+	SUN PHARM	20MG	N211913	003	Nov 05, 2019
+		28MG	N211913	005	Nov 05, 2019
ACCUTANE					
+	HOFFMANN LA ROCHE	10MG **	N018662	002	May 07, 1982
+		20MG **	N018662	004	Mar 28, 1983
+		40MG **	N018662	003	May 07, 1982
SOTRET					
	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002
		20MG	A076041	002	Dec 24, 2002
		30MG	A076503	001	Jun 20, 2003
		40MG	A076041	003	Dec 24, 2002

ISRADIPINE

CAPSULE;ORAL					
DYNACIRC					
+	SMITHKLINE BEECHAM	2.5MG **	N019546	001	Dec 20, 1990
+		5MG **	N019546	002	Dec 20, 1990
TABLET, EXTENDED RELEASE;ORAL					
DYNACIRC CR					
+	GLAXOSMITHKLINE LLC	5MG **	N020336	001	Jun 01, 1994
+		10MG **	N020336	002	Jun 01, 1994
ISRADIPINE					
	MYLAN	5MG	A201067	001	Nov 27, 2015
		10MG	A201067	002	Nov 27, 2015

ITRACONAZOLE

CAPSULE;ORAL					
ITRACONAZOLE					
	MYLAN PHARMS INC	100MG	A200463	001	Jul 20, 2012
	STRIDES PHARMA	100MG	A206410	001	Jul 02, 2019
INJECTABLE;INJECTION					
SPORANOX					
	JANSSEN PHARMS	10MG/ML	N020966	001	Mar 30, 1999
SOLUTION;ORAL					
ITRACONAZOLE					
	APOTEX	10MG/ML	A208481	001	Aug 02, 2019
TABLET;ORAL					
ONMEL					
+	SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

IVERMECTIN				
CREAM;TOPICAL				
IVERMECTIN				
PADAGIS ISRAEL	1%	A210225	001	Apr 13, 2020
TABLET;ORAL				
STROMECTOL				
+ MERCK SHARP DOHME	6MG **	N050742	001	Nov 22, 1996
KANAMYCIN SULFATE				
CAPSULE;ORAL				
KANTREX				
APOTHECON	EQ 500MG BASE	A060516	001	
	EQ 500MG BASE	A061911	001	
	EQ 500MG BASE	A062726	001	Mar 06, 1987
INJECTABLE;INJECTION				
KANAMYCIN				
HIKMA	EQ 75MG BASE/2ML	A062324	001	
	EQ 500MG BASE/2ML	A062324	002	
	EQ 1GM BASE/3ML	A062324	003	
KANAMYCIN SULFATE				
ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504	001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504	002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504	003	Apr 05, 1984
FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002
	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002
INTL MEDICATION	EQ 500MG BASE/2ML	A062466	001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466	002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021	001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022	001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025	001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668	001	May 07, 1987
	EQ 500MG BASE/2ML	A062672	001	May 07, 1987
	EQ 1GM BASE/3ML	A062669	001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605	003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605	001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605	002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092	001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML	A062520	003	May 09, 1985
KANTREX				
APOTHECON	EQ 75MG BASE/2ML	A061655	003	
	EQ 75MG BASE/2ML	A061901	003	
	EQ 75MG BASE/2ML	A062564	001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655	001	
	EQ 500MG BASE/2ML	A061901	001	
	EQ 500MG BASE/2ML	A062564	002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655	002	
	EQ 1GM BASE/3ML	A061901	002	
	EQ 1GM BASE/3ML	A062564	003	Sep 21, 1984
KLEBCIL				
KING PHARMS	EQ 75MG BASE/2ML	A062170	001	
	EQ 500MG BASE/2ML	A062170	002	
	EQ 1GM BASE/3ML	A062170	003	
KETOCONAZOLE				
CREAM;TOPICAL				
NIZORAL				
+ JANSSEN PHARMA	2% **	N019084	001	Dec 31, 1985
SHAMPOO;TOPICAL				
NIZORAL				
+ JANSSEN PHARMS	2%	N019927	001	Aug 31, 1990
SUSPENSION;ORAL				
NIZORAL				
JANSSEN PHARMA	100MG/5ML	A070767	001	Nov 07, 1986
TABLET;ORAL				
KETOCONAZOLE				
AAIPHARMA LLC	200MG	A075341	001	Jul 27, 1999
HERITAGE PHARMA	200MG	A074971	001	Jun 15, 1999
	200MG	A075362	001	Jun 15, 1999
MYLAN	200MG	A075597	001	Dec 23, 1999
SUN PHARM INDUSTRIES	200MG	A075314	001	Jun 15, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KETOCONAZOLE					
TABLET;ORAL					
KETOCONAZOLE					
	TEVA	200MG	A075273	001	Jun 15, 1999
NIZORAL					
+	JANSSEN PHARMS	200MG **	N018533	001	
KETOPROFEN					
CAPSULE;ORAL					
KETOPROFEN					
	MYLAN	50MG	A074035	002	Dec 31, 1996
		75MG	A074035	003	Dec 31, 1996
	RISING	50MG	A074024	001	Dec 29, 1995
		75MG	A074024	002	Dec 29, 1995
	TEVA	25MG	A073515	001	Dec 22, 1992
		75MG	A073517	001	Dec 22, 1992
ORUDIS					
+	WYETH AYERST	25MG **	N018754	001	Jul 31, 1987
+		50MG **	N018754	002	Jan 09, 1986
+		75MG **	N018754	003	Jan 09, 1986
CAPSULE, EXTENDED RELEASE;ORAL					
KETOPROFEN					
	ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999
		150MG	A075270	003	Mar 24, 1999
		200MG	A075270	001	Mar 24, 1999
	ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
	MYLAN	100MG	A075679	003	Feb 20, 2002
		150MG	A075679	002	Feb 20, 2002
ORUVAIL					
+	WYETH PHARMS INC	100MG **	N019816	003	Feb 08, 1995
+		150MG **	N019816	002	Feb 08, 1995
+		200MG **	N019816	001	Sep 24, 1993
FILM;ORAL					
NEXCEDE					
	NOVARTIS	12.5MG	N022470	001	Nov 25, 2009
TABLET;ORAL					
ACTRON					
	BAYER	12.5MG	N020499	001	Oct 06, 1995
KETOPROFEN					
	PERRIGO	12.5MG	A075364	001	Feb 07, 2002
ORUDIS KT					
+	WYETH CONS	12.5MG **	N020429	001	Oct 06, 1995
KETOROLAC TROMETHAMINE					
INJECTABLE;INJECTION					
KETOROLAC TROMETHAMINE					
	AMPHASTAR PHARM	15MG/ML	A076209	001	Jul 21, 2004
		30MG/ML	A076209	002	Jul 21, 2004
	APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001
		30MG/ML	A077201	001	Oct 14, 2005
	APOTHECON	15MG/ML	A075348	001	Nov 28, 2000
		30MG/ML	A075348	002	Nov 28, 2000
	ATLANTIDE	30MG/ML	A077943	001	Mar 27, 2007
	BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001
		30MG/ML	A075631	001	Jun 29, 2001
	BEDFORD	15MG/ML	A075230	002	Oct 25, 1999
		30MG/ML	A075230	001	Oct 25, 1999
	EUGIA PHARMA	15MG/ML	A212939	001	Oct 20, 2020
		30MG/ML	A212939	002	Oct 20, 2020
	GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004
		30MG/ML	A076722	002	Jul 27, 2004
	HIKMA	15MG/ML **	A075222	001	Apr 26, 1999
		15MG/ML	A075299	001	Nov 03, 1999
		30MG/ML **	A075222	002	Apr 26, 1999
		30MG/ML **	A075228	001	Apr 26, 1999
		30MG/ML	A075299	002	Nov 03, 1999
	HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997
		15MG/ML	A074993	001	Jan 27, 1999
		30MG/ML	A074801	002	Jun 05, 1997
	LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

KETOROLAC TROMETHAMINE				
INJECTABLE;INJECTION				
KETOROLAC TROMETHAMINE				
	30MG/ML	A078145	002	Jan 14, 2008
MYLAN LABS LTD	15MG/ML	A078299	001	Jul 16, 2007
	15MG/ML	A201155	001	Aug 04, 2014
	30MG/ML	A078299	002	Jul 16, 2007
	30MG/ML	A201155	002	Aug 04, 2014
SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004
SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008
	30MG/ML	A078737	002	Oct 06, 2008
TORADOL				
+ ROCHE PALO	15MG/ML **	N019698	001	Nov 30, 1989
+	30MG/ML **	N019698	002	Nov 30, 1989
SOLUTION/DROPS;OPHTHALMIC				
ACULAR PRESERVATIVE FREE				
ALLERGAN	0.5%	N020811	001	Nov 03, 1997
KETOROLAC TROMETHAMINE				
AKORN	0.45%	A203376	001	Feb 10, 2014
EUGIA PHARMA	0.4%	A205191	001	Nov 15, 2018
	0.5%	A205190	001	Dec 03, 2020
SANDOZ INC	0.4%	A078721	001	Nov 05, 2009
TABLET;ORAL				
KETOROLAC TROMETHAMINE				
CYCLE PHARMS LTD	10MG	A074790	001	Jun 26, 1997
PLIVA	10MG	A075284	001	Jun 23, 1999
WATSON LABS	10MG	A074955	001	Sep 19, 1997
TORADOL				
+ ROCHE PALO	10MG **	N019645	001	Dec 20, 1991
KETOTIFEN FUMARATE				
SOLUTION/DROPS;OPHTHALMIC				
ZADITOR				
+ ALCON PHARMA	EQ 0.025% BASE **	N021066	002	Oct 19, 2006
KRYPTON, KR-81M				
GAS;INHALATION				
MPI KRYPTON 81M GENERATOR				
GE HEALTHCARE	N/A	N018088	001	
L-GLUTAMINE				
FOR SOLUTION;ORAL				
NUTRESTORE				
+ EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004
LABETALOL HYDROCHLORIDE				
INJECTABLE;INJECTION				
LABETALOL HYDROCHLORIDE				
AKORN	5MG/ML	A075524	001	Nov 29, 1999
APOTHECON	5MG/ML	A075355	001	Nov 29, 1999
HOSPIRA	5MG/ML	A075242	001	Sep 30, 1999
MYLAN ASI	5MG/ML	A079134	001	Feb 03, 2010
NORMODYNE				
+ SCHERING	5MG/ML **	N018686	001	Aug 01, 1984
TRANDATE				
+ SEBELA IRELAND LTD	5MG/ML **	N019425	001	Dec 31, 1985
TABLET;ORAL				
LABETALOL HYDROCHLORIDE				
APOTHECON	100MG	A075223	001	Nov 20, 1998
	200MG	A075223	002	Nov 20, 1998
	300MG	A075223	003	Nov 20, 1998
TEVA	100MG	A074989	001	Sep 30, 1998
	200MG	A074989	002	Sep 30, 1998
	300MG	A074989	003	Sep 30, 1998
NORMODYNE				
+ SCHERING	100MG **	N018687	001	Aug 31, 1987
+	200MG **	N018687	002	Aug 01, 1984
+	300MG **	N018687	003	Aug 01, 1984
+	400MG **	N018687	004	Aug 01, 1984
TRANDATE				
+ ALVOGEN	100MG	N018716	001	May 24, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LABETALOL HYDROCHLORIDE					
TABLET;ORAL					
TRANDATE					
+		400MG **	N018716	004	Aug 01, 1984
LACTITOL					
FOR SOLUTION;ORAL					
PIZENSY					
+	BRAINTREE LABS	10GM	N211281	001	Feb 12, 2020
LACTULOSE					
SOLUTION;ORAL					
CHRONULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017884	001	
CONSTILAC					
	ALRA	10GM/15ML	A071054	001	Jul 26, 1988
CONSTULOSE					
	ACTAVIS MID ATLANTIC	10GM/15ML	A070288	001	Aug 15, 1988
DUPHALAC					
	SOLVAY	10GM/15ML	A072372	001	Mar 22, 1989
EVALOSE					
	TEVA PHARMS	10GM/15ML	A073497	001	May 28, 1993
LACTULOSE					
	ANI PHARMS	10GM/15ML	A078430	001	Nov 28, 2007
	HIKMA	10GM/15ML	A073591	001	May 29, 1992
	MORTON GROVE	10GM/15ML	A071841	001	Sep 22, 1988
	PACO	10GM/15ML	A073160	001	Aug 25, 1992
LAXILOSE					
	NOSTRUM LABS	10GM/15ML	A073686	001	May 28, 1993
SOLUTION;ORAL, RECTAL					
ACILAC					
	NOSTRUM LABS	10GM/15ML	A073685	001	May 28, 1993
CEPHULAC					
+	SANOFI AVENTIS US	10GM/15ML **	N017657	001	
CHOLAC					
	ALRA	10GM/15ML	A071331	001	Jul 26, 1988
ENULOSE					
	ACTAVIS MID ATLANTIC	10GM/15ML	A071548	001	Aug 15, 1988
GENERLAC					
	MORTON GROVE	10GM/15ML	A071842	001	Sep 27, 1988
HEPTALAC					
	TEVA PHARMS	10GM/15ML	A073504	001	May 28, 1993
LACTULOSE					
	ANI PHARMS	10GM/15ML	A090426	001	Nov 21, 2008
	BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003
	PACO	10GM/15ML	A072029	001	Aug 25, 1992
	ROXANE	10GM/15ML	A073590	001	May 29, 1992
	SOLVAY	10GM/15ML	N017906	001	
PORTALAC					
	SOLVAY	10GM/15ML	A072374	001	Mar 22, 1989
LAMIVUDINE					
TABLET;ORAL					
LAMIVUDINE					
	MYLAN	100MG	A204002	001	Dec 31, 2014
		150MG	A204528	001	Mar 04, 2016
		300MG	A204528	002	Mar 04, 2016
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE					
TABLET;ORAL					
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE					
+	MICRO LABS	150MG;200MG;300MG	N205626	001	Aug 13, 2018
LAMIVUDINE; RALTEGRAVIR POTASSIUM					
TABLET;ORAL					
DUTREBIS					
	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE					
TABLET;ORAL					
LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE					
+	AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018
TEMIXYS					
+	CELLTRION	300MG;300MG	N211284	001	Nov 16, 2018
LAMIVUDINE; ZIDOVUDINE					
TABLET;ORAL					
LAMIVUDINE AND ZIDOVUDINE					
	MYLAN	150MG;300MG	A204005	001	Aug 28, 2014
	MYLAN LABS LTD	150MG;300MG	A079079	001	Aug 12, 2019
	PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017
	TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011
LAMOTRIGINE					
TABLET;ORAL					
LAMICTAL					
+	GLAXOSMITHKLINE LLC	50MG **	N020241	006	Dec 27, 1994
+		250MG **	N020241	004	Dec 27, 1994
LAMOTRIGINE					
	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
		100MG	A078669	002	Apr 08, 2011
		150MG	A078669	003	Apr 08, 2011
		200MG	A078669	004	Apr 08, 2011
	CIPLA	25MG	A077783	001	Nov 01, 2010
		100MG	A077783	002	Nov 01, 2010
		150MG	A077783	003	Nov 01, 2010
		200MG	A077783	004	Nov 01, 2010
	GRANULES	25MG	A078982	001	Jan 27, 2009
		100MG	A078982	002	Jan 27, 2009
		150MG	A078982	003	Jan 27, 2009
		200MG	A078982	004	Jan 27, 2009
	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
		100MG	A078134	002	Apr 19, 2011
		150MG	A078134	003	Apr 19, 2011
		200MG	A078134	004	Apr 19, 2011
	MYLAN	25MG	A077428	001	Jan 27, 2009
		100MG	A077428	002	Jan 27, 2009
		150MG	A077428	003	Jan 27, 2009
		200MG	A077428	004	Jan 27, 2009
	MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009
		100MG	A078443	002	Feb 11, 2009
		150MG	A078443	003	Feb 11, 2009
		200MG	A078443	004	Feb 11, 2009
	RISING PHARMA	25MG	A077420	001	Jan 27, 2009
		100MG	A077420	002	Jan 27, 2009
		150MG	A077420	003	Jan 27, 2009
		200MG	A077420	004	Jan 27, 2009
	ROXANE	25MG	A077392	001	Jan 27, 2009
		100MG	A077392	002	Jan 27, 2009
		150MG	A077392	003	Jan 27, 2009
		200MG	A077392	004	Jan 27, 2009
	SANDOZ	25MG	A078645	001	Jan 27, 2009
		100MG	A078645	002	Jan 27, 2009
		150MG	A078645	003	Jan 27, 2009
		200MG	A078645	004	Jan 27, 2009
	TEVA	25MG	A076388	001	Aug 30, 2006
		100MG	A076388	002	Aug 30, 2006
		150MG	A076388	003	Aug 30, 2006
		200MG	A076388	004	Aug 30, 2006
	ZENNOVA	25MG	A078310	001	Feb 04, 2009
		100MG	A078310	002	Feb 04, 2009
		150MG	A078310	003	Feb 04, 2009
		200MG	A078310	004	Feb 04, 2009
TABLET, CHEWABLE;ORAL					
LAMICTAL CD					
	GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998
LAMOTRIGINE					
	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LAMOTRIGINE

TABLET, CHEWABLE;ORAL				
LAMOTRIGINE				
	25MG	A200220	002	Feb 28, 2011
MYLAN	5MG	A076630	001	Jan 22, 2009
	25MG	A076630	002	Jan 22, 2009
SANDOZ	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009
TEVA	5MG	A076420	001	Jun 21, 2006
	25MG	A076420	002	Jun 21, 2006
TABLET, EXTENDED RELEASE;ORAL				
LAMOTRIGINE				
RUBICON	25MG	A202887	001	Jun 17, 2013
	50MG	A202887	002	Jun 17, 2013

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL				
LANSOPRAZOLE				
AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016
	30MG	A203957	002	Oct 14, 2016
BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018
	30MG	A203964	002	Oct 17, 2018
KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013
	30MG	A091212	002	Sep 16, 2013
PREVACID				
+ TAKEDA PHARMS USA	15MG	N020406	001	May 10, 1995
FOR SUSPENSION, DELAYED RELEASE;ORAL				
PREVACID				
TAKEDA PHARMS NA	15MG/PACKET	N021281	001	May 03, 2001
	30MG/PACKET	N021281	002	May 03, 2001
INJECTABLE;INTRAVENOUS				
PREVACID IV				
+ TAKEDA PHARMS NA	30MG/VIAL **	N021566	001	May 27, 2004
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL				
LANSOPRAZOLE				
ANI PHARMS	15MG	A078730	001	Oct 15, 2010
	30MG	A078730	002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL				
PREVACID NAPRAPAC 250 (COPACKAGED)				
+ TAKEDA PHARMS NA	15MG,N/A;N/A,250MG **	N021507	002	Nov 14, 2003
PREVACID NAPRAPAC 375 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,375MG	N021507	003	Nov 14, 2003
PREVACID NAPRAPAC 500 (COPACKAGED)				
TAKEDA PHARMS NA	15MG,N/A;N/A,500MG	N021507	004	Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL				
FOSRENOL				
TAKEDA PHARMS USA	EQ 250MG BASE	N021468	001	Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL				
VIRAC REX				
CHESEBROUGH PONDS	0.5%;1.8%	N011914	001	

LASMIDITAN SUCCINATE

TABLET;ORAL				
REYVOW				
+ ELI LILLY AND CO	EQ 200MG BASE	N211280	003	Dec 18, 2020

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC				
LATANOPROST				
APOTEX INC	0.005%	A077697	001	Mar 22, 2011
EUGIA PHARMA	0.005%	A206519	001	Sep 03, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEFLUNOMIDE					
TABLET;ORAL					
LEFLUNOMIDE					
	AET PHARMA	10MG	A213497	001	May 10, 2021
		20MG	A213497	002	May 10, 2021
	BARR	10MG	A077083	001	Sep 13, 2005
		20MG	A077083	002	Sep 13, 2005
	SANDOZ	10MG	A077085	001	Sep 13, 2005
		20MG	A077085	002	Sep 13, 2005
	TEVA PHARMS	10MG	A077084	001	Sep 13, 2005
		20MG	A077084	002	Sep 13, 2005
LESINURAD					
TABLET;ORAL					
ZURAMPIC					
+	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015
LETROZOLE					
TABLET;ORAL					
LETROZOLE					
	ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011
	APOTEX INC	2.5MG	A091303	001	Apr 19, 2012
	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011
	HIKMA	2.5MG	A090838	001	Jun 03, 2011
	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016
	IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011
	JIANGSU PHARMS	2.5MG	A202716	001	May 16, 2013
	LANNETT CO INC	2.5MG	A091098	001	Jun 03, 2011
		2.5MG	A202048	001	Oct 29, 2014
	MYLAN	2.5MG	A078190	001	Dec 24, 2008
	STRIDES PHARMA	2.5MG	A090789	001	Jun 03, 2011
	SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011
	SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011
LEUCOVORIN CALCIUM					
FOR SOLUTION;ORAL					
LEUCOVORIN CALCIUM					
	HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987
INJECTABLE;INJECTION					
LEUCOVORIN CALCIUM					
	ABIC	EQ 3MG BASE/ML	A089352	001	Jun 01, 1988
		EQ 50MG BASE/VIAL	A089353	001	Jun 01, 1988
	ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
	ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
		EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
+	HOSPIRA	EQ 3MG BASE/ML **	N008107	001	
+		EQ 50MG BASE/VIAL **	N008107	002	
+		EQ 100MG BASE/VIAL **	N008107	004	May 23, 1988
+		EQ 350MG BASE/VIAL **	N008107	005	Apr 05, 1989
	NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018
	PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
	PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
		EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993
LEUCOVORIN CALCIUM PRESERVATIVE FREE					
	AM REGENT	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
	HOSPIRA	EQ 10MG BASE/ML **	A040147	001	Jun 25, 1997
	TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999
WELLCOVORIN					
	GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
		EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
		EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
		EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989
TABLET;ORAL					
LEUCOVORIN CALCIUM					
	ANI PHARMS	EQ 15MG BASE	A075327	001	Mar 24, 1999
	PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
		EQ 25MG BASE	A071598	001	Oct 14, 1987
	PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
		EQ 25MG BASE	A073101	001	Mar 28, 1997
	XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEUCOVORIN CALCIUM				
TABLET;ORAL				
LEUCOVORIN CALCIUM				
	EQ 10MG BASE	A071962	001	Nov 19, 1987
	EQ 15MG BASE	A071104	001	Mar 04, 1987
WELLCOVORIN				
+ GLAXOSMITHKLINE	EQ 5MG BASE **	N018342	001	Jul 08, 1983
+	EQ 25MG BASE **	N018342	002	Jul 08, 1983
LEUPROLIDE ACETATE				
FOR SUSPENSION;INTRAMUSCULAR				
LUTRATE DEPOT KIT				
+ GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018
IMPLANT;IMPLANTATION				
VIADUR				
ORTHO MCNEIL JANSSEN	EQ 65MG BASE	N021088	001	Mar 03, 2000
INJECTABLE;INJECTION				
LEUPROLIDE ACETATE				
GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001
LUPRON				
+ ABBVIE ENDOCRINE INC	1MG/0.2ML **	N019010	001	Apr 09, 1985
LUPRON DEPOT				
+ ABBVIE ENDOCRINE INC	3.75MG/VIAL **	N020011	001	Oct 22, 1990
POWDER;INTRAMUSCULAR				
LUPRON DEPOT-PED KIT				
+ ABBVIE ENDOCRINE INC	3.75MG,7.5MG **	N020263	003	Apr 16, 1993
+	7.5MG,7.5MG **	N020263	004	Apr 16, 1993
LEUPROLIDE ACETATE; NORETHINDRONE ACETATE				
INJECTABLE, TABLET;INTRAMUSCULAR, ORAL				
LUPANETA PACK				
+ ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N203696	001	Dec 14, 2012
+	11.25MG/VIAL,N/A;N/A,5MG	N203696	002	Dec 14, 2012
LEVALBUTEROL HYDROCHLORIDE				
SOLUTION;INHALATION				
LEVALBUTEROL HYDROCHLORIDE				
MYLAN SPECIALITY LP	EQ 0.0103% BASE	A077800	001	Mar 15, 2013
	EQ 0.021% BASE	A077800	002	Mar 15, 2013
	EQ 0.042% BASE	A077800	003	Mar 15, 2013
LEVALLORPHAN TARTRATE				
INJECTABLE;INJECTION				
LORFAN				
ROCHE	1MG/ML	N010423	001	
LEVAMISOLE HYDROCHLORIDE				
TABLET;ORAL				
ERGAMISOL				
JANSSEN PHARMA	EQ 50MG BASE	N020035	001	Jun 18, 1990
LEVAMLODIPINE MALEATE				
TABLET;ORAL				
CONJUPRI				
+ CSPC OUYI	EQ 1.25MG BASE	N212895	001	Dec 19, 2019
LEVETIRACETAM				
INJECTABLE;INTRAVENOUS				
LEVETIRACETAM				
AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018
AM REGENT	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012
FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010
JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016
SOLUTION;ORAL				
LEVETIRACETAM				
APOTEX INC	100MG/ML	A090187	001	Aug 05, 2011
TOLMAR	100MG/ML	A079107	001	Jan 15, 2009
TABLET;ORAL				
LEVETIRACETAM				
ACTAVIS LABS FL INC	250MG	A077408	001	Mar 02, 2009
	500MG	A077408	002	Mar 02, 2009
	750MG	A077408	003	Mar 02, 2009
FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVETIRACETAM				
TABLET;ORAL				
LEVETIRACETAM				
	500MG	A077324	002	Jan 15, 2009
	750MG	A077324	003	Jan 15, 2009
	1GM	A077324	004	Jan 15, 2009
LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016
	750MG	A090906	003	Oct 31, 2016
	1GM	A090906	004	Oct 31, 2016
MYLAN	250MG	A078731	001	Feb 10, 2009
	500MG	A078731	002	Feb 10, 2009
	750MG	A078731	003	Feb 10, 2009
	1GM	A078731	004	Feb 10, 2009
NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011
	500MG	A090511	002	Aug 18, 2011
	750MG	A090511	003	Aug 18, 2011
	1GM	A090511	004	Aug 18, 2011
TEVA PHARMS	250MG	A078101	001	Jan 15, 2009
	500MG	A078101	002	Jan 15, 2009
	750MG	A078101	003	Jan 15, 2009
	1GM	A078101	004	Jan 15, 2009
WATSON LABS INC	250MG	A078797	002	Jan 15, 2009
	500MG	A078797	003	Jan 15, 2009
	750MG	A078797	004	Jan 15, 2009
	1GM	A078797	001	Jan 15, 2009
TABLET, EXTENDED RELEASE;ORAL				
LEVETIRACETAM				
ACTAVIS ELIZABETH	500MG	A091557	001	Sep 12, 2011
	750MG	A091557	002	Sep 12, 2011
LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016
	750MG	A202095	001	Jun 06, 2016
MYLAN PHARMS INC	500MG	A200475	001	Dec 19, 2011
	750MG	A200475	002	Dec 19, 2011
	1GM	A200475	003	Dec 07, 2015
ROUSES POINT PHARMS	500MG	A202524	001	Aug 27, 2012
	750MG	A202524	002	Aug 27, 2012
SANDOZ	500MG	A091668	001	Nov 01, 2012
	750MG	A091668	002	Nov 01, 2012
SUN PHARM INDUSTRIES	500MG	A091285	001	Sep 12, 2011
	750MG	A091285	002	Sep 12, 2011
TEVA PHARMS	500MG	A091430	001	Sep 12, 2011
	750MG	A091430	002	Sep 12, 2011
TORRENT PHARMS LTD	500MG	A091338	001	May 29, 2012
	750MG	A091338	002	May 29, 2012
VIRTUS PHARMS	500MG	A091291	001	Sep 12, 2011
	750MG	A091291	002	Sep 12, 2011
LEVOBETAXOLOL HYDROCHLORIDE				
SUSPENSION/DROPS;OPHTHALMIC				
BETAXON				
ALCON PHARMS LTD	EQ 0.5% BASE	N021114	001	Feb 23, 2000
LEVOBUNOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
AKBETA				
AKORN	0.25%	A074779	001	Oct 29, 1996
	0.5%	A074780	001	Oct 29, 1996
BETAGAN				
+ ALLERGAN	0.25%	N019814	001	Jun 28, 1989
LEVOBUNOLOL HYDROCHLORIDE				
ALCON LABS INC	0.25%	A074851	001	Oct 28, 1996
APOTEX INC	0.25%	A075473	001	Aug 03, 2000
	0.5%	A075475	001	Aug 03, 2000
BAUSCH AND LOMB	0.25%	A074307	001	Mar 04, 1994
SANDOZ INC	0.5%	A074850	001	Oct 28, 1996

LEVOBUPIVACAINE HYDROCHLORIDE
INJECTABLE;INJECTION
CHIROCAINE

PURDUE PHARMA LP	EQ 2.5MG BASE/ML	N020997	001	Aug 05, 1999
	EQ 5MG BASE/ML	N020997	002	Aug 05, 1999
	EQ 7.5MG BASE/ML	N020997	003	Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE
SUSPENSION/DROPS;OPHTHALMIC
LIVOSTIN

NOVARTIS	EQ 0.05% BASE	N020219	001	Nov 10, 1993

LEVOCARNITINE
INJECTABLE;INJECTION
LEVOCARNITINE

TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001

SOLUTION;ORAL
CARNITOR

LEADIANT BIOSCI INC	1GM/10ML	N018948	002	Apr 27, 1988

LEVOCETIRIZINE DIHYDROCHLORIDE
SOLUTION;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX	2.5MG/5ML	A202915	001	Aug 21, 2014

XYZAL

+	SANOFI	2.5MG/5ML	N022157	001	Jan 28, 2008

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX	5MG	A203027	001	Feb 13, 2015
GRANULES	5MG	A090486	001	Mar 26, 2013
SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015
US ANTIBIOTICS	5MG	A204323	001	Dec 20, 2016

XYZAL

+	SANOFI	5MG	N022064	001	May 25, 2007

LEVODOPA
CAPSULE;ORAL
BENDOPA

VALEANT PHARM INTL	100MG	N016948	003	
	250MG	N016948	001	
	500MG	N016948	002	

DOPAR

SHIRE	100MG	N016913	003	
	250MG	N016913	001	
	500MG	N016913	002	

LARODOPA

ROCHE	100MG	N016912	002	
	250MG	N016912	001	
	500MG	N016912	006	

TABLET;ORAL
DOPAR

SHIRE	250MG	N016913	004	
	500MG	N016913	005	

LARODOPA

ROCHE	100MG	N016912	005	
	250MG	N016912	003	
	500MG	N016912	004	

LEVOFLOXACIN
INJECTABLE;INJECTION
LEVAQUIN

+	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML) **	N020635	001	Dec 20, 1996
+		EQ 750MG/30ML (EQ 25MG/ML) **	N020635	004	Dec 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML) **	N020635	002	Dec 20, 1996
+		EQ 500MG/100ML (EQ 5MG/ML) **	N020635	003	Dec 20, 1996
+		EQ 750MG/150ML (EQ 5MG/ML) **	N020635	005	Dec 20, 1996

LEVOFLOXACIN

EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013
	EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013
HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015
	EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVOFLOXACIN				
INJECTABLE;INJECTION				
LEVOFLOXACIN				
MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011
	EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011
ZYDUS PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017
	EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017
SOLUTION;ORAL				
LEVAQUIN				
+ JANSSEN PHARMS	250MG/10ML	N021721	001	Oct 21, 2004
SOLUTION/DROPS;OPHTHALMIC				
IQUIX				
+ SANTEN	1.5% **	N021571	001	Mar 01, 2004
LEVOFLOXACIN				
MYLAN LABS LTD	0.5%	A204899	001	Dec 08, 2017
RUBICON	0.5%	A078282	001	Dec 20, 2010
WATSON LABS TEVA	0.5%	A076826	001	Feb 10, 2011
QUIXIN				
+ SANTEN	0.5% **	N021199	001	Aug 18, 2000
TABLET;ORAL				
LEVAQUIN				
+ JANSSEN PHARMS	250MG **	N020634	001	Dec 20, 1996
+	500MG **	N020634	002	Dec 20, 1996
+	750MG **	N020634	003	Sep 08, 2000
LEVOFLOXACIN				
JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015
	500MG	A203613	002	Jun 19, 2015
MYLAN	250MG	A076276	001	Jun 20, 2011
	500MG	A076276	002	Jun 20, 2011
	750MG	A077097	001	Jun 20, 2011
TORRENT PHARMS	250MG	A090722	001	Jun 20, 2011
	500MG	A090722	002	Jun 20, 2011
	750MG	A090722	003	Jun 20, 2011
WATSON LABS INC	250MG	A201484	001	Nov 22, 2013
	500MG	A201484	002	Nov 22, 2013
	750MG	A201484	003	Nov 22, 2013
LEVOLEUCOVORIN CALCIUM				
POWDER;INTRAVENOUS				
LEVOLEUCOVORIN CALCIUM				
ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516	001	Feb 13, 2017
+	EQ 175MG BASE/VIAL	N208723	001	Sep 29, 2016
AMNEAL	EQ 50MG BASE/VIAL	A207547	001	Feb 13, 2017
SOLUTION;INTRAVENOUS				
FUSILEV				
+ ACROTECH	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **	N020140	002	Apr 29, 2011
+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140	003	Apr 29, 2011
LEVOLEUCOVORIN CALCIUM				
MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015
NOVAST LABS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623	001	May 03, 2018
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623	002	May 03, 2018
SANDOZ INC	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015
LEVOMEPROMAZINE				
INJECTABLE;INJECTION				
LEVOPROME				
IMMUNEX	20MG/ML	N015865	001	
LEVOMETHADYL ACETATE HYDROCHLORIDE				
CONCENTRATE;ORAL				
ORLAAM				
+ ROXANE	10MG/ML **	N020315	001	Jul 09, 1993

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
LEVOMILNACIPRAN HYDROCHLORIDE				
	AMNEAL PHARMS CO	EQ 20MG BASE	A210790 001	Feb 04, 2019
		EQ 40MG BASE	A210790 002	Feb 04, 2019
		EQ 80MG BASE	A210790 003	Feb 04, 2019
		EQ 120MG BASE	A210790 004	Feb 04, 2019
	HIKMA	EQ 20MG BASE	A210732 001	Nov 05, 2020
		EQ 40MG BASE	A210732 002	Nov 05, 2020
		EQ 80MG BASE	A210732 003	Nov 05, 2020
		EQ 120MG BASE	A210732 004	Nov 05, 2020

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
	SOLVAY	0.05MG/ML;2%	A085010 001	
CARBOCAINE W/ NEO-COBEFRIN				
	EASTMAN KODAK	0.05MG/ML;2%	N012125 002	
ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
	SEPTODONT INC	0.05MG/ML;2%	A084697 001	
MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN				
	BELMORA LLC	0.05MG/ML;2%	A084850 002	Oct 21, 1983
POLOCAINE W/ LEVONORDEFRIN				
	DENTSPLY PHARM	0.05MG/ML;2%	A089517 001	Apr 14, 1988

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN				
	EASTMAN KODAK	0.05MG/ML;2%;0.4%	N008592 007	

LEVONORGESTREL

IMPLANT;IMPLANTATION				
JADELLE				
+	POPULATION COUNCIL	75MG/IMPLANT **	N020544 001	Nov 01, 1996
LEVONORGESTREL				
	WYETH PHARMS INC	75MG/IMPLANT	N020627 001	Aug 15, 1996
NORPLANT				
	POPULATION COUNCIL	36MG/IMPLANT	N019897 001	Dec 10, 1990
NORPLANT SYSTEM IN PLASTIC CONTAINER				
	WYETH PHARMS INC	36MG/IMPLANT	N020088 001	Dec 10, 1990
TABLET;ORAL				
LEVONORGESTREL				
	ALVOGEN	1.5MG	A202246 001	Jun 05, 2015
	FDN CONSUMER	0.75MG **	A078665 001	Aug 28, 2009
		1.5MG	A200670 001	Jul 12, 2012
	LOTUS PHARM CO LTD	0.75MG	A202684 001	Sep 02, 2016
	LUPIN LTD	0.75MG	A091328 001	Jan 23, 2013
	MYLAN LABS LTD	0.75MG	A202740 001	Sep 02, 2016
	NAARI PTE LTD	1.5MG	A207660 001	May 02, 2019
	WATSON LABS	0.75MG	A078666 001	Jun 24, 2009
PLAN B				
+	FDN CONSUMER	0.75MG **	N021045 001	Jul 28, 1999
+		0.75MG **	N021045 002	Aug 24, 2006

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE	N012928 006	
		EQ 100MG BASE	N012928 004	
SUSPENSION;ORAL				
NOVRAD				
	LILLY	EQ 50MG BASE/5ML	N012928 002	

LEVORPHANOL TARTRATE

INJECTABLE;INJECTION				
LEVO-DROMORAN				
	VALEANT PHARM INTL	2MG/ML	N008719 001	Dec 19, 1991
TABLET;ORAL				
LEVO-DROMORAN				
+	VALEANT PHARM INTL	2MG **	N008720 001	Dec 19, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LEVORPHANOL TARTRATE				
TABLET;ORAL				
LEVORPHANOL TARTRATE				
SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018
LEVOTHYROXINE SODIUM				
CAPSULE;ORAL				
LEVOTHYROXINE SODIUM				
TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020
	0.088MG	A213256	001	Jan 06, 2021
	0.1MG	A213256	002	Jan 06, 2021
	0.125MG	A213256	003	Jan 06, 2021
	0.15MG	A211369	002	Oct 28, 2020
POWDER;INTRAVENOUS				
LEVOTHYROXINE SODIUM				
DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020
PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015
TABLET;ORAL				
EUTHYROX				
PROVELL	0.3MG	N021292	012	May 31, 2002
LEVOLET				
GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003
	0.05MG	N021137	002	Jun 06, 2003
	0.075MG	N021137	003	Jun 06, 2003
	0.088MG	N021137	004	Jun 06, 2003
	0.1MG	N021137	005	Jun 06, 2003
	0.112MG	N021137	006	Jun 06, 2003
	0.125MG	N021137	007	Jun 06, 2003
	0.137MG	N021137	008	Jun 06, 2003
	0.15MG	N021137	009	Jun 06, 2003
	0.175MG	N021137	010	Jun 06, 2003
	0.2MG	N021137	011	Jun 06, 2003
	0.3MG	N021137	012	Jun 06, 2003
LEVOTHYROXINE SODIUM				
AMNEAL	0.025MG	A210831	001	Feb 19, 2019
	0.05MG	A210831	002	Feb 19, 2019
	0.075MG	A210831	003	Feb 19, 2019
	0.088MG	A210831	004	Feb 19, 2019
	0.1MG	A210831	005	Feb 19, 2019
	0.112MG	A210831	006	Feb 19, 2019
	0.125MG	A210831	007	Feb 19, 2019
	0.137MG	A210831	008	Feb 19, 2019
	0.15MG	A210831	009	Feb 19, 2019
	0.175MG	A210831	010	Feb 19, 2019
	0.2MG	A210831	011	Feb 19, 2019
	0.3MG	A210831	012	Feb 19, 2019
MERCK KGAA	0.025MG	A076752	001	Jun 16, 2005
	0.05MG	A076752	002	Jun 16, 2005
	0.075MG	A076752	003	Jun 16, 2005
	0.088MG	A076752	004	Jun 16, 2005
	0.1MG	A076752	005	Jun 16, 2005
	0.112MG	A076752	006	Jun 16, 2005
	0.125MG	A076752	007	Jun 16, 2005
	0.15MG	A076752	008	Jun 16, 2005
	0.175MG	A076752	009	Jun 16, 2005
	0.2MG	A076752	010	Jun 16, 2005
	0.3MG	A076752	011	Jun 16, 2005
LEVOXYL				
+ KING PHARMS	0.3MG **	N021301	012	May 25, 2001
LIDOCAINE				
AEROSOL;ORAL				
XYLOCAINE				
ASTRAZENECA	10%	N014394	001	
FILM, EXTENDED RELEASE;BUCCAL				
DENTIPATCH				
NOVEN	23MG/PATCH	N020575	001	May 21, 1996
OINTMENT;TOPICAL				
ALPHACAINE				
CARLISLE	5%	A084944	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE				
OINTMENT;TOPICAL				
ALPHACAINE				
	5%	A084946	001	
	5%	A084947	001	
LIDOCAINE				
BELMORA LLC	5%	A080210	001	
GENEYORK PHARMS	5%	A212486	001	Oct 17, 2019
RISING	5%	A208604	001	Sep 20, 2017
TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018
XYLOCAINE				
+ ASTRAZENECA	5% **	N008048	001	
PATCH;TOPICAL				
DENTIPATCH				
NOVEN	46.1MG/PATCH	N020575	002	May 21, 1996
LIDOCAINE				
NOVEN PHARMS INC	5%	A203265	001	Dec 01, 2020
SOLUTION;TOPICAL				
XYLOCAINE				
ASTRAZENECA	5%	N014127	001	
SUPPOSITORY;RECTAL				
XYLOCAINE				
ASTRAZENECA	100MG	N013077	001	
LIDOCAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ALPHACAINE HYDROCHLORIDE				
CARLISLE	2%	A084721	001	
LIDOCAINE HYDROCHLORIDE				
ABBOTT	10%	A087980	001	Feb 02, 1983
	20%	A089362	001	May 25, 1988
ABRAXIS PHARM	1%	A080420	001	
	1%	A086761	001	
	1.5%	A080420	005	
	2%	A080420	002	
	2%	A080420	004	
	2%	A086761	002	
	2%	N017508	001	
	4%	N017508	002	
	20%	N017508	004	
AKORN	1%	A085037	001	
	2%	A085037	002	
AM REGENT	1%	A080850	001	
	1%	A091564	001	Aug 14, 2015
BEL MAR	1%	A080710	001	
	2%	A080760	001	
BELMORA LLC	2%	A080504	001	
DELL LABS	1%	A083387	001	
	2%	A083388	001	
ELKINS SINN	0.5%	A085131	001	
	4%	A084626	001	
GD SEARLE LLC	1%	A083135	001	
	2%	A083135	002	
HOSPIRA	1%	A040013	001	Jun 23, 1995
	1.5%	A088330	001	May 17, 1984
	2%	A088331	001	May 17, 1984
	20%	A083158	003	
INTL MEDICATION	1%	N017701	002	
	2%	N017701	001	
	1GM/VIAL	N018543	001	
	2GM/VIAL	N018543	002	
LUITPOLD	2%	A083198	001	
LYPHOMED	1%	A080390	001	
	2%	A080390	002	
MILES	1%	A080414	001	
	2%	A080414	002	
RISING	0.5%	A091056	001	Dec 08, 2010
	0.5%	A091058	001	Sep 30, 2010
	1%	A091056	002	Dec 08, 2010
	1%	A091058	002	Sep 30, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
LIDOCAINE HYDROCHLORIDE				
RISING PHARMA	2%	A202242	001	Apr 11, 2014
WATSON LABS	1%	A080377	001	
	1%	A083627	001	
	2%	A080377	002	
	2%	A083627	002	
WYETH AYERST	1%	A083083	001	
	2%	A083083	002	
LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	100MG/100ML	N018461	001	
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N018967	001	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%				
HOSPIRA	200MG/100ML	A083158	005	
LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	200MG/100ML	N018954	001	Jul 09, 1985
HOSPIRA	200MG/100ML	N018388	001	
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	400MG/100ML	N018967	002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%				
HOSPIRA	400MG/100ML	A083158	006	
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	400MG/100ML	N018388	002	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	800MG/100ML	N018967	003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER				
HOSPIRA	800MG/100ML	N018388	003	Nov 05, 1982
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER				
HOSPIRA	1.5%	A088326	001	Jul 31, 1984
	10%	A088367	001	Jul 31, 1984
	20%	A088368	001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE				
INTL MEDICATION	4%	N017702	002	
	20%	N017702	001	
MYLAN LABS LTD	2%	A090665	001	Sep 27, 2010
LIDOCATON				
PHARMATON	2%	A084727	001	Aug 17, 1983
LIDOPEN				
MERIDIAN MEDCL TECHN	10%	N017549	001	
XYLOCAINE				
ASTRAZENECA	1%	N010418	005	
	1.5%	N010418	009	
	2%	N010418	007	
XYLOCAINE 4% PRESERVATIVE FREE				
+ FRESENIUS KABI USA	4%	N010417	001	
XYLOCAINE DENTAL				
DENTSPLY PHARM	2%	N021380	001	
XYLOCAINE PRESERVATIVE FREE				
+ FRESENIUS KABI USA	1% **	N016801	005	Jan 19, 1988
+	2% **	N016801	001	
+	4% **	N016801	002	
	10% **	N016801	003	
+	20% **	N016801	004	
INJECTABLE;SPINAL				
XYLOCAINE 1.5% W/ DEXTROSE 7.5%				
FRESENIUS KABI USA	1.5%	N016297	001	
XYLOCAINE 5% W/ GLUCOSE 7.5%				
ASTRAZENECA	5%	N010496	002	Jul 07, 1982
JELLY;TOPICAL				
ANESTACON				
BIONPHARMA INC	2%	A080429	001	
LIDOCAINE HYDROCHLORIDE				
COSETTE	2%	A081318	001	Apr 29, 1993
WATSON LABS INC	2%	A040837	001	Mar 23, 2011
XYLOCAINE				
+ AKORN	2%	N008816	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LIDOCAINE HYDROCHLORIDE

SOLUTION;ORAL				
LIDOCAINE HYDROCHLORIDE VISCOUS				
	ACTAVIS MID ATLANTIC	2%	A086578 001	
	INTL MEDICATION	2%	A086389 001	Feb 02, 1982
XYLOCAINE VISCOUS				
+	FRESENIUS KABI USA	2% **	N009470 001	
SOLUTION;TOPICAL				
LARYNGOTRACHEAL ANESTHESIA KIT				
	KENDALL IL	4%	A087931 001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE				
	PACO	4%	A089688 001	Jun 30, 1989
LTA II KIT				
	HOSPIRA	4%	A080409 001	
		4%	A088542 001	Jul 31, 1984
PEDIATRIC LTA KIT				
	ABBOTT	2%	A088572 001	Jul 31, 1984
	HOSPIRA	2%	A085995 001	
XYLOCAINE 4% PRESERVATIVE FREE				
+	FRESENIUS KABI USA	4%	N010417 002	

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE;INJECTION				
TERRAMYCIN				
	PFIZER	2%;50MG/ML	A060567 001	
		2%;125MG/ML	A060567 002	

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL				
LIDOCAINE AND PRILOCAINE				
	RHODES PHARMS	2.5%;2.5%	A213253 001	Sep 21, 2020
DISC;TOPICAL				
EMLA				
	ASTRAZENECA	2.5%;2.5%	N020962 001	Feb 04, 1998

LINACLOTIDE

CAPSULE;ORAL				
LINACLOTIDE				
	MYLAN	145MCG	A209564 001	Feb 09, 2021
		290MCG	A209564 002	Feb 09, 2021

LINCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL				
LINCOCIN				
	PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001	
		EQ 500MG BASE	N050316 002	
INJECTABLE;INJECTION				
LINCOMYCIN HYDROCHLORIDE				
	PRAXGEN	EQ 300MG BASE/ML	A212770 001	Mar 12, 2021
	WATSON LABS	EQ 300MG BASE/ML	A063180 001	Apr 16, 1991

LINDANE

CREAM;TOPICAL				
KWELL				
	REED AND CARNRICK	1%	A084218 001	
		1%	N006309 001	
LOTION;TOPICAL				
GAMENE				
	SOLA BARNES HIND	1%	A084989 001	
KWELL				
	REED AND CARNRICK	1%	A084218 002	
		1%	N006309 003	
LINDANE				
	OLTA PHARMS	1%	A087313 001	
	WOCKHARDT BIO AG	1%	A088190 001	Aug 16, 1984
SCABENE				
	STIEFEL	1%	A086769 001	
SHAMPOO;TOPICAL				
GAMENE				
	SOLA BARNES HIND	1%	A084988 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LINDANE				
SHAMPOO;TOPICAL				
KWELL				
	REED AND CARNRICK	1%	A084219 001	
		1%	N010718 001	
LINDANE				
	OLTA PHARMS	1%	A087266 001	
SCABENE				
	STIEFEL	1%	A087940 001	Apr 08, 1983
LINEZOLID				
SOLUTION;INTRAVENOUS				
ZYVOX				
+	PFIZER	400MG/200ML (2MG/ML) **	N021131 002	Apr 18, 2000
TABLET;ORAL				
LINEZOLID				
	GATE PHARMS	600MG	A091210 001	Feb 05, 2016
	RISING	600MG	A078845 001	Dec 21, 2015
	TEVA PHARMS USA	600MG	A078061 001	May 18, 2015
ZYVOX				
+	PFIZER	400MG **	N021130 001	Apr 18, 2000
LIOTHYRONINE SODIUM				
TABLET;ORAL				
LIOTHYRONINE SODIUM				
	MYLAN	EQ 0.005MG BASE	A090326 001	Jul 14, 2009
		EQ 0.025MG BASE	A090326 002	Jul 14, 2009
		EQ 0.05MG BASE	A090326 003	Jul 14, 2009
	WATSON LABS	EQ 0.025MG BASE	A085755 001	Jan 25, 1982
		EQ 0.05MG BASE	A085753 001	Feb 03, 1982
LIOTRIX (T4;T3)				
TABLET;ORAL				
EUTHROID-0.5				
	PARKE DAVIS	0.03MG;0.0075MG	N016680 001	
EUTHROID-1				
	PARKE DAVIS	0.06MG;0.015MG	N016680 002	
EUTHROID-2				
	PARKE DAVIS	0.12MG;0.03MG	N016680 003	
EUTHROID-3				
	PARKE DAVIS	0.18MG;0.045MG	N016680 004	
THYROLAR-0.25				
+	ALLERGAN	0.0125MG;0.0031MG	N016807 001	
THYROLAR-0.5				
+	ALLERGAN	0.025MG;0.0063MG	N016807 005	
THYROLAR-1				
+	ALLERGAN	0.05MG;0.0125MG	N016807 004	
THYROLAR-2				
+	ALLERGAN	0.1MG;0.025MG	N016807 002	
THYROLAR-3				
+	ALLERGAN	0.15MG;0.0375MG	N016807 003	
THYROLAR-5				
	ALLERGAN	0.25MG;0.0625MG	N016807 006	
LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
	HERITAGE PHARMA	2.5MG	A075752 001	Jul 01, 2002
		5MG	A075752 002	Jul 01, 2002
		10MG	A075752 003	Jul 01, 2002
		20MG	A075752 004	Jul 01, 2002
		30MG	A075752 005	Jul 01, 2002
		40MG	A075752 006	Jul 01, 2002
	HIKMA INTL PHARMS	2.5MG	A076063 001	Jul 01, 2002
		5MG	A076063 002	Jul 01, 2002
		10MG	A076063 003	Jul 01, 2002
		20MG	A076063 004	Jul 01, 2002
		30MG	A076063 006	Jun 27, 2003
		40MG	A076063 005	Jul 01, 2002
	MYLAN	2.5MG	A076071 001	Jul 01, 2002
		5MG	A076071 002	Jul 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LISINOPRIL				
TABLET;ORAL				
LISINOPRIL				
	10MG		A076071 003	Jul 01, 2002
	20MG		A076071 004	Jul 01, 2002
	30MG		A076071 005	Jul 01, 2002
	40MG		A076071 006	Jul 01, 2002
PHARMGEN	2.5MG		A075999 001	Jul 01, 2002
	5MG		A075999 002	Jul 01, 2002
	10MG		A075999 003	Jul 01, 2002
	20MG		A075999 004	Jul 01, 2002
	30MG		A075999 005	Jul 01, 2002
	40MG		A075999 006	Jul 01, 2002
TEVA	2.5MG		A075783 001	Jul 01, 2002
	5MG		A075783 002	Jul 01, 2002
	10MG		A075783 003	Jul 01, 2002
	20MG		A075783 004	Jul 01, 2002
	30MG		A075783 005	Jul 01, 2002
	40MG		A075783 006	Jul 01, 2002
PRINIVIL				
MERCK	2.5MG		N019558 006	Jan 28, 1994
	10MG		N019558 002	Dec 29, 1987
	20MG		N019558 003	Dec 29, 1987
LITHIUM CARBONATE				
CAPSULE;ORAL				
ESKALITH				
NOVEN THERAP	300MG		N016860 001	
LITHIUM CARBONATE				
ABLE	150MG		A076823 001	Jun 29, 2004
	300MG		A076121 001	Sep 27, 2001
	300MG		A076823 002	Jun 29, 2004
	600MG		A076823 003	Jun 29, 2004
APOTEX INC	300MG		A076795 001	Nov 22, 2004
MYLAN	150MG		A076243 002	Feb 24, 2003
	300MG		A076243 001	Jun 27, 2002
	600MG		A078763 001	Apr 15, 2008
USL PHARMA	300MG		A072542 001	Feb 01, 1989
WATSON LABS	300MG		A070407 001	Mar 19, 1987
LITHONATE				
SOLVAY	300MG		N016782 001	
TABLET;ORAL				
ESKALITH				
JDS PHARMS	300MG		N017971 001	
LITHANE				
BAYER PHARMS	300MG		N018833 001	Jul 18, 1985
LITHIUM CARBONATE				
HIKMA INTL PHARMS	300MG		A078715 001	Dec 28, 2010
PFIZER	300MG		N016834 001	
LITHOTABS				
SOLVAY	300MG		N016980 001	
TABLET, EXTENDED RELEASE;ORAL				
ESKALITH CR				
JDS PHARMS	450MG **		N018152 001	Mar 29, 1982
LITHIUM CARBONATE				
ABLE	300MG		A076382 001	Apr 21, 2003
ALEMBIC PHARMS LTD	300MG		A204445 001	Jun 10, 2015
HERITAGE PHARMA	300MG		A076170 001	Jun 10, 2002
	450MG		A076366 001	Aug 21, 2003
HIKMA INTL PHARMS	450MG		A076490 001	Jun 17, 2003
LITHIUM CITRATE				
SYRUP;ORAL				
LITHONATE				
SOLVAY	EQ 300MG CARBONATE/5ML		N017672 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LOMEFLOXACIN HYDROCHLORIDE

TABLET;ORAL					
MAXAQUIN					
	PHARMACIA	EQ 400MG BASE	N020013	001	Feb 21, 1992

LOMITAPIDE MESYLATE

CAPSULE;ORAL					
JUXTAPID					
+	AMRYT	EQ 40MG BASE	N203858	005	Apr 23, 2015
+		EQ 60MG BASE	N203858	006	Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL					
GLEOSTINE					
+	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL					
IMODIUM					
	J AND J CONSUMER INC	2MG **	N017690	001	
+		2MG **	N017694	001	
LOPERAMIDE HYDROCHLORIDE					
	ROXANE	2MG	A073080	001	Nov 27, 1991
	TEVA	2MG	A073122	001	Aug 30, 1991
	YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992
SOLUTION;ORAL					
IMODIUM					
	JANSSEN PHARMS	1MG/5ML	N019037	001	Jul 31, 1984
LOPERAMIDE HYDROCHLORIDE					
	ALLIED	1MG/5ML	A073079	001	Apr 30, 1992
	ALPHARMA US PHARMS	1MG/5ML	A073187	001	Sep 15, 1992
	DURAMED PHARMS BARR	1MG/5ML	A074991	001	Dec 29, 1997
	TEVA	1MG/5ML	A073478	001	Jun 23, 1995
	WATSON LABS	1MG/5ML	A073062	001	May 28, 1993
TABLET;ORAL					
LOPERAMIDE HYDROCHLORIDE					
	ABLE	2MG	A073528	001	Nov 30, 1993
	CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
	PERRIGO	2MG	A074194	001	Oct 30, 1992
TABLET, CHEWABLE;ORAL					
IMODIUM A-D EZ CHEWS					
+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL					
IMODIUM MULTI-SYMPTOM RELIEF					
+	J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996

LOPINAVIR; RITONAVIR

CAPSULE;ORAL					
KALETRA					
	ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000

LORACARBEF

CAPSULE;ORAL					
LORABID					
	KING PHARMS	200MG	N050668	001	Dec 31, 1991
		400MG	N050668	002	Apr 05, 1996
FOR SUSPENSION;ORAL					
LORABID					
	KING PHARMS	100MG/5ML	N050667	001	Dec 31, 1991
		200MG/5ML	N050667	002	Dec 31, 1991

LORATADINE

CAPSULE;ORAL					
LORATADINE					
	STRIDES PHARMA	10MG	A211926	001	Jan 15, 2020
SYRUP;ORAL					
CLARITIN HIVES RELIEF					
+	BAYER HEALTHCARE LLC	1MG/ML **	N020641	003	Nov 19, 2003
LORATADINE					
	PHARM ASSOC	1MG/ML	A075565	001	Oct 05, 2004
	RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LORATADINE				
SYRUP;ORAL				
LORATADINE				
TEVA	1MG/ML	A075505	001	Nov 07, 2003
TABLET;ORAL				
LORATADINE				
MYLAN	10MG	A075790	001	Nov 07, 2008
	10MG	A078447	001	Aug 12, 2011
PERRIGO	10MG	N021512	001	Jun 24, 2004
TABLET, ORALLY DISINTEGRATING;ORAL				
LORATADINE				
ACTAVIS LABS FL INC	10MG	A075990	001	Nov 03, 2003
GLAXOSMITHKLINE	10MG	A075822	001	Feb 10, 2003
LORATADINE; PSEUDOEPHEDRINE SULFATE				
TABLET, EXTENDED RELEASE;ORAL				
LORATADINE AND PSEUDOEPHEDRINE SULFATE				
HERITAGE PHARMA	5MG;120MG	A076208	001	Jan 28, 2004
LORAZEPAM				
INJECTABLE;INJECTION				
LORAZEPAM				
AKORN	2MG/ML	A074974	001	Jul 23, 1998
BEDFORD	2MG/ML	A077076	001	Jul 13, 2005
	4MG/ML	A077076	002	Jul 13, 2005
DAVA PHARMS INC	2MG/ML	A074793	001	Mar 16, 2000
	4MG/ML	A074793	002	Mar 16, 2000
DR REDDYS	1MG/0.5ML	A074551	003	Sep 12, 1996
	2MG/ML	A074535	001	Sep 12, 1996
	2MG/ML	A074551	001	Sep 12, 1996
	4MG/ML	A074535	002	Sep 12, 1996
	4MG/ML	A074551	002	Sep 12, 1996
HIKMA	2MG/ML	A074496	001	Sep 28, 1998
	4MG/ML	A074496	002	Sep 28, 1998
HOSPIRA	2MG/ML	A074280	001	May 27, 1994
	2MG/ML	A074300	001	Apr 12, 1994
	4MG/ML	A074280	002	May 27, 1994
	4MG/ML	A074300	003	Mar 19, 1997
RISING	2MG/ML	A200217	001	Apr 04, 2017
	2MG/ML	A200542	001	Apr 28, 2017
	4MG/ML	A200217	002	Apr 04, 2017
	4MG/ML	A200542	002	Apr 28, 2017
WATSON LABS	2MG/ML	A074276	001	Apr 15, 1994
	4MG/ML	A074276	002	Apr 15, 1994
LORAZEPAM PRESERVATIVE FREE				
BEDFORD LABS	2MG/ML	A077074	001	Jul 13, 2005
	4MG/ML	A077074	002	Jul 13, 2005
SOLUTION;ORAL				
LORAZEPAM				
ROXANE	0.5MG/5ML	A074648	001	Mar 18, 1997
TABLET;ORAL				
LORAZ				
QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985
LORAZEPAM				
AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991
	1MG	A072555	003	Mar 29, 1991
	2MG	A072555	001	Mar 29, 1991
ANI PHARMS	0.5MG	A077396	001	Dec 13, 2006
	1MG	A077396	002	Dec 13, 2006
	2MG	A077396	003	Dec 13, 2006
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985

LORAZEPAM
TABLET;ORAL
LORAZEPAM

	2MG	A070474	001	Dec 10, 1985
MYLAN	0.5MG	A071591	002	Oct 13, 1987
	1MG	A071591	003	Oct 13, 1987
	2MG	A071591	001	Oct 13, 1987
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
RISING PHARMA	0.5MG	A077657	001	Mar 16, 2006
	1MG	A077657	002	Mar 16, 2006
	2MG	A077657	003	Mar 16, 2006
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001
	1MG	A076045	002	Aug 29, 2001
	2MG	A076045	003	Aug 29, 2001
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	1MG	A071118	001	Jul 24, 1986
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOSARTAN POTASSIUM
TABLET;ORAL
LOSARTAN POTASSIUM

APOTEX CORP	25MG	A090790	001	Oct 06, 2010
	50MG	A090790	002	Oct 06, 2010
	100MG	A090790	003	Oct 06, 2010
HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019
	50MG	A204795	002	Apr 04, 2019
	100MG	A204795	003	Apr 04, 2019
MYLAN	25MG	A091590	001	Oct 06, 2010
	50MG	A091590	002	Oct 06, 2010
	100MG	A091590	003	Oct 06, 2010
TEVA	25MG	A076958	001	Apr 06, 2010
	50MG	A076958	002	Apr 06, 2010
	100MG	A076958	003	Apr 06, 2010
TORRENT PHARMS	25MG	A090467	001	Oct 06, 2010
	50MG	A090467	002	Oct 06, 2010
	100MG	A090467	003	Oct 06, 2010
UPSHER SMITH LABS	25MG	A090544	001	Oct 06, 2010
	50MG	A090544	002	Oct 06, 2010
	100MG	A090544	003	Oct 06, 2010

LOTEPREDNOL ETABONATE
SUSPENSION/DROPS;OPHTHALMIC
LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998

LOVASTATIN
TABLET;ORAL
LOVASTATIN

MYLAN	10MG	A075451	001	Dec 17, 2001
	10MG	A075935	001	Dec 17, 2001
	20MG	A075451	002	Dec 17, 2001
	20MG	A075935	002	Dec 17, 2001
	40MG	A075451	003	Dec 17, 2001
	40MG	A075935	003	Dec 17, 2001
SUN PHARM INDUSTRIES	10MG	A077520	001	Apr 14, 2006
	20MG	A077520	002	Apr 14, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LOVASTATIN				
TABLET;ORAL				
LOVASTATIN				
	40MG		A077520 003	Apr 14, 2006
MEVACOR				
+ MERCK	10MG **		N019643 002	Mar 28, 1991
+	20MG **		N019643 003	Aug 31, 1987
+	40MG **		N019643 004	Dec 14, 1988
TABLET, EXTENDED RELEASE;ORAL				
ALTOPREV				
COVIS	10MG		N021316 001	Jun 26, 2002
LOXAPINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
LOXITANE C				
TEVA BRANDED PHARM	EQ 25MG BASE/ML		N017658 001	
INJECTABLE;INJECTION				
LOXITANE IM				
ACTAVIS LABS UT INC	EQ 50MG BASE/ML		N018039 001	
LOXAPINE SUCCINATE				
CAPSULE;ORAL				
LOXAPINE SUCCINATE				
RISING PHARMA	EQ 5MG BASE		A076762 001	Nov 01, 2004
	EQ 10MG BASE		A076762 002	Nov 01, 2004
	EQ 25MG BASE		A076762 003	Nov 01, 2004
	EQ 50MG BASE		A076762 004	Nov 01, 2004
LOXITANE				
+ TEVA BRANDED PHARM	EQ 5MG BASE **		N017525 001	
+	EQ 10MG BASE **		N017525 002	
+	EQ 25MG BASE **		N017525 003	
+	EQ 50MG BASE **		N017525 004	
TABLET;ORAL				
LOXITANE				
+ TEVA BRANDED PHARM	EQ 10MG BASE **		N017525 006	
+	EQ 25MG BASE **		N017525 007	
+	EQ 50MG BASE **		N017525 008	
LUCINACTANT				
SUSPENSION;INTRATRACHEAL				
SURFAXIN				
WINDTREE THERAP	8.5ML		N021746 001	Mar 06, 2012
LURASIDONE HYDROCHLORIDE				
TABLET;ORAL				
LURASIDONE HYDROCHLORIDE				
AMNEAL PHARMS CO	20MG		A208002 001	Jan 03, 2019
	40MG		A208002 002	Jan 03, 2019
	60MG		A208002 003	Jan 03, 2019
	80MG		A208002 004	Jan 03, 2019
	120MG		A208002 005	Jan 03, 2019
EMCURE PHARMS LTD	20MG		A208058 001	Sep 04, 2019
	40MG		A208058 002	Sep 04, 2019
	60MG		A208058 003	Sep 04, 2019
	80MG		A208058 004	Sep 04, 2019
INVAGEN PHARMS	20MG		A208028 001	Jan 03, 2019
	40MG		A208028 002	Jan 03, 2019
	60MG		A208028 003	Jan 03, 2019
	80MG		A208028 004	Jan 03, 2019
	120MG		A208028 005	Jan 03, 2019
LUPIN LTD	20MG		A208031 001	Jan 03, 2019
	40MG		A208031 002	Jan 03, 2019
	60MG		A208031 003	Jan 03, 2019
	80MG		A208031 004	Jan 03, 2019
	120MG		A208031 005	Jan 03, 2019
PIRAMAL HLTHCARE UK	20MG		A212091 001	Dec 28, 2020
	40MG		A212091 002	Dec 28, 2020
	60MG		A212091 003	Dec 28, 2020
	80MG		A212091 004	Dec 28, 2020
	120MG		A212091 005	Dec 28, 2020
TEVA PHARMS USA	20MG		A208060 001	May 17, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LURASIDONE HYDROCHLORIDE

TABLET;ORAL				
LURASIDONE HYDROCHLORIDE				
	40MG	A208060	002	May 17, 2019
	60MG	A208060	003	May 17, 2019
	80MG	A208060	004	May 17, 2019
	120MG	A208060	005	May 17, 2019
TORRENT	20MG	A208055	001	Jan 03, 2019
	40MG	A208055	002	Jan 03, 2019
	80MG	A208055	003	Jan 03, 2019
	120MG	A208055	004	Jan 03, 2019
WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021
	40MG	A208016	002	Feb 02, 2021
	60MG	A208016	003	Feb 02, 2021
	80MG	A208016	004	Feb 02, 2021
	120MG	A208016	005	Feb 02, 2021
ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019
	40MG	A208052	002	Mar 19, 2019
	60MG	A208052	003	Mar 19, 2019
	80MG	A208052	004	Mar 19, 2019
	120MG	A208052	005	Mar 19, 2019

LYPRESSIN

SOLUTION;NASAL				
DIAPID				
NOVARTIS	0.185MG/ML	N016755	001	

MACITENTAN

TABLET;ORAL				
MACITENTAN				
ZYDUS	10MG	A211224	001	Apr 06, 2021

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION				
PLASMA-LYTE 56 IN PLASTIC CONTAINER				
BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION				
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER				
B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006	001	Apr 04, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION				
ISOLYTE S IN PLASTIC CONTAINER				
B BRAUN	30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML	N018252	001	
SOLUTION;IRRIGATION				
PHYSIOSOL IN PLASTIC CONTAINER				
HOSPIRA INC	14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	001	
PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER				
HOSPIRA INC	30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML	N018406	002	Jul 08, 1982
SYNOVALYTE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N019326	001	Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET;ORAL				
MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE				
SANTARUS	343MG;20MG;750MG	N022456	001	Dec 04, 2009
	343MG;40MG;750MG	N022456	002	Dec 04, 2009
TABLET, CHEWABLE;ORAL				
ZEGERID				
SANTARUS	700MG;20MG;600MG	N021850	001	Mar 24, 2006
	700MG;40MG;600MG	N021850	002	Mar 24, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE				
SOLUTION;ORAL				
SUCLEAR				
+	BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM **	N203595 001	Jan 18, 2013
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE				
POWDER;ORAL				
COLPREP KIT				
+	GATOR PHARMS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N204553 001	Dec 27, 2016
MALATHION				
LOTION;TOPICAL				
MALATHION				
	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009
OVIDE				
+	TARO PHARM INDS LTD	0.5% **	N018613 001	Aug 02, 1982
MANGAFODIPIR TRISODIUM				
INJECTABLE;INJECTION				
TESLASCAN				
	IC TARGETS	37.9MG/ML	N020652 001	Nov 26, 1997
MANGANESE CHLORIDE TETRAHYDRATE				
FOR SOLUTION;ORAL				
LUMENHANCE				
	BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997
MANGANESE SULFATE				
INJECTABLE;INJECTION				
MANGANESE SULFATE				
+	ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML **	N019228 001	May 05, 1987
MANNITOL				
INJECTABLE;INJECTION				
MANNITOL 10%				
	B BRAUN	10GM/100ML	N016080 002	
	HOSPIRA	10GM/100ML	N016269 002	
	MILES	10GM/100ML	N016472 002	
MANNITOL 10% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	10GM/100ML	N019603 002	Jan 08, 1987
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER				
	B BRAUN	10GM/100ML	N016080 006	
MANNITOL 15%				
	B BRAUN	15GM/100ML	N016080 003	
	HOSPIRA	15GM/100ML	N016269 003	
	MILES	15GM/100ML	N016472 005	
MANNITOL 15% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	15GM/100ML	N019603 003	Jan 08, 1990
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%				
	B BRAUN	15GM/100ML	N016080 005	
MANNITOL 20%				
	B BRAUN	20GM/100ML	N014738 001	
		20GM/100ML	N016080 004	
	HOSPIRA	20GM/100ML	N016269 004	
	MILES	20GM/100ML	N016472 004	
MANNITOL 25%				
	ABRAXIS PHARM	12.5GM/50ML	A086754 001	
	HOSPIRA	12.5GM/50ML	N016269 005	
	IGI LABS INC	12.5GM/50ML	A089239 001	May 06, 1987
		12.5GM/50ML	A089240 001	May 06, 1987
	INTL MEDICATION	12.5GM/50ML	A083051 001	
	LUITPOLD	12.5GM/50ML	A087409 001	Jan 21, 1982
	MERCK	12.5GM/50ML	N005620 001	
	WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983
MANNITOL 5%				
	B BRAUN	5GM/100ML	N016080 001	
	HOSPIRA	5GM/100ML	N016269 001	
MANNITOL 5% IN PLASTIC CONTAINER				
	ICU MEDICAL INC	5GM/100ML	N019603 001	Jan 08, 1987

MANNITOL
INJECTABLE;INJECTION
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN	5GM/100ML	N016080	007	

SOLUTION;IRRIGATION
RESECTISOL

B BRAUN	5GM/100ML	N016704	002	

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL

HOSPIRA	540MG/100ML;2.7GM/100ML	A080224	001	

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML;2.7GM/100ML	N017636	001	

MAPROTILINE HYDROCHLORIDE
TABLET;ORAL
LUDIOMIL

NOVARTIS	25MG	N017543	001	
	50MG	N017543	002	
	75MG	N017543	003	Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP	25MG	A072129	001	Jan 14, 1988
	50MG	A072130	001	Jan 14, 1988
	75MG	A072131	001	Jan 14, 1988
HERITAGE PHARMA	25MG	A072162	001	Jun 01, 1988
	50MG	A072163	001	Jun 01, 1988
RISING PHARMA	25MG	A072285	002	Oct 03, 1988
	50MG	A072285	001	Oct 03, 1988
	75MG	A072285	003	Oct 03, 1988
WATSON LABS	25MG	A071943	001	Dec 30, 1987
	50MG	A071944	001	Dec 30, 1987
	75MG	A071945	001	Dec 30, 1987
	75MG	A072164	001	Jun 01, 1988

MASOPROCOL
CREAM;TOPICAL
ACTINEX

UNIV AZ CANCER CTR	10%	N019940	001	Sep 04, 1992

MAZINDOL
TABLET;ORAL
MAZANOR

WYETH AYERST	1MG	N017980	002	
	2MG	N017980	001	

SANOREX

+ NOVARTIS	1MG **	N017247	001	
+	2MG **	N017247	002	

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
VERMOX

+ JANSSEN PHARMS	100MG **	N017481	001	
+	500MG	N208398	001	Oct 19, 2016

MEBUTAMATE
TABLET;ORAL
DORMATE

MEDPOINTE PHARM HLC	600MG	N017374	001	

MECAMYLAMINE HYDROCHLORIDE
TABLET;ORAL
INVERSINE

+ TARGACEPT	2.5MG **	N010251	001	

MECHLORETHAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
MUSTARGEN

+ RECORDATI RARE	10MG/VIAL	N006695	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MECLIZINE HYDROCHLORIDE

TABLET;ORAL				
MECLIZINE HYDROCHLORIDE				
ABC HOLDING	12.5MG	A085253	001	
	25MG	A085252	001	
AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011
ANABOLIC	25MG	A085891	001	
ANI PHARMS	12.5MG	A085269	001	
	12.5MG	A088732	001	Dec 11, 1985
	25MG	A085740	001	
AUROBINDO PHARMA USA	12.5MG	A202640	001	Sep 17, 2012
	25MG	A202640	002	Sep 17, 2012
	50MG	A202640	003	Sep 17, 2012
BUNDY	12.5MG	A084382	001	
	25MG	A084872	001	
IVAX SUB TEVA PHARMS	12.5MG	A083784	001	
KV PHARM	12.5MG	A085524	001	
	25MG	A085523	001	
PLIVA	25MG	A088734	001	Dec 11, 1985
RISING	12.5MG	A040179	001	Jan 30, 1997
	25MG	A040179	002	Jan 30, 1997
STRIDES PHARMA	50MG	A089674	001	Mar 31, 1988
SUPERPHARM	12.5MG	A089113	001	Aug 20, 1985
	25MG	A089114	001	Aug 20, 1985
UDL	12.5MG	A088256	001	Jun 13, 1983
	25MG	A088257	001	Jun 13, 1983
VANGARD	12.5MG	A087877	001	Apr 20, 1982
	25MG	A087620	001	Jan 04, 1982
WATSON LABS	12.5MG	A085195	001	
TABLET, CHEWABLE;ORAL				
MECLIZINE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	25MG	A084976	001	
NEXGEN PHARMA INC	25MG	A086392	001	
PLIVA	25MG	A088733	001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM;TOPICAL				
MECLAN				
JOHNSON AND JOHNSON	1%	N050518	001	

MECLOFENAMATE SODIUM

CAPSULE;ORAL				
MECLODIUM				
QUANTUM PHARMICS	EQ 50MG BASE	A071380	001	Jul 14, 1987
	EQ 100MG BASE	A071381	001	Jul 14, 1987
MECLOFENAMATE SODIUM				
AM THERAP	EQ 50MG BASE	A071362	001	Feb 10, 1987
	EQ 100MG BASE	A071363	001	Feb 10, 1987
ANI PHARMS	EQ 50MG BASE	A071469	002	Apr 15, 1987
	EQ 100MG BASE	A071469	001	Apr 15, 1987
BARR	EQ 50MG BASE	A072848	001	Mar 20, 1989
	EQ 100MG BASE	A072809	001	Mar 20, 1989
FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988
	EQ 100MG BASE	A072263	001	Nov 29, 1988
PAR PHARM	EQ 50MG BASE	A072077	001	Mar 10, 1988
	EQ 100MG BASE	A072078	001	Mar 10, 1988
USL PHARMA	EQ 50MG BASE	A071007	001	Mar 25, 1988
	EQ 100MG BASE	A071008	001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071641	001	Aug 11, 1987
MECLOMEN				
PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEDROXYPROGESTERONE ACETATE				
INJECTABLE;INJECTION				
DEPO-PROVERA				
+ PFIZER	100MG/ML **	N012541	002	
+	400MG/ML	N012541	003	
MEDROXYPROGESTERONE ACETATE				
CIPLA	150MG/ML	A210335	001	Jan 25, 2019
SANDOZ INC	150MG/ML	A078711	001	May 20, 2009
TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
TABLET;ORAL				
AMEN				
AMARIN PHARMS	10MG	A083242	001	
CURRETAB				
SOLVAY	10MG	A085686	001	
CYCRIN				
ESI	2.5MG	A081239	001	Oct 30, 1992
	5MG	A081240	001	Oct 30, 1992
	10MG	A089386	001	Sep 09, 1987
MEDROXYPROGESTERONE ACETATE				
DURAMED PHARMS BARR	2.5MG	A040311	001	Dec 01, 1999
	5MG	A040311	002	Dec 01, 1999
	10MG	A040311	003	Dec 01, 1999
UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984
MEDRYSONE				
SUSPENSION;OPHTHALMIC				
HMS				
ALLERGAN	1%	N016624	003	
MEFENAMIC ACID				
CAPSULE;ORAL				
MEFENAMIC ACID				
NOSTRUM LABS INC	250MG	A090359	001	Feb 05, 2013
STRIDES PHARMA	250MG	A209209	001	Sep 18, 2020
MEFLOQUINE HYDROCHLORIDE				
TABLET;ORAL				
LARIAM				
+ ROCHE	250MG **	N019591	001	May 02, 1989
MEFLOQUINE HYDROCHLORIDE				
HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010
SANDOZ	250MG	A076175	001	Feb 20, 2002
US ARMY WALTER REED	250MG **	N019578	001	May 02, 1989
MEGESTROL ACETATE				
SUSPENSION;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	40MG/ML **	N020264	001	Sep 10, 1993
MEGESTROL ACETATE				
HIKMA	40MG/ML	A075997	001	Feb 15, 2002
PHARM ASSOC	40MG/ML	A077404	001	Feb 16, 2006
TEVA PHARMS	40MG/ML	A075681	001	May 05, 2003
TABLET;ORAL				
MEGACE				
+ BRISTOL MYERS SQUIBB	20MG **	N016979	001	
+	40MG **	N016979	002	
MEGESTROL ACETATE				
HIKMA	20MG	A074458	001	Sep 29, 1995
	40MG	A074458	002	Sep 29, 1995
TEVA	40MG	A074745	001	Feb 27, 1998
USL PHARMA	20MG	A070646	001	Oct 02, 1987
	40MG	A070647	001	Oct 02, 1987
MELOXICAM				
CAPSULE;ORAL				
VIVLODEX				
+ ZYLA	5MG **	N207233	001	Oct 22, 2015
+	10MG **	N207233	002	Oct 22, 2015
SUSPENSION;ORAL				
MOBIC				
+ AVONDALE PHARMS	7.5MG/5ML **	N021530	001	Jun 01, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MELOXICAM

TABLET;ORAL					
MELOXICAM					
	AIPING PHARM INC	7.5MG	A077920	001	Jul 19, 2006
		15MG	A077920	002	Jul 19, 2006
	ANDA REPOSITORY	7.5MG	A077935	001	Jul 19, 2006
		15MG	A077935	002	Jul 19, 2006
	CR DOUBLE CRANE	7.5MG	A078039	001	Dec 14, 2006
		15MG	A078039	002	Dec 14, 2006
	HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006
		15MG	A077936	002	Jul 19, 2006
	IMPAX LABS INC	7.5MG	A077930	001	Jul 19, 2006
		15MG	A077930	002	Jul 19, 2006
	MYLAN	7.5MG	A077923	001	Jul 19, 2006
		7.5MG	A077934	001	Jul 20, 2006
		15MG	A077923	002	Jul 19, 2006
		15MG	A077934	002	Jul 20, 2006
	ROXANE	7.5MG	A077925	001	Jul 19, 2006
		15MG	A077925	002	Jul 19, 2006
	SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006
		15MG	A077937	002	Jul 19, 2006
	YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006
		15MG	A077933	002	Jul 19, 2006
TABLET, ORALLY DISINTEGRATING;ORAL					
QMIIZ ODT					
+	TERSERA	7.5MG	N211210	001	Oct 19, 2018
+		15MG	N211210	002	Oct 19, 2018

MELPHALAN

TABLET;ORAL					
ALKERAN					
+	APOTEX	2MG	N014691	002	

MELPHALAN FLUFENAMIDE HYDROCHLORIDE

POWDER;INTRAVENOUS					
PEPAXTO					
+	ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION					
ALKERAN					
+	APOTEX	EQ 50MG BASE/VIAL **	N020207	001	Nov 18, 1992
MELPHALAN HYDROCHLORIDE					
	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009
	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016
	SCINOPHARM TAIWAN	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019
	USWM	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019
POWDER;INTRAVENOUS					
MELPHALAN HYDROCHLORIDE					
	ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
MEMANTINE HYDROCHLORIDE					
	RISING PHARMA	7MG	A206032	001	Sep 28, 2016
		14MG	A206032	002	Sep 28, 2016
		21MG	A206032	003	Sep 28, 2016
		28MG	A206032	004	Sep 28, 2016
	SUN PHARM	7MG	A205905	001	Sep 28, 2016
		14MG	A205905	002	Sep 28, 2016
		21MG	A205905	003	Sep 28, 2016
		28MG	A205905	004	Sep 28, 2016
SOLUTION;ORAL					
MEMANTINE HYDROCHLORIDE					
	TORRENT	2MG/ML	A205446	001	Dec 07, 2015
NAMENDA					
+	ALLERGAN	2MG/ML	N021627	001	Apr 18, 2005
TABLET;ORAL					
MEMANTINE HYDROCHLORIDE					
	CHARTWELL	5MG	A090244	001	Jul 11, 2018
		10MG	A090244	002	Jul 11, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEMANTINE HYDROCHLORIDE				
TABLET;ORAL				
MEMANTINE HYDROCHLORIDE				
JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015
	10MG	A091585	002	Oct 13, 2015
MYLAN	5MG	A079225	001	Jan 30, 2015
	10MG	A079225	002	Jan 30, 2015
NINGBO	5MG	A212947	001	Apr 03, 2020
	10MG	A212947	002	Apr 03, 2020
ORBION PHARMS	5MG	A090044	001	Mar 12, 2012
	10MG	A090044	002	Mar 12, 2012
TEVA PHARMS	5MG	A090052	001	Oct 25, 2011
	10MG	A090052	002	Oct 25, 2011
TORRENT	5MG	A200155	001	Oct 13, 2015
	10MG	A200155	002	Oct 13, 2015
MENADIOL SODIUM DIPHOSPHATE				
INJECTABLE;INJECTION				
KAPPADIONE				
LILLY	10MG/ML	N005725	001	
SYNKAYVITE				
ROCHE	5MG/ML	N003718	004	
	10MG/ML	N003718	006	
	37.5MG/ML	N003718	008	
TABLET;ORAL				
SYNKAYVITE				
ROCHE	5MG	N003718	010	
MENADIONE				
TABLET;ORAL				
MENADIONE				
LILLY	5MG	N002139	003	
MEPENZOLATE BROMIDE				
SOLUTION;ORAL				
CANTIL				
SANOFI AVENTIS US	25MG/5ML	N010679	004	
TABLET;ORAL				
CANTIL				
+ SANOFI AVENTIS US	25MG	N010679	003	
MEPERIDINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
DEMEROL				
VALIDUS PHARMS	25MG/ML	N005010	007	
	50MG/ML	N005010	002	
	75MG/ML	N005010	009	
	100MG/ML	N005010	003	
MEPERIDINE HYDROCHLORIDE				
ABBOTT	25MG/ML	A080388	001	
	50MG/ML	A080385	001	
	50MG/ML	A080387	001	
	75MG/ML	A080389	001	
	100MG/ML	A080386	001	
BAXTER HLTHCARE	25MG/ML	A088279	001	Jun 15, 1984
	50MG/ML	A088280	001	Jun 15, 1984
	75MG/ML	A088281	001	Jun 15, 1984
	100MG/ML	A088282	001	Jun 15, 1984
IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989
	50MG/ML	A089782	001	Mar 31, 1989
	50MG/ML	A089783	001	Mar 31, 1989
	50MG/ML	A089784	001	Mar 31, 1989
	75MG/ML	A089785	001	Mar 31, 1989
	100MG/ML	A089786	001	Mar 31, 1989
	100MG/ML	A089787	001	Mar 31, 1989
	100MG/ML	A089788	001	Mar 31, 1989
INTL MEDICATION	10MG/ML	A086332	001	
PARKE DAVIS	50MG/ML	A080364	002	
	75MG/ML	A080364	003	
	100MG/ML	A080364	001	
WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPERIDINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MEPERIDINE HYDROCHLORIDE				
	100MG/ML	A073445	001	Mar 17, 1992
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE				
HOSPIRA	10MG/ML	A040305	001	Mar 10, 1999
+ ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984
INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993
SPECGX LLC	10MG/ML	A040163	001	May 12, 1997
WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992
SYRUP;ORAL				
DEMEROL				
VALIDUS PHARMS	50MG/5ML **	N005010	005	
TABLET;ORAL				
DEMEROL				
+ VALIDUS PHARMS	50MG	N005010	001	
+	100MG	N005010	004	
MEPERIDINE HYDROCHLORIDE				
ANDA REPOSITORY	50MG	A040893	001	Jun 24, 2009
	75MG	A040893	002	Jun 24, 2009
	100MG	A040893	003	Jun 24, 2009
	150MG	A040893	004	Jun 24, 2009
BARR	50MG	A088639	001	Jul 02, 1984
	100MG	A088640	001	Sep 19, 1984
DURAMED PHARMS BARR	50MG	A040318	001	Oct 05, 1999
	100MG	A040318	002	Oct 05, 1999
HIKMA	50MG	A040110	001	Mar 12, 1997
	100MG	A040110	002	Mar 12, 1997
SPECGX LLC	50MG	A040352	001	Jun 13, 2000
	100MG	A040352	002	Jun 13, 2000
STRIDES PHARMA	50MG	A040191	001	Dec 17, 1998
	100MG	A040191	002	Dec 17, 1998
SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002
	100MG	A040446	002	Aug 08, 2002
SUN PHARM INDUSTRIES	50MG	A080448	001	
	100MG	A080448	002	
WATSON LABS	50MG	A040186	001	Jun 30, 1997
	100MG	A040186	002	Jun 30, 1997
WYETH AYERST	50MG	A080454	001	
MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
MEPERGAN				
HIKMA	25MG/ML;25MG/ML	N011730	001	
MEPHENTERMINE SULFATE				
INJECTABLE;INJECTION				
WYAMINE SULFATE				
BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248	002	
	EQ 30MG BASE/ML	N008248	001	
MEPHENYTOIN				
TABLET;ORAL				
MESANTOIN				
+ NOVARTIS	100MG **	N006008	001	
MEPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
ARESTOCAINE HYDROCHLORIDE				
SOLVAY	3%	A084777	002	Apr 18, 1982
CARBOCAINE				
+ EASTMAN KODAK	3% **	N012125	003	
ISOCAINE HYDROCHLORIDE				
SEPTODONT INC	3%	A080925	001	
MEPIVACAINE HYDROCHLORIDE				
BELMORA LLC	3%	A083559	001	
HOSPIRA INC	3%	A040806	001	Apr 28, 2008
INTL MEDICATION SYS	1%	A087509	001	Oct 05, 1982
WATSON LABS	1%	A088769	001	Nov 20, 1984
	2%	A088770	001	Nov 20, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPIVACAINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
POLOCAINE				
DENTSPLY PHARM	3%		A088653 001	Aug 21, 1984
MEPREDNISONE				
TABLET;ORAL				
BETAPAR				
SCHERING	4MG		N016053 002	
MEPROBAMATE				
CAPSULE;ORAL				
EQUANIL				
WYETH AYERST	400MG		N012455 002	
CAPSULE, EXTENDED RELEASE;ORAL				
MEPROSPAN				
MEDPOINTE PHARM HLC	200MG		N011284 001	
	400MG		N011284 002	
TABLET;ORAL				
AMOSENE				
FERNDALE LABS	400MG		A084030 001	
BAMATE				
ALRA	200MG		A080380 001	
	400MG		A080380 002	
EQUANIL				
WYETH AYERST	200MG		N010028 005	
	400MG		N010028 004	
MEPRIAM				
TEVA	400MG		N016069 001	
MEPROBAMATE				
ACELLA	400MG		A084153 001	
BARR	600MG		A084230 001	
ELKINS SINN	200MG		N015426 002	
	400MG		N015426 001	
HEATHER	400MG		N016928 003	
	600MG		A084329 001	
IMPAX LABS	200MG		N014322 002	
	400MG		N014322 001	
IVAX SUB TEVA PHARMS	200MG		N015438 001	
	400MG		N015438 002	
	600MG		A084181 001	
LANNETT	200MG		N014882 002	
	400MG		N014882 001	
LEDERLE	400MG		A086299 001	
LEE KM	400MG		A089538 001	Nov 25, 1987
MALLARD	400MG		N015072 002	
MK LABS	200MG		N014368 004	
	400MG		N014368 002	
MYLAN	400MG		A083618 001	
NEXGEN PHARMA INC	200MG		A084220 001	
	400MG		A084589 001	
PARKE DAVIS	200MG		A084744 001	
	400MG		A084744 002	
PERRIGO	200MG		A084546 001	
	400MG		A084547 001	
PHARMAVITE	400MG		A084438 001	
PUREPAC PHARM	200MG		A084804 001	
	400MG		A084804 002	
PVT FORM	400MG		N014601 001	
RISING	400MG		A080655 001	
ROXANE	600MG		A084332 001	
SANDOZ	200MG		N014547 002	
	400MG		N014547 001	
SCHERER LABS	400MG		A083343 001	
SOLVAY	200MG		A084435 001	
STANLABS PHARM	200MG		N014474 002	
	400MG		N014474 004	
SUN PHARM INDUSTRIES	200MG		A080699 001	
	400MG		A080699 002	
TABLICAPS	400MG		A083494 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MEPROBAMATE
TABLET;ORAL
MEPROBAMATE

	TARO	200MG	A200998	001	May 23, 2011
		400MG	A200998	002	May 23, 2011
	USL PHARMA	200MG	A087825	001	Mar 18, 1982
		400MG	A087826	001	Mar 18, 1982
	VALEANT PHARM INTL	200MG	N015139	006	
		400MG	N015139	005	
	VANGARD	400MG	A088011	001	Jul 14, 1982
+	WATSON LABS	200MG	A083304	001	
		200MG	A085720	001	
+		400MG	A083308	001	
		400MG	A085721	001	
		600MG	A084274	001	
		600MG	A085719	001	
	WEST WARD	200MG	N015417	003	
		400MG	N015417	002	
	WHITEWORTH TOWN PLSN	200MG	A083830	001	
		400MG	A083442	001	

MILTOWN

+	MEDPOINTE PHARM HLC	200MG **	N009698	004	
+		400MG **	N009698	002	
		600MG	A083919	001	

NEURAMATE

	HALSEY	200MG	N014359	002	
		400MG	N014359	001	

TRANMEP

	SOLVAY	400MG	A084369	001	
		400MG	N016249	001	

MEQUINOL; TRETINOIN
SOLUTION;TOPICAL
SOLAGE

	ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999

MEROPENEM
INJECTABLE;INJECTION
MEROPENEM

	HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010
		1GM/VIAL	A090940	002	Jun 22, 2010
	SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011
		1GM/VIAL	A091201	002	Mar 29, 2011

MERSALYL SODIUM; THEOPHYLLINE
INJECTABLE;INJECTION
MERSALYL-THEOPHYLLINE

	WATSON LABS	100MG/ML;50MG/ML	A084875	001	

MESALAMINE
ENEMA;RECTAL
MESALAMINE

	G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004

SUPPOSITORY;RECTAL
CANASA

	ALLERGAN	500MG	N021252	001	Jan 05, 2001

ROWASA

+	MEDA PHARMS	500MG **	N019919	001	Dec 18, 1990

TABLET, DELAYED RELEASE;ORAL
ASACOL

	APIL	400MG	N019651	001	Jan 31, 1992

MESALAMINE

	MYLAN	1.2GM	A203574	001	Nov 20, 2018

MESNA
INJECTABLE;INTRAVENOUS
MESNA

	MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012
	MYLAN LABS LTD	100MG/ML	A203364	001	Jul 18, 2014
	TEVA PHARMS USA	100MG/ML	A075764	001	Apr 27, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MESORIDAZINE BESYLATE

CONCENTRATE;ORAL				
SERENTIL				
	NOVARTIS	EQ 25MG BASE/ML	N016997 001	
INJECTABLE;INJECTION				
SERENTIL				
	NOVARTIS	EQ 25MG BASE/ML	N016775 001	
TABLET;ORAL				
SERENTIL				
	NOVARTIS	EQ 10MG BASE **	N016774 001	
		EQ 25MG BASE **	N016774 002	
		EQ 50MG BASE **	N016774 003	
		EQ 100MG BASE **	N016774 004	

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20				
NORINYL				
	ACTAVIS LABS UT INC	0.1MG;2MG	N013625 004	
TABLET;ORAL-21				
NORETHIN 1/50M-21				
	HERITAGE PHARMA	0.05MG;1MG	A071539 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070758 001	Jul 01, 1988
NORINYL 1+50 21-DAY				
	ACTAVIS LABS UT INC	0.05MG;1MG	N013625 002	
NORINYL 1+80 21-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016724 001	
ORTHO-NOVUM 1/50 21				
	ORTHO MCNEIL PHARM	0.05MG;1MG	N012728 004	
ORTHO-NOVUM 1/80 21				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 001	
ORTHO-NOVUM 10-21				
	ORTHO MCNEIL PHARM	0.06MG;10MG	N012728 001	
ORTHO-NOVUM 2-21				
	ORTHO MCNEIL PHARM	0.1MG;2MG	N012728 005	
TABLET;ORAL-28				
NORETHIN 1/50M-28				
	HERITAGE PHARMA	0.05MG;1MG	A071540 001	Apr 12, 1988
NORETHINDRONE AND MESTRANOL				
	WATSON LABS	0.05MG;1MG	A070759 001	Jul 01, 1988
NORINYL 1+50 28-DAY				
+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659 001	
NORINYL 1+80 28-DAY				
	GD SEARLE LLC	0.08MG;1MG	N016725 001	
ORTHO-NOVUM 1/50 28				
	ORTHO MCNEIL JANSSEN	0.05MG;1MG	N016709 001	
ORTHO-NOVUM 1/80 28				
	ORTHO MCNEIL PHARM	0.08MG;1MG	N016715 002	

MESTRANOL; NORETHYNODREL

TABLET;ORAL				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 008	
		0.15MG;9.85MG	N010976 005	
TABLET;ORAL-20				
ENOVID				
	GD SEARLE LLC	0.075MG;5MG	N010976 004	
ENOVID-E				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 006	
TABLET;ORAL-21				
ENOVID-E 21				
	GD SEARLE LLC	0.1MG;2.5MG	N010976 007	

METAPROTERENOL SULFATE

AEROSOL, METERED;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.65MG/INH	N016402 001	
SOLUTION;INHALATION				
ALUPENT				
	BOEHRINGER INGELHEIM	0.4%	N018761 002	Oct 10, 1986
		0.6%	N018761 001	Jun 30, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METAPROTERENOL SULFATE				
SOLUTION;INHALATION				
ALUPENT				
	5%	N017659	001	
METAPROTERENOL SULFATE				
APOTEX INC	0.4%	A075402	001	Feb 28, 2001
	0.6%	A075403	001	Feb 28, 2001
ASTRAZENECA	0.4%	A071275	001	Jul 27, 1988
	0.6%	A071018	001	Jul 27, 1988
DEY	0.33%	A071806	001	Aug 05, 1988
	0.5%	A071805	001	Aug 05, 1988
	5%	A070805	001	Aug 17, 1987
MYLAN SPECIALITY LP	0.4%	A071786	001	Aug 05, 1988
	0.6%	A070804	001	Aug 17, 1987
NEPHRON	0.4%	A071855	001	Jul 14, 1988
	0.6%	A071726	001	Jul 14, 1988
WOCKHARDT	0.4%	A075586	001	May 30, 2002
	0.6%	A075586	002	May 30, 2002
	5%	A072190	001	Jun 07, 1988
PROMETA				
MURO	5%	A073340	001	Mar 30, 1992
SYRUP;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG/5ML	N017571	001	
METAPROTERENOL SULFATE				
APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000
COSETTE	10MG/5ML	A072761	001	Feb 27, 1992
G AND W LABS INC	10MG/5ML	A073034	001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656	001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997
PROMETA				
MURO	10MG/5ML	A072023	001	Sep 15, 1988
TABLET;ORAL				
ALUPENT				
BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	
METAPROTERENOL SULFATE				
AM THERAP	10MG	A072054	001	Jun 23, 1988
	20MG	A072055	001	Jun 23, 1988
HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990
	20MG	A072520	001	Mar 30, 1990
STRIDES PHARMA	10MG	A072024	001	Jun 28, 1988
	20MG	A072025	001	Jun 28, 1988
USL PHARMA	10MG	A071013	001	Jan 25, 1988
	20MG	A071014	001	Jan 25, 1988
WATSON LABS	10MG	A073013	001	Jan 31, 1991
	20MG	A072795	001	Jan 31, 1991
METARAMINOL BITARTRATE				
INJECTABLE;INJECTION				
ARAMINE				
+ MERCK	EQ 10MG BASE/ML **	N009509	002	Dec 22, 1987
METARAMINOL BITARTRATE				
ABRAXIS PHARM	EQ 10MG BASE/ML	A080431	001	
ELKINS SINN	EQ 10MG BASE/ML	A083363	001	
FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418	001	
	EQ 20MG BASE/ML	A086418	002	
METAXALONE				
TABLET;ORAL				
METAXALONE				
INGENUS PHARMS LLC	800MG	A213836	001	Oct 21, 2020
+ PRIMUS PHARMS	640MG **	N022503	001	Jun 01, 2015
SKELAXIN				
+ KING PHARMS	400MG **	N013217	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METFORMIN HYDROCHLORIDE

FOR SUSPENSION, EXTENDED RELEASE;ORAL					
RIOMET ER					
+	SUN PHARM	500MG/5ML	N212595	001	Aug 29, 2019
TABLET;ORAL					
GLUCOPHAGE					
+	EMD SERONO INC	500MG **	N020357	001	Mar 03, 1995
+		625MG **	N020357	003	Nov 05, 1998
+		750MG **	N020357	004	Nov 05, 1998
+		850MG **	N020357	002	Mar 03, 1995
+		1GM **	N020357	005	Nov 05, 1998
METFORMIN HYDROCHLORIDE					
	BARR	500MG	A075971	001	Jan 25, 2002
		850MG	A075971	002	Jan 25, 2002
		1GM	A075971	003	Jan 25, 2002
	HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002
		850MG	A075978	002	Jan 25, 2002
		1GM	A075978	003	Nov 05, 2002
	INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008
		850MG	A079148	002	Nov 25, 2008
		1GM	A079148	003	Nov 25, 2008
	IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007
		850MG	A078422	002	Aug 06, 2007
		1GM	A078422	003	Aug 06, 2007
	IVAX SUB TEVA PHARMS	500MG	A075975	001	Jan 24, 2002
		625MG	A075975	004	Jan 24, 2002
		750MG	A075975	005	Jan 24, 2002
		850MG	A075975	002	Jan 24, 2002
		1GM	A075975	003	Jan 24, 2002
	MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017
		850MG	A205330	002	Oct 31, 2017
		1GM	A205330	003	Oct 31, 2017
	MYLAN	500MG	A075976	001	Jan 24, 2002
		850MG	A075976	002	Jan 24, 2002
		1GM	A075976	003	Jan 24, 2002
	MYLAN PHARMS INC	500MG	A075969	001	Jan 29, 2002
		850MG	A075969	002	Jan 29, 2002
		1GM	A075969	003	Jan 29, 2002
	PROVIDENT PHARM	500MG	A077853	001	Jul 28, 2006
		850MG	A077853	002	Jul 28, 2006
		1GM	A077853	003	Jul 28, 2006
	SANDOZ	500MG	A075985	001	Jan 25, 2002
		850MG	A075985	002	Jan 25, 2002
		1GM	A075985	003	Jan 25, 2002
	SUN PHARM INDUSTRIES	500MG	A076038	001	Feb 21, 2002
		850MG	A076038	002	Feb 21, 2002
		1GM	A076038	003	Feb 21, 2002
	SUNSHINE	500MG	A208999	001	Oct 12, 2018
		850MG	A208999	002	Oct 12, 2018
		1GM	A208999	003	Oct 12, 2018
	TEVA	500MG	A076328	001	Dec 16, 2002
		850MG	A076328	002	Dec 16, 2002
		1GM	A076328	003	Dec 16, 2002
	TORRENT PHARMS	500MG	A077711	001	Jan 24, 2007
		850MG	A077711	002	Jan 24, 2007
		1GM	A077711	003	Jan 24, 2007
	WATSON LABS	500MG	A075979	001	Jan 24, 2002
		850MG	A075979	002	Jan 24, 2002
		1GM	A075979	003	Jan 24, 2002
	WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002
		850MG	A075961	002	Jan 25, 2002
		1GM	A075961	003	Jan 25, 2002
TABLET, EXTENDED RELEASE;ORAL					
FORTAMET					
+	ANDRX LABS LLC	500MG **	N021574	001	Apr 27, 2004
GLUCOPHAGE XR					
+	EMD SERONO INC	500MG **	N021202	001	Oct 13, 2000
+		750MG **	N021202	004	Apr 11, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
	750MG	A076878	001	Apr 13, 2005
ACTAVIS LABS FL INC	500MG	A076172	001	Jun 16, 2004
APOTEX	500MG	A076706	001	Dec 14, 2004
	750MG	A076706	002	Dec 29, 2005
BARR	500MG	A076496	001	Nov 25, 2005
	750MG	A076863	001	Oct 14, 2004
IMPAX LABS	500MG	A076249	001	Jul 30, 2004
	750MG	A076985	001	Sep 13, 2005
IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
MYLAN	500MG	A076650	001	Sep 13, 2005
	750MG	A077113	001	Sep 08, 2005
RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
	750MG	A077211	001	Jun 29, 2005
SANDOZ	500MG	A076223	001	Dec 14, 2004
SUN PHARM INDUSTRIES	500MG	A077124	001	Dec 21, 2005
TORRENT	500MG	A090014	001	Dec 30, 2009
TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010
WATSON LABS INC	500MG	A076818	001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011
	850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011
SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013
	850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013
TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013
	850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

+	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015
	500MG;2MG	A200624	002	Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

+	SB PHARMCO	500MG;EQ 1MG BASE **	N021410	001	Oct 10, 2002
+		500MG;EQ 2MG BASE **	N021410	002	Oct 10, 2002
+		500MG;EQ 4MG BASE **	N021410	003	Oct 10, 2002
+		1GM;EQ 2MG BASE **	N021410	004	Aug 25, 2003
+		1GM;EQ 4MG BASE **	N021410	005	Aug 25, 2003

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014
	500MG;EQ 1MG BASE	A077337	005	May 19, 2017
	500MG;EQ 4MG BASE	A077337	002	May 07, 2014
	1GM;EQ 4MG BASE	A077337	004	May 07, 2014
	1GM;EQ 2MG BASE	A077337	003	May 07, 2014

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+	METHAPHARM	1600MG/VIAL	N019193	002	Aug 29, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHACYCLINE HYDROCHLORIDE				
CAPSULE;ORAL				
RONDOMYCIN				
	MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641 001	
		EQ 280MG BASE	A060641 002	
SYRUP;ORAL				
RONDOMYCIN				
	MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641 003	
METHADONE HYDROCHLORIDE				
CONCENTRATE;ORAL				
METHADONE HYDROCHLORIDE				
	LANNETT CO INC	10MG/ML	A212094 001	Mar 03, 2021
POWDER;FOR RX COMPOUNDING				
METHADONE HYDROCHLORIDE				
	MALLINCKRODT INC	50GM/BOT	N006383 002	
		100GM/BOT	N006383 003	
		500GM/BOT	N006383 004	
SYRUP;ORAL				
DOLOPHINE HYDROCHLORIDE				
	HIKMA	10MG/30ML	N006134 004	
TABLET;ORAL				
DOLOPHINE HYDROCHLORIDE				
+	HIKMA	5MG **	N006134 002	
+		10MG **	N006134 010	
METHADONE HYDROCHLORIDE				
	ROXANE	40MG	A074081 001	Apr 28, 1995
	VISTAPHARM	5MG	A040241 001	May 29, 1998
METHADOSE				
	SPECGX LLC	5MG	A040050 001	Apr 15, 1993
		10MG	A040050 002	Apr 15, 1993
TABLET, DISPERSIBLE;ORAL				
WESTADONE				
	SANDOZ	2.5MG	N017108 001	
TABLET, EFFERVESCENT;ORAL				
WESTADONE				
	SANDOZ	5MG	N017108 002	
		10MG	N017108 003	
		40MG	N017108 004	
METHAMPHETAMINE HYDROCHLORIDE				
TABLET;ORAL				
METHAMPEX				
	TEVA	10MG	A083889 001	
METHAMPHETAMINE HYDROCHLORIDE				
	ABLE	5MG	A040529 001	Feb 25, 2004
	REXAR	5MG	A084931 001	
		10MG	A084931 002	
	TEVA	5MG	A086359 001	
TABLET, EXTENDED RELEASE;ORAL				
DESOXYN				
	RECORDATI RARE	5MG	N005378 004	
		10MG	N005378 003	
		15MG	N005378 005	
METHANTHELINE BROMIDE				
TABLET;ORAL				
BANTHINE				
	SHIRE	50MG	N007390 001	
METHARBITAL				
TABLET;ORAL				
GEMONIL				
	ABBVIE	100MG	N008322 001	
METHAZOLAMIDE				
TABLET;ORAL				
METHAZOLAMIDE				
	APPLIED ANAL	25MG	A040011 001	Jul 17, 1997
		50MG	A040011 002	Jul 17, 1997
	ATHEM	25MG	A040102 001	Aug 28, 1996
		50MG	A040102 002	Aug 28, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHAZOLAMIDE				
TABLET;ORAL				
NEPTAZANE				
+ LEDERLE	25MG **	N011721	002	Nov 25, 1991
+	50MG **	N011721	001	
METHDILAZINE				
TABLET, CHEWABLE;ORAL				
TACARYL				
WESTWOOD SQUIBB	3.6MG	N011950	009	
METHDILAZINE HYDROCHLORIDE				
SYRUP;ORAL				
METHDILAZINE HYDROCHLORIDE				
ALPHARMA US PHARMS	4MG/5ML	A087122	001	
TACARYL				
WESTWOOD SQUIBB	4MG/5ML	N011950	007	
TABLET;ORAL				
TACARYL				
WESTWOOD SQUIBB	8MG	N011950	006	
METHENAMINE HIPPURATE				
TABLET;ORAL				
HIPREX				
+ VALIDUS PHARMS	1GM	N017681	001	
METHENAMINE HIPPURATE				
IMPAX LABS INC	1GM	A076411	001	Jun 20, 2003
METHICILLIN SODIUM				
INJECTABLE;INJECTION				
STAPHCILLIN				
APOTHECON	EQ 900MG BASE/VIAL	A061449	001	
	EQ 900MG BASE/VIAL	N050117	001	
	EQ 3.6GM BASE/VIAL	A061449	002	
	EQ 3.6GM BASE/VIAL	N050117	002	
	EQ 5.4GM BASE/VIAL	A061449	003	
	EQ 5.4GM BASE/VIAL	N050117	003	
METHIMAZOLE				
TABLET;ORAL				
METHIMAZOLE				
BIOPHARM	20MG	A040547	004	Feb 18, 2005
DISCOVERY THERAP	15MG	A040619	003	Jul 12, 2005
MYLAN	20MG	A040350	003	Jun 07, 2001
SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007
	10MG	A040870	002	Sep 25, 2007
TAPAZOLE				
+ KING PHARMS	5MG **	N007517	002	
+	10MG **	N007517	004	
KING PHARMS LLC	5MG	A040320	001	Mar 31, 2000
	10MG	A040320	002	Mar 31, 2000
METHIXENE HYDROCHLORIDE				
TABLET;ORAL				
TREST				
NOVARTIS	1MG	N013420	001	
METHOCARBAMOL				
INJECTABLE;INJECTION				
METHOCARBAMOL				
DR REDDYS	100MG/ML	A086459	001	
MARSAM PHARMS LLC	100MG/ML	A089849	001	Dec 27, 1991
TABLET;ORAL				
DELAXIN				
FERNDALE LABS	500MG	A085454	001	
FORBAXIN				
FOREST LABS	750MG	A085136	001	
METHOCARBAMOL				
ABLE	500MG	A040413	001	Mar 17, 2003
	750MG	A040413	002	Mar 17, 2003
AM THERAP	500MG	A089417	001	Feb 11, 1987
	750MG	A089418	001	Feb 11, 1987
ANI PHARMS	500MG	A084277	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

	750MG	A084276	002	
ASCOT	500MG	A087660	001	Oct 27, 1982
	750MG	A087661	001	Oct 27, 1982
AUROBINDO PHARMA LTD	750MG	A213967	001	Aug 12, 2020
CLONMEL HLTHCARE	500MG	A085961	001	
	750MG	A085963	001	
FOSUN PHARMA	500MG	A084616	001	
	750MG	A084615	001	
HEATHER	500MG	A084675	001	
	750MG	A084924	001	
HIKMA INTL PHARMS	500MG	A085159	001	
	750MG	A085123	001	
IMPAX LABS	500MG	A084927	001	
	750MG	A084928	001	
INWOOD LABS	500MG	A085137	001	
IVAX SUB TEVA PHARMS	500MG	A084648	001	
	750MG	A084649	001	
KV PHARM	500MG	A085660	001	
	750MG	A085658	001	
LANNETT CO INC	500MG	A084756	002	Mar 31, 2003
	750MG	A084756	001	
MYLAN	500MG	A084259	001	
	750MG	A084323	001	
NYLOS	750MG	A085033	001	
PIONEER PHARMS	500MG	A088731	001	Dec 13, 1985
	750MG	A089082	001	Dec 13, 1985
PURACAP PHARM	500MG	A084231	002	
	750MG	A084471	001	
PUREPAC PHARM	500MG	A085718	001	
	750MG	A085718	002	
ROXANE	500MG	A088646	001	Feb 29, 1984
	750MG	A088647	001	Feb 29, 1984
SANDOZ	500MG	A087283	001	
	750MG	A087282	001	
SOLVAY	500MG	A084448	001	
	750MG	A084449	001	
SUN PHARM INDUSTRIES	500MG	A084488	001	
	750MG	A084486	001	
SUPERPHARM	500MG	A087589	001	Jan 22, 1982
	750MG	A087590	001	Jan 22, 1982
TABLICAPS	500MG	A084846	001	
UPSHER SMITH	500MG	A087453	001	
	750MG	A087454	001	
WATSON LABS	500MG	A083605	001	
	500MG	A085180	001	
	750MG	A083605	002	
	750MG	A085192	001	

ROBAXIN

+ AUXILIUM PHARMS LLC	500MG **	N011011	004	

ROBAXIN-750

+ AUXILIUM PHARMS LLC	750MG **	N011011	006	

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012
+	2.5GM/VIAL	N011559	002	
	5GM/VIAL	N011559	003	

METHOTREXATE

SOLUTION;INTRAVENOUS

METHOTREXATE

+ ACCORD HLTHCARE	5GM/50ML (100MG/ML)	N214121	001	Aug 24, 2020

SOLUTION;SUBCUTANEOUS

OTREXUP

+ OTTER PHARMS	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOTREXATE					
SOLUTION;SUBCUTANEOUS					
OTREXUP PFS					
+	OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017
+		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017
+		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017
+		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017
+		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017
+		25MG/ML (25MG/ML)	N204824	014	May 31, 2017
RASUVO					
+	MEDEXUS	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014
METHOTREXATE SODIUM					
INJECTABLE;INJECTION					
ABITREXATE					
	ABIC	EQ 25MG BASE/ML	A089161	001	Mar 10, 1987
		EQ 50MG BASE/VIAL	A089354	001	Jul 17, 1987
		EQ 100MG BASE/VIAL	A089355	001	Jul 17, 1987
		EQ 250MG BASE/VIAL	A089356	001	Jul 17, 1987
FOLEX					
+	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983
		EQ 50MG BASE/VIAL	A087695	002	Apr 08, 1983
+		EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983
		EQ 250MG BASE/VIAL	A088954	001	Oct 24, 1985
FOLEX PFS					
	PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242	001	Aug 23, 1991
		EQ 25MG BASE/ML	A089180	001	Jan 03, 1986
METHOTREXATE LPF					
+	HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982
METHOTREXATE PRESERVATIVE FREE					
	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999
+	HOSPIRA	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719	013	Apr 13, 2005
METHOTREXATE SODIUM					
	ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323	001	Jun 13, 1986
		EQ 20MG BASE/VIAL	A088935	001	Oct 11, 1985
		EQ 25MG BASE/ML	A089263	001	Jun 13, 1986
		EQ 25MG BASE/ML	A089322	001	Jun 13, 1986
		EQ 50MG BASE/VIAL	A088936	001	Oct 11, 1985
		EQ 100MG BASE/VIAL	A088937	001	Oct 11, 1985
	FRESENIUS KABI USA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999
+	HOSPIRA	EQ 2.5MG BASE/ML	N011719	004	
+		EQ 20MG BASE/VIAL	N011719	001	
+		EQ 25MG BASE/ML	N011719	005	
+		EQ 50MG BASE/VIAL	N011719	003	
+		EQ 100MG BASE/VIAL	N011719	006	
	NORBROOK	EQ 25MG BASE/ML	A088648	001	May 09, 1986
	PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158	001	Jul 08, 1988
METHOTREXATE SODIUM PRESERVATIVE FREE					
	AUROMEDICS PHARMA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012
		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012
		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012
		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012
+	HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988
	MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012
MEXATE					
+	BRISTOL	EQ 20MG BASE/VIAL	A086358	001	
+		EQ 50MG BASE/VIAL	A086358	002	
+		EQ 100MG BASE/VIAL	A086358	003	
+		EQ 250MG BASE/VIAL	A086358	004	
MEXATE-AQ					
	BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985
MEXATE-AQ PRESERVED					
	BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887	001	Apr 14, 1989
TABLET;ORAL					
METHOTREXATE SODIUM					
	DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233	001	Jun 17, 1999
+	STRIDES PHARMA	EQ 2.5MG BASE **	N008085	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHOXAMINE HYDROCHLORIDE

INJECTABLE;INJECTION				
VASOXYL				
	GLAXOSMITHKLINE	10MG/ML	N006772 002	
		20MG/ML	N006772 001	

METHOXSALEN

CAPSULE;ORAL				
8-MOP				
+	VALEANT PHARM INTL	10MG	N009048 001	
METHOXSALEN				
	ACTAVIS INC	10MG	A202603 001	Jun 09, 2015
	ANI PHARMS	10MG	A087781 001	Jun 08, 1982
LOTION;TOPICAL				
OXSORALEN				
+	VALEANT PHARM INTL	1%	N009048 002	

METHSCOPOLAMINE BROMIDE

TABLET;ORAL				
METHSCOPOLAMINE BROMIDE				
	PVT FORM	2.5MG	A080970 001	
	STRIDES PHARMA	2.5MG	A040624 001	Dec 28, 2006
		5MG	A040624 002	Dec 28, 2006
PAMINE				
	FOUGERA PHARMS	2.5MG **	N008848 001	
PAMINE FORTE				
	FOUGERA PHARMS	5MG **	N008848 002	Mar 25, 2003

METHSUXIMIDE

CAPSULE;ORAL				
CELONTIN				
+	PARKE DAVIS	150MG	N010596 007	

METHYCLOTHIAZIDE

TABLET;ORAL				
AQUATENSEN				
	MEDPOINTE PHARM HLC	5MG	N017364 001	
ENDURON				
+	ABBVIE	2.5MG **	N012524 001	
+		5MG **	N012524 004	
METHYCLOTHIAZIDE				
	CHARTWELL RX	2.5MG	A089835 001	Aug 18, 1988
		5MG	A089837 001	Aug 18, 1988
	IVAX PHARMS	2.5MG	A087913 001	Jun 03, 1982
		5MG	A087786 001	May 18, 1982
	MYLAN	2.5MG	A087671 001	Aug 17, 1982
	MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982
	PAR PHARM	2.5MG	A089135 001	Feb 12, 1986
		5MG	A089136 001	Feb 12, 1986
	USL PHARMA	5MG	A088745 001	Mar 21, 1985
	WATSON LABS	2.5MG	A085487 001	Mar 11, 1982
		2.5MG	A088750 001	Sep 06, 1984
		5MG	A085476 001	Mar 11, 1982
		5MG	A088724 001	Sep 06, 1984

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET;ORAL				
EUTRON				
	ABBOTT	5MG;25MG	N016047 001	

METHYCLOTHIAZIDE; RESERPINE

TABLET;ORAL				
DIUTENSEN-R				
	MEDPOINTE PHARM HLC	2.5MG;0.1MG	N012708 005	

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM;TOPICAL				
METVIXIA				
	GALDERMA LABS LP	EQ 16.8% BASE	N021415 001	Jul 27, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLDOPA

SUSPENSION;ORAL				
ALDOMET				
	MERCK	250MG/5ML	N018389 001	
TABLET;ORAL				
ALDOMET				
+	MERCK	125MG **	N013400 003	
+		250MG **	N013400 001	
+		500MG **	N013400 002	
METHYLDOPA				
	ACCORD HLTHCARE	125MG	A070070 003	Oct 15, 1985
	CHARTWELL RX	125MG	A071700 001	Mar 02, 1988
		250MG	N018934 001	Jun 29, 1984
		500MG	N018934 002	Jun 29, 1984
	DURAMED PHARMS BARR	250MG	A071006 001	Dec 16, 1986
		500MG	A071009 001	Dec 16, 1986
	HALSEY	125MG	A071751 001	Mar 28, 1988
		250MG	A071752 001	Mar 28, 1988
		500MG	A071753 001	Mar 28, 1988
	HERITAGE PHARMA	250MG	A070098 001	Feb 20, 1986
		500MG	A070343 001	Feb 20, 1986
	PARKE DAVIS	125MG	A070331 001	Apr 15, 1986
		250MG	A070332 001	Apr 15, 1986
		500MG	A070333 001	Apr 15, 1986
	PLIVA	125MG	A072126 001	Jul 07, 1988
		250MG	A072127 001	Jul 07, 1988
		500MG	A072128 001	Jul 07, 1988
	PUREPAC PHARM	125MG	A070749 001	Feb 07, 1986
		250MG	A070750 001	Feb 07, 1986
		500MG	A070452 001	Feb 07, 1986
	RISING PHARMA	250MG	A070076 002	Apr 18, 1985
		500MG	A070076 001	Apr 18, 1985
	ROXANE	125MG	A070192 001	Apr 25, 1986
		250MG	A070193 001	Apr 25, 1986
		500MG	A070194 001	Apr 25, 1986
	STRIDES PHARMA	125MG	A070535 001	Jan 02, 1987
		250MG	A070536 001	Jan 02, 1987
		500MG	A070537 001	Jan 02, 1987
	SUN PHARM INDUSTRIES	125MG	A070073 001	Oct 09, 1986
		250MG	A070060 001	Oct 09, 1986
		500MG	A070074 001	Oct 09, 1986
	SUPERPHARM	250MG	A070669 001	Jun 23, 1989
		500MG	A070670 001	Jun 23, 1989
	TEVA	125MG	A071105 001	Dec 05, 1986
		250MG	A071106 001	Dec 05, 1986
		500MG	A071067 001	Dec 05, 1986
	WATSON LABS	125MG	A070245 001	Feb 25, 1986
		125MG	A070260 001	Jun 24, 1985
		250MG	A070246 001	Feb 25, 1986
		250MG	A070261 001	Jun 24, 1985
		250MG	A070703 001	Jun 06, 1986
		500MG	A070247 001	Feb 25, 1986
		500MG	A070262 001	Jun 24, 1985
		500MG	A070625 001	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION				
ALDOMET				
+	MERCK	50MG/ML **	N013401 001	
METHYLDOPATE HYDROCHLORIDE				
	ABRAXIS PHARM	50MG/ML	A070652 001	Jun 03, 1986
	AM REGENT	50MG/ML	A071279 001	Oct 02, 1987
	BAXTER HLTHCARE	50MG/ML	A070291 001	Jul 01, 1986
	HOSPIRA	50MG/ML	A070691 001	Jun 19, 1987
		50MG/ML	A070698 001	Jun 15, 1987
		50MG/ML	A070699 001	Jun 15, 1987
		50MG/ML	A070849 001	Jun 19, 1987
	MARSAM PHARMS LLC	50MG/ML	A071812 001	Dec 22, 1987
	SMITH AND NEPHEW	50MG/ML	A070841 001	Jan 02, 1987
	TEVA PARENTERAL	50MG/ML	A072974 001	Nov 22, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHERGINE

+	EDISON THERAPS LLC	0.2MG **	N006035	003	

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

METHYLPHENIDATE

	ACTAVIS ELIZABETH	8.6MG	A210924	001	Jun 19, 2020
		17.3MG	A210924	002	Jun 19, 2020
		25.9MG	A210924	003	Jun 19, 2020

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	BARR LABS INC	10MG	A079031	004	Oct 15, 2014
		20MG	A079031	001	Jul 13, 2012
		30MG	A079031	002	Jul 13, 2012
		40MG	A079031	003	Jul 13, 2012

RITALIN LA

+	NOVARTIS	60MG **	N021284	005	Oct 27, 2014

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	LANNETT CO INC	5MG/5ML	A207414	001	Dec 16, 2020
		10MG/5ML	A207414	002	Dec 16, 2020

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

	ABLE	5MG	A040404	001	Mar 29, 2001
		10MG	A040404	002	Mar 29, 2001
		20MG	A040404	003	Mar 29, 2001
	ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
		10MG	A040321	002	Feb 05, 2002
		20MG	A040321	003	Feb 05, 2002
	ALVOGEN	5MG	A206840	001	Sep 15, 2016
		10MG	A206840	002	Sep 15, 2016
		20MG	A206840	003	Sep 15, 2016
	AUROLIFE PHARMA LLC	5MG	A209276	001	Oct 25, 2018
		10MG	A209276	002	Oct 25, 2018
		20MG	A209276	003	Oct 25, 2018
	CEDIPROF INC	5MG	A208737	001	Feb 01, 2019
		10MG	A208737	002	Feb 01, 2019
		20MG	A208737	003	Feb 01, 2019
	LANNETT CO INC	5MG	A086429	001	
		10MG	A085799	001	
		20MG	A086428	001	
	NOSTRUM LABS INC	5MG	A207587	001	Mar 03, 2017
		10MG	A207587	002	Mar 03, 2017
		20MG	A207587	003	Mar 03, 2017
	WATSON LABS	5MG	A040220	001	Aug 29, 1997
		10MG	A040220	002	Aug 29, 1997
		20MG	A040220	003	Aug 29, 1997

TABLET, CHEWABLE;ORAL

METHYLIN

+	SPECGX LLC	2.5MG **	N021475	001	Apr 15, 2003
+		5MG **	N021475	002	Apr 15, 2003
+		10MG **	N021475	003	Apr 15, 2003

METHYLPHENIDATE HYDROCHLORIDE

	NOSTRUM LABS INC	2.5MG	A204954	001	Jan 26, 2017
		5MG	A204954	002	Jan 26, 2017
		10MG	A204954	003	Jan 26, 2017
	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015
		5MG	A204115	002	Feb 25, 2015
		10MG	A204115	003	Feb 25, 2015

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

	LANNETT CO INC	10MG	A040306	001	Oct 20, 1999
		20MG	A089601	001	Jun 01, 1988

METHYLPHENIDATE HYDROCHLORIDE

	ABLE	20MG	A076032	001	May 09, 2001
	ANI PHARMS	18MG	A208607	001	Jul 14, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPHENIDATE HYDROCHLORIDE				
TABLET, EXTENDED RELEASE;ORAL				
METHYLPHENIDATE HYDROCHLORIDE				
	27MG	A208607	002	Jul 14, 2017
	36MG	A208607	003	Jul 14, 2017
	54MG	A208607	004	Jul 14, 2017
HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001
STRIDES PHARMA	36MG	A204659	001	Jul 15, 2019
	54MG	A204659	002	Jul 15, 2019
WATSON LABS	20MG	A040410	001	Feb 09, 2001
RITALIN-SR				
+ NOVARTIS	20MG **	N018029	001	Mar 30, 1982
METHYLPREDNISOLONE				
TABLET;ORAL				
MEDROL				
PFIZER	24MG	N011153	005	
METHYLPREDNISOLONE				
DURAMED PHARMS BARR	4MG	A088497	001	Feb 21, 1984
HEATHER	4MG	A085650	001	
INVATECH	4MG	A087341	001	
LUPIN LTD	2MG	A209097	001	Feb 22, 2019
	4MG	A209097	002	Feb 22, 2019
	8MG	A209097	003	Feb 22, 2019
	16MG	A209097	004	Feb 22, 2019
	32MG	A209097	005	Feb 22, 2019
NOVAST LABS	4MG	A210985	001	Jan 09, 2019
PAR PHARM	16MG	A089207	001	Apr 25, 1988
	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982
METHYLPREDNISOLONE ACETATE				
ENEMA;RECTAL				
MEDROL				
PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
INJECTABLE;INJECTION				
M-PREDROL				
BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	
METHYLPREDNISOLONE ACETATE				
AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	
OINTMENT;TOPICAL				
MEDROL ACETATE				
PHARMACIA AND UPJOHN	0.25%	N012421	001	
	1%	N012421	002	
METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE				
CREAM;TOPICAL				
NEO-MEDROL ACETATE				
PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	A060611	002	
	1%;EQ 3.5MG BASE/GM	A060611	001	
METHYLPREDNISOLONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
A-METHAPRED				
ABBOTT	EQ 40MG BASE/VIAL	A089573	001	Feb 22, 1991
	EQ 125MG BASE/VIAL	A089574	001	Feb 22, 1991
	EQ 500MG BASE/VIAL	A089575	001	Feb 22, 1991
	EQ 1GM BASE/VIAL	A089576	001	Feb 22, 1991
HOSPIRA	EQ 40MG BASE/VIAL	A040664	001	Dec 20, 2005
	EQ 40MG BASE/VIAL	A085853	001	
	EQ 125MG BASE/VIAL	A040665	001	Dec 20, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLPREDNISOLONE SODIUM SUCCINATE				
INJECTABLE;INJECTION				
A-METHAPRED				
	EQ 125MG BASE/VIAL	A085855	001	
	EQ 500MG BASE/VIAL	A085854	001	
	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987
	EQ 1GM BASE/VIAL	A085852	001	
	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987
HOSPIRA INC	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008
	EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008
METHYLPREDNISOLONE				
ELKINS SINN	EQ 125MG BASE/VIAL	A086906	002	
	EQ 500MG BASE/VIAL	A086906	003	
	EQ 1GM BASE/VIAL	A086906	004	
ORGANON USA INC	EQ 500MG BASE/VIAL	A087535	001	Jun 25, 1982
	EQ 1GM BASE/VIAL	A087535	002	Jun 25, 1982
METHYLPREDNISOLONE SODIUM SUCCINATE				
ABRAXIS PHARM	EQ 40MG BASE/VIAL	A088676	001	Jun 08, 1984
	EQ 40MG BASE/VIAL	A089143	001	Mar 28, 1986
	EQ 125MG BASE/VIAL	A088677	001	Jun 08, 1984
	EQ 125MG BASE/VIAL	A089144	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A088678	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A089186	001	Mar 28, 1986
	EQ 500MG BASE/VIAL	A089187	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A088679	001	Jun 08, 1984
	EQ 1GM BASE/VIAL	A089188	001	Mar 28, 1986
	EQ 1GM BASE/VIAL	A089189	001	Mar 28, 1986
BEDFORD LABS	EQ 40MG BASE/VIAL	A040662	001	Feb 21, 2007
	EQ 125MG BASE/VIAL	A040641	002	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040641	003	Feb 21, 2007
	EQ 500MG BASE/VIAL	A040709	001	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040641	004	Feb 21, 2007
	EQ 1GM BASE/VIAL	A040709	002	Feb 21, 2007
ELKINS SINN	EQ 40MG BASE/VIAL	A086906	001	
INTL MEDICATION	EQ 40MG BASE/VIAL	A087812	001	Feb 09, 1983
	EQ 125MG BASE/VIAL	A087813	001	Feb 09, 1983
	EQ 500MG BASE/VIAL	A087851	001	Feb 09, 1983
	EQ 1GM BASE/VIAL	A087852	001	Feb 09, 1983
TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266	001	Nov 30, 1992
	EQ 500MG BASE/VIAL	A081267	001	Nov 30, 1992
	EQ 1GM BASE/VIAL	A081268	001	Nov 30, 1992
TIANJIN KINGYORK	EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021
	EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021
	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021
	EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021
	EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021
WATSON LABS	EQ 40MG BASE/VIAL	A086953	001	Jul 22, 1982
	EQ 125MG BASE/VIAL	A087030	001	Jul 22, 1982
	EQ 500MG BASE/VIAL	A088523	001	Jul 24, 1984
	EQ 1GM BASE/VIAL	A088524	001	Jul 24, 1984
METHYLPREDNISOLONE; NEOMYCIN SULFATE				
OINTMENT;OPHTHALMIC				
NEO-MEDROL				
PHARMACIA AND UPJOHN	0.1%;EQ 3.5MG BASE/GM	A060645	001	
METHYLTESTOSTERONE				
CAPSULE;ORAL				
METHYLTESTOSTERONE				
HEATHER	10MG	A084967	001	
TESTRED				
+ BAUSCH	10MG	A083976	001	
VIRILON				
CHARTWELL	10MG	A087750	001	Nov 24, 1982
TABLET;BUCCAL				
ANDROID 5				
VALEANT PHARM INTL	5MG	A087222	001	
ORETON				
SCHERING	10MG	A080281	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METHYLTESTOSTERONE				
TABLET;BUCCAL, SUBLINGUAL				
METANDREN				
NOVARTIS	5MG		N003240 004	
	10MG		N003240 001	
	10MG		N003240 005	
	25MG		N003240 003	
METHYLTESTOSTERONE				
IMPAX LABS	10MG		A084287 001	
LILLY	10MG		A080256 001	
	25MG		A080256 002	
PUREPAC PHARM	10MG		A080308 001	
	10MG		A080475 001	
	10MG		A080475 002	
	25MG		A080475 003	
PVT FORM	5MG		A083836 001	
TABLICAPS	10MG		A085125 001	
USL PHARMA	10MG		A080271 001	
TABLET;ORAL				
ANDROID 10				
VALEANT PHARMS NORTH	10MG		A086450 001	
METHYLTESTOSTERONE				
IMPAX LABS	25MG		A084310 001	
INWOOD LABS	10MG		A080839 001	
	25MG		A080973 001	
KV PHARM	10MG		A084312 001	
LANNETT	10MG		A087092 001	Nov 05, 1982
	25MG		A087111 001	Jan 27, 1983
PARKE DAVIS	10MG		A084244 001	
	25MG		A084241 001	
PUREPAC PHARM	10MG		A080309 001	
	25MG		A080310 001	
PVT FORM	5MG		A080214 001	
	10MG		A080214 002	
	25MG		A080214 003	
TABLICAPS	10MG		A080313 001	
	25MG		A085270 001	
WATSON LABS	10MG		A080933 001	
	25MG		A080931 001	
WEST WARD	10MG		A084331 001	
	25MG		A084331 002	
	25MG		A084642 001	
ORETON METHYL				
SCHERING	10MG		N003158 001	
	25MG		N003158 002	
METHYPRYLON				
CAPSULE;ORAL				
NOLUDAR				
ROCHE	300MG		N009660 008	
ELIXIR;ORAL				
NOLUDAR				
ROCHE	50MG/5ML		N009660 007	
TABLET;ORAL				
NOLUDAR				
ROCHE	50MG		N009660 002	
	200MG		N009660 004	
METHYSERGIDE MALEATE				
TABLET;ORAL				
SANSERT				
NOVARTIS	2MG		N012516 001	
METIPRANOLOL HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
METIPRANOLOL				
SANDOZ INC	0.3%		A075720 001	Aug 06, 2001
OPTIPRANOLOL				
+ BAUSCH AND LOMB	0.3%		N019907 001	Dec 29, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOCLOPRAMIDE HYDROCHLORIDE					
CONCENTRATE;ORAL					
METOCLOPRAMIDE INTENSOL					
	ROXANE	EQ 10MG BASE/ML	A072995	001	Jan 30, 1992
INJECTABLE;INJECTION					
METOCLOPRAMIDE HYDROCHLORIDE					
	BEDFORD	EQ 5MG BASE/ML	A072155	001	Mar 30, 1992
		EQ 5MG BASE/ML	A072244	001	Mar 30, 1992
		EQ 5MG BASE/ML	A072247	001	May 18, 1992
	HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
		EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
		EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
		EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
		EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
		EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
		EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
	LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
	NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
	SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
		EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987
REGLAN					
+	HIKMA	EQ 5MG BASE/ML	N017862	001	
		EQ 10MG BASE/ML	N017862	004	May 28, 1987
SOLUTION;ORAL					
METOCLOPRAMIDE HYDROCHLORIDE					
	ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
	LANNETT CO INC	EQ 5MG BASE/5ML	A073680	001	Oct 27, 1992
	MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
	PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
	ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
	TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
		EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993
REGLAN					
+	ROBINS AH	EQ 5MG BASE/5ML **	N018821	001	Mar 25, 1983
TABLET;ORAL					
CLOPRA					
	QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
		EQ 10MG BASE	A070294	001	Jul 29, 1985
CLOPRA-"YELLOW"					
	QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
MAXOLON					
	KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
METOCLOPRAMIDE HYDROCHLORIDE					
	CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
	HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
	INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
	MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
	NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374	001	Nov 30, 2007
		EQ 10MG BASE	A078374	002	Nov 30, 2007
	PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
	SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
		EQ 10MG BASE	A070850	001	Feb 03, 1987
	SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
	SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536	002	Jan 16, 1997
		EQ 10MG BASE	A071536	001	Apr 28, 1993
	SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
	USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
	WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
		EQ 10MG BASE	A070453	001	Jun 06, 1986
		EQ 10MG BASE	A070511	001	Jan 22, 1986
		EQ 10MG BASE	A070645	001	May 11, 1987
	YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995
		EQ 10MG BASE	A072215	001	Jan 30, 1990
		EQ 10MG BASE	A074478	002	Oct 05, 1995
TABLET, ORALLY DISINTEGRATING;ORAL					
METOZOLV ODT					
+	SALIX PHARMS	EQ 5MG BASE **	N022246	001	Sep 04, 2009
+		EQ 10MG BASE **	N022246	002	Sep 04, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOCLOPRAMIDE HYDROCHLORIDE				
TABLET, ORALLY DISINTEGRATING;ORAL				
REGLAN ODT				
MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005
METOCURINE IODIDE				
INJECTABLE;INJECTION				
METUBINE IODIDE				
LILLY	2MG/ML	N006632	003	
METOLAZONE				
TABLET;ORAL				
DIULO				
GD SEARLE LLC	2.5MG	N018535	001	
	5MG	N018535	002	
	10MG	N018535	003	
METOLAZONE				
ANI PHARMS	2.5MG	A075543	001	Jan 06, 2004
	5MG	A075543	002	Mar 01, 2004
	10MG	A075543	003	Dec 24, 2003
ROXANE	10MG	A076482	002	Apr 29, 2004
WATSON LABS	10MG	A076891	001	Jul 21, 2004
MYKROX				
LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987
ZAROXOLYN				
+ LANNETT CO INC	2.5MG	N017386	001	
+	5MG	N017386	002	
+	10MG	N017386	003	
METOPROLOL FUMARATE				
TABLET, EXTENDED RELEASE;ORAL				
LOPRESSOR				
NOVARTIS	EQ 100MG TARTRATE	N019786	001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786	002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786	003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786	004	Dec 27, 1989
METOPROLOL SUCCINATE				
TABLET, EXTENDED RELEASE;ORAL				
METOPROLOL SUCCINATE				
ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009
	EQ 100MG TARTRATE	A077298	001	Apr 15, 2010
	EQ 200MG TARTRATE	A077298	002	Apr 15, 2010
NESHER PHARMS	EQ 25MG TARTRATE	A077779	001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176	001	May 14, 2008
	EQ 100MG TARTRATE	A076640	002	May 18, 2007
	EQ 200MG TARTRATE	A076640	001	May 18, 2007
SANDOZ	EQ 25MG TARTRATE	A076969	001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969	002	May 18, 2007
	EQ 100MG TARTRATE	A076969	003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969	004	Mar 20, 2008
METOPROLOL TARTRATE				
INJECTABLE;INJECTION				
LOPRESSOR				
+ NOVARTIS	1MG/ML **	N018704	001	Mar 30, 1984
METOPROLOL TARTRATE				
AM REGENT	1MG/ML	A090386	001	Sep 30, 2009
LUITPOLD	1MG/ML	A091307	001	Dec 29, 2010
MYLAN ASI	1MG/ML	A090317	001	Apr 19, 2010
WATSON LABS	1MG/ML	A074032	001	Dec 21, 1993
TABLET;ORAL				
METOPROLOL TARTRATE				
APOTHECON	50MG	A074258	001	Jan 27, 1994
	100MG	A074258	002	Jan 27, 1994
HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995
	100MG	A074141	002	Jan 31, 1995
MYLAN	50MG	A073666	001	Dec 21, 1993
	100MG	A073666	002	Dec 21, 1993
PUREPAC PHARM	50MG	A074380	001	Jul 29, 1994
	100MG	A074380	002	Jul 29, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METOPROLOL TARTRATE				
TABLET;ORAL				
METOPROLOL TARTRATE				
RENATA	50MG	A074453	001	Apr 27, 1995
	100MG	A074453	002	Apr 27, 1995
SUN PHARM INDUSTRIES	25MG	A073654	002	Jul 15, 2009
	50MG	A073654	003	Dec 21, 1993
	100MG	A073654	001	Dec 21, 1993
TEVA	50MG	A074143	001	Sep 30, 1994
	100MG	A074143	002	Sep 30, 1994
TEVA PHARMS	50MG	A074333	001	Jan 27, 1994
	100MG	A074333	002	Jan 27, 1994
WATSON LABS	50MG	A074217	001	May 27, 1994
	100MG	A074217	002	May 27, 1994
YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994
	100MG	A073289	001	Mar 25, 1994
METRIZAMIDE				
INJECTABLE;INJECTION				
AMIPAQUE				
GE HEALTHCARE	2.5GM/VIAL	N017982	003	Sep 12, 1983
	3.75GM/VIAL	N017982	001	
	6.75GM/VIAL	N017982	002	
	13.5GM/VIAL	N017982	004	Sep 12, 1983
METRONIDAZOLE				
CAPSULE;ORAL				
METRONIDAZOLE				
ABLE	375MG	A076505	001	Nov 13, 2003
INJECTABLE;INJECTION				
FLAGYL I.V. RTU IN PLASTIC CONTAINER				
PFIZER	500MG/100ML	N018353	002	
METRO I.V.				
B BRAUN	500MG/100ML	N018674	001	Aug 31, 1982
METRONIDAZOLE				
ABBOTT	500MG/100ML	N018889	001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071	001	Dec 03, 1984
INTL MEDICATION	500MG/100ML	A070004	001	May 08, 1985
WATSON LABS	500MG/100ML	A070042	001	Dec 20, 1984
	500MG/100ML	A070170	001	Apr 01, 1986
WEST-WARD PHARMS INT	500MG/100ML	N018907	001	Mar 30, 1984
METRONIDAZOLE IN PLASTIC CONTAINER				
MYLAN LABS LTD	500MG/100ML	A205531	001	May 09, 2017
TABLET;ORAL				
METROMIDOL				
LABS AF	250MG	A074523	001	Oct 24, 1996
	500MG	A074523	002	Oct 24, 1996
METRONIDAZOLE				
ABLE	250MG	A076519	001	Jun 27, 2003
	500MG	A076519	002	Jun 27, 2003
CHARTWELL MOLECULES	250MG	N018845	001	Aug 18, 1983
	500MG	N018930	001	Aug 18, 1983
FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982
	250MG	N018740	001	Oct 22, 1982
	500MG	N018620	002	Jun 02, 1983
	500MG	N018740	002	Oct 22, 1982
HALSEY	250MG	A070021	001	Apr 02, 1985
	500MG	A070593	001	Feb 27, 1986
IVAX SUB TEVA PHARMS	250MG	N018517	001	
	500MG	N018517	002	May 05, 1982
LNK	250MG	N019029	001	Apr 10, 1984
MUTUAL PHARM	250MG	N018818	001	Feb 16, 1983
	500MG	N018818	002	Feb 16, 1983
SUPERPHARM	250MG	A070008	001	Dec 11, 1984
	500MG	A070009	001	Dec 11, 1984
WATSON LABS	250MG	N018599	001	Sep 17, 1982
	250MG	N018764	001	Sep 17, 1982
	500MG	N018599	002	Feb 13, 1984
	500MG	N018764	002	Dec 20, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

METRONIDAZOLE				
TABLET;ORAL				
PROTOSTAT				
	ORTHO MCNEIL PHARM	250MG	N018871 001	Mar 02, 1983
		500MG	N018871 002	Mar 02, 1983
SATRIC				
	SAVAGE LABS	250MG	A070029 001	Mar 19, 1985
		500MG	A070731 001	Jun 08, 1987
TABLET, EXTENDED RELEASE;ORAL				
FLAGYL ER				
+	PFIZER	750MG	N020868 001	Nov 26, 1997
METRONIDAZOLE				
	ABLE	750MG	A076462 001	Jun 25, 2003
	ALEMBIC PHARMS LTD	750MG	A090222 001	May 05, 2010
METRONIDAZOLE HYDROCHLORIDE				
INJECTABLE;INJECTION				
FLAGYL I.V.				
	PFIZER	EQ 500MG BASE/VIAL **	N018353 001	
METRONIDAZOLE HYDROCHLORIDE				
	ABRAXIS PHARM	EQ 500MG BASE/VIAL	A070295 001	Oct 15, 1985
METYRAPONE				
TABLET;ORAL				
METOPIRONE				
	HRA PHARMA	250MG	N012911 001	
MEXILETINE HYDROCHLORIDE				
CAPSULE;ORAL				
MEXILETINE HYDROCHLORIDE				
	WATSON LABS	150MG	A074711 001	Feb 26, 1997
		150MG	A074865 001	Apr 13, 1998
		200MG	A074711 002	Feb 26, 1997
		200MG	A074865 002	Apr 13, 1998
		250MG	A074711 003	Feb 26, 1997
		250MG	A074865 003	Apr 13, 1998
MEXITIL				
+	BOEHRINGER INGELHEIM	150MG	N018873 002	Dec 30, 1985
+		200MG	N018873 003	Dec 30, 1985
+		250MG	N018873 004	Dec 30, 1985
MEZLOCILLIN SODIUM MONOHYDRATE				
INJECTABLE;INJECTION				
MEZLIN				
	BAYER PHARMS	EQ 1GM BASE/VIAL	A062333 001	
		EQ 1GM BASE/VIAL	A062372 005	Jan 13, 1983
		EQ 1GM BASE/VIAL	N050549 001	
		EQ 2GM BASE/VIAL	A062333 002	
		EQ 2GM BASE/VIAL	A062372 001	May 13, 1982
		EQ 2GM BASE/VIAL	N050549 002	
		EQ 3GM BASE/VIAL	A062333 003	
		EQ 3GM BASE/VIAL	A062372 002	May 13, 1982
		EQ 3GM BASE/VIAL	A062697 001	Jan 22, 1987
		EQ 3GM BASE/VIAL	N050549 003	
		EQ 4GM BASE/VIAL	A062333 004	
		EQ 4GM BASE/VIAL	A062372 003	May 13, 1982
		EQ 4GM BASE/VIAL	A062697 002	Jan 22, 1987
		EQ 4GM BASE/VIAL	N050549 004	
		EQ 20GM BASE/VIAL	A062372 004	Mar 02, 1988
		EQ 20GM BASE/VIAL	N050549 005	Mar 02, 1988
MICAFUNGIN SODIUM				
POWDER;INTRAVENOUS				
MICAFUNGIN				
+	TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N212125 001	Jul 30, 2021
+		EQ 100MG BASE/VIAL	N212125 002	Jul 30, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MICONAZOLE

INJECTABLE;INJECTION				
MONISTAT				
JANSSEN PHARMA	10MG/ML	N018040	001	

MICONAZOLE NITRATE

CREAM;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017494	001	
CREAM;VAGINAL				
MICONAZOLE NITRATE				
TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992
CREAM, SUPPOSITORY;TOPICAL, VAGINAL				
M-ZOLE 7 DUAL PACK				
ACTAVIS MID ATLANTIC	2%,100MG	A074586	001	Jul 17, 1997
MICONAZOLE 7 COMBINATION PACK				
COSETTE	2%,100MG	A076585	001	Mar 26, 2004
LOTION;TOPICAL				
MONISTAT-DERM				
INSIGHT PHARMS	2%	N017739	001	
TAMPON;VAGINAL				
MONISTAT 5				
PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION				
MIDAZOLAM HYDROCHLORIDE				
AKORN	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
ATLANTIDE	EQ 1MG BASE/ML	A078141	001	May 30, 2008
	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141	002	May 30, 2008
	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075856	002	Jun 13, 2002
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE				
MYLAN ASI	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010
	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010
MIDOZALAM HYDROCHLORIDE				
MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011
	EQ 5MG BASE/ML	A090316	002	May 04, 2011
VERSED				
+ HLR	EQ 1MG BASE/ML **	N018654	002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654	001	Dec 20, 1985
SYRUP;ORAL				
MIDAZOLAM HYDROCHLORIDE				
PHARM ASSOC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002
VERSED				
+ ROCHE	EQ 2MG BASE/ML **	N020942	001	Oct 15, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MIDODRINE HYDROCHLORIDE

TABLET;ORAL					
MIDODRINE HYDROCHLORIDE					
	CHARTWELL RX	2.5MG	A076514	001	Sep 11, 2003
		5MG	A076514	002	Sep 11, 2003
		10MG	A076514	003	Jul 02, 2004
PROAMATINE					
+	TAKEDA PHARMS USA	2.5MG **	N019815	001	Sep 06, 1996
+		5MG **	N019815	002	Sep 06, 1996
+		10MG **	N019815	003	Mar 20, 2002

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL					
MILNACIPRAN HYDROCHLORIDE					
	AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016
		25MG	A205081	002	Apr 22, 2016
		50MG	A205081	003	Apr 22, 2016
		100MG	A205081	004	Apr 22, 2016
	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016
		25MG	A205071	002	Jan 27, 2016
		50MG	A205071	003	Jan 27, 2016
		100MG	A205071	004	Jan 27, 2016

MILRINONE LACTATE

INJECTABLE;INJECTION					
MILRINONE LACTATE					
	BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
	GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190	001	Oct 31, 2006
	HIKMA	EQ 1MG BASE/ML	A075852	001	May 28, 2002
	HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
		EQ 1MG BASE/ML	A075884	001	May 28, 2002
	INTL MEDICATED	EQ 1MG BASE/ML	A076013	001	Aug 02, 2002
	MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004
	BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
	HIKMA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
	WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005
PRIMACOR					
+	SANOFI AVENTIS US	EQ 1MG BASE/ML **	N019436	001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	SANOFI AVENTIS US	EQ 10MG BASE/100ML **	N020343	001	Aug 09, 1994
+		EQ 15MG BASE/100ML **	N020343	002	Aug 09, 1994
+		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) **	N020343	003	Aug 09, 1994
+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) **	N020343	004	Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL					
MINOCIN					
+	BAUSCH	EQ 75MG BASE **	N050649	003	Feb 12, 2001
	TRIAX PHARMS	EQ 50MG BASE	N050315	002	
		EQ 100MG BASE	N050315	001	
CAPSULE, EXTENDED RELEASE;ORAL					
XIMINO					
	JOURNEY	EQ 67.5MG BASE	N201922	002	Jul 11, 2012
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012
INJECTABLE;INJECTION					
MINOCIN					
	LEDERLE	EQ 100MG BASE/VIAL	A062139	001	
SUSPENSION;ORAL					
MINOCIN					
	BAUSCH	EQ 50MG BASE/5ML	N050445	001	
TABLET;ORAL					
MINOCYCLINE HYDROCHLORIDE					
+	TRIAX PHARMS	EQ 50MG BASE **	N050451	003	Aug 10, 1982
+		EQ 100MG BASE **	N050451	002	Aug 10, 1982
TABLET, EXTENDED RELEASE;ORAL					
MINOCYCLINE HYDROCHLORIDE					
	BARR LABS INC	EQ 45MG BASE	A065485	001	Mar 17, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
MINOCYCLINE HYDROCHLORIDE					
		EQ 65MG BASE	A065485	004	May 18, 2012
		EQ 80MG BASE	A065485	007	Apr 26, 2017
		EQ 90MG BASE	A065485	002	Mar 17, 2009
		EQ 105MG BASE	A065485	008	Apr 26, 2017
		EQ 115MG BASE	A065485	005	May 18, 2012
		EQ 135MG BASE	A065485	003	Mar 17, 2009
	IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009
		EQ 90MG BASE	A090024	002	Feb 03, 2009
		EQ 135MG BASE	A090024	003	Feb 03, 2009
	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010
		EQ 90MG BASE	A090911	002	Jul 20, 2010
		EQ 135MG BASE	A090911	003	Jul 20, 2010
	RISING	EQ 55MG BASE	A203443	001	Aug 21, 2019
		EQ 65MG BASE	A201467	001	Jul 30, 2019
		EQ 80MG BASE	A203443	002	Aug 22, 2014
		EQ 105MG BASE	A203443	003	Aug 22, 2014
		EQ 115MG BASE	A201467	002	Jul 30, 2019
SOLODYN					
+	BAUSCH	EQ 45MG BASE **	N050808	001	May 08, 2006
+		EQ 90MG BASE **	N050808	002	May 08, 2006
+		EQ 135MG BASE **	N050808	003	May 08, 2006

MINOXIDIL

SOLUTION;TOPICAL					
MINOXIDIL (FOR MEN)					
	APOTEX INC	2%	A074924	001	Apr 29, 1998
	BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
	COPLEY PHARM	2%	A074500	001	May 23, 1996
	SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
	TEVA	2%	A074589	001	Apr 05, 1996
MINOXIDIL (FOR WOMEN)					
	APOTEX INC	2%	A074924	002	Apr 29, 1998
	SIGHT PHARMS	2%	A074743	001	Oct 18, 1996
MINOXIDIL EXTRA STRENGTH (FOR MEN)					
	APOTEX INC	5%	A075839	001	Oct 01, 2001
	AVACOR PRODS	5%	A075619	001	Nov 17, 2000
TABLET;ORAL					
LONITEN					
+	PFIZER	2.5MG **	N018154	001	
+		10MG **	N018154	003	
MINODYL					
	QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
		10MG	A071534	001	Mar 19, 1987
MINOXIDIL					
	ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
		10MG	A071796	001	Nov 10, 1987
	USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS					
KYNAMRO					
+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL					
MIRABEGRON					
	SAWAI USA	25MG	A209446	001	Dec 27, 2019

MIRTAZAPINE

TABLET;ORAL					
MIRTAZAPINE					
	ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
		15MG	A076308	001	Jun 20, 2003
		30MG	A076241	002	Jun 25, 2003
		30MG	A076308	002	Jun 20, 2003
		45MG	A076241	003	Jun 25, 2003
		45MG	A076308	003	Jun 20, 2003
	ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

	30MG	A076336	002	Jun 20, 2003
	45MG	A076336	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003
	30MG	A076176	002	Jun 19, 2003
	45MG	A076176	003	Jun 19, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
UPSHER SMITH LABS	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003
WATSON LABS	15MG	A076312	001	Jun 19, 2003
	30MG	A076312	002	Jun 19, 2003
	45MG	A076312	003	Jun 19, 2003

REMERON

+ ORGANON USA INC	45MG **	N020415	003	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
	15MG	A077959	001	Feb 14, 2011
	30MG	A076689	002	Aug 31, 2005
	30MG	A077959	002	Feb 14, 2011
	45MG	A076689	003	Aug 31, 2005
	45MG	A077959	003	Feb 14, 2011
ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003
	30MG	A076307	002	Dec 17, 2003
	45MG	A076307	003	Feb 28, 2006
IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005
	30MG	A076901	002	Jun 28, 2005
	45MG	A076901	003	Jun 28, 2005

MISOPROSTOL

TABLET;ORAL

MISOPROSTOL

ACQ PHARMA	0.1MG	A210201	001	Jul 02, 2019
	0.2MG	A210201	002	Jul 02, 2019
ANI PHARMS	0.1MG	A076095	001	Jul 10, 2002
	0.2MG	A076095	002	Jul 10, 2002

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

HIKMA	5MG/VIAL	A064117	001	Apr 19, 1995
HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995

MITOZYTREX

+ SUPERGEN	5MG/VIAL **	N050763	001	Nov 14, 2002

MUTAMYCIN

+ BRISTOL	5MG/VIAL **	N050450	001	
+	20MG/VIAL **	N050450	002	
BRISTOL MYERS	5MG/VIAL	A062336	001	
	20MG/VIAL	A062336	002	
	40MG/VIAL	A062336	003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008
MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012
RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009

NOVANTRONE

+ EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987
+	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **	N019297	002	Dec 23, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MITOXANTRONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NOVANTRONE				
+		EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **	N019297 003	Dec 23, 1987
MIVACURIUM CHLORIDE				
INJECTABLE;INJECTION				
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER				
	ABBVIE	EQ 0.5MG BASE/ML	N020098 002	Jan 22, 1992
		EQ 50MG BASE/100ML	N020098 003	Jan 22, 1992
MIVACURIUM CHLORIDE				
	RISING PHARMA	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009
SOLUTION;INTRAVENOUS				
MIVACRON				
+	ABBVIE	EQ 2MG BASE/ML (EQ 2MG BASE/ML) **	N020098 001	Jan 22, 1992
+		EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098 004	Jan 22, 1992
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098 005	Jan 22, 1992
MODAFINIL				
TABLET;ORAL				
MODAFINIL				
	HIKMA PHARMS	100MG	A090543 001	Sep 26, 2012
		200MG	A090543 002	Sep 26, 2012
	MYLAN PHARMS INC	100MG	A076594 001	Jul 16, 2012
		200MG	A076594 002	Jul 16, 2012
MOEXIPRIL HYDROCHLORIDE				
TABLET;ORAL				
UNIVASC				
	UCB INC	7.5MG **	N020312 001	Apr 19, 1995
		15MG **	N020312 002	Apr 19, 1995
MOLINDONE HYDROCHLORIDE				
CAPSULE;ORAL				
MOBAN				
+	STRIDES PHARMA	5MG **	N017111 001	
+		10MG **	N017111 002	
+		25MG **	N017111 003	
CONCENTRATE;ORAL				
MOBAN				
	ENDO PHARMS	20MG/ML	N017938 001	
TABLET;ORAL				
MOBAN				
+	STRIDES PHARMA	5MG **	N017111 004	
+		10MG **	N017111 005	
+		25MG **	N017111 006	
+		50MG **	N017111 007	
+		100MG **	N017111 008	
MOMETASONE FUROATE				
CREAM;TOPICAL				
ELOCON				
	MERCK SHARP DOHME	0.1% **	N019625 001	May 06, 1987
+		0.1% **	N019625 002	Apr 19, 2013
MOMETASONE FUROATE				
	ANDA REPOSITORY	0.1%	A076591 001	Apr 18, 2007
	FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005
LOTION;TOPICAL				
MOMETASONE FUROATE				
	ANDA REPOSITORY	0.1%	A076499 001	Nov 21, 2007
OINTMENT;TOPICAL				
ELOCON				
+	MERCK SHARP DOHME	0.1%	N019543 001	Apr 30, 1987
MOMETASONE FUROATE				
	ANDA REPOSITORY	0.1%	A076481 001	Nov 14, 2003
	TARO	0.1%	A076624 001	Dec 03, 2004
	TORRENT	0.1%	A207899 001	Jul 13, 2018
SPRAY, METERED;NASAL				
NASONEX				
+	ORGANON	0.05MG/SPRAY	N020762 001	Oct 01, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MONOBENZONE				
CREAM;TOPICAL				
BENOQUIN				
VALEANT PHARM INTL	20%	N008173	003	
MONOCTANOIN				
LIQUID;PERFUSION, BILIARY				
MOCTANIN				
ETHITEK	100%	N019368	001	Oct 29, 1985
MONTELUKAST SODIUM				
GRANULE;ORAL				
MONTELUKAST SODIUM				
MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012
TABLET;ORAL				
MONTELUKAST SODIUM				
AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015
APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012
BRECKENRIDGE	EQ 10MG BASE	A205319	001	Oct 30, 2020
HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012
MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012
STRIDES PHARMA	EQ 10MG BASE	A091576	001	Aug 03, 2012
TABLET, CHEWABLE;ORAL				
MONTELUKAST SODIUM				
AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015
	EQ 5MG BASE	A203328	002	Jul 31, 2015
APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012
	EQ 5MG BASE	A201508	002	Aug 03, 2012
HIKMA	EQ 4MG BASE	A091128	001	Aug 03, 2012
	EQ 5MG BASE	A091128	002	Aug 03, 2012
JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015
	EQ 5MG BASE	A203795	002	Feb 27, 2015
MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012
	EQ 5MG BASE	A079142	002	Aug 03, 2012
STRIDES PHARMA	EQ 4MG BASE	A091588	001	Aug 03, 2012
	EQ 5MG BASE	A091588	002	Aug 03, 2012
MORICIZINE HYDROCHLORIDE				
TABLET;ORAL				
ETHMOZINE				
SHIRE	200MG	N019753	001	Jun 19, 1990
	250MG	N019753	002	Jun 19, 1990
	300MG	N019753	003	Jun 19, 1990
MORPHINE SULFATE				
CAPSULE, EXTENDED RELEASE;ORAL				
AVINZA				
KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002
	45MG	N021260	005	Dec 18, 2008
	60MG	N021260	002	Mar 20, 2002
	75MG	N021260	006	Dec 18, 2008
	90MG	N021260	003	Mar 20, 2002
	120MG	N021260	004	Mar 20, 2002
KADIAN				
+ ALLERGAN	10MG	N020616	008	Apr 20, 2007
+	20MG	N020616	001	Jul 03, 1996
+	30MG	N020616	004	Mar 09, 2001
+	40MG	N020616	009	Jul 09, 2012
+	50MG	N020616	002	Jul 03, 1996
+	60MG	N020616	005	Mar 09, 2001
+	70MG	N020616	010	Jul 09, 2012
+	80MG	N020616	006	Oct 27, 2006
+	100MG	N020616	003	Jul 03, 1996
+	130MG	N020616	011	Jul 09, 2012
+	150MG	N020616	012	Jul 09, 2012
+	200MG	N020616	007	Feb 27, 2007
MORPHINE SULFATE				
STRIDES PHARMA	20MG	A200812	001	Nov 10, 2011
	30MG	A200812	002	Nov 10, 2011
	50MG	A200812	003	Nov 10, 2011
	60MG	A200812	004	Nov 10, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL				
MORPHINE SULFATE				
	80MG	A200812	005	Nov 10, 2011
	100MG	A200812	006	Nov 10, 2011
TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014
	30MG	A202718	002	Dec 29, 2014
	40MG	A202718	007	Jun 03, 2015
	50MG	A202718	003	Dec 29, 2014
	60MG	A202718	004	Dec 29, 2014
	70MG	A202718	008	Jun 03, 2015
	80MG	A202718	005	Dec 29, 2014
	100MG	A202718	006	Dec 29, 2014
INJECTABLE;INJECTION				
ASTRAMORPH PF				
FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986
	0.5MG/ML	A071051	001	Oct 07, 1986
	1MG/ML	A071052	001	Oct 07, 1986
	1MG/ML	A071053	001	Oct 07, 1986
MORPHINE SULFATE				
HOSPIRA	1MG/ML	A071850	001	May 11, 1988
+ HOSPIRA INC	15MG/ML	N202515	005	Nov 14, 2011
ICU MEDICAL INC	0.5MG/ML	N019917	001	Oct 30, 1992
+	1MG/ML **	N019916	001	Oct 30, 1992
+	5MG/ML **	N019916	002	Oct 27, 2006
INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021
SPECGX LLC	1MG/ML	N020631	001	Jul 03, 1996
	2MG/ML	N020631	002	Jul 03, 1996
WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991
	0.5MG/ML	A073375	001	Sep 30, 1991
	1MG/ML	A073374	001	Sep 30, 1991
	1MG/ML	A073376	001	Sep 30, 1991
INJECTABLE, LIPOSOMAL;EPIDURAL				
DEPODUR				
PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671	003	May 18, 2004
SOLUTION;INTRAMUSCULAR				
MORPHINE SULFATE (AUTOINJECTOR)				
+ MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990
SOLUTION;ORAL				
MORPHINE SULFATE				
ANI PHARMS	10MG/5ML	A205509	001	Apr 17, 2018
	20MG/5ML	A205509	002	Apr 17, 2018
	100MG/5ML	A205509	003	Apr 17, 2018
LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015
	20MG/5ML	A202310	001	Oct 30, 2015
	100MG/5ML	N201517	001	Jun 23, 2011
NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014
	20MG/5ML	A201011	002	Feb 05, 2014
	100MG/5ML	A201011	003	Oct 06, 2016
VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012
	20MG/5ML	A201947	002	Jan 05, 2012
WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021
	20MG/5ML	A211454	002	Feb 12, 2021
	100MG/5ML	A211454	003	Feb 12, 2021
TABLET, EXTENDED RELEASE;ORAL				
ARYMO ER				
+ ZYLA	15MG	N208603	001	Jan 09, 2017
+	30MG	N208603	002	Jan 09, 2017
+	60MG	N208603	003	Jan 09, 2017
MORPHABOND ER				
+ DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015
+	30MG	N206544	002	Oct 02, 2015
+	60MG	N206544	003	Oct 02, 2015
+	100MG	N206544	004	Oct 02, 2015
MORPHINE SULFATE				
EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016
	30MG	A091357	002	Jun 23, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL					
MORPHINE SULFATE					
		60MG	A091357	003	Jun 23, 2016
		100MG	A091357	004	Jun 23, 2016
		200MG	A091357	005	Jun 23, 2016
	NESHER PHARMS	15MG	A076733	001	May 19, 2004
		100MG	A077855	001	Sep 27, 2007
		200MG	A077855	002	Sep 27, 2007
	RISING	15MG	A200824	001	Oct 18, 2011
		30MG	A200824	002	Oct 18, 2011
		60MG	A200824	003	Oct 18, 2011
		100MG	A200824	004	Oct 18, 2011
		200MG	A200824	005	Oct 18, 2011
	SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016
		30MG	A205634	002	Aug 25, 2016
		60MG	A205634	003	Aug 25, 2016
		100MG	A205634	004	Aug 25, 2016
		200MG	A205634	005	Aug 25, 2016
	WATSON LABS	100MG	A075656	001	Jan 30, 2001
ORAMORPH SR					
	XANODYNE PHARMS INC	15MG	N019977	004	Nov 23, 1994
		30MG	N019977	001	Aug 15, 1991
		60MG	N019977	002	Aug 15, 1991
		100MG	N019977	003	Aug 15, 1991

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
EMBEDA					
+	ALPHARMA PHARMS	20MG;0.8MG	N022321	001	Aug 13, 2009
+		30MG;1.2MG	N022321	002	Aug 13, 2009
+		50MG;2MG	N022321	003	Aug 13, 2009
+		60MG;2.4MG	N022321	004	Aug 13, 2009
+		80MG;3.2MG	N022321	005	Aug 13, 2009
+		100MG;4MG	N022321	006	Aug 13, 2009

MOXALACTAM DISODIUM

INJECTABLE;INJECTION					
MOXAM					
	LILLY	EQ 250MG BASE/VIAL	N050550	001	
		EQ 500MG BASE/VIAL	N050550	002	
		EQ 1GM BASE/VIAL	N050550	003	
		EQ 2GM BASE/VIAL	N050550	004	
		EQ 10GM BASE/VIAL	N050550	008	

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS					
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
+	BAYER HLTHCARE	400MG/250ML (1.6MG/ML) **	N021277	001	Nov 30, 2001
TABLET;ORAL					
AVELOX					
+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999
MOXIFLOXACIN HYDROCHLORIDE					
	MYLAN	EQ 400MG BASE	A204635	001	Aug 31, 2015
	SUNSHINE	EQ 400MG BASE	A206295	001	Sep 28, 2018

MUPIROCIN

OINTMENT;TOPICAL					
BACTROBAN					
+	GLAXOSMITHKLINE	2% **	N050591	001	Dec 31, 1987

MUPIROCIN CALCIUM

CREAM;TOPICAL					
BACTROBAN					
+	GLAXOSMITHKLINE	EQ 2% BASE **	N050746	001	Dec 11, 1997
OINTMENT;NASAL					
BACTROBAN					
+	GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL				
MYCOPHENOLATE MOFETIL				
APOTEX CORP	250MG	A090419	001	Apr 22, 2009
DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011
JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014
STRIDES PHARMA	250MG	A090111	001	Dec 22, 2009
ZYDUS PHARMS USA INC	250MG	A065433	001	May 04, 2009
TABLET;ORAL				
MYCOPHENOLATE MOFETIL				
AMNEAL	500MG	A090606	001	Jul 16, 2010
APOTEX	500MG	A090499	001	Apr 22, 2009
DR REDDYS LABS LTD	500MG	A090464	001	Sep 13, 2010
JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014
TEVA PHARMS	500MG	A065457	001	May 04, 2009
ZYDUS PHARMS USA INC	500MG	A065477	001	May 04, 2009

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION				
MYCOPHENOLATE MOFETIL HYDROCHLORIDE				
AMNEAL	500MG/VIAL	A211374	001	Mar 05, 2021

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL				
MYCOPHENOLIC SODIUM				
TEVA PHARMS USA	EQ 180MG BASE	A202720	001	Oct 30, 2014
	EQ 360MG BASE	A202720	002	Oct 30, 2014

NABUMETONE

TABLET;ORAL				
NABUMETONE				
COPLEY PHARM	750MG	A075179	001	Jun 06, 2000
IMPAX LABS INC	500MG	A075189	001	May 26, 2000
	750MG	A075189	002	Sep 24, 2001
MYLAN PHARMS INC	500MG	A090516	001	Jul 12, 2010
	750MG	A090516	002	Jul 12, 2010
NOSTRUM LABS INC	500MG	A090427	001	Dec 30, 2011
	750MG	A090427	002	Dec 30, 2011
OXFORD PHARMS	500MG	A079093	001	Feb 27, 2009
	750MG	A079093	002	Feb 27, 2009
SANDOZ	500MG	A075590	001	Feb 25, 2002
	750MG	A075590	002	Feb 25, 2002
RELAFEN				
+ SMITHKLINE BEECHAM	500MG **	N019583	001	Dec 24, 1991
+	750MG **	N019583	002	Dec 24, 1991

NADOLOL

TABLET;ORAL				
CORGARD				
USWM	120MG	N018063	003	
	160MG	N018063	004	
NADOLOL				
HERITAGE PHARMA	120MG	A074255	002	Jan 24, 1996
	160MG	A074255	003	Jan 24, 1996
NOVAST LABS	20MG	A210786	001	Jun 01, 2018
	40MG	A210786	002	Jun 01, 2018
	80MG	A210786	003	Jun 01, 2018
TEVA PHARMS	80MG	A074368	001	Aug 31, 1994
	120MG	A074368	002	Aug 31, 1994
	160MG	A074368	003	Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE;ORAL				
UNIPEN				
WYETH AYERST	EQ 250MG BASE	N050111	001	
FOR SOLUTION;ORAL				
UNIPEN				
WYETH AYERST	EQ 250MG BASE/5ML	N050199	001	
INJECTABLE;INJECTION				
NAFCILLIN SODIUM				
APOTHECON	EQ 500MG BASE/VIAL	A061984	001	
	EQ 1GM BASE/VIAL	A061984	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAFCILLIN SODIUM				
INJECTABLE;INJECTION				
NAFCILLIN SODIUM				
	EQ 2GM BASE/VIAL	A061984	003	
	EQ 4GM BASE/VIAL	A061984	005	
FRESENIUS	EQ 1GM BASE/VIAL	A206682	001	Dec 10, 2019
	EQ 2GM BASE/VIAL	A206682	002	Dec 10, 2019
MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014
	EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014
SANDOZ	EQ 500MG BASE/VIAL	A062527	001	Aug 02, 1984
WATSON LABS INC	EQ 500MG BASE/VIAL	A062844	001	Oct 26, 1988
	EQ 1GM BASE/VIAL	A062844	002	Oct 26, 1988
	EQ 1.5GM BASE/VIAL	A062844	003	Oct 26, 1988
	EQ 2GM BASE/VIAL	A062844	004	Oct 26, 1988
	EQ 4GM BASE/VIAL	A062844	005	Oct 26, 1988
	EQ 10GM BASE/VIAL	A063008	001	Sep 29, 1988
NALLPEN				
GLAXOSMITHKLINE	EQ 500MG BASE/VIAL	A061999	001	
	EQ 1GM BASE/VIAL	A061999	002	
	EQ 1GM BASE/VIAL	A062755	001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A061999	003	
	EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A061999	004	
UNIPEN				
WYETH AYERST	EQ 500MG BASE/VIAL **	A062717	001	Dec 16, 1986
+	EQ 500MG BASE/VIAL **	N050320	001	
	EQ 1GM BASE/VIAL **	A062717	002	Dec 16, 1986
	EQ 2GM BASE/VIAL **	A062717	004	Dec 16, 1986
+	EQ 2GM BASE/VIAL **	N050320	003	
+	EQ 4GM BASE/VIAL **	N050320	004	
+	EQ 10GM BASE/VIAL **	N050320	005	
+	EQ 20GM BASE/VIAL **	N050320	006	
UNIPEN IN PLASTIC CONTAINER				
+ WYETH AYERST	EQ 1GM BASE/VIAL **	N050320	002	
TABLET;ORAL				
UNIPEN				
WYETH AYERST	EQ 500MG BASE	N050462	001	
NAFTIFINE HYDROCHLORIDE				
CREAM;TOPICAL				
NAFTIN				
+ SEBELA IRELAND LTD	1% **	N019599	001	Feb 29, 1988
GEL;TOPICAL				
NAFTIFINE HYDROCHLORIDE				
TARO	2%	A208201	001	Apr 10, 2019
NALBUPHINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NALBUPHINE				
ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986
	20MG/ML	A070752	001	Sep 24, 1986
NALBUPHINE HYDROCHLORIDE				
ABBOTT	20MG/ML	A070917	001	Feb 03, 1989
ABBVIE	1.5MG/ML	N020200	001	Mar 12, 1993
DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998
	20MG/ML	A074471	002	Mar 19, 1998
IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989
	10MG/ML	A072071	001	Apr 10, 1989
	10MG/ML	A072072	001	Apr 10, 1989
	20MG/ML	A072073	001	Apr 10, 1989
	20MG/ML	A072074	001	Apr 10, 1989
	20MG/ML	A072075	001	Apr 10, 1989
RISING	10MG/ML	A206506	001	Feb 06, 2019
	10MG/ML	A207595	001	Jan 11, 2019
	20MG/ML	A206506	002	Feb 06, 2019
	20MG/ML	A207595	002	Jan 11, 2019
NUBAIN				
+ PAR PHARM INC	10MG/ML **	N018024	001	
+	20MG/ML **	N018024	002	May 27, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NALIDIXIC ACID				
SUSPENSION;ORAL				
NEGGRAM				
	SANOFI AVENTIS US	250MG/5ML	N017430 001	
TABLET;ORAL				
NALIDIXIC ACID				
	SUN PHARM INDUSTRIES	250MG	A070270 001	Jun 29, 1988
		500MG	A070271 001	Jun 29, 1988
		1GM	A070272 001	Jun 29, 1988
	WATSON LABS	250MG	A071936 001	Jun 29, 1988
		500MG	A072061 001	Jun 29, 1988
		1GM	A071919 001	Jun 29, 1988
NEGGRAM				
	SANOFI AVENTIS US	250MG	N014214 002	
		500MG	N014214 004	
		1GM	N014214 005	
NALMEFENE HYDROCHLORIDE				
INJECTABLE;INJECTION				
REVEX				
+	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML **	N020459 001	Apr 17, 1995
+		EQ 1MG BASE/ML **	N020459 002	Apr 17, 1995
NALOXONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
NALOXONE				
	HIKMA	0.4MG/ML	A070298 001	Sep 24, 1986
		0.4MG/ML	A070496 001	Sep 24, 1986
	WYETH AYERST	0.02MG/ML	A070188 001	Sep 24, 1986
		0.02MG/ML	A070189 001	Sep 24, 1986
		0.4MG/ML	A070190 001	Sep 24, 1986
		0.4MG/ML	A070191 001	Sep 24, 1986
NALOXONE HYDROCHLORIDE				
	ABRAXIS PHARM	0.02MG/ML	A070648 001	Nov 17, 1986
		0.02MG/ML	A070661 001	Nov 17, 1986
		0.4MG/ML	A070649 001	Nov 17, 1986
		1MG/ML	A071604 001	Dec 16, 1988
	ASTRAZENECA	0.02MG/ML	A072081 001	Apr 11, 1989
	HIKMA	0.02MG/ML	A071272 001	May 24, 1988
		1MG/ML	A071273 001	May 24, 1988
		1MG/ML	A071274 001	May 24, 1988
		1MG/ML	A071287 001	May 24, 1988
	HOSPIRA	0.02MG/ML	A070171 001	Sep 24, 1986
		0.02MG/ML	A070252 001	Jan 16, 1987
		0.02MG/ML	A070253 001	Jan 16, 1987
		0.4MG/ML	A070254 001	Jan 07, 1987
		0.4MG/ML	A070255 001	Jan 07, 1987
	IGI LABS INC	0.02MG/ML	A072082 001	Apr 11, 1989
		0.02MG/ML	A072083 001	Apr 11, 1989
		0.02MG/ML	A072084 001	Apr 11, 1989
		0.02MG/ML	A072085 001	Apr 11, 1989
		0.4MG/ML	A072086 001	Apr 11, 1989
		0.4MG/ML	A072087 001	Apr 11, 1989
		0.4MG/ML	A072088 001	Apr 11, 1989
		0.4MG/ML	A072089 001	Apr 11, 1989
		0.4MG/ML	A072090 001	Apr 11, 1989
		1MG/ML	A072091 001	Apr 11, 1989
		1MG/ML	A072092 001	Apr 11, 1989
		1MG/ML	A072093 001	Apr 11, 1989
	INTL MEDICATION	0.4MG/ML	A070417 001	Sep 24, 1986
		0.4MG/ML	A070639 001	Sep 24, 1986
		1MG/ML	A072115 001	Apr 27, 1988
	MARSAM PHARMS LLC	0.4MG/ML	A071811 001	Jul 19, 1988
	PAR STERILE PRODUCTS	0.4MG/ML	A211286 001	Jan 17, 2020
	SMITH AND NEPHEW	0.02MG/ML	A071671 001	Nov 17, 1987
		0.4MG/ML	A071681 001	Nov 17, 1987
		0.4MG/ML	A071682 001	Nov 17, 1987
	SOLOPAK	0.02MG/ML	A071672 001	Nov 17, 1987
		0.4MG/ML	A071683 001	Nov 17, 1987
	VIRTUS PHARMS	0.4MG/ML	A207846 001	Dec 17, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NALOXONE HYDROCHLORIDE					
INJECTABLE;INJECTION					
NALOXONE HYDROCHLORIDE					
	WATSON LABS	0.4MG/ML	A071339	001	Nov 18, 1987
NARCAN					
+	ADAPT	0.02MG/ML **	N016636	002	
+		0.4MG/ML **	N016636	001	
+		1MG/ML **	N016636	003	Jun 14, 1982
	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083	001	Jul 28, 1988
		1MG/ML	A071084	001	Jul 28, 1988
		1MG/ML	A071311	001	Jul 28, 1988
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
EVZIO					
+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787	001	Apr 03, 2014
EVZIO (AUTOINJECTOR)					
+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016
SPRAY, METERED;NASAL					
NARCAN					
+	EMERGENT	2MG/SPRAY **	N208411	002	Jan 24, 2017
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE					
TABLET, EXTENDED RELEASE;ORAL					
TARGINIQ					
+	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014
+		10MG;20MG	N205777	002	Jul 23, 2014
+		20MG;40MG	N205777	003	Jul 23, 2014
NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE					
TABLET;ORAL					
TALWIN NX					
	SANOFI AVENTIS US	EQ 0.5MG BASE;EQ 50MG BASE **	N018733	001	Dec 16, 1982
NALTREXONE HYDROCHLORIDE					
TABLET;ORAL					
NALTREXONE HYDROCHLORIDE					
	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000
REVIA					
+	TEVA WOMENS	50MG	N018932	001	Nov 20, 1984
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE					
CAPSULE, EXTENDED RELEASE;ORAL					
TROXYCA ER					
	PFIZER	1.2MG;10MG	N207621	001	Aug 19, 2016
		2.4MG;20MG	N207621	002	Aug 19, 2016
		3.6MG;30MG	N207621	003	Aug 19, 2016
		4.8MG;40MG	N207621	004	Aug 19, 2016
		7.2MG;60MG	N207621	005	Aug 19, 2016
		9.6MG;80MG	N207621	006	Aug 19, 2016
NANDROLONE DECANOATE					
INJECTABLE;INJECTION					
DECA-DURABOLIN					
	ASPEN GLOBAL INC	50MG/ML	N013132	001	Jun 12, 1986
		100MG/ML	N013132	002	Jun 12, 1986
+		200MG/ML **	N013132	003	Jun 12, 1986
NANDROLONE DECANOATE					
	ABRAXIS PHARM	100MG/ML	A088290	001	Oct 03, 1983
		200MG/ML	A088317	001	Oct 14, 1983
	AKORN	100MG/ML	A087519	001	Sep 28, 1983
	AM REGENT	200MG/ML	A091252	001	Aug 30, 2010
	WATSON LABS	50MG/ML	A086385	001	Jan 13, 1984
		50MG/ML	A087598	001	Oct 06, 1983
		50MG/ML	A088554	001	Feb 10, 1986
		100MG/ML	A086598	001	Jan 13, 1984
		100MG/ML	A087599	001	Oct 06, 1983
+		200MG/ML	A088128	001	Dec 05, 1983

NANDROLONE PHENPROPIONATE				
INJECTABLE;INJECTION				
DURABOLIN				
ORGANON USA INC	25MG/ML	N011891	001	
	50MG/ML	N011891	002	
NANDROLONE PHENPROPIONATE				
WATSON LABS	25MG/ML	A086386	001	Jun 17, 1983
	50MG/ML	A087488	001	Jun 17, 1983
NAPHAZOLINE HYDROCHLORIDE				
SOLUTION/DROPS;OPHTHALMIC				
ALBALON				
ALLERGAN	0.1% **	A080248	001	
NAFAZAIR				
BAUSCH AND LOMB	0.1%	A040073	001	May 25, 1994
PHARMAFAIR	0.1%	A088101	001	Apr 15, 1983
NAPHAZOLINE HYDROCHLORIDE				
AKORN	0.1%	A083590	001	
NAPHCON FORTE				
+ ALCON	0.1%	A080229	001	
OPCON				
BAUSCH AND LOMB	0.1%	A087506	001	
VASOCON				
NOVARTIS	0.1%	A080235	002	Mar 24, 1983
NAPROXEN				
TABLET;ORAL				
NAPROSYN				
+ ATNAHS PHARMA US	250MG	N017581	002	
+	375MG	N017581	003	
NAPROXEN				
CHARTWELL MOLECULES	250MG	A074410	001	Apr 28, 1995
	375MG	A074410	002	Apr 28, 1995
	500MG	A074410	003	Apr 28, 1995
DAVA PHARMS INC	250MG	A074105	001	Dec 21, 1993
	375MG	A074105	002	Dec 21, 1993
	500MG	A074105	003	Dec 21, 1993
HAMILTON PHARMS	250MG	A074110	001	Oct 30, 1992
	375MG	A074110	002	Oct 30, 1992
	500MG	A074110	003	Oct 30, 1992
HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004
	375MG	A076494	002	Jan 14, 2004
	500MG	A076494	003	Jan 14, 2004
IVAX SUB TEVA PHARMS	250MG	A074111	001	Feb 28, 1995
	375MG	A074111	002	Feb 28, 1995
	500MG	A074111	003	Feb 28, 1995
MYLAN	250MG	A074121	001	Dec 21, 1993
	375MG	A074121	002	Dec 21, 1993
	500MG	A074121	003	Dec 21, 1993
PLIVA	250MG	A074182	001	Jun 27, 1996
	375MG	A074182	002	Jun 27, 1996
	500MG	A074182	003	Jun 27, 1996
PUREPAC PHARM	250MG	A074263	001	Dec 21, 1993
	375MG	A074263	002	Dec 21, 1993
	500MG	A074263	003	Dec 21, 1993
ROXANE	250MG	A074211	001	Feb 28, 1994
	375MG	A074211	002	Feb 28, 1994
	500MG	A074211	003	Feb 28, 1994
TEVA	250MG	A074129	001	Dec 21, 1993
	250MG	A074216	001	Apr 11, 1996
	375MG	A074129	002	Dec 21, 1993
	375MG	A074216	002	Apr 11, 1996
	500MG	A074129	003	Dec 21, 1993
	500MG	A074216	003	Apr 11, 1996
TEVA PHARMS	250MG	A074207	001	Dec 21, 1993
	375MG	A074207	002	Dec 21, 1993
	500MG	A074207	003	Dec 21, 1993
WATSON LABS	250MG	A074457	001	May 31, 1995
	375MG	A074457	002	May 31, 1995
	500MG	A074457	003	May 31, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NAPROXEN

TABLET;ORAL

NAPROXEN

WATSON LABS TEVA	250MG	A074163	001	Feb 10, 1995
	375MG	A074163	002	Feb 10, 1995
	500MG	A074163	003	Feb 10, 1995

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

ACTAVIS ELIZABETH	375MG	A074936	001	Feb 24, 1998
	500MG	A074936	002	Feb 24, 1998
FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998
	500MG	A075061	002	Feb 18, 1998
MYLAN PHARMS INC	375MG	A075390	001	Apr 19, 2001
	500MG	A075390	002	Apr 19, 2001
PLIVA	375MG	A075337	001	May 26, 1999
	500MG	A075337	002	May 26, 1999

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

+ ATNAHS PHARMA US	EQ 250MG BASE **	N018164	001	

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544	001	Aug 22, 2003
	EQ 500MG BASE	A076544	002	Aug 22, 2003
CONTRACT PHARMACAL	220MG	A074789	001	Feb 27, 1997
HAMILTON PHARMS	EQ 250MG BASE	A074106	001	Aug 31, 1993
	EQ 500MG BASE	A074106	002	Aug 31, 1993
HIKMA	EQ 250MG BASE	A074480	002	Feb 18, 1998
	EQ 500MG BASE	A074480	001	May 14, 1996
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230	001	Mar 14, 1995
	EQ 500MG BASE	A074230	002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367	001	Aug 31, 1994
	EQ 500MG BASE	A074367	002	Aug 31, 1994
PLD ACQUISITIONS LLC	220MG	A074646	001	Jan 13, 1997
PLIVA	EQ 250MG BASE	A074242	001	Jun 20, 1996
	EQ 500MG BASE	A074242	002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319	001	Mar 20, 1995
	EQ 500MG BASE	A074319	002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257	001	Dec 21, 1993
	EQ 500MG BASE	A074257	002	Dec 21, 1993
SANDOZ	EQ 250MG BASE	A074162	001	Dec 21, 1993
	EQ 250MG BASE	A074495	001	Dec 05, 1994
	EQ 500MG BASE	A074162	002	Dec 21, 1993
	EQ 500MG BASE	A074495	002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142	001	Dec 21, 1993
	EQ 250MG BASE	A074198	001	Dec 21, 1993
	EQ 500MG BASE	A074142	002	Dec 21, 1993
	EQ 500MG BASE	A074198	002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289	001	Jan 27, 1994
	EQ 500MG BASE	A074289	002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195	001	Dec 21, 1993
	EQ 250MG BASE	A074455	001	May 31, 1995
	EQ 500MG BASE	A074195	002	Dec 21, 1993
	EQ 500MG BASE	A074455	002	May 31, 1995
YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

+ CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

ANI PHARMS	EQ 1MG BASE	A078751	001	Jul 07, 2010
	EQ 2.5MG BASE	A078751	002	Jul 07, 2010
APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011
	EQ 2.5MG BASE	A091373	002	Apr 22, 2011
CHARTWELL RX	EQ 1MG BASE	A090288	001	Jul 07, 2010
	EQ 2.5MG BASE	A090288	002	Jul 07, 2010
MYLAN PHARMS INC	EQ 1MG BASE	A202431	001	May 31, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NARATRIPTAN HYDROCHLORIDE				
TABLET;ORAL				
NARATRIPTAN				
	EQ 2.5MG BASE	A202431	002	May 31, 2012
NATEGLINIDE				
TABLET;ORAL				
NATEGLINIDE				
ALVOGEN	60MG	A205055	001	Dec 11, 2015
	120MG	A205055	002	Dec 11, 2015
TEVA PHARMS	60MG	A077467	001	Sep 09, 2009
	120MG	A077467	002	Sep 09, 2009
STARLIX				
+ NOVARTIS	60MG **	N021204	001	Dec 22, 2000
+	120MG **	N021204	002	Dec 22, 2000
NEBIVOLOL HYDROCHLORIDE				
TABLET;ORAL				
NEBIVOLOL HYDROCHLORIDE				
ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015
	EQ 5MG BASE	A203741	002	Jun 24, 2015
	EQ 10MG BASE	A203741	003	Jun 24, 2015
	EQ 20MG BASE	A203741	004	Jun 24, 2015
GLENMARK PHARMS LTD	EQ 2.5MG BASE	A203821	001	May 25, 2017
	EQ 5MG BASE	A203821	002	May 25, 2017
	EQ 10MG BASE	A203821	003	May 25, 2017
	EQ 20MG BASE	A203821	004	May 25, 2017
WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015
	EQ 5MG BASE	A203683	002	Nov 27, 2015
	EQ 10MG BASE	A203683	003	Nov 27, 2015
	EQ 20MG BASE	A203683	004	Nov 27, 2015
NEBIVOLOL HYDROCHLORIDE; VALSARTAN				
TABLET;ORAL				
BYVALSON				
+ ALLERGAN	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016
NEDOCROMIL SODIUM				
AEROSOL, METERED;INHALATION				
TILADE				
KING PHARMS LLC	1.75MG/INH	N019660	001	Dec 30, 1992
SOLUTION;INHALATION				
TILADE				
SANOFI AVENTIS US	0.5%	N020750	001	Oct 01, 1997
NEFAZODONE HYDROCHLORIDE				
TABLET;ORAL				
NEFAZODONE HYDROCHLORIDE				
ANI PHARMS	50MG	A076072	001	Sep 16, 2003
	100MG	A076072	002	Sep 16, 2003
	150MG	A076072	003	Sep 16, 2003
	200MG	A076072	004	Sep 16, 2003
	250MG	A076072	005	Sep 16, 2003
DR REDDYS LABS INC	50MG	A076309	001	Sep 16, 2003
	100MG	A076309	002	Sep 16, 2003
	150MG	A076309	003	Sep 16, 2003
	200MG	A076309	004	Sep 16, 2003
	250MG	A076309	005	Sep 16, 2003
FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003
	100MG	A076302	002	Sep 16, 2003
	150MG	A076302	003	Sep 16, 2003
	200MG	A076302	004	Sep 16, 2003
	250MG	A076302	005	Sep 16, 2003
IVAX SUB TEVA PHARMS	50MG	A075763	001	Sep 16, 2003
	100MG	A075763	002	Sep 16, 2003
	150MG	A075763	003	Sep 16, 2003
	200MG	A075763	004	Sep 16, 2003
	250MG	A075763	005	Sep 16, 2003
MYLAN	100MG	A076129	002	Sep 16, 2003
	150MG	A076129	003	Sep 16, 2003
	200MG	A076129	004	Sep 16, 2003
	250MG	A076129	005	Sep 16, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL				
NEFAZODONE HYDROCHLORIDE				
ROXANE	50MG	A076196	001	Sep 16, 2003
	100MG	A076196	002	Sep 16, 2003
	150MG	A076196	003	Sep 16, 2003
	200MG	A076196	004	Sep 16, 2003
	250MG	A076196	005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003
	100MG	A076409	002	Sep 16, 2003
	150MG	A076409	003	Sep 16, 2003
	200MG	A076409	004	Sep 16, 2003
	250MG	A076409	005	Sep 16, 2003
WATSON LABS	100MG	A076073	002	Sep 16, 2003
	150MG	A076073	003	Sep 16, 2003
	200MG	A076073	004	Sep 16, 2003
	250MG	A076073	005	Sep 16, 2003
SERZONE				
+ BRISTOL MYERS SQUIBB	50MG **	N020152	001	Dec 22, 1994
+	100MG **	N020152	002	Dec 22, 1994
+	150MG **	N020152	003	Dec 22, 1994
+	200MG **	N020152	004	Dec 22, 1994
+	250MG **	N020152	005	Dec 22, 1994
+	300MG **	N020152	006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER;ORAL				
VIRACEPT				
AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778	001	Mar 14, 1997

NEOMYCIN SULFATE

SOLUTION;ORAL				
MYCIFRADIN				
PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285	001	
NEO-FRADIN				
X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010	001	May 23, 2002
TABLET;ORAL				
MYCIFRADIN				
PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520	001	
NEOBIOTIC				
PFIZER	EQ 350MG BASE	A060475	001	
NEOMYCIN SULFATE				
BRISTOL MYERS SQUIBB	500MG	A060365	001	
LANNETT	500MG	A060607	001	
LANNETT CO INC	500MG	A204435	001	Jun 10, 2016
LILLY	500MG	A060385	001	
NOSTRUM LABS INC	500MG	A065468	001	Mar 29, 2010
ROXANE	500MG	A062173	001	
SANDOZ	500MG	A061586	001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL				
NEOSPORIN				
GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176	002	Jan 14, 1985
OINTMENT;OPHTHALMIC				
STATROL				
ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344	002	
SOLUTION/DROPS;OPHTHALMIC				
STATROL				
ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339	001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456	001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC				
POLY-PRED				
ALLERGAN	EQ 0.35% BASE;10,000 UNITS/ML;0.5%	N050081	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/GM;0.25%	A061039 002	
		EQ 3.5MG BASE/GM;0.5%	A061039 001	
SUSPENSION/DROPS;OPHTHALMIC				
NEO-DELTA-CORTEF				
	PHARMACIA AND UPJOHN	EQ 3.5MG BASE/ML;0.25%	A061037 001	

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC				
NEO-HYDELTRASOL				
	MERCK	EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE	N050378 001	

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062598 001	Jul 21, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062600 001	Jul 21, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062595 001	Jul 21, 1986
OINTMENT;TOPICAL				
MYTREX A				
	SAVAGE LABS	EQ 3.5MG BASE/GM;0.1%	A062609 001	May 23, 1986
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE				
	FOUGERA	EQ 3.5MG BASE/GM;0.1%	A062608 001	May 23, 1986
	PHARMADERM	EQ 3.5MG BASE/GM;0.1%	A062607 001	May 23, 1986

NESIRITIDE RECOMBINANT

FOR SOLUTION;INTRAVENOUS				
NATRECOR				
+	SCIOS LLC	1.5MG/VIAL **	N020920 001	Aug 10, 2001

NETILMICIN SULFATE

INJECTABLE;INJECTION				
NETROMYCIN				
	SCHERING	EQ 10MG BASE/ML	N050544 001	Feb 28, 1983
		EQ 25MG BASE/ML	N050544 002	Feb 28, 1983
		EQ 100MG BASE/ML	N050544 003	Feb 28, 1983

NEVIRAPINE

TABLET;ORAL				
NEVIRAPINE				
	APOTEX INC	200MG	A203021 001	May 22, 2012
	MYLAN LABS	200MG	A078864 001	May 22, 2012
	TECH ORGANIZED	200MG	A203176 001	May 22, 2012
TABLET, EXTENDED RELEASE;ORAL				
NEVIRAPINE				
	APOTEX	400MG	A205258 001	Apr 03, 2014
	CIPLA	400MG	A206448 001	Oct 15, 2015
	MYLAN	100MG	A206271 001	Nov 09, 2015
	TECH ORGANIZED	100MG	A207467 001	Jul 31, 2017
		400MG	A207467 002	Jul 31, 2017

NIACIN

CAPSULE;ORAL				
WAMPOCAP				
	MEDPOINTE PHARM HLC	500MG	N011073 003	
TABLET;ORAL				
NIACIN				
	EVERYLIFE	500MG	A083203 001	
	HALSEY	500MG	A083453 001	
	HIKMA	500MG	A083718 001	
	IMPAX LABS	500MG	A083115 001	
	IVAX SUB TEVA PHARMS	500MG	A083180 001	
	MK LABS	500MG	A083525 001	
	PUREPAC PHARM	500MG	A083271 001	
	SANDOZ	500MG	A083306 001	
	TABLICAPS	500MG	A084237 001	
	WATSON LABS	500MG	A083136 001	
		500MG	A083305 001	
		500MG	A085172 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NIACIN

TABLET;ORAL					
NIACIN					
	WOCKHARDT	500MG	A081134	001	Apr 28, 1992
NICOLAR					
+	SANOFI AVENTIS US	500MG	A083823	001	
TABLET, EXTENDED RELEASE;ORAL					
NIACIN					
	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018
		750MG	A209156	002	May 14, 2018
		1GM	A209156	003	May 14, 2018
	RISING	500MG	A203742	001	Feb 22, 2019
		750MG	A203742	002	Feb 22, 2019
		1GM	A203742	003	Feb 22, 2019
	YICHANG HUMANWELL	500MG	A212017	001	Jun 10, 2019
		750MG	A212017	002	Jun 10, 2019
		1GM	A212017	003	Jun 10, 2019
NIASPAN					
	ABBVIE	375MG	N020381	001	Jul 28, 1997
+		500MG	N020381	002	Jul 28, 1997
+		750MG	N020381	003	Jul 28, 1997
+		1GM	N020381	004	Jul 28, 1997
NIASPAN TITRATION STARTER PACK					
	ABBVIE	375MG;500MG;750MG	N020381	005	Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL					
TPN					
	INTL MINERALS	15MG/5ML;3.75MG/5ML;600MG/5ML	N008378	003	

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL					
CARDENE					
+	CHIESI	20MG **	N019488	001	Dec 21, 1988
+		30MG **	N019488	002	Dec 21, 1988
NICARDIPINE HYDROCHLORIDE					
	ANI PHARMS	20MG	A074439	001	Dec 10, 1996
		20MG	A074540	001	Oct 28, 1996
		30MG	A074439	002	Dec 10, 1996
		30MG	A074540	002	Oct 28, 1996
	MYLAN	20MG	A074642	001	Jul 18, 1996
		30MG	A074642	002	Jul 18, 1996
CAPSULE, EXTENDED RELEASE;ORAL					
CARDENE SR					
+	CHIESI	30MG **	N020005	001	Feb 21, 1992
+		45MG **	N020005	002	Feb 21, 1992
+		60MG **	N020005	003	Feb 21, 1992
INJECTABLE;INJECTION					
CARDENE					
+	CHIESI	25MG/10ML (2.5MG/ML) **	N019734	001	Jan 30, 1992
NICARDIPINE HYDROCHLORIDE					
	NAVINTA LLC	25MG/10ML (2.5MG/ML)	A090125	001	Nov 17, 2009
	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009
	WEST-WARD PHARMS INT	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009
	WOCKHARDT	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009
INJECTABLE;INTRAVENOUS					
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER					
+	CHIESI	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008

NICLOSAMIDE

TABLET, CHEWABLE;ORAL					
NICLOCIDE					
	BAYER PHARMS	500MG	N018669	001	May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL					
NICOTROL					
	MCNEIL CONS	15MG/16HR	N020536	001	Jul 03, 1996
PROSTEP					
	AVEVA	11MG/24HR	N019983	003	Dec 23, 1998
		22MG/24HR	N019983	004	Dec 23, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NICOTINE POLACRILEX					
GUM, CHEWING;BUCCAL					
NICOTINE POLACRILEX					
IVAX SUB TEVA PHARMS	EQ 2MG BASE		A076880	001	Feb 18, 2009
	EQ 4MG BASE		A077850	001	Feb 18, 2009
THRIVE					
GLAXOSMITHKLINE CONS	EQ 2MG BASE		A077658	001	Jun 19, 2007
	EQ 4MG BASE		A077656	001	Jun 19, 2007
NIFEDIPINE					
CAPSULE;ORAL					
ADALAT					
BAYER PHARMS	10MG		N019478	001	Nov 27, 1985
	20MG		N019478	002	Sep 17, 1986
NIFEDIPINE					
CHASE LABS NJ	10MG		A072409	001	Jul 04, 1990
	20MG		A073421	001	Jun 19, 1991
TEVA	10MG		A072651	001	Feb 19, 1992
PROCARDIA					
+ PFIZER	20MG **		N018482	002	Jul 24, 1986
TABLET, EXTENDED RELEASE;ORAL					
ADALAT CC					
+ NORWICH	30MG **		N020198	001	Apr 21, 1993
+	60MG **		N020198	002	Apr 21, 1993
+	90MG **		N020198	003	Apr 21, 1993
AFEDITAB CR					
WATSON LABS	60MG		A075659	001	Oct 26, 2001
WATSON LABS TEVA	30MG		A075128	001	Mar 10, 2000
NIFEDIPINE					
AUROBINDO PHARMA USA	30MG		A090649	001	Jun 21, 2010
	60MG		A090649	002	Jun 21, 2010
	90MG		A090649	003	Jun 21, 2010
MARTEC USA LLC	90MG		A075414	003	Mar 23, 2004
MYLAN	30MG		A075108	001	Dec 17, 1999
	30MG		A201071	001	Dec 03, 2010
	60MG		A201071	002	Dec 03, 2010
	90MG		A201071	003	Dec 03, 2010
MYLAN LABS LTD	30MG		A090602	001	Sep 13, 2010
	60MG		A090602	002	Sep 13, 2010
	90MG		A090602	003	Sep 13, 2010
PAR PHARM	30MG		A077899	001	Dec 13, 2006
	60MG		A077899	002	Dec 13, 2006
	90MG		A077899	003	May 25, 2012
NILUTAMIDE					
TABLET;ORAL					
NILANDRON					
CONCORDIA	50MG		N020169	001	Sep 19, 1996
NIMODIPINE					
CAPSULE;ORAL					
NIMODIPINE					
SOFGEN PHARMS	30MG		A201832	001	Jul 24, 2015
SUN PHARM INDS INC	30MG		A077067	001	Apr 17, 2007
NIMOTOP					
+ BAYER PHARMS	30MG **		N018869	001	Dec 28, 1988
SOLUTION;ORAL					
NYMALIZE					
+ ARBOR PHARMS LLC	3MG/ML **		N203340	001	May 10, 2013
NISOLDIPINE					
TABLET, EXTENDED RELEASE;ORAL					
SULAR					
+ COVIS	10MG **		N020356	001	Feb 02, 1995
+	20MG **		N020356	002	Feb 02, 1995
+	25.5MG **		N020356	006	Jan 02, 2008
+	30MG **		N020356	003	Feb 02, 1995
+	40MG **		N020356	004	Feb 02, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NITRIC OXIDE				
GAS;INHALATION				
INOMAX				
+ MALLINCKRODT HOSP	100PPM **	N020845	002	Dec 23, 1999
NITROFURANTOIN				
CAPSULE;ORAL				
NITROFURANTOIN				
WATSON LABS	50MG	A084326	001	
	100MG	A084326	002	
TABLET;ORAL				
FURADANTIN				
PROCTER AND GAMBLE	50MG	N008693	001	
	100MG	N008693	002	
FURALAN				
LANNETT	50MG	A080017	001	
	100MG	A080017	002	
NITROFURANTOIN				
ELKINS SINN	50MG	A080003	001	
	100MG	A080003	002	
IVAX SUB TEVA PHARMS	50MG	A080078	002	
	100MG	A080078	001	
SANDOZ	50MG	A080043	001	
	100MG	A080043	002	
WATSON LABS	50MG	A080447	001	
	50MG	A085797	001	
	100MG	A080447	002	
	100MG	A085796	001	
WHITEWORTH TOWN PLSN	100MG	A084085	002	
NITROFURANTOIN SODIUM				
INJECTABLE;INJECTION				
IVADANTIN				
PROCTER AND GAMBLE	EQ 180MG BASE/VIAL	N012402	001	
NITROFURANTOIN, MACROCRYSTALLINE				
CAPSULE;ORAL				
NITROFURANTOIN				
AUROBINDO PHARMA USA	50MG	A074967	001	Jul 09, 1997
	100MG	A074967	002	Jul 09, 1997
MYLAN	100MG	A077025	001	Aug 18, 2004
PHARMGEN	25MG	A074336	001	Jan 25, 1995
	50MG	A074336	002	Jan 25, 1995
	100MG	A074336	003	Jan 25, 1995
WATSON LABS	25MG	A073696	001	Dec 31, 1992
	50MG	A073696	002	Dec 31, 1992
	100MG	A073696	003	Dec 31, 1992
NITROFURANTOIN MACROCRYSTALLINE				
WATSON LABS	50MG	A070248	001	Jun 24, 1988
	100MG	A070249	001	Jun 24, 1988
NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE				
CAPSULE;ORAL				
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)				
AUROBINDO PHARMA USA	75MG;25MG	A076648	001	Mar 22, 2004
RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005
NITROFURAZONE				
CREAM;TOPICAL				
FURACIN				
SHIRE	0.2%	A083789	001	
DRESSING;TOPICAL				
ACTIN-N				
SHERWOOD MEDCL	0.2%	N017343	001	
OINTMENT;TOPICAL				
FURACIN				
SHIRE	0.2%	N005795	001	
NITROFURAZONE				
AMBIX	0.2%	A086077	001	
LANNETT	0.2%	A084393	001	
PERRIGO NEW YORK	0.2%	A084968	001	
TARO	0.2%	A086156	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NITROFURAZONE				
OINTMENT;TOPICAL				
NITROFURAZONE				
WENDT	0.2%	A086766 001		
POWDER;TOPICAL				
FURACIN				
SHIRE	0.2%	A083791 001		
SOLUTION;TOPICAL				
NITROFURAZONE				
PERRIGO NEW YORK	0.2%	A085130 001		
WENDT	0.2%	A087081 001		
NITROGLYCERIN				
AEROSOL;SUBLINGUAL				
NITROLINGUAL				
POHL BOSKAMP	0.4MG/SPRAY	N018705 001	Oct 31, 1985	
FILM, EXTENDED RELEASE;TRANSDERMAL				
MINITRAN				
BAUSCH	0.4MG/HR	A089773 001	Aug 30, 1996	
VALEANT PHARMS	0.1MG/HR	A089771 001	Aug 30, 1996	
	0.6MG/HR	A089774 001	Aug 30, 1996	
VALEANT PHARMS NORTH	0.2MG/HR	A089772 001	Aug 30, 1996	
NITROGLYCERIN				
LANNETT CO INC	0.2MG/HR	A075115 001	Aug 10, 2004	
	0.4MG/HR	A075115 002	Aug 10, 2004	
MYLAN TECHNOLOGIES	0.1MG/HR	A074992 004	Nov 12, 1999	
	0.2MG/HR	A074992 003	Nov 12, 1999	
	0.4MG/HR	A074992 002	Nov 12, 1999	
	0.6MG/HR	A074992 001	Nov 12, 1999	
TRANSDERM-NITRO				
+ NOVARTIS	0.1MG/HR **	N020144 001	Feb 27, 1996	
+	0.2MG/HR **	N020144 002	Feb 27, 1996	
+	0.4MG/HR **	N020144 003	Feb 27, 1996	
+	0.6MG/HR **	N020144 004	Feb 27, 1996	
+	0.8MG/HR **	N020144 005	Feb 27, 1996	
INJECTABLE;INJECTION				
NITRO IV				
POHL BOSKAMP	5MG/ML	N018672 002	Aug 30, 1983	
NITRO-BID				
SANOFI AVENTIS US	5MG/ML	N018621 001	Jan 05, 1982	
	10MG/ML	A071159 001	Feb 28, 1990	
NITROGLYCERIN				
ABRAXIS PHARM	5MG/ML	A070077 001	Dec 13, 1985	
	5MG/ML	A071203 001	May 08, 1987	
+ HOSPIRA	5MG/ML **	N018531 001		
INTL MEDICATION	5MG/ML	A070026 001	Sep 10, 1985	
LUITPOLD	5MG/ML	A071492 001	May 24, 1988	
SMITH AND NEPHEW	5MG/ML	A070633 001	Jun 19, 1986	
	5MG/ML	A070634 001	Jun 19, 1986	
NITROGLYCERIN IN DEXTROSE 5%				
HOSPIRA	0.1MG/ML	A074083 001	Oct 26, 1994	
	10MG/100ML	A071846 001	Aug 31, 1990	
	20MG/100ML	A071847 001	Aug 31, 1990	
	40MG/100ML	A071848 001	Aug 31, 1990	
NITROL				
RORER	0.8MG/ML	N018774 001	Jan 19, 1983	
NITRONAL				
POHL BOSKAMP	1MG/ML	N018672 001	Aug 30, 1983	
NITROSTAT				
PARKE DAVIS	0.8MG/ML	N018588 001		
	5MG/ML	A070863 001	Jan 08, 1987	
	5MG/ML	N018588 002	Dec 23, 1983	
	10MG/ML	A070871 001	Jan 08, 1987	
	10MG/ML	A070872 001	Jan 08, 1987	
TRIDIL				
HOSPIRA	0.5MG/ML	N018537 002	Jun 16, 1983	
	5MG/ML	N018537 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NITROGLYCERIN

POWDER;SUBLINGUAL					
GONITRO					
+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016
TABLET;SUBLINGUAL					
NITROGLYCERIN					
	ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017
		0.4MG	A203693	002	Oct 16, 2017
		0.6MG	A203693	003	Oct 16, 2017
	SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018
		0.4MG	A207745	002	May 07, 2018
		0.6MG	A207745	003	May 07, 2018

NIZATIDINE

CAPSULE;ORAL					
AXID					
	SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
		300MG	N019508	002	Apr 12, 1988
NIZATIDINE					
	ANI PHARMS	150MG	A075461	001	Jul 08, 2002
		150MG	A075668	001	Sep 12, 2002
		300MG	A075461	002	Jul 08, 2002
		300MG	A075668	002	Sep 12, 2002
	APOTEX INC	150MG	A076383	001	Jan 23, 2003
		300MG	A076383	002	Jan 23, 2003
	MYLAN PHARMS INC	150MG	A075806	001	Jul 05, 2002
		150MG	A075934	001	Jul 09, 2002
		300MG	A075806	002	Jul 05, 2002
		300MG	A075934	002	Jul 09, 2002
SOLUTION;ORAL					
AXID					
+	BRAINTREE	15MG/ML **	N021494	001	May 25, 2004

NONOXYNOL-9

AEROSOL;VAGINAL					
DELFEN					
	PERSONAL PRODS	12.5%	N014349	002	
SPONGE;VAGINAL					
TODAY					
+	MAYER LABS INC	1GM	N018683	001	Apr 01, 1983

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION					
NOREPINEPHRINE BITARTRATE					
	METRICS PHARM	EQ 1MG BASE/ML	A040522	001	Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION					
RAVOCAINE AND NOVOCAIN W/ LEVOPHED					
	EASTMAN KODAK	EQ 0.033MG BASE/ML;2%;0.4%	N008592	003	

NORETHINDRONE

TABLET;ORAL					
NORLUTIN					
	PARKE DAVIS	5MG	N010895	002	
TABLET;ORAL-28					
MICRONOR					
+	JANSSEN PHARMS	0.35MG	N016954	001	

NORETHINDRONE ACETATE

TABLET;ORAL					
AYGESTIN					
+	DURAMED RES	5MG **	N018405	001	Apr 21, 1982
NORETHINDRONE ACETATE					
	AUROBINDO PHARMA LTD	5MG	A204236	001	Jan 08, 2016
NORLUTATE					
	PARKE DAVIS	5MG	N012184	002	

NORFLOXACIN				
SOLUTION/DROPS;OPHTHALMIC				
CHIBROXIN				
MERCK	0.3%	N019757 001	Jun 17, 1991	
TABLET;ORAL				
NOROXIN				
+ MERCK	400MG **	N019384 002	Oct 31, 1986	
NORGESTREL				
TABLET;ORAL				
OPILL				
+ LABORATOIRE HRA	0.075MG	N017031 001		
NORTRIPTYLINE HYDROCHLORIDE				
CAPSULE;ORAL				
AVENTYL HYDROCHLORIDE				
LILLY	EQ 10MG BASE	N014684 001		
	EQ 25MG BASE	N014684 002		
NORTRIPTYLINE HYDROCHLORIDE				
ANI PHARMS	EQ 10MG BASE	A074054 001	Dec 31, 1992	
	EQ 25MG BASE	A074054 002	Dec 31, 1992	
	EQ 50MG BASE	A074054 003	Dec 31, 1992	
	EQ 75MG BASE	A074054 004	Dec 31, 1992	
AUROLIFE PHARMA LLC	EQ 10MG BASE	A074835 001	Jun 30, 1997	
	EQ 25MG BASE	A074835 002	Jun 30, 1997	
	EQ 50MG BASE	A074835 003	Jun 30, 1997	
	EQ 75MG BASE	A074835 004	Jun 30, 1997	
MYLAN	EQ 10MG BASE	A074234 001	Jul 26, 1993	
	EQ 25MG BASE	A074234 002	Jul 26, 1993	
	EQ 50MG BASE	A074234 003	Jul 26, 1993	
	EQ 75MG BASE	A074234 004	Jul 26, 1993	
TEVA	EQ 10MG BASE	A073667 001	Apr 11, 1996	
	EQ 25MG BASE	A073667 002	Apr 11, 1996	
	EQ 50MG BASE	A073667 003	Apr 11, 1996	
	EQ 75MG BASE	A073667 004	Apr 11, 1996	
ZYDUS	EQ 10MG BASE	A213441 001	Feb 24, 2021	
	EQ 25MG BASE	A213441 002	Feb 24, 2021	
	EQ 50MG BASE	A213441 003	Feb 24, 2021	
	EQ 75MG BASE	A213441 004	Feb 24, 2021	
SOLUTION;ORAL				
AVENTYL				
+ RANBAXY	EQ 10MG BASE/5ML **	N014685 001		
PAMELOR				
SPECGX LLC	EQ 10MG BASE/5ML	N018012 001		
NYSTATIN				
CREAM;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/GM	A061810 001		
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060575 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061445 001		
NYSTATIN				
STRIDES PHARMA	100,000 UNITS/GM	A065315 001	May 31, 2006	
TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983	
LOTION;TOPICAL				
CANDEX				
BAYER PHARMS	100,000 UNITS/ML	N050233 001		
OINTMENT;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060571 001		
MYKINAC				
ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986	
NILSTAT				
LEDERLE	100,000 UNITS/GM	A061444 001		

NYSTATIN

PASTILLE;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	200,000 UNITS	N050619	001	Apr 09, 1987
POWDER;ORAL				
BARSTATIN 100				
BARLAN	100%	A062489	001	Apr 27, 1988
NILSTAT				
+ STRIDES PHARMA	100% **	N050576	001	Dec 22, 1983
NYSTATIN				
PADDOCK LLC	100%	A062613	001	Nov 26, 1985
POWDER;TOPICAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/GM **	A060578	001	
NYSTATIN				
NESHER PHARMS	100,000 UNITS/GM	A065321	001	Aug 18, 2006
SUPPOSITORY;VAGINAL				
NYSERT				
WARNER CHILCOTT	100,000 UNITS	N050478	001	
SUSPENSION;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001	
NILSTAT				
+ GLENMARK GENERICS	100,000 UNITS/ML **	N050299	001	
NYSTATIN				
ALPHARMA US PHARMS	100,000 UNITS/ML	A062571	001	Oct 29, 1985
COSETTE	100,000 UNITS/ML	A062776	001	Dec 17, 1987
G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982
MORTON GROVE	100,000 UNITS/ML	A062835	001	Nov 19, 1987
PHARMADERM	100,000 UNITS/ML	A062518	001	Jul 06, 1984
PHARMAFAIR	100,000 UNITS/ML	A062541	001	Jan 16, 1985
TEVA	100,000 UNITS/ML	A062670	001	Jun 18, 1987
NYSTEX				
SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984
TABLET;ORAL				
MYCOSTATIN				
DELCOR ASSET CORP	500,000 UNITS	A060574	001	
NILSTAT				
LEDERLE	500,000 UNITS	A061151	001	
NYSTATIN				
CHARTWELL RX	500,000 UNITS	A062524	001	Nov 26, 1985
QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984
SANDOZ	500,000 UNITS	A062065	001	
WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982
TABLET;VAGINAL				
KOROSTATIN				
HOLLAND RANTOS	100,000 UNITS	A061718	001	
MYCOSTATIN				
DELCOR ASSET CORP	100,000 UNITS	A060577	001	
NILSTAT				
LEDERLE	100,000 UNITS	A061325	001	
NYSTATIN				
FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983
ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985
PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983
QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984
SANDOZ	100,000 UNITS	A061965	001	
TEVA	100,000 UNITS	A062502	001	Dec 23, 1983
WATSON LABS	100,000 UNITS	A062176	001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A061954	002	Sep 20, 1985
MYCOLOG-II				
DELCOR ASSET CORP	100,000 UNITS/GM;0.1% **	A060576	002	May 01, 1985
MYLAN	100,000 UNITS/GM;0.1% **	A062606	001	May 15, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597	001	Oct 08, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL				
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010	001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186	002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657	001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347	001	Mar 30, 1987
NYSTATIN TRIAMCINOLONE ACETONIDE				
PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985
OINTMENT;TOPICAL				
MYCO-TRIACET II				
TEVA	100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985
MYCOLOG-II				
MYLAN	100,000 UNITS/GM;0.1% **	A060572	001	Jun 28, 1985
MYTREX F				
SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985
NYSTATIN AND TRIAMCINOLONE ACETONIDE				
CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731	001	Dec 26, 2017
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986
VITRUVIAS THERAP	100,000 UNITS/GM;0.1%	A207316	001	Nov 18, 2019
NYSTATIN-TRIAMCINOLONE ACETONIDE				
PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985

OCTREOTIDE ACETATE

INJECTABLE;INJECTION				
OCTREOTIDE ACETATE				
HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018
	EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018
	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018
	EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018
	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018
SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008
	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007
	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008
	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007
	EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008
	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007
	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008
	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007
	EQ 1MG BASE/ML	A077331	001	Mar 04, 2008
	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007
WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011
	EQ 1MG BASE/ML	A090986	002	May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE				
WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011
	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011
	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011
SANDOSTATIN				
+ NOVARTIS	EQ 0.2MG BASE/ML **	N019667	004	Jun 12, 1991
+	EQ 1MG BASE/ML **	N019667	005	Jun 12, 1991

OFLOXACIN

INJECTABLE;INJECTION				
FLOXIN				
ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%				
ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
	400MG/100ML	N020087	005	Mar 31, 1992
OFLOXACIN				
BEDFORD	40MG/ML	A075762	001	Jan 16, 2002
SOLUTION/DROPS;OPHTHALMIC				
OFLOXACIN				
ALVOGEN	0.3%	A076830	001	Aug 31, 2004
SANDOZ	0.3%	A076848	001	Nov 25, 2008
SANDOZ INC	0.3%	A076231	001	May 14, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OFLOXACIN					
SOLUTION/DROPS;OTIC					
FLOXIN OTIC					
+	DAIICHI	0.3% **	N020799	001	Dec 16, 1997
OFLOXACIN					
	ALVOGEN	0.3%	A090395	001	Aug 11, 2009
	SANDOZ INC	0.3%	A078222	001	Mar 17, 2008
TABLET;ORAL					
FLOXIN					
+	JANSSEN PHARMS	200MG **	N019735	001	Dec 28, 1990
+		300MG **	N019735	002	Dec 28, 1990
+		400MG **	N019735	003	Dec 28, 1990
OFLOXACIN					
	LARKEN LABS	200MG	A076093	001	Sep 02, 2003
		300MG	A076093	002	Sep 02, 2003
	RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003
		300MG	A076220	002	Sep 02, 2003
		400MG	A076220	003	Sep 02, 2003
OLANZAPINE					
TABLET;ORAL					
OLANZAPINE					
	AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016
		5MG	A206711	002	Aug 30, 2016
		7.5MG	A206711	003	Aug 30, 2016
		10MG	A206711	004	Aug 30, 2016
		15MG	A206711	005	Aug 30, 2016
		20MG	A206711	006	Aug 30, 2016
	HIKMA	2.5MG	A204866	001	Jun 16, 2017
		5MG	A204866	002	Jun 16, 2017
		7.5MG	A204866	003	Jun 16, 2017
		10MG	A204866	004	Jun 16, 2017
		15MG	A204866	005	Jun 16, 2017
		20MG	A204866	006	Jun 16, 2017
	HISUN PHARM HANGZHOU	2.5MG	A206924	001	Dec 31, 2020
		5MG	A206924	002	Dec 31, 2020
		7.5MG	A206924	003	Dec 31, 2020
		10MG	A206924	004	Dec 31, 2020
		15MG	A206924	005	Dec 31, 2020
		20MG	A206924	006	Dec 31, 2020
	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015
	JIANGSU HANSOH PHARM	2.5MG	A209399	001	Sep 24, 2018
		5MG	A209399	002	Sep 24, 2018
		10MG	A209399	003	Sep 24, 2018
	MYLAN	2.5MG	A076866	001	Apr 23, 2012
		5MG	A076866	002	Apr 23, 2012
		7.5MG	A076866	003	Apr 23, 2012
		10MG	A076866	004	Apr 23, 2012
		15MG	A076866	005	Apr 23, 2012
		20MG	A076866	006	Apr 23, 2012
	SUNSHINE	2.5MG	A206238	001	Nov 19, 2018
		5MG	A206238	002	Nov 19, 2018
		7.5MG	A206238	003	Nov 19, 2018
		10MG	A206238	004	Nov 19, 2018
		15MG	A206238	005	Nov 19, 2018
		20MG	A206238	006	Nov 19, 2018
	TEVA PHARMS	2.5MG	A076000	001	Oct 24, 2011
		5MG	A076000	002	Oct 24, 2011
		7.5MG	A076000	003	Oct 24, 2011
		10MG	A076000	004	Oct 24, 2011
		15MG	A076000	005	Oct 24, 2011
	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012
		5MG	A091434	002	Apr 23, 2012
		7.5MG	A091434	003	Apr 23, 2012
		10MG	A091434	004	Apr 23, 2012
		15MG	A091434	005	Apr 23, 2012
		20MG	A091434	006	Apr 23, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL				
OLANZAPINE				
AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017
	10MG	A204320	002	May 30, 2017
	15MG	A204320	003	May 30, 2017
	20MG	A204320	004	May 30, 2017
HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020
	10MG	A206892	002	Dec 31, 2020
	15MG	A206892	003	Dec 31, 2020
	20MG	A206892	004	Dec 31, 2020

OLAPARIB

CAPSULE;ORAL				
LYNPARZA				
+ ASTRAZENECA	50MG	N206162	001	Dec 19, 2014

OLMESARTAN MEDOXOMIL

TABLET;ORAL				
OLMESARTAN MEDOXOMIL				
INVENTIA	5MG	A208659	001	May 18, 2020
	20MG	A208659	002	May 18, 2020
	40MG	A208659	003	May 18, 2020
JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017
	20MG	A205482	002	Apr 24, 2017
	40MG	A205482	003	Apr 24, 2017
LUPIN LTD	5MG	A206631	001	Apr 27, 2017
	20MG	A206631	002	Apr 27, 2017
	40MG	A206631	003	Apr 27, 2017
RISING PHARMA	5MG	A078276	001	Oct 26, 2016
	20MG	A078276	002	Oct 26, 2016
	40MG	A078276	003	Oct 26, 2016
TEVA PHARMS USA	5MG	A091079	001	Apr 24, 2017
	20MG	A091079	002	Apr 24, 2017
	40MG	A091079	003	Apr 24, 2017

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
OLOPATADINE HYDROCHLORIDE				
BAUSCH	EQ 0.1% BASE	A206046	001	Jul 26, 2017
CIPLA	EQ 0.2% BASE	A206087	001	Dec 05, 2017
FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019
MYLAN	EQ 0.1% BASE	A204392	001	Mar 21, 2018
WATSON LABS INC	EQ 0.7% BASE	A208637	001	Feb 19, 2020
WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017
ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL				
TECHNIVIE				
+ ABBVIE INC	12.5MG;75MG;50MG **	N207931	001	Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL				
OMEGA-3-ACID ETHYL ESTERS				
STRIDES PHARMA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014
ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL				
OMTRYG				
+ OSMOTICA PHARM US	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL				
EPANOVA				
+ ASTRAZENECA	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

	LUPIN LTD	40MG	A202384	001	Aug 25, 2015
	MYLAN	10MG	A075876	001	May 29, 2003
		10MG	A205070	001	Jun 29, 2018
		20MG	A075876	002	May 29, 2003
		20MG	A205070	002	Jun 29, 2018
		40MG	A075876	003	Jan 21, 2009
		40MG	A205070	003	Jun 29, 2018
	TEVA PHARMS USA	40MG	A204661	002	Jun 13, 2017

PRILOSEC

+	ASTRAZENECA	10MG **	N019810	003	Oct 05, 1995
+		20MG **	N019810	001	Sep 14, 1989
+		40MG **	N019810	002	Jan 15, 1998

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	STRIDES PHARMA	20MG;1.1GM	A078966	001	May 25, 2010
		20MG;1.1GM	A201946	001	Jul 15, 2016
		40MG;1.1GM	A078966	002	May 25, 2010
	UNICORN	20MG;1.1GM	A204137	001	Jul 15, 2016

ONDANSETRON

FILM;ORAL

ZUPLENZ

+	AQUESTIVE	4MG	N022524	001	Jul 02, 2010
+		8MG	N022524	002	Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

	BARR	4MG	A076693	001	Jun 25, 2007
		8MG	A076693	002	Jun 25, 2007
	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006
		8MG	A077406	004	Dec 26, 2006
		16MG	A077406	001	Dec 26, 2006
		24MG	A077406	002	Dec 26, 2006
	NESHER PHARMS	4MG	A077717	001	Jun 25, 2007
		8MG	A077717	002	Jun 25, 2007
	TEVA	4MG	A076810	001	Jun 25, 2007
		8MG	A076810	002	Jun 25, 2007

ZOFRAN ODT

+	NOVARTIS	4MG	N020781	001	Jan 27, 1999
+		8MG	N020781	002	Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

	APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006
	BAXTER HLTHCARE CORP	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013
	EMCURE PHARMS	EQ 2MG BASE/ML	A090424	001	Apr 16, 2010
	HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
		EQ 2MG BASE/ML	A077840	001	Jan 19, 2007
	LANNETT CO INC	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010
		EQ 2MG BASE/ML	A090883	001	Aug 05, 2010
	LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006
		EQ 2MG BASE/ML	A079039	001	Nov 18, 2008
	MYLAN LABS LTD	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008
	PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006
	RISING PHARMA	EQ 2MG BASE/ML	A204906	001	Jul 31, 2017
	SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007
	SUN PHARM INDS (IN)	EQ 2MG BASE/ML	A077172	001	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

	HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

	AM REGENT	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008
	APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
	EMCURE PHARMS LTD	EQ 2MG BASE/ML	A078945	001	Jan 03, 2013
	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006
	HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
	LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION				
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE				
	MYLAN LABS LTD	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008
	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A077173 001	Dec 26, 2006
	TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014 001	Mar 21, 2008
	TEVA	EQ 2MG BASE/ML	A076759 001	Nov 22, 2006
ZOFRAN				
+	NOVARTIS	EQ 2MG BASE/ML **	N020007 001	Jan 04, 1991
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER				
+	GLAXOSMITHKLINE	EQ 0.64MG BASE/ML **	N020403 001	Jan 31, 1995
ZOFRAN PRESERVATIVE FREE				
+	NOVARTIS	EQ 2MG BASE/ML **	N020007 003	Dec 10, 1993
TABLET;ORAL				
ONDANSETRON HYDROCHLORIDE				
	CHARTWELL MOLECULES	EQ 4MG BASE	A077303 001	Jun 25, 2007
		EQ 8MG BASE	A077303 002	Jun 25, 2007
		EQ 24MG BASE	A077303 004	Jun 25, 2007
	HIKMA INTL PHARMS	EQ 4MG BASE	A077545 001	Sep 06, 2007
		EQ 8MG BASE	A077545 002	Sep 06, 2007
		EQ 24MG BASE	A077545 003	Sep 06, 2007
	PLIVA HRVATSKA DOO	EQ 4MG BASE	A077112 001	Jun 25, 2007
		EQ 8MG BASE	A077112 002	Jun 25, 2007
		EQ 24MG BASE	A077112 003	Jun 25, 2007
	RISING	EQ 4MG BASE	A076930 001	Jun 25, 2007
		EQ 8MG BASE	A076930 002	Jun 25, 2007
		EQ 24MG BASE	A076930 004	Jun 25, 2007
	TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011
		EQ 8MG BASE	A077729 002	Mar 28, 2011
		EQ 24MG BASE	A077729 003	Mar 28, 2011

ORPHENADRINE CITRATE

INJECTABLE;INJECTION				
NORFLEX				
+	TELIGENT	30MG/ML	N013055 001	
ORPHENADRINE CITRATE				
	WATSON LABS	30MG/ML	A087062 001	
TABLET, EXTENDED RELEASE;ORAL				
NORFLEX				
+	BAUSCH	100MG	N012157 001	
ORPHENADRINE CITRATE				
	ASCOT	100MG	A088067 001	Apr 06, 1983
	IMPAX PHARMS	100MG	A040368 001	Jun 23, 2000
	SANDOZ	100MG	A085046 001	
	WATSON LABS	100MG	A084303 001	

ORPHENADRINE HYDROCHLORIDE

TABLET;ORAL				
DISIPAL				
	3M	50MG	N010653 001	

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL				
OSELTAMIVIR PHOSPHATE				
	RISING PHARMA	EQ 30MG BASE	A210157 001	Jan 21, 2021
		EQ 45MG BASE	A210157 002	Jan 21, 2021
		EQ 75MG BASE	A210157 003	Jan 21, 2021
	SUNSHINE	EQ 30MG BASE	A212739 001	Mar 04, 2020
		EQ 45MG BASE	A212739 002	Mar 04, 2020
		EQ 75MG BASE	A212739 003	Mar 04, 2020
FOR SUSPENSION;ORAL				
TAMIFLU				
	ROCHE	EQ 12MG BASE/ML	N021246 001	Dec 14, 2000

OXACILLIN SODIUM

CAPSULE;ORAL				
BACTOCILL				
	GLAXOSMITHKLINE	EQ 250MG BASE	A061336 001	
		EQ 250MG BASE	A062241 001	
		EQ 500MG BASE	A061336 002	
		EQ 500MG BASE	A062241 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXACILLIN SODIUM

CAPSULE;ORAL				
OXACILLIN SODIUM				
	ANI PHARMS	EQ 250MG BASE	A062222 001	
		EQ 500MG BASE	A062222 002	
	APOTHECON	EQ 250MG BASE	A061450 002	
		EQ 500MG BASE	A061450 001	
PROSTAPHLIN				
	APOTHECON	EQ 500MG BASE	N050118 002	
FOR SOLUTION;ORAL				
BACTOCILL				
	GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321 001	
OXACILLIN SODIUM				
	APOTHECON	EQ 250MG BASE/5ML	A061457 001	
	TEVA	EQ 250MG BASE/5ML	A062252 001	
PROSTAPHLIN				
	APOTHECON	EQ 250MG BASE/5ML	N050194 001	
INJECTABLE;INJECTION				
BACTOCILL				
	GLAXOSMITHKLINE	EQ 500MG BASE/VIAL **	A061334 009	Mar 26, 1982
		EQ 1GM BASE/VIAL **	A061334 006	Mar 26, 1982
		EQ 1GM BASE/VIAL **	A062736 001	Dec 19, 1986
		EQ 2GM BASE/VIAL **	A061334 007	Mar 26, 1982
		EQ 2GM BASE/VIAL **	A062736 002	Dec 19, 1986
		EQ 4GM BASE/VIAL **	A061334 008	Mar 26, 1982
		EQ 10GM BASE/VIAL **	A061334 010	
OXACILLIN SODIUM				
+	APOTHECON	EQ 250MG BASE/VIAL **	N050195 001	
+		EQ 500MG BASE/VIAL **	N050195 002	
+		EQ 1GM BASE/VIAL **	N050195 003	
+		EQ 2GM BASE/VIAL **	N050195 004	
+		EQ 4GM BASE/VIAL **	N050195 005	
	ELKINS SINN	EQ 250MG BASE/VIAL	A062711 001	Feb 03, 1989
		EQ 500MG BASE/VIAL	A062711 002	Feb 03, 1989
		EQ 1GM BASE/VIAL	A062711 003	Feb 03, 1989
		EQ 2GM BASE/VIAL	A062711 004	Feb 03, 1989
		EQ 4GM BASE/VIAL	A062711 005	Feb 03, 1989
		EQ 10GM BASE/VIAL	A062711 006	Feb 03, 1989
	HOSPIRA INC	EQ 1GM BASE/VIAL	A203950 001	Dec 11, 2015
		EQ 2GM BASE/VIAL	A203950 002	Dec 11, 2015
	ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062798 003	Dec 11, 1995
		EQ 250MG BASE/VIAL	A062798 004	Dec 11, 1995
		EQ 500MG BASE/VIAL	A062798 005	Dec 11, 1995
		EQ 1GM BASE/VIAL	A062798 001	Dec 11, 1995
		EQ 2GM BASE/VIAL	A062798 002	Dec 11, 1995
	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A091486 001	Aug 25, 2014
		EQ 2GM BASE/VIAL	A091486 002	Aug 25, 2014
	SANDOZ	EQ 250MG BASE/VIAL	A061490 001	
		EQ 500MG BASE/VIAL	A061490 002	
		EQ 1GM BASE/VIAL	A061490 003	
		EQ 2GM BASE/VIAL	A061490 004	
		EQ 10GM BASE/VIAL	A061490 006	May 09, 1991
	WATSON LABS INC	EQ 250MG BASE/VIAL	A062856 001	Oct 26, 1988
		EQ 500MG BASE/VIAL	A062856 002	Oct 26, 1988
		EQ 1GM BASE/VIAL	A062856 003	Oct 26, 1988
		EQ 2GM BASE/VIAL	A062856 004	Oct 26, 1988
		EQ 4GM BASE/VIAL	A062856 005	Oct 26, 1988
		EQ 10GM BASE/VIAL	A062984 001	Sep 29, 1988
POWDER;INTRAVENOUS				
OXACILLIN SODIUM				
	SANDOZ	EQ 1GM BASE/VIAL	A062737 001	Dec 23, 1986
		EQ 2GM BASE/VIAL	A062737 002	Dec 23, 1986

OXALIPLATIN

INJECTABLE;INTRAVENOUS				
ELOXATIN				
+	SANOFI AVENTIS US	50MG/VIAL **	N021492 001	Aug 09, 2002
+		100MG/VIAL **	N021492 002	Aug 09, 2002
+		200MG/40ML (5MG/ML) **	N021759 003	Nov 17, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXALIPLATIN

INJECTABLE;INTRAVENOUS

OXALIPLATIN

ACCORD HLTHCARE	200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017
AM REGENT	50MG/10ML (5MG/ML)	A204378	001	May 12, 2017
	100MG/20ML (5MG/ML)	A204378	002	May 12, 2017
CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017
	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017
FRESENIUS KABI ONCOL	50MG/VIAL	A078810	001	Aug 07, 2009
	100MG/VIAL	A078810	002	Aug 07, 2009
FRESENIUS KABI USA	200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017
GLAND	200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017
HOSPIRA INC	50MG/VIAL	A078815	001	Sep 30, 2009
	100MG/VIAL	A078815	002	Sep 30, 2009
MYLAN LABS LTD	50MG/VIAL	A200979	001	Aug 08, 2012
	100MG/VIAL	A200979	002	Aug 08, 2012
	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017
SANDOZ	50MG/VIAL	A090849	001	Apr 28, 2011
	100MG/VIAL	A090849	002	Apr 28, 2011
SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009
	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009
SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009
	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014
	100MG/VIAL	A078818	002	Aug 07, 2009
	100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014
	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019

OXAMNIQUINE

CAPSULE;ORAL

VANSIL

PFIZER	250MG	N018069	001	

OXANDROLONE

TABLET;ORAL

OXANDRIN

+ GEMINI LABS LLC	2.5MG	N013718	001	
+	10MG	N013718	002	Nov 05, 2001

OXANDROLONE

ROXANE	2.5MG	A077249	001	Jul 10, 2007
	10MG	A077249	002	Jul 10, 2007
SANDOZ	2.5MG	A076897	001	Dec 01, 2006
	10MG	A076897	002	Dec 01, 2006

OXAPROZIN

TABLET;ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001
IVAX SUB TEVA PHARMS	600MG	A075846	001	May 13, 2002
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075850	001	Apr 27, 2001
SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002
WATSON LABS	600MG	A075848	001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET;ORAL

DAYPRO ALTA

PFIZER	600MG	N020776	001	Oct 17, 2002

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXAZEPAM

CAPSULE;ORAL				
OXAZEPAM				
	WATSON LABS	15MG	A072953 001	Sep 28, 1990
		30MG	A072954 001	Sep 28, 1990
	WATSON LABS TEVA	10MG	A072952 001	Sep 28, 1990
SERAX				
+	ALPHARMA US PHARMS	10MG **	N015539 002	
+		15MG **	N015539 004	
+		30MG **	N015539 006	
ZAXOPAM				
	QUANTUM PHARMICS	10MG	A070650 001	Mar 01, 1988
		15MG	A070640 001	Mar 01, 1988
		30MG	A070641 001	Mar 01, 1988
TABLET;ORAL				
OXAZEPAM				
	PARKE DAVIS	15MG	A071508 001	Feb 02, 1987
	SUN PHARM INDUSTRIES	15MG	A070683 001	Jan 16, 1987
	WATSON LABS	15MG	A071494 001	Apr 21, 1987
SERAX				
	ALPHARMA US PHARMS	15MG **	N015539 008	

OXCARBAZEPINE

TABLET;ORAL				
OXCARBAZEPINE				
	ANI PHARMS	150MG	A078005 001	Dec 11, 2007
		300MG	A078005 002	Dec 11, 2007
		600MG	A078005 003	Dec 11, 2007
	HIKMA	150MG	A077795 001	Oct 09, 2007
		300MG	A077795 002	Oct 09, 2007
		600MG	A077795 003	Oct 09, 2007
	JUBILANT CADISTA	150MG	A090239 001	Jan 25, 2010
		300MG	A090239 002	Jan 25, 2010
		600MG	A090239 003	Jan 25, 2010

OXPRENOLOL HYDROCHLORIDE

CAPSULE;ORAL				
TRASICOR				
	NOVARTIS	20MG	N018166 001	Dec 28, 1983
		40MG	N018166 002	Dec 28, 1983
		80MG	N018166 003	Dec 28, 1983
		160MG	N018166 004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION;ORAL				
CHOLEDYL				
	PARKE DAVIS	100MG/5ML	N009268 012	Nov 27, 1984
OXTRIPHYLLINE				
	MORTON GROVE	100MG/5ML	A088243 001	Dec 05, 1983
SYRUP;ORAL				
CHOLEDYL				
	PARKE DAVIS	50MG/5ML	N009268 011	
OXTRIPHYLLINE PEDIATRIC				
	MORTON GROVE	50MG/5ML	A088242 001	Dec 05, 1983
TABLET, DELAYED RELEASE;ORAL				
CHOLEDYL				
	PARKE DAVIS	100MG	N009268 003	
		200MG	N009268 007	
OXTRIPHYLLINE				
	WATSON LABS	100MG	A087866 001	Aug 25, 1983
		200MG	A087835 001	Aug 25, 1983
TABLET, EXTENDED RELEASE;ORAL				
CHOLEDYL SA				
	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983
		600MG	A086742 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYBUTYNIN					
FILM, EXTENDED RELEASE;TRANSDERMAL					
OXYBUTYNIN					
	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014
GEL, METERED;TRANSDERMAL					
GELNIQUE 3%					
+	ALLERGAN	3%	N202513	001	Dec 07, 2011
OXYBUTYNIN CHLORIDE					
GEL;TRANSDERMAL					
OXYBUTYNIN CHLORIDE					
	STRIDES PHARMA	10% (100MG/PACKET)	A207329	001	May 31, 2018
SYRUP;ORAL					
DITROPAN					
+	ORTHO MCNEIL JANSSEN	5MG/5ML **	N018211	001	
OXYBUTYNIN CHLORIDE					
	ANDA REPOSITORY	5MG/5ML	A075039	001	Jan 29, 1999
	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004
	PHARM ASSOC	5MG/5ML	A074997	001	Oct 15, 1997
TABLET;ORAL					
DITROPAN					
+	JANSSEN PHARMS	5MG **	N017577	001	
OXYBUTYNIN CHLORIDE					
	QUANTUM PHARMICS	5MG	A072296	001	Dec 08, 1988
	STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020
	USL PHARMA	5MG	A070746	001	Mar 10, 1988
	WATSON LABS	5MG	A072485	001	Apr 19, 1989
TABLET, EXTENDED RELEASE;ORAL					
DITROPAN XL					
+	JANSSEN PHARMS	15MG **	N020897	003	Jun 22, 1999
OXYBUTYNIN CHLORIDE					
	IMPAX PHARMS	5MG	A076745	002	May 09, 2007
		10MG	A076745	003	May 09, 2007
		15MG	A076745	001	Nov 09, 2006
	MYLAN	5MG	A076702	001	Nov 09, 2006
	MYLAN PHARMS INC	10MG	A076644	001	Nov 09, 2006
		15MG	A076644	002	May 10, 2007
OXYCODONE HYDROCHLORIDE					
CAPSULE;ORAL					
OXYCODONE HYDROCHLORIDE					
	LANNETT CO INC	5MG	A203823	001	Aug 01, 2014
SOLUTION;ORAL					
OXYCODONE HYDROCHLORIDE					
	ANI PHARMS	100MG/5ML	A203447	001	Aug 30, 2017
	AUROLIFE PHARMA LLC	5MG/5ML	A212429	001	Jan 27, 2020
		100MG/5ML	A212429	002	Jan 27, 2020
	HIKMA	100MG/5ML	A203208	001	Jul 12, 2013
	LANNETT CO INC	100MG/5ML	A204085	001	Sep 09, 2014
	RHODES PHARMS	100MG/5ML	A205853	001	Apr 29, 2020
TABLET;ORAL					
OXYCODONE HYDROCHLORIDE					
	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015
		15MG	A076636	001	Feb 06, 2004
		30MG	A076636	002	Feb 06, 2004
	MAYNE PHARMA INC	5MG	A091313	001	Feb 18, 2011
		10MG	A091313	004	Apr 29, 2016
		15MG	A091313	002	Feb 18, 2011
		20MG	A091313	005	Apr 29, 2016
		30MG	A091313	003	Feb 18, 2011
	NESHER PHARMS	5MG	A077290	001	Dec 08, 2005
		10MG	A077290	002	Dec 08, 2005
		15MG	A077290	003	Dec 08, 2005
		20MG	A077290	004	Dec 08, 2005
		30MG	A077290	005	Dec 08, 2005
	STRIDES PHARMA	5MG	A077712	003	Mar 02, 2009
		10MG	A077712	004	Apr 13, 2015
		15MG	A077712	001	Jan 31, 2007
		20MG	A077712	005	Apr 13, 2015
		30MG	A077712	002	Jan 31, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYCODONE HYDROCHLORIDE				
TABLET;ORAL				
ROXYBOND				
OHEMO LIFE	5MG	N209777	001	Apr 20, 2017
	15MG	N209777	002	Apr 20, 2017
	30MG	N209777	003	Apr 20, 2017
TABLET, EXTENDED RELEASE;ORAL				
ROXICODONE				
ROXANE	10MG	N020932	001	Oct 26, 1998
	30MG	N020932	002	Oct 26, 1998
OXYMETAZOLINE HYDROCHLORIDE				
CREAM;TOPICAL				
OXYMETAZOLINE HYDROCHLORIDE				
TARO PHARMS	1%	A213584	001	Oct 04, 2021
SOLUTION/DROPS;OPHTHALMIC				
OCUCLEAR				
BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986
OXYMETHOLONE				
TABLET;ORAL				
ANADROL-50				
+ MYLAN SPECIALITY LP	50MG	N016848	001	
OXYMORPHONE HYDROCHLORIDE				
INJECTABLE;INJECTION				
OPANA				
+ ENDO PHARMS	1MG/ML	N011707	002	
	1.5MG/ML	N011707	001	
SUPPOSITORY;RECTAL				
NUMORPHAN				
ENDO PHARMS	5MG	N011738	004	
TABLET;ORAL				
OPANA				
+ ENDO PHARMS	5MG	N021611	001	Jun 22, 2006
+	10MG	N021611	002	Jun 22, 2006
TABLET, EXTENDED RELEASE;ORAL				
OPANA ER				
+ ENDO PHARMS	5MG **	N021610	001	Jun 22, 2006
+	5MG	N201655	001	Dec 09, 2011
+	7.5MG **	N021610	005	Feb 29, 2008
+	7.5MG	N201655	002	Dec 09, 2011
+	10MG **	N021610	002	Jun 22, 2006
+	10MG	N201655	003	Dec 09, 2011
+	15MG **	N021610	006	Feb 29, 2008
+	15MG	N201655	004	Dec 09, 2011
+	20MG **	N021610	003	Jun 22, 2006
+	20MG	N201655	005	Dec 09, 2011
+	30MG **	N021610	007	Feb 29, 2008
+	30MG	N201655	006	Dec 09, 2011
+	40MG **	N021610	004	Jun 22, 2006
+	40MG	N201655	007	Dec 09, 2011
OXYMORPHONE HYDROCHLORIDE				
ACTAVIS ELIZABETH	5MG	A079046	003	Jul 11, 2013
	7.5MG	A079046	001	Dec 13, 2010
	10MG	A079046	004	Jul 11, 2013
	15MG	A079046	002	Dec 13, 2010
	20MG	A079046	005	Jul 11, 2013
	30MG	A079046	006	Jul 11, 2013
	40MG	A079046	007	Jul 11, 2013
HIKMA	5MG	A200822	002	Jul 15, 2013
	7.5MG	A200822	003	Jul 15, 2013
	10MG	A200822	004	Jul 15, 2013
	15MG	A200822	005	Jul 15, 2013
	20MG	A200822	006	Jul 15, 2013
	30MG	A200822	007	Jul 15, 2013
	40MG	A200822	001	Jul 15, 2013
PAR PHARM	5MG	A200792	001	Oct 24, 2014
	7.5MG	A200792	002	Oct 24, 2014
	10MG	A200792	003	Oct 24, 2014
	15MG	A200792	004	Oct 24, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL				
OXYMORPHONE HYDROCHLORIDE				
	20MG	A200792	005	Oct 24, 2014
	30MG	A200792	006	Oct 24, 2014
	40MG	A200792	007	Oct 24, 2014
SPECGX LLC	5MG	A202946	001	Jun 27, 2014
	7.5MG	A202946	002	Jun 27, 2014
	10MG	A202946	003	Jun 27, 2014
	15MG	A202946	004	Jun 27, 2014
	20MG	A202946	005	Jun 27, 2014
	30MG	A202946	006	Jun 27, 2014
	40MG	A202946	007	Jun 27, 2014
SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015
	7.5MG	A203506	002	Apr 24, 2015
	10MG	A203506	003	Apr 24, 2015
	15MG	A203506	004	Apr 24, 2015
	20MG	A203506	005	Apr 24, 2015
	30MG	A203506	006	Apr 24, 2015
	40MG	A203506	007	Apr 24, 2015

OXYPHENBUTAZONE

TABLET;ORAL				
OXYPHENBUTAZONE				
WATSON LABS	100MG	A088399	001	Sep 17, 1984
TANDEARIL				
NOVARTIS	100MG	N012542	004	Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET;ORAL			
DARICON			
PFIZER	10MG	N011612	001

OXYPHENONIUM BROMIDE

TABLET;ORAL			
ANTRENYL			
NOVARTIS	5MG	N008492	002

OXYTETRACYCLINE

TABLET;ORAL			
TERRAMYCIN			
PFIZER	250MG	N050287	001

OXYTETRACYCLINE CALCIUM

SYRUP;ORAL			
TERRAMYCIN			
PFIZER	EQ 125MG BASE/5ML	A060595	001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL			
OXY-KESSO-TETRA			
FERRANTE	EQ 250MG BASE	A060179	001
OXYTETRACYCLINE HYDROCHLORIDE			
HIKMA	EQ 250MG BASE	A060770	001
IMPAX LABS	EQ 250MG BASE	A060760	001
PROTER	EQ 250MG BASE	A060869	001
PUREPAC PHARM	EQ 250MG BASE	A060634	001
TERRAMYCIN			
PFIZER	EQ 125MG BASE	N050286	001
	EQ 250MG BASE	N050286	002
INJECTABLE;INJECTION			
TERRAMYCIN			
PFIZER	EQ 250MG BASE/VIAL	A060586	001
	EQ 500MG BASE/VIAL	A060586	002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC			
TERRAMYCIN W/ POLYMYXIN B SULFATE			
CASPER PHARMA LLC	EQ 5MG BASE/GM;10,000 UNITS/GM	N061015	001
OINTMENT;OTIC			
TERRAMYCIN W/ POLYMYXIN			
PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061841	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

TABLET;VAGINAL				
TERRAMYCIN-POLYMYXIN				
	PFIZER	EQ 100MG BASE;100,000 UNITS	A061009 001	

OXYTOCIN

INJECTABLE;INJECTION				
OXYTOCIN				
	DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008
		100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008
OXYTOCIN 10 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	1USP UNITS/100ML **	N019185 004	Mar 29, 1985
+		2USP UNITS/100ML **	N019185 003	Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	2USP UNITS/100ML **	N019185 002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%				
+	ABBOTT	1USP UNITS/100ML **	N019185 001	Mar 29, 1985
SYNTOCINON				
	NOVARTIS	10USP UNITS/ML	N018245 001	
SOLUTION;NASAL				
SYNTOCINON				
	RTRX	40USP UNITS/ML	N012285 001	

PACLITAXEL

INJECTABLE;INJECTION				
PACLITAXEL				
	ACCORD HLTHCARE	6MG/ML	A075436 001	Nov 12, 2004
	HOSPIRA	6MG/ML	A076233 001	Aug 01, 2002
	MYLAN	6MG/ML	A075278 001	Jan 25, 2002
	MYLAN LABS LTD	6MG/ML	A091540 001	Sep 29, 2011
	PLIVA LACHEMA	6MG/ML	A077413 001	Mar 12, 2008
	SANDOZ INC	6MG/ML	A078167 001	Dec 26, 2007
	TEVA PHARMS USA	6MG/ML	A075297 001	Jan 25, 2002
TAXOL				
+	HQ SPCLT PHARMA	6MG/ML	N020262 001	Dec 29, 1992

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL				
INVEGA				
+	JANSSEN PHARMS	12MG **	N021999 004	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR				
PALIPERIDONE PALMITATE				
	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149 001	Jul 06, 2021
		78MG/0.5ML (78MG/0.5ML)	A211149 002	Jul 06, 2021
		117MG/0.75ML (117MG/0.75ML)	A211149 003	Jul 06, 2021
		156MG/ML (156MG/ML)	A211149 004	Jul 06, 2021
		234MG/1.5ML (156MG/ML)	A211149 005	Jul 06, 2021

PALONOSETRON HYDROCHLORIDE

CAPSULE;ORAL				
ALOXI				
+	HELSINN HLTHCARE	EQ 0.5MG BASE **	N022233 001	Aug 22, 2008
INJECTABLE;INTRAVENOUS				
ALOXI				
+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372 002	Feb 29, 2008
+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372 001	Jul 25, 2003
PALONOSETRON HYDROCHLORIDE				
	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615 001	Mar 15, 2021
	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533 001	Apr 21, 2016
	HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005 002	Sep 19, 2018
	QILU PHARM HAINAN	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648 002	Sep 19, 2018
	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713 002	Mar 23, 2018
SOLUTION;INTRAVENOUS				
PALONOSETRON HYDROCHLORIDE				
	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050 001	Mar 01, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PALONOSETRON HYDROCHLORIDE

SOLUTION;INTRAVENOUS					
PALONOSETRON HYDROCHLORIDE					
		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016
+	FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION					
AREDIA					
+	NOVARTIS	30MG/VIAL **	N020036	001	Oct 31, 1991
		60MG/VIAL	N020036	003	May 06, 1993
		90MG/VIAL	N020036	004	May 06, 1993
PAMIDRONATE DISODIUM					
	AESGEN	30MG/VIAL	A075594	001	May 06, 2002
		90MG/VIAL	A075594	002	May 06, 2002
	AM REGENT	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008
		90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008
	FRESENIUS KABI USA	30MG/VIAL	A075773	001	May 06, 2002
		30MG/10ML (3MG/ML)	A076207	001	May 17, 2002
		90MG/VIAL	A075773	002	May 06, 2002
		90MG/10ML (9MG/ML)	A076207	002	May 17, 2002
	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009
		90MG/VIAL	A078300	002	Mar 10, 2009
	SUN PHARMA GLOBAL	30MG/VIAL	A077703	001	Dec 24, 2008
		90MG/VIAL	A077703	002	Dec 24, 2008
	TEVA PHARMS USA	30MG/10ML (3MG/ML)	A076153	001	Mar 27, 2002
		90MG/10ML (9MG/ML)	A076153	002	Mar 27, 2002

PANCURONIUM BROMIDE

INJECTABLE;INJECTION					
PANCURONIUM BROMIDE					
	ELKINS SINN	1MG/ML	A072058	001	Mar 23, 1988
		2MG/ML	A072059	001	Mar 23, 1988
		2MG/ML	A072060	001	Mar 23, 1988
	HOSPIRA	2MG/ML	A072321	001	Jan 19, 1989
	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988
		2MG/ML	A072211	001	Mar 31, 1988
		2MG/ML	A072212	001	Mar 31, 1988
		2MG/ML	A072213	001	Mar 31, 1988
PAVULON					
+	ORGANON USA INC	1MG/ML **	N017015	002	
+		2MG/ML **	N017015	001	

PANOBINOSTAT LACTATE

CAPSULE;ORAL					
FARYDAK					
+	SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015
+		EQ 15MG BASE	N205353	002	Feb 23, 2015
+		EQ 20MG BASE	N205353	003	Feb 23, 2015

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS					
PANTOPRAZOLE SODIUM					
	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018
TABLET, DELAYED RELEASE;ORAL					
PANTOPRAZOLE SODIUM					
	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011
		EQ 40MG BASE	A090901	002	Aug 30, 2011
	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821	001	Feb 16, 2012
		EQ 40MG BASE	A200821	002	Feb 16, 2012
	SUN PHARM	EQ 20MG BASE	A077058	001	Sep 10, 2007
		EQ 40MG BASE	A077058	002	Sep 10, 2007
	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012
		EQ 40MG BASE	A200794	002	May 02, 2012
	TEVA	EQ 20MG BASE	A077056	001	Aug 02, 2007
		EQ 40MG BASE	A077056	002	Aug 02, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PARAMETHADIONE				
CAPSULE;ORAL				
PARADIONE				
ABBVIE	150MG	N006800 003		
	300MG	N006800 001		
SOLUTION;ORAL				
PARADIONE				
ABBVIE	300MG/ML	N006800 002		
PARAMETHASONE ACETATE				
TABLET;ORAL				
HALDRONE				
LILLY	1MG	N012772 005		
	2MG	N012772 006		
PARGYLINE HYDROCHLORIDE				
TABLET;ORAL				
EUTONYL				
ABBOTT	10MG	N013448 002		
	25MG	N013448 003		
	50MG	N013448 004		
PARICALCITOL				
CAPSULE;ORAL				
PARICALCITOL				
LOTUS PHARM CO LTD	1MCG	A206710 001	Feb 24, 2016	
	2MCG	A206710 002	Feb 24, 2016	
	4MCG	A206710 003	Feb 24, 2016	
ZEMPLAR				
+ ABBVIE	4MCG **	N021606 003	May 26, 2005	
PAROMOMYCIN SULFATE				
CAPSULE;ORAL				
HUMATIN				
KING PFIZER	EQ 250MG BASE	A062310 001		
PARKEDALE	EQ 250MG BASE	A060521 001		
SYRUP;ORAL				
HUMATIN				
PARKE DAVIS	EQ 125MG BASE/5ML	A060522 001		
PAROXETINE HYDROCHLORIDE				
CAPSULE;ORAL				
PAXIL				
+ APOTEX TECHNOLOGIES	EQ 10MG BASE **	N020885 001	Oct 09, 1998	
+	EQ 20MG BASE **	N020885 002	Oct 09, 1998	
+	EQ 30MG BASE **	N020885 003	Oct 09, 1998	
+	EQ 40MG BASE **	N020885 004	Oct 09, 1998	
SUSPENSION;ORAL				
PAROXETINE HYDROCHLORIDE				
APOTEX INC	EQ 10MG BASE/5ML	A077395 001	Dec 05, 2006	
TABLET;ORAL				
PAROXETINE HYDROCHLORIDE				
JUBILANT GENERICS	EQ 10MG BASE	A205528 001	Nov 27, 2015	
	EQ 20MG BASE	A205528 002	Nov 27, 2015	
	EQ 30MG BASE	A205528 003	Nov 27, 2015	
	EQ 40MG BASE	A205528 004	Nov 27, 2015	
MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004	
	EQ 20MG BASE	A075716 002	Mar 08, 2004	
	EQ 30MG BASE	A075716 003	Mar 08, 2004	
	EQ 40MG BASE	A075716 004	Mar 08, 2004	
ROXANE	EQ 10MG BASE	A078026 001	Jun 29, 2007	
	EQ 20MG BASE	A078026 002	Jun 29, 2007	
	EQ 30MG BASE	A078026 003	Jun 29, 2007	
	EQ 40MG BASE	A078026 004	Jun 29, 2007	
SUN PHARM INDS INC	EQ 10MG BASE	A078194 001	Jun 29, 2007	
	EQ 20MG BASE	A078194 002	Jun 29, 2007	
	EQ 30MG BASE	A078194 003	Jun 29, 2007	
	EQ 40MG BASE	A078194 004	Jun 29, 2007	
TEVA PHARMS	EQ 10MG BASE	A077082 001	Jun 29, 2007	
	EQ 20MG BASE	A077082 002	Jun 29, 2007	
	EQ 30MG BASE	A077082 003	Jun 29, 2007	
	EQ 40MG BASE	A077082 004	Jun 29, 2007	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PAROXETINE HYDROCHLORIDE

TABLET;ORAL				
PAROXETINE HYDROCHLORIDE				
UPSHER SMITH LABS	EQ 10MG BASE	A075566	001	Mar 08, 2004
	EQ 20MG BASE	A075566	002	Mar 08, 2004
	EQ 30MG BASE	A075566	003	Mar 08, 2004
	EQ 40MG BASE	A075566	004	Mar 08, 2004
PAXIL				
APOTEX TECHNOLOGIES	EQ 50MG BASE	N020031	004	Dec 29, 1992

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL				
VOTRIENT				
+ NOVARTIS	EQ 400MG BASE **	N022465	002	Oct 19, 2009

PEGAPTANIB SODIUM

INJECTABLE;INTRAVITREAL				
MACUGEN				
+ VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS				
OMONTYS				
TAKEDA PHARMS USA	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012
OMONTYS PRESERVATIVE FREE				
TAKEDA PHARMS USA	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012
	EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012
	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012
	EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012
	EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012
	EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012

PEMETREXED

SOLUTION;INTRAVENOUS				
PEMETREXED				
+ ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020
+	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020
+	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC				
ALAMAST				
SANTEN	0.1%	N021079	001	Sep 24, 1999

PEMOLINE

TABLET;ORAL				
CYLERT				
ABBOTT	18.75MG	N016832	001	
	37.5MG	N016832	002	
	75MG	N016832	003	
PEMOLINE				
ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000
	37.5MG	A075595	002	Feb 28, 2000
	75MG	A075595	003	Feb 28, 2000
FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999
	37.5MG	A075286	002	Jun 30, 1999
	75MG	A075286	003	Jun 30, 1999
MALLINCKRODT	18.75MG	A075726	003	Mar 30, 2001
	37.5MG	A075726	002	Mar 30, 2001
	75MG	A075726	001	Mar 30, 2001
TEVA PHARMS	18.75MG	A075030	003	Feb 22, 2000
	37.5MG	A075030	001	Jan 29, 1999
	75MG	A075030	002	Jan 29, 1999
VINTAGE PHARMS	18.75MG	A075328	001	Apr 19, 2000
	37.5MG	A075328	002	Apr 19, 2000
	75MG	A075328	003	Apr 19, 2000
WATSON LABS	18.75MG	A075287	001	Jun 13, 2001
	37.5MG	A075287	002	Sep 18, 2000
	75MG	A075287	003	Sep 18, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PEMOLINE				
TABLET, CHEWABLE;ORAL				
CYLERT				
ABBOTT	37.5MG		N017703 001	
PEMOLINE				
ACTAVIS ELIZABETH	37.5MG		A075678 001	Jul 26, 2000
TEVA PHARMS	37.5MG		A075555 001	Feb 18, 2000
PENBUTOLOL SULFATE				
TABLET;ORAL				
LEVATOL				
+ AUXILIUM PHARMS LLC	10MG **		N018976 001	Dec 30, 1987
+	20MG **		N018976 004	Jan 05, 1989
PENICILLAMINE				
CAPSULE;ORAL				
CUPRIMINE				
VALEANT PHARMS INTL	125MG		N019853 002	
TABLET;ORAL				
PENICILLAMINE				
TEVA PHARMS USA	250MG		A211497 001	Feb 13, 2020
PENICILLIN G BENZATHINE				
INJECTABLE;INJECTION				
BICILLIN L-A				
+ KING PHARMS LLC	300,000 UNITS/ML		N050141 003	
WYETH AYERST	300,000 UNITS/ML		N050131 001	
PERMAPEN				
CASPER PHARMA LLC	600,000 UNITS/ML		N060014 001	
SUSPENSION;ORAL				
BICILLIN				
WYETH AYERST	300,000 UNITS/5ML		N050126 002	
TABLET;ORAL				
BICILLIN				
WYETH AYERST	200,000 UNITS		N050128 001	
PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE				
INJECTABLE;INJECTION				
BICILLIN C-R				
+ KING PHARMS LLC	150,000 UNITS/ML;150,000 UNITS/ML		N050138 002	
PENICILLIN G POTASSIUM				
FOR SOLUTION;ORAL				
PENICILLIN				
TEVA	200,000 UNITS/5ML		A060307 002	
	400,000 UNITS/5ML		A060307 004	
PENICILLIN G POTASSIUM				
MYLAN	200,000 UNITS/5ML		A060752 003	
	250,000 UNITS/5ML		A060752 002	
	400,000 UNITS/5ML		A060752 001	
PUREPAC PHARM	250,000 UNITS/5ML		A061740 001	
	400,000 UNITS/5ML		A061740 002	
PENICILLIN-2				
TEVA	250,000 UNITS/5ML		A060307 003	
PENTIDS '200'				
APOTHECON	200,000 UNITS/5ML		A062149 001	
PENTIDS '400'				
APOTHECON	400,000 UNITS/5ML		A062149 002	
PFIZERPEN G				
PFIZER	400,000 UNITS/5ML		A060587 001	
INJECTABLE;INJECTION				
PENICILLIN G POTASSIUM				
APOTHECON	1,000,000 UNITS/VIAL		A060362 001	
	5,000,000 UNITS/VIAL		A060362 003	
	10,000,000 UNITS/VIAL		A060362 004	
	20,000,000 UNITS/VIAL		A060362 002	
CONSOLIDATED PHARM	500,000 UNITS/VIAL		A060806 001	
	1,000,000 UNITS/VIAL		A060806 002	
	5,000,000 UNITS/VIAL		A060806 003	
	10,000,000 UNITS/VIAL		A060806 004	
LILLY	200,000 UNITS/VIAL		A060384 004	
	500,000 UNITS/VIAL		A060384 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION				
PENICILLIN G POTASSIUM				
	1,000,000 UNITS/VIAL		A060384 002	
	5,000,000 UNITS/VIAL		A060384 001	
	20,000,000 UNITS/VIAL		A060384 005	
	20,000,000 UNITS/VIAL		A060601 001	
PARKE DAVIS	1,000,000 UNITS/VIAL		A062003 001	
	5,000,000 UNITS/VIAL		A062003 002	
PFIZER	20,000,000 UNITS/VIAL		A060074 003	
SANDOZ	1,000,000 UNITS/VIAL **		A065079 001	Aug 30, 2002
WATSON LABS INC	1,000,000 UNITS/VIAL		A062991 001	Sep 13, 1988
	5,000,000 UNITS/VIAL		A062991 002	Sep 13, 1988
	10,000,000 UNITS/VIAL		A062991 003	Sep 13, 1988
	20,000,000 UNITS/VIAL		A062991 004	Sep 13, 1988
PFIZERPEN				
PFIZER	1,000,000 UNITS/VIAL **		A060657 001	
TABLET;ORAL				
PENICILLIN G POTASSIUM				
APOTHECON	250,000 UNITS		A060392 003	
IVAX SUB TEVA PHARMS	400,000 UNITS		A060073 004	
LILLY	250,000 UNITS		A060403 001	
MYLAN	200,000 UNITS		A060781 001	
	250,000 UNITS		A060781 002	
	400,000 UNITS		A060781 003	
	500,000 UNITS		A060781 005	
	800,000 UNITS		A060781 004	
PUREPAC PHARM	200,000 UNITS		A061588 001	
	250,000 UNITS		A061588 002	
	400,000 UNITS		A061588 003	
TEVA	200,000 UNITS		A060306 001	
	250,000 UNITS		A060306 002	
	400,000 UNITS		A060306 003	
	500,000 UNITS		A060306 004	
WYETH AYERST	200,000 UNITS		A060413 001	
	250,000 UNITS		A060413 002	
	400,000 UNITS		A060413 003	
PENTIDS '200'				
APOTHECON	200,000 UNITS		A062155 001	
PENTIDS '250'				
APOTHECON	250,000 UNITS		A062155 002	
PENTIDS '400'				
APOTHECON	400,000 UNITS		A060392 004	
	400,000 UNITS		A062155 003	
PENTIDS '800'				
APOTHECON	800,000 UNITS		A060392 005	
	800,000 UNITS		A062155 004	
PFIZERPEN G				
PFIZER	50,000 UNITS		A060075 001	
	100,000 UNITS		A060075 002	
	200,000 UNITS		A060075 003	
	250,000 UNITS		A060075 004	
	400,000 UNITS		A060075 005	
	800,000 UNITS		A060075 006	

PENICILLIN G PROCAINE

INJECTABLE;INJECTION				
DURACILLIN A.S.				
LILLY	300,000 UNITS/ML		A060093 001	
PENICILLIN G PROCAINE				
CONSOLIDATED PHARM	300,000 UNITS/ML		A060800 001	
	600,000 UNITS/1.2ML		A060800 002	
PARKE DAVIS	300,000 UNITS/ML		A062029 001	
PFIZER	300,000 UNITS/VIAL		A060099 001	
	1,500,000 UNITS/VIAL		A060099 002	
PFIZERPEN-AS				
PFIZER	300,000 UNITS/ML		A060286 001	
	600,000 UNITS/ML		A060286 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN G SODIUM

INJECTABLE;INJECTION				
PENICILLIN G SODIUM				
BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL		A061935 001	
COPANOS	5,000,000 UNITS/VIAL		A061051 001	
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL		A061046 001	
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS				
PENICILLIN G SODIUM				
WATSON LABS INC	5,000,000 UNITS/VIAL		A063014 001	Sep 13, 1988

PENICILLIN V

FOR SUSPENSION;ORAL				
V-CILLIN				
LILLY	125MG/0.6ML		A060002 001	

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL				
BEEPEN-VK				
GLAXOSMITHKLINE	EQ 125MG BASE/5ML		A062270 001	
	EQ 250MG BASE/5ML		A062270 002	
BETAPEN-VK				
APOTHECON	EQ 125MG BASE/5ML		A061149 001	
	EQ 250MG BASE/5ML		A061149 002	
LEDERCILLIN VK				
LEDERLE	EQ 125MG BASE/5ML		A060136 001	
	EQ 250MG BASE/5ML		A060136 002	
PEN-VEE K				
WYETH AYERST	EQ 125MG BASE/5ML		A060007 001	
	EQ 250MG BASE/5ML		A060007 002	
PENAPAR-VK				
PARKE DAVIS	EQ 125MG BASE/5ML		A062002 001	
	EQ 250MG BASE/5ML		A062002 002	
PENICILLIN V POTASSIUM				
BELCHER PHARMS	EQ 125MG BASE/5ML		A061529 001	
	EQ 250MG BASE/5ML		A061529 002	
MYLAN	EQ 125MG BASE/5ML		A061624 002	
	EQ 250MG BASE/5ML		A061624 001	
PUREPAC PHARM	EQ 125MG BASE/5ML		A061758 001	
	EQ 250MG BASE/5ML		A061758 002	
STRIDES PHARMA	EQ 125MG BASE/5ML		A062981 001	Feb 10, 1989
	EQ 250MG BASE/5ML		A062981 002	Feb 10, 1989
PFIZERPEN VK				
PFIZER	EQ 125MG BASE/5ML		A061815 001	
	EQ 250MG BASE/5ML		A061815 002	
V-CILLIN K				
LILLY	EQ 125MG BASE/5ML		A060004 001	
	EQ 250MG BASE/5ML		A060004 002	
VEETIDS				
APOTHECON	EQ 125MG BASE/5ML		A061410 001	
	EQ 250MG BASE/5ML		A061410 002	
VEETIDS '125'				
APOTHECON	EQ 125MG BASE/5ML		A061206 001	
	EQ 125MG BASE/5ML		A062153 001	
VEETIDS '250'				
APOTHECON	EQ 250MG BASE/5ML		A061206 002	
	EQ 250MG BASE/5ML		A062153 002	
TABLET;ORAL				
BEEPEN-VK				
GLAXOSMITHKLINE	EQ 250MG BASE		A062273 001	
	EQ 500MG BASE		A062273 002	
BETAPEN-VK				
BRISTOL	EQ 250MG BASE		A061150 001	
	EQ 500MG BASE		A061150 002	
LEDERCILLIN VK				
LEDERLE	EQ 250MG BASE		A060134 001	
	EQ 500MG BASE		A060134 002	
PEN-VEE K				
WYETH AYERST	EQ 125MG BASE		A060006 001	
	EQ 250MG BASE		A060006 002	
	EQ 500MG BASE		A060006 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENICILLIN V POTASSIUM

TABLET;ORAL				
PENAPAR-VK				
	PARKE DAVIS	EQ 250MG BASE	A062001 001	
		EQ 500MG BASE	A062001 002	
PENICILLIN V POTASSIUM				
	BELCHER PHARMS	EQ 250MG BASE	A061528 001	
		EQ 500MG BASE	A061528 002	
	IVAX SUB TEVA PHARMS	EQ 125MG BASE	A060518 001	
		EQ 250MG BASE	A060518 002	
		EQ 500MG BASE	A060518 003	
	MYLAN	EQ 250MG BASE	A061530 001	
		EQ 500MG BASE	A061530 002	
	PUREPAC PHARM	EQ 125MG BASE	A061571 001	
		EQ 250MG BASE	A061571 002	
		EQ 500MG BASE	A061571 003	
PFIZERPEN VK				
	PFIZER	EQ 250MG BASE	A061836 001	
		EQ 500MG BASE	A061836 002	
UTICILLIN VK				
	PHARMACIA AND UPJOHN	EQ 250MG BASE	A061651 001	
		EQ 500MG BASE	A061651 002	
V-CILLIN K				
	LILLY	EQ 125MG BASE **	A060003 001	
		EQ 250MG BASE **	A060003 002	
		EQ 500MG BASE **	A060003 003	
VEETIDS				
	APOTHECON	EQ 250MG BASE	A061411 001	
		EQ 500MG BASE	A061411 002	
VEETIDS '250'				
	APOTHECON	EQ 250MG BASE	A061164 001	
		EQ 250MG BASE	A062156 002	
VEETIDS '500'				
	APOTHECON	EQ 500MG BASE	A061164 002	
		EQ 500MG BASE	A062156 001	

PENTAGASTRIN

INJECTABLE;INJECTION				
PEPTAVLON				
+	WYETH AYERST	0.25MG/ML **	N017048 001	

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION				
NEBUPENT				
	FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996
INJECTABLE;INJECTION				
PENTACARINAT				
	ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994
PENTAMIDINE ISETHIONATE				
	BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
	HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
	WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL				
TALWIN 50				
	SANOFI AVENTIS US	EQ 50MG BASE	N016732 001	

PENTAZOCINE LACTATE

INJECTABLE;INJECTION				
TALWIN				
+	HOSPIRA	EQ 30MG BASE/ML	N016194 001	

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS				
PENTETATE CALCIUM TRISODIUM				
+	HAMELN	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **	N021749 001	Aug 11, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE;INJECTION				
YTTERBIUM YB 169 DTPA				
	3M	2mCi/ML	N017518 001	

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS				
PENTETATE ZINC TRISODIUM				
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **	N021751 001	Aug 11, 2004

PENTOBARBITAL

ELIXIR;ORAL				
NEMBUTAL				
	AKORN	18.2MG/5ML	A083244 001	

PENTOBARBITAL SODIUM

CAPSULE;ORAL				
NEMBUTAL SODIUM				
	AKORN	30MG	A084095 001	
		50MG	A084093 001	
		100MG	A083245 001	
PENTOBARBITAL SODIUM				
	LANNETT	50MG	A085937 001	
		100MG	A085915 001	
	VITARINE	100MG	A083284 001	
	WHITEWORTH TOWN PLSN	100MG	A083338 001	
SODIUM PENTOBARBITAL				
	ANABOLIC	100MG	A084590 001	
	ELKINS SINN	100MG	A083368 001	
	EVERYLIFE	100MG	A083259 001	
	HALSEY	100MG	A084677 001	
	IVAX SUB TEVA PHARMS	50MG	A083461 001	
		100MG	A083461 002	
	PARKE DAVIS	100MG	A084156 001	
	PERRIGO	100MG	A084560 001	
	PUREPAC PHARM	100MG	A083301 001	
	VALEANT PHARM INTL	100MG	A083264 001	
	WATSON LABS	100MG	A085791 001	
	WYETH AYERST	100MG	A083239 001	
INJECTABLE;INJECTION				
PENTOBARBITAL SODIUM				
	ELKINS SINN	50MG/ML	A083270 001	
SODIUM PENTOBARBITAL				
	WYETH AYERST	50MG/ML	A083261 001	
SUPPOSITORY;RECTAL				
NEMBUTAL				
	AKORN	30MG	A083247 001	Jan 25, 1982
		60MG	A083247 002	Jan 25, 1982
		120MG	A083247 003	Jan 25, 1982
		200MG	A083247 004	Jan 25, 1982
TABLET;ORAL				
PENTOBARBITAL SODIUM				
	VITARINE	100MG	A083285 001	
SODIUM PENTOBARBITAL				
	NEXGEN PHARMA INC	100MG	A084238 001	

PENTOLINIUM TARTRATE

INJECTABLE;INJECTION				
ANSOLYSEN				
	WYETH AYERST	10MG/ML	N009372 001	

PENTOSTATIN

INJECTABLE;INJECTION				
PENTOSTATIN				
	RISING PHARMA	10MG/VIAL	A203554 001	Sep 19, 2014

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL				
PENTOXIFYLLINE				
ANI PHARMS	400MG	A074878	001	Jul 09, 1997
	400MG	A075107	001	Sep 04, 1998
	400MG	A075199	001	Sep 03, 1999
HERITAGE PHARMS INC	400MG	A074877	001	Jul 08, 1997
IMPAX LABS	400MG	A075093	001	Aug 10, 1999
PLIVA	400MG	A074874	001	May 25, 1999
RISING PHARMA	400MG	A074425	001	Jul 08, 1997
PENTOXIL				
UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999
TRENTAL				
+ VALIDUS PHARMS	400MG **	N018631	001	Aug 30, 1984

PERFLUBRON

LIQUID;ORAL				
IMAGENT				
ALLIANCE PHARM	100%	N020091	001	Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE;TOPICAL				
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS				
US ARMY	50%;50%	N021084	001	Feb 17, 2000

PERGOLIDE MESYLATE

TABLET;ORAL				
PERGOLIDE MESYLATE				
IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094	001	Sep 04, 2003
	EQ 0.25MG BASE	A076094	002	Sep 04, 2003
	EQ 1MG BASE	A076094	003	Sep 04, 2003
STRIDES PHARMA	EQ 0.05MG BASE	A076061	001	Nov 27, 2002
	EQ 0.25MG BASE	A076061	002	Nov 27, 2002
	EQ 1MG BASE	A076061	003	Nov 27, 2002
PERMAX				
VALEANT PHARM INTL	EQ 0.05MG BASE	N019385	001	Dec 30, 1988
	EQ 0.25MG BASE	N019385	002	Dec 30, 1988
	EQ 1MG BASE	N019385	003	Dec 30, 1988

PERINDOPRIL ERBUMINE

TABLET;ORAL				
ACEON				
+ SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993
+	4MG	N020184	002	Dec 30, 1993
+	8MG	N020184	003	Dec 30, 1993
PERINDOPRIL ERBUMINE				
ANI PHARMS	2MG	A078138	001	Nov 10, 2009
	4MG	A078138	002	Nov 10, 2009
	8MG	A078138	003	Nov 10, 2009
APOTEX	2MG	A090463	001	Aug 30, 2010
	4MG	A090463	002	Aug 30, 2010
	8MG	A090463	003	Aug 30, 2010
LUPIN LTD	2MG	A078263	001	Jan 27, 2010
	4MG	A078263	002	Jan 27, 2010
	8MG	A078263	003	Jan 27, 2010

PERMETHRIN

CREAM;TOPICAL				
ELIMITE				
+ AUROBINDO PHARMA USA	5%	N019855	001	Aug 25, 1989
LOTION;TOPICAL				
NIX				
GLAXOSMITHKLINE	1%	N019435	001	Mar 31, 1986

PERPHENAZINE

CONCENTRATE;ORAL				
PERPHENAZINE				
PHARM ASSOC	16MG/5ML	A040360	001	May 25, 2001
TRILAFON				
SCHERING	16MG/5ML	N011557	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PERPHENAZINE

INJECTABLE;INJECTION				
TRILAFON				
	SCHERING	5MG/ML	N011213 002	
SYRUP;ORAL				
TRILAFON				
	SCHERING	2MG/5ML	N011294 002	
TABLET;ORAL				
PERPHENAZINE				
	ANI PHARMS	2MG	A089707 001	Sep 10, 1987
		4MG	A089708 001	Sep 10, 1987
		8MG	A089456 001	Sep 10, 1987
		16MG	A089457 001	Sep 10, 1987
TRILAFON				
+	SCHERING	2MG **	N010775 001	
+		4MG **	N010775 002	
+		8MG **	N010775 003	
+		16MG **	N010775 004	
TABLET, EXTENDED RELEASE;ORAL				
TRILAFON				
	SCHERING	8MG	N011361 002	

PHENACEMIDE

TABLET;ORAL				
PHENURONE				
+	ABBVIE	500MG **	N007707 001	

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET;ORAL				
AZO GANTANOL				
+	ROCHE	100MG;500MG **	N013294 001	Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL				
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE				
	ABLE	200MG,N/A,N/A;N/A,800MG,160MG	N021105 001	Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET;ORAL				
AZO GANTRISIN				
+	ROCHE	50MG;500MG **	N019358 001	Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL				
PHENAZINE				
	MAST MM	35MG	A086523 001	
		35MG	A086524 001	
		35MG	A086525 001	
PHENDIMETRAZINE TARTRATE				
	SANDOZ	35MG	A085633 001	
		35MG	A085694 001	
		35MG	A085702 001	
	VIRTUS PHARMS	35MG	A085695 001	
	VITARINE	35MG	A085634 001	
		35MG	A085645 001	
		35MG	A085670 001	
		35MG	A086403 001	
		35MG	A086408 001	
		35MG	A086410 001	
		35MG	A087424 001	
SPRX-3				
	SOLVAY	35MG	A085897 001	
STATOBEX				
	TEVA	35MG	A085507 001	
X-TROZINE				
	SHIRE RICHWOOD	35MG	A087394 001	Sep 22, 1982
CAPSULE, EXTENDED RELEASE;ORAL				
BONTRIL				
	VALEANT	105MG	A088021 001	Sep 21, 1982
MELFIAT-105				
	NUMARK	105MG	A087487 001	Oct 13, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL				
PHENDIMETRAZINE TARTRATE				
GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
VIRTUS PHARMS	105MG	A087378	001	
SPRX-105				
NUMARK	105MG	A088024	001	Dec 22, 1982
X-TROZINE L.A.				
SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982
TABLET;ORAL				
ADPHEN				
FERNDALE LABS	35MG	A083655	001	
ALPHAZINE				
SANDOZ	35MG	A085034	001	
CAM-METRAZINE				
ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
CHARTWELL RX	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	
DI-METREX				
PVT FORM	35MG	A085698	001	
MELFIAT				
NUMARK	35MG	A083790	002	
METRA				
FOREST PHARMS	35MG	A083754	001	
PHENAZINE				
MAST MM	35MG	A087305	001	
PHENAZINE-35				
ABC HOLDING	35MG	A085512	001	
PHENDIMETRAZINE TARTRATE				
BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
CHARTWELL RX	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983
FERNDALE LABS	35MG	A086834	001	Sep 15, 1983
INWOOD LABS	35MG	A084740	001	
	35MG	A084741	001	
	35MG	A084742	001	
	35MG	A084743	001	
IVAX PHARMS	35MG	A085611	001	
	35MG	A085612	001	
IVAX SUB TEVA PHARMS	35MG	A083682	001	
KV PHARM	35MG	A084138	001	
	35MG	A084141	001	
	35MG	A085525	001	
MFG CHEMISTS	35MG	A085914	001	
NEXGEN PHARMA INC	35MG	A086020	001	
NOSTRUM LABS INC	35MG	A203600	001	Dec 27, 2017
NUMARK	35MG	A083790	001	
PVT FORM	35MG	A085199	001	
	35MG	A085697	001	
SANDOZ	35MG	A085402	001	
	35MG	A085830	001	
	35MG	A086370	001	
SOLVAY	35MG	A083993	001	
UPSHER SMITH LABS	35MG	A084399	001	
USL PHARMA	35MG	A083805	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENDIMETRAZINE TARTRATE
TABLET;ORAL
PHENDIMETRAZINE TARTRATE

	35MG		A084398 001	
VIRTUS PHARMS	35MG		A085497 001	
	35MG		A086365 001	
VITARINE	35MG		A085519 001	
	35MG		A086005 001	
	35MG		A086106 001	
WATSON LABS	35MG		A085767 001	
	35MG		A085768 001	
	35MG		A085770 001	
	35MG		A085773 001	

PLEGINE

WYETH AYERST	35MG **		N012248 001	

STATOBEX

TEVA	35MG		A086013 001	

STATOBEX-G

TEVA	35MG		A085095 001	

X-TROZINE

SHIRE RICHWOOD	35MG		A086550 001	
	35MG		A086551 001	
	35MG		A086552 001	
	35MG		A086553 001	
	35MG		A086554 001	

PHENINDIONE
TABLET;ORAL
HEDULIN

SANOFI AVENTIS US	50MG		N008767 002	

PHENMETRAZINE HYDROCHLORIDE
TABLET;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	25MG		N010460 005	

TABLET, EXTENDED RELEASE;ORAL
PRELUDIN

BOEHRINGER INGELHEIM	50MG		N011752 004	
	75MG		N011752 003	

PHENPROCOUMON
TABLET;ORAL
LIQUAMAR

ORGANON USA INC	3MG		N011228 001	

PHENSUXIMIDE
CAPSULE;ORAL
MILONTIN

PARKE DAVIS	500MG		N008855 004	

PHENTERMINE HYDROCHLORIDE
CAPSULE;ORAL
FASTIN

GLAXOSMITHKLINE	30MG **		N017352 001	

OBESTIN-30

FERNDALE LABS	30MG		A087144 001	

OBY-TRIM

SHIRE RICHWOOD	30MG		A087764 001	Mar 18, 1982

ONA-MAST

MAST MM	30MG		A086511 001	
	30MG		A086516 001	

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG		A085411 001	
ABLE	15MG		A040497 001	Mar 13, 2003
	30MG		A040403 001	Aug 30, 2001
	30MG		A040427 001	Aug 30, 2001
BARR	15MG		A090591 001	Mar 18, 2010
	30MG		A090591 002	Mar 18, 2010
CAMALL	15MG		A086735 001	
	30MG		A087226 001	
CHARTWELL RX	18.75MG		A088576 001	May 23, 1984
	30MG		A085417 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL					
PHENTERMINE HYDROCHLORIDE					
		30MG	A086732	002	
		30MG	A087215	001	
		37.5MG	A087915	001	Dec 22, 1983
		37.5MG	A087918	001	Dec 22, 1983
		37.5MG	A087930	001	Oct 14, 1983
		37.5MG	A088610	001	Jun 04, 1984
		37.5MG	A088611	001	Jun 04, 1984
		37.5MG	A088625	001	Aug 23, 1984
	DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
	ELITE LABS INC	15MG	A040460	001	Jan 14, 2003
		30MG	A040227	001	Jun 18, 1997
		30MG	A040448	001	Jan 22, 2003
	IVAX PHARMS	30MG	A086329	001	
	LANNETT CO INC	30MG	A091359	001	Jul 16, 2010
	SANDOZ	30MG	A087208	001	
		30MG	A087223	001	
		37.5MG	A088414	001	Oct 19, 1983
	SUN PHARM INDUSTRIES	37.5MG	A040527	001	Oct 23, 2003
	TEVA	30MG	A086911	001	
		30MG	A087126	001	
		30MG	A087777	001	Nov 01, 1985
		30MG	A088612	001	Apr 04, 1984
		30MG	A088613	001	Apr 09, 1984
		30MG	A088614	001	Apr 09, 1984
	TG UNITED INC	30MG	A040083	001	Mar 07, 1997
	UPSHER SMITH LABS	30MG	A084487	001	Apr 09, 1982
		30MG	A088430	001	Mar 27, 1984
	USL PHARMA	30MG	A088797	001	Dec 10, 1984
	VITARINE	30MG	A087202	001	
		30MG	A087235	001	
	WATSON LABS	30MG	A086740	001	Mar 21, 1985
TABLET;ORAL					
ONA-MAST					
	MAST MM	8MG	A086260	001	
PHENTERMINE HYDROCHLORIDE					
	ABLE	37.5MG	A040402	001	Aug 30, 2001
	ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
	BARR	37.5MG	A090470	001	Aug 31, 2009
	CHARTWELL RX	8MG	A083923	001	
		8MG	A085319	001	
		37.5MG	A087805	001	Dec 06, 1982
		37.5MG	A088596	001	Apr 04, 1984
	IVAX PHARMS	8MG	A085553	001	
	NOVAST LABS	37.5MG	A091451	001	Sep 21, 2012
	SANDOZ	8MG	A085671	001	
		8MG	A085689	001	
	SANDOZ INC	30MG	A088605	001	Sep 28, 1987
	SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007
+	USL PHARMA	8MG	A083804	001	
		37.5MG	A088910	001	Jul 17, 1985
		37.5MG	A088917	001	Jul 17, 1985
	VITARINE	8MG	A086453	001	
		8MG	A086456	001	
	WATSON LABS	8MG	A085739	001	
TORA					
	SOLVAY	8MG	A084035	001	
WILPO					
+	SANDOZ	8MG **	N012737	001	
TABLET, ORALLY DISINTEGRATING;ORAL					
SUPRENZA					
	CITIUS PHARMS	15MG **	N202088	001	Jun 13, 2011
		30MG **	N202088	002	Jun 13, 2011
		37.5MG **	N202088	003	Mar 27, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL				
IONAMIN				
	UCB INC	EQ 15MG BASE **	N011613 004	
		EQ 30MG BASE **	N011613 002	
PHENTERMINE RESIN 30				
	QUANTUM PHARMICS	EQ 30MG BASE	A089120 001	Feb 04, 1988
PHENTERMINE RESIN COMPLEX				
	LANNETT CO INC	EQ 15MG BASE	A040872 001	Jul 28, 2011
		EQ 30MG BASE	A040872 002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION				
REGITINE				
+	NOVARTIS	5MG/VIAL **	N008278 003	

PHENYL AMINOSALICYLATE

POWDER;ORAL				
PHENY-PAS-TEBAMIN				
	PHARM RES ASSOC	50%	N011695 002	
TABLET;ORAL				
PHENY-PAS-TEBAMIN				
	PHARM RES ASSOC	500MG	N011695 003	

PHENYLBUTAZONE

CAPSULE;ORAL				
AZOLID				
	SANOFI AVENTIS US	100MG	A087260 001	
BUTAZOLIDIN				
	NOVARTIS	100MG	N008319 009	
PHENYLBUTAZONE				
	FOSUN PHARMA	100MG	A087774 001	Jun 16, 1982
	IVAX PHARMS	100MG	A088218 001	Jun 24, 1983
	SUN PHARM INDUSTRIES	100MG	A088994 001	Dec 04, 1985
	WATSON LABS	100MG	A087756 001	Dec 17, 1982
TABLET;ORAL				
AZOLID				
	SANOFI AVENTIS US	100MG	A087091 001	
BUTAZOLIDIN				
	NOVARTIS	100MG	N008319 008	
PHENYLBUTAZONE				
	FOSUN PHARMA	100MG	A084339 001	
	SUN PHARM INDUSTRIES	100MG	A088863 001	Dec 04, 1985
	WATSON LABS	100MG	A086151 001	
		100MG	A087674 001	Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS				
BIORPHEN				
+	ETON PHARMS	10MG/ML (10MG/ML)	N212909 002	Mar 11, 2021
PHENYLEPHRINE HYDROCHLORIDE				
	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237 001	Jul 01, 2020
		50MG/5ML (10MG/ML)	A213237 002	Jul 01, 2020
		100MG/10ML (10MG/ML)	A213237 003	Jul 01, 2020

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL				
PHENERGAN VC				
+	ANI PHARMS	5MG/5ML;6.25MG/5ML **	N008604 003	Apr 02, 1984
PHERAZINE VC				
	HALSEY	5MG/5ML;6.25MG/5ML	A088868 001	Mar 02, 1987
PROMETH VC PLAIN				
+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761 001	Nov 08, 1984
PROMETHAZINE VC PLAIN				
	CENCI	5MG/5ML;6.25MG/5ML	A088815 001	Nov 22, 1985
	WOCKHARDT	5MG/5ML;6.25MG/5ML	A088897 001	Jan 04, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE				
SOLUTION/DROPS;OPHTHALMIC				
PREFRIN-A				
ALLERGAN	0.12%;0.1%	N007953	001	
PHENYTOIN				
SUSPENSION;ORAL				
DILANTIN-30				
UPJOHN	30MG/5ML	N008762	002	
PHENYTOIN				
ACTAVIS MID ATLANTIC	125MG/5ML	A089892	001	Sep 25, 1992
PHENYTOIN SODIUM				
CAPSULE;ORAL				
DIPHENYLAN SODIUM				
LANNETT	30MG PROMPT	A080857	001	
	100MG PROMPT	A080857	002	
EXTENDED PHENYTOIN SODIUM				
ANI PHARMS	100MG EXTENDED	A040435	001	Jun 20, 2003
	100MG EXTENDED	A089441	001	Dec 18, 1986
LUPIN LTD	100MG EXTENDED	A211633	001	Sep 30, 2019
SUN PHARM INDS (IN)	100MG EXTENDED	A040621	001	Dec 11, 2006
WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007
WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008
PHENYTEX				
WATSON LABS	100MG EXTENDED	A088711	001	Dec 21, 1984
PHENYTOIN SODIUM				
PHARMERAL	100MG PROMPT	A085435	001	
WATSON LABS	100MG PROMPT	A085894	001	
PROMPT PHENYTOIN SODIUM				
ANI PHARMS	100MG PROMPT	A080259	001	
WATSON LABS	100MG PROMPT	A080905	001	
INJECTABLE;INJECTION				
DILANTIN				
PARKE DAVIS	50MG/ML	N010151	001	
PHENYTOIN SODIUM				
AM REGENT	50MG/ML	A040781	001	Dec 04, 2007
FRESENIUS KABI USA	50MG/ML	A089003	001	May 31, 1985
HOSPIRA	50MG/ML	A089521	001	Mar 17, 1987
	50MG/ML	A089744	001	Dec 18, 1987
MARSAM PHARMS LLC	50MG/ML	A089501	001	Oct 13, 1987
	50MG/ML	A089779	001	Nov 27, 1992
SMITH AND NEPHEW	50MG/ML	A088519	001	Dec 19, 1984
	50MG/ML	A088521	001	Dec 18, 1984
SOLOPAK	50MG/ML	A088520	001	Dec 17, 1984
WARNER CHILCOTT	50MG/ML	A089900	001	Mar 30, 1990
WATSON LABS	50MG/ML	A085434	001	
PHYTONADIONE				
INJECTABLE;INJECTION				
AQUAMEPHYTON				
+ TELIGENT	1MG/0.5ML **	N012223	002	
+	10MG/ML **	N012223	001	
KONAKION				
ROCHE	1MG/0.5ML	N011745	001	
	10MG/ML	N011745	003	
PHYTONADIONE				
GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
	10MG/ML	A084060	002	
VITAMIN K1				
HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983
PILOCARPINE				
INSERT, EXTENDED RELEASE;OPHTHALMIC				
OCUSERT PILO-20				
AKORN	5MG	N017431	001	
OCUSERT PILO-40				
AKORN	11MG	N017548	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PILOCARPINE HYDROCHLORIDE

GEL;OPHTHALMIC

PILOPINE HS

	ALCON	4%	N018796	001	Oct 01, 1984

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016

PIMOZIDE

TABLET;ORAL

ORAP

+	TEVA	1MG **	N017473	003	Aug 27, 1997
+		2MG **	N017473	001	Jul 31, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE;ORAL

PINDAC

	LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
		25MG	N019456	002	Dec 28, 1989

PINDOLOL

TABLET;ORAL

PINDOLOL

	COSETTE	5MG	A073661	001	Oct 31, 1993
		5MG	A073687	001	Feb 26, 1993
		5MG	A074123	001	Apr 17, 1997
		10MG	A073661	002	Oct 31, 1993
		10MG	A073687	002	Feb 26, 1993
		10MG	A074123	002	Apr 17, 1997
	MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
		10MG	A074018	001	Sep 24, 1992
	NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
		10MG	A074474	002	Oct 28, 1996
	PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
		10MG	A074125	002	Apr 28, 1993
	WATSON LABS	5MG	A074437	001	Feb 27, 1995
		10MG	A074437	002	Feb 27, 1995
	ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017
		10MG	A209866	002	Aug 18, 2017

VISKEN

+	NOVARTIS	5MG **	N018285	001	Sep 03, 1982
+		10MG **	N018285	002	Sep 03, 1982

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012
		EQ 30MG BASE	A076801	002	Aug 17, 2012
		EQ 45MG BASE	A076801	003	Aug 17, 2012
	NOSTRUM LABS INC	EQ 15MG BASE	A078472	001	Feb 13, 2013
		EQ 30MG BASE	A078472	002	Feb 13, 2013
		EQ 45MG BASE	A078472	003	Feb 13, 2013
	PICKET PHARMS	EQ 15MG BASE	A078383	001	Mar 12, 2013
		EQ 30MG BASE	A078383	002	Mar 12, 2013
		EQ 45MG BASE	A078383	003	Mar 12, 2013
	TORRENT PHARMS LTD	EQ 15MG BASE	A091298	001	Feb 13, 2013
		EQ 30MG BASE	A091298	002	Feb 13, 2013
		EQ 45MG BASE	A091298	003	Feb 13, 2013

PIPECURONIUM BROMIDE

INJECTABLE;INJECTION

ARDUAN

	ORGANON USA INC	10MG/VIAL	N019638	001	Jun 26, 1990

PIPERACETAZINE

TABLET;ORAL

QUIDE

	DOW PHARM	10MG	N013615	001	
		25MG	N013615	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PIPERACILLIN SODIUM

INJECTABLE;INJECTION					
PIPRACIL					
	WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750	001	Oct 13, 1987
+		EQ 2GM BASE/VIAL **	N050545	002	
		EQ 3GM BASE/VIAL	A062750	002	Oct 13, 1987
+		EQ 3GM BASE/VIAL **	N050545	003	
		EQ 4GM BASE/VIAL	A062750	003	Oct 13, 1987
+		EQ 4GM BASE/VIAL **	N050545	004	
+		EQ 40GM BASE/VIAL **	N050545	006	Sep 30, 1985

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION					
PIPERACILLIN AND TAZOBACTAM					
	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009
		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009
		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009
		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009
	MYLAN LABS LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014
		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014
		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014
ZOSYN					
+	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993
+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993
+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993
+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993

PIPERAZINE CITRATE

SYRUP;ORAL					
ANTEPAR					
	GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102	001	
BRYREL					
	SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796	001	
MULTIFUGE					
	BLULINE	EQ 500MG BASE/5ML	N009452	001	
PIPERAZINE CITRATE					
	ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774	001	
	LANNETT	EQ 500MG BASE/5ML	A080963	001	
	LUITPOLD	EQ 500MG BASE/5ML	A080671	001	
VERMIDOL					
	SOLVAY	EQ 500MG BASE/5ML	A080992	001	
TABLET;ORAL					
ANTEPAR					
	GLAXOSMITHKLINE	EQ 500MG BASE	N009102	003	
PIPERAZINE CITRATE					
	IMPAX LABS	EQ 250MG BASE	A080874	001	

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL;TOPICAL					
RID MOUSSE					
	BAYER HEALTHCARE LLC	4%;EQ 0.33% BASE	N021043	001	Mar 07, 2000

PIPOBROMAN

TABLET;ORAL					
VERCYTE					
	ABBOTT	10MG	N016245	001	
		25MG	N016245	002	

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION					
MAXAIR					
	BAUSCH	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986
		EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992

PIRFENIDONE

TABLET;ORAL					
ESBRIET					
+	GENENTECH INC	534MG **	N208780	002	Jan 11, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PIROXICAM

CAPSULE;ORAL

PIROXICAM

BRECKENRIDGE	10MG	A208991	001	Feb 21, 2018
	20MG	A208991	002	Feb 21, 2018
CYCLE PHARMS LTD	10MG	A073651	001	Feb 26, 1993
	20MG	A073651	002	Feb 26, 1993
EGIS	10MG	A074808	001	Jul 08, 1997
	20MG	A074808	002	Jul 08, 1997
IVAX SUB TEVA PHARMS	10MG	A074148	001	Jun 03, 1996
	20MG	A074148	002	Jun 03, 1996
MYLAN	10MG	A074043	001	Sep 22, 1992
	10MG	A074102	001	Jul 31, 1992
	20MG	A074043	002	Sep 22, 1992
	20MG	A074102	002	Jul 31, 1992
SCS	10MG	A074036	001	May 29, 1992
	20MG	A074036	002	May 29, 1992
SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008
	20MG	A073536	001	Mar 12, 1993
TEVA	10MG	A073637	001	Jan 28, 1994
	20MG	A073638	001	Jan 28, 1994
TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
	20MG	A074103	002	Aug 28, 1992
WATSON LABS	10MG	A074287	001	May 16, 1996
	10MG	A074460	001	Sep 29, 1995
	20MG	A074287	002	May 16, 1996
	20MG	A074460	002	Sep 29, 1995

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

MYLAN	EQ 1MG BASE	A206070	001	Apr 04, 2019
	EQ 2MG BASE	A206070	002	Apr 04, 2019
	EQ 4MG BASE	A206070	003	Apr 04, 2019

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

+	MEDICURE	EQ 1MG BASE	N208379	001	Jul 14, 2017

PITAVASTATIN SODIUM

TABLET;ORAL

NIKITA

+	LUPIN LTD	EQ 1MG BASE	N209875	001	Aug 04, 2017
+		EQ 2MG BASE	N209875	002	Aug 04, 2017
+		EQ 4MG BASE	N209875	003	Aug 04, 2017

PLICAMYCIN

INJECTABLE;INJECTION

MITHRACIN

PFIZER	2.5MG/VIAL	N050109	001	

PODOFILOX

SOLUTION;TOPICAL

PODOFILOX

BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010

POLYESTRADIOL PHOSPHATE

INJECTABLE;INJECTION

ESTRADURIN

WYETH AYERST	40MG/AMP	N010753	001	

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

LANNETT CO INC	17GM/SCOOPFUL	A076652	001	Jul 02, 2004
	17GM/PACKET	A090600	001	Oct 06, 2009
	17GM/SCOOPFUL	A090600	002	Oct 06, 2009

POLYETHYLENE GLYCOL 3350

BRECKENRIDGE PHARM	17GM/SCOOPFUL	A077736	001	May 26, 2006
NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706	001	Sep 27, 2006
PADDOCK LLC	17GM/SCOOPFUL	A077893	001	May 26, 2006
	17GM/SCOOPFUL	A090567	001	Oct 15, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

TEVA PHARMS	17GM/SCOOPFUL	A077445	001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

MYLAN	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090409	001	Apr 02, 2010
NOSTRUM LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A202060	001	Mar 08, 2017

TRILYTE

AUROBINDO PHARMA USA	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A076491	001	Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

CLENZ-LYTE

PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090769	001	Jun 07, 2010

SOLUTION;ORAL

OCL

HOSPIRA	6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML	N019284	001	Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

MYLAN SPECIALITY LP	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984
	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987
	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984

COLYTE-FLAVORED

MYLAN SPECIALITY LP	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991
	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991

GOLYTELY

+	BRAINTREE	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992

PEG 3350 AND ELECTROLYTES

MYLAN	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A090928	001	Jan 28, 2010

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090712	001	Feb 25, 2010

FOR SUSPENSION;ORAL

CO-LAV

VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A073428	001	Jan 28, 1992

COLOVAGE

DYNAPHARM	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	A071320	001	Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A071278	001	Nov 21, 1988

GLYCOPREP

GOLDLINE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A072319	001	Dec 23, 1988

GO-EVAC

VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073433	001	Apr 28, 1992

PEG-LYTE

SANDOZ	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A073098	001	Aug 31, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POLYMYXIN B SULFATE

INJECTABLE;INJECTION				
AEROSPORIN				
	GLAXOSMITHKLINE	EQ 500,000 UNITS BASE/VIAL	A062036 001	
POLYMYXIN B SULFATE				
	GLAND	EQ 500,000 UNITS BASE/VIAL	A207322 001	Apr 14, 2016
	HIKMA	EQ 500,000 UNITS BASE/VIAL	A060716 001	
	RISING PHARMA	EQ 500,000 UNITS BASE/VIAL	A090110 001	Jun 29, 2011
POWDER;FOR RX COMPOUNDING				
POLY-RX				
	X GEN PHARMS	100,000,000 UNITS/BOT	A061578 001	
POLYMYXIN B SULFATE				
	PADDOCK LLC	100,000,000 UNITS/BOT	A062455 001	Jul 27, 1983

POLYTHIAZIDE

TABLET;ORAL				
RENESE				
	PFIZER	1MG	N012845 001	
		2MG	N012845 002	
		4MG	N012845 003	

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL				
MINIZIDE				
	PFIZER	0.5MG;EQ 1MG BASE	N017986 001	
		0.5MG;EQ 2MG BASE	N017986 002	
		0.5MG;EQ 5MG BASE	N017986 003	

POLYTHIAZIDE; RESERPINE

TABLET;ORAL				
RENESE-R				
	PFIZER	2MG;0.25MG	N013636 001	

POMALIDOMIDE

CAPSULE;ORAL				
POMALIDOMIDE				
	BRECKENRIDGE	1MG	A210111 001	Oct 30, 2020
		2MG	A210111 002	Oct 30, 2020
		3MG	A210111 003	Oct 30, 2020
		4MG	A210111 004	Oct 30, 2020
	EUGIA PHARMA	1MG	A210249 001	Oct 30, 2020
		2MG	A210249 002	Oct 30, 2020
		3MG	A210249 003	Oct 30, 2020
		4MG	A210249 004	Oct 30, 2020

POSACONAZOLE

SUSPENSION;ORAL				
POSACONAZOLE				
	HIKMA	40MG/ML	A208773 001	May 15, 2020

POTASSIUM AMINOSALICYLATE

CAPSULE;ORAL				
PASKALIUM				
	GLENWOOD	500MG	N009395 004	
POWDER;ORAL				
POTASSIUM AMINOSALICYLATE				
	HEXCEL	100%	A080098 001	
TABLET;ORAL				
PASKALIUM				
	GLENWOOD	1GM	N009395 003	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
K-LEASE				
	SAVAGE LABS	8MEQ	A073398 001	Jan 28, 1992
		10MEQ	A072427 001	Mar 28, 1990
MICRO-K				
+	NESHER PHARMS	8MEQ **	N018238 001	
MICRO-K 10				
+	NESHER PHARMS	10MEQ **	N018238 002	May 14, 1984
POTASSIUM CHLORIDE				
	NESHER PHARMS	10MEQ	A070980 001	Feb 17, 1987
	TEVA	8MEQ	A073531 001	Apr 26, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
POTASSIUM CHLORIDE				
	10MEQ		A073532 001	Apr 26, 1996
FOR SOLUTION;ORAL				
POTASSIUM CHLORIDE				
STRIDES PHARMA	20MEQ		A211667 001	Mar 11, 2021
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
MICRO-K LS				
+ KV PHARM	20MEQ/PACKET **		N019561 003	Aug 26, 1988
INJECTABLE;INJECTION				
POTASSIUM CHLORIDE				
+ ABRAXIS PHARM	2MEQ/ML		A080204 001	
	2MEQ/ML		A084290 001	
	2MEQ/ML		A086713 001	
	2MEQ/ML		A086714 001	
	2MEQ/ML		A087787 001	Apr 20, 1982
	2MEQ/ML		A087885 001	Feb 03, 1983
AKORN	2MEQ/ML		A088286 001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML		A080203 001	
	2MEQ/ML		A085499 001	
FRESENIUS KABI USA	2MEQ/ML		A087817 001	Oct 20, 1982
GD SEARLE LLC	1MEQ/ML		A086219 001	
	2MEQ/ML		A086219 002	
	2MEQ/ML		A086220 002	
	3MEQ/ML		A086219 003	
	3MEQ/ML		A086220 001	
	4MEQ/ML		A086219 004	
HOSPIRA	1MEQ/ML		A080205 003	
	1MEQ/ML		A083345 003	
	1.5MEQ/ML		A083345 001	
	2MEQ/ML		A083345 002	
	2.4MEQ/ML		A080205 004	
	3.2MEQ/ML		A080205 005	
INTL MEDICATION	2MEQ/ML		A083163 001	
LILLY	2MEQ/ML		N007865 002	
LUITPOLD	2MEQ/ML		A080221 001	
	2MEQ/ML		A080736 001	
	2MEQ/ML		A087584 001	
	2MEQ/ML		A087585 001	
MILES	1MEQ/ML		A080195 002	
	2MEQ/ML		A080195 001	
	3MEQ/ML		A080195 003	
	4MEQ/ML		A080195 004	
PHARMA SERVE NY	2MEQ/ML		A086297 001	
	2MEQ/ML		A087362 001	Mar 08, 1983
WATSON LABS	2MEQ/ML		A086208 001	
	2MEQ/ML		A089163 001	Mar 10, 1988
	2MEQ/ML		A089421 001	Jan 02, 1987
	3MEQ/ML		A086210 001	
POTASSIUM CHLORIDE 10MEQ				
FRESENIUS KABI USA	14.9MG/ML		A211087 001	Sep 09, 2020
	746MG/100ML		A211087 002	Sep 09, 2020
POTASSIUM CHLORIDE 20MEQ				
FRESENIUS KABI USA	29.8MG/ML		A211087 003	Sep 09, 2020
	1.49GM/100ML		A211087 005	May 07, 2021
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	2.24GM/100ML		N020161 003	Aug 11, 1998
POTASSIUM CHLORIDE 40MEQ				
FRESENIUS KABI USA	2.98GM/100ML		A211087 004	Sep 09, 2020
TABLET, EXTENDED RELEASE;ORAL				
K+10				
FUTURE PAK	10MEQ		A070999 001	Oct 22, 1987
K+8				
FUTURE PAK	8MEQ		A070998 001	Jan 25, 1993
KAON CL				
SAVAGE LABS	6.7MEQ		N017046 001	
KAON CL-10				
SAVAGE LABS	10MEQ		N017046 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KLOTRIX					
	APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE					
	AMNEAL	15MEQ	A212861	002	May 08, 2020
	AMTA	10MEQ	A214395	001	Jan 28, 2021
		20MEQ	A214395	002	Jan 28, 2021
	AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021
		15MEQ	A214728	002	Mar 31, 2021
		20MEQ	A214728	003	Mar 31, 2021
	BRECKENRIDGE	10MEQ	A213588	001	Aug 21, 2020
		20MEQ	A213588	002	Aug 21, 2020
	COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
	NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
+	SCHERING	10MEQ **	N019439	002	Jun 13, 1986
+		20MEQ **	N019439	001	Jun 13, 1986
	SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016
		10MEQ	A207528	002	Aug 19, 2016
	STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019
		10MEQ	A206630	001	Mar 29, 2019
		10MEQ	A206881	002	Jan 22, 2019
		10MEQ	A210097	001	Jun 17, 2019
		15MEQ	A206630	002	Mar 29, 2019
		20MEQ	A206630	003	Mar 29, 2019
		20MEQ	A210098	001	Apr 26, 2019
SLOW-K					
	NOVARTIS	8MEQ	N017476	002	
TEN-K					
	NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	37MG/100ML;900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	75MG/100ML;900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	110MG/100ML;900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%					
	FRESENIUS KABI USA	150MG/100ML;450MG/100ML	A212347	001	Sep 17, 2020
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%					
	FRESENIUS KABI USA	150MG/100ML;900MG/100ML	A212347	003	Jun 02, 2021
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	220MG/100ML;900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%					
+	BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648	003	
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%					
	FRESENIUS KABI USA	300MG/100ML;900MG/100ML	A212347	002	Sep 17, 2020
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	B BRAUN	300MG/100ML;900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%					
	BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER					
	B BRAUN	75MG/100ML;900MG/100ML	N018722	001	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
	B BRAUN	150MG/100ML;900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER					
	B BRAUN	220MG/100ML;900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	B BRAUN	300MG/100ML;900MG/100ML	N018722	004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE;INJECTION

THAM-E				
	HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

POTASSIUM CITRATE				
FOR SOLUTION;ORAL				
POTASSIUM CITRATE				
+ UT SW MEDCTR	10MEQ/PACKET **	N019647	002	Oct 13, 1988
+	20MEQ/PACKET **	N019647	001	Oct 13, 1988
POTASSIUM IODIDE				
SOLUTION;ORAL				
POTASSIUM IODIDE				
+ ROXANE	1GM/ML **	N018551	001	Feb 19, 1982
THYROSHIELD				
ARCO PHARMS LLC	65MG/ML	A077218	001	Jan 12, 2005
TABLET;ORAL				
THYRO-BLOCK				
MEDA PHARMS	130MG	N018307	001	
POTASSIUM PERCHLORATE				
CAPSULE;ORAL				
PERCHLORACAP				
MALLINCKRODT	200MG	N017551	001	
POVIDONE-IODINE				
SOLUTION;TOPICAL				
E-Z PREP				
CLINIPAD	10%	N019382	001	Jul 25, 1989
SPONGE;TOPICAL				
E-Z PREP				
CLINIPAD	5%	N019382	002	Jul 25, 1989
E-Z PREP 220				
CLINIPAD	5%	N019382	003	Jul 25, 1989
PRALIDOXIME CHLORIDE				
INJECTABLE;INJECTION				
PRALIDOXIME CHLORIDE				
BAXTER HLTHCARE CORP	300MG/ML	N018799	001	Dec 13, 1982
SOLUTION;INTRAMUSCULAR				
PRALIDOXIME CHLORIDE (AUTOINJECTOR)				
+ MERIDIAN MEDCL TECHN	600MG/2ML (300MG/ML)	N018986	001	Apr 26, 1983
TABLET;ORAL				
PROTOPAM CHLORIDE				
WYETH AYERST	500MG	N014122	002	
PRAMIPEXOLE DIHYDROCHLORIDE				
TABLET;ORAL				
MIRAPEX				
BOEHRINGER INGELHEIM	1.25MG	N020667	004	Jul 01, 1997
PRAMIPEXOLE DIHYDROCHLORIDE				
ALEMBIC PHARMS LTD	0.125MG	A078894	001	Oct 08, 2010
	0.25MG	A078894	002	Oct 08, 2010
	0.5MG	A078894	003	Oct 08, 2010
	1MG	A078894	004	Oct 08, 2010
	1.5MG	A078894	005	Oct 08, 2010
HERITAGE PHARMA AVET	0.125MG	A077724	001	Feb 19, 2008
	0.125MG	A078551	001	Oct 08, 2010
	0.125MG	A090241	001	Oct 08, 2010
	0.125MG	A091254	001	Nov 30, 2010
	0.25MG	A077724	002	Feb 19, 2008
	0.25MG	A078551	002	Oct 08, 2010
	0.25MG	A090241	002	Oct 08, 2010
	0.25MG	A091254	002	Nov 30, 2010
	0.5MG	A077724	003	Feb 19, 2008
	0.5MG	A078551	003	Oct 08, 2010
	0.5MG	A090241	003	Oct 08, 2010
	0.5MG	A091254	003	Nov 30, 2010
	0.75MG	A090241	004	Oct 08, 2010
	0.75MG	A091254	004	Nov 30, 2010
	1MG	A077724	004	Feb 19, 2008
	1MG	A078551	004	Oct 08, 2010
	1MG	A090241	005	Oct 08, 2010
	1MG	A091254	005	Nov 30, 2010
	1.5MG	A077724	005	Feb 19, 2008
	1.5MG	A078551	005	Oct 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL					
PRAMIPEXOLE DIHYDROCHLORIDE					
		1.5MG	A090241	006	Oct 08, 2010
		1.5MG	A091254	006	Nov 30, 2010
	MACLEODS PHARMS LTD	0.125MG	A202164	001	Sep 20, 2012
		0.25MG	A202164	002	Sep 20, 2012
		0.5MG	A202164	003	Sep 20, 2012
		1MG	A202164	004	Sep 20, 2012
		1.5MG	A202164	005	Sep 20, 2012
	MYLAN	0.125MG	A077854	001	Oct 08, 2010
		0.25MG	A077854	002	Oct 08, 2010
		0.5MG	A077854	003	Oct 08, 2010
		0.75MG	A090764	001	Apr 09, 2010
		1MG	A077854	004	Oct 08, 2010
		1.5MG	A077854	005	Oct 08, 2010
	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010
		0.25MG	A091450	002	Oct 08, 2010
		0.5MG	A091450	003	Oct 08, 2010
		1MG	A091450	004	Oct 08, 2010
		1.5MG	A091450	005	Oct 08, 2010
	SANDOZ	0.125MG	A090190	001	Jul 06, 2010
		0.25MG	A090190	002	Jul 06, 2010
		0.5MG	A090190	003	Jul 06, 2010
		0.75MG	A090190	006	Oct 08, 2010
		1MG	A090190	004	Jul 06, 2010
		1.5MG	A090190	005	Jul 06, 2010
	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013
		0.25MG	A091683	002	Mar 27, 2013
		0.5MG	A091683	003	Mar 27, 2013
		0.75MG	A091683	004	Mar 27, 2013
		1MG	A091683	005	Mar 27, 2013
		1.5MG	A091683	006	Mar 27, 2013
	UNICHEM	0.125MG	A207011	001	Dec 19, 2018
		0.25MG	A207011	002	Dec 19, 2018
		0.5MG	A207011	003	Dec 19, 2018
		0.75MG	A207011	004	Dec 19, 2018
		1MG	A207011	005	Dec 19, 2018
		1.5MG	A207011	006	Dec 19, 2018
TABLET, EXTENDED RELEASE;ORAL					
PRAMIPEXOLE DIHYDROCHLORIDE					
	ALEMBIC PHARMS LTD	0.375MG	A204518	001	Jan 02, 2019
		0.75MG	A204518	002	Jan 02, 2019
		1.5MG	A204518	003	Jan 02, 2019
		2.25MG	A204518	004	Jan 02, 2019
		3MG	A204518	005	Jan 02, 2019
		3.75MG	A204518	006	Jan 02, 2019
		4.5MG	A204518	007	Jan 02, 2019

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS					
SYMLIN					
	ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005

PRASUGREL HYDROCHLORIDE

TABLET;ORAL					
PRASUGREL					
	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020
		EQ 10MG BASE	A205926	002	Jul 07, 2020

PRAVASTATIN SODIUM

TABLET;ORAL					
PRAVACHOL					
+	BRISTOL MYERS SQUIBB	10MG **	N019898	002	Oct 31, 1991
+		20MG	N019898	003	Oct 31, 1991
+		40MG	N019898	004	Mar 22, 1993
+		80MG	N019898	008	Dec 18, 2001
PRAVASTATIN SODIUM					
	HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018
		40MG	A206061	002	Nov 23, 2018
		80MG	A206061	003	Nov 23, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

MYLAN	10MG	A077013	001	Oct 23, 2006
	20MG	A077013	002	Oct 23, 2006
	40MG	A077013	003	Oct 23, 2006
	80MG	A077013	004	Dec 28, 2007
MYLAN PHARMS INC	10MG	A079187	001	May 27, 2010
	20MG	A079187	002	May 27, 2010
	40MG	A079187	003	May 27, 2010
	80MG	A079187	004	May 27, 2010
PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006
	20MG	A077730	002	Nov 21, 2006
	30MG	A077730	003	Nov 21, 2006
	40MG	A077730	005	Nov 21, 2006
RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007
	20MG	A076445	002	Apr 23, 2007
	40MG	A076445	003	Apr 23, 2007
	80MG	A076445	004	Apr 23, 2007
ZYDUS PHARMS USA	10MG	A077751	001	Apr 30, 2008

PRAZEPAM

CAPSULE;ORAL

CENTRAX

PARKE DAVIS	5MG	N018144	001	
	10MG	N018144	002	
	20MG	N018144	003	May 10, 1982

PRAZEPAM

USL PHARMA	5MG	A070427	001	Nov 06, 1987
	10MG	A070428	001	Nov 06, 1987

TABLET;ORAL

CENTRAX

PARKE DAVIS	10MG	N017415	001	

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP	EQ 1MG BASE	A072782	001	May 16, 1989
	EQ 2MG BASE	A072783	001	May 16, 1989
	EQ 5MG BASE	A072784	001	May 16, 1989
DAVA PHARMS INC	EQ 1MG BASE	A072705	001	May 16, 1989
	EQ 2MG BASE	A072706	001	May 16, 1989
	EQ 5MG BASE	A072707	001	May 16, 1989
PUREPAC PHARM	EQ 1MG BASE	A072991	001	May 16, 1989
	EQ 2MG BASE	A072921	001	May 16, 1989
	EQ 5MG BASE	A072992	001	May 16, 1989
WATSON LABS	EQ 1MG BASE	A072352	001	May 16, 1989
	EQ 2MG BASE	A072333	001	May 16, 1989
	EQ 5MG BASE	A072609	001	May 16, 1989

TABLET, EXTENDED RELEASE;ORAL

MINIPRESS XL

PFIZER	2.5MG	N019775	001	Jan 29, 1992
	5MG	N019775	002	Jan 29, 1992

PREDNICARBATE

CREAM;TOPICAL

DERMATOP E EMOLLIENT

+	VALEANT BERMUDA	0.1%	N020279	001	Oct 29, 1993

PREDNICARBATE

FOUGERA PHARMS	0.1%	A077287	001	Sep 19, 2006

OINTMENT;TOPICAL

DERMATOP

+	VALEANT PHARMS NORTH	0.1% **	N019568	001	Sep 23, 1991

PREDNISOLONE

CREAM;TOPICAL

METI-DERM

SCHERING	0.5%	N010209	002	

SYRUP;ORAL

PREDNISOLONE

IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE

SYRUP;ORAL				
PREDNISOLONE				
NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001
	15MG/5ML	A040364	001	Apr 10, 2002
PHARM ASSOC	5MG/5ML	A040570	001	Aug 25, 2005
	15MG/5ML	A040571	001	Aug 25, 2005
TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000
WE PHARMS	15MG/5ML	A040192	001	May 28, 1998
PRELONE				
MURO	5MG/5ML	A089654	001	Jan 17, 1989
TABLET;ORAL				
CORTALONE				
HALSEY	1MG	A080304	003	
	2.5MG	A080304	002	
	5MG	A080304	001	
DELTA-CORTEF				
PHARMACIA AND UPJOHN	5MG	N009987	004	
FERNISOLONE-P				
FERNDALE LABS	5MG	A083941	001	
PREDNISOLONE				
BARR	5MG	A084426	002	
BUNDY	5MG	A083675	001	
CHARTWELL RX	5MG	A084542	001	
ELKINS SINN	5MG	A080625	001	
EVERYLIFE	1MG	A084439	001	
	2.5MG	A084439	002	
	5MG	A084439	003	
FERRANTE	2.5MG	A080562	001	
	5MG	A080562	002	
FOSUN PHARMA	5MG	A080339	001	
HEATHER	5MG	A080326	001	
IMPAX LABS	5MG	A080780	001	
INWOOD LABS	5MG	A080748	001	
IVAX SUB TEVA PHARMS	5MG	A080378	001	
LANNETT	5MG	A080531	002	
MARSHALL PHARMA	5MG	A080307	001	
PANRAY	1MG	A080351	001	
	5MG	A080351	002	
PHOENIX LABS NY	5MG	A080322	001	
PUREPAC PHARM	5MG	A080325	001	
PVT FORM	5MG	A080211	001	
RISING	5MG	A084773	001	
ROXANE	5MG	A080327	002	
SPERTI	1MG	A080358	001	
	2.5MG	A080358	002	
	5MG	A080358	003	
SUPERPHARM	5MG	A088892	001	Feb 26, 1985
TABLICAPS	5MG	A085170	001	
TEVA	5MG	A080398	001	
UDL	5MG	A087987	001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001	
VITARINE	5MG	A080534	001	
WATSON LABS	5MG	A085085	002	
	5MG	A085415	001	
	5MG	A085416	001	
WEST WARD	5MG	A080324	001	
WHITEWORTH TOWN PLSN	5MG	A080342	001	
STERANE				
PFIZER	5MG	N009996	001	

PREDNISOLONE ACETATE

INJECTABLE;INJECTION				
METICORTELONE				
SCHERING	25MG/ML	N010255	002	
PREDNISOLONE ACETATE				
AKORN	25MG/ML	A083032	001	
	50MG/ML	A084492	001	
BEL MAR	25MG/ML	A083738	001	
	50MG/ML	A083738	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE ACETATE

INJECTABLE;INJECTION			
PREDNISOLONE ACETATE			
CENT PHARMS	25MG/ML	A084717 001	
	50MG/ML	A084717 002	
WATSON LABS	25MG/ML	A083398 001	
	25MG/ML	A083654 001	
	40MG/ML	A083767 001	
	50MG/ML	A083764 001	
	50MG/ML	A085781 001	
STERANE			
PFIZER	25MG/ML	N011446 001	
SUSPENSION;ORAL			
FLO-PRED			
TARO	EQ 5MG BASE/5ML	N022067 001	Jan 17, 2008
	EQ 15MG BASE/5ML	N022067 002	Jan 17, 2008
SUSPENSION/DROPS;OPHTHALMIC			
ECONOPRED			
EYEVANCE	0.125%	N017468 001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC			
CETAPRED			
ALCON	0.25%;10%	A087771 001	Aug 06, 1993
METIMYD			
SCHERING	0.5%;10%	N010210 002	Sep 09, 1984
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	A088032 001	Apr 15, 1983
VASOCIDIN			
NOVARTIS	0.5%;10%	A088791 001	Oct 05, 1984
SUSPENSION;OPHTHALMIC			
ISOPTO CETAPRED			
ALCON	0.25%;10%	A087547 001	
SUSPENSION/DROPS;OPHTHALMIC			
METIMYD			
SCHERING	0.5%;10%	N010210 001	
PREDAMIDE			
AKORN	0.5%;10%	A088059 001	Jul 29, 1983
PREDSULFAIR			
PHARMAFAIR	0.5%;10%	A088007 001	Apr 19, 1983
PREDSULFAIR II			
PHARMAFAIR	0.2%;10%	A088837 001	Dec 24, 1985
SULPHRIN			
BAUSCH AND LOMB	0.5%;10%	A088089 001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE;INJECTION			
HYDELTRASOL			
MERCK	EQ 20MG PHOSPHATE/ML	N011583 002	
PREDNISOLONE SODIUM PHOSPHATE			
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517 001	
OINTMENT;OPHTHALMIC, OTIC			
HYDELTRASOL			
MERCK	EQ 0.25% PHOSPHATE	N011028 001	
SOLUTION;ORAL			
ORAPRED			
CONCORDIA PHARMS INC	EQ 15MG BASE/5ML **	A075117 001	Dec 14, 2000
PREDNISOLONE SODIUM PHOSPHATE			
AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345 001	Mar 10, 2009
BAUSCH	EQ 15MG BASE/5ML	A075250 001	Jul 12, 2002
NESHER PHARMS	EQ 5MG BASE/5ML	A076982 001	May 24, 2005
	EQ 15MG BASE/5ML	A076988 001	May 24, 2005
PHARM ASSOC	EQ 5MG BASE/5ML	A076123 001	Dec 23, 2002
VINTAGE	EQ 15MG BASE/5ML	A079010 001	May 26, 2009
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416 001	Oct 31, 2007
WE PHARMS	EQ 5MG BASE/5ML	A075181 001	Dec 23, 2002
SOLUTION/DROPS;OPHTHALMIC			
INFLAMASE FORTE			
+ NOVARTIS	EQ 0.9% PHOSPHATE	A080751 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISOLONE SODIUM PHOSPHATE				
SOLUTION/DROPS;OPHTHALMIC				
INFLAMASE MILD				
+	NOVARTIS	EQ 0.11% PHOSPHATE	A080751 001	
METRETON				
	SCHERING	EQ 0.5% PHOSPHATE	A083834 001	
PREDAIR				
	PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415 001	Feb 29, 1984
PREDAIR FORTE				
	PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165 001	Mar 28, 1983
PREDNISOLONE SODIUM PHOSPHATE				
	AKORN	EQ 0.11% PHOSPHATE	A083358 001	
		EQ 0.9% PHOSPHATE	A083358 002	
	ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043 001	Oct 24, 1991
		EQ 0.9% PHOSPHATE	A081044 001	Oct 24, 1991
	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065 001	Jul 29, 1994
	SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171 001	
		EQ 0.9% PHOSPHATE	A084168 001	
		EQ 0.9% PHOSPHATE	A084169 001	
		EQ 0.9% PHOSPHATE	A084172 001	
TABLET, ORALLY DISINTEGRATING;ORAL				
PREDNISOLONE SODIUM PHOSPHATE				
	MYLAN PHARMS INC	EQ 10MG BASE	A202179 001	Apr 10, 2013
		EQ 15MG BASE	A202179 002	Apr 10, 2013
		EQ 30MG BASE	A202179 003	Apr 10, 2013
PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE				
	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630 001	May 27, 1993
SULSTER				
	AKORN	EQ 0.23% PHOSPHATE;10%	A074511 001	Jul 30, 1996
VASOCIDIN				
+	NOVARTIS	EQ 0.23% PHOSPHATE;10% **	N018988 001	Aug 26, 1988
PREDNISOLONE TEBUTATE				
INJECTABLE;INJECTION				
HYDELTRA-TBA				
	MERCK	20MG/ML	N010562 001	
PREDNISOLONE TEBUTATE				
	WATSON LABS	20MG/ML	A083362 001	Feb 17, 1984
PREDNISONE				
SOLUTION;ORAL				
PREDNISONE				
	WOCKHARDT	5MG/5ML	A089726 001	Aug 02, 1988
SYRUP;ORAL				
LIQUID PRED				
	MURO	5MG/5ML	A087611 002	Sep 07, 1982
TABLET;ORAL				
CORTAN				
	HALSEY	20MG	A087480 001	
DELTA-DOME				
	BAYER PHARMS	5MG	A080293 001	
DELTASONE				
+	PHARMACIA AND UPJOHN	2.5MG **	N009986 005	
+		5MG **	N009986 002	
+		10MG **	N009986 006	
+		20MG **	N009986 007	
+		50MG **	N009986 008	
FERNISONE				
	FERNDALE LABS	5MG	A083364 001	
METICORTEN				
+	SCHERING	1MG **	N009766 002	
+		5MG **	N009766 001	
ORASONE				
	SOLVAY	1MG	A083009 001	
		5MG	A083009 002	
		10MG	A083009 003	
		20MG	A083009 004	
		50MG	A085999 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISONE

TABLET;ORAL

PARACORT				
PARKE DAVIS	5MG	N010962	002	
PREDNICEN-M				
SCHWARZ PHARMA	5MG	A084655	001	
PREDNISONE				
AM THERAP	5MG	A089387	001	Nov 06, 1986
	10MG	A089388	001	Nov 06, 1986
	20MG	A089389	001	Nov 06, 1986
AMNEAL PHARMS NY	5MG	A089597	001	Oct 05, 1987
	10MG	A089598	001	Oct 05, 1987
	20MG	A089599	001	Oct 05, 1987
BUNDY	5MG	A083676	001	
CHARTWELL RX	5MG	A083059	001	
CONTRACT PHARMACAL	5MG	A080209	001	
DURAMED PHARMS BARR	5MG	A088394	001	Oct 04, 1983
	10MG	A088395	001	Oct 04, 1983
	20MG	A088396	001	Oct 04, 1983
ELKINS SINN	5MG	A080491	001	
	20MG	A085811	001	
EVERYLIFE	1MG	A084440	001	
	2.5MG	A084440	002	
	5MG	A084440	003	
FERRANTE	2.5MG	A080563	001	
	5MG	A080563	002	
HALSEY	5MG	A080300	001	
HEATHER	5MG	A080320	001	
	10MG	A084341	001	
	20MG	A084417	001	
	20MG	A085543	001	
	50MG	A086946	001	
HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010
	2.5MG	A040538	001	Jan 08, 2004
	50MG	A088465	001	Jun 01, 1984
IMPAX LABS	5MG	A080782	001	
INWOOD LABS	1MG	A080328	001	
	2.5MG	A080306	001	
	5MG	A080279	001	
IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LANNETT	5MG	A080514	001	
	20MG	A084275	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	
	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
RISING	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PREDNISONE

TABLET;ORAL				
PREDNISONE				
	SCHERER LABS	5MG	A080371 001	
	SPERTI	1MG	A080359 001	
		2.5MG	A080359 002	
		5MG	A080359 003	
	SUN PHARM INDUSTRIES	50MG	A086596 001	
	SUPERPHARM	5MG	A088865 001	Oct 25, 1984
		10MG	A088866 001	Oct 25, 1984
		20MG	A088867 001	Oct 25, 1984
	TEVA	5MG	A080397 001	
	UDL	5MG	A087984 001	Jan 18, 1983
		10MG	A087985 001	Jan 18, 1983
		20MG	A087986 001	Jan 18, 1983
	UPSHER SMITH	5MG	A087471 001	
		20MG	A087470 001	
	VALEANT PHARM INTL	5MG	A080237 001	
	VANGARD	5MG	A087682 001	Jan 15, 1982
		20MG	A087701 001	Jan 15, 1982
	VITARINE	5MG	A080334 001	
		5MG	A080506 001	
	WATSON LABS	5MG	A085084 002	
		10MG	A087773 001	Jul 13, 1982
		20MG	A086813 001	
		50MG	A086867 001	
		50MG	A087772 001	Jul 13, 1982
	WHITEWORTH TOWN PLSN	2.5MG	A084913 001	
		5MG	A080343 001	
		10MG	A089028 001	Jul 24, 1986
		20MG	A084913 002	
SERVISONE				
	LEDERLE	5MG	A080223 001	
TABLET, DELAYED RELEASE;ORAL				
PREDNISONE				
	ACTAVIS LABS FL INC	1MG	A204867 001	Apr 25, 2017
		2MG	A204867 002	Apr 25, 2017
		5MG	A204867 003	Apr 25, 2017

PREGABALIN

CAPSULE;ORAL				
PREGABALIN				
	MYLAN	25MG	A091228 001	Sep 20, 2019
		50MG	A091228 002	Sep 20, 2019
		75MG	A091228 003	Sep 20, 2019
		100MG	A091228 004	Sep 20, 2019
		150MG	A091228 005	Sep 20, 2019
		200MG	A091228 006	Sep 20, 2019
		225MG	A091228 007	Sep 20, 2019
		300MG	A091228 008	Sep 20, 2019
TABLET, EXTENDED RELEASE;ORAL				
PREGABALIN				
	ALVOGEN	82.5MG	A211687 001	Jul 06, 2021
		165MG	A211687 002	Jul 06, 2021
		330MG	A211687 003	Jul 06, 2021
	MYLAN	330MG	A211431 001	Jul 02, 2021

PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
CITANEST				
+	ASTRAZENECA	1% **	N014763 004	
+		2% **	N014763 005	
+		3% **	N014763 003	
CITANEST PLAIN				
+	ASTRAZENECA	4% **	N014763 007	
CITANEST PLAIN DENTAL				
+	DENTSPLY PHARM	4%	N021382 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PRIMAQUINE PHOSPHATE				
TABLET;ORAL				
PRIMAQUINE PHOSPHATE				
ALVOGEN	EQ 15MG BASE	A203924	001	Feb 03, 2014
PRIMIDONE				
SUSPENSION;ORAL				
MYSOLINE				
+ NURO PHARMA	250MG/5ML	N010401	001	
TABLET;ORAL				
PRIMIDONE				
DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA INTL PHARMS	50MG	A040667	001	Jul 27, 2006
	250MG	A040667	002	Jul 27, 2006
IMPAX LABS	50MG	A040717	001	Feb 12, 2008
	250MG	A040717	002	Feb 12, 2008
WATSON LABS	250MG	A085052	001	
PROBENECID				
TABLET;ORAL				
BENEMID				
+ MERCK	500MG **	N007898	004	
PROBENECID				
IVAX SUB TEVA PHARMS	500MG	A083740	001	May 09, 1984
LEDERLE	500MG	A086917	001	
MYLAN	500MG	A084211	002	
WATSON LABS	500MG	A086150	002	Apr 23, 1982
PROBUCOL				
TABLET;ORAL				
LORELCO				
SANOFI AVENTIS US	250MG	N017535	001	
	500MG	N017535	002	Jul 06, 1988
PROCAINAMIDE HYDROCHLORIDE				
CAPSULE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS	250MG	A089219	001	Jul 01, 1986
	375MG	A089219	002	Jul 01, 1986
	500MG	A089219	003	Jul 01, 1986
ASCOT	250MG	A087542	001	Jan 08, 1982
	375MG	A087697	001	Mar 01, 1983
	500MG	A087543	001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604	001	
	375MG	A084595	001	
	500MG	A084606	001	
LANNETT	250MG	A083693	001	
	500MG	A084696	001	
LEDERLE	250MG	A086942	001	
	375MG	A086952	001	
	500MG	A086943	001	
ROXANE	250MG	A088989	001	Apr 26, 1985
	500MG	A088990	001	Apr 26, 1985
VANGARD	250MG	A087643	001	Jun 01, 1982
	500MG	A087875	001	Jun 01, 1982
WATSON LABS	250MG	A083287	001	
	250MG	A083795	001	
	250MG	A085167	001	
	375MG	A084403	001	
	375MG	A087020	001	
	500MG	A084280	001	
	500MG	A084357	001	
	500MG	A087021	001	
PROCAN				
PARKE DAVIS	250MG	A085804	001	
	375MG	A087502	001	
	500MG	A085079	001	
PROCAPAN				
PANRAY	250MG	A083553	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL				
PRONESTYL				
+ APOTHECON	250MG **	N007335 001		
+	375MG **	N007335 004		
+	500MG **	N007335 003		
INJECTABLE;INJECTION				
PROCAINAMIDE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML	A089415 001	Nov 17, 1986	
	500MG/ML	A089416 001	Nov 17, 1986	
HOSPIRA	500MG/ML	A089537 001	Aug 25, 1987	
INTL MEDICATION	500MG/ML	A088637 001	Jul 31, 1984	
PHARMAFAIR	100MG/ML	A088824 001	Nov 20, 1985	
	500MG/ML	A088830 001	Nov 20, 1985	
SMITH AND NEPHEW	100MG/ML	A088530 001	Mar 04, 1985	
	500MG/ML	A088531 001	Mar 04, 1985	
SOLOPAK	500MG/ML	A088532 001	Mar 04, 1985	
WARNER CHILCOTT	100MG/ML	A089528 001	May 03, 1988	
	500MG/ML	A089529 001	May 03, 1988	
WATSON LABS	100MG/ML	A087079 001		
	500MG/ML	A087080 001		
WEST-WARD PHARMS INT	100MG/ML	A089029 001	Apr 17, 1986	
	500MG/ML	A089030 001	Apr 17, 1986	
PRONESTYL				
+ APOTHECON	100MG/ML **	N007335 002		
+	500MG/ML **	N007335 005		
TABLET;ORAL				
PRONESTYL				
APOTHECON	250MG	N017371 001		
	375MG	N017371 002		
	500MG	N017371 003		
TABLET, EXTENDED RELEASE;ORAL				
PROCAINAMIDE HYDROCHLORIDE				
ANI PHARMS	250MG	A088958 001	Dec 02, 1985	
	250MG	A089369 001	Aug 14, 1987	
	500MG	A088959 001	Dec 02, 1985	
	500MG	A088974 001	Jul 22, 1985	
	500MG	A089369 002	Jan 09, 1987	
	750MG	A089369 003	Aug 14, 1987	
	750MG	A089438 001	Mar 23, 1987	
	1GM	A040111 001	Dec 13, 1996	
INWOOD LABS	500MG	A089840 001	Mar 06, 1989	
SANDOZ	500MG	A089284 001	Jun 23, 1986	
WATSON LABS	250MG	A088533 001	Dec 03, 1984	
	250MG	A089026 001	Oct 22, 1985	
	500MG	A088534 001	Dec 03, 1984	
	500MG	A089027 001	Oct 22, 1985	
	750MG	A088535 001	Nov 03, 1984	
	750MG	A089042 001	Oct 22, 1985	
	1GM	A089520 001	Jan 15, 1987	
PROCAN SR				
+ PARKE DAVIS	250MG	A086468 001		
+ PARKEDALE	500MG	A086065 001		
+	750MG	A087510 001	Apr 01, 1982	
	1GM	A088489 001	Jan 16, 1985	
PROCANBID				
KING PHARMS	500MG	N020545 001	Jan 31, 1996	
	1GM	N020545 002	Jan 31, 1996	
PRONESTYL-SR				
APOTHECON	500MG	A087361 001		

PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
NOVOCAIN				
HOSPIRA	1%	A085362 003		
	2%	A085362 004		
	10%	A086797 001		
PROCAINE HYDROCHLORIDE				
ABRAXIS PHARM	1%	A080384 002		
	1%	A080421 001		

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PROCAINE HYDROCHLORIDE				
		2%	A080384 003	
		2%	A080421 002	
	BEL MAR	1%	A080711 001	
		2%	A080756 001	
	ELKINS SINN	1%	A083315 001	
		2%	A083315 002	
	GD SEARLE LLC	1%	A086202 001	
		2%	A086202 002	
	HOSPIRA	1%	A080416 001	
		2%	A080416 002	
	MILES	1%	A080415 001	
		2%	A080415 002	
	WATSON LABS	1%	A080658 001	
		1%	A083535 001	
		2%	A080658 002	
		2%	A083535 002	

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION				
ACHROMYCIN				
	LEDERLE	40MG/VIAL;100MG/VIAL	N050276 001	
		40MG/VIAL;250MG/VIAL	N050276 003	
TETRACYN				
	PFIZER	40MG/VIAL;100MG/VIAL	A060285 002	
		40MG/VIAL;250MG/VIAL	A060285 003	

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE;INJECTION				
DICURIN PROCAINE				
	LILLY	100MG/ML;50MG/ML	N008869 001	

PROCHLORPERAZINE

SUPPOSITORY;RECTAL				
COMPAZINE				
	GLAXOSMITHKLINE	2.5MG **	N011127 003	
		5MG **	N011127 001	
		25MG **	N011127 002	
PROCHLORPERAZINE				
	ABLE	2.5MG	A040407 001	Jul 11, 2001
		5MG	A040407 002	Jul 11, 2001
		25MG	A040407 003	Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE;ORAL				
COMPAZINE				
+	GLAXOSMITHKLINE	EQ 10MG BASE/ML	N011276 001	
PROCHLORPERAZINE				
	ALPHARMA US PHARMS	EQ 10MG BASE/ML	A087153 001	Jun 08, 1982
PROCHLORPERAZINE EDISYLATE				
	MORTON GROVE	EQ 10MG BASE/ML	A088598 001	Oct 25, 1984
INJECTABLE;INJECTION				
COMPAZINE				
+	GLAXOSMITHKLINE	EQ 5MG BASE/ML **	N010742 002	
PROCHLORPERAZINE				
	BAXTER HLTHCARE	EQ 5MG BASE/ML	A087759 001	Oct 01, 1982
PROCHLORPERAZINE EDISYLATE				
	HIKMA	EQ 5MG BASE/ML	A089523 001	May 03, 1988
	HOSPIRA	EQ 5MG BASE/ML	A089703 001	Apr 07, 1988
	MARSAM PHARMS LLC	EQ 5MG BASE/ML	A089675 001	Dec 05, 1988
	SMITH AND NEPHEW	EQ 5MG BASE/ML	A089251 001	Dec 04, 1986
	TEVA PARENTERAL	EQ 5MG BASE/ML	A040505 001	May 30, 2003
	WATSON LABS	EQ 5MG BASE/ML	A089530 001	Jul 08, 1987
		EQ 5MG BASE/ML	A089605 001	Jul 08, 1987
		EQ 5MG BASE/ML	A089606 001	Jul 08, 1987
	WYETH AYERST	EQ 5MG BASE/ML	A086348 001	
SYRUP;ORAL				
COMPAZINE				
	GLAXOSMITHKLINE	EQ 5MG BASE/5ML	N011188 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROCHLORPERAZINE EDISYLATE

SYRUP;ORAL				
PROCHLORPERAZINE EDISYLATE				
ALPHARMA US PHARMS	EQ 5MG BASE/5ML	A087154	001	Sep 01, 1982
MORTON GROVE	EQ 5MG BASE/5ML	A088597	001	Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL				
COMPAZINE				
GLAXOSMITHKLINE	EQ 10MG BASE	N011000	001	
	EQ 10MG BASE	N021019	001	Oct 06, 1999
	EQ 15MG BASE	N011000	002	
	EQ 15MG BASE	N021019	002	Oct 06, 1999
	EQ 30MG BASE	N011000	003	
	EQ 75MG BASE	N011000	004	
TABLET;ORAL				
COMPAZINE				
+ GLAXOSMITHKLINE	EQ 5MG BASE **	N010571	001	
+	EQ 10MG BASE **	N010571	002	
+	EQ 25MG BASE **	N010571	003	
PROCHLORPERAZINE				
WATSON LABS	EQ 5MG BASE	A085580	001	
	EQ 10MG BASE	A085178	001	
	EQ 25MG BASE	A085579	001	
PROCHLORPERAZINE MALEATE				
DURAMED PHARMS BARR	EQ 5MG BASE	A040207	001	May 01, 1997
	EQ 5MG BASE	A089484	001	Jan 20, 1987
	EQ 10MG BASE	A040207	002	May 01, 1997
	EQ 10MG BASE	A089485	001	Jan 20, 1987
	EQ 25MG BASE	A089486	001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162	001	Jan 20, 1998
	EQ 10MG BASE	A040162	002	Jan 20, 1998
SANDOZ	EQ 5MG BASE	A040101	001	Jul 19, 1996
	EQ 10MG BASE	A040101	002	Jul 19, 1996
	EQ 25MG BASE	A040101	003	Jul 19, 1996
TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996
	EQ 10MG BASE	A040120	002	Jul 11, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL				
KEMADRIN				
MONARCH PHARMS	2MG	N009818	005	
	5MG	N009818	003	

PROGESTERONE

CAPSULE;ORAL				
PROGESTERONE				
TEVA PHARMS	100MG	A202121	001	Feb 29, 2012
	200MG	A202121	002	Feb 29, 2012
PROMETRIUM				
VIRTUS PHARMS	300MG	N019781	003	Oct 15, 1999
INJECTABLE;INJECTION				
PROGESTERONE				
AM REGENT	50MG/ML	A090845	001	Jun 22, 2009
LILLY	25MG/ML	N009238	002	
	50MG/ML	N009238	001	
INSERT, EXTENDED RELEASE;INTRAUTERINE				
PROGESTASERT				
ALZA	38MG	N017553	001	
SYSTEM;VAGINAL				
MILPROSA				
+ FERRING PHARMS INC	1.78GM	N201110	001	Apr 29, 2020

PROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL				
SPARINE				
WYETH AYERST	30MG/ML	N010942	001	
	100MG/ML	N010942	004	
INJECTABLE;INJECTION				
PROMAZINE HYDROCHLORIDE				
WATSON LABS	25MG/ML	A084510	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PROMAZINE HYDROCHLORIDE				
	50MG/ML	A084517	001	
SPARINE				
BAXTER HLTHCARE CORP	25MG/ML	N010349	008	
	50MG/ML	N010349	006	
SYRUP;ORAL				
SPARINE				
WYETH AYERST	10MG/5ML	N010942	003	
TABLET;ORAL				
SPARINE				
WYETH AYERST	10MG	N010348	006	
	25MG	N010348	001	
	50MG	N010348	002	
	100MG	N010348	003	
	200MG	N010348	004	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
PHENERGAN				
WYETH AYERST	25MG/ML	N008857	002	
	50MG/ML	N008857	003	
PROMETHAZINE HYDROCHLORIDE				
ABBOTT	25MG/ML	A084223	001	
	50MG/ML	A084222	001	
AKORN	25MG/ML	A083955	002	
	50MG/ML	A083955	001	
AM REGENT	25MG/ML	A040515	001	Mar 19, 2003
BEDFORD LABS	25MG/ML	A040524	001	Mar 17, 2004
	50MG/ML	A040524	002	Mar 17, 2004
HOSPIRA	25MG/ML	A040372	001	Jun 08, 2000
	50MG/ML	A040372	002	Jun 08, 2000
	50MG/ML	A083838	002	
MARSAM PHARMS LLC	25MG/ML	A089463	001	May 02, 1988
	50MG/ML	A089477	001	May 02, 1988
MYLAN INSTITUTIONAL	25MG/ML	A040471	001	Nov 21, 2002
SANDOZ	25MG/ML	A040593	001	Nov 08, 2006
	50MG/ML	A040593	002	Nov 08, 2006
TEVA PHARMS USA	25MG/ML **	A040454	001	Aug 22, 2002
	50MG/ML **	A040454	002	Aug 22, 2002
WATSON LABS	25MG/ML	A083532	001	
	25MG/ML	A084591	001	
	50MG/ML	A080629	002	
	50MG/ML	A083532	002	
WOCKHARDT	25MG/ML	A040785	001	Sep 26, 2008
	50MG/ML	A040785	002	Sep 26, 2008
ZIPAN-25				
ALTANA	25MG/ML	A083997	001	
ZIPAN-50				
ALTANA	50MG/ML	A083997	002	
SUPPOSITORY;RECTAL				
PHENERGAN				
+ MYLAN	12.5MG **	N010926	002	
+	25MG **	N010926	001	
+	50MG **	N011689	001	
PROMETHACON				
POLYMEDICA	25MG	A084901	001	
	50MG	A084902	001	
PROMETHAZINE HYDROCHLORIDE				
ABLE	12.5MG	A040504	001	Apr 11, 2003
	25MG	A040504	002	Apr 11, 2003
	50MG	A040449	001	Feb 27, 2003
WATSON LABS INC	12.5MG	A040479	001	Jun 24, 2003
	25MG	A040479	002	Jun 24, 2003
SYRUP;ORAL				
MYMETHAZINE FORTIS				
USL PHARMA	25MG/5ML	A087996	001	Jan 18, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL				
PROMETH FORTIS				
	ALPHARMA US PHARMS	25MG/5ML	A084772 001	
PROMETH PLAIN				
	ACTAVIS MID ATLANTIC	6.25MG/5ML	A085953 001	
PROMETHAZINE				
	CENCI	6.25MG/5ML	A089013 001	Sep 20, 1985
PROMETHAZINE HYDROCHLORIDE				
	KV PHARM	6.25MG/5ML	A085388 001	
		25MG/5ML	A085385 001	
	PHARM ASSOC	6.25MG/5ML	A087518 001	
	WHITEWORTH TOWN PLSN	6.25MG/5ML	A086395 001	
PROMETHAZINE HYDROCHLORIDE PLAIN				
+	ANI PHARMS	6.25MG/5ML **	N008381 004	Apr 18, 1984
+		25MG/5ML **	N008381 003	
TABLET;ORAL				
PHENERGAN				
+	DELCOR ASSET CORP	12.5MG **	N007935 002	
+		25MG **	N007935 003	
+		50MG **	N007935 004	
PROMETHAZINE HYDROCHLORIDE				
	ABBOTT	12.5MG	A084160 001	
		25MG	A084166 001	
		50MG	A084539 001	
	ABLE	12.5MG	A040558 001	Jul 01, 2004
		25MG	A040558 002	Jul 01, 2004
		50MG	A040558 003	Jul 01, 2004
	IMPAX LABS	12.5MG	A040791 002	Feb 12, 2008
		25MG	A040791 003	Feb 12, 2008
		25MG	A084214 002	Jul 07, 1982
		50MG	A040791 001	May 20, 2008
	INVATECH	12.5MG	A084233 001	
		25MG	A085146 001	
		50MG	A085146 002	
	IVAX SUB TEVA PHARMS	12.5MG	A083604 001	
		25MG	A083603 001	
		50MG	A083613 001	
	LANNETT	12.5MG	A080949 001	
		25MG	A080949 002	
		50MG	A080949 003	
	MYLAN	12.5MG	A091054 001	Aug 30, 2011
		25MG	A091054 002	Aug 30, 2011
		50MG	A091054 003	Aug 30, 2011
	PVT FORM	12.5MG	A083214 001	
		25MG	A083658 001	
	SANDOZ	12.5MG	A084176 002	May 22, 2009
	SUN PHARM INDUSTRIES	12.5MG	A084555 001	
		25MG	A084554 001	
		50MG	A084557 001	
	TABLICAPS	12.5MG	A084080 001	
		25MG	A084027 001	
	TEVA	25MG	A089109 001	Sep 10, 1985
	WATSON LABS	12.5MG	A083401 001	
		12.5MG	A083712 001	
		12.5MG	A085986 001	
		25MG	A083204 001	
		25MG	A085684 001	
		50MG	A083403 001	
		50MG	A085664 001	
REMSED				
	BRISTOL MYERS SQUIBB	25MG	A083176 002	
		50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
PROPAFENONE HYDROCHLORIDE				
MYLAN	225MG	A203803	001	Apr 29, 2016
	325MG	A203803	002	Apr 29, 2016
	425MG	A203803	003	Apr 29, 2016
TABLET;ORAL				
PROPAFENONE HYDROCHLORIDE				
NESHER PHARMS	150MG	A076193	001	Feb 07, 2002
	225MG	A076193	002	Feb 07, 2002
	300MG	A076193	003	Feb 07, 2002
RYTHMOL				
+ GLAXOSMITHKLINE LLC	150MG **	N019151	001	Nov 27, 1989
+	225MG **	N019151	003	Nov 20, 1992
+	300MG **	N019151	002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE;INJECTION				
PRO-BANTHINE				
GD SEARLE LLC	30MG/VIAL	N008843	001	
TABLET;ORAL				
PRO-BANTHINE				
+ SHIRE	7.5MG **	N008732	003	
+	15MG **	N008732	002	
PROPANTHELINE BROMIDE				
ASCOT	15MG	A087663	001	Oct 25, 1982
HEATHER	15MG	A085780	001	
HIKMA	7.5MG	A080927	001	
	15MG	A080927	002	
IMPAX LABS	15MG	A084541	002	
MYLAN	15MG	A083706	001	
PAR PHARM	15MG	A088377	001	Dec 08, 1983
PVT FORM	15MG	A080977	001	
SANDOZ	15MG	A080928	001	
TABLICAPS	15MG	A084428	001	
WATSON LABS	15MG	A083029	002	
	15MG	A083151	001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC				
KAINAIR				
PHARMAFAIR	0.5%	A088087	001	Jun 07, 1983
OPHTHAINE				
+ APOTHECON	0.5% **	N008883	001	
OPHTHETIC				
+ ALLERGAN	0.5% **	N012583	001	
PARACAINE				
OPTOPICS	0.5%	A087681	001	Aug 05, 1982
PROPARACAINE HYDROCHLORIDE				
SOLA BARNES HIND	0.5%	A084144	001	
	0.5%	A084151	001	

PROPIOLACTONE

SOLUTION;IRRIGATION				
BETAPRONE				
FOREST LABS	N/A	N011657	001	

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
LARGON				
WEST-WARD PHARMS INT	20MG/ML	N012382	002	

PROPOFOL

INJECTABLE;INJECTION				
DIPRIVAN				
FRESENIUS KABI USA	10MG/ML	N019627	001	Oct 02, 1989
PROPOFOL				
TEVA PARENTERAL	10MG/ML	A075392	001	Sep 19, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL				
DARVON				
	XANODYNE PHARM	32MG	N010997 001	
		65MG	N010997 003	
DOLENE				
	HERITAGE PHARMS INC	65MG	A080530 001	
KESSO-GESIC				
	MK LABS	65MG	A083544 001	
PROPHENE 65				
	HALSEY	65MG	A083538 002	
PROPOXYPHENE HYDROCHLORIDE				
	ALRA	65MG	A083184 001	
	IMPAX LABS	65MG	A083317 001	
	IVAX SUB TEVA PHARMS	32MG	A083597 001	
	MUTUAL PHARM	65MG	A083186 001	
	MYLAN	32MG	A083528 001	
		65MG	A040569 001	Dec 16, 2004
		65MG	A083299 001	
	NEXGEN PHARMA INC	65MG	A083185 001	
	PAR PHARM	65MG	A080269 001	
	PUREPAC PHARM	65MG	A083278 001	
	PVT FORM	32MG	A083464 001	
		65MG	A083113 001	
	ROXANE	32MG	A083089 001	
		65MG	A083089 002	
	SANDOZ	32MG	A084014 001	
		65MG	A083125 002	
		65MG	A083688 001	
		65MG	A083870 002	
		65MG	A086495 001	
	TEVA	65MG	A088615 001	Oct 22, 1984
	VALEANT PHARM INTL	65MG	A080783 001	
	VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009
	WATSON LABS	65MG	A080908 002	
		65MG	A085190 001	
	WEST WARD	65MG	A083501 001	
	WHITEWORTH TOWN PLSN	65MG	A084551 001	
PROPOXYPHENE HYDROCHLORIDE 65				
	WARNER CHILCOTT	65MG	A083786 001	

PROPOXYPHENE NAPSYLATE

SUSPENSION;ORAL				
DARVON-N				
	AAIPHARMA LLC	50MG/5ML	N016861 001	
TABLET;ORAL				
DARVON-N				
	XANODYNE PHARM	100MG	N016862 002	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
PROPRANOLOL HYDROCHLORIDE				
	INWOOD LABS	60MG	A072499 001	Apr 11, 1989
		80MG	A072500 001	Apr 11, 1989
		120MG	A072501 001	Apr 11, 1989
		160MG	A072502 001	Apr 11, 1989
	MYLAN	60MG	A078022 001	Feb 15, 2007
		80MG	A078022 002	Feb 15, 2007
		120MG	A078022 003	Feb 15, 2007
		160MG	A078022 004	Feb 15, 2007
	UPSHER SMITH LABS	60MG	A078311 001	Mar 06, 2009
		80MG	A078311 002	Mar 06, 2009
		120MG	A078311 003	Mar 06, 2009
		160MG	A078311 004	Mar 06, 2009
CONCENTRATE;ORAL				
PROPRANOLOL HYDROCHLORIDE INTENSOL				
	ROXANE	80MG/ML	A071388 001	May 15, 1987
INJECTABLE;INJECTION				
PROPRANOLOL HYDROCHLORIDE				
+	BAXTER HLTHCARE CORP	1MG/ML **	N016419 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPRANOLOL HYDROCHLORIDE

INJECTABLE;INJECTION				
PROPRANOLOL HYDROCHLORIDE				
FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003
SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
	1MG/ML	A070137	001	Apr 15, 1986
SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986
SOLUTION;ORAL				
PROPRANOLOL HYDROCHLORIDE				
MORTON GROVE	20MG/5ML	A071984	001	Mar 03, 1989
	40MG/5ML	A071985	001	Mar 03, 1989
SUSPENSION;ORAL				
INDERAL				
WYETH AYERST	10MG/ML	N019536	001	Dec 12, 1986
TABLET;ORAL				
INDERAL				
+ WYETH PHARMS	10MG **	N016418	001	
+	20MG **	N016418	003	
+	40MG **	N016418	002	
+	60MG **	N016418	009	Oct 18, 1982
+	80MG **	N016418	004	
+	90MG **	N016418	010	Oct 18, 1982
PROPRANOLOL HYDROCHLORIDE				
ANI PHARMS	60MG	A071791	001	Jul 15, 1987
	90MG	A071977	001	Apr 06, 1988
DAVA PHARMS INC	10MG	A070125	001	Jul 30, 1985
	20MG	A070126	001	Jul 30, 1985
	40MG	A070127	001	Jul 30, 1985
	60MG	A071495	001	Dec 31, 1987
	80MG	A070128	001	Jul 30, 1985
	90MG	A071496	001	Dec 31, 1987
DURAMED PHARMS BARR	10MG	A070306	001	Sep 09, 1985
	20MG	A070307	001	Sep 09, 1985
	40MG	A070308	001	Sep 09, 1985
	60MG	A070309	001	Oct 01, 1986
	80MG	A070310	001	Sep 09, 1985
	90MG	A071327	001	Oct 01, 1986
IMPAX LABS INC	80MG	A071976	001	Apr 06, 1988
INTERPHARM	10MG	A071368	001	May 05, 1987
	20MG	A071369	001	May 05, 1987
	40MG	A071370	001	May 05, 1987
	80MG	A071371	001	May 05, 1987
IVAX SUB TEVA PHARMS	10MG	A072063	001	Jul 29, 1988
	20MG	A072066	001	Jul 29, 1988
	40MG	A072067	001	Jul 29, 1988
	60MG	A072068	001	Jul 29, 1988
	80MG	A072069	001	Jul 29, 1988
LEDERLE	10MG	A072117	001	Jun 23, 1988
	20MG	A072118	001	Jun 23, 1988
	40MG	A072119	001	Jun 23, 1988
	80MG	A072120	001	Jun 23, 1988
MYLAN	60MG	A072275	001	Jun 09, 1989
PUREPAC PHARM	10MG	A070814	001	Nov 03, 1986
	20MG	A070815	001	Nov 03, 1986
	40MG	A070816	001	Nov 03, 1986
	60MG	A070817	001	Nov 03, 1986
	80MG	A070757	001	Nov 03, 1986
ROXANE	10MG	A070516	001	Jul 07, 1986
	20MG	A070517	001	Jul 07, 1986
	40MG	A070518	001	Jul 07, 1986
	60MG	A070519	001	Sep 24, 1986
	80MG	A070520	001	Jul 07, 1986
	90MG	A070521	001	Sep 24, 1986
SANDOZ	10MG	A071658	001	Jul 05, 1988
	20MG	A071687	001	Jul 05, 1988
	40MG	A071688	001	Jul 05, 1988
	60MG	A072197	001	Jul 05, 1988
	80MG	A071689	001	Jul 05, 1988
	90MG	A072198	001	Jul 05, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL				
PROPRANOLOL HYDROCHLORIDE				
SCHERING	10MG	A070120	001	Aug 06, 1985
	20MG	A070121	001	Aug 06, 1985
	40MG	A070122	001	Aug 06, 1985
	60MG	A070123	001	Oct 29, 1986
	80MG	A070124	001	Aug 06, 1985
STRIDES PHARMA	90MG	A071288	001	Oct 22, 1986
SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	60MG	A070143	001	Jan 15, 1987
	60MG	A070178	002	Apr 23, 2018
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986
	20MG	A070549	001	Apr 11, 1986
	40MG	A070550	001	Apr 11, 1986
YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986
	20MG	A070664	001	Jun 13, 1986
	40MG	A070665	001	Jun 13, 1986
	60MG	A070666	001	Oct 10, 1986
	80MG	A070667	001	Jun 13, 1986

PROPYLIODONE

SUSPENSION;INTRATRACHEAL			
DIONOSIL AQUEOUS			
GLAXOSMITHKLINE	50%	N009309	001
DIONOSIL OILY			
GLAXOSMITHKLINE	60%	N009309	002

PROPYLTHIOURACIL

TABLET;ORAL			
PROPYLTHIOURACIL			
ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
ANI PHARMS	50MG	A080215	001
CHARTWELL RX	50MG	A084543	001
HALSEY	50MG	A080015	001
IMPAX LABS	50MG	A080159	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
SUN PHARM INDUSTRIES	50MG	A083982	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PROTAMINE SULFATE
INJECTABLE;INJECTION
PROTAMINE SULFATE

	HIKMA	10MG/ML	A089474	001	Nov 05, 1986
		10MG/ML	A089475	001	Nov 05, 1986
+	LILLY	10MG/ML **	N006460	002	
	PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
		250MG/VIAL	N007413	002	Aug 02, 1984

PROTEIN HYDROLYSATE
INJECTABLE;INJECTION
AMINOSOL 5%

	ABBVIE	5%	N005932	012	Jan 31, 1985

HYPROTIGEN 5%

	B BRAUN	5%	N006170	003	Jan 10, 1984

PROTIRELIN
INJECTABLE;INJECTION
THYPINONE

	ABBOTT	0.5MG/ML	N017638	001	

THYREL TRH

	FERRING	0.5MG/ML	N018087	001	

PROTOKYLOL HYDROCHLORIDE
TABLET;ORAL
VENTAIRE

	SANOFI AVENTIS US	2MG	A083459	001	

PROTRIPTYLINE HYDROCHLORIDE
TABLET;ORAL
VIVACTIL

	HERITAGE PHARMA AVET	5MG	A073644	001	Aug 24, 1995
		10MG	A073645	001	Aug 24, 1995
	TEVA WOMENS	5MG **	N016012	001	
		10MG **	N016012	002	

PSEUDOEPHEDRINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
NOVAFED

	SANOFI AVENTIS US	120MG	N017603	001	

SUDAFED 12 HOUR

+	GLAXOSMITHKLINE	120MG **	N017941	002	

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE;ORAL
ACTIFED

	GLAXOSMITHKLINE	120MG;5MG	N018996	001	Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

	KV PHARM	120MG;5MG	A071798	001	Mar 16, 1989

SYRUP;ORAL
ACTAHIST

	CENCI	30MG/5ML;1.25MG/5ML	A088344	001	Feb 09, 1984

HISTAFED

	CENCI	30MG/5ML;1.25MG/5ML	A088283	001	Apr 20, 1984

MYFED

	USL PHARMA	30MG/5ML;1.25MG/5ML	A088116	001	Mar 04, 1983

TRILITRON

	NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	A088474	001	Feb 12, 1985

TABLET;ORAL
ALLERFED

	PVT FORM	60MG;2.5MG	A088860	001	Jan 31, 1985

CORPHED

	FOSUN PHARMA	60MG;2.5MG	A088602	001	Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

	SANDOZ	60MG;2.5MG	A088193	001	May 17, 1983

TRILITRON

	NEWTRON PHARMS	60MG;2.5MG	A088515	001	Jan 09, 1985

TRIPHED

	TEVA	60MG;2.5MG	A088630	001	May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

	WATSON LABS	60MG;2.5MG	A088318	002	Jan 13, 1984
	WEST WARD	60MG;2.5MG	A088117	001	Apr 19, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	60MG;2.5MG	A085273	001	Dec 12, 1984
SUPERPHARM	60MG;2.5MG	A088578	001	Feb 21, 1985

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM	120MG;5MG	A072758	001	Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC	EQ 60MG HYDROCHLORIDE/5ML	N019401	001	Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+	SCHERING PLOUGH	120MG	N018191	001	

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS	30MG	A040512	002	Jul 20, 2005
	60MG	A040512	001	Oct 08, 2003
IMPAX LABS INC	60MG	A040457	001	Dec 26, 2002
SOLVAY	30MG	A089572	001	Nov 27, 1990
US ARMY	30MG	N020414	001	Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY	100MG/ML	A080854	001	

PYRIDOXINE HYDROCHLORIDE

AKORN	100MG/ML	A087967	001	Oct 01, 1982
BEL MAR	100MG/ML	A080761	001	
DELL LABS	50MG/ML	A083771	001	
	100MG/ML	A083772	001	
DR REDDYS	100MG/ML	A080572	001	
ELKINS SINN	100MG/ML	A080581	001	
LUITPOLD	100MG/ML	A080669	001	
MYLAN INSTITUTIONAL	100MG/ML	A204879	001	Jul 14, 2016
WATSON LABS	100MG/ML	A083760	001	

PYRILAMINE MALEATE

TABLET;ORAL

PYRILAMINE MALEATE

IMPAX LABS	25MG	A080808	001	
WATSON LABS	25MG	A085231	001	

PYRIMETHAMINE; SULFADOXINE

TABLET;ORAL

FANSIDAR

ROCHE	25MG;500MG	N018557	001	

PYRITHIONE ZINC

LOTION;TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT	0.3%	N019412	002	Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION;ORAL

POVAN

PARKE DAVIS	EQ 50MG BASE/5ML	N011964	001	

TABLET;ORAL

POVAN

PARKE DAVIS	EQ 50MG BASE	N012485	002	

QUAZEPAM

TABLET;ORAL

DORAL

GALT PHARMS	7.5MG	N018708	003	Feb 26, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUETIAPINE FUMARATE

TABLET;ORAL				
QUETIAPINE FUMARATE				
ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013
	EQ 50MG BASE	A201762	002	Feb 27, 2013
	EQ 100MG BASE	A201762	003	Feb 27, 2013
	EQ 150MG BASE	A201762	004	Feb 27, 2013
	EQ 200MG BASE	A201762	005	Feb 27, 2013
	EQ 300MG BASE	A201762	006	Feb 27, 2013
	EQ 400MG BASE	A201762	007	Feb 27, 2013
ALEMBIC PHARMS LTD	EQ 25MG BASE	A203390	001	Oct 28, 2014
	EQ 50MG BASE	A203390	002	Oct 28, 2014
	EQ 100MG BASE	A203390	003	Oct 28, 2014
	EQ 200MG BASE	A203390	004	Oct 28, 2014
	EQ 300MG BASE	A203390	005	Oct 28, 2014
	EQ 400MG BASE	A203390	006	Oct 28, 2014
JUBILANT GENERICS	EQ 25MG BASE	A203150	001	Nov 26, 2013
MYLAN PHARMS INC	EQ 25MG BASE	A090323	001	Mar 27, 2012
TORRENT PHARMS LTD	EQ 25MG BASE	A200363	001	Mar 27, 2012
	EQ 50MG BASE	A200363	002	Mar 27, 2012
	EQ 100MG BASE	A200363	003	Mar 27, 2012
	EQ 200MG BASE	A200363	004	Mar 27, 2012
	EQ 300MG BASE	A200363	005	Mar 27, 2012
	EQ 400MG BASE	A200363	006	Mar 27, 2012
SEROQUEL				
+ ASTRAZENECA	EQ 150MG BASE **	N020639	004	Dec 20, 1998
TABLET, EXTENDED RELEASE;ORAL				
QUETIAPINE FUMARATE				
AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018
ANCHEN PHARMS	EQ 150MG BASE	A090757	001	Dec 01, 2017
	EQ 200MG BASE	A090757	002	Dec 01, 2017
	EQ 300MG BASE	A090757	003	Dec 01, 2017
	EQ 400MG BASE	A090757	004	Dec 01, 2017
RISING	EQ 50MG BASE	A202228	001	Feb 02, 2021
	EQ 150MG BASE	A202228	002	Feb 02, 2021
	EQ 200MG BASE	A202228	003	Feb 02, 2021
	EQ 300MG BASE	A202228	004	Feb 02, 2021
	EQ 400MG BASE	A202228	005	Feb 02, 2021

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	EQ 5MG BASE	A076459	001	Dec 22, 2004
	EQ 10MG BASE	A076459	002	Dec 22, 2004
	EQ 20MG BASE	A076459	003	Dec 22, 2004
	EQ 40MG BASE	A076459	004	Dec 22, 2004
ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005
	EQ 10MG BASE	A076049	002	Jan 14, 2005
	EQ 20MG BASE	A076049	003	Jan 14, 2005
	EQ 40MG BASE	A076049	004	Jan 14, 2005
ANI PHARMS	EQ 5MG BASE	A075504	001	Aug 24, 2007
	EQ 10MG BASE	A075504	002	Aug 24, 2007
	EQ 20MG BASE	A075504	003	Aug 24, 2007
	EQ 40MG BASE	A075504	004	Aug 24, 2007
APOTEX INC	EQ 5MG BASE	A076240	001	Jan 26, 2006
	EQ 10MG BASE	A076240	002	Jan 26, 2006
	EQ 20MG BASE	A076240	003	Jan 26, 2006
	EQ 40MG BASE	A076240	004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036	001	Jan 28, 2005
	EQ 5MG BASE	A076694	001	Dec 23, 2004
	EQ 10MG BASE	A076036	002	Jan 28, 2005
	EQ 10MG BASE	A076694	002	Dec 23, 2004
	EQ 20MG BASE	A076036	003	Jan 28, 2005
	EQ 20MG BASE	A076694	003	Dec 23, 2004
	EQ 40MG BASE	A076036	004	Jan 28, 2005
	EQ 40MG BASE	A076694	004	Dec 23, 2004
SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004
	EQ 5MG BASE	A090800	001	Jun 18, 2009
	EQ 10MG BASE	A076607	002	Dec 15, 2004
	EQ 10MG BASE	A090800	002	Jun 18, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL				
QUINAPRIL HYDROCHLORIDE				
	EQ 20MG BASE	A076607	003	Dec 15, 2004
	EQ 20MG BASE	A090800	003	Jun 18, 2009
	EQ 40MG BASE	A076607	004	Dec 15, 2004
	EQ 40MG BASE	A090800	004	Jun 18, 2009
YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005
	EQ 10MG BASE	A076803	002	Mar 02, 2005
	EQ 20MG BASE	A076803	003	Mar 02, 2005
	EQ 40MG BASE	A076803	004	Mar 02, 2005

QUINESTROL

TABLET;ORAL				
ESTROVIS				
PARKE DAVIS	0.1MG	N016768	002	
	0.2MG	N016768	003	

QUINETHAZONE

TABLET;ORAL				
HYDROMOX				
LEDERLE	50MG	N013264	001	

QUINETHAZONE; RESERPINE

TABLET;ORAL				
HYDROMOX R				
LEDERLE	50MG;0.125MG	N013927	001	

QUINIDINE GLUCONATE

INJECTABLE;INJECTION				
QUINIDINE GLUCONATE				
+ LILLY	80MG/ML	N007529	002	Feb 10, 1989
TABLET;ORAL				
QUINACT				
BAYER HLTHCARE	266MG	A085978	001	
	400MG	A086099	001	
TABLET, EXTENDED RELEASE;ORAL				
DURAQUIN				
WARNER CHILCOTT	330MG	N017917	001	
QUINAGLUTE				
+ BAYER HLTHCARE	324MG	N016647	001	
QUINALAN				
LANNETT	324MG	A088081	001	Feb 10, 1986
QUINATIME				
WATSON LABS	324MG	A087448	001	
QUINIDINE GLUCONATE				
ANI PHARMS	324MG	A087810	001	Sep 29, 1982
ASCOT	324MG	A088582	001	Jun 17, 1985
CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984
HALSEY	324MG	A089476	001	Apr 10, 1987
RISING	324MG	A089894	001	Dec 15, 1988
SUPERPHARM	324MG	A089164	001	Nov 21, 1985
WATSON LABS	324MG	A087785	001	Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET;ORAL				
CARDIOQUIN				
PHARM RES ASSOC	275MG	N011642	002	

QUINIDINE SULFATE

CAPSULE;ORAL				
CIN-QUIN				
SOLVAY	200MG	A085296	001	
	300MG	A085297	001	
QUINIDINE SULFATE				
LILLY	200MG	A085103	001	
TABLET;ORAL				
CIN-QUIN				
+ SOLVAY	100MG	A085299	001	
+	200MG	A084932	001	
	300MG	A085298	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

QUINIDINE SULFATE				
TABLET;ORAL				
QUINIDINE SULFATE				
BARR	200MG	A084177	001	
CONTRACT PHARMACAL	200MG	A083808	001	
CYCLE PHARMS LTD	200MG	A083640	001	
	300MG	A085632	001	
DAVA PHARMS INC	200MG	A087011	001	
ELKINS SINN	200MG	A083622	001	
EVERYLIFE	200MG	A083439	001	
HALSEY	200MG	A083583	001	
HIKMA	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUN PHARM INDUSTRIES	100MG	A081029	001	Apr 14, 1989
	200MG	A081030	001	Apr 14, 1989
	300MG	A081031	001	Apr 14, 1989
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A083288	001	
	200MG	A085140	002	
	300MG	A085583	001	
WHITEWORTH TOWN PLSN	200MG	A085444	001	
QUINORA				
KEY PHARMS	200MG	A083576	001	
+ SCHERING	300MG	A085222	001	
TABLET, EXTENDED RELEASE;ORAL				
QUINIDEX				
WYETH PHARMS INC	300MG	N012796	002	
QUINIDINE SULFATE				
COSETTE	300MG	A040045	001	Jun 30, 1994
QUININE SULFATE				
CAPSULE;ORAL				
QUININE SULFATE				
MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012
RABEPRAZOLE SODIUM				
CAPSULE, DELAYED RELEASE;ORAL				
ACIPHEX SPRINKLE				
+ AYTU	5MG	N204736	001	Mar 26, 2013
+	10MG	N204736	002	Mar 26, 2013
TABLET, DELAYED RELEASE;ORAL				
ACIPHEX				
+ WOODWARD	10MG **	N020973	001	May 29, 2002
RABEPRAZOLE SODIUM				
MYLAN	20MG	A076885	001	Nov 08, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RAMIPRIL

CAPSULE;ORAL				
RAMIPRIL				
ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009
TEVA PHARMS	1.25MG	A077470	001	Jun 18, 2008
	2.5MG	A077470	002	Jun 18, 2008
	5MG	A077470	003	Jun 18, 2008
	10MG	A077470	004	Jun 18, 2008
WATSON LABS	5MG	A076549	003	Oct 24, 2005
YAOPHARMA CO LTD	1.25MG	A077514	001	Jun 18, 2008
	2.5MG	A077514	002	Jun 18, 2008
	5MG	A077514	003	Jun 18, 2008
	10MG	A077514	004	Jun 18, 2008
TABLET;ORAL				
ALTACE				
+ KING PFIZER	1.25MG **	N022021	001	Feb 27, 2007
+	2.5MG **	N022021	002	Feb 27, 2007
+	5MG **	N022021	003	Feb 27, 2007
+	10MG **	N022021	004	Feb 27, 2007
RAMIPRIL				
APOTEX	1.25MG	A091069	001	Dec 02, 2015
	2.5MG	A091069	002	Dec 02, 2015
	5MG	A091069	003	Dec 02, 2015
	10MG	A091069	004	Dec 02, 2015
MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011
	2.5MG	A090650	002	Jun 30, 2011
	5MG	A090650	003	Jun 30, 2011
	10MG	A090650	004	Jun 30, 2011
ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009
	2.5MG	A090697	002	Sep 24, 2009
	5MG	A090697	003	Sep 24, 2009
	10MG	A090697	004	Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET;ORAL				
TRITEC				
GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL				
RANITIDINE HYDROCHLORIDE				
AJANTA PHARMA LTD	EQ 150MG BASE	A209859	001	Sep 27, 2018
	EQ 300MG BASE	A209859	002	Sep 27, 2018
APPCO	EQ 150MG BASE	A211893	001	Apr 05, 2019
	EQ 300MG BASE	A211893	002	Apr 05, 2019
AUROBINDO PHARMA LTD	EQ 150MG BASE	A211058	001	Jul 16, 2018
	EQ 300MG BASE	A211058	002	Jul 16, 2018
MYLAN	EQ 150MG BASE	A075564	001	Oct 27, 2000
	EQ 300MG BASE	A075564	002	Oct 27, 2000
NOVITIUM PHARMA	EQ 150MG BASE	A210681	001	Nov 23, 2018
	EQ 300MG BASE	A210681	002	Nov 23, 2018
TEVA	EQ 150MG BASE	A075557	001	Oct 31, 2003
	EQ 300MG BASE	A075557	002	Oct 31, 2003
ZANTAC 150				
+ GLAXOSMITHKLINE	EQ 150MG BASE **	N020095	001	Mar 08, 1994
ZANTAC 300				
+ GLAXOSMITHKLINE	EQ 300MG BASE **	N020095	002	Mar 08, 1994
GRANULE, EFFERVESCENT;ORAL				
ZANTAC 150				
GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251	002	Mar 31, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION				
RANITIDINE HYDROCHLORIDE				
BEDFORD	EQ 25MG BASE/ML	A074764	001	Nov 19, 2004
ZANTAC IN PLASTIC CONTAINER				
TELIGENT	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991
	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986
SYRUP;ORAL				
RANITIDINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007
AKORN	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011
AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008
APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007
AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010
NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009
	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011
RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007
TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011
TOLMAR	EQ 15MG BASE/ML	A090054	001	Nov 15, 2010
TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009
WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009
	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009
ZANTAC				
+ GLAXO GRP LTD	EQ 15MG BASE/ML	N019675	001	Dec 30, 1988
TABLET;ORAL				
RANITIDINE HYDROCHLORIDE				
AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006
	EQ 300MG BASE	A077824	002	Oct 13, 2006
ANI PHARMS	EQ 75MG BASE	A075212	001	Jan 14, 2000
	EQ 75MG BASE	A075296	001	Jan 14, 2000
	EQ 150MG BASE	A074488	001	Jul 31, 1997
	EQ 150MG BASE	A077426	001	Dec 19, 2005
	EQ 300MG BASE	A074488	002	Jul 31, 1997
	EQ 300MG BASE	A077426	002	Dec 19, 2005
APOTEX INC	EQ 75MG BASE	A075167	001	May 04, 2000
	EQ 150MG BASE	A200172	001	May 31, 2012
AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017
	EQ 150MG BASE	A207578	001	Nov 13, 2017
BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001	Aug 29, 1997
	EQ 300MG BASE	A074662	002	Aug 29, 1997
CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
GRANULES	EQ 150MG BASE	A210243	001	Aug 20, 2018
	EQ 150MG BASE	A210243	002	Aug 20, 2018
HERITAGE PHARMA AVET	EQ 150MG BASE	A075165	001	Sep 30, 1998
	EQ 300MG BASE	A075165	002	Sep 30, 1998
MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
	EQ 150MG BASE	A074023	001	Aug 22, 1997
	EQ 150MG BASE	A074552	001	Jul 30, 1998
	EQ 300MG BASE	A074023	002	Aug 22, 1997
	EQ 300MG BASE	A074552	002	Jul 30, 1998
NOSTRUM LABS INC	EQ 150MG BASE	A203694	001	Nov 30, 2017
	EQ 300MG BASE	A203694	002	Nov 30, 2017
RANBAXY	EQ 75MG BASE	A075254	001	Jan 14, 2000
	EQ 150MG BASE	A075000	001	Jan 30, 1998
	EQ 300MG BASE	A075000	002	Jan 30, 1998
SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002
STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
	EQ 75MG BASE	A209160	001	Mar 05, 2018
	EQ 150MG BASE	A200536	001	Jun 28, 2011
	EQ 150MG BASE	A205512	001	Aug 22, 2016
	EQ 150MG BASE	A209161	001	Feb 22, 2018
	EQ 150MG BASE	A210010	001	Aug 01, 2018
	EQ 300MG BASE	A205512	002	Aug 22, 2016
	EQ 300MG BASE	A210010	002	Aug 01, 2018
SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000
	EQ 150MG BASE	A075439	001	Apr 19, 2000
	EQ 300MG BASE	A075439	002	Apr 19, 2000
WATSON LABS	EQ 150MG BASE	A074864	001	Oct 20, 1997
	EQ 300MG BASE	A074864	002	Oct 20, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RANITIDINE HYDROCHLORIDE

TABLET;ORAL				
RANITIDINE HYDROCHLORIDE				
WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006
	EQ 75MG BASE	A078884	001	Jul 31, 2008
	EQ 150MG BASE	A078653	001	Nov 26, 2007
	EQ 150MG BASE	A078701	001	Nov 12, 2009
	EQ 300MG BASE	A078701	002	Dec 11, 2009
WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998
	EQ 300MG BASE	A075208	002	Dec 17, 1998
ZANTAC 150				
+ GLAXO GRP LTD	EQ 150MG BASE **	N018703	001	Jun 09, 1983
+ SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004
+	EQ 150MG BASE	N021698	002	Mar 13, 2007
ZANTAC 300				
+ GLAXO GRP LTD	EQ 300MG BASE **	N018703	002	Dec 09, 1985
ZANTAC 75				
+ SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995
TABLET, EFFERVESCENT;ORAL				
ZANTAC 150				
GLAXO GRP LTD	EQ 150MG BASE	N020251	001	Mar 31, 1994
ZANTAC 25				
GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004
ZANTAC 75				
+ SANOFI US	EQ 75MG BASE **	N020745	001	Feb 26, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL				
RANOLAZINE				
ACCORD HLTHCARE	500MG	A212930	001	May 18, 2021
	1GM	A212930	002	May 18, 2021
AMNEAL	500MG	A207690	001	Mar 11, 2021
	1GM	A207690	002	Mar 11, 2021
ANI PHARMS	500MG	A210482	001	Oct 29, 2019
	1GM	A210482	002	Oct 29, 2019
CIPLA	500MG	A211291	001	May 28, 2019
	1GM	A211291	002	May 28, 2019

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION				
RAPLON				
ORGANON USA INC	100MG/VIAL	N020984	001	Aug 18, 1999
	200MG/VIAL	N020984	002	Aug 18, 1999

RASAGILINE MESYLATE

TABLET;ORAL				
RASAGILINE MESYLATE				
APOTEX INC	EQ 0.5MG BASE	A201950	001	Sep 12, 2013
	EQ 1MG BASE	A201950	002	Sep 12, 2013
WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013
	EQ 1MG BASE	A201823	002	Jul 01, 2013

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL				
HIWOLFIA				
BOWMAN PHARMS	50MG	N009276	003	
	50MG	N009276	005	
	100MG	N009276	004	
HYSERPIN				
PHYS PRODS VA	50MG	N010581	001	
KOGLUCOID				
PANRAY	50MG	N009278	001	
	100MG	N009278	002	
RAUDIXIN				
APOTHECON	50MG	N008842	001	
	100MG	N008842	002	
RAUSERPIN				
FERNDALE LABS	50MG	N009926	002	
	100MG	N009926	004	
RAUVAL				
PAL PAK	50MG	N009108	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL				
RAUVAL				
	100MG		N009108 004	
RAUWOLFIA SERPENTINA				
BUNDY	50MG		N009477 001	
	100MG		N009477 002	
HALSEY	50MG		A080498 001	
	100MG		A080498 002	
IMPAX LABS	50MG		N009273 001	
	100MG		N009273 002	
IVAX SUB TEVA PHARMS	50MG		N011521 001	
	100MG		N011521 002	
PUREPAC PHARM	50MG		A080842 001	
	100MG		A080842 002	
PVT FORM	50MG		A080583 001	
	100MG		A080583 002	
SOLVAY	50MG		A080500 001	
	100MG		A080500 002	
TABLICAPS	50MG		A083867 001	
	100MG		A083444 001	
VALEANT PHARM INTL	50MG		N009668 001	
	100MG		N009668 002	
WATSON LABS	50MG		A080907 001	
	100MG		A080914 001	
WOLFINA				
FOREST PHARMS	50MG		N009255 008	
	100MG		N009255 006	

REPAGLINIDE

TABLET;ORAL				
PRANDIN				
+ GEMINI LABS LLC	0.5MG **		N020741 001	Dec 22, 1997
+	1MG **		N020741 002	Dec 22, 1997
+	2MG **		N020741 003	Dec 22, 1997
REPAGLINIDE				
ACTAVIS TOTOWA	0.5MG		A090008 001	Jan 22, 2014
	1MG		A090008 002	Jan 22, 2014
	2MG		A090008 003	Jan 22, 2014
MYLAN	0.5MG		A090252 001	Aug 23, 2013
	1MG		A090252 002	Jan 22, 2014
	2MG		A090252 003	Jan 22, 2014

RESCINNAMINE

CAPSULE;ORAL			
CINNASIL			
PANRAY	0.5MG	A084736 001	
TABLET;ORAL			
MODERIL			
PFIZER	0.25MG	N010686 003	
	0.5MG	N010686 006	

RESERPINE

ELIXIR;ORAL			
SERPASIL			
NOVARTIS	0.2MG/4ML	N009115 005	
INJECTABLE;INJECTION			
SANDRIL			
LILLY	2.5MG/ML	N010012 001	
SERPASIL			
NOVARTIS	2.5MG/ML	N009434 002	
TABLET;ORAL			
HISERPIA			
BOWMAN PHARMS	0.1MG	N009631 002	
	0.25MG	N009631 004	
RAU-SED			
BRISTOL MYERS SQUIBB	0.1MG	N009357 001	
	0.25MG	N009357 004	
	0.5MG	N009357 006	
	1MG	N009357 008	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RESERPINE

TABLET;ORAL

RESERPINE					
	BARR	0.25MG	A080721	002	
	BELL PHARMA	0.1MG	A083058	001	
		0.25MG	A083058	002	
	BUNDY	0.1MG	N009663	001	
		0.25MG	N009663	003	
	CYCLE PHARMS LTD	0.1MG	N009859	001	
		0.25MG	N009859	002	
	ELKINS SINN	0.1MG	A083145	001	
		0.25MG	A083145	002	
	EVERYLIFE	0.1MG	N010441	001	
		0.25MG	N010441	002	
		0.5MG	N010441	003	
		1MG	N010441	004	
	HALSEY	0.1MG	A080457	002	
		0.25MG	A080457	001	
		1MG	A080457	003	
	HIKMA INTL PHARMS	0.1MG	A080975	001	
		0.25MG	A080975	002	
		1MG	A080975	003	
	IMPAX LABS	0.1MG	N009627	001	
		0.25MG	N009627	002	
	IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
		0.25MG	N011185	002	
	MARSHALL PHARMA	0.1MG	A080492	001	
		0.25MG	A080492	002	
	MK LABS	0.1MG	A080525	002	
		0.25MG	A080525	001	
	MYLAN	1MG	A084974	001	
	PHARMAVITE	0.25MG	A084663	001	
	PUREPAC PHARM	0.1MG	A080753	002	
		0.25MG	A080753	001	
	PVT FORM	0.1MG	A086117	001	
		0.25MG	A080582	001	
		0.25MG	A085775	001	
		1MG	A080582	002	
	REXALL	0.25MG	A080637	001	
+	SANDOZ	0.1MG	N009838	001	
+		0.25MG	N009838	002	
	SOLVAY	0.25MG	A080446	001	
	TABLICAPS	0.25MG	A085207	001	
	TEVA	0.1MG	A089020	001	Mar 07, 1985
		0.25MG	A089019	001	Mar 07, 1985
	VALEANT PHARM INTL	0.1MG	N009667	001	
		0.25MG	N009667	002	
	WATSON LABS	0.1MG	A080679	001	
		0.25MG	A080393	001	
		0.25MG	A085401	001	
		1MG	A080749	001	
	WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
		0.25MG	A080723	002	
		1MG	A080723	003	
SANDRIL					
	LILLY	0.1MG	N009376	004	
		0.25MG	N009376	001	
SERPALAN					
	LANNETT	0.1MG	N010124	001	
		0.25MG	N010124	002	
SERPANRAY					
	PANRAY	0.1MG	N009391	001	
		0.25MG	N009391	002	
		1MG	N009391	004	
SERPASIL					
	NOVARTIS	0.1MG	N009115	001	
		0.25MG	N009115	003	
		1MG	N009115	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RESERPINE				
TABLET;ORAL				
SERPATE				
	VALE	0.1MG	N009453 001	
		0.25MG	N009453 002	
SERPIVITE				
	VITARINE	0.25MG	N009645 002	
RESERPINE; TRICHLORMETHIAZIDE				
TABLET;ORAL				
METATENSIN #2				
	SANOFI AVENTIS US	0.1MG;2MG	N012972 001	
METATENSIN #4				
	SANOFI AVENTIS US	0.1MG;4MG	N012972 002	
NAQUIVAL				
	SCHERING	0.1MG;4MG	N012265 003	
TRICHLORMETHIAZIDE W/ RESERPINE				
	WATSON LABS	0.1MG;4MG	A085248 001	
RIBAVIRIN				
CAPSULE;ORAL				
REBETOL				
	MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy**	N020903 001	Jun 03, 1998
RIBASPHERE				
	CHARTWELL RX	200MG	A076203 001	Apr 06, 2004
RIBAVIRIN				
	CHARTWELL RX	200MG	A076192 001	Apr 06, 2004
	TEVA	200MG	A076277 001	Oct 04, 2004
SOLUTION;ORAL				
REBETOL				
+	SCHERING	40MG/ML	N021546 001	Jul 29, 2003
TABLET;ORAL				
COPEGUS				
+	ROCHE	200MG **	N021511 001	Dec 03, 2002
+		400MG **	N021511 002	Jun 21, 2005
RIBAVIRIN				
	BEXIMCO PHARMS USA	200MG	A202546 001	Aug 12, 2014
		400MG	A202546 002	Aug 12, 2014
		500MG	A202546 003	Aug 12, 2014
		600MG	A202546 004	Aug 12, 2014
	CHARTWELL RX	200MG	A077456 001	Dec 05, 2005
		400MG	A077456 002	Dec 05, 2005
		600MG	A077456 003	Dec 05, 2005
	HERITAGE PHARMA AVET	200MG	A077053 001	Dec 05, 2005
	ZYDUS PHARMS USA	400MG	A077094 002	Mar 16, 2007
		500MG	A077094 004	Apr 18, 2008
		600MG	A077094 003	Mar 16, 2007
RIFAMPIN				
CAPSULE;ORAL				
RIFADIN				
	SANOFI AVENTIS US	150MG	A062303 001	
+		300MG	N050420 001	
INJECTABLE;INJECTION				
RIFAMPIN				
	EMCURE PHARMS LTD	600MG/VIAL	A204101 001	Aug 18, 2014
	WATSON PHARMS TEVA	600MG/VIAL	A206736 001	Jan 19, 2016
RILUZOLE				
TABLET;ORAL				
RILUZOLE				
	APOTEX CORP	50MG	A091300 001	Jun 18, 2013
	DAITO PHARMS CO LTD	50MG	A204430 001	Oct 16, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RIMANTADINE HYDROCHLORIDE				
SYRUP;ORAL				
FLUMADINE				
FOREST LABS	50MG/5ML	N019650	001	Sep 17, 1993
TABLET;ORAL				
RIMANTADINE HYDROCHLORIDE				
HERITAGE PHARMA AVET	100MG	A076375	001	Jan 14, 2003
IMPAX LABS INC	100MG	A075916	001	Nov 02, 2001
RIMEXOLONE				
SUSPENSION/DROPS;OPHTHALMIC				
VEXOL				
EYEVANCE	1%	N020474	001	Dec 30, 1994
RISEDRONATE SODIUM				
TABLET;ORAL				
ACTONEL				
+ APIL	75MG **	N020835	004	Apr 16, 2007
RISEDRONATE SODIUM				
HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019
MYLAN	5MG	A200477	001	Nov 30, 2015
	30MG	A200477	002	Nov 30, 2015
	35MG	A200477	003	Nov 30, 2015
	75MG	A200477	004	Jun 10, 2014
	150MG	A200477	005	Jun 10, 2014
TABLET, DELAYED RELEASE;ORAL				
RISEDRONATE SODIUM				
IMPAX LABS INC	35MG	A205066	001	Jun 29, 2018
ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018
RISPERIDONE				
SOLUTION;ORAL				
RISPERIDONE				
ANI PHARMS	1MG/ML	A076440	001	Jan 30, 2009
LANNETT CO INC	1MG/ML	A202386	001	Jan 12, 2015
PRECISION DOSE	1MG/ML	A076797	001	Jun 28, 2010
TORRENT	1MG/ML	A078909	001	Jul 29, 2009
WOCKHARDT	1MG/ML	A078744	001	Oct 08, 2009
TABLET;ORAL				
RISPERDAL				
JANSSEN PHARMS	5MG	N020272	005	Dec 29, 1993
RISPERIDONE				
HERITAGE PHARMA AVET	0.25MG	A076228	001	Jun 30, 2008
	0.25MG	A077769	001	Oct 16, 2008
	0.5MG	A076228	002	Jun 30, 2008
	0.5MG	A077769	002	Oct 16, 2008
	1MG	A076228	003	Jun 30, 2008
	1MG	A077769	003	Oct 16, 2008
	2MG	A076228	004	Jun 30, 2008
	2MG	A077769	004	Oct 16, 2008
	3MG	A076228	005	Jun 30, 2008
	3MG	A077769	005	Oct 16, 2008
	4MG	A076228	006	Jun 30, 2008
	4MG	A077769	006	Oct 16, 2008
JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009
	0.5MG	A078828	002	Mar 23, 2009
	1MG	A078828	003	Mar 23, 2009
	2MG	A078828	004	Mar 23, 2009
	3MG	A078828	005	Mar 23, 2009
	4MG	A078828	006	Mar 23, 2009
MYLAN	0.25MG	A076288	001	Sep 15, 2008
	0.5MG	A076288	002	Sep 15, 2008
	1MG	A076288	003	Sep 15, 2008
	2MG	A076288	004	Sep 15, 2008
	3MG	A076288	005	Sep 15, 2008
	4MG	A076288	006	Sep 15, 2008
RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010
	0.5MG	A077784	002	Jun 08, 2010
	1MG	A077784	003	Jun 08, 2010
	2MG	A077784	004	Jun 08, 2010
	3MG	A077784	005	Jun 08, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RISPERIDONE

TABLET;ORAL					
RISPERIDONE					
		4MG	A077784	006	Jun 08, 2010
	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014
		0.5MG	A078036	002	Mar 10, 2014
		1MG	A078036	003	Mar 10, 2014
		2MG	A078036	004	Mar 10, 2014
		3MG	A078036	005	Mar 10, 2014
		4MG	A078036	006	Mar 10, 2014
	SYNTHON PHARMS	0.25MG	A078187	001	Oct 22, 2009
		0.5MG	A078187	002	Oct 22, 2009
		1MG	A078187	003	Oct 22, 2009
		2MG	A078187	004	Oct 22, 2009
		3MG	A078187	005	Oct 22, 2009
		4MG	A078187	006	Oct 22, 2009
	WATSON LABS	0.25MG	A077860	001	Dec 05, 2008
		0.5MG	A077860	002	Dec 05, 2008
		1MG	A077860	003	Dec 05, 2008
		2MG	A077860	004	Dec 05, 2008
		3MG	A077860	005	Dec 05, 2008
		4MG	A077860	006	Dec 05, 2008
	WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009
		0.5MG	A078740	002	May 29, 2009
		1MG	A078740	003	May 29, 2009
		2MG	A078740	004	May 29, 2009
		3MG	A078740	005	May 29, 2009
		4MG	A078740	006	May 29, 2009
TABLET, ORALLY DISINTEGRATING;ORAL					
RISPERDAL					
+	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003
+		1MG	N021444	002	Apr 02, 2003
+		2MG	N021444	003	Apr 02, 2003
+		3MG	N021444	004	Dec 23, 2004
+		4MG	N021444	005	Dec 23, 2004
RISPERIDONE					
	ACTAVIS LABS FL INC	0.5MG	A076996	001	Apr 19, 2011
		1MG	A076996	002	Apr 19, 2011
		2MG	A076996	003	Apr 19, 2011
		3MG	A076996	004	Apr 19, 2011
		4MG	A076996	005	Apr 19, 2011
	HERITAGE PHARMA AVET	0.5MG	A076908	001	Mar 12, 2012
		1MG	A076908	002	Mar 12, 2012
		2MG	A076908	003	Mar 12, 2012
	MYLAN PHARMS INC	0.25MG	A091537	006	Feb 12, 2013
		0.5MG	A091537	001	Mar 30, 2011
		1MG	A091537	002	Mar 30, 2011
		2MG	A091537	003	Mar 30, 2011
		3MG	A091537	004	Mar 30, 2011
		4MG	A091537	005	Mar 30, 2011

RITODRINE HYDROCHLORIDE

INJECTABLE;INJECTION					
RITODRINE HYDROCHLORIDE					
	ABRAXIS PHARM	10MG/ML	A071188	001	Jul 23, 1987
		15MG/ML	A071189	001	Jul 23, 1987
	HOSPIRA	10MG/ML	A071618	001	Feb 28, 1991
		15MG/ML	A071619	001	Feb 28, 1991
RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	HOSPIRA	30MG/100ML	A071438	001	Jan 22, 1991
YUTOPAR					
	ASTRAZENECA	10MG/ML	N018580	001	
		15MG/ML	N018580	002	Sep 27, 1984
TABLET;ORAL					
YUTOPAR					
	ASTRAZENECA	10MG	N018555	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

RITONAVIR

CAPSULE;ORAL					
NORVIR					
	ABBOTT	100MG	N020680	001	Mar 01, 1996
+	ABBVIE	100MG **	N020945	001	Jun 29, 1999
RITONAVIR					
	HIKMA	100MG	A205801	001	Dec 03, 2020

RIVASTIGMINE TARTRATE

CAPSULE;ORAL					
EXELON					
+	NOVARTIS	EQ 1.5MG BASE **	N020823	003	Apr 21, 2000
+		EQ 3MG BASE **	N020823	004	Apr 21, 2000
+		EQ 4.5MG BASE **	N020823	005	Apr 21, 2000
+		EQ 6MG BASE **	N020823	006	Apr 21, 2000
RIVASTIGMINE TARTRATE					
	APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013
		EQ 3MG BASE	A091072	002	May 16, 2013
		EQ 4.5MG BASE	A091072	003	May 16, 2013
		EQ 6MG BASE	A091072	004	May 16, 2013
SOLUTION;ORAL					
EXELON					
	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

RIZATRIPTAN BENZOATE

TABLET;ORAL					
MAXALT					
+	MERCK	EQ 5MG BASE **	N020864	001	Jun 29, 1998
RIZATRIPTAN BENZOATE					
	APOTEX INC	EQ 5MG BASE	A202244	001	Dec 31, 2012
		EQ 10MG BASE	A202244	002	Dec 31, 2012
	EMCURE PHARMS LTD	EQ 5MG BASE	A204090	001	Nov 26, 2013
		EQ 10MG BASE	A204090	002	Nov 26, 2013
	UNICHEM	EQ 5MG BASE	A207836	001	Mar 07, 2017
		EQ 10MG BASE	A207836	002	Mar 07, 2017
TABLET, ORALLY DISINTEGRATING;ORAL					
MAXALT-MLT					
+	MERCK	EQ 5MG BASE **	N020865	001	Jun 29, 1998
RIZATRIPTAN BENZOATE					
	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013
		EQ 10MG BASE	A202477	002	Jul 01, 2013
	JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015
		EQ 10MG BASE	A203334	002	Oct 16, 2015
	MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012
		EQ 10MG BASE	A078173	002	Dec 31, 2012

ROCURONIUM BROMIDE

INJECTABLE;INJECTION					
ROCURONIUM BROMIDE					
	TEVA PHARMS	50MG/5ML (10MG/ML)	A078717	001	Nov 26, 2008
		100MG/10ML (10MG/ML)	A078717	002	Nov 26, 2008
ZEMURON					
+	ORGANON USA INC	50MG/5ML (10MG/ML) **	N020214	001	Mar 17, 1994
+		10MG/ML (10MG/ML) **	N020214	002	Mar 17, 1994
+		100MG/10ML (10MG/ML) **	N020214	003	Mar 17, 1994

ROFECOXIB

SUSPENSION;ORAL					
VIOXX					
	MERCK	12.5MG/5ML	N021052	001	May 20, 1999
		25MG/5ML	N021052	002	May 20, 1999
TABLET;ORAL					
VIOXX					
	MERCK	12.5MG	N021042	001	May 20, 1999
		25MG	N021042	002	May 20, 1999
		50MG	N021042	003	Feb 25, 2000

ROFLUMILAST				
TABLET;ORAL				
ROFLUMILAST				
	BRECKENRIDGE	500MCG	A208236 001	Oct 03, 2018
	MICRO LABS	500MCG	A208180 001	Mar 22, 2019
	MYLAN	500MCG	A208257 001	Jul 13, 2018
ROLAPITANT HYDROCHLORIDE				
EMULSION;INTRAVENOUS				
VARUBI				
+	TERSERA	EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)	N208399 001	Oct 25, 2017
ROMIDEPSIN				
SOLUTION;INTRAVENOUS				
ROMIDEPSIN				
+	TEVA PHARMS USA INC	10MG/2ML (5MG/ML)	N208574 001	Mar 13, 2020
ROPINIROLE HYDROCHLORIDE				
TABLET;ORAL				
REQUIP				
+	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658 001	Sep 19, 1997
+		EQ 0.5MG BASE	N020658 002	Sep 19, 1997
+		EQ 1MG BASE	N020658 003	Sep 19, 1997
+		EQ 2MG BASE	N020658 004	Sep 19, 1997
+		EQ 3MG BASE	N020658 006	Jan 27, 1999
+		EQ 4MG BASE	N020658 007	Jan 27, 1999
+		EQ 5MG BASE	N020658 005	Sep 19, 1997
ROPINIROLE HYDROCHLORIDE				
	COSETTE	EQ 0.25MG BASE	A077460 001	May 05, 2008
		EQ 0.5MG BASE	A077460 002	May 05, 2008
		EQ 1MG BASE	A077460 003	May 05, 2008
		EQ 2MG BASE	A077460 004	May 05, 2008
		EQ 3MG BASE	A077460 005	May 05, 2008
		EQ 4MG BASE	A077460 006	May 05, 2008
		EQ 5MG BASE	A077460 007	May 19, 2008
	EPIC PHARMA LLC	EQ 0.25MG BASE	A078230 001	May 20, 2008
		EQ 0.5MG BASE	A078230 002	May 20, 2008
		EQ 1MG BASE	A078230 003	May 20, 2008
		EQ 2MG BASE	A078230 004	May 20, 2008
		EQ 3MG BASE	A078230 005	May 20, 2008
		EQ 4MG BASE	A078230 006	May 20, 2008
		EQ 5MG BASE	A078230 007	May 20, 2008
	HIKMA	EQ 0.25MG BASE	A077852 001	May 05, 2008
		EQ 0.5MG BASE	A077852 002	May 05, 2008
		EQ 1MG BASE	A077852 003	May 05, 2008
		EQ 2MG BASE	A077852 004	May 05, 2008
		EQ 3MG BASE	A077852 005	May 05, 2008
		EQ 4MG BASE	A077852 006	May 05, 2008
		EQ 5MG BASE	A077852 007	May 19, 2008
TABLET, EXTENDED RELEASE;ORAL				
REQUIP XL				
+	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008 001	Jun 13, 2008
+		EQ 3MG BASE **	N022008 002	Jun 13, 2008
+		EQ 4MG BASE	N022008 003	Jun 13, 2008
+		EQ 6MG BASE	N022008 006	Apr 10, 2009
+		EQ 8MG BASE	N022008 004	Jun 13, 2008
+		EQ 12MG BASE	N022008 005	Oct 31, 2008
ROPINIROLE HYDROCHLORIDE				
	MYLAN PHARMS INC	EQ 2MG BASE	A200462 001	Oct 15, 2012
		EQ 3MG BASE	A200462 002	Oct 15, 2012
		EQ 4MG BASE	A200462 003	Oct 15, 2012
		EQ 6MG BASE	A200462 004	Oct 15, 2012
		EQ 8MG BASE	A200462 005	Oct 15, 2012
		EQ 12MG BASE	A200462 006	Oct 15, 2012
	WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012
		EQ 4MG BASE	A200431 002	Jun 06, 2012
		EQ 6MG BASE	A200431 003	Jun 06, 2012
		EQ 8MG BASE	A200431 004	Jun 06, 2012
		EQ 12MG BASE	A200431 005	Jun 06, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ROPIVACAINE HYDROCHLORIDE				
SOLUTION;INJECTION				
NAROPIN				
+ FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998
+	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996
ROPIVACAINE HYDROCHLORIDE				
RISING PHARMA	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014
	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014
	150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014
	200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014
ROSE BENGAL SODIUM I-131				
INJECTABLE;INJECTION				
ROBENGATOPE				
BRACCO	0.5mCi/VIAL	N016224	001	
	1mCi/VIAL	N016224	002	
	2mCi/VIAL	N016224	003	
SODIUM ROSE BENGAL I 131				
SORIN	0.5mCi/ML	N017318	001	
ROSIGLITAZONE MALEATE				
TABLET;ORAL				
AVANDIA				
+ WOODWARD	EQ 8MG BASE **	N021071	004	May 25, 1999
ROSIGLITAZONE MALEATE				
ANI PHARMS	EQ 2MG BASE	A076747	001	Jan 25, 2013
	EQ 4MG BASE	A076747	002	Jan 25, 2013
	EQ 8MG BASE	A076747	003	Jan 25, 2013
ROSUVASTATIN CALCIUM				
TABLET;ORAL				
ROSUVASTATIN CALCIUM				
AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018
	EQ 10MG BASE	A208850	002	Oct 16, 2018
	EQ 20MG BASE	A208850	003	Oct 16, 2018
	EQ 40MG BASE	A208850	004	Oct 16, 2018
APOTEX INC	EQ 5MG BASE	A079145	001	Jul 19, 2016
	EQ 10MG BASE	A079145	002	Jul 19, 2016
	EQ 20MG BASE	A079145	003	Jul 19, 2016
	EQ 40MG BASE	A079145	004	Jul 19, 2016
INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021
	EQ 10MG BASE	A207653	002	Feb 05, 2021
	EQ 20MG BASE	A207653	003	Feb 05, 2021
	EQ 40MG BASE	A207653	004	Feb 05, 2021
MYLAN	EQ 5MG BASE	A079161	001	Jul 19, 2016
	EQ 10MG BASE	A079161	002	Jul 19, 2016
	EQ 20MG BASE	A079161	003	Jul 19, 2016
	EQ 40MG BASE	A079161	004	Jul 19, 2016
SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019
	EQ 10MG BASE	A206381	002	Apr 24, 2019
	EQ 20MG BASE	A206381	003	Apr 24, 2019
	EQ 40MG BASE	A206381	004	Apr 24, 2019
SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020
	EQ 10MG BASE	A210667	002	Apr 01, 2020
	EQ 20MG BASE	A210667	003	Apr 01, 2020
	EQ 40MG BASE	A210667	004	Apr 01, 2020
TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016
	EQ 10MG BASE	A079166	002	Jul 19, 2016
	EQ 20MG BASE	A079166	003	Jul 19, 2016
	EQ 40MG BASE	A079166	004	Jul 19, 2016
UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019
	EQ 10MG BASE	A207626	002	Apr 09, 2019
	EQ 20MG BASE	A207626	003	Apr 09, 2019
	EQ 40MG BASE	A207626	004	Apr 09, 2019
ZYDUS PHARMS	EQ 5MG BASE	A206513	001	Mar 01, 2019
	EQ 10MG BASE	A206513	002	Mar 01, 2019
	EQ 20MG BASE	A206513	003	Mar 01, 2019
	EQ 40MG BASE	A206513	004	Mar 01, 2019

RUFINAMIDE				
TABLET;ORAL				
BANZEL				
+	EISAI INC	100MG **	N021911 001	Nov 14, 2008
SAFFLOWER OIL				
INJECTABLE;INJECTION				
LIPOSYN 10%				
	ABBOTT	10% (10GM/100ML)	N018203 001	
LIPOSYN 20%				
	ABBOTT	20% (20GM/100ML)	N018614 001	
SAFFLOWER OIL; SOYBEAN OIL				
INJECTABLE;INJECTION				
LIPOSYN II 10%				
	HOSPIRA	5%;5% (5GM/100ML)	N018997 001	Aug 27, 1984
LIPOSYN II 20%				
	HOSPIRA	10%;10% (10GM/100ML)	N018991 001	Aug 27, 1984
SALMETEROL XINAFOATE				
AEROSOL, METERED;INHALATION				
SEREVENT				
	GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236 001	Feb 04, 1994
SAQUINAVIR				
CAPSULE;ORAL				
FORTOVASE				
+	HOFFMANN LA ROCHE	200MG **	N020828 001	Nov 07, 1997
SAQUINAVIR MESYLATE				
CAPSULE;ORAL				
INVIRASE				
+	HOFFMANN LA ROCHE	EQ 200MG BASE	N020628 001	Dec 06, 1995
TABLET;ORAL				
INVIRASE				
+	HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004
SARALASIN ACETATE				
INJECTABLE;INJECTION				
SARENIN				
	PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009 001	
SECOBARBITAL SODIUM				
CAPSULE;ORAL				
SECOBARBITAL SODIUM				
	ANABOLIC	100MG	A084422 001	
	BARR	100MG	A084225 001	
	EVERYLIFE	100MG	A085895 001	
	HALSEY	100MG	A084676 001	
	IVAX PHARMS	100MG	A085869 001	
	KV PHARM	100MG	A085285 001	
	LANNETT	50MG	A085909 001	
		100MG	A085903 001	
	PARKE DAVIS	100MG	A084762 001	
	PERRIGO	100MG	A084561 001	
	PUREPAC PHARM	100MG	A085867 001	
	VALEANT PHARM INTL	100MG	A085477 001	
	VITARINE	100MG	A085898 001	
		100MG	A086273 001	
	WATSON LABS	100MG	A085792 001	
	WEST WARD	100MG	A084926 001	
	WHITEWORTH TOWN PLSN	100MG	A085798 001	
	WYETH AYERST	100MG	A086390 001	
SECONAL SODIUM				
	VALEANT PHARMS NORTH	50MG	A086101 001	Oct 03, 1983
		100MG	A086101 002	Oct 03, 1983
INJECTABLE;INJECTION				
SECOBARBITAL SODIUM				
	ELKINS SINN	100MG/VIAL	A083281 001	
	WYETH AYERST	50MG/ML	A083262 001	
SECONAL SODIUM				
	LILLY	50MG/ML **	N007392 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SECOBARBITAL SODIUM
SUPPOSITORY;RECTAL
SECONAL SODIUM

	LILLY	30MG	A086530 001	
		60MG	A086530 002	
		120MG	A086530 003	
		200MG	A086530 004	

SECRETIN
INJECTABLE;INJECTION
SECRETIN-FERRING

	FERRING	75CU/VIAL	N018290 001	

SECRETIN SYNTHETIC PORCINE
FOR SOLUTION;INTRAVENOUS
SECREFLO

	CHIRHOCLIN	16MCG/VIAL	N021136 001	Apr 04, 2002

SELEGILINE HYDROCHLORIDE
CAPSULE;ORAL
ELDEPRYL

+	SOMERSET	5MG **	N020647 001	May 15, 1996

SELEGILINE HYDROCHLORIDE

	LANNETT CO INC	5MG	A075145 001	Sep 15, 2003

TABLET;ORAL
SELEGILINE HYDROCHLORIDE

	CHARTWELL MOLECULES	5MG	A074565 001	Aug 02, 1996
		5MG	A074641 001	Aug 02, 1996
	COSETTE	5MG	A074744 001	Jan 27, 1997
		5MG	A074756 001	Nov 25, 1998
	G AND W LABS INC	5MG	A074537 001	Aug 02, 1996
	MYLAN	5MG	A074866 001	Nov 26, 1997
+	SOMERSET	5MG **	N019334 001	Jun 05, 1989

SELENIUM SULFIDE
LOTION/SHAMPOO;TOPICAL
EXSEL

	ALLERGAN HERBERT	2.5%	A083892 001	

SELENIUM SULFIDE

	ACTAVIS MID ATLANTIC	2.5%	A084394 001	
	COSETTE	2.5%	A086209 001	
	IVAX PHARMS	2.5%	A085777 001	

SELSUN

+	CHATTEM	2.5%	N007936 001	

SELENOMETHIONINE SE-75
INJECTABLE;INJECTION
SELENOMETHIONINE SE 75

	GE HEALTHCARE	250uCi/ML	N017257 001	
	MALLINCKRODT	100uCi/ML	N017098 001	
	PHARMALUCENCE	500uCi/ML	N017322 001	

SETHOTOPE

	BRACCO	85-550uCi/ML	N017047 001	

SERMORELIN ACETATE
INJECTABLE;INJECTION
GEREF

+	EMD SERONO	EQ 0.05MG BASE/AMP **	N019863 001	Dec 28, 1990
+	EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443 001	Sep 26, 1997
+		EQ 1MG BASE/VIAL **	N020443 002	Sep 26, 1997

SERTRALINE HYDROCHLORIDE
CONCENTRATE;ORAL
SERTRALINE HYDROCHLORIDE

	RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

	ANDA REPOSITORY	EQ 25MG BASE	A077818 001	Feb 06, 2007
		EQ 50MG BASE	A077818 002	Feb 06, 2007
		EQ 100MG BASE	A077818 003	Feb 06, 2007
	CADILA	EQ 25MG BASE	A077106 001	Feb 06, 2007
		EQ 50MG BASE	A077106 002	Feb 06, 2007
		EQ 100MG BASE	A077106 003	Feb 06, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SERTRALINE HYDROCHLORIDE

TABLET;ORAL					
SERTRALINE HYDROCHLORIDE					
	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162	001	Feb 06, 2007
		EQ 50MG BASE	A077162	002	Feb 06, 2007
		EQ 100MG BASE	A077162	003	Feb 06, 2007
	FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007
		EQ 50MG BASE	A077713	002	Feb 06, 2007
		EQ 100MG BASE	A077713	003	Feb 06, 2007
	HERITAGE PHARMA AVET	EQ 25MG BASE	A076465	001	Aug 11, 2006
		EQ 25MG BASE	A077299	001	Feb 06, 2007
		EQ 25MG BASE	A077345	001	Feb 06, 2007
		EQ 25MG BASE	A077663	001	Feb 06, 2007
		EQ 50MG BASE	A076465	002	Aug 11, 2006
		EQ 50MG BASE	A077299	002	Feb 06, 2007
		EQ 50MG BASE	A077345	002	Feb 06, 2007
		EQ 50MG BASE	A077663	002	Feb 06, 2007
		EQ 100MG BASE	A076465	003	Aug 11, 2006
		EQ 100MG BASE	A077299	003	Feb 06, 2007
		EQ 100MG BASE	A077345	003	Feb 06, 2007
		EQ 100MG BASE	A077663	003	Feb 06, 2007
	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009
		EQ 50MG BASE	A077864	002	Aug 10, 2009
		EQ 100MG BASE	A077864	003	Aug 10, 2009
	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006
		EQ 50MG BASE	A075719	001	Jun 30, 2006
		EQ 100MG BASE	A075719	002	Jun 30, 2006
	MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007
		EQ 50MG BASE	A076671	002	Feb 06, 2007
		EQ 100MG BASE	A076671	003	Feb 06, 2007
	MYLAN PHARMS INC	EQ 25MG BASE	A076540	001	Mar 20, 2007
		EQ 25MG BASE	A078626	001	Jan 31, 2008
		EQ 50MG BASE	A076540	002	Mar 20, 2007
		EQ 50MG BASE	A078626	002	Jan 31, 2008
		EQ 100MG BASE	A076540	003	Mar 20, 2007
		EQ 100MG BASE	A078626	003	Jan 31, 2008
	SUN PHARM INDS (IN)	EQ 25MG BASE	A078108	001	Feb 06, 2007
		EQ 50MG BASE	A078108	002	Feb 06, 2007
		EQ 100MG BASE	A078108	003	Feb 06, 2007
	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007
		EQ 50MG BASE	A077977	002	Feb 06, 2007
		EQ 100MG BASE	A077977	003	Feb 06, 2007
		EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007
	TORRENT PHARMS	EQ 25MG BASE	A077765	001	Feb 06, 2007
		EQ 50MG BASE	A077765	002	Feb 06, 2007
		EQ 100MG BASE	A077765	003	Feb 06, 2007
ZOLOFT					
+	UPJOHN	EQ 150MG BASE **	N019839	003	Dec 30, 1991
+		EQ 200MG BASE **	N019839	004	Dec 30, 1991

SEVELAMER CARBONATE

TABLET;ORAL					
SEVELAMER CARBONATE					
	IMPAX LABS INC	800MG	A090975	001	Oct 23, 2017
	MYLAN	800MG	A201069	001	Aug 05, 2020

SEVELAMER HYDROCHLORIDE

CAPSULE;ORAL					
RENAGEL					
	GENZYME	403MG	N020926	001	Oct 30, 1998
TABLET;ORAL					
SEVELAMER HYDROCHLORIDE					
	RISING PHARMA	400MG	A201068	001	Dec 14, 2020
		800MG	A201068	002	Dec 14, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SIBUTRAMINE HYDROCHLORIDE

CAPSULE;ORAL				
MERIDIA				
	ABBOTT	5MG	N020632 001	Nov 22, 1997
		10MG	N020632 002	Nov 22, 1997
		15MG	N020632 003	Nov 22, 1997

SILDENAFIL CITRATE

TABLET;ORAL				
SILDENAFIL CITRATE				
	ACTAVIS GRP PTC	EQ 20MG BASE	A200149 001	Feb 25, 2013
	APOTEX CORP	EQ 20MG BASE	A091379 001	Nov 06, 2012
	PERRIGO R AND D	EQ 25MG BASE	A205791 001	Apr 23, 2020
		EQ 50MG BASE	A205791 002	Apr 23, 2020
	WATSON LABS INC	EQ 25MG BASE	A202506 001	Nov 25, 2020
		EQ 50MG BASE	A202506 002	Nov 25, 2020
		EQ 100MG BASE	A202506 003	Nov 25, 2020

SILODOSIN

CAPSULE;ORAL				
SILODOSIN				
	ALEMBIC PHARMS LTD	4MG	A211731 001	Nov 22, 2019
		8MG	A211731 002	Nov 22, 2019

SILVER SULFADIAZINE

CREAM;TOPICAL				
SSD AF				
	DR REDDYS LA	1%	N018578 003	Jul 11, 1990
DRESSING;TOPICAL				
SILDAFLO				
	FRANKLIN PHARMS	1%	N019608 001	Nov 30, 1989

SIMEPREVIR SODIUM

CAPSULE;ORAL				
OLYSIO				
+	JANSSEN PRODS	EQ 150MG BASE	N205123 001	Nov 22, 2013

SIMETHICONE-CELLULOSE

SUSPENSION;ORAL				
SONORX				
	BRACCO	7.5MG/ML	N020773 001	Oct 29, 1998

SIMVASTATIN

TABLET;ORAL				
SIMVASTATIN				
	IVAX SUB TEVA PHARMS	5MG	A076052 001	Jun 23, 2006
		10MG	A076052 002	Jun 23, 2006
		20MG	A076052 003	Jun 23, 2006
		40MG	A076052 004	Jun 23, 2006
		80MG	A076052 005	Dec 20, 2006
	MYLAN PHARMS INC	5MG	A090868 001	Jun 08, 2010
		10MG	A090868 002	Jun 08, 2010
		20MG	A090868 003	Jun 08, 2010
		40MG	A090868 004	Jun 08, 2010
		80MG	A090868 005	Jun 08, 2010
	SUN PHARM INDS LTD	5MG	A076285 001	Dec 20, 2006
		10MG	A076285 002	Dec 20, 2006
		20MG	A076285 003	Dec 20, 2006
		40MG	A076285 004	Dec 20, 2006
		80MG	A076285 005	Jun 23, 2006
	YAOPHARMA CO LTD	5MG	A077766 001	Dec 20, 2006
		10MG	A077766 002	Dec 20, 2006
		20MG	A077766 003	Dec 20, 2006
		40MG	A077766 004	Dec 20, 2006
		80MG	A077766 005	Dec 20, 2006
ZOCOR				
+	ORGANON	80MG	N019766 005	Jul 10, 1998
TABLET, ORALLY DISINTEGRATING;ORAL				
SIMVASTATIN				
	SYNTHON PHARMS	10MG	N021961 001	Oct 09, 2007
		20MG	N021961 002	Oct 09, 2007
		40MG	N021961 003	Oct 09, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SIMVASTATIN					
TABLET, ORALLY DISINTEGRATING;ORAL					
SIMVASTATIN					
		80MG	N021961	004	Oct 09, 2007
SIMVASTATIN; SITAGLIPTIN PHOSPHATE					
TABLET;ORAL					
JUVISYNC					
+	MERCK SHARP DOHME	10MG;EQ 50MG BASE **	N202343	004	Sep 18, 2012
+		10MG;EQ 100MG BASE **	N202343	001	Oct 07, 2011
+		20MG;EQ 50MG BASE **	N202343	005	Sep 18, 2012
+		20MG;EQ 100MG BASE **	N202343	002	Oct 07, 2011
+		40MG;EQ 50MG BASE **	N202343	006	Sep 18, 2012
+		40MG;EQ 100MG BASE **	N202343	003	Oct 07, 2011
SIROLIMUS					
TABLET;ORAL					
RAPAMUNE					
+	PF PRISM CV	5MG **	N021110	003	Feb 23, 2004
SODIUM BENZOATE; SODIUM PHENYLACETATE					
SOLUTION;ORAL					
UCEPHAN					
	B BRAUN	100MG/ML;100MG/ML	N019530	001	Dec 23, 1987
SODIUM BICARBONATE					
INJECTABLE;INJECTION					
SODIUM BICARBONATE					
	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005
		1MEQ/ML	A077394	002	Nov 09, 2005
SODIUM BICARBONATE IN PLASTIC CONTAINER					
+	ABBOTT	0.9MEQ/ML **	N019443	001	Jun 03, 1986
+		1MEQ/ML **	N019443	002	Jun 03, 1986
SODIUM BICARBONATE; TARTARIC ACID					
GRANULE, EFFERVESCENT;ORAL					
BAROS					
	MALLINCKRODT INC	460MG/GM;420MG/GM	N018509	001	Aug 07, 1985
SODIUM CHLORIDE					
AEROSOL, METERED;INHALATION					
BRONCHO SALINE					
+	BLAIREX	0.9%	N019912	001	Sep 03, 1992
INJECTABLE;INJECTION					
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	ABRAXIS PHARM	9MG/ML	A088909	001	Feb 07, 1985
SODIUM CHLORIDE					
	ABBOTT	20GM/100ML	N017013	001	
	B BRAUN	20GM/100ML	N017038	001	
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	B BRAUN	450MG/100ML	N018184	001	
	MILES	450MG/100ML	N018503	001	
SODIUM CHLORIDE 0.9%					
+	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012
+		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012
+		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012
+		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012
+		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	ABBOTT	9MG/ML	N019218	001	Jul 13, 1984
+	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984
	JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016
+	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
	MILES	900MG/100ML	N018502	001	
SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER					
+	ABRAXIS PHARM	234MG/ML **	N019329	001	Apr 22, 1987
SOLUTION;INTRAVENOUS					
SODIUM CHLORIDE 14.6%					
+	HOSPIRA	50MEQ/20ML (2.5MEQ/ML) **	N018897	001	Jul 20, 1984
SOLUTION;IRRIGATION					
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	450MG/100ML	N017864	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM CHLORIDE				
SOLUTION;IRRIGATION				
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
	450MG/100ML	N018497	001	Feb 19, 1982
HOSPIRA	450MG/100ML	N017670	001	
	450MG/100ML	N018380	001	
SODIUM CHLORIDE IN PLASTIC CONTAINER				
MILES	900MG/100ML	N018247	001	
SODIUM CHROMATE CR-51				
INJECTABLE;INJECTION				
CHROMITOPE SODIUM				
BRACCO	2mCi/VIAL	N013993	002	
	200uCi/ML	N013993	001	
SODIUM CHROMATE CR 51				
CURIUM	100uCi/ML	N016708	001	
SODIUM FLUORIDE F-18				
INJECTABLE;INTRAVENOUS				
FLUORINE F-18				
+ GE HEALTHCARE	2mCi/ML **	N017042	001	
SODIUM FLUORIDE F 18				
NIH NCI DCTD	10-200mCi/ML **	N022494	001	Jan 26, 2011
SODIUM FLUORIDE F-18				
DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014
UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014
UIHC PET IMAGING	10-200mCi/ML	A204462	001	Nov 17, 2015
UNIV TX MD ANDERSON	10-200mCi/ML	A203247	001	Dec 23, 2013
SODIUM FLUORIDE; TRICLOSAN				
PASTE;DENTAL				
COLGATE TOTAL				
+ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997
SODIUM IODIDE I-123				
CAPSULE;ORAL				
SODIUM IODIDE I 123				
CARDINAL HEALTH 418	400uCi	N018671	003	May 27, 1982
GE HEALTHCARE	100uCi	N017630	001	
SOLUTION;ORAL				
SODIUM IODIDE I 123				
GE HEALTHCARE	2mCi/ML **	N017630	002	
SODIUM IODIDE I-131				
CAPSULE;ORAL				
IODOTOPE				
BRACCO	1-130mCi	N010929	001	
	1-150mCi	N010929	003	
SODIUM IODIDE I 131				
CIS	50uCi	N017316	001	
	100uCi	N017316	002	
CURIUM	0.8-100mCi	N016515	002	
+	0.8-100mCi	N016517	001	
	15-100uCi	N016517	002	
JUBILANT	2-200mCi	N021305	004	Nov 18, 2004
SOLUTION;ORAL				
HICON				
JUBILANT	1-250mCi/0.25ML	N021305	002	Jan 24, 2003
	1-500mCi/0.5ML	N021305	003	Jan 24, 2003
	1-1000mCi/ML	N021305	005	Apr 04, 2006
IODOTOPE				
BRACCO	7-106mCi/BOT	N010929	002	
SODIUM IODIDE I 131				
CIS	50mCi/ML	N017315	001	
+ CURIUM	3.5-150mCi/VIAL	N016515	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM LACTATE

INJECTABLE;INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

	B BRAUN	1.87GM/100ML	N018186	001	
	BAXTER HLTHCARE	1.87GM/100ML	N016692	001	
	HOSPIRA	1.87GM/100ML	N018249	001	

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

	B BRAUN	1.87GM/100ML	N020004	001	Apr 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER

+	HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM MONOFLUOROPHOSPHATE

GEL;DENTAL

EXTRA-STRENGTH AIM

	CHESEBROUGH PONDS	1.2%	N019518	002	Aug 06, 1986

PASTE;DENTAL

EXTRA-STRENGTH AIM

	CHESEBROUGH PONDS	1.2%	N019518	001	Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

NIPRIDE

	ROCHE	50MG/VIAL	N017546	001	

NITROPRESS

	ABBOTT	50MG/VIAL	A071555	001	Nov 16, 1987
+	ABBVIE	50MG/VIAL **	N018450	001	
	HOSPIRA	50MG/VIAL	A070566	001	Jun 09, 1986

SODIUM NITROPRUSSIDE

	ABRAXIS PHARM	50MG/VIAL	A070031	001	Jan 17, 1985
	AMPHASTAR PHARMS INC	25MG/ML	A209832	001	Dec 18, 2017
+	BAXTER HLTHCARE	50MG/VIAL **	N018581	001	Jul 28, 1982
	CIPLA	25MG/ML	A210855	001	Jul 16, 2018
	EUGIA PHARMA	25MG/ML	A211934	001	Dec 10, 2020
	SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018
	TEVA PARENTERAL	25MG/ML	A073465	001	Mar 30, 1992
	VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018

SOLUTION;INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+	EXELA PHARMA	10MG/50ML (0.2MG/ML) **	N209387	002	Dec 07, 2017

SODIUM OXYBATE

SOLUTION;ORAL

SODIUM OXYBATE

	HIKMA	0.5GM/ML	A202090	001	Jan 17, 2017

SODIUM PHENYLBUTYRATE

TABLET;ORAL

SODIUM PHENYLBUTYRATE

	ALVOGEN	500MG	A090910	001	Nov 18, 2011

SODIUM PHOSPHATE P-32

SOLUTION;INJECTION, ORAL

PHOSPHOTOPE

	BRACCO	1-8mCi/VIAL	N010927	001	

SODIUM PHOSPHATE P 32

	MALLINCKRODT	0.67mCi/ML	N011777	001	
		1.5mCi/VIAL	N011777	002	

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

VISICOL

	SALIX PHARMS	0.398GM;1.102GM	N021097	001	Sep 21, 2000

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KAYEXALATE

+	CONCORDIA	453.6GM/BOT **	N011287	001	

SODIUM POLYSTYRENE SULFONATE

	CITRUSPHRMA	454GM/BOT	A040909	001	Dec 03, 2008
+	WOCKHARDT	453.6GM/BOT	A088786	001	Sep 11, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SODIUM POLYSTYRENE SULFONATE				
SUSPENSION;ORAL, RECTAL				
KIONEX				
	ANI PHARMS	15GM/60ML	A040028 001	Sep 17, 2007
SODIUM POLYSTYRENE SULFONATE				
	ANI PHARMS	15GM/60ML	A090590 001	May 13, 2011
	HIKMA	15GM/60ML	A089049 001	Nov 17, 1986
	MORTON GROVE	15GM/60ML	A088717 001	Sep 11, 1984
	ROXANE	15GM/60ML	A088453 001	Nov 17, 1983
SODIUM SUCCINATE				
INJECTABLE;INJECTION				
SODIUM SUCCINATE				
	ELKINS SINN	30%	A080516 001	
SODIUM TETRADECYL SULFATE				
INJECTABLE;INJECTION				
SOTRADECOL				
+	ELKINS SINN	1% **	N005970 004	
+		3% **	N005970 005	
SODIUM THIOSULFATE				
INJECTABLE;INJECTION				
SODIUM THIOSULFATE				
+	US ARMY	250MG/ML	N020166 001	Feb 14, 1992
SOLIFENACIN SUCCINATE				
TABLET;ORAL				
SOLIFENACIN SUCCINATE				
	AJANTA PHARMA LTD	5MG	A205483 001	May 20, 2019
		10MG	A205483 002	May 20, 2019
	BRECKENRIDGE	5MG	A209818 001	May 20, 2019
		10MG	A209818 002	May 20, 2019
	SUNSHINE	5MG	A213346 001	Apr 13, 2020
		10MG	A213346 002	Apr 13, 2020
	ZYDUS PHARMS	5MG	A207721 001	Oct 19, 2020
		10MG	A207721 002	Oct 19, 2020
SORAFENIB TOSYLATE				
TABLET;ORAL				
SORAFENIB TOSYLATE				
	MYLAN	EQ 200MG BASE	A207012 001	Sep 10, 2020
	TEVA PHARMS USA INC	EQ 200MG BASE	A209567 001	Nov 12, 2020
SORBITOL				
SOLUTION;IRRIGATION				
SORBITOL 3% IN PLASTIC CONTAINER				
	BAXTER HLTHCARE	3GM/100ML	N018512 001	May 27, 1982
SOTALOL HYDROCHLORIDE				
TABLET;ORAL				
BETAPACE				
	COVIS	320MG	N019865 004	Oct 30, 1992
BETAPACE AF				
	COVIS	40MG	N021151 006	Apr 02, 2003
		60MG	N021151 007	Apr 02, 2003
		100MG	N021151 005	Mar 14, 2003
SOTALOL HYDROCHLORIDE				
	AUROBINDO PHARMA USA	80MG	A077616 001	Feb 07, 2007
		120MG	A077616 002	Feb 07, 2007
		160MG	A077616 003	Feb 07, 2007
	IMPAX PHARMS	80MG	A075663 001	Nov 07, 2000
		120MG	A075663 002	Nov 07, 2000
		160MG	A075663 003	Nov 07, 2000
		240MG	A075663 004	Nov 07, 2000
	MYLAN	80MG	A075237 001	May 01, 2000
		80MG	A075725 001	Dec 19, 2000
		120MG	A075237 002	May 01, 2000
		120MG	A075725 002	Dec 19, 2000
		160MG	A075237 003	May 01, 2000
		160MG	A075725 003	Dec 19, 2000
		240MG	A075237 004	May 01, 2000
		240MG	A075725 004	Dec 19, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

SUN PHARM INDUSTRIES	80MG	A075515	001	Oct 15, 2001
	80MG	A076576	001	Apr 08, 2004
	120MG	A075515	004	Oct 15, 2001
	120MG	A076576	002	Apr 08, 2004
	160MG	A075515	002	Oct 15, 2001
	160MG	A076576	003	Apr 08, 2004
	240MG	A075515	003	Oct 15, 2001
TEVA	80MG	A076883	001	Jul 26, 2004
	120MG	A076883	002	Jul 26, 2004
	160MG	A076883	003	Jul 26, 2004
UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000
	120MG	A075366	002	May 01, 2000
	160MG	A075366	003	May 01, 2000
	240MG	A075366	004	May 01, 2000
WATSON LABS	80MG	A075238	001	Jul 13, 2000
	120MG	A075238	002	Jul 13, 2000
	160MG	A075238	003	Jul 13, 2000
	240MG	A075238	004	Jul 13, 2000

SOYBEAN OIL

INJECTABLE;INJECTION

LIPOSYN III 10%

HOSPIRA	10%	N018969	001	Sep 24, 1984

LIPOSYN III 20%

HOSPIRA	20%	N018970	001	Sep 25, 1984

LIPOSYN III 30%

HOSPIRA	30%	N020181	001	Jan 13, 1998

SOYACAL 10%

ALPHA THERA	10%	N018465	001	Jun 29, 1983

SOYACAL 20%

ALPHA THERA	20%	N018786	001	Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE	10%	N018660	001	Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE	20%	N018758	001	Feb 15, 1983

SPARFLOXACIN

TABLET;ORAL

ZAGAM

MYLAN	200MG	N020677	001	Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

TROBICIN

PFIZER	EQ 2GM BASE/VIAL	N050347	001
	EQ 4GM BASE/VIAL	N050347	002

SPIRAPRIL HYDROCHLORIDE

TABLET;ORAL

RENORMAX

SCHERING	3MG	N020240	001	Dec 29, 1994
	6MG	N020240	002	Dec 29, 1994
	12MG	N020240	003	Dec 29, 1994
	24MG	N020240	004	Dec 29, 1994

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006
	50MG	A040353	001	Jul 29, 1999
	100MG	A040353	002	Jul 29, 1999
ASCOT	25MG	A087687	001	Oct 20, 1982
CHARTWELL RX	25MG	A086809	001	
IVAX PHARMS	25MG	A087108	001	
LEDERLE	25MG	A087634	001	
MUTUAL PHARM	25MG	A087265	001	
MYLAN	25MG	A087086	001	
OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006
	50MG	A040750	002	Aug 29, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SPIRONOLACTONE

TABLET;ORAL					
SPIRONOLACTONE					
		100MG	A040750	003	Aug 29, 2006
	PUREPAC PHARM	25MG	A087998	001	Oct 14, 1983
		25MG	A088053	001	Aug 25, 1983
	SUPERPHARM	25MG	A089364	001	Nov 07, 1986
	UPSHER SMITH	25MG	A087554	001	
	VANGARD	25MG	A087648	001	Feb 01, 1982
	WARNER CHILCOTT	25MG	A087952	001	Nov 18, 1982
	WATSON LABS	25MG	A086898	002	Mar 02, 1982
		25MG	A087078	001	

STANOZOLOL

TABLET;ORAL					
WINSTROL					
+	LUNDBECK INC	2MG	N012885	001	May 14, 1984

STAVUDINE

CAPSULE;ORAL					
STAVUDINE					
	AUROBINDO PHARMA	15MG	A077672	003	Dec 29, 2008
		20MG	A077672	004	Dec 29, 2008
		30MG	A077672	001	Dec 29, 2008
		40MG	A077672	002	Dec 29, 2008
	HETERO LABS LTD III	15MG	A078957	001	Dec 29, 2008
		20MG	A078957	002	Dec 29, 2008
		30MG	A078957	003	Dec 29, 2008
		40MG	A078957	004	Dec 29, 2008
	MYLAN	15MG	A079069	001	Dec 29, 2008
		20MG	A079069	002	Dec 29, 2008
		30MG	A079069	003	Dec 29, 2008
		40MG	A079069	004	Dec 29, 2008
	MYLAN LABS LTD	30MG	A078775	001	Jan 05, 2009
		40MG	A078775	002	Jan 05, 2009
ZERIT					
	BRISTOL-MYERS SQUIBB	5MG	N020412	001	Jun 24, 1994
+		15MG	N020412	002	Jun 24, 1994
+		20MG	N020412	003	Jun 24, 1994
+		30MG	N020412	004	Jun 24, 1994
+		40MG	N020412	005	Jun 24, 1994
CAPSULE, EXTENDED RELEASE;ORAL					
ZERIT XR					
	BRISTOL MYERS SQUIBB	37.5MG	N021453	001	Dec 31, 2002
		50MG	N021453	002	Dec 31, 2002
		75MG	N021453	003	Dec 31, 2002
		100MG	N021453	004	Dec 31, 2002
FOR SOLUTION;ORAL					
STAVUDINE					
	AUROBINDO PHARMA	1MG/ML	A077774	001	Dec 29, 2008
	CIPLA LTD	1MG/ML	A078030	001	Mar 20, 2009
ZERIT					
+	BRISTOL-MYERS SQUIBB	1MG/ML **	N020413	001	Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID;N/A					
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER					
	ABRAXIS PHARM	100%	A089099	001	Dec 29, 1987
		100%	A089100	001	Dec 29, 1987
STERILE WATER FOR INJECTION					
	HIKMA	100% (20ML)	A206369	002	Sep 02, 2015
+	HOSPIRA	100% (1ML)	N018801	001	Oct 27, 1982
	NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER					
	B BRAUN	100%	N019077	001	Mar 02, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

STERILE WATER FOR IRRIGATION				
LIQUID;IRRIGATION				
STERILE WATER IN PLASTIC CONTAINER				
	MILES	100%	N018246 001	
STREPTOMYCIN SULFATE				
INJECTABLE;INJECTION				
STREPTOMYCIN SULFATE				
	COPANOS	EQ 500MG BASE/ML	A060684 001	
	LILLY	EQ 1GM BASE/VIAL	A060107 001	
		EQ 1GM BASE/2ML	A060404 001	
		EQ 5GM BASE/VIAL	A060107 002	
	PFIZER	EQ 1GM BASE/VIAL **	A060076 001	
		EQ 1GM BASE/2.5ML	A060111 001	
		EQ 5GM BASE/VIAL **	A060076 002	
SUCCINYLCHOLINE CHLORIDE				
INJECTABLE;INJECTION				
ANECTINE				
	SANDOZ INC	50MG/ML	N008453 003	
		500MG/VIAL	N008453 001	
		1GM/VIAL	N008453 004	
QUELICIN PRESERVATIVE FREE				
+	HOSPIRA	20MG/ML **	N008845 001	
+		50MG/ML **	N008845 002	
+		100MG/ML **	N008845 004	
SUCCINYLCHOLINE CHLORIDE				
	AMPHASTAR PHARMS INC	20MG/ML	A213432 001	Jun 08, 2020
	INTL MEDICATION	100MG/VIAL	A085400 001	Feb 04, 1982
	ORGANON USA INC	20MG/ML	A080997 001	
SUCOSTRIN				
+	APOTHECON	20MG/ML	N008847 001	
+		100MG/ML	N008847 003	
SUFENTANIL CITRATE				
INJECTABLE;INJECTION				
SUFENTANIL CITRATE				
	WATSON LABS	EQ 0.05MG BASE/ML	A074406 001	Dec 15, 1995
SULFACETAMIDE SODIUM				
OINTMENT;OPHTHALMIC				
BLEPH-10				
	ALLERGAN	10%	A084015 001	
CETAMIDE				
	ALCON	10%	A080021 001	
SODIUM SULAMYD				
+	SCHERING	10% **	N005963 002	
SULFAIR 10				
	PHARMAFAIR	10%	A088000 001	Dec 22, 1982
SOLUTION/DROPS;OPHTHALMIC				
BLEPH-30				
	ALLERGAN	30%	A080028 002	
ISOPTO CETAMIDE				
	ALCON	15%	A080020 002	
OCUSULF-10				
	MIZA PHARMS USA	10%	A080660 001	
OCUSULF-30				
	MIZA PHARMS USA	30%	A080660 002	
SODIUM SULAMYD				
+	SCHERING	10% **	N005963 001	
+		30% **	N005963 003	
SODIUM SULFACETAMIDE				
	AKORN	10%	A083021 001	
		15%	A083021 002	
		30%	A083021 003	
	SOLA BARNES HIND	10%	A084143 001	
		10%	A084145 001	
		30%	A084146 001	
		30%	A084147 001	
SULF-10				
	NOVARTIS	10%	A080025 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFACETAMIDE SODIUM				
SOLUTION/DROPS;OPHTHALMIC				
SULF-15				
NOVARTIS	15%		A089047 001	Oct 31, 1995
SULFACEL-15				
OPTOPICS	15%		A080024 001	
SULFACETAMIDE SODIUM				
AKORN	30%		A040216 001	May 25, 1999
ALCON PHARMS LTD	30%		A089068 001	May 05, 1987
PHARMAFAIR	10%		A088947 001	May 17, 1985
SULFAIR 10				
PHARMAFAIR	10%		A087949 001	Dec 13, 1982
SULFAIR FORTE				
PHARMAFAIR	30%		A088385 001	Oct 13, 1983
SULFAIR-15				
PHARMAFAIR	15%		A088186 001	May 25, 1983
SULTEN-10				
BAUSCH AND LOMB	10%		A087818 001	Feb 03, 1983
SULFACYTINE				
TABLET;ORAL				
RENOQUID				
GLENWOOD	250MG		N017569 001	
SULFADIAZINE				
TABLET;ORAL				
SULFADIAZINE				
ABBVIE	300MG		N004125 005	
EVERYLIFE	500MG		A080088 001	
+ IMPAX LABS	500MG		A080081 001	
LANNETT	500MG		A080084 001	
LEDERLE	500MG		N004054 001	
+ LILLY	500MG		N004122 002	
SULFADIAZINE SODIUM				
INJECTABLE;INJECTION				
SULFADIAZINE SODIUM				
LEDERLE	250MG/ML		N004054 002	
SULFADIAZINE; SULFAMERAZINE				
SUSPENSION;ORAL				
SULFONAMIDES DUPLEX				
LILLY	250MG/5ML;250MG/5ML		N006317 007	
SULFAMETER				
TABLET;ORAL				
SULLA				
BAYER HLTHCARE	500MG		N016000 002	
SULFAMETHIZOLE				
TABLET;ORAL				
MICROSUL				
FOREST PHARMS	1GM		A086012 001	
PROKLAR				
FOREST PHARMS	500MG		A080273 001	
THIOSULFIL				
WYETH AYERST	250MG		N008565 001	
	500MG		N008565 004	
SULFAMETHOXAZOLE				
SUSPENSION;ORAL				
GANTANOL				
ROCHE	500MG/5ML		N013664 002	
TABLET;ORAL				
GANTANOL				
ROCHE	500MG		N012715 002	
GANTANOL-DS				
ROCHE	1GM		N012715 003	
SULFAMETHOXAZOLE				
ASCOT	500MG		A087662 001	Oct 20, 1982
BARR	500MG		A087189 001	Jul 25, 1983
HEATHER	500MG		A086163 001	
RISING	500MG		A085844 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFAMETHOXAZOLE

TABLET;ORAL				
SULFAMETHOXAZOLE				
WATSON LABS	500MG		A085053 001	
	1GM		A086000 001	
UROBAK				
SHIONOGI	500MG		A087307 001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION				
BACTRIM				
+ SUN PHARM INDS INC	80MG/ML;16MG/ML **		N018374 001	
SEPTRA				
MONARCH PHARMS	80MG/ML;16MG/ML **		N018452 001	
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
ABRAXIS PHARM	80MG/ML;16MG/ML		A070223 001	Dec 29, 1987
BEDFORD	80MG/ML;16MG/ML		A072383 001	Apr 29, 1992
HIKMA	80MG/ML;16MG/ML		A070627 001	Dec 29, 1987
	80MG/ML;16MG/ML		A070628 001	Dec 29, 1987
HOSPIRA	80MG/ML;16MG/ML		A073199 001	Sep 11, 1992
WATSON LABS	80MG/ML;16MG/ML		A071556 001	Dec 29, 1987
SUSPENSION;ORAL				
BACTRIM				
+ SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **		N017560 001	
BACTRIM PEDIATRIC				
SUN PHARM INDUSTRIES	200MG/5ML;40MG/5ML **		N017560 002	
SEPTRA				
MONARCH PHARMS	200MG/5ML;40MG/5ML **		N017598 001	
SEPTRA GRAPE				
MONARCH PHARMS	200MG/5ML;40MG/5ML **		N017598 002	Feb 12, 1986
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
ANI PHARMS	200MG/5ML;40MG/5ML		A070028 001	Jun 02, 1987
TEVA	200MG/5ML;40MG/5ML		N018812 001	Jan 28, 1983
	200MG/5ML;40MG/5ML		N018812 002	Jun 10, 1983
SULFATRIM				
PHARM ASSOC	200MG/5ML;40MG/5ML		N018615 002	Jan 07, 1983
SULMEPRIM				
USL PHARMA	200MG/5ML;40MG/5ML		A070063 001	Aug 01, 1986
SULMEPRIM PEDIATRIC				
USL PHARMA	200MG/5ML;40MG/5ML		A070064 001	Aug 01, 1986
TRIMETH/SULFA				
ALPHARMA US PHARMS	200MG/5ML;40MG/5ML		A072289 001	May 23, 1988
	200MG/5ML;40MG/5ML		A072398 001	May 23, 1988
NASKA	200MG/5ML;40MG/5ML		A072399 001	May 23, 1988
TABLET;ORAL				
COTRIM				
TEVA	400MG;80MG		A070034 001	May 16, 1985
COTRIM D.S.				
TEVA	800MG;160MG		A070048 001	Mar 18, 1985
SULFAMETHOPRIM				
NOVEL LABS INC	400MG;80MG		A070022 001	Feb 15, 1985
SULFAMETHOPRIM-DS				
NOVEL LABS INC	800MG;160MG		A070032 001	Feb 15, 1985
SULFAMETHOXAZOLE AND TRIMETHOPRIM				
FOSUN PHARMA	400MG;80MG		A070889 001	Nov 13, 1986
	400MG;80MG		N018598 003	May 19, 1982
	800MG;160MG		A070890 001	Nov 13, 1986
HEATHER	400MG;80MG		N018946 001	Aug 10, 1984
	800MG;160MG		N018946 002	Aug 10, 1984
INTERPHARM	400MG;80MG		A071299 001	Oct 27, 1987
	800MG;160MG		A071300 001	Oct 27, 1987
MARTEC USA LLC	400MG;80MG		A072408 001	Dec 07, 1988
MUTUAL PHARM	400MG;80MG		A070006 001	Nov 14, 1984
PLIVA	400MG;80MG		A070215 001	Sep 10, 1985
	800MG;160MG		A070216 001	Sep 10, 1985
ROXANE	400MG;80MG		A072768 001	Aug 30, 1991
TEVA	400MG;80MG		N018242 001	
	800MG;160MG		N018242 002	
USL PHARMA	400MG;80MG		A070203 001	Nov 08, 1985
	800MG;160MG		A070204 001	Nov 08, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFAMETHOXAZOLE; TRIMETHOPRIM					
TABLET;ORAL					
SULFAMETHOXAZOLE AND TRIMETHOPRIM					
	WATSON LABS	400MG;80MG	A070002	001	Nov 07, 1984
		400MG;80MG	N018852	001	May 09, 1983
		800MG;160MG	A070000	001	Nov 07, 1984
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH					
	FOSUN PHARMA	800MG;160MG	N018598	004	May 19, 1982
	HERITAGE PHARMA AVET	800MG;160MG	A070037	001	Jun 02, 1987
	MARTEC USA LLC	800MG;160MG	A072417	001	Dec 07, 1988
	MUTUAL PHARM	800MG;160MG	A070007	001	Nov 14, 1984
	ROXANE	800MG;160MG	A072769	001	Aug 30, 1991
	WATSON LABS	800MG;160MG	N018854	001	May 09, 1983
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH					
	HERITAGE PHARMA AVET	400MG;80MG	A070030	001	Jun 02, 1987
SULFATRIM-DS					
	SUPERPHARM	800MG;160MG	A070066	001	Jun 24, 1985
SULFATRIM-SS					
	SUPERPHARM	400MG;80MG	A070065	002	Jun 24, 1985
UROPLUS DS					
	SHIONOGI	800MG;160MG	A071816	001	Sep 28, 1987
UROPLUS SS					
	SHIONOGI	400MG;80MG	A071815	001	Sep 28, 1987
SULFANILAMIDE					
CREAM;VAGINAL					
AVC					
+	MYLAN SPECIALITY LP	15%	N006530	003	Jan 27, 1987
SULFANILAMIDE					
	COSETTE	15%	A088718	001	Sep 19, 1985
SUPPOSITORY;VAGINAL					
AVC					
	MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987
SULFAPHENAZOLE					
SUSPENSION;ORAL					
SULFABID					
	PHARM RES ASSOC	500MG/5ML	N013093	001	
TABLET;ORAL					
SULFABID					
	PURDUE FREDERICK	500MG	N013092	002	
SULFAPYRIDINE					
TABLET;ORAL					
SULFAPYRIDINE					
	LILLY	500MG	N000159	001	
SULFASALAZINE					
SUSPENSION;ORAL					
AZULFIDINE					
	PHARMACIA AND UPJOHN	250MG/5ML	N018605	001	
TABLET;ORAL					
S.A.S.-500					
	SOLVAY	500MG	A083450	001	
SULFASALAZINE					
	SANDOZ	500MG	A086184	001	
	SUN PHARM INDUSTRIES	500MG	A089590	001	Oct 19, 1987
	SUPERPHARM	500MG	A089339	001	Oct 26, 1987
	WATSON LABS	500MG	A084964	001	
		500MG	A087197	001	
TABLET, DELAYED RELEASE;ORAL					
SULFASALAZINE					
	WATSON LABS	500MG	A088052	001	May 24, 1983
SULFINPYRAZONE					
CAPSULE;ORAL					
ANTURANE					
+	NOVARTIS	200MG **	N011556	004	
SULFINPYRAZONE					
	BARR	200MG	A087666	001	Sep 17, 1982
	IVAX PHARMS	200MG	A087770	001	Nov 19, 1982
	PAR PHARM	200MG	A088934	001	Sep 06, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFINPYRAZONE				
CAPSULE;ORAL				
SULFINPYRAZONE				
VANGARD	200MG		A088666 001	Feb 17, 1984
TABLET;ORAL				
ANTURANE				
NOVARTIS	100MG **		N011556 003	
SULFINPYRAZONE				
BARR	100MG		A087665 001	Sep 17, 1982
IVAX PHARMS	100MG		A087769 001	Jun 01, 1982
PAR PHARM	100MG		A088933 001	Sep 06, 1985
WATSON LABS	100MG		A087667 001	May 26, 1982
SULFISOXAZOLE				
TABLET;ORAL				
GANTRISIN				
ROCHE	500MG		N006525 001	
SOSOL				
MK LABS	500MG		A080036 001	
SOXAZOLE				
ALRA	500MG		A080366 001	
SULFALAR				
PARKE DAVIS	500MG		A084955 001	
SULFISOXAZOLE				
ANI PHARMS	500MG		A080142 001	
BARR	500MG		A084031 001	
HEATHER	500MG		A080189 001	
IMPAX LABS	500MG		A080109 001	
LANNETT	500MG		A080085 001	
LEDERLE	500MG		A087649 001	
PHARMERAL	500MG		A084385 001	
PUREPAC PHARM	500MG		A080087 001	
RISING	500MG		A085628 001	
ROXANE	500MG		A080082 001	
VALEANT PHARM INTL	500MG		A080268 002	
VITARINE	500MG		A087332 001	
WATSON LABS	500MG		A085534 001	
WEST WARD	500MG		A080379 001	
SULSOXIN				
SOLVAY	500MG		A080040 001	
SULFISOXAZOLE ACETYL				
EMULSION;ORAL				
LIPO GANTRISIN				
ROCHE	EQ 1GM BASE/5ML		N009182 009	
SUSPENSION;ORAL				
GANTRISIN PEDIATRIC				
ROCHE	EQ 500MG BASE/5ML		N009182 004	
SYRUP;ORAL				
GANTRISIN				
ROCHE	EQ 500MG BASE/5ML		N009182 002	
SULFISOXAZOLE DIOLAMINE				
INJECTABLE;INJECTION				
GANTRISIN				
ROCHE	EQ 400MG BASE/ML		N006917 001	
OINTMENT;OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE		N008414 002	
SOLUTION/DROPS;OPHTHALMIC				
GANTRISIN				
ROCHE	EQ 4% BASE		N007757 002	
SULFISOXAZOLE DIOLAMINE				
SOLA BARNES HIND	EQ 4% BASE		A084148 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SULFOXONE SODIUM				
TABLET, DELAYED RELEASE;ORAL				
DIASONE SODIUM				
ABBVIE	165MG	N006044	003	
SULFUR				
POWDER;TOPICAL				
BENSULFOID				
POYTHRESS	33.32%	N002918	001	
SULINDAC				
TABLET;ORAL				
CLINORIL				
+ MERCK	150MG **	N017911	001	
+	200MG **	N017911	002	
SULINDAC				
ANI PHARMS	150MG	A072972	001	Feb 28, 1992
	200MG	A072973	001	Feb 28, 1992
EPIC PHARMA LLC	150MG	A073262	002	Sep 06, 1991
	200MG	A073262	001	Sep 06, 1991
FOSUN PHARMA	150MG	A072712	001	Aug 30, 1991
	200MG	A072713	001	Aug 30, 1991
MYLAN	150MG	A073039	002	Jun 22, 1993
	200MG	A073039	001	Jun 22, 1993
SUMATRIPTAN				
SPRAY;NASAL				
IMITREX				
GLAXOSMITHKLINE	10MG/SPRAY	N020626	002	Aug 26, 1997
SUMATRIPTAN SUCCINATE				
INJECTABLE;SUBCUTANEOUS				
ALSUMA				
MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010
SUMATRIPTAN SUCCINATE				
FRESENIUS KABI USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079240	002	Sep 18, 2009
	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A079240	001	Sep 18, 2009
MYLAN ASI	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010
MYLAN LABS LTD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014
PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009
SANDOZ INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078067	002	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078067	001	Feb 06, 2009
TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078318	001	Feb 06, 2009
	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078318	002	Feb 06, 2009
TEVA PHARMS USA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077907	001	Feb 06, 2009
ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010
SUMAVEL DOSEPRO				
+ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013
+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009
SYSTEM;IONTOPHORESIS				
ZECUITY				
+ TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013
TABLET;ORAL				
SUMATRIPTAN SUCCINATE				
FOSUN PHARMA	EQ 25MG BASE	A076976	001	Aug 10, 2009
	EQ 50MG BASE	A076976	002	Aug 10, 2009
	EQ 100MG BASE	A076976	003	Aug 10, 2009
HIKMA PHARMS	EQ 25MG BASE	A078298	001	May 21, 2013
	EQ 50MG BASE	A078298	002	May 21, 2013
	EQ 100MG BASE	A078298	003	May 21, 2013
MYLAN	EQ 25MG BASE	A077163	001	Nov 02, 2009
	EQ 50MG BASE	A077163	002	Nov 02, 2009
	EQ 100MG BASE	A077163	003	Nov 02, 2009
ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009
	EQ 50MG BASE	A078241	002	Aug 10, 2009
	EQ 100MG BASE	A078241	003	Aug 10, 2009
TEVA	EQ 25MG BASE	A076840	001	Feb 09, 2009
	EQ 50MG BASE	A076840	002	Feb 09, 2009
	EQ 100MG BASE	A076840	003	Feb 09, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SUPROFEN
SOLUTION/DROPS;OPHTHALMIC
PROFENAL

ALCON	1%	N019387	001	Dec 23, 1988

TACRINE HYDROCHLORIDE
CAPSULE;ORAL
COGNEX

SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993
	EQ 20MG BASE	N020070	002	Sep 09, 1993
	EQ 30MG BASE	N020070	003	Sep 09, 1993
	EQ 40MG BASE	N020070	004	Sep 09, 1993

TACROLIMUS
CAPSULE;ORAL
TACROLIMUS

CONCORD BIOTECH LTD	EQ 0.5MG BASE	A213112	001	Nov 10, 2020
HERITAGE PHARMA AVET	EQ 5MG BASE	A090402	001	Jul 01, 2010

TADALAFIL
TABLET;ORAL
TADALAFIL

GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29, 2020
	5MG	A210716	002	Dec 29, 2020
	10MG	A210716	003	Dec 29, 2020
	20MG	A210716	004	Dec 29, 2020
MYLAN	5MG	A206957	001	Apr 29, 2019
	20MG	A200630	001	Aug 03, 2018
RISING PHARMA	2.5MG	A206956	001	Apr 29, 2019
	10MG	A206956	002	Apr 29, 2019
	20MG	A206956	003	Apr 29, 2019
WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019
	5MG	A205885	002	Mar 29, 2019
	10MG	A205885	003	Mar 29, 2019
	20MG	A205885	004	Mar 29, 2019

TALBUTAL
TABLET;ORAL
LOTUSATE

SANOFI AVENTIS US	120MG	N009410	005	

TAMOXIFEN CITRATE
TABLET;ORAL
NOLVADEX

+	ASTRAZENECA	EQ 10MG BASE **	N017970	001	
+		EQ 20MG BASE **	N017970	002	Mar 21, 1994

TAMOXIFEN CITRATE

ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003
	EQ 20MG BASE	A076179	002	Feb 20, 2003
AEGIS PHARMS	EQ 10MG BASE	A076398	001	Mar 31, 2003
	EQ 20MG BASE	A076398	002	Mar 31, 2003
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075740	001	Feb 20, 2003
	EQ 20MG BASE	A075740	002	Feb 20, 2003
PHARMACHEMIE	EQ 10MG BASE	A074539	001	Mar 31, 2003
ROXANE	EQ 10MG BASE	A076027	001	Feb 20, 2003
	EQ 20MG BASE	A076027	002	Feb 20, 2003
TEVA	EQ 10MG BASE	A074504	001	Apr 28, 2003
	EQ 20MG BASE	A074504	002	Apr 28, 2003

TAMSULOSIN HYDROCHLORIDE
CAPSULE;ORAL
TAMSULOSIN HYDROCHLORIDE

ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013
MYLAN	0.4MG	A090408	001	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE
SOLUTION;ORAL
NUCYNTA

+	COLLEGIUM PHARM INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TAVABOROLE
SOLUTION;TOPICAL
TAVABOROLE
IDENTIRX 5% A211963 001 Feb 03, 2021

TAZAROTENE
CREAM;TOPICAL
TAZAROTENE
FOUGERA PHARMS INC 0.1% A211175 001 Jan 28, 2019

TECHNETIUM TC-99M APCITIDE
INJECTABLE;INJECTION
ACUTECT
CIS BIO INTL SA N/A N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE
INJECTABLE;INJECTION
NEO TECT KIT
CIS BIO INTL SA N/A ** N021012 001 Aug 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT
INJECTABLE;INJECTION
HEPATOLITE
SUN PHARM INDS INC N/A N018467 001 Mar 16, 1982

TECHNETIUM TC-99M ETIDRONATE KIT
INJECTABLE;INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA
GE HEALTHCARE N/A N017653 001
MPI STANNOUS DIPHOSPHONATE
GE HEALTHCARE N/A N017667 001
OSTEOSCAN
MALLINCKRODT N/A N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
GE HEALTHCARE N/A N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT
INJECTABLE;INJECTION
RENOTEC
BRACCO N/A N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT
INJECTABLE;INJECTION
GLUCOSCAN
BRISTOL MYERS SQUIBB N/A N017907 001
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT
INJECTABLE;INJECTION
TECHNESCAN HIDA
DRAXIMAGE N/A N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-10
JUBILANT N/A N018035 001

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
AMERSCAN MDP KIT
GE HEALTHCARE N/A N018335 001 Aug 05, 1982
OSTEOLITE
PHARMALUCENCE N/A N017972 001
TECHNETIUM TC 99M MPI MDP
GE HEALTHCARE N/A N018141 001
N/A N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
AN-DTPA
JUBILANT DRAXIMAGE N/A N017714 001
MPI DTPA KIT - CHELATE
GE HEALTHCARE N/A N017255 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
TECHNETIUM TC-99M PENTETATE KIT

	GE HEALTHCARE	N/A	N017264	002	

TECHNETIUM TC-99M POLYPHOSPHATE KIT
INJECTABLE;INJECTION
SODIUM POLYPHOSPHATE-TIN KIT

	GE HEALTHCARE	N/A	N017664	001	

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
INJECTABLE;INJECTION
PYROLITE

	PHARMALUCENCE	N/A	N017684	001	

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
PHOSPHOTEC

	BRACCO	N/A	N017680	001	

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
RBC-SCAN

	CADEMA	N/A	N020063	001	Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
MIRALUMA

	LANTHEUS MEDCL	N/A	N019785	003	May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE
SOLUTION;INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M

+	GE HEALTHCARE	2-100mCi/ML **	N017471	001	
+	MALLINCKRODT	10-60mCi/ML **	N017725	001	
	PHARMALUCENCE	12mCi/ML	N017321	001	
		24mCi/ML	N017321	002	
		48mCi/ML	N017321	003	

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INJECTION, ORAL
MINITEC

	BRACCO	0.22-2.22 CI/GENERATOR	N017339	001	

SOLUTION;INTRAVENOUS
TECHNELITE

	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001	

ULTRA-TECHNEKOW FM

	CURIUM	0.25-3 CI/GENERATOR	N017243	002	

SOLUTION;INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013
		830-16600mCi/GENERATOR	N017693	001	

TECHNETIUM TC-99M SUCCIMER KIT
INJECTABLE;INJECTION
MPI DMSA KIDNEY REAGENT

+	GE HEALTHCARE	N/A	N017944	001	May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID
SOLUTION;INJECTION, ORAL
TECHNETIUM TC 99M SULFUR COLLOID

	GE HEALTHCARE	4mCi/ML	N017456	001	

SOLUTION;ORAL
TECHNETIUM TC 99M SULFUR COLLOID

	MALLINCKRODT	3mCi/ML	N017724	001	

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
TECHNECOLL

	MALLINCKRODT	N/A	N017059	001	

TECHNETIUM TC 99M TSC

	GE HEALTHCARE	N/A	N017784	001	

TESULOID

	BRACCO	N/A	N016923	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TECHNETIUM TC-99M TEBOROXIME KIT				
INJECTABLE;INJECTION				
CARDIOTEC				
BRACCO	N/A	N019928	001	Dec 19, 1990
TECHNETIUM TC-99M TETROFOSMIN KIT				
INJECTABLE;INJECTION				
MYOVIEW				
+ GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996
TEGASEROD MALEATE				
TABLET;ORAL				
ZELNORM				
+ ALFASIGMA	EQ 2MG BASE	N021200	001	Jul 24, 2002
TELAPREVIR				
TABLET;ORAL				
INCIVEK				
VERTEX PHARMS	375MG	N201917	001	May 23, 2011
TELAVANCIN HYDROCHLORIDE				
POWDER;INTRAVENOUS				
VIBATIV				
+ CUMBERLAND PHARMS	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009
TELBIVUDINE				
SOLUTION;ORAL				
TYZEKA				
NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009
TABLET;ORAL				
TYZEKA				
+ NOVARTIS	600MG	N022011	001	Oct 25, 2006
TELITHROMYCIN				
TABLET;ORAL				
KETEK				
SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005
	400MG	N021144	001	Apr 01, 2004
TELMISARTAN				
TABLET;ORAL				
TELMISARTAN				
HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019
	40MG	A207843	002	Feb 19, 2019
	80MG	A207843	003	Feb 19, 2019
JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016
	40MG	A204164	002	Aug 22, 2016
	80MG	A204164	003	Aug 22, 2016
TORRENT	20MG	A203171	001	Jul 07, 2014
	40MG	A203171	002	Jul 07, 2014
	80MG	A203171	003	Jul 07, 2014
TEMAZEPAM				
CAPSULE;ORAL				
TEMAZ				
QUANTUM PHARMICS	15MG	A070564	001	Oct 15, 1985
	30MG	A070547	001	Oct 15, 1985
TEMAZEPAM				
AUROBINDO PHARMA USA	7.5MG	A070920	002	May 21, 2010
	15MG	A070920	004	Jul 07, 1986
	22.5MG	A070920	003	Jun 12, 2009
	30MG	A070920	001	Jul 10, 1986
DURAMED PHARMS BARR	15MG	A071708	001	Sep 29, 1988
	30MG	A071709	001	Sep 29, 1988
SUN PHARM INDUSTRIES	15MG	A071174	001	Jul 10, 1986
	30MG	A071175	001	Jul 10, 1986
USL PHARMA	15MG	A070489	001	Jul 07, 1986
	30MG	A070490	001	Jul 07, 1986
WATSON LABS	15MG	A070383	001	Mar 23, 1987
	15MG	A071446	001	May 21, 1993
	30MG	A070384	001	Mar 23, 1987
	30MG	A071447	001	May 21, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TEMOZOLOMIDE				
CAPSULE;ORAL				
TEMOZOLOMIDE				
APOTEX INC	5MG	A204159	001	Jul 05, 2018
	20MG	A204159	002	Jul 05, 2018
	100MG	A204159	003	Jul 05, 2018
	140MG	A204159	004	Jul 05, 2018
	180MG	A204159	005	Jul 05, 2018
	250MG	A204159	006	Jul 05, 2018
HERITAGE	5MG	A078879	001	Mar 01, 2010
	20MG	A078879	002	Mar 01, 2010
	100MG	A078879	003	Mar 01, 2010
	140MG	A078879	005	Mar 01, 2010
	180MG	A078879	006	Mar 01, 2010
	250MG	A078879	004	Mar 01, 2010
LANNETT CO INC	5MG	A203898	001	Feb 10, 2016
	20MG	A203898	002	Feb 10, 2016
	100MG	A203898	003	Feb 10, 2016
	140MG	A203898	004	Feb 10, 2016
	180MG	A203898	005	Feb 10, 2016
	250MG	A203898	006	Feb 10, 2016
MYLAN	5MG	A205227	001	Jun 29, 2016
	20MG	A205227	002	Jun 29, 2016
	100MG	A205227	003	Jun 29, 2016
	140MG	A205227	004	Jun 29, 2016
	180MG	A205227	005	Jun 29, 2016
	250MG	A205227	006	Jun 29, 2016
WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017
	20MG	A203959	002	Apr 18, 2017
	100MG	A203959	003	Apr 18, 2017
	140MG	A203959	004	Apr 18, 2017
	250MG	A203959	005	Apr 18, 2017
TENAPANOR HYDROCHLORIDE				
TABLET;ORAL				
IBSRELA				
+ ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019
TENIPOSIDE				
INJECTABLE;INJECTION				
VUMON				
+ HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992
TENOFOVIR DISOPROXIL FUMARATE				
TABLET;ORAL				
TENOFOVIR DISOPROXIL FUMARATE				
CHARTWELL	300MG	A206481	001	Jul 26, 2018
MYLAN	150MG	A206569	001	Nov 27, 2018
	200MG	A206569	002	Nov 27, 2018
	250MG	A206569	003	Nov 27, 2018
	300MG	A206569	004	Nov 27, 2018
TERAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
HYTRIN				
+ ABBOTT	EQ 1MG BASE **	N020347	001	Dec 14, 1994
+	EQ 2MG BASE **	N020347	002	Dec 14, 1994
+	EQ 5MG BASE **	N020347	003	Dec 14, 1994
+	EQ 10MG BASE **	N020347	004	Dec 14, 1994
TERAZOSIN HYDROCHLORIDE				
BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000
	EQ 2MG BASE	A075667	002	Jul 28, 2000
	EQ 5MG BASE	A075667	003	Jul 28, 2000
	EQ 10MG BASE	A075667	004	Jul 28, 2000
HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001
	EQ 2MG BASE	A075498	002	Apr 12, 2001
	EQ 5MG BASE	A075498	003	Apr 12, 2001
	EQ 10MG BASE	A075498	004	Apr 12, 2001
MYLAN	EQ 1MG BASE	A075140	002	Feb 11, 2000
	EQ 2MG BASE	A075140	003	Feb 11, 2000
	EQ 5MG BASE	A075140	001	Feb 11, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TERAZOSIN HYDROCHLORIDE				
CAPSULE;ORAL				
TERAZOSIN HYDROCHLORIDE				
	EQ 10MG BASE	A075140	004	Feb 11, 2000
MYLAN TECHNOLOGIES	EQ 1MG BASE	A075384	001	Dec 01, 2000
	EQ 2MG BASE	A075384	002	Dec 01, 2000
	EQ 5MG BASE	A075384	003	Dec 01, 2000
	EQ 10MG BASE	A075384	004	Dec 01, 2000
RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002
	EQ 2MG BASE	A076021	002	Aug 22, 2002
	EQ 5MG BASE	A076021	003	Aug 22, 2002
	EQ 10MG BASE	A076021	004	Aug 22, 2002
TABLET;ORAL				
HYTRIN				
ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987
	EQ 2MG BASE	N019057	002	Aug 07, 1987
	EQ 5MG BASE	N019057	003	Aug 07, 1987
	EQ 10MG BASE	N019057	004	Aug 07, 1987
TERAZOSIN HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A074530	001	Apr 21, 2000
	EQ 2MG BASE	A074530	002	Apr 21, 2000
	EQ 5MG BASE	A074530	003	Apr 21, 2000
	EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ	EQ 1MG BASE	A074315	001	Dec 31, 1998
	EQ 1MG BASE	A074657	001	Apr 28, 2000
	EQ 2MG BASE	A074315	002	Dec 31, 1998
	EQ 2MG BASE	A074657	002	Apr 28, 2000
	EQ 5MG BASE	A074315	003	Dec 31, 1998
	EQ 5MG BASE	A074657	003	Apr 28, 2000
	EQ 10MG BASE	A074315	004	Dec 31, 1998
	EQ 10MG BASE	A074657	004	Apr 28, 2000
TEVA	EQ 1MG BASE	A074446	001	May 18, 2000
	EQ 2MG BASE	A074446	002	May 18, 2000
	EQ 5MG BASE	A074446	003	May 18, 2000
	EQ 10MG BASE	A074446	004	May 18, 2000
TERBINAFINE				
GEL;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998
TERBINAFINE HYDROCHLORIDE				
CREAM;TOPICAL				
LAMISIL				
NOVARTIS	1% **	N020192	001	Dec 30, 1992
GRANULE;ORAL				
LAMISIL				
+ NOVARTIS	EQ 125MG BASE/PACKET	N022071	001	Sep 28, 2007
+	EQ 187.5MG BASE/PACKET	N022071	002	Sep 28, 2007
SOLUTION;TOPICAL				
LAMISIL				
GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997
TABLET;ORAL				
LAMISIL				
+ NOVARTIS	EQ 250MG BASE **	N020539	001	May 10, 1996
TERBINAFINE HYDROCHLORIDE				
CHARTWELL	EQ 250MG BASE	A078199	001	Jul 02, 2007
GEDEON RICHTER USA	EQ 250MG BASE	A077065	001	Jul 02, 2007
MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007
	EQ 250MG BASE	A077195	001	Jul 02, 2007
ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007
WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007
TERBUTALINE SULFATE				
AEROSOL, METERED;INHALATION				
BRETHAIRE				
NOVARTIS	0.2MG/INH	N018762	001	Aug 17, 1984
BRICANYL				
SANOFI AVENTIS US	0.2MG/INH	N018000	001	Mar 19, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TERBUTALINE SULFATE				
INJECTABLE;INJECTION				
BRETHINE				
+ PHARMACARE	1MG/ML **	N018571	001	
BRICANYL				
SANOFI AVENTIS US	1MG/ML	N017466	001	
TERBUTALINE SULFATE				
DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004
TABLET;ORAL				
BRICANYL				
SANOFI AVENTIS US	2.5MG	N017618	001	
	5MG	N017618	002	
TERCONAZOLE				
CREAM;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	0.8% **	N019964	001	Feb 21, 1991
TERAZOL 7				
+ JANSSEN PHARMS	0.4% **	N019579	001	Dec 31, 1987
SUPPOSITORY;VAGINAL				
TERAZOL 3				
+ JANSSEN PHARMS	80MG	N019641	001	May 24, 1988
TERCONAZOLE				
FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006
TERIFLUNOMIDE				
TABLET;ORAL				
TERIFLUNOMIDE				
AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018
	14MG	A209613	002	Sep 28, 2018
APOTEX	7MG	A209601	001	Nov 02, 2018
	14MG	A209601	002	Nov 02, 2018
AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018
	14MG	A209638	002	Oct 26, 2018
BRECKENRIDGE	7MG	A209583	001	Sep 24, 2021
	14MG	A209583	002	Sep 24, 2021
MSN	7MG	A209623	001	Apr 24, 2019
	14MG	A209623	002	Apr 24, 2019
MYLAN	7MG	A209702	001	Feb 28, 2020
	14MG	A209702	002	Feb 28, 2020
SOLA PHARMS	14MG	A209677	001	Jun 17, 2020
TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018
	14MG	A209700	002	Sep 04, 2018
WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018
	14MG	A209549	002	Jul 27, 2018
ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018
	14MG	A209668	002	Nov 30, 2018
TERIPARATIDE				
SOLUTION;SUBCUTANEOUS				
FORTEO				
LILLY	0.75MG/3ML (0.25MG/ML)	N021318	001	Nov 26, 2002
TERIPARATIDE ACETATE				
INJECTABLE;INJECTION				
PARATHAR				
SANOFI AVENTIS US	200 UNITS/VIAL	N019498	001	Dec 23, 1987
TESTOLACTONE				
INJECTABLE;INJECTION				
TESLAC				
BRISTOL MYERS SQUIBB	100MG/ML	N016119	001	
TABLET;ORAL				
TESLAC				
BRISTOL MYERS SQUIBB	50MG	N016118	001	
	250MG	N016118	002	

TESTOSTERONE				
FILM, EXTENDED RELEASE;TRANSDERMAL				
ANDRODERM				
ALLERGAN	2.5MG/24HR	N020489	001	Sep 29, 1995
	5MG/24HR	N020489	002	May 02, 1997
TESTODERM				
ALZA	4MG/24HR	N019762	001	Oct 12, 1993
	6MG/24HR	N019762	002	Oct 12, 1993
TESTODERM TTS				
ALZA	5MG/24HR	N020791	001	Dec 18, 1997
GEL;TRANSDERMAL				
TESTOSTERONE				
ANI PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012
	50MG/5GM PACKET	N202763	002	Feb 14, 2012
PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013
	50MG/5GM PACKET	N203098	003	Jan 31, 2013
GEL, METERED;TRANSDERMAL				
ANDROGEL				
+ ABBVIE	12.5MG/1.25GM ACTUATION **	N021015	003	Sep 26, 2003
TESTOSTERONE				
ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021
PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013
INJECTABLE;INJECTION				
TESTOSTERONE				
DR REDDYS	100MG/ML	A086417	001	Jul 07, 1983
WATSON LABS	25MG/ML	A086420	001	May 10, 1983
	50MG/ML	A086419	001	Aug 23, 1983
SOLUTION, METERED;TRANSDERMAL				
AXIRON				
+ ELI LILLY AND CO	30MG/1.5ML ACTUATION **	N022504	001	Nov 23, 2010
TESTOSTERONE				
ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A212882	001	Jun 14, 2021
APOTEX	30MG/1.5ML ACTUATION	A209181	001	Nov 25, 2020
TABLET, EXTENDED RELEASE;BUCCAL				
STRIANT				
+ AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003
TESTOSTERONE CYPIONATE				
INJECTABLE;INJECTION				
DEPO-TESTOSTERONE				
PFIZER	50MG/ML	A085635	001	
TESTOSTERONE CYPIONATE				
RISING PHARMA	200MG/ML	A040652	001	Dec 11, 2006
WATSON LABS	100MG/ML	A084401	001	
	100MG/ML	A086029	001	
	200MG/ML	A084401	002	
TESTOSTERONE ENANTHATE				
INJECTABLE;INJECTION				
DELATESTRYL				
ENDO PHARMS	200MG/ML	N009165	001	
+	200MG/ML	N009165	003	
TESTOSTERONE ENANTHATE				
RISING PHARMA	200MG/ML	A040647	001	Oct 05, 2009
WATSON LABS	100MG/ML	A083667	001	
	100MG/ML	A085599	001	
	200MG/ML	A083667	002	
TESTOSTERONE PROPIONATE				
INJECTABLE;INJECTION				
TESTOSTERONE PROPIONATE				
BEL MAR	25MG/ML	A080741	001	
	50MG/ML	A080742	001	
	100MG/ML	A080743	001	
ELKINS SINN	25MG/ML	A080276	001	
LILLY	50MG/ML	A080254	002	
WATSON LABS	25MG/ML	A080188	001	
	25MG/ML	A085490	001	
	50MG/ML	A080188	002	
	50MG/ML	A085490	002	
	100MG/ML	A080188	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TESTOSTERONE PROPIONATE			
INJECTABLE;INJECTION			
TESTOSTERONE PROPIONATE			
	100MG/ML	A083595 003	
TETRABENAZINE			
TABLET;ORAL			
TETRABENAZINE			
AJANTA PHARMA LTD	12.5MG	A213621 001	Dec 04, 2020
	25MG	A213621 002	Dec 04, 2020
TETRACYCLINE HYDROCHLORIDE			
CAPSULE;ORAL			
BRISTACYCLINE			
BRISTOL	250MG	A061658 001	
	250MG	A061888 001	
	500MG	A061658 002	
	500MG	A061888 002	
CYCLOPAR			
WARNER CHILCOTT	250MG	A061725 001	
	250MG	A062175 001	
	250MG	A062332 001	
	500MG	A061725 002	
	500MG	A062332 002	
PANMYCIN			
PHARMACIA AND UPJOHN	250MG	A060347 001	
RETET			
SOLVAY	250MG	A061443 001	
	500MG	A061443 002	
ROBITET			
WYETH AYERST	250MG	A061734 001	
	500MG	A061734 002	
SUMYCIN			
APOTHECON	100MG	A060429 002	
	125MG	A060429 004	
	250MG	A060429 001	
	500MG	A060429 003	
TETRACHEL			
ANGUS	250MG	A060343 001	
	500MG	A060343 003	
TETRACYCLINE HYDROCHLORIDE			
ABBOTT	250MG	A061802 001	
	500MG	A061802 002	
ANI PHARMS	250MG	A061471 001	
ELKINS SINN	250MG	A060059 001	
FERRANTE	125MG	A060173 001	
	250MG	A060173 002	
HEATHER	250MG	A061148 001	
	500MG	A061148 002	
HIKMA	250MG	A060768 001	
	500MG	A060768 002	
IMPAX LABS	100MG	A060469 002	
	250MG	A060469 001	
	500MG	A060469 003	
IVAX SUB TEVA PHARMS	250MG	A060704 001	
	500MG	A060704 002	
MAST MM	250MG	A062085 001	
MYLAN	250MG	A060783 001	
	500MG	A060783 002	
PUREPAC PHARM	250MG	A060290 001	
	500MG	A060290 002	
PVT FORM	250MG	A062686 001	Jul 24, 1986
	500MG	A062686 002	Jul 24, 1986
ROXANE	500MG	A061214 002	
SUN PHARM INDUSTRIES	250MG	A060736 001	
	500MG	A060736 002	
SUPERPHARM	250MG	A062540 001	Mar 21, 1985
	500MG	A062540 002	Mar 21, 1985
VALEANT PHARM INTL	250MG	A060471 001	
	500MG	A060471 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL				
TETRACYCLINE HYDROCHLORIDE				
	WARNER CHILCOTT	250MG	A062300 001	
		500MG	A062300 002	
	WATSON LABS	250MG	A062103 001	
		250MG	A062343 001	
		500MG	A062103 002	
		500MG	A062343 002	
	WYETH AYERST	250MG	A061685 001	
		500MG	A061685 002	
TETRACYN				
	PFIPHARMECS	250MG	A060082 003	
		500MG	A060082 004	
FIBER, EXTENDED RELEASE;PERIODONTAL				
ACTISITE				
	SCHIFF AND CO	12.7MG/FIBER	N050653 001	Mar 25, 1994
FOR SOLUTION;TOPICAL				
TOPICYCLINE				
	SHIRE	2.2MG/ML	N050493 001	
INJECTABLE;INJECTION				
ACHROMYCIN				
	LEDERLE	250MG/VIAL	N050273 002	
		500MG/VIAL	N050273 003	
TETRACYN				
	PFIZER	250MG/VIAL	A060096 001	
		500MG/VIAL	A060096 002	
OINTMENT;OPHTHALMIC				
ACHROMYCIN				
	STORZ	10MG/GM	N050266 001	
SUSPENSION;ORAL				
ACHROMYCIN V				
	LEDERLE	125MG/5ML	N050263 002	
SUMYCIN				
	PAR PHARM	125MG/5ML	A060400 001	
TETRACYCLINE HYDROCHLORIDE				
	ALPHARMA US PHARMS	125MG/5ML	A060633 001	
	FERRANTE	125MG/5ML	A060174 001	
	PROTER	125MG/5ML	A060446 001	
	PUREPAC PHARM	125MG/5ML	A060291 001	
TETRACYN				
	PFIPHARMECS	125MG/5ML	A060095 001	
TETRAMED				
	IVAX SUB TEVA PHARMS	125MG/5ML	A061468 001	
SUSPENSION/DROPS;OPHTHALMIC				
ACHROMYCIN				
	STORZ	1%	N050268 001	
TABLET;ORAL				
PANMYCIN				
	PHARMACIA AND UPJOHN	250MG	A061705 001	
		500MG	A061705 002	
SUMYCIN				
	STRIDES PHARMA	50MG	A061147 003	
		100MG	A061147 002	
		250MG	A061147 001	
		500MG	A061147 004	

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE;ORAL				
TETREX				
	BRISTOL	EQ 100MG HYDROCHLORIDE	A061653 001	
		EQ 250MG HYDROCHLORIDE	A061653 002	
		EQ 250MG HYDROCHLORIDE	A061889 002	
		EQ 250MG HYDROCHLORIDE	N050212 002	
		EQ 500MG HYDROCHLORIDE	A061653 003	
		EQ 500MG HYDROCHLORIDE	A061889 001	
		EQ 500MG HYDROCHLORIDE	N050212 003	

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION					
THALLOUS CHLORIDE TL 201					
	BRACCO	1mCi/ML	N018548	001	Dec 30, 1982
+	GE HEALTHCARE	1mCi/ML	N018110	002	Feb 27, 1996
	TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001
INJECTABLE;INTRAVENOUS					
THALLOUS CHLORIDE TL 201					
	CURIUM	2mCi/ML	A077698	001	Nov 09, 2006
+	LANTHEUS MEDCL	2mCi/ML	N017806	002	Oct 09, 1998

THEOPHYLLINE

CAPSULE;ORAL					
BRONKODYL					
	SANOFI AVENTIS US	100MG	A085264	001	
		200MG	A085264	002	
ELIXOPHYLLIN					
	FOREST LABS	100MG	A085545	001	Jul 31, 1984
		200MG	A083921	001	Jul 31, 1984
SOMOPHYLLIN-T					
	FISONS	100MG	A087155	001	Feb 25, 1985
		200MG	A087155	002	Feb 25, 1985
		250MG	A087155	003	Feb 25, 1985
THEOPHYLLINE					
	KV PHARM	100MG	A085263	001	
		200MG	A085263	002	
	SCHERER RP	100MG	A084731	002	Nov 07, 1986
		200MG	A084731	001	Nov 07, 1986
		250MG	A084731	003	Nov 07, 1986
CAPSULE, EXTENDED RELEASE;ORAL					
AEROLATE III					
	FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
AEROLATE JR					
	FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
AEROLATE SR					
	FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
ELIXOPHYLLIN SR					
	FOREST LABS	125MG	A086826	001	Jan 29, 1985
		250MG	A086826	002	Jan 29, 1985
SLO-BID					
	SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
		75MG	A089539	001	May 10, 1989
		100MG	A087892	001	Jan 31, 1985
		125MG	A089540	001	May 10, 1989
		200MG	A087893	001	Jan 31, 1985
		300MG	A087894	001	Jan 31, 1985
SLO-PHYLLIN					
	SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
+		125MG	A085203	001	May 24, 1982
		250MG	A085205	001	May 24, 1982
SOMOPHYLLIN-CRT					
	GRAHAM DM	50MG	A087763	001	Feb 27, 1985
		100MG	A087194	001	
		200MG	A088382	001	Feb 27, 1985
+		250MG	A087193	001	
		300MG	A088383	001	Feb 27, 1985
THEO-DUR					
	SCHERING	50MG	A088022	001	Sep 10, 1985
		75MG	A088015	001	Sep 10, 1985
		125MG	A088016	001	Sep 10, 1985
		200MG	A087995	001	Sep 10, 1985
THEOBID					
	WHITBY	260MG	A085983	001	Mar 20, 1985
THEOBID JR.					
	WHITBY	130MG	A087854	001	Mar 20, 1985
THEOCLEAR L.A.-130					
	SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982
THEOCLEAR L.A.-260					
	SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL					
THEOPHYL-SR					
	ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
		250MG	A086471	001	Feb 08, 1985
THEOPHYLLINE					
	CENT PHARMS	125MG	A088654	001	Feb 12, 1985
		250MG	A088689	001	Feb 12, 1985
	HOSPIRA	100MG	A089976	001	Jan 04, 1995
		200MG	A089977	001	Jan 04, 1995
		300MG	A089932	001	Jan 04, 1995
	INWOOD LABS	100MG	A040052	001	Feb 14, 1994
		125MG	A040052	002	Feb 14, 1994
		200MG	A040052	003	Feb 14, 1994
		300MG	A040052	004	Feb 14, 1994
	SANDOZ	260MG	A087462	001	May 11, 1982
THEOPHYLLINE-SR					
	SCHERER RP	300MG	A088255	001	Jun 12, 1986
THEOVENT					
	SCHERING	125MG	A087010	001	Jan 31, 1985
		250MG	A087910	001	Jan 31, 1985
ELIXIR;ORAL					
ELIXOMIN					
	CENCI	80MG/15ML	A088303	001	Jan 25, 1984
LANOPHYLLIN					
	LANNETT	80MG/15ML	A084578	001	
THEOLIXIR					
	PANRAY	80MG/15ML	A084559	001	
THEOPHYL-225					
	ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	
THEOPHYLLINE					
	ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
	CENCI	80MG/15ML	A087679	001	Apr 15, 1982
	CHARTWELL RX	80MG/15ML	A085952	001	
	HALSEY	80MG/15ML	A085169	001	
	PHARM ASSOC	80MG/15ML	A086720	001	
+	PRECISION DOSE	80MG/15ML	A085863	001	
	ROXANE	80MG/15ML	A084739	001	
	TARO	80MG/15ML	A089626	001	Oct 28, 1988
	WOCKHARDT	80MG/15ML	A086748	001	
INJECTABLE;INJECTION					
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
		200MG/100ML	N019826	004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER					
	B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
		400MG/100ML	N019212	002	Nov 07, 1984
		400MG/100ML	N019826	005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER					
	BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982
		40MG/100ML	N018649	001	Jul 26, 1982
		80MG/100ML	N018649	002	Jul 26, 1982
		160MG/100ML	N018649	003	Jul 26, 1982
		200MG/100ML	N018649	004	Jul 26, 1982
		320MG/100ML	N018649	006	Nov 13, 1985
		400MG/100ML	N018649	005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984
+		40MG/100ML	N019211	001	Dec 14, 1984
		80MG/100ML	N019211	002	Dec 14, 1984
+		160MG/100ML	N019211	003	Dec 14, 1984
		200MG/100ML	N019211	004	Dec 14, 1984
+		320MG/100ML	N019211	006	Jan 20, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE					
INJECTABLE;INJECTION					
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER					
	400MG/100ML		N019211	005	Dec 14, 1984
SOLUTION;ORAL					
AEROLATE					
FLEMING PHARMS	150MG/15ML		A089141	001	Dec 03, 1986
THEOLAIR					
3M	80MG/15ML		A086107	001	
THEOPHYLLINE					
+ ROXANE	80MG/15ML		A087449	001	Sep 15, 1983
SUSPENSION;ORAL					
ELIXICON					
FOREST LABS	100MG/5ML		A085502	001	
SYRUP;ORAL					
ACCURBRON					
SANOFI AVENTIS US	150MG/15ML		A088746	001	Nov 22, 1985
AQUAPHYLLIN					
FERNDALE LABS	80MG/15ML		A087917	001	Jan 18, 1983
SLO-PHYLLIN					
SANOFI AVENTIS US	80MG/15ML		A085187	001	
THEOCLEAR-80					
CENT PHARMS	80MG/15ML		A087095	001	Mar 01, 1982
THEOPHYLLINE					
ALPHARMA US PHARMS	80MG/15ML		A086001	001	
+	150MG/15ML		A086545	001	
TABLET;ORAL					
QUIBRON-T					
MONARCH PHARMS	300MG		A088656	001	Aug 22, 1985
SLO-PHYLLIN					
SANOFI AVENTIS US	100MG		A085202	001	
	200MG		A085204	001	
THEOCLEAR-100					
CENT PHARMS	100MG		A085353	002	
THEOCLEAR-200					
CENT PHARMS	200MG		A085353	001	
THEOLAIR					
MEDICIS	125MG		A086399	001	
	250MG		A086399	002	
THEOPHYL-225					
ORTHO MCNEIL PHARM	225MG		A084726	001	
TABLET, CHEWABLE;ORAL					
THEOPHYL					
ORTHO MCNEIL PHARM	100MG		A086506	001	Sep 12, 1985
TABLET, EXTENDED RELEASE;ORAL					
DURAPHYL					
FOREST LABS	100MG		A088503	001	Apr 03, 1985
	200MG		A088504	001	Apr 03, 1985
	300MG		A088505	001	Apr 03, 1985
LABID					
WARNER CHILCOTT	250MG		A087225	001	
QUIBRON-T/SR					
MONARCH PHARMS	300MG		A087563	001	Jun 21, 1983
SUSTAIRE					
ROERIG	100MG		A085665	001	
	300MG		A085665	002	
T-PHYL					
PHARM RES ASSOC	200MG		A088253	001	Aug 17, 1983
THEO-DUR					
SCHERING	100MG		A085328	001	
+	200MG		A086998	001	
+	300MG		A085328	002	
	450MG		A089131	001	Jun 25, 1986
THEOCHRON					
NOSTRUM PHARMS LLC	100MG		A087400	003	Feb 21, 1985
	200MG		A087400	004	Feb 21, 1985
	300MG		A087400	002	Jan 11, 1983
THEOLAIR-SR					
3M	200MG		A088369	001	Jul 16, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THEOPHYLLINE				
TABLET, EXTENDED RELEASE;ORAL				
THEOLAIR-SR				
	250MG	A086363	002	Jul 16, 1987
	300MG	A088364	001	Jul 16, 1987
	500MG	A089132	001	Jul 16, 1987
THEOPHYLLINE				
ABLE	300MG	A040548	001	Apr 30, 2004
	400MG	A040543	001	Apr 27, 2004
	450MG	A040546	001	Apr 30, 2004
	600MG	A040539	001	Apr 27, 2004
HERITAGE PHARMA AVET	100MG	A089807	001	Apr 30, 1990
	200MG	A089808	001	Apr 30, 1990
INWOOD LABS	450MG	A040034	001	Apr 28, 1995
UNI-DUR				
SCHERING	400MG	A089822	001	Jan 04, 1995
	600MG	A089823	001	Jan 04, 1995
THEOPHYLLINE SODIUM GLYCINATE				
ELIXIR;ORAL				
SYNOPHYLATE				
CENT PHARMS	EQ 165MG BASE/15ML	N006333	008	
TABLET;ORAL				
ASBRON				
NOVARTIS	EQ 150MG BASE	A085148	001	
THIABENDAZOLE				
SUSPENSION;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG/5ML	N016097	001	
TABLET, CHEWABLE;ORAL				
MINTEZOL				
MERCK SHARP DOHME	500MG	N016096	001	
THIAMINE HYDROCHLORIDE				
INJECTABLE;INJECTION				
BETALIN S				
+ LILLY	100MG/ML	A080853	001	
THIAMINE HYDROCHLORIDE				
ABRAXIS PHARM	100MG/ML	A080509	001	
AKORN	100MG/ML	A087968	001	Oct 01, 1982
BEL MAR	100MG/ML	A080718	001	
	200MG/ML	A080712	001	
DELL LABS	100MG/ML	A083775	001	
DR REDDYS	100MG/ML	A080571	001	
	200MG/ML	A080571	002	
HOSPIRA	100MG/ML	A040079	001	May 03, 1996
LUITPOLD	100MG/ML	A080667	001	
PARKE DAVIS	100MG/ML	A080770	001	
WATSON LABS	100MG/ML	A083534	001	
	200MG/ML	A083534	002	
WYETH AYERST	100MG/ML	A080553	001	
THIAMYLAL SODIUM				
INJECTABLE;INJECTION				
SURITAL				
PARKEDALE	1GM/VIAL	N007600	003	
	5GM/VIAL	N007600	005	
	10GM/VIAL	N007600	009	
THIETHYLPERAZINE MALATE				
INJECTABLE;INJECTION				
TORECAN				
NOVARTIS	5MG/ML	N012754	002	
THIETHYLPERAZINE MALEATE				
SUPPOSITORY;RECTAL				
TORECAN				
NOVARTIS	10MG	N013247	001	
TABLET;ORAL				
TORECAN				
NOVARTIS	10MG	N012753	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIOPENTAL SODIUM				
SUSPENSION;RECTAL				
PENTOTHAL				
ABBOTT	400MG/GM	N011679	001	
THIORIDAZINE				
SUSPENSION;ORAL				
MELLARIL-S				
NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML **	N017923	001	
	EQ 100MG HYDROCHLORIDE/5ML **	N017923	002	
THIORIDAZINE HYDROCHLORIDE				
CONCENTRATE;ORAL				
MELLARIL				
NOVARTIS	30MG/ML **	N011808	012	
	100MG/ML **	N011808	018	
THIORIDAZINE HYDROCHLORIDE				
ACTAVIS MID ATLANTIC	100MG/ML	A088229	001	Aug 23, 1983
AKORN	30MG/ML	A040125	001	Aug 16, 1996
	100MG/ML	A040126	001	Aug 16, 1996
ALPHARMA US PHARMS	30MG/ML	A087766	001	Apr 26, 1983
ANI PHARMS	30MG/ML	A089602	001	Nov 09, 1987
	100MG/ML	A089603	001	Nov 09, 1987
PHARM ASSOC	30MG/ML	A040187	001	Aug 28, 1997
	100MG/ML	A040213	001	May 29, 1998
SANDOZ	30MG/ML	A088307	001	Nov 23, 1983
	100MG/ML	A088308	001	Nov 23, 1983
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE INTENSOL				
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985
TABLET;ORAL				
MELLARIL				
+ NOVARTIS	10MG **	N011808	003	
+	15MG **	N011808	016	
+	25MG **	N011808	006	
+	50MG **	N011808	011	
+	100MG **	N011808	009	
+	150MG **	N011808	017	
+	200MG **	N011808	015	
THIORIDAZINE HYDROCHLORIDE				
ANI PHARMS	10MG	A088270	001	Apr 14, 1983
	10MG	A088493	001	May 17, 1985
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
	100MG	A088456	001	May 17, 1985
FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
HERITAGE PHARMA AVET	10MG	A088476	001	Nov 08, 1983
	25MG	A088478	001	Nov 08, 1983
	50MG	A088479	001	Nov 08, 1983
	100MG	A088736	001	Jul 24, 1984
MUTUAL PHARM	10MG	A088375	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983
	100MG	A088379	001	Nov 16, 1983
MYLAN	10MG	A088332	001	Jun 27, 1983
	25MG	A088333	001	Jun 27, 1983
	50MG	A088334	001	Jun 27, 1983
	100MG	A088335	001	Nov 18, 1983
PAR PHARM	10MG	A088351	001	Dec 05, 1983
	15MG	A088352	001	Dec 05, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE					
	25MG		A088336	001	Dec 05, 1983
	50MG		A088322	001	Dec 05, 1983
	100MG		A088480	001	Dec 29, 1983
	150MG		A089764	001	Feb 09, 1988
	200MG		A089765	001	Feb 09, 1988
ROXANE	10MG		A088663	001	Mar 15, 1984
	25MG		A088664	001	Mar 15, 1984
	50MG		A088665	001	Mar 15, 1984
	100MG		A089048	001	Feb 26, 1985
SUN PHARM INDUSTRIES	10MG		A089953	004	Aug 01, 1986
	15MG		A088461	001	Nov 18, 1983
	25MG		A089953	003	Aug 01, 1986
	50MG		A089953	002	Aug 01, 1986
	100MG		A089953	001	Oct 07, 1988
	150MG		A088737	001	Sep 26, 1984
	200MG		A088738	001	Oct 16, 1984
SUPERPHARM	10MG		A089103	001	Jul 02, 1985
	25MG		A089104	001	Jul 02, 1985
	50MG		A089105	001	Jul 02, 1985
WATSON LABS	10MG		A088412	001	Sep 12, 1983
	10MG		A088561	001	May 11, 1984
	15MG		A088345	001	Jul 28, 1983
	15MG		A088562	001	May 11, 1984
	25MG		A088296	001	Jul 28, 1983
	25MG		A088755	001	Jul 24, 1984
	50MG		A088323	001	Jul 28, 1983
	50MG		A088563	001	May 11, 1984
	100MG		A088284	001	Aug 25, 1983
	100MG		A088564	001	May 11, 1984
	150MG		A088410	001	Mar 05, 1984
	150MG		A088869	001	Jun 28, 1985
	200MG		A088381	001	Mar 14, 1984
WATSON LABS TEVA	15MG		A088477	001	Nov 08, 1983
	25MG		A088567	001	May 11, 1984
	200MG		A088872	001	Apr 26, 1985
WEST WARD	10MG		A088658	001	Mar 26, 1984
	15MG		A088659	001	Mar 26, 1984
	25MG		A088660	001	Mar 26, 1984
	50MG		A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE;INJECTION

THIOPLEX					
+ IMMUNEX	15MG/VIAL **		N020058	001	Dec 22, 1994
THIOTEPA					
FRESENIUS KABI USA	15MG/VIAL		A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL		N011683	001	
TEVA PARENTERAL	15MG/VIAL **		A075730	001	Apr 20, 2001
	30MG/VIAL **		A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE;ORAL

NAVANE					
+ PFIZER	1MG **		N016584	001	
+	2MG **		N016584	002	
+	5MG **		N016584	003	
+	10MG **		N016584	004	
+	20MG **		N016584	005	
THIOTHIXENE					
AM THERAP	1MG		A071884	001	Aug 12, 1987
	2MG		A071885	001	Aug 12, 1987
	5MG		A071886	001	Aug 12, 1987
	10MG		A071887	001	Aug 12, 1987
	20MG		A072200	001	Dec 17, 1987
HERITAGE PHARMA AVET	1MG		A070600	001	Jun 05, 1987
	2MG		A070601	001	Jun 05, 1987
	5MG		A070602	001	Jun 05, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

THIOTHIXENE				
CAPSULE;ORAL				
THIOTHIXENE				
	10MG		A070603 001	Jun 05, 1987
SANDOZ	1MG		A071529 002	Jun 24, 1987
	2MG		A071529 003	Jun 24, 1987
	5MG		A071529 001	Jun 24, 1987
	10MG		A071529 004	Jun 24, 1987
WATSON LABS	2MG		A071626 001	Jun 25, 1987
	5MG		A071627 001	Jun 25, 1987
	10MG		A071628 001	Jun 25, 1987
THIOTHIXENE HYDROCHLORIDE				
CONCENTRATE;ORAL				
NAVANE				
+ PFIZER	EQ 5MG BASE/ML		N016758 001	
THIOTHIXENE HYDROCHLORIDE				
ALPHARMA US PHARMS	EQ 5MG BASE/ML		A070969 001	Oct 16, 1987
PACO	EQ 1MG BASE/ML		A071917 001	Sep 20, 1989
	EQ 5MG BASE/ML		A071939 001	Dec 16, 1988
TEVA	EQ 5MG BASE/ML		A071184 001	Jun 22, 1987
TEVA PHARMS	EQ 5MG BASE/ML		A071554 001	Oct 16, 1987
THIOTHIXENE HYDROCHLORIDE INTENSOL				
HIKMA	EQ 5MG BASE/ML		A073494 001	Jun 30, 1992
INJECTABLE;INJECTION				
NAVANE				
PFIZER	EQ 2MG BASE/ML		N016904 001	
	EQ 10MG BASE/VIAL		N016904 002	
TIAGABINE HYDROCHLORIDE				
TABLET;ORAL				
GABITRIL				
CEPHALON	6MG		N020646 006	Nov 29, 2005
	8MG		N020646 007	Nov 29, 2005
	10MG		N020646 008	Nov 29, 2005
	20MG		N020646 004	Sep 30, 1997
TIAGABINE HYDROCHLORIDE				
WILSHIRE PHARMS INC	2MG		A206857 001	Oct 13, 2017
	4MG		A206857 002	Oct 13, 2017
	12MG		A206857 003	Oct 13, 2017
	16MG		A206857 004	Oct 13, 2017
TICAGRELOR				
TABLET;ORAL				
TICAGRELOR				
AMNEAL	90MG		A208531 001	Jan 23, 2019
SIGMAPHARM LABS LLC	90MG		A208596 001	Apr 07, 2020
SUNSHINE	90MG		A208508 001	Apr 06, 2020
WATSON LABS INC	60MG		A208390 001	Sep 04, 2018
	90MG		A208390 002	Sep 04, 2018
TICARCILLIN DISODIUM				
INJECTABLE;INJECTION				
TICAR				
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL		N050497 001	
	EQ 3GM BASE/VIAL		A062690 001	Dec 19, 1986
	EQ 3GM BASE/VIAL		N050497 002	
	EQ 6GM BASE/VIAL		N050497 003	
	EQ 20GM BASE/VIAL		N050497 004	
	EQ 30GM BASE/VIAL		N050497 005	Apr 04, 1984
TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLID				
ROCHE PALO	125MG		N019979 001	Mar 24, 1993
	250MG		N019979 002	Oct 31, 1991
TICLOPIDINE HYDROCHLORIDE				
ACTAVIS ELIZABETH	250MG		A075253 001	Aug 20, 1999
CHARTWELL RX	250MG		A075318 001	Aug 20, 1999
	250MG		A075326 001	Aug 20, 1999
MYLAN	250MG		A075161 001	Sep 13, 1999
	250MG		A075316 001	Nov 02, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TICLOPIDINE HYDROCHLORIDE				
TABLET;ORAL				
TICLOPIDINE HYDROCHLORIDE				
SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002
WATSON LABS	250MG	A075309	001	Apr 26, 2000
TILUDRONATE DISODIUM				
TABLET;ORAL				
SKELID				
+ SANOFI AVENTIS US	EQ 200MG BASE **	N020707	001	Mar 07, 1997
TIMOLOL MALEATE				
SOLUTION/DROPS;OPHTHALMIC				
TIMOLOL MALEATE				
AKORN	EQ 0.25% BASE	A074465	001	Mar 25, 1997
	EQ 0.25% BASE	A074515	001	Mar 25, 1997
APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000
	EQ 0.5% BASE	A075412	001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667	001	Mar 25, 1997
	EQ 0.5% BASE	A074668	001	Mar 25, 1997
TABLET;ORAL				
BLOCADREN				
+ MERCK	5MG **	N018017	001	
+	10MG **	N018017	002	
+	20MG **	N018017	004	
TIMOLOL MALEATE				
ANI PHARMS	5MG	A072917	001	Jul 31, 1991
	10MG	A072918	001	Jul 31, 1991
	20MG	A072919	001	Jul 31, 1991
CHARTWELL RX	5MG	A072550	001	Apr 13, 1989
	10MG	A072551	001	Apr 13, 1989
	20MG	A072552	001	Apr 13, 1989
QUANTUM PHARMICS	5MG	A072466	001	May 19, 1989
	10MG	A072467	001	May 19, 1989
	20MG	A072468	001	May 19, 1989
TEVA	5MG	A072648	001	Jun 16, 1993
	10MG	A072649	001	Jun 16, 1993
	20MG	A072650	001	Jun 16, 1993
USL PHARMA	5MG	A072001	001	Apr 11, 1989
	10MG	A072002	001	Apr 11, 1989
	20MG	A072003	001	Apr 11, 1989
WATSON LABS	5MG	A072269	001	Apr 11, 1989
	10MG	A072270	001	Apr 11, 1989
	20MG	A072271	001	Apr 11, 1989
TINZAPARIN SODIUM				
INJECTABLE;INJECTION				
INNOHEP				
LEO PHARMA AS	20,000 IU/ML	N020484	001	Jul 14, 2000
TIOCONAZOLE				
CREAM;TOPICAL				
TZ-3				
PFIZER	1%	N018682	001	Feb 18, 1983
TIROFIBAN HYDROCHLORIDE				
INJECTABLE;INJECTION				
AGGRASTAT				
MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912	001	May 14, 1998
SOLUTION;INTRAVENOUS				
AGGRASTAT				
MEDICURE	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998
TIZANIDINE HYDROCHLORIDE				
CAPSULE;ORAL				
TIZANIDINE HYDROCHLORIDE				
MYLAN PHARMS INC	EQ 2MG BASE	A091502	001	Nov 09, 2012
	EQ 4MG BASE	A091502	002	Nov 09, 2012
	EQ 6MG BASE	A091502	003	Nov 09, 2012
PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017
	EQ 4MG BASE	A207199	002	Mar 14, 2017
	EQ 6MG BASE	A207199	003	Mar 14, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL				
TIZANIDINE HYDROCHLORIDE				
ANI PHARMS	EQ 2MG BASE	A076283	001	Jul 12, 2002
	EQ 2MG BASE	A076284	001	Jul 03, 2002
	EQ 2MG BASE	A076321	001	Sep 30, 2004
	EQ 2MG BASE	A076371	001	Apr 09, 2003
	EQ 4MG BASE	A076283	002	Jul 12, 2002
	EQ 4MG BASE	A076284	002	Jul 03, 2002
	EQ 4MG BASE	A076321	002	Sep 30, 2004
	EQ 4MG BASE	A076371	002	Apr 09, 2003
MYLAN PHARMS INC	EQ 2MG BASE	A076282	001	Dec 16, 2003
	EQ 4MG BASE	A076282	002	Dec 16, 2003
PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017
	EQ 4MG BASE	A207170	002	Jan 26, 2017
RISING PHARMA	EQ 2MG BASE	A076354	001	Mar 28, 2003
	EQ 4MG BASE	A076354	002	Mar 28, 2003
ZANAFLEX				
+ COVIS	EQ 2MG BASE **	N020397	002	Feb 04, 2000

TOBRAMYCIN

SOLUTION;INHALATION				
TOBRAMYCIN				
LUOXIN AUROVITAS	300MG/5ML	A210871	001	Jan 22, 2021
MYLAN	300MG/5ML	A209554	001	Oct 13, 2017
SOLUTION/DROPS;OPHTHALMIC				
TOBRAMYCIN				
ALCON PHARMS LTD	0.3%	A063176	001	May 25, 1994
APOTEX INC	0.3%	A065087	001	Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION				
NEBCIN				
LILLY	EQ 10MG BASE/ML	A062008	004	
	EQ 10MG BASE/ML	A062707	001	Apr 29, 1987
+	EQ 10MG BASE/ML **	N050477	005	
	EQ 40MG BASE/ML	A062008	001	
+	EQ 1.2GM BASE/VIAL **	N050519	001	
TOBRAMYCIN SULFATE				
APOTHECON	EQ 10MG BASE/ML	A064021	001	May 31, 1994
	EQ 40MG BASE/ML	A064021	002	May 31, 1994
	EQ 40MG BASE/ML	A064026	001	May 31, 1994
HIKMA	EQ 10MG BASE/ML	A063113	001	Apr 26, 1991
	EQ 10MG BASE/ML	A063128	001	Nov 27, 1991
	EQ 40MG BASE/ML	A063118	001	Jul 29, 1991
	EQ 40MG BASE/ML	A063127	001	Nov 27, 1991
HOSPIRA	EQ 10MG BASE/ML	A063080	001	Apr 30, 1991
	EQ 40MG BASE/ML	A063161	001	May 29, 1991
IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994
	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994
WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989
	EQ 40MG BASE/ML	A062945	002	Aug 09, 1989
TOBRAMYCIN SULFATE (PHARMACY BULK)				
HOSPIRA	EQ 40MG BASE/ML **	A063116	001	May 18, 1992

TOCAINIDE HYDROCHLORIDE

TABLET;ORAL				
TONOCARD				
ASTRAZENECA	400MG	N018257	001	Nov 09, 1984
	600MG	N018257	002	Nov 09, 1984

TOFACITINIB CITRATE

TABLET;ORAL				
TOFACITINIB CITRATE				
AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOLAZAMIDE

TABLET;ORAL					
TOLAZAMIDE					
BARR	100MG		A070162	001	Jan 14, 1986
	250MG		A070163	001	Jan 14, 1986
	500MG		A070164	001	Jan 14, 1986
CHARTWELL RX	100MG		A071633	001	Dec 09, 1987
	250MG		A070289	001	Mar 13, 1986
	500MG		A070290	001	Mar 13, 1986
COSETTE	100MG		N018894	001	Nov 02, 1984
	250MG		N018894	002	Nov 02, 1984
	500MG		N018894	003	Nov 02, 1984
DURAMED PHARMS BARR	100MG		A070165	001	Jan 10, 1986
	250MG		A070166	001	Jan 10, 1986
	500MG		A070167	001	Jan 10, 1986
INTERPHARM	250MG		A071270	001	Sep 23, 1986
	500MG		A071271	001	Sep 23, 1986
MYLAN PHARMS INC	250MG		A070259	001	Jan 02, 1986
	500MG		A070259	003	Mar 17, 1986
PAR PHARM	100MG		A070159	001	Jan 06, 1986
	250MG		A070160	001	Jan 06, 1986
	500MG		A070161	001	Jan 06, 1986
SUN PHARM INDUSTRIES	100MG		A071357	001	Jul 16, 1987
	250MG		A071358	001	Jul 16, 1987
	500MG		A071359	001	Jul 16, 1987
SUPERPHARM	250MG		A070763	001	Jun 16, 1986
	500MG		A070764	001	Jun 16, 1986
USL PHARMA	100MG		A071355	001	Jan 11, 1988
	250MG		A070168	001	Apr 02, 1986
	500MG		A070169	001	Apr 02, 1986
WATSON LABS	100MG		A070242	001	Aug 01, 1986
	100MG		A070513	001	Jan 09, 1986
	250MG		A070243	001	Aug 01, 1986
	250MG		A070514	001	Jan 09, 1986
	500MG		A070244	001	Aug 01, 1986
	500MG		A070515	001	Jan 09, 1986
TOLINASE					
+ PHARMACIA AND UPJOHN	100MG **		N015500	002	
+	250MG **		N015500	004	
+	500MG **		N015500	005	

TOLAZOLINE HYDROCHLORIDE

INJECTABLE;INJECTION					
PRISCOLINE					
NOVARTIS	25MG/ML		N006403	005	Feb 22, 1985

TOLBUTAMIDE

TABLET;ORAL					
ORINASE					
PHARMACIA AND UPJOHN	250MG **		N010670	002	
	500MG **		N010670	001	
TOLBUTAMIDE					
ALRA	500MG		A086141	001	
ANI PHARMS	500MG		A087093	001	
ASCOT	500MG		A087541	001	Mar 01, 1983
BARR	500MG		A087121	001	
CHARTWELL RX	500MG		A086574	001	
DAVA PHARMS INC	500MG		A086926	001	
MYLAN PHARMS INC	500MG		A086445	001	
PARKE DAVIS	500MG		A086047	001	
PUREPAC PHARM	500MG		A088950	001	Jun 17, 1985
SANDOZ	500MG		N012678	001	
SUPERPHARM	500MG		A088893	001	Nov 19, 1984
VANGARD	500MG		A087876	001	Apr 20, 1982
WATSON LABS	250MG		A089110	001	May 29, 1987
	500MG		A086109	001	
	500MG		A087318	001	
	500MG		A089111	001	May 29, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOLBUTAMIDE SODIUM				
INJECTABLE;INJECTION				
ORINASE DIAGNOSTIC				
PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	
TOLCAPONE				
TABLET;ORAL				
TASMAR				
BAUSCH	200MG	N020697	002	Jan 29, 1998
TOLCAPONE				
ALVOGEN	100MG	A207729	001	Jul 29, 2020
MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019
TOLMETIN SODIUM				
CAPSULE;ORAL				
TOLECTIN DS				
+ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	
TOLMETIN SODIUM				
ANI PHARMS	EQ 400MG BASE	A073308	001	Jan 24, 1992
	EQ 400MG BASE	A073392	001	Jan 24, 1992
	EQ 400MG BASE	A073519	001	May 29, 1992
FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992
RISING	EQ 400MG BASE	A073393	001	May 27, 1993
SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311	001	Nov 27, 1991
TEVA	EQ 400MG BASE	A073290	001	Nov 27, 1991
TABLET;ORAL				
TOLECTIN				
+ ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001	
TOLECTIN 600				
+ ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989
TOLMETIN SODIUM				
ANI PHARMS	EQ 600MG BASE	A073527	001	Jun 30, 1992
COSETTE	EQ 600MG BASE	A074399	001	Mar 28, 1996
	EQ 600MG BASE	A074729	001	Feb 27, 1997
FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993
RISING	EQ 600MG BASE	A074473	001	Aug 30, 1994
SUN PHARM INDUSTRIES	EQ 200MG BASE	A073310	001	Nov 27, 1991
TOLTERODINE TARTRATE				
CAPSULE, EXTENDED RELEASE;ORAL				
TOLTERODINE TARTRATE				
AUROBINDO PHARMA USA	2MG	A201486	001	Oct 31, 2013
	4MG	A201486	002	Oct 31, 2013
TABLET;ORAL				
TOLTERODINE TARTRATE				
APOTEX CORP	1MG	A200164	001	Sep 25, 2012
	2MG	A200164	002	Sep 25, 2012
MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012
	2MG	A202641	002	Nov 27, 2012
TOLVAPTAN				
TABLET;ORAL				
SAMSCA				
+ OTSUKA	60MG **	N022275	003	May 19, 2009
TOPIRAMATE				
CAPSULE;ORAL				
TOPAMAX SPRINKLE				
JANSSEN PHARMS	50MG	N020844	003	Oct 26, 1998
TOPIRAMATE				
BARR	15MG	A076448	001	Apr 15, 2009
	25MG	A076448	002	Apr 15, 2009
FOSUN PHARMA	15MG	A079206	001	Oct 14, 2009
	25MG	A079206	002	Oct 14, 2009
MYLAN	15MG	A078418	001	Oct 14, 2009
	25MG	A078418	002	Oct 14, 2009
TABLET;ORAL				
TOPAMAX				
JANSSEN PHARMS	300MG	N020505	003	Dec 24, 1996
	400MG	N020505	006	Dec 24, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TOPIRAMATE

TABLET;ORAL

TOPIRAMATE

ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013
	50MG	A078637	002	Feb 27, 2013
	100MG	A078637	003	Feb 27, 2013
	200MG	A078637	004	Feb 27, 2013
BARR	25MG	A076315	001	Mar 27, 2009
	100MG	A076315	002	Mar 27, 2009
	200MG	A076315	003	Mar 27, 2009
CHARTWELL	25MG	A078410	001	Sep 11, 2013
	50MG	A078410	002	Sep 11, 2013
	100MG	A078410	003	Sep 11, 2013
	200MG	A078410	004	Sep 11, 2013
HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013
	50MG	A091185	002	Nov 25, 2013
	100MG	A091185	003	Nov 25, 2013
	200MG	A091185	004	Nov 25, 2013
MYLAN	25MG	A076314	001	Mar 27, 2009
	50MG	A076314	002	Mar 27, 2009
	100MG	A076314	003	Mar 27, 2009
	200MG	A076314	004	Mar 27, 2009
PLIVA HRVATSKA DOO	25MG	A077905	001	Mar 30, 2009
	50MG	A077905	002	Mar 30, 2009
	100MG	A077905	003	Mar 30, 2009
	200MG	A077905	004	Mar 30, 2009
ROXANE	25MG	A076306	001	Mar 27, 2009
	50MG	A076306	002	Mar 27, 2009
	100MG	A076306	003	Mar 27, 2009
	200MG	A076306	004	Mar 27, 2009
TORRENT PHARMS	25MG	A079153	001	Mar 27, 2009
	50MG	A079153	002	Mar 27, 2009
	100MG	A079153	003	Mar 27, 2009
	200MG	A079153	004	Mar 27, 2009
WATSON LABS	25MG	A077643	001	Mar 27, 2009
	50MG	A077643	002	Mar 27, 2009
	100MG	A077643	003	Mar 27, 2009
	200MG	A077643	004	Mar 27, 2009
WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010
	50MG	A090353	002	Sep 01, 2010
	100MG	A090353	003	Sep 01, 2010
	200MG	A090353	004	Sep 01, 2010

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI USA	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010
MEITHEAL	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012
MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012
SUN PHARM INDS LTD	EQ 4MG BASE/VIAL	A202203	001	Aug 29, 2013

SOLUTION;INTRAVENOUS

TOPOTECAN

+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199	001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199	002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199	003	Feb 25, 2011

TORSEMIDE

INJECTABLE;INJECTION

DEMADEX

+	ROCHE	50MG/5ML (10MG/ML) **	N020137	002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137	001	Aug 23, 1993

TORSEMIDE

AM REGENT	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010
	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010
WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008
	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008

TABLET;ORAL

DEMADEX

+	MYLAN SPECIALITY LP	5MG **	N020136	001	Aug 23, 1993
+		10MG **	N020136	002	Aug 23, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TORSEMIDE

TABLET;ORAL					
DEMADEX					
+		20MG **	N020136	003	Aug 23, 1993
+		100MG **	N020136	004	Aug 23, 1993
TORSEMIDE					
	SUN PHARM INDS	5MG	A078478	001	Feb 26, 2008
		10MG	A078478	002	Feb 26, 2008
		20MG	A078478	003	Feb 26, 2008
		100MG	A078478	004	Feb 26, 2008

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL					
CONZIP					
+	CIPHER PHARMS INC	150MG	N022370	004	Aug 01, 2011
TABLET;ORAL					
TRAMADOL HYDROCHLORIDE					
	ACCORD HLTHCARE	50MG	A202390	001	May 16, 2013
	ACTAVIS ELIZABETH	50MG	A075960	001	Jun 19, 2002
	ASTA	50MG	A075974	001	Jul 12, 2002
	GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002
	IVAX SUB TEVA PHARMS	50MG	A075963	001	Jul 03, 2002
	MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015
	MYLAN PHARMS INC	50MG	A075980	001	Nov 21, 2002
	NORTHSTAR HLTHCARE	50MG	A078935	001	May 26, 2010
	SPECGX LLC	50MG	A075983	001	Jun 25, 2002
	SUN PHARM INDUSTRIES	50MG	A076100	001	Jun 20, 2002
	WATSON LABS	50MG	A075962	001	Jun 24, 2002
ULTRAM					
	JANSSEN PHARMS	100MG	N020281	001	Mar 03, 1995
TABLET, EXTENDED RELEASE;ORAL					
RYZOLT					
+	PURDUE PHARMA	100MG **	N021745	001	Dec 30, 2008
+		200MG **	N021745	002	Dec 30, 2008
+		300MG **	N021745	003	Dec 30, 2008
TRAMADOL HYDROCHLORIDE					
	ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012
		200MG	A200491	002	Jun 27, 2012
		300MG	A200491	003	Jun 27, 2012
	AUROBINDO PHARMA LTD	100MG	A204421	001	Oct 20, 2015
		200MG	A204421	002	Oct 20, 2015
		300MG	A204421	003	Oct 20, 2015
	STRIDES PHARMA	100MG	A078783	001	Nov 13, 2009
		200MG	A078783	002	Nov 13, 2009
		300MG	A078783	003	Sep 20, 2011
ULTRAM ER					
+	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005
+		200MG	N021692	002	Sep 08, 2005
+		300MG	N021692	003	Sep 08, 2005
TABLET, ORALLY DISINTEGRATING;ORAL					
RYBIX ODT					
	SHIONOGI INC	50MG	N021693	001	May 05, 2005

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL					
MEKINIST					
+	NOVARTIS	EQ 1MG	N204114	002	May 29, 2013

TRANDOLAPRIL

TABLET;ORAL					
MAVIK					
+	ABBVIE	1MG **	N020528	001	Apr 26, 1996
+		2MG **	N020528	002	Apr 26, 1996
+		4MG **	N020528	003	Apr 26, 1996
TRANDOLAPRIL					
	CIPLA	1MG	A077307	002	Jun 12, 2007
		2MG	A077307	001	Jun 12, 2007
		4MG	A077307	003	Jun 12, 2007
	DR REDDYS LABS LTD	1MG	A078493	001	Aug 25, 2008
		2MG	A078493	002	Aug 25, 2008
		4MG	A078493	003	Aug 25, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

	EPIC PHARMA LLC	1MG	A077256 001	Jun 12, 2007
		2MG	A077256 002	Jun 12, 2007
		4MG	A077256 003	Jun 12, 2007
	INVAGEN PHARMS	1MG	A078320 001	Jun 12, 2007
		2MG	A078320 002	Jun 12, 2007
		4MG	A078320 003	Jun 12, 2007
	MYLAN	1MG	A078346 001	Apr 28, 2008
		2MG	A078346 002	Apr 28, 2008
		4MG	A078346 003	Apr 28, 2008
	WATSON LABS	1MG	A077805 001	Jun 12, 2007
		2MG	A077805 002	Jun 12, 2007
		4MG	A077805 003	Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

+	ABBVIE	1MG;240MG **	N020591 003	Oct 22, 1996
+		2MG;180MG	N020591 001	Oct 22, 1996
+		2MG;240MG	N020591 004	Oct 22, 1996
+		4MG;240MG	N020591 002	Oct 22, 1996

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

	VIRTUS PHARMS	100MG/ML	A202755 001	Feb 25, 2016
	ZYDUS PHARMS	100MG/ML	A205228 001	Jul 17, 2017

TABLET;ORAL

CYKLOKAPRON

	PHARMACIA AND UPJOHN	500MG	N019280 001	Dec 30, 1986

TRANEXAMIC ACID

	APOTEX INC	650MG	A202286 001	Jan 27, 2014
	AUROBINDO PHARMA USA	650MG	A205133 001	Sep 21, 2015

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+	NOVARTIS	0.003% **	N204822 001	May 15, 2014

TRAVATAN

+	ALCON PHARMS LTD	0.004% **	N021257 001	Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

DESYREL

+	PRAGMA	50MG **	N018207 001	
+		100MG **	N018207 002	
+		150MG **	N018207 003	Mar 25, 1985
+		300MG **	N018207 004	Nov 07, 1988

TRAZODONE HYDROCHLORIDE

	ALVOGEN	50MG	A071636 001	Apr 18, 1988
		100MG	A071514 001	Apr 18, 1988
	AM THERAP	50MG	A071139 001	Oct 29, 1986
		100MG	A071140 001	Oct 29, 1986
	FOSUN PHARMA	100MG	A072483 001	Apr 30, 1990
	MYLAN	50MG	A071405 001	Feb 27, 1991
		100MG	A071406 001	Feb 27, 1991
	MYLAN PHARMS INC	50MG	A090514 001	Jun 02, 2009
		100MG	A090514 002	Jun 02, 2009
		150MG	A090514 003	Jun 02, 2009
		300MG	A090514 004	Jun 02, 2009
	QUANTUM PHARMICS	100MG	A070921 001	Dec 01, 1986
	RISING	50MG	A072484 001	Apr 30, 1990
	TEVA	150MG	A074357 001	Apr 30, 1997
	USL PHARMA	50MG	A070491 001	Apr 29, 1987
		100MG	A070492 001	Apr 29, 1987
	WATSON LABS	50MG	A070857 001	Oct 10, 1986
		50MG	A071112 001	Nov 17, 1986
		100MG	A070858 001	Oct 10, 1986
		100MG	A071113 001	Nov 17, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRAZODONE HYDROCHLORIDE				
TABLET;ORAL				
TRIALODINE				
	QUANTUM PHARMICS	50MG	A070942 001	Dec 01, 1986
TABLET, EXTENDED RELEASE;ORAL				
OLEPTRO				
+	ANGELINI PHARMA	150MG **	N022411 001	Feb 02, 2010
+		300MG **	N022411 002	Feb 02, 2010
TREPROSTINIL				
INJECTABLE;IV (INFUSION), SUBCUTANEOUS				
TREPROSTINIL				
	DR REDDYS	1MG/ML	A210214 001	May 22, 2020
		2.5MG/ML	A210214 002	May 22, 2020
		5MG/ML	A210214 003	May 22, 2020
		10MG/ML	A210214 004	May 22, 2020
SOLUTION;INTRAVENOUS, SUBCUTANEOUS				
REMODULIN				
	UNITED THERAP	20MG/20ML (1MG/ML)	N208276 001	Jul 30, 2018
		50MG/20ML (2.5MG/ML)	N208276 002	Jul 30, 2018
		100MG/20ML (5MG/ML)	N208276 003	Jul 30, 2018
		200MG/20ML (10MG/ML)	N208276 004	Jul 30, 2018
TRETINOIN				
CAPSULE;ORAL				
VESANOID				
+	CHEPLAPHARM	10MG **	N020438 001	Nov 22, 1995
CREAM;TOPICAL				
RENOVA				
+	VALEANT PHARMS NORTH	0.05%	N019963 001	Dec 29, 1995
TRETINOIN				
	ALLERGAN	0.0375%	A090098 001	Mar 22, 2010
		0.075%	A202209 001	Oct 11, 2012
	ZO SKIN HEALTH	0.05%	A076498 001	Sep 15, 2005
GEL;TOPICAL				
TRETINOIN				
	MYLAN	0.04%	A202567 001	Jul 17, 2013
		0.1%	A202026 001	Jul 17, 2013
SOLUTION;TOPICAL				
RETIN-A				
+	VALEANT INTL	0.05%	N016921 001	
TRETINOIN				
	TEVA PHARMS	0.05%	A074873 001	Jun 19, 1998
	WOCKHARDT	0.05%	A075260 001	Jan 25, 1999
SWAB;TOPICAL				
RETIN-A				
	VALEANT INTL	0.05%	N016921 002	
TRIAMCINOLONE				
TABLET;ORAL				
ARISTOCORT				
	ASTELLAS	1MG	N011161 009	
		2MG	N011161 004	
		4MG	N011161 007	
		8MG	N011161 011	
		16MG	N011161 010	
KENACORT				
	DELCOR ASSET CORP	1MG	N011283 003	
		2MG	N011283 008	
		4MG	N011283 006	
		8MG	N011283 010	
TRIAMCINOLONE				
	BARR	2MG	A084286 001	
		2MG	A084318 001	
		4MG	A084267 001	
		4MG	A084319 001	
		8MG	A084268 001	
		8MG	A084320 001	
	IMPAX LABS	4MG	A084340 001	
	IVAX SUB TEVA PHARMS	4MG	A083750 001	
	MYLAN	2MG	A084406 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE				
TABLET;ORAL				
TRIAMCINOLONE				
PUREPAC PHARM	2MG	A084020	002	
	4MG	A084020	003	
ROXANE	2MG	A084708	001	
	4MG	A084709	001	
	8MG	A084707	001	
SANDOZ	4MG	A085601	001	
TEVA	4MG	A084775	001	
WATSON LABS	4MG	A084270	001	
	4MG	A085834	001	
TRIAMCINOLONE ACETONIDE				
AEROSOL, METERED;INHALATION				
AZMACORT				
ABBVIE	0.1MG/INH	N018117	001	Apr 23, 1982
AEROSOL, METERED;NASAL				
NASACORT				
SANOFI AVENTIS US	0.055MG/INH	N019798	001	Jul 11, 1991
CREAM;TOPICAL				
ARISTOCORT				
ASTELLAS	0.025%	A083017	003	
	0.1%	A083016	004	
+	0.5%	A083015	002	
ARISTOCORT A				
ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984
FLUTEX				
IVAX PHARMS	0.025%	A085539	001	
	0.1%	A085539	002	
	0.5%	A085539	003	
KENALOG				
+ DELCOR ASSET CORP	0.5%	A083943	001	
KENALOG-H				
DELCOR ASSET CORP	0.1%	A086240	001	
TRIACET				
TEVA	0.025%	A084908	001	
	0.1%	A084908	002	
	0.5%	A084908	003	
TRIACORT				
SOLVAY	0.1%	A087113	001	
TRIAMCINOLONE ACETONIDE				
ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
AMBIX	0.025%	A087932	001	May 09, 1983
MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
	0.1%	A088095	001	Sep 01, 1983
	0.5%	A088096	001	Sep 01, 1983
+ MYLAN	0.025% **	N011601	003	
+	0.1% **	N011601	006	
PHARMADERM	0.025%	A087990	001	Jul 07, 1983
	0.1%	A087991	001	Jul 07, 1983
	0.5%	A087992	001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
	0.1%	A087912	001	Aug 10, 1982
	0.5%	A087922	001	Aug 10, 1982
TARO	0.025%	A040038	001	Oct 26, 1994
	0.025%	A086277	001	
	0.1%	A086276	001	
	0.5%	A086275	001	
TOPIDERM	0.025%	A089274	001	Feb 21, 1989
	0.1%	A089275	001	Feb 21, 1989
	0.5%	A089276	001	Feb 21, 1989

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL					
TRIATEX					
	IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988
		0.1%	A087429	001	Nov 01, 1988
		0.5%	A087428	001	Nov 01, 1988
TRYMEX					
	SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983
		0.1%	A088197	001	Mar 25, 1983
		0.5%	A088198	001	Mar 25, 1983
GEL;TOPICAL					
ARISTOGEL					
	ASTELLAS	0.1%	A083380	001	
INJECTABLE;INJECTION					
TRIAMCINOLONE ACETONIDE					
	PARNELL	3MG/ML	N019503	001	Oct 16, 1987
	SANDOZ INC	10MG/ML	A090166	001	May 27, 2009
		40MG/ML	A090164	001	Jun 01, 2009
	WATSON LABS	40MG/ML	A085825	001	
INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL					
TRIVARIS					
+	ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220	001	Jun 16, 2008
LOTION;TOPICAL					
KENALOG					
	DELCOR ASSET CORP	0.025% **	A084343	001	
+		0.025% **	N011602	003	
		0.1% **	A084343	002	
+		0.1% **	N011602	001	
TRIAMCINOLONE ACETONIDE					
	ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982
		0.1%	A087192	001	Sep 08, 1982
OINTMENT;TOPICAL					
ARISTOCORT					
	ASTELLAS	0.1%	A080750	004	
+		0.5% **	A080745	002	
ARISTOCORT A					
	ASTELLAS	0.1%	A080750	003	
		0.1%	A088780	001	Oct 01, 1984
+		0.5% **	A080745	003	
		0.5%	A088781	001	Oct 05, 1984
FLUTEX					
	IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988
		0.1%	A087377	001	Nov 01, 1988
		0.5%	A087376	001	Nov 01, 1988
KENALOG					
+	DELCOR ASSET CORP	0.5% **	A083944	001	
TRIAMCINOLONE ACETONIDE					
	ACTAVIS MID ATLANTIC	0.1%	A087799	001	Jun 07, 1982
	ALPHARMA US PHARMS	0.5%	A089913	001	Dec 23, 1988
	MORTON GROVE	0.025%	A088090	001	Sep 01, 1983
		0.1%	A088091	001	Sep 01, 1983
		0.5%	A088092	001	Sep 01, 1983
+	MYLAN	0.025% **	N011600	003	
+		0.1% **	N011600	001	
	PHARMADERM	0.025%	A088692	001	Aug 02, 1984
		0.1%	A088690	001	Aug 02, 1984
	STRIDES PHARMA	0.1%	A211315	001	Mar 18, 2020
		0.5%	A211315	002	Mar 18, 2020
	TARO	0.025%	A040040	001	Sep 30, 1994
		0.025%	A040374	001	Jun 05, 2001
		0.1%	A087902	001	Dec 27, 1982
		0.5%	A040386	001	Jun 05, 2001
TRYMEX					
	SAVAGE LABS	0.025%	A088693	001	Aug 02, 1984
		0.1%	A088691	001	Aug 02, 1984
PASTE;DENTAL					
KENALOG IN ORABASE					
+	DELCOR ASSET CORP	0.1% **	N012097	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIAMCINOLONE ACETONIDE				
PASTE;DENTAL				
ORALONE				
TARO	0.1%	A071383	001	Jul 06, 1987
SPRAY, METERED;NASAL				
ALLERNAZE				
LUPIN ATLANTIS	0.05MG/SPRAY	N020120	001	Feb 04, 2000
NASACORT HFA				
SANOFI AVENTIS US	0.055MG/SPRAY	N020784	001	Apr 07, 2004
TRIAMCINOLONE ACETONIDE				
PERRIGO	0.055MG/SPRAY	A078104	001	Jul 30, 2009
TRIAMCINOLONE DIACETATE				
INJECTABLE;INJECTION				
ARISTOCORT				
FOSUN PHARMA	25MG/ML	N011685	003	
+	40MG/ML **	N012802	001	
TRIAMCINOLONE DIACETATE				
AKORN	25MG/ML	A085122	001	
	40MG/ML	A086394	001	
WATSON LABS	40MG/ML	A084072	001	
	40MG/ML	A085529	001	
SYRUP;ORAL				
ARISTOCORT				
ASTELLAS	2MG/5ML	N011960	004	
KENACORT				
DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515	001	
TRIAZOLAM				
TABLET;ORAL				
HALCION				
PFIZER	0.5MG	N017892	002	Nov 15, 1982
TRIAZOLAM				
MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994
	0.25MG	A074031	002	Mar 25, 1994
WATSON LABS	0.125MG	A074445	001	Oct 20, 1995
	0.25MG	A074445	002	Oct 20, 1995
TRICHLORMETHIAZIDE				
TABLET;ORAL				
METAHYDRIN				
SANOFI AVENTIS US	2MG	N012594	001	Jun 16, 1988
	4MG	N012594	002	Jun 16, 1988
NAQUA				
SCHERING	2MG	N012265	001	
	4MG	N012265	002	
TRICHLOREX				
LANNETT	4MG	A083436	001	
	4MG	A085630	001	
TRICHLORMAS				
MAST MM	4MG	A086259	001	
TRICHLORMETHIAZIDE				
CHARTWELL RX	4MG	A085568	001	
IMPAX LABS	4MG	A083967	001	
PAR PHARM	2MG	A087007	001	
	4MG	A087005	001	
SANDOZ	4MG	A086171	001	
WATSON LABS	2MG	A083847	001	
	2MG	A086458	001	
	4MG	A083462	001	
	4MG	A083855	001	
	4MG	A085962	001	
TRICLOFOS SODIUM				
SOLUTION;ORAL				
TRICLOS				
SANOFI AVENTIS US	1.5GM/15ML	N016830	001	
TABLET;ORAL				
TRICLOS				
SANOFI AVENTIS US	750MG	N016809	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIDIHEXETHYL CHLORIDE

INJECTABLE;INJECTION				
PATHILON				
	LEDERLE	10MG/ML	N009729 001	
TABLET;ORAL				
PATHILON				
	LEDERLE	25MG	N009489 005	

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL				
CLOVIQUE				
	CHARTWELL RX	250MG	A209731 001	Oct 21, 2019
TRIENTINE HYDROCHLORIDE				
	AMNEAL	250MG	A210619 001	Feb 08, 2019
	CHARTWELL RX	250MG	A209415 001	Sep 16, 2019

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 10MG BASE/ML **	N011552 006	
TRIFLUOPERAZINE HYDROCHLORIDE				
	FOSUN PHARMA	EQ 10MG BASE/ML	A085787 001	Apr 15, 1982
	WOCKHARDT	EQ 10MG BASE/ML	A088143 001	Jul 26, 1983
INJECTABLE;INJECTION				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 2MG BASE/ML **	N011552 005	
TABLET;ORAL				
STELAZINE				
+	GLAXOSMITHKLINE	EQ 1MG BASE **	N011552 001	
+		EQ 2MG BASE **	N011552 002	
+		EQ 5MG BASE **	N011552 003	
+		EQ 10MG BASE **	N011552 004	
TRIFLUOPERAZINE HYDROCHLORIDE				
	ATHEM	EQ 1MG BASE	A040153 001	Oct 25, 1996
		EQ 2MG BASE	A040153 002	Oct 25, 1996
		EQ 5MG BASE	A040153 003	Oct 25, 1996
		EQ 10MG BASE	A040153 004	Oct 25, 1996
	DURAMED PHARMS BARR	EQ 1MG BASE	A088967 001	Apr 23, 1985
		EQ 2MG BASE	A088968 001	Apr 23, 1985
		EQ 5MG BASE	A088969 001	Apr 23, 1985
		EQ 10MG BASE	A088970 001	Apr 23, 1985
	IVAX PHARMS	EQ 1MG BASE	A087612 001	Nov 19, 1982
		EQ 2MG BASE	A087613 001	Nov 19, 1982
		EQ 5MG BASE	A087328 001	Nov 19, 1982
		EQ 10MG BASE	A087614 001	Nov 19, 1982
	WATSON LABS	EQ 1MG BASE	A085975 001	Jun 23, 1988
		EQ 2MG BASE	A085976 001	Jun 23, 1988
		EQ 5MG BASE	A085973 001	Jun 23, 1988
		EQ 10MG BASE	A088710 001	Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION;ORAL				
VESPRIN				
	APOTHECON	EQ 50MG HYDROCHLORIDE/5ML	N011491 004	

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION				
VESPRIN				
	APOTHECON	3MG/ML	N011325 005	
		10MG/ML	N011325 004	
		20MG/ML	N011325 001	
TABLET;ORAL				
VESPRIN				
	BRISTOL MYERS SQUIBB	10MG	N011123 001	
		25MG	N011123 002	
		50MG	N011123 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
ARTANE				
	LEDERLE	5MG	N006773 010	
		5MG	N012947 001	
ELIXIR;ORAL				
ARTANE				
	LEDERLE	2MG/5ML	N006773 009	
TRIHEXYPHENIDYL HYDROCHLORIDE				
	PHARM VENTURES	2MG/5ML	A089514 001	Apr 07, 1989
TABLET;ORAL				
ARTANE				
+	LEDERLE	2MG **	N006773 005	
+		5MG **	N006773 003	
TREMIN				
	SCHERING	2MG	A080381 001	
		5MG	A080381 003	
TRIHEXYPHENIDYL HYDROCHLORIDE				
	HIKMA	2MG	A040337 002	Feb 16, 2000
		5MG	A040337 001	Feb 16, 2000
	NYLOS	5MG	A085622 001	
	VANGARD	2MG	A088035 001	Jul 30, 1982
	WATSON LABS	2MG	A040184 001	Feb 06, 1998
		2MG	A085117 001	
		5MG	A040184 002	Feb 06, 1998
		5MG	A085105 001	

TRILOSTANE

CAPSULE;ORAL				
MODRASTANE				
	BIOENVISION	30MG	N018719 002	Dec 31, 1984
		60MG	N018719 001	Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL				
TEMARIL				
	ALLERGAN HERBERT	EQ 5MG BASE	N011316 004	
SYRUP;ORAL				
TEMARIL				
	ALLERGAN HERBERT	EQ 2.5MG BASE/5ML	N011316 003	
TRIMEPRAZINE TARTRATE				
	ALPHARMA US PHARMS	EQ 2.5MG BASE/5ML	A085015 001	Feb 18, 1982
	MORTON GROVE	EQ 2.5MG BASE/5ML	A088285 001	Apr 11, 1985
TABLET;ORAL				
TEMARIL				
	ALLERGAN HERBERT	EQ 2.5MG BASE	N011316 001	

TRIMETHADIONE

CAPSULE;ORAL				
TRIDIONE				
	ABBVIE	300MG	N005856 005	
SOLUTION;ORAL				
TRIDIONE				
	ABBVIE	200MG/5ML	N005856 002	
TABLET;ORAL				
TRIDIONE				
+	ABBVIE	150MG	N005856 009	

TRIMETHAPHAN CAMSYLATE

INJECTABLE;INJECTION				
ARFONAD				
	ROCHE	50MG/ML	N008983 001	

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL				
TIGAN				
+	KING PHARMS LLC	300MG	N017531 006	Dec 13, 2001
INJECTABLE;INJECTION				
TRIMETHOBENZAMIDE HYDROCHLORIDE				
	AM REGENT	100MG/ML	A091330 001	Mar 08, 2011
	HOSPIRA	100MG/ML	A088804 001	Apr 03, 1987
	SMITH AND NEPHEW	100MG/ML	A088960 001	Apr 04, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

	100MG/ML	A089043	001	Apr 04, 1986
SOLOPAK	100MG/ML	A089094	001	Apr 04, 1986
WATSON LABS	100MG/ML	A086577	001	Oct 19, 1982
	100MG/ML	A087939	001	Dec 28, 1982

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AM REGENT	100MG/ML	A091329	001	Mar 08, 2011

TRIMETHOPRIM
TABLET;ORAL
PROLOPRIM

MONARCH PHARMS	100MG	N017943	001	
	200MG	N017943	003	Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDUSTRIES	100MG	A070494	001	Jan 22, 1986
	200MG	A070495	001	Sep 24, 1986
TEVA	200MG **	A071259	001	Jun 18, 1987

TRIMPEX

ROCHE	100MG	N017952	001	

TRIMPEX 200

ROCHE	200MG	N017952	002	Nov 09, 1982

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION;ORAL
PRIMSOL

ALLEGIS	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995
+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000

TRIMETREXATE GLUCURONATE
INJECTABLE;INJECTION
NEUTREXIN

MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N020326	001	Dec 17, 1993
	EQ 200MG BASE/VIAL	N020326	002	Jul 31, 1998

TRIMIPRAMINE MALEATE
CAPSULE;ORAL
SURMONTIL

+	ODYSSEY PHARMS	EQ 25MG BASE **	N016792	001	
+		EQ 50MG BASE **	N016792	002	
+		EQ 100MG BASE **	N016792	003	Sep 15, 1982

TRIMIPRAMINE MALEATE

USL PHARMA	EQ 25MG BASE	A071283	001	Dec 08, 1987
	EQ 50MG BASE	A071284	001	Dec 08, 1987
	EQ 100MG BASE	A071285	001	Dec 08, 1987

TRIOXSALEN
TABLET;ORAL
TRISORALEN

VALEANT PHARM INTL	5MG	N012697	001	

TRIPELENNAMINE CITRATE
ELIXIR;ORAL
PBZ

NOVARTIS	EQ 25MG HYDROCHLORIDE/5ML	N005914	004	

TRIPELENNAMINE HYDROCHLORIDE
TABLET;ORAL
PBZ

NOVARTIS	25MG	A083149	001	
	50MG	N005914	002	

TRIPELENNAMINE HYDROCHLORIDE

ANABOLIC	50MG	A083037	001	
BARR	50MG	A080744	001	
HEATHER	50MG	A083989	001	
IMPAX LABS	50MG	A080785	001	
LANNETT	50MG	A083557	001	
NYLOS	50MG	A085412	001	
PARKE DAVIS	25MG	A083625	001	
	50MG	A083626	001	
WATSON LABS	50MG	A080713	001	
	50MG	A080790	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRIPELENNAMINE HYDROCHLORIDE

TABLET;ORAL				
TRIPELENNAMINE HYDROCHLORIDE				
	50MG		A085188 001	
TABLET, EXTENDED RELEASE;ORAL				
PBZ-SR				
NOVARTIS	50MG		N010533 002	
	100MG		N010533 001	

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL				
GYNE-SULF				
COSETTE	3.7%;2.86%;3.42%		A088607 001	Jun 09, 1986
SULTRIN				
ORTHO MCNEIL PHARM	3.7%;2.86%;3.42%		N005794 001	
TRIPLE SULFA				
ALPHARMA US PHARMS	3.7%;2.86%;3.42%		A087864 001	Sep 01, 1982
FOUGERA	3.7%;2.86%;3.42%		A086424 001	
PADAGIS US	3.7%;2.86%;3.42%		A087285 001	Nov 15, 1982
TRYSUL				
SAVAGE LABS	3.7%;2.86%;3.42%		A087887 001	Jul 23, 1982
VAGILIA				
COSETTE	3.7%;2.86%;3.42%		A088821 001	Nov 09, 1987
TABLET;VAGINAL				
SULTRIN				
ORTHO MCNEIL PHARM	184MG;143.75MG;172.5MG		N005794 002	
TRIPLE SULFA				
FOUGERA	184MG;143.75MG;172.5MG		A088463 001	Jan 03, 1985
PHARMADERM	184MG;143.75MG;172.5MG		A088462 001	Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL				
ACTIDIL				
GLAXOSMITHKLINE	1.25MG/5ML		N011496 002	Jul 01, 1983
MYIDYL				
USL PHARMA	1.25MG/5ML		A087963 001	Jan 18, 1983
TRIPROLIDINE HYDROCHLORIDE				
ALPHARMA US PHARMS	1.25MG/5ML		A085940 001	
HALSEY	1.25MG/5ML		A088735 001	Jan 17, 1985
PHARM ASSOC	1.25MG/5ML		A087514 001	Feb 10, 1982
TABLET;ORAL				
ACTIDIL				
GLAXOSMITHKLINE	2.5MG		N011110 002	Jul 01, 1983
TRIPROLIDINE HYDROCHLORIDE				
VITARINE	2.5MG		A085610 001	
WATSON LABS	2.5MG		A085094 001	

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL				
LANTRISUL				
LANNETT	167MG/5ML;167MG/5ML;167MG/5ML		A080123 002	
NEOTRIZINE				
LILLY	167MG/5ML;167MG/5ML;167MG/5ML		N006317 012	
SULFALOID				
FOREST PHARMS	167MG/5ML;167MG/5ML;167MG/5ML		A080100 001	
SULFOSE				
WYETH AYERST	167MG/5ML;167MG/5ML;167MG/5ML		A080013 002	
TERFONYL				
BRISTOL MYERS SQUIBB	167MG/5ML;167MG/5ML;167MG/5ML		N006904 002	
TRIPLE SULFA				
ALPHARMA US PHARMS	167MG/5ML;167MG/5ML;167MG/5ML		A080280 001	
TRIPLE SULFAS				
LEDERLE	167MG/5ML;167MG/5ML;167MG/5ML		N006920 003	
TABLET;ORAL				
NEOTRIZINE				
LILLY	167MG;167MG;167MG		N006317 011	
SULFA-TRIPLE #2				
IMPAX LABS	167MG;167MG;167MG		A080079 001	
SULFALOID				
FOREST PHARMS	167MG;167MG;167MG		A080099 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

TABLET;ORAL				
SULFOSE				
	WYETH AYERST	167MG;167MG;167MG	A080013 001	
TERFONYL				
	BRISTOL MYERS SQUIBB	167MG;167MG;167MG	N006904 001	
TRIPLE SULFA				
	PUREPAC PHARM	167MG;167MG;167MG	A080086 001	
TRIPLE SULFAS				
	LEDERLE	167MG;167MG;167MG	N006920 002	
TRIPLE SULFOID				
	PAL PAK	167MG;167MG;167MG	A080094 001	

TROGLITAZONE

TABLET;ORAL				
PRELAY				
	SANKYO	200MG	N020719 001	Jan 29, 1997
		300MG	N020719 003	Aug 04, 1997
		400MG	N020719 002	Jan 29, 1997
REZULIN				
	PFIZER PHARMS	200MG	N020720 001	Jan 29, 1997
		300MG	N020720 003	Aug 04, 1997
		400MG	N020720 002	Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS;OTIC				
CERUMENEX				
	PHARM RES ASSOC	10%	N011340 002	

TROLEANDOMYCIN

CAPSULE;ORAL				
TAO				
	PFIZER	EQ 250MG BASE	N050336 002	
SUSPENSION;ORAL				
TAO				
	PFIZER	EQ 125MG BASE/5ML	N050332 001	

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC				
MYDRIACYL				
	ALCON	0.5% **	N012111 002	
		1% **	N012111 004	
MYDRIAFAIR				
	PHARMAFAIR	0.5%	A088274 001	Sep 16, 1983
		1%	A088230 001	Sep 16, 1983
TROPICAMIDE				
	AKORN	1%	A088447 001	Aug 28, 1985
	ALCON PHARMS LTD	1%	A089172 001	Dec 28, 1990
	MIZA PHARMS USA	0.5%	A087636 001	Jul 30, 1982
		1%	A087637 001	Aug 09, 1982
	WATSON LABS	0.5%	A089171 001	Dec 28, 1990

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
SANCTURA XR				
+	ALLERGAN	60MG **	N022103 001	Aug 03, 2007
TROSPIUM CHLORIDE				
	UPSHER SMITH LABS	60MG	A091635 001	Apr 29, 2015
TABLET;ORAL				
SANCTURA				
+	ALLERGAN	20MG **	N021595 001	May 28, 2004

TROVAFLOXACIN MESYLATE

TABLET;ORAL				
TROVAN				
	PFIZER	EQ 100MG BASE	N020759 001	Dec 18, 1997
		EQ 200MG BASE	N020759 002	Dec 18, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TUBOCURARINE CHLORIDE
INJECTABLE;INJECTION
TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB	3MG/ML	N005657	001	
HOSPIRA	3MG/ML	N006095	001	
LILLY	3MG/ML	N006325	001	

TYROPANOATE SODIUM
CAPSULE;ORAL
BILOPAQUE

GE HEALTHCARE	750MG	N013731	001	

UNOPROSTONE ISOPROPYL
SOLUTION/DROPS;OPHTHALMIC
RESCULA

+ SUCAMPO PHARMA LLC	0.15% **	N021214	001	Aug 03, 2000

URACIL MUSTARD
CAPSULE;ORAL
URACIL MUSTARD

SHIRE	1MG	N012892	001	

UREA
INJECTABLE;INJECTION
STERILE UREA

HOSPIRA	40GM/VIAL	N017698	001	

UREAPHIL

HOSPIRA	40GM/VIAL	N012154	001	

UREA C-13
FOR SOLUTION;ORAL
BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA	EQ 75MG/POUCH	N020586	002	May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS	125MG/VIAL	N021092	001	Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA	125MG/VIAL	N020586	001	Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES	100MG/VIAL	N020900	001	Feb 04, 1999

URSODIOL
CAPSULE;ORAL
ACTIGALL

ALLERGAN	150MG	N019594	001	Dec 31, 1987

URSODIOL

IMPAX LABS INC	300MG	A077895	001	Jul 27, 2006

TABLET;ORAL
URSODIOL

IMPAX LABS INC	250MG	A200826	001	Dec 23, 2011
	500MG	A200826	002	Dec 23, 2011
TEVA PHARMS USA	250MG	A079184	001	May 13, 2009
	500MG	A079184	002	May 13, 2009

VALACYCLOVIR HYDROCHLORIDE
TABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

HIKMA	EQ 500MG BASE	A078656	001	May 24, 2010
	EQ 1GM BASE	A078656	002	May 24, 2010
MYLAN	EQ 500MG BASE	A078070	001	May 24, 2010
	EQ 1GM BASE	A078070	002	May 24, 2010
TEVA PHARMS	EQ 500MG BASE	A077655	001	May 24, 2010
	EQ 1GM BASE	A077655	002	May 24, 2010
WATSON LABS INC	EQ 500MG BASE	A090370	001	Mar 16, 2011
	EQ 1GM BASE	A090370	002	Mar 16, 2011

VALDECOXIB
TABLET;ORAL
BEXTRA

GD SEARLE	10MG	N021341	002	Nov 16, 2001
	20MG	N021341	003	Nov 16, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VALPROATE SODIUM				
INJECTABLE;INJECTION				
DEPACON				
+	ABBVIE	EQ 100MG BASE/ML	N020593 001	Dec 30, 1996
VALPROIC ACID				
CAPSULE;ORAL				
DEPAKENE				
+	ABBVIE	250MG	N018081 001	
VALPROIC ACID				
	PAR PHARM	250MG	A070431 001	Feb 28, 1986
	SCHERER RP	250MG	A070195 001	Jul 02, 1987
	UPSHER SMITH LABS	250MG	A070631 001	Jun 11, 1987
CAPSULE, DELAYED RELEASE;ORAL				
STAVZOR				
+	BIONPHARMA INC	125MG **	N022152 001	Jul 29, 2008
+		250MG **	N022152 002	Jul 29, 2008
+		500MG **	N022152 003	Jul 29, 2008
SYRUP;ORAL				
DEPAKENE				
+	ABBVIE	250MG/5ML	N018082 001	
VALPROIC ACID				
	ANI PHARMS	250MG/5ML	A073178 001	Aug 25, 1992
	NOSTRUM LABS INC	250MG/5ML	A077105 001	Jul 29, 2005
VALSARTAN				
CAPSULE;ORAL				
DIOVAN				
	NOVARTIS	80MG	N020665 001	Dec 23, 1996
		160MG	N020665 002	Dec 23, 1996
SOLUTION;ORAL				
PREXXARTAN				
+	CARMEL BIOSCIENCES	20MG/5ML	N209139 001	Dec 19, 2017
+		80MG/20ML	N209139 002	Dec 19, 2017
TABLET;ORAL				
VALSARTAN				
	TORRENT	40MG	A202728 001	Jan 05, 2015
		80MG	A202728 002	Jan 05, 2015
		160MG	A202728 003	Jan 05, 2015
		320MG	A202728 004	Jan 05, 2015
	UNICHEM	40MG	A209261 001	May 04, 2018
		80MG	A209261 002	May 04, 2018
		160MG	A209261 003	May 04, 2018
		320MG	A209261 004	May 04, 2018
	WATSON LABS INC	40MG	A090642 001	Jan 05, 2015
		80MG	A090642 002	Jan 05, 2015
		160MG	A090642 003	Jan 05, 2015
		320MG	A090642 004	Jan 05, 2015
VANCOMYCIN HYDROCHLORIDE				
CAPSULE;ORAL				
VANCOMYCIN HYDROCHLORIDE				
	FRESENIUS KABI USA	EQ 125MG BASE	A065453 001	Jun 18, 2012
		EQ 250MG BASE	A065453 002	Jun 18, 2012
FOR SOLUTION;ORAL				
VANCOCIN HYDROCHLORIDE				
	ANI PHARMS	EQ 500MG BASE/6ML	A061667 001	
VANCOLED				
	LEDERLE	EQ 250MG BASE/5ML	A063321 002	Oct 15, 1993
		EQ 500MG BASE/6ML	A063321 003	Oct 15, 1993
INJECTABLE;INJECTION				
VANCOCIN HYDROCHLORIDE				
	ANI PHARMS	EQ 500MG BASE/VIAL **	A060180 001	
		EQ 500MG BASE/VIAL	A062476 001	Mar 15, 1984
		EQ 500MG BASE/VIAL	A062716 001	Mar 13, 1987
		EQ 500MG BASE/VIAL **	A062812 001	Nov 17, 1987
		EQ 1GM BASE/VIAL **	A060180 002	Mar 21, 1986
		EQ 1GM BASE/VIAL	A062476 002	Mar 21, 1986
		EQ 1GM BASE/VIAL	A062716 002	Mar 13, 1987
		EQ 1GM BASE/VIAL **	A062812 002	Nov 17, 1987
		EQ 10GM BASE/VIAL **	A062812 003	Nov 17, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VANCOMYCIN HYDROCHLORIDE				
INJECTABLE;INJECTION				
VANCOLED				
HIKMA	EQ 500MG BASE/VIAL **	A062682	001	Jul 22, 1986
	EQ 1GM BASE/VIAL **	A062682	002	Mar 30, 1988
	EQ 2GM BASE/VIAL **	A062682	003	May 11, 1988
	EQ 5GM BASE/VIAL **	A062682	004	May 11, 1988
	EQ 10GM BASE/VIAL **	A062682	005	May 11, 1988
VANCOMYCIN HYDROCHLORIDE				
EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202275	001	Oct 31, 2013
	EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013
	EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013
	EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013
HIKMA	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
	EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020
	EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988
	EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020
MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011
TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015
	EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015
	EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015
XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
	EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
	EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
	EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015
VANCOR				
PHARMACIA AND UPJOHN	EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
	EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988
VARDENAFIL HYDROCHLORIDE				
TABLET;ORAL				
LEVITRA				
+ BAYER HLTHCARE	EQ 2.5MG BASE **	N021400	003	Aug 19, 2003
+	EQ 5MG BASE	N021400	001	Aug 19, 2003
+	EQ 10MG BASE	N021400	002	Aug 19, 2003
VARDENAFIL HYDROCHLORIDE				
AMNEAL PHARMS CO	EQ 5MG BASE	A210738	001	Oct 31, 2018
	EQ 10MG BASE	A210738	002	Oct 31, 2018
	EQ 20MG BASE	A210738	003	Oct 31, 2018
VASOPRESSIN TANNATE				
INJECTABLE;INJECTION				
PITRESSIN TANNATE				
+ PARKE DAVIS	5PRESSOR UNITS/ML **	N003402	001	
VECURONIUM BROMIDE				
INJECTABLE;INJECTION				
NORCURON				
+ ORGANON USA INC	10MG/VIAL **	N018776	002	Apr 30, 1984
+	20MG/VIAL **	N018776	003	Jan 03, 1992
VECURONIUM BROMIDE				
HIKMA	10MG/VIAL	A075218	001	Aug 23, 1999
	20MG/VIAL	A075218	002	Aug 23, 1999
HOSPIRA	4MG/VIAL	A075558	001	Sep 11, 2001
WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995
	20MG/VIAL	A074334	002	Aug 31, 1995
VENLAFAXINE HYDROCHLORIDE				
CAPSULE, EXTENDED RELEASE;ORAL				
EFFEXOR XR				
UPJOHN	EQ 100MG BASE	N020699	003	Oct 20, 1997
VENLAFAXINE HYDROCHLORIDE				
ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012
	EQ 75MG BASE	A078087	002	Mar 16, 2012
	EQ 150MG BASE	A078087	003	Mar 16, 2012
MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011
	EQ 75MG BASE	A078789	002	Jun 01, 2011
	EQ 150MG BASE	A078789	003	Jun 01, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL				
EFFEXOR				
+	WYETH PHARMS INC	EQ 12.5MG BASE **	N020151 001	Dec 28, 1993
+		EQ 25MG BASE **	N020151 002	Dec 28, 1993
+		EQ 37.5MG BASE **	N020151 006	Dec 28, 1993
+		EQ 50MG BASE **	N020151 003	Dec 28, 1993
+		EQ 75MG BASE **	N020151 004	Dec 28, 1993
+		EQ 100MG BASE **	N020151 005	Dec 28, 1993
VENLAFAXINE HYDROCHLORIDE				
	FOSUN PHARMA	EQ 25MG BASE	A077515 001	Jun 13, 2008
		EQ 37.5MG BASE	A077515 002	Jun 13, 2008
		EQ 50MG BASE	A077515 003	Jun 13, 2008
		EQ 75MG BASE	A077515 004	Jun 13, 2008
		EQ 100MG BASE	A077515 005	Jun 13, 2008
	MYLAN	EQ 25MG BASE	A077166 001	Jun 13, 2008
		EQ 37.5MG BASE	A077166 002	Jun 13, 2008
		EQ 50MG BASE	A077166 003	Jun 13, 2008
		EQ 75MG BASE	A077166 004	Jun 13, 2008
		EQ 100MG BASE	A077166 005	Jun 13, 2008
	PLIVA HRVATSKA DOO	EQ 25MG BASE	A078517 001	Jun 13, 2008
		EQ 37.5MG BASE	A078517 002	Jun 13, 2008
		EQ 50MG BASE	A078517 003	Jun 13, 2008
		EQ 75MG BASE	A078517 004	Jun 13, 2008
		EQ 100MG BASE	A078517 005	Jun 13, 2008
	PRINSTON INC	EQ 25MG BASE	A090027 001	Aug 04, 2010
		EQ 37.5MG BASE	A090027 002	Aug 04, 2010
		EQ 50MG BASE	A090027 003	Aug 04, 2010
		EQ 75MG BASE	A090027 004	Aug 04, 2010
		EQ 100MG BASE	A090027 005	Aug 04, 2010

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL				
VERAPAMIL HYDROCHLORIDE				
	MYLAN	100MG	A078306 001	Aug 09, 2007
		200MG	A078306 002	Aug 09, 2007
		300MG	A078306 003	Aug 09, 2007
INJECTABLE;INJECTION				
CALAN				
	GD SEARLE LLC	2.5MG/ML	N019038 001	Mar 30, 1984
ISOPTIN				
+	MT ADAMS	2.5MG/ML **	N018485 001	
VERAPAMIL HYDROCHLORIDE				
	ABRAXIS PHARM	2.5MG/ML	A070348 001	May 01, 1986
	BEDFORD	2.5MG/ML	A072888 001	Jul 28, 1995
	HOSPIRA	2.5MG/ML	A070577 001	Feb 02, 1987
		2.5MG/ML	A070739 001	May 06, 1987
		2.5MG/ML	A070740 001	May 06, 1987
	INTL MEDICATION	2.5MG/ML	A070451 001	Dec 16, 1985
	LUITPOLD	2.5MG/ML	A070225 001	Nov 12, 1985
		2.5MG/ML	A070617 001	Nov 12, 1985
	MARSAM PHARMS LLC	2.5MG/ML	A072233 001	Feb 26, 1993
		2.5MG/ML	A073485 001	Sep 27, 1993
	SMITH AND NEPHEW	2.5MG/ML	A070696 001	Jul 31, 1987
		2.5MG/ML	A070697 001	Jul 31, 1987
	SOLOPAK	2.5MG/ML	A070695 001	Jul 31, 1987
SOLUTION;INTRAVENOUS				
VERAPAMIL HYDROCHLORIDE				
	EXELA PHARMA	10MG/4ML (2.5MG/ML)	N018925 002	Apr 05, 2018
TABLET;ORAL				
CALAN				
	PFIZER	40MG **	N018817 003	Feb 23, 1988
+		80MG **	N018817 001	Sep 10, 1984
+		120MG **	N018817 002	Sep 10, 1984
		160MG **	N018817 004	Feb 23, 1988
ISOPTIN				
+	MT ADAMS	40MG **	N018593 003	Nov 23, 1987
+		80MG **	N018593 001	Mar 08, 1982
+		120MG **	N018593 002	Mar 08, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VERAPAMIL HYDROCHLORIDE

TABLET;ORAL				
VERAPAMIL HYDROCHLORIDE				
ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986
	120MG	A070468	001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
	120MG	A070483	001	Sep 24, 1986
PLIVA	40MG	A072751	001	Feb 23, 1996
	80MG	A072124	001	Jan 26, 1989
	120MG	A072125	001	Jan 26, 1989
RISING PHARMA	80MG	A071483	002	Feb 15, 1989
	120MG	A071483	001	Feb 15, 1989
SUN PHARM INDUSTRIES	80MG	A071489	002	Jan 13, 1988
	120MG	A071489	001	Jan 13, 1988
WARNER CHILCOTT	80MG	A070340	001	Sep 24, 1986
	120MG	A070341	001	Sep 24, 1986
WATSON LABS	40MG	A072799	001	Apr 28, 1989
	40MG	A072923	001	Jun 29, 1993
	80MG	A070855	001	Sep 24, 1986
	80MG	A071366	001	Oct 01, 1986
	120MG	A070856	001	Sep 24, 1986
	120MG	A071367	001	Oct 01, 1986
YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992
	80MG	A071423	001	May 24, 1988
	120MG	A071424	001	May 25, 1988
TABLET, EXTENDED RELEASE;ORAL				
CALAN SR				
+ PFIZER	180MG **	N019152	002	Dec 15, 1989
COVERA-HS				
PFIZER	180MG	N020552	001	Feb 26, 1996
	240MG	N020552	002	Feb 26, 1996
VERAPAMIL HYDROCHLORIDE				
APOTEX CORP	120MG	A200878	001	Apr 20, 2012
	180MG	A200878	002	Apr 20, 2012
	240MG	A200878	003	Apr 20, 2012
PLIVA	240MG	A072922	001	Mar 01, 1996
RISING PHARMA	120MG	A074587	002	Feb 21, 1997
	180MG	A074587	003	Sep 09, 1997
	240MG	A074587	001	Mar 23, 1996

VERATRUM VIRIDE ROOT

TABLET;ORAL				
VERTAVIS				
MEDPOINTE PHARM HLC	130CSR UNIT	N005691	002	

VIDARABINE

INJECTABLE;INJECTION				
VIRA-A				
PARKEDALE	EQ 187.4MG BASE/ML	N050523	001	
OINTMENT;OPHTHALMIC				
VIRA-A				
PARKEDALE	3%	N050486	001	

VIGABATRIN

FOR SOLUTION;ORAL				
VIGABATRIN				
SPECGX LLC	500MG/PACKET	A212626	001	Jul 28, 2021

VILAZODONE HYDROCHLORIDE

TABLET;ORAL				
VILAZODONE HYDROCHLORIDE				
TEVA PHARMS USA	10MG	A208212	001	Sep 30, 2019
	20MG	A208212	002	Sep 30, 2019
	40MG	A208212	003	Sep 30, 2019

VINBLASTINE SULFATE

INJECTABLE;INJECTION				
VELBAN				
+ LILLY	10MG/VIAL **	N012665	001	
VINBLASTINE SULFATE				
ABRAXIS PHARM	10MG/VIAL	A089011	001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565	001	Aug 18, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VINCRISTINE SULFATE				
INJECTABLE;INJECTION				
ONCOVIN				
+ LILLY	1MG/VIAL **	N014103	001	
+	1MG/ML **	N014103	003	Mar 07, 1984
+	5MG/VIAL **	N014103	002	
VINCASAR PFS				
TEVA PARENTERAL	1MG/ML	A071426	001	Jul 17, 1987
VINCREX				
BRISTOL MYERS SQUIBB	5MG/VIAL	A070867	001	Jul 12, 1988
VINCRISTINE SULFATE				
ABIC	1MG/ML	A070873	001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411	001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296	001	Dec 20, 2002
	1MG/ML	A076401	001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559	001	Apr 11, 1988
	2MG/VIAL	A071560	001	Apr 11, 1988
	5MG/VIAL	A071561	001	Apr 11, 1988
INJECTABLE, LIPOSOMAL;INTRAVENOUS				
MARQIBO KIT				
+ ACROTECH	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012
VINORELBINE TARTRATE				
INJECTABLE;INJECTION				
NAVELBINE				
+ PIERRE FABRE	EQ 10MG BASE/ML **	N020388	001	Dec 23, 1994
VINORELBINE TARTRATE				
EBEWE PHARMA	EQ 10MG BASE/ML	A078408	001	Feb 13, 2008
FRESENIUS KABI USA	EQ 10MG BASE/ML	A076849	001	Apr 18, 2005
HOSPIRA	EQ 10MG BASE/ML	A076827	001	Jun 02, 2005
MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012
NOVAST LABS	EQ 10MG BASE/ML	A208997	001	Aug 05, 2019
VIOMYCIN SULFATE				
INJECTABLE;INJECTION				
VIOCIN SULFATE				
PFIZER	EQ 1GM BASE/VIAL	A061086	001	
	EQ 5GM BASE/VIAL	A061086	002	
VITAMIN A				
CAPSULE;ORAL				
AQUASOL A				
ASTRAZENECA	25,000USP UNITS	A083080	002	
	50,000USP UNITS	A083080	001	
VITAMIN A				
BANNER PHARMACAPS	50,000USP UNITS	A083973	001	
CHASE CHEM	50,000 IU	A083351	001	
EVERYLIFE	50,000 IU	A083134	001	
IMPAX LABS	50,000USP UNITS	A080952	001	
WEST WARD	50,000USP UNITS	A080985	001	
VITAMIN A PALMITATE				
CAPSULE;ORAL				
AFAXIN				
STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187	001	
ALPHALIN				
LILLY	EQ 50,000 UNITS BASE	A080883	001	
DEL-VI-A				
DEL RAY LABS	EQ 50,000 UNITS BASE	A080830	001	
VI-DOM-A				
BAYER PHARMS	EQ 50,000 UNITS BASE	A080972	001	
VITAMIN A				
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702	001	
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860	001	
CHASE CHEM	EQ 50,000 UNITS BASE	A080746	001	
	EQ 50,000 UNITS BASE	A083207	001	
ELKINS SINN	EQ 50,000 UNITS BASE	A085479	001	
EVERYLIFE	EQ 50,000 UNITS BASE	A080943	001	
	EQ 50,000 UNITS BASE	A083114	001	
IMPAX LABS	EQ 50,000 UNITS BASE	A080953	001	
	EQ 50,000 UNITS BASE	A080955	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

VITAMIN A PALMITATE

CAPSULE;ORAL				
VITAMIN A				
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035 001		
	EQ 50,000 UNITS BASE	A083190 001		
MK LABS	EQ 25,000 UNITS BASE	A083457 002		
	EQ 50,000 UNITS BASE	A083457 001		
WEST WARD	EQ 50,000 UNITS BASE	A080967 001		
WHARTON LABS	EQ 50,000 UNITS BASE	A083665 001		
VITAMIN A PALMITATE				
ARCUM	EQ 50,000 UNITS BASE	A083311 001		
	EQ 50,000 UNITS BASE	A083321 001		
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948 001		
	EQ 50,000 UNITS BASE	A083981 001		
VITAMIN A SOLUBILIZED				
TEVA	EQ 50,000 UNITS BASE	A080921 001		
INJECTABLE;INJECTION				
VITAMIN A PALMITATE				
BEL MAR	EQ 50,000 UNITS BASE/ML	A080819 001		

VORICONAZOLE

FOR SUSPENSION;ORAL				
VORICONAZOLE				
MYLAN PHARMS INC	200MG/5ML	A202361 001	May 28, 2013	
TABLET;ORAL				
VORICONAZOLE				
TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	
	200MG	A091658 002	Apr 06, 2012	

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL				
TRINTELLIX				
+ TAKEDA PHARMS USA	EQ 15MG BASE **	N204447 003	Sep 30, 2013	

WARFARIN POTASSIUM

TABLET;ORAL				
ATHROMBIN-K				
PHARM RES ASSOC	2MG	N011771 007		
	5MG	N011771 004		
	10MG	N011771 005		
	25MG	N011771 006		

WARFARIN SODIUM

INJECTABLE;INJECTION				
COUMADIN				
BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995	
	50MG/VIAL	N009218 020		
	75MG/VIAL	N009218 012		
TABLET;ORAL				
ATHROMBIN				
PHARM RES ASSOC	5MG	N011771 003		
	10MG	N011771 002		
	25MG	N011771 001		
COUMADIN				
+ BRISTOL MYERS SQUIBB	1MG	N009218 022	Mar 01, 1990	
+	2MG	N009218 013		
+	2.5MG	N009218 018		
+	3MG	N009218 025	Nov 18, 1996	
+	4MG	N009218 023	Aug 24, 1993	
+	5MG	N009218 007		
+	6MG	N009218 026	Nov 18, 1996	
+	7.5MG	N009218 016		
+	10MG	N009218 005		
PANWARFIN				
ABBOTT	2MG	N017020 001		
	2.5MG	N017020 002		
	5MG	N017020 003		
	7.5MG	N017020 004		
	10MG	N017020 005		
WARFARIN SODIUM				
CHARTWELL RX	1MG	A040196 001	Sep 30, 1997	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

WARFARIN SODIUM				
TABLET;ORAL				
WARFARIN SODIUM				
	2MG	A040196	002	Sep 30, 1997
	2.5MG	A040196	003	Sep 30, 1997
	3MG	A040196	008	Jul 26, 2000
	4MG	A040196	004	Sep 30, 1997
	5MG	A040196	005	Sep 30, 1997
	6MG	A040196	009	Jul 26, 2000
	7.5MG	A040196	006	Sep 30, 1997
	10MG	A040196	007	Sep 30, 1997
MYLAN	1MG	A040415	001	Sep 27, 2004
	2MG	A040415	002	Sep 27, 2004
	2.5MG	A040415	003	Sep 29, 2004
	3MG	A040415	004	Sep 27, 2004
	4MG	A040415	005	Sep 27, 2004
	5MG	A040415	006	Sep 27, 2004
	6MG	A040415	007	Sep 27, 2004
	7.5MG	A040415	008	Sep 27, 2004
	10MG	A040415	009	Sep 27, 2004
USL PHARMA	2MG	A088719	001	Jun 27, 1985
	2.5MG	A088720	001	Aug 06, 1985
	5MG	A088721	001	Jul 02, 1985
WATSON LABS	2MG	A086123	001	Aug 17, 1982
	2.5MG	A086120	001	Aug 17, 1982
	5MG	A086119	001	Aug 17, 1982
	7.5MG	A086118	001	Aug 17, 1982
	10MG	A086122	001	Aug 17, 1982
XENON XE-127				
GAS;INHALATION				
XENON XE 127				
MALLINCKRODT	5mCi/VIAL	N018536	001	Oct 01, 1982
	10mCi/VIAL	N018536	002	Oct 01, 1982
XENON XE-133				
GAS;INHALATION				
XENON XE 133				
GE HEALTHCARE	1 CI/AMP	N017256	002	
	10mCi/VIAL	N017687	002	
	20mCi/VIAL	N017687	003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550	001	
	0.25-5 CI/AMP	N017550	003	
XENON XE 133-V.S.S.				
GE HEALTHCARE	10mCi/VIAL	N017687	001	
INJECTABLE;INJECTION				
XENON XE 133				
GE HEALTHCARE	1.3-1.7 CI/AMP	N017256	001	
LANTHEUS MEDCL	6.3mCi/ML	N017283	001	
SOLUTION;INHALATION, INJECTION				
XENEISOL				
MALLINCKRODT	18-25mCi/AMP	N017262	002	
XYLOSE				
POWDER;ORAL				
XYLO-PFAN				
SAVAGE LABS	25GM/BOT	N017605	001	
XYLOSE				
LYNE	25GM/BOT	N018856	001	Mar 26, 1987
ZALCITABINE				
TABLET;ORAL				
HIVID				
ROCHE	0.375MG	N020199	001	Jun 19, 1992
	0.75MG	N020199	002	Jun 19, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZALEPLON

CAPSULE;ORAL				
ZALEPLON				
	HIKMA PHARMS	5MG	A078147 001	Nov 25, 2008
		10MG	A078147 002	Nov 25, 2008
	MYLAN	5MG	A077238 001	Jun 06, 2008
		10MG	A077238 002	Jun 06, 2008
	TEVA PHARMS	5MG	A077239 001	Jun 06, 2008
		10MG	A077239 002	Jun 06, 2008
	UPSHER SMITH LABS	5MG	A078095 001	Jun 06, 2008
		5MG	A078706 001	Jun 06, 2008
		10MG	A078095 002	Jun 06, 2008
		10MG	A078706 002	Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL				
PRIALT				
	TERSERA	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004

ZIDOVUDINE

INJECTABLE;INJECTION				
ZIDOVUDINE				
	AM REGENT	10MG/ML	A091457 001	May 06, 2010
	LIAONING CHENGDA	10MG/ML	A204538 001	Nov 26, 2013
TABLET;ORAL				
RETROVIR				
	VIIV HLTHCARE	200MG	N020518 001	Dec 19, 1995
+		300MG **	N020518 002	Oct 04, 1996
ZIDOVUDINE				
	AUROBINDO PHARMA	60MG	N022294 001	Jul 23, 2009
	HEC PHARM	300MG	A202058 001	Oct 07, 2011
	HIKMA	300MG	A076844 001	Sep 19, 2005
	MYLAN LABS LTD	100MG	N200732 001	Feb 23, 2011
	RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005

ZILEUTON

TABLET;ORAL				
ZYFLO				
	CHIESI	300MG	N020471 001	Dec 09, 1996

ZINC SULFATE

INJECTABLE;INJECTION				
ZINC SULFATE				
	ABRAXIS PHARM	EQ 1MG ZINC/ML	N019229 002	May 05, 1987

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL				
ZIPRASIDONE HYDROCHLORIDE				
	MYLAN	EQ 20MG BASE	A202395 001	Oct 10, 2013
		EQ 40MG BASE	A202395 002	Oct 10, 2013
		EQ 60MG BASE	A202395 003	Oct 10, 2013
		EQ 80MG BASE	A202395 004	Oct 10, 2013
SUSPENSION;ORAL				
GEODON				
	PFIZER INC	EQ 10MG BASE/ML	N021483 001	Mar 29, 2006

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS				
ZOLEDRONIC ACID				
	ACTAVIS INC	EQ 4MG BASE/5ML	A202472 001	Mar 04, 2013
	DR REDDYS LABS LTD	EQ 4MG BASE/100ML	A204344 001	Nov 19, 2018
	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783 001	Mar 12, 2013
		EQ 5MG BASE/100ML	A201801 001	Mar 29, 2013
	SHILPA	EQ 4MG BASE/5ML	A208513 001	May 15, 2019
	SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018 001	Mar 04, 2013
		EQ 4MG BASE/5ML	A202746 001	Mar 04, 2013
ZOMETA				
+	NOVARTIS	EQ 4MG BASE/VIAL **	N021223 001	Aug 20, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZOLMITRIPTAN

TABLET;ORAL				
ZOLMITRIPTAN				
ANI PHARMS	2.5MG	A090861	001	Mar 04, 2014
	5MG	A090861	002	Mar 04, 2014
APOTEX INC	2.5MG	A202078	001	May 14, 2013
	5MG	A202078	002	May 14, 2013
MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015
	5MG	A203772	002	Sep 30, 2015
MYLAN PHARMS INC	2.5MG	A203186	001	May 14, 2013
	5MG	A203186	002	May 14, 2013
SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014
	5MG	A203476	002	Nov 13, 2014
TABLET, ORALLY DISINTEGRATING;ORAL				
ZOLMITRIPTAN				
APOTEX INC	2.5MG	A202476	001	May 14, 2013
	5MG	A202476	002	May 14, 2013
MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015
	5MG	A204336	002	Oct 22, 2015
RISING PHARMA	2.5MG	A202855	001	Sep 20, 2019
	5MG	A202855	002	Sep 20, 2019

ZOLPIDEM TARTRATE

TABLET;ORAL				
ZOLPIDEM TARTRATE				
DR REDDYS LABS LTD	5MG	A077985	001	Apr 23, 2007
	10MG	A077985	002	Apr 23, 2007
HIKMA	5MG	A078129	001	Apr 30, 2008
	10MG	A078129	002	Apr 30, 2008
MYLAN PHARMS INC	5MG	A078016	001	Apr 23, 2007
	10MG	A078016	002	Apr 23, 2007
RISING PHARMA	5MG	A076578	001	Apr 23, 2007
	10MG	A076578	002	Apr 23, 2007
STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007
	5MG	A078616	001	Nov 21, 2008
	10MG	A076062	002	Apr 23, 2007
	10MG	A078616	002	Nov 21, 2008
SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007
	10MG	A077359	002	Apr 23, 2007
SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007
	10MG	A078055	002	Apr 23, 2007
SUN PHARM INDUSTRIES	5MG	A077288	001	Apr 23, 2007
	10MG	A077288	002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540	001	Apr 23, 2007
	10MG	A077540	002	Apr 23, 2007
WATSON LABS	5MG	A077773	001	Apr 23, 2007
	10MG	A077773	002	Apr 23, 2007
WOCKHARDT	5MG	A078426	001	May 15, 2007
	10MG	A078426	002	May 15, 2007
YUNG SHIN PHARM	5MG	A077990	001	Apr 23, 2007
	10MG	A077990	002	Apr 23, 2007
TABLET;SUBLINGUAL				
INTERMEZZO				
+ PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011
+	3.5MG	N022328	002	Nov 23, 2011
ZOLPIDEM TARTRATE				
MYLAN	5MG	A202657	001	Aug 08, 2016
	10MG	A202657	002	Aug 08, 2016
TABLET, EXTENDED RELEASE;ORAL				
ZOLPIDEM TARTRATE				
ACTAVIS ELIZABETH	6.25MG	A078179	002	Oct 13, 2010
	12.5MG	A078179	001	Jun 06, 2011
SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011
	12.5MG	A078483	002	Jun 06, 2011
TABLET, ORALLY DISINTEGRATING;ORAL				
TOVALT ODT				
+ BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007
+	10MG	N021412	002	Apr 25, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN					
+	CONCORDIA	50MG **	N020789	002	Aug 22, 2003
ZONISAMIDE					
	ANI PHARMS	25MG	A077639	001	Dec 22, 2005
		25MG	A077641	003	Dec 22, 2005
		50MG	A077639	002	Dec 22, 2005
		50MG	A077641	002	Dec 22, 2005
		100MG	A077639	003	Dec 22, 2005
		100MG	A077641	001	Dec 22, 2005
	EPIC PHARMA LLC	25MG	A077876	001	Feb 21, 2007
		50MG	A077876	002	Feb 21, 2007
		100MG	A077876	003	Feb 21, 2007
	HERITAGE PHARMA AVET	25MG	A077650	001	Apr 20, 2006
		50MG	A077650	002	Apr 20, 2006
		100MG	A077650	003	Apr 20, 2006
	MYLAN PHARMS INC	25MG	A077647	001	Dec 22, 2005
		50MG	A077647	002	Dec 22, 2005
		100MG	A077647	003	Dec 22, 2005
	RISING PHARMA	25MG	A077637	001	Dec 22, 2005
		50MG	A077637	002	Dec 22, 2005
		100MG	A077637	003	Dec 22, 2005
	ROXANE	25MG	A077648	001	Dec 22, 2005
		50MG	A077648	002	Dec 22, 2005
		100MG	A077648	003	Dec 22, 2005
	SUN PHARM INDUSTRIES	25MG	A077635	001	Dec 22, 2005
		50MG	A077635	002	Dec 22, 2005
		100MG	A077635	003	Dec 22, 2005
	UPSHER SMITH LABS	25MG	A077644	001	Dec 22, 2005
		50MG	A077644	002	Dec 22, 2005
		100MG	A077644	003	Dec 22, 2005

ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX

**** A ****

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ADENOSINE, ADENOSINE
ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS XR-ODT, AMPHETAMINE
AEMCOLO, RIFAMYCIN SODIUM
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKLIEF, TRIFAROTENE
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALIQOPA, COPANLISIB DIHYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMONDYS 45, CASIMERSEN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANGIOMAX RTU, BIVALIRUDIN
ANJESO, MELOXICAM
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APADAZ, ACETAMINOPHEN
APIXABAN, APIXABAN
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREMILAST, APREMILAST
APREPITANT, APREPITANT
APRETUDE, CABOTEGRAVIR
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARAZLO, TAZAROTENE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

ARGATROBAN, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARISTADA, ARIPIPRAZOLE LAUROXIL
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARMONAIR DIGIHALER, FLUTICASONE PROPIONATE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ARTESUNATE, ARTESUNATE
ARTHROTEC, DICLOFENAC SODIUM
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASENAPINE MALEATE, ASENAPINE MALEATE
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AURYXIA, FERRIC CITRATE
AUSTEDO, DEUTETRABENAZINE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE

APPENDIX A - PRODUCT NAME INDEX

**** A ****

AVAPRO, IRBESARTAN
AVEED, TESTOSTERONE UNDECANOATE
AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AVYCAZ, AVIBACTAM SODIUM
AXID AR, NIZATIDINE (OTC)
AXUMIN, FLUCICLOVINE F-18
AYUNA, ETHINYL ESTRADIOL
AYVAKIT, AVAPRITINIB
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZEDRA, IOBENGUANE I-131
AZELAIC ACID, AZELAIC ACID
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BAFIERTAM, MONOMETHYL FUMARATE
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALCOLTRA, ETHINYL ESTRADIOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALVERSA, ERDAFITINIB
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BAQSIMI, GLUCAGON
BARACLUDE, ENTECAVIR
BARHEMSYS, AMISULPRIDE
BAXDELA, DELAFLOXACIN MEGLUMINE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BELSOMRA, SUVOREXANT
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAINE, BETAINE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONJESTA, DOXYLAMINE SUCCINATE
BONSITY, TERIPARATIDE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BOSULIF, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BREO ELLIPTA, FLUTICASONE FUROATE
BRETHINE, TERBUTALINE SULFATE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** B ****

BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVITAL SODIUM, METHOHEXITAL SODIUM
BREXAFEMME, IBREXAFUNGERP CITRATE
BREZTRI AEROSPHERE, BUDESONIDE
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRINZOLAMIDE, BRINZOLAMIDE
BRISDELLE, PAROXETINE MESYLATE
BRIVIACT, BRIVARACETAM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHITOL, MANNITOL
BROVANA, ARFORMOTEROL TARTRATE
BRUKINSA, ZANUBRUTINIB
BRYHALI, HALOBETASOL PROPIONATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON BCISE, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYFAVO, REMIMAZOLAM BESYLATE
BYLVAY, ODEVIXIBAT
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABAZITAXEL, CABAZITAXEL
CABENUVA KIT, CABOTEGRAVIR
CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CAMBIA, DICLOFENAC POTASSIUM
CAMCEVI KIT, LEUPROLIDE MESYLATE
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPLYTA, LUMATEPERONE TOSYLATE
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARFILZOMIB, CARFILZOMIB
CARGLUMIC ACID, CARGLUMIC ACID
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES-TTS-1, CLONIDINE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLBAM, CHOLIC ACID
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMDUO, LAMIVUDINE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARISCAN, GADOTERATE MEGLUMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLCRYS, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONJUPRI, LEVAMLODIPINE MALEATE
CONRAY, IOTHALAMATE MEGLUMINE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE

APPENDIX A - PRODUCT NAME INDEX

**** C ****

CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
COSELA, TRILACICLIB DIHYDROCHLORIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COZAAR, LOSARTAN POTASSIUM
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUBICIN RF, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTALUX, PAFOLACIANINE SODIUM
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOTEC, MISOPROSTOL
CYTOXAN, CYCLOPHOSPHAMIDE

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DALFAMPRIDINE, DALFAMPRIDINE
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARTISLA ODT, GLYCOPYRROLATE
DARUNAVIR, DARUNAVIR
DASATINIB, DASATINIB
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAURISMO, GLASDEGIB MALEATE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DAYVIGO, LEMBOREXANT
DDAVP, DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DEFERIPRONE, DEFERIPRONE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFINITY RT, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSTRIGO, DORAVIRINE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESFLURANE, DESFLURANE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETECTNET, COPPER DOTATATE CU-64
DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXILANT, DEXLANSOPRAZOLE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTENZA, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50%, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DEXYCU KIT, DEXAMETHASONE
DHIVY, CARBIDOPA
DIABETA, GLYBURIDE
DIACOMIT, STIRIPENTOL
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIAZOXIDE, DIAZOXIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIFLUPREDNATE, DIFLUPREDNATE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DOFETILDE, DOFETILIDE
DOFETILIDE, DOFETILIDE
DOJOLVI, TRIHEPTANOIN
DOLISHALE, ETHINYL ESTRADIOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOPTELET, AVATROMBOPAG MALEATE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVATO, DOLUTEGRAVIR SODIUM
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DROXIDOPA, DROXIDOPA
DSUVIA, SUFENTANIL CITRATE

APPENDIX A - PRODUCT NAME INDEX

**** D ****

DUAC, BENZOYL PEROXIDE
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUOBRII, HALOBETASOL PROPIONATE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DURYSTA, BIMATOPROST
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUVOID, BETHANECHOL CHLORIDE
DYANAVEL XR, AMPHETAMINE
DYANAVEL XR 10, AMPHETAMINE
DYANAVEL XR 15, AMPHETAMINE
DYANAVEL XR 20, AMPHETAMINE
DYANAVEL XR 5, AMPHETAMINE
DYCLOPRO, DYCLONINE HYDROCHLORIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFINACONAZOLE, EFINACONAZOLE
EFUDEX, FLUOROURACIL
EGATEN, TRICLABENDAZOLE
ELCYS, CYSTEINE HYDROCHLORIDE
ELEPSIA XR, LEVETIRACETAM
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIGARD KIT, LEUPROLIDE ACETATE
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
ELURYNG, ETHINYL ESTRADIOL
ELYXYB, CELECOXIB
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMERPHED, EPHEDRINE SULFATE
EMFLAZA, DEFLAZACORT
EMLA, LIDOCAINE
EMPAVELI, PEGCETACOPLAN
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTADFI, FINASTERIDE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTERO VU 24%, BARIUM SULFATE
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENVARSUS XR, TACROLIMUS
ENZALUTAMIDE, ENZALUTAMIDE
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPRONTIA, TOPIRAMATE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
ETRAVIRINE, ETRAVIRINE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EUTHYROX, LEVOTHYROXINE SODIUM **
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVEKEO ODT, AMPHETAMINE SULFATE
EVEROLIMUS, EVEROLIMUS
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOMELA, MELPHALAN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** E ****

EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVRYSDI, RISDIPLAM
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXEM FOAM KIT, AIR POLYMER-TYPE A
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXKIVITY, MOBOCERTINIB SUCCINATE
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXSERVAN, RILUZOLE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTRIN
EYSUVIS, LOTEPREDNOL ETABONATE
EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM
EZETIMIBE, EZETIMIBE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE

**** F ****

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN
FASLODEX, FULVESTRANT
FEBUXOSTAT, FEBUXOSTAT
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENSOLVI KIT, LEUPROLIDE ACETATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FERRIPROX, DEFERIPRONE
FERRLECIT, FERRIC OXYHYDROXIDE
FERUMOXYTOL, FERUMOXYTOL
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXINIDAZOLE, FEXINIDAZOLE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FINTEPLA, FENFLURAMINE HYDROCHLORIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FIRMAGON, DEGARELIX ACETATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
FLAGYL, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXURIDINE, FLOXURIDINE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLURESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
FLURESCITE, FLURESCEIN SODIUM
FLURODOPA F18, FLURODOPA F-18
FLUROURACIL, FLUROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE

APPENDIX A - PRODUCT NAME INDEX

**** F ****

FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
FORTEO, TERIPARATIDE
FORTESTA, TESTOSTERONE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FOTIVDA, TIVOZANIB HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FULVESTRANT, FULVESTRANT
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
FURADANTIN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYARRO, SIROLIMUS
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GALAFOLD, MIGALASTAT HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68
GALLIUM GA 68 PSMA-11, GALLIUM GA-68 PSMA-11
GALZIN, ZINC ACETATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GANZYK-RTU, GANCICLOVIR
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GAVRETO, PRALSETINIB
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GEMMILY, ETHINYL ESTRADIOL
GEMTESA, VIBEGRON
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOSYL, NITRIC OXIDE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II ACETATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD HYDROCHLORIDE
GILOTRIF, AFATINIB DIMALEATE
GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE
GIVLAARI, GIVOSIRAN SODIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLOPERBA, COLCHICINE
GLUCAGEN, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYNASE, GLYBURIDE
GLYRX-PF, GLYCOPYRROLATE
GLYSET, MIGLITOL
GLYXAMBI, EMPAGLIFLOZIN
GOCOVRI, AMANTADINE HYDROCHLORIDE
GOLYTELY, POLYETHYLENE GLYCOL 3350
GOPRELTO, COCAINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** G ****

GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GVOKE HYPOPEN, GLUCAGON
GVOKE PFS, GLUCAGON
GYNAZOLE-1, BUTOCONAZOLE NITRATE

**** H ****

HABITROL, NICOTINE (OTC)
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1/20, ETHINYL ESTRADIOL
HALAVEN, ERIBULIN MESYLATE
HALCINONIDE, HALCINONIDE
HALCION, TRIAZOLAM
HALDOL, HALOPERIDOL DECANOATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HECTOROL, DOXERCALCIFEROL
HEMABATE, CARBOPROST TROMETHAMINE
HEMADY, DEXAMETHASONE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPSERA, ADEFOVIR DIPIVOXIL
HER STYLE, LEVONORGESTREL (OTC)
HETLIOZ, TASIMELTEON
HETLIOZ LQ, TASIMELTEON
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HICON, SODIUM IODIDE I-131
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HORIZANT, GABAPENTIN ENACARBIL
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE, HYDROCODONE BITARTRATE

APPENDIX A - PRODUCT NAME INDEX

**** H ****

HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYSINGLA ER, HYDROCODONE BITARTRATE
HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBRANCE, PALBOCICLIB
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICATIBANT ACETATE, ICATIBANT ACETATE
ICLEVIA, ETHINYL ESTRADIOL
ICLUSIG, PONATINIB HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILLUCCIX, GALLIUM GA-68 GOZETOTIDE
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMCIVREE, SETMELANOTIDE ACETATE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPEKLO, CLOBETASOL PROPIONATE
IMPOYZ, CLOBETASOL PROPIONATE

APPENDIX A - PRODUCT NAME INDEX

**** I ****

IMURAN, AZATHIOPRINE
IMVEXXY, ESTRADIOL
INAPSINE, DROPERIDOL
INBRIJA, LEVODOPA
INCASSIA, NORETHINDRONE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANT'S ADVIL, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFED, FERRIC OXYHYDROXIDE
INFUGEM, GEMCITABINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INQOVI, CEDAZURIDINE
INREBIC, FEDRATINIB HYDROCHLORIDE
INSPRA, EPLERENONE
INTELENCE, ETRAVIRINE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA HAFYERA, PALIPERIDONE PALMITATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVELTYS, LOTEPREDNOL ETABONATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** I ****

ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISTURISA, OSILODROSTAT PHOSPHATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
IVERMECTIN, IVERMECTIN (OTC)
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE

**** J ****

JADENU, DEFERASIROX
JADENU SPRINKLE, DEFERASIROX
JAIMIESS, ETHINYL ESTRADIOL
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JATENZO, TESTOSTERONE UNDECANOATE
JELMYTO, MITOMYCIN
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE
JYNARQUE, TOLVAPTAN

**** K ****

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL

APPENDIX A - PRODUCT NAME INDEX

**** K ****

KATERZIA, AMLODIPINE BENZOATE
KAZANO, ALOGLIPTIN BENZOATE
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERENDIA, FINERENONE
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHAPZORY, LEVOLEUCOVORIN
KIMIDESS, DESOGESTREL
KIMYRSA, ORITAVANCIN DIPHOSPHATE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLISYRI, TIRBANIBULIN
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOXXADO, NALOXONE HYDROCHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
KORSUVA, DIFELIKEFALIN ACETATE
KOSELUGO, SELUMETINIB SULFATE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KRINTAFEL, TAFENOQUINE SUCCINATE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYLEENA, LEVONORGESTREL
KYNMOBI, APOMORPHINE HYDROCHLORIDE
KYPROLIS, CARFILZOMIB

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPIT, NIFURTIMOX
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANREOTIDE ACETATE, LANREOTIDE ACETATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACAFT, ALCAFTADINE (OTC)
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LENALIDOMIDE, LENALIDOMIDE
LENVIMA, LENVATINIB MESYLATE
LEQVIO, INCLISIRAN SODIUM
LERIBANE, ETHINYL ESTRADIOL
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXETTE, HALOBETASOL PROPIONATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LICART, DICLOFENAC EPOLAMINE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LILETTA, LEVONORGESTREL
LINAGLIPTIN, LINAGLIPTIN
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN, LINCOMYCIN
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LIVMARLI, MARALIXIBAT CHLORIDE
LIVTENCITY, MARIBAVIR
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO SIMPESSE, ETHINYL ESTRADIOL
LO-MALMOREDE, ETHINYL ESTRADIOL
LO-ZUMANDIMINE, DROSPIRENONE
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGILIA, ULIPRISTAL ACETATE
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE

APPENDIX A - PRODUCT NAME INDEX

**** L ****

LOMAIRA, PHENTERMINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LONHALA MAGNAIR KIT, GLYCOPYRROLATE
LONSURF, TIPIRACIL HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORBRENA, LORLATINIB
LOREEV XR, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LUBIPROSTONE, LUBIPROSTONE
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
LUMAKRAS, SOTORASIB
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMI-SPORYN, BACITRACIN ZINC
LUMIFY, BRIMONIDINE TARTRATE (OTC)
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPKYNIS, VOCLOSPORIN
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
LUTATHERA, LUTETIUM DOTATATE LU-177
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYBALVI, OLANZAPINE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYRICA, PREGABALIN
LYRICA CR, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID
LYVISPAH, BACLOFEN

**** M ****

APPENDIX A - PRODUCT NAME INDEX

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M.V.I. ADULT, ASCORBIC ACID
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MACRILEN, MACIMORELIN ACETATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MALMOREDE, ETHINYL ESTRADIOL
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVENCLAD, CLADRIBINE
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAYZENT, SIPONIMOD FUMARIC ACID
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGACE ES, MEGESTROL ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB
MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPURINE, MERCAPTOPURINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MERZEE, ETHINYL ESTRADIOL
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLDOPA, METHYLDOPA
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METYROSINE, METYROSINE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICAFUNGIN, MICAFUNGIN SODIUM
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIFEPRISTONE, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGLUSTAT, MIGLUSTAT
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MIVACURIUM CHLORIDE, MIVACURIUM CHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** M ****

MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
MONODOX, DOXYCYCLINE
MONOFERRIC, FERRIC DERISOMALTOSE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIDECTIN, MOXIDECTIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULPLETA, LUSUTROMBOPAG
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTRYS, CUPRIC SULFATE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCAPSSA, OCTREOTIDE ACETATE
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
MYDAYIS, AMPHETAMINE ASPARTATE
MYDRIACYL, TROPICAMIDE
MYFEMBREE, ESTRADIOL
MYFORTIC, MYCOPHENOLIC SODIUM
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON
MYRBETRIQ GRANULES, MIRABEGRON
MYSOLINE, PRIMIDONE
MYTESI, CROFELEMER
MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASACORT AQ, TRIAMCINOLONE ACETONIDE
NASCOBAL, CYANOCOBALAMIN
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATROBA, SPINOSAD
NAYZILAM, MIDAZOLAM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NELARABINE, NELARABINE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NERLYNX, NERATINIB MALEATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXLETOL, BEMPEDOIC ACID
NEXLIZET, BEMPEDOIC ACID
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NEXTSTELLIS, DROSPIRENONE
NIACIN, NIACIN
NIACOR, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITAZOXANIDE, NITAZOXANIDE
NITHIODOTE, SODIUM NITRITE
NITISINONE, NITISINONE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)
NOCDURNA, DESMOPRESSIN ACETATE
NOR-QD, NORETHINDRONE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** N ****

NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOURIANZ, ISTRADEFYLLINE
NOXAFIL, POSACONAZOLE
NOXAFIL POWDERMIX KIT, POSACONAZOLE
NOXIVENT, NITRIC OXIDE
NUBEQA, DAROLUTAMIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
NULIBRY, FOSDENOPTERIN HYDROBROMIDE
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUMBRINO, COCAINE HYDROCHLORIDE
NUPLAZID, PIMAVANSERIN TARTRATE
NURTEC ODT, RIMEGEPANT SULFATE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUVARING, ETHINYL ESTRADIOL
NUVESSA, METRONIDAZOLE
NUVIGIL, ARMODAFINIL
NUZYRA, OMADACYCLINE TOSYLATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
NYMALIZE, NIMODIPINE
NYSTATIN, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OCALIVA, OBETICHOLIC ACID
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCUFLOX, OFLOXACIN
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIPATE
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLINVYK, OLICERIDINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUMIANT, BARICITINIB
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEGAVEN, FISH OIL TRIGLYCERIDES
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGENTYS, OPICAPONE
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONPATTRO, PATISIRAN SODIUM
ONSURA, ETHINYL ESTRADIOL
ONUREG, AZACITIDINE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPZELURA, RUXOLITINIB PHOSPHATE
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORGOVYX, RELUGOLIX
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC FORTE, ASPIRIN
ORTIKOS, BUDESONIDE
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSENI, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMOLEX ER, AMANTADINE HYDROCHLORIDE
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTICAIR, HYDROCORTISONE
OTIPRIO, CIPROFLOXACIN

APPENDIX A - PRODUCT NAME INDEX

**** O ****

OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
OTREXUP, METHOTREXATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAYDO, OXYCODONE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
OXBRYTA, VOXELOTOR
OXCARBAZEPINE, OXCARBAZEPINE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
OXISTAT, OXICONAZOLE NITRATE
OXLUMO, LUMASIRAN SODIUM
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OZEMPIC, SEMAGLUTIDE
OZOBAX, BACLOFEN
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACITAXEL, PACLITAXEL
PACLITAXEL, PACLITAXEL
PALIPERIDONE, PALIPERIDONE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSABIV, ETELCALCETIDE
PASER, AMINOSALICYLIC ACID
PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATANASE, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PEMAZYRE, PEMIGATINIB
PEMFEXY, PEMETREXED
PENICILLAMINE, PENICILLAMINE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERSERIS KIT, RISPERIDONE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHEXXI, CITRIC ACID
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PIFELTRO, DORAVIRINE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMECROLIMUS, PIMECROLIMUS
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIQRAY, ALPELISIB
PIRFENIDONE, PIRFENIDONE
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENVU, ASCORBIC ACID
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX
POLMON, DEXCHLORPHENIRAMINE MALEATE
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PONVORY, PONESIMOD
PORTIA-28, ETHINYL ESTRADIOL
POSACONAZOLE, POSACONAZOLE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZIQUANTEL, PRAZIQUANTEL

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PREDNISONE INTENSOL, PREDNISONE
PREGABALIN, PREGABALIN
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESTALIA, AMLODIPINE BESYLATE
PRETOMANID, PRETOMANID
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVYMIS, LETERMOVIR
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRINIVIL, LISINOPRIL
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR DIGIHALER, ALBUTEROL SULFATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE

APPENDIX A - PRODUCT NAME INDEX

**** P ****

PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PUR-WASH, PURIFIED WATER (OTC)
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
PURINETHOL, MERCAPTOPURINE
PURIXAN, MERCAPTOPURINE
PYLARIFY, PIFLUFOLASTAT F-18
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYRIMETHAMINE, PYRIMETHAMINE
PYTEST, UREA, C-14
PYTEST KIT, UREA, C-14

**** Q ****

QBRELIS, LISINOPRIL
QBREXZA, GLYCOPYRRONIUM TOSYLATE
QDOLO, TRAMADOL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** Q ****

QELBREE, VILOXAZINE HYDROCHLORIDE
QINLOCK, RIPRETINIB
QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QULIPTA, ATOGEPANT
QUTENZA, CAPSAICIN
QUZYTTIR, CETIRIZINE HYDROCHLORIDE
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADICAVA, EDARAVONE
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
REBETOL, RIBAVIRIN
RECARBRIO, CILASTATIN SODIUM
RECLAST, ZOLEDRONIC ACID
RECORLEV, LEVOKETOCONAZOLE
RECTIV, NITROGLYCERIN
REDITREX, METHOTREXATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

**** R ****

REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETEVMO, SELPERCATINIB
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REYVOW, LASMIDITAN SUCCINATE
REZIPRES, EPHEDRINE HYDROCHLORIDE
REZUROCK, BELUMOSUDIL MESYLATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL MESYLATE
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMPIN, RIFAMPIN
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RINVOQ, UPADACITINIB
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCKLATAN, LATANOPROST
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMIDEPSIN, ROMIDEPSIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROSZET, EZETIMIBE

APPENDIX A - PRODUCT NAME INDEX

**** R ****

ROWASA, MESALAMINE
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
ROZLYTREK, ENTRECTINIB
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
RUZURGI, AMIFAMPRIDINE
RYANODEX, DANTROLENE SODIUM
RYBELSUS, SEMAGLUTIDE
RYDAPT, MIDOSTAURIN
RYTARY, CARBIDOPA
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCEMBLIX, ASCIMINIB HYDROCHLORIDE
SCENESSE, AFAMELANOTIDE
SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECUADO, ASENAPINE
SEGLENTIS, CELECOXIB
SEGLUROMET, ERTUGLIFLOZIN
SEIZALAM, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIOUS ACID, SELENIOUS ACID
SELENIUM SULFIDE, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SEVOFLURANE, SEVOFLURANE
SEYSARA, SARECYCLINE HYDROCHLORIDE
SFROWASA, MESALAMINE
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SIKLOS, HYDROXYUREA
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILODOSIN, SILODOSIN
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMLIYA, DESOGESTREL
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN (OTC)
SKYLA, LEVONORGESTREL
SLYND, DROSPIRENONE
SMOFLIPID 20%, FISH OIL
SOAANZ, TORSEMIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, FERRIC OXYHYDROXIDE
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPECTAZOLE, ECONAZOLE NITRATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STAXYN, VARDENAFIL HYDROCHLORIDE
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN, SUMATRIPTAN SUCCINATE
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE

APPENDIX A - PRODUCT NAME INDEX

**** S ****

SUNOSI, SOLRIAMFETOL HYDROCHLORIDE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SUSTIVA, EFAVIRENZ
SUSTOL, GRANISETRON
SUTAB, MAGNESIUM SULFATE
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMDEKO (COPACKAGED), IVACAFTOR
SYMFI, EFAVIRENZ
SYMFI LO, EFAVIRENZ
SYMJEPI, EPINEPHRINE
SYMLIN, PRAMLINTIDE ACETATE
SYMPAZAN, CLOBAZAM
SYMPROIC, NALDEMEDINE TOSYLATE
SYMTUZA, COBICISTAT
SYNALAR, FLUOCINOLONE ACETONIDE
SYNAREL, NAFARELIN ACETATE
SYNDROS, DRONABINOL
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN
SYNJARDY, EMPAGLIFLOZIN
SYNJARDY XR, EMPAGLIFLOZIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TABRECTA, CAPMATINIB HYDROCHLORIDE
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TAFINLAR, DABRAFENIB MESYLATE
TAFLUPROST, TAFLUPROST
TAGAMET HB, CIMETIDINE (OTC)
TAGITOL V, BARIUM SULFATE
TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALICIA, AMOXICILLIN
TALZENNA, TALAZOPARIB TOSYLATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARPEYO, BUDESONIDE
TASCENSO ODT, FINGOLIMOD LAURYL SULFATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TASMAR, TOLCAPONE
TAUVID, FLORTAUCIPIR F-18
TAVABOROLE, TAVABOROLE
TAVALISSE, FOSTAMATINIB DISODIUM
TAVNEOS, AVACOPAN
TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZAROTENE, TAZAROTENE
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TAZVERIK, TAZEMETOSTAT HYDROBROMIDE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEGSEDI, INOTERSEN SODIUM
TEKTURNA, ALISKIREN HEMIFUMARATE
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMBEXA, BRINCIDOFOVIR
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TEPADINA, THIOTEPA
TEPMETKO, TEPOTINIB HYDROCHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIL, CARBAMAZEPINE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TETRABENAZINE, TETRABENAZINE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIOLA EC, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE

APPENDIX A - PRODUCT NAME INDEX

**** T ****

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM
TREZIX, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE, TRIAMTERENE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIANEX, TRIAMCINOLONE ACETONIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
TRIFERIC AVNU, FERRIC PYROPHOSPHATE CITRATE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIJARDY XR, EMPAGLIFLOZIN
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIOSTAT, LIOTHYRONINE SODIUM
TRIPTODUR KIT, TRIPTORELIN PAMOATE
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRIZIVIR, ABACAVIR SULFATE
TROKENDI XR, TOPIRAMATE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
TRUDHESA, DIHYDROERGOTAMINE MESYLATE
TRULANCE, PLECANATIDE
TRUSELTIQ, INFIGRATINIB PHOSPHATE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUKYSA, TUCATINIB
TURALIO, PEXIDARTINIB HYDROCHLORIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUXARIN ER, CHLORPHENIRAMINE MALEATE
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
TWIRLA, ETHINYL ESTRADIOL
TWYNEO, BENZOYL PEROXIDE
TYBLUME, ETHINYL ESTRADIOL
TYBOST, COBICISTAT
TYDEMY, DROSPIRENONE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL, ACETAMINOPHEN (OTC)
TYMLOS, ABALOPARATIDE
TYRVAYA, VARENICLINE TARTRATE
TYVASO, TREPROSTINIL
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE
UBRELVY, UBROGEPANT
UCERIS, BUDESONIDE
UKONIQ, UMBRALISIB TOSYLATE
ULORIC, FEBUXOSTAT
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE
UPTRAVI, SELEXIPAG
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UVADEX, METHOXSALEN

**** V ****

VABOMERE, MEROPENEM
VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX

** V **

VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALRUBICIN, VALRUBICIN
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTOCO, DIAZEPAM
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN, VANCOMYCIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOPRESSIN, VASOPRESSIN
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZALORE, ASPIRIN (OTC)
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEKLURY, REMDESIVIR
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, FERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, FERRIC OXYHYDROXIDE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERARING, ETHINYL ESTRADIOL
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERKAZIA, CYCLOSPORINE
VERQUVO, VERICIGUAT
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VESICARE LS, SOLIFENACIN SUCCINATE

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VILTEPSO, VILTOLARSEN
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRAKVI, LAROTRECTINIB SULFATE
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VIZAMYL, FLUTEMETAMOL F-18
VIZIMPRO, DACOMITINIB
VOCABRIA, CABOTEGRAVIR SODIUM
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)
VORICONAZOLE, VORICONAZOLE
VORTIOXETINE HYDROBROMIDE, VORTIOXETINE HYDROBROMIDE
VOSEVI, SOFOSBUVIR
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOSPIRE ER, ALBUTEROL SULFATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VOXZOGO, VOSORITIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VUITY, PILOCARPINE HYDROCHLORIDE
VUMERITY, DIROXIMEL FUMARATE
VUSION, MICONAZOLE NITRATE
VYFEMLA, ETHINYL ESTRADIOL
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE
VYONDYS 53, GOLODIRSEN

APPENDIX A - PRODUCT NAME INDEX

**** V ****

VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
VYXEOS, CYTARABINE
VYZULTA, LATANOPROSTENE BUNOD

**** W ****

WAKIX, PITOLISANT HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
WEGOVY, SEMAGLUTIDE
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELIREG, BELZUTIFAN
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WINLEVI, CLASCOTERONE
WIXELA INHUB, FLUTICASONE PROPIONATE
WOMEN'S ROGAINE, MINOXIDIL (OTC)
WYNZORA, BETAMETHASONE DIPROPIONATE

**** X ****

XACIATO, CLINDAMYCIN PHOSPHATE
XADAGO, SAFINAMIDE MESYLATE
XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARACOLL, BUPIVACAINE HYDROCHLORIDE
XARELTO, RIVAROXABAN
XATMEP, METHOTREXATE SODIUM
XCOPRI, CENOBAMATE
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XELPROS, LATANOPROST
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENLETA, LEFAMULIN ACETATE
XENON XE 133, XENON XE-133
XEPI, OZENOXACIN
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
XERESE, ACYCLOVIR
XERMELO, TELOTRISTAT ETIPRATE
XHANCE, FLUTICASONE PROPIONATE
XIFAXAN, RIFAXIMIN
XIGDUO XR, DAPAGLIFLOZIN
XIIDRA, LIFITEGRAST
XIMINO, MINOCYCLINE HYDROCHLORIDE
XIPERE, TRIAMCINOLONE ACETONIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
XOFLUZA, BALOXAVIR MARBOXIL
XOLEGEL, KETOCONAZOLE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XOSPATA, GILTERITINIB FUMARATE
XPOVIO, SELINEXOR
XTAMPZA ER, OXYCODONE
XTANDI, ENZALUTAMIDE
XULANE, ETHINYL ESTRADIOL
XURIDEN, URIDINE TRIACETATE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
XYREM, SODIUM OXYBATE
XYWAV, CALCIUM OXYBATE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX

**** Y ****

YAELA, DROSPIRENONE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE
YONDELIS, TRABECTEDIN
YONSA, ABIRATERONE ACETATE
YUPELRI, REVEFENACIN
YUTIQ, FLUOCINOLONE ACETONIDE

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZARONTIN, ETHOSUXIMIDE
ZAVESCA, MIGLUSTAT
ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE
ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEJULA, NIRAPARIB TOSYLATE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZELNORM, TEGASEROD MALEATE
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMDRI, PLAZOMICIN SULFATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZEPATIER, ELBASVIR
ZEPOSIA, OZANIMOD HYDROCHLORIDE
ZEPZELCA, LURBINECTEDIN
ZERBAXA, CEFTOLOZANE SULFATE
ZERVIATE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZILXI, MINOCYCLINE HYDROCHLORIDE
ZIMHI, NALOXONE HYDROCHLORIDE
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE, ZINC CHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOKINVY, LONAFARNIB
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN

APPENDIX A - PRODUCT NAME INDEX

**** Z ****

ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZULRESSO, BREXANOLONE
ZUMANDIMINE, DROSPIRENONE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYNRELEF KIT, BUPIVACAINE
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 3 ****

3D IMAGING DRUG
* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M
* 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M HEALTH CARE
* 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ****

60 DEGREES PHARMS
* 60 DEGREES PHARMACEUTICALS LLC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ****

AAA USA INC
* ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM DOTATATE LU-177
NETSPOT, GALLIUM DOTATATE GA-68

AADI
* AADI BIOSCIENCE INC
FYARRO, SIROLIMUS

AAIPHARMA LLC
* AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE
* ABBVIE INC
ANDROGEL, TESTOSTERONE
CYCLOSPORINE, CYCLOSPORINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SYNTHROID, LEVOTHYROXINE SODIUM **
TRICOR, FENOFIBRATE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE INC
* ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE

ABBVIE INC
* ABBVIE INC
DUOPA, CARBIDOPA
MAVYRET, GLECAPREVIR
NORVIR, RITONAVIR
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
QULIPTA, ATOGEPANT
RINVOQ, UPADACITINIB
VENCLEXTA, VENETOCLAX
VUITY, PILOCARPINE HYDROCHLORIDE

ABHAI INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ABHAI INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC

* ABHAI LLC
ATOVAQUONE, ATOVAQUONE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEFLUNOMIDE, LEFLUNOMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
URSODIOL, URSODIOL

ABON PHARMS LLC

* ABON PHARMACEUTICALS LLC
ATOVAQUONE, ATOVAQUONE
CLOFARABINE, CLOFARABINE

ABRAXIS BIOSCIENCE

* ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM

* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACACIA

* ACACIA PHARMA LTD
BARHEMSYS, AMISULPRIDE
BYFAVO, REMIMAZOLAM BESYLATE

ACADIA PHARMS INC

* ACADIA PHARMACEUTICALS INC
NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS

* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
APIXABAN, APIXABAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATROPINE SULFATE, ATROPINE SULFATE
AZACITIDINE, AZACITIDINE
BICALUTAMIDE, BICALUTAMIDE
BIVALIRUDIN, BIVALIRUDIN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CABAZITAXEL, CABAZITAXEL
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
DALFAMPRIDINE, DALFAMPRIDINE
DAPTOMYCIN, DAPTOMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOCETAXEL, DOCETAXEL
DOFETILIDE, DOFETILIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENTECAVIR, ENTECAVIR
EPLERENONE, EPLERENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUOROURACIL, FLUOROURACIL
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LISINOPRIL, LISINOPRIL
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACLITAXEL, PACLITAXEL
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA
BUSULFAN, BUSULFAN
TIGECYCLINE, TIGECYCLINE

ACELLA

* ACELLA PHARMACEUTICALS LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CICLOPIROX, CICLOPIROX
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
NIFEDIPINE, NIFEDIPINE
PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACELRX PHARMS

* ACELRX PHARMACEUTICALS INC
DSUVIA, SUFENTANIL CITRATE

ACERUS

* ACERUS PHARMACEUTICALS CORP
NATESTO, TESTOSTERONE

ACI

* ACI HEALTHCARE LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC PHARMS

* ACIC PHARMACEUTICALS INC
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TRANEXAMIC ACID, TRANEXAMIC ACID

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
INBRIJA, LEVODOPA

ACROTECH

* ACROTECH BIOPHARMA LLC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FOLOTYN, PRALATREXATE
FUSILEV, LEVOLEUCOVORIN CALCIUM
KHAPZORY, LEVOLEUCOVORIN

ACRUX DDS

* ACRUX DDS PTY LTD
EFINACONAZOLE, EFINACONAZOLE

ACRUX DDS PTY

* ACRUX DDS PTY LTD
LIDOCAINE AND PRILOCAINE, LIDOCAINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALBENDAZOLE, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LOVASTATIN, LOVASTATIN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

* ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALPRAZOLAM, ALPRAZOLAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS INC

* ACTAVIS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

ACTAVIS LABS

* ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

* ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
ISOTRETINOIN, ISOTRETINOIN
MESALAMINE, MESALAMINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ACTAVIS LABS FL INC

* ACTAVIS LABORATORIES FL INC
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
ENZALUTAMIDE, ENZALUTAMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
LEVETIRACETAM, LEVETIRACETAM
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NAPROXEN SODIUM, NAPROXEN SODIUM
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OMEPRAZOLE, OMEPRAZOLE
PALIPERIDONE, PALIPERIDONE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RAMELTEON, RAMELTEON
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
AZELAIC ACID, AZELAIC ACID
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLONIDINE, CLONIDINE
FIORICET W/ CODEINE, ACETAMINOPHEN
LIDOCAINE, LIDOCAINE
PROGESTERONE, PROGESTERONE
SCOPOLAMINE, SCOPOLAMINE
TESTOSTERONE, TESTOSTERONE

* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PIMECROLIMUS, PIMECROLIMUS
TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS LLC
AZACITIDINE, AZACITIDINE
DAPSONE, DAPSONE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
* ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DOCETAXEL, DOCETAXEL
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
OXALIPLATIN, OXALIPLATIN

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
LEVETIRACETAM, LEVETIRACETAM
MESALAMINE, MESALAMINE
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
VALNAC, BETAMETHASONE VALERATE
* ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
IBUPROFEN, IBUPROFEN
PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

* ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
MICONAZOLE NITRATE, MICONAZOLE NITRATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION

* ACTELION PHARMACEUTICALS US INC
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

* ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

ADAMAS PHARMA

* ADAMAS PHARMA LLC
GOCOVRI, AMANTADINE HYDROCHLORIDE
OSMOLEX ER, AMANTADINE HYDROCHLORIDE

ADAMIS PHARMS CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE
ZIMHI, NALOXONE HYDROCHLORIDE

ADAPTIS

* ADAPTIS PHARMA PRIVATE LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

ADARE PHARMS INC

* ADARE PHARMACEUTICALS INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ADDMEDICA SAS

* ADDMEDICA SAS
SIKLOS, HYDROXYUREA

ADHERA

* ADHERA THERAPEUTICS INC
PRESTALIA, AMLODIPINE BESYLATE

ADIENNE SA

* ADIENNE SA
TEPADINA, THIOTEPA

AERIE PHARMS INC

* AERIE PHARMACEUTICALS INC
RHOPRESSA, NETARSUDIL MESYLATE
ROCKLATAN, LATANOPROST

AET PHARMA

* AET PHARMA US INC
POSACONAZOLE, POSACONAZOLE

AGILE

* AGILE THERAPEUTICS INC
TWIRLA, ETHINYL ESTRADIOL

AGNITIO

* AGNITIO INC
ETHACRYNIC ACID, ETHACRYNIC ACID
TRIAMTERENE, TRIAMTERENE

AGOURON PHARMS

* AGOURON PHARMACEUTICALS LLC
VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC

* AILEX PHARMACEUTICALS LLC
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
CROMOLYN SODIUM, CROMOLYN SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CAPTOPRIL, CAPTOPRIL
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTACAPONE, ENTACAPONE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AJANTA PHARMA LTD
LAMOTRIGINE, LAMOTRIGINE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANOLAZINE, RANOLAZINE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

AKARX INC

* AKARX INC
DOPTELET, AVATROMBOPAG MALEATE

AKCEA THERAPS

* AKCEA THERAPEUTICS INC
TEGSEDI, INOTERSEN SODIUM

AKORN

* AKORN OPERATING CO LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZASITE, AZITHROMYCIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETIMOL, TIMOLOL
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
CALCIPOTRIENE, CALCIPOTRIENE
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COGENTIN, BENZTROPINE MESYLATE
CORMAX, CLOBETASOL PROPIONATE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN OPERATING CO LLC
COSOPT, DORZOLAMIDE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DRONABINOL, DRONABINOL
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMOTIDINE, FAMOTIDINE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
GABAPENTIN, GABAPENTIN
GATIFLOXACIN, GATIFLOXACIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IC-GREEN, INDOCYANINE GREEN
INAPSINE, DROPERIDOL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTULOSE, LACTULOSE
LATANOPROST, LATANOPROST
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM, LORAZEPAM
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
MEGESTROL ACETATE, MEGESTROL ACETATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN OPERATING CO LLC
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PYRAZINAMIDE, PYRAZINAMIDE
RIFAMPIN, RIFAMPIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOLOL, TIMOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIFLURIDINE, TRIFLURIDINE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALBIREO

* ALBIREO AB
BYLVAY, ODEVIXIBAT

ALCON

* ALCON LABORATORIES INC
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
MIOSTAT, CARBACHOL
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALCON LABS

* ALCON LABORATORIES LTD
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC

* ALCON LABORATORIES INC
ALCAINE, PROPARACAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALCON LABORATORIES INC
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
FLUORESCITE, FLUORESCEIN SODIUM
ISOPTO ATROPINE, ATROPINE SULFATE
MYDRIACYL, TROPICAMIDE
PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
SIMBRINZA, BRIMONIDINE TARTRATE

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
BETADINE, POVIDONE-IODINE
ZADITOR, KETOTIFEN FUMARATE (OTC)

ALEMBIC GLOBAL

* ALEMBIC GLOBAL HOLDING SA
TREPROSTINIL, TREPROSTINIL

ALEMBIC LABS

* ALEMBIC LABS LLC
BENZONATATE, BENZONATATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
FENOFIBRATE, FENOFIBRATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
METRONIDAZOLE, METRONIDAZOLE

ALEMBIC LTD

* ALEMBIC LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ASENAPINE MALEATE, ASENAPINE MALEATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CELECOXIB, CELECOXIB
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC PHARMACEUTICALS LTD
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PREGABALIN, PREGABALIN
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TERIFLUNOMIDE, TERIFLUNOMIDE
THEOPHYLLINE, THEOPHYLLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRAVOPROST, TRAVOPROST
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ALEOR DERMACEUTICALS

* ALEOR DERMACEUTICALS LTD
ADAPALENE, ADAPALENE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
LIDOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MUPIROCIN, MUPIROCIN CALCIUM
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TAVABOROLE, TAVABOROLE

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
ADASUVE, LOXAPINE

ALFASIGMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALFASIGMA USA INC
ZELNORM, TEGASEROD MALEATE

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
ILUVIEN, FLUOCINOLONE ACETONIDE

ALK ABELLO

* ALK-ABELLO INC
OTIPRIO, CIPROFLOXACIN

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

ALKEM

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

* ALKEM LABORATORIES LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
APREMILAST, APREMILAST
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CEFDINIR, CEFDINIR
CEFIXIME, CEFIXIME
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DALFAMPRIDINE, DALFAMPRIDINE
DEFERASIROX, DEFERASIROX
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EVEROLIMUS, EVEROLIMUS
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FEBUXOSTAT, FEBUXOSTAT
FINASTERIDE, FINASTERIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALKEM LABORATORIES LTD
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
MARINOL, DRONABINOL
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TACROLIMUS, TACROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TOLVAPTAN, TOLVAPTAN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

ALKERMES

* ALKERMES INC
VIVITROL, NALTREXONE

ALKERMES INC

* ALKERMES INC
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARISTADA, ARIPIPRAZOLE LAUROXIL
LYBALVI, OLANZAPINE

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
ZYMAXID, GATIFLOXACIN

* ALLERGAN INC
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACAFT, ALCAFTADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALLERGAN INC
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
ZYMAR, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE

* ALLERGAN SALES LLC
ACTIGALL, URSODIOL
ANDRODERM, TESTOSTERONE
AVYCAZ, AVIBACTAM SODIUM
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
CELEXA, CITALOPRAM HYDROBROMIDE
CONDYLOX, PODOFILOX
CRINONE, PROGESTERONE
DALVANCE, DALBAVANCIN HYDROCHLORIDE
ESTRACE, ESTRADIOL
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
GELNIQUE, OXYBUTYNIN CHLORIDE
INFED, FERRIC OXYHYDROXIDE
LEXAPRO, ESCITALOPRAM OXALATE
LINZESS, LINACLOTIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OXYTROL, OXYBUTYNIN
PYLERA, BISMUTH SUBCITRATE POTASSIUM
RAPAFLO, SILODOSIN
RECTIV, NITROGLYCERIN
SAPHRIS, ASENAPINE MALEATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
TEFLARO, CEFTAROLINE FOSAMIL
UBRELVY, UBROGEPANT
URSO 250, URSODIOL
URSO FORTE, URSODIOL
VIIBRYD, VILAZODONE HYDROCHLORIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE

ALLERGAN HOLDINGS

* ALLERGAN HOLDINGS UNLTD CO
VIBERZI, ELUXADOLINE

ALLERGAN INC

* ALLERGAN INC
DURYSTA, BIMATOPROST

ALMAJECT

* ALMAJECT INC
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALMAJECT INC
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

ALMATICA

* ALMATICA PHARMA INC
GRALISE, GABAPENTIN

* ALMATICA PHARMA LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE
LOREEV XR, LORAZEPAM
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
NAPRELAN, NAPROXEN SODIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL

ALMIRALL

* ALMIRALL LLC
ACTICLATE, DOXYCYCLINE HYCLATE
ACZONE, DAPSONE
ALTABAX, RETAPAMULIN
AZELEX, AZELAIC ACID
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
KLISYRI, TIRBANIBULIN
SEYSARA, SARECYCLINE HYDROCHLORIDE
VELTIN, CLINDAMYCIN PHOSPHATE
VERDESO, DESONIDE
XOLEGEL, KETOCONAZOLE

ALNYLAM PHARMS INC

* ALNYLAM PHARMACEUTICALS INC
GIVLAARI, GIVOSIRAN SODIUM
ONPATTRO, PATISIRAN SODIUM
OXLUMO, LUMASIRAN SODIUM

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALTHERA PHARMS

* ALTHERA PHARMACEUTICALS LLC
ROSZET, EZETIMIBE

ALVOGEN

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BONSITY, TERIPARATIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CARBIDOPA, CARBIDOPA
CICLOPIROX, CICLOPIROX
DAPSONE, DAPSONE
DEXAMETHASONE, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALVOGEN INC
DISULFIRAM, DISULFIRAM
DYNACIN, MINOCYCLINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
ETHACRYNIC ACID, ETHACRYNIC ACID
EXEMESTANE, EXEMESTANE
FELBAMATE, FELBAMATE
FLUOCINONIDE, FLUOCINONIDE
HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
LIDEX, FLUOCINONIDE
LIDEX-E, FLUOCINONIDE
MELPHALAN, MELPHALAN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
NITROGLYCERIN, NITROGLYCERIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIMETHAMINE, PYRIMETHAMINE
RIVASTIGMINE, RIVASTIGMINE
SPECTAZOLE, ECONAZOLE NITRATE
THYRO-TABS, LEVOTHYROXINE SODIUM **
TRANDATE, LABETALOL HYDROCHLORIDE
UREX, METHENAMINE HIPPURATE

ALVOGEN PINE BROOK

* ALVOGEN PINE BROOK LLC
HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

AM REGENT

* AMERICAN REGENT INC
ACETYLCYSTEINE, ACETYLCYSTEINE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUSULFAN, BUSULFAN
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
FOMEPIZOLE, FOMEPIZOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INJECTAFER, FERRIC CARBOXYMALTOSE
LEVOCARNITINE, LEVOCARNITINE
METHOCARBAMOL, METHOCARBAMOL
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
MULTRYS, CUPRIC SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
OLANZAPINE, OLANZAPINE
SELENIOUS ACID, SELENIOUS ACID
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TRALEMENT, CUPRIC SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VASOPRESSIN, VASOPRESSIN
VENOFER, FERRIC OXYHYDROXIDE
ZINC SULFATE, ZINC SULFATE

AMARIN PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

AMGEN

* AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC

* AMGEN INC
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
LUMAKRAS, SOTORASIB
OTEZLA, APREMILAST

AMICI

* AMICI PHARMACEUTICALS LLC
CATAFLAM, DICLOFENAC POTASSIUM
METRONIDAZOLE, METRONIDAZOLE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

AMICUS THERAP US

* AMICUS THERAPEUTICS US LLC
GALAFOLD, MIGALASTAT HYDROCHLORIDE

AMIVAS

* AMIVAS LLC
ARTESUNATE, ARTESUNATE

AMNEAL

* AMNEAL EU LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID
APREMILAST, APREMILAST
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
BUSULFAN, BUSULFAN
CARMUSTINE, CARMUSTINE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLOFARABINE, CLOFARABINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEFERASIROX, DEFERASIROX
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DIFLUPREDNATE, DIFLUPREDNATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ETRAVIRINE, ETRAVIRINE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FULVESTRANT, FULVESTRANT
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METYROSINE, METYROSINE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OFLOXACIN, OFLOXACIN
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISONE, PREDNISONE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL EU LTD
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
* AMNEAL PHARMACEUTICALS LLC
ACTIVELLA, ESTRADIOL
ACYCLOVIR, ACYCLOVIR
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BUPRENORPHINE, BUPRENORPHINE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ELURYNG, ETHINYL ESTRADIOL
ESTRADIOL, ESTRADIOL
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
FENOFIBRATE, FENOFIBRATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LUBIPROSTONE, LUBIPROSTONE
MESALAMINE, MESALAMINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN, NAPROXEN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
SIROLIMUS, SIROLIMUS
SUCRALFATE, SUCRALFATE
TAVABOROLE, TAVABOROLE
TESTOSTERONE, TESTOSTERONE
TIGECYCLINE, TIGECYCLINE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOVAQUONE, ATOVAQUONE
CALCITRIOL, CALCITRIOL
CAPECITABINE, CAPECITABINE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
COLCHICINE, COLCHICINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DIVALPROEX SODIUM, DIVALPROEX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LORAZEPAM, LORAZEPAM
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN
NIZATIDINE, NIZATIDINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TEMOZOLOMIDE, TEMOZOLOMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
WARFARIN SODIUM, WARFARIN SODIUM

* AMNEAL PHARMACEUTICALS HOLDINGS GMBH
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CELECOXIB, CELECOXIB
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PALIPERIDONE, PALIPERIDONE
PARICALCITOL, PARICALCITOL
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIVASTIGMINE, RIVASTIGMINE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SPIRONOLACTONE, SPIRONOLACTONE
TOBRAMYCIN, TOBRAMYCIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARGATROBAN, ARGATROBAN
BUMETANIDE, BUMETANIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERYTHROMYCIN, ERYTHROMYCIN
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
NADOLOL, NADOLOL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PARICALCITOL, PARICALCITOL
PHYTONADIONE, PHYTONADIONE
PREGABALIN, PREGABALIN
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
URSODIOL, URSODIOL

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS NY LLC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
BEXAROTENE, BEXAROTENE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOTRETINOIN, ISOTRETINOIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PROGESTERONE, PROGESTERONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
GLUCAGON, GLUCAGON
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

AMRING PHARMS

* AMRING PHARMACEUTICALS INC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LATANOPROST, LATANOPROST
LYSTEDA, TRANEXAMIC ACID
MESALAMINE, MESALAMINE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

AMRYT

* AMRYT PHARMACEUTICALS DAC
JUXTAPID, LOMITAPIDE MESYLATE

AMTA

* AMTA LABS LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

ANACOR PHARMS INC

* ANACOR PHARMACEUTICALS INC
EUCRISA, CRISABOROLE
KERYDIN, TAVABOROLE

ANBEX

* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANBISON LABORATORY CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

ANCHEN PHARMS

* ANCHEN PHARMACEUTICALS INC
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

ANDA REPOSITORY

* ANDA REPOSITORY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PRIMIDONE, PRIMIDONE

ANDOR PHARMS

* ANDOR PHARMACEUTICALS LLC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ANDRX LABS LLC

* ANDRX LABS LLC
FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ARIMIDEX, ANASTROZOLE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
BEXAROTENE, BEXAROTENE
BRETHINE, TERBUTALINE SULFATE
CARBIDOPA, CARBIDOPA
CASODEX, BICALUTAMIDE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CORTENEMA, HYDROCORTISONE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ETODOLAC, ETODOLAC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANI PHARMACEUTICALS INC
FELBAMATE, FELBAMATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LITHOBID, LITHIUM CARBONATE
LUVOX, FLUVOXAMINE MALEATE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIGLUSTAT, MIGLUSTAT
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NILUTAMIDE, NILUTAMIDE
OXISTAT, OXICONAZOLE NITRATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANDEL, HYDROCORTISONE PROBUTATE
PENICILLAMINE, PENICILLAMINE
PINDOLOL, PINDOLOL
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PURIFIED CORTROPHIN GEL, CORTICOTROPIN
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VEREGEN, SINECATECHINS

ANIMA

* ANIMA PHARMACEUTICALS PVT LTD
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
DEXAMETHASONE, DEXAMETHASONE

ANNORA

* ANNORA PHARMA PRIVATE LTD
DROXIDOPA, DROXIDOPA
LAMIVUDINE, LAMIVUDINE

ANNORA PHARMA

* ANNORA PHARMA PRIVATE LTD
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
DEFERASIROX, DEFERASIROX
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
ITRACONAZOLE, ITRACONAZOLE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
NABUMETONE, NABUMETONE
OXCARBAZEPINE, OXCARBAZEPINE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZAFIRLUKAST, ZAFIRLUKAST

ANTARES PHARMA INC

* ANTARES PHARMA INC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ANTIBIOTICE
* ANTIBIOTICE SA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANXIN
* ANXIN PHARMA INC
SEVELAMER CARBONATE, SEVELAMER CARBONATE

APELLIS PHARMS
* APELLIS PHARMACEUTICALS INC
EMPAVELI, PEGCETACOPLAN

APGDI
* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ GRANULES, MIRABEGRON
MYRBETRIQ, MIRABEGRON

APIL
* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
DELZICOL, MESALAMINE
LO LOESTRIN FE, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP
* APNAR PHARMA LP
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APOTEX
* APOTEX INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACYCLOVIR, ACYCLOVIR
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATOVAQUONE, ATOVAQUONE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BUSULFAN, BUSULFAN
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFTAROLINE FOSAMIL, CEFTAROLINE FOSAMIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE, CIMETIDINE (OTC)
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DASATINIB, DASATINIB
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ETODOLAC, ETODOLAC
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUNISOLIDE, FLUNISOLIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IMATINIB MESYLATE, IMATINIB MESYLATE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE, OMEPRAZOLE (OTC)
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLAMINE, PENICILLAMINE
PENTOXIFYLLINE, PENTOXIFYLLINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREGABALIN, PREGABALIN
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TETRABENAZINE, TETRABENAZINE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLVAPTAN, TOLVAPTAN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

APOTEX CORP

* APOTEX CORP
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APOTEX INC

* APOTEX INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
BENZONATATE, BENZONATATE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITONIN-SALMON, CALCITONIN SALMON
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIQUIMOD, IMIQUIMOD
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LEFLUNOMIDE, LEFLUNOMIDE
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
MIRTAZAPINE, MIRTAZAPINE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE
* APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

APOTEX TECHNOLOGIES

* APOTEX TECHNOLOGIES INC
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-80, TRIAMCINOLONE ACETONIDE

APP PHARMS

* APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO

* APPCO PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CHLORTHALIDONE, CHLORTHALIDONE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LORATADINE, LORATADINE (OTC)
METAXALONE, METAXALONE
MODAFINIL, MODAFINIL
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RAMELTEON, RAMELTEON
SILDENAFIL CITRATE, SILDENAFIL CITRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

APRECIA PHARMS

* APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

APTAPHARMA INC

* APTAPHARMA INC
IBUPROFEN, IBUPROFEN (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

AQUESTIVE

* AQUESTIVE THERAPEUTICS INC
SYMPAZAN, CLOBAZAM

ARBOR PHARMS LLC

* ARBOR PHARMACEUTICALS LLC
BIDIL, HYDRALAZINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
ERY-TAB, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
EVEKEO ODT, AMPHETAMINE SULFATE
EVEKEO, AMPHETAMINE SULFATE
GLIADEL, CARMUSTINE
HORIZANT, GABAPENTIN ENACARBIL
NYMALIZE, NIMODIPINE
SKLICE, IVERMECTIN (OTC)
SOTYLIZE, SOTALOL HYDROCHLORIDE
TRIPTODUR KIT, TRIPTORELIN PAMOATE

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

ARISE

* ARISE PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

ARMSTRONG PHARMS
* ARMSTRONG PHARMACEUTICALS INC
PRIMATENE MIST, EPINEPHRINE (OTC)

ARRAY BIOPHARMA INC
* ARRAY BIOPHARMA INC
BRAFTOVI, ENCORAFENIB
MEKTOVI, BINIMETINIB

ARROW INTL
* ARROW INTERNATIONAL LTD
LENALIDOMIDE, LENALIDOMIDE

ARTHUR GRP
* ARTHUR GROUP LLC
BUSULFAN, BUSULFAN

ASCEND THERAPS US
* ASCEND THERAPEUTICS US LLC
BINOSTO, ALENDRONATE SODIUM
ESTROGEL, ESTRADIOL

ASCENT PHARMS INC
* ASCENT PHARMACEUTICALS INC
BENZONATATE, BENZONATATE
DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DRONABINOL, DRONABINOL
DUTASTERIDE, DUTASTERIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
LISINOPRIL, LISINOPRIL
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ASPEN
* ASPEN PHARMA USA INC
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

ASPEN GLOBAL
* ASPEN GLOBAL INC
MYLERAN, BUSULFAN

ASPEN GLOBAL INC
* ASPEN GLOBAL INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CYCLESSA, DESOGESTREL
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
LEUKERAN, CHLORAMBUCIL
THIOGUANINE, THIOGUANINE

ASPIRO
* ASPIRO PHARMA LTD
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

ASSERTIO
* ASSERTIO THERAPEUTICS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ASSERTIO THERAPEUTICS INC
CAMBIA, DICLOFENAC POTASSIUM
ZIPSOR, DICLOFENAC POTASSIUM

ASTELLAS

* ASTELLAS PHARMA US INC
AMBISOME, AMPHOTERICIN B
ASTAGRAF XL, TACROLIMUS
CRESEMBA, ISAVUCONAZONIUM SULFATE
LEXISCAN, REGADENOSON
MYCAMINE, MICAFUNGIN SODIUM
PROGRAF, TACROLIMUS
VESICARE LS, SOLIFENACIN SUCCINATE
VESICARE, SOLIFENACIN SUCCINATE
XOSPATA, GILTERITINIB FUMARATE
XTANDI, ENZALUTAMIDE

ASTRAL

* ASTRAL STERITECH PVT LTD
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

ASTRAZENECA

* ASTRAZENECA LP
PULMICORT FLEXHALER, BUDESONIDE
SYMBICORT, BUDESONIDE
* ASTRAZENECA PHARMACEUTICALS LP
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BRILINTA, TICAGRELOR
DALIRESP, ROFLUMILAST
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
FASLODEX, FULVESTRANT
IRESSA, GEFITINIB
KOSELUGO, SELUMETINIB SULFATE
LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
LYNPARZA, OLAPARIB
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PULMICORT RESPULES, BUDESONIDE
SEROQUEL, QUETIAPINE FUMARATE
TAGRISSO, OSIMERTINIB MESYLATE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
* ASTRAZENECA UK LTD
CALQUENCE, ACALABRUTINIB
SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB

* ASTRAZENECA AB
BREZTRI AEROSPHERE, BUDESONIDE
BYDUREON BCISE, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
FARXIGA, DAPAGLIFLOZIN
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN
SYMLIN, PRAMLINTIDE ACETATE
XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP

* ASTRAZENECA LP
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ATHEM

* ATHEM HOLDINGS LLC
FOLIC ACID, FOLIC ACID
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

ATHENA
* ATHENA BIOSCIENCES LLC
FIBRICOR, FENOFIBRIC ACID
QDOLO, TRAMADOL HYDROCHLORIDE

ATHENEX
* ATHENEX PHARMACEUTICAL DIV
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

ATHENEX INC
* ATHENEX INC
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
VALPROATE SODIUM, VALPROATE SODIUM

ATLANTIDE
* ATLANTIDE PHARMACEUTICALS AG
ENTACAPONE, ENTACAPONE
LAMOTRIGINE, LAMOTRIGINE
LISINOPRIL, LISINOPRIL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ATLAS PHARMS LLC
* ATLAS PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATNAHS PHARMA US
* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ATON
* ATON PHARMA INC
LODOSYN, CARBIDOPA

AUCTA
* AUCTA PHARMACEUTICALS INC
DEFERASIROX, DEFERASIROX
VIGADRONE, VIGABATRIN

AUGUST
* AUGUST PHARMACEUTICALS LLC
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

AURINIA
* AURINIA PHARMACEUTICALS INC
LUPKYNIS, VOCLOSPORIN

AUROBINDO
* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATENOLOL, ATENOLOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIBAVIRIN, RIBAVIRIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LEVOFLOXACIN, LEVOFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
* AUROBINDO PHARMA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AFIRMELLE, ETHINYL ESTRADIOL
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARIPIPRAZOLE, ARIPIPRAZOLE
ARMODAFINIL, ARMODAFINIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AYUNA, ETHINYL ESTRADIOL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARBIDOPA, CARBIDOPA
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORZOXAZONE, CHLORZOXAZONE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
COLCHICINE, COLCHICINE
CYONANZ, ETHINYL ESTRADIOL
DALFAMPRIDINE, DALFAMPRIDINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOFETILDE, DOFETILIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
FELODIPINE, FELODIPINE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ICLEVIA, ETHINYL ESTRADIOL
INCASSIA, NORETHINDRONE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
KALLIGA, DESOGESTREL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEFLUNOMIDE, LEFLUNOMIDE
LEVETIRACETAM, LEVETIRACETAM
LO SIMPESSE, ETHINYL ESTRADIOL
LO-ZUMANDIMINE, DROSPIRENONE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
NEXESTA FE, ETHINYL ESTRADIOL
NIACIN, NIACIN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NIFEDIPINE, NIFEDIPINE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
OXACILLIN SODIUM, OXACILLIN SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
REPAGLINIDE, REPAGLINIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SIMLIYA, DESOGESTREL
SIMPESSE, ETHINYL ESTRADIOL
SPIRONOLACTONE, SPIRONOLACTONE
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-MILI, ETHINYL ESTRADIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZONISAMIDE, ZONISAMIDE
ZUMANDIMINE, DROSPIRENONE

* AUROBINDO PHARMA LTD INC
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA

* AUROBINDO PHARMA USA INC
BUDESONIDE, BUDESONIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA USA INC
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RASAGILINE MESYLATE, RASAGILINE MESYLATE

AUROLIFE PHARMA LLC

* AUROLIFE PHARMA LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

AUSTARPHARMA

* AUSTARPHARMA LLC
FENOFIBRATE, FENOFIBRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

AUSTARPHARMA LLC

* AUSTARPHARMA LLC
METHOCARBAMOL, METHOCARBAMOL

AUXILIUM PHARMS INC

* AUXILIUM PHARMACEUTICALS INC
TESTOPEL, TESTOSTERONE
THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC

* AUXILIUM PHARMACEUTICALS LLC
EDEX, ALPROSTADIL
TESTIM, TESTOSTERONE
THEO-24, THEOPHYLLINE

AVANIR PHARMS

* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA

* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

* AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

AVEO PHARMS
* AVEO PHARMACEUTICALS INC
  FOTIVDA, TIVOZANIB HYDROCHLORIDE

AVERITAS
* AVERITAS PHARMA INC
  QUTENZA, CAPSAICIN

AVET
* AVET PHARMACEUTICALS INC
  ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
  DOXERCALCIFEROL, DOXERCALCIFEROL

AVET LIFESCIENCES
* AVET LIFESCIENCES LTD
  BICNU, CARMUSTINE
  ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE

AVEVA
* AVEVA DRUG DELIVERY SYSTEMS INC
  BUPRENORPHINE, BUPRENORPHINE
  CLONIDINE, CLONIDINE
  FENTANYL-100, FENTANYL
  FENTANYL-12, FENTANYL
  FENTANYL-25, FENTANYL
  FENTANYL-37, FENTANYL
  FENTANYL-50, FENTANYL
  FENTANYL-62, FENTANYL
  FENTANYL-75, FENTANYL
  FENTANYL-87, FENTANYL
  NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC
* AVID RADIOPHARMACEUTICALS INC
  AMYVID, FLORBETAPIR F-18
  TAUVID, FLORTAUCIPIR F-18

AVION PHARMS
* AVION PHARMACEUTICALS LLC
  BALCOLTRA, ETHINYL ESTRADIOL
  DHIVY, CARBIDOPA
  PONSTEL, MEFENAMIC ACID

AVONDALE PHARMS
* AVONDALE PHARMACEUTICALS LLC
  NIACOR, NIACIN

AXAR PHARMS INC
* AXAR PHARMACEUTICALS INC
  ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE

AYANA PHARMA LTD
* AYANA PHARMA LTD
  DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

AYTU
* AYTU BIOSCIENCE INC
  KARBINAL ER, CARBINOXAMINE MALEATE
  TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
  ZOLPIMIST, ZOLPIDEM TARTRATE

AZURITY
* AZURITY PHARMACEUTICALS INC
  EPANED, ENALAPRIL MALEATE
  EPRONTIA, TOPIRAMATE
  FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
  KATERZIA, AMLODIPINE BENZOATE
  QBRELIS, LISINOPRIL
  XATMEP, METHOTREXATE SODIUM

**** B ****

B BRAUN
* B BRAUN MEDICAL INC
  ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
  AMINO ACIDS, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC

BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC

* B BRAUN MEDICAL INC
ACETAMINOPHEN, ACETAMINOPHEN
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ

* BAJAJ MEDICAL
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
* BAJAJ MEDICAL LLC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BANNER LIFE SCIENCES

* BANNER LIFE SCIENCES LLC
BAFIERTAM, MONOMETHYL FUMARATE

BARR

* BARR LABORATORIES INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALZIVA-28, ETHINYL ESTRADIOL
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
DANAZOL, DANAZOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DUTASTERIDE, DUTASTERIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
ISONIAZID, ISONIAZID
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
KELNOR, ETHINYL ESTRADIOL
LESSINA-28, ETHINYL ESTRADIOL
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
PORTIA-28, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BARR LABORATORIES INC
SPRINTEC, ETHINYL ESTRADIOL
TREXALL, METHOTREXATE SODIUM
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
WARFARIN SODIUM, WARFARIN SODIUM
* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS INC

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
ESTRADIOL, ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
TRETINOIN, TRETINOIN
TRI LO SPRINTEC, ETHINYL ESTRADIOL

BAUDAX

* BAUDAX BIO INC
ANJESO, MELOXICAM

BAUSCH

* BAUSCH HEALTH AMERICAS INC
ACANYA, BENZOYL PEROXIDE
ARAZLO, TAZAROTENE
BENZACLIN, BENZOYL PEROXIDE
BRYHALI, HALOBETASOL PROPIONATE
DUOBRII, HALOBETASOL PROPIONATE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EFUDEX, FLUOROURACIL
JUBLIA, EFINACONAZOLE
LOCOID, HYDROCORTISONE BUTYRATE
MEPHYTON, PHYTONADIONE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN
SYPRINE, TRIENTINE HYDROCHLORIDE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
* BAUSCH HEALTH IRELAND LTD
ERTACZO, SERTACONAZOLE NITRATE
TARGRETIN, BEXAROTENE
* BAUSCH HEALTH US LLC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALDARA, IMIQUIMOD
AMMONUL, SODIUM BENZOATE
ANCOBON, FLUCYTOSINE
APLENZIN, BUPROPION HYDROBROMIDE
ATIVAN, LORAZEPAM
BRINZOLAMIDE, BRINZOLAMIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CESAMET, NABILONE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DEMSER, METYROSINE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
ELIDEL, PIMECROLIMUS
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
ISORDIL, ISOSORBIDE DINITRATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH HEALTH US LLC
KLARON, SULFACETAMIDE SODIUM
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LOCOID, HYDROCORTISONE BUTYRATE
LOPROX, CICLOPIROX
LUZU, LULICONAZOLE
MESTINON, PYRIDOSTIGMINE BROMIDE
METHAZOLAMIDE, METHAZOLAMIDE
METROGEL-VAGINAL, METRONIDAZOLE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
TASMAR, TOLCAPONE
TIAZAC, DILTIAZEM HYDROCHLORIDE
VANOS, FLUOCINONIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
VIRAZOLE, RIBAVIRIN
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
XENAZINE, TETRABENAZINE
XERESE, ACYCLOVIR
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZIANA, CLINDAMYCIN PHOSPHATE
ZOVIRAX, ACYCLOVIR
ZYCLARA, IMIQUIMOD

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALREX, LOTEPREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICAMIDE, TROPICAMIDE
VYZULTA, LATANOPROSTENE BUNOD
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPREDNOL ETABONATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH AND LOMB PHARMACEUTICALS INC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
BEPREVE, BEPOTASTINE BESILATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTEMAX, LOTEPREDNOL ETABONATE
LUMIFY, BRIMONIDINE TARTRATE (OTC)
XIPERE, TRIAMCINOLONE ACETONIDE

BAUSCH LOMB IRELAND

* BAUSCH AND LOMB IRELAND LTD
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYTOXAN, CYCLOPHOSPHAMIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, ICODEXTRIN
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FORANE, ISOFLURANE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
IFEX, IFOSFAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION
SUPRANE, DESFLURANE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

* BAXTER HEALTHCARE CORP
ACETAMINOPHEN, ACETAMINOPHEN
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINOLIPID 20%, OLIVE OIL
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANSDERM SCOP, SCOPOLAMINE
* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER

* BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

* BAYER HEALTHCARE PHARMACEUTICALS INC
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
LAMPIT, NIFURTIMOX
NUBEQA, DAROLUTAMIDE
VITRAKVI, LAROTRECTINIB SULFATE

BAYER HEALTHCARE LLC

* BAYER HEALTHCARE LLC
CHILDREN'S CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
ZEGERID OTC, OMEPRAZOLE (OTC)

BAYER HLTHCARE

* BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
* BAYER HEALTHCARE PHARMACEUTICALS INC
ADEMPAS, RIOCIGUAT
ANGELIQ, DROSPIRENONE
BEYAZ, DROSPIRENONE
BILTRICIDE, PRAZIQUANTEL
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAYER HEALTHCARE PHARMACEUTICALS INC
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
EOVIST, GADOXETATE DISODIUM
GADAVIST, GADOBUTROL
KERENDIA, FINERENONE
KYLEENA, LEVONORGESTREL
LEVITRA, VARDENAFIL HYDROCHLORIDE
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STAXYN, VARDENAFIL HYDROCHLORIDE
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
VITRAKVI, LAROTRECTINIB SULFATE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
ETODOLAC, ETODOLAC
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METOLAZONE, METOLAZONE
PINDOLOL, PINDOLOL
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI

* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
ELYXYB, CELECOXIB
SYMPROIC, NALDEMEDINE TOSYLATE

BE PHARMS

* BE PHARMACEUTICALS AG
DAPTOMYCIN, DAPTOMYCIN
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
HEPARIN SODIUM, HEPARIN SODIUM
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

BECTON DICKINSON

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIGENE

* BEIGENE USA INC
BRUKINSA, ZANUBRUTINIB

BEIJING

* BEIJING SCIECURE PHARMACEUTICAL CO LTD
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
NIACIN, NIACIN

BEIJING TIDE PHARM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BEIJING TIDE PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE

BEIJING YILING

* BEIJING YILING BIO-ENGEERING AND TECHNOLOGY CO LTD
ANASTROZOLE, ANASTROZOLE
LETROZOLE, LETROZOLE

BELCHER

* BELCHER PHARMACEUTICALS LLC
ABLYSINOL, ALCOHOL
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CEFIXIME, CEFIXIME
EPINEPHRINE, EPINEPHRINE
MEFENAMIC ACID, MEFENAMIC ACID
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TACROLIMUS, TACROLIMUS

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLORATADINE, DESLORATADINE

BELOTECA INC

* BELOTECA INC
DIAZEPAM, DIAZEPAM
THIOTEPA, THIOTEPA

BENUVIA

* BENUVIA THERAPEUTICS INC
SYNDROS, DRONABINOL

BEXIMCO PHARMS USA

* BEXIMCO PHARMACEUTICALS USA INC
BACLOFEN, BACLOFEN
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NADOLOL, NADOLOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BIOCODEX SA

* BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON PHARMA

* BIOCON PHARMA INC
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
* BIOCON PHARMA LTD
EVEROLIMUS, EVEROLIMUS
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SIMVASTATIN, SIMVASTATIN
TACROLIMUS, TACROLIMUS

BIOCRYST

* BIOCRYST PHARMACEUTICALS INC
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
RAPIVAB, PERAMIVIR

BIOFRONTERA

* BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC

* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN INC

* BIOGEN INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIOGEN INC
TECFIDERA, DIMETHYL FUMARATE
VUMERITY, DIROXIMEL FUMARATE

BIOHAVEN IRELAND

* BIOHAVEN PHARMACEUTICAL IRELAND DESIGNATED ACTIVITY CO
NURTEC ODT, RIMEGEPANT SULFATE

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
VOXZOGO, VOSORITIDE

BIOMEDCL RES FDN

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC

* BIONPHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBAZAM, CLOBAZAM
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOFETILIDE, DOFETILIDE
DROXIDOPA, DROXIDOPA
DUTASTERIDE, DUTASTERIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NIMODIPINE, NIMODIPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
POTASSIUM CITRATE, POTASSIUM CITRATE
PROGESTERONE, PROGESTERONE
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TETRABENAZINE, TETRABENAZINE
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

BIOPHARM

* BIOPHARM DISCOVERY LLC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIOPHARM DISCOVERY LLC
VALPROIC ACID, VALPROIC ACID

BLUE EARTH

* BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18

BLUEPRINT MEDICINES

* BLUEPRINT MEDICINES CORP
AYVAKIT, AVAPRITINIB

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM
GILOTRIF, AFATINIB DIMALEATE
GLYXAMBI, EMPAGLIFLOZIN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
JARDIANCE, EMPAGLIFLOZIN
JENTADUETO XR, LINAGLIPTIN
JENTADUETO, LINAGLIPTIN
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MOBIC, MELOXICAM
OFEV, NINTEDANIB ESYLATE
PERSANTINE, DIPYRIDAMOLE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRIVA, TIOTROPIUM BROMIDE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
SYNJARDY XR, EMPAGLIFLOZIN
SYNJARDY, EMPAGLIFLOZIN
TRADJENTA, LINAGLIPTIN
TRIJARDY XR, EMPAGLIFLOZIN
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE

BOSCOGEN

* BOSCOGEN INC
ARIPIPRAZOLE, ARIPIPRAZOLE
CAPTOPRIL, CAPTOPRIL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

BPI LABS LLC

* BPI LABS LLC
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
ENTERO VU 24%, BARIUM SULFATE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BRACCO DIAGNOSTICS INC
KINEVAC, SINCALIDE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READI-CAT 2, BARIUM SULFATE
TAGITOL V, BARIUM SULFATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE

BRAINTREE

* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SUTAB, MAGNESIUM SULFATE

BRECKENRIDGE

* BRECKENRIDGE PHARMACEUTICAL INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALPRAZOLAM, ALPRAZOLAM
ASENAPINE MALEATE, ASENAPINE MALEATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
EVEROLIMUS, EVEROLIMUS
EXEMESTANE, EXEMESTANE
IMATINIB MESYLATE, IMATINIB MESYLATE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
MEGESTROL ACETATE, MEGESTROL ACETATE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OMEPRAZOLE, OMEPRAZOLE
PENICILLAMINE, PENICILLAMINE
RIVASTIGMINE, RIVASTIGMINE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
OXCARBAZEPINE, OXCARBAZEPINE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BRIGHAM AND WOMENS HOSP INC
AMMONIA N 13, AMMONIA N-13

BRIGHTGENE

* BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
ENTECAVIR, ENTECAVIR

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
* BRISTOL MYERS SQUIBB CO
DROXIA, HYDROXYUREA
HYDREA, HYDROXYUREA
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN

BRISTOL-MYERS SQUIBB

* BRISTOL-MYERS SQUIBB CO
EVOTAZ, ATAZANAVIR SULFATE

BTCP PHARMA

* BTCP PHARMA LLC
LAZANDA, FENTANYL CITRATE
SUBSYS, FENTANYL

BTG INTL

* BTG INTERNATIONAL INC
THYROSAFE, POTASSIUM IODIDE (OTC)

BWXT ITG

* BWXT ITG CANADA INC
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

**** C ****

CADILA

* CADILA HEALTHCARE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELBAMATE, FELBAMATE
FLUOCINONIDE, FLUOCINONIDE
GEMFIBROZIL, GEMFIBROZIL
INDOMETHACIN, INDOMETHACIN
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PIROXICAM, PIROXICAM
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CADILA HEALTHCARE LTD
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

CADILA PHARMS LTD

* CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
NATEGLINIDE, NATEGLINIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS
ADAPALENE, ADAPALENE

CALLIDITAS

* CALLIDITAS THERAPEUTICS AB
TARPEYO, BUDESONIDE

CAPELLON PHARMS LLC

* CAPELLON PHARMACEUTICALS LLC
POLMON, DEXCHLORPHENIRAMINE MALEATE

CAPLIN

* CAPLIN STERILES LTD
ARGATROBAN, ARGATROBAN
ETOMIDATE, ETOMIDATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CARA THERAP

* CARA THERAPEUTICS INC
KORSUVA, DIFELIKEFALIN ACETATE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARDINAL HLTH 414

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CARDINAL HEALTH 414 LLC
AMMONIA N 13, AMMONIA N-13

CARIBE HOLDINGS

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GEMFIBROZIL, GEMFIBROZIL

CARLSBAD

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY

* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

CASI PHARMS INC

* CASI PHARMACEUTICALS INC
CILOSTAZOL, CILOSTAZOL
ENTECAVIR, ENTECAVIR
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

CASPER PHARMA LLC

* CASPER PHARMA LLC
ANTIVERT, MECLIZINE HYDROCHLORIDE
AQUASOL A, VITAMIN A PALMITATE
CASPORYN HC, HYDROCORTISONE
FURADANTIN, NITROFURANTOIN
LUMI-SPORYN, BACITRACIN ZINC
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
THALITONE, CHLORTHALIDONE
ZYLOPRIM, ALLOPURINOL

CATALENT

* CATALENT PHARMA SOLUTIONS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS

* CATALYST PHARMACEUTICALS INC
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE

CEDIPROF INC

* CEDIPROF INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS

* CELATOR PHARMACEUTICALS INC
VYXEOS, CYTARABINE

CELGENE

* CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CELGENE CORP

* CELGENE CORP
IDHIFA, ENASIDENIB MESYLATE
ONUREG, AZACITIDINE

CELGENE INTL

* CELGENE INTERNATIONAL II SARL
ZEPOSIA, OZANIMOD HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CELLTRION

* CELLTRION INC
DEFERASIROX, DEFERASIROX
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FAMOTIDINE, FAMOTIDINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PREGABALIN, PREGABALIN
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TELMISARTAN, TELMISARTAN

CENTAUR PHARMS PVT

* CENTAUR PHARMACEUTICALS PVT LTD
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE

CEPHALON

* CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

CEROVENE INC

* CEROVENE INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
PYRIMETHAMINE, PYRIMETHAMINE

CHANGZHOU PHARM

* CHANGZHOU PHARMACEUTICAL FACTORY
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
PREGABALIN, PREGABALIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL

* CHARTWELL LIFE MOLECULES LLC
ALLOPURINOL, ALLOPURINOL
AMOXICILLIN, AMOXICILLIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
COLOCORT, HYDROCORTISONE
FLUCONAZOLE, FLUCONAZOLE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
TEMOZOLOMIDE, TEMOZOLOMIDE
* CHARTWELL PHARMA SCIENCE LLC
SULFASALAZINE, SULFASALAZINE
* CHARTWELL SCHEDULED LLC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

CHARTWELL MOLECULAR

* CHARTWELL MOLECULAR HOLDINGS LLC
CALCIUM ACETATE, CALCIUM ACETATE
CARVEDILOL, CARVEDILOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FOLIC ACID, FOLIC ACID
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRBESARTAN, IRBESARTAN
RAMIPRIL, RAMIPRIL
RISPERIDONE, RISPERIDONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CHARTWELL MOLECULES
* CHARTWELL MOLECULES LLC
DISULFIRAM, DISULFIRAM
GEMFIBROZIL, GEMFIBROZIL
NABUMETONE, NABUMETONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX
* CHARTWELL RX SCIENCES LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CALCIUM ACETATE, CALCIUM ACETATE
CEFPROZIL, CEFPROZIL
CEPHALEXIN, CEPHALEXIN
CILOSTAZOL, CILOSTAZOL
DUVOID, BETHANECHOL CHLORIDE
EPLERENONE, EPLERENONE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
INDOMETHACIN, INDOMETHACIN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
METHIMAZOLE, METHIMAZOLE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MONODOX, DOXYCYCLINE
NABUMETONE, NABUMETONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
REPAGLINIDE, REPAGLINIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

CHARTWELL TETRA
* CHARTWELL TETRA LLC
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM
* CHATTEM INC
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHATTEM SANOFI
* CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GAVISCON, ALUMINUM HYDROXIDE (OTC)
NICODERM CQ, NICOTINE (OTC)

CHEMI SPA
* CHEMI SPA
DECITABINE, DECITABINE
TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR
* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL
* CHEMO RESEARCH SL
BENZNIDAZOLE, BENZNIDAZOLE
NUVESSA, METRONIDAZOLE

CHEMOCENTRYX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHEMOCENTRYX INC
TAVNEOS, AVACOPAN

CHEPLAPHARM

* CHEPLAPHARM ARZNEIMITTEL GMBH
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
KLONOPIN, CLONAZEPAM
XENICAL, ORLISTAT

CHIA TAI TIANQING

* CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT

CHIASMA

* CHIASMA INC
MYCAPSSA, OCTREOTIDE ACETATE

CHIESI

* CHIESI USA INC
BETHKIS, TOBRAMYCIN
BRONCHITOL, MANNITOL
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
FERRIPROX, DEFERIPRONE
KENGREAL, CANGRELOR
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

CHILDRENS HOSP MI

* CHILDRENS HOSP MICHIGAN
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHIMERIX

* CHIMERIX INC
TEMBEXA, BRINCIDOFOVIR

CHINA RESOURCES

* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN

* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CINTEX SVCS

* CINTEX SERVICES LLC
DESONIDE, DESONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA

* CIPLA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
AZACITIDINE, AZACITIDINE
BUDESONIDE, BUDESONIDE
CELECOXIB, CELECOXIB
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CIPLA LTD
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUPREDNATE, DIFLUPREDNATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE, EMTRICITABINE
ENTECAVIR, ENTECAVIR
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
ICATIBANT ACETATE, ICATIBANT ACETATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MELOXICAM, MELOXICAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREGABALIN, PREGABALIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SUMATRIPTAN, SUMATRIPTAN
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE, TESTOSTERONE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD

* CIPLA LTD
ALBENDAZOLE, ALBENDAZOLE
CARBOPLATIN, CARBOPLATIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
TOPIRAMATE, TOPIRAMATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CIPLA USA

* CIPLA USA INC
ZEMDRI, PLAZOMICIN SULFATE

CISEN

* CISEN PHARMACEUTICAL CO LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

CLARUS

* CLARUS THERAPEUTICS INC
JATENZO, TESTOSTERONE UNDECANOATE

CLINIGEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CLINIGEN INC
ETHYOL, AMIFOSTINE

CLINIGEN HLTHCARE

* CLINIGEN HEALTHCARE LTD
FOSCAVIR, FOSCARNET SODIUM

CLIVUNEL INC

* CLINUVEL INC
SCENESSE, AFAMELANOTIDE

CLOVIS ONCOLOGY INC

* CLOVIS ONCOLOGY INC
RUBRACA, RUCAPARIB CAMSYLATE

CMP DEV LLC

* CMP DEVELOPMENT LLC
CAROSPIR, SPIRONOLACTONE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC

CMP PHARMA INC

* CMP PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIANEX, TRIAMCINOLONE ACETONIDE

CODY LABS INC

* CODY LABORATORIES INC A WHOLLY OWNED SUBSIDIARY OF LANNETT CO INC
NUMBRINO, COCAINE HYDROCHLORIDE

COLGATE PALMOLIVE CO

* COLGATE PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE-PALMOLIVE CO

* COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC

* COLLEGIUM PHARMACEUTICAL INC
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
XTAMPZA ER, OXYCODONE

COMBE

* COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

COMMAVE THERAP

* COMMAVE THERAPEUTICS SA
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE

CONCORD BIOTECH LTD

* CONCORD BIOTECH LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
TACROLIMUS, TACROLIMUS

CONCORDIA

* CONCORDIA PHARMACEUTICALS INC
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
PANRETIN, ALITRETINOIN
PARNATE, TRANYLCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
SALAGEN, PILOCARPINE HYDROCHLORIDE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE

CONCORDIA PHARMS INC

* CONCORDIA PHARMACEUTICALS INC
KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

COOPERSURGICAL

* COOPERSURGICAL INC
PARAGARD T 380A, COPPER

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

COREPHARMA

* COREPHARMA LLC
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE

COSETTE

* COSETTE PHARMACEUTICALS INC
ACEPHEN, ACETAMINOPHEN (OTC)
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
LIDOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
MOMETASONE FUROATE, MOMETASONE FUROATE
MYKACET, NYSTATIN
NYSTATIN, NYSTATIN
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

COVIS

* COVIS PHARMA GMBH
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* COVIS PHARMA GMBH
BETAPACE, SOTALOL HYDROCHLORIDE
FERAHEME, FERUMOXYTOL
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MAKENA, HYDROXYPROGESTERONE CAPROATE
OMNARIS, CICLESONIDE
PRILOSEC, OMEPRAZOLE MAGNESIUM
RILUTEK, RILUZOLE
SULAR, NISOLDIPINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZETONNA, CICLESONIDE

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CROSSMEDIKA SA

* CROSSMEDIKA SA
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS

* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

* CROWN LABORATORIES INC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

CSPC OUYI

* CSPC OUYI PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
CONJUPRI, LEVAMLODIPINE MALEATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
GABAPENTIN, GABAPENTIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PREGABALIN, PREGABALIN

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CSPC-NBP PHARM

* CSPC-NBP PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

CUBIST PHARMS

* CUBIST PHARMACEUTICALS INC
ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC

* CUBIST PHARMACEUTICALS LLC
CUBICIN RF, DAPTOMYCIN
CUBICIN, DAPTOMYCIN
DIFICID, FIDAXOMICIN
SIVEXTRO, TEDIZOLID PHOSPHATE
ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS

* CUMBERLAND PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** C **

* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE
REDITREX, METHOTREXATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VIBATIV, TELAVANCIN HYDROCHLORIDE

CURIUM

* CURIUM US LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

CURRAX

* CURRAX PHARMACEUTICALS LLC
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
SILENOR, DOXEPIN HYDROCHLORIDE
TREXIMET, NAPROXEN SODIUM

CUSTOPHARM INC

* CUSTOPHARM INC
ACETAMINOPHEN, ACETAMINOPHEN
CALCITONIN-SALMON, CALCITONIN SALMON
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
VALRUBICIN, VALRUBICIN

CYCLE PHARMS LTD

* CYCLE PHARMACEUTICALS LTD
HALOPERIDOL, HALOPERIDOL
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NITYR, NITISINONE

** D **

DAEWOONG PHARM CO

* DAEWOONG PHARMACEUTICAL CO LTD
MEROPENEM, MEROPENEM

DAIICHI SANKYO

* DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DAIICHI SANKYO INC

* DAIICHI SANKYO INC
EFFIENT, PRASUGREL HYDROCHLORIDE
EVOXAC, CEVIMELINE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
TURALIO, PEXIDARTINIB HYDROCHLORIDE

DANCO LABS LLC

* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DARE

* DARE BIOSCIENCE INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DARE BIOSCIENCE INC
XACIATO, CLINDAMYCIN PHOSPHATE

DASH PHARMS
* DASH PHARMACEUTICALS LLC
TESTOSTERONE, TESTOSTERONE
ZILEUTON, ZILEUTON

DASTECH GENERICS
* DASTECH GENERICS LLC
NYSTATIN, NYSTATIN

DAVA PHARMS INC
* DAVA PHARMACEUTICALS INC
AMOXICILLIN, AMOXICILLIN
MORPHINE SULFATE, MORPHINE SULFATE
PROPYLTHIOURACIL, PROPYLTHIOURACIL

DAVIS AND GECK
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DBL PHARMS
* DBL PHARMACEUTICALS INC
METHOCARBAMOL, METHOCARBAMOL

DECATUR
* DECATUR MEMORIAL HOSP
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

DECIPHERA PHARMS
* DECIPHERA PHARMACEUTICALS LLC
QINLOCK, RIPRETINIB

DENTSPLY PHARM
* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPROCO
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DEVA HOLDING AS
* DEVA HOLDING AS
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL LTD
* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA
* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
HEMADY, DEXAMETHASONE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

DIALYSIS SUPS
* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DORC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

* DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

* DOW PHARMACEUTICAL SCIENCES
ALTRENO, TRETINOIN
ATRALIN, TRETINOIN

DR REDDYS

* DR REDDYS LABORATORIES INC
FENOFIBRATE, FENOFIBRATE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
PROGESTERONE, PROGESTERONE
PROPOFOL, PROPOFOL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE, TESTOSTERONE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* DR REDDYS LABORATORIES LTD
ALBENDAZOLE, ALBENDAZOLE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZACITIDINE, AZACITIDINE
CARFILZOMIB, CARFILZOMIB
CARMUSTINE, CARMUSTINE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
LENALIDOMIDE, LENALIDOMIDE
LIDOCAINE, LIDOCAINE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OMEPRAZOLE, OMEPRAZOLE (OTC)
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PENICILLAMINE, PENICILLAMINE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TETRABENAZINE, TETRABENAZINE
THIOTEPA, THIOTEPA
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
VIGABATRIN, VIGABATRIN
VINORELBINE TARTRATE, VINORELBINE TARTRATE

DR REDDYS LA

* DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LOUISIANA LLC
LOPURIN, ALLOPURINOL
SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC

* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD

* DR REDDYS LABORATORIES LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* DR REDDYS LABORATORIES LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BIVALIRUDIN, BIVALIRUDIN
BORTEZOMIB, BORTEZOMIB
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPECITABINE, CAPECITABINE
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOFARABINE, CLOFARABINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOCETAXEL, DOCETAXEL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEBUXOSTAT, FEBUXOSTAT
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHYTONADIONE, PHYTONADIONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZAFIRLUKAST, ZAFIRLUKAST
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES SA
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
HABITROL, NICOTINE (OTC)
MERCAPTOPURINE, MERCAPTOPURINE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
RAMELTEON, RAMELTEON
TOBRAMYCIN, TOBRAMYCIN
VERARING, ETHINYL ESTRADIOL

DUCHESNAY

* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE
OSPHENA, OSPEMIFENE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
VELIVET, DESOGESTREL

DUSA

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DUTCH OPHTHALMIC

* DUTCH OPHTHALMIC RESEARCH CENTER INTERNATIONAL BV
TISSUEBLUE, BRILLIANT BLUE G

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ****

E5 PHARMA INC

* E5 PHARMA INC
DIAZOXIDE, DIAZOXIDE

EAGLE PHARMS

* EAGLE PHARMACEUTICALS INC
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
PEMFEXY, PEMETREXED
RYANODEX, DANTROLENE SODIUM
VASOPRESSIN, VASOPRESSIN

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
MONOKET, ISOSORBIDE MONONITRATE

ECOLAB

* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR PHARMA

* ECR PHARMA
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
ALBENDAZOLE, ALBENDAZOLE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CARBIDOPA, CARBIDOPA
DARTISLA ODT, GLYCOPYRROLATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ETHACRYNIC ACID, ETHACRYNIC ACID
ETODOLAC, ETODOLAC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EDENBRIDGE PHARMACEUTICALS LLC
IVERMECTIN, IVERMECTIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
MIGLUSTAT, MIGLUSTAT
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TINIDAZOLE, TINIDAZOLE

EDISON THERAPS LLC
* EDISON THERAPEUTICS LLC
METHERGINE, METHYLERGONOVINE MALEATE

EGALET
* EGALET US INC
INDOCIN, INDOMETHACIN

EI INC
* EI INC
THEROXIDIL, MINOXIDIL (OTC)

EIGER BIOPHARMS
* EIGER BIOPHARMACEUTICALS INC
ZOKINVY, LONAFARNIB

EIRGEN
* EIRGEN PHARMA LTD
RAYALDEE, CALCIFEDIOL

EISAI INC
* EISAI INC
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
DAYVIGO, LEMBOREXANT
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
LENVIMA, LENVATINIB MESYLATE

ELI LILLY AND CO
* ELI LILLY AND CO
BAQSIMI, GLUCAGON
OLUMIANT, BARICITINIB
PROZAC, FLUOXETINE HYDROCHLORIDE
REYVOW, LASMIDITAN SUCCINATE
VERZENIO, ABEMACICLIB

ELI LILLY CO
* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS
* ELITE LABORATORIES INC
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC
* ELITE LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ISRADIPINE, ISRADIPINE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

ELITE PHARM SOLUTION
* ELITE PHARMACEUTICAL SOLUTION INC
NIFEDIPINE, NIFEDIPINE

ELYSIUM
* ELYSIUM PHARMACEUTICALS LTD
CALCITRIOL, CALCITRIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
TIMOLOL MALEATE, TIMOLOL MALEATE

EMCURE PHARMS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ETOMIDATE, ETOMIDATE
FUROSEMIDE, FUROSEMIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPOFOL, PROPOFOL
TRANEXAMIC ACID, TRANEXAMIC ACID

EMD SERONO INC

* EMD SERONO INC
CETROTIDE, CETRORELIX
MAVENCLAD, CLADRIBINE
TEPMETKO, TEPOTINIB HYDROCHLORIDE

EMED MEDCL

* EMED MEDICAL CO LLC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

EMERALD INTL LTD

* EMERALD INTERNATIONAL LTD
BACLOFEN, BACLOFEN

EMERGENT

* EMERGENT OPERATIONS IRELAND LTD
NARCAN, NALOXONE HYDROCHLORIDE

EMMAUS MEDCL

* EMMAUS MEDICAL INC
ENDARI, L-GLUTAMINE

ENALTEC

* ENALTEC LABS INC
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE

ENCUBE

* ENCUBE ETHICALS PRIVATE LTD
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
KETOCONAZOLE, KETOCONAZOLE
MUPIROCIN, MUPIROCIN CALCIUM
TAVABOROLE, TAVABOROLE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ENCUBE ETHICALS

* ENCUBE ETHICALS PVT LTD
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
PERMETHRIN, PERMETHRIN

ENDO PHARM

* ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN

ENDO PHARMS

* ENDO PHARMACEUTICALS INC
FORTESTA, TESTOSTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ENDO PHARMACEUTICALS INC
FROVA, FROVATRIPTAN SUCCINATE
PERCODAN, ASPIRIN

ENDO PHARMS INC

* ENDO PHARMACEUTICALS INC
AVEED, TESTOSTERONE UNDECANOATE
COLY-MYCIN S, COLISTIN SULFATE
MEGACE ES, MEGESTROL ACETATE
NASCOBAL, CYANOCOBALAMIN

EPI HLTH

* EPI HEALTH LLC
CLODERM, CLOCORTOLONE PIVALATE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
SITAVIG, ACYCLOVIR

EPIC PHARMA

* EPIC PHARMA INC
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC
ESTRADIOL, ESTRADIOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FUROSEMIDE, FUROSEMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

EPIZYME INC
* EPIZYME INC
  TAZVERIK, TAZEMETOSTAT HYDROBROMIDE

ESPERION THERAPS INC
* ESPERION THERAPEUTICS INC
  NEXLETOL, BEMPEDOIC ACID
  NEXLIZET, BEMPEDOIC ACID

ESPERO
* ESPERO BIOPHARMA INC
  DURLAZA, ASPIRIN

ESSENTIAL ISOTOPES
* ESSENTIAL ISOTOPES LLC
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM
* ETHYPHARM
  BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
* ETHYPHARM SA
  ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

ETHYPHARM USA CORP
* ETHYPHARM USA CORP
  BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETON
* ETON PHARMACEUTICALS INC
  ALKINDI SPRINKLE, HYDROCORTISONE
  REZIPRES, EPHEDRINE HYDROCHLORIDE

ETON PHARMS
* ETON PHARMACEUTICALS
  BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE

EUGIA PHARMA
* EUGIA PHARMA SPECIALITIES LTD
  ACETAMINOPHEN, ACETAMINOPHEN
  ACETYLCYSTEINE, ACETYLCYSTEINE
  ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
  ADENOSINE, ADENOSINE
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  ANASTROZOLE, ANASTROZOLE
  ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
  ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
  ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
  AZITHROMYCIN, AZITHROMYCIN
  BIVALIRUDIN, BIVALIRUDIN
  BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
  BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
  CAFFEINE CITRATE, CAFFEINE CITRATE
  CAPECITABINE, CAPECITABINE
  CARBOPLATIN, CARBOPLATIN
  CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
  CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
  CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
  CYANOCOBALAMIN, CYANOCOBALAMIN
  DACTINOMYCIN, DACTINOMYCIN
  DAPTOMYCIN, DAPTOMYCIN
  DECITABINE, DECITABINE
  DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
  DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
  DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
  DOCETAXEL, DOCETAXEL
  DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
  EPHEDRINE SULFATE, EPHEDRINE SULFATE
  EPTIFIBATIDE, EPTIFIBATIDE
  ERTAPENEM SODIUM, ERTAPENEM SODIUM
  ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
  ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EUGIA PHARMA SPECIALITIES LTD
ETOMIDATE, ETOMIDATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOSULFAN BLUE, ISOSULFAN BLUE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
MEROPENEM, MEROPENEM
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROGESTERONE, PROGESTERONE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TIGECYCLINE, TIGECYCLINE
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

EUGIA PHARMA SPECLTS

* EUGIA PHARMA SPECIALITIES LTD
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
AZACITIDINE, AZACITIDINE
DROPERIDOL, DROPERIDOL
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

EVOFEM INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EVOFEM INC
PHEXXI, CITRIC ACID

EVOKE PHARMA INC

* EVOKE PHARMA INC
GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE

EVUS

* EVUS HEALTH SOLUTIONS LLC
NITROMIST, NITROGLYCERIN

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
IDKIT:HP, CITRIC ACID

EXELA PHARMA

* EXELA PHARMA SCIENCES LLC
ACETYLCYSTEINE, ACETYLCYSTEINE
AKOVAZ, EPHEDRINE SULFATE
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
CAFFEINE CITRATE, CAFFEINE CITRATE
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%, DILTIAZEM HYDROCHLORIDE
ELCYS, CYSTEINE HYDROCHLORIDE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
GANZYK-RTU, GANCICLOVIR
GLYRX-PF, GLYCOPYRROLATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZINC CHLORIDE, ZINC CHLORIDE

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EXELIXIS

* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC

* EXELTIS USA INC
SLYND, DROSPIRENONE
TYBLUME, ETHINYL ESTRADIOL

EYEPOINT PHARMS

* EYEPOINT PHARMACEUTICALS INC
DEXYCU KIT, DEXAMETHASONE
YUTIQ, FLUOCINOLONE ACETONIDE

EYEVANCE

* EYEVANCE PHARMACEUTICALS LLC
FLAREX, FLUOROMETHOLONE ACETATE
NATACYN, NATAMYCIN
TOBRADEX ST, DEXAMETHASONE
ZERVIATE, CETIRIZINE HYDROCHLORIDE

EYWA

* EYWA PHARMA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EYWA PHARMA INC
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
VALPROIC ACID, VALPROIC ACID

EYWA PHARMA

* EYWA PHARMA PTE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
BACLOFEN, BACLOFEN
URSODIOL, URSODIOL

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE
GLUCAGON, GLUCAGON
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

**** F ****

FDC LTD

* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER

* FOUNDATION CONSUMER BRANDS LLC
ALAVERT, LORATADINE (OTC)
* FOUNDATION CONSUMER HEALTHCARE LLC
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUORODOPA F18, FLUORODOPA F-18

FERA PHARMS

* FERA PHARMACEUTICALS LLC
TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC

* FERA PHARMACEUTICALS LLC
GENTAMICIN SULFATE, GENTAMICIN SULFATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE

FERRER INTERNACIONAL

* FERRER INTERNACIONAL SA
XEPI, OZENOXACIN

FERRING

* FERRING PHARMACEUTICALS INC
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE

FERRING PHARMS INC

* FERRING PHARMACEUTICALS INC
CERVIDIL, DINOPROSTONE
CLENPIQ, CITRIC ACID
DDAVP, DESMOPRESSIN ACETATE
NOCDURNA, DESMOPRESSIN ACETATE

FLAMINGO PHARMS

* FLAMINGO PHARMACEUTICALS LTD
METRONIDAZOLE, METRONIDAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FLAMINGO PHARMACEUTICALS LTD
PIROXICAM, PIROXICAM

FLEXION THERAPS INC

* FLEXION THERAPEUTICS INC
ZILRETTA, TRIAMCINOLONE ACETONIDE

FLORIDA

* FLORIDA PHARMACEUTICAL PRODUCTS LLC
LEVETIRACETAM, LEVETIRACETAM
SUMATRIPTAN, SUMATRIPTAN

FOLDRX PHARMS

* FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE

FORESEE PHARMS

* FORESEE PHARMACEUTICALS CO LTD
CAMCEVI KIT, LEUPROLIDE MESYLATE

FOSUN PHARMA

* FOSUN PHARMA USA INC
CARISOPRODOL, CARISOPRODOL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
LEFLUNOMIDE, LEFLUNOMIDE

FOUGERA PHARMS

* FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMCINONIDE, AMCINONIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CUTIVATE, FLUTICASONE PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PREDNICARBATE, PREDNICARBATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FOUGERA PHARMACEUTICALS INC
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
TACROLIMUS, TACROLIMUS
TERCONAZOLE, TERCONAZOLE

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
* FRESENIUS KABI IPSUM SRL
NAFCILLIN SODIUM, NAFCILLIN SODIUM

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
* FRESENIUS KABI AUSTRIA GMBH
LACTULOSE, LACTULOSE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CEFOTETAN, CEFOTETAN DISODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAPTOMYCIN, DAPTOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FULVESTRANT, FULVESTRANT
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGAVEN, FISH OIL TRIGLYCERIDES
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROMIDEPSIN, ROMIDEPSIN
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FRONTIDA BIOPHARM

* FRONTIDA BIOPHARM INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM

**** G ****

G1 THERAP

* G1 THERAPEUTICS INC
COSELA, TRILACICLIB DIHYDROCHLORIDE

GALDERMA LABS

* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE

* GALDERMA LABORATORIES LP
AKLIEF, TRIFAROTENE
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GALDERMA LABORATORIES LP
VECTICAL, CALCITRIOL

GALEN SPECIALTY

* GALEN SPECIALTY PHARMA US LLC
SYNERA, LIDOCAINE

GALT PHARMS

* GALT PHARMACEUTICALS LLC
DORAL, QUAZEPAM
ORAVIG, MICONAZOLE
ORPHENGESIC FORTE, ASPIRIN

GE HEALTHCARE

* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CLARISCAN, GADOTERATE MEGLUMINE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC

* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

GENBIOPRO

* GENBIOPRO INC
MIFEPRISTONE, MIFEPRISTONE

GENE YORK PHARMS

* GENE YORK PHARMACEUTICALS GROUP LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENENTECH

* GENENTECH INC
ERIVEDGE, VISMODEGIB

GENENTECH INC

* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE
EVRYSDI, RISDIPLAM
GAVRETO, PRALSETINIB
ROZLYTREK, ENTRECTINIB
XOFLUZA, BALOXAVIR MARBOXIL

GENERICS

* GENERICS INTERNATIONAL VENTURES ENTERPRISES LLC
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENEYORK PHARMS

* GENEYORK PHARMACEUTICALS GROUP LLC
PREDNISONE, PREDNISONE

GENUS

* GENUS LIFESCIENCES INC
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
HYCODAN, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LEVETIRACETAM, LEVETIRACETAM
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GENUS LIFESCIENCES INC
NYSTATIN, NYSTATIN

GENUS LIFESCIENCES

* GENUS LIFE SCIENCES INC
GOPRELTO, COCAINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GENZYME

* GENZYME CORP
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE

GENZYME CORP

* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE

GILEAD

* GILEAD SCIENCES INC
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES

* GILEAD SCIENCES LLC
ATRIPLA, EFAVIRENZ

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
BIKTARVY, BICTEGRAVIR SODIUM
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
TYBOST, COBICISTAT
VEKLURY, REMDESIVIR
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VOSEVI, SOFOSBUVIR
ZYDELIG, IDELALISIB

GISKIT

* GISKIT PHARMA BV
EXEM FOAM KIT, AIR POLYMER-TYPE A

GLAND

* GLAND PHARMA LTD
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MEROPENEM, MEROPENEM
MESNA, MESNA
OXALIPLATIN, OXALIPLATIN
TRANEXAMIC ACID, TRANEXAMIC ACID
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLAND PHARMA LTD

* GLAND PHARMA LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ETOMIDATE, ETOMIDATE
FLUOROURACIL, FLUOROURACIL
FOSCARNET SODIUM, FOSCARNET SODIUM
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACITAXEL, PACLITAXEL
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMSIROLIMUS, TEMSIROLIMUS
THIOTEPA, THIOTEPA
TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLEDRONIC, ZOLEDRONIC ACID

GLASSHOUSE PHARMS

* GLASSHOUSE PHARMACEUTICALS LTD CANADA
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HALCINONIDE, HALCINONIDE
OXCARBAZEPINE, OXCARBAZEPINE

GLAUKOS

* GLAUKOS CORP
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE
* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
EPIVIR-HBV, LAMIVUDINE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
RELENZA, ZANAMIVIR
VALTREX, VALACYCLOVIR HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
* GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
INFANT'S ADVIL, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
KRINTAFEL, TAFENOQUINE SUCCINATE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE
* GLAXOSMITHKLINE LLC
ZEJULA, NIRAPARIB TOSYLATE

GLAXOSMITHKLINE CONS

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)

GLAXOSMITHKLINE LLC

* GLAXOSMITHKLINE LLC
AMERGE, NARATRIPTAN HYDROCHLORIDE
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

* GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE
* GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
* GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK GENERICS LTD
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN, NAPROXEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIORELE, DESOGESTREL
ZOLMITRIPTAN, ZOLMITRIPTAN
* GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

* GLENMARK PHARMACEUTICALS INC
TERIFLUNOMIDE, TERIFLUNOMIDE
* GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN
* GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
* GLENMARK PHARMACEUTICALS SA
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ATOVAQUONE, ATOVAQUONE
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE, CALCIPOTRIENE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
HAILEY 1.5/30, ETHINYL ESTRADIOL
HAILEY FE 1.5/30, ETHINYL ESTRADIOL
LINEZOLID, LINEZOLID
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

GLENMARK PHARMS INC

* GLENMARK PHARMACEUTICALS INC USA
CALCIPOTRIENE, CALCIPOTRIENE
FULVESTRANT, FULVESTRANT
LITHIUM CARBONATE, LITHIUM CARBONATE
MUPIROCIN, MUPIROCIN CALCIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS INC USA
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTRADIOL, ESTRADIOL
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HAILEY FE 1/20, ETHINYL ESTRADIOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
ICATIBANT ACETATE, ICATIBANT ACETATE
INDOMETHACIN, INDOMETHACIN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LIDOCAINE, LIDOCAINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXCARBAZEPINE, OXCARBAZEPINE
PIMECROLIMUS, PIMECROLIMUS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
RUFINAMIDE, RUFINAMIDE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
TACROLIMUS, TACROLIMUS
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VORICONAZOLE, VORICONAZOLE

GLENMARK PHARMS SA

* GLENMARK PHARMACEUTICALS SA SWITZERLAND
ACYCLOVIR, ACYCLOVIR
APREPITANT, APREPITANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS SA SWITZERLAND
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
NITROGLYCERIN, NITROGLYCERIN

GLOBAL BLOOD THERAPS

* GLOBAL BLOOD THERAPEUTICS INC
OXBRYTA, VOXELOTOR

GLW

* GLW PHARMA GMBH
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

GRANULES

* GRANULES INDIA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GABAPENTIN, GABAPENTIN
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

* GRANULES PHARMACEUTICALS INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
COLCHICINE, COLCHICINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOFETILIDE, DOFETILIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PENICILLAMINE, PENICILLAMINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
RAMELTEON, RAMELTEON
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

GRANULES INDIA

* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRAVITI PHARMS

* GRAVITI PHARMACEUTICALS INC
GABAPENTIN, GABAPENTIN

* GRAVITI PHARMACEUTICALS PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE, FENOFIBRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RANOLAZINE, RANOLAZINE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

GUARDIAN DRUG

* GUARDIAN DRUG CO
GUAIFENESIN, GUAIFENESIN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GUARDIAN DRUG CO
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE

GUERBET

* GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL

GW RES LTD

* GW RESEARCH LTD
EPIDIOLEX, CANNABIDIOL

**** H ****

HAEMONETICS

* HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HAINAN POLY

* HAINAN POLY PHARM CO LTD
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

HAINAN POLY PHARM

* HAINAN POLY PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
BIVALIRUDIN, BIVALIRUDIN
EPTIFIBATIDE, EPTIFIBATIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
LEVETIRACETAM, LEVETIRACETAM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

HALOCARBON PRODS

* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HANDA

* HANDA NEUROSCIENCE LLC
TASCENSO ODT, FINGOLIMOD LAURYL SULFATE

HANGZHOU BINJIANG

* HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM

HANGZHOU ZHONGMEI

* HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
DAPTOMYCIN, DAPTOMYCIN

HARMAN FINOCHEM

* HARMAN FINOCHEM LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

HARMONY

* HARMONY BIOSCIENCES LLC
WAKIX, PITOLISANT HYDROCHLORIDE

HBT LABS INC

* HBT LABS INC
FULVESTRANT, FULVESTRANT

HEC PHARM

* HEC PHARM USA INC
CLARITHROMYCIN, CLARITHROMYCIN
LEVOFLOXACIN, LEVOFLOXACIN
OLANZAPINE, OLANZAPINE
PRASUGREL, PRASUGREL HYDROCHLORIDE

HEC PHARM CO LTD

* HEC PHARM CO LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

HELSINN

* HELSINN BIREX PHARMACEUTICALS LTD
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HELSINN HEALTHCARE SA
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
TRUSELTIQ, INFIGRATINIB PHOSPHATE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
NITROGLYCERIN, NITROGLYCERIN

HERITAGE LIFE

* HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

HERITAGE PHARMA

* HERITAGE PHARMA LABS INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NADOLOL, NADOLOL
NIFEDIPINE, NIFEDIPINE

HERITAGE PHARMA AVET

* HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
CALCIUM ACETATE, CALCIUM ACETATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ETHOSUXIMIDE, ETHOSUXIMIDE
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LEFLUNOMIDE, LEFLUNOMIDE
METRONIDAZOLE, METRONIDAZOLE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERON THERAPS INC

* HERON THERAPEUTICS INC
CINVANTI, APREPITANT
SUSTOL, GRANISETRON
ZYNRELEF KIT, BUPIVACAINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

HETERO LABS LTD

* HETERO LABS LTD
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

HETERO LABS LTD III

* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
ATOVAQUONE, ATOVAQUONE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBAZAM, CLOBAZAM
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
METHOCARBAMOL, METHOCARBAMOL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PREGABALIN, PREGABALIN
RITONAVIR, RITONAVIR
ROFLUMILAST, ROFLUMILAST
RUFINAMIDE, RUFINAMIDE
SIMVASTATIN, SIMVASTATIN
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TORSEMIDE, TORSEMIDE
ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V

* HETERO LABS LTD UNIT V
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
COLCHICINE, COLCHICINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
FAMCICLOVIR, FAMCICLOVIR
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HETERO LABS LTD UNIT V
LINEZOLID, LINEZOLID
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
TELMISARTAN, TELMISARTAN
TETRABENAZINE, TETRABENAZINE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOLVAPTAN, TOLVAPTAN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

HEYL CHEMISCH

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKAL

* HIKAL LTD
PREGABALIN, PREGABALIN

HIKMA

* HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM
* HIKMA FARMACEUTICA PORTUGAL SA
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
DOCETAXEL, DOCETAXEL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
* HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
* HIKMA PHARMACEUTICALS INTERNATIONAL LTD
CODEINE SULFATE, CODEINE SULFATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
FUROSEMIDE, FUROSEMIDE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
RUFINAMIDE, RUFINAMIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
* HIKMA PHARMACEUTICALS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIROXICAM, PIROXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC

ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMRINONE LACTATE, INAMRINONE LACTATE
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATROPINE SULFATE, ATROPINE SULFATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BEXAROTENE, BEXAROTENE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BOSENTAN, BOSENTAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAFCIT, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
CEFOXITIN, CEFOXITIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBAZAM, CLOBAZAM
CLOTRIMAZOLE, CLOTRIMAZOLE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DALFAMPRIDINE, DALFAMPRIDINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFERIPRONE, DEFERIPRONE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISULFIRAM, DISULFIRAM
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC

DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROXIDOPA, DROXIDOPA
DURAMORPH PF, MORPHINE SULFATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETHACRYNIC ACID, ETHACRYNIC ACID
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
EVEROLIMUS, EVEROLIMUS
EXEMESTANE, EXEMESTANE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ICOSAPENT ETHYL, ICOSAPENT ETHYL
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
INFUMORPH, MORPHINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KLOXXADO, NALOXONE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA PHARMACEUTICALS USA INC
MESNA, MESNA
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE, NALOXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
ROBAXIN, METHOCARBAMOL
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
RUFINAMIDE, RUFINAMIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TETRABENAZINE, TETRABENAZINE
TINIDAZOLE, TINIDAZOLE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZALEPLON, ZALEPLON

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOXITIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HIKMA FARMACEUTICA (PORTUGAL) SA
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM

* HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

* HIKMA FARMACEUTICA PORTUGAL SA
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

* HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
CAPTOPRIL, CAPTOPRIL
CORTISONE ACETATE, CORTISONE ACETATE
DIGOXIN, DIGOXIN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
MITIGARE, COLCHICINE

HIKMA PHARM CO LTD

* HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

HIKMA PHARMS

* HIKMA PHARMACEUTICALS
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

* HIKMA PHARMACEUTICALS CO LTD
PARICALCITOL, PARICALCITOL

HILL DERMAC

* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

HISAMITSU

* HISAMITSU PHARMACEUTICAL CO INC
SECUADO, ASENAPINE

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
CLADRIBINE, CLADRIBINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
SIMVASTATIN, SIMVASTATIN
* HISUN PHARMACEUTICAL HANGZHOU CO LTD
DACTINOMYCIN, DACTINOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
TICAGRELOR, TICAGRELOR

HLTHCARE

* HEALTHCARE PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

* HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE

HONG KONG

* HONG KONG KING FRIEND INDUSTRIAL CO LTD
BIVALIRUDIN, BIVALIRUDIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

HOPE PHARMS

* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON

* HORIZON MEDICINES LLC
DUEXIS, FAMOTIDINE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
* HORIZON THERAPEUTICS IRELAND DAC
PENNSAID, DICLOFENAC SODIUM
* HORIZON THERAPEUTICS USA INC
PROCYSBI, CYSTEAMINE BITARTRATE
RAYOS, PREDNISONE

HORIZON PHARMA USA

* HORIZON PHARMA USA INC
PROCYSBI, CYSTEAMINE BITARTRATE

HORIZON THERAP

* HORIZON THERAPEUTICS LLC
BUPHENYL, SODIUM PHENYLBUTYRATE
RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA

* HOSPIRA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50%, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. ADULT, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN, SUCCINYLCHOLINE CHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TAZICEF, CEFTAZIDIME
THAM, TROMETHAMINE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VITAMIN K1, PHYTONADIONE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* HOSPIRA WORLDWIDE, INC
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NITROPRESS, SODIUM NITROPRUSSIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA WORLDWIDE, INC
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

* HOSPIRA INC
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZTREONAM, AZTREONAM
BIVALIRUDIN, BIVALIRUDIN
BUSULFAN, BUSULFAN
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DAPTOMYCIN, DAPTOMYCIN
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
EPINEPHRINE, EPINEPHRINE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NIPENT, PENTOSTATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
SODIUM BICARBONATE, SODIUM BICARBONATE
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

* HOT SHOTS NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CISPLATIN, CISPLATIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEROPENEM, MEROPENEM

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HQ SPECLT PHARMA

* HQ SPECIALTY PHARMA CORP
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

HRA PHARMA
* HRA PHARMA RARE DISEASES
LYSODREN, MITOTANE
METOPIRONE, METYRAPONE

HUMANWELL PURACAP
* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
DUTASTERIDE, DUTASTERIDE
IBUPROFEN, IBUPROFEN (OTC)

HUONS
* HUONS CO LTD
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

ROCHE
* HOFFMANN LA ROCHE INC
FUZEON, ENFUVIRTIDE
TAMIFLU, OSELTAMIVIR PHOSPHATE
VALIUM, DIAZEPAM

SHUANGCHENG
* HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD
BIVALIRUDIN, BIVALIRUDIN
EPTIFIBATIDE, EPTIFIBATIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PREGABALIN, PREGABALIN

** I **

I3 PHARMS
* I3 PHARMACEUTICALS LLC
CHLORZOXAZONE, CHLORZOXAZONE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
RAMELTEON, RAMELTEON
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

IBSA INST BIO
* IBSA INSTITUT BIOCHIMIQUE SA
LICART, DICLOFENAC EPOLAMINE

ICHNOS
* ICHNOS SCIENCES SA
DEFERASIROX, DEFERASIROX

ICU MEDICAL INC
* ICU MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ICU MEDICAL INC
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IMPACT
* IMPACT BIOMEDICINES INC A WHOLLY OWNED SUB OF CELGENE CORP
INREBIC, FEDRATINIB HYDROCHLORIDE

IMPAX
* IMPAX LABORATORIES LLC
ADRENACLICK, EPINEPHRINE
BACLOFEN, BACLOFEN
SEVELAMER CARBONATE, SEVELAMER CARBONATE

IMPAX LABS
* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC
* IMPAX LABORATORIES INC
ACITRETIN, ACITRETIN
ALBENZA, ALBENDAZOLE
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* IMPAX LABORATORIES INC
EMVERM, MEBENDAZOLE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RYTARY, CARBIDOPA

IMPAX PHARMS
* IMPAX PHARMACEUTICALS
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

IMPEL NEUROPHARMA
* IMPEL NEUROPHARMA
TRUDHESA, DIHYDROERGOTAMINE MESYLATE

INCYTE CORP
* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE
OPZELURA, RUXOLITINIB PHOSPHATE
PEMAZYRE, PEMIGATINIB

INDCHEMIE HEALTH
* INDCHEMIE HEALTH SPECIALTIES PVT LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE

INDICUS PHARMA
* INDICUS PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LETROZOLE, LETROZOLE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

INDIVIOR INC
* INDIVIOR INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
PERSERIS KIT, RISPERIDONE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO
* INDOCO REMEDIES LTD
ALLOPURINOL, ALLOPURINOL
APIXABAN, APIXABAN
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FEBUXOSTAT, FEBUXOSTAT
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLANZAPINE, OLANZAPINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INDOCO REMEDIES
* INDOCO REMEDIES LTD
GLIMEPIRIDE, GLIMEPIRIDE

INFORLIFE
* INFORLIFE SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INFORLIFE SA
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC
* INGENUS PHARMACEUTICALS LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CABERGOLINE, CABERGOLINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DECITABINE, DECITABINE
DOCETAXEL, DOCETAXEL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS NJ
* INGENUS PHARMACEUTICALS NJ LLC
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN

INNOCOLL PHARMS
* INNOCOLL PHARMACEUTICALS
XARACOLL, BUPIVACAINE HYDROCHLORIDE

INNOGENIX
* INNOGENIX LLC
BACLOFEN, BACLOFEN
HALOPERIDOL, HALOPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METOLAZONE, METOLAZONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

INNOPHARMA
* INNOPHARMA LICENSING LLC A SUB OF PFIZER INC
PROPOFOL, PROPOFOL

INSMED INC
* INSMED INC
ARIKAYCE KIT, AMIKACIN SULFATE

INST BIOCHEM
* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INSTITUT BIOCHIMIQUE
* INSTITUT BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM
TIROSINT-SOL, LEVOTHYROXINE SODIUM

INTAS PHARMS USA
* INTAS PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS
* INTELLIPHARMACEUTICS CORP
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

INTERCEPT PHARMS INC
* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

INTERSECT ENT INC
* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

INTL ISOTOPES
* INTERNATIONAL ISOTOPES INC
SODIUM IODIDE I 131, SODIUM IODIDE I-131

INTL MEDICATION
* INTERNATIONAL MEDICATION SYSTEM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
ATROPINE SULFATE, ATROPINE SULFATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
DEXTROSE 50%, DEXTROSE
EPINEPHRINE, EPINEPHRINE
LORAZEPAM, LORAZEPAM
SODIUM BICARBONATE, SODIUM BICARBONATE

INTRA-CELLULAR

* INTRA-CELLULAR THERAPIES INC
CAPLYTA, LUMATEPERONE TOSYLATE

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LANREOTIDE ACETATE, LANREOTIDE ACETATE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OLANZAPINE, OLANZAPINE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PENICILLAMINE, PENICILLAMINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INVAGEN PHARMACEUTICALS INC
ZONISAMIDE, ZONISAMIDE

INVATECH

* INVATECH PHARMA SOLUTIONS LLC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

INVENTIA

* INVENTIA HEALTHCARE LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PALIPERIDONE, PALIPERIDONE
TELMISARTAN, TELMISARTAN

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

IONETIX

* IONETIX CORP
AMMONIA N 13, AMMONIA N-13

IPCA LABS LTD

* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

IPR

* IPR PHARMACEUTICALS INC
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
ONIVYDE, IRINOTECAN HYDROCHLORIDE

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

IRONSHORE PHARMS

* IRONSHORE PHARMACEUTICALS AND DEVELOPMENT INC
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

ISOLOGIC INNOVATIVE

* ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

ISOTEX

* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ISTITUTO BIOCHIMICO ITALIANO SPA
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

ITALFARMACO SPA

* ITALFARMACO SPA
TIGLUTIK KIT, RILUZOLE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
VALSARTAN, VALSARTAN

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DIAZEPAM, DIAZEPAM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ****

J AND J CONSUMER INC

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIV
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MOTRIN IB, IBUPROFEN (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
RHINOCORT ALLERGY, BUDESONIDE (OTC)
SINE-AID IB, IBUPROFEN (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TYLENOL, ACETAMINOPHEN (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JACOBUS

* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

JACOBUS PHARM CO INC

* JACOBUS PHARMACEUTICAL CO INC
RUZURGI, AMIFAMPRIDINE

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
BALVERSA, ERDAFITINIB
ERLEADA, APALUTAMIDE
ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JANSSEN PHARMACEUTICALS INC
DITROPAN XL, OXYBUTYNIN CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
INVEGA HAFYERA, PALIPERIDONE PALMITATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
PONVORY, PONESIMOD
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
TOPAMAX, TOPIRAMATE
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
XARELTO, RIVAROXABAN

JANSSEN PRODS
* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
SYMTUZA, COBICISTAT
YONDELIS, TRABECTEDIN

JANSSEN R AND D
* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

JANSSEN THERAP
* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAZZ
* JAZZ PHARMACEUTICALS IRELAND LTD
SUNOSI, SOLRIAMFETOL HYDROCHLORIDE
XYWAV, CALCIUM OXYBATE
ZEPZELCA, LURBINECTEDIN

JAZZ PHARMS
* JAZZ PHARMACEUTICALS INC
XYREM, SODIUM OXYBATE

JAZZ PHARMS INC
* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

JDP
* JDP THERAPEUTICS LLC
QUZYTTIR, CETIRIZINE HYDROCHLORIDE

JIANGSU HANSOH PHARM
* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU PHARMS
* JIANGSU HENGRUI PHARMACEUTICALS CO LTD
CARMUSTINE, CARMUSTINE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JIANGSU HENGRUI PHARMACEUTICALS CO LTD
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
THIOTEPA, THIOTEPA

JOHNS HOPKINS UNIV

* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)

JOURNEY

* JOURNEY MEDICAL CORP
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
QBREXZA, GLYCOPYRRONIUM TOSYLATE
XIMINO, MINOCYCLINE HYDROCHLORIDE

JUBILANT

* JUBILANT DRAXIMAGE INC DBA JUBILANT RADIOPHARMA
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131

JUBILANT CADISTA

* JUBILANT CADISTA PHARMACEUTICALS INC
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

* JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

* JUBILANT GENERICS LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
OLANZAPINE, OLANZAPINE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JUBILANT GENERICS LTD
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ****

GRIFFEN

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

* KADMON PHARMACEUTICALS LLC
REZUROCK, BELUMOSUDIL MESYLATE

KAI PHARMS INC

* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

KALA PHARMS INC

* KALA PHARMACEUTICALS INC
EYSUVIS, LOTEPREDNOL ETABONATE
INVELTYS, LOTEPREDNOL ETABONATE

KALEO INC

* KALEO INC
AUVI-Q, EPINEPHRINE

KARTHA

* KARTHA PHARMACEUTICALS INC
BACLOFEN, BACLOFEN

KARYOPHARM THERAPS

* KARYOPHARM THERAPEUTICS INC
XPOVIO, SELINEXOR

KENTON

* KENTON CHEMICALS AND PHARMACEUTICALS CORP
ACYCLOVIR, ACYCLOVIR
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
RILUZOLE, RILUZOLE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KINDEVA

* KINDEVA DRUG DELIVERY LP
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

KING PHARMS

* KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
SKELAXIN, METAXALONE

KING PHARMS LLC

* KING PHARMACEUTICALS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** K ****

* KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE

KNIGHT THERAPS
* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO
* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KOWA PHARMS
* KOWA PHARMACEUTICALS AMERICA INC
SEGLENTIS, CELECOXIB

KRAMER
* KRAMER LABORATORIES INC
NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)

KREITCHMAN PET CTR
* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KVK TECH
* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC
* KVK TECH INC
APADAZ, ACETAMINOPHEN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN
* KYOWA KIRIN INC
FARESTON, TOREMIFENE CITRATE
NOURIANZ, ISTRADEFYLLINE
SANCUSO, GRANISETRON

KYTHERA BIOPHARMS
* KYTHERA BIOPHARMACEUTICALS INC
KYBELLA, DEOXYCHOLIC ACID

**** L ****

L PERRIGO CO
* L PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* L PERRIGO CO
NAPROXEN, NAPROXEN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA
* LA JOLLA PHARMA LLC
GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA
* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LABORATOIRE HRA
* LABORATOIRE HRA PHARMA
LEVONORGESTREL, LEVONORGESTREL (OTC)

LABORATORIOS GRIFOLS
* LABORATORIOS GRIFOLS SA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT
* LABORATORIOS SALVAT SA
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LANDELA PHARM
* LANDELA PHARMACEUTICAL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

LANNETT
* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID

LANNETT CO INC
* LANNETT CO INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CODEINE SULFATE, CODEINE SULFATE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DANAZOL, DANAZOL
DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DRONABINOL, DRONABINOL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LANNETT CO INC
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LACTULOSE, LACTULOSE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAXALONE, METAXALONE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NIACIN, NIACIN
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE, PREDNISOLONE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN, SUMATRIPTAN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THEOPHYLLINE, THEOPHYLLINE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
URSODIOL, URSODIOL
VALPROIC ACID, VALPROIC ACID

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY RT, PERFLUTREN
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LANTHEUS MEDICAL

* LANTHEUS MEDICAL IMAGING INC
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS

* LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
OFLOXACIN, OFLOXACIN

LARKEN LABS INC

* LARKEN LABORATORIES INC
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LARKEN LABORATORIES INC
ALLZITAL, ACETAMINOPHEN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
DEXAMETHASONE, DEXAMETHASONE

LAURUS

* LAURUS LABS LTD
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

LAVIPHARM

* LAVIPHARM SA
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE

LEADIANT BIOSCI INC

* LEADIANT BIOSCIENCES INC
ABELCET, AMPHOTERICIN B
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING PHARMA LLC

* LEADING PHARMA LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYUREA, HYDROXYUREA
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LORAZEPAM, LORAZEPAM
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

LEO PHARMA AS

* LEO PHARMA AS
DOVONEX, CALCIPOTRIENE
ENSTILAR, BETAMETHASONE DIPROPIONATE
FINACEA, AZELAIC ACID
PROTOPIC, TACROLIMUS
TACLONEX, BETAMETHASONE DIPROPIONATE

LG CHEM LTD

* LG CHEM LTD
FACTIVE, GEMIFLOXACIN MESYLATE

LGM PHARMA

* LGM PHARMA SOLUTIONS LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
NABUMETONE, NABUMETONE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
URSODIOL, URSODIOL

LIEBEL-FLARSHEIM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LIEBEL-FLARSHEIM CO LLC
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR
* LIFE MOLECULAR IMAGING LTD
NEURACEQ, FLORBETABEN F-18

LNK
* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC
* LNK INTERNATIONAL INC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

LOREAL USA
* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD
* LOTUS PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
* LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
METHOTREXATE SODIUM, METHOTREXATE SODIUM

LOXO ONCOLOGY INC
* LOXO ONCOLOGY INC
RETEVMO, SELPERCATINIB

LUITPOLD
* LUITPOLD PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID

LUKARE MEDICAL LLC
* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD
* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC
* LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUOXIN AUROVITAS
* LUOXIN AUROVITAS PHARMA CHENGDU CO LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

LUPIN
* LUPIN INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ANTARA (MICRONIZED), FENOFIBRATE
BUDESONIDE, BUDESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MIBELAS 24 FE, ETHINYL ESTRADIOL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN INC
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
QUINARETIC, HYDROCHLOROTHIAZIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SOLOSEC, SECNIDAZOLE
TESTOSTERONE, TESTOSTERONE
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TRANDOLAPRIL, TRANDOLAPRIL

LUPIN LTD

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

* LUPIN LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BIMATOPROST, BIMATOPROST
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CELECOXIB, CELECOXIB
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DAYSEE, ETHINYL ESTRADIOL
DECITABINE, DECITABINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENSKYCE, DESOGESTREL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
ETHACRYNIC ACID, ETHACRYNIC ACID
FALLBACK SOLO, LEVONORGESTREL (OTC)
FAMOTIDINE, FAMOTIDINE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FYAVOLV, ETHINYL ESTRADIOL
GATIFLOXACIN, GATIFLOXACIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
JENCYCLA, NORETHINDRONE
KAITLIB FE, ETHINYL ESTRADIOL
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NADOLOL, NADOLOL
NIACIN, NIACIN
NIKKI, DROSPIRENONE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLAMINE, PENICILLAMINE
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANOLAZINE, RANOLAZINE
RIFABUTIN, RIFABUTIN
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUPRAX, CEFIXIME
TADALAFIL, TADALAFIL
TAVABOROLE, TAVABOROLE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TESTOSTERONE, TESTOSTERONE
TETRABENAZINE, TETRABENAZINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
TYDEMY, DROSPIRENONE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
ZILEUTON, ZILEUTON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS

* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLORATADINE, DESLORATADINE
DROXIDOPA, DROXIDOPA
MELOXICAM, MELOXICAM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIFAMPIN, RIFAMPIN
SUPRAX, CEFIXIME
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYNE

* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOCARNITINE, LEVOCARNITINE
NYSTATIN, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO

* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TAB-PROFEN, IBUPROFEN (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ****

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

MA GENERAL HOSP

* MASSACHUSETTS GENERAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD

* MACLEODS PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
FLUOCINONIDE, FLUOCINONIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE, LIDOCAINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PYRAZINAMIDE, PYRAZINAMIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILODOSIN, SILODOSIN
TADALAFIL, TADALAFIL
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
ANGIOMAX RTU, BIVALIRUDIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MAIA PHARMACEUTICALS INC
BACLOFEN, BACLOFEN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE

* MAINPOINTE PHARMACEUTICALS LLC
TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSP PRODUCTS IP LTD
INOMAX, NITRIC OXIDE
OFIRMEV, ACETAMINOPHEN
UVADEX, METHOXSALEN

MANKIND PHARMA

* MANKIND PHARMA LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
RANOLAZINE, RANOLAZINE
TIMOLOL MALEATE, TIMOLOL MALEATE

MARKSANS PHARMA

* MARKSANS PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL

MARNEL PHARMS

* MARNEL PHARMACEUTICALS LLC
ALA-SCALP, HYDROCORTISONE
CROTAN, CROTAMITON

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN
* MAYNE PHARMA LLC
BUDESONIDE, BUDESONIDE
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHLORZOXAZONE, CHLORZOXAZONE
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ESTAZOLAM, ESTAZOLAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MAYNE PHARMA LLC
ESTRADIOL, ESTRADIOL
FABIOR, TAZAROTENE
FLUOROURACIL, FLUOROURACIL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEXETTE, HALOBETASOL PROPIONATE
LOW-OGESTREL-28, ETHINYL ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NEXTSTELLIS, DROSPIRENONE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
SORILUX, CALCIPOTRIENE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIMETHOPRIM, TRIMETHOPRIM
TRIVORA-28, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC
* MAYNE PHARMA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DOFETILIDE, DOFETILIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
SOLTAMOX, TAMOXIFEN CITRATE

MAYNE PHARMA INTL
* MAYNE PHARMA INTERNATIONAL PTY LTD
TOLSURA, ITRACONAZOLE

MC2
* MC2 THERAPEUTICS LTD
WYNZORA, BETAMETHASONE DIPROPIONATE

MCGUFF
* MCGUFF PHARMACEUTICALS INC
ASCOR, ASCORBIC ACID

MCNEIL
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
IBUPROFEN, IBUPROFEN (OTC)

MCNEIL CONS
* MCNEIL CONSUMER HEALTHCARE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

MCPRF
* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDD US

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MDD US OPERATIONS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
XADAGO, SAFINAMIDE MESYLATE

MDGH
* MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
MOXIDECTIN, MOXIDECTIN

MEDEFIL INC
* MEDEFIL INC
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

MEDEXUS
* MEDEXUS PHARMA INC
RASUVO, METHOTREXATE

MEDICINES360
* MEDICINES360
LILETTA, LEVONORGESTREL

MEDICURE
* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
ZYPITAMAG, PITAVASTATIN MAGNESIUM

MEDIMETRIKS PHARMS
* MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

MEDLINE INDUSTRIES
* MEDLINE INDUSTRIES INC
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDTECH PRODUCTS
* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MEITHEAL
* MEITHEAL PHARMACEUTICALS INC
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZACITIDINE, AZACITIDINE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUSULFAN, BUSULFAN
CARMUSTINE, CARMUSTINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLOFARABINE, CLOFARABINE
CYTARABINE, CYTARABINE
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DOXERCALCIFEROL, DOXERCALCIFEROL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
ISOSULFAN BLUE, ISOSULFAN BLUE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MEITHEAL PHARMACEUTICALS INC
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE

MELINTA

* MELINTA SUBSIDIARY CORP
BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP

* MELINTA THERAPEUTICS LLC
KIMYRSA, ORITAVANCIN DIPHOSPHATE
ORBACTIV, ORITAVANCIN DIPHOSPHATE

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
ZOLINZA, VORINOSTAT

* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
PRINIVIL, LISINOPRIL
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

MERCK AND CO INC

* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE
FOSAMAX, ALENDRONATE SODIUM

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
BELSOMRA, SUVOREXANT
DIPROLENE, BETAMETHASONE DIPROPIONATE
ELOCON, MOMETASONE FUROATE
INVANZ, ERTAPENEM SODIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISENTRESS, RALTEGRAVIR POTASSIUM
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
LOTRISONE, BETAMETHASONE DIPROPIONATE
NOXAFIL, POSACONAZOLE
PREVYMIS, LETERMOVIR
REBETOL, RIBAVIRIN
SEGLUROMET, ERTUGLIFLOZIN
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
VERQUVO, VERICIGUAT
ZEPATIER, ELBASVIR

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
WELIREG, BELZUTIFAN

MERIDIAN MEDCL

* MERIDIAN MEDICAL TECHNOLOGIES INC
DUODOTE, ATROPINE

MERIDIAN MEDCL TECHN

* MERIDIAN MEDICAL TECHNOLOGIES INC
ATROPEN, ATROPINE
SEIZALAM, MIDAZOLAM HYDROCHLORIDE

MERRO PHARM USA

* MERRO PHARMACEUTICAL USA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MERRO PHARMACEUTICAL USA INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE

METACEL PHARMS LLC

* METACEL PHARMACEUTICALS LLC
OZOBAX, BACLOFEN

METHAPHARM

* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS

* METUCHEN PHARMACEUTICALS LLC
STENDRA, AVANAFIL

MICRO LABS

* MICRO LABS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BIMATOPROST, BIMATOPROST
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GLIMEPIRIDE, GLIMEPIRIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LINCOMYCIN, LINCOMYCIN
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIROXICAM, PIROXICAM
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
SIMVASTATIN, SIMVASTATIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TAFLUPROST, TAFLUPROST
TELMISARTAN, TELMISARTAN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD

* MICRO LABS LTD
NEVIRAPINE, NEVIRAPINE

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA
ACETAZOLAMIDE, ACETAZOLAMIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CROMOLYN SODIUM, CROMOLYN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MICRO LABS LTD INDIA
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDWEST MEDCL

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART

* MIKART LLC
BENZONATATE, BENZONATATE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
METHAZOLAMIDE, METHAZOLAMIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MIKART INC

* MIKART INC
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

MILLA PHARMS

* MILLA PHARMACEUTICALS INC
SODIUM ACETATE, SODIUM ACETATE

MILLICENT

* MILLICENT HOLDINGS LTD
FEMRING, ESTRADIOL ACETATE
* MILLICENT PHARMA LTD
INTRAROSA, PRASTERONE

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIRUM

* MIRUM PHARMACEUTICALS INC
LIVMARLI, MARALIXIBAT CHLORIDE

MISEMER

* MISEMER PHARMACEUTICALS INC
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
KETOPROFEN, KETOPROFEN

MISSION PHARMA

* MISSION PHARMACAL CO
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
THIOLA EC, TIOPRONIN

MITSUBISHI HOLDINGS

* MITSUBISHI TANABE PHARMA HOLDINGS AMERICA INC
EXSERVAN, RILUZOLE

MITSUBISHI TANABE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MITSUBISHI TANABE PHARMA CORP
RADICAVA, EDARAVONE

MLV

* MLV PHARMA LLC
CARISOPRODOL, CARISOPRODOL
METHOCARBAMOL, METHOCARBAMOL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

MOBIUS THERAP

* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS LLC
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN

* MOUNTAIN LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

MSD MERCK CO

* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
DELSTRIGO, DORAVIRINE
EMEND, APREPITANT
NOXAFIL POWDERMIX KIT, POSACONAZOLE
PIFELTRO, DORAVIRINE
RECARBRIO, CILASTATIN SODIUM
SINGULAIR, MONTELUKAST SODIUM

MSN

* MSN LABORATORIES PRIVATE LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALBENDAZOLE, ALBENDAZOLE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CAPECITABINE, CAPECITABINE
CLOFARABINE, CLOFARABINE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DOFETILIDE, DOFETILIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
FEBUXOSTAT, FEBUXOSTAT
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PACLITAXEL, PACLITAXEL
PREGABALIN, PREGABALIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
THIOTEPA, THIOTEPA
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

MSN PHARMS INC

* MSN PHARMACEUTICALS INC
DROXIDOPA, DROXIDOPA

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MYLAN

* MYLAN PHARMACEUTICALS
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

* MYLAN PHARMACEUTICALS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACETAMINOPHEN, ACETAMINOPHEN
ACITRETIN, ACITRETIN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
AVITA, TRETINOIN
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
COLCHICINE, COLCHICINE
CYSTAGON, CYSTEAMINE BITARTRATE
DENAVIR, PENCICLOVIR
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERYGEL, ERYTHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
EVEROLIMUS, EVEROLIMUS
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FUROSEMIDE, FUROSEMIDE
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLIPIZIDE, GLIPIZIDE
HALCINONIDE, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMPEKLO, CLOBETASOL PROPIONATE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LUXIQ, BETAMETHASONE VALERATE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MENTAX, BUTENAFINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NEVIRAPINE, NEVIRAPINE
NISOLDIPINE, NISOLDIPINE
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OLUX E, CLOBETASOL PROPIONATE
OLUX, CLOBETASOL PROPIONATE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENYTEK, PHENYTOIN SODIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PREGABALIN, PREGABALIN
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
RUFINAMIDE, RUFINAMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
SYMFI LO, EFAVIRENZ
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TETRABENAZINE, TETRABENAZINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TICAGRELOR, TICAGRELOR
TIMOLOL MALEATE, TIMOLOL MALEATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAVOPROST, TRAVOPROST
TRETINOIN, TRETINOIN
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
URSODIOL, URSODIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VUSION, MICONAZOLE NITRATE
WIXELA INHUB, FLUTICASONE PROPIONATE
ZONALON, DOXEPIN HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR

* MYLAN PHARMACEUTICALS INC A VIATRIS CO
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
PREDNISONE, PREDNISONE
PREGABALIN, PREGABALIN
TELMISARTAN, TELMISARTAN
VALPROATE SODIUM, VALPROATE SODIUM

MYLAN ASI

* MYLAN ASI LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
BUSULFAN, BUSULFAN
SULFAMYLON, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
ALOPRIM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
CIDOFOVIR, CIDOFOVIR
COSYNTROPIN, COSYNTROPIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ISOSULFAN BLUE, ISOSULFAN BLUE
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN IRELAND LTD
MIACALCIN, CALCITONIN SALMON
PRETOMANID, PRETOMANID
YUPELRI, REVEFENACIN

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
ADENOSINE, ADENOSINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BACLOFEN, BACLOFEN
CIMDUO, LAMIVUDINE
CLADRIBINE, CLADRIBINE
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
DAPTOMYCIN, DAPTOMYCIN
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETOMIDATE, ETOMIDATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LAMIVUDINE, LAMIVUDINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
OXALIPLATIN, OXALIPLATIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SYMFI, EFAVIRENZ
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
AMNESTEEM, ISOTRETINOIN
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AVITA, TRETINOIN
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
ESZOPICLONE, ESZOPICLONE
FENOFIBRATE, FENOFIBRATE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LITHIUM CARBONATE, LITHIUM CARBONATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PINDOLOL, PINDOLOL
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VORICONAZOLE, VORICONAZOLE
ZIDOVUDINE, ZIDOVUDINE

* MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM

MYLAN SPCLT VIATRIS

* MYLAN SPECIALTY LP A VIATRIS CO
DIPENTUM, OLSALAZINE SODIUM

MYLAN SPECIALITY LP

* MYLAN SPECIALTY LP
ACCUNEB, ALBUTEROL SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DEPEN, PENICILLAMINE
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MUSE, ALPROSTADIL
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL
TOBI PODHALER, TOBRAMYCIN
TOBI, TOBRAMYCIN

MYLAN SPECLT

* MYLAN SPECIALTY LP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN SPECIALTY LP
PERFOROMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
RIVASTIGMINE, RIVASTIGMINE
SCOPOLAMINE, SCOPOLAMINE
XULANE, ETHINYL ESTRADIOL

MYOVANT SCIENCES

* MYOVANT SCIENCES GMBH
MYFEMBREE, ESTRADIOL
ORGOVYX, RELUGOLIX

**** N ****

NAARI PTE LTD

* NAARI PTE LTD
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

NABRIVA

* NABRIVA THERAPEUTICS IRELAND DAC
XENLETA, LEFAMULIN ACETATE

NAL PHARM

* NAL PHARMACEUTICAL GROUP LTD
LIDOCAINE, LIDOCAINE

NALPROPION

* NALPROPION PHARMACEUTICALS LLC
CONTRAVE, BUPROPION HYDROCHLORIDE

NAMIGEN LLC

* NAMIGEN LLC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM

NANG KUANG PHARM CO

* NANG KUANG PHARMACEUTICAL CO LTD
ICATIBANT ACETATE, ICATIBANT ACETATE
LINEZOLID, LINEZOLID

NANJING

* NANJING SIMCERE DONGYUAN PHARMACEUTICAL CO LTD
CELECOXIB, CELECOXIB

NANJING KING-FRIEND

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

NAPO PHARMS INC

* NAPO PHARMACEUTICALS INC
MYTESI, CROFELEMER

NATCO

* NATCO PHARMA LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
CARISOPRODOL, CARISOPRODOL
GLYCOPYRROLATE, GLYCOPYRROLATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

NATCO PHARMA

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARMUSTINE, CARMUSTINE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
METHOCARBAMOL, METHOCARBAMOL
PENICILLAMINE, PENICILLAMINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC

* NCM USA BRONX LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOS THERAP INC

* NEOS THERAPEUTICS INC
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS

* NEOS THERAPEUTICS
ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC

* NEOS THERAPEUTICS INC
COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON

* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BUDESONIDE, BUDESONIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NEPHRON PHARMACEUTICALS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

NESHER PHARMS

* NESHER PHARMACEUTICALS USA LLC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

NEURELIS INC

* NEURELIS INC
VALTOCO, DIAZEPAM

NEUROCRINE

* NEUROCRINE BIOSCIENCES INC
INGREZZA, VALBENAZINE TOSYLATE
ONGENTYS, OPICAPONE

NEXTWAVE

* NEXTWAVE PHARMACEUTICALS INC A SUB OF TRIS PHARMA INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXTWAVE PHARMS

* NEXTWAVE PHARMACEUTICALS INC
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS

* NEXUS PHARMACEUTICALS INC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
BUSULFAN, BUSULFAN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
EMERPHED, EPHEDRINE SULFATE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

NIAGARA PHARMS

* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NIPPON SHINYAKU

* NIPPON SHINYAKU CO LTD
VILTEPSO, VILTOLARSEN

NIVAGEN PHARMS INC

* NIVAGEN PHARMACEUTICALS INC
DECITABINE, DECITABINE
GLYCOPYRROLATE, GLYCOPYRROLATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

NODEN PHARMA

* NODEN PHARMA DAC
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TEKTURNA, ALISKIREN HEMIFUMARATE

NORTEC DEV ASSOC

* NORTEC DEVELOPMENT ASSOC INC
MORPHINE SULFATE, MORPHINE SULFATE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHLAND

* NORTHLAND NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** N **

NORTHSTAR HLTHCARE

* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR MEDICAL

* NORTHSTAR MEDICAL RADIOISOTOPES LLC
RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

NORTON WATERFORD

* NORTON WATERFORD LTD
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NOSTRUM LABS INC

* NOSTRUM LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
CALCIUM ACETATE, CALCIUM ACETATE
CARBAMAZEPINE, CARBAMAZEPINE
CARISOPRODOL, CARISOPRODOL
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE, HYDROCODONE BITARTRATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NOVA LABS LTD

* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPURINE

NOVADAQ TECH

* NOVADAQ TECHNOLOGIES ULC
SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS

* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
ALOMIDE, LODOXAMIDE TROMETHAMINE
ARGATROBAN, ARGATROBAN
ARRANON, NELARABINE
AZOPT, BRINZOLAMIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
COARTEM, ARTEMETHER
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DUREZOL, DIFLUPREDNATE
EGATEN, TRICLABENDAZOLE
EXELON, RIVASTIGMINE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
EXJADE, DEFERASIROX
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
GILENYA, FINGOLIMOD HYDROCHLORIDE
GLEEVEC, IMATINIB MESYLATE
HYCAMTIN, TOPOTECAN HYDROCHLORIDE
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
JADENU SPRINKLE, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
LEQVIO, INCLISIRAN SODIUM
LESCOL XL, FLUVASTATIN SODIUM
LOTREL, AMLODIPINE BESYLATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MAYZENT, SIPONIMOD FUMARIC ACID
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MYFORTIC, MYCOPHENOLIC SODIUM
NEORAL, CYCLOSPORINE
NEVANAC, NEPAFENAC
OMNIPRED, PREDNISOLONE ACETATE
PATANASE, OLOPATADINE HYDROCHLORIDE
PIQRAY, ALPELISIB
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMACTA, ELTROMBOPAG OLAMINE
RECLAST, ZOLEDRONIC ACID
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RYDAPT, MIDOSTAURIN
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SCEMBLIX, ASCIMINIB HYDROCHLORIDE
TAFINLAR, DABRAFENIB MESYLATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRAVATAN Z, TRAVOPROST
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRILEPTAL, OXCARBAZEPINE
TYKERB, LAPATINIB DITOSYLATE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIVELLE-DOT, ESTRADIOL
VOTRIENT, PAZOPANIB HYDROCHLORIDE
XIIDRA, LIFITEGRAST
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS
ZYKADIA, CERITINIB

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS
TABRECTA, CAPMATINIB HYDROCHLORIDE

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
ENTRESTO, SACUBITRIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
JADENU, DEFERASIROX

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE

* NOVAST LABORATORIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBOPLATIN, CARBOPLATIN
CARISOPRODOL, CARISOPRODOL
CHABELINA FE, ETHINYL ESTRADIOL
CHLORTHALIDONE, CHLORTHALIDONE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOLISHALE, ETHINYL ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
HER STYLE, LEVONORGESTREL (OTC)
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LERIBANE, ETHINYL ESTRADIOL
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LO-MALMOREDE, ETHINYL ESTRADIOL
MAFENIDE ACETATE, MAFENIDE ACETATE
MALMOREDE, ETHINYL ESTRADIOL
MELAMISA, DROSPIRENONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE, NORETHINDRONE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PIMTREA, DESOGESTREL
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
SETLAKIN, ETHINYL ESTRADIOL
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLCAPONE, TOLCAPONE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRIAZOLAM, TRIAZOLAM
YAELA, DROSPIRENONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
PHILITH, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL

NOVATECH SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVATECH SA
STERITALC, TALC

NOVEL LABS INC

* NOVEL LABORATORIES INC
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
CALCIPOTRIENE, CALCIPOTRIENE
CARBIDOPA, CARBIDOPA
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FAMOTIDINE, FAMOTIDINE
FLUCYTOSINE, FLUCYTOSINE
FLUOCINONIDE, FLUOCINONIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MISOPROSTOL, MISOPROSTOL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
TEMAZEPAM, TEMAZEPAM
TINIDAZOLE, TINIDAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOPRIM, TRIMETHOPRIM
VORICONAZOLE, VORICONAZOLE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVELGENIX THERAPS

* NOVELGENIX THERAPEUTICS PVT LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NOVEN

* NOVEN PHARMACEUTICALS INC
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
COMBIPATCH, ESTRADIOL
DAYTRANA, METHYLPHENIDATE

NOVITIUM PHARMA

* NOVITIUM PHARMA LLC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALPRAZOLAM, ALPRAZOLAM
ATENOLOL AND CHLORTHALIDONE, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVITIUM PHARMA LLC
BETAINE, BETAINE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARGLUMIC ACID, CARGLUMIC ACID
CHLORZOXAZONE, CHLORZOXAZONE
CLOTRIMAZOLE, CLOTRIMAZOLE
DAPSONE, DAPSONE
DIAZOXIDE, DIAZOXIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ESTAZOLAM, ESTAZOLAM
FAMOTIDINE, FAMOTIDINE
FELBAMATE, FELBAMATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCARNITINE, LEVOCARNITINE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
MELOXICAM, MELOXICAM
NAPROXEN, NAPROXEN
NITISINONE, NITISINONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREDNISONE, PREDNISONE
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIFABUTIN, RIFABUTIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
THIOTHIXENE, THIOTHIXENE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALSARTAN, VALSARTAN

NOVO
* NOVO NORDISK INC
MACRILEN, MACIMORELIN ACETATE
OZEMPIC, SEMAGLUTIDE
RYBELSUS, SEMAGLUTIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
WEGOVY, SEMAGLUTIDE

NOVO NORDISK
* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE

NOVO NORDISK INC
* NOVO NORDISK INC
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL INC
* NOVOCOL INC
DYCLOPRO, DYCLONINE HYDROCHLORIDE

NPS PHARMS INC
* NPS PHARMACEUTICALS INC
GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NUKEMED
* NUKEMED INC DBA SPECTRONRX
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NUVO PHARM
* NUVO PHARMACEUTICAL INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NUVO PHARMACEUTICAL INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS INC

* NUVO PHAMACEUTICALS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULFASALAZINE, SULFASALAZINE

NXDC

* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**** O ****

OCULAR THERAPEUTIX

* OCULAR THERAPEUTIX INC
DEXTENZA, DEXAMETHASONE

OHM

* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
GUAIFENESIN, GUAIFENESIN (OTC)
VALSARTAN, VALSARTAN

OMEROS

* OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

ON TARGET LABS

* ON TARGET LABORATORIES INC
CYTALUX, PAFOLACIANINE SODIUM

ONCOGEN PHARMA

* ONCOGEN PHARMA MALAYSIA SDN BHD
ABIRATERONE ACETATE, ABIRATERONE ACETATE

ONYX THERAP

* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPTINOSE US INC

* OPTINOSE US INC
XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORBION PHARMS

* ORBION PHARMACEUTICALS PRIVATE LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORBION PHARMACEUTICALS PRIVATE LTD
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLMITRIPTAN, ZOLMITRIPTAN

ORCHID HLTHCARE

* ORCHID HEALTHCARE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN

OREXO US INC

* OREXO US INC
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON

* ORGANON LLC
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
CLARINEX-D 12 HOUR, DESLORATADINE
DULERA, FORMOTEROL FUMARATE
FOSAMAX PLUS D, ALENDRONATE SODIUM
* ORGANON LLC A SUB OF ORGANON AND CO
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CLARINEX, DESLORATADINE
COZAAR, LOSARTAN POTASSIUM
HYZAAR, HYDROCHLOROTHIAZIDE
SINEMET, CARBIDOPA
VYTORIN, EZETIMIBE
ZETIA, EZETIMIBE
ZOCOR, SIMVASTATIN

ORGANON SUB MERCK

* ORGANON USA INC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM
NUVARING, ETHINYL ESTRADIOL

ORGANON USA INC

* ORGANON USA INC
GANIRELIX ACETATE, GANIRELIX ACETATE
NEXPLANON, ETONOGESTREL
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
GLYBURIDE, GLYBURIDE
MIGLITOL, MIGLITOL
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ORIGIN

* ORIGIN BIOSCIENCES INC
NULIBRY, FOSDENOPTERIN HYDROBROMIDE

ORION PHARMA

* ORION PHARMA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

OSI PHARMS
* OSI PHARMACEUTICALS LLC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA
* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

OSMOTICA PHARM
* OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM US
* OSMOTICA PHARMACEUTICAL US LLC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

OTSUKA
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABILIFY, ARIPIPRAZOLE
DACOGEN, DECITABINE
INQOVI, CEDAZURIDINE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPRAZOLE
SAMSCA, TOLVAPTAN

OTSUKA PHARM
* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE

OTTER PHARMS
* OTTER PHARMACEUTICALS LLC
OTREXUP, METHOTREXATE

OUTLOOK PHARMS
* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OVERSEAS
* OVERSEAS PHARMACEUTICALS LTD
LEVETIRACETAM, LEVETIRACETAM

OXFORD PHARMS
* OXFORD PHARMACEUTICALS LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OXFORD PHARMACEUTICALS LLC
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

OYSTER POINT PHARMA

* OYSTER POINT PHARMA INC
TYRVAYA, VARENICLINE TARTRATE

**** P ****

P AND L

* P AND L DEVELOPMENT LLC
ADAPALENE, ADAPALENE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DOCOSANOL, DOCOSANOL (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

P AND L DEV LLC

* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

* PACIRA PHARMACEUTICALS INC
EXPAREL, BUPIVACAINE

PADAGIS ISRAEL

* PADAGIS ISRAEL PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESTRADIOL, ESTRADIOL
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PADAGIS ISRAEL PHARMACEUTICALS LTD
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PERMETHRIN, PERMETHRIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SUMATRIPTAN, SUMATRIPTAN
SUMATRIPTAN, SUMATRIPTAN SUCCINATE
TERCONAZOLE, TERCONAZOLE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

PADAGIS US

* PADAGIS US LLC
ATOVAQUONE, ATOVAQUONE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CENTANY, MUPIROCIN
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COMPRO, PROCHLORPERAZINE
CYCLOSPORINE, CYCLOSPORINE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ENTOCORT EC, BUDESONIDE
ERYTHROMYCIN, ERYTHROMYCIN
EVAMIST, ESTRADIOL
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCORTISONE, HYDROCORTISONE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NYSTATIN, NYSTATIN
NYSTOP, NYSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PADAGIS US LLC
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PODOFILOX, PODOFILOX
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SCOPOLAMINE, SCOPOLAMINE
SELENIUM SULFIDE, SELENIUM SULFIDE
STIE-CORT, HYDROCORTISONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TAVABOROLE, TAVABOROLE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

PALATIN TECHNOLOGIES

* PALATIN TECHNOLOGIES INC
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE

PANACEA

* PANACEA BIOTEC PHARMA LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

PAR FORM

* PAR FORMULATIONS PRIVATE LTD
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL
EVEROLIMUS, EVEROLIMUS
* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROXYUREA, HYDROXYUREA
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
MINOXIDIL, MINOXIDIL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
PIMOZIDE, PIMOZIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
URSODIOL, URSODIOL

PAR PHARM INC

* PAR PHARMACEUTICAL INC
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BOSENTAN, BOSENTAN
CHLORZOXAZONE, CHLORZOXAZONE
COLCHICINE, COLCHICINE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
ETHACRYNIC ACID, ETHACRYNIC ACID
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
PENICILLAMINE, PENICILLAMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PRAZIQUANTEL, PRAZIQUANTEL
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
TOLCAPONE, TOLCAPONE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VIGABATRIN, VIGABATRIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS

* PAR STERILE PRODUCTS LLC
ADRENALIN, EPINEPHRINE
ARGATROBAN, ARGATROBAN
BREVITAL SODIUM, METHOHEXITAL SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CALCITONIN-SALMON, CALCITONIN SALMON
COLY-MYCIN M, COLISTIMETHATE SODIUM
CORPHEDRA, EPHEDRINE SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
KETALAR, KETAMINE HYDROCHLORIDE
MICAFUNGIN, MICAFUNGIN SODIUM
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PITOCIN, OXYTOCIN
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TREPROSTINIL, TREPROSTINIL
TRIOSTAT, LIOTHYRONINE SODIUM
VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK

* PARAGON BIOTECK INC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC

* PARAPRO LLC
NATROBA, SPINOSAD

PARATEK PHARMS INC

* PARATEK PHARMACEUTICALS INC
NUZYRA, OMADACYCLINE TOSYLATE

PARKE DAVIS

* PARKE DAVIS DIV WARNER LAMBERT CO
CELONTIN, METHSUXIMIDE
CEREBYX, FOSPHENYTOIN SODIUM
NARDIL, PHENELZINE SULFATE
ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS

* PARKE-DAVIS DIVISION OF PFIZER INC
ZARONTIN, ETHOSUXIMIDE

PERRIGO

* PERRIGO CO

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO CO
MINOXIDIL, MINOXIDIL (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
* PERRIGO LLC
DESLORATADINE, DESLORATADINE

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
PERMETHRIN, PERMETHRIN (OTC)

PERRIGO PHARMA INTL

* PERRIGO PHARMA INTERNATIONAL DAC
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
* PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO
LORATADINE, LORATADINE (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)

PERRIGO R AND D

* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PETNET

* PETNET SOLUTIONS INC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

* PF PRISM CV
BOSULIF, BOSUTINIB MONOHYDRATE
CHANTIX, VARENICLINE TARTRATE
INLYTA, AXITINIB
PRISTIQ, DESVENLAFAXINE SUCCINATE
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS
TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE

PFIZER

* PFIZER CENTRAL RESEARCH

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER INC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
AROMASIN, EXEMESTANE
ARTHROTEC, DICLOFENAC SODIUM
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
CYTOTEC, MISOPROSTOL
DAURISMO, GLASDEGIB MALEATE
DAYPRO, OXAPROZIN
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ESTRING, ESTRADIOL
FLAGYL, METRONIDAZOLE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IBRANCE, PALBOCICLIB
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LORBRENA, LORLATINIB
MEDROL, METHYLPREDNISOLONE
MERREM, MEROPENEM
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
OGEN 5, ESTROPIPATE
PREPIDIL, DINOPROSTONE
PROCARDIA, NIFEDIPINE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
SONATA, ZALEPLON
SYNAREL, NAFARELIN ACETATE
TALZENNA, TALAZOPARIB TOSYLATE
TESSALON, BENZONATATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PFIZER INC
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
VIZIMPRO, DACOMITINIB
XELJANZ XR, TOFACITINIB CITRATE
XELJANZ, TOFACITINIB CITRATE
ZITHROMAX, AZITHROMYCIN
ZYVOX, LINEZOLID
* PFIZER LABORATORIES DIV PFIZER INC
FELDENE, PIROXICAM
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER INC

* PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
NICOTROL, NICOTINE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
LOPID, GEMFIBROZIL

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PHARMACEUTICAL ASSOCIATES INC
RISPERIDONE, RISPERIDONE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
THEOPHYLLINE, THEOPHYLLINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

PHARM SOURCING

* PHARMACEUTICAL SOURCING PARTNERS INC
MESALAMINE, MESALAMINE

PHARMA LIFE

* PHARMA LIFE SCIENCES LLC
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA

* PHARMACIA AND UPJOHN CO LLC
CADUET, AMLODIPINE BESYLATE
DILANTIN, PHENYTOIN

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN CO
CORTEF, HYDROCORTISONE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE

PHARMACOSMOS AS

* PHARMACOSMOS AS
MONOFERRIC, FERRIC DERISOMALTOSE

PHARMACYCLICS INC

* PHARMACYCLICS INC
IMBRUVICA, IBRUTINIB

PHARMADAX INC

* PHARMADAX INC
ENTECAVIR, ENTECAVIR
LEVETIRACETAM, LEVETIRACETAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

PHARMALOGIC HLDGS

* PHARMALOGIC HOLDINGS CORP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PHARMASCIENCE INC

* PHARMASCIENCE INC
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMATHEN

* PHARMATHEN SA
DIMETHYL FUMARATE, DIMETHYL FUMARATE

PHARMAXIS LTD

* PHARMAXIS LTD
ARIDOL KIT, MANNITOL

PHOTOCURE ASA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE DERMA

* PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL

* PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

PINNACLE BIOLGS

* PINNACLE BIOLOGICS INC
PHOTOFRIN, PORFIMER SODIUM

PIRAMAL CRITICAL

* PIRAMAL CRITICAL CARE INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOFLURANE, ISOFLURANE
MITIGO, MORPHINE SULFATE
OXACILLIN SODIUM, OXACILLIN SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOJOURN, SEVOFLURANE
* PIRAMAL CRITICAL CARE LTD
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

PIRAMAL HLTHCARE UK

* PIRAMAL HEALTHCARE UK LTD
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DEFERASIROX, DEFERASIROX
TETRABENAZINE, TETRABENAZINE

PIRAMAL PHARMA

* PIRAMAL PHARMA LTD
ISOFLURANE, ISOFLURANE

PLD ACQUISITIONS

* PLD ACQUISITIONS LLC DBA AVEMA PHARMA SOLUTIONS
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

PLD ACQUISITIONS LLC

* PLD ACQUISITIONS LLC
LORATADINE, LORATADINE (OTC)
ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA

* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIMETIDINE, CIMETIDINE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO

* PLIVA HRVATSKA DOO
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

PLIVA PHARM IND

* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

PLX PHARMA

* PLX PHARMA INC
VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP

* POHL BOSKAMP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS

* POLYGEN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

POWDER PHARMS

* POWDER PHARMACEUTICALS INC
ZINGO, LIDOCAINE HYDROCHLORIDE

PRASCO

* PRASCO LLC DBA PRASCO LABORATORIES
EPLERENONE, EPLERENONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

PRASCO LABS LLC

* PRASCO LABORATORIES LLC
ESTRADIOL, ESTRADIOL

PRAXAIR DISTRIBUTION

* PRAXAIR DISTRIBUTION INC
NOXIVENT, NITRIC OXIDE

PRAXGEN

* PRAXGEN PHARMACEUTICALS LLC
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
RANOLAZINE, RANOLAZINE

PRECISION DERMAT

* PRECISION DERMATOLOGY INC
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE

PRECISION DOSE INC

* PRECISION DOSE INC
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR

* PRECISION NUCLEAR LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRIMUS PHARMS

* PRIMUS PHARMACEUTICALS INC
IMPOYZ, CLOBETASOL PROPIONATE
SERNIVO, BETAMETHASONE DIPROPIONATE

PRINSTON INC

* PRINSTON PHARMACEUTICAL INC
ACYCLOVIR, ACYCLOVIR
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPTOPRIL, CAPTOPRIL
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE, FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PRINSTON PHARMACEUTICAL INC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NEVIRAPINE, NEVIRAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SILODOSIN, SILODOSIN
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VORICONAZOLE, VORICONAZOLE

PROF DSPLS

* PROFESSIONAL DISPOSABLES INC
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROGENICS PHARMS INC

* PROGENICS PHARMACEUTICALS INC
AZEDRA, IOBENGUANE I-131
PYLARIFY, PIFLUFOLASTAT F-18

PROPEL PHARMA

* PROPEL PHARMA CORP
VIGABATRIN, VIGABATRIN

PROVELL

* PROVELL PHARMACEUTICALS LLC
EUTHYROX, LEVOTHYROXINE SODIUM **

PROVENSIS

* PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVEPHARM SAS

* PROVEPHARM SAS
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROVAYBLUE, METHYLENE BLUE
TRANEXAMIC ACID, TRANEXAMIC ACID

PTC THERAP

* PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

PTS CONSULTING
* PTS CONSULTING LLC
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE

PULMOFLOW INC
* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH
* PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PUNISKA
* PUNISKA HEALTHCARE PRIVATE LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

PURACAP PHARM
* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC
* PURACAP PHARMACEUTICAL LLC
BENZONATATE, BENZONATATE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHOSUXIMIDE, ETHOSUXIMIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE
* PURDUE GMP CENTER LLC
SEROMYCIN, CYCLOSERINE

PURDUE PHARMA LP
* PURDUE PHARMA LP
ADHANSIA XR, METHYLPHENIDATE HYDROCHLORIDE
BUTRANS, BUPRENORPHINE
HYSINGLA ER, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ****

Q BIOMED
* Q BIOMED INC
METASTRON, STRONTIUM CHLORIDE SR-89
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

QILU
* QILU PHARMACEUTICAL CO LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
EXEMESTANE, EXEMESTANE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

QILU PHARM HAINAN
* QILU PHARMACEUTICAL HAINAN CO LTD
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
TADALAFIL, TADALAFIL

QINGDAO BAHEAL PHARM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Q ****

* QINGDAO BAHEAL PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE
CELECOXIB, CELECOXIB
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

QOL MEDCL

* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE

QUAGEN

* QUAGEN PHARMACEUTICALS LLC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
LIDOCAINE, LIDOCAINE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

QUEEN HAMAMATSU PET

* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ****

R-PHARM US LLC

* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

RADIOMEDIX

* RADIOMEDIX INC
DETECTNET, COPPER DOTATATE CU-64

RADIUS HEALTH INC

* RADIUS HEALTH INC
TYMLOS, ABALOPARATIDE

RANBAXY

* RANBAXY SIGNATURE LLC
RIOMET, METFORMIN HYDROCHLORIDE

RB HLTH

* RB HEALTH US LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
CARBAGLU, CARGLUMIC ACID
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
ISTURISA, OSILODROSTAT PHOSPHATE
NEOPROFEN, IBUPROFEN LYSINE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIGNIFOR, PASIREOTIDE DIASPARTATE
TRANXENE, CLORAZEPATE DIPOTASSIUM

RECRO GAINESVILLE

* RECRO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

REDHILL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** R ****

* REDHILL BIOPHARMA INC
AEMCOLO, RIFAMYCIN SODIUM
MOVANTIK, NALOXEGOL OXALATE
* REDHILL BIOPHARMA LTD
TALICIA, AMOXICILLIN

RELIANCE LIFE

* RELIANCE LIFE SCIENCES PVT LTD
CAPECITABINE, CAPECITABINE

REMPEX

* REMPEX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS LLC
MINOCIN, MINOCYCLINE HYDROCHLORIDE
VABOMERE, MEROPENEM

RENATA

* RENATA LTD
RISPERIDONE, RISPERIDONE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

RENEW PHARMS

* RENEW PHARMACEUTICALS LTD
INDOCYANINE GREEN, INDOCYANINE GREEN

RESILIA PHARMS

* RESILIA PHARMACEUTICALS INC
ECOZA, ECONAZOLE NITRATE

REYOUNG

* REYOUNG CORPORATION
FENOFIBRATE (MICRONIZED), FENOFIBRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
* REYOUNG PHARMACEUTICALS CO LTD
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LIDOCAINE, LIDOCAINE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

RHYTHM

* RHYTHM PHARMACEUTICALS INC
IMCIVREE, SETMELANOTIDE ACETATE

RICONPHARMA LLC

* RICONPHARMA LLC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
SCOPOLAMINE, SCOPOLAMINE

RIGEL PHARMS INC

* RIGEL PHARMACEUTICALS INC
TAVALISSE, FOSTAMATINIB DISODIUM

RISING

* RISING PHARMA HOLDINGS INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETIC ACID, ACETIC ACID, GLACIAL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RISING PHARMA HOLDINGS INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AZATHIOPRINE, AZATHIOPRINE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DAPSONE, DAPSONE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DOXERCALCIFEROL, DOXERCALCIFEROL
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
EXEMESTANE, EXEMESTANE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE, HYDROCORTISONE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
METHIMAZOLE, METHIMAZOLE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NITAZOXANIDE, NITAZOXANIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
PARICALCITOL, PARICALCITOL
PERPHENAZINE, PERPHENAZINE
PHENYTOIN, PHENYTOIN
POTASSIUM CITRATE, POTASSIUM CITRATE
PREGABALIN, PREGABALIN
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RISPERIDONE, RISPERIDONE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SULFAMYLON, MAFENIDE ACETATE
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
TEMOZOLOMIDE, TEMOZOLOMIDE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZILEUTON, ZILEUTON
* RISING PHARMACEUTICALS
URSODIOL, URSODIOL

RISING PHARMA

* RISING PHARMA HOLDING INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPECITABINE, CAPECITABINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYTARABINE, CYTARABINE
DIGOXIN, DIGOXIN
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** R ****

RK PHARMA
* RK PHARMA INC
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
MITOMYCIN, MITOMYCIN
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
PALIPERIDONE, PALIPERIDONE

ROCHE PALO
* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROCKWELL MEDICAL INC
* ROCKWELL MEDICAL INC
TRIFERIC AVNU, FERRIC PYROPHOSPHATE CITRATE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

ROMARK
* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROMEG
* ROMEG THERAPEUTICS LLC
GLOPERBA, COLCHICINE

ROXANE
* ROXANE LABORATORIES INC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

RUBICON
* RUBICON RESEARCH PRIVATE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
GABAPENTIN, GABAPENTIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LORATADINE, LORATADINE (OTC)
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NITROGLYCERIN, NITROGLYCERIN
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

RVL PHARMS
* RVL PHARMACEUTICALS INC
UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE

**** S ****

SAGE PRODS
* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGE THERAP
* SAGE THERAPEUTICS INC
ZULRESSO, BREXANOLONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
CAFFEINE CITRATE, CAFFEINE CITRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT PHARMS INC

* SAGENT PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYDO, LIDOCAINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OXYTOCIN, OXYTOCIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROPOFOL, PROPOFOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

SALIX

* SALIX PHARMACEUTICALS INC
FENOGLIDE, FENOFIBRATE
PLENVU, ASCORBIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SALIX PHARMACEUTICALS INC
RELISTOR, METHYLNALTREXONE BROMIDE
TRULANCE, PLECANATIDE
UCERIS, BUDESONIDE
ZEGERID, OMEPRAZOLE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
ANUSOL HC, HYDROCORTISONE
DIURIL, CHLOROTHIAZIDE
MOVIPREP, ASCORBIC ACID
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
RELISTOR, METHYLNALTREXONE BROMIDE
XIFAXAN, RIFAXIMIN

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ

* SANDOZ
DOCETAXEL, DOCETAXEL

* SANDOZ INC
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
APREPITANT, APREPITANT
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NIZATIDINE, NIZATIDINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SULFADIAZINE, SULFADIAZINE
TACROLIMUS, TACROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC

* SANDOZ CANADA INC
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID

SANDOZ INC

* SANDOZ INC
ACETAMINOPHEN, ACETAMINOPHEN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANGIOMAX, BIVALIRUDIN
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYANOCOBALAMIN, CYANOCOBALAMIN
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EZETIMIBE, EZETIMIBE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FERUMOXYTOL, FERUMOXYTOL
FLUMAZENIL, FLUMAZENIL
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT
GATIFLOXACIN, GATIFLOXACIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLATOPA, GLATIRAMER ACETATE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
ISONIAZID, ISONIAZID
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LATANOPROST, LATANOPROST
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MAXITROL, DEXAMETHASONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYDRIACYL, TROPICAMIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVIRAPINE, NEVIRAPINE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QOLIANA, BRIMONIDINE TARTRATE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REGONOL, PYRIDOSTIGMINE BROMIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TELMISARTAN, TELMISARTAN
TERIFLUNOMIDE, TERIFLUNOMIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBREX, TOBRAMYCIN
TREPROSTINIL, TREPROSTINIL
TRIFLURIDINE, TRIFLURIDINE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANOFI

* SANOFI AVENTIS US LLC
FEXINIDAZOLE, FEXINIDAZOLE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
* SANOFI GENZYME
HECTOROL, DOXERCALCIFEROL
RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL
* SANOFI AVENTIS US LLC
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
DIABETA, GLYBURIDE
ELOXATIN, OXALIPLATIN
FERRLECIT, FERRIC OXYHYDROXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANOFI AVENTIS US LLC
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASACORT AQ, TRIAMCINOLONE ACETONIDE
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
TAXOTERE, DOCETAXEL

SANTARUS INC
* SANTARUS INC
GLUMETZA, METFORMIN HYDROCHLORIDE

SANTEN
* SANTEN INC
VERKAZIA, CYCLOSPORINE

SAOL THERAPS RES LTD
* SAOL THERAPEUTICS RESEARCH LTD
LIORESAL, BACLOFEN
LYVISPAH, BACLOFEN

SAPTALIS PHARMS
* SAPTALIS PHARMACEUTICALS LLC
ACETIC ACID, ACETIC ACID, GLACIAL
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHRA-DERM, ERYTHROMYCIN
LEVOCARNITINE, LEVOCARNITINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

SAREPTA THERAPS INC
* SAREPTA THERAPEUTICS INC
AMONDYS 45, CASIMERSEN
EXONDYS 51, ETEPLIRSEN
VYONDYS 53, GOLODIRSEN

SARFE PHARMS
* SARFEZ PHARMACEUTICALS INC
SOAANZ, TORSEMIDE

SAVIOR LIFETEC CORP
* SAVIOR LIFETEC CORP
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM

SAWAI USA
* SAWAI USA INC
DIMETHYL FUMARATE, DIMETHYL FUMARATE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SCHERING
* SCHERING CORP
NOXAFIL, POSACONAZOLE

SCIARRA LABS
* SCIARRA LABORATORIES INC
SCLEROSOL, TALC
TALC, TALC

SCIECURE PHARMA INC
* SCIECURE PHARMA INC
BUDESONIDE, BUDESONIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS INC
* SCIEGEN PHARMACEUTICALS INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CELECOXIB, CELECOXIB

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SCIEGEN PHARMACEUTICALS INC
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID
EZETIMIBE, EZETIMIBE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
VALSARTAN, VALSARTAN

SCILEX PHARMS INC

* SCILEX PHARMACEUTICALS
ZTLIDO, LIDOCAINE

SCINOPHARM TAIWAN

* SCINOPHARM TAIWAN LTD
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM

SCYNEXIS

* SCYNEXIS INC
BREXAFEMME, IBREXAFUNGERP CITRATE

SEAGEN

* SEAGEN INC
TUKYSA, TUCATINIB

SEBELA IRELAND LTD

* SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
PEXEVA, PAROXETINE MESYLATE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN

SECAN PHARMS

* SECAN PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM

SECURA

* SECURA BIO INC
COPIKTRA, DUVELISIB

SENORES PHARMS

* SENORES PHARMACEUTICALS INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORZOXAZONE, CHLORZOXAZONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SENORES PHARMACEUTICALS INC
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
KETOCONAZOLE, KETOCONAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE

SENTYNL THERAPS INC

* SENTYNL THERAPEUTICS INC
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

SEPTODONT

* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

SEPTODONT HOLDING

* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

* SEPTODONT INC
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERB SA

* SERB SA
CYANOKIT, HYDROXOCOBALAMIN

SERVIER

* SERVIER PHARMACEUTICALS LLC
TIBSOVO, IVOSIDENIB

SETON PHARM

* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS

* SETON PHARMACEUTICALS LLC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANDONG

* SHANDONG NEW TIME PHARMACEUTICAL CO LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

SHANDONG XINHUA

* SHANDONG XINHUA PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

SHANGHAI HENGRUI

* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
DESFLURANE, DESFLURANE
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHIELD TX

* SHIELD TX UK LTD
ACCRUFER, FERRIC MALTOL

SHILPA

* SHILPA MEDICARE LTD
BUSULFAN, BUSULFAN
CAPECITABINE, CAPECITABINE
DOCETAXEL, DOCETAXEL
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

SHILPA MEDICARE

* SHILPA MEDICARE LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHIONOGI INC

* SHIONOGI INC
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
MULPLETA, LUSUTROMBOPAG

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES LLC
FIRAZYR, ICATIBANT ACETATE

SIDMAK LABS INDIA

* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGA TECHNOLOGIES

* SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISENTAN, AMBRISENTAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ASENAPINE MALEATE, ASENAPINE MALEATE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SINOTHERAPEUTICS INC

* SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

SK LIFE

* SK LIFE SCIENCE INC
XCOPRI, CENOBAMATE

SKINMEDICA

* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SLATE

* SLATE RUN PHARMACEUTICALS LLC
CILOSTAZOL, CILOSTAZOL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
METHOCARBAMOL, METHOCARBAMOL
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE

SLAYBACK PHARMA LLC

* SLAYBACK PHARMA LLC
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
ICATIBANT ACETATE, ICATIBANT ACETATE
MERZEE, ETHINYL ESTRADIOL
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SOFGEN PHARMACEUTICALS LLC
PROGESTERONE, PROGESTERONE

SOFIE

* SOFIE CO DBA SOFIE
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

* SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOL-GEL TECHNOLOGIES

* SOL-GEL TECHNOLOGIES LTD
TWYNEO, BENZOYL PEROXIDE

SOLARIS PHARMA CORP

* SOLARIS PHARMA CORP
ACYCLOVIR, ACYCLOVIR
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
METRONIDAZOLE, METRONIDAZOLE

SOMERSET

* SOMERSET PHARMACEUTICALS INC
EMSAM, SELEGILINE

* SOMERSET THERAPEUTICS LLC
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMERSET THERAPS LLC

* SOMERSET THERAPEUTICS LLC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TROPICAMIDE, TROPICAMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMMER PHARMS II LLC

* SOMMER PHARMACEUTICALS II LLC
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT

SPECGX LLC

* SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SPECGX LLC
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
ROXICODONE, OXYCODONE HYDROCHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE

SPECTRA MDCL DEVICES
* SPECTRA MEDICAL DEVICES INC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPIL
* SUN PHARMA INDUSTRIES LTD
AMPHOTERICIN B, AMPHOTERICIN B
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)

SPROUT PHARMS
* SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

SQUARE PHARMS
* SQUARE PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
VALSARTAN, VALSARTAN

ST RENATUS
* ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STAND HOMEOPATH
* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON PHARMS
* STASON PHARMACEUTICALS INC
PURINETHOL, MERCAPTOPURINE

STI PHARMA LLC
* STI PHARMA LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CARMUSTINE, CARMUSTINE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
THIOTEPA, THIOTEPA
TRIACIN-C, CODEINE PHOSPHATE

STIEFEL
* STIEFEL LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STRIDES PHARMA

* STRIDES PHARMA GLOBAL PTE LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZONATATE, BENZONATATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DOFETILIDE, DOFETILIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHOSUXIMIDE, ETHOSUXIMIDE
GABAPENTIN, GABAPENTIN
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LIDOCAINE, LIDOCAINE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOXSALEN, METHOXSALEN
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NATEGLINIDE, NATEGLINIDE
NEVIRAPINE, NEVIRAPINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLANZAPINE, OLANZAPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREDNISONE, PREDNISONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
ROFLUMILAST, ROFLUMILAST
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TACROLIMUS, TACROLIMUS
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TESTOSTERONE, TESTOSTERONE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVOPROST, TRAVOPROST
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
URSODIOL, URSODIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE
ZILEUTON, ZILEUTON

STRONGBRIDGE

* STRONGBRIDGE DUBLIN LTD
RECORLEV, LEVOKETOCONAZOLE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUN PHARM

* SUN PHARMACEUTICAL INDUSTRIES LTD
ABSORICA LD, ISOTRETINOIN
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMBRISENTAN, AMBRISENTAN
AMIFOSTINE, AMIFOSTINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BOSENTAN, BOSENTAN
BROMSITE, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CEQUA, CYCLOSPORINE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DALFAMPRIDINE, DALFAMPRIDINE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOFETILIDE, DOFETILIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESZOPICLONE, ESZOPICLONE
EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
INFUGEM, GEMCITABINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LORATADINE, LORATADINE (OTC)
LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE (OTC)
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANOLAZINE, RANOLAZINE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TETRABENAZINE, TETRABENAZINE
TOBRAMYCIN, TOBRAMYCIN
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WINLEVI, CLASCOTERONE
XELPROS, LATANOPROST
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ABSORICA, ISOTRETINOIN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CLONAZEPAM, CLONAZEPAM
CLOZAPINE, CLOZAPINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUMADINE, RIMANTADINE HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
HALOG, HALCINONIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
KENALOG, TRIAMCINOLONE ACETONIDE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LITHIUM CARBONATE, LITHIUM CARBONATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
ORTIKOS, BUDESONIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SUN PHARM INDS LTD

* SUN PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DOXYCYCLINE, DOXYCYCLINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
RILUZOLE, RILUZOLE
RISPERIDONE, RISPERIDONE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TOPIRAMATE, TOPIRAMATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

SUN PHARM INDUSTRIES

* SUN PHARMACEUTICAL INDUSTRIES INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CHLORTHALIDONE, CHLORTHALIDONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUALAQUIN, QUININE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE

SUN PHARMA GLOBAL

* SUN PHARMA GLOBAL FZE
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ODOMZO, SONIDEGIB PHOSPHATE
YONSA, ABIRATERONE ACETATE

SUNNY

* SUNNY PHARMTECH INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
GLYBURIDE, GLYBURIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION

* SUNOVION PHARMACEUTICALS INC
BROVANA, ARFORMOTEROL TARTRATE
XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
APTIOM, ESLICARBAZEPINE ACETATE
KYNMOBI, APOMORPHINE HYDROCHLORIDE
LATUDA, LURASIDONE HYDROCHLORIDE
LUNESTA, ESZOPICLONE

SUNOVION RESP

* SUNOVION RESPIRATORY DEVELOPMENT INC
LONHALA MAGNAIR KIT, GLYCOPYRROLATE

SUNSHINE

* SUNSHINE LAKE PHARMA CO LTD
AZITHROMYCIN, AZITHROMYCIN
CLARITHROMYCIN, CLARITHROMYCIN
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
FEBUXOSTAT, FEBUXOSTAT
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINAGLIPTIN, LINAGLIPTIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUNSHINE LAKE PHARMA CO LTD
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RANOLAZINE, RANOLAZINE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL

SUNSTAR AMERICAS

* SUNSTAR AMERICAS INC
PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
QELBREE, VILOXAZINE HYDROCHLORIDE
TROKENDI XR, TOPIRAMATE

SUVEN PHARMS

* SUVEN PHARMACEUTICALS LTD
CALCIUM ACETATE, CALCIUM ACETATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
MALATHION, MALATHION

SVC PHARMA

* SVC PHARMA LP
DRONABINOL, DRONABINOL

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

**** T ****

ACME LABS

* THE ACME LABORATORIES LTD
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

GEN HOSP

* THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

METHODIST

* THE METHODIST HOSP RESEARCH INSTITUTE
AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES

* THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RITEDOSE CORP

* THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAGI

* TAGI PHARMA INC
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE

TAIHO ONCOLOGY

* TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE

TAKEDA PHARMS USA

* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TAKEDA PHARMACEUTICALS USA INC
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
ALUNBRIG, BRIGATINIB
CARBATROL, CARBAMAZEPINE
COLCRYS, COLCHICINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
EXKIVITY, MOBOCERTINIB SUCCINATE
FOSRENOL, LANTHANUM CARBONATE
ICLUSIG, PONATINIB HYDROCHLORIDE
INTUNIV, GUANFACINE HYDROCHLORIDE
KAZANO, ALOGLIPTIN BENZOATE
LIALDA, MESALAMINE
LIVTENCITY, MARIBAVIR
MOTEGRITY, PRUCALOPRIDE SUCCINATE
MYDAYIS, AMPHETAMINE ASPARTATE
NESINA, ALOGLIPTIN BENZOATE
NINLARO, IXAZOMIB CITRATE
OSENI, ALOGLIPTIN BENZOATE
PENTASA, MESALAMINE
PREVACID, LANSOPRAZOLE
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT
VELCADE, BORTEZOMIB
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

TAMARANG

* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESONIDE, DESONIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FELBAMATE, FELBAMATE
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
IVERMECTIN, IVERMECTIN (OTC)
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN
TERIL, CARBAMAZEPINE
WARFARIN SODIUM, WARFARIN SODIUM

* TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMMONIUM LACTATE, AMMONIUM LACTATE
AZELAIC ACID, AZELAIC ACID
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DAPSONE, DAPSONE
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PHENYTOIN, PHENYTOIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICALS USA INC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE

TARO PHARM INDS LTD

* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEFERIPRONE, DEFERIPRONE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TARO PHARMS

* TARO PHARMACEUTICALS INC
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DAPSONE, DAPSONE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
PLIAGLIS, LIDOCAINE
TAVABOROLE, TAVABOROLE
TAZAROTENE, TAZAROTENE
TOPICORT, DESOXIMETASONE
TRETINOIN, TRETINOIN

TASMAN PHARMA

* TASMAN PHARMA INC
CLOTRIMAZOLE, CLOTRIMAZOLE
DROXIDOPA, DROXIDOPA
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
KETOCONAZOLE, KETOCONAZOLE
VERSACLOZ, CLOZAPINE

TCG FLUENT PHARMA

* TCG FLUENT PHARMA INVESTORS LP
FLOLIPID, SIMVASTATIN

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT OU
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
ZANTAC, RANITIDINE HYDROCHLORIDE
* TELIGENT PHARMA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TELIGENT PHARMA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CEFOTAN, CEFOTETAN DISODIUM
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE, FLUOCINONIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
ZINACEF, CEFUROXIME SODIUM

TELIX

* TELIX PHARMACEUTICALS US INC
ILLUCCIX, GALLIUM GA-68 GOZETOTIDE

TENSHI

* TENSHI KAIZEN PVT LTD
LORATADINE, LORATADINE (OTC)

TERSERA

* TERSERA THERAPEUTICS LLC
ERGOMAR, ERGOTAMINE TARTRATE
PRIALT, ZICONOTIDE ACETATE
VARUBI, ROLAPITANT HYDROCHLORIDE
XERMELO, TELOTRISTAT ETIPRATE
ZOLADEX, GOSERELIN ACETATE

TETRAPHASE PHARMS

* TETRAPHASE PHARMACEUTICALS INC
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

TEVA

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE
* TEVA PHARMACEUTICALS USA INC
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOR
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLARITHROMYCIN, CLARITHROMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC

CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRELONE, PREDNISOLONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
AUSTEDO, DEUTETRABENAZINE
CONDYLOX, PODOFILOX
EMLA, LIDOCAINE
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOSEASONIQUE, ETHINYL ESTRADIOL
MICROZIDE, HYDROCHLOROTHIAZIDE
NOR-QD, NORETHINDRONE
PROAIR DIGIHALER, ALBUTEROL SULFATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROGLYCEM, DIAZOXIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QUARTETTE, ETHINYL ESTRADIOL
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
ARMONAIR DIGIHALER, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS DEVELOPMENT INC
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
PYRIMETHAMINE, PYRIMETHAMINE

* TEVA PHARMACEUTICALS USA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LANSOPRAZOLE, LANSOPRAZOLE
LETROZOLE, LETROZOLE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL
VANDAZOLE, METRONIDAZOLE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
SYNRIBO, OMACETAXINE MEPESUCCINATE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACITRETIN, ACITRETIN
ADENOSINE, ADENOSINE
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BEXAROTENE, BEXAROTENE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUDESONIDE, BUDESONIDE
CLARAVIS, ISOTRETINOIN
CLOZAPINE, CLOZAPINE
COPAXONE, GLATIRAMER ACETATE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LOGILIA, ULIPRISTAL ACETATE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUNITINIB MALATE, SUNITINIB MALATE
TADALAFIL, TADALAFIL
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TREPROSTINIL, TREPROSTINIL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VIGABATRIN, VIGABATRIN
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZANOSAR, STREPTOZOCIN

* TEVA PHARMACEUTICALS USA INC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALYQ, TADALAFIL
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
DAPTOMYCIN, DAPTOMYCIN
DARUNAVIR, DARUNAVIR
DEFERASIROX, DEFERASIROX
EFINACONAZOLE, EFINACONAZOLE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
ESTRADIOL, ESTRADIOL
EVEROLIMUS, EVEROLIMUS
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
ICATIBANT ACETATE, ICATIBANT ACETATE
IVERMECTIN, IVERMECTIN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MESALAMINE, MESALAMINE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METRONIDAZOLE, METRONIDAZOLE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ONSURA, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
TOBRAMYCIN, TOBRAMYCIN
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
CHLORZOXAZONE, CHLORZOXAZONE
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FULVESTRANT, FULVESTRANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
MIFEPRISTONE, MIFEPRISTONE
POTASSIUM CITRATE, POTASSIUM CITRATE
ROMIDEPSIN, ROMIDEPSIN
TIOPRONIN, TIOPRONIN

TG THERAPS
* TG THERAPEUTICS INC
UKONIQ, UMBRALISIB TOSYLATE

THE FEINSTEIN INST
* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THEPHARMANETWORK LLC
* THEPHARMANETWORK LLC
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERAPEUTICSMD INC
* THERAPEUTICSMD INC
ANNOVERA, ETHINYL ESTRADIOL
BIJUVA, ESTRADIOL
IMVEXXY, ESTRADIOL

TIANJIN TIANYAO
* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
CELECOXIB, CELECOXIB
METHYLPREDNISOLONE, METHYLPREDNISOLONE

TIME-CAP LABS INC
* TIME-CAP LABORATORIES INC
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

TOLMAR
* TOLMAR INC
AZELAIC ACID, AZELAIC ACID
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
* TOLMAR INTERNATIONAL LTD
FENSOLVI KIT, LEUPROLIDE ACETATE

TOLMAR THERAP
* TOLMAR THERAPEUTICS INC
ELIGARD KIT, LEUPROLIDE ACETATE

TOPROL
* TOPROL ACQUISITION LLC
TOPROL-XL, METOPROLOL SUCCINATE

TORPHARM
* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT
* TORRENT PHARMA INC
APREPITANT, APREPITANT
ERYTHROMYCIN, ERYTHROMYCIN
LACTULOSE, LACTULOSE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
* TORRENT PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TORRENT PHARMACEUTICALS LTD
ARIPIPRAZOLE, ARIPIPRAZOLE
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GATIFLOXACIN, GATIFLOXACIN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
ROFLUMILAST, ROFLUMILAST
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LTD
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE

TRAVERE

* TRAVERE THERAPEUTICS INC
CHOLBAM, CHOLIC ACID

TREVENA

* TREVENA INC
OLINVYK, OLICERIDINE

TRIPOINT

* TRIPOINT THERAPEUTICS
ELEPSIA XR, LEVETIRACETAM

TRIS PHARMA INC

* TRIS PHARMA INC
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TRIS PHARMA INC
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DROXIDOPA, DROXIDOPA
DYANAVEL XR 10, AMPHETAMINE
DYANAVEL XR 15, AMPHETAMINE
DYANAVEL XR 20, AMPHETAMINE
DYANAVEL XR 5, AMPHETAMINE
DYANAVEL XR, AMPHETAMINE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA
* TRUSTEES OF THE UNIV OF PENNSYLVANIA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TULEX PHARMS INC
* TULEX PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

TWI PHARMS
* TWI PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
NIFEDIPINE, NIFEDIPINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE, TESTOSTERONE

TWI PHARMS INC
* TWI PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** U ****

UBI
* UBI PHARMA INC
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE

UCB INC
* UCB INC
BRIVIACT, BRIVARACETAM
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
NAYZILAM, MIDAZOLAM
NEUPRO, ROTIGOTINE
VIMPAT, LACOSAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** U **

UCLA BIOMEDICAL

* UCLA BIOMEDICAL CYCLOTRON
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM

* UCSF RADIOPHARMACEUTICAL FACILITY
  AMMONIA N 13, AMMONIA N-13
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UIHC PET IMAGING

* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
  FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
  GALLIUM DOTATOC GA 68, GALLIUM DOTATOC GA-68

ULTRAGENYX PHARM INC

* ULTRAGENYX PHARMACEUTICAL INC
  DOJOLVI, TRIHEPTANOIN

UMEDICA LABS PVT LTD

* UMEDICA LABORATORIES PRIVATE LTD
  ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
  CARBAMAZEPINE, CARBAMAZEPINE
  CELECOXIB, CELECOXIB
  CHLORTHALIDONE, CHLORTHALIDONE
  OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
  SILDENAFIL CITRATE, SILDENAFIL CITRATE
  TADALAFIL, TADALAFIL

UNICHEM

* UNICHEM LABORATORIES LTD
  ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
  ALLOPURINOL, ALLOPURINOL
  AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
  AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
  AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
  ARIPIPRAZOLE, ARIPIPRAZOLE
  ATENOLOL AND CHLORTHALIDONE, ATENOLOL
  ATENOLOL, ATENOLOL
  BACLOFEN, BACLOFEN
  BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
  BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
  BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
  CELECOXIB, CELECOXIB
  CHLORTHALIDONE, CHLORTHALIDONE
  CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
  CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
  GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
  HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  IRBESARTAN, IRBESARTAN
  LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
  LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
  MELOXICAM, MELOXICAM
  MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
  METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
  METRONIDAZOLE, METRONIDAZOLE
  MONTELUKAST SODIUM, MONTELUKAST SODIUM
  PIROXICAM, PIROXICAM
  QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
  RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
  SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
  TADALAFIL, TADALAFIL
  TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
  TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
  ZALEPLON, ZALEPLON
  ZONISAMIDE, ZONISAMIDE

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* UNICHEM LABORATORIES LTD
LAMOTRIGINE, LAMOTRIGINE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM

* UNIQUE PHARMACEUTICAL LABORATORIES
CARBAMAZEPINE, CARBAMAZEPINE
LORATADINE, LORATADINE (OTC)

UNIQUE PHARM LABS

* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TINIDAZOLE, TINIDAZOLE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO, TREPROSTINIL

UNIV CA LOS ANGELES

* UNIV CALIFORNIA LOS ANGELES
GALLIUM GA 68 PSMA-11, GALLIUM GA-68 PSMA-11

UNIV MICHIGAN

* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV OF CA SAN FRAN

* UNIV OF CALIFORNIA SAN FRANCISCO
GALLIUM GA 68 PSMA-11, GALLIUM GA-68 PSMA-11

UNIV SOUTHERN CA

* UNIV SOUTHERN CALIFORNIA DBA USC MOLECULAR IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX SW MEDCTR

* UNIV TEXAS SOUTHWESTERN MEDCTR
AMMONIA N 13, AMMONIA N-13

UNIV UTAH CYCLOTRON

* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

UNIV WISCONSIN

* UNIV WISCONSIN SYSTEM
AMMONIA N 13, AMMONIA N-13

UPJOHN

* UPJOHN MANUFACTURING IRELAND UNLTD
LIPITOR, ATORVASTATIN CALCIUM
RELPAX, ELETRIPTAN HYDROBROMIDE

* UPJOHN US 1 LLC
CARDURA XL, DOXAZOSIN MESYLATE
CARDURA, DOXAZOSIN MESYLATE
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORVASC, AMLODIPINE BESYLATE
REVATIO, SILDENAFIL CITRATE
VIAGRA, SILDENAFIL CITRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE

* UPJOHN US 2 LLC
CELEBREX, CELECOXIB
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
INSPRA, EPLERENONE
LYRICA CR, PREGABALIN
LYRICA, PREGABALIN
XALATAN, LATANOPROST
XANAX XR, ALPRAZOLAM
XANAX, ALPRAZOLAM

UPSHER SMITH LABS

* UPSHER SMITH LABORATORIES LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BEXAROTENE, BEXAROTENE
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ETHACRYNIC ACID, ETHACRYNIC ACID
EXEMESTANE, EXEMESTANE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
HALOPERIDOL, HALOPERIDOL
ISOTRETINOIN, ISOTRETINOIN
JANTOVEN, WARFARIN SODIUM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER SMITH LABORATORIES LLC
PACERONE, AMIODARONE HYDROCHLORIDE
PREVALITE, CHOLESTYRAMINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUDEXY XR, TOPIRAMATE
SILODOSIN, SILODOSIN
SORINE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TOSYMRA, SUMATRIPTAN
VOGELXO, TESTOSTERONE
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE

UROGEN PHARMA
* UROGEN PHARMA LTD
JELMYTO, MITOMYCIN

UROVANT
* UROVANT SCIENCES GMBH
GEMTESA, VIBEGRON

US ANTIBIOTICS
* US ANTIBIOTICS LLC
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
LAROTID, AMOXICILLIN

USPHARMA
* USPHARMA LTD
NITRO-DUR, NITROGLYCERIN

USPHARMA WINDLAS
* USPHARMA WINDLAS LLC
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
PRASUGREL, PRASUGREL HYDROCHLORIDE

USV
* USV PRIVATE LTD
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ZOLEDRONIC ACID, ZOLEDRONIC ACID

USWM
* USWM LLC
CORGARD, NADOLOL
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

**** V ****

VALEANT
* VALEANT PHARMACEUTICALS INTERNATIONAL
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MYSOLINE, PRIMIDONE

VALEANT BERMUDA
* VALEANT INTERNATIONAL BERMUDA
PENLAC, CICLOPIROX
RETIN-A, TRETINOIN

VALEANT INTL
* VALEANT INTERNATIONAL BARBADOS SRL
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
* VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG
* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE

VALEANT PHARMS

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
CUPRIMINE, PENICILLAMINE
LACRISERT, HYDROXYPROPYL CELLULOSE
TIMOPTIC, TIMOLOL MALEATE

VALEANT PHARMS LLC

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
CARAC, FLUOROURACIL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
NIFEDIPINE, NIFEDIPINE
NORITATE, METRONIDAZOLE
RENOVA, TRETINOIN
RETIN-A, TRETINOIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
ANZEMET, DOLASETRON MESYLATE
BUMEX, BUMETANIDE
DRISDOL, ERGOCALCIFEROL
EQUETRO, CARBAMAZEPINE
LASIX, FUROSEMIDE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

* VALIDUS PHARMACEUTICALS INC
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

* VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ LQ, TASIMELTEON
HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC

* VELOXIS PHARMACEUTICALS INC
ENVARSUS XR, TACROLIMUS

VERITY

* VERITY PHARMACEUTICALS INC
TRELSTAR, TRIPTORELIN PAMOATE

VERO BIOTECH

* VERO BIOTECH
GENOSYL, NITRIC OXIDE

VEROSCIENCE

* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERTEX PHARMS

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR
SYMDEKO (COPACKAGED), IVACAFTOR
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR

VERTICAL PHARMS LLC

* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VERU

* VERU INC
ENTADFI, FINASTERIDE

VGYAAN

* VGYAAN PHARMACEUTICALS LLC
CARBAMAZEPINE, CARBAMAZEPINE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
NADOLOL, NADOLOL
URSODIOL, URSODIOL

VICURON HOLDINGS

* VICURON HOLDINGS LLC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS

* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, FERRIC OXYHYDROXIDE

VIFOR PHARMA

* VIFOR PHARMA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

VIIV HLTHCARE

* VIIV HEALTHCARE CO
APRETUDE, CABOTEGRAVIR
CABENUVA KIT, CABOTEGRAVIR
COMBIVIR, LAMIVUDINE
DOVATO, DOLUTEGRAVIR SODIUM
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
JULUCA, DOLUTEGRAVIR SODIUM
LEXIVA, FOSAMPRENAVIR CALCIUM
RETROVIR, ZIDOVUDINE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
SELZENTRY, MARAVIROC
TIVICAY PD, DOLUTEGRAVIR SODIUM
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
VOCABRIA, CABOTEGRAVIR SODIUM
ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
DUTASTERIDE, DUTASTERIDE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
KIMIDESS, DESOGESTREL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
IBUPROFEN, IBUPROFEN (OTC)
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PERPHENAZINE, PERPHENAZINE
PREDNISONE, PREDNISONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

VINTAGE PHARMS LLC
* VINTAGE PHARMACEUTICALS LLC
FELODIPINE, FELODIPINE
MYZILRA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL

VIRTUS PHARM
* VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

VIRTUS PHARMS
* VIRTUS PHARMACEUTICALS LLC
DAPSONE, DAPSONE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROMETRIUM, PROGESTERONE

VISTA PHARMS
* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM
* VISTAPHARM INC
ACYCLOVIR, ACYCLOVIR
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ARIPIPRAZOLE, ARIPIPRAZOLE
CHLORTHALIDONE, CHLORTHALIDONE
CLOBAZAM, CLOBAZAM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
THYQUIDITY, LEVOTHYROXINE SODIUM

VISUM PHARM
* VISUM PHARMACEUTICAL CO LTD
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

VITRUVIAS THERAP
* VITRUVIAS THERAPEUTICS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
* VITRUVIAS THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
LIDOCAINE, LIDOCAINE

VIVUS
* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

VIWIT PHARM
* VIWIT PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

VKT PHARMA
* VKT PHARMA PRIVATE LTD
FAMOTIDINE, FAMOTIDINE
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TADALAFIL, TADALAFIL

VPI PHARMS INC
* VPI PHARMACEUTICALS INC
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM

VPNA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

VYERA PHARMS LLC

* VYERA PHARMACEUTICALS LLC
DARAPRIM, PYRIMETHAMINE

VYNE

* VYNE PHARMACEUTICALS INC
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
ZILXI, MINOCYCLINE HYDROCHLORIDE

**** W ****

WA UNIV SCH MED

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
RAMIPRIL, RAMIPRIL
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC

* WATSON LABORATORIES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
BOSENTAN, BOSENTAN
BRINZOLAMIDE, BRINZOLAMIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
COLCHICINE, COLCHICINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PENICILLAMINE, PENICILLAMINE
PERPHENAZINE, PERPHENAZINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPOFOL, PROPOFOL
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALVIMOPAN, ALVIMOPAN
BICALUTAMIDE, BICALUTAMIDE
BUPRENORPHINE, BUPRENORPHINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
GLIPIZIDE, GLIPIZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ISRADIPINE, ISRADIPINE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PROBENECID, PROBENECID
SIMVASTATIN, SIMVASTATIN
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WATSON PHARMS INC

* WATSON PHARMACEUTICALS INC
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WAYLIS THERAP

* WAYLIS THERAPEUTICS LLC
FLUTAMIDE, FLUTAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

WELLSTAT THERAP
* WELLSTAT THERAPEUTICS CORP
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

WES PHARMA INC
* WES PHARMA INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

WEST WARD
* WEST WARD PHARMACEUTICAL CORP
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP
* WEST WARD PHARMACEUTICAL CORP
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARMS INT
* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIGOXIN, DIGOXIN
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
PENTOSTATIN, PENTOSTATIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, FERRIC OXYHYDROXIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOTEPA, THIOTEPA

WESTMINSTER PHARMS
* WESTMINSTER PHARMACEUTICALS LLC
EPLERENONE, EPLERENONE

WILSHIRE PHARMS INC
* WILSHIRE PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
PERPHENAZINE, PERPHENAZINE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

WINDER LABS LLC
* WINDER LABORATOIRIES LLC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

WISCONSIN
* WISCONSIN MEDICAL RADIOPHARMACY LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WOCKHARDT
* WOCKHARDT LTD
AZITHROMYCIN, AZITHROMYCIN
CEFTRIAXONE, CEFTRIAXONE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WOCKHARDT LTD
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FAMOTIDINE, FAMOTIDINE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVETIRACETAM, LEVETIRACETAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

WOCKHARDT BIO AG

* WOCKHARDT BIO AG
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ACETIC ACID, ACETIC ACID, GLACIAL
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BROMFED-DM, BROMPHENIRAMINE MALEATE
CARBAMAZEPINE, CARBAMAZEPINE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOSPORINE, CYCLOSPORINE
DECITABINE, DECITABINE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MEGESTROL ACETATE, MEGESTROL ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID

WOCKHARDT LTD

* WOCKHARDT LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WOCKHARDT LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ENALAPRIL MALEATE, ENALAPRIL MALEATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)

WOCKHARDT USA

* WOCKHARDT USA INC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
* WOCKHARDT USA LLC
LANSOPRAZOLE, LANSOPRAZOLE

WOODWARD

* WOODWARD PHARMA SERVICES LLC
ACIPHEX, RABEPRAZOLE SODIUM
AVANDIA, ROSIGLITAZONE MALEATE
AVODART, DUTASTERIDE
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
JALYN, DUTASTERIDE
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MIVACURIUM CHLORIDE, MIVACURIUM CHLORIDE

WRASER PHARMS

* WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WUSM CYCLOTRON

* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS

* WYETH PHARMACEUTICALS LLC
DUAVEE, BAZEDOXIFENE ACETATE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM

**** X ****

XELLIA PHARMS APS

* XELLIA PHARMACEUTICALS APS
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN, VANCOMYCIN
VORICONAZOLE, VORICONAZOLE

XERIS

* XERIS PHARMACEUTICALS INC
GVOKE HYPOPEN, GLUCAGON
GVOKE PFS, GLUCAGON
KEVEYIS, DICHLORPHENAMIDE

XGEN PHARMS

* XGEN PHARMACEUTICALS DJB INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** X ****

* XGEN PHARMACEUTICALS DJB INC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DACTINOMYCIN, DACTINOMYCIN
FOLIC ACID, FOLIC ACID
IBUPROFEN LYSINE, IBUPROFEN LYSINE
LEVETIRACETAM, LEVETIRACETAM
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID

XIAMEN LP PHARM CO

* XIAMEN LP PHARMACUETICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

XIROMED

* XIROMED PHARMA ESPANA SL
ACYCLOVIR, ACYCLOVIR
ALTAVERA, ETHINYL ESTRADIOL
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
ESTARYLLA, ETHINYL ESTRADIOL
FLUOCINONIDE, FLUOCINONIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FULVESTRANT, FULVESTRANT
GEMMILY, ETHINYL ESTRADIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
INTROVALE, ETHINYL ESTRADIOL
ISIBLOOM, DESOGESTREL
JAIMIESS, ETHINYL ESTRADIOL
KETOCONAZOLE, KETOCONAZOLE
LANSOPRAZOLE, LANSOPRAZOLE
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LORYNA, DROSPIRENONE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
PROGESTERONE, PROGESTERONE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SYEDA, DROSPIRENONE
TESTOSTERONE, TESTOSTERONE
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL

XSPIRE PHARMA

* XSPIRE PHARMA
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
NALFON, FENOPROFEN CALCIUM
TREZIX, ACETAMINOPHEN
ZONTIVITY, VORAPAXAR SULFATE
* XSPIRE PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** X ****

* XTTRIUM LABORATORIES INC
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

XTTRIUM LABS INC

* XTTRIUM LABORATORIES INC
LACTULOSE, LACTULOSE

**** Y ****

YABAO PHARM

* YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

YANGLING BUCHANG

* YANGLING BUCHANG PHARMACEUTICAL CO LTD
TADALAFIL, TADALAFIL

YAOPHARMA CO LTD

* YAOPHARMA CO LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL

* YICHANG HUMANWELL PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YILING

* YILING PHARMACEUTICAL LTD
ACYCLOVIR, ACYCLOVIR
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
FELODIPINE, FELODIPINE
LAMOTRIGINE, LAMOTRIGINE
LISINOPRIL, LISINOPRIL
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

YOUNGTECH PHARMS INC

* YOUNGTECH PHARMACEUTICALS INC
METOPROLOL TARTRATE, METOPROLOL TARTRATE

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
ENTECAVIR, ENTECAVIR
FELODIPINE, FELODIPINE
MELOXICAM, MELOXICAM

**** Z ****

ZAMBON SPA

* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZEALAND PHARMA

* ZEALAND PHARMA US INC
ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE

ZENNOVA

* ZENNOVA PHARMACEUTICALS CHENGDU CO LTD
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

ZHEJIANG HISUN PHARM
* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZHEJIANG JINGXIN
* ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM

ZHEJIANG JUTAI PHARM
* ZHEJIANG JUTAI PHARMACEUTICAL CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

ZHEJIANG YONGTAI
* ZHEJIANG YONGTAI PHARMACEUTICAL CO LTD
GABAPENTIN, GABAPENTIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ZIONEXA
* ZIONEXA US CORP
CERIANNA, FLUOROESTRADIOL F-18

ZOGENIX INC
* ZOGENIX INC
FINTEPLA, FENFLURAMINE HYDROCHLORIDE

ZYDUS
* ZYDUS WORLDWIDE DMCC
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
URSODIOL, URSODIOL

ZYDUS HLTHCARE
* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS NOVELTECH INC
* ZYDUS NOVELTECH INC
RIVASTIGMINE, RIVASTIGMINE

ZYDUS PHARMS
* ZYDUS PHARMACEUTICALS USA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
APREMILAST, APREMILAST
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BOSENTAN, BOSENTAN
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENTECAVIR, ENTECAVIR
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
EZETIMIBE, EZETIMIBE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LINEZOLID, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NELARABINE, NELARABINE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PERPHENAZINE, PERPHENAZINE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RAMELTEON, RAMELTEON
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIROLIMUS, SIROLIMUS
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TADALAFIL, TADALAFIL
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOFACITINIB, TOFACITINIB CITRATE
TOPIRAMATE, TOPIRAMATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
VORTIOXETINE HYDROBROMIDE, VORTIOXETINE HYDROBROMIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
RISPERIDONE, RISPERIDONE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

ZYDUS PHARMS USA INC

* ZYDUS PHARMACEUTICALS USA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CARVEDILOL, CARVEDILOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OMEPRAZOLE, OMEPRAZOLE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYLA

* ZYLA LIFE SCIENCES US INC
OXAYDO, OXYCODONE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE
ZORVOLEX, DICLOFENAC

APPENDIX C

UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM
AEROSOL, METERED
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CAPSULE, PELLETS
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
CREAM, INSERT
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOAM
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GRANULES
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INJECTION, EXTENDED RELEASE
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
PELLETS
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, EXTENDED RELEASE
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION, LIPOSOMAL
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
TABLET
TABLET, CHEWABLE
TABLET, DELAYED RELEASE
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, EXTENDED RELEASE, CHEWABLE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ROUTES OF ADMINISTRATION

BUCCAL
DENTAL
ENDOCERVICAL
ENDOTRACHEAL
ENTERAL
IMPLANTATION
INHALATION
INJECTION
INTERSTITIAL
INTRA-ANAL
INTRA-ARTERIAL
INTRA-ARTICULAR
INTRACAVITARY
INTRACRANIAL
INTRADERMAL
INTRAMUSCULAR
INTRAOCULAR
INTRAOSSEOUS
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
INTRAVESICULAR
INTRAVITREAL
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION, CARDIAC
PERIARTICULAR
PERIODONTAL
PYELOCALYCEAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TRANSDERMAL
TRANSMUCOSAL
URETHRAL
VAGINAL

Note: Terms comprise currently marketed products

APPENDIX C

UNIFORM TERMS

ABBREVIATIONS

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

This *Addendum* identifies:

- Drugs approved under section 505(c) of the FD&C Act that have qualified under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for five-year and three-year periods of exclusivity pursuant to Section 505(c)(3)(E) and Section 505(j)(5)(F) of the FD&C Act
- Drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act
- Drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act
- Drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for 180-day exclusivity pursuant to Section 505(j)(5)(B)(iv) of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act

This section is arranged in alphabetical order by established name of the active ingredient, followed by the proprietary name (brand name or trade name) of the drug product. Active ingredient headings for multiple active ingredient, fixed-combination drug products are arranged alphabetically.

Individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. Such descriptions of Orphan Drug Exclusivity were included beginning with the 38th edition of the Orange Book. The ODE* code means that the timing of approval of certain follow-on applications may be subject to delay due to ODE for another drug that has the same active moiety.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. In addition, patent information must be filed on Form FDA 3542 within 30 days of the date of approval of a Section 505(b) drug application.[1] FDA publishes certain information from Form FDA 3542 in the Orange Book after approval of the new drug application (NDA) or supplement.

The Orange Book includes the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b)(2) application or abbreviated new drug application (ANDA).[2]

The patents that FDA regards as covered by the statutory provisions for submission of patent information for listing in the Orange Book are:

- Patents that claim the drug for which the applicant submitted the application and are drug substance (active ingredient) patents or drug product (formulation or composition) patents; or
- Patents that claim a method of using such drug for which approval has been granted in the application.

This information, as provided by the NDA holder on Form FDA 3542, will be published as described above. An NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the Annual Edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Orange Book, updated regularly, should be consulted for the most recent patent and exclusivity information.

[1] Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x)(1) and (2) of the FD&C Act).

[2] See 21 CFR 314.50(i)(4) and 314.94(a)(12)(vi). The submission date for patent information is determined in accordance with 21 CFR 314.53(d)(5).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ						
N 205551 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
ABALOPARATIDE - TYMLOS						
N 208743 001	10996208	Apr 30, 2038	DP		M-270	Sep 20, 2024
	7803770	Apr 28, 2031	U-2009		NCE	Apr 28, 2022
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
ABAMETAPIR - XEGLYZE						
N 206966 001	10292389	Dec 17, 2034	DP U-2863		NCE	Jul 24, 2025
	7812163	Oct 28, 2026	DP U-2863			
	8212038	Jul 16, 2024	DP U-2863			
	9357783	Jul 16, 2024	DP			
	9839631	Jul 16, 2024	DS DP U-2863			
ABEMACICLIB - VERZENIO						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2251		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
ABEMACICLIB - VERZENIO						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2251		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
ABEMACICLIB - VERZENIO						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2251		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
ABEMACICLIB - VERZENIO						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2132		NCE	Sep 28, 2022
	7855211	Dec 15, 2029	DS DP U-2135		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
ABIRATERONE ACETATE - YONSA						
N 210308 001	10292990	May 20, 2034	U-2535			
	9889144	Mar 17, 2034	DP			
ACALABRUTINIB - CALQUENCE						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-817	Nov 21, 2022
	10167291	Jul 01, 2036	DP U-2666		NCE	Oct 31, 2022
	10167291	Jul 01, 2036	DP U-2667		ODE-175	Oct 31, 2024
	10167291	Jul 01, 2036	DP U-2668		ODE-274	Nov 21, 2026
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10239883	Jul 11, 2032	U-2666			
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACALABRUTINIB - CALQUENCE						
N 210259 001	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
ACETAMINOPHEN - OFIRMEV						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
	9399012	Sep 11, 2031	U-2261			
	9399012	Sep 11, 2031	U-2262			
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028	U-2263			
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028	U-2261			
	9987238*PED	May 13, 2029				
ACETAMINOPHEN - ACETAMINOPHEN						
N 204767 001	8741959	Apr 19, 2030	DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN						
N 211733 001					NP	Feb 28, 2023
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR						
N 204031 001	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
	9468636	May 16, 2032	U-1499			
ACETYLCYSTEINE - ACETADOTE						
N 021539 001	8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025	U-1373			
	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
	9327028	Jul 21, 2031	U-1839			
ACETYLCYSTEINE - CETYLEV						
N 207916 001	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACETYLCYSTEINE - CETYLEV						
N 207916 001	9561204	May 08, 2032	U-1373			
ACETYLCYSTEINE - CETYLEV						
N 207916 002	8747894	May 08, 2032	DP U-1373			
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032	U-1373			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR						
N 202450 001	10085974	Mar 13, 2029	DP U-2513		M-256	Mar 29, 2022
	11000517	Mar 13, 2029	DP U-2513			
	6681768	Aug 07, 2022	DP			
	8051851	Apr 22, 2027	DP			
	RE46417	Feb 10, 2025	DS DP U-2513			
ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR						
N 210595 001	10085974	Mar 13, 2029	DP U-2513		NC	Mar 29, 2022
	11000517	Mar 13, 2029	DP U-2513			
	6681768	Aug 07, 2022	DP			
	8051851	Apr 22, 2027	DP			
	RE46417	Feb 10, 2025	DS DP U-2513			
ACYCLOVIR - AVACLYR						
N 202408 001					ODE-235	Mar 29, 2026
ACYCLOVIR - SITAVIG						
N 203791 001	8592434	Jun 16, 2030	DP U-1460			
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
ACYCLOVIR; HYDROCORTISONE - XERESE						
N 022436 001	7223387	Nov 13, 2022	DP U-1006			
	7223387	Nov 13, 2022	DP U-1484			
ADAPALENE - DIFFERIN						
N 021753 001	7579377	Feb 23, 2025	U-818			
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023	U-1078			
	7838558	Mar 12, 2023	DP			
	7868044	Mar 12, 2023	U-1078			
	8703820	Mar 12, 2023	U-1078			
ADAPALENE - DIFFERIN						
N 022502 001	7998467	May 31, 2028	DP U-1078			
	8435502	Sep 15, 2026	DP U-1078			
	8709392	Sep 15, 2026	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE						
A 209148 001					PC	May 30, 2022
ADAPALENE; BENZOYL PEROXIDE - EPIDUO						
N 022320 001	7820186	Nov 23, 2025	DP			
	7964202	Sep 01, 2024	DP U-1078			
	8071644	Jul 18, 2027	DP U-1078			
	8080537	Jul 18, 2027	U-1078			
	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
	8445543	Jul 12, 2027	U-1078			
	8809305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE						
N 207917 001	8445543	Dec 23, 2022	U-1078			
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8809305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE						
N 207917 001	9814690	Dec 23, 2022	DP U-1078			
AFAMELANOTIDE - SCENESSE						
N 210797 001	10076555	Feb 11, 2025	U-2638		NCE	Oct 08, 2024
	8334265	Mar 11, 2029	U-2638		ODE-270	Oct 08, 2026
AFATINIB DIMALEATE - GILOTRIF						
N 201292 001	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8545884	Dec 19, 2029	DP			
	9539258	Nov 09, 2026	U-1950			
	RE43431	Jan 13, 2026	DS			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 002	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8545884	Dec 19, 2029	DP			
	9539258	Nov 09, 2026	U-1950			
	RE43431	Jan 13, 2026	DS			
AFATINIB DIMALEATE - GILOTRIF						
N 201292 003	10004743	Jul 05, 2030	DP		ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8545884	Dec 19, 2029	DP			
	9539258	Nov 09, 2026	U-1950			
	RE43431	Jan 13, 2026	DS			
AIR POLYMER-TYPE A - EXEM FOAM KIT						
N 212279 001	9034300	Oct 15, 2030	DP U-2663		NCE	Nov 07, 2024
	9259494	May 04, 2035	DP U-2663			
	9849199	Feb 11, 2036	DP			
ALBUTEROL SULFATE - VENTOLIN HFA						
N 020983 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
ALBUTEROL SULFATE - PROAIR HFA						
N 021457 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	7105152	Sep 12, 2023	DP			
	8132712	Sep 07, 2028	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
ALBUTEROL SULFATE - PROAIR RESPICLICK						
N 205636 001	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10765820	May 19, 2025	DP			
	7540282	May 06, 2023	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
ALBUTEROL SULFATE - PROAIR DIGIHALER						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALBUTEROL SULFATE - PROAIR DIGIHALER							
N 205636	002	8651103	Mar 26, 2028	DP			
		8978966	Jan 13, 2032	DP			
		9216260	Jun 28, 2031	DP			
		9463288	May 19, 2025	DP			
		9731087	May 18, 2031	DP			
		9782550	Aug 28, 2035	DP			
		9782551	Aug 28, 2035	DP			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT							
N 021747	001	7284474	Aug 26, 2024	DP			
		7396341	Oct 10, 2026	DP			
		7837235	Mar 13, 2028	DP			
		7896264	May 26, 2025	DP			
		8733341	Oct 16, 2030	DP			
		9027967	Mar 31, 2027	DP			
ALCAFTADINE - LASTACAFT							
N 022134	001	10617695	Mar 19, 2027	DP U-3267			
		8664215	Dec 23, 2027	U-3267			
ALCOHOL - ABLYSINOL							
N 207987	001					ODE-192	Jun 21, 2025
ALCOHOL - ABLYSINOL							
N 207987	002					ODE-192	Jun 21, 2025
ALECTINIB HYDROCHLORIDE - ALECENSA							
N 208434	001	10350214	Apr 24, 2035	DP		ODE-105	Dec 11, 2022
		9126931	May 29, 2031	DS		ODE-159	Nov 06, 2024
		9365514	Mar 04, 2032	DP			
		9440922	Jun 09, 2030	DP			
ALENDRONATE SODIUM - BINOSTO							
N 202344	001	7488496	Aug 11, 2023	DS DP			
		7964212	Mar 06, 2023	DS DP			
		9592195	Dec 05, 2031	DP			
ALISKIREN HEMIFUMARATE - TEKTURNA							
N 021985	001	8617595	Feb 19, 2026	DP			
		8617595*PED	Aug 19, 2026				
ALISKIREN HEMIFUMARATE - TEKTURNA							
N 021985	002	8617595	Feb 19, 2026	DP			
		8617595*PED	Aug 19, 2026				
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	001	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	002	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	003	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N 022545	004	8613949	Dec 21, 2029	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	001	8183295	May 16, 2023	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	002	8183295	May 16, 2023	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	003	8183295	May 16, 2023	DP			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N 200045	004	8183295	May 16, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE								
N	200045	005	8183295	May 16, 2023	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	001	8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	002	8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	003	8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT								
N	022107	004	8618172	Jul 13, 2028	DP			
			9023893	Mar 03, 2022	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N	022217	001	8168616	Jul 03, 2026	DP			
ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA								
N	022217	002	8168616	Jul 03, 2026	DP			
ALLOPURINOL; LESINURAD - DUZALLO								
N	209203	001	10183012	Nov 26, 2028			U-2104	
			8003681	Aug 25, 2025	DS			
			8084483	Aug 17, 2029			U-2104	
			8283369	Nov 26, 2028			U-2104	
			8357713	Nov 26, 2028	DP		U-2104	
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029			U-2104	
			9216179	Aug 01, 2031			U-2104	
			9956205	Dec 28, 2031			U-2104	
ALLOPURINOL; LESINURAD - DUZALLO								
N	209203	002	10183012	Nov 26, 2028			U-2104	
			8003681	Aug 25, 2025	DS			
			8084483	Aug 17, 2029			U-2104	
			8283369	Nov 26, 2028			U-2104	
			8357713	Nov 26, 2028	DP		U-2104	
			8546436	Feb 29, 2032	DS			
			8546437	Apr 29, 2029			U-2104	
			9216179	Aug 01, 2031			U-2104	
			9956205	Dec 28, 2031			U-2104	
ALOGLIPTIN BENZOATE - NESINA								
N	022271	001	7807689	Jun 27, 2028	DS	DP	U-1337	
			8173663	Dec 02, 2025			U-1338	
			8288539	Mar 15, 2025	DS			
			8697125	Jun 16, 2029		DP		
ALOGLIPTIN BENZOATE - NESINA								
N	022271	002	7807689	Jun 27, 2028	DS	DP	U-1337	
			8173663	Dec 02, 2025			U-1338	
			8288539	Mar 15, 2025	DS			
			8697125	Jun 16, 2029		DP		
ALOGLIPTIN BENZOATE - NESINA								
N	022271	003	7807689	Jun 27, 2028	DS	DP	U-1337	
			8173663	Dec 02, 2025			U-1338	
			8288539	Mar 15, 2025	DS			
			8697125	Jun 16, 2029		DP		
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO								
N	203414	001	7807689	Jun 27, 2028	DS	DP	U-1337	
			8173663	Mar 15, 2025			U-1338	
			8288539	Jun 24, 2025	DS			
			8900638	May 24, 2029		DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO							
N 203414	002	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Jun 24, 2025	DS			
		8900638	May 24, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	001	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	002	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	003	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	004	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	005	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	006	7807689	Jun 27, 2028	DS DP U-1337			
		8173663	Mar 15, 2025	U-1338			
		8288539	Mar 15, 2025	DS			
		8637079	Jun 04, 2029	DP			
ALPELISIB - PIQRAY							
N 212526	001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
		8476268	Sep 10, 2029	DS DP			
ALPELISIB - PIQRAY							
N 212526	002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
		8476268	Sep 10, 2029	DS DP			
ALPELISIB - PIQRAY							
N 212526	003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
		8476268	Sep 10, 2029	DS DP			
ALVIMOPAN - ENTEREG							
N 021775	001	8946262	Feb 12, 2030	U-1655			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	001	10154971	Dec 04, 2034	U-2459		ODE-153	Aug 24, 2024
		10646456	Jun 17, 2034	U-2808			
		11065213	Aug 23, 2038	DP			
		11077073	Aug 23, 2038	U-2106			
		11077073	Aug 23, 2038	U-2224			
		11077073	Aug 23, 2038	U-3180			
		11197835	Dec 02, 2030	U-3270			
		8389578	Jan 22, 2028	U-2105			
		8741343	Dec 02, 2030	U-2106			
		8796337	Nov 23, 2025	U-2106			
		8889740	Nov 23, 2025	DP			
		8895614	Nov 23, 2025	DP			
		8895615	Nov 23, 2025	U-2106			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	001	8895616	Nov 23, 2025	U-2106			
		8895617	Nov 23, 2025	U-2106			
		8895618	Nov 23, 2025	DP			
		9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - GOCOVRI							
N 208944	002	10154971	Dec 04, 2034	U-2459		ODE-153	Aug 24, 2024
		10646456	Jun 17, 2034	U-2808			
		11065213	Aug 23, 2038	DP			
		11077073	Aug 23, 2038	U-2106			
		11077073	Aug 23, 2038	U-2224			
		11077073	Aug 23, 2038	U-3180			
		11197835	Dec 02, 2030	U-3270			
		8389578	Jan 22, 2028	U-2105			
		8741343	Dec 02, 2030	U-2106			
		8796337	Nov 23, 2025	U-2106			
		8889740	Nov 23, 2025	DP			
		8895614	Nov 23, 2025	DP			
		8895615	Nov 23, 2025	U-2106			
		8895616	Nov 23, 2025	U-2106			
		8895617	Nov 23, 2025	U-2106			
		8895618	Nov 23, 2025	DP			
		9867791	Dec 02, 2030	U-2106			
		9867792	Dec 02, 2030	U-2106			
		9867793	Dec 02, 2030	U-2106			
		9877933	Dec 02, 2030	U-2224			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	001	10213393	Feb 15, 2038	U-20			
		10213394	Feb 15, 2038	U-2497			
		10500170	Feb 15, 2038	U-20			
		10500171	Feb 15, 2038	U-2497			
		10500172	Feb 15, 2038	U-2497			
		10512617	Feb 15, 2038	U-2497			
		8252331	Mar 13, 2030	DP			
		8389578	Jan 22, 2028	U-219			
		8389578	Jan 22, 2028	U-3054			
		8574626	Nov 28, 2025	DP U-20			
		8796337	Nov 23, 2025	U-219			
		8796337	Nov 23, 2025	U-2497			
		8796337	Nov 23, 2025	U-3054			
		8889740	Nov 23, 2025	DP			
		8895614	Nov 23, 2025	DP			
		8895615	Nov 23, 2025	U-219			
		8895615	Nov 23, 2025	U-3054			
		8895616	Nov 23, 2025	U-219			
		8895616	Nov 23, 2025	U-3054			
		8895617	Nov 23, 2025	U-219			
		8895617	Nov 23, 2025	U-3054			
		8895618	Nov 23, 2025	DP			
		8987333	Nov 23, 2025	DP			
		9072697	Nov 23, 2025	U-219			
		9072697	Nov 23, 2025	U-3054			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER							
N 209410	002	10213393	Feb 15, 2038	U-20			
		10213394	Feb 15, 2038	U-2497			
		10500170	Feb 15, 2038	U-20			
		10500171	Feb 15, 2038	U-2497			
		10500172	Feb 15, 2038	U-2497			
		10512617	Feb 15, 2038	U-2497			
		8252331	Mar 13, 2030	DP			
		8389578	Jan 22, 2028	U-219			
		8389578	Jan 22, 2028	U-3054			
		8574626	Nov 28, 2025	DP U-20			
		8796337	Nov 23, 2025	U-219			
		8796337	Nov 23, 2025	U-2497			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 002	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8574626	Nov 28, 2025	DP U-20			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
AMANTADINE HYDROCHLORIDE - OSMOLEX ER						
N 209410 004	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8574626	Nov 28, 2025	DP U-20			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMBRISENTAN - LETAIRIS							
N 022081	001	8377933	Dec 11, 2027	U-1754			
		9474752	Dec 11, 2027	U-1754			
		9549926	Oct 14, 2031	U-1965			
AMBRISENTAN - LETAIRIS							
N 022081	002	8377933	Dec 11, 2027	U-1754			
		9474752	Dec 11, 2027	U-1754			
		9549926	Oct 14, 2031	U-1965			
AMIFAMPRIDINE - RUZURGI							
N 209321	001					ODE-244	May 06, 2026
AMIFAMPRIDINE PHOSPHATE - FIRDAPSE							
N 208078	001	10793893	Apr 07, 2034	U-2956		NCE	Nov 28, 2023
		11060128	Jun 29, 2032	U-2956		ODE-223	Nov 28, 2025
AMIKACIN SULFATE - ARIKAYCE KIT							
N 207356	001	10251900	May 15, 2035	U-2414		ODE-214	Sep 28, 2025
		10751355	May 15, 2035	U-2414		GAIN	Sep 28, 2030
		7718189	Jun 06, 2025	DP U-2415			
		8226975	Aug 15, 2028	DP			
		8632804	Dec 05, 2026	U-2416			
		8642075	Dec 05, 2026	DP			
		8679532	Dec 05, 2026	U-2415			
		8802137	Apr 08, 2024	DP U-2414			
		9566234	Jan 18, 2034	DP U-2415			
		9827317	Apr 08, 2024	DP U-2415			
		9895385	May 15, 2035	U-2417			
AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN							
N 020965	001	10357567	Jan 12, 2038	U-3163			
		11077192	Jan 12, 2038	U-3163			
		11135293	Jan 12, 2038	U-3163			
AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN							
N 208630	001					ODE-146	Jun 06, 2024
AMIODARONE HYDROCHLORIDE - NEXTERONE							
N 022325	001	6869939	May 04, 2022	DP			
		7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE							
N 022325	002	6869939	May 04, 2022	DP			
		7635773	Mar 13, 2029	DP			
AMIODARONE HYDROCHLORIDE - NEXTERONE							
N 022325	003	6869939	May 04, 2022	DP			
		7635773	Mar 13, 2029	DP			
AMISULPRIDE - BARHEMSYS							
N 209510	001	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
		9084765	Mar 10, 2031	U-1744			
		9084765	Mar 10, 2031	U-2754			
		9545426	Mar 10, 2031	U-1744			
		9545426	Mar 10, 2031	U-2754			
		9889118	Mar 10, 2031	U-1744			
		9889118	Mar 10, 2031	U-2754			
AMLODIPINE BENZOATE - KATERZIA							
N 211340	001	10695329	Oct 16, 2037	DP			
		10799453	Apr 11, 2039	DP			
		10894039	Oct 06, 2037	U-185			
		10894039	Oct 06, 2037	U-3			
		10952998	Oct 06, 2037	DP			
		10959991	Oct 06, 2037	U-158			
		10959991	Oct 06, 2037	U-39			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE							
N 022026	001	6828339	Nov 20, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE							
N 022026	002	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE - AMLODIPINE BESYLATE							
N 022026	003	6828339	Nov 20, 2022	DS			
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	001	10350171	Jun 14, 2038	DP			
		10925835	Jun 14, 2038			U-2410	
		10945960	Jun 14, 2038	DP			
		9408837	Feb 28, 2030			U-2410	
		9662315	May 22, 2029	DP		U-2410	
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	002	10350171	Jun 14, 2038	DP			
		10925835	Jun 14, 2038			U-2410	
		10945960	Jun 14, 2038	DP			
		9408837	Feb 28, 2030			U-2410	
		9662315	May 22, 2029	DP		U-2410	
AMLODIPINE BESYLATE; CELECOXIB - CONSENSI							
N 210045	003	10350171	Jun 14, 2038	DP			
		10925835	Jun 14, 2038			U-2410	
		10945960	Jun 14, 2038	DP			
		9408837	Feb 28, 2030			U-2410	
		9662315	May 22, 2029	DP		U-2410	
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	001	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	002	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	003	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	004	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT							
N 022314	005	8101599	May 16, 2023	DP			
		8475839	May 16, 2023	DP			
		8475839*PED	Nov 16, 2023				
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	001	6696481	Apr 15, 2023	DS DP		U-3	
		7846961	Oct 05, 2029	DS DP		U-3	
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	002	6696481	Apr 15, 2023	DS DP		U-3	
		7846961	Oct 05, 2029	DS DP		U-3	
AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA							
N 205003	003	6696481	Apr 15, 2023	DS DP		U-3	
		7846961	Oct 05, 2029	DS DP		U-3	
AMOXICILLIN - MOXATAG							
N 050813	001	8299052	May 07, 2027			U-1304	
		8357394	Dec 08, 2026	DP			
		8778924	Dec 08, 2026	DS DP		U-897	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA								
N 213004	001		10238606	Feb 12, 2034	DP			
			11135172	Feb 12, 2034	DP U-2660			
			9050263	Feb 12, 2034	DP U-2660			
			9498445	Feb 12, 2034	DP U-2660			
			9603806	Feb 12, 2034	DP U-2660			
AMPHETAMINE - ADZENYS ER								
N 204325	001		8709491	Jun 28, 2032	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	001		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	002		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	003		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	004		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	005		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE - ADZENYS XR-ODT								
N 204326	006		8709491	Jun 28, 2032	DP			
			8840924	Apr 09, 2026	DP			
			9017731	Jun 28, 2032	DP			
			9265737	Jun 28, 2032	DP			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N 022063	001		6913768	May 24, 2023	DP U-2025		M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		PED	Mar 13, 2023
			9173857	May 12, 2026	U-2025			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N 022063	002		6913768	May 24, 2023	DP U-2025		M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		PED	Mar 13, 2023
			9173857	May 12, 2026	U-2025			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N 022063	003		6913768	May 24, 2023	DP U-2025		M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		PED	Mar 13, 2023
			9173857	May 12, 2026	U-2025			
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS								
N 022063	004		6913768	May 24, 2023	DP U-2025		M-248	Sep 13, 2022
			8846100	Aug 24, 2029	DP		PED	Mar 13, 2023
			9173857	May 12, 2026	U-2025			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE SULFATE - EVEKEO ODT								
N 209905	001		10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N 209905	002		10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N 209905	003		10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N 209905	004		10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE SULFATE - EVEKEO ODT								
N 209905	005		10130580	Apr 19, 2024	DP			
			10441554	Mar 10, 2037	DP			
			11160772	Mar 10, 2037	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR								
N 208147	001		10086087	Mar 15, 2027	DP			
			8062667	Mar 29, 2029	DP			
			8597684	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			8883217	Mar 15, 2027	DP			
			9675703	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5								
N 210526	001		8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10								
N 210526	002		8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15								
N 210526	003		8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			
AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20								
N 210526	004		8337890	Mar 15, 2027	DP			
			8747902	Mar 15, 2027	DP			
			9675704	Mar 15, 2027	DP			
ANGIOTENSIN II ACETATE - GIAPREZA								
N 209360	001		10028995	Dec 18, 2034	U-2338		NCE	Dec 21, 2022
			10335451	Dec 16, 2029	U-2581			
			10493124	Dec 18, 2034	U-2679			
			10500247	Dec 16, 2029	U-2680			
			10500247	Dec 16, 2029	U-2681			
			10548943	Dec 16, 2029	U-2739			
			10548943	Dec 16, 2029	U-2740			
			11096983	Dec 18, 2034	U-3211			
			11096983	Dec 18, 2034	U-3212			
			11219662	Jan 06, 2037	U-3262			
			9220745	Dec 18, 2034	U-2217			
			9220745	Dec 18, 2034	U-2218			
			9572856	Jul 18, 2031	U-2221			
			9867863	Dec 16, 2029	U-2231			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 002	10028995	Dec 18, 2034	U-2338		NCE	Dec 21, 2022
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Nov 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
ANGIOTENSIN II ACETATE - GIAPREZA						
N 209360 003	11219662	Jan 06, 2037	U-3262		NCE	Dec 21, 2022
ANIDULAFUNGIN - ERAXIS						
N 021632 001					NPP	Sep 22, 2023
ANIDULAFUNGIN - ERAXIS						
N 021632 002					NPP	Sep 22, 2023
APALUTAMIDE - ERLEADA						
N 210951 001	10052314	Sep 23, 2033	U-2381		I-808	Sep 17, 2022
	10052314	Sep 23, 2033	U-2382		NCE	Feb 14, 2023
	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
APIXABAN - ELIQUIS						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	9326945	Feb 24, 2031	DP			
APIXABAN - ELIQUIS						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	9326945	Feb 24, 2031	DP			
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 001	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APOMORPHINE HYDROCHLORIDE - KYNMOBI							
N 210875	001	9283219	Jun 11, 2030	DP U-2825			
		9326981	Jun 11, 2030	U-2825			
		9669019	Jun 11, 2030	DP U-2825			
		9669021	Jun 11, 2030	U-2825			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
APOMORPHINE HYDROCHLORIDE - KYNMOBI							
N 210875	002	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825			
		10821074	Aug 07, 2029	DP			
		10888499	Feb 14, 2022	DP			
		10959943	Apr 19, 2036	U-2825			
		11077068	Feb 14, 2022	DP			
		8414922	Dec 16, 2031	DP U-2825			
		8603514	Apr 03, 2024	DP			
		8663687	Feb 02, 2023	DP			
		8765167	Feb 20, 2024	DP			
		8846074	Dec 16, 2031	DP U-2825			
		9044475	Jun 11, 2030	DP			
		9283219	Jun 11, 2030	DP U-2825			
		9326981	Jun 11, 2030	U-2825			
		9669019	Jun 11, 2030	DP U-2825			
		9669021	Jun 11, 2030	U-2825			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
APOMORPHINE HYDROCHLORIDE - KYNMOBI							
N 210875	003	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825			
		10821074	Aug 07, 2029	DP			
		10888499	Feb 14, 2022	DP			
		10959943	Apr 19, 2036	U-2825			
		11077068	Feb 14, 2022	DP			
		8414922	Dec 16, 2031	DP U-2825			
		8603514	Apr 03, 2024	DP			
		8663687	Feb 02, 2023	DP			
		8765167	Feb 20, 2024	DP			
		8846074	Dec 16, 2031	DP U-2825			
		9044475	Jun 11, 2030	DP			
		9283219	Jun 11, 2030	DP U-2825			
		9326981	Jun 11, 2030	U-2825			
		9669019	Jun 11, 2030	DP U-2825			
		9669021	Jun 11, 2030	U-2825			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
APOMORPHINE HYDROCHLORIDE - KYNMOBI							
N 210875	004	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
		10449146	Apr 19, 2036	U-2825			
		10821074	Aug 07, 2029	DP			
		10888499	Feb 14, 2022	DP			
		10959943	Apr 19, 2036	U-2825			
		11077068	Feb 14, 2022	DP			
		8414922	Dec 16, 2031	DP U-2825			
		8603514	Apr 03, 2024	DP			
		8663687	Feb 02, 2023	DP			
		8765167	Feb 20, 2024	DP			
		8846074	Dec 16, 2031	DP U-2825			
		9044475	Jun 11, 2030	DP			
		9283219	Jun 11, 2030	DP U-2825			
		9326981	Jun 11, 2030	U-2825			
		9669019	Jun 11, 2030	DP U-2825			
		9669021	Jun 11, 2030	U-2825			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APOMORPHINE HYDROCHLORIDE - KYNMOBI						
N 210875 005	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
	9855221	Feb 14, 2022	DP			
	9931305	Feb 14, 2022	DP			
APREMILAST - OTEZLA						
N 205437 001	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA						
N 205437 002	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREMILAST - OTEZLA						
N 205437 002	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREMILAST - OTEZLA						
N 205437 003	10092541	May 29, 2034	U-2403		I-803	Jul 19, 2022
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2657			
	6962940	Mar 19, 2023	U-2658			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2657			
	7659302	Mar 19, 2023	U-2658			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2657			
	8455536	Mar 19, 2023	U-2658			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2657			
	9018243	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2657			
	9724330	Mar 19, 2023	U-2658			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
APREPITANT - EMEND						
N 021549 001	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 021549 002	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 021549 003	8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
APREPITANT - EMEND						
N 207865 001	8258132	Sep 26, 2027	DP U-1916			
APREPITANT - CINVANTI						
N 209296 001	10500208	Sep 18, 2035	DP			
	10624850	Sep 18, 2035	U-2161			
	10953018	Sep 18, 2035	U-2161			
	11173118	Sep 18, 2035	DP			
	9561229	Sep 18, 2035	DP U-2161			
	9808465	Sep 18, 2035	U-2161			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
APREPITANT - CINVANTI						
N 209296 001	9974794	Sep 18, 2035	DP		U-2161	
ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE						
N 022434 001	7589106	Sep 26, 2027	DP		U-1163	
	7687516	Sep 26, 2027	DP		U-1164	
ARIPIPRAZOLE - ABILIFY						
N 021436 001	7053092	Jan 28, 2022			U-839	
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022			U-1492	
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027			U-1529	
	9089567	Jan 28, 2022			U-543	
	9125939	Jul 28, 2026			U-1749	
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023			U-1529	
ARIPIPRAZOLE - ABILIFY						
N 021436 002	7053092	Jan 28, 2022			U-839	
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022			U-1492	
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027			U-1529	
	9089567	Jan 28, 2022			U-543	
	9125939	Jul 28, 2026			U-1749	
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023			U-1529	
ARIPIPRAZOLE - ABILIFY						
N 021436 003	7053092	Jan 28, 2022			U-839	
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022			U-1492	
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027			U-1529	
	9089567	Jan 28, 2022			U-543	
	9125939	Jul 28, 2026			U-1749	
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023			U-1529	
ARIPIPRAZOLE - ABILIFY						
N 021436 004	7053092	Jan 28, 2022			U-839	
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022			U-1492	
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027			U-1529	
	9089567	Jan 28, 2022			U-543	
	9125939	Jul 28, 2026			U-1749	
	9359302	Sep 25, 2022	DS DP		U-1859	
	9387182	Dec 25, 2023			U-1529	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 005	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 006	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021713 001	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
	7053092	Jan 28, 2022	U-839			
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 002	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 003	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9089567	Jan 28, 2022	U-543			
	9125939	Jul 28, 2026	U-1749			
	9359302	Sep 25, 2022	DS DP U-1859			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021729 003	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 004	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021729 005	7053092	Jan 28, 2022	U-839			
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	9359302	Sep 25, 2022	DS DP U-1859			
	9387182	Dec 25, 2023	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021866 001	7115587	Jul 21, 2024	DP U-764			
	7115587*PED	Jan 21, 2025				
	7550445	Jul 21, 2024	DP			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 002	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022	U-1529			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 001	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022			U-1529	
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022			U-1529	
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 003	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022			U-1529	
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022			U-1529	
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP		U-2170	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 005	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE - ABILIFY MYCITE KIT						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	7053092	Jan 28, 2022			U-1529	
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP		U-2167	
	8580796	Sep 25, 2022	DS			
	8642760	Sep 25, 2022	DS			
	8674825	Apr 09, 2029	DP		U-2170	
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027			U-1529	
	8847766	Mar 29, 2030	DP		U-2167	
	8945005	Aug 19, 2029	DP		U-2167	
	8956288	Jul 06, 2029	DP		U-2167	
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9089567	Jan 28, 2022			U-543	
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026			U-1749	
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP		U-2168	
	9320455	Dec 15, 2031	DP			
	9359302	Sep 25, 2022	DS DP		U-1529	
	9359302	Sep 25, 2022	DS DP		U-1749	
	9359302	Sep 25, 2022	DS DP		U-543	
	9387182	Dec 25, 2023			U-1529	
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP		U-2169	
	9941931	Nov 04, 2030	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 001	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 002	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 003	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2402	
	11097006	Oct 24, 2033	DP		U-764	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
	9526726	Mar 19, 2035	DP			
ARIPIPRAZOLE LAUROXIL - ARISTADA						
N 207533 004	10112903	Jun 24, 2030	DS		U-543	
	10226458	Mar 19, 2032			U-543	
	10238651	Mar 19, 2035			U-2402	
	10813928	Mar 19, 2035			U-2983	
	11097006	Oct 24, 2033	DP		U-764	
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
	9034867	Nov 07, 2032	DP		U-543	
	9193685	Oct 24, 2033	DP		U-543	
	9452131	Mar 19, 2035			U-2402	
ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT						
N 209830 001	10016415	Sep 08, 2035	DP			
	10112903	Jun 24, 2030	DS		U-543	
	10688091	Aug 17, 2035	DP			
	10849894	Aug 17, 2035			U-543	
	11154552	Aug 17, 2035	DP			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030			U-543	
ARMODAFINIL - NUVIGIL						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARMODAFINIL - NUVIGIL						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
ARSENIC TRIOXIDE - TRISENOX						
N 021248 001					ODE-167	Jan 12, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARSENIC TRIOXIDE - TRISENOX							
N 021248	002					ODE-167	Jan 12, 2025
ARTESUNATE - ARTESUNATE							
N 213036	001					NCE	May 26, 2025
						ODE-290	May 26, 2027
ASCIMINIB HYDROCHLORIDE - SCEMBLIX							
N 215358	001	8829195	May 13, 2033	DS U-3249		NCE	Oct 29, 2026
ASCIMINIB HYDROCHLORIDE - SCEMBLIX							
N 215358	002	8829195	May 13, 2033	DS U-3249		NCE	Oct 29, 2026
ASCORBIC ACID - ASCOR							
N 209112	001					ODE-160	Oct 02, 2024
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP							
N 021881	001	7169381	Sep 01, 2024	DS DP			
		7658914	Sep 01, 2024	DS DP			
ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU							
N 209381	001	10016504	Sep 10, 2033	DP			
		10646512	Mar 25, 2032	DP			
		10780112	Mar 09, 2032	DP			
		10792306	Mar 09, 2032	DP U-2310			
		10918723	Sep 10, 2033	U-2310			
		8999313	Sep 10, 2033	DP			
		9326969	Sep 10, 2033	U-2310			
		9592252	Aug 11, 2032	DP U-2310			
		9707297	Sep 10, 2033	DP			
ASENAPINE - SECUADO							
N 212268	001	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
		10583121	Jul 25, 2033	DP U-2763			
		10814002	Jul 25, 2033	DP U-2763			
		11123305	Jul 25, 2033	DP			
		9687474	Jul 25, 2033	DP			
ASENAPINE - SECUADO							
N 212268	002	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
		10583121	Jul 25, 2033	DP U-2763			
		10814002	Jul 25, 2033	DP U-2763			
		11123305	Jul 25, 2033	DP			
		9687474	Jul 25, 2033	DP			
ASENAPINE - SECUADO							
N 212268	003	10022445	Jul 25, 2033	DP		NP	Oct 11, 2022
		10583121	Jul 25, 2033	DP U-2763			
		10814002	Jul 25, 2033	DP U-2763			
		11123305	Jul 25, 2033	DP			
		9687474	Jul 25, 2033	DP			
ASENAPINE MALEATE - SAPHRIS							
N 022117	001	7741358	Apr 06, 2026	DS DP U-1064			
		7741358	Apr 06, 2026	DS DP U-1960			
		7741358	Apr 06, 2026	DS DP U-1961			
		7741358	Apr 06, 2026	DS DP U-1962			
		7741358	Apr 06, 2026	DS DP U-1963			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117	002	7741358	Apr 06, 2026	DS DP U-1064			
		7741358	Apr 06, 2026	DS DP U-1960			
		7741358	Apr 06, 2026	DS DP U-1961			
		7741358	Apr 06, 2026	DS DP U-1962			
		7741358	Apr 06, 2026	DS DP U-1963			
		7741358*PED	Oct 06, 2026				
		8022228	Apr 06, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ASENAPINE MALEATE - SAPHRIS						
N 022117 002	8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS						
N 022117 003	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
ASPIRIN - VAZALORE						
N 203697 001	8865187	Mar 23, 2022	DP			
	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 001	6926907	Feb 28, 2023	DP U-1902			
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
	9987231	Jan 02, 2033	U-2324			
ASPIRIN; OMEPRAZOLE - YOSPRALA						
N 205103 002	6926907	Feb 28, 2023	DP U-1902			
	8206741	Feb 28, 2023	DP U-1902			
	9364439	May 31, 2022	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
	9987231	Jan 02, 2033	U-2324			
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ						
N 206353 001	10039718	Oct 06, 2032	DP			
	8148374	Sep 03, 2029	DS DP U-1279			
ATOGEPANT - QULIPTA						
N 215206 001	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
ATOGEPANT - QULIPTA						
N 215206 002	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
ATOGEPANT - QULIPTA						
N 215206 003	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
ATROPINE SULFATE - ATROPINE SULFATE						
A 212868 001					CGT	Jan 26, 2022
ATROPINE SULFATE - ATROPINE SULFATE						
A 212868 002					CGT	Jan 26, 2022
ATROPINE SULFATE - ATROPINE SULFATE						
A 212868 003					CGT	Jan 26, 2022
ATROPINE SULFATE - ATROPINE SULFATE						
A 215624 001					CGT	May 25, 2022
AVACOPAN - TAVNEOS						
N 214487 001	8445515	Feb 03, 2031	DS DP		NCE	Oct 07, 2026
	8906938	Dec 21, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AVANAFIL - STENDRA							
N 202276	001	6656935	Apr 27, 2025	DS DP U-155			
		7501409	May 05, 2023	DP			
AVANAFIL - STENDRA							
N 202276	002	6656935	Apr 27, 2025	DS DP U-155			
		7501409	May 05, 2023	DP			
AVANAFIL - STENDRA							
N 202276	003	6656935	Apr 27, 2025	DS DP U-155			
		7501409	May 05, 2023	DP			
AVAPRITINIB - AYVAKIT							
N 212608	001	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
		9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-3168		ODE-356	Jun 16, 2028
		9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
		9994575	Oct 15, 2034	DS DP U-3168			
AVAPRITINIB - AYVAKIT							
N 212608	002	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
		9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-3168		ODE-356	Jun 16, 2028
		9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
		9994575	Oct 15, 2034	DS DP U-3168			
AVAPRITINIB - AYVAKIT							
N 212608	003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
		9944651	Oct 15, 2034	DS DP U-2726		ODE-356	Jun 16, 2028
		9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
AVAPRITINIB - AYVAKIT							
N 212608	004	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
		9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
						ODE-356	Jun 16, 2028
						ODE-366	Jan 09, 2027
AVAPRITINIB - AYVAKIT							
N 212608	005	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
		9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
		9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
						ODE-356	Jun 16, 2028
						ODE-366	Jan 09, 2027
AVATROMBOPAG MALEATE - DOPTELET							
N 210238	001	7638536	May 05, 2025	DS DP		I-802	Jun 26, 2022
		8338429	Jun 30, 2023	U-2577		NCE	May 21, 2023
		8765764	Jan 15, 2023	U-2314		ODE-246	Jun 26, 2026
		8765764	Jan 15, 2023	U-2578			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	7112592	Jan 07, 2026	DS DP U-2244		NCE	Feb 25, 2020
		7112592	Jan 07, 2026	DS DP U-2508		GAIN	Feb 25, 2025
		7112592	Jan 07, 2026	DS DP U-282			
		7612087	Nov 12, 2026	DP			
		8471025	Aug 12, 2031	DS			
		8835455	Oct 08, 2030	DP			
		8969566	Jun 15, 2032	DS			
		9284314	Jun 15, 2032	DS			
		9695122	Jun 15, 2032	DS			
AXITINIB - INLYTA							
N 202324	001	10570202	Feb 03, 2035	U-2844			
		10869924	Nov 05, 2036	U-3044			
		6534524	Apr 29, 2025	DS DP			
		8791140	Dec 14, 2030	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AXITINIB - INLYTA							
N 202324	002	10570202	Feb 03, 2035	U-2844			
		10869924	Nov 05, 2036	U-3044			
		6534524	Apr 29, 2025	DS DP			
		8791140	Dec 14, 2030	DS			
AZACITIDINE - ONUREG							
N 214120	001	8846628	Jun 03, 2030	DP U-2950		NP	Sep 01, 2023
						ODE-320	Sep 01, 2027
AZACITIDINE - ONUREG							
N 214120	002	8846628	Jun 03, 2030	DP U-2950		NP	Sep 01, 2023
						ODE-320	Sep 01, 2027
AZELAIC ACID - FINACEA							
N 207071	001	10117812	Oct 18, 2027	DP U-1796			
		10322085	Oct 24, 2023	DP			
		7700076	Sep 18, 2027	DP			
		8435498	Mar 01, 2024	U-1727			
		8722021	Oct 24, 2023	DP			
		8900554	Oct 24, 2023	DP			
		9211259	Feb 28, 2029	U-1796			
		9265725	Dec 08, 2027	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	001	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-1430			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	002	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-1430			
		9919050	Nov 22, 2025	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY							
N 213872	001	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-3166			
		9919050	Nov 22, 2025	DP			
AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY							
N 213872	002	8071073	Jun 04, 2028	DP			
		8518919	Nov 22, 2025	U-3166			
		9919050	Nov 22, 2025	DP			
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236	001	8163723	Aug 29, 2023	U-1667			
		8163723	Aug 29, 2023	U-644			
		8163723	Aug 29, 2023	U-707			
		8163723	Aug 29, 2023	U-77			
		8163723	Aug 29, 2023	U-81			
		8163723*PED	Feb 29, 2024				
		8168620	Feb 24, 2026	DP			
		9259428	Jun 13, 2023	U-644			
		9259428*PED	Dec 13, 2023				
		9901585	Jun 13, 2023	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	001	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	002	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	001	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
		9387249	Jul 01, 2031	U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331	002	7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
		9066936	Mar 26, 2028	DP			
		9169238	Feb 04, 2030	DP			
		9387249	Jul 01, 2031	U-3			
AZITHROMYCIN - ZMAX							
N 050797	001	6984403	Feb 14, 2024	DP U-282			
		7887844	Feb 14, 2024	DP			
BACLOFEN - OZOBAX							
N 208193	001	10610502	Aug 30, 2039	U-2779			
BACLOFEN - LYVISPAH							
N 215422	001	10792262	Jul 29, 2039	DP U-3263			
BACLOFEN - LYVISPAH							
N 215422	002	10792262	Jul 29, 2039	DP U-3263			
BACLOFEN - LYVISPAH							
N 215422	003	10792262	Jul 29, 2039	DP U-3263			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	001	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
		10633397	Apr 27, 2036	U-2816		NCE	Oct 24, 2023
		10633397	Apr 27, 2036	U-3000			
		10759814	Aug 09, 2037	DS DP			
		8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	002	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
		10633397	Apr 27, 2036	U-2816		NCE	Oct 24, 2023
		10633397	Apr 27, 2036	U-3000			
		10759814	Aug 09, 2037	DS DP			
		8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 210854	003	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
		10633397	Apr 27, 2036	U-2816		NCE	Oct 24, 2023
		10633397	Apr 27, 2036	U-3000			
		10759814	Aug 09, 2037	DS DP			
		8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALOXAVIR MARBOXIL - XOFLUZA							
N 214410	001	10392406	Apr 27, 2036	DS		NCE	Oct 24, 2023
		10633397	Apr 27, 2036	U-2816			
		10633397	Apr 27, 2036	U-3000			
		10759814	Aug 09, 2037	DS DP			
		8927710	May 05, 2031	DP			
		8987441	Sep 21, 2031	DS DP			
		9815835	Jun 14, 2030	DP			
BALSALAZIDE DISODIUM - COLAZAL							
N 020610	001	7452872	Aug 24, 2026	U-141			
		7625884	Aug 24, 2026	U-141			
BALSALAZIDE DISODIUM - GIAZO							
N 022205	001	7452872	Aug 24, 2026	U-1229			
		7625884	Aug 24, 2026	U-1229			
		8497256	Jun 23, 2031	U-1229			
		9192616	Aug 02, 2026	U-1229			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BARICITINIB - OLUMIANT							
N 207924	001	8158616	Jun 08, 2030	DS DP		NCE	May 31, 2023
		8420629	Mar 10, 2029	U-247			
BARICITINIB - OLUMIANT							
N 207924	002	8158616	Jun 08, 2030	DS DP		NCE	May 31, 2023
		8420629	Mar 10, 2029	U-247			
BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE							
N 022247	001	6479535	May 06, 2024	DP U-594			
		6479535	May 06, 2024	DP U-904			
		7683051	Mar 10, 2027	DS DP U-594			
		7683051	Mar 10, 2027	DS DP U-904			
BECLOMETHASONE DIPROPIONATE - QVAR 80							
N 020911	001	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		10561808	Jan 01, 2032	DP			
		10695512	May 18, 2031	DP			
		9463289	May 18, 2031	DP			
		9808587	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR 40							
N 020911	002	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		10561808	Jan 01, 2032	DP			
		10695512	May 18, 2031	DP			
		9463289	May 18, 2031	DP			
		9808587	May 18, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QNASL							
N 202813	001	10188811	Oct 21, 2031	DP			
		7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QNASL							
N 202813	002	10188811	Oct 21, 2031	DP			
		7780038	Jan 24, 2027	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	001	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		10561808	Jan 01, 2032	DP			
		10695512	May 18, 2031	DP			
		10792447	Jan 25, 2039	DP			
		8132712	Sep 07, 2028	DP			
		8931476	Jul 17, 2031	DP			
BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER							
N 207921	002	10022509	May 18, 2031	DP			
		10022510	May 18, 2031	DP			
		10086156	May 18, 2031	DP			
		10561808	Jan 01, 2032	DP			
		10695512	May 18, 2031	DP			
		10792447	Jan 25, 2039	DP			
		8132712	Sep 07, 2028	DP			
		8931476	Jul 17, 2031	DP			
BEDAQUILINE FUMARATE - SIRTURO							
N 204384	001	7498343	Dec 01, 2026	DS DP U-1321		NPP	Aug 09, 2022
		8546428	Mar 19, 2029	DS DP U-1321		ODE-251	Aug 09, 2026
						ODE-307	May 27, 2027
BEDAQUILINE FUMARATE - SIRTURO							
N 204384	002	7498343	Dec 01, 2026	DS DP U-1321		ODE-307	May 27, 2027
		8546428	Mar 19, 2029	DS DP U-1321			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BELINOSTAT - BELEODAQ							
N 206256	001	6888027	Aug 10, 2026	DS DP U-1544			
		8835501	Oct 27, 2027	DP			
BELUMOSUDIL MESYLATE - REZUROCK							
N 214783	001	10183931	Oct 07, 2033	U-3246		NCE	Jul 16, 2026
		10696660	Oct 07, 2033	U-3246		ODE-362	Jul 16, 2028
		8357693	Oct 30, 2029	DS DP U-3247			
		9815820	Oct 07, 2033	U-3247			
BELZUTIFAN - WELIREG							
N 215383	001	9908845	Sep 05, 2034	DS DP U-3201		NCE	Aug 13, 2026
		9969689	Sep 05, 2034	DS DP U-3201		ODE-364	Aug 13, 2028
BEMPEDOIC ACID - NEXLETOL							
N 211616	001	10118881	Dec 23, 2023	U-2747		NCE	Feb 21, 2025
		10941095	Dec 23, 2023	U-2747			
		7335799	Dec 03, 2025	DS			
		8497301	Dec 23, 2023	U-2747			
		9000041	Dec 23, 2023	U-2747			
		9624152	Dec 23, 2023	U-2748			
BEMPEDOIC ACID; EZETIMIBE - NEXLIZET							
N 211617	001	10118881	Dec 23, 2023	U-2746		NCE	Feb 21, 2025
		10912751	Mar 14, 2036	U-3224		NP	Feb 26, 2023
		10941095	Dec 23, 2023	U-2746			
		7335799	Dec 03, 2025	DS			
		8497301	Dec 23, 2023	U-2746			
		9000041	Dec 23, 2023	U-2746			
		9624152	Dec 23, 2023	U-2749			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	001	8436190	Oct 26, 2030	DP			
		8436190*PED	Apr 26, 2031				
		8445524	Mar 26, 2029	DS DP U-1402			
		8445524*PED	Sep 26, 2029				
		8609863	Jan 12, 2026	DP			
		8609863*PED	Jul 12, 2026				
		8669279	Mar 26, 2029	DP U-1402			
		8669279*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
		8883836	Mar 26, 2029	DP U-1402			
		8883836*PED	Sep 26, 2029				
		8895756	Jan 12, 2026	DP			
		8895756*PED	Jul 12, 2026				
		9533955	Mar 26, 2029	DP U-1949			
		9533955	Mar 26, 2029	DP U-1952			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	002	8436190	Oct 26, 2030	DP			
		8436190*PED	Apr 26, 2031				
		8445524	Mar 26, 2029	DS DP U-1402			
		8445524*PED	Sep 26, 2029				
		8609863	Jan 12, 2026	DP			
		8609863*PED	Jul 12, 2026				
		8669279	Mar 26, 2029	DP U-1402			
		8669279*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
		8883836	Mar 26, 2029	DP U-1402			
		8883836*PED	Sep 26, 2029				
		8895756	Jan 12, 2026	DP			
		8895756*PED	Jul 12, 2026				
		9533955	Mar 26, 2029	DP U-1949			
		9533955	Mar 26, 2029	DP U-1952			
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	003	8344006	Sep 23, 2029	DP U-1402			
		8344006*PED	Mar 23, 2030				
		8445524	Mar 26, 2029	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	003	8445524*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
N 022249	004	8344006	Sep 23, 2029	DP U-1402			
		8344006*PED	Mar 23, 2030				
		8445524	Mar 26, 2029	DS			
		8445524*PED	Sep 26, 2029				
		8791270	Jan 12, 2026	DP U-1542			
		8791270*PED	Jul 12, 2026				
BENDAMUSTINE HYDROCHLORIDE - BELRAPZO							
N 205580	001	10010533	Jan 28, 2031	DP			
		11103483	Jan 28, 2031	DP U-1971			
		11103483	Jan 28, 2031	DP U-1972			
		8609707	Aug 11, 2031	DP U-1971			
		8609707	Aug 11, 2031	DP U-1972			
		8791270	Jan 12, 2026	DP U-1971			
		8791270	Jan 12, 2026	DP U-1972			
		9265831	Jan 28, 2031	DP			
		9572796	Jan 28, 2031	DP U-1971			
		9572796	Jan 28, 2031	DP U-1972			
		9572797	Jan 28, 2031	U-1971			
		9572797	Jan 28, 2031	U-1972			
BENDAMUSTINE HYDROCHLORIDE - BENDEKA							
N 208194	001	10010533	Jan 28, 2031	DP		ODE-179	Dec 07, 2022
		10052385	Mar 15, 2033	U-1971			
		10052385	Mar 15, 2033	U-1972			
		11103483	Jan 28, 2031	DP U-1971			
		11103483	Jan 28, 2031	DP U-1972			
		8609707	Aug 11, 2031	DP U-1542			
		8791270	Jan 12, 2026	DP U-1790			
		9000021	Mar 15, 2033	U-1542			
		9034908	Mar 15, 2033	U-1542			
		9144568	Mar 15, 2033	U-1542			
		9265831	Jan 28, 2031	DP			
		9572796	Jan 28, 2031	DP U-1971			
		9572796	Jan 28, 2031	DP U-1972			
		9572797	Jan 28, 2031	U-1971			
		9572797	Jan 28, 2031	U-1972			
		9572887	Mar 15, 2033	U-1971			
		9572887	Mar 15, 2033	U-1972			
		9579384	Mar 15, 2033	U-1971			
		9579384	Mar 15, 2033	U-1972			
		9597397	Mar 15, 2033	U-1971			
		9597397	Mar 15, 2033	U-1972			
		9597398	Mar 15, 2033	U-1971			
		9597399	Mar 15, 2033	U-1971			
		9597399	Mar 15, 2033	U-1972			
BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM - FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE							
N 211039	001	10293047	Nov 15, 2037	DP U-2755			
		10632197	Nov 15, 2037	DP U-2755			
		10842872	Nov 15, 2037	U-3001			
BENZNIDAZOLE - BENZNIDAZOLE							
N 209570	001					NCE	Aug 29, 2022
						ODE-154	Aug 29, 2024
BENZNIDAZOLE - BENZNIDAZOLE							
N 209570	002					NCE	Aug 29, 2022
						ODE-154	Aug 29, 2024
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA							
N 050819	001	10220049	Jun 03, 2029	DP U-916			
		10624918	Jun 03, 2029	U-916			
		8288434	Aug 05, 2029	DP U-124			
		8663699	Jun 03, 2029	U-124			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA								
N 050819	001	8895070	Jun 03, 2029		U-124			
		9078870	Jun 03, 2029		DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON								
N 050819	002	10137142	Jun 03, 2029		DP U-916			
		10220049	Jun 03, 2029		DP U-916			
		8288434	Aug 05, 2029		DP U-1033			
		8288434	Aug 05, 2029		DP U-124			
		8288434	Aug 05, 2029		DP U-134			
		8288434	Aug 05, 2029		DP U-818			
		8288434	Aug 05, 2029		DP U-916			
		8288434	Aug 05, 2029		DP U-921			
		9504704	Jun 03, 2029		DP U-124			
		9504704	Jun 03, 2029		DP U-134			
		9504704	Jun 03, 2029		DP U-818			
		9504704	Jun 03, 2029		DP U-916			
		9561208	Jun 03, 2029		DP U-916			
BENZOYL PEROXIDE; TRETINOIN - TWYNEO								
N 214902	001	10420743	Jul 12, 2038		U-3194		NC	Jul 26, 2024
		10653899	Dec 30, 2030		DP U-3194			
		11071878	Dec 30, 2030		DP			
		8617580	Feb 03, 2028		DP			
		9868103	Aug 08, 2028		DP U-3194			
BENZYL ALCOHOL - ULESFIA								
N 022129	001	6793931	Jul 11, 2022		DP U-970			
		7294342	May 19, 2024		U-970			
BEPOTASTINE BESILATE - BEPREVE								
N 022288	001	8784789	Jan 13, 2025		DP			
		8877168	Jul 30, 2023		DP			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO								
N 214094	001	10125102	Apr 07, 2035	DS	U-3010		NCE	Dec 03, 2025
		10329260	Mar 09, 2035	DS			ODE-333	Dec 03, 2027
		10662160	Nov 01, 2039	DS	U-3010			
		10689346	Mar 09, 2035		U-3010			
		11117867	Nov 01, 2039		DP U-3010			
BEROTRALSTAT HYDROCHLORIDE - ORLADEYO								
N 214094	002	10125102	Apr 07, 2035	DS	U-3010		NCE	Dec 03, 2025
		10329260	Mar 09, 2035	DS			ODE-333	Dec 03, 2027
		10662160	Nov 01, 2039	DS	U-3010			
		10689346	Mar 09, 2035		U-3010			
		11117867	Nov 01, 2039		DP U-3010			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE								
N 022308	001	8415342	Nov 07, 2030		U-80			
		8481526	Jan 09, 2031	DS				
		8604020	Mar 12, 2030		DP			
		8937062	Nov 13, 2029		U-80			
BETAMETHASONE DIPROPIONATE - SERNIVO								
N 208079	001	10179137	Aug 31, 2030		DP U-1858			
		9364485	Aug 31, 2030		DP U-1858			
		9433630	Aug 31, 2030		DP U-1858			
		9439911	Aug 31, 2030		DP U-1858			
		9655907	Aug 31, 2030		DP U-1858			
		9775851	Aug 31, 2030		DP U-1858			
		9877974	Aug 31, 2030		DP U-1858			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX								
N 022185	001						NPP	Jul 25, 2022
							PED	Jan 25, 2023
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR								
N 207589	001	10130640	Jun 10, 2031		DP		NPP	Jul 30, 2022
		10130640*PED	Dec 10, 2031				PED	Jan 30, 2023
		10617698	Jun 10, 2031		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR							
N 207589	001	10660908	Jun 10, 2031	DP U-2627			
		10682364	Jun 10, 2031	DP			
		10688108	Jun 10, 2031	U-2627			
		10716799	Jun 10, 2031	DP			
		9119781	Jun 10, 2031	DP U-1761			
		9119781	Jun 10, 2031	DP U-2627			
		9119781*PED	Dec 10, 2031				
		9566286	Jun 10, 2031	DP			
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA							
N 213422	001	10265265	Sep 27, 2027	DP		NDF	Jul 20, 2023
BETRIXABAN - BEVYXXA							
N 208383	001	7598276	Nov 08, 2026	DS		NCE	Jun 23, 2022
		8404724	Mar 29, 2031	DP U-2034			
		8557852	Sep 08, 2028	U-1167			
		8557852	Sep 08, 2028	U-2030			
		8987463	Dec 28, 2030	DP			
		9555023	Nov 07, 2026	U-1502			
BETRIXABAN - BEVYXXA							
N 208383	002	7598276	Nov 08, 2026	DS		NCE	Jun 23, 2022
		8404724	Mar 29, 2031	DP U-2034			
		8557852	Sep 08, 2028	U-1167			
		8557852	Sep 08, 2028	U-2030			
		8987463	Dec 28, 2030	DP			
		9555023	Nov 07, 2026	U-1502			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY							
N 210251	001	10385067	Jun 19, 2035	U-257		M-82	Feb 24, 2024
		10548846	Nov 08, 2036	DP		NCE	Feb 07, 2023
		7390791	Apr 17, 2025	DS DP		NPP	Jun 18, 2022
		7390791*PED	Oct 17, 2025			ODE-256	Jun 18, 2026
		7803788	Feb 02, 2022	U-257			
		8754065	Aug 15, 2032	DS DP U-257			
		8754065*PED	Feb 15, 2033				
		9216996	Dec 19, 2033	DS DP			
		9296769	Aug 15, 2032	DS DP U-257			
		9296769*PED	Feb 15, 2033				
		9708342	Jun 19, 2035	DS DP			
		9732092	Dec 19, 2033	DS DP			
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY							
N 210251	002	10385067	Jun 19, 2035	U-257			
		7390791	Apr 17, 2025	DS DP			
		7803788	Feb 02, 2022	U-257			
		8754065	Aug 15, 2032	DS DP U-257			
		9216996	Dec 19, 2033	DS DP			
		9296769	Aug 15, 2032	DS DP U-257			
		9708342	Jun 19, 2035	DS DP			
		9732092	Dec 19, 2033	DS DP			
BIMATOPROST - LUMIGAN							
N 022184	001	7851504	Jun 13, 2027	DS DP			
		8278353	Mar 16, 2025	DP			
		8299118	Mar 16, 2025	U-1295			
		8309605	Mar 16, 2025	U-1293			
		8309605	Mar 16, 2025	U-1294			
		8338479	Mar 16, 2025	DP U-1295			
		8524777	Mar 16, 2025	U-1235			
		8586630	Mar 16, 2025	U-1458			
		8772338	Mar 16, 2025	DP U-1528			
		8933120	Mar 16, 2025	DP			
		8933127	Mar 16, 2025	DP			
		9155716	Mar 16, 2025	DP U-1528			
		9241918	Mar 16, 2025	DP U-1814			
BIMATOPROST - LATISSE							
N 022369	001	8038988	Aug 25, 2023	DS DP U-1208			
		8101161	May 25, 2024	U-1217			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BIMATOPROST - LATISSE							
N 022369	001	8101161	May 25, 2024	U-1218			
		8263054	Jan 15, 2023	U-1277			
		8632760	Jan 15, 2023	U-1487			
		8758733	Jan 15, 2023	U-1487			
		8986715	Jan 15, 2023	U-1217			
		9216183	Jan 15, 2023	U-1487			
		9226931	Jan 15, 2023	U-1799			
BIMATOPROST - DURYSTA							
N 211911	001	10398707	Apr 30, 2024	U-2759		NP	Mar 04, 2023
		10441543	Dec 19, 2026	DP			
		7799336	Apr 24, 2029	DP			
		8206737	Apr 07, 2027	U-2759			
		8629185	Jul 15, 2031	DS DP			
		8673341	Feb 19, 2025	U-2759			
		9149428	Dec 19, 2026	DP			
		9492316	Oct 31, 2034	DP			
		9980974	Oct 31, 2034	U-2759			
BINIMETINIB - MEKTOVI							
N 210498	001	10005761	Aug 27, 2030	U-2331		NCE	Jun 27, 2023
		7777050	Mar 13, 2023	DS DP		ODE-194	Jun 27, 2025
		8178693	Mar 13, 2023	DS DP			
		8193229	Mar 13, 2023	U-2330			
		8513293	Mar 13, 2023	U-2331			
		9314464	Jul 04, 2031	U-2332			
		9562016	Oct 18, 2033	DS DP			
		9593100	Aug 27, 2030	DP			
		9598376	Oct 18, 2033	U-2330			
		9850229	Aug 27, 2030	U-2333			
		9980944	Oct 18, 2033	U-2334			
BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY							
N 021551	003	7291324	Oct 22, 2022	U-837			
BIVALIRUDIN - ANGIOMAX							
N 020873	001	7582727	Jul 27, 2028	DP			
		7598343	Jul 27, 2028	DP			
BOCEPREVIR - VICTRELIS							
N 202258	001	7772178	Nov 11, 2027	DP U-1128			
		8119602	Mar 17, 2027	U-1233			
		RE43298	Dec 22, 2024	DS DP U-1128			
BORTEZOMIB - VELCADE							
N 021602	001	6713446	Jan 25, 2022	DS DP			
		6713446*PED	Jul 25, 2022				
		6958319	Jan 25, 2022	DS DP			
		6958319*PED	Jul 25, 2022				
BORTEZOMIB - BORTEZOMIB							
N 205004	001	8962572	Nov 03, 2032	DP			
BOSENTAN - TRACLEER							
N 021290	001					ODE*	Sep 05, 2024
BOSENTAN - TRACLEER							
N 021290	002					ODE*	Sep 05, 2024
BOSENTAN - TRACLEER							
N 209279	001	7959945	Dec 28, 2027	DP		ODE-161	Sep 05, 2024
		8309126	May 15, 2026	DP			
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	001	11103497	Feb 28, 2034	U-3216		ODE-163	Dec 19, 2024
		11103497	Feb 28, 2034	U-3217			
		7417148	Dec 11, 2025	U-1283			
		7767678	Nov 23, 2026	DS DP			
		7919625	Dec 11, 2025	DP			
		RE42376	Apr 13, 2024	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	002	11103497	Feb 28, 2034	U-3216		ODE-163	Dec 19, 2024
		11103497	Feb 28, 2034	U-3217			
		7417148	Dec 11, 2025	U-1283			
		7767678	Nov 23, 2026	DS DP			
		7919625	Dec 11, 2025	DP			
		RE42376	Apr 13, 2024	DS			
BOSUTINIB MONOHYDRATE - BOSULIF							
N 203341	003	11103497	Feb 28, 2034	U-3216		ODE-163	Dec 19, 2024
		11103497	Feb 28, 2034	U-3217			
		7417148	Dec 11, 2025	U-1283			
		7767678	Nov 23, 2026	DS DP			
		7919625	Dec 11, 2025	DP			
		RE42376	Apr 13, 2024	DS			
BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)							
N 210557	001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
		6794489	Jun 28, 2025	DS DP			
		9352013	Nov 05, 2033	U-2568			
		9700592	Nov 05, 2033	U-2568			
BREXANOLONE - ZULRESSO							
N 211371	001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
		10251894	Nov 27, 2033	U-2552			
		10322139	Jan 23, 2033	DP			
		10940156	Mar 08, 2037	U-2552			
		7635773	Mar 13, 2029	DP			
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9750822	Mar 13, 2029	DP			
BREXPIPRAZOLE - REXULTI							
N 205422	001	10307419	Oct 12, 2032	DP			
		7888362	Apr 12, 2026	DS	Y		
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
		RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI							
N 205422	002	10307419	Oct 12, 2032	DP			
		7888362	Apr 12, 2026	DS	Y		
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
		RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI							
N 205422	003	10307419	Oct 12, 2032	DP			
		7888362	Apr 12, 2026	DS	Y		
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
		RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI							
N 205422	004	10307419	Oct 12, 2032	DP			
		7888362	Apr 12, 2026	DS	Y		
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
		9839637	Apr 12, 2026	DP U-1529			
		9839637	Apr 12, 2026	DP U-543			
		RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI							
N 205422	005	10307419	Oct 12, 2032	DP			
		7888362	Apr 12, 2026	DS	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI						
N 205422 005	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
BREXPIPRAZOLE - REXULTI						
N 205422 006	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
BRIGATINIB - ALUNBRIG						
N 208772 001	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Jul 31, 2030	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-2837		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-2837		ODE-300	May 22, 2027
BRIGATINIB - ALUNBRIG						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Jul 31, 2030	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-2837		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-2837		ODE-300	May 22, 2027
BRIGATINIB - ALUNBRIG						
N 208772 003	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Jul 31, 2030	DS		NCE	Apr 28, 2022
	9273077	May 21, 2029	U-2837		ODE-142	Apr 28, 2024
	9611283	Apr 10, 2034	U-2837		ODE-300	May 22, 2027
BRILLIANT BLUE G - TISSUEBLUE						
N 209569 001					NCE	Dec 20, 2024
					ODE-282	Dec 20, 2026
BRIMONIDINE TARTRATE - ALPHAGAN P						
N 021262 001	9295641*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - QOLIANA						
N 021764 001	7265117	Aug 19, 2025	DP			
BRIMONIDINE TARTRATE - ALPHAGAN P						
N 021770 001	8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				
	9295641*PED	Jan 10, 2022				
	9687443*PED	Jan 10, 2022				
BRIMONIDINE TARTRATE - MIRVASO						
N 204708 001	10201517	Jun 13, 2031	DP			
	7439241	Aug 25, 2025	U-1428			
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
	8859551	May 25, 2024	U-1428			
	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
BRIMONIDINE TARTRATE - LUMIFY						
N 208144 001	8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA						
N 204251 001	9044484	Oct 30, 2030	DP			
	9421265	Jun 17, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN						
N 021398 001	7030149	Apr 19, 2022	U-849			
	7320976	Apr 19, 2022	U-849			
	7642258	Apr 19, 2022	DS DP U-1024			
	8133890	Apr 19, 2022	U-1235			
	8354409	Apr 19, 2022	DP U-1371			
	8748425	Apr 19, 2022	DP U-1524			
	9474751	Apr 19, 2022	DP U-1524			
	9770453	Apr 19, 2022	DP U-2131			
	9907801	Apr 19, 2022	DP U-2239			
	9907802	Apr 19, 2022	DP U-2240			
BRINCIDOFOVIR - TEMBEXA						
N 214460 001	9303051	Aug 31, 2031	DS DP U-3165		NP	Jun 04, 2024
					ODE-354	Jun 04, 2028
BRINCIDOFOVIR - TEMBEXA						
N 214461 001	10112909	Oct 10, 2034	U-3165		NP	Jun 04, 2024
	10487061	Oct 10, 2034	DP U-3165		ODE-354	Jun 04, 2028
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			
BRIVARACETAM - BRIVIACT						
N 205836 001	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 002	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 003	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 004	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205836 005	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
BRIVARACETAM - BRIVIACT						
N 205837 001	6911461	Feb 21, 2026	DS DP U-1815		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2130			
BRIVARACETAM - BRIVIACT						
N 205838 001	6911461	Feb 21, 2026	DS DP U-2295		NPP	Aug 27, 2024
BROMFENAC SODIUM - PROLENSA						
N 203168 001	10085958	Nov 19, 2032	DP			
	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-1095			
	8927606	Jan 16, 2024	U-810			
	9144609	Jan 16, 2024	DP			
	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
BROMFENAC SODIUM - BROMSITE						
N 206911 001	8778999	Aug 07, 2029	DP U-1834			
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	10688094	Apr 30, 2032	U-2870			
	10688094	Apr 30, 2032	U-2871			
	10688094	Apr 30, 2032	U-2872			
	10688094	Apr 30, 2032	U-2873			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET						
N 020866 001	10688094	Apr 30, 2032	U-2874			
	10688094	Apr 30, 2032	U-2875			
	10688094	Apr 30, 2032	U-2876			
	10688094	Apr 30, 2032	U-2877			
	10688094	Apr 30, 2032	U-2878			
	10688094	Apr 30, 2032	U-2879			
	10688094	Apr 30, 2032	U-2880			
	10688094	Apr 30, 2032	U-2881			
	10688094	Apr 30, 2032	U-2882			
	10688094	Apr 30, 2032	U-2883			
	10688094	Apr 30, 2032	U-2884			
	10688094	Apr 30, 2032	U-2885			
	10688094	Apr 30, 2032	U-2886			
	10688094	Apr 30, 2032	U-2887			
	10688094	Apr 30, 2032	U-2888			
	10688155	Jun 07, 2030	U-2281			
	10688155	Jun 07, 2030	U-2890			
	10688155	Jun 07, 2030	U-2891			
	10688155	Jun 07, 2030	U-2892			
	10688155	Jun 07, 2030	U-2893			
	10688155	Jun 07, 2030	U-2894			
	10688155	Jun 07, 2030	U-2895			
	10688155	Jun 07, 2030	U-2896			
	10688155	Jun 07, 2030	U-2897			
	10688155	Jun 07, 2030	U-2898			
	10688155	Jun 07, 2030	U-2899			
	10688155	Jun 07, 2030	U-2900			
	10688155	Jun 07, 2030	U-2901			
	10688155	Jun 07, 2030	U-2902			
	10688155	Jun 07, 2030	U-2903			
	10688155	Jun 07, 2030	U-2904			
	10688155	Jun 07, 2030	U-2905			
	10688155	Jun 07, 2030	U-2906			
	10688155	Jun 07, 2030	U-2907			
	10688155	Jun 07, 2030	U-2908			
	10688155	Jun 07, 2030	U-2909			
	10688155	Jun 07, 2030	U-2910			
	10688155	Jun 07, 2030	U-2911			
	10688155	Jun 07, 2030	U-2912			
	10688155	Jun 07, 2030	U-2913			
	10688155	Jun 07, 2030	U-2914			
	10688155	Jun 07, 2030	U-2915			
	10688155	Jun 07, 2030	U-2916			
	10688155	Jun 07, 2030	U-2917			
	10688155	Jun 07, 2030	U-2918			
	10688155	Jun 07, 2030	U-2919			
	10688155	Jun 07, 2030	U-2920			
	10688155	Jun 07, 2030	U-2921			
	10688155	Jun 07, 2030	U-2922			
	10688155	Jun 07, 2030	U-2923			
	10688155	Jun 07, 2030	U-2924			
	10688155	Jun 07, 2030	U-2925			
	10688155	Jun 07, 2030	U-2926			
	10688155	Jun 07, 2030	U-2927			
	10688155	Jun 07, 2030	U-2928			
	10688155	Jun 07, 2030	U-2929			
	10688155	Jun 07, 2030	U-2930			
	10688155	Jun 07, 2030	U-2931			
	10688155	Jun 07, 2030	U-2932			
	10688155	Jun 07, 2030	U-2933			
	10688155	Jun 07, 2030	U-2934			
	10688155	Jun 07, 2030	U-2935			
	10688155	Jun 07, 2030	U-2936			
	10688155	Jun 07, 2030	U-2937			
	11000522	Apr 30, 2032	U-3119			
	11000522	Apr 30, 2032	U-3120			
	11000522	Apr 30, 2032	U-3121			
	11000522	Apr 30, 2032	U-3122			
	7888310	Jul 25, 2023	U-1433			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	8137992	Jul 25, 2023	U-1433			
		8137993	Jul 25, 2023	U-1433			
		8137994	Jul 25, 2023	U-1433			
		8431155	Apr 30, 2032	DP U-976			
		8613947	Apr 30, 2032	DP U-976			
		8877708	Jun 07, 2030	DP U-1706			
		9192576	Apr 30, 2032	DP U-976			
		9352025	Jun 07, 2030	U-2111			
		9352025	Jun 07, 2030	U-2112			
		9352025	Jun 07, 2030	U-2113			
		9352025	Jun 07, 2030	U-2114			
		9352025	Jun 07, 2030	U-2115			
		9352025	Jun 07, 2030	U-2116			
		9352025	Jun 07, 2030	U-2117			
		9352025	Jun 07, 2030	U-2118			
		9352025	Jun 07, 2030	U-2119			
		9522117	Apr 30, 2032	DP U-1939			
		9522117	Apr 30, 2032	DP U-976			
		9700555	Apr 30, 2032	DP U-2183			
		9700555	Apr 30, 2032	DP U-2184			
		9700555	Apr 30, 2032	DP U-2185			
		9700555	Apr 30, 2032	DP U-2186			
		9700555	Apr 30, 2032	DP U-2187			
		9700555	Apr 30, 2032	DP U-2188			
		9700555	Apr 30, 2032	DP U-2189			
		9700555	Apr 30, 2032	DP U-2190			
		9700555	Apr 30, 2032	DP U-2191			
		9700555	Apr 30, 2032	DP U-2192			
		9700555	Apr 30, 2032	DP U-2193			
		9700555	Apr 30, 2032	DP U-2194			
		9700555	Apr 30, 2032	DP U-2195			
		9700555	Apr 30, 2032	DP U-2196			
		9700555	Apr 30, 2032	DP U-2197			
		9700555	Apr 30, 2032	DP U-2198			
		9895422	Jun 07, 2030	U-2114			
		9895422	Jun 07, 2030	U-2116			
		9895422	Jun 07, 2030	U-2281			
		9895422	Jun 07, 2030	U-2282			
		9895422	Jun 07, 2030	U-2283			
		9895422	Jun 07, 2030	U-2284			
		9895422	Jun 07, 2030	U-2285			
		9895422	Jun 07, 2030	U-2286			
		9895422	Jun 07, 2030	U-2287			
		9993474	Apr 30, 2032	U-2384			
		9993474	Apr 30, 2032	U-2385			
		9993474	Apr 30, 2032	U-2386			
		9993474	Apr 30, 2032	U-2387			
		9993474	Apr 30, 2032	U-2388			
		9993474	Apr 30, 2032	U-2389			
		9993474	Apr 30, 2032	U-2390			
		9993474	Apr 30, 2032	U-2391			
		9993474	Apr 30, 2032	U-2392			
		9993474	Apr 30, 2032	U-2393			
BUDESONIDE - UCERIS							
N 203634	001	10307375	Sep 07, 2031	DP			
		10660858	Sep 07, 2031	DP			
		8895064	Sep 07, 2031	DP			
		9132093	Sep 07, 2031	DP			
		9192581	Sep 07, 2031	DP U-1325			
BUDESONIDE - ORTIKOS							
N 211929	001	10172802	Sep 09, 2036	U-2554			
		9707182	Sep 09, 2036	DP U-2554			
BUDESONIDE - ORTIKOS							
N 211929	002	10172802	Sep 09, 2036	U-2554			
		9707182	Sep 09, 2036	DP U-2554			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUDESONIDE - TARPEYO							
N 215935	001	8491932	May 07, 2029	DP U-3269			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	001	10166247	Jan 29, 2023	DP U-2001			
		10166247	Jan 29, 2023	DP U-2002			
		10166247	Jan 29, 2023	DP U-2122			
		10166247*PED	Jul 29, 2023				
		7587988	Apr 10, 2026	DP			
		7587988*PED	Oct 10, 2026				
		7759328	Jan 29, 2023	DP U-2001			
		7759328	Jan 29, 2023	DP U-2002			
		7759328	Jan 29, 2023	DP U-2122			
		7759328*PED	Jul 29, 2023				
		7967011*PED	Feb 11, 2022				
		8143239	Jan 29, 2023	DP U-2001			
		8143239	Jan 29, 2023	DP U-2002			
		8143239	Jan 29, 2023	DP U-2122			
		8143239*PED	Jul 29, 2023				
		8387615	Mar 26, 2027	DP			
		8387615*PED	Sep 26, 2027				
		8528545	Oct 16, 2028	DP			
		8528545*PED	Apr 16, 2029				
		8575137	Jan 29, 2023	DP U-2001			
		8575137	Jan 29, 2023	DP U-2002			
		8575137	Jan 29, 2023	DP U-2122			
		8575137*PED	Jul 29, 2023				
		8616196	Apr 07, 2029	DP			
		8616196*PED	Oct 07, 2029				
		8875699	Nov 10, 2024	DP			
		8875699*PED	May 10, 2025				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N 021929	002	10166247	Jan 29, 2023	DP U-2001			
		10166247	Jan 29, 2023	DP U-2002			
		10166247	Jan 29, 2023	DP U-2122			
		10166247*PED	Jul 29, 2023				
		7587988	Apr 10, 2026	DP			
		7587988*PED	Oct 10, 2026				
		7759328	Jan 29, 2023	DP U-2001			
		7759328	Jan 29, 2023	DP U-2002			
		7759328	Jan 29, 2023	DP U-2122			
		7759328*PED	Jul 29, 2023				
		7967011*PED	Feb 11, 2022				
		8143239	Jan 29, 2023	DP U-2001			
		8143239	Jan 29, 2023	DP U-2002			
		8143239	Jan 29, 2023	DP U-2122			
		8143239*PED	Jul 29, 2023				
		8387615	Mar 26, 2027	DP			
		8387615*PED	Sep 26, 2027				
		8528545	Oct 16, 2028	DP			
		8528545*PED	Apr 16, 2029				
		8575137	Jan 29, 2023	DP U-2001			
		8575137	Jan 29, 2023	DP U-2002			
		8575137	Jan 29, 2023	DP U-2122			
		8575137*PED	Jul 29, 2023				
		8616196	Apr 07, 2029	DP			
		8616196*PED	Oct 07, 2029				
		8875699	Nov 10, 2024	DP			
		8875699*PED	May 10, 2025				
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE							
N 212122	001	10716753	May 28, 2030	DP U-2889		NC	Jul 23, 2023
		8324266	May 28, 2030	U-2889			
		8703806	May 28, 2030	U-2889			
		8808713	May 28, 2030	DP U-2889			
		8815258	Mar 17, 2031	U-2889			
		9415009	May 28, 2030	U-2889			
		9463161	May 28, 2030	DP U-2889			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE - EXPAREL						
N 022496 001	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
	11179336	Jan 22, 2041	DP U-3250			
BUPIVACAINE - EXPAREL						
N 022496 002	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
	11179336	Jan 22, 2041	DP U-3250			
BUPIVACAINE - POSIMIR						
N 204803 001	8153149	Sep 15, 2025	DP		NP	Feb 01, 2024
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			
	8846072	Sep 15, 2025	DP U-3074			
BUPIVACAINE HYDROCHLORIDE - XARACOLL						
N 209511 001	RE47826	May 20, 2029	U-2949		NP	Aug 28, 2023
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 001	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 003	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 004	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPIVACAINE; MELOXICAM - ZYNRELEF KIT						
N 211988 004	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
BUPRENORPHINE - SUBLOCADE						
N 209819 001	10198218	Jun 06, 2031	U-2489			
	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	11000520	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE - SUBLOCADE						
N 209819 002	10198218	Jun 06, 2031	U-2489			
	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	10646484	Jun 22, 2038	U-2489			
	11000520	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE						
N 204442 001	7736665	Apr 25, 2024	U-1878			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 001	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA						
N 207932 002	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE - BELBUCA							
N 207932	003	8147866	Jul 23, 2027	DP U-1769			
		9655843	Jul 23, 2027	DP U-1556			
		9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA							
N 207932	004	8147866	Jul 23, 2027	DP U-1769			
		9655843	Jul 23, 2027	DP U-1556			
		9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA							
N 207932	005	8147866	Jul 23, 2027	DP U-1769			
		9655843	Jul 23, 2027	DP U-1556			
		9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA							
N 207932	006	8147866	Jul 23, 2027	DP U-1769			
		9655843	Jul 23, 2027	DP U-1556			
		9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE - BELBUCA							
N 207932	007	8147866	Jul 23, 2027	DP U-1769			
		9655843	Jul 23, 2027	DP U-1556			
		9901539	Dec 21, 2032	U-1556			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	001	10285910	Oct 11, 2022	DP			
		11135216	Aug 07, 2029	DP U-3111			
		8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	002	10285910	Oct 11, 2022	DP			
		11135216	Aug 07, 2029	DP U-3111			
		8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	003	10285910	Oct 11, 2022	DP			
		11135216	Aug 07, 2029	DP U-3111			
		8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE							
N 022410	004	10285910	Oct 11, 2022	DP			
		11135216	Aug 07, 2029	DP U-3111			
		8017150	Feb 13, 2023	DP			
		8475832	Mar 26, 2030	DP U-1411			
		8603514	Apr 03, 2024	DP U-1464			
		9687454	Aug 07, 2029	DP U-1464			
		9855221	Feb 14, 2022	DP			
		9931305	Feb 14, 2022	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	001	10946010	Sep 18, 2032	DP			
		11020388	Sep 18, 2032	DP U-3131			
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	001	9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	002	10874661	Sep 18, 2032	DP			
			10946010	Sep 18, 2032	DP			
			11020387	Sep 18, 2032	DP		U-3131	
			11020388	Sep 18, 2032	DP		U-3131	
			8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	003	10946010	Sep 18, 2032	DP			
			11020387	Sep 18, 2032	DP		U-3131	
			11020388	Sep 18, 2032	DP		U-3131	
			8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	004	10946010	Sep 18, 2032	DP			
			11020387	Sep 18, 2032	DP		U-3131	
			11020388	Sep 18, 2032	DP		U-3131	
			8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	005	10946010	Sep 18, 2032	DP			
			11020387	Sep 18, 2032	DP		U-3131	
			11020388	Sep 18, 2032	DP		U-3131	
			8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV								
N	204242	006	10946010	Sep 18, 2032	DP			
			11020388	Sep 18, 2032	DP		U-3131	
			8470361	May 22, 2030	DP		U-1425	
			8658198	Dec 03, 2027	DP		U-1494	
			8940330	Sep 18, 2032	DP			
			9259421	Sep 18, 2032	DP			
			9439900	Sep 18, 2032	DP	Y		
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N	205637	001	8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N	205637	002	8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL								
N	205637	003	8147866	Jul 23, 2027	DP		U-1521	
			8703177	Aug 20, 2032	DP			
			9522188	Apr 24, 2035	DP			
			9655843	Jul 23, 2027	DP		U-2017	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL						
N 205637 003	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROBROMIDE - APLENZIN						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
BUPROPION HYDROCHLORIDE - FORFIVO XL						
N 022497 001	7674479	Jun 25, 2027	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
	10403170	Jun 05, 2033	U-1583			
	10828294	Jul 02, 2034	U-1583			
	10835527	Jul 02, 2034	U-1583			
	11033543	Jan 10, 2031	U-1583			
	11139056	Jun 05, 2033	U-1583			
	7375111	Mar 26, 2025	DP			
	7462626	Jul 20, 2024	U-1583			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8815889	Jul 20, 2024	U-1586			
	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
	9125868	Nov 08, 2027	U-1585			
	9248123	Jan 13, 2032	U-1808			
	9633575	Jun 25, 2033	U-1583			
CABAZITAXEL - JEVTANA KIT						
N 201023 001	10583110	Oct 27, 2030	U-2753		M-128	Dec 18, 2023
	10716777	Oct 27, 2030	U-2856			
	7241907	Dec 10, 2025	DS			
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-3200			
	8927592*PED	Apr 27, 2031				
CABOTEGRAVIR SODIUM - VOCABRIA						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3061			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 001	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - COMETRIQ						
N 203756 002	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	10039757	Jul 18, 2031	U-1480		I-854	Jan 22, 2024
	11091439	Jan 15, 2030	DS		I-873	Sep 17, 2024
	11091440	Jan 15, 2030	DP		ODE-227	Jan 14, 2026
	11098015	Jan 15, 2030	U-1220		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11141413	Apr 17, 2037	U-3239			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	10039757	Jul 18, 2031	U-1480		I-854	Jan 22, 2024
	11091439	Jan 15, 2030	DS		I-873	Sep 17, 2024
	11091440	Jan 15, 2030	DP		ODE-227	Jan 14, 2026
	11098015	Jan 15, 2030	U-1220		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11141413	Apr 17, 2037	U-3239			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
CABOZANTINIB S-MALATE - CABOMETYX						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	10039757	Jul 18, 2031	U-1480		I-854	Jan 22, 2024
	11091439	Jan 15, 2030	DS		I-873	Sep 17, 2024
	11091440	Jan 15, 2030	DP		ODE-227	Jan 14, 2026
	11098015	Jan 15, 2030	U-1220		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CABOZANTINIB S-MALATE - CABOMETYX							
N 208692	003	11141413	Apr 17, 2037	U-3239			
		7579473	Aug 14, 2026	DS DP			
		8497284	Sep 24, 2024	U-1220			
		8497284	Sep 24, 2024	U-1480			
		8497284	Sep 24, 2024	U-2488			
		8877776	Oct 08, 2030	DS DP U-3225			
		9724342	Jul 09, 2033	DP			
CALCIFEDIOL - RAYALDEE							
N 208010	001	10213442	Feb 02, 2027	DP			
		10300078	Mar 14, 2034	DP			
		10357502	Mar 14, 2034	DP			
		11154509	Apr 25, 2028	U-3248			
		8207149	Apr 25, 2028	U-1871			
		8361488	Jul 19, 2028	DP			
		8426391	Aug 27, 2028	U-1872			
		8778373	Apr 25, 2028	U-1873			
		8906410	Feb 02, 2027	DP			
		9408858	Apr 25, 2028	U-1888			
		9498486	Apr 25, 2028	U-1920			
		9861644	Mar 14, 2034	DP			
		9925147	Apr 25, 2028	DP U-2255			
		9925147	Apr 25, 2028	DP U-2256			
		9925147	Apr 25, 2028	DP U-2257			
		9925147	Apr 25, 2028	DP U-2258			
		9925147	Apr 25, 2028	DP U-2259			
		9943530	Feb 02, 2027	U-2274			
CALCIPOTRIENE - SORILUX							
N 022563	001	8263580	May 07, 2028	DP U-1280		NPP	May 06, 2022
		8263580	May 07, 2028	DP U-2662		NPP	Nov 05, 2022
		8629128	May 26, 2026	DP U-1280			
		8629128	May 26, 2026	DP U-1767			
		8629128	May 26, 2026	DP U-2662			
CALCITRIOL - VECTICAL							
N 022087	001					NPP	Jul 17, 2023
CALCIUM ACETATE - PHOSLYRA							
N 022581	001	8591938	Feb 23, 2030	DP U-1469			
		8592480	Jul 20, 2027	U-1469			
		9089528	Jul 20, 2027	U-1469			
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
N 207026	001					ODE-85	Jan 13, 2022
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
N 207026	002					ODE-85	Jan 13, 2022
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE							
N 210906	001	10130646	Jul 25, 2037	DP			
		10342813	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE							
N 210906	002	10130646	Jul 25, 2037	DP			
		10342813	Jul 25, 2037	DP			
CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE							
N 210906	003	10130646	Jul 25, 2037	DP			
		10342813	Jul 25, 2037	DP			
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV							
N 212690	001	10195168	Jan 11, 2033	DP		I-870	Aug 12, 2024
		10213400	Mar 15, 2033	U-2499		NP	Jul 21, 2023
		10675258	Jan 11, 2033	U-2938		ODE-361	Jul 21, 2027
		10864181	Mar 15, 2033	U-3017		ODE-369	Aug 12, 2028
		8591922	Jan 11, 2033	DP			
		8731963	Dec 17, 2022	U-1110			
		8772306	Mar 15, 2033	U-1532			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV						
N 212690 001	8772306	Mar 15, 2033	U-3198			
	8901173	Jan 11, 2033	DP			
	9050302	Mar 15, 2033	U-1532			
	9132107	Jan 11, 2033	DP			
	9486426	Mar 15, 2033	U-1532			
CANAGLIFLOZIN - INVOKANA						
N 204042 001	10617668	May 11, 2031	DP U-2441		I-809	Sep 27, 2022
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN - INVOKANA						
N 204042 002	10617668	May 11, 2031	DP U-2441		I-809	Sep 27, 2022
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 002	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET						
N 204353 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 002	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 003	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR						
N 205879 004	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
CANGRELOR - KENGREAL						
N 204958 001	10039780	Jul 10, 2035	U-2260			
	6130208	Jun 29, 2023	DP U-1715			
	8680052	Mar 09, 2033	U-2979			
	9295687	Jul 10, 2035	DP			
	9427448	Nov 10, 2030	U-1926			
	9439921	Jul 10, 2035	DP			
	9700575	Jul 10, 2035	DP			
	9925265	May 13, 2029	U-2260			
CANNABIDIOL - EPIDIOLEX						
N 210365 001	10092525	Jun 17, 2035	U-2427		NCE	Sep 28, 2023
	10111840	Jun 17, 2035	U-2442		NPP	Jul 31, 2023
	10111840	Jun 17, 2035	U-2443		ODE-216	Sep 28, 2025
	10137095	Jun 17, 2035	U-2454		ODE-326	Jul 31, 2027
	10137095	Jun 17, 2035	U-2455		ODE-332	Jul 31, 2027
	10195159	May 07, 2022	DS			
	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
	10709671	Jun 17, 2035	U-2862			
	10709673	Jun 17, 2035	DP			
	10709674	Jun 17, 2035	U-2780			
	10709674	Jun 17, 2035	U-2781			
	10849860	Jun 17, 2035	U-2427			
	10849860	Jun 17, 2035	U-2454			
	10918608	Oct 14, 2035	U-3071			
	10918608	Oct 14, 2035	U-3072			
	10918608	Oct 14, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 14, 2035	U-3071			
	11096905	Oct 14, 2035	DS DP U-2780			
	11096905	Oct 14, 2035	DS DP U-2781			
	11154516	Jun 17, 2034	U-3235			
	11154516	Jun 17, 2034	U-3236			
	11160795	Mar 01, 2041	U-3233			
	9949937	Jun 17, 2035	U-2421			
	9956183	Jun 17, 2035	U-2422			
	9956183	Jun 17, 2035	U-2423			
	9956184	Jun 17, 2035	U-2424			
	9956185	Jun 17, 2035	U-2425			
	9956186	Jun 17, 2035	U-2426			
CAPMATINIB HYDROCHLORIDE - TABRECTA						
N 213591 001	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
CAPMATINIB HYDROCHLORIDE - TABRECTA						
N 213591 002	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CAPMATINIB HYDROCHLORIDE - TABRECTA						
N 213591 002	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
CAPSAICIN - QUTENZA						
N 022395 001	10034841	Sep 06, 2025	DP		I-838	Jul 17, 2023
	10463598	Sep 05, 2023	DP			
	10869827	Sep 05, 2023	DP			
	8263059	Sep 05, 2023	U-2705			
	8821920	Mar 26, 2030	DP			
	8889113	Sep 05, 2023	U-2705			
	9226903	Dec 15, 2028	DP			
CARBAMAZEPINE - EQUETRO						
N 021710 001	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO						
N 021710 002	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - EQUETRO						
N 021710 003	6977253	May 19, 2024	U-693			
CARBAMAZEPINE - CARNEXIV						
N 206030 001	7635773	Mar 13, 2029	DP		ODE-124	Oct 07, 2023
	8410077	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9629797	Nov 10, 2028	U-2004			
	9629797	Nov 10, 2028	U-2005			
	9629797	Nov 10, 2028	U-2006			
	9750822	Mar 13, 2029	DP			
	9770407	Nov 10, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 001	7094427	May 29, 2022	DP U-1645	Y		
	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	003	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - RYTARY							
N 203312	004	7094427	May 29, 2022	DP U-1645	Y		
		8377474	Dec 26, 2028	DP U-1645			
		8377474	Dec 26, 2028	DP U-219			
		8454998	Dec 26, 2028	DP U-1645			
		8454998	Dec 26, 2028	DP U-1646			
		8454998	Dec 26, 2028	DP U-1647			
		8454998	Dec 26, 2028	DP U-1649			
		8454998	Dec 26, 2028	DP U-219			
		8557283	Dec 26, 2028	DP U-1645			
		8557283	Dec 26, 2028	DP U-219			
		9089607	Dec 26, 2028	DP U-1645			
		9089607	Dec 26, 2028	DP U-1720			
		9089608	Dec 26, 2028	DP			
		9463246	Dec 26, 2028	DP U-219			
		9533046	Dec 26, 2028	DP U-219			
		9901640	Dec 26, 2028	DP U-219			
CARBIDOPA; LEVODOPA - DUOPA							
N 203952	001					ODE-84	Jan 09, 2022
CARBINOXAMINE MALEATE - KARBINAL ER							
N 022556	001	8062667	Mar 29, 2029	DP			
		9522191	Jun 15, 2027	DP			
CARFILZOMIB - KYPROLIS							
N 202714	001	7232818	Apr 14, 2025	DS DP		I-842	Aug 20, 2023
		7417042	Jul 20, 2026	DS DP			
		7491704	Apr 14, 2025	U-1260			
		7491704	Apr 14, 2025	U-2319			
		7491704	Apr 14, 2025	U-2320			
		7491704	Apr 14, 2025	U-2947			
		7737112	Dec 07, 2027	DP			
		8129346	Apr 14, 2025	U-1260			
		8129346	Apr 14, 2025	U-2319			
		8129346	Apr 14, 2025	U-2320			
		8129346	Apr 14, 2025	U-2947			
		8207125	Apr 14, 2025	DS DP			
		8207126	Apr 14, 2025	DP			
		8207127	Apr 14, 2025	U-1260			
		8207127	Apr 14, 2025	U-2319			
		8207127	Apr 14, 2025	U-2320			
		8207127	Apr 14, 2025	U-2947			
		8207297	Apr 14, 2025	DS DP			
		9493582	Feb 27, 2033	DP			
		9511109	Oct 21, 2029	U-1924			
CARFILZOMIB - KYPROLIS							
N 202714	002	7232818	Apr 14, 2025	DS DP		I-842	Aug 20, 2023
		7417042	Jul 20, 2026	DS DP			
		7491704	Apr 14, 2025	U-1260			
		7491704	Apr 14, 2025	U-2319			
		7491704	Apr 14, 2025	U-2320			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARFILZOMIB - KYPROLIS						
N 202714 002	7491704	Apr 14, 2025	U-2947			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-1260			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8129346	Apr 14, 2025	U-2947			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207127	Apr 14, 2025	U-2947			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
CARFILZOMIB - KYPROLIS						
N 202714 003	7232818	Apr 14, 2025	DS DP		I-842	Aug 20, 2023
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025	U-2319			
	7491704	Apr 14, 2025	U-2320			
	7491704	Apr 14, 2025	U-2947			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8129346	Apr 14, 2025	U-2947			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207127	Apr 14, 2025	U-2947			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
CARGLUMIC ACID - CARGLUMIC ACID						
A 213729 001					CGT	Jun 18, 2022
CARGLUMIC ACID - CARBAGLU						
N 022562 001					ODE-345	Jan 22, 2028
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7943621	Dec 16, 2028	DS DP			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7943621	Dec 16, 2028	DS DP			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			
CARIPRAZINE HYDROCHLORIDE - VRAYLAR						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARIPRAZINE HYDROCHLORIDE - VRAYLAR							
N 204370	004	7737142	Sep 17, 2029	DS DP U-1750		I-798	May 24, 2022
		7737142	Sep 17, 2029	DS DP U-2543			
		7737142	Sep 17, 2029	DS DP U-2544			
		7943621	Dec 16, 2028	DS DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	001	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	002	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	003	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CARVEDILOL PHOSPHATE - COREG CR							
N 022012	004	7268156	Jun 27, 2023	DS DP U-3			
		7268156	Jun 27, 2023	DS DP U-313			
		8101209	Sep 11, 2025	DP			
CASIMERSEN - AMONDYS 45							
N 213026	001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
		10781450	Nov 12, 2030	U-3089		ODE-347	Feb 25, 2028
		8524880	Apr 02, 2026	DS DP U-3087			
		8524880	Apr 02, 2026	DS DP U-3088			
		9228187	Nov 12, 2030	DS DP			
		9447415	Jun 28, 2025	DS DP			
		9758783	Nov 12, 2030	U-3088			
		9758783	Nov 12, 2030	U-3089			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE							
N 206110	001	9636407	Dec 21, 2032	DP			
CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE							
N 206110	002	9636407	Dec 21, 2032	DP			
CEDAZURIDINE; DECITABINE - INQOVI							
N 212576	001	8268800	Aug 22, 2030	DS U-2864		NCE	Jul 07, 2025
		8268800	Aug 22, 2030	DS U-2865		ODE-316	Jul 07, 2027
		8268800	Aug 22, 2030	DS U-2866			
		8268800	Aug 22, 2030	DS U-2867			
		8618075	Oct 16, 2028	U-2864			
		8618075	Oct 16, 2028	U-2867			
		9567363	Oct 16, 2028	DS			
CEFIDEROCOL SULFATE TOSYLATE - FETROJA							
N 209445	001	10004750	Sep 03, 2035	DS DP		I-844	Sep 25, 2023
		9238657	Nov 19, 2031	DS DP U-282		NCE	Nov 14, 2024
		9949982	Sep 03, 2035	DP		GAIN	Nov 14, 2029
CEFIXIME - SUPRAX							
N 202091	001	9233112	Dec 14, 2028	DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	001	6417175	Apr 11, 2022	DS DP U-1676		NPP	Sep 13, 2022
		8247400	Feb 10, 2031	DP U-282			
		9629861	Sep 21, 2030	DP			
CEFTAROLINE FOSAMIL - TEFLARO							
N 200327	002	6417175	Apr 11, 2022	DS DP U-1676		NPP	Sep 13, 2022
		8247400	Feb 10, 2031	DP U-282			
		9629861	Sep 21, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	10028963	Sep 07, 2032	U-2565		NCE	Dec 19, 2019
	10028963	Sep 07, 2032	U-2566		GAIN	Dec 19, 2024
	10125149	Aug 14, 2035	DP			
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
	10420841	Mar 14, 2034	U-1672			
	10420841	Mar 14, 2034	U-2631			
	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-36			
	8476425	Sep 27, 2032	DS			
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	9320740	Mar 14, 2034	DP			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
	9872906	Mar 14, 2034	DP			
CELECOXIB - ELYXYB						
N 212157 001	10376527	May 27, 2036	DP U-2718		NP	May 05, 2023
	10722456	May 27, 2036	DP U-2718			
	10799517	May 27, 2036	DP U-2718			
	9572819	May 27, 2036	DP U-2718			
	9795620	May 27, 2036	DP U-2718			
	9949990	May 27, 2036	DP U-2718			
CELECOXIB; TRAMADOL HYDROCHLORIDE - SEGLENTIS						
N 213426 001	10238668	Apr 19, 2030	DS DP U-3244		NP	Oct 15, 2024
	10245276	Apr 19, 2030	DS DP			
	10548909	Apr 19, 2030	U-3244			
	8598152	Apr 19, 2030	DS DP			
	8846744	Jun 03, 2031	DP			
	9012440	Apr 19, 2030	DS DP			
CENOBAMATE - XCOPRI						
N 212839 001	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
CENOBAMATE - XCOPRI						
N 212839 002	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
CENOBAMATE - XCOPRI						
N 212839 003	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
CENOBAMATE - XCOPRI						
N 212839 004	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
CENOBAMATE - XCOPRI						
N 212839 005	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
CENOBAMATE - XCOPRI						
N 212839 006	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
CERITINIB - ZYKADIA						
N 205755 001	7893074	Apr 25, 2026	DS DP		ODE-145	May 26, 2024
	7964592	Apr 29, 2028	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CERITINIB - ZYKADIA							
N 211225	001	7893074	Apr 25, 2026	DS DP		ODE*	May 26, 2024
		7964592	Apr 29, 2028	DS DP			
		8039479	Jun 29, 2030	DS DP			
		8188276	Jan 31, 2023	DS DP			
		8377921	Nov 20, 2027	U-1179			
		8399450	Nov 20, 2027	DS DP			
		8703787	Feb 02, 2032	U-1179			
		8835430	Jan 31, 2023	DS DP			
		9018204	Jan 31, 2023	DS DP			
		9309229	Jan 18, 2032	DS DP			
		9416112	Jan 31, 2023	DS DP			
CETIRIZINE HYDROCHLORIDE - ZERVIATE							
N 208694	001	8829005	Mar 15, 2030	U-1680			
		8829005*PED	Sep 15, 2030				
		9254286	Jul 09, 2032	DP			
		9254286*PED	Jan 09, 2033				
		9750684	Mar 15, 2030	DP			
		9993471	Mar 15, 2030	U-1680			
CETIRIZINE HYDROCHLORIDE - QUZYTTIR							
N 211415	001	8263581	Feb 28, 2030	U-2635		NP	Oct 04, 2022
		8314083	Feb 28, 2030	U-2634			
		8513259	Feb 11, 2030	U-2636			
		9119771	Feb 11, 2030	U-2635			
		9180090	Feb 11, 2030	U-2635			
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR							
N 021150	002	7014867	Jun 10, 2022	DP			
		7226614	Jun 10, 2022	U-295			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE							
N 021669	001	7066916	Feb 17, 2024	U-737			
		7427574	Apr 25, 2026	DP			
		7595021	May 12, 2023	DP U-1022			
		7717889	Feb 27, 2025	DP U-1022			
		7935093	Oct 02, 2027	DP U-1022			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	002	6729786	Mar 14, 2023	DP			
		6991394	Jan 31, 2024	DP			
		7182536	Dec 30, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	005	6729786	Mar 14, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP							
N 020832	006	6991394	Jan 31, 2024	DP			
		7182536	Dec 30, 2023	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT							
N 020832	007	6729786	Mar 14, 2023	DP			
		7241065	Mar 14, 2023	DP			
		7422388	Apr 25, 2027	DP U-1397			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP							
N 208288	001	8623935	Jul 26, 2029	DP U-1022			
CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL							
N 208791	001	8969412	Sep 05, 2026	DP U-2609			
		9504666	Dec 11, 2033	DP			
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER							
N 206323	001	9066942	Jan 03, 2032	U-1716			
		9107921	Jan 03, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS								
N	021441	001	7863287	Feb 28, 2027	DP			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS								
N	021587	001	10238640	May 25, 2024	DP			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR								
N	207768	001	8062667	Mar 29, 2029	DP			
			8790700	Mar 15, 2027	DP			
CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE								
A	214542	001					CGT	Jan 29, 2022
CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE								
A	214542	002					CGT	Jan 29, 2022
CHLORZOXAZONE - CHLORZOXAZONE								
A	215158	001					CGT	Mar 29, 2022
CHOLIC ACID - CHOLBAM								
N	205750	001					ODE-91	Mar 17, 2022
CHOLIC ACID - CHOLBAM								
N	205750	002					ODE-91	Mar 17, 2022
CHOLINE FENOFIBRATE - TRILIPIX								
N	022224	001	7259186	Jan 07, 2025	DS			
CHOLINE FENOFIBRATE - TRILIPIX								
N	022224	002	7259186	Jan 07, 2025	DS			
CICLESONIDE - ALVESCO								
N	021658	002	8371292	Feb 01, 2028		U-1355		
CICLESONIDE - ALVESCO								
N	021658	003	8371292	Feb 01, 2028		U-1355		
CICLESONIDE - OMNARIS								
N	022004	001	8371292	Feb 01, 2028		U-1356		
CICLESONIDE - ZETONNA								
N	202129	001	8371292	Feb 01, 2028		U-1357		
CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO								
N	212819	001	8487093	Nov 19, 2029	DS DP	U-2586	NCE	Jul 16, 2024
			8487093	Nov 19, 2029	DS DP	U-2587	GAIN	Jul 16, 2029
			8487093	Nov 19, 2029	DS DP	U-2840		
CINACALCET HYDROCHLORIDE - SENSIPAR								
N	021688	001	7829595	Sep 22, 2026	DP	U-1098		
			9375405	Sep 22, 2026	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR								
N	021688	002	7829595	Sep 22, 2026	DP	U-1098		
			9375405	Sep 22, 2026	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR								
N	021688	003	7829595	Sep 22, 2026	DP	U-1098		
			9375405	Sep 22, 2026	DP			
CIPROFLOXACIN - OTIPRIO								
N	207986	001	11040004	Nov 12, 2037		U-2252		
			8318817	Apr 27, 2030		U-1792		
			9205048	Apr 21, 2029		U-1793		
			9220796	Jul 01, 2035	DP			
			9233068	Dec 11, 2029	DP			
			9603796	Apr 21, 2029	DS DP	U-2252		
CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL								
N	208251	001	8932610	Mar 24, 2030	DP	U-1578		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX						
N 021537 001	8846650	Jun 04, 2025	DP U-1578			
	9149486	Sep 13, 2022	DP U-1578			
	9345714	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1578			
	9402805	Sep 13, 2022	DP U-1679			
CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI						
N 208352 001	10568855	Mar 15, 2033	U-1		NP	May 22, 2023
	6706276	Mar 06, 2022	DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ						
N 209589 001	10624879	Jun 23, 2034	DP			
	11191753	Jun 23, 2034	U-3261			
	9827231	Jun 26, 2034	DP U-2162			
CLADRIBINE - MAVENCLAD						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
CLASCOTERONE - WINLEVI						
N 213433 001	10159682	Aug 14, 2028	U-2942		NCE	Aug 26, 2025
	8143240	Jan 12, 2023	U-2942			
	8785427	Jul 25, 2030	DP			
	8865690	Jul 24, 2022	U-2942			
	9211295	Jul 24, 2022	DP			
	9433628	Feb 08, 2029	DP			
	9486458	Jul 24, 2028	U-2942			
CLEVIDIPINE - CLEVIPREX						
N 022156 001	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 002	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLEVIDIPINE - CLEVIPREX						
N 022156 003	10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
CLINDAMYCIN PHOSPHATE - CLINDESSE						
N 050793 001	6899890	Apr 27, 2023	DP U-137			
	9789057	Dec 02, 2026	DP U-137			
CLINDAMYCIN PHOSPHATE - EVOCLIN						
N 050801 001	7141237	Feb 03, 2024	DP			
	7374747	Jan 23, 2024	DP U-921			
CLOBAZAM - SYMPAZAN						
N 210833 001	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
CLOBAZAM - SYMPAZAN						
N 210833 002	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
CLOBAZAM - SYMPAZAN						
N 210833 003	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLOBETASOL PROPIONATE - CLOBEX							
N 021644	001	7700081	Jan 03, 2022	U-1044			
CLOBETASOL PROPIONATE - OLUX E							
N 022013	001	8460641	Nov 05, 2028	DP U-1410			
		8962000	Aug 31, 2025	DP U-1410			
CLOBETASOL PROPIONATE - IMPOYZ							
N 209483	001	10064875	Aug 31, 2030	DP U-1408			
		10064875	Aug 31, 2030	DP U-1858			
		10064875	Aug 31, 2030	DP U-193			
		10064875	Aug 31, 2030	DP U-742			
		10064875	Aug 31, 2030	DP U-88			
		10588914	Aug 31, 2030	DP U-2771			
		9855334	Mar 11, 2035	DP			
		9956231	Aug 31, 2030	DP U-1408			
		9956231	Aug 31, 2030	DP U-1761			
		9956231	Aug 31, 2030	DP U-1858			
		9956231	Aug 31, 2030	DP U-193			
		9956231	Aug 31, 2030	DP U-742			
		9956231	Aug 31, 2030	DP U-88			
CLONIDINE - NEXICLON XR							
N 022500	001	8337890	Apr 17, 2027	DP			
		8623409	Sep 08, 2031	DP			
CLONIDINE - NEXICLON XR							
N 022500	002	8337890	Apr 17, 2027	DP			
		8623409	Sep 08, 2031	DP			
CLOZAPINE - VERSACLOZ							
N 203479	001	8057811	May 01, 2028	DP			
COBICISTAT - TYBOST							
N 203094	001	10039718	Oct 06, 2032	DP		NPP	Aug 22, 2022
		10039718*PED	Apr 06, 2033			ODE-260	Aug 22, 2026
		8148374	Sep 03, 2029	DS DP U-1279			
		8148374*PED	Mar 03, 2030				
COBICISTAT; DARUNAVIR - PREZCOBIX							
N 205395	001	10039718	Oct 06, 2032	DP			
		7700645	Dec 26, 2026	DS DP			
		7700645*PED	Jun 26, 2027				
		8148374	Sep 03, 2029	DS DP U-1279			
		8148374	Sep 03, 2029	DS DP U-2939			
		8518987	Feb 16, 2024	DS DP			
		8518987*PED	Aug 16, 2024				
COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA							
N 210455	001	10039718	Oct 06, 2032	DP			
		10786518	Jul 19, 2038	U-2978			
		7390791	Apr 17, 2025	DS DP			
		7700645	Dec 26, 2026	DS DP			
		7803788	Feb 02, 2022	U-2352			
		7803788	Feb 02, 2022	U-2765			
		8148374	Sep 03, 2029	DS DP U-2353			
		8148374	Sep 03, 2029	DS DP U-2364			
		8148374	Sep 03, 2029	DS DP U-2365			
		8148374	Sep 03, 2029	DS DP U-2766			
		8148374	Sep 03, 2029	DS DP U-2767			
		8148374	Sep 03, 2029	DS DP U-2768			
		8518987	Feb 16, 2024	DS DP			
		8754065	Aug 15, 2032	DS DP U-2352			
		8754065	Aug 15, 2032	DS DP U-2765			
		9296769	Aug 15, 2032	DS DP U-2352			
		9296769	Aug 15, 2032	DS DP U-2765			
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA							
N 207561	001	10039718	Oct 06, 2032	DP			
		10039718*PED	Apr 06, 2033				
		7176220	Aug 27, 2026	DS DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA							
N 207561	001	7176220*PED	Feb 27, 2027				
		7390791	Apr 17, 2025	DS DP			
		7390791*PED	Oct 17, 2025				
		7635704	Oct 26, 2026	DS DP U-257			
		7635704*PED	Apr 26, 2027				
		7803788	Feb 02, 2022	U-257			
		8148374	Sep 03, 2029	DS DP U-1279			
		8148374*PED	Mar 03, 2030				
		8633219	Apr 24, 2030	DP U-257			
		8633219*PED	Oct 24, 2030				
		8754065	Aug 15, 2032	DS DP U-257			
		8754065*PED	Feb 15, 2033				
		8981103	Oct 26, 2026	DS DP			
		8981103*PED	Apr 26, 2027				
		9296769	Aug 15, 2032	DS DP U-257			
		9296769*PED	Feb 15, 2033				
		9891239	Sep 03, 2029	DP U-257			
		9891239*PED	Mar 03, 2030				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD							
N 203100	001	10039718	Oct 06, 2032	DP			
		10039718*PED	Apr 06, 2033				
		7176220	Aug 27, 2026	DS DP U-257			
		7176220*PED	Feb 27, 2027				
		7635704	Oct 26, 2026	DS DP U-257			
		7635704*PED	Apr 26, 2027				
		8148374	Sep 03, 2029	DS DP U-1279			
		8592397	Jan 13, 2024	DP U-257			
		8633219	Apr 24, 2030	DP U-257			
		8633219*PED	Oct 24, 2030				
		8716264	Jan 13, 2024	DP U-257			
		8981103	Oct 26, 2026	DS DP			
		8981103*PED	Apr 26, 2027				
		9457036	Jan 13, 2024	DP U-257			
		9744181	Jan 13, 2024	DP U-257			
		9891239	Sep 03, 2029	DP U-257			
		9891239*PED	Mar 03, 2030				
COBIMETINIB FUMARATE - COTELLIC							
N 206192	001	10478400	Jun 29, 2036	DS DP U-1776		ODE-101	Nov 10, 2022
		10590102	Jun 30, 2036	DS DP U-1776			
		11087354	Jun 22, 2034	U-1776			
		7803839	Nov 10, 2029	DS DP			
		8362002	Oct 05, 2026	U-1776			
COCAINE HYDROCHLORIDE - NUMBRINO							
N 209575	001					NCE	Dec 14, 2022
						NP	Jan 10, 2023
COCAINE HYDROCHLORIDE - GOPRELTO							
N 209963	001	10016407	Feb 07, 2037	U-2329		NCE	Dec 14, 2022
		10149843	Feb 07, 2037	U-2478			
		10149843	Feb 07, 2037	U-2479			
		10231961	Feb 07, 2037	DP			
		10413505	Feb 07, 2037	U-2479			
		10420760	Feb 07, 2037	U-2478			
		10857095	Feb 07, 2037	U-3014			
		10894012	Feb 07, 2037	U-3014			
		10933060	Feb 07, 2037	U-3014			
		10973811	Feb 07, 2037	U-2226			
		10987347	Feb 07, 2037	U-2225			
		11040032	Feb 07, 2037	DP			
		9867815	Feb 07, 2037	U-2225			
		9867815	Feb 07, 2037	U-2226			
		9867815	Feb 07, 2037	U-2227			
COLCHICINE - COLCRYS							
N 022352	001	7601758	Feb 10, 2029	U-1007			
		7619004	Dec 03, 2028	U-1020			
		7820681	Feb 17, 2029	U-1020			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLCHICINE - COLCRYS							
N 022352	001	7906519	Feb 17, 2029	U-1116			
		7915269	Feb 17, 2029	U-1007			
		7935731	Dec 03, 2028	U-1116			
		7964647	Oct 06, 2028	U-1007			
		7964648	Oct 06, 2028	U-1161			
		7981938	Oct 06, 2028	U-1166			
		8093296	Oct 06, 2028	U-1007			
		8093297	Oct 06, 2028	U-1161			
		8093298	Oct 06, 2028	U-1116			
		8097655	Oct 06, 2028	U-1020			
		8415395	Oct 06, 2028	U-1007			
		8415396	Oct 06, 2028	U-1007			
		8440721	Feb 17, 2029	U-1007			
		8440722	Feb 17, 2029	U-1020			
COLCHICINE - MITIGARE							
N 204820	001	8927607	Aug 22, 2033	U-1020			
		9399036	Aug 22, 2033	U-1020			
		9555029	Aug 22, 2033	U-1020			
		9675613	Aug 22, 2033	U-1020			
		9789108	Aug 22, 2033	U-1020			
COLCHICINE - GLOPERBA							
N 210942	001	10226423	Dec 20, 2037	DP			
		10383820	Nov 22, 2036	DP U-2814			
		10383821	Nov 22, 2036	DP			
		9907751	Nov 22, 2036	DP			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 021176	001	7229613	Apr 17, 2022	U-851			
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 022362	001	7229613	Apr 17, 2022	U-493		M-232	Oct 20, 2024
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 022362	002	7229613	Apr 17, 2022	U-493		M-232	Oct 20, 2024
COLESEVELAM HYDROCHLORIDE - WELCHOL							
N 210895	001	7229613	Apr 17, 2022	U-2516			
COPANLISIB DIHYDROCHLORIDE - ALIQOPA							
N 209936	001	10383876	Mar 29, 2032	DS DP		NCE	Sep 14, 2022
		7511041	May 13, 2024	DS DP		ODE-155	Sep 14, 2024
		9636344	Mar 29, 2032	U-2124			
		RE46856	Oct 22, 2029	DS DP U-2124			
COPPER DOTATATE CU-64 - DETECTNET							
N 213227	001	10159759	Aug 23, 2032	U-2951		NCE	Sep 03, 2025
		10383961	Aug 23, 2032	U-2951		ODE-317	Sep 03, 2027
		11160888	Aug 23, 2032	U-2951			
CRISABOROLE - EUCRISA							
N 207695	001	8039451	Jun 29, 2029	DS DP		NPP	Mar 23, 2023
		8039451*PED	Dec 29, 2029			PED	Sep 23, 2023
		8168614	Jan 20, 2030	U-1932			
		8168614*PED	Jul 20, 2030				
		8501712	Feb 16, 2027	U-1932			
		8501712*PED	Aug 16, 2027				
		9682092	Feb 16, 2027	U-1932			
		9682092*PED	Aug 16, 2027				
CRIZOTINIB - XALKORI							
N 202570	001	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
		7825137	May 12, 2027	U-3057		ODE-111	Mar 11, 2023
		7825137	May 12, 2027	U-3058		ODE-328	Jan 14, 2028
		7858643	Oct 08, 2029	DS DP			
		8217057	Nov 06, 2029	DS DP			
		8785632	Mar 01, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CRIZOTINIB - XALKORI							
N 202570	002	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
		7825137	May 12, 2027	U-3057		ODE-111	Mar 11, 2023
		7825137	May 12, 2027	U-3058		ODE-328	Jan 14, 2028
		7858643	Oct 08, 2029	DS DP			
		8217057	Nov 06, 2029	DS DP			
		8785632	Mar 01, 2025	DS			
CROFELEMER - MYTESI							
N 202292	001	7341744	Jun 02, 2022	DP U-1319			
		8962680	Oct 31, 2031	U-1319			
		9585868	Oct 31, 2031	U-1319			
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT							
N 209376	001					NCE	Apr 30, 2024
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT							
N 209376	002					NCE	Apr 30, 2024
CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS							
N 209376	003					NCE	Apr 30, 2024
CYANOCOBALAMIN - NASCOBAL							
N 021642	001	7229636	Aug 01, 2024	DP U-817			
		7404489	Mar 12, 2024	DP			
		7879349	Aug 01, 2024	DP U-1152			
		8003353	Aug 01, 2024	U-817			
		8940714	Feb 26, 2024	U-1152			
		9415007	Jul 28, 2024	U-1896			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX							
N 021777	001	7387793	Feb 26, 2025	DP			
		7544372	Nov 14, 2023	U-979			
		7790199	Nov 14, 2023	DP			
		7820203	Nov 14, 2023	DP			
		7829121	Nov 14, 2023	U-1088			
		8877245	Nov 14, 2023	U-979			
		9375410	Nov 14, 2023	U-1088			
		9399025	Nov 14, 2023	DP U-979			
CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX							
N 021777	002	7387793	Feb 26, 2025	DP			
		7544372	Nov 14, 2023	U-979			
		7790199	Nov 14, 2023	DP			
		7820203	Nov 14, 2023	DP			
		7829121	Nov 14, 2023	U-1088			
		8877245	Nov 14, 2023	U-979			
		9375410	Nov 14, 2023	U-1088			
		9399025	Nov 14, 2023	DP U-979			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE							
N 210735	001	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE							
N 210735	002	9662342	Jun 26, 2035	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE							
N 212501	001	10993952	Feb 15, 2036	DP			
CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE							
N 212501	002	10993952	Feb 15, 2036	DP			
CYCLOSPORINE - RESTASIS							
N 050790	001	8629111	Aug 27, 2024	DP			
		8633162	Aug 27, 2024	U-1479			
		8642556	Aug 27, 2024	DP			
		8648048	Aug 27, 2024	U-1483			
		8685930	Aug 27, 2024	DP			
		9248191	Aug 27, 2024	U-1479			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYCLOSPORINE - RESTASIS MULTIDOSE						
N 050790 002	8292129	Feb 25, 2031	DP			
	8561859	Apr 16, 2032	DP			
	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
	9248191	Aug 27, 2024	U-1479			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
CYCLOSPORINE - CEQUA						
N 210913 001	10441630	Aug 23, 2033	DP			
	10918694	Feb 28, 2037	DP			
	8980839	Aug 23, 2033	DP U-1483			
	9937225	Aug 23, 2033	DP U-1483			
CYCLOSPORINE - VERKAZIA						
N 214965 001	7973081	Jan 27, 2026	DP		NP	Jun 23, 2023
	8298568	Nov 03, 2027	DP		ODE-358	Jun 23, 2028
	8524779	Jan 27, 2026	DP			
	9132071	Jun 02, 2029	DP			
	9220694	Jan 27, 2026	DP			
	9956289	Jan 27, 2026	DP			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		ODE-97	Aug 14, 2022
	10548859	Aug 16, 2036	U-1399		PED	Feb 14, 2023
	10905662	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 002	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		ODE-97	Aug 14, 2022
	10548859	Aug 16, 2036	U-1399		PED	Feb 14, 2023
	10905662	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925157	Jan 26, 2027	DS DP U-1399			
	9925158	Jan 26, 2027	DS DP U-1399			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 213491 001	10143665	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	10328037	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10548859	Aug 16, 2036	U-1399		PED	Feb 14, 2023
	10905662	Aug 16, 2036	U-1399			
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI							
N 213491	001	9173851	Jun 17, 2034	DP			
		9173851*PED	Dec 17, 2034				
		9192590	Jan 26, 2027	U-1399			
		9192590*PED	Jul 26, 2027				
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				
		9925156	Jan 26, 2027	DP U-1399			
		9925157	Jan 26, 2027	DP U-1399			
		9925158	Jan 26, 2027	DP U-1399			
CYSTEAMINE BITARTRATE - PROCYSBI							
N 213491	002	10143665	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
		10328037	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
		10548859	Aug 16, 2036	U-1399		PED	Feb 14, 2023
		10905662	Aug 16, 2036	U-1399			
		8026284	Sep 22, 2027	U-1399			
		8026284*PED	Mar 22, 2028				
		9173851	Jun 17, 2034	DP			
		9173851*PED	Dec 17, 2034				
		9192590	Jan 26, 2027	U-1399			
		9192590*PED	Jul 26, 2027				
		9198882	Jan 26, 2027	U-1399			
		9198882*PED	Jul 26, 2027				
		9233077	Jun 17, 2034	DP			
		9233077*PED	Dec 17, 2034				
		9925156	Jan 26, 2027	DP U-1399			
		9925157	Jan 26, 2027	DP U-1399			
		9925158	Jan 26, 2027	DP U-1399			
CYSTEAMINE HYDROCHLORIDE - CYSTADROPS							
N 211302	001					NP	Aug 19, 2023
CYSTEINE HYDROCHLORIDE - ELCYS							
N 210660	001	10478453	Jan 15, 2039	DP U-2752			
		10583155	Jan 15, 2039	DP U-2752			
		10653719	Jan 15, 2039	DP			
		10905713	Jan 15, 2039	DP			
		10905714	Jan 15, 2039	DP			
		10912795	Jan 15, 2039	DP			
		10918662	Jan 15, 2039	DP			
		10933089	Jan 15, 2039	DP			
CYSTEINE HYDROCHLORIDE - NOURESS							
N 212535	001	10478453	Jan 15, 2039	DP U-2752			
		10493051	Mar 15, 2039	DP			
		10543186	Mar 15, 2039	U-2722			
		10583155	Jan 15, 2039	DP U-2752			
		10653719	Jan 15, 2039	DP			
		10702490	Mar 15, 2039	DP			
		10905713	Jan 15, 2039	DP			
		10905714	Jan 15, 2039	DP			
		10912795	Jan 15, 2039	DP			
		10918662	Jan 15, 2039	DP			
		10933089	Jan 15, 2039	DP			
		11045438	Mar 15, 2039	DP			
CYTARABINE; DAUNORUBICIN - VYXEOS							
N 209401	001	10028912	Sep 29, 2034	DP U-3149		NPP	Mar 30, 2024
		10028912	Sep 29, 2034	DP U-3150		ODE-287	Aug 03, 2024
		10166184	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028
		10835492	Oct 15, 2032	U-3150			
		7850990	Jan 23, 2027	DP U-3147			
		8022279	Sep 14, 2027	DP U-3147			
		8092828	Apr 01, 2029	U-3147			
		8431806	Apr 22, 2025	DP U-3147			
		8518437	Jun 07, 2026	DP			
		9271931	Jan 23, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	001	6087380*PED	Jun 28, 2022			I-862	Jun 21, 2024
		7866474	Aug 31, 2027	DP	Y	PED	Dec 21, 2024
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			
		9034822*PED	Jul 20, 2031				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	002	6087380*PED	Jun 28, 2022			I-862	Jun 21, 2024
		7866474	Aug 31, 2027	DP	Y	PED	Dec 21, 2024
		7932273	Sep 07, 2025	DS DP			
		9034822	Jan 20, 2031	U-1759			
		9034822*PED	Jul 20, 2031				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 022512	003	6087380*PED	Jun 28, 2022			I-862	Jun 21, 2024
		7866474	Aug 31, 2027	DP	Y	PED	Dec 21, 2024
		7866474*PED	Mar 02, 2028				
		7932273	Sep 07, 2025	DS DP			
		7932273*PED	Mar 07, 2026				
		9034822	Jan 20, 2031	U-1759			
		9034822*PED	Jul 20, 2031				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 214358	001	6087380*PED	Jun 28, 2022			NP	Jun 21, 2024
		7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
		7932273*PED	Mar 07, 2026				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 214358	002	6087380*PED	Jun 28, 2022			NP	Jun 21, 2024
		7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
		7932273*PED	Mar 07, 2026				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 214358	003	6087380*PED	Jun 28, 2022			NP	Jun 21, 2024
		7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
		7932273*PED	Mar 07, 2026				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 214358	004	6087380*PED	Jun 28, 2022			NP	Jun 21, 2024
		7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
		7932273*PED	Mar 07, 2026				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 214358	005	6087380*PED	Jun 28, 2022			NP	Jun 21, 2024
		7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
		7932273*PED	Mar 07, 2026				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				
DABIGATRAN ETEXILATE MESYLATE - PRADAXA							
N 214358	006	6087380*PED	Jun 28, 2022			NP	Jun 21, 2024
		7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
		7932273*PED	Mar 07, 2026				
		9925174	Jun 14, 2023	DP			
		9925174*PED	Dec 14, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 001	10869869	Aug 30, 2033	U-3185		M-246	Oct 06, 2022
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8952018	Oct 15, 2030	U-2027			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
DABRAFENIB MESYLATE - TAFINLAR						
N 202806 002	10869869	Aug 30, 2033	U-3185		M-246	Oct 06, 2022
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8952018	Oct 15, 2030	U-2027			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 001	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 002	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
DACOMITINIB - VIZIMPRO						
N 211288 001	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
	8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
					ODE-213	Sep 27, 2025
DACOMITINIB - VIZIMPRO						
N 211288 002	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
	8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
					ODE-213	Sep 27, 2025
DACOMITINIB - VIZIMPRO						
N 211288 003	7772243	Aug 26, 2028	DS DP		NCE	Sep 27, 2023
	8623883	May 05, 2025	U-1403		ODE-206	Sep 27, 2025
					ODE-213	Sep 27, 2025
DALBAVANCIN HYDROCHLORIDE - DALVANCE						
N 021883 001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		NPP	Jul 22, 2024
	7119061	Nov 14, 2023	DP		GAIN	May 23, 2024
	8143212	Nov 14, 2023	U-1517			
DALTEPARIN SODIUM - FRAGMIN						
N 020287 001					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 002					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 003					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 004					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 005					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 006					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 007					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 008					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 009					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 010					NPP	May 16, 2022
DALTEPARIN SODIUM - FRAGMIN						
N 020287 011					NPP	May 16, 2022
DANTROLENE SODIUM - RYANODEX						
N 205579 001	7758890	Jul 01, 2025	DP			
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
	9884044	Jun 13, 2022	DP U-1546			
DAPAGLIFLOZIN - FARXIGA						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		I-834	May 05, 2023
	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
	7456254	Jun 30, 2025	DP U-2139		I-857	Apr 30, 2024
	7851502	Aug 19, 2028	DP		M-238	Feb 22, 2022
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN - FARXIGA						
N 202293 001	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN - FARXIGA						
N 202293 002	10973836	Mar 09, 2040	U-3127		I-834	May 05, 2023
	6515117	Oct 04, 2025	DS DP U-2139		I-841	Oct 18, 2022
	6515117	Oct 04, 2025	DS DP U-493		I-857	Apr 30, 2024
	7456254	Jun 30, 2025	DP U-2139		M-238	Feb 22, 2022
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493		I-841	Oct 18, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 001	6515117	Oct 04, 2025	DS DP U-493		NP	May 02, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 002	6515117	Oct 04, 2025	DS DP U-493		NP	May 02, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 003	6515117	Oct 04, 2025	DS DP U-493		NP	May 02, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR						
N 210874 004	6515117	Oct 04, 2025	DS DP U-493		NP	May 02, 2022
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN						
N 209091 001	6515117	Oct 04, 2025	DS DP U-493		I-804	May 02, 2022
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN						
N 209091 002	6515117	Oct 04, 2025	DS DP U-493		NS	May 02, 2022
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
DAPSONE - ACZONE						
N 207154 001	9161926	Nov 18, 2033	DP		NPP	Sep 10, 2022
	9517219	Nov 18, 2033	U-1033			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DAPTOMYCIN - CUBICIN						
N 021572 002	8003673	Sep 04, 2028	U-1180			
DAPTOMYCIN - CUBICIN RF						
N 021572 003	9138456	Nov 23, 2030	DP			
DAPTOMYCIN - DAPTOMYCIN						
N 210282 001	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
DAPTOMYCIN - DAPTOMYCIN						
N 210282 002	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
DAROLUTAMIDE - NUBEQA						
N 212099 001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10383853	Jan 28, 2036	DS			
	10711013	Oct 27, 2030	DS DP			
	10835515	Jan 28, 2036	DP U-2605			
	11046713	Oct 27, 2030	DS			
	8975254	Oct 27, 2030	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
DARUNAVIR - PREZISTA						
N 021976 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 002	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 003	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 004	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 005	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 021976 006	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DARUNAVIR - PREZISTA						
N 202895 001	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)						
N 206619 001	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9629841	Oct 18, 2033	DP U-1753			
DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR						
N 208624 001	10105365	Jan 02, 2035	DP U-1889			
	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
	9744170	Jan 02, 2035	DP U-1889			
DASATINIB - SPRYCEL						
N 021986 001	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 002	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 003	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 004	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 005	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASATINIB - SPRYCEL						
N 021986 006	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERASIROX - EXJADE						
N 021882 001					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - EXJADE						
N 021882 002					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - EXJADE						
N 021882 003					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - JADENU						
N 206910 001	9283209	Nov 21, 2034	DS DP		M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - JADENU						
N 206910 002	9283209	Nov 21, 2034	DS DP		M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - JADENU						
N 206910 003	9283209	Nov 21, 2034	DS DP		M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - JADENU SPRINKLE						
N 207968 001					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - JADENU SPRINKLE						
N 207968 002					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERASIROX - JADENU SPRINKLE						
N 207968 003					M-241	Jul 24, 2022
					M-263	Jul 23, 2023
DEFERIPRONE - FERRIPROX						
N 021825 001					I-859	Apr 30, 2024
DEFERIPRONE - FERRIPROX						
N 021825 002					I-859	Apr 30, 2024
DEFERIPRONE - FERRIPROX						
N 208030 001	8703156	Oct 26, 2029	DP U-3083		I-859	Apr 30, 2024
DEFERIPRONE - FERRIPROX						
N 208030 002	8703156	Oct 26, 2029	DP U-3083		I-859	Apr 30, 2024
DEFERIPRONE - FERRIPROX						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
DEFIBROTIDE SODIUM - DEFITELIO						
N 208114 001	11085043	Jun 22, 2032	DP		ODE-112	Mar 30, 2023
DEFLAZACORT - EMFLAZA						
N 208684 001					NCE	Feb 09, 2022
					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 002					NCE	Feb 09, 2022
					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208684 003					NCE	Feb 09, 2022
					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFLAZACORT - EMFLAZA						
N 208684 004					NCE	Feb 09, 2022
					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEFLAZACORT - EMFLAZA						
N 208685 001					NCE	Feb 09, 2022
					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
DEGARELIX ACETATE - FIRMAGON						
N 022201 001	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
DEGARELIX ACETATE - FIRMAGON						
N 022201 002	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208610 001	7728143	Nov 20, 2027	DS		I-815	Oct 24, 2022
	8252813	Oct 02, 2026	DP U-2028		NCE	Jun 19, 2022
	8273892	Aug 06, 2026	DS		GAIN	Jun 19, 2027
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
	RE46617	Dec 28, 2029	DS			
DELAFLOXACIN MEGLUMINE - BAXDELA						
N 208611 001	7635773	Mar 13, 2029	DP		I-815	Oct 24, 2022
	7728143	Nov 20, 2027	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8410077	Mar 13, 2029	DP			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9539250	Oct 07, 2025	DS DP U-2028			
	9750822	Mar 13, 2029	DP			
	RE46617	Dec 28, 2029	DS			
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	10500214	Mar 02, 2030	DP			
	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
	9949986	Feb 21, 2028	U-1940			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR						
N 021605 001	6979463	Mar 28, 2022	DP			
	7820199	Mar 28, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DESMOPRESSIN ACETATE - NOCDURNA						
N 022517 001	10307459	May 07, 2023	DP			
	11020448	May 21, 2029	U-2327			
	7560429	Feb 02, 2024	DP U-2326			
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2326			
DESMOPRESSIN ACETATE - NOCDURNA						
N 022517 002	10137167	May 21, 2029	U-2327			
	10307459	May 07, 2023	DP			
	7560429	Feb 02, 2024	DP U-2326			
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2327			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 001	7405203	May 06, 2023	U-1980			
	7579321	May 06, 2023	U-1980			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
DESMOPRESSIN ACETATE - NOCTIVA						
N 201656 002	7405203	May 06, 2023	U-1980			
	7579321	May 06, 2023	U-1980			
	9539302	Jun 15, 2030	DP			
DESONIDE - VERDESO						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
	8962000	Aug 31, 2025	DP U-1412			
	9492384	Aug 31, 2025	DP U-1412			
DESOXIMETASONE - TOPICORT						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 001	6673838	Mar 01, 2022	DS U-1364			
	6673838	Mar 01, 2022	DS U-860			
	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 002	6673838	Mar 01, 2022	DS U-1364			
	6673838	Mar 01, 2022	DS U-860			
	8269040	Jul 05, 2027	DS			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003	6673838	Mar 01, 2022	DS U-1364			
	6673838	Mar 01, 2022	DS U-860			
	8269040	Jul 05, 2027	DS			
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	11179386	Mar 15, 2038	DP U-1995		ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Oct 03, 2022
	8524733	Apr 03, 2031	DS DP		PED	Oct 03, 2024
	8524733*PED	Oct 03, 2031			PED	Dec 24, 2024
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEUTETRABENAZINE - AUSTEDO						
N 208082 001	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO						
N 208082 002	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	11179386	Mar 15, 2038	DP U-1995		ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Oct 03, 2022
	8524733	Apr 03, 2031	DS DP		PED	Oct 03, 2024
	8524733*PED	Oct 03, 2031			PED	Dec 24, 2024
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEUTETRABENAZINE - AUSTEDO						
N 208082 003	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	11179386	Mar 15, 2038	DP U-1995		ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Oct 03, 2022
	8524733	Apr 03, 2031	DS DP		PED	Oct 03, 2024
	8524733*PED	Oct 03, 2031			PED	Dec 24, 2024
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
DEXAMETHASONE - DEXAMETHASONE						
A 215106 001					CGT	Apr 20, 2022
DEXAMETHASONE - DEXAMETHASONE						
A 215106 002					CGT	Apr 19, 2022
DEXAMETHASONE - OZURDEX						
N 022315 001	10076526	Jan 09, 2023	DP			
	10702539	Jan 09, 2023	U-1597			
	10702539	Jan 09, 2023	U-2868			
	10702539	Jan 09, 2023	U-985			
	6899717	Nov 01, 2023	U-1206			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
	9192511	Jan 09, 2023	DP			
DEXAMETHASONE - DEXTENZA						
N 208742 001	8409606	May 14, 2030	DP		I-800	Jun 20, 2022
	8563027	Feb 12, 2030	U-2487		I-876	Oct 07, 2024
	9254267	Sep 11, 2024	DP			
DEXAMETHASONE - DEXYCU KIT						
N 208912 001	10022502	Jun 22, 2034	U-2340			
	10028965	May 23, 2034	U-2340			
	10159683	May 23, 2034	DP			
	10799642	May 11, 2032	DP			
	6960346	Jul 03, 2023	DP			
	7560120	Sep 05, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXAMETHASONE - HEMADY						
N 211379 001	10537585	Dec 18, 2037	DP		ODE-271	Oct 03, 2026
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			
	8450287	Dec 19, 2027	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT SOLUTAB						
N 208056 001	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038	002	10016396	Jan 04, 2032		DP			
		8242158	Jan 04, 2032		DP			
		8242158*PED	Jul 04, 2032					
		8338470	Jan 04, 2032		DP			
		8338470*PED	Jul 04, 2032					
		8455527	Jan 04, 2032		U-421			
		8455527*PED	Jul 04, 2032					
		8648106	Jan 04, 2032		DP			
		8648106*PED	Jul 04, 2032					
		9320712	Jan 04, 2032		DP			
		9320712*PED	Jul 04, 2032					
		9616049	Jan 04, 2032		DP			
		9616049*PED	Jul 04, 2032					
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038	003	10016396	Jan 04, 2032		DP			
		8242158	Jan 04, 2032		DP			
		8242158*PED	Jul 04, 2032					
		8338470	Jan 04, 2032		DP			
		8338470*PED	Jul 04, 2032					
		8455527	Jan 04, 2032		U-421			
		8455527*PED	Jul 04, 2032					
		8648106	Jan 04, 2032		DP			
		8648106*PED	Jul 04, 2032					
		9320712	Jan 04, 2032		DP			
		9320712*PED	Jul 04, 2032					
		9616049	Jan 04, 2032		DP			
		9616049*PED	Jul 04, 2032					
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX								
N 021038	004	8242158	Jan 04, 2032		DP			
		8242158*PED	Jul 04, 2032					
		8338470	Jan 04, 2032		DP			
		8338470*PED	Jul 04, 2032					
		8455527	Jan 04, 2032		U-421			
		8455527*PED	Jul 04, 2032					
		8648106	Jan 04, 2032		DP			
		8648106*PED	Jul 04, 2032					
		9320712	Jan 04, 2032		DP			
		9320712*PED	Jul 04, 2032					
		9616049	Jan 04, 2032		DP			
		9616049*PED	Jul 04, 2032					
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE								
N 206628	003	9649296	Apr 20, 2036		DP			
		9717796	Apr 20, 2036		DP			
DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE								
N 206628	004	9649296	Apr 20, 2036		DP			
		9717796	Apr 20, 2036		DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS								
N 212994	001	10584112	Dec 09, 2037	DS	DP		NCE	May 07, 2026
		10584113	Dec 09, 2037		DP			
		10759778	Dec 09, 2037		DP			
		10858341	Dec 09, 2037		U-3094			
		10954213	Dec 09, 2037		U-3094			
		9079928	Jul 27, 2032		DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS								
N 212994	002	10584112	Dec 09, 2037	DS	DP		NCE	May 07, 2026
		10584113	Dec 09, 2037		DP			
		10759778	Dec 09, 2037		DP			
		10858341	Dec 09, 2037		U-3094			
		10954213	Dec 09, 2037		U-3094			
		9079928	Jul 27, 2032		DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS								
N 212994	003	10584112	Dec 09, 2037	DS	DP		NCE	May 07, 2026
		10584113	Dec 09, 2037		DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS							
N 212994	003	10759778	Dec 09, 2037	DP			
		10858341	Dec 09, 2037	U-3094			
		10954213	Dec 09, 2037	U-3094			
		9079928	Jul 27, 2032	DP			
DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA							
N 021879	001	7659282	Aug 13, 2026	U-1093			
		8227484	Jul 17, 2023	U-1093			
DIAZEPAM - VALTOCO							
N 211635	001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
		8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
		8927497	Jul 21, 2025	DP U-2727			
		9642913	May 11, 2025	DP			
		9763876	Mar 27, 2029	DP U-2727			
DIAZEPAM - VALTOCO							
N 211635	002	10265402	May 11, 2025	DP		NP	Jan 10, 2023
		8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
		8927497	Jul 21, 2025	DP U-2727			
		9642913	May 11, 2025	DP			
		9763876	Mar 27, 2029	DP U-2727			
DIAZEPAM - VALTOCO							
N 211635	003	10265402	May 11, 2025	DP		NP	Jan 10, 2023
		8895546	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
		8927497	Jul 21, 2025	DP U-2727			
		9642913	May 11, 2025	DP			
		9763876	Mar 27, 2029	DP U-2727			
DICHLORPHENAMIDE - KEVEYIS							
N 011366	002					ODE-96	Aug 07, 2022
DICLOFENAC - ZORVOLEX							
N 204592	001	8679544	Apr 23, 2030	DP			
		8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
		9173854	Apr 23, 2030	DP			
		9180095	Apr 23, 2030	U-55			
		9180096	Apr 23, 2030	DP			
		9186328	Apr 23, 2030	U-55			
DICLOFENAC - ZORVOLEX							
N 204592	002	8679544	Apr 23, 2030	DP			
		8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
		9173854	Apr 23, 2030	DP			
		9180095	Apr 23, 2030	U-55			
		9180096	Apr 23, 2030	DP			
		9186328	Apr 23, 2030	U-55			
DICLOFENAC POTASSIUM - CAMBIA							
N 022165	001	7759394	Jun 16, 2026	DS DP U-436			
		8097651	Jun 16, 2026	DS DP U-436			
		8927604	Jun 16, 2026	U-436			
		9827197	Jun 16, 2026	DP			
DICLOFENAC POTASSIUM - ZIPSOR							
N 022202	001	7662858	Feb 24, 2029	U-1035		NPP	May 25, 2024
		7884095	Feb 24, 2029	U-1111			
		7939518	Feb 24, 2029	U-980			
		8110606	Feb 24, 2029	U-980			
		8623920	Feb 24, 2029	U-1482			
		9561200	Feb 24, 2029	U-1482			
DICLOFENAC SODIUM - PENNSAID							
N 020947	001	8217078	Jul 10, 2029	U-1248			
		8546450	Aug 09, 2030	U-1435			
		8546450	Aug 09, 2030	U-1436			
		8618164	Jul 10, 2029	U-1477			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DICLOFENAC SODIUM - PENNSAID						
N 020947 001	8741956	Jul 10, 2029	U-1435			
DICLOFENAC SODIUM - DYLOJECT						
N 022396 001	8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID						
N 204623 001	8217078	Jul 10, 2029	U-1477			
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
	8871809	Oct 17, 2027	U-1614			
	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
	9539335	Oct 17, 2027	U-1614			
DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA						
N 022252 001	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
DIFELIKEFALIN ACETATE - KORSUVA						
N 214916 001	10017536	Nov 12, 2027	DS U-3204		NCE	Aug 23, 2026
	10138270	Nov 12, 2027	U-3204			
	10793596	Nov 12, 2027	DS DP U-3204			
	7402564	Nov 12, 2027	DS DP U-3204			
	7713937	Nov 12, 2027	DS DP U-3204			
	7727963	Nov 12, 2027	DS DP U-3204			
	8217007	Nov 12, 2027	U-3204			
	8236766	Nov 12, 2027	U-3204			
	8486894	Nov 12, 2027	U-3204			
	8536131	Nov 12, 2027	DS DP U-3204			
	9334305	Nov 12, 2027	U-3204			
	9359399	Nov 12, 2027	U-3204			
DIHYDROERGOTAMINE MESYLATE - TRUDHESA						
N 213436 001	10507295	Dec 25, 2032	DP		NP	Sep 02, 2024
	10940278	Jan 23, 2033	DP			
	11185497	Jan 04, 2039	U-3218			
	9550036	Sep 05, 2032	DP			
	9919117	Mar 17, 2033	DP U-3218			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 001	10391160	Mar 13, 2035	U-3148		M-260	Feb 05, 2023
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
	8399514	Feb 07, 2028	U-1384			
DIMETHYL FUMARATE - TECFIDERA						
N 204063 002	10391160	Mar 13, 2035	U-3148		M-260	Feb 05, 2023
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DIMETHYL FUMARATE - TECFIDERA								
N 204063	002		11129806	Nov 16, 2035	U-1384			
			8399514	Feb 07, 2028	U-1384			
DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM								
N 021394	001		8263647	May 30, 2022	DP			
DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM								
N 021393	001		8883849	Jan 17, 2022	U-1618			
			9155718	Jan 17, 2022	DP			
DIROXIMEL FUMARATE - VUMERITY								
N 211855	001		10080733	Sep 20, 2033	DS DP U-1384			
			8669281	Sep 20, 2033	DS DP			
			9090558	Sep 20, 2033	U-1384			
DOCETAXEL - DOCETAXEL								
N 205934	001		10842770	Aug 07, 2031	DP U-2998			
			8940786	Sep 30, 2033	DP U-1789			
			9308195	Sep 30, 2033	DP			
			9763880	Sep 30, 2033	U-2558			
			9763880	Sep 30, 2033	U-2559			
			9763880	Sep 30, 2033	U-2560			
			9763880	Sep 30, 2033	U-2561			
			9763880	Sep 30, 2033	U-2562			
			9763880	Sep 30, 2033	U-2563			
			9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL								
N 205934	002		10842770	Aug 07, 2031	DP U-2998			
			8940786	Sep 30, 2033	DP U-1789			
			9308195	Sep 30, 2033	DP			
			9763880	Sep 30, 2033	U-2558			
			9763880	Sep 30, 2033	U-2559			
			9763880	Sep 30, 2033	U-2560			
			9763880	Sep 30, 2033	U-2561			
			9763880	Sep 30, 2033	U-2562			
			9763880	Sep 30, 2033	U-2563			
			9763880	Sep 30, 2033	U-2564			
DOCETAXEL - DOCETAXEL								
N 205934	003		10842770	Aug 07, 2031	DP U-2998			
			8940786	Sep 30, 2033	DP U-1789			
			9308195	Sep 30, 2033	DP			
			9763880	Sep 30, 2033	U-2558			
			9763880	Sep 30, 2033	U-2559			
			9763880	Sep 30, 2033	U-2560			
			9763880	Sep 30, 2033	U-2561			
			9763880	Sep 30, 2033	U-2562			
			9763880	Sep 30, 2033	U-2563			
			9763880	Sep 30, 2033	U-2564			
DOLUTEGRAVIR SODIUM - TIVICAY								
N 204790	001		8129385	Oct 05, 2027	DS DP			
			9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM - TIVICAY								
N 204790	002		8129385	Oct 05, 2027	DS DP			
			9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM - TIVICAY								
N 204790	003		8129385	Oct 05, 2027	DS DP			
			9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM - TIVICAY PD								
N 213983	001		8129385	Oct 05, 2027	DS DP			
			9242986	Dec 08, 2029	DS DP			
DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO								
N 211994	001		8129385	Oct 05, 2027	DS DP		I-839	Aug 06, 2023
			9242986	Dec 08, 2029	DS DP		NC	Apr 08, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA							
N 210192	001	10426780	Jan 24, 2031	DS DP		U-257	
		7125879	Apr 21, 2025	DS DP		U-257	
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
		8129385	Oct 05, 2027	DS DP			
		9242986	Dec 08, 2029	DS DP			
DONEPEZIL HYDROCHLORIDE - ARICEPT							
N 022568	001	8481565	Oct 04, 2026	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	001	8039009	Mar 24, 2029			U-1641	
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029			U-1641	
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025			U-1641	
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025			U-1641	
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025			U-1641	
		8362085	Nov 22, 2025			U-1641	
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025			U-1641	
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	002	8039009	Mar 24, 2029			U-1641	
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029			U-1641	
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025			U-1641	
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025			U-1641	
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025			U-1641	
		8362085	Nov 22, 2025			U-1641	
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025			U-1641	
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	003	8039009	Mar 24, 2029			U-1641	
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029			U-1641	
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025			U-1641	
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025			U-1641	
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025			U-1641	
		8362085	Nov 22, 2025			U-1641	
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025			U-1641	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 003	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
DORAVIRINE - PIFELTRO						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		I-827	Sep 19, 2022
	8486975	Oct 07, 2031	DS DP U-2630		NCE	Aug 30, 2023
DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO						
N 210807 001	10603282	Nov 29, 2036	DP		I-806	Sep 19, 2022
	10842751	Nov 29, 2036	DP		NCE	Aug 30, 2023
	8486975	Oct 07, 2031	DS DP U-2395			
	8486975	Oct 07, 2031	DS DP U-2629			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 001	10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
DOXEPIN HYDROCHLORIDE - SILENOR						
N 022036 002	10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
DOXYCYCLINE - ORACEA						
N 050805 001	10058564	Apr 05, 2022	U-1063			
	7211267	Apr 05, 2022	U-925			
	7232572	Apr 05, 2022	U-925			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DOXYCYCLINE - ORACEA						
N 050805 001	7749532	Dec 19, 2027	DP U-1063			
	8206740	Dec 24, 2025	DP U-925			
	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
	8603506	Apr 05, 2022	U-1063			
	8709478	Apr 07, 2024	U-1063			
	9241946	Apr 05, 2022	U-1063			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 001	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 002	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 003	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 004	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 005	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
DOXYCYCLINE HYCLATE - DORYX MPC						
N 050795 007	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
DOXYCYCLINE HYCLATE - DORYX MPC						
N 050795 008	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA						
N 209661 001	9089489	Feb 18, 2033	DP U-1382			
	9375404	Feb 18, 2033	DP U-1382			
	9526703	Feb 18, 2033	DP U-1382			
	9937132	Feb 18, 2033	DP U-1382			
DRONABINOL - SYNDROS						
N 205525 001	10265293	Aug 06, 2028	DS DP			
	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
DRONEDARONE HYDROCHLORIDE - MULTAQ						
N 022425 001	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
	8602215	Jun 30, 2031	U-1473			
	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
DROSPIRENONE - SLYND						
N 211367 001	10179140	Jun 28, 2031	U-2553		NP	May 23, 2022
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DROSPIRENONE - SLYND								
N 211367	001		11123299	Jun 28, 2031	DP			
			9603860	Jun 28, 2031	U-2553			
DROSPIRENONE; ESTETROL - NEXTSTELLIS								
N 214154	001		7732430	Mar 02, 2025	DP U-3152		NCE	Apr 15, 2026
DROSPIRENONE; ESTRADIOL - ANGELIQ								
N 021355	001		8906890	Oct 22, 2031	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ								
N 022532	001		6441168	Jul 30, 2022	DS			
			7163931	Mar 03, 2022	U-1			
			8617597	Feb 08, 2030	DP			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL								
N 022574	001		7163931	Mar 03, 2022	U-1			
			8617597	Feb 08, 2030	DP			
DULOXETINE HYDROCHLORIDE - CYMBALTA								
N 021427	001						NPP	Apr 20, 2023
DULOXETINE HYDROCHLORIDE - CYMBALTA								
N 021427	002						NPP	Apr 20, 2023
DULOXETINE HYDROCHLORIDE - CYMBALTA								
N 021427	004						NPP	Apr 20, 2023
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	001		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	002		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	003		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE								
N 212516	004		10413525	Apr 13, 2037	DP			
			10959982	Apr 13, 2037	DP			
			9839626	Apr 13, 2037	DP			
DUVELISIB - COPIKTRA								
N 211155	001		8193182	Feb 13, 2030	DS		NCE	Sep 24, 2023
			9216982	Jan 05, 2029	U-2412		ODE-208	Sep 24, 2025
			9216982	Jan 05, 2029	U-2413		ODE-209	Sep 24, 2025
			9840505	Jan 10, 2032	U-2412			
			9840505	Jan 10, 2032	U-2413			
			RE46621	May 17, 2032	DS DP			
DUVELISIB - COPIKTRA								
N 211155	002		8193182	Feb 13, 2030	DS		NCE	Sep 24, 2023
			9216982	Jan 05, 2029	U-2412		ODE-208	Sep 24, 2025
			9216982	Jan 05, 2029	U-2413		ODE-209	Sep 24, 2025
			9840505	Jan 10, 2032	U-2412			
			9840505	Jan 10, 2032	U-2413			
			RE46621	May 17, 2032	DS DP			
ECONAZOLE NITRATE - ECOZA								
N 205175	001		10071054	Aug 08, 2031	DP			
EDARAVONE - RADICAVA								
N 209176	001						NCE	May 05, 2022
							ODE-144	May 05, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EDARAVONE - RADICAVA							
N 209176	002					NCE	May 05, 2022
						ODE*	May 05, 2024
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	001	7365205	Apr 18, 2027	DS		M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	002	7365205	Apr 18, 2027	DS		M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP			
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	003	7365205	Apr 18, 2027	DS		M-243	Aug 09, 2022
		9149532	Mar 28, 2028	DP			
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA							
N 021937	001	8592397	Jan 13, 2024	DP U-1170			
		8592397	Jan 13, 2024	DP U-750			
		8598185	Apr 28, 2029	DP			
		8716264	Jan 13, 2024	DP U-257			
		9018192	Jun 13, 2026	U-1170			
		9018192	Jun 13, 2026	U-750			
		9457036	Jan 13, 2024	DP U-257			
		9545414	Jun 13, 2026	DP U-1170			
		9545414	Jun 13, 2026	DP U-750			
		9744181	Jan 13, 2024	DP U-257			
EFINACONAZOLE - JUBLIA							
N 203567	001	10105444	Jul 08, 2030	DP		NPP	Apr 27, 2023
		10342875	Oct 02, 2034	DP U-2720			
		10478601	Apr 25, 2035	DP U-2721			
		10512640	Jan 03, 2028	U-1969			
		10828293	Oct 02, 2034	U-2720			
		10828369	Jan 03, 2028	DP			
		10864274	Oct 02, 2034	U-2720			
		7214506	Feb 22, 2026	U-281			
		8039494	Jul 08, 2030	U-281			
		8486978	Oct 24, 2030	DP			
		9302009	Oct 24, 2030	DP			
		9566272	Jan 03, 2028	U-1969			
		9662394	Oct 02, 2034	DP			
		9861698	Jul 08, 2030	DP			
		9877955	Jan 03, 2028	U-1969			
ELAGOLIX SODIUM - ORILISSA							
N 210450	001	10537572	Sep 01, 2036	U-2735		NCE	Jul 23, 2023
		10682351	Sep 01, 2036	U-2850			
		7056927	Sep 10, 2024	DS DP			
		7176211	Jul 06, 2024	U-2360			
		7419983	Jul 06, 2024	DS DP U-2360			
ELAGOLIX SODIUM - ORILISSA							
N 210450	002	7056927	Sep 10, 2024	DS DP		NCE	Jul 23, 2023
		7176211	Jul 06, 2024	U-2360			
		7419983	Jul 06, 2024	DS DP U-2360			
ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)							
N 213388	001	10881659	Mar 14, 2034	U-2842		NCE	Jul 23, 2023
		11045470	Mar 14, 2034	U-2842		NP	May 29, 2023
		7056927	Sep 10, 2024	DS DP			
		7419983	Jul 06, 2024	DS DP			
ELBASVIR; GRAZOPREVIR - ZEPATIER							
N 208261	001	7973040	Jul 24, 2029	DS DP U-1813			
		8871759	May 04, 2031	DS DP U-1813			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)							
N 212273	001	10022352	Apr 09, 2027	DP U-2651		NCE	Feb 12, 2023
		10022352	Apr 09, 2027	DP U-3156		NCE	Oct 21, 2024
		10081621	Mar 25, 2031	DP U-2652		NPP	Jun 08, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		ODE-275	Oct 21, 2026
	10081621	Mar 25, 2031	DP U-3157		ODE-323	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-2653		ODE-357	Jun 08, 2028
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	11179367	Dec 08, 2037	DP U-3253			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-3157		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-3158		NPP	Jun 08, 2024
	10646481	Aug 13, 2029	DP		ODE-357	Jun 08, 2028
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	11179367	Dec 08, 2037	DP U-3253			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELIGLUSTAT TARTRATE - CERDELGA							
N 205494	001	10888544	Dec 13, 2038	U-3040			
		10888544	Dec 13, 2038	U-3041			
		10888547	Jan 31, 2031	U-3042			
		10888547	Jan 31, 2031	U-3043			
		6916802	Apr 29, 2022	DS U-1571			
		7196205	Jun 26, 2026	DS			
		7253185	Apr 29, 2022	DP			
		7615573	Apr 29, 2022	U-1571			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	001	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
		7160870	Nov 20, 2022	DS DP U-2451			
		7160870*PED	May 20, 2023				
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-2451			
		7547719	Jul 13, 2025	DS DP U-2452			
		7547719*PED	Jan 13, 2026				
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-2451			
		7795293*PED	Nov 21, 2023				
		8052993	Aug 01, 2027	DP U-1306			
		8052993	Aug 01, 2027	DP U-1575			
		8052993	Aug 01, 2027	DP U-2451			
		8052993	Aug 01, 2027	DP U-930			
		8052993*PED	Feb 01, 2028				
		8052994	Aug 01, 2027	DP U-1714			
		8052994*PED	Feb 01, 2028				
		8062665	Aug 01, 2027	DP U-1714			
		8062665*PED	Feb 01, 2028				
		8071129	Aug 01, 2027	DP U-1714			
		8071129*PED	Feb 01, 2028				
		8828430	Aug 01, 2027	DP U-1306			
		8828430	Aug 01, 2027	DP U-2451			
		8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	002	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
		7160870	Nov 20, 2022	DS DP U-2451			
		7160870*PED	May 20, 2023				
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			
		7547719	Jul 13, 2025	DS DP U-2451			
		7547719	Jul 13, 2025	DS DP U-2452			
		7547719	Jul 13, 2025	DS DP U-930			
		7547719*PED	Jan 13, 2026				
		7795293	May 21, 2023	U-1306			
		7795293	May 21, 2023	U-2451			
		7795293	May 21, 2023	U-930			
		7795293*PED	Nov 21, 2023				
		8052993	Aug 01, 2027	DP U-1714			
		8052993*PED	Feb 01, 2028				
		8052994	Aug 01, 2027	DP U-1306			
		8052994	Aug 01, 2027	DP U-2451			
		8052994	Aug 01, 2027	DP U-930			
		8052994*PED	Feb 01, 2028				
		8062665	Aug 01, 2027	DP U-1714			
		8062665*PED	Feb 01, 2028				
		8071129	Aug 01, 2027	DP U-1714			
		8071129*PED	Feb 01, 2028				
		8828430	Aug 01, 2027	DP U-1306			
		8828430	Aug 01, 2027	DP U-2451			
		8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	003	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
		7160870	Nov 20, 2022	DS DP U-2451			
		7160870*PED	May 20, 2023				
		7547719	Jul 13, 2025	DS DP U-1306			
		7547719	Jul 13, 2025	DS DP U-1575			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 003	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA						
N 022291 005	7160870	Nov 20, 2022	DS DP U-1306		ODE-210	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870*PED	May 20, 2023				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306		ODE*	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 001	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
ELTROMBOPAG OLAMINE - PROMACTA KIT						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306		ODE*	Nov 16, 2025
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
ELUXADOLINE - VIBERZI						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	11160792	Mar 14, 2033	DP			
	7741356	May 27, 2029	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELUXADOLINE - VIBERZI						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	11160792	Mar 14, 2033	DP			
	7741356	May 27, 2029	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
ELVITEGRAVIR - VITEKTA						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELVITEGRAVIR - VITEKTA						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-869	Aug 18, 2024
	11090323	Apr 03, 2034	U-3191			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8551957	Oct 14, 2029	U-1651			
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002	10258637	Apr 03, 2034	U-2290			
	11090323	Apr 03, 2034	U-3191			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8551957	Oct 14, 2029	U-1651			
	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	10258637	Apr 03, 2034	U-2290		M-252	Mar 30, 2023
	11033552	May 04, 2027	DP		M-258	Jul 03, 2022
	11090323	Apr 03, 2034	U-3191			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	U-1652	Y		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772	Y		
	9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	10258637	Apr 03, 2034	U-2290		M-252	Mar 30, 2023
	11033552	May 04, 2027	DP		M-258	Jul 03, 2022
	11090323	Apr 03, 2034	U-3191			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	U-1652	Y		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772	Y		
	9949998	Jun 11, 2034	U-2290			
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	11090323	Apr 03, 2034	U-3192			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR								
N	212614	001	8551957	Oct 14, 2029	DP		U-2730	
			8883805	Nov 26, 2025	DP			
			9155705	May 21, 2030	DP			
			9415016	Apr 02, 2029	DP			
			9949998	Jun 11, 2034			U-2731	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR								
N	212614	002	10022379	Apr 02, 2029	DP		U-2732	
			10258637	Apr 03, 2034			U-2731	
			10406172	Jun 15, 2030	DP		U-2733	
			10596120	Mar 07, 2032	DP		U-2776	
			10596120	Mar 07, 2032	DP		U-2790	
			11090323	Apr 03, 2034			U-3192	
			7407955	May 02, 2025	DS DP			
			7579449	Aug 01, 2028	DS			
			7713938	Apr 15, 2027	DS DP			
			8119648	Aug 12, 2023			U-1652	
			8178541	Aug 12, 2023	DP		U-1652	
			8551957	Oct 14, 2029	DP		U-2730	
			8883805	Nov 26, 2025	DP			
			9155705	May 21, 2030	DP			
			9415016	Apr 02, 2029	DP			
			9949998	Jun 11, 2034			U-2731	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR								
N	212614	003	10022379	Apr 02, 2029	DP		U-2732	
			10258637	Apr 03, 2034			U-2731	
			10406172	Jun 15, 2030	DP		U-2733	
			10596120	Mar 07, 2032	DP		U-2776	
			10596120	Mar 07, 2032	DP		U-2790	
			11090323	Apr 03, 2034			U-3192	
			7407955	May 02, 2025	DS DP			
			7579449	Aug 01, 2028	DS			
			7713938	Apr 15, 2027	DS DP			
			8119648	Aug 12, 2023			U-1652	
			8178541	Aug 12, 2023	DP		U-1652	
			8551957	Oct 14, 2029	DP		U-2730	
			8883805	Nov 26, 2025	DP			
			9155705	May 21, 2030	DP			
			9415016	Apr 02, 2029	DP			
			9949998	Jun 11, 2034			U-2731	
EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR								
N	212614	004	10022379	Apr 02, 2029	DP		U-2732	
			10258637	Apr 03, 2034			U-2731	
			10406172	Jun 15, 2030	DP		U-2733	
			10596120	Mar 07, 2032	DP		U-2776	
			10596120	Mar 07, 2032	DP		U-2790	
			11090323	Apr 03, 2034			U-3192	
			7407955	May 02, 2025	DS DP			
			7579449	Aug 01, 2028	DS			
			7713938	Apr 15, 2027	DS DP			
			8119648	Aug 12, 2023			U-1652	
			8178541	Aug 12, 2023	DP		U-1652	
			8551957	Oct 14, 2029	DP		U-2730	
			8883805	Nov 26, 2025	DP			
			9155705	May 21, 2030	DP			
			9415016	Apr 02, 2029	DP			
			9949998	Jun 11, 2034			U-2731	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY								
N	206111	001	10258637	Apr 03, 2034			U-2290	
			10610489	Sep 30, 2030	DP			
			11090323	Apr 03, 2034			U-3193	
			7579449	Aug 01, 2028	DS			
			7713938	Apr 15, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002	10258637	Apr 03, 2034			U-2290	
	10610489	Sep 30, 2030	DP			
	11090323	Apr 03, 2034			U-3193	
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 003	10258637	Apr 03, 2034			U-2290	
	10610489	Sep 30, 2030	DP			
	11090323	Apr 03, 2034			U-3193	
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 004	10258637	Apr 03, 2034			U-2290	
	10610489	Sep 30, 2030	DP			
	11090323	Apr 03, 2034			U-3193	
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 001	10258637	Apr 03, 2034			U-2290	
	10596120	Mar 07, 2032	DP		U-2775	
	10596120	Mar 07, 2032	DP		U-2792	
	11090323	Apr 03, 2034			U-3193	
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 002	10258637	Apr 03, 2034			U-2290	
	10596120	Mar 07, 2032	DP		U-2775	
	10596120	Mar 07, 2032	DP		U-2792	
	11090323	Apr 03, 2034			U-3193	
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 003	10258637	Apr 03, 2034			U-2290	
	10596120	Mar 07, 2032	DP		U-2775	
	10596120	Mar 07, 2032	DP		U-2792	
	11090323	Apr 03, 2034			U-3193	
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR						
N 208658 004	10258637	Apr 03, 2034			U-2290	
	10596120	Mar 07, 2032	DP		U-2775	
	10596120	Mar 07, 2032	DP		U-2792	
	11090323	Apr 03, 2034			U-3193	
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034			U-2290	
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY						
N 208351 001	7125879	Apr 21, 2025	DS DP		U-257	
	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	7803788	Feb 02, 2022			U-257	
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP		U-257	
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP		U-257	
	9296769*PED	Feb 15, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA							
N 202123	001	10857102	Jan 14, 2033	DP			
		7125879	Apr 21, 2025	DS DP U-257			
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			
		8592397	Jan 13, 2024	DP U-257			
		8716264	Jan 13, 2024	DP U-257			
		8841310	Dec 09, 2025	DP U-257			
		9457036	Jan 13, 2024	DP U-257			
		9744181	Jan 13, 2024	DP U-257			
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY							
N 208215	001	7390791	Apr 17, 2025	DS DP		I-812	Oct 03, 2022
		7390791*PED	Oct 17, 2025			ODE-284	Sep 28, 2024
		7803788	Feb 02, 2022	U-1663		ODE-285	Sep 28, 2024
		8754065	Aug 15, 2032	DS DP U-1259			
		8754065	Aug 15, 2032	DS DP U-1663			
		8754065	Aug 15, 2032	DS DP U-257			
		8754065*PED	Feb 15, 2033				
		9296769	Aug 15, 2032	DS DP U-1259			
		9296769	Aug 15, 2032	DS DP U-1663			
		9296769	Aug 15, 2032	DS DP U-257			
		9296769*PED	Feb 15, 2033				
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA							
N 021752	001	8592397	Jan 13, 2024	DP U-1170			
		8592397	Jan 13, 2024	DP U-248			
		8592397	Jan 13, 2024	DP U-541			
		8716264	Jan 13, 2024	DP U-257			
		9457036	Jan 13, 2024	DP U-257			
		9744181	Jan 13, 2024	DP U-257			
ENALAPRIL MALEATE - ENALAPRIL MALEATE							
A 212408	001					PC	Feb 13, 2022
ENALAPRIL MALEATE - EPANED KIT							
N 204308	001	8568747	Nov 06, 2032	DP			
		8778366	Nov 06, 2032	U-1723			
		8778366	Nov 06, 2032	U-185			
		8778366	Nov 06, 2032	U-1892			
		8778366	Nov 06, 2032	U-3			
		8778366	Nov 06, 2032	U-71			
		9855214	Nov 06, 2032	DP			
		9968553	Nov 06, 2032	U-1723			
		9968553	Nov 06, 2032	U-185			
		9968553	Nov 06, 2032	U-1892			
		9968553	Nov 06, 2032	U-3			
		9968553	Nov 06, 2032	U-71			
ENALAPRIL MALEATE - EPANED							
N 208686	001	10039745	Mar 25, 2036	DP			
		10154987	Mar 25, 2036	U-1723			
		10154987	Mar 25, 2036	U-185			
		10154987	Mar 25, 2036	U-1892			
		10154987	Mar 25, 2036	U-3			
		10154987	Mar 25, 2036	U-71			
		10772868	Mar 25, 2036	DP			
		10786482	Mar 25, 2036	DP			
		11040023	Mar 25, 2036	DP			
		11141405	Mar 25, 2036	DP			
		9669008	Mar 25, 2036	DP			
		9808442	Mar 25, 2036	U-1723			
		9808442	Mar 25, 2036	U-185			
		9808442	Mar 25, 2036	U-1892			
		9808442	Mar 25, 2036	U-3			
		9808442	Mar 25, 2036	U-71			
ENASIDENIB MESYLATE - IDHIFA							
N 209606	001	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
		10294215	Jan 07, 2033	DP U-2087		ODE-151	Aug 01, 2024
		10610125	Jun 21, 2030	U-2087			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENASIDENIB MESYLATE - IDHIFA						
N 209606 001	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
ENASIDENIB MESYLATE - IDHIFA						
N 209606 002	10093654	Aug 01, 2034	DS DP U-2087		NCE	Aug 01, 2022
	10294215	Jan 07, 2033	DP U-2087		ODE-151	Aug 01, 2024
	10610125	Jun 21, 2030	U-2087			
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
ENCORAFENIB - BRAFTOVI						
N 210496 001	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	8501758	Mar 04, 2031	DS DP		NCE	Jun 27, 2023
	8541575	Feb 26, 2030	DS DP U-2335		ODE-194	Jun 27, 2025
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
ENCORAFENIB - BRAFTOVI						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	10005761	Aug 27, 2030	U-2802		NCE	Jun 27, 2023
	10005761	Aug 27, 2030	U-2803		ODE-194	Jun 27, 2025
	10258622	Nov 21, 2032	U-2802			
	8501758	Mar 04, 2031	DS DP			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9387208	Nov 21, 2032	DP			
	9474754	Aug 05, 2033	DP U-2802			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
ENTRECTINIB - ROZLYTREK						
N 212725 001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745			
	10738037	May 18, 2037	DS DP U-2946			
	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENTRECTINIB - ROZLYTREK							
N 212725	002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
		10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
		10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
		10561651	Feb 19, 2035	U-2745			
		10738037	May 18, 2037	DS DP U-2946			
		11091469	May 18, 2037	U-2617			
		11091469	May 18, 2037	U-2618			
		8299057	Mar 01, 2029	DS DP			
		8673893	Jul 08, 2028	U-2617			
		8673893	Jul 08, 2028	U-2618			
		9029356	Jul 08, 2028	DS DP			
		9085558	Jul 08, 2028	DP			
		9085565	May 22, 2033	DS DP			
		9255087	Jul 08, 2028	U-2617			
		9255087	Jul 08, 2028	U-2618			
		9616059	Jul 08, 2028	U-2618			
		9649306	May 22, 2033	U-2617			
		9649306	May 22, 2033	U-2618			
ENZALUTAMIDE - XTANDI							
N 203415	001	7709517	Aug 13, 2027	DS DP		I-808	Dec 16, 2022
		8183274	Aug 24, 2026	U-1281			
		8183274	Aug 24, 2026	U-1588			
		8183274	Aug 24, 2026	U-2345			
		8183274	Aug 24, 2026	U-2708			
		9126941	May 15, 2026	U-1588			
		9126941	May 15, 2026	U-2345			
		9126941	May 15, 2026	U-2708			
ENZALUTAMIDE - XTANDI							
N 213674	001	7709517	Aug 13, 2027	DS DP		I-808	Dec 16, 2022
		8183274	Aug 24, 2026	U-2345			
		8183274	Aug 24, 2026	U-2708			
		9126941	May 15, 2026	U-2345			
		9126941	May 15, 2026	U-2708			
ENZALUTAMIDE - XTANDI							
N 213674	002	7709517	Aug 13, 2027	DS DP		I-808	Dec 16, 2022
		8183274	Aug 24, 2026	U-2345			
		8183274	Aug 24, 2026	U-2708			
		9126941	May 15, 2026	U-2345			
		9126941	May 15, 2026	U-2708			
EPHEDRINE SULFATE - EMERPHED							
N 213407	001	11090278	May 16, 2040	U-3183			
EPHEDRINE SULFATE - EPHEDRINE SULFATE							
N 213994	001	10869845	Jan 22, 2040	DP			
EPINEPHRINE - EPIPEN							
N 019430	001	7449012	Sep 11, 2025	DP			
		7794432	Sep 11, 2025	DP			
		8048035	Sep 11, 2025	DP			
		8870827	Sep 11, 2025	DP			
		9586010	Sep 11, 2025	DP			
EPINEPHRINE - EPIPEN JR.							
N 019430	002	7449012	Sep 11, 2025	DP			
		7794432	Sep 11, 2025	DP			
		8048035	Sep 11, 2025	DP			
		8870827	Sep 11, 2025	DP			
		9586010	Sep 11, 2025	DP			
EPINEPHRINE - TWINJECT 0.3							
N 020800	001	7297136	Jan 18, 2025	DP			
		7621891	Feb 04, 2025	DP			
EPINEPHRINE - TWINJECT 0.15							
N 020800	002	7297136	Jan 18, 2025	DP			
		7621891	Feb 04, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - TWINJECT 0.15								
N	020800	002	7297136	Jan 18, 2025	DP			
			7621891	Feb 04, 2025	DP			
EPINEPHRINE - ADRENACLICK								
N	020800	003	10166334	Jan 21, 2025	DP			
			7905352	Apr 12, 2027	DP			
EPINEPHRINE - ADRENACLICK								
N	020800	004	10166334	Jan 21, 2025	DP			
			7905352	Apr 12, 2027	DP			
EPINEPHRINE - AUVI-Q								
N	201739	001	10314977	Nov 23, 2024	DP			
			10335549	Apr 30, 2025	DP			
			10737028	Nov 23, 2024	DP			
			10960155	Jun 25, 2026	DP			
			7731686	Jun 01, 2026	DP			
			7731690	Jan 15, 2025	DP			
			7749194	Oct 30, 2028	DP			
			7918823	Nov 23, 2024	DP			
			7947017	Mar 12, 2028	DP			
			8016788	Mar 21, 2025	DP			
			8021344	Nov 02, 2029	DP			
			8206360	Feb 27, 2027	DP			
			8226610	Apr 10, 2029	DP			
			8231573	Nov 25, 2028	DP			
			8313466	Nov 23, 2024	DP			
			8361029	Nov 23, 2024	DP			
			8425462	Nov 23, 2024	DP			
			8608698	Nov 23, 2024	DP			
			8920377	Nov 23, 2024	DP			
			8926594	Mar 31, 2026	DP			
			9056170	Nov 23, 2024	DP			
			9149579	Jul 19, 2025			U-1758	
			9238108	Feb 20, 2027	DP			
			9259539	Feb 01, 2026	DP			
			9278182	Feb 01, 2026	DP			
			9724471	May 23, 2027	DP		U-2092	
			9737669	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q								
N	201739	002	10314977	Nov 23, 2024	DP			
			10335549	Apr 30, 2025	DP			
			10688244	Dec 21, 2037	DP		U-2980	
			10737028	Nov 23, 2024	DP			
			10842938	Dec 21, 2037	DP		U-2980	
			10960155	Jun 25, 2026	DP			
			7731686	Jun 01, 2026	DP			
			7731690	Jan 15, 2025	DP			
			7749194	Oct 30, 2028	DP			
			7918823	Nov 23, 2024	DP			
			7947017	Mar 12, 2028	DP			
			8016788	Mar 21, 2025	DP			
			8021344	Nov 02, 2029	DP			
			8206360	Feb 27, 2027	DP			
			8226610	Apr 10, 2029	DP			
			8231573	Nov 25, 2028	DP			
			8313466	Nov 23, 2024	DP			
			8361029	Nov 23, 2024	DP			
			8425462	Nov 23, 2024	DP			
			8608698	Nov 23, 2024	DP			
			8920377	Nov 23, 2024	DP			
			8926594	Mar 31, 2026	DP			
			9056170	Nov 23, 2024	DP			
			9149579	Jul 19, 2025			U-1758	
			9238108	Feb 20, 2027	DP			
			9259539	Feb 01, 2026	DP			
			9278182	Feb 01, 2026	DP			
			9724471	May 23, 2027	DP		U-2092	
			9737669	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - AUVI-Q						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10688244	Dec 21, 2037	DP		U-2980	
	10737028	Nov 23, 2024	DP			
	10842938	Dec 21, 2037	DP		U-2980	
	10960155	Jun 25, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025			U-1758	
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10688244	Dec 21, 2037	DP		U-2980	
	10737028	Nov 23, 2024	DP			
	10842938	Dec 21, 2037	DP		U-2980	
	10960155	Jun 25, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025			U-1758	
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
	9833573	Nov 23, 2024			U-2172	
EPINEPHRINE - ADRENALIN						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035			U-1829	
EPINEPHRINE - ADRENALIN						
N 204640 001	10130592	Mar 13, 2035	DP			
	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035			U-1829	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EPINEPHRINE - ADRENALIN							
N 204640	001	10130592	Mar 13, 2035	DP			
		9119876	Mar 13, 2035	DP			
		9295657	Mar 13, 2035	U-1829			
EPINEPHRINE - EPINEPHRINE							
N 205029	001	10004700	Aug 14, 2034	DP U-2325			
		10039728	Aug 14, 2034	U-1828			
		9283197	Aug 15, 2034	DP U-1828			
		9283197	Aug 15, 2034	DP U-1829			
		9283197	Aug 15, 2034	DP U-1830			
EPINEPHRINE - PRIMATENE MIST							
N 205920	001	8367734	Jan 26, 2026	DP			
EPOPROSTENOL SODIUM - VELETRI							
N 022260	001	8318802	Mar 15, 2027	DP			
		8598227	Feb 02, 2027				
EPOPROSTENOL SODIUM - VELETRI							
N 022260	002	8318802	Mar 15, 2027	DP			
		8598227	Feb 02, 2027				
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA							
N 211109	001	8796245	Aug 07, 2029	U-2380		NCE	Aug 27, 2023
		8906887	Dec 28, 2030	DP		GAIN	Aug 27, 2028
ERAVACYCLINE DIHYDROCHLORIDE - XERAVA							
N 211109	002	8796245	Aug 07, 2029	U-2380		NCE	Aug 27, 2023
		8906887	Dec 28, 2030	DP		GAIN	Aug 27, 2028
ERDAFITINIB - BALVERSA							
N 212018	001	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
		10898482	Feb 09, 2036	DP U-3065			
		10898482	Feb 09, 2036	DP U-3066			
		10898482	Feb 09, 2036	DP U-3067			
		11077106	Feb 02, 2038	U-3196			
		8895601	May 22, 2031	DS DP			
		9464071	Apr 28, 2031	U-2518			
		9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA							
N 212018	002	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
		10898482	Feb 09, 2036	DP U-3065			
		10898482	Feb 09, 2036	DP U-3066			
		10898482	Feb 09, 2036	DP U-3067			
		11077106	Feb 02, 2038	U-3196			
		8895601	May 22, 2031	DS DP			
		9464071	Apr 28, 2031	U-2518			
		9902714	Mar 26, 2035	DP			
ERDAFITINIB - BALVERSA							
N 212018	003	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
		10898482	Feb 09, 2036	DP U-3065			
		10898482	Feb 09, 2036	DP U-3066			
		10898482	Feb 09, 2036	DP U-3067			
		11077106	Feb 02, 2038	U-3196			
		8895601	May 22, 2031	DS DP			
		9464071	Apr 28, 2031	U-2518			
		9902714	Mar 26, 2035	DP			
ERIBULIN MESYLATE - HALAVEN							
N 201532	001	6214865	Jul 20, 2023	DS		ODE-107	Jan 28, 2023
		RE46965	Jan 08, 2027	DP			
ERTUGLIFLOZIN - STEGLATRO							
N 209803	001	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
ERTUGLIFLOZIN - STEGLATRO							
N 209803	002	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214		NCE	Dec 19, 2022
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214		NCE	Dec 19, 2022
	6699871*PED	Jan 26, 2023				
	7326708	Nov 24, 2026	DS DP U-2214			
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214		NCE	Dec 19, 2022
	6699871*PED	Jan 26, 2023				
	7326708	Nov 24, 2026	DS DP U-2214			
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
ERYTHROMYCIN - ERYTHROMYCIN						
A 211975 001					CGT	Apr 02, 2022
ERYTHROMYCIN - ERYTHROMYCIN						
A 211975 002					CGT	Apr 02, 2022
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
ESCITALOPRAM OXALATE - LEXAPRO						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
ESKETAMINE HYDROCHLORIDE - SPRAVATO						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-840	Jul 31, 2023
	10869844	Sep 10, 2035	U-3035		NCE*	Mar 05, 2024
	10869844	Sep 10, 2035	U-3036			
	11173134	Sep 14, 2035	U-3257			
	8785500	Jul 09, 2031	U-2502			
	9592207	Mar 20, 2027	U-2502			
ESLICARBAZEPINE ACETATE - APTIOM						
N 022416 001	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	001	8372431	Apr 17, 2030	DP			
		9206135	Apr 21, 2026	DS			
		9566244	Oct 23, 2028	DP			
		9643929	Apr 21, 2026	DP			
		9750747	Aug 24, 2032			U-2041	
		9750747	Aug 24, 2032			U-2121	
		9763954	Sep 13, 2028			U-2123	
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	002	10675287	May 06, 2025			U-2041	
		10675287	May 06, 2025			U-2831	
		10695354	May 06, 2025			U-2501	
		10695354	May 06, 2025			U-2831	
		10702536	May 06, 2025			U-2501	
		10912781	Oct 23, 2028	DP			
		8372431	Apr 17, 2030	DP			
		9206135	Apr 21, 2026	DS			
		9566244	Oct 23, 2028	DP			
		9643929	Apr 21, 2026	DP			
		9750747	Aug 24, 2032			U-2041	
		9750747	Aug 24, 2032			U-2121	
		9763954	Sep 13, 2028			U-2123	
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	003	10675287	May 06, 2025			U-2041	
		10675287	May 06, 2025			U-2831	
		10695354	May 06, 2025			U-2501	
		10695354	May 06, 2025			U-2831	
		10702536	May 06, 2025			U-2501	
		10912781	Oct 23, 2028	DP			
		8372431	Apr 17, 2030	DP			
		9206135	Apr 21, 2026	DS			
		9566244	Oct 23, 2028	DP			
		9643929	Apr 21, 2026	DP			
		9750747	Aug 24, 2032			U-2041	
		9750747	Aug 24, 2032			U-2121	
		9763954	Sep 13, 2028			U-2123	
ESLICARBAZEPINE ACETATE - APTIOM							
N 022416	004	10675287	May 06, 2025			U-2041	
		10675287	May 06, 2025			U-2831	
		10695354	May 06, 2025			U-2501	
		10695354	May 06, 2025			U-2831	
		10702536	May 06, 2025			U-2501	
		10912781	Oct 23, 2028	DP			
		8372431	Apr 17, 2030	DP			
		9206135	Apr 21, 2026	DS			
		9566244	Oct 23, 2028	DP			
		9643929	Apr 21, 2026	DP			
		9750747	Aug 24, 2032			U-2041	
		9750747	Aug 24, 2032			U-2121	
		9763954	Sep 13, 2028			U-2123	
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER							
N 205703	001	8829054	Mar 15, 2033	DP			
		8835505	Mar 15, 2033	DP			
ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER							
N 205703	002	8829054	Mar 15, 2033	DP			
		8835505	Mar 15, 2033	DP			
ESOMEPRAZOLE MAGNESIUM - ESOMEPRAZOLE MAGNESIUM							
N 214278	001	10076494	Dec 08, 2036	DP			
		10835488	Dec 08, 2036	DP			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	001	6926907	Feb 28, 2023	DP		U-1052	
		8557285	May 31, 2022	DP			
		8852636	May 31, 2022	DP		U-1052	
		8858996	May 31, 2022	DP		U-1052	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	001	8945621	Oct 17, 2031			U-1661	
		9161920	May 31, 2022			U-1760	
		9198888	May 31, 2022			U-1781	
		9220698	Mar 10, 2031			U-1781	
		9345695	May 31, 2022	DP			
		9393208	Sep 03, 2029			U-1781	
		9707181	May 31, 2022	DP			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	002	6926907	Feb 28, 2023	DP		U-1052	
		8557285	May 31, 2022	DP			
		8852636	May 31, 2022	DP		U-1052	
		8858996	May 31, 2022	DP		U-1052	
		8945621	Oct 17, 2031			U-1661	
		9161920	May 31, 2022			U-1760	
		9198888	May 31, 2022			U-1781	
		9345695	May 31, 2022	DP			
		9393208	Sep 03, 2029			U-1781	
		9707181	May 31, 2022	DP			
ESTRADIOL - VAGIFEM							
N 020908	002	7018992	Sep 17, 2022			U-1023	
ESTRADIOL - ELESTRIN							
N 021813	001	7198801	Jun 25, 2022	DP			
ESTRADIOL - EVAMIST							
N 022014	001	6978945	Jul 31, 2022	DP			
ESTRADIOL - MINIVELLE							
N 203752	001	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	002	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	003	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	004	8231906	Jul 04, 2030	DS DP			
		9730900	Jul 10, 2028			U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - MINIVELLE							
N 203752	005	8231906	Jul 04, 2030	DS DP			
		9724310	Jul 10, 2028	DS DP			
		9730900	Jul 10, 2028	DP		U-2086	
		9833419	Jul 10, 2028	DP			
ESTRADIOL - IMVEXXY							
N 208564	001	10258630	Dec 20, 2033			U-2316	
		10258630	Dec 20, 2033			U-2317	
		10398708	Dec 20, 2033			U-2317	
		10398708	Dec 20, 2033			U-2614	
		10471072	Jun 18, 2033			U-2316	
		10471072	Jun 18, 2033			U-2317	
		10537581	Nov 21, 2032	DP		U-2316	
		10537581	Nov 21, 2032	DP		U-2317	
		10568891	Jun 18, 2033			U-2316	
		10568891	Jun 18, 2033			U-2317	
		10668082	Jun 18, 2033			U-2316	
		10668082	Jun 18, 2033			U-2317	
		10806697	Nov 21, 2032	DP			
		10835487	Nov 21, 2032			U-2316	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL - IMVEXXY						
N 208564 001	10835487	Nov 21, 2032	U-2317			
	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
	9180091	Dec 20, 2033	DP U-2316			
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
ESTRADIOL - IMVEXXY						
N 208564 002	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
	10471072	Jun 18, 2033	U-2316			
	10471072	Jun 18, 2033	U-2317			
	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
	10806697	Nov 21, 2032	DP			
	10835487	Nov 21, 2032	U-2316			
	10835487	Nov 21, 2032	U-2317			
	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
	9180091	Dec 20, 2033	DP U-2316			
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 001	7572779	Oct 02, 2025	U-904			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 002	7572779	Oct 02, 2025	U-904			
ESTRADIOL ACETATE - FEMTRACE						
N 021633 003	7572779	Oct 02, 2025	U-904			
ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE						
N 214846 001	11033551	Sep 29, 2037	U-3129		NCE	Dec 18, 2025
	7300935	Jan 28, 2024	DS		NP	May 26, 2024
	8058280	Jan 28, 2024	DS DP			
	9346822	Feb 17, 2024	U-3129			
ESTRADIOL; PROGESTERONE - BIJUVA						
N 210132 001	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10639375	Nov 21, 2032	DP			
	10675288	Nov 21, 2032	U-2439			
	10806740	Nov 21, 2032	DP U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11103513	Nov 21, 2032	U-2439			
	11103516	Nov 21, 2032	DP			
	11110099	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9006222	Nov 21, 2032	DP U-2439			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ESTRADIOL; PROGESTERONE - BIJUVA							
N 210132	001	10052386	Nov 21, 2032	DP			
		10206932	Nov 21, 2032	U-2439			
		10639375	Nov 21, 2032	DP			
		10675288	Nov 21, 2032	U-2439			
		10806740	Nov 21, 2032	DP U-2439			
		11033626	Nov 21, 2032	DP U-2439			
		11103513	Nov 21, 2032	U-2439			
		11103516	Nov 21, 2032	DP			
		11110099	Nov 21, 2032	DP			
		8633178	Nov 21, 2032	DP			
		8846648	Nov 21, 2032	U-2439			
		8846649	Nov 21, 2032	DP U-2439			
		8987237	Nov 21, 2032	DP			
		8993548	Nov 21, 2032	DP			
		8993549	Nov 21, 2032	DP			
		9006222	Nov 21, 2032	DP U-2439			
		9114145	Nov 21, 2032	U-2439			
		9114146	Nov 21, 2032	DP U-2439			
		9301920	Nov 21, 2032	DP U-2439			
ETELCALCETIDE - PARSABIV							
N 208325	001	10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
		11162500	Jun 27, 2034	DP			
		8377880	Jul 29, 2030	DS DP			
		8999932	Feb 07, 2031	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV							
N 208325	002	10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
		11162500	Jun 27, 2034	DP			
		8377880	Jul 29, 2030	DS DP			
		8999932	Feb 07, 2031	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETELCALCETIDE - PARSABIV							
N 208325	003	10344765	Jun 27, 2034	DP		NCE	Feb 07, 2022
		11162500	Jun 27, 2034	DP			
		8377880	Jul 29, 2030	DS DP			
		8999932	Feb 07, 2031	DS DP U-2014			
		9278995	Jul 29, 2030	DS			
		9701712	Jul 29, 2030	DS DP U-2014			
		9820938	Jun 27, 2034	DP			
ETEPLIRSEN - EXONDYS 51							
N 206488	001	10337003	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
		10364431	Mar 14, 2034	U-1918			
		10364431	Mar 14, 2034	U-1919			
		10781451	Jun 28, 2025	DS DP			
		9018368	Jun 28, 2025	DS DP			
		9243245	Oct 27, 2028	DS U-2097			
		9243245	Oct 27, 2028	DS U-2098			
		9506058	Mar 14, 2034	U-1918			
		9506058	Mar 14, 2034	U-1919			
		RE47751	Jun 28, 2025	U-1918			
		RE47751	Jun 28, 2025	U-2664			
		RE47751	Jun 28, 2025	U-2673			
		RE47751	Jun 28, 2025	U-2674			
		RE47769	Feb 02, 2029	DP			
		RE48468	Oct 27, 2028	U-2097			
ETEPLIRSEN - EXONDYS 51							
N 206488	002	10337003	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
		10364431	Mar 14, 2034	U-1918			
		10364431	Mar 14, 2034	U-1919			
		10781451	Jun 28, 2025	DS DP			
		9018368	Jun 28, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETEPLIRSEN - EXONDYS 51							
N 206488	002	9243245	Oct 27, 2028	DS U-2097			
		9243245	Oct 27, 2028	DS U-2098			
		9506058	Mar 14, 2034	U-1918			
		9506058	Mar 14, 2034	U-1919			
		RE47751	Jun 28, 2025	U-1918			
		RE47751	Jun 28, 2025	U-2664			
		RE47751	Jun 28, 2025	U-2673			
		RE47751	Jun 28, 2025	U-2674			
		RE47769	Feb 02, 2029	DP			
		RE48468	Oct 27, 2028	U-2097			
ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE							
N 021840	001	7320969	Jan 30, 2024	U-828			
		7615545	Jun 15, 2023	U-1			
		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE							
N 022262	001	7615545	Jun 15, 2023	U-1			
		7855190	Dec 05, 2028	U-1			
		7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA							
N 204017	001	8246978	Aug 26, 2028	DP		NP	Feb 14, 2023
		8747888	Jul 10, 2028	DP			
		9050348	Jul 10, 2028	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE							
N 204061	001	8415332	Mar 11, 2029	DP			
		8450299	Oct 07, 2025	U-1			
ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA							
N 208612	001	7838042	Jun 01, 2027	DS U-3251			
ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME							
N 209405	001					NDF	Mar 30, 2023
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE							
N 022501	001	7704984	Feb 02, 2029	U-1090			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE							
N 204654	001	7704984	Feb 02, 2029	U-1			
ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA							
N 209627	001	10632066	Feb 01, 2039	U-2786		NCE	Aug 10, 2023
		10632066	Feb 01, 2039	U-2787			
		10765628	Feb 01, 2039	U-2786			
		10765628	Feb 01, 2039	U-2787			
		10780047	Feb 01, 2039	U-2786			
		10780047	Feb 01, 2039	U-2787			
		10918649	Jun 21, 2039	DP			
		10925882	Jun 21, 2039	DP			
		10940157	Jun 21, 2039	DP			
ETONOGESTREL - IMPLANON							
N 021529	001	9757552	Jul 28, 2030	DP U-1			
ETONOGESTREL - NEXPLANON							
N 021529	002	10821277	May 31, 2027	DP			
		8722037	Sep 28, 2027	DP			
		8888745	Aug 28, 2026	DP			
		9757552	Jul 28, 2030	DP U-1			
EVEROLIMUS - AFINITOR							
N 022334	001	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
		8410131*PED	May 01, 2026				
		8436010	Feb 22, 2022	U-1396			
		8436010*PED	Aug 22, 2022				
		8778962	Feb 18, 2022	U-1541			
		8778962*PED	Aug 18, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR						
N 022334 001	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 002	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 003	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR						
N 022334 004	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
	9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 001	8617598	Sep 27, 2022	DP		ODE-169	Apr 10, 2025
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 002	8617598	Sep 27, 2022	DP		ODE-169	Apr 10, 2025
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EVEROLIMUS - AFINITOR DISPERZ						
N 203985 003	8617598	Sep 27, 2022	DP		ODE-169	Apr 10, 2025
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962	Feb 18, 2022	U-2280			
	8778962*PED	Aug 18, 2022				
EXENATIDE SYNTHETIC - BYETTA						
N 021773 001					M-232	Nov 04, 2024
EXENATIDE SYNTHETIC - BYETTA						
N 021773 002					M-232	Nov 04, 2024
EXENATIDE SYNTHETIC - BYDUREON						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	7456254	Jun 30, 2025	DP U-2588		PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON						
N 022200 001	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON PEN						
N 022200 002	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
EXENATIDE SYNTHETIC - BYDUREON BCISE						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EXENATIDE SYNTHETIC - BYDUREON BCISE							
N 209210	001	8501698	Jun 20, 2027	U-2588			
		8501698*PED	Dec 20, 2027				
		8895033	Oct 04, 2030	DP U-2589			
		8895033	Oct 04, 2030	DP U-2590			
		8895033	Oct 04, 2030	DP U-2597			
		8895033	Oct 04, 2030	DP U-2601			
		8895033	Oct 04, 2030	DP U-2602			
		8895033	Oct 04, 2030	DP U-3188			
		8895033	Oct 04, 2030	DP U-3189			
		8895033	Oct 04, 2030	DP U-3190			
		8895033*PED	Apr 04, 2031				
		8906851	Aug 18, 2026	U-2588			
		8906851	Aug 18, 2026	U-2589			
		8906851	Aug 18, 2026	U-2590			
		8906851	Aug 18, 2026	U-2593			
		8906851	Aug 18, 2026	U-2597			
		8906851	Aug 18, 2026	U-3188			
		8906851	Aug 18, 2026	U-3189			
		8906851	Aug 18, 2026	U-3190			
		8906851*PED	Feb 18, 2027				
		9238076	Apr 15, 2024	DP U-2588			
		9238076	Apr 15, 2024	DP U-2589			
		9238076	Apr 15, 2024	DP U-2590			
		9238076	Apr 15, 2024	DP U-2597			
		9238076	Apr 15, 2024	DP U-2599			
		9238076	Apr 15, 2024	DP U-3188			
		9238076	Apr 15, 2024	DP U-3189			
		9238076	Apr 15, 2024	DP U-3190			
		9238076*PED	Oct 15, 2024				
		9884092	Aug 18, 2026	U-2588			
		9884092	Aug 18, 2026	U-2589			
		9884092	Aug 18, 2026	U-2590			
		9884092	Aug 18, 2026	U-2593			
		9884092	Aug 18, 2026	U-2594			
		9884092	Aug 18, 2026	U-2595			
		9884092	Aug 18, 2026	U-2596			
		9884092	Aug 18, 2026	U-2597			
		9884092	Aug 18, 2026	U-3188			
		9884092	Aug 18, 2026	U-3189			
		9884092	Aug 18, 2026	U-3190			
		9884092*PED	Feb 18, 2027				
EZETIMIBE - ZETIA							
N 021445	001	7030106	Jan 25, 2022	DP			
		7612058	Oct 30, 2025	U-1027			
		7612058	Oct 30, 2025	U-1173			
		7612058*PED	Apr 30, 2026				
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET							
N 213072	001	10376470	May 01, 2033	DP U-3095			
		9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET							
N 213072	002	10376470	May 01, 2033	DP U-3095			
		9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET							
N 213072	003	10376470	May 01, 2033	DP U-3095			
		9763885	May 01, 2033	DP U-3095			
EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET							
N 213072	004	10376470	May 01, 2033	DP U-3095			
		9763885	May 01, 2033	DP U-3095			
FAMOTIDINE; IBUPROFEN - DUEXIS							
N 022519	001	8067033	Jul 18, 2026	DP			
		8067451	Jul 18, 2026	DP U-1196			
		8309127	Jul 18, 2026	DP			
		8318202	Jul 18, 2026	DP			
		8449910	Jul 18, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FAMOTIDINE; IBUPROFEN - DUEXIS							
N 022519	001	8501228	Jul 18, 2026	U-1196			
FEBUXOSTAT - ULORIC							
N 021856	001	7361676	Mar 08, 2024	DP			
		8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FEBUXOSTAT - ULORIC							
N 021856	002	7361676	Mar 08, 2024	DP			
		8372872	Sep 08, 2031	U-1346			
		9107912	Sep 08, 2031	U-1346			
FEDRATINIB HYDROCHLORIDE - INREBIC							
N 212327	001	10391094	Jun 04, 2032	DP U-2607		NCE	Aug 16, 2024
		7528143	Dec 16, 2026	DS		ODE-259	Aug 16, 2026
		7825246	Dec 16, 2026	DS			
		8138199	Jun 30, 2028	U-2607			
FENFLURAMINE HYDROCHLORIDE - FINTEPLA							
N 212102	001	10452815	Jun 29, 2038	U-2859		NP	Jun 25, 2023
		10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
		10478442	May 03, 2033	U-2860			
		10603290	Aug 02, 2037	U-2861			
		10947183	Dec 20, 2036	DS DP			
		10950331	Sep 28, 2035	U-3098			
		11040018	Aug 02, 2037	U-2861			
		9549909	May 03, 2033	U-2858			
		9603814	May 03, 2033	U-2858			
		9603815	May 03, 2033	U-2858			
		9610260	May 03, 2033	U-2858			
FENOFIBRATE - TRICOR							
N 021656	001	7276249	Feb 21, 2023	DP			
		7320802	Feb 21, 2023	U-847			
FENOFIBRATE - TRICOR							
N 021656	002	7276249	Feb 21, 2023	DP			
		7320802	Feb 21, 2023	U-847			
FENOFIBRATE - ANTARA (MICRONIZED)							
N 021695	004	8026281	Apr 22, 2025	U-1447			
		8026281	Apr 22, 2025	U-1448			
FENOFIBRATE - ANTARA (MICRONIZED)							
N 021695	005	8026281	Apr 22, 2025	U-1447			
		8026281	Apr 22, 2025	U-1448			
		9314447	May 31, 2033	DP U-1447			
		9314447	May 31, 2033	DP U-1448			
FENOFIBRATE - FENOGLIDE							
N 022118	001	7658944	Dec 09, 2024	DP			
		8124125	Oct 01, 2024	DP U-1234			
		8481078	Oct 01, 2024	DP U-1416			
		9173847	Oct 01, 2024	DP			
FENOFIBRATE - FENOGLIDE							
N 022118	002	7658944	Dec 09, 2024	DP			
		8124125	Oct 01, 2024	DP U-1234			
		8481078	Oct 01, 2024	DP U-1416			
		9173847	Oct 01, 2024	DP			
FENOFIBRIC ACID - FIBRICOR							
N 022418	001	7569612	Aug 20, 2027	U-1000			
		7741373	Aug 20, 2027	U-1059			
		7741374	Aug 20, 2027	U-1060			
		7741374	Aug 20, 2027	U-1061			
		7915247	Aug 20, 2027	U-1000			
		7915247	Aug 20, 2027	U-1059			
		7915247	Aug 20, 2027	U-1061			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRIC ACID - FIBRICOR							
N 022418	002	7569612	Aug 20, 2027	U-1000			
		7741373	Aug 20, 2027	U-1059			
		7741374	Aug 20, 2027	U-1060			
		7741374	Aug 20, 2027	U-1061			
		7915247	Aug 20, 2027	U-1000			
		7915247	Aug 20, 2027	U-1059			
		7915247	Aug 20, 2027	U-1061			
FENTANYL - SUBSYS							
N 202788	001	10016403	Jan 25, 2027	DP			
		10610523	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	002	10016403	Jan 25, 2027	DP			
		10610523	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	003	10016403	Jan 25, 2027	DP			
		10610523	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	004	10016403	Jan 25, 2027	DP			
		10610523	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	005	10016403	Jan 25, 2027	DP			
		10610523	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	006	10016403	Jan 25, 2027	DP			
		10610523	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL - SUBSYS							
N 202788	006	8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL - SUBSYS							
N 202788	007	10016403	Jan 25, 2027	DP			
		10610523	Jan 25, 2027	DP			
		8486972	Apr 27, 2030	DP			
		8486973	Apr 27, 2030	U-55			
		8835459	Jan 25, 2027	DP			
		8835460	Jan 25, 2027	DP U-55			
		9241935	Jan 25, 2027	DP			
		9289387	Jan 25, 2027	DP U-55			
		9642797	Jan 25, 2027	DP U-55			
		9642844	Jan 25, 2027	DP			
FENTANYL CITRATE - FENTORA							
N 021947	001	7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
		8092832	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA							
N 021947	002	7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
		8092832	Dec 30, 2024	DP			
		8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA							
N 021947	003	7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
		8092832	Dec 30, 2024	DP			
		8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA							
N 021947	004	7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
		8092832	Dec 30, 2024	DP			
		8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - FENTORA							
N 021947	005	7862832	Jun 15, 2028	DP			
		7862833	Jun 15, 2028	DP			
		8092832	Dec 30, 2024	DP			
		8119158	Dec 30, 2024	DP			
FENTANYL CITRATE - ONSOLIS							
N 022266	001	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS							
N 022266	002	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS							
N 022266	003	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS							
N 022266	004	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - ONSOLIS							
N 022266	005	9597288	Jul 23, 2027	DP U-767			
FENTANYL CITRATE - LAZANDA							
N 022569	001	8216604	Oct 03, 2024	U-767			
		8889176	Jan 16, 2024	U-767			
		9078814	Jan 08, 2024	DP			
		9731869	Jan 26, 2032	DP			
		9814705	Jan 08, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - LAZANDA						
N 022569 002	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
FENTANYL CITRATE - LAZANDA						
N 022569 003	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
FENTANYL HYDROCHLORIDE - IONSYS						
N 021338 001	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	U-736			
	9731121	Oct 17, 2031	DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555		NPP	Nov 19, 2024
	11123321	Oct 20, 2023	DS DP U-2557			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555		NPP	Nov 19, 2024
	11123321	Oct 20, 2023	DS DP U-2557			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
FERRIC CARBOXYMALTOSE - INJECTAFER						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555		NPP	Nov 19, 2024
	11123321	Oct 20, 2023	DS DP U-2557		NS	Apr 28, 2024
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
FERRIC CITRATE - AURYXIA						
N 205874 001	10300039	Jul 21, 2030	U-2549			
	5753706	Feb 03, 2022	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FERRIC CITRATE - AURYXIA						
N 205874 001	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
	9328133	Feb 18, 2024	DS DP U-1577			
	9387191	Jul 21, 2030	DP			
	9757416	Feb 18, 2024	DS DP U-1577			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 002	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC DERISOMALTOSE - MONOFERRIC						
N 208171 003	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
FERRIC MALTOL - ACCRUFER						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
FERRIC OXYHYDROXIDE - VELPHORO						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 206317 001	7816404	Apr 17, 2029	DP U-1656			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			
FERUMOXYTOL - FERAHEME						
N 022180 001	6599498	Jun 30, 2023	DS DP			
FESOTERODINE FUMARATE - TOVIAZ						
N 022030 001	6858650	Jul 03, 2022	DS U-913		I-861	Jun 17, 2024
	7807715	Jun 07, 2027	DP U-913		PED	Dec 17, 2024
	8088398	Jun 07, 2027	DP U-913			
	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FESOTERODINE FUMARATE - TOVIAZ							
N 022030	002	6858650	Jul 03, 2022	DS U-913		I-861	Jun 17, 2024
		7807715	Jun 07, 2027	DP U-913		PED	Dec 17, 2024
		8088398	Jun 07, 2027	DP U-913			
		8501723	Jun 07, 2027	DP			
		8501723*PED	Dec 07, 2027				
FEXINIDAZOLE - FEXINIDAZOLE							
N 214429	001					NCE	Jul 16, 2026
						ODE-359	Jul 16, 2028
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY							
N 201373	001	8933097	Aug 02, 2030	DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES							
N 201373	002	8933097	Aug 02, 2030	DP			
FIDAXOMICIN - DIFICID							
N 201699	001	7378508	Jul 31, 2027	DS DP		NPP	Jan 24, 2023
		7863249	Jul 31, 2027	DS DP		ODE-367	Jan 24, 2027
		7906489	Mar 04, 2027	U-2741		PED	Jul 24, 2023
		7906489	Mar 04, 2027	U-319			
		7906489*PED	Sep 04, 2027				
		8586551	Jul 15, 2023	DS DP			
		8586551*PED	Jan 15, 2024				
		8859510	Jul 31, 2027	U-2741			
		8859510	Jul 31, 2027	U-319			
		8859510*PED	Jan 31, 2028				
FIDAXOMICIN - DIFICID							
N 213138	001	7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
		7378508*PED	Jan 31, 2028			ODE-367	Jan 24, 2027
		7863249	Jul 31, 2027	DP		PED	Jul 24, 2023
		7863249*PED	Jan 31, 2028				
		7906489	Mar 04, 2027	U-2741			
		7906489*PED	Sep 04, 2027				
		8586551	Jul 23, 2023	DS DP			
		8586551*PED	Jan 23, 2024				
		8859510	Jul 31, 2027	U-2741			
		8859510*PED	Jan 31, 2028				
		9808530	May 28, 2034	DP			
		9808530*PED	Nov 28, 2034				
FINAFLOXACIN - XTORO							
N 206307	001	8536167	Aug 08, 2031	U-1679			
		9119859	Jul 02, 2030	U-1679			
		9504691	Nov 21, 2033	DP U-1679			
FINERENONE - KERENDIA							
N 215341	001	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
FINERENONE - KERENDIA							
N 215341	002	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
FINGOLIMOD HYDROCHLORIDE - GILENYA							
N 022527	001	10543179	Dec 25, 2027	U-2719			
		8324283	Mar 29, 2026	DP			
		8324283*PED	Sep 29, 2026				
		9187405	Jun 25, 2027	U-2613			
		9187405*PED	Dec 25, 2027				
FINGOLIMOD HYDROCHLORIDE - GILENYA							
N 022527	002	9592208	Mar 30, 2032	DP U-2315			
		9592208*PED	Sep 30, 2032				
FINGOLIMOD LAURYL SULFATE - TASCENSO ODT							
N 214962	001	10555902	Jan 19, 2036	U-3268			
		10925829	Jan 19, 2036	DP			
		9925138	Jan 19, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FISH OIL TRIGLYCERIDES - OMEGAVEN								
N 210589	001		10350186	Nov 05, 2024	U-2585		NCE	Jul 27, 2023
			9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
			9629821	Jul 11, 2025	DP U-2367			
FISH OIL TRIGLYCERIDES - OMEGAVEN								
N 210589	002		10350186	Nov 05, 2024	U-2585		NCE	Jul 27, 2023
			9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
			9629821	Jul 11, 2025	DP U-2367			
FLIBANSERIN - ADDYI								
N 022526	001		7151103	May 09, 2023	U-1734			
			7420057	Aug 01, 2022	DS DP			
			8227471	May 09, 2023	U-1734			
			9468639	Oct 16, 2022	U-1734			
FLORBETABEN F-18 - NEURACEQ								
N 204677	001		7807135	Mar 18, 2029	DS DP U-1497			
FLORBETAPIR F-18 - AMYVID								
N 202008	001		7687052	Apr 30, 2027	DS DP			
			8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID								
N 202008	002		7687052	Apr 30, 2027	DS DP			
			8506929	Apr 30, 2027	DS DP U-1423			
FLORBETAPIR F-18 - AMYVID								
N 202008	003		7687052	Apr 30, 2027	DS DP			
			8506929	Apr 30, 2027	DS DP U-1423			
FLORTAUCIPIR F-18 - TAUVID								
N 212123	001		8932557	May 19, 2029	DS		NCE	May 28, 2025
FLORTAUCIPIR F-18 - TAUVID								
N 212123	002		8932557	May 19, 2029	DS		NCE	May 28, 2025
FLUCICLOVINE F-18 - AXUMIN								
N 208054	001		10010632	Nov 28, 2026	DP			
			10124079	Dec 30, 2035	U-2450			
			10716868	Dec 30, 2035	U-2450			
			10933147	Dec 30, 2035	U-2450			
			10953112	Nov 28, 2026	U-1879			
			10967077	Dec 30, 2035	U-2450			
			9387266	Nov 28, 2026	U-1879			
FLUDARABINE PHOSPHATE - OFORTA								
N 022273	001		7148207	Dec 20, 2022	DP U-944			
FLUOCINOLONE ACETONIDE - ILUVIEN								
N 201923	001		8871241	Aug 12, 2027	DP			
FLUOCINOLONE ACETONIDE - YUTIQ								
N 210331	001		8871241	Aug 12, 2027	DP			
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA								
N 021112	001		7915243	Sep 08, 2023	DP			
			7939516	Sep 08, 2023	DP			
			8247395	Oct 25, 2022	DP			
			8653053	Oct 25, 2022	DP			
FLUOCINONIDE - VANOS								
N 021758	001		7220424	Jan 07, 2023	U-861			
			7794738	Sep 11, 2022	U-1084			
			8232264	Mar 09, 2023	DP			
FLUORODOPA F-18 - FLUORODOPA F18								
N 200655	001						NCE	Oct 10, 2024
							W	Oct 10, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUOROESTRADIOL F-18 - CERIANNA						
N 212155 001					NCE	May 20, 2025
FLUOROURACIL - TOLAK						
N 022259 001	7169401	Jul 18, 2023	DP			
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 001	7270800	Sep 03, 2025	DS DP	U-336		
	7351401	Jan 24, 2023	DS DP	U-336		
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023		U-336		
	8916131	Sep 16, 2028	DP			
FLUTEMETAMOL F-18 - VIZAMYL						
N 203137 002	7270800	Sep 03, 2025	DS DP	U-336		
	7351401	Jan 24, 2023	DS DP	U-336		
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023		U-336		
	8916131	Sep 16, 2028	DP			
FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF						
N 022051 002	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 001	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 002	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE - ARNUITY ELLIPTA						
N 205625 003	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA						
N 209482 001	11090294	Nov 29, 2030		U-3202	I-843	Sep 09, 2023
	7439393	May 21, 2025	DS DP	U-2127		
	7439393	May 21, 2025	DS DP	U-2957		
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025		U-2128		
	8183257	Jul 27, 2025		U-2129		
	8309572	Apr 27, 2025		U-2129		
	8511304	Jun 14, 2027	DP	U-2954		
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750726	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP	U-2127		
	RE44874	Mar 23, 2023	DS DP	U-2955		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA							
N 209482	002	7439393	May 21, 2025	DS DP U-2957		NS	Sep 09, 2023
		7488827	Dec 18, 2027	DS DP			
		7498440	Apr 27, 2025	DS DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-2129			
		8309572	Apr 27, 2025	U-2129			
		8511304	Jun 14, 2027	DP U-2954			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		9750726	Nov 29, 2030	DP			
		RE44874	Mar 23, 2023	DS DP U-2955			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	001	11116721	Feb 26, 2029	DP U-1401			
		11116721	Feb 26, 2029	DP U-1691			
		7439393	May 21, 2025	DS DP U-1401			
		7439393	May 21, 2025	DS DP U-1691			
		7439393	May 21, 2025	DS DP U-2099			
		7439393	May 21, 2025	DS DP U-2100			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8511304	Jun 14, 2027	DP U-1424			
		8511304	Jun 14, 2027	DP U-1691			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		RE44874	Mar 23, 2023	DS DP U-1548			
		RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA							
N 204275	002	11116721	Feb 26, 2029	DP U-1691			
		7439393	May 21, 2025	DS DP U-1691			
		7439393	May 21, 2025	DS DP U-2099			
		7439393	May 21, 2025	DS DP U-2100			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8511304	Jun 14, 2027	DP U-1691			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		RE44874	Mar 23, 2023	DS DP U-1691			
FLUTICASONE PROPIONATE - FLOVENT HFA							
N 021433	001	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA							
N 021433	002	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE - FLOVENT HFA							
N 021433	003	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	001	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
		10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
		10124131	May 18, 2031	DP			
		10124131*PED	Nov 18, 2031				
		10195375	Feb 14, 2031	DP			
		10195375*PED	Aug 14, 2031				
		10561808	Jan 01, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 001	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	003	9463288	May 19, 2025	DP			
		9463288*PED	Nov 19, 2025				
		9616024	Sep 01, 2024	DP			
		9616024*PED	Mar 01, 2025				
		9731087	May 18, 2031	DP			
		9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER							
N 208798	004	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
		10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
		10124131	May 18, 2031	DP			
		10124131*PED	Nov 18, 2031				
		10195375	Feb 14, 2031	DP			
		10195375*PED	Aug 14, 2031				
		10561808	Jan 01, 2032	DP			
		10561808*PED	Jul 01, 2032				
		10569034	Aug 16, 2036	DP			
		10569034*PED	Feb 16, 2037				
		10765820	May 19, 2025	DP			
		10765820*PED	Nov 19, 2025				
		10918816	Dec 14, 2035	DP			
		10918816*PED	Jun 14, 2036				
		11000653	Dec 18, 2038	DP			
		11000653*PED	Jun 18, 2039				
		11173259	Jul 06, 2040	DP			
		7540282	May 06, 2023	DP			
		7540282*PED	Nov 06, 2023				
		8651103	Mar 26, 2028	DP			
		8651103*PED	Sep 26, 2028				
		8714149	Feb 25, 2032	DP			
		8714149*PED	Aug 25, 2032				
		8978966	Jan 13, 2032	DP			
		8978966*PED	Jul 13, 2032				
		9216260	Jun 28, 2031	DP			
		9216260*PED	Dec 28, 2031				
		9463288	May 19, 2025	DP			
		9463288*PED	Nov 19, 2025				
		9616024	Sep 01, 2024	DP			
		9616024*PED	Mar 01, 2025				
		9731087	May 18, 2031	DP			
		9731087*PED	Nov 18, 2031				
		9782550	Aug 28, 2035	DP			
		9782550*PED	Feb 28, 2036				
		9782551	Aug 28, 2035	DP			
		9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER							
N 208798	005	10022510	May 18, 2031	DP			
		10022510*PED	Nov 18, 2031				
		10124131	May 18, 2031	DP			
		10124131*PED	Nov 18, 2031				
		10195375	Feb 14, 2031	DP			
		10195375*PED	Aug 14, 2031				
		10561808	Jan 01, 2032	DP			
		10561808*PED	Jul 01, 2032				
		10569034	Aug 16, 2036	DP			
		10569034*PED	Feb 16, 2037				
		10765820	May 19, 2025	DP			
		10765820*PED	Nov 19, 2025				
		10918816	Dec 14, 2035	DP			
		10918816*PED	Jun 14, 2036				
		11000653	Dec 18, 2038	DP			
		11000653*PED	Jun 18, 2039				
		11173259	Jul 06, 2040	DP			
		7540282	May 06, 2023	DP			
		7540282*PED	Nov 06, 2023				
		8651103	Mar 26, 2028	DP			
		8651103*PED	Sep 26, 2028				
		8714149	Feb 25, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 005	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK						
N 208798 007	10022510	May 18, 2031	DP		NS	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK							
N 208798	007	8651103*PED	Sep 26, 2028				
		8714149	Feb 25, 2032	DP			
		8714149*PED	Aug 25, 2032				
		8978966	Jan 13, 2032	DP			
		8978966*PED	Jul 13, 2032				
		9216260	Jun 28, 2031	DP			
		9216260*PED	Dec 28, 2031				
		9463288	May 19, 2025	DP			
		9463288*PED	Nov 19, 2025				
		9616024	Sep 01, 2024	DP			
		9616024*PED	Mar 01, 2025				
		9731087	May 18, 2031	DP			
		9731087*PED	Nov 18, 2031				
FLUTICASONE PROPIONATE - XHANCE							
N 209022	001	10076614	Oct 20, 2034	DP			
		10076615	Jul 30, 2029	U-2133			
		10124132	Mar 06, 2027	DP U-2133			
		10179216	Jul 08, 2033	DP U-2133			
		10252010	Feb 07, 2031	DP			
		10300229	Jul 07, 2035	DP U-2133			
		10478574	Nov 04, 2033	U-2133			
		11033696	May 20, 2033	DP			
		7975690	Dec 29, 2025	U-2133			
		8327844	Oct 08, 2023	U-2133			
		8522778	May 11, 2022	DP			
		8550073	Oct 22, 2029	DP			
		8978647	Dec 06, 2030	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	001	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	002	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
N 021254	003	7500444	Feb 26, 2026	DP			
		7500444*PED	Aug 26, 2026				
		7832351	Jun 19, 2023	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	001	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
		10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
		10124131	May 18, 2031	DP			
		10124131*PED	Nov 18, 2031				
		10195375	Feb 14, 2031	DP			
		10195375*PED	Aug 14, 2031				
		10561808	Jan 01, 2032	DP			
		10561808*PED	Jul 01, 2032				
		10765820	May 19, 2025	DP			
		10765820*PED	Nov 19, 2025				
		7540282	May 06, 2023	DP			
		7540282*PED	Nov 06, 2023				
		8651103	Mar 26, 2028	DP			
		8651103*PED	Sep 26, 2028				
		8714149	Feb 25, 2032	DP			
		8714149*PED	Aug 25, 2032				
		8978966	Jan 13, 2032	DP			
		8978966*PED	Jul 13, 2032				
		9066957	Oct 06, 2034	DP U-645			
		9066957*PED	Apr 06, 2035				
		9216260	Jun 28, 2031	DP			
		9216260*PED	Dec 28, 2031				
		9415008	Oct 06, 2034	DP U-645			
		9415008*PED	Apr 06, 2035				
		9463288	May 19, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	001	9463288*PED	Nov 19, 2025				
		9616024	Sep 01, 2024	DP			
		9616024*PED	Mar 01, 2025				
		9731087	May 18, 2031	DP			
		9731087*PED	Nov 18, 2031				
		9987229	Sep 01, 2024	DP			
		9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	002	10022510	May 18, 2031	DP			
		10022510*PED	Nov 18, 2031				
		10124131	May 18, 2031	DP			
		10124131*PED	Nov 18, 2031				
		10195375	Feb 14, 2031	DP			
		10195375*PED	Aug 14, 2031				
		10561808	Jan 01, 2032	DP			
		10561808*PED	Jul 01, 2032				
		10765820	May 19, 2025	DP			
		10765820*PED	Nov 19, 2025				
		7540282	May 06, 2023	DP			
		7540282*PED	Nov 06, 2023				
		8651103	Mar 26, 2028	DP			
		8651103*PED	Sep 26, 2028				
		8714149	Feb 25, 2032	DP			
		8714149*PED	Aug 25, 2032				
		8978966	Jan 13, 2032	DP			
		8978966*PED	Jul 13, 2032				
		9066957	Oct 06, 2034	DP U-645			
		9066957*PED	Apr 06, 2035				
		9216260	Jun 28, 2031	DP			
		9216260*PED	Dec 28, 2031				
		9463288	May 19, 2025	DP			
		9463288*PED	Nov 19, 2025				
		9616024	Sep 01, 2024	DP			
		9616024*PED	Mar 01, 2025				
		9731087	May 18, 2031	DP			
		9731087*PED	Nov 18, 2031				
		9987229	Sep 01, 2024	DP			
		9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK							
N 208799	003	10022510	May 18, 2031	DP			
		10022510*PED	Nov 18, 2031				
		10124131	May 18, 2031	DP			
		10124131*PED	Nov 18, 2031				
		10195375	Feb 14, 2031	DP			
		10195375*PED	Aug 14, 2031				
		10561808	Jan 01, 2032	DP			
		10561808*PED	Jul 01, 2032				
		10765820	May 19, 2025	DP			
		10765820*PED	Nov 19, 2025				
		7540282	May 06, 2023	DP			
		7540282*PED	Nov 06, 2023				
		8651103	Mar 26, 2028	DP			
		8651103*PED	Sep 26, 2028				
		8714149	Feb 25, 2032	DP			
		8714149*PED	Aug 25, 2032				
		8978966	Jan 13, 2032	DP			
		8978966*PED	Jul 13, 2032				
		9066957	Oct 06, 2034	DP U-645			
		9066957*PED	Apr 06, 2035				
		9216260	Jun 28, 2031	DP			
		9216260*PED	Dec 28, 2031				
		9463288	May 19, 2025	DP			
		9463288*PED	Nov 19, 2025				
		9616024	Sep 01, 2024	DP			
		9616024*PED	Mar 01, 2025				
		9731087	May 18, 2031	DP			
		9731087*PED	Nov 18, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK						
N 208799 003	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 004	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 005	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER						
N 208799 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
FOMEPIZOLE - ANTIZOL						
N 020696 001	7553863	Jun 30, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE							
N 208294	001	10716753	May 28, 2030	DP U-2889			
		8324266	May 28, 2030	U-2889			
		8703806	May 28, 2030	U-2889			
		8808713	May 28, 2030	DP U-2889			
		8815258	Mar 17, 2031	U-2889			
		9415009	May 28, 2030	U-2889			
		9463161	May 28, 2030	DP U-2889			
FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA							
N 022518	003					NS	Aug 12, 2022
						PED	Feb 12, 2023
FOSDENOPTERIN HYDROBROMIDE - NULIBRY							
N 214018	001	7504095	Jan 31, 2025	DP U-3092		NCE	Feb 26, 2026
						ODE-342	Feb 26, 2028
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493	001	10208073	May 23, 2032	U-2301		NCE	Apr 19, 2023
		10624911	Jun 02, 2037	DP			
		10717721	May 23, 2032	DS			
		10828297	Dec 17, 2030	U-2301			
		8426450	May 23, 2032	DS DP			
		8895586	May 23, 2032	U-2301			
		9186357	Nov 18, 2030	U-2301			
		9403772	May 23, 2032	DS U-2301			
		9908907	May 23, 2032	DS DP			
FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 210493	002	10208073	May 23, 2032	U-2301		NCE	Apr 19, 2023
		10624911	Jun 02, 2037	DP			
		10717721	May 23, 2032	DS			
		10828297	Dec 17, 2030	U-2301			
		8426450	May 23, 2032	DS DP			
		8895586	May 23, 2032	U-2301			
		9186357	Nov 18, 2030	U-2301			
		9403772	May 23, 2032	DS U-2301			
		9908907	May 23, 2032	DS DP			
FOSPHENYTOIN SODIUM - SESQUIENT							
N 210864	001	7635773	Mar 13, 2029	DP			
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			
		9750822	Mar 13, 2029	DP			
FOSPHENYTOIN SODIUM - SESQUIENT							
N 210864	002	7635773	Mar 13, 2029	DP			
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			
		9750822	Mar 13, 2029	DP			
FOSPROPOFOL DISODIUM - LUSEDRA							
N 022244	001	6204257	Jul 01, 2022	DS DP U-945			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294			
		8163902	Jun 17, 2026	DS U-2294			
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		9737554	Jan 19, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294			
		8163902	Jun 17, 2026	DS U-2294			
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		9737554	Jan 19, 2026	DP			
FOSTAMATINIB DISODIUM - TAVALISSE							
N 209299	002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
		7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
		7989448	Jun 12, 2026	DS U-2294			
		8163902	Jun 17, 2026	DS U-2294			
		8211889	Jan 19, 2026	DS			
		8263122	Nov 24, 2030	DP			
		8445485	Jun 17, 2026	DP			
		8652492	Nov 06, 2028	DP			
		8771648	Jul 27, 2032	DP			
		8912170	Jun 17, 2026	U-2294			
		8951504	Jul 27, 2032	U-2294			
		9266912	Jan 19, 2026	U-2294			
		9283238	Jun 17, 2026	U-2294			
		9737554	Jan 19, 2026	DP			
FOSTEMSAVIR TROMETHAMINE - RUKOBIA							
N 212950	001	7745625	Nov 19, 2027	DS		NCE	Jul 02, 2025
		8168615	Feb 25, 2025	DP			
		8461333	Feb 25, 2025	DS			
FULVESTRANT - FULVESTRANT							
N 210326	001	10188663	Feb 14, 2034	DP U-2540			
		9271990	May 17, 2034	DP U-2540			
		9833459	Feb 14, 2034	DP U-2540			
GABAPENTIN - NEURONTIN							
N 021129	001	7256216	May 28, 2022	DP			
GABAPENTIN - GRALISE							
N 022544	001	7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			
		8192756	Oct 25, 2022	DP U-1114			
		8252332	Oct 25, 2022	DP U-1114			
		8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN - GRALISE							
N 022544	002	7438927	Feb 26, 2024	U-1114			
		7731989	Oct 25, 2022	DP			
		8192756	Oct 25, 2022	DP U-1114			
		8252332	Oct 25, 2022	DP U-1114			
		8333992	Oct 25, 2022	DP U-1114			
GABAPENTIN ENACARBIL - HORIZANT							
N 022399	001	6818787	Apr 06, 2025	DS DP			
		8026279	Nov 10, 2026	DS DP			
		8048917	Nov 06, 2022	DS DP U-1247			
		8114909	Apr 11, 2026	U-1231			
		8686034	Jan 24, 2025	U-1231			
		8686034	Jan 24, 2025	U-1247			
		8795725	Jun 10, 2029	DP U-1231			
		8795725	Jun 10, 2029	DP U-1247			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN ENACARBIL - HORIZANT						
N 022399 002	6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8048917	Nov 06, 2022	DS DP U-1247			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
GADOBUTROL - GADAVIST						
N 201277 001					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 002					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 003					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 004					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 005					I-801	Jul 12, 2022
GADOBUTROL - GADAVIST						
N 201277 006					I-801	Jul 12, 2022
GALLIUM DOTATATE GA-68 - NETSPOT						
N 208547 001	9375498	Aug 10, 2032	DP		ODE-120	Jun 01, 2023
GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68						
N 210828 001					NCE	Aug 21, 2024
					W	Aug 21, 2024
GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11						
N 212642 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11						
N 212643 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
GANCICLOVIR - GANZYK-RTU						
N 209347 001	9486530	Sep 02, 2034	DP			
GEFITINIB - IRESSA						
N 206995 001					ODE-95	Jul 13, 2022
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 001	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 002	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 003	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 004	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 005	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 006	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 007	9241948	Jul 01, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 008	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 009	9241948	Jul 01, 2033	DP			
GEMCITABINE HYDROCHLORIDE - INFUGEM						
N 208313 010	9241948	Jul 01, 2033	DP			
GILTERITINIB FUMARATE - XOSPATA						
N 211349 001	10786500	Jul 01, 2036	DP		NCE	Nov 28, 2023
	8969336	Jan 27, 2031	DS DP		ODE-222	Nov 28, 2025
	9487491	Jul 28, 2030	U-2456			
GIVOSIRAN SODIUM - GIVLAARI						
N 212194 001	10119143	Oct 03, 2034	DS DP U-2672		NCE	Nov 20, 2024
	10125364	Mar 15, 2033	DS DP U-2672		ODE-273	Nov 20, 2026
	10131907	Aug 24, 2028	DS DP U-2672			
	10273477	Mar 08, 2024	DS			
	8106022	Dec 12, 2029	DS DP U-2672			
	8546143	Jan 09, 2022	DS U-2672			
	8828956	Dec 04, 2028	DS DP U-2672			
	9133461	May 14, 2033	DS DP U-2672			
	9150605	Aug 28, 2025	DS DP			
	9631193	Mar 15, 2033	U-2672			
	9708610	Jan 01, 2024	DS DP U-2672			
	9708615	Mar 08, 2024	DS			
GLASDEGIB MALEATE - DAURISMO						
N 210656 001	10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
	11168066	Apr 13, 2036	U-3254		ODE-224	Nov 21, 2025
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
GLASDEGIB MALEATE - DAURISMO						
N 210656 002	10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
	11168066	Apr 13, 2036	U-3254		ODE-224	Nov 21, 2025
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 209394 001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
	10028937	Jun 10, 2030	U-3237		M-259	Apr 10, 2023
	10028937*PED	Dec 10, 2030			NCE	Aug 03, 2022
	10039754	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-3237		ODE-232	Apr 30, 2026
	10039754*PED	Dec 10, 2030			ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-3237		ODE-372	Jun 10, 2028
	10286029*PED	Sep 14, 2034			PED	Oct 30, 2022
	8648037	Jan 19, 2032	DS DP U-2141		PED	Feb 03, 2023
	8648037	Jan 19, 2032	DS DP U-3237		PED	Mar 26, 2023
	8648037*PED	Jul 19, 2032			PED	Oct 10, 2023
	8937150	May 18, 2032	DS DP		PED	Oct 30, 2026
	8937150*PED	Nov 18, 2032			PED	Oct 30, 2026
	9321807	Jun 05, 2035	DS		PED	Dec 10, 2028
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-2141			
	9586978	Nov 06, 2030	U-3237			
	9586978*PED	May 06, 2031				
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 215110 001	10028937	Jun 10, 2030	U-3238		D-175	Sep 26, 2022
	10028937*PED	Dec 10, 2030			M-259	Apr 10, 2023
	10039754	Jun 10, 2030	U-3238		NCE	Aug 03, 2022
	10039754*PED	Dec 10, 2030			ODE-372	Jun 10, 2028
	10286029	Mar 14, 2034	U-3238		PED	Feb 03, 2023
	10286029*PED	Sep 14, 2034			PED	Mar 26, 2023
	8648037	Jan 19, 2032	DS DP U-3238		PED	Oct 10, 2023
	8648037*PED	Jul 19, 2032			PED	Dec 10, 2028
	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLECAPREVIR; PIBRENTASVIR - MAVYRET						
N 215110 001	9321807	Jun 05, 2035	DS DP			
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-3238			
	9586978*PED	May 06, 2031				
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT						
N 021925 001	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT						
N 021925 002	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
GLUCAGON - BAQSIMI						
N 210134 001	10213487	Feb 16, 2036	DP U-2604		NP	Jul 24, 2022
	10765602	Sep 23, 2039	DP			
	10894133	Jan 03, 2038	DP			
	6938798	Jan 03, 2022	DP			
GLUCAGON - GVOKE PFS						
N 212097 001	9649364	Apr 22, 2036	DP U-2742		NP	Sep 10, 2022
GLUCAGON - GVOKE PFS						
N 212097 002	9649364	Apr 22, 2036	DP U-2742		NP	Sep 10, 2022
GLUCAGON - GVOKE HYPOPEN						
N 212097 003	9649364	Apr 22, 2036	DP U-2742		NP	Sep 10, 2022
GLUCAGON - GVOKE HYPOPEN						
N 212097 004	9649364	Apr 22, 2036	DP U-2742		NP	Sep 10, 2022
GLYCEROL PHENYLBUTYRATE - RAVICTI						
N 203284 001	10045958	Sep 22, 2030	U-1816		ODE-157	Apr 28, 2024
	10045959	Sep 22, 2030	U-1816			
	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
	10668040	Sep 22, 2030	U-1816			
	8404215	Mar 09, 2032	U-1383			
	8642012	Sep 22, 2030	U-1383			
	9095559	Mar 09, 2032	U-1383			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
	9561197	Sep 22, 2030	U-1383			
	9962359	Sep 22, 2030	U-1816			
	9999608	Sep 22, 2030	U-1816			
GLYCOPYRROLATE - GLYCOPYRROLATE						
A 204438 001					PC	Jul 03, 2022
GLYCOPYRROLATE - CUVPOSA						
N 022571 001	7638552	Aug 20, 2023	U-1076			
	7816396	Aug 20, 2023	U-1076			
GLYCOPYRROLATE - SEEBRI						
N 207923 001	8182838	Oct 20, 2028	DP			
	8479730	Oct 11, 2028	DP			
GLYCOPYRROLATE - LONHALA MAGNAIR KIT						
N 208437 001	10376661	Sep 14, 2035	DP			
	10688518	Nov 12, 2036	DP			
	10744277	Dec 07, 2036	DP U-2941			
	10940110	Feb 26, 2029	DP U-1773			
	7316067	Sep 06, 2022	DP			
	7458372	Nov 18, 2024	DP			
	7931212	Nov 25, 2025	DP			
	8511581	Nov 08, 2023	DP			
	9168556	Sep 01, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLYCOPYRROLATE - LONHALA MAGNAIR KIT						
N 208437 001	9265900	Dec 07, 2028	DP			
	9604018	May 16, 2033	DP			
	9789270	Oct 30, 2030	DP			
GLYCOPYRROLATE; INDACATEROL MALEATE - UTIBRON						
N 207930 001	6878721	Feb 25, 2025	DS DP U-1773			
	8182838	Oct 20, 2028	DP			
	8479730	Oct 11, 2028	DP			
GLYCOPYRRONIUM TOSYLATE - QBREXZA						
N 210361 001	10004717	Feb 28, 2033	DP U-2398			
	10052267	Oct 17, 2028	DP U-2398			
	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
	8618160	Dec 10, 2029	DP U-2398			
	8859610	Feb 28, 2033	DP U-2398			
	9259414	Feb 28, 2033	U-2398			
	9744105	Jul 18, 2030	DP U-2398			
GOLODIRSEN - VYONDYS 53						
N 211970 001	10227590	Jun 28, 2025	DS DP		NCE	Dec 12, 2024
	10266827	Jun 28, 2025	U-2675		ODE-280	Dec 12, 2026
	10421966	Jun 28, 2025	DS DP			
	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			
	9024007	Jun 28, 2025	DS DP			
	9994851	Jun 28, 2025	DS DP			
	RE47691	Jun 28, 2025	DP			
GOSERELIN ACETATE - ZOLADEX						
N 019726 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
GOSERELIN ACETATE - ZOLADEX						
N 020578 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
GRANISETRON - SANCUSO						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
GRANISETRON - SUSTOL						
N 022445 001	10357570	Sep 28, 2024	U-2253			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
	9913910	Sep 28, 2024	U-2253			
GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON						
N 205474 001	10105324	Nov 13, 2035	DS DP U-2023			
	9549907	Nov 13, 2035	DS DP U-2023			
	9808431	Nov 13, 2035	DS DP U-2023			
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 001	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 002	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 003	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 004	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HALOBETASOL PROPIONATE - ULTRAVATE								
N 208183	001		8962028	Jun 19, 2033	DP U-1775		NPP	Aug 31, 2023
HALOBETASOL PROPIONATE - BRYHALI								
N 209355	001		10478502	Nov 02, 2031	DP U-2625			
			8809307	Nov 02, 2031	DP			
HALOBETASOL PROPIONATE - LEXETTE								
N 210566	001		10857159	Nov 30, 2036	DP			
			10857159*PED	May 30, 2037				
			11020407	Nov 30, 2036	DP U-3143			
HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII								
N 209354	001		10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
			10426787	Jun 06, 2036	U-2625			
			10478502	Nov 02, 2031	DP U-2625			
			8809307	Nov 02, 2031	DP			
HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT								
N 022555	001		10556010	Dec 19, 2036	U-2250			
HISTRELIN ACETATE - SUPPRELIN LA								
N 022058	001		8062652	Jun 16, 2026	U-1197			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	001		10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			10722511	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	002		10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			10722511	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N 202880	003		10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			10722511	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N	202880	003	9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N	202880	004	10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			10722511	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N	202880	005	10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			10722511	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - ZOHYDRO ER								
N	202880	006	10028946	Jul 25, 2033	U-1810			
			10092559	Sep 12, 2034	U-55			
			10322120	Jul 25, 2033	DP			
			10456393	Jul 25, 2033	U-1810			
			10722511	Jul 25, 2033	U-1810			
			9132096	Sep 12, 2034	DP			
			9265760	Jul 25, 2033	U-1810			
			9326982	Jul 25, 2033	U-1810			
			9333201	Jul 25, 2033	U-1810			
			9339499	Jul 25, 2033	U-1810			
			9421200	Jul 25, 2033	U-1810			
			9433619	Jul 25, 2033	U-1810			
			9452163	Sep 12, 2034	U-55			
			9486451	Sep 12, 2034	U-55			
			9610286	Jul 25, 2033	U-1810			
			9713611	Sep 12, 2034	DP U-55			
HYDROCODONE BITARTRATE - HYSINGLA ER								
N	206627	001	10130591	Nov 20, 2023	DP U-1819			
			10369109	Jun 16, 2023	DP			
			8309060	Nov 20, 2023	DP U-1556			
			8529948	Aug 06, 2022	DP			
			8808740	Dec 21, 2031	DP U-1556			
			9084816	Aug 24, 2027	DP			
			9095614	Aug 24, 2027	U-1556			
			9095615	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	001	9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9675610	Jun 16, 2023	DP			
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	002	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		8309060	Nov 20, 2023	DP		U-1556	
		8529948	Aug 06, 2022	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9675610	Jun 16, 2023	DP			
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	003	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		8309060	Nov 20, 2023	DP		U-1556	
		8529948	Aug 06, 2022	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9675610	Jun 16, 2023	DP			
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	004	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		8309060	Nov 20, 2023	DP		U-1556	
		8529948	Aug 06, 2022	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9084816	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	004	9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9675610	Jun 16, 2023	DP			
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	005	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		8309060	Nov 20, 2023	DP		U-1556	
		8529948	Aug 06, 2022	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9675610	Jun 16, 2023	DP			
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	006	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		8309060	Nov 20, 2023	DP		U-1556	
		8529948	Aug 06, 2022	DP			
		8808740	Dec 21, 2031	DP		U-1556	
		9084816	Aug 24, 2027	DP			
		9095614	Aug 24, 2027			U-1556	
		9095615	Aug 24, 2027	DP			
		9486412	Aug 24, 2027	DP			
		9486413	Aug 24, 2027	DP			
		9492389	Aug 24, 2027	DP			
		9492390	Aug 24, 2027			U-1556	
		9492391	Aug 24, 2027			U-1556	
		9545380	Aug 24, 2027			U-1556	
		9572779	Dec 21, 2031	DP			
		9675610	Jun 16, 2023	DP			
		9750703	Dec 21, 2031	DP			
		9763933	Aug 24, 2027	DP			
		9770416	Aug 24, 2027	DP			
		9775809	Aug 24, 2027	DP			
		9861584	Dec 21, 2031	DP			
		9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - HYSINGLA ER							
N 206627	007	10130591	Nov 20, 2023	DP		U-1819	
		10369109	Jun 16, 2023	DP			
		8309060	Nov 20, 2023	DP		U-1556	
		8529948	Aug 06, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA ER						
N 206627 007	8808740	Dec 21, 2031	DP		U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027			U-1556	
	9492391	Aug 24, 2027			U-1556	
	9545380	Aug 24, 2027			U-1556	
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCODONE BITARTRATE - VANTRELA ER						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 001	9649280	May 12, 2034	DP		U-3075	
	9675559	Jan 10, 2033			U-3075	
	9717740	Nov 19, 2032			U-3075	
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 002	9649280	May 12, 2034	DP		U-3075	
	9675559	Jan 10, 2033			U-3075	
	9717740	Nov 19, 2032			U-3075	
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 003	9649280	May 12, 2034	DP		U-3075	
	9675559	Jan 10, 2033			U-3075	
	9717740	Nov 19, 2032			U-3075	
HYDROCORTISONE - ALKINDI SPRINKLE						
N 213876 004	9649280	May 12, 2034	DP		U-3075	
	9675559	Jan 10, 2033			U-3075	
	9717740	Nov 19, 2032			U-3075	
HYDROCORTISONE BUTYRATE - LOCOID						
N 022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROGEN PEROXIDE - ESKATA						
N 209305 001	10098910	Apr 21, 2035	DP U-2205			
	10493103	Apr 21, 2035	DP			
	10729720	Apr 21, 2035	DP			
	7381427	Jun 08, 2022	U-2205			
	9675639	Jul 04, 2035	DP U-2205			
	9980983	Apr 21, 2035	U-2205			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROMORPHONE HYDROCHLORIDE - DILAUDID						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)						
N 021945 004	10471075	May 02, 2036	U-2236			
	11154562	May 02, 2036	U-2236			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036	U-2236			
HYDROXYUREA - SIKLOS						
N 208843 001					ODE-177	Dec 21, 2024
HYDROXYUREA - SIKLOS						
N 208843 002					ODE-177	Dec 21, 2024
IBANDRONATE SODIUM - BONIVA						
N 021455 002	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
IBREXAFUNGERP CITRATE - BREXAFEMME						
N 214900 001	10174074	Jan 19, 2035	DS DP		NCE	Jun 01, 2026
	10370406	Jan 19, 2035	U-3159		GAIN	Jun 01, 2031
	10927142	Jan 19, 2035	DS			
	8188085	Aug 28, 2030	DS DP U-3159			
IBRUTINIB - IMBRUVICA						
N 205552 001	10004746	Jun 03, 2031	U-1684		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-1946		ODE-109	Mar 04, 2023
	10004746	Jun 03, 2031	U-2241		ODE-117	May 06, 2023
	10004746	Jun 03, 2031	U-2242		ODE-128	Jan 18, 2024
	10016435	Jun 03, 2031	U-1650		ODE-152	Aug 02, 2024
	10106548	Jun 03, 2033	DS DP		ODE-86	Jan 29, 2022
	10125140	Jun 03, 2033	DS DP			
	10294231	Jun 03, 2033	DP			
	10294232	Jun 03, 2033	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 001	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10752634	Jun 03, 2033	DP			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
	9181257	Dec 28, 2026	DS DP			
	9296753	Oct 30, 2033	DS DP			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 205552 002	10004746	Jun 03, 2031	U-1684		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10294231	Jun 03, 2033	DP			
	10294232	Jun 03, 2033	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 205552 002	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 001	10004746	Jun 03, 2031	U-1684		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 001	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10752634	Jun 03, 2033	DP			
	10828259	Mar 03, 2036	DP			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	10004746	Jun 03, 2031	U-1684		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10828259	Mar 03, 2036	DP			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2969			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 002	9795604	Oct 24, 2034	U-2970			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 003	10004746	Jun 03, 2031	U-1684		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10828259	Mar 03, 2036	DP			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA						
N 210563 003	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
IBRUTINIB - IMBRUVICA						
N 210563 004	10004746	Jun 03, 2031	U-1684		M-236	Jan 25, 2022
	10004746	Jun 03, 2031	U-1946			
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10010507	Mar 03, 2036	DP			
	10016435	Jun 03, 2031	U-1650			
	10106548	Jun 03, 2033	DS DP			
	10125140	Jun 03, 2033	DS DP			
	10213386	Mar 03, 2036	DP			
	10463668	Oct 24, 2034	U-2654			
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10653696	Jun 03, 2031	U-1456			
	10695350	Oct 24, 2034	U-2846			
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10828259	Mar 03, 2036	DP			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IBRUTINIB - IMBRUVICA							
N 210563	004	8952015	Dec 28, 2026	U-1650			
		8952015	Dec 28, 2026	U-1946			
		8952015	Dec 28, 2026	U-1947			
		8952015	Dec 28, 2026	U-2241			
		8952015	Dec 28, 2026	U-2242			
		8957079	Dec 28, 2026	DS DP			
		8999999	Jun 03, 2031	U-1491			
		8999999	Jun 03, 2031	U-1946			
		8999999	Jun 03, 2031	U-2241			
		8999999	Jun 03, 2031	U-2242			
		9125889	Jun 03, 2031	U-1650			
		9181257	Dec 28, 2026	DS			
		9296753	Oct 30, 2033	DS			
		9655857	Mar 03, 2036	DP			
		9725455	Jun 03, 2033	DS			
		9795604	Oct 24, 2034	U-2969			
		9795604	Oct 24, 2034	U-2970			
		9801881	Jun 03, 2031	U-1491			
		9801881	Jun 03, 2031	U-2242			
		9801883	Jun 03, 2031	U-2159			
		9801883	Jun 03, 2031	U-2243			
		9814721	Jun 03, 2031	U-1947			
IBUPROFEN - CHILDREN'S ADVIL-FLAVORED							
N 020589	002	10238640	May 25, 2024	DP			
IBUPROFEN - CALDOLOR							
N 022348	001					M-128	Nov 19, 2024
IBUPROFEN - CALDOLOR							
N 022348	002	8735452	Sep 30, 2029	U-981		M-128	Nov 19, 2024
		8871810	Sep 30, 2029	U-981			
		9012508	Sep 14, 2030	U-981			
		9114068	Sep 30, 2029	U-1735			
		9138404	Sep 30, 2029	U-1756			
		9295639	Sep 30, 2029	U-1756			
		9649284	Sep 30, 2029	U-2018			
IBUPROFEN - CALDOLOR							
N 022348	003	8735452	Sep 30, 2029	U-981		M-128	Nov 19, 2024
		8871810	Sep 30, 2029	U-981			
		9012508	Sep 14, 2030	U-981			
		9072661	Mar 16, 2032	U-2264			
		9072710	Mar 16, 2032	U-2266			
IBUPROFEN LYSINE - NEOPROFEN							
N 021903	001	8415337	Mar 02, 2032	DS DP			
ICOSAPENT ETHYL - VASCEPA							
N 202057	001	10010517	Apr 29, 2030	U-2690		I-819	Dec 13, 2022
		10265287	Apr 29, 2030	U-2700			
		10278935	Jun 28, 2033	U-2701			
		10278936	Jun 28, 2033	U-2702			
		10278937	Jun 28, 2033	U-2703			
		10383840	Jun 28, 2033	U-2704			
		10555924	Jun 28, 2033	U-2743			
		10555925	Jun 28, 2033	U-2744			
		10568861	Jun 28, 2033	U-2756			
		10576054	Jun 28, 2033	U-2762			
		10668042	Jun 28, 2033	U-2841			
		10786478	Jun 28, 2033	U-2959			
		10786478	Jun 28, 2033	U-2960			
		10792267	Apr 29, 2030	U-2961			
		10792270	Jun 28, 2033	U-2962			
		10842766	Apr 29, 2030	U-2997			
		10842768	Jun 15, 2030	U-2688			
		10881632	Apr 29, 2030	U-3052			
		10894028	Jun 28, 2033	U-3053			
		11000499	Jun 28, 2033	U-3126			
		11103477	Apr 29, 2030	U-3209			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 001	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8455472	Jun 15, 2030	U-2690			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8618166	Apr 29, 2030	U-2689			
	8623406	Apr 29, 2030	U-1478			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	10010517	Apr 29, 2030	U-2690		I-819	Dec 13, 2022
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			
	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ICOSAPENT ETHYL - VASCEPA						
N 202057 002	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
IDELALISIB - ZYDELIG						
N 205858 001	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			
IDELALISIB - ZYDELIG						
N 205858 002	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030	U-1914			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
	RE44638	Aug 05, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT						
N 022192 001	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 002	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 003	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 004	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 005	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 006	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
ILOPERIDONE - FANAPT						
N 022192 007	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT								
N 022192	007		9074254	Dec 28, 2031	U-1674			
			9074255	Dec 17, 2030	U-1674			
			9074256	Feb 10, 2031	U-1674			
			9138432	Sep 30, 2025	U-1737			
			9157121	Apr 05, 2030	U-1674			
IMATINIB MESYLATE - GLEEVEC								
N 021588	001		6958335*PED	Jun 19, 2022				
IMATINIB MESYLATE - GLEEVEC								
N 021588	002		6958335*PED	Jun 19, 2022				
IMIQUIMOD - ALDARA								
N 020723	001		7696159	Apr 01, 2024	DS U-1047			
			7696159	Apr 01, 2024	DS U-1048			
IMIQUIMOD - ZYCLARA								
N 022483	001		10238644	Dec 11, 2029	U-68			
			10238645	Aug 18, 2029	U-1455			
			10238645	Aug 18, 2029	U-172			
			10918635	Apr 30, 2030	U-1455			
			10918635	Apr 30, 2030	U-172			
			8236816	Dec 11, 2029	U-68			
			8299109	Dec 11, 2029	U-68			
			8598196	Aug 18, 2029	U-1455			
			8598196	Aug 18, 2029	U-172			
IMIQUIMOD - ZYCLARA								
N 022483	002		8222270	Dec 11, 2029	U-68			
INDACATEROL MALEATE - ARCAPTA NEOHALER								
N 022383	001		6878721	Feb 25, 2025	DS DP U-1168			
			8479730	Oct 11, 2028	DP			
INDOCYANINE GREEN - SPY AGENT GREEN KIT								
N 211580	001		10631746	Aug 04, 2035	DP U-2815			
			8185176	Jun 04, 2028	U-2462			
			8406860	Apr 09, 2029	U-2463			
			8647605	Feb 11, 2029	U-2464			
			8647605	Feb 11, 2029	U-2468			
			9421280	Nov 24, 2025	U-2466			
			9421280	Nov 24, 2025	U-2467			
INDOMETHACIN - TIVORBEX								
N 204768	001		8734847	Apr 23, 2030	DP			
			8992982	Apr 23, 2030	DP			
			9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX								
N 204768	002		8734847	Apr 23, 2030	DP			
			8992982	Apr 23, 2030	DP			
			9089471	Apr 23, 2030	U-55			
INFIGRATINIB PHOSPHATE - TRUSELTIQ								
N 214622	001		10278969	Dec 11, 2034	DP		NCE	May 28, 2026
			11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
			8552002	Aug 25, 2029	DS DP			
			9067896	Aug 06, 2028	DS			
INFIGRATINIB PHOSPHATE - TRUSELTIQ								
N 214622	002		10278969	Dec 11, 2034	DP		NCE	May 28, 2026
			11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
			8552002	Aug 25, 2029	DS DP			
			9067896	Aug 06, 2028	DS			
INGENOL MEBUTATE - PICATO								
N 202833	001		8278292	Jul 06, 2027	DP			
			8372827	Dec 18, 2026	DP			
			8372828	Dec 18, 2026	DP			
			8377919	Dec 18, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INGENOL MEBUTATE - PICATO							
N 202833	001	8536163	Dec 18, 2026	U-1440			
		8716271	Dec 18, 2026	U-1440			
		8735375	Dec 18, 2026	U-1440			
		9789078	May 15, 2033	U-2138			
		9820959	Dec 18, 2026	DP U-1440			
		9833428	Dec 18, 2026	DP			
		9833429	Dec 18, 2026	DP			
		9861603	Dec 18, 2026	U-1440			
INGENOL MEBUTATE - PICATO							
N 202833	002	8278292	Jul 06, 2027	DP			
		8372827	Dec 18, 2026	DP			
		8372828	Dec 18, 2026	DP			
		8377919	Dec 18, 2026	DP			
		8536163	Dec 18, 2026	U-1440			
		8716271	Dec 18, 2026	U-1440			
		8735375	Dec 18, 2026	U-1440			
		9820959	Dec 18, 2026	DP U-1440			
		9833428	Dec 18, 2026	DP			
		9833429	Dec 18, 2026	DP			
		9861603	Dec 18, 2026	U-1440			
INOTERSEN SODIUM - TEGSEDI							
N 211172	001	7015315	Mar 21, 2023	DS		NCE	Oct 05, 2023
		7101993	Sep 05, 2023	DS		ODE-212	Oct 05, 2025
		8101743	Apr 01, 2025	DS DP			
		8697860	Apr 29, 2031	DP			
		9061044	Apr 29, 2031	DS			
		9399774	Apr 29, 2031	U-2430			
IOBENGUANE I-131 - AZEDRA							
N 209607	001					ODE-204	Jul 30, 2025
IPRATROPIUM BROMIDE - ATROVENT HFA							
N 021527	001	8474447	Jan 17, 2030	DP			
IRINOTECAN HYDROCHLORIDE - ONIVYDE							
N 207793	001	10456360	Oct 15, 2036	DP		ODE-99	Oct 22, 2022
		10722508	May 02, 2025	DS DP			
		10980795	Jun 12, 2033	U-1848			
		10993914	Oct 15, 2036	DP			
		8147867	Aug 29, 2028	DS DP			
		8329213	Jan 06, 2027	DS DP			
		8703181	May 02, 2025	U-1434			
		8992970	May 02, 2025	DS DP			
		9339497	Jun 12, 2033	U-1848			
		9364473	Jun 12, 2033	U-1856			
		9452162	Jun 12, 2033	U-1899			
		9492442	Jun 12, 2033	U-1848			
		9492442	Jun 12, 2033	U-1899			
		9492442	Jun 12, 2033	U-1917			
		9717724	Jun 12, 2033	U-1848			
		9717724	Jun 12, 2033	U-2091			
		9724303	May 02, 2025	DS DP			
		9730891	May 02, 2025	U-1848			
		9782349	May 02, 2025	DS DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA							
N 207500	001	10206879	Sep 14, 2027	DP		NCE	Mar 06, 2020
		10603280	Sep 14, 2027	DP		ODE-305	Mar 06, 2022
		6812238	Oct 31, 2025	DS		ODE-90	Mar 06, 2022
						GAIN	Mar 06, 2025
						GAIN	Mar 06, 2027
						GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA							
N 207501	001	6812238	Oct 31, 2025	DS		NCE	Mar 06, 2020
						ODE-305	Mar 06, 2022
						ODE-90	Mar 06, 2022
						GAIN	Mar 06, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001					GAIN	Mar 06, 2027
					GAIN	Mar 06, 2027
ISOPROPYL ALCOHOL - ZURAGARD						
N 210872 001	10688291	Dec 20, 2034	DP U-1397		M-268	Jun 24, 2024
	8226971	May 06, 2025	DP		NP	Apr 26, 2022
	8389583	Aug 09, 2029	U-1397			
	8703828	May 23, 2028	DP			
	9011897	Feb 08, 2025	DP			
	9629368	May 23, 2028	U-1397			
	9844654	Apr 24, 2036	DP U-1397			
ISOTRETINOIN - ABSORICA LD						
N 211913 001	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 002	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 003	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 004	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 005	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISOTRETINOIN - ABSORICA LD						
N 211913 006	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 001	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			
ISTRADEFYLLINE - NOURIANZ						
N 022075 002	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			
ITRACONAZOLE - ONMEL						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
ITRACONAZOLE - TOLSURA						
N 208901 001	10463740	Jun 21, 2033	DP U-2453			
	10806792	Jun 21, 2033	DP			
	8771739	Jul 25, 2023	DP			
	8921374	Jun 21, 2033	DP			
	9272046	Jun 21, 2033	DP			
	9713642	Jun 21, 2033	U-2453			
IVABRADINE - CORLANOR						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		NP	Apr 22, 2022
	7361650	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7867996	Dec 12, 2026	DS DP U-1694		PED	Oct 22, 2022
	7879842	Feb 22, 2026	DS DP U-1694		PED	Oct 22, 2026
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694			
	7361649*PED	Aug 22, 2026				
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Dec 12, 2026	DS DP U-1694			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVABRADINE HYDROCHLORIDE - CORLANOR							
N 206143	001	7867996*PED	Jun 12, 2027				
		7879842	Feb 22, 2026	DS DP U-1694			
		7879842*PED	Aug 22, 2026				
IVABRADINE HYDROCHLORIDE - CORLANOR							
N 206143	002	7361649	Feb 22, 2026	DS DP U-1694			
		7361649*PED	Aug 22, 2026				
		7361650	Feb 22, 2026	DS DP U-1694			
		7361650*PED	Aug 22, 2026				
		7867996	Dec 12, 2026	DS DP U-1694			
		7867996*PED	Jun 12, 2027				
		7879842	Feb 22, 2026	DS DP U-1694			
		7879842*PED	Aug 22, 2026				
IVACAFTOR - KALYDECO							
N 203188	001	10646481	Aug 13, 2029	DP		ODE-189	Jul 31, 2024
		7495103	May 20, 2027	DS DP		ODE-190	May 17, 2024
		8324242	Aug 05, 2027	U-1311		ODE-199	Aug 15, 2025
		8324242	Aug 05, 2027	U-1906		ODE-338	Dec 21, 2027
		8354427	Jul 06, 2026	U-1311			
		8354427	Jul 06, 2026	U-1905			
		8410274	Dec 28, 2026	DP			
		8629162	Jun 24, 2025	U-2234			
		8754224	Dec 28, 2026	DS DP			
		9670163	Dec 28, 2026	DP U-1311			
IVACAFTOR - KALYDECO							
N 207925	001	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
		10646481	Aug 13, 2029	DP		ODE-188	Mar 17, 2022
		7495103	May 20, 2027	DS DP		ODE-189	Jul 31, 2024
		8324242	Aug 05, 2027	U-1311		ODE-190	May 17, 2024
		8324242	Aug 05, 2027	U-1906		ODE-199	Aug 15, 2025
		8324242	Aug 05, 2027	U-2527		ODE-236	Apr 29, 2026
		8354427	Jul 06, 2026	U-1311		ODE-338	Dec 21, 2027
		8354427	Jul 06, 2026	U-1905			
		8354427	Jul 06, 2026	U-2528			
		8410274	Dec 28, 2026	DP			
		8629162	Jun 24, 2025	U-2234			
		8629162	Jun 24, 2025	U-2529			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			
		9670163	Dec 28, 2026	DP U-1311			
		9670163	Dec 28, 2026	DP U-2530			
IVACAFTOR - KALYDECO							
N 207925	002	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
		10646481	Aug 13, 2029	DP		ODE-188	Mar 17, 2022
		7495103	May 20, 2027	DS DP		ODE-189	Jul 31, 2024
		8324242	Aug 05, 2027	U-1311		ODE-190	May 17, 2024
		8324242	Aug 05, 2027	U-1906		ODE-199	Aug 15, 2025
		8324242	Aug 05, 2027	U-2527		ODE-236	Apr 29, 2026
		8354427	Jul 06, 2026	U-1311		ODE-338	Dec 21, 2027
		8354427	Jul 06, 2026	U-1905			
		8354427	Jul 06, 2026	U-2528			
		8410274	Dec 28, 2026	DP			
		8629162	Jun 24, 2025	U-2234			
		8629162	Jun 24, 2025	U-2529			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			
		9670163	Dec 28, 2026	DP U-1311			
		9670163	Dec 28, 2026	DP U-2530			
IVACAFTOR - KALYDECO							
N 207925	003	10272046	Feb 27, 2033	DP U-2967		NPP	Apr 29, 2022
		10646481	Aug 13, 2029	DP		ODE-188	Mar 17, 2022
		7495103	May 20, 2027	DS DP		ODE-189	Jul 31, 2024
		8324242	Aug 05, 2027	U-1311		ODE-190	May 17, 2024
		8324242	Aug 05, 2027	U-1906		ODE-199	Aug 15, 2025
		8324242	Aug 05, 2027	U-2963		ODE-236	Apr 29, 2026
		8354427	Jul 06, 2026	U-1311		ODE-338	Dec 21, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO							
N 207925	003	8354427	Jul 06, 2026	U-1905			
		8354427	Jul 06, 2026	U-2964			
		8410274	Dec 28, 2026	DP			
		8629162	Jun 24, 2025	U-2234			
		8629162	Jun 24, 2025	U-2965			
		8754224	Dec 28, 2026	DS DP			
		8883206	Feb 27, 2033	DP			
		9670163	Dec 28, 2026	DP U-1311			
		9670163	Dec 28, 2026	DP U-2966			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	001	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
		10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
		10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
		10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
		10058546	Jul 15, 2033	U-3022		ODE-335	Dec 21, 2027
		10058546	Jul 15, 2033	U-3023			
		10081621	Mar 25, 2031	DP U-2420			
		10081621	Mar 25, 2031	DP U-2571			
		10081621	Mar 25, 2031	DP U-3024			
		10081621	Mar 25, 2031	DP U-3025			
		10206877	Apr 14, 2035	DP U-2498			
		10206877	Apr 14, 2035	DP U-2570			
		10206877	Apr 14, 2035	DP U-3026			
		10206877	Apr 14, 2035	DP U-3027			
		10239867	Apr 09, 2027	DS DP U-2512			
		10239867	Apr 09, 2027	DS DP U-2569			
		10646481	Aug 13, 2029	DP			
		7495103	May 20, 2027	DS DP			
		7645789	May 01, 2027	DS DP			
		7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-2246			
		8354427	Jul 06, 2026	U-3021			
		8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2246			
		8598181	May 01, 2027	U-2246			
		8623905	May 01, 2027	DS DP			
		8629162	Jun 24, 2025	U-2247			
		8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2248			
		9670163	Dec 28, 2026	DP U-2246			
		9931334	Dec 28, 2026	DP U-2275			
		9931334	Dec 28, 2026	DP U-2575			
		9974781	Apr 09, 2027	DP U-2318			
		9974781	Apr 09, 2027	DP U-2574			
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
		10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
		10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
		10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
		10058546	Jul 15, 2033	U-3022		ODE-335	Dec 21, 2027
		10058546	Jul 15, 2033	U-3023			
		10081621	Mar 25, 2031	DP U-2420			
		10081621	Mar 25, 2031	DP U-2571			
		10081621	Mar 25, 2031	DP U-3024			
		10081621	Mar 25, 2031	DP U-3025			
		10206877	Apr 14, 2035	DP U-2498			
		10206877	Apr 14, 2035	DP U-2570			
		10206877	Apr 14, 2035	DP U-3026			
		10206877	Apr 14, 2035	DP U-3027			
		10239867	Apr 09, 2027	DS DP U-2512			
		10239867	Apr 09, 2027	DS DP U-2569			
		10646481	Aug 13, 2029	DP			
		7495103	May 20, 2027	DS DP			
		7645789	May 01, 2027	DS DP			
		7776905	Jun 03, 2027	DS DP			
		8324242	Aug 05, 2027	U-2246			
		8354427	Jul 06, 2026	U-3021			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)							
N 210491	002	8410274	Dec 28, 2026	DP			
		8415387	Nov 12, 2027	U-2246			
		8598181	May 01, 2027	U-2246			
		8623905	May 01, 2027	DS DP			
		8629162	Jun 24, 2025	U-2247			
		8754224	Dec 28, 2026	DS DP			
		9012496	Jul 15, 2033	U-2248			
		9670163	Dec 28, 2026	DP U-2246			
		9931334	Dec 28, 2026	DP U-2275			
		9931334	Dec 28, 2026	DP U-2575			
		9974781	Apr 09, 2027	DP U-2318			
		9974781	Apr 09, 2027	DP U-2574			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	001	10076513	Dec 04, 2028	DP U-2411		ODE-123	Sep 28, 2023
		10597384	Dec 04, 2028	DS DP U-2777		ODE-93	Jul 02, 2022
		10646481	Aug 13, 2029	DP			
		11052075	Dec 04, 2028	DP U-3181			
		7495103	May 20, 2027	DS DP			
		7973038	Nov 08, 2026	U-1973			
		8324242	Aug 05, 2027	U-1311			
		8324242	Aug 05, 2027	U-1911			
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-1718			
		8716338	Sep 20, 2030	DP U-1910			
		8741933	Nov 08, 2026	U-1717			
		8741933	Nov 08, 2026	U-1909			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-1717			
		8846718	Dec 04, 2028	U-1908			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-1908			
		9192606	Sep 29, 2029	DP U-1912			
		9216969	Nov 08, 2026	DS DP			
		9670163	Dec 28, 2026	DP U-1911			
		9931334	Dec 28, 2026	DP U-2276			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 206038	002	10597384	Dec 04, 2028	DS DP U-2777		ODE-123	Sep 28, 2023
		10646481	Aug 13, 2029	DP		ODE-93	Jul 02, 2022
		11052075	Dec 04, 2028	DP U-3181			
		7495103	May 20, 2027	DS DP			
		7973038	Nov 08, 2026	U-1973			
		8324242	Aug 05, 2027	U-1911			
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-1910			
		8741933	Nov 08, 2026	U-1909			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-1908			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-1908			
		9192606	Sep 29, 2029	DP U-1912			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-1911			
		9931334	Dec 28, 2026	DP U-2276			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	001	10597384	Dec 04, 2028	DS DP U-2778		ODE-195	Aug 07, 2025
		10646481	Aug 13, 2029	DP			
		7495103	May 20, 2027	DS DP			
		7973038	Nov 08, 2026	U-2374			
		8324242	Aug 05, 2027	U-2374			
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-2396			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	001	8741933	Nov 08, 2026	U-2374			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-2375			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-2375			
		9192606	Sep 29, 2029	DP U-2397			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-2376			
		9931334	Dec 28, 2026	DP U-2376			
IVACAFTOR; LUMACAFTOR - ORKAMBI							
N 211358	002	10597384	Dec 04, 2028	DS DP U-2778		ODE-195	Aug 07, 2025
		10646481	Aug 13, 2029	DP			
		7495103	May 20, 2027	DS DP			
		7973038	Nov 08, 2026	U-2374			
		8324242	Aug 05, 2027	U-2374			
		8410274	Dec 28, 2026	DP			
		8507534	Sep 20, 2030	DS DP			
		8653103	Dec 04, 2028	DP			
		8716338	Sep 20, 2030	DP U-2396			
		8741933	Nov 08, 2026	U-2374			
		8754224	Dec 28, 2026	DS DP			
		8846718	Dec 04, 2028	U-2375			
		8993600	Dec 11, 2030	DP			
		9150552	Dec 04, 2028	U-2375			
		9192606	Sep 29, 2029	DP U-2397			
		9216969	Nov 08, 2026	DP			
		9670163	Dec 28, 2026	DP U-2376			
		9931334	Dec 28, 2026	DP U-2376			
IVERMECTIN - SOOLANTRA							
N 206255	001	10206939	Mar 13, 2034	U-1631			
		11033565	Apr 22, 2024	DP			
		7550440	Apr 22, 2024	DP U-1631			
		8080530	Apr 22, 2024	DP U-1631			
		8093219	Apr 22, 2024	DP U-1631			
		8415311	Apr 22, 2024	DP U-1631			
		8470788	Apr 22, 2024	DP U-1631			
		8815816	Apr 22, 2024	DP U-1631			
		9089587	Mar 13, 2034	U-1631			
		9233117	Mar 13, 2034	U-1631			
		9233118	Mar 13, 2034	U-1631			
		9782425	Mar 13, 2034	U-1631			
IVOSIDENIB - TIBSOVO							
N 211192	001	10449184	Mar 13, 2035	DP		I-816	May 02, 2022
		10610125	Jun 21, 2030	U-2784		I-875	Aug 25, 2024
		10610125	Jun 21, 2030	U-2785		NCE	Jul 20, 2023
		10717764	Jan 18, 2033	U-3215		ODE-203	Jul 20, 2025
		10799490	Mar 13, 2035	DP U-2981		ODE-242	May 02, 2026
		10799490	Mar 13, 2035	DP U-2982		ODE-368	Aug 25, 2028
		10980788	Jun 07, 2039	U-3112			
		10980788	Jun 07, 2039	U-3113			
		10980788	Jun 07, 2039	U-3214			
		9474779	Aug 19, 2033	DS DP U-2350			
		9474779	Aug 19, 2033	DS DP U-2533			
		9474779	Aug 19, 2033	DS DP U-2534			
		9474779	Aug 19, 2033	DS DP U-3213			
		9850277	Jan 18, 2033	DS DP U-2350			
		9850277	Jan 18, 2033	DS DP U-2533			
		9850277	Jan 18, 2033	DS DP U-2534			
		9850277	Jan 18, 2033	DS DP U-3213			
		9968595	Mar 13, 2035	DP U-2351			
		9968595	Mar 13, 2035	DP U-2533			
		9968595	Mar 13, 2035	DP U-2534			
IXABEPILONE - IXEMPRA KIT							
N 022065	001	6670384	Jan 23, 2022	DP U-959			
		6670384	Jan 23, 2022	DP U-960			
		7022330	Jan 23, 2022	DP U-958			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT						
N 022065 001	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
IXABEPILONE - IXEMPRA KIT						
N 022065 002	6670384	Jan 23, 2022	DP U-959			
	6670384	Jan 23, 2022	DP U-960			
	7022330	Jan 23, 2022	DP U-958			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
IXAZOMIB CITRATE - NINLARO						
N 208462 001	7442830	Nov 20, 2029	DS DP U-2434		ODE-103	Nov 20, 2022
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO						
N 208462 002	7442830	Nov 20, 2029	DS DP U-2434		ODE-103	Nov 20, 2022
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
IXAZOMIB CITRATE - NINLARO						
N 208462 003	7442830	Nov 20, 2029	DS DP U-2434		ODE-103	Nov 20, 2022
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
KETOROLAC TROMETHAMINE - ACULAR LS						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024	DP			
	8906950	May 28, 2024	U-1626			
	8946281	May 28, 2024	U-1662			
	9216167	May 28, 2024	U-1800			
KETOROLAC TROMETHAMINE - ACUVAIL						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
	8992952	Aug 05, 2024	DP			
	9192571	Mar 07, 2028	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA						
N 205388 001	8173707	Jul 30, 2023	U-1518			
	8173707*PED	Jan 30, 2024				
	8586633	Jul 30, 2023	DP			
	8586633*PED	Jan 30, 2024				
	9066856	Oct 23, 2033	DP			
	9066856*PED	Apr 23, 2034				
	9278101	Jul 30, 2023	U-1518			
	9278101*PED	Jan 30, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA							
N 205388	001	9399040	Jul 30, 2023	DP			
		9399040*PED	Jan 30, 2024				
		9486406	Oct 23, 2033	DP			
		9486406*PED	Apr 23, 2034				
		9855246	Oct 23, 2033	DP			
L-GLUTAMINE - ENDARI							
N 208587	001					ODE-150	Jul 07, 2024
LACOSAMIDE - VIMPAT							
N 022253	001	RE38551	Mar 17, 2022	DS DP U-1567		I-878	Nov 16, 2023
		RE38551	Mar 17, 2022	DS DP U-2140			
		RE38551	Mar 17, 2022	DS DP U-2989			
		RE38551	Mar 17, 2022	DS DP U-2990			
		RE38551	Mar 17, 2022	DS DP U-2999			
LACOSAMIDE - VIMPAT							
N 022253	002	RE38551	Mar 17, 2022	DS DP U-1567		I-878	Nov 16, 2023
		RE38551	Mar 17, 2022	DS DP U-2140			
		RE38551	Mar 17, 2022	DS DP U-2989			
		RE38551	Mar 17, 2022	DS DP U-2990			
		RE38551	Mar 17, 2022	DS DP U-2999			
LACOSAMIDE - VIMPAT							
N 022253	003	RE38551	Mar 17, 2022	DS DP U-1567		I-878	Nov 16, 2023
		RE38551	Mar 17, 2022	DS DP U-2140			
		RE38551	Mar 17, 2022	DS DP U-2989			
		RE38551	Mar 17, 2022	DS DP U-2990			
		RE38551	Mar 17, 2022	DS DP U-2999			
LACOSAMIDE - VIMPAT							
N 022253	004	RE38551	Mar 17, 2022	DS DP U-1567		I-878	Nov 16, 2023
		RE38551	Mar 17, 2022	DS DP U-2140			
		RE38551	Mar 17, 2022	DS DP U-2989			
		RE38551	Mar 17, 2022	DS DP U-2990			
		RE38551	Mar 17, 2022	DS DP U-2999			
LACOSAMIDE - VIMPAT							
N 022254	001	RE38551	Mar 17, 2022	DS DP U-1565		I-878	Nov 16, 2023
		RE38551	Mar 17, 2022	DS DP U-1568		NPP	Nov 16, 2023
		RE38551	Mar 17, 2022	DS DP U-2989			
		RE38551	Mar 17, 2022	DS DP U-2990			
		RE38551	Mar 17, 2022	DS DP U-2999			
LACOSAMIDE - VIMPAT							
N 022255	001	RE38551	Mar 17, 2022	DS DP U-1567		I-878	Nov 16, 2023
		RE38551	Mar 17, 2022	DS DP U-2140			
		RE38551	Mar 17, 2022	DS DP U-2989			
		RE38551	Mar 17, 2022	DS DP U-2990			
		RE38551	Mar 17, 2022	DS DP U-2999			
LACTITOL - PIZENSY							
N 211281	001	10806743	May 12, 2037	U-1516		NCE	Feb 12, 2025
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS							
N 206510	001	7169780	Oct 03, 2023	DS DP			
		7169780*PED	Apr 03, 2024				
		7217713	Oct 21, 2022	U-1663			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-1663			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-1663			
		7754731*PED	Sep 11, 2029				
		7820660	Apr 25, 2023	DS			
LAMOTRIGINE - LAMICTAL XR							
N 022115	001	8637512	Jun 14, 2028	DP			
		9144547	Sep 22, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMICTAL XR						
N 022115 002	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 003	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 004	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 005	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL XR						
N 022115 006	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
LAMOTRIGINE - LAMICTAL ODT						
N 022251 001	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
LAMOTRIGINE - LAMICTAL ODT						
N 022251 004	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
	9339504	Jul 02, 2028	DP U-1596			
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 001					ODE-156	Sep 15, 2024
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 002					ODE-156	Sep 15, 2024
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N 022074 003					ODE-156	Sep 15, 2024
LANSOPRAZOLE - LANSOPRAZOLE						
N 208025 001	11077055	Apr 21, 2036	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 001	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 002	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 003	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 021468 004	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
LAPATINIB DITOSYLATE - TYKERB						
N 022059 001	8821927	Sep 18, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 001	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
	10047097	Oct 21, 2029	U-2474		ODE-215	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
	10285993	Nov 16, 2035	U-2470		ODE-221	Nov 26, 2025
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI						
N 210861 002	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
	10047097	Oct 21, 2029	U-2474		ODE-215	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
	10285993	Nov 16, 2035	U-2470		ODE-221	Nov 26, 2025
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
LAROTRECTINIB SULFATE - VITRAKVI						
N 211710 001	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
	10045991	Apr 04, 2037	U-2473		ODE-215	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-220	Nov 26, 2025
	10137127	Apr 04, 2037	DP		ODE-221	Nov 26, 2025
	10172861	Nov 16, 2035	DS			
	10668072	Apr 04, 2037	DP			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2471			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
LASMIDITAN SUCCINATE - REYVOW						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
LATANOPROST - XELPROS						
N 206185 001	9539262	Oct 15, 2028	U-2400			
	9629852	Sep 12, 2029	DP			
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524		NC	Mar 12, 2022
	10532993	Jul 11, 2026	U-1524		NCE	Dec 18, 2022
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN						
N 208259 001	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
	11185538	Mar 14, 2034	DP			
	11197853	Mar 14, 2034	DP			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
LATANOPROSTENE BUNOD - VYZULTA						
N 207795 001	7273946	Oct 03, 2025	DS DP U-2144			
	7629345	Jan 05, 2025	DP U-2144			
	7910767	Jan 05, 2025	DS DP U-2144			
	8058467	Jan 05, 2025	DS U-2144			
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		D-177	Nov 15, 2022
	10039779	Jan 30, 2034	DS DP U-2370		ODE*	Aug 28, 2026
	10039779*PED	Jul 30, 2034			ODE*	Aug 28, 2026
	10456414	Sep 14, 2032	DP		ODE*	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-136	Apr 07, 2024
	7964580*PED	Sep 26, 2029			PED	Oct 07, 2024
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470		D-177	Nov 15, 2022
	10039779*PED	Jul 30, 2034			ODE*	Apr 07, 2024
	10456414	Sep 14, 2032	DP		ODE*	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE*	Aug 28, 2026
	8088368	May 12, 2030	DS DP		PED	Oct 07, 2024
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 205834	002	8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8822430	May 12, 2030	DS DP U-1470			
		8822430*PED	Nov 12, 2030				
		8841278	May 12, 2030	DP U-1470			
		8841278*PED	Nov 12, 2030				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9393256	Sep 14, 2032	U-1470			
		9393256*PED	Mar 14, 2033				
		9511056	May 12, 2030	U-1470			
		9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 212477	001	10456414	Sep 14, 2032	DP		D-177	Nov 15, 2022
		7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
		7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
		8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
		8088368*PED	Nov 12, 2030				
		8273341	May 12, 2030	U-1470			
		8273341*PED	Nov 12, 2030				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8822430	May 12, 2030	DS DP U-1470			
		8822430*PED	Nov 12, 2030				
		8841278	May 12, 2030	DP U-1470			
		8841278*PED	Nov 12, 2030				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9393256	Sep 14, 2032	U-1470			
		9393256*PED	Mar 14, 2033				
		9511056	May 12, 2030	U-1470			
		9511056*PED	Nov 12, 2030				
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 212477	002	10456414	Sep 14, 2032	DP		D-177	Nov 15, 2022
		7964580	Mar 26, 2029	DS DP U-1470		ODE-262	Aug 28, 2026
		7964580*PED	Sep 26, 2029			ODE-263	Aug 28, 2026
		8088368	May 12, 2030	DS DP		ODE-264	Aug 28, 2026
		8088368*PED	Nov 12, 2030				
		8273341	May 12, 2030	U-1470			
		8273341*PED	Nov 12, 2030				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEDIPASVIR; SOFOSBUVIR - HARVONI						
N 212477 002	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
LEFAMULIN ACETATE - XENLETA						
N 211672 001	8071643	Jan 16, 2029	DS DP		NCE	Aug 19, 2024
	8153689	Mar 19, 2028	DS DP		GAIN	Aug 19, 2029
	9120727	May 23, 2031	DS DP			
LEFAMULIN ACETATE - XENLETA						
N 211673 001	8071643	Jan 16, 2029	DS DP		NCE	Aug 19, 2024
	8153689	Mar 19, 2028	DS DP		GAIN	Aug 19, 2029
LEMBOREXANT - DAYVIGO						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
LEMBOREXANT - DAYVIGO						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
LENALIDOMIDE - REVLIMID						
N 021880 001	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7465800	Apr 27, 2027	DS DP		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-1983		ODE-131	Feb 22, 2024
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7855217	Nov 24, 2024	DS DP		ODE-88	Feb 17, 2022
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 002	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7465800	Apr 27, 2027	DS DP		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-1983		ODE-131	Feb 22, 2024
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7855217	Nov 24, 2024	DS DP		ODE-88	Feb 17, 2022
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7465800	Apr 27, 2027	DS DP		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-1983		ODE-131	Feb 22, 2024
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7855217	Nov 24, 2024	DS DP		ODE-88	Feb 17, 2022
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 004	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7465800	Apr 27, 2027	DS DP		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-1983		ODE-131	Feb 22, 2024
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7855217	Nov 24, 2024	DS DP		ODE-88	Feb 17, 2022
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 005	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7465800	Apr 27, 2027	DS DP		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-1983		ODE-131	Feb 22, 2024
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7855217	Nov 24, 2024	DS DP		ODE-88	Feb 17, 2022
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENALIDOMIDE - REVLIMID						
N 021880 006	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7465800	Apr 27, 2027	DS DP		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-1983		ODE-131	Feb 22, 2024
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7855217	Nov 24, 2024	DS DP		ODE-88	Feb 17, 2022
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LENALIDOMIDE - REVLIMID						
N 021880 006	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
LENVATINIB MESYLATE - LENVIMA						
N 206947 001	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS		I-868	Aug 10, 2024
	11186547	Aug 26, 2035	DS		M-269	Jul 21, 2024
	7253286	Oct 24, 2025	DS DP		ODE-196	Aug 15, 2025
	7612208	Sep 19, 2026	DS DP		ODE-87	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
LENVATINIB MESYLATE - LENVIMA						
N 206947 002	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS		I-868	Aug 10, 2024
	11186547	Aug 26, 2035	DS		M-269	Jul 21, 2024
	7253286	Oct 24, 2025	DS DP		ODE-196	Aug 15, 2025
	7612208	Sep 19, 2026	DS DP		ODE-87	Feb 13, 2022
	9006256	Jul 27, 2027	U-1695			
LESINURAD - ZURAMPIC						
N 207988 001	10183012	Nov 26, 2028	U-2311			
	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
	9956205	Dec 28, 2031	U-2311			
LETERMOVIR - PREVYMIS						
N 209939 001	8513255	May 22, 2024	DS DP		NCE	Nov 08, 2022
	RE46791	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS						
N 209939 002	8513255	May 22, 2024	DS DP		NCE	Nov 08, 2022
	RE46791	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
LETERMOVIR - PREVYMIS						
N 209940 001	10603384	Feb 28, 2033	DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
	RE46791	May 22, 2024	DS DP			
LETERMOVIR - PREVYMIS						
N 209940 002	10603384	Feb 28, 2033	DP		NCE	Nov 08, 2022
	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
	RE46791	May 22, 2024	DS DP			
LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)						
N 209935 001	10799506	Apr 14, 2036	DP		NCE	Mar 13, 2022
	8324225	Jun 17, 2028	DS DP			
	8415355	Aug 21, 2029	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N 020517 003	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP U-1666			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEUPROLIDE ACETATE - ELIGARD KIT						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
LEUPROLIDE ACETATE - ELIGARD KIT						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
LEUPROLIDE ACETATE - ELIGARD KIT						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
LEUPROLIDE ACETATE - FENSOLVI KIT						
N 213150 001	8470359	Oct 15, 2023	DS DP U-2940		I-829	May 01, 2023
LEUPROLIDE MESYLATE - CAMCEVI KIT						
N 211488 001	10646572	Jan 16, 2027	DP		NP	May 25, 2024
	9572857	Jan 16, 2027	DP			
	9744207	Jan 16, 2027	DP			
LEVALBUTEROL TARTRATE - XOPENEX HFA						
N 021730 001	7256310	Oct 08, 2024	DS DP U-636			
	8765153	Dec 08, 2023	DP			
LEVETIRACETAM - KEPPRA						
N 021035 001	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA						
N 021035 002	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA						
N 021035 003	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA						
N 021035 004	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
LEVETIRACETAM - KEPPRA XR						
N 022285 001	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - KEPPRA XR						
N 022285 002	7858122	Sep 17, 2028	DP			
LEVETIRACETAM - ELEPSIA XR						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			
LEVETIRACETAM - ELEPSIA XR						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			
LEVETIRACETAM - SPRITAM						
N 207958 001	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 002	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVETIRACETAM - SPRITAM						
N 207958 003	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVETIRACETAM - SPRITAM						
N 207958 004	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR						
N 209090 001	8633194	Oct 16, 2027	DP			
LEVODOPA - INBRIJA						
N 209184 001	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
LEVOFLOXACIN - LEVAQUIN						
N 021721 001	6806256	Feb 26, 2022	DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N 020140 001	6500829	Mar 07, 2022	DS DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N 020140 002	6500829	Mar 07, 2022	DS DP			
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N 020140 003	6500829	Mar 07, 2022	DS DP			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 001	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 002	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 003	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA						
N 204168 004	8481598	Mar 02, 2031	U-839		M-249	Oct 07, 2022
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
LEVONORGESTREL - MIRENA						
N 021225 001	10561524	Sep 16, 2029	U-2948		D-181	Aug 20, 2023
	10987244	Apr 01, 2031	DP			
	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
LEVONORGESTREL - SKYLA						
N 203159 001	10561524	Sep 16, 2029	U-2948			
	10987244	Apr 01, 2031	DP			
	7252839	Nov 13, 2023	DP			
	9615965	Sep 16, 2029	DP U-2003			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVONORGESTREL - SKYLA						
N 203159 001	9668912	Apr 01, 2031	DP			
LEVONORGESTREL - LILETTA						
N 206229 001	10028858	Mar 22, 2034	DP		U-2348	
	11090186	Oct 24, 2033			U-2348	
LEVONORGESTREL - KYLEENA						
N 208224 001	10561524	Sep 16, 2029			U-2948	
	10987244	Apr 01, 2031	DP			
	7252839	Nov 13, 2023	DP			
	9615965	Sep 16, 2029	DP		U-2003	
	9668912	Apr 01, 2031	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 003	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 004	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 005	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 006	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 007	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 008	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 009	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 010	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 011	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOLET						
N 021137 012	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 001	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - LEVOXYL						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023			U-759	
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 003	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 004	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 005	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 006	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 007	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 008	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 009	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 010	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 011	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 012	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - TIROSINT						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 001	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 002	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 003	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 004	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 005	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 006	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 007	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 008	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 009	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 010	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 011	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 012	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 013	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 014	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - TIROSINT-SOL						
N 206977 015	11096913	Feb 28, 2037	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 001	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 002	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 210632 003	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
LEVOTHYROXINE SODIUM - THYQUIDITY						
N 214047 001	9050307	Aug 06, 2031	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM						
N 214253 001	11154498	Jul 20, 2036	DP			
LIDOCAINE - ZTLIDO						
N 207962 001	10765640	May 10, 2031	DP			
	10765749	May 10, 2031	DP			
	9283174	May 10, 2031	DP			
	9925264	May 10, 2031	DP		U-2267	
	9931403	May 10, 2031	DP			
LIDOCAINE HYDROCHLORIDE - ZINGO						
N 022114 001	8540665	Oct 22, 2029			U-1438	
	9358338	Apr 27, 2035			U-1870	
	9370622	Sep 28, 2035			U-1870	
LIDOCAINE HYDROCHLORIDE - AKTEN						
N 022221 001	8759401	Jul 24, 2026	DP		U-1523	
LIDOCAINE; TETRACAINE - PLIAGLIS						
N 021717 001	10350180	Jan 14, 2031	DP			
	10603293	Jan 14, 2031	DP			
	10751305	Jan 14, 2031	DP			
LIFITEGRAST - XIIDRA						
N 208073 001	10124000	Nov 05, 2024			U-1900	
	11058677	Dec 18, 2033	DP			
	7314938	Mar 10, 2025	DS DP			
	7745460	Nov 05, 2024	DS DP		U-1880	
	7790743	Nov 05, 2024			U-1880	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIFITEGRAST - XIIDRA							
N 208073	001	7928122	Nov 05, 2024	DS DP			
		8084047	May 17, 2026	DS DP			
		8168655	May 09, 2029	U-1880			
		8367701	Apr 15, 2029	DP U-1880			
		8592450	May 17, 2026	U-1880			
		8927574	Nov 12, 2030	DP			
		9085553	Jul 25, 2033	DP			
		9216174	Nov 05, 2024	DP			
		9353088	Oct 21, 2030	DP			
		9447077	Apr 15, 2029	U-1900			
		9890141	Oct 21, 2030	DS			
LINACLOTIDE - LINZESS							
N 202811	001	7304036	Aug 30, 2026	DS DP U-1278			
		7304036	Aug 30, 2026	DS DP U-1516			
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1278			
		8748573	Oct 30, 2031	U-1515			
		8748573	Oct 30, 2031	U-1516			
		8802628	Oct 30, 2031	DP			
		8933030	Feb 17, 2031	DP			
		9708371	Aug 16, 2033	DP U-1515			
		9708371	Aug 16, 2033	DP U-1516			
LINACLOTIDE - LINZESS							
N 202811	002	7304036	Aug 30, 2026	DS DP U-1278			
		7304036	Aug 30, 2026	DS DP U-1516			
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1278			
		8748573	Oct 30, 2031	U-1515			
		8748573	Oct 30, 2031	U-1516			
		8802628	Oct 30, 2031	DP			
		8933030	Feb 17, 2031	DP			
		9708371	Aug 16, 2033	DP U-1515			
LINACLOTIDE - LINZESS							
N 202811	003	10675325	Aug 11, 2031	DP			
		10702576	Aug 11, 2031	U-1516			
		7304036	Aug 30, 2026	DS DP U-1516			
		7371727	Jan 28, 2024	DS			
		7704947	Jan 28, 2024	DS DP			
		7745409	Jan 28, 2024	DS DP			
		8080526	Jan 28, 2024	DS DP			
		8110553	Jan 28, 2024	U-1516			
		8933030	Feb 17, 2031	DP U-1516			
		9708371	Aug 16, 2033	DP U-1516			
LINAGLIPTIN - TRADJENTA							
N 201280	001	10034877	Aug 05, 2029	U-2347		M-252	Mar 30, 2023
		11033552	May 04, 2027	DP		M-258	Jul 03, 2022
		7407955	May 02, 2025	DS DP			
		8119648	Aug 12, 2023	U-1270			
		8119648	Aug 12, 2023	U-774			
		8178541	Aug 12, 2023	U-1244			
		8178541	Aug 12, 2023	U-1245			
		8178541	Aug 12, 2023	U-1270			
		8178541	Aug 12, 2023	U-775			
		8673927	May 04, 2027	U-1503	Y		
		8846695	Jun 04, 2030	U-1503	Y		
		8853156	Mar 05, 2031	U-1642			
		8883805	Nov 26, 2025	DP			
		9486526	Aug 05, 2029	U-1915			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	10973827	Apr 02, 2029	DP		M-258	Jul 03, 2022
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503	Y		
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	10973827	Apr 02, 2029	DP		M-258	Jul 03, 2022
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503	Y		
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	10973827	Apr 02, 2029	DP		M-258	Jul 03, 2022
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503	Y		
	8846695	Jun 04, 2030	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	7407955	May 02, 2025	DS DP		M-258	Jul 03, 2022
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503	Y		
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	7407955	May 02, 2025	DS DP		M-258	Jul 03, 2022
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503	Y		
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LIRAGLUTIDE RECOMBINANT - VICTOZA							
N 022341	001	8846618	Jun 27, 2022	DP			
		8846618*PED	Dec 27, 2022				
		9265893	Sep 23, 2032	DP			
		9265893*PED	Mar 23, 2033				
		9968659	Jan 09, 2037	U-2313			
		9968659*PED	Jul 09, 2037				
LIRAGLUTIDE RECOMBINANT - SAXENDA							
N 206321	001	10220155	Jul 17, 2026	DP		NPP	Dec 04, 2023
		10220155*PED	Jan 17, 2027				
		10357616	Jan 20, 2026	DP			
		10376652	Jan 20, 2026	DP			
		11097063	Jul 17, 2026	DP			
		6268343	Aug 22, 2022	DS DP U-1255			
		6268343*PED	Feb 22, 2023				
		6899699*PED	Jul 01, 2022				
		7762994	May 23, 2024	DP			
		7762994*PED	Nov 23, 2024				
		8114833	Aug 13, 2025	DP			
		8114833*PED	Feb 13, 2026				
		8579869	Jun 30, 2023	DP			
		8579869*PED	Dec 30, 2023				
		8672898	Jan 02, 2022	DP			
		8672898*PED	Jul 02, 2022				
		8684969	Oct 20, 2025	DP			
		8684969*PED	Apr 20, 2026				
		8846618	Jun 27, 2022	DP			
		8846618*PED	Dec 27, 2022				
		8920383	Jul 17, 2026	DP			
		8920383*PED	Jan 17, 2027				
		9108002	Jan 26, 2026	DP			
		9108002*PED	Jul 26, 2026				
		9132239	Feb 01, 2032	DP			
		9132239*PED	Aug 01, 2032				
		9457154	Sep 27, 2027	DP			
		9457154*PED	Mar 27, 2028				
		9486588	Jan 02, 2022	DP			
		9486588*PED	Jul 02, 2022				
		9616180	Jan 20, 2026	DP			
		9616180*PED	Jul 20, 2026				
		9687611	Feb 27, 2027	DP			
		9687611*PED	Aug 27, 2027				
		9775953	Jul 17, 2026	DP			
		9775953*PED	Jan 17, 2027				
		9861757	Jan 20, 2026	DP			
		9861757*PED	Jul 20, 2026				
		9968659	Jan 09, 2037	U-2438			
		9968659*PED	Jul 09, 2037				
		RE46363	Aug 03, 2026	DP			
		RE46363*PED	Feb 03, 2027				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
N 021977	001	7105486	Feb 24, 2023	U-727			
		7105486*PED	Aug 24, 2023				
		7223735	Feb 24, 2023	DP			
		7223735*PED	Aug 24, 2023				
		7655630	Feb 24, 2023	DS			
		7659253	Feb 24, 2023	DS DP U-727			
		7659254	Feb 24, 2023	U-1034			
		7662787	Feb 24, 2023	DS			
		7662788	Feb 24, 2023	U-727			
		7671030	Feb 24, 2023	DP U-727			
		7671031	Feb 24, 2023	U-727			
		7671031*PED	Aug 24, 2023				
		7674774	Feb 24, 2023	DP U-842			
		7674774*PED	Aug 24, 2023				
		7678770	Feb 24, 2023	U-842			
		7678770*PED	Aug 24, 2023				
		7678771	Feb 24, 2023	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 001	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-842	
	7723305	Feb 24, 2023	DP		U-842	
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 002	7105486	Feb 24, 2023			U-727	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS	DP	U-727	
	7659254	Feb 24, 2023			U-1034	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023		DP	U-727	
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023		DP	U-842	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023		DP	U-842	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-842	
	7723305	Feb 24, 2023	DP		U-842	
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 003	7105486	Feb 24, 2023			U-727	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS	DP	U-727	
	7659254	Feb 24, 2023			U-1034	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023		DP	U-727	
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023		DP	U-842	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023		DP	U-842	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-842	
	7723305	Feb 24, 2023	DP		U-842	
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 004	7105486	Feb 24, 2023			U-727	
	7105486	Feb 24, 2023			U-842	
	7105486*PED	Aug 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 004	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP		U-727	
	7659254	Feb 24, 2023			U-1034	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023	DP		U-727	
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-842	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-842	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-842	
	7723305	Feb 24, 2023	DP		U-842	
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 005	7105486	Feb 24, 2023			U-842	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP		U-727	
	7659254	Feb 24, 2023			U-1034	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023	DP		U-727	
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-842	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-842	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-842	
	7723305	Feb 24, 2023	DP		U-842	
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006	7105486	Feb 24, 2023			U-727	
	7105486	Feb 24, 2023			U-842	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP		U-727	
	7659254	Feb 24, 2023			U-1034	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023			U-727	
	7671030	Feb 24, 2023	DP		U-727	
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-842	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-842	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP		U-842	
	7723305	Feb 24, 2023	DP		U-842	
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 007	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP		U-727	
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-1034	
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP		U-727	
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-842	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP		U-842	
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP		U-842	
	7718619*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 001	7105486	Feb 24, 2023			U-727	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP		U-727	
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-727	
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP		U-727	
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-727	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-727	
	7678770*PED	Aug 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 001	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 003	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 004	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 005	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 005	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-727	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-727	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-727	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP		U-727	
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP		U-727	
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP		U-727	
	7723305*PED	Aug 24, 2023				
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 208510 006	7105486	Feb 24, 2023			U-727	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP		U-727	
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-727	
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP		U-727	
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-727	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-727	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-727	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP		U-727	
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP		U-727	
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP		U-727	
	7723305*PED	Aug 24, 2023				
LISINOPRIL - QBRELIS						
N 208401 001	10039800	Nov 06, 2035			U-1723	
	10039800	Nov 06, 2035			U-185	
	10039800	Nov 06, 2035			U-1864	
	10039800	Nov 06, 2035			U-1991	
	10039800	Nov 06, 2035			U-3	
	10039800	Nov 06, 2035			U-71	
	10039800	Nov 06, 2035			U-8	
	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035			U-1723	
	10406199	Nov 06, 2035			U-185	
	10406199	Nov 06, 2035			U-1864	
	10406199	Nov 06, 2035			U-1991	
	10406199	Nov 06, 2035			U-3	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISINOPRIL - QBRELIS							
N 208401	001	10406199	Nov 06, 2035	U-71			
		10406199	Nov 06, 2035	U-8			
		10940177	Nov 06, 2035	DP			
		11179434	Nov 06, 2035	DP			
		9463183	Nov 06, 2035	DP			
		9616096	Nov 06, 2035	U-1723			
		9616096	Nov 06, 2035	U-185			
		9616096	Nov 06, 2035	U-1864			
		9616096	Nov 06, 2035	U-1991			
		9616096	Nov 06, 2035	U-3			
		9616096	Nov 06, 2035	U-71			
		9616096	Nov 06, 2035	U-8			
		9814751	Nov 06, 2035	DP			
LOFEXIDINE HYDROCHLORIDE - LUCEMYRA							
N 209229	001					NCE	May 16, 2023
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	001	10016404	Mar 07, 2025	U-1316			
		10555938	Mar 07, 2025	U-1316			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	002	10016404	Mar 07, 2025	U-1316			
		10555938	Mar 07, 2025	U-1316			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	003	10016404	Mar 07, 2025	U-1316			
		10555938	Mar 07, 2025	U-1316			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	004	10016404	Mar 07, 2025	U-1316			
		10555938	Mar 07, 2025	U-1316			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	005	10016404	Mar 07, 2025	U-1316			
		10555938	Mar 07, 2025	U-1316			
		7932268	Aug 19, 2027	U-1316			
		8618135	Mar 07, 2025	U-1316			
		9265758	Mar 07, 2025	U-1316			
		9364470	Mar 07, 2025	U-1851			
		9433617	Mar 07, 2025	U-1316			
		9861622	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID							
N 203858	006	10016404	Mar 07, 2025	U-1316			
		10555938	Mar 07, 2025	U-1316			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
LONAFARNIB - ZOKINVY						
N 213969 001	7838531	Jul 26, 2024	U-3070		NCE	Nov 20, 2025
	8828356	Oct 17, 2023	U-3070		ODE-324	Nov 20, 2027
LONAFARNIB - ZOKINVY						
N 213969 002	7838531	Jul 26, 2024	U-3070		NCE	Nov 20, 2025
	8828356	Oct 17, 2023	U-3070		ODE-324	Nov 20, 2027
LOPERAMIDE HYDROCHLORIDE - LOPERAMIDE HYDROCHLORIDE						
A 213070 001					CGT	Apr 20, 2022
LORAZEPAM - LOREEV XR						
N 214826 001	8999393	Jan 08, 2034	DP U-3210			
LORAZEPAM - LOREEV XR						
N 214826 002	8999393	Jan 08, 2034	DP U-3210			
LORAZEPAM - LOREEV XR						
N 214826 003	8999393	Jan 08, 2034	DP U-3210			
LORLATINIB - LORBRENA						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		NCE	Nov 02, 2023
	11020376	Jul 27, 2036	DP		ODE-217	Nov 02, 2025
	8680111	Mar 05, 2033	DS DP		ODE-218	Nov 02, 2025
					ODE-219	Nov 02, 2025
					ODE-349	Mar 03, 2028
LORLATINIB - LORBRENA						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		NCE	Nov 02, 2023
	11020376	Jul 27, 2036	DP		ODE-217	Nov 02, 2025
	8680111	Mar 05, 2033	DS DP		ODE-218	Nov 02, 2025
					ODE-219	Nov 02, 2025
					ODE-349	Mar 03, 2028
LOTEPREDNOL ETABONATE - LOTEMAX SM						
N 208219 001	10596107	Dec 23, 2036	DP U-2764		NS	Feb 22, 2022
LOTEPREDNOL ETABONATE - INVELTYS						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	10646437	May 03, 2033	DP			
	10688045	May 03, 2033	DP			
	10864219	May 03, 2033	U-3011			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
LOTEPREDNOL ETABONATE - EYSUVIS						
N 210933 001	10058511	May 03, 2033	DP U-2492		NP	Oct 26, 2023
	10646436	May 03, 2033	DP			
	10688045	May 03, 2033	DP			
	10857096	May 03, 2033	U-2985			
	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2985			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOXAPINE - ADASUVE						
N 022549 001	6716416	May 20, 2022	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
	8387612	Oct 23, 2026	DP			
	8991387	May 21, 2024	DP			
	9370629	May 20, 2024	DP			
LUBIPROSTONE - AMITIZA						
N 021908 001	6982283	Dec 04, 2022	U-1391			
	7064148	Aug 30, 2022	U-1404			
	7064148	Aug 30, 2022	U-739			
	8026393	Oct 25, 2027	DP			
	8097653	Nov 14, 2022	U-1214			
	8097653	Nov 14, 2022	U-1394			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP U-1345			
	8389542	Nov 14, 2022	DP U-1395			
	8748481	Sep 01, 2025	U-1520			
	8779187	Jan 23, 2027	DP			
LUBIPROSTONE - AMITIZA						
N 021908 002	7064148	Aug 30, 2022	U-739			
	7064148	Aug 30, 2022	U-873			
	7795312	Sep 17, 2024	U-1085			
	8026393	Oct 25, 2027	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
LULICONAZOLE - LUZU						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
LUMASIRAN SODIUM - OXLUMO						
N 214103 001	10131907	Aug 24, 2028	DS DP U-2995		NCE	Nov 23, 2025
	10435692	Dec 26, 2034	U-2995		ODE-339	Nov 23, 2027
	10465195	Dec 26, 2034	DS DP U-2995			
	10478500	Oct 09, 2035	DS DP U-2995			
	10487330	Dec 26, 2034	DS DP U-2995			
	10612024	Aug 14, 2035	DS DP U-2995			
	10612027	Aug 14, 2035	DS DP U-2995			
	11060093	Dec 26, 2034	DS DP U-2995			
	8106022	Dec 12, 2029	DS DP U-2995			
	8828956	Dec 04, 2028	DS DP U-2995			
	9828606	Dec 26, 2034	DS DP			
LUMATEPERONE TOSYLATE - CAPLYTA						
N 209500 001	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	10695345	Aug 30, 2039	DP U-543			
	10960009	Dec 03, 2034	U-814			
	8598119	Dec 28, 2029	U-543			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Mar 12, 2029	DS DP			
	RE48839	Dec 28, 2029	U-814			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	001	9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP		U-543	
		9815827	Feb 20, 2024			U-2166	
		9815827	Feb 20, 2024			U-543	
		9827242	May 23, 2031			U-2199	
		9827242	May 23, 2031			U-2201	
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	002	8729085	May 26, 2026	DP			
		8729085*PED	Nov 26, 2026				
		8883794	May 26, 2026	DP			
		8883794*PED	Nov 26, 2026				
		9174975	Feb 20, 2024			U-1770	
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031			U-1822	
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP		U-543	
		9815827	Feb 20, 2024			U-2166	
		9815827	Feb 20, 2024			U-543	
		9827242	May 23, 2031			U-2199	
		9827242	May 23, 2031			U-2201	
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	003	8729085	May 26, 2026	DP			
		8729085*PED	Nov 26, 2026				
		8883794	May 26, 2026	DP			
		8883794*PED	Nov 26, 2026				
		9174975	Feb 20, 2024			U-1770	
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031			U-1822	
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP		U-543	
		9815827	Feb 20, 2024			U-2166	
		9815827	Feb 20, 2024			U-543	
		9827242	May 23, 2031			U-2199	
		9827242	May 23, 2031			U-2201	
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	004	8729085	May 26, 2026	DP			
		8729085*PED	Nov 26, 2026				
		8883794	May 26, 2026	DP			
		8883794*PED	Nov 26, 2026				
		9174975	Feb 20, 2024			U-1770	
		9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031			U-1822	
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP		U-543	
		9815827	Feb 20, 2024			U-2166	
		9815827	Feb 20, 2024			U-543	
		9827242	May 23, 2031			U-2199	
		9827242	May 23, 2031			U-2201	
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	005	8729085	May 26, 2026	DP			
		8729085*PED	Nov 26, 2026				
		8883794	May 26, 2026	DP			
		8883794*PED	Nov 26, 2026				
		9174975	Feb 20, 2024			U-1770	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603	005	9174975*PED	Aug 20, 2024				
		9259423	May 23, 2031	U-1822			
		9259423*PED	Nov 23, 2031				
		9555027	May 26, 2026	DP U-543			
		9815827	Feb 20, 2024	U-2166			
		9815827	Feb 20, 2024	U-543			
		9827242	May 23, 2031	U-2199			
		9827242	May 23, 2031	U-2201			
		9907794	May 26, 2026	DP			
		RE45573	Jun 23, 2025	DS			
		RE45573*PED	Dec 23, 2025				
LURBINECTEDIN - ZEPZELCA							
N 213702	001	7763615	Dec 13, 2024	DS DP U-2836		NCE	Jun 15, 2025
						ODE-304	Jun 15, 2027
LUSUTROMBOPAG - MULPLETA							
N 210923	001	7601746	Sep 05, 2024	DS DP U-2344		NCE	Jul 31, 2023
		8530668	Jan 21, 2030	DS DP			
		8889722	Jul 29, 2028	DS DP			
		9427402	Sep 29, 2031	DP			
LUTETIUM DOTATATE LU-177 - LUTATHERA							
N 208700	001	10596276	Jul 25, 2038	DP		NCE	Jan 26, 2023
		10596278	Jul 25, 2038	DP		ODE-166	Jan 26, 2025
MACIMORELIN ACETATE - MACRILEN							
N 205598	001	6861409	Aug 01, 2022	DS DP U-2220		NCE	Dec 20, 2022
		8192719	Oct 12, 2027	U-2220		ODE-170	Dec 20, 2024
MACITENTAN - OPSUMIT							
N 204410	001	10946015	Sep 11, 2026	DP U-1445			
		7094781	Dec 05, 2025	DS DP			
		8268847	Apr 18, 2029	U-1446			
		8367685	Oct 04, 2028	DP U-1445			
		9265762	May 29, 2027	DP U-1820			
MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25							
N 021910	001	7300674	Mar 04, 2023	DP U-785			
MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB							
N 213135	001	10143656	Aug 04, 2037	DP		NP	Nov 10, 2023
		11033498	Aug 04, 2037	U-3164			
MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT							
N 022372	001	6946149	Mar 07, 2023	DP U-837		ODE-315	Aug 05, 2027
MALATHION - OVIDE							
N 018613	001	7560445	Feb 01, 2027	DS DP U-986			
		7977324	Aug 14, 2026	DP			
MANNITOL - BRONCHITOL							
N 202049	001					NP	Oct 30, 2023
						ODE-327	Oct 30, 2027
MARALIXIBAT CHLORIDE - LIVMARLI							
N 214662	001					NCE	Sep 29, 2026
MARAVIROC - SELZENTRY							
N 022128	001	6667314*PED	Feb 06, 2022				
		7368460	Nov 25, 2022	U-824			
		7368460*PED	May 25, 2023				
MARAVIROC - SELZENTRY							
N 022128	002	6667314*PED	Feb 06, 2022				
		7368460	Nov 25, 2022	U-824			
		7368460*PED	May 25, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MARAVIROC - SELZENTRY							
N 022128	003	6667314*PED	Feb 06, 2022				
		7368460	Nov 25, 2022	U-824			
		7368460*PED	May 25, 2023				
MARAVIROC - SELZENTRY							
N 022128	004	6667314*PED	Feb 06, 2022				
		7368460	Nov 25, 2022	U-824			
		7368460*PED	May 25, 2023				
MARAVIROC - SELZENTRY							
N 208984	001	6667314*PED	Feb 06, 2022			NPP	Oct 30, 2023
		7368460	Nov 25, 2022	U-824		PED	Apr 30, 2024
		7368460*PED	May 25, 2023				
MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR							
N 202317	001	7838564	Mar 07, 2026	DP			
		7872050	Jul 08, 2029	U-1427			
		8450375	Mar 07, 2026	DP			
		8501818	Mar 07, 2026	DP			
		8501819	Mar 07, 2026	U-1427			
		9382191	Mar 07, 2026	DP			
MEGESTROL ACETATE - MEGACE ES							
N 021778	001	7101576	Apr 22, 2024	U-755			
		9040088	Apr 22, 2024	U-755			
		9101540	Apr 22, 2024	DP U-755			
		9101549	Apr 22, 2024	U-755			
		9107827	Apr 22, 2024	U-755			
MELOXICAM - VIVLODEX							
N 207233	001	9526734	Mar 31, 2033	DP			
		9649318	Mar 31, 2035	DP			
		9808468	Mar 31, 2035	U-2160			
		9808468	Mar 31, 2035	U-2165			
MELOXICAM - VIVLODEX							
N 207233	002	9526734	Mar 31, 2033	DP			
		9649318	Mar 31, 2035	DP			
		9808468	Mar 31, 2035	U-2160			
		9808468	Mar 31, 2035	U-2165			
MELOXICAM - ANJESO							
N 210583	001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
		10471067	Feb 24, 2024	DP U-2750			
		10709713	May 26, 2030	U-2750			
		10881663	Mar 08, 2039	U-3038			
		8512727	Dec 25, 2022	DP U-2750			
		9974746	May 26, 2030	DP			
MELOXICAM - QMIIZ ODT							
N 211210	001	8545879	Aug 31, 2030	DP			
MELOXICAM - QMIIZ ODT							
N 211210	002	8545879	Aug 31, 2030	DP			
MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO							
N 214383	001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
		10322182	Apr 25, 2032	DP		ODE-348	Feb 26, 2028
		10543274	Apr 25, 2032	U-3093			
		10869928	Apr 25, 2032	DP			
		6992207	Jun 25, 2022	DS DP U-3093			
MELPHALAN HYDROCHLORIDE - EVOMELA							
N 207155	001	10040872	Jan 30, 2034	DP		ODE-110	Mar 10, 2023
		10864183	May 28, 2030	DP			
		10940128	Jun 14, 2030	DP U-3086			
		11020363	May 28, 2030	DP			
		8410077	Mar 13, 2029	DP			
		9200088	Mar 13, 2029	DP			
		9493582	Feb 27, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	001	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	002	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	003	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MEMANTINE HYDROCHLORIDE - NAMENDA XR								
N	022525	004	8039009	Mar 24, 2029	U-539			
			8039009*PED	Sep 24, 2029				
MENTHOL; METHYL SALICYLATE - SALONPAS								
N	022029	001	8809615	Jan 03, 2030	DP			
			9233184	Aug 01, 2027	DP			
MENTHOL; METHYL SALICYLATE - SALONPAS								
N	022029	002	8809615	Jan 03, 2030	DP			
			9233184	Aug 01, 2027	DP			
MEROPENEM; VABORBACTAM - VABOMERE								
N	209776	001	10172874	Aug 08, 2031	DP		NCE	Aug 29, 2022
			10183034	Aug 08, 2031	U-2490		GAIN	Aug 29, 2027
			10561675	Aug 08, 2031	U-2490			
			11007206	Aug 08, 2031	U-3128			
			8680136	Aug 29, 2031	DS DP			
			9694025	Aug 08, 2031	U-2120			
MESALAMINE - SFROWASA								
N	019618	002	7645801	Jul 24, 2027	DS DP			
MESALAMINE - CANASA								
N	021252	002	8217083	Jun 06, 2028	DP			
			8436051	Jun 06, 2028	DP			
MESALAMINE - LIALDA								
N	022000	001					NPP	Jun 26, 2023
MESALAMINE - APRISO								
N	022301	001	8865688	May 01, 2030	U-1310			
METAXALONE - SKELAXIN								
N	013217	003	7122566	Feb 06, 2026	U-915			
METFORMIN HYDROCHLORIDE - GLUMETZA								
N	021748	002	7780987	Mar 23, 2025	DS DP			
			8323692	Mar 30, 2023	DP			
METFORMIN HYDROCHLORIDE - RIOMET ER								
N	212595	001	9962336	May 01, 2035	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET								
N	021842	001	9101660	Jan 22, 2027	DP			
			9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET								
N	021842	002	9101660	Jan 22, 2027	DP			
			9320714	Feb 03, 2029	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR								
N	022024	001	7785627	Jul 31, 2026	DP			
			7959946	Jul 31, 2026	DP			
			8470368	Sep 19, 2023	DP			
			8668931	Sep 19, 2023	DP			
			9060941	Sep 19, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024	002	7785627	Jul 31, 2026	DP			
		7959946	Jul 31, 2026	DP			
		8470368	Sep 19, 2023	DP			
		8668931	Sep 19, 2023	DP			
		9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	001	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	002	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	003	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	004	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET							
N 021410	005	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	001	8628799	Jul 13, 2025	DP			
		9339472	Jul 13, 2025	DP			
		RE44186	Jul 31, 2023	DS DP U-1097			
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	002	8628799	Jul 13, 2025	DP			
		9339472	Jul 13, 2025	DP			
		RE44186	Jul 31, 2023	DS DP U-1097			
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR							
N 200678	003	8628799	Jul 13, 2025	DP			
		9339472	Jul 13, 2025	DP			
		RE44186	Jul 31, 2023	DS DP U-1097			
		RE44186	Jul 31, 2023	DS DP U-1838			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044	001	6699871	Jul 26, 2022	DS DP U-802		M-187	Dec 04, 2023
		6699871*PED	Jan 26, 2023			M-244	Aug 12, 2022
		7125873	Jul 26, 2022	DP U-1036		PED	Feb 12, 2023
		7125873	Jul 26, 2022	DP U-1038		PED	Jun 04, 2024
		7125873	Jul 26, 2022	DP U-803			
		7125873*PED	Jan 26, 2023				
		7326708	Nov 24, 2026	DS DP U-802			
		7326708*PED	May 24, 2027				
		8414921	Jul 21, 2028	DP U-1036			
		8414921*PED	Jan 21, 2029				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET							
N 022044	002	6699871	Jul 26, 2022	DS DP U-802		M-187	Dec 04, 2023
		6699871*PED	Jan 26, 2023			M-244	Aug 12, 2022
		7125873	Jul 26, 2022	DP U-1036		PED	Feb 12, 2023
		7125873	Jul 26, 2022	DP U-1038		PED	Jun 04, 2024
		7125873	Jul 26, 2022	DP U-803			
		7125873*PED	Jan 26, 2023				
		7326708	Nov 24, 2026	DS DP U-802			
		7326708*PED	May 24, 2027				
		8414921	Jul 21, 2028	DP U-1036			
		8414921*PED	Jan 21, 2029				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR							
N 202270	001	6699871	Jul 26, 2022	DS DP U-1227		M-187	Dec 04, 2023
		6699871*PED	Jan 26, 2023			M-244	Aug 12, 2022
		7125873	Jul 26, 2022	DP U-1227		PED	Feb 12, 2023
		7125873*PED	Jan 26, 2023			PED	Jun 04, 2024
		7326708	Nov 24, 2026	DS DP U-1227			
		7326708*PED	May 24, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 002	6699871	Jul 26, 2022	DS DP U-1227		M-187	Dec 04, 2023
	6699871*PED	Jan 26, 2023			M-244	Aug 12, 2022
	7125873	Jul 26, 2022	DP U-1227		PED	Feb 12, 2023
	7125873*PED	Jan 26, 2023			PED	Jun 04, 2024
	7326708	Nov 24, 2026	DS DP U-1227			
	7326708*PED	May 24, 2027				
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N 202270 003	6699871	Jul 26, 2022	DS DP U-1227		M-244	Aug 12, 2022
	6699871*PED	Jan 26, 2023			PED	Feb 12, 2023
	7125873	Jul 26, 2022	DP U-1227			
	7125873*PED	Jan 26, 2023				
	7326708	Nov 24, 2026	DS DP U-1227			
	7326708*PED	May 24, 2027				
METHOTREXATE - OTREXUP						
N 204824 001	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 002	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 003	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 004	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - OTREXUP						
N 204824 005	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 006	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 007	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - OTREXUP						
N 204824 008	10709844	Mar 10, 2029	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
METHOTREXATE - RASUVO						
N 205776 001	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 002	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 003	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 004	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 005	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 006	8664231	Jun 01, 2029	U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHOTREXATE - RASUVO						
N 205776 007	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 008	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 009	8664231	Jun 01, 2029	U-1442			
METHOTREXATE - RASUVO						
N 205776 010	8664231	Jun 01, 2029	U-1442			
METHOTREXATE SODIUM - XATMEP						
N 208400 001	10231927	Jan 02, 2033	U-1349		ODE-137	Apr 25, 2024
	10231927	Jan 02, 2033	U-1699		ODE-138	Apr 25, 2024
	10610485	Jan 02, 2033	DP			
	11116724	Jan 02, 2033	U-1349			
	11116724	Jan 02, 2033	U-1699			
	9259427	Jan 02, 2033	DP			
	9855215	Jan 02, 2033	DP			
METHYLENE BLUE - PROVAYBLUE						
N 204630 001					ODE-113	Apr 08, 2023
METHYLENE BLUE - PROVAYBLUE						
N 204630 002					ODE*	Apr 08, 2023
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 001	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 002	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 021964 003	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
METHYLNALTREXONE BROMIDE - RELISTOR						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			
METHYLPHENIDATE - DAYTRANA						
N 021514 001	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE - DAYTRANA						
N 021514 001	9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA						
N 021514 002	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA						
N 021514 003	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - DAYTRANA						
N 021514 004	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025	U-2024			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 001	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 002	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE - COTEMPLA XR-ODT						
N 205489 003	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N 021419 001	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - METHYLIN						
N 021419 002	7691880	Oct 07, 2024	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
	8778390	Feb 15, 2031	DP U-1543			
	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 001	10857143	Aug 14, 2033	DP U-2993			
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			
	9844544	Aug 14, 2033	DP U-2203			
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER						
N 207960 002	10857143	Aug 14, 2033	DP U-2993			
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			
	9844544	Aug 14, 2033	DP U-2203			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER							
N 207960	003	10857143	Aug 14, 2033	DP		U-2993	
		11103494	Aug 14, 2033	DP			
		11103495	Aug 14, 2033	DP		U-2993	
		8202537	Mar 15, 2027	DP			
		8287903	Feb 15, 2031	DP			
		8999386	Aug 14, 2033	DP			
		9295642	Aug 14, 2033	DP		U-1827	
		9545399	Aug 14, 2033	DP		U-1827	
		9844544	Aug 14, 2033	DP		U-2203	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	001	10182995	Mar 23, 2032	DP			
		10292937	Mar 23, 2032			U-2357	
		10617651	Mar 23, 2032			U-2357	
		10881618	Mar 23, 2032			U-2357	
		10905652	Mar 23, 2032	DP			
		8916588	Mar 23, 2032			U-2357	
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032			U-2357	
		9034902	Mar 23, 2032			U-2357	
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032			U-2357	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	002	10182995	Mar 23, 2032	DP			
		10292937	Mar 23, 2032			U-2357	
		10617651	Mar 23, 2032			U-2357	
		10881618	Mar 23, 2032			U-2357	
		10905652	Mar 23, 2032	DP			
		8916588	Mar 23, 2032			U-2357	
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032			U-2357	
		9034902	Mar 23, 2032			U-2357	
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032			U-2357	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	003	10182995	Mar 23, 2032	DP			
		10292937	Mar 23, 2032			U-2357	
		10617651	Mar 23, 2032			U-2357	
		10881618	Mar 23, 2032			U-2357	
		10905652	Mar 23, 2032	DP			
		8916588	Mar 23, 2032			U-2357	
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032			U-2357	
		9034902	Mar 23, 2032			U-2357	
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032			U-2357	
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM							
N 209311	004	10182995	Mar 23, 2032	DP			
		10292937	Mar 23, 2032			U-2357	
		10617651	Mar 23, 2032			U-2357	
		10881618	Mar 23, 2032			U-2357	
		10905652	Mar 23, 2032	DP			
		8916588	Mar 23, 2032			U-2357	
		8927010	Mar 23, 2032	DP			
		9023389	Mar 23, 2032	DP			
		9028868	Mar 23, 2032			U-2357	
		9034902	Mar 23, 2032			U-2357	
		9283214	Mar 23, 2032	DP			
		9498447	Mar 23, 2032	DP			
		9603809	Mar 23, 2032			U-2357	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 001	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 002	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 003	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 004	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 005	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR						
N 212038 006	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP		NP	Feb 27, 2022
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI						
N 209388 001	11020361	Dec 22, 2029	U-2843			
	8334281	May 16, 2030	DP U-2843			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
METRONIDAZOLE - METROGEL						
N 021789 001	6881726	Feb 21, 2022	DP U-743			
	7348317	Feb 21, 2022	DP U-743			
METRONIDAZOLE - VANDAZOLE						
N 021806 001	7456207	Sep 22, 2024	DP			
METRONIDAZOLE - NUVESSA						
N 205223 001	10238634	Jun 28, 2032	DP			
	10596155	Jun 28, 2032	DP			
	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
	9198858	Jun 28, 2032	U-1664			
MICAFUNGIN SODIUM - MYCAMINE						
N 021506 002					I-821	Dec 20, 2022
					PED	Jun 20, 2023
MICAFUNGIN SODIUM - MYCAMINE						
N 021506 003					I-821	Dec 20, 2022
					PED	Jun 20, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MICONAZOLE - ORAVIG								
N 022404	001		6916485	Sep 11, 2022	DP U-1051			
			7651698	Sep 11, 2022	U-1051			
			8518442	Sep 11, 2022	DP			
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION								
N 021026	001		8147852	Mar 30, 2028	U-1426			
MIDAZOLAM - NAYZILAM								
N 211321	001		8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
			8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
			9289432	Jan 18, 2028	DP U-2526			
			9687495	Jan 18, 2028	DP U-2526			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE								
N 211844	001		10966990	Jun 20, 2038	DP			
MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE								
N 211844	002		10966990	Jun 20, 2038	DP			
MIDAZOLAM HYDROCHLORIDE - SEIZALAM								
N 209566	001						ODE-207	Sep 14, 2025
MIDOSTAURIN - RYDAPT								
N 207997	001		7973031	Oct 17, 2024	U-2007		NCE	Apr 28, 2022
			8222244	Oct 29, 2022	U-2007		ODE-140	Apr 28, 2024
			8575146	Dec 02, 2030	U-2008		ODE-141	Apr 28, 2024
MIFEPRISTONE - KORLYM								
N 202107	001		10006924	Aug 12, 2036	U-1643			
			10151763	Jan 18, 2037	U-1643			
			10166242	Apr 20, 2036	U-1643			
			10166243	Apr 20, 2036	U-1643			
			10195214	Jun 19, 2037	U-1643			
			10231983	Aug 22, 2038	U-1643			
			10314850	Aug 22, 2038	U-1643			
			10495650	Aug 12, 2036	U-1643			
			10500216	Mar 05, 2033	U-1643			
			10660904	Apr 20, 2036	U-1643			
			10780097	Aug 22, 2038	U-1643			
			10842800	Jun 19, 2037	U-1643			
			10842801	Nov 15, 2032	U-1643			
			8921348	Aug 27, 2028	U-1643			
			9829495	Aug 15, 2036	U-1643			
			9943526	Apr 20, 2036	U-1643			
MIGALASTAT HYDROCHLORIDE - GALAFOLD								
N 208623	001		10076514	Mar 15, 2037	U-2371		NCE	Aug 10, 2023
			10251873	May 30, 2038	U-2371		ODE-205	Aug 10, 2025
			10383864	May 16, 2027	U-2371			
			10406143	May 16, 2027	U-2371			
			10471053	May 30, 2038	U-2371			
			10525045	Apr 28, 2028	U-2371			
			10792278	May 30, 2038	U-2371			
			10792279	May 30, 2038	U-2371			
			10799491	May 30, 2038	U-2371			
			10806727	May 30, 2038	U-2371			
			10813921	Feb 12, 2029	U-2371			
			10849889	May 30, 2038	U-2371			
			10849890	May 30, 2038	U-2371			
			10857141	May 30, 2038	U-2371			
			10857142	May 30, 2038	U-2371			
			10874655	May 30, 2038	U-2371			
			10874656	May 30, 2038	U-2371			
			10874657	May 30, 2038	U-2371			
			10925866	Apr 28, 2028	U-2371			
			11033538	Apr 28, 2028	U-2371			
			8592362	Feb 12, 2029	U-2371			
			9000011	May 16, 2027	U-2371			
			9095584	Feb 12, 2029	U-2371			
			9480682	May 16, 2027	U-2371			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIGALASTAT HYDROCHLORIDE - GALAFOLD								
N 208623	001		9987263	May 16, 2027	U-2371			
			9999618	Apr 28, 2028	U-2372			
			9999618	Apr 28, 2028	U-2373			
			RE48608	Feb 12, 2029	U-2371			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	001		6602911	Jan 14, 2023	U-882			
			7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	002		6602911	Jan 14, 2023	U-882			
			7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	003		6602911	Jan 14, 2023	U-882			
			7994220	Sep 19, 2029	U-819			
MILNACIPRAN HYDROCHLORIDE - SAVELLA								
N 022256	004		6602911	Jan 14, 2023	U-882			
			7994220	Sep 19, 2029	U-819			
MINOCYCLINE HYDROCHLORIDE - MINOCIN								
N 050444	001		9084802	May 12, 2031	U-282			
			9278105	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - ARESTIN								
N 050781	001		6682348	Mar 29, 2022	DP			
			7699609	Mar 29, 2022	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	001		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	002		7541347	Apr 02, 2027	U-917			
			7544373	Apr 02, 2027	DP			
			7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	003		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	004		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
			9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	005		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
			9192615	Nov 17, 2031	DP			
MINOCYCLINE HYDROCHLORIDE - SOLODYN								
N 050808	006		7790705	Jun 24, 2025	U-1078			
			7919483	Mar 07, 2027	U-1078			
			8252776	Jun 24, 2025	U-124			
			8268804	Jun 24, 2025	U-1078			
			8722650	Jun 24, 2025	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	007	7790705	Jun 24, 2025	U-1078			
		7919483	Mar 07, 2027	U-1078			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			
		8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN							
N 050808	008	7790705	Jun 24, 2025	U-1078			
		7919483	Mar 07, 2027	U-1078			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-1078			
		8722650	Jun 24, 2025	U-1078			
MINOCYCLINE HYDROCHLORIDE - XIMINO							
N 201922	001	7541347	Apr 02, 2027	U-917			
		7544373	Apr 02, 2027	DP			
		7790705	Jun 24, 2025	U-124			
		7919483	Mar 07, 2027	U-124			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO							
N 201922	003	7541347	Apr 02, 2027	U-917			
		7544373	Apr 02, 2027	DP			
		7790705	Jun 24, 2025	U-124			
		7919483	Mar 07, 2027	U-124			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - XIMINO							
N 201922	005	7541347	Apr 02, 2027	U-917			
		7544373	Apr 02, 2027	DP			
		7790705	Jun 24, 2025	U-124			
		7919483	Mar 07, 2027	U-124			
		8252776	Jun 24, 2025	U-124			
		8268804	Jun 24, 2025	U-124			
MINOCYCLINE HYDROCHLORIDE - MINOLIRA							
N 209269	001	11103517	Apr 07, 2036	DP			
MINOCYCLINE HYDROCHLORIDE - MINOLIRA							
N 209269	002	11103517	Apr 07, 2036	DP			
MINOCYCLINE HYDROCHLORIDE - AMZEEQ							
N 212379	001	10086080	Oct 01, 2030	U-2647			
		10137200	Oct 01, 2030	U-2647			
		10213512	Oct 01, 2030	DP U-2647			
		10265404	Oct 01, 2030	DP			
		10398641	Sep 08, 2037	U-2647			
		10517882	Oct 01, 2030	U-2647			
		10821187	Oct 01, 2030	U-2647			
		10849847	Sep 08, 2037	U-2647			
		8865139	Oct 01, 2030	DP U-2647			
		8945516	Oct 01, 2030	DP			
		8992896	Oct 01, 2030	DP U-2647			
		9675700	Oct 01, 2030	DP U-2647			
MINOCYCLINE HYDROCHLORIDE - ZILXI							
N 213690	001	10213512	Oct 01, 2030	DP U-1631			
		10265404	Oct 01, 2030	DP			
		10322186	Oct 01, 2030	U-1631			
		10946101	Oct 01, 2030	U-1631			
		8865139	Oct 01, 2030	DP U-1631			
		8945516	Oct 01, 2030	DP			
		8992896	Oct 01, 2030	DP U-1631			
		9675700	Oct 01, 2030	DP U-1631			
MIPOMERSEN SODIUM - KYNAMRO							
N 203568	001	7015315	Mar 21, 2023	DS			
		7101993	Sep 05, 2023	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MIPOMERSEN SODIUM - KYNAMRO						
N 203568 001	7511131	Jan 29, 2027	DS			
MIRABEGRON - MYRBETRIQ						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-855	Mar 25, 2024
	10842780*PED	Mar 28, 2030			PED	Sep 25, 2024
	6346532	Mar 27, 2022	DS DP			
	6346532*PED	Sep 27, 2022				
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
MIRABEGRON - MYRBETRIQ						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-855	Mar 25, 2024
	10842780*PED	Mar 28, 2030			PED	Sep 25, 2024
	6346532	Mar 27, 2022	DS DP			
	6346532*PED	Sep 27, 2022				
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
MIRABEGRON - MYRBETRIQ GRANULES						
N 213801 001	10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
	6346532	Mar 27, 2022	DS			
	6346532*PED	Sep 27, 2022				
	7342117	Nov 04, 2023	DS			
	7342117*PED	May 04, 2024				
	7982049	Nov 04, 2023	DP			
	7982049*PED	May 04, 2024				
MITOMYCIN - MITOSOL						
N 022572 001	7806265	Feb 01, 2029	DP			
	8186511	Jul 19, 2026	DP			
	9205075	Jul 19, 2026	DP			
	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
MITOMYCIN - JELMYTO						
N 211728 001	9040074	Jan 20, 2031	DP		NP	Apr 15, 2023
	9950069	Jan 20, 2031	DP		ODE-289	Apr 15, 2027
MOBOCERTINIB SUCCINATE - EXKIVITY						
N 215310 001	10227342	May 13, 2035	DS DP U-3220		NCE	Sep 15, 2026
	9796712	May 13, 2035	DS DP		ODE-374	Sep 15, 2028
MODAFINIL - PROVIGIL						
N 020717 001	7297346	Nov 29, 2023	DP			
MODAFINIL - PROVIGIL						
N 020717 002	7297346	Nov 29, 2023	DP			
MOMETASONE FUROATE - ASMANEX HFA						
N 205641 003					NS	Aug 12, 2022
					PED	Feb 12, 2023
MOMETASONE FUROATE - SINUVA						
N 209310 001	10232152	Nov 24, 2034	DP U-2272			
	10357640	Oct 03, 2031	U-2272			
	10406332	Mar 13, 2034	DP			
	7544192	Nov 29, 2026	U-2272			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOMETASONE FUROATE - SINUVA								
N 209310	001		7662141	Mar 12, 2024	U-2272			
			7713255	Mar 12, 2024	U-2272			
			7951130	Mar 12, 2024	U-2272			
			7951131	Mar 12, 2024	U-2272			
			7951133	Mar 12, 2024	U-2272			
			8025635	Jun 12, 2027	DP U-2272			
			8109918	Mar 12, 2024	U-2272			
			8763222	Feb 08, 2032	DP			
			9585681	Apr 04, 2026	U-2272			
MONOMETHYL FUMARATE - BAFIERTAM								
N 210296	001		10098863	Feb 27, 2035	DP U-1384			
			10105335	Feb 27, 2035	DP			
			10105336	Feb 27, 2035	DP U-1384			
			10105337	Feb 27, 2035	DP			
			10918615	Aug 12, 2035	DP U-1384			
			10918616	Jun 03, 2035	U-1384			
			10918617	Aug 10, 2035	DP			
			10945985	Aug 14, 2035	DP			
			9326947	Feb 27, 2035	DP			
			9326965	Feb 27, 2035	U-1384			
			9511043	Feb 27, 2035	U-1384			
			9517209	Feb 27, 2035	DP			
			9566259	Feb 27, 2035	DP			
			9636318	Feb 27, 2035	U-1384			
			9636319	Feb 27, 2035	DP			
			9814691	Feb 27, 2035	U-1384			
			9814692	Feb 27, 2035	U-1384			
			9820960	Feb 27, 2035	DP			
			9820961	Feb 27, 2035	DP U-1384			
MONTELUKAST SODIUM - SINGULAIR								
N 021409	001		8007830	Oct 24, 2022	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 022195	001						NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE								
N 022195	002						NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE								
N 022207	001						NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE								
N 022207	002						NPP	Jun 02, 2024
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	001		9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	002		9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	003		9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE								
N 204223	004		9072781	Mar 12, 2034	DP			
			9192608	Mar 12, 2034	U-43			
			9192608	Mar 12, 2034	U-55			
			9248229	Mar 12, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223	005	9072781	Mar 12, 2034	DP			
		9192608	Mar 12, 2034			U-43	
		9192608	Mar 12, 2034			U-55	
		9248229	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHABOND ER							
N 206544	001	10314788	Aug 12, 2028	DP			
		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER							
N 206544	002	10314788	Aug 12, 2028	DP			
		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER							
N 206544	003	10314788	Aug 12, 2028	DP			
		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - MORPHABOND ER							
N 206544	004	10314788	Aug 12, 2028	DP			
		7955619	Aug 12, 2028	DP			
MORPHINE SULFATE - ARYMO ER							
N 208603	001	9044402	Jul 01, 2033	DP		U-1556	
		9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER							
N 208603	002	9044402	Jul 01, 2033	DP		U-1556	
		9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE - ARYMO ER							
N 208603	003	9044402	Jul 01, 2033	DP		U-1556	
		9549899	Jul 01, 2033	DP		U-1556	
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321	001	7682633	Jun 19, 2027			U-1510	
		7682634	Jun 19, 2027	DP			
		7815934	Dec 12, 2027	DP			
		8158156	Jun 19, 2027			U-1510	
		8623418	Nov 07, 2029			U-1640	
		8685443	Jul 03, 2025			U-1508	
		8685444	Jul 03, 2025	DP			
		8846104	Jun 19, 2027	DP			
		8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321	002	7682633	Jun 19, 2027			U-1510	
		7682634	Jun 19, 2027	DP			
		7815934	Dec 12, 2027	DP			
		8158156	Jun 19, 2027			U-1510	
		8623418	Nov 07, 2029			U-1640	
		8685443	Jul 03, 2025			U-1508	
		8685444	Jul 03, 2025	DP			
		8846104	Jun 19, 2027	DP			
		8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321	003	7682633	Jun 19, 2027			U-1510	
		7682634	Jun 19, 2027	DP			
		7815934	Dec 12, 2027	DP			
		8158156	Jun 19, 2027			U-1510	
		8623418	Nov 07, 2029			U-1640	
		8685443	Jul 03, 2025			U-1508	
		8685444	Jul 03, 2025	DP			
		8846104	Jun 19, 2027	DP			
		8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321	004	7682633	Jun 19, 2027			U-1510	
		7682634	Jun 19, 2027	DP			
		7815934	Dec 12, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 004	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
MOXIDECTIN - MOXIDECTIN						
N 210867 001					NCE	Jun 13, 2023
					ODE-193	Jun 13, 2025
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N 022428 001	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
MUPIROCIN CALCIUM - MUPIROCIN						
A 213053 001					CGT	Jun 27, 2022
NAFTIFINE HYDROCHLORIDE - NAFTIN						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
	10695303	Jan 31, 2033	DP			
	10729667	Jan 31, 2033	DP			
	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033	U-540			
NALDEMEDINE TOSYLATE - SYMPROIC						
N 208854 001	10952968	May 13, 2033	DS DP		NCE	Mar 23, 2022
	9108975	Nov 11, 2031	DS DP			
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	7662365	Oct 18, 2022	DS DP			
	7786133	Sep 16, 2028	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			
NALOXEGOL OXALATE - MOVANTIK						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	7662365	Oct 18, 2022	DS DP			
	7786133	Sep 16, 2028	DS DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
	9012469	Apr 02, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE						
A 209522 001					PC	Jun 20, 2022
NALOXONE HYDROCHLORIDE - EVZIO						
N 205787 001	10143972	May 24, 2031			U-2476	
	10220158	Mar 20, 2035	DP		U-2500	
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031			U-1907	
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	10960155	Jun 25, 2026	DP			
	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP		U-1907	
	9517307	Jul 18, 2034	DP		U-1925	
	9724471	May 23, 2027	DP		U-2092	
	9737669	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE - NARCAN						
N 208411 001	10085937	Mar 16, 2035			U-1903	
	9211253	Mar 16, 2035	DP			
	9468747	Mar 16, 2035	DP		U-1903	
	9561177	Mar 16, 2035	DP		U-1903	
	9629965	Mar 16, 2035	DP		U-1903	
	9775838	Mar 16, 2035			U-1903	
NALOXONE HYDROCHLORIDE - NARCAN						
N 208411 002	9480644	Mar 16, 2035	DP		U-1903	
	9707226	Mar 16, 2035	DP		U-1903	
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)						
N 209862 001	10143792	May 24, 2031			U-2476	
	10220158	Mar 20, 2035	DP		U-2500	
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031			U-1907	
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	10960155	Jun 25, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)							
N 209862	001	8627816	Feb 04, 2032	DP			
		8926594	Mar 31, 2026	DP			
		8939943	Feb 28, 2031	DP			
		9022022	Feb 28, 2031	DP			
		9056170	Nov 23, 2024	DP			
		9238108	Feb 20, 2027	DP			
		9278182	Feb 01, 2026	DP			
		9474869	Feb 28, 2031	DP		U-1907	
		9517307	Jul 18, 2034	DP		U-1925	
		9724471	May 23, 2027	DP		U-2092	
		9737669	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE - KLOXXADO							
N 212045	001	10722510	Aug 26, 2034	DP		U-3110	
		10973814	Aug 26, 2034	DP		U-3110	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	001	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
		9555000	Apr 04, 2023	DP		U-1556	
		9907793	Apr 04, 2023	DP		U-1556	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	002	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
		9555000	Apr 04, 2023	DP		U-1556	
		9907793	Apr 04, 2023	DP		U-1556	
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	003	8846090	Apr 04, 2023	DP			
		8846091	Apr 04, 2023	DP			
		8969369	May 10, 2022	DP		U-1556	
		9056051	May 10, 2022	DP		U-1556	
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP		U-1556	
		9161937	May 10, 2022	DP		U-1556	
		9168252	May 10, 2022	DP		U-1556	
		9283216	May 10, 2022	DP		U-1819	
		9283221	May 10, 2022	DP		U-1819	
		9345701	May 10, 2022	DP		U-1819	
		9511066	May 10, 2022			U-1921	
		9522919	Mar 30, 2025	DS DP			
NALTREXONE - VIVITROL							
N 021897	001	7919499	Oct 15, 2029			U-1123	
		7919499	Oct 15, 2029			U-1124	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 001	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 002	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 003	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 004	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 005	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER						
N 207621 006	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
NAPROXEN SODIUM - NAPROXEN SODIUM						
N 021920 001	10022344	Mar 03, 2026	DP U-1731			
	10022344	Mar 03, 2026	DP U-1732			
	10028925	Mar 03, 2026	DP U-1731			
	10028925	Mar 03, 2026	DP U-1732			
	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
	11090280	Mar 03, 2026	DP U-3195			
	9693978	Mar 03, 2026	DP			
	9693979	Mar 03, 2026	DP			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET						
N 021926 001	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET						
N 021926 002	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON						
N 206302 001	7803838	Aug 29, 2026	DP			
	7838552	Oct 04, 2027	U-185			
NELARABINE - NELARABINE						
A 215037 001					CGT	May 22, 2022
NEPAFENAC - NEVANAC						
N 021862 001	7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
NEPAFENAC - ILEVRO						
N 203491 001	7947295	Jun 08, 2024	DP			
	8921337	Mar 31, 2032	DP			
	9662398	Dec 01, 2030	DP			
NERATINIB MALEATE - NERLYNX						
N 208051 001	10035788	Oct 15, 2028	U-2043		D-182	Jun 28, 2024
	10035788	Oct 15, 2028	U-3047		I-823	Feb 25, 2023
	10035788	Oct 15, 2028	U-3097		NCE	Jul 17, 2022
	7399865	Dec 29, 2030	DS DP			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NERATINIB MALEATE - NERLYNX							
N 208051	001	8790708	Nov 05, 2030	DP U-2043			
		8790708	Nov 05, 2030	DP U-3047			
		8790708	Nov 05, 2030	DP U-3097			
		9139558	Oct 15, 2028	U-2043			
		9139558	Oct 15, 2028	U-3047			
		9139558	Oct 15, 2028	U-3097			
		9211291	Mar 24, 2030	U-2043			
		9211291	Mar 24, 2030	U-3097			
		9265784	Aug 04, 2029	U-3047			
		9630946	Oct 15, 2028	U-2043			
		9630946	Oct 15, 2028	U-3047			
		9630946	Oct 15, 2028	U-3097			
NETARSUDIL MESYLATE - RHOPRESSA							
N 208254	001	10174017	Jan 27, 2030	DS DP U-1524		NCE	Dec 18, 2022
		10532993	Jul 11, 2026	U-1524			
		10588901	Mar 14, 2034	DS DP U-1524			
		10654844	Jan 27, 2030	DS DP U-1524			
		10882840	Jul 11, 2026	U-1524			
		11021456	Jul 11, 2026	U-1524			
		11028081	Jan 27, 2030	U-1524			
		11185538	Mar 14, 2034	DP			
		8394826	Nov 10, 2030	DS DP U-1524			
		8450344	Jul 11, 2026	DS DP U-1524			
		9096569	Jul 11, 2026	DS DP U-1524			
		9415043	Mar 14, 2034	DS			
		9931336	Mar 14, 2034	DS DP U-1524			
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO							
N 205718	001	10233154	Sep 25, 2035	DS			
		10676440	Sep 25, 2035	DS DP			
		10828297	Dec 17, 2030	U-2293			
		10961195	Sep 25, 2035	DS DP			
		6297375	Mar 17, 2023	DS			
		8623826	Nov 18, 2030	U-2293			
		8951969	Nov 18, 2030	DP			
		9186357	Nov 18, 2030	U-2293			
		9271975	Sep 09, 2031	U-2293			
		9943515	Nov 18, 2030	U-2293			
		9951016	Sep 25, 2035	DS DP			
NEVIRAPINE - VIRAMUNE XR							
N 201152	001	8460704	Mar 12, 2029	U-1409			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER							
N 019734	002	10758616	Apr 18, 2027	DP			
		7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER							
N 019734	003	10758616	Apr 18, 2027	DP			
		7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER							
N 019734	004	10758616	Apr 18, 2027	DP			
		7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER							
N 019734	005	7612102	Dec 26, 2027	DP			
		7659291	Apr 18, 2027	U-1029			
		8455524	Apr 18, 2027	U-1029			
		9364564	Dec 26, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
NICOTINE POLACRILEX - NICORETTE						
N 018612 002	8323683	Apr 30, 2028				
NICOTINE POLACRILEX - NICORETTE						
N 020066 002	8323683	Apr 30, 2028	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 001	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NICOTINE POLACRILEX - NICORETTE						
N 022360 002	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
NIFURTIMOX - LAMPIT						
N 213464 001					NCE	Aug 06, 2025
					ODE-319	Aug 06, 2027
NIFURTIMOX - LAMPIT						
N 213464 002					NCE	Aug 06, 2025
					ODE-319	Aug 06, 2027
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		ODE-171	Mar 22, 2025
	7169791*PED	Jan 04, 2024			ODE-172	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		PED	Sep 22, 2025
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2025
	8293756	Sep 25, 2027	DP			
	8293756*PED	Mar 25, 2028				
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		ODE-171	Mar 22, 2025
	7169791*PED	Jan 04, 2024			ODE-172	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		PED	Sep 22, 2025
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2025
	8293756	Sep 25, 2027	DP			
	8293756*PED	Mar 25, 2028				
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 003	7169791	Jul 04, 2023	DS DP U-836		ODE-171	Mar 22, 2025
	7169791*PED	Jan 04, 2024			ODE-172	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		PED	Sep 22, 2025
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2025
	8293756	Sep 25, 2027	DP			
	8293756*PED	Mar 25, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NILOTINIB HYDROCHLORIDE - TASIGNA						
N 022068 003	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
NIMODIPINE - NYMALIZE						
N 203340 002	10342787	Apr 16, 2038	DP U-2804			
	10576070	Apr 16, 2038	DP U-2804			
	7070581	Jun 23, 2023	DP			
	8517997	May 14, 2024	DP			
NINTEDANIB ESYLATE - OFEV						
N 205832 001	10105323	Jun 04, 2029	DP		I-805	Sep 06, 2022
	10154990	Dec 20, 2025	U-2620		I-825	Mar 09, 2023
	6762180	Oct 01, 2025	DS DP		ODE-261	Sep 06, 2026
	7119093	Feb 21, 2024	DS DP			
	9907756	Jun 07, 2029	DP			
NINTEDANIB ESYLATE - OFEV						
N 205832 002	10105323	Jun 04, 2029	DP		I-805	Sep 06, 2022
	10154990	Dec 20, 2025	U-2620		I-825	Mar 09, 2023
	6762180	Oct 01, 2025	DS DP		ODE-261	Sep 06, 2026
	7119093	Feb 21, 2024	DS DP			
	9907756	Jun 07, 2029	DP			
NIRAPARIB TOSYLATE - ZEJULA						
N 208447 001	11091459	Mar 27, 2038	DP		I-813	Oct 23, 2022
	8071579	Aug 12, 2027	U-2655		I-814	Oct 23, 2022
	8071623	Mar 27, 2031	DS DP		I-833	Apr 29, 2023
	8143241	Aug 12, 2027	U-2655		NCE	Mar 27, 2022
	8436185	Apr 24, 2029	DS		ODE-133	Mar 27, 2024
	8859562	Aug 04, 2031	U-2655		ODE-277	Oct 23, 2026
					ODE-278	Oct 23, 2026
					ODE-295	Apr 29, 2027
NITISINONE - ORFADIN						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			
NITISINONE - NITYR						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			
NITISINONE - NITYR						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
NITISINONE - NITYR						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
NITRIC OXIDE - INOMAX						
N 020845 002	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NITRIC OXIDE - INOMAX						
N 020845 002	8846112*PED	Dec 30, 2029				
NITRIC OXIDE - INOMAX						
N 020845 003	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			
	9408993*PED	Jul 06, 2031				
	9770570	May 03, 2036	U-2148			
	9770570*PED	Nov 03, 2036				
NITRIC OXIDE - GENOSYL						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10213572	Feb 12, 2036	DP			
	10737051	Oct 20, 2035	DP			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	11103669	Jun 21, 2030	DP			
	6758214	Feb 23, 2022	DP			
	7560076	Apr 21, 2027	DP			
	7618594	Oct 17, 2026	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9604028	Aug 13, 2029	U-2793			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
NITROGLYCERIN - NITROLINGUAL PUMPSPRAY						
N 018705 002	7872049	Mar 12, 2029	DP U-2223			
NITROGLYCERIN - GONITRO						
N 208424 001	9101592	Mar 11, 2032	DP			
NIZATIDINE - AXID						
N 021494 001	6930119	Jul 17, 2022	DP			
NUSINERSEN SODIUM - SPINRAZA						
N 209531 001	10266822	Dec 05, 2025	U-1942		ODE-127	Dec 23, 2023
	10266822	Dec 05, 2025	U-1943			
	10266822	Dec 05, 2025	U-1944			
	10436802	Sep 11, 2035	U-1941			
	10436802	Sep 11, 2035	U-1942			
	10436802	Sep 11, 2035	U-1943			
	10436802	Sep 11, 2035	U-1944			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NUSINERSEN SODIUM - SPINRAZA							
N 209531	001	10436802	Sep 11, 2035	U-2093			
		10436802	Sep 11, 2035	U-2094			
		7101993	Sep 05, 2023	DS			
		7838657	Jul 11, 2027	DS			
		8110560	Dec 05, 2025	U-1942			
		8110560	Dec 05, 2025	U-1943			
		8110560	Dec 05, 2025	U-1944			
		8361977	May 27, 2030	DS DP			
		8980853	Nov 24, 2030	U-1941			
		9717750	Jun 17, 2030	U-1942			
		9717750	Jun 17, 2030	U-1943			
		9717750	Jun 17, 2030	U-2093			
		9717750	Jun 17, 2030	U-2094			
		9926559	Jan 09, 2034	U-1943			
OBETICHOLIC ACID - OCALIVA							
N 207999	001	10047117	Sep 06, 2033	U-1854		ODE-119	May 27, 2023
		10052337	Apr 26, 2036	DP			
		10174073	Jun 17, 2033	DS			
		10751349	Apr 26, 2036	DP			
		10758549	Apr 26, 2036	U-2945			
		7138390	Nov 16, 2022	DS DP			
		8058267	Feb 21, 2022	U-1854			
		8377916	Feb 21, 2022	U-1854			
		9238673	Jun 17, 2033	DP			
		RE48286	Nov 16, 2027	DS DP			
OBETICHOLIC ACID - OCALIVA							
N 207999	002	10047117	Sep 06, 2033	U-1854		ODE-119	May 27, 2023
		10052337	Apr 26, 2036	DP			
		10174073	Jun 17, 2033	DS			
		10751349	Apr 26, 2036	DP			
		10758549	Apr 26, 2036	U-2945			
		7138390	Nov 16, 2022	DS DP			
		8058267	Feb 21, 2022	U-1854			
		8377916	Feb 21, 2022	U-1854			
		9238673	Jun 17, 2033	DP			
		RE48286	Nov 16, 2027	DS DP			
OCTREOTIDE ACETATE - MYCAPSSA							
N 208232	001	10238709	Feb 03, 2036	U-2857		NP	Jun 26, 2023
		10695397	Feb 03, 2036	U-2857			
		11052126	Feb 03, 2036	U-2857			
		11141457	Dec 28, 2040	U-3232			
		8329198	Sep 17, 2029	DP			
		8535695	Sep 17, 2029	U-2857			
		9265812	Sep 17, 2029	DP			
		9566246	Sep 17, 2029	DP			
ODEVIXIBAT - BYLVAY							
N 215498	001	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
		10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
		10487111	Nov 08, 2031	U-3186			
		10487111	Nov 08, 2031	U-3187			
		10975046	Jun 20, 2039	DS			
		10981952	Nov 08, 2031	U-3186			
		10981952	Nov 08, 2031	U-3187			
		7132416	Sep 05, 2022	DS DP			
		9694018	Nov 08, 2031	U-3186			
ODEVIXIBAT - BYLVAY							
N 215498	002	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
		10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
		10487111	Nov 08, 2031	U-3186			
		10487111	Nov 08, 2031	U-3187			
		10975046	Jun 20, 2039	DS			
		10981952	Nov 08, 2031	U-3186			
		10981952	Nov 08, 2031	U-3187			
		7132416	Sep 05, 2022	DS DP			
		9694018	Nov 08, 2031	U-3186			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ODEVIXIBAT - BYLVAY						
N 215498 002	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
ODEVIXIBAT - BYLVAY						
N 215498 003	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
ODEVIXIBAT - BYLVAY						
N 215498 004	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 003	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
OLAPARIB - LYNPARZA						
N 206162 001	7151102	Apr 29, 2022	DS DP			
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
OLAPARIB - LYNPARZA						
N 208558 001	7151102	Apr 29, 2022	DS DP		I-818	Dec 27, 2022
	7449464	Oct 11, 2024	DS DP		I-831	May 08, 2023
	7981889	Oct 11, 2024	DS DP		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2101		ODE-180	Aug 17, 2024
	8071579	Aug 12, 2027	U-2103		ODE-181	Aug 17, 2024
	8071579	Aug 12, 2027	U-2480		ODE-226	Dec 19, 2025
	8071579	Aug 12, 2027	U-2481		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2482		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 001	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
OLAPARIB - LYNPARZA						
N 208558 002	7151102	Apr 29, 2022	DS DP		I-818	Dec 27, 2022
	7449464	Oct 11, 2024	DS DP		I-831	May 08, 2023
	7981889	Oct 11, 2024	DS DP		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2101		ODE-180	Aug 17, 2024
	8071579	Aug 12, 2027	U-2103		ODE-181	Aug 17, 2024
	8071579	Aug 12, 2027	U-2480		ODE-226	Dec 19, 2025
	8071579	Aug 12, 2027	U-2481		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2482		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLAPARIB - LYNPARZA						
N 208558 002	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
OLICERIDINE - OLINVYK						
N 210730 001	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
OLICERIDINE - OLINVYK						
N 210730 002	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
OLICERIDINE - OLINVYK						
N 210730 003	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT						
N 203108 001	7056916	Dec 07, 2023	DS DP			
	7220742	May 12, 2025	DS DP U-1547			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Jan 19, 2027	DS			
	7786111	Nov 10, 2023	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT						
N 206756 001	7056916	Dec 07, 2023	DS DP			
	7220742	May 12, 2025	DS DP U-1703			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7491719	Nov 10, 2023	DS DP			
	7727984	Jan 19, 2027	DS			
	7786111	Nov 10, 2023	DP			
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT								
N 206756	001		8733341	Oct 16, 2030	DP			
			9027967	Mar 31, 2027	DP			
OLOPATADINE HYDROCHLORIDE - PATANASE								
N 021861	001		7977376	Feb 02, 2023	DP			
			8399508	Sep 17, 2022	U-726			
			8399508*PED	Mar 17, 2023				
OLOPATADINE HYDROCHLORIDE - PATADAY ONCE DAILY RELIEF								
N 206276	001		8791154	May 19, 2032	DP U-1680			
			9533053	May 19, 2032	DP			
OMACETAXINE MEPESUCCINATE - SYNRIBO								
N 203585	001		6987103	Oct 26, 2026	U-1300			
OMADACYCLINE TOSYLATE - NUZYRA								
N 209816	001		10111890	Aug 03, 2037	U-2444		NCE	Oct 02, 2023
			10124014	Mar 05, 2029	U-2449		GAIN	Oct 02, 2028
			10383884	Oct 31, 2037	U-2576			
			10835542	Oct 31, 2037	U-2576			
			7326696	Sep 24, 2023	DS			
			7553828	Jun 02, 2023	DS			
			8383610	Sep 23, 2030	DS			
			9265740	Mar 05, 2029	U-1569			
			9314475	Mar 18, 2031	DP			
			9724358	Mar 05, 2029	U-1569			
OMADACYCLINE TOSYLATE - NUZYRA								
N 209817	001		10124014	Mar 05, 2029	U-2449		NCE	Oct 02, 2023
			10383884	Oct 31, 2037	U-2576		GAIN	Oct 02, 2028
			10835542	Oct 31, 2037	U-2576			
			7326696	Sep 24, 2023	DS			
			7553828	Jun 02, 2023	DS			
			9265740	Mar 05, 2029	DP			
			9724358	Mar 05, 2029	U-1569			
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE								
N 207931	001		8268349	Aug 25, 2024	DP			
			8268349*PED	Feb 25, 2025				
			8399015	Aug 25, 2024	DP			
			8399015*PED	Feb 25, 2025				
			8420596	Apr 10, 2031	DS DP			
			8420596*PED	Oct 10, 2031				
			8642538	Sep 10, 2029	DS DP U-1638			
			8686026	Jun 09, 2031	DP			
			8691938	Apr 13, 2032	DS DP			
			9006387	Jun 10, 2030	U-1687			
			9044480	Apr 10, 2031	U-1638			
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA								
N 205060	001		10117844	Jan 04, 2033	U-2447			
			7960370	Dec 20, 2026	DP			
			8383678	Feb 07, 2025	DP U-1511			
			9012501	Feb 07, 2025	DP U-1511			
			9050308	Jan 04, 2033	U-1511			
			9050309	Jan 04, 2033	DS			
			9132112	Feb 07, 2025	DP U-1511			
OMEPRAZOLE - OMEPRAZOLE								
N 022032	001		9023391	Aug 16, 2025	DP			
OMEPRAZOLE - OMEPRAZOLE								
N 209400	001		10076494	Dec 08, 2036	DP			
			10835488	Dec 08, 2036	DP			
ONDANSETRON - ZUPLENZ								
N 022524	001		8580830	Nov 23, 2029	DP			
			9095577	Jul 13, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ONDANSETRON - ZUPLENZ						
N 022524 002	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
OPICAPONE - ONGENTYS						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
OPICAPONE - ONGENTYS						
N 212489 002	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
ORITAVANCIN DIPHOSPHATE - ORBACTIV						
N 206334 001	8420592	Aug 29, 2029	U-1570		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DP		GAIN	Aug 06, 2024
	9682061	Apr 26, 2030	U-1569			
ORITAVANCIN DIPHOSPHATE - KIMYRSA						
N 214155 001	8420592	Aug 29, 2029	U-3101		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		GAIN	Aug 06, 2024
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 001					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 002					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021087 003					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 001					M-251	Aug 02, 2022
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N 021246 002					M-251	Aug 02, 2022
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 001	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 002	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OSILODROSTAT PHOSPHATE - ISTURISA						
N 212801 003	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-102	Nov 13, 2022
	10183020	Jan 02, 2035	DP U-3016		ODE-176	Apr 18, 2025
	8946235	Aug 08, 2032	DS DP U-1777		ODE-337	Dec 18, 2027
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
OSIMERTINIB MESYLATE - TAGRISSO						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-102	Nov 13, 2022
	10183020	Jan 02, 2035	DP U-3016		ODE-176	Apr 18, 2025
	8946235	Aug 08, 2032	DS DP U-1777		ODE-337	Dec 18, 2027
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
OSPEMIFENE - OSPHENA						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8642079	Jul 09, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9566252	Nov 02, 2022	U-1370			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027	U-2041			
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027	U-2041			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXCARBAZEPINE - OXTELLAR XR							
N 202810	002	9351975	Apr 13, 2027	DP			
		9370525	Apr 13, 2027	DP			
		9855278	Apr 13, 2027	DP			
OXCARBAZEPINE - OXTELLAR XR							
N 202810	003	10220042	Apr 13, 2027			U-2501	
		11166960	Apr 13, 2027	DP			
		7722898	Apr 13, 2027	DP			
		7910131	Apr 13, 2027			U-2041	
		8617600	Apr 13, 2027	DP			
		8821930	Apr 13, 2027	DP			
		9119791	Apr 13, 2027			U-2041	
		9351975	Apr 13, 2027	DP			
		9370525	Apr 13, 2027	DP			
		9855278	Apr 13, 2027	DP			
OXYBUTYNIN - GELNIQUE 3%							
N 202513	001	7198801	Jun 25, 2022	DP			
OXYBUTYNIN CHLORIDE - GELNIQUE							
N 022204	001	10449173	Nov 06, 2029	DP		U-2637	
		8920392	Mar 26, 2031			U-1644	
		9259388	Nov 06, 2029			U-1644	
OXYCODONE - XTAMPZA ER							
N 208090	001	10004729	Dec 10, 2030	DP		U-1556	
		10188644	Sep 02, 2036	DP		U-1556	
		10525052	Jul 07, 2023	DP		U-1556	
		10525053	Jul 07, 2023	DP			
		10646485	Sep 02, 2036	DP		U-1556	
		10668060	Dec 10, 2030	DP		U-1556	
		7399488	Mar 24, 2025	DP			
		7771707	Mar 24, 2025	DP			
		8449909	Mar 24, 2025	DP			
		8557291	Mar 21, 2025	DP			
		8758813	Jun 10, 2025			U-1556	
		8840928	Jul 07, 2023	DP		U-1556	
		9044398	Jul 07, 2023	DP			
		9248195	Jul 07, 2023			U-1556	
		9592200	Jul 07, 2023	DP			
		9682075	Dec 10, 2030	DP		U-1556	
		9737530	Sep 02, 2036	DP		U-1556	
		9763883	Jul 07, 2023	DP			
		9968598	Sep 02, 2036	DP		U-1556	
OXYCODONE - XTAMPZA ER							
N 208090	002	10004729	Dec 10, 2030	DP		U-1556	
		10188644	Sep 02, 2036	DP		U-1556	
		10525052	Jul 07, 2023	DP		U-1556	
		10525053	Jul 07, 2023	DP			
		10646485	Sep 02, 2036	DP		U-1556	
		10668060	Dec 10, 2030	DP		U-1556	
		7399488	Mar 24, 2025	DP			
		7771707	Mar 24, 2025	DP			
		8449909	Mar 24, 2025	DP			
		8557291	Mar 21, 2025	DP			
		8758813	Jun 10, 2025			U-1556	
		8840928	Jul 07, 2023	DP		U-1556	
		9044398	Jul 07, 2023	DP			
		9248195	Jul 07, 2023			U-1556	
		9592200	Jul 07, 2023	DP			
		9682075	Dec 10, 2030	DP		U-1556	
		9737530	Sep 02, 2036	DP		U-1556	
		9763883	Jul 07, 2023	DP			
		9968598	Sep 02, 2036	DP		U-1556	
OXYCODONE - XTAMPZA ER							
N 208090	003	10004729	Dec 10, 2030	DP		U-1556	
		10188644	Sep 02, 2036	DP		U-1556	
		10525052	Jul 07, 2023	DP		U-1556	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE - XTAMPZA ER						
N 208090 003	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 004	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10525052	Jul 07, 2023	DP U-1556			
	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE - XTAMPZA ER						
N 208090 005	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10525052	Jul 07, 2023	DP U-1556			
	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 001	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 002	10130591	Nov 20, 2023	DP		U-1819	
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP		U-1556	
	8808741	Aug 24, 2027			U-1556	
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 003	10130591	Nov 20, 2023	DP		U-1819	
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP		U-1556	
	8808741	Aug 24, 2027			U-1556	
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	10130591	Nov 20, 2023	DP		U-1819	
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP		U-1556	
	8808741	Aug 24, 2027			U-1556	
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 004	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 005	10130591	Nov 20, 2023	DP		U-1819	
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP		U-1556	
	8808741	Aug 24, 2027			U-1556	
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 006	10130591	Nov 20, 2023	DP		U-1819	
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP		U-1556	
	8808741	Aug 24, 2027			U-1556	
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXYCONTIN						
N 022272 007	10130591	Nov 20, 2023	DP		U-1819	
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	8309060	Nov 20, 2023	DP		U-1556	
	8808741	Aug 24, 2027			U-1556	
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXAYDO								
N 202080	001		7201920	Mar 16, 2025	DP			
			7510726	Nov 26, 2023	DP			
			7981439	Nov 26, 2023	DP			
			8409616	Nov 26, 2023	DP			
			8637540	Nov 26, 2023	DP			
			9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - OXAYDO								
N 202080	002		7201920	Mar 16, 2025	DP			
			7510726	Nov 26, 2023	DP			
			7981439	Nov 26, 2023	DP			
			8409616	Nov 26, 2023	DP			
			8637540	Nov 26, 2023	DP			
			9492443	May 26, 2024	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N 209777	001		10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N 209777	002		10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
OXYCODONE HYDROCHLORIDE - ROXYBOND								
N 209777	003		10314788	Aug 12, 2028	DP			
			7955619	Aug 12, 2028	DP			
OXYMETAZOLINE HYDROCHLORIDE - RHOFADE								
N 208552	001		10335391	Jun 11, 2035	U-2567			
			10751325	Jun 11, 2035	U-2921			
			7812049	May 02, 2028	U-1959			
			8420688	Aug 02, 2024	U-1959			
			8815929	Jan 22, 2024	U-1959			
			8883838	Dec 01, 2031	DP			
			9974773	Jun 11, 2035	U-2306			
OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ								
N 212520	001		10799481	Dec 16, 2039	U-2849		NP	Jul 08, 2023
			10814001	Dec 16, 2039	DP			
			10898573	Dec 16, 2039	DP			
			10912765	Aug 26, 2031	U-2849			
			10940138	Dec 16, 2039	U-2849			
			11103482	Dec 16, 2039	DP			
			8357714	Aug 26, 2031	U-2849			
			9867808	Aug 26, 2031	U-2849			
OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE								
N 208032	001		8580282	Apr 02, 2030	DP U-1876			
			9308191	Apr 02, 2030	DP U-1876			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	001		7276250	Feb 04, 2023	DP U-826			
			8309112	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	002		7276250	Feb 04, 2023	DP U-826			
			8309112	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER								
N 021610	003		7276250	Feb 04, 2023	DP U-826			
			8309112	Feb 04, 2023	DP			
			8329216	Feb 04, 2023	DP			
			8808737	Jun 21, 2027	U-3085			
			8871779	Nov 22, 2029	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 021610	003	7276250	Feb 04, 2023	DP		U-826	
		8309112	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			
		8808737	Jun 21, 2027			U-3085	
		8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 021610	004	7276250	Feb 04, 2023	DP		U-826	
		8309112	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			
		8808737	Jun 21, 2027			U-3085	
		8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 021610	005	7276250	Feb 04, 2023	DP		U-826	
		8309112	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			
		8808737	Jun 21, 2027			U-3085	
		8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 021610	006	7276250	Feb 04, 2023	DP		U-826	
		8309112	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			
		8808737	Jun 21, 2027			U-3085	
		8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 021610	007	7276250	Feb 04, 2023	DP		U-826	
		8309112	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			
		8808737	Jun 21, 2027			U-3085	
		8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA							
N 021611	001					M-14	Oct 25, 2022
OXYMORPHONE HYDROCHLORIDE - OPANA							
N 021611	002					M-14	Oct 25, 2022
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 201655	001	7851482	Jul 10, 2029	DS			
		8075872	Nov 20, 2023	DP			
		8114383	Aug 08, 2024	DP			
		8192722	Sep 15, 2025	DP			
		8309060	Nov 20, 2023	DP			
		8309122	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			
		8808737	Jun 21, 2027			U-1598	
		8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 201655	002	7851482	Jul 10, 2029	DS			
		8075872	Nov 20, 2023	DP			
		8114383	Aug 08, 2024	DP			
		8192722	Sep 15, 2025	DP			
		8309060	Nov 20, 2023	DP			
		8309122	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			
		8808737	Jun 21, 2027			U-1598	
		8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER							
N 201655	003	7851482	Jul 10, 2029	DS			
		8075872	Nov 20, 2023	DP			
		8114383	Aug 08, 2024	DP			
		8192722	Sep 15, 2025	DP			
		8309060	Nov 20, 2023	DP			
		8309122	Feb 04, 2023	DP			
		8329216	Feb 04, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 003	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 001	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 002	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZANIMOD HYDROCHLORIDE - ZEPOSIA						
N 209899 003	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
OZENOXACIN - XEPI						
N 208945 001	6335447	Nov 09, 2023	DS		NCE	Dec 11, 2022
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PACLITAXEL - ABRAXANE						
N 021660 001	7758891	Feb 21, 2026	U-1434		M-14	Dec 06, 2022
	7758891*PED	Aug 21, 2026			PED	Jun 06, 2023
	7820788	Oct 27, 2024	DP U-1092			
	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	7820788*PED	Apr 27, 2025				
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	7923536*PED	Jun 09, 2024				
	8034375	Aug 13, 2026	U-1290			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8138229*PED	Jun 09, 2024				
	8268348	Feb 21, 2026	U-1290			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	8314156*PED	Jun 09, 2024				
	9101543	Feb 21, 2026	U-1434			
	9101543*PED	Aug 21, 2026				
	9393318	Mar 04, 2032	U-1290			
	9393318*PED	Sep 04, 2032				
	9511046	Jan 12, 2034	U-1434			
	9511046*PED	Jul 12, 2034				
	9597409	Mar 04, 2032	U-1290			
	9597409*PED	Sep 04, 2032				
PAFOLACIANINE SODIUM - CYTALUX						
N 214907 001					NCE	Nov 29, 2026
PALBOCICLIB - IBRANCE						
N 207103 001	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 207103 002	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 207103 003	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 212436 001	10723730	Feb 08, 2034	DS DP			
	11065250	May 24, 2036	DP			
	6936612	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-2515			
	RE47739	Mar 05, 2027	DS DP			
PALBOCICLIB - IBRANCE						
N 212436 002	10723730	Feb 08, 2034	DS DP			
	11065250	May 24, 2036	DP			
	6936612	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-2515			
	RE47739	Mar 05, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALBOCICLIB - IBRANCE							
N 212436	003	10723730	Feb 08, 2034	DS DP			
		11065250	May 24, 2036	DP			
		6936612	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023			U-2515	
		RE47739	Mar 05, 2027	DS DP			
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	001	9439906	Jan 26, 2031			U-1901	
		9439906	Jan 26, 2031			U-2757	
		9439906	Jan 26, 2031			U-2758	
		9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	002	9439906	Jan 26, 2031			U-1901	
		9439906	Jan 26, 2031			U-2757	
		9439906	Jan 26, 2031			U-2758	
		9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	003	9439906	Jan 26, 2031			U-1901	
		9439906	Jan 26, 2031			U-2757	
		9439906	Jan 26, 2031			U-2758	
		9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	004	9439906	Jan 26, 2031			U-1901	
		9439906	Jan 26, 2031			U-2757	
		9439906	Jan 26, 2031			U-2758	
		9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA SUSTENNA							
N 022264	005	9439906	Jan 26, 2031			U-1901	
		9439906	Jan 26, 2031			U-2757	
		9439906	Jan 26, 2031			U-2758	
		9439906	Jan 26, 2031			U-543	
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	001	10143693	Apr 05, 2036			U-2457	
		10143693	Apr 05, 2036			U-2458	
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	002	10143693	Apr 05, 2036			U-2457	
		10143693	Apr 05, 2036			U-2458	
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	003	10143693	Apr 05, 2036			U-2457	
		10143693	Apr 05, 2036			U-2458	
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	004	10143693	Apr 05, 2036			U-2457	
		10143693	Apr 05, 2036			U-2458	
PALIPERIDONE PALMITATE - INVEGA HAFYERA							
N 207946	005					NS	Aug 30, 2024
PALIPERIDONE PALMITATE - INVEGA HAFYERA							
N 207946	006					NS	Aug 30, 2024
PALONOSETRON HYDROCHLORIDE - ALOXI							
N 021372	001	7947724	Jan 30, 2024	DP			
		7947724*PED	Jul 30, 2024				
		7947725	Jan 30, 2024	DP			
		7947725*PED	Jul 30, 2024				
		7960424	Jan 30, 2024	DP			
		7960424*PED	Jul 30, 2024				
		8518981	Jan 30, 2024	DP			
		8518981*PED	Jul 30, 2024				
		8598218	Jan 30, 2024	DP			
		8598218*PED	Jul 30, 2024				
		8598219	Jan 30, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 001	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
	9457021	Jan 30, 2024	DP			
	9457021*PED	Jul 30, 2024				
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 002	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	7989494	Jan 17, 2028	DS DP		ODE-89	Feb 23, 2022
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	7989494	Jan 17, 2028	DS DP		ODE-89	Feb 23, 2022
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	7989494	Jan 17, 2028	DS DP		ODE-89	Feb 23, 2022
	8883842	Jun 13, 2028	U-1669			
PANTOPRAZOLE SODIUM - PROTONIX IV						
N 020988 001	8754108*PED	May 17, 2022				
PANTOPRAZOLE SODIUM - PROTONIX						
N 022020 001	7544370	Jun 07, 2026	DP			
	7550153	Sep 30, 2024	U-859			
	7553498	Sep 30, 2024	U-859			
	7838027	Sep 30, 2024	DP U-859			
PARICALCITOL - ZEMPLAR						
N 020819 001					ODE*	Oct 18, 2023
PARICALCITOL - ZEMPLAR						
N 020819 002					ODE*	Oct 18, 2023
PARICALCITOL - ZEMPLAR						
N 020819 003					ODE*	Oct 18, 2023
PARICALCITOL - ZEMPLAR						
N 021606 001					ODE-125	Oct 18, 2023
PARICALCITOL - ZEMPLAR						
N 021606 002					ODE-125	Oct 18, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PARICALCITOL - ZEMPLAR						
N 021606 003					ODE-125	Oct 18, 2023
PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE						
A 215003 001					CGT	Mar 12, 2022
PAROXETINE MESYLATE - PEXEVA						
N 021299 001	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 002	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 003	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - PEXEVA						
N 021299 004	7598271	May 04, 2025	DS			
PAROXETINE MESYLATE - BRISDELLE						
N 204516 001	7598271	May 04, 2025	DS			
	8658663	Apr 06, 2029	DS DP U-904			
	8946251	Aug 04, 2026	DS DP U-904			
	9393237	Aug 04, 2026	U-904			
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 001	7473761	Dec 14, 2026	DS DP			
	8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 002	7473761	Dec 14, 2026	DS DP			
	8299209	Dec 27, 2025	DS DP			
PASIREOTIDE DIASPARTATE - SIGNIFOR						
N 200677 003	7473761	Dec 14, 2026	DS DP			
	8299209	Dec 27, 2025	DS DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 001	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	8822637	Aug 06, 2023	U-1629			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 002	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	8822637	Aug 06, 2023	U-1629			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 003	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	8822637	Aug 06, 2023	U-1629			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 004	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT						
N 203255 005	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 001	10485821	Mar 30, 2024	U-1766			
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 001	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 002	10485821	Mar 30, 2024	U-1766			
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATIROMER SORBITEX CALCIUM - VELTASSA						
N 205739 003	10485821	Mar 30, 2024	U-1766			
	11123363	Oct 08, 2033	U-1766			
	7556799	Feb 27, 2025	U-1766			
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
	9492476	Oct 08, 2033	U-1766			
	9925212	Oct 08, 2033	U-1766			
PATISIRAN SODIUM - ONPATTRO						
N 210922 001	10240152	Oct 20, 2029	DS DP U-2378		NCE	Aug 10, 2023
	11079379	Aug 27, 2035	DS DP U-2378		ODE-197	Aug 10, 2025
	11141378	Apr 15, 2029	DP			
	8058069	Apr 15, 2029	DP			
	8158601	Nov 10, 2030	DP U-2378			
	8168775	Oct 20, 2029	DS DP U-2378			
	8334373	May 27, 2025	DS DP			
	8492359	Apr 15, 2029	DP			
	8642076	Oct 03, 2027	DP			
	8741866	Oct 20, 2029	U-2378			
	8802644	Oct 21, 2030	DP U-2378			
	8822668	Apr 15, 2029	DP U-2378			
	9234196	Oct 20, 2029	DP U-2378			
	9364435	Apr 15, 2029	DP U-2378			
	9943538	Nov 04, 2023	DP			
	9943539	Nov 04, 2023	DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N 022465 001	7105530	Oct 19, 2023	DS DP			
PAZOPANIB HYDROCHLORIDE - VOTRIENT						
N 022465 002	7105530	Oct 19, 2023	DS DP			
PEGCETACOPLAN - EMPAVELI						
N 215014 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		ODE-351	May 14, 2028
	10875893	Nov 15, 2033	DS U-3124			
	11040107	Apr 09, 2038	DP U-3172			
	11040107	Apr 09, 2038	DP U-3173			
	11040107	Apr 09, 2038	DP U-3174			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEGCETACOPLAN - EMPAVELI						
N 215014 001	9169307	Nov 18, 2027	DS		U-3123	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 001	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 002	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 003	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 004	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 005	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE						
N 202799 006	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS						
N 202799 007	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEGINESATIDE ACETATE - OMONTYS						
N 202799 008	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
PEMETREXED - PEMFEXY						
N 209472 001	7772209	May 24, 2022			U-2728	
	7772209	May 24, 2022			U-2729	
	9604990	Oct 28, 2035	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PEMETREXED - PEMFEXY							
N 209472	001	7772209	May 24, 2022	U-2728			
		7772209	May 24, 2022	U-2729			
		9604990	Oct 28, 2035	DS			
PEMIGATINIB - PEMAZYRE							
N 213736	001	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
		9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
PEMIGATINIB - PEMAZYRE							
N 213736	002	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
		9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
PEMIGATINIB - PEMAZYRE							
N 213736	003	10131667	Jun 12, 2033	U-2809		NCE	Apr 17, 2025
		9611267	Jan 30, 2035	DS DP		ODE-292	Apr 17, 2027
PERAMIVIR - RAPIVAB							
N 206426	001	10391075	Feb 12, 2027	U-2622			
		10391075	Feb 12, 2027	U-3069			
		6562861	Dec 16, 2023	DS			
		8778997	May 07, 2027	U-1627			
		8778997	May 07, 2027	U-2622			
		8778997	May 07, 2027	U-3069			
PERAMPANEL - FYCOMPA							
N 202834	001	6949571	Jun 08, 2022	DS DP U-106			
		6949571	Jun 08, 2022	DS DP U-2088			
		6949571	Jun 08, 2022	DS DP U-2089			
		6949571	Jun 08, 2022	DS DP U-2428			
		6949571	Jun 08, 2022	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	002	6949571	Jun 08, 2022	DS DP U-106			
		6949571	Jun 08, 2022	DS DP U-2088			
		6949571	Jun 08, 2022	DS DP U-2089			
		6949571	Jun 08, 2022	DS DP U-2428			
		6949571	Jun 08, 2022	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	003	6949571	Jun 08, 2022	DS DP U-106			
		6949571	Jun 08, 2022	DS DP U-2088			
		6949571	Jun 08, 2022	DS DP U-2089			
		6949571	Jun 08, 2022	DS DP U-2428			
		6949571	Jun 08, 2022	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	004	6949571	Jun 08, 2022	DS DP U-106			
		6949571	Jun 08, 2022	DS DP U-2088			
		6949571	Jun 08, 2022	DS DP U-2089			
		6949571	Jun 08, 2022	DS DP U-2428			
		6949571	Jun 08, 2022	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	005	6949571	Jun 08, 2022	DS DP U-106			
		6949571	Jun 08, 2022	DS DP U-2088			
		6949571	Jun 08, 2022	DS DP U-2089			
		6949571	Jun 08, 2022	DS DP U-2428			
		6949571	Jun 08, 2022	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 202834	006	6949571	Jun 08, 2022	DS DP U-106			
		6949571	Jun 08, 2022	DS DP U-2088			
		6949571	Jun 08, 2022	DS DP U-2089			
		6949571	Jun 08, 2022	DS DP U-2428			
		6949571	Jun 08, 2022	DS DP U-2429			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PERAMPANEL - FYCOMPA							
N 202834	006	8772497	Jul 01, 2026	DS			
PERAMPANEL - FYCOMPA							
N 208277	001	6949571	Jun 08, 2022	DS DP U-106			
		6949571	Jun 08, 2022	DS DP U-2088			
		6949571	Jun 08, 2022	DS DP U-2089			
		6949571	Jun 08, 2022	DS DP U-2428			
		6949571	Jun 08, 2022	DS DP U-2429			
		8772497	Jul 01, 2026	DS			
PERFLUTREN - DEFINITY							
N 021064	001	10583207	Dec 28, 2035	U-665			
		10583208	Mar 16, 2037	U-665			
		10588988	May 04, 2037	U-665			
		9789210	Mar 16, 2037	U-665			
PERFLUTREN - DEFINITY RT							
N 021064	002	10022460	Dec 28, 2035	DS DP			
		10583207	Dec 28, 2035	U-665			
		10583208	Mar 16, 2037	U-665			
		10588988	May 04, 2037	U-665			
		9789210	Mar 16, 2037	U-665			
PEXIDARTINIB HYDROCHLORIDE - TURALIO							
N 211810	001	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
		10435404	Jul 24, 2038	DP		ODE-250	Aug 02, 2026
		10730876	May 05, 2036	DS			
		10941142	Jul 24, 2038	DP			
		10961240	Jul 24, 2038	U-2606			
		7893075	Oct 13, 2028	DS			
		8404700	Nov 21, 2027	DS			
		8461169	Apr 19, 2028	U-2606			
		8722702	Nov 21, 2027	DS			
		9169250	Nov 21, 2027	DS			
		9358235	Jun 08, 2033	U-2606			
		9802932	May 05, 2036	DS			
PHENTERMINE HYDROCHLORIDE - SUPRENZA							
N 202088	001	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA							
N 202088	002	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE - SUPRENZA							
N 202088	003	8440170	Mar 14, 2029	DP			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	001	8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			
		8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	002	8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			
		8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	003	8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			
		8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580	004	8580298	May 15, 2029	DP			
		8580299	Jun 14, 2029	U-1262			
		8895057	Jun 09, 2028	U-1262			
		8895058	Jun 09, 2028	DP			
		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PHENTOLAMINE MESYLATE - ORAVERSE							
N 022159	001	7229630	Jun 20, 2023	DP			
		7569230	Oct 17, 2023	U-967			
		7575757	Apr 21, 2025	DP			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE							
N 203510	001	8859623	Nov 14, 2033	U-1594			
PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE							
N 203510	002	8859623	Nov 14, 2033	U-1594			
PIFLUFOLASTAT F-18 - PYLARIFY							
N 214793	001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
		8487129	Nov 07, 2027	DS DP			
		8778305	Sep 21, 2030	DS DP U-3130			
		9861713	Jul 31, 2029	DS DP U-3130			
PILOCARPINE HYDROCHLORIDE - VUITY							
N 214028	001	10610518	Apr 24, 2039	U-3252		NP	Oct 28, 2024
PIMAVANSERIN TARTRATE - NUPLAZID							
N 207318	001	10028944	Jan 15, 2024	U-1974			
		7601740	Apr 29, 2030	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9566271	Jan 15, 2024	U-1974			
		9765053	Jul 27, 2022	U-1974			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 207318	002	10028944	Jan 15, 2024	U-1974			
		10517860	Mar 23, 2037	U-1974			
		10953000	Mar 23, 2037	U-1974			
		7601740	Apr 29, 2030	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9566271	Jan 15, 2024	U-1974			
		9765053	Jul 27, 2022	U-1974			
PIMAVANSERIN TARTRATE - NUPLAZID							
N 210793	001	10028944	Jan 15, 2024	U-1974			
		10449185	Aug 27, 2038	DP			
		10646480	Aug 27, 2038	DP			
		10849891	Aug 27, 2038	DP U-1974			
		7601740	Apr 29, 2030	DS DP			
		7659285	Aug 24, 2026	U-1844			
		7732615	Jun 03, 2028	DS DP			
		7923564	Sep 26, 2025	DS DP			
		8618130	Jan 15, 2024	U-1845			
		8921393	Jan 15, 2024	U-1846			
		9566271	Jan 15, 2024	U-1974			
		9765053	Jul 27, 2022	U-1974			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	001	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	002	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	003	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN							
N 050684	004	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	001	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	002	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER							
N 050750	003	6900184	Apr 14, 2023	DP U-282			
		7915229	Apr 14, 2023	DP			
		8133883	Apr 14, 2023	DP U-282			
PIRFENIDONE - ESBRIET							
N 022535	001	7566729	Apr 22, 2029	U-1600			
		7635707	Apr 22, 2029	U-1609			
		7696236	Dec 18, 2027	U-1601			
		7767225	Sep 22, 2026	DP U-1602			
		7767700	Dec 18, 2027	U-1601			
		7816383	Jan 08, 2030	U-1603			
		7910610	Jan 08, 2030	U-1604			
		7988994	Sep 22, 2026	DP U-1602			
		8013002	Jan 08, 2030	U-1603			
		8084475	Jan 08, 2030	U-1605			
		8318780	Jan 08, 2030	U-1606			
		8383150	Sep 22, 2026	DP U-2361			
		8420674	Dec 18, 2027	DP U-1608			
		8592462	Apr 22, 2029	U-1609			
		8609701	Apr 22, 2029	U-1610			
		8648098	Jan 08, 2030	U-1611			
		8753679	Sep 22, 2026	DP U-1602			
		8754109	Jan 08, 2030	U-1612			
		8778947	Aug 30, 2033	U-1613			
PIRFENIDONE - ESBRIET							
N 208780	001	10188637	Mar 28, 2037	DP			
		7566729	Apr 22, 2029	U-2077			
		7566729	Apr 22, 2029	U-2078			
		7635707	Apr 22, 2029	U-2072			
		7635707	Apr 22, 2029	U-2073			
		7635707	Apr 22, 2029	U-2074			
		7635707	Apr 22, 2029	U-2075			
		7635707	Apr 22, 2029	U-2076			
		7635707	Apr 22, 2029	U-2083			
		7767700	Dec 18, 2027	U-2080			
		7816383	Jan 08, 2030	U-2042			
		7816383	Jan 08, 2030	U-2050			
		7910610	Jan 08, 2030	U-2048			
		7910610	Jan 08, 2030	U-2049			
		8013002	Jan 08, 2030	U-2047			
		8013002	Jan 08, 2030	U-2082			
		8084475	Jan 08, 2030	U-2052			
		8084475	Jan 08, 2030	U-2054			
		8318780	Jan 08, 2030	U-2046			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 001	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
PIRFENIDONE - ESBRIET						
N 208780 002	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PIRFENIDONE - ESBRIET						
N 208780 002	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
PIRFENIDONE - ESBRIET						
N 208780 003	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	Sep 22, 2026	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
	9561217	Jan 25, 2022	DP			
PITAVASTATIN CALCIUM - LIVALO						
N 022363 001	7022713	Feb 19, 2024	U-998		NPP	May 16, 2022
	7022713*PED	Aug 19, 2024			PED	Nov 16, 2022
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
PITAVASTATIN CALCIUM - LIVALO						
N 022363 002	7022713	Feb 19, 2024	U-998		NPP	May 16, 2022
	7022713*PED	Aug 19, 2024			PED	Nov 16, 2022
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
PITAVASTATIN CALCIUM - LIVALO						
N 022363 003	7022713	Feb 19, 2024	U-998		NPP	May 16, 2022
	7022713*PED	Aug 19, 2024			PED	Nov 16, 2022
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	001	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	002	8829186	Jan 19, 2031	DS DP			
PITAVASTATIN MAGNESIUM - ZYPITAMAG							
N 208379	003	8829186	Jan 19, 2031	DS DP			
PITOLISANT HYDROCHLORIDE - WAKIX							
N 211150	001	8207197	Feb 25, 2029	DS DP		I-846	Oct 13, 2023
		8354430	Feb 06, 2026	U-1101		NCE	Aug 14, 2024
		8354430	Feb 06, 2026	U-1102		ODE-255	Aug 14, 2026
		8486947	Sep 26, 2029	U-1101		ODE-331	Oct 13, 2027
		8486947	Sep 26, 2029	U-1102			
PITOLISANT HYDROCHLORIDE - WAKIX							
N 211150	002	8207197	Feb 25, 2029	DS DP		I-846	Oct 13, 2023
		8354430	Feb 06, 2026	U-1101		NCE	Aug 14, 2024
		8354430	Feb 06, 2026	U-1102		ODE-255	Aug 14, 2026
		8486947	Sep 26, 2029	U-1101		ODE-331	Oct 13, 2027
		8486947	Sep 26, 2029	U-1102			
PLAZOMICIN SULFATE - ZEMDRI							
N 210303	001	8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
		8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
		9266919	Nov 21, 2028	U-2328			
		9688711	Nov 21, 2028	DS U-2328			
PLECANATIDE - TRULANCE							
N 208745	001	10011637	Jun 05, 2034	DS		NCE	Jan 19, 2022
		11142549	Jun 05, 2034	DP			
		7041786	Jan 30, 2028	DS			
		7799897	Jun 09, 2022	DS			
		8637451	Mar 28, 2022	U-1964			
		9610321	Sep 15, 2031	U-1999			
		9610321	Sep 15, 2031	U-2230			
		9616097	Aug 20, 2032	DP			
		9919024	Sep 15, 2031	U-1999			
		9919024	Sep 15, 2031	U-2230			
		9925231	Sep 15, 2031	DP			
PLERIXAFOR - MOZOBIL							
N 022311	001	6987102	Jul 22, 2023	U-936			
		7897590	Jul 22, 2023	U-936			
POLIDOCANOL - VARITHENA							
N 205098	001	6846412	Jul 19, 2022	DP			
		7731986	Nov 17, 2024	DS DP U-1463			
		7814943	Nov 19, 2027	DP U-1461			
		8122917	Sep 09, 2024	DP			
		9480652	May 12, 2032	DP			
POMALIDOMIDE - POMALYST							
N 204026	001	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
		10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
		8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
		8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
		8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
		8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
		8673939	May 15, 2023	U-2254			
		8673939*PED	Nov 15, 2023				
		8735428	May 15, 2023	U-1360			
		8735428	May 15, 2023	U-2254			
		8735428*PED	Nov 15, 2023				
		8828427	Jun 21, 2031	DS DP			
		8828427*PED	Dec 21, 2031				
		9993467	May 19, 2030	DP			
		9993467*PED	Nov 19, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
POMALIDOMIDE - POMALYST						
N 204026 002	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 003	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
POMALIDOMIDE - POMALYST						
N 204026 004	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 001	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS DP U-1700			
	11192897	Dec 12, 2033	DS DP U-1701			
	11192897	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 002	11192897	Dec 12, 2033	DS DP U-1700			
	11192897	Dec 12, 2033	DS DP U-1701			
	11192897	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 003	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS DP U-1700			
	11192897	Dec 12, 2033	DS DP U-1701			
	11192897	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONATINIB HYDROCHLORIDE - ICLUSIG						
N 203469 004	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS DP U-1700			
	11192897	Dec 12, 2033	DS DP U-1701			
	11192897	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
PONESIMOD - PONVORY						
N 213498 001	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 002	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 003	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 004	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PONESIMOD - PONVORY						
N 213498 004	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 005	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 006	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 007	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
PONESIMOD - PONVORY						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
POSACONAZOLE - NOXAFIL						
N 022003 001	8263600	Apr 01, 2022	DP			
POSACONAZOLE - NOXAFIL						
N 205053 001					NPP	May 31, 2024
					ODE-355	Jun 17, 2028
POSACONAZOLE - NOXAFIL						
N 205596 001	10117951	Mar 13, 2029	DP		NPP	May 31, 2024
	8410077	Mar 13, 2029	DP		ODE-355	Jun 17, 2028
	9023790	Jul 04, 2031	DP U-1698			
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
POSACONAZOLE - NOXAFIL POWDERMIX KIT						
N 214770 001					NP	May 31, 2024
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRALATREXATE - FOLOTYN						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004			
	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
PRALATREXATE - FOLOTYN						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004			
	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
PRALSETINIB - GAVRETO						
N 213721 001	10030005	Nov 01, 2036	DS DP U-2827		NCE	Sep 04, 2025
	10030005	Nov 01, 2036	DS DP U-2952		ODE-318	Sep 04, 2027
	10030005	Nov 01, 2036	DS DP U-3002		ODE-340	Dec 01, 2027
					ODE-341	Dec 01, 2027
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 001	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
PRASTERONE - INTRAROSA						
N 208470 001	8268806	Mar 19, 2031	DP			
	8629129	Aug 07, 2028	DP			
	8957054	Aug 07, 2028	U-1922			
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 001	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			
PREDNISOLONE ACETATE - FLO-PRED						
N 022067 002	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			
PREDNISONE - RAYOS						
N 202020 001	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
PREDNISONE - RAYOS						
N 202020 002	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREDNISONE - RAYOS							
N 202020	003	8168218	Jan 07, 2028	DP U-1269			
		8309124	Apr 23, 2024	U-1292			
		8394407	Apr 23, 2024	DP U-1362			
		9040085	Apr 23, 2024	U-1362			
		9186332	Apr 23, 2024	U-1362			
		9504699	Aug 03, 2027	U-1362			
PREGABALIN - LYRICA							
N 021446	001					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 021446	002					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 021446	003					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 021446	004					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 021446	005					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 021446	006					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 021446	007					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 021446	008					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA							
N 022488	001					NPP	May 23, 2022
						PED	Nov 23, 2022
PREGABALIN - LYRICA CR							
N 209501	001	10022447	Nov 02, 2026	U-2136			
		10022447	Nov 02, 2026	U-2137			
		10022447*PED	May 02, 2027				
		8945620	Nov 02, 2026	DP U-2136			
		8945620	Nov 02, 2026	DP U-2137			
		8945620*PED	May 02, 2027				
		9144559	Nov 02, 2026	DP			
		9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR							
N 209501	002	10022447	Nov 02, 2026	U-2136			
		10022447	Nov 02, 2026	U-2137			
		10022447*PED	May 02, 2027				
		8945620	Nov 02, 2026	DP U-2136			
		8945620	Nov 02, 2026	DP U-2137			
		8945620*PED	May 02, 2027				
		9144559	Nov 02, 2026	DP			
		9144559*PED	May 02, 2027				
PREGABALIN - LYRICA CR							
N 209501	003	10022447	Nov 02, 2026	U-2136			
		10022447	Nov 02, 2026	U-2137			
		10022447*PED	May 02, 2027				
		8945620	Nov 02, 2026	DP U-2136			
		8945620	Nov 02, 2026	DP U-2137			
		8945620*PED	May 02, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PREGABALIN - LYRICA CR						
N 209501 003	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
PRETOMANID - PRETOMANID						
N 212862 001					NCE	Aug 14, 2024
					ODE-253	Aug 14, 2026
					GAIN	Aug 14, 2029
PROGESTERONE - MILPROSA						
N 201110 001	10537584	Feb 03, 2029	DP		NP	Apr 29, 2023
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
PROPOFOL - DIPRIVAN						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
PROPRANOLOL HYDROCHLORIDE - HEMANGEOL						
N 205410 001	8338489	Oct 16, 2028	U-1496			
	8987262	Oct 16, 2028	U-1988			
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 001					NCE	Dec 14, 2023
PRUCALOPRIDE SUCCINATE - MOTEGRITY						
N 210166 002					NCE	Dec 14, 2023
PYRIMETHAMINE - PYRIMETHAMINE						
A 211271 001					CGT	Apr 02, 2022
QUAZEPAM - DORAL						
N 018708 001	7608616	Jun 03, 2028	U-1012			
QUAZEPAM - DORAL						
N 018708 003	7608616	Jun 03, 2028	U-1012			
RADIUM RA-223 DICHLORIDE - XOFIGO						
N 203971 001	6635234	Nov 17, 2022	U-2271			
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 022145 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS HD						
N 022145 002	10772888	Mar 30, 2032	U-1663			
	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-257			
	7754731*PED	Sep 11, 2029				
	9649311	Oct 21, 2030	DP			
	9649311*PED	Apr 21, 2031				
RALTEGRAVIR POTASSIUM - ISENTRESS						
N 203045 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713	Oct 21, 2022	U-257			
	7217713*PED	Apr 21, 2023				
	7435734	Oct 21, 2022	U-257			
	7435734*PED	Apr 21, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 203045	001	7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 203045	002	7169780	Oct 03, 2023	DS DP			
		7169780*PED	Apr 03, 2024				
		7217713	Oct 21, 2022	U-257			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-257			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RALTEGRAVIR POTASSIUM - ISENTRESS							
N 205786	001	7169780	Oct 03, 2023	DS DP			
		7169780*PED	Apr 03, 2024				
		7217713	Oct 21, 2022	U-257			
		7217713*PED	Apr 21, 2023				
		7435734	Oct 21, 2022	U-257			
		7435734*PED	Apr 21, 2023				
		7754731	Mar 11, 2029	DS DP U-257			
		7754731*PED	Sep 11, 2029				
RASAGILINE MESYLATE - AZILECT							
N 021641	001	7572834	Dec 05, 2026	DP			
		7815942	Aug 27, 2027	DS DP U-219			
RASAGILINE MESYLATE - AZILECT							
N 021641	002	7572834	Dec 05, 2026	DP			
		7815942	Aug 27, 2027	DS DP U-219			
REGADENOSON - LEXISCAN							
N 022161	001	6403567	Apr 10, 2022	DS DP U-869			
		8106183	Feb 02, 2027	DS			
		RE47301	Feb 02, 2027	DP			
REGORAFENIB - STIVARGA							
N 203085	001	7351834	Jun 28, 2022	DS		ODE-139	Apr 27, 2024
		8637553	Feb 16, 2031	DS DP			
		8680124	Jun 02, 2030	U-1506			
		9458107	Apr 08, 2031	DP			
		9957232	Jul 09, 2032	DS			
RELUGOLIX - ORGOVYX							
N 214621	001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
		10449191	Sep 29, 2037	U-3020			
		10786501	Sep 29, 2037	U-3020			
		7300935	Jan 28, 2024	DS			
		8058280	Jan 28, 2024	DS DP			
		8735401	Feb 04, 2024	U-3019			
REMDESIVIR - VEKLURY							
N 214787	001	10065958	Sep 16, 2031	DS		NCE	Oct 22, 2025
		10675296	Jul 10, 2038	DP			
		10695361	Sep 16, 2036	U-2984			
		11007208	Sep 16, 2036	U-2984			
		8008264	Sep 06, 2029	DS DP			
		8318682	Apr 22, 2029	DS DP			
		9724360	Oct 29, 2035	DS DP			
		9949994	Oct 29, 2035	DS			
		RE46762	Apr 22, 2029	DS DP			
REMDESIVIR - VEKLURY							
N 214787	002	10065958	Sep 16, 2031	DS		NCE	Oct 22, 2025
		10675296	Jul 10, 2038	DP			
		10695361	Sep 16, 2036	U-2984			
		11007208	Sep 16, 2036	U-2984			
		8008264	Sep 06, 2029	DS DP			
		8318682	Apr 22, 2029	DS DP			
		9724360	Oct 29, 2035	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
REMDESIVIR - VEKLURY							
N 214787	002	9949994	Oct 29, 2035	DS			
		RE46762	Apr 22, 2029	DS DP			
REMIMAZOLAM BESYLATE - BYFAVO							
N 212295	001	10052334	Nov 07, 2031	U-2968		NCE	Oct 06, 2025
		10195210	Nov 07, 2031	U-2968			
		10342800	Nov 07, 2031	U-2968			
		10472365	Jul 10, 2027	U-2968			
		10722522	Nov 07, 2031	U-2968			
		9561236	Apr 30, 2033	U-2968			
		9737547	Nov 07, 2031	U-2968			
		9777007	Jul 10, 2027	DP			
		9827251	Nov 07, 2031	U-2968			
		9914738	Jul 10, 2027	DP			
RETAPAMULIN - ALTABAX							
N 022055	001	7875630	Feb 14, 2027	DS			
		8207191	Aug 30, 2024	U-805			
REVEFENACIN - YUPELRI							
N 210598	001	10106503	Mar 10, 2025	U-2440		NCE	Nov 09, 2023
		10343995	Mar 10, 2025	U-2440			
		10550081	Jul 14, 2030	DS			
		11008289	Jul 14, 2030	U-2440			
		7288657	Dec 23, 2025	DS			
		7491736	Mar 10, 2025	U-2440			
		7521041	Mar 10, 2025	U-2440			
		7550595	Mar 10, 2025	DP			
		7585879	Mar 10, 2025	DS DP U-2440			
		7910608	Mar 10, 2025	DS DP			
		8034946	Mar 10, 2025	DP			
		8053448	Mar 10, 2025	U-2440			
		8273894	Mar 10, 2025	DP			
		8541451	Aug 25, 2031	DS			
		9765028	Jul 14, 2030	DS			
RIBAVIRIN - REBETOL							
N 021546	001	6790837	Apr 05, 2023	DP			
RIBOCICLIB SUCCINATE - KISQALI							
N 209092	001	10799506	Apr 14, 2036	DP		NCE	Mar 13, 2022
		8324225	Jun 17, 2028	DS DP			
		8415355	Aug 21, 2029	DS DP			
		8685980	May 25, 2030	DS DP			
		8962630	Dec 09, 2029	U-1981			
		8962630	Dec 09, 2029	U-2355			
		8962630	Dec 09, 2029	U-2356			
		8962630	Dec 09, 2029	U-3265			
		8962630	Dec 09, 2029	U-3266			
		9193732	Nov 09, 2031	DS DP			
		9416136	Aug 20, 2029	U-1981			
		9416136	Aug 20, 2029	U-2355			
		9416136	Aug 20, 2029	U-2356			
		9416136	Aug 20, 2029	U-3265			
		9416136	Aug 20, 2029	U-3266			
		9868739	Nov 09, 2031	U-1981			
		9868739	Nov 09, 2031	U-2355			
		9868739	Nov 09, 2031	U-2356			
		9868739	Nov 09, 2031	U-3265			
		9868739	Nov 09, 2031	U-3266			
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA							
N 203324	001					ODE-116	Apr 15, 2023
						ODE-121	Jul 15, 2023
RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%							
N 203324	002					ODE-116	Apr 15, 2023
						ODE-121	Jul 15, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAMYCIN SODIUM - AEMCOLO							
N 210910	001	8263120	May 03, 2025	DP			
		8486446	May 03, 2025	DP			
		8529945	May 03, 2025	DP			
		8741948	May 03, 2025	DP		U-2448	
RIFAXIMIN - XIFAXAN							
N 021361	001	10703763	Feb 27, 2026			U-1708	
		10703763	Feb 27, 2026			U-2847	
		10703763	Feb 27, 2026			U-2848	
		7045620	Jun 19, 2024	DS DP			
		7612199	Jun 19, 2024	DS DP			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
		7928115	Jul 24, 2029			U-1121	
		8158644	Jun 19, 2024	DP			
		8158781	Jun 19, 2024	DS			
		8193196	Sep 02, 2027	DS DP			
		8518949	Feb 27, 2026	DP			
		8741904	Feb 27, 2026	DS		U-1526	
		8835452	Jun 19, 2024	DS DP			
		8853231	Jun 19, 2024	DP			
		9271968	Feb 27, 2026	DP			
RIFAXIMIN - XIFAXAN							
N 021361	002	10314828	Jul 24, 2029			U-1481	
		10335397	Jul 24, 2029			U-2579	
		10456384	Feb 26, 2029			U-2643	
		10456384	Feb 26, 2029			U-2644	
		10703763	Feb 27, 2026			U-1708	
		10703763	Feb 27, 2026			U-2847	
		10703763	Feb 27, 2026			U-2848	
		10709694	Jul 24, 2029			U-2579	
		10765667	Feb 26, 2029			U-2643	
		10765667	Feb 26, 2029			U-2644	
		7045620	Jun 19, 2024	DS			
		7612199	Jun 19, 2024	DS DP			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
		7915275	Feb 23, 2025			U-1707	
		7915275	Feb 23, 2025			U-1708	
		8158644	Jun 19, 2024	DP			
		8158781	Jun 19, 2024	DS			
		8193196	Sep 02, 2027	DS DP		U-1707	
		8193196	Sep 02, 2027	DS DP		U-1708	
		8309569	Jul 18, 2029			U-1707	
		8309569	Jul 18, 2029			U-1708	
		8518949	Feb 27, 2026	DP			
		8642573	Oct 02, 2029			U-1481	
		8741904	Feb 27, 2026	DS		U-1526	
		8741904	Feb 27, 2026	DS		U-1707	
		8741904	Feb 27, 2026	DS		U-1708	
		8829017	Jul 24, 2029			U-1562	
		8835452	Jun 19, 2024	DS DP			
		8853231	Jun 19, 2024	DP			
		8946252	Jul 24, 2029			U-1481	
		8969398	Oct 02, 2029			U-1481	
		9271968	Feb 27, 2026	DP			
		9421195	Jul 24, 2029			U-1481	
		9629828	Jul 24, 2029			U-1994	
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N 202022	001	7125879	Apr 21, 2025	DS DP		U-1153	
		7125879	Apr 21, 2025	DS DP		U-1307	
		7125879	Apr 21, 2025	DS DP		U-1740	
		7125879	Apr 21, 2025	DS DP		U-3068	
		7638522	Apr 14, 2023	DP			
		8080551	Apr 11, 2023	DS DP			
		8101629	Aug 09, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RILUZOLE - TIGLUTIK KIT							
N 209080	001	8765150	Mar 12, 2029	DP U-2401			
RILUZOLE - EXSERVAN							
N 212640	001	8603514	Apr 03, 2024	DP			
		8765167	Feb 20, 2024	DP			
RIMEGEPANT SULFATE - NURTEC ODT							
N 212728	001	11083724	Mar 25, 2039	DP U-2718		I-865	May 27, 2024
		11083724	Mar 25, 2039	DP U-3142		NCE	Feb 27, 2025
		8314117	Feb 22, 2031	DS DP U-2718			
		8314117	Feb 22, 2031	DS DP U-3142			
		8759372	Feb 25, 2033	DS DP			
RIOCIGUAT - ADEMPAS							
N 204819	001	10662188	Feb 18, 2034	DS DP U-2834			
		10662188	Feb 18, 2034	DS DP U-2835			
		7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS							
N 204819	002	10662188	Feb 18, 2034	DS DP U-2834			
		10662188	Feb 18, 2034	DS DP U-2835			
		7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS							
N 204819	003	10662188	Feb 18, 2034	DS DP U-2834			
		10662188	Feb 18, 2034	DS DP U-2835			
		7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS							
N 204819	004	10662188	Feb 18, 2034	DS DP U-2834			
		10662188	Feb 18, 2034	DS DP U-2835			
		7173037	Dec 04, 2026	DS DP			
RIOCIGUAT - ADEMPAS							
N 204819	005	10662188	Feb 18, 2034	DS DP U-2834			
		10662188	Feb 18, 2034	DS DP U-2835			
		7173037	Dec 04, 2026	DS DP			
RIPRETINIB - QINLOCK							
N 213973	001	10966966	Aug 12, 2040	U-3153		NCE	May 15, 2025
		11185535	Dec 30, 2040	DP		ODE-298	May 15, 2027
		8188113	Jul 27, 2030	DS DP			
		8461179	Jun 07, 2032	DS DP			
		RE48731	Jun 07, 2032	U-3219			
RISDIPLAM - EVRYSDI							
N 213535	001	9586955	Feb 08, 2033	DS DP		NCE	Aug 07, 2025
		9969754	May 11, 2035	DS DP U-1943		ODE-334	Aug 07, 2027
RISEDRONATE SODIUM - ACTONEL							
N 020835	005	7192938	May 06, 2023	U-353			
		7718634	May 06, 2023	U-662			
RISEDRONATE SODIUM - ATELVIA							
N 022560	001	7645459	Jan 09, 2028	DP U-662			
		7645460	Jan 09, 2028	DP U-662			
		8246989	Jan 16, 2026	DP			
RISPERIDONE - PERSERIS KIT							
N 210655	001	10010612	Feb 13, 2028	DP			
		10058554	Sep 26, 2026	U-2363			
		10376590	Feb 13, 2028	U-2608			
		10406160	Jun 26, 2026	DP U-2608			
		11013809	Feb 13, 2028	DP U-3135			
		11110093	Nov 05, 2026	DP U-3135			
		9180197	Feb 13, 2028	DP			
		9186413	Feb 13, 2028	U-543			
		9597402	Sep 26, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISPERIDONE - PERSERIS KIT						
N 210655 002	10010612	Feb 13, 2028	DP			
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
RIVAROXABAN - XARELTO						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP U-1302		I-867	Aug 23, 2024
	7157456*PED	Feb 28, 2025			PED	Apr 11, 2023
	9415053	Nov 13, 2024	DP U-1167		PED	Feb 23, 2025
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301		I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP U-1302		I-867	Aug 23, 2024
	7157456*PED	Feb 28, 2025			PED	Apr 11, 2023
	9415053	Nov 13, 2024	DP U-1200		PED	Feb 23, 2025
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301		I-810	Oct 11, 2022
	7157456	Aug 28, 2024	DS DP U-1302		I-867	Aug 23, 2024
	7157456*PED	Feb 28, 2025			PED	Apr 11, 2023
	9415053	Nov 13, 2024	DP U-1200		PED	Feb 23, 2025
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218*PED	Aug 17, 2034				
RIVAROXABAN - XARELTO						
N 022406 004	10828310	Jan 31, 2039	U-3207		I-810	Oct 11, 2022
	10828310	Jan 31, 2039	U-3208		I-867	Aug 23, 2024
	10828310*PED	Jul 31, 2039			PED	Apr 11, 2023
	7157456	Aug 28, 2024	DS DP		PED	Feb 23, 2025
	7157456*PED	Feb 28, 2025				
	9415053	Nov 13, 2024	DP U-2435			
	9415053	Nov 13, 2024	DP U-3205			
	9415053	Nov 13, 2024	DP U-3206			
	9415053*PED	May 13, 2025				
ROFLUMILAST - DALIRESP						
N 022522 001	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
ROFLUMILAST - DALIRESP						
N 022522 002	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROFLUMILAST - DALIRESP							
N 022522	002	9468598	Feb 19, 2023	DP			
ROLAPITANT HYDROCHLORIDE - VARUBI							
N 206500	001	7049320	Aug 19, 2028	DS DP U-1741			
		7563801	Apr 04, 2027	DP			
		7981905	Apr 04, 2027	U-1741			
		8178550	Apr 04, 2027	DS DP			
		8361500	Oct 09, 2029	DP			
		8404702	Apr 04, 2027	U-1741			
		8470842	Jan 18, 2029	U-1741			
		8796299	Dec 17, 2022	U-1741			
ROLAPITANT HYDROCHLORIDE - VARUBI							
N 208399	001	7049320	Aug 19, 2028	DS DP U-1741			
		7981905	Apr 04, 2027	U-1741			
		8178550	Apr 04, 2027	DS DP			
		8404702	Apr 04, 2027	U-1741			
		8470842	Jan 18, 2029	U-1741			
		8796299	Dec 17, 2022	U-1741			
		9101615	Jul 14, 2032	U-1741			
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	006	7828787	Oct 18, 2025	DP			
		7857802	Nov 28, 2026	DP			
		8118802	May 18, 2023	DP			
		8162915	May 23, 2024	DP			
ROPIVACAINE HYDROCHLORIDE - NAROPIN							
N 020533	007	7828787	Oct 18, 2025	DP			
		7857802	Nov 28, 2026	DP			
		8118802	May 18, 2023	DP			
		8162915	May 23, 2024	DP			
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	002	6858618*PED	Jun 17, 2022			ODE-118	May 27, 2023
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	003	6858618*PED	Jun 17, 2022			ODE-118	May 27, 2023
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	004	6858618*PED	Jun 17, 2022			ODE-118	May 27, 2023
ROSUVASTATIN CALCIUM - CRESTOR							
N 021366	005					ODE-118	May 27, 2023
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE							
N 208647	001	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE							
N 208647	002	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE							
N 208647	003	10413543	Feb 12, 2036	DP			
ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE							
N 208647	004	10413543	Feb 12, 2036	DP			
ROTIGOTINE - NEUPRO							
N 021829	001	10130589	Dec 22, 2030	DP			
		10350174	Dec 22, 2030	DP			
		8246979	Sep 01, 2027	DP U-1272			
		8246979	Sep 01, 2027	DP U-1273			
		8246980	Nov 27, 2025	DP			
		8617591	Jul 22, 2023	DP U-1474			
		9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO							
N 021829	002	10130589	Dec 22, 2030	DP			
		10350174	Dec 22, 2030	DP			
		8246979	Sep 01, 2027	DP U-1272			
		8246979	Sep 01, 2027	DP U-1273			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROTIGOTINE - NEUPRO						
N 021829 002	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 003	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 004	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 005	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
ROTIGOTINE - NEUPRO						
N 021829 006	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 001	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101		ODE-126	Dec 19, 2023
	10130636	Aug 17, 2035	U-2273		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 002	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101		ODE-126	Dec 19, 2023
	10130636	Aug 17, 2035	U-2273		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUCAPARIB CAMSYLATE - RUBRACA						
N 209115 003	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101		ODE-126	Dec 19, 2023
	10130636	Aug 17, 2035	U-2273		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
RUFINAMIDE - BANZEL						
N 021911 001	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
RUFINAMIDE - BANZEL						
N 021911 002	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
RUFINAMIDE - BANZEL						
N 021911 003	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUFINAMIDE - BANZEL						
N 201367 001	6740669	Nov 14, 2022	DS DP			
	6740669*PED	May 14, 2023				
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 001	10016429	Jun 12, 2028	U-3226		I-799	May 24, 2022
	10016429	Jun 12, 2028	U-3230		I-872	Sep 22, 2024
	7598257	Dec 24, 2027	DS DP U-3227		ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP U-3228		ODE-373	Sep 22, 2028
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 002	10016429	Jun 12, 2028	U-3226		I-799	May 24, 2022
	10016429	Jun 12, 2028	U-3230		I-872	Sep 22, 2024
	7598257	Dec 24, 2027	DS DP U-3227		ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP U-3228		ODE-373	Sep 22, 2028
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003	10016429	Jun 12, 2028	U-3226		I-799	May 24, 2022
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3228			
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9814722	Dec 12, 2026	U-3226			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 003	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 004	10016429	Jun 12, 2028	U-3226		I-799	May 24, 2022
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3228			
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - JAKAFI						
N 202192 005	10016429	Jun 12, 2028	U-3226		I-799	May 24, 2022
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3228			
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
RUXOLITINIB PHOSPHATE - OPZELURA						
N 215309 001	10610530	Jun 12, 2028	U-3229		NP	Sep 21, 2024
	10639310	Dec 12, 2026	U-3229			
	10758543	May 20, 2031	DP			
	10869870	May 20, 2031	U-3229			
	7598257	Dec 24, 2027	DS DP			
	8415362	Dec 24, 2027	DS DP			
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-3229			
	9079912	Dec 12, 2026	U-3229			
	9974790	Dec 12, 2026	U-3229			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 001	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084		NPP	Oct 01, 2022
	7468390	Nov 27, 2023	DP		PED	Apr 01, 2023
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 001	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 002	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084		NPP	Oct 01, 2022
	7468390	Nov 27, 2023	DP		PED	Apr 01, 2023
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SACUBITRIL; VALSARTAN - ENTRESTO						
N 207620 003	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084		NPP	Oct 01, 2022
	7468390	Nov 27, 2023	DP		PED	Apr 01, 2023
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
SAFINAMIDE MESYLATE - XADAGO						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Mar 21, 2031	U-1993			
SAFINAMIDE MESYLATE - XADAGO						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993		NCE	Mar 21, 2022
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Mar 21, 2031	U-1993			
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N 022181 001	7566462	Nov 16, 2025	DP			
	7566462*PED	May 16, 2026				
	7566714	Nov 17, 2024	U-989			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 16, 2026				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	9433624	Nov 17, 2024	U-1589			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 022181	001	RE43797	Nov 17, 2024	U-1156			
		RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 205065	001	7566714	Nov 17, 2024	U-1589			
		7566714*PED	May 17, 2025				
		7612073	Nov 17, 2024	U-1010			
		7612073*PED	May 17, 2025				
		8067416	Nov 17, 2024	U-1589			
		8067416*PED	May 17, 2025				
		9216178	Nov 01, 2032	DP			
		9433624	Nov 17, 2024	U-1589			
		RE43797	Nov 17, 2024	U-1590			
		RE43797*PED	May 17, 2025				
SAPROPTERIN DIHYDROCHLORIDE - KUVAN							
N 205065	002	7566714	Nov 17, 2024	U-1589			
		7566714*PED	May 17, 2025				
		7612073	Nov 17, 2024	U-1010			
		7612073*PED	May 17, 2025				
		8067416	Nov 17, 2024	U-1589			
		8067416*PED	May 17, 2025				
		9216178	Nov 01, 2032	DP			
		9433624	Nov 17, 2024	U-1589			
		RE43797	Nov 17, 2024	U-1590			
		RE43797*PED	May 17, 2025				
SARECYCLINE HYDROCHLORIDE - SEYSARA							
N 209521	001	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406			
		9255068	Feb 09, 2033	DS DP U-2407			
		9255068	Feb 09, 2033	DS DP U-2408			
		9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA							
N 209521	002	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406			
		9255068	Feb 09, 2033	DS DP U-2407			
		9255068	Feb 09, 2033	DS DP U-2408			
		9481639	Aug 10, 2028	U-2409			
SARECYCLINE HYDROCHLORIDE - SEYSARA							
N 209521	003	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
		8513223	Dec 07, 2029	U-2406			
		9255068	Feb 09, 2033	DS DP U-2407			
		9255068	Feb 09, 2033	DS DP U-2408			
		9481639	Aug 10, 2028	U-2409			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350	001	7951400	Nov 30, 2028	DP			
		RE44186	Jul 31, 2023	DS DP U-1837			
		RE44186	Jul 31, 2023	DS DP U-995			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA							
N 022350	002	7951400	Nov 30, 2028	DP			
		RE44186	Jul 31, 2023	DS DP U-1837			
		RE44186	Jul 31, 2023	DS DP U-995			
SECNIDAZOLE - SOLOSEC							
N 209363	001	10335390	Sep 04, 2035	U-2583		I-866	Jun 30, 2024
		10682338	Sep 04, 2035	U-2583		NCE	Sep 15, 2022
		10849884	Sep 04, 2035	DP U-2583		GAIN	Sep 15, 2027
		10849884	Sep 04, 2035	DP U-3169			
		10857133	Sep 04, 2035	DP U-2583			
		11000507	Sep 04, 2035	DP U-2583			
		11000507	Sep 04, 2035	DP U-3169			
		11000508	Sep 04, 2035	DP U-2583			
		11000508	Sep 04, 2035	DP U-3169			
		11020377	Sep 04, 2035	DP U-2583			
		11020377	Sep 04, 2035	DP U-3169			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SECNIDAZOLE - SOLOSEC						
N 209363 001	10335390	Sep 04, 2035	U-2583		I-866	Jun 30, 2024
	10682338	Sep 04, 2035	U-2583		NCE	Sep 15, 2022
	10849884	Sep 04, 2035	DP U-2583		GAIN	Sep 15, 2027
	10849884	Sep 04, 2035	DP U-3169			
	10857133	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
SELENIOUS ACID - SELENIOUS ACID						
N 209379 001					NCE	Apr 30, 2024
SELENIOUS ACID - SELENIOUS ACID						
N 209379 002					NCE	Apr 30, 2024
SELENIOUS ACID - SELENIOUS ACID						
N 209379 003					NCE	Apr 30, 2024
SELEXIPAG - UPTRAVI						
N 207947 001	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 002	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 003	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 004	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 005	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 006	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEXIPAG - UPTRAVI						
N 207947 007	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 207947 008	10821108	Dec 01, 2036	DP U-2992		ODE-106	Dec 21, 2022
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELEXIPAG - UPTRAVI						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
SELINEXOR - XPOVIO						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		I-837	Jun 22, 2023
	10519139	Aug 14, 2035	DS DP U-2855		NCE	Jul 03, 2024
	10519139	Aug 14, 2035	DS DP U-3018		ODE-257	Jul 03, 2026
	10544108	Jul 26, 2032	U-2584		ODE-310	Jun 22, 2027
	10544108	Jul 26, 2032	U-3018		ODE-346	Dec 18, 2027
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELINEXOR - XPOVIO						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELINEXOR - XPOVIO						
N 212306 004	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
SELPERCATINIB - RETEVMO						
N 213246 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
SELPERCATINIB - RETEVMO						
N 213246 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
SELUMETINIB SULFATE - KOSELUGO						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
SELUMETINIB SULFATE - KOSELUGO						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
SEMAGLUTIDE - OZEMPIC						
N 209637 001	10220155	Jul 17, 2026	DP		I-822	Jan 16, 2023
	10335462	Jun 21, 2033	U-2580		NCE	Dec 05, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - OZEMPIC						
N 209637 001	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - OZEMPIC						
N 209637 002	10220155	Jul 17, 2026	DP		I-822	Jan 16, 2023
	10335462	Jun 21, 2033	U-2580		NCE	Dec 05, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	6899699	Jan 02, 2022	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8579869	Jun 30, 2023	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
SEMAGLUTIDE - RYBELSUS						
N 213051 001	10086047	Dec 16, 2031	DP		M-252	Jan 16, 2023
	10278923	May 02, 2034	U-2628		NCE	Dec 05, 2022
	10933120	Mar 15, 2033	DP		NP	Sep 20, 2022
	10960052	Dec 16, 2031	DP			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 002	10086047	Dec 16, 2031	DP		M-252	Jan 16, 2023
	10278923	May 02, 2034	U-2628		NCE	Dec 05, 2022
	10933120	Mar 15, 2033	DP		NP	Sep 20, 2022
	10960052	Dec 16, 2031	DP			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - RYBELSUS						
N 213051 003	10086047	Dec 16, 2031	DP		M-252	Jan 16, 2023
	10278923	May 02, 2034	U-2628		NCE	Dec 05, 2022
	10933120	Mar 15, 2033	DP		NP	Sep 20, 2022
	10960052	Dec 16, 2031	DP			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
SEMAGLUTIDE - WEGOVY						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SEMAGLUTIDE - WEGOVY						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 004	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SEMAGLUTIDE - WEGOVY						
N 215256 005	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Dec 05, 2031	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
SETMELANOTIDE ACETATE - IMCIVREE						
N 213793 001	11129869	Jul 04, 2034	DP		NCE	Nov 25, 2025
	8039435	Oct 13, 2027	DS DP		ODE-336	Nov 25, 2027
	9458195	Oct 13, 2027	DS DP			
SEVELAMER CARBONATE - RENVELA						
N 022127 001	7985418	Oct 27, 2025	DP			
SEVELAMER CARBONATE - RENVELA						
N 022318 001	9095509	Dec 06, 2030	DP			
SEVELAMER CARBONATE - RENVELA						
N 022318 002	9095509	Dec 06, 2030	DP			
SIMEPREVIR SODIUM - OLYSIO						
N 205123 001	7671032	May 19, 2025	DS DP			
	8148399	Sep 05, 2029	DS DP U-1467			
	8349869	Jul 28, 2026	DS DP U-1467			
	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			
	9040562	Jul 28, 2026	DS DP U-1467			
	9353103	Jul 28, 2026	U-1467			
	9623022	Jul 28, 2026	U-1467			
	9856265	Jul 28, 2026	DS DP U-1467			
SIMVASTATIN - FLOLIPID						
N 206679 001	10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
SIMVASTATIN - FLOLIPID						
N 206679 002	10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 001	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 002	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 003	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 004	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 005	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC						
N 202343 006	6699871	Jul 26, 2022	DS DP U-1188			
	6699871*PED	Jan 26, 2023				
	7125873	Jul 26, 2022	DP U-1189			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1193			
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
	8168637	Jun 26, 2022	DP U-1188			
SINCALIDE - KINEVAC						
N 017697 001	6803046	Aug 16, 2022	DP			
SINECATECHINS - VEREGEN						
N 021902 001	10434059	Nov 18, 2022	DP U-172			
	7858662	Oct 02, 2026	DP U-172			
	9770406	Jul 12, 2025	DP U-172			
SIPONIMOD FUMARIC ACID - MAYZENT						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SIPONIMOD FUMARIC ACID - MAYZENT						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
SIPONIMOD FUMARIC ACID - MAYZENT						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
SIPONIMOD FUMARIC ACID - MAYZENT						
N 209884 003	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
SIROLIMUS - RAPAMUNE						
N 021083 001					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 001					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 002					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 003					ODE-92	May 28, 2022
SIROLIMUS - RAPAMUNE						
N 021110 004					ODE-92	May 28, 2022
SIROLIMUS - FYARRO						
N 213312 001	10206887	Apr 15, 2030	DP		NP	Nov 22, 2024
	10705070	Mar 05, 2036	DP			
	10973806	Jun 29, 2036	U-3258			
	8911786	Feb 14, 2029	DP U-3259			
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 001	6699871	Jul 26, 2022	DS DP U-774		M-187	Dec 04, 2023
	7125873	Jul 26, 2022	U-1036		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1037		PED	Feb 12, 2023
	7125873	Jul 26, 2022	U-1038		PED	Jun 04, 2024
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 002	6699871	Jul 26, 2022	DS DP U-774		M-187	Dec 04, 2023
	7125873	Jul 26, 2022	U-1036		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1037		PED	Feb 12, 2023
	7125873	Jul 26, 2022	U-1038		PED	Jun 04, 2024
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
SITAGLIPTIN PHOSPHATE - JANUVIA						
N 021995 003	6699871	Jul 26, 2022	DS DP U-774		M-187	Dec 04, 2023
	7125873	Jul 26, 2022	U-1036		M-244	Aug 12, 2022
	7125873	Jul 26, 2022	U-1037		PED	Feb 12, 2023
	7125873	Jul 26, 2022	U-1038		PED	Jun 04, 2024
	7125873	Jul 26, 2022	U-775			
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
SODIUM ACETATE - SODIUM ACETATE						
A 214805 001					CGT	Jan 03, 2022
SODIUM NITRITE - SODIUM NITRITE						
N 203922 001	8568793	Dec 24, 2031	DS DP			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N 201444 001	8496973	Mar 29, 2031	DS DP U-1419			
	8568793	Dec 24, 2031	DS DP			
	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - XYREM						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
	10864181	Mar 15, 2033	U-1532		PED	Apr 26, 2026
	7668730	Jun 16, 2024	U-1110	Y		
	7668730*PED	Dec 16, 2024				
	8731963	Dec 17, 2022	U-1110			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP						
N 021892 001	7687075	Jun 22, 2028	DS DP			
SODIUM THIOSULFATE - SODIUM THIOSULFATE						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419			
	9345724	Mar 29, 2031	DS DP U-2015			
	9585912	Mar 29, 2031	DS DP			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 001	10300087	Oct 14, 2035	DS U-2312		M-261	Apr 24, 2023
	10335432	Feb 10, 2032	U-2312		NCE	May 18, 2023
	10398730	Feb 10, 2032	U-2312			
	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA						
N 207078 002	10300087	Oct 14, 2035	DS U-2312		M-261	Apr 24, 2023
	10398730	Feb 10, 2032	U-2312		NCE	May 18, 2023
	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
SOFOSBUVIR - SOVALDI						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR - SOVALDI							
N 204671	002	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Apr 07, 2024
		7964580*PED	Sep 26, 2029			ODE*	Aug 28, 2026
		8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
SOFOSBUVIR - SOVALDI							
N 212480	001	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
		7964580*PED	Sep 26, 2029				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
SOFOSBUVIR - SOVALDI							
N 212480	002	7964580	Mar 26, 2029	DS DP U-1470		ODE-258	Aug 28, 2026
		7964580*PED	Sep 26, 2029				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 208341	001	10086011	Jan 30, 2034	U-1470		D-177	Nov 15, 2022
		10086011*PED	Jul 30, 2034			M-264	Jul 14, 2023
		11116783	Jan 30, 2034	DP U-1470		NPP	Mar 19, 2023
		11116783*PED	Jul 30, 2034			ODE-293	Mar 19, 2027
		7964580	Mar 26, 2029	DS DP U-1470		ODE-376	Jun 10, 2028
		7964580*PED	Sep 26, 2029			PED	May 15, 2023
		8334270	Mar 21, 2028	DS DP U-1470		PED	Sep 19, 2023
		8334270*PED	Sep 21, 2028			PED	Jan 14, 2024
		8575135	Nov 16, 2032	DS DP U-1470		PED	Sep 19, 2027
		8575135*PED	May 16, 2033			PED	Dec 10, 2028
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 208341	001	8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		8921341	Nov 16, 2032	DS DP U-1470			
		8921341*PED	May 16, 2033				
		8940718	Nov 16, 2032	DS DP U-1470			
		8940718*PED	May 16, 2033				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9757406	Jan 30, 2034	DP			
		9757406*PED	Jul 30, 2034				
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 208341	002	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
		10086011*PED	Jul 30, 2034			NS	Mar 19, 2023
		11116783	Jan 30, 2034	DP U-1470		ODE-293	Mar 19, 2027
		11116783*PED	Jul 30, 2034			ODE-376	Jun 10, 2028
		7964580	Mar 26, 2029	DS DP U-1470		PED	Sep 19, 2023
		7964580*PED	Sep 26, 2029			PED	Jan 14, 2024
		8334270	Mar 21, 2028	DS DP U-1470		PED	Sep 19, 2027
		8334270*PED	Sep 21, 2028			PED	Dec 10, 2028
		8575135	Nov 16, 2032	DS DP U-1470			
		8575135*PED	May 16, 2033				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		8921341	Nov 16, 2032	DS DP U-1470			
		8921341*PED	May 16, 2033				
		8940718	Nov 16, 2032	DS DP U-1470			
		8940718*PED	May 16, 2033				
		9085573	Mar 21, 2028	DS DP U-1470			
		9085573*PED	Sep 21, 2028				
		9284342	Sep 13, 2030	DS DP U-1470			
		9284342*PED	Mar 13, 2031				
		9757406	Jan 30, 2034	DP			
		9757406*PED	Jul 30, 2034				
SOFOSBUVIR; VELPATASVIR - EPCLUSA							
N 214187	001	11116783	Jan 30, 2034	DP U-1470		ODE-376	Jun 10, 2028
		11116783*PED	Jul 30, 2034			PED	Dec 10, 2028
		7964580	Mar 26, 2029	DS DP U-1470			
		7964580*PED	Sep 26, 2029				
		8334270	Mar 21, 2028	DS DP U-1470			
		8334270*PED	Sep 21, 2028				
		8575135	Nov 16, 2032	DS DP U-1470			
		8575135*PED	May 16, 2033				
		8580765	Mar 21, 2028	DS DP U-1470			
		8580765*PED	Sep 21, 2028				
		8618076	Dec 11, 2030	DS DP U-1470			
		8618076*PED	Jun 11, 2031				
		8633309	Mar 26, 2029	DS DP U-1470			
		8633309*PED	Sep 26, 2029				
		8735372	Mar 21, 2028	U-1470			
		8735372*PED	Sep 21, 2028				
		8889159	Mar 26, 2029	DP U-1470			
		8889159*PED	Sep 26, 2029				
		8921341	Nov 16, 2032	DS DP U-1470			
		8921341*PED	May 16, 2033				
		8940718	Nov 16, 2032	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 001	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR - EPCLUSA						
N 214187 002	11116783	Jan 30, 2034	DP U-1470		ODE-376	Jun 10, 2028
	11116783*PED	Jul 30, 2034			PED	Dec 10, 2028
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	10912814	Jun 01, 2037	DP		NCE	Jul 18, 2022
	11116783	Jan 30, 2034	DP U-2039			
	11116783	Jan 30, 2034	DP U-2040			
	11116783*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI						
N 209195 001	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			
	9585906	Mar 21, 2028	DS DP U-2040			
	9868745	Nov 16, 2032	DS DP			
SOLIFENACIN SUCCINATE - VESICARE LS						
N 209529 001	9918970	May 18, 2031	DP		NP	May 26, 2023
					PED	Nov 26, 2023
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
SOLRIAMFETOL HYDROCHLORIDE - SUNOSI						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
SONIDEGIB PHOSPHATE - ODOMZO						
N 205266 001	8063043	Sep 15, 2029	DS DP			
	8178563	Jul 24, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR						
N 021923 001	8618141	Feb 11, 2023	U-1480			
	8877933	Dec 24, 2027	DS DP U-1624			
	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE						
N 022306 001	10512620	Aug 18, 2038	U-2769			
	10799138	Apr 05, 2039	U-3125			
SOTALOL HYDROCHLORIDE - SOTYLIZE						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
	11013703	Apr 01, 2034	DP			
	9724297	Aug 31, 2035	DP U-2096			
SOTORASIB - LUMAKRAS						
N 214665 001					NCE	May 28, 2026
					ODE-352	May 28, 2028
SPINOSAD - NATROBA						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		I-858	Apr 28, 2024
SPIRONOLACTONE - CAROSPIR						
N 209478 001	10493083	Oct 28, 2036	DP			
	10624906	Oct 28, 2036	DP			
	10660907	Oct 28, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SPIRONOLACTONE - CAROSPIR						
N 209478 001	10888570	Oct 28, 2036	DP			
	9757394	Oct 28, 2036	DP U-2109			
STAVUDINE - ZERIT XR						
N 021453 001	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 002	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 003	7135465	Feb 18, 2023	DP U-167			
STAVUDINE - ZERIT XR						
N 021453 004	7135465	Feb 18, 2023	DP U-167			
STIRIPENTOL - DIACOMIT						
N 206709 001					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT						
N 206709 002					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT						
N 207223 001					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
STIRIPENTOL - DIACOMIT						
N 207223 002					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
SUFENTANIL CITRATE - DSUVIA						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
	10507180	Jan 05, 2027	DP U-1351			
	10896751	Mar 16, 2030	DP			
	8202535	Oct 22, 2030	U-1351			
	8226978	Jan 05, 2027	DP U-1351			
	8231900	Jan 05, 2027	DP			
	8252328	Jan 05, 2027	DP			
	8252329	Jan 05, 2027	DP			
	8535714	Jan 05, 2027	DP U-1351			
	8574189	Mar 16, 2030	DP			
	8778393	Jan 05, 2027	U-1351			
	8778394	Jan 05, 2027	U-1351			
	8865211	Jan 05, 2027	U-1351			
	8865743	Oct 22, 2030	U-1351			
	8945592	Jul 29, 2031	DP			
	9320710	Jan 05, 2027	U-1351			
	9744129	Jan 05, 2027	DP			
SUGAMMADEX SODIUM - BRIDION						
N 022225 001	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
					NPP	Jun 25, 2024
SUGAMMADEX SODIUM - BRIDION						
N 022225 002	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
					NPP	Jun 25, 2024
SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON						
N 203684 001	10232061	Jul 06, 2038	DP		NPP	Nov 13, 2022
	10335502	Jul 06, 2038	DP			
SUMATRIPTAN - TOSYMRA						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUMATRIPTAN - TOSYMRA							
N 210884	001	10603305	Jun 16, 2030	DP U-1719			
		8268791	May 09, 2026	DP			
		8440631	May 09, 2026	DP U-1719			
		9211282	Jul 19, 2031	DP U-1719			
		9283280	May 09, 2026	DP			
		9610280	Jun 16, 2030	DP U-1719			
		9974770	Jun 16, 2030	DP U-1719			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO							
N 022239	001	7776007	Nov 22, 2026	DP			
		7901385	Jul 31, 2026	DP			
		8118771	Aug 10, 2023	DP			
		8241243	Aug 10, 2023	DP			
		8241244	Nov 21, 2022	DP			
		8267903	Mar 18, 2023	DP			
		8287489	Dec 06, 2024	DP			
		8343130	Oct 18, 2022	DP			
		8491524	Nov 21, 2022	DP			
SUMATRIPTAN SUCCINATE - ALSUMA							
N 022377	001	7811254	Aug 26, 2027	DP U-1083			
SUMATRIPTAN SUCCINATE - ZECUITY							
N 202278	001	6745071	Feb 21, 2023	DP			
		7973058	Apr 12, 2027	U-1328			
		8155737	Apr 12, 2027	U-1328			
		8366600	Apr 21, 2029	U-1327			
		8470853	Apr 12, 2027	U-1328			
		8597272	Apr 12, 2027	DP			
		8983594	Nov 19, 2030	DP U-1328			
		9272137	Sep 07, 2027	DP			
		9327114	Oct 08, 2032	DP U-1328			
		9427578	Apr 12, 2027	DP U-1328			
SUMATRIPTAN SUCCINATE - ONZETRA XSAIL							
N 206099	001	10076614	Oct 20, 2034	DP			
		10076615	Jul 30, 2029	U-2010			
		10076615	Jul 30, 2029	U-2011			
		10076615	Jul 30, 2029	U-2404			
		10124132	Mar 06, 2027	DP U-1719			
		10124132	Mar 06, 2027	DP U-2010			
		10124132	Mar 06, 2027	DP U-2011			
		10398859	Dec 19, 2027	DP			
		10478574	Nov 04, 2033	U-2404			
		10722667	Dec 30, 2028	DP			
		7975690	Aug 18, 2025	DP U-1809			
		8047202	Jul 02, 2023	DP			
		8327844	Oct 03, 2023	U-1809			
		8550073	Oct 22, 2029	DP			
		8590530	Sep 15, 2025	DP U-1809			
		8875704	Apr 07, 2028	DP U-1809			
		8899229	Aug 18, 2030	DP			
		8978647	Dec 06, 2030	DP			
		9108015	Sep 15, 2025	DP			
		9119932	Apr 23, 2024	DP			
		9649456	Oct 21, 2030	DP U-1719			
		9649456	Oct 21, 2030	DP U-2010			
		9649456	Oct 21, 2030	DP U-2011			
SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH							
N 208223	001	10537554	Jan 29, 2036	U-72			
SUVOREXANT - BELSOMRA							
N 204569	001	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
		7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA							
N 204569	002	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
		7951797	Nov 20, 2029	DS DP U-620			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SUVOREXANT - BELSOMRA						
N 204569 003	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
	7951797	Nov 20, 2029	DS DP U-620			
SUVOREXANT - BELSOMRA						
N 204569 004	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
	7951797	Nov 20, 2029	DS DP U-620			
TACROLIMUS - PROGRAF						
N 050708 001					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050708 002					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050708 003					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF						
N 050709 001					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
TACROLIMUS - ASTAGRAF XL						
N 204096 001					ODE*	May 24, 2025
TACROLIMUS - ASTAGRAF XL						
N 204096 002					ODE*	May 24, 2025
TACROLIMUS - ASTAGRAF XL						
N 204096 003					ODE*	May 24, 2025
TACROLIMUS - ENVARSUS XR						
N 206406 001	10166190	May 30, 2028	DP		ODE-94	Jul 10, 2022
	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	10864199	May 30, 2028	U-2677			
	10864199	May 30, 2028	U-2678			
	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
	8685998	Aug 30, 2028	DP U-1752			
	8685998	Aug 30, 2028	DP U-2677			
	8685998	Aug 30, 2028	DP U-2678			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR						
N 206406 002	10166190	May 30, 2028	DP		ODE-94	Jul 10, 2022
	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	10864199	May 30, 2028	U-2677			
	10864199	May 30, 2028	U-2678			
	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP U-1752			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TACROLIMUS - ENVARSUS XR							
N 206406	002	8586084	Aug 30, 2024	U-1752			
		8591946	Aug 30, 2024	DP			
		8617599	Aug 30, 2024	DP			
		8623410	Aug 30, 2024	DP			
		8623411	Aug 30, 2024	U-1752			
		8664239	Aug 30, 2028	U-1752			
		8664239	Aug 30, 2028	U-2677			
		8664239	Aug 30, 2028	U-2678			
		8685998	Aug 30, 2028	DP U-1752			
		8685998	Aug 30, 2028	DP U-2677			
		8685998	Aug 30, 2028	DP U-2678			
		8889185	Aug 30, 2024	U-1752			
		8889186	Aug 30, 2024	U-1752			
		9161907	Aug 30, 2024	DP U-1752			
		9549918	May 30, 2028	DP			
		9757362	Aug 30, 2024	DP			
		9763920	Aug 30, 2024	DP			
TACROLIMUS - ENVARSUS XR							
N 206406	003	10166190	May 30, 2028	DP		ODE-94	Jul 10, 2022
		10548880	Aug 30, 2024	U-2677			
		10548880	Aug 30, 2024	U-2678			
		10864199	May 30, 2028	U-2677			
		10864199	May 30, 2028	U-2678			
		11110081	May 30, 2028	U-2678			
		11123331	May 30, 2028	U-2677			
		7994214	Aug 30, 2024	DP			
		8486993	Aug 30, 2024	DP U-1752			
		8586084	Aug 30, 2024	U-1752			
		8591946	Aug 30, 2024	DP			
		8617599	Aug 30, 2024	DP			
		8623410	Aug 30, 2024	DP			
		8623411	Aug 30, 2024	U-1752			
		8664239	Aug 30, 2028	U-1752			
		8664239	Aug 30, 2028	U-2677			
		8664239	Aug 30, 2028	U-2678			
		8685998	Aug 30, 2028	DP U-1752			
		8685998	Aug 30, 2028	DP U-2677			
		8685998	Aug 30, 2028	DP U-2678			
		8889185	Aug 30, 2024	U-1752			
		8889186	Aug 30, 2024	U-1752			
		9161907	Aug 30, 2024	DP U-1752			
		9549918	May 30, 2028	DP			
		9757362	Aug 30, 2024	DP			
		9763920	Aug 30, 2024	DP			
TACROLIMUS - PROGRAF							
N 210115	001					ODE-269	May 24, 2025
						ODE-360	Jul 16, 2028
TACROLIMUS - PROGRAF							
N 210115	002					ODE-269	May 24, 2025
						ODE-360	Jul 16, 2028
TAFAMIDIS - VYNDAMAX							
N 212161	001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
		7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
		9770441	Aug 31, 2035	DS DP U-2524			
TAFAMIDIS MEGLUMINE - VYNDAQEL							
N 211996	001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
		7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
		8168663	Dec 19, 2023	DS DP			
		8653119	Jan 28, 2024	U-2524			
TAFENOQUINE SUCCINATE - ARAKODA							
N 210607	001	10342791	Dec 02, 2035	U-2582		NCE	Jul 20, 2023
		10888558	Dec 02, 2035	U-2582			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAFENOQUINE SUCCINATE - KRINTAFEL						
N 210795 001					NCE	Jul 20, 2023
					ODE-201	Jul 20, 2025
TAFLUPROST - ZIOPTAN						
N 202514 001	10864159	May 28, 2029	DP U-778			
	5886035	Dec 18, 2022	DS DP U-778			
	9999593	May 28, 2029	DP			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 003	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALAZOPARIB TOSYLATE - TALZENNA						
N 211651 004	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
TALC - STERITALC						
N 205555 001					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
TALC - STERITALC						
N 205555 002					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
TALC - STERITALC						
N 205555 003					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 001	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 002	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA						
N 022304 003	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N 200533 001	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	001	8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	002	11007156	Oct 22, 2022	DP U-1178			
		11007156	Oct 22, 2022	DP U-1276			
		7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	003	11007156	Oct 22, 2022	DP U-1178			
		11007156	Oct 22, 2022	DP U-1276			
		7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	004	11007156	Oct 22, 2022	DP U-1178			
		11007156	Oct 22, 2022	DP U-1276			
		7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER							
N 200533	005	11007156	Oct 22, 2022	DP U-1178			
		11007156	Oct 22, 2022	DP U-1276			
		7994364	Jun 27, 2025	DS DP U-1178			
		7994364	Jun 27, 2025	DS DP U-1276			
		8075872	Nov 20, 2023	DP			
		8114383	Oct 10, 2024	DP	Y		
		8309060	Nov 20, 2023	DP U-1178			
		8309060	Nov 20, 2023	DP U-1276			
		8420056	Nov 20, 2023	DP			
		8536130	Sep 22, 2028	U-1276			
		RE39593	Aug 05, 2022	DS DP U-1178			
		RE39593	Aug 05, 2022	DS DP U-1276			
TAPENTADOL HYDROCHLORIDE - NUCYNTA							
N 203794	001	7994364	Jun 27, 2025	DS DP U-1289			
		RE39593	Aug 05, 2022	DS DP U-1289			
TASIMELTEON - HETLIOZ							
N 205677	001	10071977	Feb 12, 2035	DS DP		I-850	Dec 01, 2023
		10149829	Jan 25, 2033	U-2477		ODE-330	Dec 01, 2027
		10149829	Jan 25, 2033	U-3006			
		10179119	Aug 29, 2035	U-3003			
		10376487	Jul 27, 2035	U-2615			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TASIMELTEON - HETLIOZ						
N 205677 001	10376487	Jul 27, 2035	U-3007			
	10449176	Jan 25, 2033	U-2149			
	10610510	Jan 25, 2033	U-2805			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-2615			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
	11141400	Oct 10, 2034	U-2615			
	11141400	Oct 10, 2034	U-3007			
	5856529	Dec 09, 2022	DS DP U-2149			
	5856529	Dec 09, 2022	DS DP U-3003			
	9060995	Jan 25, 2033	U-1710			
	9539234	Jan 25, 2033	U-1934			
	9539234	Jan 25, 2033	U-3004			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
	9730910	May 17, 2034	U-3005			
	9855241	Jan 25, 2033	U-2149			
	RE46604	Jan 25, 2033	U-2147			
TASIMELTEON - HETLIOZ LQ						
N 214517 001	10071977	Feb 12, 2035	DS DP		NP	Dec 01, 2023
	10149829	Jan 25, 2033	U-3006		ODE-329	Dec 01, 2027
	10179119	Aug 29, 2035	U-3003			
	10376487	Jul 27, 2035	U-3007			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10980770	Jan 25, 2033	U-3106			
	11141400	Oct 10, 2034	U-3007			
	11202770	Dec 11, 2040	DP			
	5856529	Dec 09, 2022	DS DP U-3003			
	9539234	Jan 25, 2033	U-3004			
	9730910	May 17, 2034	U-3005			
TAZAROTENE - FABIOR						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
	10688071	Feb 24, 2030	DP U-2760			
	8808716	Feb 24, 2030	DP			
TAZAROTENE - ARAZLO						
N 211882 001					NP	Dec 18, 2022
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001	10155002	Apr 13, 2032	U-2736		I-835	Jun 18, 2023
	10245269	Apr 11, 2033	U-2737		I-836	Jun 18, 2023
	10245269	Apr 11, 2033	U-2851		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2854		ODE-299	Jan 23, 2027
	10369155	Oct 16, 2035	U-2736		ODE-314	Jun 18, 2027
	10369155	Oct 16, 2035	U-2852			
	10369155	Oct 16, 2035	U-2853			
	10420775	Apr 13, 2032	U-2736			
	10420775	Apr 13, 2032	U-2852			
	10420775	Apr 13, 2032	U-2853			
	10786511	Dec 19, 2035	DP			
	10821113	Apr 11, 2033	DS DP			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-3179			
	8410088	Apr 13, 2032	DS DP			
	8691507	Sep 12, 2031	U-2852			
	8765732	Apr 13, 2032	U-2852			
	8765732	Apr 13, 2032	U-2853			
	8895245	Sep 12, 2031	U-2852			
	9090562	Apr 13, 2032	DS DP			
	9175331	Sep 12, 2031	U-2852			
	9333217	Sep 12, 2031	U-2852			
	9334527	Sep 12, 2031	U-2852			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAZEMETOSTAT HYDROBROMIDE - TAZVERIK						
N 211723 001	9394283	Apr 11, 2033	DS DP U-2852			
	9394283	Apr 11, 2033	DS DP U-2853			
	9522152	Apr 13, 2032	U-2738			
	9549931	Apr 13, 2032	U-2736			
	9549931	Apr 13, 2032	U-2852			
	9549931	Apr 13, 2032	U-2853			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
	9889138	Oct 16, 2035	U-2852			
	9889138	Oct 16, 2035	U-2853			
	9949999	Sep 12, 2031	U-2851			
TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML						
N 020372 002	9549999	Mar 10, 2030	DP			
TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT						
N 202207 001	6409990	May 12, 2025	DS		NPP	May 19, 2024
	9439985	Sep 27, 2033	DS DP			
TECOVIRIMAT - TPOXX						
N 208627 001	7737168	May 03, 2027	U-2346		NCE	Jul 13, 2023
	8039504	Jul 23, 2027	DP		ODE-200	Jul 13, 2025
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-2346			
	9339466	Mar 23, 2031	DS DP			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205435 001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		NPP	Jun 19, 2023
	7816379	Jun 20, 2028	DS DP U-2507		GAIN	Jun 20, 2024
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
TEDIZOLID PHOSPHATE - SIVEXTRO						
N 205436 001	10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		NPP	Jun 19, 2023
	7816379	Jun 20, 2028	DS DP U-2507		GAIN	Jun 20, 2024
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT						
N 203441 001	7056886	Sep 18, 2022	DP U-1320		ODE-240	May 16, 2026
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TEDUGLUTIDE RECOMBINANT - GATTEX KIT							
N 203441	001	9968656	Nov 01, 2025	U-2308			
		9968656*PED	May 01, 2026				
		9968658	Nov 01, 2025	U-1320			
		9968658*PED	May 01, 2026				
		9974835	Nov 01, 2025	U-1320			
		9974835*PED	May 01, 2026				
		9974837	Nov 01, 2025	U-1320			
		9974837*PED	May 01, 2026				
		9981014	Nov 01, 2025	U-1320			
		9981014*PED	May 01, 2026				
		9981016	Nov 01, 2025	U-1320			
		9981016*PED	May 01, 2026				
		9987334	Nov 01, 2025	U-1320			
		9987334*PED	May 01, 2026				
		9987335	Nov 01, 2025	U-1320			
		9987335*PED	May 01, 2026				
		9993528	Nov 01, 2025	U-1320			
		9993528*PED	May 01, 2026				
TELAPREVIR - INCIVEK							
N 201917	001	7820671	Feb 25, 2025	DS DP			
		8431615	May 30, 2028	U-1398			
TELAVANCIN HYDROCHLORIDE - VIBATIV							
N 022110	001	6635618	Sep 11, 2023	DS DP U-728			
		6858584	Aug 24, 2022	DP			
		7531623	Jan 01, 2027	DS			
TELAVANCIN HYDROCHLORIDE - VIBATIV							
N 022110	002	6635618	Sep 11, 2023	DS DP U-728			
		6858584	Aug 24, 2022	DP			
		7531623	Jan 01, 2027	DS			
TELBIVUDINE - TYZEKA							
N 022011	001	7589079	Sep 11, 2023	DS DP U-999			
		7858594	Sep 11, 2023	DS DP U-999			
TELBIVUDINE - TYZEKA							
N 022154	001	7858594	Sep 11, 2023	DS DP U-999			
TELMISARTAN - MICARDIS							
N 020850	002	8003679	Oct 06, 2022	U-1176			
TELOTRISTAT ETIPRATE - XERMELO							
N 208794	001	7553840	Dec 11, 2027	DS		NCE	Feb 28, 2022
		7709493	Dec 11, 2027	DS U-1979		ODE-132	Feb 28, 2024
		7968559	Dec 11, 2027	U-1979			
		8193204	Feb 27, 2031	DS			
		8653094	Dec 19, 2028	U-1979			
TEMOZOLOMIDE - TEMODAR							
N 022277	001	6987108	Sep 08, 2023	DP			
		7786118	Feb 21, 2023	DP			
		8623868	Feb 21, 2023	DP			
TEMSIROLIMUS - TORISEL							
N 022088	001	8026276	Jan 20, 2026	DP			
		8299116	Jul 25, 2023	DP			
		8455539	Jul 25, 2023	DP			
		8455539*PED	Jan 25, 2024				
		8722700	Jul 25, 2023	DP			
		8722700*PED	Jan 25, 2024				
		8791097	May 10, 2032	U-1550			
		8791097	May 10, 2032	U-1551			
		8791097*PED	Nov 10, 2032				
TENAPANOR HYDROCHLORIDE - IBSRELA							
N 211801	001	8541448	Dec 30, 2029	DS DP		NCE	Sep 12, 2024
		8969377	Dec 30, 2029	DS DP			
		9006281	May 02, 2030	U-2626			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENAPANOR HYDROCHLORIDE - IBSRELA							
N 211801	001	9408840	Dec 30, 2029	U-2626			
TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY							
N 208464	001	7390791	Apr 17, 2025	DS DP		M-255	Feb 04, 2023
		7390791*PED	Oct 17, 2025			M-266	Aug 22, 2023
		7803788	Feb 02, 2022	U-999			
		8754065	Aug 15, 2032	DS DP U-999			
		8754065*PED	Feb 15, 2033				
		9296769	Aug 15, 2032	DS DP U-999			
		9296769*PED	Feb 15, 2033				
TEPOTINIB HYDROCHLORIDE - TEPMETKO							
N 214096	001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
		8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
		8658643	Jul 04, 2028	U-3077			
		8921357	May 30, 2028	DS DP			
		8927540	Jul 21, 2028	U-3078			
		9062029	Jul 04, 2028	DP			
		9284300	Apr 29, 2028	DP			
		9403799	Jul 04, 2028	U-3077			
TERIFLUNOMIDE - AUBAGIO							
N 202992	001	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
		6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
		8802735	Sep 14, 2030	DP			
		8802735*PED	Mar 14, 2031				
		9186346	Feb 04, 2034	U-1786			
		9186346*PED	Aug 04, 2034				
TERIFLUNOMIDE - AUBAGIO							
N 202992	002	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
		6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
		8802735	Sep 14, 2030	DP			
		8802735*PED	Mar 14, 2031				
		9186346	Feb 04, 2034	U-1786			
		9186346*PED	Aug 04, 2034				
TERIPARATIDE - FORTEO							
N 021318	001	7517334	Mar 25, 2025	DP			
TERIPARATIDE - FORTEO							
N 021318	002	7517334	Mar 25, 2025	DP			
TESTOSTERONE - TESTIM							
N 021454	001	7320968	Jan 18, 2025	U-843			
		7608605	Apr 21, 2023	U-1009			
		7608606	Apr 21, 2023	U-1009			
		7608607	Apr 21, 2023	U-1009			
		7608608	Apr 21, 2023	U-1009			
		7608609	Apr 21, 2023	U-1009			
		7608610	Apr 21, 2023	U-1009			
		7935690	Apr 21, 2023	U-1009			
		8063029	Apr 21, 2023	U-843			
		8178518	Apr 21, 2023	DP			
TESTOSTERONE - ANDROGEL							
N 022309	001	8466136	Oct 12, 2026	DP			
		8466137	Oct 12, 2026	U-1103			
		8466138	Oct 12, 2026	U-1103			
		8486925	Oct 12, 2026	DP			
		8729057	Oct 12, 2026	DP			
		8741881	Oct 12, 2026	U-1103			
		8754070	Oct 12, 2026	DP			
		8759329	Oct 12, 2026	DP			
TESTOSTERONE - ANDROGEL							
N 022309	002	8466136	Oct 12, 2026	DP			
		8466137	Oct 12, 2026	U-1103			
		8466138	Oct 12, 2026	U-1103			
		8486925	Oct 12, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE - ANDROGEL							
N 022309	002	8729057	Oct 12, 2026	DP			
		8741881	Oct 12, 2026	U-1103			
		8754070	Oct 12, 2026	DP			
		8759329	Oct 12, 2026	DP			
TESTOSTERONE - ANDROGEL							
N 022309	003	8466136	Oct 12, 2026	DP			
		8466137	Oct 12, 2026	U-1103			
		8466138	Oct 12, 2026	U-1103			
		8486925	Oct 12, 2026	DP			
		8729057	Oct 12, 2026	DP			
		8741881	Oct 12, 2026	U-1103			
		8754070	Oct 12, 2026	DP			
		8759329	Oct 12, 2026	DP			
TESTOSTERONE - AXIRON							
N 022504	001	8419307	Feb 26, 2027	U-1386			
		8435944	Sep 27, 2027	U-1390			
		8784878	Jul 13, 2023	DP U-1545			
		8807861	Feb 26, 2027	DP U-1563			
		8993520	Jun 02, 2026	U-1390			
		9180194	Jun 02, 2026	U-1390			
		9289586	Feb 26, 2027	U-1390			
TESTOSTERONE - VOGELXO							
N 204399	002	8785426	Feb 11, 2034	DP U-1531			
		9295675	Feb 11, 2034	DP U-1531			
		9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - VOGELXO							
N 204399	003	8785426	Feb 11, 2034	DP U-1531			
		9295675	Feb 11, 2034	DP U-1531			
		9662340	Feb 11, 2034	DP U-1531			
TESTOSTERONE - NATESTO							
N 205488	001	11090312	Mar 17, 2034	U-1616			
		8574622	Feb 04, 2024	DP			
		8784869	Feb 04, 2024	DP			
		8784882	Feb 04, 2024	DP U-1557			
		8877230	Feb 04, 2024	U-1616			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)							
N 209863	001	10238662	Feb 19, 2035	DP U-2418			
		10279131	Jul 31, 2031	DP			
		10357609	Aug 21, 2031	DP			
		10478560	Jan 24, 2026	DP			
		10646495	Aug 30, 2038	DP			
		10821072	Jun 04, 2033	DP U-2418			
		10881798	Feb 11, 2034	DP			
		10905827	Aug 21, 2031	DP			
		10912782	Feb 19, 2035	DP U-2418			
		11160751	Oct 07, 2034	DP U-2418			
		11191908	Oct 18, 2035	DP			
		8021335	Oct 04, 2026	DP			
		8562564	Jan 24, 2026	DP			
		9180259	Jan 24, 2026	DP			
		9533102	Jan 24, 2026	DP			
		9629959	Jan 24, 2026	DP			
		9744302	Nov 19, 2035	DP			
		9950125	Sep 04, 2036	DP U-2418			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)							
N 209863	002	10238662	Feb 19, 2035	DP U-2418			
		10279131	Jul 31, 2031	DP			
		10357609	Aug 21, 2031	DP			
		10478560	Jan 24, 2026	DP			
		10646495	Aug 30, 2038	DP			
		10821072	Jun 04, 2033	DP U-2418			
		10881798	Feb 11, 2034	DP			
		10905827	Aug 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 002	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)						
N 209863 003	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
TESTOSTERONE UNDECANOATE - AVEED						
N 022219 001	7718640	Mar 14, 2027	DP			
	8338395	May 08, 2027	U-1500			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 001	10543219	Apr 12, 2030	U-2506		NP	Mar 27, 2022
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 002	10543219	Apr 12, 2030	U-2506		NP	Mar 27, 2022
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
TESTOSTERONE UNDECANOATE - JATENZO						
N 206089 003	10543219	Apr 12, 2030	U-2506		NP	Mar 27, 2022
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
THALIDOMIDE - THALOMID						
N 020785 001	7230012	Dec 09, 2023	DP			
THALIDOMIDE - THALOMID						
N 020785 002	7230012	Dec 09, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N 020785 003	7230012	Dec 09, 2023	DP			
THIOTEPA - TEPADINA						
N 208264 001					ODE-129	Jan 26, 2024
THIOTEPA - TEPADINA						
N 208264 002					ODE-129	Jan 26, 2024
TICAGRELOR - BRILINTA						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	8425934	Apr 17, 2030	DP			
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
TICAGRELOR - BRILINTA						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	8425934	Apr 17, 2030	DP			
	RE46276	Oct 30, 2024	DS DP U-1935			
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
TIGECYCLINE - TYGACIL						
N 021821 001	10588975	Mar 13, 2026	DP			
	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	8975242	Oct 24, 2028	DP			
	9254328	Mar 13, 2026	DP			
	9694078	Mar 13, 2026	DP			
TIGECYCLINE - TIGECYCLINE						
N 211158 001	9855335	Apr 07, 2033	DP			
TIOPRONIN - THIOLA						
N 019569 001					ODE-267	Jun 28, 2026
TIOTROPIUM BROMIDE - SPIRIVA						
N 021395 001	6777423*PED	Mar 24, 2022				
	6908928*PED	Mar 24, 2022				
	7070800	Jan 22, 2022	DP U-566			
	7070800*PED	Jul 22, 2022				
	7309707*PED	Mar 24, 2022				
	7642268*PED	Mar 24, 2022				
	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
	RE38912*PED	Apr 11, 2022				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT						
N 021936 001	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	7988001*PED	Feb 04, 2022				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936	001	8733341	Oct 16, 2030	DP			
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP			
		9027967*PED	Oct 01, 2027				
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936	002	7284474	Aug 26, 2024	DP			
		7284474*PED	Feb 26, 2025				
		7396341	Oct 10, 2026	DP			
		7396341*PED	Apr 10, 2027				
		7837235	Mar 13, 2028	DP			
		7837235*PED	Sep 13, 2028				
		7896264	May 26, 2025	DP			
		7896264*PED	Nov 26, 2025				
		7988001*PED	Feb 04, 2022				
		8733341	Oct 16, 2030	DP			
		8733341*PED	Apr 16, 2031				
		9027967	Mar 31, 2027	DP			
		9027967*PED	Oct 01, 2027				
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	001	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
		10457666	Jun 17, 2034	DS DP		ODE-229	Feb 22, 2026
		10960004	Feb 03, 2037	U-2642			
		9527833	Jun 17, 2034	DS DP			
		RE46284	Sep 22, 2029	U-1751			
		RE46284	Sep 22, 2029	U-2503			
TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF							
N 207981	002	10456399	Feb 03, 2037	U-2642		I-794	Feb 22, 2022
		10457666	Jun 17, 2034	DS DP		ODE-229	Feb 22, 2026
		10960004	Feb 03, 2037	U-2642			
		9527833	Jun 17, 2034	DS DP			
		RE46284	Sep 22, 2029	U-1751			
		RE46284	Sep 22, 2029	U-2503			
TIRBANIBULIN - KLISYRI							
N 213189	001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
		10617693	Mar 12, 2038	U-3015			
		10669236	Sep 07, 2038	DS DP			
		7300931	Feb 06, 2026	DS DP			
		7851470	Feb 02, 2029	DS DP U-3015			
		8236799	Dec 28, 2025	DS DP			
		8980890	Dec 28, 2025	DS DP			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020912	001	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020912	002	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	001	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	002	6770660	May 01, 2023	U-1444			
TIROFIBAN HYDROCHLORIDE - AGGRASTAT							
N 020913	003	6770660	May 01, 2023	U-1444			
TIVOZANIB HYDROCHLORIDE - FOTIVDA							
N 212904	001	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
		7166722	Nov 16, 2023	DS			
TIVOZANIB HYDROCHLORIDE - FOTIVDA							
N 212904	002	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
		7166722	Nov 16, 2023	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOBRAMYCIN - TOBI PODHALER							
N 201688	001	10207066	Nov 04, 2030	DP U-909			
		7368102	Dec 19, 2022	DP U-909			
		7516741	Jan 11, 2024	DP			
		7559325	Oct 27, 2025	DP			
		8069851	Sep 24, 2024	DP			
		8664187	Jun 20, 2025	U-909			
		8715623	Dec 19, 2022	DP U-909			
		8869794	Sep 12, 2028	DP U-909			
		9421166	Dec 19, 2022	DP U-909			
		RE47526	Apr 09, 2024	DP			
TOBRAMYCIN - BETHKIS							
N 201820	001	6987094	Sep 22, 2022	DP			
		7696178	Sep 22, 2022	DP			
		7939502	Jun 14, 2022	U-1324			
TOFACITINIB CITRATE - XELJANZ							
N 203214	001	6965027	Mar 25, 2023	DS		NPP	Sep 25, 2023
		RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ							
N 203214	002	6965027	Mar 25, 2023	DS			
		RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ XR							
N 208246	001	6965027	Mar 25, 2023	DS			
		9937181	Mar 14, 2034	DP			
		RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ XR							
N 208246	002	10639309	Mar 14, 2034	DP			
		6965027	Mar 25, 2023	DS			
		RE41783	Dec 08, 2025	DS			
TOFACITINIB CITRATE - XELJANZ							
N 213082	001	RE41783	Dec 08, 2025	DS		NP	Sep 25, 2023
TOLVAPTAN - SAMSCA							
N 022275	001	10905694	Apr 07, 2030	DP			
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA							
N 022275	002	10905694	Apr 07, 2030	DP			
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - SAMSCA							
N 022275	003	10905694	Apr 07, 2030	DP			
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE							
N 204441	001	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE							
N 204441	002	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE							
N 204441	003	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE							
N 204441	004	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
		8501730	Sep 01, 2026	DS			
TOLVAPTAN - JYNARQUE							
N 204441	005	10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
		8501730	Sep 01, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - TROKENDI XR						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TROKENDI XR						
N 201635 004	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
TOPIRAMATE - QUDEXY XR						
N 205122 001	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 002	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 003	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 004	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR						
N 205122 005	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 001	8158645	Dec 10, 2024	DP			
TOPOTECAN HYDROCHLORIDE - HYCAMTIN						
N 020981 002	8158645	Dec 10, 2024	DP			
TORSEMIDE - SOAANZ						
N 213218 001	10154963	Oct 06, 2033	DP			
TORSEMIDE - SOAANZ						
N 213218 002	10154963	Oct 06, 2033	DP			
TRABECTEDIN - YONDELIS						
N 207953 001	8895557	Jan 07, 2028	DP		ODE-100	Oct 23, 2022
	8895557*PED	Jul 07, 2028			PED	Apr 23, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 001	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 002	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - RYZOLT						
N 021745 003	7988998	Oct 27, 2023	DP			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 001	7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 002	7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - CONZIP						
N 022370 003	7858118	Apr 11, 2022	DP U-1104			
TRAMADOL HYDROCHLORIDE - QDOLO						
N 214044 001	11103452	Sep 01, 2040	DP U-3197			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 001	10869869	Aug 30, 2033	U-3184		M-246	Oct 06, 2022
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	8580304	Jan 28, 2032	DP		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		ODE-183	May 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 002	10869869	Aug 30, 2033	U-3184		M-246	Oct 06, 2022
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	8580304	Jan 28, 2032	DP		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		ODE-183	May 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST						
N 204114 003	10869869	Aug 30, 2033	U-3184		M-246	Oct 06, 2022
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	8580304	Jan 28, 2032	DP		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		ODE-183	May 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8835443	Jun 10, 2025	U-1581			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST								
N 204114	003		8835443	Jun 10, 2025			U-1582	
			8835443	Jun 10, 2025			U-2020	
			8835443	Jun 10, 2025			U-2037	
			8835443	Jun 10, 2025			U-2302	
			8835443	Jun 10, 2025			U-2305	
			8952018	Oct 15, 2030			U-2020	
			9155706	Jan 28, 2032	DP			
			9271941	Jan 28, 2032	DP			
			9399021	Jan 28, 2032	DP			
TRANEXAMIC ACID - LYSTEDA								
N 022430	001		7947739	Mar 04, 2025	DP			
			8022106	Mar 04, 2025			U-1182	
			8273795	Mar 04, 2025			U-1182	
			8487005	Mar 04, 2025	DP		U-1182	
			8791160	Mar 04, 2025	DP		U-1182	
			8809394	Mar 04, 2025	DP		U-1182	
			8957113	Mar 04, 2025	DP		U-1182	
			9060939	Mar 04, 2025	DP			
TRAVOPROST - TRAVATAN Z								
N 021994	001		8268299	Oct 13, 2029	DP			
			8323630	Sep 20, 2027	DP			
			8388941	Sep 20, 2027	DP			
TRAVOPROST - IZBA								
N 204822	001		8178582	Oct 10, 2029	DP			
			8722735	Oct 10, 2029	DP			
			8754123	May 19, 2029	DP			
			9144561	Mar 13, 2029	DP			
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	001		8133893	Mar 13, 2029	DS	DP		
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	002		8133893	Mar 13, 2029	DS	DP		
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	003		8133893	Mar 13, 2029	DS	DP		
TRAZODONE HYDROCHLORIDE - DESYREL								
N 018207	004		8133893	Mar 13, 2029	DS	DP		
TRAZODONE HYDROCHLORIDE - OLEPTRO								
N 022411	001		7829120	Mar 27, 2027		DP	U-796	
			8133893	Mar 13, 2029	DS	DP		
TRAZODONE HYDROCHLORIDE - OLEPTRO								
N 022411	002		7829120	Mar 27, 2027		DP	U-796	
			8133893	Mar 13, 2029	DS	DP		
TREPROSTINIL - REMODULIN								
N 021272	001		10076505	Dec 16, 2024		DP		
			10695308	Dec 16, 2024			U-2845	
			7999007	Mar 29, 2029		DP	U-1437	
			8653137	Sep 05, 2028			U-1437	
			8658694	Sep 05, 2028			U-1437	
			9199908	May 24, 2024			U-1771	
			9593066	Dec 15, 2028	DS			
			9604901	Dec 15, 2028	DS			
			9713599	Dec 16, 2024			U-2036	
TREPROSTINIL - REMODULIN								
N 021272	002		10076505	Dec 16, 2024		DP		
			10695308	Dec 16, 2024			U-2845	
			7999007	Mar 29, 2029		DP	U-1437	
			8653137	Sep 05, 2028			U-1437	
			8658694	Sep 05, 2028			U-1437	
			9199908	May 24, 2024			U-1771	
			9593066	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL - REMODULIN						
N 021272 002	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 021272 003	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 021272 004	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 021272 005	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - TYVASO						
N 022387 001	10376525	May 14, 2027	U-1849		I-856	Mar 31, 2024
	10716793	May 14, 2027	U-1849			
	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL - REMODULIN						
N 208276 001	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 208276 002	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 208276 003	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
TREPROSTINIL - REMODULIN						
N 208276 004	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 002	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 003	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 005	7417070	Jul 30, 2026	DS		I-820	Oct 18, 2022
	7544713	Jul 14, 2024	U-1475		ODE-272	Oct 18, 2026
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM							
N 203496	005	9050311	May 24, 2024	DS DP			
		9278901	May 24, 2024	U-1475			
		9393203	Apr 27, 2026	DP U-1877			
		9422223	May 24, 2024	DP			
		9593066	Dec 15, 2028	DS			
		9604901	Dec 15, 2028	DS			
TRETINOIN - ALTRENO							
N 209353	001	10653656	Aug 22, 2038	DP U-2368			
TRIAMCINOLONE ACETONIDE - TRIESENCE							
N 022048	001	8128960	Dec 17, 2029	DP			
		8211880	Mar 10, 2029	U-1257			
		8211880	Mar 10, 2029	U-1258			
TRIAMCINOLONE ACETONIDE - ZILRETTA							
N 208845	001	8828440	Aug 04, 2031	DP			
		9555048	Aug 04, 2031	U-2151			
TRIAMCINOLONE ACETONIDE - XIPERE							
N 211950	001	8636713	May 02, 2027	U-3234		NP	Oct 22, 2024
		9636332	Nov 08, 2033	U-3234			
		9937075	May 02, 2034	DP			
TRICLABENDAZOLE - EGATEN							
N 208711	001					NCE	Feb 13, 2024
						ODE-228	Feb 13, 2026
TRIFAROTENE - AKLIEF							
N 211527	001	7807708	Oct 01, 2026	DS DP		NCE	Oct 04, 2024
		8227507	Dec 21, 2025	U-818			
		8470871	Dec 21, 2025	U-2639			
		9084778	May 30, 2033	DP U-134			
		9498465	May 30, 2033	DP U-1033			
TRIHEPTANOIN - DOJOLVI							
N 213687	001	8697748	Oct 03, 2025	DP		NCE	Jun 30, 2025
		9186344	Jul 01, 2025	DP		ODE-311	Jun 30, 2027
TRILACICLIB DIHYDROCHLORIDE - COSELA							
N 214200	001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
		10189849	Oct 25, 2031	DS			
		10189850	Oct 25, 2031	DP			
		10927120	Oct 25, 2031	DP			
		10966984	Mar 14, 2034	U-3079			
		10966984	Mar 14, 2034	U-3080			
		11040042	Mar 14, 2034	DP			
		8598186	Oct 25, 2031	DS DP			
		8598197	Oct 25, 2031	DS DP			
		9487530	Mar 14, 2034	U-3079			
		9487530	Mar 14, 2034	U-3080			
		9957276	Oct 25, 2031	DS			
TRIPTORELIN PAMOATE - TRELSTAR							
N 022437	001	10166181	Jun 30, 2029	DP			
TRIPTORELIN PAMOATE - TRIPTODUR KIT							
N 208956	001	10166181	Jun 30, 2029	DP		ODE-149	Jun 29, 2024
TUCATINIB - TUKYSA							
N 213411	001	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
		8648087	Apr 12, 2031	DS DP		ODE-309	Apr 17, 2027
		9457093	Oct 12, 2032	DP U-2788			
		9693989	May 09, 2027	DP U-2788			
TUCATINIB - TUKYSA							
N 213411	002	7452895	Nov 16, 2024	DS DP U-2788		NCE	Apr 17, 2025
		8648087	Apr 12, 2031	DS DP		ODE-309	Apr 17, 2027
		9457093	Oct 12, 2032	DP U-2788			
		9693989	May 09, 2027	DP U-2788			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UBROGEPANT - UBRELVY							
N 211765	001	10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
		8754096	Jul 19, 2032	DS DP U-2717			
		8912210	Nov 10, 2031	DS DP			
		9499545	Nov 10, 2031	DS DP U-2718			
		9833448	Nov 10, 2031	U-2718			
UBROGEPANT - UBRELVY							
N 211765	002	10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
		8754096	Jul 19, 2032	DS DP U-2717			
		8912210	Nov 10, 2031	DS DP			
		9499545	Nov 10, 2031	DS DP U-2718			
		9833448	Nov 10, 2031	U-2718			
ULIPRISTAL ACETATE - ELLA							
N 022474	001	10159681	Apr 13, 2030	U-2510			
		10772897	Apr 13, 2030	U-2958			
		8426392	Jun 12, 2030	U-1389			
		8512745	Jun 02, 2030	DP			
		8735380	Feb 20, 2029	DP			
		8962603	Jun 12, 2030	U-1657			
		9283233	Apr 13, 2030	U-1821			
		9844510	Dec 08, 2028	DP			
UMBRALISIB TOSYLATE - UKONIQ							
N 213176	001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
		10072013	Jul 02, 2033	U-3064		ODE-343	Feb 05, 2028
		10414773	May 26, 2035	DS DP U-3063		ODE-344	Feb 05, 2028
		10414773	May 26, 2035	DS DP U-3064			
		10570142	Jul 02, 2033	DS DP U-3063			
		10570142	Jul 02, 2033	DS DP U-3064			
		10947244	May 26, 2035	U-3063			
		10947244	May 26, 2035	U-3064			
		9150579	Jul 02, 2033	DS DP			
		9669033	Jul 02, 2033	U-3063			
		9669033	Jul 02, 2033	U-3064			
		9969740	May 26, 2035	DS DP U-3063			
		9969740	May 26, 2035	DS DP U-3064			
UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA							
N 205382	001	7488827	Dec 18, 2027	DS DP		M-245	Jun 09, 2022
		7498440	Apr 27, 2025	DS DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-1476			
		8201556	Feb 05, 2029	DP			
		8309572	Apr 27, 2025	U-1476			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA							
N 203975	001	11090294	Nov 29, 2030	U-3203		M-245	Jun 09, 2022
		7439393	May 21, 2025	DS DP U-1476			
		7488827	Dec 18, 2027	DS DP			
		7498440	Apr 27, 2025	DS DP			
		7776895	Sep 11, 2022	DP			
		8113199	Oct 23, 2027	DP			
		8161968	Feb 05, 2028	DP			
		8183257	Jul 27, 2025	U-1476			
		8309572	Apr 27, 2025	U-1476			
		8511304	Jun 14, 2027	DP U-1476			
		8534281	Mar 08, 2030	DP			
		8746242	Oct 11, 2030	DP			
		9333310	Oct 02, 2027	DP			
		9750726	Nov 29, 2030	DP			
		RE44874	Mar 23, 2023	DS DP U-1476			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
UPADACITINIB - RINVOQ						
N 211675 001	10519164	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10597400	Oct 17, 2036	U-3255			
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3255			
	9951080	Oct 17, 2036	DS DP			
	9963459	Oct 17, 2036	DP			
	RE47221	Dec 01, 2030	DS			
URIDINE TRIACETATE - VISTOGARD						
N 208159 001	6258795	Jul 10, 2023	DP		ODE-104	Dec 11, 2022
	7776838	Aug 17, 2027	U-1791			
URIDINE TRIACETATE - XURIDEN						
N 208169 001	6258795	Jul 10, 2023	DP		ODE-98	Sep 04, 2022
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 001	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027	U-1995			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 002	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027	U-1995			
VALBENAZINE TOSYLATE - INGREZZA						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VALBENAZINE TOSYLATE - INGREZZA							
N 209241	003	10857148	Oct 10, 2037	U-1995			
		10874648	Oct 10, 2037	U-1995			
		10874648	Oct 10, 2037	U-3046			
		10906902	Dec 22, 2036	DS DP			
		10906903	Dec 22, 2036	DS DP			
		10912771	Oct 10, 2037	U-1995			
		10912771	Oct 10, 2037	U-3076			
		10919892	Dec 22, 2036	DS DP			
		10940141	Aug 10, 2040	U-1995			
		10952997	Oct 10, 2037	U-1995			
		10993941	Oct 10, 2037	U-1995			
		11026931	Aug 14, 2039	U-1995			
		11026939	Sep 18, 2038	DP U-1995			
		11040029	Oct 10, 2037	U-1995			
		8039627	Oct 06, 2029	DS DP			
		8357697	Nov 08, 2027	U-1995			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE							
N 022257	001	8889109	Dec 11, 2027	DP			
		9642911	Dec 11, 2027	DP			
VALSARTAN - DIOVAN							
N 021283	001					NPP	Apr 19, 2024
VALSARTAN - DIOVAN							
N 021283	002					NPP	Apr 19, 2024
VALSARTAN - DIOVAN							
N 021283	004					NPP	Apr 19, 2024
VANCOMYCIN - VANCOMYCIN							
N 213895	001	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			
		11000567	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT							
N 208910	001	10493028	Mar 13, 2035	DP			
		10688046	Mar 13, 2035	DP			
		10959946	Mar 13, 2035	DP			
		10959947	Mar 13, 2035	DP U-3104			
		10959947	Mar 13, 2035	DP U-3105			
		10959948	Mar 13, 2035	DP U-3104			
		10959948	Mar 13, 2035	DP U-3105			
		10959949	Mar 13, 2035	DP U-3104			
		10959949	Mar 13, 2035	DP U-3105			
VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT							
N 208910	002	10493028	Mar 13, 2035	DP			
		10688046	Mar 13, 2035	DP			
		10959946	Mar 13, 2035	DP			
		10959947	Mar 13, 2035	DP U-3104			
		10959947	Mar 13, 2035	DP U-3105			
		10959948	Mar 13, 2035	DP U-3104			
		10959948	Mar 13, 2035	DP U-3105			
		10959949	Mar 13, 2035	DP U-3104			
		10959949	Mar 13, 2035	DP U-3105			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	001	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	002	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	003	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	004	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	005	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	006	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			
VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE							
N 211962	007	10039804	Nov 06, 2035	DP U-282			
		10188697	Nov 06, 2035	DP U-282			
		10849956	Nov 06, 2035	DP			
VANDETANIB - CAPRELSA							
N 022405	001	8067427	Aug 08, 2028	DP			
		8642608	Feb 06, 2022	U-1490			
		RE42353	Jun 27, 2022	DS DP			
VANDETANIB - CAPRELSA							
N 022405	002	8067427	Aug 08, 2028	DP			
		8642608	Feb 06, 2022	U-1490			
		RE42353	Jun 27, 2022	DS DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	001	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	002	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	003	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - LEVITRA							
N 021400	004	8273876	Jul 23, 2027	U-1288			
		8841446	Jul 03, 2023	DP			
VARDENAFIL HYDROCHLORIDE - STAXYN							
N 200179	001	8613950	Dec 23, 2028	DP			
VARENICLINE TARTRATE - CHANTIX							
N 021928	001	6890927	May 06, 2022	DS DP U-56		M-237	Feb 22, 2022
		6890927*PED	Nov 06, 2022			PED	Aug 22, 2022
		7265119	Aug 03, 2022	DS DP U-56			
		7265119*PED	Feb 03, 2023				
VARENICLINE TARTRATE - CHANTIX							
N 021928	002	6890927	May 06, 2022	DS DP U-56		M-237	Feb 22, 2022
		6890927*PED	Nov 06, 2022			PED	Aug 22, 2022
		7265119	Aug 03, 2022	DS DP U-56			
		7265119*PED	Feb 03, 2023				
VARENICLINE TARTRATE - TYRVAYA							
N 213978	001	10456396	Oct 19, 2035	DP U-1900		NP	Oct 15, 2024
		9504644	Oct 19, 2035	U-1900			
		9504645	Oct 19, 2035	DP			
		9532944	Oct 19, 2035	U-1900			
		9597284	Oct 19, 2035	U-1900			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VARENICLINE TARTRATE - TYRVAYA							
N 213978	001	10456396	Oct 19, 2035	DP U-1900		NP	Oct 15, 2024
		9504644	Oct 19, 2035	U-1900			
		9504645	Oct 19, 2035	DP			
		9532944	Oct 19, 2035	U-1900			
		9597284	Oct 19, 2035	U-1900			
VASOPRESSIN - VASOSTRICT							
N 204485	001	9375478	Jan 30, 2035	U-1857			
		9687526	Jan 30, 2035	U-1857			
		9744209	Jan 30, 2035	U-1857			
		9744239	Jan 30, 2035	U-1857			
		9750785	Jan 30, 2035	DP			
VASOPRESSIN - VASOSTRICT							
N 204485	002	9375478	Jan 30, 2035	U-1857			
		9687526	Jan 30, 2035	U-1857			
		9744209	Jan 30, 2035	U-1857			
		9744239	Jan 30, 2035	U-1857			
		9750785	Jan 30, 2035	DP			
		9937223	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT							
N 204485	003	10010575	Jan 30, 2035	U-1857			
		9919026	Jan 30, 2035	DP			
		9925233	Jan 30, 2035	U-1857			
		9925234	Jan 30, 2035	U-1857			
		9962422	Jan 30, 2035	U-1857			
		9968649	Jan 30, 2035	U-1857			
		9974827	Jan 30, 2035	U-1857			
		9981006	Jan 30, 2035	U-1857			
VASOPRESSIN - VASOSTRICT							
N 204485	004	10010575	Jan 30, 2035	U-1857			
		9919026	Jan 30, 2035	DP			
		9925233	Jan 30, 2035	U-1857			
		9925234	Jan 30, 2035	U-1857			
		9962422	Jan 30, 2035	U-1857			
		9968649	Jan 30, 2035	U-1857			
		9974827	Jan 30, 2035	U-1857			
		9981006	Jan 30, 2035	U-1857			
VEMURAFENIB - ZELBORAF							
N 202429	001	7504509	Oct 22, 2026	DS DP		ODE-158	Nov 06, 2024
		7863288	Jun 20, 2029	DS DP			
		8143271	Jun 21, 2026	DS DP			
		8470818	Aug 02, 2026	U-1418			
		8470818	Aug 02, 2026	U-2164			
		8741920	Jul 27, 2030	DS DP			
		9447089	Jun 06, 2032	DP			
VENETOCLAX - VENCLEXTA							
N 208573	001	10730873	Nov 21, 2031	DS		I-795	May 15, 2022
		10993942	Sep 06, 2033	U-3114		M-265	Oct 16, 2023
		11110087	Sep 06, 2033	U-3222		ODE-114	Apr 11, 2023
		11110087	Sep 06, 2033	U-3223		ODE-185	Jun 08, 2025
		8546399	Jun 27, 2031	DS DP		ODE-211	Nov 21, 2025
		8722657	Jan 29, 2032	DS		ODE-239	May 15, 2026
		9174982	May 26, 2030	U-2323			
		9174982	May 26, 2030	U-2445			
		9174982	May 26, 2030	U-2446			
		9174982	May 26, 2030	U-2537			
		9539251	Sep 06, 2033	U-2538			
VENETOCLAX - VENCLEXTA							
N 208573	002	10730873	Nov 21, 2031	DS		I-795	May 15, 2022
		10993942	Sep 06, 2033	U-3114		M-265	Oct 16, 2023
		11110087	Sep 06, 2033	U-3222		ODE-114	Apr 11, 2023
		11110087	Sep 06, 2033	U-3223		ODE-185	Jun 08, 2025
		8546399	Jun 27, 2031	DS DP		ODE-211	Nov 21, 2025
		8722657	Jan 29, 2032	DS		ODE-239	May 15, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VENETOCLAX - VENCLEXTA						
N 208573 002	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VENETOCLAX - VENCLEXTA						
N 208573 003	10730873	Nov 21, 2031	DS		I-795	May 15, 2022
	10993942	Sep 06, 2033	U-3114		M-265	Oct 16, 2023
	11110087	Sep 06, 2033	U-3222		ODE-114	Apr 11, 2023
	11110087	Sep 06, 2033	U-3223		ODE-185	Jun 08, 2025
	8546399	Jun 27, 2031	DS DP		ODE-211	Nov 21, 2025
	8722657	Jan 29, 2032	DS		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
VERICIGUAT - VERQUVO						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VERICIGUAT - VERQUVO						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
VIBEGRON - GEMTESA						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 002	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			
	8236804*PED	Dec 05, 2022				
	8673921	Jun 05, 2022	DS DP			
	8673921*PED	Dec 05, 2022				
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 003	7834020	Jun 05, 2022	DS DP U-839		M-254	Jan 31, 2023
	7834020*PED	Dec 05, 2022			PED	Jul 31, 2023
	8193195	Jun 05, 2022	U-839			
	8193195*PED	Dec 05, 2022				
	8236804	Jun 05, 2022	U-839			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VILAZODONE HYDROCHLORIDE - VIIBRYD							
N 022567	003	8236804*PED	Dec 05, 2022				
		8673921	Jun 05, 2022	DS DP			
		8673921*PED	Dec 05, 2022				
VILOXAZINE HYDROCHLORIDE - QELBREE							
N 211964	001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
		9603853	Feb 07, 2033	U-727			
		9662338	Feb 07, 2033	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE							
N 211964	002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
		9603853	Feb 07, 2033	U-727			
		9662338	Feb 07, 2033	DP			
VILOXAZINE HYDROCHLORIDE - QELBREE							
N 211964	003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
		9603853	Feb 07, 2033	U-727			
		9662338	Feb 07, 2033	DP			
VILTOLARSEN - VILTEPSO							
N 212154	001	10870676	Aug 31, 2031	DS DP U-3039		NCE	Aug 12, 2025
		9079934	Aug 31, 2031	DS DP		ODE-280	Aug 12, 2027
VISMODEGIB - ERIVEDGE							
N 203388	001	7888364	Nov 11, 2028	DS DP			
		9278961	Dec 15, 2028	U-1825			
		9790183	Sep 02, 2025	U-3109			
VOCLOSPORIN - LUPKYNIS							
N 213716	001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
		7332472	Oct 17, 2022	DS DP U-3056			
VORAPAXAR SULFATE - ZONTIVITY							
N 204886	001	7304078	Apr 06, 2024	DS DP U-1512			
		7713999	May 30, 2024	DS DP U-2291			
VORICONAZOLE - VFEND							
N 021266	001					NPP	Jan 29, 2022
VORICONAZOLE - VFEND							
N 021266	002					NPP	Jan 29, 2022
VORICONAZOLE - VFEND							
N 021267	001					NPP	Jan 29, 2022
VORICONAZOLE - VFEND							
N 021630	001					NPP	Jan 29, 2022
VORINOSTAT - ZOLINZA							
N 021991	001	7399787	Feb 09, 2025	U-892			
		7456219	Mar 11, 2027	DS			
		7652069	Mar 04, 2023	DP			
		7732490	Mar 04, 2023	U-892			
		7851509	Feb 21, 2024	DP U-892			
		8067472	Mar 04, 2023	U-892			
		8093295	May 16, 2026	DP			
		8101663	Mar 04, 2023	U-892			
		8450372	Mar 18, 2028	U-892			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX							
N 204447	001	7144884	Jun 17, 2026	DS DP U-1439		M-187	Jan 22, 2024
		8476279	Oct 02, 2022	DP U-1439		M-267	Nov 13, 2023
		8722684	Jun 30, 2031	DS DP			
		8969355	Jun 15, 2027	U-1668			
		9125908	Jun 15, 2027	U-2309			
		9125909	Jun 15, 2027	U-2309			
		9125910	Jun 15, 2027	U-2309			
		9227946	Jun 15, 2027	U-1668			
		9278096	Mar 21, 2032	U-2436			
		9861630	Jun 15, 2027	U-1668			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 002	7144884	Jun 17, 2026	DS DP U-1439		M-187	Jan 22, 2024
	8476279	Oct 02, 2022	DP U-1439		M-267	Nov 13, 2023
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9125908	Jun 15, 2027	U-2309			
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9227946	Jun 15, 2027	U-1668			
	9278096	Mar 21, 2032	U-2436			
	9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 003	7144884	Jun 17, 2026	DS DP U-1439		M-187	Jan 22, 2024
	8476279	Oct 02, 2022	DP U-1439		M-267	Nov 13, 2023
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9125908	Jun 15, 2027	U-2309			
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9227946	Jun 15, 2027	U-1668			
	9278096	Mar 21, 2032	U-2436			
	9861630	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - TRINTELLIX						
N 204447 004	7144884	Jun 17, 2026	DS DP U-1439		M-187	Jan 22, 2024
	8476279	Oct 02, 2022	DP U-1439		M-267	Nov 13, 2023
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9125908	Jun 15, 2027	U-2309			
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9227946	Jun 15, 2027	U-1668			
	9278096	Mar 21, 2032	U-2436			
	9861630	Jun 15, 2027	U-1668			
VOSORITIDE - VOXZOGO						
N 214938 001	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3256			
VOSORITIDE - VOXZOGO						
N 214938 002	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3256			
VOSORITIDE - VOXZOGO						
N 214938 003	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3256			
VOXELOTOR - OXBRYTA						
N 213137 001	10017491	Dec 28, 2032	DP		NCE	Nov 25, 2024
	10034879	Dec 28, 2032	DS DP		ODE-281	Nov 25, 2026
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
VOXELOTOR - OXBRYTA						
N 216157 001					NCE	Nov 25, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANUBRUTINIB - BRUKINSA						
N 213217 001	10570139	Apr 22, 2034	DS DP U-1745		I-871	Aug 31, 2024
	10570139	Apr 22, 2034	DS DP U-2145		I-874	Sep 14, 2024
	10570139	Apr 22, 2034	DS DP U-3063		NCE	Nov 14, 2024
	10927117	Aug 15, 2037	DS DP		ODE-276	Nov 14, 2026
	11142528	Apr 22, 2034	DS DP U-1745		ODE-370	Sep 14, 2028
	11142528	Apr 22, 2034	DS DP U-2145		ODE-371	Aug 31, 2028
	11142528	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-3063			
ZICONOTIDE ACETATE - PRIALT						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZICONOTIDE ACETATE - PRIALT						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
ZOLEDRONIC ACID - ZOMETA						
N 021223 002	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
	8324189	May 29, 2025	U-53			
ZOLEDRONIC ACID - ZOMETA						
N 021223 003	7932241	Feb 05, 2028	DP			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
	8324189	May 29, 2025	U-53			
ZOLEDRONIC ACID - RECLAST						
N 021817 001	7932241	Feb 05, 2028	DP			
	8052987	Oct 27, 2023	U-1199			
ZOLPIDEM TARTRATE - EDLUAR						
N 021997 001	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - EDLUAR						
N 021997 002	9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
ZOLPIDEM TARTRATE - ZOLPIMIST						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			
ZOLPIDEM TARTRATE - INTERMEZZO						
N 022328 001	7658945	Apr 15, 2027	DP U-1194			
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZOLPIDEM TARTRATE - INTERMEZZO							
N 022328	002	7658945	Apr 15, 2027	DP U-1194			
		7682628	Feb 16, 2025	U-1194			
		8242131	Aug 20, 2029	U-1266			
		8252809	Feb 16, 2025	DP			

PATENT AND EXCLUSIVITY TERMS

PATENT & EXCLUSIVITY ABBREVIATIONS

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
ODE*	FDA has not recognized Orphan-Drug Exclusivity (ODE) for this drug, but it contains the same active moiety or moieties as another drug(s) that was eligible for ODE, and also shares ODE-protected use(s) or indication(s) with that drug(s). An application seeking approval for the same active moiety or moieties, including an ANDA that cites this NDA as its basis of submission, may not be approved for such ODE-protected use(s) and indication(s)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL

EXCLUSIVITY DOSING SCHEDULE

D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING

EXCLUSIVITY DOSING SCHEDULE

D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

EXCLUSIVITY DOSING SCHEDULE

D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN
D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

EXCLUSIVITY DOSING SCHEDULE

D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.

EXCLUSIVITY DOSING SCHEDULE

D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
D-150	1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
D-151	DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
D-152	DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
D-153	IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
D-154	ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
D-155	SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-156	DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
D-157	UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
D-158	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
D-159	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
D-160	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
D-161	DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
D-162	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
D-163	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
D-164	UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
D-165	DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
D-166	BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
D-167	ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
D-168	NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
D-169	ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE

EXCLUSIVITY DOSING SCHEDULE

D-170	TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
D-171	REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY
D-172	ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
D-173	DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS
D-174	MODIFICATIONS TO THE EXISTING DOSING REGIMEN TO ALLOW FOR TREATMENT INTERRUPTIONS OF UP TO 8 WEEKS FOR INTOLERABLE ADVERSE REACTIONS
D-175	EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
D-176	IBRUTINIB IN COMBINATION WITH RITUXIMAB
D-177	INFORMATION ADDED TO THE DOSING SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
D-181	DOSING REGIMEN EXTENDING THE CONTRACEPTION USE FROM 5 YEARS TO UP TO 6 YEARS
D-182	NEW DOSING REGIMEN FOR THE PREVENTION AND MANAGEMENT OF NERATINIBASSOCIATED DIARRHEA

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER

	EXCLUSIVITY INDICATION
	CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS

	EXCLUSIVITY INDICATION
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION
I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT

	EXCLUSIVITY INDICATION
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER

EXCLUSIVITY INDICATION

I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE
I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS

EXCLUSIVITY INDICATION

I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE
I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES

EXCLUSIVITY INDICATION

I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS
I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER

EXCLUSIVITY INDICATION

FAILURE OF PRIOR CHEMOTHERAPY

I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY

I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY

I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER

I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS

I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS

I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER

I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS

I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS

I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER

I-245 TREATMENT OF ACUTE SINUSITIS

I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM

I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

EXCLUSIVITY INDICATION

I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS
I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL

EXCLUSIVITY INDICATION

I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS

EXCLUSIVITY INDICATION

I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME
I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME

EXCLUSIVITY INDICATION

I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN

EXCLUSIVITY INDICATION

PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION

I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE

I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

I-389 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS

I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....

I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY

I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL

I-393 CHRONIC BACTERIAL PROSTATITIS

I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES

I-395 TO IMPROVE PHYSICAL FUNCTION

I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION

I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY

I-398 IDIOPATHIC SHORT STATURE

I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS

I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-401 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA

I-402 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS

I-403 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE

I-404 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY

I-405 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN

I-406 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)

I-407 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION

I-408 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)

I-409 ESOPHAGEAL CANDIDIASIS

I-410 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS

I-411 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS

I-412 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-413 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

EXCLUSIVITY INDICATION

I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA
I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON

	EXCLUSIVITY INDICATION
	IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
I-444	USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS
I-445	TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
I-446	EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
I-447	USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
I-448	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
I-449	TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
I-450	TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
I-451	MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
I-452	EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
I-457	TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
I-458	USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
I-459	NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
I-460	TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER
I-461	USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
I-462	LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
I-463	TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
I-464	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
I-465	PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
I-466	FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS

EXCLUSIVITY INDICATION

I-467	USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
I-468	USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
I-469	RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
I-470	DIABETIC PERIPHERAL NEUROPATHIC PAIN
I-471	INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
I-472	USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
I-473	USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
I-474	TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
I-475	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
I-476	TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
I-477	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
I-478	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
I-479	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
I-480	PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
I-481	INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-482	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
I-483	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-484	FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
I-485	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-486	ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
I-487	INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
I-488	MAINTENANCE THERAPY IN BIPOLAR I DISORDER
I-489	FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
I-490	FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE
I-491	INFLUENZA PROPHYLAXIS
I-492	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493	ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
I-494	CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495	ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY

EXCLUSIVITY INDICATION

I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES

I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER

I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY

I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.

I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY

I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME

I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES

I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-508 PREMENSTRUAL DYSPHONIC DISORDER

I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

I-510 ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)

I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)

I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY

I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)

I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)

I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY

I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)

I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED

I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL

I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY

I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.

I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE

I-524 GENERALIZED ANXIETY DISORDER (GAD)

	EXCLUSIVITY INDICATION
I-525	USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
I-526	TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
I-527	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-528	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-529	TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
I-530	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
I-531	MAINTENANCE TREATMENT OF SCHIZOPHRENIA
I-532	TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
I-533	ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
I-534	EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
I-535	MANAGEMENT OF FIBROMYALGIA
I-536	FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
I-537	LONG TERM TREATMENT OF PANIC DISORDER
I-538	SHORT TERM TREATMENT OF PANIC DISORDER
I-539	REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
I-540	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
I-541	TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
I-542	EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
I-543	USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-544	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-545	ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
I-546	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
I-547	ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
I-548	SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
I-549	USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-550	TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
I-551	TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME
I-552	ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
I-553	FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-554	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
I-555	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
I-556	PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
I-557	USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL

	EXCLUSIVITY INDICATION
	SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
I-558	MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-559	ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION

EXCLUSIVITY INDICATION

I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
I-612	MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
I-613	MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
I-614	SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
I-615	MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-616	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
I-617	MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
I-618	ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
I-619	INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY

	EXCLUSIVITY INDICATION
I-620	FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
I-621	PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
I-622	ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
I-623	TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
I-624	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
I-625	PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
I-626	RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-627	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
I-628	MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
I-629	ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-630	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
I-638	FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
I-639	TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
I-640	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-641	TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-642	TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-643	REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
I-644	MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
I-645	MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
I-646	SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
I-647	SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
I-648	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
I-649	TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY

	EXCLUSIVITY INDICATION
I-650	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
I-651	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
I-652	MANAGEMENT OF POSTHERPETIC NEURALGIA
I-653	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
I-654	MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
I-655	TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
I-656	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
I-657	PLAQUE PSORIASIS OF THE SCALP
I-658	FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
I-659	PLAQUE PSORIASIS OF THE BODY
I-660	TREATMENT OF DEEP VEIN THROMBOSIS
I-661	TREATMENT OF PULMONARY EMBOLISM
I-662	REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
I-663	IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-664	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
I-665	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
I-666	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
I-667	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
I-668	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
I-669	SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
I-670	TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
I-671	FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-672	USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
I-673	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
I-674	TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
I-675	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-676	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE

EXCLUSIVITY INDICATION

I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT

I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT

I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS

I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED

I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS

I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE

I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY

I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY

I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE

I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION

I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY

I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.

I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY

I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA

I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION

I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)

I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL

I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA

I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)

I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN

I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE

EXCLUSIVITY INDICATION

I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.

I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.

I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY

I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE

I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION

I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.

I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY

I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY

I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.

I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.

I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.

I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.

I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY

I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE

I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.

I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION

I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL

I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS

I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY

I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS

	EXCLUSIVITY INDICATION
	(INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
I-732	TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
I-733	USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
I-734	EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
I-735	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
I-736	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
I-737	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
I-738	REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
I-739	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-740	EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE
I-741	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
I-742	TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA
I-743	INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665
I-744	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
I-745	MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
I-746	NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
I-747	FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
I-748	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER
I-749	MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
I-750	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-751	TREATMENT OF TARDIVE DYSKINESIA
I-752	CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
I-753	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
I-754	TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME
I-755	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
I-756	EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB

EXCLUSIVITY INDICATION

I-757	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
I-758	FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV
I-759	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)
I-760	FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
I-761	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
I-762	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
I-763	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-764	TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
I-765	ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
I-766	TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR
I-767	TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON
I-768	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
I-769	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
I-770	TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
I-771	REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
I-772	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
I-773	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
I-774	TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST
I-775	REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS
I-776	FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY
I-777	CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
I-778	DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

EXCLUSIVITY INDICATION

I-779	USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
I-780	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
I-781	DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
I-782	REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-783	EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
I-784	RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
I-785	TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
I-786	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-787	FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
I-788	NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
I-789	VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-790	USE OF FERRIC CITRATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH CKD NOT ON DIALYSIS
I-791	TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
I-792	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
I-793	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
I-794	TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
I-795	VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
I-796	USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
I-797	USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
I-798	TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)
I-799	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
I-800	TREATMENT OF OCULAR INFLAMMATION FOLLOWING OPHTHALMIC SURGERY
I-801	USE IN CARDIAC MRI TO ASSESS MYOCARDIAL PERFUSION (STRESS, REST) AND LATE GADOLINIUM ENHANCEMENT IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE (CAD)
I-802	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

EXCLUSIVITY INDICATION

I-803	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
I-804	EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-805	SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
I-806	EXPANDED INDICATION FOR PTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HX OF TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W RESISTANCE TO DORAVIRINE, LAMIVUDINE OR TENOFOVIR DISOPROXIL FUMARATE
I-807	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
I-808	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
I-809	TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY
I-810	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
I-811	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND ARE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS
I-812	FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX
I-813	TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
I-814	TX OF ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY DEFINED BY POSITIVE STATUS GENOMIC INSTABILITY & WHO HAVE PROGRESSED >6MO AFTER RESPONSE TO LAST PLATINUM-BASED CHEMO
I-815	TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
I-816	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-817	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
I-818	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
I-819	ADJUNCT TO MAX TOLERATED STATIN TX TO REDUCE RISK OF MI, STROKE, CORONARY REVASCULARIZATION, & UNSTABLE ANGINA REQUIRING HOSPITALIZATION IN ADULTS W/ ELEVATED TG LEVELS & ESTABLISHED CV DISEASE OR DIABETES MELLITUS & 2+ RISK FACTORS FOR CV DISEASE
I-820	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
I-821	TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
I-822	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-823	USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
I-824	RIVAROXABAN IN COMBINATION WITH ASPIRIN, IS INDICATED TO REDUCE THE RISK OF

	EXCLUSIVITY INDICATION
	MAJOR CV EVENTS (CV DEATH, MI, AND STROKE) IN PATIENTS WITH CHRONIC CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD)
I-825	TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
I-826	ENCORAFENIB, IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
I-827	EXPANDED INDICATION FOR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
I-828	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
I-829	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY (CPP)
I-830	TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
I-831	W/BEVACIZUMAB FOR MAINTENANCE TX OF ADULTS W/ADV. EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMO & CA ASSOCIATED W/ HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE STATUS
I-832	TX OF ADULT PTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
I-833	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
I-834	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION
I-835	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
I-836	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
I-837	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
I-838	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) OF THE FEET
I-839	TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
I-840	TREATMENT OF SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD) WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR.
I-841	TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
I-842	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE
I-843	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
I-844	INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS
I-845	TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED

EXCLUSIVITY INDICATION

	TEST
I-846	TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
I-847	EXPANDED INDICATION OF THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST
I-848	REDUCE THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (NIH STROKE SCALE SCORE <=5) OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK (TIA)
I-849	CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS
I-850	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
I-851	TO REDUCE THE RISK OF A FIRST MYOCARDIAL INFARCTION (MI) OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) AT HIGH RISK FOR SUCH EVENTS
I-852	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE
I-853	INDICATION OF OSIMERTINIB AS ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
I-854	FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, AS A FIRST-LINE TREATMENT IN COMBINATION WITH NIVOLUMAB
I-855	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE
I-856	INDICATION FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE TO IMPROVE EXERCISE ABILITY
I-857	TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
I-858	FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
I-859	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
I-860	FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS
I-861	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG
I-862	TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR AT LEAST 5 DAYS AND TO REDUCE THE RISK OF RECURRENCE OF VTE IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN PREVIOUSLY TREATED
I-863	TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) AND SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN)
I-864	TREATMENT OF ADULT PATIENTS WITH MAST CELL LEUKEMIA (MCL)
I-865	FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
I-866	FOR THE TREATMENT OF TRICHOMONIASIS CAUSED BY TRICHOMONAS VAGINALIS IN ADULTS
I-867	INDICATED TO REDUCE THE RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD, INCLUDING PATIENTS WHO HAVE RECENTLY UNDERGONE A LOWER EXTREMITY REVASCULARIZATION PROCEDURE DUE TO SYMPTOMATIC PAD
I-868	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
I-869	REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
I-870	INDICATED FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS
I-871	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM)

EXCLUSIVITY INDICATION

I-872	ADDITION OF THE INDICATION OF TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
I-873	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
I-874	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
I-875	FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST
I-876	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
I-877	INDICATION FOR THE USE OF ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, NODE-POSITIVE, EARLY CANCER (EBC) AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE>20% AS DETERMINED BY AN FDA APPROVED TEST
I-878	ADDITION OF A NEW INDICATION FOR ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
I-879	TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS, TO THE PRESCRIBING INFORMATION
I-880	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER
M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

EXCLUSIVITY MISCELLANEOUS

M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
M-36	ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
M-37	INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
M-38	SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
M-39	FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
M-40	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
M-41	REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
M-42	ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
M-43	INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"

EXCLUSIVITY MISCELLANEOUS

M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18

M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"

M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY

M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS

M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES

M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN

M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION

M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY

M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT

M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL

M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.

M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL

M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS

M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS

M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS

M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA

M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST

M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES

M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY

M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS

M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)

M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER

M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS

M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL

M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY

M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY

M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

EXCLUSIVITY MISCELLANEOUS

M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS

M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS

M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS

M-75 PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)

M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA

M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS

M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY

M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE

M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)

M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES

M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL

M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY

M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD

M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION

M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION

M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE

M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM

M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12

M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS

M-92 UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"

M-93 EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS

M-94 INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE

M-95 INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108

M-96 UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE

EXCLUSIVITY MISCELLANEOUS

	USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99	ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100	INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101	INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
M-102	INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
M-103	SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
M-104	INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
M-105	NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
M-106	ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
M-107	INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
M-108	CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
M-109	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-110	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-111	LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
M-112	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
M-113	LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
M-114	CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
M-115	REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
M-116	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
M-117	ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
M-118	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36
M-119	LABELING CHANGES REGARDING MISSED DOSES
M-120	CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
M-121	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
M-122	LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
M-123	UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
M-124	LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS

EXCLUSIVITY MISCELLANEOUS

	PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
M-125	LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
M-126	UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
M-127	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
M-128	CLINICAL TRIAL STUDY RESULTS
M-129	RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
M-130	ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
M-131	INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
M-132	REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
M-133	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
M-134	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
M-135	ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
M-136	ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS
M-137	LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
M-138	INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
M-139	INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
M-140	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
M-141	REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
M-142	ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
M-143	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
M-144	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
M-145	ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
M-146	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
M-147	OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES
M-148	LABELING CHANGES BASED ON STUDY H80-EW-GWDM
M-149	INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
M-150	ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
M-151	REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF

EXCLUSIVITY MISCELLANEOUS

	AGE
M-152	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
M-153	ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
M-154	UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
M-155	ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
M-156	UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
M-157	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
M-158	UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
M-159	ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
M-160	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
M-161	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
M-162	INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
M-163	INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
M-164	REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
M-165	PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"
M-166	UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS
M-167	APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".
M-168	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)
M-169	UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.
M-170	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
M-171	UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL
M-172	UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS

EXCLUSIVITY MISCELLANEOUS

M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS

M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN

M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES

M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT

M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE

M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS

M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS

M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA

M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"

M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM

M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES

M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS

M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232

M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING

M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)

M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES

M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS

M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2

M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS

M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA

M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE

M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17

M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO

EXCLUSIVITY MISCELLANEOUS

	CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1
M-197	NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
M-198	PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
M-199	INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.
M-200	CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.
M-201	REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.
M-202	INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.
M-203	PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569
M-204	CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
M-205	INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT
M-206	INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY
M-207	INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY
M-208	INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
M-209	INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY
M-210	INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
M-211	PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE
M-212	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE
M-213	INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
M-214	INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS
M-215	INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED
M-216	UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER
M-217	INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING

EXCLUSIVITY MISCELLANEOUS

M-218 ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)

M-219 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY

M-220 ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY

M-221 DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING

M-222 ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1

M-223 INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)

M-224 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN

M-225 REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES >=6 YEARS TO <18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION

M-226 CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY

M-227 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER

M-228 INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX

M-229 REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY

M-230 REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596

M-231 REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCYCLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3

M-232 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES

M-233 INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS

M-234 UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS

M-235 INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1

M-236 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB

M-237 INFORMATION ADDED TO LABELING TO DESCRIBE A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN ADOLESCENT SMOKERS

M-238 INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT

M-239 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD

M-240 INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES

EXCLUSIVITY MISCELLANEOUS

M-241 INFORMATION ADDED TO THE LABELING FOR SAFETY & EFFICACY STUDY ENTITLED, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) & TRANSFUSIONAL IRON OVERLOAD

M-242 INFORMATION ADDED TO THE LABELING REGARDING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE VS INSULIN GLARGINE IN PTS W/ TYPE 2 DIABETES INADEQUATELY CONTROLLED ON SGLT2I WITH OR WITHOUT ORAL ANTIDIABETIC THERAPIES

M-243 INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER

M-244 INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS

M-245 ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIAL

M-246 ADDITION OF STUDY BRF117277, A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, MULTI-COHORT TRIAL OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN

M-247 REVISIONS TO THE LABELING REGARDING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AS A CONDITION OF USE FOR INSULIN ASPART

M-248 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE

M-249 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY LVM-MD-15 TO FULFILL POSTMARKETING COMMITMENT 1943-4

M-250 REVISIONS TO THE PEDIATRIC USE SECTION TO INCLUDE AN OPEN-LABEL CLINICAL TRIAL TO FULFILL PMR 1655-1

M-251 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS

M-252 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME

M-253 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE

M-254 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER

M-255 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4018 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE

M-256 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT

M-257 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP

M-258 INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4

M-259 INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION

M-260 INFORMATION ADDED TO THE LABELING DESCRIBING A RANDOMIZED, OPEN-LABEL STUDY THAT EXAMINED THE CONCOMITANT USE OF DIMETHYL FUMARATE AND SEVERAL NON-LIVE VACCINES IN ADULTS 27-55 YEARS OF AGE WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

M-261 ADDITIONAL INFORMATION ADDED TO THE LABELING REGARDING THE USE IN PATIENTS ON CHRONIC HEMODIALYSIS

M-262 REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4

M-263 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3

M-264 INFORMATION ADDED TO THE LABELING DESCRIBING A PHASE 2, MULTICENTER, OPEN-LABEL

EXCLUSIVITY MISCELLANEOUS

STUDY TO EVALUATE THE SAFETY/EFFICACY OF SOFOSBUVIR/VELPATASVIR IN SUBJECTS WITH CHRONIC HCV INFECTION WHO HAVE RECEIVED A LIVER TRANSPLANT

M-265 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2

M-266 INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4035 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALFAENAMIDE

M-267 INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402

M-268 ADDITION OF INFORMATION TO THE LABEL REGARDING A CLEAR PRODUCT PRESENTATION AND 26 ML VOLUME PRODUCTS

M-269 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1

M-270 INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION

ORPHAN DRUG EXCLUSIVITY

ODE-1 TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)

ODE-2 FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

ODE-3 TO TREAT INFANTILE SPASMS

ODE-4 TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION

ODE-5 FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING

ODE-6 FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA

ODE-7 TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH

ODE-8 TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY

ODE-9 TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE

ODE-10 FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER

ODE-11 TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE

ODE-12 TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

ODE-13 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST

ODE-14 TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER

ODE-15 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST

ODE-16 TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE

ODE-17 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER

ODE-18 ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER

ODE-19 TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

ODE-20 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.

ORPHAN DRUG EXCLUSIVITY

ODE-21	AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
ODE-22	FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
ODE-23	ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
ODE-24	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
ODE-25	MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
ODE-26	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
ODE-27	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
ODE-28	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
ODE-29	LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
ODE-30	TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY
ODE-31	TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
ODE-32	TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
ODE-33	TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
ODE-34	TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-35	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
ODE-36	ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
ODE-37	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-38	PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
ODE-39	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
ODE-40	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
ODE-41	ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
ODE-42	USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-43	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
ODE-44	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
ODE-45	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND

ORPHAN DRUG EXCLUSIVITY

	OLDER.
ODE-46	IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
ODE-47	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
ODE-48	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
ODE-49	TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
ODE-50	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
ODE-51	TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
ODE-52	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
ODE-53	TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.
ODE-54	TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENED PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
ODE-55	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-56	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT.
ODE-57	TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-58	DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-59	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
ODE-60	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-61	TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
ODE-62	TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
ODE-63	TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
ODE-64	SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
ODE-65	TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
ODE-66	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
ODE-67	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
ODE-68	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

ORPHAN DRUG EXCLUSIVITY

ODE-69	TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
ODE-70	RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
ODE-71	RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-72	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-73	LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
ODE-74	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
ODE-75	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
ODE-76	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
ODE-77	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
ODE-78	TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.
ODE-79	TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
ODE-80	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
ODE-81	TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
ODE-82	TREATMENT OF PATIENTS WITH UNRESECTABLE,WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
ODE-83	USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-84	TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
ODE-85	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
ODE-86	TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
ODE-87	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
ODE-88	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
ODE-89	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
ODE-90	TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
ODE-91	TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
ODE-92	TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
ODE-93	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
ODE-94	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-95	FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

ORPHAN DRUG EXCLUSIVITY

ODE-96	TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS
ODE-97	TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
ODE-98	TREATMENT OF HEREDITARY OROTIC ACIDURIA
ODE-99	FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
ODE-100	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-101	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
ODE-102	FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
ODE-103	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-104	EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.
ODE-105	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-106	FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
ODE-107	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLNE-CONTAINING REGIMEN
ODE-108	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-109	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
ODE-110	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
ODE-111	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
ODE-112	FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
ODE-113	FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
ODE-114	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-115	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-116	TREATMENT OF PROGRESSIVE KERATOCONUS
ODE-117	FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-118	AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
ODE-119	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA

ORPHAN DRUG EXCLUSIVITY

ODE-120	FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
ODE-121	TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
ODE-122	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
ODE-123	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-124	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
ODE-125	INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
ODE-126	AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
ODE-127	TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
ODE-128	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
ODE-129	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
ODE-130	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
ODE-131	TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
ODE-132	TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
ODE-133	INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-134	TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-135	TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-136	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-137	TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
ODE-138	TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEOMOTHERAPY MAINTENANCE REGIMEN
ODE-139	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
ODE-140	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
ODE-141	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
ODE-142	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-143	TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS

ORPHAN DRUG EXCLUSIVITY

ODE-144	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ODE-145	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
ODE-146	OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
ODE-147	DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-148	TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-149	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
ODE-150	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
ODE-151	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-152	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
ODE-153	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
ODE-154	FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
ODE-155	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-156	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
ODE-157	FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS >=2 MONTHS AND < 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-158	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
ODE-159	FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-160	FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
ODE-161	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
ODE-162	TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE
ODE-163	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
ODE-164	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
ODE-165	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
ODE-166	TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
ODE-167	ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
ODE-168	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR

ORPHAN DRUG EXCLUSIVITY

	PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-169	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
ODE-170	FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
ODE-171	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
ODE-172	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
ODE-173	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-174	FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-175	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-176	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-177	TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
ODE-178	INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
ODE-179	TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
ODE-180	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-181	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-182	TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
ODE-183	TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
ODE-184	INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
ODE-185	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-186	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
ODE-187	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
ODE-188	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
ODE-189	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T

ORPHAN DRUG EXCLUSIVITY

ODE-190	TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
ODE-191	TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
ODE-192	INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
ODE-193	INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
ODE-194	ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-195	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-196	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
ODE-197	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-198	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM
ODE-199	THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-200	INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
ODE-201	INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
ODE-202	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
ODE-203	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-204	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
ODE-205	INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
ODE-206	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-207	TREATMENT OF STATUS EPILEPTICUS IN ADULTS
ODE-208	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
ODE-209	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-210	INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
ODE-211	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-212	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS

ORPHAN DRUG EXCLUSIVITY

ODE-213 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

ODE-214 TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY

ODE-215 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION

ODE-216 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER

ODE-217 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DIESASE

ODE-218 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE

ODE-219 INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE

ODE-220 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY

ODE-221 INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT

ODE-222 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST

ODE-223 INDICATED FOR THE TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN ADULTS

ODE-224 INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >=75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

ODE-225 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY

ODE-226 MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY

ODE-227 INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

ODE-228 INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER

ODE-229 TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY

ODE-230 FIRST-LINE TREATMENT OF METASTATIC NONSMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

ODE-231 INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY

ODE-232 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)

ODE-233 TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN

ORPHAN DRUG EXCLUSIVITY

	CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-234	INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
ODE-235	INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
ODE-236	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-237	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
ODE-238	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-239	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-240	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-241	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
ODE-242	TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO ARE >=75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-243	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
ODE-244	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE
ODE-245	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
ODE-246	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-247	TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
ODE-248	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
ODE-249	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGE 6 YEARS TO LESS THAN 12 YEARS WHO ARE HOMOZYGOUS FOR F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR GENE THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-250	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
ODE-251	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
ODE-252	TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
ODE-253	INDICATED AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT (XDR) OR TREATMENT-INTOLERANT OR NONRESPONSIVE MULTIDRUG-RESISTANT (MDR) TUBERCULOSIS (TB)
ODE-254	INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
ODE-255	INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY

ORPHAN DRUG EXCLUSIVITY

ODE-256	FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
ODE-257	IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
ODE-258	FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-259	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
ODE-260	INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
ODE-261	INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
ODE-262	TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-263	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-264	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-265	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ROS1-POSITIVE
ODE-266	ADULT & PED >=12YRS OLD W/ SOLID TUMORS THAT HAVE NTRK W/O KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY & HAVE EITHER PROGRESSED FOLLOWING TX OR HAVE NO SATISFACTORY ALTERNATIVE TX
ODE-267	INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE
ODE-268	INDICATED FOR TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-269	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-270	INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
ODE-271	INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
ODE-272	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
ODE-273	INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
ODE-274	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-275	INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
ODE-276	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-277	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED

ORPHAN DRUG EXCLUSIVITY

	BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
ODE-278	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY GENOMIC INSTABILITY & PROGRESSED >6 MONTHS AFTER RESPONSE TO THE LAST PLATINUM-BASED CHEMOTHERAPY
ODE-279	INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER
ODE-280	INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
ODE-281	INDICATED FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-282	INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)
ODE-283	MAINTENANCE TX OF ADULTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DZ HAS NOT PROGRESSED ON >=16WKS OF 1ST LINE PLATINUM BASED CHEMO REGIMEN. SELECT PTS FOR THERAPY BASED ON APPROVED COMPANION DIAGNOSTIC
ODE-284	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 35KG
ODE-285	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS OTHER THAN PROTEASE INHIBITORS THAT REQUIRE A CYP3A INHIBITOR, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 25KG AND LESS THAN 35KG
ODE-286	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-287	TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
ODE-288	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
ODE-289	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
ODE-290	INDICATED FOR THE INITIAL TREATMENT OF SEVERE MALARIA IN ADULT AND PEDIATRIC PATIENTS TO ALWAYS BE FOLLOWED BY A COMPLETE TREATMENT COURSE OF AN APPROPRIATE ORAL ANTIMALARIAL REGIMEN
ODE-291	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST
ODE-292	INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
ODE-293	TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-294	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY OR HEART TRANSPLANTS, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-295	INDICATED FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-296	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
ODE-297	FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
ODE-298	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
ODE-299	INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR

ORPHAN DRUG EXCLUSIVITY

	COMPLETE RESECTION
ODE-300	FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-301	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
ODE-302	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
ODE-303	ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-304	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-305	TREATMENT OF INVASIVE ASPERGILLOSIS
ODE-306	W/ BEVACIZUMAB FOR MAINT TX OF ADULTS W/ ADV EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO 1ST LINE PT BASED CHEMO & WHOSE CA IS ASSOC W/ HOMOLOGOUS RECOMB DEF + STATUS DEFINED BY GENOMIC INSTABILITY
ODE-307	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS 5 YEARS AND OLDER TO LESS THAN 12 YEARS OF AGE AND WEIGHING AT LEAST 15 KG WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
ODE-308	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE CAPACITY
ODE-309	INDICATED FOR USE IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE FOR TREATMENT OF ADULT PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER AND BRAIN METASTASES, WHO HAVE RECEIVED ONE OR MORE PRIOR ANTI-HER2-BASED REGIMENS IN THE METASTIC SETTING
ODE-310	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
ODE-311	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
ODE-312	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-313	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTENACE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE EITHER PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY
ODE-314	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
ODE-315	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-316	TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS.
ODE-317	FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
ODE-318	TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST

ORPHAN DRUG EXCLUSIVITY

ODE-319 INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI

ODE-320 INDICATED FOR CONTINUED TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY (CRI) FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY

ODE-321 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS TO LESS THAN 6 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA

ODE-322 TREATMENT OF NARCOLEPSY

ODE-323 TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA

ODE-324 TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES

ODE-325 TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING ALTERATIONS

ODE-326 TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE

ODE-327 ADD-ON MAINTENANCE THERAPY TO IMPROVE PULMONARY FUNCTION IN ADULT PATIENTS 18 YEARS OF AGE AND OLDER WITH CYSTIC FIBROSIS AND WHO HAVE PASSED THE BRONCHITOL TOLERANCE TEST

ODE-328 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE

ODE-329 FOR THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PEDIATRIC PATIENTS 3 TO 15 YEARS OF AGE

ODE-330 THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER

ODE-331 TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY

ODE-332 TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER

ODE-333 PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

ODE-334 TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PATIENTS 2 MONTHS OF AGE AND OLDER

ODE-335 FOR TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AT LEAST ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020

ODE-336 INDICATED FOR CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH OBESITY DUE TO PROOPIOMELANOCORTIN (POMC), PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 1 (PCSK1), OR LEPTIN RECEPTOR (LEPR) DEFICIENCY CONFIRMED BY GENETIC TESTING DEMONSTRATING VARIANTS IN POMC, PCSK1, OR LEPR GENES THAT ARE INTERPRETED AS PATHOGENIC, LIKELY PATHOGENIC, OR OF UNCERTAIN SIGNIFICANCE (VUS)

ODE-337 FOR ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST

ODE-338 FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS AND OLDER WHO HAVE ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020

ODE-339 TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER URINARY OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS

ODE-340 TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE

ORPHAN DRUG EXCLUSIVITY

	SYSTEMIC THERAPY
ODE-341	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-342	INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
ODE-343	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
ODE-344	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
ODE-345	IN PEDIATRIC AND ADULT PATIENTS AS ADJUNCTIVE THERAPY TO STANDARD OF CARE FOR THE TREATMENT OF ACUTE HYPERAMMONEMIA DUE TO PROPIONIC ACIDEMIA (PA) OR METHYLMALONIC ACIDEMIA (MMA)
ODE-346	FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, EXCLUDING ADULT PATIENTS COVERED BY XPOVIO'S PREVIOUS INDICATION FOR MULTIPLE MYELOMA APPROVED ON JULY 3, 2019
ODE-347	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
ODE-348	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OF THERAPY AND WHOSE DISEASE IS REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT, AND ONE CD-38 DIRECTED MONOCLONAL ANTIBODY
ODE-349	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST, EXCLUDING PATIENTS WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB OR CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-350	TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER
ODE-351	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
ODE-352	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
ODE-353	FOR TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
ODE-354	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES
ODE-355	FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
ODE-356	FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). ADVSM INCLUDES PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)
ODE-357	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 6 THROUGH 11 YEARS OLD WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
ODE-358	FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS
ODE-359	FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG
ODE-360	FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANT
ODE-361	INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY

ORPHAN DRUG EXCLUSIVITY

ODE-362	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
ODE-363	TREATMENT OF PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
ODE-364	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUORENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY
ODE-365	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY
ODE-366	INDICATED FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC GIST HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION, INCLUDING PDGFRA D842V MUTATIONS
ODE-367	PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)
ODE-368	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-369	THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS
ODE-370	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
ODE-371	TREATMENT OF ADULT PATIENTS WITH WALDENSTRM'S MACROGLOBULINEMIA (WM)
ODE-372	FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-373	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-374	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-375	THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
ODE-376	FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION

PATENT USE

U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA

PATENT USE

U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS

PATENT USE

U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
U-93	USE AS AN ANTIHISTAMINE/DECONGESTANT
U-94	TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
U-95	SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
U-96	METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
U-97	A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
U-98	A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
U-99	METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
U-100	METHOD OF TREATING OCULAR INFLAMMATION
U-101	ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
U-102	METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
U-103	TREATMENT OF OCULAR HYPERTENSION
U-104	TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
U-105	EMESIS
U-106	TREATMENT OF EPILEPSY
U-107	TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
U-108	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
U-109	ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
U-110	USE AS A RETRIEVABLE PESSARY
U-111	DIABETES
U-112	CONTRACEPTION
U-113	METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
U-114	USE FOR INHIBITING BONE RESORPTION
U-115	USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
U-116	METHOD OF MYOCARDIAL IMAGING
U-117	TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
U-118	METHOD OF LOWERING BLOOD SUGAR LEVEL
U-119	TREATMENT OF NASAL HYPERSECRETION
U-120	CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
U-121	METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122	A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123	METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124	TREATMENT OF ACNE
U-125	TREATMENT NEUROGENERATIVE DISEASES
U-126	TREATMENT OF GASTRITIS
U-127	METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128	METHOD FOR TREATMENT OF TUMORS

PATENT USE

U-129	METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION

PATENT USE

U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT

PATENT USE

U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....

PATENT USE

U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS

PATENT USE

U-272	METHOD OF TREATING CARCINOMA
U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC

PATENT USE

	PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR

PATENT USE

U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS

PATENT USE

	OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHOMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABILIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

PATENT USE

U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES
U-421	USE FOR SEDATION
U-422	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423	METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424	FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425	METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-426	PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427	METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428	METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429	METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430	METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431	POSTTRAUMATIC STRESS DISORDER
U-432	REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
U-433	USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
U-434	CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
U-435	A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
U-436	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
U-437	METHOD OF USE EQUAL TO PROCESS OF PREPARATION
U-438	TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE

PATENT USE

U-439	TREATMENT OF OBESITY
U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	TREATMENT OF MIGRAINE
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE

PATENT USE

U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION
U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT

PATENT USE

U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS
U-502	PITYRIASIS VERSICOLOR
U-503	GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR
U-504	TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS
U-505	ULTRASOUND CONTRAST AGENT
U-506	PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..
U-507	ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
U-508	METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS
U-509	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-510	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES
U-511	USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
U-512	USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA
U-513	METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA
U-514	PREVENTION OF OVULATION IN A WOMAN
U-515	TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516	METHOD OF TREATING A PSYCHOTIC DISEASE
U-517	STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518	OBSESSIVE COMPULSIVE DISORDER
U-519	POST OPERATIVE NAUSEA AND VOMITING
U-520	PREMENOPAUSAL OSTEOPOROSIS
U-521	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522	TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523	METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524	METHOD OF TREATING DIARRHEA
U-525	METHOD OF TREATING PARASITIC INFECTIONS
U-526	METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527	METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528	PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529	ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530	TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531	TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532	TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533	ERECTILE DYSFUNCTION

PATENT USE

U-534	HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547	MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548	A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549	USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551	METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552	TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553	MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554	TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556	USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558	INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
U-559	METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
U-560	METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
U-561	COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
U-562	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-563	MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
U-564	TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566	FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED

PATENT USE

	WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-567	METHOD OF TREATING INFERTILITY
U-568	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
U-570	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
U-571	TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
U-572	INTENSIVE CARE UNIT SEDATION
U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
U-576	ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

PATENT USE

U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDER
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-618	USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
U-619	TREATMENT OF MALIGNANT NEOPLASM
U-620	TREATMENT OF INSOMNIA
U-621	METHOD OF TREATING CANCER
U-622	TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
U-623	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

PATENT USE

U-624	REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
U-625	ALLERGIC RHINITIS OR NASAL POLYPS
U-626	CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
U-627	TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
U-628	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-629	METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
U-630	TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
U-631	TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
U-632	METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
U-633	METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
U-634	METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
U-635	TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
U-636	TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
U-637	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
U-638	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
U-639	TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
U-640	USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA
U-641	USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
U-642	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-643	THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
U-644	TREATMENT OF SEASONAL ALLERGIC RHINITIS
U-645	TREATMENT OF ASTHMA
U-646	METHOD OF TREATING OTITIS
U-647	TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-648	THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
U-649	A METHOD FOR TREATING A TUMOR DISEASE
U-650	TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
U-651	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
U-652	TREATMENT OF CARDIAC ARRHYTHMIA
U-653	STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
U-654	LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
U-655	TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO

PATENT USE

	MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS
U-656	REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-657	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-658	TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
U-659	TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
U-660	TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
U-661	TREATMENT OF SEIZURE DISORDER
U-662	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-663	THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
U-664	TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
U-665	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
U-666	METHOD OF TREATING ADHD
U-667	MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
U-668	LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
U-669	INDICATION OF TYPE II DIABETES
U-670	TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
U-671	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
U-672	TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
U-673	METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
U-674	METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
U-675	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
U-676	METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
U-677	A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
U-678	METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-679	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-680	A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
U-681	TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-682	NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-683	PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
U-684	TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO

PATENT USE

	CHEMOTHERAPY REGIMENS
U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATENT OF PSYCHOSIS

PATENT USE

U-720	TREATMENT OF NEUROLEPTIC DISEASES
U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES
U-725	ALLERGIC RHINITIS AND URTICARIA
U-726	ALLERGIC RHINITIS
U-727	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728	METHOD FOR TREATING BACTERIAL INFECTION
U-729	TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730	USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
U-733	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734	FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735	METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736	METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737	DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738	INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739	METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740	FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741	COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
U-742	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743	ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744	TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745	TREATMENT OR PREVENTION OF EMESIS
U-746	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747	PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748	A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749	METHOD OF CONTRACEPTION
U-750	TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751	ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752	SUNSCREEN
U-753	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754	USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755	TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757	USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL

PATENT USE

U-758	TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
U-759	METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-761	TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763	ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
U-764	TREATMENT OF SCHIZOPHRENIA
U-765	METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766	TREATMENT OF SEIZURES
U-767	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768	A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769	REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-770	LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771	METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
U-772	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
U-773	PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-774	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-775	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
U-776	TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
U-777	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-778	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-779	A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
U-780	A METHOD FOR THE TREATMENT OF CANCER
U-781	FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
U-782	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
U-783	DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
U-784	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
U-785	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
U-786	PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
U-787	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
U-788	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE

PATENT USE

U-789	TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING
U-790	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
U-791	GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
U-792	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-793	FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-794	CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
U-795	METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
U-796	METHOD OF TREATING DEPRESSION
U-797	METHOD OF TREATING ANXIETY
U-798	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
U-799	METHOD FOR INHIBITING SEROTONIN UPTAKE
U-800	TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
U-801	METHOD OF TREATING CANCER
U-802	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-803	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
U-804	TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
U-805	TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
U-806	INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
U-807	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
U-808	THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
U-809	TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
U-810	METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
U-811	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
U-812	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-813	MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-814	TREATMENT OF SCHIZOPHRENIA
U-815	TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
U-816	DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
U-817	NASAL ADMINISTRATION OF CYANOCOBALAMIN
U-818	TOPICAL TREATMENT OF ACNE VULGARIS
U-819	MANAGEMENT OF FIBROMYALGIA
U-820	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
U-821	METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A

PATENT USE

	PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
U-822	USE IN LIPID MANAGEMENT
U-823	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
U-824	METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
U-825	USE FOR PREVENTION OF BREAST CANCER
U-826	RELIEF OF MODERATE TO SEVERE PAIN
U-827	USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
U-828	PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-829	TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
U-830	TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
U-831	METHOD OF ADMINISTERING LANREOTIDE ACETATE
U-832	ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
U-833	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
U-834	INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
U-835	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
U-836	A METHOD FOR THE TREATMENT OF LEUKEMIAS
U-837	GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
U-838	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
U-839	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-840	TREATMENT FOR TYPE 2 DIABETES MELLITUS
U-841	INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
U-842	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
U-843	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-844	PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
U-845	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
U-846	USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
U-847	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-848	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-849	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
U-850	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-851	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-852	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-853	TREATMENT OR PREVENTION OF EMESIS

PATENT USE

U-854	PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
U-855	METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
U-856	SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-857	INHIBITION OF TRANSPLANT REJECTION
U-858	PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-859	EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
U-860	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
U-861	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-862	ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
U-863	TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
U-864	PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-865	TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
U-866	THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
U-867	TREATMENT OF MIGRAINE
U-868	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
U-869	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-870	METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
U-871	METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
U-872	TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-873	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
U-874	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-875	FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
U-876	TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-877	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
U-878	A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
U-879	A METHOD OF TREATING OR PREVENTING ILEUS
U-880	ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-881	TREATMENT OF NON-SMALL CELL LUNG CANCER
U-882	MANAGEMENT OF FIBROMYALGIA (FM)
U-883	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
U-884	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
U-885	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
U-886	ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC

PATENT USE

	RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
U-887	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-888	FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
U-889	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
U-890	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-891	USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
U-892	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
U-893	CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
U-894	TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
U-895	TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-896	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
U-897	METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
U-898	USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
U-899	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-900	INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
U-901	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
U-902	USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
U-903	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
U-904	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
U-905	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
U-906	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
U-907	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
U-908	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
U-909	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-910	TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
U-911	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
U-912	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-913	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
U-914	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-915	TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-916	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
U-917	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-918	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

PATENT USE

U-919	FOR THE TREATMENT OF DERMATITIS
U-920	STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS
U-921	TREATMENT OF ACNE VULGARIS
U-922	FOR THE TREATMENT OF FUNGAL INFECTIONS
U-923	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-924	TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS
U-925	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-926	MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)
U-927	METHOD FOR INCREASING TEAR PRODUCTION
U-928	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-929	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI
U-930	TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
U-931	RELIEF OF MODERATE TO SEVERE ACUTE PAIN
U-932	PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI
U-933	FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-934	IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA
U-935	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER
U-936	USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA
U-937	TREATMENT OF PROSTATE CANCER
U-938	TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-939	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-940	METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA
U-941	METHOD TO TREAT OVARIAN CANCER
U-942	METHOD TO TREAT MULTIPLE MYELOMA
U-943	GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER
U-944	TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-945	SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION
U-946	TREATMENT OF BREAST CANCER
U-947	WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS
U-948	TREATMENT OF DIABETES MELLITUS
U-949	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
U-950	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
U-951	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS

PATENT USE

U-952	USE AS AN ANALGESIC
U-953	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-954	CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
U-955	PROPHYLACTIC TREATMENT OF MIGRAINE
U-956	TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
U-957	A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
U-958	METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
U-959	METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
U-960	METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
U-961	METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
U-962	SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-963	PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-964	ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-965	USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
U-966	TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
U-967	A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
U-968	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-969	TREATMENT OF MIGRAINE
U-970	TOPICAL TREATMENT OF LICE INFESTATIONS
U-971	INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
U-972	MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
U-973	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
U-974	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-975	TREATMENT OF PULMONARY HYPERTENSION
U-976	IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
U-977	TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
U-978	METHOD OF TREATING HYPONATREMIA
U-979	RELIEF OF MUSCLE SPASM
U-980	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-981	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-982	A METHOD OF TREATING OSTEOPOROSIS

PATENT USE

U-983	METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
U-984	METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
U-985	TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-986	TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
U-987	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
U-988	TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
U-989	FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-990	TREATMENT OF PROTOZOAL INFECTION
U-991	TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
U-992	REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
U-993	METHOD OF TREATING INFERTILITY
U-994	METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
U-995	METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
U-996	AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
U-997	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
U-998	ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
U-999	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
U-1000	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
U-1001	METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
U-1002	METHOD OF TREATING INFLAMMATORY CONDITIONS
U-1003	A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
U-1004	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1005	METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
U-1006	NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
U-1007	METHOD OF TREATING GOUT FLARES
U-1008	APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
U-1009	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-1010	TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
U-1011	USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
U-1012	METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
U-1013	METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1014	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

PATENT USE

U-1015	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1016	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
U-1017	A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-1018	TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
U-1019	TREATMENT OF PULMONARY HYPERTENSION
U-1020	METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
U-1021	SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
U-1022	FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
U-1023	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
U-1024	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
U-1025	TREATING FREQUENT HEARTBURN
U-1026	A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
U-1027	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
U-1028	A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
U-1029	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
U-1030	IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
U-1031	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1032	USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
U-1033	TOPICAL TREATMENT OF ACNE VULGARIS
U-1034	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
U-1035	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1036	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
U-1037	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
U-1038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
U-1039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
U-1040	INHIBITION OF THROMBIN IN A PATIENT
U-1041	TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
U-1042	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-1043	MANAGEMENT OF MODERATE TO SEVERE PAIN
U-1044	TOPICAL TREATMENT OF SCALP PSORIASIS
U-1045	MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
U-1046	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
U-1047	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
U-1048	WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
U-1049	PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

PATENT USE

U-1050	USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-1051	TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-1052	RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1053	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
U-1054	ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
U-1055	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
U-1056	TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1057	TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
U-1058	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-1059	ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
U-1060	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
U-1061	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
U-1062	ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
U-1063	TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
U-1064	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-1065	METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-1066	METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
U-1067	TREATMENT OF CANCER
U-1068	TREATMENT OF ASTHMA
U-1069	A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1070	A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE
U-1071	METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
U-1072	THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
U-1073	USE FOR THE TREATMENT OF ASTHMA AND COPD
U-1074	USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
U-1075	USE FOR THE TREATMENT OF ASTHMA
U-1076	REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
U-1077	PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION
U-1078	TREATMENT OF ACNE
U-1079	REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1080	METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
U-1081	LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1082	USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS
U-1083	ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES

PATENT USE

U-1084	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-1085	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
U-1086	TREATMENT OF AUTOIMMUNE DISEASE
U-1087	DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-1088	RELIEF OF MUSCLE SPASM
U-1089	INHIBITION OF THROMBIN
U-1090	LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-1091	ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
U-1092	TREATMENT OF BREAST CANCER
U-1093	TREATMENT OF PSEUDOBULBAR AFFECT
U-1094	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
U-1095	METHOD OF TREATING OCULAR INFLAMMATION
U-1096	TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
U-1097	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
U-1098	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
U-1099	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1100	REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
U-1101	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1102	METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
U-1103	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1104	USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
U-1105	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
U-1106	TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
U-1107	TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
U-1108	TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
U-1109	TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-1110	METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1111	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1112	METHOD OF MR IMAGING OF A MAMMAL
U-1113	TREATMENT AND PROPHYLAXIS OF INFLUENZA
U-1114	TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
U-1115	TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
U-1116	METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
U-1117	TREATMENT OF BREAST CANCER
U-1118	USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

PATENT USE

U-1119	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-1120	TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
U-1121	METHOD OF TREATING TRAVELERS' DIARRHEA
U-1122	TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
U-1123	TREATMENT OF ALCOHOL DEPENDENCE
U-1124	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
U-1125	METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
U-1126	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
U-1127	TREATMENT OF PATENT DUCTUS ARTERIOSUS
U-1128	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
U-1129	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1130	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1131	TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1132	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1133	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1134	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1135	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
U-1136	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1137	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1138	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1139	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1140	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1141	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1142	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1143	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1144	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1145	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1146	REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1147	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF

PATENT USE

	HDL-C
U-1148	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1149	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1150	TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
U-1151	TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
U-1152	CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
U-1153	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
U-1154	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
U-1155	USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
U-1156	TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
U-1157	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1158	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1159	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-1160	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
U-1161	FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
U-1162	TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
U-1163	METHOD OF TREATING THROMBOSIS
U-1164	METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
U-1165	USE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1166	A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
U-1167	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
U-1168	THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-1169	MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
U-1170	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1171	REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
U-1172	TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
U-1173	TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
U-1174	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER

PATENT USE

	FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS

PATENT USE

U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS
U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
U-1210	USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
U-1211	USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1212	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1213	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
U-1214	METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1215	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1216	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1217	METHOD OF INCREASING HAIR GROWTH
U-1218	METHOD OF STIMULATING HAIR GROWTH
U-1219	METHOD OF INCREASING THE NUMBER OF HAIRS
U-1220	TREATMENT OF RENAL CELL CARCINOMA
U-1221	TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
U-1222	TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
U-1223	METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
U-1224	REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
U-1225	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
U-1226	A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
U-1227	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
U-1228	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
U-1229	TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
U-1230	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
U-1231	TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
U-1232	USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN
U-1233	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

PATENT USE

U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE

PATENT USE

U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1288	TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

PATENT USE

U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-1316	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1317	TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1318	TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1319	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
U-1320	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-1321	TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
U-1322	METHOD OF REDUCING OCULAR HYPERTENSION
U-1323	REDUCING THE RISK OF STROKE
U-1324	MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
U-1325	INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
U-1326	METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
U-1327	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
U-1328	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
U-1329	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
U-1330	METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1331	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

PATENT USE

U-1332	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1333	METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
U-1334	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1335	METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
U-1336	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
U-1337	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
U-1338	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
U-1339	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1340	METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1341	METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1342	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1343	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1344	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
U-1345	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1346	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
U-1347	TREATMENT OF A SKIN DISORDER
U-1348	TREATMENT OF OSTEOARTHRITIS
U-1349	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
U-1350	TREATMENT OF ANKYLOSING SPONDYLITIS
U-1351	TREATMENT OF ACUTE PAIN
U-1352	TREATMENT OF PRIMARY DYSMENORRHEA
U-1353	ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1354	INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
U-1355	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1356	TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
U-1357	TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR

PATENT USE

	TREATING A RESPIRATORY DISEASE IN A CHILD
U-1358	TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
U-1359	USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1360	USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361	USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
U-1363	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366	TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
U-1367	METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368	TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
U-1371	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372	ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373	METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375	ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-1377	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378	TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381	USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382	TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383	DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
U-1384	METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385	METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1388	TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT

PATENT USE

	SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389	ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391	METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1393	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394	METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396	TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
U-1397	USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398	METHOD OF TREATING CHRONIC HEPATITIS C
U-1399	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
U-1400	FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1401	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403	FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
U-1404	METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
U-1405	THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406	TREATMENT OF MELANOMA
U-1407	TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
U-1408	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409	TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411	THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1412	TREATMENT OF ATOPIC DERMATITIS
U-1413	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415	TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
U-1416	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

PATENT USE

U-1417	USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420	METHOD OF ONCE A DAY ADMINISTRATION
U-1421	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422	METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
U-1423	AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1424	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1425	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1426	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
U-1427	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
U-1428	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
U-1429	TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
U-1430	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-1431	METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
U-1432	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
U-1433	IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1434	TREATMENT OF PANCREATIC CANCER
U-1435	COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
U-1436	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
U-1437	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
U-1438	ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1439	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
U-1440	USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
U-1441	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
U-1442	SUBCUTANEOUS INJECTION OF METHOTREXATE
U-1443	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1444	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
U-1445	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL

PATENT USE

	COMPOSITION
U-1446	METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
U-1447	TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
U-1448	TREATING SEVERE HYPERTRIGLYCERIDEMIA
U-1449	METHOD OF ALLEVIATING A SKIN CONDITION
U-1450	TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
U-1451	APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
U-1452	METHOD FOR CHRONIC WEIGHT MANAGEMENT
U-1453	A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1454	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1455	TREATMENT OF PERIANAL WARTS
U-1456	TREATMENT OF MANTLE CELL LYMPHOMA
U-1457	A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
U-1458	A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1459	TREATMENT OF CARCINOMA OF THE THYROID
U-1460	TREATMENT OF HERPES LABIALIS
U-1461	A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
U-1462	A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
U-1463	A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
U-1464	TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
U-1465	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
U-1466	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1467	METHOD OF TREATING HEPATITIS C
U-1468	CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
U-1469	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
U-1470	FOR THE TREATMENT OF HEPATITIS C
U-1471	A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
U-1472	INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-1473	MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
U-1474	A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
U-1475	USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
U-1476	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
U-1477	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION

PATENT USE

	MEDICATION ON THE SAME KNEE
U-1478	METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1479	INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1480	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
U-1481	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1482	DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1483	INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1484	COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
U-1485	TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1486	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
U-1487	METHOD OF INCREASING EYELASH GROWTH
U-1488	USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
U-1489	USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
U-1490	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
U-1491	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1492	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1493	METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1494	SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1495	RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
U-1496	METHOD TO TREAT HEMANGIOMA.
U-1497	NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1498	METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
U-1499	MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-1500	TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
U-1501	PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
U-1502	PROPHYLAXIS OF PULMONARY EMBOLISM
U-1503	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1504	USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
U-1505	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1506	TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
U-1507	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1508	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
U-1509	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
U-1510	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM

PATENT USE

	OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
U-1511	TREATMENT OF HYPERTRIGLYCERIDEMIA
U-1512	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1513	TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-1514	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
U-1515	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
U-1516	METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
U-1517	TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
U-1518	MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
U-1519	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
U-1520	METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
U-1521	MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1522	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
U-1523	METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
U-1524	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
U-1525	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1526	THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1527	FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-1528	A METHOD OF LOWERING INTRAOCULAR PRESSURE
U-1529	ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1530	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
U-1531	METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
U-1532	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
U-1533	PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1534	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
U-1535	ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
U-1536	ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
U-1537	TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
U-1538	ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
U-1539	PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
U-1540	BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1541	TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
U-1542	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
U-1543	TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23

PATENT USE

U-1544	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
U-1545	A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
U-1546	FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
U-1547	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
U-1548	FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1549	FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
U-1550	METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
U-1551	METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
U-1552	FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
U-1553	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1554	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
U-1555	MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1556	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1557	A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
U-1558	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
U-1559	INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
U-1560	A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
U-1561	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1562	TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
U-1563	A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
U-1564	A METHOD OF TREATING GAUCHER'S DISEASE
U-1565	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1566	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-1567	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
U-1568	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1569	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
U-1570	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
U-1571	TREATMENT OF GAUCHER DISEASE TYPE 1
U-1572	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
U-1573	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.

PATENT USE

U-1574	A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
U-1575	PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-1576	TREATMENT OF LEUKEMIA
U-1577	CONTROL OF SERUM PHOSPHOROUS LEVELS
U-1578	TREATMENT OF ACUTE OTITIS MEDIA
U-1579	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1580	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
U-1581	IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
U-1582	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1584	USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
U-1585	USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
U-1586	FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
U-1587	SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
U-1588	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
U-1589	METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-1590	KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
U-1591	TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
U-1592	TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-1593	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
U-1594	DILATION OF THE PUPIL
U-1595	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
U-1596	LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
U-1597	TREATMENT OF DIABETIC MACULAR EDEMA
U-1598	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
U-1599	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-1600	DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1601	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1602	METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
U-1603	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-1604	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
U-1605	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1606	METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME

PATENT USE

	INVOLVED IN PIRFENIDONE METABOLISM
U-1607	METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
U-1608	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
U-1609	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1610	CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
U-1611	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
U-1612	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1613	DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
U-1614	USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
U-1615	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1616	NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1617	METHOD OF TREATING MEDULLARY THYROID CANCER
U-1618	A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
U-1619	TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1620	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
U-1621	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
U-1622	FOR THE TREATMENT OF POLYCYTHEMIA VERA
U-1623	USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
U-1624	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
U-1625	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
U-1626	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
U-1627	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
U-1628	METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
U-1629	METHOD OF TREATING ACROMEGALY
U-1630	TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
U-1631	TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
U-1632	TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1633	USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
U-1634	TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
U-1635	USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
U-1636	USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
U-1637	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

PATENT USE

U-1638	TREATMENT OF HCV INFECTION USING PARITAPREVIR
U-1639	USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1640	TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1641	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-1642	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
U-1643	TREATING CUSHING'S SYNDROME
U-1644	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
U-1645	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1646	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1647	TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1648	TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1649	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
U-1650	TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
U-1651	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1652	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
U-1653	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
U-1654	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
U-1655	A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
U-1656	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
U-1657	METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99
U-1658	TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN
U-1659	MANAGEMENT OF PAIN
U-1660	TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-1661	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
U-1662	A METHOD OF TREATING OCULAR PAIN
U-1663	TREATMENT OF HIV-1 INFECTION
U-1664	TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
U-1665	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1
U-1666	PALLIATIVE TREATMENT OF PROSTATE CANCER
U-1667	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS

PATENT USE

U-1668	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
U-1669	TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
U-1670	NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
U-1671	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS
U-1672	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
U-1673	TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
U-1674	DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1675	USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
U-1676	METHODS FOR TREATING BACTERIAL INFECTIONS
U-1677	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
U-1678	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1679	TREATMENT OF ACUTE OTITIS EXTERNA
U-1680	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1681	TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
U-1682	TREATMENT OF BACTERIAL VAGINOSIS
U-1683	TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-1684	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1685	DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1686	A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
U-1687	TREATMENT OF HCV INFECTION USING OMBITASVIR
U-1688	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1689	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1690	METHOD FOR REDUCTION OF SUBMENTAL FAT
U-1691	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
U-1692	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1693	METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1694	A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
U-1695	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
U-1696	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
U-1697	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.
U-1698	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1699	A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
U-1700	A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
U-1701	A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
U-1702	TREATMENT OF COPD
U-1703	TREATMENT OF RESPIRATORY COMPLAINTS
U-1704	USE FOR TREATMENT IN PATIENTS WITH DIABETES
U-1705	USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA

PATENT USE

U-1706	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
U-1707	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
U-1708	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
U-1709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
U-1710	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
U-1711	FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL
U-1712	MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1713	TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1714	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1715	P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
U-1716	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
U-1717	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
U-1718	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
U-1719	ACUTE TREATMENT OF MIGRAINE
U-1720	METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
U-1721	USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
U-1722	TREATMENT OF BASAL CELL CARCINOMA
U-1723	TREATMENT OF HEART FAILURE
U-1724	METHOD OF INHIBITING HEPATITIS C VIRUS
U-1725	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
U-1726	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1727	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1728	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1729	REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
U-1730	REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
U-1731	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
U-1732	TEMPORARY REDUCTION OF FEVER
U-1733	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
U-1734	USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-1735	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL

PATENT USE

U-1736	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1737	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
U-1738	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-1739	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1740	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY
U-1741	PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1742	ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1743	FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
U-1744	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
U-1746	MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
U-1747	FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD
U-1748	FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1749	ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-1750	TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-1751	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-1752	PROPHYLAXIS OF ORGAN REJECTION
U-1753	TREATMENT OF HCV INFECTION USING DASABUVIR
U-1754	FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
U-1755	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
U-1756	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-1757	INHIBITION ON PI3K KINASE
U-1758	METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
U-1759	METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB
U-1760	RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
U-1761	PLAQUE PSORIASIS
U-1762	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1763	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1764	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1765	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

PATENT USE

U-1766	TREATMENT OF HYPERKALEMIA
U-1767	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
U-1768	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
U-1769	TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE
U-1770	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA
U-1771	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION
U-1772	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1773	LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1774	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE
U-1775	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
U-1776	METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA
U-1777	TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
U-1778	METHOD FOR TREATING MULTIPLE MYELOMA
U-1779	METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS
U-1780	METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
U-1781	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
U-1782	FOR HEAD LICE INFESTATIONS
U-1783	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED
U-1784	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED
U-1785	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED
U-1786	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE
U-1787	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY
U-1788	TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN
U-1789	METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
U-1790	FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
U-1791	EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
U-1792	TREATMENT OF OTIC INFECTION OR INFLAMMATION
U-1793	TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1794	REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK
U-1795	REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
U-1796	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

PATENT USE

U-1797	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
U-1798	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
U-1799	METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
U-1800	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
U-1801	REDUCTION OF SERUM URIC ACID LEVELS
U-1802	TREATMENT OF GOUT
U-1803	TREATMENT OF HYPERURICEMIA
U-1804	ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
U-1805	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
U-1806	COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
U-1807	TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
U-1808	USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
U-1809	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
U-1810	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
U-1811	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
U-1812	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
U-1813	TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
U-1814	METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
U-1815	TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-1816	TREATMENT OF A UREA CYCLE DISORDER
U-1817	PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS
U-1818	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1819	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1820	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1821	METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-1822	TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
U-1823	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
U-1824	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1825	METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
U-1826	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1827	A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC

PATENT USE

	METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
U-1828	INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-1829	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-1830	INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
U-1831	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
U-1832	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1833	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1834	TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
U-1835	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-1836	TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
U-1837	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
U-1838	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
U-1839	COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
U-1840	TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
U-1841	USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1842	METHOD OF TREATING EPILEPSY
U-1843	TREATMENT OF PSYCHOSIS
U-1844	TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
U-1845	TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
U-1846	TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
U-1847	METHOD OF TREATING A BACTERIAL INFECTION
U-1848	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1849	METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-1850	METHOD OF ADMINISTERING LEVETIRACETAM
U-1851	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1852	METHOD OF TREATING TYPE 2 DIABETES
U-1853	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
U-1854	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
U-1855	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
U-1856	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-1857	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

PATENT USE

U-1858	TREATMENT OF PLAQUE PSORIASIS
U-1859	TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1860	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1861	USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
U-1862	TREATMENT OF POST-MYOCARDIAL INFARCTION
U-1863	TREATMENT OF STROKE
U-1864	TREATMENT OF MYOCARDIAL INFARCTION
U-1865	TREATMENT OF THROMBOTIC STROKE
U-1866	TREATMENT OF STABLE AND UNSTABLE ANGINA
U-1867	METHOD OF INHIBITING PLATELET AGGREGATION
U-1868	TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
U-1869	TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
U-1870	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1871	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
U-1872	USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
U-1873	ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
U-1874	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8
U-1875	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
U-1876	METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
U-1877	METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
U-1878	FOR OPIOID DEPENDENCE
U-1879	METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
U-1880	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1881	IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
U-1882	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
U-1883	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
U-1884	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1885	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1886	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1887	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1888	USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE

PATENT USE

U-1889	TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
U-1890	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
U-1891	TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
U-1892	METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
U-1893	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
U-1894	COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR
U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)

PATENT USE

U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
U-1923	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1924	KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-1925	USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
U-1926	METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
U-1927	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
U-1928	RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
U-1929	TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
U-1930	METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
U-1931	PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
U-1932	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
U-1933	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
U-1934	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-1935	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
U-1936	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1937	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1938	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1939	ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
U-1940	IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
U-1941	TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY

PATENT USE

U-1942	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
U-1943	TREATMENT OF SPINAL MUSCULAR ATROPHY
U-1944	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
U-1945	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
U-1946	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
U-1947	TREATMENT OF MARGINAL ZONE LYMPHOMA
U-1948	A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
U-1949	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1950	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
U-1951	TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL
U-1952	FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1953	REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1954	TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1955	TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1956	FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1957	PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1958	FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
U-1959	TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-1960	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-1961	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
U-1962	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
U-1963	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
U-1964	ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
U-1965	FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3
U-1966	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
U-1967	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1968	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1969	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM

PATENT USE

	AND TRICHOPHYTON MENTAGROPHYTES
U-1970	TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
U-1971	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-1972	FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1973	METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
U-1974	TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
U-1975	METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST
U-1976	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA

PATENT USE

	AND/OR INSULIN
U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM
U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY
U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

PATENT USE

U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2032	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2033	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
U-2034	INHIBITING COAGULATION
U-2035	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
U-2036	A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
U-2037	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
U-2038	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2039	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
U-2040	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
U-2041	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2042	DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2043	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
U-2044	DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2045	ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2046	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
U-2047	ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2048	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2049	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2050	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE

PATENT USE

U-2051	DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2052	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2053	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2054	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2055	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2056	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2057	DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2058	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
U-2059	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
U-2060	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
U-2061	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2062	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
U-2063	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2064	DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2065	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2066	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
U-2067	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2068	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE
U-2069	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2070	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY
U-2071	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2072	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER

PATENT USE

	AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2073	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF
U-2074	DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2075	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
U-2076	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
U-2077	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF
U-2078	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2079	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2080	PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
U-2081	DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
U-2082	MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2083	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
U-2084	TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
U-2085	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
U-2086	A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
U-2087	TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
U-2088	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
U-2089	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
U-2090	FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2091	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-2092	METHOD FOR CONFIRMING DOSE DELIVERY
U-2093	TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
U-2094	TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
U-2095	MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA

PATENT USE

	SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY
U-2096	SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
U-2097	TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2098	INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-2099	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
U-2100	INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
U-2101	MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2102	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
U-2103	MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
U-2104	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
U-2105	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2106	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2107	TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
U-2108	TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
U-2109	CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
U-2110	METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
U-2111	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
U-2112	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
U-2113	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
U-2114	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
U-2115	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10

PATENT USE

U-2116	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
U-2117	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
U-2118	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
U-2119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
U-2120	TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2121	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
U-2122	USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2123	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
U-2124	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
U-2125	THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
U-2126	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2127	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2128	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
U-2129	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
U-2130	TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-2131	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2132	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-2133	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
U-2134	THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
U-2135	AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
U-2136	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-2137	TREATMENT OF POSTHERPETIC NEURALGIA
U-2138	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
U-2139	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE

PATENT USE

U-2140	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2141	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2142	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
U-2143	AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2144	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2146	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE
U-2147	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
U-2148	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITIRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE
U-2149	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
U-2150	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2151	METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
U-2152	TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-2153	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2154	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2155	REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2156	REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2157	TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE
U-2158	DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION
U-2159	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
U-2160	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
U-2161	TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
U-2162	FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY
U-2163	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2164	ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
U-2165	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
U-2166	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-2167	METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2168	METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2169	METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A

PATENT USE

	SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2170	METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2171	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
U-2172	METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
U-2173	TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE
U-2174	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2175	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY
U-2176	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE
U-2177	TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2178	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION
U-2179	IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION
U-2180	TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE
U-2181	TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE
U-2182	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2183	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13
U-2184	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14
U-2185	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27
U-2186	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28
U-2187	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39
U-2188	ADJUNCT TO DIET AND EXECRISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40
U-2189	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52
U-2190	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53
U-2191	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64
U-2192	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65
U-2193	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75
U-2194	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76
U-2195	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87

PATENT USE

U-2196	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88
U-2197	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99
U-2198	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100
U-2199	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA
U-2200	COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2201	TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER
U-2202	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2203	A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED
U-2204	TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-2205	TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED
U-2206	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE
U-2207	TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2208	TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE
U-2209	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2210	TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE
U-2211	TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE
U-2212	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2213	REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2214	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
U-2215	ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2216	ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2217	TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2218	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE
U-2219	TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA
U-2220	A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN
U-2221	TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2222	RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS
U-2223	METHOD OF TREATING ANGINA PECTORIS
U-2224	TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

PATENT USE

U-2225	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
U-2226	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
U-2227	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
U-2228	TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
U-2229	IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
U-2230	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
U-2231	TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2232	TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE
U-2233	TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
U-2234	USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2235	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
U-2236	REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
U-2237	TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2238	METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
U-2239	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2240	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
U-2241	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2242	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-2243	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2244	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNENUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2245	A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2246	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2247	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2248	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
U-2249	MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-2250	DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

PATENT USE

U-2251	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2252	THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
U-2253	PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
U-2254	USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
U-2255	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS
U-2256	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2257	TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2258	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2259	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2260	METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
U-2261	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2262	MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
U-2263	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
U-2264	METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2265	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS
U-2266	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2267	METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
U-2268	DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2269	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2270	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2271	THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
U-2272	TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
U-2273	A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION

PATENT USE

U-2274	MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
U-2275	TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2276	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2277	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE
U-2278	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN
U-2279	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG
U-2280	ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES
U-2281	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2282	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
U-2283	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
U-2284	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
U-2285	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
U-2286	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14
U-2287	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
U-2288	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY
U-2289	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
U-2290	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2291	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
U-2292	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2293	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

PATENT USE

U-2294 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

U-2295 TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER

U-2296 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

U-2297 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15

U-2298 TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

U-2299 TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION

U-2300 USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

U-2301 USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY

U-2302 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

U-2303 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

U-2304 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION

U-2305 MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS

U-2306 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM

U-2307 TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

U-2308 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

U-2309 USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION

U-2310 FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS

U-2311 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE

U-2312 TREATMENT OF HYPERKALEMIA IN ADULTS

U-2313 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE

U-2314 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET

U-2315 TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD

U-2316 TREATMENT OF DYSPAREUNIA

U-2317 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY

U-2318 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR

PATENT USE

U-2319	KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2320	KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
U-2321	A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
U-2322	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
U-2323	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2324	FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-2325	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
U-2326	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-2327	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
U-2328	METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
U-2329	METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
U-2330	METHOD OF TREATING MELANOMA
U-2331	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
U-2332	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2333	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2334	TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2335	TREATMENT OF MELANOMA
U-2336	TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2337	INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2338	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
U-2339	USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
U-2340	TREATMENT OF POSTOPERATIVE INFLAMMATION
U-2341	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2342	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
U-2343	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2344	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE

PATENT USE

U-2345	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
U-2346	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
U-2347	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
U-2348	A METHOD FOR PREVENTION OF PREGNANCY
U-2349	FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER
U-2350	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
U-2351	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION
U-2352	TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2353	TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2354	COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV
U-2355	IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
U-2356	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
U-2357	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-2358	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2359	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2360	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
U-2361	METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
U-2362	TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2363	ADMINISTRATION OF RISPERIDONE
U-2364	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2365	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2366	TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12
U-2367	USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE
U-2368	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
U-2369	FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
U-2370	FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS

PATENT USE

U-2371	THE TREATMENT OF FABRY PATIENTS
U-2372	A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2373	A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYLCERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2374	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR
U-2375	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR
U-2376	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2377	USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY
U-2378	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
U-2379	USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY
U-2380	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-2381	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2382	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2383	METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPBTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
U-2384	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
U-2385	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11
U-2386	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19
U-2387	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20
U-2388	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28
U-2389	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29
U-2390	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41
U-2391	ADJUNCT TO DIET AND EXCERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42
U-2392	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50
U-2393	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51
U-2394	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

PATENT USE

U-2395	FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2396	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR
U-2397	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606
U-2398	TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
U-2399	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546
U-2400	REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2401	A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1
U-2402	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION
U-2403	TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE
U-2404	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
U-2405	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2406	A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2407	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2408	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2409	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
U-2410	TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE
U-2411	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR
U-2412	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
U-2413	FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
U-2414	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN
U-2415	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2416	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN
U-2417	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2418	METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
U-2419	METHOD OF OPERATING AN INJECTION DEVICE
U-2420	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES

PATENT USE

	OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2421	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2422	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2423	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2424	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2425	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2426	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2427	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2428	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
U-2429	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2430	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
U-2431	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS
U-2432	LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2433	METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA
U-2434	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2435	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD
U-2436	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
U-2437	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
U-2438	CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
U-2439	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
U-2440	FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2441	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2442	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2443	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2444	TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION
U-2445	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-2446	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2447	TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
U-2448	TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS

PATENT USE

U-2449	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION
U-2450	POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
U-2451	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-2452	COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
U-2453	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
U-2454	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2455	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2456	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
U-2457	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
U-2458	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
U-2459	TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2460	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2461	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2462	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2463	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2464	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2465	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2466	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2467	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2468	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2469	METHOD OF TREATING CANCEROUS SOLID TUMORS
U-2470	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2471	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
U-2472	METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2473	METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION
U-2474	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
U-2475	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT

PATENT USE

U-2476	USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE
U-2477	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-2478	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
U-2479	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES
U-2480	MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
U-2481	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
U-2482	TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2483	TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2484	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
U-2485	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
U-2486	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
U-2487	DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY
U-2488	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
U-2489	TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER
U-2490	TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
U-2491	A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
U-2492	A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
U-2493	A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
U-2494	INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING
U-2495	VENTRICULAR FIBRILLATION
U-2496	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-2497	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS
U-2498	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2499	METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM
U-2500	USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE
U-2501	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2502	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-2503	TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT

PATENT USE

	LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPIATE, HER2/NEU-TARGETED THERAPY
U-2504	TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
U-2505	TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2506	METHOD OF TREATING TESTOSTERONE DEFICIENCY
U-2507	METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA
U-2508	A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2509	A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2510	A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-2511	A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
U-2512	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2513	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2514	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2515	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2516	A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2517	A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-2518	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-2519	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2520	TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2521	TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE/CYCLODEXTRIN 1:10-1:16 W/W
U-2522	TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
U-2523	TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS

PATENT USE

	OF CRYST. 2CDA
U-2524	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
U-2525	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE
U-2526	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2527	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2528	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
U-2529	TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION REPSONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2530	TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2531	TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
U-2532	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
U-2533	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
U-2534	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
U-2535	USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER
U-2536	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
U-2537	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
U-2538	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
U-2539	IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER
U-2540	TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
U-2541	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
U-2542	REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
U-2543	TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE
U-2544	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-2545	TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE
U-2546	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2547	METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE

PATENT USE

U-2548	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
U-2549	CONTROL OF SERUM PHOSPHORUS LEVELS
U-2550	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2551	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2552	METHOD OF TREATING POSTPARTUM DEPRESSION
U-2553	PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
U-2554	TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON
U-2555	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-2556	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2557	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-2558	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
U-2559	USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
U-2560	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
U-2561	USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
U-2562	TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
U-2563	TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
U-2564	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
U-2565	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
U-2566	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
U-2567	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
U-2568	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-2569	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2570	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2571	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2572	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S.

PATENT USE

PATENT 10058546

U-2573 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR

U-2574 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR

U-2575 TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR

U-2576 TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

U-2577 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT

U-2578 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE

U-2579 REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE

U-2580 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF

U-2581 TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK

U-2582 FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE

U-2583 TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN

U-2584 XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES

U-2585 TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12

U-2586 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)

U-2587 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)

U-2588 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN

U-2589 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN

U-2590 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES

U-2591 LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE

U-2592 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE

U-2593 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML

U-2594 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML

U-2595 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE

PATENT USE

	A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2596	REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2597	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
U-2598	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2599	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
U-2600	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2601	STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2602	DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2603	METHOD OF TREATING IRON DEFICIENCY
U-2604	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
U-2605	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
U-2606	TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
U-2607	TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS
U-2608	METHOD OF TREATING SCHIZOPHRENIA
U-2609	A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG/ML CHLOROPROCAINE HCL
U-2610	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2611	TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2612	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER
U-2613	TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)
U-2614	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
U-2615	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-2616	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE
U-2617	TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
U-2618	TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2619	TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2620	USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
U-2621	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN
U-2622	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

PATENT USE

U-2623	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
U-2624	TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
U-2625	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
U-2626	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR
U-2627	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
U-2628	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
U-2629	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO
U-2630	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
U-2631	TREATMENT OF COMPLICATED URINARY TRACT INFECTION
U-2632	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2633	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE.
U-2634	METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
U-2635	TREATMENT OF ACUTE URTICARIA
U-2636	METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
U-2637	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
U-2638	INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
U-2639	METHOD OF ACTIVATING RARGAMMA RECEPTOR
U-2640	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
U-2641	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2642	METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF
U-2643	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
U-2644	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
U-2645	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2646	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2647	TREATMENT OF NON-NODULAR ACNE VULGARIS
U-2648	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2649	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT

PATENT USE

	LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-2650	TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR
U-2651	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2652	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-2653	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2654	TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2655	A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
U-2656	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
U-2657	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
U-2658	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
U-2659	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE
U-2660	TREATMENT OF H. PYLORI INFECTION IN ADULTS
U-2661	CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE
U-2662	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
U-2663	USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY
U-2664	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51
U-2665	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2666	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-2667	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
U-2668	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2669	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2670	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
U-2671	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
U-2672	TREATMENT OF ACUTE HEPATIC PORPHYRIA
U-2673	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN
U-2674	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION
U-2675	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-2676	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1

PATENT USE

U-2677	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
U-2678	PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
U-2679	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
U-2680	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
U-2681	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
U-2682	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
U-2683	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
U-2684	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2685	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2686	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2687	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2688	USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2689	USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG/DL) AND ON STATIN THERAPY
U-2690	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2691	USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2692	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2693	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2694	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2695	USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG/DL) AND ON STATIN THERAPY
U-2696	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2697	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2698	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2699	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS

PATENT USE

U-2700	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY
U-2701	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2702	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
U-2703	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS
U-2704	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE
U-2705	METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA
U-2706	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY
U-2707	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA
U-2708	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
U-2709	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2710	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2711	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2712	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2713	MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN SCHIZOPHRENIA
U-2714	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA
U-2715	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2
U-2716	MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
U-2717	ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS
U-2718	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
U-2719	TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS BY DETERMINING VARICELLA ZOSTER VIRUS (VZV) STATUS AND VACCINATING PRIOR TO COMMENCING TREATMENT
U-2720	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-2721	TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT
U-2722	METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF
U-2723	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
U-2724	A METHOD OF ORAL DELIVERY OF TREPROSTINIL COMPRISING ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM

PATENT USE

U-2725	A METHOD OF TREATING PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
U-2726	TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION
U-2727	NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2728	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
U-2729	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA
U-2730	METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2731	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
U-2732	METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
U-2733	METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2734	METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
U-2735	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN
U-2736	METHOD OF TREATING EPITHELIOID SARCOMA
U-2737	METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
U-2738	METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
U-2739	INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP.
U-2740	INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
U-2741	TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
U-2742	TREATMENT OF SEVERE HYPOGLYCEMIA
U-2743	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF UNSTABLE ANGINA IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2744	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2745	TREATMENT OF NEUROBLASTOMAS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2746	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2747	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2748	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2749	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

PATENT USE

U-2750	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION
U-2751	A TRANSDERMAL METHOD OF CONTRACEPTION
U-2752	METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION
U-2753	INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST
U-2754	TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-2755	OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC
U-2756	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2757	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
U-2758	DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)
U-2759	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
U-2760	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER
U-2761	INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE CONCENTRATION (EXPOSURE) FASTER COMPARED TO THE CONVENTIONAL ORAL DOSING IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING
U-2762	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A MAJOR CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE
U-2763	METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH
U-2764	TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
U-2765	TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2766	TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO
U-2767	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY
U-2768	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS
U-2769	DOSING REGIMEN FOR INTRAVENOUS SOTALOL FOR ADMINISTRATION IN A FACILITY THAT CAN PROVIDE CONTINUOUS ELECTROCARDIOGRAPHIC MONITORING AND CARDIAC RESUSCITATION.
U-2770	CUSHING'S DISEASE
U-2771	TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-2772	MAINTENANCE TREATMENT OF CHRONIC PULMONARY DISEASE (COPD)
U-2774	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
U-2775	TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN

PATENT USE

U-2776 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN

U-2777 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR

U-2778 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 2 TO 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR

U-2779 TREATMENT OF SPASTICITY

U-2780 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME

U-2781 USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME

U-2782 USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME

U-2783 USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME

U-2784 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)

U-2785 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)

U-2786 METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES

U-2787 METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION

U-2788 TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER

U-2789 POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-2790 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN

U-2791 TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE

U-2792 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN

U-2793 A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA

U-2794 TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY

U-2795 TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY

U-2796 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY

U-2797 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY

U-2798 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY

U-2799 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY

U-2800 TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

PATENT USE

U-2801	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY
U-2802	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
U-2803	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST
U-2804	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
U-2805	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-2806	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF FOOD
U-2807	TREATMENT OF MODERATE TO SEVERE MIGRAINE PAIN WITH PAIN FREE AT 2 HOURS POST ADMINISTRATION
U-2808	TREATMENT OF DYSKINESIA, DECREASING OFF TIME, AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2809	FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT
U-2810	METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-2811	METHOD OF TREATING PARKINSON'S DISEASE
U-2812	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE
U-2813	USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION
U-2814	A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION
U-2815	MEASURING TIME-VARYING CHANGE IN BLOOD IN A TISSUE VOLUME USING MODIFIED BEER-LAMBERT LAW IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2816	METHOD FOR TREATING INFLUENZA
U-2817	METHOD OF INHIBITING COMT IN THE PERIPHERY
U-2818	METHOD OF REDUCING O-METHYLATION OF L-DOPA
U-2819	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2820	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2821	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2822	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2823	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2824	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY

PATENT USE

U-2825	TREATMENT OF "OFF" EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
U-2826	TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
U-2827	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2828	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-2829	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
U-2830	A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
U-2831	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
U-2832	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2833	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2834	TREATMENT OF ADULTS WITH PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), (WHO GROUP 4) AFTER SURGICAL TREATMENT, OR INOPERABLE CTEPH, TO IMPROVE EXERCISE CAPACITY AND WHO FUNCTIONAL CLASS
U-2835	TREATMENT OF ADULTS WITH PULMONARY HYPERTENSION (PAH), (WHO GROUP 1), TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING
U-2836	TREATMENT OF ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY.
U-2837	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
U-2838	REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2839	TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2840	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)
U-2841	USE OF VASCEPA WITH HIGH INTENSITY STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND (1) ESTABLISHED CV DISEASE, OR (2) DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-2842	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)
U-2843	NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS
U-2844	IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-2845	A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION
U-2846	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
U-2847	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS
U-2848	TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2849	METHOD OF TREATING BLEPHAROPTOSIS
U-2850	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE
U-2851	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
U-2852	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN

PATENT USE

	ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
U-2853	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
U-2854	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
U-2855	XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
U-2856	INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST
U-2857	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
U-2858	USE IN COMBINATION WITH STIRIPENTOL, VALPROATE, AND CLOBAZAM FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2859	USE OF CARDIAC MONITORING AND RESTRICTED DISTRIBUTION OF FENFLURAMINE TO MITIGATE RISK OF CARDIOVASCULAR TOXICITY IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2860	USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2861	USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2862	USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2863	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
U-2864	METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE
U-2865	TREATMENT OF MYELODYSPLASTIC SYNDROME
U-2866	TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA
U-2867	METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE
U-2868	TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-2869	IV ADMINISTRATION OF CANGRELOR BEFORE PCI AND CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI AND, DURING OR AFTER THE CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR OR AN EQUIVALENT THERAPY (PER LABELING)
U-2870	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2
U-2871	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3
U-2872	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5
U-2873	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6
U-2874	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8
U-2875	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9
U-2876	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11
U-2877	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12

PATENT USE

U-2878 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14

U-2879 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15

U-2880 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17

U-2881 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18

U-2882 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20

U-2883 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21

U-2884 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24

U-2885 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26

U-2886 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27

U-2887 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29

U-2888 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30

U-2889 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2890 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2891 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MEYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2892 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2893 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2894 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2895 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2896 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN

PATENT USE

SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2897 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9

U-2898 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10

U-2899 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 11

U-2900 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13

U-2901 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2902 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2903 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2904 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2905 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1

U-2906 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2907 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2908 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2909 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22

U-2910 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2911 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

PATENT USE

U-2912 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2913 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2914 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2915 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2916 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2917 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS

U-2918 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2919 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2920 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED CLAIM 26

U-2921 ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS

U-2922 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2923 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

U-2924 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42

U-2925 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42

U-2926 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2927 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

PATENT USE

U-2928 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2929 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2930 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2931 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2932 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2933 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2934 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS

U-2935 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54

U-2936 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2937 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

U-2938 TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB

U-2939 TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE

U-2940 METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY

U-2941 A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

U-2942 METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE

U-2943 TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

U-2944 TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA

U-2945 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA

U-2946 TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION

U-2947 KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE

PATENT USE

	RECEIVED ONE TO THREE LINES OF THERAPY
U-2948	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM (IUS) BY DETERMINING A DEPTH OF THE UTERUS, HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE IUS INTO THE UTERUS
U-2949	A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
U-2950	CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
U-2951	USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
U-2952	TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
U-2953	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA
U-2954	METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
U-2955	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
U-2956	METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE
U-2957	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2958	A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-2959	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A THIRD AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>=150 MG/DL) AND ESTABLISHED CARDIOVASCULAR DISEASE
U-2960	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND OR FURTHER CARDIOVASCULAR (CV) EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>= 150 MG/DL) AND DIABETES MELLITUS AND 2 OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-2961	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS
U-2962	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2963	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2964	TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
U-2965	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2966	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2967	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
U-2968	USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
U-2969	TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE

PATENT USE

	(CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2970	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2971	THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
U-2972	THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2973	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER
U-2974	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER
U-2975	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER
U-2976	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER
U-2977	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY
U-2978	TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH <50 COPIES/ML HIV-1 RNA AFTER >= 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-2979	METHOD COMPRISING IV ADMINISTRATION OF CANGRELOR BEFORE PCI THEN CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF PCI AND, DURING OR AFTER CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR, OR AN EQUIVALENT METHOD
U-2980	METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR
U-2981	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND THE AML IS NEWLY DIAGNOSED
U-2982	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND WHERE THE AML IS RELAPSED/REFRACTORY
U-2983	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION
U-2984	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
U-2985	A METHOD FOR TREATING DRY EYE IN A PATIENT
U-2986	MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
U-2987	METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION
U-2988	REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
U-2989	METHOD OF USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2990	METHOD OF USE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2991	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG
U-2992	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG

PATENT USE

U-2993	A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED
U-2994	REDUCTION OF RISK OF MYOCARDIAL INFARCTION, STROKE OR CARDIOVASCULAR DEATH IN A PATIENT WITH CHRONIC CAD OR PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-2995	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
U-2996	ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-2997	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDES AND ATRIAL FIBRILLATION
U-2998	METHOD OF ADMINISTERING DOCETAXEL TO A SUBJECT COMBINING THE DOCETAXEL PRO-EMULSION FORMULATION WITH AN AQUEOUS MEDIUM TO PRODUCE DOCETAXEL EMULSION
U-2999	METHOD OF USE OF TREATING, AS AN INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY IN PARTIAL ONSET SEIZURE PATIENTS WITH EPILEPSY AGED 17 YEARS OR OLDER
U-3000	METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA
U-3001	PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC.
U-3002	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-3003	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
U-3004	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-3005	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
U-3006	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-3007	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-3008	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3009	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3010	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIODEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3011	A METHOD FOR TREATING OCULAR INFLAMMATION
U-3012	TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL
U-3013	TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
U-3014	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
U-3015	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP
U-3016	ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
U-3017	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3018	XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE

PATENT USE

	TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3019	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER THAT IS SEX-HORMONE-DEPENDENT
U-3020	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER
U-3021	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE
U-3022	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, & 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3023	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, AND 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3024	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3025	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3026	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3027	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3028	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3029	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3030	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3031	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3032	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-3033	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3034	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE IN CONJUNCTION WITH AN ORAL ANTIDEPRESSENT
U-3035	TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3036	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3037	A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

PATENT USE

U-3038	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT
U-3039	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-3040	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR
U-3041	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT
U-3042	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 POOR METABOLIZERS WITH 84 MG ONCE DAILY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE)
U-3043	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE OR INTERMEDIATE METABOLIZERS WITH 84 MG TWICE PER DAY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE TWICE PER DAY)
U-3044	AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-3045	TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-3046	METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3047	USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
U-3048	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3049	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3050	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3051	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3052	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION AND TRIGLYCERIDE LEVELS OF GREATER THAN 500 MG/DL
U-3053	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND ESTABLISHED CV DISEASE OR DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-3054	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE
U-3055	A METHOD OF TREATING HUNTINGTON'S CHOREA
U-3056	TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS
U-3057	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3058	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3059	TREATMENT OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3060	TREATMENT OF HIV INFECTION IN ADULTS
U-3061	TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE

PATENT USE

U-3062	REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
U-3063	RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
U-3064	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
U-3065	TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3066	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC, SURGICALLY UNRESECTABLE UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3067	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3068	TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3069	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
U-3070	REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)
U-3071	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3072	USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3073	USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3074	METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
U-3075	TREATMENT OF ADRENAL INSUFFICIENCY
U-3076	METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3077	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3078	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, HAVING A MET KINASE ALTERATION(S) BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3079	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3080	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER
U-3081	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3082	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN AN ADULT THROUGH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3083	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
U-3084	TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
U-3085	DOSE MODIFICATION FOR RENAL IMPAIRMENT
U-3086	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
U-3087	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY INDUCING EXON-SKIPPING OF EXON 45

PATENT USE

U-3088	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
U-3089	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION
U-3090	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-3091	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-3092	METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A
U-3093	IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFACTORY MULTIPLE MYELOMA (REFACTORY TO AT LEAST 1 PROTEASOME INHIBITOR, 1 IMMUNOMODULATORY AGENT, AND 1 ANTI-CD38 MAB) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR LINES OF THERAPY
U-3094	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE
U-3095	TREATMENT OF HYPERLIPIDEMIA
U-3096	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
U-3097	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
U-3098	TREATMENT OF REFRACTORY EPILEPSY PATIENTS WITH FENFLURAMINE THAT REDUCES THE RISK OF CARDIOVASCULAR TOXICITY BY USING CARDIAC MONITORING AND RESTRICTED DISTRIBUTION
U-3099	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN A PATIENT WITH MODERATE RENAL IMPAIRMENT
U-3100	A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
U-3101	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT
U-3102	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
U-3103	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
U-3104	TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA
U-3105	TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS
U-3106	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3107	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3108	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER BY ADMINISTRATION OF AN EXTENDED-RELEASE SUSPENSION FORMULATION OF MIRABEGRON
U-3109	METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA
U-3110	USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS
U-3111	TREATING OPIOID USE DISORDER
U-3112	TREATING NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL

PATENT USE

	DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3113	TREATING RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3114	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
U-3115	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3116	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3117	ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
U-3118	TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
U-3119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 11
U-3120	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12
U-3121	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 23
U-3122	ADJUNCT TO DIET EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 23, AND 24
U-3123	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF COMPLEMENT INHIBITOR PEGCETACOPLAN
U-3124	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN
U-3125	USE FOR LOADING DOSE IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM OR FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYCARDIA
U-3126	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-3127	REDUCTION OF THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND WITHOUT TYPE II DIABETES
U-3128	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
U-3129	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN
U-3130	METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER
U-3131	USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE
U-3132	INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
U-3133	TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3134	INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3135	TREATING SCHIZOPHRENIA
U-3136	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC

PATENT USE

	OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN
U-3137	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN
U-3138	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3139	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3140	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3141	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3142	PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
U-3143	FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-3144	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3145	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3146	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3147	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
U-3148	METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE
U-3149	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3150	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3151	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA) WITH A DOSING REGIMEN THAT INCLUDES A DOSE OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3152	USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY
U-3153	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
U-3154	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-3155	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3156	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3157	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621

PATENT USE

U-3158 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA

U-3159 TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)

U-3160 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED

U-3161 METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE

U-3162 METHOD FOR WEIGHT MANAGEMENT

U-3163 TREATMENT OF ACTINIC KERATOSES OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY

U-3164 GASTROINTESTINAL TABLETS INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY

U-3165 METHOD OF TREATING HUMAN SMALLPOX DISEASE

U-3166 OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARY RELIEF OF THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES: NASAL CONGESTION, RUNNY NOSE, SNEEZING AND ITCHY NOSE

U-3167 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG

U-3168 TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS, INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)

U-3169 TREATMENT OF TRICHOMONIASIS IN ADULTS

U-3170 TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE

U-3171 TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER

U-3172 TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN

U-3173 TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY

U-3174 TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN EVERY THREE DAYS

U-3175 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18

U-3176 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12

U-3177 TREATMENT OF VENOUS THROMBOTIC DISEASE

U-3178 REDUCE THE RISK OF RECURRENCE OF VENOUS THROMBOTIC DISEASE

U-3179 METHOD OF TREATING FOLLICULAR LYMPHOMA

U-3180 DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

U-3181 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET ACCORDING TO CLAIM 1 OF U.S. PATENT NO. 11,052,075, WHERE THE TABLET FURTHER COMPRISES IVACAFTOR

U-3182 METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA

U-3183 USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION

U-3184 MEKINIST(R) IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING

PATENT USE

	COMPLETE RESECTION
U-3185	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-3186	METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
U-3187	METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
U-3188	IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-3189	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
U-3190	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
U-3191	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-3192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
U-3193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
U-3194	TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
U-3195	U-1731 U-1732
U-3196	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS
U-3197	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-3198	METHOD OF TREATING PATIENTS WITH IDIOPATHIC HYPERSOMNIA WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3199	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH PLUS HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS, HEART FAILURE AND REDUCED EJECTION FRACTION BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
U-3200	INCREASING SURVIVAL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN ANTIHISTAMINE, A CORTICOSTEROID, AND AN H2-ANTAGONIST
U-3201	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY
U-3202	MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL
U-3203	MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-3204	TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD)
U-3205	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION AND STROKE) IN PATIENTS WITH CAD
U-3206	REDUCTION OF RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY)

PATENT USE

	IN PATIENTS WITH PAD
U-3207	REDUCTION OF RISK OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH CAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-3208	REDUCTION OF RISK OF MYOCARDIAL INFARCTION AND ISCHEMIC STROKE IN PATIENTS WITH PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-3209	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK MYOCARDIAL INFARCTION IN AN ADULT PATIENT HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND ELEVATED TRIGLYCERIDE LEVELS
U-3210	ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS
U-3211	TREATING DISTRIBUTIVE SHOCK WITH ANGIOTENSIN II
U-3212	TREATING SEPTIC SHOCK WITH ANGIOTENSIN II
U-3213	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA
U-3214	A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3215	A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY AN IDH1 MUTATION
U-3216	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
U-3217	A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
U-3218	NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-3219	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
U-3220	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
U-3221	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT WITH PRIOR PERCUTANEOUS CORONARY INTERVENTION
U-3222	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
U-3223	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
U-3224	A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
U-3225	TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY
U-3226	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
U-3227	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
U-3228	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
U-3229	FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE

PATENT USE

U-3230	FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
U-3231	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION
U-3232	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHILE AVOIDING CONCOMITANT ADMINISTRATION OF LEVONORGESTREL
U-3233	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS
U-3234	TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS
U-3235	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-3236	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
U-3237	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
U-3238	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
U-3239	TREATMENT OF ADVANCED RENAL CELL CARCINOMA (RCC) IN PATIENTS WHO HAVE RECEIVED PRIOR ANTI-ANGIOGENIC THERAPY
U-3240	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT HAVING TRIGLYCERIDE LEVELS OF AT LEAST ABOUT 500 MG/DL, ON ANTICOAGULANT/ANTIPLATELET/THROMBOLYTIC THERAPY, AND HAVING ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER
U-3241	IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20%
U-3242	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDROCRINE THERAPY
U-3243	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3244	A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB
U-3245	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER
U-3246	FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
U-3247	FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOLD DISEASE
U-3248	TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3/4 CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION
U-3250	METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3251	ADMINISTRATION OF FERROUS BISGLYCINATE TABLETS
U-3252	USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS
U-3253	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367
U-3254	USE, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-3255	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3256	USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES
U-3257	TREATMENT OF TRD IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION

PATENT USE

	PHASE FOR ABOUT 4 WEEKS
U-3258	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE BETWEEN ABOUT 56 MG/M2 AND ABOUT 100 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
U-3259	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)
U-3260	METHOD OF TREATING SPASTICITY
U-3261	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY
U-3262	TREATING HYPOTENSION WITH ANGIOTENSIN II IN A PATIENT RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR
U-3263	METHOD FOR TREATING SPASTICITY
U-3264	AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3265	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3266	IN COMBINATION WITH FULVESTRANT AS INITIAL ENDOCRINE-BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN OR IN MEN, FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3267	USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER
U-3268	TREATMENT OF MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER AND WEIGHING LESS THAN OR EQUAL TO 40 KG
U-3269	TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION
U-3270	U-2106: TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT COMCOMITANT DOPAMINERGIC MEDICATIONS
U-3271	TREATMENT OF BIPOLAR DEPRESSION
U-3272	AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), BY INHIBITING EXPRESSION OF THE PCSK9 GENE
U-3273	AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), BY INHIBITING EXPRESSION OF THE PCSK9 GEN
U-3274	TREATMENT OF BIPOLAR I DISORDER, BIPOLAR II DISORDER, OR BIPOLAR DEPRESSION
U-3275	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS